PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Amin, O; Powers, J; Bricker, KM; Chahroudi, A				Amin, Omayma; Powers, Jenna; Bricker, Katherine M.; Chahroudi, Ann			Understanding Viral and Immune Interplay During Vertical Transmission of HIV: Implications for Cure	FRONTIERS IN IMMUNOLOGY			English	Review						HIV; MTCT; cure; pediatric; shock and kill; antiretroviral; breast milk; reservoir	HUMAN-IMMUNODEFICIENCY-VIRUS; MOTHER-TO-CHILD; HEPATITIS-C VIRUS; CELL-ASSOCIATED HIV-1; HERPES-SIMPLEX-VIRUS; COMBINATION ANTIRETROVIRAL THERAPY; PLASMODIUM-FALCIPARUM MALARIA; MATERNAL-INFANT TRANSMISSION; ELECTIVE CESAREAN-SECTION; PERINATAL TRANSMISSION	Despite the significant progress that has been made to eliminate vertical HIV infection, more than 150,000 children were infected with HIV in 2019, emphasizing the continued need for sustainable HIV treatment strategies and ideally a cure for children. Mother-to-child-transmission (MTCT) remains the most important route of pediatric HIV acquisition and, in absence of prevention measures, transmission rates range from 15% to 45% via three distinct routes: in utero, intrapartum, and in the postnatal period through breastfeeding. The exact mechanisms and biological basis of these different routes of transmission are not yet fully understood. Some infants escape infection despite significant virus exposure, while others do not, suggesting possible maternal or fetal immune protective factors including the presence of HIV-specific antibodies. Here we summarize the unique aspects of HIV MTCT including the immunopathogenesis of the different routes of transmission, and how transmission in the antenatal or postnatal periods may affect early life immune responses and HIV persistence. A more refined understanding of the complex interaction between viral, maternal, and fetal/infant factors may enhance the pursuit of strategies to achieve an HIV cure for pediatric populations.	[Amin, Omayma; Powers, Jenna; Bricker, Katherine M.; Chahroudi, Ann] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; [Chahroudi, Ann] Childrens Healthcare Atlanta, Ctr Childhood Infect & Vaccines, Atlanta, GA 30322 USA; [Chahroudi, Ann] Emory Univ, Atlanta, GA 30322 USA	Emory University; Children's Healthcare of Atlanta (CHOA); Emory University	Chahroudi, A (corresponding author), Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA.; Chahroudi, A (corresponding author), Childrens Healthcare Atlanta, Ctr Childhood Infect & Vaccines, Atlanta, GA 30322 USA.; Chahroudi, A (corresponding author), Emory Univ, Atlanta, GA 30322 USA.	ann.m.chahroudi@emory.edu		Bricker, Katherine/0000-0003-3339-0175	NIH [R01 AI133706, P01 AI131276, R37 AI157862, UM1 AI164566]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding AC would like to acknowledge funding support from the NIH (R01 AI133706, P01 AI131276, R37 AI157862, and UM1 AI164566).	Adachi K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189851; AHMAD N, 1995, J VIROL, V69, P1001, DOI 10.1128/JVI.69.2.1001-1012.1995; Aikhionbare Felix O, 2006, AIDS Res Ther, V3, P28; Aikhionbare FO, 2001, AIDS, V15, P2196, DOI 10.1097/00002030-200111090-00019; Ajibola G, 2021, CLIN INFECT DIS, V73, pE997, DOI 10.1093/cid/ciab143; Ananworanich J, 2014, JAIDS-J ACQ IMM DEF, V67, pS99, DOI 10.1097/QAI.0000000000000262; Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; Arnsten JH, 2002, J GEN INTERN MED, V17, P377, DOI 10.1046/j.1525-1497.2002.10644.x; Arora N, 2017, CELL HOST MICROBE, V21, P561, DOI 10.1016/j.chom.2017.04.007; Avettand-Fenoel V, 2021, CLIN INFECT DIS, V73, pE4214, DOI 10.1093/cid/ciaa1931; Ayouba A, 2008, AIDS, V22, P785, DOI 10.1097/QAD.0b013e3282f560ee; Baan E, 2012, AIDS RES HUM RETROV, V28, P715, DOI [10.1089/aid.2011.0023, 10.1089/AID.2011.0023]; Bale MJ, 2021, MBIO, V12, DOI 10.1128/mBio.00568-21; Baum MK, 2009, JAIDS-J ACQ IMM DEF, V50, P93, DOI 10.1097/QAI.0b013e3181900129; Biggar RJ, 2006, JAIDS-J ACQ IMM DEF, V41, P509, DOI 10.1097/01.qai.0000191283.85578.46; Biggar RJ, 2008, AIDS, V22, P2251, DOI 10.1097/QAD.0b013e328314e36b; Bitnun A, 2020, CLIN INFECT DIS, V70, P859, DOI 10.1093/cid/ciz251; Bitnun A, 2014, CLIN INFECT DIS, V59, P1012, DOI 10.1093/cid/ciu432; Boyce CL, 2022, CLIN INFECT DIS, V74, P2001, DOI 10.1093/cid/ciab744; Brahmbhatt H, 2003, AIDS, V17, P2539, DOI 10.1097/00002030-200311210-00020; Brahmbhatt H, 2008, JAIDS-J ACQ IMM DEF, V47, P472, DOI 10.1097/QAI.0b013e318162afe0; Braida L, 2004, AIDS, V18, P1598, DOI 10.1097/01.aids.0000131363.82951.fb; Briand N, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.06.021; Bricker KM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008954; BROLIDEN K, 1993, CLIN EXP IMMUNOL, V93, P56; BROLIDEN PA, 1989, AIDS, V3, P577, DOI 10.1097/00002030-198909000-00004; Bryson YJ, 1996, AIDS, V10, pS33; BULTERYS M, 1993, AIDS, V7, P1639, DOI 10.1097/00002030-199312000-00015; Bulterys M, 1997, J ACQ IMMUN DEF SYND, V15, P76, DOI 10.1097/00042560-199705010-00012; Bunders MJ, 2012, BLOOD, V120, P4383, DOI 10.1182/blood-2012-06-437566; BURNS DN, 1994, J ACQ IMMUN DEF SYND, V7, P718; Burns DN, 1997, J INFECT DIS, V175, P1206, DOI 10.1086/593569; BWAYO J, 1995, AM J OBSTET GYNECOL, V172, P700, DOI 10.1016/0002-9378(95)90597-9; Cao YZ, 1997, NAT MED, V3, P549, DOI 10.1038/nm0597-549; Carrico AW, 2007, PSYCHOSOM MED, V69, P785, DOI 10.1097/PSY.0b013e318157b142; Centers for Disease Control (CDC), 1982, MMWR Morb Mortal Wkly Rep, V31, P665; Chahroudi A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003958; Chander G, 2006, JAIDS-J ACQ IMM DEF, V43, P411, DOI 10.1097/01.qai.0000243121.44659.a4; Choi RY, 2010, CLIN EXP IMMUNOL, V160, P461, DOI 10.1111/j.1365-2249.2010.04096.x; Chouquet C, 1999, STAT MED, V18, P815, DOI 10.1002/(SICI)1097-0258(19990415)18:7&lt;815::AID-SIM74&gt;3.0.CO;2-G; CLEMETSON DBA, 1993, JAMA-J AM MED ASSOC, V269, P2860, DOI 10.1001/jama.269.22.2860; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009; Coovadia HM, 2007, LANCET, V369, P1107, DOI 10.1016/S0140-6736(07)60283-9; Coutsoudis A, 1999, LANCET, V354, P471, DOI 10.1016/S0140-6736(99)01101-0; Coutsoudis A, 2004, J INFECT DIS, V189, P2154, DOI 10.1086/420834; Dashti A, 2020, J VIROL, V94, DOI 10.1128/JVI.00793-20; Day JH, 2004, J INFECT DIS, V190, P1677, DOI 10.1086/424851; De Rossi A, 2007, CURR OPIN HIV AIDS, V2, P399, DOI 10.1097/COH.0b013e3282ced163; DeAndreis C, 1996, AIDS, V10, P711, DOI 10.1097/00002030-199606001-00004; Derdeyn CA, 2008, CURR OPIN HIV AIDS, V3, P16, DOI 10.1097/COH.0b013e3282f2982c; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; Dickover RE, 2001, J VIROL, V75, P2194, DOI 10.1128/JVI.75.5.2194-2203.2001; Dickover R, 2006, J VIROL, V80, P6525, DOI 10.1128/JVI.02658-05; Drake AL, 2007, OBSTET GYNECOL, V109, P403, DOI 10.1097/01.AOG.0000251511.27725.5c; Ellis RJ, 2003, J INFECT DIS, V188, P1820, DOI 10.1086/379894; Embree JE, 2000, AIDS, V14, P2535, DOI 10.1097/00002030-200011100-00016; England K, 2006, LANCET INFECT DIS, V6, P83, DOI 10.1016/S1473-3099(06)70381-4; Eshleman SH, 2006, JAIDS-J ACQ IMM DEF, V42, P518, DOI 10.1097/01.qai.0000221676.22069.b8; Fabris A, 2009, AIDS, V23, P177, DOI 10.1097/QAD.0b013e32832027bf; Farquhar C, 2004, AIDS RES HUM RETROV, V20, P692, DOI 10.1089/0889222041524616; Farzin A, 2013, AIDS RES HUM RETROV, V29, P77, DOI [10.1089/aid.2011.0355, 10.1089/AID.2011.0355]; Fawzi W, 2001, AIDS, V15, P1157, DOI 10.1097/00002030-200106150-00011; FAZELY F, 1993, J ACQ IMMUN DEF SYND, V6, P107; Flynn PM, 2021, JAIDS-J ACQ IMM DEF, V88, P206, DOI 10.1097/QAI.0000000000002744; Flynn PM, 2018, JAIDS-J ACQ IMM DEF, V77, P383, DOI 10.1097/QAI.0000000000001612; Foster C, 2021, J PEDIAT INF DIS SOC, V10, P295, DOI 10.1093/jpids/piaa071; Fouda GG, 2013, P NATL ACAD SCI USA, V110, P18220, DOI 10.1073/pnas.1307336110; Fowler MG, 1996, J NUTR, V126, pS2602, DOI 10.1093/jn/126.suppl_10.2602S; Frange P, 2016, LANCET HIV, V3, pE49, DOI 10.1016/S2352-3018(15)00232-5; Garcia-Broncano P, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax7350; Gejo NG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210782; Giacomet V, 2014, LANCET, V384, P1320, DOI 10.1016/S0140-6736(14)61405-7; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; Giuliano M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068950; Goletti D, 1996, J IMMUNOL, V157, P1271; Goswami R, 2019, MBIO, V10, DOI 10.1128/mBio.01971-19; Goulder PJ, 2016, NAT REV IMMUNOL, V16, P259, DOI 10.1038/nri.2016.19; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Gray RH, 2001, AM J OBSTET GYNECOL, V185, P1209, DOI 10.1067/mob.2001.118158; Guevara H, 2002, J ACQ IMMUN DEF SYND, V29, P435, DOI 10.1097/00126334-200204150-00002; Gupta A, 2011, J INFECT DIS, V203, P358, DOI [10.1093/infdis/jiq064, 10.1093/jinfdis/jiq064]; Hebel K, 2014, J IMMUNOL, V192, P5160, DOI 10.4049/jimmunol.1302539; Hershow RC, 1997, J INFECT DIS, V176, P414, DOI 10.1086/514058; Hitti J, 1997, AM J OBSTET GYNECOL, V177, P450, DOI 10.1016/S0002-9378(97)70214-X; HIV/AIDS) UJUNPo, 2011, PRESS REL WORLD LEAD; Hoffman IF, 1999, AIDS, V13, P487, DOI 10.1097/00002030-199903110-00007; Hofmann-Lehmann R, 2001, J VIROL, V75, P7470, DOI 10.1128/JVI.75.16.7470-7480.2001; Ivy W, 2012, JAIDS-J ACQ IMM DEF, V59, P207, DOI 10.1097/QAI.0b013e31823b4554; Jani IV, 2014, JAIDS-J ACQ IMM DEF, V67, pE1, DOI 10.1097/QAI.0000000000000250; John GC, 1996, EPIDEMIOL REV, V18, P149, DOI 10.1093/oxfordjournals.epirev.a017922; John GC, 1997, J INFECT DIS, V175, P57, DOI 10.1093/infdis/175.1.57; John GC, 2001, J INFECT DIS, V183, P206, DOI 10.1086/317918; Johnson EL, 2016, CURR OPIN INFECT DIS, V29, P248, DOI 10.1097/QCO.0000000000000267; JUST JJ, 1995, J PEDIATR-US, V127, P544, DOI 10.1016/S0022-3476(95)70110-9; Katusiime MG, 2020, J VIROL, V94, DOI 10.1128/JVI.01519-19; Kazmi SH, 2006, CLIN VACCINE IMMUNOL, V13, P1111, DOI 10.1128/CDLI.00426-05; Kennedy CE, 2017, AIDS, V31, P1579, DOI [10.1097/qad.0000000000001535, 10.1097/QAD.0000000000001535]; KILPATRICK DC, 1991, DIS MARKERS, V9, P21; Kliks S, 2000, AIDS RES HUM RETROV, V16, P1223, DOI 10.1089/08892220050116998; KLIKS SC, 1994, JAMA-J AM MED ASSOC, V272, P467, DOI 10.1001/jama.272.6.467; Kostrikis LG, 1999, J VIROL, V73, P10264, DOI 10.1128/JVI.73.12.10264-10271.1999; Koulinska IN, 2006, JAIDS-J ACQ IMM DEF, V41, P93, DOI 10.1097/01.qai.0000179424.19413.24; Kuhn L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001363; Kuhn L, 2021, CLIN INFECT DIS, V72, P394, DOI 10.1093/cid/ciaa033; Kuhn L, 2020, ECLINICALMEDICINE, V18, DOI 10.1016/j.eclinm.2019.100241; Kuhn L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195514; Kumar SB, 2012, AIDS, V26, P685, DOI 10.1097/QAD.0b013e3283519b00; Kwiek JJ, 2008, AIDS, V22, P863, DOI 10.1097/QAD.0b013e3282f51ea0; Kwiek JJ, 2006, PLOS MED, V3, P70, DOI 10.1371/journal.pmed.0030010; Lagaye S, 2001, J VIROL, V75, P4780, DOI 10.1128/JVI.75.10.4780-4791.2001; Lee TH, 2010, JAIDS-J ACQ IMM DEF, V55, P143, DOI 10.1097/QAI.0b013e3181eb301e; Lehman DA, 2007, REV MED VIROL, V17, P381, DOI 10.1002/rmv.543; LEWIS SH, 1990, LANCET, V335, P565, DOI 10.1016/0140-6736(90)90349-A; Liu AY, 2015, CLIN EXP IMMUNOL, V180, P509, DOI 10.1111/cei.12599; Lobato AC, 2010, MEM I OSWALDO CRUZ, V105, P720, DOI 10.1590/S0074-02762010000500021; Lohman-Payne B, 2014, CLIN EXP IMMUNOL, V178, P86, DOI 10.1111/cei.12386; Lohman-Payne B, 2012, AIDS, V26, P2007, DOI 10.1097/QAD.0b013e328359b7e0; LoussertAjaka I, 1997, AIDS, V11, P1575, DOI 10.1097/00002030-199713000-00005; Lunney KM, 2010, CLIN INFECT DIS, V50, P762, DOI 10.1086/650535; Luoga E, 2018, JAIDS-J ACQ IMM DEF, V79, pE17, DOI [10.1097/qai.0000000000001758, 10.1097/QAI.0000000000001758]; Luzuriaga K, 2016, NEW ENGL J MED, V374, P761, DOI 10.1056/NEJMra1505256; Luzuriaga K, 2015, NEW ENGL J MED, V372, P786, DOI 10.1056/NEJMc1413931; Luzuriaga K, 2014, J INFECT DIS, V210, P1529, DOI 10.1093/infdis/jiu297; Lyimo MA, 2009, JAIDS-J ACQ IMM DEF, V51, P117, DOI 10.1097/QAI.0b013e3181a3908d; Mabuka J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002739; MacDonald KS, 1998, J INFECT DIS, V177, P551, DOI 10.1086/514243; MacDonald KS, 2001, J INFECT DIS, V183, P503, DOI 10.1086/318092; Mackelprang RD, 2008, J INFECT DIS, V197, P1156, DOI 10.1086/529528; Magder LS, 2005, JAIDS-J ACQ IMM DEF, V38, P87, DOI 10.1097/00126334-200501010-00016; Maiques V, 2003, EUR J OBSTET GYN R B, V108, P137, DOI 10.1016/S0301-2115(02)00405-0; Mall AS, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0855-9; Mandl CW, 1998, J MED VIROL, V55, P51, DOI 10.1002/(SICI)1096-9071(199805)55:1&lt;51::AID-JMV9&gt;3.0.CO;2-N; Martinez DR, 2017, J VIROL, V91, DOI 10.1128/JVI.02422-16; Martinez-Bonet M, 2015, CLIN INFECT DIS, V61, P1169, DOI 10.1093/cid/civ456; Massanella M, 2021, CLIN INFECT DIS, V73, P427, DOI 10.1093/cid/ciaa718; Matheson PB, 1996, AIDS, V10, P1249, DOI 10.1097/00002030-199609000-00011; Matheson PB, 1997, AIDS, V11, P941; Mavigner M, 2018, J VIROL, V92, DOI 10.1128/JVI.00562-18; Mayaux MJ, 1997, J INFECT DIS, V175, P172, DOI 10.1093/infdis/175.1.172; Mbopi-Keou FX, 2003, JAIDS-J ACQ IMM DEF, V33, P121, DOI 10.1097/00126334-200306010-00001; McClelland RS, 2002, AIDS, V16, P2425, DOI 10.1097/00002030-200212060-00007; McClelland RS, 2002, J INFECT DIS, V185, P1822, DOI 10.1086/340639; McManus WR, 2019, J CLIN INVEST, V129, P4529, DOI 10.1172/JCI126714; Menendez C, 1999, J MED VIROL, V58, P215, DOI 10.1002/(SICI)1096-9071(199907)58:3&lt;215::AID-JMV5&gt;3.0.CO;2-K; Menu E, 1999, J INFECT DIS, V179, P44, DOI 10.1086/314542; Milanese M, 2006, AIDS, V20, P1673, DOI 10.1097/01.aids.0000238417.05819.40; Milanese M, 2009, JAIDS-J ACQ IMM DEF, V50, P331, DOI 10.1097/QAI.0b013e3181945f39; Millar JR, 2021, J INFECT DIS, V224, P1925, DOI 10.1093/infdis/jiab223; Milligan C, 2014, J INFECT DIS, V210, pS631, DOI 10.1093/infdis/jiu344; Milush JA, 2004, AIDS, V18, P2371; Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601; Mohlala BKF, 2005, J INFECT DIS, V192, P488, DOI 10.1086/431604; Mold JE, 2008, SCIENCE, V322, P1562, DOI 10.1126/science.1164511; Mor G, 2017, NAT REV IMMUNOL, V17, P469, DOI 10.1038/nri.2017.64; Morrison CS, 2010, AIDS, V24, P573, DOI 10.1097/QAD.0b013e32833433df; Msamanga GI, 2009, AM J TROP MED HYG, V80, P508, DOI 10.4269/ajtmh.2009.80.508; Mwanyumba F, 2002, J ACQ IMMUN DEF SYND, V29, P262, DOI 10.1097/00126334-200203010-00006; Mwapasa V, 2004, AIDS, V18, P1051, DOI 10.1097/00002030-200404300-00014; Nagot N, 2016, LANCET, V387, P566, DOI 10.1016/S0140-6736(15)00984-8; Ndirangu J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051493; Nixon CC, 2020, NATURE, V578, P160, DOI 10.1038/s41586-020-1951-3; O'Shea S, 1998, J MED VIROL, V54, P113, DOI 10.1002/(SICI)1096-9071(199802)54:2&lt;113::AID-JMV8&gt;3.0.CO;2-9; Obregon-Perko V, 2021, J VIROL, V95, DOI 10.1128/JVI.01669-20; Obregon-Perko V, 2020, CURR HIV-AIDS REP, V17, P343, DOI 10.1007/s11904-020-00503-4; Omenda MM, 2013, JAIDS-J ACQ IMM DEF, V64, P163, DOI 10.1097/QAI.0b013e31829f6e41; Ometto L, 2000, AIDS, V14, P1721, DOI 10.1097/00002030-200008180-00006; Organization GWH, 2010, WHO REC DIAGN HIV IN; Organization WH, 2016, BREASTF HIV; PACCAGNINI S, 1995, PEDIATR INFECT DIS J, V14, P195, DOI 10.1097/00006454-199503000-00005; Palma P, 2020, LANCET HIV, V7, pE359, DOI 10.1016/S2352-3018(20)30100-4; Palma P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079957; Pancino G, 1998, J INFECT DIS, V177, P1737, DOI 10.1086/517435; Papaevangelou V, 1998, J INFECT DIS, V178, P1047, DOI 10.1086/515668; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; Pedersen BR, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000838; Persaud D, 2014, JAMA PEDIATR, V168, P1138, DOI 10.1001/jamapediatrics.2014.1560; Persaud D, 2013, NEW ENGL J MED, V369, P1828, DOI 10.1056/NEJMoa1302976; Philpott S, 1999, J ACQ IMMUN DEF SYND, V21, P189, DOI 10.1097/00126334-199907010-00002; Pollara J, 2015, J VIROL, V89, P9952, DOI 10.1128/JVI.01560-15; Polycarpou A, 2002, AIDS RES HUM RETROV, V18, P741, DOI 10.1089/08892220260139477; Purohit V, 2011, LIFE SCI, V88, P909, DOI 10.1016/j.lfs.2011.03.022; Renjifo B, 2003, VIROLOGY, V307, P278, DOI 10.1016/S0042-6822(02)00066-1; Ricci E, 2009, JAIDS-J ACQ IMM DEF, V51, P13, DOI 10.1097/QAI.0b013e31819df249; Rocca S, 2019, J PEDIAT INF DIS SOC, V8, P433, DOI 10.1093/jpids/piy080; Rodriguez EM, 1996, AIDS, V10, P273, DOI 10.1097/00002030-199603000-00006; Ross AL, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-46; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; Rousseau CM, 2003, J INFECT DIS, V187, P741, DOI 10.1086/374273; Rousseau CM, 2004, J INFECT DIS, V190, P1880, DOI 10.1086/425076; Rouzioux C, 1995, AM J EPIDEMIOL, V142, P1330, DOI 10.1093/oxfordjournals.aje.a117601; Salkowitz JR, 2003, CLIN IMMUNOL, V108, P234, DOI 10.1016/S1521-6616(03)00147-5; SCARLATTI G, 1993, VIROLOGY, V197, P624, DOI 10.1006/viro.1993.1637; Semba RD, 1999, J INFECT DIS, V180, P93, DOI 10.1086/314854; Semrau K, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.021; Shaffer N, 1999, J INFECT DIS, V179, P590, DOI 10.1086/314641; Shapiro RL, 2010, NEW ENGL J MED, V362, P2282, DOI 10.1056/NEJMoa0907736; Shearer WT, 1998, J ACQ IMMUN DEF SYND, V17, P180, DOI 10.1097/00042560-199802010-00014; Shivakoti R, 2016, J INFECT DIS, V213, P762, DOI 10.1093/infdis/jiv479; Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7; Singh KK, 2008, JAIDS-J ACQ IMM DEF, V49, P259, DOI 10.1097/QAI.0b013e318186eaa4; Singh V, 2021, CURR HIV-AIDS REP, V18, P117, DOI 10.1007/s11904-020-00540-z; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; Tagarro A, 2018, JAIDS-J ACQ IMM DEF, V79, P269, DOI [10.1097/qai.0000000000001789, 10.1097/QAI.0000000000001789]; Taha TE, 2005, PEDIATRICS, V115, pE167, DOI 10.1542/peds.2004-1590; Taha TE, 2000, ANN NY ACAD SCI, V918, P84; TAHA TET, 1994, T ROY SOC TROP MED H, V88, P164, DOI 10.1016/0035-9203(94)90277-1; Takahata Y, 2004, EXP HEMATOL, V32, P622, DOI 10.1016/j.exphem.2004.03.012; Takata H, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag1809; Tang YY, 2020, CELL REP, V30, P4528, DOI 10.1016/j.celrep.2020.03.016; Tess BH, 1998, AIDS, V12, P513, DOI 10.1097/00002030-199805000-00013; Thea DM, 1997, AIDS, V11, P437, DOI 10.1097/00002030-199704000-00006; Thomas DL, 1998, J INFECT DIS, V177, P1480, DOI 10.1086/515315; Tobin NH, 2013, IMMUNOL REV, V254, P143, DOI 10.1111/imr.12074; Toossi Z, 2001, CLIN EXP IMMUNOL, V123, P233, DOI 10.1046/j.1365-2249.2001.01401.x; Tovo PA, 1997, CLIN INFECT DIS, V25, P1121, DOI 10.1086/516102; Tugizov SM, 2012, J VIROL, V86, P2556, DOI 10.1128/JVI.06578-11; Turner BJ, 1997, J ACQ IMMUN DEF SYND, V14, P327, DOI 10.1097/00042560-199704010-00004; UGEN KE, 1992, J CLIN INVEST, V89, P1923, DOI 10.1172/JCI115798; UNAIDS, 2011, GLOB HIV AIDS STAT F; UNAIDS, 2020, GLOB HIV AIDS STAT F; UNAIDS, 2014, GAP REP; Uprety P, 2015, CLIN INFECT DIS, V61, P1862, DOI 10.1093/cid/civ688; Van Dyke RB, 1999, J INFECT DIS, V179, P319, DOI 10.1086/314580; Van Rompay KKA, 2005, JAIDS-J ACQ IMM DEF, V38, P124, DOI 10.1097/00126334-200502010-00002; van Zyl GU, 2015, J INFECT DIS, V212, P39, DOI 10.1093/infdis/jiu827; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; Veazey RS, 2003, J VIROL, V77, P8783, DOI 10.1128/JVI.77.16.8783-8792.2003; Veldsman KA, 2021, AIDS, V35, P1247, DOI 10.1097/QAD.0000000000002861; Veldsman KA, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25368; Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971; Violari A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08311-0; Wabwire-Mangen F, 1999, J ACQ IMMUN DEF SYND, V22, P379; Walter J, 2008, CURR OPIN HIV AIDS, V3, P146, DOI 10.1097/COH.0b013e3282f50bb2; Wang XL, 2010, BLOOD, V116, P4168, DOI 10.1182/blood-2010-03-273482; Whitney JB, 2014, NATURE, V512, P74, DOI 10.1038/nature13594; WHO, 2010, ANT DRUGS TREATM PRE; Wilson CC, 1999, J VIROL, V73, P3975, DOI 10.1128/JVI.73.5.3975-3985.1999; Winchester R, 1995, P NATL ACAD SCI USA, V92, P12374, DOI 10.1073/pnas.92.26.12374; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; Wood LF, 2018, CLIN INFECT DIS, V67, P1237, DOI 10.1093/cid/ciy265; Wu XL, 2006, J VIROL, V80, P835, DOI 10.1128/JVI.80.2.835-844.2006; Yang CF, 2003, AIDS, V17, P1667, DOI 10.1097/00002030-200307250-00011; Zachar V, 1999, AIDS RES HUM RETROV, V15, P1673, DOI 10.1089/088922299309711; Zhang H, 2002, AIDS RES HUM RETROV, V18, P1415, DOI 10.1089/088922202320935492	246	1	1	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 21	2021	12								757400	10.3389/fimmu.2021.757400	http://dx.doi.org/10.3389/fimmu.2021.757400			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI5WH	34745130	gold, Green Published			2022-12-18	WOS:000726181000001
J	Navratilova, A; Cerezo, LA; Hulejova, H; Becvar, V; Tomcik, M; Komarc, M; Veigl, D; Tegzova, D; Zavada, J; Olejarova, M; Pavelka, K; Vencovsky, J; Senolt, L				Navratilova, Adela; Cerezo, Lucie Andres; Hulejova, Hana; Becvar, Viktor; Tomcik, Michal; Komarc, Martin; Veigl, David; Tegzova, Dana; Zavada, Jakub; Olejarova, Marta; Pavelka, Karel; Vencovsky, Jiri; Senolt, Ladislav			IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis	FRONTIERS IN IMMUNOLOGY			English	Article						interleukin-40; rheumatoid arthritis; autoantibodies; disease activity; B cells; NETosis	CLASSIFICATION CRITERIA; DEPLETION THERAPY; IDENTIFICATION; EXPRESSION; DIFFERENTIATION; PATHOGENESIS	Background: Interleukin 40 (IL-40) is a newly identified B cell-associated cytokine implicated in humoral immune responses and B cell homeostasis. As B cells play a pivotal role in autoimmunity, we investigated the function of IL-40 in rheumatoid arthritis (RA). Methods: IL-40 expression was determined in the synovial tissue from RA and osteoarthritis (OA) patients. IL-40 was analysed in the serum/synovial fluid of patients with RA (n=50), systemic lupus erythematosus (SLE, n=69), OA (n=44), and healthy controls (HC, n=50). We assessed the changes of IL-40 levels in RA patients following the B cell depletion by rituximab (n=29) or after the TNF inhibition by adalimumab (n=25). We examined the relationship between IL-40, disease activity, autoantibodies, cytokines, and NETosis markers. Effect of IL-40 on synovial fibroblasts was determined. Results: IL-40 was overexpressed in RA synovial tissue, particularly by synovial lining and infiltrating immune cells. The levels of IL-40 were up-regulated in the synovial fluid of RA versus OA patients (p<0.0001). Similarly, IL-40 was increased in the serum of RA patients compared to HC, OA, or SLE (p<0.0001 for all) and decreased after 16 and 24 weeks (p<0.01 and p<0.01) following rituximab treatment. No significant effect of adalimumab on IL-40 was observed. IL-40 levels in RA patients correlated with rheumatoid factor-IgM and anti-cyclic citrullinated peptides (anti-CCP) in the serum (p<0.0001 and p<0.01), as well as in the synovial fluid (p<0.0001 and p<0.001). Synovial fluid IL-40 was also associated with disease activity score DAS28 (p<0.05), synovial fluid leukocyte count (p<0.01), neutrophil attractants IL-8 (p<0.01), MIP-1a (p<0.01), and markers of neutrophil extracellular traps externalization (NETosis) such as proteinase 3 (p<0.0001) and neutrophil elastase (p<0.0001). Synovial fibroblasts exposed to IL-40 increased the secretion of IL-8 (p<0.01), MCP-1 (p<0.05), and MMP-13 (p<0.01) compared to the unstimulated cells. Conclusions: We show the up-regulation of IL-40 in RA and its decrease following B cell depleting therapy. The association of IL-40 with autoantibodies, chemokines, and markers of NETosis may imply its potential involvement in RA development. Moreover, IL-40 up-regulates the secretion of chemokines and MMP-13 in synovial fibroblasts, indicating its role in the regulation of inflammation and tissue destruction in RA.	[Navratilova, Adela; Cerezo, Lucie Andres; Hulejova, Hana; Becvar, Viktor; Tomcik, Michal; Tegzova, Dana; Zavada, Jakub; Olejarova, Marta; Pavelka, Karel; Vencovsky, Jiri; Senolt, Ladislav] Inst Rheumatol, Dept Expt Rheumatol, Prague, Czech Republic; [Navratilova, Adela; Cerezo, Lucie Andres; Tomcik, Michal; Tegzova, Dana; Zavada, Jakub; Olejarova, Marta; Pavelka, Karel; Vencovsky, Jiri; Senolt, Ladislav] Charles Univ Prague, Fac Med 1, Dept Rheumatol, Prague, Czech Republic; [Komarc, Martin] Charles Univ Prague, Fac Phys Educ & Sport, Dept Methodol, Prague, Czech Republic; [Veigl, David] Charles Univ Prague, Fac Med 1, Orthopaed Clin 1, Prague, Czech Republic	Institute of Rheumatology; Charles University Prague; Charles University Prague; Charles University Prague	Navratilova, A (corresponding author), Inst Rheumatol, Dept Expt Rheumatol, Prague, Czech Republic.; Navratilova, A (corresponding author), Charles Univ Prague, Fac Med 1, Dept Rheumatol, Prague, Czech Republic.	navratilova@revma.cz	Tomcik, Michal/P-1510-2017; Zavada, Jakub/N-3159-2017	Tomcik, Michal/0000-0002-8616-7850; Zavada, Jakub/0000-0002-9802-6545	Agency for Healthcare Research of the Czech Republic [AZV-NU21-0500276]; Ministry of Health of the Czech Republic [023728]; Charles University [SVV 260 523]; BBMRI-CZ [LM2018125]	Agency for Healthcare Research of the Czech Republic; Ministry of Health of the Czech Republic(Ministry of Health, Czech Republic); Charles University; BBMRI-CZ	This study was funded by Research Project AZV-NU21-0500276 of the Agency for Healthcare Research of the Czech Republic and by Research Project No. 023728 of the Ministry of Health of the Czech Republic, Charles University project SVV 260 523, and BBMRI-CZ LM2018125.	Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI 10.1002/art.27584; An ZJ, 2019, CELL CYCLE, V18, P2928, DOI 10.1080/15384101.2019.1662678; Bugatti S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/681678; Cambridge G, 2003, ARTHRITIS RHEUM-US, V48, P2146, DOI 10.1002/art.11181; Cambridge G, 2014, J AUTOIMMUN, V50, P67, DOI 10.1016/j.jaut.2013.12.002; Catalan-Dibene J, 2018, J INTERF CYTOK RES, V38, P423, DOI 10.1089/jir.2018.0089; Catalan-Dibene J, 2017, J IMMUNOL, V199, P3326, DOI 10.4049/jimmunol.1700534; Feng Y, 2020, AUTOIMMUNITY, V53, P56, DOI 10.1080/08916934.2019.1700232; Fillatreau S, 2018, CLIN IMMUNOL, V186, P26, DOI 10.1016/j.clim.2017.07.020; Gao X, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-020-03283-2; Hamel KM, 2014, ARTHRITIS RHEUMATOL, V66, P60, DOI 10.1002/art.38207; Jordan LA, 2018, RHEUMATOLOGY, V57, P2042, DOI 10.1093/rheumatology/key196; Khandpur R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005580; Krishnamurthy A, 2016, ANN RHEUM DIS, V75, P721, DOI 10.1136/annrheumdis-2015-208093; Lee J, 2005, FASEB J, V19, P1356, DOI 10.1096/fj.04-3552fje; Lee SC, 2000, J IMMUNOL, V164, P3392, DOI 10.4049/jimmunol.164.6.3392; Li H, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1454-2; Liu ZJ, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3574534; Lopez-Olivo MA, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007356.pub2; McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094; Olalekan SA, 2015, EUR J IMMUNOL, V45, P988, DOI 10.1002/eji.201445036; Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473; Rantapaa-Dahlqvist S, 2003, ARTHRITIS RHEUM, V48, P2741, DOI 10.1002/art.11223; Roth RB, 2006, NEUROGENETICS, V7, P67, DOI 10.1007/s10048-006-0032-6; Senolt L, 2007, ANN RHEUM DIS, V66, P458, DOI 10.1136/ard.2006.054734; Senolt L, 2011, CYTOKINE, V55, P116, DOI 10.1016/j.cyto.2011.04.004; Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8; Tong X, 2020, MOL MED REP, V21, P1623, DOI 10.3892/mmr.2020.10969; Wigerblad G, 2016, ANN RHEUM DIS, V75, P730, DOI 10.1136/annrheumdis-2015-208094; Zhou H, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-0312-7; Zingaretti C, 2012, MOL CELL PROTEOMICS, V11, P1885, DOI 10.1074/mcp.M112.018713	31	1	1	5	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 21	2021	12								745523	10.3389/fimmu.2021.745523	http://dx.doi.org/10.3389/fimmu.2021.745523			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZY8OR	34745117	Green Published, gold			2022-12-18	WOS:000772840700001
J	Wu, LL; Han, X; Jiang, XY; Ding, HH; Qi, CJ; Yin, ZH; Xiao, JW; Xiong, L; Guo, Q; Ye, ZZ; Qu, B; Shen, N				Wu, Lingling; Han, Xiao; Jiang, Xiaoyue; Ding, Huihua; Qi, Chaojun; Yin, Zhihua; Xiao, Jianwei; Xiong, Le; Guo, Qiang; Ye, Zhizhong; Qu, Bo; Shen, Nan			Downregulation of Renal Hsa-miR-127-3p Contributes to the Overactivation of Type I Interferon Signaling Pathway in the Kidney of Lupus Nephritis	FRONTIERS IN IMMUNOLOGY			English	Article						microRNA; hsa-miR-127-3p; type I interferon; Janus Kinase 1; systemic lupus erythematosus; lupus nephritis		MicroRNAs are involved in the pathogenesis of systemic lupus erythematosus (SLE) and dysregulated in the kidneys of lupus nephritis (LN) patients, but their pathogenic roles in LN are largely unknown. Janus Kinase 1 (JAK1) mediates the activation of the downstream signaling pathways of many inflammatory cytokines, including type I interferon (IFN-I) signaling pathway which is critical to the development of SLE and LN. Thus, JAK1 is a potent therapeutic target for these autoimmune diseases. However, there are few studies demonstrating the dysregulation of JAK1 in autoimmune diseases and the molecular mechanism behind it. In this concise report, we show an inhibitory effect of hsa-miR-127-3p, a microRNA that is downregulated in the renal tissues of LN patients, on IFN-I signaling. We found the overexpression of hsa-miR-127-3p could inhibit the induction of ISRE and GAS mediated gene expression, the phosphorylation of STAT1 and STAT2, and the upregulation of IFN stimulated genes (ISGs) stimulated by IFN-I. While, hsa-miR-127-3p antagonist enhanced the activation of IFN-I signaling in primary renal mesangial cells. Subsequently, we identified JAK1 as a bona fide target gene of hsa-miR-127-3p and showed hsa-miR-127-3p targeted JAK1 through binding to its 3'UTR and coding region. Consistently, we found the downregulation of hsa-miR-127-3p was associated with the upregulation of JAK1 and ISGs in kidney tissues of LN patients. Our data indicate renal downregulation of hsa-miR-127-3p contributes to the overactivation of IFN-I signaling pathway in the kidneys of LN patients through promoting the expression of JAK1, suggesting hsa-miR-127-3p mimics may be used to inhibit JAK1 and IFN-I signaling pathway in LN.	[Wu, Lingling; Jiang, Xiaoyue; Ding, Huihua; Xiong, Le; Guo, Qiang; Qu, Bo; Shen, Nan] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Rheumatol, Shanghai, Peoples R China; [Han, Xiao] Fudan Univ, Childrens Hosp, Inst Pediat, Shanghai, Peoples R China; [Qi, Chaojun] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Nephrol,Mol Cell Lab Kidney Dis, Shanghai, Peoples R China; [Yin, Zhihua; Xiao, Jianwei; Ye, Zhizhong; Qu, Bo; Shen, Nan] Shenzhen Futian Hosp Rheumat Dis, Shenzhen, Peoples R China; [Qu, Bo; Shen, Nan] Shanghai Jiao Tong Univ, Sch Med SJTUSM, Ren Ji Hosp, State Key Lab Oncogenes & Related Genes,Shanghai, Shanghai, Peoples R China; [Shen, Nan] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol CAGE, Cincinnati, OH 45229 USA; [Shen, Nan] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45229 USA	Shanghai Jiao Tong University; Fudan University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Qu, B; Shen, N (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Rheumatol, Shanghai, Peoples R China.; Ye, ZZ; Qu, B; Shen, N (corresponding author), Shenzhen Futian Hosp Rheumat Dis, Shenzhen, Peoples R China.; Qu, B; Shen, N (corresponding author), Shanghai Jiao Tong Univ, Sch Med SJTUSM, Ren Ji Hosp, State Key Lab Oncogenes & Related Genes,Shanghai, Shanghai, Peoples R China.; Shen, N (corresponding author), Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol CAGE, Cincinnati, OH 45229 USA.; Shen, N (corresponding author), Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45229 USA.	yezhizhong@126.com; qubo.bio@gmail.com; nanshensibs@gmail.com	Shen, Nan/AGK-6807-2022; Wu, Ling/GZN-2235-2022		Shanghai Pujiang Program [2019PJD028]; National Natural Science Foundation of China [81701603, 31630021, 31930037]; Shanghai Municipal Key Medical Center Construction Project [2017ZZ01024-002]; Innovative research team of high-level local universities in Shanghai, Sanming Project of Medicine in Shenzhen [SZSM201602087]; Shenzhen Futian Public Welfare Scientific Research Project [FTWS2018005]; National Human Genetic Resources Sharing Service Platform [2005DKA21300]; Futian Healthcare Research Project [FTWS2021006]	Shanghai Pujiang Program(Shanghai Pujiang Program); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Key Medical Center Construction Project; Innovative research team of high-level local universities in Shanghai, Sanming Project of Medicine in Shenzhen; Shenzhen Futian Public Welfare Scientific Research Project; National Human Genetic Resources Sharing Service Platform; Futian Healthcare Research Project	Funding This work was supported by Shanghai Pujiang Program (2019PJD028), National Natural Science Foundation of China (No. 81701603, No. 31630021, No. 31930037), Shanghai Municipal Key Medical Center Construction Project (2017ZZ01024-002), Innovative research team of high-level local universities in Shanghai, Sanming Project of Medicine in Shenzhen (SZSM201602087), Shenzhen Futian Public Welfare Scientific Research Project (FTWS2018005), National Human Genetic Resources Sharing Service Platform (2005DKA21300), and Futian Healthcare Research Project (No. FTWS2021006).	Ceribelli A, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3377; Craft JE, 2012, NAT REV RHEUMATOL, V8, P337, DOI 10.1038/nrrheum.2012.58; Fairhurst AM, 2009, J IMMUNOL, V183, P6831, DOI 10.4049/jimmunol.0900742; Genovese MC, 2019, JAMA-J AM MED ASSOC, V322, P315, DOI 10.1001/jama.2019.9055; Hahn BH, 2012, ARTHRIT CARE RES, V64, P797, DOI 10.1002/acr.21664; Han X, 2016, ARTHRITIS RHEUMATOL, V68, P2232, DOI 10.1002/art.39725; Hong SM, 2020, CURR RHEUMATOL REP, V22, DOI 10.1007/s11926-020-00895-7; Ichinose K, 2011, J IMMUNOL, V187, P5500, DOI 10.4049/jimmunol.1102357; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; Ka SM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2226; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Morand EF, 2020, NEW ENGL J MED, V382, P211, DOI 10.1056/NEJMoa1912196; Murphy G, 2019, NAT REV RHEUMATOL, V15, P403, DOI 10.1038/s41584-019-0235-5; O'Shea JJ, 2019, NAT REV RHEUMATOL, V15, P74, DOI 10.1038/s41584-018-0155-9; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Riggs JM, 2018, LUPUS SCI MED, V5, DOI 10.1136/lupus-2018-000261; Ronnblom L, 2019, LUPUS SCI MED, V6, DOI 10.1136/lupus-2018-000270; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Yung S, 2010, J AM SOC NEPHROL, V21, P1912, DOI 10.1681/ASN.2009080805	20	1	1	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 21	2021	12								747616	10.3389/fimmu.2021.747616	http://dx.doi.org/10.3389/fimmu.2021.747616			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WU6CI	34745118	Green Published, gold			2022-12-18	WOS:000716631100001
J	Kaur, A; Chopra, M; Bhushan, M; Gupta, S; Kumari, PH; Sivagurunathan, N; Shukla, N; Rajagopal, S; Bhalothia, P; Sharma, P; Naravula, J; Suravajhala, R; Gupta, A; Abbasi, BA; Goswami, P; Singh, H; Narang, R; Polavarapu, R; Medicherla, KM; Valadi, J; Kumar, SA; Chaubey, G; Singh, KK; Bandapalli, OR; Kishor, PBK; Suravajhala, P				Kaur, Arvinpreet; Chopra, Mehak; Bhushan, Mahak; Gupta, Sonal; Kumari, Hima P.; Sivagurunathan, Narmadhaa; Shukla, Nidhi; Rajagopal, Shalini; Bhalothia, Purva; Sharma, Purnima; Naravula, Jalaja; Suravajhala, Renuka; Gupta, Ayam; Abbasi, Bilal Ahmed; Goswami, Prittam; Singh, Harpreet; Narang, Rahul; Polavarapu, Rathnagiri; Medicherla, Krishna Mohan; Valadi, Jayaraman; Kumar, Anil S.; Chaubey, Gyaneshwer; Singh, Keshav K.; Bandapalli, Obul Reddy; Kishor, Polavarapu Bilhan Kavi; Suravajhala, Prashanth			The Omic Insights on Unfolding Saga of COVID-19	FRONTIERS IN IMMUNOLOGY			English	Review						SARS-CoV-2; COVID-19; ORFs; machine learning; co-morbidities	ACUTE RESPIRATORY SYNDROME; SYNDROME CORONAVIRUS; VITAMIN-D; SARS-COV; SPIKE PROTEIN; RT-PCR; SARS-COV-2; RECEPTOR; INFECTION; OUTBREAK	The year 2019 has seen an emergence of the novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease of 2019 (COVID-19). Since the onset of the pandemic, biological and interdisciplinary research is being carried out across the world at a rapid pace to beat the pandemic. There is an increased need to comprehensively understand various aspects of the virus from detection to treatment options including drugs and vaccines for effective global management of the disease. In this review, we summarize the salient findings pertaining to SARS-CoV-2 biology, including symptoms, hosts, epidemiology, SARS-CoV-2 genome, and its emerging variants, viral diagnostics, host-pathogen interactions, alternative antiviral strategies and application of machine learning heuristics and artificial intelligence for effective management of COVID-19 and future pandemics.	[Kaur, Arvinpreet; Sharma, Purnima; Singh, Harpreet] Hans Raj Mahila Maha Vidyalaya, Dept Bioinformat, Jalandhar, Punjab, India; [Kaur, Arvinpreet; Gupta, Sonal; Kumari, Hima P.; Shukla, Nidhi; Suravajhala, Renuka; Singh, Harpreet; Valadi, Jayaraman; Bandapalli, Obul Reddy; Kishor, Polavarapu Bilhan Kavi; Suravajhala, Prashanth] Biocluesorg, Hyderabad, India; [Chopra, Mehak] Pondicherry Univ, Ctr Bioinformat, Sch Life Sci, Pondicherry, India; [Bhushan, Mahak] Indian Inst Sci Educ & Res, Dept Biol Sci, Kolkata, India; [Gupta, Sonal; Sivagurunathan, Narmadhaa; Shukla, Nidhi; Bhalothia, Purva; Medicherla, Krishna Mohan; Suravajhala, Prashanth] Birla Inst Sci Res, Dept Biotechnol & Bioinformat, Jaipur, Rajasthan, India; [Rajagopal, Shalini; Naravula, Jalaja; Gupta, Ayam; Kumar, Anil S.; Kishor, Polavarapu Bilhan Kavi] Technol & Res Deemed Univ, Vignans Fdn Sci, Guntur, Andhra Pradesh, India; [Suravajhala, Renuka] Manipal Univ Jaipur, Sch Basic Sci, Dept Chem, Jaipur, Rajasthan, India; [Abbasi, Bilal Ahmed] Inst Genom & Integrat Biol CSIR IGIB, Funct Genom Unit, Council Sci & Ind Res, Delhi, India; [Goswami, Prittam] Haldia Inst Technol, Dept Biotechnol, Haldia, W Bengal, India; [Narang, Rahul] All India Inst Med Sci, Dept Microbiol, Hyderabad, India; [Polavarapu, Rathnagiri] Genomix CARL Pvt Ltd, Pulivendula, India; [Valadi, Jayaraman] Flame Univ, Dept Comp Sci, Pune, Maharashtra, India; [Chaubey, Gyaneshwer] Benaras Hindu Univ, Dept Zool, Cytogenet Lab, Varanasi, Uttar Pradesh, India; [Singh, Keshav K.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35205 USA; [Bandapalli, Obul Reddy] German Canc Res Ctr, Heidelberg, Germany; [Bandapalli, Obul Reddy] Indian Inst Chem Technol CSIR IICT, Dept Appl Biol, Council Sci & Ind Res, Hyderabad, India; [Suravajhala, Prashanth] Amrita Vishwa Vidyapeetham, Amrita Sch Biotechnol, Vallikavu, Kerala, India	Pondicherry University; Indian Institute of Science Education & Research (IISER) - Kolkata; Manipal University Jaipur; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); Haldia Institute of Technology; Banaras Hindu University (BHU); University of Alabama System; University of Alabama Birmingham; Helmholtz Association; German Cancer Research Center (DKFZ); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Technology (IICT); Amrita Vishwa Vidyapeetham	Bandapalli, OR; Kishor, PBK; Suravajhala, P (corresponding author), Biocluesorg, Hyderabad, India.; Suravajhala, P (corresponding author), Birla Inst Sci Res, Dept Biotechnol & Bioinformat, Jaipur, Rajasthan, India.; Kishor, PBK (corresponding author), Technol & Res Deemed Univ, Vignans Fdn Sci, Guntur, Andhra Pradesh, India.; Singh, KK (corresponding author), Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35205 USA.; Bandapalli, OR (corresponding author), German Canc Res Ctr, Heidelberg, Germany.; Bandapalli, OR (corresponding author), Indian Inst Chem Technol CSIR IICT, Dept Appl Biol, Council Sci & Ind Res, Hyderabad, India.; Suravajhala, P (corresponding author), Amrita Vishwa Vidyapeetham, Amrita Sch Biotechnol, Vallikavu, Kerala, India.	kksingh@uab.edu; bandapalli@gmail.com; pbkavi@yahoo.com; prash@bioclues.org	Bhalothia, Purva/AAX-2769-2021; Suravajhala, Renuka/AAO-1405-2021; Suravajhala, Prashanth N/E-8270-2011; Abbasi, Bilal/GXA-1732-2022	Bhalothia, Purva/0000-0002-6700-4693; Suravajhala, Renuka/0000-0002-4088-5785; Suravajhala, Prashanth N/0000-0002-8535-278X; 	y	y	Acknowledgments PK is thankful to VFSTR for providing Emeritus fellowship. All authors are life members of Bioclues.org, Indias largest bioinformatics professional society.	Abbas Y, 2020, ACS APPL NANO MATER, V3, P11383, DOI 10.1021/acsanm.0c02466; Abd El Wahed A, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0071642, 10.1371/currents.outbreaks.62df1c7c75ffc96cd59034531e2e8364]; Allen JWL, 2021, TRANSFUS CLIN BIOL, V28, P51, DOI 10.1016/j.tracli.2020.10.008; Almasi F, 2021, TRANSBOUND EMERG DIS, V68, P318, DOI 10.1111/tbed.13734; Andersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9; Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20; Ton AT, 2020, MOL INFORM, V39, DOI 10.1002/minf.202000028; [Anonymous], 2021, LANCET, V398, P725, DOI 10.1016/S0140-6736(21)01900-0; Apostolopoulos ID, 2020, PHYS ENG SCI MED, V43, P635, DOI 10.1007/s13246-020-00865-4; Arora N, 2020, FUTURE VIROL, V15, P717, DOI 10.2217/fvl-2020-0130; Atkins JL, 2020, J GERONTOL A-BIOL, V75, P2224, DOI 10.1093/gerona/glaa183; Augustine R, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9080182; Baig MH, 2016, CURR PHARM DESIGN, V22, P572, DOI 10.2174/1381612822666151125000550; Banu S., 2020, DISTRICT PHYLOGENETI, DOI [10.1101/2020.05.31.126136, DOI 10.1101/2020.05.31.126136]; Barstugan M., 2003, CORONAVIRUS COVID 19; Bassendine MF, 2020, J DIABETES, V12, P649, DOI 10.1111/1753-0407.13052; Beck BR, 2020, COMPUT STRUCT BIOTEC, V18, P784, DOI 10.1016/j.csbj.2020.03.025; Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463; Bianchi M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4389089; Biesalski HK, 2004, J NUTR, V134, p3453S, DOI 10.1093/jn/134.12.3453S; Bordallo B, 2020, ADV RHEUMATOL, V60, DOI 10.1186/s42358-020-00151-7; Bouchentouf S., 2020, MOL DOCKING STUDY, DOI 10.20944/preprints202004.0079.v1; Brigger D, 2021, ALLERGY, V76, P853, DOI 10.1111/all.14608; Broughton James P, 2020, medRxiv, DOI 10.1101/2020.03.06.20032334; Bullock J, 2020, J ARTIF INTELL RES, V69, P807; Bustin SA, 2005, J MOL ENDOCRINOL, V34, P597, DOI 10.1677/jme.1.01755; Cai XF, 2020, J INFECT DIS, V222, P189, DOI 10.1093/infdis/jiaa243; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Caparros-Gonzalez RA, 2020, REV ESP SALUD PUBLIC, V94; Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14; Chen JH, 2020, J MOL BIOL, V432, P5212, DOI 10.1016/j.jmb.2020.07.009; Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658; Chu DKW, 2011, J VIROL, V85, P12815, DOI 10.1128/JVI.05838-11; Ciaccio M, 2020, DIAGNOSIS, V7, P365, DOI 10.1515/dx-2020-0057; Ciotti M, 2020, CRIT REV CL LAB SCI, V57, P365, DOI 10.1080/10408363.2020.1783198; Crespo J, 2020, REV ESP ENFERM DIG, V112, P389, DOI 10.17235/reed.2020.7128/2020; Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9; Cyranoski D, 2021, NATURE, V589, P337, DOI 10.1038/d41586-021-00065-4; De Maio F, 2020, MICROBES INFECT, V22, P592, DOI 10.1016/j.micinf.2020.08.006; Deiman B, 2002, MOL BIOTECHNOL, V20, P163, DOI 10.1385/MB:20:2:163; Dhama K, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101830; Dinnes J, 2020, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD013705, 10.1002/14651858.CD013705.pub2]; Dofferhoff Anton S M, 2021, Clin Infect Dis, V73, pe4039, DOI 10.1093/cid/ciaa1258; Dong D, 2021, IEEE REV BIOMED ENG, V14, P16, DOI 10.1109/RBME.2020.2990959; Du LY, 2007, BIOCHEM BIOPH RES CO, V359, P174, DOI 10.1016/j.bbrc.2007.05.092; Dutta NK, 2020, J VIROL, V94, DOI 10.1128/JVI.00647-20; Elfiky AA, 2021, J BIOMOL STRUCT DYN, V39, P3204, DOI 10.1080/07391102.2020.1761882; Engelsen O, 2010, NUTRIENTS, V2, P482, DOI 10.3390/nu2050482; Evans D., 2008, VIRAL RECEPTORS, V3rd ed; Faccini-Martinez AA, 2020, INT J INFECT DIS, V101, P191, DOI 10.1016/j.ijid.2020.09.1451; Flower TG, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2021785118; Fogeron ML., 2021, SARS COV 2 ORF7B BAT, DOI [10.1101/2021.02.05.428650, DOI 10.1101/2021.02.05.428650]; Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027; Gabutti G, 2020, INFECT DIS THER, V9, P241, DOI 10.1007/s40121-020-00295-5; Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498; Gootenberg JS, 2017, SCIENCE, V356, P438, DOI 10.1126/science.aam9321; Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017; Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9; Greenhalgh T, 2021, LANCET, V397, P1603, DOI 10.1016/S0140-6736(21)00869-2; Guillon P, 2008, GLYCOBIOLOGY, V18, P1085, DOI 10.1093/glycob/cwn093; Gustine JN, 2021, AM J PATHOL, V191, P4, DOI 10.1016/j.ajpath.2020.08.009; Hall DC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101646; Harmer D, 2002, FEBS LETT, V532, P107, DOI 10.1016/S0014-5793(02)03640-2; HE X, 2020, NAT MED, V26, P672, DOI DOI 10.1038/S41591-020-0869-5; Helmy YA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041225; Heneghan C.J., 2021, F1000RESEARCH, V10, DOI [DOI 10.12688/F1000RESEARCH.52091.1, 10.12688/f1000research.52091.1]; Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102; Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191; Horvath D, 2020, MOL INFORM, V39, DOI 10.1002/minf.202000080; Howson ELA, 2017, J VIROL METHODS, V249, P102, DOI 10.1016/j.jviromet.2017.08.013; Hu JC, 2021, HUM GENOMICS, V15, DOI 10.1186/s40246-021-00306-7; Hussain S, 2005, J VIROL, V79, P5288, DOI 10.1128/JVI.79.9.5288-5295.2005; Jeong IK, 2020, DIABETES RES CLIN PR, V166, DOI 10.1016/j.diabres.2020.108303; Ji TX, 2020, BIOSENS BIOELECTRON, V166, DOI 10.1016/j.bios.2020.112455; Kang SS, 2020, ACTA PHARM SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009; Keightley MC, 2005, J MED VIROL, V77, P602, DOI 10.1002/jmv.20498; Kellner MJ, 2019, NAT PROTOC, V14, P2986, DOI 10.1038/s41596-019-0210-2; Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682; Koczula KM, 2016, ESSAYS BIOCHEM, V60, P111, DOI 10.1042/EBC20150012; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0; Lee JG, 2021, CELL BIOSCI, V11, DOI 10.1186/s13578-021-00568-7; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Leung CW, 2004, PEDIATRICS, V113, pE535, DOI 10.1542/peds.113.6.e535; Leung PC, 2007, AM J CHINESE MED, V35, P575, DOI 10.1142/S0192415X07005077; Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14; Li JY, 2020, BRIT J HAEMATOL, V190, P24, DOI 10.1111/bjh.16797; Li L, 2020, RADIOLOGY, V296, pE65, DOI 10.1148/radiol.2020200905; Li YF, 2020, J MED VIROL, V92, P903, DOI 10.1002/jmv.25786; Li Y, 2014, J BIOL CHEM, V289, P12535, DOI 10.1074/jbc.M114.560094; Li ZJ, 2019, ELIFE, V8, DOI 10.7554/eLife.51230; Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125; Liu DX, 2014, ANTIVIR RES, V109, P97, DOI 10.1016/j.antiviral.2014.06.013; Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328; MACLAUGHLIN J, 1985, J CLIN INVEST, V76, P1536, DOI 10.1172/JCI112134; Maghdid Halgurd S, 2020, SN Comput Sci, V1, P271, DOI 10.1007/s42979-020-00290-0; Malas MB, 2020, ECLINICALMEDICINE, V29-30, DOI 10.1016/j.eclinm.2020.100639; Manigandan S, 2020, PROCESS BIOCHEM, V98, P233, DOI 10.1016/j.procbio.2020.08.016; Martineau AR, 2020, LANCET DIABETES ENDO, V8, P735, DOI 10.1016/S2213-8587(20)30268-0; Miorin L, 2020, P NATL ACAD SCI USA, V117, P28344, DOI 10.1073/pnas.2016650117; Mohamadou Y, 2020, APPL INTELL, V50, P3913, DOI 10.1007/s10489-020-01770-9; Mousavizadeh L, 2021, J MICROBIOL IMMUNOL, V54, P159, DOI 10.1016/j.jmii.2020.03.022; Mu JF, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-00208-3; Mu JF, 2020, SCI CHINA LIFE SCI, V63, P1413, DOI 10.1007/s11427-020-1692-1; Muniz-Diaz E, 2021, BLOOD TRANSFUS-ITALY, V19, P54, DOI 10.2450/2020.0256-20; Muralidharan N, 2021, J BIOMOL STRUCT DYN, V39, P2673, DOI 10.1080/07391102.2020.1752802; Mwalili S, 2020, BMC RES NOTES, V13, DOI 10.1186/s13104-020-05192-1; Naude W, 2020, AI SOC, V35, P761, DOI 10.1007/s00146-020-00978-0; Nelson CA, 2005, STRUCTURE, V13, P75, DOI 10.1016/j.str.2004.10.010; Nicol T, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104511; Niesters HGM, 2002, J CLIN VIROL, V25, pS3; Oster AM, 2020, MMWR-MORBID MORTAL W, V69, P1127, DOI 10.15585/mmwr.mm6933e2; Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6; Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370; Patel A, 2022, J BIOMOL STRUCT DYN, V40, P5138, DOI 10.1080/07391102.2020.1868338; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272; Pieri M, 2020, CLIN CHIM ACTA, V511, P28, DOI 10.1016/j.cca.2020.09.033; Prietl B, 2013, NUTRIENTS, V5, P2502, DOI 10.3390/nu5072502; Rabi FA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030231; Ragnesola B, 2020, BMC RES NOTES, V13, DOI 10.1186/s13104-020-05212-0; Rahman MS, 2021, GENE REP, V22, DOI 10.1016/j.genrep.2020.100997; Rakedzon S, 2020, RAMBAM MAIMONIDES ME, V11, DOI 10.5041/RMMJ.10416; Randhawa GS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246465; Randhawa P.K., 2020, FRONT PHYSIOL, V11, P611275, DOI [10.3389/fphys.2020.611275, DOI 10.3389/fphys.2020.611275]; Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743; Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722; Ren W, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.589714; Roh JS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e27; Rossi GA, 2020, INFECTION, V48, P665, DOI 10.1007/s15010-020-01486-5; Ryu S, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06204-6; Sahoo PR, 2016, VET WORLD, V9, P465, DOI 10.14202/vetworld.2016.465-469; Sanjuan R, 2016, CELL MOL LIFE SCI, V73, P4433, DOI 10.1007/s00018-016-2299-6; Santosh KC, 2020, J MED SYST, V44, DOI 10.1007/s10916-020-01562-1; Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0; Scohy A, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104455; Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652; Shanmugarajan D, 2020, RSC ADV, V10, P31385, DOI 10.1039/d0ra03167d; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shao JM, 2020, COLORECTAL DIS, V22, P993, DOI 10.1111/codi.15252; Sharma AK, 2020, INDIAN J PUBLIC HLTH, V64, P132, DOI 10.4103/ijph.IJPH_466_20; Sharma S, 2022, J QUAL ASSUR HOSP TO, V23, P539, DOI 10.1080/1528008X.2021.1891597; Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653; Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005; Shi ST, 2005, CURR TOP MICROBIOL, V287, P95, DOI 10.1007/3-540-26765-4_4; Shi TT, 2018, BIOCHEM BIOPH RES CO, V495, P860, DOI 10.1016/j.bbrc.2017.11.055; Shree P, 2022, J BIOMOL STRUCT DYN, V40, P190, DOI 10.1080/07391102.2020.1810778; Shukla N, 2021, PHYSIOL GENOMICS, V53, P433, DOI 10.1152/physiolgenomics.00075.2021; Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594; Singh KK, 2020, AM J PHYSIOL-CELL PH, V319, pC258, DOI 10.1152/ajpcell.00224.2020; Siu KL, 2009, J BIOL CHEM, V284, P16202, DOI 10.1074/jbc.M109.008227; Soares F., 2020, NOVEL HIGH SPECIFICI, P2020, DOI [10.1101/2020.04.10.20061036, DOI 10.1101/2020.04.10.20061036]; Song G, 2020, MYCOPATHOLOGIA, V185, P599, DOI 10.1007/s11046-020-00462-9; Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059; Subsoontorn P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-79237-7; Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722; Tadic M, 2020, J CLIN HYPERTENS, V22, P943, DOI 10.1111/jch.13912; Tan YX, 2007, J VIROL, V81, P6346, DOI 10.1128/JVI.00090-07; Tang A, 2020, EMERG INFECT DIS, V26, P1337, DOI 10.3201/eid2606.200301; Tang XC, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-52; Taylor JK, 2015, J VIROL, V89, P11820, DOI 10.1128/JVI.02274-15; Tsai YC, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030366; Turcios-Casco MA, 2020, BIODIVERS CONSERV, V29, P3829, DOI 10.1007/s10531-020-02053-y; Vaidyanathan G, 2021, NATURE, V593, P321, DOI 10.1038/d41586-021-01274-7; Vaishya R, 2020, DIABETES METAB SYND, V14, P337, DOI 10.1016/j.dsx.2020.04.012; Verma A, 2020, INT J RADIAT BIOL, V96, P1323, DOI 10.1080/09553002.2020.1818865; Vijaykrishna D, 2007, J VIROL, V81, P4012, DOI 10.1128/JVI.02605-06; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762; Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786; Wong SH, 2020, J GASTROEN HEPATOL, V35, P744, DOI 10.1111/jgh.15047; Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11; Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803; Wu BB, 2020, INFECT GENET EVOL, V84, DOI 10.1016/j.meegid.2020.104485; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Wu J, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01576; Wu KL, 2009, P NATL ACAD SCI USA, V106, P19970, DOI 10.1073/pnas.0908837106; Wu KE, 2020, CELL SYST, V11, P102, DOI 10.1016/j.cels.2020.06.008; Wu QX, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe5054; Xia SM, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0175-x; Xiang J., 2020, EVALUATION ENZYME LI, DOI [10.1101/2020.02.27.20028787, DOI 10.1101/2020.02.27.20028787]; Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055; Xie MX, 2020, INT J INFECT DIS, V94, P119, DOI 10.1016/j.ijid.2020.03.071; Xie YX, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.591873; Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]; Yin CC, 2020, GENOMICS, V112, P3588, DOI 10.1016/j.ygeno.2020.04.016; Yoshimoto FK, 2020, PROTEIN J, V39, P198, DOI 10.1007/s10930-020-09901-4; Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204; Yu B, 2021, CELL METAB, V33, P65, DOI 10.1016/j.cmet.2020.11.014; Yu F, 2020, MICROBES INFECT, V22, P74, DOI 10.1016/j.micinf.2020.01.003; Yu R, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106012; Zainol Rashid Z, 2020, MALAYS J PATHOL, V42, P13; Zhang D, 2013, INT J MOL MED, V32, P203, DOI 10.3892/ijmm.2013.1353; Zhang GZ, 2021, TRANSBOUND EMERG DIS, V68, P1097, DOI 10.1111/tbed.13791; Zhang W, 2020, EMERG MICROBES INFEC, V9, DOI 10.1080/22221751.2020.1729071; Zhang Y, 2020, BIORXIV, DOI [10.1101/2020.05.24.111823, DOI 10.1101/2020.05.24.111823]; Zhang Y, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000022040; Zhao J, 2021, CLIN INFECT DIS, V73, P328, DOI 10.1093/cid/ciaa1150; Zhao J, 2009, J VIROL, V83, P2368, DOI 10.1128/JVI.02371-08; Zhao ZM, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-21; Zhou P, 2021, SCIENCE, V371, P120, DOI 10.1126/science.abf6097; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3; Zietz M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19623-x	208	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 20	2021	12								724914	10.3389/fimmu.2021.724914	http://dx.doi.org/10.3389/fimmu.2021.724914			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WU5VL	34745097	Green Published, gold			2022-12-18	WOS:000716613100001
J	Liang, SY; Wang, MS; Zhang, B; Feng, YL; Tang, J; Xie, M; Huang, W; Zhang, Q; Zhang, DB; Hou, SS				Liang, Suyun; Wang, Ming-Shan; Zhang, Bo; Feng, Yulong; Tang, Jing; Xie, Ming; Huang, Wei; Zhang, Qi; Zhang, Dabing; Hou, Shuisheng			NOD1 Is Associated With the Susceptibility of Pekin Duck Flock to Duck Hepatitis A Virus Genotype 3	FRONTIERS IN IMMUNOLOGY			English	Article						Pekin duck; DHAV-3; NOD1; genome-wide association studies; transcriptome	GENETIC-RESISTANCE; MAREKS-DISEASE; INNATE; GENOME	Duck viral hepatitis (DVH) is an acute, highly lethal infectious disease of ducklings that causes huge losses in the duck industry. Duck hepatitis A virus genotype 3 (DHAV-3) has been one of the most prevalent DVH pathogen in the Asian duck industry in recent years. Here, we investigated the genetic basis of the resistance and susceptibility of ducks to DVH by comparing the genomes and transcriptomes of a resistant Pekin duck flock (Z8) and a susceptible Pekin duck flock (SZ7). Our comparative genomic and transcriptomic analyses suggested that NOD1 showed a strong signal of association with DVH susceptibility in ducks. Then, we found that NOD1 showed a significant expression difference between the livers of susceptible and resistant individuals after infection with DHAV-3, with higher expression in the SZ7 flock. Furthermore, suppression and overexpression experiments showed that the number of DHAV-3 genomic copies in primary duck hepatocytes was influenced by the expression level of NOD1. In addition, in situ RNAscope analysis showed that the localization of NOD1 and DHAV-3 in liver cells was consistent. Altogether, our data suggested that NOD1 was likely associated with DHAV-3 susceptibility in ducks, which provides a target for future investigations of the pathogenesis of DVH.	[Liang, Suyun; Zhang, Bo; Feng, Yulong; Tang, Jing; Xie, Ming; Huang, Wei; Zhang, Qi; Hou, Shuisheng] Chinese Acad Agr Sci, Inst Anim Sci, Key Lab Anim Poultry Genet Breeding & Reprod, Minist Agr & Rural Affairs, Beijing, Peoples R China; [Liang, Suyun; Zhang, Dabing] China Agr Univ, Coll Vet Med, Key Lab Anim Epidemiol, Minist Agr, Beijing, Peoples R China; [Wang, Ming-Shan] Univ Calif Santa Cruz, Howard Hughes Med Inst, Santa Cruz, CA USA	Chinese Academy of Agricultural Sciences; Institute of Animal Science, CAAS; Ministry of Agriculture & Rural Affairs; China Agricultural University; Ministry of Agriculture & Rural Affairs; Howard Hughes Medical Institute; University of California System; University of California Santa Cruz	Hou, SS (corresponding author), Chinese Acad Agr Sci, Inst Anim Sci, Key Lab Anim Poultry Genet Breeding & Reprod, Minist Agr & Rural Affairs, Beijing, Peoples R China.	houss@263.net		Wang, Ming-Shan/0000-0003-4663-2735	National Natural Science Foundation of China [31772592]; China Agriculture Research System of MOF and MARA [CARS-42]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Agriculture Research System of MOF and MARA(Ministry of Oceans & Fisheries (MOF), Republic of Korea)	This work was supported by the National Natural Science Foundation of China (31772592) and the China Agriculture Research System of MOF and MARA (CARS-42).	[Anonymous], 2011, VIRUS TAXONOMY CLASS; Boyle JP, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00317; Bradbury PJ, 2007, BIOINFORMATICS, V23, P2633, DOI 10.1093/bioinformatics/btm308; Cao JT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.568565; Caruso R, 2014, IMMUNITY, V41, P898, DOI 10.1016/j.immuni.2014.12.010; Chen Y, 2021, VIRULENCE, V12, P45, DOI 10.1080/21505594.2020.1864136; Danecek P, 2011, BIOINFORMATICS, V27, P2156, DOI 10.1093/bioinformatics/btr330; Del Vesco AP, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63074-9; Fan YH, 2016, P NATL ACAD SCI USA, V113, pE7818, DOI 10.1073/pnas.1611711113; Fang H, 2020, DEV COMP IMMUNOL, V112, DOI 10.1016/j.dci.2020.103769; Fu Y, 2008, VET MICROBIOL, V131, P247, DOI 10.1016/j.vetmic.2008.03.011; Guo X, 2021, ZOOL RES, V42, P43, DOI 10.24272/j.issn.2095-8137.2020.133; Huang YH, 2013, NAT GENET, V45, P776, DOI 10.1038/ng.2657; Doan HTT, 2016, J INFECT DEV COUNTR, V10, P988, DOI 10.3855/jidc.7239; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Iotsov S, 1981, Vet Med Nauki, V18, P43; Kang HM, 2010, NAT GENET, V42, P348, DOI 10.1038/ng.548; Keestra-Gounder AM, 2017, TRENDS IMMUNOL, V38, P758, DOI 10.1016/j.it.2017.07.004; Kersse K, 2011, CYTOKINE GROWTH F R, V22, P257, DOI 10.1016/j.cytogfr.2011.09.003; Knowles NJ, 2012, VIRUS TAXONOMY CLASS, P855, DOI DOI 10.1016/B978-0-12-384684-6.00074-4; LEE LF, 1981, J NATL CANCER I, V66, P789; Liang SY, 2020, VET MICROBIOL, V248, DOI 10.1016/j.vetmic.2020.108813; Liang SY, 2020, GENE, V748, DOI 10.1016/j.gene.2020.144710; Lin SL, 2016, ARCH VIROL, V161, P405, DOI 10.1007/s00705-015-2648-z; Lippert C, 2011, NAT METHODS, V8, P833, DOI [10.1038/nmeth.1681, 10.1038/NMETH.1681]; MAAS HJL, 1981, AVIAN PATHOL, V10, P137, DOI 10.1080/03079458108418468; Moreira LO, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00328; MORRISROE LS, 1976, AUST VET J, V52, P215, DOI 10.1111/j.1751-0813.1976.tb00069.x; Mukherjee T, 2019, ARCH BIOCHEM BIOPHYS, V670, P69, DOI 10.1016/j.abb.2018.12.022; Netea MG, 2019, CELL HOST MICROBE, V25, P13, DOI 10.1016/j.chom.2018.12.006; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Patel RK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030619; Sabbah A, 2009, NAT IMMUNOL, V10, P1073, DOI 10.1038/ni.1782; Soliman M, 2015, ARCH VIROL, V160, P493, DOI 10.1007/s00705-014-2264-3; Song SS, 2019, VACCINE, V37, P4364, DOI 10.1016/j.vaccine.2019.06.026; TAJIMA F, 1983, GENETICS, V105, P437; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Vegna S, 2016, J VIROL, V90, P6022, DOI 10.1128/JVI.03230-15; Wang MH, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1904-y; Wang XY, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01128; Woolcock P. R., 2013, DIS POULTRY, P422, DOI DOI 10.1002/9781119421481; WOOLCOCK PR, 1986, AVIAN PATHOL, V15, P75, DOI 10.1080/03079458608436267; Wu FY, 2020, VACCINE, V38, P4695, DOI 10.1016/j.vaccine.2020.05.030; Zhou ZK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04868-4	45	1	1	11	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 20	2021	12								766740	10.3389/fimmu.2021.766740	http://dx.doi.org/10.3389/fimmu.2021.766740			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WU6GE	34745142	Green Published, gold			2022-12-18	WOS:000716641100001
J	Zhong, AY; Chen, T; Xing, YF; Pan, X; Shi, MH				Zhong, Anyuan; Chen, Ting; Xing, Yufei; Pan, Xue; Shi, Minhua			FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						FUCA2; prognosis; tumor associated macrophages; immunosuppressive microenvironment; pan-cancer	ALPHA-L-FUCOSIDASE; FEATURES; INNATE	Background: The expression of Fucosidase, alpha-L-2 (FUCA2) varies across tumors. However, its role in various tumor types and relationship with the tumor immune microenvironment (TIME) is poorly defined. Methods: We analyzed profiles of FUCA2 expression using datasets from The Cancer Genome Atlas (TOGA) and Genotype-Tissue Expression (GTEx) databases. Next, gene alteration, clinical characteristics and prognostic values of FUCA2 were elucidated based on TCGA pan-cancer data. This was followed by gene set enrichment analysis by R software. Relationships between FUCA2 expression and immune infiltration and immunerelated genes were also evaluated. Moreover, the association of immune cell infiltration with FUCA2 expression was evaluated across three different sources of immune cell infiltration data, namely the TIMER online, ImmuCellAl databases, as well as a published study. In addition, MTT assays was also conducted to validate the oncogene role of FUCA2 in lung cancer cells. Results: FUCA2 was upregulated in most tumors, and this was significantly associated with poor survival rates. Gene set enrichment analysis uncovered that FUCA2 correlated with immune pathways in different tumor types. FUCA2 expression was positively related to tumor associated macrophages (TAMs), especially M2-like TAMs. Moreover, FUCA2 level showed a positive relationship with most immunosuppression genes, including programmed death-ligand 1 (PD-L1), transforming growth factor beta 1 (TGFB1), and interleukin-10 (IL10) in most cancer types. FUCA2 knockdown inhibited the cell viability in lung cancer cells. Conclusions: Our study reveals that FUCA2 is a potential oncogene and is indicative biomarker of a worse prognosis in pan-cancer. High FUCA2 expression may contribute to increased infiltration of TAMs and associates with an immunosuppressive microenvironment, providing a potential target for tumor therapy.	[Zhong, Anyuan; Chen, Ting; Xing, Yufei; Pan, Xue; Shi, Minhua] Soochow Univ, Affiliated Hosp 2, Dept Pulm & Crit Care Med, Suzhou, Peoples R China	Soochow University - China	Shi, MH (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Pulm & Crit Care Med, Suzhou, Peoples R China.	shiminhua@163.com			Science Preresearch Foundation of the Second Affiliated Hospital of Soochow University [SDFEYQN1909]; Youth Science and Education Program of Suzhou [KJXW2020018]; Capacity improvement of respiratory clinical trial institutions in the Second Affiliated Hospital of Soochow University [SLT201930]; Competitive discipline lift project of the Second Affiliated Hospital of Soochow University [XKTJ-XK202007]	Science Preresearch Foundation of the Second Affiliated Hospital of Soochow University; Youth Science and Education Program of Suzhou; Capacity improvement of respiratory clinical trial institutions in the Second Affiliated Hospital of Soochow University; Competitive discipline lift project of the Second Affiliated Hospital of Soochow University	This work was supported by grants from the Science Preresearch Foundation of the Second Affiliated Hospital of Soochow University (grant number SDFEYQN1909), Youth Science and Education Program of Suzhou ( grant number KJXW2020018), Capacity improvement of respiratory clinical trial institutions in the Second Affiliated Hospital of Soochow University ( grant number SLT201930) and Competitive discipline lift project of the Second Affiliated Hospital of Soochow University (grant number XKTJ-XK202007).	Andre F, 2014, ANN ONCOL, V25, P2295, DOI 10.1093/annonc/mdu478; Armitage JD, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010056; Barger CJ, 2019, CANCERS, V11, DOI 10.3390/cancers11020251; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Cendrowicz E, 2021, CANCERS, V13, DOI 10.3390/cancers13081946; Cordero OJ, 2001, EUR J BIOCHEM, V268, P3321, DOI 10.1046/j.1432-1327.2001.02237.x; da Silva PHR, 2021, CYTOKINE, V144, DOI 10.1016/j.cyto.2021.155548; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gangoso E, 2021, CELL, V184, P2454, DOI 10.1016/j.cell.2021.03.023; Gao AQ, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-001536; Garassino MC, 2020, LANCET ONCOL, V21, P387, DOI [10.1016/51470-2045(19)30301-0, 10.1016/S1470-2045(19)30801-0]; Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Johnson A, 2017, ONCOLOGIST, V22, P1478, DOI 10.1634/theoncologist.2017-0242; Krutsenko Y, 2021, CANCERS, V13, DOI 10.3390/cancers13081830; Li HJ, 2019, CELL, V176, P775, DOI 10.1016/j.cell.2018.11.043; Liu TW, 2009, P NATL ACAD SCI USA, V106, P14581, DOI 10.1073/pnas.0903286106; Ma XS, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01264-9; Nelson MA, 2021, CANCER METAST REV, V40, P519, DOI 10.1007/s10555-021-09968-0; Nishino M, 2017, NAT REV CLIN ONCOL, V14, P655, DOI 10.1038/nrclinonc.2017.88; Rundqvist H, 2020, ELIFE, V9, DOI 10.7554/eLife.59996; Thorsson V, 2019, IMMUNITY, V51, P411, DOI 10.1016/j.immuni.2019.08.004; Waidely E, 2017, ANAL CHEM, V89, P9459, DOI 10.1021/acs.analchem.7b02284; Woo SR, 2015, ANNU REV IMMUNOL, V33, P445, DOI 10.1146/annurev-immunol-032414-112043; Ye YQ, 2019, NAT METAB, V1, P431, DOI 10.1038/s42255-019-0045-8; Yu GC, 2016, MOL BIOSYST, V12, P477, DOI 10.1039/c5mb00663e; Yu H, 2021, HEPATOLOGY, V74, P1952, DOI 10.1002/hep.31870; Zeng F, 2021, ONCOLOGIST, V26, pE1460, DOI 10.1002/onco.13750	29	1	1	5	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 20	2021	12								758648	10.3389/fimmu.2021.758648	http://dx.doi.org/10.3389/fimmu.2021.758648			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YN5EM	34745134	Green Published, gold			2022-12-18	WOS:000747281800001
J	Boniche-Alfaro, C; Kischkel, B; Thomaz, L; Carvalho-Gomes, MM; Lopes-Bezerra, LM; Nosanchuk, JD; Taborda, CP				Boniche-Alfaro, Camila; Kischkel, Brenda; Thomaz, Luciana; Carvalho-Gomes, Monique Maria; Lopes-Bezerra, Leila M.; Nosanchuk, Joshua Daniel; Taborda, Carlos Pelleschi			Antibody- Based Immunotherapy Combined With Antimycotic Drug TMP- SMX to Treat Infection With Paracoccidioides brasiliensis	FRONTIERS IN IMMUNOLOGY			English	Article						antibody therapy; monoclonal antibodies; immunotherapy; fungal cell wall glycoconjugates; infectious diseases; systemic mycosis; paracoccidioidomycosis	FUNGAL CELL-WALL; MONOCLONAL-ANTIBODIES; CRYPTOCOCCUS-NEOFORMANS; GENE-EXPRESSION; MICE; GLUCAN; GLYCOPROTEIN	Monoclonal antibodies (mAbs) are promising alternatives to treat infectious diseases, especially given their potential for applications in combination therapies with antimicrobial drugs to enhance the antifungal efficacy. Protection mediated by mAbs used to treat experimental paracoccidioidomycosis (PCM) has been demonstrated previously. Our aim in the present work was to characterize a monoclonal antibody (mAbF1.4) raised against a cell wall glycoconjugate fraction of Paracoccidioides spp. and to analyze its efficacy combined with trimethoprim-sulfamethoxazole (TMP/SMX) as treatment for experimental PCM. We demonstrated that the epitope recognized by mAbF1.4 is consistent with branched glucose residues present on a cell wall beta-glucan polymer. In vitro, mAbF1.4 increased the phagocytic capacity and nitric oxide concentration induced by the macrophage cell line J774.1A, and this resulted in a significant reduction in the viability of the opsonophagocytized yeasts. In vivo, we detected a significant reduction in pulmonary fungal burdens of mice treated with mAbF1.4 in association with TMP/SMX, which correlated with increased pulmonary concentrations (determined by ELISA) of IFN- gamma, TNF-alpha, IL-10 and IL-17. In parallel, we observed a decrease in IL-4, suggesting that the treatment was associated with a mixed Th1-Th17 type immune response. Histopathology of lung segments from mice receiving the combination therapy showed a significant reduction in granulomas, which were well-defined, and improved maintenance of lung architecture. These findings demonstrate that mAbF1.4 + TMP/SMX therapy is a promising approach to combat PCM as well as decrease disease sequelae and highlights the potential benefits of immune mediators in PCM combined immunotherapy.</p>	[Boniche-Alfaro, Camila; Kischkel, Brenda; Thomaz, Luciana; Carvalho-Gomes, Monique Maria; Lopes-Bezerra, Leila M.; Taborda, Carlos Pelleschi] Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, Sao Paulo, Brazil; [Lopes-Bezerra, Leila M.] Univ Sao Paulo, Ctr Inovacao Empreendedorismo & Tecnol CIETEC, BIDiagnost, Sao Paulo, Brazil; [Nosanchuk, Joshua Daniel] Albert Einstein Coll Med, Dept Med Microbiol & Immunol, Div Infect Dis, New York, NY USA; [Taborda, Carlos Pelleschi] Univ Sao Paulo, Sch Med, Inst Trop Med Sao Paulo, Dept Dermatol,Lab Med Mycol, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Yeshiva University; Universidade de Sao Paulo	Boniche-Alfaro, C; Taborda, CP (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, Sao Paulo, Brazil.; Taborda, CP (corresponding author), Univ Sao Paulo, Sch Med, Inst Trop Med Sao Paulo, Dept Dermatol,Lab Med Mycol, Sao Paulo, Brazil.	bonichecamila@gmail.com; taborda@usp.br		Boniche- Alfaro, Camila/0000-0001-5901-4886; KISCHKEL, BRENDA/0000-0001-6963-1001				Ademe M, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00469; Albuquerque PC, 2012, FUNGAL GENET BIOL, V49, P943, DOI 10.1016/j.fgb.2012.09.002; Arroyo J, 2016, CELL MICROBIOL, V18, P1239, DOI 10.1111/cmi.12615; Baltazar LM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25665-5; Baltazar LM, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00085-15; Biswas PS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.671068; Boniche C, 2020, J FUNGI, V6, DOI 10.3390/jof6010031; Bueno RA, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00074; Buissa-Filho R, 2008, INFECT IMMUN, V76, P3321, DOI 10.1128/IAI.00349-08; Burnet MC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020269; Camacho E, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/5313691; Puerta-Arias JD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163985; de Oliveira HC, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01319; DESTGROTH SF, 1980, J IMMUNOL METHODS, V35, P1, DOI 10.1016/0022-1759(80)90146-5; Francoise S, 2010, MED MYCOL, V48, P35, DOI 10.3109/13693780802713356; Gonzalez A, 2020, J FUNGI, V6, DOI 10.3390/jof6040217; Grosso DD, 2003, INFECT IMMUN, V71, P6534, DOI 10.1128/IAI.71.11.6534-6542.2003; Huang HB, 2010, MBIO, V1, DOI 10.1128/mBio.00164-10; Kang X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05199-0; Kaplon H, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2019.1703531; KASHINO SS, 1995, MYCOPATHOLOGIA, V130, P131, DOI 10.1007/BF01103095; Krylov Vadim B, 2020, Drug Discov Today Technol, V35-36, P35, DOI 10.1016/j.ddtec.2020.11.002; Lopes-Bezerra LM, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006169; Martinez R, 2017, J FUNGI, V3, DOI 10.3390/jof3010001; McClelland EE, 2012, FUNGAL GENET BIOL, V49, P227, DOI 10.1016/j.fgb.2012.01.006; McClelland EE, 2010, J CLIN INVEST, V120, P1355, DOI 10.1172/JCI38322; Motley MP, 2019, CURR OPIN INFECT DIS, V32, P210, DOI 10.1097/QCO.0000000000000539; Nimrichter L, 2005, MICROBES INFECT, V7, P789, DOI 10.1016/j.micinf.2005.03.002; Souza ACO, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02445; Parente-Rocha JA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137619; Pinto MR, 2008, BRAZ J MICROBIOL, V39, P195, DOI 10.1590/S1517-83822008000200001; Pitarch A, 2002, MOL CELL PROTEOMICS, V1, P967, DOI 10.1074/mcp.M200062-MCP200; PUCCIA R, 1991, ARCH BIOCHEM BIOPHYS, V289, P298, DOI 10.1016/0003-9861(91)90475-X; Puccia R., 2017, CURR PROTEIN PEPT SC, V18, P1, DOI [10.2174/1389203717666160812, DOI 10.2174/1389203717666160812]; Puccia R, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00257; Dos Santos SR, 2020, J FUNGI, V6, DOI 10.3390/jof6030160; Rosas AL, 2001, INFECT IMMUN, V69, P3410, DOI 10.1128/IAI.69.5.3410-3412.2001; Rydahl MG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04307-2; Shikanai-Yasuda MA, 2017, REV SOC BRAS MED TRO, V50, P715, DOI 10.1590/0037-8682-0230-2017; Shikanai-Yasuda MA, 2015, REV INST MED TROP SP, V57, P31, DOI 10.1590/S0036-46652015000700007; Shokri H, 2008, NAT PROD RES, V22, P414, DOI 10.1080/14786410701591622; Silva LBR, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01057; Soto ER, 2008, BIOCONJUGATE CHEM, V19, P840, DOI 10.1021/bc700329p; Strohl WR, 2018, PROTEIN CELL, V9, P86, DOI 10.1007/s13238-017-0457-8; Taborda CP, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01743; Taborda CP, 1998, INFECT IMMUN, V66, P786, DOI 10.1128/IAI.66.2.786-793.1998; Thomaz L, 2014, MICROBES INFECT, V16, P788, DOI 10.1016/j.micinf.2014.08.004; Torosantucci A, 2005, J EXP MED, V202, P597, DOI 10.1084/jem.20050749; Travassos LR, 2008, EXPERT REV ANTI-INFE, V6, P251, DOI 10.1586/14787210.6.2.251; Travassos LR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00224; Travassos LR, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00212; Turissini DA, 2017, FUNGAL GENET BIOL, V106, P9, DOI 10.1016/j.fgb.2017.05.007; Ulrich S, 2020, J FUNGI, V6, DOI 10.3390/jof6010022; van Huijsduijnen RH, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0007860; Vink E, 2004, YEAST, V21, P1121, DOI 10.1002/yea.1156; Waszkiewicz-Robak B., 2013, LIPID METABOLISM, P261, DOI [10.5772/51530, DOI 10.5772/51530]; Xander P, 2007, MICROBES INFECT, V9, P1484, DOI 10.1016/j.micinf.2007.08.001	57	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 19	2021	12								725882	10.3389/fimmu.2021.725882	http://dx.doi.org/10.3389/fimmu.2021.725882			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT4GW	34737741	gold, Green Published			2022-12-18	WOS:000715825400001
J	Jarvis, EM; Collings, S; Authier-Hall, A; Dasyam, N; Luey, B; Nacey, J; Painter, GF; Delahunt, B; Hermans, IF; Weinkove, R				Jarvis, Ellie-May; Collings, Shaun; Authier-Hall, Astrid; Dasyam, Nathaniel; Luey, Brendan; Nacey, John; Painter, Gavin F.; Delahunt, Brett; Hermans, Ian F.; Weinkove, Robert			Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Article						prostate cancer; mucosal-associated invariant T cells; MR1 protein; PD-1 protein; human; pembrolizumab; natural killer T-cells; gamma delta T cells	DOUBLE-BLIND; IPILIMUMAB; PLACEBO; TRIAL	Prostate cancer is the second most common cancer in men worldwide. Despite an abundance of prostate-specific antigens, immunotherapies have yet to become a standard of care, potentially limited by T-cell dysfunction. Up to 10% of human circulating T-cells, and a significant fraction in the urogenital tract, are mucosal-associated invariant T (MAIT) cells. MAIT cells express stereotyped T-cell receptors that recognize riboflavin metabolites derived from microbes presented by MR-1. We evaluated the number, phenotype and function of circulating MAIT cells, alongside two other innate-like T (ILT) -cell subsets, in men with prostate cancer and age- and sex-matched controls. MAIT cells in men with prostate cancer circulated at similar frequencies to controls, but their cytokine production and proliferation was impaired. In contrast, the function of two other ILT-cell populations (natural killer T-cells and V gamma 9V delta 2 T-cells) was not impaired. In both patients and controls, MAIT cells expressed high levels of the immune checkpoint molecule PD-1 at rest, while upregulation of PD-1 in response to the MR-1 ligand 5-amino-6D-ribitylaminouracil (5-A-RU) was greater in patients. 5-A-RU also induced upregulation of PD-L1 and -L2 RNA in primary mononuclear cells. We confirmed that circulating MAIT cell number and function were preserved before and during anti-PD1 therapy with pembrolizumab in a cohort of patients with melanoma. In vitro, 5-A-RU enhanced mononuclear cell cytotoxicity against the PD-L1 positive prostate cancer cell line PC3 in an MR-1-dependent manner. Addition of pembrolizumab enhanced this cytotoxicity, and was associated with increased MAIT cell expression of CD107a and IFN-gamma. We conclude that prostate cancer is associated with MAIT-cell dysfunction, and that this might be overcome through the application of potent MR-1 ligands with PD-1 blockade. These findings may have implications for the development of cancer immunotherapies that exploit MAIT cells.</p>	[Jarvis, Ellie-May; Collings, Shaun; Authier-Hall, Astrid; Dasyam, Nathaniel; Hermans, Ian F.; Weinkove, Robert] Malaghan Inst Med Res, Canc Immunotherapy Programme, Wellington, New Zealand; [Jarvis, Ellie-May; Collings, Shaun; Luey, Brendan; Weinkove, Robert] Capital & Coast Dist Hlth Board, Wellington Blood & Canc Ctr, Wellington, New Zealand; [Jarvis, Ellie-May; Delahunt, Brett; Weinkove, Robert] Univ Otago Wellington, Dept Pathol & Mol Med, Wellington, New Zealand; [Nacey, John] Univ Otago Wellington, Dept Surg & Anaesthesia, Wellington, New Zealand; [Painter, Gavin F.] Victoria Univ Wellington, Ferrier Res Inst, Wellington, New Zealand; [Painter, Gavin F.; Hermans, Ian F.] Maurice Wilkins Ctr, Immunooncol Programme, Auckland, New Zealand	Malaghan Institute; Victoria University Wellington; University of Otago; University of Otago; Victoria University Wellington	Weinkove, R (corresponding author), Malaghan Inst Med Res, Canc Immunotherapy Programme, Wellington, New Zealand.; Weinkove, R (corresponding author), Capital & Coast Dist Hlth Board, Wellington Blood & Canc Ctr, Wellington, New Zealand.; Weinkove, R (corresponding author), Univ Otago Wellington, Dept Pathol & Mol Med, Wellington, New Zealand.	rweinkove@malaghan.org.nz	Weinkove, Robert/S-4457-2019; Weinkove, Robert/I-6991-2012	Weinkove, Robert/0000-0003-3645-7988; Weinkove, Robert/0000-0003-3645-7988				Ali Tahir SM, 2001, J IMMUNOL, V167, P4046; Amini A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.584521; Anker JF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03900-x; Antonarakis ES, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01638; Beer TM, 2017, J CLIN ONCOL, V35, P40, DOI 10.1200/JCO.2016.69.1584; Beer TM, 2011, CLIN CANCER RES, V17, P4558, DOI 10.1158/1078-0432.CCR-10-3223; Boettcher AN, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00884; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Cui Y, 2015, J CLIN INVEST, V125, P4171, DOI 10.1172/JCI82424; Culp MB, 2020, EUR UROL, V77, P38, DOI 10.1016/j.eururo.2019.08.005; De Biasi S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21928-4; Dias J, 2016, J LEUKOCYTE BIOL, V100, P233, DOI 10.1189/jlb.4TA0815-391RR; Duan M, 2019, CLIN CANCER RES, V25, P3304, DOI 10.1158/1078-0432.CCR-18-3040; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fay EK, 2020, CANCERS, V12, DOI 10.3390/cancers12071752; Flores-Mireles AL, 2015, NAT REV MICROBIOL, V13, P269, DOI 10.1038/nrmicro3432; Gherardin NA, 2018, IMMUNOL CELL BIOL, V96, P507, DOI 10.1111/imcb.12021; Godfrey DI, 2015, NAT IMMUNOL, V16, P1114, DOI 10.1038/ni.3298; Graff JN, 2016, ONCOTARGET, V7, P52810, DOI 10.18632/oncotarget.10547; Hansen AR, 2018, ANN ONCOL, V29, P1807, DOI 10.1093/annonc/mdy232; Hinks TSC, 2016, AM J RESP CRIT CARE, V194, P1208, DOI 10.1164/rccm.201601-0002OC; Koay HF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10198-w; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Mariano LL, 2020, NAT REV UROL, V17, P439, DOI 10.1038/s41585-020-0350-8; Lepore M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4866; Ling LM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20358; Martin AM, 2015, PROSTATE CANCER P D, V18, P325, DOI 10.1038/pcan.2015.39; Melo AM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01580; Mori L, 2016, ANNU REV IMMUNOL, V34, P479, DOI 10.1146/annurev-immunol-032414-112008; Peng WY, 2012, CANCER RES, V72, P5209, DOI 10.1158/0008-5472.CAN-12-1187; Rodin W, 2021, CANCER IMMUNOL IMMUN, V70, P3461, DOI 10.1007/s00262-021-02939-y; Sharma P, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.7_suppl.142; Soudais C, 2015, J IMMUNOL, V194, P4641, DOI 10.4049/jimmunol.1403224; Sundstrom P, 2015, J IMMUNOL, V195, P3472, DOI 10.4049/jimmunol.1500258; Terpstra ML, 2020, IMMUN INFLAMM DIS, V8, P80, DOI 10.1002/iid3.287; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Vella M, 2019, INVESTIG CLIN UROL, V60, P91, DOI 10.4111/icu.2019.60.2.91; Vitkin N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00603; Yao T, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01691; Zelba H, 2018, CANCER IMMUNOL IMMUN, V67, P1845, DOI 10.1007/s00262-018-2244-7	40	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 19	2021	12								748741	10.3389/fimmu.2021.748741	http://dx.doi.org/10.3389/fimmu.2021.748741			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT3KT	34737749	Green Published, gold			2022-12-18	WOS:000715767700001
J	Pallikkuth, S; Mendez, R; Russell, K; Sirupangi, T; Kvistad, D; Pahwa, R; Villinger, F; Banerjee, S; Pahwa, S				Pallikkuth, Suresh; Mendez, Roberto; Russell, Kyle; Sirupangi, Tirupataiah; Kvistad, Daniel; Pahwa, Rajendra; Villinger, Francois; Banerjee, Santanu; Pahwa, Savita			Age Associated Microbiome and Microbial Metabolites Modulation and Its Association With Systemic Inflammation in a Rhesus Macaque Model	FRONTIERS IN IMMUNOLOGY			English	Article						age and microbes; age and metabolites; microbiome and metabolites; immunity and microbiome; age and immunity	HIV-INFECTION; DYSBIOSIS; DYSFUNCTION; EXPRESSION; IMMUNITY; ACID	Aging is associated with declining immunity and inflammation as well as alterations in the gut microbiome with a decrease of beneficial microbes and increase in pathogenic ones. The aim of this study was to investigate the age associated gut microbiome in relation to immunologic and metabolic profile in a non-human primate (NHP) model. 12 geriatric (age 19-24 years) and 4 young adult (age 3-4 years) Rhesus macaques were included in this study. Immune cell subsets were characterized in peripheral blood mononuclear cells (PBMC) by flow cytometry and plasma cytokines levels were determined by bead based multiplex cytokine analysis. Stool samples were collected by ileal loop and investigated for microbiome analysis by shotgun metagenomics. Serum, gut microbial lysate, and microbe-free fecal extract were subjected to metabolomic analysis by mass-spectrometry. Our results showed that the gut microbiome in geriatric animals had higher abundance of Archaeal and Proteobacterial species and lower Firmicutes than the young adults. Highly abundant microbes in the geriatric animals showed a direct association with plasma biomarkers of inflammation and immune activation such as neopterin, CRP, TNF, IL-2, IL-6, IL-8 and IFN-gamma. Significant enrichment of metabolites that contribute to inflammatory and cytotoxic pathways was observed in serum and feces of geriatric animals compared to the young adults. We conclude that aging NHP undergo immunosenescence and age associated alterations in the gut microbiome that has a distinct metabolic profile. Aging NHP can serve as a model for investigating the relationship of the gut microbiome to particular age-associated comorbidities and for strategies aimed at modulating the microbiome.</p>	[Pallikkuth, Suresh; Russell, Kyle; Kvistad, Daniel; Pahwa, Rajendra; Pahwa, Savita] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; [Mendez, Roberto; Banerjee, Santanu] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA; [Sirupangi, Tirupataiah; Villinger, Francois] Univ Louisiana Lafayette, New Iberia Res Ctr, New Iberia, LA USA; [Banerjee, Santanu] Univ Miami, Miller Sch Med, Miami Integrat Metabol Res Ctr MIMRC, Miami, FL 33136 USA; [Banerjee, Santanu] NIH, Ctr Sci Review, Bldg 10, Bethesda, MD 20892 USA	University of Miami; University of Miami; University of Louisiana Lafayette; New Iberia Research Center; University of Miami; National Institutes of Health (NIH) - USA	Pahwa, S (corresponding author), Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.; Banerjee, S (corresponding author), Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA.; Banerjee, S (corresponding author), Univ Miami, Miller Sch Med, Miami Integrat Metabol Res Ctr MIMRC, Miami, FL 33136 USA.; Banerjee, S (corresponding author), NIH, Ctr Sci Review, Bldg 10, Bethesda, MD 20892 USA.	santanu.banerjee@med.miami.edu; spahwa@med.miami.edu		Pahwa, Savita/0000-0002-4470-4216	NIAID NIH HHS [R01 AI123048, P30 AI073961] Funding Source: Medline; NIA NIH HHS [R01 AG068110] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abubucker S, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002358; Barajas-Gomez BA, 2017, CYTOKINE, V91, P13, DOI 10.1016/j.cyto.2016.12.001; Asquith M, 2012, PATHOBIOL AGING AGE, V2, DOI 10.3402/pba.v2i0.18052; Baburina Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113499; Bauman BD, 2017, J SURG RES, V219, P214, DOI 10.1016/j.jss.2017.05.099; Biagi E, 2013, PHARMACOL RES, V69, P11, DOI 10.1016/j.phrs.2012.10.005; Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9; Daste A, 2017, EUR J CANCER, V82, P155, DOI 10.1016/j.ejca.2017.05.044; Didier ES, 2012, IMMUN AGEING, V9, DOI 10.1186/1742-4933-9-25; Elias R, 2017, J GERIATR ONCOL, V8, P229, DOI 10.1016/j.jgo.2017.02.001; Ericsen AJ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006048; Fischer KE, 2011, ILAR J, V52, P78, DOI 10.1093/ilar.52.1.78; Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016; Fukushima Y, 2018, INFLAMM REGEN, V38, DOI 10.1186/s41232-018-0082-9; Galeazzi L, 2011, J BIOL CHEM, V286, P40365, DOI 10.1074/jbc.M111.275818; Glavan TW, 2016, MUCOSAL IMMUNOL, V9, P677, DOI 10.1038/mi.2015.92; Glucksam-Galnoy Y, 2013, J IMMUNOL, V191, P337, DOI 10.4049/jimmunol.1300368; Goedert JJ, 2014, CARCINOGENESIS, V35, P2089, DOI 10.1093/carcin/bgu131; Goldberg EL, 2015, IMMUNOL REV, V265, P63, DOI 10.1111/imr.12295; Hagan T, 2019, CELL, V178, P1313, DOI 10.1016/j.cell.2019.08.010; Hao XP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9020; Heintz C, 2014, CELL, V156, P408, DOI 10.1016/j.cell.2014.01.025; Jacobs JP, 2014, FEBS LETT, V588, P4102, DOI 10.1016/j.febslet.2014.02.052; Jenny NS, 2012, DISCOV MED, V13, P451; Klase Z, 2015, MUCOSAL IMMUNOL, V8, P1009, DOI 10.1038/mi.2014.128; Liu P, 2009, NEUROSCIENCE, V164, P611, DOI 10.1016/j.neuroscience.2009.08.029; Lombo F, 2006, CHEMBIOCHEM, V7, P366, DOI 10.1002/cbic.200500325; MCGUIRE JJ, 1985, J BIOL CHEM, V260, P6747; Mendez R, 2019, METHODS MOL BIOL, V1996, P41, DOI 10.1007/978-1-4939-9488-5_4; Mudd JC, 2016, J INFECT DIS, V214, pS58, DOI 10.1093/infdis/jiw258; Muller-Werdan U, 2017, CURR OPIN CLIN NUTR, V20, P346, DOI 10.1097/MCO.0000000000000391; National Toxicology Program, 2010, Natl Toxicol Program Tech Rep Ser, P1; Nikolich-Zugich J, 2018, NAT IMMUNOL, V19, P10, DOI 10.1038/s41590-017-0006-x; Oh SJ, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e37; Ortiz AM, 2018, NAT MED, V24, P1313, DOI 10.1038/s41591-018-0132-5; Pallikkuth S, 2018, AIDS, V32, P1085, DOI 10.1097/QAD.0000000000001774; Panaro MA, 1999, IMMUNOPHARM IMMUNOT, V21, P397, DOI 10.3109/08923979909007117; Park JS, 2020, MOL CELL TOXICOL, V16, P159, DOI 10.1007/s13273-019-00066-5; Parmigiani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079816; Pinti M, 2016, EUR J IMMUNOL, V46, P2286, DOI 10.1002/eji.201546178; Puertollano E, 2014, CURR OPIN CLIN NUTR, V17, P139, DOI 10.1097/MCO.0000000000000025; Ravisankar S, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1346-x; Rezzani R, 2014, AGE, V36, P313, DOI 10.1007/s11357-013-9564-5; Shankwitz K, 2020, AGING CELL, V19, DOI 10.1111/acel.13087; Sinha R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152126; SMOLENSKI RT, 1994, CARDIOVASC RES, V28, P100, DOI 10.1093/cvr/28.1.100; Thevaranjan N, 2017, CELL HOST MICROBE, V21, P455, DOI 10.1016/j.chom.2017.03.002; Bui TPN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10062; Twitchell EL, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0136-y; van Dongen S, 2012, METHODS MOL BIOL, V804, P281, DOI 10.1007/978-1-61779-361-5_15; Vemuri R, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4178607; Vujkovic-Cvijin I, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006438; Walker EM, 2020, GEROSCIENCE, V42, P375, DOI 10.1007/s11357-019-00144-5; Williams B, 2016, CELL MICROBIOL, V18, P645, DOI 10.1111/cmi.12588; Zevin AS, 2016, CURR OPIN HIV AIDS, V11, P182, DOI 10.1097/COH.0000000000000234	55	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 19	2021	12								748397	10.3389/fimmu.2021.748397	http://dx.doi.org/10.3389/fimmu.2021.748397			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT3VW	34737748	gold, Green Published			2022-12-18	WOS:000715796800001
J	Sarr, D; Oliveira, LJ; Russ, BN; Owino, SO; Middii, JD; Mwalimu, S; Ambasa, L; Almutairi, F; Vulule, J; Rada, B; Moore, JM				Sarr, Demba; Oliveira, Lilian J.; Russ, Brittany N.; Owino, Simon O.; Middii, Joab D.; Mwalimu, Stephen; Ambasa, Linda; Almutairi, Faris; Vulule, John; Rada, Balazs; Moore, Julie M.			Myeloperoxidase and Other Markers of Neutrophil Activation Associate With Malaria and Malaria/HIV Coinfection in the Human Placenta	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophils; pregnancy; NETs (neutrophil extracellular traps); placental malaria; myeloperoxidase; Plasmodium falciparum	PLASMODIUM-FALCIPARUM MALARIA; MIGRATION INHIBITORY FACTOR; MATERNAL HIV-INFECTION; EXTRACELLULAR TRAPS; PREGNANT-WOMEN; CYSTIC-FIBROSIS; HIGH PREVALENCE; BIRTH-WEIGHT; PATHOGENESIS; PREECLAMPSIA	IntroductionPlacental malaria (PM) is characterized by accumulation of inflammatory leukocytes in the placenta, leading to poor pregnancy outcomes. Understanding of the underlying mechanisms remains incomplete. Neutrophils respond to malaria parasites by phagocytosis, generation of oxidants, and externalization of Neutrophil Extracellular Traps (NETs). NETs drive inflammation in malaria but evidence of NETosis in PM has not been reported. Neutrophil activity in the placenta has not been directly investigated in the context of PM and PM/HIV-co-infection. MethodsUsing peripheral and placental plasma samples and placental tissue collected from Kenyan women at risk for malaria and HIV infections, we assessed granulocyte levels across all gravidities and markers of neutrophil activation, including NET formation, in primi- and secundigravid women, by ELISA, western blot, immunohistochemistry and immunofluorescence. ResultsReduced peripheral blood granulocyte numbers are observed with PM and PM/HIV co-infection in association with increasing parasite density and placental leukocyte hemozoin accumulation. In contrast, placental granulocyte levels are unchanged across infection groups, resulting in enhanced placental: peripheral count ratios with PM. Within individuals, PM- women have reduced granulocyte counts in placental relative to peripheral blood; in contrast, PM stabilizes these relative counts, with HIV coinfection tending to elevate placental counts relative to the periphery. In placental blood, indicators of neutrophil activation, myeloperoxidase (MPO) and proteinase 3 (PRTN3), are significantly elevated with PM and, more profoundly, with PM/HIV co-infection, in association with placental parasite density and hemozoin-bearing leukocyte accumulation. Another neutrophil marker, matrix metalloproteinase (MMP9), together with MPO and PRTN3, is elevated with self-reported fever. None of these factors, including the neutrophil chemoattractant, CXCL8, differs in relation to infant birth weight or gestational age. CXCL8 and MPO levels in the peripheral blood do not differ with infection status nor associate with birth outcomes. Indicators of NETosis in the placental plasma do not vary with infection, and while structures consistent with NETs are observed in placental tissue, the results do not support an association with PM. ConclusionsGranulocyte levels are differentially regulated in the peripheral and placental blood in the presence and absence of PM. PM, both with and without pre-existing HIV infection, enhances neutrophil activation in the placenta. The impact of local neutrophil activation on placental function and maternal and fetal health remains unclear. Additional investigations exploring how neutrophil activation and NETosis participate in the pathogenesis of malaria in pregnant women are needed.	[Sarr, Demba; Almutairi, Faris; Rada, Balazs] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA USA; [Oliveira, Lilian J.] Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA; [Oliveira, Lilian J.; Russ, Brittany N.; Owino, Simon O.; Moore, Julie M.] Univ Florida, Coll Vet Med, Dept Infect Dis & Immunol, Gainesville, FL 32611 USA; [Owino, Simon O.; Middii, Joab D.; Mwalimu, Stephen; Ambasa, Linda; Vulule, John; Moore, Julie M.] Kenya Govt Med Res Ctr, Vector Biol & Control Res Ctr, Kisian, Kenya; [Owino, Simon O.; Middii, Joab D.; Mwalimu, Stephen; Ambasa, Linda; Moore, Julie M.] Univ Georgia, Siaya Dist Hosp, Kenya Med Res Inst Placental Malaria Study, Siaya, Kenya; [Owino, Simon O.] Maseno Univ, Fac Sci, Dept Zool, Maseno, Kenya; [Middii, Joab D.] Kisumu Specialists Hosp Lab, Kisumu, Kenya; [Mwalimu, Stephen] Int Livestock Res Inst, Anim & Human Hlth Program, Nairobi, Kenya; [Ambasa, Linda] 1 Heartsaved Adult Family Care, Marysville, WA USA; [Almutairi, Faris] Univ Georgia, Coll Pharm, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; State University System of Florida; University of Florida; Kenya Medical Research Institute; Maseno University; CGIAR; International Livestock Research Institute (ILRI); University System of Georgia; University of Georgia	Moore, JM (corresponding author), Univ Florida, Coll Vet Med, Dept Infect Dis & Immunol, Gainesville, FL 32611 USA.; Moore, JM (corresponding author), Kenya Govt Med Res Ctr, Vector Biol & Control Res Ctr, Kisian, Kenya.; Moore, JM (corresponding author), Univ Georgia, Siaya Dist Hosp, Kenya Med Res Inst Placental Malaria Study, Siaya, Kenya.	juliemoore@ufl.edu	Sarr, Demba/GOG-9376-2022; Sarr, Demba/AAP-7125-2020	Sarr, Demba/0000-0002-8306-0433; Almutairi, Faris/0000-0003-1565-4472	National Institutes of Health [R01 AI050240, R21 AI111242]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health grants R01 AI050240 and R21 AI111242, and research support from the University of Florida to JMM. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases (NIAID) or the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrams ET, 2003, J IMMUNOL, V170, P2759, DOI 10.4049/jimmunol.170.5.2759; Agarwal A, 2012, REPROD BIOL ENDOCRIN, V10, DOI 10.1186/1477-7827-10-49; Aitken EH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03005; Aly AS, 2004, AM J OBSTET GYNECOL, V190, P252, DOI 10.1016/j.ajog.2003.07.003; Ambayya A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091968; Amulic B, 2020, TRENDS PARASITOL, V36, P501, DOI 10.1016/j.pt.2020.03.003; Apoorv TS, 2015, AM J TROP MED HYG, V93, P186, DOI 10.4269/ajtmh.14-0816; Avery JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031090; Ayisi JG, 2003, AIDS, V17, P585, DOI 10.1097/00002030-200303070-00014; Baker VS, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-41; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Bauserman M, 2019, SEMIN PERINATOL, V43, P282, DOI 10.1053/j.semperi.2019.03.018; BLOLAND PB, 1995, AIDS, V9, P721, DOI 10.1097/00002030-199507000-00009; Bostrom S, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12433; Briand V, 2009, ANN TROP PAEDIATR, V29, P71, DOI 10.1179/146532809X440699; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Brinkmann V, 2007, NAT REV MICROBIOL, V5, P577, DOI 10.1038/nrmicro1710; BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x; Chaisavaneeyakorn S, 2005, INFECT IMMUN, V73, P3287, DOI 10.1128/IAI.73.6.3287-3293.2005; Chaisavaneeyakorn S, 2003, CLIN DIAGN LAB IMMUN, V10, P631, DOI 10.1128/CDLI.10.4.631-636.2003; Chaisavaneeyakorn S, 2002, J INFECT DIS, V186, P1371, DOI 10.1086/344322; Chang ZG, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11537; Choi JW, 2002, ANN CLIN LAB SCI, V32, P257; Chua CLL, 2015, INT J PARASITOL, V45, P107, DOI 10.1016/j.ijpara.2014.12.002; Dasari P, 2011, BLOOD, V118, P4946, DOI 10.1182/blood-2011-05-353920; Davison BB, 2005, J INFECT DIS, V191, P1940, DOI 10.1086/430004; Feintuch CM, 2016, MBIO, V7, DOI 10.1128/mBio.01300-15; Floyd M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005987; Fullerton JN, 2016, NAT REV DRUG DISCOV, V15, P551, DOI 10.1038/nrd.2016.39; Gandley RE, 2008, HYPERTENSION, V52, P387, DOI 10.1161/HYPERTENSIONAHA.107.107532; Gavillet M, 2015, AM J HEMATOL, V90, P1155, DOI 10.1002/ajh.24185; Giaglis S, 2016, CELL ADHES MIGR, V10, P208, DOI 10.1080/19336918.2016.1148866; Ginley BG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18099-y; Gupta AK, 2007, SEMIN IMMUNOPATHOL, V29, P163, DOI 10.1007/s00281-007-0073-4; Hahn S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00362; Hunga TH, 2012, PLACENTA, V33, P294, DOI 10.1016/j.placenta.2012.01.004; Ismail MR, 2000, HUM PATHOL, V31, P85, DOI 10.1016/S0046-8177(00)80203-8; Kessenbrock K, 2009, NAT MED, V15, P623, DOI 10.1038/nm.1959; Kho S, 2019, J INFECT DIS, V219, P1994, DOI 10.1093/infdis/jiy661; Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697; Knackstedt SL, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw0336; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Liew PX, 2019, PHYSIOL REV, V99, P1223, DOI 10.1152/physrev.00012.2018; Lucchi NW, 2011, PLACENTA, V32, P579, DOI 10.1016/j.placenta.2011.05.003; Mandala WL, 2017, AM J REPROD IMMUNOL, V78, DOI 10.1111/aji.12678; Marder W, 2016, LUPUS SCI MED, V3, DOI 10.1136/lupus-2015-000134; Vasquez AM, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-421; Masuda S, 2016, CLIN CHIM ACTA, V459, P89, DOI 10.1016/j.cca.2016.05.029; Mayadas TN, 2014, ANNU REV PATHOL-MECH, V9, P181, DOI 10.1146/annurev-pathol-020712-164023; Megnekou R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134633; Menendez C, 2000, J INFECT DIS, V181, P1740, DOI 10.1086/315449; Mockenhaupt FP, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-119; Moormann AM, 1999, J INFECT DIS, V180, P1987, DOI 10.1086/315135; Mruma HA, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.020417; Muehlenbachs A, 2010, J INFECT DIS, V202, P1608, DOI 10.1086/656723; Mwapasa V, 2004, AIDS, V18, P1051, DOI 10.1097/00002030-200404300-00014; Nakazawa D, 2012, ARTHRITIS RHEUM-US, V64, P3779, DOI 10.1002/art.34619; Naseem S., 2004, GOMAL J MED SCI, V6, P98; Nielson KS., 2008, RETROVIROLOGY, V5, DOI [DOI 10.1186/1742-4690-5-S1-O1, 10.1186/1742-4690-5-S1-O1]; Obiri D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64736-4; Okamgba OC, 2018, RES REP TROP MED, V9, P1, DOI 10.2147/RRTM.S137829; Ordi J, 1998, AM J SURG PATHOL, V22, P1006, DOI 10.1097/00000478-199808000-00011; Ordi J, 2001, J INFECT DIS, V183, P1100, DOI 10.1086/319295; Othoro C, 2006, CLIN VACCINE IMMUNOL, V13, P568, DOI 10.1128/CVI.13.5.568-574.2006; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Parise ME, 1998, AM J TROP MED HYG, V59, P813, DOI 10.4269/ajtmh.1998.59.813; Pattison DI, 2012, FREE RADICAL RES, V46, P975, DOI 10.3109/10715762.2012.667566; Pereira MA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005831; Perrault SD, 2009, AM J TROP MED HYG, V80, P119, DOI 10.4269/ajtmh.2009.80.119; Porcherie A, 2011, J EXP MED, V208, P2225, DOI 10.1084/jem.20110845; Porto BN, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00311; Prato M, 2005, J IMMUNOL, V175, P6436, DOI 10.4049/jimmunol.175.10.6436; Prato M, 2011, J TROP MED-US, V2011, DOI 10.1155/2011/628435; Prato M, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-157; Pullar JM, 2000, IUBMB LIFE, V50, P259, DOI 10.1080/15216540051080958; Rada B, 2019, METHODS MOL BIOL, V1982, P517, DOI 10.1007/978-1-4939-9424-3_31; Rada B, 2017, PATHOGENS, V6, DOI 10.3390/pathogens6010010; Rayner BS, 2014, FREE RADICAL BIO MED, V71, P240, DOI 10.1016/j.freeradbiomed.2014.03.004; Rocha BC, 2015, CELL REP, V13, P2829, DOI 10.1016/j.celrep.2015.11.055; Rodrigues DAS, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008230; Rogerson SJ, 2003, AM J TROP MED HYG, V68, P115, DOI 10.4269/ajtmh.2003.68.1.0680115; Rogerson SJ, 2007, AM J TROP MED HYG, V77, P14; Rogerson SJ, 2007, LANCET INFECT DIS, V7, P105, DOI 10.1016/S1473-3099(07)70022-1; Sarr D, 2015, PLACENTA, V36, P738, DOI 10.1016/j.placenta.2015.04.007; Sarr D, 2006, AM J TROP MED HYG, V75, P171, DOI 10.4269/ajtmh.2006.75.171; Sarr Demba, 2017, Immunohorizons, V1, P29, DOI 10.4049/immunohorizons.1700002; Sato R, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000386; Schauer C, 2014, NAT MED, V20, P511, DOI 10.1038/nm.3547; Sercundes MK, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006054; Serghides L, 2015, JAIDS-J ACQ IMM DEF, V68, P128, DOI 10.1097/QAI.0000000000000427; Sharma L, 2012, EXP PARASITOL, V131, P215, DOI 10.1016/j.exppara.2012.04.005; Sharma L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032694; Steketee RW, 1996, AM J TROP MED HYG, V55, P42, DOI 10.4269/ajtmh.1996.55.42; Stockfelt M, 2021, LUPUS SCI MED, V8, DOI 10.1136/lupus-2020-000463; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Suguitan AL, 2003, J INFECT DIS, V188, P1074, DOI 10.1086/378500; Theess W, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00475-16; Tsukimori K, 2007, HYPERTENSION, V49, P1436, DOI 10.1161/HYPERTENSIONAHA.106.086751; Tucker SL, 2021, BMC IMMUNOL, V22, DOI 10.1186/s12865-021-00397-w; Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639; Van Eijk AM, 2001, AM J TROP MED HYG, V65, P623, DOI 10.4269/ajtmh.2001.65.623; Verhoeff FH, 1999, TROP MED INT HEALTH, V4, P5, DOI 10.1046/j.1365-3156.1999.00349.x; Vita JA, 2004, CIRCULATION, V110, P1134, DOI 10.1161/01.CIR.0000140262.20831.8F; Winterbourn CC, 2013, ANTIOXID REDOX SIGN, V18, P642, DOI 10.1089/ars.2012.4827; Yadav R, 2020, AUTOIMMUNITY, V53, P476, DOI 10.1080/08916934.2020.1839890; Yadav R, 2019, J CYST FIBROS, V18, P636, DOI 10.1016/j.jcf.2018.12.010; Yoo DG, 2014, J IMMUNOL, V192, P4728, DOI 10.4049/jimmunol.1301589	108	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 19	2021	12								682668	10.3389/fimmu.2021.682668	http://dx.doi.org/10.3389/fimmu.2021.682668			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XB9HR	34737733	gold, Green Published			2022-12-18	WOS:000721632300001
J	Chen, N; Chen, S; Zhang, ZH; Cui, XX; Wu, LZ; Guo, KL; Shao, H; Ma, JX; Zhang, XM				Chen, Nu; Chen, Shuang; Zhang, Zhihui; Cui, Xuexue; Wu, Lingzi; Guo, Kailei; Shao, Hui; Ma, Jian-Xing; Zhang, Xiaomin			Overexpressing Kallistatin Aggravates Experimental Autoimmune Uveitis Through Promoting Th17 Differentiation	FRONTIERS IN IMMUNOLOGY			English	Article						kallistatin; uveitis; experimental autoimmune uveitis; autoimmune disease; immunology; interphotoreceptor retinoid-binding protein; Th17	UVEORETINITIS; INFLAMMATION; INJURY; SUPPRESSION; INHIBITION; INDUCTION; APOPTOSIS; RESIDUES; IRBP; KEY	Kallistatin or kallikrein-binding protein (KBP) has been reported to regulate angiogenesis, inflammation and tumor progression. Autoimmune uveitis is a common, sight-threatening inflammatory intraocular disease. However, the roles of kallistatin in autoimmunity and autoreactive T cells are poorly investigated. Compared to non-uveitis controls, we found that plasma levels of kallistatin were significantly upregulated in patients with Vogt-Koyanagi-Harada (VKH) disease, one of the non-infectious uveitis. Using an experimental autoimmune uveitis (EAU) model induced by human interphotoreceptor retinoid-binding protein peptide 651-670 (hIRBP(651-670)), we examined the effects of kallistatin on the pathogenesis of autoimmune diseases. Compared to wild type (WT) mice, kallistatin transgenic (KS) mice developed severe uveitis with dominant Th17 infiltrates in the eye. In addition, the proliferative antigen-specific T cells isolated from KS EAU mice produced increased levels of IL-17A, but not IFN-gamma or IL-10 cytokines. Moreover, splenic CD4(+) T cells from naive KS mice expressed higher levels of Il17a mRNA compared to WT naive mice. Under Th17 polarization conditions, KS mice exhibited enhanced differentiation of naive CD4(+) T cells into Th17 cells compared to WT controls. Together, our results indicate that kallistatin promotes Th17 differentiation and is a key regulator of aggravating autoinflammation in EAU. Targeting kallistatin might be a potential to treat autoimmune disease.	[Chen, Nu; Chen, Shuang; Zhang, Zhihui; Cui, Xuexue; Wu, Lingzi; Guo, Kailei; Zhang, Xiaomin] Tianjin Med Univ, Eye Hosp, Tianjin Key Lab Retinal Funct & Dis, Tianjin Branch,Natl Clin Res Ctr Ocular Dis,Eye I, Tianjin, Peoples R China; [Chen, Nu; Chen, Shuang; Zhang, Zhihui; Cui, Xuexue; Wu, Lingzi; Guo, Kailei; Zhang, Xiaomin] Tianjin Med Univ, Eye Hosp, Sch Optometry, Tianjin, Peoples R China; [Shao, Hui] Univ Louisville, Sch Med, Dept Ophthalmol & Visual Sci, Kentucky Lions Eye Ctr, Louisville, KY 40292 USA; [Ma, Jian-Xing] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK USA	Tianjin Medical University; Tianjin Medical University; University of Louisville; University of Oklahoma System; University of Oklahoma Health Sciences Center	Zhang, XM (corresponding author), Tianjin Med Univ, Eye Hosp, Tianjin Key Lab Retinal Funct & Dis, Tianjin Branch,Natl Clin Res Ctr Ocular Dis,Eye I, Tianjin, Peoples R China.; Zhang, XM (corresponding author), Tianjin Med Univ, Eye Hosp, Sch Optometry, Tianjin, Peoples R China.	xzhang08@tmu.edu.cn	zhang, zh/GWV-4677-2022	Zhang, Xiaomin/0000-0003-4898-4152	uu	uu	Funding This work was supported by National Natural Science Foundation of China (81671642, 81870651), Tianjin Science and Technology Support Plan (20YFZCSY00990), and Natural Science Foundation of Tianjin (20JCZDJC00100).	Amadi-Obi A, 2007, NAT MED, V13, P711, DOI 10.1038/nm1585; Avichezer D, 2000, EXP EYE RES, V71, P111, DOI 10.1006/exer.2000.0860; Caspi R, 2008, IMMUNOL RES, V42, P41, DOI 10.1007/s12026-008-8031-3; Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440; Caspi Rachel R, 2003, Curr Protoc Immunol, VChapter 15, DOI 10.1002/0471142735.im1506s53; CHAO J, 1986, BIOCHEM J, V239, P325, DOI 10.1042/bj2390325; Chao J, 2006, HUM GENE THER, V17, P1201, DOI 10.1089/hum.2006.17.1201; Chao J, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4138560; Chen VC, 2000, J BIOL CHEM, V275, P38457, DOI 10.1074/jbc.M005605200; Chen YH, 2020, EUR J IMMUNOL, V50, P1941, DOI 10.1002/eji.202048616; Cox CA, 2008, J IMMUNOL, V180, P7414, DOI 10.4049/jimmunol.180.11.7414; Feng J, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0376-9; Foxman EF, 2002, J IMMUNOL, V168, P2483, DOI 10.4049/jimmunol.168.5.2483; Gritz DC, 2004, OPHTHALMOLOGY, V111, P491, DOI 10.1016/j.ophtha.2003.06.014; Iwakura Y, 2011, IMMUNITY, V34, P149, DOI 10.1016/j.immuni.2011.02.012; Jager A, 2009, J IMMUNOL, V183, P7169, DOI 10.4049/jimmunol.0901906; Jenkins Alicia J, 2010, J Angiogenes Res, V2, P19, DOI 10.1186/2040-2384-2-19; Ke Y, 2009, J IMMUNOL, V182, P3183, DOI 10.4049/jimmunol.0802487; Lee RW, 2014, SEMIN IMMUNOPATHOL, V36, P581, DOI 10.1007/s00281-014-0433-9; Lee YK, 2009, IMMUNITY, V30, P92, DOI 10.1016/j.immuni.2008.11.005; Li PF, 2014, IMMUNOLOGY, V142, P216, DOI 10.1111/imm.12242; Liu DR, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-30; Luger D, 2008, J EXP MED, V205, P799, DOI 10.1084/jem.20071258; Maggi L, 2012, EUR J IMMUNOL, V42, P3180, DOI 10.1002/eji.201242648; Mattapallil MJ, 2015, INVEST OPHTH VIS SCI, V56, P5439, DOI 10.1167/iovs.15-17280; McBride JD, 2014, J INVEST DERMATOL, V134, P1725, DOI 10.1038/jid.2014.40; Muhammad F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00975; NUSSENBLATT RB, 1981, J CLIN INVEST, V67, P1228, DOI 10.1172/JCI110138; Prete M, 2014, J OPHTHALMIC INFLAMM, V4, DOI 10.1186/s12348-014-0017-9; Rizzo LV, 1996, J IMMUNOL, V156, P1654; Rosenbaum JT, 2010, CURR OPIN OPHTHALMOL, V21, P473, DOI 10.1097/ICU.0b013e32833f00b3; Rothova A, 1996, BRIT J OPHTHALMOL, V80, P332, DOI 10.1136/bjo.80.4.332; SALINASCARMONA MC, 1982, EUR J IMMUNOL, V12, P480, DOI 10.1002/eji.1830120606; Sallusto F, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029421; Shen B, 2008, HYPERTENSION, V51, P1358, DOI 10.1161/HYPERTENSIONAHA.107.108514; Shen B, 2010, AM J PHYSIOL-HEART C, V299, pH1419, DOI 10.1152/ajpheart.00591.2010; Wakefield D, 1994, Ocul Immunol Inflamm, V2, P153, DOI 10.3109/09273949409057071; Yan JW, 2019, CELL METAB, V29, P241, DOI 10.1016/j.cmet.2019.01.008; Yin H, 2010, HYPERTENSION, V56, P260, DOI 10.1161/HYPERTENSIONAHA.110.152330; Zhang R, 2009, CURR EYE RES, V34, P297, DOI 10.1080/02713680902741696; ZHOU GX, 1992, J BIOL CHEM, V267, P25873	41	1	1	2	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 18	2021	12								756423	10.3389/fimmu.2021.756423	http://dx.doi.org/10.3389/fimmu.2021.756423			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT1UW	34733288	gold, Green Published			2022-12-18	WOS:000715657200001
J	Guo, ZN; Liu, J; Chang, JL; Zhang, P; Jin, H; Sun, X; Yang, Y				Guo, Zhen-Ni; Liu, Jie; Chang, Junlei; Zhang, Peng; Jin, Hang; Sun, Xin; Yang, Yi			GAS6/Axl Signaling Modulates Blood-Brain Barrier Function Following Intravenous Thrombolysis in Acute Ischemic Stroke	FRONTIERS IN IMMUNOLOGY			English	Article						acute ischemic stroke; blood-brain barrier; hemorrhagic transformation; recombinant tissue plasminogen activator; growth arrest-specific 6; Axl	TISSUE-PLASMINOGEN ACTIVATOR; CEREBRAL-ARTERY OCCLUSION; HEMORRHAGIC TRANSFORMATION; INTRACEREBRAL HEMORRHAGE; PERMEABILITY; NEUROINFLAMMATION; MACROPHAGES; OXYGEN; MODEL; MICE	Background and Purpose Recent studies have shown that several proteins, including Axl, are related to hemorrhagic transformation (HT) following intravenous thrombolysis by affecting blood-brain barrier (BBB) function. However, the effects of these proteins on BBB function have been studied primarily in animal models. In this study, we aimed to identify serum protein markers that predict HT following intravenous thrombolysis in patients with acute ischemic stroke (AIS) and verify whether these serum proteins regulate BBB function and HT in animal stroke models.</p> Methods First, 118 AIS patients were enrolled in this study, including 52 HT patients and 66 non-HT patients. In Step 1, baseline serum levels of Axl, angiopoietin-like 4, C-reactive protein, ferritin, hypoxia-inducible factor-1 alpha, HTRA2, Lipocalin2, matrix metallopeptidase 9, platelet-derived growth factor-BB, and tumor necrosis factor alpha were measured using a quantitative cytokine chip. Next, sequence mutations and variations in genes encoding the differentially expressed proteins identified in Step 1 and subsequent function-related proteins were detected. Finally, we verified whether manipulation of differentially expressed proteins affected BBB function and HT in a hyperglycemia-induced rat stroke model.</p> Results Serum Axl levels were significantly lower in the HT group than in the non-HT group; none of the other protein markers differed significantly between the two groups. Genetic testing revealed that sequence variations of GAS6 (the gene encoding the Axl ligand)-derived long non-coding RNA, GAS6-AS1, were significantly correlated with an increased risk of HT after intravenous thrombolysis. In animal studies, administration of recombinant GAS6 significantly reduced brain infarction and neurological deficits and attenuated BBB disruption and HT.</p> Conclusions Lower serum Axl levels, which may result from sequence variations in GAS6-AS1, are correlated with an increased risk of HT after intravenous thrombolysis in stroke patients. Activation of the Axl signaling pathway by the GAS6 protein may serve as a therapeutic strategy to reduce HT in AIS patients.</p>	[Guo, Zhen-Ni; Liu, Jie; Zhang, Peng; Jin, Hang; Sun, Xin; Yang, Yi] First Hosp Jilin Univ, Stroke Ctr, Dept Neurol, Changchun, Peoples R China; [Guo, Zhen-Ni; Zhang, Peng; Yang, Yi] First Hosp Jilin Univ, Clin Trial & Res Ctr Stroke, Dept Neurol, Changchun, Peoples R China; [Chang, Junlei] Chinese Acad Sci, Ctr Prot & Cell Based Drugs, Inst Biomed & Biotechnol, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China	Jilin University; Jilin University; Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS	Yang, Y (corresponding author), First Hosp Jilin Univ, Stroke Ctr, Dept Neurol, Changchun, Peoples R China.; Yang, Y (corresponding author), First Hosp Jilin Univ, Clin Trial & Res Ctr Stroke, Dept Neurol, Changchun, Peoples R China.	yang_yi@jlu.edu.cn			National Natural Science Foundation of China [81771243]; Program for JLU Science and Technology Innovative Research Team [2017TD-12]; Jilin Provincial Key Laboratory [20190901005JC]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for JLU Science and Technology Innovative Research Team; Jilin Provincial Key Laboratory	This work was supported by the National Natural Science Foundation of China to YY (Grant No. 81771243), the Program for JLU Science and Technology Innovative Research Team (2017TD-12) and Jilin Provincial Key Laboratory (20190901005JC) to YY.	Belayev L, 1996, NEUROREPORT, V8, P55, DOI 10.1097/00001756-199612200-00012; Celis R, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3817; Chang CF, 2018, J CLIN INVEST, V128, P607, DOI 10.1172/JCI95612; Chen HS, 2018, TRANSL STROKE RES, V9, P515, DOI 10.1007/s12975-017-0598-3; Chen TY, 2006, J PINEAL RES, V40, P242, DOI 10.1111/j.1600-079X.2005.00307.x; Cheung JKH, 2009, J ETHNOPHARMACOL, V124, P61, DOI 10.1016/j.jep.2009.04.010; Chiou B, 2019, J CEREBR BLOOD F MET, V39, P2117, DOI 10.1177/0271678X18783372; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; Clark WM, 1997, NEUROL RES, V19, P641; Egashira Y, 2016, ACTA NEUROCHIR SUPPL, V121, P131, DOI 10.1007/978-3-319-18497-5_23; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Guo ZN, 2016, CRIT CARE MED, V44, pE403, DOI 10.1097/CCM.0000000000001468; Guo ZL, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0680-x; Hoffmann A, 2012, TRANSL STROKE RES, V3, P508, DOI 10.1007/s12975-012-0212-7; Hom J, 2011, AM J NEURORADIOL, V32, P41, DOI 10.3174/ajnr.A2244; Krafft PR, 2013, STROKE, V44, P1743, DOI 10.1161/STROKEAHA.111.000427; Kuhlmann CRW, 2009, STROKE, V40, P1458, DOI 10.1161/STROKEAHA.108.535930; Kunte H, 2012, ANN NEUROL, V72, P799, DOI 10.1002/ana.23680; Liu WC, 2016, MED GAS RES, V6, P206, DOI 10.4103/2045-9912.196902; Miner JJ, 2015, NAT MED, V21, P1464, DOI 10.1038/nm.3974; Ozkul-Wermester O, 2014, EUR NEUROL, V72, P45, DOI 10.1159/000358297; Roger Veronique L, 2011, Circulation, V123, pe18, DOI 10.1161/CIR.0b013e3182009701; Shen J, 2019, J CEREBR BLOOD F MET, V39, P1501, DOI 10.1177/0271678X18769515; Shen YF, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00288; Soejima Y, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-9; SWANSON RA, 1994, J CEREBR BLOOD F MET, V14, P697, DOI 10.1038/jcbfm.1994.88; Sweeney MD, 2016, NAT NEUROSCI, V19, P771, DOI 10.1038/nn.4288; Ta S, 2021, CNS NEUROSCI THER, V27, P71, DOI 10.1111/cns.13457; Tong LS, 2017, J CEREBR BLOOD F MET, V37, P1971, DOI 10.1177/0271678X16658490; Topkoru BC, 2013, STROKE, V44, P3189, DOI 10.1161/STROKEAHA.113.001574; Wang K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01148; Wang PF, 2018, CELL PHYSIOL BIOCHEM, V49, P2163, DOI 10.1159/000493819; Wu GY, 2018, NEUROBIOL DIS, V110, P59, DOI 10.1016/j.nbd.2017.11.009; Xu XM, 2018, J STROKE CEREBROVASC, V27, P2381, DOI 10.1016/j.jstrokecerebrovasdis.2018.04.027; Yang ZS, 2017, MED GAS RES, V7, P68, DOI 10.4103/2045-9912.202912; Zagorska A, 2014, NAT IMMUNOL, V15, P920, DOI 10.1038/ni.2986; Zeng QO, 2010, BIOMATERIALS, V31, P5772, DOI 10.1016/j.biomaterials.2010.04.022; Zhang B, 2017, NEUROSCI LETT, V645, P113, DOI 10.1016/j.neulet.2017.03.001; Zhang MJ, 2019, J STROKE CEREBROVASC, V28, P1799, DOI 10.1016/j.jstrokecerebrovasdis.2019.03.037; Zhang PC, 2019, GENE, V696, P1, DOI 10.1016/j.gene.2018.12.079; Zhang Y, 2015, STROKE, V46, P2637, DOI 10.1161/STROKEAHA.115.009792; Zhang ZY, 2019, MED GAS RES, V9, P221, DOI 10.4103/2045-9912.273960	42	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 18	2021	12								742359	10.3389/fimmu.2021.742359	http://dx.doi.org/10.3389/fimmu.2021.742359			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT2SW	34733281	Green Published, gold			2022-12-18	WOS:000715719700001
J	Randrian, V; Desette, A; Emambux, S; Derangere, V; Roussille, P; Frouin, E; Godet, J; Karayan-Tapon, L; Ghiringhelli, F; Tougeron, D				Randrian, Violaine; Desette, Amandine; Emambux, Sheik; Derangere, Valentin; Roussille, Pauline; Frouin, Eric; Godet, Julie; Karayan-Tapon, Lucie; Ghiringhelli, Francois; Tougeron, David			New Artificial Intelligence Score and Immune Infiltrates as Prognostic Factors in Colorectal Cancer With Brain Metastases	FRONTIERS IN IMMUNOLOGY			English	Article						colorectal cancer; brain metastases; anti-tumoral immunity; tumor infiltrated lymphocytes (TILs); prognostic factors; CD3	T-CELLS; MICROENVIRONMENTS; EXPRESSION; SURVIVAL; DENSITY; TUMORS; PD-L1	Incidence of brain metastases has increased in patients with colorectal cancer (CRC) as their survival has improved. CD3 T-cells and, lately, DGMate (DiGital tuMor pArameTErs) score, have been identified as prognostic factors in locally advanced CRC. Until now, there is no data concerning the prognostic value of these markers in patients with CRC-derived brain metastases. All consecutive patients with CRC-derived brain metastases diagnosed between 2000 and 2017 were retrospectively included. Staining for CD3, CD8, PD-1, PD-L1 and DGMate analyses were performed using tissue micro-array from primary tumors and, if available, brain metastases. All in all, 83 patients were included with 80 primary tumor samples and 37 brain metastases samples available. CD3 and CD8 T-cell infiltration was higher in primary tumors compared to brain metastases. We observed a significant higher DGMate score in rectal tumors compared to colon tumors (p=0.03). We also noted a trend of higher CD3 T-cell infiltration in primary tumors when brain metastases were both supra and subtentorial compared to brain metastases that were only subtentorial or supratentorial (p=0.36 and p=0.03, respectively). No correlation was found between CD3 or CD8 infiltration or DGMate score in primary tumors or brain metastases and overall survival (OS) in the overall population. In patients with rectal tumors, a high DGMate score in brain metastases was associated with longer OS (13.4 +/- 6.1 months versus 6.1 +/- 1.4 months, p=0.02). High CD3 T-cell infiltration in brain metastases was associated with lower OS in patients with supratentorial brain metastases (9.8 +/- 3.3 months versus 16.7 +/- 5.9 months, p=0.03). PD-L1 overexpression was rare, both in primary tumors and brain metastases, but PD-L1 positive primary tumors were associated with worse OS (p=0.01). In contrast to breast and lung cancer derived brain metastases, CD3 and CD8 infiltration and DGMate score are not major prognostic factors in patients with CRC-derived brain metastases.	[Randrian, Violaine; Tougeron, David] CHU Poitiers, Hepatogastroenterol Dept, Poitiers, France; [Randrian, Violaine; Desette, Amandine; Emambux, Sheik; Karayan-Tapon, Lucie; Tougeron, David] Univ Poitiers, PRODICET, INSERM, CHU Poitiers, Poitiers, France; [Desette, Amandine; Karayan-Tapon, Lucie] Univ Poitiers, LNEC, INSERM, CHU Poitiers, Poitiers, France; [Emambux, Sheik] CHU Poitiers, Med Oncol Dept, Poitiers, France; [Derangere, Valentin; Ghiringhelli, Francois] Ctr Lutte Canc Georges Francois Leclerc, Dept Biol & Pathol Tumeurs, Plateforme Transfert Biol Cancerol, Dijon, France; [Roussille, Pauline] CHU Poitiers, Radiotherapy Dept, Poitiers, France; [Frouin, Eric; Godet, Julie] CHU Poitiers, Pathol Dept, Poitiers, France; [Frouin, Eric] Univ Poitiers, LITEC, CHU Poitiers, Poitiers, France; [Karayan-Tapon, Lucie] CHU Poitiers, Canc Biol Dept, Poitiers, France; [Ghiringhelli, Francois] INSERM U1231, Dijon, France	CHU Poitiers; Universite de Poitiers; CHU Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers; CHU Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers; CHU Poitiers; Universite de Poitiers; UNICANCER; Centre Georges-Francois Leclerc; CHU Poitiers; Universite de Poitiers; CHU Poitiers; Universite de Poitiers; CHU Poitiers; Universite de Poitiers; CHU Poitiers; Universite de Poitiers; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Tougeron, D (corresponding author), CHU Poitiers, Hepatogastroenterol Dept, Poitiers, France.; Tougeron, D (corresponding author), Univ Poitiers, PRODICET, INSERM, CHU Poitiers, Poitiers, France.	davidtougeron@hotmail.fr		Frouin, Eric/0000-0002-8432-3194; ghiringhelli, francois/0000-0002-5465-8305; Derangere, Valentin/0000-0002-6311-5628				Ahtiainen M, 2021, CANCERS, V13, DOI 10.3390/cancers13071530; Angelova M, 2018, CELL, V175, P751, DOI 10.1016/j.cell.2018.09.018; Baldin P, 2021, J PATHOL CLIN RES, V7, P27, DOI 10.1002/cjp2.178; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Berghoff AS, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2015-000024; Berghoff AS, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1057388; Christensen TD, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2290-5; Donadon M, 2017, J GASTROINTEST SURG, V21, P1226, DOI 10.1007/s11605-017-3446-6; Droeser RA, 2013, EUR J CANCER, V49, P2233, DOI 10.1016/j.ejca.2013.02.015; Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gatalica Z, 2014, CANCER EPIDEM BIOMAR, V23, P2965, DOI 10.1158/1055-9965.EPI-14-0654; Halama N, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24116; Laghi L, 2009, LANCET ONCOL, V10, P877, DOI 10.1016/S1470-2045(09)70186-X; Lee LH, 2016, MODERN PATHOL, V29, P1433, DOI 10.1038/modpathol.2016.139; Mege D, 2018, ANZ J SURG, V88, P140, DOI 10.1111/ans.14107; Mlecnik B, 2020, J CLIN ONCOL, V38, P3638, DOI 10.1200/JCO.19.03205; Mlecnik B, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx123; Ogiya R, 2017, ONCOTARGET, V8, P103671, DOI 10.18632/oncotarget.22110; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Pages F, 2020, ANN ONCOL, V31, P921, DOI 10.1016/j.annonc.2020.03.310; Reichling C, 2020, GUT, V69, P681, DOI 10.1136/gutjnl-2019-319292; Rimbert J, 2018, MODERN PATHOL, V31, P517, DOI 10.1038/modpathol.2017.119; Roussille P, 2021, RADIOTHER ONCOL, V158, P67, DOI 10.1016/j.radonc.2021.02.006; Roussille P, 2018, CANCERS, V10, DOI 10.3390/cancers10120504; Schweiger T, 2016, CLIN EXP METASTAS, V33, P727, DOI 10.1007/s10585-016-9813-y; Tanriverdi O, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0152-z; Teglasi V, 2017, NEURO-ONCOLOGY, V19, P1058, DOI 10.1093/neuonc/now309; Tougeron D, 2009, MODERN PATHOL, V22, P1186, DOI 10.1038/modpathol.2009.80; Van den Eynde M, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1824316; Van den Eynde M, 2018, CANCER CELL, V34, P1012, DOI 10.1016/j.ccell.2018.11.003	31	1	1	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 18	2021	12								750407	10.3389/fimmu.2021.750407	http://dx.doi.org/10.3389/fimmu.2021.750407			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT2JI	34733283	gold, Green Published			2022-12-18	WOS:000715694800001
J	Zlatina, K; Galuska, SP				Zlatina, Kristina; Galuska, Sebastian P.			Immunoglobulin Glycosylation - An Unexploited Potential for Immunomodulatory Strategies in Farm Animals	FRONTIERS IN IMMUNOLOGY			English	Review						immunoglobulin; antibody; glycosylation; Fc receptor; pregnancy; lactation; vaccination	FC-GAMMA-RIII; IGG FAB GLYCOSYLATION; HIGH-AFFINITY BINDING; RHEUMATOID-ARTHRITIS; N-GLYCOSYLATION; ANTIINFLAMMATORY ACTIVITY; ESCHERICHIA-COLI; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; DISEASE-ACTIVITY	The function of antibodies, namely the identification and neutralization of pathogens, is mediated by their antigen binding site (Fab). In contrast, the subsequent signal transduction for activation of the immune system is mediated by the fragment crystallizable (Fc) region, which interacts with receptors or other components of the immune system, such as the complement system. This aspect of binding and interaction is more precise, readjusted by covalently attached glycan structures close to the hinge region of immunoglobulins (Ig). This fine-tuning of Ig and its actual state of knowledge is the topic of this review. It describes the function of glycosylation at Ig in general and the associated changes due to corresponding glycan structures. We discuss the functionality of IgG glycosylation during different physiological statuses, like aging, lactation and pathophysiological processes. Further, we point out what is known to date about Ig glycosylation in farm animals and how new achievements in vaccination may contribute to improved animal welfare.	[Zlatina, Kristina; Galuska, Sebastian P.] Res Inst Farm Anim Biol FBN, Inst Reprod Biol, Dummerstorf, Germany	Forschungsinstitut fur Nutztierbiologie (FBN)	Zlatina, K (corresponding author), Res Inst Farm Anim Biol FBN, Inst Reprod Biol, Dummerstorf, Germany.	zlatina@fbn-dummerstorf.de			Open Access Fund	Open Access Fund	Funding The publication of this article was funded by the Open Access Fund of the Research Institute for Farm Animal Biology (FBN).	Ackerman ME, 2013, J CLIN INVEST, V123, P2183, DOI 10.1172/JCI65708; Ahmed AA, 2014, J MOL BIOL, V426, P3166, DOI 10.1016/j.jmb.2014.07.006; Allhorn M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001413; Alter G, 2018, SEMIN IMMUNOL, V39, P102, DOI 10.1016/j.smim.2018.05.003; Anthony RM, 2008, SCIENCE, V320, P373, DOI 10.1126/science.1154315; Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134; Anthony RM, 2008, P NATL ACAD SCI USA, V105, P19571, DOI 10.1073/pnas.0810163105; Arnold JN, 2007, ANNU REV IMMUNOL, V25, P21, DOI 10.1146/annurev.immunol.25.022106.141702; Bakovic MP, 2013, J PROTEOME RES, V12, P821, DOI 10.1021/pr300887z; Bartsch YC, 2020, J ALLERGY CLIN IMMUN, V146, P652, DOI 10.1016/j.jaci.2020.04.059; Beck A, 2012, MABS-AUSTIN, V4, P419, DOI 10.4161/mabs.20996; Berge ACB, 2009, J DAIRY SCI, V92, P286, DOI 10.3168/jds.2008-1433; Bhanu LSM, 2015, GLYCOCONJUGATE J, V32, P625, DOI 10.1007/s10719-015-9608-4; Bondt A, 2014, MOL CELL PROTEOMICS, V13, P3029, DOI 10.1074/mcp.M114.039537; Bondt A, 2013, J PROTEOME RES, V12, P4522, DOI 10.1021/pr400589m; Butler JE, 2005, MUCOSAL IMMUNOLOGY, 3RD EDITION, P1763, DOI 10.1016/B978-012491543-5/50107-8; Cameron F, 2014, DRUGS, V74, P147, DOI 10.1007/s40265-013-0167-3; Ceroni A, 2008, J PROTEOME RES, V7, P1650, DOI 10.1021/pr7008252; Ching KH, 2018, MABS-AUSTIN, V10, P71, DOI 10.1080/19420862.2017.1386825; Chung S, 2012, MABS-AUSTIN, V4, P326, DOI 10.4161/mabs.19941; Colucci M, 2015, J IMMUNOL, V194, P151, DOI 10.4049/jimmunol.1402025; Crispin M, 2013, P NATL ACAD SCI USA, V110, pE3544, DOI 10.1073/pnas.1310657110; de Haan N, 2016, J PROTEOME RES, V15, P1853, DOI 10.1021/acs.jproteome.6b00038; De Man YA, 2008, ARTHRIT RHEUM-ARTHR, V59, P1241, DOI 10.1002/art.24003; Decker Y, 2016, MULT SCLER J, V22, P1794, DOI 10.1177/1352458516631036; Dekkers G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00877; Einarsdottir HK, 2013, GLYCOCONJUGATE J, V30, P147, DOI 10.1007/s10719-012-9381-6; Elsouri K, 2021, CUREUS, V13, DOI 10.7759/cureus.15543; Ercan A, 2010, ARTHRITIS RHEUM-US, V62, P2239, DOI 10.1002/art.27533; Feeney S, 2019, FOOD SCI NUTR, V7, P1564, DOI 10.1002/fsn3.950; Ferrara C, 2006, J BIOL CHEM, V281, P5032, DOI 10.1074/jbc.M510171200; Ferrara C, 2011, P NATL ACAD SCI USA, V108, P12669, DOI 10.1073/pnas.1108455108; Frank M, 2014, J MOL BIOL, V426, P1799, DOI 10.1016/j.jmb.2014.01.011; Gilgunn S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159859; HANISCH FG, 1993, INFECT IMMUN, V61, P2108, DOI 10.1128/IAI.61.5.2108-2115.1993; Hunter RL, 2006, ANN CLIN LAB SCI, V36, P371; Jensen RG., 1995, HDB MILK COMPOSITION, P919; Jinesh P, 2021, AMINO ACIDS, V53, P533, DOI 10.1007/s00726-021-02945-5; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Krapp S, 2003, J MOL BIOL, V325, P979, DOI 10.1016/S0022-2836(02)01250-0; Kristic J, 2014, J GERONTOL A-BIOL, V69, P779, DOI 10.1093/gerona/glt190; Kronimus Y, 2019, J AUTOIMMUN, V96, P14, DOI 10.1016/j.jaut.2018.10.006; Kumar BSG, 2020, INT J BIOL MACROMOL, V155, P605, DOI 10.1016/j.ijbiomac.2020.03.253; LARSSON A, 1993, POULTRY SCI, V72, P1807, DOI 10.3382/ps.0721807; Leiva CL, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2020.106269; Lilius EM, 2001, CURR OPIN INFECT DIS, V14, P295, DOI 10.1097/00001432-200106000-00008; Lu LL, 2016, CELL, V167, P433, DOI 10.1016/j.cell.2016.08.072; Lundstrom SL, 2014, J ALZHEIMERS DIS, V38, P567, DOI 10.3233/JAD-131088; MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237; Martinez-Pomares L, 2012, J LEUKOCYTE BIOL, V92, P1177, DOI 10.1189/jlb.0512231; Matsumiya S, 2007, J MOL BIOL, V368, P767, DOI 10.1016/j.jmb.2007.02.034; Mimura Y, 2000, MOL IMMUNOL, V37, P697, DOI 10.1016/S0161-5890(00)00105-X; Miyoshi E, 2016, PROTEOM CLIN APPL, V10, P384, DOI 10.1002/prca.201500089; Niwa R, 2005, J IMMUNOL METHODS, V306, P151, DOI 10.1016/j.jim.2005.08.009; PAREKH R, 1988, J EXP MED, V167, P1731, DOI 10.1084/jem.167.5.1731; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; Pereira EPV, 2019, INT IMMUNOPHARMACOL, V73, P293, DOI 10.1016/j.intimp.2019.05.015; Reiding KR, 2019, MOL CELL PROTEOMICS, V18, P3, DOI 10.1074/mcp.RA117.000454; Reiding KR, 2018, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00241; Royle L, 2003, J BIOL CHEM, V278, P20140, DOI 10.1074/jbc.M301436200; Ruhaak LR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012566; Schroten H, 1998, INFECT IMMUN, V66, P3971, DOI 10.1128/IAI.66.8.3971-3973.1998; Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140-6736(10)60826-4; Selman MHJ, 2011, J PROTEOME RES, V10, P143, DOI 10.1021/pr1004373; Shade KTC, 2020, NATURE, V582, P265, DOI 10.1038/s41586-020-2311-z; Sheng L, 2018, INT J BIOL MACROMOL, V108, P277, DOI 10.1016/j.ijbiomac.2017.12.012; Shepard HM, 2017, CLIN MED, V17, P220, DOI 10.7861/clinmedicine.17-3-220; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Sondermann P, 2013, P NATL ACAD SCI USA, V110, P9868, DOI 10.1073/pnas.1307864110; Sonneveld ME, 2016, BRIT J HAEMATOL, V174, P310, DOI 10.1111/bjh.14053; Stanley P., 2015, ESSENTIALS GLYCOBIOL; STANWORTH DR, 1993, ALLERGY, V48, P67, DOI 10.1111/j.1398-9995.1993.tb00687.x; Suzuki N, 2004, GLYCOBIOLOGY, V14, P275, DOI 10.1093/glycob/cwh031; Takimori S, 2011, FEBS J, V278, P3769, DOI 10.1111/j.1742-4658.2011.08299.x; Temming AR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46484-2; Thomann M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134949; Vaccari M, 2016, NAT MED, V22, P762, DOI 10.1038/nm.4105; van de Bovenkamp FS, 2016, J IMMUNOL, V196, P1435, DOI 10.4049/jimmunol.1502136; Vuckovic F, 2015, ARTHRITIS RHEUMATOL, V67, P2978, DOI 10.1002/art.39273; Wada R, 2019, MABS-AUSTIN, V11, P350, DOI 10.1080/19420862.2018.1551044; WOLD AE, 1990, INFECT IMMUN, V58, P3073, DOI 10.1128/IAI.58.9.3073-3077.1990; Wuhrer M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0450-1; Yu XJ, 2013, J MOL BIOL, V425, P1253, DOI 10.1016/j.jmb.2013.02.006	85	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 18	2021	12								753294	10.3389/fimmu.2021.753294	http://dx.doi.org/10.3389/fimmu.2021.753294			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT1FK	34733284	gold, Green Published			2022-12-18	WOS:000715617000001
J	Chaouat, AE; Seliger, B; Mandelboim, O; Schmiedel, D				Chaouat, Abigael Eva; Seliger, Barbara; Mandelboim, Ofer; Schmiedel, Dominik			The HHV-6A Proteins U20 and U21 Target NKG2D Ligands to Escape Immune Recognition	FRONTIERS IN IMMUNOLOGY			English	Article						NKG2D activating receptor; NK cells; HHV-6A infection; host-pathogen-interaction; viral immune evasion; herpesvirus	T-CELLS; DOWN-REGULATION; EXPRESSION; INFECTION; GENE; NK	The coevolution of the human immune system and herpesviruses led to the emergence and diversification of both cellular danger molecules recognized by immune cells on the one hand and viral countermeasures that prevent the expression of these proteins on infected cells on the other. There are eight ligands for the activating receptor NKG2D in humans - MICA, MICB, ULBP1-6. Several of them are induced and surface-expressed on herpesvirus-infected cells to serve as danger signals to activate the immune system. Therefore, these ligands are frequently targeted for suppression by viral immune evasion mechanisms. Mechanisms to downregulate NKG2D ligands and thereby escape immune recognition have been identified in all other human herpesviruses (HHV), except for HHV-6A. In this study, we identify two HHV-6A encoded immunoevasins, U20 and U21, which suppress the expression of the NKG2D ligands ULBP1 and ULBP3, respectively, during infection. Additionally, MICB is targeted by a so far unexplored viral protein. Due to the diminished NKG2D ligand surface expression on infected cells, recognition of HHV-6A infected cells by innate immune cells is impaired. Importantly, our study indicates that immune escape mechanisms between the related herpesviruses HHV-6A and HHV-6B are evolutionary conserved as the same NKG2D ligands are targeted. Our data contribute an additional piece of evidence for the importance of the NKG2D receptor - NKG2D ligand axis during human herpesvirus infections and sheds light on immune evasion mechanisms of HHV-6A.	[Chaouat, Abigael Eva; Mandelboim, Ofer; Schmiedel, Dominik] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, BioMed Res Inst Israel Canada,Fac Med, Jerusalem, Israel; [Seliger, Barbara] Martin Luther Univ Halle Wittenberg, Inst Med Immunol, Halle Wittenberg, Germany; [Seliger, Barbara; Schmiedel, Dominik] Fraunhofer Inst Cell Therapy & Immunol IZI, Dept GMP Dev & ATMP Design, Leipzig, Germany	Hebrew University of Jerusalem; Martin Luther University Halle Wittenberg; Fraunhofer Gesellschaft	Mandelboim, O; Schmiedel, D (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, BioMed Res Inst Israel Canada,Fac Med, Jerusalem, Israel.; Schmiedel, D (corresponding author), Fraunhofer Inst Cell Therapy & Immunol IZI, Dept GMP Dev & ATMP Design, Leipzig, Germany.	oferm@ekmd.huji.ac.il; dominik.schmiedel@izi.fraunhofer.de		Mandelboim, Ofer/0000-0002-9354-1855	Israel Innovation Authority	Israel Innovation Authority	This study was supported by following fundings: Israel Innovation Authority (Kamin grant) 62615; Israel Science Foundation (Moked grant) 442/18; GIF Foundation 1412-414.13/2017; ICRF professorship grant; ISF Israel- China grant 2554/18; MOST-DKFZ grant 3-14931; and Ministry of Science and Technology grant 3-14764 (all to OM).	Agut H, 2015, CLIN MICROBIOL REV, V28, P313, DOI 10.1128/CMR.00122-14; Berhani O, 2019, EUR J IMMUNOL, V49, P228, DOI 10.1002/eji.201847611; Caselli E, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002951; Chaigne-Delalande B, 2013, SCIENCE, V341, P186, DOI 10.1126/science.1240094; Dominguez G, 1999, J VIROL, V73, P8040, DOI 10.1128/JVI.73.10.8040-8052.1999; Esteso G, 2014, J IMMUNOL, V193, P1344, DOI 10.4049/jimmunol.1303441; Finkel Y, 2020, ELIFE, V9, DOI 10.7554/eLife.50960; French C, 1999, VIROLOGY, V262, P139, DOI 10.1006/viro.1999.9875; Glosson NL, 2007, VIROLOGY, V365, P125, DOI 10.1016/j.virol.2007.03.048; Krug LT, 2014, CURR OPIN VIROL, V9, P170, DOI 10.1016/j.coviro.2014.10.004; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Nielsen CB, 2007, RNA, V13, P1894, DOI 10.1261/rna.768207; Nukui M, 2015, J VIROL, V89, P2615, DOI 10.1128/JVI.02007-14; Ogata M, 2013, CLIN INFECT DIS, V57, P671, DOI 10.1093/cid/cit358; Pritchett J.C., 2014, TREATING HHV 6 INFEC; Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199; Raulet DH, 2001, ANNU REV IMMUNOL, V19, P291, DOI 10.1146/annurev.immunol.19.1.291; Rizzo R, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02143; Saez-Borderias A, 2006, EUR J IMMUNOL, V36, P3198, DOI 10.1002/eji.200636682; Schmiedel D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02040; Schmiedel D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00390; Schmiedel D, 2016, J VIROL, V90, P9608, DOI 10.1128/JVI.01164-16; Sullivan BM, 2008, J VIROL, V82, P602, DOI 10.1128/JVI.01571-07; Tang HM, 2010, VIROLOGY, V407, P360, DOI 10.1016/j.virol.2010.08.018; Tirosh O, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005288; Walsh KB, 2008, J VIROL, V82, P3031, DOI 10.1128/JVI.02033-07; Whyte ML, 2021, J VIROL, V95, DOI 10.1128/JVI.01628-20	27	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2021	12								714799	10.3389/fimmu.2021.714799	http://dx.doi.org/10.3389/fimmu.2021.714799			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WS0IT	34721381	gold, Green Published			2022-12-18	WOS:000714874700001
J	Tejwani, V; McCormack, A; Suresh, K; Woo, H; Xu, NC; Davis, MF; Brigham, E; Hansel, NN; McCormack, MC; D'Alessio, FR				Tejwani, Vickram; McCormack, Amanda; Suresh, Karthik; Woo, Han; Xu, Ningchun; Davis, Meghan F.; Brigham, Emily; Hansel, Nadia N.; McCormack, Meredith C.; D'Alessio, Franco R.			Dexamethasone-Induced FKBP51 Expression in CD4(+) T-Lymphocytes Is Uniquely Associated With Worse Asthma Control in Obese Children With Asthma	FRONTIERS IN IMMUNOLOGY			English	Article						asthma; immune mechanism; obesity; steroid-resistance; T-lymphocytes	GLUCOCORTICOID-RECEPTOR; PERIPHERAL-BLOOD; GENE-EXPRESSION; OVERWEIGHT; CELLS; CHILDHOOD	Introduction There is evidence that obesity, a risk factor for asthma severity and morbidity, has a unique asthma phenotype which is less atopic and less responsive to inhaled corticosteroids (ICS). Peripheral blood mononuclear cells (PBMC) are important to the immunologic pathways of obese asthma and steroid resistance. However, the cellular source associated with steroid resistance has remained elusive. We compared the lymphocyte landscape among obese children with asthma to matched normal weight children with asthma and assessed relationship to asthma control.</p> Methods High-dimensional flow cytometry of PBMC at baseline and after dexamethasone stimulation was performed to characterize lymphocyte subpopulations, T-lymphocyte polarization, proliferation (Ki-67+), and expression of the steroid-responsive protein FK506-binding protein 51 (FKBP51). T-lymphocyte populations were compared between obese and normal-weight participants, and an unbiased, unsupervised clustering analysis was performed. Differentially expressed clusters were compared with asthma control, adjusted for ICS and exhaled nitric oxide.</p> Results In the obese population, there was an increased cluster of CD4(+) T-lymphocytes expressing Ki-67 and FKBP51 at baseline and CD4(+) T-lymphocytes expressing FKBP51 after dexamethasone stimulation. CD4(+) Ki-67 and FKBP51 expression at baseline showed no association with asthma control. Dexamethasone-induced CD4(+) FKBP51 expression was associated with worse asthma control in obese participants with asthma. FKBP51 expression in CD8(+) T cells and CD19(+) B cells did not differ among groups, nor did polarization profiles for Th1, Th2, Th9, or Th17 percentage.</p> Discussion Dexamethasone-induced CD4(+) FKBP51 expression is uniquely associated with worse asthma control in obese children with asthma and may underlie the corticosteroid resistance observed in this population.</p>	[Tejwani, Vickram; Suresh, Karthik; Woo, Han; Brigham, Emily; Hansel, Nadia N.; McCormack, Meredith C.; D'Alessio, Franco R.] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD 21218 USA; [Tejwani, Vickram] Cleveland Clin, Resp Inst, Cleveland, OH 44106 USA; [McCormack, Amanda; Davis, Meghan F.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth & Engn, Baltimore, MD USA; [Xu, Ningchun] Johns Hopkins Univ, Flow Cytometry Core, Baltimore, MD USA; [Davis, Meghan F.] Johns Hopkins Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD USA; [Davis, Meghan F.] Johns Hopkins Sch Med, Div Infect Dis, Baltimore, MD USA	Johns Hopkins University; Cleveland Clinic Foundation; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Tejwani, V (corresponding author), Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD 21218 USA.; Tejwani, V (corresponding author), Cleveland Clin, Resp Inst, Cleveland, OH 44106 USA.	tejwanv@ccf.org		Koehl, Rachelle/0000-0002-7797-7456; Pham, Hewlett/0000-0003-0330-6104	CHEST Foundation Research Grant; Johns Hopkins Eudowood Foundation; NIH NIEHS [P50ES018176-09]; AIRWEIGHS; EPA [83615201]; National Institutes of Health (NIH) [T32HL007534-36, NHLBI 1F32HL149258-01]; NIEHS T32 grant [T32ES07141]; NIH K08 [NHLBI K08HL13205]; NIH K23 [NIEHS K23ES029105-01A1]; NIH R01 [NHLBI HL131812];  [OD K01OD019918]	CHEST Foundation Research Grant; Johns Hopkins Eudowood Foundation; NIH NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); AIRWEIGHS; EPA(United States Environmental Protection Agency); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS T32 grant; NIH K08(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH K23(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH R01(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); 	This work was directly funded by a CHEST Foundation Research Grant for Severe Asthma, a Baurenschmidt Award from the Johns Hopkins Eudowood Foundation, NIH NIEHS P50ES018176-09, AIRWEIGHS, and EPA (agreement number 83615201 to Hansel). VT is supported by a National Institutes of Health (NIH) T32 (T32HL007534-36) and F32 (NHLBI 1F32HL149258-01) grant, AM is supported by an NIEHS T32 grant (T32ES07141), KS is supported by an NIH K08 (NHLBI K08HL13205), EB is supported by an NIH K23 (NIEHS K23ES029105-01A1), MD through a K01 (OD K01OD019918), and FRD by NIH R01 (NHLBI HL131812).	Balsevich G, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01783-y; Barlow SE, 2007, PEDIATRICS, V120, pS164, DOI 10.1542/peds.2007-2329C; Bigler J, 2017, AM J RESP CRIT CARE, V195, P1311, DOI 10.1164/rccm.201604-0866OC; Bime C, 2012, J ALLERGY CLIN IMMUN, V130, P1078, DOI 10.1016/j.jaci.2012.07.058; Boulet LP, 2007, RESP MED, V101, P2240, DOI 10.1016/j.rmed.2007.06.031; Centers for Disease Control and Prevention, 2019, MOST REC ASTHM DAT; Chun E, 2011, J CLIN IMMUNOL, V31, P122, DOI 10.1007/s10875-010-9463-9; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; Forno E, 2011, J ALLERGY CLIN IMMUN, V127, P741, DOI 10.1016/j.jaci.2010.12.010; Gaali S, 2015, NAT CHEM BIOL, V11, P33, DOI 10.1038/nchembio.1699; Grant-Guimaraes J, 2016, GASTROENTEROL CLIN N, V45, P715, DOI 10.1016/j.gtc.2016.07.007; Hinds TD, 2014, PHARMACOL RES PERSPE, V2, DOI 10.1002/prp2.76; Jiang TW, 2014, ASIAN PAC J ALLERGY, V32, P75, DOI 10.12932/AP0332.32.1.2014; Joetham A, 2007, J IMMUNOL, V178, P1433, DOI 10.4049/jimmunol.178.3.1433; Kastle M, 2018, EUR J IMMUNOL, V48, P1904, DOI 10.1002/eji.201847699; McKeen HD, 2008, ENDOCRINOLOGY, V149, P5724, DOI 10.1210/en.2008-0168; Menke A, 2012, NEUROPSYCHOPHARMACOL, V37, P1455, DOI 10.1038/npp.2011.331; Muehling LM, 2017, J ALLERGY CLIN IMMUN, V140, P1523, DOI 10.1016/j.jaci.2017.02.025; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732; Pelaia C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.603312; Rastogi D, 2015, AM J RESP CRIT CARE, V191, P149, DOI 10.1164/rccm.201409-1587OC; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053; Smedlund KB, 2021, TRENDS ENDOCRIN MET, V32, P862, DOI 10.1016/j.tem.2021.08.003; Sun XM, 2018, CHROMOSOMA, V127, P175, DOI 10.1007/s00412-018-0659-8; Suresh K, 2019, J CLIN INVEST, V129, P4305, DOI 10.1172/JCI128654; Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Wei Q, 2021, ALLERGY ASTHMA CL IM, V17, DOI 10.1186/s13223-020-00504-3; Wochnik GM, 2005, J BIOL CHEM, V280, P4609, DOI 10.1074/jbc.M407498200; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Yuksel H, 2013, PEDIAT ALLER IMM PUL, V26, P193, DOI 10.1089/ped.2012.0216	35	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2021	12								744782	10.3389/fimmu.2021.744782	http://dx.doi.org/10.3389/fimmu.2021.744782			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WS4WG	34721414	Green Published, gold			2022-12-18	WOS:000715182700001
J	Castejon, P; Cabas, I; Gomez, V; Chaves-Pozo, E; Cerezo-Ortega, I; Morinigo, MA; Martinez-Manzanares, E; Galindo-Villegas, J; Garcia-Ayala, A				Castejon, Pablo; Cabas, Isabel; Gomez, Victoria; Chaves-Pozo, Elena; Cerezo-Ortega, Isabel; Morinigo, Miguel Angel; Martinez-Manzanares, Eduardo; Galindo-Villegas, Jorge; Garcia-Ayala, Alfonsa			Vaccination of Gilthead Seabream After Continuous Xenoestrogen Oral Exposure Enhances the Gut Endobolome and Immune Status via GPER1	FRONTIERS IN IMMUNOLOGY			English	Article						16S rRNA; endocrine disruptors (EDCs); endobolome; estrogens; fish; G protein-coupled receptor 1; vaccination; vitellogenin (VTG)	SPARUS-AURATA L.; ESTROGEN; MICROBIOTA; RESPONSES; ACTIVATION; FISH	In fish culture settings, the exogenous input of steroids is a matter of concern. Recently, we unveiled that in the gilthead seabream (Sparus aurata), the G protein-coupled estrogen receptor agonist G-1 (G1) and the endocrine disruptor 17 alpha-ethinylestradiol (EE2) are potent modulators in polyreactive antibody production. However, the integral role of the microbiota upon immunity and antibody processing in response to the effect of EE2 remains largely unexplored. Here, juvenile seabreams continuously exposed for 84 days to oral G1 or EE2 mixed in the fish food were intraperitoneally (i.p.) immune primed on day 42 with the model antigen keyhole limpet hemocyanin (KLH). A critical panel of systemic and mucosal immune markers, serum VTG, and humoral, enzymatic, and bacteriolytic activities were recorded and correlated with gut bacterial metagenomic analysis 1 day post-priming (dpp). Besides, at 15 dpp, animals received a boost to investigate the possible generation of specific anti-KLH antibodies at the systemic and mucosal interphases by the end of the trial. On day 43, EE2 but not G1 induced a significant shift in the serum VTG level of naive fish. Simultaneously, significant changes in some immune enzymatic activities in the serum and gut mucus of the EE2-treated group were recorded. In comparison, the vaccine priming immunization resulted in an attenuated profile of most enzymatic activities in the same group. The gut genes qPCR analysis exhibited a related pattern, only emphasized by a significant shift in the EE2 group's il1b expression. The gut bacterial microbiome status underwent 16S rRNA dynamic changes in alpha diversity indices, only with the exposure to oral G1, supporting functional alterations on cellular processes, signaling, and lipid metabolism in the microbiota. By the same token, the immunization elevated the relative abundance of Fusobacteria only in the control group, while this phylum was depleted in both the treated groups. Remarkably, the immunization also promoted changes in the bacterial class Betaproteobacteria and the estrogen-associated genus Novosphingobium. Furthermore, systemic and mucosal KLH-specific immunoglobulin (Ig)M and IgT levels in the fully vaccinated fish showed only slight changes 84 days post-estrogenic oral administration. In summary, our results highlight the intrinsic relationship among estrogens, their associated receptors, and immunization in the ubiquitous fish immune regulation and the subtle but significant crosstalk with the gut endobolome.</p>	[Castejon, Pablo; Cabas, Isabel; Gomez, Victoria; Garcia-Ayala, Alfonsa] Univ Murcia, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Inst Murciano Invest Biosanitaria IMIB, Dept Cell Biol & Histol, Reg Campus Int Excellence Campus Mare Nostrum, Murcia, Spain; [Chaves-Pozo, Elena] Spanish Inst Oceanog IEO CSIC, Oceanog Ctr Murcia, Aquaculture Dept, Murcia, Spain; [Cerezo-Ortega, Isabel; Morinigo, Miguel Angel; Martinez-Manzanares, Eduardo] Univ Malaga, Fac Sci, Dept Microbiol, Malaga, Spain; [Galindo-Villegas, Jorge] Nord Univ, Fac Biosci & Aquaculture, Bodo, Norway	CIBER - Centro de Investigacion Biomedica en Red; CIBERER; University of Murcia; Universidad de Malaga; Nord University	Galindo-Villegas, J (corresponding author), Nord Univ, Fac Biosci & Aquaculture, Bodo, Norway.	jorge.galindo-villegas@nord.no	Galindo-Villegas, Jorge/K-7075-2014	Galindo-Villegas, Jorge/0000-0002-4250-2477; Cerezo, Isabel M./0000-0002-9265-3732				Acosta F, 2021, AQUACULTURE, V532, DOI 10.1016/j.aquaculture.2020.736004; Aguilera M, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.578007; Angosto D, 2018, DEV COMP IMMUNOL, V85, P18, DOI 10.1016/j.dci.2018.03.017; Aramaki T, 2020, BIOINFORMATICS, V36, P2251, DOI 10.1093/bioinformatics/btz859; Benedek G, 2017, J NEUROIMMUNOL, V310, P51, DOI 10.1016/j.jneuroim.2017.06.007; Binda C, 2018, DIGEST LIVER DIS, V50, P421, DOI 10.1016/j.dld.2018.02.012; Brescia S, 2020, CRIT REV TOXICOL, V50, P213, DOI 10.1080/10408444.2020.1740973; Cabas I, 2013, J IMMUNOL, V191, P4628, DOI 10.4049/jimmunol.1301613; Cabas I, 2012, DEV COMP IMMUNOL, V36, P547, DOI 10.1016/j.dci.2011.09.011; Piazzon MC, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02512; Balasch JC, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00062; Cheesman SE, 2011, P NATL ACAD SCI USA, V108, P4570, DOI 10.1073/pnas.1000072107; Chen KL, 2016, TRENDS ENDOCRIN MET, V27, P752, DOI 10.1016/j.tem.2016.08.001; Chen YS, 2017, FISH SHELLFISH IMMUN, V69, P1, DOI 10.1016/j.fsi.2017.08.003; Combarnous Y, 2019, TOXICS, V7, DOI 10.3390/toxics7010005; DeLeon C, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.578536; Dhakal D, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01106; Dhariwal A, 2017, NUCLEIC ACIDS RES, V45, pW180, DOI 10.1093/nar/gkx295; Egerton S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00873; Elena CP, 2019, AQUACULTURE, V505, P137, DOI 10.1016/j.aquaculture.2019.02.039; Ervin SM, 2019, J BIOL CHEM, V294, P18586, DOI 10.1074/jbc.RA119.010950; Firmino JP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.695973; Firmino JP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.625297; Flores R, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-253; Galindo-Villegas J, 2019, FISH SHELLFISH IMMUN, V85, P31, DOI 10.1016/j.fsi.2018.02.047; Galindo-Villegas J, 2016, J IMMUNOL, V196, P738, DOI 10.4049/jimmunol.1501729; Galindo-Villegas J, 2012, P NATL ACAD SCI USA, V109, pE2605, DOI 10.1073/pnas.1209920109; Haldar S, 2010, MICROBIOL RES, V165, P639, DOI 10.1016/j.micres.2009.12.001; Hegedus B, 2018, APPL MICROBIOL BIOT, V102, P305, DOI 10.1007/s00253-017-8553-5; Hosomi K, 2020, VACCINE, V38, P6959, DOI 10.1016/j.vaccine.2020.08.079; Huang MQ, 2021, ECOTOX ENVIRON SAFE, V208, DOI 10.1016/j.ecoenv.2020.111429; Huang NN, 2021, CRIT REV FOOD SCI, V61, P2399, DOI 10.1080/10408398.2020.1777932; Ibero J, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.588300; Jami M, 2015, MICROBIOL RES, V175, P6, DOI 10.1016/j.micres.2015.01.009; Jiang I, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115644; Jin JW, 2020, J ENV SCI HEAL C-TOX, V38, P142, DOI 10.1080/26896583.2020.1761204; Khan D, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00635; Kormas KA, 2014, MICROBIOLOGYOPEN, V3, P718, DOI 10.1002/mbo3.202; La Merrill MA, 2020, NAT REV ENDOCRINOL, V16, P45, DOI 10.1038/s41574-019-0273-8; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Liarte S, 2011, DEV COMP IMMUNOL, V35, P19, DOI 10.1016/j.dci.2010.07.007; Lopez-Canovas AE, 2020, FOODS, V9, DOI 10.3390/foods9121750; Lynn DJ, 2018, J LEUKOCYTE BIOL, V103, P225, DOI 10.1189/jlb.5MR0617-216R; Maciuszek M, 2020, FISH SHELLFISH IMMUN, V107, P238, DOI 10.1016/j.fsi.2020.10.005; Magalhaes R, 2020, AQUACULTURE, V516, DOI 10.1016/j.aquaculture.2019.734644; Mauricio R, 2018, ENVIRON MONIT ASSESS, V190, DOI 10.1007/s10661-018-6701-8; Meng KF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.654758; Mhaouty-Kodja S, 2018, NEUROENDOCRINOLOGY, V107, P400, DOI 10.1159/000494558; Montalban-Arques A, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00512; Palacios-Flores K, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2025192118; Panteli N, 2020, COMP BIOCHEM PHYS D, V36, DOI 10.1016/j.cbd.2020.100738; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Piazzon MC, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00637; Pirr S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.584288; Plottel CS, 2011, CELL HOST MICROBE, V10, P324, DOI 10.1016/j.chom.2011.10.003; Ramirez-Barrantes R, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00444; Rodenas MC, 2016, FISH SHELLFISH IMMUN, V52, P189, DOI 10.1016/j.fsi.2016.03.041; Rodenas MC, 2015, DEV COMP IMMUNOL, V53, P283, DOI 10.1016/j.dci.2015.06.014; Rodenas MC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00736; Rodriguez A, 2003, ANAT REC PART A, V272A, P415, DOI 10.1002/ar.a.10048; Salwan R, 2020, MICROBIOL RES, V231, DOI 10.1016/j.micres.2019.126374; Schuler-Toprak S, 2020, J CANCER RES CLIN, V146, P3175, DOI 10.1007/s00432-020-03333-4; Shen HH, 2021, THERANOSTICS, V11, P3512, DOI 10.7150/thno.55241; Shved N, 2007, J ENDOCRINOL, V195, P513, DOI 10.1677/JOE-07-0295; Siriyappagouder P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00978; Siriyappagouder P, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01868; Sommer F, 2013, NAT REV MICROBIOL, V11, P227, DOI 10.1038/nrmicro2974; Stojanov S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111715; Taneja V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01931; Triplett KD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37951-3; Valero Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64522-2; Waghulde H, 2018, HYPERTENSION, V72, P1125, DOI 10.1161/HYPERTENSIONAHA.118.11175; Wang C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.397; Wang XW, 2020, AM J PHYSIOL-ENDOC M, V319, pE734, DOI 10.1152/ajpendo.00071.2020; Wu JF, 2020, FOOD FUNCT, V11, P9585, DOI [10.1039/d0fo02379e, 10.1039/D0FO02379E]; Joe JTX, 2021, LIFE-BASEL, V11, DOI 10.3390/life11020099; Xu Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10728; Yoon SH, 2017, INT J SYST EVOL MICR, V67, P1613, DOI 10.1099/ijsem.0.001755; Yu X, 2014, AM J PHYSIOL-ENDOC M, V307, pE398, DOI 10.1152/ajpendo.00534.2013; Zhang KS, 2014, BIOMED PHARMACOTHER, V68, P1037, DOI 10.1016/j.biopha.2014.09.003; Zhang RX, 2022, AUTOPHAGY, V18, P4, DOI 10.1080/15548627.2021.1885147; Zheng Y, 2019, J MOL ENDOCRINOL, V63, P103, DOI 10.1530/JME-18-0253	82	1	1	2	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								742827	10.3389/fimmu.2021.742827	http://dx.doi.org/10.3389/fimmu.2021.742827			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT6NR	34721409	Green Published, gold			2022-12-18	WOS:000715979800001
J	He, XL; Wang, L; Liu, LQ; Gao, J; Long, BG; Chi, F; Hu, TT; Wan, Y; Gong, ZL; Li, L; Zhen, PL; Zhang, TS; Cao, H; Huang, SH				He, Xiaolong; Wang, Lei; Liu, Liqun; Gao, Jie; Long, Beiguo; Chi, Feng; Hu, Tongtong; Wan, Yu; Gong, Zelong; Li, Li; Zhen, Peilin; Zhang, Tiesong; Cao, Hong; Huang, Sheng-He			Endogenous alpha 7 nAChR Agonist SLURP1 Facilitates Escherichia coli K1 Crossing the Blood-Brain Barrier	FRONTIERS IN IMMUNOLOGY			English	Article						SLURP1; E. coli K1 meningitis; blood-brain barrier; inflammation; alpha 7 nAChR	CHOLINERGIC ANTIINFLAMMATORY PATHWAY; ACETYLCHOLINE-RECEPTORS; NICOTINIC RECEPTOR; EXPRESSION; DIFFERENTIATION; INFLAMMATION; ACTIVATION; INVASION; PEPTIDE	Alpha 7 nicotinic acetylcholine receptor (alpha 7 nAChR) is critical for the pathogenesis of Escherichia coli (E. coli) K1 meningitis, a severe central nervous system infection of the neonates. However, little is known about how E. coli K1 manipulates alpha 7 nAChR signaling. Here, through employing immortalized cell lines, animal models, and human transcriptional analysis, we showed that E. coli K1 infection triggers releasing of secreted Ly6/Plaur domain containing 1 (SLURP1), an endogenous alpha 7 nAChR ligand. Exogenous supplement of SLURP1, combined with SLURP1 knockdown or overexpression cell lines, showed that SLURP1 is required for E. coli K1 invasion and neutrophils migrating across the blood-brain barrier (BBB). Furthermore, we found that SLURP1 is required for E. coli K1-induced alpha 7 nAChR activation. Finally, the promoting effects of SLURP1 on the pathogenesis of E. coli K1 meningitis was significantly abolished in the alpha 7 nAChR knockout mice. These results reveal that E. coli K1 exploits SLURP1 to activate alpha 7 nAChR and facilitate its pathogenesis, and blocking SLURP1-alpha 7 nAChR interaction might represent a novel therapeutic strategy for E. coli K1 meningitis.	[He, Xiaolong; Wang, Lei; Gao, Jie; Long, Beiguo; Hu, Tongtong; Wan, Yu; Gong, Zelong; Cao, Hong; Huang, Sheng-He] Southern Med Univ, Sch Publ Hlth, Dept Microbiol, Guangdong Prov Key Lab Trop Dis Res, Guangzhou, Peoples R China; [He, Xiaolong; Gao, Jie; Zhen, Peilin] Sun Yat Sen Univ, Affiliated Jiangmen Hosp, Jiangmen Cent Hosp, Dept Infect Dis, Jiangmen, Peoples R China; [Liu, Liqun; Chi, Feng; Li, Li; Huang, Sheng-He] Univ Southern Calif, Childrens Hosp Los Angeles, Saban Res Inst, Los Angeles, CA 90007 USA; [Liu, Liqun] Cent South Univ, Xiangya Hosp 2, Dept Pediat, Changsha, Peoples R China; [Li, Li; Zhang, Tiesong; Huang, Sheng-He] Kunming Childrens Hosp, Yunnan Inst Pediat, Kunming Key Lab Children Infect & Immun, Kunming, Yunnan, Peoples R China	Southern Medical University - China; Sun Yat Sen University; Children's Hospital Los Angeles; University of Southern California; Central South University	Cao, H (corresponding author), Southern Med Univ, Sch Publ Hlth, Dept Microbiol, Guangdong Prov Key Lab Trop Dis Res, Guangzhou, Peoples R China.; Zhang, TS (corresponding author), Kunming Childrens Hosp, Yunnan Inst Pediat, Kunming Key Lab Children Infect & Immun, Kunming, Yunnan, Peoples R China.	zts68420@sina.com; gzhcao@smu.edu.cn			National Natural Science Foundation of China [81871198, 81801985, 81873762, 82060192]; China Postdoctoral Science Foundation [2020M682808, 2021T140299]; Key Research Program of Hunan Provincial Department of Science and Technology, China [2022SK2032]; Postdoctoral innovative practice project of Jiang Meng [JMBSH2020B04]; Yunnan Key Laboratory of Children's Major Disease Research [202005AG070073]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Key Research Program of Hunan Provincial Department of Science and Technology, China; Postdoctoral innovative practice project of Jiang Meng; Yunnan Key Laboratory of Children's Major Disease Research	This work was financially supported by the National Natural Science Foundation of China (No. 81871198; 81801985; 81873762; 82060192), China Postdoctoral Science Foundation (No. 2020M682808; 2021T140299), the Key Research Program of Hunan Provincial Department of Science and Technology, China (No. 2022SK2032), Postdoctoral innovative practice project of Jiang Meng (No. JMBSH2020B04), and the Yunnan Key Laboratory of Children's Major Disease Research (202005AG070073).	Adermann K, 1999, PROTEIN SCI, V8, P810, DOI 10.1110/ps.8.4.810; Andersson U, 2020, MOL MED, V26, DOI 10.1186/s10020-020-00184-0; Arredondo J, 2002, J CELL BIOL, V159, P325, DOI 10.1083/jcb.200206096; Arvanitis CD, 2020, NAT REV CANCER, V20, P26, DOI 10.1038/s41568-019-0205-x; Bagaitkar Juhi, 2008, Tob Induc Dis, V4, P12, DOI 10.1186/1617-9625-4-12; Benfante R, 2021, AGING CLIN EXP RES, V33, P823, DOI 10.1007/s40520-019-01359-4; Bhattacharyya A, 2021, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.582070; Biondi EA, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0874; Campbell G, 2019, BIOCHEM BIOPH RES CO, V517, P729, DOI 10.1016/j.bbrc.2019.07.123; Chen YH, 2002, CELL MICROBIOL, V4, P503, DOI 10.1046/j.1462-5822.2002.00209.x; Chernyavsky AI, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/609086; Chernyavsky AI, 2010, AM J PHYSIOL-CELL PH, V299, pC903, DOI 10.1152/ajpcell.00216.2010; Chi F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025016; Chi F, 2011, FUTURE MICROBIOL, V6, P953, DOI 10.2217/FMB.11.65; Chi F, 2010, BIOCHEM J, V427, P79, DOI 10.1042/BJ20091097; Chimienti F, 2003, HUM MOL GENET, V12, P3017, DOI 10.1093/hmg/ddg320; Durek T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16809-0; Ertle CM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.631881; Favre B, 2007, J INVEST DERMATOL, V127, P301, DOI 10.1038/sj.jid.5700551; Fujii T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01085; Giebelen IAJ, 2009, EUR RESPIR J, V33, P375, DOI 10.1183/09031936.00103408; Giebelen IAJ, 2008, J INFECT DIS, V198, P750, DOI 10.1086/590432; Graham AJ, 2002, CNS NEUROL DISORD-DR, V1, P387, DOI 10.2174/1568007023339283; He XL, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0247-2; Hoover DB, 2017, PHARMACOL THERAPEUT, V179, P1, DOI 10.1016/j.pharmthera.2017.05.002; Huang SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162641; Huang SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062164; Kanashiro A, 2017, PHARMACOL RES, V117, P1, DOI 10.1016/j.phrs.2016.12.014; Li DJ, 2018, REDOX BIOL, V15, P22, DOI 10.1016/j.redox.2017.11.013; Liu R, 2019, J INFECT DIS, V219, P470, DOI 10.1093/infdis/jiy531; Matsunaga K, 2001, J IMMUNOL, V167, P6518, DOI 10.4049/jimmunol.167.11.6518; Moriwaki Y, 2009, NEUROSCI RES, V64, P403, DOI 10.1016/j.neures.2009.04.014; Murray RL, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1062; Narumoto O, 2013, BIOCHEM BIOPH RES CO, V438, P175, DOI 10.1016/j.bbrc.2013.07.048; Oordt-Speets AM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198772; Pimentel E, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00513; Profaci CP, 2020, J EXP MED, V217, DOI 10.1084/jem.20190062; Qiu HS, 2020, INT J INFECT DIS, V101, P132, DOI 10.1016/j.ijid.2020.09.360; Radek KA, 2010, CELL HOST MICROBE, V7, P277, DOI 10.1016/j.chom.2010.03.009; Sajja RK, 2016, J CEREBR BLOOD F MET, V36, P539, DOI 10.1177/0271678X15616978; Sarowska J, 2019, GUT PATHOG, V11, DOI 10.1186/s13099-019-0290-0; Shen YY, 2017, BLOOD ADV, V1, P662, DOI 10.1182/bloodadvances.2017004341; Stins MF, 1997, J NEUROIMMUNOL, V76, P81, DOI 10.1016/S0165-5728(97)00036-2; Su X, 2010, J IMMUNOL, V184, P401, DOI 10.4049/jimmunol.0901808; Sussan TE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116861; Swamynathan SK., 2008, INVEST OPHTH VIS SCI, V49, P4298; Swamynathan S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42437-x; Swamynathan S, 2018, INVEST OPHTH VIS SCI, V59; Swamynathan S, 2012, INVEST OPHTH VIS SCI, V53, P8433, DOI 10.1167/iovs.12-10759; Tsetlin VI, 2021, J NEUROCHEM, V158, P1223, DOI 10.1111/jnc.15123; Vasilyeva NA, 2017, BIOCHEMISTRY-MOSCOW+, V82, P1702, DOI 10.1134/S0006297917130090; Wu C, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00484; Xie H, 2020, REV ENDOCR METAB DIS, V21, P431, DOI 10.1007/s11154-020-09584-3; Xu M, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00031; Yu JY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121911; Zainel A, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9030535; Zhang B, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1075-9	57	1	1	9	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								745854	10.3389/fimmu.2021.745854	http://dx.doi.org/10.3389/fimmu.2021.745854			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT0GL	34721415	Green Published, gold			2022-12-18	WOS:000715552100001
J	Kilic, A; Harb, H				Kilic, Ayse; Harb, Hani			Editorial: The Role of the Microbiome in Regulating T-Cell Response in Asthma and Food Allergy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						asthma; food allergy; microbiota; Treg - regulatory T cell; T-cell; microbial metabolites	EXPOSURE; ATOPY; MICE		[Kilic, Ayse] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Kilic, Ayse] Harvard Med Sch, Boston, MA 02115 USA; [Harb, Hani] Justus Liebig Univ Giessen, Inst Psychosomat & Psychotherapy, Lab Psychoneuroimmunol, Giessen, Germany; [Harb, Hani] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Justus Liebig University Giessen; Harvard University; Boston Children's Hospital; Harvard Medical School	Harb, H (corresponding author), Justus Liebig Univ Giessen, Inst Psychosomat & Psychotherapy, Lab Psychoneuroimmunol, Giessen, Germany.; Harb, H (corresponding author), Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA.		Harb, Hani/HGB-7333-2022	Harb, Hani/0000-0001-8218-2538	German Research Foundation (DFG) [HA 8465/1-1]; Research Foundation (DFG) [KI 1868/3-1]	German Research Foundation (DFG)(German Research Foundation (DFG)); Research Foundation (DFG)(German Research Foundation (DFG))	For HH: German Research Foundation (DFG) grant Nr. HA 8465/1-1 and For AK: Research Foundation (DFG) grant Nr. KI 1868/3-1.	Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Fischbach MA, 2011, CELL HOST MICROBE, V10, P336, DOI 10.1016/j.chom.2011.10.002; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Haak BW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02042; Hagner S, 2013, ALLERGY, V68, P322, DOI 10.1111/all.12094; Harb H, 2013, CLIN EXP ALLERGY, V43, P353, DOI 10.1111/cea.12047; Hild B, 2021, NAT METAB, V3, P1042, DOI 10.1038/s42255-021-00439-y; Huang YC, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.714406; Koch S, 2017, SEMIN IMMUNOPATHOL, V39, P55, DOI 10.1007/s00281-016-0601-1; Lee JB, 2016, IMMUNE NETW, V16, P211, DOI 10.4110/in.2016.16.4.211; Lei QC, 2021, MOL MED REP, V24, DOI 10.3892/mmr.2021.12374; Liu H, 2018, ADV NUTR, V9, P21, DOI 10.1093/advances/nmx009; Liu XJ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.720842; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Maslinska Maria, 2021, Reumatologia (Warsaw), V59, P180, DOI 10.5114/reum.2021.107588; Venegas DP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01486; Peng LY, 2021, VET MICROBIOL, V261, DOI 10.1016/j.vetmic.2021.109187; Piccioni A, 2022, CURR MED CHEM, V19, P3147, DOI 10.2174/0929867328666210922161913; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Sehra S, 2015, J ALLERGY CLIN IMMUN, V136, P433, DOI 10.1016/j.jaci.2015.01.021; Xia GH, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.715475; Zhou D., 2021, INT J INFECT DIS, DOI [10.1016/J.IJID.2021.09.013, DOI 10.1016/J.IJID.2021.09.013]	23	1	1	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								782720	10.3389/fimmu.2021.782720	http://dx.doi.org/10.3389/fimmu.2021.782720			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT0FT	34721443	gold, Green Published			2022-12-18	WOS:000715550300001
J	Lipoldova, M; Demant, P				Lipoldova, Marie; Demant, Peter			Gene-Specific Sex Effects on Susceptibility to Infectious Diseases	FRONTIERS IN IMMUNOLOGY			English	Review						sex-bias; sex-dependent gene; mouse model; susceptibility to infection; sex influence; viruses; bacteria; parasites	QUANTITATIVE TRAIT LOCI; CUTANEOUS LEISHMANIASIS; GENDER-DIFFERENCES; UNITED-STATES; VIRUS; EPIDEMIOLOGY; FEMALE; MECHANISMS; RESPONSES; INFLAMMATION	Inflammation is an integral part of defense against most infectious diseases. These pathogen-induced immune responses are in very many instances strongly influenced by host's sex. As a consequence, sexual dimorphisms were observed in susceptibility to many infectious diseases. They are pathogen dose-dependent, and their outcomes depend on pathogen and even on its species or subspecies. Sex may differentially affect pathology of various organs and its influence is modified by interaction of host's hormonal status and genotype: sex chromosomes X and Y, as well as autosomal genes. In this Mini Review we summarize the major influences of sex in human infections and subsequently focus on 22 autosomal genes/loci that modify in a sex-dependent way the response to infectious diseases in mouse models. These genes have been observed to influence susceptibility to viruses, bacteria, parasites, fungi and worms. Some sex-dependent genes/loci affect susceptibility only in females or only in males, affect both sexes, but have stronger effect in one sex; still other genes were shown to affect the disease in both sexes, but with opposite direction of effect in females and males. The understanding of mechanisms of sex-dependent differences in the course of infectious diseases may be relevant for their personalized management.	[Lipoldova, Marie] Czech Acad Sci, Lab Mol & Cellular Immunol, Inst Mol Genet, Prague, Czech Republic; [Demant, Peter] Roswell Park Comprehens Canc Ctr, Dept Mol & Cellular Biol, Buffalo, NY USA	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Lipoldova, M (corresponding author), Czech Acad Sci, Lab Mol & Cellular Immunol, Inst Mol Genet, Prague, Czech Republic.	lipoldova@img.cas.cz	Lipoldova, Marie/G-4399-2014	Lipoldova, Marie/0000-0002-2101-0334	Czech Science Foundation [GACR 16-22346S]	Czech Science Foundation(Grant Agency of the Czech Republic)	Funding This work was supported by the by the Czech Science Foundation (Grant GACR 16-22346S), the Czech Academy of Sciences (RVO 68378050) and the Ministry of Health (Grant NV19-05-00457).	Agua-Agum J, 2016, NEW ENGL J MED, V374, P96, DOI 10.1056/NEJMc1510305; Aguirre-Gamboa R, 2016, CELL REP, V17, P2474, DOI 10.1016/j.celrep.2016.10.053; ALEXANDER J, 1988, PARASITOLOGY, V96, P297, DOI 10.1017/S0031182000058303; Alwani M, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2223; [Anonymous], 2020, HLTH PROT REP, V14, P1; Arizza V, 2013, COMP BIOCHEM PHYS A, V164, P447, DOI 10.1016/j.cbpa.2012.11.021; Bain BJ, 1996, BRIT J HAEMATOL, V94, P206, DOI 10.1046/j.1365-2141.1996.d01-1786.x; Bakuza JS, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005937; Balaton BP, 2016, TRENDS GENET, V32, P348, DOI 10.1016/j.tig.2016.03.007; Belmonte RL, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03075; Berghofer B, 2006, J IMMUNOL, V177, P2088, DOI 10.4049/jimmunol.177.4.2088; Bettaieb J, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-386; Bhasin JM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001435; Blazkova J, 2017, J IMMUNOL, V198, P2479, DOI 10.4049/jimmunol.1601855; Blos M, 2003, EUR J IMMUNOL, V33, P1224, DOI 10.1002/eji.200323825; Boivin GA, 2012, J IMMUNOL, V188, P3949, DOI 10.4049/jimmunol.1103320; Bremer V., 2012, Eurosurveillance, V17, P20222; Brown MA, 2019, J IMMUNOL, V202, P1927, DOI 10.4049/jimmunol.1801403; BROWNSTEIN DG, 1995, J VIROL, V69, P6958, DOI 10.1128/JVI.69.11.6958-6964.1995; Bryson KJ, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000930; Butterfield RJ, 2003, GENETICS, V163, P1041; BUTTERWO.M, 1967, NATURE, V214, P1224, DOI 10.1038/2141224a0; Carroll SF, 2008, GENES IMMUN, V9, P536, DOI 10.1038/gene.2008.48; Case LK, 2015, BIOL SEX DIFFER, V6, DOI 10.1186/s13293-015-0024-z; Case LK, 2012, G3-GENES GENOM GENET, V2, P115, DOI 10.1534/g3.111.001610; Chapman SJ, 2012, NAT REV GENET, V13, P175, DOI 10.1038/nrg3114; Chen CM, 2016, J VIRAL HEPATITIS, V23, P940, DOI 10.1111/jvh.12564; Chen PJ, 2012, HEPATOLOGY, V56, P632, DOI 10.1002/hep.25695; Cloots K, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0007995; Collis S, 2019, INT J INFECT DIS, V88, P14, DOI 10.1016/j.ijid.2019.08.018; Cui JT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206995; Curuvija I, 2017, INFLAMMATION, V40, P1087, DOI 10.1007/s10753-017-0551-3; Devaux CA, 2020, J MICROBIOL IMMUNOL, V53, P425, DOI 10.1016/j.jmii.2020.04.015; Dzamko NL, 2017, ADV NEUROBIOL, V14, P123, DOI 10.1007/978-3-319-49969-7_7; European Centre for Disease Prevention and Control/WHO Regional Office for Europe, 2019, HIV AIDS SURV EUR 20; Fink AL, 2015, PHYSIOLOGY, V30, P408, DOI 10.1152/physiol.00035.2015; Fischinger S, 2019, SEMIN IMMUNOPATHOL, V41, P239, DOI 10.1007/s00281-018-0726-5; FITZGERA.TJ, 1973, J APPL BACTERIOL, V36, P707, DOI 10.1111/j.1365-2672.1973.tb04156.x; Gandacu D, 2014, EMERG INFECT DIS, V20, P1605, DOI 10.3201/eid2010.140182; GARENNE M, 1994, INT J EPIDEMIOL, V23, P632, DOI 10.1093/ije/23.3.632; Gemmati D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103474; Griesbeck M, 2016, CLIN SCI, V130, P1435, DOI 10.1042/CS20160112; Gupta S, 2020, P NATL ACAD SCI USA, V117, P16481, DOI 10.1073/pnas.2003603117; Haitao T, 2020, MAYO CLIN PROC, V95, P2189, DOI 10.1016/j.mayocp.2020.07.024; Hajjeh RA, 1995, EPIDEMIOL REV, V17, P303, DOI 10.1093/oxfordjournals.epirev.a036195; Hammes SR, 2007, ENDOCR REV, V28, P726, DOI 10.1210/er.2007-0022; Harizanov R, 2013, Euro Surveill, V18, P20531, DOI 10.2807/1560-7917.ES2013.18.29.20531; Hayes KS, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-193; HAZZA YA, 1983, AM J TROP MED HYG, V32, P1023, DOI 10.4269/ajtmh.1983.32.1023; Hegdahl HK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148502; Herrador Z, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003594; Hertz D, 2019, SEMIN IMMUNOPATHOL, V41, P225, DOI 10.1007/s00281-018-0725-6; Howard ZP, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00894-19; Jarefors S, 2006, IMMUNOLOGY, V118, P224, DOI 10.1111/j.1365-2567.2006.02360.x; Jervis S, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2530-9; Jin SW, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009420; Karnam G, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002710; Kelvin EA, 2009, ANN TROP MED PARASIT, V103, P487, DOI 10.1179/000349809X12459740922291; Kerner G, 2021, CURR OPIN IMMUNOL, V72, P148, DOI 10.1016/j.coi.2021.04.006; Khramtsova EA, 2019, NAT REV GENET, V20, P173, DOI 10.1038/s41576-018-0083-1; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Kobets T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01083; Kobets T, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001667; Koeken VACM, 2020, J CLIN INVEST, V130, P5591, DOI 10.1172/JCI133935; Kosyreva AM, 2018, J INFLAMM RES, V11, P431, DOI 10.2147/JIR.S178288; Kovats S, 2015, CELL IMMUNOL, V294, P63, DOI 10.1016/j.cellimm.2015.01.018; Krayem I, 2021, CYTOKINE, V147, DOI 10.1016/j.cyto.2020.155244; Krementsov DN, 2017, P NATL ACAD SCI USA, V114, P3491, DOI 10.1073/pnas.1620889114; Kurey I, 2009, IMMUNOGENETICS, V61, P619, DOI 10.1007/s00251-009-0392-9; Lachaud L, 2013, Euro Surveill, V18, P20534, DOI 10.2807/1560-7917.ES2013.18.29.20534; Layegh P, 2013, J INFECT DEV COUNTR, V7, P614, DOI 10.3855/jidc.2939; Li YM, 2019, ONCOL LETT, V17, P4222, DOI 10.3892/ol.2019.10127; Lipoldova M, 2006, NAT REV GENET, V7, P294, DOI 10.1038/nrg1832; Lorenzo ME, 2011, VACCINE, V29, P9246, DOI 10.1016/j.vaccine.2011.09.110; Lundberg P, 2003, J VIROL, V77, P11661, DOI 10.1128/JVI.77.21.11661-11673.2003; McQuillan Geraldine, 2018, NCHS Data Brief, P1; Min-Oo G, 2008, GENES IMMUN, V9, P383, DOI 10.1038/sj.gene.6364450; Mondal S, 1999, GEN COMP ENDOCR, V116, P291, DOI 10.1006/gcen.1999.7370; Moretti S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14017; Murray LJ, 1997, INT J EPIDEMIOL, V26, P880, DOI 10.1093/ije/26.4.880; NICOLOSI A, 1994, EPIDEMIOLOGY, V5, P570, DOI 10.1097/00001648-199411000-00003; Nonnenmacher Y, 2018, CELL MOL LIFE SCI, V75, P2093, DOI 10.1007/s00018-018-2784-1; Ober C, 2008, NAT REV GENET, V9, P911, DOI 10.1038/nrg2415; Peeling RW, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.73; Pohl AM, 2019, FOODBORNE PATHOG DIS, V16, P290, DOI 10.1089/fpd.2018.2548; Preston SH, 1976, MORTALITY PATTERNS N; Rambold AS, 2018, TRENDS IMMUNOL, V39, P6, DOI 10.1016/j.it.2017.08.006; Reithinger R, 2003, EMERG INFECT DIS, V9, P727; Rijal S, 2010, TROP MED INT HEALTH, V15, P21, DOI 10.1111/j.1365-3156.2010.02518.x; Robinson DP, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002149; Rodriguez NE, 2018, AM J TROP MED HYG, V98, P142, DOI 10.4269/ajtmh.17-0563; Ruggieri A, 2010, INT J CANCER, V127, P499, DOI 10.1002/ijc.25298; Schurz H, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-018-0185-z; Schuurhof A, 2010, PEDIATR PULM, V45, P608, DOI 10.1002/ppul.21229; Schwartz AM, 2020, ZOONOSES PUBLIC HLTH, V67, P407, DOI 10.1111/zph.12699; Scotland RS, 2011, BLOOD, V118, P5918, DOI 10.1182/blood-2011-03-340281; Shaheen AAM, 2018, INT J STD AIDS, V29, P453, DOI 10.1177/0956462417732649; Shepherd R, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.604000; Shutinoski B, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aas9292; Sima M, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001173; Slapnickova M, 2016, BIOL SEX DIFFER, V7, DOI 10.1186/s13293-016-0117-3; Soares L, 2014, TROP MED INT HEALTH, V19, P988, DOI 10.1111/tmi.12337; Soldin OP, 2009, CLIN PHARMACOKINET, V48, P143, DOI 10.2165/00003088-200948030-00001; Sorensen C, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002603; Spitzer JA, 1999, LUPUS, V8, P380, DOI 10.1177/096120339900800510; Spotin A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/913510; Stenger S, 1996, J EXP MED, V183, P1501, DOI 10.1084/jem.183.4.1501; Tchuem Tchuente LA, 2003, TROP MED INT HEALTH, V8, P975, DOI 10.1046/j.1360-2276.2003.01120.x; Trevisan A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17010327; Troy JD, 2015, VACCINE, V33, P5425, DOI 10.1016/j.vaccine.2015.08.032; Uppal SS, 2003, CYTOM PART B-CLIN CY, V52B, P32, DOI 10.1002/cyto.b.10011; Valdebenito JO, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80030-9; Vermeesch JR, 1997, HUM MOL GENET, V6, P1, DOI 10.1093/hmg/6.1.1; White V, 2018, PEDIATR RES, V83, P183, DOI 10.1038/pr.2017.221; Wierman ME, 2007, ADV PHYSIOL EDUC, V31, P26, DOI 10.1152/advan.00086.2006; Wondimeneh Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/545393; Wright JE, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2656-4; Yang X, 2006, GENOME RES, V16, P995, DOI 10.1101/gr.5217506; Yoon K, 2021, J NEUROGASTROENTEROL, V27, P314, DOI 10.5056/jnm20208; Yousuf W, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002388	120	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								712688	10.3389/fimmu.2021.712688	http://dx.doi.org/10.3389/fimmu.2021.712688			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT6SY	34721380	gold, Green Published			2022-12-18	WOS:000715994100001
J	Lu, G; Ou, JJ; Cai, SQ; Lai, ZY; Zhong, LT; Yin, X; Li, SJ				Lu, Gang; Ou, Jiajun; Cai, Siqi; Lai, Zhiying; Zhong, Lintao; Yin, Xin; Li, Shoujun			Canine Interferon-Inducible Transmembrane Protein Is a Host Restriction Factor That Potently Inhibits Replication of Emerging Canine Influenza Virus	FRONTIERS IN IMMUNOLOGY			English	Article						interferon-inducible transmembrane protein; canine; influenza virus; antiviral activity; IFITM	A VIRUS; H1N1 VIRUS; IFITM3; RESISTANCE	Canine influenza virus (CIV) is an emerging virus that is associated with major hidden hazards to the canine population and public health. Until now, how canine uses its innate immunity to restrict CIV replication is seldomly investigated. Recently, studies on interferon-inducible transmembrane (IFITM) of several major hosts of influenza virus (human, chicken, duck, pig) indicated it can potently restrict the viral replication. Here, the gene locus of five previously annotated canine IFITM (caIFITM) genes was determined on chromosome 18 using multiple bioinformatics strategies, provisionally designated as caIFITM1, caIFITM2a, caIFITM2b, caIFITM3, and caIFITM5. An analysis on protein sequences between caIFITM and its homologs indicated they shared the same conserved amino acids important for the antiviral activity. Expression profile analysis showed that caIFITM was constitutively expressed in tissues and MDCK cell line. After treatment with interferon or infection with influenza virus, the expression level of caIFITM increased with different degrees in vitro. An animal challenge study demonstrated CIV infection resulted in upregulation of caIFITM in beagles. caIFITMs had a similar subcellular localization to their human homologs. caIFITM1 was present at the cell surface and caIFITM3 was present perinuclearly and colocalized with LAMP1-containing compartments. Finally, we generated A549 cell lines stably expressing caIFITM and challenged them with influenza virus. The result demonstrated caIFITM1, caIFITM2a, caIFITM2b, and caIFITM3 had a potent antiviral activity against influenza virus. Our study will help better understand the evolutional pattern of IFITM and its role in the host's defense against virus infection.</p>	[Lu, Gang; Ou, Jiajun; Cai, Siqi; Lai, Zhiying; Zhong, Lintao; Li, Shoujun] South China Agr Univ, Coll Vet Med, Guangzhou, Peoples R China; [Lu, Gang; Yin, Xin] Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin, Peoples R China; [Lu, Gang; Ou, Jiajun; Cai, Siqi; Lai, Zhiying; Zhong, Lintao; Li, Shoujun] Guangdong Prov Key Lab Prevent & Control Severe C, Guangzhou, Peoples R China; [Lu, Gang; Ou, Jiajun; Cai, Siqi; Lai, Zhiying; Zhong, Lintao; Li, Shoujun] Guangdong Technol Engn Res Ctr Pet, Guangzhou, Peoples R China	South China Agricultural University; Chinese Academy of Agricultural Sciences; Harbin Veterinary Research Institute, CAAS	Li, SJ (corresponding author), South China Agr Univ, Coll Vet Med, Guangzhou, Peoples R China.; Yin, X (corresponding author), Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin, Peoples R China.; Li, SJ (corresponding author), Guangdong Prov Key Lab Prevent & Control Severe C, Guangzhou, Peoples R China.; Li, SJ (corresponding author), Guangdong Technol Engn Res Ctr Pet, Guangzhou, Peoples R China.	yinxin@caas.cn; shoujunli@scau.edu.cn	Ou, Jiajun/GYQ-8851-2022; YIN, XIN/B-5862-2018	YIN, XIN/0000-0003-2357-6718	National Natural Science Foundation of China [31702271]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the National Natural Science Foundation of China (grant number: 31702271).	Almen MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031961; Bailey CC, 2014, ANNU REV VIROL, V1, P261, DOI 10.1146/annurev-virology-031413-085537; Bailey CC, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002909; Blyth GAD, 2016, J VIROL, V90, P103, DOI 10.1128/JVI.01593-15; Brass AL, 2009, CELL, V139, P1243, DOI 10.1016/j.cell.2009.12.017; Chesarino NM, 2014, J BIOL CHEM, V289, P11986, DOI 10.1074/jbc.M114.557694; Compton AA, 2016, EMBO REP, V17, P1657, DOI 10.15252/embr.201642771; Crawford PC, 2005, SCIENCE, V310, P482, DOI 10.1126/science.1117950; Di Pietro A, 2013, J VIROL, V87, P4523, DOI 10.1128/JVI.02548-12; Diamond MS, 2013, NAT REV IMMUNOL, V13, P46, DOI 10.1038/nri3344; Dittmann M, 2015, CELL, V160, P631, DOI 10.1016/j.cell.2015.01.040; Everitt AR, 2012, NATURE, V484, P519, DOI 10.1038/nature10921; Hanagata N, 2011, J BONE MINER METAB, V29, P279, DOI 10.1007/s00774-010-0221-0; Huang IC, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001258; Jia R, 2014, CELL MICROBIOL, V16, P1080, DOI 10.1111/cmi.12262; John SP, 2013, J VIROL, V87, P7837, DOI 10.1128/JVI.00481-13; Lanz C, 2015, J VIROL, V89, P863, DOI 10.1128/JVI.02516-14; Mangeat B, 2012, J BIOL CHEM, V287, P22015, DOI 10.1074/jbc.M111.319996; Matzinger SR, 2013, J VIROL, V87, P1150, DOI 10.1128/JVI.02271-12; Melvin WJ, 2015, VIRUSES-BASEL, V7, P3035, DOI 10.3390/v7062759; Meyerson NR, 2017, CELL HOST MICROBE, V22, P627, DOI 10.1016/j.chom.2017.10.003; Parrish CR, 2019, VET CLIN N AM-SMALL, V49, P643, DOI 10.1016/j.cvsm.2019.02.005; Sen Tan K, 2012, J GEN VIROL, V93, P1269, DOI 10.1099/vir.0.040824-0; Smith SE, 2013, J VIROL, V87, P12957, DOI 10.1128/JVI.01443-13; Yount JS, 2010, NAT CHEM BIOL, V6, P610, DOI [10.1038/nchembio.405, 10.1038/NCHEMBIO.405]; Zhang JS, 2016, J VIROL, V90, P3966, DOI 10.1128/JVI.03137-15; Zhang Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049265	27	1	1	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								710705	10.3389/fimmu.2021.710705	http://dx.doi.org/10.3389/fimmu.2021.710705			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WQ5BF	34721379	Green Published, gold			2022-12-18	WOS:000713830900001
J	Ohm-Laursen, L; Meng, HL; Hoehn, KB; Nouri, N; Jiang, Y; Clouser, C; Johnstone, TG; Hause, R; Sandhar, BS; Upton, NEG; Chevretton, EB; Lakhani, R; Corrigan, CJ; Kleinstein, SH; Gould, HJ				Ohm-Laursen, Line; Meng, Hailong; Hoehn, Kenneth B.; Nouri, Nima; Jiang, Yue; Clouser, Chris; Johnstone, Timothy G.; Hause, Ron; Sandhar, Balraj S.; Upton, Nadine E. G.; Chevretton, Elfy B.; Lakhani, Raj; Corrigan, Chris J.; Kleinstein, Steven H.; Gould, Hannah J.			B Cell Mobilization, Dissemination, Fine Tuning of Local Antigen Specificity and Isotype Selection in Asthma	FRONTIERS IN IMMUNOLOGY			English	Article						asthma; immunoglobulin; allergy; adaptive immunity; IgD; innate immunity; repertoire and AIRR-seq; sequencing	CLASS-SWITCH RECOMBINATION; STAPHYLOCOCCAL-ENTEROTOXIN; BRONCHIAL-MUCOSA; BINDING; IGD; REGION; LUNG; REPERTOIRE; SMOKERS; TOOLKIT	In order to better understand how the immune system interacts with environmental triggers to produce organ-specific disease, we here address the hypothesis that B and plasma cells are free to migrate through the mucosal surfaces of the upper and lower respiratory tracts, and that their total antibody repertoire is modified in a common respiratory tract disease, in this case atopic asthma. Using Adaptive Immune Receptor Repertoire sequencing (AIRR-seq) we have catalogued the antibody repertoires of B cell clones retrieved near contemporaneously from multiple sites in the upper and lower respiratory tract mucosa of adult volunteers with atopic asthma and non-atopic controls and traced their migration. We show that the lower and upper respiratory tracts are immunologically connected, with trafficking of B cells directionally biased from the upper to the lower respiratory tract and points of selection when migrating from the nasal mucosa and into the bronchial mucosa. The repertoires are characterized by both IgD-only B cells and others undergoing class switch recombination, with restriction of the antibody repertoire distinct in asthmatics compared with controls. We conclude that B cells and plasma cells migrate freely throughout the respiratory tract and exhibit distinct antibody repertoires in health and disease.	[Ohm-Laursen, Line; Sandhar, Balraj S.; Upton, Nadine E. G.; Gould, Hannah J.] Kings Coll London, Randall Ctr Cell & Mol Biophys, London, England; [Ohm-Laursen, Line; Sandhar, Balraj S.; Upton, Nadine E. G.; Corrigan, Chris J.; Gould, Hannah J.] Kings Coll London, Sch Basic & Med Biosci, London, England; [Ohm-Laursen, Line; Sandhar, Balraj S.; Upton, Nadine E. G.; Corrigan, Chris J.; Gould, Hannah J.] Asthma UK Ctr Allerg Mech Asthma, London, England; [Meng, Hailong; Hoehn, Kenneth B.; Nouri, Nima; Kleinstein, Steven H.] Yale Sch Med, Dept Pathol, New Haven, CT USA; [Nouri, Nima] Yale Sch Med, Med Informat Ctr, New Haven, CT USA; [Jiang, Yue; Clouser, Chris; Johnstone, Timothy G.; Hause, Ron] Bristol Myers Squibb, Seattle, WA USA; [Chevretton, Elfy B.; Lakhani, Raj] Guys & St Thomas NHS Fdn Trust, Dept Ear Nose & Throat ENT Serv, London, England; [Corrigan, Chris J.] Kings Coll London, Dept Resp Med & Allergy, London, England; [Corrigan, Chris J.] Kings Coll London, Sch Immunol & Microbial Sci, London, England; [Kleinstein, Steven H.] Yale Univ, Interdept Program Computat Biol & Bioinformat, New Haven, CT USA; [Kleinstein, Steven H.] Yale Sch Med, Dept Immunobiol, New Haven, CT USA	University of London; King's College London; University of London; King's College London; University of London; King's College London; Yale University; Yale University; Bristol-Myers Squibb; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London; Yale University; Yale University	Gould, HJ (corresponding author), Kings Coll London, Randall Ctr Cell & Mol Biophys, London, England.; Gould, HJ (corresponding author), Kings Coll London, Sch Basic & Med Biosci, London, England.; Gould, HJ (corresponding author), Asthma UK Ctr Allerg Mech Asthma, London, England.			Sandhar, Balraj/0000-0001-7569-0163	Medical Research Council	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	LO-L, BS, NU, CC and HG were supported by a research grant from The Medical Research Council, UK (grant number MR/M022943/1) and by the National Institute for Health Research (NIHR) Clinical Research Facility at Guys & St Thomas NHS Foundation Trust and NIHR Biomedical Research Centre based at Guys and St Thomas NHS Foundation Trust and Kings College London. The work of SK was supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (award number R01AI104739). The work of HG and LO-L was also supported by the award of a Leverhulme Emeritus Professorship to HG (award number EM-2019 027).	BREZINSCHEK HP, 1995, J IMMUNOL, V155, P190; Briggs AW, 2017, BIORXIV, DOI [10. 1101/134841, DOI 10.1101/134841]; Chen JB, 2017, J ALLERGY CLIN IMMUN, V139, P1195, DOI 10.1016/j.jaci.2016.06.066; Choi JH, 2017, P NATL ACAD SCI USA, V114, pE1196, DOI 10.1073/pnas.1621258114; Di Niro R, 2015, IMMUNITY, V43, P120, DOI 10.1016/j.immuni.2015.06.013; Domiati-Saad R, 1998, J IMMUNOL, V161, P1257; DomiatiSaad R, 1996, J IMMUNOL, V156, P3608; Dondelinger M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02278; Elliot JG, 2004, AM J RESP CRIT CARE, V169, P712, DOI 10.1164/rccm.200308-1167OC; Fonkou MDM, 2018, FUTURE MICROBIOL, V13, P1611, DOI 10.2217/fmb-2018-0181; Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645; Gupta NT, 2015, BIOINFORMATICS, V31, P3356, DOI 10.1093/bioinformatics/btv359; HILL MO, 1973, ECOLOGY, V54, P427, DOI 10.2307/1934352; Hoehn KB., 2020, PHYLOGENETIC ANAL MI, DOI [10.1101/2020.05.30.124446, DOI 10.1101/2020.05.30.124446]; Hoehn KB, 2019, P NATL ACAD SCI USA, V116, P22664, DOI 10.1073/pnas.1906020116; Hwang JY, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00258; Koelsch K, 2007, J CLIN INVEST, V117, P1558, DOI 10.1172/JCI27628; Koide S, 2009, ACS CHEM BIOL, V4, P325, DOI 10.1021/cb800314v; Licari A, 2017, FRONT PEDIATR, V5, P1, DOI 10.3389/fped.2017.00044; Liu YJ, 1996, IMMUNITY, V4, P603, DOI 10.1016/S1074-7613(00)80486-0; Meng WZ, 2017, NAT BIOTECHNOL, V35, P879, DOI 10.1038/nbt.3942; Mitropoulou AN, 2018, P NATL ACAD SCI USA, V115, pE8707, DOI 10.1073/pnas.1806840115; Moffatt MF, 2017, CLIN MED, V17, P525, DOI 10.7861/clinmedicine.17-6-525; Nordstrom T, 2006, J LEUKOCYTE BIOL, V79, P319, DOI 10.1189/jlb0205065; Ohm-Laursen L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01976; Pereira JP, 2010, INT IMMUNOL, V22, P413, DOI 10.1093/intimm/dxq047; Pillai P, 2014, J ALLERGY CLIN IMMUN, V133, P1770, DOI 10.1016/j.jaci.2014.03.027; Potter KN, 1996, J IMMUNOL, V157, P2982; Randall TD, 2014, MUCOSAL IMMUNOL, V7, P455, DOI 10.1038/mi.2014.11; RICHMOND I, 1993, THORAX, V48, P1130, DOI 10.1136/thx.48.11.1130; Riesbeck K, 2006, CRIT REV IMMUNOL, V26, P353, DOI 10.1615/CritRevImmunol.v26.i4.40; Rouaud P, 2014, J EXP MED, V211, P975, DOI 10.1084/jem.20131385; Samuelsson M, 2006, EUR J IMMUNOL, V36, P2525, DOI 10.1002/eji.200535594; Singh K, 2014, J INFECT DIS, V209, P1418, DOI 10.1093/infdis/jit593; Stern JNH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008879; Takhar P, 2005, J IMMUNOL, V174, P5024, DOI 10.4049/jimmunol.174.8.5024; Takhar P, 2007, J ALLERGY CLIN IMMUN, V119, P213, DOI 10.1016/j.jaci.2006.09.045; Vander Heiden JA, 2014, BIOINFORMATICS, V30, P1930, DOI 10.1093/bioinformatics/btu138; Wu YCB, 2014, J ALLERGY CLIN IMMUN, V134, P604, DOI 10.1016/j.jaci.2014.07.010; Yaari G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00358; Zhang BC, 2016, J BASIC MICROB, V56, P670, DOI 10.1002/jobm.201500751	41	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								702074	10.3389/fimmu.2021.702074	http://dx.doi.org/10.3389/fimmu.2021.702074			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WS1HI	34721376	gold, Green Published			2022-12-18	WOS:000714938600001
J	Scheurer, J; Kitt, K; Huber, HJ; Fundel-Clemens, K; Pflanz, S; Debatin, KM; Strauss, G				Scheurer, Jasmin; Kitt, Kerstin; Huber, Heinrich J.; Fundel-Clemens, Katrin; Pflanz, Stefan; Debatin, Klaus-Michael; Strauss, Gudrun			Graft-Versus-Host Disease Prevention by In Vitro-Generated Myeloid-Derived Suppressor Cells Is Exclusively Mediated by the CD11b+CD11c+MDSC Subpopulation	FRONTIERS IN IMMUNOLOGY			English	Article						graft-; versus; -host disease; prophylaxis; myeloid-derived suppressor cells; allogeneic bone marrow transplantation; mouse model; type 2 immune response; GVT effect	ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; T-CELLS; MDSCS; GVHD; CHEMOKINES; TOLERANCE; EFFICIENT; MARKERS; CANCER	Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of myeloid progenitor cells that dampen overwhelming adaptive immune responses through multiple mechanisms and are recognized as an attractive novel immune intervention therapy for counteracting the destructive effects of graft- versus -host disease (GVHD) developing after allogeneic bone marrow transplantation (BMT). MDSCs can be produced in great numbers for cellular therapy, but they present a mixture of subsets whose functions in GVHD prevention are undefined. Here, we generated MDSCs in vitro from murine BM cells in the presence of GM-CSF and defined the integrin CD11c as a marker to subdivide MDSCs into two functional subgroups: CD11b+CD11c+ and CD11b+CD11c- MDSCs. Isolated CD11b+CD11c+ and CD11b+CD11c- MDSCs both inhibited alloantigen-stimulated T-cell proliferation in vitro, although CD11b+CD11c+ MDSCs were more efficient and expressed higher levels of different immunosuppressive molecules. Likewise, expression of surface markers such as MHC class II, CD80, CD86, or PD-L1 further delineated both subsets. Most importantly, only the adoptive transfer of CD11b+CD11c+ MDSCs into a single MHC class I-disparate allogeneic BMT model prevented GVHD development and strongly decreased disease-induced mortality, while CD11b+CD11c- MDSCs were totally ineffective. Surprisingly, allogeneic T-cell homing and expansion in lymphatic and GVHD target organs were not affected by cotransplanted CD11b+CD11c+ MDSCs indicating a clear contradiction between in vitro and in vivo functions of MDSCs. However, CD11b+CD11c+ MDSCs shifted immune responses towards type 2 immunity reflected by increased Th2-specific cytokine expression of allogeneic T cells. Induction of type 2 immunity was mandatory for GVHD prevention, since CD11b+CD11c+ MDSCs were ineffective if recipients were reconstituted with STAT6-deficient T cells unable to differentiate into Th2 cells. Most importantly, the beneficial graft- versus -tumor (GVT) effect was maintained in the presence of CD11b+CD11c+ MDSCs since syngeneic tumor cells were efficiently eradicated. Strong differences in the transcriptomic landscape of both subpopulations underlined their functional differences. Defining CD11b+CD11c+ MDSCs as the subset of in vitro-generated MDSCs able to inhibit GVHD development might help to increase efficiency of MDSC therapy and to further delineate relevant target molecules and signaling pathways responsible for GVHD prevention.</p>	[Scheurer, Jasmin; Debatin, Klaus-Michael; Strauss, Gudrun] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Ulm, Germany; [Kitt, Kerstin; Pflanz, Stefan] Boehringer Ingelheim Pharma Co KG, Dept Canc Immunol & Immune Modulat, Biberach, Germany; [Huber, Heinrich J.; Fundel-Clemens, Katrin] Boehringer Ingelheim Pharma Co KG, Global Computat Biol & Digital Sci, Biberach, Germany; [Huber, Heinrich J.] Boehringer Ingelheim Reg Ctr Vienna RCV GmbH & Co, Drug Discovery Serv, Vienna, Austria	Ulm University; Boehringer Ingelheim; Boehringer Ingelheim	Strauss, G (corresponding author), Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Ulm, Germany.	gudrun.strauss@uniklinik-ulm.de	Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886	Boehringer Ingelheim Ulm University BioCenter; International Graduate School in Molecular Medicine	Boehringer Ingelheim Ulm University BioCenter; International Graduate School in Molecular Medicine	Funding This study was supported by Boehringer Ingelheim Ulm University BioCenter (TPI2) and the International Graduate School in Molecular Medicine, Ulm, Germany.	Al-Khami AA, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1344804; Arora M, 2010, MUCOSAL IMMUNOL, V3, P578, DOI 10.1038/mi.2010.41; Baumann T, 2020, NAT IMMUNOL, V21, P555, DOI 10.1038/s41590-020-0666-9; Blazar BR, 2020, NAT REV CLIN ONCOL, V17, P475, DOI 10.1038/s41571-020-0356-4; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Brudecki L, 2012, INFECT IMMUN, V80, P2026, DOI 10.1128/IAI.00239-12; Cassetta L, 2019, CANCER IMMUNOL IMMUN, V68, P687, DOI 10.1007/s00262-019-02302-2; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; D'Aveni M, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010435; Delano MJ, 2007, J EXP MED, V204, P1463, DOI 10.1084/jem.20062602; DeLuca DS, 2012, BIOINFORMATICS, V28, P1530, DOI 10.1093/bioinformatics/bts196; Demosthenous C, 2021, J CLIN MED, V10, DOI 10.3390/jcm10102050; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Eckert I, 2021, METHODS MOL BIOL, V2236, P99, DOI 10.1007/978-1-0716-1060-2_10; Gabitass RF, 2011, CANCER IMMUNOL IMMUN, V60, P1419, DOI 10.1007/s00262-011-1028-0; Gabrilovich DI, 2007, CANCER RES, V67, P425, DOI 10.1158/0008-5472.CAN-06-3037; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gao JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104453; Gao Y, 2013, IMMUNITY, V39, P722, DOI 10.1016/j.immuni.2013.08.028; Ghimire S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00079; Highfill SL, 2010, BLOOD, V116, P5738, DOI 10.1182/blood-2010-06-287839; Hossain F, 2015, CANCER IMMUNOL RES, V3, P1236, DOI 10.1158/2326-6066.CIR-15-0036; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Jeisy-Scott V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025242; Joo YD, 2009, IMMUNOLOGY, V128, pe632, DOI 10.1111/j.1365-2567.2009.03048.x; Jun G, 2015, GENOME RES, V25, P918, DOI 10.1101/gr.176552.114; Koehn BH, 2015, BLOOD, V126, P1621, DOI 10.1182/blood-2015-03-634691; Kostlin N, 2016, J IMMUNOL, V196, P1132, DOI 10.4049/jimmunol.1500340; Kumamoto Y, 2013, IMMUNITY, V39, P733, DOI 10.1016/j.immuni.2013.08.029; Kustermann M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44419-5; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Lin Y, 2018, CLIN IMMUNOL, V187, P122, DOI 10.1016/j.clim.2017.11.005; Lv M, 2015, AM J HEMATOL, V90, pE9, DOI 10.1002/ajh.23865; MacDonald KPA, 2005, J IMMUNOL, V174, P1841, DOI 10.4049/jimmunol.174.4.1841; Messmann JJ, 2015, BLOOD, V126, P1138, DOI 10.1182/blood-2015-01-624163; Morecki S, 2008, BIOL BLOOD MARROW TR, V14, P973, DOI 10.1016/j.bbmt.2008.06.018; Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood-2007-07-099226; Nakazato J, 2008, PEDIAT ALLERG IMM-UK, V19, P605, DOI 10.1111/j.1399-3038.2007.00692.x; Park MY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00183; Patel PS, 2017, J IMMUNOL, V199, P1184, DOI 10.4049/jimmunol.1700034; Rieber N, 2014, BONE MARROW TRANSPL, V49, P545, DOI 10.1038/bmt.2013.236; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sayols S, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1276-2; Scheurer J, 2020, CLIN EXP IMMUNOL, V202, P407, DOI 10.1111/cei.13496; Schmidt K, 2013, BLOOD, V121, P1740, DOI 10.1182/blood-2012-06-436568; Simpson S, 2020, CYTOKINE, V125, DOI 10.1016/j.cyto.2019.154829; Song C, 2014, SCAND J IMMUNOL, V79, P98, DOI 10.1111/sji.12140; Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581; Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450; Tussiwand R, 2015, IMMUNITY, V42, P916, DOI 10.1016/j.immuni.2015.04.017; Vasconcelos ZFM, 2006, BLOOD, V107, P2192, DOI 10.1182/blood-2005-08-3239; Veglia F, 2019, NATURE, V569, P73, DOI 10.1038/s41586-019-1118-2; Wang K, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0710-0; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Zhang JL, 2019, LEUKEMIA, V33, P2078, DOI 10.1038/s41375-019-0394-z; Zhou ZP, 2010, STEM CELLS, V28, P620, DOI 10.1002/stem.301	59	1	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								754316	10.3389/fimmu.2021.754316	http://dx.doi.org/10.3389/fimmu.2021.754316			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV0DO	34721430	Green Published, gold			2022-12-18	WOS:000716906900001
J	Shi, T; Roskin, K; Baker, BM; Woodle, ES; Hildeman, D				Shi, Tiffany; Roskin, Krishna; Baker, Brian M.; Woodle, E. Steve; Hildeman, David			Advanced Genomics-Based Approaches for Defining Allograft Rejection With Single Cell Resolution	FRONTIERS IN IMMUNOLOGY			English	Review						transplantation; allograft rejection; genomics; sequencing; single cell RNA seq	ANTIBODY-MEDIATED REJECTION; KIDNEY-TRANSPLANTS; T-CELLS; RNA-SEQ; GENE-EXPRESSION; MICROARRAY DIAGNOSIS; MOLECULAR DIAGNOSIS; PERIPHERAL-BLOOD; RECEPTOR; TECHNOLOGY	Solid organ transplant recipients require long-term immunosuppression for prevention of rejection. Calcineurin inhibitor (CNI)-based immunosuppressive regimens have remained the primary means for immunosuppression for four decades now, yet little is known about their effects on graft resident and infiltrating immune cell populations. Similarly, the understanding of rejection biology under specific types of immunosuppression remains to be defined. Furthermore, development of innovative, rationally designed targeted therapeutics for mitigating or preventing rejection requires a fundamental understanding of the immunobiology that underlies the rejection process. The established use of microarray technologies in transplantation has provided great insight into gene transcripts associated with allograft rejection but does not characterize rejection on a single cell level. Therefore, the development of novel genomics tools, such as single cell sequencing techniques, combined with powerful bioinformatics approaches, has enabled characterization of immune processes at the single cell level. This can provide profound insights into the rejection process, including identification of resident and infiltrating cell transcriptomes, cell-cell interactions, and T cell receptor alpha/beta repertoires. In this review, we discuss genomic analysis techniques, including microarray, bulk RNAseq (bulkSeq), single-cell RNAseq (scRNAseq), and spatial transcriptomic (ST) techniques, including considerations of their benefits and limitations. Further, other techniques, such as chromatin analysis via assay for transposase-accessible chromatin sequencing (ATACseq), bioinformatic regulatory network analyses, and protein-based approaches are also examined. Application of these tools will play a crucial role in redefining transplant rejection with single cell resolution and likely aid in the development of future immunomodulatory therapies in solid organ transplantation.	[Shi, Tiffany; Roskin, Krishna; Hildeman, David] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; [Shi, Tiffany; Roskin, Krishna; Hildeman, David] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA; [Shi, Tiffany; Hildeman, David] Univ Cincinnati, Coll Med, Immunol Grad Program, Cincinnati, OH 45267 USA; [Shi, Tiffany] Univ Cincinnati, Med Scientist Training Program, Coll Med, Cincinnati, OH USA; [Roskin, Krishna] Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH 45229 USA; [Baker, Brian M.] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; [Baker, Brian M.] Univ Notre Dame, Harper Canc Res Inst, Notre Dame, IN 46556 USA; [Woodle, E. Steve] Univ Cincinnati, Coll Med, Dept Surg, Div Transplantat, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University of Notre Dame; University of Notre Dame; University System of Ohio; University of Cincinnati	Hildeman, D (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA.; Hildeman, D (corresponding author), Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA.; Hildeman, D (corresponding author), Univ Cincinnati, Coll Med, Immunol Grad Program, Cincinnati, OH 45267 USA.	david.hildeman@cchmc.org		Shi, Tiffany/0000-0001-5759-3394	National Institutes of Health [R21AI142264 [DH, EW]]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding This work was supported by the National Institutes of Health (R21AI142264 [DH, EW], R01AI154932 [DH, EW], R35GM118166 [BB]) and by Novartis Pharmaceuticals. Novartis Pharmaceuticals had no involvement in the preparation of this review manuscript.	Adam M, 2017, DEVELOPMENT, V144, P3625, DOI 10.1242/dev.151142; Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]; Akalin E, 2001, TRANSPLANTATION, V72, P948, DOI 10.1097/00007890-200109150-00034; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Arazi A, 2019, NAT IMMUNOL, V20, P902, DOI 10.1038/s41590-019-0398-x; Awan AA, 2018, AM J NEPHROL, V48, P472, DOI 10.1159/000495081; Ayaub E., 2021, CELL BIOL, DOI [10.1101/2021.01.04.425268, DOI 10.1101/2021.01.04.425268]; Beechem JM, 2020, METHODS MOL BIOL, V2055, P563, DOI 10.1007/978-1-4939-9773-2_25; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Burrows SR, 1997, EUR J IMMUNOL, V27, P1726, DOI 10.1002/eji.1830270720; Byrne-Steele M, 2019, J IMMUNOL, V202; Castro-Rojas CM, 2020, TRANSPLANTATION, V104, P1058, DOI 10.1097/TP.0000000000002917; Chen JX, 2018, JOVE-J VIS EXP, DOI 10.3791/57774; Chen KH, 2015, SCIENCE, V348, DOI 10.1126/science.aaa6090; Chen R, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000940; Cheng SJ, 2021, CELL, V184, P792, DOI 10.1016/j.cell.2021.01.010; Chopp LB, 2020, IMMUNITY, V53, P1182, DOI 10.1016/j.immuni.2020.10.024; Chruscinski A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151224; Corsiero E, 2019, CURR OPIN IMMUNOL, V57, P46, DOI 10.1016/j.coi.2019.01.004; Dangi A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.141321; de Freitas DG, 2012, AM J TRANSPLANT, V12, P191, DOI 10.1111/j.1600-6143.2011.03784.x; DeWolf S, 2016, TRANSPLANTATION, V100, P1639, DOI 10.1097/TP.0000000000001064; Donlin LT, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1631-y; Einecke G, 2005, AM J TRANSPLANT, V5, P1827, DOI 10.1111/j.1600-6143.2005.00974.x; Eltahla AA, 2016, IMMUNOL CELL BIOL, V94, P604, DOI 10.1038/icb.2016.16; Emerson RO, 2017, NAT GENET, V49, P659, DOI 10.1038/ng.3822; Eng CHL, 2019, NATURE, V568, P235, DOI 10.1038/s41586-019-1049-y; Everly MJ, 2009, AM J TRANSPLANT, V9, P1063, DOI 10.1111/j.1600-6143.2009.02577.x; Famulski KS, 2010, AM J TRANSPLANT, V10, P810, DOI 10.1111/j.1600-6143.2009.03007.x; Fawkner-Corbett D, 2021, CELL, V184, P810, DOI 10.1016/j.cell.2020.12.016; Felix NJ, 2007, NAT REV IMMUNOL, V7, P942, DOI 10.1038/nri2200; Flechner SM, 2004, AM J TRANSPLANT, V4, P1776, DOI 10.1111/j.1600-6143.2004.00627.x; Foley JW, 2019, GENOME RES, V29, P1816, DOI 10.1101/gr.234807.118; Fu JN, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI141698; Fu JN, 2019, CELL STEM CELL, V24, P227, DOI 10.1016/j.stem.2018.11.007; Gamadia LE, 2004, TRANSPLANTATION, V77, P1879, DOI 10.1097/01.tp.0000131158.81346.64; Georgiou G, 2014, NAT BIOTECHNOL, V32, P158, DOI 10.1038/nbt.2782; Giesen C, 2014, NAT METHODS, V11, P417, DOI [10.1038/nmeth.2869, 10.1038/NMETH.2869]; Glanville J, 2017, NATURE, V547, P94, DOI 10.1038/nature22976; Goltsev Y, 2018, CELL, V174, P968, DOI 10.1016/j.cell.2018.07.010; Gomes RM, 2016, EXPERT REV CLIN PHAR, V9, P991, DOI 10.1080/17512433.2016.1190270; Gonwa T, 2003, TRANSPLANTATION, V75, P1213, DOI 10.1097/01.TP.0000062837.99400.60; Govindarajan R, 2012, J PHARM BIOALLIED SC, V4, pS310, DOI 10.4103/0975-7406.100283; Goytain A, 2020, METHODS MOL BIOL, V2079, P125, DOI 10.1007/978-1-4939-9904-0_10; Habal MV, 2021, AM J TRANSPLANT, V21, P1465, DOI 10.1111/ajt.16333; Halloran KM, 2019, J HEART LUNG TRANSPL, V38, P504, DOI 10.1016/j.healun.2019.01.1317; Halloran PF, 2017, AM J TRANSPLANT, V17, P2851, DOI 10.1111/ajt.14329; Halloran PF, 2017, AM J TRANSPLANT, V17, P1754, DOI 10.1111/ajt.14200; Halloran PF, 2013, AM J TRANSPLANT, V13, P2865, DOI 10.1111/ajt.12465; Halloran PF, 2013, AM J TRANSPLANT, V13, P2352, DOI 10.1111/ajt.12387; Halloran P FK., 2020, AM J TRANSPLANT, V20; Halloran PF, 2018, AM J TRANSPLANT, V18, P785, DOI 10.1111/ajt.14600; Halloran PF, 2017, J HEART LUNG TRANSPL, V36, P1192, DOI 10.1016/j.healun.2017.05.029; Halloran PF, 2015, J AM SOC NEPHROL, V26, P1711, DOI 10.1681/ASN.2014060588; Han A, 2014, NAT BIOTECHNOL, V32, P684, DOI 10.1038/nbt.2938; Hanamsagar R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58939-y; Higdon LE, 2019, J IMMUNOL METHODS, V466, P17, DOI 10.1016/j.jim.2018.12.006; Hurd Paul J., 2009, Briefings in Functional Genomics & Proteomics, V8, P174, DOI 10.1093/bfgp/elp013; Hwang B, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0071-8; Jia QZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07767-w; Jin SQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21246-9; Kaech SM, 2002, CELL, V111, P837, DOI 10.1016/S0092-8674(02)01139-X; Kashima Y, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79385-w; Khatri P, 2013, J EXP MED, V210, P2205, DOI 10.1084/jem.20122709; Klein AM, 2015, CELL, V161, P1187, DOI 10.1016/j.cell.2015.04.044; Kloc M, 2014, BURNS TRAUMA, V2, DOI 10.4103/2321-3868.121646; Koenig A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00646; Kurian SM, 2017, AM J TRANSPLANT, V17, P2103, DOI 10.1111/ajt.14224; La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6; Larsen CP, 2005, AM J TRANSPLANT, V5, P443, DOI 10.1111/j.1600-6143.2005.00749.x; Lein E, 2017, SCIENCE, V358, P64, DOI 10.1126/science.aan6827; Li JQ, 2016, BIOTECHNOL LETT, V38, P33, DOI 10.1007/s10529-015-1963-5; Liu YC, 2015, GENOMICS, V105, P83, DOI 10.1016/j.ygeno.2014.12.002; Loupy A, 2017, CIRCULATION, V135, P917, DOI 10.1161/CIRCULATIONAHA.116.022907; Lubeck E, 2014, NAT METHODS, V11, P360, DOI 10.1038/nmeth.2892; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Malone AF, 2020, J AM SOC NEPHROL, V31, P1977, DOI 10.1681/ASN.2020030326; Matas AJ, 2008, AM J TRANSPLANT, V8, P2410, DOI 10.1111/j.1600-6143.2008.02414.x; Matula K, 2020, ADV BIOSYST, V4, DOI 10.1002/adbi.201900188; McNally JP, 2017, P NATL ACAD SCI USA, V114, pE4782, DOI 10.1073/pnas.1703683114; Menon R, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133267; Merritt CR, 2020, NAT BIOTECHNOL, V38, P586, DOI 10.1038/s41587-020-0472-9; Morris H, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010760; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Mueller TF, 2007, AM J TRANSPLANT, V7, P2712, DOI 10.1111/j.1600-6143.2007.02005.x; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Neale Jill, 2015, World J Transplant, V5, P183, DOI 10.5500/wjt.v5.i4.183; Parkes MD, 2018, AM J TRANSPLANT, V18, P63, DOI 10.1111/ajt.14410; Peterson VM, 2017, NAT BIOTECHNOL, V35, P936, DOI 10.1038/nbt.3973; Pineda S, 2020, KIDNEY INT REP, V5, P1706, DOI 10.1016/j.ekir.2020.07.023; Pineda S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09930-3; Pokrovskii M, 2019, IMMUNITY, V51, P185, DOI 10.1016/j.immuni.2019.06.001; Puram SV, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2018.1448244; Raddassi K, 2011, J IMMUNOL, V187, P1039, DOI 10.4049/jimmunol.1001543; Ranzoni AM, 2021, CELL STEM CELL, V28, P472, DOI 10.1016/j.stem.2020.11.015; Reeve J, 2013, AM J TRANSPLANT, V13, P645, DOI 10.1111/ajt.12079; Reijonen H, 2004, DIABETES, V53, P1987, DOI 10.2337/diabetes.53.8.1987; Reyfman PA, 2019, AM J RESP CRIT CARE, V199, P1517, DOI 10.1164/rccm.201712-2410OC; Ristov J, 2018, AM J TRANSPLANT, V18, P2895, DOI 10.1111/ajt.14872; Saint-Mezard P, 2009, TRANSPL INT, V22, P293, DOI 10.1111/j.1432-2277.2008.00790.x; Salcedo S, 2018, TRANSPLANTATION, V102, pS642, DOI 10.1097/01.tp.0000543560.52840.a4; Sarwal M, 2003, NEW ENGL J MED, V349, P125, DOI 10.1056/NEJMoa035588; Savage TM, 2020, AM J TRANSPLANT, V20, P538, DOI 10.1111/ajt.15592; Sellares J, 2013, AM J TRANSPLANT, V13, P971, DOI 10.1111/ajt.12150; Sen R, 2018, METHODS MOL BIOL, V1741, P151, DOI 10.1007/978-1-4939-7659-1_12; Shih AJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206785; Sigdel TK, 2018, KIDNEY INT REP, V3, P722, DOI 10.1016/j.ekir.2018.01.014; Sirbu A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050986; Sis B, 2009, AM J TRANSPLANT, V9, P2312, DOI 10.1111/j.1600-6143.2009.02761.x; Snyder ME, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav5581; Sousa IG, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-5967-8; Stoeckius M, 2017, NAT METHODS, V14, P865, DOI [10.1038/NMETH.4380, 10.1038/nmeth.4380]; Stubbington MJT, 2016, NAT METHODS, V13, P329, DOI [10.1038/NMETH.3800, 10.1038/nmeth.3800]; Su JH, 2020, CELL, V182, P1641, DOI 10.1016/j.cell.2020.07.032; Sun Kaiming, 2018, Oncotarget, V9, P37080, DOI 10.18632/oncotarget.26354; Thareja G, 2018, AM J TRANSPLANT, V18, P2429, DOI 10.1111/ajt.14870; Thrane K, 2018, CANCER RES, V78, P5970, DOI 10.1158/0008-5472.CAN-18-0747; Toulza F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74794-3; Van Herck Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.636681; Venner JM, 2014, AM J TRANSPLANT, V14, P2565, DOI 10.1111/ajt.12946; Vincenti F, 2016, NEW ENGL J MED, V374, P333, DOI 10.1056/NEJMoa1506027; Vollmers C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001890; Wang N, 2021, BIOTECHNOL J, V16, DOI 10.1002/biot.202100041; Wang Y, 2017, P NATL ACAD SCI USA, V114, pE4792, DOI 10.1073/pnas.1700459114; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Weigt SS, 2019, J HEART LUNG TRANSPL, V38, P845, DOI 10.1016/j.healun.2019.05.001; Weintraub LA, 2006, TRANSPL INT, V19, P775, DOI 10.1111/j.1432-2277.2006.00349.x; Woodle ES, 2020, AM J TRANSPLANT, V20, P1039, DOI 10.1111/ajt.15688; Wu HJ, 2018, J AM SOC NEPHROL, V29, P2069, DOI 10.1681/ASN.2018020125; Yee C, 1999, J IMMUNOL, V162, P2227; Young G, 2018, SCIENCE, V360, P423, DOI 10.1126/science.aar5839; Zhao SR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0078644; Zhao YM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216050; Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049; Zilionis R, 2017, NAT PROTOC, V12, DOI 10.1038/nprot.2016.154	135	1	1	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								750754	10.3389/fimmu.2021.750754	http://dx.doi.org/10.3389/fimmu.2021.750754			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WT6SH	34721421	Green Published, gold			2022-12-18	WOS:000715992400001
J	Wirchnianski, AS; Wec, AZ; Nyakatura, EK; Herbert, AS; Slough, MM; Kuehne, AI; Mittler, E; Jangra, RK; Teruya, J; Dye, JM; Lai, JATR; Chandran, K				Wirchnianski, Ariel S.; Wec, Anna Z.; Nyakatura, Elisabeth K.; Herbert, Andrew S.; Slough, Megan M.; Kuehne, Ana I.; Mittler, Eva; Jangra, Rohit K.; Teruya, Jonathan; Dye, John M.; Lai, Jonathan R.; Chandran, Kartik			Two Distinct Lysosomal Targeting Strategies Afford Trojan Horse Antibodies With Pan-Filovirus Activity	FRONTIERS IN IMMUNOLOGY			English	Article						filovirus; NPC2; IGF2; Ebola; Marburg; Trojan Horse bispecific antibodies; NPC1; cryptic epitopes<bold; >	GROWTH-FACTOR-II; ACID ALPHA-GLUCOSIDASE; NIEMANN-PICK C1; MANNOSE 6-PHOSPHATE RECEPTOR; VIRUS ENTRY REQUIRES; CHOLESTEROL TRANSFER; BROAD PROTECTION; IGF RECEPTOR; EBOLA; INSULIN	Multiple agents in the family Filoviridae (filoviruses) are associated with sporadic human outbreaks of highly lethal disease, while others, including several recently identified agents, possess strong zoonotic potential. Although viral glycoprotein (GP)-specific monoclonal antibodies have demonstrated therapeutic utility against filovirus disease, currently FDA-approved molecules lack antiviral breadth. The development of broadly neutralizing antibodies has been challenged by the high sequence divergence among filovirus GPs and the complex GP proteolytic cleavage cascade that accompanies filovirus entry. Despite this variability in the antigenic surface of GP, all filoviruses share a site of vulnerability-the binding site for the universal filovirus entry receptor, Niemann-Pick C1 (NPC1). Unfortunately, this site is shielded in extracellular GP and only uncovered by proteolytic cleavage by host proteases in late endosomes and lysosomes, which are generally inaccessible to antibodies. To overcome this obstacle, we previously developed a 'Trojan horse' therapeutic approach in which engineered bispecific antibodies (bsAbs) coopt viral particles to deliver GP:NPC1 interaction-blocking antibodies to their endo/lysosomal sites of action. This approach afforded broad protection against members of the genus Ebolavirus but could not neutralize more divergent filoviruses. Here, we describe next-generation Trojan horse bsAbs that target the endo/lysosomal GP:NPC1 interface with pan-filovirus breadth by exploiting the conserved and widely expressed host cation-independent mannose-6-phosphate receptor for intracellular delivery. Our work highlights a new avenue for the development of single therapeutics protecting against all known and newly emerging filoviruses.</p>	[Wirchnianski, Ariel S.; Wec, Anna Z.; Slough, Megan M.; Mittler, Eva; Jangra, Rohit K.; Chandran, Kartik] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA; [Wirchnianski, Ariel S.; Nyakatura, Elisabeth K.; Lai, Jonathan R.] Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10467 USA; [Herbert, Andrew S.; Kuehne, Ana I.; Dye, John M.] US Army, Virol Div, Med Res Inst Infect Dis, Frederick, MD USA; [Herbert, Andrew S.] Geneva Fdn, Tacoma, WA USA; [Teruya, Jonathan] Mapp Biopharmaceut, Antibody Discovery & Res Grp, San Diego, CA USA; [Wec, Anna Z.] Dyno Therapeut, Appl Biol, Cambridge, MA USA; [Nyakatura, Elisabeth K.] Triinst Therapeut Discovery Inst, New York, NY USA; [Jangra, Rohit K.] Louisiana State Univ, Hlth Sci Ctr Shreveport, Dept Microbiol & Immunol, Shreveport, LA 71105 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Chandran, K (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.; Lai, JATR (corresponding author), Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10467 USA.			Mittler, Eva/0000-0002-5935-6314	NIAID NIH HHS [R01 AI125462, R01 AI134824, T32 AI070117] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], FDA APPROVES TREATME; [Anonymous], FDA APPROVES 1 TREAT; Aoyagi-Scharber M, 2017, MOL THER-METH CLIN D, V6, P43, DOI 10.1016/j.omtm.2017.05.009; Banik SM, 2020, NATURE, V584, P291, DOI 10.1038/s41586-020-2545-9; Beck M, 2018, DEV MED CHILD NEUROL, V60, P13, DOI 10.1111/dmcn.13600; Beck M, 2010, IUBMB LIFE, V62, P33, DOI 10.1002/iub.284; BEUKERS MW, 1991, ENDOCRINOLOGY, V128, P1201, DOI 10.1210/endo-128-2-1201; Bohnsack RN, 2009, J BIOL CHEM, V284, P35215, DOI 10.1074/jbc.M109.056184; Bornholdt ZA, 2019, CELL HOST MICROBE, V25, P49, DOI 10.1016/j.chom.2018.12.005; Bornholdt ZA, 2016, MBIO, V7, DOI 10.1128/mBio.02154-15; Brindley MA, 2007, J VIROL, V81, P7702, DOI 10.1128/JVI.02433-06; Brown J, 2009, TRENDS BIOCHEM SCI, V34, P612, DOI 10.1016/j.tibs.2009.07.003; Carette JE, 2011, NATURE, V477, P340, DOI 10.1038/nature10348; Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656; Corti D, 2016, SCIENCE, V351, P1339, DOI 10.1126/science.aad5224; Cote M, 2011, NATURE, V477, P344, DOI 10.1038/nature10380; Dahms NM, 2008, GLYCOBIOLOGY, V18, P664, DOI 10.1093/glycob/cwn061; Dahms NM, 2002, BBA-GEN SUBJECTS, V1572, P317, DOI 10.1016/S0304-4165(02)00317-3; de Vries RD, 2021, SCIENCE, V371, P1379, DOI 10.1126/science.abf4896; Devi GR, 1998, MOL ENDOCRINOL, V12, P1661, DOI 10.1210/me.12.11.1661; Figueira TN, 2018, BIOCONJUGATE CHEM, V29, P3362, DOI 10.1021/acs.bioconjchem.8b00527; Flyak AI, 2016, CELL, V164, P392, DOI 10.1016/j.cell.2015.12.022; Flyak AI, 2015, CELL, V160, P893, DOI 10.1016/j.cell.2015.01.031; Forbes BE, 2002, EUR J BIOCHEM, V269, P961, DOI 10.1046/j.0014-2956.2001.02735.x; FRATANTONI JC, 1968, SCIENCE, V162, P570, DOI 10.1126/science.162.3853.570; Frei JC, 2016, SCI REP-UK, V6, DOI 10.1038/srep19193; Gilchuk P, 2018, IMMUNITY, V49, P363, DOI 10.1016/j.immuni.2018.06.018; Goldstein T, 2018, NAT MICROBIOL, V3, P1084, DOI 10.1038/s41564-018-0227-2; Gong X, 2016, CELL, V165, P1467, DOI 10.1016/j.cell.2016.05.022; Grubb JH, 2010, REJUV RES, V13, P229, DOI 10.1089/rej.2009.0920; Hashiguchi T, 2015, CELL, V160, P904, DOI 10.1016/j.cell.2015.01.041; HASHIMOTO R, 1995, J BIOL CHEM, V270, P18013, DOI 10.1074/jbc.270.30.18013; Herbert AS, 2015, MBIO, V6, DOI 10.1128/mBio.00565-15; Higgins ME, 1999, MOL GENET METAB, V68, P1, DOI 10.1006/mgme.1999.2882; Hoenen T, 2019, NAT REV MICROBIOL, V17, P593, DOI 10.1038/s41579-019-0233-2; Holtsberg FW, 2016, J VIROL, V90, P266, DOI 10.1128/JVI.02171-15; Bortz RH, 2020, J VIROL, V94, DOI 10.1128/JVI.00336-20; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; Kan S, 2014, P NATL ACAD SCI USA, V111, P14870, DOI 10.1073/pnas.1416660111; Kan SH, 2014, BIOCHEM J, V458, P281, DOI 10.1042/BJ20130845; Kleinfelter LM, 2015, MBIO, V6, DOI 10.1128/mBio.00801-15; LeBowitz JH, 2004, P NATL ACAD SCI USA, V101, P3083, DOI 10.1073/pnas.0308728100; Lee KK, 2011, J BIOL CHEM, V286, P42141, DOI 10.1074/jbc.M111.254243; Li XC, 2016, P NATL ACAD SCI USA, V113, P10079, DOI 10.1073/pnas.1611956113; Linnell J, 2001, J BIOL CHEM, V276, P23986, DOI 10.1074/jbc.M100700200; Lu FR, 2015, ELIFE, V4, DOI 10.7554/eLife.12177; Maga JA, 2013, J BIOL CHEM, V288, P1428, DOI 10.1074/jbc.M112.438663; Manicassamy B, 2005, J VIROL, V79, P4793, DOI 10.1128/JVI.79.8.4793-4805.2005; Maruyama J, 2014, J VIROL, V88, P99, DOI 10.1128/JVI.02265-13; Mathieu C, 2017, SCI REP-UK, V7, DOI 10.1038/srep43610; Miller EH, 2012, EMBO J, V31, P1947, DOI 10.1038/emboj.2012.53; Miller EH, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.207084; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Negredo A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002304; Ng M, 2015, ELIFE, V4, DOI 10.7554/eLife.11785; Ng M, 2014, VIROLOGY, V468, P637, DOI 10.1016/j.virol.2014.08.019; Nielsen GK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027287; Nyakatura EK, 2018, J BIOL CHEM, V293, P6201, DOI [10.1074/jbc.RA117.001627, 10.1074/jbc.ra117.001627]; O'Donnell KL, 2021, BIOL-TARGETS THER, V15, P79, DOI [10.2147/STT.S259069, 10.2147/BTT.S259069]; Olson LJ, 2015, GLYCOBIOLOGY, V25, P591, DOI 10.1093/glycob/cwv001; Outlaw VK, 2020, MBIO, V11, DOI 10.1128/mBio.01935-20; Pascal KE, 2018, J INFECT DIS, V218, pS612, DOI 10.1093/infdis/jiy285; Pessi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036833; ROTH BV, 1991, BIOCHEM BIOPH RES CO, V181, P907, DOI 10.1016/0006-291X(91)91277-J; Rougeron V, 2015, J CLIN VIROL, V64, P111, DOI 10.1016/j.jcv.2015.01.014; Schornberg K, 2006, J VIROL, V80, P4174, DOI 10.1128/JVI.80.8.4174-4178.2006; Seesuay W, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0031-3; Singh K, 2019, BIOCONJUGATE CHEM, V30, P1028, DOI 10.1021/acs.bioconjchem.9b00025; Starr T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193601; Wang H, 2016, CELL, V164, P258, DOI 10.1016/j.cell.2015.12.044; Wang R, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz1466; Wang Y, 2017, MOL NEUROBIOL, V54, P2636, DOI 10.1007/s12035-016-9849-7; Wang YW, 2015, INT IMMUNOPHARMACOL, V25, P363, DOI 10.1016/j.intimp.2015.01.028; Wec AZ, 2019, CELL HOST MICROBE, V25, P39, DOI 10.1016/j.chom.2018.12.004; Wec AZ, 2017, CELL, V169, P878, DOI 10.1016/j.cell.2017.04.037; Wec AZ, 2016, SCIENCE, V354, P350, DOI 10.1126/science.aag3267; Willenborg M, 2005, J LIPID RES, V46, P2559, DOI 10.1194/jlr.M500131-JLR200; Wong AC, 2010, J VIROL, V84, P163, DOI 10.1128/JVI.01832-09; Xu YB, 2020, STRUCTURE, V28, P786, DOI 10.1016/j.str.2020.05.002; Yang XL, 2019, NAT MICROBIOL, V4, P390, DOI 10.1038/s41564-018-0328-y; Zhao XL, 2017, CELL, V169, P891, DOI 10.1016/j.cell.2017.04.038; Zhu YX, 2009, MOL THER, V17, P954, DOI 10.1038/mt.2009.37; Zhu YX, 2005, BIOCHEM J, V389, P619, DOI 10.1042/BJ20050364	83	1	1	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2021	12								729851	10.3389/fimmu.2021.729851	http://dx.doi.org/10.3389/fimmu.2021.729851			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WQ5AG	34721393	Green Published, gold			2022-12-18	WOS:000713828400001
J	de la Rosa, IA; Escudero-Contreras, A; Ruiz-Ponce, M; Roman-Rodriguez, C; Perez-Sanchez, C; Abalos-Aguilera, MD; Ortega-Castro, R; Alcaide, J; Murri, M; Font, P; Calvo-Gutierrez, J; Luque-Tevar, M; Patino-Trives, AM; Guzman-Ruiz, R; Malagon, MD; Tinahones, FJ; Collantes-Estevez, E; Lopez-Pedrera, C; Barbarroja, N				Arias de la Rosa, Ivan; Escudero-Contreras, Alejandro; Ruiz-Ponce, Miriam; Roman-Rodriguez, Cristobal; Perez-Sanchez, Carlos; Abalos-Aguilera, Maria del Carmen; Ortega-Castro, Rafaela; Alcaide, Juan; Murri, Mora; Font, Pilar; Calvo-Gutierrez, Jerusalem; Luque-Tevar, Maria; Patino-Trives, Alejandra Maria; Guzman-Ruiz, Rocio; Malagon, Maria del Mar; Tinahones, Francisco Jose; Collantes-Estevez, Eduardo; Lopez-Pedrera, Chary; Barbarroja, Nuria			Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs	FRONTIERS IN IMMUNOLOGY			English	Article						rheumatoid arthritis; obesity; inflammation; adipose tissue; cDMARDs; leflunomide; hydroxychloroquine; methotrexate	BODY-MASS INDEX; INSULIN-RESISTANCE; RHEUMATOLOGY/EUROPEAN LEAGUE; CLASSIFICATION CRITERIA; INFLAMMATORY MARKERS; AMERICAN-COLLEGE; NECROSIS-FACTOR; OBESITY; HYDROXYCHLOROQUINE; ASSOCIATION	Disease severity, progression and response to therapy might be worse in obese rheumatoid arthritis (RA) patients, but paradoxically, obesity also might protect from radiographic joint damage. Thus, the intricate relationship between obesity and RA needs urgent clarification. The aim of this study was to assess the influence of obesity on the onset and development of RA and to determine whether arthritis could modify the adipose tissue biology and whether conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) can modulate these alterations. Two strategies were followed: (1) clinical profiling of two cohorts of RA: non-obese and obese patients; and (2) mechanistic studies carried out in both a collagen-induced arthritis (CIA) in an obese mouse model and 3T3-L1 adipocytes treated with cDMARDs (leflunomide, methotrexate, and hydroxychloroquine). In our cohort of RA patients with low-moderate disease activity, the presence of obesity was not related to a higher activity of the disease; actually, disease activity score 28-erythrocyte sedimentation rate (DAS28-ESR) was reduced in the obese RA patients. However, the induction of arthritis promoted transcriptomic changes in the adipose tissue under obesity condition in the obese CIA model. Treatment with hydroxychloroquine reduced weight and insulin resistance, accompanied by beneficial metabolic effects in the adipose tissue. These molecular changes in adipose tissue were also observed after methotrexate administration. In sum, arthritis might affect directly the inflammatory burden and metabolic alterations associated with obesity in adipose tissue. Clinicians should be cautious measuring the activity of the disease in obesity and managing the best therapeutic options for the metabolic comorbidities of these patients, where the combination of hydroxychloroquine and methotrexate should be considered to improve adipose tissue dysfunction in obese RA.	[Arias de la Rosa, Ivan; Escudero-Contreras, Alejandro; Ruiz-Ponce, Miriam; Roman-Rodriguez, Cristobal; Perez-Sanchez, Carlos; Abalos-Aguilera, Maria del Carmen; Ortega-Castro, Rafaela; Font, Pilar; Calvo-Gutierrez, Jerusalem; Luque-Tevar, Maria; Patino-Trives, Alejandra Maria; Collantes-Estevez, Eduardo; Lopez-Pedrera, Chary; Barbarroja, Nuria] Univ Cordoba, Maimonides Inst Res Biomedicine Cordoba IMIBIC, Reina Sofia Hosp, Rheumatol Serv Dept Med & Surg Sci, Cordoba, Spain; [Tinahones, Francisco Jose] Malaga Hosp Complex, Biomed Res Inst IBIMA, Serv Endocrinol & Nutr, Virgen Victoria, Malaga, Spain; [Malagon, Maria del Mar] Inst Salud Carlos III, Cetr Investigac Biomed Red CIBER, Fisiopatol Obesidad Nutric CIBEROBN, Madrid, Spain; [Guzman-Ruiz, Rocio; Malagon, Maria del Mar] Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Inst Res Biomedicine Cordoba IMIBIC, Dept Cell Biol, Cordoba, Spain	Universidad de Cordoba; Universidad de Malaga; Instituto de Salud Carlos III; Universidad de Cordoba	de la Rosa, IA; Barbarroja, N (corresponding author), Univ Cordoba, Maimonides Inst Res Biomedicine Cordoba IMIBIC, Reina Sofia Hosp, Rheumatol Serv Dept Med & Surg Sci, Cordoba, Spain.		Escudero, Alejandro/AGR-5004-2022; Ábalos Aguilera, Mari Carmen/AGN-0218-2022; Ugalde, Pilar Font/AAH-8622-2021; Malagon, Maria M/L-5386-2014	Ábalos Aguilera, Mari Carmen/0000-0001-8680-6096; Ugalde, Pilar Font/0000-0002-0811-9079; Malagon, Maria M/0000-0002-2419-2727; PEREZ-SANCHEZ, CARLOS/0000-0002-1903-5970; Arias de la Rosa, Ivan/0000-0002-1145-4935; Ortega Castro, Rafaela/0000-0002-7552-3469; Calvo Gutierrez, Jerusalem/0000-0001-6822-5589; Tinahones, Francisco J/0000-0001-6871-4403	Instituto de Salud Carlos III	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission)	Funding This research was funded by grants from the Instituto de Salud Carlos III (PI17/01316 and PI18/00837), co-financed by the European Regional Development Fund (ERDF), a way to make Europe, Spain, MINECO (RyC-2017-23437), and the Spanish Inflammatory and Rheumatic diseases Network (RIER, RD16/0012/0015). CL-P was supported by a contract from the Junta de Andalucia (Nicolas Monardes programme).	Abdel-Hamid AAM, 2016, ACTA HISTOCHEM, V118, P560, DOI 10.1016/j.acthis.2016.06.002; Ajeganova S, 2013, ARTHRIT CARE RES, V65, P78, DOI 10.1002/acr.21710; AL-Suhaimi EA, 2013, EUR J MED RES, V18, DOI 10.1186/2047-783X-18-12; Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI 10.1002/art.27584; Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584; de la Rosa IA, 2018, J INTERN MED, V284, P61, DOI 10.1111/joim.12743; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Caplan L, 2013, ARTHRIT CARE RES, V65, P101, DOI 10.1002/acr.21734; Chen JH, 2018, J ENDOCRINOL, V237, P43, DOI 10.1530/JOE-17-0536; Choe JY, 2014, CLIN RHEUMATOL, V33, P485, DOI 10.1007/s10067-013-2427-8; del Rincon I, 2001, ARTHRITIS RHEUM-US, V44, P2737, DOI 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#; Elkan AC, 2009, EUR J NUTR, V48, P315, DOI 10.1007/s00394-009-0017-y; Garcia-Poma A, 2007, CLIN RHEUMATOL, V26, P1831, DOI 10.1007/s10067-007-0583-4; George MD, 2017, ARTHRIT CARE RES, V69, P1789, DOI 10.1002/acr.23229; Giles JT, 2018, ARTHRIT CARE RES, V70, P175, DOI 10.1002/acr.23253; Gomez R, 2011, NAT REV RHEUMATOL, V7, P528, DOI 10.1038/nrrheum.2011.107; Gremese E, 2013, ARTHRIT CARE RES, V65, P94, DOI 10.1002/acr.21768; Guzman-Ruiz R, 2020, FASEB J, V34, P7520, DOI 10.1096/fj.201902703R; Hage MP, 2014, THER ADV ENDOCRINOL, V5, P77, DOI 10.1177/2042018814547204; Huh JY, 2014, MOL CELLS, V37, P365, DOI 10.14348/molcells.2014.0074; Jawaheer D, 2010, CLIN EXP RHEUMATOL, V28, P454; Jhun JY, 2012, EXP MOL MED, V44, P424, DOI 10.3858/emm.2012.44.7.047; Kapoor D, 2007, EUR J ENDOCRINOL, V156, P595, DOI 10.1530/EJE-06-0737; Kim SJ, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-209206; Kremers HM, 2008, ARTHRITIS RHEUM-US, V58, P2268, DOI 10.1002/art.23650; Lee J, 2013, ARCH PHARM RES, V36, P208, DOI 10.1007/s12272-013-0023-8; Liu D, 2015, INT IMMUNOPHARMACOL, V28, P1084, DOI 10.1016/j.intimp.2015.08.013; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mencarelli A, 2012, ANTIVIR THER, V17, P669, DOI 10.3851/IMP2039; Mercer E, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3868; Minamino H, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229998; Nicolau J, 2017, JOINT BONE SPINE, V84, P411, DOI 10.1016/j.jbspin.2016.09.001; Pereira SS, 2014, CURR OBES REP, V3, P422, DOI 10.1007/s13679-014-0124-9; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; Rempenault C, 2018, ANN RHEUM DIS, V77, P98, DOI 10.1136/annrheumdis-2017-211836; Sharma Ashish, 2020, Reumatologia (Warsaw), V58, P9, DOI 10.5114/reum.2020.93506; Smolen JS, 2020, ANN RHEUM DIS, V79, P685, DOI 10.1136/annrheumdis-2019-216655; Solomon DH, 2014, ARTHRIT CARE RES, V66, P1246, DOI 10.1002/acr.22285; Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937; van der Helm-van Mil AHM, 2008, ANN RHEUM DIS, V67, P769, DOI 10.1136/ard.2007.078832; Van Raemdonck K, 2018, AUTOIMMUN REV, V17, P821, DOI 10.1016/j.autrev.2018.02.007; Versini M, 2014, AUTOIMMUN REV, V13, P981, DOI 10.1016/j.autrev.2014.07.001; Vieira-Potter VJ, 2014, CELL MICROBIOL, V16, P1484, DOI 10.1111/cmi.12336; Walsmith J, 2002, INT J CARDIOL, V85, P89, DOI 10.1016/S0167-5273(02)00237-1; Zhang HH, 2002, DIABETES, V51, P2929, DOI 10.2337/diabetes.51.10.2929	45	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 13	2021	12								744022	10.3389/fimmu.2021.744022	http://dx.doi.org/10.3389/fimmu.2021.744022			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WP6SI	34721412	Green Published, gold			2022-12-18	WOS:000713258500001
J	Felismino, ES; Santos, JMB; Rossi, M; Santos, CAF; Durigon, EL; Oliveira, DBL; Thomazelli, LM; Monteiro, FR; Sperandio, A; Apostolico, JS; Franca, CN; Amaral, JB; Amirato, GR; Vieira, RP; Vaisberg, M; Bachi, ALL				Felismino, Eduardo S.; Santos, Juliana M. B.; Rossi, Marcelo; Santos, Carlos A. F.; Durigon, Edison L.; Oliveira, Danielle B. L.; Thomazelli, Luciano M.; Monteiro, Fernanda R.; Sperandio, Adriane; Apostolico, Juliana S.; Franca, Carolina N.; Amaral, Jonatas B.; Amirato, Gislene R.; Vieira, Rodolfo P.; Vaisberg, Mauro; Bachi, Andre L. L.			Better Response to Influenza Virus Vaccination in Physically Trained Older Adults Is Associated With Reductions of Cytomegalovirus-Specific Immunoglobulins as Well as Improvements in the Inflammatory and CD8(+) T-Cell Profiles	FRONTIERS IN IMMUNOLOGY			English	Article						cytomegalovirus; influenza virus vaccine; cytokines; immunoglobulin; exercise training; elderly	CYTOKINE PRODUCTION; LATENT INFECTION; IMMUNE FUNCTION; UNITED-STATES; EXERCISE; EFFICACY; SEROPREVALENCE; INTERLEUKIN-10; REACTIVATION; REPERTOIRE	Chronic cytomegalovirus (CMV) infection is a trigger factor for the development of immunosenescence and negatively impacts the immune response to influenza virus vaccination (IVV) in older adults. However, the role of physical exercise training in this context is unknown. Thus, the aim of this study was to investigate whether the regular practice of combined exercise training can improve the specific antibody response to IVV in CMV-seropositive older adults. Eighty older adults were distributed into two groups-non-practitioners (NP, n = 31, age = 74.06 +/- 6.4 years) and practitioners of combined exercise training (CET, n = 49, age = 71.7 +/- 5.8 years)-for at least 12 months. Both volunteer groups were submitted to IVV and blood samples were collected before (pre) and 30 days after (post) the vaccination. Concerning the specific antibody response to IVV, higher serum levels of specific immunoglobulin A (IgA) were found in the CET group post- than pre-vaccination (p < 0.01), whereas higher levels of specific immunoglobulin M (IgM) were observed both in the NP (p < 0.05) and CET (p < 0.001) groups post-vaccination as compared to the pre-vaccination values. Serum levels of specific immunoglobulin G (IgG) for IVV and CMV, as well as interleukin 6 (IL-6) and IL-10, were similar between the time points evaluated. However, the IL-10/IL-6 ratio post-vaccination was higher (p < 0.05) in the CET group than that before vaccination. Negative correlations were observed between the specific IgG levels for IVV and CMV only in the CET group, both pre- and post-vaccination. In addition, negative correlations were found between IL-10 and specific IgG for CMV in all volunteer groups pre- and post-vaccination, whereas a positive correlation between IL-10 and specific-IgG for IVV pre- and post-vaccination was observed in the CET group. In addition, with the hemagglutination inhibition (HAI) assay, it was found that 32.2% of the NP group and 32.6% of the CET group were responders to IVV and displayed reductions in the CMV serostatus (p < 0.05 and p < 0.001, respectively) and increases in naive and effector CD8(+) T cells post-vaccination (p < 0.01). However, only the responders from the CET group showed significant reductions in the ratio of effector to naive CD8(+) T cells (p < 0.05) and increased IL-10 levels post-vaccination (p < 0.001). In summary, this study demonstrates that the improvement in the response to IVV in CMV-seropositive older adults was related to an anti-inflammatory status and enhancement of naive CD8(+) T cells, particularly associated with regular practice of CET.	[Felismino, Eduardo S.; Franca, Carolina N.; Bachi, Andre L. L.] Univ Santo Amaro, Postgrad Program Hlth Sci, Sao Paulo, Brazil; [Santos, Juliana M. B.; Vieira, Rodolfo P.] Univ Fed Sao Paulo, Postgrad Program Sci Human Movement & Rehabil, Santos, SP, Brazil; [Rossi, Marcelo; Monteiro, Fernanda R.; Amaral, Jonatas B.; Amirato, Gislene R.; Vaisberg, Mauro; Bachi, Andre L. L.] Univ Fed Sao Paulo, Dept Otorhinolaryngol, Ear Nose & Throat ENT Lab, Sao Paulo, Brazil; [Santos, Carlos A. F.] Paulista Sch Med EPM, Dept Med, Geriatry, Sao Paulo, Brazil; [Durigon, Edison L.; Oliveira, Danielle B. L.; Thomazelli, Luciano M.] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Lab Clin & Mol Virol, Sao Paulo, Brazil; [Durigon, Edison L.] Univ Sao Paulo, Sci Platform Pasteur, Sao Paulo, Brazil; [Oliveira, Danielle B. L.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil; [Monteiro, Fernanda R.; Sperandio, Adriane] Method Fac Sao Paulo, Sao Paulo, Brazil; [Apostolico, Juliana S.] Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, Sao Paulo, Brazil; [Vieira, Rodolfo P.] Univ Brasil, Postgrad Program Bioengn, Sao Paulo, Brazil; [Vieira, Rodolfo P.; Bachi, Andre L. L.] Brazilian Inst Teaching & Res Pulm & Exercise Imm, Sao Jose Dos Campos, Brazil	Universidade de Santo Amaro (UNISA); Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo; Universidade de Sao Paulo; Hospital Israelita Albert Einstein; Universidade Federal de Sao Paulo (UNIFESP); Universidade Brasil	Santos, JMB (corresponding author), Univ Fed Sao Paulo, Postgrad Program Sci Human Movement & Rehabil, Santos, SP, Brazil.		dos Santos, Juliana de Melo Batista/U-2855-2019; Bachi, Andre L.L./G-2946-2012; Bachi, Andre/T-6931-2018; Monteiro, Fernanda Rodrigues/AFN-1365-2022; Apostolico, Juliana/W-8804-2018	dos Santos, Juliana de Melo Batista/0000-0003-0527-0723; Bachi, Andre L.L./0000-0001-8266-1416; Bachi, Andre/0000-0001-8266-1416; Monteiro, Fernanda Rodrigues/0000-0001-9413-447X; Oliveira, Danielle/0000-0002-0534-0886; Apostolico, Juliana/0000-0002-3507-3117	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/15165-2, 2016/20045-7, 2020/06409-1, 2010/50025-1, 2019/14115-0]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	Funding was granted by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP): grant nos. 2012/15165-2 (to RV), 2016/20045-7 and 2020/06409-1 (to ED), and 2010/50025-1 and 2019/14115-0 (to AB).	Almanzar G, 2005, J VIROL, V79, P3675, DOI 10.1128/JVI.79.6.3675-3683.2005; Alvarez-Rodriguez L, 2012, CELL IMMUNOL, V273, P124, DOI 10.1016/j.cellimm.2012.01.001; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Bachi ALL, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6469213; Bachi Andre L L, 2013, Results Immunol, V3, P10, DOI 10.1016/j.rinim.2013.01.001; Benedetti Tânia R. Bertoldo, 2007, Rev Bras Med Esporte, V13, P11, DOI 10.1590/S1517-86922007000100004; Carlock MA, 2019, HUM VACC IMMUNOTHER, V15, P2030, DOI 10.1080/21645515.2019.1642056; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; den Elzen WPJ, 2011, VACCINE, V29, P4869, DOI 10.1016/j.vaccine.2011.03.086; Derhovanessian E, 2014, J IMMUNOL, V193, P3624, DOI 10.4049/jimmunol.1303361; Derhovanessian E, 2013, VACCINE, V31, P685, DOI 10.1016/j.vaccine.2012.11.041; DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727; Fletcher JM, 2005, J IMMUNOL, V175, P8218, DOI 10.4049/jimmunol.175.12.8218; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Frasca D, 2016, HUM VACC IMMUNOTHER, V12, P682, DOI 10.1080/21645515.2015.1105413; Frasca D, 2015, VACCINE, V33, P1433, DOI 10.1016/j.vaccine.2015.01.071; Furman D, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa2293; Furtado GE, 2021, EUR J CLIN INVEST, V51, DOI 10.1111/eci.13485; Geist LJ, 1996, TRANSPLANTATION, V62, P653, DOI 10.1097/00007890-199609150-00020; Holtappels R, 2000, J VIROL, V74, P11495, DOI 10.1128/JVI.74.24.11495-11503.2000; Jankord R, 2004, MED SCI SPORT EXER, V36, P960, DOI 10.1249/01.MSS.0000128186.09416.18; Khan N, 2002, J IMMUNOL, V169, P1984, DOI 10.4049/jimmunol.169.4.1984; Kilgour AHM, 2013, IMMUN AGEING, V10, DOI 10.1186/1742-4933-10-33; Kim DK, 2013, YONSEI MED J, V54, P560, DOI 10.3349/ymj.2013.54.3.560; Kuijpers TW, 2003, J IMMUNOL, V170, P4342, DOI 10.4049/jimmunol.170.8.4342; Lee JKH, 2021, VACCINE, V39, pA24, DOI 10.1016/j.vaccine.2020.09.004; Looney RJ, 1999, CLIN IMMUNOL, V90, P213, DOI 10.1006/clim.1998.4638; Lopo S, 2011, EUROSURVEILLANCE, V16, P17; McLean HQ, 2015, J INFECT DIS, V211, P1529, DOI 10.1093/infdis/jiu647; Merani S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00784; Mocarski Jr E, 2013, FIELDS VIROLOGY, V2, P1960; Mohanty S, 2015, J INFECT DIS, V211, P1174, DOI 10.1093/infdis/jiu573; Monteiro FR, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040685; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Muller L, 2014, BRAIN BEHAV IMMUN, V39, P8, DOI 10.1016/j.bbi.2013.11.015; NIEMAN DC, 1993, MED SCI SPORT EXER, V25, P823, DOI 10.1249/00005768-199307000-00011; Oh SJ, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e37; Paixao V, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020107; Parry HM, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-015-0056-6; Pascoe AR, 2014, BRAIN BEHAV IMMUN, V39, P33, DOI 10.1016/j.bbi.2013.10.003; Pawelec G, 2009, REV MED VIROL, V19, P47, DOI 10.1002/rmv.598; Prelog M, 2006, AUTOIMMUN REV, V5, P136, DOI 10.1016/j.autrev.2005.09.008; PROSCH S, 1995, VIROLOGY, V208, P197, DOI 10.1006/viro.1995.1143; Prosch S, 1999, INTERVIROLOGY, V42, P308, DOI 10.1159/000053965; Silva LCR, 2016, AGE, V38, DOI 10.1007/s11357-016-9879-0; Rong YD, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-1007-9; Sapan HB, 2016, INT J BURNS TRAUMA, V6, P37; de Pablo-Bernal RS, 2016, J GERONTOL A-BIOL, V71, P610, DOI 10.1093/gerona/glv121; Schmaltz HN, 2005, J AM GERIATR SOC, V53, P747, DOI 10.1111/j.1532-5415.2005.53250.x; Shimizu K, 2011, J STRENGTH COND RES, V25, P2565, DOI 10.1519/JSC.0b013e3181fc5e67; Simpson RJ, 2016, EXERC IMMUNOL REV, V22, P8; Simpson RJ, 2014, BRAIN BEHAV IMMUN, V39, P1, DOI 10.1016/j.bbi.2014.03.006; Simpson RJ, 2011, EXERC SPORT SCI REV, V39, P23, DOI 10.1097/JES.0b013e318201f39d; Smith JK, 1999, JAMA-J AM MED ASSOC, V281, P1722, DOI 10.1001/jama.281.18.1722; Soderberg-Naucler C, 1999, INTERVIROLOGY, V42, P314, DOI 10.1159/000053966; Sperandio A., 2021, BRAZ J GLOB HLTH, V02; Staras SAS, 2006, CLIN INFECT DIS, V43, P1143, DOI 10.1086/508173; Sun J, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/1583951; Trzonkowski P, 2003, VACCINE, V21, P3826, DOI 10.1016/S0264-410X(03)00309-8; Turner JE, 2016, BIOGERONTOLOGY, V17, P581, DOI 10.1007/s10522-016-9642-z; van den Berg SPH, 2019, MED MICROBIOL IMMUN, V208, P305, DOI 10.1007/s00430-019-00602-z; van den Berg SPH, 2019, MED MICROBIOL IMMUN, V208, P365, DOI 10.1007/s00430-019-00608-7; Walsh NP, 2011, EXERC IMMUNOL REV, V17, P6; Weinberger B, 2007, HUM IMMUNOL, V68, P86, DOI 10.1016/j.humimm.2006.10.019; Wilkinson K, 2017, VACCINE, V35, P2775, DOI 10.1016/j.vaccine.2017.03.092; [Anonymous], 2000, JAMA, V284, P3043, DOI 10.1001/jama.2013.281053	66	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 12	2021	12								713763	10.3389/fimmu.2021.713763	http://dx.doi.org/10.3389/fimmu.2021.713763			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WP9LH	34712226	gold, Green Published			2022-12-18	WOS:000713445900001
J	Jacqueline, C; Dracz, M; Boothman, S; Minden, JS; Gottschalk, RA; Finn, OJ				Jacqueline, Camille; Dracz, Matthew; Boothman, Sarah; Minden, Jonathan S.; Gottschalk, Rachel A.; Finn, Olivera J.			Identification of Cell Surface Molecules That Determine the Macrophage Activation Threshold Associated With an Early Stage of Malignant Transformation	FRONTIERS IN IMMUNOLOGY			English	Article						breast cancer; TNF-alpha; 2D-DIGE; phagocytosis; annexin A1; CEACAM1	CLONAL EVOLUTION; BREAST-CANCER; ADHESION; AGE	The ability of immune cells to sense changes associated with malignant transformation as early as possible is likely to be important for the successful outcome of cancer immunosurveillance. In this process, the immune system faces a trade-off between elimination of cells harboring premalignant or malignant changes, and autoimmune pathologies. We hypothesized that the immune system has therefore evolved a threshold for the stage of transformation from normal to fully malignant cells that first provides a threat (danger) signal requiring a response. We co-cultured human macrophages with a unique set of genetically related human cell lines that recapitulate successive stages in breast cancer development: MCF10A (immortalized, normal); MCFNeoT (benign hyperplasia); MCFT1 (atypical hyperplasia); MCFCA1 (invasive cancer). Using cytokines-based assays, we found that macrophages were inert towards MCF10A and MCFNeoT but were strongly activated by MCFT1 and MCFCA1 to produce inflammatory cytokines, placing the threshold for recognition between two premalignant stages, the earlier stage MCFNeoT and the more advanced MCFT1. The cytokine activation threshold paralleled the threshold for enhanced phagocytosis. Using proteomic and transcriptomic approaches, we identified surface molecules, some of which are well-known tumor-associated antigens, that were absent or expressed at low levels in MCF10A and MCFNeoT but turned on or over-expressed in MCFT1 and MCFCA1. Adding antibodies specific for two of these molecules, Annexin-A1 and CEACAM1, inhibited macrophage activation, supporting their role as cancer "danger signals" recognized by macrophages.	[Jacqueline, Camille; Dracz, Matthew; Gottschalk, Rachel A.; Finn, Olivera J.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15260 USA; [Boothman, Sarah; Minden, Jonathan S.] Carnegie Mellon Univ, Dept Biol Sci, 4400 5th Ave, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University	Finn, OJ (corresponding author), Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15260 USA.	ojfinn@pitt.edu		Boothman, Sarah/0000-0003-1837-5639	NIH [R35 CA210039]; Forbeck Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Forbeck Foundation	Funding This work was supported by NIH grant R35 CA210039 to OJF and Forbeck Foundation grant to CJ.	Aarons CB, 2007, CLIN EXP METASTAS, V24, P201, DOI 10.1007/s10585-007-9069-7; Aktipis CA, 2013, EVOL APPL, V6, P144, DOI 10.1111/eva.12034; Balasubramani M, 2011, MUTAT RES-GEN TOX EN, V722, P154, DOI 10.1016/j.mrgentox.2010.08.019; Barreda DR, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD-0007-2015; Beauchemin N, 2013, CANCER METAST REV, V32, P643, DOI 10.1007/s10555-013-9444-6; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; CAIRNS J, 1975, SCI AM, V233, P64, DOI 10.1038/scientificamerican1175-64; Cascio S, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6040039; Chao MP, 2012, NAT REV CANCER, V12, P58, DOI 10.1038/nrc3171; Coteur G, 2002, EUR J CELL BIOL, V81, P413, DOI 10.1078/0171-9335-00254; Crespi B, 2005, TRENDS ECOL EVOL, V20, P545, DOI 10.1016/j.tree.2005.07.007; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Feng MY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05211-7; Feng MY, 2015, P NATL ACAD SCI USA, V112, P2145, DOI 10.1073/pnas.1424907112; GAO YL, 1994, GENE, V143, P179, DOI 10.1016/0378-1119(94)90094-9; Gottschalk RA, 2016, CELL SYST, V2, P378, DOI 10.1016/j.cels.2016.04.016; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang EY, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4254-4; Jacqueline C, 2017, EVOL APPL, V10, P215, DOI 10.1111/eva.12444; Kolbl AC, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00219; KOVACIC RT, 1991, BIOCHEMISTRY-US, V30, P9015, DOI 10.1021/bi00101a015; Krysko DV, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06807-9; Mapara MY, 2004, J CLIN ONCOL, V22, P1136, DOI 10.1200/JCO.2004.10.041; Mascaux C, 2019, NATURE, V571, P570, DOI 10.1038/s41586-019-1330-0; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Minden Jonathan S, 2012, Methods Mol Biol, V869, P287, DOI 10.1007/978-1-61779-821-4_24; Moraes LA, 2018, CELL ADHES MIGR, V12, P417, DOI 10.1080/19336918.2018.1486143; Mullins SR, 2012, BIOL CHEM, V393, P1405, DOI 10.1515/hsz-2012-0252; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ravichandran KS, 2010, J EXP MED, V207, P1807, DOI 10.1084/jem.20101157; Roh JS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e27; Rozhok AI, 2016, TRENDS CANCER, V2, P552, DOI 10.1016/j.trecan.2016.09.004; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Schloer S, 2019, FASEB J, V33, P12188, DOI 10.1096/fj.201901265R; Shao YB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133830; Tedesco S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00071; Thomas F, 2016, TRENDS CANCER, V2, P409, DOI 10.1016/j.trecan.2016.06.009; Toomer KH, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00116; Walens A, 2019, ELIFE, V8, DOI 10.7554/eLife.43653; WILLIAMS GC, 1991, Q REV BIOL, V66, P1, DOI 10.1086/417048; Wolf Y, 2020, NAT REV IMMUNOL, V20, P173, DOI 10.1038/s41577-019-0224-6; Zebhauser R, 2005, GENOMICS, V86, P566, DOI 10.1016/j.ygeno.2005.07.008; Zitvogel L, 2021, NAT REV CLIN ONCOL, V18, P591, DOI 10.1038/s41571-021-00508-x	45	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 12	2021	12								749597	10.3389/fimmu.2021.749597	http://dx.doi.org/10.3389/fimmu.2021.749597			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WQ1ZW	34712237	gold, Green Published			2022-12-18	WOS:000713621200001
J	Ji, WH; Li, DD; Wei, DP; Gu, AQ; Yang, Y; Peng, JP				Ji, Wen-Heng; Li, Dan-Dan; Wei, Dan-Ping; Gu, Ai-Qin; Yang, Ying; Peng, Jing-Pian			Cytochrome P450 26A1 Modulates the Polarization of Uterine Macrophages During the Peri-Implantation Period	FRONTIERS IN IMMUNOLOGY			English	Article						peri-implantation period; embryo implantation; uterine macrophages polarization (M1; M2); inflammatory response	ACID-METABOLIZING ENZYME; RETINOIC ACID; IMMUNE CELLS; DECIDUAL MACROPHAGES; EMBRYO IMPLANTATION; LOCAL INJURY; CYP26A1; EXPRESSION; INFLAMMATION; ENDOMETRIUM	Uterine M1/M2 macrophages activation states undergo dynamic changes throughout pregnancy, and inappropriate macrophages polarization can cause adverse pregnancy outcomes, especially during the peri-implantation period. Our previous studies have confirmed that Cytochrome P450 26A1 (CYP26A1) can affect embryo implantation by regulating uterine NK cells and DCs. The aim of this study was to investigate whether CYP26A1 regulates the polarization of uterine macrophages in early pregnancy. Here, we observed that Cyp26a1 was significantly upregulated in M1 as compared with M2 of uterine macrophages, Raw264.7 and iBMDM. Knockdown of CYP26A1 in mice uterine significantly decreased the number of embryo implantation sites and the proportion of CD45(+)F4/80(+)CD206(-) M1-like uterine macrophages. Primary uterine macrophages treated with anti-CYP26A1 antibody expressed significantly lower levels of M1 markers Nos2, Il1b, Il6 and Tnf-a. In CYP26A1 knockout Raw264.7 cells, the protein levels of M1 markers TNF-alpha, IL-6 and CD86 were significantly decreased as compared with the wild type cells. Moreover, CYP26A1 deficiency decreased the ability to produce nitric oxide and increased the phagocytosis capacity of Raw264.7 cells under M1 stimulation state. The re-introduction of CYP26A1 partially reversed the polarization levels of M1 in CYP26A1 knockout Raw264.7 cells. CYP26A1 may regulate the polarization of uterine macrophages to M1 through Stap1 and Slc7a2. In summary, these results indicate that CYP26A1 plays a significant role in macrophage polarization, and knockdown of CYP26A1 can cause insufficient M1 polarization during the peri-implantation period, which has adverse effects on blastocyst implantation.	[Ji, Wen-Heng; Li, Dan-Dan; Wei, Dan-Ping; Gu, Ai-Qin; Yang, Ying; Peng, Jing-Pian] Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing, Peoples R China; [Ji, Wen-Heng; Li, Dan-Dan; Wei, Dan-Ping; Gu, Ai-Qin; Yang, Ying; Peng, Jing-Pian] Univ Chinese Acad Sci, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Zoology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Peng, JP (corresponding author), Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing, Peoples R China.; Peng, JP (corresponding author), Univ Chinese Acad Sci, Beijing, Peoples R China.				National Natural Science Foundation of China [31571552]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (no. 31571552).	Abrahams VM, 2004, AM J REPROD IMMUNOL, V51, P275, DOI 10.1111/j.1600-0897.2004.00156.x; Abu-Abed S, 2001, GENE DEV, V15, P226, DOI 10.1101/gad.855001; Abu-Abed S, 2002, MECH DEVELOP, V110, P173, DOI 10.1016/S0925-4773(01)00572-X; Abu-Abed S, 2003, DEVELOPMENT, V130, P1449, DOI 10.1242/dev.00357; Barash A, 2003, FERTIL STERIL, V79, P1317, DOI 10.1016/S0015-0282(03)00345-5; Billington WD, 2003, J REPROD IMMUNOL, V60, P1, DOI 10.1016/S0165-0378(03)00083-4; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Brown MB, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00606; BULMER JN, 1991, HUM REPROD, V6, P791, DOI 10.1093/oxfordjournals.humrep.a137430; Bulmer JN, 2010, INT J DEV BIOL, V54, P281, DOI 10.1387/ijdb.082763jb; Care AS, 2013, J CLIN INVEST, V123, P3472, DOI 10.1172/JCI60561; Chabtini L, 2013, J IMMUNOL, V190, P88, DOI 10.4049/jimmunol.1202176; Coburn LA, 2019, ONCOGENE, V38, P1067, DOI 10.1038/s41388-018-0492-9; DE M, 1993, J REPROD FERTIL, V97, P83, DOI 10.1530/jrf.0.0970083; Dekel N, 2014, AM J REPROD IMMUNOL, V72, P141, DOI 10.1111/aji.12266; Duque-Correa MA, 2014, P NATL ACAD SCI USA, V111, pE4024, DOI 10.1073/pnas.1408839111; Emoto Y, 2005, DEV BIOL, V278, P415, DOI 10.1016/j.ydbio.2004.11.023; Feng P, 2014, J NEUROSCI, V34, P2689, DOI 10.1523/JNEUROSCI.3074-13.2014; Fonken LK, 2010, P NATL ACAD SCI USA, V107, P18664, DOI 10.1073/pnas.1008734107; Fritzsche B, 2010, REPROD TOXICOL, V30, P446, DOI 10.1016/j.reprotox.2010.05.005; Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419; Granot I, 2012, REPRODUCTION, V144, P661, DOI 10.1530/REP-12-0217; Gu AQ, 2019, J CELL MOL MED, V23, P5403, DOI 10.1111/jcmm.14423; Hamilton S, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.095505; Han BC, 2010, J CELL PHYSIOL, V223, P471, DOI 10.1002/jcp.22056; Hannemann N, 2017, J IMMUNOL, V198, P3605, DOI 10.4049/jimmunol.1601330; Hazan AD, 2010, AM J PATHOL, V177, P1017, DOI 10.2353/ajpath.2010.091105; Inui M, 2011, J IMMUNOL, V186, P423, DOI 10.4049/jimmunol.1000043; Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514; Jaiswal MK, 2012, REPRODUCTION, V143, P713, DOI 10.1530/REP-12-0036; Khan S, 2000, BIOL REPROD, V62, P1075, DOI 10.1095/biolreprod62.4.1075; Liu TT, 2013, PARASITOL RES, V112, P3019, DOI 10.1007/s00436-013-3475-3; Liu YQ, 2021, J CELL MOL MED, V25, P7690, DOI 10.1111/jcmm.16616; Luu KC, 2004, P NATL ACAD SCI USA, V101, P8028, DOI 10.1073/pnas.0401069101; Malyshev I, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/341308; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Meng CY, 2017, J CELL MOL MED, V21, P697, DOI 10.1111/jcmm.13013; Ning F, 2016, AM J REPROD IMMUNOL, V75, P298, DOI 10.1111/aji.12477; Prins JR, 2012, PLACENTA, V33, P453, DOI 10.1016/j.placenta.2012.02.010; Qiu X, 2009, INFECT IMMUN, V77, P85, DOI 10.1128/IAI.01022-08; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rat E, 2006, BIRTH DEFECTS RES A, V76, P491, DOI 10.1002/bdra.20275; Raziel A, 2007, FERTIL STERIL, V87, P198, DOI 10.1016/j.fertnstert.2006.05.062; Robertson SA, 2010, J REPROD IMMUNOL, V85, P51, DOI 10.1016/j.jri.2010.01.008; Robinson SC, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0178-x; Sakai Y, 2001, GENE DEV, V15, P213, DOI 10.1101/gad.851501; Shakhawat A, 2010, J REPROD IMMUNOL, V85, P40, DOI 10.1016/j.jri.2010.02.004; Shaul ME, 2010, DIABETES, V59, P1171, DOI 10.2337/db09-1402; Shynlova O, 2013, J CELL MOL MED, V17, P311, DOI 10.1111/jcmm.12012; Shynlova O, 2013, J CELL MOL MED, V17, P90, DOI 10.1111/j.1582-4934.2012.01650.x; Singh U, 2005, REPRODUCTION, V129, P631, DOI 10.1530/rep.1.00331; Smith SD, 2009, AM J PATHOL, V174, P1959, DOI 10.2353/ajpath.2009.080995; Stoecker K, 2009, BIOCHEM BIOPH RES CO, V379, P121, DOI 10.1016/j.bbrc.2008.12.021; Svensson J, 2011, J IMMUNOL, V187, P3671, DOI 10.4049/jimmunol.1100130; Tang F, 2017, MOL MED REP, V16, P6708, DOI 10.3892/mmr.2017.7466; Tiboni GM, 2011, J REPROD MED, V56, P504; Trundley A, 2004, TISSUE ANTIGENS, V63, P1, DOI 10.1111/j.1399-0039.2004.00170.x; Uehara M, 2007, DEV BIOL, V302, P399, DOI 10.1016/j.ydbio.2006.09.045; Wei DP, 2021, J CELL MOL MED, V25, P1771, DOI 10.1111/jcmm.16285; Weng XD, 2021, IMMUNOL CELL BIOL, V99, P274, DOI 10.1111/imcb.12405; Xia HF, 2010, HUM REPROD, V25, P2985, DOI 10.1093/humrep/deq268; Xin Q, 2015, J IMMUNOL, V194, P5437, DOI 10.4049/jimmunol.1403028; Xu ZH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11422; Yamakawa I, 2011, AM J PHYSIOL-ENDOC M, V301, pE844, DOI 10.1152/ajpendo.00029.2011; Zhang YH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00120; Zhong G, 2019, J BIOL CHEM, V294, P11166, DOI 10.1074/jbc.RA119.009023	66	1	1	2	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 12	2021	12								763067	10.3389/fimmu.2021.763067	http://dx.doi.org/10.3389/fimmu.2021.763067			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WP9IH	34712245	Green Published, gold			2022-12-18	WOS:000713438000001
J	Quenum, AJI; Shukla, A; Rexhepi, F; Cloutier, M; Ghosh, A; Kufer, TA; Ramanathan, S; Ilangumaran, S				Quenum, Akouavi Julite I.; Shukla, Akhil; Rexhepi, Fjolla; Cloutier, Maryse; Ghosh, Amit; Kufer, Thomas A.; Ramanathan, Sheela; Ilangumaran, Subburaj			NLRC5 Deficiency Deregulates Hepatic Inflammatory Response but Does Not Aggravate Carbon Tetrachloride-Induced Liver Fibrosis	FRONTIERS IN IMMUNOLOGY			English	Article						NLRC5; NF-kappa B; liver fibrosis; carbon tetrachloride; hepatic stellate cells	NF-KAPPA-B; STELLATE CELLS; INTERFERON; ACTIVATION; MECHANISMS; MACROPHAGES; IL-6; MHC; PROLIFERATION; PATHOGENESIS	The nucleotide-binding leucine-rich repeat-containing receptor (NLR) family protein-5 (NLRC5) controls NF-kappa B activation and production of inflammatory cytokines in certain cell types. NLRC5 is considered a potential regulator of hepatic fibrogenic response due to its ability to inhibit hepatic stellate activation in vitro. To test whether NLRC5 is critical to control liver fibrosis, we treated wildtype and NLRC5-deficient mice with carbon tetrachloride (CCl4) and assessed pathological changes in the liver. Serum alanine transaminase levels and histopathology examination of liver sections revealed that NLRC5 deficiency did not exacerbate CCl4-induced liver damage or inflammatory cell infiltration. Sirius red staining of collagen fibers and hydroxyproline content showed comparable levels of liver fibrosis in CCl4-treated NLRC5-deficient and control mice. Myofibroblast differentiation and induction of collagen genes were similarly increased in both groups. Strikingly, the fibrotic livers of NLRC5-deficient mice showed reduced expression of matrix metalloproteinase-3 (Mmp3) and tissue inhibitor of MMPs-1 (Timp1) but not Mmp2 or Timp2. Fibrotic livers of NLRC5-deficient mice had increased expression of TNF but similar induction of TGF beta compared to wildtype mice. CCl4-treated control and NLRC5-deficient mice displayed similar upregulation of Cx3cr1, a monocyte chemoattractant receptor gene, and the Cd68 macrophage marker. However, the fibrotic livers of NLRC5-deficient mice showed increased expression of F4/80 (Adgre1), a marker of tissue-resident macrophages. NLRC5-deficient livers showed increased phosphorylation of the NF-kappa B subunit p65 that remained elevated following fibrosis induction. Taken together, NLRC5 deficiency deregulates hepatic inflammatory response following chemical injury but does not significantly aggravate the fibrogenic response, showing that NLRC5 is not a critical regulator of liver fibrosis pathogenesis.</p>	[Quenum, Akouavi Julite I.; Shukla, Akhil; Rexhepi, Fjolla; Cloutier, Maryse; Ghosh, Amit; Ramanathan, Sheela; Ilangumaran, Subburaj] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Immunol & Cell Biol, Sherbrooke, PQ, Canada; [Kufer, Thomas A.] Univ Hohenheim, Inst Nutrit Med, Dept Immunol 180b, Stuttgart, Germany; [Ilangumaran, Subburaj] Ctr Rech Ctr Hosp Univ Sherbrooke CR CHUS, Sherbrooke, PQ, Canada	University of Sherbrooke; University Hohenheim	Ilangumaran, S (corresponding author), Univ Sherbrooke, Fac Med & Hlth Sci, Dept Immunol & Cell Biol, Sherbrooke, PQ, Canada.; Ilangumaran, S (corresponding author), Ctr Rech Ctr Hosp Univ Sherbrooke CR CHUS, Sherbrooke, PQ, Canada.		Kufer, Thomas A/I-5146-2015	Kufer, Thomas A/0000-0003-4563-0412; Ilangumaran, Subburaj/0000-0002-7563-576X	Canadian Institutes of Health Research [PJT-153255]; FRQS	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); FRQS	& nbsp;This work was supported by the Canadian Institutes of Health Research project grant PJT-153255 to SI. AG is a recipient of a postdoctoral fellowship from FRQS. CR-CHUS is an FRQS-funded research center.	Baroni GS, 1996, HEPATOLOGY, V23, P1189; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Benko S, 2010, J IMMUNOL, V185, P1681, DOI 10.4049/jimmunol.0903900; Benko S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00150; Byass P, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0159-5; Chaisson ML, 2002, J CLIN INVEST, V110, P193, DOI 10.1172/JCI200215295; Conti BJ, 2005, J BIOL CHEM, V280, P18375, DOI 10.1074/jbc.M413169200; Cui J, 2010, CELL, V141, P483, DOI 10.1016/j.cell.2010.03.040; Davis BK, 2011, J IMMUNOL, V186, P1333, DOI 10.4049/jimmunol.1003111; Dewidar B, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111419; Duffield JS, 2013, ANNU REV PATHOL-MECH, V8, P241, DOI 10.1146/annurev-pathol-020712-163930; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Friedman SL, 2008, GASTROENTEROLOGY, V134, P1655, DOI 10.1053/j.gastro.2008.03.003; Giannandrea M, 2014, DIS MODEL MECH, V7, P193, DOI 10.1242/dmm.012062; Gieling RG, 2010, HEPATOLOGY, V51, P922, DOI 10.1002/hep.23385; Gressner AM, 2006, J CELL MOL MED, V10, P76, DOI 10.1111/j.1582-4934.2006.tb00292.x; Hammerich L, 2014, CLIN EXP GASTROENTER, V7, P297, DOI 10.2147/CEG.S43737; Henderson NC, 2020, NATURE, V587, P555, DOI 10.1038/s41586-020-2938-9; Hernandez-Gea V, 2011, ANNU REV PATHOL-MECH, V6, P425, DOI 10.1146/annurev-pathol-011110-130246; Higashi T, 2017, ADV DRUG DELIVER REV, V121, P27, DOI 10.1016/j.addr.2017.05.007; Hu YB, 2007, J GENE MED, V9, P217, DOI 10.1002/jgm.1009; Kandhi R, 2016, CYTOKINE, V82, P58, DOI 10.1016/j.cyto.2015.12.007; Kim IH, 2016, AGE, V38, P291, DOI 10.1007/s11357-016-9938-6; Knight B, 2007, J HEPATOL, V47, P826, DOI 10.1016/j.jhep.2007.06.022; Kobayashi KS, 2012, NAT REV IMMUNOL, V12, P813, DOI 10.1038/nri3339; Kumar H, 2011, J IMMUNOL, V186, P994, DOI 10.4049/jimmunol.1002094; Landsman L, 2009, BLOOD, V113, P963, DOI 10.1182/blood-2008-07-170787; Li L, 2014, INFLAMMATION, V37, P835, DOI 10.1007/s10753-013-9804-y; Liedtke C, 2013, FIBROGENESIS TISSUE, V6, DOI 10.1186/1755-1536-6-19; Liu XJ, 2016, TOXICOL APPL PHARM, V294, P43, DOI 10.1016/j.taap.2016.01.012; Lozano R, 2013, LANCET, V381, P991, DOI 10.1016/S0140-6736(13)60704-7; Luedde T, 2011, NAT REV GASTRO HEPAT, V8, P108, DOI 10.1038/nrgastro.2010.213; Maekawa T, 2011, NAT IMMUNOL, V12, P818, DOI 10.1038/ni.2083; Marra F, 2014, GASTROENTEROLOGY, V147, P577, DOI 10.1053/j.gastro.2014.06.043; Meng QC, 2015, J CELL BIOL, V211, P1025, DOI 10.1083/jcb.201505091; Mokdad AA, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0145-y; Moreno M, 2008, CLIN LIVER DIS, V12, P825, DOI 10.1016/j.cld.2008.07.013; Motta V, 2015, PHYSIOL REV, V95, P149, DOI 10.1152/physrev.00009.2014; Murtha LA, 2019, AGING DIS, V10, P419, DOI 10.14336/AD.2018.0601; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Osawa Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065251; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Pellicoro A, 2014, NAT REV IMMUNOL, V14, P181, DOI 10.1038/nri3623; Radbill BD, 2011, DIGEST DIS SCI, V56, P406, DOI 10.1007/s10620-010-1296-0; Ratziu Vlad, 2020, Gastroenterology, DOI 10.1053/j.gastro.2020.05.046; Reddy GK, 1996, CLIN BIOCHEM, V29, P225, DOI 10.1016/0009-9120(96)00003-6; Robbins GR, 2012, J BIOL CHEM, V287, P24294, DOI 10.1074/jbc.M112.364604; Rockey DC, 2015, NEW ENGL J MED, V372, P1138, DOI 10.1056/NEJMra1300575; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Schneider M, 2012, NAT IMMUNOL, V13, P823, DOI 10.1038/ni.2378; Schuppan D, 2013, J CLIN INVEST, V123, P1887, DOI 10.1172/JCI66028; Schuppan D, 2012, J HEPATOL, V56, pS66, DOI 10.1016/S0168-8278(12)60008-7; Seki E, 2015, HEPATOLOGY, V61, P1066, DOI 10.1002/hep.27332; Shi ZD, 1997, P NATL ACAD SCI USA, V94, P10663, DOI 10.1073/pnas.94.20.10663; Shukla A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041964; Stahl EC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02795; Sudo K, 2005, CYTOKINE, V29, P236, DOI 10.1016/j.cyto.2004.11.001; Sun T, 2019, IMMUNOL CELL BIOL, V97, P552, DOI 10.1111/imcb.12244; Tacke F, 2017, J HEPATOL, V66, P1300, DOI 10.1016/j.jhep.2017.02.026; Tarrats N, 2011, HEPATOLOGY, V54, P319, DOI 10.1002/hep.24388; Thiele ND, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00671-1; Ting JPY, 2008, IMMUNITY, V28, P285, DOI 10.1016/j.immuni.2008.02.005; Tong YZ, 2012, CELL RES, V22, P822, DOI 10.1038/cr.2012.53; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Trautwein C, 2015, J HEPATOL, V62, pS15, DOI 10.1016/j.jhep.2015.02.039; Waddell LA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02246; Weng HL, 2001, WORLD J GASTROENTERO, V7, P42; Weston CJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00893; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; WHO, 2011, GLOBAL HLTH AGING; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Xia XJ, 2011, IMMUNITY, V34, P843, DOI 10.1016/j.immuni.2011.02.022; Xu T, 2016, INT J BIOCHEM CELL B, V70, P92, DOI 10.1016/j.biocel.2015.11.010; Xu T, 2015, INFLAMMATION, V38, P1794, DOI 10.1007/s10753-015-0157-6; Yang L, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00138; Yang Yoon Mee, 2015, Curr Pathobiol Rep, V3, P253; Yao Y, 2012, CELL RES, V22, P836, DOI 10.1038/cr.2012.56; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001	79	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 12	2021	12								749646	10.3389/fimmu.2021.749646	http://dx.doi.org/10.3389/fimmu.2021.749646			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WQ1TS	34712238	gold, Green Published			2022-12-18	WOS:000713604800001
J	Velasquez, E; Szeitz, B; Gil, J; Rodriguez, J; Palkovits, M; Renner, E; Hortobagyi, T; Dome, P; Nogueira, FCS; Marko-Varga, G; Domont, GB; Rezeli, M				Velasquez, Erika; Szeitz, Beata; Gil, Jeovanis; Rodriguez, Jimmy; Palkovits, Miklos; Renner, Eva; Hortobagyi, Tibor; Dome, Peter; Nogueira, Fabio C. S.; Marko-Varga, Gyoergy; Domont, Gilberto B.; Rezeli, Melinda			Topological Dissection of Proteomic Changes Linked to the Limbic Stage of Alzheimer's Disease	FRONTIERS IN IMMUNOLOGY			English	Article						Alzheimer's disease; limbic stage; proteomics; phosphoproteomics; acetylomics; neuroinflammation	T-CELL-ACTIVATION; LYSINE ACETYLATION; BRAIN; CD14; POLARIZATION; RECEPTOR; PATHWAY; STOICHIOMETRY; HIPPOCAMPUS; MICROGLIA	Alzheimer's disease (AD) is a neurodegenerative disorder and the most common cause of dementia worldwide. In AD, neurodegeneration spreads throughout different areas of the central nervous system (CNS) in a gradual and predictable pattern, causing progressive memory decline and cognitive impairment. Deposition of neurofibrillary tangles (NFTs) in specific CNS regions correlates with the severity of AD and constitutes the basis for disease classification into different Braak stages (I-VI). Early clinical symptoms are typically associated with stages III-IV (i.e., limbic stages) when the involvement of the hippocampus begins. Histopathological changes in AD have been linked to brain proteome alterations, including aberrant posttranslational modifications (PTMs) such as the hyperphosphorylation of Tau. Most proteomic studies to date have focused on AD progression across different stages of the disease, by targeting one specific brain area at a time. However, in AD vulnerable regions, stage-specific proteomic alterations, including changes in PTM status occur in parallel and remain poorly characterized. Here, we conducted proteomic, phosphoproteomic, and acetylomic analyses of human postmortem tissue samples from AD (Braak stage III-IV, n=11) and control brains (n=12), covering all anatomical areas affected during the limbic stage of the disease (total hippocampus, CA1, entorhinal and perirhinal cortices). Overall, similar to 6000 proteins, similar to 9000 unique phosphopeptides and 221 acetylated peptides were accurately quantified across all tissues. Our results reveal significant proteome changes in AD brains compared to controls. Among others, we have observed the dysregulation of pathways related to the adaptive and innate immune responses, including several altered antimicrobial peptides (AMPs). Notably, some of these changes were restricted to specific anatomical areas, while others altered according to disease progression across the regions studied. Our data highlights the molecular heterogeneity of AD and the relevance of neuroinflammation as a major player in AD pathology. Data are available via ProteomeXchange with identifier PXD027173.	[Velasquez, Erika; Gil, Jeovanis] Lund Univ, Skane Univ Hosp Malmo, Dept Translat Med, Sect Clin Chem, Malmo, Sweden; [Szeitz, Beata] Semmelweis Univ, Dept Internal Med & Oncol, Div Oncol, Budapest, Hungary; [Gil, Jeovanis] Lund Univ, Dept Clin Sci Lund, Div Oncol, Lund, Sweden; [Rodriguez, Jimmy] Karolinska Inst, Dept Med Biochem & Biophys, Div Chem 1, Stockholm, Sweden; [Palkovits, Miklos; Renner, Eva] Semmelweis Univ, Human Brain Tissue Bank, Budapest, Hungary; [Hortobagyi, Tibor] Univ Szeged, Inst Pathol, Fac Med, Szeged, Hungary; [Hortobagyi, Tibor] Univ Debrecen, Dept Neurol, ELKH Cerebrovascular & Neurodegenerat Res Grp, Fac Med, Debrecen, Hungary; [Dome, Peter] Semmelweis Univ, Dept Psychiat & Psychotherapy, Budapest, Hungary; [Dome, Peter] Natl Inst Mental Hlth Neurol & Neurosurg, Budapest, Hungary; [Nogueira, Fabio C. S.; Domont, Gilberto B.] Univ Fed Rio de Janeiro, Inst Chem, Dept Biochem, Prote Unit, Rio De Janeiro, Brazil; [Nogueira, Fabio C. S.] Univ Fed Rio de Janeiro, Inst Chem, Lab Apoioao Desenvolvimento Tecnol LADETEC, Lab Prote, Rio De Janeiro, Brazil; [Marko-Varga, Gyoergy; Rezeli, Melinda] Lund Univ, Dept Biomed Engn, Div Clin Prot Sci & Imaging, Lund, Sweden	Lund University; Skane University Hospital; Semmelweis University; Lund University; Karolinska Institutet; Semmelweis University; Szeged University; University of Debrecen; Semmelweis University; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Lund University	Domont, GB (corresponding author), Univ Fed Rio de Janeiro, Inst Chem, Dept Biochem, Prote Unit, Rio De Janeiro, Brazil.; Rezeli, M (corresponding author), Lund Univ, Dept Biomed Engn, Div Clin Prot Sci & Imaging, Lund, Sweden.	gilbertodomont@gmail.com; melinda.rezeli@bme.lth.se	Nogueira, Fabio/G-9580-2011; Gil Valdes, Jeovanis/G-6390-2016	Nogueira, Fabio/0000-0001-5507-7142; Gil Valdes, Jeovanis/0000-0003-3601-3893; Szeitz, Beata/0000-0001-6414-0537	Hungarian National Brain Research Program [2017-1.2.1-NKP-2017-00002]; FAPERJ [E 26/202.650/2018, E-26/210.173/2018]; CNPq [315167/2020-3, 440613/2016-7, 308341-2019-8]; Brazilian foundation CAPES [88887.130697]; Erasmus+ and Campus Mundi Programme	Hungarian National Brain Research Program; FAPERJ(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Brazilian foundation CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Erasmus+ and Campus Mundi Programme	This study was supported by the Hungarian National Brain Research Program (2017-1.2.1-NKP-2017-00002) for MP and ER; by FAPERJ (grant E 26/202.650/2018 and grant E-26/210.173/2018) and CNPq (grant 315167/2020-3, 440613/2016-7 and grant 308341-2019-8) for FN and GD. EV thanks the financial support from the Brazilian foundation CAPES (grant 88887.130697) and BS acknowledges support from the Erasmus+ and Campus Mundi Programme.	Aki D, 2015, IMMUNOL REV, V266, P6, DOI 10.1111/imr.12301; Augustinack JC, 2013, NEUROIMAGE, V64, P32, DOI 10.1016/j.neuroimage.2012.08.071; Baeza J, 2014, J BIOL CHEM, V289, P21326, DOI 10.1074/jbc.M114.581843; Bai B, 2020, NEURON, V105, P975, DOI 10.1016/j.neuron.2019.12.015; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Chakrabarty P, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-36; Chakraborty A, 2002, J CHROMATOGR A, V949, P173, DOI 10.1016/S0021-9673(02)00047-X; Chung WS, 2013, NATURE, V504, P394, DOI 10.1038/nature12776; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; D'Acquisto F, 2007, BLOOD, V109, P1095, DOI 10.1182/blood-2006-05-022798; Doorn KJ, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00084; Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351; Silva MVF, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0524-y; Ferretti MT, 2016, BRAIN BEHAV IMMUN, V54, P211, DOI 10.1016/j.bbi.2016.02.009; Frost GR, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00337; Gabande-Rodriguez E, 2020, J NEUROSCI RES, V98, P284, DOI 10.1002/jnr.24419; Galea I, 2007, J EXP MED, V204, P2023, DOI 10.1084/jem.20070064; Gil J, 2017, J BIOL CHEM, V292, P18129, DOI 10.1074/jbc.M117.784546; Godec J, 2016, IMMUNITY, V44, P194, DOI 10.1016/j.immuni.2015.12.006; Gong CX, 2008, CURR MED CHEM, V15, P2321, DOI 10.2174/092986708785909111; Gong M, 2017, MED SCI MONIT BASIC, V23, P240, DOI 10.12659/MSMBR.904014; Guillozet AL, 2003, ARCH NEUROL-CHICAGO, V60, P729, DOI 10.1001/archneur.60.5.729; Guo TT, 2020, MOL NEURODEGENER, V15, DOI 10.1186/s13024-020-00391-7; Guzman-Martinez L, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01008; Halnner R, 2015, CELL PHYSIOL BIOCHEM, V37, P269, DOI 10.1159/000430351; Hampel H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00456; He Y, 2020, NEUROSCIENCE, V437, P161, DOI 10.1016/j.neuroscience.2020.03.008; Hemphill WO, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.660184; Iram T, 2016, J NEUROSCI, V36, P5185, DOI 10.1523/JNEUROSCI.3850-15.2016; Janova H, 2016, GLIA, V64, P635, DOI 10.1002/glia.22955; Ji JY, 2000, J CHROMATOGR B, V745, P197, DOI 10.1016/S0378-4347(00)00192-4; Jimenez S, 2008, J NEUROSCI, V28, P11650, DOI 10.1523/JNEUROSCI.3024-08.2008; Johnson ECB, 2020, NAT MED, V26, P769, DOI 10.1038/s41591-020-0815-6; Johnson ECB, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0282-4; Jones SV, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01805; Kanehisa M, 2020, PROTEIN SCI, V29, P28, DOI 10.1002/pro.3711; Kinney Jefferson W, 2018, Alzheimers Dement (N Y), V4, P575, DOI 10.1016/j.trci.2018.06.014; Konrad C, 2009, NEUROIMAGE, V47, P1185, DOI 10.1016/j.neuroimage.2009.05.019; Korolainen MA, 2005, NEUROBIOL DIS, V20, P858, DOI 10.1016/j.nbd.2005.05.021; Kumar A, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.633050; Leng K, 2021, NAT NEUROSCI, V24, P276, DOI 10.1038/s41593-020-00764-7; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lopez JAS, 2019, HAND CLINIC, V167, P231, DOI 10.1016/B978-0-12-804766-8.00013-3; Maier E, 2012, EUR J IMMUNOL, V42, P2827, DOI 10.1002/eji.201242433; Matias I, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00059; McKetney J, 2019, J PROTEOME RES, V18, P1380, DOI 10.1021/acs.jproteome.9b00004; Mendez MF, 2017, NEUROL CLIN, V35, P263, DOI 10.1016/j.ncl.2017.01.005; Mendonca CF, 2019, NEUROBIOL DIS, V130, DOI 10.1016/j.nbd.2019.104509; Meraz-Rios MA, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00059; Metz KS, 2018, CELL SYST, V7, P347, DOI 10.1016/j.cels.2018.07.001; Minter MR, 2016, J NEUROCHEM, V136, P457, DOI 10.1111/jnc.13411; Moir RD, 2018, ALZHEIMERS DEMENT, V14, P1602, DOI 10.1016/j.jalz.2018.06.3040; Mrdjen D, 2019, ACTA NEUROPATHOL, V138, P729, DOI 10.1007/s00401-019-02054-4; Nores JER, 1999, EUR J IMMUNOL, V29, P265, DOI 10.1002/(SICI)1521-4141(199901)29:01<265::AID-IMMU265>3.3.CO;2-7; PALKOVITS M, 1973, BRAIN RES, V59, P449, DOI 10.1016/0006-8993(73)90290-4; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Rangaraju S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00405; Rayaprolu S, 2021, NEUROPSYCHOPHARMACOL, V46, P98, DOI 10.1038/s41386-020-00840-3; Reitz Christiane, 2012, Int J Alzheimers Dis, V2012, P369808, DOI 10.1155/2012/369808; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Skogseth R, 2017, J ALZHEIMERS DIS, V59, P1139, DOI 10.3233/JAD-170274; Suire CN, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00649-8; Tan YL, 2020, MOL PSYCHIATR, V25, P351, DOI 10.1038/s41380-019-0609-8; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Togo T, 2002, J NEUROIMMUNOL, V124, P83, DOI 10.1016/S0165-5728(01)00496-9; TOOYAMA I, 1990, BRAIN RES, V523, P273, DOI 10.1016/0006-8993(90)91496-4; Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]; Weaver DF, 2020, ALZH DEMENT-TRCI, V6, DOI 10.1002/trc2.12100; Wen L, 2018, J NEUROTRAUM, V35, P2330, DOI 10.1089/neu.2017.5540; Xu JS, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-018-0254-9; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zamani F, 2013, ADV PHARM BULL, V3, P329, DOI 10.5681/apb.2013.053	72	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 12	2021	12								750665	10.3389/fimmu.2021.750665	http://dx.doi.org/10.3389/fimmu.2021.750665			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WP9LI	34712240	Green Accepted, Green Published, gold			2022-12-18	WOS:000713446000001
J	Wang, DD; Jueraitetibaike, K; Tang, T; Wang, YB; Jing, J; Xue, TM; Ma, JZ; Cao, SY; Lin, Y; Li, XY; Ma, RJ; Chen, X; Yao, B				Wang, Dandan; Jueraitetibaike, Kadiliya; Tang, Ting; Wang, Yanbo; Jing, Jun; Xue, Tongmin; Ma, Jinzhao; Cao, Siyuan; Lin, Ying; Li, Xiaoyan; Ma, Rujun; Chen, Xi; Yao, Bing			Seminal Plasma and Seminal Plasma Exosomes of Aged Male Mice Affect Early Embryo Implantation via Immunomodulation	FRONTIERS IN IMMUNOLOGY			English	Article						seminal plasma; seminal plasma exosomes; dendritic cells; advanced-age male fertility; uterine immune microenvironment; embryo implantation	LEUKOCYTIC REACTION; GENE-EXPRESSION; CELLS; FLUID; INDUCTION; PROMOTES; SECRETION; CYTOKINE; OUTCOMES; CERVIX	Seminal plasma (SP), particularly SP exosomes (sExos), alters with age and can affect female mouse uterine immune microenvironment. However, the relationship between fertility decline in reproductively older males, and SP and sExos age-related changes, which may compromise the uterine immune microenvironment, remains unclear. The present study demonstrated that the implantation rate of female mice treated with SP from reproductively older male mice (aged-SP group) was lower than that of those treated with SP from younger male mice (young-SP group). RNA-sequencing analysis revealed altered levels of dendritic cell (DC)-related cytokines and chemokines in the uteri of the former group compared with those of the latter group. In vivo and in vitro experiments demonstrated a weaker inhibitory effect of aged SP on DC maturation than of young SP upon stimulation. After isolating and characterizing sExos from young and advanced-age male mice, we discovered that insemination of a subset of the aged-SP group with sExos from young male mice partially recovered the implantation rate decline. Additional in vivo and in vitro experiments revealed that sExos extracted from age male mice exerted a similar effect on DC maturation as SP of aged mice, indicating an age-related sExos inhibitory effect. In conclusion, our study demonstrated that age-related alterations of sExos may be partially responsible for lower implantation rates in the aged-SP group compared with those in the young-SP group, which were mediated by uterine immunomodulation. These findings provide new insights for clinical seminal adjuvant therapy.	[Wang, Dandan; Jueraitetibaike, Kadiliya; Jing, Jun; Ma, Jinzhao; Cao, Siyuan; Lin, Ying; Li, Xiaoyan; Ma, Rujun; Yao, Bing] Nanjing Univ, Med Sch, Affiliated Jinling Hosp, Dept Reprod Med, Nanjing, Peoples R China; [Tang, Ting; Xue, Tongmin] Nanjing Med Univ, Affiliated Jinling Hosp, Dept Reprod Med, Nanjing, Peoples R China; [Wang, Yanbo; Chen, Xi] Nanjing Univ, Sch Life Sci, Nanjing, Peoples R China	Nanjing University; Nanjing Medical University; Nanjing University	Yao, B (corresponding author), Nanjing Univ, Med Sch, Affiliated Jinling Hosp, Dept Reprod Med, Nanjing, Peoples R China.; Chen, X (corresponding author), Nanjing Univ, Sch Life Sci, Nanjing, Peoples R China.	xichen@nju.edu.cn; yaobing@nju.edu.cn	li, xiao/GSN-6181-2022; li, xiaofeng/GXF-9442-2022; Ma, Jinzhao/M-6520-2014	Ma, Jinzhao/0000-0002-9367-6602	yy; National Key Research and Development Program of China	yy; National Key Research and Development Program of China	This work was supported by the National Key Research and Development Program of China (2018YFC1004700) and National Natural Science Foundation of China (81971373).	Bai RL, 2018, BIOCHEM BIOPH RES CO, V495, P1094, DOI 10.1016/j.bbrc.2017.11.100; Baranyai T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145686; Berlier W, 2006, HUM REPROD, V21, P1135, DOI 10.1093/humrep/dei496; Bermejo-Alvarez P, 2014, JOVE-J VIS EXP, DOI 10.3791/51214; Blanco P, 2008, CYTOKINE GROWTH F R, V19, P41, DOI 10.1016/j.cytogfr.2007.10.004; Blois SM, 2007, NAT MED, V13, P1450, DOI 10.1038/nm1680; Bromfield JJ, 2016, REPRODUCTION, V152, pR223, DOI 10.1530/REP-16-0313; Bromfield JJ, 2014, J ASSIST REPROD GEN, V31, P627, DOI 10.1007/s10815-014-0243-y; Caligioni Claudia S, 2009, Curr Protoc Neurosci, VAppendix 4, p4I, DOI 10.1002/0471142301.nsa04is48; Carracedo J, 2019, CURR VASC PHARMACOL, V17, P447, DOI 10.2174/1570161116666180820115726; Chicea R, 2013, J ASSIST REPROD GEN, V30, P569, DOI 10.1007/s10815-013-9955-7; Chung HY, 2006, ANTIOXID REDOX SIGN, V8, P572, DOI 10.1089/ars.2006.8.572; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Crawford G, 2015, HUM REPROD UPDATE, V21, P275, DOI 10.1093/humupd/dmu052; Erlich Z, 2019, NAT IMMUNOL, V20, P397, DOI 10.1038/s41590-019-0313-5; George AF, 2020, HUM REPROD, V35, P617, DOI 10.1093/humrep/deaa015; Green RF, 2010, ANN EPIDEMIOL, V20, P241, DOI 10.1016/j.annepidem.2009.10.009; Gu AQ, 2019, J CELL MOL MED, V23, P5403, DOI 10.1111/jcmm.14423; Helft J, 2015, IMMUNITY, V42, P1197, DOI 10.1016/j.immuni.2015.05.018; Ibrahim LA, 2019, BIOL REPROD, V100, P660, DOI 10.1093/biolre/ioy226; Johnson SL, 2015, AGEING RES REV, V19, P22, DOI 10.1016/j.arr.2014.10.007; Joseph T, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.101956; Kreger BT, 2016, J BIOL CHEM, V291, P19774, DOI 10.1074/jbc.M116.725705; Kuhnert B, 2004, HUM REPROD UPDATE, V10, P327, DOI 10.1093/humupd/dmh030; Lin Y, 2018, J REPROD DEVELOP, V64, P49, DOI 10.1262/jrd.2017-042; Majumdar A, 2011, MOL BIOL CELL, V22, P1664, DOI 10.1091/mbc.E10-09-0745; Moldenhauer LM, 2009, J IMMUNOL, V182, P8080, DOI 10.4049/jimmunol.0804018; Morgan HL, 2020, SEMIN CELL DEV BIOL, V97, P131, DOI 10.1016/j.semcdb.2019.06.008; NARUKAWA S, 1994, J CLIN ENDOCR METAB, V78, P165, DOI 10.1210/jc.78.1.165; Olivieri F, 2015, ONCOTARGET, V6, P35509, DOI 10.18632/oncotarget.5899; Paktinat S, 2019, EUR J OBSTET GYN R B, V235, P71, DOI 10.1016/j.ejogrb.2019.02.010; PANDYA IJ, 1985, FERTIL STERIL, V43, P417; Qasim SM, 1996, HUM REPROD, V11, P1008; Lenicov FR, 2012, J IMMUNOL, V189, P4777, DOI 10.4049/jimmunol.1202089; Robertson NJ, 2007, P NATL ACAD SCI USA, V104, P20920, DOI 10.1073/pnas.0710265105; Robertson SA, 2016, FERTIL STERIL, V106, P511, DOI 10.1016/j.fertnstert.2016.07.1101; Robertson SA, 2010, J REPROD IMMUNOL, V85, P51, DOI 10.1016/j.jri.2010.01.008; Rolland AD, 2013, HUM REPROD, V28, P199, DOI 10.1093/humrep/des360; Saito S, 2016, AM J REPROD IMMUNOL, V75, P310, DOI 10.1111/aji.12469; Samstein RM, 2012, CELL, V150, P29, DOI 10.1016/j.cell.2012.05.031; Sartorius GA, 2010, HUM REPROD UPDATE, V16, P65, DOI 10.1093/humupd/dmp027; Schjenken JE, 2015, BIOL REPROD, V93, DOI 10.1095/biolreprod.114.125740; Sharkey DJ, 2007, MOL HUM REPROD, V13, P491, DOI 10.1093/molehr/gam028; Sharkey DJ, 2012, J IMMUNOL, V188, P2445, DOI 10.4049/jimmunol.1102736; Sharma R, 2015, REPROD BIOL ENDOCRIN, V13, DOI 10.1186/s12958-015-0028-x; Sidhom K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186466; Song ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep25118; Sun L, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00263; THOMPSON LA, 1992, AM J REPROD IMMUNOL, V28, P85, DOI 10.1111/j.1600-0897.1992.tb00765.x; Vojtech L, 2014, NUCLEIC ACIDS RES, V42, P7290, DOI 10.1093/nar/gku347; Yasuda I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.557720; Zhao ZJ, 2020, PHOTODIAGN PHOTODYN, V30, DOI 10.1016/j.pdpdt.2020.101746	52	1	1	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 12	2021	12								723409	10.3389/fimmu.2021.723409	http://dx.doi.org/10.3389/fimmu.2021.723409			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WP6OC	34712227	gold, Green Published			2022-12-18	WOS:000713247500001
J	Hsieh, MS; Hsu, CW; Tu, LL; Chai, KM; Yu, LL; Wu, CC; Chen, MY; Chiang, CY; Liu, SJ; Liao, CL; Chen, HW				Hsieh, Ming-Shu; Hsu, Chia-Wei; Tu, Ling-Ling; Chai, Kit Man; Yu, Li-Lu; Wu, Chiao-Chieh; Chen, Mei-Yu; Chiang, Chen-Yi; Liu, Shih-Jen; Liao, Ching-Len; Chen, Hsin-Wei			Intranasal Vaccination With Recombinant Antigen-FLIPr Fusion Protein Alone Induces Long-Lasting Systemic Antibody Responses and Broad T Cell Responses	FRONTIERS IN IMMUNOLOGY			English	Article						intranasal vaccination; mucosal vaccines; Zika vaccines; Fc gamma receptor; formyl peptide receptor-like 1 inhibitory protein (FLIPr)	ZIKA VIRUS; DENDRITIC CELLS; LYMPHOID-TISSUE; SEXUAL TRANSMISSION; INFLUENZA VACCINE; IMMUNE-RESPONSES; MUCOSAL VACCINES; STRATEGIES; PROTECTION; ADJUVANT	A simple formulation is urgently needed for mucosal vaccine development. We employed formyl peptide receptor-like 1 inhibitory protein (FLIPr), an Fc gamma R antagonist secreted by Staphylococcus aureus, as a vector to target ovalbumin (OVA) to dendritic cells (DCs) via intranasal administration. Our results demonstrate that intranasal administration of recombinant OVA-FLIPr fusion protein (rOVA-FLIPr) alone efficiently delivers OVA to DCs in nasal lymphoid tissue. Subsequently, OVA-specific IgG and IgA antibodies in the circulatory system and IgA antibodies in mucosal tissue were detected. Importantly, activation of OVA-specific CD4(+) and CD8(+) T cells and induction of a broad-spectrum cytokine secretion profile were detected after intranasal administration of rOVA-FLIPr alone in immunocompetent C57BL/6 mice. Furthermore, we employed immunodeficient AG129 mice as a Zika virus infection model and demonstrated that intranasal administration of recombinant Zika virus envelope protein domain III-FLIPr fusion protein induced protective immune responses against the Zika virus. These results suggest that antigen-FLIPr fusion protein alone via intranasal administration can be applied to mucosal vaccine development.	[Hsieh, Ming-Shu; Hsu, Chia-Wei; Tu, Ling-Ling; Chai, Kit Man; Yu, Li-Lu; Wu, Chiao-Chieh; Chen, Mei-Yu; Chiang, Chen-Yi; Liu, Shih-Jen; Liao, Ching-Len; Chen, Hsin-Wei] Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Miaoli, Taiwan; [Liu, Shih-Jen; Chen, Hsin-Wei] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan; [Liu, Shih-Jen; Chen, Hsin-Wei] Kaohsiung Med Univ, Grad Inst Med, Kaohsiung, Taiwan	National Health Research Institutes - Taiwan; China Medical University Taiwan; Kaohsiung Medical University	Chen, HW (corresponding author), Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Miaoli, Taiwan.; Chen, HW (corresponding author), China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.; Chen, HW (corresponding author), Kaohsiung Med Univ, Grad Inst Med, Kaohsiung, Taiwan.		Chen, Hsin-Wei/ABA-7436-2021	Chen, Hsin-Wei/0000-0002-3207-2397; Liu, Shih-Jen/0000-0002-8736-1452	Ministry of Science and Technology, Taiwan [MOST 106-2321-B-400-009, MOST 107-2321-B-400-006, MOST 108-2321-B-400-012]; National Health Research Institutes, Taiwan [IV-106-PP-18, IV-107-PP-18]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan)	Funding This work was supported by grants from the Ministry of Science and Technology, Taiwan (MOST 106-2321-B-400-009, MOST 107-2321-B-400-006, and MOST 108-2321-B-400-012) and National Health Research Institutes, Taiwan (IV-106-PP-18 and IV-107-PP-18).	Aliota MT, 2016, PLOS NEGLECT TROP D, V10, DOI [10.1371/journal.pntd.0004682, 10.1371/journal.pntd.0004750]; Arsuaga M, 2016, LANCET INFECT DIS, V16, P1107, DOI 10.1016/S1473-3099(16)30320-6; Asanuma H, 2012, VACCINE, V30, P803, DOI 10.1016/j.vaccine.2011.10.093; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bellmunt A, 1999, VIROLOGY, V265, P178, DOI 10.1006/viro.1999.0003; Bitsaktsis C, 2015, INFECT IMMUN, V83, P77, DOI 10.1128/IAI.02289-14; Boyaka PN, 2017, J IMMUNOL, V199, P9, DOI 10.4049/jimmunol.1601775; Calzas C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01605; Chen MY, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00646-x; Chiang CY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01839; Czajkowsky DM, 2012, EMBO MOL MED, V4, P1015, DOI 10.1002/emmm.201201379; D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449; DUNN G, 1990, J MED VIROL, V32, P92, DOI 10.1002/jmv.1890320205; Freytag LC, 2005, VACCINE, V23, P1804, DOI 10.1016/j.vaccine.2004.11.010; Gluck R, 2000, J INFECT DIS, V181, P1129, DOI 10.1086/315337; Gosselin EJ, 2009, ARCH IMMUNOL THER EX, V57, P311, DOI 10.1007/s00005-009-0040-y; Hassan AO, 2020, CELL, V183, P169, DOI 10.1016/j.cell.2020.08.026; Hassert M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01678; Heritage PL, 1997, AM J RESP CRIT CARE, V156, P1256, DOI 10.1164/ajrccm.156.4.97-03017; Hessert M, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007237; Holmgren J, 2012, CURR OPIN IMMUNOL, V24, P343, DOI 10.1016/j.coi.2012.03.014; Joseph A, 2002, VACCINE, V20, P3342, DOI 10.1016/S0264-410X(02)00295-5; Kiyono H, 2004, NAT REV IMMUNOL, V4, P699, DOI 10.1038/nri1439; Lambrecht BN, 2009, CURR OPIN IMMUNOL, V21, P23, DOI 10.1016/j.coi.2009.01.004; Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952; Lee H, 2015, MUCOSAL IMMUNOL, V8, P1083, DOI 10.1038/mi.2014.135; Li M, 2020, IMMUNOL LETT, V217, P116, DOI 10.1016/j.imlet.2019.10.013; Liang B, 2001, J VIROL, V75, P5416, DOI 10.1128/JVI.75.11.5416-5420.2001; Liu Y, 2017, NATURE, V545, P482, DOI 10.1038/nature22365; Lucas CGO, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05519-4; Lycke N, 2010, MUCOSAL IMMUNOL, V3, P556, DOI 10.1038/mi.2010.54; Lycke N, 2012, NAT REV IMMUNOL, V12, P592, DOI 10.1038/nri3251; Manicassamy S, 2009, SEMIN IMMUNOL, V21, P185, DOI 10.1016/j.smim.2009.05.005; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Miquel-Clopes A, 2019, CLIN EXP IMMUNOL, V196, P205, DOI 10.1111/cei.13285; Miyata T, 2010, INFECT IMMUN, V78, P3773, DOI 10.1128/IAI.00306-10; Moldoveanu Z, 1998, VACCINE, V16, P1216, DOI 10.1016/S0264-410X(98)80122-9; Murray KO, 2017, EMERG INFECT DIS, V23, P99, DOI 10.3201/eid2301.161394; Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595; Nazerai L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00593; Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777; Noda K, 2010, VACCINE, V28, P5068, DOI 10.1016/j.vaccine.2010.05.005; Ogra PL, 2001, CLIN MICROBIOL REV, V14, P430, DOI 10.1128/CMR.14.2.430-445.2001; Pardy RD, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080820; Pham GH, 2014, VACCINE, V32, P5212, DOI 10.1016/j.vaccine.2014.07.050; Platt LR, 2014, J INFECT DIS, V210, pS380, DOI 10.1093/infdis/jiu184; Pliaka V, 2012, EXPERT REV VACCINES, V11, P609, DOI [10.1586/ERV.12.28, 10.1586/erv.12.28]; Prisant N, 2016, LANCET INFECT DIS, V16, P1000, DOI 10.1016/S1473-3099(16)30193-1; Ruane D, 2016, J EXP MED, V213, P53, DOI 10.1084/jem.20150567; Ruane DT, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00025; Sanchez-Montalva A, 2018, TROP MED INT HEALTH, V23, P92, DOI 10.1111/tmi.13019; Singh SM, 2016, VIRAL IMMUNOL, V29, P269, DOI 10.1089/vim.2015.0144; Stemerding AM, 2013, J IMMUNOL, V191, P353, DOI 10.4049/jimmunol.1203243; Takaki H, 2018, MUCOSAL IMMUNOL, V11, P82, DOI 10.1038/mi.2017.48; Tao WQ, 2014, NANOMEDICINE-UK, V9, P237, DOI 10.2217/nnm.13.58; Uematsu S, 2008, NAT IMMUNOL, V9, P769, DOI 10.1038/ni.1622; van Ginkel FW, 2000, J IMMUNOL, V165, P4778, DOI 10.4049/jimmunol.165.9.4778; Wiedinger K, 2020, VACCINE, V38, P5634, DOI 10.1016/j.vaccine.2020.06.067; Wu CC, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9070806; Wu HY, 1997, SCAND J IMMUNOL, V46, P506, DOI 10.1046/j.1365-3083.1997.d01-159.x; Yang M, 2017, VACCINE, V35, P4287, DOI 10.1016/j.vaccine.2017.04.052; Yu JF, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00916-17; Zhang W, 2019, ANTIVIR RES, V170, DOI 10.1016/j.antiviral.2019.104578; Zhang YJ, 2019, ANTIVIR RES, V165, P11, DOI 10.1016/j.antiviral.2019.02.017	65	1	1	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 11	2021	12								751883	10.3389/fimmu.2021.751883	http://dx.doi.org/10.3389/fimmu.2021.751883			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WP5MY	34707615	gold, Green Published			2022-12-18	WOS:000713176800001
J	Kulu, H; Atasoy, M; Ozyurt, K; Maurer, M; Avci, A; Akkus, MR; Ertas, R				Kulu, Huzeyfe; Atasoy, Mustafa; Ozyurt, Kemal; Maurer, Marcus; Avci, Atil; Akkus, Muhammet Resat; Ertas, Ragip			The COVID-19 Pandemic Affects Male Patients With Chronic Spontaneous Urticaria More Than Female Patients	FRONTIERS IN IMMUNOLOGY			English	Article						chronic spontaneous urticaria; chronic skin diseases; COVID-19; psoriasis; pandemic (COVID19)	LIFE	Introduction The COVID-19 pandemic dramatically disrupts health care for patients with chronic diseases including chronic spontaneous urticaria (CSU). As of now, it is unknown if the effects of the pandemic in CSU are different than in other chronic diseases. We also do not know, if different groups of CSU patients, for example female and male patients, are affected differently.</p> Aim To understand how CSU patients and subgroups are affected by the COVID-19 pandemic in their disease activity and control and treatment, using psoriasis as control.</p> Patients and Methods We analyzed 399 patients (450 visits) with CSU or psoriasis assessed during August 2019, i.e. before the pandemic, or August 2020, i.e. during the pandemic, for changes in disease activity, disease control, and the treatment they used, and how these changes are linked to age, gender, and disease duration.</p> Results Male but not female patients with CSU had markedly increased disease activity during the pandemic. CSU patients' age or disease duration were not linked to changes. Male and female patients with psoriasis showed similar increases in disease activity and decreases in disease control. The rate of omalizumab treatment, during the pandemic, was unchanged in male patients and increased in female patients with CSU. The efficacy of omalizumab treatment, during the pandemic, was reduced in male patients but not female patients with CSU.</p> Conclusion Male but not female CSU patients, during the COVID-19 pandemic, show loss of disease control linked to loss of omalizumab efficacy. The reasons for this need to be investigated.</p>	[Kulu, Huzeyfe; Atasoy, Mustafa; Ozyurt, Kemal; Avci, Atil; Akkus, Muhammet Resat; Ertas, Ragip] Kayseri City Hosp, Urticaria Ctr Reference & Excellence UCARE, Chron Skin Dis Unit, Dept Dermatol, Kayseri, Turkey; [Maurer, Marcus] Charite Univ Med Berlin, Dept Dermatol & Allergy, Dermatol Allergol, Urticaria Ctr Reference & Excellence UCARE, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Maurer, M (corresponding author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Dermatol Allergol, Urticaria Ctr Reference & Excellence UCARE, Berlin, Germany.		Ertas, Ragip/M-3340-2017; Maurer, Marcus/ABG-2174-2020	Ertas, Ragip/0000-0002-9269-2619; Maurer, Marcus/0000-0002-4121-481X	GA2LEN network of urticaria centers of reference and excellence (UCARE)	GA2LEN network of urticaria centers of reference and excellence (UCARE)	This work benefitted from the support of the GA2LEN network of urticaria centers of reference and excellence (UCARE, www.ga2len-ucare.com).	ALPER S, 2012, TURKDERM-ARCH TURK D, V46, P1; Barzilay R, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-00982-4; Baskan EB, 2016, Turkderm-Turk Arch D, V50, P4; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Beyaz S, 2021, ALLERGY ASTHMA PROC, V42, pE107, DOI 10.2500/aap.2021.42.210026; Chudasama YV, 2020, DIABETES METAB SYND, V14, P965, DOI 10.1016/j.dsx.2020.06.042; Elmas OF, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13858; Ertas R, 2020, J ALLER CL IMM-PRACT, V8, P1074, DOI 10.1016/j.jaip.2019.10.046; Kamiya K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184347; Kobayashi T, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000530; Kocaturk E, 2021, ALLERGY, V76, P816, DOI 10.1111/all.14687; Maurer M, 2016, ALLERGY, V71, P1210, DOI 10.1111/all.12901; Maurer M, 2009, ALLERGY, V64, P581, DOI 10.1111/j.1398-9995.2008.01853.x; Maurer M, 2020, ALLERGY, V75, P2115, DOI 10.1111/all.14293; Ozyurt K, 2020, ISTANBUL KANUNI SULT, V12, P156, DOI [10.5222/iksstd.2020.81994, DOI 10.5222/IKSSTD.2020.81994]; Peckham H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19741-6; Weller K, 2014, J ALLERGY CLIN IMMUN, V133, P1365, DOI 10.1016/j.jaci.2013.12.1076; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570; Zuberbier T, 2018, ALLERGY, V73, P1393, DOI 10.1111/all.13397	19	1	1	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 11	2021	12								722406	10.3389/fimmu.2021.722406	http://dx.doi.org/10.3389/fimmu.2021.722406			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WO9QV	34804011	Green Published, gold			2022-12-18	WOS:000712780400001
J	Lavergne, M; Hernandez-Castaneda, MA; Mantel, PY; Martinvalet, D; Walch, M				Lavergne, Marilyne; Hernandez-Castaneda, Maria Andrea; Mantel, Pierre-Yves; Martinvalet, Denis; Walch, Michael			Oxidative and Non-Oxidative Antimicrobial Activities of the Granzymes	FRONTIERS IN IMMUNOLOGY			English	Review						granzymes; ROS; reactive oxygen species; caspases; antimicrobial defense; apoptosis; mitochondria	CYTOCHROME-C RELEASE; CELL-DEATH; MEDIATED APOPTOSIS; CASPASE ACTIVATION; COMPLEX-I; INTRACELLULAR BACTERIA; MITOCHONDRIAL-FUNCTION; SUBSTRATE-SPECIFICITY; EXTRACELLULAR-MATRIX; NUCLEAR TRANSPORT	Cell-mediated cytotoxicity is an essential immune defense mechanism to fight against viral, bacterial or parasitic infections. Upon recognition of an infected target cell, killer lymphocytes form an immunological synapse to release the content of their cytotoxic granules. Cytotoxic granules of humans contain two membrane-disrupting proteins, perforin and granulysin, as well as a homologous family of five death-inducing serine proteases, the granzymes. The granzymes, after delivery into infected host cells by the membrane disrupting proteins, may contribute to the clearance of microbial pathogens through different mechanisms. The granzymes can induce host cell apoptosis, which deprives intracellular pathogens of their protective niche, therefore limiting their replication. However, many obligate intracellular pathogens have evolved mechanisms to inhibit programed cells death. To overcome these limitations, the granzymes can exert non-cytolytic antimicrobial activities by directly degrading microbial substrates or hijacked host proteins crucial for the replication or survival of the pathogens. The granzymes may also attack factors that mediate microbial virulence, therefore directly affecting their pathogenicity. Many mechanisms applied by the granzymes to eliminate infected cells and microbial pathogens rely on the induction of reactive oxygen species. These reactive oxygen species may be directly cytotoxic or enhance death programs triggered by the granzymes. Here, in the light of the latest advances, we review the antimicrobial activities of the granzymes in regards to their cytolytic and non-cytolytic activities to inhibit pathogen replication and invasion. We also discuss how reactive oxygen species contribute to the various antimicrobial mechanisms exerted by the granzymes.	[Lavergne, Marilyne; Mantel, Pierre-Yves; Walch, Michael] Univ Fribourg, Fac Sci & Med, Dept Oncol Microbiol & Immunol, Anat Unit, Fribourg, Switzerland; [Hernandez-Castaneda, Maria Andrea] Ctr Immunol, Dept Med, Div Infect Dis & Int Med, Minneapolis, MN USA; [Martinvalet, Denis] Venetian Inst Mol Med, Dept Biomed Sci, Padua, Italy; [Martinvalet, Denis] Univ Padua, Dept Biomed Sci, Padua, Italy	University of Fribourg; Veneto Institute Molecular Medicine; University of Padua	Walch, M (corresponding author), Univ Fribourg, Fac Sci & Med, Dept Oncol Microbiol & Immunol, Anat Unit, Fribourg, Switzerland.	michael.walch@unifr.ch		Hernandez-Castaneda, Maria Andrea/0000-0002-7151-3546; LAVERGNE, Marilyne/0000-0002-4101-8675; Walch, Michael/0000-0001-7284-3291	y	y	Funding This work was supported by the Swiss National Science Foundation (SNSF grant # 310030_169928), the Novartis Foundation for Medical-Biological Research (Novartis grant # 20B136), and the Vontobel-Foundation (all to MW). The~funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Aguilo JI, 2010, IMMUNOL CELL BIOL, V88, P545, DOI 10.1038/icb.2010.5; Akula S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143091; Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Andrade F, 2001, IMMUNITY, V14, P751, DOI 10.1016/S1074-7613(01)00149-2; Andrade F, 2007, EMBO J, V26, P2148, DOI 10.1038/sj.emboj.7601650; Anthony DA, 2010, J IMMUNOL, V185, P1794, DOI 10.4049/jimmunol.1000430; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Behar SM, 2019, CURR OPIN IMMUNOL, V60, P103, DOI 10.1016/j.coi.2019.05.007; Ben Safta T, 2015, J IMMUNOL, V194, P418, DOI 10.4049/jimmunol.1401978; Beresford PJ, 1999, IMMUNITY, V10, P585, DOI 10.1016/S1074-7613(00)80058-8; Boivin WA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033163; Boivin WA, 2009, LAB INVEST, V89, P1195, DOI 10.1038/labinvest.2009.91; Boulouis C, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000644; Bouwman AC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.677707; Bovenschen N, 2010, IMMUNOL REV, V235, P117, DOI 10.1111/j.0105-2896.2010.00889.x; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Buzza MS, 2005, J BIOL CHEM, V280, P23549, DOI 10.1074/jbc.M412001200; Byrne GI, 2004, NAT REV MICROBIOL, V2, P802, DOI 10.1038/nrmicro1007; Casciola-Rosen L, 2007, J BIOL CHEM, V282, P4545, DOI 10.1074/jbc.M606564200; Chiusolo V, 2017, CELL DEATH DIFFER, V24, P747, DOI 10.1038/cdd.2017.3; Chowdhury D, 2008, ANNU REV IMMUNOL, V26, P389, DOI 10.1146/annurev.immunol.26.021607.090404; Chowdhury D, 2006, MOL CELL, V23, P133, DOI 10.1016/j.molcel.2006.06.005; D'Eliseo D, 2010, INT J CANCER, V127, P1283, DOI 10.1002/ijc.25135; de Poot SAH, 2011, BIOCHEM J, V437, P431, DOI 10.1042/BJ20110210; DosReis GA, 2001, ADV PARASIT, V49, P133, DOI 10.1016/S0065-308X(01)49039-7; Dotiwala F, 2017, CELL, V171, P1125, DOI 10.1016/j.cell.2017.10.004; Dotiwala F, 2016, NAT MED, V22, P210, DOI 10.1038/nm.4023; Dotiwala F, 2015, JOVE-J VIS EXP, DOI 10.3791/52911; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Elavazhagan S, 2015, J IMMUNOL, V194, P2786, DOI 10.4049/jimmunol.1402316; Ettersperger J, 2016, IMMUNITY, V45, P610, DOI 10.1016/j.immuni.2016.07.018; Faherty CS, 2008, TRENDS MICROBIOL, V16, P173, DOI 10.1016/j.tim.2008.02.001; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V227, P658, DOI 10.1006/bbrc.1996.1565; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; Gerada C, 2019, J VIROL, V93, DOI 10.1128/JVI.01140-19; Goping IS, 2003, IMMUNITY, V18, P355, DOI 10.1016/S1074-7613(03)00032-3; Greenberg AH, 1996, CELL DEATH DIFFER, V3, P269; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Hernandez-Castaneda MA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.643746; Hernandez-Castaneda MA, 2020, J IMMUNOL, V204, P1798, DOI 10.4049/jimmunol.1900725; Heussler VT, 2001, INT J PARASITOL, V31, P1166, DOI 10.1016/S0020-7519(01)00271-5; Hiebert PR, 2013, CELL DEATH DIFFER, V20, P1404, DOI 10.1038/cdd.2013.96; Hiebert PR, 2012, TRENDS MOL MED, V18, P732, DOI 10.1016/j.molmed.2012.09.009; Hoek KL, 2021, MUCOSAL IMMUNOL, V14, P1088, DOI 10.1038/s41385-021-00427-1; Jacquemin G, 2015, CELL DEATH DIFFER, V22, P862, DOI 10.1038/cdd.2014.180; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; Joeckel LT, 2011, CELL DEATH DIFFER, V18, P1112, DOI 10.1038/cdd.2011.5; Junqueira C, 2021, NAT IMMUNOL, V22, P347, DOI 10.1038/s41590-020-00847-4; Kaminskyy V, 2010, J INTERN MED, V267, P473, DOI 10.1111/j.1365-2796.2010.02222.x; Knickelbein JE, 2008, SCIENCE, V322, P268, DOI 10.1126/science.1164164; Krensky AM, 2009, TISSUE ANTIGENS, V73, P193, DOI 10.1111/j.1399-0039.2008.01218.x; Kvansakul M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.436; Labbe K, 2008, CELL DEATH DIFFER, V15, P1339, DOI 10.1038/cdd.2008.91; Lauw FN, 2000, J INFECT DIS, V182, P206, DOI 10.1086/315642; Leeansyah E, 2021, TRENDS MICROBIOL, V29, P504, DOI 10.1016/j.tim.2020.11.008; Leon DL, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.100932; Leon DL, 2017, METHODS MOL BIOL, V1535, P275, DOI 10.1007/978-1-4939-6673-8_18; LICHTENHELD MG, 1988, NATURE, V335, P448, DOI 10.1038/335448a0; Lionello S, 2020, PHARMACOL RES, V160, DOI 10.1016/j.phrs.2020.105196; Lowin B, 1995, Curr Top Microbiol Immunol, V198, P1; Marcet-Palacios M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002447; Marino J, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-32; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Martinvalet D, 2008, METHOD ENZYMOL, V442, P213, DOI [10.1016/S0070-6879(08)01411-0, 10.1016/S0076-6879(08)01411-0]; Martinvalet D, 2008, CELL, V133, P681, DOI 10.1016/j.cell.2008.03.032; MASSON D, 1986, FEBS LETT, V208, P84, DOI 10.1016/0014-5793(86)81537-X; McIlroy D, 1999, ONCOGENE, V18, P4401, DOI 10.1038/sj.onc.1202868; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; Narni-Mancinelli E, 2014, CELL, V157, P1251, DOI 10.1016/j.cell.2014.05.023; Nishikawa Y, 2002, PARASITE IMMUNOL, V24, P347, DOI 10.1046/j.1365-3024.2002.00476.x; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; Omoto Y, 2010, J DERMATOL SCI, V59, P129, DOI 10.1016/j.jdermsci.2010.05.004; Orzalli MH, 2017, TRENDS CELL BIOL, V27, P810, DOI 10.1016/j.tcb.2017.05.007; Pearson JD, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-199; Pereira RA, 2000, J VIROL, V74, P1029, DOI 10.1128/JVI.74.2.1029-1032.2000; Pipkin ME, 2010, IMMUNOL REV, V235, P55, DOI 10.1111/j.0105-2896.2010.00905.x; Plasman K, 2014, J PROTEOME RES, V13, P6067, DOI 10.1021/pr500968d; PODACK ER, 1988, ANN NY ACAD SCI, V532, P292, DOI 10.1111/j.1749-6632.1988.tb36347.x; Rajalingam K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003102; Rajani DK, 2012, P NATL ACAD SCI USA, V109, P8688, DOI 10.1073/pnas.1201327109; Rasi V, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.712678; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Ricci JE, 2003, CELL DEATH DIFFER, V10, P488, DOI 10.1038/sj.cdd.4401225; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Romero V, 2009, CELL DEATH DIFFER, V16, P340, DOI 10.1038/cdd.2008.165; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Rugles SW, 2004, J BIOL CHEM, V279, P30751, DOI 10.1074/jbc.M400949200; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; Shan LL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008426; SHRESTA S, 1995, IMMUNOL REV, V146, P211, DOI 10.1111/j.1600-065X.1995.tb00690.x; SIMON HG, 1987, FEBS LETT, V223, P352, DOI 10.1016/0014-5793(87)80318-6; Skaletskaya A, 2001, P NATL ACAD SCI USA, V98, P7829, DOI 10.1073/pnas.141108798; Spencer CT, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003119; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Sutton VR, 2003, IMMUNITY, V18, P319, DOI 10.1016/S1074-7613(03)00050-5; Tang HD, 2012, J IMMUNOL, V188, P824, DOI 10.4049/jimmunol.1102205; Thakur A, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/1356540; Thiery J, 2011, NAT IMMUNOL, V12, P770, DOI 10.1038/ni.2050; Thiery J, 2010, BLOOD, V115, P1582, DOI 10.1182/blood-2009-10-246116; Thomas MP, 2014, J IMMUNOL, V192, P5390, DOI 10.4049/jimmunol.1303296; Trapani JA, 2001, GENOME BIOL, V2; Turner PC, 1999, J VIROL, V73, P6394, DOI 10.1128/JVI.73.8.6394-6404.1999; Vaccaro AM, 1999, NEUROCHEM RES, V24, P307, DOI 10.1023/A:1022530508763; Van Damme P, 2010, BIOL CHEM, V391, P983, DOI 10.1515/BC.2010.096; van Domselaar R, 2013, CELL DEATH DIFFER, V20, P419, DOI 10.1038/cdd.2012.132; van Domselaar R, 2010, J IMMUNOL, V185, P7605, DOI 10.4049/jimmunol.1001503; van Domselaar R, 2010, EXPERT REV PROTEOMIC, V7, P347, DOI 10.1586/EPR.10.24; Walch M, 2005, J IMMUNOL, V174, P4220, DOI 10.4049/jimmunol.174.7.4220; Walch M, 2014, CELL, V157, P1309, DOI 10.1016/j.cell.2014.03.062; Walch M, 2009, J IMMUNOL, V182, P7569, DOI 10.4049/jimmunol.0800296; Walch M, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-14; Wang HR, 2015, ONCOTARGET, V6, P5818, DOI 10.18632/oncotarget.3461; Wang L, 2012, J IMMUNOL, V188, P765, DOI 10.4049/jimmunol.1101381; Waterhouse NJ, 2006, CELL DEATH DIFFER, V13, P607, DOI 10.1038/sj.cdd.4401772; Waterhouse NJ, 2005, J BIOL CHEM, V280, P4476, DOI 10.1074/jbc.M410985200; Zamaraev AV, 2020, BIOCHEMISTRY-MOSCOW+, V85, P1191, DOI 10.1134/S0006297920100077; Zhang D, 2001, P NATL ACAD SCI USA, V98, P5746, DOI 10.1073/pnas.101329598; Zhang D, 2001, J BIOL CHEM, V276, P3683, DOI 10.1074/jbc.M005390200; Zhong C, 2012, CELL DEATH DIFFER, V19, P882, DOI 10.1038/cdd.2011.178; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zhu PC, 2006, EMBO REP, V7, P431, DOI 10.1038/sj.embor.7400622; Zychlinsky A, 1997, J CLIN INVEST, V100, P493, DOI 10.1172/JCI119557	128	1	1	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 11	2021	12								750512	10.3389/fimmu.2021.750512	http://dx.doi.org/10.3389/fimmu.2021.750512			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WU7BN	34707614	Green Published, gold			2022-12-18	WOS:000716696600001
J	Liao, CC; Tsai, CH; Lo, HR; Lin, PR; Lin, CC; Chao, YC				Liao, Chih-Chi; Tsai, Chih-Hsuan; Lo, Huei-Ru; Lin, Pey-Ru; Lin, Chang-Chi; Chao, Yu-Chan			Development of a Scrub Typhus Diagnostic Platform Incorporating Cell-Surface Display Technology	FRONTIERS IN IMMUNOLOGY			English	Article						baculovirus surface display; cell-based ELISA; Orientia tsutsugamushi; scrub typhus; serological diagnosis	LINKED-IMMUNOSORBENT-ASSAY; ORIENTIA-TSUTSUGAMUSHI INFECTION; PROTEIN EXPRESSION; RICKETTSIA-TSUTSUGAMUSHI; SEROLOGICAL DIAGNOSIS; VERSATILE VECTORS; ANTIGEN GENE; ANTIBODIES; BACULOVIRUS; INSECT	Scrub typhus (ST), also known as tsutsugamushi disease and caused by rickettsia Orientia tsutsugamushi, is an underestimated fatal epidemic in the Asia-Pacific region, resulting in a million human infections each year. ST is easily misdiagnosed as clinical diagnosis is based on non-specific skin eschar and flu-like symptoms. Thus, the lack of accurate, convenient, and low-cost detection methods for ST poses a global health threat. To address this problem, we adopted baculovirus surface-display technology to express three variants of TSA56, the major membrane antigen of O. tsutsugamushi, as well as the passenger domain of ScaC (ScaC-PD), on insect Sf21 cell surfaces rather than biosafety level 3 bacteria in an enzyme-linked immunosorbent assay (ELISA). Recombinant TSA56 and ScaC-PD were all properly expressed and displayed on Sf21 cells. Our cell-based ELISA comprising the four antigen-displaying cell types interacted with monoclonal antibodies as well as serum samples from ST-positive field-caught rats. This cell-based ELISA presented high accuracy (96.3%), sensitivity (98.6%), and specificity (84.6%) when tested against the ST-positive rat sera. Results of a pilot study using human sera were also highly consistent with the results of immunofluorescence analyses. By adopting this approach, we circumvented complex purification and refolding processes required to generate recombinant O. tsutsugamushi antigens and reduced the need for expensive equipment and extensively trained operators. Thus, our system has the potential to become a widely used serological platform for diagnosing ST.	[Liao, Chih-Chi; Tsai, Chih-Hsuan; Lo, Huei-Ru; Chao, Yu-Chan] Acad Sinica, Inst Mol Biol, Inst Mol Biol, Taipei, Taiwan; [Lin, Pey-Ru; Lin, Chang-Chi] Natl Def Med Ctr, Inst Prevent Med, Taipei, Taiwan; [Chao, Yu-Chan] Natl Chung Hsing Univ, Dept Entomol, Taichung, Taiwan; [Chao, Yu-Chan] Natl Taiwan Univ, Coll Bioresources & Agr, Dept Entomol, Taipei, Taiwan; [Chao, Yu-Chan] Natl Taiwan Univ, Coll Bioresources & Agr, Dept Entomol, Taipei, Taiwan; [Chao, Yu-Chan] Natl Taiwan Univ, Coll Bioresources & Agr, Dept Plant Pathol & Microbiol, Taipei, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; National Chung Hsing University; National Taiwan University; National Taiwan University; National Taiwan University	Chao, YC (corresponding author), Acad Sinica, Inst Mol Biol, Inst Mol Biol, Taipei, Taiwan.; Lin, CC (corresponding author), Natl Def Med Ctr, Inst Prevent Med, Taipei, Taiwan.; Chao, YC (corresponding author), Natl Chung Hsing Univ, Dept Entomol, Taichung, Taiwan.; Chao, YC (corresponding author), Natl Taiwan Univ, Coll Bioresources & Agr, Dept Entomol, Taipei, Taiwan.; Chao, YC (corresponding author), Natl Taiwan Univ, Coll Bioresources & Agr, Dept Entomol, Taipei, Taiwan.; Chao, YC (corresponding author), Natl Taiwan Univ, Coll Bioresources & Agr, Dept Plant Pathol & Microbiol, Taipei, Taiwan.	chalin3@ndmctsgh.edu.tw; mbycchao@imb.sinica.edu.tw	Chao, Yu-Chan/ABF-6571-2021	Chao, Yu-Chan/0000-0002-9528-8806	MOST	MOST	Funding This research was funded by grants MOST 109-2927-I-001-511, MOST 109-2321-B-033-001, MOST 109-2327-B-016-004, MOST 110-2923-B-001-001, and MOST 110-2313-B-001-010 from the Ministry of Science and Technology of Taiwan, ROC; IPM108-G1-2 from the Institute of Preventive Medicine, National Defense Medical Center; VTA110-A-4-1 from VGH, TSGH, AS Joint Research Program; and grants under the 2020 NBRP Translational Research Project, Academia Sinica, Taiwan, ROC.	Assenberg R, 2013, CURR OPIN STRUC BIOL, V23, P393, DOI 10.1016/j.sbi.2013.03.008; Chang CY, 2020, AMB EXPRESS, V10, DOI 10.1186/s13568-020-0952-9; Chao CC, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2512-8; Chao CC, 2011, AM J TROP MED HYG, V84, P967, DOI 10.4269/ajtmh.2011.10-0545; Chao YC, 1998, J VIROL, V72, P2233, DOI 10.1128/JVI.72.3.2233-2245.1998; Ching WM, 1998, CLIN DIAGN LAB IMMUN, V5, P519, DOI 10.1128/CDLI.5.4.519-526.1998; DASCH GA, 1979, J CLIN MICROBIOL, V9, P38; Ha NY, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003585; Ha NY, 2012, CLIN VACCINE IMMUNOL, V19, P1442, DOI 10.1128/CVI.00285-12; Ha NY, 2011, INFECT IMMUN, V79, P1718, DOI 10.1128/IAI.01239-10; Hsu WT, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020303; Jeong YJ, 2007, RADIOGRAPHICS, V27, P161, DOI 10.1148/rg.271065074; Kelly DJ, 2009, CLIN INFECT DIS, V48, pS203, DOI 10.1086/596576; KIM IS, 1993, J CLIN MICROBIOL, V31, P598, DOI 10.1128/JCM.31.3.598-605.1993; KIM IS, 1993, J CLIN MICROBIOL, V31, P2057, DOI 10.1128/JCM.31.8.2057-2060.1993; Koh GCKW, 2010, AM J TROP MED HYG, V82, P368, DOI 10.4269/ajtmh.2010.09-0233; Koraluru M, 2015, MICROBIOL IMMUNOL, V59, P371, DOI 10.1111/1348-0421.12268; Kost TA, 2005, NAT BIOTECHNOL, V23, P567, DOI 10.1038/nbt1095; KOST TA, 2002, APPL BIOSAFETY, V7, P167; Lamis RJS, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11060966; Land MV, 2000, J CLIN MICROBIOL, V38, P2701, DOI 10.1128/JCM.38.7.2701-2705.2000; Lim C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114930; Lin PR, 2014, ACTA TROP, V131, P117, DOI 10.1016/j.actatropica.2013.11.029; Lin PR, 2011, APPL ENVIRON MICROB, V77, P3398, DOI 10.1128/AEM.02796-10; Lu HY, 2010, AM J TROP MED HYG, V83, P658, DOI 10.4269/ajtmh.2010.09-0608; Ogawa M, 2020, JPN J INFECT DIS, V73, P330, DOI 10.7883/yoken.JJID.2019.334; OHASHI N, 1992, J BIOL CHEM, V267, P12728; Paris DH, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001307; REED L. J., 1938, AMER JOUR HYG, V27, P493; RICHARDSON MD, 1983, J IMMUNOL METHODS, V56, P201, DOI 10.1016/0022-1759(83)90412-X; Tsai CH, 2019, ACS SYNTH BIOL, V8, P2472, DOI 10.1021/acssynbio.9b00094; Tsai CH, 2019, CURR ISSUES MOL BIOL, V34, P231, DOI 10.21775/cimb.034.231; van Oers MM, 2007, CURR DRUG TARGETS, V8, P1051, DOI 10.2174/138945007782151333; van Oers MM, 2015, J GEN VIROL, V96, P6, DOI 10.1099/vir.0.067108-0; Varghese GM, 2018, INT J INFECT DIS, V71, P53, DOI 10.1016/j.ijid.2018.03.018; Wang YC, 2003, CLIN DIAGN LAB IMMUN, V10, P451, DOI 10.1128/CDLI.10.3.451-458.2003; Xu G, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006062; Yang SL, 2019, AM J TROP MED HYG, V100, P532, DOI 10.4269/ajtmh.18-0391; ZREIN M, 1986, J IMMUNOL METHODS, V87, P229, DOI 10.1016/0022-1759(86)90536-3	39	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 11	2021	12								761136	10.3389/fimmu.2021.761136	http://dx.doi.org/10.3389/fimmu.2021.761136			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WO9MN	34707621	gold, Green Published			2022-12-18	WOS:000712769200001
J	Qian, GH; Zhu, LY; Li, G; Liu, Y; Zhang, ZM; Pan, J; Lv, HT				Qian, Guanghui; Zhu, Liyan; Li, Gen; Liu, Ying; Zhang, Zimu; Pan, Jian; Lv, Haitao			An Integrated View of Deubiquitinating Enzymes Involved in Type I Interferon Signaling, Host Defense and Antiviral Activities	FRONTIERS IN IMMUNOLOGY			English	Review						deubiquitinating enzymes; type I IFN signaling; ubiquitin; virus infection; innate immunity	NF-KAPPA-B; E3 UBIQUITIN LIGASE; IMMUNE PATTERN-RECOGNITION; IFN-BETA PRODUCTION; RIG-I; LINEAR POLYUBIQUITIN; NEGATIVE REGULATION; INNATE IMMUNITY; ACTIVATION; USP18	Viral infectious diseases pose a great challenge to human health around the world. Type I interferons (IFN-Is) function as the first line of host defense and thus play critical roles during virus infection by mediating the transcriptional induction of hundreds of genes. Nevertheless, overactive cytokine immune responses also cause autoimmune diseases, and thus, tight regulation of the innate immune response is needed to achieve viral clearance without causing excessive immune responses. Emerging studies have recently uncovered that the ubiquitin system, particularly deubiquitinating enzymes (DUBs), plays a critical role in regulating innate immune responses. In this review, we highlight recent advances on the diverse mechanisms of human DUBs implicated in IFN-I signaling. These DUBs function dynamically to calibrate host defenses against various virus infections by targeting hub proteins in the IFN-I signaling transduction pathway. We also present a future perspective on the roles of DUB-substrate interaction networks in innate antiviral activities, discuss the promises and challenges of DUB-based drug development, and identify the open questions that remain to be clarified. Our review provides a comprehensive description of DUBs, particularly their differential mechanisms that have evolved in the host to regulate IFN-I-signaling-mediated antiviral responses.</p>	[Qian, Guanghui; Li, Gen; Liu, Ying; Zhang, Zimu; Pan, Jian; Lv, Haitao] Soochow Univ, Childrens Hosp, Inst Pediat Res, Suzhou, Peoples R China; [Zhu, Liyan] Soochow Univ, Med Coll, Dept Expt Ctr, Suzhou, Peoples R China	Soochow University - China; Soochow University - China	Qian, GH; Pan, J; Lv, HT (corresponding author), Soochow Univ, Childrens Hosp, Inst Pediat Res, Suzhou, Peoples R China.	ghqian@suda.edu.cn; panjian2008@163.com; haitaossz@163.com						Alsohime F, 2020, NEW ENGL J MED, V382, P256, DOI 10.1056/NEJMoa1905633; Altun M, 2011, CHEM BIOL, V18, P1401, DOI 10.1016/j.chembiol.2011.08.018; Arimoto KI, 2007, P NATL ACAD SCI USA, V104, P7500, DOI 10.1073/pnas.0611551104; Bailey-Elkin BA, 2017, J MOL BIOL, V429, P3441, DOI 10.1016/j.jmb.2017.06.010; Barrat FJ, 2016, ANNU REV MED, V67, P323, DOI 10.1146/annurev-med-052814-023338; Basters A, 2014, FEBS J, V281, P1918, DOI 10.1111/febs.12754; Bhoj VG, 2009, NATURE, V458, P430, DOI 10.1038/nature07959; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Borden EC, 2007, NAT REV DRUG DISCOV, V6, P975, DOI 10.1038/nrd2422; Brubaker SW, 2015, ANNU REV IMMUNOL, V33, P257, DOI 10.1146/annurev-immunol-032414-112240; Cai J, 2018, FASEB J, V32, P5238, DOI 10.1096/fj.201700473RR; Cai Z, 2020, J EXP MED, V217, DOI 10.1084/jem.20191174; Carbone CJ, 2012, P NATL ACAD SCI USA, V109, P19226, DOI 10.1073/pnas.1211491109; Carty M, 2021, BIOCHEM PHARMACOL, V183, DOI 10.1016/j.bcp.2020.114316; Catrysse L, 2014, TRENDS IMMUNOL, V35, P22, DOI 10.1016/j.it.2013.10.005; Chen JQ, 2013, CURR OPIN IMMUNOL, V25, P4, DOI 10.1016/j.coi.2012.12.005; Chen MX, 2016, MOL CELL, V64, P105, DOI 10.1016/j.molcel.2016.08.025; Chen R, 2010, CELL RES, V20, P802, DOI 10.1038/cr.2010.41; Chen WL, 2013, CELL, V152, P467, DOI 10.1016/j.cell.2013.01.011; Chen X, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00487-z; Chen XJ, 2018, BIOCHEM BIOPH RES CO, V503, P830, DOI 10.1016/j.bbrc.2018.06.083; Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014; Cheng Q, 2021, EUR J IMMUNOL, V51, P296, DOI 10.1002/eji.202048537; Cheng ZL, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0198-7; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; Clague MJ, 2019, NAT REV MOL CELL BIO, V20, P338, DOI 10.1038/s41580-019-0099-1; Coleman KE, 2018, MOL CELL, V70, P1, DOI 10.1016/j.molcel.2018.03.022; Colleran A, 2013, P NATL ACAD SCI USA, V110, P618, DOI 10.1073/pnas.1208446110; Crow MK, 2019, ANNU REV PATHOL-MECH, V14, P369, DOI 10.1146/annurev-pathol-020117-043952; Cui J, 2014, CELL RES, V24, P400, DOI 10.1038/cr.2013.170; Cui J, 2012, NAT IMMUNOL, V13, P387, DOI 10.1038/ni.2239; Dauphinee SM, 2014, GENES IMMUN, V15, P282, DOI 10.1038/gene.2014.17; Davis ME, 2015, VIROLOGY, V479, P52, DOI 10.1016/j.virol.2015.02.033; Ebner P, 2017, CRIT REV BIOCHEM MOL, V52, P425, DOI 10.1080/10409238.2017.1325829; Enesa K, 2008, J BIOL CHEM, V283, P7036, DOI 10.1074/jbc.M708690200; Fan YH, 2014, J EXP MED, V211, P313, DOI 10.1084/jem.20122844; Feng Q, 2018, J IMMUNOL, V201, P675, DOI 10.4049/jimmunol.1800285; Friedman CS, 2008, EMBO REP, V9, P930, DOI 10.1038/embor.2008.136; Fuchs SY, 2012, GROWTH FACTORS, V30, P141, DOI 10.3109/08977194.2012.669382; Gack MU, 2007, NATURE, V446, P916, DOI 10.1038/nature05732; Goldmann T, 2015, EMBO J, V34, P1612, DOI 10.15252/embj.201490791; Gruber C, 2020, J EXP MED, V217, DOI 10.1084/jem.20192319; Guo YY, 2021, CELL MOL IMMUNOL, V18, P1945, DOI 10.1038/s41423-020-00531-5; Guo YY, 2019, J IMMUNOL, V203, P2049, DOI 10.4049/jimmunol.1900514; Haakonsen DL, 2019, TRENDS CELL BIOL, V29, P704, DOI 10.1016/j.tcb.2019.06.003; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Harrigan JA, 2018, NAT REV DRUG DISCOV, V17, P57, DOI 10.1038/nrd.2017.152; Hartmann G, 2017, ADV IMMUNOL, V133, P121, DOI 10.1016/bs.ai.2016.11.001; Heaton SM, 2016, J EXP MED, V213, P1, DOI 10.1084/jem.20151531; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoffmann HH, 2015, TRENDS IMMUNOL, V36, P124, DOI 10.1016/j.it.2015.01.004; Honda K, 2005, NATURE, V434, P1035, DOI 10.1038/nature03547; Honda K, 2006, IMMUNITY, V25, P349, DOI 10.1016/j.immuni.2006.08.009; Hu HB, 2013, NATURE, V494, P371, DOI 10.1038/nature11831; Ji YX, 2018, J CELL BIOCHEM, V119, P1979, DOI 10.1002/jcb.26359; Jiang XM, 2012, IMMUNITY, V36, P959, DOI 10.1016/j.immuni.2012.03.022; Jiang XM, 2012, NAT REV IMMUNOL, V12, P35, DOI 10.1038/nri3111; Karim R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003384; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kayagaki N, 2007, SCIENCE, V318, P1628, DOI 10.1126/science.1145918; Kemp M, 2016, PROGR MED CHEM, V55, P149, DOI 10.1016/bs.pmch.2015.10.002; Kirisako T, 2006, EMBO J, V25, P4877, DOI 10.1038/sj.emboj.7601360; Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328; Kopitar-Jerala N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00873; Kowalinski E, 2011, CELL, V147, P423, DOI 10.1016/j.cell.2011.09.039; Kulathu Y, 2012, NAT REV MOL CELL BIO, V13, P508, DOI 10.1038/nrm3394; Kwasna D, 2018, MOL CELL, V70, P150, DOI 10.1016/j.molcel.2018.02.023; Li HR, 2019, EUR J IMMUNOL, V49, P42, DOI 10.1002/eji.201847603; Li S, 2010, J BIOL CHEM, V285, P4291, DOI 10.1074/jbc.M109.074971; Li S, 2018, FASEB J, V32, P230, DOI 10.1096/fj.201700415RR; Liang JA, 2010, J EXP MED, V207, P2959, DOI 10.1084/jem.20092641; Lin DD, 2015, P NATL ACAD SCI USA, V112, P11324, DOI 10.1073/pnas.1509968112; Lin M, 2016, MOL CELL, V64, P267, DOI 10.1016/j.molcel.2016.08.029; Lin RT, 2006, J BIOL CHEM, V281, P2095, DOI 10.1074/jbc.M510326200; Liu BY, 2017, NAT IMMUNOL, V18, P214, DOI 10.1038/ni.3641; Liu J, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008215; Liu J, 2016, IMMUNITY, V45, P15, DOI 10.1016/j.immuni.2016.06.020; Liu QX, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar2824; Liuyu TZ, 2019, CELL RES, V29, P67, DOI 10.1038/s41422-018-0107-6; Lopez-Castejon G, 2013, J BIOL CHEM, V288, P2721, DOI 10.1074/jbc.M112.422238; Love KR, 2007, NAT CHEM BIOL, V3, P697, DOI 10.1038/nchembio.2007.43; Lu D, 2018, J AUTOIMMUN, V94, P156, DOI 10.1016/j.jaut.2018.07.019; Luong LA, 2013, CIRC RES, V112, P1583, DOI 10.1161/CIRCRESAHA.111.300119; Malakhova OA, 2006, EMBO J, V25, P2358, DOI 10.1038/sj.emboj.7601149; Matsushita K, 2009, NATURE, V458, P1185, DOI 10.1038/nature07924; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; Meuwissen MEC, 2016, J EXP MED, V213, P1163, DOI 10.1084/jem.20151529; Mevissen TET, 2017, ANNU REV BIOCHEM, V86, P159, DOI 10.1146/annurev-biochem-061516-044916; Muromoto R, 2013, J BIOL CHEM, V288, P30969, DOI 10.1074/jbc.M113.485847; Nakhaei P, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000650; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Ning SB, 2010, J VIROL, V84, P6130, DOI 10.1128/JVI.00364-10; Niu JX, 2013, EMBO J, V32, P3206, DOI 10.1038/emboj.2013.247; Ohtake F, 2017, J BIOCHEM, V161, P125, DOI 10.1093/jb/mvw088; Ohtake F, 2016, MOL CELL, V64, P251, DOI 10.1016/j.molcel.2016.09.014; Okamoto M, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01942; Oshiumi H, 2009, J BIOL CHEM, V284, P807, DOI 10.1074/jbc.M804259200; Panda S, 2015, IMMUNITY, V43, P647, DOI 10.1016/j.immuni.2015.09.010; Parvatiyar K, 2010, J BIOL CHEM, V285, P14999, DOI 10.1074/jbc.M110.109819; Pauli EK, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004577; Paz S, 2009, MOL CELL BIOL, V29, P3401, DOI 10.1128/MCB.00880-08; Peng YH, 2020, J IMMUNOL, V205, P3167, DOI 10.4049/jimmunol.1901384; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Piganis RAR, 2011, J BIOL CHEM, V286, P33811, DOI 10.1074/jbc.M111.270207; Qian GH, 2020, INT IMMUNOPHARMACOL, V87, DOI 10.1016/j.intimp.2020.106763; Qian LP, 2018, BIOCHEM BIOPH RES CO, V498, P891, DOI 10.1016/j.bbrc.2018.03.076; Rehman SAA, 2016, MOL CELL, V63, P146, DOI 10.1016/j.molcel.2016.05.009; Rehwinkel J, 2020, NAT REV IMMUNOL, V20, P537, DOI 10.1038/s41577-020-0288-3; Ren Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005764; Reyes-Turcu FE, 2009, CHEM REV, V109, P1495, DOI 10.1021/cr800470j; Ritchie KJ, 2004, NAT MED, V10, P1374, DOI 10.1038/nm1133; Ruan J, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01783-8; Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314; Sarasin-Filipowicz M, 2009, MOL CELL BIOL, V29, P4841, DOI 10.1128/MCB.00224-09; Schauer NJ, 2020, J MED CHEM, V63, P2731, DOI 10.1021/acs.jmedchem.9b01138; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364; Skaug B, 2011, MOL CELL, V44, P559, DOI 10.1016/j.molcel.2011.09.015; Song GH, 2016, NAT IMMUNOL, V17, P1342, DOI 10.1038/ni.3588; Song K, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020145; Sun H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15534; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tanaka T, 2005, IMMUNITY, V22, P729, DOI 10.1016/j.immuni.2005.04.008; Tao XY, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008293; Tian MF, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108297; Tokunaga F, 2012, EMBO J, V31, P3856, DOI 10.1038/emboj.2012.241; Tomala MD, 2018, EUR J MED CHEM, V150, P261, DOI 10.1016/j.ejmech.2018.03.009; Torre S, 2017, NAT IMMUNOL, V18, P54, DOI 10.1038/ni.3581; van Huizen M, 2020, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00392; Verhelst K, 2012, EMBO J, V31, P3845, DOI 10.1038/emboj.2012.240; Wagner SA, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.013284; Wang LJ, 2013, J VIROL, V87, P4507, DOI 10.1128/JVI.00031-13; Wang L, 2016, EUR J IMMUNOL, V46, P2409, DOI 10.1002/eji.201646491; Wang WD, 2016, P NATL ACAD SCI USA, V113, P9581, DOI 10.1073/pnas.1604277113; Wang XF, 2017, VIRAL IMMUNOL, V30, P342, DOI 10.1089/vim.2017.0015; Wang YF, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.685011; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wu HQ, 2020, BIOCHEM SOC T, V48, P479, DOI 10.1042/BST20190535; Wu JX, 2014, ANNU REV IMMUNOL, V32, P461, DOI 10.1146/annurev-immunol-032713-120156; Wu X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12145-1; Xie XW, 2017, BIOCHEM BIOPH RES CO, V488, P291, DOI 10.1016/j.bbrc.2017.04.161; Xu C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31734-6; Yang ZF, 2015, SCI REP-UK, V5, DOI 10.1038/srep12738; Yau R, 2016, NAT CELL BIOL, V18, P579, DOI 10.1038/ncb3358; Ye LY, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007680; Yeh HM, 2013, J IMMUNOL, V191, P3328, DOI 10.4049/jimmunol.1300225; Yoo YS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8910; Yu ZX, 2017, J EXP MED, V214, P3553, DOI 10.1084/jem.20170180; Yuan C, 2012, J BIOL CHEM, V287, P17006, DOI 10.1074/jbc.M112.341198; Yuan YK, 2020, IMMUNOLOGY, V159, P309, DOI 10.1111/imm.13147; Zeng WW, 2009, MOL CELL, V36, P315, DOI 10.1016/j.molcel.2009.09.037; Zhang HY, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008178; Zhang H, 2015, SCI REP-UK, V5, DOI 10.1038/srep11220; Zhang J, 2006, J CLIN INVEST, V116, P3042, DOI 10.1172/JCI28746; Zhang L, 2014, J IMMUNOL, V193, P2230, DOI 10.4049/jimmunol.1302634; Zhang LL, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007435; Zhang LT, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007067; Zhang M, 2016, CELL RES, V26, P1302, DOI 10.1038/cr.2016.125; Zhang M, 2012, J EXP MED, V209, P1703, DOI 10.1084/jem.20120024; Zhang MX, 2019, J IMMUNOL, V202, P2397, DOI 10.4049/jimmunol.1801447; Zhang Q, 2020, CELL RES, V30, P914, DOI 10.1038/s41422-020-0341-6; Zhang ZM, 2020, J IMMUNOL, V204, P1904, DOI 10.4049/jimmunol.1900305; Zhang ZK, 2020, MOL CELL, V79, P304, DOI 10.1016/j.molcel.2020.06.020; Zhao CY, 2017, CELL REP, V21, P1613, DOI 10.1016/j.celrep.2017.10.020; Zhao P, 2017, ANTIVIR RES, V144, P120, DOI 10.1016/j.antiviral.2017.06.002; Zhao Y, 2018, MOL CELL, V69, P505, DOI 10.1016/j.molcel.2018.01.009; Zheng H, 2013, CELL REP, V5, P180, DOI 10.1016/j.celrep.2013.08.025; Zheng H, 2011, MOL CELL BIOL, V31, P710, DOI 10.1128/MCB.01154-10; Zhong HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080976; Zhou PP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03563-8; Zhou YL, 2017, EUR J IMMUNOL, V47, P1414, DOI 10.1002/eji.201746959; Zong Z, 2021, ADV SCI, V8, DOI 10.1002/advs.202002484	172	1	1	8	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 11	2021	12								742542	10.3389/fimmu.2021.742542	http://dx.doi.org/10.3389/fimmu.2021.742542			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WO9LZ	34707613	gold, Green Published			2022-12-18	WOS:000712767800001
J	Walo-Delgado, PE; Monreal, E; Medina, S; Quintana, E; De la Maza, SS; Fernandez-Velasco, JI; Lapuente, P; Comabella, M; Ramio-Torrenta, L; Montalban, X; Midaglia, L; Villarrubia, N; Carrasco-Sayalero, A; Rodriguez-Martin, E; Roldan, E; Meca-Lallana, J; Alvarez-Lafuente, R; Masjuan, J; Costa-Frossard, L; Villar, LM				Esperanza Walo-Delgado, Paulette; Monreal, Enric; Medina, Silvia; Quintana, Ester; Sainz de la Maza, Susana; Ignacio Fernandez-Velasco, Jose; Lapuente, Paloma; Comabella, Manuel; Ramio-Torrenta, Lluis; Montalban, Xavier; Midaglia, Luciana; Villarrubia, Noelia; Carrasco-Sayalero, Angela; Rodriguez-Martin, Eulalia; Roldan, Ernesto; Meca-Lallana, Jose; Alvarez-Lafuente, Roberto; Masjuan, Jaime; Costa-Frossard, Lucienne; Maria Villar, Luisa			Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; side effects; autoimmunity; disease modifying treatments; alemtuzumab; biomarkers; B cells	REMITTING MULTIPLE-SCLEROSIS; RECONSTITUTION; SUBSETS; BLOOD; BETA	Objective To explore if baseline blood lymphocyte profile could identify relapsing remitting multiple sclerosis (RRMS) patients at higher risk of developing secondary autoimmune adverse events (AIAEs) after alemtuzumab treatment.</p> Methods Multicenter prospective study including 57 RRMS patients treated with alemtuzumab followed for 3.25 [3.5-4.21] years, (median [interquartile range]). Blood samples were collected at baseline, and leukocyte subsets determined by flow cytometry. We had additional samples one year after the first cycle of alemtuzumab treatment in 39 cases.</p> Results Twenty-two patients (38.6%) developed AIAEs during follow-up. They had higher B-cell percentages at baseline (p=0.0014), being differences mainly due to plasmablasts/plasma cells (PB/PC, p=0.0011). Those with no AIAEs had higher percentages of CD4+ T cells (p=0.013), mainly due to terminally differentiated (TD) (p=0.034) and effector memory (EM) (p=0.031) phenotypes. AIAEs- patients also showed higher values of TNF-alpha-producing CD8+ T cells (p=0.029). The percentage of PB/PC was the best variable to differentiate both groups of patients. Baseline values >0.10% closely associated with higher AIAE risk (Odds ratio [OR]: 5.91, 95% CI: 1.83-19.10, p=0.004). When excluding the 12 patients with natalizumab, which decreases blood PB/PC percentages, being the last treatment before alemtuzumab, baseline PB/PC >0.1% even predicted more accurately the risk of AIAEs (OR: 11.67, 95% CI: 2.62-51.89, p=0.0007). The AIAEs+ group continued having high percentages of PB/PC after a year of alemtuzumab treatment (p=0.0058).</p> Conclusions A PB/PC percentage <0.1% at baseline identifies MS patients at low risk of secondary autoimmunity during alemtuzumab treatment. </p>	[Esperanza Walo-Delgado, Paulette; Medina, Silvia; Ignacio Fernandez-Velasco, Jose; Lapuente, Paloma; Villarrubia, Noelia; Carrasco-Sayalero, Angela; Rodriguez-Martin, Eulalia; Roldan, Ernesto; Maria Villar, Luisa] Ramon y Cajal Univ Hosp, Inst Ramon y Cajal Invest Sanitaria IRYCIS, Dept Immunol, Red Espanola Esclerosis Multiple REEM, Madrid, Spain; [Monreal, Enric; Sainz de la Maza, Susana; Masjuan, Jaime; Costa-Frossard, Lucienne] Ramon y Cajal Univ Hosp, Dept Neurol, Red Espanola Esclerosis Multiple REEM, IRYCIS, Madrid, Spain; [Quintana, Ester; Ramio-Torrenta, Lluis] Biomed Res Inst IDIBGI, Neurol Dept, Neuroimmunol & Multiple Sclerosis Unit, Girona, Spain; [Comabella, Manuel; Montalban, Xavier; Midaglia, Luciana] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Ctr Esclerosi Multiple Catalunya Cemcat, Inst Recerca Vall dHebron VHIR, Barcelona, Spain; [Meca-Lallana, Jose] Virgen de la Arrixaca Univ Hosp, Dept Neurol, Murcia, Spain; [Alvarez-Lafuente, Roberto] Hosp Clin San Carlos, Inst Invest Sanitaria, Red Espanola Esclerosis Multiple REEM, Grp Invest Factores Ambientales Enfermedades Dege, Madrid, Spain	Hospital Universitario Ramon y Cajal; Hospital Universitario Ramon y Cajal; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona (IDIBGI); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital Clinico Universitario Virgen de la Arrixaca; Hospital Clinico San Carlos	Villar, LM (corresponding author), Ramon y Cajal Univ Hosp, Inst Ramon y Cajal Invest Sanitaria IRYCIS, Dept Immunol, Red Espanola Esclerosis Multiple REEM, Madrid, Spain.	luisamaria.villar@salud.madrid.org	masjuan, Jaime/DIW-6614-2022; Montalban, Xavier/J-5938-2016	masjuan, Jaime/0000-0003-1329-0943; Montalban, Xavier/0000-0002-0098-9918; Alvarez-Lafuente, Roberto/0000-0002-3132-1486				Alenda R, 2018, J NEUROL, V265, P24, DOI 10.1007/s00415-017-8625-6; Azzopardi L, 2014, J NEUROL NEUROSUR PS, V85, P795, DOI 10.1136/jnnp-2013-307042; Baker D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00124; Baker D, 2017, JAMA NEUROL, V74, P961, DOI 10.1001/jamaneurol.2017.0676; Buonomo AR, 2018, EXPERT OPIN DRUG SAF, V17, P709, DOI 10.1080/14740338.2018.1483330; Cohen JA, 2012, LANCET, V380, P1819, DOI 10.1016/S0140-6736(12)61769-3; Coles AJ, 2017, NEUROLOGY, V89, P1117, DOI 10.1212/WNL.0000000000004354; Comini-Frota ER, 2020, MULT SCLER RELAT DIS, V44, DOI 10.1016/j.msard.2020.102181; Costelloe L, 2012, EXPERT REV NEUROTHER, V12, P335, DOI [10.1586/ERN.12.5, 10.1586/ern.12.5]; Ellebedy AH, 2016, NAT IMMUNOL, V17, P1226, DOI 10.1038/ni.3533; Fernandez-Velasco JI, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000000940; Gilmore W, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01847-9; Gross CC, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000289; Henriksen AC, 2021, MULT SCLER RELAT DIS, V52, DOI 10.1016/j.msard.2021.102987; Jones JL, 2009, J CLIN INVEST, V119, P2052, DOI 10.1172/JCI37878; Kemmerer CL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235449; Kuhlmann T, 2017, ACTA NEUROPATHOL, V133, P13, DOI 10.1007/s00401-016-1653-y; Lisak RP, 2012, J NEUROIMMUNOL, V246, P85, DOI 10.1016/j.jneuroim.2012.02.015; Long D, 2019, J AUTOIMMUN, V99, P1, DOI 10.1016/j.jaut.2019.01.013; Medina S, 2018, MULT SCLER J, V24, P1317, DOI 10.1177/1352458517717088; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Reindl M, 2019, EBIOMEDICINE, V47, P22, DOI 10.1016/j.ebiom.2019.08.065; Ruck T, 2018, NEUROLOGY, V91, pE2233, DOI 10.1212/WNL.0000000000006648; Thompson SAJ, 2010, J CLIN IMMUNOL, V30, P99, DOI 10.1007/s10875-009-9327-3; Tuohy O, 2015, J NEUROL NEUROSUR PS, V86, P208, DOI 10.1136/jnnp-2014-307721; Wiendl H, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000635; Zhang X, 2013, J IMMUNOL, V191, P5867, DOI 10.4049/jimmunol.1301926; Ziemssen T, 2017, THER ADV NEUROL DISO, V10, P343, DOI 10.1177/1756285617722706	28	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 8	2021	12								760546	10.3389/fimmu.2021.760546	http://dx.doi.org/10.3389/fimmu.2021.760546			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WM2DW	34691084	Green Published, gold			2022-12-18	WOS:000710902500001
J	Ma, YX; Yang, L; Bao, YH; Yang, Y; Chen, LT; Zheng, M				Ma, Yaxian; Yang, Li; Bao, Yuhan; Yang, Yang; Chen, Liting; Zheng, Miao			Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						hepatitis B virus; reactivation; CAR T; lymphoma; antiviral therapy	CHRONIC HEPATITIS-B; STRATEGIES; MANAGEMENT; INFECTION; GENOTYPES	Hepatitis B virus (HBV) reactivation is a common complication in chronic or resolved HBV infection patients undergoing immunosuppressive chemotherapy. Furthermore, few articles have been published regarding the risk of HBV reactivation in lymphoma patients receiving chimeric antigen receptor (CAR) T-cell therapy and anti-HBV prophylaxis. Few guidelines or clear optimal strategies are available for managing these patients. Here, we present two cases of patients who underwent CAR-T-cell cocktail therapy with anti-CD19 and anti-CD22 CAR (CAR19/22) T cell for lymphoma. Patients had previous history of HBV infection, and blood tests on initial admission indicated positive results for hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc), and antibody to hepatitis B e antigen (anti-HBe), while serum HBV DNA level was undetectable. Therefore, two patients received entecavir as antiviral prophylactic therapy during their entire treatment. They were diagnosed with HBV reactivation based on positive serum HBV DNA test results, 2 weeks after CAR-T-cell infusion. Liver function assay indicated elevated levels of alanine transaminase (ALT) and aspartate transaminase (AST), combined with increased levels of total bilirubin (TBIL) and direct bilirubin (DBIL). Subsequently, they received anti-HBV treatment with entecavir and tenofovir. As a result, their serum HBV DNA copies and AST/ALT levels returned to normal after 1 week. These cases show that there is a risk of HBV reactivation in lymphoma patients with CAR-T-cell therapy despite entecavir preventive therapy, and combination treatment of entecavir and tenofovir may be an effective treatment option for such patients with HBV reactivation.	[Ma, Yaxian; Yang, Li; Bao, Yuhan; Yang, Yang; Chen, Liting; Zheng, Miao] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China	Huazhong University of Science & Technology	Zheng, M (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China.	zmzk@sina.com		Ma, Yaxian/0000-0002-4412-5564	National Natural Science Foundation of China [81974005]; Chen Xiao-Ping Foundation for the development of Science and Technology of Hubei Province	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chen Xiao-Ping Foundation for the development of Science and Technology of Hubei Province	The work was supported by the National Natural Science Foundation of China (no. 81974005) and the Chen Xiao-Ping Foundation for the development of Science and Technology of Hubei Province.	Brudno JN, 2018, NAT REV CLIN ONCOL, V15, P31, DOI 10.1038/nrclinonc.2017.128; Cao WY, 2020, BLOOD, V136, P516, DOI 10.1182/blood.2020004907; Chien RN, 2008, BEST PRACT RES CL GA, V22, P1081, DOI 10.1016/j.bpg.2008.11.003; Chinese Society of Lymphoma CA-cA, 2021, ZHONGHUA XUE YE XUE, V42, P441, DOI [10.3760/cma.j.issn.0253-2727.2021.06.001, DOI 10.3760/CMA.J.ISSN.0253-2727.2021.06.001]; Hamieh M, 2019, NATURE, V568, P112, DOI 10.1038/s41586-019-1054-1; Hwang JP, 2020, J CLIN ONCOL, V38, P3698, DOI 10.1200/JCO.20.01757; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Kusumoto S, 2019, BLOOD, V133, P137, DOI 10.1182/blood-2018-04-848044; Kusumoto S, 2015, CLIN INFECT DIS, V61, P719, DOI 10.1093/cid/civ344; Li HM, 2015, WORLD J GASTROENTERO, V21, P6684, DOI 10.3748/wjg.v21.i21.6684; Lin CL, 2017, BEST PRACT RES CL GA, V31, P249, DOI 10.1016/j.bpg.2017.04.010; Loomba R, 2017, GASTROENTEROLOGY, V152, P1297, DOI 10.1053/j.gastro.2017.02.009; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Sagnelli C, 2019, WORLD J GASTROENTERO, V25, P3299, DOI 10.3748/wjg.v25.i26.3299; Sarmati L, 2017, CLIN MICROBIOL INFEC, V23, P935, DOI 10.1016/j.cmi.2017.06.023; Schneider D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abc6401; Strati P, 2019, BLOOD, V133, P2800, DOI 10.1182/blood.2019000888; Tan CJ, 2021, PHARMACOTHERAPY, V41, P332, DOI 10.1002/phar.2508; Tang LSY, 2018, JAMA-J AM MED ASSOC, V319, P1802, DOI 10.1001/jama.2018.3795; Terrault NA, 2018, HEPATOLOGY, V67, P1560, DOI 10.1002/hep.29800; Wei J, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0790-y; Yang CM, 2020, LEUKEMIA, V34, P3055, DOI 10.1038/s41375-020-0913-y	22	1	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 8	2021	12								751754	10.3389/fimmu.2021.751754	http://dx.doi.org/10.3389/fimmu.2021.751754			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WM2TE	34691067	gold, Green Published			2022-12-18	WOS:000710942300001
J	Najem, H; Marisetty, A; Horbinski, C; Long, J; Huse, JT; Oliva, ICG; Ferguson, SD; Kumthekar, PU; Wainwright, DA; Chen, PW; Lesniak, MS; Burks, JK; Heimberger, AB				Najem, Hinda; Marisetty, Anantha; Horbinski, Craig; Long, James; Huse, Jason T.; Oliva, Isabella C. Glitza; Ferguson, Sherise D.; Kumthekar, Priya U.; Wainwright, Derek A.; Chen, Peiwen; Lesniak, Maciej S.; Burks, Jared K.; Heimberger, Amy B.			CD11c+CD163+Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease	FRONTIERS IN IMMUNOLOGY			English	Article						melanoma; LMD; tumor microenvironment; T cells; dendritic cells; macrophages; STAT3	OPEN-LABEL; BRAIN METASTASES; POLARIZATION; MACROPHAGES; IPILIMUMAB; IMMUNE; CELLS	Leptomeningeal disease (LMD) in melanoma patients is associated with significant neurological sequela and has a dismal outcome, with survival measured typically in weeks. Despite the therapeutic benefit of targeted therapies and immunotherapies for Stage IV melanoma, patients with LMD do not typically benefit. A deeper understanding of the tumor microenvironment (TME) of LMD may provide more appropriate therapeutic selection. A retrospective analysis of subjects who underwent surgical resection with LMD (n=8) were profiled with seven color multiplex staining to evaluate the expression of the global immune suppressive hub - the signal transducer and activator of transcription 3 (STAT3) and for the presence of CD3+ T cells, CD68+ monocyte-derived cells, CD163+ immune suppressive macrophages, and CD11c+ cells [potential dendritic cells (DCs)] in association with the melanoma tumor marker S100B and DAPI for cellular nuclear identification. High-resolution cellular imaging and quantification was conducted using the Akoya Vectra Polaris. CD11c+ cells predominate in the TME (10% of total cells), along with immunosuppressive macrophages (2%). Another potential subset of DCs co-expressing CD11c+ and the CD163+ immunosuppressive marker is frequently present (8/8 of specimens, 8%). Occasional CD3+ T cells are identified, especially in the stroma of the tumor (p=0.039). pSTAT3 nuclear expression is heterogeneous in the various immune cell populations. Occasional immune cluster interactions can be seen in the stroma and on the edge. In conclusion, the TME of LMD is largely devoid of CD3+ T cells but is enriched in immune suppression and innate immunity.	[Najem, Hinda; Horbinski, Craig; Wainwright, Derek A.; Chen, Peiwen; Lesniak, Maciej S.; Heimberger, Amy B.] Northwestern Univ, Dept Neurol Surg, Malnati Brain Tumor Inst, Lurie Comprehens Canc Ctr,Feinberg Sch Med, Chicago, IL 60611 USA; [Marisetty, Anantha] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Horbinski, Craig] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Long, James] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Huse, Jason T.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Oliva, Isabella C. Glitza] Univ Texas MD Anderson Canc Ctr, Dept Melanoma, Houston, TX 77030 USA; [Ferguson, Sherise D.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; [Kumthekar, Priya U.] Northwestern Univ, Feinberg Sch Med, Dept Neurooncol, Chicago, IL 60611 USA; [Burks, Jared K.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Baylor College of Medicine; Northwestern University; Feinberg School of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Northwestern University; Feinberg School of Medicine; University of Texas System; UTMD Anderson Cancer Center	Heimberger, AB (corresponding author), Northwestern Univ, Dept Neurol Surg, Malnati Brain Tumor Inst, Lurie Comprehens Canc Ctr,Feinberg Sch Med, Chicago, IL 60611 USA.	amy.heimberger@northwestern.edu		Najem, Hinda/0000-0003-4432-9708; Chen, Peiwen/0000-0002-8129-9328	National Institutes of Health; NCIs Research Specialist;  [CA016672];  [1 R50 CA243707]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCIs Research Specialist; ; 	This research was performed in the Flow Cytometry & CellularImaging Core Facility, which is supported in part by the National Institutes of Health through M. D. Andersons Cancer Center Support Grant CA016672 and the NCIs Research Specialist 1R50 CA243707	Amon L, 2020, MOL IMMUNOL, V120, P122, DOI 10.1016/j.molimm.2020.02.010; Barry KC, 2018, NAT MED, V24, P1178, DOI 10.1038/s41591-018-0085-8; Becco P, 2020, CANCERS, V12, DOI 10.3390/cancers12061640; Ferguson SD, 2019, J NEURO-ONCOL, V142, P499, DOI 10.1007/s11060-019-03121-2; Fu XQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2440-1; Glitza IC, 2020, PIGM CELL MELANOMA R, V33, P527, DOI 10.1111/pcmr.12861; Goldberg SB, 2016, LANCET ONCOL, V17, P976, DOI 10.1016/S1470-2045(16)30053-5; Huang FJ, 2008, CANCER RES, V68, P9634, DOI 10.1158/0008-5472.CAN-08-1429; Klarquist JS, 2012, ONCOIMMUNOLOGY, V1, P1584, DOI 10.4161/onci.22660; Kluger HM, 2019, J CLIN ONCOL, V37, P52, DOI 10.1200/JCO.18.00204; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Lin T, 2004, BIOCHEM BIOPH RES CO, V321, P828, DOI 10.1016/j.bbrc.2004.07.039; Long GV, 2012, LANCET ONCOL, V13, P1087, DOI 10.1016/S1470-2045(12)70431-X; Margolin K, 2012, LANCET ONCOL, V13, P459, DOI 10.1016/S1470-2045(12)70090-6; Martin GR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50656-5; Mok S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1377-8; Nakajima S, 2016, J IMMUNOL, V197, P3735, DOI 10.4049/jimmunol.1600895; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Parikh SV, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.621039; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Rao G, 2020, CLIN CANCER RES, V26, P4699, DOI 10.1158/1078-0432.CCR-19-4110; Santegoets SJ, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001053; Smalley I, 2021, CLIN CANCER RES, V27, P4109, DOI 10.1158/1078-0432.CCR-21-1694; Smalley KSM, 2016, INT J CANCER, V139, P1195, DOI 10.1002/ijc.30147; Srivastava S, 2019, CANCERS, V11, DOI 10.3390/cancers11040537; Tawbi HA, 2018, NEW ENGL J MED, V379, P722, DOI 10.1056/NEJMoa1805453; Tetu P, 2020, CANCERS, V12, DOI 10.3390/cancers12092635; Tucci M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01148; Weiss SA, 2021, J NEURO-ONCOL, V152, P15, DOI 10.1007/s11060-020-03619-0; Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747	30	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 8	2021	12								745893	10.3389/fimmu.2021.745893	http://dx.doi.org/10.3389/fimmu.2021.745893			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WM2TI	34691054	gold, Green Published			2022-12-18	WOS:000710942700001
J	Wagner, M; Koyasu, S				Wagner, Marek; Koyasu, Shigeo			Innate Lymphoid Cells in Skin Homeostasis and Malignancy	FRONTIERS IN IMMUNOLOGY			English	Review						innate lymphoid cells; skin; skin cancer; melanoma; immunity; immunosurveillance	MELANOMA-CELLS; 3-DIMENSIONAL ARCHITECTURES; TUMORS; IL-12; INFLAMMATION; RECOGNITION; LYMPHOCYTES; CYTOKINES; RESPONSES; IMMUNITY	Innate lymphoid cells (ILCs) are mostly tissue resident lymphocytes that are preferentially enriched in barrier tissues such as the skin. Although they lack the expression of somatically rearranged antigen receptors present on T and B cells, ILCs partake in multiple immune pathways by regulating tissue inflammation and potentiating adaptive immunity. Emerging evidence indicates that ILCs play a critical role in the control of melanoma, a type of skin malignancy thought to trigger immunity mediated mainly by adaptive immune responses. Here, we compile our current understanding of ILCs with regard to their role as the first line of defence against melanoma development and progression. We also discuss areas that merit further investigation. We envisage that the possibility to harness therapeutic potential of ILCs might benefit patients suffering from skin malignancies such as melanoma.</p>	[Wagner, Marek; Koyasu, Shigeo] RIKEN Ctr Integrat Med Sci, Lab Immune Cell Syst, Yokohama, Kanagawa, Japan; [Wagner, Marek] Univ Bergen, Dept Biomed, Bergen, Norway	RIKEN; University of Bergen	Wagner, M; Koyasu, S (corresponding author), RIKEN Ctr Integrat Med Sci, Lab Immune Cell Syst, Yokohama, Kanagawa, Japan.; Wagner, M (corresponding author), Univ Bergen, Dept Biomed, Bergen, Norway.	marek.wagner@uib.no; shigeo.koyasu@riken.jp	Koyasu, Shigeo/J-5583-2015	Koyasu, Shigeo/0000-0001-9585-3038; Wagner, Marek/0000-0003-3967-9527	FRIPRO Mobility Grant Fellowship from the Research Council of Norway [302241, 20H00511]; Japan Society for the Promotion of Science	FRIPRO Mobility Grant Fellowship from the Research Council of Norway; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	Funding This work was supported by the FRIPRO Mobility Grant Fellowship from the Research Council of Norway (302241) to MW and by a Grant-in-Aid for Scientific Research (A) (20H00511) from the Japan Society for the Promotion of Science, to SK.	Bal SM, 2020, NAT REV IMMUNOL, V20, P552, DOI 10.1038/s41577-020-0282-9; Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Bald T, 2019, SEMIN IMMUNOL, V41, DOI 10.1016/j.smim.2019.04.001; Balsamo M, 2012, ONCOIMMUNOLOGY, V1, P1607, DOI 10.4161/onci.21456; Barry KC, 2018, NAT MED, V24, P1178, DOI 10.1038/s41591-018-0085-8; Benci JL, 2019, CELL, V178, P933, DOI 10.1016/j.cell.2019.07.019; Bernink JH, 2019, NAT IMMUNOL, V20, P992, DOI 10.1038/s41590-019-0423-0; Bielecki P, 2021, NATURE, V592, P128, DOI 10.1038/s41586-021-03188-w; Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Boudreau JE, 2018, TRENDS IMMUNOL, V39, P222, DOI 10.1016/j.it.2017.12.001; Bruggen MC, 2016, J INVEST DERMATOL, V136, P2396, DOI 10.1016/j.jid.2016.07.017; Chiossone L, 2018, NAT REV IMMUNOL, V18, P671, DOI 10.1038/s41577-018-0061-z; de Jonge K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40933-8; DelGiorno KE, 2020, GASTROENTEROLOGY, V159, P1866, DOI 10.1053/j.gastro.2020.07.037; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Eisenring M, 2010, NAT IMMUNOL, V11, P1030, DOI 10.1038/ni.1947; Ercolano G, 2020, CANCER IMMUNOL RES, V8, P556, DOI 10.1158/2326-6066.CIR-19-0504; Feder-Mengus C, 2007, BRIT J CANCER, V96, P1072, DOI 10.1038/sj.bjc.6603664; Fuchs A, 2013, IMMUNITY, V38, P769, DOI 10.1016/j.immuni.2013.02.010; Ghosh S, 2005, ANN SURG, V242, P851, DOI 10.1097/01.sla.0000189571.84213.b0; Grisaru-Tal S, 2020, NAT REV CANCER, V20, P594, DOI 10.1038/s41568-020-0283-9; Gudjonsson JE, 2007, J INVEST DERMATOL, V127, P1292, DOI 10.1038/sj.jid.5700807; Hepworth MR, 2013, NATURE, V498, P113, DOI 10.1038/nature12240; Ikutani M, 2012, J IMMUNOL, V188, P703, DOI 10.4049/jimmunol.1101270; Jacquelot N, 2021, NAT IMMUNOL, V22, P851, DOI 10.1038/s41590-021-00943-z; Kabashima K, 2019, NAT REV IMMUNOL, V19, P19, DOI 10.1038/s41577-018-0084-5; Kabata H, 2018, IMMUNOL REV, V286, P37, DOI 10.1111/imr.12706; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kim J, 2016, J IMMUNOL, V196, P2410, DOI 10.4049/jimmunol.1501730; Kiniwa T, 2021, INT IMMUNOL, V33, P251, DOI 10.1093/intimm/dxab001; Klose CSN, 2020, CELL RES, V30, P475, DOI 10.1038/s41422-020-0323-8; Kobayashi T, 2019, IMMUNITY, V50, P552, DOI 10.1016/j.immuni.2019.02.023; Kobayashi T, 2019, CELL, V176, P982, DOI 10.1016/j.cell.2018.12.031; Lakshmikanth T, 2009, J CLIN INVEST, V119, P1251, DOI 10.1172/JCI36022; Li Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11394; Long A, 2018, J IMMUNOL, V201, P3456, DOI 10.4049/jimmunol.1800173; Lopez-Soto A, 2017, CANCER CELL, V32, P135, DOI 10.1016/j.ccell.2017.06.009; Lucarini V, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1317420; MacLeod AS, 2013, J CLIN INVEST, V123, P4364, DOI 10.1172/JCI70064; Maric J, 2019, J ALLERGY CLIN IMMUN, V143, P2202, DOI 10.1016/j.jaci.2018.10.069; Mattes J, 2003, J EXP MED, V197, P387, DOI 10.1084/jem.20021683; Mazzurana L, 2021, CELL RES, V31, P554, DOI 10.1038/s41422-020-00445-x; Meininger I, 2020, TRENDS IMMUNOL, V41, P902, DOI 10.1016/j.it.2020.08.009; Moreira A, 2017, IMMUNOTHERAPY-UK, V9, P115, DOI 10.2217/imt-2016-0138; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Moskalenko M, 2015, CANCER IMMUNOL RES, V3, P296, DOI 10.1158/2326-6066.CIR-14-0120; Nagao K, 2012, NAT IMMUNOL, V13, P744, DOI 10.1038/ni.2353; Nagasawa M, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a030304; Nussbaum K, 2017, J EXP MED, V214, P2331, DOI 10.1084/jem.20162031; Ohne Y, 2016, NAT IMMUNOL, V17, P646, DOI 10.1038/ni.3447; Oyesola OO, 2021, J EXP MED, V218, DOI 10.1084/jem.20202178; Pietra G, 2012, ONCOIMMUNOLOGY, V1, P974, DOI 10.4161/onci.20405; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Rak GD, 2016, J INVEST DERMATOL, V136, P487, DOI 10.1038/JID.2015.406; Roediger B, 2013, NAT IMMUNOL, V14, P564, DOI 10.1038/ni.2584; Rosenberg HF, 2013, NAT REV IMMUNOL, V13, P9, DOI 10.1038/nri3341; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Slominski AT, 2017, LAB INVEST, V97, P706, DOI 10.1038/labinvest.2017.3; Sun Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12733-1; Tarazona R, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00649; Teng MWL, 2015, NAT MED, V21, P719, DOI 10.1038/nm.3895; Teunissen MBM, 2014, J INVEST DERMATOL, V134, P2351, DOI 10.1038/jid.2014.146; Villanova F, 2014, J INVEST DERMATOL, V134, P984, DOI 10.1038/jid.2013.477; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Wagner M, 2020, BIO-PROTOCOL, V10, DOI 10.21769/BioProtoc.3839; Wagner M, 2020, CELL REP, V30, P2743, DOI 10.1016/j.celrep.2020.01.103; Wagner M, 2019, TRENDS IMMUNOL, V40, P415, DOI 10.1016/j.it.2019.03.004; Wagner M, 2017, TRENDS CANCER, V3, P326, DOI 10.1016/j.trecan.2017.03.008; Wagner M, 2013, ADIPOCYTE, V2, P176, DOI 10.4161/adip.24472; Wagner M, 2013, ADIPOCYTE, V2, P67, DOI 10.4161/adip.23016; Wagner M, 2012, ANGIOGENESIS, V15, P481, DOI 10.1007/s10456-012-9276-y; Werner F, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.675146; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Yang J, 2016, NAT IMMUNOL, V17, P48, DOI 10.1038/ni.3312	74	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 8	2021	12								758522	10.3389/fimmu.2021.758522	http://dx.doi.org/10.3389/fimmu.2021.758522			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WM2QU	34691082	Green Published, gold			2022-12-18	WOS:000710936100001
J	Lorvik, KB; Meyer-Myklestad, MH; Kushekar, K; Handeland, C; Medhus, AW; Lund-Iversen, M; Stiksrud, B; Kvale, D; Dyrhol-Riise, AM; Tasken, K; Reikvam, DH				Lorvik, Kristina Berg; Meyer-Myklestad, Malin Holm; Kushekar, Kushi; Handeland, Charlotte; Medhus, Asle Wilhelm; Lund-Iversen, Marius; Stiksrud, Birgitte; Kvale, Dag; Dyrhol-Riise, Anne Margarita; Tasken, Kjetil; Reikvam, Dag Henrik			Enhanced Gut-Homing Dynamics and Pronounced Exhaustion of Mucosal and Blood CD4(+) T Cells in HIV-Infected Immunological Non-Responders	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; immunological non-responder; PD1; CD4 T cell; TIGIT; gut-homing CD4(+) T cell; lamina propria; exhaustion	HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; INTEGRIN ALPHA(4)BETA(7); RECOVERY; RESERVOIR; IMMUNE; INFLAMMATION; INDIVIDUALS; LYMPHOCYTES; ACTIVATION	Immunological non-responders (INR), a subgroup of people living with HIV (PLHIV) who fail to restore CD4(+) T cell numbers upon effective antiretroviral treatment, have impaired gut mucosal barrier function and an inferior clinical prognosis compared with immunological responders (IR). The contribution of gut-homing and exhaustion of mucosal T cells to the INR phenotype was previously unknown. Flow cytometry analysis of mononuclear cells from peripheral blood and ileal and colonic lamina propria showed that INR had higher fractions of gut-homing CD4(+) T cells in blood compared with IR. In addition, gut-homing cells were more likely to display signs of exhaustion in INR. The increased CD4(+) T cell exhaustion in INR was ubiquitous and not restricted to subpopulations defined by activation, differentiation or regulatory T cell markers. In INR, colon CD4(+) T cell exhaustion correlated negatively with the fraction of CD4(+) T cells in the same compartment, this was not apparent in the ileum. The fraction of exhausted mucosal CD4(+) T cells correlated with I-FABP and REG3 alpha, markers of enterocyte damage. We conclude that alterations of gut-homing and exhaustion of T cells may contribute to impaired gut immune and barrier functions associated with immunological non-response in PLHIV.	[Lorvik, Kristina Berg; Meyer-Myklestad, Malin Holm; Stiksrud, Birgitte; Kvale, Dag; Dyrhol-Riise, Anne Margarita; Reikvam, Dag Henrik] Oslo Univ Hosp, Dept Infect Dis, Oslo, Norway; [Lorvik, Kristina Berg; Kushekar, Kushi; Tasken, Kjetil] Oslo Univ Hosp, Inst Canc Res, Dept Canc Immunol, Oslo, Norway; [Lorvik, Kristina Berg; Kushekar, Kushi; Handeland, Charlotte; Tasken, Kjetil] Univ Oslo, Ctr Mol Med Norway, Nordic EMBL Partnership, Oslo, Norway; [Meyer-Myklestad, Malin Holm; Kvale, Dag; Dyrhol-Riise, Anne Margarita; Tasken, Kjetil; Reikvam, Dag Henrik] Univ Oslo, Inst Clin Med, Oslo, Norway; [Medhus, Asle Wilhelm] Oslo Univ Hosp, Dept Gastroenterol, Oslo, Norway; [Lund-Iversen, Marius] Oslo Univ Hosp, Dept Pathol, Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo	Lorvik, KB (corresponding author), Oslo Univ Hosp, Dept Infect Dis, Oslo, Norway.; Lorvik, KB (corresponding author), Oslo Univ Hosp, Inst Canc Res, Dept Canc Immunol, Oslo, Norway.; Lorvik, KB (corresponding author), Univ Oslo, Ctr Mol Med Norway, Nordic EMBL Partnership, Oslo, Norway.	k.b.lorvik@ous-research.no			South-Eastern Norway Regional Health Authority [2013074, 2016018]; Research Council of Norway [187615]; Sastads Legat; Stiftelsen Kristian Gerhard Jebsen (K.G. Jebsen Inflammation Research Centre); Gilead Sciences Nordic Fellowship Programme; Pasteurlegatet	South-Eastern Norway Regional Health Authority; Research Council of Norway(Research Council of Norway); Sastads Legat; Stiftelsen Kristian Gerhard Jebsen (K.G. Jebsen Inflammation Research Centre); Gilead Sciences Nordic Fellowship Programme; Pasteurlegatet	This work was supported by grants from the South-Eastern Norway Regional Health Authority (grant no. 2013074 to KT and grant no. 2016018 to DK), the Research Council of Norway (grant no. 187615 to KT), Sastads Legat (to KL and MM-M), Stiftelsen Kristian Gerhard Jebsen (K.G. Jebsen Inflammation Research Centre) (to DR), Gilead Sciences Nordic Fellowship Programme 2017 (to DR) and Pasteurlegatet (to MM-M).	Arthos J, 2008, NAT IMMUNOL, V9, P301, DOI 10.1038/ni1566; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Booiman T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183357; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; Cattin A, 2021, J IMMUNOL, V206, P2638, DOI 10.4049/jimmunol.2001436; Chevalier MF, 2013, BLOOD, V121, P29, DOI 10.1182/blood-2012-07-409755; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; Chun TW, 2002, J INFECT DIS, V185, P1672, DOI 10.1086/340521; Cicala C, 2009, P NATL ACAD SCI USA, V106, P20877, DOI 10.1073/pnas.0911796106; Ciccone EJ, 2010, MUCOSAL IMMUNOL, V3, P172, DOI 10.1038/mi.2009.129; Costiniuk CT, 2012, MUCOSAL IMMUNOL, V5, P596, DOI 10.1038/mi.2012.82; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Deeks SG, 2013, IMMUNITY, V39, P633, DOI 10.1016/j.immuni.2013.10.001; Fenwick C, 2019, IMMUNOL REV, V292, P149, DOI 10.1111/imr.12823; Fromentin R, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005761; Girard A, 2016, JAIDS-J ACQ IMM DEF, V72, P259, DOI 10.1097/QAI.0000000000000943; Grabmeier-Pfistershammer Katharina, 2011, J Acquir Immune Defic Syndr, V56, P118, DOI 10.1097/QAI.0b013e3181fbab9f; Guihot A, 2018, ANN ONCOL, V29, P517, DOI 10.1093/annonc/mdx696; Guihot A, 2010, AIDS, V24, P614, DOI 10.1097/QAD.0b013e32833556f3; Joller N, 2014, IMMUNITY, V40, P569, DOI 10.1016/j.immuni.2014.02.012; Kahan SM, 2015, VIROLOGY, V479, P180, DOI 10.1016/j.virol.2014.12.033; Kamada T, 2019, P NATL ACAD SCI USA, V116, P9999, DOI 10.1073/pnas.1822001116; Lederman MM, 2011, J INFECT DIS, V204, P1217, DOI 10.1093/infdis/jir507; Massanella M, 2013, EXPERT REV CLIN IMMU, V9, P1135, DOI 10.1586/1744666X.2013.842897; Massanella M, 2010, AIDS, V24, P959, DOI 10.1097/QAD.0b013e328337b957; Rueda CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030307; Mavigner M, 2012, J CLIN INVEST, V122, P62, DOI 10.1172/JCI59011; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; Mehandru S, 2006, PLOS MED, V3, P2335, DOI 10.1371/journal.pmed.0030484; Meyer-Myklestad MH, 2022, J INFECT DIS, V225, P661, DOI 10.1093/infdis/jiaa714; Moore RD, 2007, CLIN INFECT DIS, V44, P441, DOI 10.1086/510746; Mutoh Y, 2018, CLIN INFECT DIS, V67, P927, DOI 10.1093/cid/ciy176; Nakanjako D, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-43; Nawaz F, 2018, MUCOSAL IMMUNOL, V11, P1342, DOI 10.1038/s41385-018-0044-1; Pacheco YM, 2015, ANTIVIR RES, V117, P69, DOI 10.1016/j.antiviral.2015.03.002; Planas D, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93230; Ramirez CM, 2016, AIDS, V30, P1553, DOI 10.1097/QAD.0000000000001049; Rosado-Sanchez I, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01673; Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078; Sivro A, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam6354; Somsouk M, 2015, AIDS, V29, P43, DOI 10.1097/QAD.0000000000000511; Stiksrud B, 2016, JAIDS-J ACQ IMM DEF, V73, P138, DOI 10.1097/QAI.0000000000001080; Tincati C, 2016, AIDS, V30, P991, DOI 10.1097/QAD.0000000000001015; Toker A, 2018, CLIN CANCER RES, V24, P5685, DOI 10.1158/1078-0432.CCR-18-0554; Udall M, 2018, DIAGN PATHOL, V13, DOI 10.1186/s13000-018-0689-9; van Lelyveld SFL, 2012, AIDS, V26, P465, DOI 10.1097/QAD.0b013e32834f32f8; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wightman F, 2015, AIDS, V29, P504, DOI 10.1097/QAD.0000000000000562; Yukl SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121290; Zhang LX, 2021, CLIN IMMUNOL, V229, DOI 10.1016/j.clim.2021.108773	51	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 7	2021	12								744155	10.3389/fimmu.2021.744155	http://dx.doi.org/10.3389/fimmu.2021.744155			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WM0MX	34691047	Green Published, gold			2022-12-18	WOS:000710790500001
J	Schroeter, CB; Huntemann, N; Bock, S; Nelke, C; Kremer, D; Pfeffer, K; Meuth, SG; Ruck, T				Schroeter, Christina B.; Huntemann, Niklas; Bock, Stefanie; Nelke, Christopher; Kremer, David; Pfeffer, Klaus; Meuth, Sven G.; Ruck, Tobias			Crosstalk of Microorganisms and Immune Responses in Autoimmune Neuroinflammation: A Focus on Regulatory T Cells	FRONTIERS IN IMMUNOLOGY			English	Review						T cells; regulatory T cells; microorganism; pathogens; neuroinflammation; autoimmunity; microbiome; immunometabolomics	EPSTEIN-BARR-VIRUS; HUMAN ENDOGENOUS RETROVIRUS; SCLEROSIS-ASSOCIATED RETROVIRUS; HELICOBACTER-PYLORI INFECTION; REMITTING MULTIPLE-SCLEROSIS; HUMAN-IMMUNODEFICIENCY-VIRUS; CHLAMYDIA-PNEUMONIAE INFECTION; HUMANIZED MONOCLONAL-ANTIBODY; LEISHMANIA-MAJOR INFECTION; MYELIN BASIC-PROTEIN	Regulatory T cells (Tregs) are the major determinant of peripheral immune tolerance. Many Treg subsets have been described, however thymus-derived and peripherally induced Tregs remain the most important subpopulations. In multiple sclerosis, a prototypical autoimmune disorder of the central nervous system, Treg dysfunction is a pathogenic hallmark. In contrast, induction of Treg proliferation and enhancement of their function are central immune evasion mechanisms of infectious pathogens. In accordance, Treg expansion is compartmentalized to tissues with high viral replication and prolonged in chronic infections. In friend retrovirus infection, Treg expansion is mainly based on excessive interleukin-2 production by infected effector T cells. Moreover, pathogens seem also to enhance Treg functions as shown in human immunodeficiency virus infection, where Tregs express higher levels of effector molecules such as cytotoxic T-lymphocyte-associated protein 4, CD39 and cAMP and show increased suppressive capacity. Thus, insights into the molecular mechanisms by which intracellular pathogens alter Treg functions might aid to find new therapeutic approaches to target central nervous system autoimmunity. In this review, we summarize the current knowledge of the role of pathogens for Treg function in the context of autoimmune neuroinflammation. We discuss the mechanistic implications for future therapies and provide an outlook for new research directions.</p>	[Schroeter, Christina B.; Huntemann, Niklas; Nelke, Christopher; Kremer, David; Meuth, Sven G.; Ruck, Tobias] Heinrich Heine Univ Dusseldorf, Med Fac, Dept Neurol, Dusseldorf, Germany; [Bock, Stefanie] Univ Munster, Inst Translat Neurol, Dept Neurol, Munster, Germany; [Pfeffer, Klaus] Heinrich Heine Univ Dusseldorf, Inst Med Microbiol & Hosp Hyg, Dusseldorf, Germany	Heinrich Heine University Dusseldorf; University of Munster; Heinrich Heine University Dusseldorf	Ruck, T (corresponding author), Heinrich Heine Univ Dusseldorf, Med Fac, Dept Neurol, Dusseldorf, Germany.	tobias.ruck@med.uni-duesseldorf.de	Meuth, Sven G/HHM-8941-2022	Meuth, Sven G/0000-0003-2571-3501; Ruck, Tobias/0000-0001-6332-8650; Huntemann, Niklas/0000-0003-0015-8484				Aandahl EM, 2004, J VIROL, V78, P2454, DOI 10.1128/JVI.78.5.2454-2459.2004; Abbas AK, 2013, NAT IMMUNOL, V14, P307, DOI 10.1038/ni.2554; Agarwal AK, 1997, J ASTHMA, V34, P539, DOI 10.3109/02770909709055398; Andersen CJ, 2016, ADV NUTR, V7, P66, DOI 10.3945/an.115.010207; Andersson J, 2005, J IMMUNOL, V174, P3143, DOI 10.4049/jimmunol.174.6.3143; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Arce-Sillas A, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/1720827; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Aseffa A, 2002, J IMMUNOL, V169, P3232, DOI 10.4049/jimmunol.169.6.3232; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Awasthi A, 2009, INT IMMUNOL, V21, P489, DOI 10.1093/intimm/dxp021; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Bagos PG, 2006, MULT SCLER J, V12, P397, DOI 10.1191/1352458506ms1291oa; Bailey-Bucktrout SL, 2013, IMMUNITY, V39, P949, DOI 10.1016/j.immuni.2013.10.016; Bar-Or A, 2020, TRENDS MOL MED, V26, P296, DOI 10.1016/j.molmed.2019.11.003; Barrington WT, 2017, NAT REV CARDIOL, V14, P699, DOI 10.1038/nrcardio.2017.169; Becker C, 2009, BLOOD, V114, P1263, DOI 10.1182/blood-2009-02-206730; Beier UH, 2015, FASEB J, V29, P2315, DOI 10.1096/fj.14-268409; Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Belkaid Y, 2007, NAT REV IMMUNOL, V7, P875, DOI 10.1038/nri2189; Belkaid Y, 2006, IMMUNOL REV, V212, P287, DOI 10.1111/j.0105-2896.2006.00409.x; Belkaid Y, 2009, ANNU REV IMMUNOL, V27, P551, DOI 10.1146/annurev.immunol.021908.132723; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bertolini TB, 2021, CELL IMMUNOL, V359, DOI 10.1016/j.cellimm.2020.104251; Beswick EJ, 2011, INFECT IMMUN, V79, P2737, DOI 10.1128/IAI.01146-10; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Bi Y, 2012, SCAND J IMMUNOL, V75, P543, DOI 10.1111/j.1365-3083.2012.02686.x; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Boer MC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00217; Boettler T, 2005, J VIROL, V79, P7860, DOI 10.1128/JVI.79.12.7860-7867.2005; Bolacchi F, 2006, CLIN EXP IMMUNOL, V144, P188, DOI 10.1111/j.1365-2249.2006.03048.x; Bopp T, 2007, J EXP MED, V204, P1303, DOI 10.1084/jem.20062129; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; Boyer O, 2004, BLOOD, V103, P3428, DOI 10.1182/blood-2003-07-2598; Breuer J, 2014, ANN NEUROL, V75, P739, DOI 10.1002/ana.24165; Brutting C, 2016, MOL BIOL REP, V43, P827, DOI 10.1007/s11033-016-4004-0; Burzyn D, 2013, NAT IMMUNOL, V14, P1007, DOI 10.1038/ni.2683; Bystrom J, 2013, VIRUSES-BASEL, V5, P777, DOI 10.3390/v5030777; Cabrera R, 2004, HEPATOLOGY, V40, P1062, DOI 10.1002/hep.20454; Cai XP, 2006, ACTA BIOCH BIOPH SIN, V38, P299, DOI 10.1111/j.1745-7270.2006.00168.x; Campanelli AP, 2006, J INFECT DIS, V193, P1313, DOI 10.1086/502980; Cao XF, 2007, IMMUNITY, V27, P635, DOI 10.1016/j.immuni.2007.08.014; Cao YH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8038; Cardona P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02139; Cavallo S, 2020, J TRANSL AUTOIMMUN, V3, DOI 10.1016/j.jtauto.2020.100039; Cebula A, 2013, NATURE, V497, P258, DOI 10.1038/nature12079; Cecere TE, 2012, VIRUSES-BASEL, V4, P833, DOI 10.3390/v4050833; Cekanaviciute E, 2017, P NATL ACAD SCI USA, V114, P10713, DOI 10.1073/pnas.1711235114; Chabaud M, 1999, ARTHRITIS RHEUM-US, V42, P963, DOI 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E; Chai JN, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aal5068; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; Chapman NM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04392-5; Chase AJ, 2008, J VIROL, V82, P8307, DOI 10.1128/JVI.00520-08; Chen X, 2006, EUR J IMMUNOL, V36, P671, DOI 10.1002/eji.200535353; Chen XC, 2007, CLIN IMMUNOL, V123, P50, DOI 10.1016/j.clim.2006.11.009; Chen Y, 2015, EXP THER MED, V9, P573, DOI 10.3892/etm.2014.2104; Chinen T, 2016, NAT IMMUNOL, V17, P1322, DOI 10.1038/ni.3540; Christensen T, 2007, J NEUROIMMUNOL, V183, P175, DOI 10.1016/j.jneuroim.2006.09.014; Chu HT, 2016, SCIENCE, V352, P1116, DOI 10.1126/science.aad9948; Cipolletta D, 2012, NATURE, V486, P549, DOI 10.1038/nature11132; Clottu AS, 2017, CELL REP, V18, P213, DOI 10.1016/j.celrep.2016.12.006; Cluxton D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00115; Cook KW, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00052; Correale J, 2008, ANN NEUROL, V64, P187, DOI 10.1002/ana.21438; Correale J, 2007, ANN NEUROL, V61, P97, DOI 10.1002/ana.21067; Correale J, 2011, J NEUROIMMUNOL, V233, P6, DOI 10.1016/j.jneuroim.2011.01.002; Costa FRC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152622; Curti A, 2007, BLOOD, V109, P2871, DOI 10.1182/blood-2006-07-036863; Curtin F, 2016, MABS-AUSTIN, V8, P854, DOI 10.1080/19420862.2016.1168956; Curtin F, 2015, MABS-AUSTIN, V7, P265, DOI 10.4161/19420862.2014.985021; Curtin F, 2012, CLIN THER, V34, P2268, DOI 10.1016/j.clinthera.2012.11.006; D'Addario M, 2001, J MOL BIOL, V308, P501, DOI 10.1006/jmbi.2001.4589; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; de la Rosa M, 2004, EUR J IMMUNOL, V34, P2480, DOI 10.1002/eji.200425274; De Luca F, 2019, CLIN EXP IMMUNOL, V195, P74, DOI 10.1111/cei.13158; de Luca V, 2019, MICRON, V120, P66, DOI 10.1016/j.micron.2019.02.005; De Rosa V, 2015, NAT IMMUNOL, V16, P1174, DOI 10.1038/ni.3269; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Derfuss T, 2015, MULT SCLER J, V21, P885, DOI 10.1177/1352458514554052; Di Cesare A, 2009, J INVEST DERMATOL, V129, P1339, DOI 10.1038/jid.2009.59; Di Giacinto C, 2005, J IMMUNOL, V174, P3237, DOI 10.4049/jimmunol.174.6.3237; Dickerson F, 2017, BRAIN BEHAV IMMUN, V62, P46, DOI 10.1016/j.bbi.2016.12.010; Dittmer U, 2004, IMMUNITY, V20, P293, DOI 10.1016/S1074-7613(04)00054-8; Dobson Ruth, 2017, Neurol Neuroimmunol Neuroinflamm, V4, pe318, DOI 10.1212/NXI.0000000000000318; Dolei A, 2002, NEUROLOGY, V58, P471, DOI 10.1212/WNL.58.3.471; Dominguez-Villar M, 2011, NAT MED, V17, P673, DOI 10.1038/nm.2389; Douglas B, 2021, ANNU REV IMMUNOL, V39, P639, DOI [10.1146/annurev-immunol-093019-122827, 10.1146/annurev-immunol-102119-074236]; Du CG, 2002, J EXP MED, V196, P1639, DOI 10.1084/jem.20020393; Duarte JH, 2009, EUR J IMMUNOL, V39, P948, DOI 10.1002/eji.200839196; Duperray A, 2015, INT IMMUNOL, V27, P545, DOI 10.1093/intimm/dxv025; Durant LR, 2013, J VIROL, V87, P10946, DOI 10.1128/JVI.01295-13; Duscha A, 2020, CELL, V180, P1067, DOI 10.1016/j.cell.2020.02.035; Eggena MP, 2005, J IMMUNOL, V174, P4407, DOI 10.4049/jimmunol.174.7.4407; Engelhardt B, 2012, TRENDS IMMUNOL, V33, P579, DOI 10.1016/j.it.2012.07.004; Esplugues E, 2011, NATURE, V475, P514, DOI 10.1038/nature10228; Facciabene A, 2011, NATURE, V475, P226, DOI 10.1038/nature10169; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Farrell RA, 2009, NEUROLOGY, V73, P32, DOI 10.1212/WNL.0b013e3181aa29fe; Fasching P, 2017, MOLECULES, V22, DOI 10.3390/molecules22010134; Feng YQ, 2014, CELL, V158, P749, DOI 10.1016/j.cell.2014.07.031; Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002; Firouzi R, 2003, J NEUROVIROL, V9, P79, DOI 10.1080/13550280390173328; Fleming JO, 2011, MULT SCLER J, V17, P743, DOI 10.1177/1352458511398054; Fleming J, 2019, MULT SCLER J, V25, P81, DOI 10.1177/1352458517736377; Fleming JO, 2006, NEUROLOGY, V67, P2085, DOI 10.1212/01.wnl.0000247663.40297.2d; Fletcher JM, 2009, J IMMUNOL, V183, P7602, DOI 10.4049/jimmunol.0901881; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Frisullo G, 2009, IMMUNOLOGY, V127, P418, DOI 10.1111/j.1365-2567.2008.02963.x; Frydrych L, 2018, J LEUKOCYTE BIOL, V104, P525, DOI 10.1002/JLB.5VMR0118-021RR; Fulton RB, 2010, J IMMUNOL, V185, P2382, DOI 10.4049/jimmunol.1000423; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Ganeshan K, 2014, ANNU REV IMMUNOL, V32, P609, DOI 10.1146/annurev-immunol-032713-120236; Garcia-Montojo M, 2020, EUR J IMMUNOL, V50, P685, DOI 10.1002/eji.201948423; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Geltink RIK, 2018, ANNU REV IMMUNOL, V36, P461, DOI 10.1146/annurev-immunol-042617-053019; Gerriets VA, 2016, NAT IMMUNOL, V17, P1459, DOI 10.1038/ni.3577; Getts DR, 2013, IMMUNOL REV, V255, P197, DOI 10.1111/imr.12091; Ghelani A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01106; Gifford R, 2003, VIRUS GENES, V26, P291, DOI 10.1023/A:1024455415443; Gobel K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11626; Gobel K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-41; Gold J, 2018, MULT SCLER RELAT DIS, V24, P123, DOI 10.1016/j.msard.2018.06.002; Gondek DC, 2008, J IMMUNOL, V181, P4752, DOI 10.4049/jimmunol.181.7.4752; Goodman AD, 2003, J INFECT DIS, V187, P1365, DOI 10.1086/368172; Graham JB, 2014, J IMMUNOL, V192, P683, DOI 10.4049/jimmunol.1202153; Grainger JR, 2010, J EXP MED, V207, P2331, DOI 10.1084/jem.20101074; Grandi N, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00462; Gross CC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13593-5; Grossman WJ, 2004, IMMUNITY, V21, P589, DOI 10.1016/j.immuni.2004.09.002; Gualdoni GA, 2016, FASEB J, V30, P3800, DOI 10.1096/fj.201600522R; Guo JT, 2015, CELL MOL IMMUNOL, V12, P525, DOI 10.1038/cmi.2015.12; Gupta N, 2014, EUR J IMMUNOL, V44, P1363, DOI 10.1002/eji.201343701; Guyot-Revol V, 2006, AM J RESP CRIT CARE, V173, P803, DOI 10.1164/rccm.200508-1294OC; Haas J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01204; Haas J, 2009, J NEUROIMMUNOL, V216, P113, DOI 10.1016/j.jneuroim.2009.06.011; Haase AT, 2005, NAT REV IMMUNOL, V5, P783, DOI 10.1038/nri1706; Haeryfar SMM, 2005, J IMMUNOL, V174, P3344, DOI 10.4049/jimmunol.174.6.3344; Haghikia A, 2015, IMMUNITY, V43, P817, DOI 10.1016/j.immuni.2015.09.007; Hall CHT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012154; Hartung HP, 2022, MULT SCLER J, V28, P429, DOI 10.1177/13524585211024997; Hasenkrug KJ, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006776; Hassani A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192109; He H, 2004, J VIROL, V78, P11641, DOI 10.1128/JVI.78.21.11641-11647.2004; He NH, 2017, P NATL ACAD SCI USA, V114, P12542, DOI 10.1073/pnas.1715363114; Hesse M, 2004, J IMMUNOL, V172, P3157, DOI 10.4049/jimmunol.172.5.3157; Heylen M, 2014, PHARMACOL THERAPEUT, V143, P153, DOI 10.1016/j.pharmthera.2014.02.011; Hisaeda H, 2004, NAT MED, V10, P29, DOI 10.1038/nm975; Hisaeda H, 2008, J IMMUNOL, V180, P2496, DOI 10.4049/jimmunol.180.4.2496; Hoe E, 2017, MICROBIOL IMMUNOL, V61, P49, DOI 10.1111/1348-0421.12471; Hogestyn JM, 2018, NEURAL REGEN RES, V13, P211, DOI 10.4103/1673-5374.226380; Holmoy T, 2004, J NEUROVIROL, V10, P278, DOI 10.1080/13550280490499524; Hori S, 2002, EUR J IMMUNOL, V32, P1282, DOI 10.1002/1521-4141(200205)32:5<1282::AID-IMMU1282>3.0.CO;2-#; Hornero RA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00253; Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474; Humme S, 2003, P NATL ACAD SCI USA, V100, P10989, DOI 10.1073/pnas.1832776100; Hunt PW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015924; Huntemann N, 2021, DRUGS, V81, P1031, DOI 10.1007/s40265-021-01526-w; Huynh A, 2015, NAT IMMUNOL, V16, P188, DOI 10.1038/ni.3077; Iwashiro M, 2001, P NATL ACAD SCI USA, V98, P9226, DOI 10.1073/pnas.151174198; Jakimovski D, 2020, MULT SCLER J, V26, P322, DOI 10.1177/1352458519828667; Jamshidian A, 2013, J NEUROIMMUNOL, V262, P106, DOI 10.1016/j.jneuroim.2013.06.007; Jangi S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12015; Jaruvongvanich V, 2016, MULT SCLER RELAT DIS, V7, P92, DOI 10.1016/j.msard.2016.03.013; Ji JX, 2009, INT IMMUNOL, V21, P283, DOI 10.1093/intimm/dxn146; Jin RM, 2017, J IMMUNOL, V198, P352, DOI 10.4049/jimmunol.1600914; Joedicke Jara J., 2014, Virologica Sinica, V29, P48, DOI 10.1007/s12250-014-3396-z; Johanns TM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001043; Joller N, 2014, IMMUNITY, V40, P569, DOI 10.1016/j.immuni.2014.02.012; Jones AP, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.18; Kadowaki A, 2019, BRAIN, V142, P916, DOI 10.1093/brain/awz012; Kalfaoglu B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.589380; Kaparakis M, 2006, INFECT IMMUN, V74, P3519, DOI 10.1128/IAI.01314-05; Kassiotis G, 2008, SCIENCE, V320, P1168, DOI 10.1126/science.1159090; Kempkes RWM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02839; Kikuchi J, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0526-4; Kim J, 2009, J IMMUNOL, V183, P7631, DOI 10.4049/jimmunol.0804308; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391; Kimura K., 2020, CLIN EXP NEUROIMMUNO, V11, P148, DOI DOI 10.1111/CEN3.12591; Kimura K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02406-2; Kinter AL, 2004, J EXP MED, V200, P331, DOI 10.1084/jem.20032069; Kinter A, 2007, P NATL ACAD SCI USA, V104, P3390, DOI 10.1073/pnas.0611423104; Kishore M, 2017, IMMUNITY, V47, P875, DOI 10.1016/j.immuni.2017.10.017; Kitagaki K, 2006, J IMMUNOL, V177, P1628, DOI 10.4049/jimmunol.177.3.1628; Klein M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00315; Kleinewietfeld M, 2014, IMMUNOL REV, V259, P231, DOI 10.1111/imr.12169; Kleinewietfeld M, 2013, SEMIN IMMUNOL, V25, P305, DOI 10.1016/j.smim.2013.10.009; Klingenberg R, 2013, J CLIN INVEST, V123, P1323, DOI 10.1172/JCI63891; Knochelmann HM, 2018, CELL MOL IMMUNOL, V15, P458, DOI 10.1038/s41423-018-0004-4; Korn T, 2007, NAT MED, V13, P423, DOI 10.1038/nm1564; Kornberg MD, 2018, SCIENCE, V360, P449, DOI 10.1126/science.aan4665; Korporal M, 2008, ARCH NEUROL-CHICAGO, V65, P1434, DOI 10.1001/archneur.65.11.1434; Koutrolos M, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0163-1; Kremer D, 2019, P NATL ACAD SCI USA, V116, P15216, DOI 10.1073/pnas.1901283116; Kremer D, 2015, MULT SCLER J, V21, P1200, DOI 10.1177/1352458514560926; Kremer D, 2013, ANN NEUROL, V74, P721, DOI 10.1002/ana.23970; Kullberg MC, 2002, J EXP MED, V196, P505, DOI 10.1084/jem.20020556; Kursar M, 2002, J EXP MED, V196, P1585, DOI 10.1084/jem.20011347; Kurtulus S, 2015, J CLIN INVEST, V125, P4053, DOI 10.1172/JCI81187; Kwon HK, 2010, P NATL ACAD SCI USA, V107, P2159, DOI 10.1073/pnas.0904055107; La Flamme AC, 2003, INFECT IMMUN, V71, P4996, DOI 10.1128/IAI.71.9.4996-5004.2003; Lan YT, 2019, DIAGN PATHOL, V14, DOI 10.1186/s13000-019-0891-4; Lavasani S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009009; Lee DCP, 2010, J VIROL, V84, P8790, DOI 10.1128/JVI.00796-10; Lee JC, 2011, J CLIN INVEST, V121, P4170, DOI 10.1172/JCI59255; Lee J, 2015, INT IMMUNOPHARMACOL, V26, P103, DOI 10.1016/j.intimp.2015.03.017; Legoux FP, 2015, IMMUNITY, V43, P896, DOI 10.1016/j.immuni.2015.10.011; Lei H, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00184; Leibovitch EC, 2018, P NATL ACAD SCI USA, V115, P11292, DOI 10.1073/pnas.1811974115; Leon MA, 2019, MICROBES INFECT, V21, P449, DOI 10.1016/j.micinf.2019.05.001; Levin LI, 2005, JAMA-J AM MED ASSOC, V293, P2496, DOI 10.1001/jama.293.20.2496; Levin LI, 2010, ANN NEUROL, V67, P824, DOI 10.1002/ana.21978; Levine AG, 2014, NAT IMMUNOL, V15, P1070, DOI 10.1038/ni.3004; Li MO, 2008, CELL, V134, P392, DOI 10.1016/j.cell.2008.07.025; Li MY, 2020, CELL MOL IMMUNOL, V17, P507, DOI 10.1038/s41423-019-0246-9; Li R, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00626; Li S, 2008, J VIROL, V82, P21, DOI 10.1128/JVI.01768-07; Li S, 2007, IMMUNOL CELL BIOL, V85, P197, DOI 10.1038/sj.icb.7100020; Li SS, 2016, MED SCI MONITOR, V22, P2113, DOI 10.12659/MSM.896355; Li WN, 2019, CANCER LETT, V447, P41, DOI 10.1016/j.canlet.2019.01.015; Li XD, 2014, CELL, V158, P734, DOI 10.1016/j.cell.2014.07.030; Li YH, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/6587296; Libbey JE, 2014, INT REV IMMUNOL, V33, P266, DOI 10.3109/08830185.2013.823422; Lippens C, 2016, J AUTOIMMUN, V75, P39, DOI 10.1016/j.jaut.2016.07.004; Liu HY, 2003, J IMMUNOL, V171, P5012, DOI 10.4049/jimmunol.171.10.5012; Lo YC, 2014, CURR OPIN ORGAN TRAN, V19, P363, DOI 10.1097/MOT.0000000000000098; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Loebbermann J, 2012, MUCOSAL IMMUNOL, V5, P161, DOI 10.1038/mi.2011.62; Losikoff PT, 2015, J HEPATOL, V62, P48, DOI 10.1016/j.jhep.2014.08.026; Lu XX, 2015, VIRUS RES, V195, P162, DOI 10.1016/j.virusres.2014.10.011; Lunemann JD, 2008, J EXP MED, V205, P1763, DOI 10.1084/jem.20072397; Lunemann JD, 2010, ANN NEUROL, V67, P159, DOI 10.1002/ana.21886; Lund JM, 2008, SCIENCE, V320, P1220, DOI 10.1126/science.1155209; Lundgren A, 2003, INFECT IMMUN, V71, P1755, DOI 10.1128/IAI.71.4.1755-1762.2003; Luther J, 2010, INFLAMM BOWEL DIS, V16, P1077, DOI 10.1002/ibd.21116; Madeira A, 2016, J NEUROIMMUNOL, V291, P29, DOI 10.1016/j.jneuroim.2015.12.006; Magliozzi R, 2013, J NEUROPATH EXP NEUR, V72, P29, DOI 10.1097/NEN.0b013e31827bfc62; Maizels RM, 2011, ADV IMMUNOL, V112, P73, DOI 10.1016/B978-0-12-387827-4.00003-6; Maloy KJ, 2003, J EXP MED, V197, P111, DOI 10.1084/jem.20021345; Mameli G, 2007, J GEN VIROL, V88, P264, DOI 10.1099/vir.0.81890-0; Mameli G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044991; Mangodt TC, 2015, PEDIATR RES, V78, P483, DOI 10.1038/pr.2015.143; Marrodan M, 2019, MULT SCLER J, V25, P891, DOI 10.1177/1352458518823940; Maruszak H, 2011, EUR J NEUROL, V18, pE110, DOI 10.1111/j.1468-1331.2011.03430.x; Mathis D, 2011, CELL HOST MICROBE, V10, P297, DOI 10.1016/j.chom.2011.09.007; Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1177/135245859900500206; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; McCune A, 2003, EUR J GASTROEN HEPAT, V15, P637, DOI 10.1097/00042737-200306000-00010; McKee AS, 2004, J IMMUNOL, V173, P1224, DOI 10.4049/jimmunol.173.2.1224; McKinley L, 2006, J IMMUNOL, V177, P6215, DOI 10.4049/jimmunol.177.9.6215; McKinney EF, 2010, NAT MED, V16, P586, DOI 10.1038/nm.2130; Mendez S, 2004, J EXP MED, V200, P201, DOI 10.1084/jem.20040298; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Miska J, 2019, CELL REP, V27, P226, DOI 10.1016/j.celrep.2019.03.029; Miyake S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137429; Mizuno M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173032; Monack DM, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a010348; Montagnoli C, 2002, J IMMUNOL, V169, P6298, DOI 10.4049/jimmunol.169.11.6298; Moore TC, 2017, MBIO, V8, DOI 10.1128/mBio.01122-17; Morandi E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172415; Moreno-Fernandez ME, 2011, BLOOD, V117, P5372, DOI 10.1182/blood-2010-12-323162; Morton AM, 2014, P NATL ACAD SCI USA, V111, P6696, DOI 10.1073/pnas.1405634111; Mukherjee S, 2011, AM J PATHOL, V179, P248, DOI 10.1016/j.ajpath.2011.03.003; Muls N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113025; Myers L, 2013, J IMMUNOL, V190, P5485, DOI 10.4049/jimmunol.1202951; Myers L, 2009, J IMMUNOL, V183, P1636, DOI 10.4049/jimmunol.0900350; Myers L, 2009, IMMUNOL RES, V43, P160, DOI 10.1007/s12026-008-8061-x; Mykicki N, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8732; Neill DR, 2014, AM J RESP CRIT CARE, V189, P1250, DOI 10.1164/rccm.201401-0128OC; Netea MG, 2004, J IMMUNOL, V172, P3712, DOI 10.4049/jimmunol.172.6.3712; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Nikolova M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002110; Nilsson J, 2006, BLOOD, V108, P3808, DOI 10.1182/blood-2006-05-021576; Noack M, 2014, AUTOIMMUN REV, V13, P668, DOI 10.1016/j.autrev.2013.12.004; Ochoa-Reparaz J, 2009, J IMMUNOL, V183, P6041, DOI 10.4049/jimmunol.0900747; Oderup C, 2006, IMMUNOLOGY, V118, P240, DOI 10.1111/j.1365-2567.2006.02362.x; Oh U, 2006, J INFECT DIS, V193, P1557, DOI 10.1086/503874; Omenetti S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00639; Oswald-Richter K, 2004, PLOS BIOL, V2, P955, DOI 10.1371/journal.pbio.0020198; Oswald-Richter K, 2004, EUR J IMMUNOL, V34, P1705, DOI 10.1002/eji.200424892; Othy S, 2020, P NATL ACAD SCI USA, V117, P20088, DOI 10.1073/pnas.2006895117; Pacella I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01889; Pacheco Y, 2019, J AUTOIMMUN, V103, DOI 10.1016/j.jaut.2019.06.012; Pakpoor J, 2013, MULT SCLER J, V19, P162, DOI 10.1177/1352458512449682; Palma C, 2021, CELL METAB, V33, P300, DOI 10.1016/j.cmet.2020.12.016; Palsson-McDermott EM, 2020, CELL RES, V30, P300, DOI 10.1038/s41422-020-0291-z; Pankratz S, 2014, FASEB J, V28, P3435, DOI 10.1096/fj.14-251074; Tenorio EP, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/786078; Pearce EL, 2013, IMMUNITY, V38, P633, DOI 10.1016/j.immuni.2013.04.005; Pearce EL, 2010, CURR OPIN IMMUNOL, V22, P314, DOI 10.1016/j.coi.2010.01.018; Pearce EL, 2009, NATURE, V460, P103, DOI 10.1038/nature08097; Pedrini MJF, 2015, J NEUROL NEUROSUR PS, V86, P603, DOI 10.1136/jnnp-2014-309495; Pender MP, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.124714; Pender MP, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2016.87; Pender MP, 2014, MULT SCLER J, V20, P1541, DOI 10.1177/1352458514521888; Periasamy S, 2011, J INFECT DIS, V203, P1256, DOI 10.1093/infdis/jir011; PERRON H, 1989, RES VIROLOGY, V140, P551, DOI 10.1016/S0923-2516(89)80141-4; Perron H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080128; PETTE M, 1990, NEUROLOGY, V40, P1770, DOI 10.1212/WNL.40.11.1770; Prinz M, 2017, NAT NEUROSCI, V20, P136, DOI 10.1038/nn.4475; Procaccini C, 2016, IMMUNITY, V44, P406, DOI 10.1016/j.immuni.2016.01.028; Qin L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027113; Raghavan S, 2004, SCAND J IMMUNOL, V60, P82, DOI 10.1111/j.0300-9475.2004.01447.x; Revu S, 2018, CELL REP, V22, P2642, DOI 10.1016/j.celrep.2018.02.044; Ribeiro-Rodrigues R, 2006, CLIN EXP IMMUNOL, V144, P25, DOI 10.1111/j.1365-2249.2006.03027.x; Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058; Robertson SJ, 2006, J IMMUNOL, V176, P3342, DOI 10.4049/jimmunol.176.6.3342; Rojas M, 2018, J AUTOIMMUN, V95, P100, DOI 10.1016/j.jaut.2018.10.012; Rolland A, 2006, J IMMUNOL, V176, P7636, DOI 10.4049/jimmunol.176.12.7636; Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42; Diaz YR, 2010, J INFECT DIS, V202, P406, DOI 10.1086/653829; Round JL, 2011, SCIENCE, V332, P974, DOI 10.1126/science.1206095; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Rowan AG, 2008, J IMMUNOL, V181, P4485, DOI 10.4049/jimmunol.181.7.4485; Rubtsov YP, 2010, SCIENCE, V329, P1667, DOI 10.1126/science.1191996; Ruckwardt TJ, 2009, J VIROL, V83, P3019, DOI 10.1128/JVI.00036-09; Rudensky AY, 2011, IMMUNOL REV, V241, P260, DOI 10.1111/j.1600-065X.2011.01018.x; Rueda CM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00216; Rutkowska A, 2018, NEUROPHARMACOLOGY, V133, P121, DOI 10.1016/j.neuropharm.2018.01.029; Sadeghi A, 2021, J CELL PHYSIOL, V236, P2829, DOI 10.1002/jcp.30047; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Samson M, 2012, ARTHRITIS RHEUM-US, V64, P2499, DOI 10.1002/art.34477; Sanders VJ, 1996, J NEUROVIROL, V2, P249, DOI 10.3109/13550289609146888; SCHEPPACH W, 1992, GASTROENTEROLOGY, V103, P51, DOI 10.1016/0016-5085(92)91094-K; Scher JU, 2011, NAT REV RHEUMATOL, V7, P569, DOI 10.1038/nrrheum.2011.121; Schmidleithner L, 2019, IMMUNITY, V50, P1232, DOI 10.1016/j.immuni.2019.03.014; Schmidt A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00051; Schneider A, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004970; Scholzen A, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000543; Schuler PJ, 2014, CLIN EXP IMMUNOL, V177, P531, DOI 10.1111/cei.12354; Scott-Browne JP, 2007, J EXP MED, V204, P2159, DOI 10.1084/jem.20062105; Sehrawat Sharvan, 2017, Front Immunol, V8, P341, DOI 10.3389/fimmu.2017.00341; Sena LA, 2013, IMMUNITY, V38, P225, DOI 10.1016/j.immuni.2012.10.020; Serafini B, 2004, BRAIN PATHOL, V14, P164, DOI 10.1111/j.1750-3639.2004.tb00049.x; Serafini B, 2007, J EXP MED, V204, P2899, DOI 10.1084/jem.20071030; Sereshgi MMA, 2019, MICROB PATHOGENESIS, V131, P135, DOI 10.1016/j.micpath.2019.03.029; Seth RB, 2006, CELL RES, V16, P141, DOI 10.1038/sj.cr.7310019; Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982; Sewell D, 2003, INT IMMUNOL, V15, P59, DOI 10.1093/intimm/dxg012; Shafiani S, 2013, IMMUNITY, V38, P1261, DOI 10.1016/j.immuni.2013.06.003; Shafiani S, 2010, J EXP MED, V207, P1409, DOI 10.1084/jem.20091885; Sharma A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00883; Sharma S, 2014, MICROBES INFECT, V16, P648, DOI 10.1016/j.micinf.2014.06.005; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Silva-Campa E, 2009, VIROLOGY, V387, P373, DOI 10.1016/j.virol.2009.02.033; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Smits HH, 2005, J ALLERGY CLIN IMMUN, V115, P1260, DOI 10.1016/j.jaci.2005.03.036; Soldan SS, 1997, NAT MED, V3, P1394, DOI 10.1038/nm1297-1394; Sotgiu S, 2010, MULT SCLER, V16, P1248, DOI 10.1177/1352458510376956; Sprouse ML, 2019, IMMUNOLOGY, V156, P305, DOI 10.1111/imm.13037; Sriram S, 2005, J NEUROL SCI, V234, P87, DOI 10.1016/j.jns.2005.03.042; Stoop JN, 2007, VIROLOGY, V361, P141, DOI 10.1016/j.virol.2006.11.018; Su WR, 2019, J IMMUNOL, V203, P1436, DOI 10.4049/jimmunol.1801306; Suchard MS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011762; Suffia I, 2005, J IMMUNOL, V174, P5444, DOI 10.4049/jimmunol.174.9.5444; Sugimoto K, 2003, HEPATOLOGY, V38, P1437, DOI 10.1016/j.hep.2003.09.026; Sun J, 2015, IMMUNITY, V43, P304, DOI 10.1016/j.immuni.2015.07.013; Suri-Payer E, 1998, J IMMUNOL, V160, P1212; Sutkowski N, 1996, J EXP MED, V184, P971, DOI 10.1084/jem.184.3.971; Suvas S, 2004, J IMMUNOL, V172, P4123, DOI 10.4049/jimmunol.172.7.4123; Suvas S, 2003, J EXP MED, V198, P889, DOI 10.1084/jem.20030171; Tai AK, 2009, J CLIN VIROL, V46, P47, DOI 10.1016/j.jcv.2009.05.019; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707; Tanasescu R, 2020, JAMA NEUROL, V77, P1089, DOI 10.1001/jamaneurol.2020.1118; Tankou SK, 2018, ANN NEUROL, V83, P1147, DOI 10.1002/ana.25244; Tanoue T, 2016, NAT REV IMMUNOL, V16, P295, DOI 10.1038/nri.2016.36; Tarlinton RE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060643; Taylor JJ, 2006, J IMMUNOL, V176, P5839, DOI 10.4049/jimmunol.176.10.5839; Tejada-Simon MV, 2003, ANN NEUROL, V53, P189, DOI 10.1002/ana.10425; Tengvall K, 2019, P NATL ACAD SCI USA, V116, P16955, DOI 10.1073/pnas.1902623116; Teratani T, 2020, NATURE, V585, P591, DOI 10.1038/s41586-020-2425-3; Tesmer LA, 2008, IMMUNOL REV, V223, P87, DOI 10.1111/j.1600-065X.2008.00628.x; Thacker EL, 2006, ANN NEUROL, V59, P499, DOI 10.1002/ana.20820; Thaiss CA, 2016, NATURE, V535, P65, DOI 10.1038/nature18847; Thornton AM, 2019, EUR J IMMUNOL, V49, P398, DOI 10.1002/eji.201847935; Thurnher M, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005970; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Toussirot Eric, 2012, Inflammation & Allergy Drug Targets, V11, P159; Tran DQ, 2012, J MOL CELL BIOL, V4, P29, DOI 10.1093/jmcb/mjr033; Trinath J, 2012, J INFECT DIS, V205, P694, DOI 10.1093/infdis/jir820; Trinschek B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077634; Turner MS, 2009, J IMMUNOL, V183, P4895, DOI 10.4049/jimmunol.0901459; Vahl JC, 2014, IMMUNITY, V41, P722, DOI 10.1016/j.immuni.2014.10.012; van der Windt GJW, 2012, IMMUNOL REV, V249, P27, DOI 10.1111/j.1600-065X.2012.01150.x; van der Windt GJW, 2012, IMMUNITY, V36, P68, DOI 10.1016/j.immuni.2011.12.007; van Noort JM, 2000, J NEUROIMMUNOL, V105, P46, DOI 10.1016/S0165-5728(00)00181-8; Venken K, 2008, J IMMUNOL, V180, P6411, DOI 10.4049/jimmunol.180.9.6411; Venken K, 2008, IMMUNOLOGY, V123, P79, DOI 10.1111/j.1365-2567.2007.02690.x; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; Voldsgaard A, 2015, MULT SCLER J, V21, P1723, DOI 10.1177/1352458514568173; Wagner NM, 2013, OBESITY, V21, P461, DOI 10.1002/oby.20087; Waickman AT, 2012, IMMUNOL REV, V249, P43, DOI 10.1111/j.1600-065X.2012.01152.x; Waisman A, 2018, J MOL MED, V96, P1279, DOI 10.1007/s00109-018-1709-7; Walsh KP, 2009, J IMMUNOL, V183, P1577, DOI 10.4049/jimmunol.0803803; Walsh PT, 2006, J INVEST DERMATOL, V126, P690, DOI 10.1038/sj.jid.5700121; Wan ZK, 2020, SCAND J IMMUNOL, V91, DOI 10.1111/sji.12873; Wang J, 2020, CELL, V183, P1264, DOI 10.1016/j.cell.2020.09.054; Wang RN, 2012, NAT IMMUNOL, V13, P907, DOI 10.1038/ni.2386; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Wanke F, 2017, CELL REP, V18, P1270, DOI 10.1016/j.celrep.2017.01.020; WARNER HB, 1981, LANCET, V2, P1290; Waschbisch A, 2010, J NEUROIMMUNOL, V225, P137, DOI 10.1016/j.jneuroim.2010.03.013; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Weinberg SE, 2019, NATURE, V565, P495, DOI 10.1038/s41586-018-0846-z; Weiss L, 2004, BLOOD, V104, P3249, DOI 10.1182/blood-2004-01-0365; Whibley N, 2019, NAT IMMUNOL, V20, P386, DOI 10.1038/s41590-019-0351-z; Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437; Wu B, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2020.106187; Wu D, 2019, EUR J IMMUNOL, V49, P336, DOI 10.1002/eji.201847570; Wu YC, 2020, J CHIN MED ASSOC, V83, P217, DOI 10.1097/JCMA.0000000000000270; Xia LY, 2019, CELL METAB, V29, P103, DOI 10.1016/j.cmet.2018.09.020; Xia MC, 2014, J ALLERGY CLIN IMMUN, V134, P634, DOI 10.1016/j.jaci.2014.03.010; Xie M, 2006, P NATL ACAD SCI USA, V103, P17378, DOI 10.1073/pnas.0604708103; Xu DM, 2003, J IMMUNOL, V170, P394, DOI 10.4049/jimmunol.170.1.394; Xu DP, 2006, J IMMUNOL, V177, P739, DOI 10.4049/jimmunol.177.1.739; Yamano Y, 2005, J CLIN INVEST, V115, P1361, DOI [10.1172/JCI200523913, 10.1172/JCI23913]; Yan YQ, 2021, IMMUNITY, V54, P499, DOI 10.1016/j.immuni.2021.02.002; Yang GL, 2007, INT IMMUNOL, V19, P133, DOI 10.1093/intimm/dxl130; Yang K, 2017, NATURE, V548, P602, DOI 10.1038/nature23665; Yang XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007; Yang Z, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7151; Ye Y, 2020, PATHOG DIS, V78, DOI 10.1093/femspd/ftaa038; Yordanova IA, 2021, LIFE-BASEL, V11, DOI 10.3390/life11020101; Yurchenko E, 2006, J EXP MED, V203, P2451, DOI 10.1084/jem.20060956; Zarrouk M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106710; Zelinskyy G, 2006, EUR J IMMUNOL, V36, P2658, DOI 10.1002/eji.200636059; Zelinskyy G, 2009, BLOOD, V114, P3199, DOI 10.1182/blood-2009-03-208736; Zeng H, 2013, NATURE, V499, P485, DOI 10.1038/nature12297; Zhang HY, 2015, CLIN EXP DERMATOL, V40, P182, DOI 10.1111/ced.12497; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774; Ziklo N, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3843-4; Zivadinov R, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000190; zur Wiesch JS, 2011, J VIROL, V85, P1287, DOI 10.1128/JVI.01758-10	438	1	1	4	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 7	2021	12								747143	10.3389/fimmu.2021.747143	http://dx.doi.org/10.3389/fimmu.2021.747143			29	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WM0MR	34691057	Green Published, gold			2022-12-18	WOS:000710789900001
J	Callejas, BE; Blyth, GAD; Jendzjowsky, N; Wang, AR; Babbar, A; Koro, K; Wilson, RJA; Kelly, MM; Cobo, ER; McKay, DM				Callejas, Blanca E.; Blyth, Graham A. D.; Jendzjowsky, Nicholas; Wang, Arthur; Babbar, Anshu; Koro, Konstantin; Wilson, Richard J. A.; Kelly, Margaret M.; Cobo, Eduardo R.; McKay, Derek M.			Interleukin-4 Programmed Macrophages Suppress Colitis and Do Not Enhance Infectious-Colitis, Inflammation-Associated Colon Cancer or Airway Hypersensitivity	FRONTIERS IN IMMUNOLOGY			English	Article						intestinal inflammation; macrophage-based therapy; colitis-associated colorectal cancer; Citrobacter rodentium; airway inflammation	ALTERNATIVELY ACTIVATED MACROPHAGES; REGULATORY T-CELLS; M2 MACROPHAGES; ADOPTIVE TRANSFER; DEFICIENT MICE; STROMAL CELLS; POLARIZATION; MODEL; PHAGOCYTOSIS; RESPONSES	The murine interleukin-4 treated macrophage (MIL4) exerts anti-inflammatory and pro-healing effects and has been shown to reduce the severity of chemical-induced colitis. Positing M(IL4) transfer as an anti-inflammatory therapy, the possibility of side-effects must be considered. Consequently, bone marrow-derived M(IL4)s were administered via intraperitoneal injection to mice concomitant with Citrobacter rodentium infection (infections colitis), azoxymethane/dextran sodium sulphate (AOM/DSS) treatment [a model of colorectal cancer (CRC)], or ovalbumin sensitization (airway inflammation). The impact of M(IL4) treatment on C. rodentium infectivity, colon histopathology, tumor number and size and tissue-specific inflammation was examined in these models. The anti-colitic effect of the M(IL4)s were confirmed in the di-nitrobenzene sulphonic acid model of colitis and the lumen-to-blood movement of 4kDa FITC-dextran and bacterial translocation to the spleen and liver was also improved by M(IL4) treatment. Analysis of the other models of disease, that represent comorbidities that can occur in human inflammatory bowel disease (IBD), revealed that M(IL4) treatment did not exaggerate the severity of any of the conditions. Rather, there was reduction in the size (but not number) of polyps in the colon of AOM/DSS-mice and reduced infectivity and inflammation in C. rodentium-infected mice in M(IL4)-treated mice. Thus, while any new therapy can have unforeseen side effects, our data confirm and extend the anti-colitic capacity of murine M(IL4)s and indicate that systemic delivery of one million M(IL4)s did not exaggerate disease in models of colonic or airways inflammation or colonic tumorigenesis.	[Callejas, Blanca E.; Wang, Arthur; McKay, Derek M.] Univ Calgary, Inflammat Res Network & Hostparasite Interact Grp, Cumming Sch Med,Calvin Phoebe & Joan Snyder Inst, Dept Physiol & Pharmacol,Gastrointestinal Res Grp, Calgary, AB, Canada; [Blyth, Graham A. D.] Univ Calgary, Univ Calgary & Prod Anim Hlth, Cumming Sch Med, Dept Microbiol Immunol & Infect Dis,Fac Vet Med, Calgary, AB, Canada; [Jendzjowsky, Nicholas] Univ Calgary, Hotchkiss Brain Inst, Cumming Sch Med, Dept Physiol & Pharmacol, Calgary, AB, Canada; [Babbar, Anshu; Cobo, Eduardo R.] Univ Calgary, Prod Anim Hlth, Fac Vet Med, Calgary, AB, Canada; [Koro, Konstantin; Kelly, Margaret M.] Univ Calgary, Calvin Phoebe & Joan Snyder Inst Chron Dis, Cumming Sch Med, Dept Pathol & Lab Med, Calgary, AB, Canada; [Kelly, Margaret M.] Univ Calgary, Cumming Sch Med, Alberta Childrens Hosp Res Inst, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary	McKay, DM (corresponding author), Univ Calgary, Inflammat Res Network & Hostparasite Interact Grp, Cumming Sch Med,Calvin Phoebe & Joan Snyder Inst, Dept Physiol & Pharmacol,Gastrointestinal Res Grp, Calgary, AB, Canada.	dmckay@ucalgary.ca	McKay, Derek/HCH-3240-2022; Kelly, Margaret M/G-4128-2012	Kelly, Margaret M/0000-0002-1629-3210; Wilson, Richard/0000-0001-9942-4775	Crohn's Colitis Canada; Alberta Innovates-Health Sciences Post-doctoral Fellowship; Francis Family Foundation; Discovery Grant from the Natural Sciences and Engineering Council of Canada (NSERC) [RGPAS-2017-507827]	Crohn's Colitis Canada; Alberta Innovates-Health Sciences Post-doctoral Fellowship; Francis Family Foundation; Discovery Grant from the Natural Sciences and Engineering Council of Canada (NSERC)	This work was supported by a Grant-in-Aid from Crohn's Colitis Canada to DM. BC is supported by an Alberta Innovates-Health Sciences Post-doctoral Fellowship. NJ is supported by the Francis Family Foundation as a Parker B Francis Fellow. Work from the Cobo laboratory is supported by a Discovery Grant from the Natural Sciences and Engineering Council of Canada (NSERC), RGPAS-2017-507827.	Bleriot C, 2020, IMMUNITY, V52, P957, DOI 10.1016/j.immuni.2020.05.014; Bosurgi L, 2017, SCIENCE, V356, P1072, DOI 10.1126/science.aai8132; Callejas BE, 2019, INT J CANCER, V145, P3126, DOI 10.1002/ijc.32626; Canavan JB, 2016, GUT, V65, P584, DOI 10.1136/gutjnl-2014-306919; Cao YT, 2017, DIGEST DIS SCI, V62, P851, DOI 10.1007/s10620-017-4453-x; Chassaing B, 2014, GUT, V63, P1069, DOI 10.1136/gutjnl-2013-304909; Chow MT, 2014, CANCER IMMUNOL RES, V2, P1125, DOI 10.1158/2326-6066.CIR-14-0160; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; da Silva ZEV, 2014, PATHOBIOLOGY, V81, P86, DOI 10.1159/000357306; Du QN, 2016, AM J PATHOL, V186, P3176, DOI 10.1016/j.ajpath.2016.08.012; Du YY, 2021, EXPERT OPIN THER TAR, V25, P191, DOI 10.1080/14728222.2021.1901079; Ford AQ, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-6; Girodet PO, 2016, AM J RESP CELL MOL, V55, P467, DOI 10.1165/rcmb.2015-0295OC; Gratchev A, 2005, SCAND J IMMUNOL, V61, P10, DOI 10.1111/j.0300-9475.2005.01524.x; Haribhai D, 2016, J IMMUNOL, V196, P3305, DOI 10.4049/jimmunol.1501956; Henderson NC, 2020, NATURE, V587, P555, DOI 10.1038/s41586-020-2938-9; Holani R, 2020, GUT MICROBES, V12, DOI 10.1080/19490976.2020.1785802; Huang YH, 2015, WORLD J GASTROENTERO, V21, P4216, DOI 10.3748/wjg.v21.i14.4216; Hunter MM, 2010, GASTROENTEROLOGY, V138, P1395, DOI 10.1053/j.gastro.2009.12.041; Hunter MM, 2005, J IMMUNOL, V174, P7368, DOI 10.4049/jimmunol.174.11.7368; Inagaki K, 2021, CANCER SCI, V112, P2692, DOI 10.1111/cas.14940; Jayme TS, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba4376; Jendzjowsky NG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06189-y; Jin XM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.698494; Jordakieva G, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1880687; Kamper P, 2011, HAEMATOL-HEMATOL J, V96, P269, DOI 10.3324/haematol.2010.031542; Kang SA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43057-1; Kim SY, 2019, IMMUNOL CELL BIOL, V97, P258, DOI 10.1111/imcb.12236; Kim YG, 2014, CELL HOST MICROBE, V15, P95, DOI 10.1016/j.chom.2013.12.010; Koroleva EP, 2015, J IMMUNOL METHODS, V421, P61, DOI 10.1016/j.jim.2015.02.003; Lee C, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0610-4; Leung G, 2015, MOL MED, V21, P924, DOI 10.2119/molmed.2015.00193; Leung G, 2013, AM J PHYSIOL-GASTR L, V304, pG781, DOI 10.1152/ajpgi.00055.2013; Lewis PS, 2020, J HEPATOL, V73, P349, DOI 10.1016/j.jhep.2020.02.031; Ma SF, 2015, BRAIN BEHAV IMMUN, V45, P157, DOI 10.1016/j.bbi.2014.11.007; Mcmillan SJ, 2004, CLIN EXP ALLERGY, V34, P497, DOI 10.1111/j.1365-2222.2004.01895.x; Melief SM, 2013, STEM CELLS, V31, P1980, DOI 10.1002/stem.1432; Mola S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186866; Moreira AP, 2010, J ALLERGY CLIN IMMUN, V126, P712, DOI 10.1016/j.jaci.2010.06.010; Moroni F, 2019, NAT MED, V25, P1560, DOI 10.1038/s41591-019-0599-8; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Parsa R, 2012, DIABETES, V61, P2881, DOI 10.2337/db11-1635; Pesce JT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000371; Podaru MN, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0742-1; Rizzo A, 2012, INFLAMM BOWEL DIS, V18, P449, DOI 10.1002/ibd.21799; Satyanarayanan SK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10903-9; Savage NDL, 2008, J IMMUNOL, V181, P2220, DOI 10.4049/jimmunol.181.3.2220; Schuster M, 2000, AM J RESP CRIT CARE, V161, P558, DOI 10.1164/ajrccm.161.2.9812021; Tanaka T, 2012, INT J INFLAMM, V2012, DOI 10.1155/2012/658786; Taveras NT, 2021, CUREUS, V13, DOI 10.7759/cureus.14216; Varin A, 2010, BLOOD, V115, P353, DOI 10.1182/blood-2009-08-236711; Wang A, 2014, AM J PATHOL, V184, P2516, DOI 10.1016/j.ajpath.2014.05.019; Wang HW, 2010, CELL CYCLE, V9, P4824, DOI 10.4161/cc.9.24.14322; Weisser SB, 2014, EUR J IMMUNOL, V44, P3353, DOI 10.1002/eji.201343981; Weng MQ, 2007, J IMMUNOL, V179, P4721, DOI 10.4049/jimmunol.179.7.4721; Wijnands AM, 2021, GASTROENTEROLOGY, V160, P1584, DOI 10.1053/j.gastro.2020.12.036; Zeldin DC, 2001, AM J RESP CELL MOL, V25, P457, DOI 10.1165/ajrcmb.25.4.4505; Zhang QZ, 2010, STEM CELLS, V28, P1856, DOI 10.1002/stem.503; Zhang XM, 2014, GLIA, V62, P804, DOI 10.1002/glia.22643	60	1	1	4	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 6	2021	12								744738	10.3389/fimmu.2021.744738	http://dx.doi.org/10.3389/fimmu.2021.744738			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WJ5YT	34691050	gold, Green Published			2022-12-18	WOS:000709121200001
J	Frau, J; Coghe, G; Lorefice, L; Fenu, G; Cocco, E				Frau, Jessica; Coghe, Giancarlo; Lorefice, Lorena; Fenu, Giuseppe; Cocco, Eleonora			Infections and Multiple Sclerosis: From the World to Sardinia, From Sardinia to the World	FRONTIERS IN IMMUNOLOGY			English	Review						multiple sclerosis; Epstein; Barr virus; human endogeneous retrovirus-W; mycobacterium avium subspecies paratuberculosis; infections; genetic; Sardinia (Italy)	EPSTEIN-BARR-VIRUS; AVIUM SUBSP PARATUBERCULOSIS; HUMAN ENDOGENOUS RETROVIRUSES; ENVIRONMENTAL RISK-FACTORS; HEAT-SHOCK PROTEINS; IMMUNE-RESPONSE; MOLECULAR MIMICRY; BASIC-PROTEIN; T-CELLS; AUTOIMMUNITY	Multiple Sclerosis (MS) is an inflammatory disease of the central nervous system. Sardinia, an Italian island, is one of the areas with the highest global prevalence of MS. Genetic factors have been widely explored to explain this greater prevalence among some populations; the genetic makeup of the Sardinians appears to make them more likely to develop autoimmune diseases. A strong association between MS and some infections have been reported globally. The most robust evidence indicating the role of infections is MS development concerns the Epstein-Barr virus (EBV). Anti-EBV antibodies in patients once infected by EBV are associated with the development of MS years later. These features have also been noted in Sardinian patients with MS. Many groups have found an increased expression of the Human endogenous retroviruses (HERV) family in patients with MS. A role in pathogenesis, prognosis, and prediction of treatment response has been proposed for HERV. A European multi-centre study has shown that their presence was variable among populations, ranging from 59% to 100% of patients, with higher HERV expression noted in Sardinian patients with MS. The mycobacterium avium subspecies paratuberculosis (MAP) DNA and antibodies against MAP2694 protein were found to be associated with MS in Sardinian patients. More recently, this association has also been reported in Japanese patients with MS. In this study, we analysed the role of infectious factors in Sardinian patients with MS and compared it with the findings reported in other populations.	[Frau, Jessica; Coghe, Giancarlo; Lorefice, Lorena; Fenu, Giuseppe; Cocco, Eleonora] Univ Cagliari, Azienda Tutela Salute ATS Sardegna, Multiple Sclerosis Ctr, Cagliari, Italy	University of Cagliari	Frau, J (corresponding author), Univ Cagliari, Azienda Tutela Salute ATS Sardegna, Multiple Sclerosis Ctr, Cagliari, Italy.	jessicafrauneuro@gmail.com	Cocco, Eleonora/G-5064-2012	Cocco, Eleonora/0000-0002-3878-8820				ADAMS JM, 1975, WESTERN J MED, V122, P380; Ariza ME, 2011, J INVEST DERMATOL, V131, P2419, DOI 10.1038/jid.2011.217; Arru G, 2020, J NEUROIMMUNOL, V338, DOI 10.1016/j.jneuroim.2019.577110; Arru G, 2014, MULT SCLER J, V20, P174, DOI 10.1177/1352458513494957; Arru Giannina, 2007, Int J Biomed Sci, V3, P292; Ascherio A, 2007, ANN NEUROL, V61, P504, DOI 10.1002/ana.21141; Ascherio A, 2007, ANN NEUROL, V61, P288, DOI 10.1002/ana.21117; Bellamy R, 2003, GENES IMMUN, V4, P4, DOI 10.1038/sj.gene.6363915; Brettschneider J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007638; Brudek T, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-104; Cocco E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059790; Cocco E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033972; Comabella M, 2012, MULT SCLER J, V18, P605, DOI 10.1177/1352458511426816; Coppotelli G, 2013, NUCLEIC ACIDS RES, V41, P2950, DOI 10.1093/nar/gkt032; Cossu D, 2013, J NEUROL SCI, V335, P131, DOI 10.1016/j.jns.2013.09.011; Cossu D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03370-z; Cossu D, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00216; Cossu D, 2016, SCI REP-UK, V6, DOI 10.1038/srep29227; Cossu D, 2015, MULT SCLER J, V21, P984, DOI 10.1177/1352458514557304; Cossu D, 2014, J NEUROL SCI, V347, P78, DOI 10.1016/j.jns.2014.09.023; Cossu D, 2013, J INFECT DEV COUNTR, V7, P203, DOI 10.3855/jidc.2737; Cossu D, 2012, MULT SCLER J, V18, P1181, DOI 10.1177/1352458511433430; Cossu D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018482; Cusick MF, 2013, CURR OPIN RHEUMATOL, V25, P496, DOI 10.1097/BOR.0b013e328362004d; de Villiers JNP, 2006, METAB BRAIN DIS, V21, P163, DOI 10.1007/s11011-006-9016-3; Dolei A, 2002, NEUROLOGY, V58, P471, DOI 10.1212/WNL.58.3.471; Dolei A, 2018, MULT SCLER J, V24, P42, DOI 10.1177/1352458517737370; Dolei A, 2009, J NEUROVIROL, V15, P4, DOI 10.1080/13550280802448451; Donati Donatella, 2020, Drug Discov Today Dis Models, V32, P27, DOI 10.1016/j.ddmod.2020.02.003; DUKE RC, 1989, J EXP MED, V170, P59, DOI 10.1084/jem.170.1.59; FERRANTE P, 1987, ITAL J NEUROL SCI, P45; Frau J, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0669-1; Frau J, 2013, MULT SCLER J, V19, P1437, DOI 10.1177/1352458513477926; Frau J, 2015, J NEUROL SCI, V349, P249, DOI 10.1016/j.jns.2015.01.004; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; Garcia-Montojo M, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-2; Garson JA, 1998, LANCET, V351, P33, DOI 10.1016/S0140-6736(98)24001-3; Geginat J, 2017, TRENDS IMMUNOL, V38, P498, DOI 10.1016/j.it.2017.04.006; Grandi N, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9070162; Handel AE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012496; Houen G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.587078; Jarius S, 2017, J NEUROL, V264, P453, DOI 10.1007/s00415-016-8360-4; Jog NR, 2020, J AUTOIMMUN, V106, DOI 10.1016/j.jaut.2019.102332; Kleinewietfeld M, 2013, SEMIN IMMUNOL, V25, P305, DOI 10.1016/j.smim.2013.10.009; Kremer D, 2015, MULT SCLER J, V21, P1200, DOI 10.1177/1352458514560926; Kremer D, 2013, ANN NEUROL, V74, P721, DOI 10.1002/ana.23970; Kucukali CI, 2015, NEUROMOL MED, V17, P83, DOI 10.1007/s12017-014-8298-6; Kumar A, 2015, NEW J CHEM, V39, P1355, DOI 10.1039/c4nj01903b; KURTZKE JF, 1975, ACTA NEUROL SCAND, V51, P110; Lassmann H, 2011, BRAIN, V134, P2772, DOI 10.1093/brain/awr197; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; Mameli G, 2016, EUR J NEUROL, V23, P140, DOI 10.1111/ene.12821; Mameli G, 2008, J NEUROVIROL, V14, P73, DOI 10.1080/13550280701801107; Mameli G, 2016, SCI REP-UK, V6, DOI 10.1038/srep22401; Mameli G, 2014, J NEUROIMMUNOL, V270, P51, DOI 10.1016/j.jneuroim.2014.02.013; Mameli G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078474; Mameli G, 2013, J NEUROIMMUNOL, V264, P120, DOI 10.1016/j.jneuroim.2013.07.017; Mameli G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044991; Morandi E, 2017, MULT SCLER J, V23, P1050, DOI 10.1177/1352458517704711; Morris G, 2019, MOL NEUROBIOL, V56, P2590, DOI 10.1007/s12035-018-1255-x; Munger KL, 2011, MULT SCLER J, V17, P1185, DOI 10.1177/1352458511408991; Niedobitek G, 2001, INT J EXP PATHOL, V82, P149, DOI 10.1111/j.1365-2613.2001.iep190.x; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; Pakpoor J, 2013, MULT SCLER J, V19, P1690, DOI 10.1177/1352458513506505; Paroni M, 2017, J ALLERGY CLIN IMMUN, V140, P797, DOI 10.1016/j.jaci.2016.11.045; Pender MP, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.25; Pormohammad A, 2018, J CELL PHYSIOL, V233, P2850, DOI 10.1002/jcp.26000; Ricigliano VAG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119605; Saito T, 2017, CIRCULATION, V136, P1920, DOI 10.1161/CIRCULATIONAHA.117.027589; Salvetti M, 1996, J NEUROIMMUNOL, V65, P143, DOI 10.1016/0165-5728(96)00013-6; SALVETTI M, 1992, J AUTOIMMUN, V5, P691, DOI 10.1016/0896-8411(92)90186-T; Serra C, 2001, NEUROL SCI, V22, P171, DOI 10.1007/s100720170019; Shannon-Lowe C, 2014, CURR OPIN VIROL, V4, P78, DOI 10.1016/j.coviro.2013.12.001; Sidore C, 2021, MULT SCLER J, V27, P1332, DOI 10.1177/1352458520963937; Slavin YN, 2018, J NEUROIMMUNOL, V323, P49, DOI 10.1016/j.jneuroim.2018.07.007; Sotgiu S, 2006, MULT SCLER J, V12, P357, DOI 10.1191/135248506ms1303sr; Sotgiu S, 2002, NEUROLOGY, V59, P1071, DOI 10.1212/WNL.59.7.1071; Steri M, 2017, NEW ENGL J MED, V376, P1615, DOI 10.1056/NEJMoa1610528; Tarlinton RE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060643; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; Yokoyama K, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120522; Zhao B, 2011, P NATL ACAD SCI USA, V108, P14902, DOI 10.1073/pnas.1108892108; Zivadinov R, 2019, MULT SCLER RELAT DIS, V36, DOI 10.1016/j.msard.2019.101388	83	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 6	2021	12								728677	10.3389/fimmu.2021.728677	http://dx.doi.org/10.3389/fimmu.2021.728677			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WL0JP	34691035	gold, Green Published			2022-12-18	WOS:000710103000001
J	Wu, XD; Zhang, YT; Wang, MS; Chen, S; Liu, MF; Zhu, DK; Zhao, XX; Wu, Y; Yang, Q; Zhang, SQ; Huang, J; Ou, XM; Zhang, L; Liu, YY; Yu, YL; Gao, Q; Mao, S; Sun, D; Tian, B; Yin, ZQ; Jing, B; Cheng, AC; Jia, RY				Wu, Xuedong; Zhang, Yuetian; Wang, Mingshu; Chen, Shun; Liu, Mafeng; Zhu, Dekang; Zhao, Xinxin; Wu, Ying; Yang, Qiao; Zhang, Shaqiu; Huang, Juan; Ou, Xumin; Zhang, Ling; Liu, Yunya; Yu, Yanling; Gao, Qun; Mao, Sai; Sun, Di; Tian, Bin; Yin, Zhongqiong; Jing, Bo; Cheng, Anchun; Jia, Renyong			Methyltransferase-Deficient Avian Flaviviruses Are Attenuated Due to Suppression of Viral RNA Translation and Induction of a Higher Innate Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						Tembusu virus; methyltransferase; attenuated; translation; innate immunity	TEMBUSU VIRUS; RECOGNITION; 2'-O-METHYLATION; METHYLATION; INHIBITION; PROVIDES; PLATFORM; SELF	The 5' end of the flavivirus genome contains a type 1 cap structure formed by sequential N-7 and 2'-O methylations by viral methyltransferase (MTase). Cap methylation of flavivirus genome is an essential structural modification to ensure the normal proliferation of the virus. Tembusu virus (TMUV) (genus Flavivirus) is a causative agent of duck egg drop syndrome and has zoonotic potential. Here, we identified the in vitro activity of TMUV MTase and determined the effect of K61-D146-K182-E218 enzymatic tetrad on N-7 and 2'-O methylation. The entire K61-D146-K182-E218 motif is essential for 2'-O MTase activity, whereas N-7 MTase activity requires only D146. To investigate its phenotype, the single point mutation (K61A, D146A, K182A or E218A) was introduced into TMUV replicon (pCMV-Rep-NanoLuc) and TMUV infectious cDNA clone (pACYC-TMUV). K-D-K-E mutations reduced the replication ability of replicon. K61A, K182A and E218A viruses were genetically stable, whereas D146A virus was unstable and reverted to WT virus. Mutant viruses were replication and virulence impaired, showing reduced growth and attenuated cytopathic effects and reduced mortality of duck embryos. Molecular mechanism studies showed that the translation efficiency of mutant viruses was inhibited and a higher host innate immunity was induced. Furthermore, we found that the translation inhibition of MTase-deficient viruses was caused by a defect in N-7 methylation, whereas the absence of 2'-O methylation did not affect viral translation. Taken together, our data validate the debilitating mechanism of MTase-deficient avian flavivirus and reveal an important role for cap-methylation in viral translation, proliferation, and escape from innate immunity.	[Wu, Xuedong; Zhang, Yuetian; Wang, Mingshu; Chen, Shun; Liu, Mafeng; Zhu, Dekang; Zhao, Xinxin; Wu, Ying; Yang, Qiao; Zhang, Shaqiu; Huang, Juan; Ou, Xumin; Zhang, Ling; Liu, Yunya; Yu, Yanling; Gao, Qun; Mao, Sai; Sun, Di; Tian, Bin; Cheng, Anchun; Jia, Renyong] Sichuan Agr Univ, Coll Vet Med, Res Ctr Avian Dis, Chengdu, Peoples R China; [Wu, Xuedong; Zhang, Yuetian; Wang, Mingshu; Chen, Shun; Liu, Mafeng; Zhu, Dekang; Zhao, Xinxin; Wu, Ying; Yang, Qiao; Zhang, Shaqiu; Huang, Juan; Ou, Xumin; Zhang, Ling; Liu, Yunya; Yu, Yanling; Gao, Qun; Mao, Sai; Sun, Di; Tian, Bin; Cheng, Anchun; Jia, Renyong] Sichuan Agr Univ, Inst Prevent Vet Med, Chengdu, Peoples R China; [Wang, Mingshu; Chen, Shun; Liu, Mafeng; Zhu, Dekang; Zhao, Xinxin; Wu, Ying; Yang, Qiao; Zhang, Shaqiu; Huang, Juan; Ou, Xumin; Yin, Zhongqiong; Jing, Bo; Cheng, Anchun; Jia, Renyong] Sichuan Agr Univ, Key Lab Anim Dis & Human Hlth Sichuan Prov, Chengdu, Peoples R China	Sichuan Agricultural University; Sichuan Agricultural University; Key Laboratory of Animal Disease & Human Health of Sichuan Province; Sichuan Agricultural University	Cheng, AC; Jia, RY (corresponding author), Sichuan Agr Univ, Coll Vet Med, Res Ctr Avian Dis, Chengdu, Peoples R China.; Cheng, AC; Jia, RY (corresponding author), Sichuan Agr Univ, Inst Prevent Vet Med, Chengdu, Peoples R China.; Cheng, AC; Jia, RY (corresponding author), Sichuan Agr Univ, Key Lab Anim Dis & Human Hlth Sichuan Prov, Chengdu, Peoples R China.	chenganchun@vip.163.com; jiary@sicau.edu.cn	Yu, Yan/GYV-4514-2022		National Natural Science Foundation of China [31872475]; Sichuan Veterinary Medicine and Drug Innovation Group of China Agricultural Research System (CARS-SVDIP); China Agricultural Research System [CARS-42-17]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sichuan Veterinary Medicine and Drug Innovation Group of China Agricultural Research System (CARS-SVDIP); China Agricultural Research System	This work was supported by the National Natural Science Foundation of China (31872475), Sichuan Veterinary Medicine and Drug Innovation Group of China Agricultural Research System (CARS-SVDIP), and China Agricultural Research System (CARS-42-17).	Abbas YM, 2017, P NATL ACAD SCI USA, V114, pE2106, DOI 10.1073/pnas.1612444114; Ahmed-Belkacem R, 2020, EUR J MED CHEM, V201, DOI 10.1016/j.ejmech.2020.112557; Bradrick SS, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02374; Cao ZZ, 2011, EMERG INFECT DIS, V17, P1873, DOI 10.3201/eid1710.101890; Chang DC, 2016, VIROLOGY, V499, P259, DOI 10.1016/j.virol.2016.09.022; Chen H, 2013, ANTIVIR RES, V97, P232, DOI 10.1016/j.antiviral.2012.12.012; Chen S, 2018, ANTIVIR RES, V157, P120, DOI 10.1016/j.antiviral.2018.06.016; Coloma J, 2016, CELL REP, V16, P3097, DOI 10.1016/j.celrep.2016.08.091; Daffis S, 2010, NATURE, V468, P452, DOI 10.1038/nature09489; Decroly E, 2012, NAT REV MICROBIOL, V10, P51, DOI 10.1038/nrmicro2675; Devarkar SC, 2016, P NATL ACAD SCI USA, V113, P596, DOI 10.1073/pnas.1515152113; Dong HP, 2014, J GEN VIROL, V95, P763, DOI 10.1099/vir.0.062208-0; Dong HP, 2010, VIROLOGY, V405, P568, DOI 10.1016/j.virol.2010.06.039; Edgil D, 2006, J VIROL, V80, P2976, DOI 10.1128/JVI.80.6.2976-2986.2006; Garcia-Blanco MA, 2016, ANTIVIR RES, V134, P244, DOI 10.1016/j.antiviral.2016.09.010; Ghosh A, 2010, WIRES RNA, V1, P152, DOI 10.1002/wrna.19; Gillespie LK, 2010, J VIROL, V84, P10438, DOI 10.1128/JVI.00986-10; Habjan M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003663; He Y, 2019, VIROLOGY, V533, P86, DOI 10.1016/j.virol.2019.05.003; Kaiser JA, 2019, VACCINE, V37, P7155, DOI 10.1016/j.vaccine.2019.09.045; Katibah GE, 2014, P NATL ACAD SCI USA, V111, P12025, DOI 10.1073/pnas.1412842111; Klema VJ, 2015, VIRUSES-BASEL, V7, P4640, DOI 10.3390/v7082837; Li SH, 2013, J VIROL, V87, P5812, DOI 10.1128/JVI.02806-12; Liu PP, 2013, SCI CHINA LIFE SCI, V56, P701, DOI 10.1007/s11427-013-4515-z; Pulmanausahakul R, 2022, TRANSBOUND EMERG DIS, V69, P870, DOI 10.1111/tbed.13998; Ray D, 2006, J VIROL, V80, P8362, DOI 10.1128/JVI.00814-06; Ren XM, 2019, CELL REP, V26, P2019, DOI 10.1016/j.celrep.2019.01.107; Schuberth-Wagner C, 2015, IMMUNITY, V43, P41, DOI 10.1016/j.immuni.2015.06.015; Song YT, 2019, MBIO, V10, DOI [10.1128/mBio.00459-19, 10.1128/mbio.00459-19]; Tang Y, 2013, TRANSBOUND EMERG DIS, V60, P193, DOI 10.1111/tbed.12085; Wang T, 2020, J VIROL, V94, DOI 10.1128/JVI.00906-20; Xie XP, 2016, EBIOMEDICINE, V12, P156, DOI 10.1016/j.ebiom.2016.09.013; Yang YJ, 2017, EBIOMEDICINE, V17, P145, DOI 10.1016/j.ebiom.2017.02.003; Yao XG, 2018, EUR J PHARMACOL, V821, P11, DOI 10.1016/j.ejphar.2017.12.029; Yap LJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012836; Yu GL, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090485; Zhang W, 2017, J GEN VIROL, V98, P2413, DOI 10.1099/jgv.0.000908; Zhao YQ, 2015, P NATL ACAD SCI USA, V112, P14834, DOI 10.1073/pnas.1514978112; Zhou YS, 2007, J VIROL, V81, P3891, DOI 10.1128/JVI.02704-06; Zhu KS, 2015, ARCH VIROL, V160, P2781, DOI 10.1007/s00705-015-2513-0; Zust R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003521; Zust R, 2011, NAT IMMUNOL, V12, P137, DOI 10.1038/ni.1979	42	1	1	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 6	2021	12								751688	10.3389/fimmu.2021.751688	http://dx.doi.org/10.3389/fimmu.2021.751688			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WL1DX	34691066	Green Published, gold			2022-12-18	WOS:000710155800001
J	Bason, C; Barbieri, A; Martinelli, N; Olivieri, B; Argentino, G; Bartoloni, E; Beri, R; Jadav, G; Puccetti, A; Tinazzi, E; Lunardi, C				Bason, Caterina; Barbieri, Alessandro; Martinelli, Nicola; Olivieri, Bianca; Argentino, Giuseppe; Bartoloni, Elena; Beri, Ruggero; Jadav, Gnaneshwer; Puccetti, Antonio; Tinazzi, Elisa; Lunardi, Claudio			Identification of a Novel Serological Marker in Seronegative Rheumatoid Arthritis Using the Peptide Library Approach	FRONTIERS IN IMMUNOLOGY			English	Article						peptide library approach; RA-peptide; seronegative rheumatoid arthritis; autoantibodies; autoantigen targets	CITRULLINATED PROTEIN ANTIBODIES; RHEUMATOLOGY/EUROPEAN LEAGUE; CLASSIFICATION CRITERIA; SYSTEMIC-SCLEROSIS; AMERICAN-COLLEGE; INNER-EAR; AUTOANTIBODIES; LIPRIN-ALPHA-1; ACTIVATION; AUTOIMMUNITY	Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation mainly affecting the joints leading to cartilage and bone destruction. The definition of seropositive or seronegative RA is based on the presence or absence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPAs). Other autoantibodies have been identified in the last decade such as antibodies directed against carbamylated antigens, peptidyl-arginine deiminase type 4 and v-Raf murine sarcoma viral oncogene homologue B. In order to identify relevant autoantigens, we screened a random peptide library (RPL) with pooled IgGs obtained from 50 patients with seronegative RA. Patients' sera were then used in an ELISA test to identify the most frequently recognized peptide among those obtained by screening the RPL. Sera from age- and sex-matched healthy subjects were used as controls. We identified a specific peptide (RA-peptide) recognized by RA patients' sera, but not by healthy subjects or by patients with other immune-mediated diseases. The majority of sera from seronegative and seropositive RA patients (73.8% and 63.6% respectively) contained IgG antibodies directed against the RA-peptide. Interestingly, this peptide shares homology with some self-antigens, such as Protein-tyrosine kinase 2 beta, B cell scaffold protein, Liprin-alfa1 and Cytotoxic T lymphocyte protein 4. Affinity purified anti-RA-peptide antibodies were able to cross react with these autoantigens. In conclusion, we identified a peptide that is recognized by seropositive and, most importantly, by seronegative RA patients' sera, but not by healthy subjects, conferring to this epitope a high degree of specificity. This peptide shares also homology with other autoantigens which can be recognized by autoantibodies present in seronegative RA sera. These newly identified autoantibodies, although present also in a percentage of seropositive RA patients, may be considered as novel serum biomarkers for seronegative RA, which lacks the presence of RF and/or ACPAs.</p>	[Bason, Caterina; Martinelli, Nicola; Olivieri, Bianca; Argentino, Giuseppe; Beri, Ruggero; Jadav, Gnaneshwer; Tinazzi, Elisa; Lunardi, Claudio] Univ Verona, Dept Med, Verona, Italy; [Barbieri, Alessandro] Harvard Med Sch, Boston Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA; [Bartoloni, Elena] Univ Perugia, Dept Med, Div Rheumatol, Perugia, Italy; [Puccetti, Antonio] Univ Genoa, Dept Expt Med, Sect Histol, Genoa, Italy	University of Verona; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Perugia; University of Genoa	Bason, C (corresponding author), Univ Verona, Dept Med, Verona, Italy.; Barbieri, A (corresponding author), Harvard Med Sch, Boston Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA.	caterina.bason@univr.it; alessandro.barbieri@childrens.harvard.edu		Olivieri, Bianca/0000-0003-1690-6774; Argentino, Giuseppe/0000-0002-4747-4655	University of Verona; FIRB [RBFR10A0G1]	University of Verona; FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB))	This research was partially supported by a grant from the University of Verona (CL) and by FIRB (Futuro in Ricerca-Bando Giovani) 2010, project number RBFR10A0G1 (ET)	Aiba Y, 2006, IMMUNITY, V24, P259, DOI 10.1016/j.immuni.2006.01.002; Ajeganova S, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-210892; Alessandri C, 2015, CLIN EXP RHEUMATOL, V33, P824; Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584; Alexiou I, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-37; Alkaissi H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199979; Anolik JH, 2009, IMMUNOL RES, V45, P144, DOI 10.1007/s12026-009-8096-7; Asperti C, 2010, EXP CELL RES, V316, P915, DOI 10.1016/j.yexcr.2010.01.017; Asperti C, 2009, J CELL SCI, V122, P3225, DOI 10.1242/jcs.054155; Auger I, 2012, AUTOIMMUN REV, V11, P801, DOI 10.1016/j.autrev.2012.02.009; Avouac J, 2006, ANN RHEUM DIS, V65, P845, DOI 10.1136/ard.2006.051391; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Bason C, 2017, LUPUS, V26, P835, DOI 10.1177/0961203316682099; Bason C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057729; Bauer S, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2080; Bell DA, 2017, CLIN EXP RHEUMATOL, V35, P948; Bernal-Quiros M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059842; Berti E, 2013, AUTOIMMUNITY, V46, P525, DOI 10.3109/08916934.2013.822074; Bukhari M, 2007, ARTHRITIS RHEUM-US, V56, P2929, DOI 10.1002/art.22868; Cantaert T, 2013, RHEUMATOLOGY, V52, P252, DOI 10.1093/rheumatology/kes247; Choi ST, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195550; Colasanti T, 2020, J AUTOIMMUN, V113, DOI 10.1016/j.jaut.2020.102470; de Curtis I, 2011, EXP CELL RES, V317, P1, DOI 10.1016/j.yexcr.2010.09.014; Gibofsky Allan, 2012, Am J Manag Care, V18, pS295; Greiner A, 2005, ANN NY ACAD SCI, V1050, P295, DOI 10.1196/annals.1313.031; Hall JE, 2011, INT REV CEL MOL BIO, V288, P185, DOI 10.1016/B978-0-12-386041-5.00005-4; Harris ML, 2008, ARTHRITIS RHEUM-US, V58, P1958, DOI 10.1002/art.23596; Jilani AA, 2015, INT J RHEUMATOL, V2015, DOI 10.1155/2015/728610; Kastbom A, 2016, ANN RHEUM DIS, V75, P356, DOI 10.1136/annrheumdis-2014-205698; Klein K, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4074; Kokkonen H, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3237; Korb-Pap A, 2016, RHEUMATOLOGY, V55, P64, DOI 10.1093/rheumatology/kew347; Lefevre S, 2009, NAT MED, V15, P1414, DOI 10.1038/nm.2050; Lunardi C, 2002, LANCET, V360, P915, DOI 10.1016/S0140-6736(02)11028-2; Lunardi C, 2000, NAT MED, V6, P1183, DOI 10.1038/80533; Machold KP, 2007, RHEUMATOLOGY, V46, P342, DOI 10.1093/rheumatology/kel237; Martinez-Prat L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01113; Mease P, 2013, CURR OPIN RHEUMATOL, V25, P287, DOI 10.1097/BOR.0b013e32835fd8d5; Michelutti A, 2011, MOL MED, V17, P901, DOI 10.2119/molmed.2011.00034; Monti S, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen-2015-000057; Nachat R, 2009, J CELL SCI, V122, P4035, DOI 10.1242/jcs.047266; Ostergaard HL, 2005, IMMUNOL RES, V31, P267, DOI 10.1385/IR:31:3:267; Palanichamy A, 2008, ARTHRITIS RHEUM-US, V58, P3665, DOI 10.1002/art.24141; Pehkonen H, 2016, SCI REP-UK, V6, DOI 10.1038/srep24486; Pfaff M, 2001, J CELL SCI, V114, P2775; Raychaudhuri SP, 2014, J AUTOIMMUN, V48-49, P128, DOI 10.1016/j.jaut.2014.01.015; Rocha SD, 2019, ADV RHEUMATOL, V59, DOI 10.1186/s42358-018-0042-8; Sakkas LI, 2014, AUTOIMMUN REV, V13, P1114, DOI 10.1016/j.autrev.2014.08.012; Seano G, 2014, NAT CELL BIOL, V16, P931, DOI 10.1038/ncb3036; Shelef MA, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0464-6; Shi J, 2013, ARTHRITIS RHEUM-US, V65, P911, DOI 10.1002/art.37830; Shi J, 2011, P NATL ACAD SCI USA, V108, P17372, DOI 10.1073/pnas.1114465108; Sokolove J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035296; Somers K, 2011, J AUTOIMMUN, V36, P33, DOI 10.1016/j.jaut.2010.10.003; Spinardi L, 2006, EUR J CELL BIOL, V85, P191, DOI 10.1016/j.ejcb.2005.08.005; Trouw LA, 2017, NAT REV RHEUMATOL, V13, P331, DOI 10.1038/nrrheum.2017.15; van Delft MAM, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2019.102392; van den Hoogen F, 2013, ANN RHEUM DIS, V72, P1747, DOI [10.1136/annrheumdis-2013-204424, 10.1002/art.38098]; Vander Cruyssen B, 2005, AUTOIMMUN REV, V4, P468, DOI 10.1016/j.autrev.2005.04.018; Vital EM, 2008, J AUTOIMMUN, V31, P219, DOI 10.1016/j.jaut.2008.04.006; Wang MY, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-141; Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036; Wei ZY, 2011, MOL CELL, V43, P586, DOI 10.1016/j.molcel.2011.07.021; Yang J, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-017-1503-x; Zhu XD, 2018, CANCERS, V10, DOI 10.3390/cancers10050139	65	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 5	2021	12								753400	10.3389/fimmu.2021.753400	http://dx.doi.org/10.3389/fimmu.2021.753400			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WK8RW	34675934	gold, Green Published			2022-12-18	WOS:000709989300001
J	Chen, C; Zhou, YX; Zhang, XY; Wang, YH; He, LN; Lin, ZA; Chen, T; Jiang, YL; Hong, SD; Zhang, L				Chen, Chen; Zhou, Yixin; Zhang, Xuanye; Wang, Yuhong; He, Li-na; Lin, Zuan; Chen, Tao; Jiang, Yongluo; Hong, Shaodong; Zhang, Li			Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						reporting quality; clinical trials; immune checkpoint inhibitor; immune therapy; cancer; evaluating	CHALLENGES; NIVOLUMAB; PSEUDOPROGRESSION; IMMUNOTHERAPY; OPPORTUNITIES; GUIDELINES; DESIGN	Background More and more immune-oncology trials have been conducted for treating various cancers, yet it is unclear what the reporting quality of immune-oncology trials is,and characteristics associated with higher reporting quality. Objective This study aims to evaluate the reporting quality of immune-oncology trials. Methods The PubMed and Cochrane library were searched to identify all English publications of clinical trials assessing immunotherapy for cancer. Reporting quality of immune-oncology trials was evaluated by a quality score with 11 points derived from the Trial Reporting in Immuno-Oncology (TRIO) statement, which contained two parts: an efficacy score of 6 points and toxicity score of 5 point. Linear regression was used to identify characteristics associated with higher scores. Results Of the 10,169 studies screened, 298 immune-oncology trial reports were enrolled. The mean quality score, efficacy score, and toxicity score were 6.46, 3.61, and 2.85, respectively. The most common well-reported items were response evaluation criteria (96.0%) and toxicity grade (98.7%), followed by Kaplan-Meier survival analyses (80.5%). Treatment details beyond progression (12.8%) and toxicity onset time and duration (7.7%) were poorly reported. Multivariate regression revealed that higher impact factor (IF) (IF >20 vs. IF <5, p < 0.001), specific tumor type (p = 0.018 for lung, p = 0.021 for urinary system, vs. pan cancer), and a certain kind of immune checkpoint blocking agent (p < 0.001 for anti-PD-1 or multiagents, vs. anti-CTLA-4) were independent predictors of higher-quality score. Similar independent predictive characteristics were revealed for high-efficacy score. Only IF >20 had a significant high-toxicity score (p < 0.001). Conclusion Immune-oncology trial reports presented an unsatisfied quality score, especially in the reporting of treatment details beyond progression and toxicity onset time and duration. High IF journals have better reporting quality. Future improvement of trial reporting was warranted to the benefit-risk assessment of immunotherapy.	[Chen, Chen] Sun Yat Sen Univ, Dept Radiat Oncol, Canc Ctr, Guangzhou, Peoples R China; [Chen, Chen; Zhou, Yixin; Zhang, Xuanye; Wang, Yuhong; He, Li-na; Lin, Zuan; Chen, Tao; Jiang, Yongluo; Hong, Shaodong; Zhang, Li] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangdong Key Lab Nasopharyrgeal Carcinoma Diag &, Guangzhou, Peoples R China; [Zhou, Yixin] Sun Yat Sen Univ, Dept Very Important Person VIP Reg, Canc Ctr, Guangzhou, Peoples R China; [Zhang, Xuanye; He, Li-na; Hong, Shaodong; Zhang, Li] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China; [Wang, Yuhong] Sun Yat Sen Univ, Dept Endoscopy, Canc Ctr, Guangzhou, Peoples R China; [Lin, Zuan] Sun Yat Sen Univ, Dept Clin Res, Canc Ctr, Guangzhou, Peoples R China; [Chen, Tao; Jiang, Yongluo] Sun Yat Sen Univ, Dept Nucl Med, Canc Ctr, Guangzhou, Peoples R China	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Hong, SD; Zhang, L (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangdong Key Lab Nasopharyrgeal Carcinoma Diag &, Guangzhou, Peoples R China.; Hong, SD; Zhang, L (corresponding author), Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China.	hongshd@sysucc.org.cn; zhangli6@mail.sysu.edu.cn	Wang, Yu/GZL-9655-2022					Anagnostou V, 2017, CLIN CANCER RES, V23, P4959, DOI 10.1158/1078-0432.CCR-16-3065; Baik CS, 2017, CLIN CANCER RES, V23, P4992, DOI 10.1158/1078-0432.CCR-16-3066; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Chiou VL, 2015, J CLIN ONCOL, V33, P3541, DOI 10.1200/JCO.2015.61.6870; Emens LA, 2017, EUR J CANCER, V81, P116, DOI 10.1016/j.ejca.2017.01.035; Hargadon KM, 2018, INT IMMUNOPHARMACOL, V62, P29, DOI 10.1016/j.intimp.2018.06.001; Hodi FS, 2018, J CLIN ONCOL, V36, P850, DOI 10.1200/JCO.2017.75.1644; Peron J, 2013, J CLIN ONCOL, V31, P3957, DOI 10.1200/JCO.2013.49.3981; Peron J, 2012, JNCI-J NATL CANCER I, V104, P982, DOI 10.1093/jnci/djs259; Reckamp KL, 2018, J THORAC ONCOL, V13, P880, DOI 10.1016/j.jtho.2018.05.011; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Sadreddini S, 2019, J CELL PHYSIOL, V234, P8541, DOI 10.1002/jcp.27816; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; Sharon E, 2014, CHIN J CANCER, V33, P434, DOI 10.5732/cjc.014.10122; Siu LL, 2017, CLIN CANCER RES, V23, P4950, DOI 10.1158/1078-0432.CCR-16-3079; Sznol M, 2017, J CLIN ONCOL, V35, P3815, DOI 10.1200/JCO.2016.72.1167; Tardy MP, 2018, ONCOLOGIST, V23, P337, DOI 10.1634/theoncologist.2017-0196; Tsimberidou AM, 2019, J CLIN ONCOL, V37, P72, DOI 10.1200/JCO.18.00145; Tsimberidou AM, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0426-7; Weber JS, 2017, J CLIN ONCOL, V35, P785, DOI 10.1200/JCO.2015.66.1389	22	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 5	2021	12								736943	10.3389/fimmu.2021.736943	http://dx.doi.org/10.3389/fimmu.2021.736943			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WI5TW	34675926	gold, Green Published			2022-12-18	WOS:000708423500001
J	Gan, ZD; Zhang, MY; Xie, DH; Wu, XY; Hong, CM; Fu, J; Fan, LJ; Wang, SY; Han, SF				Gan, Zhending; Zhang, Meiyu; Xie, Donghui; Wu, Xiaoyan; Hong, Changming; Fu, Jian; Fan, Lijuan; Wang, Shengyi; Han, Sufang			Glycinergic Signaling in Macrophages and Its Application in Macrophage-Associated Diseases	FRONTIERS IN IMMUNOLOGY			English	Review						glycine; macrophage; NF-kappa B; miRNA; inflammation	ISCHEMIA-REPERFUSION INJURY; NF-KAPPA-B; INSULIN-RESISTANCE; ADIPOSE-TISSUE; SPINAL NEURONS; KUPFFER CELLS; TNF-ALPHA; METABOLISM; INHIBITION; SERINE	Accumulating evidences support that amino acids direct the fate decision of immune cells. Glycine is a simple structural amino acid acting as an inhibitory neurotransmitter. Besides, glycine receptors as well as glycine transporters are found in macrophages, indicating that glycine alters the functions of macrophages besides as an inhibitory neurotransmitter. Mechanistically, glycine shapes macrophage polarization via cellular signaling pathways (e.g., NF-kappa B, NRF2, and Akt) and microRNAs. Moreover, glycine has beneficial effects in preventing and/or treating macrophage-associated diseases such as colitis, NAFLD and ischemia-reperfusion injury. Collectively, this review highlights the conceivable role of glycinergic signaling for macrophage polarization and indicates the potential application of glycine supplementation as an adjuvant therapy in macrophage-associated diseases.	[Gan, Zhending; Wu, Xiaoyan; Hong, Changming; Fu, Jian; Fan, Lijuan; Han, Sufang] South China Agr Univ, Coll Anim Sci, Guangzhou, Peoples R China; [Zhang, Meiyu] Guangdong Polytech Sci & Trade, Coll Anim Sci & Technol, Guangzhou, Peoples R China; [Xie, Donghui] Nanchang Acad Agr Sci, Nanchang, Jiangxi, Peoples R China; [Wu, Xiaoyan; Wang, Shengyi] Chinese Acad Agr Sci, Lanzhou Inst Husb & Pharmaceut Sci, Key Lab Vet Pharmaceut Dev, Minist Agr & Rural Affairs, Lanzhou, Peoples R China	South China Agricultural University; Chinese Academy of Agricultural Sciences; Lanzhou Institute of Husbandry & Pharmaceutical Sciences, CAAS; Ministry of Agriculture & Rural Affairs	Han, SF (corresponding author), South China Agr Univ, Coll Anim Sci, Guangzhou, Peoples R China.; Wang, SY (corresponding author), Chinese Acad Agr Sci, Lanzhou Inst Husb & Pharmaceut Sci, Key Lab Vet Pharmaceut Dev, Minist Agr & Rural Affairs, Lanzhou, Peoples R China.	wangshengyi@caas.cn; sfhan@scau.edu.cn		wang, shengyi/0000-0001-5195-5059	Guangdong Basic and Applied Basic Research Foundation [2019B1515210002]; National Natural Science Foundation of China [31922079]	Guangdong Basic and Applied Basic Research Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This study was supported by the Guangdong Basic and Applied Basic Research Foundation (2019B1515210002) and National Natural Science Foundation of China (31922079).	Adeva-Andany M, 2018, AMINO ACIDS, V50, P11, DOI 10.1007/s00726-017-2508-0; Al-Saeedi M, 2019, AMINO ACIDS, V51, P903, DOI 10.1007/s00726-019-02722-5; Alisi A, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/8162421; Almanza-Perez JC, 2010, BIOMED PHARMACOTHER, V64, P534, DOI 10.1016/j.biopha.2009.04.047; Alves A, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061356; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; APRISON M. H., 1965, LIFE SCI, V4, P2075, DOI 10.1016/0024-3205(65)90325-5; ARNSTEIN HRV, 1953, BIOCHEM J, V55, P271, DOI 10.1042/bj0550271; Arranz A, 2012, P NATL ACAD SCI USA, V109, P9517, DOI 10.1073/pnas.1119038109; Betz H, 2006, J NEUROCHEM, V97, P1600, DOI 10.1111/j.1471-4159.2006.03908.x; Blancas-Flores G, 2012, EUR J PHARMACOL, V689, P270, DOI 10.1016/j.ejphar.2012.06.025; Carmans S, 2010, J NEUROSCI RES, V88, P2420, DOI 10.1002/jnr.22395; Ceyhan GO, 2011, PANCREATOLOGY, V11, P57, DOI 10.1159/000325972; Chen J, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0241-3; Chen SY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01866; Chen ZJ, 2020, DRUG DES DEV THER, V14, P2021, DOI 10.2147/DDDT.S248104; Contreras-Nunez E, 2018, BIOMED PHARMACOTHER, V102, P120, DOI 10.1016/j.biopha.2018.03.048; CURTIS DR, 1967, NATURE, V215, P1502, DOI 10.1038/2151502a0; Dixon LJ, 2013, COMPR PHYSIOL, V3, P785, DOI 10.1002/cphy.c120026; Dorrington MG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00705; Ducker GS, 2017, P NATL ACAD SCI USA, V114, P11404, DOI 10.1073/pnas.1706617114; Eder C, 1998, AM J PHYSIOL-CELL PH, V275, pC327, DOI 10.1152/ajpcell.1998.275.2.C327; Epelman S, 2014, IMMUNITY, V41, P21, DOI 10.1016/j.immuni.2014.06.013; Essandoh K, 2016, SHOCK, V46, P122, DOI 10.1097/SHK.0000000000000604; Froh M, 2002, AM J PHYSIOL-GASTR L, V283, pG856, DOI 10.1152/ajpgi.00503.2001; Galvan-Pena S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00420; Gambardella V, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102015; Gannon MC, 2002, AM J CLIN NUTR, V76, P1302, DOI 10.1093/ajcn/76.6.1302; Garcia-Macedo R, 2008, EUR J PHARMACOL, V587, P317, DOI 10.1016/j.ejphar.2008.03.051; Gazoni LM, 2007, ANN THORAC SURG, V84, P247, DOI 10.1016/j.athoracsur.2007.02.036; Gibson NR, 2002, AM J CLIN NUTR, V75, P511, DOI 10.1093/ajcn/75.3.511; Gogoi M, 2016, CURR OPIN MICROBIOL, V29, P43, DOI 10.1016/j.mib.2015.10.005; Habib MM, 2006, CURR PHARM DESIGN, V12, P2953, DOI 10.2174/138161206777947605; Hague MA, 2018, INT IMMUNOPHARMACOL, V55, P312, DOI 10.1016/j.intimp.2018.01.001; Hill AA, 2014, IMMUNOL REV, V262, P134, DOI 10.1111/imr.12216; Hyde R, 2003, BIOCHEM J, V373, P1, DOI 10.1042/BJ20030405; Ikejima K, 1997, AM J PHYSIOL-GASTR L, V272, pG1581, DOI 10.1152/ajpgi.1997.272.6.G1581; Ikejima K, 1996, AM J PHYSIOL-GASTR L, V271, pG97, DOI 10.1152/ajpgi.1996.271.1.G97; Ito K, 2008, CLIN NUTR, V27, P773, DOI 10.1016/j.clnu.2008.06.012; Ivashkiv LB, 2018, NAT REV IMMUNOL, V18, P545, DOI 10.1038/s41577-018-0029-z; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595; Jimenez E, 2022, NEUROCHEM RES, V47, P138, DOI 10.1007/s11064-021-03228-x; Kahn J, 2018, VISC MED, V34, P444, DOI 10.1159/000493889; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; Kazankov K, 2019, NAT REV GASTRO HEPAT, V16, P145, DOI 10.1038/s41575-018-0082-x; LAZENBY AJ, 1992, NEW ENGL J MED, V326, P574; Lee MA, 2002, JPEN-PARENTER ENTER, V26, P130, DOI 10.1177/0148607102026002130; Lee MA, 2001, ANN PLAS SURG, V46, P320, DOI 10.1097/00000637-200103000-00020; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; Li P, 2007, BRIT J NUTR, V98, P237, DOI 10.1017/S000711450769936X; Li XG, 2001, INFECT IMMUN, V69, P5883, DOI 10.1128/IAI.69.9.5883-5891.2001; Liu AD, 2012, CYTOKINE, V57, P150, DOI 10.1016/j.cyto.2011.11.009; Liu R, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02998-6; Liu R, 2019, J IMMUNOL, V202, P1704, DOI 10.4049/jimmunol.1801166; Liu YH, 2019, AM J PHYSIOL-CELL PH, V317, pC762, DOI 10.1152/ajpcell.00212.2019; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Luo GT, 2018, EXP CELL RES, V369, P120, DOI 10.1016/j.yexcr.2018.05.013; Ly CH, 2020, CELL METAB, V31, P1052, DOI 10.1016/j.cmet.2020.04.022; MANGINO MJ, 1991, AM J PHYSIOL, V261, pF841, DOI 10.1152/ajprenal.1991.261.5.F841; Mehrabi A, 2007, NEPHROL DIAL TRANSPL, V22, P54, DOI 10.1093/ndt/gfm651; Melendez-Hevia E, 2009, J BIOSCIENCES, V34, P853, DOI 10.1007/s12038-009-0100-9; Mills CD, 2014, J INNATE IMMUN, V6, P716, DOI 10.1159/000364945; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Neuschwander-Tetri BA, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0806-8; Newman AC, 2017, TRENDS CELL BIOL, V27, P645, DOI 10.1016/j.tcb.2017.05.001; Okekunle AP, 2017, DIABETES RES CLIN PR, V132, P45, DOI 10.1016/j.diabres.2017.07.023; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; Qin XP, 2019, NEUROSURGERY, V66, P51, DOI 10.1007/s11064-019-02886-2; Raiha Meri R, 2018, Chronic Dis Transl Med, V4, P156, DOI 10.1016/j.cdtm.2018.07.001; Recasens M, 2004, Rev Med Univ Navarra, V48, P49; Redalen KR, 2016, RADIOTHER ONCOL, V118, P393, DOI 10.1016/j.radonc.2015.11.031; Ren WK, 2019, ADV NUTR, V10, P321, DOI 10.1093/advances/nmy084; Ren WK, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12394; Rodriguez AE, 2019, CELL METAB, V29, P1003, DOI 10.1016/j.cmet.2019.01.014; Rohm TV, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.668654; Rohm TV, 2018, DIABETES, V67, DOI 10.2337/db18-283-OR; Rom O, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz2841; Schaumann T, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/808367; Schilling T, 2004, J PHYSIOL-LONDON, V559, P35, DOI 10.1113/jphysiol.2004.070763; Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429; Simmons RM, 2020, AMINO ACIDS, V52, P1413, DOI 10.1007/s00726-020-02901-9; Solt LA, 2008, IMMUNOL RES, V42, P3, DOI 10.1007/s12026-008-8025-1; Song WX, 2020, ACTA PHARMACOL SIN B, V10, P61, DOI 10.1016/j.apsb.2019.12.006; Suzuki T, 2013, CELL MOL LIFE SCI, V70, P631, DOI 10.1007/s00018-012-1070-x; Takashima S, 2016, AM J PHYSIOL-GASTR L, V311, pG1105, DOI 10.1152/ajpgi.00465.2015; Thapa B, 2019, BMB REP, V52, P360, DOI 10.5483/BMBRep.2019.52.6.140; Tsune I, 2003, GASTROENTEROLOGY, V125, P775, DOI 10.1016/S0016-5085(03)01067-9; Vieira CP, 2015, ANAT REC, V298, P538, DOI 10.1002/ar.23041; Wang MH, 2019, TRANSPLANTATION, V103, pE188, DOI 10.1097/TP.0000000000002747; Wang WW, 2013, AMINO ACIDS, V45, P463, DOI 10.1007/s00726-013-1493-1; Wang XF, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87748; Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008-5472.CAN-17-3841; Wheeler MD, 1999, AM J PHYSIOL-LUNG C, V277, pL952, DOI 10.1152/ajplung.1999.277.5.L952; Wheeler MD, 1999, CELL MOL LIFE SCI, V56, P843, DOI 10.1007/s000180050030; White PJ, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108375; Wolf SA, 2017, ANNU REV PHYSIOL, V79, P619, DOI 10.1146/annurev-physiol-022516-034406; Wu GJ, 2013, J NEUROPHYSIOL, V109, P193, DOI 10.1152/jn.01081.2011; Wu X, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/5867627; Xia YY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.669566; Xia YY, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12547; Yamanouchi K, 2007, LIVER INT, V27, P1249, DOI 10.1111/j.1478-3231.2007.01564.x; Yang J, 2014, ONCOGENE, V33, P3014, DOI 10.1038/onc.2013.258; Yin HL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21514-8; Yu WW, 2019, MOL CELL, V75, P1147, DOI 10.1016/j.molcel.2019.06.039; Zhang YC, 2022, AMINO ACIDS, V54, P353, DOI 10.1007/s00726-021-03011-w; Zhang YC, 2021, MOL NUTR FOOD RES, V65, DOI 10.1002/mnfr.202001065; Zhang YC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030611; Zhao D, 2018, BIOCHEM BIOPH RES CO, V501, P85, DOI 10.1016/j.bbrc.2018.04.171; Zhao Y, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26461; Zhong Z, 2003, CURR OPIN CLIN NUTR, V6, P229, DOI 10.1097/00075197-200303000-00013; Zhou X, 2016, ONCOTARGET, V7, P80223, DOI 10.18632/oncotarget.12831; Zhu XX, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.614044	114	1	1	5	17	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 5	2021	12								762564	10.3389/fimmu.2021.762564	http://dx.doi.org/10.3389/fimmu.2021.762564			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WK5EG	34675940	Green Published, gold			2022-12-18	WOS:000709748000001
J	George, J; Zhang, YY; Sloan, J; Sims, JM; Imig, JD; Zhao, XY				George, Jasmine; Zhang, Yuanyuan; Sloan, Jacob; Sims, Joya M.; Imig, John D.; Zhao, Xueying			Tim-1 Deficiency Aggravates High-Fat Diet-Induced Steatohepatitis in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						non-alcoholic steatohepatitis; high-fat diet; lipid metabolism; inflammation; Tim-1	ISCHEMIA-REPERFUSION INJURY; LIVER-INJURY; INDUCED OBESITY; MACROPHAGE ACTIVATION; TARGETING TIM-1; CELL-ACTIVATION; KIDNEY-DISEASE; EMERGING ROLE; MOUSE MODEL; ACID UPTAKE	Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) is commonly associated with obesity and characterized by excessive lipid accumulation and liver inflammation. The T cell immunoglobulin and mucin domain 1 (Tim-1), also known as hepatitis A virus cellular receptor 1 (Havcr-1) and kidney injury molecule 1 (Kim-1), has been shown to affect innate immunity-driven proinflammatory cascade in liver ischemia-reperfusion injury. However, its contribution to obesity-related NAFLD/NASH remains unknown. Thus, this study was designed to evaluate the role of Tim-1 in obesity-related liver inflammation and injury in wild-type (WT) and Tim-1-deficient (Tim-1(-/-)) C57BL/6J mice fed a high-fat diet (HFD) for 5-6 months. HFD feeding induced steatosis and upregulated Tim-1 gene expression in the liver of WT mice. Surprisingly, Tim-1(-/-) mice on HFD diet exhibited an exacerbation of hepatic steatosis, accompanied with an elevation of protein levels of fatty acid translocase CD36 and sterol regulatory element binding protein 1 (SREBP1). Tim-1 deficiency also enhanced HFD-induced liver inflammation and injury, as evidenced by augmented increase in hepatic expression of pro-inflammatory factor lipocalin 2 and elevated serum alanine transaminase (ALT). In addition, gene expression of type I, III and IV collagens and liver fibrosis were greatly enhanced in HFD Tim-1(-/-) mice compared with HFD WT mice. HFD-induced hepatic expression of YM-1, a specific mouse M2 macrophage marker, was further upregulated by deletion of Tim-1. Together, these results show that Tim-1 deficiency aggravates the effects of HFD diet on lipid accumulation and liver fibrosis, most likely through enhanced infiltration and activation of inflammatory cells.	[George, Jasmine; Zhang, Yuanyuan; Sloan, Jacob; Sims, Joya M.; Zhao, Xueying] Morehouse Sch Med, Dept Physiol, 720 Westview Dr Sw, Atlanta, GA 30310 USA; [Imig, John D.] Med Coll Wisconsin, Drug Discovery Ctr, Milwaukee, WI 53226 USA	Morehouse School of Medicine; Medical College of Wisconsin	Zhao, XY (corresponding author), Morehouse Sch Med, Dept Physiol, 720 Westview Dr Sw, Atlanta, GA 30310 USA.	xzhao@msm.edu	zhang, yuanyuan/GYA-4428-2022		National Institutes of Health [SC1DK112151, S21MD000101]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health Grants SC1DK112151 and S21MD000101.	Aly FZ, 2011, ADV ANAT PATHOL, V18, P294, DOI 10.1097/PAP.0b013e318220f59b; Asimakopoulou A, 2016, HEPATOLOGY, V63, P669, DOI 10.1002/hep.27930; Beljaars L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00430; Borkham-Kamphorst E, 2013, BBA-MOL BASIS DIS, V1832, P660, DOI 10.1016/j.bbadis.2013.01.014; Borkham-Kamphorst E, 2011, LIVER INT, V31, P656, DOI 10.1111/j.1478-3231.2011.02495.x; Brunt EM, 2009, HEPATOLOGY, V49, P809, DOI 10.1002/hep.22724; Chen JG, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72172-7; Curtiss ML, 2012, EUR J IMMUNOL, V42, P651, DOI 10.1002/eji.201141581; D Sizing I, 2007, J IMMUNOL, V178, P2249, DOI 10.4049/jimmunol.178.4.2249; Deng X, 2002, BIOCHEM BIOPH RES CO, V290, P256, DOI 10.1006/bbrc.2001.6148; Diehl AM, 2017, NEW ENGL J MED, V377, P2063, DOI 10.1056/NEJMra1503519; Doege H, 2006, PHYSIOLOGY, V21, P259, DOI 10.1152/physiol.00014.2006; Duffield JS, 2003, CLIN SCI, V104, P27, DOI 10.1042/CS20020240; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; Encinas JA, 2005, J ALLERGY CLIN IMMUN, V116, P1343, DOI 10.1016/j.jaci.2005.08.031; Fengler VHI, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155163; Foks AC, 2016, ARTERIOSCL THROM VAS, V36, P456, DOI 10.1161/ATVBAHA.115.306860; Garcia-Monzon C, 2014, EUR J CLIN INVEST, V44, P65, DOI 10.1111/eci.12192; Gibbons MA, 2011, AM J RESP CRIT CARE, V184, P569, DOI 10.1164/rccm.201010-1719OC; Greco D, 2008, AM J PHYSIOL-GASTR L, V294, pG1281, DOI 10.1152/ajpgi.00074.2008; Han JQ, 2019, J PATHOL, V248, P488, DOI 10.1002/path.5275; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Ichimura T, 2008, J CLIN INVEST, V118, P1657, DOI 10.1172/JCI34487; Kaplan G, 1996, EMBO J, V15, P4282, DOI 10.1002/j.1460-2075.1996.tb00803.x; Koonen DPY, 2007, DIABETES, V56, P2863, DOI 10.2337/db07-0907; Liaskou E, 2013, HEPATOLOGY, V57, P385, DOI 10.1002/hep.26016; Lopez-Navarrete G, 2011, INT J BIOL SCI, V7, P1273, DOI 10.7150/ijbs.7.1273; Machado MV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127991; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Michelotti GA, 2013, NAT REV GASTRO HEPAT, V10, P656, DOI 10.1038/nrgastro.2013.183; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Musso G, 2016, DIABETES CARE, V39, P1830, DOI 10.2337/dc15-1182; Nandi A, 2004, PHYSIOL REV, V84, P623, DOI 10.1152/physrev.00032.2003; Raes G, 2005, J IMMUNOL, V174, P6561, DOI 10.4049/jimmunol.174.11.6561; Rennert PD, 2011, IMMUNOL LETT, V141, P28, DOI 10.1016/j.imlet.2011.08.003; Roberts-Toler C, 2015, OBESITY, V23, P1765, DOI 10.1002/oby.21134; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shimano H, 2009, FEBS J, V276, P616, DOI 10.1111/j.1742-4658.2008.06806.x; Sonar SS, 2010, J CLIN INVEST, V120, P2767, DOI 10.1172/JCI39543; Song EW, 2000, CELL IMMUNOL, V204, P19, DOI 10.1006/cimm.2000.1687; Stahl A, 2001, TRENDS ENDOCRIN MET, V12, P266, DOI 10.1016/S1043-2760(01)00427-1; Tacke F, 2014, J HEPATOL, V60, P1090, DOI 10.1016/j.jhep.2013.12.025; Tajiri K, 2009, EUR J GASTROEN HEPAT, V21, P673, DOI 10.1097/MEG.0b013e32831bc3d6; Tarjus A, 2015, HYPERTENSION, V66, P158, DOI 10.1161/HYPERTENSIONAHA.115.05431; Uchida Y, 2010, HEPATOLOGY, V51, P1363, DOI 10.1002/hep.23442; Ueno T, 2008, J CLIN INVEST, V118, P742, DOI 10.1172/JCI32451; Umetsu SE, 2005, NAT IMMUNOL, V6, P447, DOI 10.1038/ni1186; Wang CY, 2012, METHODS MOL BIOL, V821, P421, DOI 10.1007/978-1-61779-430-8_27; Wang X, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.596329; Wicks SE, 2016, BIOCHIMIE, V124, P65, DOI 10.1016/j.biochi.2015.08.001; Wieser V, 2016, J HEPATOL, V64, P872, DOI 10.1016/j.jhep.2015.11.037; Wilson CG, 2016, ENDOCRINOLOGY, V157, P570, DOI 10.1210/en.2015-1866; Wu LH, 2020, HEPATOL INT, V14, P652, DOI 10.1007/s12072-020-10081-7; Xiao S, 2007, J EXP MED, V204, P1691, DOI 10.1084/jem.20062498; Xu MJ, 2015, HEPATOLOGY, V61, P692, DOI 10.1002/hep.27447; Xu S, 2013, BIOCHEMISTRY-US, V52, P7254, DOI 10.1021/bi400914c; Yang L, 2015, J CLIN INVEST, V125, P1620, DOI 10.1172/JCI75417; Ye DW, 2016, J HEPATOL, V65, P988, DOI 10.1016/j.jhep.2016.05.041; Yuan XL, 2009, P NATL ACAD SCI USA, V106, P10734, DOI 10.1073/pnas.0812538106; Zhang SH, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020201; Zhang Y, 2013, AM J TRANSPLANT, V13, P56, DOI 10.1111/j.1600-6143.2012.04316.x; Zhang Y, 2017, AM J TRANSL RES, V9, P3665	62	1	1	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 5	2021	12								747794	10.3389/fimmu.2021.747794	http://dx.doi.org/10.3389/fimmu.2021.747794			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WI6AV	34675931	Green Published, gold			2022-12-18	WOS:000708441800001
J	Jiang, N; Fan, YD; Zhou, Y; Meng, Y; Liu, WZ; Li, YQ; Xue, MY; Robert, J; Zeng, LB				Jiang, Nan; Fan, Yuding; Zhou, Yong; Meng, Yan; Liu, Wenzhi; Li, Yiqun; Xue, Mingyang; Robert, Jacques; Zeng, Lingbing			The Immune System and the Antiviral Responses in Chinese Giant Salamander, Andrias davidianus	FRONTIERS IN IMMUNOLOGY			English	Review						Chinese giant salamander; amphibian; antiviral response; immune system; Ranavirus infection	FROG-VIRUS 3; TOLL-LIKE RECEPTORS; ANTIMICROBIAL PEPTIDE DEFENSES; XENOPUS-LAEVIS TADPOLES; INVARIANT T-CELLS; AMPHIBIAN XENOPUS; HEAVY-CHAIN; EXPRESSION ANALYSIS; ADAPTIVE IMMUNITY; CHANNEL CATFISH	The Chinese giant salamander, belonging to an ancient amphibian lineage, is the largest amphibian existing in the world, and is also an important animal for artificial cultivation in China. However, some aspects of the innate and adaptive immune system of the Chinese giant salamander are still unknown. The Chinese giant salamander iridovirus (GSIV), a member of the Ranavirus genus (family Iridoviridae), is a prominent pathogen causing high mortality and severe economic losses in Chinese giant salamander aquaculture. As a serious threat to amphibians worldwide, the etiology of ranaviruses has been mainly studied in model organisms, such as the Ambystoma tigrinum and Xenopus. Nevertheless, the immunity to ranavirus in Chinese giant salamander is distinct from other amphibians and less known. We review the unique immune system and antiviral responses of the Chinese giant salamander, in order to establish effective management of virus disease in Chinese giant salamander artificial cultivation.	[Jiang, Nan; Fan, Yuding; Zhou, Yong; Meng, Yan; Liu, Wenzhi; Li, Yiqun; Xue, Mingyang; Zeng, Lingbing] Chinese Acad Fishery Sci, Yangtze River Fisheries Res Inst, Div Fish Dis, Wuhan, Peoples R China; [Jiang, Nan; Robert, Jacques] Univ Rochester, Med Ctr, Dept Microbiol & Immunol, New York, NY 14610 USA	Chinese Academy of Fishery Sciences; Yangtze River Fisheries Research Institute, CAFS; University of Rochester	Zeng, LB (corresponding author), Chinese Acad Fishery Sci, Yangtze River Fisheries Res Inst, Div Fish Dis, Wuhan, Peoples R China.; Robert, J (corresponding author), Univ Rochester, Med Ctr, Dept Microbiol & Immunol, New York, NY 14610 USA.	Jacques_Robert@URMC.Rochester.edu; zlb@yfi.ac.cn	zhou, yong/HDM-5825-2022; Meng, Yan/HGC-0394-2022; meng, yan/GSE-2653-2022	zhou, yong/0000-0003-0373-5734; 	National Natural Science Foundation of China [31702033]; Special Fund for Agro-Scientific Research in the Public Interest [2020XT0401]; Hubei Provincial Natural Science Foundation of China [2020CFB347]; National Science Foundation [IOS-1456213]; National Institute of Allergy and Infectious Diseases (NIH/NIAID) of USA [R24AI059830]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Special Fund for Agro-Scientific Research in the Public Interest; Hubei Provincial Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Foundation(National Science Foundation (NSF)); National Institute of Allergy and Infectious Diseases (NIH/NIAID) of USA	The work was supported by the National Natural Science Foundation of China (Grant No. 31702033), the Special Fund for Agro-Scientific Research in the Public Interest (2020XT0401), and the Hubei Provincial Natural Science Foundation of China (2020CFB347), as well as the IOS-1456213 from the National Science Foundation and R24AI059830 from the National Institute of Allergy and Infectious Diseases (NIH/NIAID) of USA.	Afshar M, 2013, VET DERMATOL, V24, P32, DOI 10.1111/j.1365-3164.2012.01082.x; AMEMIYA CT, 1989, NUCLEIC ACIDS RES, V17, P5388, DOI 10.1093/nar/17.13.5388; Andino FD, 2015, VIROLOGY, V485, P162, DOI 10.1016/j.virol.2015.07.011; Andino FD, 2012, VIROLOGY, V432, P435, DOI 10.1016/j.virol.2012.07.001; Ariffin JK, 2013, CURR OPIN MICROBIOL, V16, P303, DOI 10.1016/j.mib.2013.03.002; Bernard D, 2007, DEV COMP IMMUNOL, V31, P255, DOI 10.1016/j.dci.2006.06.003; Bricker NK, 2012, VET CLIN PATH, V41, P353, DOI 10.1111/j.1939-165X.2012.00452.x; CASTILLO A, 1990, THYMUS, V15, P153; Chen GC, 2011, VIRUSES-BASEL, V3, P2065, DOI 10.3390/v3112065; Chen GC, 2011, J VIROL, V85, P11131, DOI 10.1128/JVI.05589-11; Chen Q, 2015, MOL IMMUNOL, V65, P350, DOI 10.1016/j.molimm.2015.02.015; Chen ZY, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020052; Chen ZY, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-101; Chinchar VG, 2009, CURR TOP MICROBIOL, V328, P123; Chinchar VG, 2011, VIRUSES-BASEL, V3, P1959, DOI 10.3390/v3101959; Chinchar VG, 2004, VIROLOGY, V323, P268, DOI 10.1016/j.virol.2004.02.029; Chinchar VG, 2001, VIROLOGY, V288, P351, DOI 10.1006/viro.2001.1080; Chretien I, 1997, EUR J IMMUNOL, V27, P763, DOI 10.1002/eji.1830270327; Cotter JD, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-493; Cusaac JPW, 2021, J AQUAT ANIM HEALTH, V33, P24, DOI 10.1002/aah.10117; Dong WZ, 2011, EMERG INFECT DIS, V17, P2388, DOI 10.3201/eid1712.101758; Du Pasquier L, 2000, IMMUNOL REV, V175, P201, DOI 10.1034/j.1600-065X.2000.017501.x; Durand C, 1999, IMMUNOGENETICS, V50, P336, DOI 10.1007/s002510050610; Durand C, 2000, IMMUNOGENETICS, V51, P681, DOI 10.1007/s002510000191; Edholm ES, 2016, IMMUNOGENETICS, V68, P525, DOI 10.1007/s00251-016-0929-7; Edholm ES, 2015, J IMMUNOL, V195, P576, DOI 10.4049/jimmunol.1500458; Edholm ES, 2014, IMMUNOGENETICS, V66, P411, DOI 10.1007/s00251-014-0774-5; Edholm ES, 2013, P NATL ACAD SCI USA, V110, P14342, DOI 10.1073/pnas.1309840110; Edholm ESI, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040330; Fan YD, 2015, VET RES, V46, DOI 10.1186/s13567-015-0279-8; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; FLAJNIK MF, 1990, IMMUNOL REV, V113, P47; Fujita T, 2004, MOL IMMUNOL, V41, P103, DOI 10.1016/j.molimm.2004.03.026; Gantress J, 2003, VIROLOGY, V311, P254, DOI 10.1016/S0042-6822(03)00151-X; Geng Y, 2011, J COMP PATHOL, V145, P95, DOI 10.1016/j.jcpa.2010.11.012; Gobel TWF, 2000, EUR J IMMUNOL, V30, P2775, DOI 10.1002/1521-4141(200010)30:10<2775::AID-IMMU2775>3.0.CO;2-U; Godwin JW, 2014, DIFFERENTIATION, V87, P66, DOI 10.1016/j.diff.2014.02.002; Gordon J, 2011, DEVELOPMENT, V138, P3865, DOI 10.1242/dev.059998; Gray MJ, 2009, DIS AQUAT ORGAN, V87, P243, DOI 10.3354/dao02138; Grayfer L, 2015, J VIROL, V89, P5072, DOI 10.1128/JVI.00051-15; GREENHALGH P, 1993, J IMMUNOL, V151, P3100; Grogan LF, 2020, J FUNGI, V6, DOI 10.3390/jof6040234; Grogan LF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02536; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020; Gui Lang, 2018, Aquaculture and Fisheries, V3, P1, DOI 10.1016/j.aaf.2017.12.003; Guselnikov SV, 2003, DEV COMP IMMUNOL, V27, P727, DOI 10.1016/S0145-305X(03)00055-7; HAIRE RN, 1989, NUCLEIC ACIDS RES, V17, P1776, DOI 10.1093/nar/17.4.1776; Haire RN, 2002, IMMUNOGENETICS, V54, P431, DOI 10.1007/s00251-002-0474-4; Hansen JD, 1998, IMMUNOL REV, V166, P199, DOI 10.1111/j.1600-065X.1998.tb01264.x; Huang LL, 2015, COMP BIOCHEM PHYS B, V184, P52, DOI 10.1016/j.cbpb.2015.02.006; Ichikawa HT, 2006, J IMMUNOL, V177, P355, DOI 10.4049/jimmunol.177.1.355; Ishii A, 2007, IMMUNOGENETICS, V59, P281, DOI 10.1007/s00251-007-0193-y; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jancovich JK, 2011, J VIROL, V85, P5061, DOI 10.1128/JVI.01488-10; Jiang N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36376-2; Jiang N, 2018, DEV COMP IMMUNOL, V87, P24, DOI 10.1016/j.dci.2018.05.018; Jiang N, 2015, DIS AQUAT ORGAN, V114, P229, DOI 10.3354/dao02868; Kanwal Z, 2014, DEV COMP IMMUNOL, V46, P35, DOI 10.1016/j.dci.2014.02.003; Ke F, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4596-y; Langenau DM, 2004, P NATL ACAD SCI USA, V101, P7369, DOI 10.1073/pnas.0402248101; LEE A, 1994, J IMMUNOL, V152, P4500; Liu WZ, 2014, VET MICROBIOL, V174, P382, DOI 10.1016/j.vetmic.2014.10.028; Liu Y, 2002, DEV COMP IMMUNOL, V26, P735, DOI 10.1016/S0145-305X(02)00034-4; Liu YN, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062246; MANNING MJ, 1969, J EMBRYOL EXP MORPH, V22, P265; Marr S, 2007, J IMMUNOL, V179, P6783, DOI 10.4049/jimmunol.179.10.6783; Matthijs S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086339; MENG Y, 2018, RUSSIAN J GENET, V54, P75, DOI DOI 10.1134/S102279541801012X; Meng Y, 2014, ARCH VIROL, V159, P1403, DOI 10.1007/s00705-013-1962-6; Morales HD, 2007, J VIROL, V81, P2240, DOI 10.1128/JVI.01104-06; Morales HD, 2010, J VIROL, V84, P4912, DOI 10.1128/JVI.02486-09; Mussmann R, 1996, EUR J IMMUNOL, V26, P2823, DOI 10.1002/eji.1830261205; Neely HR, 2018, EUR J IMMUNOL, V48, P430, DOI 10.1002/eji.201747260; Nowoshilow S, 2018, NATURE, V554, P50, DOI 10.1038/nature25458; Ohta Y, 2006, P NATL ACAD SCI USA, V103, P10723, DOI 10.1073/pnas.0601407103; Ohta Y, 2006, J IMMUNOL, V176, P3674, DOI 10.4049/jimmunol.176.6.3674; Osorio F, 2011, IMMUNITY, V34, P651, DOI 10.1016/j.immuni.2011.05.001; Ota T, 2003, P NATL ACAD SCI USA, V100, P2501, DOI 10.1073/pnas.0538029100; Piertney SB, 2006, HEREDITY, V96, P7, DOI 10.1038/sj.hdy.6800724; Pietretti D, 2014, DEV COMP IMMUNOL, V43, P205, DOI 10.1016/j.dci.2013.08.010; Pyron RA, 2011, MOL PHYLOGENET EVOL, V61, P543, DOI 10.1016/j.ympev.2011.06.012; Qi ZT, 2008, IMMUNOGENETICS, V60, P699, DOI 10.1007/s00251-008-0326-y; Qin T, 2008, DEV COMP IMMUNOL, V32, P156, DOI 10.1016/j.dci.2007.05.007; Quiniou SMA, 2013, IMMUNOGENETICS, V65, P511, DOI 10.1007/s00251-013-0694-9; Roach JC, 2005, P NATL ACAD SCI USA, V102, P9577, DOI 10.1073/pnas.0502272102; Robert J, 2005, VIROLOGY, V332, P667, DOI 10.1016/j.virol.2004.12.012; Robert J, 1998, DEV COMP IMMUNOL, V22, P605, DOI 10.1016/S0145-305X(98)00028-7; Robert J, 2017, VIROLOGY, V511, P309, DOI 10.1016/j.virol.2017.06.005; Robert J, 2014, IMMUNOGENETICS, V66, P513, DOI 10.1007/s00251-014-0781-6; Robert J, 2009, DEV DYNAM, V238, P1249, DOI 10.1002/dvdy.21891; Rollins-Smith LA, 2005, DEV COMP IMMUNOL, V29, P589, DOI 10.1016/j.dci.2004.11.004; Sang YM, 2016, SCI REP-UK, V6, DOI 10.1038/srep29072; SATO K, 1993, J IMMUNOL, V150, P2831; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; SCHWAGER J, 1991, EMBO J, V10, P505, DOI 10.1002/j.1460-2075.1991.tb07976.x; SCHWAGER J, 1988, P NATL ACAD SCI USA, V85, P2245, DOI 10.1073/pnas.85.7.2245; Sheafor B, 2008, J WILDLIFE DIS, V44, P226, DOI 10.7589/0090-3558-44.2.226; SHUM BP, 1993, J IMMUNOL, V151, P5376; Stewart R, 2005, DEV COMP IMMUNOL, V29, P723, DOI 10.1016/j.dci.2004.12.004; Stohr AC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118633; Teacher AGF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004616; Trede NS, 1998, DEV COMP IMMUNOL, V22, P253, DOI 10.1016/S0145-305X(98)00009-3; Turvey ST, 2021, PEOPLE NAT, V3, P446, DOI 10.1002/pan3.10185; Vo NTK, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020093; Wang LZ, 2020, DEV COMP IMMUNOL, V106, DOI 10.1016/j.dci.2019.103598; Wang Y, 2017, J COMPUT AID MOL DES, V31, P1029, DOI 10.1007/s10822-017-0080-z; Wendel ES, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10070372; Wendel ES, 2017, VIROLOGY, V503, P12, DOI 10.1016/j.virol.2017.01.001; Xu YP, 2020, DEV COMP IMMUNOL, V110, DOI 10.1016/j.dci.2020.103710; Yang H, 2017, DEV COMP IMMUNOL, V70, P59, DOI 10.1016/j.dci.2017.01.004; Yoneyama M, 2015, CURR OPIN IMMUNOL, V32, P48, DOI 10.1016/j.coi.2014.12.012; Yoneyama M, 2009, IMMUNOL REV, V227, P54, DOI 10.1111/j.1600-065X.2008.00727.x; Yu NT, 2020, ACTA VIROL, V64, P10, DOI 10.4149/av_2020_102; Yu NT, 2019, 3 BIOTECH, V9, DOI 10.1007/s13205-019-1961-8; Zhang P, 2003, GENE, V311, P93, DOI 10.1016/S0378-1119(03)00560-2; Zhang QY, 2015, SCI CHINA LIFE SCI, V58, P156, DOI 10.1007/s11427-015-4802-y; Zhao F, 2014, DNA RES, V21, P1, DOI 10.1093/dnares/dst035; Zhao YF, 2006, P NATL ACAD SCI USA, V103, P12087, DOI 10.1073/pnas.0600291103; Zhou Y, 2015, VACCINE, V33, P5662, DOI 10.1016/j.vaccine.2015.08.054; Zhu LY, 2013, DEV COMP IMMUNOL, V39, P39, DOI 10.1016/j.dci.2012.04.001; Zhu R, 2016, FISH SHELLFISH IMMUN, V55, P699, DOI 10.1016/j.fsi.2016.06.051; Zhu R, 2014, DEV COMP IMMUNOL, V46, P413, DOI 10.1016/j.dci.2014.05.019; Zhu R, 2014, DEV COMP IMMUNOL, V42, P311, DOI 10.1016/j.dci.2013.10.001	123	1	1	15	32	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 5	2021	12								718627	10.3389/fimmu.2021.718627	http://dx.doi.org/10.3389/fimmu.2021.718627			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WK5GD	34675918	Green Published, gold			2022-12-18	WOS:000709752900001
J	Jin, X; Jian, ZY; Chen, XT; Ma, YC; Ma, HW; Liu, Y; Gong, LN; Xiang, LY; Zhu, SY; Shu, XL; Qi, SQ; Li, H; Wang, KJ				Jin, Xi; Jian, Zhongyu; Chen, Xiaoting; Ma, Yucheng; Ma, Hongwen; Liu, Yu; Gong, Lina; Xiang, Liyuan; Zhu, Shiyu; Shu, Xiaoling; Qi, Shiqian; Li, Hong; Wang, Kunjie			Short Chain Fatty Acids Prevent Glyoxylate-Induced Calcium Oxalate Stones by GPR43-Dependent Immunomodulatory Mechanism	FRONTIERS IN IMMUNOLOGY			English	Article						calcium oxalate stones; short chain fatty acid; macrophage; neutrophil; GPR43	GUT MICROBIOTA; NEUTROPHIL RECRUITMENT; RECEPTOR; CELL; INFLAMMATION; PHENOTYPE; SEQUENCES; CRYSTALS; IMPACT; INJURY	Calcium oxalate (CaOx) stones are the most common type of kidney stones and are associated with high recurrence, short chain fatty acids (SCFAs), and inflammation. However, it remains uncertain whether SCFAs affect the formation of CaOx stones through immunomodulation. We first performed mass cytometry (CyTOF) and RNA sequencing on kidney immune cells with glyoxylate-induced CaOx crystals (to elucidate the landscape of the associated immune cell population) and explored the role of SCFAs in renal CaOx stone formation through immunomodulation. We identified 29 distinct immune cell subtypes in kidneys with CaOx crystals, where CX3CR1(+)CD24(-) macrophages significantly decreased and GR1(+) neutrophils significantly increased. In accordance with the CyTOF data, RNA sequencing showed that most genes involved were related to monocytes and neutrophils. SCFAs reduced kidney CaOx crystals by increasing the frequency of CX3CR1(+)CD24(-) macrophages and decreasing GR1(+) neutrophil infiltration in kidneys with CaOx crystals, which was dependent on the gut microbiota. GPR43 knockdown by transduction with adeno-associated virus inhibited the alleviation of crystal formation and immunomodulatory effects in the kidney, due to SCFAs. Moreover, CX3CR1(+)CD24(-) macrophages regulated GR1(+) neutrophils via GPR43. Our results demonstrated a unique trilateral relationship among SCFAs, immune cells, and the kidneys during CaOx formation. These findings suggest that future immunotherapies may be used to prevent kidney stones using SCFAs.	[Jin, Xi; Jian, Zhongyu; Chen, Xiaoting; Ma, Yucheng; Ma, Hongwen; Liu, Yu; Gong, Lina; Xiang, Liyuan; Zhu, Shiyu; Qi, Shiqian; Li, Hong; Wang, Kunjie] Sichuan Univ, Inst Urol Lab Reconstruct Urol, West China Hosp, Dept Urol, Chengdu, Peoples R China; [Chen, Xiaoting] Sichuan Univ, West China Hosp, Ctr Expt Anim, Chengdu, Peoples R China; [Shu, Xiaoling; Qi, Shiqian] Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Chengdu, Peoples R China	Sichuan University; Sichuan University; Sichuan University	Wang, KJ (corresponding author), Sichuan Univ, Inst Urol Lab Reconstruct Urol, West China Hosp, Dept Urol, Chengdu, Peoples R China.	wangkj@scu.edu.cn			National Natural Science Foundation of China [81970602, 81770703]; Foundation of Science & Technology Department of Sichuan Province [2021YFS0116]; 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University [ZYJC18015, ZYGD18011]; West China Hospital, Sichuan University [2019HXBH087]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation of Science & Technology Department of Sichuan Province; 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University; West China Hospital, Sichuan University(Sichuan University)	This study was supported by the National Natural Science Foundation of China [81970602, 81770703], the Foundation of Science & Technology Department of Sichuan Province [2021YFS0116], the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University [ZYJC18015, ZYGD18011], and the Post-Doctor Research Project, West China Hospital, Sichuan University [2019HXBH087].	Anders HJ, 2018, KIDNEY INT, V93, P656, DOI 10.1016/j.kint.2017.09.022; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Bouchery T, 2019, IMMUNOL CELL BIOL, V97, P289, DOI 10.1111/imcb.12241; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Cao Q, 2018, J AM SOC NEPHROL, V29, P961, DOI 10.1681/ASN.2017070774; Chen SF, 2018, BIOINFORMATICS, V34, P884, DOI 10.1093/bioinformatics/bty560; De Filippo K, 2013, BLOOD, V121, P4930, DOI 10.1182/blood-2013-02-486217; de Oliveira S, 2016, NAT REV IMMUNOL, V16, P378, DOI 10.1038/nri.2016.49; Dominguez-Gutierrez PR, 2020, CURR OPIN UROL, V30, P183, DOI 10.1097/MOU.0000000000000729; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Duscha A, 2020, CELL, V180, P1067, DOI 10.1016/j.cell.2020.02.035; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Fachi JL, 2020, J EXP MED, V217, DOI 10.1084/jem.20190489; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Howles SA, 2020, NAT REV UROL, V17, P407, DOI 10.1038/s41585-020-0332-x; Ji J, 2016, SCI REP-UK, V6, DOI 10.1038/srep24838; Joshi S, 2015, J UROLOGY, V193, P1684, DOI 10.1016/j.juro.2014.11.093; Kamp ME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163750; Khan A, 2018, INT UROL NEPHROL, V50, P799, DOI 10.1007/s11255-018-1849-2; Kim CH, 2018, IMMUNOLOGY, V154, P220, DOI 10.1111/imm.12930; Kimura I, 2020, PHYSIOL REV, V100, P171, DOI 10.1152/physrev.00041.2018; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kusmartsev S, 2016, J UROLOGY, V195, P1143, DOI 10.1016/j.juro.2015.11.048; Lavelle A, 2020, NAT REV GASTRO HEPAT, V17, P223, DOI 10.1038/s41575-019-0258-z; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li LZ, 2017, DRUG DES DEV THER, V11, P3531, DOI 10.2147/DDDT.S150825; Liu HR, 2020, THERANOSTICS, V10, P7319, DOI 10.7150/thno.44054; Liu Y, 2020, FASEB J, V34, P11200, DOI 10.1096/fj.202000786R; Liu Y, 2018, ASIAN J UROL, V5, P205, DOI 10.1016/j.ajur.2018.08.007; Luz HL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56560-2; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Makki MS, 2020, KIDNEY INT REP, V5, P663, DOI 10.1016/j.ekir.2020.02.1025; Marelli G, 2017, IMMUNOBIOLOGY, V222, P463, DOI 10.1016/j.imbio.2016.07.013; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; McLoughlin RM, 2003, J CLIN INVEST, V112, P598, DOI 10.1172/JCI200317129; Mulay SR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10274; Mulay SR, 2013, J CLIN INVEST, V123, P236, DOI 10.1172/JCI63679; Munoz LE, 2019, IMMUNITY, V51, P443, DOI 10.1016/j.immuni.2019.07.002; Nakajima A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179696; Nilsson NE, 2003, BIOCHEM BIOPH RES CO, V303, P1047, DOI 10.1016/S0006-291X(03)00488-1; Ohno H, 2020, INT IMMUNOL, V32, P629, DOI 10.1093/intimm/dxaa041; Okada A, 2009, J BONE MINER RES, V24, P908, DOI [10.1359/JBMR.081245, 10.1359/jbmr.081245]; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Samusik N, 2016, NAT METHODS, V13, P493, DOI [10.1038/NMETH.3863, 10.1038/nmeth.3863]; Sayer JA, 2017, J AM SOC NEPHROL, V28, P748, DOI 10.1681/ASN.2016050576; Schauer C, 2014, NAT MED, V20, P511, DOI 10.1038/nm.3547; Sun MM, 2017, J GASTROENTEROL, V52, P1, DOI 10.1007/s00535-016-1242-9; Sun Y, 2020, IUBMB LIFE, V72, P1065, DOI 10.1002/iub.2250; Taguchi K, 2020, KIDNEY INT, V97, P1042, DOI 10.1016/j.kint.2020.01.042; Taguchi K, 2017, J AM SOC NEPHROL, V28, P333, DOI 10.1681/ASN.2015111271; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Vieira AT, 2015, ARTHRITIS RHEUMATOL, V67, P1646, DOI 10.1002/art.39107; Vinolo MAR, 2011, J NUTR BIOCHEM, V22, P849, DOI 10.1016/j.jnutbio.2010.07.009; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Xi JH, 2019, J CELL PHYSIOL, V234, P11463, DOI 10.1002/jcp.27803; Zhao WM, 2016, FASEB J, V30, P380, DOI 10.1096/fj.14-270090; Zhu C, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2022-0; Zisman AL, 2017, CLIN J AM SOC NEPHRO, V12, P1699, DOI 10.2215/CJN.11201016	59	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 5	2021	12								729382	10.3389/fimmu.2021.729382	http://dx.doi.org/10.3389/fimmu.2021.729382			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ZT6YT	34675921	gold, Green Published			2022-12-18	WOS:000769300100001
J	Kempter, E; Amoroso, M; Duffner, HL; Werner, AM; Langgartner, D; Kupfer, S; Reber, SO				Kempter, Elena; Amoroso, Mattia; Duffner, Hannah L.; Werner, Andrea M.; Langgartner, Dominik; Kupfer, Sandra; Reber, Stefan O.			Changes in Functional Glucocorticoid Sensitivity of Isolated Splenocytes Induced by Chronic Psychosocial Stress - A Time Course Study	FRONTIERS IN IMMUNOLOGY			English	Article						chronic psychosocial stress; chronic subordinate colony housing (CSC); glucocorticoid resistance; corticosterone; spleen; bite wounds	MIGRATION INHIBITORY FACTOR; SOCIAL STRESS; REGULATORY ROLE; RESISTANCE; INFLAMMATION; MICE; SUSCEPTIBILITY; DISRUPTION; MECHANISMS; EXPRESSION	Chronic psychosocial stress is a risk factor for the development of numerous disorders, of which most are associated with chronic low-grade inflammation. Given the immunosuppressive effects of glucocorticoids (GC), one underlying mechanism might be the development of stress-induced GC resistance in certain immune cell subpopulations. In line with this hypothesis, male mice exposed to the chronic subordinate colony housing (CSC, 19 days) model develop GC resistance of in vitro lipopolysaccharide (LPS)-stimulated splenocytes, splenomegaly and an increased percentage of splenic CD11b(+) cells. Here male C57BL/6N mice were euthanized at different days during CSC, and following 30 days of single housing after stressor termination to assess when CSC-induced splenic GC resistance starts to develop and whether this is a transient effect. Moreover, splenic CD11b, GC receptor (GR) and/or macrophage migration inhibiting factor (MIF) protein levels were quantified at respective days. While mild forms of CSC-induced GC resistance, increased splenic CD11b expression and/or splenomegaly were detectable on days 8 and 9 of CSC, more severe forms took until days 15 and 16 to develop, but normalized almost completely within 30 days following stressor termination (day 51). In contrast, splenic GR expression was decreased in CSC versus single-housed control (SHC) mice at all days assessed. While MIF expression was increased on days 15 and 16 of CSC, it was decreased in CSC versus SHC mice on day 20 despite persisting splenomegaly, increased CD11b expression and functional GC resistance. In summary, our data indicate that GC resistance and CD11b(+) cell-mediated splenomegaly develop gradually and in parallel over time during CSC exposure and are transient in nature. Moreover, while we can exclude that CSC-induced reduction in splenic GR expression is sufficient to induce functional GC resistance, the role of MIF in CD11b(+) cell-mediated splenomegaly and GC resistance requires further investigation.	[Kempter, Elena; Amoroso, Mattia; Duffner, Hannah L.; Werner, Andrea M.; Langgartner, Dominik; Kupfer, Sandra; Reber, Stefan O.] Ulm Univ, Dept Psychosomat Med & Psychotherapy, Lab Mol Psychosomat, Ulm, Germany	Ulm University	Reber, SO (corresponding author), Ulm Univ, Dept Psychosomat Med & Psychotherapy, Lab Mol Psychosomat, Ulm, Germany.	Stefan.reber@uni-ulm.de		Amoroso, Mattia/0000-0003-4899-7287	Collaborative Research Centre CRC1149 - Deutsche Forschungsgemeinschat (DFG, German Research Foundation) [251293561]	Collaborative Research Centre CRC1149 - Deutsche Forschungsgemeinschat (DFG, German Research Foundation)(German Research Foundation (DFG))	Parts of the presented work in this article were supported by the Collaborative Research Centre CRC1149 funded by the Deutsche Forschungsgemeinscha?t (DFG, German Research Foundation) - Project ID 251293561.	Aldridge GM, 2008, J NEUROSCI METH, V172, P250, DOI 10.1016/j.jneumeth.2008.05.003; Amoroso M, 2020, BRAIN BEHAV IMMUN, V87, P309, DOI 10.1016/j.bbi.2019.12.018; Amoroso M, 2019, BRAIN BEHAV IMMUN, V80, P595, DOI 10.1016/j.bbi.2019.05.005; Avitsur R, 2003, J LEUKOCYTE BIOL, V74, P507, DOI 10.1189/jlb.0303090; Avitsur R, 2002, J NEUROIMMUNOL, V124, P54, DOI 10.1016/S0165-5728(02)00010-3; Avitsur R, 2001, HORM BEHAV, V39, P247, DOI 10.1006/hbeh.2001.1653; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Bailey MT, 2004, BRAIN BEHAV IMMUN, V18, P416, DOI 10.1016/j.bbi.2003.09.012; Bartolomucci A, 2003, PSYCHONEUROENDOCRINO, V28, P540, DOI 10.1016/S0306-4530(02)00039-2; Baugh JA, 2002, CRIT CARE MED, V30, pS27, DOI 10.1097/00003246-200201001-00004; Bellingrath S, 2013, BIOL PSYCHOL, V92, P403, DOI 10.1016/j.biopsycho.2012.12.003; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Chrousos GP, 2009, NAT REV ENDOCRINOL, V5, P374, DOI 10.1038/nrendo.2009.106; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Diegelmann RF, 1997, J UROLOGY, V157, P298, DOI 10.1016/S0022-5347(01)65364-3; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; Engler H, 2005, J NEUROIMMUNOL, V163, P110, DOI 10.1016/j.jneuroim.2005.03.002; Engler H, 2017, MOL PSYCHIATR, V22, P1448, DOI 10.1038/mp.2016.264; Engler H, 2004, J NEUROIMMUNOL, V148, P106, DOI 10.1016/j.jneuroim.2003.11.011; Eraly SA, 2014, JAMA PSYCHIAT, V71, P423, DOI 10.1001/jamapsychiatry.2013.4374; Fan HP, 2014, ARTHRITIS RHEUMATOL, V66, P2059, DOI 10.1002/art.38689; Foertsch S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63419-4; Foertsch S, 2020, NEUROSCI BIOBEHAV R, V113, P169, DOI 10.1016/j.neubiorev.2020.02.025; Foertsch S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15897-2; Galvao I, 2016, J LEUKOCYTE BIOL, V99, P1035, DOI 10.1189/jlb.3MA0915-418R; Haffner-Luntzer M, 2019, P NATL ACAD SCI USA, V116, P8615, DOI 10.1073/pnas.1819218116; Hodes GE, 2014, P NATL ACAD SCI USA, V111, P16136, DOI 10.1073/pnas.1415191111; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kivimaki M, 2014, MOL PSYCHIATR, V19, P149, DOI 10.1038/mp.2013.35; Langgartner D, 2020, PSYCHONEUROENDOCRINO, V122, DOI 10.1016/j.psyneuen.2020.104880; Langgartner D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202471; Langgartner D, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00018; McEwen BS, 2008, EUR J PHARMACOL, V583, P174, DOI 10.1016/j.ejphar.2007.11.071; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; Miller AH, 2016, NAT REV IMMUNOL, V16, P22, DOI 10.1038/nri.2015.5; Palanza P, 2001, NEUROSCI BIOBEHAV R, V25, P219, DOI 10.1016/S0149-7634(01)00010-0; Palanza P, 2001, PHYSIOL BEHAV, V73, P411, DOI 10.1016/S0031-9384(01)00494-2; Powell ND, 2013, P NATL ACAD SCI USA, V110, P16574, DOI 10.1073/pnas.1310655110; Quan N, 2003, J NEUROIMMUNOL, V137, P51, DOI 10.1016/S0165-5728(03)00042-0; Quax RA, 2013, NAT REV ENDOCRINOL, V9, P670, DOI 10.1038/nrendo.2013.183; Raison CL, 2003, AM J PSYCHIAT, V160, P1554, DOI 10.1176/appi.ajp.160.9.1554; Reber SO, 2007, ENDOCRINOLOGY, V148, P670, DOI 10.1210/en.2006-0983; Reber SO, 2008, STRESS, V11, P225, DOI 10.1080/10253890701733351; Reber SO, 2016, PSYCHONEUROENDOCRINO, V74, P221, DOI 10.1016/j.psyneuen.2016.08.031; Rohleder N, 2009, J CLIN ONCOL, V27, P2909, DOI 10.1200/JCO.2008.18.7435; Salminen A, 2011, CELL SIGNAL, V23, P747, DOI 10.1016/j.cellsig.2010.10.012; Schmidt D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159059; Sheridan JF, 2000, ANN NY ACAD SCI, V917, P894; Singewald GM, 2009, STRESS, V12, P58, DOI 10.1080/10253890802042082; Stark JL, 2001, AM J PHYSIOL-REG I, V280, pR1799, DOI 10.1152/ajpregu.2001.280.6.R1799; van der Geest R, 2016, TOXICOL APPL PHARM, V306, P1, DOI 10.1016/j.taap.2016.06.031	52	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 5	2021	12								753822	10.3389/fimmu.2021.753822	http://dx.doi.org/10.3389/fimmu.2021.753822			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WI6JK	34675935	gold, Green Published			2022-12-18	WOS:000708464100001
J	Noonepalle, SKR; Karabon, L; Chiappinelli, KB; Villagra, A				Noonepalle, Satish Kumar R.; Karabon, Lidia; Chiappinelli, Katherine B.; Villagra, Alejandro			Editorial: Genetic and Epigenetic Control of Immune Responses	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						tumor microenvironment; tumor immunology; tumor immune escape mechanisms; checkpoint inhibition therapy; genetic and epigenetic alterations; DNA methylation; HDAC inhibitor	HISTONE DEACETYLASE 6; T-CELLS; INFLAMMATORY CYTOKINES; HUMAN LUNG; IFN-GAMMA; CANCER; MACROPHAGE; ACTIVATION; EXPRESSION; INHIBITOR		[Noonepalle, Satish Kumar R.; Villagra, Alejandro] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, GW Canc Ctr, Washington, DC 20052 USA; [Karabon, Lidia] Polish Acad Sci, Ludwik Hirszfeld Inst Immunol & Expt Therapy, Dept Expt Therapy, Wroclaw, Poland; [Chiappinelli, Katherine B.] George Washington Univ, Sch Med & Hlth Sci, Dept Microbiol Immunol & Trop Med, GW Canc Ctr, Washington, DC 20052 USA	George Washington University; Polish Academy of Sciences; Hirszfeld Institute of Immunology & Experimental Therapy of the Polish Academy of Sciences; George Washington University	Villagra, A (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, GW Canc Ctr, Washington, DC 20052 USA.	avillagra@gwu.edu	Noonepalle, Satish/ABD-6753-2021	Noonepalle, Satish kumar/0000-0002-0346-3882; Villagra, Alejandro/0000-0001-9346-8355				Amabile A, 2016, CELL, V167, P219, DOI 10.1016/j.cell.2016.09.006; Bernstein BE, 2010, NAT BIOTECHNOL, V28, P1045, DOI 10.1038/nbt1010-1045; Bode JG, 2012, CELL SIGNAL, V24, P1185, DOI 10.1016/j.cellsig.2012.01.018; Buglio D, 2011, BLOOD, V117, P2910, DOI 10.1182/blood-2010-08-303701; Burr ML, 2019, CANCER CELL, V36, P385, DOI 10.1016/j.ccell.2019.08.008; Chen HL, 1996, INT J CANCER, V67, P756, DOI 10.1002/(SICI)1097-0215(19960917)67:6<756::AID-IJC2>3.0.CO;2-Q; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Chen SY, 2020, CELL MOL IMMUNOL, V17, P36, DOI 10.1038/s41423-019-0315-0; Cheng C, 2014, TOXICOL LETT, V225, P488, DOI 10.1016/j.toxlet.2013.12.023; Cheng F, 2014, J IMMUNOL, V193, P2850, DOI 10.4049/jimmunol.1302778; Chiappinelli KB, 2015, CELL, V162, P974, DOI 10.1016/j.cell.2015.07.011; Cowan LA, 2010, EPIGENOMICS-UK, V2, P71, DOI 10.2217/EPI.09.44; Croker BA, 2008, SEMIN CELL DEV BIOL, V19, P414, DOI 10.1016/j.semcdb.2008.07.010; Curtsinger JM, 1999, J IMMUNOL, V162, P3256; De Santa F, 2009, EMBO J, V28, P3341, DOI 10.1038/emboj.2009.271; Dewi DL, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1274477; Dhatchinamoorthy K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.636568; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Dustin ML, 2016, ANNU REV CELL DEV BI, V32, P303, DOI 10.1146/annurev-cellbio-100814-125330; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Facchinetti F, 2016, CLIN CANCER RES, V22, P5983, DOI 10.1158/1078-0432.CCR-16-0917; Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380; Gao XF, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku836; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hashimoto D, 2013, IMMUNITY, V38, P792, DOI 10.1016/j.immuni.2013.04.004; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoeffel G, 2012, J EXP MED, V209, P1167, DOI 10.1084/jem.20120340; Huang SCC, 2016, IMMUNITY, V45, P817, DOI 10.1016/j.immuni.2016.09.016; Hume DA, 2014, IMMUNOL REV, V262, P74, DOI 10.1111/imr.12211; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214; Kawakami H, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0348-2; Kelderman S, 2014, MOL ONCOL, V8, P1132, DOI 10.1016/j.molonc.2014.07.011; Keung AJ, 2014, CELL, V158, P110, DOI 10.1016/j.cell.2014.04.047; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82; Knox T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42237-3; Kolb R, 2014, PROTEIN CELL, V5, P12, DOI 10.1007/s13238-013-0001-4; Kong LC, 2016, NUCLEIC ACIDS RES, V44, P8682, DOI 10.1093/nar/gkw529; Kruidenier L, 2012, NATURE, V488, P404, DOI 10.1038/nature11262; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Li DF, 2019, NUCLEIC ACIDS RES, V47, pW158, DOI 10.1093/nar/gkz348; Li J, 2020, J CLIN INVEST, V130, P2712, DOI 10.1172/JCI134402; Lienlaf M, 2016, MOL ONCOL, V10, P735, DOI 10.1016/j.molonc.2015.12.012; Lin F, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax1608; Marabelle A, 2020, J CLIN ONCOL, V38, P1, DOI 10.1200/JCO.19.02105; Moufarrij S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60409-4; Murnane JP, 2006, DNA REPAIR, V5, P1082, DOI 10.1016/j.dnarep.2006.05.030; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Nagarsheth N, 2016, CANCER RES, V76, P275, DOI 10.1158/0008-5472.CAN-15-1938; Nair VS, 2017, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0539-3; Nair VS, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0512-1; Nakamura K, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00356-8; Nakamura M, 2021, NAT CELL BIOL, V23, P11, DOI 10.1038/s41556-020-00620-7; Noonepalle SK, 2017, CANCER IMMUNOL RES, V5, P330, DOI 10.1158/2326-6066.CIR-16-0182; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pi YN, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.697083; Qiao Y, 2016, CELL REP, V16, P3121, DOI 10.1016/j.celrep.2016.08.051; Qin S, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1091-2; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086; Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008; Satoh T, 2010, NAT IMMUNOL, V11, P936, DOI 10.1038/ni.1920; Schneider-Stock R, 2005, J PHARMACOL EXP THER, V312, P525, DOI 10.1124/jpet.104.074195; Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Stender JD, 2012, MOL CELL, V48, P28, DOI 10.1016/j.molcel.2012.07.020; Stoler DL, 1999, P NATL ACAD SCI USA, V96, P15121, DOI 10.1073/pnas.96.26.15121; Stunnenberg HG, 2016, CELL, V167, P1145, DOI 10.1016/j.cell.2016.11.007; Subramanian S, 2010, PHARMACEUTICALS, V3, P2751, DOI 10.3390/ph3092751; Tan YF, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2431-2; von Knethen A, 1999, MOL BIOL CELL, V10, P361, DOI 10.1091/mbc.10.2.361; Wallner S, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0079-z; Wei ML, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4323281; Woan KV, 2015, MOL ONCOL, V9, P1447, DOI 10.1016/j.molonc.2015.04.002; Woods DM, 2017, BLOOD, V130, P146, DOI 10.1182/blood-2016-08-731505; Woods DM, 2015, CANCER IMMUNOL RES, V3, P1375, DOI 10.1158/2326-6066.CIR-15-0077-T; Wu XK, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.590618; Ye Q, 2010, TISSUE ANTIGENS, V75, P30, DOI 10.1111/j.1399-0039.2009.01390.x; You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008; Zheng H, 2016, CLIN CANCER RES, V22, P4119, DOI 10.1158/1078-0432.CCR-15-2584; Zhu SG, 2015, PHARM RES-DORDR, V32, P779, DOI 10.1007/s11095-013-1231-0; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	92	1	1	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 5	2021	12								775101	10.3389/fimmu.2021.775101	http://dx.doi.org/10.3389/fimmu.2021.775101			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WL9OY	34675944	gold, Green Published			2022-12-18	WOS:000710728200001
J	Sumagin, R; Henson, SM; Morrison, VL; McGettrick, HM				Sumagin, Ronen; Henson, Sian M.; Morrison, Vicky L.; McGettrick, Helen M.			Editorial: Targeting Leukocyte Trafficking: Insights and Future Directions	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						adhesion; ageing; chronic inflammatory diseases; Integrins; leukocyte; leukocyte recruitment; migration; T-cells			[Sumagin, Ronen] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL USA; [Henson, Sian M.] Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med & Dent, Translat Med & Therapeut, London, England; [Morrison, Vicky L.] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland; [McGettrick, Helen M.] Univ Birmingham, Inst Inflammat & Ageing, Birmingham, W Midlands, England	Northwestern University; Feinberg School of Medicine; University of London; Queen Mary University London; University of Glasgow; University of Birmingham	McGettrick, HM (corresponding author), Univ Birmingham, Inst Inflammat & Ageing, Birmingham, W Midlands, England.	h.m.mcgettrick@bham.ac.uk		Henson, Sian/0000-0003-1893-4912	NIAID NIH HHS [R01 AI153568] Funding Source: Medline; NIDDK NIH HHS [R01 DK124199] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))			0	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 5	2021	12								777002	10.3389/fimmu.2021.777002	http://dx.doi.org/10.3389/fimmu.2021.777002			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WL9PL	34675945	Green Accepted, Green Published, gold			2022-12-18	WOS:000710729500001
J	Wulfken, LM; Becker, JC; Hayajneh, R; Wagner, AD; Schaper-Gerhardt, K; Flatt, N; Grimmelmann, I; Gutzmer, R				Wulfken, Lena Margarethe; Becker, Juergen Christian; Hayajneh, Rami; Wagner, Annette Doris; Schaper-Gerhardt, Katrin; Flatt, Nina; Grimmelmann, Imke; Gutzmer, Ralf			Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells	FRONTIERS IN IMMUNOLOGY			English	Article						case report; B cell depletion; immune checkpoint blockade; CD20; melanoma	IMMUNOTHERAPY	Introduction Checkpoint-Inhibition (CPI) with PD-1- and PD-L1-inhibitors is a well-established therapy for advanced stage melanoma patients. CPI mainly acts via T-lymphocytes. However, recent literature suggests also a role for B cells modulating its efficacy and tolerability of CPI. Case Report We report a 48-year-old female patient with metastatic melanoma affecting brain, lung, skin and lymph nodes. A preexisting granulomatosis with polyangiitis was treated with rituximab over five years prior to the diagnosis of melanoma, resulting in a complete depletion of B cells both in peripheral blood as well as the tumor tissue. In the absence of the mutation of the proto-oncogene b-raf, treatment with the PD-1 inhibitor nivolumab was initiated. This therapy was well tolerated and resulted in a deep partial response, which is ongoing for 14+ months. Flow cytometric analysis of peripheral blood mononuclear cells revealed 15% IL-10 producing and 14% CD24 and CD38 double positive regulatory B cells. Conclusion The exceptional clinical response to nivolumab monotherapy in our patient with depleted B cells sheds a new light on the relevance of B cells in the modulation of immune responses to melanoma. Obviously, B cells were not required for the efficacy of CPI in our patient. Moreover, the depletion of regulatory B cells may have improved efficacy of CPI.	[Wulfken, Lena Margarethe; Schaper-Gerhardt, Katrin; Flatt, Nina; Grimmelmann, Imke; Gutzmer, Ralf] Hannover Med Sch, Skin Canc Ctr Hannover, Dept Dermatol & Allergy, Hannover, Germany; [Becker, Juergen Christian; Hayajneh, Rami] Univ Duisburg Essen, Translat Skin Canc Res TSCR, Essen, Germany; [Becker, Juergen Christian; Hayajneh, Rami] German Canc Consortium DKTK, Heidelberg, Germany; [Becker, Juergen Christian; Hayajneh, Rami] German Canc Res Ctr, Heidelberg, Germany; [Becker, Juergen Christian; Hayajneh, Rami] Univ Hosp Essen, Dept Dermatol, Essen, Germany; [Becker, Juergen Christian; Hayajneh, Rami] Ctr Med Biol, Essen, Germany; [Wagner, Annette Doris] Hannover Med Sch, Clin Kidney & Hypertens Dis, Hannover, Germany; [Schaper-Gerhardt, Katrin; Gutzmer, Ralf] Ruhr Univ Bochum, Dept Dermatol, Minden, Germany	Hannover Medical School; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Duisburg Essen; Hannover Medical School; Ruhr University Bochum	Wulfken, LM (corresponding author), Hannover Med Sch, Skin Canc Ctr Hannover, Dept Dermatol & Allergy, Hannover, Germany.	wulfken.lena@mh-hannover.de			Claudia-von-Schilling Foundation; BMS Immunooncology Foundation	Claudia-von-Schilling Foundation; BMS Immunooncology Foundation	This study was supported by grants from the Claudia-von-Schilling Foundation and the BMS Immunooncology Foundation.	Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Damsky W, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0613-1; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Kobayashi T, 2019, J INVEST DERMATOL, V139, P1535, DOI 10.1016/j.jid.2019.02.016; Leiter U, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000897; Murakami Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49581-4; Sautes-Fridman C, 2019, NAT REV CANCER, V19, P307, DOI 10.1038/s41568-019-0144-6; Schrama D, 2001, IMMUNITY, V14, P111, DOI 10.1016/S1074-7613(09)00094-6; Somasundaram R, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00452-4; Thiel J, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1306-0; Wang WW, 2015, ONCOTARGET, V6, P33486, DOI 10.18632/oncotarget.5588; Yamada T, 2019, INTERNAL MED, V58, P3129, DOI 10.2169/internalmedicine.3018-19; Zaimoku Y, 2020, BRIT J HAEMATOL, V190, P610, DOI 10.1111/bjh.16651	13	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 5	2021	12								733961	10.3389/fimmu.2021.733961	http://dx.doi.org/10.3389/fimmu.2021.733961			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WK8RU	34675925	gold, Green Published			2022-12-18	WOS:000709989100001
J	de Fremont, GM; Hirsch, P; de Mestral, SG; Moguelet, P; Ditchi, Y; Emile, JF; Senet, P; Georgin-Lavialle, S; Hanslik, T; Maurier, F; Adedjouma, A; Abisror, N; Mahevas, T; Malard, F; Ades, L; Fenaux, P; Fain, O; Chasset, F; Mekinian, A				de Fremont, Gregoire Martin; Hirsch, Pierre; de Mestral, Santiago Gimenez; Moguelet, Philippe; Ditchi, Yoan; Emile, Jean-Francois; Senet, Patricia; Georgin-Lavialle, Sophie; Hanslik, Thomas; Maurier, Francois; Adedjouma, Amir; Abisror, Noemie; Mahevas, Thibault; Malard, Florent; Ades, Lionel; Fenaux, Pierre; Fain, Olivier; Chasset, Francois; Mekinian, Arsene		MINHEMON French Network Dysimmune	Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series	FRONTIERS IN IMMUNOLOGY			English	Article						myelodysplastic syndrome; chronic myelomonocytic leukemia; skin; next-generation sequencing; clonal hematopoiesis	HISTIOCYTOID SWEET-SYNDROME; AUTOIMMUNE MANIFESTATIONS; PREVALENCE; NEOPLASMS; CUTIS	Background Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are associated with cutaneous manifestations. Next-generation sequencing (NGS) is a tool capable of identifying clonal myeloid cells in the skin infiltrate and thus better characterize the link between hematological diseases and skin lesions. Objective To assess whether skin lesions of MDS/CMML are clonally related to blood or bone marrow cells using NGS. Methods Comparisons of blood or bone marrow and skin samples NGS findings from patients presenting with MDS/CMML and skin lesions in three French hospitals. Results Among the 14 patients recruited, 12 patients (86%) had mutations in the skin lesions biopsied, 12 patients (86%) had a globally similar mutational profile between blood/bone marrow and skin, and 10 patients (71%) had mutations with a high variant allele frequency (>10%) found in the myeloid skin infiltrate. Mutations in TET2 and DNMT3A, both in four patients, were the most frequent. Two patients harbored a UBA1 mutation on hematopoietic samples. Limitations Limited number of patients and retrospective collection of the data. Blood and skin sampling were not performed at the exact same time point for two patients. Conclusion Skin lesions in the setting of MDS/CMML are characterized by a clonal myeloid infiltrate in most cases.	[de Fremont, Gregoire Martin; Adedjouma, Amir; Abisror, Noemie; Mahevas, Thibault; Fain, Olivier; Mekinian, Arsene] Univ Paris 06, Sorborine Univ, Hop St Antoine, AP HP,Serv Med Interne & Inflammat,Dept Med Univ, Paris, France; [Hirsch, Pierre] Univ Paris 06, Sorborine Univ, Hop St Antoine, AP HP,Ctr Rech St Antoine,Serv Hematol Biol,INSER, Paris, France; [de Mestral, Santiago Gimenez; Ditchi, Yoan] Univ Paris 06, Sorborine Univ, Hop St Antoine, AP HP,Serv Anatomopathol, Paris, France; [Moguelet, Philippe] Hop Ambroise Pare, AP HP, Serv Anatomopathol, Boulogne Billancourt, France; [Moguelet, Philippe] Univ Versailles St Quentin En Yvelines, Boulogne Billancourt, France; [Emile, Jean-Francois] Univ Paris 06, Sorbonne Univ, Hop Tenon, AP HP,Serv Anatomopalhol, Paris, France; [Senet, Patricia; Chasset, Francois] Univ Paris 06, Serv Dermatol, Hop Tenon, AP HP,Sorbonne Univ, Paris, France; [Georgin-Lavialle, Sophie] Univ Paris 06, Serv Med Interne, Hop Tenon, AP HP,Sorbonne Univ, Paris, France; [Hanslik, Thomas] Hop Ambroise Pare, AP HP, Serv Med Interne, Boulogne Bilancourt, France; [Hanslik, Thomas] Univ Versailles St Quentin En Yvelines, Boulogne Bilancourt, France; [Maurier, Francois] Grp Hosp UNEOS, Serv Med Interne & Immunol Clin, Metz, France; [Malard, Florent] Univ Paris 06, Sorbonne Univ, Hop St Antoine, AP HP,Serv Hematol Clin, Paris, France; [Ades, Lionel; Fenaux, Pierre] Hop St Louis, AP HP, Serv Hematol, Paris, France; [Ades, Lionel; Fenaux, Pierre] Univ Paris, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Mekinian, A (corresponding author), Univ Paris 06, Sorborine Univ, Hop St Antoine, AP HP,Serv Med Interne & Inflammat,Dept Med Univ, Paris, France.	arsene.mekinian@aphp.fr		Malard, Florent/0000-0002-3474-0002				Al Ustwani O, 2013, LEUKEMIA RES, V37, P894, DOI 10.1016/j.leukres.2013.04.007; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Bacher U, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0148-6; Balin SJ, 2011, ARCH DERMATOL, V147, P331, DOI 10.1001/archdermatol.2011.39; Beck DB, 2020, NEW ENGL J MED, V383, P2628, DOI 10.1056/NEJMoa2026834; Bonnet P, 2019, HAEMATOLOGICA, V104, pE530, DOI 10.3324/haematol.2019.223552; Braun T, 2013, BEST PRACT RES CL HA, V26, P327, DOI 10.1016/j.beha.2013.09.003; CASTRO M, 1991, J RHEUMATOL, V18, P721; Chavan RN, 2014, J AM ACAD DERMATOL, V70, P1021, DOI 10.1016/j.jaad.2014.01.874; Cull AH, 2017, EXP HEMATOL, V55, P56, DOI 10.1016/j.exphem.2017.08.001; Delaleu J, 2021, BRIT J DERMATOL, V184, P367, DOI 10.1111/bjd.19547; Delplanque M, 2019, RHEUMATOLOGY, V58, P554, DOI 10.1093/rheumatology/key413; Fain O, 2011, REV MED INTERNE, V32, P552, DOI 10.1016/j.revmed.2010.08.005; Farah C, 2010, J EUR ACAD DERMATOL, V24, P1171, DOI 10.1111/j.1468-3083.2010.03614.x; Fraison JB, 2016, LEUKEMIA RES, V43, P13, DOI 10.1016/j.leukres.2016.02.005; Franzini A, 2019, BLOOD ADV, V3, P2949, DOI 10.1182/bloodadvances.2019000585; Guermouche H, 2020, BLOOD ADV, V4, P3550, DOI 10.1182/bloodadvances.2020001582; Mekinian A, 2016, RHEUMATOLOGY, V55, P291, DOI 10.1093/rheumatology/kev294; Osio A, 2015, J INVEST DERMATOL, V135, P2321, DOI 10.1038/jid.2015.146; Papo M, 2017, BLOOD, V130, P1007, DOI 10.1182/blood-2017-01-761718; Passet M, 2020, J INVEST DERMATOL, V140, P1873, DOI 10.1016/j.jid.2019.12.040; Pochlauer S, 2014, ANN HEMATOL, V93, P1775, DOI 10.1007/s00277-014-2012-5; Requena L, 2005, ARCH DERMATOL, V141, P834, DOI 10.1001/archderm.141.7.834; Spaulding TP, 2020, BRIT J HAEMATOL, V188, P224, DOI 10.1111/bjh.16212; Sujobert P, 2013, J INVEST DERMATOL, V133, P1111, DOI 10.1038/jid.2012.408; Van Loon K, 2012, AM J CLIN PATHOL, V137, P310, DOI 10.1309/AJCP9I7NRWYLTJHV; Wesner N, 2019, LEUKEMIA LYMPHOMA, V60, P1782, DOI 10.1080/10428194.2018.1542152; Yoneta K, 2016, EUR J DERMATOL, V26, P398, DOI 10.1684/ejd.2016.2812	28	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 4	2021	12								715053	10.3389/fimmu.2021.715053	http://dx.doi.org/10.3389/fimmu.2021.715053			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV3NH	34671345	Green Published, gold			2022-12-18	WOS:000717145700001
J	Fan, YX; Wang, YB; Zhang, J; Dong, XC; Gao, P; Liu, K; Ma, CY; Zhao, G				Fan, Yuxiang; Wang, Yubo; Zhang, Jian; Dong, Xuechao; Gao, Pu; Liu, Kai; Ma, Chengyuan; Zhao, Gang			Breaking Bad: Autophagy Tweaks the Interplay Between Glioma and the Tumor Immune Microenvironment	FRONTIERS IN IMMUNOLOGY			English	Review						autophagy; glioma; MDSC; neutrophil; tumor-associated macrophage; tumor immune microenvironment	REGULATORY T-CELLS; ALTERS MACROPHAGE POLARIZATION; RADIATION-INDUCED AUTOPHAGY; SUPPRESSOR-CELLS; DENDRITIC CELLS; TEMOZOLOMIDE CYTOTOXICITY; GLIOBLASTOMA-MULTIFORME; HEPATOCELLULAR-CARCINOMA; CYTOPROTECTIVE AUTOPHAGY; CANCER-IMMUNOTHERAPY	Though significant strides in tumorigenic comprehension and therapy modality have been witnessed over the past decades, glioma remains one of the most common and malignant brain tumors characterized by recurrence, dismal prognosis, and therapy resistance. Immunotherapy advance holds promise in glioma recently. However, the efficacy of immunotherapy varies among individuals with glioma, which drives researchers to consider the modest levels of immunity in the central nervous system, as well as the immunosuppressive tumor immune microenvironment (TIME). Considering the highly conserved property for sustaining energy homeostasis in mammalian cells and repeatedly reported links in malignancy and drug resistance, autophagy is determined as a cutting angle to elucidate the relations between glioma and the TIME. In this review, heterogeneity of TIME in glioma is outlined along with the reciprocal impacts between them. In addition, controversies on whether autophagy behaves cytoprotectively or cytotoxically in cancers are covered. How autophagy collapses from its homeostasis and aids glioma malignancy, which may depend on the cell type and the cellular context such as reactive oxygen species (ROS) and adenosine triphosphate (ATP) level, are briefly discussed. The consecutive application of autophagy inducers and inhibitors may improve the drug resistance in glioma after overtreatments. It also highlights that autophagy plays a pivotal part in modulating glioma and the TIME, respectively, and the intricate interactions among them. Specifically, autophagy is manipulated by either glioma or tumor-associated macrophages to conform one side to the other through exosomal microRNAs and thereby adjust the interactions. Given that some of the crosstalk between glioma and the TIME highly depend on the autophagy process or autophagic components, there are interconnections influenced by the status and well-being of cells presumably associated with autophagic flux. By updating the most recent knowledge concerning glioma and the TIME from an autophagic perspective enhances comprehension and inspires more applicable and effective strategies targeting TIME while harnessing autophagy collaboratively against cancer.	[Fan, Yuxiang; Wang, Yubo; Zhang, Jian; Dong, Xuechao; Gao, Pu; Liu, Kai; Ma, Chengyuan; Zhao, Gang] First Hosp Jilin Univ, Dept Neurosurg, Changchun, Peoples R China	Jilin University	Ma, CY; Zhao, G (corresponding author), First Hosp Jilin Univ, Dept Neurosurg, Changchun, Peoples R China.	macyjdyy@126.com; zhaogjdyy@126.com			National Nature and Science Foundation of China	National Nature and Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding We acknowledge the funding support from National Nature and Science Foundation of China (Grant Number: 81772684 and 81872050), the S&T Development Planning Program of Jilin Province (Grant Number: 20200201469JC, 20200201613JC, and 20200201388JC), and Foundation from the Development and Reform Commission of Jilin Province (Grant Number: 2017C059-2, and Chinese People's Brain Neural Network Research and Innovation Cooperation Platform Construction Project).	Alban TJ, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122264; Alissafi T, 2018, J CLIN INVEST, V128, P3840, DOI 10.1172/JCI120888; Andrews LP, 2017, IMMUNOL REV, V276, P80, DOI 10.1111/imr.12519; Anguille S, 2014, LANCET ONCOL, V15, pE257, DOI 10.1016/S1470-2045(13)70585-0; Attarha S, 2017, CELL SIGNAL, V37, P81, DOI 10.1016/j.cellsig.2017.06.004; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bhattacharya A, 2015, CELL REP, V12, P1731, DOI 10.1016/j.celrep.2015.08.019; Botbol Y, 2015, AUTOPHAGY, V11, P1864, DOI 10.1080/15548627.2015.1089374; Bowman RL, 2016, CELL REP, V17, P2445, DOI 10.1016/j.celrep.2016.10.052; Bruyere C, 2011, INT J ONCOL, V38, P1453, DOI 10.3892/ijo.2011.964; Buccarelli M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0864-7; Candolfi M, 2012, NEOPLASIA, V14, P757, DOI 10.1593/neo.12794; Cantini G, 2011, CANCER IMMUNOL IMMUN, V60, P1739, DOI 10.1007/s00262-011-1069-4; Chang AL, 2016, CANCER RES, V76, P5671, DOI 10.1158/0008-5472.CAN-16-0144; Chang CP, 2013, AUTOPHAGY, V9, P619, DOI 10.4161/auto.23546; Chen PW, 2019, CANCER CELL, V35, P868, DOI 10.1016/j.ccell.2019.05.003; Chen PW, 2014, AUTOPHAGY, V10, P192, DOI 10.4161/auto.26927; Chen Q, 2019, INT J CANCER, V145, P517, DOI 10.1002/ijc.32102; Chen R, 2019, NEOPLASIA, V21, P52, DOI 10.1016/j.neo.2018.11.007; Chen W, 2012, CANCER RES, V72, P1363, DOI 10.1158/0008-5472.CAN-11-2684; Chen XB, 2014, CANCER RES, V74, P7285, DOI 10.1158/0008-5472.CAN-14-1240; Chen ZH, 2017, CANCER RES, V77, P2266, DOI 10.1158/0008-5472.CAN-16-2310; Clarke AJ, 2019, NAT REV IMMUNOL, V19, P170, DOI 10.1038/s41577-018-0095-2; Collin M, 2018, IMMUNOLOGY, V154, P3, DOI 10.1111/imm.12888; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Cunha LD, 2018, CELL, V175, P429, DOI 10.1016/j.cell.2018.08.061; Darmanis S, 2017, CELL REP, V21, P1399, DOI 10.1016/j.celrep.2017.10.030; De Leo A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010018; Desland FA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197358; DeVorkin L, 2019, CELL REP, V27, P502, DOI 10.1016/j.celrep.2019.03.037; Dey M, 2015, J IMMUNOL, V195, P367, DOI 10.4049/jimmunol.1401607; Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4; Domingues P, 2016, BRAIN BEHAV IMMUN, V53, P1, DOI 10.1016/j.bbi.2015.07.019; Dowling SD, 2018, CANCER LETT, V419, P20, DOI 10.1016/j.canlet.2018.01.033; Fan YX, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/1872962; Fazi B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102496; Feng F, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109441; Filippi-Chiela EC, 2015, AUTOPHAGY, V11, P1099, DOI 10.1080/15548627.2015.1009795; Filley AC, 2017, J NEURO-ONCOL, V133, P223, DOI 10.1007/s11060-017-2446-4; Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150; Flores-Toro JA, 2020, P NATL ACAD SCI USA, V117, P1129, DOI 10.1073/pnas.1910856117; Folgiero V, 2016, ONCOTARGET, V7, P52900, DOI 10.18632/oncotarget.9284; Fortin C, 2012, J IMMUNOL, V189, P1843, DOI 10.4049/jimmunol.1200584; Fossati G, 1999, ACTA NEUROPATHOL, V98, P349, DOI 10.1007/s004010051093; Friebel E, 2020, CELL, V181, P1626, DOI 10.1016/j.cell.2020.04.055; Fu WL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00835; Fujita M, 2011, CANCER RES, V71, P2664, DOI 10.1158/0008-5472.CAN-10-3055; Fujita M, 2010, CLIN CANCER RES, V16, P3409, DOI 10.1158/1078-0432.CCR-10-0644; Galan-Moya EM, 2011, EMBO REP, V12, P470, DOI 10.1038/embor.2011.39; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Gammoh N, 2016, AUTOPHAGY, V12, P1431, DOI 10.1080/15548627.2016.1190053; Gargini R, 2020, CANCERS, V12, DOI 10.3390/cancers12061622; Gerada C, 2020, MOL ONCOL, V14, P1913, DOI 10.1002/1878-0261.12774; Germic N, 2019, CELL DEATH DIFFER, V26, P715, DOI 10.1038/s41418-019-0297-6; Gewirtz DA, 2014, AUTOPHAGY, V10, P391, DOI 10.4161/auto.27719; Ghirelli C, 2015, CANCER RES, V75, P2775, DOI 10.1158/0008-5472.CAN-14-2386; Gielen PR, 2015, J NEUROPATH EXP NEUR, V74, P390, DOI 10.1097/NEN.0000000000000183; Gieryng A, 2017, LAB INVEST, V97, P498, DOI 10.1038/labinvest.2017.19; Golden EB, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.9.FOCUS14504; Goncalves RM, 2019, BIOCHEM PHARMACOL, V163, P440, DOI 10.1016/j.bcp.2019.03.015; Guo XF, 2019, INT J CANCER, V144, P3111, DOI 10.1002/ijc.32052; Guo XF, 2018, ONCOGENE, V37, P4239, DOI 10.1038/s41388-018-0261-9; Gutmann DH, 2019, NEURON, V104, P442, DOI 10.1016/j.neuron.2019.08.028; Hambardzumyan D, 2016, NAT NEUROSCI, V19, P20, DOI 10.1038/nn.4185; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hanihara M, 2016, J NEUROSURG, V124, P1594, DOI 10.3171/2015.5.JNS141901; Hegazy AM, 2016, J BIOL CHEM, V291, P21496, DOI 10.1074/jbc.M116.734756; Heimberger AB, 2008, CLIN CANCER RES, V14, P5166, DOI 10.1158/1078-0432.CCR-08-0320; Hoechst B, 2009, HEPATOLOGY, V50, P799, DOI 10.1002/hep.23054; Hombach-Klonisch S, 2018, PHARMACOL THERAPEUT, V184, P13, DOI 10.1016/j.pharmthera.2017.10.017; Hor WS, 2003, J LEUKOCYTE BIOL, V73, P363, DOI 10.1189/jlb.0702375; Hori YS, 2015, J NEURO-ONCOL, V122, P11, DOI 10.1007/s11060-014-1686-9; Hou WC, 2017, ONCOL RES, V25, P43, DOI 10.3727/096504016X14719078133285; Houtman J, 2019, EMBO J, V38, DOI 10.15252/embj.201899430; Hsu SPC, 2020, J NEURO-ONCOL, V146, P417, DOI 10.1007/s11060-019-03360-3; Hu CE, 2011, SCAND J GASTROENTERO, V46, P156, DOI 10.3109/00365521.2010.516450; Hu F, 2015, NEURO-ONCOLOGY, V17, P200, DOI 10.1093/neuonc/nou324; Hu F, 2014, INT J CANCER, V135, P2569, DOI 10.1002/ijc.28908; Hu XY, 2005, NEOPLASIA, V7, P356, DOI 10.1593/neo.04595; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Huang TZ, 2019, AUTOPHAGY, V15, P1100, DOI 10.1080/15548627.2019.1569947; Huang TZ, 2017, CANCER CELL, V32, P840, DOI 10.1016/j.ccell.2017.11.005; Huang YM, 2020, J NEUROSCI, V40, P6428, DOI 10.1523/JNEUROSCI.0666-20.2020; Hubbard VM, 2010, J IMMUNOL, V185, P7349, DOI 10.4049/jimmunol.1000576; Hutter G, 2019, P NATL ACAD SCI USA, V116, P997, DOI 10.1073/pnas.1721434116; Inda MD, 2014, CANCERS, V6, P226, DOI 10.3390/cancers6010226; Ito H, 2005, INT J ONCOL, V26, P1401; Iwatsuki K, 2000, NEUROL RES, V22, P465; Jacquel A, 2012, BLOOD, V119, P4527, DOI 10.1182/blood-2011-11-392167; Jalota A, 2016, TUMOR BIOL, V37, P12347, DOI 10.1007/s13277-016-5089-8; Jansen T, 2010, NEURO-ONCOLOGY, V12, P482, DOI 10.1093/neuonc/nop052; Jawhari S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.318; Jhanwar-Uniyal M, 2011, ADV ENZYME REGUL, V51, P164, DOI 10.1016/j.advenzreg.2010.09.017; Jia W, 2015, AUTOPHAGY, V11, P2335, DOI 10.1080/15548627.2015.1110666; Jia W, 2011, J IMMUNOL, V186, P5313, DOI 10.4049/jimmunol.1002404; Jia WT, 2010, J NEUROIMMUNOL, V223, P20, DOI 10.1016/j.jneuroim.2010.03.011; Jiang CM, 2018, BIOMED PHARMACOTHER, V97, P844, DOI 10.1016/j.biopha.2017.10.146; Jo GH, 2015, CANCER RES TREAT, V47, P221, DOI 10.4143/crt.2013.159; Kahlert UD, 2012, J NEUROPATH EXP NEUR, V71, P1086, DOI 10.1097/NEN.0b013e3182772d83; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030; Khan S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061954; Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004; Klemm F, 2020, CELL, V181, P1643, DOI 10.1016/j.cell.2020.05.007; Knizhnik AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055665; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Koukourakis MI, 2016, BRIT J CANCER, V114, P485, DOI 10.1038/bjc.2016.19; Kouo T, 2015, CANCER IMMUNOL RES, V3, P412, DOI 10.1158/2326-6066.CIR-14-0150; Kriel J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28590-9; Kumar V, 2016, IMMUNITY, V44, P303, DOI 10.1016/j.immuni.2016.01.014; Lapointe S, 2018, LANCET, V392, P432, DOI 10.1016/S0140-6736(18)30990-5; Lee SW, 2015, CANCER LETT, V360, P195, DOI 10.1016/j.canlet.2015.02.012; Lee-Chang C, 2019, CANCER IMMUNOL RES, V7, P1928, DOI 10.1158/2326-6066.CIR-19-0240; Li HQ, 2009, J IMMUNOL, V182, P240, DOI 10.4049/jimmunol.182.1.240; Li TF, 2019, ACTA BIOMATER, V86, P381, DOI 10.1016/j.actbio.2019.01.020; Liang J, 2014, CLIN CANCER RES, V20, P187, DOI 10.1158/1078-0432.CCR-13-1279; Lim EJ, 2018, BMB REP, V51, P182, DOI 10.5483/BMBRep.2018.51.4.185; Lin CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038706; Lin JZ, 2021, GENOMICS, V113, P767, DOI 10.1016/j.ygeno.2020.10.008; Lin JC, 2013, INT IMMUNOPHARMACOL, V15, P333, DOI 10.1016/j.intimp.2013.01.006; Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708; Liu K, 2015, AUTOPHAGY, V11, P271, DOI 10.1080/15548627.2015.1009787; Liu L, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00076; Liu T, 2019, ONCOL REP, V41, P1883, DOI 10.3892/or.2019.6970; Liu Y, 2020, ONCOGENE, V39, P6190, DOI 10.1038/s41388-020-01422-9; Liu YF, 2015, IMMUNOPHARM IMMUNOT, V37, P359, DOI 10.3109/08923973.2015.1059442; Lohr J, 2011, CLIN CANCER RES, V17, P4296, DOI 10.1158/1078-0432.CCR-10-2557; Lopez-Valero I, 2018, BIOCHEM PHARMACOL, V157, P275, DOI 10.1016/j.bcp.2018.08.023; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Lu H, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1805-9; Lu J, 2020, CANCER SCI, V111, P1979, DOI 10.1111/cas.14408; Lv QL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.560543; Ma BB, 2017, BBA-MOL CELL RES, V1864, P1393, DOI 10.1016/j.bbamcr.2017.05.008; Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Mbongue JC, 2015, VACCINES-BASEL, V3, P703, DOI 10.3390/vaccines3030703; Mellor AL, 2011, J IMMUNOL, V186, P4535, DOI 10.4049/jimmunol.1002937; Metz R, 2012, ONCOIMMUNOLOGY, V1, P1460, DOI 10.4161/onci.21716; Mi YJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00737; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Mocholi E, 2018, CELL REP, V24, P1136, DOI 10.1016/j.celrep.2018.06.065; Molina ML, 2020, CANCERS, V12, DOI 10.3390/cancers12010102; Mora R, 2009, AUTOPHAGY, V5, P419, DOI 10.4161/auto.5.3.7881; Mora R, 2009, GLIA, V57, P561, DOI 10.1002/glia.20785; Muller A, 2015, INT J CANCER, V137, P278, DOI 10.1002/ijc.29379; Muller S, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1362-4; Munn DH, 2005, IMMUNITY, V22, P633, DOI 10.1016/j.immuni.2005.03.013; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Ostrand-Rosenberg S, 2012, SEMIN CANCER BIOL, V22, P275, DOI 10.1016/j.semcancer.2012.01.011; Paladugu M, 2013, CANCER IMMUNOL IMMUN, V62, P75, DOI 10.1007/s00262-012-1312-7; Palucka K, 2012, NAT REV CANCER, V12, P265, DOI 10.1038/nrc3258; Palumbo S, 2014, J CELL PHYSIOL, V229, P1863, DOI 10.1002/jcp.24640; Palumbo S, 2012, J CELL BIOCHEM, V113, P2308, DOI 10.1002/jcb.24102; Perng P, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00153; Pinton L, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0536-x; Pires-Afonso Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030689; Platten M, 2003, ANN NEUROL, V54, P388, DOI 10.1002/ana.10679; Poillet-Perez L, 2018, NATURE, V563, P569, DOI 10.1038/s41586-018-0697-7; Polajeva J, 2014, MOL ONCOL, V8, P50, DOI 10.1016/j.molonc.2013.09.002; Polajeva J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025222; Pratt J, 2014, CELL SIGNAL, V26, P917, DOI 10.1016/j.cellsig.2014.01.012; Pua HH, 2009, AUTOPHAGY, V5, P745, DOI 10.4161/auto.5.5.8702; Puleston DJ, 2014, ELIFE, V3, DOI 10.7554/eLife.03706; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Qian MY, 2020, ONCOGENE, V39, P428, DOI 10.1038/s41388-019-0996-y; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Raber PL, 2014, INT J CANCER, V134, P2853, DOI 10.1002/ijc.28622; Rahbar A, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1075693; Rashidi A, 2020, CANCER IMMUNOL IMMUN, V69, P81, DOI 10.1007/s00262-019-02441-6; Raychaudhuri B, 2011, NEURO-ONCOLOGY, V13, P591, DOI 10.1093/neuonc/nor042; Roesch S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020436; Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984; Ryabaya OO, 2017, ANTI-CANCER DRUG, V28, P307, DOI 10.1097/CAD.0000000000000463; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Sampson JH, 2020, NAT REV CANCER, V20, P12, DOI 10.1038/s41568-019-0224-7; Sayour EJ, 2015, CANCER IMMUNOL IMMUN, V64, P419, DOI 10.1007/s00262-014-1651-7; Schiff D, 2019, NEURO-ONCOLOGY, V21, P837, DOI 10.1093/neuonc/noz033; Shand FHW, 2014, P NATL ACAD SCI USA, V111, P7771, DOI 10.1073/pnas.1402914111; Shao NY, 2019, J NEURO-ONCOL, V141, P277, DOI 10.1007/s11060-018-03043-5; Shchors K, 2015, CANCER CELL, V28, DOI 10.1016/j.ccell.2015.08.012; Shi F, 2017, NEUROSCIENCE, V346, P298, DOI 10.1016/j.neuroscience.2017.01.032; Shingu T, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0803-2; Singer E, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.566; Skendros P, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00109; Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008; Sugihara H, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0618-7; Sunayama J, 2010, NEURO-ONCOLOGY, V12, P1205, DOI 10.1093/neuonc/noq103; Szulzewsky F, 2016, GLIA, V64, P1416, DOI 10.1002/glia.23014; Szulzewsky F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116644; Tamrakar S, 2019, ANTICANCER RES, V39, P1233, DOI 10.21873/anticanres.13233; Taylor MA, 2018, APOPTOSIS, V23, P563, DOI 10.1007/s10495-018-1480-9; Tekirdag K, 2018, J BIOL CHEM, V293, P5414, DOI 10.1074/jbc.R117.818237; Ugolini A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138581; Ulasov I, 2020, TRENDS MOL MED, V26, P252, DOI 10.1016/j.molmed.2019.11.001; Valdor R, 2019, P NATL ACAD SCI USA, V116, P20655, DOI 10.1073/pnas.1903542116; Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590-017-0022-x; Vidyarthi A, 2019, CANCER IMMUNOL IMMUN, V68, P1995, DOI 10.1007/s00262-019-02423-8; Vinnakota K, 2013, NEURO-ONCOLOGY, V15, P1457, DOI 10.1093/neuonc/not115; Wainwright DA, 2012, CLIN CANCER RES, V18, P6110, DOI 10.1158/1078-0432.CCR-12-2130; Waisman A, 2017, SEMIN IMMUNOPATHOL, V39, P153, DOI 10.1007/s00281-016-0583-z; Wallmann T, 2018, ISCIENCE, V9, P71, DOI 10.1016/j.isci.2018.10.011; Wang B, 2019, CANCER LETT, V447, P93, DOI 10.1016/j.canlet.2019.01.008; Wang HY, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.603128; Wang PF, 2020, AGING-US, V12, P15290, DOI 10.18632/aging.103428; Wang QW, 2020, ONCOTARGETS THER, V13, P95, DOI 10.2147/OTT.S238332; Wang SC, 2012, LAB INVEST, V92, P151, DOI 10.1038/labinvest.2011.128; Wang T, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2506-0; Wang YL, 2020, J CELL MOL MED, V24, P3807, DOI 10.1111/jcmm.14938; Wei J, 2020, NEURO-ONCOLOGY, V22, P180, DOI 10.1093/neuonc/noz212; Weil J, 2016, NAT IMMUNOL, V17, P277, DOI 10.1038/ni.3365; Weiss N, 2009, BBA-BIOMEMBRANES, V1788, P842, DOI 10.1016/j.bbamem.2008.10.022; Wen ZP, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1287-8; Whipple CA, 2014, BRIT J CANCER, V111, P1625, DOI 10.1038/bjc.2014.452; Wiendl H, 2002, J IMMUNOL, V168, P4772, DOI 10.4049/jimmunol.168.9.4772; Workman CJ, 2003, EUR J IMMUNOL, V33, P970, DOI 10.1002/eji.200323382; Woroniecka K, 2018, CLIN CANCER RES, V24, P4175, DOI 10.1158/1078-0432.CCR-17-1846; Wu CYJ, 2020, NEURO-ONCOLOGY, V22, P253, DOI 10.1093/neuonc/noz189; Xu JY, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03664-1; Xu LX, 2020, CANCER SCI, V111, P2284, DOI 10.1111/cas.14427; Xu SC, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.694633; Xu XJ, 2014, NAT IMMUNOL, V15, P1152, DOI 10.1038/ni.3025; Xu Y, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.571189; Xue H, 2016, AUTOPHAGY, V12, P1129, DOI 10.1080/15548627.2016.1178446; Yan YL, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0303-5; Yang LQ, 2012, EXP CELL RES, V318, P2417, DOI 10.1016/j.yexcr.2012.07.017; Yang M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-43; Yang ZH, 2020, ONCOTARGETS THER, V13, P989, DOI 10.2147/OTT.S239648; Yao J, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-021-02766-w; Yee PP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19193-y; Yu X, 2009, NAT IMMUNOL, V10, P48, DOI 10.1038/ni.1674; Zanotto-Filho A, 2015, CANCER LETT, V358, P220, DOI 10.1016/j.canlet.2014.12.044; Zha CJ, 2020, CANCER BIOL MED, V17, P154, DOI 10.20892/j.issn.2095-3941.2019.0353; Zhang C, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0628-8; Zhang H, 2017, ONCOGENE, V36, P2095, DOI 10.1038/onc.2016.367; Zhang H, 2021, COMPUT STRUCT BIOTEC, V19, P4603, DOI 10.1016/j.csbj.2021.08.019; Zhang H, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.110086; Zhang N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.656541; Zhang X, 2020, LAB INVEST, V100, P619, DOI 10.1038/s41374-019-0345-3; Zhang XR, 2021, CANCER GENE THER, V28, P971, DOI 10.1038/s41417-020-0205-8; Zhang XY, 2018, APPL MICROBIOL BIOT, V102, P6503, DOI 10.1007/s00253-018-9069-3; Zhang XY, 2018, CARCINOGENESIS, V39, P689, DOI 10.1093/carcin/bgy041; Zhang Y, 2012, BLOOD, V119, P2895, DOI 10.1182/blood-2011-08-372383; Zheng Y, 2009, J IMMUNOL, V183, P6095, DOI 10.4049/jimmunol.0803510; Zheng Y, 2021, CELL BIOSCI, V11, DOI 10.1186/s13578-021-00575-8; Zheng ZN, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000207; Zhuang WZ, 2011, INT J CANCER, V129, P2720, DOI 10.1002/ijc.25975	247	1	1	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 4	2021	12								746621	10.3389/fimmu.2021.746621	http://dx.doi.org/10.3389/fimmu.2021.746621			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV2VR	34671362	gold, Green Published			2022-12-18	WOS:000717096500001
J	Giron, LB; Dweep, H; Yin, XF; Wang, H; Damra, M; Goldman, AR; Gorman, N; Palmer, CS; Tang, HY; Shaikh, MW; Forsyth, CB; Balk, RA; Zilberstein, NF; Liu, Q; Kossenkov, A; Keshavarzian, A; Landay, A; Abdel-Mohsen, M				Giron, Leila B.; Dweep, Harsh; Yin, Xiangfan; Wang, Han; Damra, Mohammad; Goldman, Aaron R.; Gorman, Nicole; Palmer, Clovis S.; Tang, Hsin-Yao; Shaikh, Maliha W.; Forsyth, Christopher B.; Balk, Robert A.; Zilberstein, Netanel F.; Liu, Qin; Kossenkov, Andrew; Keshavarzian, Ali; Landay, Alan; Abdel-Mohsen, Mohamed			Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients (vol 12, 686240, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						SARS-CoV-2; COVID-19; microbial translocation; inflammation; zonulin; metabolomics; glycomics; lipidomics			[Giron, Leila B.; Dweep, Harsh; Yin, Xiangfan; Wang, Han; Damra, Mohammad; Goldman, Aaron R.; Gorman, Nicole; Tang, Hsin-Yao; Liu, Qin; Kossenkov, Andrew; Abdel-Mohsen, Mohamed] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA; [Palmer, Clovis S.] Burnet Inst, Melbourne, Vic, Australia; [Palmer, Clovis S.] Monash Univ, Dept Infect Dis, Melbourne, Vic, Australia; [Shaikh, Maliha W.; Forsyth, Christopher B.; Keshavarzian, Ali] Rush Univ, Rush Ctr Integrated Microbiome & Chronobiol Res, Chicago, IL 60612 USA; [Forsyth, Christopher B.; Balk, Robert A.; Zilberstein, Netanel F.; Keshavarzian, Ali; Landay, Alan] Rush Univ, Med Ctr, Dept Internal Med, Chicago, IL 60612 USA	The Wistar Institute; Burnet Institute; Monash University; Rush University; Rush University	Abdel-Mohsen, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	mmohsen@wistar.org						Giron LB, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.686240	1	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 4	2021	12								779064	10.3389/fimmu.2021.779064	http://dx.doi.org/10.3389/fimmu.2021.779064			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WL8ZA	34671365	Green Published, gold			2022-12-18	WOS:000710685900001
J	Peng, YM; Tao, JJ; Kuang, SF; Jiang, M; Peng, XX; Li, H				Peng, Yu-ming; Tao, Jian-jun; Kuang, Su-fang; Jiang, Ming; Peng, Xuan-xian; Li, Hui			Identification of Polyvalent Vaccine Candidates From Extracellular Secretory Proteins in Vibrio alginolyticus	FRONTIERS IN IMMUNOLOGY			English	Article						vaccine; polyvalent vaccine; DNA vaccine; extracellular secretory proteome; bacteria	OUTER-MEMBRANE PROTEINS; PROTECTIVE IMMUNOGENS; IMMUNE PROTECTION; ANTIBIOTICS; ZEBRAFISH; OMPAS; CAP; PARAHAEMOLYTICUS; CONSTRUCTION; AQUACULTURE	Bacterial infections cause huge losses in aquaculture and a wide range of health issues in humans. A vaccine is the most economical, efficient, and environment-friendly agent for protecting hosts against bacterial infections. This study aimed to identify broad, cross-protective antigens from the extracellular secretory proteome of the marine bacterium Vibrio alginolyticus. Of the 69 predicted extracellular secretory proteins in its genome, 16 were randomly selected for gene cloning to construct DNA vaccines, which were used to immunize zebrafish (Danio rerio). The innate immune response genes were also investigated. Among the 16 DNA vaccines, 3 (AT730_21605, AT730_22220, and AT730_22910) were protective against V. alginolyticus infection with 47-66.7% increased survival compared to the control, while other vaccines had lower or no protective effects. Furthermore, AT730_22220, AT730_22910, and AT730_21605 also exhibited cross-immune protective effects against Pseudomonas fluorescens and/or Aeromonas hydrophila infection. Mechanisms for cross-protective ability was explored based on conserved epitopes, innate immune responses, and antibody neutralizing ability. These results indicate that AT730_21605, AT730_22220, and AT730_22910 are potential polyvalent vaccine candidates against bacterial infections. Additionally, our results suggest that the extracellular secretory proteome is an antigen pool that can be used for the identification of cross-protective immunogens.</p>	[Peng, Yu-ming; Tao, Jian-jun; Kuang, Su-fang; Jiang, Ming; Peng, Xuan-xian; Li, Hui] Sun Yat Sen Univ, Southern Marine Sci & Engn Guangdong Lab Zhuhai, Sch Life Sci, State Key Lab Biocontrol, Guangzhou, Peoples R China; [Peng, Xuan-xian; Li, Hui] Qingdao Natl Lab Marine Sci & Technol, Lab Marine Fisheries Sci & Food Prod Proc, Qingdao, Peoples R China; [Peng, Yu-ming] Sun Yat Sen Univ, Sch Life Sci, Guangzhou, Peoples R China	Southern Marine Science & Engineering Guangdong Laboratory; Sun Yat Sen University; Qingdao National Laboratory for Marine Science & Technology; Sun Yat Sen University	Li, H (corresponding author), Sun Yat Sen Univ, Southern Marine Sci & Engn Guangdong Lab Zhuhai, Sch Life Sci, State Key Lab Biocontrol, Guangzhou, Peoples R China.; Li, H (corresponding author), Qingdao Natl Lab Marine Sci & Technol, Lab Marine Fisheries Sci & Food Prod Proc, Qingdao, Peoples R China.	lihui32@sysu.edu.cn			Guangzhou Science and Technology Project [201904020042]; Innovation Group Project of Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai) [311021006]; International Exchanges Scheme (NSFC-RS) [31911530183]	Guangzhou Science and Technology Project; Innovation Group Project of Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai); International Exchanges Scheme (NSFC-RS)	Funding This work was sponsored by grants from Guangzhou Science and Technology Project (201904020042), Innovation Group Project of Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai) (No. 311021006), and International Exchanges Scheme (NSFC-RS, 31911530183).	Bedke T, 2019, SEMIN IMMUNOL, V44, DOI 10.1016/j.smim.2019.101335; Cabello FC, 2006, ENVIRON MICROBIOL, V8, P1137, DOI 10.1111/j.1462-2920.2006.01054.x; Celik MO, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133093; Cheng ZX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11129-5; Cheng ZX, 2018, FISH SHELLFISH IMMUN, V75, P308, DOI 10.1016/j.fsi.2018.02.022; Cho SY, 2017, BIOCHEM BIOPH RES CO, V489, P63, DOI 10.1016/j.bbrc.2017.05.093; Ge LK, 2018, SCI TOTAL ENVIRON, V633, P1192, DOI 10.1016/j.scitotenv.2018.03.279; Gentry RR, 2017, NAT ECOL EVOL, V1, P1317, DOI 10.1038/s41559-017-0257-9; Ghasemi A, 2018, VACCINE, V36, P5124, DOI 10.1016/j.vaccine.2018.07.033; Ghasemi A, 2018, MOL IMMUNOL, V94, P176, DOI 10.1016/j.molimm.2018.01.001; Gong QY, 2020, MICROB BIOTECHNOL, V13, P796, DOI 10.1111/1751-7915.13553; Hiseni A, 2011, APPL MICROBIOL BIOT, V91, P1029, DOI 10.1007/s00253-011-3324-1; HUNT JD, 1994, VACCINE, V12, P457, DOI 10.1016/0264-410X(94)90125-2; IKEDA T, 1985, J MOL BIOL, V184, P735, DOI 10.1016/0022-2836(85)90317-1; Jiang M, 2020, VIRULENCE, V11, P877, DOI 10.1080/21505594.2020.1787604; Jiang M, 2020, MICROB BIOTECHNOL, V13, P1213, DOI 10.1111/1751-7915.13582; Jiang M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01991; Jiang M, 2019, FISH SHELLFISH IMMUN, V84, P912, DOI 10.1016/j.fsi.2018.10.071; Kandel PP, 2014, FEMS MICROBIOL ECOL, V89, P149, DOI 10.1111/1574-6941.12342; Kuang SF, 2021, VIRULENCE, V12, P1737, DOI 10.1080/21505594.2021.1947447; Li H, 2016, FISH SHELLFISH IMMUN, V58, P508, DOI 10.1016/j.fsi.2016.09.058; Li H, 2016, FISH SHELLFISH IMMUN, V49, P230, DOI 10.1016/j.fsi.2015.12.024; Li H, 2010, J PROTEOME RES, V9, P2573, DOI 10.1021/pr1000219; Li H, 2009, J PROTEOME RES, V8, P4342, DOI 10.1021/pr900439j; Li L, 2020, ENVIRON MICROBIOL, V22, P4295, DOI 10.1111/1462-2920.15021; Lipsitch M, 2016, MBIO, V7, DOI 10.1128/mBio.00428-16; Maki-Yonekura S, 2003, P NATL ACAD SCI USA, V100, P15528, DOI 10.1073/pnas.2534343100; Medina-Gali R, 2018, FISH SHELLFISH IMMUN, V82, P514, DOI 10.1016/j.fsi.2018.08.056; Munzone A, 2020, FEBS J, V287, P3298, DOI 10.1111/febs.15203; Oh T, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-2091-6; Peng B, 2018, FISH SHELLFISH IMMUN, V72, P104, DOI 10.1016/j.fsi.2017.10.046; Peng B, 2016, FISH SHELLFISH IMMUN, V54, P204, DOI 10.1016/j.fsi.2016.04.012; Santos L, 2018, INT J ANTIMICROB AG, V52, P135, DOI 10.1016/j.ijantimicag.2018.03.010; Shoemaker CA, 2012, AQUACULTURE, V354, P45, DOI 10.1016/j.aquaculture.2012.04.033; Song M, 2013, FISH SHELLFISH IMMUN, V35, P1932, DOI 10.1016/j.fsi.2013.09.033; Tang RY, 2007, ACTA BIOCH BIOPH SIN, V39, P384, DOI 10.1111/j.1745-7270.2007.00283.x; Tian Y, 2016, TRENDS IMMUNOL, V37, P557, DOI 10.1016/j.it.2016.06.001; Wang SN, 2018, FISH SHELLFISH IMMUN, V74, P325, DOI 10.1016/j.fsi.2017.12.048; Wang YQ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00256; Yang DX, 2021, MSYSTEMS, V6, DOI 10.1128/mSystems.00426-21; Yang DX, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.644957; Yang MJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.682724; Yang MJ, 2020, VIRULENCE, V11, P349, DOI 10.1080/21505594.2020.1750123; Yin GY, 2017, CHEMOSPHERE, V171, P118, DOI 10.1016/j.chemosphere.2016.12.068; Zhang S, 2020, ENVIRON MICROBIOL, V22, P4367, DOI 10.1111/1462-2920.15085	45	1	1	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 4	2021	12								736360	10.3389/fimmu.2021.736360	http://dx.doi.org/10.3389/fimmu.2021.736360			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV2KI	34671354	gold, Green Published			2022-12-18	WOS:000717066300001
J	Suresh, M; Li, B; Huang, X; Korolowicz, KE; Murreddu, MG; Gudima, SO; Menne, S				Suresh, Manasa; Li, Bin; Huang, Xu; Korolowicz, Kyle E.; Murreddu, Marta G.; Gudima, Severin O.; Menne, Stephan			Agonistic Activation of Cytosolic DNA Sensing Receptors in Woodchuck Hepatocyte Cultures and Liver for Inducing Antiviral Effects	FRONTIERS IN IMMUNOLOGY			English	Article						pattern recognition receptors; hepatitis B virus; viral DNA sensing receptors; innate immune response; woodchuck; chronic hepatitis B	HEPATITIS-B-VIRUS; INNATE IMMUNE-RESPONSE; VIRAL REPLICATION; HBV; INFECTION; THERAPY; MODEL; INHIBITION; INDUCTION; GS-9620	Immune modulation for the treatment of chronic hepatitis B (CHB) has gained more traction in recent years, with an increasing number of compounds designed for targeting different host pattern recognition receptors (PRRs). These agonistic molecules activate the receptor signaling pathway and trigger an innate immune response that will eventually shape the adaptive immunity for control of chronic infection with hepatitis B virus (HBV). While definitive recognition of HBV nucleic acids by PRRs during viral infection still needs to be elucidated, several viral RNA sensing receptors, including toll-like receptors 7/8/9 and retinoic acid inducible gene-I-like receptors, are explored preclinically and clinically as possible anti-HBV targets. The antiviral potential of viral DNA sensing receptors is less investigated. In the present study, treatment of primary woodchuck hepatocytes generated from animals with CHB with HSV-60 or poly(dA:dT) agonists resulted in increased expression of interferon-gamma inducible protein 16 (IFI16) or Z-DNA-binding protein 1 (ZBP1/DAI) and absent in melanoma 2 (AIM2) receptors and their respective adaptor molecules and effector cytokines. Cytosolic DNA sensing receptor pathway activation correlated with a decline in woodchuck hepatitis virus (WHV) replication and secretion in these cells. Combination treatment with HSV-60 and poly(dA:dT) achieved a superior antiviral effect over monotreatment with either agonist that was associated with an increased expression of effector cytokines. The antiviral effect, however, could not be enhanced further by providing additional type-I interferons (IFNs) exogenously, indicating a saturated level of effector cytokines produced by these receptors following agonism. In WHV-uninfected woodchucks, a single poly(dA:dT) dose administered via liver-targeted delivery was well-tolerated and induced the intrahepatic expression of ZBP1/DAI and AIM2 receptors and their effector cytokines, IFN-beta and interleukins 1 beta and 18. Receptor agonism also resulted in increased IFN-gamma secretion of peripheral blood cells. Altogether, the effect on WHV replication and secretion following in vitro activation of IFI16, ZBP1/DAI, and AIM2 receptor pathways suggested an antiviral benefit of targeting more than one cytosolic DNA receptor. In addition, the in vivo activation of ZBP1/DAI and AIM2 receptor pathways in liver indicated the feasibility of the agonist delivery approach for future evaluation of therapeutic efficacy against HBV in woodchucks with CHB.</p>	[Suresh, Manasa; Li, Bin; Huang, Xu; Korolowicz, Kyle E.; Murreddu, Marta G.; Menne, Stephan] Georgetown Univ, Med Ctr, Dept Microbiol & Immunol, Washington, DC 20007 USA; [Gudima, Severin O.] Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, Kansas City, KS 66103 USA	Georgetown University; University of Kansas; University of Kansas Medical Center	Menne, S (corresponding author), Georgetown Univ, Med Ctr, Dept Microbiol & Immunol, Washington, DC 20007 USA.	Stephan.Menne@georgetown.edu		Huang, Xu/0000-0001-9108-5115	NCI NIH HHS [R01 CA166213] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ablasser A, 2009, NAT IMMUNOL, V10, P1065, DOI 10.1038/ni.1779; Amarante-Mendes GP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02379; Bartenschlager R, 2019, Z GASTROENTEROL, V57, P61, DOI 10.1055/a-0824-1576; Bellezza C. A., 2002, Laboratory animal medicine, P309, DOI 10.1016/B978-012263951-7/50011-9; Bertoletti A, 2020, CURR OPIN IMMUNOL, V66, P35, DOI 10.1016/j.coi.2020.04.003; Bertoletti A, 2020, J EXP MED, V217, DOI 10.1084/jem.20191663; Bertoletti A, 2016, J HEPATOL, V64, pS71, DOI 10.1016/j.jhep.2016.01.026; Carty M, 2021, BIOCHEM PHARMACOL, V183, DOI 10.1016/j.bcp.2020.114316; Cheng XM, 2017, HEPATOLOGY, V66, P1779, DOI 10.1002/hep.29348; Chiale C, 2021, CURR OPIN VIROL, V49, P13, DOI 10.1016/j.coviro.2021.04.003; Cote PJ, 2000, HEPATOLOGY, V31, P190, DOI 10.1002/hep.510310128; Daffis S, 2021, HEPATOLOGY, V73, P53, DOI 10.1002/hep.31255; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Fanning GC, 2019, NAT REV DRUG DISCOV, V18, P827, DOI 10.1038/s41573-019-0037-0; Faure-Dupuy S, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050095; Fletcher SP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005103; Freitas N, 2015, J VIROL, V89, P8749, DOI 10.1128/JVI.00984-15; Gane EJ, 2015, J HEPATOL, V63, P320, DOI 10.1016/j.jhep.2015.02.037; Harris Rebecca Louise, 2012, Mol Biol Int, V2012, P283974, DOI 10.1155/2012/283974; Hoogeveen RC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00401; Iyer RP, 2004, ANTIMICROB AGENTS CH, V48, P2318, DOI 10.1128/AAC.48.6.2318-2320.2004; Jeffries AM, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.576263; Korolowicz KE, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092321; Korolowicz KE, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040648; Korolowicz KE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161313; Korolowizc KE, 2019, HEPATOL COMMUN, V3, P1296, DOI 10.1002/hep4.1397; Kosinska AD, 2017, CURR OPIN VIROL, V23, P75, DOI 10.1016/j.coviro.2017.03.011; Kuriakose T, 2018, TRENDS IMMUNOL, V39, P123, DOI 10.1016/j.it.2017.11.002; Lanford RE, 2013, GASTROENTEROLOGY, V144, P1508, DOI 10.1053/j.gastro.2013.02.003; Lauterbach-Riviere L, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060592; Liu GQ, 2020, IMMUNITY, V53, P26, DOI 10.1016/j.immuni.2020.03.017; Liu YJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006296; Lucifora J, 2014, SCIENCE, V343, P1221, DOI 10.1126/science.1243462; Maini MK, 2016, J HEPATOL, V64, pS60, DOI 10.1016/j.jhep.2016.01.028; Megahed FAK, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030285; Meng ZJ, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03127; Meng ZJ, 2016, ANTIVIR RES, V125, P14, DOI 10.1016/j.antiviral.2015.11.001; Menne S, 2007, HEPATOLOGY, V45, P614, DOI 10.1002/hep.21558; Menne S, 2007, WORLD J GASTROENTERO, V13, P104, DOI 10.3748/wjg.v13.i1.104; Menne S, 2015, J HEPATOL, V62, P1237, DOI 10.1016/j.jhep.2014.12.026; Michalska A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01135; Murreddu MG, 2017, METHODS MOL BIOL, V1540, P277, DOI 10.1007/978-1-4939-6700-1_24; Nakanishi K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00763; Niu CG, 2018, J HEPATOL, V68, P922, DOI 10.1016/j.jhep.2017.12.007; Park JH, 2006, BIOTECHNOL LETT, V28, P1061, DOI 10.1007/s10529-006-9064-0; Revill P, 2013, ANTIVIR THER, V18, P1, DOI 10.3851/IMP2542; Revill PA, 2019, LANCET GASTROENTEROL, V4, P545, DOI 10.1016/S2468-1253(19)30119-0; Sato S, 2015, IMMUNITY, V42, P123, DOI 10.1016/j.immuni.2014.12.016; Suresh M., 2020, IMMUNE RESPONSES RES; Suresh M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.713420; Suresh M, 2021, WORLD J GASTRO ONCOL, V13, DOI 10.4251/wjgo.v13.i6.509; Suresh M, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008248; Suresh M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169631; Suslov A, 2018, GASTROENTEROLOGY, V154, P1778, DOI 10.1053/j.gastro.2018.01.034; Suslov A, 2018, CURR OPIN VIROL, V30, P9, DOI 10.1016/j.coviro.2018.01.008; Wieland S, 2004, P NATL ACAD SCI USA, V101, P6669, DOI 10.1073/pnas.0401771101; Wieland SF, 2000, J VIROL, V74, P4165, DOI 10.1128/JVI.74.9.4165-4173.2000; World Health Organization, 2021, HEPATITIS B; Wu J, 2014, J VIROL, V88, P10421, DOI 10.1128/JVI.00996-14; Yan Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep28776; Yang YY, 2020, HEPATOLOGY, V71, P1154, DOI 10.1002/hep.30897; Yuen MF, 2018, NAT REV DIS PRIMERS, V4, DOI [10.1038/nrdp.2018.36, 10.1038/nrdp.2018.35]; Zheng DP, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0167-x	63	1	1	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 4	2021	12								745802	10.3389/fimmu.2021.745802	http://dx.doi.org/10.3389/fimmu.2021.745802			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV1WV	34671360	gold, Green Published			2022-12-18	WOS:000717028900001
J	Lee, M; Seo, JH; Song, S; Song, IH; Kim, SY; Kim, YA; Gong, G; Kim, JE; Lee, HJ				Lee, Miseon; Seo, Jeong-Han; Song, Sungjae; Song, In Hye; Kim, Su Yeon; Kim, Young-Ae; Gong, Gyungyub; Kim, Jeong Eun; Lee, Hee Jin			A New Human Leukocyte Antigen Typing Algorithm Combined With Currently Available Genotyping Tools Based on Next-Generation Sequencing Data and Guidelines to Select the Most Likely Human Leukocyte Antigen Genotype	FRONTIERS IN IMMUNOLOGY			English	Article						human leukocyte antigen (HLA); HLA genotype; next-generation sequencing data (NGS); HLA typing algorithm; immunotherapy; neoantigen	HLA; MAP	Background High-precision human leukocyte antigen (HLA) genotyping is crucial for anti-cancer immunotherapy, but existing tools predicting HLA genotypes using next-generation sequencing (NGS) data are insufficiently accurate. Materials and Methods We compared availability, accuracy, correction score, and complementary ratio of eight HLA genotyping tools (OptiType, HLA-HD, PHLAT, seq2HLA, arcasHLA, HLAscan, HLA*LA, and Kourami) using 1,005 cases from the 1000 Genomes Project data. We created a new HLA-genotyping algorithm combining tools based on the precision and the accuracy of tools' combinations. Then, we assessed the new algorithm's performance in 39 in-house samples with normal whole-exome sequencing (WES) data and polymerase chain reaction-sequencing-based typing (PCR-SBT) results. Results Regardless of the type of tool, the calls presented by more than six tools concordantly showed high accuracy and precision. The accuracy of the group with at least six concordant calls was 100% (97/97) in HLA-A, 98.2% (112/114) in HLA-B, 97.3% (142/146) in HLA-C. The precision of the group with at least six concordant calls was over 98% in HLA-ABC. We additionally calculated the accuracy of the combination tools considering the complementary ratio of each tool and the accuracy of each tool, and the accuracy was over 98% in all groups with six or more concordant calls. We created a new algorithm that matches the above results. It was to select the HLA type if more than six out of eight tools presented a matched type. Otherwise, determine the HLA type experimentally through PCR-SBT. When we applied the new algorithm to 39 in-house cases, there were more than six matching calls in all HLA-A, B, and C, and the accuracy of these concordant calls was 100%. Conclusions HLA genotyping accuracy using NGS data could be increased by combining the current HLA genotyping tools. This new algorithm could also be useful for preliminary screening to decide whether to perform an additional PCR-based experimental method instead of using tools with NGS data.	[Lee, Miseon; Song, In Hye] Catholic Univ Korea, Dept Hosp Pathol, Coll Med, Seoul St Marys Hosp, Seoul, South Korea; [Seo, Jeong-Han; Lee, Hee Jin] Univ Ulsan, Asan Med Ctr, Asan Med Inst Convergence Sci & Technol, Dept Biomed Sci,Coll Med, Seoul, South Korea; [Seo, Jeong-Han; Song, Sungjae; Kim, Young-Ae; Lee, Hee Jin] NeogenTC Corp, Seoul, South Korea; [Kim, Su Yeon] Univ Ulsan, Coll Med, Seoul, South Korea; [Gong, Gyungyub; Lee, Hee Jin] Univ Ulsan, Asan Med Ctr, Dept Pathol, Coll Med, Seoul, South Korea; [Kim, Jeong Eun] Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea	Catholic University of Korea; Seoul St. Mary's Hospital; University of Ulsan; Asan Medical Center; University of Ulsan; University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center	Lee, HJ (corresponding author), Univ Ulsan, Asan Med Ctr, Asan Med Inst Convergence Sci & Technol, Dept Biomed Sci,Coll Med, Seoul, South Korea.; Lee, HJ (corresponding author), NeogenTC Corp, Seoul, South Korea.; Lee, HJ (corresponding author), Univ Ulsan, Asan Med Ctr, Dept Pathol, Coll Med, Seoul, South Korea.; Kim, JE (corresponding author), Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea.	jeongeunkim@amc.seoul.kr; backlila@gmail.com			Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea [2018IL0733, 2019IL0733, 2020IL0019]	Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea	This study was supported by the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea (2018IL0733, 2019IL0733, and 2020IL0019).	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; ANGELINI G, 1986, P NATL ACAD SCI USA, V83, P4489, DOI 10.1073/pnas.83.12.4489; Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; Boegel S, 2012, GENOME MED, V4, DOI 10.1186/gm403; Buchkovich ML, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0473-6; Conway JR, 2017, BIOINFORMATICS, V33, P2938, DOI 10.1093/bioinformatics/btx364; Dilthey AT, 2019, BIOINFORMATICS, V35, P4394, DOI 10.1093/bioinformatics/btz235; Hosomichi K, 2015, J HUM GENET, V60, P665, DOI 10.1038/jhg.2015.102; Huang YZ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0145-3; Ka S, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1671-3; Kawaguchi S, 2017, HUM MUTAT, V38, P788, DOI 10.1002/humu.23230; Kiyotani K, 2017, J HUM GENET, V62, P397, DOI 10.1038/jhg.2016.141; Lange V, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-63; Larjo A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01815; Lee H, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1388-2; Liu C, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt481; Nariai N, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S2-S7; Orenbuch R, 2020, BIOINFORMATICS, V36, P33, DOI 10.1093/bioinformatics/btz474; Profaizer T, 2018, CLIN LAB MED, V38, P565, DOI 10.1016/j.cll.2018.07.006; Robinson J, 2015, NUCLEIC ACIDS RES, V43, pD423, DOI 10.1093/nar/gku1161; Szolek A, 2014, BIOINFORMATICS, V30, P3310, DOI 10.1093/bioinformatics/btu548; Wang YY, 2019, HUM GENOME VAR, V6, DOI 10.1038/s41439-019-0061-y; Xie C, 2017, P NATL ACAD SCI USA, V114, P8059, DOI 10.1073/pnas.1707945114; Yu YC, 2021, HLA, V97, P481, DOI 10.1111/tan.14244	24	1	1	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 1	2021	12								688183	10.3389/fimmu.2021.688183	http://dx.doi.org/10.3389/fimmu.2021.688183			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WH6OT	34659196	gold, Green Published			2022-12-18	WOS:000707795100001
J	Snyder, A; Jedreski, K; Fitch, J; Wijeratne, S; Wetzel, A; Hensley, J; Flowers, M; Bline, K; Hall, MW; Muszynski, JA				Snyder, Andrew; Jedreski, Kathleen; Fitch, James; Wijeratne, Saranga; Wetzel, Amy; Hensley, Josey; Flowers, Margaret; Bline, Katherine; Hall, Mark W.; Muszynski, Jennifer A.			Transcriptomic Profiles in Children With Septic Shock With or Without Immunoparalysis	FRONTIERS IN IMMUNOLOGY			English	Article						pediatric; sepsis; innate immunity; adaptive immunity; transcriptome	CORTICOTROPIN-RELEASING HORMONE; LACKING T-BET; MORTALITY; SEPSIS; EXPRESSION; CELLS; RESISTANCE; INFECTION; EFFECTOR; MICE	Background Severe innate immune suppression, termed immunoparalysis, is associated with increased risks of nosocomial infection and mortality in children with septic shock. Currently, immunoparalysis cannot be clinically diagnosed in children, and mechanisms remain unclear. Transcriptomic studies identify subsets of septic children with downregulation of genes within adaptive immune pathways, but assays of immune function have not been performed as part of these studies, and little is known about transcriptomic profiles of children with immunoparalysis. Methods We performed a nested case-control study to identify differences in RNA expression patterns between children with septic shock with immunoparalysis (defined as lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)alpha response < 200 pg/ml) vs those with normal LPS-induced TNF alpha response. Children were enrolled within 48 hours of the onset of septic shock and divided into two groups based on LPS-induced TNF alpha response. RNA was extracted from whole blood for RNAseq, differential expression analyses using DESeq2 software, and pathway analyses using Ingenuity Pathway Analysis. Results 32 children were included in analyses. Comparing those with immunoparalysis (n =19) to those with normal TNF alpha response (n = 13), 2,303 transcripts were differentially expressed with absolute value fold change >= 1.5 and false discovery rate <= 0.05. The majority of downregulated pathways in children with immunoparalysis were pathways that involved interactions between innate and adaptive immune cells necessary for cell-mediated immunity, crosstalk between dendritic cells and natural killer cells, and natural killer cell signaling pathways. Upregulated pathways included those involved in humoral immunity (T helper cell type 2), corticotropin signaling, platelet activation (GP6 signaling), and leukocyte migration and extravasation. Conclusions Our study suggests that gene expression data might be useful to identify children with immunoparalysis and identifies several key differentially regulated pathways involved in both innate and adaptive immunity. Our ongoing work in this area aims to dissect interactions between innate and adaptive immunity in septic children and to more fully elucidate patient-specific immunologic pathophysiology to guide individualized immunotherapeutic targets.	[Snyder, Andrew; Jedreski, Kathleen; Hensley, Josey; Flowers, Margaret; Hall, Mark W.; Muszynski, Jennifer A.] Nationwide Childrens Hosp, Abigail Wexner Res Inst, Ctr Clin & Translat Res, Columbus, OH 43205 USA; [Fitch, James; Wijeratne, Saranga; Wetzel, Amy] Nationwide Childrens Hosp, Abigail Wexner Res Inst, Inst Genom Med, Columbus, OH 43205 USA; [Bline, Katherine; Hall, Mark W.; Muszynski, Jennifer A.] Nationwide Childrens Hosp, Div Crit Care Med, Columbus, OH 43205 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Muszynski, JA (corresponding author), Nationwide Childrens Hosp, Abigail Wexner Res Inst, Ctr Clin & Translat Res, Columbus, OH 43205 USA.; Muszynski, JA (corresponding author), Nationwide Childrens Hosp, Div Crit Care Med, Columbus, OH 43205 USA.	Jennifer.Muszynski@nationwidechildrens.org			Nationwide Foundation Pediatric Innovation Fund (Institute of Genomic Services Core); National Cancer Institute (Institute of Genomic Services Core) [P30CA016058]; National Heart, Lung and Blood Institute [K08HL123925]	Nationwide Foundation Pediatric Innovation Fund (Institute of Genomic Services Core); National Cancer Institute (Institute of Genomic Services Core); National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the Nationwide Foundation Pediatric Innovation Fund (Institute of Genomic Services Core), P30CA016058 from the National Cancer Institute (Institute of Genomic Services Core), and K08HL123925 from the National Heart, Lung and Blood Institute (JM).	Atkinson SJ, 2016, MOL MED, V22, DOI 10.2119/molmed.2016.00058; Baigent SM, 2001, PEPTIDES, V22, P809, DOI 10.1016/S0196-9781(01)00395-3; Carcillo JA, 2019, PEDIATR CRIT CARE ME, V20, P1137, DOI 10.1097/PCC.0000000000002105; Carcillo JA, 2017, PEDIATR CRIT CARE ME, V18, P513, DOI 10.1097/PCC.0000000000001122; Cruz-Guilloty F, 2009, J EXP MED, V206, P51, DOI 10.1084/jem.20081242; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Felmet KA, 2005, J IMMUNOL, V174, P3765, DOI 10.4049/jimmunol.174.6.3765; Feudtner C, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-199; Gaies MG, 2010, PEDIATR CRIT CARE ME, V11, P234, DOI 10.1097/PCC.0b013e3181b806fc; Garraud O, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00070; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Gordon SM, 2012, IMMUNITY, V36, P55, DOI 10.1016/j.immuni.2011.11.016; Gupta DL, 2016, CYTOKINE, V88, P214, DOI 10.1016/j.cyto.2016.09.010; Hall MW, 2013, CRIT CARE MED, V41, P224, DOI 10.1097/CCM.0b013e318267633c; Hall MW, 2011, INTENS CARE MED, V37, P525, DOI 10.1007/s00134-010-2088-x; Harle G, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18401-y; Intlekofer AM, 2005, NAT IMMUNOL, V6, P1236, DOI 10.1038/ni1268; Intlekofer AM, 2008, SCIENCE, V321, P408, DOI 10.1126/science.1159806; Joint Genome Institute, DOE OFF SCI US FAC B; Kim BJ, 2011, J NEUROIMMUNOL, V237, P57, DOI 10.1016/j.jneuroim.2011.06.016; Kokkotou E, 2006, J IMMUNOL, V177, P3355, DOI 10.4049/jimmunol.177.5.3355; Landelle C, 2010, INTENS CARE MED, V36, P1859, DOI 10.1007/s00134-010-1962-x; Lauhio A, 2011, PHARMACOL RES, V64, P590, DOI 10.1016/j.phrs.2011.06.019; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Monneret G, 2006, INTENS CARE MED, V32, P1175, DOI 10.1007/s00134-006-0204-8; Muszynski JA, 2018, AM J RESP CRIT CARE, V198, P361, DOI 10.1164/rccm.201710-2006OC; Muszynski JA, 2014, CRIT CARE, V18, DOI 10.1186/cc13980; Palmer C, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-115; Pipkin ME, 2010, IMMUNITY, V32, P79, DOI 10.1016/j.immuni.2009.11.012; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Ravindran R, 2005, J IMMUNOL, V175, P4603, DOI 10.4049/jimmunol.175.7.4603; Rinchai Darawan, 2016, F1000Res, V5, P1385, DOI 10.12688/f1000research.8841.1; Romero V, 2008, TISSUE ANTIGENS, V71, P409, DOI 10.1111/j.1399-0039.2008.01013.x; Rudd KE, 2020, LANCET, V395, P200, DOI 10.1016/S0140-6736(19)32989-7; Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402; Smyth MJ, 2001, J LEUKOCYTE BIOL, V70, P18; Sullivan BM, 2005, J IMMUNOL, V175, P4593, DOI 10.4049/jimmunol.175.7.4593; Sullivan BM, 2003, P NATL ACAD SCI USA, V100, P15818, DOI 10.1073/pnas.2636938100; Sun L, 2012, ACTA PHARMACOL SIN, V33, P342, DOI 10.1038/aps.2011.200; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Townsend MJ, 2004, IMMUNITY, V20, P477, DOI 10.1016/S1074-7613(04)00076-7; van Domselaar R, 2012, J BIOL CHEM, V287, P22854, DOI 10.1074/jbc.M112.365692; Vermette D, 2018, INTENS CARE MED EXP, V6, DOI 10.1186/s40635-018-0203-4; Walter and Eliza Hall Institute of Medical Research, FEAT ULTR ACC READ S; Wang L, 2013, J IMMUNOL, V190, P1319, DOI 10.4049/jimmunol.1202542; Weiss SL, 2015, AM J RESP CRIT CARE, V191, P1147, DOI 10.1164/rccm.201412-2323OC; Werneck MBF, 2008, J IMMUNOL, V180, P8004, DOI 10.4049/jimmunol.180.12.8004; Wong HR, 2015, AM J RESP CRIT CARE, V191, P309, DOI 10.1164/rccm.201410-1864OC; Wong HR, 2013, PEDIATR RES, V73, P564, DOI 10.1038/pr.2013.11; Wong HR, 2011, CRIT CARE MED, V39, P2511, DOI 10.1097/CCM.0b013e3182257675; Wu HP, 2013, INFLAMM RES, V62, P751, DOI 10.1007/s00011-013-0630-3; Xue M, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1811-9	53	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 1	2021	12								733834	10.3389/fimmu.2021.733834	http://dx.doi.org/10.3389/fimmu.2021.733834			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WJ5LR	34659221	gold, Green Published			2022-12-18	WOS:000709086600001
J	Al-Herz, W; Zainal, M; Nanda, A				Al-Herz, Waleed; Zainal, Mohammad; Nanda, Arti			A Prospective Survey of Skin Manifestations in Children With Inborn Errors of Immunity From a National Registry Over 17 Years	FRONTIERS IN IMMUNOLOGY			English	Article						skin manifestations; inborn errors of immunity; eczematoid rashes; cutaneous infections; autoimmunity; non-infectious cutaneous granulomas; immunodeficiency	PRIMARY IMMUNODEFICIENCY DISEASES; CUTANEOUS GRANULOMAS	Background and Objectives Reports on skin manifestations in inborn errors of immunity (IEI) are based on retrospective analysis, small series, or isolated case reports. The present prospective study aimed to determine the spectrum of skin manifestations in children with IEI and their relevance to specific molecular defects. Materials and Methods The data were obtained from the Kuwait National Primary Immunodeficiency Disorders Registry during the period of 2004-2020. Results A total of 313 pediatric cases of IEI, 71% diagnosed at molecular level, were registered with a cumulative follow-up period of 29,734 months. Skin manifestations were seen in 40.3% of the patients, and they were among the presenting manifestations in 33%. Patients with skin manifestations were older at both onset and diagnosis ages of IEI symptoms, but this was statistically significant for the latter only. The diagnosis delay was significantly longer in patients with skin manifestations. There was a statistically significant association between having skin manifestations and IEI category, being more common in patients with complement deficiencies, combined immunodeficiencies, and diseases of immune dysregulation. There was no statistically significant association between having skin manifestations and both gender and survival. Skin infections were the most frequent manifestations followed by eczema and autoimmune associations. Among IEI with more than 10 cases, skin lesions were a consistent finding in dedicator of cytokinesis 8 (DOCK8) deficiency, hyper IgE syndrome, ataxia-telangiectasia, and recombination activation gene (RAG)1 deficiency. Conclusions Skin manifestations are common in IEI patients, and they had significant diagnosis delay and referral to specialists. Improvement of awareness about IEI is needed among pediatricians and dermatologists.	[Al-Herz, Waleed] Kuwait Univ, Fac Med, Dept Pediat, Kuwait, Kuwait; [Al-Herz, Waleed] Al Sabah Hosp, Pediat Dept, Allergy & Clin Immunol Unit, Kuwait, Kuwait; [Zainal, Mohammad] Kuwait Univ, Coll Business Adm, Dept Quantitat Methods & Informat Syst, Kuwait, Kuwait; [Nanda, Arti] Asad Al Hamad Dermatol Ctr, Kuwait, Kuwait	Kuwait University; Al Sabah Hospital; Kuwait University	Al-Herz, W (corresponding author), Kuwait Univ, Fac Med, Dept Pediat, Kuwait, Kuwait.; Al-Herz, W (corresponding author), Al Sabah Hosp, Pediat Dept, Allergy & Clin Immunol Unit, Kuwait, Kuwait.	wemh@hotmail.com		Nanda, Arti/0000-0002-1223-3181				Abolhassani H, 2020, EXPERT REV CLIN IMMU, V16, P717, DOI 10.1080/1744666X.2020.1801422; Martinez-Longoria CA, 2017, AN BRAS DERMATOL, V92, P697, DOI 10.1590/abd1806-4841.20175580; Al-Herz W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01754; Al-Herz W, 2012, CLIN IMMUNOL, V143, P266, DOI 10.1016/j.clim.2012.03.002; Al-Herz W, 2011, PEDIATR DERMATOL, V28, P494, DOI 10.1111/j.1525-1470.2011.01409.x; Amaya-Uribe L, 2019, J AUTOIMMUN, V99, P52, DOI 10.1016/j.jaut.2019.01.011; Berron-Ruiz A, 2000, PEDIATR DERMATOL, V17, P91, DOI 10.1046/j.1525-1470.2000.01721.x; Bousfiha AA, 2013, J CLIN IMMUNOL, V33, P1, DOI 10.1007/s10875-012-9751-7; de Wit J, 2019, ALLERGY, V74, P464, DOI 10.1111/all.13681; Dhouib NG, 2018, MEDITERR J HEMATOL I, V10, DOI 10.4084/MJHID.2018.065; Fischer A, 2017, J ALLERGY CLIN IMMUN, V140, P1388, DOI 10.1016/j.jaci.2016.12.978; Harp J, 2015, INT J DERMATOL, V54, P617, DOI 10.1111/ijd.12765; Huang HX, 2020, BMC PEDIATR, V20, DOI 10.1186/s12887-020-02436-8; Leclerc-Mercier S, 2019, J EUR ACAD DERMATOL, V33, P1412, DOI 10.1111/jdv.15568; Lewis Daniel J, 2019, Dermatol Online J, V25; Lopez-Quintero W, 2021, WORLD ALLERGY ORGAN, V14, DOI 10.1016/j.waojou.2021.100527; Massaad MJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01119; Moin Athar, 2006, Iran J Allergy Asthma Immunol, V5, P121; Nanda A, 2019, PEDIATR DERMATOL, V36, P258, DOI 10.1111/pde.13757; Nanda A, 2014, AM J DERMATOPATH, V36, P832, DOI 10.1097/DAD.0000000000000112; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x	21	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2021	12								751469	10.3389/fimmu.2021.751469	http://dx.doi.org/10.3389/fimmu.2021.751469			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WH1XZ	34659256	Green Published, gold			2022-12-18	WOS:000707481100001
J	Li, X; Feng, M; Zhao, YQ; Zhang, YH; Zhou, RX; Zhou, H; Pang, Z; Tachibana, H; Cheng, XJ				Li, Xia; Feng, Meng; Zhao, Yanqing; Zhang, Yuhan; Zhou, Ruixue; Zhou, Hang; Pang, Zhen; Tachibana, Hiroshi; Cheng, Xunjia			A Novel TLR4-Binding Domain of Peroxiredoxin From Entamoeba histolytica Triggers NLRP3 Inflammasome Activation in Macrophages	FRONTIERS IN IMMUNOLOGY			English	Article						Entamoeba histolytica; NLRP3 inflammasome; peroxiredoxin; TLR4-binding domain; macrophage	GAL-LECTIN; PROTEIN; IDENTIFICATION; RESPONSES; ANTIGEN; ROLES	Macrophages promote early host responses to infection by releasing pro-inflammatory cytokines, and they are crucial to combat amoebiasis, a disease affecting millions of people worldwide. Macrophages elicit pro-inflammatory responses following direct cell/cell interaction of Entamoeba histolytica, inducing NLRP3 inflammasome activation with high-output IL-1 beta/IL-18 secretion. Here, we found that trophozoites could upregulate peroxiredoxins (Prx) expression and abundantly secrete Prxs when encountering host cells. The C-terminal of Prx was identified as the key functional domain in promoting NLRP3 inflammasome activation, and a recombinant C-terminal domain could act directly on macrophage. The Prxs derived from E. histolytica triggered toll-like receptor 4-dependent activation of NLRP3 inflammasome in a cell/cell contact-independent manner. Through genetic, immunoblotting or pharmacological inhibition methods, NLRP3 inflammasome activation was induced through caspase-1-dependent canonical pathway. Our data suggest that E. histolytica Prxs had stable and durable cell/cell contact-independent effects on macrophages following abundantly secretion during invasion, and the C-terminal of Prx was responsible for activating NLRP3 inflammasome in macrophages. This new alternative pathway may represent a potential novel therapeutic approach for amoebiasis, a global threat to millions.	[Li, Xia; Feng, Meng; Zhao, Yanqing; Zhang, Yuhan; Zhou, Ruixue; Zhou, Hang; Pang, Zhen; Cheng, Xunjia] Fudan Univ, Sch Basic Med Sci, Dept Med Microbiol & Parasitol, Shanghai, Peoples R China; [Tachibana, Hiroshi; Cheng, Xunjia] Tokai Univ, Sch Med, Dept Infect Dis, Isehara, Kanagawa, Japan; [Li, Xia] Guizhou Med Univ, Affiliated Hosp, Guiyang, Peoples R China	Fudan University; Tokai University; Guizhou Medical University	Cheng, XJ (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Med Microbiol & Parasitol, Shanghai, Peoples R China.; Tachibana, H; Cheng, XJ (corresponding author), Tokai Univ, Sch Med, Dept Infect Dis, Isehara, Kanagawa, Japan.	htachiba@is.icc.u-tokai.ac.jp; xjcheng@shmu.edu.cn			National Key Research and Development Program of China [2018YFA0507304]; National Natural Science Foundation of China [81630057]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Key Research and Development Program of China (2018YFA0507304) (http://service.most.gov.cn/) and National Natural Science Foundation of China (81630057) (http://www.nsfc.gov.cn/) to XC.	Abais JM, 2015, ANTIOXID REDOX SIGN, V22, P1111, DOI 10.1089/ars.2014.5994; Angelucci F, 2016, MOL BIOCHEM PARASIT, V206, P2, DOI 10.1016/j.molbiopara.2016.03.005; Begum S, 2020, J LEUKOCYTE BIOL, V108, P801, DOI 10.1002/JLB.3MR0420-465R; Begum S, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01394; Boaru SG, 2012, J INFLAMM-LOND, V9, DOI 10.1186/1476-9255-9-49; BRUCHHAUS I, 1993, TROP MED PARASITOL, V44, P116; Bruchhaus I, 1997, BIOCHEM J, V326, P785, DOI 10.1042/bj3260785; Campbell D, 2000, EUR J IMMUNOL, V30, P423, DOI 10.1002/1521-4141(200002)30:2&lt;423::AID-IMMU423&gt;3.0.CO;2-0; Campos-Rodriguez R, 2016, PARASITE, V23, DOI 10.1051/parasite/2016006; Cheng XJ, 2004, MOL BIOCHEM PARASIT, V138, P195, DOI 10.1016/j.molbiopara.2004.08.009; Choi MH, 2005, MOL BIOCHEM PARASIT, V143, P80, DOI 10.1016/j.molbiopara.2005.04.014; Donnelly S, 2008, FASEB J, V22, P4022, DOI 10.1096/fj.08-106278; Furuta T, 2008, EUR J IMMUNOL, V38, P1341, DOI 10.1002/eji.200738059; Gorman H., 2019, ENCY MICROBIOL, P147; Hughes MA, 2003, MOL BIOCHEM PARASIT, V127, P113, DOI 10.1016/S0166-6851(02)00326-2; Kammanadiminti SJ, 2004, FASEB J, V18, P155, DOI 10.1096/fj.03-0578fje; Knoops B, 2016, MOL CELLS, V39, P60, DOI 10.14348/molcells.2016.2341; Komada T, 2019, NAT REV NEPHROL, V15, P501, DOI 10.1038/s41581-019-0158-z; Li X, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112462; Maldonado-Bernal C, 2005, PARASITE IMMUNOL, V27, P127, DOI 10.1111/j.1365-3024.2005.00754.x; Marshall ES, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-80; Mortimer L, 2014, MUCOSAL IMMUNOL, V7, P829, DOI 10.1038/mi.2013.100; Mortimer L, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004887; Mortimer L, 2010, EXP PARASITOL, V126, P366, DOI 10.1016/j.exppara.2010.03.005; Pacheco-Yepez J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/324230; Pulido-Ortega J, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00540-19; Quach J, 2019, MUCOSAL IMMUNOL, V12, P323, DOI 10.1038/s41385-018-0101-9; REED SL, 1992, INFECT IMMUN, V60, P542, DOI 10.1128/IAI.60.2.542-549.1992; Seguin R, 1995, P NATL ACAD SCI USA, V92, P12175, DOI 10.1073/pnas.92.26.12175; Sen A, 2007, EUKARYOT CELL, V6, P664, DOI 10.1128/EC.00308-06; SOONG CJG, 1995, INFECT IMMUN, V63, P472, DOI 10.1128/IAI.63.2.472-477.1995; St-Pierre J, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006592; Stanley SL, 2003, LANCET, V361, P1025, DOI 10.1016/S0140-6736(03)12830-9; Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0; TACHIBANA H, 1991, J CLIN MICROBIOL, V29, P2234, DOI 10.1128/JCM.29.10.2234-2239.1991; TACHIBANA H, 1990, INFECT IMMUN, V58, P955, DOI 10.1128/IAI.58.4.955-960.1990; TORIAN BE, 1990, P NATL ACAD SCI USA, V87, P6358, DOI 10.1073/pnas.87.16.6358; Zhang Z, 2000, MOL MICROBIOL, V37, P542, DOI 10.1046/j.1365-2958.2000.02037.x	38	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2021	12								758451	10.3389/fimmu.2021.758451	http://dx.doi.org/10.3389/fimmu.2021.758451			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WH3PW	34659265	Green Published, gold			2022-12-18	WOS:000707595200001
J	Manna, PT; Chiang, SCC; Bryceson, YT; Orange, JS; Ammann, S				Manna, Paul T.; Chiang, Samuel C. C.; Bryceson, Yenan T.; Orange, Jordan S.; Ammann, Sandra			Editorial: Membrane Trafficking in Immunology-How Membrane Transport and Exocytosis Defects Underlie Immunodeficiencies	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						membrane trafficking; primary immunodeficiencies (PID); inborn errors of immunity; STING; cytotoxic T cells			[Manna, Paul T.] Univ Gothenburg, Inst Neurosci & Physiol, Gothenburg, Sweden; [Chiang, Samuel C. C.] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45229 USA; [Chiang, Samuel C. C.] Univ Cincinnati, Dept Pediat, Cincinnati, OH USA; [Bryceson, Yenan T.] Karolinska Inst, Dept Med, Ctr Hematol & Regenerat Med, Stockholm, Sweden; [Bryceson, Yenan T.] Karolinska Univ Hosp Huddinge, Clin Immunol & Transfus Med Clin, Primary Immunodeficiency Unit, Stockholm, Sweden; [Bryceson, Yenan T.] Univ Bergen, Dept Clin Sci, Broegelmann Res Lab, Bergen, Norway; [Orange, Jordan S.] Columbia Univ, Dept Pediat, Vagelos Coll Phys & Surg, Irving Med Ctr, New York, NY 10027 USA; [Ammann, Sandra] Univ Freiburg, Fac Med, Ctr Chron Immunodeficiency CCI, Inst Immunodeficiency,Med Ctr, Freiburg, Germany	University of Gothenburg; Cincinnati Children's Hospital Medical Center; University of Cincinnati; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of Bergen; Columbia University; NewYork-Presbyterian Hospital; University of Freiburg	Ammann, S (corresponding author), Univ Freiburg, Fac Med, Ctr Chron Immunodeficiency CCI, Inst Immunodeficiency,Med Ctr, Freiburg, Germany.	Sandra.Ammann@uniklinik-freiburg.de		Ammann, Sandra/0000-0003-0385-1890	Swedish Research Council [SFB 1160]; Cancer Foundation; Childhood Cancer Foundation; Knut and Alice Wallenberg Foundation; Center for Innovative Medicine and Stockholm Region	Swedish Research Council(Swedish Research CouncilEuropean Commission); Cancer Foundation; Childhood Cancer Foundation; Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Center for Innovative Medicine and Stockholm Region	Funding SFB 1160/IMPATH for SA and YTB is supported by the Swedish Research Council, Cancer Foundation, Childhood Cancer Foundation, the Knut and Alice Wallenberg Foundation, the Center for Innovative Medicine and Stockholm Region.	Bowman SL, 2019, TRAFFIC, V20, P404, DOI 10.1111/tra.12646; Centonze FG, 2019, J CELL BIOL, V218, P2470, DOI 10.1083/jcb.201903068; Janka GE, 2007, BLOOD REV, V21, P245, DOI 10.1016/j.blre.2007.05.001; Meeths M, 2021, ACTA PAEDIATR, V110, P2903, DOI 10.1111/apa.16013; Yarwood R, 2020, DIS MODEL MECH, V13, DOI 10.1242/dmm.043448	5	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2021	12								769815	10.3389/fimmu.2021.769815	http://dx.doi.org/10.3389/fimmu.2021.769815			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WL5RZ	34659271	Green Published, gold			2022-12-18	WOS:000710464000001
J	Shibata, T; Shah, S; Evans, T; Coleman, H; Lieblong, BJ; Spencer, HJ; Quick, CM; Sasagawa, T; Stephens, OW; Peterson, E; Johann, D; Lu, YC; Nakagawa, M				Shibata, Takeo; Shah, Sumit; Evans, Teresa; Coleman, Hannah; Lieblong, Benjamin J.; Spencer, Horace J.; Quick, Charles M.; Sasagawa, Toshiyuki; Stephens, Owen W.; Peterson, Erich; Johann, Donald; Lu, Yong-Chen; Nakagawa, Mayumi			Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed	FRONTIERS IN IMMUNOLOGY			English	Article						cervical intraepithelial neoplasia; human papillomavirus; T cell receptor; therapeutic vaccine; clonal expansion	IN-VITRO FERTILIZATION; TYPE-16 E6; E7 PROTEINS; PREVALENCE; CARCINOMA; RESPONSES; EPITOPES; WOMEN; DNA	Advances in high-throughput sequencing have revolutionized the manner with which we can study T cell responses. We describe a woman who received a human papillomavirus (HPV) therapeutic vaccine called PepCan, and experienced complete resolution of her cervical high-grade squamous intraepithelial lesion. By performing bulk T cell receptor (TCR) beta deep sequencing of peripheral blood mononuclear cells before and after 4 vaccinations, 70 putatively vaccine-specific clonotypes were identified for being significantly increased using a beta-binomial model. In order to verify the vaccine-specificity of these clonotypes, T cells with specificity to a region, HPV 16 E6 91-115, previously identified to be vaccine-induced using an interferon-gamma enzyme-linked immunospot assay, were sorted and analyzed using single-cell RNA-seq and TCR sequencing. HPV specificity in 60 of the 70 clonotypes identified to be vaccine-specific was demonstrated. TCR beta bulk sequencing of the cervical liquid-based cytology samples and cervical formalin-fixed paraffin-embedded samples before and after 4 vaccinations demonstrated the presence of these HPV-specific T cells in the cervix. Combining traditional and cutting-edge immunomonitoring techniques enabled us to demonstrate expansion of HPV-antigen specific T cells not only in the periphery but also in the cervix. Such an approach should be useful as a novel approach to assess vaccine-specific responses in various anatomical areas.	[Shibata, Takeo; Shah, Sumit; Evans, Teresa; Coleman, Hannah; Lieblong, Benjamin J.; Quick, Charles M.; Lu, Yong-Chen; Nakagawa, Mayumi] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA; [Shibata, Takeo; Sasagawa, Toshiyuki] Kanazawa Med Univ, Dept Obstet & Gynecol, Uchinada, Ishikawa, Japan; [Spencer, Horace J.] Univ Arkansas Med Sci, Dept Biostat, Little Rock, AR USA; [Stephens, Owen W.; Peterson, Erich] Univ Arkansas Med Sci, Dept Biomed Informat, Little Rock, AR USA; [Johann, Donald] Univ Arkansas Med Sci, Dept Internal Med, Div Hematol Oncol, Little Rock, AR USA	University of Arkansas System; University of Arkansas Medical Sciences; Kanazawa Medical University; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Nakagawa, M (corresponding author), Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA.	mnakagawa@uams.edu	Shibata, Takeo/N-2568-2019; Lu, Yong-Chen/G-4520-2014	Shibata, Takeo/0000-0002-5569-9301; Lu, Yong-Chen/0000-0002-0275-9825	National Institutes of Health (USA) [R01CA143130]; Drs. Mae and Anderson Nettleship Endowed Chair of Oncologic Pathology (USA) [31005156]; Arkansas Biosciences Institute (the major component of the Tobacco Settlement Proceeds Act of 2000, USA) [AWD00053655]	National Institutes of Health (USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Drs. Mae and Anderson Nettleship Endowed Chair of Oncologic Pathology (USA); Arkansas Biosciences Institute (the major component of the Tobacco Settlement Proceeds Act of 2000, USA)	This work was supported by the grant from the National Institutes of Health (R01CA143130, USA), Drs. Mae and Anderson Nettleship Endowed Chair of Oncologic Pathology (31005156, USA), and the Arkansas Biosciences Institute (the major component of the Tobacco Settlement Proceeds Act of 2000, AWD00053655, USA).	[Anonymous], 2019, HPV ASS CANC STAT, V2019; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; Bruinsma FJ, 2011, BJOG-INT J OBSTET GY, V118, P1031, DOI 10.1111/j.1471-0528.2011.02944.x; Coleman HN, 2016, CANCER IMMUNOL IMMUN, V65, P563, DOI 10.1007/s00262-016-1821-x; Coleman Hannah N, 2014, MOJ Immunol, V1; Cui JH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02729; de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716; Depuydt CE, 2016, GYNECOL OBSTET INVES, V81, P41, DOI 10.1159/000434749; Draper LM, 2015, CLIN CANCER RES, V21, P4431, DOI 10.1158/1078-0432.CCR-14-3341; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; Fink K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00110; Garolla A, 2016, FERTIL STERIL, V105, P65, DOI 10.1016/j.fertnstert.2015.09.018; Garolla A, 2011, CURR OPIN OBSTET GYN, V23, P232, DOI 10.1097/GCO.0b013e328348a3a4; Godi A, 2019, VACCINE, V37, P2455, DOI 10.1016/j.vaccine.2019.03.052; Greenfield WW, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1031439; Hermonat PL, 1997, VIRUS GENES, V14, P13; Hopkins AC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122092; Inoue H, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1204507; Kenter GG, 2009, NEW ENGL J MED, V361, P1838, DOI 10.1056/NEJMoa0810097; Kim KH, 2012, CANCER IMMUNOL IMMUN, V61, P63, DOI 10.1007/s00262-011-1092-5; Kuhs KAL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0178167; Laydon DJ, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0291; Lefranc MP, 2015, NUCLEIC ACIDS RES, V43, pD413, DOI 10.1093/nar/gku1056; Lo Presti E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00607; Lu YC, 2018, MOL THER, V26, P379, DOI 10.1016/j.ymthe.2017.10.018; Maciag PC, 2009, VACCINE, V27, P3975, DOI 10.1016/j.vaccine.2009.04.041; Massad LS, 2013, OBSTET GYNECOL, V121, P829, DOI 10.1097/AOG.0b013e3182883a34; Massarelli E, 2019, JAMA ONCOL, V5, P67, DOI 10.1001/jamaoncol.2018.4051; Melief CJM, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz8235; Monod MY, 2004, BIOINFORMATICS, V20, P379, DOI 10.1093/bioinformatics/bth945; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Morrow MP, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.25; Nakagawa M, 2004, CLIN DIAGN LAB IMMUN, V11, P889, DOI 10.1128/CDLI.11.5.889-896.2004; Nakagawa M, 1997, J INFECT DIS, V175, P927, DOI 10.1086/513992; Nakagawa M, 2007, J VIROL, V81, P1412, DOI 10.1128/JVI.01768-06; Nieminen P., 2012, 28 INT PAP C PUERT R; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Rytlewski J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213684; Sankaranarayanan R, 2016, LANCET ONCOL, V17, P67, DOI 10.1016/S1470-2045(15)00414-3; Schiffman M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.86; Spandorfer SD, 2006, FERTIL STERIL, V86, P765, DOI 10.1016/j.fertnstert.2006.01.051; Tarver T, 2012, J CONS HLTH INTERNET, V16, P366, DOI 10.1080/15398285.2012.701177; Trimble CL, 2015, LANCET, V386, P2078, DOI 10.1016/S0140-6736(15)00239-1; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Van Damme P, 2016, CLIN CANCER RES, V22, P3238, DOI 10.1158/1078-0432.CCR-16-0085; Wang XL, 2012, JOVE-J VIS EXP, DOI 10.3791/3657; Wang XL, 2009, CANCER IMMUNOL IMMUN, V58, P301, DOI 10.1007/s00262-008-0525-2; Wu D, 2014, CLIN CANCER RES, V20, P4540, DOI 10.1158/1078-0432.CCR-13-3231	48	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2021	12								645299	10.3389/fimmu.2021.645299	http://dx.doi.org/10.3389/fimmu.2021.645299			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WI5DL	34659195	Green Published, gold, Green Submitted			2022-12-18	WOS:000708380500001
J	Sun, LY; Wang, R; Wu, CC; Gong, JM; Ma, HQ; Fung, SY; Yang, H				Sun, Liya; Wang, Rui; Wu, Chenchen; Gong, Jiameng; Ma, Huiqiang; Fung, Shan-Yu; Yang, Hong			The Modulatory Activity of Tryptophan Displaying Nanodevices on Macrophage Activation for Preventing Acute Lung Injury	FRONTIERS IN IMMUNOLOGY			English	Article						immunomodulatory nanoparticles; acute lung injury; Toll-like receptor; peptide; gold nanoparticle; trained immunity	IRAK-M; NEGATIVE REGULATOR; INFLAMMATION; INDUCTION; TOLERANCE	Macrophages play an important role in the initiation, progression and resolution of inflammation in many human diseases. Effective regulation of their activation and immune responses could be a promising therapeutic strategy to manage various inflammatory conditions. Nanodevices that naturally target macrophages are ideal agents to regulate immune responses of macrophages. Here we described a special tryptophan (Trp)-containing hexapeptide-coated gold nanoparticle hybrid, PW, which had unique immunomodulatory activities on macrophages. The Trp residues enabled PW higher affinity to cell membranes, and contributed to inducing mild pro-inflammatory responses of NF-kappa B/AP-1 activation. However, in the presence of TLR stimuli, PW exhibited potent anti-inflammatory activities through inhibiting multiple TLR signaling pathways. Mechanistically, PW was internalized primarily through micropinocytosis pathway into macrophages and attenuated the endosomal acidification process, and hence preferentially affected the endosomal TLR signaling. Interestingly, PW could induce the expression of the TLR negative regulator IRAK-M, which may also contribute to the observed TLR inhibitory activities. In two acute lung injury (ALI) mouse models, PW could effectively ameliorate lung inflammation and protect lung from injuries. This work demonstrated that nanodevices with thoughtful design could serve as novel immunomodulatory agents to manage the dysregulated inflammatory responses for treating many chronic and acute inflammatory conditions, such as ALI.	[Sun, Liya; Wang, Rui; Gong, Jiameng; Ma, Huiqiang; Yang, Hong] Tianjin Med Univ, Sch Biomed Engn, Tianjin, Peoples R China; [Sun, Liya; Wang, Rui; Gong, Jiameng; Ma, Huiqiang; Yang, Hong] Tianjin Med Univ, Prov & Minist Cosponsored Collaborat Innovat Ctr, Tianjin, Peoples R China; [Wu, Chenchen] Tianjin Med Univ, Sch Basic Med Sci, Dept Pharmacol, Tianjin, Peoples R China; [Fung, Shan-Yu] Tianjin Med Univ, Sch Basic Med Sci, Key Lab Immune Microenvironm & Dis, Minist Educ, Tianjin, Peoples R China; [Fung, Shan-Yu] Tianjin Med Univ, Sch Basic Med Sci, Dept Immunol, Tianjin, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University	Yang, H (corresponding author), Tianjin Med Univ, Sch Biomed Engn, Tianjin, Peoples R China.; Yang, H (corresponding author), Tianjin Med Univ, Prov & Minist Cosponsored Collaborat Innovat Ctr, Tianjin, Peoples R China.; Fung, SY (corresponding author), Tianjin Med Univ, Sch Basic Med Sci, Dept Immunol, Tianjin, Peoples R China.	shanefung@tmu.edu.cn; hongyang@tmu.edu.cn	Yang, Hong/E-3478-2014; Fung, Shan-Yu/E-3477-2014	Yang, Hong/0000-0002-6707-8481; Fung, Shan-Yu/0000-0002-4547-8740	National Natural Science Foundation of China [81770070, 81971549]; Natural Science Foundation of Tianjin Municipal Science and Technology Commission [20JCYBJC00040]; Tianjin Medical University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Tianjin Municipal Science and Technology Commission; Tianjin Medical University	This work was supported by the National Natural Science Foundation of China (No. 81770070 for HY and No. 81971549 for SYF), the Natural Science Foundation of Tianjin Municipal Science and Technology Commission (20JCYBJC00040 for HY) and the starting fund from Tianjin Medical University.	Aggarwal NR, 2014, AM J PHYSIOL-LUNG C, V306, pL709, DOI 10.1152/ajplung.00341.2013; Bayyurt B, 2017, J CONTROL RELEASE, V247, P134, DOI 10.1016/j.jconrel.2017.01.004; Belhadj Z, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1806444; Biswas SK, 2009, TRENDS IMMUNOL, V30, P475, DOI 10.1016/j.it.2009.07.009; Bonam SR, 2019, NAT REV DRUG DISCOV, V18, P923, DOI 10.1038/s41573-019-0036-1; Chung CH, 2020, ACS NANO, V14, P6887, DOI 10.1021/acsnano.0c01018; Ciesielska A, 2021, CELL MOL LIFE SCI, V78, P1233, DOI 10.1007/s00018-020-03656-y; de Jesus AJ, 2013, BBA-BIOMEMBRANES, V1828, P864, DOI 10.1016/j.bbamem.2012.09.009; Fam SY, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10040787; Flannery S, 2010, BIOCHEM PHARMACOL, V80, P1981, DOI 10.1016/j.bcp.2010.06.020; Fu ZY, 2013, METHODS, V64, P260, DOI 10.1016/j.ymeth.2013.08.003; Gao W, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00508; Guo JW, 2019, ADV MATER, V31, DOI 10.1002/adma.201904607; Hubbard LLN, 2010, INFECT DIS REP, V2, P22, DOI 10.4081/idr.2010.e9; Jin PP, 2016, BIOMED PHARMACOTHER, V83, P1212, DOI 10.1016/j.biopha.2016.08.024; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Larson TA, 2012, ACS NANO, V6, P9182, DOI 10.1021/nn3035155; Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0; Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST; Miyata M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7062; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Nguyen HA, 2012, AM J PHYSIOL-LUNG C, V303, pL608, DOI 10.1152/ajplung.00067.2012; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; Pathak SK, 2005, J BIOL CHEM, V280, P42794, DOI 10.1074/jbc.M506471200; Pelaz B, 2015, ACS NANO, V9, P6996, DOI 10.1021/acsnano.5b01326; Rodriguez PL, 2013, SCIENCE, V339, P971, DOI 10.1126/science.1229568; Rothschild DE, 2018, J LEUKOCYTE BIOL, V103, P1131, DOI 10.1002/JLB.3MIR0817-346RRR; Seki M, 2010, J IMMUNOL, V184, P1410, DOI 10.4049/jimmunol.0901709; Subramanian K, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012695; Subramanian K, 2019, NAT MICROBIOL, V4, P62, DOI 10.1038/s41564-018-0280-x; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; van 't Veer C, 2007, J IMMUNOL, V179, P7110, DOI 10.4049/jimmunol.179.10.7110; Wang L, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-00593-7; Wang ZJ, 2014, NAT NANOTECHNOL, V9, P204, DOI [10.1038/NNANO.2014.17, 10.1038/nnano.2014.17]; Xiong YB, 2011, J LEUKOCYTE BIOL, V90, P1141, DOI 10.1189/jlb.0611273; Xiong Y, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800510; Yang H, 2016, BIOMATERIALS, V111, P90, DOI 10.1016/j.biomaterials.2016.09.032; Yang H, 2015, ACS NANO, V9, P6774, DOI 10.1021/nn505634h; Yang L, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00138; Zhang MQ, 2017, AM J RESP CELL MOL, V57, P547, DOI 10.1165/rcmb.2016-0370OC; Zhou H, 2013, EMBO J, V32, P583, DOI 10.1038/emboj.2013.2	41	1	1	3	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2021	12								750128	10.3389/fimmu.2021.750128	http://dx.doi.org/10.3389/fimmu.2021.750128			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WH2AR	34659253	Green Published, gold			2022-12-18	WOS:000707488100001
J	van Heerden, PV; Abutbul, A; Sviri, S; Zlotnick, E; Nama, A; Zimro, S; El-Amore, R; Shabat, Y; Reicher, B; Falah, B; Mevorach, D				van Heerden, Peter Vernon; Abutbul, Avraham; Sviri, Sigal; Zlotnick, Eitan; Nama, Ahmad; Zimro, Sebastian; El-Amore, Raja; Shabat, Yehudit; Reicher, Barak; Falah, Batla; Mevorach, Dror			Apoptotic Cells for Therapeutic Use in Cytokine Storm Associated With Sepsis- A Phase Ib Clinical Trial	FRONTIERS IN IMMUNOLOGY			English	Article						sepsis; Inflammation; pneumonia; apoptotic cells; cell therapeutics; cytokine storm	APACHE-II; DISEASE; MORTALITY; SECRETOME; SEVERITY; TRENDS; TISSUE; SCORE	Background Sepsis has no proven specific pharmacologic treatment and reported mortality ranges from 30%-45%. The primary aim of this phase IB study was to determine the safety profile of Allocetra (TM)-OTS (early apoptotic cell) infusion in subjects presenting to the emergency room with sepsis. The secondary aims were to measure organ dysfunction, intensive care unit (ICU) and hospital stays, and mortality. Exploratory endpoints included measuring immune modulator agents to elucidate the mechanism of action. Methods Ten patients presenting to the emergency room at the Hadassah Medical Center with sepsis were enrolled in this phase Ib clinical study. Enrolled patients were males and females aged 51-83 years, who had a Sequential Organ Failure Assessment (SOFA) score >= 2 above baseline and were septic due to presumed infection. Allocetra (TM)-OTS was administered as a single dose (day +1) or in two doses of 140x10(6) cells/kg on (day +1 and +3), following initiation of standard-of-care (SOC) treatment for septic patients. Safety was evaluated by serious adverse events (SAEs) and adverse events (AEs). Organ dysfunction, ICU and hospital stays, and mortality, were compared to historical controls. Immune modulator agents were measured using Luminex(R) multiplex analysis. Results All 10 patients had mild-to-moderate sepsis with SOFA scores ranging from 2-6 upon entering the study. No SAEs and no related AEs were reported. All 10 study subjects survived, while matched historical controls had a mortality rate of 27%. The study subjects exhibited rapid resolution of organ dysfunction and had significantly shorter ICU stays compared to matched historical controls (p<0.0001). All patients had both elevated pro- and anti-inflammatory cytokines, chemokines, and additional immune modulators that gradually decreased following treatment. Conclusion Administration of apoptotic cells to patients with mild-to-moderate sepsis was safe and had a significant immuno-modulating effect, leading to early resolution of the cytokine storm.	[van Heerden, Peter Vernon; Zimro, Sebastian] Hadassah Hebrew Univ, Gen Intens Care Unit, Med Ctr, Jerusalem, Israel; [Abutbul, Avraham; Sviri, Sigal] Hadassah Hebrew Univ, Med Intens Care Unit, Med Ctr, Jerusalem, Israel; [Zlotnick, Eitan; El-Amore, Raja; Mevorach, Dror] Hadassah Hebrew Univ, Med Ctr & Sch, Rheumatol & Rare Dis Res Ctr, Wohl Inst Translat Med, Jerusalem, Israel; [Nama, Ahmad] Hadassah Hebrew Univ, Dept Emergency Med, Med Ctr & Sch, Jerusalem, Israel; [Shabat, Yehudit; Reicher, Barak] Enlivex Therapeut Ltd, Dept Res, Ness Ziona, Israel; [Falah, Batla] Hadassah Hebrew Univ, Dept Cardiol, Med Ctr, Jerusalem, Israel; [Mevorach, Dror] Hadassah Hebrew Univ, Dept Med, Med Ctr, Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	Mevorach, D (corresponding author), Hadassah Hebrew Univ, Med Ctr & Sch, Rheumatol & Rare Dis Res Ctr, Wohl Inst Translat Med, Jerusalem, Israel.; Mevorach, D (corresponding author), Hadassah Hebrew Univ, Dept Med, Med Ctr, Jerusalem, Israel.	mevorachd@hadassah.org.il			Enlivex Therapeutics Ltd.	Enlivex Therapeutics Ltd.	The study received funding from Enlivex Therapeutics Ltd. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Aziz M, 2013, J LEUKOCYTE BIOL, V93, P329, DOI 10.1189/jlb.0912437; Beer L, 2016, APOPTOSIS, V21, P1336, DOI 10.1007/s10495-016-1292-8; Bonnefoy F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02586; Chaudhry H, 2013, IN VIVO, V27, P669; Chousterman BG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01015; Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8; Cohen J, 2012, LANCET INFECT DIS, V12, P503, DOI 10.1016/S1473-3099(12)70136-6; Finfer S, 2004, INTENS CARE MED, V30, P589, DOI 10.1007/s00134-004-2157-0; Fleischmann C, 2016, AM J RESP CRIT CARE, V193, P259, DOI 10.1164/rccm.201504-0781OC; Gauthier J, 2018, CURR RES TRANSL MED, V66, P50, DOI 10.1016/j.retram.2018.03.003; Giavridis T, 2018, NAT MED, V24, P731, DOI 10.1038/s41591-018-0041-7; Hacker S, 2016, SCI REP-UK, V6, DOI 10.1038/srep25168; Hoetzenecker K, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395-012-0292-2; Hotchkiss RS, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.45; Huang R, 2020, LANCET INFECT DIS, V20, P534, DOI 10.1016/S1473-3099(20)30147-X; Jones BJ, 2012, ENDOCRINOLOGY, V153, P1049, DOI 10.1210/en.2011-1979; Kasiri MM, 2016, EUR J CLIN INVEST, V46, P853, DOI 10.1111/eci.12667; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Krispin A, 2006, BLOOD, V108, P3580, DOI 10.1182/blood-2006-03-013334; Lee YJ, 2012, EUR RESPIR J, V40, P424, DOI 10.1183/09031936.00096711; Li X, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179050; Libraty DH, 2002, J INFECT DIS, V185, P1213, DOI 10.1086/340365; Lichtenauer M, 2011, BASIC RES CARDIOL, V106, P1283, DOI 10.1007/s00395-011-0224-6; Lichtenauer M, 2011, BASIC RES CARDIOL, V106, P645, DOI 10.1007/s00395-011-0173-0; Liu V, 2014, JAMA-J AM MED ASSOC, V312, P90, DOI 10.1001/jama.2014.5804; Machado FR, 2017, LANCET INFECT DIS, V17, P1180, DOI 10.1016/S1473-3099(17)30322-5; Martin-Loeches I, 2015, DRUG DES DEV THER, V9, P2079, DOI 10.2147/DDDT.S78757; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Mevorach D, 2014, BIOL BLOOD MARROW TR, V20, P58, DOI 10.1016/j.bbmt.2013.10.010; Meyer S, 2011, ENDOCRINE, V39, P167, DOI 10.1007/s12020-010-9431-4; Minne L, 2008, CRIT CARE, V12, DOI 10.1186/cc7160; Moon BH, 2015, J CLIN NEUROSCI, V22, P111, DOI 10.1016/j.jocn.2014.05.031; Plikat K, 2007, METABOLISM, V56, P239, DOI 10.1016/j.metabol.2006.09.020; Poon IKH, 2014, NAT REV IMMUNOL, V14, P166, DOI 10.1038/nri3607; Pugin J, 1996, AM J RESP CRIT CARE, V153, P1850, DOI 10.1164/ajrccm.153.6.8665045; Raith EP, 2017, JAMA-J AM MED ASSOC, V317, P290, DOI 10.1001/jama.2016.20328; Reinhart K, 2017, NEW ENGL J MED, V377, P414, DOI 10.1056/NEJMp1707170; Rello J, 2017, ADV THER, V34, P2393, DOI 10.1007/s12325-017-0622-8; Ren Y, 2008, J IMMUNOL, V180, P4978, DOI 10.4049/jimmunol.180.7.4978; Rhee C, 2017, JAMA-J AM MED ASSOC, V318, P1241, DOI 10.1001/jama.2017.13836; ROWAN KM, 1993, BRIT MED J, V307, P972, DOI 10.1136/bmj.307.6910.972; Saas P, 2016, STEM CELLS, V34, P1464, DOI 10.1002/stem.2361; Seymour CW., 2018, HDB SEPSIS; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Tamayo E, 2011, EUR CYTOKINE NETW, V22, P82, DOI 10.1684/ecn.2011.0281; Tang DL, 2012, IMMUNOL REV, V249, P158, DOI 10.1111/j.1600-065X.2012.01146.x; Trahtemberg U, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01356; Venkatesh B, 2018, NEW ENGL J MED, V378, P797, DOI 10.1056/NEJMoa1705835; Vincent JL, 2018, CRIT CARE CLIN, V34, P161, DOI 10.1016/j.ccc.2017.08.012; Vincent JL, 2010, CRIT CARE, V14, DOI 10.1186/cc8204; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751	51	1	1	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2021	12								718191	10.3389/fimmu.2021.718191	http://dx.doi.org/10.3389/fimmu.2021.718191			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WH5WN	34659208	gold, Green Published			2022-12-18	WOS:000707747700001
J	Mayumi, H				Mayumi, Hisanori			A Review of Cyclophosphamide-Induced Transplantation Tolerance in Mice and Its Relationship With the HLA-Haploidentical Bone Marrow Transplantation/Post-Transplantation Cyclophosphamide Platform	FRONTIERS IN IMMUNOLOGY			English	Review						cyclophosphamide-induced tolerance; drug-induced tolerance; haploBMT; PTCy; PTCY; PTCy-haplo HSCT; clonal destruction; clonal deletion	DRUG-INDUCED TOLERANCE; SKIN ALLOGRAFT TOLERANCE; INTRATHYMIC CLONAL DELETION; VERSUS-HOST-DISEASE; INDUCED IMMUNOLOGICAL-TOLERANCE; IN-VITRO TOLERANCE; T-CELLS; POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; ALLOGENEIC ANTIGENS; MIXED CHIMERISM	The bone marrow transplantation (BMT) between haplo-identical combinations (haploBMT) could cause unacceptable bone marrow graft rejection and graft-versus-host disease (GVHD). To cross such barriers, Johns Hopkins platform consisting of haploBMT followed by post-transplantation (PT) cyclophosphamide (Cy) has been used. Although the central mechanism of the Johns Hopkins regimen is Cy-induced tolerance with bone marrow cells (BMC) followed by Cy on days 3 and 4, the mechanisms of Cy-induced tolerance may not be well understood. Here, I review our studies in pursuing skin-tolerance from minor histocompatibility (H) antigen disparity to xenogeneic antigen disparity through fully allogeneic antigen disparity. To overcome fully allogeneic antigen barriers or xenogeneic barriers for skin grafting, pretreatment of the recipients with monoclonal antibodies (mAb) against T cells before cell injection was required. In the cells-followed-by-Cy system providing successful skin tolerance, five mechanisms were identified using the correlation between super-antigens and T-cell receptor (TCR) V beta segments mainly in the H-2-identical murine combinations. Those consist of: 1) clonal destruction of antigen-stimulated-thus-proliferating mature T cells with Cy; 2) peripheral clonal deletion associated with immediate peripheral chimerism; 3) intrathymic clonal deletion associated with intrathymic chimerism; 4) delayed generation of suppressor T (Ts) cells; and 5) delayed generation of clonal anergy. These five mechanisms are insufficient to induce tolerance when the donor-recipient combinations are disparate in MHC antigens plus minor H antigens as is seen in haploBMT. Clonal destruction is incomplete when the antigenic disparity is too strong to establish intrathymic mixed chimerism. Although this incomplete clonal destruction leaves the less-proliferative, antigen-stimulated T cells behind, these cells may confer graft-versus-leukemia (GVL) effects after haploBMT/PTCy.	[Mayumi, Hisanori] Mayumi GP & Cardiol Clin, Saitama, Japan		Mayumi, H (corresponding author), Mayumi GP & Cardiol Clin, Saitama, Japan.	mayumi.clinic@cat3600.xsrv.jp						AISENBERG AC, 1967, J EXP MED, V125, P833, DOI 10.1084/jem.125.5.833; Al Malki MM, 2020, BONE MARROW TRANSPL, V55, P409, DOI 10.1038/s41409-019-0694-y; Auphan-Anezin N, 2006, EUR J IMMUNOL, V36, P1856, DOI 10.1002/eji.200635895; Bemelman F, 1998, J IMMUNOL, V160, P2645; BERENBAUM MC, 1963, NATURE, V200, P84, DOI 10.1038/200084a0; Colf LA, 2007, CELL, V129, P135, DOI 10.1016/j.cell.2007.01.048; DUKOR P, 1970, P SOC EXP BIOL MED, V133, P280; ETO M, 1990, J IMMUNOL, V145, P1303; ETO M, 1990, J EXP MED, V171, P97, DOI 10.1084/jem.171.1.97; ETO M, 1991, J IMMUNOL, V146, P1402; ETO M, 1990, EUR J IMMUNOL, V20, P2005, DOI 10.1002/eji.1830200919; ETO M, 1991, J IMMUNOL, V147, P2439; FAN JL, 1987, TRANSPLANT P, V19, P3513; FINBERG R, 1978, P NATL ACAD SCI USA, V75, P5145, DOI 10.1073/pnas.75.10.5145; Fuchs EJ, 2015, BONE MARROW TRANSPL, V50, pS31, DOI 10.1038/bmt.2015.92; Ganguly S, 2014, BLOOD, V124, P2131, DOI 10.1182/blood-2013-10-525873; Guo HD, 2021, CELL MOL IMMUNOL, V18, P1172, DOI 10.1038/s41423-020-00597-1; Ikegawa S, 2019, BLOOD ADV, V3, P4081, DOI 10.1182/bloodadvances.2019000134; Kanakry CG, 2014, BLOOD, V124, P3817, DOI 10.1182/blood-2014-07-587477; Kanakry CG, 2014, J CLIN ONCOL, V32, P3497, DOI 10.1200/JCO.2013.54.0625; Kanakry CG, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006960; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; Kato K, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03138; Kolb HJ, 2008, BLOOD, V112, P4371, DOI 10.1182/blood-2008-03-077974; Lightbourn CO, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.636789; Luznik L, 2001, BLOOD, V98, P3456, DOI 10.1182/blood.V98.12.3456; Luznik L, 2008, BIOL BLOOD MARROW TR, V14, P641, DOI 10.1016/j.bbmt.2008.03.005; Luznik L, 2012, SEMIN ONCOL, V39, P683, DOI 10.1053/j.seminoncol.2012.09.005; MACDONALD HR, 1988, J EXP MED, V167, P2005, DOI 10.1084/jem.167.6.2005; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; Macdonald WA, 2009, IMMUNITY, V31, P897, DOI 10.1016/j.immuni.2009.09.025; MAEDA T, 1993, IMMUNOLOGY, V78, P113; MAEDA T, 1993, J IMMUNOL, V150, P753; MARQUET R, 1975, J IMMUNOL, V115, P405; MAYUMI H, 1990, Fukuoka Acta Medica, V81, P20; MAYUMI H, 1989, IMMUNOBIOLOGY, V178, P287, DOI 10.1016/S0171-2985(89)80053-1; Mayumi H, 1996, IMMUNOBIOLOGY, V195, P129, DOI 10.1016/S0171-2985(96)80033-7; MAYUMI H, 1985, TRANSPLANTATION, V39, P209, DOI 10.1097/00007890-198502000-00019; MAYUMI H, 1985, IMMUNOBIOLOGY, V169, P147, DOI 10.1016/S0171-2985(85)80029-2; MAYUMI H, 1989, J EXP MED, V169, P213, DOI 10.1084/jem.169.1.213; MAYUMI H, 1986, TRANSPLANTATION, V42, P417, DOI 10.1097/00007890-198610000-00018; MAYUMI H, 1986, TRANSPL P, V18, P363; MAYUMI H, 1985, TRANSPLANTATION, V39, P335, DOI 10.1097/00007890-198503000-00032; MAYUMI H, 1987, TRANSPLANTATION, V44, P286, DOI 10.1097/00007890-198708000-00021; MAYUMI H, 1988, JPN J SURG, V18, P548, DOI 10.1007/BF02471489; MAYUMI H, 1987, IMMUNOBIOLOGY, V174, P274, DOI 10.1016/S0171-2985(87)80003-7; MAYUMI H, 1989, IMMUNOBIOLOGY, V179, P86, DOI 10.1016/S0171-2985(89)80009-9; MAYUMI H, 1988, TRANSPLANTATION, V46, P451, DOI 10.1097/00007890-198809000-00024; MAYUMI H, 1985, TRANSPLANTATION, V40, P438; MAYUMI H, 1985, TRANSPLANTATION, V40, P188, DOI 10.1097/00007890-198508000-00016; MEEKER WR, 1960, ANN NY ACAD SCI, V87, P203, DOI 10.1111/j.1749-6632.1960.tb23193.x; NIRMUL G, 1971, Surgical Forum (Chicago), V22, P287; NOMOTO K, 1992, J IMMUNOL, V149, P2668; O'Donnell PV, 2002, BIOL BLOOD MARROW TR, V8, P377, DOI 10.1053/bbmt.2002.v8.pm12171484; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; Ringden O, 2014, BLOOD, V124, P3672, DOI 10.1182/blood-2014-10-607879; Salik B, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00947-6; SANTOS GW, 1965, B JOHNS HOPKINS HOSP, V116, P327; SCHWARTZ R, 1959, NATURE, V183, P1682, DOI 10.1038/1831682a0; SHARABI Y, 1990, J EXP MED, V172, P195, DOI 10.1084/jem.172.1.195; SHIN T, 1984, TRANSPLANTATION, V37, P580, DOI 10.1097/00007890-198406000-00011; STARZL TE, 1971, LANCET, V2, P70; SUTTON WT, 1963, ARCH SURG-CHICAGO, V87, P840; Szeto C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010068; TOKUDA N, 1986, TRANSPLANTATION, V42, P281, DOI 10.1097/00007890-198609000-00011; TOKUDA N, 1988, TRANSPLANTATION, V45, P464, DOI 10.1097/00007890-198802000-00044; TOMITA Y, 1990, J IMMUNOL, V145, P4026; TOMITA Y, 1990, J IMMUNOL, V144, P463; TOMITA Y, 1992, TRANSPLANTATION, V53, P602, DOI 10.1097/00007890-199203000-00022; Umesue M, 1996, TRANSPLANTATION, V61, P116, DOI 10.1097/00007890-199601150-00023; UPHOFF DE, 1961, TRANSPLAN B, V28, P110; Wachsmuth LP, 2019, J CLIN INVEST, V129, P2357, DOI 10.1172/JCI124218; Wagner JE, 2005, LANCET, V366, P733, DOI 10.1016/S0140-6736(05)66996-6; WINKELSTEIN A, 1973, BLOOD, V41, P273, DOI 10.1182/blood.V41.2.273.273; Zhang QW, 1997, TRANSPLANTATION, V63, P1667, DOI 10.1097/00007890-199706150-00022	76	1	1	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2021	12								744430	10.3389/fimmu.2021.744430	http://dx.doi.org/10.3389/fimmu.2021.744430			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WH3OH	34659242	Green Published, gold			2022-12-18	WOS:000707591100001
J	Zhou, WY; Zhou, YW; Yi, C; Shu, XY; Wei, GX; Chen, XR; Shen, XD; Qiu, M				Zhou, Wenyue; Zhou, Yuwen; Yi, Cheng; Shu, Xinyao; Wei, Guixia; Chen, Xiaorong; Shen, Xudong; Qiu, Meng			Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody	FRONTIERS IN IMMUNOLOGY			English	Article						MSI-H; dMMR; immune checkpoint inhibitors; hyperprogression; gastrointestinal cancer; case report	TUMOR-INFILTRATING LYMPHOCYTES; PD-1 BLOCKADE; OPEN-LABEL; TGF-BETA; NIVOLUMAB; NEOANTIGENS; MELANOMA	Microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) status of tumors is a distinct predictive biomarker of immune checkpoint inhibitors (ICIs) for colorectal and non-colorectal cancer populations. The overall response rate (ORR) varies from approximately 40% to 60%, indicating that nearly half of MSI-H tumors do not respond to ICIs. The mechanism of response heterogeneity in MSI-H/dMMR cancers is unclear. Some patients who have been treated with ICIs have developed a novel pattern of progression called hyperprogression, which is defined as unexpected accelerated tumor growth. No case of MSI-H/dMMR immunotherapy-associated hyperprogression has been reported in the literature. Here, we present the case of a patient with dMMR gastrointestinal cancer who suffered hyperprogressive disease (HPD) after treatment with nivolumab. We explored the potential mechanisms of HPD by clinical, immune, and genomic characteristics. Extremely high levels of serum LDH, low TMB and TILs, and the disruption of TGF beta signaling, may be related to hyperprogression.	[Zhou, Wenyue; Zhou, Yuwen; Yi, Cheng; Shu, Xinyao; Wei, Guixia; Chen, Xiaorong; Qiu, Meng] Sichuan Univ, West China Hosp, Dept Oncol, Chengdu, Peoples R China; [Shen, Xudong] 3D Med Inc, Dept Med, Shanghai, Peoples R China	Sichuan University	Qiu, M (corresponding author), Sichuan Univ, West China Hosp, Dept Oncol, Chengdu, Peoples R China.	qiumeng33@hotmail.com						Baretti M, 2018, PHARMACOL THERAPEUT, V189, P45, DOI 10.1016/j.pharmthera.2018.04.004; Biton J, 2018, CLIN CANCER RES, V24, P5710, DOI 10.1158/1078-0432.CCR-18-0163; Bremnes RM, 2016, J THORAC ONCOL, V11, P789, DOI 10.1016/j.jtho.2016.01.015; Champiat S, 2017, CLIN CANCER RES, V23, P1920, DOI 10.1158/1078-0432.CCR-16-1741; Chida K, 2021, CLIN CANCER RES, V27, P3714, DOI 10.1158/1078-0432.CCR-21-0401; Chiou SH, 2005, J REPROD IMMUNOL, V67, P35, DOI 10.1016/j.jri.2005.06.002; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Fuentes-Antras J, 2018, CANCER TREAT REV, V70, P16, DOI 10.1016/j.ctrv.2018.07.006; Galluzzi L, 2019, TRENDS CELL BIOL, V29, P44, DOI 10.1016/j.tcb.2018.08.005; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Gatalica Z, 2018, EUR J CANCER, V94, P179, DOI 10.1016/j.ejca.2018.02.021; Jones S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7161; Kas B, 2020, JAMA ONCOL, V6, P1039, DOI 10.1001/jamaoncol.2020.1634; Kim JY, 2019, CANCERS, V11, DOI 10.3390/cancers11111699; Kim TK, 2018, TRENDS IMMUNOL, V39, P624, DOI 10.1016/j.it.2018.05.001; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Leslie M, 2018, CANCER DISCOV, V8, P668, DOI 10.1158/2159-8290.CD-NB2018-048; Liu L, 2019, CLIN CANCER RES, V25, P7413, DOI 10.1158/1078-0432.CCR-19-0558; Lu S, 2019, JAMA ONCOL, V5, P1195, DOI 10.1001/jamaoncol.2019.1549; Marabelle A, 2020, J CLIN ONCOL, V38, P1, DOI 10.1200/JCO.19.02105; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Morikawa M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021873; Muro K, 2016, LANCET ONCOL, V17, P717, DOI 10.1016/S1470-2045(16)00175-3; Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9; Petrelli F, 2020, JAMA ONCOL, V6, P1068, DOI 10.1001/jamaoncol.2020.1046; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Saada-Bouzid E, 2017, ANN ONCOL, V28, P1605, DOI 10.1093/annonc/mdx178; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Weide B, 2016, CLIN CANCER RES, V22, P5487, DOI 10.1158/1078-0432.CCR-16-0127; Xiong DH, 2018, ISCIENCE, V9, P258, DOI 10.1016/j.isci.2018.10.021; Yang L, 2010, TRENDS IMMUNOL, V31, P220, DOI 10.1016/j.it.2010.04.002; Yang W, 2019, NAT MED, V25, P767, DOI 10.1038/s41591-019-0434-2; Yoon HH, 2019, CLIN CANCER RES, V25, P125, DOI 10.1158/1078-0432.CCR-18-1984	39	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2021	12								749204	10.3389/fimmu.2021.749204	http://dx.doi.org/10.3389/fimmu.2021.749204			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WG8QM	34659249	Green Published, gold			2022-12-18	WOS:000707257400001
J	Al-Mrahleh, M; Matar, S; Jafar, H; Wehaibi, S; Aslam, N; Awidi, A				Al-Mrahleh, Mairvat; Matar, Suzan; Jafar, Hanan; Wehaibi, Suha; Aslam, Nazneen; Awidi, Abdalla			Human Wharton's Jelly-Derived Mesenchymal Stromal Cells Primed by Tumor Necrosis Factor-alpha and Interferon-gamma Modulate the Innate and Adaptive Immune Cells of Type 1 Diabetic Patients	FRONTIERS IN IMMUNOLOGY			English	Article						type 1 diabetes; Immunomodulation; priming; Wharton's jelly-derived mesenchymal stromal cells; regulatory T cells; tolerogenic dendritic cells	GLUTAMIC-ACID DECARBOXYLASE; STEM-CELLS; IMMUNOSUPPRESSIVE PROPERTIES; DENDRITIC CELLS; DIFFERENTIATION; THERAPY; INDUCE; SERIES	The unique immunomodulation and immunosuppressive potential of Wharton's jelly-derived mesenchymal stromal cells (WJ-MSCs) make them a promising therapeutic approach for autoimmune diseases including type 1 diabetes (T1D). The immunomodulatory effect of MSCs is exerted either by cell-cell contact or by secretome secretion. Cell-cell contact is a critical mechanism by which MSCs regulate immune-responses and generate immune regulatory cells such as tolerogenic dendritic cells (tolDCs) and regulatory T cell (Tregs). In this study, we primed WJ-MSCs with TNF-alpha and IFN-gamma and investigated the immunomodulatory properties of primed WJ-MSCs on mature dendritic cells (mDCs) and activated T cells differentiated from mononuclear cells (MNCs) of T1D patient's. Our findings revealed that primed WJ-MSCs impaired the antigen-mediated immunity, upregulated immune-tolerance genes and downregulated immune-response genes. We also found an increase in the production of anti-inflammatory cytokines and suppression of the production of pro-inflammatory cytokines. Significant upregulation of FOXP3, IL10 and TGFB1 augmented an immunosuppressive effect on adaptive T cell immunity which represented a strong evidence in support of the formation of Tregs. Furthermore, upregulation of many critical genes involved in the immune-tolerance mechanism (IDO1 and PTGES2/PTGS) was detected. Interestingly, upregulation of ENTPD1/NT5E genes express a strong evidence to switch immunostimulatory response toward immunoregulatory response. We conclude that WJ-MSCs primed by TNF-alpha and IFN-gamma may represent a promising tool to treat the autoimmune disorders and can provide a new evidence to consider MSCs- based therapeutic approach for the treatment of TID.	[Al-Mrahleh, Mairvat; Jafar, Hanan; Wehaibi, Suha; Aslam, Nazneen; Awidi, Abdalla] Univ Jordan, Cell Therapy Ctr, Amman, Jordan; [Matar, Suzan] Univ Jordan, Sch Sci, Dept Clin Lab Sci, Amman, Jordan; [Jafar, Hanan] Univ Jordan, Sch Med, Dept Anat & Histol, Amman, Jordan; [Awidi, Abdalla] Univ Jordan, Sch Med, Dept Hematol & Oncol, Amman, Jordan	University of Jordan; University of Jordan; University of Jordan; University of Jordan	Awidi, A (corresponding author), Univ Jordan, Cell Therapy Ctr, Amman, Jordan.; Awidi, A (corresponding author), Univ Jordan, Sch Med, Dept Hematol & Oncol, Amman, Jordan.	aabbadi@ju.edu.jo		Aslam, Nazneen/0000-0002-6806-9843	University of Jordan; Cell Therapy Center/The University of Jordan	University of Jordan; Cell Therapy Center/The University of Jordan	This work was financed by The University of Jordan, Dean of Scientific Research, and Cell Therapy Center/The University of Jordan.	Andreeva E, 2017, CYTOTHERAPY, V19, P1152, DOI 10.1016/j.jcyt.2017.07.001; Awidi A, 2015, J MATER SCI-MATER M, V26, DOI 10.1007/s10856-015-5404-8; Bernardo ME, 2013, CELL STEM CELL, V13, P392, DOI 10.1016/j.stem.2013.09.006; Bhat P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.67; Bulati M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00054; Calderon B, 2012, CURR OPIN IMMUNOL, V24, P119, DOI 10.1016/j.coi.2011.11.005; Carrero R, 2012, STEM CELL REV REP, V8, P905, DOI 10.1007/s12015-012-9364-9; Cesarz Z, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9176357; Chen GL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00499; Chen S, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01793-6; Chinnadurai R, 2016, STEM CELLS, V34, P2429, DOI 10.1002/stem.2415; Cipriani P, 2013, AUTOIMMUN REV, V12, P709, DOI 10.1016/j.autrev.2012.10.004; DelaRosa O, 2012, CURR OPIN BIOTECH, V23, P978, DOI 10.1016/j.copbio.2012.05.005; Di Lorenzo TP, 2007, CLIN EXP IMMUNOL, V148, P1, DOI 10.1111/j.1365-2249.2006.03244.x; Fan MY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00069; Favaro E, 2016, DIABETOLOGIA, V59, P325, DOI 10.1007/s00125-015-3808-0; Favaro E, 2014, DIABETOLOGIA, V57, P1664, DOI 10.1007/s00125-014-3262-4; Figliuzzi Marina, 2014, World J Stem Cells, V6, P163, DOI 10.4252/wjsc.v6.i2.163; Galipeau J, 2016, CYTOTHERAPY, V18, P151, DOI 10.1016/j.jcyt.2015.11.008; Garcia-Gonzalez P, 2016, AUTOIMMUN REV, V15, P1071, DOI 10.1016/j.autrev.2016.07.032; Gebler A, 2012, TRENDS MOL MED, V18, P128, DOI 10.1016/j.molmed.2011.10.004; Ghannam S, 2010, J IMMUNOL, V185, P302, DOI 10.4049/jimmunol.0902007; Haddad R, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/216806; Hross S, 2016, BIOINFORMATICS, V32, P2321, DOI 10.1093/bioinformatics/btw131; Hu CX, 2018, J CELL MOL MED, V22, P1428, DOI 10.1111/jcmm.13492; Huang C, 2015, BBA-GEN SUBJECTS, V1850, P1261, DOI 10.1016/j.bbagen.2015.02.011; Ilgun Handenur, 2015, J Stem Cell Res Transplant, V2; Ji ST, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/3945403; Jorgovanovic D, 2020, BIOMARK RES, V8, DOI 10.1186/s40364-020-00228-x; Kim DS, 2018, EBIOMEDICINE, V28, P261, DOI 10.1016/j.ebiom.2018.01.002; Klinker MW, 2017, P NATL ACAD SCI USA, V114, pE2598, DOI 10.1073/pnas.1617933114; Kyurkchiev Dobroslav, 2014, World J Stem Cells, V6, P552, DOI 10.4252/wjsc.v6.i5.552; Laurence A, 2007, IMMUNITY, V26, P371, DOI 10.1016/j.immuni.2007.02.009; Li W, 2012, CELL DEATH DIFFER, V19, P1505, DOI 10.1038/cdd.2012.26; Lilly MA, 2016, AM J STEM CELLS, V5, P87; Liu QL, 2015, CELL MOL IMMUNOL, V12, P708, DOI 10.1038/cmi.2014.118; Liu XX, 2015, IMMUNOL RES, V61, P219, DOI 10.1007/s12026-014-8612-2; Ludvigsson J, 2012, NEW ENGL J MED, V366, P433, DOI 10.1056/NEJMoa1107096; Mattar P, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00560; Munn DH, 2013, TRENDS IMMUNOL, V34, P137, DOI 10.1016/j.it.2012.10.001; Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363; Noronha NCND, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1224-y; Najar M, 2018, INFLAMM RES, V67, P467, DOI 10.1007/s00011-018-1131-1; Najar M, 2016, CYTOTHERAPY, V18, P160, DOI 10.1016/j.jcyt.2015.10.011; Nava MM, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/797410; Nguyen NT, 2010, P NATL ACAD SCI USA, V107, P19961, DOI 10.1073/pnas.1014465107; Opal SM, 2000, CHEST, V117, P1162, DOI 10.1378/chest.117.4.1162; Opitz CA, 2009, STEM CELLS, V27, P909, DOI 10.1002/stem.7; Park Chae Woon, 2009, Int J Stem Cells, V2, P59; Prasanna SJ, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0014189, 10.1371/journal.pone.0009016]; Rafei M, 2009, J IMMUNOL, V182, P5994, DOI 10.4049/jimmunol.0803962; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Scotto M, 2012, DIABETOLOGIA, V55, P2026, DOI 10.1007/s00125-012-2543-z; Siegel G, 2009, TRANSPLANTATION, V87, pS45, DOI 10.1097/TP.0b013e3181a285b0; Soleymaninejadian E, 2012, AM J REPROD IMMUNOL, V67, P1, DOI 10.1111/j.1600-0897.2011.01069.x; Steensberg A, 2003, AM J PHYSIOL-ENDOC M, V285, pE433, DOI 10.1152/ajpendo.00074.2003; Tu ZD, 2010, STEM CELLS DEV, V19, P1803, DOI 10.1089/scd.2009.0418; Wallberg M, 2013, TRENDS IMMUNOL, V34, P583, DOI 10.1016/j.it.2013.08.005; Wang MY, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3057624; Yang C, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02158-3; Yu PF, 2017, ONCOGENE, V36, P482, DOI 10.1038/onc.2016.217; Zanone MM, 2010, J CLIN ENDOCR METAB, V95, P3788, DOI 10.1210/jc.2009-2350; Zhou YX, 2017, ANN NY ACAD SCI, V1409, P3, DOI 10.1111/nyas.13451	63	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 28	2021	12								732549	10.3389/fimmu.2021.732549	http://dx.doi.org/10.3389/fimmu.2021.732549			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WF4ZE	34650558	gold, Green Published			2022-12-18	WOS:000706313500001
J	Jin, BY; Li, Z; Xia, YN; Li, LX; Zhao, ZX; Li, XY; Li, Y; Li, B; Zhou, RC; Fu, SC; Li, SY; Li, YQ				Jin, Bi-Ying; Li, Zhen; Xia, Ya-Nan; Li, Li-Xiang; Zhao, Zi-Xiao; Li, Xiao-Yu; Li, Yan; Li, Bing; Zhou, Ru-Chen; Fu, Shi-Chen; Li, Shi-Yang; Li, Yan-Qing			Probiotic Interventions Alleviate Food Allergy Symptoms Correlated With Cesarean Section: A Murine Model	FRONTIERS IN IMMUNOLOGY			English	Article						food allergy; cesarean section; intestinal microbiota; probiotics; Th2 response; tight junction	COWS MILK ALLERGY; FECAL MICROFLORA; INTESTINAL MICROBIOTA; ATOPIC-DERMATITIS; GUT MICROBIOTA; DELIVERY MODE; PERMEABILITY; INFANTS; SENSITIZATION; CHILDREN	Delivery by cesarean section (CS) is linked to an increased incidence of food allergies in children and affects early gut microbiota colonization. Furthermore, emerging evidence has connected disordered intestinal microbiota to food allergies. Here, we investigated the impact of CS on a rat model for food allergy to ovalbumin (OVA). Rats delivered by CS were found to be more responsive to OVA sensitization than vaginally born ones, displaying a greater reduction in rectal temperature upon challenge, worse diarrhea, and higher levels of OVA-specific antibodies and histamine. 16S rRNA sequencing of feces revealed reduced levels of Lactobacillus and Bifidobacterium in the CS rats. Preventative supplementation with a probiotic combination containing Lactobacillus and Bifidobacterium could protect CS rats against an allergic response to OVA, indicating that the microbiota dysbiosis contributes to CS-related response. Additionally, probiotic intervention early in life might help to rebuild aberrant Th2 responses and tight junction proteins, both of which have been linked to CS-related high allergic reactions. Taken together, this study shows that disordered intestinal microbiota plays an essential role in the pathogenesis of food allergy mediated by CS. More importantly, interventions that modulate the microbiota composition in early life are therapeutically relevant for CS-related food allergies.	[Jin, Bi-Ying; Li, Zhen; Xia, Ya-Nan; Li, Li-Xiang; Zhao, Zi-Xiao; Li, Xiao-Yu; Li, Yan; Li, Bing; Zhou, Ru-Chen; Fu, Shi-Chen; Li, Yan-Qing] Shandong Univ, Dept Gastroenterol, Qilu Hosp, Jinan, Peoples R China; [Jin, Bi-Ying; Li, Zhen; Xia, Ya-Nan; Li, Li-Xiang; Zhao, Zi-Xiao; Li, Xiao-Yu; Li, Yan; Li, Bing; Zhou, Ru-Chen; Fu, Shi-Chen; Li, Yan-Qing] Shandong Univ, Qilu Hosp, Lab Translat Gastroenterol, Jinan, Peoples R China; [Jin, Bi-Ying; Li, Zhen; Xia, Ya-Nan; Li, Li-Xiang; Zhao, Zi-Xiao; Li, Xiao-Yu; Li, Yan; Li, Bing; Zhou, Ru-Chen; Fu, Shi-Chen; Li, Yan-Qing] Shandong Univ, Qilu Hosp, Robot Engn Lab Precise Diag & Therapy Gastrointes, Jinan, Peoples R China; [Li, Shi-Yang] Shandong Univ, Cheeloo Coll Med, Adv Med Res Inst, Jinan, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong University	Li, YQ (corresponding author), Shandong Univ, Dept Gastroenterol, Qilu Hosp, Jinan, Peoples R China.; Li, YQ (corresponding author), Shandong Univ, Qilu Hosp, Lab Translat Gastroenterol, Jinan, Peoples R China.; Li, YQ (corresponding author), Shandong Univ, Qilu Hosp, Robot Engn Lab Precise Diag & Therapy Gastrointes, Jinan, Peoples R China.	liyanqing@sdu.edu.cn	Li, Zhen/HHM-3328-2022	Li, Zhen/0000-0002-9783-169X	National Natural Science Foundation of China [81873550, 82070552]; Shandong Provincial Key Research and Development Program (Major Scientific and Technological Innovation Project) [2019JZZY011007]; Taishan Scholars Program of Shandong Province; National Clinical Research Center for Digestive Diseases supporting technology project [2015BAI13B07]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Provincial Key Research and Development Program (Major Scientific and Technological Innovation Project); Taishan Scholars Program of Shandong Province; National Clinical Research Center for Digestive Diseases supporting technology project	This study was supported by the National Natural Science Foundation of China (81873550 and 82070552) and Shandong Provincial Key Research and Development Program (Major Scientific and Technological Innovation Project) (No. 2019JZZY011007). This study was also supported by the Taishan Scholars Program of Shandong Province and National Clinical Research Center for Digestive Diseases supporting technology project (2015BAI13B07).	Abdel-Gadir A, 2019, NAT MED, V25, P1164, DOI 10.1038/s41591-019-0461-z; [Anonymous], 2017, Obstet Gynecol, V130, pe274, DOI 10.1097/AOG.0000000000002402; Avery NJ, 2003, PEDIAT ALLERG IMM-UK, V14, P378, DOI 10.1034/j.1399-3038.2003.00072.x; Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; Becattini S, 2016, TRENDS MOL MED, V22, P458, DOI 10.1016/j.molmed.2016.04.003; Berin MC, 1999, AM J PHYSIOL-CELL PH, V276, pC1046, DOI 10.1152/ajpcell.1999.276.5.C1046; Boerma T, 2018, LANCET, V392, P1341, DOI 10.1016/S0140-6736(18)31928-7; Bosmans G, 2019, ALLERGY, V74, P1748, DOI 10.1111/all.13790; Cabana MD, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2016-3000; Canani RB, 2012, J ALLERGY CLIN IMMUN, V129, P580, DOI 10.1016/j.jaci.2011.10.004; Castro MS, 2012, INT ARCH ALLERGY IMM, V157, P11, DOI 10.1159/000324673; Ceponis PJM, 2000, J BIOL CHEM, V275, P29132, DOI 10.1074/jbc.M003516200; Chen CC, 2016, PEDIAT ALLERG IMM-UK, V27, P254, DOI 10.1111/pai.12522; Chen T, 2014, ASIAN PAC J ALLERGY, V32, P345, DOI [10.12932/AP0443.32.4.2014, 10.12932/ap0443.32.4.2014]; Chinthrajah RS, 2016, J ALLERGY CLIN IMMUN, V137, P984, DOI 10.1016/j.jaci.2016.02.004; Coppola MD, 2005, FOOD AGR IMMUNOL, V16, P213, DOI 10.1080/09540100500244138; Dominguez-Bello MG, 2016, NAT MED, V22, P250, DOI 10.1038/nm.4039; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Ellenbogen Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051447; Escribano J, 2018, PEDIATR RES, V83, P1120, DOI 10.1038/pr.2018.34; Feehley T, 2019, NAT MED, V25, P448, DOI 10.1038/s41591-018-0324-z; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Gupta VK, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01162; Hopkins MJ, 2005, FEMS MICROBIOL ECOL, V54, P77, DOI 10.1016/j.femsec.2005.03.001; Huang YJ, 2017, J ALLERGY CLIN IMMUN, V139, P1099, DOI 10.1016/j.jaci.2017.02.007; Jakobsson HE, 2014, GUT, V63, P559, DOI 10.1136/gutjnl-2012-303249; Jung SY, 2019, J SCI FOOD AGR, V99, P7008, DOI 10.1002/jsfa.9993; Koplin J, 2008, PEDIAT ALLERG IMM-UK, V19, P682, DOI 10.1111/j.1399-3038.2008.00731.x; Kourosh A, 2018, PEDIAT ALLERG IMM-UK, V29, P545, DOI 10.1111/pai.12904; Lee E, 2016, ALLERGY ASTHMA IMMUN, V8, P471, DOI 10.4168/aair.2016.8.5.471; Lee SH, 2015, INTEST RES, V13, P11, DOI 10.5217/ir.2015.13.1.11; Li Y, 2014, SCAND J GASTROENTERO, V49, P834, DOI 10.3109/00365521.2014.910834; Maradiaga N, 2018, MICROB PATHOGENESIS, V121, P27, DOI 10.1016/j.micpath.2018.05.007; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; Mitselou N, 2018, J ALLERGY CLIN IMMUN, V142, P1510, DOI 10.1016/j.jaci.2018.06.044; Mitsou EK, 2008, ANAEROBE, V14, P94, DOI 10.1016/j.anaerobe.2007.11.002; Mohamadi-Jorjaiki E, 2020, CAN J PHYSIOL PHARM, V98, P717, DOI 10.1139/cjpp-2019-0370; Morais LH, 2021, NEUROPSYCHOPHARMACOL, V46, P1958, DOI 10.1038/s41386-021-01040-3; Morais LH, 2020, CURR BIOL, V30, P3761, DOI 10.1016/j.cub.2020.07.044; Pandey PK, 2012, J BIOSCIENCES, V37, P989, DOI 10.1007/s12038-012-9268-5; Pannaraj PS, 2017, JAMA PEDIATR, V171, P647, DOI 10.1001/jamapediatrics.2017.0378; Papathoma E, 2016, PEDIAT ALLERG IMM-UK, V27, P419, DOI 10.1111/pai.12552; Penders J, 2007, ALLERGY, V62, P1223, DOI 10.1111/j.1398-9995.2007.01462.x; Pizzuti D, 2011, SCAND J GASTROENTERO, V46, P177, DOI 10.3109/00365521.2010.525716; Rautava S, 2004, J PEDIATR GASTR NUTR, V38, P378, DOI 10.1097/00005176-200404000-00004; Renz H, 2018, J ALLERGY CLIN IMMUN, V141, P1212, DOI 10.1016/j.jaci.2017.11.019; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Rodriguez B, 2011, FEMS MICROBIOL ECOL, V76, P133, DOI 10.1111/j.1574-6941.2010.01035.x; Roze JC, 2012, BRIT J NUTR, V107, P1616, DOI 10.1017/S000711451100479X; SCUDAMORE CL, 1995, J EXP MED, V182, P1871, DOI 10.1084/jem.182.6.1871; Sevelsted A, 2015, PEDIATRICS, V135, pE92, DOI 10.1542/peds.2014-0596; Shao Y, 2019, NATURE, V574, P117, DOI 10.1038/s41586-019-1560-1; Sjogren YM, 2009, CLIN EXP ALLERGY, V39, P518, DOI 10.1111/j.1365-2222.2008.03156.x; Song SJ, 2013, ELIFE, V2, DOI 10.7554/eLife.00458; Stiehm M, 2013, CLIN EXP ALLERGY, V43, P785, DOI 10.1111/cea.12116; Stokholm J, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax9929; Toh ZQ, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00171; Torii S, 2011, INT ARCH ALLERGY IMM, V154, P236, DOI 10.1159/000321110; Tulic MK, 2011, J ALLERGY CLIN IMMUN, V127, P470, DOI 10.1016/j.jaci.2010.09.020; Underwood MA, 2015, PEDIATR RES, V77, P229, DOI 10.1038/pr.2014.156; Zachariassen LF, 2019, MUCOSAL IMMUNOL, V12, P1348, DOI 10.1038/s41385-019-0207-8; Zachariassen LF, 2019, J IMMUNOL, V202, P142, DOI 10.4049/jimmunol.1800666; Zhang ZW, 2018, APPL MICROBIOL BIOT, V102, P8135, DOI 10.1007/s00253-018-9217-9; Zhao Y, 2014, INT J MOL SCI, V15, P1915, DOI 10.3390/ijms15021915	64	1	1	8	31	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 28	2021	12								741371	10.3389/fimmu.2021.741371	http://dx.doi.org/10.3389/fimmu.2021.741371			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WF2ZZ	34650564	Green Published, gold			2022-12-18	WOS:000706180200001
J	Malo, AI; Peraire, J; Ruiz-Mateos, E; Masip, J; Amigo, N; Alcami, J; Moreno, S; Girona, J; Garcia-Pardo, G; Reig, R; Vidal, F; Castro, A; Masana, L; Rull, A				Malo, Ana-Irene; Peraire, Joaquim; Ruiz-Mateos, Ezequiel; Masip, Jenifer; Amigo, Nuria; Alcami, Jose; Moreno, Santiago; Girona, Josefa; Garcia-Pardo, Graciano; Reig, Rosaura; Vidal, Francesc; Castro, Antoni; Masana, Lluis; Rull, Anna			Evolution of Serum Acute-Phase Glycoproteins Assessed by H-1-NMR in HIV Elite Controllers	FRONTIERS IN IMMUNOLOGY			English	Article						elite controllers; HIV; inflammation; acute-phase glycoproteins; proton nuclear magnetic resonance	MECHANISMS; GLYCOSYLATION; INFLAMMATION; REPLICATION; BIOMARKERS; PROTEINS; EVENTS; GLYCA	Elite controllers (ECs) are an exceptional group of people living with HIV (PLWH) who maintain undetectable viral loads (VLs) despite not being on antiretroviral therapy (ART). However, this phenotype is heterogeneous, with some of these subjects losing virological control over time. In this longitudinal retrospective study, serum acute-phase glycoprotein profile assessed by proton nuclear magnetic resonance (H-1-NMR) was determined in 11 transient controllers (TCs) who spontaneously lost virological control and 11 persistent controllers (PCs) who persistently maintained virological control over time. Both PCs and TCs showed similar acute-phase glycoprotein profiles, even when TCs lost the virological control (GlycB, p = 0.824 and GlycA, p = 0.710), and the serum acute-phase glycoprotein signature in PCs did not differ from that in HIV-negative subjects (GlycB, p = 0.151 and GlycA, p = 0.243). Differences in serum glycoproteins A and B were significant only in ECs compared to HIV-typical progressors (TPs) with < 100 CD4+ T-cells (p < 0.001). H-1-NMR acute-phase glycoprotein profile does not distinguish TCs form PCs before the loss of viral control. ECs maintain a low-grade inflammatory state compared to TPs. PCs revealed a closer serum signature to HIV-negative subjects, reaffirming this phenotype as a closer model of functional control of HIV.	[Malo, Ana-Irene; Castro, Antoni; Masana, Lluis] Hosp Univ St Joan, Vasc Med & Metab Unit, Reus, Spain; [Peraire, Joaquim; Masip, Jenifer; Garcia-Pardo, Graciano; Reig, Rosaura; Vidal, Francesc; Rull, Anna] Hosp Univ Tarragona Joan XXIII, Tarragona, Spain; [Peraire, Joaquim; Masip, Jenifer; Garcia-Pardo, Graciano; Vidal, Francesc; Rull, Anna] Inst Invest Sanitaria Pere Virgili IISPV, Infect & Immun Res Grp INIM, Reus, Spain; [Peraire, Joaquim; Masip, Jenifer; Amigo, Nuria; Girona, Josefa; Garcia-Pardo, Graciano; Vidal, Francesc; Castro, Antoni; Masana, Lluis; Rull, Anna] Univ Rovira & Virgili, Tarragona, Spain; [Peraire, Joaquim; Alcami, Jose; Moreno, Santiago; Vidal, Francesc; Rull, Anna] Inst Salud Carlos III ISCIII, Ctr Invest Biomed Red Enfermedades Infecciosas Mi, Madrid, Spain; [Ruiz-Mateos, Ezequiel] Univ Seville, CSIC, Unidad Clin Enfermedades Infecciosas Microbiol &, Inst Biomed Sevilla,Hosp Univ Virgen del Rocio, Seville, Spain; [Amigo, Nuria] Biosfer Teslab, Reus, Spain; [Amigo, Nuria; Girona, Josefa; Masana, Lluis] Inst Salud Carlos III ISCIII, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain; [Alcami, Jose] Inst Salud Carlos III, AIDS Immunopathogenesis Unit, Madrid, Spain; [Alcami, Jose] Inst Invest Biomed August Pi iSunyer IDIBAPS, HIV Unit, Hosp Clin, Barcelona, Spain; [Moreno, Santiago] Univ Alcala, Inst Ramon y Cajal Invest Sanitaria IRYCIS, Hosp Univ Ramon y Cajal, Madrid, Spain; [Girona, Josefa; Castro, Antoni; Masana, Lluis] Inst Invest Sanitaria Pere Virgili IISPV, Res Unit Lipids & Atherosclerosis, Reus, Spain	Universitat Rovira i Virgili; Hospital Universitari De Tarragona Joan XXIII; Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); Universitat Rovira i Virgili; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; CIBER - Centro de Investigacion Biomedica en Red; CIBERDEM; Instituto de Salud Carlos III; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Hospital Universitario Ramon y Cajal; Universidad de Alcala; Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV)	Masana, L (corresponding author), Hosp Univ St Joan, Vasc Med & Metab Unit, Reus, Spain.; Rull, A (corresponding author), Hosp Univ Tarragona Joan XXIII, Tarragona, Spain.; Rull, A (corresponding author), Inst Invest Sanitaria Pere Virgili IISPV, Infect & Immun Res Grp INIM, Reus, Spain.; Masana, L; Rull, A (corresponding author), Univ Rovira & Virgili, Tarragona, Spain.; Rull, A (corresponding author), Inst Salud Carlos III ISCIII, Ctr Invest Biomed Red Enfermedades Infecciosas Mi, Madrid, Spain.; Masana, L (corresponding author), Inst Salud Carlos III ISCIII, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain.; Masana, L (corresponding author), Inst Invest Sanitaria Pere Virgili IISPV, Res Unit Lipids & Atherosclerosis, Reus, Spain.	luis.masana@urv.cat; anna.rull@iispv.cat	Alcami, Pepe/T-2242-2018; MASANA, LUIS/M-7002-2019; Rull, Anna/A-9438-2017	Alcami, Pepe/0000-0003-0023-7377; MASANA, LUIS/0000-0002-0789-4954; Rull, Anna/0000-0002-8907-7754; /0000-0001-7808-5479; Masip Morcillo, Jenifer/0000-0002-9233-5195	Fondo de Investigacion Sanitaria-ISCIII-FEDER (European Regional Development Fund/European Social Fund; "A way to make Europe"/"Investing in your future") [PI16/00503, PI19/01337, PI20/00326]; Programa de Suport als Grups de RecercaAGAUR [2017SGR948]; SPANISH AIDS Research Network-ISCIII-FEDER (Spain) [RD12/0017/0005, RD12/0025/0001, RD16/0025/0006]; Centro de Investigacion Biomedica en Red de Enfermedades InfecciosasISCIII, Madrid, Spain [CB21/13/00015, CB21/13/00020, CB13/21/00086]; Universitat Rovira i Virgili through the call "Marti Franques Research Fellowship Programme" [2019PMF-PIPF-18]; Programa de Intensificacio'n de Investigadores-ISCIII [INT20/00031]; IISPV [2019/IISPV/05]; GeSIDA through the "III Premio para Jovenes Investigadores 2019"; Instituto de Salud Carlos III (ISCIII) through the Miguel Servet Program [CP19/00146]	Fondo de Investigacion Sanitaria-ISCIII-FEDER (European Regional Development Fund/European Social Fund; "A way to make Europe"/"Investing in your future"); Programa de Suport als Grups de RecercaAGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); SPANISH AIDS Research Network-ISCIII-FEDER (Spain); Centro de Investigacion Biomedica en Red de Enfermedades InfecciosasISCIII, Madrid, Spain; Universitat Rovira i Virgili through the call "Marti Franques Research Fellowship Programme"; Programa de Intensificacio'n de Investigadores-ISCIII; IISPV; GeSIDA through the "III Premio para Jovenes Investigadores 2019"; Instituto de Salud Carlos III (ISCIII) through the Miguel Servet Program	This research was funded by the Fondo de Investigacion Sanitaria [PI16/00503, PI19/01337 and PI20/00326]-ISCIII-FEDER (cofunded by the European Regional Development Fund/European Social Fund; "A way to make Europe"/"Investing in your future"); Programa de Suport als Grups de RecercaAGAUR(2017SGR948); the SPANISH AIDS Research Network [RD12/0017/0005, RD12/0025/0001, RD16/0025/0006]-ISCIII-FEDER (Spain) and Centro de Investigacio ' n Biome ' dica en Red de Enfermedades InfecciosasISCIII [CB21/13/00015, CB21/13/00020, CB13/21/00086], Madrid, Spain. JM is supported by the Universitat Rovira i Virgili under grant agreement "2019PMF-PIPF-18," through the call "Marti ' Franques Research Fellowship Programme". FV is supported by grants from the Programa de Intensificacio ' n de Investigadores (INT20/00031)-ISCIII. AR is supported by a grant from IISPV through the project "2019/IISPV/05" (Boosting Young Talent), by GeSIDA through the "III Premio para Jo ' venes Investigadores 2019" and by the Instituto de Salud Carlos III (ISCIII) under grant agreement "CP19/00146" through the Miguel Servet Program.	Akinkuolie AO, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001221; Benito JM, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1026-6; Casado C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58696-y; Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010; Dominguez-Molina B, 2016, CLIN INFECT DIS, V62, P1304, DOI 10.1093/cid/ciw120; Duprez DA, 2016, CLIN CHEM, V62, P1020, DOI 10.1373/clinchem.2016.255828; Fuertes-Martin R, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020354; Fuertes-Martin R, 2019, J PROTEOME RES, V18, P4038, DOI 10.1021/acs.jproteome.9b00528; Fuertes-Martin R, 2018, J PROTEOME RES, V17, P3730, DOI 10.1021/acs.jproteome.8b00411; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27; Gornik O, 2008, DIS MARKERS, V25, P267, DOI 10.1155/2008/493289; Gruys E, 2005, J Zhejiang Univ Sci B, V6, P1045, DOI 10.1631/jzus.2005.B1045; Justice AC, 2018, J INFECT DIS, V217, P521, DOI 10.1093/infdis/jix586; Kelesidis T, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.019324; Kelesidis T, 2015, CLIN INFECT DIS, V61, P651, DOI 10.1093/cid/civ327; Lopez-Galindez C, 2019, CURR OPIN VIROL, V38, P31, DOI 10.1016/j.coviro.2019.05.010; Malo AI, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051344; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Navarrete-Munoz MA, 2020, VIRULENCE, V11, P889, DOI 10.1080/21505594.2020.1788887; Noel N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131922; Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019; Otvos JD, 2015, CLIN CHEM, V61, P714, DOI 10.1373/clinchem.2014.232918; Pernas M, 2018, J VIROL, V92, DOI 10.1128/JVI.01805-17; Rodriguez-Gallego E, 2019, J INFECT DIS, V219, P867, DOI 10.1093/infdis/jiy599; Ruiz-Mateos Ezequiel, 2020, Pathog Immun, V5, P121, DOI 10.20411/pai.v5i1.364; Sokoya T, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/6825493; Tarancon-Diez L, 2019, EBIOMEDICINE, V42, P86, DOI 10.1016/j.ebiom.2019.03.004; Tibuakuu M, 2019, AIDS, V33, P547, DOI 10.1097/QAD.0000000000002079; Walker-Sperling VE, 2017, EBIOMEDICINE, V16, P141, DOI 10.1016/j.ebiom.2017.01.034; Yeregui E, 2020, EBIOMEDICINE, V62, DOI 10.1016/j.ebiom.2020.103077	31	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 28	2021	12								730691	10.3389/fimmu.2021.730691	http://dx.doi.org/10.3389/fimmu.2021.730691			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WF4GU	34650556	Green Published, gold			2022-12-18	WOS:000706265700001
J	Netsrithong, R; Wattanapanitch, M				Netsrithong, Ratchapong; Wattanapanitch, Methichit			Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells	FRONTIERS IN IMMUNOLOGY			English	Review						adoptive cell therapy; induced pluripotent stem cells; T cells; chimeric antigen receptor; tumor infiltrating lymphocytes; cancer immunotherapy; off-the-shelf T cells	CHIMERIC-ANTIGEN-RECEPTOR; HEMATOPOIETIC STEM; AUTOLOGOUS TUMOR; CORD BLOOD; LINEAGE COMMITMENT; CANCER REGRESSION; PROGENITOR CELLS; DOWN-REGULATION; GENERATION; DIFFERENTIATION	Adoptive cell therapy (ACT) using chimeric antigen receptor (CAR) T cells holds impressive clinical outcomes especially in patients who are refractory to other kinds of therapy. However, many challenges hinder its clinical applications. For example, patients who undergo chemotherapy usually have an insufficient number of autologous T cells due to lymphopenia. Long-term ex vivo expansion can result in T cell exhaustion, which reduces the effector function. There is also a batch-to-batch variation during the manufacturing process, making it difficult to standardize and validate the cell products. In addition, the process is labor-intensive and costly. Generation of universal off-the-shelf CAR T cells, which can be broadly given to any patient, prepared in advance and ready to use, would be ideal and more cost-effective. Human induced pluripotent stem cells (iPSCs) provide a renewable source of cells that can be genetically engineered and differentiated into immune cells with enhanced anti-tumor cytotoxicity. This review describes basic knowledge of T cell biology, applications in ACT, the use of iPSCs as a new source of T cells and current differentiation strategies used to generate T cells as well as recent advances in genome engineering to produce next-generation off-the-shelf T cells with improved effector functions. We also discuss challenges in the field and future perspectives toward the final universal off-the-shelf immunotherapeutic products.	[Netsrithong, Ratchapong; Wattanapanitch, Methichit] Mahidol Univ, Siriraj Hosp, Fac Med, Siriraj Ctr Regenerat Med, Bangkok, Thailand; [Netsrithong, Ratchapong] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Immunol, Bangkok, Thailand	Mahidol University; Mahidol University	Wattanapanitch, M (corresponding author), Mahidol Univ, Siriraj Hosp, Fac Med, Siriraj Ctr Regenerat Med, Bangkok, Thailand.	methichit.wat@mahidol.ac.th			Thailand Research Fund [RSA6280090]; Program Management Unit for Human Resources & Institutional Development, Research and Innovation [B05F630080]; Siriraj Research Fund, Faculty of Medicine Siriraj Hospital, Mahidol University [(IO) R016234002]; Mahidol University; Development and Promotion of Science and Technology Talents Project; Chalermphrakiat Grant, Faculty of Medicine Siriraj Hospital, Mahidol University	Thailand Research Fund(Thailand Research Fund (TRF)); Program Management Unit for Human Resources & Institutional Development, Research and Innovation; Siriraj Research Fund, Faculty of Medicine Siriraj Hospital, Mahidol University; Mahidol University; Development and Promotion of Science and Technology Talents Project; Chalermphrakiat Grant, Faculty of Medicine Siriraj Hospital, Mahidol University	This study was supported by grants from the Thailand Research Fund (grant no. RSA6280090), the Program Management Unit for Human Resources & Institutional Development, Research and Innovation (grant no. B05F630080), the Siriraj Research Fund, Faculty of Medicine Siriraj Hospital, Mahidol University (grant number (IO) R016234002) and Mahidol University. RN is supported by the Development and Promotion of Science and Technology Talents Project. MW is supported by Chalermphrakiat Grant, Faculty of Medicine Siriraj Hospital, Mahidol University.	Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Ando M, 2020, HAEMATOLOGICA, V105, P796, DOI 10.3324/haematol.2019.223511; Ando M, 2017, EXP HEMATOL, V47, P2, DOI 10.1016/j.exphem.2016.10.009; Ando M, 2015, STEM CELL REP, V5, P597, DOI 10.1016/j.stemcr.2015.07.011; Andrawes MB, 2013, J BIOL CHEM, V288, P25477, DOI 10.1074/jbc.M113.454850; Benjamin R, 2020, LANCET, V396, P1885, DOI 10.1016/S0140-6736(20)32334-5; Besseyrias V, 2007, J EXP MED, V204, P331, DOI 10.1084/jem.20061442; Brauer PM, 2016, BLOOD, V128, P783, DOI 10.1182/blood-2015-10-676304; Bridgeman JS, 2010, J IMMUNOL, V184, P6938, DOI 10.4049/jimmunol.0901766; Cahan P, 2013, NAT REV MOL CELL BIO, V14, P357, DOI 10.1038/nrm3584; Calvo J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050495; Canu G, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02058-4; Chang CW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097335; Chang CW, 2020, BLOOD, V136, DOI 10.1182/blood-2020-138930; Chang CW, 2019, BLOOD, V134, DOI 10.1182/blood-2019-130584; Chen YH, 2019, CLIN CANCER RES, V25, P2915, DOI 10.1158/1078-0432.CCR-18-1811; Chmielewski M, 2017, CELL REP, V21, P3205, DOI 10.1016/j.celrep.2017.11.063; Chung B, 2014, STEM CELLS, V32, P2386, DOI 10.1002/stem.1731; Clarke R, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-116843; Crowther MD, 2020, NAT IMMUNOL, V21, P178, DOI 10.1038/s41590-019-0578-8; Dejaco C, 2006, IMMUNOLOGY, V117, P289, DOI 10.1111/j.1365-2567.2005.02317.x; Depil S, 2020, NAT REV DRUG DISCOV, V19, P185, DOI 10.1038/s41573-019-0051-2; Deuse T, 2019, NAT BIOTECHNOL, V37, P252, DOI 10.1038/s41587-019-0016-3; DiNofia AM, 2021, NAT REV CLIN ONCOL, V18, P195, DOI 10.1038/s41571-021-00485-1; Ditadi A, 2016, METHODS, V101, P65, DOI 10.1016/j.ymeth.2015.10.001; Doi D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17165-w; Dudley ME, 2002, J IMMUNOTHER, V25, P243, DOI 10.1097/00002371-200205000-00007; Dzilic E, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/4136473; Eyquem J, 2017, NATURE, V543, P113, DOI 10.1038/nature21405; Fauriat C, 2008, J IMMUNOL, V181, P6010, DOI 10.4049/jimmunol.181.9.6010; Feucht J, 2019, NAT MED, V25, P82, DOI 10.1038/s41591-018-0290-5; Fiorenza S, 2020, BONE MARROW TRANSPL, V55, P1706, DOI 10.1038/s41409-020-0956-8; Gornalusse GG, 2017, NAT BIOTECHNOL, V35, P765, DOI 10.1038/nbt.3860; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; GROSS G, 1992, FASEB J, V6, P3370, DOI 10.1096/fasebj.6.15.1464371; Guo Rongqun, 2020, Blood Sci, V2, P22, DOI 10.1097/BS9.0000000000000037; Hague M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126471; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Han X, 2019, P NATL ACAD SCI USA, V116, P10441, DOI 10.1073/pnas.1902566116; Haque R, 2012, J IMMUNOL, V189, P1228, DOI 10.4049/jimmunol.1200633; Harman BC, 2003, SEMIN IMMUNOL, V15, P91, DOI 10.1016/S1044-5323(03)00005-8; Hawkins ER, 2021, BIOL-TARGETS THER, V15, P95, DOI 10.2147/BTT.S291768; Hew M, 2015, J CLIN MED, V4, P1193, DOI 10.3390/jcm4061193; Hinterberger M, 2010, NAT IMMUNOL, V11, P512, DOI 10.1038/ni.1874; Honda T, 2020, MOL THER, V28, P2394, DOI 10.1016/j.ymthe.2020.07.004; Hozumi K, 2004, NAT IMMUNOL, V5, P638, DOI 10.1038/ni1075; Ikawa T, 2010, SCIENCE, V329, P93, DOI 10.1126/science.1188995; Iriguchi S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20658-3; Ito T, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02195-x; Johnson LA, 2009, BLOOD, V114, P535, DOI 10.1182/blood-2009-03-211714; Karagiannis P, 2016, SEMIN IMMUNOL, V28, P35, DOI 10.1016/j.smim.2015.10.007; Karanu FN, 2001, BLOOD, V97, P1960, DOI 10.1182/blood.V97.7.1960; Kashima S, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.100998; Kawai Y, 2021, MOL THER, V29, P3027, DOI 10.1016/j.ymthe.2021.05.016; Kennedy M, 2012, CELL REP, V2, P1722, DOI 10.1016/j.celrep.2012.11.003; Kimbrel EA, 2020, NAT REV DRUG DISCOV, V19, P463, DOI 10.1038/s41573-020-0064-x; Kishino Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097397; Kitayama S, 2016, STEM CELL REP, V6, P213, DOI 10.1016/j.stemcr.2016.01.005; Klein L, 2014, NAT REV IMMUNOL, V14, P377, DOI 10.1038/nri3667; KODAMA H, 1994, EXP HEMATOL, V22, P979; Koga K, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232-020-00132-9; Kumar A, 2019, J IMMUNOL, V202, P770, DOI 10.4049/jimmunol.1801027; La Motte-Mohs RN, 2005, BLOOD, V105, P1431, DOI 10.1182/blood-2004-04-1293; Laiosa CV, 2006, ANNU REV IMMUNOL, V24, P705, DOI 10.1146/annurev.immunol.24.021605.090742; Lanza R, 2019, NAT REV IMMUNOL, V19, P723, DOI 10.1038/s41577-019-0200-1; Lapenna A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069572; Leen AM, 2013, BLOOD, V121, P5113, DOI 10.1182/blood-2013-02-486324; Lei FY, 2009, CELL IMMUNOL, V260, P1, DOI 10.1016/j.cellimm.2009.09.005; Lind EF, 2001, J EXP MED, V194, P127, DOI 10.1084/jem.194.2.127; Lyman GH, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.2072; Macedo C, 2009, AM J TRANSPLANT, V9, P2057, DOI 10.1111/j.1600-6143.2009.02742.x; Maeda T, 2020, MOL THER-METH CLIN D, V19, P250, DOI 10.1016/j.omtm.2020.09.011; Maeda T, 2016, CANCER RES, V76, P6839, DOI 10.1158/0008-5472.CAN-16-1149; Malik NN, 2019, REGEN MED, V14, P983, DOI 10.2217/rme-2019-0117; Mandal M, 2020, CANCER RES, V80, DOI 10.1158/1538-7445.AM2020-3245; Masuda K, 2007, CANCER SCI, V98, P102, DOI 10.1111/j.1349-7006.2006.00356.x; Maus MV, 2014, ANNU REV IMMUNOL, V32, P189, DOI 10.1146/annurev-immunol-032713-120136; Menon AG, 2002, LAB INVEST, V82, P1725, DOI 10.1097/01.LAB.0000043124.75633.ED; Menon T, 2015, CELL STEM CELL, V16, P367, DOI 10.1016/j.stem.2015.02.005; Minagawa A, 2018, CELL STEM CELL, V23, P850, DOI 10.1016/j.stem.2018.10.005; Minagawa A, 2014, HUM CELL, V27, P47, DOI 10.1007/s13577-014-0089-8; Mohtashami M, 2013, INT IMMUNOL, V25, P601, DOI 10.1093/intimm/dxt027; Mohtashami M, 2010, J IMMUNOL, V185, P867, DOI 10.4049/jimmunol.1000782; Montel-Hagen A, 2019, CELL STEM CELL, V24, P376, DOI 10.1016/j.stem.2018.12.011; Montel-Hagen A, 2019, EXP HEMATOL, V71, P24, DOI 10.1016/j.exphem.2018.12.001; Morgan MA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01965; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Mullard A, 2021, NAT REV DRUG DISCOV, V20, P166, DOI 10.1038/d41573-021-00031-9; MUUL LM, 1987, J IMMUNOL, V138, P989; Nagano S, 2020, MOL THER-METH CLIN D, V16, P126, DOI 10.1016/j.omtm.2019.12.006; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Netsrithong R, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01997-w; Nguyen C, 2020, BLOOD S1, V136, P32, DOI [10.1182/blood-2020- 141507, DOI 10.1182/BLOOD-2020-141507]; Nianias A, 2019, CURR HEMATOL MALIG R, V14, P261, DOI 10.1007/s11899-019-00528-6; Nishimura T, 2019, METHODS MOL BIOL, V1899, P25, DOI 10.1007/978-1-4939-8938-6_3; Nishimura T, 2013, CELL STEM CELL, V12, P114, DOI 10.1016/j.stem.2012.11.002; Okita K, 2013, STEM CELLS, V31, P458, DOI 10.1002/stem.1293; Palmer E, 2009, NAT REV IMMUNOL, V9, P206, DOI 10.1038/nri2469; Park JH, 2020, BLOOD, V136, DOI 10.1182/blood-2020-142423; Pegram HJ, 2015, LEUKEMIA, V29, P415, DOI 10.1038/leu.2014.215; Ping Y, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00803; Poirot L, 2015, CANCER RES, V75, P3853, DOI 10.1158/0008-5472.CAN-14-3321; Qasim W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj2013; Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537; ROSENBERG SA, 1994, J NATL CANCER I, V86, P1159, DOI 10.1093/jnci/86.15.1159; Sadelain M, 2017, NATURE, V545, P423, DOI 10.1038/nature22395; Saito H, 2016, CANCER RES, V76, P3473, DOI 10.1158/0008-5472.CAN-15-1742; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0; Seet CS, 2017, NAT METHODS, V14, P521, DOI [10.1038/NMETH.4237, 10.1038/nmeth.4237]; Seki T, 2012, NAT PROTOC, V7, P718, DOI 10.1038/nprot.2012.015; Seki Tomohisa, 2011, Curr Protoc Stem Cell Biol, VChapter 4, DOI 10.1002/9780470151808.sc04a03s18; Shi L, 2020, STEM CELLS, V38, P1423, DOI 10.1002/stem.3269; Shukla S, 2017, NAT METHODS, V14, P531, DOI 10.1038/nmeth.4258; Singer A, 2008, NAT REV IMMUNOL, V8, P788, DOI 10.1038/nri2416; Sturgeon CM, 2014, NAT BIOTECHNOL, V32, P554, DOI 10.1038/nbt.2915; Suchin EJ, 2001, J IMMUNOL, V166, P973, DOI 10.4049/jimmunol.166.2.973; Sugita S, 2018, INVEST OPHTH VIS SCI, V59, P1719, DOI 10.1167/iovs.17-22703; Suwanpitak Siriwal, 2022, Methods Mol Biol, V2454, P423, DOI 10.1007/7651_2021_355; Takahashi Jun, 2020, Regen Ther, V13, P18, DOI 10.1016/j.reth.2020.06.002; Takahashi K, 2007, NAT PROTOC, V2, P3081, DOI 10.1038/nprot.2007.418; Tang Q, 2008, IMMUNITY, V28, P687, DOI 10.1016/j.immuni.2008.03.016; Taqvi S, 2006, J BIOMED MATER RES A, V79A, P689, DOI 10.1002/jbm.a.30916; Themeli M, 2015, CELL STEM CELL, V16, P357, DOI 10.1016/j.stem.2015.03.011; Themeli M, 2013, NAT BIOTECHNOL, V31, P928, DOI 10.1038/nbt.2678; Thongsin Nontaphat, 2022, Methods Mol Biol, V2454, P607, DOI 10.1007/7651_2021_352; Timmermans F, 2009, J IMMUNOL, V182, P6879, DOI 10.4049/jimmunol.0803670; Torikai H, 2016, MOL THER, V24, P1178, DOI 10.1038/mt.2016.106; Torikai H, 2012, BLOOD, V119, P5697, DOI 10.1182/blood-2012-01-405365; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Ueda N, 2018, STEM CELL REP, V10, P1935, DOI 10.1016/j.stemcr.2018.04.025; Umekage M, 2019, INFLAMM REGEN, V39, DOI 10.1186/s41232-019-0106-0; Van der Stegen S, 2020, BLOOD, V136, DOI 10.1182/blood-2020-142894; Varnum-Finney B, 2003, BLOOD, V101, P1784, DOI 10.1182/blood-2002-06-1862; Vizcardo R, 2013, CELL STEM CELL, V12, P31, DOI 10.1016/j.stem.2012.12.006; Wang B, 2021, NAT BIOMED ENG, V5, P429, DOI 10.1038/s41551-021-00730-z; Watarai H, 2010, BLOOD, V115, P230, DOI 10.1182/blood-2009-04-217729; Wattanapanitch M, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/5171032; Wrzesinski C, 2010, J IMMUNOTHER, V33, P1, DOI 10.1097/CJI.0b013e3181b88ffc; Xu HG, 2019, CELL STEM CELL, V24, P566, DOI 10.1016/j.stem.2019.02.005; Yamada D, 2016, STEM CELLS, V34, P2852, DOI 10.1002/stem.2465; Yano H, 2019, BLOOD, V134, DOI 10.1182/blood-2019-122193; Zhang L, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00983-2; Zhou JT, 2020, CANCER MANAG RES, V12, P8893, DOI 10.2147/CMAR.S260915; Zhu H, 2018, STEM CELLS, V36, P134, DOI 10.1002/stem.2754	146	1	1	2	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 28	2021	12								759558	10.3389/fimmu.2021.759558	http://dx.doi.org/10.3389/fimmu.2021.759558			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WF3JT	34650571	Green Published, gold			2022-12-18	WOS:000706205600001
J	Saito, T; Sako, Y; Sato-Kaneko, F; Hosoya, T; Yao, SY; Lao, FS; Shpigelman, J; Messer, K; Pu, MY; Shukla, NM; Chan, M; Chu, PJ; Cottam, HB; Hayashi, T; Carson, DA; Corr, M				Saito, Tetsuya; Sako, Yukiya; Sato-Kaneko, Fumi; Hosoya, Tadashi; Yao, Shiyin; Lao, Fitzgerald S.; Shpigelman, Jonathan; Messer, Karen; Pu, Minya; Shukla, Nikunj M.; Chan, Michael; Chu, Paul J.; Cottam, Howard B.; Hayashi, Tomoko; Carson, Dennis A.; Corr, Maripat			Small Molecule Potentiator of Adjuvant Activity Enhancing Survival to Influenza Viral Challenge	FRONTIERS IN IMMUNOLOGY			English	Article						vaccine; adjuvant; influenza virus; Toll-like receptor4; monophosphoryl lipid A; NF-kappa B	ZOSTER SUBUNIT VACCINE; NF-KAPPA-B; SAFETY; IMMUNOGENICITY; ACTIVATION; EFFICACY	As viruses continue to mutate the need for rapid high titer neutralizing antibody responses has been highlighted. To meet these emerging threats, agents that enhance vaccine adjuvant activity are needed that are safe with minimal local or systemic side effects. To respond to this demand, we sought small molecules that would sustain and improve the protective effect of a currently approved adjuvant, monophosphoryl lipid A (MPLA), a Toll-like receptor 4 (TLR4) agonist. A lead molecule from a high-throughput screen, (N-(4-(2,5-dimethylphenyl)thiazol-2-yl)-4-(piperidin-1-ylsulfonyl)benzamide, was identified as a hit compound that sustained NF-kappa B activation by a TLR4 ligand, lipopolysaccharide (LPS), after an extended incubation (16 h). In vitro, the resynthesized compound (2D216) enhanced TLR4 ligand-induced innate immune activation and antigen presenting function in primary murine bone marrow-derived dendritic cells without direct activation of T cells. In vivo murine vaccination studies demonstrated that compound 2D216 acted as a potent co-adjuvant when used in combination with MPLA that enhanced antigen-specific IgG equivalent to that of AS01B. The combination adjuvant MPLA/2D216 produced Th1 dominant immune responses and importantly protected mice from lethal influenza virus challenge. 2D216 alone or 2D216/MPLA demonstrated minimal local reactogenicity and no systemic inflammatory response. In summary, 2D216 augmented the beneficial protective immune responses of MPLA as a co-adjuvant and showed an excellent safety profile.	[Saito, Tetsuya; Sako, Yukiya; Sato-Kaneko, Fumi; Hosoya, Tadashi; Yao, Shiyin; Lao, Fitzgerald S.; Shpigelman, Jonathan; Shukla, Nikunj M.; Chan, Michael; Chu, Paul J.; Cottam, Howard B.; Hayashi, Tomoko; Carson, Dennis A.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Saito, Tetsuya; Hosoya, Tadashi] Tokyo Med & Dent Univ TMDU, Grad Sch Med & Dent Sci, Dept Rheumatol, Tokyo, Japan; [Messer, Karen; Pu, Minya] Univ Calif San Diego, Herbert Wertheim Sch Publ Hlth & Longev, La Jolla, CA 92093 USA; [Corr, Maripat] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Tokyo Medical & Dental University (TMDU); University of California System; University of California San Diego; University of California System; University of California San Diego	Carson, DA (corresponding author), Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.; Corr, M (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	dcarson@health.ucsd.edu; mpcorr@health.ucsd.edu	Hosoya, Tadashi/K-7641-2019	Hosoya, Tadashi/0000-0001-5177-6413; Shpigelman, Jonathan/0000-0002-9757-6350	National Institute of Health/National Institute of Allergy and Infectious Diseases [HHSN272201400051C, 75N93019C00042]	National Institute of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the National Institute of Health/National Institute of Allergy and Infectious Diseases under contracts HHSN272201400051C and 75N93019C00042 (Principal Investigator-DC).	Allen JC, 2020, VACCINE, V38, P8264, DOI 10.1016/j.vaccine.2020.11.002; Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114; Chan M, 2017, ACS COMB SCI, V19, P533, DOI 10.1021/acscombsci.7b00080; Chan M, 2009, BIOCONJUGATE CHEM, V20, P1194, DOI 10.1021/bc900054q; Ciabattini A, 2018, SEMIN IMMUNOL, V40, P83, DOI 10.1016/j.smim.2018.10.010; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800; Datta SK, 2003, J IMMUNOL, V170, P4102, DOI 10.4049/jimmunol.170.8.4102; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Glenny AT, 1931, J PATHOL BACTERIOL, V34, P267, DOI 10.1002/path.1700340214; Herve C, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0132-6; Vo HTM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00641; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Knudsen NPH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19570; La Gruta NL, 2014, TRENDS IMMUNOL, V35, P396, DOI 10.1016/j.it.2014.06.004; Lal H, 2018, VACCINE, V36, P148, DOI 10.1016/j.vaccine.2017.11.019; Laupeze B, 2019, VACCINE, V37, P5660, DOI 10.1016/j.vaccine.2019.07.098; Lecrenier N, 2018, EXPERT REV VACCINES, V17, P619, DOI 10.1080/14760584.2018.1495565; Li HF, 2008, J IMMUNOL, V181, P17, DOI 10.4049/jimmunol.181.1.17; Linterman Michelle A, 2016, F1000Res, V5, DOI 10.12688/f1000research.7388.1; McElhaney JE, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00041; Paovonen J, 2009, LANCET, V374, P301, DOI 10.1016/S0140-6736(09)61248-4; Pedersen GK, 2018, SEMIN IMMUNOL, V39, P4, DOI 10.1016/j.smim.2018.10.003; Sato-Kaneko F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01207; Shi ST, 2019, VACCINE, V37, P3167, DOI 10.1016/j.vaccine.2019.04.055; Sicard T, 2020, EXPERT REV VACCINES, V19, P1023, DOI 10.1080/14760584.2020.1857736; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Tong NKC, 2005, KIDNEY INT, V68, P2298, DOI 10.1111/j.1523-1755.2005.00689.x; Topp MS, 2015, LANCET ONCOL, V16, P57, DOI 10.1016/S1470-2045(14)71170-2; Vono M, 2013, P NATL ACAD SCI USA, V110, P21095, DOI 10.1073/pnas.1319784110	31	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 28	2021	12								701445	10.3389/fimmu.2021.701445	http://dx.doi.org/10.3389/fimmu.2021.701445			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WF6XT	34650551	gold, Green Published			2022-12-18	WOS:000706446800001
J	Wu, N; Waagbo, R; Wan, M; Feijoo, CG; Jiang, WD				Wu, Nan; Waagbo, Rune; Wan, Min; Feijoo, Carmen G.; Jiang, Wei-Dan			Editorial: Gastrointestinal Immunity and Crosstalk With Internal Organs in Fish	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						teleost fish; gastrointestinal immunity; crosstalk; foodborne inflammation; pathogen; vaccine			[Wu, Nan] Chinese Acad Sci, Inst Hydrobiol, Wuhan, Peoples R China; [Waagbo, Rune] Univ Bergen, Dept Biol Sci, Inst Marine Res, Bergen, Norway; [Wan, Min] Ocean Univ China, Dept Aquaculture, Coll Fisheries, Qingdao, Peoples R China; [Feijoo, Carmen G.] Univ Andres Bello, Fac Ciencias Vida, Santiago, Chile; [Jiang, Wei-Dan] Sichuan Agr Univ, Inst Anim Nutr, Yaan, Peoples R China	Chinese Academy of Sciences; Institute of Hydrobiology, CAS; Institute of Marine Research - Norway; University of Bergen; Ocean University of China; Universidad Andres Bello; Sichuan Agricultural University	Wu, N (corresponding author), Chinese Acad Sci, Inst Hydrobiol, Wuhan, Peoples R China.	wunan@ihb.ac.cn	Feijoo, Carmen G/AAF-9003-2019		National Natural Science Foundation of China [31872592]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was funded by the grant from National Natural Science Foundation of China (31872592) to NW.		0	1	1	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 28	2021	12								734538	10.3389/fimmu.2021.734538	http://dx.doi.org/10.3389/fimmu.2021.734538			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WF7CI	34650559	Green Published, gold			2022-12-18	WOS:000706459300001
J	Yeh, YW; Sen Chaudhuri, A; Zhou, L; Fang, Y; Boysen, P; Xiang, Z				Yeh, Yu-Wen; Sen Chaudhuri, Arka; Zhou, Ling; Fang, Yu; Boysen, Preben; Xiang, Zou			Mast Cells Are Identified in the Lung Parenchyma of Wild Mice, Which Can Be Recapitulated in Naturalized Laboratory Mice	FRONTIERS IN IMMUNOLOGY			English	Article						laboratory mouse; mast cell; wild mouse; lung; mouse naturalization	MOUSE MODELS; INFLAMMATION; PROGENITORS; MATURATION; BASOPHILS; MIGRATION; ASTHMA; ROLES; IGE	Background It is well documented that laboratory mice bred and maintained in ultra-hygienic specific pathogen-free (SPF) barriers display reduced richness and complexity of microbiota compared with wild mice. The laboratory mice profoundly lack lung parenchymal mast cells. Hence, we aimed to investigate the lung distribution of mast cells in free-living wild mice. Methods Wild house mice were trapped in South-Eastern Norway and Hemtabad, West Bengal, India. C57BL/6 laboratory mice were bred in a purposefully built, closed environment with bedding material obtained from the natural environment in order to normalize the gut microbiota of these laboratory mice to that of the wild mice, and the offspring were collected for study at eight weeks of age. Results Mast cells were easily identified at a substantial density in the lung parenchymal tissues of wild mice from both Norway and India, which stands in clear contrast to the rare distribution of lung parenchymal mast cells in the conventional laboratory SPF mice. Consistently, wild mice also expressed higher pulmonary levels of stem cell factor, a critical growth factor for mast cell survival. Higher levels of histamine were recorded in the lung tissues of the wild mice. Interestingly, "naturalized" C57BL/6 laboratory mice which spent their entire life in a semi-natural environment developed lung parenchymal mast cells at an appreciable density. Conclusion Our observations support that environmental factors, possibly through modulation of microbiota, may impact the tissue distribution of mast cells in mouse lung parenchyma.	[Yeh, Yu-Wen; Sen Chaudhuri, Arka; Xiang, Zou] Hong Kong Polytech Univ, Fac Hlth & Social Sci, Dept Hlth Technol & Informat, Hong Kong, Peoples R China; [Zhou, Ling; Fang, Yu] Guizhou Med Univ, Ctr Clin Lab, Affiliated Hosp, Guiyang, Peoples R China; [Zhou, Ling; Fang, Yu] Guizhou Med Univ, Sch Clin Lab, Guiyang, Peoples R China; [Boysen, Preben] Norwegian Univ Life Sci NMBU, Fac Vet Med, Oslo, Norway; [Xiang, Zou] Hong Kong Polytech Univ, Shenzhen Res Inst, Shenzhen, Peoples R China	Hong Kong Polytechnic University; Guizhou Medical University; Guizhou Medical University; Norwegian University of Life Sciences; Hong Kong Polytechnic University	Xiang, Z (corresponding author), Hong Kong Polytech Univ, Fac Hlth & Social Sci, Dept Hlth Technol & Informat, Hong Kong, Peoples R China.; Fang, Y (corresponding author), Guizhou Med Univ, Ctr Clin Lab, Affiliated Hosp, Guiyang, Peoples R China.; Fang, Y (corresponding author), Guizhou Med Univ, Sch Clin Lab, Guiyang, Peoples R China.; Boysen, P (corresponding author), Norwegian Univ Life Sci NMBU, Fac Vet Med, Oslo, Norway.; Xiang, Z (corresponding author), Hong Kong Polytech Univ, Shenzhen Res Inst, Shenzhen, Peoples R China.	yu.fang@gmc.edu.cn; preben.boysen@nmbu.no; xiang.y.zou@polyu.edu.hk	Sen Chaudhuri, Arka/GLN-3613-2022; Boysen, Preben/C-5238-2013	Sen Chaudhuri, Arka/0000-0001-6771-3089; Boysen, Preben/0000-0002-0084-1251	Shenzhen Science and Technology Commission, China [JCYJ20170818103812122]; Hong Kong Research Grants Council [15104418]; National Natural Science Foundation of China [81560266, 81760294]	Shenzhen Science and Technology Commission, China; Hong Kong Research Grants Council(Hong Kong Research Grants Council); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from Shenzhen Science and Technology Commission, China (JCYJ20170818103812122) (ZX), General research fund from Hong Kong Research Grants Council (15104418) (ZX), and the National Natural Science Foundation of China (81560266 and 81760294) (YF).	Abolins S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14811; Abolins SR, 2011, MOL ECOL, V20, P881, DOI 10.1111/j.1365-294X.2010.04910.x; Andersson CK, 2009, THORAX, V64, P297, DOI 10.1136/thx.2008.101683; Andersson CK, 2010, AM J RESP CRIT CARE, V181, P206, DOI 10.1164/rccm.200906-0932OC; Arnesen H, 2021, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.615661; Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC; Bankova LG, 2015, MUCOSAL IMMUNOL, V8, P596, DOI 10.1038/mi.2014.91; Beura LK, 2016, NATURE, V532, P512, DOI 10.1038/nature17655; Boysen P, 2011, MOL ECOL, V20, P5103, DOI 10.1111/j.1365-294X.2011.05269.x; Collington SJ, 2010, J IMMUNOL, V184, P6114, DOI 10.4049/jimmunol.0904177; Dahlin JS, 2015, MOL IMMUNOL, V63, P9, DOI 10.1016/j.molimm.2014.01.018; Devalapalli AP, 2006, SCAND J IMMUNOL, V64, P125, DOI 10.1111/j.1365-3083.2006.01785.x; Dharmage SC, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00246; Ericsson AC, 2017, YALE J BIOL MED, V90, P361; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gersch C, 2002, HISTOCHEM CELL BIOL, V118, P41, DOI 10.1007/s00418-002-0425-z; Graham AL, 2021, NAT IMMUNOL, V22, P111, DOI 10.1038/s41590-020-00857-2; Hallgren J, 2007, P NATL ACAD SCI USA, V104, P20478, DOI 10.1073/pnas.0709651104; Ikeda RK, 2003, J IMMUNOL, V171, P4860, DOI 10.4049/jimmunol.171.9.4860; Knutsen LE, 2019, IMMUNOGENETICS, V71, P321, DOI 10.1007/s00251-018-01100-x; Lantz CS, 1998, NATURE, V392, P90, DOI 10.1038/32190; Lei Y, 2013, PULM PHARMACOL THER, V26, P532, DOI 10.1016/j.pupt.2013.03.019; Lindner C, 2015, NAT IMMUNOL, V16, P880, DOI 10.1038/ni.3213; Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097; Nabe T, 2013, BRIT J PHARMACOL, V169, P462, DOI 10.1111/bph.12154; Perlman RL, 2016, EVOL MED PUBLIC HLTH, P170, DOI 10.1093/emph/eow014; Reese TA, 2016, CELL HOST MICROBE, V19, P713, DOI 10.1016/j.chom.2016.04.003; Riley JP, 2013, CLIN SCI, V125, P533, DOI 10.1042/CS20130092; Rosshart SP, 2019, SCIENCE, V365, P461, DOI 10.1126/science.aaw4361; Shay T, 2013, P NATL ACAD SCI USA, V110, P2946, DOI 10.1073/pnas.1222738110; Springer MS, 2007, BIOL REV, V82, P375, DOI 10.1111/j.1469-185X.2007.00016.x; Tao LL, 2017, TRENDS IMMUNOL, V38, P181, DOI 10.1016/j.it.2016.12.007; Wang ZP, 2017, J ALLERGY CLIN IMMUN, V139, P1205, DOI 10.1016/j.jaci.2016.09.019; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0; Yu M, 2006, J CLIN INVEST, V116, P1633, DOI 10.1172/JCI25702; Zarnegar B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00310; Zheng DP, 2020, CELL RES, V30, P492, DOI 10.1038/s41422-020-0332-7	38	1	1	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 27	2021	12								736692	10.3389/fimmu.2021.736692	http://dx.doi.org/10.3389/fimmu.2021.736692			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV5RZ	34646271	gold, Green Published			2022-12-18	WOS:000717295500001
J	Davis, JE; Du, K; Ludford-Menting, MJ; Prabahran, A; Wong, E; Huntington, ND; Koldej, RM; Ritchie, DS				Davis, Joanne E.; Du, Kelei; Ludford-Menting, Mandy J.; Prabahran, Ashvind; Wong, Eric; Huntington, Nicholas D.; Koldej, Rachel M.; Ritchie, David S.			Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients	FRONTIERS IN IMMUNOLOGY			English	Article						venetoclax; ruxolitinib; reduced intensity conditioning; graft versus tumour effect; MHC class-II; graft versus host disease; allogeneic stem cell transplantation	VERSUS-HOST-DISEASE; NATURAL-KILLER; DOUBLE-BLIND; ACTIVATION; RESPONSES; PLACEBO	Allogeneic stem cell transplantation (alloSCT) is utilised to cure haematological malignancies through a combination of conditioning regimen intensity and immunological disease control via the graft versus tumour (GVT) effect. Currently, conventional myeloablative chemotherapeutic or chemoradiation conditioning regimens are associated with significant side effects including graft versus host disease (GVHD), infection, and organ toxicity. Conversely, more tolerable reduced intensity conditioning (RIC) regimens are associated with unacceptably higher rates of disease relapse, partly through an excess incidence of mixed chimerism. Improvement in post-alloSCT outcomes therefore depends on promotion of the GVT effect whilst simultaneously reducing conditioning-related toxicity. We have previously shown that this could be achieved through BCL-2 inhibition, and in this study, we explored the modulation of JAK1/2 as a strategy to lower the barrier to donor engraftment in the setting of RIC. We investigated the impact of short-term treatment of BCL2 (venetoclax) or JAK1/2 (ruxolitinib) inhibition on recipient natural killer and T cell immunity and the subsequent effect on donor engraftment. We identified striking differences in mechanism of action of these two drugs on immune cell subsets in the bone marrow of recipients, and in the regulation of MHC class-II and interferon-inducible gene expression, leading to different rates of GVHD. This study demonstrates that the repurposed use of ruxolitinib or venetoclax can be utilised as pre-transplant immune-modulators to promote the efficacy of alloSCT, whilst reducing its toxicity.</p>	[Davis, Joanne E.; Du, Kelei; Ludford-Menting, Mandy J.; Prabahran, Ashvind; Wong, Eric; Koldej, Rachel M.; Ritchie, David S.] Royal Melbourne Hosp, Translat Res Lab, Australian Canc Res Fdn ACRF, Melbourne, Vic, Australia; [Davis, Joanne E.; Du, Kelei; Ludford-Menting, Mandy J.; Prabahran, Ashvind; Wong, Eric; Koldej, Rachel M.; Ritchie, David S.] Univ Melbourne, Dept Med, Melbourne, Vic, Australia; [Du, Kelei] Tsinghua Univ, Sch Med, Beijing, Peoples R China; [Du, Kelei; Huntington, Nicholas D.] Walter & Eliza Hall Inst Med Res, Mol Immunol Div, Melbourne, Vic, Australia; [Du, Kelei; Huntington, Nicholas D.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Prabahran, Ashvind; Wong, Eric; Ritchie, David S.] Royal Melbourne Hosp, Clin Haematol & Bone Marrow Transplantat Serv, Melbourne, Vic, Australia; [Huntington, Nicholas D.] Monash Univ, Biomed Discovery Inst, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Huntington, Nicholas D.] ONKo Innate Pty Ltd, Moonee Ponds, Vic, Australia	Royal Melbourne Hospital; University of Melbourne; Tsinghua University; University of Melbourne; Royal Melbourne Hospital; Monash University	Ritchie, DS (corresponding author), Royal Melbourne Hosp, Translat Res Lab, Australian Canc Res Fdn ACRF, Melbourne, Vic, Australia.; Ritchie, DS (corresponding author), Univ Melbourne, Dept Med, Melbourne, Vic, Australia.	David.Ritchie@mh.org.au		Prabahran, Ashvind/0000-0003-3135-0401	Cancer Council Victoria [APP1145730]; Royal Melbourne Hospital [GIA-109-2019]	Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Royal Melbourne Hospital	This study was supported by a Cancer Council Victoria grant-in-aid (APP1145730) and Royal Melbourne Hospital grant-in-aid (GIA-109-2019).	[Anonymous], 2019, AUSTR BONE MARROW TR; Carlyle JR, 1999, J IMMUNOL, V162, P5917; Craddock C, 2021, J CLIN ONCOL, V39, P768, DOI 10.1200/JCO.20.02308; D'Souza A, 2020, BIOL BLOOD MARROW TR, V26, pE177, DOI 10.1016/j.bbmt.2020.04.013; Davis JE, 2015, BIOL BLOOD MARROW TR, V21, P242, DOI 10.1016/j.bbmt.2014.11.003; Delconte RB, 2016, NAT IMMUNOL, V17, P816, DOI 10.1038/ni.3470; Gratwohl A, 2015, LANCET HAEMATOL, V2, pE91, DOI 10.1016/S2352-3026(15)00028-9; Gupta V, 2019, BIOL BLOOD MARROW TR, V25, P256, DOI 10.1016/j.bbmt.2018.09.001; Heine A, 2013, BLOOD, V122, P1192, DOI 10.1182/blood-2013-03-484642; Huntington ND, 2007, NAT IMMUNOL, V8, P856, DOI 10.1038/ni1487; Jagasia M, 2020, BLOOD, V135, P1739, DOI 10.1182/blood.2020004823; Jiao YH, 2019, CELL DEATH DIFFER, V26, P1516, DOI 10.1038/s41418-018-0228-y; Kennedy GA, 2021, BLOOD, V137, P1970, DOI 10.1182/blood.2020009050; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Koyama M, 2019, IMMUNITY, V51, P885, DOI 10.1016/j.immuni.2019.08.011; Kroger N, 2018, BIOL BLOOD MARROW TR, V24, P2152, DOI 10.1016/j.bbmt.2018.05.023; Nunamaker EA, 2013, COMPARATIVE MED, V63, P313; Pasic I, 2021, LEUKEMIA LYMPHOMA, V62, P2193, DOI 10.1080/10428194.2021.1910688; Phelan R, 2020, CURRENT USE OUTCOME; Przepiorka D, 2020, ONCOLOGIST, V25, pE328, DOI 10.1634/theoncologist.2019-0627; Qiu LQ, 2009, BLOOD, V113, P3520, DOI 10.1182/blood-2008-07-171942; Scott BL, 2017, J CLIN ONCOL, V35, P1154, DOI 10.1200/JCO.2016.70.7091; Tawara I, 2011, CLIN CANCER RES, V17, P77, DOI 10.1158/1078-0432.CCR-10-1198; Verstovsek S, 2012, NEW ENGL J MED, V366, P799, DOI 10.1056/NEJMoa1110557; Wong E, 2017, BIOL BLOOD MARROW TR, V23, P840, DOI 10.1016/j.bbmt.2017.01.086; Zeiser R, 2015, LEUKEMIA, V29, P2062, DOI 10.1038/leu.2015.212; Zeiser R, 2020, BLOOD ADV, V4, P3789, DOI 10.1182/bloodadvances.2020002097; Zeiser R, 2020, NEW ENGL J MED, V382, P1800, DOI 10.1056/NEJMoa1917635; Zhao YM, 2020, BIOL BLOOD MARROW TR, V26, pE128, DOI 10.1016/j.bbmt.2020.01.012	29	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 24	2021	12								749094	10.3389/fimmu.2021.749094	http://dx.doi.org/10.3389/fimmu.2021.749094			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WE8WL	34630428	gold, Green Published			2022-12-18	WOS:000705899600001
J	Maulloo, CD; Cao, SJ; Watkins, EA; Raczy, MM; Solanki, AS; Nguyen, M; Reda, JW; Shim, HN; Wilson, DS; Swartz, MA; Hubbell, JA				Maulloo, Chitavi D.; Cao, Shijie; Watkins, Elyse A.; Raczy, Michal M.; Solanki, Ani. S.; Nguyen, Mindy; Reda, Joseph W.; Shim, Ha-Na; Wilson, D. Scott; Swartz, Melody A.; Hubbell, Jeffrey A.			Lymph Node-Targeted Synthetically Glycosylated Antigen Leads to Antigen-Specific Immunological Tolerance	FRONTIERS IN IMMUNOLOGY			English	Article						lymph node; subcutaneous; tolerance; glycopolymer; regulatory T cell; dendritic cell; lymphatics; co-inhibition	CD8(+) T-CELLS; CD8-ALPHA(+) DENDRITIC CELLS; CROSS-PRESENTATION; STEADY-STATE; CD4(+); MACROPHAGES; RECEPTORS; INDUCTION; IMMUNITY; PEPTIDE	Inverse vaccines that tolerogenically target antigens to antigen-presenting cells (APCs) offer promise in prevention of immunity to allergens and protein drugs and treatment of autoimmunity. We have previously shown that targeting hepatic APCs through intravenous injection of synthetically glycosylated antigen leads to effective induction of antigen-specific immunological tolerance. Here, we demonstrate that targeting these glycoconjugates to lymph node (LN) APCs under homeostatic conditions leads to local and increased accumulation in the LNs compared to unmodified antigen and induces a tolerogenic state both locally and systemically. Subcutaneous administration directs the polymeric glycoconjugate to the draining LN, where the glycoconjugated antigen generates robust antigen-specific CD4(+) and CD8(+) T cell tolerance and hypo-responsiveness to antigenic challenge via a number of mechanisms, including clonal deletion, anergy of activated T cells, and expansion of regulatory T cells. Lag-3 up-regulation on CD4(+) and CD8(+) T cells represents an essential mechanism of suppression. Additionally, presentation of antigen released from the glycoconjugate to naive T cells is mediated mainly by LN-resident CD8(+) and CD11b(+) dendritic cells. Thus, here we demonstrate that antigen targeting via synthetic glycosylation to impart affinity for APC scavenger receptors generates tolerance when LN dendritic cells are the cellular target.	[Maulloo, Chitavi D.; Cao, Shijie; Watkins, Elyse A.; Raczy, Michal M.; Nguyen, Mindy; Reda, Joseph W.; Shim, Ha-Na; Wilson, D. Scott; Swartz, Melody A.; Hubbell, Jeffrey A.] Univ Chicago, Pritzker Sch Mol Engn, Chicago, IL 60637 USA; [Solanki, Ani. S.] Univ Chicago, Anim Resources Ctr, Chicago, IL 60637 USA; [Wilson, D. Scott] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA; [Swartz, Melody A.; Hubbell, Jeffrey A.] Univ Chicago, Comm Immunol, Chicago, IL 60637 USA; [Swartz, Melody A.] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA; [Hubbell, Jeffrey A.] Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; Johns Hopkins University; University of Chicago; University of Chicago; University of Chicago	Wilson, DS; Swartz, MA; Hubbell, JA (corresponding author), Univ Chicago, Pritzker Sch Mol Engn, Chicago, IL 60637 USA.; Wilson, DS (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA.; Swartz, MA; Hubbell, JA (corresponding author), Univ Chicago, Comm Immunol, Chicago, IL 60637 USA.; Swartz, MA (corresponding author), Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA.; Hubbell, JA (corresponding author), Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA.	scott.wilson@jhmi.edu; melodyswartz@uchicago.edu; jhubbell@uchicago.edu			Chicago Immunoengineering Innovation Center at the University of Chicago; NIH [1R01CA219304]	Chicago Immunoengineering Innovation Center at the University of Chicago; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by seed funding from the Chicago Immunoengineering Innovation Center at the University of Chicago as well as the NIH (1R01CA219304 to MS).	Aanoudse CA, 2008, INT J CANCER, V122, P839, DOI 10.1002/ijc.23101; Akkaya B, 2019, NAT IMMUNOL, V20, P218, DOI 10.1038/s41590-018-0280-2; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Andorko JI, 2015, AAPS J, V17, P323, DOI 10.1208/s12248-014-9708-2; Ardouin L, 2016, IMMUNITY, V45, P305, DOI 10.1016/j.immuni.2016.07.019; Baratin M, 2017, IMMUNITY, V47, P349, DOI 10.1016/j.immuni.2017.07.019; Bashuda H, 1997, TRANSPLANTATION, V63, P113, DOI 10.1097/00007890-199701150-00021; Berendam SJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00816; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Burgdorf S, 2007, SCIENCE, V316, P612, DOI 10.1126/science.1137971; Cappellano G, 2014, VACCINE, V32, P5681, DOI 10.1016/j.vaccine.2014.08.016; Carballido JM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00472; Card CM, 2014, J CLIN INVEST, V124, P943, DOI 10.1172/JCI73316; Cemerski S., 2015, J IMMUNOTHER CANC S2, V3, P183; Chihara N, 2018, NATURE, V558, P454, DOI 10.1038/s41586-018-0206-z; Chung Y, 2005, BLOOD, V106, P201, DOI 10.1182/blood-2004-11-4240; Damo M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.555095; Dubrot J, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800164; Dubrot J, 2014, J EXP MED, V211, P1153, DOI 10.1084/jem.20132000; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Fasting C, 2012, ANGEW CHEM INT EDIT, V51, P10472, DOI 10.1002/anie.201201114; Feuille E, 2018, ALLERGY ASTHMA IMMUN, V10, P189, DOI 10.4168/aair.2018.10.3.189; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Foulds KE, 2002, J IMMUNOL, V168, P1528, DOI 10.4049/jimmunol.168.4.1528; Francis DM, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay3575; Gardner JM, 2008, SCIENCE, V321, P843, DOI 10.1126/science.1159407; Gerner MY, 2017, J EXP MED, V214, P3105, DOI 10.1084/jem.20170335; Gerner MY, 2015, IMMUNITY, V42, P172, DOI 10.1016/j.immuni.2014.12.024; Getts DR, 2012, NAT BIOTECHNOL, V30, P1217, DOI 10.1038/nbt.2434; Goel G., 2016, GASTROENTEROLOGY, V150, pS304, DOI [10.1016/s0016-5085(16)31065-4, DOI 10.1016/S0016-5085(16)31065-4]; Grabowska J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02472; Gray EE, 2012, J INNATE IMMUN, V4, P424, DOI 10.1159/000337007; Henrickson SE, 2008, NAT IMMUNOL, V9, P282, DOI 10.1038/ni1559; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Hirosue S, 2014, J IMMUNOL, V192, P5002, DOI 10.4049/jimmunol.1302492; Hubbell JA, 2009, NATURE, V462, P449, DOI 10.1038/nature08604; Hugues S, 2004, NAT IMMUNOL, V5, P1235, DOI 10.1038/ni1134; Irvine DJ, 2013, NAT MATER, V12, P978, DOI [10.1038/NMAT3775, 10.1038/nmat3775]; Kang HK, 2005, J IMMUNOL, V174, P3247, DOI 10.4049/jimmunol.174.6.3247; Kikkeri R, 2009, J AM CHEM SOC, V131, P2110, DOI 10.1021/ja807711w; Kim J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8994; Krupnick AS, 2014, J CLIN INVEST, V124, P1130, DOI 10.1172/JCI71359; Kurts C, 1997, J EXP MED, V186, P2057, DOI 10.1084/jem.186.12.2057; Lepenies B, 2010, CURR OPIN CHEM BIOL, V14, P404, DOI 10.1016/j.cbpa.2010.02.016; Lewis JS, 2012, BIOMATERIALS, V33, P7221, DOI 10.1016/j.biomaterials.2012.06.049; Li B, 2020, IMMUNOL CELL BIOL, V98, P563, DOI 10.1111/imcb.12342; Maldonado RA, 2015, P NATL ACAD SCI USA, V112, pE156, DOI 10.1073/pnas.1408686111; Martens JH, 2006, J PATHOL, V208, P574, DOI 10.1002/path.1921; Mondor I, 2019, IMMUNITY, V50, P1453, DOI 10.1016/j.immuni.2019.04.002; Mukhopadhaya A, 2008, P NATL ACAD SCI USA, V105, P6374, DOI 10.1073/pnas.0802644105; Nadafi R, 2020, CELL REP, V30, P4110, DOI 10.1016/j.celrep.2020.03.007; Nadesalingam J, 2005, J IMMUNOL, V175, P1785, DOI 10.4049/jimmunol.175.3.1785; Nizza ST, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091054; Novy P, 2007, J IMMUNOL, V179, P8243, DOI 10.4049/jimmunol.179.12.8243; Pearson RM, 2017, ADV DRUG DELIVER REV, V114, P240, DOI 10.1016/j.addr.2017.04.005; Picarda E, 2019, CELL REP, V29, P4245, DOI 10.1016/j.celrep.2019.11.106; Rabenstein H, 2014, J IMMUNOL, V192, P3507, DOI 10.4049/jimmunol.1302725; Rodda LB, 2018, IMMUNITY, V48, P1014, DOI 10.1016/j.immuni.2018.04.006; Roggenbuck D, 2012, AUTOIMMUN HIGHLIGHTS, V3, P119, DOI 10.1007/s13317-012-0041-4; Rohner NA, 2017, ACS BIOMATER SCI ENG, V3, P153, DOI 10.1021/acsbiomaterials.6b00438; Rouhani SJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7771; Ruhland MK, 2020, CANCER CELL, V37, P786, DOI 10.1016/j.ccell.2020.05.002; Sagoo P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002076; Schreibelt G, 2012, BLOOD, V119, P2284, DOI 10.1182/blood-2011-08-373944; Schulke S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00455; Segura E, 2009, P NATL ACAD SCI USA, V106, P20377, DOI 10.1073/pnas.0910295106; Serra P, 2019, NAT BIOTECHNOL, V37, P238, DOI 10.1038/s41587-019-0015-4; Sestak JO, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.8; Shakhar G, 2005, NAT IMMUNOL, V6, P707, DOI 10.1038/ni1210; Sharma A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00883; Streeter HB, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000093; Sugita S, 2007, EXP EYE RES, V85, P626, DOI 10.1016/j.exer.2007.07.015; Tang L, 2009, GASTROENTEROLOGY, V137, P1498, DOI 10.1053/j.gastro.2009.07.051; Tay SS, 2014, P NATL ACAD SCI USA, V111, pE2540, DOI 10.1073/pnas.1406674111; Thomas SN, 2012, J IMMUNOL, V189, P2181, DOI 10.4049/jimmunol.1103545; Thrower SL, 2009, CLIN EXP IMMUNOL, V155, P156, DOI 10.1111/j.1365-2249.2008.03814.x; Tsai SE, 2010, IMMUNITY, V32, P568, DOI 10.1016/j.immuni.2010.03.015; Utzschneider DT, 2016, IMMUNITY, V45, P415, DOI 10.1016/j.immuni.2016.07.021; van Dinther D, 2018, CELL REP, V22, P1484, DOI 10.1016/j.celrep.2018.01.021; Villadangos JA, 2007, NAT REV IMMUNOL, V7, P543, DOI 10.1038/nri2103; Webb MW, 2018, INT J CANCER, V143, P1483, DOI 10.1002/ijc.31532; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wilson DS, 2019, NAT BIOMED ENG, V3, P817, DOI 10.1038/s41551-019-0424-1; Workman CJ, 2004, J IMMUNOL, V172, P5450, DOI 10.4049/jimmunol.172.9.5450; Xystrakis E, 2004, BLOOD, V104, P3294, DOI 10.1182/blood-2004-03-1214; Ye ZM, 2008, AUTOIMMUNITY, V41, P501, DOI 10.1080/08916930802069256	87	1	1	4	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 24	2021	12								714842	10.3389/fimmu.2021.714842	http://dx.doi.org/10.3389/fimmu.2021.714842			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WD7JX	34630389	Green Published, gold			2022-12-18	WOS:000705114500001
J	Soliman, AM; Yoon, T; Wang, JH; Stafford, JL; Barreda, DR				Soliman, Amro M.; Yoon, Taekwan; Wang, Jiahui; Stafford, James L.; Barreda, Daniel R.			Isolation of Skin Leukocytes Uncovers Phagocyte Inflammatory Responses During Induction and Resolution of Cutaneous Inflammation in Fish	FRONTIERS IN IMMUNOLOGY			English	Article						leukocytes; Aeromonas; inflammation; skin; immune response	VERONII BIOVAR SOBRIA; NITRIC-OXIDE; AEROMONAS-VERONII; ANTIMICROBIAL MECHANISMS; APOPTOTIC CELLS; MEDICINAL LEECH; T-LYMPHOCYTES; GROWTH-FACTOR; TELEOST SKIN; BONE-MARROW	Leukocytes offer a critical layer of protection to the host following skin infections. Delineating the kinetics of cutaneous leukocyte recruitment as well as their anti-microbial and regulatory profiles is challenging since it requires the isolation of adequate cell numbers and maintenance of their functional properties. Herein, we took advantage of a modified procedure to gain insights into the contributions of fish phagocytes through induction and resolution phases of acute cutaneous inflammation in goldfish (Carassius auratus). Our data shows early upregulation of pro-inflammatory cytokines and chemokines, which was paired with neutrophil-dominant leukocyte migration of neutrophils from circulation to the injury site. Recruited neutrophils were associated with high levels of reactive oxygen species (ROS). Following pathogen elimination, a reduction in ROS levels and pro-inflammatory cytokines expression preceded the resolution of inflammation. These results provide a better understanding of the cutaneous immune responses in fish. Moreover, the increased viability and functionality of isolated skin leukocytes opens the door to better understand a range of additional skin diseases.	[Soliman, Amro M.; Yoon, Taekwan; Wang, Jiahui; Stafford, James L.; Barreda, Daniel R.] Univ Alberta, Dept Biol Sci, Edmonton, AB, Canada; [Barreda, Daniel R.] Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB, Canada	University of Alberta; University of Alberta	Barreda, DR (corresponding author), Univ Alberta, Dept Biol Sci, Edmonton, AB, Canada.; Barreda, DR (corresponding author), Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB, Canada.	dan.barreda@ualberta.ca	Soliman, Amro M./AAV-7572-2021; Barreda, Daniel/A-2613-2014	Soliman, Amro M./0000-0003-4195-7186; Barreda, Daniel/0000-0003-4630-2840	Natural Sciences and Engineering Council of Canada [RGPIN-2018-05768]	Natural Sciences and Engineering Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC))	This work was supported by the Natural Sciences and Engineering Council of Canada grant to DRB (RGPIN-2018-05768).	Abdallah F, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/5095293; Autengruber A, 2012, EUR J MICROBIOL IMMU, V2, P112, DOI 10.1556/EuJMI.2.2012.2.3; Bao P, 2009, J SURG RES, V153, P347, DOI 10.1016/j.jss.2008.04.023; BARBUL A, 1989, ANN SURG, V209, P479, DOI 10.1097/00000658-198904000-00015; Beaz-Hidalgo R, 2013, J FISH DIS, V36, P371, DOI 10.1111/jfd.12025; Benck CJ, 2016, JOVE-J VIS EXP, DOI 10.3791/53638; Bin Kingombe CI, 2010, APPL ENVIRON MICROB, V76, P425, DOI 10.1128/AEM.01357-09; Boxio R, 2004, J LEUKOCYTE BIOL, V75, P604, DOI 10.1189/jlb.0703340; Bruhn JB, 2005, DIS AQUAT ORGAN, V65, P43, DOI 10.3354/dao065043; D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256; Delavary BM, 2011, IMMUNOBIOLOGY, V216, P753, DOI 10.1016/j.imbio.2011.01.001; Deng Q, 2012, J CELL SCI, V125, P3949, DOI 10.1242/jcs.093633; DEODHAR LP, 1991, J CLIN MICROBIOL, V29, P853, DOI 10.1128/JCM.29.5.853-856.1991; Deupree SM, 2009, ACTA BIOMATER, V5, P1405, DOI 10.1016/j.actbio.2009.01.025; DORING G, 1995, J IMMUNOL, V154, P4842; Eming SA, 2007, J INVEST DERMATOL, V127, P514, DOI 10.1038/sj.jid.5700701; Esmann L, 2010, J IMMUNOL, V184, P391, DOI 10.4049/jimmunol.0900564; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Flannagan RS, 2009, NAT REV MICROBIOL, V7, P355, DOI 10.1038/nrmicro2128; Ford AL, 1996, J IMMUNOL METHODS, V194, P71, DOI 10.1016/0022-1759(96)00067-1; Furze RC, 2008, IMMUNOLOGY, V125, P281, DOI 10.1111/j.1365-2567.2008.02950.x; Gonzalez-Serrano CJ, 2002, J APPL MICROBIOL, V93, P414, DOI 10.1046/j.1365-2672.2002.01705.x; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Graf J, 1999, INFECT IMMUN, V67, P1; Granja AG, 2015, J IMMUNOL, V195, P1825, DOI 10.4049/jimmunol.1500322; Grayfer L, 2011, MOL IMMUNOL, V48, P563, DOI 10.1016/j.molimm.2010.10.013; Guilliams M, 2017, NAT REV IMMUNOL, V17, P451, DOI 10.1038/nri.2017.42; Haddad G, 2008, DEV COMP IMMUNOL, V32, P654, DOI 10.1016/j.dci.2007.10.003; Hadi N, 2012, INFECT IMMUN, V80, P1351, DOI 10.1128/IAI.06304-11; Havixbeck JJ, 2017, FISH SHELLFISH IMMUN, V63, P18, DOI 10.1016/j.fsi.2017.02.001; Havixbeck JJ, 2016, J LEUKOCYTE BIOL, V99, P241, DOI 10.1189/jlb.3HI0215-064R; HICKMANBRENNER FW, 1987, J CLIN MICROBIOL, V25, P900, DOI 10.1128/JCM.25.5.900-906.1987; Hofmann U, 2012, CIRCULATION, V125, P1652, DOI 10.1161/CIRCULATIONAHA.111.044164; Horne TH, 1928, J HYG-CAMBRIDGE, V28, P67, DOI 10.1017/S0022172400009396; Johann AM, 2006, CELL DEATH DIFFER, V13, P1533, DOI 10.1038/sj.cdd.4401832; Khushiramani RM, 2012, RES MICROBIOL, V163, P286, DOI 10.1016/j.resmic.2012.03.001; Koh TJ, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001943; Krzyminska S, 2009, CURR MICROBIOL, V58, P252, DOI 10.1007/s00284-008-9316-4; Kuijpers T, 2012, CELL MOL LIFE SCI, V69, P7, DOI 10.1007/s00018-011-0834-z; Laplante AF, 1998, J HISTOCHEM CYTOCHEM, V46, P1291, DOI 10.1177/002215549804601109; Laval F., 2005, REV PHYSL BIOCH PHAR, P175, DOI [10.1007/3-540-61992-5_8, DOI 10.1007/3-540-61992-5_8]; Leal E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147477; Lee RH, 2001, J SURG RES, V101, P104, DOI 10.1006/jsre.2001.6261; Lei YL, 2015, MED RES REV, V35, P306, DOI 10.1002/med.21330; Lillico DME, 2016, DEV COMP IMMUNOL, V65, P231, DOI 10.1016/j.dci.2016.07.014; Loynes CA, 2010, J LEUKOCYTE BIOL, V87, P203, DOI 10.1189/jlb.0409255; Mai NC, 2014, DIS MODEL MECH, V7, P871, DOI 10.1242/dmm.014498; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Martin P, 2005, TRENDS CELL BIOL, V15, P599, DOI 10.1016/j.tcb.2005.09.002; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Blanco AM, 2018, GEN COMP ENDOCR, V257, P13, DOI 10.1016/j.ygcen.2017.02.001; Milich LM, 2019, ACTA NEUROPATHOL, V137, P785, DOI 10.1007/s00401-019-01992-3; Nawaz M, 2010, FOOD MICROBIOL, V27, P327, DOI 10.1016/j.fm.2009.11.007; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; Omori Y, 2019, J BIOCHEM, V165, P209, DOI 10.1093/jb/mvy076; Ota KG, 2016, WIRES DEV BIOL, V5, P272, DOI 10.1002/wdev.224; Ozer A, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv002; PACELLI R, 1995, J EXP MED, V182, P1469, DOI 10.1084/jem.182.5.1469; PETERSON JM, 1987, SURGERY, V102, P300; Raj NS, 2019, AQUACULTURE, V512, DOI 10.1016/j.aquaculture.2019.734278; Rankin SM, 2010, J LEUKOCYTE BIOL, V88, P241, DOI 10.1189/jlb.0210112; Rieger AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047070; Rieger AM, 2011, DEV COMP IMMUNOL, V35, P1238, DOI 10.1016/j.dci.2011.03.009; Rosenzweig JA, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00070; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Schairer DO, 2012, VIRULENCE, V3, P271, DOI 10.4161/viru.20328; Shi HP, 2000, SURGERY, V128, P374, DOI 10.1067/msy.2000.107372; Silver AC, 2007, J BACTERIOL, V189, P6763, DOI 10.1128/JB.00685-07; Quaresma JAS, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00034-18; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Sun JJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040496; Hoai TD, 2019, AQUACULTURE, V513, DOI 10.1016/j.aquaculture.2019.734425; Wang J, 2016, CELL, V165, P668, DOI 10.1016/j.cell.2016.03.009; Wang XY, 2019, ADV WOUND CARE, V8, P527, DOI 10.1089/wound.2019.0981; Wei H, 2015, FISH SHELLFISH IMMUN, V44, P445, DOI 10.1016/j.fsi.2015.03.023; Wentzel AS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70248-y; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Wink DA, 2011, J LEUKOCYTE BIOL, V89, P873, DOI 10.1189/jlb.1010550; Witte MB, 2002, AM J SURG, V183, P406, DOI 10.1016/S0002-9610(02)00815-2; Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015; Xu Z, 2013, P NATL ACAD SCI USA, V110, P13097, DOI 10.1073/pnas.1304319110; Yoo SK, 2011, J LEUKOCYTE BIOL, V89, P661, DOI 10.1189/jlb.1010567; Young A., 2011, SURG, V29, P475, DOI DOI 10.1016/J.MPSUR.2011.06.011; Zamboni DS, 2003, INFECT IMMUN, V71, P1225, DOI 10.1128/IAI.71.3.1225-1233.2003; Zhang X, 2008, J PATHOL, V214, P161, DOI 10.1002/path.2284	86	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 24	2021	12								725063	10.3389/fimmu.2021.725063	http://dx.doi.org/10.3389/fimmu.2021.725063			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WE8XP	34630399	Green Published, gold			2022-12-18	WOS:000705902600001
J	de Jesus, JDR; Murari, ASD; Radloff, K; de Moraes, RCM; Figueredo, RG; Pessoa, AFM; Rosa-Neto, JC; Matos-Neto, EM; Alcantara, PSM; Tokeshi, F; Maximiano, LF; Bin, FC; Formiga, FB; Otoch, JP; Seelaender, M				de Jesus, Joyce de Cassia Rosa; Murari, Ariene Soares de Pinho; Radloff, Katrin; de Moraes, Ruan Carlos Macedo; Figueredo, Raquel Galvao; Pessoa, Ana Flavia Marcal; Rosa-Neto, Jose Cesar; Matos-Neto, Emidio Marques; Alcantara, Paulo S. M.; Tokeshi, Flavio; Maximiano, Linda Ferreira; Bin, Fang Chia; Formiga, Fernanda Bellotti; Otoch, Jose P.; Seelaender, Marilia			Activation of the Adipose Tissue NLRP3 Inflammasome Pathway in Cancer Cachexia	FRONTIERS IN IMMUNOLOGY			English	Article						neoplasms; cachexia; adipose tissue heterogeneity; inflammation; NLRP3 inflammasome	TOLL-LIKE RECEPTORS; NF-KAPPA-B; INNATE IMMUNITY; CD36; EXPRESSION; MECHANISM; VARIANTS; CASPASES; COLON	Background Cachexia is a paraneoplastic syndrome that accompanies and compromises cancer treatment, especially in advanced stages, affecting the metabolism and function of several organs. The adipose tissue is the first to respond to the presence of the tumor, contributing to the secretion of factors which drive the systemic inflammation, a hallmark of the syndrome. While inflammation is a defensive innate response, the control mechanisms have been reported to be disrupted in cachexia. On the other hand, little is known about the role of NLRP3 inflammasome in this scenario, a multiprotein complex involved in caspase-1 activation and the processing of the cytokines IL-1 beta and IL-18. Aim based on the evidence from our previous study with a rodent model of cachexia, we examined the activation of the NLRP3 inflammasome pathway in two adipose tissue depots obtained from patients with colorectal cancer and compared with that another inflammatory pathway, NF-kappa B. Results For CC we found opposite modulation in ScAT and PtAT for the gene expression of TLR4, Caspase-1 (cachectic group) and for NF-kappa B p50, NF-kappa B p65, IL-1 beta. CD36, expression was decreased in both depots while that of NLRP3 and IL-18 was higher in both tissues, as compared with controls and weight stable patients (WSC). Caspase-1 basal protein levels in the ScAT culture supernatant were higher in WSC and (weight stable patients) CC, when compared to controls. Basal ScAT explant culture medium IL-1 beta and IL-18 protein content in ScAT supernatant was decreased in the WSC and CC as compared to CTL explants. Conclusions The results demonstrate heterogeneous responses in the activation of genes of the NLRP3 inflammasome pathway in the adipose tissue of patients with cancer cachexia, rendering t</p>	[de Jesus, Joyce de Cassia Rosa; Murari, Ariene Soares de Pinho; Radloff, Katrin; de Moraes, Ruan Carlos Macedo; Figueredo, Raquel Galvao; Pessoa, Ana Flavia Marcal; Matos-Neto, Emidio Marques; Otoch, Jose P.; Seelaender, Marilia] Univ Sao Paulo, Fac Med, Dept Surg, Canc Metab Res Grp,Lab Invest Med LIM26, Sao Paulo, Brazil; [Rosa-Neto, Jose Cesar] Univ Sao Paulo, Inst Biomed Sci, Immunometab Lab, Sao Paulo, Brazil; [Alcantara, Paulo S. M.; Tokeshi, Flavio; Maximiano, Linda Ferreira; Otoch, Jose P.] Univ Sao Paulo, Dept Surg Clin, Univ Hosp, Sao Paulo, Brazil; [Bin, Fang Chia; Formiga, Fernanda Bellotti] Santa Casa Sao Paulo, Dept Coloproctol, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo	de Jesus, JDR; Seelaender, M (corresponding author), Univ Sao Paulo, Fac Med, Dept Surg, Canc Metab Res Grp,Lab Invest Med LIM26, Sao Paulo, Brazil.	joyrosa@usp.br; seelaender@usp.br	Neto, Jose Rosa/G-6336-2012; de Jesus, Joyce Rosa/AAZ-6070-2021; Moraes, Ruan/D-6423-2018	Neto, Jose Rosa/0000-0001-7019-9762; de Jesus, Joyce Rosa/0000-0001-9598-9170; Moraes, Ruan/0000-0002-0178-8480; Murari Soares de Pinho, Ariene/0000-0003-4221-1597	CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior); FAPESP [12/50079-0, 20/7765-6]	CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	We thank CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) for the scholarship. Financial support was provided by FAPESP 12/50079-0 and 20/7765-6.	Ahechu P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02918; Al-Zhoughbi W, 2014, SEMIN ONCOL, V41, P281, DOI 10.1053/j.seminoncol.2014.02.005; Alves MJ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3178-8; Anderson LJ, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0562-0; Anker MS, 2019, J CACHEXIA SARCOPENI, V10, P22, DOI 10.1002/jcsm.12402; Aoyagi T, 2015, WORLD J GASTRO ONCOL, V7, P17, DOI 10.4251/wjgo.v7.i4.17; Baracos VE, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2017.105; Batista ML, 2012, J ENDOCRINOL, V215, P363, DOI 10.1530/JOE-12-0307; Batista ML, 2012, CYTOKINE, V57, P9, DOI 10.1016/j.cyto.2011.10.008; Batista ML, 2016, J CACHEXIA SARCOPENI, V7, P37, DOI 10.1002/jcsm.12037; Becker C, 2013, GASTROENTEROLOGY, V144, P283, DOI 10.1053/j.gastro.2012.11.035; Bertevello PS, 2001, BRAZ J MED BIOL RES, V34, P1161, DOI 10.1590/S0100-879X2001000900009; Bing C, 2009, P NUTR SOC, V68, P385, DOI 10.1017/S0029665109990267; Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58; Camargo RG, 2015, NUTRIENTS, V7, P4465, DOI 10.3390/nu7064465; Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x; Choi JSA., 2014, J LEUKOCYTE BIOL, V7, P193, DOI [10.14348/mollcells.2014.0104, DOI 10.14348/MOLLCELLS.2014.0104]; Cildir G, 2016, TRENDS MOL MED, V22, P414, DOI 10.1016/j.molmed.2016.03.002; de Matos-Neto EM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00629; Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0; Deng T, 2016, ANNU REV PATHOL-MECH, V11, P421, DOI 10.1146/annurev-pathol-012615-044359; Dev R, 2019, ANN PALLIAT MED, V8, P24, DOI 10.21037/apm.2018.08.07; Dupaul-Chicoine J, 2010, IMMUNITY, V32, P367, DOI 10.1016/j.immuni.2010.02.012; Evans WJ, 2008, CLIN NUTR, V27, P793, DOI 10.1016/j.clnu.2008.06.013; Fearon KCH, 2012, CELL METAB, V16, P153, DOI 10.1016/j.cmet.2012.06.011; Federico A, 2010, WORLD J GASTROENTERO, V16, P4762, DOI 10.3748/wjg.v16.i38.4762; Giuliani C, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00471; Grant RW, 2015, OBESITY, V23, P512, DOI 10.1002/oby.21003; Guerra F, 2019, CANCERS, V11, DOI 10.3390/cancers11081096; Heni M, 2011, OBESITY, V19, P1004, DOI 10.1038/oby.2010.251; Henriques FS, 2017, FASEB J, V31, P1976, DOI 10.1096/fj.201601151R; Hirota SA, 2011, INFLAMM BOWEL DIS, V17, P1359, DOI 10.1002/ibd.21478; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Karin M, 2020, WIEN KLIN WOCHENSCHR, V132, P431, DOI 10.1007/s00508-020-01671-4; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Karki R, 2019, NAT REV CANCER, V19, P197, DOI 10.1038/s41568-019-0123-y; Karki R, 2017, CANCER IMMUNOL RES, V5, P94, DOI 10.1158/2326-6066.CIR-16-0269; Khatami M, 2011, EXPERT OPIN BIOL TH, V11, P1419, DOI 10.1517/14712598.2011.592826; Kolb R, 2014, PROTEIN CELL, V5, P12, DOI 10.1007/s13238-013-0001-4; Kopp A, 2009, OBESITY, V17, P648, DOI 10.1038/oby.2008.607; Li YJ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-87; LIM DR, 2017, MEDICINE, V96, DOI DOI 10.1097/MD.0000000000008241; Lin L, 2012, J AM SOC NEPHROL, V23, P1329, DOI 10.1681/ASN.2011111123; Lira FS, 2009, CELL BIOCHEM FUNCT, V27, P71, DOI 10.1002/cbf.1540; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lurje G, 2009, PHARMACOGENET GENOM, V19, P95, DOI 10.1097/FPC.0b013e32831a9ad1; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Menu P, 2011, CLIN EXP IMMUNOL, V166, P1, DOI 10.1111/j.1365-2249.2011.04440.x; Ministerio Da Saude. Instituto Nacional do Cancer Jose Alencar Gomes Da Silva (INCA), 2019, EST 2020 INC CANC NO; Neves RX, 2016, J CACHEXIA SARCOPENI, V7, P193, DOI 10.1002/jcsm.12041; Paramel GV, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/846782; Patel M, 2018, BRIT J CANCER, V118, P705, DOI 10.1038/bjc.2017.441; Pietka TA, 2014, DIABETES CARE, V37, P1990, DOI 10.2337/dc13-2835; Neto NIP, 2018, J CACHEXIA SARCOPENI, V9, P1101, DOI 10.1002/jcsm.12345; Qin Qiong, 2017, Chronic Dis Transl Med, V3, P51, DOI 10.1016/j.cdtm.2017.02.004; Rakoff-Nahoum S, 2009, NAT REV CANCER, V9, P57, DOI 10.1038/nrc2541; Rathinam VAK, 2018, TRENDS MOL MED, V24, P304, DOI 10.1016/j.molmed.2018.01.004; Riccardi DM., 2015, THESIS U SAO PAULO I; Santosa S, 2015, INT J OBESITY, V39, P874, DOI 10.1038/ijo.2014.185; Schaffaler A, 2010, TRENDS IMMUNOL, V31, P228, DOI 10.1016/j.it.2010.03.001; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Seelaender MCL, 2014, HORM MOL BIOL CLIN I, V17, P5, DOI 10.1515/hmbci-2013-0040; Sharma BR, 2021, NAT IMMUNOL, V22, P550, DOI 10.1038/s41590-021-00886-5; Sheedy FJ, 2013, NAT IMMUNOL, V14, P812, DOI 10.1038/ni.2639; Silverio R, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0547-x; Szalowska E, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-71; Vaitkus JA, 2017, EXP BIOL MED, V242, P473, DOI 10.1177/1535370216683282; Vatier C, 2012, NUTR DIABETES, V2, DOI 10.1038/nutd.2012.29; Villani AC, 2009, NAT GENET, V41, P71, DOI 10.1038/ng.285; Wang B, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2019.152737; Wang JC, 2019, THERANOSTICS, V9, P4893, DOI 10.7150/thno.36037; World Cancer Reserach Fund American Institute for Cancer Research, 2018, CONT UPD PROJ EXP RE; Wronska A, 2012, ACTA PHYSIOL, V205, P194, DOI 10.1111/j.1748-1716.2012.02409.x; Yamashita AS, 2017, CYTOKINE, V89, P122, DOI 10.1016/j.cyto.2016.02.015; Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003; Zaki MH, 2010, J IMMUNOL, V185, P4912, DOI 10.4049/jimmunol.1002046; Zhang J, 2014, MUCOSAL IMMUNOL, V7, P1139, DOI 10.1038/mi.2014.1; Zoico E, 2017, OBESITY, V25, pS87, DOI 10.1002/oby.22008	78	1	1	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 23	2021	12								729182	10.3389/fimmu.2021.729182	http://dx.doi.org/10.3389/fimmu.2021.729182			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WE8RG	34630405	Green Published, gold			2022-12-18	WOS:000705885900001
J	DiAntonio, A; Milbrandt, J; Figley, MDD				DiAntonio, Aaron; Milbrandt, Jeffrey; Figley, Matthew D. D.			The SARM1 TIR NADase: Mechanistic Similarities to Bacterial Phage Defense and Toxin-Antitoxin Systems	FRONTIERS IN IMMUNOLOGY			English	Review						NAD(+); innate immunity; NMNAT2; axon degeneration; plant; metabolism; TIR domain; abortive infection	NAD(+) CLEAVAGE ACTIVITY; TRAUMATIC BRAIN-INJURY; DEGENERATION; DOMAIN; DEATH; ACTIVATION; PROTEINS; SURVIVAL; IMMUNITY; DEFECTS	The Toll/interleukin-1 receptor (TIR) domain is the signature signalling motif of innate immunity, with essential roles in innate immune signalling in bacteria, plants, and animals. TIR domains canonically function as scaffolds, with stimulus-dependent multimerization generating binding sites for signalling molecules such as kinases and ligases that activate downstream immune mechanisms. Recent studies have dramatically expanded our understanding of the TIR domain, demonstrating that the primordial function of the TIR domain is to metabolize NAD(+). Mammalian SARM1, the central executioner of pathological axon degeneration, is the founding member of the TIR-domain class of NAD(+) hydrolases. This unexpected NADase activity of TIR domains is evolutionarily conserved, with archaeal, bacterial, and plant TIR domains all sharing this catalytic function. Moreover, this enzymatic activity is essential for the innate immune function of these proteins. These evolutionary relationships suggest a link between SARM1 and ancient self-defense mechanisms that has only been strengthened by the recent discovery of the SARM1 activation mechanism which, we will argue, is strikingly similar to bacterial toxin-antitoxin systems. In this brief review we will describe the regulation and function of SARM1 in programmed axon self-destruction, and highlight the parallels between the SARM1 axon degeneration pathway and bacterial innate immune mechanisms.	[DiAntonio, Aaron; Figley, Matthew D. D.] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63130 USA; [DiAntonio, Aaron; Milbrandt, Jeffrey] Washington Univ, Sch Med, Needleman Ctr Neurometab & Axonal Therapeut, St Louis, MO 63130 USA; [Milbrandt, Jeffrey] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63130 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	DiAntonio, A (corresponding author), Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63130 USA.; DiAntonio, A (corresponding author), Washington Univ, Sch Med, Needleman Ctr Neurometab & Axonal Therapeut, St Louis, MO 63130 USA.	diantonio@wustl.edu			National Institutes of Health [R37NS065053, RO1NS087632]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was funded by National Institutes of Healthgrants R37NS065053 to AD and RO1NS087632 to AD and JM.	Bradshaw DV, 2021, ACTA NEUROPATHOL COM, V9, DOI 10.1186/s40478-021-01193-8; Burroughs AM, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv1267; Cetinkaya-Fisgin A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78896-w; Coronas-Serna JM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1007979; Di Stefano M, 2015, CELL DEATH DIFFER, V22, P731, DOI 10.1038/cdd.2014.164; Di Stefano M, 2017, CURR BIOL, V27, P784, DOI 10.1016/j.cub.2017.01.070; Doron S., 2021, ANTIVIRAL ACTIVITY B, DOI [DOI: 10.1101/2021.01.06.425286, DOI 10.1101/2021.01.06.425286, 10.1101/2021.01.06.425286]; Doron S, 2018, SCIENCE, V359, DOI 10.1126/science.aar4120; Essuman K, 2018, CURR BIOL, V28, P421, DOI 10.1016/j.cub.2017.12.024; Essuman K, 2017, NEURON, V93, P1334, DOI 10.1016/j.neuron.2017.02.022; Figley MD, 2021, NEURON, V109, DOI 10.1016/j.neuron.2021.02.009; Figley MD, 2020, CURR OPIN NEUROBIOL, V63, P59, DOI 10.1016/j.conb.2020.02.012; Freire DM, 2019, MOL CELL, V73, P1282, DOI 10.1016/j.molcel.2019.01.028; Geisler S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129920; Geisler S, 2016, BRAIN, V139, P3092, DOI 10.1093/brain/aww251; Gerdts J, 2013, J NEUROSCI, V33, P13569, DOI 10.1523/JNEUROSCI.1197-13.2013; Gilley J, 2015, CELL REP, V10, P1974, DOI 10.1016/j.celrep.2015.02.060; Gilley J, 2013, J NEUROSCI, V33, P13410, DOI 10.1523/JNEUROSCI.1534-13.2013; Gilley J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000300; Gould SA, 2021, EXP NEUROL, V338, DOI 10.1016/j.expneurol.2021.113607; Harms A, 2018, MOL CELL, V70, P768, DOI 10.1016/j.molcel.2018.01.003; Henninger N, 2016, BRAIN, V139, P1094, DOI 10.1093/brain/aww001; Hicks AN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047869; Horsefield S, 2019, SCIENCE, V365, P793, DOI 10.1126/science.aax1911; Jiang YF, 2020, NATURE, V588, P658, DOI 10.1038/s41586-020-2862-z; Ko KW, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201912047; Ma SC, 2020, SCIENCE, V370, P1184, DOI 10.1126/science.abe3069; Marion CM, 2019, EXP NEUROL, V321, DOI 10.1016/j.expneurol.2019.113040; Maynard ME, 2020, EXP NEUROL, V327, DOI 10.1016/j.expneurol.2020.113207; Morehouse BR, 2020, NATURE, V586, P429, DOI 10.1038/s41586-020-2719-5; Mukherjee P, 2013, IMMUNITY, V38, P705, DOI 10.1016/j.immuni.2013.02.013; Nanson JD, 2019, J LEUKOCYTE BIOL, V105, P363, DOI 10.1002/JLB.MR0318-123R; Osterloh JM, 2012, SCIENCE, V337, P481, DOI 10.1126/science.1223899; Ozaki E, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.201900618; Roussin M, 2021, FEMS MICROBIOL REV, V45, DOI 10.1093/femsre/fuab037; Sasaki Y, 2020, ELIFE, V9, DOI 10.7554/eLife.62027; Sasaki Y, 2016, ELIFE, V5, DOI 10.7554/eLife.19749; Shen C, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2023151118; Skjerning RB, 2019, MOL MICROBIOL, V111, P221, DOI 10.1111/mmi.14150; Smith CL, 2011, STRUCTURE, V19, P192, DOI 10.1016/j.str.2010.12.013; Sporny M, 2020, ELIFE, V9, DOI 10.7554/eLife.62021; Summers DW, 2020, MOL NEUROBIOL, V57, P1146, DOI 10.1007/s12035-019-01796-2; Summers DW, 2016, P NATL ACAD SCI USA, V113, pE6271, DOI 10.1073/pnas.1601506113; Sun J, 2015, NAT STRUCT MOL BIOL, V22, P672, DOI 10.1038/nsmb.3064; Sun Y, 2021, PROTEIN CELL, V12, P621, DOI 10.1007/s13238-021-00835-w; Sundaramoorthy V, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008343; Swiderski MR, 2009, MOL PLANT MICROBE IN, V22, P157, DOI 10.1094/MPMI-22-2-0157; Tang JY, 2018, J BIOL CHEM, V293, P1504, DOI 10.1074/jbc.RA117.000178; Walker LJ, 2017, ELIFE, V6, DOI 10.7554/eLife.22540; Wan L, 2019, SCIENCE, V365, P799, DOI 10.1126/science.aax1771; Zhang Q, 2011, DEV COMP IMMUNOL, V35, P461, DOI 10.1016/j.dci.2010.11.013; Zhao ZY, 2019, ISCIENCE, V15, P452, DOI 10.1016/j.isci.2019.05.001; Ziogas NK, 2018, J NEUROSCI, V38, P4031, DOI 10.1523/JNEUROSCI.2343-17.2018	53	1	1	2	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 23	2021	12								752898	10.3389/fimmu.2021.752898	http://dx.doi.org/10.3389/fimmu.2021.752898			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WC3NV	34630431	gold, Green Published			2022-12-18	WOS:000704167600001
J	Pineda, S; de Maturana, EL; Yu, K; Ravoor, A; Wood, I; Malats, N; Sirota, M				Pineda, Silvia; Lopez de Maturana, Evangelina; Yu, Katharine; Ravoor, Akshay; Wood, Ines; Malats, Nuria; Sirota, Marina			Tumor-Infiltrating B- and T-Cell Repertoire in Pancreatic Cancer Associated With Host and Tumor Features	FRONTIERS IN IMMUNOLOGY			English	Article						B-cell repertoire; immunoglobulins; T-cell repertoire; pancreatic cancer; tumor microenvironment; tumor infiltration; compositional analysis	PLASMA-CELLS; PROGNOSTIC IMPACT; RISK; MICROENVIRONMENT; EXPRESSION; IMMUNITY	Background Infiltrating B and T cells have been observed in several tumor tissues, including pancreatic ductal adenocarcinoma (PDAC). The majority known PDAC risk factors point to a chronic inflammatory process leading to different forms of immunological infiltration. Understanding pancreatic tumor infiltration may lead to improved knowledge of this devastating disease. Methods We extracted the immunoglobulins (IGs) and T cell receptors (TCRs) from RNA-sequencing of 144 PDAC from TCGA and 180 pancreatic normal tissue from GTEx. We used Shannon entropy to find differences in IG/TCR diversity. We performed a clonotype analysis considering the IG clone definition (same V and J segments, same CDR3 length, and 90% nucleotide identity between CDR3s) to study differences among the tumor samples. Finally, we performed an association analysis to find host and tumor factors associated with the IG/TCR. Results PDAC presented a richer and more diverse IG and TCR infiltration than normal pancreatic tissue. A higher IG infiltration was present in heavy smokers and females and it was associated with better overall survival. In addition, specific IG clonotypes classified samples with better prognosis explaining 24% of the prognosis phenotypic variance. On the other hand, a larger TCR infiltration was present in patients with previous history of diabetes and was associated with lower nonantigen load. Conclusions Our findings support PDAC subtyping according to its immune repertoire landscape with a potential impact on the understanding of the inflammatory basis of PDAC risk factors as well as the design of treatment options and prognosis monitoring.	[Pineda, Silvia; Lopez de Maturana, Evangelina; Wood, Ines; Malats, Nuria] Spanish Natl Canc Res Ctr CNIO, Genet & Mol Epidemiol Grp, Madrid, Spain; [Pineda, Silvia; Lopez de Maturana, Evangelina; Wood, Ines; Malats, Nuria] Ctr Invest Biomed Red Canc CIBERONO, Madrid, Spain; [Yu, Katharine; Sirota, Marina] Univ Calif San Francisco UCSF, Bakar Computat Hlth Sci Inst, San Francisco, CA 94143 USA; [Yu, Katharine; Sirota, Marina] Univ Calif San Francisco UCSF, Dept Pediat, San Francisco, CA USA	Centro Nacional de Investigaciones Oncologicas (CNIO); University of California System; University of California San Francisco; University of California System; University of California San Francisco	Pineda, S (corresponding author), Spanish Natl Canc Res Ctr CNIO, Genet & Mol Epidemiol Grp, Madrid, Spain.; Pineda, S (corresponding author), Ctr Invest Biomed Red Canc CIBERONO, Madrid, Spain.; Sirota, M (corresponding author), Univ Calif San Francisco UCSF, Bakar Computat Hlth Sci Inst, San Francisco, CA 94143 USA.; Sirota, M (corresponding author), Univ Calif San Francisco UCSF, Dept Pediat, San Francisco, CA USA.	spineda@cnio.es; marina.sirota@ucsf.edu			AstraZeneca Immunooncology research fellowship; Fondo de InvestigacionesSanitarias (FIS); Instituto de Salud Carlos III, Spain [PI18/01347]; Pancreatic Cancer Collective (PCC): Lustgarten Foundation & Stand-Up to Cancer (SU2C) [6179]	AstraZeneca Immunooncology research fellowship; Fondo de InvestigacionesSanitarias (FIS)(Instituto de Salud Carlos III); Instituto de Salud Carlos III, Spain(Instituto de Salud Carlos III); Pancreatic Cancer Collective (PCC): Lustgarten Foundation & Stand-Up to Cancer (SU2C)	AstraZeneca Immuno-oncology research fellowship. The funder was not involved in the study design, collection, analysis, interpretation of data, the written of this article or the decision to submit it for publication. This work was also partially supported by Fondo de InvestigacionesSanitarias (FIS), Instituto de Salud Carlos III, Spain (#PI18/01347), and Pancreatic Cancer Collective (PCC): Lustgarten Foundation & Stand-Up to Cancer (SU2C #6179).	Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Bai XL, 2015, SCI REP-UK, V5, DOI 10.1038/srep13664; Bailey P, 2016, SCI REP-UK, V6, DOI 10.1038/srep35848; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Barnes TA, 2017, BRIT J CANCER, V117, P451, DOI 10.1038/bjc.2017.220; Bashford-Rogers RJM, 2013, GENOME RES, V23, P1874, DOI 10.1101/gr.154815.113; Berntsson J, 2016, INT J CANCER, V139, P1129, DOI 10.1002/ijc.30138; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Bosetti C, 2014, ANN ONCOL, V25, P2065, DOI 10.1093/annonc/mdu276; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chenard S., 2021, SEXUAL DIMORPHISM OU, V2021, P1, DOI [10.1101/2021.01.23.427909, DOI 10.1101/2021.01.23.427909]; Cui C, 2019, CANCER SCI, V110, P61, DOI 10.1111/cas.13877; DeNardo DG, 2019, NAT REV IMMUNOL, V19, P369, DOI 10.1038/s41577-019-0127-6; Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600; Foucher ED, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01044; Gomez-Rubio P, 2017, GUT, V66, P314, DOI 10.1136/gutjnl-2015-310442; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hopkins AC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122092; Ino Y, 2013, BRIT J CANCER, V108, P914, DOI 10.1038/bjc.2013.32; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Largeot A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050449; Lin J, 2019, MOL CARCINOGEN, V58, P206, DOI 10.1002/mc.22920; Liu C, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0899-6; Lohr M, 2013, CANCER LETT, V333, P222, DOI 10.1016/j.canlet.2013.01.036; Lundgren S, 2016, J OVARIAN RES, V9, DOI 10.1186/s13048-016-0232-0; Maisonneuve P, 2015, INT J EPIDEMIOL, V44, P186, DOI 10.1093/ije/dyu240; Martinez-Bosch N, 2018, CANCERS, V10, DOI 10.3390/cancers10010006; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Molina-Montes E, 2018, INT J EPIDEMIOL, V47, P473, DOI 10.1093/ije/dyx269; Molina-Montes E, 2020, CANCER EPIDEM BIOMAR, V29, P1009, DOI 10.1158/1055-9965.EPI-19-1027; Peran I, 2018, CLIN CANCER RES, V24, P3813, DOI 10.1158/1078-0432.CCR-18-0290; Perez P, 2014, GENETICS, V198, P483, DOI 10.1534/genetics.114.164442; Pineda S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09930-3; Qi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069509; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Sharonov GV, 2020, NAT REV IMMUNOL, V20, P294, DOI 10.1038/s41577-019-0257-x; Susin A, 2020, NAR GENOM BIOINFORM, V2, DOI 10.1093/nargab/lqaa029; Takada K, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1773-y; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wahba G., 2003, IFAC P VOLUMES, P525, DOI [10.1016/S1474-6670(17)34815-2, DOI 10.1016/S1474-6670(17)34815-2]; Whiteside TL, 2012, CLIN CANCER RES, V18, P2417, DOI 10.1158/1078-0432.CCR-12-0566; Wouters MCA, 2018, CLIN CANCER RES, V24, P6125, DOI 10.1158/1078-0432.CCR-18-1481	45	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 23	2021	12								730746	10.3389/fimmu.2021.730746	http://dx.doi.org/10.3389/fimmu.2021.730746			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WE8VM	34630409	Green Published, gold			2022-12-18	WOS:000705897100001
J	Saha, S; Hazra, A; Ghatak, D; Singh, AV; Roy, S; BoseDasgupta, S				Saha, Saradindu; Hazra, Arnab; Ghatak, Debika; Singh, Ajay Vir; Roy, Sadhana; BoseDasgupta, Somdeb			A Bumpy Ride of Mycobacterial Phagosome Maturation: Roleplay of Coronin1 Through Cofilin1 and cAMP	FRONTIERS IN IMMUNOLOGY			English	Article						mycobacteria; BMDM; Coronin1; cAMP; Cofilin1	CYCLIC-AMP; PATHOGENIC MYCOBACTERIA; MACROPHAGES; TUBERCULOSIS; SURVIVAL; ACTIVATION; EXPRESSION	Phagosome-lysosome fusion in innate immune cells like macrophages and neutrophils marshal an essential role in eliminating intracellular microorganisms. In microbe-challenged macrophages, phagosome-lysosome fusion occurs 4 to 6 h after the phagocytic uptake of the microbe. However, live pathogenic mycobacteria hinder the transfer of phagosomes to lysosomes, up to 20 h post-phagocytic uptake. This period is required to evade pro-inflammatory response and upregulate the acid-stress tolerant proteins. The exact sequence of events through which mycobacteria retards phagolysosome formation remains an enigma. The macrophage coat protein Coronin1(Cor1) is recruited and retained by mycobacteria on the phagosome membrane to retard its maturation by hindering the access of phagosome maturation factors. Mycobacteria-infected macrophages exhibit an increased cAMP level, and based on receptor stimulus, Cor1 expressing cells show a higher level of cAMP than non-Cor1 expressing cells. Here we have shown that infection of bone marrow-derived macrophages with H37Rv causes a Cor1 dependent rise of intracellular cAMP levels at the vicinity of the phagosomes. This increased cAMP fuels cytoskeletal protein Cofilin1 to depolymerize F-actin around the mycobacteria-containing phagosome. Owing to reduced F-actin levels, the movement of the phagosome toward the lysosomes is hindered, thus contributing to the retarded phagosome maturation process. Additionally, Cor1 mediated upregulation of Cofilin1 also contributes to the prevention of phagosomal acidification, which further aids in the retardation of phagosome maturation. Overall, our study provides first-hand information on Cor1 mediated retardation of phagosome maturation, which can be utilized in developing novel peptidomimetics as part of host-directed therapeutics against tuberculosis.	[Saha, Saradindu; Hazra, Arnab; Ghatak, Debika; Roy, Sadhana; BoseDasgupta, Somdeb] Indian Inst Technol Kharagpur, Dept Biotechnol, Mol Immunol & Cellular Microbiol Lab, Kharagpur, W Bengal, India; [Singh, Ajay Vir] ICMR Natl JALMA Inst Leprosy & Other Mycobacteria, Dept Microbiol & Mol Biol, Agra, Uttar Pradesh, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kharagpur; Indian Council of Medical Research (ICMR); ICMR - National JALMA Institute for Leprosy & Other Mycobacterial Diseases, Agra	BoseDasgupta, S (corresponding author), Indian Inst Technol Kharagpur, Dept Biotechnol, Mol Immunol & Cellular Microbiol Lab, Kharagpur, W Bengal, India.	somdeb@iitkgp.ac.in			DBT, India [BT/RLF/Re-entry/33/2014]; DST-SERB [YSS/2015/000471, CRG/2020/000748]; IIT Kharagpur under MoE	DBT, India(Department of Biotechnology (DBT) India); DST-SERB(Department of Science & Technology (India)Science Engineering Research Board (SERB), India); IIT Kharagpur under MoE	We would like to thank DBT, India (BT/RLF/Re-entry/33/2014), and DST-SERB (YSS/2015/000471 and CRG/2020/000748) for providing financial assistance for conducting the research. SS, AH, DG, and SR were provided financial assistance through a fellowship from IIT Kharagpur under MoE.	Abdellatif MEA, 2019, HISTOCHEM CELL BIOL, V152, P133, DOI 10.1007/s00418-019-01795-3; Agarwal N, 2009, NATURE, V460, P98, DOI 10.1038/nature08123; Agarwal N, 2009, INDIAN J EXP BIOL, V47, P393; Anes E, 2003, NAT CELL BIOL, V5, P793, DOI 10.1038/ncb1036; Bai GC, 2009, FEMS IMMUNOL MED MIC, V55, P68, DOI 10.1111/j.1574-695X.2008.00500.x; BoseDasgupta S, 2015, FEBS J, V282, P1167, DOI 10.1111/febs.13214; BoseDasgupta S, 2014, FEBS LETT, V588, P3898, DOI 10.1016/j.febslet.2014.08.036; BoseDasgupta S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003879; Cai L, 2007, CELL, V128, P915, DOI 10.1016/j.cell.2007.01.031; Constantoulakis P, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-243; Deghmane AE, 2007, J CELL SCI, V120, P2796, DOI 10.1242/jcs.006221; Dey B, 2014, SEMIN IMMUNOL, V26, P486, DOI 10.1016/j.smim.2014.09.002; Ehrt S, 2009, CELL MICROBIOL, V11, P1170, DOI 10.1111/j.1462-5822.2009.01335.x; GLAUERT AM, 1978, J CELL SCI, V34, P173, DOI 10.1007/BF01944659; Hmama Z, 2015, IMMUNOL REV, V264, P220, DOI 10.1111/imr.12268; Jayachandran R, 2007, CELL, V130, P37, DOI 10.1016/j.cell.2007.04.043; Jayachandran R, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001820; Kalamidas SA, 2006, J CELL SCI, V119, P3686, DOI 10.1242/jcs.03091; Kim HK, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00885; Kumar D, 2010, CELL, V140, P731, DOI 10.1016/j.cell.2010.02.012; Kurita S, 2008, J BIOL CHEM, V283, P32542, DOI 10.1074/jbc.M804627200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOWRIE DB, 1975, NATURE, V254, P600, DOI 10.1038/254600a0; McDonough KA, 2012, NAT REV MICROBIOL, V10, P27, DOI 10.1038/nrmicro2688; Mikati MA, 2015, J MOL BIOL, V427, P3137, DOI 10.1016/j.jmb.2015.08.011; Nguyen L, 2005, TRENDS CELL BIOL, V15, P269, DOI 10.1016/j.tcb.2005.03.009; Oehrl S, 2017, J DERMATOL SCI, V87, P110, DOI 10.1016/j.jdermsci.2017.04.005; Pasquinelli V, 2013, J INFECT DIS, V207, P340, DOI 10.1093/infdis/jis672; Punwani D, 2015, J CLIN IMMUNOL, V35, P100, DOI 10.1007/s10875-015-0130-z; Ramachandran C, 2011, INVEST OPHTH VIS SCI, V52, P1474, DOI 10.1167/iovs.10-6241; Ross SE, 1997, J IMMUNOL, V159, P6253; Saha S, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.582563; Siegmund K, 2016, J BIOL CHEM, V291, P22086, DOI 10.1074/jbc.M116.748012; Sousa J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15832-6; Ullrich M, 2014, NAT PROTOC, V9, P2237, DOI 10.1038/nprot.2014.150; Wang J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00279-z; Watson RO, 2012, CELL, V150, P803, DOI 10.1016/j.cell.2012.06.040; Yadav M, 2004, J IMMUNOL, V172, P5588, DOI 10.4049/jimmunol.172.9.5588	38	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 23	2021	12								687044	10.3389/fimmu.2021.687044	http://dx.doi.org/10.3389/fimmu.2021.687044			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WE8NI	34630380	gold, Green Published			2022-12-18	WOS:000705875700001
J	Song, Q; Zheng, YT; Wu, JZ; Wang, S; Meng, L; Yao, Q; Li, ZW; Lian, SY				Song, Qian; Zheng, Yutian; Wu, Junzhou; Wang, Sheng; Meng, Lin; Yao, Qian; Li, Zhongwu; Lian, Shenyi			PTP4A3 Is a Prognostic Biomarker Correlated With Immune Infiltrates in Papillary Renal Cell Carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						renal cancer; prognosis; tumor infiltration; biomarker	BREAST-CANCER; TUMOR-GROWTH; WEB SERVER; EXPRESSION; PRL-3; PHOSPHATASE; OVEREXPRESSION; EXHAUSTION; THERAPY; PROTEIN	PTP4A3 plays an important role in the tumorigenesis and metastasis of multiple tumors, but its prognostic role in renal cancer is not well understood. We utilized the Oncomine and Tumor Immunoassay Resource databases to examine the differential expression of PTP4A3 in tumor tissues and normal tissues in breast, urinary tract, gastrointestinal tract and skin. Using the GEPIA and PrognoScan databases, the independent prognostic role of PTP4A3 was confirmed in clear cell renal cell cancer and papillary renal cell cancer. Expression of PTP4A3 were obviously higher in tumor tissue compare with normal tissues (P=0.028). We haven't found the associations of PTP4A3 and clinicopathological features in our IHC cohort. Ectopic expression of PTP4A3 promotes proliferation, migration and invasion and increased the mRNA level of TGFB1 in RCC cell lines. Immunohistochemical staining indicated that the expression of PTP4A3 associates with CD3+ (P =0.037)/CD8+ (P =0.037) intratumor TILs, not with invasive margins in renal cancer. Comprehensive analysis of immune infiltration in the TIMER database correlated PTP4A3 expression with the infiltration of B cells, CD8+ T cells, CD4+ T cells and neutrophils in both clear cell renal cell carcinoma and papillary renal cell carcinoma. PTP4A3 expression was associated with the infiltration of dendritic cells in papillary renal cell carcinoma. We further confirmed that the infiltration of B cells and CD8+ T cells was associated with poor prognosis in papillary renal cell carcinoma patients, consistent with the prognostic role of PTP4A3 in papillary renal cell carcinoma. PTP4A3 expression correlated genes involved in B cells, monocytes, M1 macrophages, Th2 and Treg cells in papillary renal cell carcinoma. These results suggest PTP4A3 as a prognostic factor with a role in regulating immune cell infiltration in papillary renal cell carcinoma.	[Song, Qian; Wang, Sheng] Univ Chinese Acad Sci, Canc Hosp, Dept Clin Lab, Zhejiang Canc Hosp, Hangzhou, Peoples R China; [Zheng, Yutian; Meng, Lin] Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China; [Zheng, Yutian; Meng, Lin] Peking Univ Canc Hosp & Inst, Dept Biochem & Mol Biol, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China; [Wu, Junzhou] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Canc Res Inst, Hangzhou, Peoples R China; [Wu, Junzhou] Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China; [Yao, Qian; Li, Zhongwu; Lian, Shenyi] Peking Univ Canc Hosp & Inst, Dept Pathol, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China	Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Zhejiang Cancer Hospital; Chinese Academy of Sciences; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Zhejiang Cancer Hospital; Chinese Academy of Sciences	Li, ZW; Lian, SY (corresponding author), Peking Univ Canc Hosp & Inst, Dept Pathol, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China.	zhwuli@hotmail.com; liansy2007@bjmu.edu.cn	song, qian/HDL-9868-2022		Natural Science Foundation of China [81872309]; Beijing Hospitals Authority Youth Programme [QML20191109]; Zhejiang Provincial Natural Science Foundation of China [LQ21H200001]; General Research Program of Health Department of Zhejiang Province [2020KY480]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Hospitals Authority Youth Programme; Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province); General Research Program of Health Department of Zhejiang Province	This research was supported by Natural Science Foundation of China [grant number 81872309], Beijing Hospitals Authority Youth Programme [grant number QML20191109], Zhejiang Provincial Natural Science Foundation of China [grant number LQ21H200001] and General Research Program of Health Department of Zhejiang Province [grant number 2020KY480].	Azimi F, 2012, J CLIN ONCOL, V30, P2678, DOI 10.1200/JCO.2011.37.8539; Bersanelli Melissa, 2019, Acta Biomed, V90, P468, DOI 10.23750/abm.v90i4.7057; Chen FJ, 2016, CELL REP, V14, P2476, DOI 10.1016/j.celrep.2016.02.024; Cillo AR, 2020, IMMUNITY, V52, P183, DOI 10.1016/j.immuni.2019.11.014; Curry JM, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00436; Da N, 2009, WORLD J GASTROENTERO, V15, P1499, DOI 10.3748/wjg.15.1499; Danaher P, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0215-8; den Hollander P, 2016, CANCER RES, V76, P1942, DOI 10.1158/0008-5472.CAN-14-0673; Durinck S, 2015, NAT GENET, V47, P13, DOI 10.1038/ng.3146; Forte E, 2008, BBA-MOL CELL RES, V1783, P334, DOI 10.1016/j.bbamcr.2007.11.004; Geissler K, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.985082; Ghatalia P, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0621-1; Giraldo NA, 2015, CLIN CANCER RES, V21, P3031, DOI 10.1158/1078-0432.CCR-14-2926; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Guo K, 2012, ONCOTARGET, V3, P158; Gupta K, 2008, CANCER TREAT REV, V34, P193, DOI 10.1016/j.ctrv.2007.12.001; Johansson JA, 2020, DEV CELL, V54, P317, DOI 10.1016/j.devcel.2020.06.013; Lai W, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0566-z; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Lian SY, 2017, NUCLEIC ACIDS RES, V45, P6546, DOI 10.1093/nar/gkx392; Lian SY, 2013, BIOCHEM BIOPH RES CO, V430, P196, DOI 10.1016/j.bbrc.2012.11.036; Liang F, 2008, J BIOL CHEM, V283, P10339, DOI 10.1074/jbc.M708285200; Linehan WM, 2019, NAT REV UROL, V16, P539, DOI 10.1038/s41585-019-0211-5; Lv J, 2013, GENE THER, V20, P834, DOI 10.1038/gt.2013.5; Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18; Mizuuchi E, 2009, INT J CANCER, V124, P1802, DOI 10.1002/ijc.24111; Niu BL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01888; Ohtani Haruo, 2007, Cancer Immun, V7, P4; Pryczynicz A, 2010, FOLIA HISTOCHEM CYTO, V48, P632, DOI 10.2478/v10042-010-0070-7; Pu YQ, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17030910; Qi Y, 2020, CANCER IMMUNOL IMMUN, V69, P1565, DOI 10.1007/s00262-020-02563-2; Qu S, 2014, CANCER-AM CANCER SOC, V120, P2130, DOI 10.1002/cncr.28668; Reich R, 2011, INT J MOL SCI, V12, P1133, DOI 10.3390/ijms12021133; Ren TT, 2009, PATHOL ONCOL RES, V15, P555, DOI 10.1007/s12253-009-9153-1; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Ricketts CJ, 2018, CELL REP, V23, P313, DOI [10.1016/j.celrep.2018.03.075, 10.1016/j.celrep.2018.06.032]; Rios P, 2013, FEBS J, V280, P505, DOI 10.1111/j.1742-4658.2012.08565.x; Ruiz-Cordero Roberto, 2020, Surg Pathol Clin, V13, P17, DOI 10.1016/j.path.2019.11.002; Sawant A, 2012, J IMMUNOL, V189, P4258, DOI 10.4049/jimmunol.1101855; Sengal A, 2021, BLOOD, V137, P1777, DOI 10.1182/blood.2020005867; Shroff GS, 2018, RADIOL CLIN N AM, V56, P485, DOI 10.1016/j.rcl.2018.01.012; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Siemers NO, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179726; Sousa S, 2016, J BONE ONCOL, V5, P135, DOI 10.1016/j.jbo.2016.03.004; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Thura M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10127-x; Thura M, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87607; Tian W, 2012, BMC BIOCHEM, V13, DOI 10.1186/1471-2091-13-22; Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598; Wang L, 2006, ANN ONCOL, V17, P1517, DOI 10.1093/annonc/mdl159; Xie J, 2021, PATHOL RES PRACT, V218, DOI 10.1016/j.prp.2020.153322; Xing XF, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-309; Xing XF, 2009, HISTOPATHOLOGY, V54, P309, DOI 10.1111/j.1365-2559.2009.03226.x; Xu HY, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-330; Yang YY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169665; Zhang C, 2019, CANCER RES, V79, P928, DOI 10.1158/0008-5472.CAN-18-0520; Zimmerman MW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058300	58	1	1	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 23	2021	12								717688	10.3389/fimmu.2021.717688	http://dx.doi.org/10.3389/fimmu.2021.717688			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WE8TV	34630392	Green Published, gold			2022-12-18	WOS:000705892700001
J	Gao, LC; Wu, M; Liu, HY; He, M; Jiang, H; Shang, RS; Wang, QQ; Song, Z; Huang, YF; Han, JY				Gao, Liuchuang; Wu, Min; Liu, Hangyu; He, Miao; Jiang, Han; Shang, Runshi; Wang, Qiangqiang; Song, Zhu; Huang, Yafei; Han, Junyan			Neonatal LPS Administered Before Sensitization Reduced the Number of Inflammatory Monocytes and Abrogated the Development of OVA-Induced Th2 Allergic Airway Inflammation	FRONTIERS IN IMMUNOLOGY			English	Article						neonates; time window; LPS; hygiene hypothesis; allergic asthma	DENDRITIC CELLS; IN-VIVO; ENDOTOXIN; IMMUNITY; NEUTROPHILS; EXPOSURE; ASTHMA; DUST	It is becoming increasingly clear that environment factors during early life play a pivotal role in the development of allergic asthma. Among these, a traditional farm is one of the strongest protective environments, and the protective effects have been, at least in part, attributed to the high-level exposure to lipopolysaccharide (LPS) on farms. However, the underlying mechanisms remain elusive, especially in ovalbumin (OVA)-induced neonatal allergic asthma model. Here, we used the OVA-induced asthma model in two age groups, neonatal and adult, when mice were first sensitized with peritoneal OVA/alum as neonates and adults, respectively. LPS was injected in the peritoneal cavity before OVA/alum sensitization. The effects of LPS treatment on allergic airway inflammation in the lung and the immune milieu in the peritoneal cavity were determined and compared between these two age groups. We found that LPS treatment abrogated the development of Th2 allergic airway responses in the neonatal group. In the adult group, the ameliorated Th2 allergic responses were accompanied with Th17 responses and neutrophil infiltration upon LPS treatment. We further investigated the immune milieu in the peritoneal cavity to elucidate the underlying mechanisms of this age-dependent difference. Our data show that in neonatal mice, LPS treatment significantly reduced the number of inflammatory monocytes in the peritoneal cavity. In the adult group, LPS treatment shifted the function of these cells which associated with Th1 and Th17 polarization. Our results provide more evidence that immunity in early life is distinct from that in adults, especially in the peritoneal cavity, and emphasize the importance of timing for the intervention of allergic asthma. Our results suggest that LPS treatment during early life is protective for the development of Th2 allergic responses. On the other hand, it might lead to a more severe phenotype of asthma when dampening the Th2 responses in adult mice.	[Gao, Liuchuang; He, Miao; Jiang, Han; Wang, Qiangqiang; Song, Zhu; Han, Junyan] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Immunol, Tongji Med Coll, Wuhan, Peoples R China; [Wu, Min] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Obstet & Gynecol, Tongji Med Coll, Wuhan, Peoples R China; [Liu, Hangyu; Huang, Yafei] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Pathogen Biol, Tongji Med Coll, Wuhan, Peoples R China; [Shang, Runshi] Huazhong Univ Sci & Technol, Inst Organ Transplantat, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Han, JY (corresponding author), Huazhong Univ Sci & Technol, Sch Basic Med, Dept Immunol, Tongji Med Coll, Wuhan, Peoples R China.; Huang, YF (corresponding author), Huazhong Univ Sci & Technol, Sch Basic Med, Dept Pathogen Biol, Tongji Med Coll, Wuhan, Peoples R China.	huangy2018@hust.edu.cn; hanj2014@hust.edu.cn			National Natural Science Foundation of China [31770994, 31970865]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the National Natural Science Foundation of China (31770994 and 31970865 to JH).	Basha S, 2014, EXPERT REV CLIN IMMU, V10, P1171, DOI 10.1586/1744666X.2014.942288; Ghosn EEB, 2010, P NATL ACAD SCI USA, V107, P2568, DOI 10.1073/pnas.0915000107; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Crofts KF, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040558; de Kleer IM, 2016, IMMUNITY, V45, P1285, DOI 10.1016/j.immuni.2016.10.031; Ding FX, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02150; Gehring U, 2020, CLIN EXP ALLERGY, V50, P1055, DOI 10.1111/cea.13705; Han JY, 2012, J ALLERGY CLIN IMMUN, V130, P1175, DOI 10.1016/j.jaci.2012.08.033; Huang C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02591; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Lloyd CM, 2019, TRENDS IMMUNOL, V40, P786, DOI 10.1016/j.it.2019.07.004; Mangan JK, 2004, BLOOD, V103, P4093, DOI 10.1182/blood-2003-06-2165; Marichal T, 2011, NAT MED, V17, P996, DOI 10.1038/nm.2403; Mckee AS, 2008, INT IMMUNOL, V20, P659, DOI 10.1093/intimm/dxn025; Mckee AS, 2009, J IMMUNOL, V183, P4403, DOI 10.4049/jimmunol.0900164; Na H, 2018, J ALLERGY CLIN IMMUN, V141, P2061, DOI 10.1016/j.jaci.2017.07.050; NELSON DS, 1963, LANCET, V2, P175; Nowroozilarki N, 2018, IMMUNOL LETT, V204, P67, DOI 10.1016/j.imlet.2018.10.007; Ober C, 2017, CURR OPIN IMMUNOL, V48, P51, DOI 10.1016/j.coi.2017.08.003; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; Oleszycka E, 2016, FEBS J, V283, P9, DOI 10.1111/febs.13546; Patel DF, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aax7006; Pierau M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.617731; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Radermecker C, 2018, CURR OPIN IMMUNOL, V54, P28, DOI 10.1016/j.coi.2018.05.006; Reynolds LA, 2017, NAT REV IMMUNOL, V17, P518, DOI 10.1038/nri.2017.39; Rose WA, 2015, SCI REP-UK, V5, DOI 10.1038/srep13146; Rotta G, 2003, J EXP MED, V198, P1253, DOI 10.1084/jem.20030335; SACHS L, 1989, ANN NY ACAD SCI, V557, P417; Saluzzo S, 2017, CELL REP, V18, P1893, DOI 10.1016/j.celrep.2017.01.071; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Schuster S, 2013, J LEUKOCYTE BIOL, V94, P671, DOI 10.1189/jlb.1012540; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Stiemsma LT, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-016-0173-6; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Wlasiuk G, 2012, CURR OPIN ALLERGY CL, V12, P461, DOI 10.1097/ACI.0b013e328357a3bc; Wu M, 2020, CELL MOL IMMUNOL, V17, P519, DOI 10.1038/s41423-019-0333-y; Xirakia C, 2010, AM J RESP CRIT CARE, V181, P1207, DOI 10.1164/rccm.200908-1255OC; Zaghouani H, 2009, TRENDS IMMUNOL, V30, P585, DOI 10.1016/j.it.2009.09.002; Zakeri A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01027; Zhang N, 2019, J EXP MED, V216, P1291, DOI 10.1084/jem.20182024; Zhu Z, 2010, CLIN EXP ALLERGY, V40, P536, DOI 10.1111/j.1365-2222.2010.03477.x	44	1	1	4	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 22	2021	12								725906	10.3389/fimmu.2021.725906	http://dx.doi.org/10.3389/fimmu.2021.725906			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WC0CY	34630401	gold, Green Published			2022-12-18	WOS:000703932800001
J	Gao, Y; Yue, Y; Xiong, SD				Gao, Yue; Yue, Yan; Xiong, Sidong			An Albumin-Binding Domain Peptide Confers Enhanced Immunoprotection Against Viral Myocarditis by CVB3 VP1 Vaccine	FRONTIERS IN IMMUNOLOGY			English	Article						Coxsackievirus B3; viral myocarditis; ABD; draining lymph nodes; vaccine; CTL	LYMPH-NODE; HALF-LIFE; IMMUNIZATION; DELIVERY; PROTEIN; FUSION	Coxsackievirus B3 (CVB3)-induced viral myocarditis is a common clinical cardiovascular disease without effective available vaccine. In this study, we tried to potentiate the immunoprotection efficacy of our previous CVB3-specific VP1 protein vaccine by introducing a streptococcal protein G-derived, draining lymph nodes (dLNs)-targeting albumin-binding domain (ABD) peptide. We found that compared with the original VP1 vaccine, ABD-fused VP1 (ABD-VP1) vaccine gained the new ability to efficiently bind murine albumin both in vitro and in vivo, possessed a much longer serum half-life in serum and exhibited more abundance in the dLNs after immunization. Accordingly, ABD-VP1 immunization not only significantly facilitated the enrichment and maturation of dendritic cells (DCs), induced higher percentages of IFN-gamma(+) CD8 (+) cells in the dLNs, but also robustly promoted VP1-induced T cell proliferation and cytotoxic T lymphocyte (CTL) responses in the spleens. More importantly, ABD-VP1 also elicited higher percentages of protective CD44(hi) CD62L(hi) memory T cells in dLNs and spleens. Consequently, obvious protective effect against viral myocarditis was conferred by ABD-VP1 vaccine compared to the VP1 vaccine, reflected by the less body weight loss, improved cardiac function, alleviated cardiac histomorphological changes and an increased 28-day survival rate. Our results indicated that the ABD might be a promising immune-enhancing regime for vaccine design and development.</p>	[Gao, Yue; Yue, Yan; Xiong, Sidong] Soochow Univ, Inst Biol & Med Sci, Jiangsu Prov Key Lab Infect & Immun, Suzhou, Peoples R China	Soochow University - China	Yue, Y; Xiong, SD (corresponding author), Soochow Univ, Inst Biol & Med Sci, Jiangsu Prov Key Lab Infect & Immun, Suzhou, Peoples R China.	yysherry@163.com; sdxiongfd@126.com			National Natural Science Foundation of China - Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Jiangsu Provincial Innovative Research Team Funding [31770962, 81970318, 31970844, 31170878, 31370894]	National Natural Science Foundation of China - Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Jiangsu Provincial Innovative Research Team Funding	This work was supported by grants from the National Natural Science Foundation of China (31770962, 81970318, 31970844, 31170878, 31370894), A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Jiangsu Provincial Innovative Research Team Funding.	Abdallah M, 2020, J CONTROL RELEASE, V327, P117, DOI 10.1016/j.jconrel.2020.07.046; Rojas LA, 2016, J CONTROL RELEASE, V237, P78, DOI 10.1016/j.jconrel.2016.07.004; Baptista AP, 2019, IMMUNITY, V50, P1188, DOI 10.1016/j.immuni.2019.04.001; Bubba L, 2020, LANCET INFECT DIS, V20, P350, DOI 10.1016/S1473-3099(19)30566-3; Cai YP, 2020, METHODS MOL BIOL, V2176, P163, DOI 10.1007/978-1-0716-0771-8_12; Chen Y, 2020, ACCOUNTS CHEM RES, V53, P2055, DOI 10.1021/acs.accounts.0c00260; Cioncada R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185843; Cronkite DA, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/1467538; Czub MP, 2020, MOL PHARMACOL, V98, P648, DOI 10.1124/molpharm.120.000131; Elsadek B, 2012, J CONTROL RELEASE, V157, P4, DOI 10.1016/j.jconrel.2011.09.069; Fairley CK, 1996, J INFECTION, V32, P223, DOI 10.1016/S0163-4453(96)80023-5; Hauri S, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12090810; Jeanbart L, 2014, CANCER IMMUNOL RES, V2, P436, DOI 10.1158/2326-6066.CIR-14-0019-T; Jiang H, 2017, J CONTROL RELEASE, V267, P47, DOI 10.1016/j.jconrel.2017.08.009; Johansson MU, 2002, J BIOL CHEM, V277, P8114, DOI 10.1074/jbc.M109943200; Kratz F, 2008, J CONTROL RELEASE, V132, P171, DOI 10.1016/j.jconrel.2008.05.010; Kudarha RR, 2017, MAT SCI ENG C-MATER, V81, P607, DOI 10.1016/j.msec.2017.08.004; Laucella S, 1996, PARASITE IMMUNOL, V18, P227, DOI 10.1046/j.1365-3024.1996.d01-95.x; Lederman MM, 2008, SEMIN IMMUNOL, V20, P187, DOI 10.1016/j.smim.2008.06.001; Li R, 2016, J CONTROL RELEASE, V228, P96, DOI 10.1016/j.jconrel.2016.03.004; Liu HP, 2014, NATURE, V507, P519, DOI 10.1038/nature12978; Macedo R, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1164363; Maghsoudi Nader, 2007, Iran Biomed J, V11, P147; Moyer TJ, 2016, J CLIN INVEST, V126, P799, DOI 10.1172/JCI81083; NEWEY R, 1989, VET REC, V124, P104, DOI 10.1136/vr.124.4.104; Nilvebrant J, 2013, COMPUT STRUCT BIOTEC, V6, DOI 10.5936/csbj.201303009; O'Keeffe M, 2015, CELL MOL LIFE SCI, V72, P4309, DOI 10.1007/s00018-015-2005-0; Petrokova H, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11120642; Pfaender S, 2020, NAT MICROBIOL, V5, P1330, DOI [10.1038/s41564-020-0769-y, 10.1101/2020.03.05.979260]; Pollack A, 2015, NAT REV CARDIOL, V12, P670, DOI 10.1038/nrcardio.2015.108; Powell AE, 2021, ACS CENTRAL SCI, V7, P183, DOI 10.1021/acscentsci.0c01405; Qi XM, 2017, SCI REP-UK, V7, DOI 10.1038/srep41485; Qiao DD, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2021.120674; Schudel A, 2019, NAT REV MATER, V4, P415, DOI 10.1038/s41578-019-0110-7; Sleep D, 2013, BBA-GEN SUBJECTS, V1830, P5526, DOI 10.1016/j.bbagen.2013.04.023; SOLE MJ, 1993, J AM COLL CARDIOL, V22, pA99, DOI 10.1016/0735-1097(93)90470-L; Stork R, 2007, PROTEIN ENG DES SEL, V20, P569, DOI 10.1093/protein/gzm061; Van Linthout S, 2011, EUR HEART J, V32, P2168, DOI 10.1093/eurheartj/ehq467; Wang MW, 2013, CLIN VACCINE IMMUNOL, V20, P1743, DOI 10.1128/CVI.00466-13; Wang P, 2018, BIOMATERIALS, V182, P92, DOI 10.1016/j.biomaterials.2018.08.008; Wang P, 2018, THERANOSTICS, V8, P223, DOI 10.7150/thno.21691; Wei JX, 2018, P NATL ACAD SCI USA, V115, pE3501, DOI 10.1073/pnas.1721780115; WHITTAKER P, 1994, BASIC RES CARDIOL, V89, P397, DOI 10.1007/BF00788278; Xu Wei, 2003, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V19, P239; Yin L, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00247; Yue Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018186; Zhang H, 2017, SCI REP-UK, V7, DOI 10.1038/srep42162; Zhang HY, 2000, J HISTOCHEM CYTOCHEM, V48, P579, DOI 10.1177/002215540004800501; Zhu GZ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02191-y; Zhu YN, 2020, J CONTROL RELEASE, V322, P300, DOI 10.1016/j.jconrel.2020.03.045; Zhuang Z, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01388; Zorzi A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16092	52	1	1	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 22	2021	12								666594	10.3389/fimmu.2021.666594	http://dx.doi.org/10.3389/fimmu.2021.666594			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WC0ZT	34630378	Green Published, gold			2022-12-18	WOS:000703993700001
J	Lutfi, F; Wu, L; Sunshine, S; Cao, XF				Lutfi, Forat; Wu, Long; Sunshine, Sarah; Cao, Xuefang			Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Review						CD27; CD70; immunotherapy; allogeneic hematopoietic cell transplant (alloHCT); graft-versus-host disease (GVHD)	VERSUS-HOST-DISEASE; ACUTE MYELOID-LEUKEMIA; DENDRITIC CELLS; CONDITIONING REGIMEN; HIGH-RISK; T-CELLS; CD27; STEM; CD70; ACTIVATION	Immune checkpoint inhibitor therapies and allogeneic hematopoietic cell transplant (alloHCT) represent two distinct modalities that offer a chance for long-term cure in a diverse array of malignancies and have experienced many breakthroughs in recent years. Herein, we review the CD27-CD70 co-stimulatory pathway and its therapeutic potential in 1) combination with checkpoint inhibitor and other immune therapies and 2) its potential ability to serve as a novel approach in graft-versus-host disease (GVHD) prevention. We further review recent advances in the understanding of GVHD as a complex immune phenomenon between donor and host immune systems, particularly in the early stages with mixed chimerism, and potential novel therapeutic approaches to prevent the development of GVHD.	[Lutfi, Forat] Univ Maryland Med Ctr, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD USA; [Wu, Long; Cao, Xuefang] Univ Maryland Baltimore, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA; [Sunshine, Sarah] Univ Maryland Med Ctr, Dept Ophthalmol & Visual Sci, Marlene & Stewart Greenebaum Comprehens Canc, Baltimore, MD USA; [Cao, Xuefang] Univ Maryland Baltimore, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Cao, XF (corresponding author), Univ Maryland Baltimore, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA.; Cao, XF (corresponding author), Univ Maryland Baltimore, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.	XuefangCao@som.umaryland.edu			University of Maryland School of Medicine, Oncology Fellow Research Grant;  [5T32CA154274-10];  [R01HL135325]	University of Maryland School of Medicine, Oncology Fellow Research Grant; ; 	Funding 5T32CA154274-10, University of Maryland School of Medicine, Oncology Fellow Research Grant (FL), R01HL135325 (XC).	Ahrends T, 2016, CANCER RES, V76, P2921, DOI 10.1158/0008-5472.CAN-15-3130; [Anonymous], 2011, STUDY CDX 1127 VARLI; Ansell SM, 2020, BLOOD ADV, V4, P1917, DOI 10.1182/bloodadvances.2019001079; Auffermann-Gretzinger S, 2002, BLOOD, V99, P1442, DOI 10.1182/blood.V99.4.1442; Baudard M, 2002, BONE MARROW TRANSPL, V30, P287, DOI 10.1038/sj.bmt.1703633; Boursalian TE, 2009, ADV EXP MED BIOL, V647, P108, DOI 10.1007/978-0-387-89520-8_7; Buchan SL, 2018, CLIN CANCER RES, V24, P2383, DOI 10.1158/1078-0432.CCR-17-3057; Catakovic K, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-016-0160-z; Ciomber A, 2016, EXP HEMATOL, V44, P1172, DOI 10.1016/j.exphem.2016.08.001; Cooke KR, 2017, BIOL BLOOD MARROW TR, V23, P211, DOI 10.1016/j.bbmt.2016.09.023; Croker BA, 2015, CURR OPIN HEMATOL, V22, P293, DOI 10.1097/MOH.0000000000000148; Denoeud J, 2011, J LEUKOCYTE BIOL, V89, P195, DOI 10.1189/jlb.0610351; Dong H, 2019, J LEUKOCYTE BIOL, V106, P1007, DOI 10.1002/JLB.1HI0219-064R; Duffner UA, 2004, J IMMUNOL, V172, P7393, DOI 10.4049/jimmunol.172.12.7393; EI-Jawahri A, 2016, BIOL BLOOD MARROW TR, V22, P910, DOI 10.1016/j.bbmt.2015.12.024; Erlacher M, 2015, FRONT PEDIATR, V3, DOI 10.3389/fped.2015.00064; Ghosh S, 2020, BLOOD, V136, P2638, DOI 10.1182/blood.2020006738; Gomez VE, 2020, BONE MARROW TRANSPL, V55, P641, DOI 10.1038/s41409-019-0731-x; Haslam A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2535; Hatano R, 2013, BRIT J HAEMATOL, V162, P263, DOI 10.1111/bjh.12378; Hatano R, 2013, IMMUNOLOGY, V138, P165, DOI 10.1111/imm.12028; Hendricks J, 2003, J EXP MED, V198, P1369, DOI 10.1084/jem.20030916; HINTZEN RQ, 1991, J NEUROIMMUNOL, V35, P211, DOI 10.1016/0165-5728(91)90175-7; Holtan SG, 2014, BLOOD, V124, P363, DOI 10.1182/blood-2014-01-514786; HOROWITZ MM, 1990, BLOOD, V75, P555; Inamoto Y, 2019, BONE MARROW TRANSPL, V54, P662, DOI 10.1038/s41409-018-0340-0; Jacobs J, 2015, PHARMACOL THERAPEUT, V155, P1, DOI 10.1016/j.pharmthera.2015.07.007; Jacobson P, 1998, BONE MARROW TRANSPL, V22, P217, DOI 10.1038/sj.bmt.1701331; Jain MD, 2018, THER CLIN RISK MANAG, V14, P1007, DOI 10.2147/TCRM.S145039; Jardine L, 2020, J CLIN INVEST, V130, P4574, DOI 10.1172/JCI133909; KEYTRUDA HIGHLIGHTS OF PRESCRIBING INFORMATION, 2014, FDA PACK INS; Koyama M, 2016, BLOOD, V127, P2963, DOI 10.1182/blood-2016-02-697250; Kuka M, 2013, J IMMUNOL, V191, P2282, DOI 10.4049/jimmunol.1300868; Kuruvilla J, 2020, J CLIN ONCOL, V38; Leigh ND, 2017, J IMMUNOL, V199, P336, DOI 10.4049/jimmunol.1502181; Lim SH, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2996-6; Linz BM, 2016, J IMMUNOL, V196; Mak TW, 2006, IMMUNE RESPONSE: BASIC AND CLINICAL PRINCIPLES, P373, DOI 10.1016/B978-012088451-3/50016-8; Martin PJ, 2021, NEW ENGL J MED, V384, P70, DOI 10.1056/NEJMe2032581; MAURER D, 1990, EUR J IMMUNOL, V20, P2679, DOI 10.1002/eji.1830201223; Mir MA., 2015, DEVELOPING COSTIMULA, P185, DOI [10.1016/B978-0-12-802585-7.00005-4, DOI 10.1016/B978-0-12-802585-7.00005-4]; Nachbaur D, 2003, BRIT J HAEMATOL, V123, P119, DOI 10.1046/j.1365-2141.2003.04588.x; Nandi D, 2020, J BIOSCIENCES, V45, DOI 10.1007/s12038-020-0020-2; Nolte MA, 2005, NAT IMMUNOL, V6, P412, DOI 10.1038/ni1174; O'Donnell PV, 2002, BIOL BLOOD MARROW TR, V8, P377, DOI 10.1053/bbmt.2002.v8.pm12171484; O'Neill RE, 2017, J IMMUNOL, V199, P3700, DOI 10.4049/jimmunol.1700380; Ott PA, 2019, CANCER-AM CANCER SOC, V125, P1113, DOI 10.1002/cncr.31892; Peperzak V, 2013, J IMMUNOL, V191, P3025, DOI 10.4049/jimmunol.1202222; Pucella JN, 2020, ANNU REV CELL DEV BI, V36, P529, DOI 10.1146/annurev-cellbio-020520-114601; Ramakrishna V, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0080-2; Reardon D, 2018, NEURO-ONCOLOGY, V20, P6; Remedios KA, 2019, J IMMUNOL, V203, P639, DOI 10.4049/jimmunol.1900288; Ribot JC, 2009, NAT IMMUNOL, V10, P427, DOI 10.1038/ni.1717; Riccione KA, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1502904; Ronchetti S, 2012, SCI WORLD J, DOI 10.1100/2012/308265; Saada JI, 2006, J IMMUNOL, V177, P5968, DOI 10.4049/jimmunol.177.9.5968; Sanborn RE, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.3001; Sanborn RE, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3007; Saraceni F, 2018, AM J HEMATOL, V93, P1211, DOI 10.1002/ajh.25225; Schildknecht A, 2007, EUR J IMMUNOL, V37, P716, DOI 10.1002/eji.200636824; Shimoni A, 2011, BEST PRACT RES CL HA, V24, P369, DOI 10.1016/j.beha.2011.05.002; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; Starzer Angelika M, 2020, ESMO Open, V4, pe000629, DOI 10.1136/esmoopen-2019-000629; Takeda K, 2000, J IMMUNOL, V164, P1741, DOI 10.4049/jimmunol.164.4.1741; Tauro S, 2005, J CLIN ONCOL, V23, P9387, DOI 10.1200/JCO.2005.02.0057; Tesi RJ, 2019, TRENDS PHARMACOL SCI, V40, P4, DOI 10.1016/j.tips.2018.10.008; Thiemann M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00387; Tian C, 2016, ANN HEMATOL, V95, P543, DOI 10.1007/s00277-016-2608-z; Turaj AH, 2017, CANCER CELL, V32, P777, DOI 10.1016/j.ccell.2017.11.001; van Montfrans JM, 2012, J ALLERGY CLIN IMMUN, V129, P787, DOI 10.1016/j.jaci.2011.11.013; van Nieuwenhuijze A, 2015, PROG MOL BIOL TRANSL, V136, P69, DOI 10.1016/bs.pmbts.2015.09.001; Villasboas JC, 2019, J CLIN ONCOL, V37; Vitale LA, 2020, CANCER IMMUNOL IMMUN, V69, P2125, DOI 10.1007/s00262-020-02610-y; Wasiuk A, 2017, J IMMUNOL, V199, P4110, DOI 10.4049/jimmunol.1700606; Webster R, 2014, NAT REV DRUG DISCOV, V13, P883, DOI 10.1038/nrd4476; Weinkove R, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1049; Wiesmann A, 2000, IMMUNITY, V12, P193, DOI 10.1016/S1074-7613(00)80172-7; Zeiser R, 2020, NEW ENGL J MED, V382, P1800, DOI 10.1056/NEJMoa1917635; Zhang Y, 2002, J CLIN INVEST, V109, P1335, DOI 10.1172/JCI200214989	79	1	1	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 22	2021	12								715909	10.3389/fimmu.2021.715909	http://dx.doi.org/10.3389/fimmu.2021.715909			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WC2UZ	34630390	gold, Green Published			2022-12-18	WOS:000704118100001
J	Sherwood, KR; Nicholl, DDM; Fenninger, F; Wu, V; Wong, P; Benedicto, V; Cina, DP; Wang, M; Pobran, TD; De Marco, ML; Marquez, AC; Jassem, AN; Sekirov, I; Morshed, MG; Bardi, M; Sekhon, M; Keown, P; Kadatz, M; Lan, JH				Sherwood, Karen R.; Nicholl, David D. M.; Fenninger, Franz; Wu, Vivian; Wong, Paaksum; Benedicto, Vince; Cina, Davide P.; Wang, Meng; Pobran, Taylor D.; De Marco, Mari L.; Marquez, Anna Citlali; Jassem, Agatha N.; Sekirov, Inna; Morshed, Muhammad G.; Bardi, Mohammad; Sekhon, Mypinder; Keown, Paul; Kadatz, Matthew; Lan, James H.			Comprehensive Immune Profiling of a Kidney Transplant Recipient With Peri-Operative SARS-CoV-2 Infection: A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; transplant; induction therapy; immunosuppressants; immune response	COVID-19	To date there is limited data on the immune profile and outcomes of solid organ transplant recipients who encounter COVID-19 infection early post-transplant. Here we present a unique case where the kidney recipient's transplant surgery coincided with a positive SARS-CoV-2 test and the patient subsequently developed symptomatic COVID-19 perioperatively. We performed comprehensive immunological monitoring of cellular, proteomic, and serological changes during the first 4 critical months post-infection. We showed that continuation of basiliximab induction and maintenance of triple immunosuppression did not significantly impair the host's ability to mount a robust immune response against symptomatic COVID-19 infection diagnosed within the first week post-transplant.</p>	[Sherwood, Karen R.; Wu, Vivian; Wong, Paaksum; Benedicto, Vince; Bardi, Mohammad; Sekhon, Mypinder; Keown, Paul; Kadatz, Matthew; Lan, James H.] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Sherwood, Karen R.; Wang, Meng; Pobran, Taylor D.; De Marco, Mari L.; Morshed, Muhammad G.; Keown, Paul; Lan, James H.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Nicholl, David D. M.; Kadatz, Matthew; Lan, James H.] Univ British Columbia, Div Nephrol, Vancouver, BC, Canada; [Benedicto, Vince] Univ British Columbia, British Columbia Prov Immunol Lab, Vancouver, BC, Canada; [Cina, Davide P.] Univ British Columbia, British Columbia Prov Immunol Lab, Vancouver, BC, Canada; [De Marco, Mari L.] Providence Hlth Care, Dept Pathol & Lab Med, Providence, BC, Canada; [Marquez, Anna Citlali; Jassem, Agatha N.; Sekirov, Inna; Morshed, Muhammad G.] British Columbia Ctr, Dis Control Publ Hlth Lab, Prov Hlth Serv Author, Vancouver, BC, Canada; [Bardi, Mohammad] Univ British Columbia, Div Rheumatol, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Sherwood, KR (corresponding author), Univ British Columbia, Dept Med, Vancouver, BC, Canada.; Sherwood, KR (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada.	Karen.sherwood@vch.ca	Lan, James/ABB-7521-2021		Vancouver Coastal Health Research Institute 2020 COVID-19 Research fund; Michael Smith Foundation for Health Research [16353, 2020-1199]; Canadian Foundation for Innovation [40962]	Vancouver Coastal Health Research Institute 2020 COVID-19 Research fund; Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); Canadian Foundation for Innovation(Canada Foundation for Innovation)	This work was supported by funding to JHL from the Vancouver Coastal Health Research Institute 2020 COVID-19 Research fund, and to MLD from the Michael Smith Foundation for Health Research (16353; 2020-1199) and the Canadian Foundation for Innovation (40962).	Benotmane I, 2020, AM J TRANSPLANT, V20, P3162, DOI 10.1111/ajt.16251; Biancotto A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076091; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763; Ma H, 2020, CELL MOL IMMUNOL, V17, P773, DOI 10.1038/s41423-020-0474-z; Masia M, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab005; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Minervina AA, 2021, ELIFE, V10, DOI 10.7554/eLife.63502; Mudd PA, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abe3024; NasrAllah MM, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2149; Novick D, 2001, CYTOKINE, V14, P334, DOI 10.1006/cyto.2001.0914; Rammohan Ashwin, 2020, World J Transplant, V10, P267, DOI 10.5500/wjt.v10.i9.267; Rytlewski J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213684; Schultheiss C, 2020, IMMUNITY, V53, P442, DOI 10.1016/j.immuni.2020.06.024; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9	20	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 22	2021	12								753558	10.3389/fimmu.2021.753558	http://dx.doi.org/10.3389/fimmu.2021.753558			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WB9YZ	34630432	gold, Green Published			2022-12-18	WOS:000703922400001
J	Dainichi, T; Kabashima, K; Ivanov, III; Goto, Y				Dainichi, Teruki; Kabashima, Kenji; Ivanov, Ivaylo I. I.; Goto, Yoshiyuki			Editorial: Regulation of Immunity by Non-Immune Cells	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						nonimmune cell; mucosal tissue; skin; fat; stroma; joints; blood vessels			[Dainichi, Teruki] Kagawa Univ, Dept Dermatol, Fac Med, Miki, Kagawa, Japan; [Kabashima, Kenji] Kyoto Univ, Dept Dermatol, Grad Sch Med, Kyoto, Japan; [Kabashima, Kenji] Singapore Immunol Network SIgN, Singapore, Singapore; [Kabashima, Kenji] ASTAR, Skin Res Inst Singapore SRIS, Biopolis, Singapore, Singapore; [Ivanov, Ivaylo I. I.] Columbia Univ, Vagelos Coll Phys & Surg, Dept Microbiol & Immunol, New York, NY USA; [Goto, Yoshiyuki] Chiba Univ, Med Mycol Res Ctr, Div Mol Immunol, Chiba, Japan; [Goto, Yoshiyuki] Univ Tokyo, Inst Med Sci, Int Res & Dev Ctr Mucosal Vaccines, Div Mucosal Symbiosis, Tokyo, Japan	Kagawa University; Kyoto University; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); Agency for Science Technology & Research (A*STAR); Columbia University; Chiba University; University of Tokyo	Dainichi, T (corresponding author), Kagawa Univ, Dept Dermatol, Fac Med, Miki, Kagawa, Japan.; Goto, Y (corresponding author), Chiba Univ, Med Mycol Res Ctr, Div Mol Immunol, Chiba, Japan.; Goto, Y (corresponding author), Univ Tokyo, Inst Med Sci, Int Res & Dev Ctr Mucosal Vaccines, Div Mucosal Symbiosis, Tokyo, Japan.	dainichi.teruki@kagawa-u.ac.jp; y-gotoh@chiba-u.jp							0	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 21	2021	12								770847	10.3389/fimmu.2021.770847	http://dx.doi.org/10.3389/fimmu.2021.770847			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WB4BF	34621281	Green Published, gold			2022-12-18	WOS:000703518500001
J	Ding, F; Luo, X; Tu, YT; Duan, XL; Liu, J; Jia, LJ; Zheng, PL				Ding, Fei; Luo, Xi; Tu, Yiting; Duan, Xianlan; Liu, Jia; Jia, Lijing; Zheng, Peilin			Alpk1 Sensitizes Pancreatic Beta Cells to Cytokine-Induced Apoptosis via Upregulating TNF-a Signaling Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						Alpk1; pancreatic beta cells; apoptosis; pro-inflammatory cytokines; TNF-alpha signaling	ALPHA-KINASE; GENE-EXPRESSION; TLR9 DEFICIENCY; T-CELLS; ACTIVATION; INFLAMMATION; RECEPTORS; INSULITIS	Pancreatic beta cell failure is the hallmark of type 1 diabetes (T1D). Recent studies have suggested that pathogen recognizing receptors (PRRs) are involved in the survival, proliferation and function of pancreatic beta cells. So far, little is known about the role of alpha-protein kinase 1 (ALPK1), a newly identified cytosolic PRR specific for ADP-beta-D-manno-heptose (ADP-heptose), in beta cell survival. In current study we aimed to fill the knowledge gap by investigating the role of Alpk1 in the apoptosis of MIN6 cells, a murine pancreatic beta cell line. We found that the expression of Alpk1 was significantly elevated in MIN6 cells exposed to pro-inflammatory cytokines, but not to streptozotocin, low-dose or high-dose glucose. Activation of Alpk1 by ADP heptose alone was insufficient to induce beta cell apoptosis. However, it significantly exacerbated cytokine-induced apoptosis in MIN6 cells. Mechanistic investigations showed that Alpk1 activation was potent to further induce the expression of tumor necrosis factor (TNF)-alpha and Fas after cytokine stimulation, possibly due to enhanced activation of the TIFA/TAK1/NF-kappa B signaling axis. Treatment of GLP-1 receptor agonist decreased the expression of TNF-alpha and Fas and improved the survival of beta cells exposed to pro-inflammatory cytokines and ADP heptose. In summary, our data suggest that Alpk1 sensitizes beta cells to cytokine-induced apoptosis by potentiating TNF-alpha signaling pathway, which may provide novel insight into beta cell failure and T1D development.	[Ding, Fei; Luo, Xi; Duan, Xianlan; Jia, Lijing; Zheng, Peilin] Southern Univ Sci & Technol, Jinan Univ, Affiliated Hosp 1, Clin Med Coll 2,Dept Endocrinol,Shenzhen Peoples, Shenzhen, Peoples R China; [Tu, Yiting] Fourth Peoples Hosp Shenzhen, Shenzhen Samii Int Med Ctr, Dept Neurol, Shenzhen, Peoples R China; [Liu, Jia] Southern Univ Sci & Technol, Sch Med, Shenzhen, Peoples R China	Jinan University; Southern University of Science & Technology; Southern University of Science & Technology	Jia, LJ; Zheng, PL (corresponding author), Southern Univ Sci & Technol, Jinan Univ, Affiliated Hosp 1, Clin Med Coll 2,Dept Endocrinol,Shenzhen Peoples, Shenzhen, Peoples R China.	jialijing2012@126.com; plzheng83@163.com			Natural science foundation of Hunan province [2019JJ30036]; Natural science foundation of Guangdong province [2020A1515010085]; Shenzhen Municipal Science and Technology Innovation Committee Project [JCYJ20190807150619047]	Natural science foundation of Hunan province(Natural Science Foundation of Hunan Province); Natural science foundation of Guangdong province(National Natural Science Foundation of Guangdong Province); Shenzhen Municipal Science and Technology Innovation Committee Project	This work was funded by the Natural science foundation of Hunan province (2019JJ30036), Natural science foundation of Guangdong province (2020A1515010085), Shenzhen Municipal Science and Technology Innovation Committee Project (JCYJ20190807150619047).	Amyot J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036200; Atkinson MA, 2019, LANCET DIABETES ENDO, V7, P52, DOI 10.1016/S2213-8587(18)30112-8; Bluestone JA, 2010, NATURE, V464, P1293, DOI 10.1038/nature08933; Bosi E, 2006, DIABETOLOGIA, V49, P2824, DOI 10.1007/s00125-006-0465-3; Costa FRC, 2016, J EXP MED, V213, P1223, DOI 10.1084/jem.20150744; Dogusan Z, 2008, DIABETES, V57, P1236, DOI 10.2337/db07-0844; Donath MY, 2008, ENDOCR REV, V29, P334, DOI 10.1210/er.2007-0033; Eizirik DL, 2009, NAT REV ENDOCRINOL, V5, P219, DOI 10.1038/nrendo.2009.21; Fields JK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01412; Garay-Malpartida HM, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-18; Giarratana N, 2004, J IMMUNOL, V173, P2280, DOI 10.4049/jimmunol.173.4.2280; He W, 2019, BBA-MOL BASIS DIS, V1865, P86, DOI 10.1016/j.bbadis.2018.09.030; Hotamisligil GS, 2017, NATURE, V542, P177, DOI 10.1038/nature21363; Hu XY, 2019, CARBOHYD RES, V473, P123, DOI 10.1016/j.carres.2018.12.011; Huang CCF, 2012, MOL CELL BIOL, V32, P2664, DOI 10.1128/MCB.00438-12; Huang J, 2021, CELL MOL IMMUNOL, V18, P328, DOI 10.1038/s41423-020-00590-8; Kuo TM, 2016, BBA-MOL BASIS DIS, V1862, P2034, DOI 10.1016/j.bbadis.2016.08.010; Larsen L, 2005, DIABETOLOGIA, V48, P2582, DOI 10.1007/s00125-005-0039-9; Lee CP, 2019, J CELL MOL MED, V23, P7699, DOI 10.1111/jcmm.14643; Li ZX, 2019, FASEB J, V33, P8241, DOI 10.1096/fj.201900146R; LIKE AA, 1976, SCIENCE, V193, P415, DOI 10.1126/science.180605; Liu MJ, 2018, DIABETOLOGIA, V61, P2333, DOI 10.1007/s00125-018-4705-0; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Milivojevic M, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006224; Roggli E, 2010, DIABETES, V59, P978, DOI 10.2337/db09-0881; Saltiel AR, 2017, J CLIN INVEST, V127, P1, DOI [10.1172/JCI92035, 10.1172/jci92035]; Sha S, 2021, DIABETES, V70, P504, DOI 10.2337/db20-0373; Shimokata S, 2013, BIOMED REP, V1, P940, DOI 10.3892/br.2013.173; Sorini C, 2019, P NATL ACAD SCI USA, V116, P15140, DOI 10.1073/pnas.1814558116; Suk K, 2001, J IMMUNOL, V166, P4481, DOI 10.4049/jimmunol.166.7.4481; Tai NW, 2016, J EXP MED, V213, P2129, DOI 10.1084/jem.20160526; Tai NW, 2013, J IMMUNOL, V191, P2926, DOI 10.4049/jimmunol.1300547; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang SJ, 2011, J MOL MED, V89, P1241, DOI 10.1007/s00109-011-0796-5; Wen L, 2004, J IMMUNOL, V172, P3173, DOI 10.4049/jimmunol.172.5.3173; WILSON GL, 1990, CURR TOP MICROBIOL, V156, P27; Yamada Y, 2015, BIOMED REP, V3, P347, DOI 10.3892/br.2015.439; Yusta B, 2006, CELL METAB, V4, P391, DOI 10.1016/j.cmet.2006.10.001; Zhang YQ, 2010, J IMMUNOL, V184, P5645, DOI 10.4049/jimmunol.0901814; Zheng PL, 2018, DIABETES-METAB RES, V34, DOI 10.1002/dmrr.3043; Zhou P, 2018, NATURE, V561, P122, DOI 10.1038/s41586-018-0433-3; Zimmermann S, 2017, CELL REP, V20, P2384, DOI 10.1016/j.celrep.2017.08.039	43	1	1	7	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 21	2021	12								705751	10.3389/fimmu.2021.705751	http://dx.doi.org/10.3389/fimmu.2021.705751			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WB4EK	34621265	gold, Green Published			2022-12-18	WOS:000703526800001
J	Nogueira, OC; Gandini, M; Cabral, N; de Figueiredo, V; Rodrigues-da-Silva, RN; Lima, JD; Pinheiro, RO; Pereira, GMB; Pessolani, MCV; de Macedo, CS				Nogueira, Otto Castro; Gandini, Mariana; Cabral, Natasha; de Figueiredo, Vilma; Rodrigues-da-Silva, Rodrigo Nunes; Lima-Junior, Josue da Costa; Pinheiro, Roberta Olmo; Batista Pereira, Geraldo Moura; Vidal Pessolani, Maria Cristina; de Macedo, Cristiana Santos			Changes in B Cell Pool of Patients With Multibacillary Leprosy: Diminished Memory B Cell and Enhanced Mature B in Peripheral Blood	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacterium leprae; B lymphocytes; B cell differentiation; active immune response; erythema nodosum leprosum	NERVE INJURY; ANTIBODY; DIFFERENTIATION; PROLIFERATION; COMPLEMENT; ACTIVATION; RESPONSES; IMMUNITY	Despite being treatable, leprosy still represents a major public health problem, and many mechanisms that drive leprosy immunopathogenesis still need to be elucidated. B cells play important roles in immune defense, being classified in different subgroups that present distinct roles in the immune response. Here, the profile of B cell subpopulations in peripheral blood of patients with paucibacillary (TT/BT), multibacillary (LL/BL) and erythema nodosum leprosum was analyzed. B cell subpopulations (memory, transition, plasmablasts, and mature B cells) and levels of IgG were analyzed by flow cytometry and ELISA, respectively. It was observed that Mycobacterium leprae infection can alter the proportions of B cell subpopulations (increase of mature and decrease of memory B cells) in patients affected by leprosy. This modulation is associated with an increase in total IgG and the patient's clinical condition. Circulating B cells may be acting in the modulation of the immune response in patients with various forms of leprosy, which may reflect the patient's ability to respond to M. leprae.	[Nogueira, Otto Castro; Gandini, Mariana; Cabral, Natasha; de Figueiredo, Vilma; Batista Pereira, Geraldo Moura; Vidal Pessolani, Maria Cristina; de Macedo, Cristiana Santos] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Cellular Microbiol Lab, Rio De Janeiro, Brazil; [Rodrigues-da-Silva, Rodrigo Nunes; Lima-Junior, Josue da Costa] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Immunoparasitol Lab, Rio De Janeiro, Brazil; [Pinheiro, Roberta Olmo] Fundacao Oswaldo Cruz, Leprosy Lab, Oswaldo Cruz Inst, Rio De Janeiro, Brazil; [de Macedo, Cristiana Santos] Fundacao Oswaldo Cruz, Ctr Technol Dev Hlth, Rio De Janeiro, Brazil	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Center for Technological Development in Health (CDTS); Fundacao Oswaldo Cruz	de Macedo, CS (corresponding author), Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Cellular Microbiol Lab, Rio De Janeiro, Brazil.; de Macedo, CS (corresponding author), Fundacao Oswaldo Cruz, Ctr Technol Dev Hlth, Rio De Janeiro, Brazil.	cristiana.macedo@cdts.fiocruz.br	; Pinheiro, Roberta/A-2525-2013	Gandini, Mariana/0000-0003-3603-6921; Pinheiro, Roberta/0000-0001-8471-4227	The New York Community Trust/Heiser Program for Research on Leprosy; The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIAID/NIH) [RO1AI129835]	The New York Community Trust/Heiser Program for Research on Leprosy; The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIAID/NIH)	This work was supported by The New York Community Trust/Heiser Program for Research on Leprosy and The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIAID/NIH) under the award number RO1AI129835.	Amorim FM, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007089; Bemark M, 2015, J BIOMED RES, V29, P264, DOI 10.7555/JBR.29.20150035; Biswas D, 2021, AM J DERMATOPATH, V43, P700, DOI 10.1097/DAD.0000000000001860; Bonomo L, 1969, Int J Lepr Other Mycobact Dis, V37, P280; Capolunghi F, 2008, J IMMUNOL, V180, P800, DOI 10.4049/jimmunol.180.2.800; Carsetti R, 2005, J ALLERGY CLIN IMMUN, V115, P412, DOI 10.1016/j.jaci.2004.10.048; CHO SN, 1991, INT J LEPROSY, V59, P25; Crowley JE, 2008, IMMUNOL RES, V42, P75, DOI 10.1007/s12026-008-8036-y; Das A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016524; Daumerie D, 2002, ELIMINATION LEPROSY; de Macedo CS, 2015, J MASS SPECTROM, V50, P1374, DOI 10.1002/jms.3708; de Macedo Cristiana Santos, 2020, F1000Res, V9, DOI 10.12688/f1000research.21383.1; DeFranco AL, 2012, IMMUNOL REV, V247, P64, DOI 10.1111/j.1600-065X.2012.01115.x; Dias AA, 2016, J IMMUNOL, V197, P1905, DOI 10.4049/jimmunol.1600042; Dorner M, 2009, IMMUNOLOGY, V128, P573, DOI 10.1111/j.1365-2567.2009.03143.x; DRUTZ DJ, 1972, NEW ENGL J MED, V287, P159, DOI 10.1056/NEJM197207272870402; Duppre NC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001711; Dupnik KM, 2015, J INFECT DIS, V211, P1658, DOI 10.1093/infdis/jiu612; Duthie MS, 2011, EUR J CLIN MICROBIOL, V30, P1257, DOI 10.1007/s10096-011-1221-2; Fabel A, 2019, AM J DERMATOPATH, V41, P422, DOI 10.1097/DAD.0000000000001310; Freeman SA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7168; Gomes GI, 2008, AM J TROP MED HYG, V78, P605, DOI 10.4269/ajtmh.2008.78.605; Hacker MA, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81643-4; Huggins J, 2007, BLOOD, V109, P1611, DOI 10.1182/blood-2006-03-008441; Iyer AM, 2007, HUM PATHOL, V38, P1065, DOI 10.1016/j.humpath.2006.12.017; JHA P, 1971, International Journal of Leprosy and Other Mycobacterial Diseases, V39, P14; Kotb A, 2019, J INFECT PUBLIC HEAL, V12, P656, DOI 10.1016/j.jiph.2019.03.001; Lahiri R, 2008, LEPROSY REV, V79, P311; Liu AQ, 2008, BLOOD, V111, P2693, DOI 10.1182/blood-2007-08-102319; MABALAY M C, 1965, Int J Lepr, V33, P28; Matos AD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02230; Moura DF, 2012, EUR J IMMUNOL, V42, P2925, DOI 10.1002/eji.201142198; Murn J, 2008, J EXP MED, V205, P3091, DOI 10.1084/jem.20081163; Negera E, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006121; Palm AKE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01787; Polycarpou A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00233; Portugal S, 2017, CELL IMMUNOL, V321, P18, DOI 10.1016/j.cellimm.2017.07.003; Portugal S, 2015, ELIFE, V4, DOI 10.7554/eLife.07218; Ramon S, 2014, EUR J IMMUNOL, V44, P357, DOI 10.1002/eji.201343316; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; Sakurai I, 1970, Int J Lepr Other Mycobact Dis, V38, P389; Schmitz V, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00495; Scollard DM, 2015, CLIN DERMATOL, V33, P46, DOI 10.1016/j.clindermatol.2014.07.008; Scollard DM, 2008, LEPROSY REV, V79, P242; Scollard DM, 2006, CLIN MICROBIOL REV, V19, P338, DOI 10.1128/CMR.19.2.338-381.2006; Silva CAM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00134; Simon Q, 2016, J ALLERGY CLIN IMMUN, V137, P1577, DOI 10.1016/j.jaci.2015.09.014; Spencer JS, 2011, LEPROSY REV, V82, P344; Sutton HJ, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108684; Tarique M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01636; Cardoso LPV, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-497; Vieira Leila M. M., 1996, Revista do Instituto de Medicina Tropical de Sao Paulo, V38, P103, DOI 10.1590/S0036-46651996000200004; WHO, 1982, CHEM LEPR CONTR PROG; World Health Organization, 2020, ORG MOND S WEEKL EP, V95, P36	54	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 21	2021	12								727580	10.3389/fimmu.2021.727580	http://dx.doi.org/10.3389/fimmu.2021.727580			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WB4PU	34621273	Green Published, gold			2022-12-18	WOS:000703556400001
J	Rivas, MA; Durmaz, C; Kloetgen, A; Chin, CR; Chen, ZM; Bhinder, B; Koren, A; Viny, AD; Scharer, CD; Boss, JM; Elemento, O; Mason, CE; Melnick, AM				Rivas, Martin A.; Durmaz, Ceyda; Kloetgen, Andreas; Chin, Cristopher R.; Chen, Zhengming; Bhinder, Bhavneet; Koren, Amnon; Viny, Aaron D.; Scharer, Christopher D.; Boss, Jeremy M.; Elemento, Olivier; Mason, Christopher E.; Melnick, Ari M.			Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes	FRONTIERS IN IMMUNOLOGY			English	Article						cohesin; lymphoma; B-cell; chromosomal architecture; Hi-C; Tet2 gene; GCB-subtype DLBCL	B-CELL LYMPHOMA; CHROMATID COHESION; BLADDER-CANCER; HUMAN GENOME; EXPRESSION; INACTIVATION; MUTATIONS; PROGRAM; ORIGIN; STAG2	The cohesin complex plays critical roles in genomic stability and gene expression through effects on 3D architecture. Cohesin core subunit genes are mutated across a wide cross-section of cancers, but not in germinal center (GC) derived lymphomas. In spite of this, haploinsufficiency of cohesin ATPase subunit Smc3 was shown to contribute to malignant transformation of GC B-cells in mice. Herein we explored potential mechanisms and clinical relevance of Smc3 deficiency in GC lymphomagenesis. Transcriptional profiling of Smc3 haploinsufficient murine lymphomas revealed downregulation of genes repressed by loss of epigenetic tumor suppressors Tet2 and Kmt2d. Profiling 3D chromosomal interactions in lymphomas revealed impaired enhancer-promoter interactions affecting genes like Tet2, which was aberrantly downregulated in Smc3 deficient lymphomas. Tet2 plays important roles in B-cell exit from the GC reaction, and single cell RNA-seq profiles and phenotypic trajectory analysis in Smc3 mutant mice revealed a specific defect in commitment to the final steps of plasma cell differentiation. Although Smc3 deficiency resulted in structural abnormalities in GC B-cells, there was no increase of somatic mutations or structural variants in Smc3 haploinsufficient lymphomas, suggesting that cohesin deficiency largely induces lymphomas through disruption of enhancer-promoter interactions of terminal differentiation and tumor suppressor genes. Strikingly, the presence of the Smc3 haploinsufficient GC B-cell transcriptional signature in human patients with GC-derived diffuse large B-cell lymphoma (DLBCL) was linked to inferior clinical outcome and low expression of cohesin core subunits. Reciprocally, reduced expression of cohesin subunits was an independent risk factor for worse survival int DLBCL patient cohorts. Collectively, the data suggest that Smc3 functions as a bona fide tumor suppressor for lymphomas through non-genetic mechanisms, and drives disease by disrupting the commitment of GC B-cells to the plasma cell fate.</p>	[Rivas, Martin A.; Melnick, Ari M.] Weill Cornell Med, Div Hematol & Med Oncol, Dept Med, New York, NY 10065 USA; [Durmaz, Ceyda] Weill Cornell Med, Grad Program Physiol Biophys & Syst Biol, New York, NY USA; [Kloetgen, Andreas] Helmholtz Ctr Infect Res, Dept Computat Biol Infect Res, Braunschweig, Germany; [Chin, Cristopher R.; Bhinder, Bhavneet; Elemento, Olivier; Mason, Christopher E.] Weill Cornell Med, Dept Physiol & Biophys, New York, NY USA; [Chin, Cristopher R.; Bhinder, Bhavneet; Elemento, Olivier; Mason, Christopher E.] Weill Cornell Med, HRH Prince Alwaleed Bin Talal Bin Abdulaziz Al Sa, New York, NY USA; [Chen, Zhengming] Weill Cornell Med Coll, Dept Populat Hlth Sci, Div Biostat & Epidemiol, New York, NY USA; [Bhinder, Bhavneet; Elemento, Olivier] Weill Cornell Med, Caryl & Israel Englander Inst Precis Med, New York, NY USA; [Koren, Amnon] Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY USA; [Viny, Aaron D.] Columbia Univ, Dept Med, Div Hematol Oncol, Irving Med Ctr, New York, NY USA; [Viny, Aaron D.] Columbia Univ, Dept Genet & Dev, Columbia Stem Cell Initiat, New York, NY USA; [Scharer, Christopher D.; Boss, Jeremy M.] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; [Mason, Christopher E.] Weill Cornell Med, WorldQuant Initiat Quantitat Predict, New York, NY USA; [Mason, Christopher E.] Weill Cornell Med, Feil Family Brain & Mind Res Inst, New York, NY USA	Cornell University; Cornell University; Helmholtz Association; Helmholtz-Center for Infection Research; Cornell University; Cornell University; Cornell University; Cornell University; Cornell University; Columbia University; NewYork-Presbyterian Hospital; Columbia University; Emory University; Cornell University; Cornell University	Rivas, MA; Melnick, AM (corresponding author), Weill Cornell Med, Div Hematol & Med Oncol, Dept Med, New York, NY 10065 USA.	mar2091@med.cornell.edu; amm2014@med.cornell.edu	Mason, Christopher/HCH-3977-2022	Rivas, Martin/0000-0002-9603-6897	Lymphoma Research Foundation; NHLBI [5 T32 HL135465-3]; NCI/NIH [R35 CA220499, P01 CA229086-01A1]; LLS-SCOR [7012-16]; LLS-TRP [6572-19]; Samuel Waxman Cancer Research Foundation; Follicular Lymphoma Consortium; Chemotherapy Foundation; NCI [K08 CA215317]; William Raveis Charitable Fund Fellowship of the Damon Runyon Cancer Research Foundation [DRG 11715]; Evans MDS Young Investigator grant from the Edward P. Evans Foundation; WorldQuant Foundation; Pershing Square Sohn Cancer Research Alliance; NIH [R01 CA249054, R01 AI151059, P01 CA214274, R01 AI125416-03, R21 AI129851-02]; Leukemia and Lymphoma Society grants [LLS 9238-16, LLS MCL-982]; National Institutes of Health [DP2GM123495]	Lymphoma Research Foundation; NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); LLS-SCOR; LLS-TRP; Samuel Waxman Cancer Research Foundation; Follicular Lymphoma Consortium; Chemotherapy Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); William Raveis Charitable Fund Fellowship of the Damon Runyon Cancer Research Foundation; Evans MDS Young Investigator grant from the Edward P. Evans Foundation; WorldQuant Foundation; Pershing Square Sohn Cancer Research Alliance(Pershing Square Sohn Cancer Research Alliance); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society grants(Leukemia and Lymphoma Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	MR was a recipient of a postdoctoral fellowship grant from the Lymphoma Research Foundation and is funded by an NHLBI 5 T32 HL135465-3 training grant. AM is supported by NCI/NIH R35 CA220499, NCI/NIH P01 CA229086-01A1, LLS-SCOR 7012-16, LLS-TRP 6572-19, the Samuel Waxman Cancer Research Foundation, the Follicular Lymphoma Consortium and the Chemotherapy Foundation. AV is supported by NCI K08 CA215317, the William Raveis Charitable Fund Fellowship of the Damon Runyon Cancer Research Foundation (DRG 11715) and an Evans MDS Young Investigator grant from the Edward P. Evans Foundation. CM thanks the Scientific Computing Unit, XSEDE Supercomputing Resources as well as the Starr Cancer Consortium (I7-A765, I9-A9-071 and I130052) and acknowledges funding from the WorldQuant Foundation, The Pershing Square Sohn Cancer Research Alliance, the NIH (grants R01 CA249054, R01 AI151059, P01 CA214274, R01 AI125416-03 and R21 AI129851-02) and Leukemia and Lymphoma Society grants LLS 9238-16 and LLS MCL-982. AKo is supported by DP2GM123495 from the National Institutes of Health.	Agirre X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08679-z; Arnould C, 2021, NATURE, V590, DOI 10.1038/s41586-021-03193-z; Balbas-Martinez C, 2013, NAT GENET, V45, P1464, DOI 10.1038/ng.2799; Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105; BISHOP GA, 1986, P NATL ACAD SCI USA, V83, P7410, DOI 10.1073/pnas.83.19.7410; Bunting KL, 2016, IMMUNITY, V45, P497, DOI 10.1016/j.immuni.2016.08.012; Caron P, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002460; Casola S, 2006, P NATL ACAD SCI USA, V103, P7396, DOI 10.1073/pnas.0602353103; Cattoretti G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037; Davis CA, 2018, NUCLEIC ACIDS RES, V46, pD794, DOI 10.1093/nar/gkx1081; De Paepe P, 2007, LEUKEMIA, V21, P37, DOI 10.1038/sj.leu.2404449; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dominguez PM, 2018, CANCER DISCOV, V8, P1632, DOI 10.1158/2159-8290.CD-18-0657; Ersching J, 2017, IMMUNITY, V46, P1045, DOI 10.1016/j.immuni.2017.06.005; Ewels PA, 2020, NAT BIOTECHNOL, V38, P276, DOI 10.1038/s41587-020-0439-x; Froimchuk E, 2017, GENE, V627, P337, DOI 10.1016/j.gene.2017.06.056; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Hill VK, 2016, BBA-REV CANCER, V1866, P1, DOI 10.1016/j.bbcan.2016.05.002; Hummel M, 2006, NEW ENGL J MED, V354, P2419, DOI 10.1056/NEJMoa055351; Imakaev M, 2012, NAT METHODS, V9, P999, DOI [10.1038/NMETH.2148, 10.1038/nmeth.2148]; Isshiki Y, 2021, CURR CANCER DRUG TAR, V21, P274, DOI 10.2174/1568009620666210106122750; Jais JP, 2008, LEUKEMIA, V22, P1917, DOI 10.1038/leu.2008.188; Jiang YW, 2017, CANCER DISCOV, V7, P38, DOI 10.1158/2159-8290.CD-16-0975; Karube K, 2018, LEUKEMIA, V32, P675, DOI 10.1038/leu.2017.251; Koren A, 2021, BIOINFORMATICS, V37, P4001, DOI 10.1093/bioinformatics/btab166; Laidlaw BJ, 2017, J EXP MED, V214, P639, DOI 10.1084/jem.20161461; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lazaris C, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-016-3387-6; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Li B, 2010, BIOINFORMATICS, V26, P493, DOI 10.1093/bioinformatics/btp692; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Losada A, 2014, NAT REV CANCER, V14, P389, DOI 10.1038/nrc3743; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mazumdar C, 2015, CELL STEM CELL, V17, P1, DOI 10.1016/j.stem.2015.09.017; Merkenschlager M, 2016, ANNU REV GENOM HUM G, V17, P17, DOI 10.1146/annurev-genom-083115-022339; Mesin L, 2016, IMMUNITY, V45, P471, DOI 10.1016/j.immuni.2016.09.001; Mullenders J, 2015, J EXP MED, V212, P1833, DOI 10.1084/jem.20151323; Nojima T, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1475; Ortega-Molina A, 2015, NAT MED, V21, P1199, DOI 10.1038/nm.3943; Peters JM, 2008, GENE DEV, V22, P3089, DOI 10.1101/gad.1724308; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Phanstiel DH, 2015, BIOINFORMATICS, V31, P3092, DOI 10.1093/bioinformatics/btv336; Ranuncolo SM, 2007, NAT IMMUNOL, V8, P705, DOI 10.1038/ni1478; Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021; Rasmussen KD, 2016, GENE DEV, V30, P733, DOI 10.1101/gad.276568.115; Rivas MA, 2021, NAT IMMUNOL, V22, P240, DOI 10.1038/s41590-020-00827-8; Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192; Scharer CD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17798-x; Schwarzer W, 2017, NATURE, V551, P51, DOI 10.1038/nature24281; Shaknovich R, 2010, BLOOD, V116, pE81, DOI 10.1182/blood-2010-05-285320; Solomon DA, 2011, SCIENCE, V333, P1039, DOI 10.1126/science.1203619; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thota S, 2014, BLOOD, V124, P1790, DOI 10.1182/blood-2014-04-567057; Victora GD, 2012, BLOOD, V120, P2240, DOI 10.1182/blood-2012-03-415380; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Viny AD, 2015, J EXP MED, V212, P1819, DOI 10.1084/jem.20151317; Watrin E, 2009, EMBO J, V28, P2625, DOI 10.1038/emboj.2009.202; Welch JS, 2012, CELL, V150, P264, DOI 10.1016/j.cell.2012.06.023; Wright GW, 2020, CANCER CELL, V37, P551, DOI 10.1016/j.ccell.2020.03.015; Zhang J, 2013, P NATL ACAD SCI USA, V110, P1398, DOI 10.1073/pnas.1205299110; Zheng XB, 2018, BIOINFORMATICS, V34, P1568, DOI 10.1093/bioinformatics/btx802; 2016, bioRxiv, DOI 10.1101/060012	63	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 21	2021	12								688493	10.3389/fimmu.2021.688493	http://dx.doi.org/10.3389/fimmu.2021.688493			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WB3QC	34621263	Green Published, gold			2022-12-18	WOS:000703489200001
J	Coker, MO; Cairo, C; Garzino-Demo, A				Coker, Modupe O.; Cairo, Cristiana; Garzino-Demo, Alfredo			HIV-Associated Interactions Between Oral Microbiota and Mucosal Immune Cells: Knowledge Gaps and Future Directions	FRONTIERS IN IMMUNOLOGY			English	Review						immune; microbiome; oral; HIV; mucosal immunity	HUMAN-IMMUNODEFICIENCY-VIRUS; TH17 CELLS; DENTAL-CARIES; TRYPTOPHAN CATABOLISM; STREPTOCOCCUS-MUTANS; INFECTED CHILDREN; GUT MICROBIOTA; DISEASE PROGRESSION; BETA-DEFENSINS; HOST-DEFENSE	Even with sustained use of antiretroviral therapy (ART), HIV-infected individuals have an increased risk of systemic comorbid conditions and oral pathologies, including opportunistic infections, oral mucosal inflammation, and gingival and periodontal diseases. The immune-mediated mechanisms that drive this increased risk, in the context of sustained viral suppression, are unclear. HIV infection, even when controlled, alters microbial communities contributing to a chronic low-grade inflammatory state that underlies these non-HIV co-morbidities. The higher prevalence of dental caries, and mucosal and periodontal inflammation reported in HIV-infected individuals on ART is often associated with differentially abundant oral microbial communities, possibly leading to a heightened susceptibility to inflammation. This mini-review highlights current gaps in knowledge regarding the microbe-mediated oral mucosal immunity with HIV infection while discussing opportunities for future research investigations and implementation of novel approaches to elucidate these gaps. Interventions targeting both inflammation and microbial diversity are needed to mitigate oral inflammation-related comorbidities, particularly in HIV-infected individuals. More broadly, additional research is needed to bolster general models of microbiome-mediated chronic immune activation and aid the development of precise microbiota-targeted interventions to reverse or mitigate adverse outcomes.</p>	[Coker, Modupe O.] Sch Dent Med Rutgers, Dept Oral Biol, Newark, NJ 07103 USA; [Coker, Modupe O.] Sch Publ Hlth Rutgers, Dept Epidemiol, Newark, NJ 07103 USA; [Cairo, Cristiana; Garzino-Demo, Alfredo] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD USA; [Cairo, Cristiana] Univ Maryland, Sch Med, Dept Med, Baltimore, MD USA; [Garzino-Demo, Alfredo] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD USA; [Garzino-Demo, Alfredo] Univ Padua, Dept Mol Med, Padua, Italy	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Padua	Coker, MO (corresponding author), Sch Dent Med Rutgers, Dept Oral Biol, Newark, NJ 07103 USA.; Coker, MO (corresponding author), Sch Publ Hlth Rutgers, Dept Epidemiol, Newark, NJ 07103 USA.	mc2190@sdm.rutgers.edu			National Institute of Health (NIDCR) [R01DE028154]; National Institute of Health (NICHD) [U01HD092308]	National Institute of Health (NIDCR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); National Institute of Health (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported in part by grant from the National Institutes of Health (NIDCR R01DE028154; NICHD U01HD092308).	Amini A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.584521; Annavajhala MK, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00798-19; Bajpai S, 2010, CONTEMP CLIN DENT, V1, P1, DOI 10.4103/0976-237X.62510; Bastard JP, 2012, ANTIVIR THER, V17, P915, DOI 10.3851/IMP2093; Beena JP, 2011, EUR J PAEDIATR DENT, V12, P87; Bipath P, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1087-5; Blignaut E, 2019, PEDIATR INFECT DIS J, V38, pE112, DOI 10.1097/INF.0000000000002166; Brandtzaeg P, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00222; Brenchley JM, 2008, BLOOD, V112, P2826, DOI 10.1182/blood-2008-05-159301; Burne R A, 2018, Adv Dent Res, V29, P66, DOI 10.1177/0022034517735293; Byakwaga H, 2014, J INFECT DIS, V210, P383, DOI 10.1093/infdis/jiu115; Cecchinato V, 2008, MUCOSAL IMMUNOL, V1, P279, DOI 10.1038/mi.2008.14; Coker MO, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67487-4; Coker MO., 2020, DEVELOPING MICROBIOM, P43, DOI [10.1016/B978-0-12-820602-7.00003-9, DOI 10.1016/B978-0-12-820602-7.00003-9]; Coker M, 2018, PEDIATR INFECT DIS J, V37, P59, DOI 10.1097/INF.0000000000001702; Conti HR, 2009, J EXP MED, V206, P299, DOI 10.1084/jem.20081463; Corbett AJ, 2014, NATURE, V509, P361, DOI 10.1038/nature13160; Cosgrove C, 2013, BLOOD, V121, P951, DOI 10.1182/blood-2012-06-436436; Dang AT, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-153; Dillon SM, 2014, MUCOSAL IMMUNOL, V7, P983, DOI 10.1038/mi.2013.116; Dillon SM, 2016, AIDS, V30, P2737, DOI 10.1097/QAD.0000000000001289; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Dubourg G, 2017, MICROB PATHOGENESIS, V106, P85, DOI 10.1016/j.micpath.2016.05.015; Eberhard JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111323; Eckle SBG, 2015, J BIOL CHEM, V290, P30204, DOI 10.1074/jbc.R115.685990; El Hed A, 2010, J INFECT DIS, V201, P843, DOI 10.1086/651021; Favre D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000632; Fernandez CS, 2015, IMMUNOL CELL BIOL, V93, P177, DOI 10.1038/icb.2014.91; Fidel PL, 2021, MBIO, V12, DOI 10.1128/mBio.00294-21; Fidel PL, 2020, ORAL DIS, V26, P59, DOI 10.1111/odi.13515; Fulcher JA, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00034-20; Gaardbo JC, 2015, JAIDS-J ACQ IMM DEF, V70, P228, DOI 10.1097/QAI.0000000000000758; Gaboriau-Routhiau V, 2009, IMMUNITY, V31, P677, DOI 10.1016/j.immuni.2009.08.020; Goldberg BE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131615; Gorr SU, 2011, J CLIN PERIODONTOL, V38, P126, DOI 10.1111/j.1600-051X.2010.01664.x; Gosselin A, 2010, J IMMUNOL, V184, P1604, DOI 10.4049/jimmunol.0903058; Greenspan NS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00335; Griffen AL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55703-9; Gruffaz M, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008114; Gruner D, 2016, J DENT, V48, P16, DOI 10.1016/j.jdent.2016.03.002; Hajishengallis G, 1999, ORAL MICROBIOL IMMUN, V14, P1, DOI 10.1034/j.1399-302X.1999.140101.x; Hartigan-O'Connor DJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003941; Hensley-McBain T, 2016, J VIROL, V90, P4981, DOI 10.1128/JVI.00099-16; Hicks M. John, 2000, Pediatric Dentistry, V22, P359; Hillman JD, 2007, J APPL MICROBIOL, V102, P1209, DOI 10.1111/j.1365-2672.2007.03316.x; Honda K, 2016, NATURE, V535, P75, DOI 10.1038/nature18848; Howell R. Bruce, 1992, Pediatric Dentistry, V14, P370; Huan YC, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.582779; Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668; Huengsberg M, 1998, CLIN CHEM, V44, P858; Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786; Imahashi M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80247-8; Iwai S, 2012, J CLIN MICROBIOL, V50, P2995, DOI 10.1128/JCM.00278-12; Jenabian MA, 2015, J INFECT DIS, V212, P355, DOI 10.1093/infdis/jiv037; Joosab Z, 2012, SADJ, V67, P314; Juno JA, 2019, J IMMUNOL, V202, P2105, DOI 10.4049/jimmunol.1801405; Kalayjian RC, 2010, J INFECT DIS, V201, P1796, DOI 10.1086/652750; Khaitan A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161786; Kistler JO, 2015, J MED MICROBIOL, V64, P1094, DOI 10.1099/jmm.0.000128; Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605; Klatt NR, 2012, MUCOSAL IMMUNOL, V5, P646, DOI 10.1038/mi.2012.38; Klatt NR, 2017, SCIENCE, V356, P938, DOI 10.1126/science.aai9383; Klatt NR, 2013, TRENDS MICROBIOL, V21, P6, DOI 10.1016/j.tim.2012.09.001; Krause JL, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00755; Kulkarni V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01581; Kurita-Ochiai T, 2008, J DENT RES, V87, P51, DOI 10.1177/154405910808700108; Lafferty MK, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050111; Lafferty MK, 2010, BLOOD, V115, P1564, DOI 10.1182/blood-2009-06-226423; Lauritano D, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020088; Lazar V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01830; Leeansyah E, 2013, BLOOD, V121, P1124, DOI 10.1182/blood-2012-07-445429; Lewy T, 2019, AIDS RES HUM RETROV, V35, P276, DOI [10.1089/aid.2017.0200, 10.1089/AID.2017.0200]; Li XX, 2019, NAT IMMUNOL, V20, P1594, DOI 10.1038/s41590-019-0514-y; Li YH, 2014, J CLIN MICROBIOL, V52, P1400, DOI 10.1128/JCM.02954-13; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Liu G, 2012, J DENT RES, V91, P834, DOI 10.1177/0022034512454298; Lozupone CA, 2013, CELL HOST MICROBE, V14, P329, DOI 10.1016/j.chom.2013.08.006; Macal M, 2008, MUCOSAL IMMUNOL, V1, P475, DOI 10.1038/mi.2008.35; Madigan Ann, 1996, Pediatric Dentistry, V18, P129; Magrin GL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144895; Malamud D, 2010, AIDS, V24, P5, DOI 10.1097/QAD.0b013e328333525f; Marcotte H, 1998, MICROBIOL MOL BIOL R, V62, P71, DOI 10.1128/MMBR.62.1.71-109.1998; Mataftsi M, 2011, ORAL DIS, V17, P13, DOI 10.1111/j.1601-0825.2010.01727.x; McHardy IH, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-26; MCNABB PC, 1981, ANNU REV MICROBIOL, V35, P477, DOI 10.1146/annurev.mi.35.100181.002401; Mehandru S, 2006, PLOS MED, V3, P2335, DOI 10.1371/journal.pmed.0030484; Merlini E, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01972; Moscicki AB, 2019, J CLIN PERIODONTOL, V46, P1072, DOI 10.1111/jcpe.13179; Moyes DL, 2016, ORAL DIS, V22, P166, DOI 10.1111/odi.12415; Mukherjee PK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200285; Mutlu EA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003829; Navazesh M, 2005, ORAL SURG ORAL MED O, V100, P701, DOI 10.1016/j.tripleo.2004.10.011; Neuhaus J, 2010, J INFECT DIS, V201, P1788, DOI 10.1086/652749; Nobbs AH, 2011, J DENT RES, V90, P1271, DOI 10.1177/0022034511399096; Nogueira RD, 2005, INFECT IMMUN, V73, P5675, DOI 10.1128/IAI.73.9.5675-5684.2005; Nowak P, 2015, AIDS, V29, P2409, DOI 10.1097/QAD.0000000000000869; Obileye M F, 2009, Nig Q J Hosp Med, V19, P210; Ottria L, 2018, J BIOL REG HOMEOS AG, V32, P51; Page EE, 2014, JAIDS-J ACQ IMM DEF, V67, P227, DOI 10.1097/QAI.0000000000000294; Caruso MP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38547-1; Pinheiro RD, 2009, J ORAL PATHOL MED, V38, P613, DOI 10.1111/j.1600-0714.2009.00789.x; Prendergast A, 2010, AIDS, V24, P491, DOI 10.1097/QAD.0b013e3283344895; Presti RM, 2018, AIDS, V32, P1279, DOI 10.1097/QAD.0000000000001811; Raffatellu M, 2008, NAT MED, V14, P421, DOI 10.1038/nm1743; Rajonson N, 2017, J PUBLIC HEALTH DENT, V77, P234, DOI 10.1111/jphd.12203; Rhoades N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00463; Ryan ES, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005412; Ryder MI, 2020, PERIODONTOL 2000, V82, P65, DOI 10.1111/prd.12321; Sandler NG, 2012, NAT REV MICROBIOL, V10, P655, DOI 10.1038/nrmicro2848; Sauce D, 2011, BLOOD, V117, P5142, DOI 10.1182/blood-2011-01-331306; Saxena D, 2012, CURR HIV-AIDS REP, V9, P44, DOI 10.1007/s11904-011-0103-7; Schoen Diane H., 2000, Pediatric Dentistry, V22, P365; Schuetz A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004543; Semple CAM, 2006, BIOCHEM SOC T, V34, P257, DOI 10.1042/BST0340257; Shiboski CH, 2018, AIDS, V32, P2497, DOI [10.1097/QAD.0000000000001965, 10.1097/qad.0000000000001965]; Skott P, 1999, J ACQ IMMUN DEF SYND, V21, P73; Spaan M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159243; Starr JR, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0484-6; Stockinger B, 2017, NAT REV IMMUNOL, V17, P535, DOI 10.1038/nri.2017.50; Sultan AS, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006719; Sun LL, 2005, J VIROL, V79, P14318, DOI 10.1128/JVI.79.22.14318-14329.2005; TANZER JM, 1982, INFECT IMMUN, V35, P138, DOI 10.1128/IAI.35.1.138-142.1982; Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x; Tofsky Nanci, 2000, Pediatric Dentistry, V22, P207; VALDEZ IH, 1994, J DENT CHILD, V61, P114; Velloza J, 2017, CURR HIV-AIDS REP, V14, P153, DOI 10.1007/s11904-017-0362-z; Vieira Alexandre Rezende, 1998, Pediatric Dentistry, V20, P169; Vinton C, 2016, J VIROL, V90, P4520, DOI 10.1128/JVI.02876-15; Vujkovic-Cvijin I, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006438; Wacleche VS, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100303; Xiao E, 2017, CELL HOST MICROBE, V22, P120, DOI 10.1016/j.chom.2017.06.014; Xiao XX, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01540; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang LB, 2020, AM J RESP CRIT CARE, V201, P445, DOI 10.1164/rccm.201905-1016OC; Yiu JHC, 2017, J MOL MED, V95, P13, DOI 10.1007/s00109-016-1474-4; Zenobia C, 2015, PERIODONTOL 2000, V69, P142, DOI 10.1111/prd.12083	136	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 20	2021	12								676669	10.3389/fimmu.2021.676669	http://dx.doi.org/10.3389/fimmu.2021.676669			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WA7IL	34616391	Green Published, gold			2022-12-18	WOS:000703059200001
J	Zhao, XB; Zhao, SK; Chen, YJ; Zhang, ZJ; Li, XT; Liu, X; Lv, RJ; Wang, Q; Ai, L				Zhao, Xiaobin; Zhao, Shaokun; Chen, Yaojing; Zhang, Zhanjun; Li, Xiaotong; Liu, Xiao; Lv, Ruijuan; Wang, Qun; Ai, Lin			Subcortical Hypermetabolism Associated With Cortical Hypometabolism Is a Common Metabolic Pattern in Patients With Anti-Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis	FRONTIERS IN IMMUNOLOGY			English	Article						fluorodeoxyglucose; metabolic pattern; positron emission tomography; LGI1; autoimmune encephalitis	LIMBIC ENCEPHALITIS; CLINICAL-MANIFESTATIONS; COGNITIVE DEFICITS; F-18-FDG PET/CT; LGI1; MRI; OUTCOMES	Purpose Brain 18F-fluorodeoxyglucose positron emission tomography (FDG PET) is a sensitive technique for assisting in the diagnosis of patients with anti-leucine-rich glioma-inactivated 1 (LGI1) antibody encephalitis. However, the common pattern of this disorder assessed by FDG PET remains unknown. The present study aimed to explore the glucose metabolic patterns of this disorder based on PET voxel analysis. Methods This retrospective study enrolled 25 patients with anti-LGI1 encephalitis, who were admitted in Beijing Tiantan Hospital between September 2014 and July 2019. The glucose metabolic pattern was compared between the included patients and 44 age- and gender-matched healthy controls using Statistical Parametric Mapping. Then, the correlation between the metabolic pattern and scaled activities of daily living (ADLs) of the patients was assessed. Results The median time from symptom onset to PET scans was 9 w (range:2-53w). The groupwise analysis revealed that patients with anti-LGI1 encephalitis had left hippocampal hypermetabolism and hypometabolism in almost all neocortical regions. The individual-level results showed most patients presented a decreased metabolism in neocortical regions, as well as an increase in metabolism in the hippocampus and basal ganglia. Furthermore, the metabolic gradient between hippocampus and neocortical regions was positively associated with the ADLs (frontal lobe, r=0.529, P=0.008; parietal lobe, r=0.474, P=0.019; occipital lobe, r=0.413, P=0.045; temporal lobe, r=0.490, P=0.015), respectively. In addition, the patients with facio-brachial dystonic seizures (FBDS) presented bilateral putamen hypermetabolism, when compared to patients without FBDS and healthy controls. Conclusion Subcortical hypermetabolism associated with cortical hypometabolism presented with a common metabolic pattern in patients with anti-LGI1 encephalitis in the present study. The resolution of the metabolic gradient of the hippocampal hypermetabolism and neocortical hypometabolism may bring about improved clinical neurologic disability.	[Zhao, Xiaobin; Li, Xiaotong; Ai, Lin] Capital Med Univ, Beijing Tiantan Hosp, Dept Nucl Med, Beijing, Peoples R China; [Zhao, Shaokun; Chen, Yaojing; Zhang, Zhanjun] Beijing Normal Univ, State Key Lab Cognit Neurosci, Beijing, Peoples R China; [Zhao, Shaokun; Chen, Yaojing; Zhang, Zhanjun] Beijing Normal Univ, Learning & Int Data Grp, McGovern Inst Brain Res, Beijing, Peoples R China; [Zhao, Shaokun; Chen, Yaojing; Zhang, Zhanjun] Beijing Normal Univ, Beijing Aging Brain Rejuvenat Initiat Ctr, Beijing, Peoples R China; [Liu, Xiao; Lv, Ruijuan; Wang, Qun] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China	Capital Medical University; Beijing Normal University; Beijing Normal University; Beijing Normal University; Capital Medical University	Ai, L (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Dept Nucl Med, Beijing, Peoples R China.; Wang, Q (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China.	wangq@ccmu.edu.cn; ailin@bjtth.org	Li, xiaotong/GYV-4890-2022		National Natural Science Foundation of China [2018YFC1315201]; Beijing Natural Science Foundation [81771143]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation)	Funding This work was supported by funds from the National Natural Science Foundation of China (81527805), the National Natural Science Foundation of China (2018YFC1315201), and Beijing Natural Science Foundation (81771143).	Ances BM, 2005, BRAIN, V128, P1764, DOI 10.1093/brain/awh526; Baumgartner A, 2013, J NEUROL, V260, P2744, DOI 10.1007/s00415-013-7048-2; Bien CG, 2012, BRAIN, V135, P1622, DOI 10.1093/brain/aws082; Dalmau J, 2011, LANCET NEUROL, V10, P63, DOI 10.1016/S1474-4422(10)70253-2; Ferracci F, 2004, J NEUROL SCI, V217, P165, DOI 10.1016/j.jns.2003.09.007; Finke C, 2017, JAMA NEUROL, V74, P50, DOI 10.1001/jamaneurol.2016.4226; Finke C, 2012, J NEUROL NEUROSUR PS, V83, P195, DOI 10.1136/jnnp-2011-300411; Flanagan EP, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000161; Fox CJ, 2005, NAT REV IMMUNOL, V5, P844, DOI 10.1038/nri1710; FULHAM MJ, 1995, J NEUROSURG, V83, P657, DOI 10.3171/jns.1995.83.4.0657; Giuliani C, 2014, J CLIN MED, V3, P1163, DOI 10.3390/jcm3041163; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Heine J, 2015, NEUROSCIENCE, V309, P68, DOI 10.1016/j.neuroscience.2015.05.037; Heine J, 2018, J NEUROL NEUROSUR PS, V89, P1191, DOI 10.1136/jnnp-2017-317780; Irani SR, 2011, ANN NEUROL, V69, P892, DOI 10.1002/ana.22307; Irani SR, 2010, BRAIN, V133, P2734, DOI 10.1093/brain/awq213; Jang Y, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1314-2; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kim TJ, 2014, J NEUROIMMUNOL, V270, P45, DOI 10.1016/j.jneuroim.2014.02.011; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Leypoldt F, 2012, J NEUROL NEUROSUR PS, V83, P681, DOI 10.1136/jnnp-2011-301969; Li TR, 2021, CNS NEUROSCI THER, V27, P1173, DOI 10.1111/cns.13707; Liu X, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00418; Liu X, 2017, EPILEPSIA, V58, P2104, DOI 10.1111/epi.13929; Loane C, 2019, J NEUROL NEUROSUR PS, V90, P965, DOI 10.1136/jnnp-2018-320168; Lv RJ, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00576; Masangkay N, 2014, NUCL MED COMMUN, V35, P1038, DOI 10.1097/MNM.0000000000000163; Moubtakir A, 2018, CLIN NUCL MED, V43, P520, DOI 10.1097/RLU.0000000000002098; Navarro V, 2016, BRAIN, V139, P1079, DOI 10.1093/brain/aww012; Palmer CS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00001; Park S, 2015, CLIN NUCL MED, V40, P156, DOI 10.1097/RLU.0000000000000546; Probasco JC, 2018, NEUROL-NEUROIMMUNOL, V5, DOI 10.1212/NXI.0000000000000413; Probasco JC, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000352; Seniaray N, 2021, CLIN NUCL MED, V46, pe27, DOI 10.1097/RLU.0000000000003258; Shan W, 2019, NEUROLOGY, V93, pE1917, DOI 10.1212/WNL.0000000000008473; Shin YW, 2013, J NEUROIMMUNOL, V265, P75, DOI 10.1016/j.jneuroim.2013.10.005; Takkar A, 2016, J CLIN NEUROL, V12, P519, DOI 10.3988/jcn.2016.12.4.519; Thompson J, 2018, BRAIN, V141, P348, DOI 10.1093/brain/awx323; Thouin A, 2021, J NEUROL, V268, P1818, DOI 10.1007/s00415-020-10329-0; Tripathi M, 2018, NEURORADIOLOGY, V60, P189, DOI 10.1007/s00234-017-1956-2; van Sonderen A, 2016, AUTOIMMUN REV, V15, P970, DOI 10.1016/j.autrev.2016.07.018; Wegner F, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-136; Yuan J, 2016, CLIN NUCL MED, V41, P366, DOI 10.1097/RLU.0000000000001164	43	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 20	2021	12								672846	10.3389/fimmu.2021.672846	http://dx.doi.org/10.3389/fimmu.2021.672846			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WC2ZA	34616389	gold, Green Published			2022-12-18	WOS:000704128600001
J	Dong, ZM; An, LN; Lu, MY; Tang, MY; Chen, HQ; Huang, X; Hou, Y; Shen, GW; Zhang, XL; Zhang, Y; Xia, QY; Zhao, P				Dong, Zhaoming; An, Lingna; Lu, Mengyao; Tang, Muya; Chen, Haiqin; Huang, Xuan; Hou, Yong; Shen, Guanwang; Zhang, Xiaolu; Zhang, Yan; Xia, Qingyou; Zhao, Ping			SPINK7 Recognizes Fungi and Initiates Hemocyte-Mediated Immune Defense Against Fungal Infections	FRONTIERS IN IMMUNOLOGY			English	Article						protease inhibitor; SPINK; cell immunity; hemocyte; nodulation; encapsulation; insect; kazal	SERINE-PROTEASE INHIBITOR; SILKWORM BOMBYX-MORI; ANTIMICROBIAL ACTIVITY; PROTEINASE-INHIBITOR; NODULE FORMATION; DOMAIN; PHAGOCYTOSIS; OVOINHIBITOR; EXPRESSION; MECHANISM	Serine protease inhibitors of Kazal-type (SPINKs) were widely identified in vertebrates and invertebrates, and played regulatory roles in digestion, coagulation, and fibrinolysis. In this study, we reported the important role of SPINK7 in regulating immune defense of silkworm, Bombyx mori. SPINK7 contains three Kazal domains and has 6 conserved cysteine residues in each domain. Quantitative real-time PCR analyses revealed that SPINK7 was exclusively expressed in hemocytes and was upregulated after infection with two fungi, Saccharomyces cerevisiae and Candida albicans. Enzyme activity inhibition test showed that SPINK7 significantly inhibited the activity of proteinase K from C. albicans. Additionally, SPINK7 inhibited the growth of three fungal spores, including S. cerevisiae, C. albicans, and Beauveria bassiana. The pathogen-associated molecular patterns (PAMP) binding assays suggested that SPINK7 could bind to beta-D-glucan and agglutinate B. bassiana and C. albicans. In vitro assays were performed using SPINK7-coated agarose beads, and indicated that SPINK7 promoted encapsulation and melanization of agarose beads by B. mori hemocytes. Furthermore, co-localization studies using immunofluorescence revealed that SPINK7 induced hemocytes to aggregate and entrap the fungi spores of B. bassiana and C. albicans. Our study revealed that SPINK7 could recognize fungal PAMP and induce the aggregation, melanization, and encapsulation of hemocytes, and provided valuable clues for understanding the innate immunity and cellular immunity in insects.	[Dong, Zhaoming; An, Lingna; Lu, Mengyao; Tang, Muya; Chen, Haiqin; Huang, Xuan; Hou, Yong; Shen, Guanwang; Zhang, Xiaolu; Zhang, Yan; Xia, Qingyou; Zhao, Ping] Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing, Peoples R China; [Dong, Zhaoming; An, Lingna; Lu, Mengyao; Tang, Muya; Chen, Haiqin; Huang, Xuan; Hou, Yong; Shen, Guanwang; Zhang, Xiaolu; Zhang, Yan; Xia, Qingyou; Zhao, Ping] Southwest Univ, Biol Sci Res Ctr, Chongqing, Peoples R China; [Dong, Zhaoming; An, Lingna; Lu, Mengyao; Tang, Muya; Chen, Haiqin; Huang, Xuan; Hou, Yong; Shen, Guanwang; Zhang, Xiaolu; Zhang, Yan; Xia, Qingyou; Zhao, Ping] Southwest Univ, Chongqing Engn & Technol Res Ctr Novel Silk Mat, Chongqing Key Lab Sericultural Sci, Chongqing, Peoples R China	Southwest University - China; Southwest University - China; Southwest University - China	Zhao, P (corresponding author), Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing, Peoples R China.; Zhao, P (corresponding author), Southwest Univ, Biol Sci Res Ctr, Chongqing, Peoples R China.; Zhao, P (corresponding author), Southwest Univ, Chongqing Engn & Technol Res Ctr Novel Silk Mat, Chongqing Key Lab Sericultural Sci, Chongqing, Peoples R China.	zhaop@swu.edu.cn	Dong, Zhaoming/AAK-1802-2021; Lu, Meng/GQZ-7036-2022	Dong, Zhaoming/0000-0001-5665-9953; 	Natural Science Foundation of Chongqing [cstc2020jcyj-cxttX0001]; Chongqing Research Program of Basic Research and Frontier Technology [cstc2019jcyj-msxmX0272]	Natural Science Foundation of Chongqing(Natural Science Foundation of Chongqing); Chongqing Research Program of Basic Research and Frontier Technology	Funding This work was supported by the Natural Science Foundation of Chongqing (cstc2020jcyj-cxttX0001), and Chongqing Research Program of Basic Research and Frontier Technology (cstc2019jcyj-msxmX0272).	Ao JQ, 2007, MOL IMMUNOL, V44, P2541, DOI 10.1016/j.molimm.2006.12.024; Bourin M, 2011, J AGR FOOD CHEM, V59, P12368, DOI 10.1021/jf203339t; Brillard-Bourdet M, 2006, BIOCHEM J, V400, P467, DOI 10.1042/BJ20060437; Chen KK, 2018, DEV COMP IMMUNOL, V83, P3, DOI 10.1016/j.dci.2017.12.024; Chen SY, 2019, J INSECT SCI, V19, DOI 10.1093/jisesa/iez056; Dietrich MA, 2017, FISH SHELLFISH IMMUN, V60, P150, DOI 10.1016/j.fsi.2016.11.041; Dziarski R, 2004, MOL IMMUNOL, V40, P877, DOI 10.1016/j.molimm.2003.10.011; Egelrud T, 2005, BRIT J DERMATOL, V153, P1200, DOI 10.1111/j.1365-2133.2005.06834.x; Ge KK, 2017, ONCOTARGET, V8, P5965, DOI 10.18632/oncotarget.13983; Geng T, 2016, GENE, V595, P69, DOI 10.1016/j.gene.2016.09.043; Gerphagnon M, 2013, APPL ENVIRON MICROB, V79, P3943, DOI 10.1128/AEM.00696-13; Guo PC, 2015, SCI REP-UK, V5, DOI 10.1038/srep11863; Hou CX, 2013, J INSECT SCI, V13, DOI 10.1673/031.013.13801; Irving P, 2005, CELL MICROBIOL, V7, P335, DOI 10.1111/j.1462-5822.2004.00462.x; KAZAL LA, 1948, J AM CHEM SOC, V70, P3034, DOI 10.1021/ja01189a060; Kim BY, 2013, TOXICON, V76, P110, DOI 10.1016/j.toxicon.2013.09.017; LASKOWSKI M, 1990, J PROTEIN CHEM, V9, P715, DOI 10.1007/BF01024766; Levashina EA, 2001, CELL, V104, P709, DOI 10.1016/S0092-8674(01)00267-7; Li XC, 2010, FISH SHELLFISH IMMUN, V28, P942, DOI 10.1016/j.fsi.2010.02.011; Li YS, 2015, INSECT BIOCHEM MOLEC, V57, P11, DOI 10.1016/j.ibmb.2014.11.006; Li YS, 2012, INSECT BIOCHEM MOLEC, V42, P766, DOI 10.1016/j.ibmb.2012.07.004; Ling EJ, 2006, DEV COMP IMMUNOL, V30, P289, DOI 10.1016/j.dci.2005.05.005; Lovato DV, 2006, BIOCHIMIE, V88, P673, DOI 10.1016/j.biochi.2005.11.011; Matsumoto Y, 2019, MICROBIOL IMMUNOL, V63, P41, DOI 10.1111/1348-0421.12668; Moita LF, 2005, IMMUNITY, V23, P65, DOI 10.1016/j.immuni.2005.05.006; RATCLIFFE NA, 1976, J INVERTEBR PATHOL, V28, P373, DOI 10.1016/0022-2011(76)90013-6; RATCLIFFE NA, 1977, TISSUE CELL, V9, P73, DOI 10.1016/0040-8166(77)90050-7; Rendic D, 2008, CROAT CHEM ACTA, V81, P7; Rimphanitchayakit V, 2010, DEV COMP IMMUNOL, V34, P377, DOI 10.1016/j.dci.2009.12.004; Romanelli D, 2016, SCI REP-UK, V6, DOI 10.1038/srep32939; Satyavathi VV, 2014, CELL SIGNAL, V26, P1753, DOI 10.1016/j.cellsig.2014.02.024; SCOTT MJ, 1987, J BIOL CHEM, V262, P5899; Strand MR, 2008, INSECT IMMUNOLOGY, P25, DOI 10.1016/S0965-1748(02)00092-9; Strand Michael R., 2008, Insect Science, V15, P1, DOI 10.1111/j.1744-7917.2008.00183.x; STRAND MR, 1995, ANNU REV ENTOMOL, V40, P31, DOI 10.1146/annurev.en.40.010195.000335; Stubbs MT, 1997, J BIOL CHEM, V272, P19931, DOI 10.1074/jbc.272.32.19931; Takahasi K, 2009, P NATL ACAD SCI USA, V106, P11679, DOI 10.1073/pnas.0901671106; Tang MY, 2019, INSECT BIOCHEM MOLEC, V110, P1, DOI 10.1016/j.ibmb.2019.03.011; Toubarro D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075691; Wang GH, 2008, INSECT SCI, V15, P405, DOI 10.1111/j.1744-7917.2008.00227.x; Wang LL, 2019, DEV COMP IMMUNOL, V91, P123, DOI 10.1016/j.dci.2018.10.006; Wang XH, 2006, SCIENCE, V312, P452, DOI 10.1126/science.1125694; Watanabe RMO, 2011, BIOCHIMIE, V93, P618, DOI 10.1016/j.biochi.2010.12.006; Wertheim B, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-11-r94; Williams SC, 1998, J MICROBIOL METH, V32, P225, DOI 10.1016/S0167-7012(98)00014-1; Wu ZH, 2019, J INVEST DERMATOL, V139, P1135, DOI 10.1016/j.jid.2018.11.004; Yang JL, 2010, DEV COMP IMMUNOL, V34, P1274, DOI 10.1016/j.dci.2010.07.004; Yang L, 2020, ARCH INSECT BIOCHEM, V105, DOI 10.1002/arch.21736; Zhang XL, 2020, INSECT BIOCHEM MOLEC, V116, DOI 10.1016/j.ibmb.2019.103258; Zhang Y, 2014, AMINO ACIDS, V46, P1021, DOI 10.1007/s00726-014-1665-7; Zhao P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031168; Zheng QL, 2007, COMP BIOCHEM PHYS B, V146, P234, DOI 10.1016/j.cbpb.2006.10.106; Zhou YH, 2018, INT J BIOL MACROMOL, V107, P1945, DOI 10.1016/j.ijbiomac.2017.10.069; Zhu L, 2006, FISH SHELLFISH IMMUN, V20, P320, DOI 10.1016/j.fsi.2005.05.009	54	1	1	3	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 17	2021	12								735497	10.3389/fimmu.2021.735497	http://dx.doi.org/10.3389/fimmu.2021.735497			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV5NV	34603317	Green Published, gold			2022-12-18	WOS:000717284700001
J	Moreno-Canadas, R; Luque-Martin, L; Arroyo, AG				Moreno-Canadas, Rocio; Luque-Martin, Laura; Arroyo, Alicia G.			Intravascular Crawling of Patrolling Monocytes: A Levy-Like Motility for Unique Search Functions?	FRONTIERS IN IMMUNOLOGY			English	Review						patrolling monocytes; crawling; search theory; Levy-like walk; intravascular surveillance; microparticle deposits; alpha M beta 2 integrin; CD36	T-CELL MIGRATION; LY6C(LOW) MONOCYTES; ENDOTHELIAL-CELLS; NEUTROPHIL ADHESION; LFA-1; MAC-1; FORCES; ICAM-1; SPEED	Patrolling monocytes (PMo) are the organism's preeminent intravascular guardians by their continuous search of damaged endothelial cells and harmful microparticles for their removal and to restore homeostasis. This surveillance is accomplished by PMo crawling on the apical side of the endothelium through regulated interactions of integrins and chemokine receptors with their endothelial ligands. We propose that the search mode governs the intravascular motility of PMo in vivo in a similar way to T cells looking for antigen in tissues. Signs of damage to the luminal side of the endothelium (local death, oxidized LDL, amyloid deposits, tumor cells, pathogens, abnormal red cells, etc.) will change the diffusive random towards a Levy-like crawling enhancing their recognition and clearance by PMo damage receptors as the integrin alpha M beta 2 and CD36. This new perspective can help identify new actors to promote unique PMo intravascular actions aimed at maintaining endothelial fitness and combating harmful microparticles involved in diseases as lung metastasis, Alzheimer's angiopathy, vaso-occlusive disorders, and sepsis.</p>	[Moreno-Canadas, Rocio; Luque-Martin, Laura; Arroyo, Alicia G.] CSIC, Ctr Invest Biol Margarit, Mol Biomed Dept, CIB, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Arroyo, AG (corresponding author), CSIC, Ctr Invest Biol Margarit, Mol Biomed Dept, CIB, Madrid, Spain.	agarroyo@cib.csic.es			Spanish Ministry of Science and Innovation [SAF2017-83229-R, PID2020-112981RB-I00, PRE2018-085163]; Community of Madrid - European Social Fund for Youth Employment; CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI)	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Community of Madrid - European Social Fund for Youth Employment; CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI)	& nbsp;The work in this manuscript has been funded by the Spanish Ministry of Science and Innovation (grants SAF2017-83229-R and PID2020-112981RB-I00 to AGA and fellowship PRE2018-085163 to LL-M). RM-C has a contract with the Community of Madrid co-financed by the European Social Fund for Youth Employment. We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI).	Ahmad F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00948; Akenhead ML, 2017, J LEUKOCYTE BIOL, V102, P117, DOI 10.1189/jlb.3A0716-317RR; Allali S, 2020, HAEMATOLOGICA, V105, P273, DOI 10.3324/haematol.2019.229989; Amich J, 2020, MBIO, V11, DOI 10.1128/mBio.02752-19; Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883; Babendreyer A, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/1515389; Barreiro O, 2002, J CELL BIOL, V157, P1233, DOI 10.1083/jcb.200112126; Bednarczyk M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041402; Bianchini M, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aar3054; Bouti P, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.619925; Brust M, 2014, SCI REP-UK, V4, DOI 10.1038/srep04348; Buscher K, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00080; Carlin L M, 2013, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1433s101; Carlin LM, 2013, CELL, V153, P362, DOI 10.1016/j.cell.2013.03.010; Cassetta L, 2016, CELL RES, V26, P3, DOI 10.1038/cr.2015.144; Cheng Y, 2020, TRANSL NEURODEGENER, V9, DOI 10.1186/s40035-020-00195-1; Clemente C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03351-4; Collison JL, 2015, J IMMUNOL, V195, P1162, DOI 10.4049/jimmunol.1401806; Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012; Finsterbusch M, 2016, P NATL ACAD SCI USA, V113, pE5172, DOI 10.1073/pnas.1606253113; Franz J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146598; Gamrekelashvili J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12597; Geissmann F, 2005, PLOS BIOL, V3, P650, DOI 10.1371/journal.pbio.0030113; Gerard A, 2014, CELL, V158, P492, DOI 10.1016/j.cell.2014.05.044; Goda S, 2000, J IMMUNOL, V164, P4313, DOI 10.4049/jimmunol.164.8.4313; Graff RM, 2018, BRAIN BEHAV IMMUN, V74, P143, DOI 10.1016/j.bbi.2018.08.017; Hanna RN, 2015, SCIENCE, V350, P985, DOI 10.1126/science.aac9407; Harris TH, 2012, NATURE, V486, P545, DOI 10.1038/nature11098; Hermand P, 2008, J BIOL CHEM, V283, P30225, DOI 10.1074/jbc.M802638200; Herter J, 2013, J IMMUNOL, V190, P4451, DOI 10.4049/jimmunol.1203179; Hofer TP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02052; Imhof BA, 2016, P NATL ACAD SCI USA, V113, pE4847, DOI 10.1073/pnas.1607710113; Katakai T, 2013, J IMMUNOL, V191, P1188, DOI 10.4049/jimmunol.1300739; Krummel MF, 2016, NAT REV IMMUNOL, V16, P193, DOI 10.1038/nri.2015.16; Lammermann T, 2009, CURR OPIN CELL BIOL, V21, P636, DOI 10.1016/j.ceb.2009.05.003; Lau D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01514; Le Master E, 2018, ARTERIOSCL THROM VAS, V38, P64, DOI 10.1161/ATVBAHA.117.309907; Lessard AJ, 2017, CELL REP, V20, P1830, DOI 10.1016/j.celrep.2017.08.009; Li N, 2018, MOL BIOL CELL, V29, P408, DOI 10.1091/mbc.E16-12-0827; Li WQ, 2018, BIOMECH MODEL MECHAN, V17, P147, DOI 10.1007/s10237-017-0950-2; Liu YF, 2019, BLOOD, V134, P579, DOI 10.1182/blood.2019000172; Liu YF, 2018, BLOOD, V131, P1600, DOI 10.1182/blood-2017-12-819870; Maiuri P, 2015, CELL, V161, P374, DOI 10.1016/j.cell.2015.01.056; Marcovecchio PM, 2020, J LEUKOCYTE BIOL, V107, P883, DOI 10.1002/JLB.4HI0420-098R; Marcovecchio PM, 2017, ARTERIOSCL THROM VAS, V37, P2043, DOI 10.1161/ATVBAHA.117.309123; Michaud JP, 2013, CELL REP, V5, P646, DOI 10.1016/j.celrep.2013.10.010; Mikaty G, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000314; Miller H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01073; Mrass P, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01032-2; Mylvaganam S, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107798; Narasimhan PB, 2020, J IMMUNOL, V204, P192, DOI 10.4049/jimmunol.1900998; Neelamegham S, 1998, BLOOD, V92, P1626, DOI 10.1182/blood.V92.5.1626.417a02_1626_1638; Orndorff RL, 2014, AM J PHYSIOL-LUNG C, V306, pL260, DOI 10.1152/ajplung.00278.2013; Ostuni MA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65988-w; Piechocka IK, 2021, BIOPHYS J, V120, P2644, DOI 10.1016/j.bpj.2021.05.016; Plebanek MP, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01433-3; Quintar A, 2017, CIRC RES, V120, P1789, DOI 10.1161/CIRCRESAHA.117.310739; Reynolds AM, 2018, BIOL OPEN, V7, DOI 10.1242/bio.030106; Rodero MP, 2015, ELIFE, V4, DOI 10.7554/eLife.07847; Shulman Z, 2009, IMMUNITY, V30, P384, DOI 10.1016/j.immuni.2008.12.020; Sidibe A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02610-0; Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3; Steppich B, 2000, AM J PHYSIOL-CELL PH, V279, pC578, DOI 10.1152/ajpcell.2000.279.3.C578; Sumagin R, 2010, J IMMUNOL, V185, P7057, DOI 10.4049/jimmunol.1001638; Tahir S, 2021, AM J PHYSIOL-CELL PH, V320, pC761, DOI 10.1152/ajpcell.00326.2020; Thomas G, 2015, ARTERIOSCL THROM VAS, V35, P1306, DOI 10.1161/ATVBAHA.114.304650; Vaisar T, 2009, MOL CELL PROTEOMICS, V8, P1044, DOI 10.1074/mcp.M800449-MCP200; van Zanten TS, 2009, P NATL ACAD SCI USA, V106, P18557, DOI 10.1073/pnas.0905217106; Westhorpe CLV, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03181-4; White GE, 2014, ARTERIOSCL THROM VAS, V34, P2554, DOI 10.1161/ATVBAHA.114.304717; Yakubenko VP, 2002, J BIOL CHEM, V277, P48635, DOI 10.1074/jbc.M208877200; Zen K, 2011, BLOOD, V117, P4885, DOI 10.1182/blood-2010-05-287722; Zhang H, 2006, IMMUNITY, V25, P285, DOI 10.1016/j.immuni.2006.06.014	73	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 17	2021	12								730835	10.3389/fimmu.2021.730835	http://dx.doi.org/10.3389/fimmu.2021.730835			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV9OF	34603307	gold, Green Published			2022-12-18	WOS:000717557900001
J	Ross, SH; Rollings, CM; Cantrell, DA				Ross, Sarah H.; Rollings, Christina M.; Cantrell, Doreen A.			Quantitative Analyses Reveal How Hypoxia Reconfigures the Proteome of Primary Cytotoxic T Lymphocytes	FRONTIERS IN IMMUNOLOGY			English	Article						hypoxia; oxygen sensing; CTLs; cytotoxic lymphocytes; quantitative proteomics; CD8 T cells	CELL-CYCLE PROGRESSION; OXYGEN; METABOLISM; EXPRESSION; RESPONSES; DIFFERENTIATION; HIF-1-ALPHA; CYTOLYSIS; TRANSPORT; IMPROVES	Metabolic and nutrient-sensing pathways play an important role in controlling the efficacy of effector T cells. Oxygen is a critical regulator of cellular metabolism. However, during immune responses T cells must function in oxygen-deficient, or hypoxic, environments. Here, we used high resolution mass spectrometry to investigate how the proteome of primary murine CD8(+) cytotoxic T lymphocytes (CTLs) is reconfigured in response to hypoxia in vitro. We identified and quantified over 7,600 proteins and discovered that hypoxia increased the abundance of a selected number of proteins in CTLs. This included glucose transporters, metabolic enzymes, transcription factors, cytolytic effector molecules, checkpoint receptors and adhesion molecules. While some of these proteins may augment the effector functions of CTLs, others may limit their cytotoxicity. Moreover, we determined that hypoxia could inhibit IL-2-induced proliferation cues and antigen-induced pro-inflammatory cytokine production in CTLs. These data provide a comprehensive resource for understanding the magnitude of the CTL response to hypoxia and emphasise the importance of oxygen-sensing pathways for controlling CD8(+) T cells. Additionally, this study provides new understanding about how hypoxia may promote the effector function of CTLs, while contributing to their dysfunction in some contexts.	[Ross, Sarah H.] Babraham Inst, Immunol Programme, Cambridge, England; [Ross, Sarah H.; Rollings, Christina M.; Cantrell, Doreen A.] Univ Dundee, Sch Life Sci, Div Cell Signalling & Immunol, Dundee, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Dundee	Ross, SH (corresponding author), Babraham Inst, Immunol Programme, Cambridge, England.; Ross, SH (corresponding author), Univ Dundee, Sch Life Sci, Div Cell Signalling & Immunol, Dundee, Scotland.	sarah.ross@babraham.ac.uk		Ross, Sarah/0000-0001-7302-6875	Wellcome Trust [205023/Z/16/Z]; Tenovus Scotland; Biotechnology and Biological Sciences Research Council; GlaxoSmithKline; Biotechnology and Biological Sciences Research Council [BBS/E/B/000C0427, BBS/E/B/000C0428]	Wellcome Trust(Wellcome TrustEuropean Commission); Tenovus Scotland; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); GlaxoSmithKline(GlaxoSmithKline); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by the Wellcome Trust (Principal Research Fellowship 205023/Z/16/Z to DC) and Tenovus Scotland (SR). CR was the recipient of a studentship from the Biotechnology and Biological Sciences Research Council and GlaxoSmithKline. Additionally, this work was supported by the Biotechnology and Biological Sciences Research Council through Institute Strategic Program Grant funding, BBS/E/B/000C0427 and BBS/E/B/000C0428.	Balsa E, 2012, CELL METAB, V16, P378, DOI 10.1016/j.cmet.2012.07.015; Batie M, 2019, MOL CELL ONCOL, V6, DOI 10.1080/23723556.2019.1608501; Batie M, 2019, SCIENCE, V363, P1222, DOI 10.1126/science.aau5870; BRANDLE D, 1995, EUR J IMMUNOL, V25, P2650, DOI 10.1002/eji.1830250937; Caldwell CC, 2001, J IMMUNOL, V167, P6140, DOI 10.4049/jimmunol.167.11.6140; Chakraborty AA, 2019, SCIENCE, V363, P1217, DOI 10.1126/science.aaw1026; Cham CM, 2008, EUR J IMMUNOL, V38, P2438, DOI 10.1002/eji.200838289; Chee NT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0968-4; Cho SH, 2016, NATURE, V537, P234, DOI 10.1038/nature19334; Clever D, 2016, CELL, V166, P1117, DOI 10.1016/j.cell.2016.07.032; Colgan SP, 2010, NAT REV GASTRO HEPAT, V7, P281, DOI 10.1038/nrgastro.2010.39; Conforti L, 2003, J IMMUNOL, V170, P695, DOI 10.4049/jimmunol.170.2.695; de Silly RV, 2015, EUR J IMMUNOL, V45, P2263, DOI 10.1002/eji.201445284; Dimeloe S, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav3334; Doedens AL, 2013, NAT IMMUNOL, V14, P1173, DOI 10.1038/ni.2714; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; Fernandez-Vizarra E, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00134; Filaci G, 2011, AUTOIMMUNITY, V44, P51, DOI 10.3109/08916931003782171; Finlay DK, 2012, J EXP MED, V209, P2441, DOI 10.1084/jem.20112607; Geltink RIK, 2018, ANNU REV IMMUNOL, V36, P461, DOI 10.1146/annurev-immunol-042617-053019; Georgiev P, 2013, EUR J IMMUNOL, V43, P655, DOI 10.1002/eji.201242765; Gropper Y, 2017, CELL REP, V20, P2547, DOI 10.1016/j.celrep.2017.08.071; Hatfield SM, 2020, J CLIN INVEST, V130, P5629, DOI 10.1172/JCI137554; Ho JJD, 2021, TRENDS BIOCHEM SCI, V46, P171, DOI 10.1016/j.tibs.2020.11.006; Hoekstra AS, 2013, BBA-BIOENERGETICS, V1827, P543, DOI 10.1016/j.bbabio.2012.11.005; Howden AJM, 2019, NAT IMMUNOL, V20, P1542, DOI 10.1038/s41590-019-0495-x; Hughes CS, 2014, MOL SYST BIOL, V10, DOI 10.15252/msb.20145625; Ivan M, 2017, MOL CELL, V66, P772, DOI 10.1016/j.molcel.2017.06.002; Ivanova IG, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020114; Ivetic A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01068; Jagarlamudi KK, 2018, BIOMARK MED, V12, P1035, DOI 10.2217/bmm-2018-0157; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Labiano S, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1283468; Larbi A, 2010, J LEUKOCYTE BIOL, V87, P265, DOI 10.1189/jlb.0509304; Liu YN, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01906; Loh PG, 2009, EMBO J, V28, P274, DOI 10.1038/emboj.2008.278; Ma EH, 2019, IMMUNITY, V51, P856, DOI 10.1016/j.immuni.2019.09.003; MACDONALD HR, 1977, J EXP MED, V146, P699, DOI 10.1084/jem.146.3.698; MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956; Maruhashi T, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001014; Masson N, 2019, SCIENCE, V365, P65, DOI 10.1126/science.aaw0112; Mohammed RN, 2016, CELL REP, V14, P760, DOI 10.1016/j.celrep.2015.12.090; Moser SC, 2013, DEV CELL, V26, P381, DOI 10.1016/j.devcel.2013.06.014; Motomura Y, 2011, NAT IMMUNOL, V12, P450, DOI 10.1038/ni.2020; Murthy Aditi, 2019, Immunohorizons, V3, P149, DOI 10.4049/immunohorizons.1900017; Nakagawa Y, 2015, IMMUNOL LETT, V167, P72, DOI 10.1016/j.imlet.2015.07.003; Naldini A, 1997, J CELL PHYSIOL, V173, P335, DOI 10.1002/(SICI)1097-4652(199712)173:3<335::AID-JCP5>3.3.CO;2-T; Naldini A, 1999, J CELL PHYSIOL, V181, P448, DOI 10.1002/(SICI)1097-4652(199912)181:3<448::AID-JCP8>3.0.CO;2-F; Niederlova V, 2021, EUR J IMMUNOL, V51, P512, DOI 10.1002/eji.202048614; Noble A, 2006, BLOOD, V107, P4475, DOI 10.1182/blood-2005-10-3994; Oh YM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9698; Ohta A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00109; Ohta A, 2014, INT IMMUNOL, V26, P83, DOI 10.1093/intimm/dxt045; Okazaki T, 2011, J EXP MED, V208, P395, DOI 10.1084/jem.20100466; Ortmann B, 2014, CELL MOL LIFE SCI, V71, P3569, DOI 10.1007/s00018-014-1645-9; Ostergaard L, 2021, PHYSIOL REP, V9, DOI 10.14814/phy2.14726; Palazon A, 2017, CANCER CELL, V32, P669, DOI 10.1016/j.ccell.2017.10.003; Pellegrino M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210839; Petrova V, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0011-9; Phan AT, 2016, IMMUNITY, V45, P1024, DOI 10.1016/j.immuni.2016.10.017; Ramsay G, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00099; Rollings CM, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aap8112; Roman J, 2010, AM J RESP CELL MOL, V42, P123, DOI 10.1165/rcmb.2008-0139OC; Scharping NE, 2021, NAT IMMUNOL, V22, P205, DOI 10.1038/s41590-020-00834-9; Semenza GL, 2019, ANNU REV PHARMACOL, V59, P379, DOI 10.1146/annurev-pharmtox-010818-021637; Sieni E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00167; Sinclair LV, 2019, ELIFE, V8, DOI 10.7554/eLife.44210; Sinclair LV, 2013, NAT IMMUNOL, V14, P500, DOI 10.1038/ni.2556; Smith LK, 2018, IMMUNITY, V48, P299, DOI 10.1016/j.immuni.2018.01.006; Smith TRF, 2008, TRENDS IMMUNOL, V29, P337, DOI 10.1016/j.it.2008.04.002; So L, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad8463; Sorensen BS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00562; Strowitzki MJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050384; Tanner LB, 2018, CELL SYST, V7, P49, DOI 10.1016/j.cels.2018.06.003; Terrell CE, 2013, BLOOD, V121, P5184, DOI 10.1182/blood-2013-04-495309; Trandem K, 2011, J IMMUNOL, V186, P3642, DOI 10.4049/jimmunol.1003292; Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5; Watson HA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01321; Wilczynska A, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1857-2; Wisniewski JR, 2014, MOL CELL PROTEOMICS, V13, P3497, DOI 10.1074/mcp.M113.037309; Xi Y, 2017, NAT CELL BIOL, V19, P904, DOI 10.1038/ncb3580; Xu Y, 2016, J CLIN INVEST, V126, P2678, DOI 10.1172/JCI85834; Yu YR, 2020, NAT IMMUNOL, V21, P1540, DOI 10.1038/s41590-020-0793-3; Zhang N, 2011, IMMUNITY, V35, P161, DOI 10.1016/j.immuni.2011.07.010; Zhang SB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0796-2; Zhu C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7072	86	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 17	2021	12								712402	10.3389/fimmu.2021.712402	http://dx.doi.org/10.3389/fimmu.2021.712402			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV5WV	34603285	Green Published, gold			2022-12-18	WOS:000717308100001
J	Watanabe, A; Mizoguchi, I; Hasegawa, H; Katahira, Y; Inoue, S; Sakamoto, E; Furusaka, Y; Sekine, A; Miyakawa, S; Murakami, F; Xu, ML; Yoneto, T; Yoshimoto, T				Watanabe, Aruma; Mizoguchi, Izuru; Hasegawa, Hideaki; Katahira, Yasuhiro; Inoue, Shinya; Sakamoto, Eri; Furusaka, Yuma; Sekine, Ami; Miyakawa, Satomi; Murakami, Fumihiro; Xu, Mingli; Yoneto, Toshihiko; Yoshimoto, Takayuki			A Chaperone-Like Role for EBI3 in Collaboration With Calnexin Under Inflammatory Conditions	FRONTIERS IN IMMUNOLOGY			English	Review						EBI3; calnexin; chaperone; heterodimer; tumor growth	INDUCED GENE 3; CD4(+) T-CELLS; P35 SUBUNIT; CYTOKINE; RECEPTOR; PROTEIN; EXPRESSION; IL-35; CONTRIBUTES; SIGNAL	The interleukin-6 (IL-6)/IL-12 family of cytokines plays critical roles in the induction and regulation of innate and adaptive immune responses. Among the various cytokines, only this family has the unique characteristic of being composed of two distinct subunits, alpha- and beta-subunits, which form a heterodimer with subunits that occur in other cytokines as well. Recently, we found a novel intracellular role for one of the alpha-subunits, Epstein-Barr virus-induced gene 3 (EBI3), in promoting the proper folding of target proteins and augmenting its expression at the protein level by binding to its target protein and a well-characterized lectin chaperone, calnexin, presumably through enhancing chaperone activity. Because calnexin is ubiquitously and constitutively expressed but EBI3 expression is inducible, these results could open an avenue to establish a new paradigm in which EBI3 plays an important role in further increasing the expression of target molecules at the protein level in collaboration with calnexin under inflammatory conditions. This theory well accounts for the heterodimer formation of EBI3 with p28, and probably with p35 and p19 to produce IL-27, IL-35, and IL-39, respectively. In line with this concept, another beta-subunit, p40, plays a critical role in the assembly-induced proper folding of p35 and p19 to produce IL-12 and IL-23, respectively. Thus, chaperone-like activities in proper folding and maturation, which allow the secretion of biologically active heterodimeric cytokines, have recently been highlighted. This review summarizes the current understanding of chaperone-like activities of EBI3 to form heterodimers and other associations together with their possible biological implications.	[Watanabe, Aruma; Mizoguchi, Izuru; Hasegawa, Hideaki; Katahira, Yasuhiro; Inoue, Shinya; Sakamoto, Eri; Furusaka, Yuma; Sekine, Ami; Miyakawa, Satomi; Murakami, Fumihiro; Xu, Mingli; Yoneto, Toshihiko; Yoshimoto, Takayuki] Tokyo Med Univ, Inst Med Sci, Dept Immunoregulat, Tokyo, Japan	Tokyo Medical University	Yoshimoto, T (corresponding author), Tokyo Med Univ, Inst Med Sci, Dept Immunoregulat, Tokyo, Japan.	yoshimot@tokyo-med.ac.jp		Katahira, Yasuhiro/0000-0003-3493-1172; Yoshimoto, Takayuki/0000-0002-2847-0341	Ministry of Education, Culture, Sports, Science, and Technology, Japan.	Ministry of Education, Culture, Sports, Science, and Technology, Japan.(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Funding This study was supported in part by grants from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.	Abbas W, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00075; Abdi K, 2014, J IMMUNOL, V192, P6028, DOI 10.4049/jimmunol.1400159; Aparicio-Siegmund S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107990; BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; Braakman I, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a013201; Cassatella MA, 2020, J LEUKOCYTE BIOL, V108, P1515, DOI 10.1002/JLB.3MA0520-054R; Chehboun S, 2017, J BIOL CHEM, V292, P6644, DOI 10.1074/jbc.M116.762021; CHUA AO, 1994, J IMMUNOL, V153, P128; Collison LW, 2007, NATURE, V450, P566, DOI 10.1038/nature06306; Collison LW, 2012, NAT IMMUNOL, V13, P290, DOI 10.1038/ni.2227; Collison LW, 2010, NAT IMMUNOL, V11, P1093, DOI 10.1038/ni.1952; Crabe S, 2009, J IMMUNOL, V183, P7692, DOI 10.4049/jimmunol.0901464; Deng JH, 2019, PATHOG DIS, V77, DOI 10.1093/femspd/ftz007; Detry S, 2019, BIOCHEM PHARMACOL, V165, P240, DOI 10.1016/j.bcp.2019.03.026; Devergne O, 1996, J VIROL, V70, P1143, DOI 10.1128/JVI.70.2.1143-1153.1996; Devergne O, 1997, P NATL ACAD SCI USA, V94, P12041, DOI 10.1073/pnas.94.22.12041; Edahiro Y, 2020, CANCER SCI, V111, P2682, DOI 10.1111/cas.14503; Fan Yong-Gang, 2015, Asian Pac J Cancer Prev, V16, P2845; Floss DM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15173-3; Garbers C, 2013, J BIOL CHEM, V288, P4346, DOI 10.1074/jbc.M112.432955; Gonin J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024617; Hasegawa H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84624-9; Hasegawa H, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00479; Heidemann J, 2007, AM J PHYSIOL-GASTR L, V293, pG1315, DOI 10.1152/ajpgi.00142.2007; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hennig P, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9070707; Hou YM, 2016, ONCOL LETT, V11, P330, DOI 10.3892/ol.2015.3849; How J, 2019, BLOOD, V134, P2242, DOI 10.1182/blood.2019000622; Iranshahi N, 2019, IMMUNOL INVEST, V48, P367, DOI 10.1080/08820139.2018.1549066; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Jalah R, 2013, J BIOL CHEM, V288, P6763, DOI 10.1074/jbc.M112.436675; Jiang JY, 2018, ONCOL RES TREAT, V41, P111, DOI 10.1159/000484935; Jin P, 2014, HUM IMMUNOL, V75, P29, DOI 10.1016/j.humimm.2013.09.018; Jones LL, 2012, MOL IMMUNOL, V51, P234, DOI 10.1016/j.molimm.2012.03.025; Kamiya S, 2004, J IMMUNOL, V173, P3871, DOI 10.4049/jimmunol.173.6.3871; Kimura D, 2016, IMMUNITY, V44, P672, DOI 10.1016/j.immuni.2016.02.011; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Kudo H, 2015, J IMMUNOL, V195, P3565, DOI 10.4049/jimmunol.1402362; Liang YF, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/3214105; Lucas S, 2003, P NATL ACAD SCI USA, V100, P15047, DOI 10.1073/pnas.2536517100; Meier S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12006-x; Min B, 2021, EXP MOL MED, V53, P823, DOI 10.1038/s12276-021-00630-x; Mizoguchi I, 2020, J CLIN INVEST, V130, P6124, DOI 10.1172/JCI122732; Muller SI, 2019, J MOL BIOL, V431, P2383, DOI 10.1016/j.jmb.2019.04.032; Muller SI, 2019, P NATL ACAD SCI USA, V116, P1585, DOI 10.1073/pnas.1816698116; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Nishino R, 2011, CLIN CANCER RES, V17, P6272, DOI 10.1158/1078-0432.CCR-11-0060; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2; Pflanz S, 2004, J IMMUNOL, V172, P2225, DOI 10.4049/jimmunol.172.4.2225; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; Ramnath D, 2015, IMMUNOL CELL BIOL, V93, P771, DOI 10.1038/icb.2015.77; Reitberger S, 2017, J BIOL CHEM, V292, P8073, DOI 10.1074/jbc.M117.782284; Rose-John S, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028415; Sanchez-Martin P, 2018, J CELL SCI, V131, DOI 10.1242/jcs.222836; Schmidt-Arras D, 2014, J CELL SCI, V127, P341, DOI 10.1242/jcs.130294; Scholz GM, 2018, IMMUNOL CELL BIOL, V96, P646, DOI 10.1111/imcb.12029; Sivanesan D, 2016, J BIOL CHEM, V291, P8673, DOI 10.1074/jbc.M116.715870; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; Tumis ME, 2016, IMMUNITY, V44, P316, DOI 10.1016/j.immuni.2016.01.013; Wang RX, 2014, NAT MED, V20, P633, DOI 10.1038/nm.3554; Wang RX, 2012, J BIOL CHEM, V287, P36012, DOI 10.1074/jbc.M112.390625; Wang X, 2016, CLIN EXP IMMUNOL, V186, P144, DOI 10.1111/cei.12840; Wang XQ, 2016, EUR J IMMUNOL, V46, P1343, DOI 10.1002/eji.201546095; Wang ZH, 2013, J IMMUNOL, V190, P2415, DOI 10.4049/jimmunol.1202535; Wetzel A, 2020, CELL MOL LIFE SCI, V77, P5017, DOI 10.1007/s00018-020-03451-9; Wiersma VR, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00007; Wirtz S, 2005, J IMMUNOL, V174, P2814, DOI 10.4049/jimmunol.174.5.2814; Yoshimoto T, 2015, CANCER SCI, V106, P1103, DOI 10.1111/cas.12731; Zhang YQ, 2015, WSPOLCZESNA ONKOL, V19, P120, DOI 10.5114/wo.2014.44754	74	1	1	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 17	2021	12								757669	10.3389/fimmu.2021.757669	http://dx.doi.org/10.3389/fimmu.2021.757669			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV6CL	34603342	gold, Green Published			2022-12-18	WOS:000717322700001
J	Malik, MS; Nyman, IB; Wessel, O; Dahle, MK; Rimstad, E				Malik, Muhammad Salman; Nyman, Ingvild Berg; Wessel, Oystein; Dahle, Maria K.; Rimstad, Espen			Dynamics of Polarized Macrophages and Activated CD8(+) Cells in Heart Tissue of Atlantic Salmon Infected With Piscine Orthoreovirus-1	FRONTIERS IN IMMUNOLOGY			English	Article						Atlantic salmon; cell mediated immunity; heart and skeletal muscle inflammation; macrophage polarization; Piscine orthoreovirus 1	SKELETAL-MUSCLE INFLAMMATION; SALAR L.; EXPRESSION; RESPONSES; STRAIN; VIRUS; FISH; HSMI	Piscine orthoreovirus (PRV-1) infection causes heart and skeletal muscle inflammation (HSMI) in farmed Atlantic salmon (Salmo salar). The virus is also associated with focal melanized changes in white skeletal muscle where PRV-1 infection of macrophages appears to be important. In this study, we studied the macrophage polarization into M1 (pro-inflammatory) and M2 (anti-inflammatory) phenotypes during experimentally induced HSMI. The immune response in heart with HSMI lesions was characterized by CD8(+) and MHC-I expressing cells and not by polarized macrophages. Fluorescent in situ hybridization (FISH) assays revealed localization of PRV-1 in a few M1 macrophages in both heart and skeletal muscle. M2 type macrophages were widely scattered in the heart and were more abundant in heart compared to the skeletal muscle. However, the M2 macrophages did not co-stain for PRV-1. There was a strong cellular immune response to the infection in the heart compared to that of the skeletal muscle, seen as increased MHC-I expression, partly in cells also containing PRV-1 RNA, and a high number of cytotoxic CD8(+) granzyme producing cells that targeted PRV-1. In skeletal muscle, MHC-I expressing cells and CD8(+) cells were dispersed between myocytes, but these cells did not stain for PRV-1. Gene expression analysis by RT-qPCR complied with the FISH results and confirmed a drop in level of PRV-1 following the cell mediated immune response. Overall, the results indicated that M1 macrophages do not contribute to the initial development of HSMI. However, large numbers of M2 macrophages reside in the heart and may contribute to the subsequent fast recovery following clearance of PRV-1 infection.</p>	[Malik, Muhammad Salman; Nyman, Ingvild Berg; Wessel, Oystein; Rimstad, Espen] Norwegian Univ Life Sci, Fac Vet Med, Sect Virol, As, Norway; [Dahle, Maria K.] Norwegian Vet Inst, Dept Fish Hlth, As, Norway	Norwegian University of Life Sciences; Norwegian Veterinary Institute	Rimstad, E (corresponding author), Norwegian Univ Life Sci, Fac Vet Med, Sect Virol, As, Norway.	espen.rimstad@nmbu.no			Research Council of Norway [280847/E40]; Norwegian University of Life Science	Research Council of Norway(Research Council of Norway); Norwegian University of Life Science	The study was supported by the Research Council of Norway, grant 280847/E40 (ViVaAct) and by Norwegian University of Life Science.	Bjorgen H, 2019, J FISH DIS, V42, P935, DOI 10.1111/jfd.12995; Bjorgen H, 2015, VET RES, V46, DOI 10.1186/s13567-015-0244-6; Chaves-Pozo E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02579; Dahle MK, 2015, FISH SHELLFISH IMMUN, V45, P780, DOI 10.1016/j.fsi.2015.05.049; Dhamotharan K, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020143; Di Cicco E, 2018, FACETS, V3, P599, DOI 10.1139/facets-2018-0008; Di Cicco E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171471; Ferguson HW, 2005, J FISH DIS, V28, P119, DOI 10.1111/j.1365-2761.2004.00602.x; Finstad OW, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-35; Godoy MG, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0554-y; Gonzalez-Fernandez C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072439; Grayfer L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01105; Haatveit HM, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9030049; Johansen LH, 2015, FISH SHELLFISH IMMUN, V46, P612, DOI 10.1016/j.fsi.2015.07.023; Jorgensen SM, 2006, FISH SHELLFISH IMMUN, V21, P548, DOI 10.1016/j.fsi.2006.03.004; Kongtorp RT, 2004, DIS AQUAT ORGAN, V59, P217, DOI 10.3354/dao059217; Kongtorp RT, 2004, J FISH DIS, V27, P351, DOI 10.1111/j.1365-2761.2004.00549.x; Lassalle MW, 2003, PIGM CELL RES, V16, P81, DOI 10.1034/j.1600-0749.2003.00004.x; Lovoll M, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-8; Malik MS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664624; Malik MS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090824; Marjara IS, 2012, CYTOKINE, V60, P186, DOI 10.1016/j.cyto.2012.05.027; Mikalsen AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037269; Munang'andu HM, 2013, VACCINE, V31, P1956, DOI 10.1016/j.vaccine.2013.02.008; Mutoloki S, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-336; Nakanishi Teruyuki, 2015, Biology-Basel, V4, P640, DOI 10.3390/biology4040640; O'Hara D, 2001, J VIROL, V75, P5027, DOI 10.1128/JVI.75.11.5027-5035.2001; Polinski MP, 2020, J FISH DIS, V43, P1331, DOI 10.1111/jfd.13228; Rosaeg MV, 2017, FISH SHELLFISH IMMUN, V64, P308, DOI 10.1016/j.fsi.2017.03.036; Schulze PC, 2004, CIRC RES, V95, P552, DOI 10.1161/01.RES.0000143420.87587.9e; Svendsen J., 2018, CARDIOMYOPATHY SYNDR; Takizawa F, 2011, DEV COMP IMMUNOL, V35, P752, DOI 10.1016/j.dci.2011.02.008; Viola A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01462; Wentzel AS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70248-y; Wessel O, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183781; Wessel O, 2015, VET RES, V46, DOI 10.1186/s13567-015-0154-7; Wiegertjes GF, 2016, MOL IMMUNOL, V69, P146, DOI 10.1016/j.molimm.2015.09.026; Zhang YS, 2020, AQUACULTURE, V520, DOI 10.1016/j.aquaculture.2020.734969	38	1	1	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 16	2021	12								729017	10.3389/fimmu.2021.729017	http://dx.doi.org/10.3389/fimmu.2021.729017			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UY2DR	34603301	Green Published, gold			2022-12-18	WOS:000701340100001
J	Qiu, XY; Sun, H; Wang, D; Ren, JQ; Wang, XY; Zhang, AY; Yang, K; Zhou, H				Qiu, Xingyang; Sun, Hao; Wang, Dan; Ren, Jingqi; Wang, Xinyan; Zhang, Anying; Yang, Kun; Zhou, Hong			Stimulus-Specific Expression, Selective Generation and Novel Function of Grass Carp (Ctenopharyngodon idella) IL-12 Isoforms: New Insights Into the Heterodimeric Cytokines in Teleosts	FRONTIERS IN IMMUNOLOGY			English	Article						grass carp; Il-12; p35 paralogues; heterodimeric form; Th17-like response	NF-KAPPA-B; CELL STIMULATORY FACTOR; IFN-GAMMA; TYROSINE PHOSPHORYLATION; DIFFERENTIAL EXPRESSION; INTERLEUKIN-12 IL-12; IN-VITRO; T-CELLS; IDENTIFICATION; P40	Interleukin-12 (IL-12) is a heterodimeric cytokine composed of a p35 subunit specific to IL-12 and a p40 subunit shared with IL-23. In this study, we unveiled the existence of two p35 paralogues in grass carp (named gcp35a and gcp35b). Notably, gcp35a and gcp35b displayed distinct inducible expression patterns, as poly I:C merely induced the gene expression of gcp35a but not gcp35b, while recombinant grass carp interferon-gamma (rgcIfn-gamma) only enhanced the transcription of gcp35b but not gcp35a. Moreover, the signaling mechanisms responsible for the inducible expression of gcp35a and gcp35b mRNA were elucidated. Because of the existence of three grass carp p40 genes (gcp40a, gcp40b and gcp40c) and two p35 paralogues, six gcIl-12 isoforms were predicted by 3D modeling. Results showed that gcp40a and gcp40b but not gcp40c had the potential for forming heterodimers with both gcp35 paralogues via the disulfide bonds. Non-reducing electrophoresis experiments further disclosed that only gcp40b but not gcp40a or gcp40c could form heterodimers with gcp35 to produce secretory heterodimeric gcp35a/gcp40b (gcIl-12AB) and gcp35b/gcp40b (gcIl-12BB), which prompted us to prepare their recombinant proteins. These two recombinant proteins exhibited their extensive regulation on Ifn-gamma production in various immune cells. Intriguingly, both gcIl-12 isoforms significantly enhanced the transcription of il-17a/f1 and il-22 in lymphocytes, and their regulation on il-17a/f1 expression was mediated by Stat3/Ror gamma t signaling, supporting the potential of gcIl-12 isoforms for inducing Th17-like responses. Additionally, stimulatory effects of gcIl-12 isoforms on il-17a/f1 and ifn-gamma expression were attenuated by gcTgf-beta 1 via suppressing the activation of Stat3 signaling, implying that their signaling could be manipulated. In brief, our works provide new insights into the inducible expression pattern, heterodimeric generation and functional novelty of Il-12 isoforms in teleosts.	[Qiu, Xingyang; Sun, Hao; Wang, Dan; Ren, Jingqi; Wang, Xinyan; Zhang, Anying; Yang, Kun; Zhou, Hong] Univ Elect Sci & Technol China, Sch Life Sci & Technol, Chengdu, Peoples R China	University of Electronic Science & Technology of China	Zhou, H (corresponding author), Univ Elect Sci & Technol China, Sch Life Sci & Technol, Chengdu, Peoples R China.	zhouhongzh@uestc.edu.cn	Zhang, An/GRS-5852-2022	qiu, xingyang/0000-0003-2792-3289	National Natural Science Foundation of China [31572650]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the grant from the National Natural Science Foundation of China (31572650).	Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Ahn HJ, 1998, J IMMUNOL, V161, P5893; Babik JM, 1999, J IMMUNOL, V162, P4069; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; Bohnacker S, 2020, MOL IMMUNOL, V126, P120, DOI 10.1016/j.molimm.2020.07.015; Bright JJ, 1998, J IMMUNOL, V161, P1772; Cai S, 2016, MUCOSAL IMMUNOL, V9, P718, DOI 10.1038/mi.2015.95; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; Ding X, 2018, FISH SHELLFISH IMMUN, V72, P646, DOI 10.1016/j.fsi.2017.11.042; Du LY, 2017, DEV COMP IMMUNOL, V76, P326, DOI 10.1016/j.dci.2017.07.008; Du LY, 2015, DEV COMP IMMUNOL, V51, P202, DOI 10.1016/j.dci.2015.03.014; Feng SY, 2020, FISH SHELLFISH IMMUN, V98, P995, DOI 10.1016/j.fsi.2019.11.025; Feng SY, 2019, FISH SHELLFISH IMMUN, V89, P403, DOI 10.1016/j.fsi.2019.04.015; Gessani S, 1998, CYTOKINE GROWTH F R, V9, P117, DOI 10.1016/S1359-6101(98)00007-0; GILLESSEN S, 1995, EUR J IMMUNOL, V25, P200, DOI 10.1002/eji.1830250133; Hirahara K, 2010, CYTOKINE GROWTH F R, V21, P425, DOI 10.1016/j.cytogfr.2010.10.006; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Huising MO, 2006, MOL IMMUNOL, V43, P1519, DOI 10.1016/j.molimm.2005.10.010; Ivanov II, 2007, SEMIN IMMUNOL, V19, P409, DOI 10.1016/j.smim.2007.10.011; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Kim D, 2019, FISH SHELLFISH IMMUN, V92, P151, DOI 10.1016/j.fsi.2019.05.033; Kother K, 2014, FASEB J, V28, P4235, DOI 10.1096/fj.14-249599; Liu X, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6152713; Mahmoudzadeh S, 2021, PARASITOL RES, V120, P2303, DOI 10.1007/s00436-021-07204-w; Matsumoto M, 2016, FISH SHELLFISH IMMUN, V55, P281, DOI 10.1016/j.fsi.2016.05.025; Nascimento DS, 2007, MOL IMMUNOL, V44, P2277, DOI 10.1016/j.molimm.2006.11.006; Nishikawa K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108494; Pandit NP, 2015, GENET MOL RES, V14, P1169, DOI 10.4238/2015.February.6.20; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; Qiu XY, 2017, FISH SHELLFISH IMMUN, V66, P148, DOI 10.1016/j.fsi.2017.05.024; Reitberger S, 2017, J BIOL CHEM, V292, P8073, DOI 10.1074/jbc.M117.782284; Robinson RT, 2008, J IMMUNOL, V181, P5560, DOI 10.4049/jimmunol.181.8.5560; Secombes CJ, 2016, EVOLUTION OF THE IMMUNE SYSTEM: CONSERVATION AND DIVERSIFICATION, P87, DOI 10.1016/B978-0-12-801975-7.00005-0; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Tsai JL, 2014, FISH SHELLFISH IMMUN, V36, P27, DOI 10.1016/j.fsi.2013.10.009; Wang TH, 2014, DEV COMP IMMUNOL, V46, P194, DOI 10.1016/j.dci.2014.04.008; Wang TH, 2014, EUR J IMMUNOL, V44, P1541, DOI 10.1002/eji.201344273; Wang XY, 2019, FISH SHELLFISH IMMUN, V86, P1072, DOI 10.1016/j.fsi.2018.12.031; Wang XY, 2017, FISH SHELLFISH IMMUN, V71, P434, DOI 10.1016/j.fsi.2017.10.009; Wangkahart E, 2019, FISH SHELLFISH IMMUN, V85, P18, DOI 10.1016/j.fsi.2017.07.056; Watford WT, 2003, CYTOKINE GROWTH F R, V14, P361, DOI 10.1016/S1359-6101(03)00043-1; Wei H, 2015, FISH SHELLFISH IMMUN, V44, P445, DOI 10.1016/j.fsi.2015.03.023; Wen C, 2020, GENE, V741, DOI 10.1016/j.gene.2020.144579; WOLF SF, 1991, J IMMUNOL, V146, P3074; WU CY, 1993, J IMMUNOL, V151, P1938; Yang K, 2013, FISH SHELLFISH IMMUN, V35, P1635, DOI 10.1016/j.fsi.2013.09.017; Yang M, 2012, DEV COMP IMMUNOL, V38, P98, DOI 10.1016/j.dci.2012.04.010; Yang M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035011; Yang X, 2014, DEV COMP IMMUNOL, V47, P197, DOI 10.1016/j.dci.2014.07.023; Yin LC, 2021, J IMMUNOL, V207, P1087, DOI 10.4049/jimmunol.2100151; Yin LC, 2019, FISH SHELLFISH IMMUN, V92, P315, DOI 10.1016/j.fsi.2019.06.028; Yoon C, 2000, EMBO J, V19, P3530, DOI 10.1093/emboj/19.14.3530; Zhang AY, 2020, FISH SHELLFISH IMMUN, V99, P19, DOI 10.1016/j.fsi.2020.01.059; Zhang AY, 2012, FISH SHELLFISH IMMUN, V33, P1123, DOI 10.1016/j.fsi.2012.08.029; Zhang AY, 2011, COMP BIOCHEM PHYS B, V159, P109, DOI 10.1016/j.cbpb.2011.02.009; Zhang S, 2008, BIOCHEM BIOPH RES CO, V372, P509, DOI 10.1016/j.bbrc.2008.05.081; Zhang SN, 2019, FISH SHELLFISH IMMUN, V86, P393, DOI 10.1016/j.fsi.2018.11.061	57	1	1	2	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 16	2021	12								734535	10.3389/fimmu.2021.734535	http://dx.doi.org/10.3389/fimmu.2021.734535			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UZ1ZA	34603315	gold, Green Published			2022-12-18	WOS:000702008500001
J	van Dorsten, RT; Wagh, K; Moore, PL; Morris, L				van Dorsten, Rebecca T.; Wagh, Kshitij; Moore, Penny L.; Morris, Lynn			Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; broadly neutralizing antibodies; single chain variable fragments; combinations of scFv; HIV prevention	ADENOASSOCIATED VIRAL VECTORS; IMMUNODEFICIENCY-VIRUS; GENE-TRANSFER; FV; INFECTION; PROTEINS; FUSION; VRC01; TRIAL	Broadly neutralizing antibodies (bNAbs) are currently being assessed in clinical trials for their ability to prevent HIV infection. Single chain variable fragments (scFv) of bNAbs have advantages over full antibodies as their smaller size permits improved diffusion into mucosal tissues and facilitates vector-driven gene expression. We have previously shown that scFv of bNAbs individually retain significant breadth and potency. Here we tested combinations of five scFv derived from bNAbs CAP256-VRC26.25 (V2-apex), PGT121 (N332-supersite), 3BNC117 (CD4bs), 8ANC195 (gp120-gp41 interface) and 10E8v4 (MPER). Either two or three scFv were combined in equimolar amounts and tested in the TZM-bl neutralization assay against a multiclade panel of 17 viruses. Experimental IC50 and IC80 data were compared to predicted neutralization titers based on single scFv titers using the Loewe additive and the Bliss-Hill model. Like full-sized antibodies, combinations of scFv showed significantly improved potency and breadth compared to single scFv. Combinations of two or three scFv generally followed an independent action model for breadth and potency with no significant synergy or antagonism observed overall although some exceptions were noted. The Loewe model underestimated potency for some dual and triple combinations while the Bliss-Hill model was better at predicting IC80 titers of triple combinations. Given this, we used the Bliss-Hill model to predict the coverage of scFv against a 45-virus panel at concentrations that correlated with protection in the AMP trials. Using IC80 titers and concentrations of 1 mu g/mL, there was 93% coverage for one dual scFv combination (3BNC117+10E8v4), and 96% coverage for two of the triple combinations (CAP256.25+3BNC117+10E8v4 and PGT121+3BNC117+10E8v4). Combinations of scFv, therefore, show significantly improved breadth and potency over individual scFv and given their size advantage, have potential for use in passive immunization.	[van Dorsten, Rebecca T.; Moore, Penny L.; Morris, Lynn] Natl Inst Communicable Dis Natl Hlth Lab Serv, Ctr HIV & STIs, Johannesburg, South Africa; [van Dorsten, Rebecca T.; Moore, Penny L.; Morris, Lynn] Univ Witwatersrand, Med Res Council MRC, Antibody Immun Res Unit, Fac Hlth Sci, Johannesburg, South Africa; [Wagh, Kshitij] Los Alamos Natl Lab, Div Theoret, Los Alamos, NM USA; [Moore, Penny L.; Morris, Lynn] Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa CAPRISA, Durban, South Africa	University of Witwatersrand; United States Department of Energy (DOE); Los Alamos National Laboratory; University of Kwazulu Natal	Morris, L (corresponding author), Natl Inst Communicable Dis Natl Hlth Lab Serv, Ctr HIV & STIs, Johannesburg, South Africa.; Morris, L (corresponding author), Univ Witwatersrand, Med Res Council MRC, Antibody Immun Res Unit, Fac Hlth Sci, Johannesburg, South Africa.; Morris, L (corresponding author), Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa CAPRISA, Durban, South Africa.	lynnm@nicd.ac.za		van Dorsten, Rebecca T/0000-0002-1808-1588	South African Medical Research Council (SAMRC) Flagship Project; NIH through aU01 grant [U01AI116086]; Poliomyelitis Research Fund (PRF) through a PRF research grant [17/15]; Center for the AIDS Program of Research (CAPRISA); South African HIV/AIDS Research and Innovation Platform of the South African Department of Science and Technology; U.S.NIAID, NIH, U.S. Department of Health and Human Services grant [U19 AI51794]; Poliomyelitis Research Foundation [W 16/72]; South African Research Chairs Initiative of the Department of Science and Innovation; National Research Foundation of South Africa [98341]; Bill and Melinda Gates Foundation [OPP1032144]	South African Medical Research Council (SAMRC) Flagship Project; NIH through aU01 grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Poliomyelitis Research Fund (PRF) through a PRF research grant; Center for the AIDS Program of Research (CAPRISA); South African HIV/AIDS Research and Innovation Platform of the South African Department of Science and Technology; U.S.NIAID, NIH, U.S. Department of Health and Human Services grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Poliomyelitis Research Foundation; South African Research Chairs Initiative of the Department of Science and Innovation; National Research Foundation of South Africa(National Research Foundation - South Africa); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	We acknowledge research funding from the South African Medical Research Council (SAMRC) Flagship Project, the NIH through aU01 grant (U01AI116086), the Poliomyelitis Research Fund (PRF) through a PRF research grant (17/15), and the Center for the AIDS Program of Research (CAPRISA). CAPRISA is funded by the South African HIV/AIDS Research and Innovation Platform of the South African Department of Science and Technology and was initially supported by the U.S.NIAID, NIH, U.S. Department of Health and Human Services grant U19 AI51794. R.T.V.D. is supported by a Poliomyelitis Research Foundation Ph.D. bursary (W 16/72). PM is supported by the South African Research Chairs Initiative of the Department of Science and Innovation and National Research Foundation of South Africa (grant no. 98341). KW is supported by the Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery grant OPP1032144 (Comprehensive Antibody Vaccine Immune Monitoring Consortium CAVIMC) (https://www.cavd.org/Pages/default.aspx). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Alam MM, 2019, BIOCHEM BIOPHYS REP, V20, DOI 10.1016/j.bbrep.2019.100687; Bekker LG, 2018, LANCET HIV, V5, pE366, DOI 10.1016/S2352-3018(18)30071-7; Bhiman JN, 2017, CURR HIV-AIDS REP, V14, P54, DOI 10.1007/s11904-017-0352-1; Brady JM, 2017, IMMUNOL REV, V275, P324, DOI 10.1111/imr.12478; Burton DR, 2016, ANNU REV IMMUNOL, V34, P635, DOI 10.1146/annurev-immunol-041015-055515; CAPRISA, 2020, CAPRISA STUD; Cohen YZ, 2018, J VIROL, V92, DOI 10.1128/JVI.01883-17; Colcher D, 1998, Q J NUCL MED, V42, P225; Corey L, 2021, NEW ENGL J MED, V384, P1003, DOI 10.1056/NEJMoa2031738; Crowell TA, 2019, LANCET HIV, V6, pE297, DOI 10.1016/S2352-3018(19)30053-0; Davis-Gardner ME, 2020, MBIO, V11, DOI 10.1128/mBio.03080-19; Dong JY, 1996, HUM GENE THER, V7, P2101, DOI 10.1089/hum.1996.7.17-2101; Doria-Rose NA, 2016, J VIROL, V90, P76, DOI 10.1128/JVI.01791-15; Doria-Rose NA, 2014, NATURE, V509, P55, DOI 10.1038/nature13036; Edupuganti S, 2021, JAIDS-J ACQ IMM DEF, V87, P671, DOI 10.1097/QAI.0000000000002639; Foucquier J, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.149; Fu QS, 2018, P NATL ACAD SCI USA, V115, pE8892, DOI 10.1073/pnas.1807259115; Gasteiger E., 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Gray ES, 2011, J VIROL, V85, P4828, DOI 10.1128/JVI.00198-11; Greineder CF, 2018, BIOCONJUGATE CHEM, V29, P56, DOI 10.1021/acs.bioconjchem.7b00592; Gruenert AK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152589; Hay CE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200060; Huang YX, 2016, CELL, V165, P1621, DOI 10.1016/j.cell.2016.05.024; Huang YD, 2021, EBIOMEDICINE, V64, DOI 10.1016/j.ebiom.2020.103203; Julg B, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4235; Karasavvas N, 2012, AIDS RES HUM RETROV, V28, P1444, DOI 10.1089/aid.2012.0103; Karuna ST, 2020, ANNU REV MED, V71, P329, DOI 10.1146/annurev-med-110118-045506; Karuna ST., 2021, PHASE 1 BROADLY NEUT; Khan SN, 2018, J VIROL, V92, DOI 10.1128/JVI.00384-18; Kim AS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004271; Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144; Kong R, 2015, J VIROL, V89, P2659, DOI 10.1128/JVI.03136-14; Krishnaswamy S, 2020, NEUROBIOL DIS, V137, DOI 10.1016/j.nbd.2020.104770; Kumar S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01568; Lin A, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0449-7; Liu Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08658-4; Liu ZQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02460-2; Lorenzi JCC, 2021, J VIROL, V95, DOI 10.1128/JVI.01909-20; Mahomed S, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-042247; Marcotte H., 2015, MUCOSAL IMMUNOL, V2015, P1403, DOI [10.1016/B978-0-12-415847-4.00071-9, DOI 10.1016/B978-0-12-415847-4.00071-9]; Martinez-Navio JM, 2019, IMMUNITY, V50, P567, DOI 10.1016/j.immuni.2019.02.005; Mascola JR, 2005, J VIROL, V79, P10103, DOI 10.1128/JVI.79.16.10103-10107.2005; Mgodi NM, 2021, JAIDS-J ACQ IMM DEF, V87, P680, DOI 10.1097/QAI.0000000000002649; Monnier PP, 2013, ANTIBODIES, V2, P193, DOI 10.3390/antib2020193; Moore PL, 2013, J VIROL, V87, P4882, DOI 10.1128/JVI.03424-12; Morita S, 2016, NAT BIOTECHNOL, V34, P1060, DOI 10.1038/nbt.3658; Moshoette T, 2019, RETROVIROLOGY, V16, DOI 10.1186/s12977-019-0493-y; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Patel P, 2014, MOL THER, V22, P498, DOI 10.1038/mt.2013.239; Phoolcharoen W, 2019, VACCINE, V37, P4673, DOI 10.1016/j.vaccine.2018.02.057; Pinto D, 2019, CELL HOST MICROBE, V26, P623, DOI 10.1016/j.chom.2019.09.016; Portolano N, 2014, JOVE-J VIS EXP, DOI 10.3791/51897; Rafiq S, 2018, NAT BIOTECHNOL, V36, P847, DOI 10.1038/nbt.4195; Raj D, 2011, EXPERT REV HEMATOL, V4, P539, DOI [10.1586/ehm.11.48, 10.1586/EHM.11.48]; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Rosenberg YJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212649; Rujas E, 2016, SCI REP-UK, V6, DOI 10.1038/srep38177; Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022; Saunders KO, 2015, J VIROL, V89, P8334, DOI 10.1128/JVI.00908-15; Song RJ, 2016, JAIDS-J ACQ IMM DEF, V73, P365, DOI 10.1097/QAI.0000000000001119; Todd CA, 2012, J IMMUNOL METHODS, V375, P57, DOI 10.1016/j.jim.2011.09.007; Unverdorben F, 2016, MABS-AUSTIN, V8, P120, DOI 10.1080/19420862.2015.1113360; Unverdorben F, 2012, PROTEIN ENG DES SEL, V25, P81, DOI 10.1093/protein/gzr061; van den Berg FT, 2019, MOL THER-METH CLIN D, V14, P100, DOI 10.1016/j.omtm.2019.06.002; van Dorsten RT, 2020, J VIROL, V94, DOI 10.1128/JVI.01533-19; Wagh K, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006860; Wagh K, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005520; Wang Y, 2019, P NATL ACAD SCI USA, V116, P22556, DOI 10.1073/pnas.1912427116; West AP, 2012, J VIROL, V86, P195, DOI 10.1128/JVI.05848-11; Wu ZJ, 2010, MOL THER, V18, P80, DOI 10.1038/mt.2009.255; YOKOTA T, 1992, CANCER RES, V52, P3402; Zhou TQ, 2017, CELL REP, V19, P719, DOI 10.1016/j.celrep.2017.04.013	72	1	1	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 16	2021	12								734110	10.3389/fimmu.2021.734110	http://dx.doi.org/10.3389/fimmu.2021.734110			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UZ2GK	34603312	Green Published, gold			2022-12-18	WOS:000702028300001
J	Schaap-Johansen, AL; Vujovic, M; Borch, A; Hadrup, SR; Marcatili, P				Schaap-Johansen, Anna-Lisa; Vujovic, Milena; Borch, Annie; Hadrup, Sine Reker; Marcatili, Paolo			T Cell Epitope Prediction and Its Application to Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Review						epitope prediction; neoantigens; neoepitope prediction; T cell; TCR; T cell receptor	MHC CLASS-I; BINDING-AFFINITY; NEURAL-NETWORKS; PEPTIDES; CANCER; IMMUNOGENICITY; IDENTIFICATION; PIPELINE; TRANSCRIPTOME; NEOEPITOPES	T cells play a crucial role in controlling and driving the immune response with their ability to discriminate peptides derived from healthy as well as pathogenic proteins. In this review, we focus on the currently available computational tools for epitope prediction, with a particular focus on tools aimed at identifying neoepitopes, i.e. cancer-specific peptides and their potential for use in immunotherapy for cancer treatment. This review will cover how these tools work, what kind of data they use, as well as pros and cons in their respective applications.	[Schaap-Johansen, Anna-Lisa; Vujovic, Milena; Borch, Annie; Hadrup, Sine Reker; Marcatili, Paolo] Tech Univ Denmark, Dept Hlth Technol, Lyngby, Denmark	Technical University of Denmark	Marcatili, P (corresponding author), Tech Univ Denmark, Dept Hlth Technol, Lyngby, Denmark.	pamar@dtu.dk	Vujovic, Milena/B-5260-2017; Hadrup, Sine Reker/P-3388-2014	Vujovic, Milena/0000-0002-6027-7648; Hadrup, Sine Reker/0000-0002-5937-4344; Marcatili, Paolo/0000-0003-2615-5695	2018 SDC grants	2018 SDC grants	A-LS-J is funded by the 2018 SDC grants.	Abelin JG, 2017, IMMUNITY, V46, P315, DOI 10.1016/j.immuni.2017.02.007; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Aranha MP, 2020, J IMMUNOL, V205, P1962, DOI 10.4049/jimmunol.1900918; Bagaev DV, 2020, NUCLEIC ACIDS RES, V48, pD1057, DOI 10.1093/nar/gkz874; Bais P, 2017, BIOINFORMATICS, V33, P3110, DOI 10.1093/bioinformatics/btx375; Bentzen AK, 2018, NAT BIOTECHNOL, V36, P1191, DOI 10.1038/nbt.4303; Bjerregaard AM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01566; Bjerregaard AM, 2017, CANCER IMMUNOL IMMUN, V66, P1123, DOI 10.1007/s00262-017-2001-3; Borrman T, 2017, PROTEINS, V85, P908, DOI 10.1002/prot.25260; Bulik-Sullivan B, 2019, NAT BIOTECHNOL, V37, P55, DOI 10.1038/nbt.4313; BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1; Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266; Croft NP, 2019, P NATL ACAD SCI USA, V116, P3112, DOI 10.1073/pnas.1815239116; de Leoz MLA, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002717; Donnes P, 2005, PROTEIN SCI, V14, P2132, DOI 10.1110/ps.051352405; Duan F, 2014, J EXP MED, V211, P2231, DOI 10.1084/jem.20141308; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Fleri W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00278; Fotakis G, 2020, BIOINFORMATICS, V36, P2260, DOI 10.1093/bioinformatics/btz879; Fritsch EF, 2014, CANCER IMMUNOL RES, V2, P522, DOI 10.1158/2326-6066.CIR-13-0227; Galluzzi L, 2014, ONCOTARGET, V5, P12472, DOI 10.18632/oncotarget.2998; Ghorani E, 2018, ANN ONCOL, V29, P271, DOI 10.1093/annonc/mdx687; Gielis S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02820; Grade Marian, 2015, Recent Results Cancer Res, V200, P115, DOI 10.1007/978-3-319-20291-4_6; Humphries C, 2013, NATURE, V504, pS13, DOI 10.1038/504S13a; Hundal J, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0264-5; Jenkins MK, 2010, ANNU REV IMMUNOL, V28, P275, DOI 10.1146/annurev-immunol-030409-101253; Jensen KK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50932-4; Jorgensen KW, 2014, IMMUNOLOGY, V141, P18, DOI 10.1111/imm.12160; Jurtz VI, 2018, BIORXIV, DOI [10.1101/433706., DOI 10.1101/433706, 10.1101/433706]; Karosiene E, 2012, IMMUNOGENETICS, V64, P177, DOI 10.1007/s00251-011-0579-8; Keskin DB, 2019, NATURE, V565, P234, DOI 10.1038/s41586-018-0792-9; Kim S, 2018, ANN ONCOL, V29, P1030, DOI 10.1093/annonc/mdy022; Knapp B, 2016, J CHEM INF MODEL, V56, P46, DOI 10.1021/acs.jcim.5b00511; Kodysh J, 2020, METHODS MOL BIOL, V2120, P147, DOI 10.1007/978-1-0716-0327-7_10; Kosaloglu-Yalcin Z, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1492508; Lanzarotti E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02080; Lanzarotti E, 2018, MOL IMMUNOL, V94, P91, DOI 10.1016/j.molimm.2017.12.019; Laumont CM, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aau5516; Leem J, 2018, NUCLEIC ACIDS RES, V46, pD406, DOI 10.1093/nar/gkx971; Li SL, 2019, METHODS MOL BIOL, V2048, P207, DOI 10.1007/978-1-4939-9728-2_17; Lund O, 1997, PROTEIN ENG, V10, P1241, DOI 10.1093/protein/10.11.1241; Malaker SA, 2017, CANCER IMMUNOL RES, V5, P376, DOI 10.1158/2326-6066.CIR-16-0280; Mommen GPM, 2014, P NATL ACAD SCI USA, V111, P4507, DOI 10.1073/pnas.1321458111; Mondet S, 2017, BIORXIV213884, DOI [10. 1101/213884, 10.1101/213884, DOI 10.1101/213884]; Nagasawa DT, 2012, NEUROSURG CLIN N AM, V23, P481, DOI 10.1016/j.nec.2012.04.008; Nicolae M, 2011, ALGORITHM MOL BIOL, V6, DOI 10.1186/1748-7188-6-9; Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403; Nielsen M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000796; O'Donnell TJ, 2018, CELL SYST, V7, P129, DOI 10.1016/j.cels.2018.05.014; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Peters B, 2020, ANNU REV IMMUNOL, V38, P123, DOI 10.1146/annurev-immunol-082119-124838; Pickrell JK, 2010, NATURE, V464, P768, DOI 10.1038/nature08872; Qi Q, 2014, P NATL ACAD SCI USA, V111, P13139, DOI 10.1073/pnas.1409155111; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Raposo B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02763-y; Rasmussen M, 2016, J IMMUNOL, V197, P1517, DOI 10.4049/jimmunol.1600582; Rice J, 2008, NAT REV CANCER, V8, P108, DOI 10.1038/nrc2326; Richman LP, 2019, CELL SYST, V9, P375, DOI 10.1016/j.cels.2019.08.009; Rudolph MG, 2002, CURR OPIN IMMUNOL, V14, P52, DOI 10.1016/S0952-7915(01)00298-9; Saethang T, 2013, J IMMUNOL METHODS, V387, P293, DOI 10.1016/j.jim.2012.09.016; Satoh Yuji, 2002, J Exp Ther Oncol, V2, P337, DOI 10.1046/j.1359-4117.2002.01050.x; Schenck RO, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2876-4; Schmidt J, 2017, J BIOL CHEM, V292, P11840, DOI 10.1074/jbc.M117.789511; Schymkowitz J, 2005, NUCLEIC ACIDS RES, V33, pW382, DOI 10.1093/nar/gki387; SETTE A, 1994, J IMMUNOL, V153, P5586; Shi Y, 2020, BIOINFORMATICS, V36, P4894, DOI 10.1093/bioinformatics/btaa596; Simons KT, 1999, PROTEINS, P171; Singh-Jasuja H, 2004, CANCER IMMUNOL IMMUN, V53, P187, DOI 10.1007/s00262-003-0480-x; Smart AC, 2018, NAT BIOTECHNOL, V36, P1056, DOI 10.1038/nbt.4239; Solleder M, 2020, MOL CELL PROTEOMICS, V19, P390, DOI 10.1074/mcp.TIR119.001641; Tappeiner E, 2017, BIOINFORMATICS, V33, P3140, DOI 10.1093/bioinformatics/btx377; Tesarova P, 2007, NEOPLASMA, V54, P219; THOMAS L, 1982, YALE J BIOL MED, V55, P329; Tickotsky N, 2017, BIOINFORMATICS, V33, P2924, DOI 10.1093/bioinformatics/btx286; Trolle T, 2014, IMMUNOGENETICS, V66, P449, DOI 10.1007/s00251-014-0779-0; Tung CW, 2007, BIOINFORMATICS, V23, P942, DOI 10.1093/bioinformatics/btm061; Tung CW, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-446; van Berkum Nynke L, 2010, J Vis Exp, DOI 10.3791/1869; Wang TY, 2019, BIOINFORMATICS, V35, P4159, DOI 10.1093/bioinformatics/btz193; Warren RL, 2012, GENOME MED, V4, DOI 10.1186/gm396; Wei ZT, 2019, ISCIENCE, V21, P249, DOI 10.1016/j.isci.2019.10.028; Wickstrom SL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02766; Wood MA, 2020, BIOINFORMATICS, V36, P713, DOI 10.1093/bioinformatics/btz653; Wu JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02559; Yewdell JTW, 1999, ANNU REV IMMUNOL, V17, P51, DOI 10.1146/annurev.immunol.17.1.51; Zhang J, 2017, BIOINFORMATICS, V33, P555, DOI 10.1093/bioinformatics/btw674; Zhang J, 2016, GENOME RES, V26, P108, DOI 10.1101/gr.186114.114; Zhang W, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.628456; Zhong WM, 2003, J BIOL CHEM, V278, P45135, DOI 10.1074/jbc.M307417200; Zhou C, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0679-x; Zhou Z, 2017, ROY SOC OPEN SCI, V4, DOI 10.1098/rsos.170050	93	1	1	4	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 15	2021	12								712488	10.3389/fimmu.2021.712488	http://dx.doi.org/10.3389/fimmu.2021.712488			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UY1FY	34603286	Green Published, gold			2022-12-18	WOS:000701278400001
J	Li, GQ; Chen, HZ; Liu, LW; Xiao, P; Xie, Y; Geng, XL; Zhang, T; Zhang, Y; Lu, TQ; Tan, HT; Li, L; Sun, B				Li, Guanqun; Chen, Hongze; Liu, Liwei; Xiao, Peng; Xie, Yu; Geng, Xinglong; Zhang, Tao; Zhang, Yang; Lu, Tianqi; Tan, Hongtao; Li, Le; Sun, Bei			Role of Interleukin-17 in Acute Pancreatitis	FRONTIERS IN IMMUNOLOGY			English	Review						interleukin-17; acute pancreatitis; T helper 17 cells; immune response; gut microbiome	C-REACTIVE PROTEIN; NF-KAPPA-B; GUT MICROBIOTA; IL-17 RECEPTOR; TH17 CELLS; METABOLITES MODULATE; DENDRITIC CELLS; DOUBLE-BLIND; SERUM-LEVELS; T-CELLS	Acute pancreatitis (AP) is a leading cause of death and is commonly accompanied by systemic manifestations that are generally associated with a poor prognosis. Many cytokines contribute to pancreatic tissue damage and cause systemic injury. Interleukin-17 (IL-17) is a cytokine that may play a vital role in AP. Specifically, IL-17 has important effects on the immune response and causes interactions between different inflammatory mediators in the AP-related microenvironment. In this literature review, we will discuss the existing academic understanding of IL-17 and the impacts of IL-17 in different cells (especially in acinar cells and immune system cells) in AP pathogenesis. The clinical significance and potential mechanisms of IL-17 on AP deterioration are emphasized. The evidence suggests that inhibiting the IL-17 cytokine family could alleviate the pathogenic process of AP, and we highlight therapeutic strategies that directly or indirectly target IL-17 cytokines in acute pancreatitis.	[Li, Guanqun; Chen, Hongze; Liu, Liwei; Xiao, Peng; Xie, Yu; Geng, Xinglong; Zhang, Tao; Zhang, Yang; Lu, Tianqi; Tan, Hongtao; Li, Le; Sun, Bei] Harbin Med Univ, Affiliated Hosp 1, Dept Pancreat & Biliary Surg, Harbin, Peoples R China; [Sun, Bei] Minist Educ, Key Lab Hepatosplen Surg, Harbin, Peoples R China	Harbin Medical University	Li, L; Sun, B (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Dept Pancreat & Biliary Surg, Harbin, Peoples R China.; Sun, B (corresponding author), Minist Educ, Key Lab Hepatosplen Surg, Harbin, Peoples R China.	lile@hrbmu.edu.cn; sunbei70@outlook.com			National Natural Science Foundation of China [81871974, 82070658, 81800572]; Natural Science Foundation of Heilongjiang Province [LH2021H048]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Heilongjiang Province(Natural Science Foundation of Heilongjiang Province)	This study was supported by The National Natural Science Foundation of China (81871974, 82070658, 81800572) and The Natural Science Foundation of Heilongjiang Province (LH2021H048).	Abusleme L, 2017, ORAL DIS, V23, P854, DOI 10.1111/odi.12598; Adolph TE, 2019, ANNU REV NUTR, V39, P249, DOI 10.1146/annurev-nutr-082018-124306; Akitsu A, 2018, IMMUNOLOGY, V155, P418, DOI 10.1111/imm.12993; Andoh A, 2002, BBA-MOL CELL RES, V1591, P69, DOI 10.1016/S0167-4889(02)00250-1; Ang QY, 2020, CELL, V181, P1263, DOI 10.1016/j.cell.2020.04.027; Aqel SI, 2019, CLIN EXP IMMUNOL, V196, P215, DOI 10.1111/cei.13258; Awane M, 1999, J IMMUNOL, V162, P5337; Bedrosian AS, 2011, GASTROENTEROLOGY, V141, P1915, DOI 10.1053/j.gastro.2011.07.033; Beringer A, 2019, NAT REV RHEUMATOL, V15, P491, DOI 10.1038/s41584-019-0243-5; Beringer A, 2018, AUTOIMMUN REV, V17, P1176, DOI 10.1016/j.autrev.2018.06.008; Beringer A, 2016, TRENDS MOL MED, V22, P230, DOI 10.1016/j.molmed.2016.01.001; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Beurel E, 2018, BRAIN BEHAV IMMUN, V69, P28, DOI 10.1016/j.bbi.2017.08.001; Boxhoorn L, 2020, LANCET, V396, P726, DOI 10.1016/S0140-6736(20)31310-6; Brevi A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.565470; Britton GJ, 2020, P NATL ACAD SCI USA, V117, P21536, DOI 10.1073/pnas.1922189117; Brubaker L, 2021, PANCREATOLOGY, V21, P1, DOI 10.1016/j.pan.2020.12.013; Bulek K, 2011, NAT IMMUNOL, V12, P844, DOI 10.1038/ni.2080; Campbell C, 2018, IMMUNITY, V48, P1245, DOI 10.1016/j.immuni.2018.04.013; Cen ME, 2018, APOPTOSIS, V23, P377, DOI 10.1007/s10495-018-1464-9; Chand SK, 2018, CYTOKINE, V103, P90, DOI 10.1016/j.cyto.2017.09.014; Chen H, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-00309-8; Chen ZL, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9682; Chi DZ, 2015, GENET MOL RES, V14, P975, DOI 10.4238/2015.February.3.5; Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8; Cosmi L, 2014, CURR OPIN PHARMACOL, V17, P12, DOI 10.1016/j.coph.2014.06.004; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; Curtis MM, 2009, IMMUNOLOGY, V126, P177, DOI 10.1111/j.1365-2567.2008.03017.x; Dai SR, 2015, INT J ARTIF ORGANS, V38, P192, DOI 10.5301/ijao.5000406; Mora-Ruiz MD, 2019, MOL IMMUNOL, V107, P71, DOI 10.1016/j.molimm.2019.01.008; Dawra R, 2011, GASTROENTEROLOGY, V141, P2210, DOI 10.1053/j.gastro.2011.08.033; Dolff S, 2019, AUTOIMMUN REV, V18, P129, DOI 10.1016/j.autrev.2018.08.006; Douzandeh-Mobarrez B, 2019, PROBIOTICS ANTIMICRO, V11, P1, DOI 10.1007/s12602-017-9329-z; El-Salhy M, 2020, GUT, V69, P859, DOI 10.1136/gutjnl-2019-319630; Evans-Marin H, 2018, ARTHRITIS RHEUMATOL, V70, P1971, DOI 10.1002/art.40657; Flierl MA, 2008, FASEB J, V22, P2198, DOI 10.1096/fj.07-105221; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; Gagliani N, 2015, NATURE, V523, P221, DOI 10.1038/nature14452; Gao N, 2018, MED SCI MONITOR, V24, P5881, DOI 10.12659/MSM.910099; Gouda MM, 2019, INFLAMMATION, V42, P1160, DOI 10.1007/s10753-019-01010-4; Gu CF, 2013, CYTOKINE, V64, P477, DOI 10.1016/j.cyto.2013.07.022; Guo JG, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021491; Habtezion A, 2019, GASTROENTEROLOGY, V156, P1941, DOI 10.1053/j.gastro.2018.11.082; Hang SY, 2019, NATURE, V576, P143, DOI 10.1038/s41586-019-1785-z; Hata K, 2002, AM J PHYSIOL-GASTR L, V282, pG1035, DOI 10.1152/ajpgi.00494.2001; Hohenberger M, 2018, J DERMATOL TREAT, V29, P13, DOI 10.1080/09546634.2017.1329511; Hoque R, 2016, CURR OPIN GASTROEN, V32, P507, DOI 10.1097/MOG.0000000000000311; Hoque R, 2012, PANCREAS, V41, P353, DOI 10.1097/MPA.0b013e3182321500; Huang JL, 2021, IMMUNITY, V54, P673, DOI 10.1016/j.immuni.2021.03.018; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Iwakura Y, 2011, IMMUNITY, V34, P149, DOI 10.1016/j.immuni.2011.02.012; Jakkampudi A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15479-2; Jakkampudi A, 2016, PANCREATOLOGY, V16, P477, DOI 10.1016/j.pan.2016.05.001; Jia RR, 2015, PANCREAS, V44, P321, DOI 10.1097/MPA.0000000000000284; Jiang X, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00265-5; Kanda T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159705; Kenna TJ, 2012, ARTHRITIS RHEUM-US, V64, P1420, DOI 10.1002/art.33507; Kinugasa T, 2000, GASTROENTEROLOGY, V118, P1001, DOI 10.1016/S0016-5085(00)70351-9; Kloppel G, 2007, MODERN PATHOL, V20, pS113, DOI 10.1038/modpathol.3800690; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Knight JS, 2014, CIRC RES, V114, P947, DOI 10.1161/CIRCRESAHA.114.303312; Lau HY, 2005, BIOCHEM BIOPH RES CO, V327, P509, DOI 10.1016/j.bbrc.2004.12.030; Lavocat F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00647; Lee JH, 2020, HEPATOLOGY, V72, P609, DOI 10.1002/hep.31041; Leonardi C, 2012, NEW ENGL J MED, V366, P1190, DOI 10.1056/NEJMoa1109997; Leppkes M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10973; Li XX, 2019, NAT IMMUNOL, V20, P1594, DOI 10.1038/s41590-019-0514-y; Li XL, 2020, BIOCHEM PHARMACOL, V177, DOI 10.1016/j.bcp.2020.113992; Li XY, 2020, WORLD J GASTROENTERO, V26, P2187, DOI 10.3748/wjg.v26.i18.2187; Li XY, 2020, GUT MICROBES, V11, P1774, DOI 10.1080/19490976.2020.1770042; Liu LY, 2019, MOL MED REP, V20, P473, DOI 10.3892/mmr.2019.10274; Liu Y, 2018, BIOCHEM BIOPH RES CO, V497, P897, DOI 10.1016/j.bbrc.2018.02.166; Martinez-Lopez M, 2019, IMMUNITY, V50, P446, DOI 10.1016/j.immuni.2018.12.020; Mayerle J, 2009, GUT, V58, P1440, DOI 10.1136/gut.2009.186692; McGeachy MJ, 2019, IMMUNITY, V50, P892, DOI 10.1016/j.immuni.2019.03.021; Mofidi R, 2009, BRIT J SURG, V96, P137, DOI 10.1002/bjs.6431; Nakamura Y, 2010, AM J PHYSIOL-GASTR L, V298, pG92, DOI 10.1152/ajpgi.00324.2009; Neuhofer P, 2013, GASTROENTEROLOGY, V144, P192, DOI 10.1053/j.gastro.2012.09.058; Ni JB, 2013, INFLAMMATION, V36, P53, DOI 10.1007/s10753-012-9519-5; Nirula A, 2016, RHEUMATOLOGY, V55, P43, DOI 10.1093/rheumatology/kew346; Omary MB, 2007, J CLIN INVEST, V117, P50, DOI 10.1172/JCI30082; Omenetti S, 2019, IMMUNITY, V51, P77, DOI 10.1016/j.immuni.2019.05.004; Omenetti S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00639; Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365-2567.2009.03240.x; Pan XH, 2019, BRIT J PHARMACOL, V176, P4446, DOI 10.1111/bph.14806; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Rahimzadeh M, 2020, ENDOCR METAB IMMUNE, V20, P400, DOI 10.2174/1871530319666191009152048; Rich P, 2013, BRIT J DERMATOL, V168, P402, DOI 10.1111/bjd.12112; Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42; Schmidt MV, 2011, AM J RESP CRIT CARE, V184, P64, DOI 10.1164/rccm.201010-1585OC; Sendler M, 2013, GUT, V62, P430, DOI 10.1136/gutjnl-2011-300771; Shabgah AG, 2014, POSTEP DERM ALERGOL, V31, P256, DOI 10.5114/pdia.2014.40954; Shamoon M, 2016, EXPERT OPIN THER TAR, V20, P73, DOI 10.1517/14728222.2015.1077227; Shen YF, 2012, INFLAMM RES, V61, P743, DOI 10.1007/s00011-012-0467-1; Shi N, 2017, MILITARY MED RES, V4, DOI 10.1186/s40779-017-0122-9; Shibata A, 2018, BIOCHEM PHARMACOL, V150, P35, DOI 10.1016/j.bcp.2018.01.023; Shimada M, 2002, J IMMUNOL, V168, P861, DOI 10.4049/jimmunol.168.2.861; Song XY, 2020, NATURE, V577, P410, DOI 10.1038/s41586-019-1865-0; Staubli SM, 2015, CRIT REV CL LAB SCI, V52, P273, DOI 10.3109/10408363.2015.1051659; Sun L, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-00298-8; Sung KF, 2009, EXP CELL RES, V315, P1975, DOI 10.1016/j.yexcr.2009.01.009; Syed SN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080785; Tan J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02891-2; Tanabe S, 2013, INT REV IMMUNOL, V32, P511, DOI 10.3109/08830185.2013.839665; Tanoue T, 2016, NAT REV IMMUNOL, V16, P295, DOI 10.1038/nri.2016.36; Thomson JE, 2018, PANCREATOLOGY, V18, P246, DOI 10.1016/j.pan.2018.01.007; Tokoro T, 2020, PANCREAS, V49, P830, DOI 10.1097/MPA.0000000000001585; Trikudanathan G, 2019, GASTROENTEROLOGY, V156, P1994, DOI 10.1053/j.gastro.2019.01.269; Ueno A, 2018, J AUTOIMMUN, V87, P38, DOI 10.1016/j.jaut.2017.12.004; van den Berg FF, 2021, GUT, V70, P915, DOI 10.1136/gutjnl-2019-320430; Vecellio M, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.596086; Vege SS, 2018, GASTROENTEROLOGY, V154, P1103, DOI 10.1053/j.gastro.2018.01.031; Vege SS, 2015, GASTROENTEROLOGY, V149, P318, DOI 10.1053/j.gastro.2015.04.019; Veldhoen M, 2017, NAT IMMUNOL, V18, P612, DOI 10.1038/ni.3742; Vlachos S, 2014, J HEPATO-BIL-PAN SCI, V21, P911, DOI 10.1002/jhbp.162; Vonlaufen A, 2007, J PATHOL, V213, P239, DOI 10.1002/path.2231; Wan JH, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.565758; Wan YD, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00650; Wang CY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01873; Wang DY, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00686; Wang F, 2020, KIDNEY INT, V97, P1219, DOI 10.1016/j.kint.2020.01.015; Wang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090153; Wang J, 2019, IMMUNOL INVEST, V48, P39, DOI 10.1080/08820139.2018.1496097; Westfall S, 2021, BRAIN BEHAV IMMUN, V91, P350, DOI 10.1016/j.bbi.2020.10.013; Wetterholm E, 2016, TRANSL RES, V176, P105, DOI 10.1016/j.trsl.2016.04.006; Withers DR, 2016, NAT MED, V22, P319, DOI 10.1038/nm.4046; Xie RL, 2018, INT J CLIN EXP PATHO, V11, P5300; Xu D, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2517-x; Xu S, 2010, CELL MOL IMMUNOL, V7, P164, DOI 10.1038/cmi.2010.21; Yan K, 2019, J IMMUNOL, V203, P3301, DOI 10.4049/jimmunol.1900787; Yang ZW, 2016, J CELL MOL MED, V20, P441, DOI 10.1111/jcmm.12738; Zhang JL, 2018, AM J PATHOL, V188, P1693, DOI 10.1016/j.ajpath.2018.04.005; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506; Zhang S, 2017, NATURE, V551, P105, DOI 10.1038/nature24283; Zhang XM, 2018, BIOMED ENVIRON SCI, V31, P81, DOI 10.3967/bes2018.010; Zhang Y, 2020, J EXP MED, V217, DOI 10.1084/jem.20190354; Zhang ZQ, 2019, PHARM BIOL, V57, P595, DOI 10.1080/13880209.2019.1657906; Zhao QL, 2019, GUT, V68, P1827, DOI 10.1136/gutjnl-2018-317098; Zhao QL, 2018, GASTROENTEROLOGY, V154, P1822, DOI 10.1053/j.gastro.2018.01.065; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488; Zhu Y, 2019, J GASTROENTEROL, V54, P347, DOI 10.1007/s00535-018-1529-0; Zrioual S, 2009, J IMMUNOL, V182, P3112, DOI 10.4049/jimmunol.0801967	144	1	1	5	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 14	2021	12								674803	10.3389/fimmu.2021.674803	http://dx.doi.org/10.3389/fimmu.2021.674803			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WC9OO	34594321	gold, Green Published			2022-12-18	WOS:000704579700001
J	Zhang, XY; Sui, DJ; Wang, D; Zhang, LN; Wang, RY				Zhang, Xiaoyan; Sui, Dongjiang; Wang, Dong; Zhang, Lina; Wang, Ruiyan			Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid	FRONTIERS IN IMMUNOLOGY			English	Article						bullous pemphigoid; pembrolizumab; programmed cell death protein 1; immunotherapy; glucocorticoid	ADVERSE EVENTS; INHIBITORS; MANAGEMENT; CANCER; PD-1	The programmed cell death protein 1 inhibitor pembrolizumab, an immune checkpoint inhibitor, has subsequently been approved for the treatment of a wide variety of malignant tumors. Compared with conventional chemotherapy, immunotherapy is associated with a unique set of immune reactions, known collectively as immune-related adverse events. Although often mild, dermatologic toxicity can occasionally be high grade and potentially life-threatening. Here we describe a rare case of bullous pemphigoid (BP) associated with pembrolizumab. A 79-year-old male patient presented with scattered erythema, papules, blisters, and pruritus after pembrolizumab treatment. Then, the rash gradually aggravated and spread to the whole body. The extensive edematous erythema, blisters, bullae, and blood blisters were loose and easy to rupture, forming an erosive surface and with pruritus and obvious pain. The hemidesmosomal protein BP180 (type XVII collagen) was detectable in the serum, and the histological examination diagnosis was bullous pemphigoid. After 10 days of glucocorticoid (methylprednisolone, iv, 80 mg/day) treatment, new blister formation ceased. We need to increase the awareness on and facilitate the earlier identification of the cutaneous adverse effects of BP with immunotherapy so that treat can begin early in order to limit the duration and severity of toxicity.	[Zhang, Xiaoyan; Sui, Dongjiang; Wang, Dong; Zhang, Lina] Air Force Med Ctr, Dept Pulm & Crit Care Med, Beijing, Peoples R China; [Wang, Ruiyan] Air Force Med Ctr, Dept Dermatol, Beijing, Peoples R China		Zhang, XY (corresponding author), Air Force Med Ctr, Dept Pulm & Crit Care Med, Beijing, Peoples R China.	zhangxyrespirology@163.com						Belum VR, 2016, EUR J CANCER, V60, P12, DOI 10.1016/j.ejca.2016.02.010; Champiat S, 2016, ANN ONCOL, V27, P559, DOI 10.1093/annonc/mdv623; Chen TW, 2015, ANN ONCOL, V26, P1824, DOI 10.1093/annonc/mdv182; Cosimati A, 2021, J ONCOL PHARM PRACT, V27, P727, DOI 10.1177/1078155220946370; De Velasco G, 2017, CANCER IMMUNOL RES, V5, P312, DOI 10.1158/2326-6066.CIR-16-0237; Honigman AD, 2019, CLIN CASE REP, V7, P773, DOI 10.1002/ccr3.2090; Kennedy LB, 2020, CA-CANCER J CLIN, V70, P86, DOI 10.3322/caac.21596; Lopez AT, 2018, INT J DERMATOL, V57, P664, DOI 10.1111/ijd.13984; Morris LM, 2020, J CUTAN PATHOL, V47, P742, DOI 10.1111/cup.13687; Naidoo J, 2016, CANCER IMMUNOL RES, V4, P383, DOI 10.1158/2326-6066.CIR-15-0123; O'Kane GM, 2017, ONCOLOGIST, V22, P70, DOI 10.1634/theoncologist.2016-0164; Sadik CD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01934; Yoest JM, 2017, IMMUNOTARGETS THER, V6, P73, DOI 10.2147/ITT.S126227	13	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 14	2021	12								731774	10.3389/fimmu.2021.731774	http://dx.doi.org/10.3389/fimmu.2021.731774			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UY2CR	34594337	gold, Green Published			2022-12-18	WOS:000701337500001
J	Gritsenko, A; Yu, S; Martin-Sanchez, F; Diaz-del-Olmo, I; Nichols, EM; Davis, DM; Brough, D; Lopez-Castejon, G				Gritsenko, Anna; Yu, Shi; Martin-Sanchez, Fatima; Diaz-del-Olmo, Ines; Nichols, Eva-Maria; Davis, Daniel M.; Brough, David; Lopez-Castejon, Gloria			Priming Is Dispensable for NLRP3 Inflammasome Activation in Human Monocytes In Vitro (vol 11,565924, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						macrophage; inflammasome; NLRP3; priming; monocytes; IL-18; GSDMD			[Gritsenko, Anna; Martin-Sanchez, Fatima; Diaz-del-Olmo, Ines; Davis, Daniel M.; Lopez-Castejon, Gloria] Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Fac Biol Med & Hlth, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Yu, Shi; Brough, David] Univ Manchester, Manchester Acad Hlth Sci Ctr, Lydia Becker Inst Immunol & Inflammat, Div Neurosci & Expt Psychol,Fac Biol Med & Hlth, Manchester, Lancs, England; [Nichols, Eva-Maria] GSK, Adapt Immun Res Unit, Stevenage, Herts, England	University of Manchester; University of Manchester; GlaxoSmithKline	Lopez-Castejon, G (corresponding author), Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Fac Biol Med & Hlth, Div Infect Immun & Resp Med, Manchester, Lancs, England.	gloria.lopez-castejon@manchester.ac.uk						Gritsenko A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.565924	1	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 13	2021	12								763899	10.3389/fimmu.2021.763899	http://dx.doi.org/10.3389/fimmu.2021.763899			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WB6TP	34589091	Green Published, gold			2022-12-18	WOS:000703703400001
J	Herta, T; Bhattacharyya, A; Rosolowski, M; Conrad, C; Gurtner, C; Gruber, AD; Ahnert, P; Gutbier, B; Frey, D; Suttorp, N; Hippenstiel, S; Zahlten, J				Herta, Toni; Bhattacharyya, Aritra; Rosolowski, Maciej; Conrad, Claudia; Gurtner, Corinne; Gruber, Achim D.; Ahnert, Peter; Gutbier, Birgitt; Frey, Doris; Suttorp, Norbert; Hippenstiel, Stefan; Zahlten, Janine			Krueppel-Like Factor 4 Expression in Phagocytes Regulates Early Inflammatory Response and Disease Severity in Pneumococcal Pneumonia	FRONTIERS IN IMMUNOLOGY			English	Article						Krueppel-like factor 4; Streptococcus pneumoniae; community-acquired pneumonia; innate immunity; myeloid cells	HOST-DEFENSE; INTERLEUKIN-10; MACROPHAGES; RECRUITMENT; INFECTION; PROTECTS; ADULTS; PLAYS; LOAD; MICE	The transcription factor Krueppel-like factor (KLF) 4 fosters the pro-inflammatory immune response in macrophages and polymorphonuclear neutrophils (PMNs) when stimulated with Streptococcus pneumoniae, the main causative pathogen of community-acquired pneumonia (CAP). Here, we investigated the impact of KLF4 expression in myeloid cells such as macrophages and PMNs on inflammatory response and disease severity in a pneumococcal pneumonia mouse model and in patients admitted to hospital with CAP. We found that mice with a myeloid-specific knockout of KLF4 mount an insufficient early immune response with reduced levels of pro-inflammatory cytokines and increased levels of the anti-inflammatory cytokine interleukin (IL) 10 in bronchoalveolar lavage fluid and plasma and an impaired bacterial clearance from the lungs 24 hours after infection with S. pneumoniae. This results in higher rates of bacteremia, increased lung tissue damage, more severe symptoms of infection and reduced survival. Higher KLF4 gene expression levels in the peripheral blood of patients with CAP at hospital admission correlate with a favourable clinical presentation (lower sequential organ failure assessment (SOFA) score), lower serum levels of IL-10 at admission, shorter hospital stay and lower mortality or requirement of intensive care unit treatment within 28 days after admission. Thus, KLF4 in myeloid cells such as macrophages and PMNs is an important regulator of the early pro-inflammatory immune response and, therefore, a potentially interesting target for therapeutic interventions in pneumococcal pneumonia.	[Herta, Toni; Bhattacharyya, Aritra; Conrad, Claudia; Gutbier, Birgitt; Frey, Doris; Suttorp, Norbert; Hippenstiel, Stefan; Zahlten, Janine] Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany; [Rosolowski, Maciej; Ahnert, Peter] Univ Leipzig, Inst Med Informat Stat & Epidemiol IMISE, Leipzig, Germany; [Gurtner, Corinne; Gruber, Achim D.] Free Univ Berlin, Dept Vet Pathol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Leipzig University; Free University of Berlin	Zahlten, J (corresponding author), Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany.	Janine.Zahlten@charite.de	Ahnert, Peter/I-8150-2015	Ahnert, Peter/0000-0002-1771-0856	DFG [SFB-TR84]; Jurgen Manchot Stiftung; German Federal Ministry of Education and Research (BMBF) [01ZX1906B]; German Center fur Lung Research (PROGRESS) [82DZU19A2, 82DZLJ19B2]	DFG(German Research Foundation (DFG)); Jurgen Manchot Stiftung; German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); German Center fur Lung Research (PROGRESS)	This work was supported by DFG SFB-TR84 grants to JZ, SH, AG, and NS (projects C2, B1, Z1b and B6), Jurgen Manchot Stiftung to TH and AB and the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (project SYMAPATH, grant number 01ZX1906B) and the German Center fur Lung Research (PROGRESS, grant numbers 82DZU19A2 und 82DZLJ19B2), MR, PA, and NS.	Aberdein JD, 2013, CLIN EXP IMMUNOL, V174, P193, DOI 10.1111/cei.12170; Ahnert P, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2316-x; Ahnert P, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0255-8; [Anonymous], 2021, HUMAN PROTEIN ATLAS; [Anonymous], 2021, GENOTYPE TISSUE EXPR; [Anonymous], 2021, FUNCTIONAL ANNOTATIO; Bhattacharyya A, 2021, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.582070; Brooks LRK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01366; Byrne AJ, 2015, THORAX, V70, P1189, DOI 10.1136/thoraxjnl-2015-207020; Calbo E, 2008, ANTIMICROB AGENTS CH, V52, P2395, DOI 10.1128/AAC.00658-07; Casilag F., 2020, BIORXIV202002189555, DOI [10.1101/2020.02.18.955500, DOI 10.1101/2020.02.18.955500]; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Clement CG, 2008, AM J RESP CRIT CARE, V177, P1322, DOI 10.1164/rccm.200607-1038OC; Craig A, 2009, INFECT IMMUN, V77, P568, DOI 10.1128/IAI.00832-08; Dietert K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188251; Duell BL, 2012, FEMS IMMUNOL MED MIC, V64, P295, DOI 10.1111/j.1574-695X.2012.00931.x; Feinberg MW, 2005, J BIOL CHEM, V280, P38247, DOI 10.1074/jbc.M509378200; Fernandez-Serrano S, 2003, CLIN DIAGN LAB IMMUN, V10, P813, DOI 10.1128/CDLI.10.5.813-820.2003; Gordon S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01893; Hammerschmidt S., 2007, COMMUNITY ACQUIRED P, P139; He M, 2015, FASEB J, V29, P4059, DOI 10.1096/fj.15-272658; Herta T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24152-1; Huang Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.433; Huss A, 2009, CAN MED ASSOC J, V180, P48, DOI 10.1503/cmaj.080734; Igonin AA, 2004, CLIN BIOCHEM, V37, P204, DOI 10.1016/j.clinbiochem.2003.11.001; Kadioglu A, 2004, TRENDS IMMUNOL, V25, P143, DOI 10.1016/j.it.2003.12.006; Knapp S, 2004, J IMMUNOL, V172, P3132, DOI 10.4049/jimmunol.172.5.3132; Kumar KP, 2018, CELL TISSUE RES, V371, P551, DOI 10.1007/s00441-017-2753-2; Lavin Y, 2015, NAT REV IMMUNOL, V15, P731, DOI 10.1038/nri3920; Liu JW, 2007, BIOCHEM BIOPH RES CO, V362, P575, DOI 10.1016/j.bbrc.2007.07.157; Lizio M, 2019, NUCLEIC ACIDS RES, V47, pD752, DOI 10.1093/nar/gky1099; Lizio M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0560-6; Loonen AJM, 2017, EUR J CLIN MICROBIOL, V36, P1541, DOI 10.1007/s10096-017-2963-2; Martinez R, 2011, EUR RESPIR J, V37, P393, DOI 10.1183/09031936.00040710; Mayadas TN, 2014, ANNU REV PATHOL-MECH, V9, P181, DOI 10.1146/annurev-pathol-020712-164023; Mege JL, 2006, LANCET INFECT DIS, V6, P557, DOI 10.1016/S1473-3099(06)70577-1; Meijvis SCA, 2012, J INTERN MED, V272, P25, DOI 10.1111/j.1365-2796.2012.02554.x; Mizgerd JP, 2017, CURR OPIN PULM MED, V23, P193, DOI [10.1097/mcp.0000000000000365, 10.1097/MCP.0000000000000365]; Musher DM, 2014, NEW ENGL J MED, V371, P1619, DOI 10.1056/NEJMra1312885; Olfert E D, 2000, ILAR J, V41, P99; Penaloza HF, 2015, IMMUNOLOGY, V146, P100, DOI 10.1111/imm.12486; Peters RPH, 2009, J CLIN MICROBIOL, V47, P3308, DOI 10.1128/JCM.01071-09; R Core Team, 2021, R LANG ENV STAT COMP; Reinert RR, 2009, CLIN MICROBIOL INFEC, V15, P7, DOI 10.1111/j.1469-0691.2009.02724.x; Rello J, 2009, CHEST, V136, P832, DOI 10.1378/chest.09-0258; Reppe K, 2015, INFECT IMMUN, V83, P4617, DOI 10.1128/IAI.00948-15; Rosolowski M, 2020, CYTOKINE, V136, DOI 10.1016/j.cyto.2020.155263; Schauer AE, 2017, J INNATE IMMUN, V9, P403, DOI 10.1159/000469661; Shen YY, 2017, BLOOD ADV, V1, P662, DOI 10.1182/bloodadvances.2017004341; Steinwede K, 2011, J IMMUNOL, V187, P5346, DOI 10.4049/jimmunol.1101413; Szigety KM, 2020, GENE DEV, V34, P973, DOI 10.1101/gad.333674.119; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Van Bambeke F, 2007, DRUGS, V67, P2355, DOI 10.2165/00003495-200767160-00005; vanderPoll T, 1996, J INFECT DIS, V174, P994, DOI 10.1093/infdis/174.5.994; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wang XL, 2021, IMMUNOL CELL BIOL, V99, P724, DOI 10.1111/imcb.12455; Werno AM, 2012, J MED MICROBIOL, V61, P1129, DOI 10.1099/jmm.0.044107-0; Zahlten J, 2015, AM J RESP CELL MOL, V53, P544, DOI 10.1165/rcmb.2014-0024OC; Zahlten J, 2013, EUR RESPIR J, V41, P384, DOI 10.1183/09031936.00196311	59	1	1	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 13	2021	12								726135	10.3389/fimmu.2021.726135	http://dx.doi.org/10.3389/fimmu.2021.726135			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UV9FA	34589087	Green Published, gold			2022-12-18	WOS:000699773600001
J	Klammer, MG; Dzaye, O; Wallach, T; Krueger, C; Gaessler, D; Buonfiglioli, A; Derkow, K; Kettenmann, H; Brinkmann, MM; Lehnardt, S				Klammer, Markus G.; Dzaye, Omar; Wallach, Thomas; Krueger, Christina; Gaessler, Dorothea; Buonfiglioli, Alice; Derkow, Katja; Kettenmann, Helmut; Brinkmann, Melanie M.; Lehnardt, Seija			UNC93B1 Is Widely Expressed in the Murine CNS and Is Required for Neuroinflammation and Neuronal Injury Induced by MicroRNA let-7b	FRONTIERS IN IMMUNOLOGY			English	Article						microRNA; let-7b; toll-like receptor; neurodegeneration; neuroinflammation; neurons; microglia	TOLL-LIKE RECEPTOR-3; NEGATIVE REGULATOR; IMMUNE-RESPONSES; INNATE IMMUNITY; PROTEIN UNC93B; NUCLEIC-ACID; CELLS; RNA; RECOGNITION; ACTIVATION	The chaperone protein Unc-93 homolog B1 (UNC93B1) regulates internalization, trafficking, and stabilization of nucleic acid-sensing Toll-like receptors (TLR) in peripheral immune cells. We sought to determine UNC93B1 expression and its functional relevance in inflammatory and injurious processes in the central nervous system (CNS). We found that UNC93B1 is expressed in various CNS cells including microglia, astrocytes, oligodendrocytes, and neurons, as assessed by PCR, immunocyto-/histochemistry, and flow cytometry. UNC93B1 expression in the murine brain increased during development. Exposure to the microRNA let-7b, a recently discovered endogenous TLR7 activator, but also to TLR3 and TLR4 agonists, led to increased UNC93B1 expression in microglia and neurons. Microglial activation by extracellular let-7b required functional UNC93B1, as assessed by TNF ELISA. Neuronal injury induced by extracellular let-7b was dependent on UNC93B1, as UNC93B1-deficient neurons were unaffected by the microRNA's neurotoxicity in vitro. Intrathecal application of let-7b triggered neurodegeneration in wild-type mice, whereas mice deficient for UNC93B1 were protected against injurious effects on neurons and axons. In summary, our data demonstrate broad UNC93B1 expression in the murine brain and establish this chaperone as a modulator of neuroinflammation and neuronal injury triggered by extracellular microRNA and subsequent induction of TLR signaling.	[Klammer, Markus G.; Wallach, Thomas; Krueger, Christina; Gaessler, Dorothea; Buonfiglioli, Alice; Derkow, Katja; Lehnardt, Seija] Charite Univ Med Berlin, Inst Cell Biol & Neurobiol, Berlin, Germany; [Klammer, Markus G.; Wallach, Thomas; Krueger, Christina; Gaessler, Dorothea; Buonfiglioli, Alice; Derkow, Katja; Lehnardt, Seija] Free Univ Berlin, Berlin, Germany; [Klammer, Markus G.; Wallach, Thomas; Krueger, Christina; Gaessler, Dorothea; Buonfiglioli, Alice; Derkow, Katja; Lehnardt, Seija] Humboldt Univ, Berlin, Germany; [Klammer, Markus G.; Dzaye, Omar; Wallach, Thomas; Krueger, Christina; Gaessler, Dorothea; Buonfiglioli, Alice; Derkow, Katja; Lehnardt, Seija] Berlin Inst Hlth, Berlin, Germany; [Klammer, Markus G.; Lehnardt, Seija] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany; [Dzaye, Omar] Charite Univ Med Berlin, Dept Radiol & Neuroradiol, Berlin, Germany; [Kettenmann, Helmut] Max Delbruck Ctr Mol Med Helmholtz Assoc, Cellular Neurosci, Berlin, Germany; [Brinkmann, Melanie M.] Helmholtz Ctr Infect Res, Viral Immune Modulat Res Grp, Braunschweig, Germany; [Brinkmann, Melanie M.] Tech Univ Carolo Wilhelmina Braunschweig, Inst Genet, Braunschweig, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Helmholtz-Center for Infection Research; Braunschweig University of Technology	Lehnardt, S (corresponding author), Charite Univ Med Berlin, Inst Cell Biol & Neurobiol, Berlin, Germany.; Lehnardt, S (corresponding author), Free Univ Berlin, Berlin, Germany.; Lehnardt, S (corresponding author), Humboldt Univ, Berlin, Germany.; Lehnardt, S (corresponding author), Berlin Inst Hlth, Berlin, Germany.; Lehnardt, S (corresponding author), Charite Univ Med Berlin, Dept Neurol, Berlin, Germany.	seija.lehnardt@charite.de	Lehnardt, Seija/AAA-4113-2022	Klammer, Markus Gabriel/0000-0002-8990-262X	NeuroCure [Exc 257]; Deutsche Forschungsgemeinschaft (DFG) [LE 2420/2-1, SFB-TRR167/B03]; Helmholtz Association [W2/W3-090]; Berliner Krebsgesellschaft; Monika Kutzner Foundation; Else Kroener-Fresenius Foundation	NeuroCure; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Helmholtz Association(Helmholtz Association); Berliner Krebsgesellschaft; Monika Kutzner Foundation; Else Kroener-Fresenius Foundation	This work was supported by NeuroCure Exc 257, Deutsche Forschungsgemeinschaft (DFG; LE 2420/2-1, SFB-TRR167/B03, to SL), the Helmholtz Association (W2/W3-090 to MMB), Berliner Krebsgesellschaft, Monika Kutzner Foundation, and Else Kroener-Fresenius Foundation (to OD).	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Brinkmann MM, 2007, J CELL BIOL, V177, P265, DOI 10.1083/jcb.200612056; Buonfiglioli A, 2019, CELL REP, V29, P3460, DOI 10.1016/j.celrep.2019.11.029; Bussey KA, 2019, J VIROL, V93, DOI 10.1128/JVI.01173-18; Cameron JS, 2007, J NEUROSCI, V27, P13033, DOI 10.1523/JNEUROSCI.4290-06.2007; Casrouge A, 2006, SCIENCE, V314, P308, DOI 10.1126/science.1128346; Diers-Fenger M, 2001, GLIA, V34, P213, DOI 10.1002/glia.1055; Eacker SM, 2009, NAT REV NEUROSCI, V10, P837, DOI 10.1038/nrn2726; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Fukui R, 2011, IMMUNITY, V35, P69, DOI 10.1016/j.immuni.2011.05.010; Fukui R, 2009, J EXP MED, V206, P1339, DOI 10.1084/jem.20082316; Hanke ML, 2011, CLIN SCI, V121, P367, DOI 10.1042/CS20110164; Harris KG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141383; He S, 2013, BLOOD, V121, P4663, DOI 10.1182/blood-2012-07-441360; Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705; Hoffmann O, 2007, J IMMUNOL, V178, P6476, DOI 10.4049/jimmunol.178.10.6476; Huh JW, 2014, P NATL ACAD SCI USA, V111, P7072, DOI 10.1073/pnas.1322838111; Kaul D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037767; Kim YM, 2008, NATURE, V452, P234, DOI 10.1038/nature06726; Kolter J, 2016, J IMMUNOL, V196, P2733, DOI 10.4049/jimmunol.1501014; Lafaille FG, 2012, NATURE, V491, P769, DOI 10.1038/nature11583; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lathia JD, 2008, J NEUROSCI, V28, P13978, DOI 10.1523/JNEUROSCI.2140-08.2008; Lee BL, 2013, ELIFE, V2, DOI [10.7554/eLife.00291, 10.1155/2013/961957]; Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Lehnardt S, 2002, J NEUROSCI, V22, P2478, DOI 10.1523/JNEUROSCI.22-07-02478.2002; Lehnardt S, 2010, GLIA, V58, P253, DOI 10.1002/glia.20928; Ma YH, 2006, J CELL BIOL, V175, P209, DOI 10.1083/jcb.200606016; Matcovitch-Natan O, 2016, SCIENCE, V353, DOI 10.1126/science.aad8670; Nakano S, 2010, RHEUMATOLOGY, V49, P876, DOI 10.1093/rheumatology/keq001; Oldenburg M, 2012, SCIENCE, V337, P1111, DOI 10.1126/science.1220363; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Owens T, 2009, CURR TOP MICROBIOL, V336, P105, DOI 10.1007/978-3-642-00549-7_6; Pelka K, 2018, IMMUNITY, V48, P911, DOI 10.1016/j.immuni.2018.04.011; Pohar J, 2013, J BIOL CHEM, V288, P442, DOI 10.1074/jbc.M112.413922; Prinz M, 1999, J NEUROCHEM, V72, P2215, DOI 10.1046/j.1471-4159.1999.0722215.x; Qi RS, 2012, J BIOL CHEM, V287, P32617, DOI 10.1074/jbc.M112.387803; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007; Schroeder P, 2021, BRAIN BEHAV IMMUN, V91, P181, DOI 10.1016/j.bbi.2020.09.024; Shi ZC, 2011, J BIOL CHEM, V286, P4517, DOI 10.1074/jbc.M110.159590; Tabeta K, 2006, NAT IMMUNOL, V7, P156, DOI 10.1038/ni1297; Wallach T, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010186; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522; Zhang Y, 2016, NEURON, V89, P37, DOI 10.1016/j.neuron.2015.11.013; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.1523/JNEUROSCI.1860-14.2014, 10.11772/j.issn.1001-9081.2014.07.1929]	50	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 13	2021	12								715774	10.3389/fimmu.2021.715774	http://dx.doi.org/10.3389/fimmu.2021.715774			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WB7DF	34589086	Green Published, gold, Green Accepted			2022-12-18	WOS:000703729100001
J	Renaudineau, Y; Berindan-Neagoe, I; Stanciu, LA				Renaudineau, Yves; Berindan-Neagoe, Ioana; Stanciu, Luminita Aurelia			Editorial: Role of Macrophage MicroRNAs in Inflammatory Diseases and Cancer	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						macrophages; microRNAs; cancer; inflammatory diseases; M1-or M2-macrophages			[Renaudineau, Yves] Univ Toulouse III, CHU Toulouse, CNRS, INSERM,Lab Immunol,UMR1291,UMR5051, Toulouse, France; [Berindan-Neagoe, Ioana] Iuliu Hatieganu Univ Med & Pharm, Res Ctr Funct Genom Biomed & Translat Med, Cluj Napoca, Romania; [Stanciu, Luminita Aurelia] Imperial Coll London, Natl Heart & Lung Inst, London, England	Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Iuliu Hatieganu University of Medicine & Pharmacy; Imperial College London	Renaudineau, Y (corresponding author), Univ Toulouse III, CHU Toulouse, CNRS, INSERM,Lab Immunol,UMR1291,UMR5051, Toulouse, France.; Stanciu, LA (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, London, England.	renaudineau.y@chu-toulouse.fr; l.stanciu@imperial.ac.uk	Renaudineau, Yves/K-5191-2013	Renaudineau, Yves/0000-0001-5098-5002				Brooks WH, 2010, J AUTOIMMUN, V34, pJ207, DOI 10.1016/j.jaut.2009.12.006; Feketea G, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050420; Hackett EE, 2020, CELL REP, V30, P124, DOI 10.1016/j.celrep.2019.12.015; Runtsch MC, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007970; Takano Y, 2017, ONCOTARGET, V8, P78598, DOI 10.18632/oncotarget.20009; Yang J, 2014, ONCOGENE, V33, P3014, DOI 10.1038/onc.2013.258; Yin CL, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1601479; Zare-Shahabadi A, 2013, EXPERT OPIN THER TAR, V17, P1497, DOI 10.1517/14728222.2013.838219	8	1	1	5	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 13	2021	12								764525	10.3389/fimmu.2021.764525	http://dx.doi.org/10.3389/fimmu.2021.764525			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	YY1QG	34594345	Green Published, gold			2022-12-18	WOS:000754568100001
J	Yoo, SK; Mehdi, SF; Pusapati, S; Mathur, N; Anipindi, M; Lunenfeld, B; Lowell, B; Yang, H; Metz, CN; Khan, SA; Leroith, D; Roth, J				Yoo, Sun Koo; Mehdi, Syed Faizan; Pusapati, Suma; Mathur, Nimisha; Anipindi, Manasa; Lunenfeld, Bruno; Lowell, Barbara; Yang, Huan; Metz, Christine Noel; Khan, Sawleha Arshi; Leroith, Derek; Roth, Jesse			Human Chorionic Gonadotropin and Related Peptides: Candidate Anti-Inflammatory Therapy in Early Stages of Sepsis	FRONTIERS IN IMMUNOLOGY			English	Review						inflammation; sepsis; cytokine storm; human chorionic gonadotrophic hormone (hCG); anti-inflammatory	CHORIOGONADOTROPIN-LIKE MATERIAL; AMINO-ACID-SEQUENCE; BETA-SUBUNIT; INTERCELLULAR COMMUNICATION; STIMULATING-HORMONE; DENDRITIC CELLS; BINDING-SITES; ALPHA-SUBUNIT; PREGNANCY; BACTERIA	Sepsis continues to be a major cause of morbidity, mortality, and post-recovery disability in patients with a wide range of non-infectious and infectious inflammatory disorders, including COVID-19. The clinical onset of sepsis is often marked by the explosive release into the extracellular fluids of a multiplicity of host-derived cytokines and other pro-inflammatory hormone-like messengers from endogenous sources ("cytokine storm"). In patients with sepsis, therapies to counter the pro-inflammatory torrent, even when administered early, typically fall short. The major focus of our proposed essay is to promote pre-clinical studies with hCG (human chorionic gonadotropin) as a potential anti-inflammatory therapy for sepsis.	[Yoo, Sun Koo; Mehdi, Syed Faizan; Pusapati, Suma; Mathur, Nimisha; Anipindi, Manasa; Lowell, Barbara; Yang, Huan; Metz, Christine Noel; Khan, Sawleha Arshi; Roth, Jesse] Northwell Hlth, Feinstein Inst Med Res, Manhasset, NY 11004 USA; [Lunenfeld, Bruno] Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel; [Leroith, Derek] Icahn Sch Med Mt Sinai, Div Endocrinol Diabet Bone Dis, New York, NY USA	Northwell Health; Bar Ilan University; Icahn School of Medicine at Mount Sinai	Roth, J (corresponding author), Northwell Hlth, Feinstein Inst Med Res, Manhasset, NY 11004 USA.	jroth2@northwell.edu			Altronix Inc.	Altronix Inc.	The authors declare that this study received philanthropic funding from Alan and Tatyana Forman through Altronix Inc. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	ACEVEDO HF, 1985, INFECT IMMUN, V50, P860, DOI 10.1128/IAI.50.3.860-868.1985; ACEVEDO HF, 1987, J GEN MICROBIOL, V133, P783; ACEVEDO HF, 1978, CANCER-AM CANCER SOC, V41, P1217, DOI 10.1002/1097-0142(197804)41:4<1217::AID-CNCR2820410401>3.0.CO;2-A; ACEVEDO HF, 1981, INFECT IMMUN, V31, P487, DOI 10.1128/IAI.31.1.487-494.1981; ACEVEDO HF, 1979, INFECT IMMUN, V24, P920, DOI 10.1128/IAI.24.3.920-924.1979; Amer Soc Reprod Med, 2008, FERTIL STERIL, V90, pS13, DOI 10.1016/j.fertnstert.2008.08.031; Anderson RC, 2018, ENDOCR REV, V39, P911, DOI 10.1210/er.2018-00052; [Anonymous], 2019, LUTEINIZING HORMONE; ASCOLI M, 1989, ENDOCR REV, V10, P27, DOI 10.1210/edrv-10-1-27; BACKUS BT, 1981, INFECT IMMUN, V32, P1211, DOI 10.1128/IAI.32.3.1211-1215.1981; Best CH, 1933, CAN MED ASSOC J, V28, P599; BHATNAGAR YM, 1981, PEPTIDES, V2, P51, DOI 10.1016/S0196-9781(81)80011-3; Bischof P., 2017, SEXUAL HORMONES; BORTH R, 1959, Acta Obstet Gynecol Scand, V38, P417; BRAMLEY TA, 1990, BIOCHEM BIOPH RES CO, V167, P1050, DOI 10.1016/0006-291X(90)90629-2; Brooke JS, 2012, CLIN MICROBIOL REV, V25, P2, DOI 10.1128/CMR.00019-11; CARRELL DT, 1993, ENDOCRINOLOGY, V132, P1085, DOI 10.1210/en.132.3.1085; CARRELL DT, 1992, ENDOCR RES, V18, P51, DOI 10.3109/07435809209035928; CATICHA O, 1994, ENDOCR RES, V20, P1, DOI 10.3109/07435809409035853; Clark GJ, 2000, MICROBES INFECT, V2, P257, DOI 10.1016/S1286-4579(00)00302-6; Clinic M., 2018, SEPSIS; Closset J., 1973, OBSTETGYNECOLSURV, V28, P736, DOI [10.1097/00006254-197310000-00018, DOI 10.1097/00006254-197310000-00018]; Cole LA., 2015, STRUCTURES HCG FREE, DOI [10.1016/b978-0-12-800749-5.00006-7, DOI 10.1016/B978-0-12-800749-5.00006-7]; Cole LA., 2010, STRUCTURES FREE ALPH, V1st ed, DOI [10.1016/B978-0-12-384907-6.00007-4, DOI 10.1016/B978-0-12-384907-6.00007-4]; Cole LA, 2010, REPROD BIOL ENDOCRIN, V8, DOI 10.1186/1477-7827-8-102; Cole LA, 2010, HUMAN CHORIONIC GONADOTROPIN (HCG), P13, DOI 10.1016/B978-0-12-384907-6.00002-5; Cole LA, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-8; Cooke DJ, 1996, ANIM REPROD SCI, V41, P77, DOI 10.1016/0378-4320(95)01449-7; Costa MA, 2016, REPROD BIOMED ONLINE, V32, P14, DOI 10.1016/j.rbmo.2015.10.005; Crow, 2013, GONADOTROPIN, P155, DOI DOI 10.5772/48681; DOMINGUE GJ, 1986, INFECT IMMUN, V53, P95, DOI 10.1128/IAI.53.1.95-98.1986; Edwards JG, 2003, EXP BIOL MED, V228, P926, DOI 10.1177/153537020322800808; Esteves Sandro C., 2015, MedicalExpress (São Paulo, online), V2, pM150302, DOI 10.5935/MedicalExpress.2015.03.02; Ettinger G H, 1931, Can Med Assoc J, V24, P491; Fournier T, 2015, PLACENTA, V36, pS60, DOI 10.1016/j.placenta.2015.02.002; Fournier T, 2016, ANN ENDOCRINOL-PARIS, V77, P75, DOI 10.1016/j.ando.2016.04.012; FUJIKI Y, 1978, J BIOL CHEM, V253, P5363; Furcron AE, 2016, BIOL REPROD, V94, DOI 10.1095/biolreprod.116.139345; GIPPONI M, 1985, CHEMIOTERAPIA, V4, P214; GROVER S, 1995, GENE, V156, P75, DOI 10.1016/0378-1119(95)00056-C; GROVER S, 1993, BIOCHEM BIOPH RES CO, V190, P371, DOI 10.1006/bbrc.1993.1057; GROVER S, 1993, BIOCHEM BIOPH RES CO, V193, P841, DOI 10.1006/bbrc.1993.1702; Gurin S, 1940, J BIOL CHEM, V133, P467; HAZES JMW, 1990, ARTHRITIS RHEUM, V33, P1770, DOI 10.1002/art.1780331203; Hirose T., 1920, J JPN GYNECOL SOC, V16, P1055; Howard C. J., 2004, Animal Health Research Reviews, V5, P1, DOI [10.1079/AHRR200464, 10.1079/AHR200468]; Isojima S, 1968, Nihon Naibunpi Gakkai Zasshi, V43, P1097; IWASA Y, 1981, BIOCHEM BIOPH RES CO, V98, P656, DOI 10.1016/0006-291X(81)91164-5; Katzman PA, 1943, J BIOL CHEM, V148, P501; Khan NA, 2010, CLIN EXP IMMUNOL, V160, P466, DOI 10.1111/j.1365-2249.2010.04112.x; Khan NA, 2009, NEPHROL DIAL TRANSPL, V24, P2701, DOI 10.1093/ndt/gfp369; Kobata A, 1999, BBA-MOL BASIS DIS, V1455, P315, DOI 10.1016/S0925-4439(99)00060-5; Leao RDF, 2014, CLINICS, V69, P279, DOI 10.6061/clinics/2014(04)10; LEROITH D, 1981, J BIOL CHEM, V256, P6533; LIVINGSTON VW, 1974, T NEW YORK ACAD SCI, V36, P569, DOI 10.1111/j.2164-0947.1974.tb01602.x; Lunenfeld B, 2004, HUM REPROD UPDATE, V10, P453, DOI 10.1093/humupd/dmh044; Lunenfeld B., 1962, CR SOC FRANC GYNECOL, V32, P346; Lunenfeld B, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00429; Lunenfeld Bruno, 2012, Reproductive Medicine and Biology, V11, P11, DOI 10.1007/s12522-011-0097-2; Lustbader JW, 1996, MOL CELL ENDOCRINOL, V125, P21, DOI 10.1016/S0303-7207(96)03952-4; MACCHIA V, 1967, J BIOL CHEM, V242, P3726; MARUO T, 1979, P NATL ACAD SCI USA, V76, P6622, DOI 10.1073/pnas.76.12.6622; Miguel B., 2012, PATHOGEN STRATEGIES, DOI [10.5772/37771, DOI 10.5772/37771]; Mor Gil, 2003, Reprod Biol Endocrinol, V1, P119, DOI 10.1186/1477-7827-1-119; Mor G, 2011, ANN NY ACAD SCI, V1221, P80, DOI 10.1111/j.1749-6632.2010.05938.x; MORGAN FJ, 1975, J BIOL CHEM, V250, P5247; Napolitano LM, 2018, SURG INFECT, V19, P117, DOI 10.1089/sur.2017.278; NIH, 2019, SEPSIS; Nwabuobi C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102037; Odell WD., 1992, T AM CLIN CLIMATOL A, V103, P235; Opal SM, 2000, CHEST, V117, P1162, DOI 10.1378/chest.117.4.1162; Qiang XL, 2017, NPJ BIOFILMS MICROBI, V3, DOI 10.1038/s41522-017-0039-9; Rao CV, 2016, REPROD SCI, V23, P566, DOI 10.1177/1933719115597765; Rello J, 2017, ADV THER, V34, P2393, DOI 10.1007/s12325-017-0622-8; RICHERT ND, 1977, P NATL ACAD SCI USA, V74, P878, DOI 10.1073/pnas.74.3.878; Rolle L, 2013, AM J REPROD IMMUNOL, V70, P448, DOI 10.1111/aji.12157; ROTH J, 1986, PROG BRAIN RES, V68, P71, DOI 10.1016/S0079-6123(08)60231-9; ROTH J, 1986, ANN NY ACAD SCI, V463, P1, DOI 10.1111/j.1749-6632.1986.tb21498.x; Rubens M, 2020, J INTENSIVE CARE MED, V35, P858, DOI 10.1177/0885066618794136; Sargent IL, 2006, TRENDS IMMUNOL, V27, P399, DOI 10.1016/j.it.2006.06.009; Schumacher A, 2013, J IMMUNOL, V190, P2650, DOI 10.4049/jimmunol.1202698; Schumacher A, 2009, J IMMUNOL, V182, P5488, DOI 10.4049/jimmunol.0803177; Solarski M, 2017, PATHOL RES PRACT, V213, P1130, DOI 10.1016/j.prp.2017.07.010; Steinmetz C, 2017, HEPATOLOGY, V65, P2074, DOI 10.1002/hep.29072; Szkudlinski MW, 2002, PHYSIOL REV, V82, P473, DOI 10.1152/physrev.00031.2001; Tavakoli A, 2021, SEMIN ONCOL NURS, V37, DOI 10.1016/j.soncn.2021.151130; Uckan D, 1997, MOL HUM REPROD, V3, P655, DOI 10.1093/molehr/3.8.655; van den Berg HR, 2009, SHOCK, V31, P285, DOI 10.1097/SHK.0b013e31817fd62a; van den Berg JW, 2011, CRIT CARE MED, V39, P126, DOI 10.1097/CCM.0b013e3181fa3a93; van der Zee M, 2010, J IMMUNOL, V185, P5066, DOI 10.4049/jimmunol.1001414; Vincent JL, 2013, LANCET, V381, P774, DOI 10.1016/S0140-6736(12)61815-7; Wan H, 2008, J LEUKOCYTE BIOL, V83, P894, DOI 10.1189/jlb.0407258; Wan H, 2007, J LEUKOCYTE BIOL, V82, P926, DOI 10.1189/jlb.0207092; Wan H, 2009, J LEUKOCYTE BIOL, V86, P361, DOI 10.1189/jlb.0208126; Ward PA, 2012, EMBO MOL MED, V4, P1234, DOI 10.1002/emmm.201201375; WIDE L, 1960, ACTA ENDOCRINOL-COP, V35, P261; Wilder RL, 1998, ANN NY ACAD SCI, V840, P45, DOI 10.1111/j.1749-6632.1998.tb09547.x; Zamorina SA, 2015, B EXP BIOL MED+, V160, P72, DOI 10.1007/s10517-015-3101-8; Zhou JJ, 2012, AM J REPROD IMMUNOL, V68, P100, DOI 10.1111/j.1600-0897.2012.01153.x	99	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 13	2021	12								714177	10.3389/fimmu.2021.714177	http://dx.doi.org/10.3389/fimmu.2021.714177			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WB8JD	34589085	gold, Green Published			2022-12-18	WOS:000703812900001
J	Zhen, XX; Yang, L; Gu, Y; Yang, Q; Gu, WW; He, YP; Wang, YL; Wang, J				Zhen, Xing-Xing; Yang, Long; Gu, Yan; Yang, Qian; Gu, Wen-Wen; He, Ya-Ping; Wang, Yan-Ling; Wang, Jian			MNSF beta Regulates TNF alpha Production by Interacting with RC3H1 in Human Macrophages, and Dysfunction of MNSF beta in Decidual Macrophages Is Associated With Recurrent Pregnancy Loss	FRONTIERS IN IMMUNOLOGY			English	Article						decidual macrophages; TNF alpha; MNSF beta; recurrent pregnancy loss	CELL-LINE; IN-VITRO; PROTEIN; ESTABLISHMENT; MODULATION; ACTIVATION; SECRETION; BINDS	Decidual macrophages (dM phi) are the second largest population of leukocytes at the maternal-fetal interface and play critical roles in maintaining pregnancy. Our previous studies demonstrated the active involvement of monoclonal nonspecific suppressor factor-beta (MNSF beta) in embryonic implantation and pregnancy success. MNSF beta is a ubiquitously expressed ubiquitin-like protein that also exhibits immune regulatory potential, but its function in human dM phi remains unknown. Here, we observed that the proportion of CD11c(high) (CD11cHI) dM phi was significantly increased in dM phi derived from patients with recurrent pregnancy loss (RPL dM phi) compared to those derived from normal pregnant women (Control dM phi). The production of MNSF beta and TNF alpha by RPL dM phi was also significantly increased compared to that by Control dM phi. Conditioned medium from RPL dM phi exerted an inhibitory effect on the invasiveness of human trophoblastic HTR8/SVneo cells, and this effect could be partially reversed by a neutralizing antibody against TNF alpha. Bioinformatics analysis indicated a potential interaction between MNSF beta and RC3H1, a suppressor of TNF alpha transcription. Immunoprecipitation experiments with human M phi differentiated from the human monocyte cell line Thp1 (Thp1-derived M phi) proved the binding of MNSF beta to RC3H1. Specific knockdown of MNSF beta in Thp1-derived M phi led to a marked decrease in TNF alpha production, which could be reversed by inhibiting RC3H1 expression. Interestingly, a significant decrease in the protein level of RC3H1 was observed in RPL dM phi. Together, our findings indicate that aberrantly increased MNSF beta expression in dM phi may promote TNF alpha production via its interaction with RC3H1, and these phenomena could result in the disruption of the immune balance at the maternal-fetal interface and thus pregnancy loss.	[Zhen, Xing-Xing; Yang, Long; Yang, Qian; Gu, Wen-Wen; He, Ya-Ping; Wang, Jian] Fudan Univ, Shanghai Inst Biomed & Pharmaceut Technol, Peoples Republ China Key Lab Reprod Regulat, Natl Hlth Commiss NHC,Sch Pharm, Shanghai, Peoples R China; [Zhen, Xing-Xing; Yang, Qian; Wang, Yan-Ling] Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing, Peoples R China; [Gu, Yan] Tianjin Med Univ, Hosp 2, Dept Gynecol & Obstet, Tianjin, Peoples R China; [Wang, Yan-Ling] Beijing Inst Stem Cell & Regenerat Med, Beijing, Peoples R China; [Wang, Yan-Ling] Univ Chinese Acad Sci, Savaid Med Sch, Beijing, Peoples R China	Fudan University; Chinese Academy of Sciences; Institute of Zoology, CAS; Tianjin Medical University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Wang, J (corresponding author), Fudan Univ, Shanghai Inst Biomed & Pharmaceut Technol, Peoples Republ China Key Lab Reprod Regulat, Natl Hlth Commiss NHC,Sch Pharm, Shanghai, Peoples R China.; Wang, YL (corresponding author), Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing, Peoples R China.; Wang, YL (corresponding author), Beijing Inst Stem Cell & Regenerat Med, Beijing, Peoples R China.; Wang, YL (corresponding author), Univ Chinese Acad Sci, Savaid Med Sch, Beijing, Peoples R China.	wangyl@ioz.ac.cn; wangjian@sippr.org.cn			National Key Research and Development Program of China [2018YFC1002801]; Natural Science Foundation of China [81671459, 81730040, 81973327, 82001640]; Shanghai S& T Innovation Plan [18140902901]	National Key Research and Development Program of China; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai S& T Innovation Plan	This work was supported by grants from the National Key Research and Development Program of China (2018YFC1002801), the Natural Science Foundation of China (81671459, 81730040, 81973327, and 82001640), and Shanghai S& T Innovation Plan (18140902901).	Atik RB, 2018, HUM REPROD OPEN, V2018, DOI 10.1093/hropen/hoy004; Burton GJ, 2010, INT J DEV BIOL, V54, P303, DOI 10.1387/ijdb.082764gb; Chanput W, 2014, INT IMMUNOPHARMACOL, V23, P37, DOI 10.1016/j.intimp.2014.08.002; De Oliveira LG, 2010, PLACENTA, V31, P595, DOI 10.1016/j.placenta.2010.04.012; Ding JL, 2021, J CELL MOL MED, V25, P2136, DOI 10.1111/jcmm.16191; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; GRAHAM CH, 1993, EXP CELL RES, V206, P204, DOI 10.1006/excr.1993.1139; Gu Y, 2015, MOL REPROD DEV, V82, P475, DOI 10.1002/mrd.22495; He Y., 2011, ISRN IMMUNOL, V2011, P1, DOI [10.5402/2011/186541, DOI 10.5402/2011/186541]; Houser BL, 2011, J IMMUNOL, V186, P2633, DOI 10.4049/jimmunol.1003153; Huber AV, 2006, PLACENTA, V27, P127, DOI 10.1016/j.placenta.2005.02.012; Jena MK, 2019, ARCH IMMUNOL THER EX, V67, P295, DOI 10.1007/s00005-019-00552-7; Jiang XX, 2018, CELL MOL IMMUNOL, V15, P1027, DOI 10.1038/s41423-018-0008-0; Kim HJ, 2012, BIOCHEM BIOPH RES CO, V417, P280, DOI 10.1016/j.bbrc.2011.11.101; Lash GE, 2016, J LEUKOCYTE BIOL, V100, P315, DOI 10.1189/jlb.1A0815-351R; Leppek K, 2013, CELL, V153, P869, DOI 10.1016/j.cell.2013.04.016; Li S, 2017, CENT EUR J IMMUNOL, V42, P156, DOI 10.5114/ceji.2017.69357; MICHIELS L, 1993, ONCOGENE, V8, P2537; Mori M, 2016, SEMIN IMMUNOPATHOL, V38, P635, DOI 10.1007/s00281-016-0574-0; Murakawa Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8367; NAKAMURA M, 1995, EUR J IMMUNOL, V25, P2417, DOI 10.1002/eji.1830250844; NAKAMURA M, 1986, J IMMUNOL, V136, P2904; NAKAMURA M, 1994, FEBS LETT, V339, P239, DOI 10.1016/0014-5793(94)80423-0; Nakamura M, 2019, MOL CELL BIOCHEM, V456, P29, DOI 10.1007/s11010-018-3487-5; Nakamura M, 2010, BIOCHEM BIOPH RES CO, V401, P257, DOI 10.1016/j.bbrc.2010.09.045; Nie GY, 2000, MOL REPROD DEV, V55, P351, DOI 10.1002/(SICI)1098-2795(200004)55:4&lt;351::AID-MRD1&gt;3.0.CO;2-L; Ning F, 2016, AM J REPROD IMMUNOL, V75, P298, DOI 10.1111/aji.12477; Notsu K, 2016, MOL CELL BIOCHEM, V421, P149, DOI 10.1007/s11010-016-2795-x; Pique-Regi R, 2019, ELIFE, V8, DOI 10.7554/eLife.52004; Pollheimer J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02597; Prutsch N, 2012, PLACENTA, V33, P696, DOI 10.1016/j.placenta.2012.05.008; Renaud SJ, 2005, BIOL REPROD, V73, P237, DOI 10.1095/biolreprod.104.038000; Suzuki K, 1996, IMMUNOBIOLOGY, V195, P187, DOI 10.1016/S0171-2985(96)80038-6; Svensson-Arvelund J, 2015, AM J REPROD IMMUNOL, V74, P100, DOI 10.1111/aji.12357; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; Uchida K, 2015, CLIN EXP IMMUNOL, V180, P551, DOI 10.1111/cei.12607; Wang J, 2007, MOL REPROD DEV, V74, P1419, DOI 10.1002/mrd.20713; Wang N, 2021, GYNECOL OBSTET INVES, V86, P27, DOI 10.1159/000506309; Wang WJ, 2011, J REPROD IMMUNOL, V92, P97, DOI 10.1016/j.jri.2011.08.004; Watanabe J, 2013, FEBS J, V280, P1281, DOI 10.1111/febs.12120; Xu Y, 2016, J IMMUNOL, V196, P2476, DOI 10.4049/jimmunol.1502055	41	1	1	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 13	2021	12								691908	10.3389/fimmu.2021.691908	http://dx.doi.org/10.3389/fimmu.2021.691908			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WB6TE	34589082	Green Published, gold			2022-12-18	WOS:000703702300001
J	Chen, BA; Chen, YH; Rai, KR; Wang, XF; Liu, SS; Li, YY; Xiao, M; Ma, Y; Wang, GQ; Guo, GJ; Huang, SL; Chen, JL				Chen, Biao; Chen, Yuhai; Rai, Kul Raj; Wang, Xuefei; Liu, Shasha; Li, Yingying; Xiao, Meng; Ma, Yun; Wang, Guoqing; Guo, Guijie; Huang, Shile; Chen, Ji-Long			Deficiency of eIF4B Increases Mouse Mortality and Impairs Antiviral Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						eIF4B; mouse mortality; viral infection; inflammation; antiviral immunity	INITIATION-FACTOR 4B; NATURAL-KILLER-CELLS; TRANSLATION INITIATION; PROTEIN-SYNTHESIS; INFLUENZA INFECTION; HELICASE ACTIVITY; PHOSPHORYLATION; MICE; MECHANISMS; INTERFERON	Eukaryotic translation initiation factor 4B (eIF4B) plays an important role in mRNA translation initiation, cell survival and proliferation in vitro. However, its function in vivo is poorly understood. Here, we identified that eIF4B knockout (KO) in mice led to embryonic lethality, and the embryos displayed severe liver damage. Conditional KO (CKO) of eIF4B in adulthood profoundly increased the mortality of mice, characterized by severe pathological changes in several organs and reduced number of peripheral blood lymphocytes. Strikingly, eIF4B CKO mice were highly susceptible to viral infection with severe pulmonary inflammation. Selective deletion of eIF4B in lung epithelium also markedly promoted replication of influenza A virus (IAV) in the lung of infected animals. Furthermore, we observed that eIF4B deficiency significantly enhanced the expression of several important inflammation-associated factors and chemokines, including serum amyloid A1 (Saa1), Marco, Cxcr1, Ccl6, Ccl8, Ccl20, Cxcl2, Cxcl17 that are implicated in recruitment and activation of neutrophiles and macrophages. Moreover, the eIF4B-deficient mice exhibited impaired natural killer (NK) cell-mediated cytotoxicity during the IAV infection. Collectively, the results reveal that eIF4B is essential for mouse survival and host antiviral responses, and establish previously uncharacterized roles for eIF4B in regulating normal animal development and antiviral immunity in vivo.	[Chen, Biao; Chen, Yuhai; Rai, Kul Raj; Wang, Xuefei; Liu, Shasha; Li, Yingying; Xiao, Meng; Ma, Yun; Guo, Guijie] Chinese Acad Sci, Inst Mirobiol, CAS Key Lab Pathogen Mic 3Biol & Immunol, Beijing, Peoples R China; [Chen, Biao; Rai, Kul Raj; Li, Yingying] Univ Chinese Acad Sci, Coll Life Sci, Beijing, Peoples R China; [Liu, Shasha; Xiao, Meng; Wang, Guoqing; Chen, Ji-Long] Fujian Agr & Forestry Univ, Coll Anim Sci, Fuzhou, Peoples R China; [Huang, Shile] Louisiana State Univ, Dept Biochem & Mol Biol, Hlth Sci Ctr, Shreveport, LA USA	Chinese Academy of Sciences; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Fujian Agriculture & Forestry University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Chen, JL (corresponding author), Fujian Agr & Forestry Univ, Coll Anim Sci, Fuzhou, Peoples R China.	chenjl@im.ac.cn	Huang, Shile/I-1632-2019; Chen, Ji-Long/AAJ-2134-2021	Huang, Shile/0000-0002-3239-1072; Chen, Ji-Long/0000-0002-4274-0563; Rai, Kul Raj/0000-0002-0286-2347	National Science Foundation of China [U1805231, 32030110]; Science and Technology Innovation Project of FAFU [CXZX2018014]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Innovation Project of FAFU	This work was supported by National Science Foundation of China (U1805231, 32030110) and Science and Technology Innovation Project of FAFU (CXZX2018014).	Abdul-Careem MF, 2012, J INFECT DIS, V206, P167, DOI 10.1093/infdis/jis340; Ali A, 2019, CURR OPIN VIROL, V34, P130, DOI 10.1016/j.coviro.2019.02.005; Andreou AZ, 2013, RNA BIOL, V10, P19, DOI 10.4161/rna.21966; Andreou AZ, 2017, RNA BIOL, V14, P113, DOI 10.1080/15476286.2016.1259782; Ballif BA, 2004, MOL CELL PROTEOMICS, V3, P1093, DOI 10.1074/mcp.M400085-MCP200; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; Bettegazzi B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11096-1; Capossela S, 2012, AM J PATHOL, V180, P1121, DOI 10.1016/j.ajpath.2011.12.008; Chen K, 2016, ONCOTARGET, V7, P10073, DOI 10.18632/oncotarget.7164; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Eisfelder BJ, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00433-3; Eom T, 2014, J CELL BIOL, V207, P237, DOI 10.1083/jcb.201401005; Fang ST, 2016, BLOOD, V128, P710, DOI 10.1182/blood-2015-12-687970; Gainey MD, 2008, J VIROL, V82, P828, DOI 10.1128/JVI.02023-07; Gao SW, 2018, SCI CHINA LIFE SCI, V61, P885, DOI 10.1007/s11427-018-9313-4; Gazit R, 2006, NAT IMMUNOL, V7, P517, DOI 10.1038/ni1322; Golob-Schwarzl N, 2017, EUR J CANCER, V83, P56, DOI 10.1016/j.ejca.2017.06.003; Gouwy M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01081; Herdy B, 2012, NAT IMMUNOL, V13, P543, DOI 10.1038/ni.2291; Hernandez G, 2004, EUR J BIOCHEM, V271, P2923, DOI 10.1111/j.1432-1033.2004.04217.x; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Horvilleur E, 2014, LEUKEMIA, V28, P1092, DOI 10.1038/leu.2013.295; Hua LQ, 2013, J VIROL, V87, P11884, DOI 10.1128/JVI.01461-13; Joshi S, 2010, CYTOKINE, V52, P123, DOI 10.1016/j.cyto.2010.03.019; Kapadia B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03028-y; Kroczynska B, 2009, MOL CELL BIOL, V29, P2865, DOI 10.1128/MCB.01537-08; Kuang ES, 2011, J BIOL CHEM, V286, P41171, DOI 10.1074/jbc.M111.280982; Lee JA, 2018, J BIOL CHEM, V293, P9636, DOI 10.1074/jbc.RA118.002012; Li F, 2015, NUCLEIC ACIDS RES, V43, P10321, DOI 10.1093/nar/gkv1078; Lin YW, 2007, LEUKEMIA, V21, P1276, DOI 10.1038/sj.leu.2404685; Liu LL, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0567-7; Liu SS, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108627; Lu J, 2018, AGING DIS, V9, P358, DOI 10.14336/AD.2017.0701; Lu Q, 2016, CELL HOST MICROBE, V19, P102, DOI 10.1016/j.chom.2015.12.011; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Madden JM, 2014, BREAST CANCER RES TR, V147, P283, DOI 10.1007/s10549-014-3102-8; Maelfait J, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005410; Maelfait J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002570; Maler MD, 2017, MBIO, V8, DOI 10.1128/mBio.00670-17; Micalizzi DS, 2021, CANCER RES, V81, P517, DOI 10.1158/0008-5472.CAN-20-2720; Modelska A, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.542; Nogusa S, 2008, MECH AGEING DEV, V129, P223, DOI 10.1016/j.mad.2008.01.003; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Ochs K, 2002, J VIROL, V76, P2113, DOI 10.1128/JVI.76.5.2113-2122.2002; Parsyan A, 2011, NAT REV MOL CELL BIO, V12, P235, DOI 10.1038/nrm3083; Pegram HJ, 2011, IMMUNOL CELL BIOL, V89, P216, DOI 10.1038/icb.2010.78; Pelletier J, 2019, ANNU REV BIOCHEM, V88, P307, DOI 10.1146/annurev-biochem-013118-111042; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Prevot D, 2003, BIOL CELL, V95, P141, DOI 10.1016/S0248-4900(03)00031-5; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; Rogers GW, 2001, J BIOL CHEM, V276, P30914, DOI 10.1074/jbc.M100157200; Ruzankina Y, 2007, CELL STEM CELL, V1, P113, DOI 10.1016/j.stem.2007.03.002; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; Shahbazian D, 2010, CELL CYCLE, V9, P4106, DOI 10.4161/cc.9.20.13630; Shahbazian D, 2010, MOL CELL BIOL, V30, P1478, DOI 10.1128/MCB.01218-09; Sonenberg N, 2007, MOL CELL, V28, P721, DOI 10.1016/j.molcel.2007.11.018; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Tavares LP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01799; Truitt ML, 2015, CELL, V162, P59, DOI 10.1016/j.cell.2015.05.049; van Gorp AGM, 2009, ONCOGENE, V28, P95, DOI 10.1038/onc.2008.367; Walsh D, 2005, J VIROL, V79, P8057, DOI 10.1128/JVI.79.13.8057-8064.2005; Walsh D, 2008, MOL CELL BIOL, V28, P2648, DOI 10.1128/MCB.01631-07; Walsh D, 2011, NAT REV MICROBIOL, V9, P860, DOI 10.1038/nrmicro2655; Wang S, 2014, J VIROL, V88, P8375, DOI 10.1128/JVI.00126-14; Wang YB, 2016, P NATL ACAD SCI USA, V113, P9810, DOI 10.1073/pnas.1606862113; Wei JY, 2017, VET MICROBIOL, V203, P234, DOI 10.1016/j.vetmic.2017.03.022; White MR, 2021, J LEUKOCYTE BIOL, V110, P155, DOI 10.1002/JLB.4AB0220-116RR; Xu JB, 2020, CANCER LETT, V473, P1, DOI 10.1016/j.canlet.2019.12.032; Yang JL, 2013, CANCER RES, V73, P4898, DOI 10.1158/0008-5472.CAN-12-4277; Yokoyama WM, 2004, ANNU REV IMMUNOL, V22, P405, DOI 10.1146/annurev.immunol.22.012703.104711; Zhu BL, 2019, BRAIN, V142, P176, DOI 10.1093/brain/awy305	73	1	2	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 10	2021	12								723885	10.3389/fimmu.2021.723885	http://dx.doi.org/10.3389/fimmu.2021.723885			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU2OB	34566982	gold, Green Published			2022-12-18	WOS:000698639600001
J	Lin, ZL; Wu, ZY; Luo, W				Lin, Zili; Wu, Ziyi; Luo, Wei			A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy	FRONTIERS IN IMMUNOLOGY			English	Review						Ewing's sarcoma; CAR-T therapy; solid tumors; immune targets; targeted therapy	ENDOTHELIAL GROWTH-FACTOR; FACTOR TYPE-1 RECEPTOR; MONOCLONAL-ANTIBODY; TUMOR-GROWTH; STANDARD CHEMOTHERAPY; TYROSINE KINASE; PHASE-II; NK CELLS; EXPRESSION; TARGET	Ewing's sarcoma (EWS) is a malignant and aggressive tumor type that predominantly occurs in children and adolescents. Traditional treatments such as surgery, radiotherapy and chemotherapy, while successful in the early disease stages, are ineffective in patients with metastases and relapses who often have poor prognosis. Therefore, new treatments for EWS are needed to improve patient's outcomes. Chimeric antigen receptor (CAR)-T cells therapy, a novel adoptive immunotherapy, has been developing over the past few decades, and is increasingly popular in researches and treatments of various cancers. CAR-T cell therapy has been approved by the Food and Drug Administration (FDA) for the treatment of leukemia and lymphoma. Recently, this therapeutic approach has been employed for solid tumors including EWS. In this review, we summarize the safety, specificity and clinical transformation of the treatment targets of EWS, and point out the directions for further research.	[Lin, Zili; Wu, Ziyi; Luo, Wei] Cent South Univ, Xiangya Hosp, Dept Orthopaed, Changsha, Peoples R China	Central South University	Luo, W (corresponding author), Cent South Univ, Xiangya Hosp, Dept Orthopaed, Changsha, Peoples R China.	luowei0928@126.com			special funds for the construction of innovative provinces in Hunan Province [2020RC3058]	special funds for the construction of innovative provinces in Hunan Province	This work was funded by special funds for the construction of innovative provinces in Hunan Province (2020RC3058).	Ahmed N, 2009, MOL THER, V17, P1779, DOI 10.1038/mt.2009.133; Ahn YO, 2010, CLIN CANCER RES, V16, P3819, DOI 10.1158/1078-0432.CCR-10-1368; Anders K, 2013, CLIN CANCER RES, V19, P320, DOI 10.1158/1078-0432.CCR-12-3017; Balakrishnan A, 2017, CLIN CANCER RES, V23, P3061, DOI 10.1158/1078-0432.CCR-16-2083; Balamuth NJ, 2010, LANCET ONCOL, V11, P184, DOI 10.1016/S1470-2045(09)70286-4; Berger C, 2015, CANCER IMMUNOL RES, V3, P206, DOI 10.1158/2326-6066.CIR-14-0163; Berghuis D, 2012, CLIN SARCOMA RES, V2, DOI 10.1186/2045-3329-2-8; Bielamowicz K, 2018, NEURO-ONCOLOGY, V20, P506, DOI 10.1093/neuonc/nox182; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Britten CM, 2021, NAT REV DRUG DISCOV, V20, P476, DOI 10.1038/s41573-021-00175-8; BURDACH S, 1993, J CLIN ONCOL, V11, P1482, DOI 10.1200/JCO.1993.11.8.1482; Caruana I, 2015, NAT MED, V21, P524, DOI 10.1038/nm.3833; Caruso HG, 2015, CANCER RES, V75, P3505, DOI 10.1158/0008-5472.CAN-15-0139; Charan M, 2020, INT J CANCER, V146, P3184, DOI 10.1002/ijc.32743; Chitnis MM, 2008, CLIN CANCER RES, V14, P6364, DOI 10.1158/1078-0432.CCR-07-4879; Chmielewski M, 2004, J IMMUNOL, V173, P7647, DOI 10.4049/jimmunol.173.12.7647; Comoli P, 2019, ANN ONCOL, V30, P1740, DOI 10.1093/annonc/mdz285; Craddock JA, 2010, J IMMUNOTHER, V33, P780, DOI 10.1097/CJI.0b013e3181ee6675; D'Onofrio A, 2021, EUR J PHARM BIOPHARM, V158, P233, DOI 10.1016/j.ejpb.2020.11.015; Dalal S, 2005, CLIN CANCER RES, V11, P2364, DOI 10.1158/1078-0432.CCR-04-1201; Dobrenkov K, 2014, SEMIN ONCOL, V41, P589, DOI 10.1053/j.seminoncol.2014.07.003; Du HW, 2019, CANCER CELL, V35, P221, DOI 10.1016/j.ccell.2019.01.002; Eagle RA, 2007, NAT REV IMMUNOL, V7, P737, DOI 10.1038/nri2144; Elsallab M, 2020, LANCET ONCOL, V21, pE104, DOI 10.1016/S1470-2045(19)30729-6; Englisch A, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28313; Esiashvili N, 2008, J PEDIAT HEMATOL ONC, V30, P425, DOI 10.1097/MPH.0b013e31816e22f3; Fedorov VD, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006597; Feins S, 2019, AM J HEMATOL, V94, pS3, DOI 10.1002/ajh.25418; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Finney HM, 2004, J IMMUNOL, V172, P104, DOI 10.4049/jimmunol.172.1.104; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flem-Karlsen K, 2018, TRENDS CANCER, V4, P401, DOI 10.1016/j.trecan.2018.03.010; Flem-Karlsen K, 2017, PIGM CELL MELANOMA R, V30, P467, DOI 10.1111/pcmr.12599; Folkert IW, 2019, J BONE MINER RES, V34, P1780, DOI 10.1002/jbmr.3852; Garcia-Monclus S, 2018, INT J CANCER, V143, P1188, DOI 10.1002/ijc.31405; Gaspar N, 2015, J CLIN ONCOL, V33, P3036, DOI 10.1200/JCO.2014.59.5256; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Granowetter L, 2009, J CLIN ONCOL, V27, P2536, DOI 10.1200/JCO.2008.19.1478; Grier HE, 2003, NEW ENGL J MED, V348, P694, DOI 10.1056/NEJMoa020890; Grunewald TGP, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0003-x; Grunewald TGP, 2012, ANN ONCOL, V23, P2185, DOI 10.1093/annonc/mdr605; Guan H, 2009, ONCOL RES, V18, P117, DOI 10.3727/096504009789954627; Guerzoni C, 2015, CLIN CANCER RES, V21, P146, DOI 10.1158/1078-0432.CCR-14-0492; He LL, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.04.012; He YR, 2019, JCI INSIGHT, V4, DOI [10.1172/jci.insight.130416, 10.1172/jci.insight.135306]; Heitzeneder S, 2019, JNCI-J NATL CANCER I, V111, P970, DOI 10.1093/jnci/djy209; Hinrichs CS, 2009, P NATL ACAD SCI USA, V106, P17469, DOI 10.1073/pnas.0907448106; Ho AL, 2011, J CLIN ONCOL, V29, P4581, DOI 10.1200/JCO.2011.38.2374; Hojjat-Farsangi M, 2014, SEMIN CANCER BIOL, V29, P21, DOI 10.1016/j.semcancer.2014.07.005; Holzer TR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080292; Hong MH, 2020, CANCER CELL, V38, P473, DOI 10.1016/j.ccell.2020.07.005; Hong MS, 2004, MECH AGEING DEV, V125, P615, DOI 10.1016/j.mad.2004.07.001; Hou AJ, 2021, NAT REV DRUG DISCOV, V20, P531, DOI 10.1038/s41573-021-00189-2; Hsu K, 2021, CANCER GENE THER, V28, P321, DOI 10.1038/s41417-020-00221-4; Huang X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133152; Idso John M, 2020, Oncotarget, V11, P1799, DOI 10.18632/oncotarget.27546; Jasinski S, 2020, PEDIATR DRUGS, V22, P485, DOI 10.1007/s40272-020-00413-3; Johnson LA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4963; Juergens H, 2011, J CLIN ONCOL, V29, P4534, DOI 10.1200/JCO.2010.33.0670; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Kailayangiri S, 2012, BRIT J CANCER, V106, P1123, DOI 10.1038/bjc.2012.57; Kailayangiri S, 2019, MOL THER, V27, P933, DOI 10.1016/j.ymthe.2019.02.014; Kang BH, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003624; Kasten BB, 2017, NUCL MED BIOL, V47, P23, DOI 10.1016/j.nucmedbio.2017.01.003; Kennedy LB, 2020, CA-CANCER J CLIN, V70, P86, DOI 10.3322/caac.21596; Kersting N, 2018, ONCOLOGY-BASEL, V94, P383, DOI 10.1159/000487143; Klebanoff CA, 2016, NAT MED, V22, P26, DOI 10.1038/nm.4015; Koksal H, 2019, SCAND J IMMUNOL, V89, DOI 10.1111/sji.12741; Kreuter M, 2006, EUR J CANCER, V42, P1904, DOI 10.1016/j.ejca.2006.01.063; Lee TH, 2006, INT J CANCER, V119, P839, DOI 10.1002/ijc.21916; Lee YH, 2017, CELL RES, V27, P1034, DOI 10.1038/cr.2017.90; Lehner M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031210; Liebsch L, 2013, BRIT J CANCER, V109, P658, DOI 10.1038/bjc.2013.356; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LIPINSKI M, 1986, J CELL BIOCHEM, V31, P289, DOI 10.1002/jcb.240310406; LIPINSKI M, 1987, CANCER RES, V47, P183; Liu H, 2011, MOL CANCER THER, V10, P960, DOI 10.1158/1535-7163.MCT-11-0072; Liu XJ, 2015, CANCER RES, V75, P3596, DOI 10.1158/0008-5472.CAN-15-0159; Liu Y, 2020, CYTOTHERAPY, V22, P573, DOI 10.1016/j.jcyt.2020.04.088; Mackall CL, 2014, NAT REV CLIN ONCOL, V11, P693, DOI 10.1038/nrclinonc.2014.177; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Majzner RG, 2019, CLIN CANCER RES, V25, P2560, DOI 10.1158/1078-0432.CCR-18-0432; Marofi F, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-020-02128-1; McCaughan GJB, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0278-x; Modak S, 2001, CANCER RES, V61, P4048; Moon EK, 2011, CLIN CANCER RES, V17, P4719, DOI 10.1158/1078-0432.CCR-11-0351; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Nordberg J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050819; Nunes-Xavier CE, 2016, ONCOTARGET, V7, P6891, DOI 10.18632/oncotarget.6902; Pahl JHW, 2013, CANCER IMMUNOL IMMUN, V62, P1235, DOI 10.1007/s00262-013-1406-x; Pappo AS, 2011, J CLIN ONCOL, V29, P4541, DOI 10.1200/JCO.2010.34.0000; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Posey AD, 2016, IMMUNITY, V44, P1444, DOI 10.1016/j.immuni.2016.05.014; Potratz J, 2016, MOL ONCOL, V10, P677, DOI 10.1016/j.molonc.2015.12.009; Rashidijahanabad Z, 2020, SEMIN IMMUNOL, V47, DOI 10.1016/j.smim.2020.101390; Reddy K, 2008, ANGIOGENESIS, V11, P257, DOI 10.1007/s10456-008-9109-1; Rennel ES, 2008, BRIT J CANCER, V98, P1250, DOI 10.1038/sj.bjc.6604309; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Roybal KT, 2016, CELL, V164, P770, DOI 10.1016/j.cell.2016.01.011; Sadelain M, 2009, CURR OPIN IMMUNOL, V21, P215, DOI 10.1016/j.coi.2009.02.009; Sainz-Jaspeado M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071449; Saxena M, 2021, NAT REV CANCER, V21, P360, DOI 10.1038/s41568-021-00346-0; Seaman S, 2017, CANCER CELL, V31, P501, DOI 10.1016/j.ccell.2017.03.005; Sha HH, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160332; Shalabi H, 2018, J IMMUNOTHER, V41, P350, DOI 10.1097/CJI.0000000000000241; Sharma P, 2020, P NATL ACAD SCI USA, V117, P15148, DOI 10.1073/pnas.1920662117; Spurny Christian, 2018, Oncotarget, V9, P6536, DOI 10.18632/oncotarget.23815; Srivastava S, 2019, CANCER CELL, V35, P489, DOI 10.1016/j.ccell.2019.02.003; Steffin DHM, 2019, MOL THER, V27, P900, DOI 10.1016/j.ymthe.2019.04.007; Stone JD, 2012, ONCOIMMUNOLOGY, V1, P863, DOI 10.4161/onci.20592; Straathof K, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abd6169; Sukumaran S, 2018, CANCER DISCOV, V8, P972, DOI 10.1158/2159-8290.CD-17-1298; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; Tap WD, 2012, J CLIN ONCOL, V30, P1849, DOI 10.1200/JCO.2011.37.2359; Toretsky JA, 2010, LANCET ONCOL, V11, P105, DOI 10.1016/S1470-2045(09)70391-2; Verhoeven DHJ, 2008, MOL IMMUNOL, V45, P3917, DOI 10.1016/j.molimm.2008.06.016; Weiner GJ, 2015, NAT REV CANCER, V15, P361, DOI 10.1038/nrc3930; Xie C, 2016, SCI REP-UK, V6, DOI 10.1038/srep27528; Yang S, 2020, INT J BIOL SCI, V16, P1767, DOI 10.7150/ijbs.41105; Yu SN, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0444-9; Zah E, 2016, CANCER IMMUNOL RES, V4, P498, DOI 10.1158/2326-6066.CIR-15-0231; Zhou Z, 2007, MOL CANCER RES, V5, P1125, DOI 10.1158/1541-7786.MCR-07-0174; Zhou ZC, 2007, CLIN CANCER RES, V13, P4867, DOI 10.1158/1078-0432.CCR-07-0133	124	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 10	2021	12								707211	10.3389/fimmu.2021.707211	http://dx.doi.org/10.3389/fimmu.2021.707211			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU2LT	34566963	Green Published, gold			2022-12-18	WOS:000698633600001
J	Ming, SQ; Yin, H; Li, XY; Gong, ST; Zhang, GL; Wu, YJ				Ming, Siqi; Yin, Huan; Li, Xingyu; Gong, Sitang; Zhang, Guoliang; Wu, Yongjian			GITR Promotes the Polarization of TFH-Like Cells in Helicobacter pylori-Positive Gastritis	FRONTIERS IN IMMUNOLOGY			English	Article						TFH-like cells; H; pylori; gastritis; IL-21; GITR	FOLLICULAR HELPER; EXPERIMENTAL COLITIS; T-CELLS; RECEPTOR; IL-21; DIFFERENTIATION; INTERLEUKIN-21; INFLAMMATION; PATHOGENESIS; FIBROBLASTS	Gastric CD4(+)T cells contribute to Helicobacter pylori (H. pylori)-induced gastritis by amplifying mucosal inflammation and exacerbating mucosal injuries. However, the pathogenic CD4(+) T cell subset involved in gastritis and the potential regulators are still unclear. Here we identified an IL-21-producing gastric CD4(+)T cell subset, which exhibited tissue-resident CXCR5(-)BTLA(-)PD-1(hi) TFH-like phenotype in H. pylori-positive gastritis patients. Meanwhile, we identified glucocorticoid-induced tumor necrosis factor receptor (GITR) as an important regulator to facilitate IL-21 production by CD4(+)T cells and accelerate mucosal inflammation in gastritis patients with H. pylori infection. Moreover, GITR expression was increased in gastric CD4(+)T cells of gastritis patients compared to healthy controls, along with the upregulated expression of its ligand GITRL in mucosal macrophages (M phi) of gastritis patients. Further observations showed that the activation of GITR/GITRL signal promoted the IL-21 production of CD4(+)T cells via the STAT3 pathway. Besides this, IL-21 from CD4(+)T cells induced the proliferation of B cell and promoted the production of inflammatory cytokines IL-1 beta and IL-6 and chemokines MIP-3 alpha and CCL-25 as well as matrix metalloproteinase (MMP)-3 and MMP-9 by human gastric epithelial cells, suggesting the facilitating effect of IL-21-producing CD4(+)T cells on mucosal inflammation and injuries. Taking these data together, we revealed that GITR/GITRL signal promoted the polarization of mucosal IL-21-producing CD4(+)T cells in H. pylori-positive gastritis, which may provide therapeutic strategies for the clinical treatment of H. pylori-induced gastritis.	[Ming, Siqi; Zhang, Guoliang] Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Natl Clin Res Ctr Infect Dis, Shenzhen, Peoples R China; [Yin, Huan; Li, Xingyu; Wu, Yongjian] Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Infect & Immun, Zhuhai, Peoples R China; [Gong, Sitang; Wu, Yongjian] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Guangzhou Inst Pediat, Dept Gastroenterol, Guangzhou, Peoples R China	Southern University of Science & Technology; Sun Yat Sen University; Guangzhou Medical University	Zhang, GL (corresponding author), Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Natl Clin Res Ctr Infect Dis, Shenzhen, Peoples R China.; Wu, YJ (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Infect & Immun, Zhuhai, Peoples R China.; Gong, ST; Wu, YJ (corresponding author), Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Guangzhou Inst Pediat, Dept Gastroenterol, Guangzhou, Peoples R China.	sitangg@126.com; szdsyy@aliyun.com; wuyongj2@mail2.sysu.edu.cn	Zhang, Guoliang/C-7678-2017	Zhang, Guoliang/0000-0002-3617-5449	National Natural Science Foundation of China [81770552, 81801571, 82102249]; China Postdoctoral Science Foundation [2020T130131]; National Key Research and Development Plan [2019YFC0840602]; Guangdong Scientific and Technological Foundation [2020B1111170014, 2019A1515110055]; Shenzhen Scientific and Technological Foundation [KCXFZ202002011007083, JCYJ20180228162321234]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); National Key Research and Development Plan; Guangdong Scientific and Technological Foundation; Shenzhen Scientific and Technological Foundation	This work was supported by grants from the National Natural Science Foundation of China (81770552, 81801571 and 82102249), the China Postdoctoral Science Foundation (2020T130131), the National Key Research and Development Plan (2019YFC0840602), the Guangdong Scientific and Technological Foundation (2020B1111170014 and 2019A1515110055), and the Shenzhen Scientific and Technological Foundation (KCXFZ202002011007083 and JCYJ20180228162321234).	Algood HMS, 2020, J IMMUNOL, V204, P1421, DOI 10.4049/jimmunol.1901307; Bai XS, 2020, EXP THER MED, V20, P269, DOI 10.3892/etm.2020.8710; Carbo A, 2014, MBIO, V5, DOI 10.1128/mBio.01243-14; Caruso R, 2007, J IMMUNOL, V178, P5957, DOI 10.4049/jimmunol.178.9.5957; Caruso R, 2007, GASTROENTEROLOGY, V132, P166, DOI 10.1053/j.gastro.2006.09.053; Chen PY, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00436; Choi YS, 2011, IMMUNITY, V34, P932, DOI 10.1016/j.immuni.2011.03.023; Clouthier DL, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004517; Craig VJ, 2010, LEUKEMIA, V24, P1186, DOI 10.1038/leu.2010.76; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Crowe SE, 2019, NEW ENGL J MED, V380, P1158, DOI 10.1056/NEJMcp1710945; Fantini MC, 2007, EUR J IMMUNOL, V37, P3155, DOI 10.1002/eji.200737766; Fazilleau N, 2009, NAT IMMUNOL, V10, P375, DOI 10.1038/ni.1704; Genta RM, 1997, GASTROENTEROLOGY, V113, pS51, DOI 10.1016/S0016-5085(97)80012-1; Guan LJ, 2015, CYTOKINE, V72, P160, DOI 10.1016/j.cyto.2014.11.005; Jafarzadeh A, 2018, MICROB PATHOGENESIS, V116, P227, DOI 10.1016/j.micpath.2018.01.040; Jogdand GM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00520; Jungel A, 2004, ARTHRITIS RHEUM, V50, P1468, DOI 10.1002/art.20218; Koh CH, 2020, CANCER IMMUNOL RES, V8, P698, DOI 10.1158/2326-6066.CIR-19-0748; Leber A, 2016, J THEOR BIOL, V398, P74, DOI 10.1016/j.jtbi.2016.02.036; Liao GX, 2012, GASTROENTEROLOGY, V142, P582, DOI 10.1053/j.gastro.2011.11.031; Long D, 2019, J AUTOIMMUN, V99, P1, DOI 10.1016/j.jaut.2019.01.013; Ma J, 2016, AM J PATHOL, V186, P1559, DOI 10.1016/j.ajpath.2016.02.010; Mahne AE, 2017, CANCER RES, V77, P1108, DOI 10.1158/0008-5472.CAN-16-0797; McDonald PW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10285; Ming SQ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.626017; Mintz MA, 2020, IMMUNOL REV, V296, P48, DOI 10.1111/imr.12860; Monteleone G, 2006, GUT, V55, P1774, DOI 10.1136/gut.2006.093187; Monteleone G, 2005, GASTROENTEROLOGY, V128, P687, DOI 10.1053/j.gastro.2004.12.042; Nakamura S, 1998, AM J PATHOL, V152, P1271; Nocentini G, 2009, ADV EXP MED BIOL, V647, P156, DOI 10.1007/978-0-387-89520-8_11; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Ozaki K, 2004, J IMMUNOL, V173, P5361, DOI 10.4049/jimmunol.173.9.5361; Sakurai T, 2020, FASEB J, V34, P14820, DOI 10.1096/fj.202001675R; Santucci L, 2007, GUT, V56, P52, DOI 10.1136/gut.2006.091181; Schmitt N, 2014, NAT IMMUNOL, V15, P856, DOI 10.1038/ni.2947; Schmitt N, 2009, IMMUNITY, V31, P158, DOI 10.1016/j.immuni.2009.04.016; Siddiqui ST, 2011, J PAK MED ASSOC, V61, P138; Tsai HF, 2010, CELL MOL IMMUNOL, V7, P255, DOI 10.1038/cmi.2010.2; Uraushihara K, 2003, J IMMUNOL, V171, P708, DOI 10.4049/jimmunol.171.2.708; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; Xiao X, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9266; Zhang SX, 2021, INT IMMUNOPHARMACOL, V96, DOI 10.1016/j.intimp.2021.107644	44	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 10	2021	12								736269	10.3389/fimmu.2021.736269	http://dx.doi.org/10.3389/fimmu.2021.736269			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WB8GY	34589088	Green Published, gold			2022-12-18	WOS:000703807200001
J	Sibi, JM; Mohan, V; Munisankar, S; Babu, S; Aravindhan, V				Sibi, Joy Manohar; Mohan, Viswanathan; Munisankar, Saravanan; Babu, Subash; Aravindhan, Vivekanandhan			Augmented Innate and Adaptive Immune Responses Under Conditions of Diabetes-Filariasis Comorbidity	FRONTIERS IN IMMUNOLOGY			English	Article						diabetes; filariasis; TLR; immunomodulation; Th cell; inflammation	TOLL-LIKE RECEPTOR; PATENT LYMPHATIC FILARIASIS; TH9 CELLS; INFECTION; TLR4; IMMUNOMODULATION; ASSOCIATION; INHIBITION; PREVALENCE; ACTIVATION	Metainflammation, as seen in chronic diabetes subjects, impairs immunity and increases the susceptibility to infections. In the present study, the effect of diabetes on immune response against filariasis was studied. Both toll-like receptor (TLR)-mediated and crude antigen-induced immune responses were quantified, in whole blood cultures from filariasis-infected subjects (LF+), with and without diabetes. Blood cultures were stimulated with TLR ligands (TLR2 and TLR4) or filarial antigen or were left unstimulated (control) for 18 h. Cytokine, chemokine, and defensin secretion was quantified by ELISA. Expression of HLA-DR, B7-1, B7-2, activation marker (CD69), and Th (Th1, Th2, Th17, and Th9) phenotypes was quantified by flow cytometry. Expression of immunomodulatory effectors (Cox-2, HO-1, IDO-1, and p47Phox) and Th-polarizing transcription factors (T-bet, GATA3, and ROR-gamma t) was quantified by quantitative PCR. Secretion of IL-27, IL-1Ra, IL-12, IL-33, IL-9, and SDF-1 was increased under diabetes conditions with increased Th9 polarization and increased expression of Cox-2 and IDO. Overall, diabetes was found to augment both TLR-mediated and antigen-induced inflammation, which can promote chronic pathology in LF+ subjects.	[Sibi, Joy Manohar; Aravindhan, Vivekanandhan] Univ Madras, Dr AL Mudaliar Post Grad Inst Basic Med Sci ALM P, Dept Genet, Chennai, Tamil Nadu, India; [Mohan, Viswanathan] Madras Diabet Res Fdn, Chennai, Tamil Nadu, India; [Mohan, Viswanathan] Dr Mohans Diabet Specialties Ctr, Chennai, Tamil Nadu, India; [Munisankar, Saravanan; Babu, Subash] Natl Inst Res TB, Natl Inst Hlth, Int Ctr Excellence Res, Chennai, Tamil Nadu, India	University of Madras; Madras Diabetes Research Foundation; Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Tuberculosis (NIRT)	Aravindhan, V (corresponding author), Univ Madras, Dr AL Mudaliar Post Grad Inst Basic Med Sci ALM P, Dept Genet, Chennai, Tamil Nadu, India.	cvaravindhan@gmail.com	Babu, Subash/GXG-4746-2022	Aravindhan, Vivekanandhan/0000-0002-5639-4948	DST-FIST; UGC-SAP	DST-FIST(Department of Science & Technology (India)); UGC-SAP(University Grants Commission, India)	The Department of Genetics, University of Madras, has received funds for infrastructural support from DST-FIST and UGC-SAP programs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anjana RM, 2017, LANCET DIABETES ENDO, V5, P585, DOI 10.1016/S2213-8587(17)30174-2; Anuradha R, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002749; Anuradha R, 2013, J IMMUNOL, V191, P2466, DOI 10.4049/jimmunol.1300911; Aravindhan V, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/6264149; Aravindhan V, 2017, AM J TROP MED HYG, V97, P1650, DOI 10.4269/ajtmh.17-0236; Aravindhan V, 2012, AM J TROP MED HYG, V86, P828, DOI 10.4269/ajtmh.2012.11-0773; Aravindhan V, 2010, AM J TROP MED HYG, V83, P1336, DOI 10.4269/ajtmh.2010.10-0410; Aravindhan V, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000707; Babu S, 2006, J IMMUNOL, V176, P3248, DOI 10.4049/jimmunol.176.5.3248; Babu S, 2005, J IMMUNOL, V175, P1170, DOI 10.4049/jimmunol.175.2.1170; Babu S, 2005, INFECT IMMUN, V73, P3394, DOI 10.1128/IAI.73.6.3394-3401.2005; Babu S, 2012, INFECT IMMUN, V80, P2509, DOI 10.1128/IAI.06179-11; Babu S, 2011, INFECT IMMUN, V79, P4600, DOI 10.1128/IAI.05419-11; Babu S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000420; Badolati I, 2020, SCAND J IMMUNOL, V91, DOI 10.1111/sji.12857; BANCROFT AJ, 1994, PARASITE IMMUNOL, V16, P385, DOI 10.1111/j.1365-3024.1994.tb00364.x; Beadling C, 2006, ARCH IMMUNOL THER EX, V54, P15, DOI 10.1007/s00005-006-0002-6; Berbudi A, 2016, J INNATE IMMUN, V8, P601, DOI 10.1159/000448401; Buchta CM, 2014, IMMUNOL RES, V59, P12, DOI 10.1007/s12026-014-8523-2; Chen JY, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0410-1; Chen YH, 2013, J CLIN ENDOCR METAB, V98, pE283, DOI 10.1210/jc.2012-2517; Evans H, 2015, J ALLERGY CLIN IMMUN, V135, P343, DOI 10.1016/j.jaci.2014.07.007; Goodridge HS, 2005, J IMMUNOL, V174, P284, DOI 10.4049/jimmunol.174.1.284; Guo XH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00158; He Y, 2020, ADV EXP MED BIOL, V1240, P35, DOI 10.1007/978-3-030-38315-2_3; Hubner MP, 2009, IMMUNOLOGY, V127, P512, DOI 10.1111/j.1365-2567.2008.02958.x; Hubner MP, 2012, J IMMUNOL, V188, P559, DOI 10.4049/jimmunol.1100335; Junpee A, 2010, PARASITOL RES, V107, P807, DOI 10.1007/s00436-010-1932-9; Kwarteng A, 2017, SCAND J IMMUNOL, V85, P251, DOI 10.1111/sji.12533; Lata S, 2008, PROTEIN ENG DES SEL, V21, P279, DOI 10.1093/protein/gzn006; Lee SY, 2009, J IMMUNOTHER, V32, P22, DOI 10.1097/CJI.0b013e31818ac2f7; Madhumitha H, 2018, CYTOKINE, V104, P65, DOI 10.1016/j.cyto.2017.09.032; McCoy CE, 2008, FRONT BIOSCI-LANDMRK, V13, P62, DOI 10.2741/2660; Milam AV, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00621; Mossel DM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01071; Mukherjee S, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0392-8; Mukherjee S, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12771; Mukherjee S, 2017, J INFECT DIS, V215, P954, DOI 10.1093/infdis/jix067; Nathan AA, 2017, TROP MED INT HEALTH, V22, P1414, DOI 10.1111/tmi.12969; Pal D, 2012, NAT MED, V18, P1279, DOI 10.1038/nm.2851; Panda SK, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002717; Raizada N., 2000, ENDOTEXT; Sabroe I, 2005, CLIN INFECT DIS, V41, pS421, DOI 10.1086/431992; Satapathy AK, 2006, MICROBES INFECT, V8, P2414, DOI 10.1016/j.micinf.2006.05.003; Semnani RT, 2008, BLOOD, V112, P1290, DOI 10.1182/blood-2008-04-149856; Taniuchi I, 2018, ANNU REV IMMUNOL, V36, P579, DOI 10.1146/annurev-immunol-042617-053411; Tartey S, 2017, INT REV IMMUNOL, V36, P57, DOI 10.1080/08830185.2016.1261318; Unnikrishnan R, 2020, DIABETES METAB SYND, V14, P1889, DOI 10.1016/j.dsx.2020.09.022; Venugopal PG, 2009, IMMUNOL RES, V43, P252, DOI 10.1007/s12026-008-8079-0; Villeneuve LM, 2008, P NATL ACAD SCI USA, V105, P9047, DOI 10.1073/pnas.0803623105; Wang WJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02025; Wiria AE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127746; Zeytun A, 2010, CRIT REV IMMUNOL, V30, P53, DOI 10.1615/CritRevImmunol.v30.i1.40	53	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 10	2021	12								716515	10.3389/fimmu.2021.716515	http://dx.doi.org/10.3389/fimmu.2021.716515			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV9DA	34566972	Green Published, gold			2022-12-18	WOS:000717528300001
J	Liao, YT; Tsai, HP; Wang, SM; Chen, SH				Liao, Yu-Ting; Tsai, Huey-Pin; Wang, Shih-Min; Chen, Shun-Hua			Clinical and Immune Responses of Peripheral Chemical Sympathectomy in Enterovirus 71 Infection	FRONTIERS IN IMMUNOLOGY			English	Article						enterovirus 71; brainstem encephalitis; 6-hydroxydopamine; cytokines; immunophenotypes	BRAIN-STEM ENCEPHALITIS; CEREBROSPINAL-FLUID; PATHOGENESIS; CYTOKINES; SYSTEM; VIRUS	The activation of the sympathetic nervous system, release of norepinephrine (NE), and adrenergic receptor signaling participate in and regulate the complicated enterovirus 71 (EV71) brainstem encephalitis (BE). The neurotoxin 6-hydroxydopamine (6-OHDA) selectively ablates sympathetic nerves and markedly depletes NE in innervated organs. Changes in the plasma levels of NE, severity score, cytokine profiles, and percentages of immunophenotype expression in 7-day-old Bltw : CD1 (ICR) mice infected with EV71, with or without 6-OHDA treatment, were compared. The survival rate (76.9%) of EV71-infected and 6-OHDA (30 mu g/g)-treated mice was increased significantly. The clinical scores were decreased markedly on days 8-12 in MP4-infected and 6-OHDA-treated mice compared to those without treatment. The results showed that the plasma levels of NE, epinephrine, and dopamine were decreased on days 4-8 after 6-OHDA treatment and at most on day 8. The plasma levels of interleukin (IL)-12p70, tumor necrosis factor, IL-6, and IL-10 did not change significantly after 6-OHDA treatment. Interferon-gamma levels decreased evidently on days 4, 6, and 8 after 6-OHDA treatment. The absolute events of CD3(+)CD4(+), CD3(+)CD8(+), and CD3(+)NK1.1(+) cells of peripheral blood mononuclear cells were increased significantly in MP4-infected and 6-OHDA-treated mice compared to those without treatment. In splenocytes, the absolute cells of CD3(-)NK1.1(+), CD3(+)NK1.1(+) and CD11b(+)Gr-1(+) cells of EV71-infected mice were increased significantly after 6-OHDA treatment. These findings suggested that 6-OHDA may be used a probe to explore clinical improvements and immune responses in the complicated EV71 infection. Taken together, peripheral chemical sympathectomy contribute to further understand the immunopathogenesis of EV71 BE with autonomic nervous system dysregulation.	[Liao, Yu-Ting; Wang, Shih-Min] Natl Cheng Kung Univ & Hosp, Coll Med, Dept Pediat, Tainan, Taiwan; [Tsai, Huey-Pin] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pathol, Tainan, Taiwan; [Tsai, Huey-Pin] Natl Cheng Kung Univ, Dept Med Lab Sci & Biotechnol, Coll Med, Tainan, Taiwan; [Wang, Shih-Min; Chen, Shun-Hua] Natl Cheng Kung Univ, Ctr Infect Dis & Signaling Res, Tainan, Taiwan; [Chen, Shun-Hua] Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan, Taiwan; [Liao, Yu-Ting] Natl Hlth Res Inst, Immunol Res Ctr, Zhunan, Taiwan	National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Health Research Institutes - Taiwan	Wang, SM (corresponding author), Natl Cheng Kung Univ & Hosp, Coll Med, Dept Pediat, Tainan, Taiwan.; Wang, SM (corresponding author), Natl Cheng Kung Univ, Ctr Infect Dis & Signaling Res, Tainan, Taiwan.	pedwang@mail.ncku.edu.tw			Ministry of Science and Technology, Taiwan [MOST 107-2314-B-006-045, MOST 109-2327-B-006-009]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by grant (MOST 107-2314-B-006-045, MOST 109-2327-B-006-009) Ministry of Science and Technology, Taiwan.	Ding XF, 2019, CELL REP, V27, P3799, DOI 10.1016/j.celrep.2019.05.082; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; Fu YC, 2004, ARCH DIS CHILD, V89, P368, DOI 10.1136/adc.2003.029645; Grebe KM, 2010, J IMMUNOL, V184, P540, DOI 10.4049/jimmunol.0903395; Grebe KM, 2009, P NATL ACAD SCI USA, V106, P5300, DOI 10.1073/pnas.0808851106; KRUSZEWSKA B, 1995, J IMMUNOL, V155, P4613; Liao YT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135154; Lin TY, 2002, CLIN INFECT DIS, V34, pS52, DOI 10.1086/338819; Liou AT, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0585-y; LORTON D, 1990, BRAIN BEHAV IMMUN, V4, P198, DOI 10.1016/0889-1591(90)90023-J; MADDEN K S, 1989, Brain Behavior and Immunity, V3, P72, DOI 10.1016/0889-1591(89)90007-X; MADDEN KS, 1994, J NEUROIMMUNOL, V49, P67, DOI 10.1016/0165-5728(94)90182-1; Monteiro S, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01945-8; Ooi MH, 2010, LANCET NEUROL, V9, P1097, DOI 10.1016/S1474-4422(10)70209-X; Qi WB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051029; Shih C, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120674; Solomon T, 2010, LANCET INFECT DIS, V10, P778, DOI 10.1016/S1473-3099(10)70194-8; ThyagaRajan S, 2011, J NEUROIMMUNOL, V233, P54, DOI 10.1016/j.jneuroim.2010.11.012; Wang SM, 2007, CLIN MICROBIOL INFEC, V13, P677, DOI 10.1111/j.1469-0691.2007.01729.x; Wang SM, 2008, J INFECT DIS, V198, P1002, DOI 10.1086/591462; Wang SM, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/876241; Wang SM, 2009, EXPERT REV ANTI-INFE, V7, P735, DOI 10.1586/ERI.09.45; Wang Shih-Min, 2008, Pediatrics and Neonatology, V49, P113, DOI 10.1016/S1875-9572(08)60024-8; Wang SM, 2003, J INFECT DIS, V188, P564, DOI 10.1086/376998; Weng KF, 2010, MICROBES INFECT, V12, P505, DOI 10.1016/j.micinf.2010.03.006; Willemze RA, 2019, MOL MED, V25, DOI 10.1186/s10020-018-0068-8; Wrona D, 2006, J NEUROIMMUNOL, V172, P38, DOI 10.1016/j.jneuroim.2005.10.017	27	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 9	2021	12								700903	10.3389/fimmu.2021.700903	http://dx.doi.org/10.3389/fimmu.2021.700903			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UT9TP	34566960	Green Published, gold			2022-12-18	WOS:000698450500001
J	Rao, JS; Hosny, N; Kumbha, R; Naqvi, RA; Singh, A; Swanson, Z; Levy, H; Matson, AW; Steinhoff, M; Forneris, N; Walters, E; Hering, BJ; Burlak, C				Rao, Joseph Sushil; Hosny, Nora; Kumbha, Ramesh; Naqvi, Raza Ali; Singh, Amar; Swanson, Zachary; Levy, Heather; Matson, Anders W.; Steinhoff, Magie; Forneris, Nicole; Walters, Eric; Hering, Bernhard J.; Burlak, Christopher			HLA-G1(+) Expression in GGTA1KO Pigs Suppresses Human and Monkey Anti-Pig T, B and NK Cell Responses	FRONTIERS IN IMMUNOLOGY			English	Article						HLAG-1; CRIPSR; Cas9; porcine; islet; xenotransplantation	NATURAL-KILLER-CELLS; HLA-G EXPRESSION; CLASS-I GENES; INHIBITORY RECEPTORS; DIABETES REVERSAL; MAMU-AG; REJECTION; MACROPHAGES; XENOGRAFTS; MOLECULE	The human leukocyte antigen G1 (HLA-G1), a non-classical class I major histocompatibility complex (MHC-I) protein, is a potent immunomodulatory molecule at the maternal/fetal interface and other environments to regulate the cellular immune response. We created GGTA1(-)/HLAG1(+) pigs to explore their use as organ and cell donors that may extend xenograft survival and function in both preclinical nonhuman primate (NHP) models and future clinical trials. In the present study, HLA-G1 was expressed from the porcine ROSA26 locus by homology directed repair (HDR) mediated knock-in (KI) with simultaneous deletion of alpha-1-3-galactotransferase gene (GGTA1; GTKO) using the clustered regularly interspersed palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) (CRISPR/Cas9) gene-editing system. GTKO/HLAG1(+) pigs showing immune inhibitory functions were generated through somatic cell nuclear transfer (SCNT). The presence of HLA-G1 at the ROSA26 locus and the deletion of GGTA1 were confirmed by next generation sequencing (NGS) and Sanger's sequencing. Fibroblasts from piglets, biopsies from transplantable organs, and islets were positive for HLA-G1 expression by confocal microscopy, flow cytometry, or q-PCR. The expression of cell surface HLA-G1 molecule associated with endogenous beta 2-microglobulin (beta 2m) was confirmed by staining genetically engineered cells with fluorescently labeled recombinant ILT2 protein. Fibroblasts obtained from GTKO/HLAG1(+) pigs were shown to modulate the immune response by lowering IFN-gamma production by T cells and proliferation of CD4(+) and CD8(+) T cells, B cells and natural killer (NK) cells, as well as by augmenting phosphorylation of Src homology region 2 domain-containing phosphatase-2 (SHP-2), which plays a central role in immune suppression. Islets isolated from GTKO/HLA-G1(+) genetically engineered pigs and transplanted into streptozotocin-diabetic nude mice restored normoglycemia, suggesting that the expression of HLA-G1 did not interfere with their ability to reverse diabetes. The findings presented here suggest that the HLA-G1(+) transgene can be stably expressed from the ROSA26 locus of non-fetal maternal tissue at the cell surface. By providing an immunomodulatory signal, expression of HLA-G1(+) may extend survival of porcine pancreatic islet and organ xenografts.</p>	[Rao, Joseph Sushil; Hosny, Nora; Kumbha, Ramesh; Naqvi, Raza Ali; Singh, Amar; Swanson, Zachary; Levy, Heather; Matson, Anders W.; Steinhoff, Magie; Forneris, Nicole; Hering, Bernhard J.; Burlak, Christopher] Univ Minnesota, Dept Surg, Schulze Diabet Inst, Box 242 UMHC, Minneapolis, MN 55455 USA; [Rao, Joseph Sushil] Univ Minnesota, Dept Surg, Div Solid Organ Transplantat, Box 242 UMHC, Minneapolis, MN 55455 USA; [Hosny, Nora] Suez Canal Univ, Fac Med, Med Biochem & Mol Biol Dept, Ismailia, Egypt	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Egyptian Knowledge Bank (EKB); Suez Canal University	Burlak, C (corresponding author), Univ Minnesota, Dept Surg, Schulze Diabet Inst, Box 242 UMHC, Minneapolis, MN 55455 USA.	cburlak@umn.edu	Naqvi, Raza/AAE-5550-2022; Naqvi, Raza/GPP-1388-2022	Naqvi, Raza/0000-0003-0187-2081; Swanson, Zachary/0000-0002-2580-2865	University of Minnesota; Diabetes Free, Inc.	University of Minnesota(University of Minnesota System); Diabetes Free, Inc.	This study was funded by sponsored research agreements governed by the University of Minnesota with Diabetes Free, Inc. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Abicht JM, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12390; Allan DSJ, 2000, IMMUNOBIOLOGY, V202, P34, DOI 10.1016/S0171-2985(00)80050-9; Amodio G, 2014, TISSUE ANTIGENS, V84, P255, DOI 10.1111/tan.12427; Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Apps R, 2007, EUR J IMMUNOL, V37, P1924, DOI 10.1002/eji.200737089; Ballinger MB., 2011, GUIDE CARE USE LAB A, VEighth; Blaschitz A, 2005, MOL HUM REPROD, V11, P699, DOI 10.1093/molehr/gah185; Bondarenko GI, 2007, J IMMUNOL, V179, P8042, DOI 10.4049/jimmunol.179.12.8042; Bondarenko GI, 2009, IMMUNOGENETICS, V61, P431, DOI 10.1007/s00251-009-0376-9; Boyson JE, 2002, P NATL ACAD SCI USA, V99, P16180, DOI 10.1073/pnas.212643199; Boyson JE, 1997, J IMMUNOL, V159, P3311; Brandhorst H, 2003, DIABETES, V52, P1143, DOI 10.2337/diabetes.52.5.1143; Brugiere O, 2015, AM J TRANSPLANT, V15, P461, DOI 10.1111/ajt.12977; Burlak C, 2014, AM J TRANSPLANT, V14, P1895, DOI 10.1111/ajt.12744; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Butler JR, 2016, TRANSPL IMMUNOL, V35, P47, DOI 10.1016/j.trim.2016.02.001; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; Colonna M, 1999, J LEUKOCYTE BIOL, V66, P718, DOI 10.1002/jlb.66.5.718; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Cooper MA, 2001, BLOOD, V97, P3146, DOI 10.1182/blood.V97.10.3146; Cowan PJ, 1998, TRANSPLANTATION, V65, P1599, DOI 10.1097/00007890-199806270-00010; Crew MD, 2004, IMMUNOGENETICS, V56, P111, DOI 10.1007/s00251-004-0676-z; Drake PM, 2001, J EXP MED, V193, P1199, DOI 10.1084/jem.193.10.1199; Esquivel EL, 2015, TRANSPL IMMUNOL, V32, P109, DOI 10.1016/j.trim.2014.12.004; Ezzelarab M, 2011, XENOTRANSPLANTATION, V18, P183, DOI 10.1111/j.1399-3089.2011.00635.x; Faas MM, 2017, PLACENTA, V56, P44, DOI 10.1016/j.placenta.2017.03.001; Feger U, 2007, BLOOD, V110, P568, DOI 10.1182/blood-2006-11-057125; Gaynor LM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00467; Gonen-Gross T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008941; Graham ML, 2011, COMPARATIVE MED, V61, P356; Hering BJ, 2006, NAT MED, V12, P301, DOI 10.1038/nm1369; Ihm SH, 2006, DIABETES, V55, P1361, DOI 10.2337/db05-1333; Itescu S, 1998, HUM IMMUNOL, V59, P275, DOI 10.1016/S0198-8859(98)00026-3; Kaneku Hugo, 2006, Clin Transpl, P447; Kapasi K, 2000, IMMUNOLOGY, V101, P191, DOI 10.1046/j.1365-2567.2000.00109.x; Ketroussi F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022776; Kroemer A, 2008, J IMMUNOL, V180, P7818, DOI 10.4049/jimmunol.180.12.7818; Li CL, 2009, P NATL ACAD SCI USA, V106, P5767, DOI 10.1073/pnas.0901173106; Li P., 2014, TRANSPLANT TECHNOL, V2, P1, DOI [10.7243/2053-6623-2-1, DOI 10.7243/2053-6623-2-1]; Liang S, 2008, P NATL ACAD SCI USA, V105, P8357, DOI 10.1073/pnas.0803341105; Lila N, 2000, LANCET, V355, P2138, DOI 10.1016/S0140-6736(00)02386-2; Lila N, 2002, CIRCULATION, V105, P1949, DOI 10.1161/01.CIR.0000015075.89984.46; Lin Y, 1997, J IMMUNOL, V158, P5658; Lorenz U, 2009, IMMUNOL REV, V228, P342, DOI 10.1111/j.1600-065X.2008.00760.x; Lutz AJ, 2013, XENOTRANSPLANTATION, V20, P27, DOI 10.1111/xen.12019; Mas VR, 2013, AM J TRANSPLANT, V13, P11, DOI 10.1111/j.1600-6143.2012.04313.x; Matson AW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226107; Matsunami K, 2001, CLIN EXP IMMUNOL, V126, P165, DOI 10.1046/j.1365-2249.2001.01622.x; Matsunami K, 2000, TRANSPLANT P, V32, P939, DOI 10.1016/S0041-1345(00)01048-4; Miyagawa S, 2003, TRANSPL IMMUNOL, V11, P147, DOI 10.1016/S0966-3274(02)00151-X; Naji A, 2014, J IMMUNOL, V192, P1536, DOI 10.4049/jimmunol.1300438; O'Callaghan CA, 1998, IMMUNOL REV, V163, P129, DOI 10.1111/j.1600-065X.1998.tb01192.x; Pankratz S, 2014, FASEB J, V28, P3435, DOI 10.1096/fj.14-251074; Papas KK, 2007, AM J TRANSPLANT, V7, P707, DOI 10.1111/j.1600-6143.2006.01655.x; Papas KK, 2009, CURR OPIN ORGAN TRAN, V14, P674, DOI 10.1097/MOT.0b013e328332a489; Qiu J, 2006, AM J TRANSPLANT, V6, P2152, DOI 10.1111/j.1600-6143.2006.01417.x; Rajagopalan S, 1999, J EXP MED, V189, P1093, DOI 10.1084/jem.189.7.1093; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Rebmann V, 2009, HUM IMMUNOL, V70, P995, DOI 10.1016/j.humimm.2009.07.016; Ristich V, 2007, HUM IMMUNOL, V68, P264, DOI 10.1016/j.humimm.2006.11.008; RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P11520, DOI 10.1073/pnas.94.21.11520; Seebach JD, 1997, J IMMUNOL, V159, P3655; Shiroishi M, 2003, P NATL ACAD SCI USA, V100, P8856, DOI 10.1073/pnas.1431057100; Slukvin II, 2006, TISSUE ANTIGENS, V67, P331, DOI 10.1111/j.1399-0039.2006.00579.x; Sullivan JA, 1997, J IMMUNOL, V159, P2318; Umesue M, 1996, TRANSPLANTATION, V61, P116, DOI 10.1097/00007890-199601150-00023; Wang ZY, 2020, XENOTRANSPLANTATION, V27, DOI 10.1111/xen.12619; Watzl C, 2014, ADV IMMUNOL, V124, P137, DOI 10.1016/B978-0-12-800147-9.00005-4; Weiss EH, 2009, TRANSPLANTATION, V87, P35, DOI 10.1097/TP.0b013e318191c784; Wilhite T, 2012, XENOTRANSPLANTATION, V19, P56, DOI 10.1111/j.1399-3089.2011.00691.x; Xie ZC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02785-y; Xu XC, 2002, AM J TRANSPLANT, V2, P314, DOI 10.1034/j.1600-6143.2002.20405.x; Yi SN, 2000, TRANSPLANTATION, V70, P896, DOI 10.1097/00007890-200009270-00007; Yung GP, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12357; Zarkhin V, 2010, TRANSPLANTATION, V90, P1000, DOI 10.1097/TP.0b013e3181f546af; Zhan YF, 2001, J IMMUNOL, V167, P6279, DOI 10.4049/jimmunol.167.11.6279; Zhou M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081232	77	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 9	2021	12								730545	10.3389/fimmu.2021.730545	http://dx.doi.org/10.3389/fimmu.2021.730545			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU2WM	34566993	Green Published, gold			2022-12-18	WOS:000698661600001
J	Rodina, Y; Deripapa, E; Shvets, O; Mukhina, A; Roppelt, A; Yuhacheva, D; Laberko, A; Burlakov, V; Abramov, D; Tereshchenko, G; Novichkova, G; Shcherbina, A				Rodina, Yulia; Deripapa, E.; Shvets, O.; Mukhina, A.; Roppelt, A.; Yuhacheva, D.; Laberko, A.; Burlakov, V.; Abramov, D.; Tereshchenko, G.; Novichkova, G.; Shcherbina, Anna			Rituximab and Abatacept Are Effective in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies	FRONTIERS IN IMMUNOLOGY			English	Article						ILLD; primary immunodeficiency; children; treatment; rituximab; abatacept	COMMON VARIABLE IMMUNODEFICIENCY; GRANULOMATOUS-DISEASE; MANAGEMENT; DISORDERS; INFLIXIMAB; STATEMENT; UPDATE	BackgroundInterstitial lymphocytic lung disease (ILLD), a recently recognized complication of primary immunodeficiencies (PID), is caused by immune dysregulation, abnormal bronchus-associated lymphoid tissue (BALT) hyperplasia, with subsequent progressive loss of pulmonary function. Various modes of standard immunosuppressive therapy for ILLD have been shown as only partially effective. ObjectivesTo retrospectively evaluate the safety and efficacy of abatacept or rituximab in treatment of ILLD in children with PID. Methods29 children (median age 11 years) with various forms of PID received one of the two therapy regimens predominantly based on the lesions' immunohistopathology: children with prevalent B-cell lung infiltration received rituximab (n = 16), and those with predominantly T-cell infiltration received abatacept (n = 17). Clinical and radiological symptoms were assessed using a severity scale developed for the study. ResultsThe targeted therapy with abatacept (A) or rituximab (R) enabled long-term control of clinical (A 3.4 +/- 1.3 vs. 0.6 +/- 0.1; R 2.8 +/- 1 vs. 0.7 +/- 0.05, p < 0.01) and radiological (A 18.4 +/- 3.1 vs. 6.0 +/- 2.0; R 30 +/- 7.1 vs. 10 +/- 1.7, p < 0.01) symptoms of ILLD in both groups and significantly improved patients' quality of life, as measured by the total scale (TS) score of 57 +/- 2.1 in treatment recipients vs. 31.2 +/- 1.9 before therapy (p < 0.01). ConclusionsILLD histopathology should be considered when selecting treatment. Abatacept and rituximab are effective and safe in differential treatment of ILLD in children.	[Rodina, Yulia; Deripapa, E.; Shvets, O.; Mukhina, A.; Roppelt, A.; Yuhacheva, D.; Laberko, A.; Burlakov, V.; Shcherbina, Anna] Dmitry Rogachev Natl Med Res Ctr Pediat Hematol, Dept Immunol, Moscow, Russia; [Abramov, D.] Dmitry Rogachev Natl Med Res Ctr Pediat Hematol, Dept Pathol, Moscow, Russia; [Tereshchenko, G.] Dmitry Rogachev Natl Med Res Ctr Pediat Hematol, Dept Radiol, Moscow, Russia; [Novichkova, G.] Dmitry Rogachev Natl Med Ctr Pediat Hematol, Dept Hematol, Moscow, Russia	Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology & Immunology; Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology & Immunology; Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology & Immunology	Rodina, Y (corresponding author), Dmitry Rogachev Natl Med Res Ctr Pediat Hematol, Dept Immunol, Moscow, Russia.	r.j.doctor77@gmail.com		Yukhacheva, Daria/0000-0001-9078-8206				Arandi N, 2013, CELL IMMUNOL, V281, P129, DOI 10.1016/j.cellimm.2013.03.003; Bates CA, 2004, J ALLERGY CLIN IMMUN, V114, P415, DOI 10.1016/j.jaci.2004.05.057; Bhatt JM, 2015, EUR RESPIR REV, V24, P565, DOI 10.1183/16000617.0066-2015; Boursiquot JN, 2013, J CLIN IMMUNOL, V33, P84, DOI 10.1007/s10875-012-9778-9; Bousfiha A, 2020, J CLIN IMMUNOL, V40, P66, DOI 10.1007/s10875-020-00758-x; Chapel H, 2009, BRIT J HAEMATOL, V145, P709, DOI 10.1111/j.1365-2141.2009.07669.x; Chase NM, 2013, J CLIN IMMUNOL, V33, P30, DOI 10.1007/s10875-012-9755-3; Chitale S, 2008, EXPERT OPIN BIOL TH, V8, P115, DOI 10.1517/14712598.8.1.115; Davies CWH, 2000, THORAX, V55, P88, DOI 10.1136/thorax.55.1.88; de Gracia J, 2004, INT IMMUNOPHARMACOL, V4, P745, DOI 10.1016/j.intimp.2004.02.011; ESID Registry, WORK DEF CLIN DIAGN; Franxman TJ, 2014, J CLIN IMMUNOL, V34, P820, DOI 10.1007/s10875-014-0079-3; Gamez-Diaz L, 2016, J ALLERGY CLIN IMMUN, V137, P223, DOI 10.1016/j.jaci.2015.09.025; Guinee DG, 2010, ARCH PATHOL LAB MED, V134, P691, DOI 10.1043/1543-2165-134.5.691; Hurst JR, 2017, J ALLER CL IMM-PRACT, V5, P938, DOI 10.1016/j.jaip.2017.01.021; Jesenak M, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00077; Kiykim A, 2019, J ALLER CL IMM-PRACT, V7, P2790, DOI 10.1016/j.jaip.2019.06.011; Lehman HK, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0553-x; Lucas M, 2010, J ALLERGY CLIN IMMUN, V125, P1354, DOI 10.1016/j.jaci.2010.02.040; Maglione PJ, 2014, J ALLERGY CLIN IMMUN, V133, P535, DOI 10.1016/j.jaci.2013.08.022; Morimoto Y, 2005, CURR ALLERGY ASTHM R, V5, P370, DOI 10.1007/s11882-005-0008-x; NICE, 2016, NICE NG52 NONH LYMPH; Patel S, 2019, CLIN EXP IMMUNOL, V198, P212, DOI 10.1111/cei.13343; Pathria Mohini, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2016-215624; Pierpont TM, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00163; Poletti V, 2013, EUR RESPIR REV, V22, P427, DOI 10.1183/09059180.00004313; Rao N, 2015, HUM PATHOL, V46, P1306, DOI 10.1016/j.humpath.2015.05.011; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Schwab C, 2018, J ALLERGY CLIN IMMUN, V142, P1932, DOI 10.1016/j.jaci.2018.02.055; Thatayatikom A, 2005, ANN ALLERG ASTHMA IM, V95, P293, DOI 10.1016/S1081-1206(10)61228-8; Torigian DA, 2008, J THORAC IMAG, V23, P162, DOI 10.1097/RTI.0b013e318166d32f; Walter JE, 2019, CURR OPIN PEDIATR, V31, P851, DOI 10.1097/MOP.0000000000000833	32	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 9	2021	12								704261	10.3389/fimmu.2021.704261	http://dx.doi.org/10.3389/fimmu.2021.704261			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XM4UA	34566961	Green Published, gold			2022-12-18	WOS:000728823000001
J	Wang, P; Li, JY; Wu, MJ; Ye, MH; Huang, K; Zhu, XG				Wang, Peng; Li, Jingying; Wu, Miaojing; Ye, Minghua; Huang, Kai; Zhu, Xingen			Human Mitochondrial Ribosomal RNA Modification-Based Classification Contributes to Discriminate the Prognosis and Immunotherapy Response of Glioma Patients	FRONTIERS IN IMMUNOLOGY			English	Article						mt-rRNA; tumor microenvironment; genomic variation; immunotherapy; temozolomide; glioma	GLIOBLASTOMA; TEMOZOLOMIDE; BEVACIZUMAB; SURVIVAL; SUBUNIT	Background Epigenetic regulations of the tumor microenvironment (TME) and immunotherapy have been investigated in recent years. Nevertheless, the potential value of mitochondrial ribosomal RNA (mt-rRNA) modification in regulation of the TME and immunotherapy remains unknown. Methods We comprehensively investigated the mt-rRNA-modification patterns in glioma patients based on nine regulators of mt-rRNA. Subsequently, these modification patterns were correlated systematically with immunologic characteristics and immunotherapy. An "mt-rRNA predictor" was constructed and validated in multiple publicly available cohorts to provide guidance for prognosis prediction and immunotherapy of glioma patients. Results Two distinct patterns of mt-rRNA modification were determined based on the evidence that nine regulators of mt-rRNA correlated significantly with most clinicopathologic characteristics, immunomodulators, TME, immune-checkpoint blockers (ICBs), and prognosis. Patients with mt-rRNA subtype II presented significantly poorer overall survival/progression-free survival (OS/PFS), but higher tumor mutational burden (TMB), more somatic mutations, and copy number variation (CNV). These two mt-rRNA subtypes had distinct TME patterns and responses to ICB therapy. An mt-rRNA predictor was constructed and validated in four glioma cohorts. The subtype with high mt-rRNA score, characterized by increased TMB, infiltration of immune cells, and activation of immunity, suggested an immune-activated phenotype, and was also linked to greater sensitivity to immunotherapy using anti-programmed cell death protein 1 (PD-1) but resistance to temozolomide. Conclusions Regulators of mt-rRNA modification have indispensable roles in the complexity and diversity of the TME and prognosis. This novel classification based on patterns of mt-rRNA modification could provide an effective prognostic predictor and guide more appropriate immunotherapy/chemotherapy strategies for glioma patients.	[Wang, Peng; Wu, Miaojing; Ye, Minghua; Huang, Kai; Zhu, Xingen] Nanchang Univ, Dept Neurosurg, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China; [Wang, Peng; Zhu, Xingen] Nanchang Univ, Inst Neurosci, Nanchang, Jiangxi, Peoples R China; [Li, Jingying; Huang, Kai] Nanchang Univ, Comprehens Intens Care Unit, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China; [Huang, Kai] East China Inst Digital Med Engn, Shangrao, Peoples R China	Nanchang University; Nanchang University; Nanchang University	Huang, K; Zhu, XG (corresponding author), Nanchang Univ, Dept Neurosurg, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China.; Zhu, XG (corresponding author), Nanchang Univ, Inst Neurosci, Nanchang, Jiangxi, Peoples R China.; Huang, K (corresponding author), Nanchang Univ, Comprehens Intens Care Unit, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China.; Huang, K (corresponding author), East China Inst Digital Med Engn, Shangrao, Peoples R China.	kaihuang@ncu.edu.cn; nde6fy89006@ncu.edu.cn			National Natural Science Foundation of China [81960456, 82002660, 81760445, 81760446]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The present study was supported by the National Natural Science Foundation of China (grant nos. 81960456, 82002660, 81760445, and 81760446).	[Anonymous], 2018, N Engl J Med, V379, P2185, DOI 10.1056/NEJMx180040; Auslander N, 2018, NAT MED, V24, P1545, DOI 10.1038/s41591-018-0157-9; Blanco S, 2014, CURR OPIN CELL BIOL, V31, P1, DOI 10.1016/j.ceb.2014.06.006; Boccaletto P, 2021, METHODS MOL BIOL, V2284, P481, DOI 10.1007/978-1-0716-1307-8_26; Bohnsack MT, 2018, CELL MOL LIFE SCI, V75, P241, DOI 10.1007/s00018-017-2598-6; Brown A, 2014, SCIENCE, V346, P718, DOI 10.1126/science.1258026; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chen H, 2020, J BIOL CHEM, V295, P8505, DOI 10.1074/jbc.RA119.012127; Du JY, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbab013; Gajewski TF, 2015, SEMIN ONCOL, V42, P663, DOI 10.1053/j.seminoncol.2015.05.011; Garone C, 2017, HUM MOL GENET, V26, P4257, DOI 10.1093/hmg/ddx314; Geeleher P, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r47; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Greber BJ, 2015, SCIENCE, V348, P303, DOI 10.1126/science.aaa3872; Greber BJ, 2014, NATURE, V515, P283, DOI 10.1038/nature13895; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; He Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-1002-1; Hoshida Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001195; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Jiang T, 2016, CANCER LETT, V375, P263, DOI 10.1016/j.canlet.2016.01.024; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Khasraw M, 2020, CLIN CANCER RES, V26, P5287, DOI 10.1158/1078-0432.CCR-20-1135; Marcel V, 2013, CANCER CELL, V24, P318, DOI 10.1016/j.ccr.2013.08.013; Mayakonda A, 2018, GENOME RES, V28, P1747, DOI 10.1101/gr.239244.118; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Pitt JM, 2016, ANN ONCOL, V27, P1482, DOI 10.1093/annonc/mdw168; Powell CA, 2020, RNA BIOL, V17, P451, DOI 10.1080/15476286.2020.1712544; Reardon DA, 2020, JAMA ONCOL, V6, P1003, DOI 10.1001/jamaoncol.2020.1024; Rebelo-Guiomar P, 2019, BBA-GENE REGUL MECH, V1862, P429, DOI 10.1016/j.bbagrm.2018.11.005; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rorbach J, 2012, BIOCHEM J, V444, P357, DOI 10.1042/BJ20112208; Sanchez MIGL, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00761; Sandmann T, 2015, J CLIN ONCOL, V33, P2735, DOI 10.1200/JCO.2015.61.5005; Segura-Collar B, 2020, CANCERS, V12, DOI 10.3390/cancers12010208; Senbabaoglu Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06207; Skidmore ZL, 2016, BIOINFORMATICS, V32, P3012, DOI 10.1093/bioinformatics/btw325; Stupp R, 2017, JAMA-J AM MED ASSOC, V318, P2306, DOI 10.1001/jama.2017.18718; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Touat M, 2020, NATURE, V580, P517, DOI 10.1038/s41586-020-2209-9; Turley SJ, 2015, NAT REV IMMUNOL, V15, P669, DOI 10.1038/nri3902; Wang P, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01119; Wang X, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1085-3; Weller M, 2017, LANCET ONCOL, V18, P1373, DOI 10.1016/S1470-2045(17)30517-X; Weller M, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.17; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Yang TR, 2021, HUM VACC IMMUNOTHER, V17, P546, DOI 10.1080/21645515.2020.1782692; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zhang B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01170-0; Zhang H, 2019, J CANCER, V10, P4793, DOI 10.7150/jca.32475; Zhang HE, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-244	52	1	1	2	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 9	2021	12								722479	10.3389/fimmu.2021.722479	http://dx.doi.org/10.3389/fimmu.2021.722479			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU2ZF	34566979	Green Published, gold			2022-12-18	WOS:000698668800001
J	Boni, C; Cavazzini, D; Bolchi, A; Rossi, M; Vecchi, A; Tiezzi, C; Barili, V; Fisicaro, P; Ferrari, C; Ottonello, S				Boni, Carolina; Cavazzini, Davide; Bolchi, Angelo; Rossi, Marzia; Vecchi, Andrea; Tiezzi, Camilla; Barili, Valeria; Fisicaro, Paola; Ferrari, Carlo; Ottonello, Simone			Degenerate CD8 Epitopes Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out From the SARS-CoV-2 Variants Storm	FRONTIERS IN IMMUNOLOGY			English	Review						SARS-Cov-2; CD8 T cells; CD8 T cell epitopes; neutralizing antibodies; SARS-Cov-2 variants; spike region	ANTIBODY-RESPONSES; B-CELL; BINDING	There is an urgent need for new generation anti-SARS-Cov-2 vaccines in order to increase the efficacy of immunization and its broadness of protection against viral variants that are continuously arising and spreading. The effect of variants on protective immunity afforded by vaccination has been mostly analyzed with regard to B cell responses. This analysis revealed variable levels of cross-neutralization capacity for presently available SARS-Cov-2 vaccines. Despite the dampened immune responses documented for some SARS-Cov-2 mutations, available vaccines appear to maintain an overall satisfactory protective activity against most variants of concern (VoC). This may be attributed, at least in part, to cell-mediated immunity. Indeed, the widely multi-specific nature of CD8 T cell responses should allow to avoid VoC-mediated viral escape, because mutational inactivation of a given CD8 T cell epitope is expected to be compensated by the persistent responses directed against unchanged co-existing CD8 epitopes. This is particularly relevant because some immunodominant CD8 T cell epitopes are located within highly conserved SARS-Cov-2 regions that cannot mutate without impairing SARS-Cov-2 functionality. Importantly, some of these conserved epitopes are degenerate, meaning that they are able to associate with different HLA class I molecules and to be simultaneously presented to CD8 T cell populations of different HLA restriction. Based on these concepts, vaccination strategies aimed at potentiating the stimulatory effect on SARS-Cov-2-specific CD8 T cells should greatly enhance the efficacy of immunization against SARS-Cov-2 variants. Our review recollects, discusses and puts into a translational perspective all available experimental data supporting these "hot" concepts, with special emphasis on the structural constraints that limit SARS-CoV-2 S-protein evolution and on potentially invariant and degenerate CD8 epitopes that lend themselves as excellent candidates for the rational development of next-generation, CD8 T-cell response-reinforced, COVID-19 vaccines.	[Boni, Carolina; Rossi, Marzia; Vecchi, Andrea; Tiezzi, Camilla; Barili, Valeria; Fisicaro, Paola; Ferrari, Carlo] Univ Parma, Azienda Osped, Unit Infect Dis & Hepatol, Lab Viral Immunopathol, Parma, Italy; [Cavazzini, Davide; Bolchi, Angelo; Ottonello, Simone] Univ Parma, Dept Chem Life Sci & Environm Sustainabil, Parma, Italy; [Bolchi, Angelo; Ottonello, Simone] Univ Parma, Interdept Ctr Biopharmanet Tec, Parma, Italy; [Rossi, Marzia; Barili, Valeria; Fisicaro, Paola; Ferrari, Carlo] Univ Parma, Dept Med & Surg, Parma, Italy	University of Parma; University Hospital of Parma; University of Parma; University of Parma; University of Parma	Ferrari, C (corresponding author), Univ Parma, Azienda Osped, Unit Infect Dis & Hepatol, Lab Viral Immunopathol, Parma, Italy.; Ferrari, C (corresponding author), Univ Parma, Dept Med & Surg, Parma, Italy.	carlo.ferrari@unipr.it	Bolchi, Angelo/GOJ-9730-2022; Fisicaro, Paola/AAB-8643-2019	Fisicaro, Paola/0000-0003-3720-9214	University of Parma	University of Parma	This work was supported by private donations to the Unit of Infectious Diseases and Hepatology (CB, MR, AV, CT, VB, PF, and CF) of the Azienda Ospedaliero-Universitaria of Parma and by a grant from the University of Parma (DC, AB, and SO) supporting research activities in the field of Covid-19 infection.	Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Agerer B, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abg6461; Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639; Annavajhala MK., 2021, NOVEL SARS COV 2 VAR, DOI 10.1101/2021.02.23.21252259; Arya R, 2021, J MOL BIOL, V433, DOI 10.1016/j.jmb.2020.11.024; Barnes CO, 2020, NATURE, V588, P682, DOI 10.1038/s41586-020-2852-1; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Brant AC, 2021, CELL BIOSCI, V11, DOI 10.1186/s13578-021-00643-z; Cai YF, 2020, SCIENCE, V369, P1586, DOI [10.1126/science.abd4251, 10.1101/2020.05.16.099317]; Cantuti-Castelvetri L, 2020, SCIENCE, V370, P856, DOI 10.1126/science.abd2985; Cathcart A. L., 2021, DUAL FUNCTION MONOCL, DOI [10.1101/2021.03.09.434607v6, DOI 10.1101/2021.03.09.434607, 10.1101/2021.03.09.434607, 10.1101/2021.03.09.434607(2021]; Chen ZW, 2021, J CELL MOL MED, V25, P1274, DOI 10.1111/jcmm.16200; Cherian S., 2021, CONVERGENT EVOLUTION, DOI [10.1101/2021.04.22.440932, DOI 10.1101/2021.04.22.440932]; Cohen KW, 2021, CELL REP MED, V2, DOI [10.1016/j.xcrm.2021.100354, 10.1101/2021.04.19.21255739]; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644, 10.1101/2021.02.26.21252554, 10.1126/science.abh2644Article]; Ferretti AP, 2020, IMMUNITY, V53, P1095, DOI 10.1016/j.immuni.2020.10.006; Frampton D, 2021, LANCET INFECT DIS, V21, P1246, DOI 10.1016/S1473-3099(21)00170-5; Funk T, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.16.2100348; Gangaev A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22811-y; Geers D, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj1750; Gobeil SMC, 2021, SCIENCE, V373, P641, DOI [10.1126/science.abi6226, 10.1101/2021.03.11.435037]; Golstein P, 2018, NAT REV IMMUNOL, V18, P526, DOI 10.1038/s41577-018-0009-3; Grifoni A, 2021, CELL HOST MICROBE, V29, P1076, DOI 10.1016/j.chom.2021.05.010; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; Habel JR, 2020, P NATL ACAD SCI USA, V117, P24384, DOI 10.1073/pnas.2015486117; Hanke L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18174-5; Harrison AG, 2020, TRENDS IMMUNOL, V41, P1100, DOI 10.1016/j.it.2020.10.004; Hashimoto M, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a028464; Hsieh CL, 2020, SCIENCE, V369, P1501, DOI 10.1126/science.abd0826; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Jackson L, 2021, SARS COV 2 CELL TO C, DOI [10.1101/2021.06.01.446516, DOI 10.1101/2021.06.01.446516]; Kalimuddin S, 2021, MED-CAMBRIDGE, V2, P682, DOI 10.1016/j.medj.2021.04.003; Kared H, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI145476; Ke ZL, 2020, NATURE, V588, P498, DOI 10.1038/s41586-020-2665-2; Kirby T, 2021, LANCET RESP MED, V9, pE20, DOI 10.1016/S2213-2600(21)00005-9; Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7; Koenig PA, 2021, SCIENCE, V371, P691, DOI 10.1126/science.abe6230; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Lempp F. A., 2021, MEMBRANE LECTINS ENH, DOI [10.1101/2021.04.03.438258, DOI 10.1101/2021.04.03.438258]; Martinez-Flores D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.701501; Mast Fred D, 2021, bioRxiv, DOI 10.1101/2021.04.08.438911; Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3; McCarthy KR, 2021, SCIENCE, V371, P1139, DOI 10.1126/science.abf6950; Moriyama S, 2021, IMMUNITY, V54, P1841, DOI 10.1016/j.immuni.2021.06.015; Muecksch F, 2021, IMMUNITY, V54, P1853, DOI 10.1016/j.immuni.2021.07.008; Naranbhai V., 2021, IMMUNOGENICITY MRNA, DOI [10.1101/2021.07.18.21260732, DOI 10.1101/2021.07.18.21260732]; Nasreen S., 2021, EFFECTIVENESS COVID, DOI [10.1101/2021.06.28.21259420, DOI 10.1101/2021.06.28.21259420, https://doi.org/10.1101/2021.06.28.21259420]; Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x; Nguyen THO, 2021, IMMUNITY, V54, P1066, DOI 10.1016/j.immuni.2021.04.009; Nielsen SCA, 2020, CELL HOST MICROBE, V28, P516, DOI 10.1016/j.chom.2020.09.002; Nielsen SSF, 2021, EBIOMEDICINE, V68, DOI 10.1016/j.ebiom.2021.103410; Ozer Egon A, 2021, medRxiv, DOI 10.1101/2021.04.09.21255206; Painter MM., 2021, RAPID INDUCTION ANTI, P1, DOI [10.1101/2021.04.21.440862, DOI 10.1101/2021.04.21.440862]; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI [10.1038/s41590-020-0782-6, 10.1101/2020.06.05.134551]; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Poran A, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00767-w; Prakash S, 2021, J IMMUNOL, V206, P2566, DOI 10.4049/jimmunol.2001438; Qiu C., 2021, CD8 T CELL EPITOPE V, DOI [10.1101/2021.01.22.427863, DOI 10.1101/2021.01.22.427863]; Quadeer AA, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100312; Ranjan R, 2021, CURR SCI INDIA, V121, P85, DOI 10.18520/cs/v121/i1/85-93; Rha MS, 2021, IMMUNITY, V54, P44, DOI 10.1016/j.immuni.2020.12.002; Sahin U, 2021, NATURE, V595, P572, DOI 10.1038/s41586-021-03653-6; Schreibing F., 2021, DISSECTING CD8 T CEL, DOI 10.1101/ 2021.03.03.432690; Schulien I, 2021, NAT MED, V27, P78, DOI 10.1038/s41591-020-01143-2; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Shomuradova AS, 2020, IMMUNITY, V53, P1245, DOI 10.1016/j.immuni.2020.11.004; Skelly DT., 2021, RES SQ, V12, P1, DOI [10.21203/rs.3.rs-226857, DOI 10.21203/RS.3.RS-226857]; Stewart JJ, 1997, MOL IMMUNOL, V34, P1067, DOI 10.1016/S0161-5890(97)00130-2; Tada Takuya, 2021, bioRxiv, DOI 10.1101/2021.07.19.452771; Tan AT., 2021, RAPID DETERMINATION, V2021, P06, DOI [10.1101/2021.06.29.450293, DOI 10.1101/2021.06.29.450293]; Tarke A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100355; Tarke A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100204; Tauzin A, 2021, CELL HOST MICROBE, V29, P1137, DOI 10.1016/j.chom.2021.06.001; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Thompson CN, 2021, MMWR-MORBID MORTAL W, V70, P712, DOI 10.15585/mmwr.mm7019e1; Turner JS, 2021, NATURE, V596, P109, DOI 10.1038/s41586-021-03738-2; Turonova B, 2020, SCIENCE, V370, P203, DOI 10.1126/science.abd5223; V'kovski P, 2021, NAT REV MICROBIOL, V19, P155, DOI 10.1038/s41579-020-00468-6; Verkhivker GM, 2021, J PHYS CHEM B, V125, P4596, DOI 10.1021/acs.jpcb.1c00395; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang MY, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.587269; Wang ZJ, 2021, NATURE, V595, P426, DOI 10.1038/s41586-021-03696-9; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Zeng C, 2022, P NATL ACAD SCI USA, V119, DOI [10.1101/2021.06.01.446579, 10.1073/pnas.2111400119]; Zhang J, 2021, SCIENCE, V372, P525, DOI 10.1126/science.abf2303; Zhang WJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.24191; Zhou TQ, 2020, CELL HOST MICROBE, V28, P867, DOI 10.1016/j.chom.2020.11.004	92	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 8	2021	12								730051	10.3389/fimmu.2021.730051	http://dx.doi.org/10.3389/fimmu.2021.730051			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UT3MM	34566990	gold, Green Published			2022-12-18	WOS:000698023900001
J	Hamieh, M; Chatillon, JF; Dupel, E; Bayeux, F; Fauquembergue, E; Maby, P; Drouet, A; Duval-Modeste, AB; Adriouch, S; Boyer, O; Latouche, JB				Hamieh, Mohamad; Chatillon, Jean-Francois; Dupel, Estelle; Bayeux, Florence; Fauquembergue, Emilie; Maby, Pauline; Drouet, Aurelie; Duval-Modeste, Anne-Benedicte; Adriouch, Sahil; Boyer, Olivier; Latouche, Jean-Baptiste			Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Article						adoptive cell therapy; MART-1; Melan-A; anti-tumor cytotoxic T lymphocytes; stem cell-like memory T cells; artificial antigen presenting cells	TUMOR-INFILTRATING LYMPHOCYTES; ANTIGEN-PRESENTING CELLS; IN-VIVO PERSISTENCE; METASTATIC MELANOMA; ADOPTIVE TRANSFER; PHASE-I; EFFECTOR; REGRESSION; EXPANSION; CLONES	Adoptive immunotherapy based on the transfer of anti-tumor cytotoxic T lymphocytes (CTLs) is a promising strategy to cure cancers. However, rapid expansion of numerous highly functional CTLs with long-lived features remains a challenge. Here, we constructed NIH/3T3 mouse fibroblast-based artificial antigen presenting cells (AAPCs) and precisely evaluated their ability to circumvent this difficulty. These AAPCs stably express the essential molecules involved in CTL activation in the HLA-A*0201 context and an immunogenic HLA-A*0201 restricted analogue peptide derived from MART-1, an auto-antigen overexpressed in melanoma. Using these AAPCs and pentamer-based magnetic bead-sorting, we defined, in a preclinical setting, the optimal conditions to expand pure MART-1-specific CTLs. Numerous highly purified MART-1-specific CTLs were rapidly obtained from healthy donors and melanoma patients. Both TCR repertoire and CDR3 sequence analyses revealed that MART-1-specific CTL responses were similar to those reported in the literature and obtained with autologous or allogeneic presenting cells. These MART-1-specific CTLs were highly cytotoxic against HLA-A*0201(+) MART-1(+) tumor cells. Moreover, they harbored a suitable phenotype for immunotherapy, with effector memory, central memory and, most importantly, stem cell-like memory T cell features. Notably, the cells harboring stem cell-like memory phenotype features were capable of self-renewal and of differentiation into potent effector anti-tumor T cells. These "off-the-shelf" AAPCs represent a unique tool to rapidly and easily expand large numbers of long-lived highly functional pure specific CTLs with stem cell-like memory T cell properties, for the development of efficient adoptive immunotherapy strategies against cancers.	[Hamieh, Mohamad; Dupel, Estelle; Fauquembergue, Emilie; Maby, Pauline; Drouet, Aurelie; Latouche, Jean-Baptiste] Normandie Univ, Inst Res & Innovat Biomed IRIB, Inserm U1245, UNIROUEN, Rouen, France; [Chatillon, Jean-Francois; Bayeux, Florence; Adriouch, Sahil; Boyer, Olivier] Normandie Univ, IRIB, Inserm U1234 Pathophysiol Autoimmun Neur, UNIROUEN, Rouen, France; [Duval-Modeste, Anne-Benedicte] Rouen Univ Hosp, Dept Dermatol, Rouen, France; [Boyer, Olivier] Rouen Univ Hosp, Dept Immunol & Biotherapy, Rouen, France; [Latouche, Jean-Baptiste] Rouen Univ Hosp, Dept Genet, Rouen, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Rouen; CHU de Rouen; CHU de Rouen	Latouche, JB (corresponding author), Normandie Univ, Inst Res & Innovat Biomed IRIB, Inserm U1245, UNIROUEN, Rouen, France.; Latouche, JB (corresponding author), Rouen Univ Hosp, Dept Genet, Rouen, France.	jean-baptiste.latouche@chu-rouen.fr	ADRIOUCH, Sahil/G-8999-2012	ADRIOUCH, Sahil/0000-0002-0265-7773	"La Ligue Contre le Cancer de Seine-Maritime", France; "La Ligue Contre le Cancer de Haute-Normandie", France	"La Ligue Contre le Cancer de Seine-Maritime", France; "La Ligue Contre le Cancer de Haute-Normandie", France	MH and J-FC's PhD fellowships were provided by "La Ligue Contre le Cancer de Seine-Maritime", France. This study was supported by "La Ligue Contre le Cancer de Haute-Normandie", France.	Alanio C, 2010, BLOOD, V115, P3718, DOI 10.1182/blood-2009-10-251124; Ando Makoto, 2020, Immunol Med, V43, P1, DOI 10.1080/25785826.2019.1698261; Anichini A, 2010, CANCER RES, V70, P8378, DOI 10.1158/0008-5472.CAN-10-2028; Aspord C, 2012, J INVEST DERMATOL, V132, P2395, DOI 10.1038/jid.2012.152; Benlalam H, 2007, CANCER IMMUNOL IMMUN, V56, P515, DOI 10.1007/s00262-006-0204-0; Berard F, 2000, J EXP MED, V192, P1535, DOI 10.1084/jem.192.11.1535; Berger C, 2008, J CLIN INVEST, V118, P294, DOI 10.1172/JCI32103; Butler MO, 2007, CLIN CANCER RES, V13, P1857, DOI 10.1158/1078-0432.CCR-06-1905; Cai ZL, 1996, P NATL ACAD SCI USA, V93, P14736, DOI 10.1073/pnas.93.25.14736; Cieri N, 2013, BLOOD, V121, P573, DOI 10.1182/blood-2012-05-431718; Dubsky P, 2007, EUR J IMMUNOL, V37, P1678, DOI 10.1002/eji.200636329; Dudley ME, 2010, CLIN CANCER RES, V16, P6122, DOI 10.1158/1078-0432.CCR-10-1297; Dupont J, 2005, CANCER RES, V65, P5417, DOI 10.1158/0008-5472.CAN-04-2991; Eddy K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21238984; Effros RB, 1997, IMMUNOL TODAY, V18, P450, DOI 10.1016/S0167-5699(97)01079-7; Fauquembergue E, 2010, J IMMUNOTHER, V33, P402, DOI 10.1097/CJI.0b013e3181d366da; Galletti G, 2020, NAT IMMUNOL, V21, P1552, DOI 10.1038/s41590-020-0791-5; Gattinoni L, 2005, J CLIN INVEST, V115, P1616, DOI 10.1172/JCI24480; Gattinoni L, 2006, NAT REV IMMUNOL, V6, P383, DOI 10.1038/nri1842; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Gattinoni L, 2009, NAT MED, V15, P808, DOI 10.1038/nm.1982; Gerdemann U, 2011, MOL THER, V19, P2258, DOI 10.1038/mt.2011.167; Hinrichs CS, 2009, P NATL ACAD SCI USA, V106, P17469, DOI 10.1073/pnas.0907448106; Kagoya Y, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89580; Kebriaei P, 2016, J CLIN INVEST, V126, P3363, DOI 10.1172/JCI86721; Kim JV, 2004, NAT BIOTECHNOL, V22, P403, DOI 10.1038/nbt955; Kondo T, 2018, CANCER SCI, V109, P2130, DOI 10.1111/cas.13648; Krishna S, 2020, SCIENCE, V370, P1328, DOI 10.1126/science.abb9847; Labarriere N, 2008, CANCER IMMUNOL IMMUN, V57, P185, DOI 10.1007/s00262-007-0361-9; Latouche JB, 2000, NAT BIOTECHNOL, V18, P405, DOI 10.1038/74455; Li YX, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-104; Lugli E, 2020, TRENDS IMMUNOL, V41, P17, DOI 10.1016/j.it.2019.11.004; Lugli E, 2013, J CLIN INVEST, V123, P594, DOI 10.1172/JCI66327; Mackensen A, 2006, J CLIN ONCOL, V24, P5060, DOI 10.1200/JCO.2006.07.1100; Maus MV, 2002, NAT BIOTECHNOL, V20, P143, DOI 10.1038/nbt0202-143; Mazzarella T, 2012, CANCER IMMUNOL IMMUN, V61, P1169, DOI 10.1007/s00262-011-1179-z; Musette P, 1999, J IMMUNOL, V162, P1789; Neal Lillian R, 2017, J Immunol Res Ther, V2, P68; Oelke M, 2003, NAT MED, V9, P619, DOI 10.1038/nm869; Palermo B, 2010, CANCER RES, V70, P7084, DOI 10.1158/0008-5472.CAN-10-1326; Pittet MJ, 1999, J EXP MED, V190, P705, DOI 10.1084/jem.190.5.705; Powell DJ, 2005, BLOOD, V105, P241, DOI 10.1182/blood-2004-06-2482; Przybyla A, 2019, CANCER IMMUNOL IMMUN, V68, P709, DOI 10.1007/s00262-018-02292-7; Rapoport AP, 2011, BLOOD, V117, P788, DOI 10.1182/blood-2010-08-299396; Rolle CE, 2008, CANCER RES, V68, P2984, DOI 10.1158/0008-5472.CAN-07-3040; Romano E, 2011, CLIN CANCER RES, V17, P1984, DOI 10.1158/1078-0432.CCR-10-3421; Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116; Schultze JL, 1997, J CLIN INVEST, V100, P2757, DOI 10.1172/JCI119822; TOPALIAN SL, 1994, INT J CANCER, V58, P69, DOI 10.1002/ijc.2910580113; Vignard V, 2005, J IMMUNOL, V175, P4797, DOI 10.4049/jimmunol.175.7.4797; Wood FM, 2006, BURNS, V32, P395, DOI 10.1016/j.burns.2006.01.008; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099; Zha SJ, 2019, IMMUNOTHERAPY-UK, V11, P967, DOI 10.2217/imt-2018-0211; Zhang Y, 2005, NAT MED, V11, P1299, DOI 10.1038/nm1326; Zhou JH, 2005, J IMMUNOL, V175, P7046, DOI 10.4049/jimmunol.175.10.7046; Zhou JH, 2005, J IMMUNOTHER, V28, P53, DOI 10.1097/00002371-200501000-00007	56	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 8	2021	12								674276	10.3389/fimmu.2021.674276	http://dx.doi.org/10.3389/fimmu.2021.674276			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UT9ZE	34566953	gold, Green Published			2022-12-18	WOS:000698465000001
J	Qiu, LR; Zhang, J; Huang, YF; Chen, G; Chen, ZS; Ming, CS; Lu, X; Gong, NQ				Qiu, Liru; Zhang, Ji; Huang, Yafei; Chen, Gen; Chen, Zhishui; Ming, Changsheng; Lu, Xia; Gong, Nianqiao			Long-Term Clinical and Immunological Impact of Severe COVID-19 on a Living Kidney Transplant Recipient - A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; living kidney transplant; lung injury; renal tubular injury; immunity		The long-term impact of COVID-19 on transplant recipients remains unknown. We describe the case of a 30-year-old male kidney transplant recipient from Wuhan, China that was treated for severe COVID-19 in February 2020. He suffered an acute lung and renal injury and required systemic treatment including adjustment of his immunosuppressant regime. He was followed up to 1-year after discharge. No chronic lung fibrosis or deterioration of his pulmonary function was observed. Despite COVID-19 mediated damage to his renal tubular cells, no transplant rejection occurred. His immunological profile demonstrated both cellular anti-SARS-CoV-2 reactivity and specific humoral immunity, indicating that it is beneficial for the transplanted patients to be immunized with SARS-CoV-2 virus vaccine. This case will help guide clinical decision making for immunocompromised individuals that become infected with SARS-CoV-2.	[Qiu, Liru] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pediat, Wuhan, Peoples R China; [Zhang, Ji] Anhui Med Univ, Dept Urol, Affiliated Hosp 1, Hefei, Peoples R China; [Zhang, Ji] Anhui Med Univ, Inst Urol, Hefei, Peoples R China; [Zhang, Ji] Anhui Med Univ, Anhui Prov Key Lab Genitourinary Dis, Hefei, Peoples R China; [Zhang, Ji; Chen, Zhishui; Ming, Changsheng; Lu, Xia; Gong, Nianqiao] Huazhong Univ Sci & Technol, Inst Organ Transplantat, Key Lab Organ Transplantat, Tongji Med Coll,Tongji Hosp,Minist Educ,Natl Hlth, Wuhan, Peoples R China; [Zhang, Ji; Chen, Zhishui; Ming, Changsheng; Lu, Xia; Gong, Nianqiao] Chinese Acad Med Sci, Wuhan, Peoples R China; [Huang, Yafei] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, Wuhan, Peoples R China; [Chen, Gen] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Radiol, Wuhan, Peoples R China	Huazhong University of Science & Technology; Anhui Medical University; Anhui Medical University; Anhui Medical University; Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Lu, X; Gong, NQ (corresponding author), Huazhong Univ Sci & Technol, Inst Organ Transplantat, Key Lab Organ Transplantat, Tongji Med Coll,Tongji Hosp,Minist Educ,Natl Hlth, Wuhan, Peoples R China.; Lu, X; Gong, NQ (corresponding author), Chinese Acad Med Sci, Wuhan, Peoples R China.	15972976712@163.com; nqgong@tjh.tjmu.edu.cn	qiu, liru/AAA-4648-2022; Gong, Nianqiao/ABD-9276-2021	qiu, liru/0000-0002-1583-7183; 	National Natural Science Foundation of China [81570678]; Major State Basic Research Development Program of China [2013CB530803, 973]; Special Project of the Ministry of Health [201302009]; Clinical Research Physician Program of Tongji Medical College, HUST	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major State Basic Research Development Program of China(National Basic Research Program of China); Special Project of the Ministry of Health; Clinical Research Physician Program of Tongji Medical College, HUST	This work was supported by grants to NG from the National Natural Science Foundation of China (No. 81570678), to NG from the Major State Basic Research Development Program of China (NO. 2013CB530803, 973), to XC from the Special Project of the Ministry of Health (201302009), and to NG from the Clinical Research Physician Program of Tongji Medical College, HUST.	Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117; Banerjee D, 2020, KIDNEY INT, V97, P1076, DOI 10.1016/j.kint.2020.03.018; Chavarot N, 2021, AM J TRANSPLANT, V21, P1285, DOI 10.1111/ajt.16416; Fava A, 2021, AM J TRANSPLANT, V21, P2749, DOI 10.1111/ajt.16570; Fernandez-Ruiz Mario, 2021, Transplantation, V105, P1372, DOI 10.1097/TP.0000000000003672; Francone M, 2020, EUR RADIOL, V30, P6808, DOI 10.1007/s00330-020-07033-y; Galvez-Romero JL, 2021, J INTERN MED, V289, P906, DOI 10.1111/joim.13223; Gandolfini I, 2020, AM J TRANSPLANT, V20, P1941, DOI 10.1111/ajt.15891; Rahbar MG, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13406; Gong NQ, 2011, CHINESE MED J-PEKING, V124, P1290, DOI 10.3760/cma.j.issn.0366-6999.2011.09.003; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Husain-Syed F, 2020, NEPHROL DIAL TRANSPL, V35, P1271, DOI 10.1093/ndt/gfaa162; Kliment CR, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0124-x; Luo XZ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.630710; Nagpal Prashant, 2021, BJR Open, V3, P20200043, DOI 10.1259/bjro.20200043; Ouahmi H, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.611772; Perez-Saez MJ, 2020, AM J TRANSPLANT, V20, P3182, DOI 10.1111/ajt.16192; Prasad K, 2021, ACS CHEM NEUROSCI, V12, P930, DOI 10.1021/acschemneuro.1c00019; Susanto AD, 2021, J INFECT DEV COUNTR, V15, P360, DOI 10.3855/jidc.13686; Turner JS, 2021, NATURE, V595, P421, DOI 10.1038/s41586-021-03647-4; Zhu L, 2020, EUR UROL, V77, P748, DOI 10.1016/j.eururo.2020.03.039	21	1	1	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 8	2021	12								741765	10.3389/fimmu.2021.741765	http://dx.doi.org/10.3389/fimmu.2021.741765			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UT3DJ	34567007	Green Published, gold			2022-12-18	WOS:000698000100001
J	Roy, U; de Oliveira, RS; Galvez, EJC; Gronow, A; Basic, M; Perez, LG; Gagliani, N; Bleich, A; Huber, S; Strowig, T				Roy, Urmi; de Oliveira, Romulo S.; Galvez, Eric J. C.; Gronow, Achim; Basic, Marijana; Perez, Laura Garcia; Gagliani, Nicola; Bleich, Andre; Huber, Samuel; Strowig, Till			Induction of IL-22-Producing CD4+T Cells by Segmented Filamentous Bacteria Independent of Classical Th17 Cells	FRONTIERS IN IMMUNOLOGY			English	Article						segmented filamentous bacteria (SFB); cytokine knock-in reporter mice; IL-22; Th22 cells; bystander activation of T cells; Salmonella infection	REGULATORY T-CELLS; GROWTH-FACTOR-BETA; T(H)17 CELLS; INFLAMMATORY RESPONSES; AUTOIMMUNE ARTHRITIS; INTERLEUKIN 22; TH22 CELLS; IFN-GAMMA; IL-22; DISTINCT	The intestinal microbiota modulates IL-22 production in the intestine, including the induction of IL-22-producing CD4+ T helper cells. Which specific bacteria are responsible for the induction of these cells is less well understood. Here, we demonstrate through the use of novel gnotobiotic knock-in reporter mice that segmented filamentous bacteria (SFB), which are known for their ability to induce Th17 cells, also induce distinct IL-17A negative CD4+ T cell populations in the intestine. A subset of these cells instead produces IL-22 upon restimulation ex vivo and also during enteric infections. Furthermore, they produce a distinct set of cytokines compared to Th17 cells including the differential expression of IL-17F and IFN-gamma. Importantly, genetic models demonstrate that these cells, presumably Th22 cells, develop independently of intestinal Th17 cells. Together, our data identifies that besides Th17, SFB also induces CD4+ T cell populations, which serve as immediate source of IL-22 during intestinal inflammation.</p>	[Roy, Urmi; de Oliveira, Romulo S.; Galvez, Eric J. C.; Gronow, Achim; Strowig, Till] Helmholtz Ctr Infect Res, Dept Microbial Immune Regulat, Braunschweig, Germany; [Basic, Marijana; Bleich, Andre] Hannover Med Sch, Inst Lab Anim Sci, Hannover, Germany; [Perez, Laura Garcia; Gagliani, Nicola; Huber, Samuel] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany; [Gagliani, Nicola] Univ Med Ctr Hamburg Eppendorf, Dept Gen Visceral & Thorac Surg, Hamburg, Germany	Helmholtz Association; Helmholtz-Center for Infection Research; Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Strowig, T (corresponding author), Helmholtz Ctr Infect Res, Dept Microbial Immune Regulat, Braunschweig, Germany.	till.strowig@helmholtz-hzi.de		Huber, Samuel/0000-0001-9325-8227; Gagliani, Nicola/0000-0001-8514-1395	Helmholtz Association [VH-NG-933]; DFG [STR-1343/1]; EU [StG337251]; ERC [CoG 865466]	Helmholtz Association(Helmholtz Association); DFG(German Research Foundation (DFG)); EU(European Commission); ERC(European Research Council (ERC)European Commission)	The project was supported by the Helmholtz Association (VH-NG-933 to TS), by the DFG (STR-1343/1 to TS), the EU (StG337251 to SH) and the ERC (CoG 865466 to SH).	Ahlfors H, 2014, J IMMUNOL, V193, P4602, DOI 10.4049/jimmunol.1401244; Andoh A, 2005, GASTROENTEROLOGY, V129, P969, DOI 10.1053/j.gastro.2005.06.071; Atarashi K, 2015, CELL, V163, P367, DOI 10.1016/j.cell.2015.08.058; Barthel M, 2003, INFECT IMMUN, V71, P2839, DOI 10.1128/IAI.71.5.2839-2858.2003; Basu R, 2012, IMMUNITY, V37, P1061, DOI 10.1016/j.immuni.2012.08.024; Besnard AG, 2011, AM J RESP CRIT CARE, V183, P1153, DOI 10.1164/rccm.201008-1383OC; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bradley CP, 2017, CELL HOST MICROBE, V22, P697, DOI 10.1016/j.chom.2017.10.007; Brand S, 2006, AM J PHYSIOL-GASTR L, V290, pG827, DOI 10.1152/ajpgi.00513.2005; Brembilla NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01682; Britton GJ, 2019, IMMUNITY, V50, P212, DOI 10.1016/j.immuni.2018.12.015; Cosorich I, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700492; Dudakov JA, 2015, ANNU REV IMMUNOL, V33, P747, DOI 10.1146/annurev-immunol-032414-112123; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Esplugues E, 2011, NATURE, V475, P514, DOI 10.1038/nature10228; Fletcher JM, 2009, J IMMUNOL, V183, P7602, DOI 10.4049/jimmunol.0901881; Gaboriau-Routhiau V, 2009, IMMUNITY, V31, P677, DOI 10.1016/j.immuni.2009.08.020; Gagliani N, 2015, NATURE, V523, P221, DOI 10.1038/nature14452; Geddes K, 2011, NAT MED, V17, P837, DOI 10.1038/nm.2391; Ghoreschi K, 2010, NATURE, V467, P967, DOI 10.1038/nature09447; Godinez I, 2008, INFECT IMMUN, V76, P2008, DOI 10.1128/IAI.01691-07; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397; Hirota K, 2011, NAT IMMUNOL, V12, P255, DOI 10.1038/ni.1993; Huber S, 2009, J IMMUNOL, V182, P4633, DOI 10.4049/jimmunol.0803143; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Killig M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00142; Kiner E, 2021, NAT IMMUNOL, V22, P216, DOI 10.1038/s41590-020-00836-7; KLAASEN HLBM, 1993, INFECT IMMUN, V61, P303, DOI 10.1128/IAI.61.1.303-306.1993; Lee JY, 2020, CELL, V180, P79, DOI 10.1016/j.cell.2019.11.026; McGeachy MJ, 2019, IMMUNITY, V50, P892, DOI 10.1016/j.immuni.2019.03.021; McGinley AM, 2020, IMMUNITY, V52, P342, DOI 10.1016/j.immuni.2020.01.002; Nistala K, 2010, P NATL ACAD SCI USA, V107, P14751, DOI 10.1073/pnas.1003852107; O'Donnell H, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00621; Omenetti S, 2019, IMMUNITY, V51, P77, DOI 10.1016/j.immuni.2019.05.004; Perez LG, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16363-w; Plank MW, 2017, J IMMUNOL, V198, P2182, DOI 10.4049/jimmunol.1601480; Regen T, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.aaz6563; Rhee SJ, 2005, J IMMUNOL, V175, P1127, DOI 10.4049/jimmunol.175.2.1127; Sano T, 2015, CELL, V163, P381, DOI 10.1016/j.cell.2015.08.061; Shen W, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00662; Songhet P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022459; Sonnenberg GF, 2010, J EXP MED, V207, P1293, DOI 10.1084/jem.20092054; Teng F, 2016, IMMUNITY, V44, P875, DOI 10.1016/j.immuni.2016.03.013; Thiemann S, 2017, CELL HOST MICROBE, V21, P682, DOI 10.1016/j.chom.2017.05.005; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Veldhoen M, 2006, NAT IMMUNOL, V7, P1151, DOI 10.1038/ni1391; Veldhoen M, 2017, NAT IMMUNOL, V18, P612, DOI 10.1038/ni.3742; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; Weigmann B, 2007, NAT PROTOC, V2, P2307, DOI 10.1038/nprot.2007.315; Wilck N, 2017, NATURE, V551, P585, DOI 10.1038/nature24628; Wong MT, 2016, IMMUNITY, V45, P442, DOI 10.1016/j.immuni.2016.07.007; Xu H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17097-5; Yang BH, 2016, MUCOSAL IMMUNOL, V9, P444, DOI 10.1038/mi.2015.74; Yang P, 2019, J LEUKOCYTE BIOL, V106, P1233, DOI 10.1002/JLB.4RU0619-197R; Yang Y, 2014, NATURE, V510, P152, DOI 10.1038/nature13279; Yu Q, 2011, J IMMUNOL, V186, P3946, DOI 10.4049/jimmunol.1003497; Zenewicz LA, 2008, IMMUNITY, V29, P947, DOI 10.1016/j.immuni.2008.11.003	60	1	1	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 8	2021	12								671331	10.3389/fimmu.2021.671331	http://dx.doi.org/10.3389/fimmu.2021.671331			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UT4JP	34566952	gold, Green Published			2022-12-18	WOS:000698084000001
J	Wang, YJ; Yu, SJ; Tsai, JJ; Yu, CH; Liao, EC				Wang, Yun-Ju; Yu, Sheng-Jie; Tsai, Jaw-Ji; Yu, Ching-Hsiang; Liao, En-Chih			Antagonism of Protease Activated Receptor-2 by GB88 Reduces Inflammation Triggered by Protease Allergen Tyr-p3	FRONTIERS IN IMMUNOLOGY			English	Article						storage mite allergy; Tyrophagus putrescentiae (schrank); protease activated receptor-2 (PAR-2); GB88 (PubChem CID; 73755230); protease allergen	AIRWAY EPITHELIAL-CELLS; ENDOTHELIAL GROWTH-FACTOR; DER-P-I; HOUSE-DUST; DERMATOPHAGOIDES-PTERONYSSINUS; COCKROACH ALLERGENS; IL-8 EXPRESSION; MITE ALLERGENS; SENSITIZATION; INDUCTION	The occurrence of allergic diseases induced by aeroallergens has increased in the past decades. Among inhalant allergens, mites remain the important causal agent of allergic diseases. Storage mites- Tyrophagus putrescentiae are found in stored products or domestic environments. Major allergen Tyr-p3 plays a significant role in triggering IgE-mediated hypersensitivity. However, its effects on pulmonary inflammation, internalization, and activation in human epithelium remain elusive. Protease-activated receptors (PARs) are activated upon cleavage by proteases. A549 cells were used as an epithelial model to examine the PAR activation by Tyr-p3 and therapeutic potential of PAR-2 antagonist (GB88) in allergic responses. Enzymatic properties and allergen localization of Tyr-p3 were performed. The release of inflammatory mediators, phosphorylation of mitogen-activated protein kinase (MAPK), and cell junction disruptions were evaluated after Tyr-p3 challenge. Enzymatic properties determined by substrate digestion and protease inhibitors indicated that Tyr-p3 processes a trypsin-like serine protease activity. The PAR-2 mRNA levels were significantly increased by nTyr-p3 but inhibited by protease inhibitors or GB88. Protease allergen of nTyr-p3 significantly increased the levels of pro-inflammatory cytokines (IL-6 and TNF-alpha), chemokine (IL-8), and IL-1 beta in epithelial cells. nTyr-p3 markedly increased phosphorylation of extracellular signal-regulated kinase (ERK)1/2 and MAP kinase. When cells were pretreated with GB88 then added nTyr-p3, the phosphorylated ERK1/2 did not inhibit by GB88. GB88 increased ERK1/2 phosphorylation in human epithelium cells. GB88 is able to block PAR-2-mediated calcium signaling which inhibits the nTyr-p3-induced Ca2+ release. Among the pharmacologic inhibitors, the most effective inhibitor of the nTyr-p3 in the induction of IL-8 or IL-1 beta levels was GB88 followed by SBTI, MAPK/ERK, ERK, and p38 inhibitors. Levels of inflammatory mediators, including GM-CSF, VEGF, COX-2, TSLP, and IL-33 were reduced by treatment of GB88 or SBTI. Further, GB88 treatment down-regulated the nTyr-p3-induced PAR-2 expression in allergic patients with asthma or rhinitis. Tight junction and adherens junction were disrupted in epithelial cells by nTyr-p3 exposure; however, this effect was avoided by GB88. Immunostaining with frozen sections of the mite body showed the presence of Tyr-p3 throughout the intestinal digestive system, especially in the hindgut around the excretion site. In conclusion, our findings suggest that Tyr-p3 from domestic mites leads to disruption of the airway epithelial barrier after inhalation. Proteolytic activity of Tyr-p3 causes the PAR-2 mRNA expression, thus leading to the release of numerous inflammatory mediators. Antagonism of PAR2 activity suggests GB88 as the therapeutic potential for anti-inflammation medicine, especially in allergy development triggered by protease allergens.</p>	[Wang, Yun-Ju; Liao, En-Chih] Mackay Med Coll, Inst Biomed Sci, New Taipei, Taiwan; [Yu, Sheng-Jie] Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung, Taiwan; [Tsai, Jaw-Ji] Asia Univ Hosp, Dept Internal Med, Div Allergy Immunol & Rheumatol, Taichung, Taiwan; [Tsai, Jaw-Ji] Taichung Vet Gen Hosp, Dept Internal Med, Div Allergy Immunol & Rheumatol, Taichung, Taiwan; [Yu, Ching-Hsiang; Liao, En-Chih] Mackay Med Coll, Dept Med, New Taipei, Taiwan	Mackay Medical College; Kaohsiung Veterans General Hospital; Taichung Veterans General Hospital; Mackay Medical College	Liao, EC (corresponding author), Mackay Med Coll, Inst Biomed Sci, New Taipei, Taiwan.; Liao, EC (corresponding author), Mackay Med Coll, Dept Med, New Taipei, Taiwan.	enchih@mmc.edu.tw			Ministry of Science and Technology, Taiwan, Republic of China [MOST 105-2320-B-715-004, MOST 106-2320-B-715-005-MY3]; MacKay Medical College [1051B27, 1071B15]; MacKay Memorial Hospital, New Taipei City, Taiwan [MMH-MM-10716]	Ministry of Science and Technology, Taiwan, Republic of China; MacKay Medical College; MacKay Memorial Hospital, New Taipei City, Taiwan	This study was supported in part by the research grants (MOST 105-2320-B-715-004 and MOST 106-2320-B-715-005-MY3) by the Ministry of Science and Technology, Taiwan, Republic of China. This project was also supported by the grants (1051B27 and 1071B15) from MacKay Medical College, and by the grant (MMH-MM-10716) from the MacKay Memorial Hospital, New Taipei City, Taiwan.	Adam E, 2006, J BIOL CHEM, V281, P6910, DOI 10.1074/jbc.M507140200; ANDO T, 1993, CLIN EXP ALLERGY, V23, P777, DOI 10.1111/j.1365-2222.1993.tb00366.x; Baum B, 2011, J CELL BIOL, V192, P907, DOI 10.1083/jcb.201009141; Belham CL, 1996, BIOCHEM J, V320, P939, DOI 10.1042/bj3200939; Calderon MA, 2015, J ALLERGY CLIN IMMUN, V136, P38, DOI 10.1016/j.jaci.2014.10.012; Chapman MD, 2007, CURR ALLERGY ASTHM R, V7, P363, DOI 10.1007/s11882-007-0055-6; Chew FT, 1999, ALLERGY, V54, P1150, DOI 10.1034/j.1398-9995.1999.00050.x; Chiu CY, 2018, PEDIAT ALLERG IMM-UK, V29, P496, DOI 10.1111/pai.12909; Chiu LL, 2007, J IMMUNOL, V178, P5237, DOI 10.4049/jimmunol.178.8.5237; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dumez ME, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00138; Ebeling C, 2005, J ALLERGY CLIN IMMUN, V115, P623, DOI 10.1016/j.jaci.2004.11.042; Erban T, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00053; Erban T, 2015, ENVIRON ENTOMOL, V44, P1599, DOI 10.1093/ee/nvv129; Erban T, 2015, EXP APPL ACAROL, V65, P73, DOI 10.1007/s10493-014-9848-1; Erban T, 2010, J INSECT SCI, V10, DOI 10.1673/031.010.4201; Gandhi VD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00147; Ge SQ, 2016, CELL BIOL TOXICOL, V32, P529, DOI 10.1007/s10565-016-9353-x; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Hibberson CE, 2014, AUST VET J, V92, P219, DOI 10.1111/avj.12185; Hollenberg MD, 2014, BRIT J PHARMACOL, V171, P1180, DOI 10.1111/bph.12544; Holzhausen M, 2005, MEM I OSWALDO CRUZ, V100, P177, DOI 10.1590/S0074-02762005000900030; Hou L, 1998, IMMUNOLOGY, V94, P356, DOI 10.1046/j.1365-2567.1998.00528.x; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Jacquet A, 2011, TRENDS MOL MED, V17, P604, DOI 10.1016/j.molmed.2011.05.014; Jairaman A, 2016, SCI REP-UK, V6, DOI 10.1038/srep32311; Jeon SK, 2008, J INVEST DERMATOL, V128, P1930, DOI 10.1038/jid.2008.13; Kato T, 2009, ALLERGY, V64, P1366, DOI 10.1111/j.1398-9995.2009.02023.x; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797, DOI 10.1067/mai.2001.119025; Kondo S, 2004, INFLAMM RES, V53, P489, DOI 10.1007/s00011-004-1287-8; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; LEDFORD DK, 1994, J ALLERGY CLIN IMMUN, V94, P327, DOI 10.1053/ai.1994.v94.a56012; Lee MF, 2010, ANN ALLERG ASTHMA IM, V105, P234, DOI 10.1016/j.anai.2010.07.008; Leung R, 1997, J ALLERGY CLIN IMMUN, V99, P594, DOI 10.1016/S0091-6749(97)70018-6; LI CS, 1994, J ALLERGY CLIN IMMUN, V94, P131, DOI 10.1016/0091-6749(94)90080-9; Li DQ, 2006, EXP EYE RES, V82, P588, DOI 10.1016/j.exer.2005.08.019; Liao EC, 2013, J INVEST ALLERG CLIN, V23, P20; Liao EC, 2010, INT ARCH ALLERGY IMM, V152, P368, DOI 10.1159/000288290; Liao EC, 2009, INT ARCH ALLERGY IMM, V150, P15, DOI 10.1159/000210376; Liu Y, 2006, BIOCHEM BIOPH RES CO, V344, P1263, DOI 10.1016/j.bbrc.2006.04.005; Lohman RJ, 2012, FASEB J, V26, P2877, DOI 10.1096/fj.11-201004; Lohman RJ, 2012, J PHARMACOL EXP THER, V340, P256, DOI 10.1124/jpet.111.187062; Matsumoto T, 1996, INT ARCH ALLERGY IMM, V109, P197, DOI 10.1159/000237220; McGuire JJ, 2004, J PHARMACOL EXP THER, V309, P1124, DOI 10.1124/jpet.103.064584; MILLER I, 1992, ELECTROPHORESIS, V13, P450, DOI 10.1002/elps.1150130193; Musken H, 2002, J INVEST ALLERG CLIN, V12, P177; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; Ortego F, 2000, ARCH INSECT BIOCHEM, V43, P116, DOI 10.1002/(SICI)1520-6327(200003)43:3&lt;116::AID-ARCH3&gt;3.0.CO;2-R; Page K, 2003, J ALLERGY CLIN IMMUN, V112, P1112, DOI 10.1016/j.jaci.2003.08.050; Palyvos NE, 2008, EXP APPL ACAROL, V44, P213, DOI 10.1007/s10493-008-9145-y; Park GM, 2000, CLIN EXP ALLERGY, V30, P1293, DOI 10.1046/j.1365-2222.2000.00883.x; Park JW, 1999, ANN ALLERG ASTHMA IM, V83, P533, DOI 10.1016/S1081-1206(10)62865-7; Platts-Mills TAE, 2011, IMMUNOL REV, V242, P51, DOI 10.1111/j.1600-065X.2011.01021.x; Ramachandran R, 2012, NAT REV DRUG DISCOV, V11, P69, DOI 10.1038/nrd3615; Reed CE, 2004, J ALLERGY CLIN IMMUN, V114, P997, DOI 10.1016/j.jaci.2004.07.060; REES JA, 1992, CLIN EXP ALLERGY, V22, P640, DOI 10.1111/j.1365-2222.1992.tb00181.x; Ren H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165225; Schmidlin F, 2002, J IMMUNOL, V169, P5315, DOI 10.4049/jimmunol.169.9.5315; Shpacovitch V, 2008, J LEUKOCYTE BIOL, V83, P1309, DOI 10.1189/jlb.0108001; STEWART GA, 1992, IMMUNOLOGY, V75, P29; Suen JY, 2014, BRIT J PHARMACOL, V171, P4112, DOI 10.1111/bph.12757; Suen JY, 2012, BRIT J PHARMACOL, V165, P1413, DOI 10.1111/j.1476-5381.2011.01610.x; Sun G, 2001, J IMMUNOL, V167, P1014, DOI 10.4049/jimmunol.167.2.1014; Sundaram K, 2015, AM J RESP CELL MOL, V53, P400, DOI 10.1165/rcmb.2014-0370OC; Syeda F, 2006, J BIOL CHEM, V281, P11792, DOI 10.1074/jbc.M509292200; Thomas WR, 2010, TRENDS MOL MED, V16, P321, DOI 10.1016/j.molmed.2010.04.008; Thomsen SF, 2015, EUR CLIN RESPIR J, V2, DOI 10.3402/ecrj.v2.24642; Vidal C, 2004, ALLERGY, V59, P401, DOI 10.1111/j.1398-9995.2003.00430.x; Vliagoftis H, 2001, J ALLERGY CLIN IMMUN, V107, P679, DOI 10.1067/mai.2001.114245; Walker JKL, 2014, CURR OPIN PHARMACOL, V16, P142, DOI 10.1016/j.coph.2014.03.007; Warner A, 1999, ALLERGY, V54, P681, DOI 10.1034/j.1398-9995.1999.00850.x; Yau MK, 2016, ACS MED CHEM LETT, V7, P1179, DOI 10.1021/acsmedchemlett.6b00306; Yin SC, 2018, IMMUNOBIOLOGY, V223, P443, DOI 10.1016/j.imbio.2017.10.032; Yin SC, 2015, ALLERGY ASTHMA IMMUN, V7, P393, DOI 10.4168/aair.2015.7.4.393; Yu CH, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10090665; Zhang C, 2012, ONCOL REP, V28, P1917, DOI 10.3892/or.2012.1998	77	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 8	2021	12								557433	10.3389/fimmu.2021.557433	http://dx.doi.org/10.3389/fimmu.2021.557433			22	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UT9SH	34566947	Green Published, gold			2022-12-18	WOS:000698447100001
J	Bader, A; Gao, JC; Riviere, T; Schmid, B; Walzog, B; Maier-Begandt, D				Bader, Almke; Gao, Jincheng; Riviere, Thibaud; Schmid, Bettina; Walzog, Barbara; Maier-Begandt, Daniela			Molecular Insights Into Neutrophil Biology From the Zebrafish Perspective: Lessons From CD18 Deficiency	FRONTIERS IN IMMUNOLOGY			English	Article						zebrafish; neutrophils; integrins; inflammation; trafficking; CD18	LEUKOCYTE ADHESION; EXPRESSION ANALYSIS; HOST-DEFENSE; BONE-MARROW; MAC-1; MIGRATION; LFA-1; CELL; MOTILITY; INFLAMMATION	Neutrophils are key players in innate immunity and originate from the bone marrow of the adult mammalian organism. In mammals, mature neutrophils are released from the bone marrow into the peripheral blood where they circulate until their recruitment to sites of inflammation in a multistep adhesion cascade. Here, adhesion molecules of the beta(2) integrin family (CD11/CD18) are critically required for the initial neutrophil adhesion to the inflamed endothelium and several post-adhesion steps allowing their extravasation into the inflamed tissue. Within the mammalian tissue, interstitial neutrophil migration can occur widely independent of beta(2) integrins. This is in sharp contrast to neutrophil recruitment in zebrafish larvae (Danio rerio) where neutrophils originate from the caudal hematopoietic tissue and mainly migrate interstitially to sites of lesion upon the early onset of inflammation. However, neutrophils extravasate from the circulation to the inflamed tissue in zebrafish larvae at later-time points. Although zebrafish larvae are a widely accepted model system to analyze neutrophil trafficking in vivo, the functional impact of beta(2) integrins for neutrophil trafficking during acute inflammation is completely unknown in this model. In this study, we generated zebrafish with a genetic deletion of CD18, the beta subunit of beta(2) integrins, using CRISPR/Cas9 technology. Sequence alignments demonstrated a high similarity of the amino acid sequences between zebrafish and human CD18 especially in the functionally relevant I-like domain. In addition, the cytoplasmic domain of CD18 harbors two highly conserved NXXF motifs suggesting that zebrafish CD18 may share functional properties of human CD18. Accordingly, CD18 knock-out (KO) zebrafish larvae displayed the key symptoms of patients suffering from leukocyte adhesion deficiency (LAD) type I due to defects in ITGB2, the gene for CD18. Importantly, CD18 KO zebrafish larvae showed reduced neutrophil trafficking to sites of sterile inflammation despite the fact that an increased number of neutrophils was detectable in the circulation. By demonstrating the functional importance of CD18 for neutrophil trafficking in zebrafish larvae, our findings shed new light on neutrophil biology in vertebrates and introduce a new model organism for studying LAD type I.	[Bader, Almke; Gao, Jincheng; Riviere, Thibaud; Walzog, Barbara; Maier-Begandt, Daniela] Ludwig Maximilians Univ Munchen, Biomed Ctr, Inst Cardiovasc Physiol & Pathophysiol, Planegg Martinsried, Germany; [Bader, Almke; Gao, Jincheng; Riviere, Thibaud; Walzog, Barbara; Maier-Begandt, Daniela] Ludwig Maximilians Univ Munchen, Univ Hosp, Walter Brendel Ctr Expt Med, Munich, Germany; [Schmid, Bettina] German Ctr Neurodegenerat Dis DZNE, Fish Core Unit, Munich, Germany	University of Munich; University of Munich; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE)	Walzog, B; Maier-Begandt, D (corresponding author), Ludwig Maximilians Univ Munchen, Biomed Ctr, Inst Cardiovasc Physiol & Pathophysiol, Planegg Martinsried, Germany.; Walzog, B; Maier-Begandt, D (corresponding author), Ludwig Maximilians Univ Munchen, Univ Hosp, Walter Brendel Ctr Expt Med, Munich, Germany.	Walzog@lrz.uni-muenchen.de; Daniela.maier@lrz.uni-muenchen.de		Begandt, Daniela/0000-0001-8491-9820; Bader, Almke/0000-0003-2313-598X	Deutsche Forschungsgemeinschaft [SFB 914/A02, SFB 914/Z03]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by grants from the Deutsche Forschungsgemeinschaft [SFB 914/A02 (DM-B and BW) and Z03 (BW)].	ANDERSON DC, 1985, J INFECT DIS, V152, P668, DOI 10.1093/infdis/152.4.668; ARNAOUT MA, 1990, BLOOD, V75, P1037; Baisse B, 2019, J LEUKOCYTE BIOL, V106, P1271, DOI 10.1002/JLB.2A0818-327RR; Barros-Becker F, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101699; Barros-Becker F, 2017, J CELL SCI, V130, P3801, DOI 10.1242/jcs.206128; Bennett CM, 2001, BLOOD, V98, P643, DOI 10.1182/blood.V98.3.643; Bertrand JY, 2007, DEVELOPMENT, V134, P4147, DOI 10.1242/dev.012385; Bullard DC, 1996, P NATL ACAD SCI USA, V93, P2116, DOI 10.1073/pnas.93.5.2116; Burdon PCE, 2005, BLOOD, V105, P2543, DOI 10.1182/blood-2004-08-3193; Campbell ID, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004994; Casanova-Acebes M, 2018, J EXP MED, V215, P2778, DOI 10.1084/jem.20181468; Christoffersson G, 2018, CELL TISSUE RES, V371, P415, DOI 10.1007/s00441-017-2780-z; Colucci-Guyon E, 2011, J CELL SCI, V124, P3053, DOI 10.1242/jcs.082792; Deng Q, 2013, J LEUKOCYTE BIOL, V93, P761, DOI 10.1189/jlb.1012534; Deng Q, 2012, J CELL SCI, V125, P3949, DOI 10.1242/jcs.093633; Deng Q, 2011, DEV CELL, V21, P735, DOI 10.1016/j.devcel.2011.07.013; Ding ZM, 1999, J IMMUNOL, V163, P5029; Dixon Giles, 2012, ISRN Hematol, V2012, P915868, DOI 10.5402/2012/915868; Dunne JL, 2003, J IMMUNOL, V171, P6105, DOI 10.4049/jimmunol.171.11.6105; Dunne JL, 2002, BLOOD, V99, P336, DOI 10.1182/blood.V99.1.336; Elks PM, 2011, METHODS MOL BIOL, V769, P261, DOI 10.1007/978-1-61779-207-6_18; Farnsworth DR, 2020, DEV BIOL, V459, P100, DOI 10.1016/j.ydbio.2019.11.008; Forlow SB, 2001, BLOOD, V98, P3309, DOI 10.1182/blood.V98.12.3309; Galdames JA, 2014, J IMMUNOL, V193, P372, DOI 10.4049/jimmunol.1303220; Gomez JC, 2010, LAB INVEST, V90, P599, DOI 10.1038/labinvest.2010.4; Hall C, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-42; Harvie EA, 2015, J LEUKOCYTE BIOL, V98, P523, DOI 10.1189/jlb.4MR1114-524R; Heit B, 2005, J CELL SCI, V118, P5205, DOI 10.1242/jcs.02632; Herbomel P, 1999, DEVELOPMENT, V126, P3735; Hirahashi J, 2006, IMMUNITY, V25, P271, DOI 10.1016/j.immuni.2006.05.014; Holmes RS, 2011, BIOMOLECULES, V1, P3, DOI 10.3390/biom1010003; Hruscha A, 2015, METHODS MOL BIOL, V1254, P341, DOI 10.1007/978-1-4939-2152-2_24; Hruscha A, 2013, DEVELOPMENT, V140, P4982, DOI 10.1242/dev.099085; Konantz M, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.040360; Labun K, 2019, NUCLEIC ACIDS RES, V47, pW171, DOI 10.1093/nar/gkz365; Lammermann T, 2008, NATURE, V453, P51, DOI 10.1038/nature06887; Langenau DM, 2004, P NATL ACAD SCI USA, V101, P7369, DOI 10.1073/pnas.0402248101; Lawrence SM, 2018, MICROBIOL MOL BIOL R, V82, DOI 10.1128/MMBR.00057-17; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Le Guyader D, 2008, BLOOD, V111, P132, DOI 10.1182/blood-2007-06-095398; Lefort CT, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00157; Lefort CT, 2012, BLOOD, V119, P4275, DOI 10.1182/blood-2011-08-373118; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Lieschke GJ, 2009, CURR BIOL, V19, pR678, DOI 10.1016/j.cub.2009.06.068; Liew PX, 2019, PHYSIOL REV, V99, P1223, DOI 10.1152/physrev.00012.2018; Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268; Maiguel D, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001811; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; Mathias JR, 2006, J LEUKOCYTE BIOL, V80, P1281, DOI 10.1189/jlb.0506346; Mathias JR, 2009, METHODS MOL BIOL, V571, P151, DOI 10.1007/978-1-60761-198-1_10; McCracken Jenna M, 2014, J Cell Death, V7, P15, DOI 10.4137/JCD.S11038; Moser M, 2009, SCIENCE, V324, P895, DOI 10.1126/science.1163865; Moser M, 2009, NAT MED, V15, P300, DOI 10.1038/nm.1921; Murayama E, 2006, IMMUNITY, V25, P963, DOI 10.1016/j.immuni.2006.10.015; Paik EJ, 2010, INT J DEV BIOL, V54, P1127, DOI 10.1387/ijdb.093042ep; Palic D, 2007, J IMMUNOL METHODS, V319, P87, DOI 10.1016/j.jim.2006.11.003; Phillipson M, 2006, J EXP MED, V203, P2569, DOI 10.1084/jem.20060925; Pillay J, 2010, J LEUKOCYTE BIOL, V88, P211, DOI 10.1189/jlb.1209793; Renshaw SA, 2012, DIS MODEL MECH, V5, P38, DOI 10.1242/dmm.007138; Rosetti F, 2016, IMMUNOL REV, V269, P175, DOI 10.1111/imr.12373; Rosetti F, 2012, J IMMUNOL, V189, P3714, DOI 10.4049/jimmunol.1201594; Rosowski EE, 2016, J IMMUNOL, V197, P4780, DOI 10.4049/jimmunol.1600928; Sarris M, 2012, CURR BIOL, V22, P2375, DOI 10.1016/j.cub.2012.11.018; Scharffetter-Kochanek K, 1998, J EXP MED, V188, P119, DOI 10.1084/jem.188.1.119; Schild Y, 2020, FEBS J, V287, P3925, DOI 10.1111/febs.15433; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; SCHLEIFFENBAUM B, 1989, J IMMUNOL, V142, P3537; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Stark K, 2013, NAT IMMUNOL, V14, P41, DOI 10.1038/ni.2477; Starnes Taylor W, 2012, Adv Hematol, V2012, P398640, DOI 10.1155/2012/398640; Sun GJ, 2015, MOLECULES, V20, P18539, DOI 10.3390/molecules201018539; Sun GJ, 2010, INT J MOL SCI, V11, P4618, DOI 10.3390/ijms11114618; Tang T, 1997, J EXP MED, V186, P1853, DOI 10.1084/jem.186.11.1853; Thome S, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12966; Walzog B, 1999, AM J PHYSIOL-GASTR L, V276, pG1125, DOI 10.1152/ajpgi.1999.276.5.G1125; Wei H, 2018, FISH SHELLFISH IMMUN, V81, P67, DOI 10.1016/j.fsi.2018.07.011; Weinmann P, 2003, BLOOD, V101, P739, DOI 10.1182/blood-2002-01-0239; Woodfin A, 2011, NAT IMMUNOL, V12, P761, DOI 10.1038/ni.2062; Xue YY, 2019, CELL REP, V27, P1567, DOI 10.1016/j.celrep.2019.04.030; Yoo SK, 2011, J LEUKOCYTE BIOL, V89, P661, DOI 10.1189/jlb.1010567	81	1	1	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 7	2021	12								677994	10.3389/fimmu.2021.677994	http://dx.doi.org/10.3389/fimmu.2021.677994			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	US3ZJ	34557186	Green Published, gold			2022-12-18	WOS:000697371300001
J	Byersdorfer, CA; Turnquist, HR				Byersdorfer, Craig A.; Turnquist, Heth R.			Editorial: Beyond Histocompatibility - Understanding the Non-MHC Determinants Shaping Transplantation Outcome and Tolerance Induction	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						transplantation; innate and adaptive immune response; damage associated molecular pattern (DAMP); immunometabolism; solid organ transplantation; allogeneic stem cell transplantation; macrophages; GvHD			[Byersdorfer, Craig A.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [Byersdorfer, Craig A.; Turnquist, Heth R.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15260 USA; [Turnquist, Heth R.] Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15260 USA; [Turnquist, Heth R.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA; [Turnquist, Heth R.] Univ Pittsburgh, Sch Med, McGowan Inst Regenerat Med, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Turnquist, HR (corresponding author), Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15260 USA.; Turnquist, HR (corresponding author), Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15260 USA.; Turnquist, HR (corresponding author), Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA.; Turnquist, HR (corresponding author), Univ Pittsburgh, Sch Med, McGowan Inst Regenerat Med, Pittsburgh, PA 15260 USA.	het5@pitt.edu	Turnquist, Heth R/L-2319-2016	Turnquist, Heth R/0000-0002-4173-4014	NIH [R01AR073527, R01HL22489, R56AI139327, R01HL144556]; DoD grant [CA180681]; Hope on Wheels Scholar grant from the Hyundai Motor Company	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD grant; Hope on Wheels Scholar grant from the Hyundai Motor Company	The authors are supported by NIH grants: R01AR073527 (HT), R01HL22489 (HT), R56AI139327 (HT), and R01HL144556 (CB), DoD grant CA180681 (CB) and a Hope on Wheels Scholar grant from the Hyundai Motor Company (CB).	Barker CF, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014977; Blazar BR, 2012, NAT REV IMMUNOL, V12, P443, DOI 10.1038/nri3212; Forman SJ., 2015, THOMAS HEMATOPOIETIC; Lowsky R, 2019, BONE MARROW TRANSPL, V54, P793, DOI 10.1038/s41409-019-0603-4; Mehra MR, 2017, LANCET, V390, pE43, DOI 10.1016/S0140-6736(17)33093-3; Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950; Patel CH, 2017, CURR OPIN IMMUNOL, V46, P82, DOI 10.1016/j.coi.2017.04.006; Song ATW, 2014, WORLD J GASTROENTERO, V20, P5363, DOI 10.3748/wjg.v20.i18.5363; Wedel J, 2015, CURR OPIN ORGAN TRAN, V20, P13, DOI 10.1097/MOT.0000000000000155	9	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 7	2021	12								759706	10.3389/fimmu.2021.759706	http://dx.doi.org/10.3389/fimmu.2021.759706			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WB0OI	34557204	Green Published, gold			2022-12-18	WOS:000703280500001
J	Carneiro, MB; Peters, NC				Carneiro, Matheus B.; Peters, Nathan C.			The Paradox of a Phagosomal Lifestyle: How Innate Host Cell-Leishmania amazonensis Interactions Lead to a Progressive Chronic Disease	FRONTIERS IN IMMUNOLOGY			English	Review						Leishmania; Leishmania amazonensis; neutrophils; monocytes; macrophages; dendritic cells; phagolysosome	NITRIC-OXIDE SYNTHASE; CD4(+) T-CELLS; RECEPTOR-MEDIATED ENTRY; DENDRITIC CELLS; PARASITOPHOROUS VACUOLES; INTERFERON-GAMMA; MAJOR INFECTION; IN-VITRO; CUTANEOUS LEISHMANIASIS; MONOCYTE DIFFERENTIATION	Intracellular phagosomal pathogens represent a formidable challenge for innate immune cells, as, paradoxically, these phagocytic cells can act as both host cells that support pathogen replication and, when properly activated, are the critical cells that mediate pathogen elimination. Infection by parasites of the Leishmania genus provides an excellent model organism to investigate this complex host-pathogen interaction. In this review we focus on the dynamics of Leishmania amazonensis infection and the host innate immune response, including the impact of the adaptive immune response on phagocytic host cell recruitment and activation. L. amazonensis infection represents an important public health problem in South America where, distinct from other Leishmania parasites, it has been associated with all three clinical forms of leishmaniasis in humans: cutaneous, muco-cutaneous and visceral. Experimental observations demonstrate that most experimental mouse strains are susceptible to L. amazonensis infection, including the C57BL/6 mouse, which is resistant to other species such as Leishmania major, Leishmania braziliensis and Leishmania infantum. In general, the CD4(+) T helper (Th)1/Th2 paradigm does not sufficiently explain the progressive chronic disease established by L. amazonensis, as strong cell-mediated Th1 immunity, or a lack of Th2 immunity, does not provide protection as would be predicted. Recent findings in which the balance between Th1/Th2 immunity was found to influence permissive host cell availability via recruitment of inflammatory monocytes has also added to the complexity of the Th1/Th2 paradigm. In this review we discuss the roles played by innate cells starting from parasite recognition through to priming of the adaptive immune response. We highlight the relative importance of neutrophils, monocytes, dendritic cells and resident macrophages for the establishment and progressive nature of disease following L. amazonensis infection.</p>	[Carneiro, Matheus B.; Peters, Nathan C.] Univ Calgary, Snyder Inst Chron Dis, Dept Microbiol, Cumming Sch Med, Calgary, AB, Canada; Univ Calgary, Snyder Inst Chron Dis, Dept Immunol, Cumming Sch Med, Calgary, AB, Canada; Univ Calgary, Snyder Inst Chron Dis, Dept Infect Dis, Cumming Sch Med, Calgary, AB, Canada; Univ Calgary, Fac Vet Med, Comparat Biol & Expt Med, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary	Carneiro, MB (corresponding author), Univ Calgary, Snyder Inst Chron Dis, Dept Microbiol, Cumming Sch Med, Calgary, AB, Canada.	matheus.batistaheito@ucalgary.ca	Peters, Nathan/AAW-8289-2020	Peters, Nathan/0000-0002-2548-9581	Canadian Institutes of Health Research [MOP-142302]; Canadian Foundation for Innovation [RCP-16-027-SEG]; Snyder Institute for Chronic Diseases Beverley Phillips Rising Star Fellowship; Cumming School of Medicine Post-Doctoral Fellowship; University of Calgary Host-Parasite Interactions Program	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Innovation(Canada Foundation for Innovation); Snyder Institute for Chronic Diseases Beverley Phillips Rising Star Fellowship; Cumming School of Medicine Post-Doctoral Fellowship; University of Calgary Host-Parasite Interactions Program	This work was supported by Canadian Institutes of Health Research grant MOP-142302 and Canadian Foundation for Innovation grant RCP-16-027-SEG to NCP. A Snyder Institute for Chronic Diseases Beverley Phillips Rising Star Fellowship and Cumming School of Medicine Post-Doctoral Fellowship supported MBC. MBC received professional development training and travel funding from The University of Calgary Host-Parasite Interactions Program.	Abidin BM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006422; AFONSO LCC, 1993, INFECT IMMUN, V61, P2952, DOI 10.1128/IAI.61.7.2952-2959.1993; Afonso L, 2008, J LEUKOCYTE BIOL, V84, P389, DOI 10.1189/jlb.0108018; ALEXANDER J, 1975, J PROTOZOOL, V22, P502, DOI 10.1111/j.1550-7408.1975.tb05219.x; Almeida RP, 1996, AM J TROP MED HYG, V54, P178, DOI 10.4269/ajtmh.1996.54.178; Anderson CF, 2007, J EXP MED, V204, P285, DOI 10.1084/jem.20061886; Anderson DA, 2021, NAT REV IMMUNOL, V21, P101, DOI 10.1038/s41577-020-00413-x; ANTOINE JC, 1990, INFECT IMMUN, V58, P779, DOI 10.1128/IAI.58.3.779-787.1990; ANTOINE JC, 1987, EXP PARASITOL, V64, P485, DOI 10.1016/0014-4894(87)90063-4; Aoki JI, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006025; Arnold IC, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007866; Ashok D, 2014, EUR J IMMUNOL, V44, P1422, DOI 10.1002/eji.201344242; Bain CC, 2014, NAT IMMUNOL, V15, P929, DOI 10.1038/ni.2967; Baldwin T, 2004, INFECT IMMUN, V72, P1991, DOI 10.1128/IAI.72.4.1991-2001.2004; Balestieri FMP, 2002, MICROBES INFECT, V4, P23, DOI 10.1016/S1286-4579(01)01505-2; Ballesteros I, 2020, CELL, V183, P1282, DOI 10.1016/j.cell.2020.10.003; BARBIERI CL, 1985, Z PARASITENKD, V71, P159, DOI 10.1007/BF00926266; Barreto-de-Souza V, 2015, IMMUNOBIOLOGY, V220, P437, DOI 10.1016/j.imbio.2014.11.006; BATES PA, 1992, PARASITOLOGY, V105, P193, DOI 10.1017/S0031182000074102; Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497; Bertholet S, 2006, J IMMUNOL, V177, P3525, DOI 10.4049/jimmunol.177.6.3525; BLACKWELL JM, 1985, J EXP MED, V162, P324, DOI 10.1084/jem.162.1.324; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; Boggiatto PM, 2009, AM J PATHOL, V174, P1818, DOI 10.2353/ajpath.2009.080905; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Bosetto MC, 2007, EXP PARASITOL, V116, P306, DOI 10.1016/j.exppara.2007.01.003; Briseno CG, 2016, CELL REP, V15, P2462, DOI 10.1016/j.celrep.2016.05.025; Brittingham A, 1996, PARASITOL TODAY, V12, P444, DOI 10.1016/0169-4758(96)10067-3; BRITTINGHAM A, 1995, J IMMUNOL, V155, P3102; Burza S, 2018, LANCET, V392, P951, DOI 10.1016/S0140-6736(18)31204-2; Calegari-Silva TC, 2018, EUR J IMMUNOL, V48, P1188, DOI 10.1002/eji.201747257; Calegari-Silva TC, 2009, IMMUNOL LETT, V127, P19, DOI 10.1016/j.imlet.2009.08.009; Campbell KA, 1996, IMMUNITY, V4, P283, DOI 10.1016/S1074-7613(00)80436-7; Campos MB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194383; Canesso MCC, 2014, J IMMUNOL, V193, P5171, DOI 10.4049/jimmunol.1400625; Canton J, 2012, CELL MICROBIOL, V14, P937, DOI 10.1111/j.1462-5822.2012.01767.x; Carlsen ED, 2013, INFECT IMMUN, V81, P3966, DOI 10.1128/IAI.00770-13; Carneiro MB, 2021, CYTOKINE, V147, DOI 10.1016/j.cyto.2020.155309; Carneiro MBH, 2018, J IMMUNOL, V200, P196, DOI 10.4049/jimmunol.1700899; Carneiro MB, 2020, CELL HOST MICROBE, V27, P752, DOI 10.1016/j.chom.2020.03.011; Carneiro MB, 2017, METHODS, V127, P45, DOI 10.1016/j.ymeth.2017.04.012; Cavalcante-Costa VS, 2019, J CELL SCI, V132, DOI 10.1242/jcs.226183; CHANG KP, 1978, J EXP MED, V147, P515, DOI 10.1084/jem.147.2.515; CHANG KP, 1976, SCIENCE, V193, P678, DOI 10.1126/science.948742; Charmoy M, 2016, EUR J IMMUNOL, V46, P897, DOI 10.1002/eji.201546015; Charmoy M, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/719361; Charmoy M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000755; Chauhan P, 2017, CLIN EXP IMMUNOL, V190, P167, DOI 10.1111/cei.13014; Chaves MM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008674; Chaves MM, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007887; Chomarat P, 2003, J IMMUNOL, V171, P2262, DOI 10.4049/jimmunol.171.5.2262; Chomarat P, 2000, NAT IMMUNOL, V1, P510, DOI 10.1038/82763; Cortes DF, 2010, MEM I OSWALDO CRUZ, V105, P736, DOI 10.1590/S0074-02762010000600002; Costa DL, 2016, J LEUKOCYTE BIOL, V100, P423, DOI 10.1189/jlb.4A0715-288R; Courret N, 2002, J CELL SCI, V115, P2303; da Silva ER, 2008, MOL BIOCHEM PARASIT, V159, P104, DOI 10.1016/j.molbiopara.2008.02.011; DASILVA RP, 1989, J IMMUNOL, V143, P617; David BA, 2019, IMMUNOL REV, V289, P9, DOI 10.1111/imr.12757; de Carvalho RVH, 2019, CELL REP, V26, P429, DOI 10.1016/j.celrep.2018.12.047; de Souza VL, 2000, MICROBES INFECT, V2, P1807, DOI 10.1016/S1286-4579(00)01340-X; De Trez C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000494; Delneste Y, 2003, BLOOD, V101, P143, DOI 10.1182/blood-2002-04-1164; Desjardins M, 1997, J EXP MED, V185, P2061, DOI 10.1084/jem.185.12.2061; Dey R, 2018, CELL HOST MICROBE, V23, P134, DOI 10.1016/j.chom.2017.12.002; Diefenbach A, 1998, IMMUNITY, V8, P77, DOI 10.1016/S1074-7613(00)80460-4; Dominguez M, 1999, J EXP MED, V189, P25, DOI 10.1084/jem.189.1.25; Dyer DP, 2019, IMMUNITY, V50, P378, DOI 10.1016/j.immuni.2019.01.009; Eash KJ, 2010, J CLIN INVEST, V120, P2423, DOI 10.1172/JCI41649; Falcao SAC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003601; Favali C, 2007, J LEUKOCYTE BIOL, V82, P1401, DOI 10.1189/jlb.0307187; Ferrer-Sueta G, 2018, CHEM REV, V118, P462, DOI 10.1021/acs.chemrev.7b00568; Figueiredo AB, 2012, EUR J IMMUNOL, V42, P1203, DOI 10.1002/eji.201141926; Figueiredo AB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00849; Franco Luis H., 2012, Journal of Parasitology Research, P165126, DOI 10.1155/2012/165126; Gaylo-Moynihan A, 2019, IMMUNITY, V51, P298, DOI 10.1016/j.immuni.2019.06.026; Gerner MY, 2012, IMMUNITY, V37, P364, DOI 10.1016/j.immuni.2012.07.011; Giraud E., 2019, COMMUN BIOL, V2, P84, DOI [10.1038/s42003-019-0323-8, DOI 10.1038/S42003-019-0323-8]; Glennie ND, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006349; Goldman-Pinkovich A, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005494; Gomes RS, 2015, MICROBES INFECT, V17, P295, DOI 10.1016/j.micinf.2014.12.009; Gordon S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00127; GREEN SJ, 1990, J IMMUNOL, V145, P4290; Guerra CS, 2010, INT J EXP PATHOL, V91, P451, DOI 10.1111/j.1365-2613.2010.00717.x; Guilliams M, 2018, IMMUNITY, V49, P595, DOI 10.1016/j.immuni.2018.10.005; Guimaraes-Costa AB, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23002-5; Guimaraes-Costa AB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00523; Guimaraes-Costa AB, 2014, INFECT IMMUN, V82, P1732, DOI 10.1128/IAI.01232-13; Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106; Gundra UM, 2014, BLOOD, V123, pE110, DOI 10.1182/blood-2013-08-520619; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; GUY RA, 1993, INFECT IMMUN, V61, P1553, DOI 10.1128/IAI.61.4.1553-1558.1993; Carneiro MBH, 2015, J INTERF CYTOK RES, V35, P935, DOI 10.1089/jir.2015.0043; Henard CA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003000; Heyde S, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007374; Hohman LS, 2019, TRENDS PARASITOL, V35, P423, DOI 10.1016/j.pt.2019.04.002; Holzmuller P, 2002, INFECT IMMUN, V70, P3727, DOI 10.1128/IAI.70.7.3727-3735.2002; Horta Maria Fatima, 2012, J Parasitol Res, V2012, P203818, DOI 10.1155/2012/203818; Hu XY, 2009, IMMUNITY, V31, P539, DOI 10.1016/j.immuni.2009.09.002; Hurrell BP, 2017, J LEUKOCYTE BIOL, V102, P1187, DOI [10.1189/jlb.4hi0417-158r, 10.1189/jlb.4HI0417-158R]; Hurrell BP, 2016, TRENDS PARASITOL, V32, P392, DOI 10.1016/j.pt.2016.02.003; Hurrell BP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004929; Igyarto BZ, 2011, IMMUNITY, V35, P260, DOI 10.1016/j.immuni.2011.06.005; Iniesta V, 2005, INFECT IMMUN, V73, P6085, DOI 10.1128/IAI.73.9.6085-6090.2005; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jankowski A, 2002, J BIOL CHEM, V277, P6059, DOI 10.1074/jbc.M110059200; Ji JX, 2002, AM J TROP MED HYG, V66, P338, DOI 10.4269/ajtmh.2002.66.338; Jones DE, 2000, J IMMUNOL, V165, P364, DOI 10.4049/jimmunol.165.1.364; Jones DE, 2002, INFECT IMMUN, V70, P2151, DOI 10.1128/IAI.70.4.2151-2158.2002; Kane MM, 2001, J IMMUNOL, V166, P1141, DOI 10.4049/jimmunol.166.2.1141; Kashem SW, 2017, ANNU REV IMMUNOL, V35, P469, DOI 10.1146/annurev-immunol-051116-052215; Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860; Kienle K, 2016, IMMUNOL REV, V273, P76, DOI 10.1111/imr.12458; Kima PE, 2000, J EXP MED, V191, P1063, DOI 10.1084/jem.191.6.1063; Kima PE, 1997, J IMMUNOL, V159, P1828; Kolter J, 2019, IMMUNITY, V50, P1482, DOI 10.1016/j.immuni.2019.05.009; Kropf P, 2005, FASEB J, V19, P1000, DOI 10.1096/fj.04-3416fje; Lammermann T, 2013, NATURE, V498, P371, DOI 10.1038/nature12175; da Silva MFL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034022; Laurenti MD, 2004, BRAZ J MED BIOL RES, V37, P427, DOI 10.1590/S0100-879X2004000300021; Lavin Y, 2014, CELL, V159, P1312, DOI 10.1016/j.cell.2014.11.018; Leal JM, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abb9435; Lecoeur H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01098; Lecoeur H, 2020, CELL REP, V30, P1870, DOI 10.1016/j.celrep.2020.01.030; Lee SH, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz4415; Lee SH, 2018, J EXP MED, V215, P357, DOI 10.1084/jem.20171389; Leon B, 2007, IMMUNITY, V26, P519, DOI 10.1016/j.immuni.2007.01.017; Levin R, 2016, IMMUNOL REV, V273, P156, DOI 10.1111/imr.12439; LEWIS DH, 1977, ANN TROP MED PARASIT, V71, P295, DOI 10.1080/00034983.1977.11687192; Ley K, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat4579; LIEW FY, 1990, J IMMUNOL, V144, P4794; Lima DS, 2017, J IMMUNOL, V199, P2055, DOI 10.4049/jimmunol.1700258; Lima DS, 2013, NAT MED, V19, P909, DOI 10.1038/nm.3221; Linhares-Lacerda L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59486-2; Liu ZY, 2019, CELL, V178, P1509, DOI 10.1016/j.cell.2019.08.009; Liu Z, 2018, J INVEST DERMATOL, V138, P1328, DOI 10.1016/j.jid.2018.01.018; Love DC, 1998, EXP PARASITOL, V88, P161, DOI 10.1006/expr.1998.4232; Manfredi AA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00288; Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024; Manz MG, 2014, NAT REV IMMUNOL, V14, P302, DOI 10.1038/nri3660; Martinez-Lopez M, 2015, EUR J IMMUNOL, V45, P119, DOI 10.1002/eji.201444651; Matheoud D, 2013, CELL HOST MICROBE, V14, P15, DOI 10.1016/j.chom.2013.06.003; McConville MJ, 2007, TRENDS PARASITOL, V23, P368, DOI 10.1016/j.pt.2007.06.009; McGwire BS, 2003, INFECT IMMUN, V71, P1008, DOI 10.1128/IAI.71.2.1008-1010.2003; Merien F, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00125; Metchnikoff E., 1893, LECT COMP PATHOLOGY; Miller BH, 2004, INFECT IMMUN, V72, P2872, DOI 10.1128/IAI.72.5.2872-2878.2004; Mittra B, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005340; Mittra B, 2013, J EXP MED, V210, P401, DOI 10.1084/jem.20121368; Mollinedo F, 2010, J BIOL CHEM, V285, P34528, DOI 10.1074/jbc.M110.125302; Mosser DM, 2008, IMMUNOL REV, V226, P205, DOI 10.1111/j.1600-065X.2008.00706.x; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; MOSSER DM, 1985, J IMMUNOL, V135, P2785; Muller AJ, 2013, CELL HOST MICROBE, V14, P460, DOI 10.1016/j.chom.2013.09.008; Muller AJ, 2012, IMMUNITY, V37, P147, DOI 10.1016/j.immuni.2012.05.015; Mukbel RM, 2007, AM J TROP MED HYG, V76, P669, DOI 10.4269/ajtmh.2007.76.669; Munder M, 1999, J IMMUNOL, V163, P3771; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Muxel SM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02792; N'Diaye EN, 1998, J IMMUNOL, V161, P4983; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; Ndjamen B, 2010, CELL MICROBIOL, V12, P1480, DOI 10.1111/j.1462-5822.2010.01483.x; Ng LG, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000222; Nogueira PM, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004848; Novais FO, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006196; Nunes AC, 1997, PARASITOLOGY, V115, P601, DOI 10.1017/S0031182097001704; Okuda K, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005669; Olekhnovitch R, 2014, J CLIN INVEST, V124, P1711, DOI 10.1172/JCI72058; Owens BMJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002827; Paduch K, 2019, J IMMUNOL, V202, P1453, DOI 10.4049/jimmunol.1801249; Pessoa CC, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007834; Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194; Peters NC, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004538; Peters NC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000484; Petritus PM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001858; Piacenza L, 2019, J EXP MED, V216, P501, DOI 10.1084/jem.20181886; Pinheiro RO, 2007, MEM I OSWALDO CRUZ, V102, P79, DOI 10.1590/S0074-02762007000100013; POMPEU ML, 1991, ACTA TROP, V48, P185, DOI 10.1016/0001-706X(91)90046-M; Prina E, 2004, J CELL SCI, V117, P315, DOI 10.1242/jcs.00860; PRINA E, 1990, INFECT IMMUN, V58, P1730, DOI 10.1128/IAI.58.6.1730-1737.1990; Qadoumi M, 2002, INFECT IMMUN, V70, P4638, DOI 10.1128/IAI.70.8.4638-4642.2002; Qi H, 2004, INFECT IMMUN, V72, P988, DOI 10.1128/IAI.72.2.988-995.2004; Qi H, 2001, J IMMUNOL, V167, P4534, DOI 10.4049/jimmunol.167.8.4534; RABINOVITCH M, 1985, J LEUKOCYTE BIOL, V37, P247, DOI 10.1002/jlb.37.3.247; RABINOVITCH M, 1995, TRENDS CELL BIOL, V5, P85, DOI 10.1016/S0962-8924(00)88955-2; Rath CT, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007500; Real F, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001518; Regli IB, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107746; Ribeiro-Gomes FL, 2004, J IMMUNOL, V172, P4454, DOI 10.4049/jimmunol.172.7.4454; Ribeiro-Gomes FL, 2014, INFECT IMMUN, V82, P2713, DOI 10.1128/IAI.01600-13; Ribeiro-Gomes FL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002536; Roberts SC, 2004, J BIOL CHEM, V279, P23668, DOI 10.1074/jbc.M402042200; Rochael NC, 2015, SCI REP-UK, V5, DOI 10.1038/srep18302; Rogers M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000555; Roma EH, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1472-y; Romano A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006479; Rosales C, 2020, J LEUKOCYTE BIOL, V108, P377, DOI 10.1002/JLB.4MIR0220-574RR; RUSSELL DG, 1992, J CELL SCI, V103, P1193; Sacks D, 2002, NAT IMMUNOL, V3, P1041, DOI 10.1038/ni1102-1041; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sarkar A, 2013, MED MICROBIOL IMMUN, V202, P25, DOI 10.1007/s00430-012-0246-1; Sato N, 2000, J EXP MED, V192, P205, DOI 10.1084/jem.192.2.205; Sauter IP, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126207; SCHARTON TM, 1993, J EXP MED, V178, P567, DOI 10.1084/jem.178.2.567; Schleicher U, 2007, J EXP MED, V204, P893, DOI 10.1084/jem.20061293; Schleicher U, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00079; Schleicher U, 2016, CELL REP, V15, P1062, DOI 10.1016/j.celrep.2016.04.001; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Serbina NV, 2003, IMMUNITY, V19, P59, DOI 10.1016/S1074-7613(03)00171-7; SHEPHERD VL, 1983, J EXP MED, V157, P1471, DOI 10.1084/jem.157.5.1471; Silveira FT, 2004, MEM I OSWALDO CRUZ, V99, P239, DOI 10.1590/S0074-02762004000300001; Pratti JES, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007146; Sokol CL, 2018, IMMUNITY, V49, P449, DOI 10.1016/j.immuni.2018.07.012; Soong L, 1996, IMMUNITY, V4, P263, DOI 10.1016/S1074-7613(00)80434-3; Soto M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.590934; Sousa LMA, 2014, PARASITE IMMUNOL, V36, P13, DOI 10.1111/pim.12078; Sousa LMA, 2015, CYTOKINE, V74, P327, DOI 10.1016/j.cyto.2015.01.021; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; TALAMASROHANA P, 1990, J IMMUNOL, V144, P4817; Tamoutounour S, 2013, IMMUNITY, V39, P925, DOI 10.1016/j.immuni.2013.10.004; Tavares N, 2016, J IMMUNOL, V196, P1865, DOI 10.4049/jimmunol.1502224; Tavares NM, 2014, J INFECT DIS, V210, P656, DOI 10.1093/infdis/jiu158; Terrazas C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14935-3; Thiam HR, 2020, ANNU REV CELL DEV BI, V36, P191, DOI 10.1146/annurev-cellbio-020520-111016; Tiburcio R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00227; Turco SJ, 2001, TRENDS PARASITOL, V17, P223, DOI 10.1016/S1471-4922(01)01895-5; Ueno N, 2012, TRENDS PARASITOL, V28, P335, DOI 10.1016/j.pt.2012.05.002; Uribe-Querol E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01368; van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521; Vargas-Inchaustegui DA, 2010, INFECT IMMUN, V78, P301, DOI 10.1128/IAI.00959-09; Vargas-Inchaustegui DA, 2009, INFECT IMMUN, V77, P2948, DOI 10.1128/IAI.00154-09; Vinet AF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000628; Vivarini AD, 2011, FASEB J, V25, P4162, DOI 10.1096/fj.11-185165; VODOVOTZ Y, 1995, J IMMUNOL, V154, P2914; von Stebut E, 1998, J EXP MED, V188, P1547, DOI 10.1084/jem.188.8.1547; Wakil AE, 1998, J EXP MED, V188, P1651, DOI 10.1084/jem.188.9.1651; Wanasen N, 2007, INFECT IMMUN, V75, P2802, DOI 10.1128/IAI.00026-07; Wang YW, 2011, INFECT IMMUN, V79, P1124, DOI 10.1128/IAI.00658-10; Wilson J, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000179; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; WYLER DJ, 1985, INFECT IMMUN, V49, P305, DOI 10.1128/IAI.49.2.305-311.1985; Xin LJ, 2008, MOL IMMUNOL, V45, P3371, DOI 10.1016/j.molimm.2008.04.018; Xin LJ, 2007, INFECT IMMUN, V75, P5018, DOI 10.1128/IAI.00499-07; Xin LJ, 2010, J IMMUNOL, V184, P7047, DOI 10.4049/jimmunol.0903273; Yang ZY, 2007, J IMMUNOL, V178, P1077, DOI 10.4049/jimmunol.178.2.1077	248	1	1	6	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 7	2021	12								728848	10.3389/fimmu.2021.728848	http://dx.doi.org/10.3389/fimmu.2021.728848			22	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WB0AU	34557194	gold, Green Published			2022-12-18	WOS:000703244900001
J	Romano, A; Brown, N; Ashwin, H; Doehl, JSP; Hamp, J; Osman, M; Dey, N; Rani, GF; Ferreira, TR; Kaye, PM				Romano, Audrey; Brown, Najmeeyah; Ashwin, Helen; Doehl, Johannes S. P.; Hamp, Jonathan; Osman, Mohamed; Dey, Nidhi; Rani, Gulab Fatima; Ferreira, Tiago Rodrigues; Kaye, Paul M.			Interferon-?-Producing CD4(+) T Cells Drive Monocyte Activation in the Bone Marrow During Experimental Leishmania donovani Infection	FRONTIERS IN IMMUNOLOGY			English	Article						visceral leishmaniasis; mouse models; monocytes; CD4(+) T cells; interferon-gamma; IL-10; bone marrow	MHC CLASS-II; LY6C(HI) MONOCYTES; DIFFERENTIATION; MACROPHAGES; INDUCTION; IL-12P40; IL-10	Ly6C(hi) inflammatory monocytes develop in the bone marrow and migrate to the site of infection during inflammation. Upon recruitment, Ly6C(hi) monocytes can differentiate into dendritic cells or macrophages. According to the tissue environment they can also acquire different functions. Several studies have described pre-activation of Ly6C(hi) monocytes in the bone marrow during parasitic infection, but whether this process occurs during experimental visceral leishmaniasis and, if so, the mechanisms contributing to their activation are yet to be established. In wild type C57BL/6 (B6) mice infected with Leishmania donovani, the number of bone marrow Ly6C(hi) monocytes increased over time. Ly6C(hi) monocytes displayed a highly activated phenotype from 28 days to 5 months post infection (p.i), with >90% expressing MHCII and >20% expressing iNOS. In comparison, in B6.Rag2 (-/-) mice <10% of bone marrow monocytes were MHCII+ at day 28 p.i., an activation deficiency that was reversed by adoptive transfer of CD4(+) T cells. Depletion of CD4(+) T cells in B6 mice and the use of mixed bone marrow chimeras further indicated that monocyte activation was driven by IFN gamma produced by CD4(+) T cells. In B6.Il10 (-/-) mice, L. donovani infection induced a faster but transient activation of bone marrow monocytes, which correlated with the magnitude of CD4(+) T cell production of IFN gamma and resolution of the infection. Under all of the above conditions, monocyte activation was associated with greater control of parasite load in the bone marrow. Through reinfection studies in B6.Il10 (-/-) mice and drug (AmBisome(R)) treatment of B6 mice, we also show the dependence of monocyte activation on parasite load. In summary, these data demonstrate that during L. donovani infection, Ly6C(hi) monocytes are primed in the bone marrow in a process driven by CD4(+) T cells and whereby IFN gamma promotes and IL-10 limits monocyte activation and that the presence of parasites/parasite antigen plays a crucial role in maintaining bone marrow monocyte activation.</p>	[Romano, Audrey; Brown, Najmeeyah; Ashwin, Helen; Doehl, Johannes S. P.; Hamp, Jonathan; Osman, Mohamed; Dey, Nidhi; Rani, Gulab Fatima; Ferreira, Tiago Rodrigues; Kaye, Paul M.] Univ York, Hull York Med Sch, York Biomed Res Inst, York, N Yorkshire, England; [Romano, Audrey] BILHI Genet, Marseille, France; [Doehl, Johannes S. P.] NIAID, Vector Mol Biol Unit, Lab Malaria & Vector Res, NIH, Rockville, MD USA; [Hamp, Jonathan] Univ Oxford, Kennedy Inst Rheumatol, Oxford, England; [Ferreira, Tiago Rodrigues] NIAID, Lab Parasit Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	University of Hull; University of York - UK; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Oxford; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kaye, PM (corresponding author), Univ York, Hull York Med Sch, York Biomed Res Inst, York, N Yorkshire, England.	paul.kaye@york.ac.uk	Rani, Gulab Fatima/AAR-3395-2021	Rani, Gulab Fatima/0000-0002-2209-1893; Dey, Nidhi Sharma/0000-0001-9432-0221	Wellcome Trust [WT104726]	Wellcome Trust(Wellcome Trust)	This work was funded by a Wellcome Trust Senior Investigator Award to PMK (WT104726).	Abidin BM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006422; Ashwin Helen, 2018, Wellcome Open Res, V3, P135, DOI 10.12688/wellcomeopenres.14867.1; Askenase MH, 2015, IMMUNITY, V42, P1130, DOI 10.1016/j.immuni.2015.05.011; Ben-Shachar M., 2020, JOSS, V5, P2815, DOI [10.21105/joss.02815, DOI 10.21105/JOSS.02815]; Champely S, 2020, BASIC FUNCTIONS POWE; Chandra D, 2008, CLIN EXP IMMUNOL, V154, P224, DOI 10.1111/j.1365-2249.2008.03741.x; Dragulescu A., 2020, XLSX READ WRITE FORM; Firke S, 2021, JANITOR SIMPLE TOOLS; Forrester Sarah, 2019, Wellcome Open Res, V4, P198, DOI 10.12688/wellcomeopenres.15606.1; Fox J., 2019, R COMPANION APPL REG, V3rd; Galbas T, 2017, J IMMUNOL, V198, P852, DOI 10.4049/jimmunol.1601168; Hester J., 2019, J OPEN SOURCE SOFTW, V4, P1686, DOI [10.21105/joss.01686, DOI 10.21105/JOSS.01686]; Hoang ATN, 2010, J IMMUNOL, V185, P2360, DOI 10.4049/jimmunol.0903673; Jakubzick CV, 2017, NAT REV IMMUNOL, V17, P349, DOI 10.1038/nri.2017.28; Kassambara A, 2021, **DATA OBJECT**; Komsta L., 2015, **DATA OBJECT**; Kong FP, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006165; Lenth R., 2022, COMPUTER SOFTWARE; Leon B, 2007, IMMUNITY, V26, P519, DOI 10.1016/j.immuni.2007.01.017; Lu P., 2017, PWR2 POWER SAMPLE SI; MacKinnon AC, 2008, J IMMUNOL, V180, P2650, DOI 10.4049/jimmunol.180.4.2650; Mair P, 2020, BEHAV RES METHODS, V52, P464, DOI 10.3758/s13428-019-01246-w; Maroof A, 2008, IMMUNITY, V29, P295, DOI 10.1016/j.immuni.2008.06.012; Menezes S, 2016, IMMUNITY, V45, P1205, DOI 10.1016/j.immuni.2016.12.001; Meng LZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01183; Mittal SK, 2015, J BIOL CHEM, V290, P27158, DOI 10.1074/jbc.M115.682708; Montes de Oca Marcela, 2020, Cytokine X, V2, P100036, DOI 10.1016/j.cytox.2020.100036; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; Murphy ML, 2001, EUR J IMMUNOL, V31, P2848, DOI 10.1002/1521-4141(2001010)31:10&lt;2848::AID-IMMU2848&gt;3.0.CO;2-T; Ohmura-Hoshino M, 2006, J BIOCHEM, V140, P147, DOI 10.1093/jb/mvj160; Owens BMJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002827; Park J, 2020, PARASITE IMMUNOL, V42, DOI 10.1111/pim.12712; Parmar N, 2020, J IMMUNOL, V204, P2762, DOI 10.4049/jimmunol.1900251; Pinto AI, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006465; Preham O, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02958; Reith W, 1999, MICROBES INFECT, V1, P839; Ren K., 2016, RLIST TOOLBOX NONTAB; Romano A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006479; Roy S, 2018, PARASITE IMMUNOL, V40, DOI 10.1111/pim.12535; Sato N, 1999, J IMMUNOL, V163, P5519; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Silva-Barrios S, 2016, CELL REP, V15, P2427, DOI 10.1016/j.celrep.2016.05.028; Sokal R.R., 1981, BIOMETRY PRINCIPLES, P859; Stager S, 2006, EUR J IMMUNOL, V36, P1764, DOI 10.1002/eji.200635937; Svensson M, 2006, TRENDS IMMUNOL, V27, P580, DOI 10.1016/j.it.2006.10.006; Teh YC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00834; Terrazas C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14935-3; Terry RL, 2014, CELL IMMUNOL, V291, P16, DOI 10.1016/j.cellimm.2014.02.008; Thibodeau J, 2008, EUR J IMMUNOL, V38, P1225, DOI 10.1002/eji.200737902; Wickham H., 2019, READXL READ EXCEL FI; Wickham H, 2007, J STAT SOFTW, V21, P1; Yanez A, 2017, IMMUNITY, V47, P890, DOI 10.1016/j.immuni.2017.10.021; Yurdakul P, 2011, AM J PATHOL, V179, P23, DOI 10.1016/j.ajpath.2011.03.009; Zhu JG, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89880; Zigmond E, 2020, IMMUNITY, V53, P479, DOI 10.1016/j.immuni.2020.08.006; Zigmond E, 2012, IMMUNITY, V37, P1076, DOI 10.1016/j.immuni.2012.08.026	56	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 7	2021	12								700501	10.3389/fimmu.2021.700501	http://dx.doi.org/10.3389/fimmu.2021.700501			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WB1QU	34557190	Green Published, Green Submitted, Green Accepted, gold			2022-12-18	WOS:000703354700001
J	Kretschmer, D; Breitmeyer, R; Gekeler, C; Lebtig, M; Schlatterer, K; Nega, M; Stahl, M; Stapels, D; Rooijakkers, S; Peschel, A				Kretschmer, Dorothee; Breitmeyer, Ricarda; Gekeler, Cordula; Lebtig, Marco; Schlatterer, Katja; Nega, Mulugeta; Stahl, Mark; Stapels, Daphne; Rooijakkers, Suzan; Peschel, Andreas			Staphylococcus aureus Depends on Eap Proteins for Preventing Degradation of Its Phenol-Soluble Modulin Toxins by Neutrophil Serine Proteases	FRONTIERS IN IMMUNOLOGY			English	Article						Staphylococci; Staphylococcus aureus; neutrophil serine proteases; neutrophil serine protease inhibitors; phenol-soluble modulins; formyl-peptide receptor 2	STREPTOCOCCUS-PNEUMONIAE; REGULATOR AGR; HOST-DEFENSE; VIRULENCE; ELASTASE; PEPTIDES; CAPACITY; IMMUNITY; EVASION; ESCAPE	Neutrophil granulocytes act as a first line of defense against pathogenic staphylococci. However, Staphylococcus aureus has a remarkable capacity to survive neutrophil killing, which distinguishes it from the less-pathogenic Staphylococcus epidermidis. Both species release phenol-soluble modulin (PSM) toxins, which activate the neutrophil formyl-peptide receptor 2 (FPR2) to promote neutrophil influx and phagocytosis, and which disrupt neutrophils or their phagosomal membranes at high concentrations. We show here that the neutrophil serine proteases (NSPs) neutrophil elastase, cathepsin G and proteinase 3, which are released into the extracellular space or the phagosome upon neutrophil FPR2 stimulation, effectively degrade PSMs thereby preventing their capacity to activate and destroy neutrophils. Notably, S. aureus, but not S. epidermidis, secretes potent NSP-inhibitory proteins, Eap, EapH1, EapH2, which prevented the degradation of PSMs by NSPs. Accordingly, a S. aureus mutant lacking all three NSP inhibitory proteins was less effective in activating and destroying neutrophils and it survived less well in the presence of neutrophils than the parental strain. We show that Eap proteins promote pathology via PSM-mediated FPR2 activation since murine intraperitoneal infection with the S. aureus parental but not with the NSP inhibitors mutant strain, led to a significantly higher bacterial load in the peritoneum and kidneys of mFpr2(-/-) compared to wild-type mice. These data demonstrate that NSPs can very effectively detoxify some of the most potent staphylococcal toxins and that the prominent human pathogen S. aureus has developed efficient inhibitors to preserve PSM functions. Preventing PSM degradation during infection represents an important survival strategy to ensure FPR2 activation.	[Kretschmer, Dorothee; Breitmeyer, Ricarda; Gekeler, Cordula; Lebtig, Marco; Schlatterer, Katja; Peschel, Andreas] Univ Tubingen, Infect Biol, Interfac Inst Microbiol & Infect Med Tubingen IMI, Tubingen, Germany; [Kretschmer, Dorothee; Breitmeyer, Ricarda; Gekeler, Cordula; Lebtig, Marco; Schlatterer, Katja; Peschel, Andreas] German Ctr Infect Res, Partner Site Tubingen, Tubingen, Germany; [Kretschmer, Dorothee; Breitmeyer, Ricarda; Gekeler, Cordula; Lebtig, Marco; Schlatterer, Katja; Nega, Mulugeta; Peschel, Andreas] Cluster Excellence EXC2124 Controlling Microbes F, Tubingen, Germany; [Nega, Mulugeta] Univ Tubingen, Microbial Genet, Interfac Inst Microbiol & Infect Med Tubingen IMI, Tubingen, Germany; [Stahl, Mark] Univ Tubingen, Ctr Plant Mol Biol ZMBP, Tubingen, Germany; [Stapels, Daphne; Rooijakkers, Suzan] Univ Utrecht, Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; German Center for Infection Research; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Utrecht University; Utrecht University Medical Center	Kretschmer, D (corresponding author), Univ Tubingen, Infect Biol, Interfac Inst Microbiol & Infect Med Tubingen IMI, Tubingen, Germany.; Kretschmer, D (corresponding author), German Ctr Infect Res, Partner Site Tubingen, Tubingen, Germany.; Kretschmer, D (corresponding author), Cluster Excellence EXC2124 Controlling Microbes F, Tubingen, Germany.	dorothee.kretschmer@uni-tuebingen.de		Peschel, Andreas/0000-0002-3209-8626; Stapels, Daphne/0000-0001-7058-541X; Breitmeyer, Ricarda/0000-0003-4796-1231; Gekeler, Cordula/0000-0001-9041-6672	German Research Foundation [TRR156/2 246807620, DFG KR4395/3-1]; German Center for Infection Research (DZIF); Cluster of Excellence Controlling Microbes to fight Infections [EXC2124, 390838134]	German Research Foundation(German Research Foundation (DFG)); German Center for Infection Research (DZIF); Cluster of Excellence Controlling Microbes to fight Infections	This study was funded by grants from the German Research Foundation with the funding grant numbers TRR156/2 246807620 to DK, AP, and DFG KR4395/3-1 to DK and the German Center for Infection Research (DZIF) to AP and DK. The authors acknowledge infrastructural support by the Cluster of Excellence EXC2124 Controlling Microbes to fight Infections, project ID 390838134.	Beavers WN, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw060; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Belaaouaj AA, 2000, SCIENCE, V289, P1185, DOI 10.1126/science.289.5482.1185; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Chen KQ, 2010, J IMMUNOL, V184, P3331, DOI 10.4049/jimmunol.0903022; Cheung GYC, 2015, SCI REP-UK, V5, DOI 10.1038/srep18023; Cheung GYC, 2014, FASEB J, V28, P153, DOI 10.1096/fj.13-232041; Cheung GYC, 2011, INFECT IMMUN, V79, P1927, DOI 10.1128/IAI.00046-11; Flack CE, 2014, P NATL ACAD SCI USA, V111, pE2037, DOI 10.1073/pnas.1322125111; Fu ZR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020651; Geiger T, 2008, J BACTERIOL, V190, P3419, DOI 10.1128/JB.01927-07; Giebeler A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100522; Gimza BD, 2021, MBIO, V12, DOI 10.1128/mBio.03288-20; Grosz M, 2014, CELL MICROBIOL, V16, P451, DOI 10.1111/cmi.12233; Guerra FE, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00286; Hahn I, 2011, INFECT IMMUN, V79, P4893, DOI 10.1128/IAI.05593-11; Hazenbos WLW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003653; Johansson A, 2000, J PERIODONTAL RES, V35, P85, DOI 10.1034/j.1600-0765.2000.035002085.x; Joo HS, 2011, J BIOL CHEM, V286, P8933, DOI 10.1074/jbc.M111.221382; Joost I, 2009, J INFECT DIS, V199, P1471, DOI 10.1086/598484; Kavanaugh JS, 2021, J INFECT DIS, V223, P1865, DOI 10.1093/infdis/jiaa612; Kraus D, 2008, FUTURE MICROBIOL, V3, P437, DOI 10.2217/17460913.3.4.437; Kretschmer D, 2015, J LEUKOCYTE BIOL, V97, P689, DOI 10.1189/jlb.2A0514-275R; Kretschmer D, 2012, J INNATE IMMUN, V4, P201, DOI 10.1159/000332142; Kretschmer D, 2010, CELL HOST MICROBE, V7, P463, DOI 10.1016/j.chom.2010.05.012; Liu Y, 2013, CANCER RES, V73, P550, DOI 10.1158/0008-5472.CAN-12-2290; Morais SB, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006870; Munzenmayer L, 2016, CELL MICROBIOL, V18, P1172, DOI 10.1111/cmi.12577; ODEBERG H, 1976, INFECT IMMUN, V14, P1276; Palazzolo-Ballance AM, 2008, J IMMUNOL, V180, P500, DOI 10.4049/jimmunol.180.1.500; Perera NC, 2012, P NATL ACAD SCI USA, V109, P6229, DOI 10.1073/pnas.1200470109; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; Prat C, 2006, J IMMUNOL, V177, P8017, DOI 10.4049/jimmunol.177.11.8017; Prat C, 2009, J IMMUNOL, V183, P6569, DOI 10.4049/jimmunol.0801523; Rautenberg M, 2011, FASEB J, V25, P1254, DOI 10.1096/fj.10-175208; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; Standish AJ, 2009, J IMMUNOL, V183, P2602, DOI 10.4049/jimmunol.0900688; Stapels DAC, 2016, CELL MICROBIOL, V18, P536, DOI 10.1111/cmi.12528; Stapels DAC, 2014, P NATL ACAD SCI USA, V111, P13187, DOI 10.1073/pnas.1407616111; Staubitz P, 2004, FEMS MICROBIOL LETT, V231, P67, DOI 10.1016/S0378-1097(03)00921-2; Surewaard BGJ, 2013, CELL MICROBIOL, V15, P1427, DOI 10.1111/cmi.12130; Surewaard BGJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002606; Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639; Viglio S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031065; Vuong C, 2003, J INFECT DIS, V188, P706, DOI 10.1086/377239; Wang R, 2007, NAT MED, V13, P1510, DOI 10.1038/nm1656; Weinrauch Y, 2002, NATURE, V417, P91, DOI 10.1038/417091a; Weiss E, 2020, J INFECT DIS, V221, P668, DOI 10.1093/infdis/jiz498; Weiss E, 2018, FASEB J, V32, P26, DOI 10.1096/fj.201700441R; Yang SJ, 2013, ANTIMICROB AGENTS CH, V57, P3875, DOI 10.1128/AAC.00412-13; Ye RD, 2009, PHARMACOL REV, V61, P119, DOI 10.1124/pr.109.001578; Zurek OW, 2014, J INNATE IMMUN, V6, P21, DOI 10.1159/000351200	53	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 6	2021	12								701093	10.3389/fimmu.2021.701093	http://dx.doi.org/10.3389/fimmu.2021.701093			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	US0LO	34552584	Green Published, gold			2022-12-18	WOS:000697129100001
J	van Tok, MN; Mandour, M; Wahle, J; Labadia, ME; van de Sande, MGH; Nabozny, G; Baeten, DL; van Duivenvoorde, LM				van Tok, Melissa N.; Mandour, Mohamed; Wahle, Joseph; Labadia, Mark E.; van de Sande, Marleen G. H.; Nabozny, Gerald; Baeten, Dominique L.; van Duivenvoorde, Leonie M.			Paradoxical Augmentation of Experimental Spondyloarthritis by RORC Inhibition in HLA-B27 Transgenic Rats	FRONTIERS IN IMMUNOLOGY			English	Article						spondyloarthritis; IL-17A; RORC; IL-22; HLA-B27 transgenic rats	INTESTINAL INFLAMMATION; MONOCLONAL-ANTIBODY; GENE-EXPRESSION; T(H)17 CELLS; DOUBLE-BLIND; TH17 CELLS; GAMMA; DIFFERENTIATION; IL-17A; USTEKINUMAB	Objective IL-17A plays a major role in the pathogenesis of spondyloarthritis (SpA). Here we assessed the impact of inhibition of RAR related orphan receptor-gamma (RORC), the key transcription factor controlling IL-17 production, on experimental SpA in HLA-B27 transgenic (tg) rats. Methods Experimental SpA was induced by immunization of HLA-B27 tg rats with heat-inactivated Mycobacterium tuberculosis. Splenocytes obtained at day 7, 14 and 21 after immunization were restimulated ex vivo to assess the induction of pro-inflammatory cytokines. Rats were then prophylactically treated with a RORC inhibitor versus vehicle control. The biologic effect of RORC inhibition was assessed by pro-inflammatory cytokine expression in draining lymph nodes. Arthritis and spondylitis were monitored clinically, and the degree of peripheral and axial inflammation, destruction and new bone formation was confirmed by histology. Results Ex vivo mRNA and protein analyses revealed the rapid and selective induction of IL-17A and IL-22 production by a variety of lymphocyte subsets upon disease induction in HLA-B27 tg rats. Prophylactic RORC inhibition in vivo suppressed the expression of IL-17A, IL17F, and IL-22 without affecting the expression of other T helper cell subset related genes. This biological effect did not translate into clinical efficacy as RORC inhibition significantly accelerated the onset of arthritis and spondylitis, and aggravated the clinical severity of arthritis. This worsening of experimental SpA was confirmed by histopathological demonstration of increased inflammation, destruction, and new bone formation. Conclusion Despite a significant suppression of the IL-17 axis, RORC inhibitor treatment accelerates and aggravates experimental SpA in the HLA-B27 tg rat model.	[van Tok, Melissa N.; Mandour, Mohamed; van de Sande, Marleen G. H.; Baeten, Dominique L.; van Duivenvoorde, Leonie M.] Univ Amsterdam, Amsterdam Univ Med Ctr UMC, Amsterdam Rheumatol & Immunol Ctr ARC, Dept Clin Immunol & Rheumatol,Locat Acad Med Ctr, Amsterdam, Netherlands; [van Tok, Melissa N.; Mandour, Mohamed; van de Sande, Marleen G. H.; Baeten, Dominique L.; van Duivenvoorde, Leonie M.] Univ Amsterdam, Amsterdam Univ Med Ctr, Infect & Immun Inst, Dept Expt Immunol, Amsterdam, Netherlands; [Wahle, Joseph; Labadia, Mark E.; Nabozny, Gerald] Boehringer Ingelheim Pharmaceut Inc, Immunol & Resp Dis, Ridgefield, CT USA	University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Boehringer Ingelheim	Mandour, M (corresponding author), Univ Amsterdam, Amsterdam Univ Med Ctr UMC, Amsterdam Rheumatol & Immunol Ctr ARC, Dept Clin Immunol & Rheumatol,Locat Acad Med Ctr, Amsterdam, Netherlands.; Mandour, M (corresponding author), Univ Amsterdam, Amsterdam Univ Med Ctr, Infect & Immun Inst, Dept Expt Immunol, Amsterdam, Netherlands.	m.a.f.m.m.mandour@amsterdamumc.nl			Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA	Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA	This work was sponsored by Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.	Baeten D, 2018, ANN RHEUM DIS, V77, P1295, DOI 10.1136/annrheumdis-2018-213328; Baeten D, 2015, NEW ENGL J MED, V373, P2534, DOI 10.1056/NEJMoa1505066; Baeten D, 2013, LANCET, V382, P1705, DOI 10.1016/S0140-6736(13)61134-4; Banerjee D, 2016, IMMUNOLOGY, V147, P399, DOI 10.1111/imm.12570; Bassolas-Molina H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02307; Benham H, 2014, ARTHRITIS RHEUMATOL, V66, P1755, DOI 10.1002/art.38638; Chong WP, 2020, IMMUNITY, V53, P384, DOI 10.1016/j.immuni.2020.06.022; Ecoeur F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00577; Feagan BG, 2017, LANCET, V389, P1699, DOI 10.1016/S0140-6736(17)30570-6; Glatt S, 2018, ANN RHEUM DIS, V77, P523, DOI 10.1136/annrheumdis-2017-212127; Guendisch U, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188391; Guntermann C, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91127; Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668; Igaki K, 2019, INFLAMM RES, V68, P493, DOI 10.1007/s00011-019-01234-y; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kleinewietfeld M, 2013, SEMIN IMMUNOL, V25, P305, DOI 10.1016/j.smim.2013.10.009; Langley RG, 2015, BRIT J DERMATOL, V172, P1371, DOI 10.1111/bjd.13469; Leppkes M, 2009, GASTROENTEROLOGY, V136, P257, DOI 10.1053/j.gastro.2008.10.018; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mease PJ, 2017, ANN RHEUM DIS, V76, P79, DOI 10.1136/annrheumdis-2016-209709; Mease PJ KH., 2017, ARTHRITIS RHEUMATOL, V69, DOI [10.1136/annrheumdis-2018-eular.2140, DOI 10.1136/ANNRHEUMDIS-2018-EULAR.2140]; Mickael ME, 2020, AM J PATHOL, V190, P1984, DOI 10.1016/j.ajpath.2020.07.010; O'Brien RL, 2009, EUR J IMMUNOL, V39, P662, DOI 10.1002/eji.200839120; Ohnmacht C, 2015, SCIENCE, V349, P989, DOI 10.1126/science.aac4263; Olsson RI, 2016, CHEMMEDCHEM, V11, P207, DOI 10.1002/cmdc.201500432; Papp K, 2015, BRIT J DERMATOL, V173, P930, DOI 10.1111/bjd.13932; Rene O, 2015, ACS MED CHEM LETT, V6, P276, DOI 10.1021/ml500420y; Sandborn WJ, 2008, GASTROENTEROLOGY, V135, P1130, DOI 10.1053/j.gastro.2008.07.014; Sefik E, 2015, SCIENCE, V349, P993, DOI 10.1126/science.aaa9420; Sherlock JP, 2012, NAT MED, V18, P1069, DOI 10.1038/nm.2817; Solt LA, 2011, NATURE, V472, P491, DOI 10.1038/nature10075; Sonnenberg GF, 2012, SCIENCE, V336, P1321, DOI 10.1126/science.1222551; Spits H, 2011, NAT IMMUNOL, V12, P21, DOI 10.1038/ni.1962; Tan J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02891-2; Taurog J, 2018, ARTHRITIS RHEUMATOL, V70; Tran TM, 2006, ARTHRITIS RHEUM-US, V54, P1317, DOI 10.1002/art.21740; van Duivenvoorde LM, 2012, ARTHRITIS RHEUM-US, V64, P3210, DOI 10.1002/art.34600; van Tok MN, 2019, ARTHRITIS RHEUMATOL, V71, P612, DOI 10.1002/art.40770; Van Tok MN, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01550; van Tok MN, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00920; Venken K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07911-6; Withers DR, 2016, NAT MED, V22, P319, DOI 10.1038/nm.4046; Xue XH, 2016, SCI REP-UK, V6, DOI 10.1038/srep37977; Yang BH, 2016, MUCOSAL IMMUNOL, V9, P444, DOI 10.1038/mi.2015.74; Yeremenko N, 2014, CURR OPIN RHEUMATOL, V26, P361, DOI 10.1097/BOR.0000000000000069; Zhang W, 2012, MOL PHARMACOL, V82, P583, DOI 10.1124/mol.112.078667	46	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 6	2021	12								699987	10.3389/fimmu.2021.699987	http://dx.doi.org/10.3389/fimmu.2021.699987			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UT9VC	34552583	Green Published, gold			2022-12-18	WOS:000698454400001
J	Shindiapina, P; Pietrzak, M; Seweryn, M; McLaughlin, E; Zhang, XL; Makowski, M; Ahmed, EH; Schlotter, S; Pearson, R; Kitzler, R; Mozhenkova, A; Le-Rademacher, J; Little, RF; Akpek, G; Ayala, E; Devine, SM; Kaplan, LD; Noy, A; Popat, UR; Hsu, JW; Morris, LE; Mendizabal, AM; Krishnan, A; Wachsman, W; Williams, N; Sharma, N; Hofmeister, CC; Forman, SJ; Navarro, WH; Alvarnas, JC; Ambinder, RF; Lozanski, G; Baiocchi, RA				Shindiapina, Polina; Pietrzak, Maciej; Seweryn, Michal; McLaughlin, Eric; Zhang, Xiaoli; Makowski, Mat; Ahmed, Elshafa Hassan; Schlotter, Sarah; Pearson, Rebecca; Kitzler, Rhonda; Mozhenkova, Anna; Le-Rademacher, Jennifer; Little, Richard F.; Akpek, Gorgun; Ayala, Ernesto; Devine, Steven M.; Kaplan, Lawrence D.; Noy, Ariela; Popat, Uday R.; Hsu, Jack W.; Morris, Lawrence E.; Mendizabal, Adam M.; Krishnan, Amrita; Wachsman, William; Williams, Nita; Sharma, Nidhi; Hofmeister, Craig C.; Forman, Stephen J.; Navarro, Willis H.; Alvarnas, Joseph C.; Ambinder, Richard F.; Lozanski, Gerard; Baiocchi, Robert A.			Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial	FRONTIERS IN IMMUNOLOGY			English	Article						human immunodeficiency virus (HIV); hematopoeietic stem cell transplantation; Hodgkin lymphoma (HL); Non-Hodgkin lymphoma; multiple myeloma	INFUSIONAL EPOCH CHEMOTHERAPY; NATURAL-KILLER-CELLS; NON-HODGKIN-LYMPHOMA; HIGH-DOSE THERAPY; CD4(+) T-CELLS; ANTIRETROVIRAL THERAPY; IMMUNOLOGICAL RECOVERY; CODOX-M/IVAC; NK CELLS; B-CELLS	We report a first in-depth comparison of immune reconstitution in patients with HIV-related lymphoma following autologous hematopoietic cell transplant (AHCT) recipients (n=37, lymphoma, BEAM conditioning), HIV(-) AHCT recipients (n=30, myeloma, melphalan conditioning) at 56, 180, and 365 days post-AHCT, and 71 healthy control subjects. Principal component analysis showed that immune cell composition in HIV(+) and HIV(-) AHCT recipients clustered away from healthy controls and from each other at each time point, but approached healthy controls over time. Unsupervised feature importance score analysis identified activated T cells, cytotoxic memory and effector T cells [higher in HIV(+)], and naive and memory T helper cells [lower HIV(+)] as a having a significant impact on differences between HIV(+) AHCT recipient and healthy control lymphocyte composition (p<0.0033). HIV(+) AHCT recipients also demonstrated lower median absolute numbers of activated B cells and lower NK cell sub-populations, compared to healthy controls (p<0.0033) and HIV(-) AHCT recipients (p<0.006). HIV(+) patient T cells showed robust IFN gamma production in response to HIV and EBV recall antigens. Overall, HIV(+) AHCT recipients, but not HIV(-) AHCT recipients, exhibited reconstitution of pro-inflammatory immune profiling that was consistent with that seen in patients with chronic HIV infection treated with antiretroviral regimens. Our results further support the use of AHCT in HIV(+) individuals with relapsed/refractory lymphoma.	[Shindiapina, Polina; Baiocchi, Robert A.] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA; [Shindiapina, Polina; Ahmed, Elshafa Hassan; Mozhenkova, Anna; Williams, Nita; Sharma, Nidhi; Baiocchi, Robert A.] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA; [Pietrzak, Maciej; McLaughlin, Eric; Zhang, Xiaoli] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA; [Seweryn, Michal] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Biophys, Biobank Lab, Lodz, Poland; [Makowski, Mat; Mendizabal, Adam M.] Emmes Co, Rockville, MD USA; [Ahmed, Elshafa Hassan] Ohio State Univ, Coll Vet Med, Dept Vet Biosci, Columbus, OH 43210 USA; [Schlotter, Sarah] Ohio State Univ, Coll Med, Columbus, OH 43210 USA; [Pearson, Rebecca; Kitzler, Rhonda; Lozanski, Gerard] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Le-Rademacher, Jennifer] Mayo Clin, Div Clin Trials & Biostat, Dept Quantitat Hlth Sci, Rochester, MN USA; [Little, Richard F.] NCI, NIH, Bethesda, MD 20892 USA; [Akpek, Gorgun] Pacific Cent Coast Hlth Ctr, San Luis Obispo, CA USA; [Ayala, Ernesto] Mayo Clin, Dept Internal Med Hematol & Oncol, Jacksonville, FL USA; [Devine, Steven M.] Ctr Int Blood & Marrow Transplant Res, Natl Marrow Donor Program Be Match, Minneapolis, MN USA; [Kaplan, Lawrence D.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Noy, Ariela] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Noy, Ariela] Weill Cornell Med Coll, New York, NY USA; [Popat, Uday R.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA; [Hsu, Jack W.] Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL USA; [Morris, Lawrence E.] Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA; [Krishnan, Amrita; Forman, Stephen J.; Alvarnas, Joseph C.] City Hope Comprehens Canc Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA; [Wachsman, William] Moores Univ Calif San Diego Canc Ctr, La Jolla, CA USA; [Wachsman, William] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Hofmeister, Craig C.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA; [Navarro, Willis H.] Univ Minnesota, Div Hematol Oncol Transplantat, Minneapolis, MN USA; [Navarro, Willis H.] Atara Biotherapeut Inc, Global Res & Dev, San Francisco, CA USA; [Ambinder, Richard F.] Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr SKCCC, Div Hematol Malignancies, Baltimore, MD USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Lodz; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic; Center for International Blood & Marrow Transplant Research; National Marrow Donor Program; University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center; Cornell University; University of Texas System; UTMD Anderson Cancer Center; State University System of Florida; University of Florida; City of Hope; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; Emory University; University of Minnesota System; University of Minnesota Twin Cities; Johns Hopkins University; Johns Hopkins Medicine	Shindiapina, P; Baiocchi, RA (corresponding author), Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA.; Shindiapina, P; Baiocchi, RA (corresponding author), Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA.; Lozanski, G (corresponding author), Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA.	polina.shindiapina@osumc.edu; gerard.lozanski@osumc.edu; robert.baiocchi@osumc.edu		Seweryn, Michal/0000-0002-9090-3435				Ahmad F, 2015, AIDS RES HUM RETROV, V31, P1206, DOI 10.1089/aid.2015.0115; Akpek G, 2001, BONE MARROW TRANSPL, V28, P1105, DOI 10.1038/sj.bmt.1703298; Alvarnas JC, 2016, BLOOD, V128, P1050, DOI 10.1182/blood-2015-08-664706; Balsalobre P, 2009, J CLIN ONCOL, V27, P2192, DOI 10.1200/JCO.2008.18.2683; Barta SK, 2012, CANCER-AM CANCER SOC, V118, P3977, DOI 10.1002/cncr.26723; de Armas LR, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95726; Dunleavy K, 2013, NEW ENGL J MED, V369, P1915, DOI 10.1056/NEJMoa1308392; Fernandez S, 2006, CLIN IMMUNOL, V120, P163, DOI 10.1016/j.clim.2006.04.570; Ferreri AJM, 2012, BRIT J HAEMATOL, V159, P252, DOI 10.1111/bjh.12020; Freud AG, 2016, CELL REP, V16, P379, DOI 10.1016/j.celrep.2016.05.095; Gabarre J, 2004, HAEMATOLOGICA, V89, P1100; Hakki M, 2003, BLOOD, V102, P3060, DOI 10.1182/blood-2002-11-3472; Huddleston CA, 2006, EUR J IMMUNOL, V36, P1093, DOI 10.1002/eji.200535637; Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143; Hunt PW, 2016, J INFECT DIS, V214, pS44, DOI 10.1093/infdis/jiw275; Jimenez VC, 2016, J INFECT DIS, V214, P216, DOI 10.1093/infdis/jiw146; Krishnan A, 2005, BLOOD, V105, P874, DOI 10.1182/blood-2004-04-1532; Krishnan AY, 2006, BLOOD, V108, p149A; Kuylenstierna C, 2011, SCAND J IMMUNOL, V73, P141, DOI 10.1111/j.1365-3083.2010.02484.x; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; Lathrop SK, 2004, J IMMUNOL, V172, P6735, DOI 10.4049/jimmunol.172.11.6735; Lopez-Verges S, 2010, BLOOD, V116, P3865, DOI 10.1182/blood-2010-04-282301; Mavilio D, 2003, P NATL ACAD SCI USA, V100, P15011, DOI 10.1073/pnas.2336091100; Moir S, 2004, J EXP MED, V200, P587, DOI 10.1084/jem.20032236; Montoto S, 2012, J CLIN ONCOL, V30, P4111, DOI 10.1200/JCO.2011.41.4193; Montoto S, 2010, AIDS, V24, P851, DOI 10.1097/QAD.0b013e3283301578; Notermans DW, 2001, AIDS RES HUM RETROV, V17, P1003, DOI 10.1089/088922201300343681; Noy A, 2015, BLOOD, V126, P160, DOI 10.1182/blood-2015-01-623900; Pietrzak Maciej, 2020, International Journal of Computational Biology and Drug Design, V13, P555, DOI 10.1504/IJCBDD.2020.113878; Ramos JC, 2018, CL LYMPH MYELOM LEUK, V18, P180, DOI 10.1016/j.clml.2018.01.004; Re A, 2018, BONE MARROW TRANSPL, V53, P228, DOI 10.1038/bmt.2017.230; Redmond WL, 2007, J IMMUNOL, V179, P7244, DOI 10.4049/jimmunol.179.11.7244; Rempala GA, 2013, J MATH BIOL, V67, P1339, DOI 10.1007/s00285-012-0589-7; Rubinstein PG, 2018, AIDS, V32, P605, DOI 10.1097/QAD.0000000000001729; Rueff Jessica, 2014, Biol Blood Marrow Transplant, V20, P896, DOI 10.1016/j.bbmt.2014.03.007; Saliba RM, 2015, BIOL BLOOD MARROW TR, V21, P1284, DOI 10.1016/j.bbmt.2015.02.017; Schommers P, 2018, HAEMATOLOGICA, V103, P857, DOI 10.3324/haematol.2017.180893; Serghides L, 2005, J IMMUNOL, V175, P6368, DOI 10.4049/jimmunol.175.10.6368; Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078; Simonelli C, 2010, CLIN INFECT DIS, V50, P1672, DOI 10.1086/652866; Song AH, 2005, J IMMUNOL, V175, P3534, DOI 10.4049/jimmunol.175.6.3534; Song JX, 2008, J IMMUNOL, V180, P7240, DOI 10.4049/jimmunol.180.11.7240; Song JX, 2005, IMMUNITY, V22, P621, DOI 10.1016/j.immuni.2005.03.012; de Paula HHS, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0458-6; Sparano JA, 2010, BLOOD, V115, P3008, DOI 10.1182/blood-2009-08-231613; Steiner K, 1999, CLIN EXP IMMUNOL, V115, P451; Strauss-Albee DM, 2017, CYTOM PART B-CLIN CY, V92, P33, DOI 10.1002/cyto.b.21485; Tan CS, 2014, BIOL BLOOD MARROW TR, V20, P992, DOI 10.1016/j.bbmt.2014.03.018; Van Grevenynghe J, 2011, J CLIN INVEST, V121, P3877, DOI 10.1172/JCI59211; Vasu S, 2016, BIOL BLOOD MARROW TR, V22, P658, DOI 10.1016/j.bbmt.2015.12.015	50	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 3	2021	12								700045	10.3389/fimmu.2021.700045	http://dx.doi.org/10.3389/fimmu.2021.700045			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XF8BB	34539628	Green Published, gold			2022-12-18	WOS:000724290700001
J	Song, QX; Kong, XH; Martin, PJ; Zeng, DF				Song, Qingxiao; Kong, Xiaohui; Martin, Paul J.; Zeng, Defu			Murine Models Provide New Insights Into Pathogenesis of Chronic Graft-Versus-Host Disease in Humans	FRONTIERS IN IMMUNOLOGY			English	Review						hematopoietic cell transplantation; chronic graft-versus-host disease; mouse models; tissue resident memory T cell; B cell	CD4(+) T-CELLS; MINOR HISTOCOMPATIBILITY BARRIERS; BONE-MARROW-TRANSPLANTATION; FOLLICULAR HELPER-CELLS; DONOR B-CELLS; DENDRITIC CELLS; NEGATIVE SELECTION; CENTRAL TOLERANCE; MIXED CHIMERISM; ACUTE GVHD	Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative therapy for hematologic malignancies, but its success is complicated by graft-versus-host disease (GVHD). GVHD can be divided into acute and chronic types. Acute GVHD represents an acute alloimmune inflammatory response initiated by donor T cells that recognize recipient alloantigens. Chronic GVHD has a more complex pathophysiology involving donor-derived T cells that recognize recipient-specific antigens, donor-specific antigens, and antigens shared by the recipient and donor. Antibodies produced by donor B cells contribute to the pathogenesis of chronic GVHD but not acute GVHD. Acute GVHD can often be effectively controlled by treatment with corticosteroids or other immunosuppressant for a period of weeks, but successful control of chronic GVHD requires much longer treatment. Therefore, chronic GVHD remains the major cause of long-term morbidity and mortality after allo-HCT. Murine models of allo-HCT have made great contributions to our understanding pathogenesis of acute and chronic GVHD. In this review, we summarize new mechanistic findings from murine models of chronic GVHD, and we discuss the relevance of these insights to chronic GVHD pathogenesis in humans and their potential impact on clinical prevention and treatment.	[Song, Qingxiao; Kong, Xiaohui; Zeng, Defu] City Hope Natl Med Ctr, Beckman Res Inst, Riggs Inst, Duarte, CA 91010 USA; [Song, Qingxiao; Kong, Xiaohui; Zeng, Defu] City Hope Natl Med Ctr, Hematol Malignancies & Stem Cell Transplantat Ins, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Song, Qingxiao] Fujian Med Univ, Ctr Translat Hematol, Union Hosp, Fuzhou, Peoples R China; [Martin, Paul J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA; [Martin, Paul J.] Univ Washington, Dept Med, Seattle, WA USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Fujian Medical University; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Zeng, DF (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Riggs Inst, Duarte, CA 91010 USA.; Zeng, DF (corresponding author), City Hope Natl Med Ctr, Hematol Malignancies & Stem Cell Transplantat Ins, 1500 E Duarte Rd, Duarte, CA 91010 USA.	dzeng@coh.org	Song, Qingxiao/HGC-1595-2022	Song, Qingxiao/0000-0001-9243-5666	National Institutes of Health [R01 AI066008, R01 CA228465]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health Grant R01 AI066008 and R01 CA228465 (to DZ).	Alexander KA, 2014, J CLIN INVEST, V124, P4266, DOI 10.1172/JCI75935; Amarnath S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003130; Amarnath S, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000302; Anderson BE, 2003, J CLIN INVEST, V112, P101, DOI 10.1172/JCI200317601; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Baba T, 2009, J IMMUNOL, V183, P3053, DOI 10.4049/jimmunol.0900438; Baroni SS, 2006, NEW ENGL J MED, V354, P2667; Beilhack A, 2005, BLOOD, V106, P1113, DOI 10.1182/blood-2005-02-0509; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; Betts BC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01797; Biernacki MA, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.134939; Bleakley M, 2004, NAT REV CANCER, V4, P371, DOI 10.1038/nrc1365; Bleakley M, 2015, J CLIN INVEST, V125, P2677, DOI 10.1172/JCI81229; Cooke KR, 2017, BIOL BLOOD MARROW TR, V23, P211, DOI 10.1016/j.bbmt.2016.09.023; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; DECLERCK Y, 1986, J IMMUNOL, V136, P3549; DeFilipp Z, 2019, BIOL BLOOD MARROW TR, V25, P2113, DOI 10.1016/j.bbmt.2019.08.014; Deng RS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00880-2; Dignan FL, 2012, BRIT J HAEMATOL, V158, P30, DOI 10.1111/j.1365-2141.2012.09129.x; Dudakov JA, 2012, SCIENCE, V336, P91, DOI 10.1126/science.1218004; Dulude G, 1999, J EXP MED, V189, P1329, DOI 10.1084/jem.189.8.1329; Eyrich M, 2005, BIOL BLOOD MARROW TR, V11, P371, DOI 10.1016/j.bbmt.2005.02.002; Felix NJ, 2007, NAT IMMUNOL, V8, P388, DOI 10.1038/ni1446; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Flynn R, 2014, BLOOD, V123, P3988, DOI 10.1182/blood-2014-03-562231; Forcade E, 2016, BLOOD, V127, P2489, DOI 10.1182/blood-2015-12-688895; Furlan SN, 2016, BLOOD, V128, P2568, DOI 10.1182/blood-2016-07-726547; Glas AM, 2000, BLOOD, V96, P1064, DOI 10.1182/blood.V96.3.1064.015k38_1064_1069; Hadeiba H, 2012, IMMUNITY, V36, P438, DOI 10.1016/j.immuni.2012.01.017; HAMILTON BL, 1983, TRANSPLANTATION, V36, P150, DOI 10.1097/00007890-198308000-00008; Herbin O, 2016, J AUTOIMMUN, V75, P141, DOI 10.1016/j.jaut.2016.08.002; Hill GR, 1997, BLOOD, V90, P3204, DOI 10.1182/blood.V90.8.3204; Hirakawa M, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89278; HOROWITZ MM, 1990, BLOOD, V75, P555; Inamoto Y, 2014, BLOOD, V124, P1363, DOI 10.1182/blood-2014-03-563544; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; Jin H, 2016, BLOOD, V127, P2249, DOI 10.1182/blood-2015-09-668145; Johnston RJ, 2019, NATURE, V574, P565, DOI 10.1038/s41586-019-1674-5; Kassim Adetola A, 2017, Hematol Oncol Stem Cell Ther, V10, P245, DOI 10.1016/j.hemonc.2017.05.021; Kong XH, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI135468; KORNGOLD R, 1978, J EXP MED, V148, P1687; KORNGOLD R, 1985, J IMMUNOL, V135, P3004; KORNGOLD R, 1987, J EXP MED, V165, P1552, DOI 10.1084/jem.165.6.1552; KORNGOLD R, 1982, J EXP MED, V155, P872, DOI 10.1084/jem.155.3.872; Korngold R, 2009, THOMAS HEMATOPOIETIC, P176; Koyama M, 2016, BLOOD, V127, P2963, DOI 10.1182/blood-2016-02-697250; Kuzmina Z, 2015, AM J HEMATOL, V90, P114, DOI 10.1002/ajh.23885; Lan FS, 2001, J IMMUNOL, V167, P2087, DOI 10.4049/jimmunol.167.4.2087; Lee SJ, 2017, BLOOD, V129, P30, DOI 10.1182/blood-2016-07-686642; Leventhal DS, 2016, IMMUNITY, V44, P847, DOI 10.1016/j.immuni.2016.01.025; Leveque-El Mouttie L, 2016, BLOOD, V128, P794, DOI 10.1182/blood-2015-11-680876; Liu YQ, 2020, J CLIN INVEST, V130, P6457, DOI 10.1172/JCI131799; Lowsky R, 2005, NEW ENGL J MED, V353, P1321, DOI 10.1056/NEJMoa050642; Lowsky R, 2019, BONE MARROW TRANSPL, V54, P793, DOI 10.1038/s41409-019-0603-4; Lu Y, 2012, BLOOD, V119, P1075, DOI 10.1182/blood-2010-12-322891; MacDonald KPA, 2017, BLOOD, V129, P13, DOI 10.1182/blood-2016-06-686618; Matsuoka K, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005265; Matsuoka K, 2010, J CLIN INVEST, V120, P1479, DOI 10.1172/JCI41072; Matsuzawa-Ishimoto Y, 2020, BLOOD, V135, P2388, DOI 10.1182/blood.2019004116; Na IK, 2010, J CLIN INVEST, V120, P343, DOI 10.1172/JCI39395; Naymagon S, 2017, NAT REV GASTRO HEPAT, V14, P711, DOI 10.1038/nrgastro.2017.126; Ni X, 2017, J CLIN INVEST, V127, P1960, DOI 10.1172/JCI91138; Nikolic B, 2000, J CLIN INVEST, V105, P1289, DOI 10.1172/JCI7894; Odegard JM, 2008, J EXP MED, V205, P2873, DOI 10.1084/jem.20080840; Panoskaltsis-Mortari A, 2007, AM J RESP CRIT CARE, V176, P713, DOI 10.1164/rccm.200702-335OC; Paz K, 2019, BLOOD, V133, P94, DOI 10.1182/blood-2018-03-839993; Pillai AB, 2007, J IMMUNOL, V178, P6242, DOI 10.4049/jimmunol.178.10.6242; Reddy P, 2008, MOUSE MODELS GRAFT V; ROZANS MK, 1986, J IMMUNOL, V136, P4040; Sarantopoulos S, 2015, BLOOD, V125, P1703, DOI 10.1182/blood-2014-12-567834; Schroeder MA, 2011, DIS MODEL MECH, V4, P318, DOI 10.1242/dmm.006668; Seth A, 2019, CURR OPIN IMMUNOL, V61, P1, DOI 10.1016/j.coi.2019.06.005; Socie G, 2014, BLOOD, V124, P374, DOI 10.1182/blood-2014-01-514752; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; STORB R, 1985, IMMUNOL REV, V88, P215, DOI 10.1111/j.1600-065X.1985.tb01160.x; Suzuki I, 1996, BLOOD, V87, P1873; Sykes M, 2001, IMMUNITY, V14, P417, DOI 10.1016/S1074-7613(01)00122-4; Takaba H, 2017, TRENDS IMMUNOL, V38, P805, DOI 10.1016/j.it.2017.07.010; Takaba H, 2015, CELL, V163, P975, DOI 10.1016/j.cell.2015.10.013; Teshima T, 2003, BLOOD, V102, P429, DOI 10.1182/blood-2003-01-0266; Teshima T, 2002, NAT MED, V8, P575, DOI 10.1038/nm0602-575; Tian YY, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI136774; WEIDEN PL, 1979, NEW ENGL J MED, V300, P1068, DOI 10.1056/NEJM197905103001902; Whangbo JS, 2019, BLOOD ADV, V3, P984, DOI 10.1182/bloodadvances.2018027474; Wu LM, 2015, P NATL ACAD SCI USA, V112, P15994, DOI 10.1073/pnas.1521157112; Wu T, 2013, J IMMUNOL, V191, P488, DOI 10.4049/jimmunol.1300657; Wu YX, 2015, BIOL BLOOD MARROW TR, V21, P1195, DOI 10.1016/j.bbmt.2015.03.016; Yi TS, 2011, J IMMUNOL, V186, P2739, DOI 10.4049/jimmunol.1002939; Young JS, 2012, J IMMUNOL, V189, P222, DOI 10.4049/jimmunol.1200677; Yu W, 2015, IMMUNITY, V42, P929, DOI 10.1016/j.immuni.2015.05.001; Zeiser R, 2019, BRIT J HAEMATOL, V187, P563, DOI 10.1111/bjh.16190; Zeiser R, 2017, NEW ENGL J MED, V377, P2565, DOI 10.1056/NEJMra1703472; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337; Zeng D., 2015, THOMAS HEMATOPOIETIC, P136, DOI [10.1002/9781118416426.ch12, DOI 10.1002/9781118416426.CH12]; Zeng DF, 1999, J EXP MED, V189, P1073, DOI 10.1084/jem.189.7.1073; Zeng DF, 2002, BLOOD, V99, P1449, DOI 10.1182/blood.V99.4.1449; Zhang CY, 2006, BLOOD, V107, P2993, DOI 10.1182/blood-2005-09-3623; Zhang MF, 2018, P NATL ACAD SCI USA, V115, pE2329, DOI 10.1073/pnas.1720169115; Zhang P, 2012, BIOL BLOOD MARROW TR, V18, P1488, DOI 10.1016/j.bbmt.2012.07.009; Zhang Y, 2005, J IMMUNOL, V174, P3051, DOI 10.4049/jimmunol.174.5.3051; Zhang Y, 2002, J CLIN INVEST, V109, P1335, DOI 10.1172/JCI200214989; Zhao DC, 2008, BLOOD, V112, P2129, DOI 10.1182/blood-2008-02-140277; Zhao DC, 2011, J IMMUNOL, V186, P856, DOI 10.4049/jimmunol.1002195; Zorn E, 2005, BLOOD, V106, P2903, DOI 10.1182/blood-2005-03-1257; Zundler S, 2019, NAT IMMUNOL, V20, P288, DOI 10.1038/s41590-018-0298-5	105	1	1	2	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 3	2021	12								700857	10.3389/fimmu.2021.700857	http://dx.doi.org/10.3389/fimmu.2021.700857			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UR1VQ	34539630	Green Published, gold			2022-12-18	WOS:000696543600001
J	Tersigni, C; Lucchetti, D; Franco, R; Colella, F; Neri, C; Crispino, L; Sgambato, A; Lanzone, A; Scambia, G; Vatish, M; Di Simone, N				Tersigni, Chiara; Lucchetti, Donatella; Franco, Rita; Colella, Filomena; Neri, Caterina; Crispino, Laura; Sgambato, Alessandro; Lanzone, Antonio; Scambia, Giovanni; Vatish, Manu; Di Simone, Nicoletta			Circulating Placental Vesicles Carry HLA-DR in Pre-Eclampsia: A New Potential Marker of the Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						human leukocyte antigen; syncytiotrophoblast extracellular vesicles; placenta; pregnancy; pre-eclampsia	TROPHOBLAST CELLS; EXPRESSION; PREGNANCY	Background Pre-eclampsia (PE) is a common disorder of pregnancy that usually presents with hypertension and proteinuria. The clinical presentation arises from soluble factors released into the maternal circulation from the placenta owing to the stress of syncytiotrophoblast, consequence of defective placentation occurring in the first half of pregnancy. Reduced tolerance of the semiallogeneic fetus by the maternal immune system has been proposed as first trigger leading to poor placentation. We previously observed aberrant expression of human leukocyte antigen (HLA)-DR molecules in the syncytiotrophoblast of a subset of women with PE. Aim of this study was to investigate abnormal expression of circulating HLA-DR in syncytiotrophoblast-derived extracellular vesicles (STBEVs) in women with PE compared to normal pregnant women. Methods peripheral venous blood was collected from 22 women with PE and 22 normal pregnant women. Circulating STBEVs were collected by ultra-centrifugation (120000 g) and analyzed for the expression of HLA-DR and placental alkaline phosphatase (PLAP), a specific marker of the placenta, by Western blot analysis and flow cytometry. Results circulating STBEVs positive for HLA-DR were observed in 64% of PE women while no HLA-DR positivity was detected in any of the controls (P<0.01). Conclusions Aberrant expression of HLA-DR in circulating STBEVs is specifically associated to PE. Further studies are required: a) to define the role of aberrant placental expression of HLA-DR molecules in the pathogenesis of PE; b) evaluate a possible application of detecting circulating HLA-DR positive STBEVs in the diagnosis and prediction of PE in the first and second trimester of pregnancy.	[Tersigni, Chiara; Neri, Caterina; Lanzone, Antonio] Fdn Policlin Univ A Gemelli, Ist Ricovero & Cura Carattere Sci IRCCS, Dipartimento Sci Salute Donna & Bambino & Sanita, Unita Operat Complessa Ostetricia & Patol Ostetr, Rome, Italy; [Lucchetti, Donatella; Colella, Filomena; Sgambato, Alessandro] Univ Cattolica Sacro Cuore, Dipartimento Univ Med & Chirurg Traslaz, Rome, Italy; [Franco, Rita; Crispino, Laura; Lanzone, Antonio; Scambia, Giovanni] Univ Cattolica Sacro Cuore, Ist Clin Ostetr & Ginecol, Rome, Italy; [Scambia, Giovanni] Fdn Policlin Univ A Gemelli, Dipartimento Sci Salute Donna & Bambino & Sanita, Unita Operat Complessa Ginecol Oncol, Ist Ricovero & Cura Carattere Sci IRCCS, Rome, Italy; [Vatish, Manu] Univ Oxford, Nuffield Dept Womens & Reprod Hlth, Oxford, England; [Di Simone, Nicoletta] Humanitas Univ, Dept Biomed Sci, Milan, Italy; [Di Simone, Nicoletta] Humanitas Res Hosp, Ist Ricovero & Cura Carattere Sci IRCCS, Milan, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Fondazione IRCCS Istituto Nazionale Tumori Milan; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Oxford; Humanitas University; Fondazione IRCCS Istituto Nazionale Tumori Milan	Tersigni, C (corresponding author), Fdn Policlin Univ A Gemelli, Ist Ricovero & Cura Carattere Sci IRCCS, Dipartimento Sci Salute Donna & Bambino & Sanita, Unita Operat Complessa Ostetricia & Patol Ostetr, Rome, Italy.	chiara.tersigni@policlinicogemelli.it	Neri, Caterina/AEZ-4395-2022; LUCCHETTI, Donatella/AAC-5760-2022; Lucchetti, Donatella/AAC-7541-2022; TERSIGNI, CHIARA/AAB-8388-2022; Neri, Caterina/AAG-7345-2022	Lucchetti, Donatella/0000-0001-8147-0079; TERSIGNI, CHIARA/0000-0003-1590-3942; DI SIMONE, NICOLETTA/0000-0003-1273-3335; LANZONE, Antonio/0000-0003-4119-414X; Scambia, Giovanni/0000-0002-9503-9041; vatish, manu/0000-0002-6012-2574	Fondazione Policlinico A. Gemelli IRCCS [590002910]	Fondazione Policlinico A. Gemelli IRCCS	This research was supported by a small grant from Fondazione Policlinico A. Gemelli IRCCS (grant number 590002910).	Abalos E, 2014, BJOG-INT J OBSTET GY, V121, P14, DOI 10.1111/1471-0528.12629; Apps R, 2009, IMMUNOLOGY, V127, P26, DOI 10.1111/j.1365-2567.2008.03019.x; Brown MA, 2018, HYPERTENSION, V72, P24, DOI 10.1161/HYPERTENSIONAHA.117.10803; DAVIES JO, 1985, J ROY SOC MED, V78, P899, DOI 10.1177/014107688507801104; Dragovic RA, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.113266; Lok CAR, 2008, HYPERTENS PREGNANCY, V27, P344, DOI 10.1080/10641950801955733; Lucchetti D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176257; Murphy SP, 1998, MOL REPROD DEV, V51, P1; Pillay P, 2016, PLACENTA, V46, P18, DOI 10.1016/j.placenta.2016.08.078; Redman CWG, 2010, AM J REPROD IMMUNOL, V63, P534, DOI 10.1111/j.1600-0897.2010.00831.x; Tersigni C, 2018, J REPROD IMMUNOL, V129, P48, DOI 10.1016/j.jri.2018.06.024; Tersigni C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134756	12	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 3	2021	12								717879	10.3389/fimmu.2021.717879	http://dx.doi.org/10.3389/fimmu.2021.717879			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UR1RD	34539654	Green Published, gold			2022-12-18	WOS:000696531900001
J	Yang, C; Ng, CT; Li, D; Zhang, L				Yang, Chao; Ng, Chan-Tat; Li, Dan; Zhang, Lei			Targeting Indoleamine 2,3-Dioxygenase 1: Fighting Cancers via Dormancy Regulation	FRONTIERS IN IMMUNOLOGY			English	Review						tumour dormancy; immunosuppression; kynurenine; nanotechnology; IDO1 regulation; aryl hydrocarbon receptor	ARYL-HYDROCARBON RECEPTOR; DENDRITIC CELLS; T-CELLS; IDO1 INHIBITORS; EXPRESSION; MECHANISMS; MTOR; DISCOVERY; GROWTH; CYCLOOXYGENASE-2	The connection between indoleamine 2,3-dioxygenase 1 (IDO1) and tumour dormancy - a quiescent state of tumour cells which has been consistently linked to metastasis and cancer recurrence - is rarely discussed despite the pivotal role of IDO1 in cancer development and progression. Whilst the underlying mechanisms of IDO1-mediated dormancy are elusive, we summarize the IDO1 pathways which potentially contribute to dormancy in this review. Critically, distinct IDO1 activities are involved in dormancy initiation and maintenance; factors outside the well-studied IDO1/kynurenine/aryl hydrocarbon receptor axis, including the mammalian target of rapamycin and general control nonderepressible 2, appear to be implicated in dormancy. We also discuss various strategies for cancer treatment via regulating IDO1-dependent dormancy and suggest the application of nanotechnology to deliver effective treatment.	[Yang, Chao] Zhejiang Ocean Univ, Inst Innovat & Applicat, Natl Engn Res Ctr Marine Aquaculture, Zhoushan, Peoples R China; [Ng, Chan-Tat] Natl Chengchi Univ, Dept Psychol, Taipei, Taiwan; [Ng, Chan-Tat] Natl Chengchi Univ, Dept English, Taipei, Taiwan; [Li, Dan] Chengdu Univ Tradit Chinese Med, Sch Pharm, State Key Lab Southwestern Chinese Med Resources, Chengdu, Peoples R China; [Zhang, Lei] Jiangsu Univ Sci & Technol, Sericultural Res Inst, Coll Biotechnol, Zhenjiang, Jiangsu, Peoples R China; [Zhang, Lei] Univ Waterloo, Waterloo Inst Nanotechnol, Dept Chem Engn, Waterloo, ON, Canada	Zhejiang Ocean University; National Chengchi University; National Chengchi University; Chengdu University of Traditional Chinese Medicine; Jiangsu University of Science & Technology; University of Waterloo	Li, D (corresponding author), Chengdu Univ Tradit Chinese Med, Sch Pharm, State Key Lab Southwestern Chinese Med Resources, Chengdu, Peoples R China.; Zhang, L (corresponding author), Jiangsu Univ Sci & Technol, Sericultural Res Inst, Coll Biotechnol, Zhenjiang, Jiangsu, Peoples R China.; Zhang, L (corresponding author), Univ Waterloo, Waterloo Inst Nanotechnol, Dept Chem Engn, Waterloo, ON, Canada.	lidan@cdutcm.edu.cn; l78zhang@uwaterloo.ca	Lei, Zhang/M-2798-2019; Zhang, Lei/GPX-3488-2022; Ng, Chan-Tat/Y-7357-2018	Lei, Zhang/0000-0001-5454-8758; Zhang, Lei/0000-0001-5454-8758; Ng, Chan-Tat/0000-0002-5241-0349	Natural Science Foundation of Jiangsu Province, China [BK20190960]; Natural Science Foundation of the Jiangsu Higher Education Institutions of China [19KJB180014]; China Postdoctoral Science Foundation [2019M663456, 2019TQ0044]; Xinglin Scholar Research Promotion Project of Chengdu University of TCM [BSH2019008]; Sichuan Province Science and technology innovation seedling project [2020091]; Open Research Fund of Chengdu University of Traditional Chinese Medicine Key Laboratory of Systematic Research of Distinctive Chinese Medicine Resources in Southwest China [2020BSH004]; Canada Mitacs Fellowship [IT18262]	Natural Science Foundation of Jiangsu Province, China(Natural Science Foundation of Jiangsu Province); Natural Science Foundation of the Jiangsu Higher Education Institutions of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Xinglin Scholar Research Promotion Project of Chengdu University of TCM; Sichuan Province Science and technology innovation seedling project; Open Research Fund of Chengdu University of Traditional Chinese Medicine Key Laboratory of Systematic Research of Distinctive Chinese Medicine Resources in Southwest China; Canada Mitacs Fellowship	The work was supported by the Natural Science Foundation of Jiangsu Province, China (Grant No. BK20190960), the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (Grant No. 19KJB180014), China Postdoctoral Science Foundation (2019M663456 and 2019TQ0044), Xinglin Scholar Research Promotion Project of Chengdu University of TCM (BSH2019008), Sichuan Province Science and technology innovation seedling project (2020091), Open Research Fund of Chengdu University of Traditional Chinese Medicine Key Laboratory of Systematic Research of Distinctive Chinese Medicine Resources in Southwest China (2020BSH004) and Canada Mitacs Fellowship (IT18262).	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Albini E, 2017, J CELL MOL MED, V21, P165, DOI 10.1111/jcmm.12954; [Anonymous], J ONCOL SCI, DOI DOI 10.1016/J.JONS.2017.04.001; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Bessede A, 2014, NATURE, V511, P184, DOI 10.1038/nature13323; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chen SL, 2021, BIOORG CHEM, V110, DOI 10.1016/j.bioorg.2021.104815; Chen YC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13443; Chotechuang N, 2009, AM J PHYSIOL-ENDOC M, V297, pE1313, DOI 10.1152/ajpendo.91000.2008; Cobbold SP, 2009, P NATL ACAD SCI USA, V106, P12055, DOI 10.1073/pnas.0903919106; Corthay A, 2022, SEMIN CANCER BIOL, V78, P5, DOI 10.1016/j.semcancer.2021.02.002; Cuyas E, 2014, METHODS MOL BIOL, V1170, P113, DOI 10.1007/978-1-4939-0888-2_7; Darnell M, 2018, BIOMATERIALS, V181, P182, DOI 10.1016/j.biomaterials.2018.07.039; De Angelis ML, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00626; Du QM, 2019, EUR J MED CHEM, V182, DOI 10.1016/j.ejmech.2019.111629; Fallarino F, 2006, J IMMUNOL, V176, P6752, DOI 10.4049/jimmunol.176.11.6752; Fallarino I, 2002, CELL DEATH DIFFER, V9, P1069, DOI 10.1038/sj.cdd.4401073; Fluegen G, 2017, NAT CELL BIOL, V19, P120, DOI 10.1038/ncb3465; Fu S, 2004, AM J TRANSPLANT, V4, P1614, DOI 10.1111/j.1600-6143.2004.00566.x; Gao XL, 2017, ONCOTARGETS THER, V10, P5219, DOI 10.2147/OTT.S140854; Goldberg MS, 2019, NAT REV CANCER, V19, P587, DOI 10.1038/s41568-019-0186-9; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Grimm D, 2020, SEMIN CANCER BIOL, V67, P122, DOI 10.1016/j.semcancer.2019.03.004; Haxhinasto S, 2008, J EXP MED, V205, P565, DOI 10.1084/jem.20071477; Hennequart M, 2017, CANCER IMMUNOL RES, V5, P695, DOI 10.1158/2326-6066.CIR-16-0400; Hida T, 1998, CANCER RES, V58, P3761; Holmgaard RB, 2015, CELL REP, V13, P412, DOI 10.1016/j.celrep.2015.08.077; Holtzhausen A, 2015, CANCER IMMUNOL RES, V3, P1082, DOI 10.1158/2326-6066.CIR-14-0167; Hou DY, 2007, CANCER RES, V67, P792, DOI 10.1158/0008-5472.CAN-06-2925; Hou WZ, 2016, CANCER CELL, V30, P108, DOI 10.1016/j.ccell.2016.05.012; Huang H, 2019, NANO LETT, V19, P5356, DOI 10.1021/acs.nanolett.9b01807; Jahanban-Esfahlan R, 2019, CANCERS, V11, DOI 10.3390/cancers11081207; Jia Q, 2019, THERANOSTICS, V9, P424, DOI 10.7150/thno.29698; Kim J, 2016, INTEGR CANCER THER, V15, P467, DOI 10.1177/1534735416639714; Kimura A, 2008, P NATL ACAD SCI USA, V105, P9721, DOI 10.1073/pnas.0804231105; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Konkel JE, 2017, IMMUNITY, V46, P660, DOI 10.1016/j.immuni.2017.03.015; Kudo Y, 2001, J PHYSIOL-LONDON, V531, P417, DOI 10.1111/j.1469-7793.2001.0417i.x; Labadie BW, 2019, CLIN CANCER RES, V25, P1462, DOI 10.1158/1078-0432.CCR-18-2882; Lan Q, 2019, ONCOGENE, V38, P2814, DOI 10.1038/s41388-018-0624-2; Lee JH, 2013, J PHARMACOPUNCT, V16, P12, DOI [10.3831/KPI.2013.16.005, 10.3831/KPI.2013.16.003]; Li QS, 2016, J IMMUNOL, V197, P962, DOI 10.4049/jimmunol.1502615; Liou JY, 2007, STEM CELLS, V25, P1096, DOI 10.1634/stemcells.2006-0505; LIU CM, 1986, J EXP MED, V164, P1259, DOI 10.1084/jem.164.4.1259; Liu M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0644-y; Liu Q, 2018, ACS NANO, V12, P7812, DOI 10.1021/acsnano.8b01890; Liu YY, 2018, CANCER RES, V78, P3926, DOI 10.1158/0008-5472.CAN-17-3719; Liu YY, 2018, CANCER CELL, V33, P480, DOI 10.1016/j.ccell.2018.02.005; Liu YY, 2018, J CLIN INVEST, V128, P1057, DOI 10.1172/JCI96329; Liu YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15207; Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470-2045(19)30274-8; Lu JQ, 2018, ACS NANO, V12, P11041, DOI 10.1021/acsnano.8b05189; Manjili MH, 2017, CANCER RES, V77, P2564, DOI 10.1158/0008-5472.CAN-17-0068; Metz R, 2014, INT IMMUNOL, V26, P357, DOI 10.1093/intimm/dxt073; Metz R, 2012, ONCOIMMUNOLOGY, V1, P1460, DOI 10.4161/onci.21716; Mezrich JD, 2010, J IMMUNOL, V185, P3190, DOI 10.4049/jimmunol.0903670; Munn DH, 2005, IMMUNITY, V22, P633, DOI 10.1016/j.immuni.2005.03.013; Negishi T, 2005, J IMMUNOL, V175, P7348, DOI 10.4049/jimmunol.175.11.7348; Novak D, 2020, SEMIN CANCER BIOL, V67, P74, DOI 10.1016/j.semcancer.2019.08.007; Ozawa Y, 2020, BIOCHEM BIOPH RES CO, V524, P723, DOI 10.1016/j.bbrc.2020.01.148; Pallotta MT, 2011, NAT IMMUNOL, V12, P870, DOI 10.1038/ni.2077; Pang PH, 2008, J CELL PHYSIOL, V215, P161, DOI 10.1002/jcp.21299; Peyvandi S., 2019, J CANC METASTASIS TR, V5, DOI [10.20517/2394-4722.2019.16, DOI 10.20517/2394-4722.2019.16]; Phan TG, 2020, NAT REV CANCER, V20, P398, DOI 10.1038/s41568-020-0263-0; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Platten M, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00673; Prendergast GC, 2017, CANCER RES, V77, P6795, DOI 10.1158/0008-5472.CAN-17-2285; Prendergast GC, 2014, CANCER IMMUNOL IMMUN, V63, P721, DOI 10.1007/s00262-014-1549-4; Qiao HS, 2019, BIOMATER SCI-UK, V7, P2749, DOI 10.1039/c9bm00324j; Riley RS, 2019, NAT REV DRUG DISCOV, V18, P175, DOI 10.1038/s41573-018-0006-z; Rohrig UF, 2019, J MED CHEM, V62, P8784, DOI 10.1021/acs.jmedchem.9b00942; Romero I, 2014, CANCER RES, V74, P6750, DOI 10.1158/0008-5472.CAN-14-2406; Saito M, 2020, ANTICANCER RES, V40, P1247, DOI 10.21873/anticanres.14066; Sang W, 2019, CHEM SOC REV, V48, P3771, DOI 10.1039/c8cs00896e; Sauer S, 2008, P NATL ACAD SCI USA, V105, P7797, DOI 10.1073/pnas.0800928105; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Song WT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04605-x; Sonner JK, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1240858; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Sosnoski DM, 2015, CLIN EXP METASTAS, V32, P335, DOI 10.1007/s10585-015-9710-9; Staschke KA, 2010, J BIOL CHEM, V285, P16893, DOI 10.1074/jbc.M110.121947; Sun X, 2012, J CLIN IMMUNOL, V32, P837, DOI 10.1007/s10875-012-9681-4; Tjiu JW, 2006, J INVEST DERMATOL, V126, P1143, DOI 10.1038/sj.jid.5700191; Tomek P, 2017, EUR J MED CHEM, V126, P983, DOI 10.1016/j.ejmech.2016.12.029; Trabanelli S, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/253191; Tucker ON, 1999, CANCER RES, V59, P987; Van den Eynde BJ, 2020, ANNU REV CANC BIOL, V4, P241, DOI 10.1146/annurev-cancerbio-030419-033635; von Bergwelt-Baildon MS, 2006, BLOOD, V108, P228, DOI 10.1182/blood-2005-08-3507; Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011; Wang YX, 2018, EUR J MED CHEM, V143, P1858, DOI 10.1016/j.ejmech.2017.10.078; Weng TW, 2018, EUR J MED CHEM, V143, P656, DOI 10.1016/j.ejmech.2017.11.088; Yao CC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2684; Yoshimura N, 2003, SURG TODAY, V33, P805, DOI 10.1007/s00595-003-2606-3; Zhang SZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00242-3; Zou Y, 2019, EUR J MED CHEM, V184, DOI 10.1016/j.ejmech.2019.111750; Zou Y, 2017, EUR J MED CHEM, V138, P199, DOI 10.1016/j.ejmech.2017.06.039	96	1	1	6	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 3	2021	12								725204	10.3389/fimmu.2021.725204	http://dx.doi.org/10.3389/fimmu.2021.725204			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	US0HN	34539663	Green Published, gold			2022-12-18	WOS:000697118600001
J	Bettoni, S; Maziarz, K; Stone, MRL; Blaskovich, MAT; Potempa, J; Bazzo, ML; Unemo, M; Ram, S; Blom, AM				Bettoni, Serena; Maziarz, Karolina; Stone, M. Rhia L.; Blaskovich, Mark A. T.; Potempa, Jan; Bazzo, Maria Luiza; Unemo, Magnus; Ram, Sanjay; Blom, Anna M.			Serum Complement Activation by C4BP-IgM Fusion Protein Can Restore Susceptibility to Antibiotics in Neisseria gonorrhoeae	FRONTIERS IN IMMUNOLOGY			English	Article						complement; antibiotic resisitance; Neisseria gonorrhoeae; C4b binding protein; membrane attack complex (MAC)	MEMBRANE ATTACK COMPLEX; EFFLUX PUMP SYSTEM; BACTERICIDAL ACTIVITY; ANTIMICROBIAL RESISTANCE; POTENTIATION; ADAPTATION; GUIDELINE; INFECTION; SYNERGY; ANTIGEN	Neisseria gonorrhoeae is the etiological agent of gonorrhea, the second most common bacterial sexually transmitted infection worldwide. Reproductive sequelae of gonorrhea include infertility, ectopic pregnancy and chronic pelvic pain. Most antibiotics currently in clinical use have been rendered ineffective due to the rapid spread of antimicrobial resistance among gonococci. The developmental pipeline of new antibiotics is sparse and novel therapeutic approaches are urgently needed. Previously, we utilized the ability of N. gonorrhoeae to bind the complement inhibitor C4b-binding protein (C4BP) to evade killing by human complement to design a chimeric protein that linked the two N-terminal gonococcal binding domains of C4BP with the Fc domain of IgM. The resulting molecule, C4BP-IgM, enhanced complement-mediated killing of gonococci. Here we show that C4BP-IgM induced membrane perturbation through complement deposition and membrane attack complex pore insertion facilitates the access of antibiotics to their intracellular targets. Consequently, bacteria become more susceptible to killing by antibiotics. Remarkably, C4BP-IgM restored susceptibility to azithromycin of two azithromycin-resistant clinical gonococcal strains because of overexpression of the MtrC-MtrD-MtrE efflux pump. Our data show that complement activation can potentiate activity of antibiotics and suggest a role for C4BP-IgM as an adjuvant for antibiotic treatment of drug-resistant gonorrhea.	[Bettoni, Serena; Maziarz, Karolina; Blom, Anna M.] Lund Univ, Dept Translat Med, Malmo, Sweden; [Stone, M. Rhia L.; Blaskovich, Mark A. T.] Univ Queensland, Inst Mol Biosci, Ctr Superbug Solut, Brisbane, Qld, Australia; [Potempa, Jan] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Krakow, Poland; [Potempa, Jan] Univ Louisville, Sch Dent, Dept Oral Immun & Infect Dis, Louisville, KY 40292 USA; [Bazzo, Maria Luiza] Univ Fed Santa Catarina, Mol Biol Microbiol & Serol Lab, Florianopolis, SC, Brazil; [Unemo, Magnus] Orebro Univ, WHO, Collaborating Ctr Gonorrhoea & Other STIs, Dept Lab Med, Orebro, Sweden; [Ram, Sanjay] Univ Massachusetts, Med Sch, Div Infect Dis, Dept Med, Worcester, MA 01605 USA	Lund University; University of Queensland; Jagiellonian University; University of Louisville; Universidade Federal de Santa Catarina (UFSC); Orebro University; World Health Organization; University of Massachusetts System; University of Massachusetts Worcester	Blom, AM (corresponding author), Lund Univ, Dept Translat Med, Malmo, Sweden.	anna.blom@med.lu.se	Blom, Anna/AFS-7369-2022; Blom, Anna/AFS-7343-2022; Unemo, Magnus/ABD-6653-2021; Blom, Anna/B-9607-2009; Stone, Rhia/C-7940-2017	Blom, Anna/0000-0002-1348-1734; Bettoni, Serena/0000-0002-7840-4596; Stone, Rhia/0000-0001-9825-2596	Swedish Research Council [2018-02392]	Swedish Research Council(Swedish Research CouncilEuropean Commission)	Funding The study was supported by grants from Swedish Research Council (2018-02392), Torsten Soderberg Foundation (MT3/18), The Osterlund Foundation (to AB) as well as grants from Sten K. Johnsons Foundation (2019), the Tore Nilsons Foundation (2019-00750), the Royal Physiographic Society of Lund (40824), the O. E. och Edla Johanssons Foundation (2020 and 2021), The Lars Hierta Memorial Foundation (FO2020-0257), Langmanska kulturfonden (BA20-1272, BA21-0550) and Clas Groschinskys Fondation (M21106) (to SB). MS was supported by an Australian Postgraduate Award and an Institute for Molecular Biosciences Research Advancement Award. SR was supported by National Institutes of Health grants R01 AI32296 and R44 AI147930.	Alamiri F, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.01193-19; Berends ETM, 2015, MOL IMMUNOL, V65, P328, DOI 10.1016/j.molimm.2015.01.020; Bettoni S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131886; Bignell C, 2013, INT J STD AIDS, V24, P85, DOI 10.1177/0956462412472837; Blom AM, 2014, CLIN EXP IMMUNOL, V178, P142, DOI 10.1111/cei.12388; Bolla JM, 2011, FEBS LETT, V585, P1682, DOI 10.1016/j.febslet.2011.04.054; BOSLEGO JW, 1991, VACCINE, V9, P154, DOI 10.1016/0264-410X(91)90147-X; Citterio L, 2016, RES MICROBIOL, V167, P72, DOI 10.1016/j.resmic.2015.10.002; DALHOFF A, 1984, INFECTION, V12, P214, DOI 10.1007/BF01640908; DARVEAU RP, 1990, J INFECT DIS, V162, P914, DOI 10.1093/infdis/162.4.914; DUTCHER BS, 1978, ANTIMICROB AGENTS CH, V13, P820, DOI 10.1128/AAC.13.5.820; Fifer H, 2020, INT J STD AIDS, V31, P4, DOI 10.1177/0956462419886775; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; FRANICZEK R, 1993, ACTA MICROBIOL POL, V42, P243; Golparian D, 2020, J ANTIMICROB CHEMOTH, V75, P3163, DOI 10.1093/jac/dkaa318; GREENBERG L, 1974, CAN J PUBLIC HEALTH, V65, P29; Gulati S, 2019, METHODS MOL BIOL, V1997, P267, DOI 10.1007/978-1-4939-9496-0_16; Hagman KE, 1997, MICROBIOL-SGM, V143, P2117, DOI 10.1099/00221287-143-7-2117; Heesterbeek DAC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38577-9; HITCHCOCK PJ, 1985, J EXP MED, V162, P2017, DOI 10.1084/jem.162.6.2017; Jennings LK., 2021, MASSIVE TRANSFUSION; Jerse AE, 2003, INFECT IMMUN, V71, P5576, DOI 10.1128/IAI.71.10.5576-5582.2003; Ma KC, 2020, MBIO, V11, DOI 10.1128/mBio.01509-20; Ma KC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17980-1; Mahmood HY, 2016, CURR MED CHEM, V23, P1062, DOI 10.2174/0929867323666160304150522; Mastellos DC, 2015, EUR J CLIN INVEST, V45, P423, DOI 10.1111/eci.12419; MCQUILLEN DP, 1994, METHOD ENZYMOL, V236, P137; National Center for Emerging Zoonotic and Infectious Diseases (U.S.), 2019, ANT RES COORD STRAT, DOI [10.15620/cdc:82532, DOI 10.15620/CDC:82532]; Nordahl EA, 2004, P NATL ACAD SCI USA, V101, P16879, DOI 10.1073/pnas.0406678101; Lan PT, 2020, J ANTIMICROB CHEMOTH, V75, P1432, DOI 10.1093/jac/dkaa040; PRUUL H, 1972, INFECT IMMUN, V6, P709, DOI 10.1128/IAI.6.5.709-717.1972; PRUUL H, 1992, ANTIMICROB AGENTS CH, V36, P10, DOI 10.1128/AAC.36.1.10; Quillin SJ, 2018, NAT REV MICROBIOL, V16, P226, DOI 10.1038/nrmicro.2017.169; Ram S, 2001, J EXP MED, V193, P281, DOI 10.1084/jem.193.3.281; Reekie J, 2019, CLIN INFECT DIS, V69, P1621, DOI 10.1093/cid/ciz145; Rouquette C, 1999, MOL MICROBIOL, V33, P651, DOI 10.1046/j.1365-2958.1999.01517.x; Rowley J, 2019, B WORLD HEALTH ORGAN, V97, P548, DOI 10.2471/BLT.18.228486; Shaughnessy J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583305; Shaughnessy J, 2018, J IMMUNOL, V201, P2700, DOI 10.4049/jimmunol.1701666; St Cyr S, 2020, MMWR-MORBID MORTAL W, V69, P1911, DOI 10.15585/mmwr.mm6950a6; Stokes JM, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.28; Stone MRL, 2020, RSC CHEM BIOL, V1, P395, DOI 10.1039/d0cb00118j; Stone MRL, 2019, MEDCHEMCOMM, V10, P901, DOI 10.1039/c9md00124g; Tacconelli E, 2018, LANCET INFECT DIS, V18, P318, DOI [10.1016/S1473-3099(17)30753-3, 10.1016/s1473-3099(17)30753-3]; Tan AK, 2019, NEW ENGL J MED, V380, pE2, DOI 10.1056/NEJMicm1808613; Unemo M, 2020, INT J STD AIDS, DOI 10.1177/0956462420949126; Unemo M, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0136-6, 10.1038/s41572-019-0128-6]; Unemo M, 2019, SEX HEALTH, V16, P412, DOI 10.1071/SH19023; Unemo M, 2014, CLIN MICROBIOL REV, V27, P587, DOI 10.1128/CMR.00010-14; VAARA M, 1983, NATURE, V303, P526, DOI 10.1038/303526a0; WATANABE K, 1986, CHEMOTHERAPY, V32, P113, DOI 10.1159/000238399; WHO, 2015, WHO GUIDELINES TREAT; Wi T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002344; Xhindoli D, 2016, BBA-BIOMEMBRANES, V1858, P546, DOI 10.1016/j.bbamem.2015.11.003; Xie CB, 2020, AM J PATHOL, V190, P1138, DOI 10.1016/j.ajpath.2020.02.006	55	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 1	2021	12								726801	10.3389/fimmu.2021.726801	http://dx.doi.org/10.3389/fimmu.2021.726801			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UR4AN	34539665	Green Published, gold			2022-12-18	WOS:000696693200001
J	Bright, F; Katzeff, JSS; Hodges, JRR; Piguet, O; Kril, JJJ; Halliday, GMM; Kim, WS				Bright, Fiona; Katzeff, Jared S. S.; Hodges, John R. R.; Piguet, Olivier; Kril, Jillian J. J.; Halliday, Glenda M. M.; Kim, Woojin Scott			Glycoprotein Pathways Altered in Frontotemporal Dementia With Autoimmune Disease	FRONTIERS IN IMMUNOLOGY			English	Article						frontotemporal dementia; autoimmune disease; proteomics; serum; thyroid; glycoprotein; glycome; biomarker	LOBAR DEGENERATION; INSULIN-RESISTANCE; GLYCOSYLATION; PREVALENCE; ASSOCIATIONS; MECHANISMS; ANTIBODIES; RECEPTORS; CRITERIA; COHORT	Behavioral variant frontotemporal dementia (bvFTD) is a younger onset form of neurodegeneration initiated in the frontal and/or temporal lobes with a slow clinical onset but rapid progression. bvFTD is highly complex biologically with different pathological signatures and genetic variants that can exhibit a spectrum of overlapping clinical manifestations. Although the role of innate immunity has been extensively investigated in bvFTD, the involvement of adaptive immunity in bvFTD pathogenesis is poorly understood. We analyzed blood serum proteomics to identify proteins that are associated with autoimmune disease in bvFTD. Eleven proteins (increased: ATP5B, CALML5, COLEC11, FCGBP, PLEK, PLXND1; decreased: APOB, ATP8B1, FAM20C, LOXL3, TIMD4) were significantly altered in bvFTD with autoimmune disease compared to those without autoimmune disease. The majority of these proteins were enriched for glycoprotein-associated proteins and pathways, suggesting that the glycome is targeted in bvFTD with autoimmune disease.	[Bright, Fiona; Katzeff, Jared S. S.; Hodges, John R. R.; Kril, Jillian J. J.; Halliday, Glenda M. M.; Kim, Woojin Scott] Univ Sydney, Sch Med Sci, Sydney, NSW, Australia; [Katzeff, Jared S. S.; Hodges, John R. R.; Piguet, Olivier; Halliday, Glenda M. M.; Kim, Woojin Scott] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia; [Piguet, Olivier] Univ Sydney, Sch Psychol, Sydney, NSW, Australia	University of Sydney; University of Sydney; University of Sydney	Kim, WS (corresponding author), Univ Sydney, Sch Med Sci, Sydney, NSW, Australia.; Kim, WS (corresponding author), Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia.	woojin.kim@sydney.edu.au	Halliday, Glenda M/E-8555-2011	Halliday, Glenda M/0000-0003-0422-8398; Bright, Fiona/0000-0002-1255-2350	National Health and Medical Research Council of Australia (NHMRC) program [1037746]	National Health and Medical Research Council of Australia (NHMRC) program(National Health and Medical Research Council (NHMRC) of Australia)	Funding This work was supported by funding to ForeFront, a collaborative research group dedicated to the study of frontotemporal dementia and motor neuron disease, from the National Health and Medical Research Council of Australia (NHMRC) program grant (#1037746). GMH is a NHMRC Senior Leadership Fellow (#1176607) and OP is a NHMRC Senior Research Fellow (#1103258).	Akasaka-Manya K, 2017, J BIOCHEM, V161, P99, DOI 10.1093/jb/mvw056; Allcock RJN, 2003, EUR J IMMUNOL, V33, P567, DOI 10.1002/immu.200310033; Antonov AV, 2011, NUCLEIC ACIDS RES, V39, pW323, DOI 10.1093/nar/gkr372; ASCIA, 2019, FAST FACTS AUT DIS; Bellucci A, 2011, NEURODEGENER DIS, V8, P221, DOI 10.1159/000322228; Borroni B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06117-y; Bouchon A, 2000, J IMMUNOL, V164, P4991, DOI 10.4049/jimmunol.164.10.4991; Bras IC, 2019, J HUNTINGTONS DIS, V8, P245, DOI 10.3233/JHD-190366; Bright F, 2019, NAT REV NEUROL, V15, P540, DOI 10.1038/s41582-019-0231-z; Broce I, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002487; Cavazzana I, 2018, J NEUROIMMUNOL, V325, P61, DOI 10.1016/j.jneuroim.2018.10.006; Connelly MA, 2016, CLIN CHIM ACTA, V459, P177, DOI 10.1016/j.cca.2016.06.012; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Coyle-Gilchrist ITS, 2016, NEUROLOGY, V86, P1736, DOI 10.1212/WNL.0000000000002638; de Haan P, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00046; Desai MK, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00265; Edri-Brami M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035772; Ferrari R, 2014, LANCET NEUROL, V13, P686, DOI 10.1016/S1474-4422(14)70065-1; Frenkel-Pinter M, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1601576; Gaunitz S, 2021, J NEUROCHEM, V159, P292, DOI 10.1111/jnc.15202; Gelpi E, 2016, ACTA NEUROPATHOL, V132, P531, DOI 10.1007/s00401-016-1591-8; Geschwind MD, 2007, NEUROL CLIN, V25, P783, DOI 10.1016/j.ncl.2007.04.001; Gough SCL, 2007, CURR GENOMICS, V8, P453, DOI 10.2174/138920207783591690; Goulabchand R, 2014, AUTOIMMUN REV, V13, P742, DOI 10.1016/j.autrev.2014.02.005; Hogan DB, 2016, CAN J NEUROL SCI, V43, pS96, DOI 10.1017/cjn.2016.25; Hu MH, 2019, PROG MOL BIOL TRANSL, V162, P1, DOI 10.1016/bs.pmbts.2018.12.002; Iqbal S, 2019, BIOCHEM SOC T, V47, P89, DOI 10.1042/BST20180330; Jian JL, 2018, CYTOKINE, V101, P48, DOI 10.1016/j.cyto.2016.08.007; Katisko K, 2018, J NEUROIMMUNOL, V321, P29, DOI 10.1016/j.jneuroim.2018.05.011; Katzeff JS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70687-7; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Lant SB, 2014, NEUROPATH APPL NEURO, V40, P686, DOI 10.1111/nan.12092; Lin TM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0186475; Matsubara T, 2012, CELL METAB, V15, P38, DOI 10.1016/j.cmet.2011.12.002; Matzaraki V, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1207-1; Maverakis E, 2015, J AUTOIMMUN, V57, P1, DOI 10.1016/j.jaut.2014.12.002; Merleev AA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73588-x; Miller ZA, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000301; Miller ZA, 2013, J NEUROL NEUROSUR PS, V84, P956, DOI 10.1136/jnnp-2012-304644; Molania R, 2019, NUCLEIC ACIDS RES, V47, P6073, DOI 10.1093/nar/gkz433; Moll T, 2020, BRAIN, V143, P1332, DOI 10.1093/brain/awz358; Ngo ST, 2014, FRONT NEUROENDOCRIN, V35, P347, DOI 10.1016/j.yfrne.2014.04.004; Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019; Palese F, 2020, NEUROBIOL AGING, V86, P143, DOI 10.1016/j.neurobiolaging.2019.10.015; Plomp R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12495-0; Pottier C, 2019, ACTA NEUROPATHOL, V137, P879, DOI 10.1007/s00401-019-01962-9; Rascovsky K, 2011, BRAIN, V134, P2456, DOI 10.1093/brain/awr179; Reily C, 2019, NAT REV NEPHROL, V15, P346, DOI 10.1038/s41581-019-0129-4; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sakae N, 2019, ANN CLIN TRANSL NEUR, V6, P1782, DOI 10.1002/acn3.50875; Schnaar RL, 2016, J LEUKOCYTE BIOL, V99, P825, DOI 10.1189/jlb.3RI0116-021R; Schwartz M, 2006, J NEUROIMMUNE PHARM, V1, P4, DOI 10.1007/s11481-005-9010-2; Scott Hilary, 2014, Adv Neurobiol, V9, P367, DOI 10.1007/978-1-4939-1154-7_17; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Taipa R, 2017, NEURODEGENER DIS, V17, P145, DOI 10.1159/000457127; Tang W, 2011, SCIENCE, V332, P478, DOI 10.1126/science.1199214; Thurner L, 2013, J AUTOIMMUN, V42, P29, DOI 10.1016/j.jaut.2012.10.003; Ting L, 2011, NAT METHODS, V8, P937, DOI [10.1038/NMETH.1714, 10.1038/nmeth.1714]; van Kooyk Y, 2008, NAT IMMUNOL, V9, P593, DOI 10.1038/ni.f.203; Varadi C, 2019, MOLECULES, V24, DOI 10.3390/molecules24122220; Varki A, 2017, GLYCOBIOLOGY, V27, P3, DOI 10.1093/glycob/cww086; Verhelst X, 2020, GASTROENTEROLOGY, V158, P95, DOI 10.1053/j.gastro.2019.08.060; Wahl A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00277; Wei FH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112110; Wotton CJ, 2017, J EPIDEMIOL COMMUN H, V71, P576, DOI 10.1136/jech-2016-207809; Zhang Q, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc5802; Zhao YP, 2013, FEBS LETT, V587, P1805, DOI 10.1016/j.febslet.2013.04.037; Zhou B, 2015, J MOL ENDOCRINOL, V55, P231, DOI 10.1530/JME-15-0075; Zolotarjova N, 2008, J CHROMATOGR A, V1189, P332, DOI 10.1016/j.chroma.2007.11.082	69	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 1	2021	12								736260	10.3389/fimmu.2021.736260	http://dx.doi.org/10.3389/fimmu.2021.736260			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UR5HV	34539672	Green Published, gold			2022-12-18	WOS:000696781300001
J	Hoffman, E; Napieralska, P; Mahendran, R; Murnane, D; Hutter, V				Hoffman, Ewelina; Napieralska, Paulina; Mahendran, Rhamiya; Murnane, Darragh; Hutter, Victoria			High Content Image Analysis as a Tool to Morphologically Distinguish Macrophage Activation and Determine Its Importance for Foamy Alveolar Macrophage Responses	FRONTIERS IN IMMUNOLOGY			English	Article						alveolar macrophages; foamy alveolar macrophages; macrophage morphometrics; vacuolation; cytokine activation	FEATURES; RAT	Introduction Lung diseases are an increasing global health burden affecting millions of people worldwide. Only a few new inhaled medicines have reached the market in the last 30 years, in part due to foamy alveolar macrophage (FAM) responses observed in pre-clinical rat studies. The induction mechanism and signaling pathways involved in the development of highly vacuolated 'foamy' phenotype is not known. Furthermore, it has not been determined if these observations are adaptive or adverse responses. Aim To determine if high content image analysis techniques can distinguish between alveolar macrophage activation (LPS/IFN-gamma activated and IL-4 activated macrophages) and if this could be applied to understanding the generation of 'foamy' macrophage phenotypes. Methods NR8383 rat alveolar macrophages were stimulated with a mix of cytokines (LPS/IFN-gamma or IL-4) for 24 h. The cells were further exposed to FAM inducing-compounds amiodarone and staurosporine. Following 24 h incubation, phagocytosis and lipid accumulation were measured using flow cytometry and high content image analysis techniques. The alveolar macrophages responses after exposure to cytokines were assessed by evaluation: (i) cell surface and biochemical markers such as: nitric oxide production, arginase-1 activity and MRC-1 receptor expression (ii) cellular morphology (iii) cellular functionality (phagocytic activity and lipids accumulation). Results Macrophages activated with LPS/IFN-gamma showed distinct morphological (increased vacuolation) features and functionality (increased lipidosis, decreased phagocytic activity). Foamy macrophage phenotypes induced by amiodarone also displayed characteristics of proinflammatory macrophages (significantly increased nitric oxide production, increased vacuolation and lipidosis and decreased phagocytosis). In contrast, staurosporine treatment resulted in increased NO production, as well as arginase-1 activity. Conclusion High content image analysis was able to determine distinct differences in morphology between non-activated and LPS/IFN-gamma activated macrophages, characterized by increased vacuolation and lipidosis. When exposed to compounds that induce a FAM phenotype, healthy non-activated macrophages displayed proinflammatory (amiodarone) or pro-apoptotic (staurosporine) characteristics but these responses were independent of a change in activation status. This technique could be applied in early drug discovery safety assessment to identify immune responses earlier and increase the understanding of alveolar macrophage responses to new molecules challenge in development of new inhalation therapies, which in turn will enhance decision-making in an early safety assessment of novel drug candidates.	[Hoffman, Ewelina; Mahendran, Rhamiya; Murnane, Darragh; Hutter, Victoria] Univ Hertfordshire, Sch Life & Med Sci, Ctr Topical Drug Delivery & Toxicol, Hatfield, Herts, England; [Napieralska, Paulina] Med Univ Lodz, Fac Pharm, Dept Biochem & Mol Diagnost, Lodz, Poland	University of Hertfordshire; Medical University Lodz	Hoffman, E (corresponding author), Univ Hertfordshire, Sch Life & Med Sci, Ctr Topical Drug Delivery & Toxicol, Hatfield, Herts, England.	e.hoffman@herts.ac.uk		Hoffman, Ewelina/0000-0002-7998-924X	Hertfordshire Science Partnership - Hertfordshire Local Enterprise Partnership's "Growth Deal 2" under the Single Local Growth Fund Settlement	Hertfordshire Science Partnership - Hertfordshire Local Enterprise Partnership's "Growth Deal 2" under the Single Local Growth Fund Settlement	This work was supported by the Hertfordshire Science Partnership, an initiative part-financed by the Hertfordshire Local Enterprise Partnership's "Growth Deal 2" under the Single Local Growth Fund Settlement.	Allard B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01777; Atri C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061801; Bazzan E, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0522-0; Belmokhtar CA, 2001, ONCOGENE, V20, P3354, DOI 10.1038/sj.onc.1204436; Bertani FR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08121-8; Byrne AJ, 2015, THORAX, V70, P1189, DOI 10.1136/thoraxjnl-2015-207020; Eapen MS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13888-x; Forbes B, 2014, ADV DRUG DELIVER REV, V71, P15, DOI 10.1016/j.addr.2014.02.001; Gibson MS, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00654; Haupt A, 2018, J CELL SCI, V131, DOI 10.1242/jcs.214015; He SY, 2017, INT J CHRONIC OBSTR, V12, P3029, DOI 10.2147/COPD.S147144; Hoffman E, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030262; Hoffman E, 2017, PHARM RES-DORDR, V34, P2466, DOI 10.1007/s11095-017-2176-5; Hoffman E, 2015, MOL PHARMACEUT, V12, P2675, DOI 10.1021/acs.molpharmaceut.5b00048; Huang WC, 2016, ONCOTARGET, V7, P39363, DOI 10.18632/oncotarget.8101; Kim YS, 2017, TOX RESEARCH, V33, P239, DOI 10.5487/TR.2017.33.3.239; Lewis DJ, 2014, J APPL TOXICOL, V34, P319, DOI 10.1002/jat.2950; Lundborg M, 2001, ENVIRON RES, V86, P244, DOI 10.1006/enrs.2001.4269; Martinez FO, 2014, F1000PRIME REP, V6, P13, DOI DOI 10.12703/P6-13; Palmieri EM, 2018, J IMMUNOL, V200; Patel A, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11070345; Saradna A, 2018, TRANSL RES, V191, P1, DOI 10.1016/j.trsl.2017.09.002; Shim I, 2015, INT J TOXICOL, V34, P491, DOI 10.1177/1091581815607068; Staitieh B. S., 2015, J CLIN CELL IMMUNOL, V6, P365; Tarique AA, 2015, AM J RESP CELL MOL, V53, P676, DOI 10.1165/rcmb.2015-0012OC; Van Ginderachter JA, 2006, IMMUNOBIOLOGY, V211, P487, DOI 10.1016/j.imbio.2006.06.002; Wolkove N, 2009, CAN RESPIR J, V16, P43, DOI 10.1155/2009/282540; Yao YL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00792; Yuan A, 2015, SCI REP-UK, V5, DOI 10.1038/srep14273; Ziegler U, 2004, NEWS PHYSIOL SCI, V19, P124, DOI 10.1152/nips.01519.2004	30	1	1	4	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 1	2021	12								611280	10.3389/fimmu.2021.611280	http://dx.doi.org/10.3389/fimmu.2021.611280			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UR7JE	34539620	gold, Green Published			2022-12-18	WOS:000696920100001
J	Lee, DJ; Xu, HP; Taylor, AW				Lee, Darren J.; Xu, Heping; Taylor, Andrew W.			Editorial: Retinal Immunobiology and Retinopathy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						ocular immune privilege; age-related macular degeneration; diabetic retinopathy; glaucoma; uveitis; immune tolerance; retinal pigment epithelial cells; microglial cells			[Lee, Darren J.] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA; [Lee, Darren J.] Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Dean McGee Eye Inst, Oklahoma City, OK USA; [Xu, Heping] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland; [Taylor, Andrew W.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Queens University Belfast; Boston University	Taylor, AW (corresponding author), Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.	awtaylor@bu.edu		Xu, Heping/0000-0003-4000-931X	 [EY024951];  [EY025961]	; 	Grant funding: EY024951 (DL) and EY025961 (AT).	MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; Taylor AW, 2018, J LEUKOCYTE BIOL, V103, P1179, DOI 10.1002/JLB.3MIR0817-337R	2	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 1	2021	12								758375	10.3389/fimmu.2021.758375	http://dx.doi.org/10.3389/fimmu.2021.758375			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UZ1ZH	34539681	Green Published, gold			2022-12-18	WOS:000702009200001
J	Reading, JL; Roobrouck, VD; Hull, CM; Becker, PD; Beyens, J; Valentin-Torres, A; Boardman, D; Lamperti, EN; Stubblefield, S; Lombardi, G; Deans, R; Ting, AE; Tree, T				Reading, James L.; Roobrouck, Valerie D.; Hull, Caroline M.; Becker, Pablo Daniel; Beyens, Jelle; Valentin-Torres, Alice; Boardman, Dominic; Lamperti, Estefania Nova; Stubblefield, Samantha; Lombardi, Giovanna; Deans, Robert; Ting, Anthony E.; Tree, Timothy			Augmented Expansion of Treg Cells From Healthy and Autoimmune Subjects via Adult Progenitor Cell Co-Culture	FRONTIERS IN IMMUNOLOGY			English	Article						ex vivo expansion; autoimmune diseases; adult progenitor cells; co-culture; regulatory T (Treg) cells	REGULATORY T-CELLS; TRANSPLANTATION; RESPONSES; THERAPY	Recent clinical experience has demonstrated that adoptive regulatory T (Treg) cell therapy is a safe and feasible strategy to suppress immunopathology via induction of host tolerance to allo- and autoantigens. However, clinical trials continue to be compromised due to an inability to manufacture a sufficient Treg cell dose. Multipotent adult progenitor cells (MAPC(?)) promote Treg cell differentiation in vitro, suggesting they may be repurposed to enhance ex vivo expansion of Tregs for adoptive cellular therapy. Here, we use a Good Manufacturing Practice (GMP) compatible Treg expansion platform to demonstrate that MAPC cell-co-cultured Tregs (MulTreg) exhibit a log-fold increase in yield across two independent cohorts, reducing time to target dose by an average of 30%. Enhanced expansion is coupled to a distinct Treg cell-intrinsic transcriptional program characterized by elevated expression of replication-related genes (CDK1, PLK1, CDC20), downregulation of progenitor and lymph node-homing molecules (LEF1 CCR7, SELL) and induction of intestinal and inflammatory tissue migratory markers (ITGA4, CXCR1) consistent with expression of a gut homing (CCR7lo beta(7)hi) phenotype. Importantly, we find that MulTreg are more readily expanded from patients with autoimmune disease compared to matched Treg lines, suggesting clinical utility in gut and/or T helper type1 (Th1)-driven pathology associated with autoimmunity or transplantation. Relative to expanded Tregs, MulTreg retain equivalent and robust purity, FoxP3 Treg-Specific Demethylated Region (TSDR) demethylation, nominal effector cytokine production and potent suppression of Th1-driven antigen specific and polyclonal responses in vitro and xeno Graft vs Host Disease (xGvHD) in vivo. These data support the use of MAPC cell co-culture in adoptive Treg therapy platforms as a means to rescue expansion failure and reduce the time required to manufacture a stable, potently suppressive product.	[Reading, James L.] UCL, Res Dept Haematol, Canc Immunol Unit, Canc Inst, London, England; [Reading, James L.; Hull, Caroline M.; Tree, Timothy] Kings Coll London, Sch Immunol & Microbial Sci, Peter Gorer Dept Immunobiol, London, England; [Reading, James L.; Becker, Pablo Daniel] Kings Coll London, Guys Hosp, Dept Immunoregulat & Immune Int, London, England; [Roobrouck, Valerie D.; Beyens, Jelle; Deans, Robert] ReGenesys BV, Dept R&D, Leuven, Belgium; [Valentin-Torres, Alice; Stubblefield, Samantha; Deans, Robert; Ting, Anthony E.] Athersys Inc, Dept R&D, Cleveland, OH USA; [Boardman, Dominic] Univ British Columbia, Dept Surg, Vancouver, BC, Canada; [Boardman, Dominic] BC Childrens Hosp Res Inst, Dept Surg, Vancouver, BC, Canada; [Lamperti, Estefania Nova] Univ Concepcion, Fac Pharm, Dept Clin Biochem & Immunol, Mol & Translat Immunol Lab, Concepcion, Chile; [Lombardi, Giovanna] Kings Coll London, Fac Life Sci & Med, MRC Ctr Transplantat, Peter Gorer Dept Immunobiol, London, England; [Tree, Timothy] Guys & St Thomas NHS Fdn Trust, NIHR Biomed Res Ctr, London, England; [Tree, Timothy] Kings Coll London, London, England	University of London; University College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of British Columbia; Universidad de Concepcion; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Reading, JL (corresponding author), UCL, Res Dept Haematol, Canc Immunol Unit, Canc Inst, London, England.; Reading, JL; Tree, T (corresponding author), Kings Coll London, Sch Immunol & Microbial Sci, Peter Gorer Dept Immunobiol, London, England.; Reading, JL (corresponding author), Kings Coll London, Guys Hosp, Dept Immunoregulat & Immune Int, London, England.; Roobrouck, VD (corresponding author), ReGenesys BV, Dept R&D, Leuven, Belgium.; Tree, T (corresponding author), Guys & St Thomas NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.; Tree, T (corresponding author), Kings Coll London, London, England.	j.reading@ucl.ac.uk; vroobrouck@regenesys.eu; timothy.tree@kcl.ac.uk		READING, JAMES/0000-0001-5381-978X	National Institute for Health Research (NIHR) Biomedical Research Centre based at Guys and St Thomas NHS Foundation Trust and Kings College London; NIHR Clinical Research Facility; T1DUK Consortium Mechanistic Core - Diabetes UK [15/0005232]	National Institute for Health Research (NIHR) Biomedical Research Centre based at Guys and St Thomas NHS Foundation Trust and Kings College London(General Electric); NIHR Clinical Research Facility; T1DUK Consortium Mechanistic Core - Diabetes UK	This research was funded/supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guys and St Thomas NHS Foundation Trust and Kings College London and/or the NIHR Clinical Research Facility. Work at Kings College London was supported by T1DUK Consortium Mechanistic Core funded by a grant from Diabetes UK (Ref: 15/0005232).	Ali N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044219; Alissafi T, 2020, CELL METAB, V32, P591, DOI 10.1016/j.cmet.2020.07.001; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Arif S, 2004, J CLIN INVEST, V113, P451, DOI 10.1172/JCI200419585; Battaglia M, 2005, BLOOD, V105, P4743, DOI 10.1182/blood-2004-10-3932; Battaglia M, 2006, J IMMUNOL, V177, P8338, DOI 10.4049/jimmunol.177.12.8338; Bluestone JA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad4134; Boozer Sherry, 2009, J Stem Cells, V4, P17, DOI jsc.2009.4.1.17; Canavan JB, 2016, GUT, V65, P584, DOI 10.1136/gutjnl-2014-306919; Carty F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00645; Cook KW, 2014, GUT, V63, P1550, DOI 10.1136/gutjnl-2013-306253; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Donato M, 2013, GENOME RES, V23, P1885, DOI 10.1101/gr.153551.112; Draghici S, 2007, GENOME RES, V17, P1537, DOI 10.1101/gr.6202607; Elyahu Y, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw8330; Engel JA, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137990; Ferreira LMR, 2019, NAT REV DRUG DISCOV, V18, P749, DOI 10.1038/s41573-019-0041-4; Fraser H, 2018, MOL THER-METH CLIN D, V8, P198, DOI 10.1016/j.omtm.2018.01.006; Fritsche E, 2020, TRENDS BIOTECHNOL, V38, P1099, DOI 10.1016/j.tibtech.2019.12.009; Guo XY, 2018, NAT MED, V24, P978, DOI 10.1038/s41591-018-0045-3; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Harden PN, 2021, AM J TRANSPLANT, V21, P1603, DOI 10.1111/ajt.16395; Hess DC, 2011, CELL PROLIFERAT, V44, P1, DOI 10.1111/j.1365-2184.2010.00718.x; Hull CM, 2017, DIABETOLOGIA, V60, P1839, DOI 10.1007/s00125-017-4377-1; Hull CM, 2017, J AUTOIMMUN, V79, P63, DOI 10.1016/j.jaut.2017.01.001; Koizumi SI, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080939; Konkel JE, 2017, IMMUNITY, V46, P660, DOI 10.1016/j.immuni.2017.03.015; Li DY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02104; Li HJ, 2020, CELL, V181, P747, DOI 10.1016/j.cell.2020.04.017; MacDonald KN, 2019, CLIN EXP IMMUNOL, V197, P52, DOI 10.1111/cei.13297; Matos TR, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.570550; Maziarz RT, 2015, BIOL BLOOD MARROW TR, V21, P720, DOI 10.1016/j.bbmt.2014.12.025; Miragaia RJ, 2019, IMMUNITY, V50, P493, DOI 10.1016/j.immuni.2019.01.001; Novakovsky G., 2020, REPEATED STIMULATION, DOI [10.1101/2020.06.27.175158, DOI 10.1101/2020.06.27.175158]; Penn MS, 2012, CIRC RES, V110, P304, DOI 10.1161/CIRCRESAHA.111.253427; Raffin C, 2020, NAT REV IMMUNOL, V20, P158, DOI 10.1038/s41577-019-0232-6; Reading JL, 2015, MOL THER, V23, P1783, DOI 10.1038/mt.2015.131; Reading JL, 2013, J IMMUNOL, V190, P4542, DOI 10.4049/jimmunol.1202710; Reading JL, 2013, CURR OPIN ORGAN TRAN, V18, P59, DOI 10.1097/MOT.0b013e32835c2adf; Roep BO, 2014, NAT REV ENDOCRINOL, V10, P229, DOI 10.1038/nrendo.2014.2; Romano M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00043; Safinia N, 2016, ONCOTARGET, V7, P7563, DOI 10.18632/oncotarget.6927; Sakaguchi S, 2020, ANNU REV IMMUNOL, V38, P541, DOI 10.1146/annurev-immunol-042718-041717; Sanchez-Fueyo A, 2020, AM J TRANSPLANT, V20, P1125, DOI 10.1111/ajt.15700; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Soeder Y, 2015, STEM CELL TRANSL MED, V4, P899, DOI 10.5966/sctm.2015-0002; Strauss L, 2007, J IMMUNOL, V178, P320, DOI 10.4049/jimmunol.178.1.320; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Tarca AL, 2009, BIOINFORMATICS, V25, P75, DOI 10.1093/bioinformatics/btn577; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Valentin-Torres A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-93025-x; Voskens CJ, 2017, INFLAMM BOWEL DIS, V23, P348, DOI 10.1097/MIB.0000000000001192; Zeng H, 2013, NATURE, V499, P485, DOI 10.1038/nature12297	54	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 1	2021	12								716606	10.3389/fimmu.2021.716606	http://dx.doi.org/10.3389/fimmu.2021.716606			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UR1XX	34539651	Green Published, gold, Green Submitted			2022-12-18	WOS:000696549500001
J	Heusler, M; Einenkel, R; Ehrhardt, J; Muzzio, DO; Zygmunt, M				Heusler, Martha; Einenkel, Rebekka; Ehrhardt, Jens; Muzzio, Damian Oscar; Zygmunt, Marek			Low Abundance Fusobacterium Nucleatum Supports Early Pregnancy Development - An In Vitro Study	FRONTIERS IN IMMUNOLOGY			English	Article						microbiome; pregnancy; trophoblast; Fusobacterium nucleatum; HTR8; SVneo; BeWo; JEG-3	POTENTIATES INTESTINAL TUMORIGENESIS; ESCHERICHIA-COLI LIPOPOLYSACCHARIDE; E-CADHERIN; INTRAUTERINE INFUSION; PRETERM LABOR; TROPHOBLAST; INVASION; PROMOTES; CELLS; EXPRESSION	Pregnancy success depends greatly on a balanced immune homeostasis. The detection of bacterial components in the upper reproductive tract in non-pregnant and pregnant women raised questions on its possible beneficial role in reproductive health. The local conditions that allow the presence of bacteria to harmonize with the establishment of pregnancy are still unknown. Among the described bacterial species in endometrial and placental samples, Fusobacterium nucleatum was found. It has been observed that F. nucleatum can induce tumorigenesis in colon carcinoma, a process that shares several features with embryo implantation. We propose that low concentrations of F. nucleatum may improve trophoblast function without exerting destructive responses. Inactivated F. nucleatum and E. coli were incubated with the trophoblastic cell lines HTR8/SVneo, BeWo, and JEG-3. Viability, proliferation, migratory capacity, invasiveness and the secretion of chemokines, other cytokines and matrix metalloproteinases were assessed. The presence of F. nucleatum significantly induced HTR8/SVneo invasion, accompanied by the secretion of soluble mediators (CXCL1, IL-6 and IL-8) and metalloproteinases (MMP-2 and MMP-9). However, as concentrations of F. nucleatum increased, these did not improve invasiveness, hindered migration, reduced cell viability and induced alterations in the cell cycle. Part of the F. nucleatum effects on cytokine release were reverted with the addition of a TLR4 blocking antibody. Other effects correlated with the level of expression of E-cadherin on the different cell lines tested. Low amounts of F. nucleatum promote invasion of HTR8/SVneo cells and induce the secretion of important mediators for pregnancy establishment. Some effects were independent of LPS and correlated with the expression of E-cadherin on trophoblasts.	[Heusler, Martha; Einenkel, Rebekka; Ehrhardt, Jens; Muzzio, Damian Oscar; Zygmunt, Marek] Univ Greifswald, Dept Obstet & Gynecol, Greifswald, Germany	Ernst Moritz Arndt Universitat Greifswald	Muzzio, DO (corresponding author), Univ Greifswald, Dept Obstet & Gynecol, Greifswald, Germany.	Damian.Muzzio@med.uni-greifswald.de		Muzzio, Damian/0000-0002-9963-8551	Greifswald University; Research Network Molecular Medicine (Forschungsverbund Molekulare Medizin) [FOVB-2021-10]	Greifswald University; Research Network Molecular Medicine (Forschungsverbund Molekulare Medizin)	This study was supported by intramural funding from Greifswald University. We also acknowledge the support of the Research Network Molecular Medicine (Forschungsverbund Molekulare Medizin, FVMM, FOVB-2021-10).	Aagaard K, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008599; Abed J, 2016, CELL HOST MICROBE, V20, P215, DOI 10.1016/j.chom.2016.07.006; Abrahams VM, 2004, J IMMUNOL, V173, P4286, DOI 10.4049/jimmunol.173.7.4286; Aldo P, 2016, AM J REPROD IMMUNOL, V76, P348, DOI 10.1111/aji.12578; Baker JM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00208; Bashir A, 2015, EUR J CANCER PREV, V24, P373, DOI 10.1097/CEJ.0000000000000116; Beijar ECE, 2006, PLACENTA, V27, P322, DOI 10.1016/j.placenta.2004.12.012; BIRCHMEIER W, 1995, CIBA F SYMP, V189, P124; Bolstad AI, 1996, CLIN MICROBIOL REV, V9, P55, DOI 10.1128/CMR.9.1.55; Bowes Watson A, 2009, F1000 Med Rep, V1, DOI 10.3410/M1-22; Brundin M, 2015, INT ENDOD J, V48, P37, DOI 10.1111/iej.12273; Cao B, 2014, PLACENTA, V35, P139, DOI 10.1016/j.placenta.2013.12.007; Cardenas I, 2011, AM J REPROD IMMUNOL, V65, P110, DOI 10.1111/j.1600-0897.2010.00908.x; Collado MC, 2016, SCI REP-UK, V6, DOI 10.1038/srep23129; Castellarin M, 2012, GENOME RES, V22, P299, DOI 10.1101/gr.126516.111; Chan E, 2019, PATHOLOGY, V51, P320, DOI 10.1016/j.pathol.2018.11.013; Chen T, 2018, CANCER IMMUNOL IMMUN, V67, P1635, DOI 10.1007/s00262-018-2233-x; Chua CLL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.621382; Cicinelli E, 2009, GYNECOL OBSTET INVES, V68, P108, DOI 10.1159/000223819; Clemente JC, 2012, CELL, V148, P1258, DOI 10.1016/j.cell.2012.01.035; de Goffau MC, 2019, NATURE, V572, P329, DOI 10.1038/s41586-019-1451-5; Demuth DR, 1996, INFECT IMMUN, V64, P1335, DOI 10.1128/IAI.64.4.1335-1341.1996; Einenkel R, 2020, REPRODUCTION, V160, P155, DOI 10.1530/REP-19-0554; Einenkel R, 2019, REPRODUCTION, V158, P323, DOI 10.1530/REP-19-0171; Einenkel R, 2019, REPROD BIOL, V19, P113, DOI 10.1016/j.repbio.2019.04.001; Erlebacher A, 2013, ANNU REV IMMUNOL, V31, P387, DOI 10.1146/annurev-immunol-032712-100003; Fest S, 2007, AM J REPROD IMMUNOL, V57, P55, DOI 10.1111/j.1600-0897.2006.00446.x; Floridon C, 2000, MOL HUM REPROD, V6, P943, DOI 10.1093/molehr/6.10.943; Frohlich C, 2020, REPRODUCTION, V159, P351, DOI 10.1530/REP-19-0407; GARCIA AGP, 1985, PLACENTA, V6, P281, DOI 10.1016/S0143-4004(85)80038-2; Garcia-So J, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125436; Gauthier S, 2011, J MATERN-FETAL NEO M, V24, P1329, DOI 10.3109/14767058.2010.550977; Gendron R, 2004, INFECT IMMUN, V72, P6160, DOI 10.1128/IAI.72.10.6160-6163.2004; Ghosh SK, 2011, INFECT IMMUN, V79, P4578, DOI 10.1128/IAI.05586-11; Goodrich JK, 2014, CELL, V159, P789, DOI 10.1016/j.cell.2014.09.053; Grasso E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097147; Grenier D, 2006, ORAL MICROBIOL IMMUN, V21, P190, DOI 10.1111/j.1399-302X.2006.00278.x; Gur C, 2015, IMMUNITY, V42, P344, DOI 10.1016/j.immuni.2015.01.010; Gursoy UK, 2008, ORAL MICROBIOL IMMUN, V23, P432, DOI 10.1111/j.1399-302X.2008.00453.x; Haake SK, 1997, J PERIODONTOL, V68, P39, DOI 10.1902/jop.1997.68.1.39; Han YPW, 2010, OBSTET GYNECOL, V115, P442, DOI 10.1097/AOG.0b013e3181cb9955; Han YPW, 2004, INFECT IMMUN, V72, P2272, DOI 10.1128/IAI.72.4.2272-2279.2004; Holmlund U, 2002, IMMUNOLOGY, V107, P145, DOI 10.1046/j.1365-2567.2002.01491.x; Holtan SG, 2009, MAYO CLIN PROC, V84, P985, DOI 10.1016/S0025-6196(11)60669-1; Hounkonnou CPA, 2020, CLIN INFECT DIS, V71, P166, DOI 10.1093/cid/ciz748; Hu LJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.658681; Ikegami A, 2009, INFECT IMMUN, V77, P3075, DOI 10.1128/IAI.00209-09; Jensen F, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.110791; Jimenez E, 2005, CURR MICROBIOL, V51, P270, DOI 10.1007/s00284-005-0020-3; Kang WY, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00429; Koh YQ, 2014, EUR J OBSTET GYN R B, V175, P129, DOI 10.1016/j.ejogrb.2013.12.032; Kokkinos MI, 2010, PLACENTA, V31, P747, DOI 10.1016/j.placenta.2010.06.017; Kong C, 2021, CANCER RES, V81, P4485, DOI 10.1158/0008-5472.CAN-21-0453; Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007; Kuperman A, 2020, BJOG-INT J OBSTET GY, V127, P159, DOI 10.1111/1471-0528.15896; Lauder AP, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0172-3; Lima PDA, 2014, CELL MOL IMMUNOL, V11, P522, DOI 10.1038/cmi.2014.63; Liu HQ, 2007, J IMMUNOL, V179, P2501, DOI 10.4049/jimmunol.179.4.2501; Ma CT, 2018, ONCOL LETT, V16, P2606, DOI 10.3892/ol.2018.8947; Madan JC, 2016, JAMA PEDIATR, V170, P212, DOI 10.1001/jamapediatrics.2015.3732; Mahtout H, 2011, J PERIODONTOL, V82, P311, DOI 10.1902/jop.2010.100458; MANGAN DF, 1984, INFECT IMMUN, V46, P332, DOI 10.1128/IAI.46.2.332-339.1984; Martin R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158498; Mbakwa CA, 2016, J PEDIATR-US, V176, P105, DOI 10.1016/j.jpeds.2016.06.015; Mor Gil, 2003, Reprod Biol Endocrinol, V1, P119, DOI 10.1186/1477-7827-1-119; Mor G, 2015, AM J OBSTET GYNECOL, V213, pS131, DOI 10.1016/j.ajog.2015.06.039; Mor G, 2010, AM J REPROD IMMUNOL, V63, P425, DOI 10.1111/j.1600-0897.2010.00836.x; Moraes JGN, 2017, J DAIRY SCI, V100, P4772, DOI 10.3168/jds.2016-11630; Moraes JGN, 2017, J DAIRY SCI, V100, P4784, DOI 10.3168/jds.2016-11643; Muzzio D, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00039; Muzzio DO, 2016, REPRODUCTION, V151, P29, DOI 10.1530/REP-15-0274; Muzzio DO, 2014, BIOL REPROD, V91, DOI 10.1095/biolreprod.114.122366; Ndam NT, 2018, CLIN INFECT DIS, V67, P1890, DOI 10.1093/cid/ciy380; Nikolov A, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11030480; Nosho K, 2016, WORLD J GASTROENTERO, V22, P557, DOI 10.3748/wjg.v22.i2.557; Packhauser KRH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00486; Parnell LA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11514-4; Pelzer Elise S, 2018, Oncotarget, V9, P21541, DOI 10.18632/oncotarget.25059; Petrova YI, 2016, MOL BIOL CELL, V27, P3233, DOI 10.1091/mbc.E16-01-0058; Pollheimer J, 2006, AM J PATHOL, V168, P1134, DOI 10.2353/ajpath.2006.050686; PrabhuDas M, 2015, NAT IMMUNOL, V16, P328, DOI 10.1038/ni.3131; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Robertson SA, 2014, INT J DEV BIOL, V58, P205, DOI 10.1387/ijdb.140096sr; Romero R, 2014, SCIENCE, V345, P760, DOI 10.1126/science.1251816; Rubinstein MR, 2019, EMBO REP, V20, DOI 10.15252/embr.201847638; Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012; Sayed IM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9091980; Seferovic MD, 2019, AM J OBSTET GYNECOL, V221, DOI 10.1016/j.ajog.2019.04.036; Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533; SHENKER BJ, 1995, INFECT IMMUN, V63, P4830, DOI 10.1128/IAI.63.12.4830-4836.1995; SHENKER BJ, 1984, J IMMUNOL, V132, P2357; Shi YC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21657-7; Stinson LF, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01124; Stockham S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120050; Stout MJ, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2013.01.018; Tang B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165701; Theis KR, 2019, AM J OBSTET GYNECOL, V220, DOI 10.1016/j.ajog.2018.10.018; TUTTLE RS, 1990, J PERIODONTAL RES, V25, P364, DOI 10.1111/j.1600-0765.1990.tb00929.x; Uitto VJ, 2005, INFECT IMMUN, V73, P1171, DOI 10.1128/IAI.73.2.1171-1179.2005; Vander Haar EL, 2018, ANAEROBE, V50, P55, DOI 10.1016/j.anaerobe.2018.01.008; Walker RW, 2017, PEDIATR OBES, V12, P3, DOI 10.1111/ijpo.12217; Wallace AE, 2012, HUM REPROD UPDATE, V18, P458, DOI 10.1093/humupd/dms015; WATSON JV, 1987, CYTOMETRY, V8, P1, DOI 10.1002/cyto.990080101; Wong SHM, 2018, CRIT REV ONCOL HEMAT, V121, P11, DOI 10.1016/j.critrevonc.2017.11.010; Wu YX, 2018, DIGEST DIS SCI, V63, P1210, DOI 10.1007/s10620-018-4999-2; Yoshida T, 2021, PLACENTA, V111, P76, DOI 10.1016/j.placenta.2021.06.006; Younge N, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127806; Yu B., 2020, GYNECOL ONCOL, V156, pE26, DOI [10.1016/j.ygyno.2019.11.085, DOI 10.1016/J.YGYNO.2019.11.085]; Zhou B, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38031-2; Zygmunt M, 2003, EUR J OBSTET GYN R B, V110, pS10, DOI 10.1016/S0301-2115(03)00168-4	110	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 31	2021	12								698045	10.3389/fimmu.2021.698045	http://dx.doi.org/10.3389/fimmu.2021.698045			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UT9SF	34531854	Green Published, gold			2022-12-18	WOS:000698446900001
J	Liu, XS; Zhou, LM; Yuan, LL; Gao, Y; Kui, XY; Liu, XY; Pei, ZJ				Liu, Xu-Sheng; Zhou, Lu-Meng; Yuan, Ling-Ling; Gao, Yan; Kui, Xue-Yan; Liu, Xiao-Yu; Pei, Zhi-Jun			NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis	FRONTIERS IN IMMUNOLOGY			English	Correction						NPM1; lung adenocarcinoma; immune infiltration; m6A modification; glycolysis			[Liu, Xu-Sheng; Gao, Yan; Kui, Xue-Yan; Liu, Xiao-Yu; Pei, Zhi-Jun] Hubei Univ Med, Dept Nucl Med, Shiyan, Peoples R China; [Liu, Xu-Sheng; Gao, Yan; Kui, Xue-Yan; Liu, Xiao-Yu; Pei, Zhi-Jun] Hubei Univ Med, Inst Anesthesiol & Pain, Taihe Hosp, Shiyan, Peoples R China; [Liu, Xu-Sheng; Pei, Zhi-Jun] Hubei Key Lab Embryon Stem Cell Res, Shiyan, Peoples R China; [Zhou, Lu-Meng] Huanggang Cent Hosp, Dept Nucl Med, Huanggang, Peoples R China; [Yuan, Ling-Ling] Hubei Univ Med, Taihe Hosp, Dept Pathol, Shiyan, Peoples R China	Hubei University of Medicine; Hubei University of Medicine; Hubei University of Medicine	Pei, ZJ (corresponding author), Hubei Univ Med, Dept Nucl Med, Shiyan, Peoples R China.; Pei, ZJ (corresponding author), Hubei Univ Med, Inst Anesthesiol & Pain, Taihe Hosp, Shiyan, Peoples R China.; Pei, ZJ (corresponding author), Hubei Key Lab Embryon Stem Cell Res, Shiyan, Peoples R China.	pzjzml1980@taihehospital.com	Liu, Xu-Sheng/AAM-8320-2021	Liu, Xu-Sheng/0000-0002-3663-1096					0	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 31	2021	12								751004	10.3389/fimmu.2021.751004	http://dx.doi.org/10.3389/fimmu.2021.751004			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU2YK	34531879	Green Published, gold			2022-12-18	WOS:000698666700001
J	Rais, A; Mekki, N; Fedhila, F; Alosaimi, MF; Ben Khaled, M; Zameli, A; Agrebi, N; Sellami, MK; Geha, R; Ben-Mustapha, I; Barbouche, MR				Rais, Afef; Mekki, Najla; Fedhila, Faten; Alosaimi, Mohammed Faraj; Ben Khaled, Monia; Zameli, Amal; Agrebi, Nourhen; Sellami, Maryam Kallel; Geha, Raif; Ben-Mustapha, Imen; Barbouche, Mohamed-Ridha			Case Report: FOXP3 Mutation in a Patient Presenting With ALPS	FRONTIERS IN IMMUNOLOGY			English	Article						FOXP3; IPEX; ALPS; NGS; inborn errors of immunity	SYNDROME-LIKE DISEASE; NEGATIVE T-CELLS; LYMPHOCYTE APOPTOSIS; AUTOIMMUNE; CLASSIFICATION; MARKERS; NAIVE	ALPS and IPEX are two well-characterized inborn errors of immunity with immune dysregulation, considered as two master models of monogenic auto-immune diseases. Thus, with autoimmunity as their primary clinical manifestation, these two entities may show clinical overlap. Traditionally, immunological biomarkers are used to establish an accurate differential diagnosis. Herein, we describe a patient who presented with clinical features and biomarkers fulfilling the diagnostic criteria of ALPS. Severe apoptotic defect was also shown in the patient's cell lines and PHA-activated peripheral blood lymphocytes. Sanger sequencing of the FAS gene did not reveal any causal mutation. NGS screening revealed a novel deleterious variant located in the N terminal repressor domain of FOXP3 but no mutations in the FAS pathway-related genes. TEMRA cells (terminally differentiated effector memory cells re-expressing CD45RA) and PD1 expression were increased arguing in favor of T-cell exhaustion, which could be induced by unrestrained activation of T effector cells because of Treg deficiency. Moreover, defective FOXP3 observed in the patient could intrinsically induce increased proliferation and resistance to apoptosis in T effector cells. This observation expands the spectrum of FOXP3 deficiency and underscores the role of NGS in detecting mutations that induce overlapping phenotypes among inborn errors of immunity with immune dysregulation. In addition, these findings suggest a potential link between FOXP3 and FAS pathways.	[Rais, Afef; Mekki, Najla; Zameli, Amal; Agrebi, Nourhen; Ben-Mustapha, Imen; Barbouche, Mohamed-Ridha] Inst Pasteur Tunis, Lab Transmiss Control & Immunobiol Infect LR11IPT, Tunis, Tunisia; [Rais, Afef; Mekki, Najla; Fedhila, Faten; Ben Khaled, Monia; Sellami, Maryam Kallel; Ben-Mustapha, Imen; Barbouche, Mohamed-Ridha] Univ Tunis El Manar, Fac Med, Tunis, Tunisia; [Rais, Afef; Mekki, Najla; Fedhila, Faten; Ben Khaled, Monia; Zameli, Amal; Agrebi, Nourhen; Sellami, Maryam Kallel; Ben-Mustapha, Imen; Barbouche, Mohamed-Ridha] Univ Tunis El Manar, Tunis, Tunisia; [Fedhila, Faten] Childrens Hosp, Dept Pediat A, Tunis, Tunisia; [Alosaimi, Mohammed Faraj] King Saud Univ, Coll Med, Dept Pediat, Riyadh, Saudi Arabia; [Ben Khaled, Monia] Bone Marrow Transplantat Ctr Tunis, Pediat Immunohematol Unit, Tunis, Tunisia; [Sellami, Maryam Kallel] La Rabta Univ Hosp, Dept Immunol, Tunis, Tunisia; [Geha, Raif] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA	Le Reseau International des Instituts Pasteur (RIIP); Universite de Tunis-El-Manar; Institut Pasteur Tunis; Universite de Tunis-El-Manar; Faculte de Medecine de Tunis (FMT); Universite de Tunis-El-Manar; Universite de Tunis-El-Manar; Hopital d'Enfants; King Saud University; Universite de Tunis-El-Manar; Centre Nationale de Greffe de la Moelle Osseuse; Universite de Tunis-El-Manar; Hopital La Rabta; Harvard University; Boston Children's Hospital; Harvard Medical School	Ben-Mustapha, I (corresponding author), Inst Pasteur Tunis, Lab Transmiss Control & Immunobiol Infect LR11IPT, Tunis, Tunisia.; Ben-Mustapha, I (corresponding author), Univ Tunis El Manar, Fac Med, Tunis, Tunisia.; Ben-Mustapha, I (corresponding author), Univ Tunis El Manar, Tunis, Tunisia.	imen.benmustapha@pasteur.rns.tn		MEKKI, NAJLA/0000-0002-5842-9147	Tunisian ministry of higher education and research	Tunisian ministry of higher education and research	This work was supported by the Tunisian ministry of higher education and research.	Bacchetta R, 2018, ANN NY ACAD SCI, V1417, P5, DOI 10.1111/nyas.13011; Barzaghi F, 2018, J ALLERGY CLIN IMMUN, V141, P1036, DOI 10.1016/j.jaci.2017.10.041; Bousfiha A, 2018, J CLIN IMMUNOL, V38, P129, DOI 10.1007/s10875-017-0465-8; Butt D, 2015, IMMUNITY, V42, P890, DOI 10.1016/j.immuni.2015.04.010; Cagdas D, 2019, J CLIN IMMUNOL, V39, P726, DOI 10.1007/s10875-019-00677-6; Caminha I, 2010, J ALLERGY CLIN IMMUN, V125, P946, DOI 10.1016/j.jaci.2009.12.983; Cepika AM, 2018, J ALLERGY CLIN IMMUN, V142, P1679, DOI 10.1016/j.jaci.2018.10.026; Chandrakasan S, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27619; Consonni F, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.643094; Crispin JC, 2008, J IMMUNOL, V181, P8761, DOI 10.4049/jimmunol.181.12.8761; Deng GP, 2012, EXP MOL PATHOL, V93, P334, DOI 10.1016/j.yexmp.2012.09.013; El-Sayed ZA, 2018, MOD RHEUMATOL, V28, P654, DOI 10.1080/14397595.2017.1377146; Gambineri E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02411; Gambineri Eleonora, 2008, J Allergy Clin Immunol, V122, P1105, DOI 10.1016/j.jaci.2008.09.027; Gupta S, 2008, EXP GERONTOL, V43, P266, DOI 10.1016/j.exger.2007.12.006; Jamee M, 2020, J ALLER CL IMM-PRACT, V8, P2747, DOI 10.1016/j.jaip.2020.04.070; Kasprowicz DJ, 2005, EUR J IMMUNOL, V35, P3424, DOI 10.1002/eji.200526339; Kim YJ, 2007, AM J HEMATOL, V82, P615, DOI 10.1002/ajh.20851; Larbi A, 2014, CYTOM PART A, V85A, P25, DOI 10.1002/cyto.a.22351; Magerus-Chatinet A, 2009, BLOOD, V113, P3027, DOI 10.1182/blood-2008-09-179630; Magg T, 2012, EUR J IMMUNOL, V42, P1627, DOI 10.1002/eji.201141838; Mailer RKW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00530; Matson DR, 2020, ARCH PATHOL LAB MED, V144, P245, DOI 10.5858/arpa.2018-0190-RS; Molnar E, 2020, BLOOD, V136, P1933, DOI 10.1182/blood.2020005486; Nabhani S, 2017, CLIN IMMUNOL, V181, P32, DOI 10.1016/j.clim.2017.05.021; Oliveira JB, 2010, BLOOD, V116, pE35, DOI 10.1182/blood-2010-04-280347; Oliveira JB, 2013, CURR OPIN PEDIATR, V25, P722, DOI 10.1097/MOP.0000000000000032; Pangrazzi L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00715; Price S, 2014, BLOOD, V123, P1989, DOI 10.1182/blood-2013-10-535393; Revel-Vilk S, 2015, CLIN IMMUNOL, V159, P84, DOI 10.1016/j.clim.2015.04.007; Sayar E, 2014, PEDIAT ALLERG IMM-UK, V25, P601, DOI 10.1111/pai.12219; Seidel MG, 2019, J ALLER CL IMM-PRACT, V7, P1763, DOI 10.1016/j.jaip.2019.02.004; Seidel MG, 2014, BLOOD, V124, P2337, DOI 10.1182/blood-2014-06-583260; Straus SE, 1999, ANN INTERN MED, V130, P591, DOI 10.7326/0003-4819-130-7-199904060-00020; Takagi M, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26831; Tan QKG., 2004, GENEREVIEWS; Tarbox JA, 2014, J CLIN IMMUNOL, V34, P594, DOI 10.1007/s10875-014-0038-z; Wallace JG, 2021, J ALLERGY CLIN IMMUN, V147, P743, DOI 10.1016/j.jaci.2020.06.019; Weekes MP, 1999, IMMUNOLOGY, V98, P443, DOI 10.1046/j.1365-2567.1999.00901.x; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035	40	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 31	2021	12								692107	10.3389/fimmu.2021.692107	http://dx.doi.org/10.3389/fimmu.2021.692107			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UT2LI	34531853	Green Published, gold			2022-12-18	WOS:000697952200001
J	Yang, G; Van Kaer, L				Yang, Guan; Van Kaer, Luc			Therapeutic Targeting of Immune Cell Autophagy in Multiple Sclerosis: Russian Roulette or Silver Bullet?	FRONTIERS IN IMMUNOLOGY			English	Review						multiple sclerosis; experimental autoimmune encephalomyelitis (EAE); autophagy; LC3-associated phagocytosis (LAP); immune cells; therapy	DENDRITIC CELLS; AUTOIMMUNE ENCEPHALOMYELITIS; KINASE VPS34; INFLAMMATION; HOMEOSTASIS; NEUROINFLAMMATION; MODULATION; EXPRESSION; CLEARANCE; TOLERANCE	Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) in which the immune system damages the protective insulation surrounding nerve fibers that project from neurons. The pathological hallmark of MS is multiple areas of myelin loss accompanied by inflammation within the CNS, resulting in loss of cognitive function that ultimately leads to paralysis. Recent studies in MS have focused on autophagy, a cellular self-eating process, as a potential target for MS treatment. Here, we review the contribution of immune cell autophagy to the pathogenesis of experimental autoimmune encephalomyelitis (EAE), the prototypic animal model of MS. A better understanding of the role of autophagy in different immune cells to EAE might inform the development of novel therapeutic approaches in MS and other autoimmune and inflammatory diseases.</p>	[Yang, Guan; Van Kaer, Luc] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA	Vanderbilt University	Yang, G; Van Kaer, L (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA.	gyang25@city.edu.hk; luc.van.kaer@vumc.org		YANG, Guan/0000-0002-2131-8435	NIH [AI139046]; National Multiple Sclerosis Society [60006625]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Multiple Sclerosis Society(National Multiple Sclerosis Society)	Work in the authors lab was supported by grants from the NIH (AI139046 to LVK) and the National Multiple Sclerosis Society (60006625 to LVK).	Alirezaei M, 2009, AUTOPHAGY, V5, P152, DOI 10.4161/auto.5.2.7348; Alissafi T, 2017, J CLIN INVEST, V127, P2789, DOI 10.1172/JCI92079; Amersfoort J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02937; Bagherpour B, 2018, MULT SCLER RELAT DIS, V26, P40, DOI 10.1016/j.msard.2018.08.009; Berglund R, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb5077; Bhattacharya A, 2015, CELL REP, V12, P1731, DOI 10.1016/j.celrep.2015.08.019; Bhattacharya A, 2014, J BIOL CHEM, V289, P26525, DOI 10.1074/jbc.M114.575860; Bonam SR, 2018, J AUTOIMMUN, V94, P16, DOI 10.1016/j.jaut.2018.08.009; Brooks CR, 2015, EMBO J, V34, P2441, DOI 10.15252/embj.201489838; Cachat J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01555; Caton ML, 2007, J EXP MED, V204, P1653, DOI 10.1084/jem.20062648; Chen X, 2014, J BIOL CHEM, V289, P11162, DOI 10.1074/jbc.M113.531855; Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069; Corti O, 2020, J NEUROCHEM, V154, P354, DOI 10.1111/jnc.15002; Jordao MJC, 2019, SCIENCE, V363, P365, DOI 10.1126/science.aat7554; Dang SP, 2014, AUTOPHAGY, V10, P1301, DOI 10.4161/auto.28771; Deretic V, 2018, AUTOPHAGY, V14, P179, DOI 10.1080/15548627.2017.1412229; Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532; Dong YF, 2019, NAT REV NEUROL, V15, P704, DOI 10.1038/s41582-019-0253-6; Esposito M, 2010, J NEUROIMMUNOL, V220, P52, DOI 10.1016/j.jneuroim.2010.01.001; Filippi M., 2018, NAT REV DIS PRIMERS, V4, P43, DOI [10.1038/s41572-018-0041-4, DOI 10.1038/s41572-018-0041-4, DOI 10.1038/S41572-018-0041-4]; Galluzzi L, 2019, CELL, V177, P1682, DOI 10.1016/j.cell.2019.05.026; Germic N, 2019, CELL DEATH DIFFER, V26, P715, DOI 10.1038/s41418-019-0297-6; Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697; Goverman J, 2009, NAT REV IMMUNOL, V9, P393, DOI 10.1038/nri2550; Hohlfeldt R, 2017, J IMMUNOL, V198, P3381, DOI 10.4049/jimmunol.1700346; Igci M, 2016, GENE, V588, P38, DOI 10.1016/j.gene.2016.04.042; Ireland JM, 2011, J EXP MED, V208, P2625, DOI 10.1084/jem.20110640; Isaksson M, 2009, EUR J IMMUNOL, V39, P2925, DOI 10.1002/eji.200839179; Kanayama M, 2016, INT IMMUNOL, V28, P463, DOI 10.1093/intimm/dxw013; Kandadai KS, 2021, AUTOPHAGY, V17, P3566, DOI 10.1080/15548627.2021.1883880; Keller CW, 2021, AUTOPHAGY, V17, P1244, DOI 10.1080/15548627.2020.1756678; Keller CW, 2017, P NATL ACAD SCI USA, V114, pE11228, DOI 10.1073/pnas.1713664114; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Kocak M, 2022, AUTOPHAGY, V18, P473, DOI 10.1080/15548627.2021.1936359; Kotsias F, 2013, ANTIOXID REDOX SIGN, V18, P714, DOI 10.1089/ars.2012.4557; Kovacs JR, 2012, CELL DEATH DIFFER, V19, P144, DOI 10.1038/cdd.2011.78; Levesque SA, 2016, J EXP MED, V213, P929, DOI 10.1084/jem.20151437; Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Li Y, 2019, AUTOPHAGY, V15, P478, DOI 10.1080/15548627.2018.1522467; Lisi L, 2012, J NEUROIMMUNOL, V243, P43, DOI 10.1016/j.jneuroim.2011.12.018; Martinez J., 2021, AUTOPHAGY, P1, DOI [10.1080/15548627.2021.1922051, DOI 10.1080/15548627.2021.1922051]; McGinley MP, 2021, JAMA-J AM MED ASSOC, V325, P765, DOI 10.1001/jama.2020.26858; McLeod IX, 2011, J IMMUNOL, V187, P5051, DOI 10.4049/jimmunol.1100710; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Mocholi E, 2018, CELL REP, V24, P1136, DOI 10.1016/j.celrep.2018.06.065; Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169; Parekh VV, 2013, J IMMUNOL, V190, P5086, DOI 10.4049/jimmunol.1202071; Patergnani S, 2018, J NEUROL NEUROSUR PS, V89, P439, DOI 10.1136/jnnp-2017-316234; Pei B, 2015, J IMMUNOL, V194, P5872, DOI 10.4049/jimmunol.1402154; Pendyala S, 2009, ANTIOXID REDOX SIGN, V11, P747, DOI [10.1089/ars.2008.2203, 10.1089/ARS.2008.2203]; Piehl F, 2021, J INTERN MED, V289, P771, DOI 10.1111/joim.13215; Pua HH, 2009, J IMMUNOL, V182, P4046, DOI 10.4049/jimmunol.0801143; Rangachari M, 2013, J AUTOIMMUN, V45, P31, DOI 10.1016/j.jaut.2013.06.008; Rumble JM, 2015, J EXP MED, V212, P23, DOI 10.1084/jem.20141015; Shao BZ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00553; Shi JY, 2018, METHODS MOL BIOL, V1784, P263, DOI 10.1007/978-1-4939-7837-3_24; Sospedra M, 2005, ANNU REV IMMUNOL, V23, P683, DOI 10.1146/annurev.immunol.23.021704.115707; Steinman L, 2006, ANN NEUROL, V60, P12, DOI 10.1002/ana.20913; Steinman L, 2019, CURR OPIN IMMUNOL, V61, P46, DOI 10.1016/j.coi.2019.07.011; Su P, 2016, NEUROSCIENCE, V319, P155, DOI 10.1016/j.neuroscience.2016.01.035; Thome R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065913; Thompson AJ, 2018, LANCET, V391, P1622, DOI 10.1016/S0140-6736(18)30481-1; Thurston TLM, 2012, NATURE, V482, P414, DOI 10.1038/nature10744; Touyz RM, 2005, HYPERTENSION, V45, P530, DOI 10.1161/01.HYP.0000158845.49943.5e; Van Kaer L, 2019, CELL MOL IMMUNOL, V16, P531, DOI 10.1038/s41423-019-0221-5; Wang JY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00286; Wieghofer P, 2016, BBA-MOL BASIS DIS, V1862, P299, DOI 10.1016/j.bbadis.2015.09.019; Willinger T, 2012, P NATL ACAD SCI USA, V109, P8670, DOI 10.1073/pnas.1205305109; Winkelmann A, 2016, NAT REV NEUROL, V12, P217, DOI 10.1038/nrneurol.2016.21; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Yang G, 2021, CELL MOL IMMUNOL, V18, P2024, DOI 10.1038/s41423-020-00589-1; Yang G, 2021, AUTOPHAGY, V17, P1193, DOI 10.1080/15548627.2020.1752979; Yang Y, 2020, CELL DEATH DIFFER, V27, P858, DOI 10.1038/s41418-019-0480-9; Yin H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01512; Yin LL, 2014, NEUROSCI LETT, V562, P34, DOI 10.1016/j.neulet.2013.12.070; Yogev N, 2012, IMMUNITY, V37, P264, DOI 10.1016/j.immuni.2012.05.025	79	1	1	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 31	2021	12								724108	10.3389/fimmu.2021.724108	http://dx.doi.org/10.3389/fimmu.2021.724108			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UT1FB	34531871	Green Published, gold			2022-12-18	WOS:000697868100001
J	Madhok, A; Bhat, SA; Philip, CS; Sureshbabu, SK; Chiplunkar, S; Galande, S				Madhok, Ayush; Bhat, Sajad Ahmad; Philip, Chinna Susan; Sureshbabu, Shalini Kashipathi; Chiplunkar, Shubhada; Galande, Sanjeev			Transcriptome Signature of V gamma 9V delta 2 T Cells Treated With Phosphoantigens and Notch Inhibitor Reveals Interplay Between TCR and Notch Signaling Pathways	FRONTIERS IN IMMUNOLOGY			English	Article						gamma delta T cells; transcriptome; gamma delta activation; HDMAPP; Notch signaling; TCR signaling; IPP	NONPEPTIDE ANTIGENS; DELTA; STIMULATION; RESPONSES; IMMUNOTHERAPY; ACTIVATION; INTERLEUKIN-2; INVOLVEMENT; ZOLEDRONATE; RECOGNITION	Gamma delta (gamma delta) T cells, especially the V gamma 9V delta 2 subtype, have been implicated in cancer therapy and thus have earned the spotlight in the past decade. Although one of the most important properties of gamma delta T cells is their activation by phosphoantigens, which are intermediates of the Mevalonate and Rohmer pathway of isoprenoid biosynthesis, such as IPP and HDMAPP, respectively, the global effects of such treatments on V gamma 9V delta 2 T cells remain elusive. Here, we used the high-throughput transcriptomics approach to elucidate the transcriptional changes in human V gamma 9V delta 2 T cells upon HDMAPP, IPP, and anti-CD3 treatments in combination with interleukin 2 (IL2) cytokine stimulation. These activation treatments exhibited a dramatic surge in transcription with distinctly enriched pathways. We further assessed the transcriptional dynamics upon inhibition of Notch signaling coupled with activation treatments. We observed that the metabolic processes are most affected upon Notch inhibition via GSI-X. The key effector genes involved in gamma-delta cytotoxic function were downregulated upon Notch blockade even in combination with activation treatment, suggesting a transcriptional crosstalk between T-cell receptor (TCR) signaling and Notch signaling in V gamma 9V delta 2 T cells. Collectively, we demonstrate the effect of the activation of TCR signaling by phosphoantigens or anti-CD3 on the transcriptional status of V gamma 9V delta 2 T cells along with IL2 stimulation. We further show that the blockade of Notch signaling antagonistically affects this activation.	[Madhok, Ayush; Galande, Sanjeev] Indian Inst Sci & Educ & Res IISER, Ctr Excellence Epigenet, Dept Biol, Pune, Maharashtra, India; [Bhat, Sajad Ahmad; Philip, Chinna Susan; Sureshbabu, Shalini Kashipathi; Chiplunkar, Shubhada] Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc ACTREC, Navi Mumbai, India; [Bhat, Sajad Ahmad; Philip, Chinna Susan; Sureshbabu, Shalini Kashipathi; Chiplunkar, Shubhada] Homi Bhabha Natl Inst HBNI, Mumbai, Maharashtra, India; [Galande, Sanjeev] Shiv Nadar Univ, Sch Nat Sci, Dept Life Sci, Greater Noida, India	Indian Institute of Science Education & Research (IISER) Pune; Tata Memorial Centre (TMC); Advance Centre for Treatment, Research & Education in Cancer (ACTREC); Tata Memorial Hospital; Homi Bhabha National Institute; Shiv Nadar University	Galande, S (corresponding author), Indian Inst Sci & Educ & Res IISER, Ctr Excellence Epigenet, Dept Biol, Pune, Maharashtra, India.; Chiplunkar, S (corresponding author), Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc ACTREC, Navi Mumbai, India.; Chiplunkar, S (corresponding author), Homi Bhabha Natl Inst HBNI, Mumbai, Maharashtra, India.; Galande, S (corresponding author), Shiv Nadar Univ, Sch Nat Sci, Dept Life Sci, Greater Noida, India.	shubhachiplunkar@gmail.com; sanjeev@iiserpune.ac.in		chiplunkar, shubhada/0000-0003-3421-0076	Unit of Excellence program of the Department of Biotechnology (DBT), Government of India [BT/MED/30/SP11288/2015]; JC Bose Fellowship from the Science and Engineering Research Board, Government of India [JCB/2019/000013]; Council of Scientific and Industrial Research, Government of India; Department of Biotechnology, Government of India; Department of Atomic Energy, Government of India	Unit of Excellence program of the Department of Biotechnology (DBT), Government of India; JC Bose Fellowship from the Science and Engineering Research Board, Government of India; Council of Scientific and Industrial Research, Government of India(Council of Scientific & Industrial Research (CSIR) - India); Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); Department of Atomic Energy, Government of India(Department of Atomic Energy (DAE))	This work was supported by a grant from the Unit of Excellence (BT/MED/30/SP11288/2015) program of the Department of Biotechnology (DBT), Government of India, to SC and SG. SG is a recipient of the JC Bose Fellowship (JCB/2019/000013) from the Science and Engineering Research Board, Government of India. AM is supported by a fellowship from the Council of Scientific and Industrial Research, Government of India. SB is supported by a fellowship from the Department of Biotechnology, Government of India. SKS is supported by fellowship from Department of Atomic Energy, Government of India.	Bennouna J, 2010, CANCER IMMUNOL IMMUN, V59, P1521, DOI 10.1007/s00262-010-0879-0; Bhat SA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01615; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Brandes M, 2003, BLOOD, V102, P3693, DOI 10.1182/blood-2003-04-1016; Brionne A, 2019, BIODATA MIN, V12, DOI 10.1186/s13040-019-0204-1; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; Carmona SJ, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1737369; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen Y, 2008, BLOOD, V111, P4220, DOI 10.1182/blood-2007-07-101691; Chiplunkar S, 2009, IMMUNOTHERAPY-UK, V1, P663, DOI [10.2217/IMT.09.27, 10.2217/imt.09.27]; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; Correia DV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005657; Dalessandri T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12080; Dar AA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00366; Dhar Swati, 2010, Cancer Immun, V10, P10; Dopfer EP, 2014, CELL REP, V7, P1704, DOI 10.1016/j.celrep.2014.04.049; Efremova M, 2020, ANNU REV IMMUNOL, V38, P727, DOI 10.1146/annurev-immunol-090419-020340; Fowler DW, 2015, CLIN EXP IMMUNOL, V180, P1, DOI 10.1111/cei.12564; Gogoi D, 2014, J IMMUNOL, V192, P2054, DOI 10.4049/jimmunol.1300369; Harly C, 2012, BLOOD, V120, P2269, DOI 10.1182/blood-2012-05-430470; HAYDAY AC, 1985, CELL, V40, P259, DOI 10.1016/0092-8674(85)90140-0; Hayday AC, 2000, ANNU REV IMMUNOL, V18, P975, DOI 10.1146/annurev.immunol.18.1.975; Helgeland H, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864-020-6755-1; Holtmeier Wolfgang, 2005, V86, P151, DOI 10.1159/000086659; Iwata A, 2017, NAT IMMUNOL, V18, P563, DOI 10.1038/ni.3714; Juraske C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01579; Kadivar M, 2016, J IMMUNOL, V197, P4584, DOI 10.4049/jimmunol.1601146; Karunakaran MM, 2020, IMMUNITY, V52, P487, DOI 10.1016/j.immuni.2020.02.014; Keerthivasan S, 2011, J IMMUNOL, V187, P692, DOI 10.4049/jimmunol.1003658; Kelliher MA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01718; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914; Kunzmann V, 2000, BLOOD, V96, P384; LANG F, 1995, J IMMUNOL, V154, P5986; Li HS, 2008, J IMMUNOL, V181, P7131, DOI 10.4049/jimmunol.181.10.7131; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Magen A, 2019, CELL REP, V29, P3019, DOI 10.1016/j.celrep.2019.10.131; Mattarollo SR, 2007, CANCER IMMUNOL IMMUN, V56, P1285, DOI 10.1007/s00262-007-0279-2; Meng X, 2011, LEUKEMIA, V25, P1135, DOI 10.1038/leu.2011.50; Meraviglia S, 2010, CLIN EXP IMMUNOL, V161, P290, DOI 10.1111/j.1365-2249.2010.04167.x; Miller BC, 2019, NAT IMMUNOL, V20, P326, DOI 10.1038/s41590-019-0312-6; Moens E, 2011, J LEUKOCYTE BIOL, V89, P743, DOI 10.1189/jlb.0910501; Morita CT, 2007, IMMUNOL REV, V215, P59, DOI 10.1111/j.1600-065X.2006.00479.x; Niu C, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0124-x; Papotto PH, 2017, EMBO REP, V18, P1957, DOI 10.15252/embr.201744200; Patta I, 2020, NUCLEIC ACIDS RES, V48, P5873, DOI 10.1093/nar/gkaa321; Peters C, 2016, P NATL ACAD SCI USA, V113, P12520, DOI 10.1073/pnas.1607136113; Pizzolato G, 2019, P NATL ACAD SCI USA, V116, P11906, DOI 10.1073/pnas.1818488116; Pont F, 2012, EUR J IMMUNOL, V42, P228, DOI 10.1002/eji.201141870; Powell JD, 2013, NAT IMMUNOL, V14, P422, DOI 10.1038/ni.2594; Ravens S, 2017, NAT IMMUNOL, V18, P393, DOI 10.1038/ni.3686; Ribot JC, 2014, J IMMUNOL, V192, P2237, DOI 10.4049/jimmunol.1303119; Ribot JC, 2012, J IMMUNOL, V189, P1202, DOI 10.4049/jimmunol.1200268; Rigau M, 2020, SCIENCE, V367, P642, DOI 10.1126/science.aay5516; Roh TY, 2006, P NATL ACAD SCI USA, V103, P15782, DOI 10.1073/pnas.0607617103; Ross SH, 2018, ANNU REV IMMUNOL, V36, P411, DOI 10.1146/annurev-immunol-042617-053352; Sandstrom A, 2014, IMMUNITY, V40, P490, DOI 10.1016/j.immuni.2014.03.003; Sebestyen Z, 2020, NAT REV DRUG DISCOV, V19, P169, DOI 10.1038/s41573-019-0038-z; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shibata K, 2011, BLOOD, V118, P586, DOI 10.1182/blood-2011-02-334995; Silva-Santos B, 2015, NAT REV IMMUNOL, V15, P683, DOI 10.1038/nri3904; Sinclair LV, 2013, NAT IMMUNOL, V14, P500, DOI 10.1038/ni.2556; Sureshbabu SK, 2020, CLIN EXP IMMUNOL, V201, P40, DOI 10.1111/cei.13436; Szabo PA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12464-3; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175; Tanigaki K, 2004, IMMUNITY, V20, P611, DOI 10.1016/S1074-7613(04)00109-8; Vantourout P, 2009, J IMMUNOL, V183, P3848, DOI 10.4049/jimmunol.0901085; Vermijlen D, 2007, J IMMUNOL, V178, P4304, DOI 10.4049/jimmunol.178.7.4304; Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood-2002-12-3665; Yin SS, 2015, SCI REP-UK, V5, DOI 10.1038/srep14432; Yofe I, 2020, NAT MED, V26, P171, DOI 10.1038/s41591-019-0736-4; Yu GC, 2016, MOL BIOSYST, V12, P477, DOI 10.1039/c5mb00663e; Yuan JS, 2010, ANNU REV IMMUNOL, V28, P343, DOI 10.1146/annurev.immunol.021908.132719; Zhao YJ, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-017-1378-2; Zhou JH, 2012, CELL MOL IMMUNOL, V9, P34, DOI 10.1038/cmi.2011.16; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	77	1	1	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 30	2021	12								660361	10.3389/fimmu.2021.660361	http://dx.doi.org/10.3389/fimmu.2021.660361			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU6AJ	34526984	gold, Green Published			2022-12-18	WOS:000698880300001
J	Mpande, CAM; Steigler, P; Lloyd, T; Rozot, V; Mosito, B; Schreuder, C; Reid, TD; Bilek, N; Ruhwald, M; Andrews, JR; Hatherill, M; Little, F; Scriba, TJ; Nemes, E				Mpande, Cheleka A. M.; Steigler, Pia; Lloyd, Tessa; Rozot, Virginie; Mosito, Boitumelo; Schreuder, Constance; Reid, Timothy D.; Bilek, Nicole; Ruhwald, Morten; Andrews, Jason R.; Hatherill, Mark; Little, Francesca; Scriba, Thomas J.; Nemes, Elisa		ACS Study Team	Mycobacterium tuberculosis-Specific T Cell Functional, Memory, and Activation Profiles in QuantiFERON-Reverters Are Consistent With Controlled Infection	FRONTIERS IN IMMUNOLOGY			English	Article						QuantiFERON reversion; memory T cell; donor unrestricted T cells; innate immune response; Mycobacterium tuberculosis infection	PREVENTION; IMMUNITY; SUBSETS; EXPRESSION; VACCINE; ASSAYS; GAMMA	Reversion of immune sensitization tests for Mycobacterium tuberculosis (M.tb) infection, such as interferon-gamma release assays or tuberculin skin test, has been reported in multiple studies. We hypothesized that QuantiFERON-TB Gold (QFT) reversion is associated with a decline of M.tb-specific functional T cell responses, and a distinct pattern of T cell and innate responses compared to persistent QFT+ and QFT- individuals. We compared groups of healthy adolescents (n=~30 each), defined by four, 6-monthly QFT tests: reverters (QFT+/+/-/-), non-converters (QFT-/-/-/-) and persistent positives (QFT+/+/+/+). We stimulated peripheral blood mononuclear cells with M.tb antigens (M.tb lysate; CFP-10/ESAT-6 and EspC/EspF/Rv2348 peptide pools) and measured M.tb-specific adaptive T cell memory, activation, and functional profiles; as well as functional innate (monocytes, natural killer cells), donor-unrestricted T cells (DURT: gamma delta T cells, mucosal-associated invariant T and natural killer T-like cells) and B cells by flow cytometry. Projection to latent space discriminant analysis was applied to determine features that best distinguished between QFT reverters, non-converters and persistent positives. No longitudinal changes in immune responses to M.tb were observed upon QFT reversion. M.tb-specific Th1 responses detected in reverters were of intermediate magnitude, higher than responses in QFT non-converters and lower than responses in persistent positives. About one third of reverters had a robust response to CFP-10/ESAT-6. Among those with measurable responses, lower proportions of T-SCM (CD45RA+CCR7+CD27+) and early differentiated (CD45RA-) IFN-gamma-TNF+IL-2- M.tb lysate-specific CD4+ cells were observed in reverters compared with non-converters. Conversely, higher proportions of early differentiated and lower proportions of effector (CD45RA-CCR7-) CFP10/ESAT6-specific Th1 cells were observed in reverters compared to persistent-positives. No differences in M.tb-specific innate, DURT or B cell functional responses were observed between the groups. Statistical modelling misclassified the majority of reverters as non-converters more frequently than they were correctly classified as reverters or misclassified as persistent positives. These findings suggest that QFT reversion occurs in a heterogeneous group of individuals with low M.tb-specific T cell responses. In some individuals QFT reversion may result from assay variability, while in others the magnitude and differentiation status of M.tb-specific Th1 cells are consistent with well-controlled M.tb infection.</p>	[Mpande, Cheleka A. M.; Steigler, Pia; Lloyd, Tessa; Rozot, Virginie; Mosito, Boitumelo; Schreuder, Constance; Reid, Timothy D.; Bilek, Nicole; Hatherill, Mark; Scriba, Thomas J.; Nemes, Elisa; ACS Study Team] Univ Cape Town, South African TB Vaccine Initiat, Inst Infect Dis & Mol Med, Div Immunol,Dept Pathol, Cape Town, South Africa; [Steigler, Pia] Univ Cape Town, Wellcome Ctr Infect Dis Res CIDRI Africa, Inst Infect Dis & Mol Med, Cape Town, South Africa; [Steigler, Pia] Univ Cape Town, Div Immunol, Dept Med, Cape Town, South Africa; [Lloyd, Tessa; Little, Francesca] Univ Cape Town, Dept Stat Sci, Cape Town, South Africa; [Ruhwald, Morten] Statens Serum Inst, Copenhagen, Denmark; Fdn Innovat New Diagnost, Geneva, Switzerland; [Andrews, Jason R.] Stanford Univ, Dept Med, Stanford, CA 94305 USA	University of Cape Town; University of Cape Town; University of Cape Town; University of Cape Town; Statens Serum Institut; Foundation For Innovative New Diagnostics; Stanford University	Nemes, E (corresponding author), Univ Cape Town, South African TB Vaccine Initiat, Inst Infect Dis & Mol Med, Div Immunol,Dept Pathol, Cape Town, South Africa.	elisa.nemes@uct.ac.za	Scriba, Thomas/AAH-9413-2020; Scriba, Thomas/GPX-2573-2022	Scriba, Thomas/0000-0002-0641-1359; Steigler, Pia/0000-0001-8948-1493; Nemes, Elisa/0000-0003-1662-4961; Andrews, Jason/0000-0002-5967-251X	US NIH [R21AI127121, BAA-NIAID-NIHAI201700104]; Global Health Grant from the Bill & Melinda Gates Foundation [OPP1066265]; BMGF GC12 [37885]; South African National Research Foundation; University of Cape Town; Wellcome Centre for Infectious Diseases Research (CIDRI) in Africa; National Research Foundation (NRF) of South Africa	US NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Global Health Grant from the Bill & Melinda Gates Foundation; BMGF GC12; South African National Research Foundation(National Research Foundation - South Africa); University of Cape Town; Wellcome Centre for Infectious Diseases Research (CIDRI) in Africa; National Research Foundation (NRF) of South Africa(National Research Foundation - South Africa)	US NIH (R21AI127121 and BAA-NIAID-NIHAI201700104) funded the study. This work was also supported by Global Health Grant OPP1066265 from the Bill & Melinda Gates Foundation. The ACS study was supported by Aeras and BMGF GC12 (grant 37885) for QFT testing. The South African National Research Foundation and the University of Cape Town funded scholarships to CM. PS received a fellowship from the Wellcome Centre for Infectious Diseases Research (CIDRI) in Africa. TL received a bursary from the National Research Foundation (NRF) of South Africa.	ADAMS JM, 1959, DIS CHEST, V35, P348; Adekambi T, 2015, J CLIN INVEST, V125, P1827, DOI 10.1172/JCI77990; Bruggner RV, 2014, P NATL ACAD SCI USA, V111, pE2770, DOI 10.1073/pnas.1408792111; Butera O, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-182; DAHLSTROM ARTHUR W., 1940, AMER REV TUBERC, V42, P471; Darrah PA, 2020, NATURE, V577, P95, DOI 10.1038/s41586-019-1817-8; Dharmadhikari AS, 2011, TUBERCULOSIS, V91, P329, DOI 10.1016/j.tube.2011.03.002; Dijkman K, 2019, NAT MED, V25, P255, DOI 10.1038/s41591-018-0319-9; Domingo-Gonzalez R, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.TBTB2-0018-2016; Ewer K, 2006, AM J RESP CRIT CARE, V174, P831, DOI 10.1164/rccm.200511-1783OC; Finak G, 2014, BIOSTATISTICS, V15, P87, DOI 10.1093/biostatistics/kxt024; Hawn TR, 2014, MICROBIOL MOL BIOL R, V78, P650, DOI 10.1128/MMBR.00021-14; Hill PC, 2007, PLOS MED, V4, P1061, DOI 10.1371/journal.pmed.0040192; Jenum S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101224; Johnson DF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096613; Lin L, 2015, NAT BIOTECHNOL, V33, P610, DOI 10.1038/nbt.3187; Lin PL, 2014, NAT MED, V20, P75, DOI 10.1038/nm.3412; Lloyd T, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1009197; Lu LL, 2019, NAT MED, V25, P977, DOI 10.1038/s41591-019-0441-3; Lugli E, 2013, J CLIN INVEST, V123, P594, DOI 10.1172/JCI66327; Mahomed H, 2011, INT J TUBERC LUNG D, V15, P331; Mahomed H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017984; Medawar L, 2019, IMMUN INFLAMM DIS, V7, P260, DOI 10.1002/iid3.269; Moguche AO, 2017, CELL HOST MICROBE, V21, P695, DOI 10.1016/j.chom.2017.05.012; Mogues T, 2001, J EXP MED, V193, P271, DOI 10.1084/jem.193.3.271; Mpande CAM, 2021, EBIOMEDICINE, V64, DOI 10.1016/j.ebiom.2021.103233; Mpande CAM, 2021, AM J RESP CRIT CARE, V203, P1556, DOI [10.1164/rccm.202007-2686OC, 10.25375/uct.14761596]; Musvosvi M, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00153-2018; Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/nejmoa1714021, 10.1056/NEJMoa1714021]; Nemes E, 2017, AM J RESP CRIT CARE, V196, P638, DOI 10.1164/rccm.201704-0817OC; North RJ, 2004, ANNU REV IMMUNOL, V22, P599, DOI 10.1146/annurev.immunol.22.012703.104635; Pai M, 2009, INT J TUBERC LUNG D, V13, P84; Penn-Nicholson A, 2015, TUBERCULOSIS, V95, P350, DOI 10.1016/j.tube.2015.03.002; RILEY RL, 1962, AM REV RESPIR DIS, V85, P511; RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069; Riou C, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1176; Riou C, 2017, FRONT IMMUNOL, V8, P1, DOI 10.3389/fimmu.2017.00968; Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015; Rogerson BJ, 2006, IMMUNOLOGY, V118, P195, DOI 10.1111/j.1365-2567.2006.02355.x; Ruhwald M, 2017, SCI REP-UK, V7, DOI 10.1038/srep45969; Scriba TJ, 2008, J IMMUNOL, V180, P1962, DOI 10.4049/jimmunol.180.3.1962; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Shi LB, 2003, P NATL ACAD SCI USA, V100, P241, DOI 10.1073/pnas.0136863100; Suliman S, 2016, J IMMUNOL, V197, P1100, DOI 10.4049/jimmunol.1501996; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; van Zyl-Smit RN, 2009, AM J RESP CRIT CARE, V180, P49, DOI 10.1164/rccm.200811-1704OC; WHO, 2021, TUBERCULOSIS; Wilkinson KA, 2016, AM J RESP CRIT CARE, V193, P1307, DOI 10.1164/rccm.201601-0116LE; Wold H, 1982, ENCY STAT SCI, P1; Xin HA, 2020, CLIN INFECT DIS, V70, P947, DOI 10.1093/cid/ciz581; Zhang HR, 2019, J INFECTION, V78, P305, DOI 10.1016/j.jinf.2019.01.008	51	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 30	2021	12								712480	10.3389/fimmu.2021.712480	http://dx.doi.org/10.3389/fimmu.2021.712480			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UT0XJ	34526988	gold, Green Published			2022-12-18	WOS:000697848100001
J	Parras, D; Sole, P; Delong, T; Santamaria, P; Serra, P				Parras, Daniel; Sole, Patricia; Delong, Thomas; Santamaria, Pere; Serra, Pau			Recognition of Multiple Hybrid Insulin Peptides by a Single Highly Diabetogenic T-Cell Receptor	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmunity; type 1 diabetes; epitope discovery; TCR-transgenic NOD mice; hybrid insulin peptides; antigenic promiscuity; major histocompatibility complex; genetic susceptibility and resistance	COMPLEX-LINKED RESISTANCE; ANTIGENS; ASSOCIATION; AUTOANTIGEN; MECHANISM; MODEL	The mechanisms underlying the major histocompatibility complex class II (MHCII) type 1 diabetes (T1D) association remain incompletely understood. We have previously shown that thymocytes expressing the highly diabetogenic, I-A(g7)-restricted 4.1-T-cell receptor (TCR) are MHCII-promiscuous, and that, in MHCII-heterozygous mice, they sequentially undergo positive and negative selection/Treg deviation by recognizing pro- and anti-diabetogenic MHCII molecules on cortical thymic epithelial cells and medullary hematopoietic antigen-presenting cells (APCs), respectively. Here, we use a novel autoantigen discovery approach to define the antigenic specificity of this TCR in the context of I-A(g7). This was done by screening the ability of random epitope-GS linker-I- A(beta)(g7) chain fusion pools to form agonistic peptide-MHCII complexes on the surface of I- A alpha d chain-transgenic artificial APCs. Pool deconvolution, I-A(g7)-binding register-fixing, TCR contact residue mapping, and alanine scanning mutagenesis resulted in the identification of a 4.1-TCR recognition motif XL(G/A)XEXE(D/E)X that was shared by seven agonistic hybrid insulin peptides (HIPs) resulting from the fusion of several different chromogranin A and/or insulin C fragments, including post-translationally modified variants. These data validate a novel, highly sensitive MHCII-restricted epitope discovery approach for orphan TCRs and suggest thymic selection of autoantigen-promiscuous TCRs as a mechanism for the murine T1D-I-A(g7)-association.</p>	[Parras, Daniel; Sole, Patricia; Santamaria, Pere; Serra, Pau] Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain; [Delong, Thomas] Univ Colorado, SSPPS, Dept Pharmaceut Sci, Aurora, CO USA; [Santamaria, Pere] Univ Calgary, Cumming Sch Med, Snyder Inst Chron Dis, Julia McFarlane Diabet Res Ctr JMDRC, Calgary, AB, Canada; [Santamaria, Pere] Univ Calgary, Cumming Sch Med, Snyder Inst Chron Dis, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Calgary; University of Calgary	Santamaria, P; Serra, P (corresponding author), Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain.; Santamaria, P (corresponding author), Univ Calgary, Cumming Sch Med, Snyder Inst Chron Dis, Julia McFarlane Diabet Res Ctr JMDRC, Calgary, AB, Canada.; Santamaria, P (corresponding author), Univ Calgary, Cumming Sch Med, Snyder Inst Chron Dis, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada.	psantama@ucalgary.ca; pserra1@clinic.cat	Santamaria, Pere/ABF-6823-2021	Parras, Daniel/0000-0002-2677-4245	Ministerio de Economia y Competitividad of Spain (MINECO) [RTI2018-093964-B-I00]; Generalitat de Catalunya (SGR Programme); Generalitat de Catalunya (CERCA Programme); Canadian Institutes of Health Research (CIHR); ISCIII [PIE14/00027, PI15/0797]; FEDER [PIE14/00027, PI15/0797]; FPU (MINECO); JDRF Career Development Award; Diabetes Canada	Ministerio de Economia y Competitividad of Spain (MINECO); Generalitat de Catalunya (SGR Programme)(Generalitat de Catalunya); Generalitat de Catalunya (CERCA Programme); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); ISCIII(Instituto de Salud Carlos III); FEDER(European Commission); FPU (MINECO); JDRF Career Development Award(Juvenile Diabetes Research Foundation); Diabetes Canada	This work was supported by the Ministerio de Economia y Competitividad of Spain (MINECO, RTI2018-093964-B-I00), Generalitat de Catalunya (SGR and CERCA Programmes), the Canadian Institutes of Health Research (CIHR), and the ISCIII and FEDER (PIE14/00027, PI15/0797). DP and PSo were supported by predoctoral studentships from FPU (MINECO). PSe was an investigator of the Ramon y Cajal re-integration program and was supported by a JDRF Career Development Award. The JMDRC is supported by Diabetes Canada.	Aarnoudse CA, 2002, INT J CANCER, V99, P7, DOI 10.1002/ijc.10317; Arribas-Layton D, 2020, DIABETES, V69, P1492, DOI 10.2337/db19-0620; Babad J, 2010, IMMUNOLOGY, V131, P459, DOI 10.1111/j.1365-2567.2010.03362.x; Baker RL, 2019, DIABETES, V68, P1830, DOI 10.2337/db19-0128; Crawford F, 2006, IMMUNOL REV, V210, P156, DOI 10.1111/j.0105-2896.2006.00365.x; Delong T, 2016, SCIENCE, V351, P711, DOI 10.1126/science.aad2791; Lieberman SM, 2003, TISSUE ANTIGENS, V62, P359, DOI 10.1034/j.1399-0039.2003.00152.x; Santamaria P, 2010, IMMUNITY, V32, P437, DOI 10.1016/j.immuni.2010.04.003; Schmidt D, 1999, J IMMUNOL, V162, P4627; Schmidt D, 1997, J EXP MED, V186, P1059, DOI 10.1084/jem.186.7.1059; Serra P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12902-2; Sollid LM, 2011, CURR OPIN IMMUNOL, V23, P732, DOI 10.1016/j.coi.2011.08.006; Stadinski BD, 2010, P NATL ACAD SCI USA, V107, P10978, DOI 10.1073/pnas.1006545107; Stadinski BD, 2010, NAT IMMUNOL, V11, P225, DOI 10.1038/ni.1844; Suri A, 2008, J IMMUNOL, V180, P3849, DOI 10.4049/jimmunol.180.6.3849; Thiessen S, 2002, DIABETES, V51, P325, DOI 10.2337/diabetes.51.2.325; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; Tsai S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00321; Tsai S, 2013, J IMMUNOL, V191, P70, DOI 10.4049/jimmunol.1300168; Tsai S, 2013, P NATL ACAD SCI USA, V110, P3471, DOI 10.1073/pnas.1211391110; Verchere CB, 1996, J BIOL CHEM, V271, P27475, DOI 10.1074/jbc.271.44.27475; Verdaguer J, 1997, J EXP MED, V186, P1663, DOI 10.1084/jem.186.10.1663; Wan XX, 2020, NAT IMMUNOL, V21, P455, DOI 10.1038/s41590-020-0623-7; Wang RF, 1999, SCIENCE, V284, P1351, DOI 10.1126/science.284.5418.1351; Wang WYS, 2005, NAT REV GENET, V6, P109, DOI 10.1038/nrg1522; Wegner N, 2010, IMMUNOL REV, V233, P34, DOI 10.1111/j.0105-2896.2009.00850.x; Wiles TA, 2019, J PROTEOME RES, V18, P814, DOI 10.1021/acs.jproteome.8b00875; Wiles TA, 2017, J AUTOIMMUN, V78, P11, DOI 10.1016/j.jaut.2016.10.007	28	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 30	2021	12								737428	10.3389/fimmu.2021.737428	http://dx.doi.org/10.3389/fimmu.2021.737428			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU0TO	34527002	gold, Green Published			2022-12-18	WOS:000698518000001
J	Zhang, MJ; Wang, YQ; Li, XQ; Meng, G; Chen, XL; Wang, LA; Lin, ZH; Wang, L				Zhang, Mengjun; Wang, Yuanqiang; Li, Xiangqian; Meng, Gang; Chen, Xiaoling; Wang, Lina; Lin, Zhihua; Wang, Li			A Single L/D-Substitution at Q4 of the mInsA(2-10) Epitope Prevents Type 1 Diabetes in Humanized NOD Mice	FRONTIERS IN IMMUNOLOGY			English	Article						type 1 diabetes; altered peptide ligand; D-amino acid substitution; mInsA(2-10); NOD; beta 2m(null); HHD mice	T-CELLS; PEPTIDE; STABILITY; PREPROINSULIN; AUTOIMMUNITY; PATHOGENESIS; INSULITIS; AFFINITY; MOUSE; MODEL	Autoreactive CD8(+) T cells play an indispensable key role in the destruction of pancreatic islet beta-cells and the initiation of type 1 diabetes (T1D). Insulin is an essential beta-cell autoantigen in T1D. An HLA-A*0201-restricted epitope of insulin A chain (mInsA(2-10)) is an immunodominant ligand for autoreactive CD8(+) T cells in NOD.beta 2m(null).HHD mice. Altered peptide ligands (APLs) carrying amino acid substitutions at T cell receptor (TCR) contact positions within an epitope are potential to modulate autoimmune responses via triggering altered TCR signaling. Here, we used a molecular simulation strategy to guide the generation of APL candidates by substitution of L-amino acids with D-amino acids at potential TCR contact residues (positions 4 and 6) of mInsA(2-10), named mInsA(2-10)DQ4 and mInsA(2-10)DC6, respectively. We found that administration of mInsA(2-10)DQ4, but not DC6, significantly suppressed the development of T1D in NOD.beta 2m(null).HHD mice. Mechanistically, treatment with mInsA(2-10)DQ4 not only notably eliminated mInsA(2-10) autoreactive CD8(+) T cell responses but also prevented the infiltration of CD4(+) T and CD8(+) T cells, as well as the inflammatory responses in the pancreas of NOD.beta 2m(null).HHD mice. This study provides a new strategy for the development of APL vaccines for T1D prevention.	[Zhang, Mengjun] Third Mil Med Univ, Dept Pharmaceut Anal, Coll Pharm, Army Med Univ, Chongqing, Peoples R China; [Zhang, Mengjun; Li, Xiangqian; Chen, Xiaoling; Wang, Li] Third Mil Med Univ, Inst Immunol Peoples Librat Army PLA, Army Med Univ, Chongqing, Peoples R China; [Zhang, Mengjun; Li, Xiangqian; Chen, Xiaoling; Wang, Li] Third Mil Med Univ, Dept Immunol, Army Med Univ, Chongqing, Peoples R China; [Wang, Yuanqiang; Lin, Zhihua] Chongqing Univ Technol, Dept Pharmaceut Engn, Sch Pharm & Bioengn, Chongqing, Peoples R China; [Meng, Gang] Third Mil Med Univ, Dept Pathol, Southwest Hosp, Army Med Univ, Chongqing, Peoples R China; [Wang, Lina] Weifang Med Univ, Dept Immunol, Weifang, Peoples R China	Army Medical University; Army Medical University; Army Medical University; Chongqing University of Technology; Army Medical University; Weifang Medical University	Wang, L (corresponding author), Third Mil Med Univ, Inst Immunol Peoples Librat Army PLA, Army Med Univ, Chongqing, Peoples R China.; Wang, L (corresponding author), Third Mil Med Univ, Dept Immunol, Army Med Univ, Chongqing, Peoples R China.	1306858097@qq.com	wang, lina/HGC-1592-2022		National Natural Science Foundation of China [31771002, 81871301, 82071825]; National Key Project for Research & Development of China [2016YFA0502204]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Project for Research & Development of China	Funding This work was supported by the National Natural Science Foundation of China (Nos. 31771002, 81871301, and 82071825) and the National Key Project for Research & Development of China (No. 2016YFA0502204).	Baker C, 2008, J CLIN IMMUNOL, V28, P350, DOI 10.1007/s10875-008-9177-4; Bartnes K, 1997, EUR J IMMUNOL, V27, P1387, DOI 10.1002/eji.1830270614; Bashford D, 2000, ANNU REV PHYS CHEM, V51, P129, DOI 10.1146/annurev.physchem.51.1.129; Chen SY, 2013, CHEMBIOCHEM, V14, P1316, DOI 10.1002/cbic.201300228; de Marquesini LGP, 2008, EUR J IMMUNOL, V38, P240, DOI 10.1002/eji.2007377621; Delovitch TL, 1997, IMMUNITY, V7, P727, DOI 10.1016/S1074-7613(00)80392-1; Desai S, 2021, CURR DIABETES REV, V17, P30, DOI 10.2174/1573399816666200330145501; Hamamoto K, 2002, MICROBIOL IMMUNOL, V46, P741, DOI 10.1111/j.1348-0421.2002.tb02759.x; Han BY, 2005, NAT MED, V11, P645, DOI 10.1038/nm1250; Hartemann-Heurtier A, 2004, J IMMUNOL, V172, P915, DOI 10.4049/jimmunol.172.2.915; Haskins K, 2011, CURR OPIN IMMUNOL, V23, P739, DOI 10.1016/j.coi.2011.08.004; HERNANDEZ JF, 1994, PEPTIDES, V15, P583, DOI 10.1016/0196-9781(94)90080-9; Homann D, 2006, J CLIN INVEST, V116, P1212, DOI 10.1172/JCI28506; Kanagawa O, 1998, P NATL ACAD SCI USA, V95, P1721, DOI 10.1073/pnas.95.4.1721; KATZ J, 1993, EUR J IMMUNOL, V23, P3358, DOI 10.1002/eji.1830231244; Liblau RS, 2002, IMMUNITY, V17, P1, DOI 10.1016/S1074-7613(02)00338-2; Lombardi A, 2020, J AUTOIMMUN, V115, DOI 10.1016/j.jaut.2020.102543; Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255; Maillere B, 1995, MOL IMMUNOL, V32, P1073, DOI 10.1016/0161-5890(95)00073-9; MARKS DI, 1991, AUTOIMMUNITY, V11, P73, DOI 10.3109/08916939109035137; Nakagawa Y, 2007, BIOPHYS J, V92, P2570, DOI 10.1529/biophysj.106.095208; Niens M, 2011, DIABETES, V60, P1229, DOI 10.2337/db10-1523; Prasad S, 2012, J AUTOIMMUN, V39, P347, DOI 10.1016/j.jaut.2012.04.005; Rathmann S, 2004, ANN NY ACAD SCI, V1037, P22, DOI 10.1196/annals.1337.004; Salomon-Ferrer R, 2013, J CHEM THEORY COMPUT, V9, P3878, DOI 10.1021/ct400314y; Shang XY, 2009, EUR J IMMUNOL, V39, P2248, DOI 10.1002/eji.200939338; SUMIDA T, 1994, INT IMMUNOL, V6, P1445, DOI 10.1093/intimm/6.9.1445; Takaki T, 2006, J IMMUNOL, V176, P3257, DOI 10.4049/jimmunol.176.5.3257; Tsai SE, 2010, IMMUNITY, V32, P568, DOI 10.1016/j.immuni.2010.03.015; Tugyi R, 2005, P NATL ACAD SCI USA, V102, P413, DOI 10.1073/pnas.0407677102; Van Regenmortel MHV, 1998, CURR OPIN BIOTECH, V9, P377, DOI 10.1016/S0958-1669(98)80011-6; Wang JM, 2012, J CHEM INF MODEL, V52, P1199, DOI 10.1021/ci300064d; Wilson DB, 2005, NATURE, V438, pE5, DOI 10.1038/nature04423; Zhang MJ, 2019, CELL MOL IMMUNOL, V16, P590, DOI 10.1038/s41423-018-0058-3	34	1	1	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 30	2021	12								713276	10.3389/fimmu.2021.713276	http://dx.doi.org/10.3389/fimmu.2021.713276			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XG2OM	34526989	Green Published, gold			2022-12-18	WOS:000724597400001
J	Fortmann, I; Dammann, MT; Siller, B; Humberg, A; Demmert, M; Tushaus, L; Lindert, J; van Zandbergen, V; Pagel, J; Rupp, J; Herting, E; Hartel, C				Fortmann, Ingmar; Dammann, Marie-Theres; Siller, Bastian; Humberg, Alexander; Demmert, Martin; Tueshaus, Ludger; Lindert, Judith; van Zandbergen, Vera; Pagel, Julia; Rupp, Jan; Herting, Egbert; Haertel, Christoph			Infants Younger Than 90 Days Admitted for Late-Onset Sepsis Display a Reduced Abundance of Regulatory T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						neonatal immunity; sepsis; infants < 90 days; regulatory T cells; invasive bacterial infection; lymphocyte subsets; sepsis workup	SERIOUS BACTERIAL-INFECTIONS; RESPONSES; BIRTH	Objective To provide epidemiological data of infants < 90 days of age with suspected late-onset sepsis (LOS) and evaluate distinct immunological specificities. We hypothesized that previously healthy infants < 3 months of age with sepsis have a yet undefined immunological predisposition; e.g. differences in lymphocyte subsets including regulatory T cells. Methods We performed an exploratory, single center study between January 1(st), 2019 and June 1(st), 2021. Routine diagnostics included conventional culture (blood, cerebrospinal fluid, urine), PCR and inflammatory markers in infants < 90 days of age with suspected sepsis. We additionally analyzed lymphocyte subsets and CD4+ CD25+ forkhead box protein (FoxP3)(+) Tregs at admission for sepsis workup as compared to age-matched controls. Results A convenience sample cohort of n= 51 infants with sepsis workup was enrolled. Invasive bacterial infection (IBI) was diagnosed in 25 (49.0%) patients including two infants with a rhinovirus co-infection and viral infection in 14 (27.5%) neonates. No infectious cause was found in 12 cases. Infants with suspected LOS displayed a decreased abundance of CD4+ FoxP3+ T cells as compared to controls, which was most pronounced in the subgroup of infants with IBI. We also noticed elevated HLA-DR-positive CD3+ cells in infants with LOS and a higher CD4/CD8-ratio in infants with viral infection as compared to healthy controls. Infants with viral infections had a higher number of natural killer cells as compared to infants with IBI. Conclusion Our exploratory data support the concept of a potential immaturity state and failed immune tolerance development for young infants with LOS. Future large-scale studies are needed to elucidate pre-sepsis conditions and to target the microbiome-immunity interplay as a potential risk pattern.	[Fortmann, Ingmar; Dammann, Marie-Theres; Siller, Bastian; Humberg, Alexander; Demmert, Martin; van Zandbergen, Vera; Pagel, Julia; Herting, Egbert] Univ Lubeck, Dept Pediat, Lubeck, Germany; [Fortmann, Ingmar; Demmert, Martin; Pagel, Julia; Rupp, Jan] German Ctr Infect Res DZIF, Partner Site Hamburg Lubeck Borstel Riems, Lubeck, Germany; [Tueshaus, Ludger; Lindert, Judith] Univ Lubeck, Dept Pediat Surg, Lubeck, Germany; [Rupp, Jan] Univ Lubeck, Dept Infect Dis & Microbiol, Lubeck, Germany; [Haertel, Christoph] Univ Hosp Wurzburg, Dept Pediat, Wurzburg, Germany	University of Lubeck; German Center for Infection Research; University of Lubeck; University of Lubeck; University of Wurzburg	Fortmann, I (corresponding author), Univ Lubeck, Dept Pediat, Lubeck, Germany.; Fortmann, I (corresponding author), German Ctr Infect Res DZIF, Partner Site Hamburg Lubeck Borstel Riems, Lubeck, Germany.	Matsingmar.Fortmann@uksh.de	Tüshaus, Ludger/ABG-5092-2021; Rupp, Jan/C-8794-2011	Rupp, Jan/0000-0001-8722-1233; Demmert, Martin/0000-0001-7552-3736	German Center for Infection Research (DZIF) - German Ministry for Education and Research; University of Lubeck; Lubeck-Hilfe fur krebskranke Kinder; Annemarie-Konig-Stiftung	German Center for Infection Research (DZIF) - German Ministry for Education and Research; University of Lubeck; Lubeck-Hilfe fur krebskranke Kinder; Annemarie-Konig-Stiftung	The FWS study is part of a clinician scientist grant provided by the German Center for Infection Research (DZIF) which is funded by the German Ministry for Education and Research. There has been no involvement in study design, collection of analysis, interpretation of data, writing of the report and decision to submit the manuscript for publication by the German Ministry for Education and Research. The first version of the manuscript was written by IF and CH. No payment, honorarium, grant or other form of payment has been given to the authors. The study was also supported by the University of Lubeck junior research grant (IF), Lubeck-Hilfe fur krebskranke Kinder (https://luebeck-hilfe-fuerkrebskranke-kinder.de) and Annemarie-Konig-Stiftung.	Ashkenazi-Hoffnung L, 2011, SCAND J INFECT DIS, V43, P489, DOI 10.3109/00365548.2011.555918; Bachur RG, 2001, PEDIATRICS, V108, P311, DOI 10.1542/peds.108.2.311; Basha S, 2014, EXPERT REV CLIN IMMU, V10, P1171, DOI 10.1586/1744666X.2014.942288; BD Biosciences, 2014, BD MULT 6 COL TBNK; Bjorkstrom NK, 2022, NAT REV IMMUNOL, V22, P112, DOI 10.1038/s41577-021-00558-3; Bolognese AC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00833; Byington CL, 2004, PEDIATRICS, V113, P1662, DOI 10.1542/peds.113.6.1662; Cebula A, 2013, NATURE, V497, P258, DOI 10.1038/nature12079; Chen K, 2015, WORLD J EMERG MED, V6, P40, DOI 10.5847/wjem.j.1920-8642.2015.01.007; Chiche L, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/986491; Christiaansen AF, 2016, PEDIATR RES, V80, P702, DOI 10.1038/pr.2016.130; Delespesse G, 1998, VACCINE, V16, P1415, DOI 10.1016/S0264-410X(98)00101-7; Freudenhammer M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.617925; Fulton RB, 2010, J IMMUNOL, V185, P2382, DOI 10.4049/jimmunol.1000423; Geffers C, 2008, J HOSP INFECT, V68, P214, DOI 10.1016/j.jhin.2008.01.016; Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378; Heuer JG, 2005, J IMMUNOL, V174, P7141, DOI 10.4049/jimmunol.174.11.7141; Kelly-Scumpia KM, 2011, J EXP MED, V208, P1673, DOI 10.1084/jem.20101715; Kollmann TR, 2017, IMMUNITY, V46, P350, DOI 10.1016/j.immuni.2017.03.009; Lee DCP, 2010, J VIROL, V84, P8790, DOI 10.1128/JVI.00796-10; Ma L, 2014, SCAND J IMMUNOL, V80, P50, DOI 10.1111/sji.12181; Omana-Zapata I, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211207; Pagel J, 2016, CLIN EXP IMMUNOL, V185, P219, DOI 10.1111/cei.12810; Pagel J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.565257; Panaro A, 1991, Allergol Immunopathol (Madr), V19, P109; Pantell RH, 2004, JAMA-J AM MED ASSOC, V291, P1203, DOI 10.1001/jama.291.10.1203; Powell EC, 2018, ANN EMERG MED, V71, P211, DOI 10.1016/j.annemergmed.2017.07.488; Raiden S, 2014, AM J RESP CRIT CARE, V189, P865, DOI 10.1164/rccm.201311-1977LE; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P639, DOI 10.1016/j.jaci.2016.06.003; Rudd BD, 2020, ANNU REV IMMUNOL, V38, P229, DOI 10.1146/annurev-immunol-091319-083608; Rueda CM, 2015, EUR J IMMUNOL, V45, P2582, DOI 10.1002/eji.201445371; Rueda CM, 2015, HUM IMMUNOL, V76, P65, DOI 10.1016/j.humimm.2014.10.016; Schelonka RL, 1996, J PEDIATR-US, V129, P275, DOI 10.1016/S0022-3476(96)70254-8; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Troger B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159821; Wing K, 2003, EUR J IMMUNOL, V33, P579, DOI 10.1002/eji.200323701; Wynn JL., 2017, PATHOPHYSIOLOGY NEON, V2, P2, DOI [10.1016/B978-0-323-35214-7.00152-9, DOI 10.1016/B978-0-323-35214-7.00152-9]	37	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 27	2021	12								666447	10.3389/fimmu.2021.666447	http://dx.doi.org/10.3389/fimmu.2021.666447			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UT0XB	34512621	Green Published, gold			2022-12-18	WOS:000697847300001
J	Fujiwara, H				Fujiwara, Hideaki			Crosstalk Between Intestinal Microbiota Derived Metabolites and Tissues in Allogeneic Hematopoietic Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Review						graft-versus-host disease; microbial metabolite; dysbiosis; microbiota; allogeneic stem cell transplantation	VERSUS-HOST-DISEASE; CHAIN FATTY-ACIDS; ARYL-HYDROCARBON RECEPTOR; STEM-CELL; FECAL MICROBIOTA; GASTROINTESTINAL-TRACT; ESCHERICHIA-COLI; BARRIER FUNCTION; GUT MICROBIOTA; T-CELLS	Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an evidence based- cellular immunotherapy for hematological malignancies. Immune reactions not only promote graft-versus-tumor effects that kill hematological malignant cells but also graft-versus-host disease (GVHD) that is the primary complication characterized by systemic organ damages consisting of T-cells and antigen presenting cells (APCs) activation. GVHD has long been recognized as an immunological reaction that requires an immunosuppressive treatment targeting immune cells. However immune suppression cannot always prevent GVHD or effectively treat it once it has developed. Recent studies using high-throughput sequencing technology investigated the impact of microbial flora on GVHD and provided profound insights of the mechanism of GVHD other than immune cells. Allo-HSCT affects the intestinal microbiota and microbiome-metabolome axis that can alter intestinal homeostasis and the severity of experimental GVHD. This axis can potentially be manipulated via dietary intervention or metabolites produced by intestinal bacteria affected post-allo-HSCT. In this review, we discuss the mechanism of experimental GVHD regulation by the complex microbial community-metabolites-host tissue axis. Furthermore, we summarize the major findings of microbiome-based immunotherapeutic approaches that protect tissues from experimental GVHD. Understanding the complex relationships between gut microbiota-metabolites-host tissues axis provides crucial insight into the pathogenesis of GVHD and advances the development of new therapeutic approaches.	[Fujiwara, Hideaki] Okayama Univ Hosp, Dept Hematol & Oncol, Okayama, Japan	Okayama University	Fujiwara, H (corresponding author), Okayama Univ Hosp, Dept Hematol & Oncol, Okayama, Japan.	pmex9v3q@okayama-u.ac.jp			JSPS KAKENHI [JP20K22901, JP21H02904]; Kawasaki Foundation of Medical Science and Medical Welfare, The Ryobiteien Memorial Foundation; MSD Life Science Foundation Public Interest Incorporated Foundation; Okayama Medical Foundation; SENSHIN Medical Research Foundation; Kato Memorial Bioscience Foundation; NOVARTIS Foundation (Japan) for the Promotion of Science; Ryobiteien Memorial Foundation	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Kawasaki Foundation of Medical Science and Medical Welfare, The Ryobiteien Memorial Foundation; MSD Life Science Foundation Public Interest Incorporated Foundation; Okayama Medical Foundation; SENSHIN Medical Research Foundation(SENSHIN Medical Research Foundation); Kato Memorial Bioscience Foundation; NOVARTIS Foundation (Japan) for the Promotion of Science(Novartis); Ryobiteien Memorial Foundation	This work was supported by JSPS KAKENHI Grant number JP20K22901, JP21H02904, The Kawasaki Foundation of Medical Science and Medical Welfare, The Ryobiteien Memorial Foundation, The MSD Life Science Foundation Public Interest Incorporated Foundation, The Okayama Medical Foundation, The SENSHIN Medical Research Foundation, The Kato Memorial Bioscience Foundation and the NOVARTIS Foundation (Japan) for the Promotion of Science.	Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Barker N, 2008, GENE DEV, V22, P1856, DOI 10.1101/gad.1674008; Baxter NT, 2019, MBIO, V10, DOI [10.1128/mBio.02566-18, 10.1128/mbio.02566-18]; Belenguer A, 2006, APPL ENVIRON MICROB, V72, P3593, DOI 10.1128/AEM.72.5.3593-3599.2006; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Bhattacharyya A, 2018, BIOL BLOOD MARROW TR, V24, P242, DOI 10.1016/j.bbmt.2017.10.003; Blouin JM, 2011, INT J CANCER, V128, P2591, DOI 10.1002/ijc.25599; BODET CA, 1985, ANTIMICROB AGENTS CH, V28, P437, DOI 10.1128/AAC.28.3.437; Bowerman KL, 2020, GUT MICROBES, V11, DOI 10.1080/19490976.2019.1705729; Bronner DN, 2018, CELL HOST MICROBE, V23, P266, DOI 10.1016/j.chom.2018.01.004; BUCKNER CD, 1978, ANN INTERN MED, V89, P893, DOI 10.7326/0003-4819-89-6-893; Byndloss MX, 2017, SCIENCE, V357, P570, DOI 10.1126/science.aam9949; Cabral ME, 2007, CAN J MICROBIOL, V53, P607, DOI 10.1139/W07-011; Cammarota G, 2019, GUT, V68, P2111, DOI 10.1136/gutjnl-2019-319548; Campbell C, 2020, NATURE, V581, P475, DOI 10.1038/s41586-020-2193-0; Choi SW, 2014, NAT REV CLIN ONCOL, V11, P536, DOI 10.1038/nrclinonc.2014.102; CLAUSEN MR, 1994, GASTROENTEROLOGY, V106, P423, DOI 10.1016/0016-5085(94)90601-7; Colgan SP, 2010, NAT REV GASTRO HEPAT, V7, P281, DOI 10.1038/nrgastro.2010.39; Dant TA, 2017, BLOOD, V130, P348, DOI 10.1182/blood-2016-08-734244; David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; de Loor H, 2005, CLIN CHEM, V51, P1535, DOI 10.1373/clinchem.2005.050781; DeFilipp Z, 2019, NEW ENGL J MED, V381, P2043, DOI 10.1056/NEJMoa1910437; DeFilipp Z, 2018, BLOOD ADV, V2, P745, DOI 10.1182/bloodadvances.2018017731; den Besten G, 2013, J LIPID RES, V54, P2325, DOI 10.1194/jlr.R036012; Devkota S, 2012, NATURE, V487, P104, DOI 10.1038/nature11225; Di Martino ML, 2013, INT J MED MICROBIOL, V303, P484, DOI 10.1016/j.ijmm.2013.06.008; Donohoe DR, 2011, CELL METAB, V13, P517, DOI 10.1016/j.cmet.2011.02.018; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; El Kaoutari A, 2013, NAT REV MICROBIOL, V11, P497, DOI 10.1038/nrmicro3050; Espey MG, 2013, FREE RADICAL BIO MED, V55, P130, DOI 10.1016/j.freeradbiomed.2012.10.554; Falony G, 2009, APPL ENVIRON MICROB, V75, P2312, DOI 10.1128/AEM.02649-08; Fernstrom JD, 2007, J NUTR, V137, p1539S, DOI 10.1093/jn/137.6.1539S; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Foster KR, 2017, NATURE, V548, P43, DOI 10.1038/nature23292; Freifeld AG, 2011, CLIN INFECT DIS, V52, P427, DOI 10.1093/cid/ciq147; Fujiwara H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06048-w; Fukuda S, 2011, NATURE, V469, P543, DOI 10.1038/nature09646; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; Gafter-Gvili A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004386.pub2; Galloway-Pena JR, 2016, CANCER-AM CANCER SOC, V122, P2186, DOI 10.1002/cncr.30039; Gaudier E, 2004, AM J PHYSIOL-GASTR L, V287, pG1168, DOI 10.1152/ajpgi.00219.2004; Ghimire L, 2020, MUCOSAL IMMUNOL, V13, P388, DOI 10.1038/s41385-020-0256-z; Gillis CC, 2018, CELL HOST MICROBE, V23, P54, DOI 10.1016/j.chom.2017.11.006; Gold MC, 2013, NAT REV MICROBIOL, V11, P14, DOI 10.1038/nrmicro2918; Golob JL, 2019, BLOOD ADV, V3, P2866, DOI 10.1182/bloodadvances.2019000362; Guo H, 2020, SCIENCE, V370, P549, DOI 10.1126/science.aay9097; Gupta S, 2016, THER ADV GASTROENTER, V9, P229, DOI 10.1177/1756283X15607414; Haak BW, 2018, BLOOD, V131, P2978, DOI 10.1182/blood-2018-01-828996; Han K, 2021, NAT BIOMED ENG, V5, DOI 10.1038/s41551-021-00749-2; Haring E, 2021, HAEMATOLOGICA, V106, P2131, DOI 10.3324/haematol.2019.242990; He GL, 1999, P NATL ACAD SCI USA, V96, P4586, DOI 10.1073/pnas.96.8.4586; Henig I, 2021, HAEMATOLOGICA, V106, P933, DOI 10.3324/haematol.2020.247395; Huang YK, 2012, EXP BIOL MED, V237, P305, DOI 10.1258/ebm.2011.011297; Huycke MM, 2002, CARCINOGENESIS, V23, P529, DOI 10.1093/carcin/23.3.529; Inagaki T, 2006, P NATL ACAD SCI USA, V103, P3920, DOI 10.1073/pnas.0509592103; Innocentin YLS, 2011, CELL, V147, P629, DOI 10.1016/j.cell.2011.09.025; Janeiro MH, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101398; Jenq RR, 2010, NAT REV CANCER, V10, P213, DOI 10.1038/nrc2804; JONES JM, 1971, RADIAT RES, V45, P577, DOI 10.2307/3573066; Joshi NM, 2012, BRIT J HAEMATOL, V157, P403, DOI 10.1111/j.1365-2141.2011.09014.x; Kakihana K, 2016, BLOOD, V128, P2083, DOI 10.1182/blood-2016-05-717652; Kawaguchi K, 2018, INT J HEMATOL, V108, P66, DOI 10.1007/s12185-018-2442-2; Kelly CJ, 2015, CELL HOST MICROBE, V17, P662, DOI 10.1016/j.chom.2015.03.005; Kibe R, 2014, SCI REP-UK, V4, DOI 10.1038/srep04548; Kim HY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03130-z; Kim YG, 2017, SCIENCE, V356, P312, DOI 10.1126/science.aag2029; Kiss EA, 2011, SCIENCE, V334, P1561, DOI 10.1126/science.1214914; Kohler N, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03179; Koh A, 2016, CELL, V165, P1332, DOI 10.1016/j.cell.2016.05.041; Konuma T, 2020, J IMMUNOL, V204, P1462, DOI 10.4049/jimmunol.1900681; Koyama M, 2019, IMMUNITY, V51, P885, DOI 10.1016/j.immuni.2019.08.011; Krogius-Kurikka L, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-95; Kuhn S, 2019, PSYCHOL RES-PSYCH FO, V83, P1097, DOI 10.1007/s00426-017-0957-4; Kusakabe S, 2020, BRIT J HAEMATOL, V188, P438, DOI 10.1111/bjh.16205; Lamont RJ, 2018, NAT REV MICROBIOL, V16, P745, DOI 10.1038/s41579-018-0089-x; Lee SE, 2019, BIOL BLOOD MARROW TR, V25, P1933, DOI 10.1016/j.bbmt.2019.06.001; Lefebvre AM, 1999, J ENDOCRINOL, V162, P331, DOI 10.1677/joe.0.1620331; Legoff J, 2017, NAT MED, V23, P1080, DOI 10.1038/nm.4380; Li XQ, 2020, EBIOMEDICINE, V61, DOI 10.1016/j.ebiom.2020.103048; Lindsay JO, 2006, GUT, V55, P348, DOI 10.1136/gut.2005.074971; Litvak Y, 2018, SCIENCE, V362, P1017, DOI 10.1126/science.aat9076; Litvak Y, 2017, CURR OPIN MICROBIOL, V39, P1, DOI 10.1016/j.mib.2017.07.003; Long CX, 2018, 3 BIOTECH, V8, DOI 10.1007/s13205-018-1191-5; Macia L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7734; Makarova K, 2006, P NATL ACAD SCI USA, V103, P15611, DOI 10.1073/pnas.0607117103; Mancini N, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx215; Markey KA, 2020, BLOOD, V136, P130, DOI 10.1182/blood.2019003369; Martinez-Medina M, 2014, GUT, V63, P116, DOI 10.1136/gutjnl-2012-304119; Mathewson ND, 2016, NAT IMMUNOL, V17, P505, DOI 10.1038/ni.3400; Michonneau D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13498-3; Montassier E, 2014, MICROB ECOL, V67, P690, DOI 10.1007/s00248-013-0355-4; Monte MJ, 2009, WORLD J GASTROENTERO, V15, P804, DOI 10.3748/wjg.15.804; Morgan XC, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r79; Morjaria S, 2019, INFECT IMMUN, V87, DOI [10.1128/IAI.00206-19, 10.1128/iai.00206-19]; Normann E, 2013, ACTA PAEDIATR, V102, P129, DOI 10.1111/apa.12059; Oku S, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008348; Peled JU, 2020, NEW ENGL J MED, V382, P822, DOI 10.1056/NEJMoa1900623; Peled JU, 2017, J CLIN ONCOL, V35, P1650, DOI 10.1200/JCO.2016.70.3348; Perez-Cano FJ, 2010, DEV COMP IMMUNOL, V34, P210, DOI 10.1016/j.dci.2009.10.001; Peterson CT, 2020, NUTRIENTS, V12, DOI 10.3390/nu12113380; Pichereau C, 2012, BIOL BLOOD MARROW TR, V18, P141, DOI 10.1016/j.bbmt.2011.07.018; Pols TWH, 2011, CELL METAB, V14, P747, DOI 10.1016/j.cmet.2011.11.006; Porter NT, 2017, ANNU REV MICROBIOL, V71, P349, DOI 10.1146/annurev-micro-102215-095316; Postler TS, 2017, CELL METAB, V26, P110, DOI 10.1016/j.cmet.2017.05.008; Qi XF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02195; Rashidi A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42652-6; Reese AT, 2018, ELIFE, V7, DOI 10.7554/eLife.35987; Reikvam H, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-015-0880-x; Rhimi M, 2009, RES MICROBIOL, V160, P775, DOI 10.1016/j.resmic.2009.09.004; Rigottier-Gois L, 2013, ISME J, V7, P1256, DOI 10.1038/ismej.2013.80; Rivera-Chavez F, 2017, FREE RADICAL BIO MED, V105, P93, DOI 10.1016/j.freeradbiomed.2016.09.022; Riwes M, 2020, SEMIN HEMATOL, V57, P1, DOI 10.1053/j.seminhematol.2020.06.001; Rizzatti G, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9351507; Roager HM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05470-4; ROEDIGER WEW, 1980, GUT, V21, P793, DOI 10.1136/gut.21.9.793; Romano KA, 2015, MBIO, V6, DOI 10.1128/mBio.02481-14; Romick-Rosendale LE, 2018, BIOL BLOOD MARROW TR, V24, P2418, DOI 10.1016/j.bbmt.2018.07.030; Routy B, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1258506; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Russo P, 2017, INT J FOOD MICROBIOL, V247, P48, DOI 10.1016/j.ijfoodmicro.2016.04.027; Ruutu T, 2002, BLOOD, V100, P1977, DOI 10.1182/blood-2001-12-0159; Saha SK, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071544; Schiering C, 2017, NATURE, V542, P242, DOI 10.1038/nature21080; Shin NR, 2015, TRENDS BIOTECHNOL, V33, P496, DOI 10.1016/j.tibtech.2015.06.011; Shono Y, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2311; Shouval R, 2020, BLOOD ADV, V4, P2912, DOI 10.1182/bloodadvances.2020001827; Sigalet DL, 2004, CAN J SURG, V47, P109; Simms-Waldrip TR, 2017, BIOL BLOOD MARROW TR, V23, P820, DOI 10.1016/j.bbmt.2017.02.004; Singh N, 2014, IMMUNITY, V40, P128, DOI 10.1016/j.immuni.2013.12.007; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Solders M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01861; Spees AM, 2013, MBIO, V4, DOI 10.1128/mBio.00430-13; Spiga L, 2017, CELL HOST MICROBE, V22, P291, DOI 10.1016/j.chom.2017.07.018; Spindelboeck W, 2017, HAEMATOLOGICA, V102, pE210, DOI 10.3324/haematol.2016.154351; Staffas A, 2018, CELL HOST MICROBE, V23, P447, DOI 10.1016/j.chom.2018.03.002; Stein-Thoeringer CK, 2019, SCIENCE, V366, P1143, DOI 10.1126/science.aax3760; Swimm A, 2018, BLOOD, V132, P2506, DOI 10.1182/blood-2018-03-838193; Taur Y, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aap9489; Taur Y, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0306-z; Taur Y, 2012, CLIN INFECT DIS, V55, P905, DOI 10.1093/cid/cis580; Toubai T, 2020, BLOOD, V136, P429, DOI 10.1182/blood.2019000953; Toubai T, 2019, NAT MICROBIOL, V4, P800, DOI 10.1038/s41564-019-0373-1; Tuohy KM, 2001, BRIT J NUTR, V86, P341, DOI 10.1079/BJN2001394; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; Varelias A, 2018, J CLIN INVEST, V128, P1919, DOI 10.1172/JCI91646; Velasco E, 2006, EUR J CLIN MICROBIOL, V25, P1, DOI 10.1007/s10096-005-0077-8; Velazquez OC, 1997, ADV EXP MED BIOL, V427, P123; Venkataraman A, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0178-x; Vital M, 2014, MBIO, V5, DOI 10.1128/mBio.00889-14; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Wang ZQ, 2019, J CELL MOL MED, V23, P3747, DOI 10.1111/jcmm.14289; Weber D, 2016, BONE MARROW TRANSPL, V51, P1087, DOI 10.1038/bmt.2016.66; Weber D, 2019, CLIN INFECT DIS, V68, P1303, DOI 10.1093/cid/ciy711; Weber D, 2017, BIOL BLOOD MARROW TR, V23, P845, DOI 10.1016/j.bbmt.2017.02.006; Weber D, 2015, BLOOD, V126, P1723, DOI 10.1182/blood-2015-04-638858; Willemsen LEM, 2003, GUT, V52, P1442, DOI 10.1136/gut.52.10.1442; Wrzosek L, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-61; Wu C, 2016, IMMUNOLOGY, V148, P304, DOI 10.1111/imm.12612; Wu KP, 2020, BLOOD, V136, P501, DOI 10.1182/blood.2019003990; Wu SR, 2017, BLOOD, V129, P1747, DOI 10.1182/blood-2016-09-740431; Wu Y, 1999, ANN SURG, V229, P662, DOI 10.1097/00000658-199905000-00008; Zeiser R, 2016, BRIT J HAEMATOL, V175, P191, DOI 10.1111/bjh.14295; Zelante T, 2013, IMMUNITY, V39, P372, DOI 10.1016/j.immuni.2013.08.003; Zhai B, 2020, NAT MED, V26, P59, DOI 10.1038/s41591-019-0709-7; Zhang F, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20240-x; Zhang MH, 2000, CRIT CARE MED, V28, pN60, DOI 10.1097/00003246-200004001-00007; Zinter MS, 2021, BLOOD, V137, P1679, DOI 10.1182/blood.2020009246; Zitvogel L, 2019, SCIENCE, V366, P1077, DOI 10.1126/science.aaz7595	173	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 27	2021	12								703298	10.3389/fimmu.2021.703298	http://dx.doi.org/10.3389/fimmu.2021.703298			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XI8SH	34512627	Green Published, gold			2022-12-18	WOS:000726373500001
J	Howard, GP; Bender, NG; Khare, P; Lopez-Gutierrez, B; Nyasembe, V; Weiss, WJ; Simecka, JW; Hamerly, T; Mao, HQ; Dinglasan, RR				Howard, Gregory P.; Bender, Nicole G.; Khare, Prachi; Lopez-Gutierrez, Borja; Nyasembe, Vincent; Weiss, William J.; Simecka, Jerry W.; Hamerly, Timothy; Mao, Hai-Quan; Dinglasan, Rhoel R.			Immunopotentiation by Lymph-Node Targeting of a Malaria Transmission-Blocking Nanovaccine	FRONTIERS IN IMMUNOLOGY			English	Article						nanoparticle; malaria transmission-blocking vaccine; humoral immune response; lymph node; vaccine; biodegradable; trafficking	PLASMODIUM-FALCIPARUM; VACCINE; NANOPARTICLES; ANTIBODIES; RESPONSES; ANTIGENS	A successful malaria transmission blocking vaccine (TBV) requires the induction of a high antibody titer that leads to abrogation of parasite traversal of the mosquito midgut following ingestion of an infectious bloodmeal, thereby blocking the cascade of secondary human infections. Previously, we developed an optimized construct UF6b that elicits an antigen-specific antibody response to a neutralizing epitope of Anopheline alanyl aminopeptidase N (AnAPN1), an evolutionarily conserved pan-malaria mosquito midgut-based TBV target, as well as established a size-controlled lymph node targeting biodegradable nanoparticle delivery system that leads to efficient and durable antigen-specific antibody responses using the model antigen ovalbumin. Herein, we demonstrate that co-delivery of UF6b with the adjuvant CpG oligodeoxynucleotide immunostimulatory sequence (ODN ISS) 1018 using this biodegradable nanoparticle vaccine delivery system generates an AnAPN1-specific immune response that blocks parasite transmission in a standard membrane feeding assay. Importantly, this platform allows for antigen dose-sparing, wherein lower antigen payloads elicit higher-quality antibodies, therefore less antigen-specific IgG is needed for potent transmission-reducing activity. By targeting lymph nodes directly, the resulting immunopotentiation of AnAPN1 suggests that the de facto assumption that high antibody titers are needed for a TBV to be successful needs to be re-examined. This nanovaccine formulation is stable at -20 degrees C storage for at least 3 months, an important consideration for vaccine transport and distribution in regions with poor healthcare infrastructure. Together, these data support further development of this nanovaccine platform for malaria TBVs.	[Howard, Gregory P.; Mao, Hai-Quan] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA; [Howard, Gregory P.; Mao, Hai-Quan] Johns Hopkins Univ, Inst NanoBioTechnol, Baltimore, MD 21218 USA; [Bender, Nicole G.; Khare, Prachi; Lopez-Gutierrez, Borja; Nyasembe, Vincent; Hamerly, Timothy; Dinglasan, Rhoel R.] Univ Florida, Coll Vet Med, Dept Infect Dis & Immunol, Emerging Pathogens Inst, Gainesville, FL 32611 USA; [Weiss, William J.; Simecka, Jerry W.] Univ North Texas, Hlth Sci Ctr, Dept Pharmaceut Sci, Univ North Texas Syst,Coll Pharm, Ft Worth, TX USA; [Weiss, William J.; Simecka, Jerry W.] Univ North Texas, UNTHSC Preclin Serv, Univ North Texas Syst, Coll Pharm,Hlth Sci Ctr, Ft Worth, TX USA; [Mao, Hai-Quan] Johns Hopkins Univ, Dept Mat Sci & Engn, Willing Sch Engn, Baltimore, MD 21218 USA; [Mao, Hai-Quan] Johns Hopkins Univ, Sch Med, Translat Tissue Engn Ctr, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; State University System of Florida; University of Florida; University of North Texas System; University of North Texas Denton; University of North Texas System; University of North Texas Denton; Johns Hopkins University; Johns Hopkins University	Mao, HQ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.; Mao, HQ (corresponding author), Johns Hopkins Univ, Inst NanoBioTechnol, Baltimore, MD 21218 USA.; Dinglasan, RR (corresponding author), Univ Florida, Coll Vet Med, Dept Infect Dis & Immunol, Emerging Pathogens Inst, Gainesville, FL 32611 USA.; Mao, HQ (corresponding author), Johns Hopkins Univ, Dept Mat Sci & Engn, Willing Sch Engn, Baltimore, MD 21218 USA.; Mao, HQ (corresponding author), Johns Hopkins Univ, Sch Med, Translat Tissue Engn Ctr, Baltimore, MD 21218 USA.	hmao@jhu.edu; rdinglasan@epi.ufl.edu		Weidner, Nicole/0000-0003-1084-9596	National Institutes of Health [R01 AI144609, U01 AI155361]; National Science Foundation [DGE174891]; University of Florida (UF) Preeminence Initiative through the UF College of Veterinary Medicine; UF Emerging Pathogens Institute; University of North Texas Health Science Center (UNTHSC) Preclinical Services group	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); University of Florida (UF) Preeminence Initiative through the UF College of Veterinary Medicine; UF Emerging Pathogens Institute; University of North Texas Health Science Center (UNTHSC) Preclinical Services group	This work was funded by support from the National Institutes of Health (R01 AI144609 and U01 AI155361), National Science Foundation Graduate Research Fellowship Program (DGE174891), and funding from the University of Florida (UF) Preeminence Initiative through the UF College of Veterinary Medicine and the UF Emerging Pathogens Institute. Support was also provided by University of North Texas Health Science Center (UNTHSC) Preclinical Services group.	Andersen TK, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0101-0; Armistead JS, 2014, INFECT IMMUN, V82, P818, DOI 10.1128/IAI.01222-13; Atkinson SC, 2015, NAT STRUCT MOL BIOL, V22, P532, DOI 10.1038/nsmb.3048; Barry M, 2007, EXPERT OPIN BIOL TH, V7, P1731, DOI 10.1517/14712598.7.11.1731; Bender NG, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00309-4; Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596; Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]; Brewer MG, 2017, VACCINE, V35, P774, DOI 10.1016/j.vaccine.2016.12.049; Brouwer PJM, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00285-9; Chaney EJ, 2010, MOL IMAGING, V9, P153, DOI 10.2310/7290.2010.00012; Chattopadhyay Saborni, 2017, Nanotheranostics, V1, P244, DOI 10.7150/ntno.19796; Delves MJ, 2018, TRENDS PARASITOL, V34, P735, DOI 10.1016/j.pt.2018.07.001; Dinglasan RR, 2007, P NATL ACAD SCI USA, V104, P13461, DOI 10.1073/pnas.0702239104; He LL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12041; Healy SA, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI146221; Howard GP, 2019, NANO RES, V12, P837, DOI 10.1007/s12274-019-2301-3; Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202; Ke XY, 2019, ADV DRUG DELIVER REV, V151, P72, DOI 10.1016/j.addr.2019.09.005; Leleux JA, 2017, CELL REP, V18, P700, DOI 10.1016/j.celrep.2016.12.073; Lytle AG, 2015, J VIROL, V89, P2842, DOI 10.1128/JVI.03409-14; Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377; Maldonado RA, 2015, P NATL ACAD SCI USA, V112, pE156, DOI 10.1073/pnas.1408686111; Mathias DK, 2012, INFECT IMMUN, V80, P1606, DOI 10.1128/IAI.06212-11; Mathias DK, 2014, INFECT GENET EVOL, V28, P635, DOI 10.1016/j.meegid.2014.05.025; McCoy KD, 2021, MALARIA J, V20, DOI 10.1186/s12936-021-03723-0; Miura K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69513-x; Miura K, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3470-3; Nunes JK, 2014, VACCINE, V32, P5531, DOI 10.1016/j.vaccine.2014.07.030; Pati R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02224; Rabinovich RN, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002456; Research CfBEa, 2017, HEPLISAV B HEP B VAC; Steichen JM, 2016, IMMUNITY, V45, P483, DOI 10.1016/j.immuni.2016.08.016; Swartz MA, 2001, ADV DRUG DELIVER REV, V50, P3, DOI 10.1016/S0169-409X(01)00150-8; Swartz MA, 2008, SEMIN IMMUNOL, V20, P147, DOI 10.1016/j.smim.2007.11.007; Swartz MA, 2007, ANNU REV BIOMED ENG, V9, P229, DOI 10.1146/annurev.bioeng.9.060906.151850; Tostanoski LH, 2016, CELL REP, V16, P2940, DOI 10.1016/j.celrep.2016.08.033; Wilson KL, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020261; Wilson NS, 2003, BLOOD, V102, P2187, DOI 10.1182/blood-2003-02-0513; World Health O, 2020, WORLD MALARIA REPORT, V2020; Xi XB, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/3714960; Zhang WF, 2014, BIOMATERIALS, V35, P6086, DOI 10.1016/j.biomaterials.2014.04.022; Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069; Zheng SS, 2018, INT J NANOMED, V13, P569, DOI 10.2147/IJN.S153567	43	1	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 27	2021	12								729086	10.3389/fimmu.2021.729086	http://dx.doi.org/10.3389/fimmu.2021.729086			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UT2XT	34512663	Green Published, gold			2022-12-18	WOS:000697984800001
J	Kusmartsev, S; Serafini, P; Bharadwaj, SN; Kortylewski, M				Kusmartsev, Sergei; Serafini, Paolo; Bharadwaj, Srinivas Nagaraj; Kortylewski, Marcin			Editorial: Roles of Tumor-Recruited Myeloid Cells in Immune Evasion in Cancer	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						tumor microenvironment; immune evasion; immune tolerance; MDSC (myeloid-derived suppressor cell); tumor-associated macrophage			[Kusmartsev, Sergei] Univ Florida, Dept Urol, Gainesville, FL 32611 USA; [Serafini, Paolo] Univ Miami, Dept Microbiol & Immunol, Miami, FL USA; [Bharadwaj, Srinivas Nagaraj] Univ S Florida, Dept Internal Med, Tampa, FL 33620 USA; [Kortylewski, Marcin] City Hope Comprehens Canc Ctr, Beckman Res Inst, Dept Immunooncol, Duarte, CA USA	State University System of Florida; University of Florida; University of Miami; State University System of Florida; University of South Florida; City of Hope; Beckman Research Institute of City of Hope	Kusmartsev, S (corresponding author), Univ Florida, Dept Urol, Gainesville, FL 32611 USA.	sakus61@ufl.edu		Kusmartsev, Sergei/0000-0002-0837-8310	SCCC Translational Science Grant; National Cancer Institute/National Institutes of Health [R01CA215183]; Department of Defense [W81XWH1910852]; Fund 1923	SCCC Translational Science Grant; National Cancer Institute/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); Fund 1923	This work was supported by DYFund 1923 to SK, SCCC Translational Science Grant to PS and by the National Cancer Institute/National Institutes of Health award number R01CA215183 and the Department of Defense grant W81XWH1910852 to MK.	Jamieson T, 2012, J CLIN INVEST, V122, P3127, DOI 10.1172/JCI61067; Peired AJ, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw6003; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Zhou XN, 2021, CANCER RES, V81, P2690, DOI 10.1158/0008-5472.CAN-20-2930	4	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 27	2021	12								749605	10.3389/fimmu.2021.749605	http://dx.doi.org/10.3389/fimmu.2021.749605			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU5EI	34512674	Green Published, gold			2022-12-18	WOS:000698823000001
J	Kammers, K; Chen, ATA; Monaco, DR; Hudelson, SE; Grant-McAuley, W; Moore, RD; Alter, G; Deeks, SG; Morrison, CS; Eller, LA; Blankson, JN; Laeyendecker, O; Ruczinski, I; Eshleman, SH; Larman, HB				Kammers, Kai; Chen, Athena; Monaco, Daniel R.; Hudelson, Sarah E.; Grant-McAuley, Wendy; Moore, Richard D.; Alter, Galit; Deeks, Steven G.; Morrison, Charles S.; Eller, Leigh A.; Blankson, Joel N.; Laeyendecker, Oliver; Ruczinski, Ingo; Eshleman, Susan H.; Larman, H. Benjamin			HIV Antibody Profiles in HIV Controllers and Persons With Treatment-Induced Viral Suppression	FRONTIERS IN IMMUNOLOGY			English	Article						HIV control; viral load set point; antibody profiling; phage display; VirScan	DEPENDENT CELLULAR CYTOTOXICITY; MATRIX PROTEIN P17; IMMUNODEFICIENCY-VIRUS TYPE-1; CD4(+) T-CELLS; HIV-1-INFECTED PATIENTS; ELITE SUPPRESSORS; HLA-B; INFECTION; REPLICATION; PROGRESSION	IntroductionLow HIV viral load is associated with delayed disease progression and reduced HIV transmission. HIV controllers suppress viral load to low levels in the absence of antiretroviral treatment (ART). We used an antibody profiling system, VirScan, to compare antibody reactivity and specificity in HIV controllers, non-controllers with treatment-induced viral suppression, and viremic non-controllers. MethodsThe VirScan library contains 3,384 phage-displayed peptides spanning the HIV proteome. Antibody reactivity to these peptides was measured in plasma from a Discovery Cohort that included 13 elite controllers, 27 viremic controllers, 12 viremic non-controllers, and 21 non-controllers who were virally suppressed on ART. Antibody reactivity to selected peptides was also assessed in an independent cohort of 29 elite controllers and 37 non-controllers who were virally suppressed on ART (Validation Cohort) and in a longitudinal cohort of non-controllers. ResultsIn the Discovery Cohort, 62 peptides were preferentially targeted in HIV controllers compared to non-controllers who were virally suppressed on ART. These specificities were not significantly different when comparing controllers versus viremic non-controllers. Aggregate reactivity to these peptides was also high in elite controllers from the independent Validation Cohort. The 62 peptides formed seven clusters of homologous epitopes in env, gag, integrase, and vpu. Reactivity to one of these clusters located in gag p17 was inversely correlated with viral load set point in an independent cohort of non-controllers. ConclusionsAntibody reactivity was low in non-controllers suppressed on ART, but remained high in viremic controllers despite viral suppression. Antibodies in controllers and viremic non-controllers were directed against epitopes in diverse HIV proteins; higher reactivity against p17 peptides was associated with lower viral load set point. Further studies are needed to determine if these antibodies play a role in regulation of HIV viral load.	[Kammers, Kai] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Div Biostat & Bioinformat,Dept Oncol, Baltimore, MD USA; [Chen, Athena; Ruczinski, Ingo] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Monaco, Daniel R.; Hudelson, Sarah E.; Grant-McAuley, Wendy; Eshleman, Susan H.; Larman, H. Benjamin] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Monaco, Daniel R.; Larman, H. Benjamin] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21218 USA; [Moore, Richard D.; Blankson, Joel N.; Laeyendecker, Oliver] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Alter, Galit] Massachusetts Inst Technol MIT & Harvard, Massachusetts Gen Hosp, Ragon Inst, Dept Med, Cambridge, MA USA; [Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Morrison, Charles S.] Family Hlth Int FHI 360, Behav Epidemiol & Clin Sci, Durham, NC USA; [Eller, Leigh A.] US Mil HIV Res Program, Walter Reed Army Inst Res, Silver Spring, MD USA; [Eller, Leigh A.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA; [Laeyendecker, Oliver] NIAID, Lab Immunoregulat, NIH, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; University of California System; University of California San Francisco; FHI 360; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); NIH National Institute on Aging (NIA)	Eshleman, SH; Larman, HB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.; Larman, HB (corresponding author), Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21218 USA.	seshlem@jhmi.edu; hlarman1@jhmi.edu		Laeyendecker, Oliver/0000-0002-6429-4760; Greenawalt, Wendy/0000-0002-7002-3676				Ackerman ME, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005315; Asher AK, 2013, AIDS, V27, P2691, DOI 10.1097/01.aids.0000433242.86362.21; Bailey JR, 2006, J EXP MED, V203, P1357, DOI 10.1084/jem.20052319; Bailey JR, 2006, J VIROL, V80, P4758, DOI 10.1128/JVI.80.10.4758-4770.2006; Bao LY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16742-2; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Blankson JN, 2007, J VIROL, V81, P2508, DOI 10.1128/JVI.02165-06; Burbelo PD, 2020, J INFECT DIS, V222, P206, DOI 10.1093/infdis/jiaa273; Caccuri F, 2016, CURR DRUG TARGETS, V17, P23, DOI 10.2174/1389450116666150825110840; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1600693, 10.1056/NEJMoa1105243]; Corrales I, 2014, CLIN VACCINE IMMUNOL, V21, P684, DOI 10.1128/CVI.00104-14; Curtis KA, 2012, AIDS RES HUM RETROV, V28, P188, DOI [10.1089/aid.2011.0037, 10.1089/AID.2011.0037]; De Francesco MA, 2002, P NATL ACAD SCI USA, V99, P9972, DOI 10.1073/pnas.142274699; Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010; Dotsey EY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125581; Eshleman SH, 2019, CELL REP, V27, P1422, DOI 10.1016/j.celrep.2019.03.097; Fellay J, 2007, SCIENCE, V317, P944, DOI 10.1126/science.1143767; Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005; Fiorentini S, 2006, NEW MICROBIOL, V29, P1; Fiorentini S, 2010, PHARMACOL THERAPEUT, V128, P433, DOI 10.1016/j.pharmthera.2010.08.005; Fisher R. A., 1946, Statistical methods for research workers.; Foca E, 2015, HIV CLIN TRIALS, V16, P157, DOI 10.1179/1528433614Z.0000000018; Friedrich TC, 2007, J VIROL, V81, P3465, DOI 10.1128/JVI.02392-06; Gonzalo-Gil E, 2017, YALE J BIOL MED, V90, P245; Gruell H, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0455-9; Hunt PW, 2011, CLIN INFECT DIS, V52, P681, DOI 10.1093/cid/ciq202; Iaria ML, 2014, VACCINE, V32, P1072, DOI 10.1016/j.vaccine.2013.12.051; Isitman G, 2016, AIDS RES HUM RETROV, V32, P1079, DOI 10.1089/aid.2016.0157; Kong WW, 2016, J VIROL METHODS, V227, P1, DOI 10.1016/j.jviromet.2015.10.007; Kramski M, 2015, AIDS, V29, P137, DOI 10.1097/QAD.0000000000000523; Laeyendecker O, 2008, JAIDS-J ACQ IMM DEF, V48, P211, DOI 10.1097/QAI.0b013e3181743980; Lambotte O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074855; Lambotte O, 2009, AIDS, V23, P897, DOI 10.1097/QAD.0b013e328329f97d; Lamine A, 2007, AIDS, V21, P1043, DOI 10.1097/QAD.0b013e3280d5a7ac; Leon A, 2016, AIDS, V30, P1209, DOI 10.1097/QAD.0000000000001050; Madhavi V, 2017, J VIROL, V91, DOI 10.1128/JVI.00700-17; Margolis DM, 2017, IMMUNOL REV, V275, P313, DOI 10.1111/imr.12506; Martin MP, 2007, NAT GENET, V39, P733, DOI 10.1038/ng2035; Martin MP, 2018, J CLIN INVEST, V128, P1903, DOI 10.1172/JCI98463; Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010; Mohan D, 2019, NAT PROTOC, V14, P2596, DOI 10.1038/s41596-018-0088-4; Moore RD, 1998, J ACQ IMMUN DEF SYND, V17, pS38, DOI 10.1097/00042560-199801001-00011; Pandrea I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002170; Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786; Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271; Robb ML, 2016, NEW ENGL J MED, V374, P2120, DOI 10.1056/NEJMoa1508952; Rondon IJ, 1997, ANNU REV MICROBIOL, V51, P257, DOI 10.1146/annurev.micro.51.1.257; Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104; Salgado M, 2014, J VIROL, V88, P3340, DOI 10.1128/JVI.03380-13; Smalls-Mantey A, 2012, J VIROL, V86, P8672, DOI 10.1128/JVI.00287-12; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Tehrani ZR, 2018, J VIROL METHODS, V253, P5, DOI 10.1016/j.jviromet.2017.12.003; Veenhuis RT, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122795; Wendel SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055525; Wren LH, 2013, IMMUNOLOGY, V138, P116, DOI 10.1111/imm.12016; Xu GJ, 2015, SCIENCE, V348, DOI 10.1126/science.aaa0698	60	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 26	2021	12								740395	10.3389/fimmu.2021.740395	http://dx.doi.org/10.3389/fimmu.2021.740395			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XM5AW	34512672	Green Published, gold			2022-12-18	WOS:000728840800001
J	Oulee, A; Ma, FY; Teles, RMB; Silva, BDJ; Pellegrini, M; Klechevsky, E; Harman, AN; Rhodes, JW; Modlin, RL				Oulee, Aislyn; Ma, Feiyang; Teles, Rosane M. B.; de Andrade Silva, Bruno J.; Pellegrini, Matteo; Klechevsky, Eynav; Harman, Andrew N.; Rhodes, Jake W.; Modlin, Robert L.			Identification of Genes Encoding Antimicrobial Proteins in Langerhans Cells	FRONTIERS IN IMMUNOLOGY			English	Article						Langerhans cells; dendritic cells; antimicrobial peptides; immunity; skin; transcriptome; bioinformatics	SOFT-TISSUE INFECTIONS; DENDRITIC CELLS; T-CELLS; DIFFERENTIAL PRODUCTION; EXPRESSION; RECEPTOR; SKIN; RECOGNITION; CHEMOKINES; MATURATION	Langerhans cells (LCs) reside in the epidermis where they are poised to mount an antimicrobial response against microbial pathogens invading from the outside environment. To elucidate potential pathways by which LCs contribute to host defense, we mined published LC transcriptomes deposited in GEO and the scientific literature for genes that participate in antimicrobial responses. Overall, we identified 31 genes in LCs that encode proteins that contribute to antimicrobial activity, ten of which were cross-validated in at least two separate experiments. Seven of these ten antimicrobial genes encode chemokines, CCL1, CCL17, CCL19, CCL2, CCL22, CXCL14 and CXCL2, which mediate both antimicrobial and inflammatory responses. Of these, CCL22 was detected in seven of nine transcriptomes and by PCR in cultured LCs. Overall, the antimicrobial genes identified in LCs encode proteins with broad antibacterial activity, including against Staphylococcus aureus, which is the leading cause of skin infections. Thus, this study illustrates that LCs, consistent with their anatomical location, are programmed to mount an antimicrobial response against invading pathogens in skin.	[Oulee, Aislyn; Ma, Feiyang; Teles, Rosane M. B.; de Andrade Silva, Bruno J.; Modlin, Robert L.] Univ Calif Los Angeles, Div Dermatol, Dept Med, Los Angeles, CA 90024 USA; [Ma, Feiyang; Modlin, Robert L.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90024 USA; [Ma, Feiyang; Pellegrini, Matteo] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA USA; [Klechevsky, Eynav] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Harman, Andrew N.; Rhodes, Jake W.] Westmead Inst Med Res, Ctr Virus Res, Westmead, NSW, Australia; [Harman, Andrew N.; Rhodes, Jake W.] Univ Sydney, Sch Med Sci, Fac Med & Hlth Sydney, Westmead, NSW, Australia	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Washington University (WUSTL); University of Sydney; Westmead Institute for Medical Research; University of Sydney	Modlin, RL (corresponding author), Univ Calif Los Angeles, Div Dermatol, Dept Med, Los Angeles, CA 90024 USA.; Modlin, RL (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90024 USA.	rmodlin@mednet.ucla.edu	Ma, Feiyang/GLN-6180-2022; Rhodes, Jake William/AAA-7376-2022	Rhodes, Jake/0000-0001-9507-4894	NIH [R01 AI022553, R01 AR040312, R01 AR073252, R01 AR074302]; NHMRCIdeas [APP1181482, 5R21EB024767-02, 1R01AR075959-01];  [1R01CA245277-01A1]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHMRCIdeas; 	& nbsp;NIH grants R01 AI022553 (RLM, MP), R01 AR040312 (RLM, MP), R01 AR073252 (RLM, MP), R01 AR074302 (RLM, MP), NHMRCIdeas Grant APP1181482 (AH), 5R21EB024767-02 (EK), 1R01AR075959-01 (EK) and 1R01CA245277-01A1 (EK).	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Alferink J, 2003, J EXP MED, V197, P585, DOI 10.1084/jem.20021859; Arlehamn CSL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003130; Artyomov MN, 2015, J EXP MED, V212, P743, DOI 10.1084/jem.20131675; Balin SJ, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat7668; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Banchereau J, 2012, P NATL ACAD SCI USA, V109, P18885, DOI 10.1073/pnas.1205785109; Banchereau J, 2012, BLOOD, V119, P5742, DOI 10.1182/blood-2011-08-371245; Berthier-Vergnes O, 2005, FEBS LETT, V579, P3660, DOI 10.1016/j.febslet.2005.04.087; Bertram KM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10697-w; Botting RA, 2017, J LEUKOCYTE BIOL, V101, P1393, DOI 10.1189/jlb.4A1116-496R; Boyd A, 2013, INFECT IMMUN, V81, P1420, DOI 10.1128/IAI.01301-12; Burkhardt AM, 2012, J IMMUNOL, V188, P6399, DOI 10.4049/jimmunol.1102903; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Dang AT, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126955; de Jong A, 2014, NAT IMMUNOL, V15, P177, DOI 10.1038/ni.2790; de Jong MAWP, 2010, TRENDS IMMUNOL, V31, P452, DOI 10.1016/j.it.2010.08.002; de Witte L, 2007, NAT MED, V13, P367, DOI 10.1038/nm1541; Dhiman R, 2014, J INFECT DIS, V209, P578, DOI 10.1093/infdis/jit495; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; FITHIAN E, 1981, P NATL ACAD SCI-BIOL, V78, P2541, DOI 10.1073/pnas.78.4.2541; Fujita H, 2005, J INVEST DERMATOL, V124, P343, DOI 10.1111/j.0022-202X.2004.23607.x; Fujita H, 2009, P NATL ACAD SCI USA, V106, P21795, DOI 10.1073/pnas.0911472106; Ghadially H, 2005, J IMMUNOL, V174, P5620, DOI 10.4049/jimmunol.174.9.5620; Harman AN, 2006, J IMMUNOL, V177, P7103, DOI 10.4049/jimmunol.177.10.7103; HEUFLER C, 1992, J EXP MED, V176, P1221, DOI 10.1084/jem.176.4.1221; Hoover DM, 2002, J BIOL CHEM, V277, P37647, DOI 10.1074/jbc.M203907200; Hunger RE, 2004, J CLIN INVEST, V113, P701, DOI 10.1172/JCI200419655; Hutter C, 2012, BLOOD, V120, P5199, DOI 10.1182/blood-2012-02-410241; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Kashem SW, 2017, ANNU REV IMMUNOL, V35, P469, DOI 10.1146/annurev-immunol-051116-052215; KIMBER I, 1992, J INVEST DERMATOL, V99, pS48, DOI 10.1111/1523-1747.ep12668986; Klechevsky E, 2008, IMMUNITY, V29, P497, DOI 10.1016/j.immuni.2008.07.013; Klechevsky E, 2015, ADV EXP MED BIOL, V850, P43, DOI 10.1007/978-3-319-15774-0_4; Korenfeld D, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.96101; Kotarsky K, 2010, MUCOSAL IMMUNOL, V3, P40, DOI 10.1038/mi.2009.115; Krijgsveld J, 2000, J BIOL CHEM, V275, P20374, DOI 10.1074/jbc.275.27.20374; Kubo A, 2009, J EXP MED, V206, P2937, DOI 10.1084/jem.20091527; Kunkel EJ, 2002, AM J PATHOL, V160, P347, DOI 10.1016/S0002-9440(10)64378-7; Lambert RW, 2002, NEUROPEPTIDES, V36, P246, DOI 10.1016/S0143-4179(02)00020-3; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; LENZ A, 1993, J CLIN INVEST, V92, P2587, DOI 10.1172/JCI116873; Lim KPH, 2020, BLOOD ADV, V4, P87, DOI 10.1182/bloodadvances.2019000488; Lu Q, 2005, J PERIODONTAL RES, V40, P474, DOI 10.1111/j.1600-0765.2005.00827.x; Luger TA, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P87, DOI 10.1038/jidsymp.1997.17; Lukacs NW, 2001, NAT REV IMMUNOL, V1, P108, DOI 10.1038/35100503; McGovern N, 2014, IMMUNITY, V41, P465, DOI 10.1016/j.immuni.2014.08.006; Merad M, 2008, NAT REV IMMUNOL, V8, P935, DOI 10.1038/nri2455; Moet GJ, 2007, DIAGN MICR INFEC DIS, V57, P7, DOI 10.1016/j.diagmicrobio.2006.05.009; Nasr N, 2014, J IMMUNOL, V193, P2554, DOI 10.4049/jimmunol.1400630; NESTLE FO, 1993, J IMMUNOL, V151, P6535; O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189; Oliveros JC, 2007, VENNY 2 1 0; Osorio F, 2011, IMMUNITY, V34, P651, DOI 10.1016/j.immuni.2011.05.001; Penel-Sotirakis K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045680; Pilkington SM, 2018, BRIT J DERMATOL, V179, P1170, DOI 10.1111/bjd.16770; Polak ME, 2014, J INVEST DERMATOL, V134, P695, DOI 10.1038/jid.2013.375; Polak ME, 2012, J INVEST DERMATOL, V132, P1636, DOI 10.1038/jid.2012.26; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; Ratzinger G, 2004, J IMMUNOL, V173, P2780, DOI 10.4049/jimmunol.173.4.2780; Ray GT, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-252; Reiss Y, 2001, J EXP MED, V194, P1541, DOI 10.1084/jem.194.10.1541; Renn CN, 2006, J IMMUNOL, V177, P298, DOI 10.4049/jimmunol.177.1.298; Rennie RP, 2003, DIAGN MICR INFEC DIS, V45, P287, DOI 10.1016/S0732-8893(02)00543-6; Rhodes JW., 2020, IDENTIFICATION HIV T, DOI [10.1101/2020.05.26.117408, DOI 10.1101/2020.05.26.117408]; Ribeiro CMS, 2016, NATURE, V540, P448, DOI 10.1038/nature20567; Ross R, 1999, J INVEST DERMATOL, V113, P991, DOI 10.1046/j.1523-1747.1999.00803.x; Sallusto F, 2009, EUR J IMMUNOL, V39, P2076, DOI 10.1002/eji.200939722; Schaerli P, 2004, J EXP MED, V199, P1265, DOI 10.1084/jem.20032177; Sirvent S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14125-x; STEINBAKK M, 1990, LANCET, V336, P763, DOI 10.1016/0140-6736(90)93237-J; Strbo N, 2019, EXP DERMATOL, V28, P225, DOI 10.1111/exd.13870; Szeles L, 2010, MOL ENDOCRINOL, V24, P2218, DOI 10.1210/me.2010-0215; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; Ueno H, 2007, IMMUNOL REV, V219, P118, DOI 10.1111/j.1600-065X.2007.00551.x; Valladeau J, 2000, IMMUNITY, V12, P71, DOI 10.1016/S1074-7613(00)80160-0; van der Vlist M, 2010, IMMUNOL CELL BIOL, V88, P410, DOI 10.1038/icb.2010.32; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Wang BH, 1999, J LEUKOCYTE BIOL, V66, P33, DOI 10.1002/jlb.66.1.33; Wang GS, 2016, NUCLEIC ACIDS RES, V44, pD1087, DOI 10.1093/nar/gkv1278; Wu XD, 2016, J EXP MED, V213, P2553, DOI 10.1084/jem.20160600; Yang D, 2003, J LEUKOCYTE BIOL, V74, P448, DOI 10.1189/jlb.0103024; Zaba LC, 2007, J CLIN INVEST, V117, P2517, DOI 10.1172/JCI32282	84	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 26	2021	12								695373	10.3389/fimmu.2021.695373	http://dx.doi.org/10.3389/fimmu.2021.695373			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	XM7EY	34512625	gold, Green Published			2022-12-18	WOS:000728986700001
J	Peng, ZL; Zhang, YW; Ma, XC; Zhou, M; Wu, SY; Song, Z; Yuan, YC; Chen, YS; Li, YZ; Wang, GW; Huang, F; Qiao, YD; Xia, BJ; Liu, WW; Liu, J; Zhang, X; He, X; Pan, T; Xu, HS; Zhang, H				Peng, Zhilin; Zhang, Yiwen; Ma, Xiancai; Zhou, Mo; Wu, Shiyu; Song, Zheng; Yuan, Yaochang; Chen, Yingshi; Li, Yuzhuang; Wang, Guanwen; Huang, Feng; Qiao, Yidan; Xia, Baijing; Liu, Weiwei; Liu, Jun; Zhang, Xu; He, Xin; Pan, Ting; Xu, Hanshi; Zhang, Hui			Brd4 Regulates the Homeostasis of CD8(+) T-Lymphocytes and Their Proliferation in Response to Antigen Stimulation	FRONTIERS IN IMMUNOLOGY			English	Article						CD8(+) T cell homeostasis; CD8(+) T cell proliferation; Brd4; glucose metabolism; antiviral immunity	BROMODOMAIN INHIBITOR OTX015; MITOCHONDRIAL-FUNCTION; CELL HOMEOSTASIS; DOSE-ESCALATION; MEMORY; NAIVE; DIFFERENTIATION; TRANSCRIPTION; METABOLISM; ACTIVATION	CD8(+) T cells are major components of adaptive immunity and confer robust protective cellular immunity, which requires adequate T-cell numbers, targeted migration, and efficient T-cell proliferation. Altered CD8(+) T-cell homeostasis and impaired proliferation result in dysfunctional immune response to infection or tumorigenesis. However, intrinsic factors controlling CD8(+) T-cell homeostasis and immunity remain largely elusive. Here, we demonstrate the prominent role of Brd4 on CD8(+) T cell homeostasis and immune response. By upregulating Myc and GLUT1 expression, Brd4 facilitates glucose uptake and energy production in mitochondria, subsequently supporting naive CD8(+) T-cell survival. Besides, Brd4 promotes the trafficking of naive CD8(+) T cells partially through maintaining the expression of homing receptors (CD62L and LFA-1). Furthermore, Brd4 is required for CD8(+) T cell response to antigen stimulation, as Brd4 deficiency leads to a severe defect in clonal expansion and terminal differentiation by decreasing glycolysis. Importantly, as JQ1, a pan-BRD inhibitor, severely dampens CD8(+) T-cell immune response, its usage as an anti-tumor agent or latency-reversing agent for human immunodeficiency virus type I (HIV-1) should be more cautious. Collectively, our study identifies a previously-unexpected role of Brd4 in the metabolic regulation of CD8(+) T cell-mediated immune surveillance and also provides a potential immunomodulation target.	[Peng, Zhilin; Zhang, Yiwen; Ma, Xiancai; Zhou, Mo; Wu, Shiyu; Song, Zheng; Yuan, Yaochang; Chen, Yingshi; Li, Yuzhuang; Qiao, Yidan; Xia, Baijing; Liu, Weiwei; Liu, Jun; Zhang, Xu; He, Xin; Zhang, Hui] Sun Yat Sen Univ, Guangdong Engn Res Ctr Antimicrobial Agent & Immu, Zhongshan Sch Med, Inst Human Virol,Key Lab Trop Dis Control,Minist, Guangzhou, Peoples R China; [Wang, Guanwen] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China; [Huang, Feng] Guangzhou Regenerat Med & Hlth Guangdong Lab, Bioland Lab, Guangzhou, Peoples R China; [Pan, Ting] Sun Yat Sen Univ, Ctr Infect & Immun Studies, Sch Med, Shenzhen, Peoples R China; [Xu, Hanshi] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Rheumatol, Guangzhou, Peoples R China	Sun Yat Sen University; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Guangzhou Regenerative Medicine & Health Guangdong Laboratory (Bioisland Laboratory); Sun Yat Sen University; Sun Yat Sen University	Zhang, H (corresponding author), Sun Yat Sen Univ, Guangdong Engn Res Ctr Antimicrobial Agent & Immu, Zhongshan Sch Med, Inst Human Virol,Key Lab Trop Dis Control,Minist, Guangzhou, Peoples R China.; Pan, T (corresponding author), Sun Yat Sen Univ, Ctr Infect & Immun Studies, Sch Med, Shenzhen, Peoples R China.; Xu, HS (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Rheumatol, Guangzhou, Peoples R China.	pant8@mail.sysu.edu.cn; xuhanshi@mail.sysu.edu.cn; zhangh92@mail.sysu.edu.cn	Chen, Yingshi/GLT-9645-2022	Chen, Yingshi/0000-0002-5391-5103; Ma, Xiancai/0000-0002-4934-4221; He, Xin/0000-0002-2131-2092	National Special Research Program of China for Important Infectious Diseases [2017ZX10202102, 2018ZX10302103]; Important Key Program of Natural Science Foundation of China [81730060]; Joint-innovation Program in Healthcare for Special Scientific Research Projects of Guangzhou [201803040002]; Guangzhou Science and Technology Project [201803010042]; National Natural Science Foundation of China [81971918]; Shenzhen Science and Technology Program [JSGG20200225150431472, JCYJ20200109142601702]; Pearl River S&T Nova Program of Guangzhou [201806010118]; Fundamental Research Funds for the Central Universities, Sun Yat-sen University [2021qntd43]	National Special Research Program of China for Important Infectious Diseases; Important Key Program of Natural Science Foundation of China; Joint-innovation Program in Healthcare for Special Scientific Research Projects of Guangzhou; Guangzhou Science and Technology Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Science and Technology Program; Pearl River S&T Nova Program of Guangzhou; Fundamental Research Funds for the Central Universities, Sun Yat-sen University(Fundamental Research Funds for the Central Universities)	This work was supported by the National Special Research Program of China for Important Infectious Diseases (2017ZX10202102 and 2018ZX10302103), the Important Key Program of Natural Science Foundation of China (81730060) and the Joint-innovation Program in Healthcare for Special Scientific Research Projects of Guangzhou (201803040002) to HZ and Guangzhou Science and Technology Project (201803010042)to XH. This work was also supported by National Natural Science Foundation of China (81971918), Shenzhen Science and Technology Program (Grant No. JSGG20200225150431472 and JCYJ20200109142601702), the Pearl River S&T Nova Program of Guangzhou (201806010118) and the Fundamental Research Funds for the Central Universities, Sun Yat-sen University (2021qntd43) to TP.	Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1; Amsen D, 2018, NAT IMMUNOL, V19, P538, DOI 10.1038/s41590-018-0114-2; Bao Y, 2017, P NATL ACAD SCI USA, V114, pE3993, DOI 10.1073/pnas.1700109114; Barber DL, 2003, J IMMUNOL, V171, P27, DOI 10.4049/jimmunol.171.1.27; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Blattman JN, 2009, J VIROL, V83, P4386, DOI 10.1128/JVI.02524-08; Borck PC, 2020, CIRC RES, V126, P1190, DOI 10.1161/CIRCRESAHA.120.315929; Carlson CM, 2006, NATURE, V442, P299, DOI 10.1038/nature04882; Cham CM, 2008, EUR J IMMUNOL, V38, P2438, DOI 10.1002/eji.200838289; Cham CM, 2005, J IMMUNOL, V174, P4670, DOI 10.4049/jimmunol.174.8.4670; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Cheung KL, 2017, MOL CELL, V65, P1068, DOI 10.1016/j.molcel.2016.12.022; Cheung KL, 2017, P NATL ACAD SCI USA, V114, P2952, DOI 10.1073/pnas.1615601114; Conrad RJ, 2017, MOL CELL, V67, P1001, DOI 10.1016/j.molcel.2017.07.025; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Desdin-Mico G, 2018, MITOCHONDRION, V41, P51, DOI 10.1016/j.mito.2017.10.006; Devaiah BN, 2016, J LEUKOCYTE BIOL, V100, P679, DOI 10.1189/jlb.2RI0616-250R; Dey A, 2019, EMBO J, V38, DOI 10.15252/embj.2018100293; Fischer A, 2005, IMMUNOL REV, V203, P98, DOI 10.1111/j.0105-2896.2005.00223.x; Franciszkiewicz K, 2013, CANCER RES, V73, P617, DOI 10.1158/0008-5472.CAN-12-2569; Gegonne A, 2018, CELL REP, V24, P117, DOI 10.1016/j.celrep.2018.06.007; Geltink RIK, 2018, ANNU REV IMMUNOL, V36, P461, DOI 10.1146/annurev-immunol-042617-053019; Georgiev Peter, 2019, Immunohorizons, V3, P294, DOI 10.4049/immunohorizons.1900037; Gibbons HR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46516-x; He ZP, 2020, J VIROL, V94, DOI 10.1128/JVI.01923-19; Ho PC, 2015, CELL, V162, P1217, DOI 10.1016/j.cell.2015.08.012; Kannan-Sundhari A, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.576654; Kaya-Okur HS, 2020, NAT PROTOC, V15, P3264, DOI 10.1038/s41596-020-0373-x; Kerdiles YM, 2009, NAT IMMUNOL, V10, P176, DOI 10.1038/ni.1689; Khandekar D, 2020, CANCERS, V12, DOI 10.3390/cancers12040784; Kochl R, 2016, NAT IMMUNOL, V17, P1075, DOI 10.1038/ni.3495; Kondo N, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00424-16; Korb E, 2015, NAT NEUROSCI, V18, P1464, DOI 10.1038/nn.4095; Ledderose C, 2018, J CLIN INVEST, V128, P3583, DOI 10.1172/JCI120972; Li D, 2009, J BIOL CHEM, V284, P21001, DOI 10.1074/jbc.M109.002865; Li GM, 2019, J VIROL, V93, DOI 10.1128/JVI.00233-19; Li ZC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007012; Li ZC, 2013, NUCLEIC ACIDS RES, V41, P277, DOI 10.1093/nar/gks976; Liu C, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0517-y; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Ma EH, 2019, IMMUNITY, V51, P856, DOI 10.1016/j.immuni.2019.09.003; Ma XC, 2021, EMBO J, V40, DOI 10.15252/embj.2020106632; Ma XC, 2019, ELIFE, V8, DOI 10.7554/eLife.42426; MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956; Masopust D, 2013, NAT REV IMMUNOL, V13, P309, DOI 10.1038/nri3442; McNamara HA, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aaj1996; Mele DA, 2013, J EXP MED, V210, P2181, DOI 10.1084/jem.20130376; Mendoza A, 2017, NATURE, V546, P158, DOI 10.1038/nature22352; Milasta S, 2016, IMMUNITY, V44, P88, DOI 10.1016/j.immuni.2015.12.002; Milner JJ, 2021, J EXP MED, V218, DOI 10.1084/jem.20202512; Ott CJ, 2012, BLOOD, V120, P2843, DOI 10.1182/blood-2012-02-413021; Phan AT, 2016, IMMUNITY, V45, P1024, DOI 10.1016/j.immuni.2016.10.017; Qiu J, 2019, CELL REP, V27, P2063, DOI 10.1016/j.celrep.2019.04.022; Sebzda E, 2008, NAT IMMUNOL, V9, P292, DOI 10.1038/ni1565; Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016; Sprent J, 2011, NAT IMMUNOL, V12, P478, DOI 10.1038/ni.2018; Stanlie A, 2014, MOL CELL, V55, P97, DOI 10.1016/j.molcel.2014.05.018; Surh CD, 2008, IMMUNITY, V29, P848, DOI 10.1016/j.immuni.2008.11.002; Takada K, 2009, NAT REV IMMUNOL, V9, P823, DOI 10.1038/nri2657; Vaeth M, 2017, IMMUNITY, V47, P664, DOI 10.1016/j.immuni.2017.09.003; Varga G, 2010, J INVEST DERMATOL, V130, P1005, DOI 10.1038/jid.2009.398; Walling BL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00952; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Wein AN, 2019, J EXP MED, V216, P2748, DOI 10.1084/jem.20181308; Zhu J, 2012, CELL REP, V2, P807, DOI 10.1016/j.celrep.2012.09.008	66	1	1	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 26	2021	12								728082	10.3389/fimmu.2021.728082	http://dx.doi.org/10.3389/fimmu.2021.728082			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU4WF	34512660	Green Published, gold			2022-12-18	WOS:000698801900001
J	Plaza-Sirvent, C; Zhao, B; Bronietzki, AW; Pils, MC; Tafrishi, N; Schuster, M; Strowig, T; Schmitz, I				Plaza-Sirvent, Carlos; Zhao, Bei; Bronietzki, Alisha W.; Pils, Marina C.; Tafrishi, Neda; Schuster, Marc; Strowig, Till; Schmitz, Ingo			A Central Role for Atg5 in Microbiota-Dependent Foxp3(+) ROR gamma t(+) Treg Cell Preservation to Maintain Intestinal Immune Homeostasis	FRONTIERS IN IMMUNOLOGY			English	Article						autophagy; Atg5; ROR gamma t(+) Foxp3(+) Treg cells; intestinal homeostasis; inflammation	REGULATORY T-CELLS; CHAIN FATTY-ACIDS; AUTOPHAGY; DIFFERENTIATION; ENTEROPATHY; METABOLITES; SEQUENCES; CAPACITY; SURVIVAL; PROTEIN	Autophagy is an evolutionary conserved catabolic pathway that ensures the degradation of intracellular components. The autophagic pathway is regulated by autophagy-related (Atg) proteins that govern formation of double-membraned vesicles called autophagosomes. Autophagy deficiency in regulatory T (Treg) cells leads to increased apoptosis of these cells and to the development of autoimmune disorders, predominantly characterized by intestinal inflammation. Recently, ROR gamma t-expressing Treg cells have been identified as key regulators of gut homeostasis, preventing intestinal immunopathology. To study the role of autophagy in ROR gamma t(+) Foxp3(+) Treg cells, we generated mice lacking the essential component of the core autophagy machinery Atg5 in Foxp3(+) cells. Atg5 deficiency in Treg cells led to a predominant intestinal inflammation. While Atg5-deficient Treg cells were reduced in peripheral lymphoid organs, the intestinal ROR gamma t(+) Foxp3(+) subpopulation of Treg cells was most severely affected. Our data indicated that autophagy is essential to maintain the intestinal ROR gamma t(+) Foxp3(+) Treg population, thereby protecting the mice from gut inflammatory disorders.	[Plaza-Sirvent, Carlos; Schmitz, Ingo] Ruhr Univ Bochum, Dept Mol Immunol, Bochum, Germany; [Plaza-Sirvent, Carlos; Bronietzki, Alisha W.; Tafrishi, Neda; Schuster, Marc; Schmitz, Ingo] Helmholtz Ctr Infect Res, Syst Oriented Immunol & Inflammat Res Grp, Braunschweig, Germany; [Plaza-Sirvent, Carlos; Bronietzki, Alisha W.; Schuster, Marc; Schmitz, Ingo] Otto Von Guericke Univ, Inst Mol & Clin Immunol, Magdeburg, Germany; [Zhao, Bei] Helmholtz Ctr Infect Res, Dept Microbial Immune Regulat, Braunschweig, Germany; [Pils, Marina C.] Helmholtz Ctr Infect Res, Mouse Pathol Platform, Braunschweig, Germany; [Strowig, Till] Hannover Med Sch, Hannover, Germany	Ruhr University Bochum; Helmholtz Association; Helmholtz-Center for Infection Research; Otto von Guericke University; Helmholtz Association; Helmholtz-Center for Infection Research; Helmholtz Association; Helmholtz-Center for Infection Research; Hannover Medical School	Schmitz, I (corresponding author), Ruhr Univ Bochum, Dept Mol Immunol, Bochum, Germany.; Schmitz, I (corresponding author), Helmholtz Ctr Infect Res, Syst Oriented Immunol & Inflammat Res Grp, Braunschweig, Germany.; Schmitz, I (corresponding author), Otto Von Guericke Univ, Inst Mol & Clin Immunol, Magdeburg, Germany.	ingo.schmitz@rub.de	; Schmitz, Ingo/G-2093-2013	Plaza-Sirvent, Carlos/0000-0003-2767-0402; Schmitz, Ingo/0000-0002-5360-0419	Deutsche Forschungsgemeinschaft [SCHM1586/3-1, SCHM1586/6-1]; Fritz Thyssen foundation; China Scholarship Council (CSC) [201704910936]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Fritz Thyssen foundation; China Scholarship Council (CSC)(China Scholarship Council)	This work was supported by grants of the Deutsche Forschungsgemeinschaft to I.S. (SCHM1586/3-1, SCHM1586/6-1), the Fritz Thyssen foundation to IS and the China Scholarship Council (CSC) to BZ (Grant #201704910936).	Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Brandtzaeg P, 2010, NAT REV GASTRO HEPAT, V7, P380, DOI 10.1038/nrgastro.2010.80; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Carriche GM, 2021, J ALLERGY CLIN IMMUN, V147, P335, DOI 10.1016/j.jaci.2020.04.037; Chassaing B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044328; Cosovanu C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.600973; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Griseri T, 2015, IMMUNITY, V43, P187, DOI 10.1016/j.immuni.2015.07.008; Hanada T, 2007, J BIOL CHEM, V282, P37298, DOI 10.1074/jbc.C700195200; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Jacquin E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01023; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Kabat AM, 2016, ELIFE, V5, DOI 10.7554/eLife.12444; Kim BS, 2017, CELL REP, V21, P195, DOI 10.1016/j.celrep.2017.09.021; Klionsky DJ, 2014, NAT STRUCT MOL BIOL, V21, P336, DOI 10.1038/nsmb.2787; Krammer PH, 2007, NAT REV IMMUNOL, V7, P532, DOI 10.1038/nri2115; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Lathrop SK, 2011, NATURE, V478, P250, DOI 10.1038/nature10434; Le Texier L, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86850; Liston A, 2014, NAT REV IMMUNOL, V14, P154, DOI 10.1038/nri3605; Lochner M, 2008, J EXP MED, V205, P1381, DOI 10.1084/jem.20080034; Loos B, 2014, AUTOPHAGY, V10, P2087, DOI 10.4161/15548627.2014.973338; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Ohnmacht C, 2015, SCIENCE, V349, P989, DOI 10.1126/science.aac4263; Pierson W, 2013, NAT IMMUNOL, V14, P959, DOI 10.1038/ni.2649; Plaza-Sirvent C, 2017, CELL REP, V18, P12, DOI 10.1016/j.celrep.2016.12.022; Poillet-Perez L, 2020, NAT CANCER, V1, P923, DOI 10.1038/s43018-020-00110-7; Rizzo A, 2018, CANCER IMMUNOL RES, V6, P1082, DOI 10.1158/2326-6066.CIR-17-0698; Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017; Schonfeld P, 2016, J LIPID RES, V57, P943, DOI 10.1194/jlr.R067629; Sefik E, 2015, SCIENCE, V349, P993, DOI 10.1126/science.aaa9420; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Stehr M, 2009, LAB ANIM-UK, V43, P362, DOI 10.1258/la.2009.0080075; Swidsinski A, 2002, GASTROENTEROLOGY, V122, P44, DOI 10.1053/gast.2002.30294; Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4; Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Walczak M, 2013, AUTOPHAGY, V9, P424, DOI 10.4161/auto.22931; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Weidberg H, 2010, EMBO J, V29, P1792, DOI 10.1038/emboj.2010.74; Weil J, 2016, NAT IMMUNOL, V17, P277, DOI 10.1038/ni.3365; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Xu M, 2018, NATURE, V554, P373, DOI 10.1038/nature25500; Yang BH, 2016, MUCOSAL IMMUNOL, V9, P444, DOI 10.1038/mi.2015.74; Zhu JF, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a030338	58	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 26	2021	12								705436	10.3389/fimmu.2021.705436	http://dx.doi.org/10.3389/fimmu.2021.705436			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV9SG	34512629	Green Published, gold			2022-12-18	WOS:000717568400001
J	Han, L; Shi, CC; Zeng, X; Cen, LF; Mei, XB; Fan, JJ; Ju, DW; Zhu, HY				Han, Lei; Shi, Chenchen; Zeng, Xian; Cen, Lifeng; Mei, Xiaobin; Fan, Jiajun; Ju, Dianwen; Zhu, Haiyan			A Novel Bifunctional Fusion Protein, Vunakizumab-IL22, for Protection Against Pulmonary Immune Injury Caused by Influenza Virus	FRONTIERS IN IMMUNOLOGY			English	Article						bifunctional fusion protein; tissue repair; anti-inflammatory effects; IL-17A; IL-22; lung injury	LUNG INFLAMMATION; IL-22; CELLS; INFECTION; IL-17; EXPRESSION; STABILITY; RECEPTOR; A(H1N1); REPAIR	Influenza A virus infection is usually associated with acute lung injury, which is typically characterized by tracheal mucosal barrier damage and an interleukin 17A (IL-17A)-mediated inflammatory response in lung tissues. Although targeting IL-17A has been proven to be beneficial for attenuating inflammation around lung cells, it still has a limited effect on pulmonary tissue recovery after influenza A virus infection. In this research, interleukin 22 (IL-22), a cytokine involved in the repair of the pulmonary mucosal barrier, was fused to the C-terminus of the anti-IL-17A antibody vunakizumab to endow the antibody with a tissue recovery function. The vunakizumab-IL22 (vmab-IL-22) fusion protein exhibits favorable stability and retains the biological activities of both the anti-IL-17A antibody and IL-22 in vitro. Mice infected with lethal H1N1 influenza A virus and treated with vmab-mIL22 showed attenuation of lung index scores and edema when compared to those of mice treated with saline or vmab or mIL22 alone. Our results also illustrate that vmab-mIL22 triggers the upregulation of MUC2 and ZO1, as well as the modulation of cytokines such as IL-1 beta, HMGB1 and IL-10, indicating the recovery of pulmonary goblet cells and the suppression of excessive inflammation in mice after influenza A virus infection. Moreover, transcriptome profiling analysis suggest the downregulation of fibrosis-related genes and signaling pathways, including genes related to focal adhesion, the inflammatory response pathway, the TGF-beta signaling pathway and lung fibrosis upon vmab-mIL22 treatment, which indicates that the probable mechanism of vmab-mIL22 in ameliorating H1N1 influenza A-induced lung injury. Our results reveal that the bifunctional fusion protein vmab-mIL22 can trigger potent therapeutic effects in H1N1-infected mice by enhancing lung tissue recovery and inhibiting pulmonary inflammation, which highlights a potential approach for treating influenza A virus infection by targeting IL-17A and IL-22 simultaneously.	[Han, Lei; Shi, Chenchen; Zeng, Xian; Cen, Lifeng; Fan, Jiajun; Ju, Dianwen; Zhu, Haiyan] Fudan Univ, Dept Biol Med, Sch Pharm, Shanghai, Peoples R China; [Han, Lei; Shi, Chenchen; Zeng, Xian; Cen, Lifeng; Fan, Jiajun; Ju, Dianwen; Zhu, Haiyan] Fudan Univ, Shanghai Engn Res Ctr Immunotherapeut, Sch Pharm, Shanghai, Peoples R China; [Shi, Chenchen] Tongji Univ, Tongji Hosp, Sch Med, Div Spine,Dept Orthoped, Shanghai, Peoples R China; [Mei, Xiaobin] Second Mil Med Univ, Changhai Hosp, Dept Nephrol, Shanghai, Peoples R China	Fudan University; Fudan University; Tongji University; Naval Medical University	Fan, JJ; Ju, DW; Zhu, HY (corresponding author), Fudan Univ, Dept Biol Med, Sch Pharm, Shanghai, Peoples R China.; Fan, JJ; Ju, DW; Zhu, HY (corresponding author), Fudan Univ, Shanghai Engn Res Ctr Immunotherapeut, Sch Pharm, Shanghai, Peoples R China.	jiajunfan12@fudan.edu.cn; dianwenju@fudan.edu.cn; haiyanzhu@fudan.edu.cn			National Natural Science Foundation of China [81773620, 82073752, 32070935,81673713, 32000479]; Shanghai Science and Technology Fund [20JC1411000, 20S11904700]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Fund	This study was supported by grants from the National Natural Science Foundation of China (Grant Nos. 81773620, 82073752, 32070935,81673713 and 32000479) and the Shanghai Science and Technology Fund (20JC1411000 and 20S11904700).	Abelin A, 2011, VACCINE, V29, P1135, DOI 10.1016/j.vaccine.2010.11.042; Abood RN, 2019, MUCOSAL IMMUNOL, V12, P1231, DOI 10.1038/s41385-019-0188-7; Baumgartner K, 2016, J PHARMACEUT BIOMED, V128, P216, DOI 10.1016/j.jpba.2016.04.040; Bermejo-Martin JF, 2009, CRIT CARE, V13, DOI 10.1186/cc8208; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Bray NL, 2016, NAT BIOTECHNOL, V34, P525, DOI 10.1038/nbt.3519; Crowe CR, 2009, J IMMUNOL, V183, P5301, DOI 10.4049/jimmunol.0900995; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536; Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; Gopal R, 2014, AM J PATHOL, V184, P55, DOI 10.1016/j.ajpath.2013.09.012; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Hebert KD, 2020, MUCOSAL IMMUNOL, V13, P64, DOI 10.1038/s41385-019-0206-9; Herold S, 2015, EUR RESPIR J, V45, P1463, DOI 10.1183/09031936.00186214; Hong MJ, 2018, MUCOSAL IMMUNOL, V11, P894, DOI 10.1038/mi.2017.93; Hurt AC, 2009, J VIROL, V83, P10366, DOI 10.1128/JVI.01200-09; Ivanov S, 2013, J VIROL, V87, P6911, DOI 10.1128/JVI.02943-12; Kamali Amanda, 2013, Infect Drug Resist, V6, P187, DOI 10.2147/IDR.S36601; Kim KS, 2015, J MED VIROL, V87, P1104, DOI 10.1002/jmv.24138; Krstic J, 2015, PROTEIN PEPTIDE LETT, V22, P570, DOI 10.2174/0929866522666150520145554; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Kumar P, 2013, MUCOSAL IMMUNOL, V6, P69, DOI 10.1038/mi.2012.49; Lanfranca MP, 2016, J MOL MED, V94, P523, DOI 10.1007/s00109-016-1391-6; Li CG, 2012, CELL RES, V22, P528, DOI 10.1038/cr.2011.165; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Liao Y, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz114; Louie JK, 2009, JAMA-J AM MED ASSOC, V302, P1896, DOI 10.1001/jama.2009.1583; Manning MC, 2010, PHARM RES-DORDR, V27, P544, DOI 10.1007/s11095-009-0045-6; McAleer JP, 2014, IMMUNOL REV, V260, P129, DOI 10.1111/imr.12183; Mcgee HM, 2013, J INVEST DERMATOL, V133, P1321, DOI 10.1038/jid.2012.463; Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794; Mishin VP, 2005, ANTIMICROB AGENTS CH, V49, P4515, DOI 10.1128/AAC.49.11.4515-4520.2005; Momonaka H, 2014, BRAIN DEV-JPN, V36, P484, DOI 10.1016/j.braindev.2013.07.001; Morgenstern J, 2017, INT J PHARMACEUT, V519, P408, DOI 10.1016/j.ijpharm.2017.01.040; Nosaka N, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0983-9; Pickert G, 2009, J EXP MED, V206, P1465, DOI 10.1084/jem.20082683; Pociask DA, 2013, AM J PATHOL, V182, P1286, DOI 10.1016/j.ajpath.2012.12.007; Pulendran B, 2015, CURR TOP MICROBIOL, V386, P23, DOI 10.1007/82_2014_405; Ren XD, 2010, AM J PHYSIOL-GASTR L, V298, pG74, DOI 10.1152/ajpgi.00075.2009; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rutz S, 2013, IMMUNOL REV, V252, P116, DOI 10.1111/imr.12027; Sabat R, 2014, NAT REV DRUG DISCOV, V13, P21, DOI 10.1038/nrd4176; Sichelstiel A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098440; Sonnenberg GF, 2011, NAT IMMUNOL, V12, P383, DOI 10.1038/ni.2025; Sonnenberg GF, 2010, ADV IMMUNOL, V107, P1, DOI [10.1016/S0065-2776(10)07008-2, 10.1016/B978-0-12-381300-8.00001-0]; Tzeng A, 2015, P NATL ACAD SCI USA, V112, P3320, DOI 10.1073/pnas.1416159112; Wang J, 2014, J EXP MED, V211, P2397, DOI 10.1084/jem.20140625; Wang LL, 2018, SCAND J IMMUNOL, V88, DOI 10.1111/sji.12715; Wang W, 2010, INT J PHARMACEUT, V390, P89, DOI 10.1016/j.ijpharm.2010.02.025; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Xue CX, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01054; Xue J, 2012, GASTROENTEROLOGY, V143, P1670, DOI 10.1053/j.gastro.2012.08.051; Zenewicz Lauren A, 2018, Immunohorizons, V2, P198, DOI 10.4049/immunohorizons.1800006	54	1	1	2	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 24	2021	12									10.3389/fimmu.2021.727941	http://dx.doi.org/10.3389/fimmu.2021.727941			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UQ3NT	34504501	gold, Green Published			2022-12-18	WOS:000695974800001
J	Wesley, MS; Chiong, KT; Seaton, KE; Arocena, CA; Sawant, S; Hare, J; Hernandez, K; Rojas, M; Heptinstall, J; Beaumont, D; Crisafi, K; Nkolola, J; Barouch, DH; Sarzotti-Kelsoe, M; Tomaras, GD; Yates, NL				Wesley, Martina S.; Chiong, Kelvin T.; Seaton, Kelly E.; Arocena, Christine A.; Sawant, Sheetal; Hare, Jonathan; Hernandez, Kasey; Rojas, Michelle; Heptinstall, Jack; Beaumont, David; Crisafi, Katherine; Nkolola, Joseph; Barouch, Dan H.; Sarzotti-Kelsoe, Marcella; Tomaras, Georgia D.; Yates, Nicole L.			Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS	FRONTIERS IN IMMUNOLOGY			English	Article						antibody; immunoprophilaxis; HIV- human immunodeficiency virus; pharmacokinetics; validation; broadly neutralizing antibodies	INFECTION; RESPONSES; THERAPY; INDIVIDUALS; PLASMA; VRC01; RISK	The outcome of the recent Antibody Mediated Prevention (AMP) trials that tested infusion of the broadly neutralizing antibody (bnAb) VRC01 provides proof of concept for blocking infection from sensitive HIV-1 strains. These results also open up the possibility that triple combinations of bnAbs such as PGT121, PGDM1400, as well as long-lasting LS variants such as VRC07-523 LS, have immunoprophylactic potential. PGT121 and PGDM1400 target the HIV-1 V3 and V2 glycan regions of the gp120 envelope protein, respectively, while VRC07-523LS targets the HIV-1 CD4 binding site. These bnAbs demonstrate neutralization potency and complementary breadth of HIV-1 strain coverage. An important clinical trial outcome is the accurate measurement of in vivo concentrations of passively infused bnAbs to determine effective doses for therapy and/or prevention. Standardization and validation of this testing method is a key element for clinical studies as is the ability to simultaneously detect multiple bnAbs in a specific manner. Here we report the development of a sensitive, specific, accurate, and precise multiplexed microsphere-based assay that simultaneously quantifies the respective physiological concentrations of passively infused bnAbs in human serum to ultimately define the threshold needed for protection from HIV-1 infection.	[Wesley, Martina S.; Chiong, Kelvin T.; Seaton, Kelly E.; Arocena, Christine A.; Sawant, Sheetal; Hernandez, Kasey; Rojas, Michelle; Heptinstall, Jack; Beaumont, David; Tomaras, Georgia D.; Yates, Nicole L.] Duke Univ, Ctr Human Syst Immunol, Durham, NC 27708 USA; [Wesley, Martina S.; Chiong, Kelvin T.; Seaton, Kelly E.; Sawant, Sheetal; Heptinstall, Jack; Beaumont, David; Sarzotti-Kelsoe, Marcella; Tomaras, Georgia D.; Yates, Nicole L.] Duke Univ, Dept Surg, Durham, NC 27708 USA; [Hare, Jonathan] Imperial Coll, Human Immunol Lab, Int AIDS Vaccine Initiat IAVI, London, England; [Hare, Jonathan; Crisafi, Katherine] Int AIDS Vaccine Initiat IAVI, New York, NY USA; [Nkolola, Joseph; Barouch, Dan H.] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA; [Nkolola, Joseph; Barouch, Dan H.] Ragon Inst Massachusetts Gen Hosp MGH Massachuset, Cambridge, MA USA; [Sarzotti-Kelsoe, Marcella; Tomaras, Georgia D.] Duke Univ, Dept Immunol, Durham, NC USA; [Tomaras, Georgia D.] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC USA	Duke University; Duke University; Imperial College London; International AIDS Vaccine Initiative; International AIDS Vaccine Initiative; Harvard University; Beth Israel Deaconess Medical Center; Duke University; Duke University	Yates, NL (corresponding author), Duke Univ, Ctr Human Syst Immunol, Durham, NC 27708 USA.; Yates, NL (corresponding author), Duke Univ, Dept Surg, Durham, NC 27708 USA.	Nicole.yates@duke.edu			Bill & Melinda Gates Foundation, Collaboration for AIDS Vaccine Discovery, Vaccine Immune Monitoring Center (CAVIMC) [OPP1146996]; National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID, Duke Center for AIDS Research (CFAR) [P30 AI064518]; HIV Vaccine Trials Network Laboratory Program [NIH U01 AI068618]	Bill & Melinda Gates Foundation, Collaboration for AIDS Vaccine Discovery, Vaccine Immune Monitoring Center (CAVIMC); National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID, Duke Center for AIDS Research (CFAR); HIV Vaccine Trials Network Laboratory Program	This work was supported by the Bill & Melinda Gates Foundation, Collaboration for AIDS Vaccine Discovery, Vaccine Immune Monitoring Center (CAVIMC) (OPP1146996); and the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID, Duke Center for AIDS Research (CFAR) (P30 AI064518) and HIV Vaccine Trials Network Laboratory Program (NIH U01 AI068618).	[Anonymous], 2005, VAL AN PROC TEXT MET; Armbruster David A, 2008, Clin Biochem Rev, V29 Suppl 1, pS49; Bar-On Y, 2018, NAT MED, V24, P1701, DOI 10.1038/s41591-018-0186-4; Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411; Corey L, 2021, NEW ENGL J MED, V384, P1003, DOI 10.1056/NEJMoa2031738; Eckels J, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-145; Edupuganti S, 2021, JAIDS-J ACQ IMM DEF, V87, P671, DOI 10.1097/QAI.0000000000002639; Fouda GG, 2011, J VIROL, V85, P9555, DOI 10.1128/JVI.05174-11; Gaudinski MR, 2019, LANCET HIV, V6, pE667, DOI 10.1016/S2352-3018(19)30181-X; Gilbert Peter B, 2017, Stat Commun Infect Dis, V9, DOI 10.1515/scid-2016-0001; Glassman PM, 2019, DRUG METAB PHARMACOK, V34, P3, DOI 10.1016/j.dmpk.2018.11.002; Grobben M, 2019, CURR OPIN VIROL, V38, P70, DOI 10.1016/j.coviro.2019.07.007; Haraya K, 2019, DRUG METAB PHARMACOK, V34, P25, DOI 10.1016/j.dmpk.2018.10.003; Hoy JF, 2017, J BONE MINER RES, V32, P1945, DOI 10.1002/jbmr.3183; Huang YD, 2021, EBIOMEDICINE, V64, DOI 10.1016/j.ebiom.2020.103203; Julg B, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal1321; Ledgerwood JE, 2015, CLIN EXP IMMUNOL, V182, P289, DOI 10.1111/cei.12692; Li YX, 2007, NAT MED, V13, P1032, DOI 10.1038/nm1624; Liu PH, 2011, J VIROL, V85, P11196, DOI 10.1128/JVI.05601-11; Liu Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08658-4; Marcus JL, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.7954; Mayer KH, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002435; Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2; Rasmussen LD, 2015, LANCET HIV, V2, pE288, DOI 10.1016/S2352-3018(15)00077-6; Rosenberg YJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152760; Rudicell RS, 2014, J VIROL, V88, P12669, DOI 10.1128/JVI.02213-14; Schouten J, 2014, CLIN INFECT DIS, V59, P1787, DOI 10.1093/cid/ciu701; Shankar G, 2008, J PHARMACEUT BIOMED, V48, P1267, DOI 10.1016/j.jpba.2008.09.020; Sok D, 2014, P NATL ACAD SCI USA, V111, P17624, DOI 10.1073/pnas.1415789111; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Yates NL, 2011, AIDS, V25, P2089, DOI 10.1097/QAD.0b013e32834b348e; Zhang JC, 2017, J IMMUNOL METHODS, V442, P29, DOI 10.1016/j.jim.2017.01.001	34	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 24	2021	12								709994	10.3389/fimmu.2021.709994	http://dx.doi.org/10.3389/fimmu.2021.709994			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UM6IT	34504492	gold, Green Published			2022-12-18	WOS:000693434800001
J	Piza, CFSD; Aranda, CS; Sole, D; Jolles, S; Condino-Neto, A				Sartorelli de Toledo Piza, Cristina Frias; Aranda, Carolina Sanchez; Sole, Dirceu; Jolles, Stephen; Condino-Neto, Antonio			Serum Protein Electrophoresis May Be Used as a Screening Tool for Antibody Deficiency in Children and Adolescents	FRONTIERS IN IMMUNOLOGY			English	Article						antibody deficiency; calculated globulin (CG); gamma globulin fraction; children; immunoglobulin G (IgG); serum protein electrophoresis (SEP)	IMMUNODEFICIENCY; IMMUNOGLOBULIN; PRINCIPLES; DISEASE	Background Patients with antibody deficiency may experience exceptionally long diagnostic delays, increasing the risk of life-threatening infections, end-organ damage, mortality, and health costs. Objective This study aimed to analyze serum protein electrophoresis and verify the correlation between calculated globulin (CG, total protein minus albumin levels) or electrophoretically determined serum gamma globulin fraction (Gamma) with IgG levels in children and adolescents under 18 years old (yo). Methods We analyzed serum protein electrophoresis (GC or Gamma) and IgG levels from 1215 children and adolescents under 18 yo, classified into 5 age groups. We verified the correlation between CG or Gamma with serum IgG levels. Results Serum IgG levels varied according to age groups (from 4.3 +/- 2.3 g/l in children under 6 months old to 11.4 +/- 3.2 g/l in adolescents in the 10-< 18 yo group). CG sensitivity and specificity to detect IgG below the reference range for all patients were 93.1% and 81.8%, respectively, and varied according to age group. Gamma sensitivity and specificity for all patients were 100% and 87.8%, respectively, and varied according to age group as well. We found serum IgG levels below the age reference level in 29 patients (2.4% of the cases) using CG or Gamma levels. Conclusion Both CG and Gamma levels may be of utility as a screening tool for earlier diagnosis of antibody deficiency in children and adolescents under 18 yo.	[Sartorelli de Toledo Piza, Cristina Frias] Sao Leopoldo Mandic Med Sch, Dept Immunol, Campinas, Brazil; [Aranda, Carolina Sanchez; Sole, Dirceu] Univ Fed Sao Paulo, Dept Pediat, Div Allergy Immunol & Rheumatol, Sao Paulo, Brazil; [Jolles, Stephen] Univ Hosp Wales, Immunodeficiency Ctr Wales, Cardiff, Wales; [Condino-Neto, Antonio] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Cardiff University; Universidade de Sao Paulo	Condino-Neto, A (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, Brazil.	antoniocondino@gmail.com	Solé, Dirceu/D-7789-2013; Condino-Neto, Antonio/D-4762-2012	Condino-Neto, Antonio/0000-0002-1069-3117	Takeda; CSL Behring	Takeda(Takeda Pharmaceutical Company Ltd); CSL Behring	This work received research grants from Takeda and CSL Behring.	Abolhassani H, 2020, EXPERT REV CLIN IMMU, V16, P717, DOI 10.1080/1744666X.2020.1801422; Adeli K, 2017, CRIT REV CL LAB SCI, V54, P358, DOI 10.1080/10408363.2017.1379945; Bazregari S, 2017, CENT EUR J IMMUNOL, V42, P336, DOI 10.5114/ceji.2017.72825; Bonilla FA, 2015, J ALLERGY CLIN IMMUN, V136, P1186, DOI 10.1016/j.jaci.2015.04.049; Cole T.J, 1991, STAT MED, V10, P1162, DOI [10.1002/sim.4780100718, DOI 10.1002/SIM.4780100718]; Dasouki M, 2020, CLIN EXP IMMUNOL, V202, P60, DOI 10.1111/cei.13484; Dobrow MJ, 2018, CAN MED ASSOC J, V190, pE422, DOI 10.1503/cmaj.171154; Durandy A, 2013, NAT REV IMMUNOL, V13, P519, DOI 10.1038/nri3466; El-Helou SM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01272; El-Sayed ZA, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02987; Elsink K, 2020, CLIN IMMUNOL, V213, DOI 10.1016/j.clim.2020.108359; Gonzalez-Quintela A, 2008, CLIN EXP IMMUNOL, V151, P42, DOI 10.1111/j.1365-2249.2007.03545.x; Holding S, 2015, CURR OPIN ALLERGY CL, V15, P547, DOI 10.1097/ACI.0000000000000222; Ilkjaer FV, 2019, J CLIN IMMUNOL, V39, P641, DOI 10.1007/s10875-019-00666-9; Inmetro, ACREDITACAO LAB AN C; Jolles S, 2014, CLIN EXP IMMUNOL, V177, P671, DOI 10.1111/cei.12369; Min Q, 2020, ADV EXP MED BIOL, V1254, P117, DOI 10.1007/978-981-15-3532-1_10; Palmeira P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/985646; Patel SY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00033; Pecoraro A, 2018, CURR PHARM BIOTECHNO, V19, P728, DOI 10.2174/1389201019666180808163311; Perez EE, 2017, J ALLERGY CLIN IMMUN, V139, pS1, DOI 10.1016/j.jaci.2016.09.023; Puck JM, 2019, IMMUNOL REV, V287, P241, DOI 10.1111/imr.12729; Reust CE, 2013, AM FAM PHYSICIAN, V87, P773; SBPC/ML, PROGR QUAL CAT PALC; Shehata N, 2010, TRANSFUS MED REV, V24, pS28, DOI 10.1016/j.tmrv.2009.09.011; Slade CA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00694; Sottini A, 2014, JOVE-J VIS EXP, DOI 10.3791/52184; Srivastava S, 2016, CLIN MED, V16, P571, DOI 10.7861/clinmedicine.16-6-571; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; WILSON JMG, 1968, B OFIC SANIT PANAM, V65, P281; Wood PM, 2010, CURR OPIN HEMATOL, V17, P356, DOI 10.1097/MOH.0b013e328338f69e; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	32	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 23	2021	12								712637	10.3389/fimmu.2021.712637	http://dx.doi.org/10.3389/fimmu.2021.712637			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UL3ZV	34497609	Green Accepted, gold, Green Published			2022-12-18	WOS:000692594100001
J	Shen, XK; Zhang, HY; Xie, H; Chen, LP; Li, SN; Zheng, JJ; Chai, RN; Wang, Z; Zang, YY; He, SH				Shen, Xiaokun; Zhang, Huiyun; Xie, Hua; Chen, Liping; Li, Shinan; Zheng, Junjuan; Chai, Ruonan; Wang, Zhao; Zang, Yanyan; He, Shaoheng			Reduced CCR6(+)IL-17A(+)Treg Cells in Blood and CCR6-Dependent Accumulation of IL-17A(+)Treg Cells in Lungs of Patients With Allergic Asthma	FRONTIERS IN IMMUNOLOGY			English	Article						asthma; HDM; CCR6(+) Treg; IL-17; CCL20	REGULATORY T-CELLS; IMMUNE-RESPONSE; DIFFERENTIATION; EFFECTOR; RECEPTOR; IDENTIFICATION; EXPRESSION; REPRESENT; LINEAGE; IL-17	Human regulatory T (Treg) cells play a central role in controlling allergic inflammation in the airways. A reduced number of peripheral Treg cells and decreased suppressive function have been previously reported in the pathogenesis of allergic asthma. However, the characteristic role of specific Treg cell subsets and their mechanisms in the pathogenesis of allergic asthma remain unclear. In this study, we examined the proportion of different Treg cell subsets in both healthy subjects and patients with allergic asthma using flow cytometry and single-cell RNA sequencing. The migration function of the cells was compared using cell sorting and Transwell experiments. Furthermore, two allergen-challenged mouse models and a cell transfer experiment were used to examine the role of these Treg subsets. We found that the proportion of CD25(+)Foxp3(+)CD127(-) Treg cells in the peripheral blood of patients with allergic asthma was lower than in those of healthy subjects. Furthermore, the circulating Treg cells expressed lower levels of CCR6 and IL-17 compared with healthy subjects. The chemokine from the airway mucosa, CCL20, was abundantly expressed, and Transwell experiments further proved that this chemokine promoted CCR6(+) Treg cell migration in vitro. A mouse model induced by house dust mite (HDM) revealed that the number of CCR6(+) Treg cells in the lung tissue increased remarkably. The incidence of allergic asthma may be related to an increase in Treg cells secreting IL-17 in the lung tissue. Recruited CCR6(+) Treg cells are likely to differentiate into Th17-like cells under the Th17 environment present in the lungs. IL-17 derived from Th17-like cells could be associated with the pathology of allergic asthma by promoting Th17 responses, thereby favoring HDM-induced asthma exacerbations.	[Shen, Xiaokun; Li, Shinan; Wang, Zhao; Zang, Yanyan; He, Shaoheng] Jinzhou Med Univ, Inst Translat Med, Affiliated Hosp 1, Jinzhou, Peoples R China; [Zhang, Huiyun; He, Shaoheng] Shenyang Med Coll, Inst Translat Med, Shenyang, Peoples R China; [Xie, Hua; Chai, Ruonan] Gen Hosp Shenyang Mil Area Command, Peoples Liberat Army PLA Ctr Resp & Allerg Dis Di, Shenyang, Peoples R China; [Chen, Liping] Shenyang Med Coll, Resp Methane Dept, Affiliated Hosp 2, Shenyang, Peoples R China; [Zheng, Junjuan] Chinese Acad Sci, Kunming Inst Zool, State Key Lab Genet Resources & Evolut, Key Lab Hlth Aging Res Yunnan Prov, Kunming, Yunnan, Peoples R China	Jinzhou Medical University; Shenyang Medical College; Shenyang Medical College; Chinese Academy of Sciences; Kunming Institute of Zoology	He, SH (corresponding author), Jinzhou Med Univ, Inst Translat Med, Affiliated Hosp 1, Jinzhou, Peoples R China.; He, SH (corresponding author), Shenyang Med Coll, Inst Translat Med, Shenyang, Peoples R China.	shoahenghe@126.com	Zhang, Hui/HHN-8494-2022	Shen, Xiaokun/0000-0003-3999-5191	National Natural Science Foundation of China [31800761, 81601372]; Natural Science Foundation of Liaoning Province [20170520057, 201601356]; Educational Department of Liaoning Province [JYTQN201918]; Liaoning Revitalization Talents Program [XLYC2007097]; Jinzhou Medical University; Climbing Scholar Project in Liaoning province [2018-38]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Liaoning Province(Natural Science Foundation of Liaoning Province); Educational Department of Liaoning Province; Liaoning Revitalization Talents Program; Jinzhou Medical University; Climbing Scholar Project in Liaoning province	This project was sponsored by grants from the National Natural Science Foundation of China (31800761, 81601372), the Natural Science Foundation of Liaoning Province (20170520057, 201601356), the Educational Department of Liaoning Province (JYTQN201918), the Liaoning Revitalization Talents Program (XLYC2007097), the Leader Team Project of Jinzhou Medical University (2017-2020), and grants from the Climbing Scholar Project in Liaoning province (2018-38).	Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Boonpiyathad T, 2020, ASIAN PAC J ALLERGY, V38, P139, DOI 10.12932/AP-030220-0754; Bullone M, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00068-2019; Cevhertas L, 2020, ALLERGY, V75, P3124, DOI 10.1111/all.14607; Chen CC, 2017, J ALLERGY CLIN IMMUN, V140, P1351, DOI 10.1016/j.jaci.2017.01.015; Cheng X, 2012, ACTA OTO-LARYNGOL, V132, P1311, DOI 10.3109/00016489.2012.709320; Chesne J, 2014, AM J RESP CRIT CARE, V190, P1094, DOI 10.1164/rccm.201405-0859PP; Cosmi L, 2010, J ALLERGY CLIN IMMUN, V125, P222, DOI 10.1016/j.jaci.2009.10.012; Cretney E, 2013, TRENDS IMMUNOL, V34, P74, DOI 10.1016/j.it.2012.11.002; Gonzalo JA, 2001, NAT IMMUNOL, V2, P597, DOI 10.1038/89739; Greaves DR, 1997, J EXP MED, V186, P837, DOI 10.1084/jem.186.6.837; Harb H, 2020, NAT IMMUNOL, V21, P1359, DOI 10.1038/s41590-020-0777-3; Haxhinasto S, 2008, J EXP MED, V205, P565, DOI 10.1084/jem.20071477; Holgate ST, 2006, J ALLERGY CLIN IMMUN, V117, P496, DOI 10.1016/j.jaci.2006.01.039; Huang C, 2018, J AUTOIMMUN, V93, P104, DOI 10.1016/j.jaut.2018.07.003; Joetham A, 2017, J ALLERGY CLIN IMMUN, V139, P1331, DOI 10.1016/j.jaci.2016.06.051; Kim BS, 2017, CELL REP, V21, P195, DOI 10.1016/j.celrep.2017.09.021; Kistler A, 2007, J INFECT DIS, V196, P817, DOI 10.1086/520816; Kluger MA, 2016, KIDNEY INT, V89, P158, DOI 10.1038/ki.2015.296; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Kulkarni N, 2018, J AUTOIMMUN, V88, P121, DOI 10.1016/j.jaut.2017.10.013; Lundy SK, 2005, J IMMUNOL, V174, P2054, DOI 10.4049/jimmunol.174.4.2054; Malhotra N, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao6923; Massoud AH, 2016, NAT MED, V22, P1013, DOI 10.1038/nm.4147; Mcgee HS, 2009, AM J RESP CRIT CARE, V180, P211, DOI 10.1164/rccm.200809-1505OC; Mercer F, 2014, J IMMUNOL, V193, P1047, DOI 10.4049/jimmunol.1302936; Morishima Y, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/609395; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Noble A, 2006, BLOOD, V107, P4475, DOI 10.1182/blood-2005-10-3994; Palomares O, 2017, IMMUNOL REV, V278, P219, DOI 10.1111/imr.12555; Provoost S, 2009, ALLERGY, V64, P1539, DOI 10.1111/j.1398-9995.2009.02056.x; Saffarzadeh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032366; Sauer S, 2008, P NATL ACAD SCI USA, V105, P7797, DOI 10.1073/pnas.0800928105; Schulten V, 2018, J ALLERGY CLIN IMMUN, V141, P775, DOI 10.1016/j.jaci.2017.04.032; Schulz-Kuhnt A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00691; Shanmugasundaram U, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137858; Shin JW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2495-z; Smyth LJC, 2010, CHEST, V138, P905, DOI 10.1378/chest.09-3079; Tan HTT, 2019, ALLERGY, V74, P294, DOI 10.1111/all.13619; Ueno A, 2013, INFLAMM BOWEL DIS, V19, P2522, DOI 10.1097/MIB.0b013e3182a85709; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Voo KS, 2009, P NATL ACAD SCI USA, V106, P4793, DOI 10.1073/pnas.0900408106; Walker JA, 2018, NAT REV IMMUNOL, V18, P121, DOI 10.1038/nri.2017.118; Xirakia C, 2010, AM J RESP CRIT CARE, V181, P1207, DOI 10.1164/rccm.200908-1255OC; Yang BH, 2016, MUCOSAL IMMUNOL, V9, P444, DOI 10.1038/mi.2015.74; Zhang HY, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-125	47	1	1	4	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 23	2021	12									10.3389/fimmu.2021.710750	http://dx.doi.org/10.3389/fimmu.2021.710750			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UN3OO	34497608	Green Published, gold			2022-12-18	WOS:000693927200001
J	Williams, B; Lopez-Garcia, M; Gillard, JJ; Laws, TR; Lythe, G; Carruthers, J; Finnie, T; Molina-Paris, C				Williams, Bevelynn; Lopez-Garcia, Martin; Gillard, Joseph J.; Laws, Thomas R.; Lythe, Grant; Carruthers, Jonathan; Finnie, Thomas; Molina-Paris, Carmen			A Stochastic Intracellular Model of Anthrax Infection With Spore Germination Heterogeneity	FRONTIERS IN IMMUNOLOGY			English	Article						Bacillus anthracis; Markov process; intracellular model; spore germination; rupture size distribution; approximate Bayesian computation; time to macrophage rupture; dose-response	BACILLUS-ANTHRACIS; INCUBATION PERIOD; MACROPHAGES; CELLS; PATHOLOGY; CAPSULE	We present a stochastic mathematical model of the intracellular infection dynamics of Bacillus anthracis in macrophages. Following inhalation of B. anthracis spores, these are ingested by alveolar phagocytes. Ingested spores then begin to germinate and divide intracellularly. This can lead to the eventual death of the host cell and the extracellular release of bacterial progeny. Some macrophages successfully eliminate the intracellular bacteria and will recover. Here, a stochastic birth-and-death process with catastrophe is proposed, which includes the mechanism of spore germination and maturation of B. anthracis. The resulting model is used to explore the potential for heterogeneity in the spore germination rate, with the consideration of two extreme cases for the rate distribution: continuous Gaussian and discrete Bernoulli. We make use of approximate Bayesian computation to calibrate our model using experimental measurements from in vitro infection of murine peritoneal macrophages with spores of the Sterne 34F2 strain of B. anthracis. The calibrated stochastic model allows us to compute the probability of rupture, mean time to rupture, and rupture size distribution, of a macrophage that has been infected with one spore. We also obtain the mean spore and bacterial loads over time for a population of cells, each assumed to be initially infected with a single spore. Our results support the existence of significant heterogeneity in the germination rate, with a subset of spores expected to germinate much later than the majority. Furthermore, in agreement with experimental evidence, our results suggest that most of the spores taken up by macrophages are likely to be eliminated by the host cell, but a few germinated spores may survive phagocytosis and lead to the death of the infected cell. Finally, we discuss how this stochastic modelling approach, together with dose-response data, allows us to quantify and predict individual infection risk following exposure.	[Williams, Bevelynn; Lopez-Garcia, Martin; Lythe, Grant; Molina-Paris, Carmen] Univ Leeds, Sch Math, Dept Appl Math, Leeds, W Yorkshire, England; [Gillard, Joseph J.; Laws, Thomas R.] Def Sci & Technol Lab, CBR Div, Salisbury, Wilts, England; [Carruthers, Jonathan; Finnie, Thomas] Publ Hlth England, Emergency Response Dept, Salisbury, Wilts, England; [Molina-Paris, Carmen] Los Alamos Natl Lab, Theoret Biol & Biophys, Theoret Div, T6, Los Alamos, NM 87545 USA	University of Leeds; Defence Science & Technology Laboratory; Public Health England; United States Department of Energy (DOE); Los Alamos National Laboratory	Lopez-Garcia, M; Molina-Paris, C (corresponding author), Univ Leeds, Sch Math, Dept Appl Math, Leeds, W Yorkshire, England.; Molina-Paris, C (corresponding author), Los Alamos Natl Lab, Theoret Biol & Biophys, Theoret Div, T6, Los Alamos, NM 87545 USA.	m.lopezgarcia@leeds.ac.uk; molina-paris@lanl.gov	Molina-Paris, Carmen/ABG-1274-2021; molina-paris, carmen/GRN-8674-2022		EPSRC CASE studentship [2345914]; Dstl [DSTLX-1000142022]	EPSRC CASE studentship(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Dstl	BW is supported by an EPSRC CASE studentship, project reference 2345914, in partnership with Dstl under contract number DSTLX-1000142022.	Akoachere M, 2007, J BIOL CHEM, V282, P12112, DOI 10.1074/jbc.M611432200; Altboum Z, 2002, INFECT IMMUN, V70, P6231, DOI 10.1128/IAI.70.11.6231-6241.2002; Banks DJ, 2005, CELL MICROBIOL, V7, P1173, DOI 10.1111/j.1462-5822.2005.00545.x; Brittingham KC, 2005, J IMMUNOL, V174, P5545, DOI 10.4049/jimmunol.174.9.5545; Brookmeyer R, 2005, STAT MED, V24, P531, DOI 10.1002/sim.2033; Carruthers J, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007752; Carruthers J, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01165; Cleret A, 2007, J IMMUNOL, V178, P7994, DOI 10.4049/jimmunol.178.12.7994; Cleret A, 2006, J INFECT DIS, V194, P86, DOI 10.1086/504686; Cote CK, 2008, MICROBES INFECT, V10, P613, DOI 10.1016/j.micinf.2008.02.006; Cote CK, 2011, MICROBES INFECT, V13, P1146, DOI 10.1016/j.micinf.2011.07.005; Day J, 2011, J THEOR BIOL, V276, P199, DOI 10.1016/j.jtbi.2011.01.054; Dixon TC, 2000, CELL MICROBIOL, V2, P453, DOI 10.1046/j.1462-5822.2000.00067.x; Ezzell JW, 1999, J APPL MICROBIOL, V87, P250, DOI 10.1046/j.1365-2672.1999.00881.x; Gimenez AP, 2004, J IMMUNOL, V173, P521, DOI 10.4049/jimmunol.173.1.521; Goel AK, 2015, WORLD J CLIN CASES, V3, P20, DOI 10.12998/wjcc.v3.i1.20; Goggans PM, 2014, AIP CONF PROC, V1636, P94, DOI 10.1063/1.4903716; Guarner J, 2003, AM J PATHOL, V163, P701, DOI 10.1016/S0002-9440(10)63697-8; Guidi-Rontani C, 1999, MOL MICROBIOL, V31, P9, DOI 10.1046/j.1365-2958.1999.01137.x; Guidi-Rontani C, 2002, TRENDS MICROBIOL, V10, P405, DOI 10.1016/S0966-842X(02)02422-8; Haas CN, 2002, RISK ANAL, V22, P189, DOI 10.1111/0272-4332.00028; Heppell CW, 2017, EPIDEMICS-NETH, V21, P30, DOI 10.1016/j.epidem.2017.06.001; Jang J, 2011, INFECT IMMUN, V79, P3846, DOI 10.1128/IAI.01145-10; Jenkins SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066177; JONES WI, 1967, J BACTERIOL, V94, P600, DOI 10.1128/JB.94.3.600-608.1967; Kalns J, 2002, BIOCHEM BIOPH RES CO, V297, P506, DOI 10.1016/S0006-291X(02)02226-X; Kang TJ, 2005, INFECT IMMUN, V73, P7495, DOI 10.1128/IAI.73.11.7495-7501.2005; KARLIN S, 1982, J APPL PROBAB, V19, P477, DOI 10.2307/3213507; Liu JZ, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00002; Moayeri M, 2015, ANNU REV MICROBIOL, V69, P185, DOI 10.1146/annurev-micro-091014-104523; Oyston PCF, 2004, NAT REV MICROBIOL, V2, P967, DOI 10.1038/nrmicro1045; Pantha B, 2018, MATH BIOSCI, V305, P18, DOI 10.1016/j.mbs.2018.08.010; Powell JD, 2015, J APPL MICROBIOL, V119, P711, DOI 10.1111/jam.12872; Pratt A, 2021, RISK ANAL, V41, P67, DOI 10.1111/risa.13597; Ruthel G, 2004, J INFECT DIS, V189, P1313, DOI 10.1086/382656; Setlow P, 2003, CURR OPIN MICROBIOL, V6, P550, DOI 10.1016/j.mib.2003.10.001; Setlow P, 2013, J APPL MICROBIOL, V115, P1251, DOI 10.1111/jam.12343; Setlow P, 2014, J BACTERIOL, V196, P1297, DOI 10.1128/JB.01455-13; Sharma S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00462; Shetron-Rama LM, 2010, MICROB PATHOGENESIS, V49, P38, DOI 10.1016/j.micpath.2010.02.004; TITBALL RW, 1987, J APPL BACTERIOL, V62, P269, DOI 10.1111/j.1365-2672.1987.tb02408.x; Toni T, 2009, J R SOC INTERFACE, V6, P187, DOI 10.1098/rsif.2008.0172; Twenhafel NA, 2010, VET PATHOL, V47, P819, DOI 10.1177/0300985810378112; Weir MH, 2011, ENVIRON SCI TECHNOL, V45, P5828, DOI 10.1021/es200901e; Welkos S, 2002, J MED MICROBIOL, V51, P821, DOI 10.1099/0022-1317-51-10-821; WHO, 2008, ANTHRAX HUMANS ANIMA, VFourth edition; Wilkening DA, 2008, MED DECIS MAKING, V28, P593, DOI 10.1177/0272989X08315245; Williams B., 2021, STOCHASTIC INTRACELL, DOI [10.5518/1026, DOI 10.5518/1026]	48	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 23	2021	12									10.3389/fimmu.2021.688257	http://dx.doi.org/10.3389/fimmu.2021.688257			23	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UQ3JV	34497601	gold, Green Published			2022-12-18	WOS:000695964600001
J	Ciregia, F; Nys, G; Cobraiville, G; Badot, V; Di Romana, S; Sidiras, P; Sokolova, T; Durez, P; Fillet, M; Malaise, MG; de Seny, D				Ciregia, Federica; Nys, Gwenael; Cobraiville, Gael; Badot, Valerie; Di Romana, Silvana; Sidiras, Paschalis; Sokolova, Tatiana; Durez, Patrick; Fillet, Marianne; Malaise, Michel G.; de Seny, Dominique			A Cross-Sectional and Longitudinal Study to Define Alarmins and A-SAA Variants as Companion Markers in Early Rheumatoid Arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						early RA; A-SAA variants; alarmins; DMARDs; companion markers	DISEASE-ACTIVITY; RADIOLOGICAL DAMAGE; CALPROTECTIN; PROTEIN; INFLAMMATION; PLASMA; DAS28; ASSOCIATION; EXPRESSION; BIOMARKERS	Nowadays, in the study of rheumatoid arthritis (RA), more and more interest is directed towards an earlier effective therapeutic intervention and the determination of companion markers for predicting response to therapy with the goal to prevent progressive joint damage, deformities, and functional disability. With the present work, we aimed at quantifying in a cohort of early RA (ERA) patients naive to DMARD therapy, proteins whose increase was previously found associated with RA: serum amyloid A (A-SAA) and alarmins. Five A-SAA variants (SAA1 alpha, SAA1 beta, SAA1 gamma, SAA2 alpha, and SAA2 beta) but also S100A8 and S100A9 proteins were simultaneously quantified in plasma applying a method based on single targeted bottom-up proteomics LC-MS/MS. First, we compared their expression between ERA (n = 100) and healthy subjects (n = 100), then we focused on their trend by monitoring ERA patients naive to DMARD treatment, 1 year after starting therapy. Only SAA1 alpha and SAA2 alpha levels were increased in ERA patients, and SAA2 alpha appears to mostly mediate the pathological role of A-SAA. Levels of these variants, together with SAA1 beta, only decreased under biologic DMARD treatment but not under methotrexate monotherapy. This study highlights the importance to better understand the modulation of expression of these variants in ERA in order to subsequently better characterize their biological function. On the other hand, alarmin expression increased in ERA compared to controls but remained elevated after 12 months of methotrexate or biologic treatment. The work overcomes the concept of considering these proteins as biomarkers for diagnosis, demonstrating that SAA1 alpha, SAA1 beta, and SAA2 alpha variants but also S100A8 and S100A9 do not respond to all early treatment in ERA and should be rather considered as companion markers useful to improve the follow-up of treatment response and remission state. Moreover, it suggests that earlier use of biologics in addition to methotrexate may be worth considering.	[Ciregia, Federica; Cobraiville, Gael; Malaise, Michel G.; de Seny, Dominique] Univ Liege, Ctr Hosp Univ CHU Liege, Lab Rheumatol, Liege, Belgium; [Nys, Gwenael; Fillet, Marianne] Univ Liege, Ctr Interdisciplinaire Rech Sur Medicament CIRM, Dept Pharm, Lab Anal Med, Liege, Belgium; [Badot, Valerie] Ctr Hosp Univ CHU Brugmann, Dept Rheumatol, Brussels, Belgium; [Di Romana, Silvana] Ctr Hosp Univ CHU St Pierre, Dept Rheumatol, Brussels, Belgium; [Sidiras, Paschalis] Univ Libre Bruxelles, Dept Rheumatol, Hop Erasme, Brussels, Belgium; [Sokolova, Tatiana; Durez, Patrick] Catholic Univ Louvain, Inst Rech Expt & Clin IREC, Dept Rheumatol, Clin Univ St Luc, Brussels, Belgium	University of Liege; University of Liege; Universite Libre de Bruxelles; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Ciregia, F (corresponding author), Univ Liege, Ctr Hosp Univ CHU Liege, Lab Rheumatol, Liege, Belgium.	federica.ciregia@chuliege.be		Sidiras, Paschalis/0000-0003-1127-7665; durez, patrick/0000-0002-7156-2356	CAP48 (RTBF) via the arthritis medical research project [CAP48]	CAP48 (RTBF) via the arthritis medical research project	Funding This work was supported by CAP48 (RTBF) via the arthritis medical research project.	Salama SA, 2021, IMMUNOLOGY, V163, P115, DOI 10.1111/imm.13295; Salama SA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00843; Aletaha D, 2018, JAMA-J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103; Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584; Bernardy C, 2020, JOINT BONE SPINE, V87, P99, DOI 10.1016/j.jbspin.2019.07.001; Bjorkman L, 2010, ARTHRITIS RHEUM-US, V62, P1660, DOI 10.1002/art.27440; Burgess EJ, 2018, J IMMUNOL, V201, P2377, DOI 10.4049/jimmunol.1800503; Burri E, 2014, EXPERT REV GASTROENT, V8, P197, DOI 10.1586/17474124.2014.869476; CHAMBERS RE, 1983, ANN RHEUM DIS, V42, P665, DOI 10.1136/ard.42.6.665; Choi IY, 2015, ANN RHEUM DIS, V74, P499, DOI 10.1136/annrheumdis-2013-203923; Christenson K, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00092; Cohen G, 2007, ANN RHEUM DIS, V66, P358, DOI 10.1136/ard.2006.057497; Cohen J., 1988, STAT POWER ANAL BEHA; Cunnane G, 2000, J RHEUMATOL, V27, P58; Daien C, 2019, JOINT BONE SPINE, V86, P135, DOI 10.1016/j.jbspin.2018.10.002; De Buck M, 2016, CURR MED CHEM, V23, P1725, DOI 10.2174/0929867323666160418114600; de Seny D, 2008, CLIN CHEM, V54, P1066, DOI 10.1373/clinchem.2007.099549; Di Ceglie I, 2019, RHEUMATOLOGY, V58, P1331, DOI 10.1093/rheumatology/kez218; Di Ceglie I, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1584-1; Foell D, 2009, GUT, V58, P859, DOI 10.1136/gut.2008.170019; Garcia-Arias M, 2013, MOL DIAGN THER, V17, P49, DOI 10.1007/s40291-013-0016-9; Gavrila B I, 2016, J Med Life, V9, P144; Hammer HB, 2010, ANN RHEUM DIS, V69, P150, DOI 10.1136/ard.2008.103739; Hammer HB, 2007, ANN RHEUM DIS, V66, P1093, DOI 10.1136/ard.2006.064741; Hensor EMA, 2020, EXPERT REV CLIN IMMU, V16, P1, DOI 10.1080/1744666X.2019.1697679; Hensor EMA, 2019, RHEUMATOLOGY, V58, P1400, DOI 10.1093/rheumatology/kez049; Hwang YG, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1009-y; Jonsson MK, 2017, ANN RHEUM DIS, V76, P2031, DOI 10.1136/annrheumdis-2017-211695; Kang KY, 2014, KOREAN J INTERN MED, V29, P12, DOI 10.3904/kjim.2014.29.1.12; Kim YJ, 2015, PROTEOMICS, V15, P3116, DOI 10.1002/pmic.201400382; Larson MA, 2003, BIOCHEM BIOPH RES CO, V301, P1030, DOI 10.1016/S0006-291X(03)00045-7; Lee JY, 2020, CELL, V183, P2036, DOI 10.1016/j.cell.2020.12.008; Matsui T, 2007, ANN RHEUM DIS, V66, P1221, DOI 10.1136/ard.2006.063834; Molenaar ETH, 2002, J RHEUMATOL, V29, P267; Nordal HH, 2016, SCAND J RHEUMATOL, V45, P274, DOI 10.3109/03009742.2015.1107128; Nordal HH, 2018, SCAND J CLIN LAB INV, V78, P102, DOI 10.1080/00365513.2017.1419371; Nordal HH, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-016-1201-0; Nys G, 2019, TALANTA, V204, P507, DOI 10.1016/j.talanta.2019.06.044; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; Orr CK, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00185; Patro PS, 2016, J RHEUMATOL, V43, P731, DOI 10.3899/jrheum.150998; Salama SA, 2019, CYTOKINE GROWTH F R, V50, P29, DOI 10.1016/j.cytogfr.2019.10.006; SAROV I, 1982, J INFECT DIS, V146, P443, DOI 10.1093/infdis/146.3.443; Shen C, 2015, MOL MED REP, V11, P1528, DOI 10.3892/mmr.2014.2804; Smole U, 2020, NAT IMMUNOL, V21, P756, DOI 10.1038/s41590-020-0698-1; Smolen JS, 2020, ANN RHEUM DIS, V79, P685, DOI 10.1136/annrheumdis-2019-216655; Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8; Hosman IS, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.631299; Sunahori K, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1939; Targonska-Stepniak B, 2010, PHARMACOL REP, V62, P719, DOI 10.1016/S1734-1140(10)70329-7; van den Hoek J, 2017, RHEUMATOL INT, V37, P487, DOI 10.1007/s00296-016-3638-5; van der Linden MPM, 2010, ARTHRITIS RHEUM-US, V62, P3537, DOI 10.1002/art.27692; van Riel PLCM, 2016, CLIN EXP RHEUMATOL, V34, pS40; Wang Q, 2019, J TRANSL INTERN MED, V7, P126, DOI 10.2478/jtim-2019-0026; Wang SW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01298; Wicker E, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5967816; Zhou JL, 2018, POSTGRAD MED J, V94, P499, DOI 10.1136/postgradmedj-2018-136004	57	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 20	2021	12									10.3389/fimmu.2021.638814	http://dx.doi.org/10.3389/fimmu.2021.638814			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UN2OV	34489924	Green Published, gold			2022-12-18	WOS:000693860000001
J	Hauser, KA; Singer, JC; Hossainey, MRH; Moore, TE; Wendel, ES; Yaparla, A; Kalia, N; Grayfer, L				Hauser, Kelsey A.; Singer, Julia C.; Hossainey, Muhammad Riadul H.; Moore, Tyler E.; Wendel, Emily S.; Yaparla, Amulya; Kalia, Namarta; Grayfer, Leon			Amphibian (Xenopus laevis) Tadpoles and Adult Frogs Differ in Their Antiviral Responses to Intestinal Frog Virus 3 Infections	FRONTIERS IN IMMUNOLOGY			English	Article						amphibian; ranavirus; intestine; myeloid cells; interferons	STIMULATING FACTOR-I; MACROPHAGE DEVELOPMENT; FAMILY IRIDOVIRIDAE; INTERFERON RESPONSE; RANAVIRUS; SUSCEPTIBILITY; ROLES; METAMORPHOSIS; FISH	The global amphibian declines are compounded by ranavirus infections such as Frog Virus 3 (FV3), and amphibian tadpoles more frequently succumb to these pathogens than adult animals. Amphibian gastrointestinal tracts represent a major route of ranavirus entry, and viral pathogenesis often leads to hemorrhaging and necrosis within this tissue. Alas, the differences between tadpole and adult amphibian immune responses to intestinal ranavirus infections remain poorly defined. As interferon (IFN) cytokine responses represent a cornerstone of vertebrate antiviral immunity, it is pertinent that the tadpoles and adults of the anuran Xenopus laevis frog mount disparate IFN responses to FV3 infections. Presently, we compared the tadpole and adult X. laevis responses to intestinal FV3 infections. Our results indicate that FV3-challenged tadpoles mount more robust intestinal type I and III IFN responses than adult frogs. These tadpole antiviral responses appear to be mediated by myeloid cells, which are recruited into tadpole intestines in response to FV3 infections. Conversely, myeloid cells bearing similar cytology already reside within the intestines of healthy (uninfected) adult frogs, possibly accounting for some of the anti-FV3 resistance of these animals. Further insight into the differences between tadpole and adult frog responses to ranaviral infections is critical to understanding the facets of susceptibility and resistance to these pathogens.	[Hauser, Kelsey A.; Singer, Julia C.; Hossainey, Muhammad Riadul H.; Moore, Tyler E.; Wendel, Emily S.; Yaparla, Amulya; Kalia, Namarta; Grayfer, Leon] George Washington Univ, Dept Biol Sci, Washington, DC 20052 USA	George Washington University	Grayfer, L (corresponding author), George Washington Univ, Dept Biol Sci, Washington, DC 20052 USA.	leon_grayfer@gwu.edu			National Science Foundation CAREER Award [IOS: 1749427]	National Science Foundation CAREER Award(National Science Foundation (NSF))	This work was supported by a National Science Foundation CAREER Award (IOS: 1749427) to LG.	Andino FD, 2012, VIROLOGY, V432, P435, DOI 10.1016/j.virol.2012.07.001; Bayley AE, 2013, DIS AQUAT ORGAN, V103, P171, DOI 10.3354/dao02574; Chihara T, 2010, CELL DEATH DIFFER, V17, P1917, DOI 10.1038/cdd.2010.60; Chinchar VG, 2009, CURR TOP MICROBIOL, V328, P123; Chinchar VG, 2002, ARCH VIROL, V147, P447, DOI 10.1007/s007050200000; Conway JG, 2005, P NATL ACAD SCI USA, V102, P16078, DOI 10.1073/pnas.0502000102; Gan Z, 2017, DEV COMP IMMUNOL, V67, P166, DOI 10.1016/j.dci.2016.10.007; Grayfer L, 2016, DEV COMP IMMUNOL, V58, P60, DOI 10.1016/j.dci.2015.12.008; Grayfer L, 2015, J LEUKOCYTE BIOL, V98, P641, DOI 10.1189/jlb.4AB0315-117RR; Grayfer L, 2014, INT J DEV BIOL, V58, P757, DOI 10.1387/ijdb.140271jr; Grayfer L, 2015, J VIROL, V89, P5072, DOI 10.1128/JVI.00051-15; Grayfer L, 2014, J LEUKOCYTE BIOL, V96, P1143, DOI 10.1189/jlb.4A0614-295R; Grayfer L, 2014, J VIROL, V88, P5766, DOI 10.1128/JVI.00223-14; Grayfer L, 2013, J INNATE IMMUN, V5, P531, DOI 10.1159/000346928; Hauser K, 2020, FACETS, V5, P571, DOI 10.1139/facets-2020-0010; Hoverman JT, 2010, DIS AQUAT ORGAN, V89, P97, DOI 10.3354/dao02200; Koubourli DV, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02058; Koubourli DV, 2017, DEV COMP IMMUNOL, V72, P112, DOI 10.1016/j.dci.2017.02.016; Landsberg JH, 2013, DIS AQUAT ORGAN, V105, P89, DOI 10.3354/dao02625; Morales HD, 2010, J VIROL, V84, P4912, DOI 10.1128/JVI.02486-09; Reeve BC, 2013, ECOHEALTH, V10, P190, DOI 10.1007/s10393-013-0834-6; Robert J, 2011, VIROLOGY, V417, P410, DOI 10.1016/j.virol.2011.06.026; Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314; Sang YM, 2016, SCI REP-UK, V6, DOI 10.1038/srep29072; Schreiber AM, 2009, DEV BIOL, V331, P89, DOI 10.1016/j.ydbio.2009.04.033; Schreiber AM, 2005, P NATL ACAD SCI USA, V102, P3720, DOI 10.1073/pnas.0409868102; Shi YB, 1996, CURR TOP DEV BIOL, V32, P205, DOI 10.1016/S0070-2153(08)60429-9; Shibata Y, 2020, THYROID, V30, P300, DOI 10.1089/thy.2019.0366; Wendel ES, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10070372; Wendel ES, 2017, VIROLOGY, V503, P12, DOI 10.1016/j.virol.2017.01.001; Williams T, 2005, ADV VIRUS RES, V65, P173, DOI 10.1016/S0065-3527(05)65006-3; Yaparla A, 2020, DEV COMP IMMUNOL, V113, DOI 10.1016/j.dci.2020.103798; Yaparla A, 2018, J BIOL CHEM, V293, P1736, DOI 10.1074/jbc.M117.794065; YOURNO J, 1986, J HISTOCHEM CYTOCHEM, V34, P727, DOI 10.1177/34.6.3457861; Zou J, 2011, DEV COMP IMMUNOL, V35, P1376, DOI 10.1016/j.dci.2011.07.001	35	1	1	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 20	2021	12									10.3389/fimmu.2021.737403	http://dx.doi.org/10.3389/fimmu.2021.737403			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UN2OE	34489981	Green Published, gold			2022-12-18	WOS:000693858300001
J	Gonde, H; Demeules, M; Hardet, R; Scarpitta, A; Junge, M; Pinto-Espinoza, C; Varin, R; Koch-Nolte, F; Boyer, O; Adriouch, S				Gonde, Henri; Demeules, Melanie; Hardet, Romain; Scarpitta, Allan; Junge, Marten; Pinto-Espinoza, Carolina; Varin, Remi; Koch-Nolte, Friedrich; Boyer, Olivier; Adriouch, Sahil			A Methodological Approach Using rAAV Vectors Encoding Nanobody-Based Biologics to Evaluate ARTC2.2 and P2X7 In Vivo	FRONTIERS IN IMMUNOLOGY			English	Article						AAV vectors; nanobodies (V-HH); animal models; extracellular ATP (eATP); extracellular NAD(+); methodological approach	ECTO-ADP-RIBOSYLTRANSFERASE; SINGLE-DOMAIN ANTIBODIES; EXTRACELLULAR NAD(+); RECEPTOR; TUMOR; RIBOSYLATION; INFECTION; PROTEINS; CHANNEL; BINDING	On murine T cells, mono-ADP ribosyltransferase ARTC2.2 catalyzes ADP-ribosylation of various surface proteins when nicotinamide adenine dinucleotide (NAD(+)) is released into the extracellular compartment. Covalent ADP-ribosylation of the P2X7 receptor by ARTC2.2 thereby represents an additional mechanism of activation, complementary to its triggering by extracellular ATP. P2X7 is a multifaceted receptor that may represents a potential target in inflammatory, and neurodegenerative diseases, as well as in cancer. We present herein an experimental approach using intramuscular injection of recombinant AAV vectors (rAAV) encoding nanobody-based biologics targeting ARTC2.2 or P2X7. We demonstrate the ability of these in vivo generated biologics to potently and durably block P2X7 or ARTC2.2 activities in vivo, or in contrast, to potentiate NAD(+)- or ATP-induced activation of P2X7. We additionally demonstrate the ability of rAAV-encoded functional heavy chain antibodies to elicit long-term depletion of T cells expressing high levels of ARTC2.2 or P2X7. Our approach of using rAAV to generate functional nanobody-based biologics in vivo appears promising to evaluate the role of ARTC2.2 and P2X7 in murine acute as well as chronic disease models.	[Gonde, Henri; Demeules, Melanie; Hardet, Romain; Scarpitta, Allan; Varin, Remi; Boyer, Olivier; Adriouch, Sahil] Normandie Univ, Pathophysiol Autoimmun Neuromuscular Dis & Regene, UNIROUEN, INSERM U1234, Rouen, France; [Gonde, Henri; Varin, Remi] Rouen Univ Hosp, Dept Pharm, Rouen, France; [Junge, Marten; Pinto-Espinoza, Carolina; Koch-Nolte, Friedrich] Univ Med Ctr Hamburg Eppendorf, Inst Immunol, Hamburg, Germany; [Boyer, Olivier] Rouen Univ Hosp, Dept Immunol & Biotherapy, Rouen, France	CHU de Rouen; University of Hamburg; University Medical Center Hamburg-Eppendorf; CHU de Rouen	Adriouch, S (corresponding author), Normandie Univ, Pathophysiol Autoimmun Neuromuscular Dis & Regene, UNIROUEN, INSERM U1234, Rouen, France.	sahil.adriouch@univ-rouen.fr	Hardet, Romain/M-1547-2019; ADRIOUCH, Sahil/G-8999-2012	Hardet, Romain/0000-0002-9919-4874; ADRIOUCH, Sahil/0000-0002-0265-7773; Gonde, Henri/0000-0001-7364-3785; Demeules, Melanie/0000-0003-1300-6893	Deutsche Forschungsgemeinschaft (DFG) [No310/13, No310/14, SFB1192-B5]; Werner-Otto Foundation; Agence Nationale de la Recherche (ANR) [ANR-18-CE92-0046]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Werner-Otto Foundation; Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR))	Funding This work was supported by a grant from the Deutsche Forschungsgemeinschaft (DFG) to FK-N (No310/13, No310/14, and SFB1192-B5), by a stipend from the Werner-Otto Foundation to MJ, and by a grant from the Agence Nationale de la Recherche (ANR) to SA (ANR-18-CE92-0046).	Adinolfi E, 2012, CANCER RES, V72, P2957, DOI 10.1158/0008-5472.CAN-11-1947; Adriouch S, 2008, FASEB J, V22, P861, DOI 10.1096/fj.07-9294com; Adriouch S, 2012, MICROBES INFECT, V14, P1284, DOI 10.1016/j.micinf.2012.05.011; Anderson KG, 2014, NAT PROTOC, V9, P209, DOI 10.1038/nprot.2014.005; Balazs AB, 2012, NATURE, V481, P81, DOI 10.1038/nature10660; Bartlett R, 2014, PHARMACOL REV, V66, P638, DOI 10.1124/pr.113.008003; Bazan JF, 1997, ADV EXP MED BIOL, V419, P99; Burnstock G, 2018, PURINERG SIGNAL, V14, P1, DOI 10.1007/s11302-017-9593-0; Chen HF, 2011, METHODS MOL BIOL, V737, P235, DOI 10.1007/978-1-61779-095-9_10; da Silva HB, 2019, J IMMUNOL, V202, P2153, DOI 10.4049/jimmunol.1801613; Danquah W, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8463; De Genst E, 2006, P NATL ACAD SCI USA, V103, P4586, DOI 10.1073/pnas.0505379103; De Marchi E, 2019, ONCOGENE, V38, P3636, DOI 10.1038/s41388-019-0684-y; De Marchi E, 2016, ADV PROTEIN CHEM STR, V104, P39, DOI 10.1016/bs.apcsb.2015.11.004; Demeules M, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01699; Di Virgilio F, 2018, NAT REV CANCER, V18, P601, DOI 10.1038/s41568-018-0037-0; Di Virgilio F, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00039; Di Virgilio F, 2017, IMMUNITY, V47, P15, DOI 10.1016/j.immuni.2017.06.020; Douguet L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-20912-2; Georgiev H, 2018, EUR J IMMUNOL, V48, P1078, DOI 10.1002/eji.201747420; Ghetie V, 1997, NAT BIOTECHNOL, V15, P637, DOI 10.1038/nbt0797-637; Glowacki G, 2002, PROTEIN SCI, V11, P1657, DOI 10.1110/ps.0200602; Hong SY, 2009, PURINERG SIGNAL, V5, P369, DOI 10.1007/s11302-009-9162-2; Hubert S, 2010, J EXP MED, V207, P2561, DOI 10.1084/jem.20091154; Ingram JR, 2018, ANNU REV IMMUNOL, V36, P695, DOI 10.1146/annurev-immunol-042617-053327; Jacobson KA, 2016, NEUROPHARMACOLOGY, V104, P31, DOI 10.1016/j.neuropharm.2015.12.001; Kaczmarek-Hajek K, 2018, ELIFE, V7, DOI 10.7554/eLife.36217; Koch-Nolte F, 1999, J IMMUNOL, V163, P6014; Koch-Nolte F, 2008, FRONT BIOSCI-LANDMRK, V13, P6716, DOI 10.2741/3184; Koch-Nolte F, 2007, FASEB J, V21, P3490, DOI 10.1096/fj.07-8661com; Koch-Nolte F, 2019, CURR OPIN PHARMACOL, V47, P110, DOI 10.1016/j.coph.2019.03.001; Koch-Nolte F, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.257mr1; KochNolte F, 1996, J BIOL CHEM, V271, P7686, DOI 10.1074/jbc.271.13.7686; Linden J, 2019, ANNU REV IMMUNOL, V37, P325, DOI 10.1146/annurev-immunol-051116-052406; Mueller SN, 2016, NAT REV IMMUNOL, V16, P79, DOI 10.1038/nri.2015.3; Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; Rissiek B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01580; Rissiek B, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00204; Rissiek B, 2014, J LEUKOCYTE BIOL, V95, P543, DOI 10.1189/jlb.0713407; Saunders KO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01296; Schenkel JM, 2014, IMMUNITY, V41, P886, DOI 10.1016/j.immuni.2014.12.007; Scheuplein F, 2009, J IMMUNOL, V182, P2898, DOI 10.4049/jimmunol.0801711; Seman M, 2003, IMMUNITY, V19, P571, DOI 10.1016/S1074-7613(03)00266-8; Sluyter R, 2017, ADV EXP MED BIOL, V1051, P17, DOI 10.1007/5584_2017_59; Stark R, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aau1022; Stokes L, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00627; Tijink BM, 2008, MOL CANCER THER, V7, P2288, DOI 10.1158/1535-7163.MCT-07-2384; Wesolowski J, 2009, MED MICROBIOL IMMUN, V198, P157, DOI 10.1007/s00430-009-0116-7	49	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 19	2021	12									10.3389/fimmu.2021.704408	http://dx.doi.org/10.3389/fimmu.2021.704408			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UM7TO	34489954	gold, Green Published			2022-12-18	WOS:000693530800001
J	Li, WR; Guan, XL; Sun, B; Sun, L				Li, Wenrui; Guan, Xiaolu; Sun, Bin; Sun, Li			A Novel microRNA of Japanese Flounder Regulates Antimicrobial Immunity Involving a Bacteria-Binding CSF3	FRONTIERS IN IMMUNOLOGY			English	Article						Paralichthys olivaceus; fish microRNA; granulocyte colony stimulating factor 3; bacterial and viral pathogens; antimicrobial immune defense	COLONY-STIMULATING FACTOR; ROCK BREAM; GRANULOCYTE; INFECTION; RESPONSES; FISH; MECHANISMS; RESISTANCE; AUTOPHAGY; CROAKER	MicroRNAs (miRNAs) are small non-coding RNAs that regulate diverse biological processes including immunity. In a previous high-throughput RNA sequencing study, a novel miRNA, pol-miR-novel_642, was identified from Japanese flounder (Paralichthys olivaceus), a farmed fish species with important economic value. In this study, we investigated the regulatory mechanism and the function of pol-miR-novel_642 and its target gene. We found that pol-miR-novel_642 targeted, in a sequence-specific manner, a flounder gene encoding an uncharacterized protein that is a structural homologue of murine granulocyte colony stimulating factor 3 (CSF3). The expression of pol-miR-novel_642 and its target gene (named PoCSF3-1) was regulated, in different manners, by the bacterial pathogen Edwardsiella tarda and the viral pathogen megalocytivirus. Overexpression of pol-miR-novel_642 or interference with PoCSF3-1 expression in flounder cells strongly potentiated E. tarda infection. Consistently, in vivo knockdown of PoCSF3-1 enhanced bacterial dissemination in flounder tissues but blocked viral replication, whereas in vivo overexpression of PoCSF3-1 inhibited bacterial dissemination and facilitated viral infection. Overexpression/knockdown of PoCSF3-1 and pol-miR-novel_642 also affected the activation of autophagy. Recombinant PoCSF3-1 (rPoCSF3-1) interacted with and inhibited the growth of Gram-negative bacteria in a manner relying on a PoCSF3-1-characteristic structural motif that is absent in mouse CSF3. rPoCSF3-1 also regulated the proliferation, inflammatory response, and immune defense of flounder head kidney leukocytes in a structure-dependent fashion. Together, these results reveal the function of a novel miRNA-CSF3 regulatory system of flounder, and add new insights into the role and mechanism of fish miRNA and CSF3 in antimicrobial immunity.	[Li, Wenrui; Guan, Xiaolu; Sun, Bin; Sun, Li] Chinese Acad Sci, Ctr Ocean Megasci, Inst Oceanol, CAS Key Lab Expt Marine Biol, Beijing, Peoples R China; [Li, Wenrui; Guan, Xiaolu; Sun, Bin; Sun, Li] Pilot Natl Lab Marine Sci & Technol Qingdao, Lab Marine Biol & Biotechnol, Qingdao, Peoples R China; [Li, Wenrui; Sun, Bin; Sun, Li] Univ Chinese Acad Sci, Coll Marine Sci, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Oceanology, CAS; Qingdao National Laboratory for Marine Science & Technology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Sun, L (corresponding author), Chinese Acad Sci, Ctr Ocean Megasci, Inst Oceanol, CAS Key Lab Expt Marine Biol, Beijing, Peoples R China.; Sun, L (corresponding author), Pilot Natl Lab Marine Sci & Technol Qingdao, Lab Marine Biol & Biotechnol, Qingdao, Peoples R China.; Sun, L (corresponding author), Univ Chinese Acad Sci, Coll Marine Sci, Beijing, Peoples R China.	lsun@qdio.ac.cn			National Natural Science Foundation of China [31730100]; Marine S&T Fund of Shandong Province for Pilot National Laboratory for Marine Science and Technology (Qingdao) [2018SDKJ0302-2]; Taishan Scholar Program of Shandong Province	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Marine S&T Fund of Shandong Province for Pilot National Laboratory for Marine Science and Technology (Qingdao); Taishan Scholar Program of Shandong Province	Funding This work was supported by the grants of the National Natural Science Foundation of China (31730100), the Marine S&T Fund of Shandong Province for Pilot National Laboratory for Marine Science and Technology (Qingdao) (2018SDKJ0302-2), and the Taishan Scholar Program of Shandong Province.	Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Barreda DR, 2004, DEV COMP IMMUNOL, V28, P509, DOI 10.1016/j.dci.2003.09.010; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Basu S, 2000, BLOOD, V95, P3725; Becher B, 2016, IMMUNITY, V45, P963, DOI 10.1016/j.immuni.2016.10.026; Chen XM, 2004, SCIENCE, V303, P2022, DOI 10.1126/science.1088060; Chu Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04354-9; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; Delamare-Deboutteville J, 2019, FISH SHELLFISH IMMUN, V90, P250, DOI 10.1016/j.fsi.2019.04.058; DEMETRI GD, 1991, BLOOD, V78, P2791; Didiano D, 2008, RNA, V14, P1297, DOI 10.1261/rna.1082708; Du HH, 2019, FISH SHELLFISH IMMUN, V89, P27, DOI 10.1016/j.fsi.2019.03.015; Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008; Eulalio A, 2012, RNA BIOL, V9, P742, DOI 10.4161/rna.20018; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Guan XL, 2020, DEV COMP IMMUNOL, V103, DOI 10.1016/j.dci.2019.103531; Guan XL, 2019, FISH SHELLFISH IMMUN, V87, P220, DOI 10.1016/j.fsi.2019.01.017; Guo YJ, 2015, LAB INVEST, V95, P1439, DOI 10.1038/labinvest.2015.120; Han JJ, 2017, DEV COMP IMMUNOL, V68, P79, DOI 10.1016/j.dci.2016.11.021; Harada M, 2005, NAT MED, V11, P305, DOI 10.1038/nm1199; Hu YH, 2017, VIRULENCE, V8, P1457, DOI 10.1080/21505594.2017.1356541; Ingersoll MA, 2008, CELL MICROBIOL, V10, P2568, DOI 10.1111/j.1462-5822.2008.01230.x; Jafari M, 2019, J CELL PHYSIOL, V234, P2373, DOI 10.1002/jcp.27262; Jeswin J, 2017, FISH SHELLFISH IMMUN, V65, P206, DOI 10.1016/j.fsi.2017.04.006; Katakura F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00255; Kloosterman WP, 2004, NUCLEIC ACIDS RES, V32, P6284, DOI 10.1093/nar/gkh968; Kumar R, 2016, CELL MICROBIOL, V18, P679, DOI 10.1111/cmi.12540; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li QH, 2020, FISH SHELLFISH IMMUN, V98, P167, DOI 10.1016/j.fsi.2020.01.003; Li QH, 2019, FISH SHELLFISH IMMUN, V90, P20, DOI 10.1016/j.fsi.2019.04.048; Li WR, 2020, DEV COMP IMMUNOL, V106, DOI 10.1016/j.dci.2020.103616; Li WR, 2019, FISH SHELLFISH IMMUN, V93, P766, DOI 10.1016/j.fsi.2019.07.078; Li WR, 2021, DEV COMP IMMUNOL, V123, DOI 10.1016/j.dci.2021.104170; Li WR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207725; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Liongue C, 2009, BLOOD, V113, P2535, DOI 10.1182/blood-2008-07-171967; Liu YZ, 2019, FISH SHELLFISH IMMUN, V89, P477, DOI 10.1016/j.fsi.2019.03.076; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Ma F, 2011, NAT IMMUNOL, V12, P861, DOI 10.1038/ni.2073; Marino VJ, 2008, J CELL BIOCHEM, V103, P1512, DOI 10.1002/jcb.21542; McKnight Nicole C, 2013, Curr Pathobiol Rep, V1, P231; Nahid MA, 2011, J IMMUNOL, V186, P1723, DOI 10.4049/jimmunol.1002311; Nam BH, 2009, FISH SHELLFISH IMMUN, V27, P360, DOI 10.1016/j.fsi.2009.06.005; Nie L, 2019, FISH SHELLFISH IMMUN, V86, P70, DOI 10.1016/j.fsi.2018.11.030; O'Connell RM, 2012, ANNU REV IMMUNOL, V30, P295, DOI 10.1146/annurev-immunol-020711-075013; O'Neill LA, 2011, NAT REV IMMUNOL, V11, P163, DOI 10.1038/nri2957; Roberts AW, 2005, GROWTH FACTORS, V23, P33, DOI 10.1080/08977190500055836; Sakamoto C, 2003, INT J HEMATOL, V77, P60, DOI 10.1007/BF02982604; Santos MD, 2006, IMMUNOGENETICS, V58, P422, DOI 10.1007/s00251-006-0106-5; Shi BH, 2019, J CELL PHYSIOL, V234, P12562, DOI 10.1002/jcp.28125; Stachura DL, 2013, BLOOD, V122, P3918, DOI 10.1182/blood-2012-12-475392; Standart N, 2007, GENE DEV, V21, P1975, DOI 10.1101/gad.1591507; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; Sun K, 2009, AQUACULTURE, V289, P134, DOI 10.1016/j.aquaculture.2008.12.021; Sun Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136015; Tong SL, 1997, AQUACULTURE, V156, P327, DOI 10.1016/S0044-8486(97)00070-7; Touzelet O, 2020, MOL CELL PROTEOMICS, V19, P793, DOI 10.1074/mcp.RA119.001546; Wang HR, 2009, VACCINE, V27, P4047, DOI 10.1016/j.vaccine.2009.04.023; Wang T, 2016, DEV COMP IMMUNOL, V55, P12, DOI 10.1016/j.dci.2015.10.002; WELTE K, 1985, P NATL ACAD SCI USA, V82, P1526, DOI 10.1073/pnas.82.5.1526; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Xiu YJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.623764; Xiu YJ, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00731; Xu JZ, 2012, AUTOPHAGY, V8, P873, DOI 10.4161/auto.19629; Xu TJ, 2018, J BIOL CHEM, V293, P1386, DOI [10.1074/jbc.ra117.000158, 10.1074/jbc.RA117.000158]; Yao ZY, 2015, AUTOPHAGY, V11, P2288, DOI 10.1080/15548627.2015.1107692; Zhang BC, 2016, SCI REP-UK, V6, DOI 10.1038/srep28354; Zhang BC, 2013, DIS AQUAT ORGAN, V104, P203, DOI 10.3354/dao02587; Zhang J, 2013, VET IMMUNOL IMMUNOP, V152, P303, DOI 10.1016/j.vetimm.2012.12.018; Zheng WJ, 2011, FISH SHELLFISH IMMUN, V30, P638, DOI 10.1016/j.fsi.2010.12.014; Zhou XK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4619	71	1	1	3	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 19	2021	12									10.3389/fimmu.2021.723401	http://dx.doi.org/10.3389/fimmu.2021.723401			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UM7UG	34489973	gold, Green Published			2022-12-18	WOS:000693532600001
J	Shelyakin, PV; Lupyr, KR; Egorov, ES; Kofiadi, IA; Staroverov, DB; Kasatskaya, SA; Kriukova, VV; Shagina, IA; Merzlyak, EM; Nakonechnaya, TO; Latysheva, EA; Manto, IA; Khaitov, MR; Lukyanov, SA; Chudakov, DM; Britanova, OV				Shelyakin, Pavel, V; Lupyr, Ksenia R.; Egorov, Evgeny S.; Kofiadi, Ilya A.; Staroverov, Dmitriy B.; Kasatskaya, Sofya A.; Kriukova, Valeriia V.; Shagina, Irina A.; Merzlyak, Ekaterina M.; Nakonechnaya, Tatiana O.; Latysheva, Elena A.; Manto, Irina A.; Khaitov, Musa R.; Lukyanov, Sergey A.; Chudakov, Dmitriy M.; Britanova, Olga, V			Naive Regulatory T Cell Subset Is Altered in X-Linked Agammaglobulinemia	FRONTIERS IN IMMUNOLOGY			English	Article						X-linked agammaglobulinemia (XLA); TCR repertoire; T cell gene expression; naive regulatory T cells; CDR3 beta features	THYMIC B-CELLS; SELF-ANTIGENS; RECEPTOR; DIFFERENTIATION; LYMPHOCYTES; REPERTOIRE; EXPRESSION; EMIGRANTS; MECHANISM; EXPANSION	The interplay between T- and B-cell compartments during naive, effector and memory T cell maturation is critical for a balanced immune response. Primary B-cell immunodeficiency arising from X-linked agammaglobulinemia (XLA) offers a model to explore B cell impact on T cell subsets, starting from the thymic selection. Here we investigated characteristics of naive and effector T cell subsets in XLA patients, revealing prominent alterations in the corresponding T-cell receptor (TCR) repertoires. We observed immunosenescence in terms of decreased diversity of naive CD4(+) and CD8(+) TCR repertoires in XLA donors. The most substantial alterations were found within naive CD4(+) subsets, and we have investigated these in greater detail. In particular, increased clonality and convergence, along with shorter CDR3 regions, suggested narrower focused antigen-specific maturation of thymus-derived naive T-reg (CD4(+)CD45RA(+)CD27(+)CD25(+)) in the absence of B cells - normally presenting diverse self and commensal antigens. The naive T-reg proportion among naive CD4 T cells was decreased in XLA patients, supporting the concept of impaired thymic naive T-reg selection. Furthermore, the naive T-reg subset showed prominent differences at the transcriptome level, including increased expression of genes specific for antigen-presenting and myeloid cells. Altogether, our findings suggest active B cell involvement in CD4 T cell subsets maturation, including B cell-dependent expansion of the naive Treg TCR repertoire that enables better control of self-reactive T cells.	[Shelyakin, Pavel, V; Lupyr, Ksenia R.; Egorov, Evgeny S.; Staroverov, Dmitriy B.; Kasatskaya, Sofya A.; Kriukova, Valeriia V.; Shagina, Irina A.; Merzlyak, Ekaterina M.; Chudakov, Dmitriy M.; Britanova, Olga, V] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow, Russia; [Lupyr, Ksenia R.; Kasatskaya, Sofya A.; Kriukova, Valeriia V.; Chudakov, Dmitriy M.] Skolkovo Inst Sci & Technol, Ctr Life Sci, Moscow, Russia; [Kofiadi, Ilya A.; Latysheva, Elena A.; Manto, Irina A.; Khaitov, Musa R.] FSBI NRC Inst Immunol FMBA Russia, Moscow, Russia; [Staroverov, Dmitriy B.; Kasatskaya, Sofya A.; Shagina, Irina A.; Merzlyak, Ekaterina M.; Nakonechnaya, Tatiana O.; Lukyanov, Sergey A.; Chudakov, Dmitriy M.] Pirogov Russian Natl Res Med Univ, Inst Translat Med, Moscow, Russia	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Skolkovo Institute of Science & Technology; NRC Institute of Immunology FMBA of Russia; Pirogov Russian National Research Medical University	Britanova, OV (corresponding author), Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow, Russia.	olbritan@gmail.com	Kofiadi, Ilya A/P-5523-2015; Chudakov, Dmitriy M/G-7741-2014; Khaitov, Musa/AAC-1516-2021	Kofiadi, Ilya A/0000-0001-9280-8282; Chudakov, Dmitriy M/0000-0003-0430-790X; Khaitov, Musa/0000-0003-4961-9640; Nakonechnaya, Tatiana/0000-0003-2873-9977; Kriukova, Valeriia/0000-0002-5168-6511; Manto, Irina/0000-0001-6432-394X	Ministry of Science and Higher Education of the Russian Federation ? [075-15-2020-807]	Ministry of Science and Higher Education of the Russian Federation ?	The work was supported by grant of the Ministry of Science and Higher Education of the Russian Federation ? 075-15-2020-807.	Affandi AJ, 2018, EUR J IMMUNOL, V48, P522, DOI 10.1002/eji.201747195; Arlt A, 2011, EUR J CELL BIOL, V90, P545, DOI 10.1016/j.ejcb.2010.10.002; Bateman EAL, 2012, CLIN EXP IMMUNOL, V170, P202, DOI 10.1111/j.1365-2249.2012.04643.x; Bigot J, 2016, AM J TRANSPLANT, V16, P3430, DOI 10.1111/ajt.13904; Brincks EL, 2013, J IMMUNOL, V190, P3438, DOI 10.4049/jimmunol.1203140; Cepeda S, 2018, CELL REP, V22, P1276, DOI 10.1016/j.celrep.2018.01.015; Cerezo LA, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1288-y; Crawford A, 2006, J IMMUNOL, V176, P3498, DOI 10.4049/jimmunol.176.6.3498; Cunningham CA, 2018, CURR OPIN IMMUNOL, V51, P1, DOI 10.1016/j.coi.2017.12.006; Egorov ES, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01618; El-Sayed ZA, 2019, WORLD ALLERGY ORGAN, V12, DOI 10.1016/j.waojou.2019.100018; Feng YQ, 2015, NATURE, V528, P132, DOI 10.1038/nature16141; Friesen TJ, 2016, J EXP MED, V213, P913, DOI 10.1084/jem.20151990; Frommer F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015372; Geginat J, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00630; Gubser C, 2016, SCI REP-UK, V6, DOI 10.1038/srep25758; Hernandez-Trujillo VP, 2014, J CLIN IMMUNOL, V34, P627, DOI 10.1007/s10875-014-0056-x; Hua J, 2015, J IMMUNOL, V195, P3642, DOI 10.4049/jimmunol.1500349; Kaizuka Y, 2009, J CELL BIOL, V185, P521, DOI 10.1083/jcb.200809136; Kasatskaya SA, 2020, ELIFE, V9, DOI 10.7554/eLife.57063; Kosmrlj A, 2008, P NATL ACAD SCI USA, V105, P16671, DOI 10.1073/pnas.0808081105; LeBien TW, 2008, BLOOD, V112, P1570, DOI 10.1182/blood-2008-02-078071; Lee YN, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah6109; Linton PJ, 2000, J IMMUNOL, V165, P5558, DOI 10.4049/jimmunol.165.10.5558; Logunova NN, 2020, P NATL ACAD SCI USA, V117, P13659, DOI 10.1073/pnas.2003170117; Lu FT, 2015, J AUTOIMMUN, V61, P62, DOI 10.1016/j.jaut.2015.05.008; Martini H, 2011, CLIN EXP IMMUNOL, V164, P381, DOI 10.1111/j.1365-2249.2011.04377.x; Moran AE, 2011, J EXP MED, V208, P1279, DOI 10.1084/jem.20110308; Nogueira JD, 2016, IMMUNOLOGY, V147, P221, DOI 10.1111/imm.12555; Ono M, 2016, IMMUNOL CELL BIOL, V94, P3, DOI 10.1038/icb.2015.65; Paroli M, 2002, BLOOD, V99, P2131, DOI 10.1182/blood.V99.6.2131; Perera J, 2013, P NATL ACAD SCI USA, V110, P17011, DOI 10.1073/pnas.1313001110; Plitas G, 2016, IMMUNITY, V45, P1122, DOI 10.1016/j.immuni.2016.10.032; Pulugulla SH, 2018, CYTOKINE, V111, P373, DOI 10.1016/j.cyto.2018.10.001; Qi Q, 2014, P NATL ACAD SCI USA, V111, P13139, DOI 10.1073/pnas.1409155111; Ramesh M, 2015, CLIN IMMUNOL, V161, P190, DOI 10.1016/j.clim.2015.09.002; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sharapova SO, 2018, ALLERGOL IMMUNOPATH, V46, P58, DOI 10.1016/j.aller.2017.01.011; Shugay M, 2014, NAT METHODS, V11, P653, DOI [10.1038/nmeth.2960, 10.1038/NMETH.2960]; Stadinski BD, 2016, NAT IMMUNOL, V17, P946, DOI 10.1038/ni.3491; Tadmor T, 2011, CANCER IMMUNOL IMMUN, V60, P609, DOI 10.1007/s00262-011-0972-z; Tai YT, 2019, LEUKEMIA, V33, P426, DOI 10.1038/s41375-018-0242-6; Wakkach A, 2001, J IMMUNOL, V167, P3107, DOI 10.4049/jimmunol.167.6.3107; Walters SN, 2014, J IMMUNOL, V193, P170, DOI 10.4049/jimmunol.1302519; Wang ECY, 2018, P NATL ACAD SCI USA, V115, P4998, DOI 10.1073/pnas.1720950115; Wang T, 2012, J LEUKOCYTE BIOL, V91, P449, DOI 10.1189/jlb.1011498; Whitmire JK, 2009, J IMMUNOL, V182, P1868, DOI 10.4049/jimmunol.0802501; Wu YM, 2000, J BIOL CHEM, V275, P35478, DOI 10.1074/jbc.M005224200; Yamano T, 2015, IMMUNITY, V42, P1048, DOI 10.1016/j.immuni.2015.05.013; Yamazaki T, 2008, J IMMUNOL, V181, P8391, DOI 10.4049/jimmunol.181.12.8391; Zhang J, 1999, J EXP MED, V190, P1329, DOI 10.1084/jem.190.9.1329; Zhao JX, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004279; Zinzow-Kramer WM, 2019, P NATL ACAD SCI USA, V116, P15160, DOI 10.1073/pnas.1904096116	53	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 19	2021	12								697307	10.3389/fimmu.2021.697307	http://dx.doi.org/10.3389/fimmu.2021.697307			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UL3CT	34489944	Green Published, gold			2022-12-18	WOS:000692534000001
J	Schenz, J; Obermaier, M; Uhle, S; Weigand, MA; Uhle, F				Schenz, Judith; Obermaier, Manuel; Uhle, Sandra; Weigand, Markus Alexander; Uhle, Florian			Low-Density Granulocyte Contamination From Peripheral Blood Mononuclear Cells of Patients With Sepsis and How to Remove It - A Technical Report	FRONTIERS IN IMMUNOLOGY			English	Article						cell isolation; centrifugation; Ficoll; MACS; density gradient; Sepsis; PBMC (peripheral blood mononuclear cells); low-density granulocytes	DEFINITIONS	Elucidating the mechanisms contributing to the dysregulated host response to infection as part of the syndrome is a current challenge in sepsis research. Peripheral blood mononuclear cells are widely used in immunological studies. Density gradient centrifugation, a common method, is of limited use for blood drawn from patients with sepsis. A significant number of low-density granulocytes co-purify contributing to low purity of isolated peripheral blood mononuclear cells. Whole blood anticoagulated with lithium heparin was drawn from patients with sepsis (n=14) and healthy volunteers (n=11). Immediately after drawing, the plasma fraction was removed and PBMC were isolated from the cellular fraction by density gradient centrifugation. Samples derived from patients with sepsis were subsequently incubated with cluster of differentiation 15 MicroBeads and granulocytes were depleted using magnetic-activated cell sorting. Core cellular functions as antigen presentation and cytokine secretion were analyzed in cells isolated from healthy volunteers (n=3) before and after depletion to confirm consistent functionality. We report here that depleting CD15(+) cells after density gradient centrifugation is a feasible way to get rid of the low-density granulocyte contamination. Afterwards, the purity of isolated, functionally intact peripheral blood mononuclear cells is comparable to healthy volunteers. Information on the isolation purity and identification of the containing cell types are necessary for good comparability between different studies. Depletion of CD15(+) cells after density gradient centrifugation is an easy but highly efficient way to gain a higher quality and more reliability in studies using peripheral blood mononuclear cells from septic patients without affecting the functionality of the cells.	[Schenz, Judith; Obermaier, Manuel; Uhle, Sandra; Weigand, Markus Alexander; Uhle, Florian] Heidelberg Univ Hosp, Dept Anesthesiol, Heidelberg, Germany	Ruprecht Karls University Heidelberg	Schenz, J (corresponding author), Heidelberg Univ Hosp, Dept Anesthesiol, Heidelberg, Germany.	judith.schenz@med.uni-heidelberg.de	Obermaier, Manuel/AAH-2210-2021	Obermaier, Manuel/0000-0003-0881-4757; Schenz, Judith/0000-0002-6771-8864	SEPSDIA project within the framework of the European funding program "Eurostars" [11501]; German Federal Ministry of Education and Research (BMBF), Berlin	SEPSDIA project within the framework of the European funding program "Eurostars"; German Federal Ministry of Education and Research (BMBF), Berlin(Federal Ministry of Education & Research (BMBF))	The SEPSDIA project (reference number 11501) has been conducted within the framework of the European funding program "Eurostars". The German consortium partner has received financial support from the German Federal Ministry of Education and Research (BMBF), Berlin.	CALVANO SE, 1988, J TRAUMA, V28, P353, DOI 10.1097/00005373-198803000-00011; Carmona-Rivera C, 2013, SEMIN IMMUNOPATHOL, V35, P455, DOI 10.1007/s00281-013-0375-7; Clere-Jehl R, 2019, SHOCK, V51, P97, DOI 10.1097/SHK.0000000000001125; Cloke T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048939; Darcy CJ, 2014, CRIT CARE, V18, DOI 10.1186/cc14003; Daumas A, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3266-7; DEITCH EA, 1989, J TRAUMA, V29, P277, DOI 10.1097/00005373-198903000-00001; Deng YT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153567; Denny MR, 2010, J IMMUNOL, V184, P3284, DOI 10.4049/jimmunol.0902199; Drewry AM, 2014, SHOCK, V42, P383, DOI 10.1097/SHK.0000000000000234; Famous KR, 2017, AM J RESP CRIT CARE, V195, P331, DOI 10.1164/rccm.201603-0645OC; Hassani M, 2020, J LEUKOCYTE BIOL, V107, P809, DOI 10.1002/JLB.5HR0120-459R; He JB, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2180-0; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Liu ZL, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7497314; Maldifassi MC, 2018, J BIOL CHEM, V293, P13874, DOI 10.1074/jbc.RA118.003443; Marshall JC, 2014, TRENDS MOL MED, V20, P195, DOI 10.1016/j.molmed.2014.01.007; Mazer M, 2019, J IMMUNOL, V203, P2088, DOI 10.4049/jimmunol.1900637; Parikh R, 2020, CLIN NUTR, V39, P958, DOI 10.1016/j.clnu.2019.03.040; Peters Van Ton AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01926; Preobrazhensky SN, 2009, CRYOBIOLOGY, V59, P366, DOI 10.1016/j.cryobiol.2009.09.008; Qian MZ, 2018, FREE RADICAL BIO MED, V118, P23, DOI 10.1016/j.freeradbiomed.2018.02.028; Rubio I, 2019, LANCET INFECT DIS, V19, pE422, DOI 10.1016/S1473-3099(19)30567-5; Scicluna BP, 2017, LANCET RESP MED, V5, P816, DOI 10.1016/S2213-2600(17)30294-1; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Ssemaganda A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085696; Sweeney TE, 2018, CRIT CARE MED, V46, P915, DOI 10.1097/CCM.0000000000003084; Tong YQ, 2019, SCAND J IMMUNOL, V89, DOI 10.1111/sji.12748; van den Akker ELT, 2008, INTENS CARE MED, V34, P912, DOI 10.1007/s00134-007-0989-0; Wang YC, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/9152140; Weiss SL, 2020, SHOCK, V54, P285, DOI 10.1097/SHK.0000000000001486; Zhang JP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02358; Zheng GP, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/4370983	33	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 18	2021	12								684119	10.3389/fimmu.2021.684119	http://dx.doi.org/10.3389/fimmu.2021.684119			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UL9VJ	34484182	Green Published, gold			2022-12-18	WOS:000692989900001
J	Wang, WC; Lin, YS; Chang, YF; Yeh, CC; Su, CT; Wu, JS; Su, FH				Wang, Wen-Chang; Lin, Yu-Shiang; Chang, Yin-Fan; Yeh, Chih-Ching; Su, Chien-Tien; Wu, Jin-Shang; Su, Fu-Hsiung			Association of HLA-DPA1, HLA-DPB1, and HLA-DQB1 Alleles With the Long-Term and Booster Immune Responses of Young Adults Vaccinated Against the Hepatitis B Virus as Neonates	FRONTIERS IN IMMUNOLOGY			English	Article						hepatitis B vaccine; human leukocyte antigen; booster; HBV serology; immunogenic response	HBS-SERONEGATIVE ADOLESCENTS; SURFACE-ANTIGEN; HLA; IMMUNIZATION; RESPONSIVENESS; INFECTION; EFFICACY; TAIWAN; IMPACT	The neonatal hepatitis B vaccination (HBVac) was implemented 35 years ago in Taiwan, but many vaccinees exhibit inadequate long-term vaccine-induced seroprotective hepatitis B surface antibody (anti-HBs) levels. We investigated the association of the human leukocyte antigen (HLA) alleles (DPA1, DPB1, DQA1, and DQB1) with the long-term immunological response to the neonatal HBVac and adolescent booster HBVac in a Taiwanese cohort. We divided 281 Han students (median age 22, age range 17-29 years) into the following groups: (1) Group A (n = 61): anti-HBs titer >= 10 mIU/mL at the beginning of the study; (2) Group B (n = 75): anti-HBs level > 1000 mIU/mL after the first booster; (3) Group C (n = 37): anti-HBs level < 10 mIU/mL after the first booster; and (4) Group D (n = 5): anti-HBs level < 10 mIU/mL after three boosters. DQA1, DQB1, DPA1, and DPB1 typing of the participants was performed using sequence-specific oligonucleotides. Associations of HLA alleles and haplotypes with effects on neonatal HBVac and booster HBVac were examined through logistic regression analysis and Fisher's exact test. A false discovery rate-based measure of significance, the q-value, was used for multiple comparisons, and an association was considered significant if the corresponding q-value was < 0.1. DPA1 alleles were associated with the long-term immunological response to the neonatal HBVac. The estimated odds ratio (OR) of the lack of HBV protective immunity when carrying an additional DPA1*01 and DPA1*02 was 0.36 [95% confidence interval (CI) = 0.17-0.76, p = 0.0076] and 2.39 (95% CI = 1.17-4.87, p = 0.016), respectively. DPB1 and DQB1 alleles were associated with a response to the adolescent booster vaccination. The estimated ORs of being nonresponsive to the first booster when carrying an additional DPB1*05 and DQB1*02 were 2.11 (95% CI = 1.13-3.93, p = 0.019) and 3.73 (95% CI = 1.43-9.71, p = 0.0070), respectively. All DPB1*03 carriers responded to the first booster (p of Fisher's exact test = 0.0045). In our study, we discovered that HLA-DPA1 was primarily associated with the long-term response of primary infantile HBVac, and HLA-DPB1 and HLA-DQB1 exhibited associations with the HBV booster vaccination.	[Wang, Wen-Chang] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Translatiomt Med, Taipei, Taiwan; [Wang, Wen-Chang; Yeh, Chih-Ching] Taipei Med Univ, Wan Fang Hosp, Canc Ctr, Taipei, Taiwan; [Lin, Yu-Shiang; Yeh, Chih-Ching; Su, Chien-Tien] Taipei Med Univ, Coll Publ Hlth, Sch Publ Hlth, Taipei, Taiwan; [Lin, Yu-Shiang] Xi An Jiao Tong Univ, Affiliated Hosp 1, Sch Med, Dept Clin Lab, Xian, Peoples R China; [Chang, Yin-Fan; Wu, Jin-Shang] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Family Med, Tainan, Taiwan; [Yeh, Chih-Ching] China Med Univ, Coll Publ Hlth, Dept Publ Hlth, Taichung, Taiwan; [Yeh, Chih-Ching] Taipei Med Univ, Coll Publ Hlth, Master Program Appl Epidemiol, Taipei, Taiwan; [Su, Chien-Tien] Taipei Med Univ Hosp, Dept Fami61Med, Taipei, Taiwan; [Wu, Jin-Shang] Natl Cheng Kung Univ Hos Fal, Natl Cheng Kung Univ, Coll Med, Dept Faintly Med,Douliou Branch, Yunlin, Taiwan; [Wu, Jin-Shang] Natl Cheng Kung Univ, Coll Med, Dept Family Med, Tainan, Taiwan; [Su, Fu-Hsiung] Fu Jen Catholic Univ, Cardnal Tien Hosp, Dept Famiy Med, New Taipei, Taiwan; [Su, Fu-Hsiung] Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Xi'an Jiaotong University; National Cheng Kung University; National Cheng Kung University Hospital; China Medical University Taiwan; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; National Cheng Kung University; National Cheng Kung University; Fu Jen Catholic University; Fu Jen Catholic University	Su, FH (corresponding author), Fu Jen Catholic Univ, Cardnal Tien Hosp, Dept Famiy Med, New Taipei, Taiwan.; Su, FH (corresponding author), Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei, Taiwan.	williamsufh1@yahoo.com.tw						Amirzargar Ali Akbar, 2008, Iran J Immunol, V5, P92, DOI IJIv5i2A3; BEASLEY RP, 1984, SEMIN LIVER DIS, V4, P113, DOI 10.1055/s-2008-1040651; Chien YC, 2006, EPIDEMIOL REV, V28, P126, DOI 10.1093/epirev/mxj010; Desombere I, 1998, TISSUE ANTIGENS, V51, P593, DOI 10.1111/j.1399-0039.1998.tb03001.x; Ertem D, 2010, EUR J GASTROEN HEPAT, V22, P787, DOI 10.1097/MEG.0b013e32832e9d41; Gust ID, 1996, GUT, V38, pS67, DOI 10.1136/gut.38.Suppl_2.S67; Haulien Civil Affairs Department, STAT TABL POP IND PO; Hohler T, 2002, LANCET, V360, P991, DOI 10.1016/S0140-6736(02)11083-X; Hsu HM, 1999, J INFECT DIS, V179, P367, DOI 10.1086/314585; HSU HY, 1993, VACCINE, V11, P1437, DOI 10.1016/0264-410X(93)90173-U; Hu YC, 2018, PEERJ, V6, DOI 10.7717/peerj.4297; Huang YH, 2020, ALIMENT PHARM THER, V52, P682, DOI 10.1111/apt.15887; Immunization Action Coalition, HEP B HEALTHC IAC AN; LEE PI, 1995, J PEDIATR-US, V126, P716, DOI 10.1016/S0022-3476(95)70398-5; Li ZK, 2013, VACCINE, V31, P4355, DOI 10.1016/j.vaccine.2013.06.108; Lin CL, 2020, GASTROENTEROL CLIN N, V49, P201, DOI 10.1016/j.gtc.2020.01.010; Lin HH, 2008, VACCINE, V26, P3414, DOI 10.1016/j.vaccine.2008.04.038; Lu CY, 2008, J INFECT DIS, V197, P1419, DOI 10.1086/587695; Lu FT, 2020, PEDIATR GASTROENTERO, V23, P311, DOI 10.5223/pghn.2020.23.4.311; McDermott AB, 1997, TISSUE ANTIGENS, V50, P8, DOI 10.1111/j.1399-0039.1997.tb02827.x; Mineta M, 1996, INT IMMUNOL, V8, P525, DOI 10.1093/intimm/8.4.525; Namgyal P, 2003, J HEPATOL, V39, pS77, DOI 10.1016/S0168-8278(03)00269-1; Newport MJ, 2004, GENES IMMUN, V5, P122, DOI 10.1038/sj.gene.6364051; Nishida N, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82986-8; Schillie S, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6701a1; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Su FH, 2013, J HEPATOL, V58, P684, DOI 10.1016/j.jhep.2012.11.036; SUNG J-L, 1984, Gastroenterologia Japonica, V19, P363; VARLALEFTHERIOTI M, 1990, TISSUE ANTIGENS, V35, P60, DOI 10.1111/j.1399-0039.1990.tb01757.x; Wang CB, 2004, HEPATOLOGY, V39, P978, DOI 10.1002/hep.20142; Wang LY, 2007, J HEPATOL, V46, P1018, DOI 10.1016/j.jhep.2007.01.022; Wang LY, 2019, VACCINE, V37, P6435, DOI 10.1016/j.vaccine.2019.09.001; WHO, IMM COV; World Health Organization, 2017, GLOBAL HEPATITIS REP; World Health Organization, HEP B VACC; Wu TW, 2014, GENES IMMUN, V15, P47, DOI 10.1038/gene.2013.62; Wu TW, 2013, HUM GENET, V132, P1131, DOI 10.1007/s00439-013-1320-5; Wu TW, 2013, HEPATOLOGY, V57, P38, DOI 10.1002/hep.25988; Yang SG, 2016, SCI REP-UK, V6, DOI 10.1038/srep27251	40	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 18	2021	12									10.3389/fimmu.2021.710414	http://dx.doi.org/10.3389/fimmu.2021.710414			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UM8MV	34484213	Green Published, gold			2022-12-18	WOS:000693580900001
J	Izati, AF; Shukri, NDM; Ghazali, WSW; Hussin, CMC; Wong, KK				Izati, Aziz Farah; Shukri, Nur Diyana Mohd; Ghazali, Wan Syamimee Wan; Hussin, Che Maraina Che; Wong, Kah Keng			Increased IL-23R(+) Th Cells Population Exhibits Higher SLEDAI-2K Scores in Systemic Lupus Erythematosus Patients	FRONTIERS IN IMMUNOLOGY			English	Article						systemic lupus erythematosus; IL-23; IL-17 axis; IL-17; IL-17RA; IL-23R; SLEDAI-2K	DISEASE-ACTIVITY; INTERLEUKIN 17; HYDROXYCHLOROQUINE; IL-17; CLASSIFICATION; ASSOCIATION; CYTOKINES; LUMINA; DAMAGE; NEPHRITIS	The IL-23/IL-17 axis plays causative roles in the development and progression of systemic lupus erythematosus (SLE). However, it remains unclear if the IL-17RA(+) and IL-23R(+) T helper (Th) cells populations are associated with the serum IL-17 and IL-23 levels, or with the immunological parameters and disease activities in SLE patients. Herein, we examined the proportion of IL-17RA(+) and IL-23R(+) Th cells and serum levels of IL-17 and IL-23 in established SLE patients (n = 50) compared with healthy controls (n = 50). The associations of these interleukins and their receptors with immunological parameters [anti-nuclear antibody (ANA), anti-dsDNA antibody, and C-reactive protein (CRP)] and SLE disease activity (SLEDAI-2K scores) in SLE patients were assessed. CD3(+)CD4(+) Th cells of SLE patients demonstrated significantly elevated IL-17RA(+) (p = 1.12 x 10(-4)) or IL-23R(+) (p = 1.98 x 10(-29)) populations compared with the healthy controls. Serum IL-17 levels were significantly lower in SLE patients compared with the healthy controls (p = 8.32 x 10(-5)), while no significant difference was observed for the IL-23 serum levels between both groups. IL-23R(+) Th cells population was significantly associated with higher SLEDAI-2K scores (p = 0.017). In multivariate analysis, the proportion of IL-23R(+) Th cells remained significantly associated with higher SLEDAI-2K scores independent of prednisolone intake (p = 0.027). No associations were observed between the interleukin parameters (i.e., IL-17, IL-23, IL-17RA(+) Th cells, and IL-23R(+) Th cells) with ANA, anti-dsDNA, and CRP status, suggesting that the IL-17/IL-23 axis acts independently of these immunological parameters. In conclusion, our results support that therapeutic inhibition of the IL-23/IL-17 axis receptors on Th cells, particularly IL-23R, is potentially relevant in SLE patients.	[Izati, Aziz Farah; Shukri, Nur Diyana Mohd; Hussin, Che Maraina Che; Wong, Kah Keng] Univ Sains Malaysia, Dept Immunol, Sch Med Sci, Kubang Kerian, Malaysia; [Izati, Aziz Farah; Shukri, Nur Diyana Mohd; Ghazali, Wan Syamimee Wan; Hussin, Che Maraina Che; Wong, Kah Keng] Hosp Univ Sains Malaysia, Kubang Kerian, Malaysia; [Ghazali, Wan Syamimee Wan] Univ Sains Malaysia, Sch Med Sci, Dept Internal Med, Kubang Kerian, Malaysia	Universiti Sains Malaysia; Universiti Sains Malaysia; Universiti Sains Malaysia	Hussin, CMC; Wong, KK (corresponding author), Univ Sains Malaysia, Dept Immunol, Sch Med Sci, Kubang Kerian, Malaysia.; Hussin, CMC; Wong, KK (corresponding author), Hosp Univ Sains Malaysia, Kubang Kerian, Malaysia.	maraina@usm.my; kahkeng@usm.my	Wong, Kah Keng/AAC-2807-2022	Wong, Kah Keng/0000-0001-7359-6202				Abou Ghanima Ahmed T, 2012, Egypt J Immunol, V19, P25; Alarcon GS, 2007, ANN RHEUM DIS, V66, P1168, DOI 10.1136/ard.2006.068676; Astry B, 2015, CYTOKINE, V74, P54, DOI 10.1016/j.cyto.2014.11.020; Atamaniuk J, 2011, EUR J CLIN INVEST, V41, P579, DOI 10.1111/j.1365-2362.2010.02435.x; Bedoya SK, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/986789; Butler JM, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00093; Cervera R, 2014, AUTOIMMUN REV, V13, P621, DOI 10.1016/j.autrev.2013.11.007; Chan EKL, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00412; Chen K, 2017, GENE, V614, P8, DOI 10.1016/j.gene.2017.01.016; Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584-018-0109-2; Cheng F, 2009, ANN RHEUM DIS, V68, P604, DOI 10.1136/ard.2008.097089; Coquet JM, 2008, P NATL ACAD SCI USA, V105, P11287, DOI 10.1073/pnas.0801631105; Crosslin KL, 2009, ETHNIC DIS, V19, P301; da Silva JC, 2013, CLINICS, V68, P766, DOI 10.6061/clinics/2013(06)07; Dai H, 2017, J IMMUNOL, V199, P903, DOI 10.4049/jimmunol.1700418; DeQuattro K, 2022, ARTHRIT CARE RES, V74, P896, DOI 10.1002/acr.24544; Du J, 2014, J INT MED RES, V42, P1123, DOI 10.1177/0300060513509130; Fabrizio C, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/328078; Fernandez M, 2006, LUPUS, V15, P700, DOI 10.1177/0961203306072426; Fessler BJ, 2005, ARTHRITIS RHEUM, V52, P1473, DOI 10.1002/art.21039; Fischer K, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/9401432; Frodlund M, 2020, CLIN EXP IMMUNOL, V199, P245, DOI 10.1111/cei.13402; Galil SMA, 2015, CYTOKINE, V76, P280, DOI 10.1016/j.cyto.2015.05.007; Garg S, 2021, ARTHRIT CARE RES, V73, P707, DOI 10.1002/acr.24155; Gheita TA, 2018, LUPUS, V27, P1081, DOI 10.1177/0961203318760209; Gladman DD, 2002, J RHEUMATOL, V29, P288; Guerra ES, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006175; Ho AW, 2010, SEMIN IMMUNOPATHOL, V32, P33, DOI 10.1007/s00281-009-0185-0; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Huang Xinfang, 2007, Mod Rheumatol, V17, P220; Isganaitis E, 2019, AM J CLIN NUTR, V110, P111, DOI 10.1093/ajcn/nqy334; Izati AF, 2020, MALAYS J PATHOL, V42, P333; Jesus D, 2019, LUPUS, V28, P607, DOI 10.1177/0961203319836717; Kasper IR, 2016, TRENDS MOL MED, V22, P784, DOI 10.1016/j.molmed.2016.07.003; Kastelein RA, 2007, ANNU REV IMMUNOL, V25, P221, DOI 10.1146/annurev.immunol.22.012703.104758; Katsuyama T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01088; Kim Hae-Young, 2017, Restor Dent Endod, V42, P152, DOI 10.5395/rde.2017.42.2.152; Kim SK, 2018, YONSEI MED J, V59, P857, DOI 10.3349/ymj.2018.59.7.857; Kyttaris VC, 2010, J IMMUNOL, V184, P4605, DOI 10.4049/jimmunol.0903595; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Lee PW, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91663; Lopez P, 2016, SCI REP-UK, V6, DOI 10.1038/srep20651; Ma HS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157772; Martin JC, 2014, CLIN IMMUNOL, V154, P1, DOI 10.1016/j.clim.2014.05.004; McKenzie BS, 2006, TRENDS IMMUNOL, V27, P17, DOI 10.1016/j.it.2005.10.003; Mok MY, 2010, J RHEUMATOL, V37, P2046, DOI 10.3899/jrheum.100293; Nazri SKSM, 2018, SAUDI MED J, V39, P627, DOI 10.15537/smj.2018.6.22112; Nordin F, 2019, INT J RHEUM DIS, V22, P1419, DOI 10.1111/1756-185X.13615; Parodis I, 2019, EXPERT OPIN BIOL TH, V19, P157, DOI 10.1080/14712598.2019.1561856; Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473; Pisetsky DS, 2019, ARTHRITIS RHEUMATOL, V71, P1534, DOI 10.1002/art.40910; Pisetsky DS, 2018, ANN RHEUM DIS, V77, P911, DOI 10.1136/annrheumdis-2017-212599; Puwipirom H, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3194; Raymond W, 2017, EUR J RHEUMATOL, V4, P29, DOI 10.5152/eurjrheum.2017.16059; Rekvig OP, 2015, CLIN EXP IMMUNOL, V179, P5, DOI 10.1111/cei.12296; Riol-Blanco L, 2010, J IMMUNOL, V184, P1710, DOI 10.4049/jimmunol.0902796; Ronnblom L, 2006, ARTHRITIS RHEUM-US, V54, P408, DOI 10.1002/art.21571; Shahin D, 2017, LUPUS, V26, P917, DOI 10.1177/0961203316682095; Sharabi A, 2020, NAT REV RHEUMATOL, V16, P100, DOI 10.1038/s41584-019-0356-x; Shukri NDM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.675250; Suarez-Fueyo A, 2017, NAT REV NEPHROL, V13, DOI 10.1038/nrneph.2017.34; Syahidatulamali CS, 2017, J POSTGRAD MED, V63, P257, DOI 10.4103/jpgm.JPGM_499_16; Tang CL, 2012, IMMUNOLOGY, V135, P112, DOI 10.1111/j.1365-2567.2011.03522.x; Tsakonas E, 1998, LUPUS, V7, P80; Villalta D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071458; Vincent FB, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4277; Wallace DJ, 2009, ARTHRIT RHEUM-ARTHR, V61, P1168, DOI 10.1002/art.24699; Willems P, 2019, ANN RHEUM DIS, V78, DOI 10.1136/annrheumdis-2018-213821; Willis R, 2012, LUPUS, V21, P830, DOI 10.1177/0961203312437270; Wong CK, 2008, CLIN IMMUNOL, V127, P385, DOI 10.1016/j.clim.2008.01.019; Yang J, 2018, J RHEUMATOL, V45, P818, DOI 10.3899/jrheum.170737; Zhao XF, 2010, MOL BIOL REP, V37, P81, DOI 10.1007/s11033-009-9533-3	72	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 17	2021	12									10.3389/fimmu.2021.690908	http://dx.doi.org/10.3389/fimmu.2021.690908			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UM8XG	34484186	gold, Green Published			2022-12-18	WOS:000693608000001
J	Pfefferle, PI; Postigo, I; Garn, H				Pfefferle, Petra Ina; Postigo, Idoia; Garn, Holger			Editorial: The Immunological Implications of the Hygiene Hypothesis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						hygiene hypothesis; inflammation; microbiome; bacteria; parasites; environment			[Pfefferle, Petra Ina] Philipps Univ Marburg, Comprehens Biobank Marburg CBBMR, Med Fac, Marburg, Germany; [Pfefferle, Petra Ina] German Biobank Alliance GBA, Marburg, Germany; [Pfefferle, Petra Ina] Philipps Univ Marburg, German Ctr Lung Res DZL, Marburg, Germany; [Postigo, Idoia] Univ Basque Country UPV EHU, Fac Pharm, Vitoria, Spain; [Postigo, Idoia] Univ Basque Country UPV EHU, Lascaray Res Ctr, Parasitol & Allergy Res Grp, Vitoria, Spain; [Garn, Holger] Philipps Univ Marburg, Med Fac, Biochem Pharmacol Ctr BPC, Translat Inflammat Res Div, Marburg, Germany; [Garn, Holger] Philipps Univ Marburg, Core Facil Single Cell Multiom, German Ctr Lung Res, Marburg, Germany	Philipps University Marburg; Philipps University Marburg; University of Basque Country; University of Basque Country; Philipps University Marburg; Philipps University Marburg	Garn, H (corresponding author), Philipps Univ Marburg, Med Fac, Biochem Pharmacol Ctr BPC, Translat Inflammat Res Div, Marburg, Germany.; Garn, H (corresponding author), Philipps Univ Marburg, Core Facil Single Cell Multiom, German Ctr Lung Res, Marburg, Germany.	garn@staff.uni-marburg.de	Postigo, Idoia/AFU-6322-2022	Postigo, Idoia/0000-0002-6307-3990; Garn, Holger/0000-0002-5178-4023				Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Wibowo MC, 2021, NATURE, V594, P234, DOI 10.1038/s41586-021-03532-0	3	1	1	3	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 17	2021	12								732127	10.3389/fimmu.2021.732127	http://dx.doi.org/10.3389/fimmu.2021.732127			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UL8OD	34484244	Green Published, gold			2022-12-18	WOS:000692903500001
J	Yang, LJ; Gong, TQ; Shen, HL; Pei, JN; Zhang, L; Zhang, QQ; Huang, YY; Hu, ZJ; Pan, ZY; Yang, PY; Lin, L; Yu, HX				Yang, Lujie; Gong, Tianqi; Shen, Huali; Pei, Jiangnan; Zhang, Lei; Zhang, Quanqing; Huang, Yuanyu; Hu, Zuojian; Pan, Ziyue; Yang, Pengyuan; Lin, Ling; Yu, Hongxiu			Precision N-Glycoproteomic Profiling of Murine Peritoneal Macrophages After Different Stimulations	FRONTIERS IN IMMUNOLOGY			English	Article						macrophage; N-glycosylation; Toll-like receptors; glycoproteomics; inflammatory response	GLYCOSYLATION; TRAFFICKING; RESIDENT; RECEPTOR	Macrophages are important immune cells that participate in both innate and adaptive immune responses, such as phagocytosis, recognition of molecular patterns, and activation of the immune response. In this study, murine peritoneal macrophages were isolated and then activated by LPS, HSV and VSV. Integrative proteomic and precision N-glycoproteomic profiling were conducted to assess the underlying macrophage activation. We identified a total of 587 glycoproteins, including 1239 glycopeptides, 526 monosaccharide components, and 8326 intact glycopeptides in glycoproteomics, as well as a total of 4496 proteins identified in proteomic analysis. These glycoproteins are widely involved in important biological processes, such as antigen presentation, cytokine production and glycosylation progression. Under the stimulation of the different pathogens, glycoproteins showed a dramatic change. We found that receptors in the Toll-like receptor pathway, such as Tlr2 and CD14, were increased under LPS and HSV stimulation. Glycosylation of those proteins was proven to influence their subcellular locations.	[Yang, Lujie; Gong, Tianqi; Shen, Huali; Zhang, Lei; Huang, Yuanyu; Pan, Ziyue; Yang, Pengyuan; Yu, Hongxiu] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China; [Yang, Lujie; Gong, Tianqi; Shen, Huali; Zhang, Lei; Huang, Yuanyu; Pan, Ziyue; Yang, Pengyuan; Yu, Hongxiu] Fudan Univ, Shanghai Stomatol Hosp, Shanghai, Peoples R China; [Pei, Jiangnan] Fudan Univ, Obestet & Gynecol Hosp, Shanghai, Peoples R China; [Zhang, Quanqing] Univ Calif Riverside, Dept Chem, Riverside, CA 92521 USA; [Zhang, Quanqing] Univ Calif Riverside, Environm Toxicol Grad Program, Riverside, CA 92521 USA; [Hu, Zuojian] Guangxi Med Univ, Dept Clin Lab, Affiliated Hosp 1, Nanning, Peoples R China; [Lin, Ling] Xiamen Univ, Xiamen Cardiovasc Hosp, Xiamen, Peoples R China	Fudan University; Fudan University; Fudan University; University of California System; University of California Riverside; University of California System; University of California Riverside; Guangxi Medical University; Xiamen University	Yu, HX (corresponding author), Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China.; Yu, HX (corresponding author), Fudan Univ, Shanghai Stomatol Hosp, Shanghai, Peoples R China.; Lin, L (corresponding author), Xiamen Univ, Xiamen Cardiovasc Hosp, Xiamen, Peoples R China.	linemail00@gmail.com; hongxiuyu@fudan.edu.cn						Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; Bard F, 2016, TRENDS CELL BIOL, V26, P379, DOI 10.1016/j.tcb.2015.12.004; Brun P, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02148; Chistiakov DA, 2017, LAB INVEST, V97, P4, DOI 10.1038/labinvest.2016.116; Cunto-Amesty G, 2001, J BIOL CHEM, V276, P30490, DOI 10.1074/jbc.M103257200; Delannoy C, 2020, MOL OMICS, V16, P345, DOI 10.1039/c9mo00173e; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Fang P, 2020, ANAL CHEM, V92, P867, DOI 10.1021/acs.analchem.9b03555; Gangloff SC, 2005, J IMMUNOL, V175, P3940, DOI 10.4049/jimmunol.175.6.3940; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Gould JR, 2020, J VIROL, V94, DOI 10.1128/JVI.01729-19; Hare NJ, 2017, J PROTEOME RES, V16, P247, DOI 10.1021/acs.jproteome.6b00685; Hinneburg H, 2020, GLYCOBIOLOGY, V30, P679, DOI 10.1093/glycob/cwaa020; Hirabayashi J, 2013, CHEM SOC REV, V42, P4443, DOI 10.1039/c3cs35419a; Houben T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03796-5; Lavin Y, 2014, CELL, V159, P1312, DOI 10.1016/j.cell.2014.11.018; Liu MQ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00535-2; Lu HJ, 2016, NATL SCI REV, V3, P345, DOI 10.1093/nsr/nww019; Lu SM, 2020, VIEW-CHINA, V1, DOI 10.1002/VIW.20200006; Meyer RC, 2014, BRAIN RES, V1585, P1, DOI 10.1016/j.brainres.2014.08.022; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019; Oldenburg M, 2012, SCIENCE, V337, P1111, DOI 10.1126/science.1220363; Park DD, 2021, CELL CHEM BIOL, V28, P567, DOI 10.1016/j.chembiol.2020.12.005; Reynders E, 2011, GLYCOBIOLOGY, V21, P853, DOI 10.1093/glycob/cwq179; Riley NM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09222-w; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rosenberger CM, 2003, NAT REV MOL CELL BIO, V4, P385, DOI 10.1038/nrm1104; Samarah LZ, 2020, VIEW-CHINA, V1, DOI 10.1002/VIW.20200063; Schwake M, 2013, TRAFFIC, V14, P739, DOI 10.1111/tra.12056; Shental-Bechor D, 2008, P NATL ACAD SCI USA, V105, P8256, DOI 10.1073/pnas.0801340105; Suttapitugsakul S, 2020, ANAL CHEM, V92, P267, DOI 10.1021/acs.analchem.9b04651; Trombetta ES, 2003, GLYCOBIOLOGY, V13, p77R, DOI 10.1093/glycob/cwg075; Uyangaa E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00905; Van Gool B, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00271; Xiao HP, 2017, CHEM SCI, V8, P268, DOI 10.1039/c6sc01814a; Xu CC, 2015, NAT REV MOL CELL BIO, V16, P742, DOI 10.1038/nrm4073; Xu W, 2020, ADV SCI, V7, DOI 10.1002/advs.202002021; Xu W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15487-3; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang Xia, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1401s83	41	1	1	3	30	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 17	2021	12									10.3389/fimmu.2021.722293	http://dx.doi.org/10.3389/fimmu.2021.722293			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UM8WV	34484231	gold, Green Published			2022-12-18	WOS:000693606900001
J	Darden, DB; Dong, XR; Brusko, MA; Kelly, L; Fenner, B; Rincon, JC; Dirain, ML; Ungaro, R; Nacionales, DC; Gauthier, M; Kladde, M; Brusko, TM; Bihorac, A; Moore, FA; Loftus, T; Bacher, R; Moldawer, LL; Mohr, AM; Efron, PA				Darden, Dijoia B.; Dong, Xiaoru; Brusko, Maigan A.; Kelly, Lauren; Fenner, Brittany; Rincon, Jaimar C.; Dirain, Marvin L.; Ungaro, Ricardo; Nacionales, Dina C.; Gauthier, Marie; Kladde, Michael; Brusko, Todd M.; Bihorac, Azra; Moore, Frederick A.; Loftus, Tyler; Bacher, Rhonda; Moldawer, Lyle L.; Mohr, Alicia M.; Efron, Philip A.			A Novel Single Cell RNA-seq Analysis of Non-Myeloid Circulating Cells in Late Sepsis	FRONTIERS IN IMMUNOLOGY			English	Article						lymphocytes; immune cells; sepsis; transcriptome; scRNA-seq; chronic critical illness	COLONY-STIMULATING FACTOR; CHRONIC CRITICAL ILLNESS; IMMUNE-RESPONSE; PERSISTENT INFLAMMATION; GENE-EXPRESSION; T-CELLS; HLA-DR; IMMUNOSUPPRESSION; MORTALITY; BLOOD	Background With the successful implementation of the Surviving Sepsis Campaign guidelines, post-sepsis in-hospital mortality to sepsis continues to decrease. Those who acutely survive surgical sepsis will either rapidly recover or develop a chronic critical illness (CCI). CCI is associated with adverse long-term outcomes and 1-year mortality. Although the pathobiology of CCI remains undefined, emerging evidence suggests a post-sepsis state of pathologic myeloid activation, inducing suboptimal lymphopoiesis and erythropoiesis, as well as downstream leukocyte dysfunction. Our goal was to use single-cell RNA sequencing (scRNA-seq) to perform a detailed transcriptomic analysis of lymphoid-derived leukocytes to better understand the pathology of late sepsis. Methods A mixture of whole blood myeloid-enriched and Ficoll-enriched peripheral blood mononuclear cells from four late septic patients (post-sepsis day 14-21) and five healthy subjects underwent Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq). Results We identified unique transcriptomic patterns for multiple circulating immune cell subtypes, including B- and CD4(+), CD8(+), activated CD4(+) and activated CD8(+) T-lymphocytes, as well as natural killer (NK), NKT, and plasmacytoid dendritic cells in late sepsis patients. Analysis demonstrated that the circulating lymphoid cells maintained a transcriptome reflecting immunosuppression and low-grade inflammation. We also identified transcriptomic differences between patients with bacterial versus fungal sepsis, such as greater expression of cytotoxic genes among CD8(+) T-lymphocytes in late bacterial sepsis. Conclusion Circulating non-myeloid cells display a unique transcriptomic pattern late after sepsis. Non-myeloid leukocytes in particular reveal a host endotype of inflammation, immunosuppression, and dysfunction, suggesting a role for precision medicine-guided immunomodulatory therapy.	[Darden, Dijoia B.; Kelly, Lauren; Fenner, Brittany; Rincon, Jaimar C.; Dirain, Marvin L.; Ungaro, Ricardo; Nacionales, Dina C.; Moore, Frederick A.; Loftus, Tyler; Moldawer, Lyle L.; Mohr, Alicia M.; Efron, Philip A.] Univ Florida, Coll Med, Dept Surg, Gainesville, FL 32611 USA; [Dong, Xiaoru] Univ Florida, Coll Med, Dept Biomed Engn, Gainesville, FL USA; [Brusko, Maigan A.; Brusko, Todd M.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA; [Gauthier, Marie; Kladde, Michael] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL USA; [Bihorac, Azra] Univ Florida, Coll Med, Dept Med, Gainesville, FL USA; [Bacher, Rhonda] Univ Florida, Dept Biostat, Gainesville, FL USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Efron, PA (corresponding author), Univ Florida, Coll Med, Dept Surg, Gainesville, FL 32611 USA.	philip.efron@surgery.ufl.edu		Dong, Xiaoru/0000-0003-3039-3004; Moldawer, Lyle/0000-0002-9041-9838; Brusko, Todd/0000-0003-2878-9296	National Institutes of Health [NIGMS: R01 GM-104481, R01 GM-113945, P50 GM-111152, RM1 GM-139690-01, T32 GM-008721]; NIA [1P30AG028740]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported in part by the following National Institutes of Health grants: NIGMS: R01 GM-104481, R01 GM-113945, P50 GM-111152, RM1 GM-139690-01. T32 GM-008721; and NIA: 1P30AG028740.	Angajala A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01605; Bailey CC, 2014, ANNU REV VIROL, V1, P261, DOI 10.1146/annurev-virology-031413-085537; Brakenridge SC, 2019, ANN SURG, V270, P502, DOI 10.1097/SLA.0000000000003458; Brakenridge SC, 2019, J AM COLL SURGEONS, V229, P58, DOI 10.1016/j.jamcollsurg.2019.04.014; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Chen K, 2017, CELL, V170, P492, DOI 10.1016/j.cell.2017.06.042; Cox MC, 2020, AM J SURG, V220, P1467, DOI 10.1016/j.amjsurg.2020.07.016; Darden DB, 2021, SHOCK, V55, P587, DOI 10.1097/SHK.0000000000001671; Efron PA, 2018, SURGERY, V164, P178, DOI 10.1016/j.surg.2018.04.011; Fenner BP, 2021, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.616694; Ferenczi K, 2000, J AUTOIMMUN, V14, P63, DOI 10.1006/jaut.1999.0343; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; GANSBACHER B, 1988, CELL IMMUNOL, V117, P22, DOI 10.1016/0008-8749(88)90073-1; Gardner AK, 2019, CRIT CARE MED, V47, P566, DOI 10.1097/CCM.0000000000003655; Gentile LF, 2014, J IMMUNOL, V192, P3156, DOI 10.4049/jimmunol.1301726; Gentile LF, 2012, J TRAUMA ACUTE CARE, V72, P1491, DOI 10.1097/TA.0b013e318256e000; Giang S, 2017, CELL MOL IMMUNOL, V14, P652, DOI 10.1038/cmi.2017.38; Gupta DL, 2016, CYTOKINE, V88, P214, DOI 10.1016/j.cyto.2016.09.010; Hawkins RB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01511; Hendriks J, 2000, NAT IMMUNOL, V1, P433, DOI 10.1038/80877; Horiguchi H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00595; Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552; Hou Q, 2008, MOL IMMUNOL, V45, P1044, DOI 10.1016/j.molimm.2007.07.032; Ishikawa E, 2005, J VIROL, V79, P7658, DOI 10.1128/JVI.79.12.7658-7663.2005; Jensen IJ, 2018, J IMMUNOL, V200, P1543, DOI 10.4049/jimmunol.1701618; Kasamatsu J, 2014, J IMMUNOL, V193, P5199, DOI 10.4049/jimmunol.1400924; Khan HN, 2019, J LEUKOCYTE BIOL, V106, P1153, DOI 10.1002/JLB.4A0219-050R; Kim SH, 2005, IMMUNITY, V22, P131, DOI 10.1016/j.immuni.2004.12.003; Kroger A, 2017, CELL MOL IMMUNOL, V14, P649, DOI 10.1038/cmi.2017.37; Langerholc T, 2005, FEBS J, V272, P1535, DOI 10.1111/j.1742-4658.2005.04594.x; Loftus TJ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015136; Loss Sergio Henrique, 2017, Rev. bras. ter. intensiva, V29, P87, DOI [10.5935/0103-507X.20170013, 10.5935/0103-507x.20170013]; Lun ATL, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1662-y; Malik Uzma, 2016, Int Rev Immunol, P1; Man SM, 2016, EUR J IMMUNOL, V46, P269, DOI 10.1002/eji.201545839; Mankowski RT, 2020, J AM GERIATR SOC, V68, P1962, DOI 10.1111/jgs.16435; McCarthy DJ, 2017, BIOINFORMATICS, V33, P1179, DOI 10.1093/bioinformatics/btw777; McKinley BA, 2011, J TRAUMA, V70, P1153, DOI 10.1097/TA.0b013e31821598e9; Mira JC, 2017, CRIT CARE MED, V45, P253, DOI [10.1097/CCM.0000000000002074, 10.1097/ccm.0000000000002074]; Mira JC, 2016, PHYSIOL GENOMICS, V48, P135, DOI 10.1152/physiolgenomics.00072.2015; Moisan J, 2007, J EXP MED, V204, P2825, DOI 10.1084/jem.20070994; Munier CML, 2016, VACCINE, V34, P5251, DOI 10.1016/j.vaccine.2016.09.009; Netea MG, 2005, P NATL ACAD SCI USA, V102, P16309, DOI 10.1073/pnas.0508237102; Ng SS, 2020, NAT IMMUNOL, V21, P1205, DOI 10.1038/s41590-020-0758-6; Nicolet BP, 2020, P NATL ACAD SCI USA, V117, P6686, DOI 10.1073/pnas.1913940117; Ouyang WJ, 2008, IMMUNITY, V28, P454, DOI 10.1016/j.immuni.2008.03.004; Patel S, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0817-3; Pegram HJ, 2011, IMMUNOL CELL BIOL, V89, P216, DOI 10.1038/icb.2010.78; Prescott HC, 2018, JAMA-J AM MED ASSOC, V319, P62, DOI 10.1001/jama.2017.17687; Ramos-Sevillano E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00358; Raymond SL, 2018, J MOL MED, V96, P673, DOI 10.1007/s00109-018-1646-5; Reddy M, 2004, J IMMUNOL METHODS, V293, P127, DOI 10.1016/j.jim.2004.07.006; Rendon JL, 2012, J LEUKOCYTE BIOL, V92, P529, DOI 10.1189/jlb.0212083; Reyes M, 2020, NAT MED, V26, P333, DOI 10.1038/s41591-020-0752-4; Rhee C, 2017, JAMA-J AM MED ASSOC, V318, P1241, DOI 10.1001/jama.2017.13836; Roh JS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e27; Saeidi A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02569; Saha D, 2014, INT J INFLAMM, V2014, DOI 10.1155/2014/803237; Schaefer U, 2007, FRONT BIOSCI, V12, P3813, DOI 10.2741/2354; Schwarzenberger P, 2000, J IMMUNOL, V164, P4783, DOI 10.4049/jimmunol.164.9.4783; Sehrawat Sharvan, 2017, Front Immunol, V8, P341, DOI 10.3389/fimmu.2017.00341; Shi GL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00522; Shukeri WFM, 2018, J CRIT CARE, V43, P163, DOI 10.1016/j.jcrc.2017.09.009; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Soni C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01601; Stevenson EK, 2014, CRIT CARE MED, V42, P625, DOI 10.1097/CCM.0000000000000026; Stortz JA, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02917-3; Stortz JA, 2018, J TRAUMA ACUTE CARE, V84, P342, DOI 10.1097/TA.0000000000001758; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Sweeney TE, 2018, CRIT CARE MED, V46, P915, DOI 10.1097/CCM.0000000000003084; Szabo PA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12464-3; Talwar S, 2006, PHYSIOL GENOMICS, V25, P203, DOI 10.1152/physiolgenomics.00192.2005; Ulas T, 2017, NAT IMMUNOL, V18, P622, DOI 10.1038/ni.3745; Wang SW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01298; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Wu HP, 2013, INFLAMM RES, V62, P751, DOI 10.1007/s00011-013-0630-3; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhu JF, 2010, IMMUNOL REV, V238, P247, DOI 10.1111/j.1600-065X.2010.00951.x	79	1	1	4	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 16	2021	12								696536	10.3389/fimmu.2021.696536	http://dx.doi.org/10.3389/fimmu.2021.696536			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UM1HZ	34484194	Green Published, gold			2022-12-18	WOS:000693090800001
J	Johnston, SC; Wilhelmsen, CL; Shamblin, J; Kimmel, A; Zelko, J; Wollen, S; Goff, AJ				Johnston, Sara C.; Wilhelmsen, Catherine L.; Shamblin, Joshua; Kimmel, Adrienne; Zelko, Justine; Wollen, Suzanne; Goff, Arthur J.			Delayed Disease in Cynomolgus Macaques Exposed to Ebola Virus by an Intranasal Route	FRONTIERS IN IMMUNOLOGY			English	Article						Ebola; EBOV; macaque; NHP; mucosal; intranasal; animal model	NONHUMAN-PRIMATES; INFECTIONS	Ebola virus remains a significant public health concern due to high morbidity and mortality rates during recurrent outbreaks in endemic areas. Therefore, the development of countermeasures against Ebola virus remains a high priority, and requires the availability of appropriate animal models for efficacy evaluations. The most commonly used nonhuman primate models for efficacy evaluations against Ebola virus utilize the intramuscular or aerosol route of exposure. Although clinical disease signs are similar to human cases, disease progression in these models is much more rapid, and this can pose significant hurdles for countermeasure evaluations. The objective of the present study was to evaluate the Ebola virus disease course that arises after cynomolgus macaques are exposed to Ebola virus by a mucosal route (the intranasal route). Two different doses (10 pfu and 100 pfu) and delivery methodologies (drop-wise and mucosal atomization device) were evaluated on this study. Differences in clinical disease between dose and delivery groups were not noted. However, a delayed disease course was identified for approximately half of the animals on study, and this delayed disease was dose and administration method independent. Therefore, it appears that mucosal exposure with Ebola virus results in a disease course in cynomolgus macaques that more accurately replicates that which is documented for human cases. In summary, the data presented support the need for further development of this model as a possible alternative to parenteral and small-particle aerosol models for the study of human Ebola virus disease and for countermeasure evaluations.	[Johnston, Sara C.; Kimmel, Adrienne; Zelko, Justine; Wollen, Suzanne] US Army Med Res Inst Infect Dis, Virol Div, Ft Detrick, MD 21702 USA; [Wilhelmsen, Catherine L.] US Army Med Res Inst Infect Dis, Pathol Div, Ft Detrick, MD USA; [Shamblin, Joshua] US Army Med Res Inst Infect Dis, Vet Med Div, Ft Detrick, MD USA; [Goff, Arthur J.] US Army Med Res Inst Infect Dis, Res Program Off, Ft Detrick, MD 21702 USA; [Kimmel, Adrienne] NCI, NIH, Bethesda, MD USA; [Wollen, Suzanne] US Mil HIV Res Program Us, Bethesda, MD USA; [Zelko, Justine] BIOQUAL Inc, Qual Assurance, Rockville, MD USA	United States Army Medical Research Institute of Infectious Diseases; United States Department of Defense; United States Army; United States Army Medical Research Institute of Infectious Diseases; United States Department of Defense; United States Army; United States Army Medical Research Institute of Infectious Diseases; United States Department of Defense; United States Army; United States Army Medical Research Institute of Infectious Diseases; United States Department of Defense; United States Army; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); BIOQUAL Inc.	Johnston, SC (corresponding author), US Army Med Res Inst Infect Dis, Virol Div, Ft Detrick, MD 21702 USA.; Goff, AJ (corresponding author), US Army Med Res Inst Infect Dis, Res Program Off, Ft Detrick, MD 21702 USA.	sara.c.johnston2.civ@mail.mil; arthur.j.goff.civ@mail.mil		Wollen-Roberts, Suzanne/0000-0002-9409-2756	National Institutes of Allergy and Infectious Diseases [188104641]	National Institutes of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Funding for this effort was provided by the National Institutes of Allergy and Infectious Diseases under project number 188104641.	Alfson KJ, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9110319; Bennett RS, 2017, CURR TOP MICROBIOL, V411, P171, DOI 10.1007/82_2017_20; Bin Liu W, 2015, MILITARY MED RES, V2, DOI 10.1186/s40779-015-0035-4; Chowell G, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0196-0; Feldmann H, 2011, LANCET, V377, P849, DOI 10.1016/S0140-6736(10)60667-8; Geisbert TW, 2003, AM J PATHOL, V163, P2347, DOI 10.1016/S0002-9440(10)63591-2; Geisbert TW, 2002, EMERG INFECT DIS, V8, P503; Nakayama E, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00267; Osterholm MT, 2015, MBIO, V6, DOI 10.1128/mBio.00137-15; Pratt WD, 2010, CLIN VACCINE IMMUNOL, V17, P572, DOI 10.1128/CVI.00467-09; Schou S, 2000, COMPARATIVE MED, V50, P108; Singh S., 2014, VIRAL HEMORRHAGIC FE, P444; Speranza E, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaq1016; Zaki SR, 1999, CURR TOP MICROBIOL, V235, P97	14	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 16	2021	12								709772	10.3389/fimmu.2021.709772	http://dx.doi.org/10.3389/fimmu.2021.709772			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UL2YJ	34484210	gold, Green Published			2022-12-18	WOS:000692522300001
J	Oladiran, O; Shi, XQ; Fournier, S; Zhang, J				Oladiran, Oladayo; Shi, Xiang Qun; Fournier, Sylvie; Zhang, Ji			CX3CR1 But Not CCR2 Expression Is Required for the Development of Autoimmune Peripheral Neuropathy in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						macrophages; CD8(+) T cells; autoimmune peripheral neuropathy; CX3CR1; CCR2; apoptosis; phagocytosis	GUILLAIN-BARRE-SYNDROME; RESIDENT ENDONEURIAL MACROPHAGES; CHEMOKINE RECEPTOR CCR2; CD8(+) T-CELLS; RECRUITMENT; MONOCYTE; INJURY; MODEL; PATHOGENESIS; NEURITIS	One hallmark of Guillain-Barre syndrome (GBS), a prototypic autoimmune peripheral neuropathy (APN) is infiltration of leukocytes (macrophages and T cells) into peripheral nerves, where chemokines and their receptors play major roles. In this study, we aimed to understand the potential contribution of chemokine receptors CCR2 and CX3CR1 in APN by using a well-established mouse model, B7.2 transgenic (L31) mice, which possesses a predisposed inflammatory background. We crossbred respectively CCR2KO and CX3CR1KO mice with L31 mice. The disease was initiated by partial ligation on one of the sciatic nerves. APN pathology and neurological function were evaluated on the other non-ligated sciatic nerve/limb. Our results revealed that L31/CX3CR1KO but not L31/CCR2KO mice were resistant to APN. CX3CR1 is needed for maintaining circulating monocyte and CD8(+) T cell survival. While migration of a significant number of activated CD8(+) T cells to peripheral nerves is essential in autoimmune response in nerve, recruitment of monocytes into PNS seems optional. Disease onset is independent of CCR2 mediated blood-derived macrophage recruitment, which can be replaced by compensatory proliferation of resident macrophages in peripheral nerve. CX3CR1 could also contribute to APN via its critical involvement in maintaining nerve macrophage phagocytic ability. We conclude that blockade of CX3CR1 signaling may represent an interesting anti-inflammatory strategy to improve therapeutic management for GBS patients.	[Oladiran, Oladayo; Shi, Xiang Qun; Zhang, Ji] McGill Univ, Alan Edwards Ctr Res Pain, Montreal, PQ, Canada; [Fournier, Sylvie; Zhang, Ji] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; [Zhang, Ji] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [Zhang, Ji] McGill Univ, Fac Dent, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University	Zhang, J (corresponding author), McGill Univ, Alan Edwards Ctr Res Pain, Montreal, PQ, Canada.; Fournier, S; Zhang, J (corresponding author), McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada.; Zhang, J (corresponding author), McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada.; Zhang, J (corresponding author), McGill Univ, Fac Dent, Montreal, PQ, Canada.	Sylvie.Fournier@mcgill.ca; Ji.Zhang@mcgill.ca			Canadian Institutes for Health Research (CIHR) [PJT-155929]; Louise and Alan Edwards Foundation	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Louise and Alan Edwards Foundation	Funding This work was supported by funding from the Canadian Institutes for Health Research (CIHR) PJT-155929, the Louise and Alan Edwards Foundation to JZ.	Archelos JJ, 1999, TRENDS NEUROSCI, V22, P30, DOI 10.1016/S0166-2236(98)01287-9; Blomster LV, 2011, MOL CELL NEUROSCI, V48, P236, DOI 10.1016/j.mcn.2011.08.004; Bottcher JP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9306; Bourque PR, 2015, CLIN CHIM ACTA, V449, P37, DOI 10.1016/j.cca.2015.02.039; Brisebois M, 2006, J IMMUNOL, V177, P2403, DOI 10.4049/jimmunol.177.4.2403; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chiang S, 2013, MUSCLE NERVE, V48, P320, DOI 10.1002/mus.23829; Dalakas MC., 2019, CLIN IMMUNOL, V1, DOI [10.1016/B978-0-7020-6896-6.00067-3, DOI 10.1016/B978-0-7020-6896-6.00067-3, 10.1016/8978-0-7020-6896-6.00067-3]; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Fujimura N, 2015, SCI REP-UK, V5, DOI 10.1038/srep11664; Gerlach C, 2016, IMMUNITY, V45, P1270, DOI 10.1016/j.immuni.2016.10.018; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Jones BA, 2010, MOL INTERV, V10, P263, DOI 10.1124/mi.10.5.3; Kieseier BC, 2000, J NEUROIMMUNOL, V110, P121, DOI 10.1016/S0165-5728(00)00323-4; Kieseier BC, 2002, BRAIN, V125, P823, DOI 10.1093/brain/awf070; Klein D, 2016, BRAIN RES, V1641, P130, DOI 10.1016/j.brainres.2015.11.033; Lampron A, 2015, J EXP MED, V212, P481, DOI 10.1084/jem.20141656; Landsman L, 2009, BLOOD, V113, P963, DOI 10.1182/blood-2008-07-170787; Li X, 2018, INT J LAB HEMATOL, V40, P488, DOI 10.1111/ijlh.12845; Maurer M, 2003, MOL CELL NEUROSCI, V23, P351, DOI 10.1016/S1044-7431(03)00055-1; Mueller M, 2003, LAB INVEST, V83, P175, DOI 10.1097/01.LAB.0000056993.28149.BF; Mueller M, 2001, AM J PATHOL, V159, P2187, DOI 10.1016/S0002-9440(10)63070-2; Muller M, 2006, J NEUROPATH EXP NEUR, V65, P499; Nansen A, 2000, EUR J IMMUNOL, V30, P1797, DOI 10.1002/1521-4141(200007)30:7<1797::AID-IMMU1797>3.0.CO;2-B; Oladiran O, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02126-x; Oladiran O, 2019, J NEUROIMMUNOL, V335, DOI 10.1016/j.jneuroim.2019.577017; Orlikowski D, 2003, J NEUROIMMUNOL, V134, P118, DOI 10.1016/S0165-5728(02)00393-4; Sainaghi PP, 2010, CYTOKINE, V51, P138, DOI 10.1016/j.cyto.2010.05.005; Siebert H, 2000, J NEUROIMMUNOL, V110, P177, DOI 10.1016/S0165-5728(00)00343-X; Sommer C, 2005, NEUROLOGY, V65, P1924, DOI 10.1212/01.wnl.0000188879.19900.b7; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Sun T, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00717; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; Ubogu Eroboghene E., 2011, Endocrine Metabolic & Immune Disorders-Drug Targets, V11, P141; van den Berg B, 2014, NAT REV NEUROL, V10, P469, DOI 10.1038/nrneurol.2014.121; van den Berg B, 2013, NEUROLOGY, V80, P1650, DOI 10.1212/WNL.0b013e3182904fcc; Wang PL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16355-w; Xia RH, 2010, NEUROPATH APPL NEURO, V36, P388, DOI 10.1111/j.1365-2990.2010.01092.x; Yan YY, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97828; Yang M, 2018, BRAIN BEHAV IMMUN, V71, P142, DOI 10.1016/j.bbi.2018.04.001; Yang M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00532; Yang M, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-5; Ydens E, 2020, NAT NEUROSCI, V23, P676, DOI 10.1038/s41593-020-0618-6; Zehntner SP, 2003, FASEB J, V17, P1910, DOI 10.1096/fj.03-0199fje; Zhao WM, 2016, FASEB J, V30, P380, DOI 10.1096/fj.14-270090; Zhu J, 1998, J NEUROIMMUNOL, V84, P40, DOI 10.1016/S0165-5728(97)00238-5	46	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 16	2021	12									10.3389/fimmu.2021.720733	http://dx.doi.org/10.3389/fimmu.2021.720733			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UM7CL	34484228	gold, Green Published			2022-12-18	WOS:000693486300001
J	Yaegashi, LB; Baldavira, CM; Prieto, TG; Machado-Rugolo, J; Velosa, APP; da Silveira, LKR; Assato, A; Ab'Saber, AM; Falzoni, R; Takagaki, T; Silva, PL; Teodoro, WR; Capelozzi, VL				Yaegashi, Lygia Bertalha; Baldavira, Camila Machado; Prieto, Tabatha Gutierrez; Machado-Rugolo, Juliana; Pereira Velosa, Ana Paula; Ramos da Silveira, Lizandre Keren; Assato, Aline; Ab'Saber, Alexandre Muxfeldt; Falzoni, Roberto; Takagaki, Teresa; Silva, Pedro Leme; Teodoro, Walcy Rosolia; Capelozzi, Vera Luiza			In Situ Overexpression of Matricellular Mechanical Proteins Demands Functional Immune Signature and Mitigates Non-Small Cell Lung Cancer Progression	FRONTIERS IN IMMUNOLOGY			English	Article						lung cancer; immune cells; collagen; cancer-associated fibroblasts; immunofluorescence; immunohistochemistry; non-small cell lung cancer	TUMOR-INFILTRATING LYMPHOCYTES; REGULATORY T-CELLS; FOXP3 EXPRESSION; CLINICAL-SIGNIFICANCE; ALIGNED COLLAGEN; MIGRATION; MICROENVIRONMENT; SURVIVAL; CLASSIFICATION; MACROPHAGES	Non-small cell lung carcinoma (NSCLC) is a complex cancer biome composed of malignant cells embedded in a sophisticated tumor microenvironment (TME) combined with different initiating cell types, including immune cells and cancer-associated fibroblasts (CAFs), and extracellular matrix (ECM) proteins. However, little is known about these tumors' immune-matricellular relationship as functional and mechanical barriers. This study investigated 120 patients with NSCLC to describe the immune-matricellular phenotypes of their TME and their relationship with malignant cells. Immunohistochemistry (IHC) was performed to characterize immune checkpoints (PD-L1, LAG-3, CTLA-4+, VISTA 1), T cells (CD3+), cytotoxic T cells (CD8(+), Granzyme B), macrophages (CD68+), regulatory T cells (FOXP3+, CD4+), natural killer cells (CD57+), and B lymphocytes (CD20+), whereas CAFs and collagen types I, III, and V were characterized by immunofluorescence (IF). We observed two distinct functional immune-cellular barriers-the first of which showed proximity between malignant cells and cytotoxic T cells, and the second of which showed distant proximity between non-cohesive nests of malignant cells and regulatory T cells. We also identified three tumor-associated matricellular barriers: the first, with a localized increase in CAFs and a low deposition of Col V, the second with increased CAFs, Col III and Col I fibers, and the third with a high amount of Col fibers and CAFs bundled and aligned perpendicularly to the tumor border. The Cox regression analysis was designed in two steps. First, we investigated the relationship between the immune-matricellular components and tumor pathological stage (I, II, and IIIA), and better survival rates were seen in patients whose tumors expressed collagen type III > 24.89 fibers/mm(2). Then, we included patients who had progressed to pathological stage IV and found an association between poor survival and tumor VISTA 1 expression > 52.86 cells/mm(2) and CD3+ <= 278.5 cells/mm(2). We thus concluded that differential patterns in the distribution of immune-matricellular phenotypes in the TME of NSCLC patients could be used in translational studies to predict new treatment strategies and improve patient outcome. These data raise the possibility that proteins with mechanical barrier function in NSCLC may be used by cancer cells to protect them from immune cell infiltration and immune-mediated destruction, which can otherwise be targeted effectively with immunotherapy or collagen therapy.	[Yaegashi, Lygia Bertalha; Baldavira, Camila Machado; Prieto, Tabatha Gutierrez; Machado-Rugolo, Juliana; Assato, Aline; Ab'Saber, Alexandre Muxfeldt; Falzoni, Roberto; Capelozzi, Vera Luiza] Univ Sao Paulo, Dept Pathol, Med Sch, Sao Paulo, Brazil; [Machado-Rugolo, Juliana] Sao Paulo State Univ UNESP, Clin Hosp HCFMB, Hlth Technol Assessment Ctr NATS, Med Sch, Botucatu, SP, Brazil; [Pereira Velosa, Ana Paula; Ramos da Silveira, Lizandre Keren; Teodoro, Walcy Rosolia] Univ Sao Paulo, Hosp Clin, Med Sch, Rheumatol Div, Sao Paulo, Brazil; [Takagaki, Teresa] Univ Sao Paulo, Inst Coracao Incor, Div Pneumol, Med Sch USP, Sao Paulo, Brazil; [Silva, Pedro Leme] Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Carlos Chagas Filho Biophys Inst, Lab Pulm Invest, Rio De Janeiro, Brazil; [Silva, Pedro Leme] Natl Inst Sci & Technol Regenerat Med, Rio De Janeiro, Brazil	Universidade de Sao Paulo; Universidade Estadual Paulista; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade Federal do Rio de Janeiro	Capelozzi, VL (corresponding author), Univ Sao Paulo, Dept Pathol, Med Sch, Sao Paulo, Brazil.	vera.capelozzi@fm.usp.br	, Capelozzi/N-1737-2019; Teodoro, Walcy/H-5133-2017; MACHADO-RUGOLO, JULIANA/AAK-1525-2021; Prieto, Tabatha Gutierrez/AAO-8866-2021; Silva, Pedro Leme/AAD-8236-2019; Pereira Velosa, Ana Paula/AGH-4935-2022	, Capelozzi/0000-0001-9732-5853; Teodoro, Walcy/0000-0001-7559-4542; MACHADO-RUGOLO, JULIANA/0000-0003-3984-4959; Prieto, Tabatha Gutierrez/0000-0002-2615-6922; Silva, Pedro Leme/0000-0001-5838-4949; Machado Baldavira, Camila/0000-0002-5364-7305; Pereira Velosa, Ana Paula/0000-0002-6465-0796				Acerbi I, 2015, INTEGR BIOL-UK, V7, P1120, DOI 10.1039/c5ib00040h; Afik R, 2016, J EXP MED, V213, P2315, DOI 10.1084/jem.20151193; Altorki NK, 2019, NAT REV CANCER, V19, P9, DOI 10.1038/s41568-018-0081-9; Balancin ML, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.153277; Balancin ML, 2020, CANCER MED-US, V9, P4836, DOI 10.1002/cam4.3111; Batista ML, 2016, J CACHEXIA SARCOPENI, V7, P37, DOI 10.1002/jcsm.12037; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Blessin NC, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/5160565; Bougherara H, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00500; Bourgot I, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01488; Brcic L, 2018, VIRCHOWS ARCH, V472, P589, DOI 10.1007/s00428-018-2326-0; Brodsky AS, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2302-5; Budhu S, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aak9702; Carstens JL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15095; Champiat S, 2014, J THORAC ONCOL, V9, P144, DOI 10.1097/JTO.0000000000000074; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Conklin MW, 2011, AM J PATHOL, V178, P1221, DOI 10.1016/j.ajpath.2010.11.076; Coussens LM, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003285; Cox TR, 2021, NAT REV CANCER, V21, P217, DOI 10.1038/s41568-020-00329-7; DeLong P, 2005, CANCER BIOL THER, V4, P342, DOI 10.4161/cbt.4.3.1644; Devaud C, 2014, CANCER IMMUNOL IMMUN, V63, P869, DOI 10.1007/s00262-014-1581-4; Durham NM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109080; Gieniec KA, 2019, BRIT J CANCER, V121, P293, DOI 10.1038/s41416-019-0509-3; Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726; Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Graydon CG, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.615317; Guo CC, 2013, J THORAC ONCOL, V8, P301, DOI 10.1097/JTO.0b013e318282def7; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hao Q, 2013, BIOCHEM BIOPH RES CO, V430, P436, DOI 10.1016/j.bbrc.2012.11.039; Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hiraoka K, 2006, BRIT J CANCER, V94, P275, DOI 10.1038/sj.bjc.6602934; Horne ZD, 2011, J SURG RES, V171, P1, DOI 10.1016/j.jss.2011.03.068; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Job S, 2020, HEPATOLOGY, V72, P965, DOI 10.1002/hep.31092; Kai F, 2019, DEV CELL, V49, P332, DOI 10.1016/j.devcel.2019.03.026; Kataki A, 2002, J LAB CLIN MED, V140, P320, DOI 10.1067/mlc.2002.128317; Kilic A, 2011, J SURG RES, V167, P207, DOI 10.1016/j.jss.2009.08.029; Kuczek DE, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0556-6; Lal A, 2013, BREAST CANCER RES TR, V139, P381, DOI 10.1007/s10549-013-2556-4; Liu WB, 2018, GENE, V665, P57, DOI 10.1016/j.gene.2018.04.066; Mahajan UM, 2018, GASTROENTEROLOGY, V155, P1625, DOI 10.1053/j.gastro.2018.08.009; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Nicolas-Boluda A, 2021, ELIFE, V10, DOI 10.7554/eLife.58688; Oudin MJ, 2016, COLD SH Q B, V81, P189, DOI 10.1101/sqb.2016.81.030817; Pankova D, 2016, MOL CANCER RES, V14, P287, DOI 10.1158/1541-7786.MCR-15-0307; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ray A, 2017, BIOPHYS J, V112, P1023, DOI 10.1016/j.bpj.2017.01.007; Ruffini E, 2009, ANN THORAC SURG, V87, P365, DOI 10.1016/j.athoracsur.2008.10.067; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Salmon H, 2012, J CLIN INVEST, V122, P899, DOI 10.1172/JCI45817; Sharma P, 2017, MOL BIOL CELL, V28, P2579, DOI 10.1091/mbc.E17-05-0305; Shechter R, 2013, NAT REV IMMUNOL, V13, P206, DOI 10.1038/nri3391; Tao H, 2012, LUNG CANCER, V75, P95, DOI 10.1016/j.lungcan.2011.06.002; Tarver T, 2012, J CONS HLTH INTERNET, V16, P366, DOI 10.1080/15398285.2012.701177; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Turley SJ, 2015, NAT REV IMMUNOL, V15, P669, DOI 10.1038/nri3902; Venning FA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00224; Wakabayashi O, 2003, CANCER SCI, V94, P1003, DOI 10.1111/j.1349-7006.2003.tb01392.x; Willimsky G, 2005, NATURE, V437, P141, DOI 10.1038/nature03954; Xia M, 2013, J INT MED RES, V41, P1002, DOI 10.1177/0300060513488504; Yoon SM, 2017, WORLD J CLIN ONCOL, V8, P1, DOI 10.5306/wjco.v8.i1.1; Yoshii M, 2012, BRIT J CANCER, V106, P1668, DOI 10.1038/bjc.2012.141; Zhou J, 2021, LUNG CANCER, V153, P143, DOI 10.1016/j.lungcan.2021.01.010	67	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 16	2021	12									10.3389/fimmu.2021.714230	http://dx.doi.org/10.3389/fimmu.2021.714230			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UM7FJ	34484217	Green Published, gold			2022-12-18	WOS:000693493900001
J	Zhou, XF; Moore, BB				Zhou, Xiaofeng; Moore, Bethany B.			Experimental Models of Infectious Pulmonary Complications Following Hematopoietic Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Review						hematopoietic cell transplantation; bone marrow transplantation; infectious pulmonary complications; herpesvirus; Pseudomonas aeruginosa; Aspergillus fumigatus	BONE-MARROW TRANSPLANT; ALVEOLAR MACROPHAGE DYSFUNCTION; VERSUS-HOST-DISEASE; ASPERGILLUS-FUMIGATUS; PSEUDOMONAS-AERUGINOSA; INVASIVE ASPERGILLOSIS; MURINE MODEL; CYTOMEGALOVIRUS REACTIVATION; INNATE IMMUNITY; RISK-FACTORS	Pulmonary infections remain a major cause of morbidity and mortality in hematopoietic cell transplantation (HCT) recipients. The prevalence and type of infection changes over time and is influenced by the course of immune reconstitution post-transplant. The interaction between pathogens and host immune responses is complex in HCT settings, since the conditioning regimens create periods of neutropenia and immunosuppressive drugs are often needed to prevent graft rejection and limit graft-versus-host disease (GVHD). Experimental murine models of transplantation are valuable tools for dissecting the procedure-related alterations to innate and adaptive immunity. Here we review mouse models of post-HCT infectious pulmonary complications, primarily focused on three groups of pathogens that frequently infect HCT recipients: bacteria (often P. aeruginosa), fungus (primarily Aspergillus fumigatus), and viruses (primarily herpesviruses). These mouse models have advanced our knowledge regarding how the conditioning and HCT process negatively impacts innate immunity and have provided new potential strategies of managing the infections. Studies using mouse models have also validated clinical observations suggesting that prior or occult infections are a potential etiology of noninfectious pulmonary complications post-HCT as well.	[Zhou, Xiaofeng; Moore, Bethany B.] Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; [Zhou, Xiaofeng; Moore, Bethany B.] Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Zhou, XF (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.; Zhou, XF (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA.	xiazhou@umich.edu						Adler H, 1998, BLOOD, V92, P2581, DOI 10.1182/blood.V92.7.2581.2581_2581_2589; Afessa B, 2012, CHEST, V141, P442, DOI 10.1378/chest.10-2889; Al-Bader N, 2016, VIRULENCE, V7, P950, DOI 10.1080/21505594.2016.1231278; Alexander KA, 2014, J CLIN INVEST, V124, P4266, DOI 10.1172/JCI75935; Arber C, 2005, J INFECT DIS, V192, P1666, DOI 10.1086/491743; Averbuch D, 2017, CLIN INFECT DIS, V65, P1819, DOI 10.1093/cid/cix646; Ballinger MN, 2007, ARCH IMMUNOL THER EX, V55, P1, DOI 10.1007/s00005-007-0001-2; Ballinger MN, 2006, J IMMUNOL, V177, P5499, DOI 10.4049/jimmunol.177.8.5499; Balloy V, 2005, INFECT IMMUN, V73, P5420, DOI 10.1128/IAI.73.9.5420-5425.2005; Balloy V, 2005, INFECT IMMUN, V73, P494, DOI 10.1128/IAI.73.1.494-503.2005; Bellocchio S, 2004, J IMMUNOL, V172, P3059, DOI 10.4049/jimmunol.172.5.3059; Bernal-Martinez L, 2021, VIRULENCE, V12, P570, DOI 10.1080/21505594.2021.1879471; Boeckh M, 2003, BIOL BLOOD MARROW TR, V9, P543, DOI 10.1016/S1083-8791(03)00287-8; Boieri M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00333; Bottazzi B, 2009, IMMUNOL REV, V227, P9, DOI 10.1111/j.1600-065X.2008.00719.x; Bozza S, 2003, BLOOD, V102, P3807, DOI 10.1182/blood-2003-03-0748; Bozza S, 2002, MICROBES INFECT, V4, P1281, DOI 10.1016/S1286-4579(02)00007-2; Carreras E, 2019, EBMT HANDBOOK: HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELLULAR THERAPIES, P393, DOI 10.1007/978-3-030-02278-5_52; CAYEUX SJ, 1993, BONE MARROW TRANSPL, V12, P603; Cenci E, 2002, INFECT IMMUN, V70, P2375, DOI 10.1128/IAI.70.5.2375-2382.2002; Cenci E, 1999, J INFECT DIS, V180, P1957, DOI 10.1086/315142; Cenci E, 2000, J IMMUNOL, V165, P381, DOI 10.4049/jimmunol.165.1.381; Cesaro S, 2018, CLIN INFECT DIS, V67, P564, DOI 10.1093/cid/ciy150; Chen CS, 2003, BONE MARROW TRANSPL, V32, P515, DOI 10.1038/sj.bmt.1704162; Cheretakis C, 2006, BLOOD, V108, P2821, DOI 10.1182/blood-2006-04-018184; Clemons KV, 2000, CLIN EXP IMMUNOL, V122, P186, DOI 10.1046/j.1365-2249.2000.01382.x; Cooke KR, 2017, BIOL BLOOD MARROW TR, V23, P211, DOI 10.1016/j.bbmt.2016.09.023; Coomes SM, 2011, AM J PATHOL, V179, P2382, DOI 10.1016/j.ajpath.2011.08.002; Coomes SM, 2010, J IMMUNOL, V184, P5130, DOI 10.4049/jimmunol.0901871; Cunha C, 2010, BLOOD, V116, P5394, DOI 10.1182/blood-2010-04-279307; D'Souza A, 2020, BIOL BLOOD MARROW TR, V26, pE177, DOI 10.1016/j.bbmt.2020.04.013; Dagenais TRT, 2009, CLIN MICROBIOL REV, V22, P447, DOI 10.1128/CMR.00055-08; Davis FM, 2019, ARTERIOSCL THROM VAS, V39, P623, DOI 10.1161/ATVBAHA.118.312135; de Luca A, 2010, CELL MOL IMMUNOL, V7, P459, DOI 10.1038/cmi.2010.43; Del Sero G, 1999, MICROBES INFECT, V1, P1169, DOI 10.1016/S1286-4579(99)00245-2; Desoubeaux G, 2018, COMPARATIVE MED, V68, P109; Diab KJ, 2012, BIOL BLOOD MARROW TR, V18, P1827, DOI 10.1016/j.bbmt.2012.06.013; Diab M, 2016, EXP CLIN TRANSPLANT, V14, P259, DOI 10.6002/ect.2015.0275; Domingo-Gonzalez R, 2016, AM J RESP CRIT CARE, V193, P186, DOI 10.1164/rccm.201501-0161OC; Domingo-Gonzalez R, 2015, AM J PHYSIOL-LUNG C, V308, pL86, DOI 10.1152/ajplung.00283.2014; Domingo-Gonzalez R, 2012, J IMMUNOL, V189, P4528, DOI 10.4049/jimmunol.1201116; Domingo-Gonzalez R, 2013, J IMMUNOL, V190, P5809, DOI 10.4049/jimmunol.1203274; Dubovsky JA, 2014, J CLIN INVEST, V124, P4867, DOI 10.1172/JCI75328; Duran-Struuck R, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-10; Einsele H, 2020, BLOOD, V135, P1619, DOI 10.1182/blood.2019000956; Erard V, 2015, CLIN INFECT DIS, V61, P31, DOI 10.1093/cid/civ215; Flynn R, 2015, BLOOD, V125, P4085, DOI 10.1182/blood-2014-08-595470; Flynn R, 2014, BLOOD, V123, P3988, DOI 10.1182/blood-2014-03-562231; Ford CD, 2017, BIOL BLOOD MARROW TR, V23, P340, DOI 10.1016/j.bbmt.2016.11.017; Gosselin J, 2005, J IMMUNOL, V174, P1587, DOI 10.4049/jimmunol.174.3.1587; Gowdy KM, 2015, TRANSPL IMMUNOL, V32, P51, DOI 10.1016/j.trim.2014.10.005; Granot N, 2020, HAEMATOLOGICA, V105, P2716, DOI 10.3324/haematol.2019.245688; Graves SS, 2018, ILAR J, V59, P263, DOI 10.1093/ilar/ily006; Green ML, 2016, LANCET HAEMATOL, V3, pE119, DOI 10.1016/S2352-3026(15)00289-6; Gresnigt MS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04912-3; Gurczynski SJ, 2018, MUCOSAL IMMUNOL, V11, P881, DOI 10.1038/mi.2017.85; Gurczynski SJ, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.139965; Hakki M, 2007, BONE MARROW TRANSPL, V39, P687, DOI 10.1038/sj.bmt.1705653; Harris B, 2016, AM J RESP CRIT CARE, V194, P450, DOI 10.1164/rccm.201507-1491OC; Hartigan AJ, 2009, J IMMUNOL, V183, P5171, DOI 10.4049/jimmunol.0901027; Herbst S, 2015, EMBO MOL MED, V7, P240, DOI 10.15252/emmm.201404556; Hildebrandt GC, 2006, BIOL BLOOD MARROW TR, V12, P6, DOI 10.1016/j.bbmt.2005.11.024; Holtappels R, 1998, J VIROL, V72, P7201, DOI 10.1128/JVI.72.9.7201-7212.1998; Hubbard LLN, 2008, EXP LUNG RES, V34, P263, DOI 10.1080/01902140802022518; Hubbard LLN, 2011, AM J RESP CELL MOL, V45, P1050, DOI 10.1165/rcmb.2011-0079OC; Hubbard LLN, 2010, J IMMUNOL, V184, P6299, DOI 10.4049/jimmunol.0902828; Kalleda N, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01107; Karki R, 2015, CELL HOST MICROBE, V17, P357, DOI 10.1016/j.chom.2015.01.006; Karthaus M, 2011, EUR J MED RES, V16, P145, DOI 10.1186/2047-783X-16-4-145; Kasperkovitz PV, 2010, J IMMUNOL, V185, P7614, DOI 10.4049/jimmunol.1002760; Khan NS, 2016, J IMMUNOL, V196, P2249, DOI 10.4049/jimmunol.1401545; Kobayashi H, 2009, J INFECT CHEMOTHER, V15, P125, DOI 10.1007/s10156-008-0691-3; Kontoyiannis DP, 2010, CLIN INFECT DIS, V50, P1091, DOI 10.1086/651263; Langelier C, 2018, AM J RESP CRIT CARE, V197, P524, DOI 10.1164/rccm.201706-1097LE; Ljungman P, 2019, LANCET INFECT DIS, V19, pE260, DOI 10.1016/S1473-3099(19)30107-0; Lortholary O, 2011, CLIN MICROBIOL INFEC, V17, P1882, DOI 10.1111/j.1469-0691.2011.03548.x; LOSSOS IS, 1995, TRANSPLANTATION, V60, P672, DOI 10.1097/00007890-199510150-00010; MARKARYAN A, 1994, INFECT IMMUN, V62, P2149, DOI 10.1128/IAI.62.6.2149-2157.1994; Marsland BJ, 2015, ANN AM THORAC SOC, V12, pS150, DOI 10.1513/AnnalsATS.201503-133AW; Martinez-Colon GJ, 2018, MUCOSAL IMMUNOL, V11, P319, DOI 10.1038/mi.2017.51; Martins JP, 2019, SCIENCE, V363, P288, DOI 10.1126/science.aat0066; McCarthy MK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139235; McNeil MM, 2001, CLIN INFECT DIS, V33, P641, DOI 10.1086/322606; Mudau M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055985; Nichols WG, 2002, J INFECT DIS, V185, P273, DOI 10.1086/338624; O'Dwyer DN, 2018, AM J RESP CRIT CARE, V198, P1312, DOI 10.1164/rccm.201712-2456OC; O'Dwyer DN, 2016, J IMMUNOL, V196, P4839, DOI 10.4049/jimmunol.1600279; Ojielo CI, 2003, J IMMUNOL, V171, P4416, DOI 10.4049/jimmunol.171.8.4416; Olearo F, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa246; Panoskaltsis-Mortari A, 2007, AM J RESP CRIT CARE, V176, P713, DOI 10.1164/rccm.200702-335OC; Panoskaltsis-Mortari A, 2011, AM J RESP CRIT CARE, V183, P1262, DOI 10.1164/rccm.2007-413ST; Park BG, 2015, LEUKEMIA RES, V39, P1334, DOI 10.1016/j.leukres.2015.09.010; Passweg JR, 2020, BONE MARROW TRANSPL, V55, P1604, DOI 10.1038/s41409-020-0826-4; Podlech J, 2000, J VIROL, V74, P7496, DOI 10.1128/JVI.74.16.7496-7507.2000; Reid GE, 2016, SEMIN RESP CRIT CARE, V37, P603, DOI 10.1055/s-0036-1584793; Reynaud JM, 2014, J VIROL, V88, P5421, DOI 10.1128/JVI.03763-13; ROESLER J, 1989, J IMMUNOL, V143, P1710; Rowan C, 2014, J PEDIATR INTENSIVE, V3, P133, DOI 10.3233/PIC-14095; Sadowska-Klasa A, 2018, ANN HEMATOL, V97, P509, DOI 10.1007/s00277-017-3205-5; Said-Sadier N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010008; Samuelson DR, 2015, FRONT MICROBIOL, V6, DOI [10.5389/fmicb.2015.01085, 10.3389/fmicb.2015.01085]; Satwani P, 2017, BIOL BLOOD MARROW TR, V23, P642, DOI 10.1016/j.bbmt.2017.01.073; Segal BH, 2006, AM J RESP CRIT CARE, V173, P707, DOI 10.1164/rccm.200505-727SO; Seo S, 2015, BLOOD, V125, P3789, DOI 10.1182/blood-2014-12-617035; Shay T, 2013, P NATL ACAD SCI USA, V110, P2946, DOI 10.1073/pnas.1222738110; Sheppard DC, 2004, ANTIMICROB AGENTS CH, V48, P1908, DOI 10.1128/AAC.48.5.1908-1911.2004; Smith MS, 2010, CELL HOST MICROBE, V8, P284, DOI 10.1016/j.chom.2010.08.001; Srinivasan M, 2012, BLOOD, V119, P1570, DOI 10.1182/blood-2011-07-364414; Storek J, 2004, CLIN IMMUNOL, V113, P285, DOI 10.1016/j.clim.2004.07.006; Tamburro RF, 2021, ANN AM THORAC SOC, V18, P381, DOI 10.1513/AnnalsATS.202001-006OT; Taur Y, 2014, BLOOD, V124, P1174, DOI 10.1182/blood-2014-02-554725; Taur Y, 2012, CLIN INFECT DIS, V55, P905, DOI 10.1093/cid/cis580; Tomblyn M, 2009, BONE MARROW TRANSPL, V44, P453, DOI 10.1038/bmt.2009.254; Trecarichi EM, 2011, HAEMATOL-HEMATOL J, V96, pE1, DOI 10.3324/haematol.2010.036640; Urb M, 2015, INFECT IMMUN, V83, P3590, DOI 10.1128/IAI.00359-15; Verghese DA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.124646; Versluys AB, 2010, BIOL BLOOD MARROW TR, V16, P782, DOI 10.1016/j.bbmt.2009.12.534; Wald A, 1997, J INFECT DIS, V175, P1459, DOI 10.1086/516480; Werner JL, 2009, J IMMUNOL, V182, P4938, DOI 10.4049/jimmunol.0804250; Wilke CA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130210; Wingard JR, 2010, INFECT DIS CLIN N AM, V24, P257, DOI 10.1016/j.idc.2010.01.010; WINSTON DJ, 1982, AM J MED, V73, P859, DOI 10.1016/0002-9343(82)90777-X; Yanik G, 2006, SEMIN HEMATOL, V43, P42, DOI 10.1053/j.seminhematol.2005.09.004; Zhou X, 2016, MUCOSAL IMMUNOL, V9, P610, DOI 10.1038/mi.2015.85; Zhou XF, 2019, AM J RESP CRIT CARE, V200, P63, DOI 10.1164/rccm.201809-1635OC; Zimecki M, 2010, MED MICROBIOL IMMUN, V199, P71, DOI 10.1007/s00430-009-0135-4; Zinter MS, 2021, BLOOD, V137, P1679, DOI 10.1182/blood.2020009246; Zinter MS, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.634566	128	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 16	2021	12									10.3389/fimmu.2021.718603	http://dx.doi.org/10.3389/fimmu.2021.718603			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UM6YO	34484223	Green Published, gold			2022-12-18	WOS:000693476200001
J	Ayo, CM; Bestetti, RB; Junior, ED; Ronchi, LS; Borim, AA; Brandao, CC; de Matttos, LC				Ayo, Christiane Maria; Bestetti, Reinaldo Bulgarelli; Junior, Eumildo de Campos; Ronchi, Luiz Sergio; Borim, Aldenis Albaneze; Brandao, Cinara Cassia; de Matttos, Luiz Carlos			MICA and KIR: Immunogenetic Factors Influencing Left Ventricular Systolic Dysfunction and Digestive Clinical Form of Chronic Chagas Disease	FRONTIERS IN IMMUNOLOGY			English	Article						MHC class I; KIR receptors; Chagas disease; chronic chagasic heart disease; chagasic megacolon; chagasic megaesophagus	CD8(+) T-CELLS; TRYPANOSOMA-CRUZI; PARASITE PERSISTENCE; IMMUNE-RESPONSE; MHC MOLECULES; MISSING SELF; NK CELLS; NKG2D; PATHOGENESIS; LIGANDS	Tissue damage observed in the clinical forms of chronic symptomatic Chagas disease seems to have a close relationship with the intensity of the inflammatory process. The objective of this study was to investigate whether the MICA (MHC class I-related chain A) and KIR (killer cell immunoglobulin-like receptors) polymorphisms are associated with the cardiac and digestive clinical forms of chronic Chagas disease. Possible influence of these genes polymorphisms on the left ventricular systolic dysfunction (LVSD) in patients with chronic Chagas heart disease was also evaluated. This study enrolled 185 patients with positive serology for Trypanosoma cruzi classified according to the clinical form of the disease: cardiac (n=107) and digestive (n=78). Subsequently, patients with the cardiac form of the disease were sub-classified as with LVSD (n=52) and without LVSD (n=55). A control group was formed of 110 healthy individuals. Genotyping was performed by polymerase chain reaction-sequence specific oligonucleotide probes (PCR-SSOP). Statistical analyzes were carried out using the Chi-square test and odds ratio with 95% confidence interval was also calculated to evaluate the risk association. MICA-129 allele with high affinity for the NKG2D receptor was associated to the LVSD in patients with CCHD. The haplotype MICA*008~HLA-C*06 and the KIR2DS2(-)/KIR2DL2(-)/KIR2DL3(+)/C1(+) combination were associated to the digestive clinical form of the disease. Our data showed that the MICA and KIR polymorphisms may exert a role in the LVSD of cardiac patients, and in digestive form of Chagas disease.</p>	[Ayo, Christiane Maria; Brandao, Cinara Cassia; de Matttos, Luiz Carlos] Med Sch Sao Jose Do Rio Preto, Mol Biol Dept, Immunogenet Lab, Sao Jose Do Rio Preto, Brazil; [Bestetti, Reinaldo Bulgarelli] Med Sch Sao Jose Do Rio Preto, Dept Cardiol & Cardiovasc Surg, Sao Jose Do Rio Preto, Brazil; [Junior, Eumildo de Campos; Ronchi, Luiz Sergio; Borim, Aldenis Albaneze] Med Sch Sao Jose Do Rio Preto, Surg Dept, Sao Jose Do Rio Preto, Brazil; [Bestetti, Reinaldo Bulgarelli] Univ Ribeirao Preto, Dept Med, Ribeirao Preto, Brazil	Universidade de Sao Paulo; Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP); Universidade de Sao Paulo; Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP); Universidade de Sao Paulo; Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP); Universidade de Ribeirao Preto	de Matttos, LC (corresponding author), Med Sch Sao Jose Do Rio Preto, Mol Biol Dept, Immunogenet Lab, Sao Jose Do Rio Preto, Brazil.	luiz.demattos@famerp.br	BRANDÃO, CINARA/B-3650-2008; de Mattos, Luiz Carlos/P-4005-2019	BRANDÃO, CINARA/0000-0002-4836-3113; de Mattos, Luiz Carlos/0000-0002-8572-8177; Ayo, Christiane/0000-0003-3983-0119	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/06580-9, 2011/08075-4]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) [001]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This study was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [grant numbers: 2013/06580-9 and 2011/08075-4] and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) -Finance Code 001.	Ayo CM, 2015, CLIN INFECT DIS, V61, P1310, DOI 10.1093/cid/civ540; Ayo CM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003753; Bahram S, 2005, CURR OPIN IMMUNOL, V17, P505, DOI 10.1016/j.coi.2005.07.016; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Benvenuti LA, 2008, ANN TROP MED PARASIT, V102, P481, DOI 10.1179/136485908X311740; Bestetti RB, 1996, LANCET, V347, P913, DOI 10.1016/S0140-6736(96)91403-8; BESTETTI RB, 1990, INT J CARDIOL, V29, P39, DOI 10.1016/0167-5273(90)90271-6; BESTETTI RB, 1992, INT J CARDIOL, V35, P371, DOI 10.1016/0167-5273(92)90236-V; Bestetti RB, 2011, INT J CARDIOL, V151, P205, DOI 10.1016/j.ijcard.2010.05.033; Bocchi EA, 2017, J AM COLL CARDIOL, V70, P1510, DOI 10.1016/j.jacc.2017.08.004; Bonney KM, 2015, AM J PATHOL, V185, P1537, DOI 10.1016/j.ajpath.2014.12.023; Brener Z, 1997, INT ARCH ALLERGY IMM, V114, P103, DOI 10.1159/000237653; Cardillo F, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv082; Carr WH, 2005, J IMMUNOL, V175, P5222, DOI 10.4049/jimmunol.175.8.5222; Corbett CEP, 2001, DIS COLON RECTUM, V44, P993, DOI 10.1007/BF02235488; Cunha-Neto E, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/683230; de Oliveira RB, 1998, AM J GASTROENTEROL, V93, P884, DOI 10.1111/j.1572-0241.1998.270_r.x; del Puerto F, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001587; Dutra WO, 2009, MEM I OSWALDO CRUZ, V104, P208, DOI 10.1590/S0074-02762009000900027; GAZZINELLI RT, 1992, EUR J IMMUNOL, V22, P2501, DOI 10.1002/eji.1830221006; Golding J, 2013, INT J EPIDEMIOL, V42, P1145, DOI 10.1093/ije/dyt095; Groh V, 2003, P NATL ACAD SCI USA, V100, P9452, DOI 10.1073/pnas.1632807100; Groh V, 1998, SCIENCE, V279, P1737, DOI 10.1126/science.279.5357.1737; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296; Hollenbach JA, 2009, IMMUNOGENETICS, V61, P663, DOI 10.1007/s00251-009-0396-5; Hue S, 2004, IMMUNITY, V21, P367, DOI 10.1016/j.immuni.2004.06.018; Imanish T, 1992, HLA 1991, V1, P1065; Jimenez P, 2019, PARASITOLOGY, V146, P269, DOI 10.1017/S0031182018001506; Jones DC, 2006, GENES IMMUN, V7, P576, DOI 10.1038/sj.gene.6364333; Karacki PS, 2004, GENES IMMUN, V5, P261, DOI 10.1038/sj.gene.6364065; Khakoo SI, 2006, IMMUNOL REV, V214, P186, DOI 10.1111/j.1600-065X.2006.00459.x; Kulkarni S, 2008, SEMIN IMMUNOL, V20, P343, DOI 10.1016/j.smim.2008.06.003; Lanier LL, 2015, CANCER IMMUNOL RES, V3, P575, DOI 10.1158/2326-6066.CIR-15-0098; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Little J, 2009, PLOS MED, V6, P151, DOI 10.1371/journal.pmed.1000022; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Martins Paulo Roberto Juliano, 2013, Rev. Bras. Hematol. Hemoter., V35, P180, DOI 10.5581/1516-8484.20130040; Middleton D, 2010, IMMUNOLOGY, V129, P8, DOI 10.1111/j.1365-2567.2009.03208.x; Moesta AK, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00336; Pardoll DM, 2001, SCIENCE, V294, P534, DOI 10.1126/science.1066284; Parra FC, 2003, P NATL ACAD SCI USA, V100, P177, DOI 10.1073/pnas.0126614100; Dias JCP, 2016, REV SOC BRAS MED TRO, V49, P3, DOI 10.1590/0037-8682-0505-2016; Reis DD, 2001, T ROY SOC TROP MED H, V95, P177, DOI 10.1016/S0035-9203(01)90153-1; Sathler-Avelar R, 2009, MEM I OSWALDO CRUZ, V104, P246, DOI 10.1590/S0074-02762009000900031; Shifrin N, 2014, SEMIN IMMUNOL, V26, P138, DOI 10.1016/j.smim.2014.02.007; Steinle A, 2001, IMMUNOGENETICS, V53, P279, DOI 10.1007/s002510100325; Stephens HAF, 2001, TRENDS IMMUNOL, V22, P378, DOI 10.1016/S1471-4906(01)01960-3; Suemizu H, 2002, P NATL ACAD SCI USA, V99, P2971, DOI 10.1073/pnas.052701099; Tarleton RL, 2015, SEMIN IMMUNOPATHOL, V37, P233, DOI 10.1007/s00281-015-0481-9; Teixeira ARL, 2006, MEM I OSWALDO CRUZ, V101, P463, DOI 10.1590/S0074-02762006000500001; Teixeira ARL, 2011, CLIN MICROBIOL REV, V24, P592, DOI 10.1128/CMR.00063-10; Thananchai H, 2007, J IMMUNOL, V178, P33, DOI 10.4049/jimmunol.178.1.33; Vitelli-Avelar DM, 2006, CLIN EXP IMMUNOL, V145, P81, DOI 10.1111/j.1365-2249.2006.03123.x; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; Williams AP, 2005, MOL INTERV, V5, P226, DOI 10.1124/mi.5.4.6; Wong P, 2003, ANNU REV IMMUNOL, V21, P29, DOI 10.1146/annurev.immunol.21.120601.141114; World Health Organization, 2017, CHAG DIS AM TRYP; Zwirner NW, 1999, HUM IMMUNOL, V60, P323, DOI 10.1016/S0198-8859(98)00128-1; [No title captured]	60	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 13	2021	12								714766	10.3389/fimmu.2021.714766	http://dx.doi.org/10.3389/fimmu.2021.714766			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UU1ON	34489964	gold, Green Published			2022-12-18	WOS:000698572500001
J	Bosticardo, M; Ohigashi, I; Cowan, JE; Alves, NL				Bosticardo, Marita; Ohigashi, Izumi; Cowan, Jennifer E.; Alves, Nuno L.			Editorial: Thymic Epithelial Cells: New Insights Into the Essential Driving Force of T-Cell Differentiation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						thymus; thymic stromal cells; thymic epithelial cells; immunodeficiency; central tolerance			[Bosticardo, Marita] NIAID, Lab Clin Immunol & Microbiol, IDGS, DIR,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Ohigashi, Izumi] Univ Tokushima, Inst Adv Med Sci, Div Expt Immunol, Tokushima, Japan; [Cowan, Jennifer E.] NCI, Lab Genome Integr, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Alves, Nuno L.] Univ Porto, i3S Inst Invest & Inovacao Saude, Porto, Portugal; [Alves, Nuno L.] Univ Porto, IBMC Inst Biol Mol & Celular, Porto, Portugal	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Tokushima University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto	Bosticardo, M (corresponding author), NIAID, Lab Clin Immunol & Microbiol, IDGS, DIR,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	marita.bosticardo@nih.gov	Bosticardo, Marita/ABA-2688-2021	Bosticardo, Marita/0000-0002-1771-4523	Intramural Research Program of the NIH; MEXT-JSPS [17K08884]; Takeda Science Foundation; European Research Council (ERC) [637843]; FEDER Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020; Portuguese funds through FCT - Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Ensino Superior [POCI-01-0145FEDER-029129 (PTDC/MED-IMU/29129/2017), PTDC/MED-IMU/1416/2020]	Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MEXT-JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Takeda Science Foundation(Takeda Science Foundation (TSF)); European Research Council (ERC)(European Research Council (ERC)European Commission); FEDER Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020; Portuguese funds through FCT - Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Ensino Superior	M.B. is supported by the Intramural Research Program of the NIH. I.O. is supported by grant from the MEXT-JSPS 17K08884 and Takeda Science Foundation. The laboratory of N.L.A. is supported by a starting grant from the European Research Council (ERC) under the project 637843 and by FEDER Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT - Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Ensino Superior in the framework of the project POCI-01-0145FEDER-029129 (PTDC/MED-IMU/29129/2017) and PTDC/MED-IMU/1416/2020.	Kadouri N, 2020, NAT REV IMMUNOL, V20, P239, DOI 10.1038/s41577-019-0238-0; Takahama Y, 2017, NAT REV IMMUNOL, V17, P295, DOI 10.1038/nri.2017.12	2	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 13	2021	12								744623	10.3389/fimmu.2021.744623	http://dx.doi.org/10.3389/fimmu.2021.744623			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UL8WR	34484248	gold, Green Published			2022-12-18	WOS:000692925700001
J	Dawes, JC; Uren, AG				Dawes, Joanna C.; Uren, Anthony G.			Forward and Reverse Genetics of B Cell Malignancies: From Insertional Mutagenesis to CRISPR-Cas	FRONTIERS IN IMMUNOLOGY			English	Review						B cell leukemia; B cell lymphoma; mouse models; insertional mutagenesis; exome sequencing; reverse genetics; CRISPR-Cas; shRNA<bold; >	MURINE LEUKEMIA-VIRUS; ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC PROGENITOR CELLS; CHRONIC MYELOGENOUS LEUKEMIA; PRECEDES MULTIPLE-MYELOMA; MYC TRANSGENIC MICE; ONE-STEP GENERATION; IN-VIVO; TUMOR-SUPPRESSOR; MOUSE MODELS	Cancer genome sequencing has identified dozens of mutations with a putative role in lymphomagenesis and leukemogenesis. Validation of driver mutations responsible for B cell neoplasms is complicated by the volume of mutations worthy of investigation and by the complex ways that multiple mutations arising from different stages of B cell development can cooperate. Forward and reverse genetic strategies in mice can provide complementary validation of human driver genes and in some cases comparative genomics of these models with human tumors has directed the identification of new drivers in human malignancies. We review a collection of forward genetic screens performed using insertional mutagenesis, chemical mutagenesis and exome sequencing and discuss how the high coverage of subclonal mutations in insertional mutagenesis screens can identify cooperating mutations at rates not possible using human tumor genomes. We also compare a set of independently conducted screens from Pax5 mutant mice that converge upon a common set of mutations observed in human acute lymphoblastic leukemia (ALL). We also discuss reverse genetic models and screens that use CRISPR-Cas, ORFs and shRNAs to provide high throughput in vivo proof of oncogenic function, with an emphasis on models using adoptive transfer of ex vivo cultured cells. Finally, we summarize mouse models that offer temporal regulation of candidate genes in an in vivo setting to demonstrate the potential of their encoded proteins as therapeutic targets.</p>	[Dawes, Joanna C.; Uren, Anthony G.] MRC, London Inst Med Sci, London, England; [Dawes, Joanna C.; Uren, Anthony G.] Imperial Coll London, Fac Med, Inst Clin Sci ICS, London, England	Imperial College London	Dawes, JC; Uren, AG (corresponding author), MRC, London Inst Med Sci, London, England.; Dawes, JC; Uren, AG (corresponding author), Imperial Coll London, Fac Med, Inst Clin Sci ICS, London, England.	dawesjoanna@gmail.com; anthony.uren@gmail.com	Uren, Anthony G/A-5784-2009	Uren, Anthony G/0000-0002-6019-7111	MRC programme [MC_A652_5PZ20]	MRC programme(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	JD and AU were supported by MRC programme grant MC_A652_5PZ20.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adikusuma F, 2018, NATURE, V560, pE8, DOI 10.1038/s41586-018-0380-z; Al-Mansour M, 2010, J CLIN ONCOL, V28, P793, DOI 10.1200/JCO.2009.24.9516; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; Anzalone AV, 2019, NATURE, V576, P149, DOI 10.1038/s41586-019-1711-4; Arita K, 2013, EXP HEMATOL, V41, P731, DOI 10.1016/j.exphem.2013.04.001; Arnold C, 1991, PCR Methods Appl, V1, P39; Aubrey BJ, 2015, CELL REP, V10, P1422, DOI 10.1016/j.celrep.2015.02.002; Auer F, 2014, LEUKEMIA, V28, P1136, DOI 10.1038/leu.2013.363; Barabe F, 2007, SCIENCE, V316, P600, DOI 10.1126/science.1139851; Basso K, 2015, NAT REV IMMUNOL, V15, P172, DOI 10.1038/nri3814; Bastian L, 2019, LEUKEMIA, V33, P1895, DOI 10.1038/s41375-019-0430-z; Beckmann PJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031172; Berry CC, 2012, BIOINFORMATICS, V28, P755, DOI 10.1093/bioinformatics/bts004; Boroviak K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12740-6; Bouquet C, 2012, EUR J IMMUNOL, V42, P522, DOI 10.1002/eji.201141987; Braun CJ, 2016, P NATL ACAD SCI USA, V113, pE3892, DOI 10.1073/pnas.1600582113; Bric A, 2009, CANCER CELL, V16, P324, DOI 10.1016/j.ccr.2009.08.015; Bronner IF, 2016, GENOME RES, V26, P980, DOI 10.1101/gr.200279.115; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; Canver MC, 2014, J BIOL CHEM, V289, P21312, DOI 10.1074/jbc.M114.564625; Cao J, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw660; Cao ZW, 2014, CANCER CELL, V25, P350, DOI 10.1016/j.ccr.2014.02.005; CHAN JKC, 1990, AM J PATHOL, V136, P1153; Chavez A, 2015, NAT METHODS, V12, P326, DOI [10.1038/NMETH.3312, 10.1038/nmeth.3312]; Chen Y., 2020, NOVEL MOSAIC MICE DI, DOI DOI 10.1101/2020.03.21.001388; Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572; Chu V, 2016, BMC BIOTECHNOL, V16, DOI 10.1186/s12896-016-0234-4; Cimmino L, 2015, NAT IMMUNOL, V16, P653, DOI 10.1038/ni.3148; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Coyaud E, 2010, BLOOD, V115, P3089, DOI 10.1182/blood-2009-07-234229; Csikos T, 2008, J IMMUNOL METHODS, V339, P259, DOI 10.1016/j.jim.2008.08.009; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Damm F, 2014, CANCER DISCOV, V4, P1088, DOI 10.1158/2159-8290.CD-14-0104; Dang JJ, 2015, BLOOD, V125, P3609, DOI 10.1182/blood-2015-02-626127; Dawes JC, 2020, MOBILE DNA-UK, V11, DOI 10.1186/s13100-020-0201-4; de Jong J, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004250; de Jong J, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr447; De La Rochere P, 2018, TRENDS IMMUNOL, V39, P748, DOI 10.1016/j.it.2018.07.001; de Ridder J, 2006, PLOS COMPUT BIOL, V2, P1530, DOI 10.1371/journal.pcbi.0020166; DEVON RS, 1995, NUCLEIC ACIDS RES, V23, P1644, DOI 10.1093/nar/23.9.1644; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Doman JL, 2020, NAT BIOTECHNOL, V38, P620, DOI 10.1038/s41587-020-0414-6; Dominguez PM, 2018, CANCER DISCOV, V8, P1632, DOI 10.1158/2159-8290.CD-18-0657; Donnou Sabrina, 2012, Adv Hematol, V2012, P701704, DOI 10.1155/2012/701704; Dow LE, 2015, NAT BIOTECHNOL, V33, P390, DOI 10.1038/nbt.3155; Dugray A, 2001, LEUKEMIA, V15, P1658, DOI 10.1038/sj.leu.2402225; Duployez N, 2021, BLOOD, V137, P1424, DOI 10.1182/blood.2020005756; Duque-Afonso J, 2016, CANCER RES, V76, P6937, DOI 10.1158/0008-5472.CAN-16-1899; Duque-Afonso J, 2015, J CLIN INVEST, V125, P3667, DOI 10.1172/JCI81158; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Espinoza JL, 2018, CANCER LETT, V414, P147, DOI 10.1016/j.canlet.2017.11.009; EVA A, 1987, ANN NY ACAD SCI, V511, P148, DOI 10.1111/j.1749-6632.1987.tb36245.x; Familiades J, 2009, LEUKEMIA, V23, P1989, DOI 10.1038/leu.2009.135; Fan H, 1997, TRENDS MICROBIOL, V5, P74, DOI 10.1016/S0966-842X(96)10076-7; Fellmann C, 2013, CELL REP, V5, P1704, DOI 10.1016/j.celrep.2013.11.020; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Filippova J, 2019, BIOCHIMIE, V167, P49, DOI 10.1016/j.biochi.2019.09.003; Flumann R, 2021, BLOOD CANCER DISCOV, V2, P70, DOI 10.1158/2643-3230.BCD-19-0059; FREDRICKSON TN, 1984, J NATL CANCER I, V73, P521, DOI 10.1093/jnci/73.2.521; FREDRICKSON TN, 1985, AM J PATHOL, V121, P349; Fu YF, 2014, NAT BIOTECHNOL, V32, P279, DOI 10.1038/nbt.2808; Gahn B, 1997, BLOOD, V89, P4275, DOI 10.1182/blood.V89.12.4275; Gaj T, 2013, TRENDS BIOTECHNOL, V31, P397, DOI 10.1016/j.tibtech.2013.04.004; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; Gilbert LA, 2014, CELL, V159, P647, DOI 10.1016/j.cell.2014.09.029; Gonzalez-Martin A, 2016, NAT IMMUNOL, V17, P433, DOI 10.1038/ni.3385; Gough SM, 2017, BLOOD ADV, V1, P1749, DOI 10.1182/bloodadvances.2017009837; Gough SM., 2014, BLOOD, V124, P3573, DOI [10.1182/blood.V124.21.3573.3573, DOI 10.1182/BLOOD.V124.21.3573.3573]; Gu B, 2018, NAT BIOTECHNOL, V36, P632, DOI 10.1038/nbt.4166; Gundry MC, 2016, CELL REP, V17, P1453, DOI 10.1016/j.celrep.2016.09.092; HANECAK R, 1988, J VIROL, V62, P2427, DOI 10.1128/JVI.62.7.2427-2436.1988; Hartley JW, 2000, LAB INVEST, V80, P159, DOI 10.1038/labinvest.3780020; Hartweger H, 2019, J EXP MED, V216, P1301, DOI 10.1084/jem.20190287; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HAWLEY RG, 1995, ONCOGENE, V11, P1113; Hawley TS, 1998, BLOOD, V92, P2003, DOI 10.1182/blood.V92.6.2003.418k11_2003_2011; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; Heltemes-Harris LM, 2016, ONCOGENE, V35, P3454, DOI 10.1038/onc.2015.405; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Herbst A, 2005, EMBO REP, V6, P177, DOI 10.1038/sj.embor.7400333; Hirakawa MP, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20200127; Hoelbl A, 2006, BLOOD, V107, P4898, DOI 10.1182/blood-2005-09-3596; Hoelbl A, 2010, EMBO MOL MED, V2, P98, DOI 10.1002/emmm.201000062; Hoellein A, 2014, BLOOD, V124, P2081, DOI 10.1182/blood-2014-06-584524; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Hui EKW, 1998, CELL MOL LIFE SCI, V54, P1403, DOI 10.1007/s000180050262; Huijbers IJ, 2017, METHODS MOL BIOL, V1642, P1, DOI 10.1007/978-1-4939-7169-5_1; Huijbers IJ, 2015, NAT PROTOC, V10, P1755, DOI 10.1038/nprot.2015.114; Huijbers IJ, 2014, EMBO MOL MED, V6, P212, DOI 10.1002/emmm.201303297; Husby S, 2017, BLOOD ADV, V1, P2444, DOI 10.1182/bloodadvances.2017008854; Huser CA, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004167; Jager U, 2000, BLOOD, V95, P3520, DOI 10.1182/blood.V95.11.3520.011k12_3520_3529; Jain S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20672-5; Jamrog L, 2018, P NATL ACAD SCI USA, V115, P10357, DOI 10.1073/pnas.1721678115; Janic A, 2018, NAT MED, V24, P947, DOI 10.1038/s41591-018-0043-5; Jeong J, 2019, BLOOD ADV, V3, P2825, DOI 10.1182/bloodadvances.2019000450; Jiang YW, 2017, CANCER DISCOV, V7, P38, DOI 10.1158/2159-8290.CD-16-0975; Jin G, 2003, CANCER SCI, V94, P791, DOI 10.1111/j.1349-7006.2003.tb01520.x; Johnson MJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30358-0; Katigbak A, 2018, G3-GENES GENOM GENET, V8, P1627, DOI 10.1534/g3.117.300327; Katigbak A, 2016, SCI REP-UK, V6, DOI 10.1038/srep38968; Kawakami K, 2017, TRENDS GENET, V33, P784, DOI 10.1016/j.tig.2017.07.006; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Khodabakhshi AH, 2012, ONCOTARGET, V3, P1308; Kikushige Y, 2011, CANCER CELL, V20, P246, DOI 10.1016/j.ccr.2011.06.029; Kitayama H, 1996, BLOOD, V88, P995; Kleinstiver BP, 2019, NAT BIOTECHNOL, V37, P276, DOI 10.1038/s41587-018-0011-0; Kleinstiver BP, 2016, NATURE, V529, P490, DOI 10.1038/nature16526; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Koblan LW, 2018, NAT BIOTECHNOL, V36, P843, DOI 10.1038/nbt.4172; Kohnken R, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00022; Kool J, 2010, CANCER RES, V70, P520, DOI 10.1158/0008-5472.CAN-09-2736; Kool J, 2009, NAT REV CANCER, V9, P389, DOI 10.1038/nrc2647; Kosicki M, 2018, NAT BIOTECHNOL, V36, P765, DOI 10.1038/nbt.4192; Koudijs MJ, 2011, GENOME RES, V21, P2181, DOI 10.1101/gr.112763.110; Kovacic B, 2012, EMBO MOL MED, V4, P283, DOI 10.1002/emmm.201100208; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Kuiper RP, 2007, LEUKEMIA, V21, P1258, DOI 10.1038/sj.leu.2404691; Kuppers R, 2005, NAT REV CANCER, V5, P251, DOI 10.1038/nrc1589; LaFleur MW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09656-2; Landgren O, 2009, BLOOD, V113, P5412, DOI 10.1182/blood-2008-12-194241; Landgren O, 2009, NEW ENGL J MED, V360, P659, DOI 10.1056/NEJMoa0806122; Lee K, 2017, ELIFE, V6, DOI 10.7554/eLife.25312; Lefebure M, 2017, NAT COMMUN, V8, P1, DOI 10.1038/ncomms14581; Lenz G, 2008, P NATL ACAD SCI USA, V105, P13520, DOI 10.1073/pnas.0804295105; Leskov I, 2013, ONCOGENE, V32, P1066, DOI 10.1038/onc.2012.117; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Li HX, 2014, BLOOD, V123, P1487, DOI 10.1182/blood-2013-05-500264; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li XX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05084-w; LIMPENS J, 1995, BLOOD, V85, P2528, DOI 10.1182/blood.V85.9.2528.bloodjournal8592528; Liu GJ, 2014, GENE DEV, V28, P1337, DOI 10.1101/gad.240416.114; Liu JH, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-2; Lovmand J, 1998, J VIROL, V72, P5745, DOI 10.1128/JVI.72.7.5745-5756.1998; Lundin A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18548-9; Ma M, 2017, CELL RES, V27, P578, DOI 10.1038/cr.2017.29; Ma SL, 2006, VIROLOGY, V352, P306, DOI 10.1016/j.virol.2006.05.006; Maddalo D, 2014, NATURE, V516, P423, DOI 10.1038/nature13902; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Malina A, 2013, GENE DEV, V27, P2602, DOI 10.1101/gad.227132.113; Manghwar H, 2020, ADV SCI, V7, DOI 10.1002/advs.201902312; Mann K.M., 2016, PROTOC EXCH, DOI [10.1038/protex.2016.053, DOI 10.1038/PROTEX.2016.053]; Mann KM, 2016, NAT BIOTECHNOL, V34, P962, DOI 10.1038/nbt.3637; Mansouri L, 2016, SEMIN CANCER BIOL, V39, P40, DOI 10.1016/j.semcancer.2016.07.005; Marinkovic D, 2004, INT J CANCER, V110, P336, DOI 10.1002/ijc.20099; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Martin-Hernandez J, 2001, J VIROL, V75, P11907, DOI 10.1128/JVI.75.23.11907-11912.2001; Martin-Lorenzo A, 2015, CANCER DISCOV, V5, P1328, DOI 10.1158/2159-8290.CD-15-0892; Martinov T, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.643852; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Matthews GM, 2015, BLOOD, V126, P2392, DOI 10.1182/blood-2015-03-632984; McHugh D, 2017, CELL HOST MICROBE, V22, P61, DOI 10.1016/j.chom.2017.06.009; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Meacham CE, 2009, NAT GENET, V41, P1133, DOI 10.1038/ng.451; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Miles LA, 2020, NATURE, V587, P477, DOI 10.1038/s41586-020-2864-x; Miura H, 2018, NAT PROTOC, V13, P195, DOI 10.1038/nprot.2017.153; Moffett HF, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aax0644; Montgomery Nathan D, 2016, Surg Pathol Clin, V9, P79, DOI 10.1016/j.path.2015.09.004; Morgens DW, 2016, NAT BIOTECHNOL, V34, P634, DOI 10.1038/nbt.3567; Mossadegh-Keller N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.683597; Mouly E, 2018, BLOOD ADV, V2, P703, DOI 10.1182/bloodadvances.2017014118; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; MUCENSKI ML, 1988, J VIROL, V62, P839, DOI 10.1128/JVI.62.3.839-846.1988; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Nahmad AD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19649-1; Nakade S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6560; Nakagawa M, 2011, HAEMATOL-HEMATOL J, V96, P1318, DOI 10.3324/haematol.2011.041053; NISHIKAWA SI, 1988, EUR J IMMUNOL, V18, P1767, DOI 10.1002/eji.1830181117; Nojima T, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1475; O'Donnell KA, 2018, CURR OPIN GENET DEV, V49, P85, DOI 10.1016/j.gde.2018.03.006; Ortega-Molina A, 2015, NAT MED, V21, P1199, DOI 10.1038/nm.3943; Parikh BA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116484; Pasqualucci L, 2004, BLOOD, V104, p428A, DOI 10.1182/blood.V104.11.1528.1528; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Pasqualucci L., 2021, FRONT IMMUNOL, V12, DOI [10.3389/fimmu.2021.710711, DOI 10.3389/FIMMU.2021.710711]; Pasqualucci L, 2008, NAT GENET, V40, P108, DOI 10.1038/ng.2007.35; Peng H, 1997, HISTOPATHOLOGY, V30, P425, DOI 10.1046/j.1365-2559.1997.5450786.x; Perez-Chacon G., 2012, CHRONIC LYMPHOCYTIC; Perez-Chacon G, 2012, J IMMUNOL, V189, P1053, DOI 10.4049/jimmunol.1200814; Petti AA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11591-1; Pfeifer M, 2013, CELL CYCLE, V12, P3347, DOI 10.4161/cc.26575; PIERCE JH, 1986, CLIN HAEMATOL, V15, P573; Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014; Pyrz M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-86; Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003; Rahrmann EP, 2019, MOL CANCER RES, V17, P567, DOI 10.1158/1541-7786.MCR-18-0582; Rajan SS, 2019, BLOOD ADV, V3, P1788, DOI 10.1182/bloodadvances.2018025247; Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021; Refaeli Y, 2008, PLOS BIOL, V6, P1208, DOI 10.1371/journal.pbio.0060152; Reimer J, 2017, HAEMATOLOGICA, V102, P1558, DOI 10.3324/haematol.2017.164046; Rodriguez-Hernandez G, 2017, CANCER RES, V77, P4365, DOI 10.1158/0008-5472.CAN-17-0701; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; Saito Y, 2020, TRENDS IMMUNOL, V41, P706, DOI 10.1016/j.it.2020.06.004; Sander S, 2012, CANCER CELL, V22, P167, DOI 10.1016/j.ccr.2012.06.012; Sarver AL, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-154; Scheicher R, 2015, BLOOD, V125, P90, DOI 10.1182/blood-2014-06-584417; Scheijen B, 2004, ONCOGENE, V23, P3338, DOI 10.1038/sj.onc.1207456; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt CA, 2001, BLOOD CELL MOL DIS, V27, P206, DOI 10.1006/bcmd.2000.0372; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; Scott CL, 2004, J CELL BIOL, V164, P89, DOI 10.1083/jcb.200310041; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shah S, 2013, NAT GENET, V45, P1226, DOI 10.1038/ng.2754; Sheppard RD, 1998, ONCOGENE, V17, P2073, DOI 10.1038/sj.onc.1202125; Sherman E, 2017, MOL THER-METH CLIN D, V4, P39, DOI 10.1016/j.omtm.2016.11.002; Shin MS, 2004, CANCER RES, V64, P4419, DOI 10.1158/0008-5472.CAN-03-3885; SHINTO Y, 1995, ONCOGENE, V11, P1729; Slaymaker IM, 2016, SCIENCE, V351, P84, DOI 10.1126/science.aad5227; Smeenk L, 2017, EMBO J, V36, P718, DOI 10.15252/embj.201695495; Sorensen AB, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-46; Sorensen KD, 2007, VIROLOGY, V362, P179, DOI 10.1016/j.virol.2006.12.016; Stripecke R, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201708662; Sungalee S, 2014, J CLIN INVEST, V124, P5337, DOI 10.1172/JCI72415; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Suzuki T, 2006, EMBO J, V25, P3422, DOI 10.1038/sj.emboj.7601215; Tarantul VZ, 2004, INT REV CYTOL, V236, P123, DOI 10.1016/S0074-7696(04)36004-3; Ten Hacken E, 2019, BLOOD, V134, DOI 10.1182/blood-2019-127673; Thome KC, 1997, J VIROL, V71, P8149, DOI 10.1128/JVI.71.11.8149-8156.1997; Tsuruyama T, 2002, P NATL ACAD SCI USA, V99, P8253, DOI 10.1073/pnas.112202899; Tsuruyama T, 2010, J LEUKOCYTE BIOL, V88, P107, DOI 10.1189/jlb.1109748; Uren AG, 2008, CELL, V133, P727, DOI 10.1016/j.cell.2008.03.021; van der Weyden L, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1586-1; van der Weyden L, 2011, BLOOD, V118, P1041, DOI 10.1182/blood-2011-02-338848; van Galen P, 2019, CELL, V176, P1265, DOI 10.1016/j.cell.2019.01.031; van Oosterwijk JG, 2017, P NATL ACAD SCI USA, V114, P7420, DOI 10.1073/pnas.1707292114; Chu VT, 2016, P NATL ACAD SCI USA, V113, P12514, DOI 10.1073/pnas.1613884113; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Verma D, 2020, LEUKEMIA, V34, P1540, DOI 10.1038/s41375-019-0674-7; Vicente-Duenas C, 2020, BLOOD, V136, P2003, DOI 10.1182/blood.2019004381; von Muenchow L, 2017, EUR J IMMUNOL, V47, P394, DOI 10.1002/eji.201646638; Walton RT, 2020, SCIENCE, V368, P290, DOI 10.1126/science.aba8853; Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025; Wang PY, 2008, BLOOD, V112, P4184, DOI 10.1182/blood-2008-02-142190; Weber J, 2020, NAT REV CANCER, V20, P573, DOI 10.1038/s41568-020-0275-9; Weber J, 2019, CURR OPIN GENET DEV, V54, P88, DOI 10.1016/j.gde.2019.04.001; Weber J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09180-3; Webster P, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05069-9; Weiser KC, 2007, MAMM GENOME, V18, P709, DOI 10.1007/s00335-007-9060-2; Weiss BM, 2009, BLOOD, V113, P5418, DOI 10.1182/blood-2008-12-195008; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0; Williams RT, 2006, P NATL ACAD SCI USA, V103, P6688, DOI 10.1073/pnas.0602030103; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; Wolf I, 2017, EUR J IMMUNOL, V47, P911, DOI 10.1002/eji.201746937; Wolf I, 2016, EUR J IMMUNOL, V46, P2555, DOI 10.1002/eji.201646419; Wu JQ, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00941-y; YAMADA Y, 1994, CANCER RES, V54, P403; Yang H, 2013, CELL, V154, P1370, DOI 10.1016/j.cell.2013.08.022; Yao X, 2017, CELL RES, V27, P801, DOI 10.1038/cr.2017.76; Yazdanparast S, 2015, GENET MOL RES, V14, P17768, DOI 10.4238/2015.December.22.1; Yin MM, 2019, BLOOD, V133, P2610, DOI 10.1182/blood.2018864173; You MJ, 2010, CONTEMP HEMATOL, P583, DOI 10.1007/978-1-60761-384-8_36; Young RM, 2009, BLOOD, V113, P2508, DOI 10.1182/blood-2008-05-158618; Yudovich D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-79724-x; Zaborsky N, 2019, LEUKEMIA, V33, P957, DOI 10.1038/s41375-018-0260-4; Zanesi N, 2013, BLOOD, V121, P4355, DOI 10.1182/blood-2013-02-486035; Zapata JM, 2004, P NATL ACAD SCI USA, V101, P16600, DOI 10.1073/pnas.0407541101; Zhang JF, 2019, COMPUT STRUCT BIOTEC, V17, P1171, DOI 10.1016/j.csbj.2019.07.015; Zhao RQ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01025; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720	269	1	1	0	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 13	2021	12								670280	10.3389/fimmu.2021.670280	http://dx.doi.org/10.3389/fimmu.2021.670280			26	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UT9RK	34484175	Green Published, gold			2022-12-18	WOS:000698444800001
J	Zhang, YF; Chen, TJ; Zeng, HK; Yang, XJ; Xu, QX; Zhang, YX; Chen, Y; Wang, MH; Zhu, Y; Lan, CH; Wang, QL; Tang, HP; Zhang, Y; Wang, CR; Xie, WX; Ma, CY; Guan, JJ; Guo, SX; Chen, S; Yang, W; Wei, L; Ren, J; Yu, XQ; Zhang, ZH				Zhang, Yanfang; Chen, Tianjian; Zeng, Huikun; Yang, Xiujia; Xu, Qingxian; Zhang, Yanxia; Chen, Yuan; Wang, Minhui; Zhu, Yan; Lan, Chunhong; Wang, Qilong; Tang, Haipei; Zhang, Yan; Wang, Chengrui; Xie, Wenxi; Ma, Cuiyu; Guan, Junjie; Guo, Shixin; Chen, Sen; Yang, Wei; Wei, Lai; Ren, Jian; Yu, Xueqing; Zhang, Zhenhai			RAPID: A Rep-Seq Dataset Analysis Platform With an Integrated Antibody Database	FRONTIERS IN IMMUNOLOGY			English	Article						antibody database; Rep-Seq; comparative analysis; antibody annotation; public clone	CELL-RECEPTOR REPERTOIRE; MONOCLONAL-ANTIBODIES; IMMUNOGLOBULIN; SIGNATURES; DIVERSITY; RESPONSES; SEQUENCE; DISPLAY	The antibody repertoire is a critical component of the adaptive immune system and is believed to reflect an individual's immune history and current immune status. Delineating the antibody repertoire has advanced our understanding of humoral immunity, facilitated antibody discovery, and showed great potential for improving the diagnosis and treatment of disease. However, no tool to date has effectively integrated big Rep-seq data and prior knowledge of functional antibodies to elucidate the remarkably diverse antibody repertoire. We developed a Rep-seq dataset Analysis Platform with an Integrated antibody Database (RAPID; https://rapid.zzhlab.org/), a free and web-based tool that allows researchers to process and analyse Rep-seq datasets. RAPID consolidates 521 WHO-recognized therapeutic antibodies, 88,059 antigen- or disease-specific antibodies, and 306 million clones extracted from 2,449 human IGH Rep-seq datasets generated from individuals with 29 different health conditions. RAPID also integrates a standardized Rep-seq dataset analysis pipeline to enable users to upload and analyse their datasets. In the process, users can also select set of existing repertoires for comparison. RAPID automatically annotates clones based on integrated therapeutic and known antibodies, and users can easily query antibodies or repertoires based on sequence or optional keywords. With its powerful analysis functions and rich set of antibody and antibody repertoire information, RAPID will benefit researchers in adaptive immune studies.</p>	[Zhang, Yanfang; Zeng, Huikun; Yang, Xiujia; Zhang, Yanxia; Wang, Minhui; Zhu, Yan; Lan, Chunhong; Xie, Wenxi; Ma, Cuiyu; Guan, Junjie; Zhang, Zhenhai] Southern Med Univ, Nanfang Hosp, Ctr Kidney Dis,Natl Clin Res, Div Nephrol,State Key Lab Organ Failure Res, Guangzhou, Peoples R China; [Zhang, Yanfang; Zeng, Huikun; Yang, Xiujia; Zhang, Yanxia; Zhu, Yan; Zhang, Yan; Wang, Chengrui; Xie, Wenxi; Ma, Cuiyu; Guan, Junjie; Chen, Sen; Zhang, Zhenhai] Southern Med Univ, Sch Basic Med Sci, Dept Bioinformat, Guangzhou, Peoples R China; [Zhang, Yanfang; Zeng, Huikun; Yang, Xiujia; Chen, Yuan; Lan, Chunhong; Wang, Qilong; Tang, Haipei; Zhang, Zhenhai] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Ctr Precis Med, Guangzhou, Peoples R China; [Zhang, Yanfang; Zeng, Huikun; Yang, Xiujia; Zhang, Zhenhai] Southern Med Univ, Guangdong Hong Kong Macao Greater Bay Area Ctr Br, Key Lab Mental Hlth, Minist Educ, Guangzhou, Peoples R China; [Zhang, Yanfang; Zeng, Huikun; Yang, Xiujia; Yu, Xueqing; Zhang, Zhenhai] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Hong Kong Joint Lab Immunol & Genet Kid, Guangzhou, Peoples R China; [Chen, Tianjian; Xu, Qingxian; Ren, Jian] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Sch Life Sci,State Key Lab Oncol South China, Guangzhou, Peoples R China; [Wang, Minhui] Hainan Gen Hosp, Dept Nephrol, Haikou, Hainan, Peoples R China; [Wang, Minhui] Hainan Med Coll, Hainan Affiliated Hosp, Haikou, Hainan, Peoples R China; [Guo, Shixin; Wei, Lai] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China; [Yang, Wei] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China; [Yu, Xueqing] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Div Nephrol, Guangzhou, Peoples R China	Southern Medical University - China; Southern Medical University - China; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Southern Medical University - China; Guangdong Academy of Medical Sciences & Guangdong General Hospital; State Key Lab Oncology South China; Sun Yat Sen University; Hainan Medical University; Sun Yat Sen University; Southern Medical University - China; Guangdong Academy of Medical Sciences & Guangdong General Hospital	Zhang, ZH (corresponding author), Southern Med Univ, Nanfang Hosp, Ctr Kidney Dis,Natl Clin Res, Div Nephrol,State Key Lab Organ Failure Res, Guangzhou, Peoples R China.; Zhang, ZH (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Bioinformat, Guangzhou, Peoples R China.; Zhang, ZH (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Ctr Precis Med, Guangzhou, Peoples R China.; Zhang, ZH (corresponding author), Southern Med Univ, Guangdong Hong Kong Macao Greater Bay Area Ctr Br, Key Lab Mental Hlth, Minist Educ, Guangzhou, Peoples R China.; Yu, XQ; Zhang, ZH (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Hong Kong Joint Lab Immunol & Genet Kid, Guangzhou, Peoples R China.; Ren, J (corresponding author), Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Sch Life Sci,State Key Lab Oncol South China, Guangzhou, Peoples R China.; Yu, XQ (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Div Nephrol, Guangzhou, Peoples R China.	renjian@sysucc.org.cn; yuxueqing@gdph.org.cn; zhangzhenhai@gdph.org.cn	Zhang, Zhenhai/GRX-5887-2022; Ren, Jian/D-3270-2011; xie, wenxi/HEJ-0264-2022	Zhang, Zhenhai/0000-0002-4310-0525; Ren, Jian/0000-0002-4161-1292; Yang, Xiujia/0000-0003-4036-4995	National Natural Science Foundation of China (NSFC); NSFC Projects of International Cooperation and Exchanges of NSFC; Guangdong-Hong Kong-Macao-Joint Labs Program from Guangdong Science and Technology; Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); NSFC Projects of International Cooperation and Exchanges of NSFC; Guangdong-Hong Kong-Macao-Joint Labs Program from Guangdong Science and Technology; Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program	This work was supported by the National Natural Science Foundation of China (NSFC) (31771479 to ZZ), NSFC Projects of International Cooperation and Exchanges of NSFC (61661146004 to ZZ), the Guangdong-Hong Kong-Macao-Joint Labs Program from Guangdong Science and Technology (2019B121205005 to XQY), and the Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2017BT01S131 to ZZ).	Alamyar Eltaf, 2012, Methods Mol Biol, V882, P569, DOI 10.1007/978-1-61779-842-9_32; Amid C, 2020, NUCLEIC ACIDS RES, V48, pD70, DOI 10.1093/nar/gkz1063; Bashford-Rogers RJM, 2019, NATURE, V574, P122, DOI 10.1038/s41586-019-1595-3; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; Burckert JP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01834; Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025; Corrie BD, 2018, IMMUNOL REV, V284, P24, DOI 10.1111/imr.12666; Cowell LG, 2020, CANCER RES, V80, P643, DOI 10.1158/0008-5472.CAN-19-1457; Daberdaku S, 2019, BIOINFORMATICS, V35, P1870, DOI 10.1093/bioinformatics/bty918; Dunbar J, 2016, BIOINFORMATICS, V32, P298, DOI 10.1093/bioinformatics/btv552; Eroshkin AM, 2014, NUCLEIC ACIDS RES, V42, pD1133, DOI 10.1093/nar/gkt1083; Georgiou G, 2014, NAT BIOTECHNOL, V32, P158, DOI 10.1038/nbt.2782; Giudicelli V, 2006, NUCLEIC ACIDS RES, V34, pD781, DOI 10.1093/nar/gkj088; HOOKS MA, 1991, PHARMACOTHERAPY, V11, P26; Huang C, 2019, J AUTOIMMUN, V97, P100, DOI 10.1016/j.jaut.2018.10.018; IJspeert H, 2017, J IMMUNOL, V198, P4156, DOI 10.4049/jimmunol.1601921; Jackson KJL, 2014, CELL HOST MICROBE, V16, P105, DOI 10.1016/j.chom.2014.05.013; Joyce MG, 2016, CELL, V166, P609, DOI 10.1016/j.cell.2016.06.043; Kempeni J, 2000, ANN RHEUM DIS, V59, P44; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kovaltsuk A, 2018, J IMMUNOL, V201, P2502, DOI 10.4049/jimmunol.1800708; Leaman R, 2016, BIOINFORMATICS, V32, P2839, DOI 10.1093/bioinformatics/btw343; Li J, 2006, P NATL ACAD SCI USA, V103, P3557, DOI 10.1073/pnas.0511285103; Liberis E, 2018, BIOINFORMATICS, V34, P2944, DOI 10.1093/bioinformatics/bty305; Liu X, 2019, ANN RHEUM DIS, V78, P1070, DOI 10.1136/annrheumdis-2019-215442; Lu RM, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0592-z; Margreitter C, 2018, NUCLEIC ACIDS RES, V46, pW264, DOI 10.1093/nar/gky276; Montague Z., 2020, DYNAMICS B CELL REPE, P1, DOI [10.1101/2020.07.13.20153114, DOI 10.1101/2020.07.13.20153114]; Murphy K WC., 2017, JANEWAYS IMMUNOBIOLO; Nielsen SCA, 2020, CELL HOST MICROBE, V28, P516, DOI 10.1016/j.chom.2020.09.002; Raybould MIJ, 2020, NUCLEIC ACIDS RES, V48, pD383, DOI 10.1093/nar/gkz827; Reddy ST, 2010, NAT BIOTECHNOL, V28, P965, DOI 10.1038/nbt.1673; Robinson WH, 2015, NAT REV RHEUMATOL, V11, P171, DOI 10.1038/nrrheum.2014.220; Roskin KM, 2020, NAT IMMUNOL, V21, P199, DOI 10.1038/s41590-019-0581-0; Schramm CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00372; Schultheiss C, 2020, IMMUNITY, V53, P442, DOI 10.1016/j.immuni.2020.06.024; Setliff I, 2018, CELL HOST MICROBE, V23, P845, DOI 10.1016/j.chom.2018.05.001; Shoukat MS, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100192; Swindells MB, 2017, J MOL BIOL, V429, P356, DOI 10.1016/j.jmb.2016.08.019; Wilson PC, 2012, NAT REV IMMUNOL, V12, P709, DOI 10.1038/nri3285; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890; Wu XL, 2015, CELL, V161, P470, DOI 10.1016/j.cell.2015.03.004; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6; Yaari G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00358; Yang XJ, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109110; Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382; Yusim K., 2018, HIV MOL IMMUNOLOGY 2; Zhang W, 2020, BIOINFORMATICS, V36, P897, DOI 10.1093/bioinformatics/btz614; Zhang W, 2017, J IMMUNOL, V198, P3719, DOI 10.4049/jimmunol.1602039; Zhang YF, 2020, BRIEF BIOINFORM, V21, P1706, DOI 10.1093/bib/bbz092	52	1	1	3	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 13	2021	12								717496	10.3389/fimmu.2021.717496	http://dx.doi.org/10.3389/fimmu.2021.717496			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WV9TU	34484220	Green Published, gold			2022-12-18	WOS:000717572400001
J	Alves, E; McLeish, E; Blancafort, P; Coudert, JDD; Gaudieri, S				Alves, Eric; McLeish, Emily; Blancafort, Pilar; Coudert, Jerome D. D.; Gaudieri, Silvana			Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						NKG2D; CRISPR; precision medicine; NK cells; viral infection; cancer; immune evasion; immunotherapy	I-RELATED CHAIN; STRESS-INDUCED LIGAND; T-CELLS; NK CELLS; DOWN-REGULATION; CUTTING EDGE; INTRACELLULAR SEQUESTRATION; NATURAL CYTOTOXICITY; REGULATES EXPRESSION; GLYCOPROTEIN UL16	The activating immune receptor natural killer group member D (NKG2D) and its cognate ligands represent a fundamental surveillance system of cellular distress, damage or transformation. Signaling through the NKG2D receptor-ligand axis is critical for early detection of viral infection or oncogenic transformation and the presence of functional NKG2D ligands (NKG2D-L) is associated with tumor rejection and viral clearance. Many viruses and tumors have developed mechanisms to evade NKG2D recognition via transcriptional, post-transcriptional or post-translational interference with NKG2D-L, supporting the concept that circumventing immune evasion of the NKG2D receptor-ligand axis may be an attractive therapeutic avenue for antiviral therapy or cancer immunotherapy. To date, the complexity of the NKG2D receptor-ligand axis and the lack of specificity of current NKG2D-targeting therapies has not allowed for the precise manipulation required to optimally harness NKG2D-mediated immunity. However, with the discovery of clustered regularly interspaced short palindromic repeats (CRISPRs) and CRISPR-associated (Cas) proteins, novel opportunities have arisen in the realm of locus-specific gene editing and regulation. Here, we give a brief overview of the NKG2D receptor-ligand axis in humans and discuss the levels at which NKG2D-L are regulated and dysregulated during viral infection and oncogenesis. Moreover, we explore the potential for CRISPR-based technologies to provide novel therapeutic avenues to improve and maximize NKG2D-mediated immunity.	[Alves, Eric; Blancafort, Pilar; Gaudieri, Silvana] Univ Western Australia, Sch Human Sci, Perth, WA, Australia; [Alves, Eric; Blancafort, Pilar] Harry Perkins Inst Med Res, Canc Epigenet Lab, Perth, WA, Australia; [McLeish, Emily; Coudert, Jerome D. D.] Murdoch Univ, Ctr Mol Med & Innovat Therapeut, Perth, WA, Australia; [Blancafort, Pilar] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA; [Coudert, Jerome D. D.] Perron Inst Neurol & Translat Sci, Perth, WA, Australia; [Coudert, Jerome D. D.] Univ Notre Dame, Sch Med, Fremantle, WA, Australia; [Gaudieri, Silvana] Murdoch Univ, Inst Immunol & Infect Dis, Perth, WA, Australia; [Gaudieri, Silvana] Vanderbilt Univ, Med Ctr, Dept Med, Div Infect Dis, Nashville, TN USA	University of Western Australia; Harry Perkins Institute of Medical Research; Murdoch University; University of Texas System; University of Texas Health San Antonio; University of Notre Dame Australia; Murdoch University; Vanderbilt University	Alves, E (corresponding author), Univ Western Australia, Sch Human Sci, Perth, WA, Australia.; Alves, E (corresponding author), Harry Perkins Inst Med Res, Canc Epigenet Lab, Perth, WA, Australia.	eric.alves@research.uwa.edu.au	Alves, Eric/GLS-9991-2022; Coudert, Jerome D/B-2628-2008	Alves, Eric/0000-0002-6072-708X; Coudert, Jerome D/0000-0001-6081-8494; , Silvana/0000-0001-6873-0198; McLeish, Emily/0000-0001-6666-342X	Australian Government Research Training Program Scholarship at The University of Western Australia; BioZone PhD Scholarship at the University of Western Australia; Cancer Council WA PhD Top Up Scholarship; Australian Government Research Training Program Scholarship at Murdoch University; Australian Research Council Future Fellowship [FT130101767]; Cancer Council WA Research Fellowship; Wesfarmers Women's Cancers Fellowship; National Health and Medical Research Council [APP1187328, APP1109428, APP1165208, APP1147528, APP1130212, APP1148284]; National Institutes of Health [R01CA170370, R01DA036906]; National Breast Cancer Foundation and Cure Brain Cancer [NBCNBCF19-009]; US DOD Peer Reviewed Cancer Research Program [CA190006]	Australian Government Research Training Program Scholarship at The University of Western Australia(Australian Government); BioZone PhD Scholarship at the University of Western Australia; Cancer Council WA PhD Top Up Scholarship(Cancer Council Western Australia); Australian Government Research Training Program Scholarship at Murdoch University; Australian Research Council Future Fellowship(Australian Research Council); Cancer Council WA Research Fellowship(Cancer Council Western Australia); Wesfarmers Women's Cancers Fellowship; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Breast Cancer Foundation and Cure Brain Cancer; US DOD Peer Reviewed Cancer Research Program	EA is a recipient of an Australian Government Research Training Program Scholarship at The University of Western Australia, BioZone PhD Scholarship at the University of Western Australia and Cancer Council WA PhD Top Up Scholarship. EM is a recipient of an Australian Government Research Training Program Scholarship at Murdoch University. PB is a recipient of an Australian Research Council Future Fellowship (FT130101767), Cancer Council WA Research Fellowship and Wesfarmers Women's Cancers Fellowship. PB has support from the National Health and Medical Research Council (APP1187328, APP1109428, APP1165208, APP1147528 and APP1130212), the National Institutes of Health (R01CA170370 and R01DA036906), the National Breast Cancer Foundation and Cure Brain Cancer (NBCNBCF19-009), and the US DOD Peer Reviewed Cancer Research Program (CA190006). SG has support from the National Health and Medical Research Council (APP1148284).	Abudayyeh OO, 2016, SCIENCE, V353, DOI 10.1126/science.aaf5573; Aida K, 2002, IMMUNOGENETICS, V54, P439, DOI 10.1007/s00251-002-0485-1; Allez M, 2007, GASTROENTEROLOGY, V132, P2346, DOI 10.1053/j.gastro.2007.03.025; Alves E, 2021, MOL THER-METH CLIN D, V21, P592, DOI 10.1016/j.omtm.2021.04.009; Antoun A, 2010, HUM IMMUNOL, V71, P610, DOI 10.1016/j.humimm.2010.02.018; Anzai T, 2003, P NATL ACAD SCI USA, V100, P7708, DOI 10.1073/pnas.1230533100; Arai J, 2018, J GASTROEN HEPATOL, V33, P1075, DOI 10.1111/jgh.14029; Ashiru O, 2009, J VIROL, V83, P12345, DOI 10.1128/JVI.01175-09; BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; Bak RO, 2017, CELL REP, V20, P750, DOI 10.1016/j.celrep.2017.06.064; Raneros AB, 2015, GENES IMMUN, V16, P71, DOI 10.1038/gene.2014.58; Barber A, 2011, BLOOD, V117, P6571, DOI 10.1182/blood-2011-01-329417; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Baugh R, 2020, CANCERS, V12, DOI 10.3390/cancers12123827; Bauman Y, 2011, RNA BIOL, V8, P591, DOI 10.4161/rna.8.4.15587; Bauman Y, 2011, CELL HOST MICROBE, V9, P93, DOI 10.1016/j.chom.2011.01.008; Baumeister SH, 2019, CANCER IMMUNOL RES, V7, P100, DOI 10.1158/2326-6066.CIR-18-0307; Bazzone LE, 2019, MBIO, V10, DOI 10.1128/mBio.02734-18; Bedel R, 2011, CANCER RES, V71, P1615, DOI 10.1158/0008-5472.CAN-09-4540; Bennett NJ, 2010, J IMMUNOL, V185, P1093, DOI 10.4049/jimmunol.1000789; Berhani O, 2017, J IMMUNOL, V198, P3662, DOI 10.4049/jimmunol.1601589; Boissel N, 2006, J IMMUNOL, V176, P5108, DOI 10.4049/jimmunol.176.8.5108; Boontanrart MY, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107993; Borchers MT, 2006, AM J PHYSIOL-LUNG C, V291, pL222, DOI 10.1152/ajplung.00327.2005; Boutet P, 2009, J IMMUNOL, V182, P49, DOI 10.4049/jimmunol.182.1.49; Braun CJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007280; Bryceson YT, 2009, BLOOD, V114, P2657, DOI 10.1182/blood-2009-01-201632; Bryceson YT, 2006, BLOOD, V107, P159, DOI 10.1182/blood-2005-04-1351; Cao W, 2008, INT IMMUNOL, V20, P981, DOI 10.1093/intimm/dxn057; Carapito R, 2015, IMMUNOL REV, V267, P88, DOI 10.1111/imr.12328; Cebo C, 2006, J IMMUNOL, V176, P864, DOI 10.4049/jimmunol.176.2.864; Cerboni C, 2007, J GEN VIROL, V88, P242, DOI 10.1099/vir.0.82125-0; Chalupny NJ, 2003, BIOCHEM BIOPH RES CO, V305, P129, DOI 10.1016/S0006-291X(03)00714-9; Chang YH, 2013, CANCER RES, V73, P1777, DOI 10.1158/0008-5472.CAN-12-3558; Chitadze G, 2013, INT J CANCER, V133, P1557, DOI 10.1002/ijc.28174; Chylinski K, 2014, NUCLEIC ACIDS RES, V42, P6091, DOI 10.1093/nar/gku241; Correia MP, 2011, IMMUNOBIOLOGY, V216, P604, DOI 10.1016/j.imbio.2010.09.012; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4; Coudert JD, 2005, BLOOD, V106, P1711, DOI 10.1182/blood-2005-03-0918; Coudert JD, 2008, BLOOD, V111, P3571, DOI 10.1182/blood-2007-07-100057; Coudert JD, 2006, SEMIN CANCER BIOL, V16, P333, DOI 10.1016/j.semcancer.2006.07.008; Cox ST, 2016, HUM IMMUNOL, V77, P96, DOI 10.1016/j.humimm.2015.10.017; Cox ST, 2013, HUM IMMUNOL, V74, P775, DOI 10.1016/j.humimm.2013.01.030; Crane CA, 2014, P NATL ACAD SCI USA, V111, P12823, DOI 10.1073/pnas.1413933111; Currenti J, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008177; Dai ZP, 2009, J EXP MED, V206, P793, DOI 10.1084/jem.20081648; Das H, 2001, IMMUNITY, V15, P83, DOI 10.1016/S1074-7613(01)00168-6; Dias J, 2018, P NATL ACAD SCI USA, V115, pE11513, DOI 10.1073/pnas.1812273115; Dunn C, 2003, J EXP MED, V197, P1427, DOI 10.1084/jem.20022059; Eagle RA, 2006, HUM IMMUNOL, V67, P159, DOI 10.1016/j.humimm.2006.02.015; Eagle RA, 2009, EUR J IMMUNOL, V39, P3207, DOI 10.1002/eji.200939502; Eagle RA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004503; Eissmann P, 2010, J IMMUNOL, V184, P6901, DOI 10.4049/jimmunol.0903985; El Fatimy R, 2017, MOL THER, V25, P368, DOI 10.1016/j.ymthe.2016.11.004; Enk J, 2016, CELL REP, V17, P949, DOI 10.1016/j.celrep.2016.09.077; Espinoza JL, 2016, SCI REP-UK, V6, DOI 10.1038/srep39231; Esteso G, 2014, J IMMUNOL, V193, P1344, DOI 10.4049/jimmunol.1303441; Fasth AER, 2010, EUR J IMMUNOL, V40, P378, DOI 10.1002/eji.200939399; Fuertes MB, 2008, J IMMUNOL, V180, P4606, DOI 10.4049/jimmunol.180.7.4606; Fujita H, 2015, J HISTOCHEM CYTOCHEM, V63, P217, DOI 10.1369/0022155414563800; Garcia-Bloj B, 2016, ONCOTARGET, V7, P60535, DOI 10.18632/oncotarget.11142; Garrity D, 2005, P NATL ACAD SCI USA, V102, P7641, DOI 10.1073/pnas.0502439102; Gaudieri S, 1999, GENOME RES, V9, P541; Gaudieri S, 1997, J MOL EVOL, V44, pS147, DOI 10.1007/PL00000064; Gaudieri S, 1997, IMMUNOGENETICS, V45, P209, DOI 10.1007/s002510050191; Gavlovsky PJ, 2016, J IMMUNOL, V197, P736, DOI 10.4049/jimmunol.1501416; Ghadially H, 2017, BRIT J CANCER, V116, P1208, DOI 10.1038/bjc.2017.79; Ghasemi R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12878; Gomez-Cadena A, 2021, CELL MOL IMMUNOL, V18, P484, DOI 10.1038/s41423-020-00596-2; Gowen BG, 2015, ELIFE, V4, DOI 10.7554/eLife.08474; Groh V, 2003, P NATL ACAD SCI USA, V100, P9452, DOI 10.1073/pnas.1632807100; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; Groh V, 1998, SCIENCE, V279, P1737, DOI 10.1126/science.279.5357.1737; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; Guan Y, 2016, ONCOTARGET, V7, P56107, DOI 10.18632/oncotarget.11271; Guilloton F, 2005, LEUKEMIA, V19, P2206, DOI 10.1038/sj.leu.2403952; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Hayashi T, 2006, CANCER RES, V66, P563, DOI 10.1158/0008-5472.CAN-05-2776; Hedlund M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016899; Heinemann A, 2012, CANCER RES, V72, P460, DOI 10.1158/0008-5472.CAN-11-1977; Herrmann F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020913; Herzig E, 2019, CELL, V179, P880, DOI 10.1016/j.cell.2019.10.002; Horng T, 2007, NAT IMMUNOL, V8, P1345, DOI 10.1038/ni1524; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; Hu Z, 2015, J CLIN INVEST, V125, P425, DOI 10.1172/JCI78206; Hue S, 2004, IMMUNITY, V21, P367, DOI 10.1016/j.immuni.2004.06.018; Isernhagen A, 2016, IMMUNOGENETICS, V68, P109, DOI 10.1007/s00251-015-0884-8; Isernhagen A, 2015, EMBO MOL MED, V7, P1480, DOI 10.15252/emmm.201505246; Iwaszko M, 2020, PHARMACOGENOMICS J, V20, P760, DOI 10.1038/s41397-020-0164-3; Jiang Q, 2014, RNA BIOL, V11, P1243, DOI 10.1080/15476286.2014.996067; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Kaiser BK, 2007, NATURE, V447, P482, DOI 10.1038/nature05768; Kararoudi MN, 2018, JOVE-J VIS EXP, DOI 10.3791/58237; Karnes JH, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8708; Kim Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00960; Klann TS, 2017, NAT BIOTECHNOL, V35, P561, DOI 10.1038/nbt.3853; Klose CSN, 2014, CELL, V157, P340, DOI 10.1016/j.cell.2014.03.030; Kohga K, 2010, HEPATOLOGY, V51, P1264, DOI 10.1002/hep.23456; Komatsu-Wakui M, 1999, IMMUNOGENETICS, V49, P620, DOI 10.1007/s002510050658; Komatsu-Wakui M, 2001, TISSUE ANTIGENS, V57, P1, DOI 10.1034/j.1399-0039.2001.057001001.x; Kong Y, 2009, BLOOD, V114, P310, DOI 10.1182/blood-2008-12-196287; Kretzmann JA, 2019, CHEM SCI, V10, P7718, DOI 10.1039/c9sc01432b; Kumar V, 2011, NAT GENET, V43, P455, DOI 10.1038/ng.809; Kuylenstierna C, 2011, EUR J IMMUNOL, V41, P1913, DOI 10.1002/eji.200940278; Lanier LL, 2015, CANCER IMMUNOL RES, V3, P575, DOI 10.1158/2326-6066.CIR-15-0098; Le Bourhis L, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003681; Lee JC, 2004, J IMMUNOL, V172, P7335, DOI 10.4049/jimmunol.172.12.7335; Lee JH, 2013, MOL CELL, V49, P668, DOI 10.1016/j.molcel.2012.12.004; Lee YS, 2019, MOL MED REP, V20, P3301, DOI 10.3892/mmr.2019.10583; LEELAYUWAT C, 1994, IMMUNOGENETICS, V40, P339, DOI 10.1007/BF01246675; Li PW, 2001, NAT IMMUNOL, V2, P443, DOI 10.1038/87757; Lin D, 2012, J BIOL CHEM, V287, P4299, DOI 10.1074/jbc.M111.282152; Liu G, 2010, J IMMUNOL, V184, P3346, DOI 10.4049/jimmunol.0903789; Lopez-Cobo S, 2015, IMMUNOLOGY, V146, P70, DOI 10.1111/imm.12482; Lu Y, 2020, NAT MED, V26, P732, DOI 10.1038/s41591-020-0840-5; Lucas M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25559-6; Luo ZH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1229-5; Maasho K, 2005, J IMMUNOL, V174, P4480, DOI 10.4049/jimmunol.174.8.4480; Magaret A, 2016, GENES IMMUN, V17, P412, DOI 10.1038/gene.2016.42; Matusali G, 2013, FASEB J, V27, P2440, DOI 10.1096/fj.12-223057; McCarty NS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15053-x; Meresse B, 2004, IMMUNITY, V21, P357, DOI 10.1016/j.immuni.2004.06.020; Molinero LL, 2004, J IMMUNOL, V173, P5583, DOI 10.4049/jimmunol.173.9.5583; Molinero LL, 2003, J LEUKOCYTE BIOL, V73, P815, DOI 10.1189/jlb.0602329; Molinero LL, 2002, J LEUKOCYTE BIOL, V71, P791; Moses C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68257-y; Moses C, 2019, MOL THER-NUCL ACIDS, V14, P287, DOI 10.1016/j.omtn.2018.12.003; Nachmani D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5186; Nachmani D, 2009, CELL HOST MICROBE, V5, P376, DOI 10.1016/j.chom.2009.03.003; Nagai Y, 2012, IMMUNOLOGY, V136, P103, DOI 10.1111/j.1365-2567.2012.03565.x; Najm FJ, 2018, NAT BIOTECHNOL, V36, P179, DOI 10.1038/nbt.4048; Nanbakhsh A, 2014, BLOOD, V123, P3585, DOI 10.1182/blood-2013-11-536219; Nolting A, 2010, VIROLOGY, V406, P12, DOI 10.1016/j.virol.2010.05.014; O'Geen H, 2017, NUCLEIC ACIDS RES, V45, P9901, DOI 10.1093/nar/gkx578; Okita R, 2012, J IMMUNOL, V188, P2136, DOI 10.4049/jimmunol.1102237; Peraldi MN, 2009, J IMMUNOL, V182, P1696, DOI 10.4049/jimmunol.182.3.1696; Perez C, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0531-2; Poggi A, 2004, CANCER RES, V64, P9172, DOI 10.1158/0008-5472.CAN-04-2417; Pomeroy EJ, 2020, MOL THER, V28, P52, DOI 10.1016/j.ymthe.2019.10.009; Qi LS, 2013, CELL, V152, P1173, DOI 10.1016/j.cell.2013.02.022; Radaev S, 2001, IMMUNITY, V15, P1039, DOI 10.1016/S1074-7613(01)00241-2; Raulet DH, 2013, ANNU REV IMMUNOL, V31, P413, DOI 10.1146/annurev-immunol-032712-095951; Rha MS, 2020, J HEPATOL, V73, P640, DOI 10.1016/j.jhep.2020.03.033; Riethmueller S, 2016, SCI REP-UK, V6, DOI 10.1038/srep25550; Rincon-Orozco B, 2005, J IMMUNOL, V175, P2144, DOI 10.4049/jimmunol.175.4.2144; Romphruk AV, 2009, IMMUNOGENETICS, V61, P611, DOI 10.1007/s00251-009-0394-7; Rosen DB, 2004, J IMMUNOL, V173, P2470, DOI 10.4049/jimmunol.173.4.2470; Roy S, 2008, J IMMUNOL, V180, P1729, DOI 10.4049/jimmunol.180.3.1729; Salih HR, 2002, J IMMUNOL, V169, P4098, DOI 10.4049/jimmunol.169.8.4098; Salome B, 2019, BLOOD ADV, V3, P3674, DOI 10.1182/bloodadvances.2018030478; Santos-Moreno J, 2020, BIOCHEM SOC T, V48, P1979, DOI 10.1042/BST20200020; Schary Y, 2020, EUR HEART J, V41, P3658; Schmiedel D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02040; Schmiedel D, 2016, ELIFE, V5, DOI 10.7554/eLife.13426; Schneider T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09769-8; Sekiba K, 2017, BIOCHEM BIOPH RES CO, V486, P521, DOI 10.1016/j.bbrc.2017.03.076; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Shen JY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.158; Shiraishi K, 2016, J GASTROENTEROL, V51, P1101, DOI 10.1007/s00535-016-1197-x; Shum BP, 2002, J IMMUNOL, V168, P240, DOI 10.4049/jimmunol.168.1.240; Soriani A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1264564; Soriani A, 2014, J IMMUNOL, V193, P950, DOI 10.4049/jimmunol.1400271; Stadtmauer EA, 2020, SCIENCE, V367, P1001, DOI 10.1126/science.aba7365; Steinle A, 2001, IMMUNOGENETICS, V53, P279, DOI 10.1007/s002510100325; Stern-Ginossar N, 2008, NAT IMMUNOL, V9, P1065, DOI 10.1038/ni.1642; Stern-Ginossar N, 2007, SCIENCE, V317, P376, DOI 10.1126/science.1140956; Sun DH, 2011, CELL BIOL INT, V35, P569, DOI 10.1042/CBI20100431; Sutherland CL, 2002, J IMMUNOL, V168, P671, DOI 10.4049/jimmunol.168.2.671; Sutherland CL, 2006, BLOOD, V108, P1313, DOI 10.1182/blood-2005-11-011320; Tan YT, 2020, HAEMATOLOGICA, V105, pE232, DOI 10.3324/haematol.2019.229013; Textor S, 2011, CANCER RES, V71, P5998, DOI 10.1158/0008-5472.CAN-10-3211; Thakore PI, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04048-4; Thakore PI, 2015, NAT METHODS, V12, P1143, DOI 10.1038/nmeth.3630; Thomas M, 2008, P NATL ACAD SCI USA, V105, P1656, DOI 10.1073/pnas.0707883105; Tong HV, 2013, J VIRAL HEPATITIS, V20, P687, DOI 10.1111/jvh.12089; Tsukerman P, 2012, CANCER RES, V72, P5463, DOI 10.1158/0008-5472.CAN-11-2671; Venkataraman GM, 2007, J IMMUNOL, V178, P961, DOI 10.4049/jimmunol.178.2.961; Viaud S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004942; Waldhauer I, 2008, CANCER RES, V68, P6368, DOI 10.1158/0008-5472.CAN-07-6768; Wang GC, 2019, NAT IMMUNOL, V20, P1494, DOI 10.1038/s41590-019-0500-4; Wang H, 2017, CANCER LETT, V385, P137, DOI 10.1016/j.canlet.2016.10.033; Wang XW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07405-5; Welte SA, 2003, EUR J IMMUNOL, V33, P194, DOI 10.1002/immu.200390022; Wolpert F, 2014, NEURO-ONCOLOGY, V16, P382, DOI 10.1093/neuonc/not232; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730; Xie BW, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101189; Yadav D, 2009, J IMMUNOL, V182, P39, DOI 10.4049/jimmunol.182.1.39; Yadav SK, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2367-6; Yamamoto K, 2001, BBA-GEN SUBJECTS, V1526, P10, DOI 10.1016/S0304-4165(01)00099-X; Zetsche B, 2015, CELL, V163, P759, DOI 10.1016/j.cell.2015.09.038; Zhan HJ, 2018, ACS SYNTH BIOL, V7, P1798, DOI 10.1021/acssynbio.8b00202; Zhang L, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1112-1; Zhang T, 2005, BLOOD, V106, P1544, DOI 10.1182/blood-2004-11-4365; Zhang XY, 2016, NAT GENET, V48, P176, DOI 10.1038/ng.3470; Zhao YC, 2014, SCI REP-UK, V4, DOI 10.1038/srep03943; Zingoni A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00476	196	1	1	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 12	2021	12								712722	10.3389/fimmu.2021.712722	http://dx.doi.org/10.3389/fimmu.2021.712722			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UI7ID	34456921	gold, Green Published			2022-12-18	WOS:000690775000001
J	Chen, ZY; Na, H; Wu, AP				Chen, Ziyi; Na, Han; Wu, Aiping			ImmuCellDB: An Indicative Database of Immune Cell Composition From Different Tissues and Disease Conditions in Mouse and Human	FRONTIERS IN IMMUNOLOGY			English	Article						immune cell; deconvolution; human; mouse; transcriptome; database		Immune cell composition is highly divergent across different tissues and diseases. A comprehensive resource of tissue immune cells across different conditions in mouse and human will thus provide great understanding of the immune microenvironment of many diseases. Recently, computational methods for estimating immune cell abundance from tissue transcriptome data have been developed and are now widely used. Using these computational tools, large-scale estimation of immune cell composition across tissues and conditions should be possible using gene expression data collected from public databases. In total, 266 tissue types and 706 disease types in humans, as well as 143 tissue types and 61 disease types, and 206 genotypes in mouse had been included in a database we have named ImmuCellDB (http://wap-lab.org:3200/ImmuCellDB/). In ImmuCellDB, users can search and browse immune cell proportions based on tissues, disease or genotype in mouse or humans. Additionally, the variation and correlation of immune cell abundance and gene expression level between different conditions can be compared and viewed in this database. We believe that ImmuCellDB provides not only an indicative view of tissue-dependent or disease-dependent immune cell profiles, but also represents an easy way to pre-determine immune cell abundance and gene expression profiles for specific situations.	[Chen, Ziyi; Na, Han; Wu, Aiping] Chinese Acad Med Sci & Peking Union Med Coll, Inst Syst Med, Beijing, Peoples R China; [Chen, Ziyi; Na, Han; Wu, Aiping] Suzhou Inst Syst Med, Suzhou, Peoples R China; [Chen, Ziyi] Nanjing Univ Chinese Med, Dept Infect Dis, Hosp Nanjing 2, Affiliated Hosp, Nanjing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Nanjing University of Chinese Medicine	Wu, AP (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Syst Med, Beijing, Peoples R China.; Wu, AP (corresponding author), Suzhou Inst Syst Med, Suzhou, Peoples R China.	wap@ism.cams.cn		Wu, Aiping/0000-0002-5869-651X	The National Key Plan for Scientific Research and Development of China	The National Key Plan for Scientific Research and Development of China	Funding This work was supported by: 1 The National Key Plan for Scientific Research and Development of China (2016YFD0500301), 2 The CAMS Initiative for Innovative Medicine (2016-I2M-1-005), 3 The Six-talent Peaks Project in the Jiangsu Province (SWYY-169), 4 The~Open Project Program of the National Laboratory of Pattern Recognition (NLPR) (201900004), 5 The Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2018RC310022), 6 Central Public-Interest Scientific Institution Basal Research Fund (2016ZX310195, 2017PT31026 and 2018PT31016).	Abdelaal T, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1795-z; Ali HR, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002194; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Bhattacharya S, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.15; Cabral-Marques O, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02742; Chen ZY, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbaa358; Chen ZY, 2020, BIOINFORMATICS, V36, P819, DOI 10.1093/bioinformatics/btz672; Chen ZY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01286; Chen ZY, 2017, SCI REP-UK, V7, DOI 10.1038/srep40508; Cobos FA, 2018, BIOINFORMATICS, V34, P1969, DOI 10.1093/bioinformatics/bty019; Duraiyan J, 2012, J PHARM BIOALLIED SC, V4, pS307, DOI 10.4103/0975-7406.100281; Gomes T, 2019, TRENDS IMMUNOL, V40, P1011, DOI 10.1016/j.it.2019.09.004; Harrison PF, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1674-7; Hartmann FJ, 2020, NAT REV RHEUMATOL, V16, P87, DOI 10.1038/s41584-019-0338-z; Li HM, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00392; McClanahan F, 2015, BLOOD, V126, P212, DOI 10.1182/blood-2015-02-626754; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Onuchic V, 2016, CELL REP, V17, P2075, DOI 10.1016/j.celrep.2016.10.057; Spidlen J, 2012, CYTOM PART A, V81A, P727, DOI 10.1002/cyto.a.22106; Tisoncik-Go J, 2016, CELL HOST MICROBE, V19, P254, DOI 10.1016/j.chom.2016.01.002; Zhu YL, 2008, BIOINFORMATICS, V24, P2798, DOI 10.1093/bioinformatics/btn520	21	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 12	2021	12								670070	10.3389/fimmu.2021.670070	http://dx.doi.org/10.3389/fimmu.2021.670070			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	WU5IG	34456903	gold, Green Published			2022-12-18	WOS:000716578000001
J	Dias, AA; Silva, CADE; da Silva, CO; Linhares, NRC; Santos, JPS; Vivarini, AD; Marques, MAD; Rosa, PS; Lopes, UG; Berredo-Pinho, M; Pessolani, MCV				Dias, Andre Alves; de Matos e Silva, Carlos Adriano; da Silva, Camila Oliveira; Cardoso Linhares, Natasha Ribeiro; Sousa Santos, Joao Pedro; Vivarini, Aislan de Carvalho; de Mello Marques, Maria Angela; Rosa, Patricia Sammarco; Lopes, Ulisses Gazos; Berredo-Pinho, Marcia; Vidal Pessolani, Maria Cristina			TLR-9 Plays a Role in Mycobacterium leprae-Induced Innate Immune Activation of A549 Alveolar Epithelial Cells	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacterium leprae; Toll-like receptor 9 (TLR-9); extracellular DNA; histone-like protein (Hlp); respiratory epithelial cells; innate immune response; chemokines	DNA-BINDING PROTEIN-1; ADHESION MOLECULE EXPRESSION; HUMAN BETA-DEFENSIN-2; ANTIMICROBIAL PEPTIDES; TUBERCULOSIS INFECTION; LAMININ-BINDING; DENDRITIC CELLS; II CELLS; TRANSCRIPTION; IDENTIFICATION	The respiratory tract is considered the main port of entry of Mycobacterium leprae, the causative agent of leprosy. However, the great majority of individuals exposed to the leprosy bacillus will never manifest the disease due to their capacity to develop protective immunity. Besides acting as a physical barrier, airway epithelium cells are recognized as key players by initiating a local innate immune response that orchestrates subsequent adaptive immunity to control airborne infections. However, to date, studies exploring the interaction of M. leprae with the respiratory epithelium have been scarce. In this work, the capacity of M. leprae to immune activate human alveolar epithelial cells was investigated, demonstrating that M. leprae-infected A549 cells secrete significantly increased IL-8 that is dependent on NF-kappa B activation. M. leprae was also able to induce IL-8 production in human primary nasal epithelial cells. M. leprae-treated A549 cells also showed higher expression levels of human beta-defensin-2 (h beta D-2), MCP-1, MHC-II and the co-stimulatory molecule CD80. Furthermore, the TLR-9 antagonist inhibited both the secretion of IL-8 and NF-kappa B activation in response to M. leprae, indicating that bacterial DNA sensing by this Toll-like receptor constitutes an important innate immune pathway activated by the pathogen. Finally, evidence is presented suggesting that extracellular DNA molecules anchored to Hlp, a histone-like protein present on the M. leprae surface, constitute major TLR-9 ligands triggering this pathway. The ability of M. leprae to immune activate respiratory epithelial cells herein demonstrated may represent a very early event during infection that could possibly be essential to the generation of a protective response.	[Dias, Andre Alves; de Matos e Silva, Carlos Adriano; da Silva, Camila Oliveira; Cardoso Linhares, Natasha Ribeiro; Sousa Santos, Joao Pedro; Berredo-Pinho, Marcia; Vidal Pessolani, Maria Cristina] Oswaldo Cruz Fdn FIOCRUZ, Oswaldo Cruz Inst, Lab Cellular Microbiol, Rio De Janeiro, Brazil; [Vivarini, Aislan de Carvalho; Lopes, Ulisses Gazos] Fed Univ Rio de Janeiro UFRJ, Inst Biophys Carlos Chagas Filho, Lab Mol Parasitol, Rio De Janeiro, Brazil; [de Mello Marques, Maria Angela] Colorado State Univ CSU, Dept Microbiol Immunol & Pathol, Mycobacteria Res Labs, Ft Collins, CO USA; [Rosa, Patricia Sammarco] Lauro de Souza Lima Inst, Div Res & Teaching, Bauru, SP, Brazil	Fundacao Oswaldo Cruz; Universidade Federal do Rio de Janeiro; Colorado State University	Pessolani, MCV (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Oswaldo Cruz Inst, Lab Cellular Microbiol, Rio De Janeiro, Brazil.	cpessola@ioc.fiocruz.br	Silva, Carlos Adriano M./D-3383-2015; Vivarini, Aislan/ABC-9774-2021; Pinho, Marcia/AAZ-7571-2021	Silva, Carlos Adriano M./0000-0003-0441-7703; de Mello Marques, Maria Angela/0000-0002-4680-2653	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [310155/2017-7]; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) [110.527/2014]; Oswaldo Cruz Institute (IOC/FIOCRUZ/Brazil)	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Oswaldo Cruz Institute (IOC/FIOCRUZ/Brazil)	This work was supported by grants awarded to MCVP by the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; 310155/2017-7), and the Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ; 110.527/2014). AD was the recipient of a fellowship from Oswaldo Cruz Institute (IOC/FIOCRUZ/Brazil). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas S, 2003, J BIOL CHEM, V278, P20077, DOI 10.1074/jbc.M208619200; Aoki K, 2004, J BIOL CHEM, V279, P39798, DOI 10.1074/jbc.M402677200; Ashitani J, 2001, CHEST, V119, P1131, DOI 10.1378/chest.119.4.1131; Bafica A, 2005, J EXP MED, V202, P1715, DOI 10.1084/jem.20051782; Bahar AA, 2013, PHARMACEUTICALS-BASE, V6, P1543, DOI 10.3390/ph6121543; Boggaram V, 2013, J BIOL CHEM, V288, P25500, DOI 10.1074/jbc.M112.448217; Bratschi MW, 2015, LEPROSY REV, V86, P142; Caselli E, 2012, ARCH VIROL, V157, P63, DOI 10.1007/s00705-011-1144-3; Chiplunkar SS, 2019, FUTURE MICROBIOL, V14, P293, DOI 10.2217/fmb-2018-0249; Cho SO, 2013, J ETHNOPHARMACOL, V150, P761, DOI 10.1016/j.jep.2013.09.013; Corbiere V, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-15; CUNNINGHAM AC, 1995, IMMUNOLOGY, V86, P279; Silva BJD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006103; de Lima CS, 2005, MICROBES INFECT, V7, P1097, DOI 10.1016/j.micinf.2005.02.013; Dias AA, 2016, J IMMUNOL, V197, P1905, DOI 10.4049/jimmunol.1600042; Dias AA, 2012, MEM I OSWALDO CRUZ, V107, P174, DOI 10.1590/S0074-02762012000900025; Acosta CCD, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007151; Dong HD, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/7515687; Durr M, 2002, INFECT IMMUN, V70, P6515, DOI 10.1128/IAI.70.12.6515-6517.2002; Franklin BS, 2011, P NATL ACAD SCI USA, V108, P3689, DOI 10.1073/pnas.1015406108; Furugen M, 2001, MICROB PATHOGENESIS, V30, P129, DOI 10.1006/mpat.2000.0416; GODAL T, 1973, BRIT MED J, V3, P557, DOI 10.1136/bmj.3.5880.557; Gowda NM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020398; Gupta N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00709; Hadifar S, 2019, J CELL PHYSIOL, V234, P4739, DOI 10.1002/jcp.27271; Hasan Z, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-14; Hjelm BE, 2014, HUM VACC IMMUNOTHER, V10, P410, DOI 10.4161/hv.27147; Hughes CE, 2018, FEBS J, V285, P2944, DOI 10.1111/febs.14466; Ishikawa T, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.019247; Job CK, 2008, AM J TROP MED HYG, V78, P518, DOI 10.4269/ajtmh.2008.78.518; Kao CY, 2008, J BIOL CHEM, V283, P15309, DOI [10.1074/jbc.M708289200, 10.1074/jbc.M804331200]; Kobori M, 2004, CELL DEATH DIFFER, V11, P123, DOI 10.1038/sj.cdd.4401325; Krupa A, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/124762; Kurashima K, 1997, AM J RESP CRIT CARE, V155, P1474, DOI 10.1164/ajrccm.155.4.9105097; Kuroda M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233390; Lamphier M, 2014, MOL PHARMACOL, V85, P429, DOI 10.1124/mol.113.089821; Lamphier MS, 2006, ANN NY ACAD SCI, V1082, P31, DOI 10.1196/annals.1348.005; Lefrancois LH, 2011, MICROBES INFECT, V13, P585, DOI 10.1016/j.micinf.2011.02.002; Li RR, 2011, CANCER BIOTHER RADIO, V26, P69, DOI 10.1089/cbr.2010.0849; Li Y, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/791392; Li Y, 2012, EMBO J, V31, P919, DOI 10.1038/emboj.2011.441; Lin YG, 1998, INFECT IMMUN, V66, P1121, DOI 10.1128/IAI.66.3.1121-1126.1998; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lo B, 2008, J IMMUNOL, V180, P881, DOI 10.4049/jimmunol.180.2.881; Manzanillo PS, 2012, CELL HOST MICROBE, V11, P469, DOI 10.1016/j.chom.2012.03.007; Marques MAD, 2000, MICROBES INFECT, V2, P1407; Martins MVSB, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001616; Matsumoto S, 2005, J IMMUNOL, V175, P441, DOI 10.4049/jimmunol.175.1.441; Matsumoto S, 1999, MICROBIOL IMMUNOL, V43, P1027, DOI 10.1111/j.1348-0421.1999.tb01232.x; Mattos KA, 2011, J IMMUNOL, V187, P2548, DOI 10.4049/jimmunol.1101344; MCGHEE JR, 1992, VACCINE, V10, P75, DOI 10.1016/0264-410X(92)90021-B; Mendez-Samperio P, 2006, CELL IMMUNOL, V239, P61, DOI 10.1016/j.cellimm.2006.04.001; Miquel-Clopes A, 2019, CLIN EXP IMMUNOL, V196, P205, DOI 10.1111/cei.13285; Morizane S, 2012, J INVEST DERMATOL, V132, P135, DOI 10.1038/jid.2011.259; Mvubu NE, 2018, CYTOKINE, V104, P53, DOI 10.1016/j.cyto.2017.09.027; Napetschnig J, 2013, ANNU REV BIOPHYS, V42, P443, DOI 10.1146/annurev-biophys-083012-130338; Niyonsaba F, 2002, INT IMMUNOL, V14, P421, DOI 10.1093/intimm/14.4.421; Pereira RMS, 2005, BIOCHEM BIOPH RES CO, V335, P20, DOI 10.1016/j.bbrc.2005.07.061; Pethe K, 2001, NATURE, V412, P190, DOI 10.1038/35084083; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Pompei L, 2007, J IMMUNOL, V178, P5192, DOI 10.4049/jimmunol.178.8.5192; Portugal MI, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-75; REES RJW, 1977, J MED MICROBIOL, V10, P63, DOI 10.1099/00222615-10-1-63; Rivas-Santiago B, 2005, INFECT IMMUN, V73, P4505, DOI 10.1128/IAI.73.8.4505-4511.2005; Rivas-Santiago B, 2012, ARCH MED RES, V43, P324, DOI 10.1016/j.arcmed.2012.06.005; Rodriguez-Carlos A, 2020, MICROBES INFECT, V22, P111, DOI 10.1016/j.micinf.2019.10.002; Rose SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128772; Sadek MI, 1998, AM J RESP CELL MOL, V19, P513, DOI 10.1165/ajrcmb.19.3.2815; Salik E, 1999, AM J RESP CELL MOL, V21, P365, DOI 10.1165/ajrcmb.21.3.3529; SANTOS AR, 1993, J MED MICROBIOL, V39, P298, DOI 10.1099/00222615-39-4-298; Schneberger D, 2013, J ANAT, V222, P495, DOI 10.1111/joa.12039; Schreiber O, 2008, J INFECT DIS, V198, P1044, DOI 10.1086/591501; Scollard DM, 2006, CLIN MICROBIOL REV, V19, P338, DOI 10.1128/CMR.19.2.338-381.2006; Scordo JM, 2016, J INNATE IMMUN, V8, P3, DOI 10.1159/000439275; Sequeira PC, 2014, PATHOG DIS, V70, P132, DOI 10.1111/2049-632X.12110; Shen HT, 2015, J CELL PHYSIOL, V230, P1199, DOI 10.1002/jcp.24852; Shimoji Y, 1999, P NATL ACAD SCI USA, V96, P9857, DOI 10.1073/pnas.96.17.9857; Shiozawa A, 2020, MICROBES INFECT, V22, P567, DOI 10.1016/j.micinf.2020.08.003; Silva CAM, 2013, INFECT IMMUN, V81, P2645, DOI 10.1128/IAI.00147-13; Sinsimer D, 2010, INFECT IMMUN, V78, P293, DOI 10.1128/IAI.00816-09; Solt LA, 2008, IMMUNOL RES, V42, P3, DOI 10.1007/s12026-008-8025-1; Steubesand N, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-36; TAUB DD, 1995, J CLIN INVEST, V95, P1370, DOI 10.1172/JCI117788; Troy A, 2020, TUBERCULOSIS, V123, DOI 10.1016/j.tube.2020.101949; Tsutsumi-Ishii Y, 2002, J LEUKOCYTE BIOL, V71, P154; Ueda H, 2019, JACC-BASIC TRANSL SC, V4, P348, DOI 10.1016/j.jacbts.2019.01.002; Watson RO, 2012, CELL, V150, P803, DOI 10.1016/j.cell.2012.06.040; Whitsett JA, 2015, NAT IMMUNOL, V16, P27, DOI 10.1038/ni.3045; Wickremasinghe MI, 2004, J BIOL CHEM, V279, P27199, DOI 10.1074/jbc.M403107200; World Health Organization, LEPROSY; Wu XZ, 2010, J IMMUNOL, V184, P4338, DOI 10.4049/jimmunol.0903824; XU LL, 1995, J LEUKOCYTE BIOL, V57, P335, DOI 10.1002/jlb.57.2.335; Yan CG, 2019, MOL IMMUNOL, V111, P95, DOI 10.1016/j.molimm.2019.04.013; Yang D, 2002, TRENDS IMMUNOL, V23, P291, DOI 10.1016/S1471-4906(02)02246-9; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yoshida K, 2019, CARDIOVASC RES, V115, P658, DOI 10.1093/cvr/cvy209	96	1	2	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 12	2021	12									10.3389/fimmu.2021.657449	http://dx.doi.org/10.3389/fimmu.2021.657449			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UN2EF	34456901	gold, Green Published			2022-12-18	WOS:000693832400001
J	Kim, ES; Kim, D; Yoon, Y; Kwon, Y; Park, S; Kim, J; Ahn, KM; Ahn, S; Choe, YH; Kim, YJ; Kim, MJ				Kim, Eun Sil; Kim, Dongsub; Yoon, Yoonsun; Kwon, Yiyoung; Park, Sangwoo; Kim, Jihyun; Ahn, Kang Mo; Ahn, Soomin; Choe, Yon Ho; Kim, Yae-Jean; Kim, Mi Jin			Needs for Increased Awareness of Gastrointestinal Manifestations in Patients With Human Inborn Errors of Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						inborn errors of immunity; primary immunodeficiencies; gastrointestinal; endoscopy; malignancy; inflammatory bowel disease	PRIMARY IMMUNODEFICIENCY DISEASES; THROMBOCYTOPENIC PURPURA; ULCERATIVE-COLITIS; CANCER; DEFICIENCY; FEATURES; CHILDREN	The gastrointestinal (GI) tract is frequently affected by inborn errors of immunity (IEI), and GI manifestations can be present in IEI patients before a diagnosis is confirmed. We aimed to investigate clinical features, endoscopic and histopathologic findings in IEI patients. This was a retrospective cohort study conducted from 1995 to 2020. Eligible patients were diagnosed with IEI and had GI manifestations that were enough to require endoscopies. IEI was classified according to the International Union of Immunological Societies classification. Of 165 patients with IEI, 55 (33.3%) had GI manifestations, and 19 (11.5%) underwent endoscopy. Among those 19 patients, nine (47.4%) initially presented with GI manifestations. Thirteen patients (68.4%) were male, and the mean age of patients 11.5 +/- 7.9 years (range, 0.6 - 26.6) when they were consulted and evaluated with endoscopy. The most common type of IEI with severe GI symptoms was "Disease of immune dysregulation" (31.6%) followed by "Phagocyte defects" (26.3%), according to the International Union of Immunological Societies classification criteria. Patients had variable GI symptoms such as chronic diarrhea (68.4%), hematochezia (36.8%), abdominal pain (31.6%), perianal disease (10.5%), and recurrent oral ulcers (10.5%). During the follow-up period, three patients developed GI tract neoplasms (early gastric carcinoma, mucosa associated lymphoid tissue lymphoma of colon, and colonic tubular adenoma, 15.8%), and 12 patients (63.2%) were diagnosed with inflammatory bowel disease (IBD)-like colitis. Investigating immunodeficiency in patients with atypical GI symptoms can provide an opportunity for correct diagnosis and appropriate disease-specific therapy. Gastroenterologists and immunologists should consider endoscopy when atypical GI manifestations appear in IEI patients to determine if IBD-like colitis or neoplasms including premalignant and malignant lesions have developed. Also, if physicians in various fields are better educated about IEI-specific complications, early diagnosis and disease-specific treatment for IEI will be made possible.	[Kim, Eun Sil; Kim, Dongsub; Yoon, Yoonsun; Kwon, Yiyoung; Park, Sangwoo; Kim, Jihyun; Ahn, Kang Mo; Choe, Yon Ho; Kim, Yae-Jean; Kim, Mi Jin] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pediat, Sch Med, Seoul, South Korea; [Kim, Dongsub] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Pediat, Daegu, South Korea; [Yoon, Yoonsun] Korea Univ, Guro Hosp, Coll Med, Dept Pediat, Seoul, South Korea; [Ahn, Soomin] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pathol, Sch Med, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Kyungpook National University; Kyungpook National University Hospital; Korea University; Korea University Medicine (KU Medicine); Sungkyunkwan University (SKKU); Samsung Medical Center	Kim, YJ; Kim, MJ (corresponding author), Sungkyunkwan Univ, Samsung Med Ctr, Dept Pediat, Sch Med, Seoul, South Korea.	yaejean.kim@samsung.com; mijin1217.kim@samsung.com	Kim, Mi Jin/GXH-9639-2022					Agarwal S, 2019, IMMUNOL ALLERGY CLIN, V39, P81, DOI 10.1016/j.iac.2018.08.006; Agarwal S, 2013, CLIN GASTROENTEROL H, V11, P1050, DOI 10.1016/j.cgh.2013.02.024; Akkelle BS, 2019, DIGEST DIS, V37, P45, DOI 10.1159/000492569; Aldirmaz S, 2014, TURK PEDIATR ARSIVI, V49, P210, DOI 10.5152/tpa.2014.1810; Alimchandani M, 2013, AM J SURG PATHOL, V37, P1365, DOI 10.1097/PAS.0b013e318297427d; Amaya-Uribe L, 2019, J AUTOIMMUN, V99, P52, DOI 10.1016/j.jaut.2019.01.011; Borzutzky A, 2010, CLIN IMMUNOL, V134, P251, DOI 10.1016/j.clim.2009.05.005; Bousfiha A, 2020, J CLIN IMMUNOL, V40, P66, DOI 10.1007/s10875-020-00758-x; Broides A, 2016, IMMUNOL RES, V64, P155, DOI 10.1007/s12026-015-8733-2; Dieckgraefe BK, 2002, EUR J PEDIATR, V161, pS88, DOI 10.1007/s00431-002-1011-z; Dieli-Crimi R, 2018, CLIN IMMUNOL, V195, P49, DOI 10.1016/j.clim.2018.07.015; Girschick H, 2018, RHEUMATOLOGY, V57, P1203, DOI 10.1093/rheumatology/key058; Glassner KL, 2020, J ALLERGY CLIN IMMUN, V145, P16, DOI 10.1016/j.jaci.2019.11.003; Goudouris ES, 2019, J PEDIAT-BRAZIL, V95, pS49, DOI 10.1016/j.jped.2018.11.006; Guerrerio AL, 2010, J PEDIATR GASTR NUTR, V51, P548, DOI 10.1097/MPG.0b013e3181efe56b; Hartono S, 2019, CLIN REV ALLERG IMMU, V57, P145, DOI 10.1007/s12016-018-8689-9; Herber M, 2020, LEUKEMIA LYMPHOMA, V61, P274, DOI 10.1080/10428194.2019.1672056; Hyams JS, 2005, PEDIATR REV, V26, P314, DOI 10.1542/pir.26-9-314; Iwasa T, 2017, INTERNAL MED, V56, P1331, DOI 10.2169/internalmedicine.56.7909; Kanegane Hirokazu, 2018, Rinsho Ketsueki, V59, P2459, DOI 10.11406/rinketsu.59.2459; Kang JM, 2020, YONSEI MED J, V61, P542, DOI 10.3349/ymj.2020.61.6.542; Kebudi R, 2019, CURR PEDIATR REV, V15, P245, DOI 10.2174/1573396315666190917154058; Khangura SK, 2016, CLIN GASTROENTEROL H, V14, P395, DOI 10.1016/j.cgh.2015.10.030; Kiykim A, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28091; Kouhkan Azam, 2004, Iran J Allergy Asthma Immunol, V3, P189; Kyle UG, 2015, NUTR CLIN PRACT, V30, P227, DOI 10.1177/0884533614555234; Ludvigsson JF, 2015, J CLIN IMMUNOL, V35, P182, DOI 10.1007/s10875-014-0124-2; Mayor PC, 2018, J ALLERGY CLIN IMMUN, V141, P1028, DOI 10.1016/j.jaci.2017.05.024; Negoro A, 2014, INT J COLORECTAL DIS, V29, P1179, DOI 10.1007/s00384-014-1903-1; Reda SM, 2009, J CLIN IMMUNOL, V29, P343, DOI 10.1007/s10875-008-9260-x; Reis BS, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/157948; Ruemmele FM, 2014, J CROHNS COLITIS, V8, P1179, DOI 10.1016/j.crohns.2014.04.005; Salavoura K, 2008, ANTICANCER RES, V28, P1263; Schmidt RE, 2018, NAT REV RHEUMATOL, V14, P7, DOI 10.1038/nrrheum.2017.198; Schwimmer D, 2019, GASTROENTEROL CLIN N, V48, P199, DOI 10.1016/j.gtc.2019.02.004; Shim JO, 2019, PEDIATR GASTROENTERO, V22, P41, DOI 10.5223/pghn.2019.22.1.41; Shouval DS, 2018, J CLIN IMMUNOL, V38, P579, DOI 10.1007/s10875-018-0524-9; Son Sohee, 2021, Clin Exp Pediatr, V64, P141, DOI 10.3345/cep.2019.01347; Spahn TW, 2004, GUT, V53, P456, DOI 10.1136/gut.2003.023671; Subbarayan A, 2011, PEDIATRICS, V127, P810, DOI 10.1542/peds.2010-3680; Tegtmeyer D, 2017, PEDIAT ALLERG IMM-UK, V28, P412, DOI 10.1111/pai.12734	41	1	1	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 12	2021	12									10.3389/fimmu.2021.698721	http://dx.doi.org/10.3389/fimmu.2021.698721			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UN2EU	34456911	gold, Green Published			2022-12-18	WOS:000693833900001
J	Meyer, SNN; Koul, S; Pasqualucci, L				Meyer, Stefanie N. N.; Koul, Sanjay; Pasqualucci, Laura			Mouse Models of Germinal Center Derived B-Cell Lymphomas	FRONTIERS IN IMMUNOLOGY			English	Review						germinal center; lymphoma; genetics; mouse models; transgenic	NF-KAPPA-B; ONE-STEP GENERATION; FOLLICULAR LYMPHOMA; C-MYC; BURKITT-LYMPHOMA; TUMOR-SUPPRESSOR; XENOGRAFT MODELS; TRANSGENIC MICE; NEGATIVE AUTOREGULATION; SOMATIC MUTATIONS	Over the last decades, the revolution in DNA sequencing has changed the way we understand the genetics and biology of B-cell lymphomas by uncovering a large number of recurrently mutated genes, whose aberrant function is likely to play an important role in the initiation and/or maintenance of these cancers. Dissecting how the involved genes contribute to the physiology and pathology of germinal center (GC) B cells -the origin of most B-cell lymphomas- will be key to advance our ability to diagnose and treat these patients. Genetically engineered mouse models (GEMM) that faithfully recapitulate lymphoma-associated genetic alterations offer a valuable platform to investigate the pathogenic roles of candidate oncogenes and tumor suppressors in vivo, and to pre-clinically develop new therapeutic principles in the context of an intact tumor immune microenvironment. In this review, we provide a summary of state-of-the art GEMMs obtained by accurately modelling the most common genetic alterations found in human GC B cell malignancies, with a focus on Burkitt lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma, and we discuss how lessons learned from these models can help guide the design of novel therapeutic approaches for this disease.	[Meyer, Stefanie N. N.; Pasqualucci, Laura] Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; [Koul, Sanjay] CUNY Queensborough Community Coll, Dept Biol Sci & Geol, Bayside, NY USA; [Pasqualucci, Laura] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Pasqualucci, Laura] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; City University of New York (CUNY) System; Columbia University; Columbia University	Pasqualucci, L (corresponding author), Columbia Univ, Inst Canc Genet, New York, NY 10032 USA.; Pasqualucci, L (corresponding author), Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.; Pasqualucci, L (corresponding author), Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA.	lp171@cumc.columbia.edu			NCI NIH HHS [R01 CA172492] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Allen CDC, 2004, NAT IMMUNOL, V5, P943, DOI 10.1038/ni1100; Ba ZQ, 2015, CANCER IMMUNOL RES, V3, P641, DOI 10.1158/2326-6066.CIR-15-0058; Bea S, 2013, P NATL ACAD SCI USA, V110, P18250, DOI 10.1073/pnas.1314608110; Beguelin W, 2020, CANCER CELL, V37, P655, DOI 10.1016/j.ccell.2020.04.004; Beguelin W, 2016, CANCER CELL, V30, P197, DOI 10.1016/j.ccell.2016.07.006; Beguelin W, 2013, CANCER CELL, V23, P677, DOI 10.1016/j.ccr.2013.04.011; Ben-David U, 2017, NAT GENET, V49, P1567, DOI 10.1038/ng.3967; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109; Boice M, 2016, CELL, V167, P405, DOI 10.1016/j.cell.2016.08.032; Brehm MA, 2014, J IMMUNOL METHODS, V410, P3, DOI 10.1016/j.jim.2014.02.011; Brescia P, 2018, CANCER CELL, V34, P453, DOI 10.1016/j.ccell.2018.08.006; Busque L, 2012, NAT GENET, V44, P1179, DOI 10.1038/ng.2413; Butzler C, 1997, ONCOGENE, V14, P1383, DOI 10.1038/sj.onc.1200968; Caganova M, 2013, J CLIN INVEST, V123, P5009, DOI 10.1172/JCI70626; Calado DP, 2012, NAT IMMUNOL, V13, P1092, DOI 10.1038/ni.2418; Calado DP, 2010, CANCER CELL, V18, P580, DOI 10.1016/j.ccr.2010.11.024; Casola S, 2006, P NATL ACAD SCI USA, V103, P7396, DOI 10.1073/pnas.0602353103; Casulo C, 2015, BLOOD, V125, P40, DOI 10.1182/blood-2014-04-516815; Cato MH, 2011, MOL CELL BIOL, V31, P127, DOI 10.1128/MCB.00650-10; Cattoretti G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037; Cattoretti G, 2009, CANCER RES, V69, P8686, DOI 10.1158/0008-5472.CAN-09-1110; Challa-Malladi M, 2011, CANCER CELL, V20, P728, DOI 10.1016/j.ccr.2011.11.006; Chapuy B, 2018, NAT MED, V24, P679, DOI 10.1038/s41591-018-0016-8; Chapuy B, 2016, BLOOD, V127, P2203, DOI 10.1182/blood-2015-09-672352; Cheung KJJ, 2010, CANCER RES, V70, P9166, DOI 10.1158/0008-5472.CAN-10-2460; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Crouch EE, 2007, J EXP MED, V204, P1145, DOI 10.1084/jem.20061952; Culjkovic-Kraljacic B, 2016, BLOOD, V127, P858, DOI 10.1182/blood-2015-05-645069; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; De Silva NS, 2016, P NATL ACAD SCI USA, V113, P9063, DOI 10.1073/pnas.1602728113; De Silva NS, 2015, NAT REV IMMUNOL, V15, P137, DOI 10.1038/nri3804; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Dominguez PM, 2018, CANCER DISCOV, V8, P1632, DOI 10.1158/2159-8290.CD-18-0657; Dominguez-Sola D, 2012, NAT IMMUNOL, V13, P1083, DOI 10.1038/ni.2428; Duan S, 2012, NATURE, V481, P90, DOI 10.1038/nature10688; Efeyan A, 2015, NATURE, V517, P302, DOI 10.1038/nature14190; Egle A, 2004, BLOOD, V103, P2276, DOI 10.1182/blood-2003-07-2469; Ennishi D, 2019, CANCER DISCOV, V9, P546, DOI 10.1158/2159-8290.CD-18-1090; Fangazio M, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2104504118; Flori M, 2016, BLOOD, V127, P1438, DOI [10.1182/blood-2015-08662635, 10.1182/blood-2015-08-662635]; Flumann R, 2021, BLOOD CANCER DISCOV, V2, P70, DOI 10.1158/2643-3230.BCD-19-0059; Fujimura S, 2010, J AM SOC NEPHROL, V21, P803, DOI 10.1681/ASN.2009040353; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Garcia-Ramirez I, 2017, BLOOD, V129, P2645, DOI 10.1182/blood-2016-08-733469; Green MR, 2015, P NATL ACAD SCI USA, V112, pE1116, DOI 10.1073/pnas.1501199112; Hampel F, 2011, BLOOD, V118, P6321, DOI 10.1182/blood-2010-12-325944; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Healy JA, 2016, BLOOD, V127, P2723, DOI [10.1182/blood-2015-07659938, 10.1182/blood-2015-07-659938]; Heise N, 2014, J EXP MED, V211, P2103, DOI 10.1084/jem.20132613; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Hobeika E, 2006, P NATL ACAD SCI USA, V103, P13789, DOI 10.1073/pnas.0605944103; Holmes AB, 2020, J EXP MED, V217, DOI 10.1084/jem.20200483; Horn M, 2014, DEV CELL, V28, P697, DOI 10.1016/j.devcel.2014.01.028; Horton SJ, 2017, NAT CELL BIOL, V19, P1093, DOI 10.1038/ncb3597; Huang SY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.639844; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Jiang YW, 2017, CANCER DISCOV, V7, P38, DOI 10.1158/2159-8290.CD-16-0975; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Johnson NA, 2012, J CLIN ONCOL, V30, P3452, DOI 10.1200/JCO.2011.41.0985; Kabrani E, 2018, BLOOD, V132, P2670, DOI 10.1182/blood-2018-06-856203; Karube K, 2018, LEUKEMIA, V32, P675, DOI 10.1038/leu.2017.251; Klein U, 2008, NAT REV IMMUNOL, V8, P22, DOI 10.1038/nri2217; Kline J, 2020, BLOOD, V135, P523, DOI 10.1182/blood.2019000847; Knittel G, 2016, BLOOD, V127, P2732, DOI [10.1182/blood-2015-11684183, 10.1182/blood-2015-11-684183]; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Kraus M, 2004, CELL, V117, P787, DOI 10.1016/j.cell.2004.05.014; Kridel R, 2012, J CLIN INVEST, V122, P3424, DOI 10.1172/JCI63186; Kuppers R, 1999, NEW ENGL J MED, V341, P1520; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Lamaison C, 2019, IMMUNOL LETT, V215, P12, DOI 10.1016/j.imlet.2019.02.005; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Li HX, 2014, BLOOD, V123, P1487, DOI 10.1182/blood-2013-05-500264; LIMPENS J, 1995, BLOOD, V85, P2528, DOI 10.1182/blood.V85.9.2528.bloodjournal8592528; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Lossos IS, 2011, BEST PRACT RES CL HA, V24, P147, DOI 10.1016/j.beha.2011.02.006; Mandelbaum J, 2010, CANCER CELL, V18, P568, DOI 10.1016/j.ccr.2010.10.030; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Mesin L, 2016, IMMUNITY, V45, P471, DOI 10.1016/j.immuni.2016.09.001; Meyer SN, 2019, IMMUNITY, V51, P535, DOI 10.1016/j.immuni.2019.08.006; Milpied P, 2018, NAT IMMUNOL, V19, P1013, DOI 10.1038/s41590-018-0181-4; Mintz MA, 2020, IMMUNOL REV, V296, P48, DOI 10.1111/imr.12860; Mondello P, 2020, CANCER DISCOV, V10, P440, DOI 10.1158/2159-8290.CD-19-0116; Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Mottok A, 2018, BLOOD, V131, P1654, DOI 10.1182/blood-2017-09-772632; Mou HW, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0178-7; Muppidi JR, 2014, NATURE, V516, P254, DOI 10.1038/nature13765; Nakagawa MM, 2015, J EXP MED, V212, P203, DOI 10.1084/jem.20132544; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Okosun J, 2016, NAT GENET, V48, P183, DOI 10.1038/ng.3473; Okosun J, 2014, NAT GENET, V46, P176, DOI 10.1038/ng.2856; Oricchio E, 2014, CELL REP, V8, P1677, DOI 10.1016/j.celrep.2014.08.039; Oricchio E, 2010, DIS MODEL MECH, V3, P701, DOI 10.1242/dmm.006296; Ortega-Molina A, 2019, NAT METAB, V1, P775, DOI 10.1038/s42255-019-0098-8; Ortega-Molina A, 2015, NAT MED, V21, P1199, DOI 10.1038/nm.3943; Pasqualucci L, 2006, J EXP MED, V203, P311, DOI 10.1084/jem.20052204; Pasqualucci L, 2003, BLOOD, V101, P2914, DOI 10.1182/blood-2002-11-3387; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Pasqualucci L, 2008, NAT GENET, V40, P108, DOI 10.1038/ng.2007.35; Pasqualucci L, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a034827; Pasqualucci L, 2019, IMMUNOL REV, V288, P240, DOI 10.1111/imr.12745; Pasqualucci L, 2014, CELL REP, V6, P130, DOI 10.1016/j.celrep.2013.12.027; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Peled JU, 2010, CELL RES, V20, P631, DOI 10.1038/cr.2010.55; Phelan JD, 2018, NATURE, V560, P387, DOI 10.1038/s41586-018-0290-0; Pizzi M, 2017, CURR OPIN HEMATOL, V24, P384, DOI 10.1097/MOH.0000000000000349; Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Ramezani-Rad P, 2017, CURR OPIN IMMUNOL, V45, P31, DOI 10.1016/j.coi.2016.12.002; Rava M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan8723; Reddy A, 2017, CELL, V171, P481, DOI 10.1016/j.cell.2017.09.027; Richmond A, 2008, DIS MODEL MECH, V1, P78, DOI 10.1242/dmm.000976; Richter J, 2012, NAT GENET, V44, P1316, DOI 10.1038/ng.2469; Rickert Robert C., 1997, Nucleic Acids Research, V25, P1317, DOI 10.1093/nar/25.6.1317; Robbiani DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062; Roco JA, 2019, IMMUNITY, V51, P337, DOI 10.1016/j.immuni.2019.07.001; Roulland S, 2006, J EXP MED, V203, P2425, DOI 10.1084/jem.20061292; Roulland S, 2011, ADV IMMUNOL, V111, P1, DOI 10.1016/B978-0-12-385991-4.00001-5; Saito M, 2007, CANCER CELL, V12, P280, DOI 10.1016/j.ccr.2007.08.011; Sander S, 2012, CANCER CELL, V22, P167, DOI 10.1016/j.ccr.2012.06.012; Sarkozy Clementine, 2015, Lancet Oncol, V16, pe555, DOI 10.1016/S1470-2045(15)00005-4; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schmitz R, 2018, NEW ENGL J MED, V378, P1396, DOI 10.1056/NEJMoa1801445; Schmitz R, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014282; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Schneider C, 2016, BLOOD, V128, P660, DOI 10.1182/blood-2015-11-684357; Scott DW, 2014, NAT REV CANCER, V14, P517, DOI 10.1038/nrc3774; Scuoppo C, 2019, P NATL ACAD SCI USA, V116, P16981, DOI 10.1073/pnas.1905239116; Sesques P, 2017, BLOOD, V129, P280, DOI 10.1182/blood-2016-02-636316; Sewastianik T, 2014, BBA-REV CANCER, V1846, P457, DOI 10.1016/j.bbcan.2014.08.006; Shaffer AL, 2006, IMMUNOL REV, V210, P67, DOI 10.1111/j.0105-2896.2006.00373.x; Shaffer AL, 2012, ANNU REV IMMUNOL, V30, P565, DOI 10.1146/annurev-immunol-020711-075027; Shi JH, 2020, INT J CANCER, V146, P2078, DOI 10.1002/ijc.32662; Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Souroullas GP, 2016, NAT MED, V22, P632, DOI 10.1038/nm.4092; Stevenson F, 1998, IMMUNOL REV, V162, P247, DOI 10.1111/j.1600-065X.1998.tb01446.x; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Sungalee S, 2014, J CLIN INVEST, V124, P5337, DOI 10.1172/JCI72415; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Sze CC, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026427; Tam W, 2006, BLOOD, V107, P4090, DOI 10.1182/blood-2005-09-3778; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Townsend EC, 2016, CANCER CELL, V30, P183, DOI 10.1016/j.ccell.2016.06.008; Truffinet V, 2007, J IMMUNOL, V179, P6033, DOI 10.4049/jimmunol.179.9.6033; Valls E, 2017, CANCER DISCOV, V7, P506, DOI 10.1158/2159-8290.CD-16-1189; Varano G, 2017, NATURE, V546, P302, DOI 10.1038/nature22353; Venturutti L, 2020, CELL, V182, P297, DOI 10.1016/j.cell.2020.05.049; Victora GD, 2012, BLOOD, V120, P2240, DOI 10.1182/blood-2012-03-415380; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025; Wang JQ, 2017, J EXP MED, V214, P2759, DOI 10.1084/jem.20161454; Wang X, 2002, P NATL ACAD SCI USA, V99, P15018, DOI 10.1073/pnas.232581199; Weniger MA, 2021, LEUKEMIA, V35, P968, DOI 10.1038/s41375-021-01204-6; Wright GW, 2020, CANCER CELL, V37, P551, DOI 10.1016/j.ccell.2020.03.015; Yabe D, 2007, GENESIS, V45, P300, DOI 10.1002/dvg.20296; Yang H, 2013, CELL, V154, P1370, DOI 10.1016/j.cell.2013.08.022; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Ying CY, 2013, NAT IMMUNOL, V14, P1084, DOI 10.1038/ni.2688; Young RM, 2015, P NATL ACAD SCI USA, V112, P13447, DOI 10.1073/pnas.1514944112; Yusufova N, 2021, NATURE, V589, P299, DOI 10.1038/s41586-020-3017-y; Zhang BC, 2015, CELL REP, V11, P715, DOI 10.1016/j.celrep.2015.03.059; Zhang JY, 2017, CANCER DISCOV, V7, P322, DOI 10.1158/2159-8290.CD-16-1417; Zhang JY, 2015, NAT MED, V21, P1190, DOI 10.1038/nm.3940; Zhang L, 2017, CLIN CANCER RES, V23, P4212, DOI 10.1158/1078-0432.CCR-16-2703	175	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 12	2021	12									10.3389/fimmu.2021.710711	http://dx.doi.org/10.3389/fimmu.2021.710711			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UN2DF	34456919	gold, Green Published			2022-12-18	WOS:000693829800001
J	Szeifert, V; Kolonics, F; Bartos, B; Khamari, D; Vagi, P; Barna, L; Ligeti, E; Lorincz, AM				Szeifert, Viktoria; Kolonics, Ferenc; Bartos, Balazs; Khamari, Delaram; Vagi, Pal; Barna, Laszlo; Ligeti, Erzsebet; Lorincz, Akos M.			Mac-1 Receptor Clustering Initiates Production of Pro-Inflammatory, Antibacterial Extracellular Vesicles From Neutrophils	FRONTIERS IN IMMUNOLOGY			English	Article						Mac-1; integrins; receptor clustering; neutrophils; extracellular vesicles; pro-inflammatory cytokine; calcium signal	CELLULAR-ORIGIN; MICROPARTICLES; MICROVESICLES; POPULATIONS; BIOGENESIS; SECRETION; EXOSOMES; CELLS	Depending on the prevailing environmental conditions, neutrophilic granulocytes release extracellular vesicles (EV) which have either anti-inflammatory effects on other neutrophils or pro-inflammatory and antibacterial effects. In the present study we investigated the molecular mechanisms underlying the biogenesis of functionally heterogenic EVs. We show that selective stimulation of Mac-1 integrin (complement receptor 3) by specific ligands initiates the generation of EVs which are able to impair bacterial growth and to induce the secretion of the pro-inflammatory cytokine IL-8 (aEV). However, direct Mac-1 stimulation results in aEV release only if neutrophils were activated on ligand coated surfaces whereas soluble ligands are ineffective. Using total internal reflection fluorescence (TIRF) microcopy, an increased clustering of Mac-1 molecules could be visualized in neutrophils added to C3bi coated surfaces; moreover antibody induced cluster formation triggers aEV release as well. Mac-1 induced production of aEV apparently necessitates a strong calcium signal as it fully depends on the presence of extracellular calcium. However, initiation of a strong calcium signal by an ionophore only results the generation of EV devoid of any antibacterial or pro-inflammatory effect. Our results thus demonstrate that stimulation and clustering of Mac-1 is necessary and sufficient for initiation of aEV biogenesis. In contrast, an intracellular calcium signal is necessary but by itself not sufficient for the production of antibacterial and pro-inflammatory EVs.	[Szeifert, Viktoria; Kolonics, Ferenc; Bartos, Balazs; Ligeti, Erzsebet; Lorincz, Akos M.] Semmelweis Univ, Dept Physiol, Budapest, Hungary; [Khamari, Delaram] Semmelweis Univ, Dept Genet Cell & Immunobiol, Budapest, Hungary; [Vagi, Pal; Barna, Laszlo] Hungarian Acad Sci, Nikon Ctr Excellence, Inst Expt Med, Budapest, Hungary; [Lorincz, Akos M.] Szent Gyorgy Hosp, Dept Internal Med 2, Szekesfehervar, Hungary	Semmelweis University; Semmelweis University; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine	Ligeti, E; Lorincz, AM (corresponding author), Semmelweis Univ, Dept Physiol, Budapest, Hungary.; Lorincz, AM (corresponding author), Szent Gyorgy Hosp, Dept Internal Med 2, Szekesfehervar, Hungary.	ligeti.erzsebet@med.semmelweis-univ.hu; lorincz.akos@med.semmelweis-univ.hu		Barna, Laszlo/0000-0002-3856-5774; Khamari, Delaram/0000-0001-7162-0694; Szeifert, Viktoria/0000-0002-4678-6497				Alvarez-Jimenez VD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00272; Ambattu LA, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01277-6; Batista FD, 2001, NATURE, V411, P489, DOI 10.1038/35078099; Chakraborty AK, 2014, NAT IMMUNOL, V15, P798, DOI 10.1038/ni.2940; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Dalli J, 2013, MOL CELL PROTEOMICS, V12, P2205, DOI 10.1074/mcp.M113.028589; DETMERS PA, 1987, J CELL BIOL, V105, P1137, DOI 10.1083/jcb.105.3.1137; Erdei A, 2019, SEMIN CELL DEV BIOL, V85, P110, DOI 10.1016/j.semcdb.2017.11.025; Gasser O, 2003, EXP CELL RES, V285, P243, DOI 10.1016/S0014-4827(03)00055-7; Gyorgy B, 2011, CELL MOL LIFE SCI, V68, P2667, DOI 10.1007/s00018-011-0689-3; Herrmann IK, 2015, NANOSCALE, V7, P13511, DOI 10.1039/c5nr01851j; Hess C, 1999, J IMMUNOL, V163, P4564; Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018-017-2595-9; Jongstra-Bilen J, 2003, J BIOL CHEM, V278, P45720, DOI 10.1074/jbc.M303704200; Kolonics F, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122718; Kolonics F, 2021, J LEUKOCYTE BIOL, V109, P793, DOI 10.1002/JLB.3A0320-210R; Kormelink TG, 2018, SEMIN IMMUNOPATHOL, V40, P439, DOI 10.1007/s00281-018-0681-1; Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113; Kowal J, 2014, CURR OPIN CELL BIOL, V29, P116, DOI 10.1016/j.ceb.2014.05.004; Li YC, 2020, COMPUT STRUCT BIOTEC, V18, P2851, DOI 10.1016/j.csbj.2020.10.002; Lishko VK, 2018, J BIOL CHEM, V293, P6869, DOI 10.1074/jbc.RA117.000515; Lorincz AM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02942; Lorincz AM, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2019.1698889; Lorincz AM, 2018, J LEUKOCYTE BIOL, V103, P955, DOI 10.1002/JLB.4TA0817-317R; Lorincz AM, 2015, J LEUKOCYTE BIOL, V98, P583, DOI 10.1189/jlb.3VMA1014-514R; Lorincz AM, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.25465; Nieuwland R, 2000, BLOOD, V95, P930, DOI 10.1182/blood.V95.3.930.003k46_930_935; Pitanga TN, 2014, BMC CELL BIOL, V15, DOI 10.1186/1471-2121-15-21; Rada BK, 2004, BLOOD, V104, P2947, DOI 10.1182/blood-2004-03-1005; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Robbins PD, 2014, NAT REV IMMUNOL, V14, P195, DOI 10.1038/nri3622; Savina A, 2003, J BIOL CHEM, V278, P20083, DOI 10.1074/jbc.M301642200; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Sedgwick AE, 2018, TRAFFIC, V19, P319, DOI 10.1111/tra.12558; Shopova IA, 2020, MBIO, V11, DOI 10.1128/mBio.00596-20; Taylor J, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1734326; Timar CI, 2013, BLOOD, V121, P510, DOI 10.1182/blood-2012-05-431114; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066	38	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 12	2021	12									10.3389/fimmu.2021.671995	http://dx.doi.org/10.3389/fimmu.2021.671995			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UN2FK	34456905	gold, Green Published, Green Accepted			2022-12-18	WOS:000693835500001
J	Esposito, S; Abu-Raya, B; Bonanni, P; Cahn-Sellem, F; Flanagan, KL; Torres, FM; Mejias, A; Nadel, S; Safadi, MAP; Simon, A				Esposito, Susanna; Abu-Raya, Bahaa; Bonanni, Paolo; Cahn-Sellem, Fabianne; Flanagan, Katie L.; Martinon Torres, Federico; Mejias, Asuncion; Nadel, Simon; Safadi, Marco A. P.; Simon, Arne		World Assoc Infect Dis Immunologi	Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper	FRONTIERS IN IMMUNOLOGY			English	Review						monoclonal antibodies; nirsevimab; palivizumab; vaccine; RSV	RESPIRATORY SYNCYTIAL VIRUS; DIPHTHERIA-TETANUS-PERTUSSIS; MUMPS-RUBELLA VACCINE; YOUNG-CHILDREN; REDUCES HOSPITALIZATION; IMMUNIZATION PRACTICES; MATERNAL IMMUNIZATION; ADVISORY-COMMITTEE; CONJUGATE VACCINE; INFLUENZA VACCINE	Routine childhood vaccinations are key for the protection of children from a variety of serious and potentially fatal diseases. Current pediatric vaccine schedules mainly cover active vaccines. Active vaccination in infants is a highly effective approach against several infectious diseases; however, thus far, for some important viral pathogens, including respiratory syncytial virus (RSV), vaccine development and license by healthcare authorities have not been accomplished. Nirsevimab is a human-derived, highly potent monoclonal antibody (mAb) with an extended half-life for RSV prophylaxis in all infants. In this manuscript, we consider the potential implications for the introduction of an anti-viral mAb, such as nirsevimab, into the routine pediatric vaccine schedule, as well as considerations for coadministration. Specifically, we present evidence on the general mechanism of action of anti-viral mAbs and experience with palivizumab, the only approved mAb for the prevention of RSV infection in preterm infants, infants with chronic lung disease of prematurity and certain infants with hemodynamically significant heart disease. Palivizumab has been used for over two decades in infants who also receive routine vaccinations without any alerts concerning the safety and efficacy of coadministration. Immunization guidelines (Advisory Committee on Immunization Practices, Joint Committee on Vaccination and Immunization, National Advisory Committee on Immunization, Centers for Disease Control and Prevention, American Academy of Pediatrics, The Association of the Scientific Medical Societies in Germany) support coadministration of palivizumab with routine pediatric vaccines, noting that immunobiologics, such as palivizumab, do not interfere with the immune response to licensed live or inactivated active vaccines. Based on the mechanism of action of the new generation of anti-viral mAbs, such as nirsevimab, which is highly specific targeting viral antigenic sites, it is unlikely that it could interfere with the immune response to other vaccines. Taken together, we anticipate that nirsevimab could be concomitantly administered to infants with routine pediatric vaccines during the same clinic visit.	[Esposito, Susanna] Univ Parma, Univ Hosp, Dept Med & Surg, Pediat Clin, Parma, Italy; [Abu-Raya, Bahaa] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada; [Bonanni, Paolo] Univ Florence, Specializat Med Sch Hyg, Dept Hlth Sci, Florence, Italy; [Cahn-Sellem, Fabianne] Assoc Francaise Pediatrie Ambulatoire AFPA, Paris, France; [Flanagan, Katie L.] Launceston Gen Hosp, Tasmanian Vaccine Trial Ctr, Launceston, Tas, Australia; [Flanagan, Katie L.] Univ Tasmania, Sch Med, Launceston, Tas, Australia; [Flanagan, Katie L.] Monash Univ, Dept Pathol & Immunol, Melbourne, Vic, Australia; [Flanagan, Katie L.] Royal Melbourne Inst Technol RMIT Univ, Sch Hlth & Biomed Sci, Melbourne, Vic, Australia; [Martinon Torres, Federico] Univ Santiago Compostela, Translat Pediat & Infect Dis Pediat Dept, Hosp Clin, Santiago De Compostela, Spain; [Martinon Torres, Federico] Univ Santiago, Inst Investigac Sanitaria Santiago Comp, Genet Vaccines & Pediat Res Grp, Santiago De Compostela, Spain; [Mejias, Asuncion] Ohio State Univ, Div Infect Dis, Ctr Vaccines & Immun, Nationwide Childrens Hosp,Dept Pediat,Coll Med, Columbus, OH USA; [Mejias, Asuncion] Univ Malaga, Malaga Med Sch, Dept Pediat & Pharmacol, Malaga, Spain; [Nadel, Simon] St Marys Hosp, London, England; [Safadi, Marco A. P.] Santa Casa Sao Paulo Sch Med Sci, Dept Pediat, Sao Paulo, Brazil; [Simon, Arne] Klin Padiatr Onkol & Hamatol Univ Saarlandes, Homburg, Germany	University of Parma; University Hospital of Parma; University of British Columbia; University of Florence; University of Tasmania; Monash University; Royal Melbourne Institute of Technology (RMIT); Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; Universidad de Malaga; Imperial College London; Universidade Federal de Sao Paulo (UNIFESP)	Esposito, S (corresponding author), Univ Parma, Univ Hosp, Dept Med & Surg, Pediat Clin, Parma, Italy.	susanna.esposito@unimi.it	Abu-Raya, Bahaa/ABC-9889-2021; safadi, marco aurelio palazzi/B-7157-2015; Esposito, Susanna/AAA-8275-2022; Martinon-Torres, Federico/E-4982-2016	safadi, marco aurelio palazzi/0000-0002-4401-9446; Martinon-Torres, Federico/0000-0002-9023-581X; Flanagan, Katie/0000-0002-1575-1953	Sanofi Pasteur [Waidid_2021_03]	Sanofi Pasteur	The World Association of Infectious Diseases and Immunological Disorders received an unrestricted grant from Sanofi Pasteur for research and medical education activities on RSV monoclonal antibodies and co-administration with pediatric vaccines (Waidid_2021_03). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	AbbVie, SYN SMPC; Abu Raya B, 2014, VACCINE, V32, P5787, DOI 10.1016/j.vaccine.2014.08.038; Abu-Raya B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01282; Achten NB, 2017, J INFECT DIS, V215, P1102, DOI 10.1093/infdis/jix031; Advisory Committee on Immunization Practices, TIM SPAC IMM; Advisory Committee on Immunization Practices, GUID VACC PREGN WOM; Advisory Committee on Immunization Practices. Altered Immunocompetence, GEN BEST PRACTICE GU; American Academy of Pediatrics, RED BOOK SIM ADM MUL; Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P1391; Arriola CS, 2020, J PEDIAT INF DIS SOC, V9, P587, DOI 10.1093/jpids/piz087; B Laupland Kevin, 2002, Can J Infect Dis, V13, P100; Backman K, 2018, CLIN EXP ALLERGY, V48, P138, DOI 10.1111/cea.13062; Boonyaratanakornkit J, 2019, PEDIATR INFECT DIS J, V38, pS28, DOI [10.1097/INF.0000000000002312, 10.1097/inf.0000000000002312]; Brady MT, 2014, PEDIATRICS, V134, P415, DOI [10.1542/peds.2014-1666, 10.1542/peds.2014-1665]; Breese C, 2013, PEDIATRICS, V132, pE341, DOI 10.1542/peds.2013-0303; Centers for Disease Control and Prevention, PINK BOOK PRINC VACC; Centers for Disease Control and Prevention, IMM SCHED; Centers for Disease Control and Prevention, RSV SYMPT CAR; ClinicalTrials.gov, STUDY EVALUATE SAFET; Cohen MS, 2021, CLIN INFECT DIS, V2021, DOI [10.1093/cid/ciab494, DOI 10.1093/CID/CIAB494]; Cutrera R, 2019, ITAL J PEDIATR, V45, DOI 10.1186/s13052-019-0736-5; DASHEFSKY B, 1990, PEDIATRICS, V85, P682; Deb Paroma, 2021, Biosaf Health, V3, P87, DOI 10.1016/j.bsheal.2021.02.001; DEFOREST A, 1988, PEDIATRICS, V81, P237; Dohme MS., ZINPLAVA SMPC; Domachowske JB, 2018, PEDIATR INFECT DIS J, V37, P886, DOI [10.1097/inf.0000000000001916, 10.1097/INF.0000000000001916]; Driscoll AJ, 2020, VACCINE, V38, P2435, DOI 10.1016/j.vaccine.2020.01.020; Drysdale SB, 2016, THER ADV INFECT DIS, V3, P63, DOI 10.1177/2049936116630243; Ehreth J, 2003, VACCINE, V21, P596, DOI 10.1016/S0264-410X(02)00623-0; Englund J, 1998, VACCINE, V16, P1456, DOI 10.1016/S0264-410X(98)00108-X; European Medicines Agency, 2018, GUID CLIN EV VACC; European Vaccination Information Portal, VACC SCHED EU EEA; Feltes TF, 2003, J PEDIATR-US, V143, P532, DOI 10.1067/S0022-3476(03)00454-2; Food and Drug Administration, 2017, RESP SYNCYTIAL VIRUS; Food and Drug Administration, 2020, GUID DOC DRUG DRUG I; Food and Drug Administration, GUID IND GEN PRINC D; Griffin MP, 2020, NEW ENGL J MED, V383, P415, DOI 10.1056/NEJMoa1913556; Griffin MP, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01714-16, 10.1128/aac.01714-16]; Grohskopf LA, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6505a1; Guzman-Holst A, 2020, VACCINE, V38, P470, DOI 10.1016/j.vaccine.2019.10.088; Homaira N, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017936; HUTCHINS SS, 1989, PEDIATRICS, V83, P369; Immunization NACo, STAT REC US MON ANT; Karppinen S, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2015.10.002; KING GE, 1994, PEDIATR INFECT DIS J, V13, P394, DOI 10.1097/00006454-199405000-00012; Leader S, 2002, PEDIATR INFECT DIS J, V21, P629, DOI 10.1097/00006454-200207000-00005; Leroy Z, 2012, VACCINE, V30, P2020, DOI 10.1016/j.vaccine.2011.12.042; Lozano R, 2013, LANCET, V381, P991, DOI 10.1016/S0140-6736(13)60704-7; Madhi SA, 2020, NEW ENGL J MED, V383, P426, DOI 10.1056/NEJMoa1908380; Man WH, 2020, LANCET RESP MED, V8, P1022, DOI 10.1016/S2213-2600(19)30470-9; Marodi L, 2006, INFECT IMMUN, V74, P1999, DOI 10.1128/IAI.74.4.1999-2006.2006; Martin Joyce A, 2018, Natl Vital Stat Rep, V67, P1; McLaurin KK, 2016, J PERINATOL, V36, P990, DOI 10.1038/jp.2016.113; MedImmune, SYN PRESCR INF; Ministu┐re des Solidaritus et de la Santu, 2020, CALENDRIER VACCINATI; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Novartis, COS SMPC; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; Obando-Pacheco P, 2018, J INFECT DIS, V217, P1356, DOI 10.1093/infdis/jiy056; Palmer L, 2010, PEDIATR PULM, V45, P772, DOI 10.1002/ppul.21244; Piedimonte G, 2014, PEDIATR REV, V35, P519, DOI 10.1542/pir.35-12-519; Public Health England, GREEN BOOK; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; Rao DS., 2018, OVERVIEW COMPARTMENT, V7th, P199; Rha B, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2019-3611; Robbie GJ, 2012, ANTIMICROB AGENTS CH, V56, P4927, DOI 10.1128/AAC.06446-11; Salazar G, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0019-3; Luna MS, 2019, AN PEDIATR, V91, P348, DOI 10.1016/j.anpedi.2019.08.003; Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/s0140-6736(17)30938-8, 10.1016/S0140-6736(17)30938-8]; Simoes EAF, 2020, J INFECT DIS, V221, P1256, DOI 10.1093/infdis/jiz278; Slifka M. K., 2018, PLOTKINS VACCINES, VSeventh; Taylor PC, 2021, NAT REV IMMUNOL, V21, P382, DOI 10.1038/s41577-021-00542-x; The Association of the Scientific Medical Societies in Germany (AWMF), 2018, GUID PROPH SER DIS C; Toishi S EA., 2017, J GLOBAL, V121, P1063; Tomczyk S, 2014, MMWR-MORBID MORTAL W, V63, P822; Tse A, 2012, VACCINE, V30, P2024, DOI 10.1016/j.vaccine.2012.01.027; Waaijenborg S, 2013, J INFECT DIS, V208, P10, DOI 10.1093/infdis/jit143; Walker LM, 2018, NAT REV IMMUNOL, V18, P297, DOI 10.1038/nri.2017.148; Wessel AW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19096-y; WHO, IMM COV; World Health Organization, REC ROUT IMM; World Health Organization, CHILDR IMPR SURV WEL; World Health Organization, POL BRIEF GUID PREV; World Health Organization, VACC GREATL RED DIS; World Health Organization, 2021, PREF PROD CHAR MON A; Zhu Q, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj1928; Zimmermann P, 2019, ECLINICALMEDICINE, V13, P21, DOI 10.1016/j.eclinm.2019.06.010	88	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 11	2021	12									10.3389/fimmu.2021.708939	http://dx.doi.org/10.3389/fimmu.2021.708939			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UN2LF	34456918	gold, Green Published			2022-12-18	WOS:000693850600001
J	Moris, D; Cendales, LC				Moris, Dimitrios; Cendales, Linda C.			Sensitization and Desensitization in Vascularized Composite Allotransplantation	FRONTIERS IN IMMUNOLOGY			English	Review						vascular composite allotransplantation; sensitization; desensitization; antibody-mediated rejection; hand transplantation; face transplantation; burns	ANTIBODY-MEDIATED REJECTION; DONOR-SPECIFIC ANTIBODIES; INTERNATIONAL SOCIETY; NONHUMAN PRIMATE; COSTIMULATION BLOCKADE; HLA SENSITIZATION; C4D DEPOSITION; ALLOGRAFT; HAND; TRANSPLANTATION	Vascularized composite allotransplantation (VCA) is a field under research and has emerged as an alternative option for the repair of severe disfiguring defects that result from severe tissue loss in a selected group of patients. Lifelong immunosuppressive therapy, immunosuppression associated complications, and the effects of the host immune response in the graft are major concerns in this type of quality-of-life transplant. The initial management of extensive soft tissue injury can lead to the development of anti-HLA antibodies through injury-related factors, transfusion and cadaveric grafting. The role of antibody-mediated rejection, donor-specific antibody (DSA) formation and graft rejection in the context of VCA still remain poorly understood. The most common antigenic target of preexisting alloantibodies are MHC mismatches, though recognition of ABO incompatible antigens, minor histocompatibility complexes and endothelial cells has also been shown to contribute to rejection. Mechanistically, alloantibody-mediated tissue damage occurs primarily through complement fixation as well as through antibody-dependent cellular toxicity. If DSA exist, activation of complement and coagulation cascades can result in vascular thrombosis and infarction and thus rejection and graft loss. Both preexisting DSA but especially de-novo DSA are currently considered as main contributors to late allograft injury and graft failure. Desensitization protocols are currently being developed for VCA, mainly including removal of alloantibodies whereas treatment of established antibody-mediated rejection is achieved through high dose intravenous immunoglobulins. The long-term efficacy of such therapies in sensitized VCA recipients is currently unknown. The current evidence base for sensitizing events and outcomes in reconstructive transplantation is limited. However, current data show that VCA transplantation has been performed in the setting of HLA-sensitization.	[Moris, Dimitrios; Cendales, Linda C.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Duke University	Cendales, LC (corresponding author), Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.	linda.cendales@duke.edu		Moris, Dimitrios/0000-0002-5276-0699				Atia A, 2020, TRANSPL INT, V33, P1294, DOI 10.1111/tri.13612; Aubert O, 2017, J AM SOC NEPHROL, V28, P1912, DOI 10.1681/ASN.2016070797; Berglund E, 2019, TRANSPLANTATION, V103, P2173, DOI 10.1097/TP.0000000000002650; Berry GJ, 2013, J HEART LUNG TRANSPL, V32, P1147, DOI 10.1016/j.healun.2013.08.011; Burghuber CK, 2016, AM J TRANSPLANT, V16, P1726, DOI 10.1111/ajt.13688; Cendales L, 2015, AM J TRANSPLANT, V15, P2250, DOI 10.1111/ajt.13217; Cendales L, 2000, MICROSURG, V20, P412, DOI 10.1002/1098-2752(2000)20:8<412::AID-MICR12>3.0.CO;2-M; Cendales LC, 2008, AM J TRANSPLANT, V8, P1396, DOI 10.1111/j.1600-6143.2008.02243.x; Cendales LC, 2018, AM J TRANSPLANT, V18, P1804, DOI 10.1111/ajt.14910; Chandraker A, 2014, AM J TRANSPLANT, V14, P1446, DOI 10.1111/ajt.12715; Colvin RB, 2005, NAT REV IMMUNOL, V5, P807, DOI 10.1038/nri1702; Cross AR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00106; Demetris AJ, 2016, AM J TRANSPLANT, V16, P2816, DOI 10.1111/ajt.13909; Diaz-Siso JR, 2015, AM J TRANSPLANT, V15, P1421, DOI 10.1111/ajt.13103; Drachenberg CB, 2011, AM J TRANSPLANT, V11, P1792, DOI 10.1111/j.1600-6143.2011.03670.x; Duhamel P, 2015, TRANSPL INT, V28, P582, DOI 10.1111/tri.12540; Ezekian B, 2019, J AM SOC NEPHROL, V30, P2399, DOI 10.1681/ASN.2019030304; Fischer S, 2014, CURR OPIN ORGAN TRAN, V19, P531, DOI 10.1097/MOT.0000000000000140; Freitas AM, 2015, AM J TRANSPLANT, V15, P2240, DOI 10.1111/ajt.13379; Garces JC, 2017, OCHSNER J, V17, P46; Garza RM, 2017, J BURN CARE RES, V38, P169, DOI 10.1097/BCR.0000000000000458; Geoghegan L, 2020, J PLAST RECONSTR AES, V73, P1593, DOI 10.1016/j.bjps.2020.05.010; Giannis D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.544186; Grahammer J, 2017, AM J TRANSPLANT, V17, P3228, DOI 10.1111/ajt.14440; Haas M, 2014, AM J TRANSPLANT, V14, P272, DOI 10.1111/ajt.12590; Haas M, 2017, KIDNEY INT, V91, P729, DOI 10.1016/j.kint.2016.10.040; Hautz T, 2014, TRANSPL INT, V27, P966, DOI 10.1111/tri.12358; Howsare M, 2017, CURR OPIN ORGAN TRAN, V22, P463, DOI 10.1097/MOT.0000000000000456; Kanitakis J, 2007, TRANSPLANTATION, V84, P265, DOI 10.1097/01.tp.0000266899.93315.52; Kaufman CL, 2012, AM J TRANSPLANT, V12, P1004, DOI 10.1111/j.1600-6143.2011.03915.x; Khalifian S, 2014, LANCET, V384, P2153, DOI 10.1016/S0140-6736(13)62632-X; KISSMEYE F, 1966, LANCET, V2, P662, DOI 10.1016/S0140-6736(66)92829-7; Klein HJ, 2016, BURNS, V42, P246, DOI 10.1016/j.burns.2015.05.019; Klein HJ, 2018, BURNS, V44, P1330, DOI 10.1016/j.burns.2018.01.010; Kueckelhaus M, 2016, TRANSPL INT, V29, P655, DOI 10.1111/tri.12652; Kwun J, 2020, AM J TRANSPLANT, V20, P2, DOI 10.1111/ajt.15873; Landin L, 2009, TRANSPLANTATION, V87, P776, DOI 10.1097/TP.0b013e318198dbc7; Levine DJ, 2016, J HEART LUNG TRANSPL, V35, P397, DOI 10.1016/j.healun.2016.01.1223; Lewis HC, 2021, AM J TRANSPLANT, V21, P291, DOI 10.1111/ajt.16086; Manook M, 2018, TRANSPLANT REV-ORLAN, V32, P119, DOI 10.1016/j.trre.2018.01.001; McCaughan J, 2019, HEPATOBIL SURG NUTR, V8, P37, DOI 10.21037/hbsn.2019.01.01; Mengel M, 2012, AM J TRANSPLANT, V12, P563, DOI 10.1111/j.1600-6143.2011.03926.x; Morelon E, 2017, AM J TRANSPLANT, V17, P1935, DOI 10.1111/ajt.14218; Moris D, 2021, TRANSPL INT, V34, P572, DOI 10.1111/tri.13820; Petruzzo P, 2011, AM J TRANSPLANT, V11, P808, DOI 10.1111/j.1600-6143.2011.03469.x; Petruzzo Palmina, 2011, Clin Transpl, P247; Schneider M, 2016, TRANSPL INT, V29, P663, DOI 10.1111/tri.12750; Schroder PM, 2021, KIDNEY INT, V99, P161, DOI 10.1016/j.kint.2020.08.020; Stites E, 2015, J IMMUNOL, V195, P5525, DOI 10.4049/jimmunol.1501686; Tassin DH, 2020, J BURN CARE RES, V41, P1216, DOI 10.1093/jbcr/iraa070; Wang HD, 2018, TRANSPLANTATION, V102, P593, DOI 10.1097/TP.0000000000002070; Wang J, 2020, AM J TRANSPLANT, V20, P3558, DOI 10.1111/ajt.15912; Wang YM, 2021, BMC NEPHROL, V22, DOI 10.1186/s12882-021-02363-5; Weissenbacher A, 2018, TRANSPLANTATION, V102, P1250, DOI 10.1097/TP.0000000000002207; Weissenbacher A, 2016, CURR OPIN ORGAN TRAN, V21, P510, DOI 10.1097/MOT.0000000000000349; Weissenbacher A, 2014, TRANSPL INT, V27, pE13, DOI 10.1111/tri.12233; Wu Guo-Sheng, 2016, World J Transplant, V6, P719, DOI 10.5500/wjt.v6.i4.719	57	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 11	2021	12									10.3389/fimmu.2021.682180	http://dx.doi.org/10.3389/fimmu.2021.682180			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UN2KN	34456906	Green Published, gold			2022-12-18	WOS:000693848800001
J	Dieterlen, MT; Klaeske, K; Bernhardt, AA; Borger, MA; Klein, S; Garbade, J; Lehmann, S; Ayuk, FA; Reichenspurner, H; Barten, MJ				Dieterlen, Maja-Theresa; Klaeske, Kristin; Bernhardt, Alexander A.; Borger, Michael A.; Klein, Sara; Garbade, Jens; Lehmann, Sven; Ayuk, Francis Ayuketang; Reichenspurner, Herrmann; Barten, Markus J.			Immune Monitoring Assay for Extracorporeal Photopheresis Treatment Optimization After Heart Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						extracorporeal photopheresis; heart transplantation; regulatory T cells; dendrite cells; immune tolerance	REGULATORY T-CELLS; VERSUS-HOST-DISEASE; DENDRITIC CELLS; NEUROPILIN-1; PHOTOCHEMOTHERAPY; COLLECTION; INDUCTION; REJECTION; APHERESIS	Background: Extracorporeal photopheresis (ECP) induces immunological changes that lead to a reduced risk of transplant rejection. The aim of the present study was to determine optimum conditions for ECP treatment by analyzing a variety of tolerance-inducing immune cells to optimize the treatment. Methods: Ten ECP treatments were applied to each of 17 heart-transplant patients from month 3 to month 9 post-HTx. Blood samples were taken at baseline, three times during treatment, and four months after the last ECP treatment. The abundance of subsets of tolerance-inducing regulatory T cells (T-regs) and dendritic cells (DCs) in the samples was determined by flow cytometry. A multivariate statistical model describing the immunological status of rejection-free heart transplanted patients was used to visualize the patient-specific immunological improvement induced by ECP. Results: All BDCA(+) DC subsets (BDCA1(+) DCs: p < 0.01. BDCA2(+) DCs: p < 0.01, BDCA3(+) DCs: p < 0.01, BDCA4(+) DCs: p < 0.01) as well as total T-regs (p < 0.01) and CD39(+) T-regs (p < 0.01) increased during ECP treatment, while CD62L(+) T-regs decreased (p < 0.01). The cell surface expression level of BDCA1 (p < 0.01) and BDCA4 (p < 0.01) on DCs as well as of CD120b (p < 0.01) on T-regs increased during the study period, while CD62L expression on T-regs decreased significantly (p = 0.04). The cell surface expression level of BDCA2 (p = 0.47) and BDCA3 (p = 0.22) on DCs as well as of CD39 (p = 0.14) and CD147 (p = 0.08) on T-regs remained constant during the study period. A cluster analysis showed that ECP treatment led to a sustained immunological improvement. Conclusions: We developed an immune monitoring assay for ECP treatment after heart transplantation by analyzing changes in tolerance-inducing immune cells. This assay allowed differentiation of patients who did and did not show immunological improvement. Based on these results, we propose classification criteria that may allow optimization of the duration of ECP treatment.	[Dieterlen, Maja-Theresa; Klaeske, Kristin; Borger, Michael A.; Klein, Sara; Garbade, Jens; Lehmann, Sven] Univ Hosp Leipzig, Heart Ctr, Dept Cardiac Surg, HELIOS Clin, Leipzig, Germany; [Bernhardt, Alexander A.; Ayuk, Francis Ayuketang] Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany; [Reichenspurner, Herrmann; Barten, Markus J.] Univ Heart & Vasc Ctr Hamburg, Dept Cardiovasc Surg, Hamburg, Germany	Heart Center Leipzig GMBH; Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Dieterlen, MT (corresponding author), Univ Hosp Leipzig, Heart Ctr, Dept Cardiac Surg, HELIOS Clin, Leipzig, Germany.	mdieterlen@web.de						Ahrens N, 2018, TRANSPLANTATION, V102, P1279, DOI 10.1097/TP.0000000000002244; Barr ML, 1998, NEW ENGL J MED, V339, P1744, DOI 10.1056/NEJM199812103392404; Barten MJ, 2018, TRANSPLANT REV-ORLAN, V32, P207, DOI 10.1016/j.trre.2018.05.002; Barten MJ, 2014, IMMUNOTHERAPY-UK, V6, P927, DOI [10.2217/IMT.14.69, 10.2217/imt.14.69]; Beyrend G, 2018, COMPUT STRUCT BIOTEC, V16, P435, DOI 10.1016/j.csbj.2018.10.004; Biagi E, 2007, TRANSPLANTATION, V84, P31, DOI 10.1097/01.tp.0000267785.52567.9c; Capuano M, 2015, THER APHER DIAL, V19, P103, DOI 10.1111/1744-9987.12245; Corbel C, 2007, DEV COMP IMMUNOL, V31, P1082, DOI 10.1016/j.dci.2007.01.009; Del Fante C, 2016, TRANSFUSION, V56, P2078, DOI 10.1111/trf.13672; Del Fante C, 2013, TRANSFUSION, V53, P2027, DOI 10.1111/trf.12065; Dieterlen MT, 2014, CLIN EXP IMMUNOL, V176, P120, DOI 10.1111/cei.12254; Dieterlen MT, 2018, J CLIN APHERESIS, V33, P591, DOI 10.1002/jca.21647; Dunbar NM, 2017, J CLIN APHERESIS, V32, P215, DOI 10.1002/jca.21486; Dzionek A, 2001, J EXP MED, V194, P1823, DOI 10.1084/jem.194.12.1823; Ermann J, 2005, BLOOD, V105, P2220, DOI 10.1182/blood-2004-05-2044; Florek M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145763; Fu S, 2004, AM J TRANSPLANT, V4, P65, DOI 10.1046/j.1600-6143.2003.00293.x; George JF, 2008, J HEART LUNG TRANSPL, V27, P616, DOI 10.1016/j.healun.2008.02.015; Gustafson MP, 2013, J IMMUNOTHER CANCER, V1, DOI 10.1186/2051-1426-1-7; Hoffmann J, 2020, THROMB HAEMOSTASIS, V120, P141, DOI 10.1055/s-0039-1700871; Klaeske K, 2020, TRANSPL IMMUNOL, V59, DOI 10.1016/j.trim.2019.101259; Knobler R, 2021, J EUR ACAD DERMATOL, V35, P27, DOI 10.1111/jdv.16889; Lamioni A, 2005, TRANSPLANTATION, V79, P846, DOI 10.1097/01.TP.0000157278.02848.C7; Lamioni A, 2007, TRANSPLANTATION, V83, P1393, DOI 10.1097/01.tp.0000261635.30578.d8; Lu SY, 2011, CLIN EXP IMMUNOL, V165, P264, DOI 10.1111/j.1365-2249.2011.04418.x; Meloni F, 2007, TRANSPL P, V39, P213, DOI 10.1016/j.transproceed.2006.10.227; Padmanabhan A, 2019, J CLIN APHERESIS, V34, P171, DOI 10.1002/jca.21705; Schmitt S, 2009, TRANSPLANTATION, V88, P411, DOI 10.1097/TP.0b013e3181aed927; Shiue LH, 2013, J INVEST DERMATOL, V133, P2098, DOI 10.1038/jid.2013.142; Tsirigotis P, 2012, TRANSFUS APHER SCI, V46, P181, DOI 10.1016/j.transci.2011.10.028; Yadav M, 2012, J EXP MED, V209, P1713, DOI 10.1084/jem.20120822; Yuan Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061151; Zhou H, 2007, TRANSPL P, V39, P81, DOI 10.1016/j.transproceed.2006.10.221	33	1	1	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 10	2021	12								676175	10.3389/fimmu.2021.676175	http://dx.doi.org/10.3389/fimmu.2021.676175			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6I0OD	34447372	gold, Green Published			2022-12-18	WOS:000885826600001
J	Gao, ZQ; Fu, R; Li, XB; Wang, J; He, YX				Gao, Zhengqin; Fu, Rui; Li, Xiaobo; Wang, Ji; He, Yuxian			Safety Assessment of Microbicide 2P23 on the Rectal and Vaginal Microbiota and Its Antiviral Activity on HIV Infection	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; membrane fusion inhibitor; inflammatory cytokines; microbiota; mucosal immune system	IMMUNODEFICIENCY-VIRUS TYPE-1; FUSION INHIBITOR T-20; RNA GENE DATABASE; PREEXPOSURE PROPHYLAXIS; PREVENTION; TRANSMISSION; GEL; EFFICACY; SEQUENCES; FAILURE	Containment of the AIDS pandemic requires reducing HIV transmission. HIV infection is initiated by the fusion of the membrane between the virus and the cell membrane of the host. 2P23 is an effective HIV membrane fusion inhibitor that may be a good entry inhibitor microbicide candidate. This study evaluated the potential of using gel-formulated 2P23 as a topical microbicide to prevent sexual transmission of HIV in the rectum and vagina. Our data revealed that 2P23 formulated in gel is effective against HIV. There was no change in antiviral activity at 25 degrees C for 4 months or 60 degrees C for 1 week. In addition, we demonstrated that the 2P23 gel was stable and fully functional at pH 4.0-8.0 and under different concentrations of H2O2. Finally, the 2P23 gel exhibited no cytotoxicity or antimicrobial activity and did not induce inflammatory changes in the rectal or vaginal mucosal epithelium in New Zealand rabbits after 20 mg/day daily rectovaginal application for 14 consecutive days. Despite repeated tissue sampling and 2P23 gel treatment, the inflammatory cytokines and microbiota of the rectum and vagina remained stable. These results add to general knowledge on the in vivo evaluation of anti-HIV microbicide application concerning inflammatory cytokines and microbiota changes in the rectum and vagina. These findings suggest that the 2P23 gel is an excellent candidate for further development as a safe and effective pre-exposure prophylactic microbicide for the prevention of HIV transmission.	[Gao, Zhengqin; He, Yuxian] Chinese Acad Med Sci & Peking Union Med Coll, Inst Pathogen Biol, NHC Key Lab Syst Biol Pathogens, Beijing, Peoples R China; [Gao, Zhengqin; He, Yuxian] Chinese Acad Med Sci & Peking Union Med Coll, Ctr AIDS Res, Beijing, Peoples R China; [Gao, Zhengqin; Fu, Rui; Li, Xiaobo; Wang, Ji] Natl Inst Food & Drug Control, Inst Lab Anim Resources, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; National Institute of Food & Drug Control - China	Gao, ZQ; He, YX (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Pathogen Biol, NHC Key Lab Syst Biol Pathogens, Beijing, Peoples R China.; Gao, ZQ; He, YX (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Ctr AIDS Res, Beijing, Peoples R China.; Gao, ZQ (corresponding author), Natl Inst Food & Drug Control, Inst Lab Anim Resources, Beijing, Peoples R China.	gaozhengqin@126.com; yhe@ipb.pumc.edu.cn			CAMS Innovation Fund for Medical Sciences [2017-I2M-1014]	CAMS Innovation Fund for Medical Sciences	This study was supported by the grant from the CAMS Innovation Fund for Medical Sciences (2017-I2M-1014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Mushrif S., 1998, Journal of Obstetrics and Gynaecology (Abingdon), V18, P63; [Anonymous], 2017, 1099352009 ISO; [Anonymous], 2010, 1099310 ISO; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Baeten J, 2013, ANNU REV MED, V64, P219, DOI 10.1146/annurev-med-050911-163701; Bartolo I, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195744; Boretzki J, 2017, PATIENT PREFER ADHER, V11, P1897, DOI 10.2147/PPA.S141762; Burgener A, 2015, CURR OPIN IMMUNOL, V36, P22, DOI 10.1016/j.coi.2015.06.004; CHESEBRO B, 1988, J VIROL, V62, P3779, DOI 10.1128/JVI.62.10.3779-3788.1988; CHESEBRO B, 1990, J VIROL, V64, P215, DOI 10.1128/JVI.64.1.215-221.1990; Cheu RK, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009024; CHVAPIL M, 1979, J BIOMED MATER RES, V13, P1, DOI 10.1002/jbm.820130103; Claborn KR, 2015, PSYCHOL HEALTH MED, V20, P255, DOI 10.1080/13548506.2014.945601; Clinical and Laboratory Standards Institute, 2018, M100 CLIN LAB STAND, V28th, DOI DOI 10.1108/08876049410065598; Cole JR, 2014, NUCLEIC ACIDS RES, V42, pD633, DOI 10.1093/nar/gkt1244; Communications and Global Advocacy, 2020, UNAIDS FACT SHEET WO; Cranston RD, 2017, CLIN INFECT DIS, V64, P614, DOI 10.1093/cid/ciw832; Delany-Moretlwe S, 2018, LANCET INFECT DIS, V18, P1241, DOI 10.1016/s1473-3099(18)30428-6; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; ECKSTEIN P, 1969, J REPROD FERTIL, V20, P85; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Foss AM, 2003, AIDS, V17, P1227, DOI 10.1097/00002030-200305230-00015; Gregson J, 2016, LANCET INFECT DIS, V16, P565, DOI 10.1016/S1473-3099(15)00536-8; Gupta SK, 2013, HIV AIDS-RES PALLIAT, V5, P295, DOI 10.2147/HIV.S39164; Huerta-Cepas J, 2016, MOL BIOL EVOL, V33, P1635, DOI 10.1093/molbev/msw046; KAMINSKY M, 1982, FOOD CHEM TOXICOL, V20, P193, DOI 10.1016/S0015-6264(82)80008-4; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Klatt NR, 2017, SCIENCE, V356, P938, DOI 10.1126/science.aai9383; Klindworth A, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks808; Kochling T, 2015, APPL MICROBIOL BIOT, V99, P5657, DOI 10.1007/s00253-015-6409-4; Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13; Liebenberg LJP, 2017, JAIDS-J ACQ IMM DEF, V74, P318, DOI 10.1097/QAI.0000000000001218; Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269; Morris GC, 2010, CURR OPIN INFECT DIS, V23, P57, DOI 10.1097/QCO.0b013e328334de6d; MULLER P, 1988, EXP PATHOL-JENA, V34, P223; Nel A, 2016, NEW ENGL J MED, V375, P2133, DOI 10.1056/NEJMoa1602046; Ngandu NK, 2017, JAIDS-J ACQ IMM DEF, V76, P43, DOI 10.1097/QAI.0000000000001458; Noguera-Julian M, 2016, EBIOMEDICINE, V5, P135, DOI 10.1016/j.ebiom.2016.01.032; Petrova MI, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00081; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Platt EJ, 2009, J VIROL, V83, P8289, DOI 10.1128/JVI.00709-09; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; REED L. J., 1938, AMER JOUR HYG, V27, P493; Remis RS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107540; Richardson BA, 2013, JAIDS-J ACQ IMM DEF, V63, P120, DOI 10.1097/QAI.0b013e31828607c5; Rohan LC, 2014, CURR TOP MICROBIOL, V383, P27, DOI 10.1007/82_2013_357; Schwartz JL, 2007, CONTRACEPTION, V75, P136, DOI 10.1016/j.contraception.2006.09.003; Shaw GM, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006965; Stannah J, 2020, AIDS BEHAV, V24, P667, DOI 10.1007/s10461-019-02651-0; STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460; Takeuchi Y, 2008, J VIROL, V82, P12585, DOI 10.1128/JVI.01726-08; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; Tien D, 2005, AIDS RES HUM RETROV, V21, P845, DOI 10.1089/aid.2005.21.845; Turpin JA, 2002, EXPERT OPIN INV DRUG, V11, P1077, DOI 10.1517/13543784.11.8.1077; Van Damme L, 2008, NEW ENGL J MED, V359, P463, DOI 10.1056/NEJMoa0707957; Velloza J, 2017, CURR HIV-AIDS REP, V14, P153, DOI 10.1007/s11904-017-0362-z; Vujkovic-Cvijin I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16222-8; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Weinsteinet, 2018, METHODS DILUTION ANT, V1; WEIR SS, 1995, GENITOURIN MED, V71, P78; WHO, 2018, FOC KEY POP NAT HIV; Xiong SW, 2017, J VIROL, V91, DOI 10.1128/JVI.01839-16	66	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 10	2021	12								702172	10.3389/fimmu.2021.702172	http://dx.doi.org/10.3389/fimmu.2021.702172			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UE4KU	34447373	Green Published, gold			2022-12-18	WOS:000687860100001
J	Wang, G; Zhuo, N; Luo, XW; Tian, F; Wen, ZH; Li, JY				Wang, Gang; Zhuo, Ning; Luo, Xiaowen; Tian, Feng; Wen, Zhenhua; Li, Jingyang			IgG4-Related Disease With Testicular Involvement: A Case Report and Review of Literature	FRONTIERS IN IMMUNOLOGY			English	Review						IgG4-related disease; testis; clinical feature; treatment; glucocorticoids	PARATESTICULAR FIBROUS PSEUDOTUMOR; RETROPERITONEAL FIBROSIS; MANIFESTATION; ENTITY	Immunoglobulin G4-related disease (IgG4-RD) is an autoimmune inflammatory disease characterized by infiltration of IgG4+ plasma cells that can simulate a tumor manifesting as a tumor-like mass. This disease involves the pancreas, biliary tract, kidneys, salivary glands, lymph nodes, aorta, and retroperitoneum amongst other organs. However, testicular involvement is a rare entity in this disease. The treatment of testicular involvement in IgG4-RD is currently controversial. We present the case of a 65-year-old man with swelling and pain in his right scrotum three months ago. On examination, a mobile mass of approximately 2 cm in diameter was found in the right scrotum. Serological tests showed elevated levels of IgG4 and negative for tumor markers. Enhanced computed tomography of the scrotum showed a nodular hyperdense shadow with a diameter of approximately 23 mm on the right epididymis. Pathological biopsy of the right epididymis showed infiltration of plasma cells, lymphocytes, and a few neutrophils. IgG4+ plasma cells stained positive, with an IgG4/IgG ratio of more than 40% and more than 30 IgG4+ plasma cells per high-power field. A diagnosis of IgG4-RD involving the testicles was made. Prednisone 30 mg/d was given for three weeks. No scrotum swelling or pain was observed at the follow-up after six months. IgG4-related disease should be considered whenever a mass-like lesion with typical histomorphologic features involving multiple organs/anatomical sites is encountered. The testicles are an important male reproductive organ, especially for young male patients with fertility requirements. For patients with IgG4-RD testicular involvement, surgical or medical treatment requires further study.	[Wang, Gang; Luo, Xiaowen; Tian, Feng; Wen, Zhenhua; Li, Jingyang] Cent South Univ, Zhuzhou Hosp Affiliated, Xiangya Med Coll, Dept Rheumatol & Immunol, Zhuzhou, Peoples R China; [Zhuo, Ning] Cent South Univ, Xiangya Hosp 2, Dept Nephrol, Changsha, Peoples R China	Central South University	Li, JY (corresponding author), Cent South Univ, Zhuzhou Hosp Affiliated, Xiangya Med Coll, Dept Rheumatol & Immunol, Zhuzhou, Peoples R China.	wgzncsu@csu.edu.cn		Wang, Gang/0000-0002-8836-1593				Bosmuller H, 2011, VIRCHOWS ARCH, V458, P109, DOI 10.1007/s00428-010-0995-4; ChangChien YC, 2018, ANN CLIN LAB SCI, V48, P381; Cho YJ, 2018, RHEUMATOL INT, V38, P1941, DOI 10.1007/s00296-018-4089-y; Dieckmann Klaus-Peter, 2013, J Med Case Rep, V7, P225, DOI 10.1186/1752-1947-7-225; Garber ME, 2021, UROL CASE REP, V36, DOI 10.1016/j.eucr.2021.101584; Hart PA, 2012, HUM PATHOL, V43, P2084, DOI 10.1016/j.humpath.2012.05.017; Inoue D, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000680; Karashima T, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0225-5; Kim KH, 2015, UROL INT, V94, P369, DOI 10.1159/000362215; Lal J, 2016, INDIAN J UROL, V32, P326, DOI 10.4103/0970-1591.191273; Lanzillotta M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1067; Lu H, 2021, RHEUMATOLOGY, V60, P2635, DOI 10.1093/rheumatology/keaa651; Mahajan VS, 2014, ANNU REV PATHOL-MECH, V9, P315, DOI 10.1146/annurev-pathol-012513-104708; Migita K, 2014, MOD RHEUMATOL, V24, P188, DOI 10.3109/14397595.2013.852841; Mochizuki K, 2019, DIAGN CYTOPATHOL, V47, P130, DOI 10.1002/dc.24099; Shams A, 2021, TURK J PATHOL, V37, P78, DOI 10.5146/tjpath.2020.01493; Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650; Tokura Y, 2017, INT J UROL, V24, P771, DOI 10.1111/iju.13430; Wallace ZS, 2015, ARTHRITIS RHEUMATOL, V67, P2466, DOI 10.1002/art.39205; Wenniger LMD, 2013, UROLOGY, V82, pE15, DOI 10.1016/j.urology.2013.04.046	20	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 10	2021	12								717902	10.3389/fimmu.2021.717902	http://dx.doi.org/10.3389/fimmu.2021.717902			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UE4OP	34447384	gold, Green Published			2022-12-18	WOS:000687870000001
J	Watts, D; Janssen, M; Jaykar, M; Palmucci, F; Weigelt, M; Petzold, C; Hommel, A; Sparwasser, T; Bonifacio, E; Kretschmer, K				Watts, Deepika; Janssen, Marthe; Jaykar, Mangesh; Palmucci, Francesco; Weigelt, Marc; Petzold, Cathleen; Hommel, Angela; Sparwasser, Tim; Bonifacio, Ezio; Kretschmer, Karsten			Transient Depletion of Foxp3(+) Regulatory T Cells Selectively Promotes Aggressive beta Cell Autoimmunity in Genetically Susceptible DEREG Mice	FRONTIERS IN IMMUNOLOGY			English	Article						type 1 diabetes; immune regulation; Treg cells; Foxp3; cell ablation	NONOBESE DIABETIC MICE; INVARIANT NKT CELLS; MONOCLONAL-ANTIBODY; POLYENDOCRINOPATHY; ENTEROPATHY; PROTECTION; TOLERANCE; INSULITIS; REQUIRES; MOUSE	Type 1 diabetes (T1D) represents a hallmark of the fatal multiorgan autoimmune syndrome affecting humans with abrogated Foxp3(+) regulatory T (Treg) cell function due to Foxp3 gene mutations, but whether the loss of Foxp3(+) Treg cell activity is indeed sufficient to promote beta cell autoimmunity requires further scrutiny. As opposed to human Treg cell deficiency, beta cell autoimmunity has not been observed in non-autoimmune-prone mice with constitutive Foxp3 deficiency or after diphtheria toxin receptor (DTR)-mediated ablation of Foxp3(+) Treg cells. In the spontaneous nonobese diabetic (NOD) mouse model of T1D, constitutive Foxp3 deficiency did not result in invasive insulitis and hyperglycemia, and previous studies on Foxp3(+) Treg cell ablation focused on Foxp3(DTR) NOD mice, in which expression of a transgenic BDC2.5 T cell receptor (TCR) restricted the CD4(+) TCR repertoire to a single diabetogenic specificity. Here we revisited the effect of acute Foxp3(+) Treg cell ablation on beta cell autoimmunity in NOD mice in the context of a polyclonal TCR repertoire. For this, we took advantage of the well-established DTR/GFP transgene of DEREG mice, which allows for specific ablation of Foxp3(+) Treg cells without promoting catastrophic autoimmune diseases. We show that the transient loss of Foxp3(+) Treg cells in prediabetic NOD.DEREG mice is sufficient to precipitate severe insulitis and persistent hyperglycemia within 5 days after DT administration. Importantly, DT-treated NOD.DEREG mice preserved many clinical features of spontaneous diabetes progression in the NOD model, including a prominent role of diabetogenic CD8(+) T cells in terminal beta cell destruction. Despite the severity of destructive beta cell autoimmunity, anti-CD3 mAb therapy of DT-treated mice interfered with the progression to overt diabetes, indicating that the novel NOD.DEREG model can be exploited for preclinical studies on T1D under experimental conditions of synchronized, advanced beta cell autoimmunity. Overall, our studies highlight the continuous requirement of Foxp3(+) Treg cell activity for the control of genetically pre-installed autoimmune diabetes.	[Watts, Deepika; Janssen, Marthe; Jaykar, Mangesh; Palmucci, Francesco; Petzold, Cathleen; Kretschmer, Karsten] Tech Univ Dresden, Ctr Regenerat Therapies Dresden CRTD, Ctr Mol & Cellular Bioengn CMCB, Mol & Cellular Immunol Immune Regulat, Dresden, Germany; [Watts, Deepika; Janssen, Marthe; Palmucci, Francesco; Bonifacio, Ezio; Kretschmer, Karsten] Univ Hosp, Paul Langerhans Inst Dresden PLID, Helmholtz Zentrum Munchen, Dresden, Germany; [Watts, Deepika; Janssen, Marthe; Palmucci, Francesco; Bonifacio, Ezio; Kretschmer, Karsten] Tech Univ Dresden, Med Fac Carl Gustav Carus, Dresden, Germany; [Watts, Deepika; Janssen, Marthe; Palmucci, Francesco; Bonifacio, Ezio; Kretschmer, Karsten] German Ctr Diabet Res DZD eV, Neuherberg, Germany; [Weigelt, Marc; Hommel, Angela; Bonifacio, Ezio] Tech Univ Dresden, Ctr Regenerat Therapies Dresden CRTD, Ctr Mol & Cellular Bioengn CMCB, Regenerat Therapies Diabet, Dresden, Germany; [Sparwasser, Tim] TWINCORE Ctr Expt & Clin Infect Res, Inst Infect Immunol, Hannover, Germany	Technische Universitat Dresden; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Helmholtz Association; Helmholtz-Center for Infection Research	Kretschmer, K (corresponding author), Tech Univ Dresden, Ctr Regenerat Therapies Dresden CRTD, Ctr Mol & Cellular Bioengn CMCB, Mol & Cellular Immunol Immune Regulat, Dresden, Germany.; Kretschmer, K (corresponding author), Univ Hosp, Paul Langerhans Inst Dresden PLID, Helmholtz Zentrum Munchen, Dresden, Germany.; Kretschmer, K (corresponding author), Tech Univ Dresden, Med Fac Carl Gustav Carus, Dresden, Germany.; Kretschmer, K (corresponding author), German Ctr Diabet Res DZD eV, Neuherberg, Germany.	karsten.kretschmer@tu-dresden.de	Bonifacio, Ezio/E-7700-2010; Sparwasser, Tim D/AAA-4306-2022	Bonifacio, Ezio/0000-0002-8704-4713; 	CRTD/Center for Regenerative Therapies Dresden, DFG [FZT 111]; BMBF (German Ministry for Education and Research) [FKZ01GI0924]	CRTD/Center for Regenerative Therapies Dresden, DFG(German Research Foundation (DFG)); BMBF (German Ministry for Education and Research)(Federal Ministry of Education & Research (BMBF))	This work was supported by the FZT 111 (CRTD/Center for Regenerative Therapies Dresden, DFG), and by a BMBF (German Ministry for Education and Research) grant to the German Center for Diabetes Research (DZD e.V., FKZ01GI0924).	Anderson MS, 2005, ANNU REV IMMUNOL, V23, P447, DOI 10.1146/annurev.immunol.23.021704.115643; Bacchetta R, 2018, ANN NY ACAD SCI, V1417, P5, DOI 10.1111/nyas.13011; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; BERNARD NF, 1992, DIABETES, V41, P40, DOI 10.2337/diabetes.41.1.40; Berod L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102804; Billiard F, 2012, J EXP MED, V209, P1011, DOI 10.1084/jem.20111615; Bour-Jordan H, 2013, J AUTOIMMUN, V45, P58, DOI 10.1016/j.jaut.2013.06.005; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Chatenoud L, 1997, J IMMUNOL, V158, P2947; CHATENOUD L, 1994, P NATL ACAD SCI USA, V91, P123, DOI 10.1073/pnas.91.1.123; Chen YG, 2018, FRONT ENDOCRINOL, V9, DOI [10.3389/fpls.2018.00779, 10.3389/fendo.2018.00051]; Chen ZB, 2005, J EXP MED, V202, P1387, DOI 10.1084/jem.20051409; Feuerer M, 2009, IMMUNITY, V31, P654, DOI 10.1016/j.immuni.2009.08.023; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fukushima K, 2008, BIOCHEM BIOPH RES CO, V367, P719, DOI 10.1016/j.bbrc.2007.12.191; Gomez-Diaz RA, 2011, CURR DIABETES REV, V7, P278, DOI 10.2174/157339911796397839; Griseri T, 2005, J IMMUNOL, V175, P2091, DOI 10.4049/jimmunol.175.4.2091; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; Herold KC, 2019, NEW ENGL J MED, V381, P603, DOI 10.1056/NEJMoa1902226; Hubner MP, 2012, J IMMUNOL, V188, P559, DOI 10.4049/jimmunol.1100335; Hull CM, 2017, DIABETOLOGIA, V60, P1839, DOI 10.1007/s00125-017-4377-1; Kim J, 2009, J IMMUNOL, V183, P7631, DOI 10.4049/jimmunol.0804308; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; Kohm AP, 2006, J IMMUNOL, V176, P3301, DOI 10.4049/jimmunol.176.6.3301; Kuhn C, 2016, IMMUNOTHERAPY-UK, V8, P889, DOI 10.2217/imt-2016-0049; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Lahl K, 2011, METHODS MOL BIOL, V707, P157, DOI 10.1007/978-1-61737-979-6_10; Li L, 2013, J IMMUNOL, V191, P3694, DOI 10.4049/jimmunol.1300408; Li XR, 2010, EUR J IMMUNOL, V40, P3325, DOI 10.1002/eji.201041093; Liu Q, 2009, INFECT IMMUN, V77, P5347, DOI 10.1128/IAI.01170-08; Long SA, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aai7793; Luo XR, 2008, P NATL ACAD SCI USA, V105, P14527, DOI 10.1073/pnas.0805204105; Ly D, 2006, J IMMUNOL, V177, P3695, DOI 10.4049/jimmunol.177.6.3695; Marino E, 2009, DIABETES, V58, P1568, DOI 10.2337/db08-1504; Mayer CT, 2014, IMMUN INFLAMM DIS, V2, P162, DOI 10.1002/iid3.33; Mayer CT, 2014, EUR J IMMUNOL, V44, P2990, DOI 10.1002/eji.201344315; McDevitt HO, 2008, ADV IMMUNOL, V100, P1, DOI 10.1016/S0065-2776(08)00801-8; Mellanby RJ, 2007, IMMUNOLOGY, V121, P15, DOI 10.1111/j.1365-2567.2007.02546.x; Nishio J, 2010, J EXP MED, V207, P1879, DOI 10.1084/jem.20100205; Novak J, 2007, INT REV IMMUNOL, V26, P49, DOI 10.1080/08830180601070229; Novak J, 2007, J IMMUNOL, V178, P1332, DOI 10.4049/jimmunol.178.3.1332; Petzold C, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/940710; Phillips Jenny M, 2009, Rev Diabet Stud, V6, P97, DOI 10.1900/RDS.2009.6.97; Rausch S, 2009, EUR J IMMUNOL, V39, P3066, DOI 10.1002/eji.200939644; Riewaldt J, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00141; Rui JX, 2017, CELL METAB, V25, P727, DOI 10.1016/j.cmet.2017.01.005; Suffner J, 2010, J IMMUNOL, V184, P1810, DOI 10.4049/jimmunol.0902420; Tang SS, 2020, P NATL ACAD SCI USA, V117, P31219, DOI 10.1073/pnas.2012389117; Tooley JE, 2016, EUR J IMMUNOL, V46, P230, DOI 10.1002/eji.201545708; Wang H, 2014, REPRODUCTION, V148, P73, DOI 10.1530/REP-13-0614; Wildin RS, 2002, J MED GENET, V39, P537, DOI 10.1136/jmg.39.8.537; You S, 2004, P NATL ACAD SCI USA, V101, P14580, DOI 10.1073/pnas.0404870101; Zelenay S, 2006, J IMMUNOL, V177, P2036, DOI 10.4049/jimmunol.177.4.2036-a	53	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 10	2021	12								720133	10.3389/fimmu.2021.720133	http://dx.doi.org/10.3389/fimmu.2021.720133			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UE4SU	34447385	Green Published, gold			2022-12-18	WOS:000687880900001
J	Wahid, AA; Dunphy, RW; Macpherson, A; Gibson, BG; Kulik, L; Whale, K; Back, C; Hallam, TM; Alkhawaja, B; Martin, RL; Meschede, I; Laabei, M; Lawson, ADG; Holers, VM; Watts, AG; Crennell, SJ; Harris, CL; Marchbank, KJ; van den Elsen, JMHV				Wahid, Ayla A.; Dunphy, Rhys W.; Macpherson, Alex; Gibson, Beth G.; Kulik, Liudmila; Whale, Kevin; Back, Catherine; Hallam, Thomas M.; Alkhawaja, Bayan; Martin, Rebecca L.; Meschede, Ingrid; Laabei, Maisem; Lawson, Alastair D. G.; Holers, V. Michael; Watts, Andrew G.; Crennell, Susan J.; Harris, Claire L.; Marchbank, Kevin J.; van den Elsen, Jean M. H.			Insights Into the Structure-Function Relationships of Dimeric C3d Fragments	FRONTIERS IN IMMUNOLOGY			English	Article						complement; B cell; tolerance; C3d dimers; X-ray crystal and molecular structure	ALTERNATIVE COMPLEMENT PATHWAY; SYSTEMIC-LUPUS-ERYTHEMATOSUS; FACTOR-H; CD40 LIGAND; B-CELLS; CRYSTAL-STRUCTURE; C5 CONVERTASE; RECEPTOR; ACTIVATION; EXPRESSION	Cleavage of C3 to C3a and C3b plays a central role in the generation of complement-mediated defences. Although the thioester-mediated surface deposition of C3b has been well-studied, fluid phase dimers of C3 fragments remain largely unexplored. Here we show C3 cleavage results in the spontaneous formation of C3b dimers and present the first X-ray crystal structure of a disulphide-linked human C3d dimer. Binding studies reveal these dimers are capable of crosslinking complement receptor 2 and preliminary cell-based analyses suggest they could modulate B cell activation to influence tolerogenic pathways. Altogether, insights into the physiologically-relevant functions of C3d(g) dimers gained from our findings will pave the way to enhancing our understanding surrounding the importance of complement in the fluid phase and could inform the design of novel therapies for immune system disorders in the future.	[Wahid, Ayla A.; Dunphy, Rhys W.; Macpherson, Alex; Back, Catherine; Laabei, Maisem; Crennell, Susan J.; van den Elsen, Jean M. H.] Univ Bath, Dept Biol & Biochem, Bath, Avon, England; [Macpherson, Alex] UCB Pharma, Slough, Berks, England; [Gibson, Beth G.; Hallam, Thomas M.; Harris, Claire L.; Marchbank, Kevin J.] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Kulik, Liudmila; Holers, V. Michael] Univ Colorado, Div Rheumatol, Aurora, CO USA; [Alkhawaja, Bayan; Martin, Rebecca L.; Watts, Andrew G.] Univ Bath, Dept Pharm & Pharmacol, Bath, Avon, England; [Watts, Andrew G.; van den Elsen, Jean M. H.] Univ Bath, Ctr Therapeut Innovat, Bath, Avon, England	University of Bath; UCB Pharma SA; Newcastle University - UK; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Bath; University of Bath	Wahid, AA; van den Elsen, JMHV (corresponding author), Univ Bath, Dept Biol & Biochem, Bath, Avon, England.; van den Elsen, JMHV (corresponding author), Univ Bath, Ctr Therapeut Innovat, Bath, Avon, England.	aw931@cam.ac.uk; J.M.H.V.Elsen@bath.ac.uk	Laabei, Maisem/AAH-6383-2021	Laabei, Maisem/0000-0002-8425-3704; marchbank, kevin james/0000-0003-1312-5411; van den Elsen, Jean/0000-0002-0367-1956; Hallam, Thomas/0000-0002-4632-9640; Wahid, Ayla A./0000-0001-8128-9632	Biotechnology and Biological Sciences Research Council Follow On Fund [BB/N022165/1]; University of Bath Alumni Fund; Medical Research Council GW4 Doctoral Training Partnership; Alexion Pharmaceuticals; Kidney Research UK [RP-006-20270301]; Newcastle University; Northern Counties Kidney Research Grant	Biotechnology and Biological Sciences Research Council Follow On Fund; University of Bath Alumni Fund; Medical Research Council GW4 Doctoral Training Partnership; Alexion Pharmaceuticals; Kidney Research UK(Kidney Research UK (KRUK)); Newcastle University; Northern Counties Kidney Research Grant	This research was supported by the Biotechnology and Biological Sciences Research Council Follow On Fund BB/N022165/1.AAW was sponsored by a PhD studentship granted by Raoul and Catherine Hughes and the University of Bath Alumni Fund. RD was supported by a Medical Research Council GW4 Doctoral Training Partnership. BG and KM were funded by a Northern Counties Kidney Research Grant and Alexion Pharmaceuticals funded TH's PhD studentship via Complement UK. KM also recognises the support from Kidney Research UK grant (RP-006-20270301). CH was funded by Newcastle University.	Amdahl H, 2013, J IMMUNOL, V191, P1775, DOI 10.4049/jimmunol.1300638; ARNAOUT MA, 1981, J IMMUNOL, V127, P1348; Aversa G, 1994, Semin Immunol, V6, P295, DOI 10.1006/smim.1994.1038; Bexborn F, 2008, MOL IMMUNOL, V45, P2370, DOI 10.1016/j.molimm.2007.11.003; Birrell L, 2005, J IMMUNOL, V174, P6974, DOI 10.4049/jimmunol.174.11.6974; CARTER RH, 1989, J IMMUNOL, V143, P1755; Clark EA, 2011, MOL IMMUNOL, V48, P452, DOI 10.1016/j.molimm.2010.09.017; Clemenza L, 2004, J IMMUNOL, V172, P1670, DOI 10.4049/jimmunol.172.3.1670; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DesaiMehta A, 1996, J CLIN INVEST, V97, P2063, DOI 10.1172/JCI118643; ERIS JM, 1994, P NATL ACAD SCI USA, V91, P4392, DOI 10.1073/pnas.91.10.4392; FISCHER E, 1991, J IMMUNOL, V146, P865; Forneris F, 2016, EMBO J, V35, P1133, DOI 10.15252/embj.201593673; Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821; Gilbert HE, 2005, J MOL BIOL, V346, P859, DOI 10.1016/j.jmb.2004.12.006; Green TD, 2003, J VIROL, V77, P2046, DOI 10.1128/JVI.77.3.2046-2055.2003; Green TD, 2001, VACCINE, V20, P242, DOI 10.1016/S0264-410X(01)00266-3; Hammel M, 2007, J BIOL CHEM, V282, P30051, DOI 10.1074/jbc.M704247200; Hammel M, 2007, NAT IMMUNOL, V8, P430, DOI 10.1038/ni1450; HAN SH, 1995, J IMMUNOL, V155, P556; He YG, 2017, IMMUNOBIOLOGY, V223, P125, DOI 10.1016/j.imbio.2017.10.002; Henson SE, 2001, J IMMUNOL METHODS, V258, P97, DOI 10.1016/S0022-1759(01)00471-9; Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200; HONG KS, 1991, J IMMUNOL, V146, P1868; Isenman DE, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P111, DOI 10.1201/9780849350368.ch5; Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172; Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005; Jelezarova E, 2003, J BIOL CHEM, V278, P51806, DOI 10.1074/jbc.M304613200; Kajander T, 2011, P NATL ACAD SCI USA, V108, P2897, DOI 10.1073/pnas.1017087108; Kaneko Y, 1996, EUR J IMMUNOL, V26, P3061, DOI 10.1002/eji.1830261236; KINOSHITA T, 1988, J IMMUNOL, V141, P3895; Kovacs KG, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.620427; Kulik L, 2007, EUR J IMMUNOL, V37, P623, DOI 10.1002/eji.200636248; Kulik L, 2011, MOL IMMUNOL, V48, P883, DOI 10.1016/j.molimm.2010.12.019; Law SKA, 1997, PROTEIN SCI, V6, P263; Lee Y, 2005, J IMMUNOL, V175, P8011, DOI 10.4049/jimmunol.175.12.8011; LEVY E, 1992, CLIN EXP IMMUNOL, V90, P235; Li KY, 2008, J MOL BIOL, V384, P137, DOI 10.1016/j.jmb.2008.08.084; Lyubchenko T, 2005, J IMMUNOL, V174, P3264, DOI 10.4049/jimmunol.174.6.3264; MELAMED J, 1982, J IMMUNOL, V128, P2313; Min XY, 2014, IMMUNOBIOLOGY, V219, P671, DOI 10.1016/j.imbio.2014.03.018; Morgan HP, 2011, NAT STRUCT MOL BIOL, V18, P463, DOI 10.1038/nsmb.2018; Nagar B, 1998, SCIENCE, V280, P1277, DOI 10.1126/science.280.5367.1277; Nilsson B, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/962702; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P155, DOI 10.1111/j.1432-1033.1986.tb09652.x; Prodeus AP, 1998, IMMUNITY, V9, P721, DOI 10.1016/S1074-7613(00)80669-X; Qi JQ, 2017, ANN HEMATOL, V96, P1849, DOI 10.1007/s00277-017-3092-9; Ricklin D, 2008, J IMMUNOL, V181, P7463, DOI 10.4049/jimmunol.181.11.7463; Ross TM, 2000, NAT IMMUNOL, V1, P127, DOI 10.1038/77802; SHIGEOKA AO, 1988, AM J PATHOL, V133, P623; Suradhat S, 2001, VET IMMUNOL IMMUNOP, V83, P79, DOI 10.1016/S0165-2427(01)00369-5; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4513, DOI 10.1021/bi00665a028; Tokunaga M, 2005, RHEUMATOLOGY, V44, P176, DOI 10.1093/rheumatology/keh443; TSOUKAS CD, 1988, EUR J IMMUNOL, V18, P1299, DOI 10.1002/eji.1830180823; van den Elsen JMH, 2011, SCIENCE, V332, P608, DOI 10.1126/science.1201954; Vorup-Jensen T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02716; Wagner C, 2001, EUR J IMMUNOL, V31, P1173, DOI 10.1002/1521-4141(200104)31:4<1173::AID-IMMU1173>3.0.CO;2-9; Xue XG, 2017, NAT STRUCT MOL BIOL, V24, P643, DOI 10.1038/nsmb.3427; Yang PY, 2016, P NATL ACAD SCI USA, V113, P4140, DOI 10.1073/pnas.1601653113; Yang Y, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03139; Zan H, 1999, J IMMUNOL, V162, P3437; Zanotti G, 2000, BBA-PROTEIN STRUCT M, V1478, P232, DOI 10.1016/S0167-4838(00)00040-6; Zirlik A, 2007, CIRCULATION, V115, P1571, DOI 10.1161/CIRCULATIONAHA.106.683201	63	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 9	2021	12								714055	10.3389/fimmu.2021.714055	http://dx.doi.org/10.3389/fimmu.2021.714055			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UE4GR	34434196	Green Submitted, gold, Green Published			2022-12-18	WOS:000687849200001
J	Xu, H; Yu, JZ; Cui, JK; Chen, Z; Zhang, X; Zou, YQ; Du, YF; Li, Y; Le, S; Jiang, L; Xia, JH; Wu, J				Xu, Heng; Yu, Jizhang; Cui, Jikai; Chen, Zhang; Zhang, Xi; Zou, Yanqiang; Du, Yifan; Li, Yuan; Le, Sheng; Jiang, Lang; Xia, Jiahong; Wu, Jie			Ablation of Survivin in T Cells Attenuates Acute Allograft Rejection after Murine Heterotopic Heart Transplantation by Inducing Apoptosis	FRONTIERS IN IMMUNOLOGY			English	Article						transplantation immunology; survivin; Birc5; T cell; apoptosis	PROTEIN; YM155; INHIBITOR; PROLIFERATION; SUPPRESSANT; DEATH	Although studies in oncology have well explored the pharmacological effects of Birc5, little is known about its role in allogeneic T-cell responses. Therefore, the present study used a mouse model of acute heart allograft rejection to investigate the protective effect and mechanism of conditional knockout of Birc5 in T cells. Survivin (encoded by Birc5) was up-regulated in T cells activated in vivo and in vitro. Deletion of Birc5 in T cells attenuated acute heart allograft rejection by reducing the ratio of effector to naive T cells and Th1 to Tregs. In addition, deletion of Birc5 had no noticeable effect on proliferation but on apoptosis and the secretion of IFN-gamma. The results revealed a significant increase in the percentage of Annexin V positive CD4(+) T cells in the Birc5(-/-) group, compared to the WT. Moreover, there was significant increase in early apoptotic alloreactive T cells in Birc5(-/-) mice and this was partly mediated by caspase-3. Furthermore, treatment with YM155 inhibited acute heart allograft rejection in vivo and increased T-cell apoptosis in healthy human PBMCs in vitro. The results highlight a potential therapeutic target for the prevention and treatment of acute transplant rejection.	[Xu, Heng; Yu, Jizhang; Cui, Jikai; Chen, Zhang; Zhang, Xi; Zou, Yanqiang; Du, Yifan; Li, Yuan; Le, Sheng; Jiang, Lang; Xia, Jiahong; Wu, Jie] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Cardiovasc Surg, Wuhan, Peoples R China	Huazhong University of Science & Technology	Xia, JH; Wu, J (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Cardiovasc Surg, Wuhan, Peoples R China.	jiehong.xia@hust.edu.cn; wujie426@hust.edu.cn			National Natural Science Foundation of China [82071803, 81730015]; Natural science fund of Hubei Province [2019AAA032]; Fundamental Research Funds for the Central Universities (HUST) [2021GCRC037, 2021yjsCXCY118, 2021yjsCXCY103]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural science fund of Hubei Province; Fundamental Research Funds for the Central Universities (HUST)(Fundamental Research Funds for the Central Universities)	This work was supported by the National Natural Science Foundation of China (82071803, 81730015), Natural science fund of Hubei Province (2019AAA032) and the Fundamental Research Funds for the Central Universities (HUST No. 2021GCRC037, No. 2021yjsCXCY118, No. 2021yjsCXCY103).	Altieri DC, 2015, SEMIN CELL DEV BIOL, V39, P91, DOI 10.1016/j.semcdb.2014.12.007; Andersson KME, 2015, J LEUKOCYTE BIOL, V97, P135, DOI 10.1189/jlb.3A0714-317R; Cassis P, 2014, AM J TRANSPLANT, V14, P1046, DOI 10.1111/ajt.12677; Chih S, 2016, J AM COLL CARDIOL, V68, P80, DOI 10.1016/j.jacc.2016.04.033; Cui JK, 2020, THERANOSTICS, V10, P8051, DOI 10.7150/thno.43507; de Souza HSP, 2012, GASTROENTEROLOGY, V143, P1017, DOI 10.1053/j.gastro.2012.06.039; Fantus D, 2017, TRANSPLANTATION, V101, P2830, DOI 10.1097/TP.0000000000001933; Fernandez-Ruiz I, 2019, NAT REV CARDIOL, V16, P69, DOI 10.1038/s41569-018-0151-4; Ford ML, 2016, IMMUNITY, V44, P1020, DOI 10.1016/j.immuni.2016.04.012; Fukuda S, 2015, LEUKEMIA, V29, P433, DOI 10.1038/leu.2014.183; Gravina G, 2017, AUTOIMMUN REV, V16, P845, DOI 10.1016/j.autrev.2017.05.016; Kang BH, 2011, J BIOL CHEM, V286, P16758, DOI 10.1074/jbc.M110.210120; Kelly RJ, 2013, ANN ONCOL, V24, P2601, DOI 10.1093/annonc/mdt249; Kittleson MM, 2017, JACC-HEART FAIL, V5, P857, DOI 10.1016/j.jchf.2017.08.021; Kuo HH, 2018, IMMUNITY, V48, P1183, DOI 10.1016/j.immuni.2018.04.004; Kwok C, 2017, TRANSPLANTATION, V101, P2026, DOI 10.1097/TP.0000000000001578; Marino J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00582; Mehra MR, 2016, J HEART LUNG TRANSPL, V35, P1, DOI 10.1016/j.healun.2015.10.023; Meng XB, 2018, NATURE, V564, P130, DOI 10.1038/s41586-018-0756-0; Nakahara T, 2007, CANCER RES, V67, P8014, DOI 10.1158/0008-5472.CAN-07-1343; Oh J, 2020, J MOL CELL CARDIOL, V138, P244, DOI 10.1016/j.yjmcc.2019.12.007; Qiu FF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.646831; Ruchaud S, 2007, CELL, V131, P230, DOI 10.1016/j.cell.2007.10.002; Sasaki R, 2015, LEUKEMIA RES, V39, P1473, DOI 10.1016/j.leukres.2015.10.012; Siu JHY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02548; Tamm I, 1998, CANCER RES, V58, P5315; Tsang TJ, 2017, THERANOSTICS, V7, P4577, DOI 10.7150/thno.20005; Vallet C, 2020, ANGEW CHEM INT EDIT, V59, P5567, DOI 10.1002/anie.201915400; Wheatley SP, 2019, J CELL SCI, V132, DOI 10.1242/jcs.223826; Wu J, 2017, IMMUNITY, V47, P1114, DOI 10.1016/j.immuni.2017.11.003; Wu J, 2013, TRANSPLANTATION, V95, P434, DOI 10.1097/TP.0b013e31827a48f5; Xiang M, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.008604; Xing Z, 2004, J EXP MED, V199, P69, DOI 10.1084/jem.20031588; Yamanaka K, 2011, CLIN CANCER RES, V17, P5423, DOI 10.1158/1078-0432.CCR-10-3410; Yu JZ, 2020, AGING-US, V12, P11636, DOI 10.18632/aging.103330; Zhang L, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.139; Zou YQ, 2020, LIFE SCI, V241, DOI 10.1016/j.lfs.2019.117141	37	1	1	7	17	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 6	2021	12								710904	10.3389/fimmu.2021.710904	http://dx.doi.org/10.3389/fimmu.2021.710904			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UD4WY	34421916	gold, Green Published			2022-12-18	WOS:000687209500001
J	Chen, MR; Kuo, HC; Lee, YJ; Chi, H; Li, SC; Lee, HC; Yang, KD				Chen, Ming-Ren; Kuo, Ho-Chang; Lee, Yann-Jinn; Chi, Hsin; Li, Sung Chou; Lee, Hung-Chang; Yang, Kuender D.			Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children (vol 12, 632890, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						Kawasaki disease; multisystem inflammatory syndrome in children; susceptibility; autoimmunity; immunotherapy; coronavirus disease-19			[Chen, Ming-Ren; Lee, Yann-Jinn; Chi, Hsin; Lee, Hung-Chang; Yang, Kuender D.] MacKay Childrens Hosp, Taipei, Taiwan; [Chen, Ming-Ren] MacKay Jr Coll Med Nursing & Management, New Taipei, Taiwan; [Kuo, Ho-Chang] Kaohsiung Chang Gung Mem Hosp, Kawasaki Dis Ctr, Kaohsiung, Taiwan; [Kuo, Ho-Chang] Kaohsiung Chang Gung Mem Hosp, Dept Pediat, Kaohsiung, Taiwan; [Li, Sung Chou] Kaohsiung Chang Gung Mem Hosp, Genom & Prote Ctr, Kaohsiung, Taiwan; [Yang, Kuender D.] Natl Def Med Ctr, Dept Microbiol & Immunol, Taipei, Taiwan; [Yang, Kuender D.] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan	Mackay Junior College of Medicine, Nursing & Management; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; National Defense Medical Center; National Yang Ming Chiao Tung University	Yang, KD (corresponding author), MacKay Childrens Hosp, Taipei, Taiwan.; Yang, KD (corresponding author), Natl Def Med Ctr, Dept Microbiol & Immunol, Taipei, Taiwan.; Yang, KD (corresponding author), Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan.	yangkd.yeh@hotmail.com	Li, Sung-Chou/AGZ-8626-2022	Li, Sung-Chou/0000-0002-3016-9718				Chen MR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.632890	1	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 5	2021	12								722582	10.3389/fimmu.2021.722582	http://dx.doi.org/10.3389/fimmu.2021.722582			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UD8KE	34421927	gold, Green Published			2022-12-18	WOS:000687451000001
J	Li, Y; Lv, J; Shi, WK; Feng, J; Liu, MX; Gan, SA; Wu, HJ; Fan, WW; Shi, M				Li, Ying; Lv, Jiao; Shi, Weikai; Feng, Jia; Liu, Mingxi; Gan, Shenao; Wu, Hongjin; Fan, Weiwei; Shi, Ming			Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Review						inflammasome; pyroptosis; NETosis; innate immunity; gasdermins; cancer immunotherapy	GASDERMIN D; NONCANONICAL INFLAMMASOME; CELL-DEATH; PYROPTOSIS; ACTIVATION; GSDMD; CASPASES; INHIBITION; NETOSIS; MICROENVIRONMENT	Inflammasomes are fundamental innate immune mechanisms that promote inflammation and induce an inflammatory form of programmed cell death, pyroptosis. Pyroptotic inflammasome has been reported to be closely associated with tumorigenesis and prognosis of multiple cancers. Emerging studies show that the inflammasome assembly into a higher-order supramolecular complex has been utilized to evaluate the status of the innate immune response. The inflammasomes are now regarded as cellular signaling hubs of the innate immunity that drive the production of inflammatory cytokines and consequent recruitment of immune cells to the tumor sites. Herein, we provided an overview of molecular characteristics and biological properties of canonical and non-canonical inflammasome signaling in cancer immunology and immunotherapy. We also focus on the mechanism of regulating pyroptotic inflammasome in tumor cells, as well as the potential roles of inflammasome-mediated pyroptotic cell death in cancers, to explore the potential diagnostic and therapeutic markers contributing to the prevention and treatment of cancers.	[Li, Ying; Lv, Jiao; Shi, Weikai; Feng, Jia; Liu, Mingxi; Gan, Shenao; Shi, Ming] Harbin Inst Technol, Sch Life Sci & Technol, Harbin, Peoples R China; [Li, Ying; Wu, Hongjin] BOAO Int Hosp, Int Res Ctr Regenerat Med, Qionghai, Peoples R China; [Fan, Weiwei] Hellongjiang Prov Hosp, Dept Infect & Med, Harbin, Peoples R China	Harbin Institute of Technology	Shi, M (corresponding author), Harbin Inst Technol, Sch Life Sci & Technol, Harbin, Peoples R China.; Fan, WW (corresponding author), Hellongjiang Prov Hosp, Dept Infect & Med, Harbin, Peoples R China.	ww7069@sina.com; shiming@hit.edu.cn	Frank, Viki/GXZ-9902-2022; Wu, Hongjin/AAF-6122-2019	Wu, Hongjin/0000-0002-2053-7441	National Natural Science Foundation of China [31870891, 81502781]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Acknowledgments This work was supported by funding from the National Natural Science Foundation of China (31870891 and 81502781). Figures were created with Biorender.com. We apologize to authors whose work could not be cited due to space limitation.	Aachoui Y, 2013, CURR OPIN MICROBIOL, V16, P319, DOI 10.1016/j.mib.2013.04.004; Ahechu P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02918; Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227; Arpinati L, 2020, CANCER IMMUNOL IMMUN, V69, P199, DOI 10.1007/s00262-019-02474-x; Ballesteros I, 2020, CELL, V183, P1282, DOI 10.1016/j.cell.2020.10.003; Banerjee I, 2018, IMMUNITY, V49, P413, DOI 10.1016/j.immuni.2018.07.006; Binet F, 2020, SCIENCE, V369, P934, DOI 10.1126/science.aay5356; Branzk N, 2013, SEMIN IMMUNOPATHOL, V35, P513, DOI 10.1007/s00281-013-0384-6; Broz P, 2020, NAT REV IMMUNOL, V20, P143, DOI 10.1038/s41577-019-0228-2; Bunt SK, 2007, CANCER RES, V67, P10019, DOI 10.1158/0008-5472.CAN-07-2354; Burgener SS, 2019, CELL REP, V27, P3646, DOI 10.1016/j.celrep.2019.05.065; Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586-018-0392-8; Chen H, 2020, CELL DEATH DIFFER, V27, P2568, DOI 10.1038/s41418-020-0524-1; Chen KW, 2020, EMBO J, V39, DOI 10.15252/embj.2019103397; Chen KW, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar6676; Chen Q, 2019, AM J PATHOL, V189, P1041, DOI 10.1016/j.ajpath.2019.01.012; Chen Q, 2019, J MOL CELL BIOL, V11, P496, DOI 10.1093/jmcb/mjy056; Chow MT, 2014, CANCER IMMUNOL RES, V2, P1125, DOI 10.1158/2326-6066.CIR-14-0160; Chung C, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00936-9; Cornut M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218087; Deets KA, 2021, NAT IMMUNOL, V22, P412, DOI 10.1038/s41590-021-00869-6; Deigendesch N, 2018, J IMMUNOL, V200, P1607, DOI 10.4049/jimmunol.1700712; Demers M, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1134073; Diebolder CA, 2015, STRUCTURE, V23, P2349, DOI 10.1016/j.str.2015.10.001; Ding JJ, 2016, NATURE, V535, P111, DOI 10.1038/nature18590; Dixon KO, 2021, NATURE, V595, P101, DOI 10.1038/s41586-021-03626-9; Downs KP, 2020, MOL ASPECTS MED, V76, DOI 10.1016/j.mam.2020.100924; Dupaul-Chicoine J, 2015, IMMUNITY, V43, P751, DOI 10.1016/j.immuni.2015.08.013; Dupaul-Chicoine J, 2010, IMMUNITY, V32, P367, DOI 10.1016/j.immuni.2010.02.012; Erkes DA, 2020, CANCER DISCOV, V10, P254, DOI 10.1158/2159-8290.CD-19-0672; Feng SY, 2018, J MOL BIOL, V430, P3068, DOI 10.1016/j.jmb.2018.07.002; Franklin BS, 2014, NAT IMMUNOL, V15, P727, DOI 10.1038/ni.2913; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Gouravani M, 2020, EXPERT REV CLIN IMMU, V16, P175, DOI 10.1080/1744666X.2020.1713755; Guglietta S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11037; Guo WJ, 2014, AUTOPHAGY, V10, P972, DOI 10.4161/auto.28374; He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139; Hergueta-Redondo M, 2016, ONCOTARGET, V7, P56295, DOI 10.18632/oncotarget.10787; Hergueta-Redondo M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090099; Hou JW, 2020, NAT CELL BIOL, V22, P1264, DOI 10.1038/s41556-020-0575-z; Hu L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2476-2; Huang ZX, 2020, AM J CANCER RES, V10, P4287; Inoue M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07550-x; Jiang MX, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-00349-0; Karki R, 2019, NAT REV CANCER, V19, P197, DOI 10.1038/s41568-019-0123-y; Karki R, 2017, CANCER IMMUNOL RES, V5, P94, DOI 10.1158/2326-6066.CIR-16-0269; Karmakar M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16043-9; Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541; Kesavardhana S, 2017, INT IMMUNOL, V29, P201, DOI 10.1093/intimm/dxx018; Khanova E, 2018, HEPATOLOGY, V67, P1737, DOI 10.1002/hep.29645; Kiss M, 2021, CANCER IMMUNOL RES, V9, P309, DOI 10.1158/2326-6066.CIR-20-0431; Kovacs SB, 2017, TRENDS CELL BIOL, V27, P673, DOI 10.1016/j.tcb.2017.05.005; Lamkanfi M, 2011, NAT REV IMMUNOL, V11, P213, DOI 10.1038/nri2936; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Lin PH, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0152-0; Liu J, 2021, CANCER GENE THER, V28, P1, DOI 10.1038/s41417-020-0200-0; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Liu YY, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aax7969; Loi S, 2019, LANCET ONCOL, V20, P371, DOI 10.1016/S1470-2045(18)30812-X; Lu HJ, 2018, CLIN CANCER RES, V24, P6066, DOI 10.1158/1078-0432.CCR-18-1478; Magupalli VG, 2020, SCIENCE, V369, P1448, DOI 10.1126/science.aas8995; Mai FY, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12663; Malireddi RKS, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00406; Miguchi M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166422; Minton K, 2020, NAT REV DRUG DISCOV, V19, P309, DOI [10.1038/d41573-020-00062-8, 10.1038/s41577-020-0297-2]; Molina-Crespo A, 2019, CLIN CANCER RES, V25, P4846, DOI 10.1158/1078-0432.CCR-18-2381; Monie TP, 2017, SUBCELL BIOCHEM, V83, P43, DOI 10.1007/978-3-319-46503-6_2; Moossavi M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0900-3; Orning P, 2018, SCIENCE, V362, P1064, DOI 10.1126/science.aau2818; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Pasto A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093352; Platnich JM, 2019, ARCH BIOCHEM BIOPHYS, V670, P4, DOI 10.1016/j.abb.2019.02.008; Poli G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165758; Prochnicki T, 2017, CELL METAB, V26, P71, DOI 10.1016/j.cmet.2017.06.018; Rathinam VAK, 2018, TRENDS MOL MED, V24, P304, DOI 10.1016/j.molmed.2018.01.004; Ruan JB, 2018, NATURE, V557, P62, DOI 10.1038/s41586-018-0058-6; Ruhl S, 2018, SCIENCE, V362, P956, DOI 10.1126/science.aar7607; Samir P, 2019, NATURE, V573, P590, DOI 10.1038/s41586-019-1551-2; Sborgi L, 2016, EMBO J, V35, P1766, DOI 10.15252/embj.201694696; Schwarzer R, 2020, IMMUNITY, V52, P978, DOI 10.1016/j.immuni.2020.04.002; Segovia M, 2020, CLIN EXP IMMUNOL, V200, P155, DOI 10.1111/cei.13433; Sharif H, 2019, NATURE, V570, P338, DOI 10.1038/s41586-019-1295-z; SHI HX, 2016, NAT IMMUNOL, V17, P250, DOI DOI 10.1038/NI.3333; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Shi JJ, 2014, NATURE, V514, P187, DOI 10.1038/nature13683; Shi M, 2020, CURR OPIN CELL BIOL, V63, P194, DOI 10.1016/j.ceb.2020.03.002; Singel KL, 2019, BRIT J CANCER, V120, P207, DOI 10.1038/s41416-018-0339-8; Song XP, 2005, J IMMUNOL, V175, P8200, DOI 10.4049/jimmunol.175.12.8200; Stutz Andrea, 2013, Methods Mol Biol, V1040, P91, DOI 10.1007/978-1-62703-523-1_8; Teijeira A, 2020, IMMUNITY, V52, P856, DOI 10.1016/j.immuni.2020.03.001; Thanabalasuriar A, 2019, CELL HOST MICROBE, V25, P526, DOI 10.1016/j.chom.2019.02.007; Theivanthiran B, 2020, J CLIN INVEST, V130, P2570, DOI 10.1172/JCI133055; Thiam HR, 2020, ANNU REV CELL DEV BI, V36, P191, DOI 10.1146/annurev-cellbio-020520-111016; Tsuchiya K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09753-2; van Deventer HW, 2010, CANCER RES, V70, P10161, DOI 10.1158/0008-5472.CAN-10-1921; Van Gorp H, 2019, EMBO REP, V20, DOI 10.15252/embr.201847575; von Moltke J, 2012, NATURE, V490, P107, DOI 10.1038/nature11351; Wang K, 2020, CELL, V180, P941, DOI 10.1016/j.cell.2020.02.002; Wang QY, 2020, NATURE, V579, P421, DOI 10.1038/s41586-020-2079-1; Wang YP, 2017, NATURE, V547, P99, DOI 10.1038/nature22393; Wei J, 2020, MOL MED REP, V21, P360, DOI 10.3892/mmr.2019.10837; Xia SY, 2021, PROTEIN CELL, V12, P680, DOI 10.1007/s13238-021-00839-6; Xia XJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1883-8; Xu SC, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0755-0; Yang CX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1719-6; Yang JL, 2015, CURR OPIN IMMUNOL, V32, P78, DOI 10.1016/j.coi.2015.01.007; Yang LB, 2020, NATURE, V583, P133, DOI 10.1038/s41586-020-2394-6; Yang XY, 2019, IMMUNITY, V51, P983, DOI 10.1016/j.immuni.2019.11.005; Yi YS, 2017, IMMUNOLOGY, V152, P207, DOI 10.1111/imm.12787; Yipp BG, 2012, NAT MED, V18, P1386, DOI 10.1038/nm.2847; Yu JH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1441-4; Yuan B, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2248-z; Yue E, 2019, PHYTOMEDICINE, V56, P286, DOI 10.1016/j.phymed.2018.09.223; Zhang LM, 2015, SCIENCE, V350, P404, DOI 10.1126/science.aac5789; Zhang ZB, 2020, NATURE, V579, P415, DOI 10.1038/s41586-020-2071-9; Zhao PF, 2020, BIOMATERIALS, V254, DOI 10.1016/j.biomaterials.2020.120142; Zhou ZW, 2020, SCIENCE, V368, P965, DOI 10.1126/science.aaz7548	117	1	1	4	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 5	2021	12								710110	10.3389/fimmu.2021.710110	http://dx.doi.org/10.3389/fimmu.2021.710110			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UD8HT	34421915	gold, Green Published			2022-12-18	WOS:000687444700001
J	Thomas, R; Carballido, JM; Wesley, JD; Ahmed, ST				Thomas, Ranjeny; Carballido, Jose M.; Wesley, Johnna D.; Ahmed, Simi T.			Overcoming Obstacles in the Development of Antigen-Specific Immunotherapies for Type 1 Diabetes	FRONTIERS IN IMMUNOLOGY			English	Article						T1D; autoimmunity; immunotherapy; tolerance; precision medicine		Antigen-specific immunotherapy (ASI) holds great promise for type 1 diabetes (T1D). Preclinical success for this approach has been demonstrated in vivo, however, clinical translation is still pending. Reasons explaining the slow progress to approve ASI are complex and span all stages of research and development, in both academic and industry environments. The basic four hurdles comprise a lack of translatability of pre-clinical research to human trials; an absence of robust prognostic and predictive biomarkers for therapeutic outcome; a need for a clear regulatory path addressing ASI modalities; and the limited acceptance to develop therapies intervening at the pre-symptomatic stages of disease. The core theme to address these challenges is collaboration-early, transparent, and engaged interactions between academic labs, pharmaceutical research and clinical development teams, advocacy groups, and regulatory agencies to drive a fundamental shift in how we think and treat T1D.	[Thomas, Ranjeny] Univ Queensland, Princess Alexandra Hosp, Diamantina Inst, Woolloongabba, Qld, Australia; [Carballido, Jose M.] Novartis Inst Biomed Res, Translat Med Preclin Safety, Basel, Switzerland; [Wesley, Johnna D.] Novo Nordisk Res Ctr Seattle, Type 1 Diabet Immunol & Kidney Dis Res, Seattle, WA USA; [Ahmed, Simi T.] New York Stem Cell Fdn, Strateg Partnerships, Res Inst, New York, NY 10019 USA	University of Queensland; Novartis; The New York Stem Cell Foundation	Ahmed, ST (corresponding author), New York Stem Cell Fdn, Strateg Partnerships, Res Inst, New York, NY 10019 USA.	sahmed@nyscf.org	Thomas, Ranjeny/B-4504-2013	Thomas, Ranjeny/0000-0002-0518-8386	Leona M. and Harry B. Helmsley Charitable Trust; Juvenile Diabetes Research Foundation Australia	Leona M. and Harry B. Helmsley Charitable Trust; Juvenile Diabetes Research Foundation Australia(Juvenile Diabetes Research Foundation)	Supported by a grant from The Leona M. and Harry B. Helmsley Charitable Trust and Juvenile Diabetes Research Foundation Australia to RT.	Ahmed S, 2019, DIABETES, V68, P1366, DOI 10.2337/db19-0119; Ali MA, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf7779; Battaglia M, 2020, DIABETES CARE, V43, P5, DOI 10.2337/dc19-0880; Carballido JM, 2019, J EXP MED, V216, P247, DOI 10.1084/jem.20182287; Chataway J, 2018, NEUROLOGY, V90, pE955, DOI 10.1212/WNL.0000000000005118; Coppieters K, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00283; Diggins KE, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.142680; Heninger AK, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf8848; Huo LL, 2016, DIABETOLOGIA, V59, P1177, DOI 10.1007/s00125-015-3857-4; Insel RA, 2015, DIABETES CARE, V38, P1964, DOI 10.2337/dc15-1419; Keenan HA, 2010, DIABETES, V59, P2846, DOI 10.2337/db10-0676; Kelly CP, 2021, GASTROENTEROLOGY, V161, P66, DOI 10.1053/j.gastro.2021.03.014; Li YZ, 2021, ACS CENTRAL SCI, V7, P512, DOI 10.1021/acscentsci.1c00120; Linsley PS, 2021, DIABETES, V70, P831, DOI 10.2337/db20-1185; Naranjo JDL, 2020, CURR DIABETES REP, V20, DOI 10.1007/s11892-020-01363-3; Long SA, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aai7793; Ludvigsson J, 2021, DIABETES CARE, V44, P1604, DOI 10.2337/dc21-0318; Musthaffa Y, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1315; Musthaffa Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.587469; Narsale A, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.136114; Nel HJ, 2020, LANCET RHEUMATOL, V2, pE712; Oram RA, 2019, DIABETOLOGIA, V62, P567, DOI 10.1007/s00125-019-4822-4; Pathiraja V, 2015, DIABETES, V64, P172, DOI 10.2337/db14-0858; Roep BO, 2021, NAT REV ENDOCRINOL, V17, P150, DOI 10.1038/s41574-020-00443-4; Roep BO, 2019, LANCET DIABETES ENDO, V7, P65, DOI 10.1016/S2213-8587(18)30109-8; Roep BO, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007781; Serra P, 2019, NAT BIOTECHNOL, V37, P238, DOI 10.1038/s41587-019-0015-4; Skowera A, 2015, DIABETES, V64, P916, DOI 10.2337/db14-0332; Streeter HB, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000093; Wagar LE, 2021, NAT MED, V27, P125, DOI 10.1038/s41591-020-01145-0; Wiedeman AE, 2020, J CLIN INVEST, V130, P480, DOI 10.1172/JCI126595; Yeo L, 2018, J CLIN INVEST, V128, P3460, DOI 10.1172/JCI120555; Ziegler AG, 2013, JAMA-J AM MED ASSOC, V309, P2473, DOI 10.1001/jama.2013.6285	33	1	1	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 5	2021	12								730414	10.3389/fimmu.2021.730414	http://dx.doi.org/10.3389/fimmu.2021.730414			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UE1GX	34421931	gold, Green Published			2022-12-18	WOS:000687645800001
J	He, Y; Wang, XL; Guo, JQ; Mao, L; Zhang, SZ; Hu, T; Wang, MS; Jia, RY; Zhu, DK; Liu, MF; Zhao, XX; Yang, Q; Wu, Y; Zhang, SQ; Huang, J; Mao, S; Ou, XM; Gao, Q; Sun, D; Liu, YY; Zhang, L; Yu, YL; Cheng, AC; Chen, S				He, Yu; Wang, Xiaoli; Guo, Jiaqi; Mao, Li; Zhang, Senzhao; Hu, Tao; Wang, Mingshu; Jia, Renyong; Zhu, Dekang; Liu, Mafeng; Zhao, Xinxin; Yang, Qiao; Wu, Ying; Zhang, Shaqiu; Huang, Juan; Mao, Sai; Ou, Xumin; Gao, Qun; Sun, Di; Liu, Yunya; Zhang, Ling; Yu, Yanling; Cheng, Anchun; Chen, Shun			Replication/Assembly Defective Avian Flavivirus With Internal Deletions in the Capsid Can Be Used as an Approach for Living Attenuated Vaccine	FRONTIERS IN IMMUNOLOGY			English	Article						live attenuated vaccine; assembly deficient; avian Tembusu virus; capsid protein deletion; protective immunity; immune response; replication deficient	VIRUS CORE PROTEIN; MUTANTS	Avian Tembusu virus (TMUV) is a novel flavivirus causing severe egg drop and fatal encephalitis in avian in Asia. In the present study, we screened the structural and functional requirements of TMUV capsid protein (CP) for viral morphogenesis using reverse genetics methods in combination with replicon packaging assays. TMUV-CP showed dramatic functional and structural flexibility, and even though 44 residues were removed from the N-terminus, it was still capable of packaging replicon RNA; in addition, 33 residues were deleted from the C-terminus (containing nearly the entire alpha 4-helix), and infectious particles were still produced, although alpha 4-alpha 4' is supposedly vital for CP dimerization and nucleocapsid formation. We further analyzed two mutants (Delta C20-43 and Delta C64-96 viruses) with relatively large deletions that still replicated well in BHK-21 cells. Our data indicate that internal deletions within CP impaired viral replication or assembly, resulting in attenuated virus proliferation in cells and attenuated virulence in duck embryos, and these deletion mutations are quite stable in cell culture. An in vivo assay indicated that both Delta C20-43 virus and Delta C64-96 virus were highly attenuated in ducklings but still immunogenic. Single-dose immunization with Delta C20-43 virus or Delta C64-96 virus could protect ducklings from a lethal challenge with good antigen clearance. Together, our data shed light on replication/assembly defective TMUV with internal deletions in CP and provide an effective approach to attenuate viral virulence in live vaccines without changing the antigen composition.	[He, Yu; Wang, Xiaoli; Guo, Jiaqi; Mao, Li; Zhang, Senzhao; Hu, Tao; Wang, Mingshu; Jia, Renyong; Liu, Mafeng; Zhao, Xinxin; Yang, Qiao; Wu, Ying; Zhang, Shaqiu; Huang, Juan; Mao, Sai; Ou, Xumin; Gao, Qun; Sun, Di; Liu, Yunya; Zhang, Ling; Yu, Yanling; Cheng, Anchun; Chen, Shun] Sichuan Agr Univ, Inst Prevent Vet Med, Chengdu, Peoples R China; [Wang, Mingshu; Jia, Renyong; Zhu, Dekang; Liu, Mafeng; Zhao, Xinxin; Yang, Qiao; Wu, Ying; Zhang, Shaqiu; Huang, Juan; Mao, Sai; Ou, Xumin; Gao, Qun; Sun, Di; Cheng, Anchun; Chen, Shun] Sichuan Agr Univ, Coll Vet Med, Res Ctr Avian Dis, Chengdu, Peoples R China; [Wang, Mingshu; Jia, Renyong; Zhu, Dekang; Liu, Mafeng; Zhao, Xinxin; Yang, Qiao; Wu, Ying; Zhang, Shaqiu; Huang, Juan; Mao, Sai; Ou, Xumin; Gao, Qun; Sun, Di; Cheng, Anchun; Chen, Shun] Sichuan Agr Univ, Key Lab Anim Dis & Human Hlth Sichuan Prov, Chengdu, Peoples R China	Sichuan Agricultural University; Sichuan Agricultural University; Key Laboratory of Animal Disease & Human Health of Sichuan Province; Sichuan Agricultural University	Cheng, AC; Chen, S (corresponding author), Sichuan Agr Univ, Inst Prevent Vet Med, Chengdu, Peoples R China.; Cheng, AC; Chen, S (corresponding author), Sichuan Agr Univ, Coll Vet Med, Res Ctr Avian Dis, Chengdu, Peoples R China.; Cheng, AC; Chen, S (corresponding author), Sichuan Agr Univ, Key Lab Anim Dis & Human Hlth Sichuan Prov, Chengdu, Peoples R China.	chenganchun@vip.163.com; shunchen@sicau.edu.cn	Guo, Jiaqi/GSO-0702-2022; Yu, Yan/GYV-4514-2022		National Key Research and Development Program of China [2017YFD0500800]; China Agriculture Research System of MOF and MARA; Program Sichuan Veterinary Medicine and Drug Innovation Group of China Agricultural Research System [SCCXTD2021-18]	National Key Research and Development Program of China; China Agriculture Research System of MOF and MARA(Ministry of Oceans & Fisheries (MOF), Republic of Korea); Program Sichuan Veterinary Medicine and Drug Innovation Group of China Agricultural Research System	This work was funded by grants from the National Key Research and Development Program of China (2017YFD0500800), the China Agriculture Research System of MOF and MARA, and the Program Sichuan Veterinary Medicine and Drug Innovation Group of China Agricultural Research System (SCCXTD2021-18).	Allison SL, 2003, J VIROL, V77, P11357, DOI 10.1128/JVI.77.21.11357-11366.2003; Barnard TR, 2021, TRENDS BIOCHEM SCI, V46, P378, DOI 10.1016/j.tibs.2020.12.007; Chen S, 2018, ANTIVIR RES, V157, P120, DOI 10.1016/j.antiviral.2018.06.016; Dokland T, 2004, STRUCTURE, V12, P1157, DOI 10.1016/j.str.2004.04.024; Guo JQ, 2020, J VIROL METHODS, V283, DOI 10.1016/j.jviromet.2020.113922; He Y, 2020, VACCINE, V38, P6872, DOI 10.1016/j.vaccine.2020.08.053; He Y, 2019, VIROLOGY, V533, P86, DOI 10.1016/j.virol.2019.05.003; Khromykh AA, 1996, ARCH VIROL, V141, P685, DOI 10.1007/BF01718326; Kofler RM, 2003, J VIROL, V77, P443, DOI 10.1128/JVI.77.1.443-451.2003; Kofler RM, 2002, J VIROL, V76, P3534, DOI 10.1128/JVI.76.7.3534-3543.2002; Li N, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00581; Li T, 2018, CELL RES, V28, P497, DOI 10.1038/s41422-018-0007-9; Lv JF, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00442; Ma LX, 2004, P NATL ACAD SCI USA, V101, P3414, DOI 10.1073/pnas.0305892101; Mandl CW, 2004, VIRAL IMMUNOL, V17, P461, DOI 10.1089/vim.2004.17.461; Mishra N, 2020, MBIO, V11, DOI 10.1128/mBio.02494-19; Patkar CG, 2007, J VIROL, V81, P6471, DOI 10.1128/JVI.02120-06; Poonsiri T, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11070623; Samsa MM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000632; Schlick P, 2009, J VIROL, V83, P5581, DOI 10.1128/JVI.02653-08; Shang ZF, 2018, J MOL BIOL, V430, P948, DOI 10.1016/j.jmb.2018.02.006; Su JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018106; Sun MX, 2020, J VIROL, V94, DOI 10.1128/JVI.02011-19; Teoh PG, 2014, J VIROL, V88, P7998, DOI 10.1128/JVI.00940-14; Wu Z, 2019, J IMMUNOL, V203, P3374, DOI 10.4049/jimmunol.1900956; Xie XP, 2018, CELL HOST MICROBE, V24, P487, DOI 10.1016/j.chom.2018.09.008; Xie XP, 2016, EBIOMEDICINE, V12, P156, DOI 10.1016/j.ebiom.2016.09.013; Yan PX, 2011, VIROLOGY, V417, P1, DOI 10.1016/j.virol.2011.06.003; Zhang W, 2020, J VIROL, V94, DOI 10.1128/JVI.01850-19; Zou Z, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01554-1	30	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 4	2021	12								694959	10.3389/fimmu.2021.694959	http://dx.doi.org/10.3389/fimmu.2021.694959			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UE4JA	34421904	Green Published, gold			2022-12-18	WOS:000687855400001
J	Elter, A; Yanakieva, D; Fiebig, D; Hallstein, K; Becker, S; Betz, U; Kolmar, H				Elter, Adrian; Yanakieva, Desislava; Fiebig, David; Hallstein, Kerstin; Becker, Stefan; Betz, Ulrich; Kolmar, Harald			Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity	FRONTIERS IN IMMUNOLOGY			English	Article						Fc gamma receptor; off-target cytotoxicity; effector function; Fc-silencing; masked therapeutic antibody; MMP-9; ADCC; CDC	BREAST-CANCER; HUMAN IGG1; RECEPTOR; EXPRESSION; BINDING; CELLS; MMP-9; SITE	The interaction of the Fc region of therapeutic antibodies and antibody-drug conjugates with Fc gamma receptors (Fc gamma Rs) can lead to unpredictable and severe side effects. Over the last decades several strategies have been developed to overcome this drawback, including extensive Fc- and glycoengineering and antibody isotype switching. However, these approaches result in permanently Fc-silenced antibody derivates which partially or completely lack antibody-mediated effector functions. Nevertheless, for a majority of antibody-based drugs, Fc-mediated effector functions, like antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP) as well as complement-dependent cytotoxicity (CDC), represent the most substantial modes of action. We argued that a new strategy combining the beneficial properties of Fc-silencing and controlled activation of effector functions can pave the way to potent antibody therapeutics, reducing the Fc gamma Rs-mediated off-target toxicity. We present a novel Fc-tamed antibody format, where the Fc gamma R-binding sites of antibodies are blocked by anti-isotypic masking units, hindering the association of Fc gamma R and complement component 1 (c1q) to the Fc domain. The masking units were genetically fused to trastuzumab, including a protease-addressable peptide-liker. Our Fc-tamed antibodies demonstrated completely abolished interaction to soluble high-affinity Fc gamma-Receptor I and c1q. In reporter cell-based ADCC assays, our Fc-tamed antibodies exhibited a 2,700 to 7,100-fold reduction in activation, compared to trastuzumab. Upon demasking by a tumor-associated protease, the Fc-activated antibodies demonstrated restored Fc gamma R-binding, c1q-binding and the ability to induce potent ADCC activation. Furthermore, cell killing assays using donor-derived NK cells were performed to validate the functionality of the Fc-tamed antibody variants. To our knowledge, this approach represents the first non-permanently Fc-silenced antibody, which can be re-activated by a tumor-associated protease, eventually extending the field of novel antibody formats.	[Elter, Adrian; Yanakieva, Desislava; Fiebig, David; Kolmar, Harald] Tech Univ Darmstadt, Inst Organ Chem & Biochem, Darmstadt, Germany; [Yanakieva, Desislava; Hallstein, Kerstin; Becker, Stefan; Betz, Ulrich] Merck Healthcare KGaA, Prot Engn & Antibody Technol, Darmstadt, Germany	Technical University of Darmstadt	Kolmar, H (corresponding author), Tech Univ Darmstadt, Inst Organ Chem & Biochem, Darmstadt, Germany.	Harald.Kolmar@TU-Darmstadt.de			MerckLab@TU Darmstadt; Department of Protein Engineering and Antibody Technologies at Merck KGaA, Darmstadt; Deutsche Forschungsgemeinschaft [KO 1390/14-1]; Deutsche Forschungsgemeinschaft (DFG - German Research Foundation); Open Access Publishing Fund of Technical University of Darmstadt	MerckLab@TU Darmstadt; Department of Protein Engineering and Antibody Technologies at Merck KGaA, Darmstadt; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft (DFG - German Research Foundation)(German Research Foundation (DFG)); Open Access Publishing Fund of Technical University of Darmstadt	This work was supported by the MerckLab@TU Darmstadt, by the Department of Protein Engineering and Antibody Technologies at Merck KGaA, Darmstadt and by Deutsche Forschungsgemeinschaft through grant KO 1390/14-1. We acknowledge support by the Deutsche Forschungsgemeinschaft (DFG - German Research Foundation) and the Open Access Publishing Fund of Technical University of Darmstadt. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Arlotta KJ, 2018, ANTIBODIES, V7, DOI 10.3390/antib7010006; Beck A, 2017, NAT REV DRUG DISCOV, V16, P315, DOI 10.1038/nrd.2016.268; Bournazos S, 2009, CLIN EXP IMMUNOL, V157, P244, DOI 10.1111/j.1365-2249.2009.03980.x; Chen X, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00292; Dahan R, 2015, CANCER CELL, V28, P285, DOI 10.1016/j.ccell.2015.08.004; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; Eckhard U, 2016, MATRIX BIOL, V49, P37, DOI 10.1016/j.matbio.2015.09.003; Elter A, 2021, BIOTECHNOL J, V16, DOI 10.1002/biot.202000231; Ganesan LP, 2012, J IMMUNOL, V189, P4981, DOI 10.4049/jimmunol.1202017; Geiger M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16838-w; Gjetting T, 2019, MABS-AUSTIN, V11, P666, DOI 10.1080/19420862.2019.1596514; Grzeschik J, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201800466; Guilliams M, 2014, NAT REV IMMUNOL, V14, P94, DOI 10.1038/nri3582; Herter S, 2014, J IMMUNOL, V192, P2252, DOI 10.4049/jimmunol.1301249; Hinz SC, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00688; Hoffmann RM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1395127; Kang TH, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0345-9; Kiyoshi M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7866; LARSSON A, 1993, POULTRY SCI, V72, P1807, DOI 10.3382/ps.0721807; Li G, 2016, APPL MICROBIOL BIOT, V100, P215, DOI 10.1007/s00253-015-6985-3; Li MH, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85329-9; Li TZ, 2017, P NATL ACAD SCI USA, V114, P3485, DOI 10.1073/pnas.1702173114; Lin WW, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00652-z; Liu RN, 2020, ANTIBODIES, V9, DOI 10.3390/antib9040064; Lu JH, 2015, P NATL ACAD SCI USA, V112, P833, DOI 10.1073/pnas.1418812112; Lu RM, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0592-z; Martin C, 2018, MABS-AUSTIN, V10, P210, DOI 10.1080/19420862.2017.1412130; McGowan PM, 2008, ANN ONCOL, V19, P1566, DOI 10.1093/annonc/mdn180; Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957; Pekar L, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2020.1812210; Polu KR, 2014, EXPERT OPIN BIOL TH, V14, P1049, DOI 10.1517/14712598.2014.920814; Saris A, 2018, BLOOD, V131, P144, DOI 10.1182/blood-2017-07-799270; Schlothauer T, 2016, PROTEIN ENG DES SEL, V29, P457, DOI 10.1093/protein/gzw040; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; Singh S, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-2975; Sorensen KK, 2012, AM J PHYSIOL-REG I, V303, pR1217, DOI 10.1152/ajpregu.00686.2011; Sorkin LS, 2010, PAIN, V149, P135, DOI 10.1016/j.pain.2010.01.024; Spira AI, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.TPS3107; Tamura Y, 1998, J MED CHEM, V41, P640, DOI 10.1021/jm9707582; Tolcher Anthony W, 2020, Am Soc Clin Oncol Educ Book, V40, P1, DOI 10.1200/EDBK_281103; Uppal H, 2015, CLIN CANCER RES, V21, P123, DOI 10.1158/1078-0432.CCR-14-2093; VAICKUS L, 1988, CLIN IMMUNOL IMMUNOP, V47, P106, DOI 10.1016/0090-1229(88)90149-3; Vasiljeva O, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62339-7; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Woodle ES, 1999, TRANSPLANTATION, V68, P608, DOI 10.1097/00007890-199909150-00003; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Zhao H, 2017, MOL CANCER THER, V16, P1877, DOI 10.1158/1535-7163.MCT-16-0710	47	1	1	12	17	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 3	2021	12								715719	10.3389/fimmu.2021.715719	http://dx.doi.org/10.3389/fimmu.2021.715719			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UO8FA	34413859	Green Published, gold			2022-12-18	WOS:000694925700001
J	Gong, SQ; Lakhashe, SK; Hariraju, D; Scinto, H; Lanzavecchia, A; Cameroni, E; Corti, D; Ratcliffe, SJ; Rogers, KA; Xiao, P; Fontenot, J; Villinger, F; Ruprecht, RM				Gong, Siqi; Lakhashe, Samir K.; Hariraju, Dinesh; Scinto, Hanna; Lanzavecchia, Antonio; Cameroni, Elisabetta; Corti, Davide; Ratcliffe, Sarah J.; Rogers, Kenneth A.; Xiao, Peng; Fontenot, Jane; Villinger, Francois; Ruprecht, Ruth M.			Cooperation Between Systemic IgG1 and Mucosal Dimeric IgA2 Monoclonal Anti-HIV Env Antibodies: Passive Immunization Protects Indian Rhesus Macaques Against Mucosal SHIV Challenges	FRONTIERS IN IMMUNOLOGY			English	Article						dimeric IgA; IgG; passive mucosal and systemic immunization; rhesus macaque model; SHIV; immune exclusion	IMMUNOGLOBULIN	Understanding the interplay between systemic and mucosal anti-HIV antibodies can provide important insights to develop new prevention strategies. We used passive immunization via systemic and/or mucosal routes to establish cause-and-effect between well-characterized monoclonal antibodies and protection against intrarectal (i.r.) SHIV challenge. In a pilot study, for which we re-used animals previously exposed to SHIV but completely protected from viremia by different classes of anti-HIV neutralizing monoclonal antibodies (mAbs), we made a surprise finding: low-dose intravenous (i.v.) HGN194-IgG1, a human neutralizing mAb against the conserved V3-loop crown, was ineffective when given alone but protected 100% of animals when combined with i.r. applied HGN194-dIgA2 that by itself had only protected 17% of the animals. Here we sought to confirm the unexpected synergy between systemically administered IgG1 and mucosally applied dIgA HGN194 forms using six groups of naive macaques (n=6/group). Animals received i.v. HGN194-IgG1 alone or combined with i.r.-administered dIgA forms; controls remained untreated. HGN194-IgG1 i.v. doses were given 24 hours before - and all i.r. dIgA doses 30 min before - i.r. exposure to a single high-dose of SHIV-1157ipEL-p. All controls became viremic. Among passively immunized animals, the combination of IgG1+dIgA2 again protected 100% of the animals. In contrast, single-agent i.v. IgG1 protected only one of six animals (17%) - consistent with our pilot data. IgG1 combined with dIgA1 or dIgA1+dIgA2 protected 83% (5/6) of the animals. The dIgA1+dIgA2 combination without the systemically administered dose of IgG1 protected 67% (4/6) of the macaques. We conclude that combining suboptimal antibody defenses at systemic and mucosal levels can yield synergy and completely prevent virus acquisition.	[Gong, Siqi; Lakhashe, Samir K.; Hariraju, Dinesh; Scinto, Hanna; Ruprecht, Ruth M.] Texas Biomed Res Inst, San Antonio, TX 78227 USA; [Gong, Siqi; Hariraju, Dinesh; Rogers, Kenneth A.; Xiao, Peng; Fontenot, Jane; Villinger, Francois; Ruprecht, Ruth M.] Univ Louisiana Lafayette, New Iberia Res Ctr, Lafayette, LA 70504 USA; [Scinto, Hanna; Ruprecht, Ruth M.] Univ Texas Hlth San Antonio, Dept Microbiol Immunol & Mol Genet, San Antonio, TX 78229 USA; [Lanzavecchia, Antonio; Cameroni, Elisabetta; Corti, Davide] Inst Res Biomed, Bellinzona, Switzerland; [Lanzavecchia, Antonio; Cameroni, Elisabetta; Corti, Davide] Humabs BioMed, Bellinzona, Switzerland; [Ratcliffe, Sarah J.] Univ Penn, Philadelphia, PA 19104 USA; [Rogers, Kenneth A.; Villinger, Francois; Ruprecht, Ruth M.] Univ Louisiana Lafayette, Dept Biol, Lafayette, LA 70504 USA	Texas Biomedical Research Institute; University of Louisiana Lafayette; New Iberia Research Center; University of Texas System; University of Texas Health San Antonio; Universita della Svizzera Italiana; University of Pennsylvania; University of Louisiana Lafayette	Ruprecht, RM (corresponding author), Texas Biomed Res Inst, San Antonio, TX 78227 USA.; Ruprecht, RM (corresponding author), Univ Louisiana Lafayette, New Iberia Res Ctr, Lafayette, LA 70504 USA.; Ruprecht, RM (corresponding author), Univ Texas Hlth San Antonio, Dept Microbiol Immunol & Mol Genet, San Antonio, TX 78229 USA.; Ruprecht, RM (corresponding author), Univ Louisiana Lafayette, Dept Biol, Lafayette, LA 70504 USA.	ruth.ruprecht@louisiana.edu	Xiao, Peng/GLS-6934-2022; Ratcliffe, Sarah J/GYR-1110-2022	Ratcliffe, Sarah J/0000-0002-6644-8284; Xiao, Peng/0000-0002-5308-8400	National Institutes of Health [P01 AI048240]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health grant P01 AI048240 to RR.	BAENZIGER J, 1974, J BIOL CHEM, V249, P7270; Bomsel M, 2011, IMMUNITY, V34, P269, DOI 10.1016/j.immuni.2011.01.015; Bonner A, 2008, J IMMUNOL, V180, P1008, DOI 10.4049/jimmunol.180.2.1008; Bonner A, 2009, J BIOL CHEM, V284, P5077, DOI 10.1074/jbc.M807529200; BRANDTZAEG P, 1983, MOL IMMUNOL, V20, P941, DOI 10.1016/0161-5890(83)90036-6; Corti D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008805; Fagarasan S, 2003, NAT REV IMMUNOL, V3, P63, DOI 10.1038/nri982; Gong S, 2018, AIDS, V32, pF5, DOI [10.1097/qad.0000000000001857, 10.1097/QAD.0000000000001857]; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Kaul R, 2004, AIDS, V18, P2087, DOI 10.1097/00002030-200410210-00015; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; Kulkarni V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01581; Montefiori D.C., 2005, CURR PROTOC IMMUNOL, DOI DOI 10.1002/0471142735.IM1211S64; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; Ohyama Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57510-z; Patel P, 2014, AIDS, V28, P1509, DOI 10.1097/QAD.0000000000000298; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Rogers KA, 2008, J IMMUNOL, V180, P4816, DOI 10.4049/jimmunol.180.7.4816; Ruprecht RM, 2017, CURR OPIN HIV AIDS, V12, P222, DOI 10.1097/COH.0000000000000369; Sholukh AM, 2015, VACCINE, V33, P2086, DOI 10.1016/j.vaccine.2015.02.020; Siddappa NB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011689; Takahashi K, 2010, MOL CELL PROTEOMICS, V9, P2545, DOI 10.1074/mcp.M110.001834; Taylor RA, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009632; Watkins JD, 2013, AIDS, V27, pF13, DOI 10.1097/QAD.0b013e328360eac6; Watkins JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018207; Zhou MK, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0109-5	26	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 3	2021	12								705592	10.3389/fimmu.2021.705592	http://dx.doi.org/10.3389/fimmu.2021.705592			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UB0XK	34413855	gold, Green Published			2022-12-18	WOS:000685576000001
J	Jeljeli, M; Chene, C; Chouzenoux, S; Thomas, M; Segain, B; Doridot, L; Nicco, C; Batteux, F				Jeljeli, Mohamed; Chene, Charlotte; Chouzenoux, Sandrine; Thomas, Marine; Segain, Benjamin; Doridot, Ludivine; Nicco, Carole; Batteux, Frederic			LPSlow-Macrophages Alleviate the Outcome of Graft-Versus-Host Disease Without Aggravating Lymphoma Growth in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						macrophages; trained immunity; graft-versus-host disease; alloimmunity; inflammation; anti-tumoral action	CD4(+) T-CELLS; GENE-EXPRESSION; INNATE IMMUNITY; FREE SURVIVAL; PATHOGENESIS; MECHANISMS; MEMORY; TRANSPLANTATION; GVHD; DIFFERENTIATION	Despite significant therapeutic advances, graft-versus-host disease (GvHD) remains the main life-threatening complication following allogeneic hematopoietic stem cell transplantation. The pathogenesis of GvHD is dominated by a dysregulated allogeneic immune response that drives fibrosis and autoimmunity in chronic forms. A multitude of cell therapy approaches, including infusion of myeloid cells, has been proposed to prevent GvHD through tolerance induction but yielded variable results. Myeloid cells like macrophages can be reprogrammed to develop adaptive-like features following antigenic challenge to reinforce or inhibit a subsequent immune response; a phenomenon termed 'trained immunity'. Here we report that, whereas LPSlow-trained macrophages elicit a suppressor effect on allogeneic T cell proliferation and function in vitro in an IL-10-dependent manner, Bacille Calmette et Guerin (BCG)-trained macrophages exert an opposite effect. In a murine model of sclerodermatous chronic GvHD, LPSlow-trained macrophages attenuate clinical signs of GvHD with significant effects on T cell phenotype and function, autoantibodies production, and tissue fibrosis. Furthermore, infusion of LPSlow-macrophages significantly improves survival in mice with acute GvHD. Importantly, we also provide evidence that LPSlow-macrophages do not accelerate A20-lymphoma tumor growth, which is significantly reduced upon transfer of BCG-macrophages. Collectively, these data indicate that macrophages can be trained to significantly inhibit in vitro and in vivo allo-reactive T cell proliferation without exhibiting pro-tumoral effect, thereby opening the way to promising clinical applications.	[Jeljeli, Mohamed; Chene, Charlotte; Chouzenoux, Sandrine; Thomas, Marine; Segain, Benjamin; Doridot, Ludivine; Nicco, Carole; Batteux, Frederic] Univ Paris, INSERM U1016, Inst Cochin, Dept 3I Infect Immunite & Inflammat, Paris, France; [Jeljeli, Mohamed; Batteux, Frederic] Univ Paris, Hop Cochin, AP HP, Fac Med,Ctr Univ Paris,Serv Immunol Biol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Batteux, F (corresponding author), Univ Paris, INSERM U1016, Inst Cochin, Dept 3I Infect Immunite & Inflammat, Paris, France.; Batteux, F (corresponding author), Univ Paris, Hop Cochin, AP HP, Fac Med,Ctr Univ Paris,Serv Immunol Biol, Paris, France.	frederic.batteux@aphp.fr	Nicco, Carole/O-8169-2017; Doridot, Ludivine/O-8610-2017	Nicco, Carole/0000-0001-8211-2556; Chene, Charlotte/0000-0001-6543-8642	University Paris Descartes INSERM	University Paris Descartes INSERM	This work was supported by grants from University Paris Descartes INSERM.	Albeituni SH, 2016, J IMMUNOL, V196, P2167, DOI 10.4049/jimmunol.1501853; Anderson BE, 2004, BLOOD, V104, P1565, DOI 10.1182/blood-2004-01-0328; Antoniv TT, 2011, IMMUNOLOGY, V132, P567, DOI 10.1111/j.1365-2567.2010.03402.x; Arts RJW, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD-0023-2015; Ayroldi E, 1998, BLOOD, V92, P4212, DOI 10.1182/blood.V92.11.4212.423k42_4212_4219; Baird K, 2006, CURR OPIN HEMATOL, V13, P426, DOI 10.1097/01.moh.0000245689.47333.ff; Banerjee D, 2005, IMMUNITY, V23, P445, DOI 10.1016/j.immuni.2005.09.012; Bascuas T, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1073-8; Biswas SK, 2009, TRENDS IMMUNOL, V30, P475, DOI 10.1016/j.it.2009.07.009; Blazar BR, 2012, NAT REV IMMUNOL, V12, P443, DOI 10.1038/nri3212; Bouazzaoui A, 2009, GENES IMMUN, V10, P687, DOI 10.1038/gene.2009.49; Brubaker AL, 2011, J IMMUNOL METHODS, V373, P161, DOI 10.1016/j.jim.2011.08.013; Cao J, 2020, TRENDS CANCER, V6, P580, DOI 10.1016/j.trecan.2020.02.003; Castor MGM, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00023; Cetkovic-Cvrlje M, 2001, BLOOD, V98, P1607, DOI 10.1182/blood.V98.5.1607; Cevey AC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01267; Chang YJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03041; Chavez-Galan L, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/4048235; Choi SW, 2010, IMMUNOL ALLERGY CLIN, V30, P75, DOI 10.1016/j.iac.2009.10.001; Coghill JM, 2011, BLOOD, V117, P3268, DOI 10.1182/blood-2010-12-290403; Cooke KR, 2017, BIOL BLOOD MARROW TR, V23, P211, DOI 10.1016/j.bbmt.2016.09.023; Cooke KR., 2013, JOHNS HOPKINS U, V18, P393, DOI [10.1016/B978-0-12-416004-0.00017-3, DOI 10.1016/B978-0-12-416004-0.00017-3]; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Crawford A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002098; Croudace JE, 2012, BLOOD, V120, P4246, DOI 10.1182/blood-2012-02-413260; Huu DL, 2012, J INVEST DERMATOL, V132, P2752, DOI 10.1038/jid.2012.226; Dunavin N, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5030039; Elpek KG, 2007, J IMMUNOL, V178, P6840, DOI 10.4049/jimmunol.178.11.6840; Faaij CMJM, 2006, BRIT J HAEMATOL, V133, P538, DOI 10.1111/j.1365-2141.2006.06058.x; Flowers MED, 2015, BLOOD, V125, P606, DOI 10.1182/blood-2014-08-551994; Ford GS, 1999, J IMMUNOL, V162, P4037; Gardiner CM, 2016, SEMIN IMMUNOL, V28, P343, DOI 10.1016/j.smim.2016.03.001; Garnett C, 2013, THER ADV HEMATOL, V4, P366, DOI 10.1177/2040620713489842; Ghimire S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00079; Gilet J, 2009, J INVEST DERMATOL, V129, P879, DOI 10.1038/jid.2008.333; Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017; Hashimoto D, 2011, J EXP MED, V208, P1069, DOI 10.1084/jem.20101709; He S, 2008, J IMMUNOL, V181, P7581, DOI 10.4049/jimmunol.181.11.7581; Highfill SL, 2010, BLOOD, V116, P5738, DOI 10.1182/blood-2010-06-287839; Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552; Jeljeli M, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108325; Jeljeli M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13636-x; Kadlecek TA, 1998, J IMMUNOL, V161, P4688; Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031; Kavian N, 2012, J IMMUNOL, V188, P5142, DOI 10.4049/jimmunol.1103538; KIM KJ, 1979, J IMMUNOL, V122, P549; Kitko CL, 2012, BIOL BLOOD MARROW TR, V18, pS46, DOI 10.1016/j.bbmt.2011.10.021; Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Krenger W, 1996, IMMUNOL RES, V15, P50, DOI 10.1007/BF02918284; Lefebvre DC, 2010, MOL IMMUNOL, V47, P1882, DOI 10.1016/j.molimm.2010.03.018; Levine JE, 2011, INT J HEMATOL, V93, P571, DOI 10.1007/s12185-011-0803-1; Libraty Daniel H, 2014, Trials Vaccinol, V3, P1, DOI 10.1016/j.trivac.2013.11.004; Liu QH, 2015, MOL CELLS, V38, P886, DOI 10.14348/molcells.2015.0125; Loschi Michael, 2015, Biol Blood Marrow Transplant, V21, P569, DOI 10.1016/j.bbmt.2014.12.009; MacDonald KPA, 2017, J CLIN INVEST, V127, P2452, DOI 10.1172/JCI90593; MacDonald KPA, 2017, BLOOD, V129, P13, DOI 10.1182/blood-2016-06-686618; Magenau J, 2016, BRIT J HAEMATOL, V173, P190, DOI 10.1111/bjh.13959; McCormick LL, 1999, J IMMUNOL, V163, P5693; Mencarelli A, 2016, SCI REP-UK, V6, DOI 10.1038/srep30802; Morante MP, 2006, CLIN EXP IMMUNOL, V145, P36, DOI 10.1111/j.1365-2249.2006.03104.x; MORTON DL, 1974, ANN SURG, V180, P635, DOI 10.1097/00000658-197410000-00029; Murai M, 1999, J CLIN INVEST, V104, P49, DOI 10.1172/JCI6642; Najafi M, 2019, J CELL BIOCHEM, V120, P2756, DOI 10.1002/jcb.27646; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Netea MG, 2013, EUR J CLIN INVEST, V43, P881, DOI 10.1111/eci.12132; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Ogawa S, 2001, J IMMUNOL, V167, P5741, DOI 10.4049/jimmunol.167.10.5741; Paul CD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38186-y; Pettenati C, 2018, NAT REV UROL, V15, P615, DOI 10.1038/s41585-018-0055-4; Piper C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00163; Quinn SM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01109; Quintin J, 2012, CELL HOST MICROBE, V12, P223, DOI 10.1016/j.chom.2012.06.006; Rachfal AW, 2003, HEPATOL RES, V26, P1, DOI 10.1016/S1386-6346(03)00115-3; Riegel C, 2020, LEUKEMIA, V34, P895, DOI 10.1038/s41375-019-0625-3; Ross SH, 2018, ANNU REV IMMUNOL, V36, P411, DOI 10.1146/annurev-immunol-042617-053352; Schroeder MA, 2011, DIS MODEL MECH, V4, P318, DOI 10.1242/dmm.006668; Seeley JJ, 2017, J LEUKOCYTE BIOL, V101, P107, DOI 10.1189/jlb.3MR0316-118RR; Serody JS, 2012, BIOL BLOOD MARROW TR, V18, pS56, DOI 10.1016/j.bbmt.2011.10.001; Silva R, 2005, Int J Biomed Sci, V1, P46; Soler D, 2003, BLOOD, V101, P1677, DOI 10.1182/blood-2002-07-2348; Suzuki T, 2014, NATURE, V514, P450, DOI 10.1038/nature13807; TANAKA J, 1994, BRIT J HAEMATOL, V87, P415, DOI 10.1111/j.1365-2141.1994.tb04935.x; Tarlow BD, 2014, CELL STEM CELL, V15, P605, DOI 10.1016/j.stem.2014.09.008; Teague TK, 1997, J IMMUNOL, V158, P5791; Toubai T, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00539; Weisdorf D, 2012, BIOL BLOOD MARROW TR, V18, P1727, DOI 10.1016/j.bbmt.2012.06.014; Wikenheiser DJ, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00304; Wingard JR, 2011, J CLIN ONCOL, V29, P2230, DOI 10.1200/JCO.2010.33.7212; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; YOKOTA S, 1988, J IMMUNOL, V140, P531; Yu XZ, 2006, J IMMUNOL, V176, P7394, DOI 10.4049/jimmunol.176.12.7394; Zeiser R, 2018, BLOOD, V131, P1399, DOI 10.1182/blood-2017-11-784017; Zhang MM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01461; Zhang SN, 2014, INT J CLIN EXP PATHO, V7, P6626; Zhang Y, 2005, J IMMUNOL, V174, P3051, DOI 10.4049/jimmunol.174.5.3051; Zhang Y, 2002, J IMMUNOL, V168, P3088, DOI 10.4049/jimmunol.168.6.3088; Zheng CC, 2017, BONE MARROW TRANSPL, V52, P88, DOI 10.1038/bmt.2016.182	99	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 3	2021	12								670776	10.3389/fimmu.2021.670776	http://dx.doi.org/10.3389/fimmu.2021.670776			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UL7HP	34413847	Green Published, gold			2022-12-18	WOS:000692818200001
J	Bottaro, A; Brown, DMM; Frelinger, JGG				Bottaro, Andrea; Brown, Deborah M. M.; Frelinger, John G. G.			Editorial: The Present and Future of Immunology Education	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immunology; medical; active; learning; education; undergraduate; diversity; laboratory			[Bottaro, Andrea] Rowan Univ, Cooper Med Sch, Dept Biomed Sci, Camden, NJ USA; [Brown, Deborah M. M.] Trudeau Inst, Dept Viral Immunol, Saranac Lake, NY USA; [Frelinger, John G. G.] Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA; [Frelinger, John G. G.] Univ Rochester, Sch Med & Dent, Wilmot Canc Ctr, Rochester, NY 14642 USA	Rowan University; Cooper Medical School of Rowan University; Trudeau Institute; University of Rochester; University of Rochester	Frelinger, JGG (corresponding author), Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA.; Frelinger, JGG (corresponding author), Univ Rochester, Sch Med & Dent, Wilmot Canc Ctr, Rochester, NY 14642 USA.	JFrelinger@gmail.com						Asai DJ, 2020, CELL, V181, P754, DOI 10.1016/j.cell.2020.03.044; Justement Louis B, 2020, Immunohorizons, V4, P745, DOI 10.4049/immunohorizons.2000086; Porter Edith, 2021, Immunohorizons, V5, P448, DOI 10.4049/immunohorizons.2100030	3	1	1	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 2	2021	12								744090	10.3389/fimmu.2021.744090	http://dx.doi.org/10.3389/fimmu.2021.744090			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UA8VX	34408756	gold, Green Published			2022-12-18	WOS:000685435000001
J	de Oliveira, GLV; Cardoso, CRD; Taneja, V; Fasano, A				de Oliveira, Gislane Lelis Vilela; Cardoso, Cristina Ribeiro de Barros; Taneja, Veena; Fasano, Alessio			Editorial: Intestinal Dysbiosis in Inflammatory Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						inflammatory diseases; gut microbiota; dysbiosis; gut permeability; microbiota modulators	GUT MICROBIOTA; BOWEL-DISEASE; HEALTH; RISK		[de Oliveira, Gislane Lelis Vilela] Sao Paulo State Univ, Inst Biosci Humanities & Exact Sci, Microbiol Program, Sao Jose Do Rio Preto, Brazil; [de Oliveira, Gislane Lelis Vilela] Sao Paulo State Univ, Inst Biosci Humanities & Exact Sci, Dept Food Engn & Technol, Sao Jose Do Rio Preto, Brazil; [Cardoso, Cristina Ribeiro de Barros] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal Toxicol & Food Sci, Ribeirao Preto, Brazil; [Taneja, Veena] Mayo Clin, Dept Immunol, Rochester, MN USA; [Taneja, Veena] Mayo Clin, Dept Med, Div Rheumatol, Rochester, MN USA; [Fasano, Alessio] Massachusetts Gen Hosp, Mucosal Immunol & Biol Res Ctr, Ctr Celiac Res, Div Pediat Gastroenterol & Nutr, Boston, MA 02114 USA; [Fasano, Alessio] Harvard Med Sch, Gastroenterol & Nutr, Boston, MA 02115 USA; [Fasano, Alessio] European Biomed Res Inst Salerno, Salerno, Italy	Universidade Estadual Paulista; Universidade Estadual Paulista; Universidade de Sao Paulo; Mayo Clinic; Mayo Clinic; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	de Oliveira, GLV (corresponding author), Sao Paulo State Univ, Inst Biosci Humanities & Exact Sci, Microbiol Program, Sao Jose Do Rio Preto, Brazil.; de Oliveira, GLV (corresponding author), Sao Paulo State Univ, Inst Biosci Humanities & Exact Sci, Dept Food Engn & Technol, Sao Jose Do Rio Preto, Brazil.	gislane.lelis@unesp.br	de Oliveira, Gislane L. V./I-4896-2013; Ribeiro de Barros Cardoso, Cristina/AGO-5764-2022	de Oliveira, Gislane L. V./0000-0002-0269-9973; Ribeiro de Barros Cardoso, Cristina/0000-0002-6156-3144; Lelis Vilela de Oliveira, Gislane/0000-0002-8883-5541				Brown EM, 2019, ANNU REV IMMUNOL, V37, P599, DOI 10.1146/annurev-immunol-042718-041841; Chen J, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0299-7; De Luca F, 2019, CLIN EXP IMMUNOL, V195, P74, DOI 10.1111/cei.13158; de Paiva CS, 2016, SCI REP-UK, V6, DOI 10.1038/srep23561; de Souza PR, 2018, IMMUNOBIOLOGY, V223, P577, DOI 10.1016/j.imbio.2018.07.003; Deng ZX, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.538077; Donaldson GP, 2016, NAT REV MICROBIOL, V14, P20, DOI 10.1038/nrmicro3552; Fan Y, 2021, NAT REV MICROBIOL, V19, P55, DOI 10.1038/s41579-020-0433-9; Hu YJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33571-z; Jiao YH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00282; Johnson BM, 2020, J AUTOIMMUN, V108, DOI 10.1016/j.jaut.2020.102420; Jubair WK, 2018, ARTHRITIS RHEUMATOL, V70, P1220, DOI 10.1002/art.40490; Labarca G, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-0963-y; Lee J, 2019, WORLD J GASTROENTERO, V25, P6354, DOI 10.3748/wjg.v25.i42.6354; Lerner A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00084; Levy M, 2017, NAT REV IMMUNOL, V17, P219, DOI 10.1038/nri.2017.7; Luo XM, 2018, APPL ENVIRON MICROB, V84, DOI 10.1128/AEM.02288-17; Lynch SV, 2016, NEW ENGL J MED, V375, P2369, DOI 10.1056/NEJMra1600266; Ma YYZ, 2019, MOL MED, V25, DOI 10.1186/s10020-019-0102-5; Maeda Y, 2016, ARTHRITIS RHEUMATOL, V68, P2646, DOI 10.1002/art.39783; Marietta E, 2019, CELL IMMUNOL, V339, P50, DOI 10.1016/j.cellimm.2018.10.005; Masetti G, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0478-4; Moshkelgosha S, 2018, HORM METAB RES, V50, P932, DOI 10.1055/a-0653-3766; Mu QH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00598; Neuman V, 2019, DIABETOLOGIA, V62, P1291, DOI 10.1007/s00125-019-4869-2; Palm NW, 2015, CLIN IMMUNOL, V159, P122, DOI 10.1016/j.clim.2015.05.014; Ratajczak W, 2019, ACTA BIOCHIM POL, V66, P1, DOI 10.18388/abp.2018_2648; Rosser EC, 2016, J AUTOIMMUN, V74, P85, DOI 10.1016/j.jaut.2016.06.009; Ruff WE, 2020, NAT REV MICROBIOL, V18, P521, DOI 10.1038/s41579-020-0367-2; Simon MC, 2020, J BIOL CHEM, V295, P969, DOI 10.1074/jbc.RA119.010816; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Tamburini S, 2016, NAT MED, V22, P713, DOI 10.1038/nm.4142; de Oliveira GLV, 2017, IMMUNOLOGY, V152, P1, DOI 10.1111/imm.12765; Vutcovici M, 2016, EUR RESPIR J, V47, P1357, DOI 10.1183/13993003.01945-2015; Wu HJ, 2012, GUT MICROBES, V3, P4, DOI 10.4161/gmic.19320; Yi L, 2021, SCI TOTAL ENVIRON, V763, DOI 10.1016/j.scitotenv.2020.143031	36	1	1	16	61	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 30	2021	12								727485	10.3389/fimmu.2021.727485	http://dx.doi.org/10.3389/fimmu.2021.727485			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UA2QU	34394133	Green Published, gold			2022-12-18	WOS:000685009500001
J	Kamuyu, G; Cheng, YS; Willcocks, S; Kewcharoenwong, C; Kiratisin, P; Taylor, PW; Wren, BW; Lertmemongkolchai, G; Stabler, RA; Brown, J				Kamuyu, Gathoni; Cheng, Yat Suen; Willcocks, Sam; Kewcharoenwong, Chidchamai; Kiratisin, Pattarachai; Taylor, Peter W.; Wren, Brendan W.; Lertmemongkolchai, Ganjana; Stabler, Richard A.; Brown, Jeremy			Sequential Vaccination With Heterologous Acinetobacter baumannii Strains Induces Broadly Reactive Antibody Responses	FRONTIERS IN IMMUNOLOGY			English	Article						antibodies; growth inhibition; neutrophils; heterologous protection; A. baumannii	TRIMERIC AUTOTRANSPORTER; CAPSULAR POLYSACCHARIDE; PROTECTIVE IMMUNITY; INFECTION; IMMUNIZATION; PROTEIN; IDENTIFICATION; NEUTROPHILS; CANDIDATE; TARGET	Antibody therapy may be an alternative treatment option for infections caused by the multi-drug resistant (MDR) bacterium Acinetobacter baumannii. As A. baumannii has multiple capsular serotypes, a universal antibody therapy would need to target conserved protein antigens rather than the capsular polysaccharides. We have immunized mice with single or multiple A. baumannii strains to induce antibody responses to protein antigens, and then assessed whether these responses provide cross-protection against a collection of genetically diverse clinical A. baumannii isolates. Immunized mice developed antibody responses to multiple protein antigens. Flow cytometry IgG binding assays and immunoblots demonstrated improved recognition of both homologous and heterologous clinical strains in sera from mice immunized with multiple strains compared to a single strain. The capsule partially inhibited bacterial recognition by IgG and the promotion of phagocytosis by human neutrophils. However, after immunization with multiple strains, serum antibodies to protein antigens promoted neutrophil phagocytosis of heterologous A. baumannii strains. In an infection model, mice immunized with multiple strains had lower bacterial counts in the spleen and liver following challenge with a heterologous strain. These data demonstrate that antibodies targeting protein antigens can improve immune recognition and protection against diverse A. baumannii strains, providing support for their use as an antibody therapy.	[Kamuyu, Gathoni; Cheng, Yat Suen; Brown, Jeremy] Univ Coll London UCL Resp, Ctr Inflammat & Tissue Repair, London, England; [Willcocks, Sam; Wren, Brendan W.; Stabler, Richard A.] London Sch Hyg & Trop Med, Dept Infect Biol, Infect & Trop Dis, London, England; [Kewcharoenwong, Chidchamai; Lertmemongkolchai, Ganjana] Khon Kaen Univ, Fac Associated Med Sci, Ctr Res & Dev Med Diagnost Labs CMDL, Cellular & Mol Immunol Unit, Khon Kaen, Thailand; [Kiratisin, Pattarachai] Mahidol Univ, Fac Med Siriraj Hosp, Dept Microbiol, Bangkok, Thailand; [Taylor, Peter W.] UCL, Sch Pharm, London, England; [Lertmemongkolchai, Ganjana] Chiang Mai Univ, Fac Associated Med Sci, Dept Med Technol, Chiang Mai, Thailand	University of London; London School of Hygiene & Tropical Medicine; Khon Kaen University; Mahidol University; University of London; University College London; University of London School of Pharmacy; Chiang Mai University	Brown, J (corresponding author), Univ Coll London UCL Resp, Ctr Inflammat & Tissue Repair, London, England.	jeremy.brown@ucl.ac.uk			Department of Health's NIHR Biomedical Research Centre's funding scheme; MRC DPFS [MR/S004394/1]	Department of Health's NIHR Biomedical Research Centre's funding scheme(National Institute for Health Research (NIHR)); MRC DPFS(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health's NIHR Biomedical Research Centre's funding scheme and was also supported by an MRC DPFS MR/S004394/1 to RS, BW, GL and JB. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.	Ainsworth S, 2017, VACCINE, V35, P3387, DOI 10.1016/j.vaccine.2017.05.017; Allegranzi B, 2011, LANCET, V377, P228, DOI 10.1016/S0140-6736(10)61458-4; Bentancor LV, 2012, INFECT IMMUN, V80, P3381, DOI 10.1128/IAI.06096-11; Bentancor LV, 2012, J BACTERIOL, V194, P3950, DOI 10.1128/JB.06769-11; Breslow JM, 2011, INFECT IMMUN, V79, P3317, DOI 10.1128/IAI.00069-11; Chiang MH, 2015, HUM VACC IMMUNOTHER, V11, P1065, DOI 10.1080/21645515.2015.1010910; Delany I, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a012476; ECDC, 2016, CARB RES AC BAUM HEA; Esmaeikhani Hamid, 2019, Avicenna Journal of Medical Biotechnology, V11, P180; Fattahian Y, 2011, MICROB PATHOGENESIS, V51, P402, DOI 10.1016/j.micpath.2011.09.004; Garcia-Quintanilla M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114410; Garg N, 2016, INT J MED MICROBIOL, V306, P1, DOI 10.1016/j.ijmm.2015.10.005; Guo SJ, 2018, BIOMED ENVIRON SCI, V31, P155, DOI 10.3967/bes2018.019; Huang WW, 2016, SCI REP-UK, V6, DOI 10.1038/srep20724; Huang WW, 2015, VACCINE, V33, P4479, DOI 10.1016/j.vaccine.2015.07.031; Huang WQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100727; Hyams C, 2013, INFECT IMMUN, V81, P354, DOI 10.1128/IAI.00862-12; Hyams C, 2010, INFECT IMMUN, V78, P704, DOI 10.1128/IAI.00881-09; Isler B, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.01110-18; Jahangiri A, 2019, J APPL MICROBIOL, V126, P624, DOI 10.1111/jam.14135; Kang SH, 2021, BIOTECHNOL BIOPROC E, V26, P295, DOI 10.1007/s12257-020-0181-8; Krammer F, 2017, EXPERT REV VACCINES, V16, P503, DOI 10.1080/14760584.2017.1299576; KuoLee R, 2015, VACCINE, V33, P260, DOI 10.1016/j.vaccine.2014.02.083; Lim C, 2016, ELIFE, V5, DOI 10.7554/eLife.18082; Lindahl G, 2021, MICROBIOL MOL BIOL R, V85, DOI 10.1128/MMBR.00078-20; Loraine J, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00548; Luo GPS, 2012, PLOS ONE, V7, P46, DOI 10.1371/journal.pone.0029446; Mahmoudi Z, 2020, APMIS, V128, P476, DOI 10.1111/apm.13061; Mangas EL, 2019, MICROB GENOMICS, V5, DOI 10.1099/mgen.0.000309; McConnell MJ, 2019, DRUG DISCOV TODAY, V24, P1132, DOI 10.1016/j.drudis.2019.03.002; McConnell MJ, 2013, FEMS MICROBIOL REV, V37, P130, DOI 10.1111/j.1574-6976.2012.00344.x; McConnell MJ, 2011, INFECT IMMUN, V79, P518, DOI 10.1128/IAI.00741-10; McConnell MJ, 2010, VACCINE, V29, P1, DOI 10.1016/j.vaccine.2010.10.052; Moe GR, 2002, INFECT IMMUN, V70, P6021, DOI 10.1128/IAI.70.11.6021-6031.2002; Nielsen TB, 2017, J INFECT DIS, V216, P489, DOI 10.1093/infdis/jix315; Pulido MR, 2018, VACCINE, V36, P4153, DOI 10.1016/j.vaccine.2018.05.113; Qamsari MM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00158; Ramezanalizadeh F, 2020, VACCINE, V38, P5436, DOI 10.1016/j.vaccine.2020.06.052; Russo TA, 2013, INFECT IMMUN, V81, P915, DOI 10.1128/IAI.01184-12; Schultz MB, 2016, MICROB GENOMICS, V2, DOI 10.1099/mgen.0.000050; Shu MH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22332; Singh JK, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03301; Singh R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12789-3; Singh R, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00158; Tacconelli E, 2018, LANCET INFECT DIS, V18, P318, DOI [10.1016/S1473-3099(17)30753-3, 10.1016/s1473-3099(17)30753-3]; Van Faassen H, 2007, INFECT IMMUN, V75, P5597, DOI 10.1128/IAI.00762-07; Wang-Lin SX, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00591-17; WHO, 2017, GLOBAL PRIORITY LIST; WHO, 2011, WHO LIB CAT PUBL DAT; Wilson R, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006137; Wong D, 2017, CLIN MICROBIOL REV, V30, P409, DOI 10.1128/CMR.00058-16; Wyres KL, 2020, MICROB GENOMICS, V6, DOI 10.1099/mgen.0.000339; Yang AQ, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12769; Yang FL, 2017, VACCINE, V35, P1440, DOI 10.1016/j.vaccine.2017.01.060; Zhou H, 2017, VACCINE, V35, P305, DOI 10.1016/j.vaccine.2016.11.051; Zurawski DV, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9040155	56	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 30	2021	12								705533	10.3389/fimmu.2021.705533	http://dx.doi.org/10.3389/fimmu.2021.705533			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UG9BA	34394105	Green Published, gold			2022-12-18	WOS:000689537000001
J	Mondanelli, G; Albini, E; Orecchini, E; Pallotta, MT; Belladonna, ML; Ricci, G; Grohmann, U; Orabona, C				Mondanelli, Giada; Albini, Elisa; Orecchini, Elena; Pallotta, Maria Teresa; Belladonna, Maria Laura; Ricci, Giovanni; Grohmann, Ursula; Orabona, Ciriana			Pathogenetic Interplay Between IL-6 and Tryptophan Metabolism in an Experimental Model of Obesity	FRONTIERS IN IMMUNOLOGY			English	Article						experimental obesity; tryptophan metabolism; ndoleamine 2, 3 dioxygenase 1 (IDO1); tocilizumab (TCZ); white adipose tissue (WAT); IL-6 receptor (IL-6R); high fat diet (HFD)	BODY-MASS INDEX; INDOLEAMINE 2,3-DIOXYGENASE; RHEUMATOID-ARTHRITIS; IDO EXPRESSION; TOLERANCE; HETEROGENEITY; INFLAMMATION; TOCILIZUMAB; INDUCTION; PROTEIN	Obesity is a metabolic disease characterized by a state of chronic, low-grade inflammation and dominated by pro-inflammatory cytokines such as IL-6. Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that catalyzes the first step in the kynurenine pathway by transforming l-tryptophan (Trp) into l-kynurenine (Kyn), a metabolite endowed with anti-inflammatory and immunoregulatory effects. In dendritic cells, IL-6 induces IDO1 proteasomal degradation and shuts down IDO1-mediated immunosuppressive effects. In tumor cells, IL-6 upregulates IDO1 expression and favors tumor immune escape mechanisms. To investigate the role of IDO1 and its possible relationship with IL-6 in obesity, we induced the disease by feeding mice with a high fat diet (HFD). Mice on a standard diet were used as control. Experimental obesity was associated with high IDO1 expression and Kyn levels in the stromal vascular fraction of visceral white adipose tissue (SVF WAT). IDO1-deficient mice on HFD gained less weight and were less insulin resistant as compared to wild type counterparts. Administration of tocilizumab (TCZ), an IL-6 receptor (IL-6R) antagonist, to mice on HFD significantly reduced weight gain, controlled adipose tissue hypertrophy, increased insulin sensitivity, and induced a better glucose tolerance. TCZ also induced a dramatic inhibition of IDO1 expression and Kyn production in the SVF WAT. Thus our data indicated that the IL-6/IDO1 axis may play a pathogenetic role in a chronic, low-grade inflammation condition, and, perhaps most importantly, IL-6R blockade may be considered a valid option for obesity treatment.	[Mondanelli, Giada; Albini, Elisa; Orecchini, Elena; Pallotta, Maria Teresa; Belladonna, Maria Laura; Grohmann, Ursula; Orabona, Ciriana] Univ Perugia, Dept Med & Surg, Perugia, Italy; [Ricci, Giovanni] Univ Perugia, Serv Ctr Preclin Res, Perugia, Italy	University of Perugia; University of Perugia	Orabona, C (corresponding author), Univ Perugia, Dept Med & Surg, Perugia, Italy.	ciriana.orabona@unipg.it		Orecchini, Elena/0000-0003-1872-4042	Associazione Italiana per la Ricerca sul Cancro (AIRC) [2019-23084]; Italian Ministry of Education, University and Research [PRIN2017-2017BA9LM5]	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Education, University and Research(Ministry of Education, Universities and Research (MIUR))	This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC 2019-23084; to UG) and the Italian Ministry of Education, University, and Research (PRIN2017-2017BA9LM5 to CO).	Bernstein LE, 2006, ARCH INTERN MED, V166, P902, DOI 10.1001/archinte.166.8.902; Brandacher G, 2007, CURR DRUG METAB, V8, P289, DOI 10.2174/138920007780362590; Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408; Castoldi A, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00637; Rafols ME, 2014, ENDOCRINOL NUTR, V61, P100, DOI 10.1016/j.endonu.2013.03.011; Fujigaki H, 2006, J BIOCHEM, V139, P655, DOI 10.1093/jb/mvj072; Gardette A, 2016, CLIN RHEUMATOL, V35, P857, DOI 10.1007/s10067-016-3183-3; Grohmann U, 2003, TRENDS IMMUNOL, V24, P242, DOI 10.1016/S1471-4906(03)00072-3; Hotamisligil GS, 2017, NATURE, V542, P177, DOI 10.1038/nature21363; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Jones SA, 2018, NAT REV IMMUNOL, V18, P773, DOI 10.1038/s41577-018-0066-7; Kurylowicz A, 2020, MOLECULES, V25, DOI 10.3390/molecules25092224; Laurans L, 2018, NAT MED, V24, P1113, DOI 10.1038/s41591-018-0060-4; Litzenburger UM, 2014, ONCOTARGET, V5, P1038, DOI 10.18632/oncotarget.1637; Liu LH, 2017, METHODS MOL BIOL, V1566, P9, DOI 10.1007/978-1-4939-6820-6_2; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Molinaro A, 2019, CELL METAB, V29, P1400, DOI 10.1016/j.cmet.2019.03.010; Mondanelli G, 2020, P NATL ACAD SCI USA, V117, P3848, DOI 10.1073/pnas.1918215117; Mondanelli G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01565; Mondanelli G, 2017, IMMUNITY, V46, P233, DOI 10.1016/j.immuni.2017.01.005; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Orabona C, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96244; Orabona C, 2012, MOL MED, V18, P834, DOI 10.2119/molmed.2012.00029; Pallotta MT, 2011, NAT IMMUNOL, V12, P870, DOI 10.1038/ni.2077; Pers YM, 2015, J RHEUMATOL, V42, P580, DOI 10.3899/jrheum.140673; Prunet-Marcassus B, 2006, EXP CELL RES, V312, P727, DOI 10.1016/j.yexcr.2005.11.021; Puccetti P, 2007, NAT REV IMMUNOL, V7, P817, DOI 10.1038/nri2163; Romani L, 2008, NATURE, V451, P211, DOI 10.1038/nature06471; Saltiel AR, 2017, J CLIN INVEST, V127, P1, DOI [10.1172/JCI92035, 10.1172/jci92035]; Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887; van Asseldonk EJP, 2011, J CLIN ENDOCR METAB, V96, P2119, DOI 10.1210/jc.2010-2992; van Baren N, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00034; Wang YT, 2010, NAT MED, V16, P279, DOI 10.1038/nm.2092; Xue Y, 2016, P NATL ACAD SCI USA, V113, P5552, DOI 10.1073/pnas.1603840113; YOSHIDA R, 1981, P NATL ACAD SCI-BIOL, V78, P129, DOI 10.1073/pnas.78.1.129	36	1	1	0	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 30	2021	12								713989	10.3389/fimmu.2021.713989	http://dx.doi.org/10.3389/fimmu.2021.713989			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UB7BC	34394118	Green Published, gold			2022-12-18	WOS:000685996100001
J	Yin, H; Pranzatelli, TJF; French, BN; Zhang, N; Warner, BM; Chiorini, JA				Yin, Hongen; Pranzatelli, Thomas J. F.; French, Benjamin N.; Zhang, Nan; Warner, Blake M.; Chiorini, John A.		NIDCD NIDCR Genomics Computational	Sclerosing Sialadenitis Is Associated With Salivary Gland Hypofunction and a Unique Gene Expression Profile in Sjogren's Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						Sjogren's syndrome; salivary gland interstitial fibrosis; sclerosing sialadenitis; salivary gland hypofunction; transcriptomic gene expression profile	TGF-BETA; MESENCHYMAL TRANSITION; RHEUMATOID-ARTHRITIS; FIBROSIS; MECHANISMS; FIBROBLASTS; DISEASE	Purpose To develop a novel method to quantify the amount of fibrosis in the salivary gland and to investigate the relationship between fibrosis and specific symptoms associated with Sjogren's syndrome (SS) using this method. Materials and Methods Paraffin-embedded labial salivary gland (LSG) slides from 20 female SS patients and their clinical and LSG pathology data were obtained from the Sjogren's International Collaborative Clinical Alliance. Relative interstitial fibrosis area (RIFA) in Masson's trichrome-stained LSG sections was quantified from digitally scanned slides and used for correlation analysis. Gene expression levels were assessed by microarray analysis. Core promoter accessibility for RIFA-correlated genes was determined using DNase I hypersensitive sites sequencing analysis. Results RIFA was significantly correlated with unstimulated whole saliva flow rate in SS patients. Sixteen genes were significantly and positively correlated with RIFA. In a separate analysis, a group of differentially expressed genes was identified by comparing severe and moderate fibrosis groups. This combined set of genes was distinct from differentially expressed genes identified in lung epithelium from idiopathic pulmonary fibrosis patients compared with controls. Single-cell RNA sequencing analysis of salivary glands suggested most of the RIFA-correlated genes are expressed by fibroblasts in the gland and are in a permissive chromatin state. Conclusion RIFA quantification is a novel method for assessing interstitial fibrosis and the impact of fibrosis on SS symptoms. Loss of gland function may be associated with salivary gland fibrosis, which is likely to be driven by a unique set of genes that are mainly expressed by fibroblasts.	[Yin, Hongen; Pranzatelli, Thomas J. F.; French, Benjamin N.; Zhang, Nan; Chiorini, John A.] NIDCR, Adeno Associated Virus AAV Biol Sect, NIH, Bethesda, MD 20892 USA; [Warner, Blake M.] NIDCR, Salivary Disorders Unit, NIH, Bethesda, MD USA; [NIDCD NIDCR Genomics Computational] NIDCR, Genom & Computat Biol Core, NIDOCD, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Chiorini, JA (corresponding author), NIDCR, Adeno Associated Virus AAV Biol Sect, NIH, Bethesda, MD 20892 USA.	jchiorini@dir.nidcr.nih.gov		Pranzatelli, Thomas/0000-0002-5763-1036	National Institute of Dental and Craniofacial Research (NIDCR); National Institutes of Health (NIH) [NIDCR Z01-DE000704]; National Institute on Deafness and Other Communication Disorders (NIDCD) Division of Intramural Research, NIH [NIDCR Z01-DE000704, ZIC DC000086]; NIH [1ZIADE000695]	National Institute of Dental and Craniofacial Research (NIDCR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Deafness and Other Communication Disorders (NIDCD) Division of Intramural Research, NIH; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The microarray analysis is supported by a National Institute of Dental and Craniofacial Research (NIDCR) grant to HY and JC. The single-cell RNA sequencing analysis was supported by funds to BW (NIDCR Z01-DE000704) through the National Institutes of Health (NIH) and National Institute on Deafness and Other Communication Disorders (NIDCD) Division of Intramural Research, NIH (ZIC DC000086). This work utilized computational resources from the NIH HPC Biowulf cluster. (http://hpc.nih.gov).The remainder of the research was supported by an NIH intramural grant to JC (1ZIADE000695).	Bookman AAM, 2011, ARTHRITIS RHEUM-US, V63, P2014, DOI 10.1002/art.30295; Borges S, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3460; Cha B, 2016, GENE DEV, V30, P1454, DOI 10.1101/gad.282400.116; Chou RH, 2011, BIOCHEM BIOPH RES CO, V409, P442, DOI 10.1016/j.bbrc.2011.05.022; Colby TV, 1998, CLIN CHEST MED, V19, P587, DOI 10.1016/S0272-5231(05)70105-2; Dai W, 2016, P NATL ACAD SCI USA, V113, P3317, DOI 10.1073/pnas.1523436113; Daniels TE, 2011, ARTHRITIS RHEUM-US, V63, P2021, DOI 10.1002/art.30381; Das V, 2019, J CELL PHYSIOL, V234, P14535, DOI 10.1002/jcp.28160; de Marval PLM, 2001, AM J PATHOL, V159, P369, DOI 10.1016/S0002-9440(10)61703-8; Denton CP, 2006, NAT CLIN PRACT RHEUM, V2, P134, DOI 10.1038/ncprheum0115; Dillon LAL, 2015, NUCLEIC ACIDS RES, V43, P6799, DOI 10.1093/nar/gkv656; DiRocco DP, 2013, J AM SOC NEPHROL, V24, P1399, DOI 10.1681/ASN.2012050512; Fernandez IE, 2012, LANCET, V380, P680, DOI 10.1016/S0140-6736(12)61144-1; Fox RI, 2005, LANCET, V366, P321, DOI 10.1016/S0140-6736(05)66990-5; Gerhard GS, 2018, J ENDOCR SOC, V2, P710, DOI 10.1210/js.2018-00122; Giovelli RA, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0482-9; Guan SH, 2017, EXP CELL RES, V359, P226, DOI 10.1016/j.yexcr.2017.07.025; Gulino A, 2010, EXP CELL RES, V316, P900, DOI 10.1016/j.yexcr.2009.11.017; Hall BE, 2010, LAB INVEST, V90, P543, DOI 10.1038/labinvest.2010.5; Hardy K, 2016, NUCLEUS-PHILA, V7, P50, DOI 10.1080/19491034.2016.1150392; Hassane S, 2010, J PATHOL, V222, P21, DOI 10.1002/path.2734; Huang Ni, 2020, medRxiv, DOI 10.1101/2020.10.26.20219089; Ito I, 2005, AM J RESP CRIT CARE, V171, P632, DOI 10.1164/rccm.200403-417OC; Johnson K.S., 2020, GENE EXPRESSION CHRO, DOI [10.1101/2020.05.11.089110, DOI 10.1101/2020.05.11.089110]; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kamisawa T, 2006, PANCREATOLOGY, V6, P132, DOI 10.1159/000090033; Kaur H, 2012, MOL CANCER RES, V10, P293, DOI 10.1158/1541-7786.MCR-11-0457; Kim MH, 2020, J CELL MOL MED, V24, P830, DOI 10.1111/jcmm.14793; KOSKI H, 1995, ANN RHEUM DIS, V54, P744, DOI 10.1136/ard.54.9.744; Leehan Kerry M, 2018, Clin Exp Rheumatol, V36 Suppl 112, P80; Li L, 2018, ONCOL LETT, V16, P2490, DOI 10.3892/ol.2018.8903; Liu F, 2014, HISTOL HISTOPATHOL, V29, P305, DOI 10.14670/HH-29.305; Maslinska Maria, 2019, Reumatologia (Warsaw), V57, P309, DOI 10.5114/reum.2019.91276; Michael DG, 2019, J DENT RES, V98, P209, DOI 10.1177/0022034518806518; MILANI S, 1991, AM J PATHOL, V139, P1221; Milite C, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0268-4; O'Connor KS, 2014, GENES IMMUN, V15, P88, DOI 10.1038/gene.2013.66; Pedroza M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218971; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; Plones T, 2016, J PERS MED, V6, DOI 10.3390/jpm6010003; Porcheri C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090976; Potts SJ, 2009, DRUG DISCOV TODAY, V14, P935, DOI 10.1016/j.drudis.2009.06.013; Rastaldi MP, 2002, KIDNEY INT, V62, P137, DOI 10.1046/j.1523-1755.2002.00430.x; Romualdi C, 2009, OMICS, V13, P173, DOI 10.1089/omi.2009.0003; Shiboski CH, 2017, ANN RHEUM DIS, V76, P9, DOI [10.1136/annrheumdis-2016-210571, 10.1002/art.39859]; Srivastava SP, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/125469; Strutz F, 2001, KIDNEY INT, V59, P579, DOI 10.1046/j.1523-1755.2001.059002579.x; Talbot Lindsay J, 2012, Int J Biochem Mol Biol, V3, P117; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Teman CJ, 2010, LEUKEMIA RES, V34, P871, DOI 10.1016/j.leukres.2010.01.005; Voulgarelis M, 2010, NAT REV RHEUMATOL, V6, P529, DOI 10.1038/nrrheum.2010.118; Vukmirovic M, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-016-0356-4; Wang YK, 2020, ANN RHEUM DIS, V79, P268, DOI 10.1136/annrheumdis-2019-215533; Wei J, 2011, AUTOIMMUN REV, V10, P267, DOI 10.1016/j.autrev.2010.09.015; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Yin H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59443-z; Yin HG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082852; Young A, 2007, RHEUMATOLOGY, V46, P350, DOI 10.1093/rheumatology/kel253; Yu XT, 2017, ONCOTARGET, V8, P80531, DOI 10.18632/oncotarget.20083; Zeisberg M, 2007, J BIOL CHEM, V282, P23337, DOI 10.1074/jbc.M700194200	60	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 30	2021	12								699722	10.3389/fimmu.2021.699722	http://dx.doi.org/10.3389/fimmu.2021.699722			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UI9IA	34400910	gold, Green Published			2022-12-18	WOS:000690909900001
J	Lei, B; Sleiman, MM; Cheng, Q; Tu, ZX; Zhu, P; Goddard, M; Martins, PN; Langerude, L; Nadig, S; Tomlinson, S; Atkinson, C				Lei, Biao; Sleiman, M. Mahdi; Cheng, Qi; Tu, Zhenxiao; Zhu, Peng; Goddard, Martin; Martins, Paulo N.; Langerude, Logan; Nadig, Satish; Tomlinson, Stephen; Atkinson, Carl			In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries	FRONTIERS IN IMMUNOLOGY			English	Article						vascularized composite allotransplantation; graft treatment; transplantation; complement inhibition; brain death; ischemia reperfusion injury; preservation; immunogenicity	ORGAN DYSFUNCTION; RENAL-ALLOGRAFTS; COLD ISCHEMIA; T-CELLS; DONOR; REJECTION; ACTIVATION; TRANSPLANTATION; INDUCTION; TOLERANCE	Introduction: Donor brain death (BD) is an unavoidable component of vascularized composite allograft (VCA) transplantation and a key contributor to ischemia-reperfusion injury (IRI). Complement is activated and deposited within solid organ grafts as a consequence of BD and has been shown to exacerbate IRI, although the role of BD and complement in VCA and the role it plays in IRI and VCA rejection has not been studied. Methods: BD was induced in Balb/c donors, and the VCA perfused prior to graft procurement with UW solution supplemented with or without CR2-Crry, a C3 convertase complement inhibitor that binds at sites of complement activation, such as that induced on the endothelium by induction of BD. Following perfusion, donor VCAs were cold stored for 6 hours before transplantation into C57BL/6 recipients. Donor VCAs from living donors (LD) were also procured and stored. Analyses included CR2-Crry graft binding, complement activation, toxicity, injury/inflammation, graft gene expression and survival. Results: Compared to LD VCAs, BD donor VCAs had exacerbated IRI and rejected earlier. Following pretransplant in-situ perfusion of the donor graft, CR2-Crry bound within the graft and was retained post-transplantation. CR2-Crry treatment significantly reduced complement deposition, inflammation and IRI as compared to vehicle-treated BD donors. Treatment of BD donor VCAs with CR2-Crry led to an injury profile not dissimilar to that seen in recipients of LD VCAs. Conclusion: Pre-coating a VCA with CR2-Crry in a clinically relevant treatment paradigm provides localized, and therefore minimally immunosuppressive, protection from the complement-mediated effects of BD induced exacerbated IRI.	[Lei, Biao] Guangxi Med Univ, Div Hepatobiliary Surg, Affiliated Hosp 1, Nanning, Peoples R China; [Sleiman, M. Mahdi; Cheng, Qi; Tu, Zhenxiao; Zhu, Peng; Nadig, Satish; Tomlinson, Stephen; Atkinson, Carl] Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; [Cheng, Qi] Huazhong Univ Sci & Technol, Inst Organ Transplantat, Tongji Hosp, Dept Surg, Wuhan, Peoples R China; [Cheng, Qi; Tu, Zhenxiao] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Surg, Tongji Med Coll,Hepat & Vasc Surg Ctr, Wuhan, Peoples R China; [Goddard, Martin] Papworth Hosp NHS Trust, Dept Pathol, Cambridge, England; [Martins, Paulo N.] Univ Massachusetts, Transplant Div, Dept Surg, UMass Mem Med Ctr, Worcester, MA USA; [Langerude, Logan; Atkinson, Carl] Univ Florida, Div Pulm Med, Gainesville, FL 32611 USA; [Nadig, Satish; Tomlinson, Stephen; Atkinson, Carl] Med Univ South Carolina, Dept Surg, Lee Patterson Allen Transplant Immunobiol Lab, Microbiol & Immunol, Charleston, SC USA; [Tomlinson, Stephen] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA	Guangxi Medical University; Medical University of South Carolina; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Papworth Hospital; University of Massachusetts System; University of Massachusetts Worcester; State University System of Florida; University of Florida; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Tomlinson, S; Atkinson, C (corresponding author), Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.; Atkinson, C (corresponding author), Univ Florida, Div Pulm Med, Gainesville, FL 32611 USA.; Tomlinson, S; Atkinson, C (corresponding author), Med Univ South Carolina, Dept Surg, Lee Patterson Allen Transplant Immunobiol Lab, Microbiol & Immunol, Charleston, SC USA.; Tomlinson, S (corresponding author), Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.	tomlinss@musc.edu; atkinsoc@musc.edu			NIH [NIAID 1U01 AI132894-01, 1R56AI156383-01]; Department of Defense [RW81XWH-16-1-0783, W81XWH2010743]; American Heart Association [18PRE34070023]; 111 Projects [D17011]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); American Heart Association(American Heart Association); 111 Projects(Ministry of Education, China - 111 Project)	These studies were supported by grants from the NIH (NIAID 1U01 AI132894-01, 1R56AI156383-01 to CA/ST), the Department of Defense (RW81XWH-16-1-0783 to CA, W81XWH2010743 to ST), American Heart Association (18PRE34070023 to MS), and 111 Projects (D17011 to BL).	Atkinson C, 2005, J CLIN INVEST, V115, P2444, DOI 10.1172/JCI25208; Atkinson C, 2013, CIRCULATION, V127, P1290, DOI 10.1161/CIRCULATIONAHA.112.000784; Atkinson C, 2010, J IMMUNOL, V185, P7007, DOI 10.4049/jimmunol.1001504; Atkinson C, 2009, CIRC RES, V105, P1094, DOI 10.1161/CIRCRESAHA.109.194977; Borges TJ, 2016, AM J TRANSPLANT, V16, P2158, DOI 10.1111/ajt.13705; Brazio PS, 2013, AM J TRANSPLANT, V13, P2743, DOI 10.1111/ajt.12382; Caterson EJ, 2013, J CRANIOFAC SURG, V24, P51, DOI 10.1097/SCS.0b013e31827104e1; Chadha R, 2014, CURR OPIN ORGAN TRAN, V19, P566, DOI 10.1097/MOT.0000000000000136; Cheng Q, 2018, AM J TRANSPLANT, V18, P2417, DOI 10.1111/ajt.14717; Cole S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585134; Cravedi P, 2013, AM J TRANSPLANT, V13, P2530, DOI 10.1111/ajt.12405; Damman J, 2011, NEPHROL DIAL TRANSPL, V26, P2345, DOI 10.1093/ndt/gfq717; Damman J, 2011, TRANSPL IMMUNOL, V24, P233, DOI 10.1016/j.trim.2011.03.001; Damman J, 2011, AM J TRANSPLANT, V11, P660, DOI 10.1111/j.1600-6143.2011.03475.x; Datta N, 2017, AM J TRANSPLANT, V17, P2572, DOI 10.1111/ajt.14290; de Vries DK, 2011, AM J TRANSPLANT, V11, P1064, DOI 10.1111/j.1600-6143.2011.03466.x; Durigutto P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01093; Essien EOI, 2017, WORLD J SURG, V41, P2933, DOI 10.1007/s00268-017-4089-1; Ferraresso M, 2008, TRANSPLANTATION, V86, P1445, DOI 10.1097/TP.0b013e31818a68e2; Floerchinger B, 2012, TRANSPLANT REV-ORLAN, V26, P54, DOI 10.1016/j.trre.2011.10.001; Friedrich M, 2015, MUCOSAL IMMUNOL, V8, P943, DOI 10.1038/mi.2014.124; Gasser M, 2000, Ann Transplant, V5, P61; Gasser M, 2002, J AM SOC NEPHROL, V13, P1937, DOI 10.1097/01.ASN.0000019401.12257.C4; Hart A, 2019, Am J Transplant, V19 Suppl 2, P19, DOI 10.1111/ajt.15274; Hautz T, 2014, TRANSPLANTATION, V98, P713, DOI 10.1097/TP.0000000000000300; Hoeger S, 2014, NEPHROL DIAL TRANSPL, V29, P544, DOI 10.1093/ndt/gft451; Keshavjee S, 2005, J THORAC CARDIOV SUR, V129, P423, DOI 10.1016/j.jtcvs.2004.06.048; Lin CH, 2014, PLAST RECONSTR SURG, V133, p133E, DOI 10.1097/01.prs.0000437229.69811.3a; Marasco S, 2013, TRANSPL P, V45, P33, DOI 10.1016/j.transproceed.2012.08.008; Martins PNA, 2006, TRANSPL INT, V19, P351, DOI 10.1111/j.1432-2277.2006.00301.x; Michel SG, 2018, AM J TRANSPLANT, V18, P1262, DOI 10.1111/ajt.14674; Molitor M., 2016, ACTA CHIR PLAST, V58, P18; Moseley EL, 2010, J HEART LUNG TRANSPL, V29, P417, DOI 10.1016/j.healun.2009.12.018; Pratschke J, 2001, ANN SURG, V234, P732, DOI 10.1097/00000658-200112000-00004; Pratschke J, 2001, J AM SOC NEPHROL, V12, P2474, DOI 10.1681/ASN.V12112474; Pratschke J, 2000, ANN SURG, V232, P263, DOI 10.1097/00000658-200008000-00017; Pratt JR, 2003, AM J PATHOL, V163, P1457, DOI 10.1016/S0002-9440(10)63503-1; Raedler H, 2011, AM J TRANSPLANT, V11, P1397, DOI 10.1111/j.1600-6143.2011.03561.x; Rahmel Axel, 2014, Curr Transplant Rep, V1, P173; Schroppel B, 2020, AM J TRANSPLANT, V20, P564, DOI 10.1111/ajt.15580; Stegall MD, 2011, AM J TRANSPLANT, V11, P2405, DOI 10.1111/j.1600-6143.2011.03757.x; Suzuki H, 2013, J IMMUNOL, V191, P4431, DOI 10.4049/jimmunol.1202242; van der Touw W, 2013, J IMMUNOL, V190, P5921, DOI 10.4049/jimmunol.1300847; Watts RP, 2013, J TRANSPLANT, V2013, DOI 10.1155/2013/521369; Weiss S, 2007, AM J TRANSPLANT, V7, P1584, DOI 10.1111/j.1600-6143.2007.01799.x; Weissenbacher A, 2013, CURR OPIN ORGAN TRAN, V18, P640, DOI 10.1097/MOT.0000000000000019; Wu L, 2015, J EXP MED, V212, P1571, DOI 10.1084/jem.20150204; Yu ZX, 2016, AM J TRANSPLANT, V16, P2589, DOI 10.1111/ajt.13797; Zhu P, 2017, TRANSPLANTATION, V101, pE75, DOI 10.1097/TP.0000000000001625	49	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 29	2021	12								630581	10.3389/fimmu.2021.630581	http://dx.doi.org/10.3389/fimmu.2021.630581			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UA5VI	34394069	gold, Green Published			2022-12-18	WOS:000685229200001
J	Liu, YF; Wang, XZ; Yang, F; Zheng, YY; Ye, TH; Yang, L				Liu, Yifeng; Wang, Xiaoze; Yang, Fan; Zheng, Yanyi; Ye, Tinghong; Yang, Li			Immunomodulatory Role and Therapeutic Potential of Non-Coding RNAs Mediated by Dendritic Cells in Autoimmune and Immune Tolerance-Related Diseases	FRONTIERS IN IMMUNOLOGY			English	Review						autoimmune disease; immune tolerance; dendritic cell; non-coding RNA; ce-RNAs	SYSTEMIC-LUPUS-ERYTHEMATOSUS; REGULATORY T-CELLS; VERSUS-HOST-DISEASE; NF-KAPPA-B; CIRCULAR RNAS; MICRORNA EXPRESSION; INNATE IMMUNITY; ACTIVATION; ARTHRITIS; RESPONSES	Dendritic cells (DCs) are professional antigen-presenting cells that act as a bridge between innate immunity and adaptive immunity. After activation, DCs differentiate into subtypes with different functions, at which point they upregulate co-stimulatory molecules and produce various cytokines and chemokines. Activated DCs also process antigens for presentation to T cells and regulate the differentiation and function of T cells to modulate the immune state of the body. Non-coding RNAs, RNA transcripts that are unable to encode proteins, not only participate in the pathological mechanisms of autoimmune-related diseases but also regulate the function of immune cells in these diseases. Accumulating evidence suggests that dysregulation of non-coding RNAs contributes to DC differentiation, functions, and so on, consequently producing effects in various autoimmune diseases. In this review, we summarize the main non-coding RNAs (miRNAs, lncRNAs, circRNAs) that regulate DCs in pathological mechanisms and have tremendous potential to give rise to novel therapeutic targets and strategies for multiple autoimmune diseases and immune tolerance-related diseases.	[Liu, Yifeng; Wang, Xiaoze; Yang, Fan; Zheng, Yanyi; Ye, Tinghong; Yang, Li] Sichuan Univ, Sichuan Univ Oxford Huaxi Joint Ctr Gastrointesti, West China Hosp, Dept Gastroenterol & Hepatol, Chengdu, Peoples R China	Sichuan University	Yang, L (corresponding author), Sichuan Univ, Sichuan Univ Oxford Huaxi Joint Ctr Gastrointesti, West China Hosp, Dept Gastroenterol & Hepatol, Chengdu, Peoples R China.	yangli_hx@scu.edu.cn	liu, yi/GXE-9662-2022; Zheng, Yanyi/GYU-9344-2022		National Natural Science Foundation of China [81770568]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (No. 81770568 to LY).	Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Alevizos I, 2011, ARTHRITIS RHEUM-US, V63, P535, DOI 10.1002/art.30131; Allman D, 2006, BLOOD, V108, P4025, DOI 10.1182/blood-2006-03-007757; Audiger C, 2017, J IMMUNOL, V198, P2223, DOI 10.4049/jimmunol.1601629; Bailey SL, 2007, NAT IMMUNOL, V8, P172, DOI 10.1038/ni1430; Barrat FJ, 2019, J EXP MED, V216, P1974, DOI 10.1084/jem.20181359; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Bonasio R, 2006, NAT IMMUNOL, V7, P1092, DOI 10.1038/ni1385; Boule MW, 2004, J EXP MED, V199, P1631, DOI 10.1084/jem.20031942; Brito-Zeron P, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.47; Brown CC, 2019, CELL, V179, P846, DOI 10.1016/j.cell.2019.09.035; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Carotta S, 2010, IMMUNITY, V32, P628, DOI 10.1016/j.immuni.2010.05.005; Chen LQ, 2020, MOL IMMUNOL, V117, P73, DOI 10.1016/j.molimm.2019.10.027; Chen Q, 2020, MOL THER, V28, P2503, DOI 10.1016/j.ymthe.2020.07.001; Chen S, 2015, BLOOD, V126, P103, DOI 10.1182/blood-2014-12-617258; Chen YG, 2017, NAT IMMUNOL, V18, P962, DOI 10.1038/ni.3771; Chyuan IT, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090963; Collin M, 2018, IMMUNOLOGY, V154, P3, DOI 10.1111/imm.12888; Cross M, 2014, ANN RHEUM DIS, V73, P1316, DOI 10.1136/annrheumdis-2013-204627; Crowson CS, 2011, ARTHRITIS RHEUM-US, V63, P633, DOI 10.1002/art.30155; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Fan XL, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2217-6; Farkas L, 2001, AM J PATHOL, V159, P237, DOI 10.1016/S0002-9440(10)61689-6; Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136; Funes SC, 2019, IMMUNOLOGY, V158, P322, DOI 10.1111/imm.13119; Furie R, 2019, J CLIN INVEST, V129, P1359, DOI 10.1172/JCI124466; Gao S, 2017, MOL IMMUNOL, V81, P127, DOI 10.1016/j.molimm.2016.12.006; Gill MA, 2002, HUM IMMUNOL, V63, P1172, DOI 10.1016/S0198-8859(02)00756-5; Gottenberg JE, 2006, P NATL ACAD SCI USA, V103, P2770, DOI 10.1073/pnas.0510837103; Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Hillen MR, 2019, RHEUMATOLOGY, V58, P2305, DOI 10.1093/rheumatology/kez195; Hong YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069926; Hoye ML, 2018, IMMUNOLOGY, V155, P112, DOI 10.1111/imm.12934; Ifergan I, 2016, J IMMUNOL, V196, P1455, DOI 10.4049/jimmunol.1501965; Jaen O, 2009, IMMUNOLOGY, V126, P35, DOI 10.1111/j.1365-2567.2008.02875.x; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jin O, 2008, LUPUS, V17, P654, DOI 10.1177/0961203308089410; Jongbloed SL, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1864; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Junker A, 2009, BRAIN, V132, P3342, DOI 10.1093/brain/awp300; Kanneganti TD, 2007, IMMUNITY, V27, P549, DOI 10.1016/j.immuni.2007.10.002; Ke Y, 2009, J IMMUNOL, V182, P3183, DOI 10.4049/jimmunol.0802487; Kim SS, 2019, MOL CELLS, V42, P379, DOI 10.14348/molcells.2019.0077; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; King IL, 2009, BLOOD, V113, P3190, DOI 10.1182/blood-2008-07-168575; Kioon MDA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam8458; Kiripolsky J, 2017, CLIN IMMUNOL, V182, P4, DOI 10.1016/j.clim.2017.04.003; Kuipers H, 2010, J IMMUNOL, V185, P400, DOI 10.4049/jimmunol.0903912; Kurowska-Stolarska M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15877; Li HX, 2018, CLIN CHIM ACTA, V480, P17, DOI 10.1016/j.cca.2018.01.026; Li JZ, 2014, TRANSPLANTATION, V97, P626, DOI 10.1097/TP.0000000000000061; Li LJ, 2016, EXP CELL RES, V346, P248, DOI 10.1016/j.yexcr.2016.07.021; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lopes AP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01335; Luan JJ, 2018, MOL THER-NUCL ACIDS, V10, P245, DOI 10.1016/j.omtn.2017.12.006; Mackie RI, 1999, AM J CLIN NUTR, V69, p1035S, DOI 10.1093/ajcn/69.5.1035s; Mahnke K, 2003, BLOOD, V101, P4862, DOI 10.1182/blood-2002-10-3229; Malladi AS, 2012, ARTHRIT CARE RES, V64, P911, DOI 10.1002/acr.21610; Marin E, 2019, CELL METAB, V30, P1075, DOI 10.1016/j.cmet.2019.11.011; Mascanfroni ID, 2013, NAT IMMUNOL, V14, P1054, DOI 10.1038/ni.2695; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950; Migita K, 2005, CLIN EXP IMMUNOL, V142, P84, DOI 10.1111/j.1365-2249.2005.02897.X; Molad Y, 2013, INFLAMMATION, V36, P1519, DOI 10.1007/s10753-013-9694-z; Morante-Palacios O, 2021, TRENDS IMMUNOL, V42, P59, DOI 10.1016/j.it.2020.11.001; Moret FM, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4338; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Nestle FO, 2005, J EXP MED, V202, P135, DOI 10.1084/jem.20050500; Niess JH, 2005, CURR OPIN GASTROEN, V21, P687, DOI 10.1097/01.mog.0000181710.96904.58; Niu LM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz2059; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ohnmacht C, 2009, J EXP MED, V206, P549, DOI 10.1084/jem.20082394; Onodera K, 2016, BLOOD, V128, P508, DOI 10.1182/blood-2016-02-698118; Page G, 2004, J PATHOL, V204, P28, DOI 10.1002/path.1607; Pan F, 2017, SCAND J IMMUNOL, V85, P441, DOI 10.1111/sji.12550; Peng HY, 2012, J BIOL CHEM, V287, P28017, DOI 10.1074/jbc.M112.383380; Power CA, 1997, J EXP MED, V186, P825, DOI 10.1084/jem.186.6.825; Puhr S, 2015, SEMIN IMMUNOL, V27, P388, DOI 10.1016/j.smim.2016.03.012; Quan MY, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1438-z; Ranganathan P, 2017, J IMMUNOL, V198, P2500, DOI 10.4049/jimmunol.1601778; Rathinam C, 2005, IMMUNITY, V22, P717, DOI 10.1016/j.immuni.2005.04.007; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Rossato M, 2017, ARTHRITIS RHEUMATOL, V69, P1891, DOI 10.1002/art.40163; Sacre SM, 2008, J IMMUNOL, V181, P8002, DOI 10.4049/jimmunol.181.11.8002; Salvi V, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98204; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Segura E, 2013, TRENDS IMMUNOL, V34, P440, DOI 10.1016/j.it.2013.06.001; Sichien D, 2017, MUCOSAL IMMUNOL, V10, P831, DOI 10.1038/mi.2017.8; Sigova AA, 2013, P NATL ACAD SCI USA, V110, P2876, DOI 10.1073/pnas.1221904110; Soni C, 2020, IMMUNITY, V52, P1022, DOI 10.1016/j.immuni.2020.04.015; Sozzani S, 2010, TRENDS IMMUNOL, V31, P270, DOI 10.1016/j.it.2010.05.004; Spurlock CF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7932; STEINMAN RM, 1979, J EXP MED, V149, P1, DOI 10.1084/jem.149.1.1; Stickel N, 2017, LEUKEMIA, V31, P2732, DOI 10.1038/leu.2017.137; Szperl A, 2011, INFLAMM BOWEL DIS, V17, pE38, DOI 10.1002/ibd.21670; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Takenaka MC, 2017, SEMIN IMMUNOPATHOL, V39, P113, DOI 10.1007/s00281-016-0587-8; Travis MA, 2007, NATURE, V449, P361, DOI 10.1038/nature06110; Tsokos GC, 2016, NAT REV RHEUMATOL, V12, P716, DOI 10.1038/nrrheum.2016.186; UNANUE ER, 1970, J EXP MED, V131, P711, DOI 10.1084/jem.131.4.711; van den Hoogen LL, 2018, RHEUMATOLOGY, V57, P1669, DOI 10.1093/rheumatology/key159; Vogelsang P, 2010, ANN RHEUM DIS, V69, P1235, DOI 10.1136/ard.2009.118158; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Wang YL, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1640-x; Wang YL, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1158-z; Wang-Renault SF, 2018, ANN RHEUM DIS, V77, P133, DOI 10.1136/annrheumdis-2017-211417; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Worbs T, 2017, NAT REV IMMUNOL, V17, P30, DOI 10.1038/nri.2016.116; Wu J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01847; Wu W, 2015, GUT, V64, P1755, DOI 10.1136/gutjnl-2014-307980; Xu ZH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00009; Xue XC, 2011, J IMMUNOL, V187, P5879, DOI 10.4049/jimmunol.1100535; Yan S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081282; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337; Zhang CZ, 2018, CLIN SCI, V132, P2285, DOI 10.1042/CS20180403; Zhang MM, 2019, THERANOSTICS, V9, P3425, DOI 10.7150/thno.33178; Zhang YX, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02407; Zhao JD, 2016, MOD RHEUMATOL, V26, P716, DOI 10.3109/14397595.2015.1129694	121	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 29	2021	12								678918	10.3389/fimmu.2021.678918	http://dx.doi.org/10.3389/fimmu.2021.678918			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UA6IP	34394079	Green Published, gold			2022-12-18	WOS:000685264000001
J	Sandgaard, KS; Margetts, B; Attenborough, T; Gkouleli, T; Adams, S; Holm, M; Gibb, D; Gibbons, D; Giaquinto, C; De Rossi, A; Bamford, A; Palma, P; Chain, B; Gkazi, AS; Klein, N				Sandgaard, Katrine Schou; Margetts, Ben; Attenborough, Teresa; Gkouleli, Triantafylia; Adams, Stuart; Holm, Mette; Gibb, Diana; Gibbons, Deena; Giaquinto, Carlo; De Rossi, Anita; Bamford, Alasdair; Palma, Paolo; Chain, Benny; Gkazi, Athina S.; Klein, Nigel			Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1; T cells; thymic output; antiretroviral treatment interruption; T cell receptor; immune repertoires; T cell receptor clonal expansions; high throughout sequencing	ANTIRETROVIRAL THERAPY; THYMIC OUTPUT; CELLS; CLONOTYPES; AGE	It is intriguing that, unlike adults with HIV-1, children with HIV-1 reach a greater CD4(+) T cell recovery following planned treatment cessation. The reasons for the better outcomes in children remain unknown but may be related to increased thymic output and diversity of T cell receptor repertoires. HIV-1 infected children from the PENTA 11 trial tolerated planned treatment interruption without adverse long-term clinical, virological, or immunological consequences, once antiretroviral therapy was re-introduced. This contrasts to treatment interruption trials of HIV-1 infected adults, who had rapid changes in T cells and slow recovery when antiretroviral therapy was restarted. How children can develop such effective immune responses to planned treatment interruption may be critical for future studies. PENTA 11 was a randomized, phase II trial of planned treatment interruptions in HIV-1-infected children (ISRCTN 36694210). In this sub-study, eight patients in long-term follow-up were chosen with CD4(+) count>500/ml, viral load <50c/ml at baseline: four patients on treatment interruption and four on continuous treatment. Together with measurements of thymic output, we used high-throughput next generation sequencing and bioinformatics to systematically organize memory CD8(+) and naive CD4(+) T cell receptors according to diversity, clonal expansions, sequence sharing, antigen specificity, and T cell receptor similarities following treatment interruption compared to continuous treatment. We observed an increase in thymic output following treatment interruption compared to continuous treatment. This was accompanied by an increase in T cell receptor clonal expansions, increased T cell receptor sharing, and higher sequence similarities between patients, suggesting a more focused T cell receptor repertoire. The low numbers of patients included is a limitation and the data should be interpreted with caution. Nonetheless, the high levels of thymic output and the high diversity of the T cell receptor repertoire in children may be sufficient to reconstitute the T cell immune repertoire and reverse the impact of interruption of antiretroviral therapy. Importantly, the effective T cell receptor repertoires following treatment interruption may inform novel therapeutic strategies in children infected with HIV-1.	[Sandgaard, Katrine Schou; Attenborough, Teresa; Gkouleli, Triantafylia; Adams, Stuart; Bamford, Alasdair; Klein, Nigel] UCL, Great Ormond St Inst Child Hlth, London, England; [Sandgaard, Katrine Schou; Holm, Mette] Aarhus Univ Hosp, Dept Pediat & Adolescent Med, Aarhus, Denmark; [Margetts, Ben; Adams, Stuart; Bamford, Alasdair] Great Ormond St Hosp Sick Children, Mol Haematol, London, England; [Attenborough, Teresa] UCL Ctr Computat, Math & Phys Life Sci & Expt Biol CoMPLEX, London, England; [Gibb, Diana] Med Res Council Clin Trials Unit, London, England; [Gibbons, Deena] Kings Coll London, Peter Gorer Dept Immunobiol, London, England; [Giaquinto, Carlo] Univ Padua, Dept Mother & Child Hlth, Padua, Italy; [De Rossi, Anita] Univ Padua, Dept Surg Oncol & Gastroenterol, Sect Oncol & Immunol, Padua, Italy; [De Rossi, Anita] Veneto Inst Oncol IOV IRCCS, Immunol & Mol Oncol Unit, Padua, Italy; [Palma, Paolo] Children Hosp Bambino Gesu IRCCS, Acad Dept Pediat, Clin & Res Unit Clin Immunol & Vaccinol, Rome, Italy; [Chain, Benny] UCL, Div Infect & Immun, London, England; [Gkazi, Athina S.] UCL, Zayed Ctr Res Rare Dis Children, London, England	University of London; University College London; Aarhus University; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Medical Research Council Clinical Trials Unit; University of London; King's College London; University of Padua; University of Padua; IRCCS Istituto Oncologico Veneto (IOV); IRCCS Bambino Gesu; University of London; University College London; University of London; University College London	Sandgaard, KS (corresponding author), UCL, Great Ormond St Inst Child Hlth, London, England.; Sandgaard, KS (corresponding author), Aarhus Univ Hosp, Dept Pediat & Adolescent Med, Aarhus, Denmark.	katrineschousandgaard@clin.au.dk	Palma, Paolo/AAK-9275-2020; Palma, Paolo/K-3379-2016	Palma, Paolo/0000-0002-3066-4719; Klein, Nigel/0000-0003-3925-9258; Gibb, Diana/0000-0002-9738-5490; GIAQUINTO, CARLO/0000-0001-9365-0413; Gibbons, Deena/0000-0002-7953-3576; Schou Sandgaard, Katrine/0000-0001-5468-7870	Reuben Centre for Virology and Metagenomics; Health Research Foundation of Central Denmark Region; Lundbeck Foundation, Denmark; Action Medical Research; PENTA Foundation; ViiV; UK Medical Research Council, United Kingdom; Aarhus University Research Foundation	Reuben Centre for Virology and Metagenomics; Health Research Foundation of Central Denmark Region; Lundbeck Foundation, Denmark(Lundbeckfonden); Action Medical Research; PENTA Foundation; ViiV; UK Medical Research Council, United Kingdom; Aarhus University Research Foundation	This work was supported by Reuben Centre for Virology and Metagenomics, Action Medical Research, PENTA Foundation, ViiV, UK Medical Research Council, United Kingdom, the Health Research Foundation of Central Denmark Region, Aarhus University Research Foundation, and the Lundbeck Foundation, Denmark. The funding source had no involvement in the study design, data collection, analysis, interpretation or drafting the paper. The corresponding author confirms that she had full access to all the data in the study and had final responsibility for the decision to submit for publication.	Adams SP, 2018, CLIN EXP IMMUNOL, V191, P198, DOI 10.1111/cei.13062; Bains I, 2009, J IMMUNOL, V183, P4329, DOI 10.4049/jimmunol.0900743; Bains I, 2009, BLOOD, V113, P5480, DOI 10.1182/blood-2008-10-184184; Bunupuradah T, 2013, AIDS, V27, P579, DOI 10.1097/QAD.0b013e32835c1181; Castro H, 2010, AIDS, V24, P231, DOI 10.1097/QAD.0b013e328333d343; Chen HB, 2012, NAT IMMUNOL, V13, P691, DOI 10.1038/ni.2342; Das A, 2017, J IMMUNOL, V199, P1696, DOI 10.4049/jimmunol.1700551; Dash P, 2017, NATURE, V547, P89, DOI 10.1038/nature22383; Douek DC, 2001, J IMMUNOL, V167, P6663, DOI 10.4049/jimmunol.167.11.6663; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Freguja R, 2021, HIV MED, V22, P172, DOI 10.1111/hiv.12986; Gantner P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17898-8; Gattinoni L, 2017, NAT MED, V23, P18, DOI 10.1038/nm.4241; Gibbons D, 2014, NAT MED, V20, P1206, DOI 10.1038/nm.3670; Gkazi AS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02547; Glanville J, 2017, NATURE, V547, P94, DOI 10.1038/nature22976; Goronzy JJ, 2005, CURR OPIN IMMUNOL, V17, P468, DOI 10.1016/j.coi.2005.07.020; Heather JM, 2018, BRIEF BIOINFORM, V19, P554, DOI 10.1093/bib/bbw138; Huenecke S, 2008, EUR J HAEMATOL, V80, P532, DOI 10.1111/j.1600-0609.2008.01052.x; Iglesias MC, 2011, BLOOD, V118, P2138, DOI 10.1182/blood-2011-01-328781; Joshi K, 2019, NAT MED, V25, P1549, DOI 10.1038/s41591-019-0592-2; Klein N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076582; Koch S, 2008, IMMUN AGEING, V5, DOI [10.1186/1742-4933-5-6, 10.1186/1742-4933-5-11]; LINDERKAMP O, 1977, EUR J PEDIATR, V125, P227, DOI 10.1007/BF00493567; Naylor K, 2005, J IMMUNOL, V174, P7446, DOI 10.4049/jimmunol.174.11.7446; Oakes T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01267; Picat MQ, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001542; Russell JN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073849; Sandgaard KS, 2014, AIDS, V28, P209, DOI 10.1097/QAD.0000000000000063; Steffens CM, 2001, AIDS, V15, P1757, DOI 10.1097/00002030-200109280-00003; Thomas N, 2013, BIOINFORMATICS, V29, P542, DOI 10.1093/bioinformatics/btt004; Turkova A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196239; Uddin I, 2019, METHODS MOL BIOL, V1884, P15, DOI 10.1007/978-1-4939-8885-3_2	33	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 29	2021	12								643189	10.3389/fimmu.2021.643189	http://dx.doi.org/10.3389/fimmu.2021.643189			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UJ6ZA	34475868	Green Published, gold			2022-12-18	WOS:000691430500001
J	Scaglione, A; Opp, S; Hurtado, A; Lin, ZY; Pampeno, C; Noval, MG; Thannickal, SA; Stapleford, KA; Meruelo, D				Scaglione, Antonella; Opp, Silvana; Hurtado, Alicia; Lin, Ziyan; Pampeno, Christine; Noval, Maria G.; Thannickal, Sara A.; Stapleford, Kenneth A.; Meruelo, Daniel			Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and alpha OX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						Sindbis virus vaccine; alpha OX40; synergistic combination SARS-CoV-2 vaccine strategy; SARS-CoV-2 immunity; alphavirus vaccine; COVID19; SARS-CoV-2 vaccine	RESPIRATORY SYNCYTIAL VIRUS; SINDBIS VIRAL VECTORS; TUMOR MICROENVIRONMENT; REPLICON PARTICLES; RNA REPLICONS; GUINEA-PIGS; OX40; RESPONSES; MOLECULE; MICE	The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 is a major global public threat. Currently, a worldwide effort has been mounted to generate billions of effective SARS-CoV-2 vaccine doses to immunize the world's population at record speeds. However, there is still a demand for alternative effective vaccines that rapidly confer long-term protection and rely upon cost-effective, easily scaled-up manufacturing. Here, we present a Sindbis alphavirus vector (SV), transiently expressing the SARS-CoV-2 spike protein (SV.Spike), combined with the OX40 immunostimulatory antibody (alpha OX40) as a novel, highly effective vaccine approach. We show that SV.Spike plus alpha OX40 elicits long-lasting neutralizing antibodies and a vigorous T-cell response in mice. Protein binding, immunohistochemical, and cellular infection assays all show that vaccinated mice sera inhibits spike functions. Immunophenotyping, RNA Seq transcriptome profiles, and metabolic analysis indicate a reprogramming of T cells in vaccinated mice. Activated T cells were found to mobilize to lung tissue. Most importantly, SV.Spike plus alpha OX40 provided robust immune protection against infection with authentic coronavirus in transgenic mice expressing the human ACE2 receptor (hACE2-Tg). Finally, our immunization strategy induced strong effector memory response, potentiating protective immunity against re-exposure to SARS-CoV-2 spike protein. Our results show the potential of a new Sindbis virus-based vaccine platform to counteract waning immune response, which can be used as a new candidate to combat SARS-CoV-2. Given the T-cell responses elicited, our vaccine is likely to be effective against variants that are proving challenging, as well as serve as a platform to develop a broader spectrum pancoronavirus vaccine. Similarly, the vaccine approach is likely to be applicable to other pathogens.	[Scaglione, Antonella; Opp, Silvana; Hurtado, Alicia; Lin, Ziyan; Pampeno, Christine; Meruelo, Daniel] NYU, Dept Pathol, Grossman Sch Med, New York, NY 10016 USA; [Noval, Maria G.; Thannickal, Sara A.; Stapleford, Kenneth A.] NYU, Dept Microbiol, Grossman Sch Med, New York, NY 10016 USA	New York University; New York University	Meruelo, D (corresponding author), NYU, Dept Pathol, Grossman Sch Med, New York, NY 10016 USA.	Daniel.meruelo@nyulangone.org	Noval, Maria Gabriela/GLV-0239-2022	Thannickal, Sara/0000-0002-7028-3507	NIH [5R44CA206606]; NYU Grossman School of Medicine Institutional COVID-19 research fund	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NYU Grossman School of Medicine Institutional COVID-19 research fund	Funding was provided by NIH 5R44CA206606 and by an NYU Grossman School of Medicine Institutional COVID-19 research fund. We would like to thank the NYU High Throughput Biology Laboratory for Seahorse usage, the NYU Genome Technology Center for RNA sequencing service, and Dr. Shohei Koide for his contribution in reading the manuscript and providing helpful suggestions. Additionally, we would like to thank the NYU Gross Pathology Lab for the guidance and expertise. Preprint of this manuscript is available on the bioRxiv repository (96).	Addetia Amin, 2020, medRxiv, DOI 10.1101/2020.08.13.20173161; Andersson C, 2000, FEMS IMMUNOL MED MIC, V29, P247, DOI 10.1111/j.1574-695X.2000.tb01530.x; [Anonymous], 2021, LANCET INFECT DIS, V21, P149, DOI 10.1016/S1473-3099(21)00008-6; Avogadri F, 2014, CANCER IMMUNOL RES, V2, P448, DOI 10.1158/2326-6066.CIR-13-0220; Bansal-Pakala P, 2004, J IMMUNOL, V172, P4821, DOI 10.4049/jimmunol.172.8.4821; Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y; Bell P, 2005, HISTOCHEM CELL BIOL, V124, P77, DOI 10.1007/s00418-005-0793-2; Bernstein DI, 2009, VACCINE, V28, P484, DOI 10.1016/j.vaccine.2009.09.135; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993; CALDERHEAD DM, 1993, J IMMUNOL, V151, P5261; Cardeno A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20740-3; Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Croft M, 2010, ANNU REV IMMUNOL, V28, P57, DOI 10.1146/annurev-immunol-030409-101243; Davis NL, 2002, IUBMB LIFE, V53, P209, DOI 10.1080/15216540212657; Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Erasmus JH, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc9396; Erdman MM, 2010, VACCINE, V28, P594, DOI 10.1016/j.vaccine.2009.10.015; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Fleeton MN, 2001, J INFECT DIS, V183, P1395, DOI 10.1086/319857; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Gramaglia I, 1998, J IMMUNOL, V161, P6510; Granot T, 2014, MOL THER, V22, P112, DOI 10.1038/mt.2013.215; Granot T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020598; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Hashimoto K, 2019, P NATL ACAD SCI USA, V116, P24242, DOI 10.1073/pnas.1907883116; Henning L, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.598847; Hevey M, 1998, VIROLOGY, V251, P28, DOI 10.1006/viro.1998.9367; Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036; Hooper JW, 2009, VACCINE, V28, P494, DOI 10.1016/j.vaccine.2009.09.133; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jones N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01516; Khalil SM, 2014, J VIROL, V88, P9182, DOI 10.1128/JVI.00327-14; Langereis M.A, 2021, ALPHAVIRUS REPLICON, DOI [10.1101/2021.04.01.436305, DOI 10.1101/2021.04.01.436305]; Li SZ, 2017, CELL, V169, P862, DOI 10.1016/j.cell.2017.04.026; Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214; Lindgren G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01539; Linterman Michelle A, 2016, F1000Res, V5, DOI 10.12688/f1000research.7388.1; Ljungberg K, 2015, EXPERT REV VACCINES, V14, P177, DOI 10.1586/14760584.2015.965690; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4067; Lundstrom K, 2014, VIRUSES-BASEL, V6, P2392, DOI 10.3390/v6062392; Lundstrom Kenneth, 2003, Expert Rev Vaccines, V2, P447; McElhaney JE, 2009, VACCINE, V27, P2418, DOI 10.1016/j.vaccine.2009.01.136; McElhaney JE, 2006, J IMMUNOL, V176, P6333, DOI 10.4049/jimmunol.176.10.6333; Menk AV, 2018, CELL REP, V22, P1509, DOI 10.1016/j.celrep.2018.01.040; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Moore AC, 2007, EXPERT REV VACCINES, V6, P111, DOI 10.1586/14760584.6.1.111; Moore JP, 2021, JAMA-J AM MED ASSOC, V325, P821, DOI 10.1001/jama.2021.1114; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mousavi SF, 2008, J IMMUNOL, V181, P5990, DOI 10.4049/jimmunol.181.9.5990; Otani N, 2016, CELL IMMUNOL, V310, P165, DOI 10.1016/j.cellimm.2016.09.005; Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9; Pastorino B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118963; PATERSON DJ, 1987, MOL IMMUNOL, V24, P1281, DOI 10.1016/0161-5890(87)90122-2; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Pushko P, 2000, VACCINE, V19, P142, DOI 10.1016/S0264-410X(00)00113-4; Reed DS, 2014, J VIROL, V88, P12077, DOI 10.1128/JVI.01406-14; Rice Charles M., 1992, Current Opinion in Biotechnology, V3, P523, DOI 10.1016/0958-1669(92)90081-S; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Roques P, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.83527; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Scaglione A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04863-9; Scharping NE, 2016, IMMUNITY, V45, P374, DOI [10.1016/j.immuni.2016.07.009, 10.1016/j.immuni.2016.08.009]; Scherwitzl I, 2020, MOL THER-ONCOLYTICS, V17, P431, DOI 10.1016/j.omto.2020.04.012; Scherwitzl I, 2018, MOL THER-ONCOLYTICS, V9, P51, DOI 10.1016/j.omto.2018.04.004; Schmidt F, 2020, J EXP MED, V217, DOI 10.1084/jem.20201181; Segundo FDS, 2013, J VIROL, V87, P5447, DOI 10.1128/JVI.03462-12; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Skibinski DAG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36703-7; Song AH, 2005, J IMMUNOL, V175, P3534, DOI 10.4049/jimmunol.175.6.3534; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Szurgot I, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82498-5; Tahiliani V, 2017, J IMMUNOL, V198, P218, DOI 10.4049/jimmunol.1601356; Thompson RN, 2021, LANCET INFECT DIS, V21, P913, DOI 10.1016/S1473-3099(21)00202-4; Tseng JC, 2002, JNCI-J NATL CANCER I, V94, P1790; Tseng JC, 2004, CANCER RES, V64, P6684, DOI 10.1158/0008-5472.CAN-04-1924; van de Wall S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1487913; van der Windt GJW, 2012, IMMUNITY, V36, P68, DOI 10.1016/j.immuni.2011.12.007; van Doremalen N., 2020, NATURE, V586, P578, DOI [10.1038/s41586-020-2608-y, DOI 10.1038/s41586-020-2608-y]; Wang PF, 2021, NATURE, V593, P130, DOI 10.1038/s41586-021-03398-2; Wang Q, 2016, MOL CELL ENDOCRINOL, V430, P115, DOI 10.1016/j.mce.2016.04.008; Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n359; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Wressnigg N, 2020, LANCET INFECT DIS, V20, P1193, DOI 10.1016/S1473-3099(20)30238-3; Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x; Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580; Yu MJ, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0664-3; Zander RA, 2017, CELL REP, V21, P1839, DOI 10.1016/j.celrep.2017.10.077; Zander RA, 2015, CELL HOST MICROBE, V17, P628, DOI 10.1016/j.chom.2015.03.007; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	96	1	1	1	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 29	2021	12								719077	10.3389/fimmu.2021.719077	http://dx.doi.org/10.3389/fimmu.2021.719077			26	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UL9DK	34394127	Green Published, gold, Green Submitted			2022-12-18	WOS:000692943200001
J	Tatomir, A; Beltrand, A; Nguyen, V; Courneya, JP; Boodhoo, D; Cudrici, C; Muresanu, DF; Rus, V; Badea, TC; Rus, H				Tatomir, Alexandru; Beltrand, Austin; Nguyen, Vinh; Courneya, Jean-Paul; Boodhoo, Dallas; Cudrici, Cornelia; Muresanu, Dafin F.; Rus, Violeta; Badea, Tudor C.; Rus, Horea			RGC-32 Acts as a Hub to Regulate the Transcriptomic Changes Associated With Astrocyte Development and Reactive Astrocytosis	FRONTIERS IN IMMUNOLOGY			English	Article						RGC-32; astrocyte; radial glia; experimental autoimmune encephalomyelitis; RNA sequencing; TGF-beta; CD133; HOPX	CELL-DIFFERENTIATION; SCAR FORMATION; UP-REGULATION; RADIAL GLIA; GENE; EXPRESSION; STANNIOCALCIN-1; PROLIFERATION; BINDING; INJURY	Response Gene to Complement 32 (RGC-32) is an important mediator of the TGF-beta signaling pathway, and an increasing amount of evidence implicates this protein in regulating astrocyte biology. We showed recently that spinal cord astrocytes in mice lacking RGC-32 display an immature phenotype reminiscent of progenitors and radial glia, with an overall elongated morphology, increased proliferative capacity, and increased expression of progenitor markers when compared to their wild-type (WT) counterparts that make them incapable of undergoing reactive changes during the acute phase of experimental autoimmune encephalomyelitis (EAE). Here, in order to decipher the molecular networks underlying RGC-32's ability to regulate astrocytic maturation and reactivity, we performed next-generation sequencing of RNA from WT and RGC-32 knockout (KO) neonatal mouse brain astrocytes, either unstimulated or stimulated with the pleiotropic cytokine TGF-beta. Pathway enrichment analysis showed that RGC-32 is critical for the TGF-beta-induced up-regulation of transcripts encoding proteins involved in brain development and tissue remodeling, such as axonal guidance molecules, transcription factors, extracellular matrix (ECM)-related proteins, and proteoglycans. Our next-generation sequencing of RNA analysis also demonstrated that a lack of RGC-32 results in a significant induction of WD repeat and FYVE domain-containing protein 1 (Wdfy1) and stanniocalcin-1 (Stc1). Immunohistochemical analysis of spinal cords isolated from normal adult mice and mice with EAE at the peak of disease showed that RGC-32 is necessary for the in vivo expression of ephrin receptor type A7 in reactive astrocytes, and that the lack of RGC-32 results in a higher number of homeodomain-only protein homeobox (HOPX)(+) and CD133(+) radial glia cells. Collectively, these findings suggest that RGC-32 plays a major role in modulating the transcriptomic changes in astrocytes that ultimately lead to molecular programs involved in astrocytic differentiation and reactive changes during neuroinflammation.	[Tatomir, Alexandru; Beltrand, Austin; Boodhoo, Dallas; Rus, Horea] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; [Tatomir, Alexandru; Muresanu, Dafin F.] Iuliu Hatieganu Univ Med & Pharm, Dept Neurosci, Cluj Napoca, Romania; [Nguyen, Vinh; Rus, Violeta] Univ Maryland, Sch Med, Dept Med, Div Rheumatol & Clin Immunol, Baltimore, MD 21201 USA; [Courneya, Jean-Paul] Univ Maryland, Hlth Sci & Human Serv Lib, Baltimore, MD 21201 USA; [Cudrici, Cornelia] NHLBI, Translat Vasc Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA; [Badea, Tudor C.] NEI, Retinal Circuit Dev & Genet Unit, N NRL, Bethesda, MD 20892 USA; [Badea, Tudor C.] Transylvania Univ Brasov, Fac Med, Res & Dev Inst, Brasov, Romania; [Rus, Horea] Vet Adm Maryland Hlth Care Syst, Res Serv, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Iuliu Hatieganu University of Medicine & Pharmacy; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Transylvania University of Brasov	Rus, H (corresponding author), Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA.; Rus, H (corresponding author), Vet Adm Maryland Hlth Care Syst, Res Serv, Baltimore, MD 21201 USA.	hrus@umaryland.edu	Badea, Tudor Constantin/B-1654-2018	Badea, Tudor Constantin/0000-0003-3086-6713	Veterans Administration Merit Award [I01BX001458]; Foundation of the Consortium of Multiple Sclerosis Centers' MS Workforce of the Future; Proposed Research Initiated by Students and Mentors (PRISM) program, University of Maryland School of Medicine Office of Student Research, Baltimore, USA;  [RO1 NS42011]	Veterans Administration Merit Award; Foundation of the Consortium of Multiple Sclerosis Centers' MS Workforce of the Future; Proposed Research Initiated by Students and Mentors (PRISM) program, University of Maryland School of Medicine Office of Student Research, Baltimore, USA; 	This work was supported in part by a grant from Veterans Administration Merit Award (I01BX001458 to HR) and by an RO1 NS42011 grant (to HR). Austin Beltrand was supported in part by a medical student research grant from the Foundation of the Consortium of Multiple Sclerosis Centers' MS Workforce of the Future and by the Proposed Research Initiated by Students and Mentors (PRISM) program, University of Maryland School of Medicine Office of Student Research, Baltimore, USA.	Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Benner EJ, 2013, NATURE, V497, P369, DOI 10.1038/nature12069; Brambilla R, 2019, ACTA NEUROPATHOL, V137, P757, DOI 10.1007/s00401-019-01980-7; Cornwell M, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2139-9; Correale J, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00180; Cregg JM, 2014, EXP NEUROL, V253, P197, DOI 10.1016/j.expneurol.2013.12.024; Cudrici C, 2008, J NEUROIMMUNOL, V203, P94, DOI 10.1016/j.jneuroim.2008.06.040; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Escartin C, 2021, NAT NEUROSCI, V24, P312, DOI 10.1038/s41593-020-00783-4; Escartin C, 2019, GLIA, V67, P2221, DOI 10.1002/glia.23687; Figueroa JD, 2006, J NEUROSCI RES, V84, P1438, DOI 10.1002/jnr.21048; Fosbrink M, 2009, EXP MOL PATHOL, V86, P87, DOI 10.1016/j.yexmp.2008.12.005; Giovannoni F, 2020, TRENDS IMMUNOL, V41, P805, DOI 10.1016/j.it.2020.07.007; Gnanaguru G, 2013, DEVELOPMENT, V140, P2050, DOI 10.1242/dev.087817; Gorris R, 2015, GLIA, V63, P2152, DOI 10.1002/glia.22882; Haindl MT, 2019, GLIA, V67, P467, DOI 10.1002/glia.23556; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hu YH, 2015, EMBO REP, V16, P447, DOI 10.15252/embr.201439637; Kikkawa T, 2013, GENES CELLS, V18, P636, DOI 10.1111/gtc.12061; Lee WS, 2019, EXP NEUROBIOL, V28, P311, DOI 10.5607/en.2019.28.3.311; Li Y, 2018, CANCER LETT, V416, P66, DOI 10.1016/j.canlet.2017.11.033; Liao H, 2008, J BIOL CHEM, V283, P27927, DOI 10.1074/jbc.M804764200; Liddelow SA, 2017, IMMUNITY, V46, P957, DOI 10.1016/j.immuni.2017.06.006; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ludwig K, 2017, J NEURO-ONCOL, V134, P505, DOI 10.1007/s11060-017-2379-y; Luo WJ, 2020, ONCOL LETT, V20, P2248, DOI 10.3892/ol.2020.11792; Mariotto A, 2016, J INVEST DERMATOL, V136, P905, DOI 10.1016/j.jid.2016.01.032; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Nataf S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102097; Okawa S, 2016, STEM CELL REP, V7, P307, DOI 10.1016/j.stemcr.2016.07.014; Ouyang L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75264-6; Penisson M, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00381; Petit A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024538; Pollen AA, 2015, CELL, V163, P55, DOI 10.1016/j.cell.2015.09.004; Ponath G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00217; Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369; Renault-Mihara F, 2017, J CELL BIOL, V216, P2533, DOI 10.1083/jcb.201610102; Rozbesky D, 2020, CURR OPIN STRUC BIOL, V61, P79, DOI 10.1016/j.sbi.2019.11.007; Rus V, 2017, J IMMUNOL, V198, P3869, DOI 10.4049/jimmunol.1602158; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Sobel RA, 2005, BRAIN PATHOL, V15, P35; Sofroniew MV, 2020, TRENDS IMMUNOL, V41, P758, DOI 10.1016/j.it.2020.07.004; Su JY, 2015, TUMOR BIOL, V36, P6333, DOI 10.1007/s13277-015-3319-0; Sun Y, 2020, THERANOSTICS, V10, P8430, DOI 10.7150/thno.44370; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Tatomir A, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.608294; Tatomir A, 2018, IMMUNOL RES, V66, P445, DOI 10.1007/s12026-018-9011-x; Tegla CA, 2015, EXP MOL PATHOL, V98, P328, DOI 10.1016/j.yexmp.2015.03.011; Tegla CA, 2013, EXP MOL PATHOL, V94, P17, DOI 10.1016/j.yexmp.2012.09.005; Tiwari N, 2018, CELL STEM CELL, V23, P557, DOI 10.1016/j.stem.2018.09.008; Tsai HL, 2014, TISSUE ENG PT A, V20, P1908, DOI [10.1089/ten.tea.2013.0188, 10.1089/ten.TEA.2013.0188]; Vaid S, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.169276; Vlaicu SI, 2016, EXP MOL PATHOL, V101, P221, DOI 10.1016/j.yexmp.2016.09.004; Wheeler MA, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a029009; Willson CA, 2002, CELL TRANSPLANT, V11, P229; Xiong Y, 2019, MOL MED REP, V20, P3055, DOI 10.3892/mmr.2019.10579; Yanagisawa M, 2000, J NEUROCHEM, V74, P1498, DOI 10.1046/j.1471-4159.2000.0741498.x; Yeo IJ, 2019, MOL NEUROBIOL, V56, P3132, DOI 10.1007/s12035-018-1287-2; Yi WJ, 2019, BRAIN BEHAV IMMUN, V80, P10, DOI 10.1016/j.bbi.2019.05.029; Zhang MY, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-85; Zhao FY, 2020, J CELL MOL MED, V24, P7686, DOI 10.1111/jcmm.15348; Zweifel S, 2018, STEM CELL REP, V11, P770, DOI 10.1016/j.stemcr.2018.08.006	63	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 29	2021	12								705308	10.3389/fimmu.2021.705308	http://dx.doi.org/10.3389/fimmu.2021.705308			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	UJ5HW	34394104	Green Published, gold			2022-12-18	WOS:000691317000001
J	Ye, XL; Zhao, Y; Li, R; Li, T; Zheng, X; Xiong, W; Zeng, JF; Xu, M; Chen, LM				Ye, Xianlin; Zhao, Yu; Li, Ran; Li, Tong; Zheng, Xin; Xiong, Wen; Zeng, Jinfeng; Xu, Min; Chen, Limin			High Frequency Occult Hepatitis B Virus Infection Detected in Non-Resolved Donations Suggests the Requirement of Anti-HBc Test in Blood Donors in Southern China	FRONTIERS IN IMMUNOLOGY			English	Article						blood safety; occult hepatitis B infection; nucleic acid testing; anti-HBc; minipool	NUCLEIC-ACID; TRANSMISSION RISK; C-VIRUS; TRANSFUSION; COMPONENTS; SAFETY; YIELD; MODEL	Background Most Chinese Blood Centers adopted mini pool (MP) nucleic acid testing (NAT) for HBV screening due to high cost of Individual donation (ID) NAT, and different proportions of MP-reactive but ID-non-reactive donations (MP+/ID-, defined as non-resolved donations) have been observed during daily donor screening process. Some of these non-resolved donations are occult HBV infections (OBIs), which pose potential risk of HBV transmission if they are not deferred. This study is aimed to further analyze these non-resolved donations. Methods The non-resolved plasma samples were further analyzed by serological tests and various HBV DNA amplification assays including quantitative PCR (qPCR) and nested PCR amplifying the basic core and pre-core promoter regions (BCP/PC; 295 base pairs) and HBsAg (S) region (496 base pairs). Molecular characterizations of HBV DNA+ non-resolved samples were determined by sequencing analysis. Results Of 17,226 MPs from 103,356 seronegative blood donations, 98 MPs were detected reactive for HBV. Fifty-six out of these 98 (57.1%) reactive MPs were resolved as HBV DNA+, but the remaining 42 pools (42.9%, 252 donations) were left non-resolved with a high rate (53.2%) of anti-HBc+. Surprisingly, among 42 non-resolved MPs, 17 contained one donation identified as OBIs by alternative NAT assays. Sequence analysis on HBV DNAs extracted from these OBI donations showed some key mutations in the S region that may lead to failure in HBsAg detection and vaccine escape. Conclusion A total of 53.2% of the non-resolved donations were anti-HBc+, and OBIs were identified in 40.5% of these non-resolved pools. Therefore, non-resolved donations with anti-HBc+ might pose potential risk for HBV transmission. Our present analysis indicates that anti-HBc testing in non-resolved donations should be used to identify OBIs in order to further increase blood safety in China.	[Ye, Xianlin; Zhao, Yu; Li, Ran; Li, Tong; Zheng, Xin; Xiong, Wen; Zeng, Jinfeng] Shenzhen Blood Ctr, Dept Lab, Shenzhen, Peoples R China; [Xu, Min; Chen, Limin] Chinese Acad Med Sci CAMS & Peking Union Med Coll, Prov Key Lab Transfus Transmitted Infect Dis, Inst Blood Transfus, Chengdu, Peoples R China; [Chen, Limin] Chinese Acad Med Sci, Joint Lab Transfus Transmitted Dis TTD Inst Blood, Nanning Blood Ctr, Nanning, Peoples R China; [Chen, Limin] Nanning Blood Ctr, Nanning, Peoples R China; [Chen, Limin] Univ Toronto, Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON, Canada	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Blood Transfusion - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Chen, LM (corresponding author), Chinese Acad Med Sci CAMS & Peking Union Med Coll, Prov Key Lab Transfus Transmitted Infect Dis, Inst Blood Transfus, Chengdu, Peoples R China.; Chen, LM (corresponding author), Chinese Acad Med Sci, Joint Lab Transfus Transmitted Dis TTD Inst Blood, Nanning Blood Ctr, Nanning, Peoples R China.; Chen, LM (corresponding author), Nanning Blood Ctr, Nanning, Peoples R China.; Chen, LM (corresponding author), Univ Toronto, Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON, Canada.	limin_chen_99@126.com			Nature and Science Fund of Shenzhen and Guangdong [JCYJ20190806112201646, 2021A515010979]; Shenzhen Key Medical Discipline Construction Fund [SZXK070]; CAMS Initiative for Innovative Medicine [CAMS-2016-I2M-3-025, CAMS-2017-I2M-BR-15]; National Key Research and Development Program [2018YFE0107500]; Science and Technology Partnership Program, Ministry of Science and Technology of China [KY201904011]	Nature and Science Fund of Shenzhen and Guangdong; Shenzhen Key Medical Discipline Construction Fund; CAMS Initiative for Innovative Medicine; National Key Research and Development Program; Science and Technology Partnership Program, Ministry of Science and Technology of China	This work was supported by the Nature and Science Fund of Shenzhen and Guangdong (JCYJ20190806112201646 and 2021A515010979) and Shenzhen Key Medical Discipline Construction Fund (SZXK070) to XY and CAMS Initiative for Innovative Medicine (CAMS-2016-I2M-3-025 and CAMS-2017-I2M-B&R-15), National Key Research and Development Program (2018YFE0107500), Science and Technology Partnership Program, Ministry of Science and Technology of China (KY201904011) to LC.	Akcam FZ, 2005, TRANSFUSION MED, V15, P61, DOI 10.1111/j.1365-3148.2005.00551.x; Allain JP, 2007, VOX SANG, V92, P254, DOI 10.1111/j.1423-0410.2006.00874.x; Allain JP, 2013, TRANSFUSION, V53, P1405, DOI 10.1111/trf.12096; Allain JP, 2011, CURR OPIN HEMATOL, V18, P461, DOI 10.1097/MOH.0b013e32834bac10; Busch MP, 2004, TRANSFUS CLIN BIOL, V11, P26, DOI 10.1016/j.tracli.2003.12.003; Candotti D, 2017, TRANSFUS CLIN BIOL, V24, P189, DOI 10.1016/j.tracli.2017.06.014; Candotti D, 2008, J HEPATOL, V49, P537, DOI 10.1016/j.jhep.2008.04.017; Candotti D, 2019, GUT, V68, P313, DOI 10.1136/gutjnl-2018-316490; Candotti D, 2012, GUT, V61, P1744, DOI 10.1136/gutjnl-2011-301281; Candotti D, 2009, J HEPATOL, V51, P798, DOI 10.1016/j.jhep.2009.05.020; Castells L, 1999, TRANSPLANT P, V31, P2464, DOI 10.1016/S0041-1345(99)00419-4; [寸伟 Cun Wei], 2014, [中国输血杂志, Chinese Journal of Blood Transfusion], V27, P166; Dodd RY, 2018, TRANSFUSION, V58, P2166, DOI 10.1111/trf.14784; Enjalbert F, 2014, TRANSFUSION, V54, P2485, DOI 10.1111/trf.12653; Fopa D, 2019, BLOOD TRANSFUS-ITALY, V17, P403, DOI 10.2450/2019.0182-19; Hass M, 2005, HEPATOLOGY, V42, P93, DOI 10.1002/hep.20748; Hollinger FB, 2008, TRANSFUSION, V48, P1001, DOI 10.1111/j.1537-2995.2008.01701.x; Hoshi Y, 2019, TRANSFUSION, V59, P2602, DOI 10.1111/trf.15393; Hourfar MK, 2009, INT J LAB HEMATOL, V31, P649, DOI 10.1111/j.1751-553X.2008.01092.x; Huang CH, 2012, J HEPATOL, V57, P720, DOI 10.1016/j.jhep.2012.05.009; Jarvis L, 2008, TRANSFUSION, V48, P1853, DOI 10.1111/j.1537-2995.2008.01779.x; Jiao FP, 2019, J VIRAL HEPATITIS, V26, P710, DOI 10.1111/jvh.13070; Kleinman SH, 2009, TRANSFUSION, V49, P2454, DOI 10.1111/j.1537-2995.2009.02322.x; Laperche S, 2003, TRANSFUSION, V43, P1428, DOI 10.1046/j.1537-2995.2003.00541.x; Levicnik-Stezinar S, 2008, J HEPATOL, V48, P1022, DOI 10.1016/j.jhep.2008.02.016; Margaritis AR, 2007, TRANSFUSION, V47, P1783, DOI 10.1111/j.1537-2995.2007.01343.x; Matanhire TB, 2021, VOX SANG, V116, P564, DOI 10.1111/vox.13045; Matsumoto C, 2001, TRANSFUSION, V41, P878, DOI 10.1046/j.1537-2995.2001.41070878.x; Nubling CM, 2009, TRANSFUSION, V49, P1850, DOI 10.1111/j.1537-2995.2009.02212.x; Ohhashi Y, 2010, J VIROL METHODS, V165, P246, DOI 10.1016/j.jviromet.2010.02.004; Oluyinka OO, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131912; Pollicino T, 2004, GASTROENTEROLOGY, V126, P102, DOI 10.1053/j.gastro.2003.10.048; Raimondo G, 2008, J HEPATOL, V49, P652, DOI 10.1016/j.jhep.2008.07.014; Reddy R., 2014, VOX SANG S1, V107, P146; Roth WK, 2012, VOX SANG, V102, P82, DOI 10.1111/j.1423-0410.2011.01506.x; Seed CR, 2015, VOX SANG, V108, P113, DOI 10.1111/vox.12198; Spreafico M, 2015, J HEPATOL, V63, P1068, DOI 10.1016/j.jhep.2015.06.016; Stramer SL, 2011, NEW ENGL J MED, V364, P236, DOI 10.1056/NEJMoa1007644; Taira R, 2013, TRANSFUSION, V53, P1393, DOI 10.1111/j.1537-2995.2012.03909.x; Urbani S, 2010, CLIN CHEM LAB MED, V48, P23, DOI 10.1515/CCLM.2010.002; Wang LN, 2015, TRANSFUSION, V55, P395, DOI 10.1111/trf.12818; Weusten J, 2017, TRANSFUSION, V57, P841, DOI 10.1111/trf.14050; Weusten J, 2011, TRANSFUSION, V51, P203, DOI 10.1111/j.1537-2995.2010.02804.x; Ye XL, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4215-9; Ye XL, 2013, TRANSFUS APHER SCI, V49, P318, DOI 10.1016/j.transci.2013.08.005; Yu DM, 2014, J HEPATOL, V60, P515, DOI 10.1016/j.jhep.2013.11.004; Yuen MF, 2010, GUT, V59, P1389, DOI 10.1136/gut.2010.209148; Zheng X, 2011, J CLIN MICROBIOL, V49, P1730, DOI 10.1128/JCM.00145-11	48	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 28	2021	12								699217	10.3389/fimmu.2021.699217	http://dx.doi.org/10.3389/fimmu.2021.699217			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TY5WW	34394093	gold, Green Published			2022-12-18	WOS:000683855500001
J	Manjunath, P; Ahmad, J; Samal, J; Sheikh, JA; Arora, SK; Khubaib, M; Aggarwal, H; Kumari, I; Luthra, K; Rahman, SA; Hasnain, SE; Ehtesham, NZ				Manjunath, P.; Ahmad, Javeed; Samal, Jasmine; Sheikh, Javaid Ahmad; Arora, Simran Kaur; Khubaib, Mohd; Aggarwal, Heena; Kumari, Indu; Luthra, Kalpana; Rahman, Syed Asad; Hasnain, Seyed E.; Ehtesham, Nasreen Z.			Mycobacterium tuberculosis Specific Protein Rv1509 Evokes Efficient Innate and Adaptive Immune Response Indicative of Protective Th1 Immune Signature	FRONTIERS IN IMMUNOLOGY			English	Article						B cells; dendritic cells; effector memory; human TB patients; pathogenesis; T cells	T-CELL IMMUNITY; PREDICTION; DISCOVERY; BCG	Dissecting the function(s) of proteins present exclusively in Mycobacterium tuberculosis (M.tb) will provide important clues regarding the role of these proteins in mycobacterial pathogenesis. Using extensive computational approaches, we shortlisted ORFs/proteins unique to M.tb among 13 different species of mycobacteria and identified a hypothetical protein Rv1509 as a 'signature protein' of M.tb. This unique protein was found to be present only in M.tb and absent in all other mycobacterial species, including BCG. In silico analysis identified numerous putative T cell and B cell epitopes in Rv1509. Initial in vitro experiments using innate immune cells demonstrated Rv1509 to be immunogenic with potential to modulate innate immune responses. Macrophages treated with Rv1509 exhibited higher activation status along with substantial release of pro-inflammatory cytokines. Besides, Rv1509 protein boosts dendritic cell maturation by increasing the expression of activation markers such as CD80, HLA-DR and decreasing DC-SIGN expression and this interaction was mediated by innate immune receptor TLR2. Further, in vivo experiments in mice demonstrated that Rv1509 protein promotes the expansion of multifunctional CD4+ and CD8+T cells and induces effector memory response along with evoking a canonical Th1 type of immune response. Rv1509 also induces substantial B cell response as revealed by increased IgG reactivity in sera of immunized animals. This allowed us to demonstrate the diagnostic efficacy of this protein in sera of human TB patients compared to the healthy controls. Taken together, our results reveal that Rv1509 signature protein has immunomodulatory functions evoking immunological memory response with possible implications in serodiagnosis and TB vaccine development.	[Manjunath, P.; Ahmad, Javeed; Samal, Jasmine; Arora, Simran Kaur; Khubaib, Mohd; Kumari, Indu; Ehtesham, Nasreen Z.] Natl Inst Pathol, Inflammat Biol & Cell Signaling Lab, New Delhi, India; [Manjunath, P.; Sheikh, Javaid Ahmad; Arora, Simran Kaur; Khubaib, Mohd] Jamie Hamdard, Dept Biotechnol, New Delhi, India; [Ahmad, Javeed] All India Inst Med Sci, Dept Biophys, New Delhi, India; [Aggarwal, Heena; Luthra, Kalpana] All India Inst Med Sci, Dept Biochem, New Delhi, India; [Rahman, Syed Asad] BioInceptionPvt Ltd, Chelmsford, Essex, England; [Hasnain, Seyed E.] Indian Inst Technol, Dept Biochem Engn & Biotechnol, New Delhi, India; [Hasnain, Seyed E.] Sharda Univ, Sch Basic Sci & Res, Dept Life Sci, Greater Noida, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Pathology (IOP); Jamia Hamdard University; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Delhi; Sharda University	Ehtesham, NZ (corresponding author), Natl Inst Pathol, Inflammat Biol & Cell Signaling Lab, New Delhi, India.; Hasnain, SE (corresponding author), Indian Inst Technol, Dept Biochem Engn & Biotechnol, New Delhi, India.; Hasnain, SE (corresponding author), Sharda Univ, Sch Basic Sci & Res, Dept Life Sci, Greater Noida, India.	seyedhasnain@gmail.com; nzehtesham@gmail.com	Kumari, Indu/ABG-1305-2020	Kumari, Indu/0000-0003-4236-231X; Aggarwal, Heena/0000-0002-4535-3497; Sheikh, Javaid/0000-0002-9628-3169	DST	DST(Department of Science & Technology (India))	SH is a JC Bose National Fellow of the Department of Science and Technology (MoS&T, GoI) and Robert Koch Fellow of the Robert Koch Institute, Berlin, Germany. We thank DST for the PURSE Grant. MP is a DST-inspire Senior Research Fellow. JS is ICMR-Postdoctoral Fellow. The following reagents were obtained through BEI resources, NIAID, NIH: Macrophage cell lines derived from; TLR2/TLR4 double knockout mice, NR-19975, TLR4 knockout mice, NR-9458.	Ahmad J, 2020, FEBS OPEN BIO, V10, P70, DOI 10.1002/2211-5463.12749; Ahmad J, 2018, MBIO, V9, DOI 10.1128/mBio.01712-17; Ali S, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.622487; [Anonymous], 2020, GLOBAL TUBERCULOSIS; Arora SK, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01199; Bansal K, 2010, J IMMUNOL, V184, P3495, DOI 10.4049/jimmunol.0903299; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Blundell TL, 2020, PROG BIOPHYS MOL BIO, V156, P34, DOI 10.1016/j.pbiomolbio.2020.06.004; Chakaya J, 2021, INT J INFECT DIS, V113, pS7, DOI 10.1016/j.ijid.2021.02.107; Chakaya JM, 2020, LANCET RESP MED, V8, P334, DOI 10.1016/S2213-2600(20)30104-1; Chatterjee N, 2018, INT J BIOL MACROMOL, V118, P180, DOI 10.1016/j.ijbiomac.2018.06.080; Ciabattini A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00427; Coppola M, 2018, SEMIN IMMUNOL, V39, P88, DOI 10.1016/j.smim.2018.07.001; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; Dockrell HM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01134; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Webb Benjamin, 2016, Curr Protoc Bioinformatics, V54, DOI [10.1002/0471140864.ps0209s50, 10.1002/cpps.20, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3]; Fomenko DE, 2008, MOL CELLS, V26, P228; Grover S, 2018, MBIO, V9, DOI 10.1128/mBio.01017-18; Gupta MN, 2020, BIOCHIMIE, V175, P50, DOI 10.1016/j.biochi.2020.05.004; Hu ZD, 2017, MOL THER, V25, P1222, DOI 10.1016/j.ymthe.2017.02.018; Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2; Khader SA, 2019, J CLIN INVEST, V129, P3482, DOI 10.1172/JCI128877; Khubaib M, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00719; Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438; Knudsen NPH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19570; Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u; Lewinsohn DA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01262; Loxton AG, 2019, MOL IMMUNOL, V111, P145, DOI 10.1016/j.molimm.2019.04.012; Maglione PJ, 2009, EUR J IMMUNOL, V39, P676, DOI 10.1002/eji.200839148; Marino S, 2004, J IMMUNOL, V173, P494, DOI 10.4049/jimmunol.173.1.494; Moliva Juan I, 2017, Front Immunol, V8, P407, DOI 10.3389/fimmu.2017.00407; Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403; Pandey S, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00038; Parkash O, 2009, SCAND J IMMUNOL, V70, P345, DOI 10.1111/j.1365-3083.2009.02312.x; Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514; Pradhan D, 2017, INTERDISCIP SCI, V9, P468, DOI 10.1007/s12539-017-0238-3; Prezzemolo T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00180; Rahman SA, 2014, MBIO, V5, DOI 10.1128/mBio.02020-14; Rzepa HS, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-6; Shariq M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.636644; Sharma T, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00451; Sheikh JA, 2020, LANCET INFECT DIS, V20, P272, DOI 10.1016/S1473-3099(19)30702-9; Sigal LJ, 1999, NATURE, V398, P77, DOI 10.1038/18038; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; Tenzer S, 2005, CELL MOL LIFE SCI, V62, P1025, DOI 10.1007/s00018-005-4528-2; Tiwari B, 2014, FEBS J, V281, P1556, DOI 10.1111/febs.12723; Tundup S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003586; van Crevel R, 2002, CLIN MICROBIOL REV, V15, P294, DOI 10.1128/CMR.15.2.294-309.2002; Wang P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000048; Wolf AJ, 2007, J IMMUNOL, V179, P2509, DOI 10.4049/jimmunol.179.4.2509; Zeng GC, 2018, CELL MOL IMMUNOL, V15, P206, DOI 10.1038/cmi.2017.113	52	1	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 27	2021	12								706081	10.3389/fimmu.2021.706081	http://dx.doi.org/10.3389/fimmu.2021.706081			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TY0CS	34386011	gold, Green Published			2022-12-18	WOS:000683452400001
J	Sutherland, TE; Shaw, TN; Lennon, R; Herrick, SE; Ruckerl, D				Sutherland, Tara E.; Shaw, Tovah N.; Lennon, Rachel; Herrick, Sarah E.; Rueckerl, Dominik			Ongoing Exposure to Peritoneal Dialysis Fluid Alters Resident Peritoneal Macrophage Phenotype and Activation Propensity	FRONTIERS IN IMMUNOLOGY			English	Article						peritoneal dialysis; fibrosis; macrophage; inflammation; tissue resident; glucose degradation product	TISSUE MACROPHAGES; APOPTOTIC CELLS; FIBROSIS; EXPRESSION; INFLAMMATION; POLARIZATION; CLEARANCE; MONOCYTES; TRANSPORT; MEMBRANE	Peritoneal dialysis (PD) is a more continuous alternative to haemodialysis, for patients with chronic kidney disease, with considerable initial benefits for survival, patient independence and healthcare costs. However, long-term PD is associated with significant pathology, negating the positive effects over haemodialysis. Importantly, peritonitis and activation of macrophages is closely associated with disease progression and treatment failure. However, recent advances in macrophage biology suggest opposite functions for macrophages of different cellular origins. While monocyte-derived macrophages promote disease progression in some models of fibrosis, tissue resident macrophages have rather been associated with protective roles. Thus, we aimed to identify the relative contribution of tissue resident macrophages to PD induced inflammation in mice. Unexpectedly, we found an incremental loss of homeostatic characteristics, anti-inflammatory and efferocytic functionality in peritoneal resident macrophages, accompanied by enhanced inflammatory responses to external stimuli. Moreover, presence of glucose degradation products within the dialysis fluid led to markedly enhanced inflammation and almost complete disappearance of tissue resident cells. Thus, alterations in tissue resident macrophages may render long-term PD patients sensitive to developing peritonitis and consequently fibrosis/sclerosis.	[Sutherland, Tara E.; Shaw, Tovah N.; Herrick, Sarah E.; Rueckerl, Dominik] Univ Manchester, Fac Biol Med & Hlth, Div Infect Immun & Resp Med, Lydia Becker Inst Immunol & Inflammat, Manchester, Lancs, England; [Sutherland, Tara E.; Shaw, Tovah N.] Univ Manchester, Manchester Collaborat Ctr Inflammat Res MCCIR, Manchester, Lancs, England; [Sutherland, Tara E.; Lennon, Rachel] Univ Manchester, Wellcome Ctr Cell Matrix Res, Manchester, Lancs, England; [Shaw, Tovah N.] Univ Edinburgh, Sch Biol Sci, Inst Immunol & Infect Res, Edinburgh, Midlothian, Scotland; [Lennon, Rachel; Herrick, Sarah E.] Univ Manchester, Fac Biol Med & Hlth, Sch Biol Sci, Div Cell Matrix Biol & Regenerat Med, Manchester, Lancs, England	University of Manchester; University of Manchester; University of Manchester; University of Edinburgh; University of Manchester	Ruckerl, D (corresponding author), Univ Manchester, Fac Biol Med & Hlth, Div Infect Immun & Resp Med, Lydia Becker Inst Immunol & Inflammat, Manchester, Lancs, England.	Dominik.Ruckerl@manchester.ac.uk		Lennon, Rachel/0000-0001-6400-0227; Shaw, Tovah/0000-0002-8107-2836; Ruckerl, Dominik/0000-0002-0206-1451; Sutherland, Tara/0000-0001-9334-8206	Medical Research Council UK [MR/P02615X/1]; Medical Research Foundation/Asthma UK [MRFAUK-2015-302]; BBSRC [BB/S01103X/1]; Wellcome Trust [202860/Z/16/Z]; MRC [MRC MR/S02560X/1]; University of Manchester Immunology Gene Expression Panel Grant (NanoString Technologies Inc., Seattle, WA); MRC [MR/S02560X/1, MR/P02615X/1] Funding Source: UKRI	Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Foundation/Asthma UK; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University of Manchester Immunology Gene Expression Panel Grant (NanoString Technologies Inc., Seattle, WA); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Medical Research Council UK (MR/P02615X/1, DR) and the Medical Research Foundation/Asthma UK (MRFAUK-2015-302, TES). TNS was supported by a BBSRC Discovery Research Fellowship (BB/S01103X/1, TNS), RL was supported by a Wellcome Trust Senior Fellowship award (202860/Z/16/Z, RL) and SH and DR were supported by an MRC Research Grant (MRC MR/S02560X/1, SH). The nCounter transcript analysis was supported by a University of Manchester Immunology Gene Expression Panel Grant (NanoString Technologies Inc., Seattle, WA).	Accarias S, 2016, INNATE IMMUN-LONDON, V22, P382, DOI 10.1177/1753425916651330; Adhyatmika A, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00081; Allen JE, 2017, IMMUNITY, V47, P810, DOI 10.1016/j.immuni.2017.10.010; Bacchetta J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116530; Bain CC, 2018, CELL IMMUNOL, V330, P126, DOI 10.1016/j.cellimm.2018.01.003; Bain CC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11852; BARTH MW, 1995, J LEUKOCYTE BIOL, V57, P361, DOI 10.1002/jlb.57.3.361; Bartosova M, 2019, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01853; Bazargani F, 2006, PERITON DIALYSIS INT, V26, P688; Bellon T, 2011, NEPHROL DIAL TRANSPL, V26, P2995, DOI 10.1093/ndt/gfq771; Bieber S, 2020, KIDNEY MED, V2, P692, DOI 10.1016/j.xkme.2020.06.014; Blake PG, 2018, KIDNEY INT, V94, P246, DOI 10.1016/j.kint.2018.04.014; Boulanger E, 2007, KIDNEY INT, V71, P126, DOI 10.1038/sj.ki.5002016; Braga TT, 2018, INFLAMMOPHARMACOLOGY, V26, P403, DOI 10.1007/s10787-017-0317-4; Calvente CJ, 2019, J CLIN INVEST, V129, P4091, DOI 10.1172/JCI122258; Campbell SM, 2018, ELIFE, V7, DOI 10.7554/eLife.30947; Chandrasekaran P, 2019, J IMMUNOL, V203, P2130, DOI 10.4049/jimmunol.1900270; Chen YT, 2020, J PATHOL, V250, P55, DOI 10.1002/path.5350; Chui BK, 2013, AM J KIDNEY DIS, V61, P104, DOI 10.1053/j.ajkd.2012.07.010; Danford CJ, 2018, WORLD J GASTROENTERO, V24, P3101, DOI 10.3748/wjg.v24.i28.3101; Davies LC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2877; Davies LC, 2011, EUR J IMMUNOL, V41, P2155, DOI 10.1002/eji.201141817; Ferenbach DA, 2012, KIDNEY INT, V82, P928, DOI 10.1038/ki.2012.207; Francois K, 2014, INT J NEPHROL RENOV, V7, P447, DOI 10.2147/IJNRD.S50527; Gautier EL, 2013, BLOOD, V122, P2714, DOI 10.1182/blood-2013-01-478206; Gordon S, 2017, BMC BIOL, V15, DOI 10.1186/s12915-017-0392-4; Guillot A, 2019, HEPATOL COMMUN, V3, P730, DOI 10.1002/hep4.1356; Gundra UM, 2014, BLOOD, V123, pE110, DOI 10.1182/blood-2013-08-520619; Han YJ, 2013, AM J PHYSIOL-RENAL, V304, pF1043, DOI 10.1152/ajprenal.00389.2012; Hasko G, 2011, J IMMUNOL, V187, P4256, DOI 10.4049/jimmunol.1003379; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Horckmans M, 2017, EUR HEART J, V38, P187, DOI 10.1093/eurheartj/ehw002; Jakubzick CV, 2017, NAT REV IMMUNOL, V17, P349, DOI 10.1038/nri.2017.28; Johnson DW, 2010, KIDNEY INT, V77, P904, DOI 10.1038/ki.2010.16; JONJIC N, 1992, J EXP MED, V176, P1165, DOI 10.1084/jem.176.4.1165; Khalil N, 1996, AM J RESP CELL MOL, V15, P252, DOI 10.1165/ajrcmb.15.2.8703482; Kitamura M, 2012, CHEM-BIOL INTERACT, V195, P95, DOI 10.1016/j.cbi.2011.11.002; Kitterer D, 2017, KIDNEY BLOOD PRESS R, V42, P276, DOI 10.1159/000477449; Kramer A, 2019, CLIN KIDNEY J, V12, P702, DOI 10.1093/ckj/sfz011; Krishnan Murali, 2005, International Urology and Nephrology, V37, P409, DOI 10.1007/s11255-004-1392-1; Lambie MR, 2016, NEPHROL DIAL TRANSPL, V31, P480, DOI 10.1093/ndt/gfv440; Lee SH, 2012, LAB INVEST, V92, P1698, DOI 10.1038/labinvest.2012.132; Li JL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01327-4; Li Q, 2018, MOL IMMUNOL, V94, P131, DOI 10.1016/j.molimm.2017.12.023; Liao CT, 2017, KIDNEY INT, V91, P1088, DOI 10.1016/j.kint.2016.10.030; Lopez-Castejon G, 2011, CELL MOL LIFE SCI, V68, P3095, DOI 10.1007/s00018-010-0609-y; Luyckx VA, 2018, B WORLD HEALTH ORGAN, V96, P414, DOI 10.2471/BLT.17.206441; Menzies FM, 2010, CLIN EXP IMMUNOL, V160, P369, DOI 10.1111/j.1365-2249.2009.04086.x; Miksa M, 2009, J IMMUNOL METHODS, V342, P71, DOI 10.1016/j.jim.2008.11.019; Minutti CM, 2017, SCIENCE, V356, P1076, DOI 10.1126/science.aaj2067; Misharin AV, 2017, J EXP MED, V214, P2387, DOI 10.1084/jem.20162152; Miyanishi M, 2007, NATURE, V450, P435, DOI 10.1038/nature06307; Miyanishi M, 2012, INT IMMUNOL, V24, P551, DOI 10.1093/intimm/dxs064; Moinuddin Z, 2015, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00470; Morelle J, 2015, J AM SOC NEPHROL, V26, P2521, DOI 10.1681/ASN.2014090939; Moriishi Misaki, 2002, Adv Perit Dial, V18, P149; Mortier S, 2005, KIDNEY INT, V67, P1559, DOI 10.1111/j.1523-1755.2005.00237.x; Nikolic-Paterson DJ, 2014, KIDNEY INT SUPPL, V4, P34, DOI 10.1038/kisup.2014.7; Okabe Y, 2014, CELL, V157, P832, DOI 10.1016/j.cell.2014.04.016; Perciani CT, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaz0749; Pesce JT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000371; Puranik AS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31887-4; Reddy AT, 2014, FASEB J, V28, P5299, DOI 10.1096/fj.14-256263; Ribatti D, 2013, IMMUNOL LETT, V152, P83, DOI 10.1016/j.imlet.2013.05.003; Roederer M, 2001, CYTOMETRY, V45, P194, DOI 10.1002/1097-0320(20011101)45:3<194::AID-CYTO1163>3.0.CO;2-C; Rosas M, 2014, SCIENCE, V344, P645, DOI 10.1126/science.1251414; Ruckerl D, 2019, EUR J IMMUNOL, V49, P996, DOI 10.1002/eji.201948158; Ruckerl D, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006233; Schaefer B, 2018, KIDNEY INT, V94, P419, DOI 10.1016/j.kint.2018.02.022; Sica A, 2015, CELL MOL LIFE SCI, V72, P4111, DOI 10.1007/s00018-015-1995-y; Sommerfeld SD, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aax4783; Song L, 2016, ENDOCRINOLOGY, V157, P4066, DOI 10.1210/en.2016-1474; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Sutherland TE, 2021, ONGOING EXPOSURE PER, DOI [10.1101/2020.03.02.973404, DOI 10.1101/2020.03.02.973404]; Uderhardt S, 2012, IMMUNITY, V36, P834, DOI 10.1016/j.immuni.2012.03.010; de Luijtgaarden MWM, 2016, NEPHROL DIAL TRANSPL, V31, P120, DOI 10.1093/ndt/gfv295; Wang J, 2013, INT J MOL SCI, V14, P10369, DOI 10.3390/ijms140510369; Wang J, 2016, CELL, V165, P668, DOI 10.1016/j.cell.2016.03.009; Wang Y, 2007, KIDNEY INT, V72, P290, DOI 10.1038/sj.ki.5002275; Wieslander A, 1996, ADV PERIT D, V12, P57; Williams JD, 2002, J AM SOC NEPHROL, V13, P470, DOI 10.1681/ASN.V132470; Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001; Yuan XM, 2017, ELIFE, V6, DOI 10.7554/eLife.29540; Yurdagul A, 2020, CELL METAB, V31, P518, DOI 10.1016/j.cmet.2020.01.001; Zeng YS, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/4634736; Zhang N, 2019, J EXP MED, V216, P1291, DOI 10.1084/jem.20182024; Zhang SY, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000648; Zhao Y, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26461	90	1	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 27	2021	12								715209	10.3389/fimmu.2021.715209	http://dx.doi.org/10.3389/fimmu.2021.715209			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TX7WA	34386014	Green Published, Green Submitted, gold			2022-12-18	WOS:000683297800001
J	Yamaguchi, T; Katano, I; Otsuka, I; Ito, R; Mochizuki, M; Goto, M; Takahashi, T				Yamaguchi, Takuya; Katano, Ikumi; Otsuka, Iyo; Ito, Ryoji; Mochizuki, Misa; Goto, Motohito; Takahashi, Takeshi			Generation of Novel Human Red Blood Cell-Bearing Humanized Mouse Models Based on C3-Deficient NOG Mice	FRONTIERS IN IMMUNOLOGY			English	Article						humanized mouse; red blood cell; complements; NOG; macrophage; gadolinium chloride	GADOLINIUM CHLORIDE; RECONSTITUTION; ESTABLISHMENT; TRANSFUSION; CRISPR-CAS9; ENGRAFTMENT; ACTIVATION; CLEARANCE; DEPLETION	Despite recent advances in immunodeficient mouse models bearing human red blood cells (hRBCs), the elimination of circulating hRBCs by residual innate immune systems remains a significant challenge. In this study, we evaluated the role of mouse complement C3 in the elimination of circulating hRBCs by developing a novel NOG substrain harboring a truncated version of the murine C3 gene (NOG-C3(Delta MG2-3)). Genetic C3 deletion prolonged the survival of transfused hRBCs in the circulation. Chemical depletion and functional impairment of mouse macrophages, using clodronate liposomes (Clo-lip) or gadolinium chloride (GdCl3), respectively, further extended the survival of hRBCs in NOG-C3(Delta MG2-3) mice. Low GdCl3 toxicity allowed the establishment of hRBC-bearing mice, in which hRBCs survived for more than 4 weeks with transfusion once a week. In addition, erythropoiesis of human hematopoietic stem cells (hHSCs) was possible in NOG-C3(Delta MG2-3)/human GM-CSF-IL-3 transgenic mice with Clo-lip treatment. These findings indicate that mouse models harboring hRBCs can be achieved using NOG-C3(Delta MG2-3) mice, which could facilitate studies of human diseases associated with RBCs.	[Yamaguchi, Takuya; Katano, Ikumi; Otsuka, Iyo; Ito, Ryoji; Takahashi, Takeshi] Cent Inst Expt Anim CIEA, Lab Anim Res Dept, Kawasaki, Kanagawa, Japan; [Mochizuki, Misa] CIEA, Pathol Anal Ctr, Kawasaki, Kanagawa, Japan; [Goto, Motohito] CIEA, Anim Resource & Tech Res Ctr, Kawasaki, Kanagawa, Japan; [Yamaguchi, Takuya] Nihon Univ, Coll Bioresource Sci, Dept Vet Med, Lab Vet Pharmacol, Fujisawa, Kanagawa, Japan	Nihon University	Takahashi, T (corresponding author), Cent Inst Expt Anim CIEA, Lab Anim Res Dept, Kawasaki, Kanagawa, Japan.	takeshi-takahashi@ciea.or.jp			Japan Agency for Medical Research and Development [18H02368, 20K15704]	Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED))	This work was supported in part by a Grant-in-Aid for Scientific Research (B) (18H02368 to TT) and Grant-in-Aid for EarlyCareer Scientists (20K15704 to TY). This project was commissioned by a Grant-in-Aid for Research on Hepatitis from the Japan Agency for Medical Research and Development.	Angulo-Barturen I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002252; BAXTER AG, 1993, DIABETES, V42, P1574, DOI 10.2337/diabetes.42.11.1574; Belarif L, 2019, J CLIN INVEST, V129, P1910, DOI 10.1172/JCI121668; Billerbeck E, 2011, BLOOD, V117, P3076, DOI 10.1182/blood-2010-08-301507; Chen B, 2017, STEM CELL REP, V9, P1034, DOI 10.1016/j.stemcr.2017.08.018; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Danner R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019826; Goettel JA, 2016, CELL REP, V17, P1318, DOI 10.1016/j.celrep.2016.09.082; Harui A, 2011, J NEUROIMMUNE PHARM, V6, P148, DOI 10.1007/s11481-010-9223-x; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Hu Z, 2011, BLOOD, V118, P5938, DOI 10.1182/blood-2010-11-321414; Ishihara C, 1998, IMMUNOPHARMACOLOGY, V38, P223, DOI 10.1016/S0162-3109(97)00054-4; ISHIHARA C, 1994, J VET MED SCI, V56, P1149, DOI 10.1292/jvms.56.1149; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Ito R, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121580; Ito R, 2013, J IMMUNOL, V191, P2890, DOI 10.4049/jimmunol.1203543; Ito R, 2012, CELL MOL IMMUNOL, V9, P208, DOI 10.1038/cmi.2012.2; Katano I, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17442-7; Katano I, 2015, J IMMUNOL, V194, P3513, DOI 10.4049/jimmunol.1401323; Kaushansky A, 2014, CELL MICROBIOL, V16, P602, DOI 10.1111/cmi.12277; Mashiko D, 2013, SCI REP-UK, V3, DOI 10.1038/srep03355; Mathews S, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0311-y; McIntosh BE, 2015, STEM CELL REP, V4, P171, DOI 10.1016/j.stemcr.2014.12.005; Minkah NK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00807; Nishioka T, 2007, J LEUKOCYTE BIOL, V82, P327, DOI 10.1189/jlb.1006598; Perdomo-Celis F, 2020, CLIN EXP IMMUNOL, V200, P185, DOI 10.1111/cei.13416; Rahmig S, 2016, STEM CELL REP, V7, P591, DOI 10.1016/j.stemcr.2016.08.005; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rongvaux A, 2014, NAT BIOTECHNOL, V32, P364, DOI 10.1038/nbt.2858; Saito-Ito A, 2000, J CLIN MICROBIOL, V38, P4511, DOI 10.1128/JCM.38.12.4511-4516.2000; Schuster MC, 2008, MOL IMMUNOL, V45, P3142, DOI 10.1016/j.molimm.2008.03.010; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017; Song YB, 2021, SCIENCE, V371, P1019, DOI 10.1126/science.abe2485; Soulard V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8690; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; TSUJI M, 1995, VACCINE, V13, P1389, DOI 10.1016/0264-410X(95)00081-B; Vollmar B, 1996, SHOCK, V6, P434, DOI 10.1097/00024382-199612000-00008; Waldman JP, 2014, TRANSPLANTATION, V97, P385, DOI 10.1097/01.TP.0000441321.87915.82; Waldman JP, 2013, XENOTRANSPLANTATION, V20, P239, DOI 10.1111/xen.12043; WETSEL RA, 1990, J BIOL CHEM, V265, P2435; Zhu RT, 2018, MOL MED REP, V17, P6357, DOI 10.3892/mmr.2018.8646	42	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 27	2021	12								671648	10.3389/fimmu.2021.671648	http://dx.doi.org/10.3389/fimmu.2021.671648			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TX8MP	34386001	Green Published, gold			2022-12-18	WOS:000683341100001
J	Furubeppu, H; Ito, T; Kakuuchi, M; Yasuda, T; Kamikokuryo, C; Yamada, S; Maruyama, I; Kakihana, Y				Furubeppu, Hiroaki; Ito, Takashi; Kakuuchi, Midori; Yasuda, Tomotsugu; Kamikokuryo, Chinatsu; Yamada, Shingo; Maruyama, Ikuro; Kakihana, Yasuyuki			Differential Regulation of Damage-Associated Molecular Pattern Release in a Mouse Model of Skeletal Muscle Ischemia/Reperfusion Injury	FRONTIERS IN IMMUNOLOGY			English	Article						ischemia reperfusion injury; high mobility group box 1; extracellular histones; damage-associated molecular patterns; skeletal muscle	GROUP BOX 1; PROTEIN; RHABDOMYOLYSIS	Background Skeletal muscle ischemia/reperfusion (I/R) injury is an important clinical issue that can cause remote organ injury. Although its pathogenesis has not been fully elucidated, recent studies have suggested that damage-associated molecular patterns (DAMPs) are mediators of remote organ injury in sterile inflammation. The purpose of this study was to investigate the possible involvement of DAMPs, including the nuclear proteins high-mobility group box 1 (HMGB1) and histone H3, in the pathogenesis of skeletal muscle I/R injury in mice. Methods Hindlimb ischemia was induced in mice through bilateral ligation of inguinal regions using rubber grommets. Reperfusion was induced by cutting the rubber grommets after 2-12 h of ischemic period. Survival rates, localization of HMGB1 and histone H3 in the gastrocnemius muscle, and circulating HMGB1 and histone H3 levels were analyzed. The effect of anti-HMGB1 and anti-histone H3 antibodies on survival was analyzed in mice with I/R injury. Results All mice with hindlimb ischemia survived for at least 36 h, while all mice died within 24 h if the hindlimbs were reperfused after ischemia for 4-12 h. Immunohistochemical analysis revealed that HMGB1 translocated from the nucleus to the cytoplasm in the ischemic gastrocnemius muscle, while histone H3 was confined to the nucleus. Accordingly, serum HMGB1 levels were significantly elevated in mice with hindlimb I/R compared with normal mice or mice with hindlimb ischemia (P < 0.05). Serum histone H3 levels were not elevated after I/R. Treatment with anti-HMGB1 antibodies significantly improved survival of mice with hindlimb I/R injury compared with control antibodies (P < 0.05). Conclusions HMGB1, but not histone H3, translocated to the cytoplasm during skeletal muscle ischemia, and was released into the systemic circulation after reperfusion in mice with I/R injury. Treatment with anti-HMGB1 antibodies partially improved survival.	[Furubeppu, Hiroaki; Kakuuchi, Midori; Yasuda, Tomotsugu; Kamikokuryo, Chinatsu; Kakihana, Yasuyuki] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Emergency & Intens Care Med, Kagoshima, Japan; [Ito, Takashi; Maruyama, Ikuro] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Syst Biol Thromboregulat, Kagoshima, Japan; [Yamada, Shingo] Shinotest Corp, R&D Ctr, Sagamihara, Kanagawa, Japan	Kagoshima University; Kagoshima University	Ito, T (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Syst Biol Thromboregulat, Kagoshima, Japan.	takashi@m3.kufm.kagoshima-u.ac.jp			Japan Society for the Promotion of Science [17K17056]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by a research grant from the Japan Society for the Promotion of Science (17K17056).	Abrams ST, 2013, AM J RESP CRIT CARE, V187, P160, DOI 10.1164/rccm.201206-1037OC; Chavez LO, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1314-5; Chen R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.337; Cohen MJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8152; Falciola L, 1997, J CELL BIOL, V137, P19, DOI 10.1083/jcb.137.1.19; Giannoglou GD, 2007, EUR J INTERN MED, V18, P90, DOI 10.1016/j.ejim.2006.09.020; Gonzalez Dario, 2005, Crit Care Med, V33, pS34; Ito T, 2018, J INTENSIVE CARE, V6, DOI 10.1186/s40560-018-0348-y; Kang R, 2014, MOL ASPECTS MED, V40, P1, DOI 10.1016/j.mam.2014.05.001; Kang R, 2014, GASTROENTEROLOGY, V146, P1097, DOI 10.1053/j.gastro.2013.12.015; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P1389, DOI 10.1097/TA.0b013e318270d595; Lu B, 2014, EXPERT REV CLIN IMMU, V10, P713, DOI 10.1586/1744666X.2014.909730; Murai S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06985-6; Cuong NT, 2013, SHOCK, V39, P89, DOI 10.1097/SHK.0b013e31827a2412; Okubo K, 2018, NAT MED, V24, P232, DOI 10.1038/nm.4462; Sever MS, 2002, CRIT CARE MED, V30, P2443, DOI 10.1097/00003246-200211000-00007; Shimazaki J, 2012, SHOCK, V37, P634, DOI 10.1097/SHK.0b013e31824ed6b7	17	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 26	2021	12								628822	10.3389/fimmu.2021.628822	http://dx.doi.org/10.3389/fimmu.2021.628822			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TX1YP	34381442	Green Published, gold			2022-12-18	WOS:000682887400001
J	Jing, YC; Cao, M; Zhang, B; Long, XH; Wang, XM				Jing, Yuchao; Cao, Min; Zhang, Bei; Long, Xuehui; Wang, Xiaoming			cDC1 Dependent Accumulation o f Memory T Cells Is Required for Chronic Autoimmune Inflammation in Murine Testis	FRONTIERS IN IMMUNOLOGY			English	Article						testis; T cells; dendritic cell; spermatogenesis; chronic autoimmune orchitis	EXPERIMENTAL ALLERGIC ORCHITIS; CD8-ALPHA(+) DENDRITIC CELLS; TISSUE; MACROPHAGES; INFECTION; SUBSETS; REVEALS; SYSTEM; MICE	As an immune privilege site, there are various types of immune cells in the testis. Previous research has been focused on the testicular macrophages, and much less is known about the T cells in the testis. Here, we found that T cells with memory phenotypes were the most abundant leukocyte in the testis except for macrophages. Our results showed that the proportion of testicular T cells increases gradually from birth to adulthood in mice and that the primary type of T cells changed from gamma delta TCR+T cells to alpha beta TCR+T cells. In addition, under homeostatic conditions, CD8(+)T cells are the dominant subgroup and have different phenotypic characteristics from CD4(+)T cells. We found that cDC1, but not cDC2, is necessary for the presence of T cells in the testis under physiological state. A significant decrease of T cells does not have a deleterious effect on the development of the testis or spermatogenesis. However, cDC1 -dependent T cells play an indispensable role in chronic autoimmune orchitis of the testis. Collectively, our multifaceted data provide a comprehensive picture of the accumulation, localization, and function of testicular T cells.	[Jing, Yuchao; Cao, Min; Zhang, Bei; Long, Xuehui; Wang, Xiaoming] Nanjing Med Univ, State Key Lab Reprod Med, Key Lab Immune Microenvironm & Dis, Dept Immunol, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University	Wang, XM (corresponding author), Nanjing Med Univ, State Key Lab Reprod Med, Key Lab Immune Microenvironm & Dis, Dept Immunol, Nanjing, Jiangsu, Peoples R China.	xmwang@njmu.edu.cn			National Key R&D Program of China [2018YFC1003900]; Jiangsu Outstanding Young Investigator Program [BK20200030]	National Key R&D Program of China; Jiangsu Outstanding Young Investigator Program	This work was supported by the National Key R&D Program of China (2018YFC1003900) and the Jiangsu Outstanding Young Investigator Program (BK20200030).	ADEKUNLE AO, 1987, J REPROD IMMUNOL, V12, P49, DOI 10.1016/0165-0378(87)90080-5; Amann RP, 2014, THERIOGENOLOGY, V81, P5, DOI 10.1016/j.theriogenology.2013.09.004; Anderson KG, 2012, J IMMUNOL, V189, P2702, DOI 10.4049/jimmunol.1201682; [Anonymous], 2020, NEW ENGL J MED, DOI [DOI 10.1515/cclm-2020-0198, DOI 10.1056/NEJMOA2002032]; Bhushan S, 2017, J REPROD IMMUNOL, V119, P107, DOI 10.1016/j.jri.2016.06.008; Bonneville M, 2010, NAT REV IMMUNOL, V10, P467, DOI 10.1038/nri2781; Busch DH, 2016, SEMIN IMMUNOL, V28, P28, DOI 10.1016/j.smim.2016.02.001; Cheng CY, 2012, PHARMACOL REV, V64, P16, DOI 10.1124/pr.110.002790; DeFalco T, 2015, CELL REP, V12, P1107, DOI 10.1016/j.celrep.2015.07.015; DeFalco T, 2014, P NATL ACAD SCI USA, V111, pE2384, DOI 10.1073/pnas.1400057111; Desai P, 2018, J VIROL, V92, DOI 10.1128/JVI.00495-18; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; Edelson BT, 2011, IMMUNITY, V35, P236, DOI 10.1016/j.immuni.2011.06.012; Fernandez-Ruiz D, 2019, IMMUNITY, V51, P780, DOI 10.1016/j.immuni.2019.09.019; Fijak M, 2018, HUM REPROD UPDATE, V24, P416, DOI 10.1093/humupd/dmy009; Fijak M, 2006, IMMUNOL REV, V213, P66, DOI 10.1111/j.1600-065X.2006.00438.x; Fribourg M, 2019, KIDNEY INT, V96, P436, DOI 10.1016/j.kint.2019.01.040; Gebhardt T, 2009, NAT IMMUNOL, V10, P524, DOI 10.1038/ni.1718; Grajales-Reyes GE, 2015, NAT IMMUNOL, V16, P708, DOI 10.1038/ni.3197; Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712; Guo JT, 2018, CELL RES, V28, P1141, DOI 10.1038/s41422-018-0099-2; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Ichikawa T, 2019, NAT IMMUNOL, V20, P1469, DOI 10.1038/s41590-019-0494-y; Khalil S, 2020, INFLAMM RES, V69, P245, DOI 10.1007/s00011-020-01320-6; Kimura MY, 2017, IMMUNOL REV, V278, P87, DOI 10.1111/imr.12559; Kurd NS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz6894; Li JH, 2016, NATURE, V533, P110, DOI 10.1038/nature17947; Lokka E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18206-0; Lucas B, 2016, IMMUNOL REV, V271, P23, DOI 10.1111/imr.12406; LUSTIG L, 1982, J REPROD IMMUNOL, V4, P79, DOI 10.1016/0165-0378(82)90039-0; Mackay LK, 2013, NAT IMMUNOL, V14, P1294, DOI 10.1038/ni.2744; Masopust D, 2019, ANNU REV IMMUNOL, V37, P521, DOI 10.1146/annurev-immunol-042617-053214; Mildner A, 2014, IMMUNITY, V40, P642, DOI 10.1016/j.immuni.2014.04.016; Molodtsov A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02810; Mossadegh-Keller N, 2018, CELL IMMUNOL, V330, P120, DOI 10.1016/j.cellimm.2018.03.009; Mossadegh-Keller N, 2017, J EXP MED, V214, P2829, DOI 10.1084/jem.20170829; Mueller SN, 2016, NAT REV IMMUNOL, V16, P79, DOI 10.1038/nri.2015.3; Nicolas N, 2017, REPRODUCTION, V154, P293, DOI 10.1530/REP-17-0010; NIEMI M, 1986, CELL TISSUE RES, V243, P337; Richmond JM, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam7710; Ritzel RM, 2016, J IMMUNOL, V196, P3318, DOI 10.4049/jimmunol.1502021; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; SATO K, 1981, VIRCHOWS ARCH A, V392, P147, DOI 10.1007/BF00430817; Schlitzer A, 2015, NAT IMMUNOL, V16, P718, DOI 10.1038/ni.3200; Schlitzer A, 2013, IMMUNITY, V38, P970, DOI 10.1016/j.immuni.2013.04.011; Wakim LM, 2012, J IMMUNOL, V189, P3462, DOI 10.4049/jimmunol.1201305; Wang M, 2017, J IMMUNOL, V198, P4327, DOI 10.4049/jimmunol.1700162; Wculek SK, 2020, NAT REV IMMUNOL, V20, P7, DOI 10.1038/s41577-019-0210-z; Zhou R, 2019, CELL MOL LIFE SCI, V76, P2681, DOI 10.1007/s00018-019-03101-9	49	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 26	2021	12								651860	10.3389/fimmu.2021.651860	http://dx.doi.org/10.3389/fimmu.2021.651860			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TX3AH	34381443	Green Published, gold			2022-12-18	WOS:000682961000001
J	Lopez-Lopez, V; Perez-Sanz, F; de Torre-Minguela, C; Marco-Abenza, J; Robles-Campos, R; Sanchez-Bueno, F; Pons, JA; Ramirez, P; Baroja-Mazo, A				Lopez-Lopez, Victor; Perez-Sanz, Fernando; de Torre-Minguela, Carlos; Marco-Abenza, Josefa; Robles-Campos, Ricardo; Sanchez-Bueno, Francisco; Pons, Jose A.; Ramirez, Pablo; Baroja-Mazo, Alberto			Proteomics in Liver Transplantation: A Systematic Review	FRONTIERS IN IMMUNOLOGY			English	Review						rejection; tolerance; mass spectrometry; ischemia; reperfusion; PRISMA	ISCHEMIA-REPERFUSION INJURY; BLOOD MONONUCLEAR-CELLS; HUMAN PLASMA PROTEOME; OPERATIONAL TOLERANCE; 2-DIMENSIONAL ELECTROPHORESIS; FUNCTIONAL PROTEOMICS; BIOMARKER DISCOVERY; PROTEINS; RAT; REJECTION	Background Although proteomics has been employed in the study of several models of liver injury, proteomic methods have only recently been applied not only to biomarker discovery and validation but also to improve understanding of the molecular mechanisms involved in transplantation. Methods The study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology and the guidelines for performing systematic literature reviews in bioinformatics (BiSLR). The PubMed, ScienceDirect, and Scopus databases were searched for publications through April 2020. Proteomics studies designed to understand liver transplant outcomes, including ischemia-reperfusion injury (IRI), rejection, or operational tolerance in human or rat samples that applied methodologies for differential expression analysis were considered. Results The analysis included 22 studies after application of the inclusion and exclusion criteria. Among the 497 proteins annotated, 68 were shared between species and 10 were shared between sample sources. Among the types of studies analyzed, IRI and rejection shared a higher number of proteins. The most enriched pathway for liver biopsy samples, IRI, and rejection was metabolism, compared to cytokine-cytokine receptor interactions for tolerance. Conclusions Proteomics is a promising technique to detect large numbers of proteins. However, our study shows that several technical issues such as the identification of proteoforms or the dynamic range of protein concentration in clinical samples hinder the successful identification of biomarkers in liver transplantation. In addition, there is a need to minimize the experimental variability between studies, increase the sample size and remove high-abundance plasma proteins.	[Lopez-Lopez, Victor; Robles-Campos, Ricardo; Sanchez-Bueno, Francisco; Ramirez, Pablo] Hosp Clin Univ Virgen Arrixaca, Dept Surg, Murcia, Spain; [Lopez-Lopez, Victor; de Torre-Minguela, Carlos; Robles-Campos, Ricardo; Sanchez-Bueno, Francisco; Pons, Jose A.; Ramirez, Pablo; Baroja-Mazo, Alberto] Biomed Res Inst Murcia IMIB Arrixaca, Digest & Endocrine Surg & Transplantat Abdominal, Murcia, Spain; [Perez-Sanz, Fernando] Biomed Res Inst Murcia IMIB Arrixaca, Biomed Informat & Bioinformat Platform, Murcia, Spain; [Marco-Abenza, Josefa] Univ Murcia, Sch Nursing, Murcia, Spain; [Pons, Jose A.] Hosp Clin Univ Virgen Arrixaca, Dept Gastroenterol, Unit Hepatol, Murcia, Spain	Hospital Clinico Universitario Virgen de la Arrixaca; Hospital Clinico Universitario Virgen de la Arrixaca; Hospital Clinico Universitario Virgen de la Arrixaca; University of Murcia; Hospital Clinico Universitario Virgen de la Arrixaca	Baroja-Mazo, A (corresponding author), Biomed Res Inst Murcia IMIB Arrixaca, Digest & Endocrine Surg & Transplantat Abdominal, Murcia, Spain.	alberto.baroja@ffis.es	Perez-Sanz, Fernando/P-8144-2019; Baroja-Mazo, Alberto/E-6270-2016; Miñano, Jose Antonio Pons/S-4644-2019	Perez-Sanz, Fernando/0000-0002-8143-7794; Baroja-Mazo, Alberto/0000-0001-5212-5006; Miñano, Jose Antonio Pons/0000-0001-5017-7240; Robles, Ricardo/0000-0003-0007-562X	Fundacio'n Mutua Madrilena [AP171362019]; Instituto de Salud Carlos III [PI17/00489, PI13/02870]	Fundacio'n Mutua Madrilena(Instituto de Salud Carlos III); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission)	AB-M was funded by Fundacio ' n Mutua Madrilena, Grant/Award Number: AP171362019 and Instituto de Salud Carlos III, Grant/Award Number: PI20/00185. JP and RR-C were funded by Instituto de Salud Carlos III, Grant/Award Numbers: PI17/00489 and PI13/02870, respectively. Funding sources provided financial support but had no involvement in study design, collection, analysis and interpretation of data.	Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200; Baroja-Mazo A, 2016, WORLD J GASTROENTERO, V22, P7676, DOI 10.3748/wjg.v22.i34.7676; Bohne F, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008793; Boschetti E, 2009, PROTEOMICS, V9, P1492, DOI 10.1002/pmic.200800389; Bryda Elizabeth C, 2013, Mo Med, V110, P207; Cascante M., 1997, NEW BEER OLD BOTTLE; Chandrasekharan D, 2013, TRANSPL INT, V26, P576, DOI 10.1111/tri.12081; Cheng J, 2010, EUR SURG RES, V44, P43, DOI 10.1159/000264602; Cho William C. S., 2007, Genomics Proteomics & Bioinformatics, V5, P77, DOI 10.1016/S1672-0229(07)60018-7; Choudhary NS, 2017, J CLIN EXP HEPATOL, V7, P358, DOI 10.1016/j.jceh.2017.10.003; Christians U, 2016, THER DRUG MONIT, V38, pS70, DOI 10.1097/FTD.0000000000000243; Colland F, 2004, GENOME RES, V14, P1324, DOI 10.1101/gr.2334104; Coskun A, 2019, CURR PROTEOMICS, V16, P119, DOI 10.2174/1570164615666180905104543; Cursio R, 2008, TRANSPL P, V40, P2042, DOI 10.1016/j.transproceed.2008.05.037; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Farid WRR, 2014, TRANSPL INT, V27, P1222, DOI 10.1111/tri.12379; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Gorg A, 2004, PROTEOMICS, V4, P3665, DOI 10.1002/pmic.200401031; Henzel WJ, 2003, J AM SOC MASS SPECTR, V14, P931, DOI 10.1016/S1044-0305(03)00214-9; Hortin GL, 2008, CLIN CHEM, V54, P1608, DOI 10.1373/clinchem.2008.108175; Hsu LW, 2007, TRANSPL IMMUNOL, V17, P137, DOI 10.1016/j.trim.2006.06.001; Huang SZ, 2019, EPIGENOMICS-UK, V11, P527, DOI 10.2217/epi-2018-0189; Jiang Q, 2019, TRANSPL IMMUNOL, V53, P7, DOI 10.1016/j.trim.2018.11.005; Karp NA, 2009, PROTEOMICS, V9, P388, DOI 10.1002/pmic.200800485; Kienzl-Wagner K, 2014, ADV CLIN CHEM, V67, P215, DOI 10.1016/bs.acc.2014.09.004; Kienzl-Wagner K, 2013, CLIN BIOCHEM, V46, P497, DOI 10.1016/j.clinbiochem.2012.10.010; Knecht C, 2018, CRYOBIOLOGY, V85, P47, DOI 10.1016/j.cryobiol.2018.10.003; Konishi Takanori, 2017, Gene Expression, V17, P277, DOI 10.3727/105221617X15042750874156; Kornasiewicz O, 2012, INT J MOL MED, V30, P755, DOI 10.3892/ijmm.2012.1062; Kuscuoglu D, 2018, J HEPATOL, V69, P512, DOI 10.1016/j.jhep.2018.04.018; Levitsky J, 2011, AM J TRANSPLANT, V11, P1972, DOI 10.1111/j.1600-6143.2011.03669.x; Levitsky J, 2013, HEPATOLOGY, V57, P239, DOI 10.1002/hep.25579; Li L, 2012, AM J TRANSPLANT, V12, P1218, DOI 10.1111/j.1600-6143.2011.03928.x; Li Y, 2004, AM J TRANSPLANT, V4, P2118, DOI 10.1111/j.1600-6143.2004.00611.x; Lu BW, 2008, ANAL CHEM, V80, P2018, DOI 10.1021/ac701697w; Mariano DCB., 2017, ARXIV170705813; Martinez-Llordella M, 2007, AM J TRANSPLANT, V7, P309, DOI 10.1111/j.1600-6143.2006.01621.x; Martinez-Llordella M, 2008, J CLIN INVEST, V118, P2845, DOI 10.1172/JCI35342; Massoud O, 2011, LIVER TRANSPLANT, V17, P723, DOI 10.1002/lt.22266; McManus CA., 2006, TRANSPLANT REV-ORLAN, V20, P195, DOI [10.1016/j.trre.2006.08.001, DOI 10.1016/J.TRRE.2006.08.001]; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]; Nesvizhskii AI, 2005, MOL CELL PROTEOMICS, V4, P1419, DOI 10.1074/mcp.R500012-MCP200; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Ong SE, 2005, NAT CHEM BIOL, V1, P252, DOI 10.1038/nchembio736; Paladini SV, 2019, MOL DIAGN THER, V23, P439, DOI 10.1007/s40291-019-00397-y; Pan TL, 2011, CLIN CHIM ACTA, V412, P604, DOI 10.1016/j.cca.2010.12.014; Pan TL, 2004, IMMUNOLOGY, V113, P57, DOI 10.1111/j.1365-2567.2004.01924.x; Parent R, 2005, J HEPATOL, V43, P177, DOI 10.1016/j.jhep.2005.04.001; Parviainen V, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/248613; Perez-Sanz F, 2019, TRANSPLANTATION, V103, P1887, DOI 10.1097/TP.0000000000002587; Pieper R, 2003, PROTEOMICS, V3, P422, DOI 10.1002/pmic.200390057; Rampes S, 2019, J BIOMED RES, V33, P221, DOI 10.7555/JBR.32.20180087; Revilla-Nuin B, 2017, LIVER TRANSPLANT, V23, P933, DOI 10.1002/lt.24691; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Roedder S, 2011, GENOME MED, V3, DOI 10.1186/gm253; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sigdel TK, 2011, EXPERT REV PROTEOMIC, V8, P705, DOI [10.1586/EPR.11.66, 10.1586/epr.11.66]; Smith LM, 2013, NAT METHODS, V10, P186, DOI 10.1038/nmeth.2369; Svetlov SI, 2006, BIOMARKERS, V11, P355, DOI 10.1080/13547500600775110; Thompson A, 2003, ANAL CHEM, V75, P1895, DOI 10.1021/ac0262560; Tiriveedhi V, 2012, BMC BIOCHEM, V13, DOI 10.1186/1471-2091-13-17; Toby TK, 2017, AM J TRANSPLANT, V17, P2458, DOI 10.1111/ajt.14359; Tran JC, 2011, NATURE, V480, P254, DOI 10.1038/nature10575; Tran JC, 2009, ANAL CHEM, V81, P6201, DOI 10.1021/ac900729r; Traum AZ, 2005, PEDIATR TRANSPLANT, V9, P700, DOI 10.1111/j.1399-3046.2005.00408.x; Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133; Vascotto C, 2006, PROTEOMICS, V6, P3455, DOI 10.1002/pmic.200500770; Wain HM, 2002, GENOMICS, V79, P464, DOI 10.1006/geno.2002.6748; Wang PW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02216; Wei W, 2015, CLIN RES HEPATOL GAS, V39, P340, DOI 10.1016/j.clinre.2014.10.005; Wu B, 2013, HEPATOL INT, V7, P286, DOI 10.1007/s12072-012-9346-7; Wu JD, 2010, J HEPATOL, V53, P73, DOI 10.1016/j.jhep.2010.01.032; Yagi S., 2013, EXPT ORG TRANSPLANAT; Yu Y, 2010, GENOMICS, V96, P281, DOI 10.1016/j.ygeno.2010.08.003; Zhai Y, 2013, NAT REV GASTRO HEPAT, V10, P79, DOI 10.1038/nrgastro.2012.225; Zhan XQ, 2018, ELECTROPHORESIS, V39, P965, DOI 10.1002/elps.201700330; Zhang CC, 2007, SCI CHINA SER C, V50, P312, DOI 10.1007/s11427-007-0038-9; Zhang Ruohan, 2019, Oncotarget, V10, P2508, DOI 10.18632/oncotarget.26761; ZIMMERMANN FA, 1984, TRANSPLANTATION, V37, P406, DOI 10.1097/00007890-198404000-00019; Zubarev RA, 2013, PROTEOMICS, V13, P723, DOI 10.1002/pmic.201200451	82	1	1	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 26	2021	12								672829	10.3389/fimmu.2021.672829	http://dx.doi.org/10.3389/fimmu.2021.672829			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TX2VW	34381445	gold, Green Published			2022-12-18	WOS:000682949400001
J	Garcia, LS; Gomez-Torres, N; Cabanas, F; Gonzalez-Sanchez, R; Lopez-Azorin, M; Moral-Pumarega, MT; Escuder-Vieco, D; Cabanes-Alonso, E; Castro, I; Alba, C; Gomez, JMR; Pellicer, A				Sanchez Garcia, Laura; Gomez-Torres, Natalia; Cabanas, Fernando; Gonzalez-Sanchez, Raquel; Lopez-Azorin, Manuela; Moral-Pumarega, M. Teresa; Escuder-Vieco, Diana; Cabanes-Alonso, Esther; Castro, Irma; Alba, Claudio; Rodriguez Gomez, Juan Miguel; Pellicer, Adelina			Immediate Pre-Partum SARS-CoV-2 Status and Immune Profiling of Breastmilk: A Case-Control Study	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; vertical infectious disease transmission; breastfeeding; immunologic factors; immune system	GROWTH-FACTOR-BETA; IMMUNOMODULATORY CONSTITUENTS; PRETERM; INFANT; CHEMOKINES; CYTOKINES; MOTHERS; TERM	Objetive To address the prevalence of SARS-CoV-2 and the evolutionary profile of immune compounds in breastmilk of positive mothers according to time and disease state. Methods Forty-five women with term pregnancies with confirmed non-severe SARS-CoV-2 infection (case group), and 96 SARS-CoV-2 negative women in identical conditions (control group) were approached, using consecutive sample. Weekly (1st to 5th week postpartum) reverse transcription polymerase chain reaction (RT-PCR) in nasopharyngeal swabs (cases) and breastmilk (cases and controls) were obtained. Concentration of cytokines, chemokines, and growth factors in breastmilk (cases and controls) were determined at 1st and 5th week post-partum. Results Thirty-seven (study group) and 45 (control group) women were enrolled. Symptomatic infection occurred in 56.8% of women in the study group (48% fever, 48% anosmia, 43% cough). SARS-CoV-2 RNA was not found in breastmilk samples. Concentrations of cytokines (IFN-gamma, IL-1ra, IL-4, IL-6, IL-9, IL-13, and TNF-alpha) chemokines (eotaxin, IP-10, MIP-1 alpha, and RANTES) and growth factors (FGF, GM-CSF, IL7, and PDGF-BB) were higher in breastmilk of the study compared with the control group at 1st week postpartum. Immune compounds concentrations decreased on time, particularly in the control group milk samples. Time of nasopharyngeal swab to become negative influenced the immune compound concentration pattern. Severity of disease (symptomatic or asymptomatic infection) did not affect the immunological profile in breast milk. Conclusions This study confirms no viral RNA and a distinct immunological profile in breastmilk according to mother's SARS-CoV-2 status. Additional studies should address whether these findings indicate efficient reaction against SARS-CoV-2 infection, which might be suitable to protect the recipient child.	[Sanchez Garcia, Laura; Pellicer, Adelina] La Paz Univ Hosp, Dept Neonatol, Biomed Res Fdn IDIPAZ, Madrid, Spain; [Gomez-Torres, Natalia; Castro, Irma; Alba, Claudio; Rodriguez Gomez, Juan Miguel] Univ Complutense Madrid, Nutr & Food Sci Dept, Madrid, Spain; [Cabanas, Fernando] La Paz Univ Hosp, Dept Neonatol, Quironsalud Madrid Univ Hosp, Madrid, Spain; [Cabanas, Fernando] La Paz Univ Hosp, Quironsalud San Jose Hosp, Biomed Res Fdn IDIPAZ, Madrid, Spain; [Gonzalez-Sanchez, Raquel; Lopez-Azorin, Manuela] Quironsalud Madrid Univ Hosp, Dept Neonatol, Madrid, Spain; [Gonzalez-Sanchez, Raquel; Lopez-Azorin, Manuela] Quironsalud San Jose Hosp, Madrid, Spain; [Moral-Pumarega, M. Teresa; Escuder-Vieco, Diana] 12 Octubre Univ Hosp, Dept Neonatol, Madrid, Spain; [Cabanes-Alonso, Esther] 12 Octubre Univ Hosp, Dept Neonatol, Madrid, Spain; [Cabanes-Alonso, Esther] 12 Octubre Univ Hosp, Reg Human Milk Bank, Madrid, Spain	Hospital Universitario La Paz; Complutense University of Madrid; Hospital Universitario La Paz; quironsalud Group; Hospital Universitario La Paz; quironsalud Group; quironsalud Group; quironsalud Group; Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre	Garcia, LS (corresponding author), La Paz Univ Hosp, Dept Neonatol, Biomed Res Fdn IDIPAZ, Madrid, Spain.	laurasg_alcobendas@yahoo.es	Rodriguez, Juan Miguel/ABB-6650-2020	Rodriguez, Juan Miguel/0000-0002-1285-9686; Gomez-Torres, Natalia/0000-0003-4279-2977; Alba, Claudio/0000-0003-0620-0313; Castro Navarro, Irma/0000-0002-5605-3422	Instituto de Salud San Carlos III [COV20/01046]; Ministerio de Ciencia, Innovacion y Universidades (Spain) [BES-2017-080713]; RETICS "Maternal and Child Health and Development Network" (SAMID Network) - PN I+D+i 2013-2016 (Spain),; ISCIII-Sub-Directorate General for Research Assessment and Promotion; European Regional Development Fund (ERDF) [RD16/0022]	Instituto de Salud San Carlos III; Ministerio de Ciencia, Innovacion y Universidades (Spain)(Spanish Government); RETICS "Maternal and Child Health and Development Network" (SAMID Network) - PN I+D+i 2013-2016 (Spain),; ISCIII-Sub-Directorate General for Research Assessment and Promotion; European Regional Development Fund (ERDF)(European Commission)	This work was supported by Instituto de Salud San Carlos III [COV20/01046]; Ministerio de Ciencia, Innovacio ' n y Universidades (Spain) by Irma Castro predoctoral contract [BES-2017-080713] and RETICS "Maternal and Child Health and Development Network" (SAMID Network), funded by the PN I+D+i 2013-2016 (Spain), ISCIII-Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (ERDF) [RD16/0022].	Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364; Bertino E, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.597699; Bosire R, 2007, BREASTFEED MED, V2, P129, DOI 10.1089/bfm.2007.0009; Bryan DL, 2007, PEDIATR ALLERGY IMMU, V18, P495, DOI 10.1111/j.1399-3038.2007.00565.x; Collado MC, 2015, NUTRIENTS, V7, P8577, DOI 10.3390/nu7105415; Centeno-Tablante E, 2021, ANN NY ACAD SCI, V1484, P32, DOI 10.1111/nyas.14477; Chambers C, 2020, JAMA-J AM MED ASSOC, V324, P1347, DOI 10.1001/jama.2020.15580; Chatterjee SK, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00196; Cheema Ritu, 2020, Am J Perinatol, DOI 10.1055/s-0040-1714277; Chen L, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009226; Chollet-Hinton LS, 2014, BREASTFEED MED, V9, P530, DOI 10.1089/bfm.2014.0043; Choudhary S, 2021, MICROB PATHOGENESIS, V150, DOI 10.1016/j.micpath.2020.104673; Costa S, 2020, CLIN MICROBIOL INFEC, V26, P1430, DOI 10.1016/j.cmi.2020.05.027; Dawod B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00016; de Quental OB, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/9020519; De Rose DU, 2020, ITAL J PEDIATR, V46, DOI 10.1186/s13052-020-0820-x; Demers-Mathieu V, 2021, J PERINATOL, V41, P850, DOI 10.1038/s41372-020-00805-w; Dvorak B, 2010, J PEDIATR-US, V156, pS31, DOI 10.1016/j.jpeds.2009.11.018; Farquhar C, 2005, CURR HIV RES, V3, P361, DOI 10.2174/157016205774370393; Colomer BF, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.580584; Field CJ, 2005, J NUTR, V135, P1; Fox A, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101735; Garofalo R, 2010, J PEDIATR-US, V156, pS36, DOI 10.1016/j.jpeds.2009.11.019; Gross R, 2020, LANCET, V395, P1757, DOI 10.1016/S0140?6736(20)31181?8; Hinojosa-Velasco A, 2020, INT J INFECT DIS, V100, P21, DOI 10.1016/j.ijid.2020.08.055; Lackey KA, 2020, MATERN CHILD NUTR, V16, DOI 10.1111/mcn.13032; Lugli L, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-004960; Gabriel MMA, 2020, ACTA PAEDIATR, V109, P2302, DOI 10.1111/apa.15474; Marotz Clarisse, 2020, medRxiv, DOI 10.1101/2020.11.19.20234229; Martins PR, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.59; Moles L, 2015, J PEDIATR GASTR NUTR, V60, P120, DOI 10.1097/MPG.0000000000000560; Pace Ryan M, 2020, medRxiv, DOI 10.1101/2020.09.16.20196071; Penttila IA, 2010, J PEDIATR-US, V156, pS21, DOI 10.1016/j.jpeds.2009.11.016; Pereira A, 2020, INT BREASTFEED J, V15, DOI 10.1186/s13006-020-00314-8; Rabe T, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8020289; Riskin A, 2012, PEDIATR RES, V71, P220, DOI 10.1038/pr.2011.34; Ruiz L., 2020, IMMUNE FACTORS HUMAN; Ruiz L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00696; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Trend S, 2016, BRIT J NUTR, V115, P1178, DOI 10.1017/S0007114516000234; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Verhasselt V, 2010, J PEDIATR-US, V156, pS16, DOI 10.1016/j.jpeds.2009.11.015; Walker KF, 2020, BJOG-INT J OBSTET GY, V127, P1324, DOI 10.1111/1471-0528.16362; Walter J, 2009, J INFECT DIS, V200, P1498, DOI 10.1086/644603; Wei M, 2020, JAMA-J AM MED ASSOC, V323, P1313, DOI 10.1001/jama.2020.2131; White A, 2021, NEONATOLOGY, V117, P641, DOI 10.1159/000508962; Wolfel R, 2020, NATURE, V581, P465, DOI 10.1038/s41586-020-2196-x; Yang N, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-3299	49	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 26	2021	12								720716	10.3389/fimmu.2021.720716	http://dx.doi.org/10.3389/fimmu.2021.720716			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TX2KB	34381462	Green Published, gold			2022-12-18	WOS:000682918100001
J	Sangild, PT; Strunk, T; Currie, AJ; Nguyen, DN				Sangild, Per T.; Strunk, Tobias; Currie, Andrew J.; Nguyen, Duc Ninh			Editorial: Immunity in Compromised Newborns	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immune development; inflammation; antibiotics; preterm; birth; milk; sepsis; necrotizing enterocolitis	BIRTH-WEIGHT INFANTS; NECROTIZING ENTEROCOLITIS; BOVINE COLOSTRUM; GUT DYSFUNCTION; PRETERM INFANTS; HUMAN-MILK; FORMULA; GROWTH; MORTALITY; SEPSIS		[Sangild, Per T.; Nguyen, Duc Ninh] Univ Copenhagen, Dept Vet & Anim Sci, Comparat Pediat & Nutr, Frederiksberg, Denmark; [Sangild, Per T.] Rigshospitalet, Dept Neonatol, Copenhagen, Denmark; [Sangild, Per T.] Odense Univ Hosp, Dept Pediat, Odense, Denmark; [Strunk, Tobias] Murdoch Univ, Ctr Mol Med & Innovat Therapeut, Perth, WA, Australia; [Strunk, Tobias] Telethon Kids Inst, Wesfarmers Ctr Vaccines & Infect Dis, Perth, WA, Australia; [Strunk, Tobias; Currie, Andrew J.] Child & Adolescent Hlth Serv, Neonatal Directorate, Western, Australia; [Currie, Andrew J.] Univ Western Australia, Ctr Neonatal Res & Educ, Perth, WA, Australia	University of Copenhagen; Rigshospitalet; University of Southern Denmark; Odense University Hospital; Murdoch University; Telethon Kids Institute; Wesfarmers Limited; University of Western Australia	Sangild, PT; Nguyen, DN (corresponding author), Univ Copenhagen, Dept Vet & Anim Sci, Comparat Pediat & Nutr, Frederiksberg, Denmark.; Sangild, PT (corresponding author), Rigshospitalet, Dept Neonatol, Copenhagen, Denmark.; Sangild, PT (corresponding author), Odense Univ Hosp, Dept Pediat, Odense, Denmark.; Strunk, T (corresponding author), Murdoch Univ, Ctr Mol Med & Innovat Therapeut, Perth, WA, Australia.; Strunk, T; Currie, AJ (corresponding author), Child & Adolescent Hlth Serv, Neonatal Directorate, Western, Australia.; Currie, AJ (corresponding author), Univ Western Australia, Ctr Neonatal Res & Educ, Perth, WA, Australia.	pts@sund.ku.dk; tobiasstrunk@yahoo.de; A.Currie@murdoch.edu.au; dnn@sund.ku.dk	Strunk, Tobias/AIE-3407-2022	Strunk, Tobias/0000-0001-7079-2339; Nguyen, Duc Ninh/0000-0002-4997-555X	Innovation Fund Denmark	Innovation Fund Denmark	The work was funded in part by grants from Innovation Fund Denmark (NEOMUNE and NEOCOL grants).	Ahnfeldt AM, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3367-7; Ahnfeldt AM, 2020, J NUTR, V150, P1196, DOI 10.1093/jn/nxaa030; Baek O, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.626101; Birck MM, 2016, AM J PHYSIOL-GASTR L, V310, pG323, DOI 10.1152/ajpgi.00392.2015; Brunse A, 2021, GUT MICROBES, V13, P1, DOI 10.1080/19490976.2020.1849997; Brunse A, 2018, DEV NEUROSCI-BASEL, V40, P198, DOI 10.1159/000488979; Brunse A, 2019, SHOCK, V51, P337, DOI 10.1097/SHK.0000000000001131; Brunse A, 2019, ISME J, V13, P720, DOI 10.1038/s41396-018-0301-z; Che LQ, 2010, PEDIATR RES, V67, P54, DOI 10.1203/PDR.0b013e3181c1b15e; Christensen N, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2019-1892; Cilieborg MS, 2011, BRIT J NUTR, V106, P852, DOI 10.1017/S000711451100047X; Conti MG, 2020, PEDIATR RES, V87, P399, DOI 10.1038/s41390-019-0647-6; D'Angio CT, 2014, AM J PHYSIOL-LUNG C, V307, pL959, DOI 10.1152/ajplung.00228.2014; de Jong E, 2018, J MOL MED, V96, P147, DOI 10.1007/s00109-017-1609-2; de Waard M, 2019, JPEN-PARENTER ENTER, V43, P658, DOI 10.1002/jpen.1466; Nguyen DN, 2018, AM J PATHOL, V188, P2629, DOI 10.1016/j.ajpath.2018.07.020; Nguyen DN, 2017, INNATE IMMUN-LONDON, V23, P524, DOI 10.1177/1753425917719995; Nguyen DN, 2016, SCI REP-UK, V6, DOI 10.1038/srep36816; Nguyen DN, 2016, INNATE IMMUN-LONDON, V22, P51, DOI 10.1177/1753425915615195; Easter SR, 2017, VACCINE, V35, P6546, DOI 10.1016/j.vaccine.2017.01.042; Foster JP, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001816.pub3; Gussenhoven R, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1149-x; Hodzic Z, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00040; Jiang PP, 2017, J PROTEOME RES, V16, P3547, DOI 10.1021/acs.jproteome.7b00263; Jiang PP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044929; Johnson-Henry KC, 2016, ADV NUTR, V7, P928, DOI 10.3945/an.116.012237; Juhl SM, 2018, J PEDIATR GASTR NUTR, V66, P471, DOI [10.1097/mpg.0000000000001774, 10.1097/MPG.0000000000001774]; Kollmann TR, 2017, IMMUNITY, V46, P350, DOI 10.1016/j.immuni.2017.03.009; Lawrence SM, 2020, TRENDS IMMUNOL, V41, P531, DOI 10.1016/j.it.2020.03.008; Lee AH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08794-x; Li YQ, 2020, J PEDIATR-US, V227, P128, DOI 10.1016/j.jpeds.2020.06.032; Li YQ, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00042; Liang GX, 2020, NATURE, V581, P470, DOI 10.1038/s41586-020-2192-1; Miller JE, 2016, LANCET INFECT DIS, V16, P952, DOI 10.1016/S1473-3099(16)00150-X; Morgan RL, 2020, GASTROENTEROLOGY, V159, P467, DOI 10.1053/j.gastro.2020.05.096; Ng S, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00070; Nolan LS, 2020, SHOCK, V53, P596, DOI 10.1097/SHK.0000000000001507; Ohlsson A, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000361.pub4; Palmeira P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/985646; Pan XY, 2022, PEDIATR RES, V91, P1113, DOI 10.1038/s41390-021-01605-4; Pan XY, 2018, DNA RES, V25, P287, DOI 10.1093/dnares/dsy001; Pan XY, 2018, EPIGENOMICS-UK, V10, P395, DOI 10.2217/epi-2017-0122; Quigley MA, 2016, EUR J CLIN NUTR, V70, P1420, DOI 10.1038/ejcn.2016.135; Rasmussen SO, 2016, AM J PHYSIOL-GASTR L, V311, pG480, DOI 10.1152/ajpgi.00139.2016; Ren SQ, 2021, AM J PHYSIOL-GASTR L, V321, pG18, DOI 10.1152/ajpgi.00408.2020; Ren SQ, 2020, FASEB J, V34, P2896, DOI 10.1096/fj.201902629R; Ren SQ, 2018, AM J PHYSIOL-GASTR L, V315, pG855, DOI 10.1152/ajpgi.00169.2018; Sangild PT, 2013, J ANIM SCI, V91, P4713, DOI 10.2527/jas.2013-6359; Sangild PT., 2021, NUTRIENTS; Shah JA, 2022, AM J PERINAT, V39, P965, DOI 10.1055/s-0040-1721133; Sharma AA, 2012, CLIN IMMUNOL, V145, P61, DOI 10.1016/j.clim.2012.08.006; Shen RL, 2015, AM J PHYSIOL-GASTR L, V309, pG310, DOI 10.1152/ajpgi.00163.2015; Soni D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.590373; Stewart CJ, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0295-1; Stoy ACF, 2016, J PEDIATR GASTR NUTR, V63, P280, DOI 10.1097/MPG.0000000000001056; Strunk T, 2021, CLIN INFECT DIS, V72, P271, DOI 10.1093/cid/ciaa063; Strunk T, 2012, PEDIATRICS, V129, pE134, DOI 10.1542/peds.2010-3493; Sun J, 2019, JPEN-PARENTER ENTER, V43, P252, DOI 10.1002/jpen.1422; Sun J, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1201-x; Taylor AW, 2020, LANCET GLOB HEALTH, V8, pE909, DOI 10.1016/S2214-109X(20)30205-9; Ting JY, 2016, JAMA PEDIATR, V170, P1181, DOI 10.1001/jamapediatrics.2016.2132; Ulfman LH, 2018, FRONT NUTR, V5, DOI 10.3389/fnut.2018.00052; Wirbelauer J, 2010, AM J PERINAT, V27, P819, DOI 10.1055/s-0030-1254547; Yan XD, 2021, J PEDIATR GASTR NUTR, V73, pE39, DOI 10.1097/MPG.0000000000003147; Zhou QJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.aay6621	65	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 26	2021	12								732332	10.3389/fimmu.2021.732332	http://dx.doi.org/10.3389/fimmu.2021.732332			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TX1WB	34381463	Green Published, gold			2022-12-18	WOS:000682880500001
J	Scherman, K; Raberg, L; Westerdahl, H				Scherman, Kristin; Raberg, Lars; Westerdahl, Helena			Borrelia Infection in Bank Voles Myodes glareolus Is Associated With Specific DQB Haplotypes Which Affect Allelic Divergence Within Individuals	FRONTIERS IN IMMUNOLOGY			English	Article						major histocompatibility complex; DQB; Borrelia; bank vole; disease resistance	CLASS-II DRB; MHC CLASS-I; HETEROZYGOTE ADVANTAGE; BALANCING SELECTION; GENETIC-VARIATION; PARASITE LOAD; DIVERSITY; POLYMORPHISM; RESISTANCE; LOCI	The high polymorphism of Major Histocompatibility Complex (MHC) genes is generally considered to be a result of pathogen-mediated balancing selection. Such selection may operate in the form of heterozygote advantage, and/or through specific MHC allele-pathogen interactions. Specific MHC allele-pathogen interactions may promote polymorphism via negative frequency-dependent selection (NFDS), or selection that varies in time and/or space because of variability in the composition of the pathogen community (fluctuating selection; FS). In addition, divergent allele advantage (DAA) may act on top of these forms of balancing selection, explaining the high sequence divergence between MHC alleles. DAA has primarily been thought of as an extension of heterozygote advantage. However, DAA could also work in concert with NFDS though this is yet to be tested explicitly. To evaluate the importance of DAA in pathogen-mediated balancing selection, we surveyed allelic polymorphism of MHC class II DQB genes in wild bank voles (Myodes glareolus) and tested for associations between DQB haplotypes and infection by Borrelia afzelii, a tick-transmitted bacterium causing Lyme disease in humans. We found two significant associations between DQB haplotypes and infection status: one haplotype was associated with lower risk of infection (resistance), while another was associated with higher risk of infection (susceptibility). Interestingly, allelic divergence within individuals was higher for voles with the resistance haplotype compared to other voles. In contrast, allelic divergence was lower for voles with the susceptibility haplotype than other voles. The pattern of higher allelic divergence in individuals with the resistance haplotype is consistent with NFDS favouring divergent alleles in a natural population, hence selection where DAA works in concert with NFDS.	[Scherman, Kristin; Westerdahl, Helena] Lund Univ, Dept Biol, Mol Ecol & Evolut Lab, Lund, Sweden; [Raberg, Lars] Lund Univ, Dept Biol, Funct Zool, Lund, Sweden	Lund University; Lund University	Westerdahl, H (corresponding author), Lund Univ, Dept Biol, Mol Ecol & Evolut Lab, Lund, Sweden.	helena.westerdahl@biol.lu.se			Swedish Research Council [621-2006-2876, 621-2006-4551]; Carl Tryggers Stiftelse for Vetenskaplig Forskning; Crafoordska stiftelsen; Stiftelsen Lunds Djurskyddsfond	Swedish Research Council(Swedish Research CouncilEuropean Commission); Carl Tryggers Stiftelse for Vetenskaplig Forskning; Crafoordska stiftelsen; Stiftelsen Lunds Djurskyddsfond	The project was funded by the Swedish Research Council (Grants 621-2006-2876 and 621-2006-4551 to HW and LR, respectively), by Carl Tryggers Stiftelse for Vetenskaplig Forskning to HW, by Crafoordska stiftelsen to HW and LR, and by Stiftelsen Lunds Djurskyddsfond to KS.	Andersson M, 2013, AM NAT, V181, P545, DOI 10.1086/669905; Assarsson E, 2007, J IMMUNOL, V178, P7890, DOI 10.4049/jimmunol.178.12.7890; Axtner J, 2007, IMMUNOGENETICS, V59, P417, DOI 10.1007/s00251-007-0205-y; Babik W, 2009, MOL ECOL RESOUR, V9, P713, DOI 10.1111/j.1755-0998.2009.02622.x; Calis JJA, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002412; Carrington M, 2003, ANNU REV MED, V54, P535, DOI 10.1146/annurev.med.54.101601.152346; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; Cayol C, 2018, P ROY SOC B-BIOL SCI, V285, DOI 10.1098/rspb.2018.1056; Cobble KR, 2016, ECOL EVOL, V6, P2624, DOI 10.1002/ece3.2077; Consuegra S, 2008, P ROY SOC B-BIOL SCI, V275, P1397, DOI 10.1098/rspb.2008.0066; DOHERTY PC, 1975, NATURE, V256, P50, DOI 10.1038/256050a0; Drews A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55800-9; Frankild S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001831; Froeschke G, 2005, MOL BIOL EVOL, V22, P1254, DOI 10.1093/molbev/msi112; Froeschke G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031820; Gaigher A, 2019, MOL ECOL, V28, P5115, DOI 10.1111/mec.15276; Gaigher A, 2018, HEREDITY, V120, P396, DOI 10.1038/s41437-017-0047-9; Galan M, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-296; Harf R, 2005, MOL ECOL, V14, P85, DOI 10.1111/j.1365-294X.2004.02402.x; He L, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-S4-S1; Hedrick PW, 2002, EVOLUTION, V56, P1902, DOI 10.1111/j.0014-3820.2002.tb00116.x; Hellgren O, 2011, J EVOLUTION BIOL, V24, P159, DOI 10.1111/j.1420-9101.2010.02148.x; Huchard E, 2008, IMMUNOGENETICS, V60, P585, DOI 10.1007/s00251-008-0319-x; KALISH RA, 1993, INFECT IMMUN, V61, P2774, DOI 10.1128/IAI.61.7.2774-2779.1993; Kamath PL, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2014.0077; Kawashima Y, 2009, NATURE, V458, P641, DOI 10.1038/nature07746; Kloch A, 2013, EVOL ECOL, V27, P635, DOI 10.1007/s10682-012-9611-1; Kloch A, 2010, MOL ECOL, V19, P255, DOI 10.1111/j.1365-294X.2009.04476.x; Lenz TL, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0714; Lenz TL, 2011, EVOLUTION, V65, P2380, DOI 10.1111/j.1558-5646.2011.01288.x; Lenz TL, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-269; Matzaraki V, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1207-1; McClelland EE, 2003, INFECT IMMUN, V71, P2079, DOI 10.1128/IAI.71.4.2079-2086.2003; Meyer-Lucht Y, 2005, MOL ECOL, V14, P2233, DOI 10.1111/j.1365-294X.2005.02557.x; Murphy K, 2012, JANEWAYS IMMUNOBIOLO, V8th; Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084; Niskanen AK, 2014, MOL ECOL, V23, P875, DOI 10.1111/mec.12647; NOWAK MA, 1992, P NATL ACAD SCI USA, V89, P10896, DOI 10.1073/pnas.89.22.10896; Oliver MK, 2009, P ROY SOC B-BIOL SCI, V276, P1119, DOI 10.1098/rspb.2008.1525; Oppelt C, 2010, MOL ECOL, V19, P4155, DOI 10.1111/j.1365-294X.2010.04766.x; Osborne AJ, 2015, MOL ECOL, V24, P1419, DOI 10.1111/mec.13128; Cutrera AP, 2011, INFECT GENET EVOL, V11, P1023, DOI 10.1016/j.meegid.2011.03.016; Pierini F, 2018, MOL BIOL EVOL, V35, P2145, DOI 10.1093/molbev/msy116; POTTS WK, 1995, IMMUNOL REV, V143, P181, DOI 10.1111/j.1600-065X.1995.tb00675.x; Raberg L, 2012, J EVOLUTION BIOL, V25, P1448, DOI 10.1111/j.1420-9101.2012.02515.x; Radwan J, 2020, TRENDS GENET, V36, P298, DOI 10.1016/j.tig.2020.01.008; Razali Haslina, 2017, BMC Res Notes, V10, P346, DOI 10.1186/s13104-017-2654-1; ROSENTHAL AS, 1978, IMMUNOL REV, V40, P136, DOI 10.1111/j.1600-065X.1978.tb00404.x; Savage AE, 2018, CONSERV GENET, V19, P309, DOI 10.1007/s10592-017-1001-3; Scherman K, 2014, J MOL EVOL, V78, P293, DOI 10.1007/s00239-014-9618-z; SCHWARTZ RH, 1978, SCAND J IMMUNOL, V7, P3, DOI 10.1111/j.1365-3083.1978.tb00420.x; Sin YW, 2014, MOL ECOL, V23, P5072, DOI 10.1111/mec.12917; Solberg OD, 2008, HUM IMMUNOL, V69, P443, DOI 10.1016/j.humimm.2008.05.001; Stecher G, 2020, MOL BIOL EVOL, V37, P1237, DOI 10.1093/molbev/msz312; Steere AC, 2004, NAT REV IMMUNOL, V4, P143, DOI 10.1038/nri1267; Steere AC, 2011, CLIN INFECT DIS, V52, pS259, DOI 10.1093/cid/ciq117; STENSETH NC, 1985, ANN ZOOL FENN, V22, P215; Stuglik MT, 2011, MOL ECOL RESOUR, V11, P739, DOI 10.1111/j.1755-0998.2011.02997.x; Stutz WE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100587; TAKAHATA N, 1990, GENETICS, V124, P967; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Tollenaere C, 2008, J EVOLUTION BIOL, V21, P1307, DOI 10.1111/j.1420-9101.2008.01563.x; Trowsdale J, 2013, ANNU REV GENOM HUM G, V14, P301, DOI 10.1146/annurev-genom-091212-153455; Tschirren B, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0364; Vukmanovic S, 2003, TRENDS MOL MED, V9, P139, DOI 10.1016/S1471-4914(03)00029-7; WAKELAND EK, 1990, IMMUNOL RES, V9, P115, DOI 10.1007/BF02918202; Westerdahl H, 2005, P ROY SOC B-BIOL SCI, V272, P1511, DOI 10.1098/rspb.2005.3113; Westerdahl H, 2004, HEREDITY, V92, P534, DOI 10.1038/sj.hdy.6800450; Westerdahl H, 2012, P ROY SOC B-BIOL SCI, V279, P577, DOI 10.1098/rspb.2011.0917; Woelfing B, 2009, PHILOS T R SOC B, V364, P117, DOI 10.1098/rstb.2008.0174; Yewdell JTW, 1999, ANNU REV IMMUNOL, V17, P51, DOI 10.1146/annurev.immunol.17.1.51	71	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 26	2021	12								703025	10.3389/fimmu.2021.703025	http://dx.doi.org/10.3389/fimmu.2021.703025			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TX2ON	34381454	gold, Green Published			2022-12-18	WOS:000682930000001
J	Wan, S; Sun, XQ; Tang, WY; Wang, LF; Wu, ZD; Sun, X				Wan, Shuo; Sun, Xiaoqiang; Tang, Wenyan; Wang, Lifu; Wu, Zhongdao; Sun, Xi			Exosome-Depleted Excretory-Secretory Products of the Fourth-Stage Larval Angiostrongylus cantonensis Promotes Alternative Activation of Macrophages Through Metabolic Reprogramming by the PI3K-Akt Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						Angiostrongylus cantonensis; exosome-depleted excretory-secretory products; N-linked glycoproteins; macrophage polarization; mechanism	VESICLES; ANTIGEN; HEXOSAMINIDASE; GLYCOSYLATION; RESPONSES; GLYCANS; DEFINES; CD163; IL-10; MTOR	Angiostrongylus cantonensis (AC), which parasitizes in the brain of the non-permissive host, such as mouse and human, is an etiologic agent of eosinophilic meningitis. Excretory-secretory (ES) products play an important role in the interaction between parasites and hosts' immune responses. Inflammatory macrophages are responsible for eosinophilic meningitis induced by AC, and the soluble antigens of Angiostrongylus cantonensis fourth stage larva (AC L4), a mimic of dead AC L4, aggravate eosinophilic meningitis in AC-infected mice model via promoting alternative activation of macrophages. In this study, we investigated the key molecules in the ES products of AC L4 on macrophages and observed the relationship between metabolic reprogramming and the PI3K-Akt pathway. First, a co-culture system of macrophage and AC L4 was established to define the role of AC L4 ES products on macrophage polarization. Then, AC L4 exosome and exosome-depleted excretory-secretory products (exofree) were separated from AC L4 ES products using differential centrifugation, and their distinct roles on macrophage polarization were confirmed using qPCR and ELISA experiments. Moreover, AC L4 exofree induced alternative activation of macrophages, which is partially associated with metabolic reprogramming by the PI3K-Akt pathway. Next, lectin blot and deglycosylation assay were done, suggesting the key role of N-linked glycoproteins in exofree. Then, glycoproteomic analysis of exofree and RNA-seq analysis of exofree-treated macrophage were performed. Bi-layer PPI network analysis based on these results identified macrophage-related protein Hexa as a key molecule in inducing alternative activation of macrophages. Our results indicate a great value for research of helminth-derived immunoregulatory molecules, which might contribute to drug development for immune-related diseases.	[Wan, Shuo; Wang, Lifu; Wu, Zhongdao; Sun, Xi] Sun Yat Sen Univ, Dept Parasitol, Zhongshan Sch Med, Guangzhou, Peoples R China; [Wan, Shuo; Sun, Xiaoqiang; Wang, Lifu; Wu, Zhongdao; Sun, Xi] Minist Educ, Key Lab Trop Dis Control SYSU, Guangzhou, Peoples R China; [Wan, Shuo; Wang, Lifu; Wu, Zhongdao; Sun, Xi] Prov Engn Technol Res Ctr Biol Vector Control, Guangzhou, Peoples R China; [Wan, Shuo] Jinan Univ, Affiliated Hosp 1, Guangzhou, Peoples R China; [Sun, Xiaoqiang] Sun Yat Sen Univ, Zhongshan Sch Math, Guangzhou, Peoples R China; [Tang, Wenyan] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Dept Neonatol, Guangzhou, Peoples R China	Sun Yat Sen University; Jinan University; Sun Yat Sen University; Guangzhou Medical University	Sun, X (corresponding author), Sun Yat Sen Univ, Dept Parasitol, Zhongshan Sch Med, Guangzhou, Peoples R China.; Sun, X (corresponding author), Minist Educ, Key Lab Trop Dis Control SYSU, Guangzhou, Peoples R China.; Sun, X (corresponding author), Prov Engn Technol Res Ctr Biol Vector Control, Guangzhou, Peoples R China.	sunxi2@mail.sysu.edu.cn	Sun, Xi/AGH-6499-2022	Wan, Shuo/0000-0003-2765-6002	Science and Technology Planning Project of Guangdong Province [2016A020219004]; National Key R&D Program of China [2020YFC1200100]; Natural Science Foundation of Guangdong Province [2019A1515012068, 2021A1515010976]; Pearl River Nova Program of Guangzhou [201710010030]; 111 Project [B12003]; China Postdoctoral Science Foundation [2021M691236]; National Natural Science Foundation of China [11871070]; Guangdong Basic and Applied Basic Research Foundation [2020B151502120]; Fundamental Research Funds for the Central Universities [20ykzd20]; Guangdong Key Field RD Plan [2019B020228001]	Science and Technology Planning Project of Guangdong Province; National Key R&D Program of China; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Pearl River Nova Program of Guangzhou; 111 Project(Ministry of Education, China - 111 Project); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Guangdong Key Field RD Plan	This project was supported by the Science and Technology Planning Project of Guangdong Province (2016A020219004), the National Key R&D Program of China (2020YFC1200100), Natural Science Foundation of Guangdong Province (No 2019A1515012068, 2021A1515010976), the Pearl River Nova Program of Guangzhou (No. 201710010030), 111 Project (Grant No. B12003). Shuo Wan was supported by the Project funded by China Postdoctoral Science Foundation (2021M691236). Xiaoqiang Sun was supported by the National Natural Science Foundation of China (11871070), the Guangdong Basic and Applied Basic Research Foundation (2020B151502120), the Fundamental Research Funds for the Central Universities (20ykzd20), and Guangdong Key Field R&D Plan (2019B020228001).	Ahmed SF, 1997, INFECT IMMUN, V65, P219, DOI 10.1128/IAI.65.1.219-226.1997; Buck AH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6488; Coakley G, 2017, CELL REP, V19, P1545, DOI 10.1016/j.celrep.2017.05.001; Covarrubias AJ, 2016, ELIFE, V5, DOI 10.7554/eLife.11612; Danilowicz-Luebert E, 2013, INT J PARASITOL, V43, P201, DOI 10.1016/j.ijpara.2012.10.014; Domin J, 2000, J BIOL CHEM, V275, P11943, DOI 10.1074/jbc.275.16.11943; Du LL, 2014, CELL IMMUNOL, V288, P1, DOI 10.1016/j.cellimm.2014.01.010; Eichenberger RM, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1428004; Etzerodt A, 2013, ANTIOXID REDOX SIGN, V18, P2352, DOI 10.1089/ars.2012.4834; Everts B, 2012, J EXP MED, V209, P1753, DOI 10.1084/jem.20111381; Hallowell RW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14208; Hassani K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095007; HECHTMAN P, 1979, AM J HUM GENET, V31, P428; Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514; Iyer SS, 2010, J IMMUNOL, V185, P6599, DOI 10.4049/jimmunol.1002041; Jayaprakash NG, 2017, BIOCHEM J, V474, P2333, DOI 10.1042/BCJ20170111; Khoo KH, 2001, ADV EXP MED BIOL, V491, P185; Klaver EJ, 2013, INT J PARASITOL, V43, P191, DOI 10.1016/j.ijpara.2012.10.021; Koo IC, 2008, P NATL ACAD SCI USA, V105, P710, DOI 10.1073/pnas.0708110105; Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113; Li YW, 2018, INT J NANOMED, V13, P467, DOI 10.2147/IJN.S151110; Liu JT, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007817; Maffucci T, 2005, J CELL BIOL, V169, P789, DOI 10.1083/jcb.200408005; Medzihradszky Katalin F., 2008, V446, P293, DOI 10.1007/978-1-60327-084-7_21; Morassutti AL, 2012, VECTOR-BORNE ZOONOT, V12, P961, DOI 10.1089/vbz.2011.0957; Nawaz M, 2019, ACTA TROP, V196, P30, DOI 10.1016/j.actatropica.2019.05.004; Nyame AK, 2003, EXP PARASITOL, V104, P1, DOI 10.1016/S0014-4894(03)00110-3; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Philippidis P, 2004, CIRC RES, V94, P119, DOI 10.1161/01.RES.0000109414.78907.F9; Prasanphanich NS, 2014, GLYCOBIOLOGY, V24, P619, DOI 10.1093/glycob/cwu027; Prieto-Lafuente L, 2009, J LEUKOCYTE BIOL, V85, P844, DOI 10.1189/jlb.0808459; Ramos-Benitez MJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05735-w; Restrepo BI, 2000, INT J PARASITOL, V30, P689, DOI 10.1016/S0020-7519(00)00057-6; Robinson MW, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002042; Rodriguez E, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004234; Sato T, 2014, METHODS MOL BIOL, V1200, P93, DOI 10.1007/978-1-4939-1292-6_8; Schieke SM, 2006, J BIOL CHEM, V281, P27643, DOI 10.1074/jbc.M603536200; Shen J, 2017, P NATL ACAD SCI USA, V114, P10214, DOI 10.1073/pnas.1708578114; Silva VO, 2018, PARASITE IMMUNOL, V40, DOI 10.1111/pim.12571; Soulat D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01838; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Torrecilhas ACT, 2009, MICROBES INFECT, V11, P29, DOI 10.1016/j.micinf.2008.10.003; Verissimo CM, 2016, EXP PARASITOL, V166, P137, DOI 10.1016/j.exppara.2016.04.012; Wan S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1071-2; Wang LF, 2015, PARASITOL RES, V114, P1865, DOI 10.1007/s00436-015-4373-7; Wei J, 2015, PARASITOL RES, V114, P3247, DOI 10.1007/s00436-015-4541-9; Weichhart T, 2009, TRENDS IMMUNOL, V30, P218, DOI 10.1016/j.it.2009.02.002; Wu F, 2016, PARASITOL RES, V115, P3737, DOI 10.1007/s00436-016-5135-x; Zhang JJ, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1007435; Zhao J, 2013, PARASITOL RES, V112, P2689, DOI 10.1007/s00436-013-3436-x; Zhao Z, 2017, CELL RES, V27, P849, DOI 10.1038/cr.2017.71; Zheng XP, 2008, J NEUROIMMUNOL, V194, P107, DOI 10.1016/j.jneuroim.2007.12.001; Zhu J, 2014, J PROTEOME RES, V13, P1713, DOI 10.1021/pr401200h; Ziegler T, 2015, J IMMUNOL, V194, P1555, DOI 10.4049/jimmunol.1401217	54	1	1	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 23	2021	12								685984	10.3389/fimmu.2021.685984	http://dx.doi.org/10.3389/fimmu.2021.685984			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TV3KW	34367145	Green Published, gold			2022-12-18	WOS:000681623100001
J	Cai, JY; Cui, XW; Wang, X; You, LH; Ji, CB; Cao, Y				Cai, Jinyang; Cui, Xianwei; Wang, Xing; You, Lianghui; Ji, Chenbo; Cao, Yan			A Novel Anti-Infective Peptide BCCY-1 With Immunomodulatory Activities	FRONTIERS IN IMMUNOLOGY			English	Article						anti-infective strategy; peptide; BCCY-1; innate immunity; monocyte	MILK; INFECTION; PHASE; MICE	Antibiotic resistance has been considered to be a global threat which underscores the need to develop novel anti-infective therapeutics. Modulation of innate immunity by synthetic peptides is an attractive strategy to overcome this circumstance. We recently reported that BCCY-1, a human beta-casein-derived peptide displays regulatory activities on monocytes, thereby enhancing their actions in innate immune responses. However, the function of peptide BCCY-1 in host defense against infection remains unknown. In this study, we investigated the in vivo characteristics and effects of peptide BCCY-1 in mouse models of bacterial infection. Following intraperitoneal injection, the peptide BCCY-1 exhibited high level of cellular uptake by monocytes without obvious toxicities. Results revealed that peptide BCCY-1, but not the scrambled version, stimulated the chemokine production and monocyte recruitment in vivo. Treatment with BCCY-1 enhanced the pathogen clearance and protected mice against lethal infections. Because the anti-infective effects of BCCY-1 was abolished by in vivo depletion of monocytes/macrophages rather than lymphocytes and granulocytes, we conclude that monocytes/macrophages are key effector cells in BCCY-1-mediated anti-infective protection. Additionally, BCCY-1 lacks direct antimicrobial activity. To our knowledge, a human beta-casein-derived peptide that counters infection by selective regulation of innate immunity has not been reported previously. These results suggest peptide BCCY-1 as a promising alternative approach and a valuable complement to current anti-infective strategy.	[Cai, Jinyang; Cui, Xianwei; Wang, Xing; You, Lianghui; Ji, Chenbo; Cao, Yan] Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Nanjing Matern & Child Hlth Care Inst, Womens Hosp, Nanjing, Peoples R China; [Cai, Jinyang] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Peoples R China	Nanjing Medical University; Nanjing Medical University	Cao, Y (corresponding author), Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Nanjing Matern & Child Hlth Care Inst, Womens Hosp, Nanjing, Peoples R China.	yancao@njmu.edu.cn			National Natural Science Foundation of China [81701491]; Natural Science Foundation of Jiangsu Province, China [BK20170152]; Science and Technology Development Foundation of Nanjing Medical University [2016NJMUZD060, 2017NJMU017]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province, China(Natural Science Foundation of Jiangsu Province); Science and Technology Development Foundation of Nanjing Medical University	This study was supported by National Natural Science Foundation of China (81701491); The Natural Science Foundation of Jiangsu Province, China (BK20170152); Science and Technology Development Foundation of Nanjing Medical University (2016NJMUZD060, 2017NJMU017).	Bjorn C, 2016, PEPTIDES, V81, P21, DOI 10.1016/j.peptides.2016.04.005; Cacho NT, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00584; Cai JY, 2021, FOOD CHEM, V348, DOI 10.1016/j.foodchem.2021.129111; Cai JY, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2020.151936; Casson CN, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006309; de Marcken M, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw1347; Harbeson D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01077; Hemshekhar M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01871; Hill DR, 2015, NUTR REV, V73, P463, DOI 10.1093/nutrit/nuv009; Jakala P, 2010, PHARMACEUTICALS-BASE, V3, P251, DOI 10.3390/ph3010251; Kamau SM, 2010, FOOD REV INT, V26, P386, DOI 10.1080/87559129.2010.496025; Kang SJ, 2008, IMMUNITY, V29, P819, DOI 10.1016/j.immuni.2008.09.017; Mohanty D, 2016, INT J FOOD PROP, V19, P837, DOI 10.1080/10942912.2015.1048356; Muller U, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02794; Nagpal R, 2011, FOOD FUNCT, V2, P18, DOI 10.1039/c0fo00016g; NAKANO Y, 1994, INFECT IMMUN, V62, P377, DOI 10.1128/IAI.62.2.377-383.1994; Narasaraju T, 2010, AM J RESP CELL MOL, V42, P732, DOI 10.1165/rcmb.2008-0423OC; Niyonsaba F, 2013, J LEUKOCYTE BIOL, V94, P159, DOI 10.1189/jlb.1012497; Pacios O, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9020065; Scott MG, 2007, NAT BIOTECHNOL, V25, P465, DOI 10.1038/nbt1288; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Silva ON, 2015, ANTIMICROB AGENTS CH, V59, P1625, DOI 10.1128/AAC.03732-14; Stables MJ, 2011, BLOOD, V118, pE192, DOI 10.1182/blood-2011-04-345330; Tu T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074124; Wada Y, 2014, J NUTR BIOCHEM, V25, P503, DOI 10.1016/j.jnutbio.2013.10.012; Wan J, 2013, BIOCHEM BIOPH RES CO, V438, P236, DOI 10.1016/j.bbrc.2013.07.068; Wang XY, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801247; Zisman DA, 1997, J CLIN INVEST, V99, P2832, DOI 10.1172/JCI119475	28	1	1	4	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 22	2021	12								713960	10.3389/fimmu.2021.713960	http://dx.doi.org/10.3389/fimmu.2021.713960			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TX0PJ	34367182	gold, Green Published			2022-12-18	WOS:000682793000001
J	de Jong, E; Lauzon-Joset, JF; Leffler, J; Serralha, M; Larcombe, AN; Christophersen, CT; Holt, PG; Strickland, DH; Bosco, A				de Jong, Emma; Lauzon-Joset, Jean-Francois; Leffler, Jonatan; Serralha, Michael; Larcombe, Alexander N.; Christophersen, Claus T.; Holt, Patrick G.; Strickland, Deborah H.; Bosco, Anthony			IRF7-Associated Immunophenotypes Have Dichotomous Responses to Virus/Allergen Coexposure and OM-85-Induced Reprogramming	FRONTIERS IN IMMUNOLOGY			English	Article						asthma exacerbation; rhinovirus; allergen; immunomodulation; IRF7; systems biology	GROWTH-FACTOR-BETA; ASTHMA EXACERBATIONS; ADHESION MOLECULES; IMMUNE-RESPONSES; DENDRITIC CELLS; RISK; SUSCEPTIBILITY; INFECTION; SEVERITY; ATOPY	High risk for virus-induced asthma exacerbations in children is associated with an IRF7lo immunophenotype, but the underlying mechanisms are unclear. Here, we applied a Systems Biology approach to an animal model comprising rat strains manifesting high (BN) versus low susceptibility (PVG) to experimental asthma, induced by virus/allergen coexposure, to elucidate the mechanism(s)-of-action of the high-risk asthma immunophenotype. We also investigated potential risk mitigation via pretreatment with the immune training agent OM-85. Virus/allergen coexposure in low-risk PVG rats resulted in rapid and transient airways inflammation alongside IRF7 gene network formation. In contrast, responses in high-risk BN rats were characterized by severe airways eosinophilia and exaggerated proinflammatory responses that failed to resolve, and complete absence of IRF7 gene networks. OM-85 had more profound effects in high-risk BN rats, inducing immune-related gene expression changes in lung at baseline and reducing exaggerated airway inflammatory responses to virus/allergen coexposure. In low-risk PVG rats, OM-85 boosted IRF7 gene networks in the lung but did not alter baseline gene expression or cellular influx. Distinct IRF7-associated asthma risk immunophenotypes have dichotomous responses to virus/allergen coexposure and respond differentially to OM-85 pretreatment. Extrapolating to humans, our findings suggest that the beneficial effects OM-85 pretreatment may preferentially target those in high-risk subgroups.	[de Jong, Emma; Lauzon-Joset, Jean-Francois; Leffler, Jonatan; Serralha, Michael; Larcombe, Alexander N.; Holt, Patrick G.; Strickland, Deborah H.; Bosco, Anthony] Telethon Kids Inst, Perth, WA, Australia; [de Jong, Emma; Leffler, Jonatan; Bosco, Anthony] Univ Western Australia, Nedlands, WA, Australia; [Lauzon-Joset, Jean-Francois] Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, Quebec City, PQ, Canada; [Larcombe, Alexander N.] Curtin Univ, Sch Publ Hlth, Perth, WA, Australia; [Christophersen, Claus T.] Curtin Univ, WA Human Microbiome Collaborat Ctr, Sch Mol & Life Sci, Bentley, WA, Australia; [Christophersen, Claus T.] Edith Cowan Univ, Ctr Integrat Metabol & Computat Biol, Sch Med & Hlth Sci, Joondalup, WA, Australia	Telethon Kids Institute; University of Western Australia; Laval University; Curtin University; Curtin University; Edith Cowan University	Bosco, A (corresponding author), Telethon Kids Inst, Perth, WA, Australia.; Bosco, A (corresponding author), Univ Western Australia, Nedlands, WA, Australia.	anthony.bosco@telethonkids.org.au	Bosco, Anthony/AAC-6900-2022; Strickland, Deborah/AGV-6937-2022; Serralha, Michael/CAA-0940-2022; Leffler, Jonatan/A-8748-2018; de Jong, Emma/AHC-9300-2022; Christophersen, Claus T/C-5512-2008; Holt, Patrick/H-1548-2011	Strickland, Deborah/0000-0003-0114-4201; Leffler, Jonatan/0000-0001-5674-8462; de Jong, Emma/0000-0002-2501-6119; Serralha, Michael/0000-0002-0121-2879; Lauzon-Joset, Jean-Francois/0000-0002-6915-3967; Bosco, Anthony/0000-0002-4335-615X; Christophersen, Claus T/0000-0003-1591-5871; Holt, Patrick/0000-0003-1193-0935	NHMRC [1129996]; Fonds de recherche du Quebec en Sante	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Fonds de recherche du Quebec en Sante(Fonds de la Recherche en Sante du Quebec)	This study was supported by NHMRC 1129996. JFLJ was supported by a fellowship from the Fonds de recherche du Quebec en Sante.	Altman MC, 2019, NAT IMMUNOL, V20, P637, DOI 10.1038/s41590-019-0347-8; Andrews S, FASTQC QUALITY CONTR; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; BESSLER WG, 1990, LUNG, V168, P707, DOI 10.1007/BF02718197; BESSLER WG, 1993, ARZNEIMITTEL-FORSCH, V43-1, P502; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Bosco A, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2405-z; Bosco A, 2012, J ALLERGY CLIN IMMUN, V129, P88, DOI 10.1016/j.jaci.2011.10.038; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/nmeth.3869, 10.1038/NMETH.3869]; Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055; Cardinale F, 2020, EXPERT REV RESP MED, V14, P1019, DOI 10.1080/17476348.2020.1793673; Chiu CY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70528-7; Ciancanelli MJ, 2015, SCIENCE, V348, P448, DOI 10.1126/science.aaa1578; Davis NM, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0605-2; DeVries A, 2017, J ALLERGY CLIN IMMUN, V140, P534, DOI 10.1016/j.jaci.2016.10.041; DUCHOW J, 1992, INT J IMMUNOPHARMACO, V14, P761, DOI 10.1016/0192-0561(92)90073-T; Durack J, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00528; Esposito S, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2040-y; Fazlollahi M, 2018, J ALLERGY CLIN IMMUN, V142, P834, DOI 10.1016/j.jaci.2018.02.020; Fitzgerald-Bocarsly P, 2008, CYTOKINE GROWTH F R, V19, P3, DOI 10.1016/j.cytogfr.2007.10.006; Gern JE, 2020, J ALLERGY CLIN IMMUN, V146, P513, DOI 10.1016/j.jaci.2020.06.031; Halwani R, 2011, AM J RESP CELL MOL, V44, P127, DOI 10.1165/rcmb.2010-0027TR; Hollams EM, 2009, J ALLERGY CLIN IMMUN, V124, P463, DOI 10.1016/j.jaci.2009.06.019; Holt PG, 2011, CHEST, V139, P1165, DOI 10.1378/chest.10-2397; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Janulaityte I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051837; Jones AC, 2019, AM J RESP CRIT CARE, V199, P1537, DOI 10.1164/rccm.201804-0715OC; Khoo SK, 2019, J IMMUNOL, V202, P1845, DOI 10.4049/jimmunol.1800178; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lassmann T, 2011, BIOINFORMATICS, V27, P130, DOI 10.1093/bioinformatics/btq614; Lauzon-Joset JF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01805; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Loh ZX, 2020, PLOS PATHOG, V16, DOI [10.1371/journal.ppat.1008651, 10.1371/journal.ppat.1008651.r001, 10.1371/journal.ppat.1008651.r002, 10.1371/journal.ppat.1008651.r003, 10.1371/journal.ppat.1008651.r004]; Loss GJ, 2016, AM J RESP CRIT CARE, V193, P889, DOI 10.1164/rccm.201507-1493OC; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006; Marchant A, 1996, INT J IMMUNOPHARMACO, V18, P259, DOI 10.1016/0192-0561(96)84505-X; Martin LR, 1996, J VIROL, V70, P2027, DOI 10.1128/JVI.70.3.2027-2031.1996; Martin M., 2011, EMBNET J, V17, P5, DOI 10.14806/ej.17.1.200; Martinez FD, 2019, IMMUNOL ALLERGY CLIN, V39, P141, DOI 10.1016/j.iac.2018.12.001; Mincham KT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.601494; Mincham KT, 2018, J CLIN INVEST, V128, P4856, DOI 10.1172/JCI122631; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Olafsdottir TA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14144-8; Parks DH, 2018, NAT BIOTECHNOL, V36, P996, DOI 10.1038/nbt.4229; Parola C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082867; Pasquali C, 2014, FRONT MED, V1, DOI 10.3389/fmed.2014.00041; Ravi A, 2019, CLIN EXP ALLERGY, V49, P1587, DOI 10.1111/cea.13481; Rosenthal LA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032061; Rosenthal LA, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-122; Rozy Adriana, 2008, Pneumonol Alergol Pol, V76, P353; Samitas K, 2018, ALLERGY, V73, P993, DOI 10.1111/all.13373; Savage JH, 2018, ALLERGY, V73, P145, DOI 10.1111/all.13232; Scott NM, 2017, MUCOSAL IMMUNOL, V10, P789, DOI 10.1038/mi.2016.85; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Strickland DH, 2012, MUCOSAL IMMUNOL, V5, P332, DOI 10.1038/mi.2012.13; Strickland DH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111520; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Wang L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13734-w; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Xi Y, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01351; Yang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079729; Zhou GY, 2019, NUCLEIC ACIDS RES, V47, pW234, DOI 10.1093/nar/gkz240	70	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 22	2021	12								699633	10.3389/fimmu.2021.699633	http://dx.doi.org/10.3389/fimmu.2021.699633			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TX0QG	34367159	Green Published, gold			2022-12-18	WOS:000682795400001
J	Zhang, J; Huang, XJ; Tang, WM; Chu, ZX; Hu, QH; Liu, J; Ding, HB; Han, XX; Zhang, ZN; Jiang, YJ; Geng, WQ; Xia, W; Xu, JJ; Shang, H				Zhang, Jing; Huang, Xiao-jie; Tang, Wei-ming; Chu, Zhenxing; Hu, Qinghai; Liu, Jing; Ding, Haibo; Han, Xiaoxu; Zhang, Zining; Jiang, Yong-jun; Geng, Wenqing; Xia, Wei; Xu, Junjie; Shang, Hong			Rapid Clinical Progression and Its Correlates Among Acute HIV Infected Men Who Have Sex With Men in China: Findings From a 5-Year Multicenter Prospective Cohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; Antiretroviral (ARV); MSM; acute infection; rapid progressor	CD4 CELL COUNT; DISEASE PROGRESSION; VIRAL LOAD; LYMPHOCYTE COUNT; RISK; AIDS; ACQUISITION; PROGNOSIS; ANEMIA; IMPACT	Background In the "treat all " era, there are few data on the nature of HIV clinical progression in middle-income countries. The aim of the current study was to prospectively analyze the clinical progression of HIV and its indicators among men in China with acute HIV who have sex with men. & nbsp; Methods From 2009-2014 a total of 400 men with acute HIV infection (AHI) were identified among 7,893 men who have sex with men via periodic pooled nucleic acid amplification testing, and they were assigned to an AHI prospective cohort in Beijing and Shenyang, China. Rapid progression was defined as two consecutive CD4(+) T cell counts < 350/mu L within 3-24 months post-infection. Kaplan-Meier and Cox-regression analyses were conducted to identify predictors of rapid progression. & nbsp; Results Among 400 men with AHI 46.5% were rapid progressors, 35.1% reached rapid progressor status by 12 months post-infection, and 63.9% reached rapid progressor status by 24 months. Rapid progression was associated with herpes simplex-2 virus coinfection (adjusted hazard ratio [aHR] 1.7, 95% confidence interval [CI] 1.2-2.3], depression (aHR 1.9, 95% CI 1.5-2.6), baseline CD4(+) T cell count < 500/mu L (aHR 3.5, 95% CI 2.4-5.1), higher baseline HIV viral load (aHR 1.6, 95% CI 1.2-2.3), acute symptoms lasting >= 2 weeks (aHR 1.6, 95% CI 1.1-2.2), higher body mass index (aHR 0.9, 95% CI 0.9-1.0), higher HIV viral load (aHR 1.7, 95% CI 1.4-2.1), set point viral load at 3 months (aHR 2.0, 95% CI 1.6-2.5), each 100-cell/mu L decrease in CD4(+) T cell count at 3 months (aHR 2.2, 95% CI 1.9-2.5), and baseline routine blood tests including white blood cell count < 5.32, hemoglobin >= 151, mean corpuscular hemoglobin >= 30.5, hemoglobin concentration >= 342, mean platelet count >= 342, lymphocytes >= 1.98, and mixed cell count >= 0.4 (all p < 0.05). & nbsp; Conclusion Almost half of the patients underwent rapid clinical progression within 2 years after HIV infection. A treat-all policy is necessary and should be strengthened globally. Rapid progression was correlated with herpes simplex-2 virus coinfection, depression, low CD4(+) T cell counts, and high set point viral load in acute infection stage. Rapid progression can be identified via simple indicators such as body mass index and routine blood test parameters in low and middle-income countries.	[Zhang, Jing; Chu, Zhenxing; Hu, Qinghai; Liu, Jing; Ding, Haibo; Han, Xiaoxu; Zhang, Zining; Jiang, Yong-jun; Geng, Wenqing; Xu, Junjie; Shang, Hong] China Med Univ, NHC Key Lab Aids Immunol, Natl Clin Res Ctr Lab Med, Affiliated Hosp 1, Shenyang, Peoples R China; [Zhang, Jing; Chu, Zhenxing; Hu, Qinghai; Liu, Jing; Ding, Haibo; Han, Xiaoxu; Zhang, Zining; Jiang, Yong-jun; Geng, Wenqing; Xu, Junjie; Shang, Hong] Chinese Acad Med Sci, Key Lab Aids Immunol, Shenyang, Peoples R China; [Zhang, Jing; Chu, Zhenxing; Hu, Qinghai; Liu, Jing; Ding, Haibo; Han, Xiaoxu; Zhang, Zining; Jiang, Yong-jun; Geng, Wenqing; Xu, Junjie; Shang, Hong] Key Lab AIDS Immunol Liaoning Prov, Shenyang, Peoples R China; [Zhang, Jing; Chu, Zhenxing; Hu, Qinghai; Liu, Jing; Ding, Haibo; Han, Xiaoxu; Zhang, Zining; Jiang, Yong-jun; Geng, Wenqing; Xu, Junjie; Shang, Hong] Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Peoples R China; [Huang, Xiao-jie; Xia, Wei] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China; [Tang, Wei-ming] Southern Med Univ, Dermatol Hosp, Guangzhou, Peoples R China; [Tang, Wei-ming] Univ North Carolina Project China, Guangzhou, Peoples R China; [Tang, Wei-ming] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA	China Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Collaborative Innovation Center for Diagnosis & Treatment of Infectious Diseases; Capital Medical University; Southern Medical University - China; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Xu, JJ; Shang, H (corresponding author), China Med Univ, NHC Key Lab Aids Immunol, Natl Clin Res Ctr Lab Med, Affiliated Hosp 1, Shenyang, Peoples R China.; Xu, JJ; Shang, H (corresponding author), Chinese Acad Med Sci, Key Lab Aids Immunol, Shenyang, Peoples R China.; Xu, JJ; Shang, H (corresponding author), Key Lab AIDS Immunol Liaoning Prov, Shenyang, Peoples R China.; Xu, JJ; Shang, H (corresponding author), Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Peoples R China.	xjjcmu@163.com; hongshang100@hotmail.com			National Science and Technology Major Project of China during the 13th Five-year plan period [2017ZX10201101]; Beijing Excellent Talent Plan [2018000021223ZK04]; National Institutes of Health [NIAID 1R01AI114310-01]; UNC-South China STD Research Training Center [FIC 1D43TW009532-01]; UNC Centerfor AIDS Research [NIAID 5P30AI050410]; Beijing Talent Project in the New Millennium [2020A35]; Mega-Project of National Science Research (11th Five-Year Plan) [2008ZX10001-001]; Mega-Project of National Science Research (12th Five-Year Plan) [2012ZX10001-006]; Mega-Project of National Science Research (13th Five-Year Plan) [2017ZX10201101]	National Science and Technology Major Project of China during the 13th Five-year plan period; Beijing Excellent Talent Plan; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UNC-South China STD Research Training Center; UNC Centerfor AIDS Research; Beijing Talent Project in the New Millennium; Mega-Project of National Science Research (11th Five-Year Plan); Mega-Project of National Science Research (12th Five-Year Plan); Mega-Project of National Science Research (13th Five-Year Plan)	This study was funded by the Mega-Projects of National Science Research (11th Five-Year Plan [2008ZX10001-001], 12th Five-Year Plan [2012ZX10001-006], and 13th Five-Year Plan [2017ZX10201101]), the National Science and Technology Major Project of China during the 13th Five-year plan period (2017ZX10201101), the Beijing Excellent Talent Plan (2018000021223ZK04), the Beijing Talent Project in the New Millennium (2020A35), the National Institutes of Health (NIAID 1R01AI114310-01), UNC-South China STD Research Training Center (FIC 1D43TW009532-01), and the UNC Centerfor AIDS Research (NIAID 5P30AI050410).	Altinbas K, 2014, J AFFECT DISORDERS, V152, P478, DOI 10.1016/j.jad.2013.07.032; Barnabas RV, 2011, JAIDS-J ACQ IMM DEF, V57, P238, DOI 10.1097/QAI.0b013e31821acb5; Beral V, 2004, AIDS, V18, P51, DOI [10.1097/00002030-200401020-00006, 10.1097/01.aids.0000096908.73209.5d]; Passaes CPB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101780; Brazier E, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25331; Chida Y, 2009, BRAIN BEHAV IMMUN, V23, P434, DOI 10.1016/j.bbi.2009.01.013; Chow EPF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089959; Cohen MS, 2010, J INFECT DIS, V202, pS270, DOI 10.1086/655651; Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7; Gao L, 2009, SEX TRANSM INFECT, V85, P354, DOI 10.1136/sti.2008.034702; Goujard C, 2006, CLIN INFECT DIS, V42, P709, DOI 10.1086/500213; HENRARD DR, 1995, J ACQ IMMUN DEF SYND, V9, P305; Huang XJ, 2013, JAIDS-J ACQ IMM DEF, V62, P441, DOI 10.1097/QAI.0b013e31827f5c9a; Ioannidis JPA, 1999, J ACQ IMMUN DEF SYND, V20, P129, DOI 10.1097/00042560-199902010-00004; Jiang Hui-hui, 2013, Zhonghua Yu Fang Yi Xue Za Zhi, V47, P843; Jiao YM, 2012, VIRAL IMMUNOL, V25, P262, DOI 10.1089/vim.2012.0035; Leserman J, 2002, PSYCHOL MED, V32, P1059, DOI 10.1017/S0033291702005949; Li XS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089462; Marcus JL, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.7954; McLaren PJ, 2015, NAT IMMUNOL, V16, P577, DOI 10.1038/ni.3147; Minga AK, 2011, AIDS, V25, P819, DOI 10.1097/QAD.0b013e32834625d3; Mlisana K, 2014, CLIN INFECT DIS, V59, P1322, DOI 10.1093/cid/ciu573; Mocroft A, 1999, AIDS, V13, P943, DOI 10.1097/00002030-199905280-00010; National Health and Family Planning Commission of the People's Republic of China, 2014, UPD GUID US FREE ANT UPD GUID US FREE ANT; 中国疾病预防控制中心, 2017, [中国艾滋病性病, Chinese JOurnal of Aids & STD], V23, P93; Phillips AN, 2006, CURR OPIN HIV AIDS, V1, P43, DOI 10.1097/01.COH.0000194106.12816.b1; Smiley CL, 2021, LANCET HIV, V8, pe266, DOI 10.1016/S2352-3018(20)30358-1; Spacek LA, 2003, AIDS, V17, P1311, DOI 10.1097/00002030-200306130-00005; Sullivan PS, 1998, BLOOD, V91, P301, DOI 10.1182/blood.V91.1.301.301_301_308; Teixeira SLM, 2014, GENES IMMUN, V15, P256, DOI 10.1038/gene.2014.14; van Leth F, 2005, AIDS, V19, P463, DOI 10.1097/01.aids.0000162334.12815.5b; WHO, TREAT ALL END AIDS; World Health Organization, 2002, SCAL ANT THER RES LT; Wu HaiBin, 2013, Disease Surveillance, V28, P829; Yan HJ, 2014, AIDS BEHAV, V18, pS5, DOI 10.1007/s10461-013-0520-2; Zhang W, 2016, SEX HEALTH, V13, P373, DOI 10.1071/SH16001; Zhang YH, 2015, AIDS, V29, P889, DOI 10.1097/QAD.0000000000000632; Zhang ZN, 2013, CLIN CHEM, V59, P1175, DOI 10.1373/clinchem.2012.197335	38	1	1	3	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 22	2021	12								712802	10.3389/fimmu.2021.712802	http://dx.doi.org/10.3389/fimmu.2021.712802			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TY5FB	34367176	Green Published, gold			2022-12-18	WOS:000683809100001
J	Ameratunga, R; Longhurst, H; Lehnert, K; Steele, R; Edwards, ESJ; Woon, ST				Ameratunga, Rohan; Longhurst, Hilary; Lehnert, Klaus; Steele, Richard; Edwards, Emily S. J.; Woon, See-Tarn			Are All Primary Immunodeficiency Disorders Inborn Errors of Immunity?	FRONTIERS IN IMMUNOLOGY			English	Article						inborn error of immunity; primary immunodeficiency; THI; common variable immunodeficiency disorders; THA	COMMON VARIABLE IMMUNODEFICIENCY; DEFICIENCY; TACI		[Ameratunga, Rohan; Longhurst, Hilary] Auckland Hosp, Dept Clin Immunol, Auckland, New Zealand; [Ameratunga, Rohan; Steele, Richard; Woon, See-Tarn] Auckland Hosp, Dept Virol & Immunol, Auckland, New Zealand; [Ameratunga, Rohan] Univ Auckland, Sch Med, Dept Mol Med & Pathol, Fac Med & Hlth Sci, Auckland, New Zealand; [Longhurst, Hilary] Univ Auckland, Sch Med, Dept Med, Fac Med & Hlth Sci, Auckland, New Zealand; [Lehnert, Klaus] Univ Auckland, Sch Biol Sci, Auckland, New Zealand; [Edwards, Emily S. J.] Monash Univ, Dept Pathol & Immunol, Cent Clin Sch, Cell Differentiat Lab B, Melbourne, Vic, Australia	Auckland City Hospital; Auckland City Hospital; University of Auckland; University of Auckland; University of Auckland; Monash University	Ameratunga, R (corresponding author), Auckland Hosp, Dept Clin Immunol, Auckland, New Zealand.; Ameratunga, R (corresponding author), Auckland Hosp, Dept Virol & Immunol, Auckland, New Zealand.; Ameratunga, R (corresponding author), Univ Auckland, Sch Med, Dept Mol Med & Pathol, Fac Med & Hlth Sci, Auckland, New Zealand.	rohana@adhb.govt.nz						Abolhassani H, 2020, BLOOD, V135, P656, DOI 10.1182/blood.2019000929; Aggarwal V, 2020, GENES DIS, V7, P26, DOI 10.1016/j.gendis.2019.10.002; Al-Herz W, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03146; Albin-Leeds S, 2017, CLIN IMMUNOL, V183, P36, DOI 10.1016/j.clim.2017.07.002; Ameratunga R, 2021, CLIN EXP IMMUNOL, V204, P352, DOI 10.1111/cei.13595; Ameratunga R, 2019, CLIN EXP IMMUNOL, V198, P224, DOI 10.1111/cei.13345; Ameratunga R, 2013, CLIN EXP IMMUNOL, V174, P203, DOI 10.1111/cei.12178; Ameratunga R, 2021, CLIN REV ALLERG IMMU, V61, P226, DOI 10.1007/s12016-020-08828-z; Ameratunga R, 2020, IMMUNOL ALLERGY CLIN, V40, P403, DOI 10.1016/j.iac.2020.03.001; Ameratunga R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02678; Ameratunga R, 2020, CLIN REV ALLERG IMMU, V59, P109, DOI 10.1007/s12016-019-08765-6; Ameratunga R, 2018, EXPERT REV CLIN IMMU, V14, P549, DOI 10.1080/1744666X.2018.1481750; Ameratunga R, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01965; Ameratunga R, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.41; Ameratunga R, 2011, ANN NY ACAD SCI, V1238, P53, DOI 10.1111/j.1749-6632.2011.06238.x; Ameratunga Rohan, 2010, Allergy Asthma Clin Immunol, V6, P12, DOI 10.1186/1710-1492-6-12; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; BRUTON O C, 1953, Med Ann Dist Columbia, V22, P648; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; CLARK JA, 1983, AM J CLIN PATHOL, V80, P210, DOI 10.1093/ajcp/80.2.210; Duraisingham SS, 2014, EXPERT REV CLIN IMMU, V10, P583, DOI 10.1586/1744666X.2014.902314; Edwards ESJ, 2021, CELL MOL IMMUNOL, V18, P588, DOI 10.1038/s41423-020-00520-8; Fliegauf M, 2015, AM J HUM GENET, V97, P389, DOI 10.1016/j.ajhg.2015.07.008; GOOD RA, 1991, IMMUNOL TODAY, V12, P283, DOI 10.1016/0167-5699(91)90127-F; Ishimura M, 2011, J CLIN IMMUNOL, V31, P968, DOI 10.1007/s10875-011-9594-7; Koopmans W, 2013, J CLIN IMMUNOL, V33, P68, DOI 10.1007/s10875-012-9793-x; Maffucci P, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00220; Malphettes M, 2015, CLIN INFECT DIS, V61, pE13, DOI 10.1093/cid/civ269; Pan-Hammarstrom Q, 2007, NAT GENET, V39, P429, DOI 10.1038/ng0407-429; Rhim JW, 2012, J KOREAN MED SCI, V27, P788, DOI 10.3346/jkms.2012.27.7.788; Rodriguez-Cortez VC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8335; Seidel MG, 2019, J ALLER CL IMM-PRACT, V7, P1763, DOI 10.1016/j.jaip.2019.02.004; Son Sohee, 2021, Clin Exp Pediatr, V64, P141, DOI 10.3345/cep.2019.01347; Swain S, 2019, J TRANSL AUTOIMMUN, V2, DOI 10.1016/j.jtauto.2019.100025; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; TILLER TL, 1978, J PEDIATR-US, V92, P347, DOI 10.1016/S0022-3476(78)80417-X; Tseng CW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140473; Zhang SL, 2020, J ALLERGY CLIN IMMUN, V145, pAB214	38	1	1	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 21	2021	12								706796	10.3389/fimmu.2021.706796	http://dx.doi.org/10.3389/fimmu.2021.706796			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TU4YJ	34367167	gold, Green Published			2022-12-18	WOS:000681043600001
J	Ferreira, H; Mendes, MA; Barbosa, MGD; de Oliveira, EB; Sales, AM; Moraes, MO; Sarno, EN; Pinheiro, RO				Ferreira, Helen; Mendes, Mayara Abud; Barbosa, Mayara Garcia de Mattos; de Oliveira, Eliane Barbosa; Sales, Anna Maria; Moraes, Milton Ozorio; Sarno, Euzenir Nunes; Pinheiro, Roberta Olmo			Potential Role of CXCL10 in Monitoring Response to Treatment in Leprosy Patients	FRONTIERS IN IMMUNOLOGY			English	Article						leprosy; skin cells; IFN-gamma; CXCL-10; multidrug therapy	MULTIDRUG THERAPY; GAMMA-INTERFERON; IMMUNE-RESPONSES; ARGININE METABOLISM; GENE-EXPRESSION; CYTOKINES; ARGINASE; PATHOGENESIS; RECEPTOR; SKIN	The treatment of multibacillary cases of leprosy with multidrug therapy (MDT) comprises 12 doses of a combination of rifampicin, dapsone and clofazimine. Previous studies have described the immunological phenotypic pattern in skin lesions in multibacillary patients. Here, we evaluated the effect of MDT on skin cell phenotype and on the Mycobacterium leprae-specific immune response. An analysis of skin cell phenotype demonstrated a significant decrease in MRS1 (SR-A), CXCL10 (IP-10) and IFNG (IFN-gamma) gene and protein expression after MDT release. Patients were randomized according to whether they experienced a reduction in bacillary load after MDT. A reduction in CXCL10 (IP-10) in sera was associated with the absence of a reduction in the bacillary load at release. Although IFN-gamma production in response to M. leprae was not affected by MDT, CXCL10 (IP-10) levels in response to M. leprae increased in cells from patients who experienced a reduction in bacillary load after treatment. Together, our results suggest that CXCL10 (IP-10) may be a good marker for monitoring treatment efficacy in multibacillary patients.	[Ferreira, Helen; Mendes, Mayara Abud; de Oliveira, Eliane Barbosa; Sales, Anna Maria; Moraes, Milton Ozorio; Sarno, Euzenir Nunes; Pinheiro, Roberta Olmo] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Leprosy Lab, Rio De Janeiro, Brazil; [Barbosa, Mayara Garcia de Mattos] Univ Michigan, Dept Surg, Cascalho Platt Lab, Ann Arbor, MI 48109 USA	Fundacao Oswaldo Cruz; University of Michigan System; University of Michigan	Pinheiro, RO (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Leprosy Lab, Rio De Janeiro, Brazil.	robertaolmo@gmail.com	Moraes, Milton Ozório/G-9753-2011; Moraes, Milton/AFF-1842-2022; Pinheiro, Roberta/A-2525-2013	Moraes, Milton Ozório/0000-0003-2653-0037; Pinheiro, Roberta/0000-0001-8471-4227	CAPES; FAPERJ; CNPq; National Council for Scientific and Technological Development (CNPq) [303834/2017-0]; Rio de Janeiro Carlos Chagas Filho Research Foundation (FAPERJ) [E-26/010.002231/2019]	CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); FAPERJ(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Rio de Janeiro Carlos Chagas Filho Research Foundation (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ))	We thank CAPES, FAPERJ, and CNPq funding institutions for all their financial support. National Council for Scientific and Technological Development (CNPq) - Finance Code 303834/2017-0. Rio de Janeiro Carlos Chagas Filho Research Foundation (FAPERJ) - Finance Code E-26/010.002231/2019.	Aamir M, 2018, CURR TOP MED CHEM, V18, P1550, DOI 10.2174/1568026618666181025100434; Albina JE, 1995, J LEUKOCYTE BIOL, V58, P643, DOI 10.1002/jlb.58.6.643; [Anonymous], 2014, Wkly Epidemiol Rec, V89, P389; Attia EAS, 2014, ARCH DERMATOL RES, V306, P793, DOI 10.1007/s00403-014-1486-2; Bittencourt TL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.674241; Brancato SK, 2011, AM J PATHOL, V178, P19, DOI 10.1016/j.ajpath.2010.08.003; Cassirer-Costa F, 2017, CYTOKINE, V97, P42, DOI 10.1016/j.cyto.2017.05.020; Cogen AL, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001869; da Silva Prata R.B., 2019, MACROPHAGES ACTIVATI, P1, DOI [10.5772/INTECHOPEN.88754IntechOpen, DOI 10.5772/INTECHOPEN.88754INTECHOPEN]; de Macedo CS, 2015, J MASS SPECTROM, V50, P1374, DOI 10.1002/jms.3708; Barbosa MGD, 2017, MICROBES INFECT, V19, P505, DOI 10.1016/j.micinf.2017.06.006; de Sousa JR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01635; Sales JD, 2011, CLIN EXP IMMUNOL, V165, P251, DOI 10.1111/j.1365-2249.2011.04412.x; Debol SM, 1997, J LEUKOCYTE BIOL, V62, P827, DOI 10.1002/jlb.62.6.827; Degang Y, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001936; dos Santos DF, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006086; Dyer KD, 2009, BLOOD, V114, P2649, DOI 10.1182/blood-2009-01-199497; Ferrari SM, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/5878960; Freitas AA, 2015, DIAGN MICR INFEC DIS, V83, P154, DOI 10.1016/j.diagmicrobio.2015.06.021; Froes LAR, 2022, INT REV IMMUNOL, V41, P72, DOI 10.1080/08830185.2020.1851370; Fulco TD, 2014, INFECT IMMUN, V82, P3968, DOI 10.1128/IAI.02194-14; Geluk A, 2014, J CLIN IMMUNOL, V34, P245, DOI 10.1007/s10875-013-9979-x; Geluk A, 2012, J IMMUNOL, V188, P4782, DOI 10.4049/jimmunol.1103452; Graham A., 2010, INFECT DIS CLIN PRAC, V18, P235, DOI [10.1097/IPC.0b013e3181deba2a, DOI 10.1097/IPC.0B013E3181DEBA2A]; Hungria EM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00915; JANSEN A, 1992, KIDNEY INT, V42, P1107, DOI 10.1038/ki.1992.394; Job C.K., 1994, LEPROSY, V. p, P93; Kamble R R, 2010, Indian J Lepr, V82, P23; Kampfer H, 2003, J INVEST DERMATOL, V121, P1544, DOI 10.1046/j.1523-1747.2003.12610.x; KAPLAN G, 1987, J EXP MED, V166, P1098, DOI 10.1084/jem.166.4.1098; Kelsen SG, 2004, AM J PHYSIOL-LUNG C, V287, pL584, DOI 10.1152/ajplung.00453.2003; Lima MCBS, 2000, SCAND J IMMUNOL, V51, P419, DOI 10.1046/j.1365-3083.2000.00703.x; Liu ML, 2011, CYTOKINE GROWTH F R, V22, P121, DOI 10.1016/j.cytogfr.2011.06.001; Lo BKK, 2010, AM J PATHOL, V176, P2435, DOI 10.2353/ajpath.2010.081059; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; Massone C, 2015, CLIN DERMATOL, V33, P38, DOI 10.1016/j.clindermatol.2014.10.003; Miao MY, 2012, WOUND REPAIR REGEN, V20, P203, DOI 10.1111/j.1524-475X.2012.00772.x; MODLIN RL, 1994, J INVEST DERMATOL, V102, P828, DOI 10.1111/1523-1747.ep12381958; Montoya D, 2010, ADV IMMUNOL, V105, P1, DOI 10.1016/S0065-2776(10)05001-7; Montoya D, 2009, CELL HOST MICROBE, V6, P343, DOI 10.1016/j.chom.2009.09.002; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Moubasher AEDA, 1998, INT J DERMATOL, V37, P733, DOI 10.1046/j.1365-4362.1998.00381.x; Moura DF, 2012, EUR J IMMUNOL, V42, P2925, DOI 10.1002/eji.201142198; Mu XQ, 2013, CHEMOTHERAPY, V59, P395, DOI 10.1159/000358818; Munder M, 2005, BLOOD, V105, P2549, DOI 10.1182/blood-2004-07-2521; Nobre ML, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005364; Novak ML, 2013, J LEUKOCYTE BIOL, V93, P875, DOI 10.1189/jlb.1012512; Nunzi E., 2012, C MAGAZINE, P115; PARAK RB, 1991, BIOTHERAPY, V3, P265, DOI 10.1007/BF02171691; Pinheiro RO, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00518; Polycarpou A, 2013, CURR OPIN INFECT DIS, V26, P413, DOI 10.1097/QCO.0b013e3283638b04; Raes G, 2005, J IMMUNOL, V174, P6561, DOI 10.4049/jimmunol.174.11.6561; Ren YZR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004009; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; RIDLEY DS, 1974, B WORLD HEALTH ORGAN, V51, P451; Shearer JD, 1997, AM J PHYSIOL-ENDOC M, V272, pE181, DOI 10.1152/ajpendo.1997.272.2.E181; SHINDE SR, 1993, INT J LEPROSY, V61, P51; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Suda T, 2005, BRIT J DERMATOL, V152, P887, DOI 10.1111/j.1365-2133.2005.06559.x; Tamaru M, 1998, BIOCHEM BIOPH RES CO, V251, P41, DOI 10.1006/bbrc.1998.9404; White C, 2015, CLIN MICROBIOL REV, V28, P80, DOI 10.1128/CMR.00079-13; WHO World Health Organization, 2020, MDT DUR TREAT FAQ MDT DUR TREAT FAQ; Witte MB, 2002, J SURG RES, V105, P35, DOI 10.1006/jsre.2002.6443	64	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 20	2021	12								662307	10.3389/fimmu.2021.662307	http://dx.doi.org/10.3389/fimmu.2021.662307			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TT6SJ	34354699	gold, Green Published			2022-12-18	WOS:000680476000001
J	Li, QJ; Yuan, M; Jiao, X; Huang, YF; Li, J; Li, D; Ji, MM; Wang, GY				Li, Qiuju; Yuan, Ming; Jiao, Xue; Huang, Yufei; Li, Jing; Li, Dong; Ji, Miaomiao; Wang, Guoyun			M1 Macrophage-Derived Nanovesicles Repolarize M2 Macrophages for Inhibiting the Development of Endometriosis	FRONTIERS IN IMMUNOLOGY			English	Article						endometriosis; macrophage polarization; reprogramming; extracellular vesicles; treatment	PERITONEAL-MACROPHAGES; STROMAL CELLS; MIGRATION; PROMOTES; INVASION	Background Endometriosis is a common nonmalignant gynecological disorder that affects 10-15% women of reproductive age and causes several symptoms that result in decreased quality of life and a huge social burden. In recent decades, extracellular vesicles (EVs) have gained attention as a potential therapeutic tool; however, the therapeutic effects of EVs against endometriosis have not been reported. Accordingly, in this study, we investigated the feasibility of nanovesicles (NVs) derived from M1 macrophages (M1NVs) in treating endometriosis. Methods M1NVs were prepared by serial extrusion. Co-culture assays were performed to investigate changes in tube formation and migration/invasion of eutopic endometrial stroma cells (ESCs) obtained from patients with endometriosis (EM-ESCs). A mouse model of endometriosis was established, and mice were treated with phosphate-buffered saline, M0NVs, or M1NVs to evaluate the efficacy and safety of M1NV for treating endometriosis. Results M1NVs directly or indirectly inhibited the migration and invasion of EM-ESCs and reduced tube formation. In the mouse model, M1NVs suppressed the development of endometriosis through reprogramming of M2 macrophages, without causing damage to the organs. Conclusions M1NVs inhibit the development of endometriosis directly, or through repolarizing macrophages from M2 to M1 phenotype. Hence, administration of M1NVs may represent a novel method for the treatment of endometriosis.	[Li, Qiuju; Yuan, Ming; Jiao, Xue; Huang, Yufei; Li, Jing; Ji, Miaomiao; Wang, Guoyun] Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, Jinan, Peoples R China; [Li, Dong] Shandong Univ, Qilu Hosp, Cryomed Lab, Jinan, Peoples R China	Shandong University; Shandong University	Wang, GY (corresponding author), Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, Jinan, Peoples R China.	wangguoy@sdu.edu.cn		Yuan, Ming/0000-0001-6471-9266; Ji, Miaomiao/0000-0001-6514-0950; Li, Qiuju/0000-0003-0141-4216; Jiao, Xue/0000-0002-4172-6794	National Natural Science Foundation of China [82071621, 81771552, 81901458]; Key Technology Research and Development Program of Shandong [2019GSF108071]; Clinical Practical New Technology Development Fund of Qilu Hospital of Shandong University [2019-23]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Technology Research and Development Program of Shandong; Clinical Practical New Technology Development Fund of Qilu Hospital of Shandong University	This work was supported by the National Natural Science Foundation of China [grant numbers 82071621, 81771552, and 81901458], the Key Technology Research and Development Program of Shandong [grant number 2019GSF108071], and the Clinical Practical New Technology Development Fund of Qilu Hospital of Shandong University [grant number 2019-23. The funders had no role in study design; the collection, analysis and interpretation of data; the writing of the report; and the decision to submit the article for publication.	Asante A, 2011, ANNU REV PHYSIOL, V73, P163, DOI 10.1146/annurev-physiol-012110-142158; Bacci M, 2009, AM J PATHOL, V175, P547, DOI 10.2353/ajpath.2009.081011; Bain CC, 2018, CELL IMMUNOL, V330, P126, DOI 10.1016/j.cellimm.2018.01.003; Brouwer PJM, 2021, CELL, V184, P1188, DOI 10.1016/j.cell.2021.01.035; Capobianco A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00009; Choo YW, 2018, ACS NANO, V12, P8977, DOI 10.1021/acsnano.8b02446; Ding JJ, 2021, ADV MATER, V33, DOI 10.1002/adma.202005562; Duan J, 2018, REPROD BIOMED ONLINE, V37, P254, DOI 10.1016/j.rbmo.2018.05.017; Fitzgerald W, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27190-x; Gaetje R, 1997, AM J PATHOL, V150, P461; Groothuis P. G., 2005, Angiogenesis, V8, P147, DOI 10.1007/s10456-005-9005-x; Guan YT, 2016, HUM REPROD, V31, P986, DOI 10.1093/humrep/dew034; Haber E, 2009, HUM REPROD, V24, P398, DOI 10.1093/humrep/den375; Harada T., 2014, ENDOMETR PATHOG TREA, V10, P1, DOI [10.1007/978-4-431-54421-0, DOI 10.1007/978-4-431-54421-0]; Hogg C, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2013776118; Itoh F, 2013, FERTIL STERIL, V99, P1705, DOI 10.1016/j.fertnstert.2013.01.133; Jang SC, 2013, ACS NANO, V7, P7698, DOI 10.1021/nn402232g; Jeyaram A, 2018, AAPS J, V20, DOI 10.1208/s12248-017-0160-y; Johan MZ, 2019, J REPROD IMMUNOL, V132, P1, DOI 10.1016/j.jri.2019.01.002; Kim H, 2019, ADV SCI, V6, DOI 10.1002/advs.201900513; Lan JQ, 2019, CANCER RES, V79, P146, DOI 10.1158/0008-5472.CAN-18-0014; Laschke MW, 2011, HUM REPROD UPDATE, V17, P628, DOI 10.1093/humupd/dmr023; Laschke MW, 2018, HUM REPROD UPDATE, V24, P207, DOI 10.1093/humupd/dmy001; Laskin DL, 2011, ANNU REV PHARMACOL, V51, P267, DOI 10.1146/annurev.pharmtox.010909.105812; Li QJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb0202; Li WN, 2020, P NATL ACAD SCI USA, V117, P25859, DOI 10.1073/pnas.1920037117; Liu HW, 2017, REPRODUCTION, V153, P809, DOI 10.1530/REP-16-0643; Marar C, 2021, NAT IMMUNOL, V22, P560, DOI 10.1038/s41590-021-00899-0; Matsumoto A, 2020, BIOMATERIALS, V252, DOI 10.1016/j.biomaterials.2020.120112; Ono Y, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79578-3; Qiu JJ, 2020, EXP CELL RES, V388, DOI 10.1016/j.yexcr.2020.111815; Rao L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18626-y; Simoens S, 2012, HUM REPROD, V27, P1292, DOI 10.1093/humrep/des073; Sun HH, 2019, MOL HUM REPROD, V25, P5, DOI 10.1093/molehr/gay049; Sun HH, 2019, BIOL REPROD, V100, P649, DOI 10.1093/biolre/ioy212; Tang TT, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz0748; Van Deun J, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081797; Wang Y, 2014, INT J CLIN EXP PATHO, V7, P194; Woo JH, 2017, BIOL REPROD, V97, P660, DOI 10.1093/biolre/iox118; Wu JJ, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0828-3; Xu Z, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120647; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Yuan DF, 2017, BIOMATERIALS, V142, P1, DOI 10.1016/j.biomaterials.2017.07.011; Yuan M, 2017, HUM REPROD, V32, P94, DOI 10.1093/humrep/dew274; Zhang GS, 2020, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12030; Zinger A, 2021, ACS NANO, V15, P6326, DOI 10.1021/acsnano.0c05792; Zondervan KT, 2020, NEW ENGL J MED, V382, P1244, DOI 10.1056/NEJMra1810764; Zondervan KT, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0008-5	48	1	1	0	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 20	2021	12								707784	10.3389/fimmu.2021.707784	http://dx.doi.org/10.3389/fimmu.2021.707784			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TT6RU	34354711	gold, Green Published			2022-12-18	WOS:000680474500001
J	Resch, T; Hackl, H; Esser, H; Gunther, J; Schwelberger, H; Ritschl, PV; Ebner, S; Maglione, M; Mellitzer, V; Biebl, M; Ollinger, R; Zoller, H; Schneeberger, S; Kotsch, K				Resch, Thomas; Hackl, Hubert; Esser, Hannah; Gunther, Julia; Schwelberger, Hubert; Ritschl, Paul Viktor; Ebner, Susanne; Maglione, Manuel; Mellitzer, Vanessa; Biebl, Matthias; Oellinger, Robert; Zoller, Heinz; Schneeberger, Stefan; Kotsch, Katja			Expression of MICA in Zero Hour Biopsies Predicts Graft Survival After Liver Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						biomarker; liver transplantation; graft quality assessment; graft survival; marginal donor; donor risk index; mortality	DONOR RISK INDEX; KIDNEY BIOPSIES; LEPTIN; NKG2D; PRESERVATION; BIOMARKERS; LIGANDS; QUALITY; CHAIN	In search for novel biomarkers to assess graft quality, we investigated whether defined candidate genes are predictive for outcome after liver transplantation (LT). Zero-hour liver biopsies were obtained from 88 livers. Gene expression of selected candidate markers was analyzed and correlated with clinical parameters as well as short and long-term outcomes post LT. Whereas both, the calculated Eurotransplant Donor-Risk-Index and the donor body mass index, had either a poor or no predictive value concerning serum levels indicative for liver function (ALT, AST, GGT, bilirubin) after 6 months, chronological donor age was weakly predictive for serum bilirubin (AUC=0.67). In contrast, the major histcompatibility complex class I related chain A (MICA) mRNA expression demonstrated a high predictive value for serum liver function parameters revealing an inverse correlation (e.g. for ALT: 3 months p=0.0332; 6 months p=0.007, 12 months 0.0256, 24 months p=0.0098, 36 months, p=0.0153) and proved significant also in a multivariate regression model. Importantly, high expression of MICA mRNA revealed to be associated with prolonged graft survival (p=0.024; log rank test) after 10 years of observation, whereas low expression was associated with the occurrence of death in patients with transplant related mortality (p=0.031). Given the observed correlation with short and long-term graft function, we suggest MICA as a biomarker for pre-transplant graft evaluation.	[Resch, Thomas; Esser, Hannah; Gunther, Julia; Schwelberger, Hubert; Ebner, Susanne; Maglione, Manuel; Mellitzer, Vanessa; Schneeberger, Stefan] Med Univ Innsbruck, Ctr Operat Med, Dept Visceral Transplant & Thorac Surg, Innsbruck, Austria; [Hackl, Hubert] Med Univ Innsbruck, Bioctr, Inst Bioinformat, Innsbruck, Austria; [Ritschl, Paul Viktor; Biebl, Matthias; Oellinger, Robert] Charite, Dept Surg, Berlin, Germany; [Zoller, Heinz] Med Univ Innsbruck, Dept Med Gastroenterol Hepatol & Endocrinol 1, Innsbruck, Austria; [Kotsch, Katja] Charite Univ Med Berlin, Dept Gen & Visceral Surg, Berlin, Germany; [Kotsch, Katja] Free Univ Berlin, Berlin, Germany; [Kotsch, Katja] Humboldt Univ, Berlin, Germany	Medical University of Innsbruck; Medical University of Innsbruck; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Medical University of Innsbruck; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin	Resch, T (corresponding author), Med Univ Innsbruck, Ctr Operat Med, Dept Visceral Transplant & Thorac Surg, Innsbruck, Austria.; Kotsch, K (corresponding author), Charite Univ Med Berlin, Dept Gen & Visceral Surg, Berlin, Germany.; Kotsch, K (corresponding author), Free Univ Berlin, Berlin, Germany.; Kotsch, K (corresponding author), Humboldt Univ, Berlin, Germany.	thomas.resch@i-med.ac.at; katja.kotsch@charite.de	; Hackl, Hubert/B-3168-2018	Ebner, Susanne/0000-0002-0394-9620; Hackl, Hubert/0000-0003-4055-3841; Maglione, Manuel/0000-0003-1479-6129; /0000-0003-4610-1766	Deutsche Forschungsgemeinschaft [Ko-2270/4-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This study was supported by a grant from the Deutsche Forschungsgemeinschaft to KK (Ko-2270/4-1).	Amitani M, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00051; Baranwal AK, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00182; Braat AE, 2012, AM J TRANSPLANT, V12, P2789, DOI 10.1111/j.1600-6143.2012.04195.x; Chang SH, 2017, TRANSPLANT DIRECT, V3, DOI 10.1097/TXD.0000000000000681; Ciszek M, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/828201; Dasari BV, 2017, CLIN TRANSPLANT, V31, DOI 10.1111/ctr.13139; Dasari BVM, 2017, BEST PRACT RES CL GA, V31, P211, DOI 10.1016/j.bpg.2017.03.002; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Detelich D, 2018, CURR OPIN ORGAN TRAN, V23, P151, DOI 10.1097/MOT.0000000000000500; Dutkowski P, 2014, J HEPATOL, V60, P765, DOI 10.1016/j.jhep.2013.11.023; Esser H, 2019, TRANSPLANTATION, V103, P2506, DOI 10.1097/TP.0000000000002759; Flechtenmacher C, 2015, LANGENBECK ARCH SURG, V400, P551, DOI 10.1007/s00423-015-1298-7; Flores A, 2017, LIVER TRANSPLANT, V23, P1216, DOI 10.1002/lt.24799; Fonseca I, 2015, METABOLISM, V64, P202, DOI 10.1016/j.metabol.2014.10.003; Ghadially H, 2017, BRIT J CANCER, V116, P1208, DOI 10.1038/bjc.2017.79; Graziadei I, 2016, WIEN KLIN WOCHENSCHR, V128, P679, DOI 10.1007/s00508-016-1046-1; Gunther J, 2017, KIDNEY INT, V91, P1447, DOI 10.1016/j.kint.2016.12.018; Huang WC, 2017, J IMMUNOL, V198, P1172, DOI 10.4049/jimmunol.1601313; Huntington ND, 2015, ONCOTARGET, V6, P28537, DOI 10.18632/oncotarget.5952; Jadlowiec CC, 2016, WORLD J GASTROENTERO, V22, P4438, DOI 10.3748/wjg.v22.i18.4438; Jimenez-Romero C, 2014, WORLD J GASTROENTERO, V20, P10691, DOI 10.3748/wjg.v20.i31.10691; Kahraman A, 2010, HEPATOLOGY, V51, P92, DOI 10.1002/hep.23253; Kotsch K, 2010, TRANSPLANTATION, V90, P958, DOI 10.1097/TP.0b013e3181f546e8; Lanaspa MA, 2018, P NATL ACAD SCI USA, V115, P3138, DOI 10.1073/pnas.1713837115; Lu Jun, 2011, J Evid Based Med, V4, P106, DOI 10.1111/j.1756-5391.2011.01125.x; Lue A, 2016, WORLD J GASTROENTERO, V22, P4966, DOI 10.3748/wjg.v22.i21.4966; Modan-Moses D, 2002, ISR MED ASSOC J, V4, P207; Nasralla D, 2018, NATURE, V557, P50, DOI 10.1038/s41586-018-0047-9; Nuttall F.Q., 2015, NUTR TODAY, V50, P117, DOI [10.1097/NT.0000000000000092, DOI 10.1097/NT.0000000000000092]; Pelletier SJ, 2007, LIVER TRANSPLANT, V13, P1678, DOI 10.1002/lt.21183; Polyzos SA, 2015, METABOLISM, V64, P60, DOI 10.1016/j.metabol.2014.10.012; Ravikumar R, 2015, TRANSPL INT, V28, P690, DOI 10.1111/tri.12576; Resch T, 2017, J HEART LUNG TRANSPL, V36, P732, DOI 10.1016/j.healun.2017.03.004; Ritschl PV, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01911; Schlegel Andrea, 2018, Curr Transplant Rep, V5, P93, DOI 10.1007/s40472-018-0183-z; Sheppard S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01808; Sivori S, 2019, CELL MOL IMMUNOL, V16, P430, DOI 10.1038/s41423-019-0206-4; Suarez-Alvarez B, 2009, AM J TRANSPLANT, V9, P251, DOI 10.1111/j.1600-6143.2008.02526.x; Uzunel M, 2008, LIVER TRANSPLANT, V14, P1793, DOI 10.1002/lt.21620; Vadstrup K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091997; Verhoeven CJ, 2014, J HEPATOL, V61, P672, DOI 10.1016/j.jhep.2014.04.031; Vodkin I, 2017, CLIN LIVER DIS, V21, P289, DOI 10.1016/j.cld.2016.12.004	42	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 20	2021	12								606146	10.3389/fimmu.2021.606146	http://dx.doi.org/10.3389/fimmu.2021.606146			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G9OQ	34354697	Green Published, gold			2022-12-18	WOS:000885080700001
J	Copley, HC; Gragert, L; Leach, AR; Kosmoliaptsis, V				Copley, Hannah C.; Gragert, Loren; Leach, Andrew R.; Kosmoliaptsis, Vasilis			Influence of HLA Class II Polymorphism on Predicted Cellular Immunity Against SARS-CoV-2 at the Population and Individual Level	FRONTIERS IN IMMUNOLOGY			English	Article						human leukocyte antigens; SARS-CoV-2; T-cells; cellular immunity; COVID-19	COVID-19; ASSOCIATIONS; VACCINES	Development of adaptive immunity after COVID-19 and after vaccination against SARS-CoV-2 is predicated on recognition of viral peptides, presented on HLA class II molecules, by CD4+ T-cells. We capitalised on extensive high-resolution HLA data on twenty five human race/ethnic populations to investigate the role of HLA polymorphism on SARS-CoV-2 immunogenicity at the population and individual level. Within populations, we identify wide inter-individual variability in predicted peptide presentation from structural, non-structural and accessory SARS-CoV-2 proteins, according to individual HLA genotype. However, we find similar potential for anti-SARS-CoV-2 cellular immunity at the population level suggesting that HLA polymorphism is unlikely to account for observed disparities in clinical outcomes after COVID-19 among different race/ethnic groups. Our findings provide important insight on the potential role of HLA polymorphism on development of protective immunity after SARS-CoV-2 infection and after vaccination and a firm basis for further experimental studies in this field.	[Copley, Hannah C.; Kosmoliaptsis, Vasilis] Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge, England; [Copley, Hannah C.; Leach, Andrew R.] European Bioinformat Inst EMBL EBI, Cambridge, England; [Gragert, Loren] Tulane Univ, Sch Med, Dept Pathol, New Orleans, LA 70112 USA; [Gragert, Loren] Natl Marrow Donor Program, Bioinformat Res, Minneapolis, MN USA; [Kosmoliaptsis, Vasilis] Univ Cambridge, Natl Inst Hlth Res NIHR, Blood & Transplant Res Unit Organ Donat & Transpl, Cambridge, England; [Kosmoliaptsis, Vasilis] NIHR Cambridge Biomed Res Ctr, Cambridge, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; European Molecular Biology Laboratory (EMBL); Tulane University; National Marrow Donor Program; University of Cambridge; University of Cambridge	Kosmoliaptsis, V (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge, England.; Kosmoliaptsis, V (corresponding author), Univ Cambridge, Natl Inst Hlth Res NIHR, Blood & Transplant Res Unit Organ Donat & Transpl, Cambridge, England.; Kosmoliaptsis, V (corresponding author), NIHR Cambridge Biomed Res Ctr, Cambridge, England.	vj256@cam.ac.uk	; Leach, Andrew/N-9949-2017	Kosmoliaptsis, Vasilis/0000-0001-7298-1387; Leach, Andrew/0000-0001-8178-0253	NIHR Blood and Transplant Research Unit in Organ Donation and Transplantation at the University of Cambridge; NIHR Cambridge Biomedical Research Centre; NIHR [PDF-2016-09-065]; MRC Clinical Research Training Fellowship [MR/S006745/1]; European Molecular Biology Laboratory (EMBL)	NIHR Blood and Transplant Research Unit in Organ Donation and Transplantation at the University of Cambridge; NIHR Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); NIHR(National Institute for Health Research (NIHR)); MRC Clinical Research Training Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Molecular Biology Laboratory (EMBL)	The research presented in this manuscript has received funding from the NIHR Blood and Transplant Research Unit in Organ Donation and Transplantation at the University of Cambridge, from the NIHR Cambridge Biomedical Research Centre and from an NIHR Fellowship (PDF-2016-09-065, VK). We gratefully acknowledge funding from an MRC Clinical Research Training Fellowship to HC (MR/S006745/1). VL acknowledges funding as a P. I. Terasaki Scholar. AL acknowledges funding by the Member States of the European Molecular Biology Laboratory (EMBL).	Aldridge Robert W, 2020, Wellcome Open Res, V5, P88, DOI [10.12688/wellcomeopenres.15922.1, 10.12688/wellcomeopenres.15922.2]; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], 2021, MED, DOI DOI 10.1164/RCCM.202009-3442OC; Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049; Behmard E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77547-4; Blackwell JM, 2009, CLIN MICROBIOL REV, V22, P370, DOI 10.1128/CMR.00048-08; Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Dong YT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00352-y; Gelder CM, 2002, J INFECT DIS, V185, P114, DOI 10.1086/338014; Godkin A, 2005, HEPATOLOGY, V41, P1383, DOI 10.1002/hep.20716; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; Gragert L, 2014, NEW ENGL J MED, V371, P339, DOI 10.1056/NEJMsa1311707; Gragert L, 2013, HUM IMMUNOL, V74, P1313, DOI 10.1016/j.humimm.2013.06.025; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Gregoriadis G, 1978, Ann N Y Acad Sci, V308, P343, DOI 10.1111/j.1749-6632.1978.tb22034.x; Grifoni, 2020, IMMUNOLOGICAL MEMORY, DOI [10.1101/2020.11.15.383323, DOI 10.1101/2020.11.15.383323]; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Guo XC, 2011, HEPATOLOGY, V53, P422, DOI 10.1002/hep.24048; Hsu HE, 2020, MMWR-MORBID MORTAL W, V69, P864, DOI 10.15585/mmwr.mm6927a3; Huang M, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-00209-2; Iyer AS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe0367; Juno JA, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0995-0; Keller MD, 2020, BLOOD, V136, P2905, DOI 10.1182/blood.2020008488; Kimman TG, 2007, COMMUNITY GENET, V10, P201, DOI 10.1159/000106559; Langton D.J., 2020, INFLUENCE HLA GENOTY, DOI [10.1101/2020.12.31.20249081, DOI 10.1101/2020.12.31.20249081]; Lassale C, 2020, BRAIN BEHAV IMMUN, V88, P44, DOI 10.1016/j.bbi.2020.05.074; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Liu G, 2021, CELL SYST, V12, P102, DOI 10.1016/j.cels.2020.11.010; Liu G, 2020, CELL SYST, V11, P131, DOI 10.1016/j.cels.2020.06.009; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Madbouly A, 2014, TISSUE ANTIGENS, V84, P285, DOI 10.1111/tan.12390; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; Mentzer AJ, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0341; Messaoudi I, 2002, SCIENCE, V298, P1797, DOI 10.1126/science.1076064; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x; Nolan Sean, 2020, Res Sq, DOI 10.21203/rs.3.rs-51964/v1; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI [10.1038/s41590-020-0782-6, 10.1101/2020.06.05.134551]; Pisanti S, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02515-5; Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5; Prachar M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77466-4; Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Reynisson B, 2020, J PROTEOME RES, V19, P2304, DOI 10.1021/acs.jproteome.9b00874; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI 10.1001/jama.2020.7681; Roche PA, 2015, NAT REV IMMUNOL, V15, P203, DOI 10.1038/nri3818; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Simanovsky AL, 2019, IMMUNOGENETICS, V71, P589, DOI 10.1007/s00251-019-01144-7; Snyder Thomas M, 2020, medRxiv, DOI 10.1101/2020.07.31.20165647; Staines HM, 2021, EMERG INFECT DIS, V27, P85, DOI 10.3201/eid2701.203074; Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002; Wajnberg A, 2020, LANCET MICROBE, V1, pE283, DOI 10.1016/S2666-5247(20)30120-8; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762; Wiedermann U, 2016, HUM VACC IMMUNOTHER, V12, P239, DOI 10.1080/21645515.2015.1093263; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Yarmarkovich M, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100036; Yehia BR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.18039; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	67	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 19	2021	12								669357	10.3389/fimmu.2021.669357	http://dx.doi.org/10.3389/fimmu.2021.669357			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TT2WB	34349756	Green Published, gold, Green Submitted			2022-12-18	WOS:000680210100001
J	Fukui, S; Hidaka, M; Fukui, S; Morimoto, S; Hara, T; Soyama, A; Adachi, T; Matsushima, H; Tanaka, T; Fuchigami, M; Hasegawa, H; Yanagihara, K; Eguchi, S				Fukui, Saeko; Hidaka, Masaaki; Fukui, Shoichi; Morimoto, Shimpei; Hara, Takanobu; Soyama, Akihiko; Adachi, Tomohiko; Matsushima, Hajime; Tanaka, Takayuki; Fuchigami, Mai; Hasegawa, Hiroo; Yanagihara, Katsunori; Eguchi, Susumu			The Contribution of Serum Complement Component 3 Levels to 90-Day Mortality in Living Donor Liver Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						C3; C4; immunoglobulin G; posttransplant infection; leukocyte populations	RISK; INFECTION; RECIPIENTS; DISEASE; C3	The contributions of the complement system have been elucidated in the process of solid organ transplantation, including kidney transplantation. However, the role of complement in liver transplantation is unknown. We sought to elucidate the time-dependent changes of peritransplantational serum complement levels and the relationships with posttransplant outcomes and other immunological biomarkers. We enrolled 82 patients who underwent living-related donor liver transplantation (LDLT). Nine patients (11%) died within 90 days after LDLT (non-survivors). The following immunomarkers were collected preoperatively and at 1, 2, and 4 week(s) after LDLT: serum C3, C4, immunoglobulin G (IgG), and peripheral blood leukocyte populations characterized by CD3, CD4, CD8, CD16, CD19, CD20, CD22, and CD56. Consequently, C3 and C4 increased time-dependently after LDLT. Preoperatively, C3 was negatively correlated with the MELD score, Child-Pugh score, CD16-positive leukocyte percentage, and the CD56-positive leukocyte percentage. Non-survivors had lower levels of C3 at 2 weeks in comparison to survivors (median [interquartile range]: 56 [49-70] mg/dL vs. 88 [71-116] md/dL, p=0.0059). When the cutoff value of C3 at 2 weeks to distinguish non-survivors was set to 71 mg/dL, the sensitivity, specificity, and area under the ROC curve were 87.5%, 75.0%, and 0.80, respectively. A principal component analysis showed an inverse relationship between the C3 and C4 levels and the percentage of CD8-, CD16-, and CD56-positive leukocytes at 1 and 2 week(s). All non-survivors were included in the cluster that showed higher percentages of CD8-, CD16-, and CD56-positive leukocytes at 2 weeks. In conclusion, we demonstrated the relationship between complement, outcomes, and other immunomarkers in LDLT and suggested the usefulness of C3 at 2 weeks after LDLT in distinguishing the mortality.	[Fukui, Saeko; Hidaka, Masaaki; Hara, Takanobu; Soyama, Akihiko; Adachi, Tomohiko; Matsushima, Hajime; Tanaka, Takayuki; Eguchi, Susumu] Nagasaki Univ, Dept Surg, Grad Sch Biomed Sci, Nagasaki, Japan; [Fukui, Shoichi] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA; [Morimoto, Shimpei] Nagasaki Univ, Innovat Platform & Off Precis Med, Grad Sch Biomed Sci, Nagasaki, Japan; [Fuchigami, Mai; Hasegawa, Hiroo; Yanagihara, Katsunori] Nagasaki Univ, Dept Lab Med, Grad Sch Biomed Sci, Nagasaki, Japan	Nagasaki University; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Nagasaki University; Nagasaki University	Eguchi, S (corresponding author), Nagasaki Univ, Dept Surg, Grad Sch Biomed Sci, Nagasaki, Japan.	sueguchi@nagasaki-u.ac.jp			Ministry of Health, Labour and Welfare of Japan	Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	This work was supported in part by a Grant-in-Aid for Research on HIV/AIDS from the Ministry of Health, Labour and Welfare of Japan.	Awad SM, 2020, TRANSPL IMMUNOL, V60, DOI 10.1016/j.trim.2020.101294; Carbone J, 2008, TRANSPL INFECT DIS, V10, P396, DOI 10.1111/j.1399-3062.2008.00329.x; CHARLESWORTH JA, 1974, CLIN SCI MOL MED, V46, P223, DOI 10.1042/cs0460223; Eguchi S, 2008, TRANSPL INT, V21, P531, DOI 10.1111/j.1432-2277.2008.00656.x; Fernandez-Ruiz M, 2016, TRANSPL INFECT DIS, V18, P552, DOI 10.1111/tid.12564; Fernandez-Ruiz M, 2009, LIVER TRANSPLANT, V15, P1209, DOI 10.1002/lt.21833; Fisher RA, 2004, CLIN TRANSPLANT, V18, P463, DOI 10.1111/j.1399-0012.2004.00192.x; Fuller W.A, 2011, SAMPLING STAT, V560; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Glotz D, 2019, AM J TRANSPLANT, V19, P2865, DOI 10.1111/ajt.15397; Gonzalez-Quintela A, 2003, TRANSPL IMMUNOL, V11, P73, DOI 10.1016/S0966-3274(02)00084-9; Gournay J, 1996, GASTROENTEROLOGY, V110, P265, DOI 10.1053/gast.1996.v110.pm8536866; Grafals M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02380; Hara T, 2014, ANN TRANSPL, V19, P674, DOI 10.12659/AOT.892095; Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830; HEBERT LA, 1991, KIDNEY INT, V39, P811, DOI 10.1038/ki.1991.102; Hester J., 2019, J OPEN SOURCE SOFTW, V4, P1686, DOI [10.21105/joss.01686, DOI 10.21105/JOSS.01686]; Horowitz A, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00088; INAI S, 1976, ANN REP CTR ADULT DI, V16, P51; Kassambara A., 2017, DRAW SURVIV CURVES U; Kassambara A., 2017, EXTR VIS RESULTS MUL, V76; Kassimatis T, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1972-x; Liaskou E, 2013, HEPATOLOGY, V57, P385, DOI 10.1002/hep.26016; Liu XM, 2021, INDIAN J HEMATOL BLO, V37, P140, DOI 10.1007/s12288-020-01338-0; Lumley T., 2010, COMPLEX SURVEYS GUID, DOI [10.1002/9780470580066, DOI 10.1002/9780470580066]; Lumley T, 2017, STAT SCI, V32, P265, DOI 10.1214/16-STS605; Mozer-Glassberg Y, 2013, CLIN TRANSPLANT, V27, pE289, DOI 10.1111/ctr.12116; Neumann UP, 2002, TRANSPLANT INT, V15, P226, DOI 10.1007/s00147-002-0399-8; Neuwirth Erich, 2014, CRAN; Nierenberg NE, 2014, LIVER TRANSPLANT, V20, P1497, DOI 10.1002/lt.23991; Nwaba A, 2013, INTERN MED J, V43, P328, DOI 10.1111/imj.12048; Olthoff KM, 2010, LIVER TRANSPLANT, V16, P943, DOI 10.1002/lt.22091; Ormonde DG, 1999, LIVER TRANSPLANT SUR, V5, P261, DOI 10.1002/lt.500050418; Pires M, 2021, INT J HEPATOL, V2021, DOI 10.1155/2021/6636456; R Core Team, 2021, R LANG ENV STAT COMP; Sachs MC, 2017, J STAT SOFTW, V79, DOI 10.18637/jss.v079.c02; Sacks SH, 2012, NAT REV IMMUNOL, V12, P431, DOI 10.1038/nri3225; Takatsuki M, 2006, SURGERY, V140, P824, DOI 10.1016/j.surg.2006.02.021; Therneau T.M., 2014, SURVIVAL ANAL PUBLIS, V2, P3, DOI DOI 10.1038/S41525-021-00179-8; Thorgersen EB, 2019, HEPATOLOGY, V70, P725, DOI 10.1002/hep.30508; Wei T., 2017, J ROY STAT SOC D-STA, V56, pe24; Wickham H, 2011, WIRES COMPUT STAT, V3, P180, DOI 10.1002/wics.147; Yoshida K., 2020, TABLEONE CREATE TABL; Yoshizumi T, 2014, TRANSPL INFECT DIS, V16, P225, DOI 10.1111/tid.12188	45	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 19	2021	12								652677	10.3389/fimmu.2021.652677	http://dx.doi.org/10.3389/fimmu.2021.652677			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TT5FC	34349754	Green Published, gold			2022-12-18	WOS:000680372700001
J	Luan, CX; Zhou, JJ; Wang, HX; Ma, XY; Long, ZBA; Cheng, X; Chen, XW; Huang, ZQ; Zhang, DG; Xia, RX; Ge, J				Luan, Chengxin; Zhou, Junjie; Wang, Haixia; Ma, Xiaoyu; Long, Zhangbiao; Cheng, Xin; Chen, Xiaowen; Huang, Zhenqi; Zhang, Dagan; Xia, Ruixiang; Ge, Jian			Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective	FRONTIERS IN IMMUNOLOGY			English	Review						local cytokine-release syndrome; acute lymphoblastic leukemia; possible model; systemic cytokine-release syndrome; chimeric antigen receptor T therapy		Chimeric antigen receptor T (CAR-T) cell therapy has achieved remarkable clinical efficacy in treatment of many malignancies especially for B-cell hematologic malignancies. However, the application of CAR-T cells is hampered by potentially adverse events, of which cytokine release syndrome (CRS) is one of the severest and the most studied. Local cytokine-release syndrome (L-CRS) at particular parts of the body has been reported once in a while in B-cell lymphoma or other compartmental tumors. The underlying mechanism of L-CRS is not well understood and the existing reports attempting to illustrate it only involve compartmental tumors, some of which even indicated L-CRS only happens in compartmental tumors. Acute lymphoblastic leukemia (ALL) is systemic and our center treated a B-cell ALL patient who exhibited life threatening dyspnea, L-CRS was under suspicion and the patient was successfully rescued with treatment algorithm of CRS. The case is the firstly reported L-CRS related to systemic malignancies and we tentatively propose a model to illustrate the occurrence and development of L-CRS of systemic malignancies inspired by the case and literature, with emphasis on the new recognition of L-CRS.	[Luan, Chengxin; Zhou, Junjie; Wang, Haixia; Ma, Xiaoyu; Long, Zhangbiao; Cheng, Xin; Chen, Xiaowen; Huang, Zhenqi; Xia, Ruixiang; Ge, Jian] Anhui Med Univ, Dept Hematol, Affiliated Hosp 1, Hefei, Peoples R China; [Zhang, Dagan] Nanjing Univ, Affiliated Drum Tower Hosp, Inst Translat Med, Med Sch, Nanjing, Peoples R China	Anhui Medical University; Nanjing University	Ge, J (corresponding author), Anhui Med Univ, Dept Hematol, Affiliated Hosp 1, Hefei, Peoples R China.	gejian52@163.com			Natural Science Foundation of Anhui province [2008085QH365]; Key Research and Development Project of Anhui Province [201904a07020057]; Research Foundation of Anhui Medical University [2020xkj166]	Natural Science Foundation of Anhui province(Natural Science Foundation of Anhui Province); Key Research and Development Project of Anhui Province; Research Foundation of Anhui Medical University	This work was supported by the Natural Science Foundation of Anhui province (Grant No.2008085QH365); Key Research and Development Project of Anhui Province (Grant No. 201904a07020057); Research Foundation of Anhui Medical University (Grant No. 2020xkj166).	Brudno JN, 2016, BLOOD, V127, P3321, DOI 10.1182/blood-2016-04-703751; Cooper ML, 2018, LEUKEMIA, V32, P1970, DOI 10.1038/s41375-018-0065-5; Ding Lijuan, 2021, Stem Cell Investig, V8, P1, DOI 10.21037/sci-2020-029; Feins S, 2019, AM J HEMATOL, V94, pS3, DOI 10.1002/ajh.25418; Filley AC, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00453; Frey Noelle, 2019, Biol Blood Marrow Transplant, V25, pe123, DOI 10.1016/j.bbmt.2018.12.756; Gardner RA, 2019, BLOOD, V134, P2149, DOI 10.1182/blood.2019001463; Jin AY, 2019, BONE MARROW TRANSPL, V54, P969, DOI 10.1038/s41409-018-0412-1; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Li L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.594271; Lichtman EI, 2021, CLIN CANCER RES, V27, P3141, DOI 10.1158/1078-0432.CCR-20-2540; Maus MV, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001511; Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4; Reiser Victoria, 2020, J Adv Pract Oncol, V11, P159, DOI 10.6004/jadpro.2020.11.2.4; Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034; Tanyi JL, 2017, J IMMUNOTHER, V40, P104, DOI 10.1097/CJI.0000000000000160; Topp MS, 2020, BIOL BLOOD MARROW TR, V26, pS101; Wang Y, 2020, LEUKEMIA, V34, P2704, DOI 10.1038/s41375-020-0936-4; Wei JS, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00256-x	20	1	2	1	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 19	2021	12								707191	10.3389/fimmu.2021.707191	http://dx.doi.org/10.3389/fimmu.2021.707191			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TT5EL	34349766	gold, Green Published			2022-12-18	WOS:000680371000001
J	Mohammad, S; Al Zoubi, S; Collotta, D; Krieg, N; Wissuwa, B; Alves, GF; Purvis, GSD; Norata, GD; Baragetti, A; Catapano, AL; Solito, E; Zechendorf, E; Schurholz, T; Correa-Vargas, W; Brandenburg, K; Coldewey, SM; Collino, M; Yaqoob, MM; Martin, L; Thiemermann, C				Mohammad, Shireen; Al Zoubi, Sura; Collotta, Debora; Krieg, Nadine; Wissuwa, Bianka; Alves, Gustavo Ferreira; Purvis, Gareth S. D.; Norata, Giuseppe Danilo; Baragetti, Andrea; Catapano, Alberico Luigi; Solito, Egle; Zechendorf, Elisabeth; Schuerholz, Tobias; Correa-Vargas, Wilmar; Brandenburg, Klaus; Coldewey, Sina M.; Collino, Massimo; Yaqoob, Muhammad M.; Martin, Lukas; Thiemermann, Christoph			A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						peptide 19-2.5; high-fat die; type-2 diabetes; antimicrobial peptide; insulin resistance; steatohepatitis; microalbuminuria	HIGH-DENSITY-LIPOPROTEIN; SCAVENGER RECEPTOR CD36; NF-KAPPA-B; INSULIN-RESISTANCE; CHOLESTEROL LEVELS; ADIPOSE-TISSUE; LIVER-INJURY; FATTY LIVER; L-CARNITINE; ACTIVATION	Metabolic endotoxemia has been suggested to play a role in the pathophysiology of metaflammation, insulin-resistance and ultimately type-2 diabetes mellitus (T2DM). The role of endogenous antimicrobial peptides (AMPs), such as the cathelicidin LL-37, in T2DM is unknown. We report here for the first time that patients with T2DM compared to healthy volunteers have elevated plasma levels of LL-37. In a reverse-translational approach, we have investigated the effects of the AMP, peptide 19-2.5, in a murine model of high-fat diet (HFD)-induced insulin-resistance, steatohepatitis and T2DM. HFD-fed mice for 12 weeks caused obesity, an impairment in glycemic regulations, hypercholesterolemia, microalbuminuria and steatohepatitis, all of which were attenuated by Peptide 19-2.5. The liver steatosis caused by feeding mice a HFD resulted in the activation of nuclear factor kappa light chain enhancer of activated B cells (NF-kappa B) (phosphorylation of inhibitor of kappa beta kinase (IKK)alpha/beta, I kappa B alpha, translocation of p65 to the nucleus), expression of NF-kappa B-dependent protein inducible nitric oxide synthase (iNOS) and activation of the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome, all of which were reduced by Peptide 19-2.5. Feeding mice, a HFD also resulted in an enhanced expression of the lipid scavenger receptor cluster of differentiation 36 (CD36) secondary to activation of extracellular signal-regulated kinases (ERK)1/2, both of which were abolished by Peptide 19-2.5. Taken together, these results demonstrate that the AMP, Peptide 19-2.5 reduces insulin-resistance, steatohepatitis and proteinuria. These effects are, at least in part, due to prevention of the expression of CD36 and may provide further evidence for a role of metabolic endotoxemia in the pathogenesis of metaflammation and ultimately T2DM. The observed increase in the levels of the endogenous AMP LL-37 in patients with T2DM may serve to limit the severity of the disease.	[Mohammad, Shireen; Al Zoubi, Sura; Purvis, Gareth S. D.; Solito, Egle; Yaqoob, Muhammad M.; Martin, Lukas; Thiemermann, Christoph] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, London, England; [Al Zoubi, Sura] Al Balqa Appl Univ, Sch Med, Dept Basic Med Sci, As Salt, Jordan; [Collotta, Debora; Alves, Gustavo Ferreira] Univ Turin, Dept Drug Sci & Technol, Turin, Italy; [Krieg, Nadine; Wissuwa, Bianka; Coldewey, Sina M.] Jena Univ Hosp, Dept Anesthesiol & Intens Care Med, Jena, Germany; [Krieg, Nadine; Wissuwa, Bianka; Coldewey, Sina M.] Jena Univ Hosp, Septom Res Ctr, Jena, Germany; [Purvis, Gareth S. D.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford, England; [Norata, Giuseppe Danilo; Baragetti, Andrea; Catapano, Alberico Luigi] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy; [Norata, Giuseppe Danilo; Baragetti, Andrea; Catapano, Alberico Luigi] IRCCS Multimed, Milan, Italy; [Norata, Giuseppe Danilo; Catapano, Alberico Luigi] Bassini Hosp, Soc Italiana Studio Aterosclerosi SISA, Ctr Study Atherosclerosis, Milan, Italy; [Solito, Egle] Univ Napoli Federico II, Dipartimento Med Mol & Biotecnol Med, Naples, Italy; [Zechendorf, Elisabeth; Schuerholz, Tobias; Martin, Lukas] Univ Hosp RWTH Aachen, Dept Intens Care & Intermediate Care, Aachen, Germany; [Correa-Vargas, Wilmar] Forschungszentrum Borstel, Dept Biophys, Borstel, Germany; [Brandenburg, Klaus] Forschungszentrum Borstel, Brandenburg Antiinfekt GmbH, Borstel, Germany; [Collino, Massimo] Univ Turin, Dept Neurosci Rita Levi Montalcini, Turin, Italy	University of London; Queen Mary University London; Al-Balqa Applied University; University of Turin; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; University of Oxford; University of Milan; IRCCS Multimedica; University of Naples Federico II; RWTH Aachen University; RWTH Aachen University Hospital; Forschungszentrum Borstel; Forschungszentrum Borstel; University of Turin	Mohammad, S; Thiemermann, C (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, London, England.	s.mohammad@qmul.ac.uk; c.thiemermann@qmul.ac.uk	Alves, Gustavo Ferreira/AAT-8049-2021	Alves, Gustavo Ferreira/0000-0003-2529-2006; Solito, Egle/0000-0001-5279-0049; Thiemermann, Christoph/0000-0003-4228-9722; Norata, Giuseppe Danilo/0000-0002-6081-1257	British Heart Foundation (BHF) [FS/17/69/33484]; German Research Foundation (DFG) [MA 7082/3-1]; William Harvey research Foundation; Federal Ministry of Education and Research, Germany [03Z22JN12]; "Cibo, Microbiota, Salute" by "Vini di Batasiolo S.p.A" [AL_RIC19ABARA_01]; "Post-Doctoral Fellowship 2020" of "Fondazione Umberto Veronesi" [2020-3318]; "The Peanut Nutrition Grant 2021" of " the Peanut Institute"; Fondazione Cariplo [2016-0852, 2015-0524, 2015-0564]; EFSD/Lilly European Diabetes Research Programme 2018; Fondazione Telethon [GGP19146]; PRIN [2017K55HLC, 2017H5F943]; H2020 REPROGRAM [PHC-03-2015/667837-2]; ERANET [ER-2017-2364981]; Ministry of Health-IRCCS MultiMedica [GR-2011-02346974]; Ministry of Health - Ricerca Corrente - IRCCS MultiMedica	British Heart Foundation (BHF)(British Heart Foundation); German Research Foundation (DFG)(German Research Foundation (DFG)); William Harvey research Foundation; Federal Ministry of Education and Research, Germany(Federal Ministry of Education & Research (BMBF)); "Cibo, Microbiota, Salute" by "Vini di Batasiolo S.p.A"; "Post-Doctoral Fellowship 2020" of "Fondazione Umberto Veronesi"; "The Peanut Nutrition Grant 2021" of " the Peanut Institute"; Fondazione Cariplo(Fondazione Cariplo); EFSD/Lilly European Diabetes Research Programme 2018; Fondazione Telethon(Fondazione TelethonEuropean Commission); PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); H2020 REPROGRAM; ERANET; Ministry of Health-IRCCS MultiMedica; Ministry of Health - Ricerca Corrente - IRCCS MultiMedica	SM is supported by the British Heart Foundation (BHF) MRes/PhD Scholarship (Award number: FS/17/69/33484). This work was partially funded by a grant from the German Research Foundation to LM (DFG, MA 7082/3-1). This work was, in part, supported by the William Harvey research Foundation and the Federal Ministry of Education and Research, Germany (Grant 03Z22JN12 to SMC). AB was supported by "Cibo, Microbiota, Salute" by "Vini di Batasiolo S.p.A" (AL_RIC19ABARA_01), by "Post-Doctoral Fellowship 2020" of "Fondazione Umberto Veronesi" (2020-3318) and by Award of the "The Peanut Nutrition Grant 2021" of " the Peanut Institute. GDN was supported by Fondazione Cariplo 2016-0852; EFSD/Lilly European Diabetes Research Programme 2018, Fondazione Telethon GGP19146, PRIN 2017K55HLC. ALC was supported by H2020 REPROGRAM PHC-03-2015/667837-2; Fondazione Cariplo 2015-0524 and 2015-0564; ERANET ER-2017-2364981; Ministry of Health-IRCCS MultiMedica GR-2011-02346974; PRIN 2017H5F943. This work has been also supported by Ministry of Health -Ricerca Corrente -IRCCS MultiMedica.	Ahmad R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04989-8; Al-Attas OS, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-20; Aldukhayel Abdulrhman, 2017, Int J Health Sci (Qassim), V11, P1; Alkhatatbeh MJ, 2013, NUTR DIABETES, V3, DOI 10.1038/nutd.2013.1; Awad WA, 2017, TOXINS, V9, DOI 10.3390/toxins9020060; Baragetti A, 2016, INT J CARDIOL, V223, P43, DOI 10.1016/j.ijcard.2016.08.164; Baragetti A, 2013, J INTERN MED, V274, P252, DOI 10.1111/joim.12081; Baragetti A, 2021, NUTRIENTS, V13, DOI 10.3390/nu13020304; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berbee JFP, 2005, J ENDOTOXIN RES, V11, P97, DOI 10.1179/096805105X35215; Bharrhan S, 2012, INNATE IMMUN-LONDON, V18, P70, DOI 10.1177/1753425910393369; Bjorkbacka H, 2004, NAT MED, V10, P416, DOI 10.1038/nm1008; Boutagy NE, 2016, BIOCHIMIE, V124, P11, DOI 10.1016/j.biochi.2015.06.020; Brandenburg K, 2016, BBA-BIOMEMBRANES, V1858, P971, DOI 10.1016/j.bbamem.2016.01.011; Brastert Q, 2016, THROMB HAEMOSTASIS, V115, P1237, DOI 10.1160/TH16-02-0112; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Cave MC, 2008, NUTR CLIN PRACT, V23, P16, DOI 10.1177/011542650802300116; Chelakkot Chaithanya, 2018, Exp Mol Med, V50, P1, DOI 10.1038/s12276-018-0126-x; Coats BR, 2017, CELL REP, V20, P3149, DOI 10.1016/j.celrep.2017.08.096; Correa W, 2019, FEBS J, V286, P1576, DOI 10.1111/febs.14805; da Silva FP, 2009, IMMUNOL CELL BIOL, V87, P496, DOI 10.1038/icb.2009.19; Dabla PK, 2010, WORLD J DIABETES, V1, P48, DOI 10.4239/wjd.v1.i2.48; Davies MJ, 2018, DIABETES CARE, V41, P2669, DOI 10.2337/dci18-0033; Fracanzani AL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162473; Fujimoto M, 2005, DIABETES, V54, P1340, DOI 10.2337/diabetes.54.5.1340; Fujisawa K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02924-5; Fukumoto K, 2005, PEDIATR SURG INT, V21, P20, DOI 10.1007/s00383-004-1256-x; Galloway SDR, 2011, AMINO ACIDS, V41, P507, DOI 10.1007/s00726-010-0770-5; Gao MM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119784; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Gutsmann T, 2010, ANTIMICROB AGENTS CH, V54, P3817, DOI 10.1128/AAC.00534-10; He WQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030993; Heinbockel L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01704; Tran DHY, 2016, INT J OBESITY, V40, P1424, DOI 10.1038/ijo.2016.90; Hui ST, 2015, ELIFE, V4, DOI 10.7554/eLife.05607; Jia L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4878; Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718; Kaconis Y, 2011, BIOPHYS J, V100, P2652, DOI 10.1016/j.bpj.2011.04.041; Kahlenberg JM, 2013, J IMMUNOL, V191, P4895, DOI 10.4049/jimmunol.1302005; Kennedy DJ, 2011, METAB SYNDR RELAT D, V9, P239, DOI 10.1089/met.2011.0003; Kim KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047713; Koonen DPY, 2007, DIABETES, V56, P2863, DOI 10.2337/db07-0907; Lee JJ, 2015, INVEST OPHTH VIS SCI, V56, P3041, DOI 10.1167/iovs.15-16504; Luedde T, 2011, NAT REV GASTRO HEPAT, V8, P108, DOI 10.1038/nrgastro.2010.213; Martin L, 2016, SCI REP-UK, V6, DOI 10.1038/srep37277; Martin L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143583; Mattix HJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341034; Mingrone G, 2004, ANN NY ACAD SCI, V1033, P99, DOI 10.1196/annals.1320.009; Mohammad S, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.594150; Mridha AR, 2017, J HEPATOL, V66, P1037, DOI 10.1016/j.jhep.2017.01.022; Noh H, 2007, KIDNEY INT, V72, pS49, DOI 10.1038/sj.ki.5002386; O'Brien PD, 2014, ILAR J, V54, P259, DOI 10.1093/ilar/ilt052; Palsson R, 2014, ADV CHRONIC KIDNEY D, V21, P273, DOI 10.1053/j.ackd.2014.03.003; Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x; Papa S, 2009, BIOL CHEM, V390, P965, DOI 10.1515/BC.2009.111; Pearce K, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10060428; Perreault M, 2001, NAT MED, V7, P1138, DOI 10.1038/nm1001-1138; Pirmadah F, 2020, EUR J NUTR, V59, P1767, DOI 10.1007/s00394-019-02068-4; Pooyandjoo M, 2016, OBES REV, V17, P970, DOI 10.1111/obr.12436; Puchalowicz K, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081877; Rahbar AR, 2005, EUR J CLIN NUTR, V59, P592, DOI 10.1038/sj.ejcn.1602109; Ress C, 2016, WORLD J GASTROENTERO, V22, P1664, DOI 10.3748/wjg.v22.i4.1664; RUBLER S, 1972, AM J CARDIOL, V30, P595, DOI 10.1016/0002-9149(72)90595-4; Scheenstra MR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01137; Schneider VAF, 2016, SCI REP-UK, V6, DOI 10.1038/srep32948; Sini S, 2017, MOL CELL BIOCHEM, V427, P23, DOI 10.1007/s11010-016-2895-7; Sokka T, 2008, CLIN EXP RHEUMATOL, V26, pS35, DOI 10.1161/CIRCULATIONAHA.109.192644; Turcotte LP, 2005, ACTA PHYSIOL SCAND, V184, P131, DOI 10.1111/j.1365-201X.2005.01445.x; Vancamelbeke M, 2017, EXPERT REV GASTROENT, V11, P821, DOI 10.1080/17474124.2017.1343143; Velazquez KT, 2019, WORLD J HEPATOL, V11, P619, DOI 10.4254/wjh.v11.i8.619; Viana LV, 2012, J DIABETES COMPLICAT, V26, P407, DOI 10.1016/j.jdiacomp.2012.04.014; Wan XY, 2016, CAN J GASTROENTEROL, V2016, DOI 10.1155/2016/6489012; Wilson CG, 2016, ENDOCRINOLOGY, V157, P570, DOI 10.1210/en.2015-1866; Winzell MS, 2004, DIABETES, V53, pS215, DOI 10.2337/diabetes.53.suppl_3.S215; Wree A, 2018, HEPATOLOGY, V67, P736, DOI 10.1002/hep.29523; Wree A, 2014, J MOL MED, V92, P1069, DOI 10.1007/s00109-014-1170-1; Wu HM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00172	78	1	1	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 19	2021	12								701275	10.3389/fimmu.2021.701275	http://dx.doi.org/10.3389/fimmu.2021.701275			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TT5AT	34349763	Green Published, gold			2022-12-18	WOS:000680361400001
J	Chang, HX; Cong, HR; Wang, HB; Du, L; Tian, DC; Ma, YT; Xu, Y; Wang, YP; Yin, LL; Zhang, XH				Chang, Haoxiao; Cong, Hengri; Wang, Huabing; Du, Li; Tian, De-Cai; Ma, Yuetao; Xu, Yun; Wang, Yupeng; Yin, Linlin; Zhang, Xinghu			Thymic Involution and Altered Naive CD4 T Cell Homeostasis in Neuromyelitis Optica Spectrum Disorder	FRONTIERS IN IMMUNOLOGY			English	Article						neuromyelitis optica spectrum disorder; thymic involution; CT; naive T cells; flow cytometry	DISEASE; AGE; DIVERSITY; IL-6; CT	Circulating T helper cells with a type 17-polarized phenotype (TH17) and expansion of aquaporin-4 (AQP4)-specific T cells are frequently observed in patients with neuromyelitis optica spectrum disorder (NMOSD). However, naive T cell populations, which give rise to T helper cells, and the primary site of T cell maturation, namely the thymus, have not been studied in these patients. Here, we report the alterations of naive CD4 T cell homeostasis and the changes in thymic characteristics in NMOSD patients. Flow cytometry was performed to investigate the naive CD4(+) T cell subpopulations in 44 NMOSD patients and 21 healthy controls (HC). On immunological evaluation, NMOSD patients exhibited increased counts of CD31(+thymic) naive CD4(+) T cells and CD31(-cental) naive CD4(+) T cells along with significantly higher fraction and absolute counts of peripheral blood CD45RA(+) CD62L(+) naive CD4(+) T cells. Chest computed tomography (CT) images of 60 NMOSD patients and 65 HCs were retrospectively reviewed to characterize the thymus in NMOSD. Thymus gland of NMOSD patients exhibited unique morphological characteristics with respect to size, shape, and density. NMOSD patients showed exacerbated age-dependent thymus involution than HC, which showed a significant association with disease duration. These findings broaden our understanding of the immunological mechanisms that drive severe disease in NMOSD.	[Chang, Haoxiao; Cong, Hengri; Wang, Huabing; Du, Li; Tian, De-Cai; Ma, Yuetao; Xu, Yun; Wang, Yupeng; Yin, Linlin; Zhang, Xinghu] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China; [Chang, Haoxiao; Yin, Linlin] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China; [Yin, Linlin] Adv Innovat Ctr Human Brain Protect, Beijing, Peoples R China	Capital Medical University	Yin, LL; Zhang, XH (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China.; Yin, LL (corresponding author), China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.; Yin, LL (corresponding author), Adv Innovat Ctr Human Brain Protect, Beijing, Peoples R China.	yinlinlin@bjtth.org; xhzhtiantan@hotmail.com		Chang, Haoxiao/0000-0001-6338-7562	Beijing Natural Science Foundation [7162208]; National Key Research and Development Program of China [2019YFC0121202]; Beijing Health and Technical Personal of High-level Plan [2014-3-052]	Beijing Natural Science Foundation(Beijing Natural Science Foundation); National Key Research and Development Program of China; Beijing Health and Technical Personal of High-level Plan	This work was supported by the Beijing Natural Science Foundation (No. 7162208), the National Key Research and Development Program of China (No. 2019YFC0121202) and Beijing Health and Technical Personal of High-level Plan (No. 2014-3-052).	Antoine JC, 2004, NEUROLOGY, V62, P978, DOI 10.1212/01.WNL.0000115168.73299.88; Appay V, 2014, EXP GERONTOL, V54, P90, DOI 10.1016/j.exger.2014.01.003; Araki T, 2016, EUR RADIOL, V26, P15, DOI 10.1007/s00330-015-3796-y; Araki T, 2014, ACAD RADIOL, V21, P733, DOI 10.1016/j.acra.2014.02.006; Barros PO, 2016, CLIN EXP IMMUNOL, V183, P480, DOI 10.1111/cei.12733; Carvalho-Silva WHV, 2020, J LEUKOCYTE BIOL, V107, P85, DOI 10.1002/JLB.4A0919-235R; Chan KH, 2010, J NEUROIMMUNOL, V227, P178, DOI 10.1016/j.jneuroim.2010.07.016; Chapman NM, 2020, NAT REV IMMUNOL, V20, P55, DOI 10.1038/s41577-019-0203-y; Chaudhry MS, 2016, IMMUNOL REV, V271, P56, DOI 10.1111/imr.12418; Chihara N, 2011, P NATL ACAD SCI USA, V108, P3701, DOI 10.1073/pnas.1017385108; De Rosa SC, 2001, NAT MED, V7, P245, DOI 10.1038/84701; den Braber I, 2012, IMMUNITY, V36, P288, DOI 10.1016/j.immuni.2012.02.006; Dixit VD, 2012, SEMIN IMMUNOL, V24, P321, DOI 10.1016/j.smim.2012.04.002; Dixit VD, 2010, CURR OPIN IMMUNOL, V22, P521, DOI 10.1016/j.coi.2010.06.010; Fahy GM, 2019, AGING CELL, V18, DOI 10.1111/acel.13028; Handel AE, 2018, NAT REV NEUROL, V14, P724, DOI 10.1038/s41582-018-0095-7; Held K, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000107; James KD, 2018, J LEUKOCYTE BIOL, V104, P275, DOI 10.1002/JLB.1MR1217-496R; Johnson PLF, 2012, P NATL ACAD SCI USA, V109, P21432, DOI 10.1073/pnas.1209283110; Kadouri N, 2020, NAT REV IMMUNOL, V20, P239, DOI 10.1038/s41577-019-0238-0; Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391; Kimura K, 2019, J NEUROL, V266, P2743, DOI 10.1007/s00415-019-09461-3; Kohler S, 2005, EUR J IMMUNOL, V35, P1987, DOI 10.1002/eji.200526181; Kohler S, 2019, J NEUROIMMUNOL, V327, P10, DOI 10.1016/j.jneuroim.2019.01.005; Kohler S, 2009, BLOOD, V113, P769, DOI 10.1182/blood-2008-02-139154; Lin J, 2016, INT J NEUROSCI, V126, P1051, DOI 10.3109/00207454.2016.1163550; Mold JE, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000383; Okoye AA, 2015, J IMMUNOL, V195, P4292, DOI 10.4049/jimmunol.1500609; Palmer S, 2018, P NATL ACAD SCI USA, V115, P1883, DOI 10.1073/pnas.1714478115; Procaccini C, 2015, METABOLISM, V64, P92, DOI 10.1016/j.metabol.2014.10.014; Rosado-Sanchez I, 2017, CLIN INFECT DIS, V64, P152, DOI 10.1093/cid/ciw711; Sempowski GD, 2000, J IMMUNOL, V164, P2180, DOI 10.4049/jimmunol.164.4.2180; Shimamoto A, 2017, BRIT J RADIOL, V90, DOI 10.1259/bjr.20150341; Silva SL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00020; Simanovsky N, 2012, EUR J RADIOL, V81, P3581, DOI 10.1016/j.ejrad.2011.12.015; Takahama Y, 2017, NAT REV IMMUNOL, V17, P295, DOI 10.1038/nri.2017.12; Tan JX, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0311-1; Thompson HL, 2019, AGING CELL, V18, DOI 10.1111/acel.12865; Uzawa A, 2017, CLIN CHIM ACTA, V469, P144, DOI 10.1016/j.cca.2017.03.006; van den Broek T, 2018, NAT REV IMMUNOL, V18, P363, DOI 10.1038/s41577-018-0001-y; Varrin-Doyer M, 2012, ANN NEUROL, V72, P53, DOI 10.1002/ana.23651; Wei YZ, 2018, NEUROIMMUNOMODULAT, V25, P215, DOI 10.1159/000494976; Weinshenker BG, 2017, MAYO CLIN PROC, V92, P663, DOI 10.1016/j.mayocp.2016.12.014; Yamamura T, 2019, NEW ENGL J MED, V381, P2114, DOI 10.1056/NEJMoa1901747; Yan FG, 2017, MOL MED REP, V16, P7175, DOI 10.3892/mmr.2017.7525; Yin C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02653-9; Zeka B, 2015, ACTA NEUROPATHOL, V130, P783, DOI 10.1007/s00401-015-1501-5; Zhang C, 2020, LANCET NEUROL, V19, P391, DOI 10.1016/S1474-4422(20)30070-3	48	1	1	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 16	2021	12								645277	10.3389/fimmu.2021.645277	http://dx.doi.org/10.3389/fimmu.2021.645277			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TU0GM	34335563	Green Published, gold			2022-12-18	WOS:000680720100001
J	Gilchuk, P; Guthals, A; Bonissone, SR; Shaw, JB; Ilinykh, PA; Huang, K; Bombardi, RG; Liang, JN; Grinyo, A; Davidson, E; Chen, EC; Gunn, BM; Alter, G; Saphire, EO; Doranz, BJ; Bukreyev, A; Zeitlin, L; Castellana, N; Crowe, JE				Gilchuk, Pavlo; Guthals, Adrian; Bonissone, Stefano R.; Shaw, Jared B.; Ilinykh, Philipp A.; Huang, Kai; Bombardi, Robin G.; Liang, Jenny; Grinyo, Ariadna; Davidson, Edgar; Chen, Elaine C.; Gunn, Bronwyn M.; Alter, Galit; Saphire, Erica Ollmann; Doranz, Benjamin J.; Bukreyev, Alexander; Zeitlin, Larry; Castellana, Natalie; Crowe Jr, James E. E.			Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma	FRONTIERS IN IMMUNOLOGY			English	Article						ebolavirus; ebolavirus infection; glycoprotein; proteo-genomics; convalescent plasma; viral antibodies; neutralizing antibodies; epitope mapping	MONOCLONAL-ANTIBODIES; VIRUS GLYCOPROTEIN; STRUCTURAL BASIS; PROTECTION; BROAD; FILOVIRUSES; REPERTOIRE; MECHANISM; INFECTION; RESPONSES	Three clinically relevant ebolaviruses - Ebola (EBOV), Bundibugyo (BDBV), and Sudan (SUDV) viruses, are responsible for severe disease and occasional deadly outbreaks in Africa. The largest Ebola virus disease (EVD) epidemic to date in 2013-2016 in West Africa highlighted the urgent need for countermeasures, leading to the development and FDA approval of the Ebola virus vaccine rVSV-ZEBOV (Ervebo(R)) in 2020 and two monoclonal antibody (mAb)-based therapeutics (Inmazeb(R) [atoltivimab, maftivimab, and odesivimab-ebgn] and Ebanga(R) (ansuvimab-zykl) in 2020. The humoral response plays an indispensable role in ebolavirus immunity, based on studies of mAbs isolated from the antibody genes in peripheral blood circulating ebolavirus-specific human memory B cells. However, antibodies in the body are not secreted by circulating memory B cells in the blood but rather principally by plasma cells in the bone marrow. Little is known about the protective polyclonal antibody responses in convalescent plasma. Here we exploited both single-cell antibody gene sequencing and proteomic sequencing approaches to assess the composition of the ebolavirus glycoprotein (GP)-reactive antibody repertoire in the plasma of an EVD survivor. We first identified 1,512 GP-specific mAb variable gene sequences from single cells in the memory B cell compartment. Using mass spectrometric analysis of the corresponding GP-specific plasma IgG, we found that only a portion of the large B cell antibody repertoire was represented in the plasma. Molecular and functional analysis of proteomics-identified mAbs revealed recognition of epitopes in three major antigenic sites - the GP head domain, the glycan cap, and the base region, with a high prevalence of neutralizing and protective mAb specificities that targeted the base and glycan cap regions on the GP. Polyclonal plasma antibodies from the survivor reacted broadly to EBOV, BDBV, and SUDV GP, while reactivity of the potently neutralizing mAbs we identified was limited mostly to the homologous EBOV GP. Together these results reveal a restricted diversity of neutralizing humoral response in which mAbs targeting two antigenic sites on GP - glycan cap and base - play a principal role in plasma-antibody-mediated protective immunity against EVD.	[Gilchuk, Pavlo; Bombardi, Robin G.; Crowe Jr, James E. E.] Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Ctr, Nashville, TN USA; [Guthals, Adrian; Zeitlin, Larry] Mapp Biopharmaceutical Inc, San Diego, CA USA; [Bonissone, Stefano R.; Castellana, Natalie] Digital Prote LLC, Abterra Biosci, San Diego, CA USA; [Shaw, Jared B.] Pacific Northwest Natl Lab, Environm Mol Sci Lab, Richland, WA 99352 USA; [Ilinykh, Philipp A.; Huang, Kai; Bukreyev, Alexander] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA; [Ilinykh, Philipp A.; Huang, Kai; Bukreyev, Alexander] Galveston Natl Lab, Galveston, TX USA; [Liang, Jenny; Grinyo, Ariadna; Davidson, Edgar; Doranz, Benjamin J.] Integral Mol Inc, Philadelphia, PA USA; [Chen, Elaine C.; Crowe Jr, James E. E.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Gunn, Bronwyn M.; Alter, Galit] MIT, Ragon Inst MGH, Harvard, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Saphire, Erica Ollmann] La Jolla Inst Immunol, Ctr Infect Dis & Vaccine Res, La Jolla, CA USA; [Bukreyev, Alexander] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; [Crowe Jr, James E. E.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA	Vanderbilt University; United States Department of Energy (DOE); Pacific Northwest National Laboratory; University of Texas System; University of Texas Medical Branch Galveston; Vanderbilt University; Harvard University; Massachusetts Institute of Technology (MIT); Ragon Institute; La Jolla Institute for Immunology; University of Texas System; University of Texas Medical Branch Galveston; Vanderbilt University	Crowe, JE (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Ctr, Nashville, TN USA.; Crowe, JE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA.; Crowe, JE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.	james.crowe@vumc.org	Huang, Kai/H-9309-2018; Crowe, James/B-5549-2009	Huang, Kai/0000-0002-3373-5594; Crowe, James/0000-0002-0049-1079; Grinyo i Escuer, Ariadna/0000-0003-0185-2734	U.S. N.I.H [U19 AI109711, 1R43AI129082-01, 1R44GM122102]; HHS [HHSN272201400058C]; NIAID [U19 109762]; DTRA [HDTRA1-13-1-0034, T32AI138932]; National Center for Advancing Translational Sciences [2 UL1 TR000445-06]; "High Resolution and Mass Accuracy Capability" development project at the Environmental Molecular Science Laboratory located at the Pacific Northwest National Laboratory; Animal Resource Center of the Galveston National Laboratory; NIH [5UC7AI094660-07]	U.S. N.I.H(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HHS(United States Department of Health & Human Services); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); DTRA(United States Department of DefenseDefense Threat Reduction Agency); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); "High Resolution and Mass Accuracy Capability" development project at the Environmental Molecular Science Laboratory located at the Pacific Northwest National Laboratory; Animal Resource Center of the Galveston National Laboratory; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by U.S. N.I.H. grants U19 AI109711 (to JC and AB), 1R43AI129082-01 (to AdG, 1R43AI129082-01 (to LZ), and 1R44GM122102 (to SB and NC), HHS contract HHSN272201400058C (to BD and JC), NIAID U19 109762 (to ES), DTRA grant HDTRA1-13-1-0034 (to JC), and T32AI138932 (to EC). The project described was supported by the National Center for Research Resources, Grant UL1 RR024975-01, and is now at the National Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06. This work was supported in part by the "High Resolution and Mass Accuracy Capability" development project at the Environmental Molecular Science Laboratory located at the Pacific Northwest National Laboratory. Work in BSL-4 and ABSL-4 was supported by NIH grant 5UC7AI094660-07 and by the Animal Resource Center of the Galveston National Laboratory. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Akkaya M, 2020, NAT REV IMMUNOL, V20, P229, DOI 10.1038/s41577-019-0244-2; Bonissone SR., 2020, BIORXIV, P833871, DOI [10.1101/833871, DOI 10.1101/833871]; Bornholdt ZA, 2019, CELL HOST MICROBE, V25, P49, DOI 10.1016/j.chom.2018.12.005; Bornholdt ZA, 2016, MBIO, V7, DOI 10.1128/mBio.02154-15; Bornholdt ZA, 2016, SCIENCE, V351, P1078, DOI 10.1126/science.aad5788; Bray M, 1998, J INFECT DIS, V178, P651, DOI 10.1086/515386; Carette JE, 2011, NATURE, V477, P340, DOI 10.1038/nature10348; Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656; Cheung WC, 2012, NAT BIOTECHNOL, V30, P447, DOI 10.1038/nbt.2167; Cohen-Dvashi H, 2020, CELL HOST MICROBE, V27, P418, DOI 10.1016/j.chom.2020.01.007; Corti D, 2016, SCIENCE, V351, P1339, DOI 10.1126/science.aad5224; Cote M, 2011, NATURE, V477, P344, DOI 10.1038/nature10380; Davidson E, 2015, J VIROL, V89, P10982, DOI 10.1128/JVI.01490-15; Davis CW, 2019, CELL, V177, P1566, DOI 10.1016/j.cell.2019.04.036; Ehrhardt SA, 2019, NAT MED, V25, P1589, DOI 10.1038/s41591-019-0602-4; FDA, 2020, FDA APPR 1 TREAT EBO; FDA, 2020, FDA APPR TREATM EBOL; Feldmann H, 2020, NEW ENGL J MED, V382, P1832, DOI 10.1056/NEJMra1901594; Fibriansah G, 2015, SCIENCE, V349, P88, DOI 10.1126/science.aaa8651; Flyak AI, 2016, CELL, V164, P392, DOI 10.1016/j.cell.2015.12.022; Flyak AI, 2015, CELL, V160, P893, DOI 10.1016/j.cell.2015.01.031; Garbutt M, 2004, J VIROL, V78, P5458, DOI 10.1128/JVI.78.10.5458-5465.2004; Gilchuk P, 2020, NAT BIOMED ENG, V4, P1030, DOI 10.1038/s41551-020-0594-x; Gilchuk P, 2020, IMMUNITY, V52, P388, DOI 10.1016/j.immuni.2020.01.001; Gilchuk P, 2018, IMMUNITY, V49, P363, DOI 10.1016/j.immuni.2018.06.018; Giudicelli Veronique, 2011, Cold Spring Harb Protoc, V2011, P716, DOI 10.1101/pdb.prot5634; Goldstein T, 2018, NAT MICROBIOL, V3, P1084, DOI 10.1038/s41564-018-0227-2; Gunn BM, 2021, IMMUNITY, V54, P815, DOI 10.1016/j.immuni.2021.03.009; Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6; Howell KA, 2017, CELL REP, V19, P413, DOI 10.1016/j.celrep.2017.03.049; Huttner A, 2018, LANCET INFECT DIS, V18, P738, DOI 10.1016/S1473-3099(18)30165-8; Ilinykh PA, 2016, J VIROL, V90, P3890, DOI 10.1128/JVI.00101-16; King LB, 2018, CURR OPIN IMMUNOL, V53, P196, DOI 10.1016/j.coi.2018.05.001; Lee JE, 2008, NATURE, V454, P177, DOI 10.1038/nature07082; Lee JE, 2009, CURR OPIN STRUC BIOL, V19, P408, DOI 10.1016/j.sbi.2009.05.004; Lee J, 2019, CELL HOST MICROBE, V25, P367, DOI 10.1016/j.chom.2019.01.010; Lee J, 2016, NAT MED, V22, P1456, DOI 10.1038/nm.4224; Levine MM, 2019, NEW ENGL J MED, V381, P2365, DOI 10.1056/NEJMe1915350; Lindesmith LC, 2019, IMMUNITY, V50, P1530, DOI 10.1016/j.immuni.2019.05.007; McLean GR, 2000, MOL IMMUNOL, V37, P837, DOI 10.1016/S0161-5890(00)00101-2; Murin CD, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108984; Pascal KE, 2018, J INFECT DIS, V218, pS612, DOI 10.1093/infdis/jiy285; Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777; Qiu XG, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001575; Rijal P, 2019, CELL REP, V27, P172, DOI 10.1016/j.celrep.2019.03.020; Sato S, 2012, NAT BIOTECHNOL, V30, P1039, DOI 10.1038/nbt.2406; Shaw JB, 2018, ANAL CHEM, V90, P10819, DOI 10.1021/acs.analchem.8b01901; Towner JS, 2005, VIROLOGY, V332, P20, DOI 10.1016/j.virol.2004.10.048; US Food and Drug Administration, 2019, 1 FDA APPR VACC PREV; Voss WN, 2021, SCIENCE, V372, P1108, DOI 10.1126/science.abg5268; Wec AZ, 2017, CELL, V169, P878, DOI 10.1016/j.cell.2017.04.037; Williamson LE, 2019, J VIROL, V93, DOI 10.1128/JVI.01439-18; Wine Y, 2013, P NATL ACAD SCI USA, V110, P2993, DOI 10.1073/pnas.1213737110; World Health Organization, 2021, 107 STUD FOUND EB OR; Zhao XL, 2017, CELL, V169, P891, DOI 10.1016/j.cell.2017.04.038	57	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 16	2021	12								706757	10.3389/fimmu.2021.706757	http://dx.doi.org/10.3389/fimmu.2021.706757			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TS9NB	34335620	Green Submitted, Green Published, gold			2022-12-18	WOS:000679975300001
J	Lv, LX; Qin, T; Huang, QS; Jiang, H; Chen, F; Long, F; Ren, L; Liu, JP; Xie, YG; Zeng, M				Lv, Linxi; Qin, Ting; Huang, Qiushi; Jiang, Hui; Chen, Feng; Long, Fan; Ren, Long; Liu, Jianpin; Xie, Yongen; Zeng, Mei			Targeting Tristetraprolin Expression or Functional Activity Regulates Inflammatory Response Induced by MSU Crystals	FRONTIERS IN IMMUNOLOGY			English	Article						TTP; Arctigenin; NLRP3 inflammasome; mitochondrial ROS; autophagic flux 3	ACTIVATED PROTEIN-KINASE; LYSOSOMAL MEMBRANE PERMEABILIZATION; NLRP3 INFLAMMASOME; PHOSPHATASE 2A; CELL-DEATH; TTP; BINDING; GOUT; DESTABILIZATION; STABILITY	The RNA-binding protein tristetraprolin (TTP) is an anti-inflammatory factor that prompts the mRNA decay of target mRNAs and is involved in inflammatory diseases such as rheumatoid arthritis (RA). TTP is regulated by phosphorylation, and protein phosphatase 2A (PP2A) can dephosphorylate TTP to activate its mRNA-degrading function. Some small molecules can enhance PP2A activation. Short interfering RNA (siRNA) targeting TTP expression or PP2A agonist (Arctigenin) was administered to monosodium urate (MSU) crystal-induced J774A.1 cells, and the expression of inflammatory related genes was detected by RT-PCR and Western blot assays. The effects of Arctigenin in mouse models of acute inflammation induced by MSU crystals, including peritonitis and arthritis, were evaluated. The data indicated that TTP expression levels and endogenous PP2A activity were increased in MSU-crystal treated J774A.1 cells. TTP knockdown exacerbated inflammation-related genes expression and NLRP3 inflammasome activation. However, PP2A agonist treatment (Arctigenin) suppressed MSU crystal-induced inflammation in J774A.1 cells. Arctigenin also relieved mitochondrial reactive oxygen species (mtROS) production and improved lysosomal membrane permeability in MSU crystal-treated J774A.1 cells. Moreover, TTP knockdown reversed the anti-inflammatory and antioxidant effects of Arctigenin. Oral administration of Arctigenin significantly alleviated foot pad swelling, the number of inflammatory cells in peritoneal lavage fluids and the production of IL-1 beta in the mouse model of inflammation induced by MSU crystals. Collectively, these data imply that targeting TTP expression or functional activity may provide a potential therapeutic strategy for inflammation caused by MSU crystals.	[Lv, Linxi; Qin, Ting; Huang, Qiushi; Jiang, Hui; Chen, Feng; Liu, Jianpin; Zeng, Mei] North Sichuan Med Coll, Inst Rheumatol & Immunol, Affiliated Hosp, Nanchong, Peoples R China; [Lv, Linxi; Huang, Qiushi; Jiang, Hui; Chen, Feng; Xie, Yongen; Zeng, Mei] North SiChuan Med Coll, Biol Grp Preclin Sch, Nanchong, Peoples R China; [Long, Fan; Ren, Long; Zeng, Mei] Fifth Peoples Hosp Nanchong City, Clin Lab, Nanchong, Peoples R China; [Zeng, Mei] North SiChuan Med Coll, Med Imaging Key Lab Sichuan, Nanchong, Peoples R China; [Zeng, Mei] North Sichuan Med Coll, Academician Expert Workstn, Affiliated Hosp, Nanchong, Peoples R China	North Sichuan Medical University; North Sichuan Medical University; North Sichuan Medical University; North Sichuan Medical University	Zeng, M (corresponding author), North Sichuan Med Coll, Inst Rheumatol & Immunol, Affiliated Hosp, Nanchong, Peoples R China.; Zeng, M (corresponding author), North SiChuan Med Coll, Biol Grp Preclin Sch, Nanchong, Peoples R China.; Zeng, M (corresponding author), Fifth Peoples Hosp Nanchong City, Clin Lab, Nanchong, Peoples R China.; Zeng, M (corresponding author), North SiChuan Med Coll, Med Imaging Key Lab Sichuan, Nanchong, Peoples R China.; Zeng, M (corresponding author), North Sichuan Med Coll, Academician Expert Workstn, Affiliated Hosp, Nanchong, Peoples R China.	zengmei123@gmail.com			National Natural Science Foundation of China [81972119]; Sichuan Province Science and Technology Support Project [2018JY0158]; Nanchong City Science and Technology Support Project;  [19SXHZ0456];  [19YFZJ0045]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sichuan Province Science and Technology Support Project; Nanchong City Science and Technology Support Project; ; 	This research was supported by grants (No. 81972119) from the National Natural Science Foundation of China; the Sichuan Province Science and Technology Support Project (2018JY0158); and the Nanchong City Science and Technology Support Project (19SXHZ0456 and 19YFZJ0045).	Abais JM, 2015, ANTIOXID REDOX SIGN, V22, P1111, DOI 10.1089/ars.2014.5994; Brook M, 2006, MOL CELL BIOL, V26, P2408, DOI 10.1128/MCB.26.6.2408-2418.2006; Brooks SA, 2002, ARTHRITIS RHEUM, V46, P1362, DOI 10.1002/art.10235; Cai XY, 2018, REDOX BIOL, V18, P65, DOI 10.1016/j.redox.2018.06.010; Chen BF, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1974-z; Chen Y, 2015, BBA-MOL CELL RES, V1853, P396, DOI 10.1016/j.bbamcr.2014.11.012; Choe JY, 2014, RHEUMATOLOGY, V53, P1043, DOI 10.1093/rheumatology/ket474; Eshelman MA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50957-9; FAIRES JS, 1962, LANCET, V2, P682; Haneklaus M, 2017, J BIOL CHEM, V292, P6869, DOI 10.1074/jbc.M116.772947; Hitti E, 2006, MOL CELL BIOL, V26, P2399, DOI 10.1128/MCB.26.6.2399-2407.2006; Joe Y, 2020, CELL REP, V30, P1063, DOI 10.1016/j.celrep.2019.12.090; Khanna PP, 2015, PATIENT PREFER ADHER, V9, P971, DOI 10.2147/PPA.S83700; Kuo CF, 2015, NAT REV RHEUMATOL, V11, P649, DOI 10.1038/nrrheum.2015.91; Kuo HH, 2016, ONCOTARGET, V7, P38078, DOI 10.18632/oncotarget.9348; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Li HY, 2019, AUTOPHAGY, V15, P113, DOI 10.1080/15548627.2018.1509818; Lin YZ, 2010, INVEST OPHTH VIS SCI, V51, P6483, DOI 10.1167/iovs.10-5410; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Marchese FP, 2010, J BIOL CHEM, V285, P27590, DOI 10.1074/jbc.M110.136473; Marchetti C, 2018, P NATL ACAD SCI USA, V115, pE1530, DOI 10.1073/pnas.1716095115; McWherter C, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1699-4; Qadri M, 2021, J PHARMACOL EXP THER, V376, P222, DOI 10.1124/jpet.120.000321; Qiao SM, 2020, CANCER LETT, V491, P162, DOI 10.1016/j.canlet.2020.08.033; Ragab G, 2017, J ADV RES, V8, P495, DOI 10.1016/j.jare.2017.04.008; Rahman MM, 2016, CELL SIGNAL, V28, P325, DOI 10.1016/j.cellsig.2016.01.009; Ross CR, 2012, AGEING RES REV, V11, P473, DOI 10.1016/j.arr.2012.02.005; Ross EA, 2017, ANN RHEUM DIS, V76, P612, DOI 10.1136/annrheumdis-2016-209424; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Shi HX, 2016, NAT IMMUNOL, V17, P250, DOI 10.1038/ni.3333; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Sun L, 2007, J BIOL CHEM, V282, P3766, DOI 10.1074/jbc.M607347200; VARNUM BC, 1989, ONCOGENE, V4, P119; Yin J, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00096; Young LE, 2009, GASTROENTEROLOGY, V136, P1669, DOI 10.1053/j.gastro.2009.01.010; Zhang HC, 2013, ARTERIOSCL THROM VAS, V33, P1212, DOI 10.1161/ATVBAHA.113.301496; Zhang SM, 2017, BIOCHEM BIOPH RES CO, V493, P821, DOI 10.1016/j.bbrc.2017.08.062; Zhang WZ, 2015, INFLAMMATION, V38, P1406, DOI 10.1007/s10753-015-0115-3; Zhao WP, 2011, J INTERF CYTOK RES, V31, P629, DOI 10.1089/jir.2010.0154; Zhong YF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12433-w	41	1	1	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 16	2021	12								675534	10.3389/fimmu.2021.675534	http://dx.doi.org/10.3389/fimmu.2021.675534			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TS7GT	34335573	gold, Green Published			2022-12-18	WOS:000679815500001
J	Li, P; Guo, ZL; Wan, YSY				Li, Ping; Guo, Zengli; Wan, Yisong Y.			SKI Expression Suppresses Pathogenic Th17 Cell Response and Mitigates Experimental Autoimmune Encephalomyelitis	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmune disease; multiple sclerosis; experimental autoimmune encephalomyelitis; pathogenic Th17; SKI; transforming growth factor	TGF-BETA; T(H)17 CELLS; T-CELLS; DIFFERENTIATION; GENERATION; INDUCTION; DRIVES	Pathogenic Th17 cells are critically involved in many autoimmune diseases, while non-pathogenic Th17 cells are more immune regulatory. Understanding the mechanisms of the induction and maintenance of pathogenic Th17 cells will benefit the development of therapeutic treatments of related diseases. We have shown that the transforming growth factor-beta (TGF beta) induced SKI degradation and dissociation from Smad4 complex is a prerequisite for TGF beta-induced Th17 cell differentiation. However, it is unclear whether and how SKI regulates pathogenic Th17 differentiation, which does not require TGF beta cytokine. Here we showed that SKI expression was downregulated during pathogenic Th17 cell differentiation and the ectopic expression of SKI abrogated the differentiation of pathogenic Th17 cells. Functionally, using a knock-in mouse model, we found ectopic SKI expression specifically in T cells prevented myelin oligodendrocyte glycoprotein peptide (MOG(33-55)) induced experimental autoimmune encephalomyelitis (EAE), an animal model of human multiple sclerosis. We further revealed that induced SKI expression in already differentiated pathogenic Th17 cells reduced the maintenance of Th17 program and ameliorated EAE in an adoptive T cell transfer model. Therefore, our study provides valuable insights of targeting SKI to modulate pathogenic Th17 cell function and treat Th17-related diseases.	[Li, Ping; Guo, Zengli; Wan, Yisong Y.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Li, Ping; Guo, Zengli; Wan, Yisong Y.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USA; [Li, Ping] Jilin Univ, China Japan Union Hosp, Dept Rheumatol & Immunol, Changchun, Jilin, Peoples R China	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Jilin University	Guo, ZL; Wan, YSY (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA.; Guo, ZL; Wan, YSY (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USA.	zlguo@email.unc.edu; wany@email.unc.edu	Guo, Zengli/F-5743-2019; Wan, Yisong/ABE-1200-2021; Guo, Zengli/AAE-4706-2021	Guo, Zengli/0000-0003-2950-4790; Wan, Yisong/0000-0003-4346-9717; Guo, Zengli/0000-0003-2950-4790	NIH [AI123193, AI160774]; National Multiple Sclerosis Society [RG-1802-30483]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Multiple Sclerosis Society(National Multiple Sclerosis Society)	This study was supported by the NIH (AI123193, AI160774) and the National Multiple Sclerosis Society (RG-1802-30483) for YYW.	Akhurst RJ, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022301; Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Bettelli E, 2003, J EXP MED, V197, P1073, DOI 10.1084/jem.20021603; Chen WJ, 2016, NAT REV IMMUNOL, V16, P723, DOI 10.1038/nri.2016.112; Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008; Constantinescu CS, 2011, BRIT J PHARMACOL, V164, P1079, DOI 10.1111/j.1476-5381.2011.01302.x; Eberl G, 2004, NAT IMMUNOL, V5, P64, DOI 10.1038/ni1022; Esplugues E, 2011, NATURE, V475, P514, DOI 10.1038/nature10228; Ghoreschi K, 2011, TRENDS IMMUNOL, V32, P395, DOI 10.1016/j.it.2011.06.007; Ghoreschi K, 2010, NATURE, V467, P967, DOI 10.1038/nature09447; Gold R, 2006, BRAIN, V129, P1953, DOI 10.1093/brain/awl075; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Jager A, 2009, J IMMUNOL, V183, P7169, DOI 10.4049/jimmunol.0901906; Komuczki J, 2019, IMMUNITY, V50, P1289, DOI 10.1016/j.immuni.2019.04.006; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Le Scolan E, 2008, CANCER RES, V68, P3277, DOI 10.1158/0008-5472.CAN-07-6793; Lee Y, 2012, NAT IMMUNOL, V13, P991, DOI 10.1038/ni.2416; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Malhotra N, 2010, J BIOL CHEM, V285, P29044, DOI 10.1074/jbc.C110.156745; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; Nagano Y, 2007, J BIOL CHEM, V282, P20492, DOI 10.1074/jbc.M701294200; Omenetti S, 2019, IMMUNITY, V51, P77, DOI 10.1016/j.immuni.2019.05.004; Sanjabi S, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022236; Shapiro-Shelef M, 2005, J EXP MED, V202, P1471, DOI 10.1084/jem.20051611; Stockinger B, 2017, NAT REV IMMUNOL, V17, P535, DOI 10.1038/nri.2017.50; Sutton C, 2006, J EXP MED, V203, P1685, DOI 10.1084/jem.20060285; Tesmer LA, 2008, IMMUNOL REV, V223, P87, DOI 10.1111/j.1600-065X.2008.00628.x; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Waite JC, 2012, INT J INFLAMM, V2012, DOI 10.1155/2012/819467; Wu B, 2021, IMMUNITY, V54, P308, DOI 10.1016/j.immuni.2020.12.010; Wu B, 2021, CELL MOL IMMUNOL, V18, P2410, DOI 10.1038/s41423-020-0495-7; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016; Yasuda K, 2019, SEMIN IMMUNOPATHOL, V41, P283, DOI 10.1007/s00281-019-00733-8; Zhang S, 2017, NATURE, V551, P105, DOI 10.1038/nature24283	35	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 15	2021	12								707899	10.3389/fimmu.2021.707899	http://dx.doi.org/10.3389/fimmu.2021.707899			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TR6WO	34335622	Green Published, gold			2022-12-18	WOS:000679103300001
J	Ricci, ADD; Brunner, M; Ramoa, D; Carmona, SJJ; Nielsen, M; Aguero, F				Ricci, Alejandro D. D.; Brunner, Mauricio; Ramoa, Diego; Carmona, Santiago J. J.; Nielsen, Morten; Aguero, Fernan			APRANK: Computational Prioritization of Antigenic Proteins and Peptides From Complete Pathogen Proteomes	FRONTIERS IN IMMUNOLOGY			English	Article						antigens; linear epitopes; antigenicity; prediction; human pathogens	HUMAN-ANTIBODY RESPONSES; PREDICTION; MICROARRAY; GENERATION; DISEASES; ARRAY	Availability of highly parallelized immunoassays has renewed interest in the discovery of serology biomarkers for infectious diseases. Protein and peptide microarrays now provide a rapid, high-throughput platform for immunological testing and validation of potential antigens and B-cell epitopes. However, there is still a need for tools to prioritize and select relevant probes when designing these arrays. In this work we describe a computational method called APRANK (Antigenic Protein and Peptide Ranker) which integrates multiple molecular features to prioritize potentially antigenic proteins and peptides in a given pathogen proteome. These features include subcellular localization, presence of repetitive motifs, natively disordered regions, secondary structure, transmembrane spans and predicted interaction with the immune system. We trained and tested this method with a number of bacteria and protozoa causing human diseases: Borrelia burgdorferi (Lyme disease), Brucella melitensis (Brucellosis), Coxiella burnetii (Q fever), Escherichia coli (Gastroenteritis), Francisella tularensis (Tularemia), Leishmania braziliensis (Leishmaniasis), Leptospira interrogans (Leptospirosis), Mycobacterium leprae (Leprae), Mycobacterium tuberculosis (Tuberculosis), Plasmodium falciparum (Malaria), Porphyromonas gingivalis (Periodontal disease), Staphylococcus aureus (Bacteremia), Streptococcus pyogenes (Group A Streptococcal infections), Toxoplasma gondii (Toxoplasmosis) and Trypanosoma cruzi (Chagas Disease). We have evaluated this integrative method using non-parametric ROC-curves and made an unbiased validation using Onchocerca volvulus as an independent data set. We found that APRANK is successful in predicting antigenicity for all pathogen species tested, facilitating the production of antigen-enriched protein subsets. We make APRANK available to facilitate the identification of novel diagnostic antigens in infectious diseases.	[Ricci, Alejandro D. D.; Brunner, Mauricio; Ramoa, Diego; Carmona, Santiago J. J.; Nielsen, Morten; Aguero, Fernan] Univ San Martin UNSAM, CONICET, Consejo Nacl Invest Cient & Tecn, Inst Invest Biotecnol Rodolfo Ugalde IIB, Buenos Aires, DF, Argentina; [Nielsen, Morten] Tech Univ Denmark, Dept Hlth Technol, Lyngby, Denmark; [Brunner, Mauricio] Hosp Italiano Buenos Aires, Dept Informat Salud, Buenos Aires, DF, Argentina; [Carmona, Santiago J. J.] Univ Lausanne, CHU Vaudois, Ludwig Inst Canc Res, Dept Oncol, Lausanne, Switzerland	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Technical University of Denmark; Hospital Italiano de Buenos Aires; University of Buenos Aires; Ludwig Institute for Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Aguero, F (corresponding author), Univ San Martin UNSAM, CONICET, Consejo Nacl Invest Cient & Tecn, Inst Invest Biotecnol Rodolfo Ugalde IIB, Buenos Aires, DF, Argentina.	fernan@iib.unsam.edu.ar	Carmona, Santiago J/E-9356-2015; Nielsen, Morten/E-7754-2011	Carmona, Santiago J/0000-0002-2495-0671; Ricci, Alejandro Daniel/0000-0002-1814-0568; Nielsen, Morten/0000-0001-7885-4311	National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI123070]; Agencia Nacional de Promocion Cientifica (Argentina ) [PICT-2013-1193, PICT-2017-0175]	National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Agencia Nacional de Promocion Cientifica (Argentina )(ANPCyT)	Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number R01AI123070 and by Agencia Nacional de Promocion Cientifica (Argentina )under award numbers PICT-2013-1193 and PICT-2017-0175	Balouz V, 2021, TRENDS PARASITOL, V37, P214, DOI 10.1016/j.pt.2020.12.002; Barbour AG, 2008, INFECT IMMUN, V76, P3374, DOI 10.1128/IAI.00048-08; Beare PA, 2008, CLIN VACCINE IMMUNOL, V15, P1771, DOI 10.1128/CVI.00300-08; Buus S, 2012, MOL CELL PROTEOMICS, V11, P1790, DOI 10.1074/mcp.M112.020800; Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421; Carmona SJ, 2015, MOL CELL PROTEOMICS, V14, P1871, DOI 10.1074/mcp.M114.045906; Carmona SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050748; Chen C, 2009, CLIN MICROBIOL INFEC, V15, P156, DOI 10.1111/j.1469-0691.2008.02206.x; Dalsass M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00113; Dosztanyi Z, 2005, J MOL BIOL, V347, P827, DOI 10.1016/j.jmb.2005.01.071; Dosztanyi Z, 2018, PROTEIN SCI, V27, P331, DOI 10.1002/pro.3334; Durante IM, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005986; Eyles JE, 2007, PROTEOMICS, V7, P2172, DOI 10.1002/pmic.200600985; Holmes P, 2014, LANCET, V383, P1803, DOI 10.1016/S0140-6736(14)60875-8; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; Kilmury SLN, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2010.00143; Klausen MS, 2019, PROTEINS, V87, P520, DOI 10.1002/prot.25674; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lagatie O, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005330; Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2; Lawrenz MB, 1999, J CLIN MICROBIOL, V37, P3997, DOI 10.1128/JCM.37.12.3997-4004.1999; Lessa-Aquino C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002499; Liang L, 2012, CHEM BIODIVERS, V9, P977, DOI 10.1002/cbdv.201100360; Liang L, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000673; Liu EW, 2018, AM J TROP MED HYG, V98, P57, DOI 10.4269/ajtmh.17-0437; Lu Z, 2007, IMMUNOL LETT, V112, P92, DOI 10.1016/j.imlet.2007.07.006; Lunardon N, 2014, R J, V6, P79; Martini S, 2020, IMMUNOGENETICS, V72, P57, DOI 10.1007/s00251-019-01137-6; McDonnell AV, 2006, BIOINFORMATICS, V22, P356, DOI 10.1093/bioinformatics/bti797; Menardi G, 2014, DATA MIN KNOWL DISC, V28, P92, DOI 10.1007/s10618-012-0295-5; Mucci J, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005972; Newman AM, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-382; Nielsen Morten, 2010, Immunome Res, V6, P9, DOI 10.1186/1745-7580-6-9; Obiero JM, 2019, MSPHERE, V4, DOI [10.1128/mSphereDirect.00027-19, 10.1128/mspheredirect.00027-19]; Peeling RW, 2011, INFECT DIS CLIN N AM, V25, P693, DOI 10.1016/j.idc.2011.06.002; Pellois JP, 2002, NAT BIOTECHNOL, V20, P922, DOI 10.1038/nbt723; Petersen B, 2009, BMC STRUCT BIOL, V9, DOI 10.1186/1472-6807-9-51; Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701; Pierleoni A, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-392; Ricci A., 2021, APRANK RELEASE V1 0; Richer J, 2015, MOL CELL PROTEOMICS, V14, P136, DOI 10.1074/mcp.M114.043513; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Sutandy F X Reymond, 2013, Curr Protoc Protein Sci, VChapter 27, DOI 10.1002/0471140864.ps2701s72; Vainionp R., 2008, ENCY VIROLOGY, P29, DOI [10.1016/B978- 012374410-4.00585-9, DOI 10.1016/B978-012374410-4.00585-9]; Vigil A, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.006304; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Wang XL, 2013, SCI CHINA LIFE SCI, V56, P453, DOI 10.1007/s11427-013-4472-6; Washington J.A., 1996, MED MICROBIOLOGY, V4th ed.; Xiong XL, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-35; Xu Y, 2008, MICROB PATHOGENESIS, V45, P403, DOI 10.1016/j.micpath.2008.09.006	50	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 15	2021	12								702552	10.3389/fimmu.2021.702552	http://dx.doi.org/10.3389/fimmu.2021.702552			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TR8AL	34335615	Green Published, gold, Green Submitted			2022-12-18	WOS:000679182600001
J	Romani, L; Williamson, PR; Di Cesare, S; Di Matteo, G; De Luca, M; Carsetti, R; Figa-Talamanca, L; Cancrini, C; Rossi, P; Finocchi, A				Romani, Lorenza; Williamson, Peter Richard; Di Cesare, Silvia; Di Matteo, Gigliola; De Luca, Maia; Carsetti, Rita; Figa-Talamanca, Lorenzo; Cancrini, Caterina; Rossi, Paolo; Finocchi, Andrea			Cryptococcal Meningitis and Post-Infectious Inflammatory Response Syndrome in a Patient With X-Linked Hyper IgM Syndrome: A Case Report and Review of the Literature	FRONTIERS IN IMMUNOLOGY			English	Review						X-linked Hyper IgM syndrome; cryptococcal meningoencephalitis; post-infectious inflammatory response syndrome; primary immunodeficiency; fungal infection	CORTICOSTEROIDS; INFECTION; DAMAGE	The hyper IgM syndromes are a rare group of primary immunodeficiency. The X-linked Hyper IgM syndrome (HIGM), due to a gene defect in CD40L, is the commonest variant; it is characterized by an increased susceptibility to a narrow spectrum of opportunistic infection. A few cases of HIGM patients with Cryptococcal meningoencephalitis (CM) have been described in the literature. Herein we report the case of a young male diagnosed in infancy with HIGM who developed CM complicated by a post-infectious inflammatory response syndrome (PIIRS), despite regular immunoglobulin replacement therapy and appropriate antimicrobial prophylaxis. The patient was admitted because of a headache and CM was diagnosed through detection of Cryptococcus neoformans in the cerebrospinal fluid. Despite the antifungal therapy resulting to negative CSF culture, the patient exhibited persistent headaches and developed diplopia. An analysis of inflammatory cytokines on CSF, as well as the brain MRI, suggested a diagnosis of PIIRS. Therefore, a prolonged corticosteroids therapy was started obtaining a complete resolution of symptoms without any relapse.	[Romani, Lorenza; De Luca, Maia; Cancrini, Caterina; Rossi, Paolo; Finocchi, Andrea] Bambino Gesu Pediat Hosp, Unit Immune & Infect Dis, IRCCS, Rome, Italy; [Williamson, Peter Richard] NIH, Lab Clin Immunol & Microbiol, Bldg 10, Bethesda, MD 20892 USA; [Di Cesare, Silvia; Di Matteo, Gigliola; Cancrini, Caterina; Rossi, Paolo; Finocchi, Andrea] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy; [Carsetti, Rita] Bambino Gesu Pediat Hosp, B Cell Physiopathol Unit, IRCCS, Immunol Res Area, Rome, Italy; [Figa-Talamanca, Lorenzo] Bambino Gesu Pediat Hosp, Imaging Dept, Neuroradiol Unit, IRCCS, Rome, Italy	IRCCS Bambino Gesu; National Institutes of Health (NIH) - USA; University of Rome Tor Vergata; IRCCS Bambino Gesu; IRCCS Bambino Gesu	Finocchi, A (corresponding author), Bambino Gesu Pediat Hosp, Unit Immune & Infect Dis, IRCCS, Rome, Italy.; Finocchi, A (corresponding author), Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy.	andrea.finocchi@opbg.net	FINOCCHI, ANDREA/K-5926-2016	FINOCCHI, ANDREA/0000-0003-0958-8536; DI MATTEO, GIGLIOLA/0000-0001-8344-5635; DI CESARE, SILVIA/0000-0002-9912-7997	NIH Intramural Research Program; Bambino Gesu Children's Hospital Research Program [RIC-2020 -PI AF]	NIH Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bambino Gesu Children's Hospital Research Program	This work was partially supported by the NIH Intramural Research Program and by Bambino Gesu Children's Hospital Research Program (RIC-2020 -PI AF).	Aghamohammadi A, 2009, J CLIN IMMUNOL, V29, P769, DOI 10.1007/s10875-009-9315-7; Anjum S, 2021, CLIN INFECT DIS, V73, pE2789, DOI 10.1093/cid/ciaa1901; Anjum S, 2019, CURR FUNGAL INFECT R, V13, P99, DOI 10.1007/s12281-019-00345-7; Antachopoulos C, 2010, CLIN MICROBIOL INFEC, V16, P1335, DOI 10.1111/j.1469-0691.2010.03289.x; Ara A, 2018, IMMUNOTARGETS THER, V7, P55, DOI 10.2147/ITT.S163614; Ballou ER, 2017, CURR OPIN MICROBIOL, V40, P88, DOI 10.1016/j.mib.2017.10.012; Beardsley J, 2016, NEW ENGL J MED, V374, P542, DOI 10.1056/NEJMoa1509024; Beardsley J, 2019, J FUNGI, V5, DOI 10.3390/jof5030071; Bishu S, 2009, PEDIATR NEUROL, V41, P419, DOI 10.1016/j.pediatrneurol.2009.07.003; De Gorgolas M, 2005, SCAND J INFECT DIS, V37, P526, DOI 10.1080/00365540510036570; de la Morena MT, 2016, J ALLER CL IMM-PRACT, V4, P1023, DOI 10.1016/j.jaip.2016.09.013; Du X, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12798; Elsegeiny W, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00651; Franca TT, 2019, EXPERT REV CLIN IMMU, V15, P529, DOI 10.1080/1744666X.2019.1573674; Hammoud DA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09694-0; Jenny-Avital ER, 2002, CLIN INFECT DIS, V35, pE128, DOI 10.1086/344467; Katchanov J, 2014, INT J INFECT DIS, V18, P87, DOI 10.1016/j.ijid.2013.08.012; Kulkarni A, 2019, ANN INDIAN ACAD NEUR, V22, P322, DOI 10.4103/aian.AIAN_29_18; Leman JD, 2017, CRIT REV IMMUNOL, V37, P371, DOI 10.1615/CritRevImmunol.v37.i2-6.100; Malheiro Luis, 2014, BMC Res Notes, V7, P566, DOI 10.1186/1756-0500-7-566; Marr KA, 2020, CLIN INFECT DIS, V70, P252, DOI 10.1093/cid/ciz193; Maziarz EK, 2016, INFECT DIS CLIN N AM, V30, P179, DOI 10.1016/j.idc.2015.10.006; Mehta GU, 2018, J NEUROL NEUROSUR PS, V89, P219, DOI 10.1136/jnnp-2017-315830; Pacharn P, 2021, ASIAN PAC J ALLERGY, V39, P31, DOI 10.12932/AP-190618-0341; Panackal AA, 2016, MBIO, V7, DOI 10.1128/mBio.01906-15; Panackal AA, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004884; Pietrella D, 2004, FEMS IMMUNOL MED MIC, V40, P63, DOI 10.1016/S0928-8244(03)00297-9; Pirofski LA, 2008, ADV EXP MED BIOL, V635, P135, DOI 10.1007/978-0-387-09550-9_11; Pirofski LA, 2017, MBIO, V8, DOI 10.1128/mBio.02063-17; RINEHART JJ, 1974, J CLIN INVEST, V54, P1337, DOI 10.1172/JCI107880; Suzuki SML, 2019, J MYCOL MED, V29, P273, DOI 10.1016/j.mycmed.2019.07.002; Viviani MA., 2003, CLIN MYCOLOGY, V1st edition, P240; Warkentien T, 2010, INT J STD AIDS, V21, P679, DOI 10.1258/ijsa.2010.010182; Williamson Peter R, 2015, Macrophage (Houst), V2; Williamson PR, 2017, NAT REV NEUROL, V13, P13, DOI 10.1038/nrneurol.2016.167; Yazdani R, 2019, CLIN IMMUNOL, V198, P19, DOI 10.1016/j.clim.2018.11.007; Zhu LP, 2010, MED MYCOL, V48, P570, DOI 10.3109/13693780903437876	37	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 15	2021	12								708837	10.3389/fimmu.2021.708837	http://dx.doi.org/10.3389/fimmu.2021.708837			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5X8CP	34335625	Green Published, gold			2022-12-18	WOS:000878825300001
J	Sarcina, D; Giovannini, M; Oranges, T; Barni, S; Pedaci, FA; Liccioli, G; Canessa, C; Sarti, L; Lodi, L; Filippeschi, C; Azzari, C; Ricci, S; Mori, F				Sarcina, Davide; Giovannini, Mattia; Oranges, Teresa; Barni, Simona; Pedaci, Fausto Andrea; Liccioli, Giulia; Canessa, Clementina; Sarti, Lucrezia; Lodi, Lorenzo; Filippeschi, Cesare; Azzari, Chiara; Ricci, Silvia; Mori, Francesca			Case Report and Review of the Literature: Bullous Skin Eruption After the Booster-Dose of Influenza Vaccine in a Pediatric Patient With Polymorphic Maculopapular Cutaneous Mastocytosis	FRONTIERS IN IMMUNOLOGY			English	Review						vaccination; cutaneous mastocytosis; prevention; premedication; adverse reaction; pediatrics	CHILDREN; ANAPHYLAXIS; MANAGEMENT; DIAGNOSIS; TRYPTASE	Vaccination is a well-known trigger for mast cell degranulation in subjects affected by mastocytosis. Nevertheless, there is no exact standardized protocol to prevent a possible reaction after a vaccine injection, especially for patients who have already presented a previous vaccine-related adverse event, considering that these patients frequently tolerate future vaccine doses. For this reason, we aim to share our experience at Meyer Children's University Hospital in Florence to raise awareness on the potential risk for future vaccinations and to discuss the valuable therapeutic strategies intended to prevent them, taking into account what is proposed by experts in literature. We describe the case of an 18-month-old female affected by a polymorphic variant of maculopapular cutaneous mastocytosis that presented an extensive bullous cutaneous reaction 24 hours after the second dose (booster dose) of inactivated-tetravalent influenza vaccine, treated with a single dose of oral corticosteroid therapy with betamethasone (0.1 mg/kg) and an oral antihistamine therapy with oxatomide (1 mg/kg/daily) for a week, until resolution. To the best of our knowledge, in the literature, no documented case of reaction to influenza vaccine in maculopapular cutaneous mastocytosis is described. Subsequently, the patient started a background therapy with ketotifen daily (0.05 mg/kg twice daily), a non-competitive H1-antihistamine, and a mast cell stabilizer (dual activity). A non-standardized pharmacological premedication protocol with an H1-receptor antagonist (oxatomide, 0.5 mg/kg) administered 12 hours before the immunizations, and a single dose of betamethasone (0.05 mg/kg) together with another dose of oxatomide (0.5 mg/kg) administered 2 hours before the injections was followed to make it possible for the patient to continue with the scheduled vaccinations. Indeed, no reactions were subsequently reported. Thus, in our experience, a background therapy with ketotifen associated with a premedication protocol made by two doses of oxatomide and a single dose of betamethasone was helpful to make possible the execution of the other vaccines. We suggest how in these children, it could be considered the idea of taking precaution when vaccination is planned, regardless of the kind of vaccine and if a dose of the same vaccine was previously received. However, international consensus needs to be reached to manage vaccinations in children with mastocytosis and previous adverse reactions to vaccines.	[Sarcina, Davide; Giovannini, Mattia; Barni, Simona; Liccioli, Giulia; Sarti, Lucrezia; Mori, Francesca] Meyer Childrens Univ Hosp, Allergy Unit, Dept Pediat, Florence, Italy; [Oranges, Teresa; Pedaci, Fausto Andrea; Filippeschi, Cesare] Meyer Childrens Univ Hosp, Dept Pediat, Dermatol Unit, Florence, Italy; [Canessa, Clementina; Lodi, Lorenzo; Azzari, Chiara; Ricci, Silvia] Meyer Childrens Univ Hosp, Immunol Unit, Dept Pediat, Florence, Italy	University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER	Giovannini, M (corresponding author), Meyer Childrens Univ Hosp, Allergy Unit, Dept Pediat, Florence, Italy.	mattiag88@hotmail.it	Ricci, silvia/AAY-6957-2021; Giovannini, Mattia/AAP-2693-2021; Liccioli, Giulia/AAC-3862-2022; /K-2737-2018	Giovannini, Mattia/0000-0001-9568-6882; Liccioli, Giulia/0000-0002-5216-0423; /0000-0001-7140-1694				Arase N, 2020, J DERMATOL, V47, P426, DOI 10.1111/1346-8138.15266; Bankova LG, 2013, J ALLER CL IMM-PRACT, V1, P94, DOI 10.1016/j.jaip.2012.08.008; Bodemer C, 2010, J INVEST DERMATOL, V130, P804, DOI 10.1038/jid.2009.281; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Brockow K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052684; Broesby-Olsen S, 2018, IMMUNOL ALLERGY CLIN, V38, P365, DOI 10.1016/j.iac.2018.04.009; Carter MC, 2015, J ALLERGY CLIN IMMUN, V136, P1673, DOI 10.1016/j.jaci.2015.04.024; Castells M, 2011, AM J CLIN DERMATOL, V12, P259, DOI 10.2165/11588890-000000000-00000; Ferreira S, 2020, ACTA MEDICA PORT, V33, P275, DOI 10.20344/amp.12189; Hartmann K, 2016, J ALLERGY CLIN IMMUN, V137, P35, DOI 10.1016/j.jaci.2015.08.034; Heide R, 2008, PEDIATR DERMATOL, V25, P493, DOI 10.1111/j.1525-1470.2008.00738.x; Hudson A, 2016, J CUTAN MED SURG, V20, P596, DOI 10.1177/1203475416661312; Hussain SH, 2020, CURR OPIN PEDIATR, V32, P531, DOI 10.1097/MOP.0000000000000922; Istituto Superiore di Sanita, GUID CONTR ALL VACC GUID CONTR ALL VACC; Johansen ML, 2021, PEDIATR DERMATOL, V38, P502, DOI 10.1111/pde.14492; Klaiber N, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0748-4; Leung AKC, 2019, CURR PEDIATR REV, V15, P42, DOI 10.2174/1573396315666181120163952; Paoloni G., 2011, MED BAMBINO, V30, P155; Parente R, 2017, PEDIAT ALLERG IMM-UK, V28, P93, DOI 10.1111/pai.12647; Platzgummer S, 2020, EUR ANN ALLERGY CLIN, V52, P51, DOI 10.23822/EurAnnACI.1764-1489.133; Siebenhaar F, 2012, HAUTARZT, V63, P104, DOI 10.1007/s00105-011-2201-2; Sollai S, 2016, J CHEMOTHERAPY, V28, P355, DOI 10.1080/1120009X.2016.1173318; Valent P, 2017, CANCER RES, V77, P1261, DOI 10.1158/0008-5472.CAN-16-2234; Wiechers T, 2015, J ALLERGY CLIN IMMUN, V136, P1581, DOI 10.1016/j.jaci.2015.05.034; Zanoni G, 2017, CLIN EXP ALLERGY, V47, P593, DOI 10.1111/cea.12882	25	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 15	2021	12								688364	10.3389/fimmu.2021.688364	http://dx.doi.org/10.3389/fimmu.2021.688364			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TT0JN	34335590	gold, Green Published			2022-12-18	WOS:000680038100001
J	Shou, YJ; Koroleva, E; Spencer, CMM; Shein, SAA; Korchagina, AAA; Yusoof, KAA; Parthasarathy, R; Leadbetter, EAA; Akopian, ANN; Munoz, ARR; Tumanov, AVV				Shou, Yajun; Koroleva, Ekaterina; Spencer, Cody M. M.; Shein, Sergey A. A.; Korchagina, Anna A. A.; Yusoof, Kizil A. A.; Parthasarathy, Raksha; Leadbetter, Elizabeth A. A.; Akopian, Armen N. N.; Munoz, Amanda R. R.; Tumanov, Alexei V. V.			Redefining the Role of Lymphotoxin Beta Receptor in the Maintenance of Lymphoid Organs and Immune Cell Homeostasis in Adulthood	FRONTIERS IN IMMUNOLOGY			English	Article						lymphotoxin; LT beta R; lymphoid organs; FDCs; IgA; Citrobacter rodentium	TUMOR-NECROSIS-FACTOR; TISSUE-INDUCER CELLS; SUBCAPSULAR SINUS MACROPHAGES; IMMUNOGLOBULIN-A GENERATION; MEMBRANE LYMPHOTOXIN; DENDRITIC CELLS; B-CELLS; FOLLICLE FORMATION; STROMAL CELLS; FAMILY-MEMBER	Lymphotoxin beta receptor (LT beta R) is a promising therapeutic target in autoimmune and infectious diseases as well as cancer. Mice with genetic inactivation of LT beta R display multiple defects in development and organization of lymphoid organs, mucosal immune responses, IgA production and an autoimmune phenotype. As these defects are imprinted in embryogenesis and neonate stages, the impact of LT beta R signaling in adulthood remains unclear. Here, to overcome developmental defects, we generated mice with inducible ubiquitous genetic inactivation of LT beta R in adult mice (iLT beta R-Delta/Delta mice) and redefined the role of LT beta R signaling in organization of lymphoid organs, immune response to mucosal bacterial pathogen, IgA production and autoimmunity. In spleen, postnatal LT beta R signaling is required for development of B cell follicles, follicular dendritic cells (FDCs), recruitment of neutrophils and maintenance of the marginal zone. Lymph nodes of iLT beta R-Delta/Delta mice were reduced in size, lacked FDCs, and had disorganized subcapsular sinus macrophages. Peyer's patches were smaller in size and numbers, and displayed reduced FDCs. The number of isolated lymphoid follicles in small intestine and colon were also reduced. In contrast to LT beta R-/- mice, iLT beta R-Delta/Delta mice displayed normal thymus structure and did not develop signs of systemic inflammation and autoimmunity. Further, our results suggest that LT beta R signaling in adulthood is required for homeostasis of neutrophils, NK, and iNKT cells, but is dispensable for the maintenance of polyclonal IgA production. However, iLT beta R-Delta/Delta mice exhibited an increased sensitivity to C. rodentium infection and failed to develop pathogen-specific IgA responses. Collectively, our study uncovers new insights of LT beta R signaling in adulthood for the maintenance of lymphoid organs, neutrophils, NK and iNKT cells, and IgA production in response to mucosal bacterial pathogen.	[Shou, Yajun; Koroleva, Ekaterina; Shein, Sergey A. A.; Korchagina, Anna A. A.; Yusoof, Kizil A. A.; Parthasarathy, Raksha; Leadbetter, Elizabeth A. A.; Munoz, Amanda R. R.; Tumanov, Alexei V. V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol Immunol & Mol Genet, San Antonio, TX 78229 USA; [Shou, Yajun] Cent South Univ, Dept Gastroenterol, Xiangya Hosp 2, Changsha, Peoples R China; [Spencer, Cody M. M.] Trudeau Inst, Saranac Lake, NY USA; [Akopian, Armen N. N.] Univ Texas Hlth Sci Ctr San Antonio, Dept Endodont, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Central South University; Trudeau Institute; University of Texas System; University of Texas Health San Antonio	Tumanov, AVV (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol Immunol & Mol Genet, San Antonio, TX 78229 USA.	tumanov@uthscsa.edu		Yusoof, Kizil/0000-0002-0726-0599; Anna, Korchagina/0000-0003-3633-2392	NIH [AI135574, NS112263, NCI P30 CA054174]; Max and Minnie Tomerlin Voelcker Fund; William and Ella Owens Medical Research Foundation; San Antonio Biomedical Education and Research Institutional Research and Academic Career Development Award (SABER-IRACDA) [K12 GM111726]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Max and Minnie Tomerlin Voelcker Fund; William and Ella Owens Medical Research Foundation; San Antonio Biomedical Education and Research Institutional Research and Academic Career Development Award (SABER-IRACDA)	This research was supported by grant from NIH (AI135574, NS112263). AT was supported by the Max and Minnie Tomerlin Voelcker Fund, William and Ella Owens Medical Research Foundation. AM was supported by K12 GM111726 San Antonio Biomedical Education and ResearchInstitutional Research and Academic Career Development Award (SABER-IRACDA). Flow Cytometry and Optical Imaging Core facilities at UT Health San Antonio is supported with funding from University and the NIH (NCI P30 CA054174).	Albarbar B, 2015, CYTOKINE GROWTH F R, V26, P659, DOI 10.1016/j.cytogfr.2015.05.001; Boehm T, 2003, J EXP MED, V198, P757, DOI 10.1084/jem.20030794; Browning JL, 2008, IMMUNOL REV, V223, P202, DOI 10.1111/j.1600-065X.2008.00633.x; Browning JL, 2005, IMMUNITY, V23, P539, DOI 10.1016/j.immuni.2005.10.002; Browning JL, 2002, J IMMUNOL, V168, P5079, DOI 10.4049/jimmunol.168.10.5079; Chai Q, 2013, IMMUNITY, V38, P1013, DOI 10.1016/j.immuni.2013.03.012; Chin RK, 2003, NAT IMMUNOL, V4, P1121, DOI 10.1038/ni982; Chin RK, 2006, J IMMUNOL, V177, P290, DOI 10.4049/jimmunol.177.1.290; Cosway EJ, 2017, J EXP MED, V214, P3183, DOI 10.1084/jem.20171000; Croft M, 2017, NAT REV RHEUMATOL, V13, P217, DOI 10.1038/nrrheum.2017.22; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Dohi T, 2001, J IMMUNOL, V167, P2781, DOI 10.4049/jimmunol.167.5.2781; Drennan MB, 2014, J IMMUNOL, V193, P5960, DOI 10.4049/jimmunol.1401601; Eberl G, 2004, NAT IMMUNOL, V5, P64, DOI 10.1038/ni1022; Elewaut D, 2000, J IMMUNOL, V165, P671, DOI 10.4049/jimmunol.165.2.671; Fagarasan S, 2010, ANNU REV IMMUNOL, V28, P243, DOI 10.1146/annurev-immunol-030409-101314; Fernandes MT, 2016, BBA-REV CANCER, V1865, P204, DOI 10.1016/j.bbcan.2016.02.005; Franki AS, 2006, P NATL ACAD SCI USA, V103, P9160, DOI 10.1073/pnas.0508892103; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Girbl T, 2018, IMMUNITY, V49, P1062, DOI 10.1016/j.immuni.2018.09.018; Gonzalez M, 1998, J EXP MED, V187, P997, DOI 10.1084/jem.187.7.997; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Hamada H, 2002, J IMMUNOL, V168, P57, DOI 10.4049/jimmunol.168.1.57; Herro R, 2018, J EXP MED, V215, P415, DOI 10.1084/jem.20170536; Iizuka K, 1999, P NATL ACAD SCI USA, V96, P6336, DOI 10.1073/pnas.96.11.6336; James KD, 2018, J EXP MED, V215, P2984, DOI 10.1084/jem.20181345; Kabashima K, 2005, IMMUNITY, V22, P439, DOI 10.1016/j.immuni.2005.02.007; Kang HS, 2002, NAT IMMUNOL, V3, P576, DOI 10.1038/ni795; Kim TJ, 2014, J EXP MED, V211, P1414, DOI 10.1084/jem.20131501; Koroleva EP, 2015, J IMMUNOL METHODS, V421, P61, DOI 10.1016/j.jim.2015.02.003; Kranich J, 2008, J EXP MED, V205, P1293, DOI 10.1084/jem.20071019; Krause P, 2014, GASTROENTEROLOGY, V146, P1752, DOI 10.1053/j.gastro.2014.02.010; Kruglov AA, 2013, SCIENCE, V342, P1243, DOI 10.1126/science.1243364; Kweon MN, 2005, J IMMUNOL, V174, P4365, DOI 10.4049/jimmunol.174.7.4365; Lewis SM, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau6085; Li CL, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aax1027; Lopes N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03619-9; Lorenz RG, 2003, J IMMUNOL, V170, P5475, DOI 10.4049/jimmunol.170.11.5475; Louie DAP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00347; Macho-Fernandez E, 2015, MUCOSAL IMMUNOL, V8, P403, DOI 10.1038/mi.2014.78; Mackay F, 1997, EUR J IMMUNOL, V27, P2033, DOI 10.1002/eji.1830270830; Mackay F, 1998, NATURE, V395, P26, DOI 10.1038/25630; Martins VC, 2008, J IMMUNOL, V181, P400, DOI 10.4049/jimmunol.181.1.400; Mebius RE, 2005, NAT REV IMMUNOL, V5, P606, DOI 10.1038/nri1669; Mehta AK, 2018, ALLERGY, V73, P1415, DOI 10.1111/all.13390; Milicevic NM, 2011, J IMMUNOL, V186, P1486, DOI 10.4049/jimmunol.1000740; Moseman EA, 2012, IMMUNITY, V36, P415, DOI 10.1016/j.immuni.2012.01.013; Murphy TL, 2010, ANNU REV IMMUNOL, V28, P389, DOI 10.1146/annurev-immunol-030409-101202; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Nitta T, 2020, NAT IMMUNOL, V21, P1172, DOI 10.1038/s41590-020-0756-8; Onder L, 2018, TRENDS IMMUNOL, V39, P775, DOI 10.1016/j.it.2018.08.003; Onder L, 2017, IMMUNITY, V47, P80, DOI 10.1016/j.immuni.2017.05.008; Ota N, 2011, NAT IMMUNOL, V12, P941, DOI 10.1038/ni.2089; Pabst O, 2012, NAT REV IMMUNOL, V12, P821, DOI 10.1038/nri3322; Phan TG, 2009, NAT IMMUNOL, V10, P786, DOI 10.1038/ni.1745; Piao WJ, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040747; Pikor NB, 2015, IMMUNITY, V43, P1160, DOI 10.1016/j.immuni.2015.11.010; Pozo AL, 2009, BLOOD REV, V23, P105, DOI 10.1016/j.blre.2008.10.001; Reboldi A, 2016, SCIENCE, V352, DOI 10.1126/science.aaf4822; Riffelmacher T, 2021, MUCOSAL IMMUNOL, V14, P679, DOI 10.1038/s41385-021-00378-7; Scandella E, 2008, NAT IMMUNOL, V9, P667, DOI 10.1038/ni.1605; Schaeuble K, 2017, CELL REP, V21, P2500, DOI 10.1016/j.celrep.2017.10.119; Scheu S, 2002, J EXP MED, V195, P1613, DOI 10.1084/jem.20020215; Sedimbi SK, 2020, P NATL ACAD SCI USA, V117, P9054, DOI 10.1073/pnas.1920463117; Shihan MH, 2021, BIOCHEM BIOPHYS REP, V25, DOI 10.1016/j.bbrep.2021.100916; Shui JW, 2011, J LEUKOCYTE BIOL, V89, P517, DOI 10.1189/jlb.0910528; Spahn TW, 2004, GASTROENTEROLOGY, V127, P1463, DOI 10.1053/j.gastro.2004.08.022; Sperinde G, 2020, AAPS J, V22, DOI 10.1208/s12248-020-00447-y; Steinberg MW, 2009, SEMIN IMMUNOPATHOL, V31, P207, DOI 10.1007/s00281-009-0157-4; Suzuki K, 2010, IMMUNITY, V33, P71, DOI 10.1016/j.immuni.2010.07.003; Tsuji M, 2008, IMMUNITY, V29, P261, DOI 10.1016/j.immuni.2008.05.014; Tumanov AV, 2011, CELL HOST MICROBE, V10, P44, DOI 10.1016/j.chom.2011.06.002; Tumanov AV, 2003, IMMUNOL REV, V195, P106, DOI 10.1034/j.1600-065X.2003.00071.x; Tumanov AV, 2002, IMMUNITY, V17, P239, DOI 10.1016/S1074-7613(02)00397-7; van de Pavert SA, 2010, NAT REV IMMUNOL, V10, P664, DOI 10.1038/nri2832; Van Praet JT, 2015, EMBO J, V34, P466, DOI 10.15252/embj.201489966; Vanderkerken M., 2021, J EXP MED, V218, DOI [10.1084/jem.20190835, DOI 10.1084/JEM.20190835]; Venanzi ES, 2007, J IMMUNOL, V179, P5693, DOI 10.4049/jimmunol.179.9.5693; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Wang J, 2002, EUR J IMMUNOL, V32, P1969, DOI 10.1002/1521-4141(200207)32:7<1969::AID-IMMU1969>3.0.CO;2-M; Wang YG, 2010, IMMUNITY, V32, P403, DOI 10.1016/j.immuni.2010.02.011; Wang ZN, 2018, J IMMUNOL, V201, P69, DOI 10.4049/jimmunol.1701080; Ware CF, 2005, ANNU REV IMMUNOL, V23, P787, DOI 10.1146/annurev.immunol.23.021704.115719; Withers DR, 2007, EUR J IMMUNOL, V37, P3240, DOI 10.1002/eji.200737541; Wu Q, 2001, J IMMUNOL, V166, P1684, DOI 10.4049/jimmunol.166.3.1684; Wu Q, 1999, J EXP MED, V190, P629, DOI 10.1084/jem.190.5.629; Yang CP, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01860; Zhang Y, 2018, CELL MOL IMMUNOL, V15, P697, DOI 10.1038/cmi.2017.25; Zheng Y, 2008, NAT MED, V14, P282, DOI 10.1038/nm1720; Zhu MZ, 2011, J IMMUNOL, V186, P7156, DOI 10.4049/jimmunol.1002097; Zindl CL, 2009, IMMUNITY, V30, P408, DOI 10.1016/j.immuni.2009.01.010	92	1	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 15	2021	12								712632	10.3389/fimmu.2021.712632	http://dx.doi.org/10.3389/fimmu.2021.712632			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TR7UE	34335629	gold, Green Published			2022-12-18	WOS:000679165900001
J	Pradeep, SP; Venkatesh, PH; Manchala, NRR; Veedu, AV; Basavaraju, RKK; Selvasundari, L; Ramakrishna, M; Chandrakiran, Y; Krishnamurthy, V; Holigi, S; Thomas, T; Ross, CRR; Dias, M; Satchidanandam, V				Pradeep, Sai Pallavi; Hoovina Venkatesh, Pooja; Manchala, Nageswar R. R.; Vayal Veedu, Arjun; Basavaraju, Rajani K. K.; Selvasundari, Leela; Ramakrishna, Manikanta; Chandrakiran, Yogitha; Krishnamurthy, Vishwanath; Holigi, Shivaranjani; Thomas, Tinku; Ross, Cecil R. R.; Dias, Mary; Satchidanandam, Vijaya			Innate Immune Cytokine Profiling and Biomarker Identification for Outcome in Dengue Patients	FRONTIERS IN IMMUNOLOGY			English	Article						dengue virus; innate immune cells; cytokines; biomarker; progression to severity; flow cytometry; intracellular cytokine staining (ICS)	HEMORRHAGIC-FEVER; VIRAL LOAD; LYMPHOCYTE SUBPOPULATIONS; PERIPHERAL-BLOOD; VIRUS-INFECTIONS; FLOW-CYTOMETRY; SERUM-LEVELS; ANTIBODY; VIREMIA; CELLS	Background: Early biomarkers of progression to severe dengue are urgently required to enable effective patient management and control treatment costs. Innate immune cells, which comprise the earliest responders to infection and along with the cytokines and chemokines they secrete, play a vital role in orchestrating the subsequent adaptive immune response and have been implicated in the enhancement of infection and "cytokine storm " associated with dengue severity. We investigated the early innate immune cytokine profile of dengue patients during acute phase of disease in a prospective blinded study that included subjects with acute dengue and febrile controls from four major hospitals in Bengaluru, India along with healthy controls. We used intracellular cytokine staining and flow cytometry to identify innate immune biomarkers that can predict progression to severe dengue. Results Dengue infection resulted in enhanced secretion of multiple cytokines by all queried innate immune cell subsets, dominated by TNF-alpha from CD56(+)CD3(+) NKT cells, monocyte subsets, and granulocytes along with IFN-gamma from CD56(+)CD3(+) NKT cells. Of note, significantly higher proportions of TNF-alpha secreting granulocytes and monocyte subsets at admission were associated with mild dengue and minimal symptoms. Dengue NS1 antigenemia used as a surrogate of viral load directly correlated with proportion of cytokine-secreting innate immune cells and was significantly higher in those who went on to recover with minimal symptoms. In patients with secondary dengue or those with bleeding or elevated liver enzymes who revealed predisposition to severe outcomes, early activation as well as efficient downregulation of innate responses were compromised. Conclusion Our findings suggested that faulty/delayed kinetics of innate immune activation and downregulation was a driver of disease severity. We identified IFN-gamma (+)CD56(+)CD3(+) NKT cells and IL-6(+) granulocytes at admission as novel early biomarkers that can predict the risk of progression to severity (composite AUC = 0.85-0.9). Strong correlations among multiple cytokine-secreting innate cell subsets revealed that coordinated early activation of the entire innate immune system in response to dengue virus infection contributed to resolution of infection and speedy recovery.	[Pradeep, Sai Pallavi; Hoovina Venkatesh, Pooja; Satchidanandam, Vijaya] Indian Inst Sci, Dept Microbiol & Cell Biol, Bengaluru, India; [Manchala, Nageswar R. R.; Vayal Veedu, Arjun] St Johns Med Coll, St Johns Res Inst, Div Infect Dis Unit, Bengaluru, India; [Basavaraju, Rajani K. K.; Chandrakiran, Yogitha] Kempegowda Inst Med Sci & Res Ctr, Dept Med, Bengaluru, India; [Selvasundari, Leela; Krishnamurthy, Vishwanath] MS Ramaiah Med Coll, Dept Med, Bengaluru, India; [Ramakrishna, Manikanta; Holigi, Shivaranjani] Bengaluru Med Coll & Res Inst, Dept Med, Bengaluru, India; [Thomas, Tinku] St Johns Med Coll, Dept Biostat, Bengaluru, India; [Ross, Cecil R. R.] St Johns Med Coll, Dept Med, Bengaluru, India; [Dias, Mary] St Johns Med Coll, Dept Microbiol, Bengaluru, India	Indian Institute of Science (IISC) - Bangalore; St. John's National Academy of Health Sciences; St. John's Medical College; St. John's Research Institute; Kempegowda Institute of Medical Sciences (KIMS); Bangalore Medical College & Research Institute (BMCRI); St. John's National Academy of Health Sciences; St. John's Medical College; St. John's National Academy of Health Sciences; St. John's Medical College; St. John's National Academy of Health Sciences; St. John's Medical College	Satchidanandam, V (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bengaluru, India.	vijaya@iisc.ac.in		Vayal veedu, Arjun/0000-0002-9772-2741	Rajiv Gandhi University of Health Sciences	Rajiv Gandhi University of Health Sciences	This work was funded by Rajiv Gandhi University of Health Sciences (Grant number -RGU/ADV. RES/016/2017-2018).	Alvarez M, 2006, AM J TROP MED HYG, V75, P1113, DOI 10.4269/ajtmh.2006.75.1113; Apoil PA, 2017, DATA BRIEF, V12, P400, DOI 10.1016/j.dib.2017.04.019; Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Blacksell SD, 2012, CLIN VACCINE IMMUNOL, V19, P804, DOI 10.1128/CVI.05717-11; BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172; Chandele A, 2016, J VIROL, V90, P11259, DOI 10.1128/JVI.01424-16; Chen RF, 2005, FEMS IMMUNOL MED MIC, V44, P43, DOI 10.1016/j.femsim.2004.11.012; Cossarizza A, 2019, EUR J IMMUNOL, V49, P1457, DOI 10.1002/eji.201970107; Cui L, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004607; Endy TP, 2004, J INFECT DIS, V189, P990, DOI 10.1086/382280; GUBLER DJ, 1981, B WORLD HEALTH ORGAN, V59, P623; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Halstead SB, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0022-2014; Han LF, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02836; Hapugaswatta H, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-0620-z; HOBER D, 1993, AM J TROP MED HYG, V48, P324, DOI 10.4269/ajtmh.1993.48.324; Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152; Kamaladasa A, 2016, CLIN EXP IMMUNOL, V185, P228, DOI 10.1111/cei.12778; Khursheed M, 2013, J PAK MED ASSOC, V63, P670; KLIKS SC, 1989, AM J TROP MED HYG, V40, P444, DOI 10.4269/ajtmh.1989.40.444; Koenderman L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00544; Kokuina E, 2019, MEDICC REV, V21, P16, DOI 10.37757/MR2019.V21.N2-3.5; Krutzik PO, 2003, CYTOM PART A, V55A, P61, DOI 10.1002/cyto.a.10072; KUBERSKI T, 1977, AM J TROP MED HYG, V26, P775, DOI 10.4269/ajtmh.1977.26.775; Kuri-Cervantes L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd7114; Kwissa M, 2014, CELL HOST MICROBE, V16, P115, DOI 10.1016/j.chom.2014.06.001; Lee YH, 2016, J GEN VIROL, V97, P3103, DOI 10.1099/jgv.0.000637; Lepone Lauren M, 2016, J Circ Biomark, V5, P5, DOI 10.5772/62322; Lian JS, 2020, AGING-US, V12, P13849, DOI 10.18632/aging.103582; Libraty DH, 2002, J INFECT DIS, V185, P1213, DOI 10.1086/340365; Liu YW, 2020, J INFECTION, V81, pE6, DOI 10.1016/j.jinf.2020.04.002; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; Malavige GN, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002409; Malavige GN, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-341; Malavige GN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050387; Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09; Matangkasombut P, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002955; Melzer S, 2015, CYTOM PART B-CLIN CY, V88, P270, DOI 10.1002/cyto.b.21234; Morsy S, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2121; Murgue B, 2000, J MED VIROL, V60, P432, DOI 10.1002/(SICI)1096-9071(200004)60:4&lt;432::AID-JMV11&gt;3.0.CO;2-7; Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007892; Peckham H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19741-6; Perdomo-Celis F, 2018, J INFECT DIS, V217, P1472, DOI 10.1093/infdis/jiy053; Rathakrishnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052215; Robinson M, 2019, CELL REP, V26, P1104, DOI 10.1016/j.celrep.2019.01.033; Roe B, 2007, J INFECT DIS, V196, P1053, DOI 10.1086/520935; Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014; SANGKAWIBHA N, 1984, AM J EPIDEMIOL, V120, P653, DOI 10.1093/oxfordjournals.aje.a113932; Sani SSM, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2601-8; Shirk EN, 2017, CYTOM PART A, V91A, P364, DOI 10.1002/cyto.a.23098; Simmons CP, 2007, J INFECT DIS, V196, P416, DOI 10.1086/519170; Srikiatkhachorn A, 2017, SEMIN IMMUNOPATHOL, V39, P563, DOI 10.1007/s00281-017-0625-1; Sudiro TM, 2001, J MED VIROL, V63, P29, DOI 10.1002/1096-9071(200101)63:1&lt;29::AID-JMV1004&gt;3.0.CO;2-S; Sun PF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002298; Sun PF, 2011, VIROLOGY, V421, P245, DOI 10.1016/j.virol.2011.08.026; Tatum D, 2020, SHOCK, V54, P652, DOI 10.1097/SHK.0000000000001585; Thomas L, 2008, AM J TROP MED HYG, V78, P990; Tissera H, 2017, J INFECT DIS, V216, P1112, DOI 10.1093/infdis/jix447; Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215; Vazquez S, 2007, J CLIN VIROL, V39, P194, DOI 10.1016/j.jcv.2007.04.003; Wang WK, 2006, CLIN INFECT DIS, V43, P1023, DOI 10.1086/507635; Wang WK, 2003, VIROLOGY, V305, P330, DOI 10.1006/viro.2002.1704; WHO, 2009, WHO TECH REP SER, V958, P1; Wong KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036435; Ferreira RAX, 2015, ACTA TROP, V149, P138, DOI 10.1016/j.actatropica.2015.04.023; Xu W, 2012, J EXP MED, V209, P1813, DOI 10.1084/jem.20112142; Yin Yuzhi, 2015, Curr Protoc Immunol, V110, DOI 10.1002/0471142735.im0624s110; Zhao LZ, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1596-x; Zhao Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.139834; Zimmer CL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11878-3	71	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 14	2021	12								677874	10.3389/fimmu.2021.677874	http://dx.doi.org/10.3389/fimmu.2021.677874			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TQ7DL	34335578	gold, Green Published, Green Accepted, Green Submitted			2022-12-18	WOS:000678440000001
J	Song, SL; Manook, M; Kwun, J; Jackson, AM; Knechtle, SJ; Kelsoe, G				Song, Shengli; Manook, Miriam; Kwun, Jean; Jackson, Annette M.; Knechtle, Stuart J.; Kelsoe, Garnett			Allo-Specific Humoral Responses: New Methods for Screening Donor-Specific Antibody and Characterization of HLA-Specific Memory B Cells	FRONTIERS IN IMMUNOLOGY			English	Article						donor specific antibody (DSA); B cell; sensitization; transplantation; antibody mediated rejection (AMR)	MEDIATED REJECTION; CLASS-II; STRUCTURAL BASIS; BINDING; AUTOANTIBODIES; TRANSPLANTS; REDEMPTION; EXPRESSION; MUTATION; ENABLES	Antibody-mediated allograft rejection (AMR) causes more kidney transplant failure than any other single cause. AMR is mediated by antibodies recognizing antigens expressed by the graft, and antibodies generated against major histocompatibility complex (MHC) mismatches are especially problematic. Most research directed towards the management of clinical AMR has focused on identifying and characterizing circulating donor-specific HLA antibody (DSA) and optimizing therapies that reduce B-cell activation and/or block antibody secretion by inhibiting plasmacyte survival. Here we describe a novel set of reagents and techniques to allow more specific measurements of MHC sensitization across different animal transplant models. Additionally, we have used these approaches to isolate and clone individual HLA-specific B cells from patients sensitized by pregnancy or transplantation. We have identified and characterized the phenotypes of individual HLA-specific B cells, determined the V(D)J rearrangements of their paired H and L chains, and generated recombinant antibodies to determine affinity and specificity. Knowledge of the BCR genes of individual HLA-specific B cells will allow identification of clonally related B cells by high-throughput sequence analysis of peripheral blood mononuclear cells and permit us to re-construct the origins of HLA-specific B cells and follow their somatic evolution by mutation and selection.	[Song, Shengli; Jackson, Annette M.; Kelsoe, Garnett] Duke Univ, Sch Med, Dept Immunol, Durham, NC 27708 USA; [Manook, Miriam; Kwun, Jean; Jackson, Annette M.; Knechtle, Stuart J.; Kelsoe, Garnett] Duke Univ, Sch Med, Dept Surg, Durham, NC 27708 USA	Duke University; Duke University	Kelsoe, G (corresponding author), Duke Univ, Sch Med, Dept Immunol, Durham, NC 27708 USA.; Kelsoe, G (corresponding author), Duke Univ, Sch Med, Dept Surg, Durham, NC 27708 USA.	garnett.kelsoe@duke.edu	Kwun, Jean/F-2384-2018; Manook, Miriam/GZG-4089-2022	Kwun, Jean/0000-0002-8563-5472; Song, Shengli/0000-0003-0507-5194; Kelsoe, Garnett/0000-0002-8770-040X	National Institutes of Health [R01 AI128832]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health as part of the NHP Transplantation Tolerance Cooperative Study Group [U19AI131471]; Immune Tolerance Network; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health [UM1AI109565]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases of the National Institutes of Health as part of the NHP Transplantation Tolerance Cooperative Study Group; Immune Tolerance Network; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The research was partially supported by National Institutes of Health grant R01 AI128832 (to GK), and by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health as part of the NHP Transplantation Tolerance Cooperative Study Group under the U19AI131471 (to SK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. HLA-Reporter cell line development was supported by the Immune Tolerance Network and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health under Award Number UM1AI109565. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Achour A, 2006, J MOL BIOL, V356, P382, DOI 10.1016/j.jmb.2005.11.068; Barton GM, 1998, INT IMMUNOL, V10, P1159, DOI 10.1093/intimm/10.8.1159; Benoit LA, 2007, J IMMUNOL, V179, P3588, DOI 10.4049/jimmunol.179.6.3588; Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Burghuber CK, 2016, AM J TRANSPLANT, V16, P1726, DOI 10.1111/ajt.13688; Burnett DL, 2018, SCIENCE, V360, P223, DOI 10.1126/science.aao3859; Butler MO, 2010, INT IMMUNOL, V22, P863, DOI 10.1093/intimm/dxq440; Chan TD, 2012, IMMUNITY, V37, P893, DOI 10.1016/j.immuni.2012.07.017; Chen S, 2011, AM J TRANSPLANT, V11, P2057, DOI 10.1111/j.1600-6143.2011.03646.x; Chong AS, 2019, AM J TRANSPLANT, V19, P2155, DOI 10.1111/ajt.15323; Donnelly MLL, 2001, J GEN VIROL, V82, P1027, DOI 10.1099/0022-1317-82-5-1027; Fitch Z, 2019, TRANSPLANT REV-ORLAN, V33, P115, DOI 10.1016/j.trre.2019.03.002; Hassan C, 2015, J BIOL CHEM, V290, P2593, DOI 10.1074/jbc.M114.607028; Hayer A, 2016, NAT CELL BIOL, V18, P1311, DOI 10.1038/ncb3438; Holman N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179039; Karahan GE, 2019, TRANSPLANTATION, V103, P716, DOI 10.1097/TP.0000000000002516; Kelishadi SS, 2010, J CLIN INVEST, V120, P1275, DOI 10.1172/JCI41861; Kepler TB, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00170; Kim EJ, 2014, AM J TRANSPLANT, V14, P59, DOI 10.1111/ajt.12526; Kim SC, 2019, AM J TRANSPLANT, V19, P2174, DOI 10.1111/ajt.15329; Knechtle SJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau0143; Kramer CSM, 2020, AM J TRANSPLANT, V20, P3341, DOI 10.1111/ajt.15950; Ladowski JM, 2018, J IMMUNOL, V200, P2957, DOI 10.4049/jimmunol.1800022; Ladowski JM, 2018, TRANSPLANTATION, V102, P249, DOI 10.1097/TP.0000000000001924; Lobashevsky Andrew L, 2014, World J Transplant, V4, P153, DOI 10.5500/wjt.v4.i3.153; Luo XM, 2009, BLOOD, V113, P1422, DOI 10.1182/blood-2008-09-177139; Luque S, 2018, J IMMUNOL METHODS, V462, P23, DOI 10.1016/j.jim.2018.07.011; Ma BJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002200; McCarthy KR, 2018, IMMUNITY, V48, P174, DOI 10.1016/j.immuni.2017.12.009; Orandi BJ, 2016, NEW ENGL J MED, V374, P940, DOI 10.1056/NEJMoa1508380; Park BG, 2020, ANN LAB MED, V40, P424, DOI 10.3343/alm.2020.40.5.424; PEDERSEN LO, 1995, EUR J IMMUNOL, V25, P1609, DOI 10.1002/eji.1830250621; Reed JH, 2016, J EXP MED, V213, P1255, DOI 10.1084/jem.20151978; Sabouri Z, 2014, P NATL ACAD SCI USA, V111, pE2567, DOI 10.1073/pnas.1406974111; Sellares J, 2012, AM J TRANSPLANT, V12, P388, DOI 10.1111/j.1600-6143.2011.03840.x; Shinnakasu R, 2017, CURR OPIN IMMUNOL, V45, P126, DOI 10.1016/j.coi.2017.03.003; Su KY, 2016, J IMMUNOL, V197, P4163, DOI 10.4049/jimmunol.1502193; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Tiller T, 2009, J IMMUNOL METHODS, V350, P183, DOI 10.1016/j.jim.2009.08.009; Truscott SM, 2007, J IMMUNOL, V178, P6280, DOI 10.4049/jimmunol.178.10.6280; Valenzuela NM, 2017, J CLIN INVEST, V127, P2492, DOI 10.1172/JCI90597; Chu VT, 2015, NAT BIOTECHNOL, V33, P543, DOI 10.1038/nbt.3198; Visentin J, 2014, TRANSPLANTATION, V98, P738, DOI 10.1097/TP.0000000000000229; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Watanabe A, 2019, CELL, V177, P1124, DOI 10.1016/j.cell.2019.03.048; Watanabe A, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122551; Zachary AA, 2009, HUM IMMUNOL, V70, P574, DOI 10.1016/j.humimm.2009.06.007; Zhang SH, 2011, MOL IMMUNOL, V49, P395, DOI 10.1016/j.molimm.2011.08.015	48	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 13	2021	12								705140	10.3389/fimmu.2021.705140	http://dx.doi.org/10.3389/fimmu.2021.705140			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TR1FB	34326847	gold, Green Published			2022-12-18	WOS:000678716500001
J	Jakob, MO; Kofoed-Branzk, M; Deshpande, D; Murugan, S; Klose, CSN				Jakob, Manuel O.; Kofoed-Branzk, Michael; Deshpande, Divija; Murugan, Shaira; Klose, Christoph S. N.			An Integrated View on Neuronal Subsets in the Peripheral Nervous System and Their Role in Immunoregulation	FRONTIERS IN IMMUNOLOGY			English	Review						neuro-immune interactions; neuronal classification; peripheral nervous system; enteric nervous system; dorsal root ganglia (DRG); function of neurons	GENE-RELATED PEPTIDE; INNATE LYMPHOID-CELLS; PRIMARY AFFERENT NEURONS; ROOT GANGLION NEURONS; SUBSTANCE-P; NEUROMEDIN-U; SENSORY NEURONS; NITRIC-OXIDE; PAIN MECHANISMS; NEUROPEPTIDE	The peripheral nervous system consists of sensory circuits that respond to external and internal stimuli and effector circuits that adapt physiologic functions to environmental challenges. Identifying neurotransmitters and neuropeptides and the corresponding receptors on immune cells implies an essential role for the nervous system in regulating immune reactions. Vice versa, neurons express functional cytokine receptors to respond to inflammatory signals directly. Recent advances in single-cell and single-nuclei sequencing have provided an unprecedented depth in neuronal analysis and allowed to refine the classification of distinct neuronal subsets of the peripheral nervous system. Delineating the sensory and immunoregulatory capacity of different neuronal subsets could inform a better understanding of the response happening in tissues that coordinate physiologic functions, tissue homeostasis and immunity. Here, we summarize current subsets of peripheral neurons and discuss neuronal regulation of immune responses, focusing on neuro-immune interactions in the gastrointestinal tract. The nervous system as a central coordinator of immune reactions and tissue homeostasis may predispose for novel promising therapeutic approaches for a large variety of diseases including but not limited to chronic inflammation.	[Jakob, Manuel O.; Kofoed-Branzk, Michael; Deshpande, Divija; Klose, Christoph S. N.] Charite Univ Med Berlin, Dept Microbiol Infect Dis & Immunol, Berlin, Germany; [Jakob, Manuel O.; Kofoed-Branzk, Michael; Deshpande, Divija; Klose, Christoph S. N.] Free Univ Berlin, Berlin, Germany; [Jakob, Manuel O.; Kofoed-Branzk, Michael; Deshpande, Divija; Klose, Christoph S. N.] Humboldt Univ, Berlin, Germany; [Murugan, Shaira] Univ Bern, Dept BioMed Res, Grp Visceral Surg & Med, Bern, Switzerland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; University of Bern	Klose, CSN (corresponding author), Charite Univ Med Berlin, Dept Microbiol Infect Dis & Immunol, Berlin, Germany.; Klose, CSN (corresponding author), Free Univ Berlin, Berlin, Germany.; Klose, CSN (corresponding author), Humboldt Univ, Berlin, Germany.	christoph.klose@charite.de		Jakob, Manuel/0000-0003-3638-3114	Swiss National Science foundation [184425]; German Research Foundation (DFG) [FOR2599, KL 2963/5-2, KL 2963/2-1, KL 2963/3-1, SPP1937-DI764/9]; European Research Council Starting Grant (ERCEA) [803087]	Swiss National Science foundation(Swiss National Science Foundation (SNSF)European Commission); German Research Foundation (DFG)(German Research Foundation (DFG)); European Research Council Starting Grant (ERCEA)	This work was supported by grants from the Swiss National Science foundation (Grant-ID: 184425 to MJ), the German Research Foundation (DFG; Neuromac SFB TR project B17, FOR2599 project 5 - KL 2963/5-2, KL 2963/2-1 and KL 2963/3-1 to CK), (DFG; SPP1937-DI764/9 to MK-B), and the European Research Council Starting Grant (ERCEA; 803087 to CK).	Abraira VE, 2013, NEURON, V79, P618, DOI 10.1016/j.neuron.2013.07.051; Alcaino C, 2017, CURR TOP MEMBR, V79, P219, DOI 10.1016/bs.ctm.2016.11.003; Anitha M, 2012, GASTROENTEROLOGY, V143, P1006, DOI 10.1053/j.gastro.2012.06.034; Assas BM, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00023; AVERILL S, 1995, EUR J NEUROSCI, V7, P1484, DOI 10.1111/j.1460-9568.1995.tb01143.x; Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028; Bellono NW, 2017, CELL, V170, DOI 10.1016/j.cell.2017.05.034; Bertrand PP, 1997, AM J PHYSIOL-GASTR L, V273, pG422; Bonaz B, 2016, NEUROGASTROENT MOTIL, V28, P948, DOI 10.1111/nmo.12792; Bornstein JC, 2018, PHYSL GASTROINTESTIN, VSixth Edition, P429; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Bracci-Laudiero L, 2005, BLOOD, V106, P3507, DOI 10.1182/blood-2004-10-4055; Brighton PJ, 2004, PHARMACOL REV, V56, P231, DOI 10.1124/pr.56.2.3; Burnstock G, 2006, TRENDS PHARMACOL SCI, V27, P166, DOI 10.1016/j.tips.2006.01.005; BURTON PR, 1992, J COMP NEUROL, V317, P396, DOI 10.1002/cne.903170406; Cardoso V, 2017, NATURE, V549, P277, DOI 10.1038/nature23469; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chu C, 2019, NATURE, V574, P543, DOI 10.1038/s41586-019-1644-y; Clerc N, 2004, NEUROGASTROENT MOTIL, V16, P24, DOI 10.1111/j.1743-3150.2004.00470.x; Collamati A, 2016, AGING CLIN EXP RES, V28, P25, DOI 10.1007/s40520-015-0359-7; Collins J, 2014, NEUROGASTROENT MOTIL, V26, P98, DOI 10.1111/nmo.12236; Cooke HJ, 2004, J COMP NEUROL, V469, P1, DOI 10.1002/cne.10960; Crosson T, 2021, J ALLERGY CLIN IMMUN, V147, P2330, DOI 10.1016/j.jaci.2020.12.644; Dalli J, 2017, IMMUNITY, V46, P92, DOI 10.1016/j.immuni.2016.12.009; Darby M, 2021, J ALLERGY CLIN IMMUN, V147, P1513, DOI 10.1016/j.jaci.2020.10.038; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; Deshpande D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20677-0; Drokhlyansky E, 2020, CELL, V182, P1606, DOI 10.1016/j.cell.2020.08.003; Emery E. C., 2018, OXFORD HDB NEUROBIOL; Engel MA, 2012, J GASTROENTEROL, V47, P256, DOI 10.1007/s00535-011-0495-6; Engel MA, 2012, DIGEST LIVER DIS, V44, P24, DOI 10.1016/j.dld.2011.08.030; Engel MA, 2011, GASTROENTEROLOGY, V141, P1346, DOI 10.1053/j.gastro.2011.07.002; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; EVANGELISTA S, 1993, J PHYSIOLOGY-PARIS, V87, P277, DOI 10.1016/0928-4257(93)90017-N; Faure L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17929-4; Finno CJ, 2019, ISCIENCE, V21, P720, DOI 10.1016/j.isci.2019.10.064; Fung C, 2020, CELL MOL LIFE SCI, V77, P4505, DOI 10.1007/s00018-020-03543-6; Furness JB, 2008, NEUROGASTROENT MOTIL, V20, P32, DOI 10.1111/j.1365-2982.2008.01094.x; Furness JB, 1999, AM J PHYSIOL-GASTR L, V277, pG922, DOI 10.1152/ajpgi.1999.277.5.G922; Furness JB, 2000, J AUTONOM NERV SYST, V81, P87, DOI 10.1016/S0165-1838(00)00127-2; Furness JB, 2004, PROG NEUROBIOL, V72, P143, DOI 10.1016/j.pneurobio.2003.12.004; Furness JB, 2014, ADV EXP MED BIOL, V817, P39, DOI 10.1007/978-1-4939-0897-4_3; Gabanyi I, 2016, CELL, V164, P378, DOI 10.1016/j.cell.2015.12.023; Galle-Treger L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13202; Guyenet PG, 2006, NAT REV NEUROSCI, V7, P335, DOI 10.1038/nrn1902; Han L, 2013, NAT NEUROSCI, V16, P174, DOI 10.1038/nn.3289; Hansen MB, 2003, PHARMACOL TOXICOL, V92, P249, DOI 10.1034/j.1600-0773.2003.920601.x; Hao Yuhan, 2021, Cell, V184, P3573, DOI 10.1016/j.cell.2021.04.048; Haring M, 2018, NAT NEUROSCI, V21, P869, DOI 10.1038/s41593-018-0141-1; Hockley JRF, 2019, GUT, V68, P633, DOI 10.1136/gutjnl-2017-315631; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HOKFELT T, 1982, CIBA F SYMP, V91, P84; HOLZER P, 1993, J PHARMACOL EXP THER, V264, P391; HOSOI J, 1993, NATURE, V363, P159, DOI 10.1038/363159a0; Hu GL, 2016, SCI REP-UK, V6, DOI 10.1038/srep31851; Huang J, 2018, NAT NEUROSCI, V21, P707, DOI 10.1038/s41593-018-0119-z; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Huang SY, 2021, CELL, V184, P441, DOI 10.1016/j.cell.2020.11.028; Iyengar S, 2017, PAIN, V158, P543, DOI 10.1097/j.pain.0000000000000831; Jakob MO, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00308; JANSEN ASP, 1995, SCIENCE, V270, P644, DOI 10.1126/science.270.5236.644; Johnson CD, 2018, FASEB J, V32, P4744, DOI 10.1096/fj.201701474RR; Kaelberer MM, 2018, SCIENCE, V361, P1219, DOI 10.1126/science.aat5236; Kang SA, 2021, MUSCLE NERVE, V63, P563, DOI 10.1002/mus.27153; Kashem SW, 2015, IMMUNITY, V43, P515, DOI 10.1016/j.immuni.2015.08.016; Kato J, 2016, EUR J PHARMACOL, V788, P261, DOI 10.1016/j.ejphar.2016.06.039; KEEF KD, 1994, NEUROPHARMACOLOGY, V33, P1303, DOI 10.1016/0028-3908(94)90030-2; KIRCHGESSNER AL, 1992, J NEUROSCI, V12, P235; Klose CSN, 2017, NATURE, V549, P282, DOI 10.1038/nature23676; Koopman FA, 2016, P NATL ACAD SCI USA, V113, P8284, DOI 10.1073/pnas.1605635113; Kupari J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21725-z; Lai NY, 2017, J INTERN MED, V282, P5, DOI 10.1111/joim.12591; Lai NY, 2020, CELL, V180, P33, DOI 10.1016/j.cell.2019.11.014; LAWSON SN, 1991, J PHYSIOL-LONDON, V435, P41, DOI 10.1113/jphysiol.1991.sp018497; Le Pichon CE, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00021; Lecci A, 2002, CURR OPIN PHARMACOL, V2, P630, DOI 10.1016/S1471-4892(02)00225-4; Li CL, 2016, CELL RES, V26, P967, DOI 10.1038/cr.2016.90; Li LS, 2011, CELL, V147, P1615, DOI 10.1016/j.cell.2011.11.027; Liu Q, 2012, J NEUROSCI, V32, P14532, DOI 10.1523/JNEUROSCI.3509-12.2012; Lolignier S, 2016, J NEUROSCI, V36, P11435, DOI 10.1523/JNEUROSCI.2327-16.2016; Lomax AE, 2000, CELL TISSUE RES, V302, P59, DOI 10.1007/s004410000260; Mantyh PW, 2002, J CLIN PSYCHIAT, V63, P6; Matheis F, 2020, CELL, V180, P64, DOI 10.1016/j.cell.2019.12.002; Mazelin L, 1999, PEPTIDES, V20, P1367, DOI 10.1016/S0196-9781(99)00144-8; Mazzuoli-Weber G, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3339/fncel.2015.00408, 10.3389/fncel.2015.00408]; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Meseguer V, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4125; Mishra SK, 2013, SCIENCE, V340, P968, DOI 10.1126/science.1233765; Morarach K, 2021, NAT NEUROSCI, V24, P34, DOI 10.1038/s41593-020-00736-x; Moriyama M, 2006, AM J PHYSIOL-LUNG C, V290, pL971, DOI 10.1152/ajplung.00345.2005; Moriyama M, 2006, BIOCHEM BIOPH RES CO, V341, P1149, DOI 10.1016/j.bbrc.2006.01.075; Moriyama M, 2005, J EXP MED, V202, P217, DOI 10.1084/jem.20050248; Moriyama S, 2018, SCIENCE, V359, P1056, DOI 10.1126/science.aan4829; Morton GJ, 2006, NATURE, V443, P289, DOI 10.1038/nature05026; Muller PA, 2020, SCIENCE, V370, P314, DOI 10.1126/science.abd6176; Muller PA, 2020, NATURE, V583, P441, DOI 10.1038/s41586-020-2474-7; Nagashima H, 2019, IMMUNITY, V51, P682, DOI 10.1016/j.immuni.2019.06.009; Neal KB, 2008, NEUROGASTROENT MOTIL, V20, P566, DOI 10.1111/j.1365-2982.2007.01052.x; Neufeld KAM, 2013, NEUROGASTROENT MOTIL, V25, P183, DOI 10.1111/nmo.12049; Nicholls AJ, 2018, J LEUKOCYTE BIOL, V103, P295, DOI 10.1002/JLB.3MA0517-194RR; Obata Y, 2020, NATURE, V578, P284, DOI 10.1038/s41586-020-1975-8; Oetjen LK, 2017, CELL, V171, P217, DOI 10.1016/j.cell.2017.08.006; Olson CA, 2018, CELL, V174, P497, DOI 10.1016/j.cell.2018.06.051; Pan H, 2000, J NEUROSCI, V20, P3295, DOI 10.1523/JNEUROSCI.20-09-03295.2000; Peirs C, 2016, SCIENCE, V354, P578, DOI 10.1126/science.aaf8933; Perner C, 2020, IMMUNITY, V53, P1063, DOI 10.1016/j.immuni.2020.10.001; Pinho-Ribeiro FA, 2018, CELL, V173, P1083, DOI 10.1016/j.cell.2018.04.006; Prescott SL, 2020, CELL, V181, P574, DOI 10.1016/j.cell.2020.03.004; Qu ZD, 2008, CELL TISSUE RES, V334, P147, DOI 10.1007/s00441-008-0684-7; Rao M, 2018, NAT REV NEUROSCI, V19, P552, DOI 10.1038/s41583-018-0041-0; Rao M, 2016, NAT REV GASTRO HEPAT, V13, DOI 10.1038/nrgastro.2016.107; Rau KK, 2009, J NEUROSCI, V29, P8612, DOI 10.1523/JNEUROSCI.1057-09.2009; Reinshagen M, 1998, J PHARMACOL EXP THER, V286, P657; Renthal W, 2020, NEURON, V108, P128, DOI 10.1016/j.neuron.2020.07.026; Robinson DR, 2004, NEUROGASTROENT MOTIL, V16, P113, DOI 10.1046/j.1365-2982.2003.00456.x; Rutlin M, 2014, CELL, V159, P1640, DOI 10.1016/j.cell.2014.11.038; Sanz Elisenda, 2019, Curr Protoc Neurosci, V88, pe77, DOI 10.1002/cpns.77; Sathyamurthy A, 2018, CELL REP, V22, P2216, DOI 10.1016/j.celrep.2018.02.003; Seal RP, 2009, NATURE, V462, P651, DOI 10.1038/nature08505; Seillet C, 2020, NAT IMMUNOL, V21, P168, DOI 10.1038/s41590-019-0567-y; SERRA MC, 1988, J IMMUNOL, V141, P2118; Sharma N, 2020, NATURE, V577, P392, DOI 10.1038/s41586-019-1900-1; Shimizu Y, 2008, CELL MOL LIFE SCI, V65, P295, DOI 10.1007/s00018-007-7148-1; Solis AG, 2019, NATURE, V573, P69, DOI 10.1038/s41586-019-1485-8; Steinert EM, 2015, CELL, V161, P737, DOI 10.1016/j.cell.2015.03.031; STERNINI C, 1987, GASTROENTEROLOGY, V93, P852, DOI 10.1016/0016-5085(87)90450-1; Steyn E, 2013, INT J EMERG MED, V6, DOI 10.1186/1865-1380-6-7; Stifani N, 2014, FRONT CELL NEUROSCI, V8, P1, DOI 10.3389/fncel.2014.00293; Suvas S, 2017, J IMMUNOL, V199, P1543, DOI 10.4049/jimmunol.1601751; Talbot J, 2020, NATURE, V579, P575, DOI 10.1038/s41586-020-2039-9; Talbot S, 2015, NEURON, V87, P341, DOI 10.1016/j.neuron.2015.06.007; Tan LL, 2008, NEUROSCIENCE, V156, P334, DOI 10.1016/j.neuroscience.2008.06.071; TAYLOR GS, 1986, NEUROSCI LETT, V63, P23, DOI 10.1016/0304-3940(86)90006-6; Theoharides TC, 2010, P NATL ACAD SCI USA, V107, P4448, DOI 10.1073/pnas.1000803107; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Tracey KJ, 2009, NAT REV IMMUNOL, V9, P418, DOI 10.1038/nri2566; Ulrich-Lai YM, 2009, NAT REV NEUROSCI, V10, P397, DOI 10.1038/nrn2647; Usoskin D, 2015, NAT NEUROSCI, V18, P145, DOI 10.1038/nn.3881; Wallrapp A, 2019, IMMUNITY, V51, P709, DOI 10.1016/j.immuni.2019.09.005; Wallrapp A, 2017, NATURE, V549, P351, DOI 10.1038/nature24029; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wang X, 1999, J NEUROIMMUNOL, V94, P95, DOI 10.1016/S0165-5728(98)00230-6; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Wu XJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125225; Xu HP, 2019, IMMUNITY, V51, P696, DOI 10.1016/j.immuni.2019.09.004; Xue L, 2000, P NATL ACAD SCI USA, V97, P1851, DOI 10.1073/pnas.97.4.1851; Yadav M, 2011, CELL IMMUNOL, V267, P124, DOI 10.1016/j.cellimm.2011.01.001; Yissachar N, 2017, CELL, V168, P1135, DOI 10.1016/j.cell.2017.02.009; Yuan AD, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a018309; Yuan AD, 2012, J CELL SCI, V125, P3257, DOI 10.1242/jcs.104729; Zeisel A, 2018, CELL, V174, P999, DOI 10.1016/j.cell.2018.06.021	151	1	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 12	2021	12								679055	10.3389/fimmu.2021.679055	http://dx.doi.org/10.3389/fimmu.2021.679055			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TR4VC	34322118	gold, Green Published			2022-12-18	WOS:000678962800001
J	Quartuccio, L; De Marchi, G; Longhino, S; Manfre, V; Rizzo, MT; Gandolfo, S; Tommasini, A; De Vita, S; Fox, R				Quartuccio, Luca; De Marchi, Ginevra; Longhino, Simone; Manfre, Valeria; Rizzo, Maria Teresa; Gandolfo, Saviana; Tommasini, Alberto; De Vita, Salvatore; Fox, Robert			Shared Pathogenetic Features Between Common Variable Immunodeficiency and Sjogren's Syndrome: Clues for a Personalized Medicine	FRONTIERS IN IMMUNOLOGY			English	Review						immunodeficiency; Sjogren's syndrome; autoimmunity; lymphoproliferation; B cells	MEMORY B-CELLS; BLYS UP-REGULATION; INTERFERON TYPE-I; IMMUNE DYSREGULATION; SALIVARY-GLANDS; LYMPHOID-TISSUE; GENE-EXPRESSION; LYMPHOPROLIFERATIVE DISORDERS; CLINICAL PHENOTYPES; AUTOIMMUNE-DISEASES	Common variable immunodeficiency disorders (CVID) are a group of rare diseases of the immune system and the most common symptomatic primary antibody deficiency in adults. The "variable " aspect of CVID refers to the approximately half of the patients who develop non-infective complications, mainly autoimmune features, in particular organ specific autoimmune diseases including thyroiditis, and cytopenias. Among these associated conditions, the incidence of lymphoma, including mucosal associated lymphoid tissue (MALT) type, is increased. Although these associated autoimmune disorders in CVID are generally attributed to Systemic Lupus Erythematosus (SLE), we propose that Sjogren's syndrome (SS) is perhaps a better candidate for the associated disease. SS is an autoimmune disorder characterized by the lymphocytic infiltrates of lacrimal and salivary glands, leading to dryness of the eyes and mouth. Thus, it is a lymphocyte aggressive disorder, in contrast to SLE where pathology is generally attributed to auto-antibody and complement activation. Although systemic lupus erythematosus (SLE) shares these features with SS, a much higher frequency of MALT lymphoma distinguishes SS from SLE. Also, the higher frequency of germ line encoded paraproteins such as the monoclonal rheumatoid factor found in SS patients would be more consistent with the failure of B-cell VDJ switching found in CVID; and in contrast to the hypermutation that characterizes SLE autoantibodies. Thus, we suggest that SS may fit as a better "autoimmune " association with CVID. Examining the common underlying biologic mechanisms that promote lymphoid infiltration by dysregulated lymphocytes and lymphoma in CVID may provide new avenues for treatment in both the diseases. Since the diagnosis of SLE or rheumatoid arthritis is usually based on specific autoantibodies, the associated autoimmune features of CVID patients may not be recognized in the absence of autoantibodies.	[Quartuccio, Luca; De Marchi, Ginevra; Longhino, Simone; Manfre, Valeria; Rizzo, Maria Teresa; Gandolfo, Saviana; De Vita, Salvatore] ASU FC, Rheumatol Clin, Udine, Italy; [Quartuccio, Luca; Longhino, Simone; Manfre, Valeria; Rizzo, Maria Teresa; De Vita, Salvatore] Univ Udine, Dept Med, Udine, Italy; [Tommasini, Alberto] IRCCS Burlo Garofolo, Pediat Immunol, Trieste, Italy; [Tommasini, Alberto] Univ Trieste, Dept Med Sci, Trieste, Italy; [Fox, Robert] Scripps Mem Hosp & Res Fdn, Rheumatol Clin, La Jolla, CA USA	University of Udine; IRCCS Burlo Garofolo; University of Trieste	Quartuccio, L (corresponding author), ASU FC, Rheumatol Clin, Udine, Italy.; Quartuccio, L (corresponding author), Univ Udine, Dept Med, Udine, Italy.	luca.quartuccio@uniud.it	Quartuccio, Luca/AAC-4803-2022; Rizzo, Maria/HGD-6576-2022	Gandolfo, Saviana/0000-0001-9406-3632; Quartuccio, Luca/0000-0002-0134-6439				Adler S, 2013, ARTHRIT CARE RES, V65, P1862, DOI 10.1002/acr.22052; Agarwal S, 2019, ANN ALLERG ASTHMA IM, V123, P454, DOI 10.1016/j.anai.2019.07.014; Ameratunga R, 2014, EXPERT REV CLIN IMMU, V10, P183, DOI 10.1586/1744666X.2014.875274; ANDERSON LG, 1972, CLIN EXP IMMUNOL, V10, P199; Anolik JH, 2004, ARTHRITIS RHEUM-US, V50, P3580, DOI 10.1002/art.20592; Arumugakani G, 2010, J CLIN IMMUNOL, V30, P292, DOI 10.1007/s10875-009-9351-3; Babaha F, 2021, ALLERGOL IMMUNOPATH, V49, P84, DOI 10.15586/aei.v49i2.39; Baer AN, 2021, ANN RHEUM DIS, V80, P339, DOI 10.1136/annrheumdis-2020-218599; Barcelos F, 2018, RHEUMATOL INT, V38, P1063, DOI 10.1007/s00296-018-4018-0; Bateman EAL, 2012, CLIN EXP IMMUNOL, V170, P202, DOI 10.1111/j.1365-2249.2012.04643.x; Berentsen Sigbjorn, 2007, Cardiovascular & Hematological Disorders - Drug Targets, V7, P219, DOI 10.2174/187152907781745279; Berentsen S, 2009, CLIN LYMPHOMA MYELOM, V9, P110, DOI 10.3816/CLM.2009.n.030; Bodewes ILA, 2021, RHEUMATOLOGY, V60, P2561, DOI 10.1093/rheumatology/key360; Bodewes ILA, 2018, RHEUMATOLOGY, V57, P921, DOI 10.1093/rheumatology/kex490; Bohnhorst JO, 2001, J IMMUNOL, V167, P3610, DOI 10.4049/jimmunol.167.7.3610; Boileau J, 2011, J AUTOIMMUN, V36, P25, DOI 10.1016/j.jaut.2010.10.002; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Brkic Z, 2013, ANN RHEUM DIS, V72, P728, DOI 10.1136/annrheumdis-2012-201381; Chan KK, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m736; Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; Charles ED, 2011, BLOOD, V117, P5425, DOI 10.1182/blood-2010-10-312942; Ciccia F, 2012, ANN RHEUM DIS, V71, P295, DOI 10.1136/ard.2011.154013; Cols M, 2016, J ALLERGY CLIN IMMUN, V137, P1206, DOI 10.1016/j.jaci.2015.09.013; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; CROWLEY JJ, 1988, J IMMUNOL, V140, P3411; Cunningham-Rundles C, 2002, AM J HEMATOL, V69, P171, DOI 10.1002/ajh.10050; Daridon C, 2007, ARTHRITIS RHEUM-US, V56, P1134, DOI 10.1002/art.22458; De Re V, 2002, EUR J IMMUNOL, V32, P903, DOI 10.1002/1521-4141(200203)32:3<903::AID-IMMU903>3.0.CO;2-D; de Valles-Ibanez G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00636; De Vita S, 2014, CLIN EXP RHEUMATOL, V32, P490; De Vita S, 2001, BLOOD CELL MOL DIS, V27, P757, DOI 10.1006/bcmd.2001.0446; De Vita S, 2015, RHEUMATOLOGY, V54, P2249, DOI 10.1093/rheumatology/kev257; Desar IME, 2006, NETH J MED, V64, P136; Devauchelle-Pensec V, 2014, ANN INTERN MED, V160, P233, DOI 10.7326/M13-1085; DeVita S, 1997, ARTHRITIS RHEUM, V40, P318, DOI 10.1002/art.1780400217; Dhalla F, 2011, CLIN EXP IMMUNOL, V165, P1, DOI 10.1111/j.1365-2249.2011.04384.x; Dorner T, 2018, ANN RHEUM DIS, V77, P174, DOI 10.1136/annrheumdis-2018-eular.3111; Dong X, 2018, CLIN RHEUMATOL, V37, P2981, DOI 10.1007/s10067-018-4289-6; Emamian ES, 2009, GENES IMMUN, V10, P285, DOI 10.1038/gene.2009.20; Fabris M, 2007, RHEUMATOLOGY, V46, P37, DOI 10.1093/rheumatology/kel174; Felten R, 2021, ANN RHEUM DIS, DOI [10.1136/annrheumdis-2021-219882, 10.1136/annrheumdis-2020-218467]; Forbes LR, 2018, J ALLERGY CLIN IMMUN, V142, P1665, DOI 10.1016/j.jaci.2018.07.020; Fox R I, 1988, In Vivo, V2, P47; FUDENBERG H, 1971, PEDIATRICS, V47, P927; Gandolfo S, 2019, CLIN EXP RHEUMATOL, V37, pS199; Gangemi S, 2015, LEUKEMIA RES, V39, P389, DOI 10.1016/j.leukres.2015.02.002; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; Ghraichy M, 2018, IMMUNOLOGY, V153, P145, DOI 10.1111/imm.12865; Glauzy S, 2018, ARTHRITIS RHEUMATOL, V70, P298, DOI 10.1002/art.40352; Gottenberg JE, 2006, P NATL ACAD SCI USA, V103, P2770, DOI 10.1073/pnas.0510837103; Groom J, 2002, J CLIN INVEST, V109, P59, DOI 10.1172/JCI200214121; Gutierrez MJ, 2018, SEMIN ARTHRITIS RHEU, V48, P318, DOI 10.1016/j.semarthrit.2018.02.013; Haapaniemi EM, 2015, BLOOD, V125, P639, DOI 10.1182/blood-2014-04-570101; Hall JC, 2015, ARTHRITIS RHEUMATOL, V67, P2437, DOI 10.1002/art.39204; Hansen A, 2006, ARTHRITIS RHEUM-US, V54, P127, DOI 10.1002/art.21558; Hjelmervik TOR, 2005, ARTHRITIS RHEUM, V52, P1534, DOI 10.1002/art.21006; Hoegenauer K, 2017, ACS MED CHEM LETT, V8, P975, DOI 10.1021/acsmedchemlett.7b00293; Imgenberg-Kreuz J, 2016, ANN RHEUM DIS, V75, P2029, DOI 10.1136/annrheumdis-2015-208659; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Justet Aurelien, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2014-209076; Karnell JL, 2017, CELL IMMUNOL, V321, P40, DOI 10.1016/j.cellimm.2017.05.008; Khanna D, 2020, LANCET RESP MED, V8, P963, DOI 10.1016/S2213-2600(20)30318-0; Kiefer K, 2012, IMMUNOL CELL BIOL, V90, P498, DOI 10.1038/icb.2012.10; Kiripolsky J, 2017, CLIN IMMUNOL, V182, P4, DOI 10.1016/j.clim.2017.04.003; Knight AK, 2007, CLIN IMMUNOL, V124, P182, DOI 10.1016/j.clim.2007.04.012; Konttinen YT, 2015, J STEROID BIOCHEM, V145, P237, DOI 10.1016/j.jsbmb.2014.08.014; Kreuzaler M, 2012, J IMMUNOL, V188, P497, DOI 10.4049/jimmunol.1102321; KUNKEL HG, 1964, NATURE, V203, P413, DOI 10.1038/203413a0; Ladouceur A, 2020, RHEUM DIS CLIN N AM, V46, P533, DOI 10.1016/j.rdc.2020.05.005; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Longhurst C, 1996, IMMUNOLOGY, V87, P334, DOI 10.1046/j.1365-2567.1996.463529.x; Low HZ, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3318; Lucas M, 2010, J ALLERGY CLIN IMMUN, V125, P1354, DOI 10.1016/j.jaci.2010.02.040; Maffucci P, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00220; Maglione PJ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122728; Maglione PJ, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0597-6; Maglione PJ, 2014, ANN ALLERG ASTHMA IM, V113, P452, DOI 10.1016/j.anai.2014.04.024; Magliozzi R, 2020, EXPERT OPIN THER TAR, V24, P1135, DOI 10.1080/14728222.2020.1821647; Mariette X, 2003, ANN RHEUM DIS, V62, P168, DOI 10.1136/ard.62.2.168; Mariette X, 2015, ANN RHEUM DIS, V74, P526, DOI 10.1136/annrheumdis-2013-203991; Matson EM, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.622114; Mavragani CP, 2007, ARTHRITIS RHEUM, V56, P3995, DOI 10.1002/art.23062; Meiners PM, 2014, ANN RHEUM DIS, V73, P1393, DOI 10.1136/annrheumdis-2013-204653; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; Modell V, 2018, IMMUNOL RES, V66, P367, DOI 10.1007/s12026-018-8996-5; Mockel T, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2020.102736; Mouillot G, 2010, J CLIN IMMUNOL, V30, P746, DOI 10.1007/s10875-010-9424-3; Nakayamada S, 2016, INFLAMM REGEN, V36, DOI 10.1186/s41232-016-0015-4; Nezos A, 2015, J AUTOIMMUN, V63, P47, DOI 10.1016/j.jaut.2015.07.002; Ng YS, 2004, J EXP MED, V200, P927, DOI 10.1084/jem.20040920; Nocturne G, 2016, ANN RHEUM DIS, V75, P780, DOI 10.1136/annrheumdis-2015-207731; Nocturne G, 2015, BRIT J HAEMATOL, V168, P317, DOI 10.1111/bjh.13192; Nunes-Santos CJ, 2019, J ALLERGY CLIN IMMUN, V143, P1676, DOI 10.1016/j.jaci.2019.03.017; Odnoletkova I, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0941-0; Olee T, 1997, BRIT J HAEMATOL, V96, P836, DOI 10.1046/j.1365-2141.1997.d01-2112.x; Papageorgiou A, 2015, ARTHRITIS RHEUMATOL, V67, P2732, DOI 10.1002/art.39231; Papageorgiou A, 2015, AUTOIMMUN REV, V14, P641, DOI 10.1016/j.autrev.2015.03.004; Park J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074893; Pecoraro Antonio, 2019, Clin Mol Allergy, V17, P9, DOI 10.1186/s12948-019-0113-3; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Quartuccio L, 2013, RHEUMATOLOGY, V52, P276, DOI 10.1093/rheumatology/kes180; Quinti I, 2007, J CLIN IMMUNOL, V27, P308, DOI 10.1007/s10875-007-9075-1; Rakhmanov M, 2009, P NATL ACAD SCI USA, V106, P13451, DOI 10.1073/pnas.0901984106; Ramos-Casals M, 2015, RHEUMATOLOGY, V54, P2230, DOI 10.1093/rheumatology/kev200; Rao VK, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-113426; Rasmussen A, 2016, RHEUMATOLOGY, V55, P1195, DOI 10.1093/rheumatology/kew023; Reichenberger F, 2001, RESPIRATION, V68, P109, DOI 10.1159/000050475; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Retamozo S, 2019, LUPUS, V28, P923, DOI 10.1177/0961203319857132; Ronnblom L, 2013, CURR OPIN RHEUMATOL, V25, P248, DOI 10.1097/BOR.0b013e32835c7e32; Roskin KM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab1216; Saadoun D, 2013, ARTHRITIS RHEUM-US, V65, P1085, DOI 10.1002/art.37828; Salomonsson S, 2003, ARTHRITIS RHEUM-US, V48, P3187, DOI 10.1002/art.11311; Salzer U, 2009, BLOOD, V113, P1967, DOI 10.1182/blood-2008-02-141937; Sambataro G, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2019.102447; Sanchez-Ramon S, 2008, CLIN IMMUNOL, V128, P314, DOI 10.1016/j.clim.2008.02.013; Sato Y, 2006, MODERN PATHOL, V19, P1578, DOI 10.1038/modpathol.3800692; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Seidel MG, 2019, J ALLER CL IMM-PRACT, V7, P1763, DOI 10.1016/j.jaip.2019.02.004; Simon KL, 2014, J ALLERGY CLIN IMMUN, V133, P896, DOI 10.1016/j.jaci.2013.08.050; Singh M, 2020, CELL, V180, P878, DOI 10.1016/j.cell.2020.01.029; Stohl W, 2005, ARTHRITIS RHEUM-US, V52, P2080, DOI 10.1002/art.21138; Strandberg L, 2008, J CLIN IMMUNOL, V28, P220, DOI 10.1007/s10875-007-9157-0; Szabo K, 2016, CLIN EXP IMMUNOL, V183, P76, DOI 10.1111/cei.12703; Szodoray P, 2005, SCAND J IMMUNOL, V62, P421, DOI 10.1111/j.1365-3083.2005.01688.x; Tavasolian P, 2018, EUR CYTOKINE NETW, V29, P153, DOI 10.1684/ecn.2018.0420; Terrier B, 2014, ARTHRITIS RHEUMATOL, V66, P433, DOI 10.1002/art.38222; Theander E, 2006, ANN RHEUM DIS, V65, P796, DOI 10.1136/ard.2005.041186; Tipton CM, 2015, NAT IMMUNOL, V16, P755, DOI 10.1038/ni.3175; Unger S, 2018, J ALLERGY CLIN IMMUN, V141, P730, DOI 10.1016/j.jaci.2017.04.041; van Maldegem F, 2012, LEUKEMIA, V26, P1647, DOI 10.1038/leu.2012.28; Varzaneh FN, 2014, J CLIN IMMUNOL, V34, P524, DOI 10.1007/s10875-014-0053-0; Verma N, 2017, CLIN EXP IMMUNOL, V190, P1, DOI 10.1111/cei.12997; Visentini M, 2014, J ALLERGY CLIN IMMUN, V134, P401, DOI 10.1016/j.jaci.2014.03.017; Vodjgani M, 2007, J INVEST ALLERG CLIN, V17, P321; Wang XY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200212; Warnatz K, 2002, IMMUNOBIOLOGY, V206, P502, DOI 10.1078/0171-2985-00198; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Weinberger T, 2019, J CLIN IMMUNOL, V39, P440, DOI 10.1007/s10875-019-00640-5; Wildenberg ME, 2008, EUR J IMMUNOL, V38, P2024, DOI 10.1002/eji.200738008; Yakaboski E, 2020, J CLIN IMMUNOL, V40, P524, DOI 10.1007/s10875-020-00769-8; Yang XP, 2011, NAT IMMUNOL, V12, P247, DOI 10.1038/ni.1995; Yazdani R, 2020, J INVEST ALLERG CLIN, V30, P14, DOI 10.18176/jiaci.0388; Zintzaras E, 2005, ARCH INTERN MED, V165, P2337, DOI 10.1001/archinte.165.20.2337	146	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 12	2021	12								703780	10.3389/fimmu.2021.703780	http://dx.doi.org/10.3389/fimmu.2021.703780			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TR5DU	34322134	Green Published, gold			2022-12-18	WOS:000678985400001
J	Huang, XH; Chen, LL; Lan, L; Ren, PP; Ni, AQ; Ma, YH; Wang, YM; Zhu, YL; Xu, Y; Chen, JH; Han, F				Huang, Xiaohan; Chen, Liangliang; Lan, Lan; Ren, Pingping; Ni, Anqi; Ma, Yanhong; Wang, Yaomin; Zhu, Yilin; Xu, Ying; Chen, Jianghua; Han, Fei			Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Acute Kidney Injury: Short-Term Recovery Predicts Long-Term Outcome	FRONTIERS IN IMMUNOLOGY			English	Article						ANCA associated vasculitis; acute kidney injury; end stage renal disease; mortality; outcome	STAGE RENAL-DISEASE; MYCOPHENOLATE-MOFETIL; ANCA VASCULITIS	Background Kidney involvement is common in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). It tends to be aggressive, and in some patients, the kidney involvement may reach the criteria of acute kidney injury (AKI). Here, we aim to describe the clinical characteristics of these patients and find risk factors for poor outcomes. Methods Patients diagnosed with AAV in our hospital from February 2003 to February 2017 were included. Those who reached the KDIGO AKI criteria were reclassified according to the KDIGO AKI stage. The clinical features of these patients were analyzed. Also, according to the variation of serum creatinine 3 months after AKI episode, patients were further divided into two groups: patients whose serum creatinine (Scr) level at the third month decreased by 30% or more from the peak Scr level was classified into G1 and others were classified into G2. Long-term renal and survival outcomes of these patients were analyzed with a Cox model. The renal endpoint was reaching end-stage renal disease (ESRD), and the survival endpoint was death. Nomograms were built based on cox models. Results Of 141 AAV patients included, during the median follow-up period of 64.0 (IQR 34.8, 85.4) months, 36 (25.5%) patients reached renal endpoints, and 22 (15.6%) patients died. The median renal survival time was 35.9 (IQR 21.3, 72.6) months and the median survival time was 48.4 (IQR 26.8, 82.8) months. Multivariate analysis showed that poor recovery of Scr level at 90 days (P < 0.001, RR = 9.150, 95%CI 4.163-20.113), BVAS score (P = 0.014, RR = 1.110, 95% CI1.021-1.207), and AKI stage 3 (P = 0.012 RR = 3.116, 95%CI 1.278-7.598) were independent risk factors for renal endpoints; poor recovery of Scr level at 90 days (P = 0.010, RR = 3.264, 95%CI 1.326-8.035), BVAS score (P = 0.010, RR = 1.171, 95%CI 1.038-1.320) and age (P = 0.017, RR = 1.046, 95%CI 1.008-1.086) were independent risk factors for all-cause death. The c-index of nomograms is 0.830 for the renal outcome and 0.763 for the survival outcome. Conclusion KDIGO AKI stage 3 is the risk factor for ESRD in AAV patients with AKI. The BVAS score and level of kidney function recovery at 90 days are the independent risk factors for both ESRD and all-cause death and are of predictive value for the outcome.	[Huang, Xiaohan; Chen, Liangliang; Lan, Lan; Ren, Pingping; Ni, Anqi; Ma, Yanhong; Wang, Yaomin; Zhu, Yilin; Xu, Ying; Chen, Jianghua; Han, Fei] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Kidney Dis Ctr, Hangzhou, Peoples R China; [Huang, Xiaohan; Chen, Liangliang; Lan, Lan; Ren, Pingping; Ni, Anqi; Ma, Yanhong; Wang, Yaomin; Zhu, Yilin; Xu, Ying; Chen, Jianghua; Han, Fei] Zhejiang Univ, Inst Nephrol, Hangzhou, Peoples R China; [Huang, Xiaohan; Chen, Liangliang; Lan, Lan; Ren, Pingping; Ni, Anqi; Ma, Yanhong; Wang, Yaomin; Zhu, Yilin; Xu, Ying; Chen, Jianghua; Han, Fei] Key Lab Kidney Dis Prevent & Control Technol, Hangzhou, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Han, F (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Kidney Dis Ctr, Hangzhou, Peoples R China.; Han, F (corresponding author), Zhejiang Univ, Inst Nephrol, Hangzhou, Peoples R China.; Han, F (corresponding author), Key Lab Kidney Dis Prevent & Control Technol, Hangzhou, Zhejiang, Peoples R China.	hanf8876@zju.edu.cn	MA, YAN/HHN-2912-2022		Primary Research and Development Plan of Zhejiang Province [2020C03034]; Zhejiang Medical and Health Science and Technology Project [2018258985, 2019RC036]; Natural Science Foundation of Zhejiang Province [Q19H050030]	Primary Research and Development Plan of Zhejiang Province; Zhejiang Medical and Health Science and Technology Project; Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province)	This study was supported by the funds from the Primary Research and Development Plan of Zhejiang Province (2020C03034) to FH, Zhejiang Medical and Health Science and Technology Project (2018258985, 2019RC036) to LC and LL, and Project of Natural Science Foundation of Zhejiang Province (Q19H050030) to PR.	Altman DG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b605; Berden AE, 2010, J AM SOC NEPHROL, V21, P1628, DOI 10.1681/ASN.2010050477; Brix SR, 2018, KIDNEY INT, V94, P1177, DOI 10.1016/j.kint.2018.07.020; Chawla LS, 2017, NAT REV NEPHROL, V13, P241, DOI 10.1038/nrneph.2017.2; Coca SG, 2012, KIDNEY INT, V81, P442, DOI 10.1038/ki.2011.379; Doi K, 2018, J INTENSIVE CARE, V6, DOI 10.1186/s40560-018-0308-6; Exley AR, 1997, ARTHRITIS RHEUM, V40, P371, DOI 10.1002/art.1780400222; Geetha D, 2020, AM J KIDNEY DIS, V75, P124, DOI 10.1053/j.ajkd.2019.04.031; Gercik O, 2020, ANN RHEUM DIS, V79, P675, DOI 10.1136/annrheumdis-2019-216742; Gopaluni S, 2019, ARTHRITIS RHEUMATOL, V71, P784, DOI 10.1002/art.40776; Han F, 2011, AM J NEPHROL, V33, P185, DOI 10.1159/000324364; Hilhorst M, 2013, J AM SOC NEPHROL, V24, P1371, DOI 10.1681/ASN.2012090912; Hu WH, 2008, NEPHROL DIAL TRANSPL, V23, P1307, DOI 10.1093/ndt/gfm780; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; Jones RB, 2019, ANN RHEUM DIS, V78, P399, DOI 10.1136/annrheumdis-2018-214245; Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789; Kitching AR, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0204-y; Levey AS, 2020, KIDNEY INT, V97, P1117, DOI 10.1016/j.kint.2020.02.010; Lionaki S, 2009, KIDNEY INT, V76, P644, DOI 10.1038/ki.2009.218; Mahoney SL, 2018, CLIN J AM SOC NEPHRO, V13, P201, DOI 10.2215/CJN.14101217; Moiseev S, 2017, NEPHROL DIAL TRANSPL, V32, P248, DOI 10.1093/ndt/gfw046; Palevsky PM, 2018, INTENS CARE MED, V44, P363, DOI 10.1007/s00134-017-4841-x; Ronco C, 2019, LANCET, V394, P1949, DOI 10.1016/S0140-6736(19)32563-2; Sinico RA, 2013, AUTOIMMUN REV, V12, P477, DOI 10.1016/j.autrev.2012.08.006; Webster AC, 2017, LANCET, V389, P1238, DOI 10.1016/S0140-6736(16)32064-5; Yeun J Y, 1998, Am J Kidney Dis, V32, pS118, DOI 10.1016/S0272-6386(98)70174-X; Zhou ZR, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.08.63	27	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 9	2021	12								641655	10.3389/fimmu.2021.641655	http://dx.doi.org/10.3389/fimmu.2021.641655			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TM9MU	34305886	Green Published, gold			2022-12-18	WOS:000675871600001
J	Shi, L; Ding, R; Zhang, TT; Wu, W; Wang, ZY; Jia, XZ; Li, KI; Liang, Y; Li, J; Zhu, MY; Huang, B; Wu, LX; Wu, M; Chen, J; Wang, CC; Huang, B; Liu, CD; Shen, HB; Wang, QH; Xia, XY; Li, PP; Lyu, S; Xiao, Y				Shi, Lei; Ding, Rong; Zhang, Tingting; Wu, Wei; Wang, Ziyu; Jia, Xiuzhi; Li, Kening; Liang, Yuan; Li, Jie; Zhu, Mengyan; Huang, Bin; Wu, Lingxiang; Wu, Min; Chen, Jing; Wang, Chaochen; Huang, Bin; Liu, Caidong; Shen, Hongbing; Wang, Qianghu; Xia, Xinyi; Li, Pengping; Lyu, Sali; Xiao, Ying			Comparative Characterization and Risk Stratification of Asymptomatic and Presymptomatic Patients With COVID-19	FRONTIERS IN IMMUNOLOGY			English	Article						risk stratification; COVID-19; asymptomatic patients; presymptomatic patients; T cell exhaustion	DISEASE 2019 COVID-19	The identification of asymptomatic, non-severe presymptomatic, and severe presymptomatic coronavirus disease 2019 (COVID-19) in patients may help optimize risk-stratified clinical management and improve prognosis. This single-center case series from Wuhan Huoshenshan Hospital, China, included 2,980 patients with COVID-19 who were hospitalized between February 4, 2020 and April 10, 2020. Patients were diagnosed as asymptomatic (n = 39), presymptomatic (n = 34), and symptomatic (n = 2,907) upon admission. This study provided an overview of asymptomatic, presymptomatic, and symptomatic COVID-19 patients, including detection, demographics, clinical characteristics, and outcomes. Upon admission, there was no significant difference in clinical symptoms and CT image between asymptomatic and presymptomatic patients for diagnosis reference. The mean area under the receiver operating characteristic curve (AUC) of the differential diagnosis model to discriminate presymptomatic patients from asymptomatic patients was 0.89 (95% CI, 0.81-0.98). Importantly, the severe and non-severe presymptomatic patients can be further stratified (AUC = 0.82). In conclusion, the two-step risk-stratification model based on 10 laboratory indicators can distinguish among asymptomatic, severe presymptomatic, and non-severe presymptomatic COVID-19 patients on admission. Moreover, single-cell data analyses revealed that the CD8+T cell exhaustion correlated to the progression of COVID-19.	[Shi, Lei] Nanjing Med Univ, Gusu Coll, Affiliated Peoples Hosp Kunshan 1, Suzhou, Peoples R China; [Ding, Rong; Zhang, Tingting; Wu, Wei; Wang, Ziyu; Li, Kening; Liang, Yuan; Li, Jie; Zhu, Mengyan; Huang, Bin; Wu, Lingxiang; Wu, Min; Shen, Hongbing; Wang, Qianghu; Li, Pengping; Lyu, Sali] Nanjing Med Univ, Sch Publ Hlth, Ctr Global Hlth, Nanjing, Peoples R China; [Ding, Rong; Zhang, Tingting; Wu, Wei; Wang, Ziyu; Li, Kening; Liang, Yuan; Li, Jie; Zhu, Mengyan; Huang, Bin; Wu, Lingxiang; Wu, Min; Wang, Qianghu; Li, Pengping; Lyu, Sali] Nanjing Med Univ, Dept Bioinformat, Nanjing, Peoples R China; [Wu, Wei; Wang, Qianghu] Southeast Univ, Sch Biol Sci & Med Engn, Nanjing, Peoples R China; [Jia, Xiuzhi; Xiao, Ying] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Biomed Res Ctr,Cent Lab, Hangzhou, Peoples R China; [Chen, Jing; Wang, Chaochen] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Breast Surg, Hangzhou, Peoples R China; [Chen, Jing; Wang, Chaochen] Zhejiang Univ, Sch Med, ZJU UoE Inst, Haining, Peoples R China; [Huang, Bin] Nanjing Univ, Affiliated Hosp, Nanjing Drum Tower Hosp, Med Sch,Comprehens Canc Ctr, Nanjing, Peoples R China; [Huang, Bin] Nanjing Univ, Clin Canc Inst, Nanjing, Peoples R China; [Liu, Caidong] Nanjing Med Univ, Nanjing Hosp 1, Dept Lab Med, Nanjing, Peoples R China; [Shen, Hongbing; Wang, Qianghu] Nanjing Med Univ, Collaborat Innovat Ctr Personalized Canc Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Peoples R China; [Wang, Qianghu] Collaborat Innovat Ctr Cardiovasc Dis Translat Me, Nanjing, Peoples R China; [Xia, Xinyi] Southern Med Univ, Nanjing Univ, COVID 19 Res Ctr, Nanjing Clin Coll,Jinling Hosp,Inst Lab Med,Sch M, Nanjing, Peoples R China; [Xia, Xinyi] Wuhan Huoshenshan Hosp, Dept Lab Med & Blood Transfus, Joint Expert Grp COVID 19, Wuhan, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Southeast University - China; Zhejiang University; Zhejiang University; Zhejiang University; Nanjing University; Nanjing University; Nanjing Medical University; Nanjing Medical University; Nanjing University; Southern Medical University - China	Li, PP; Lyu, S (corresponding author), Nanjing Med Univ, Sch Publ Hlth, Ctr Global Hlth, Nanjing, Peoples R China.; Li, PP; Lyu, S (corresponding author), Nanjing Med Univ, Dept Bioinformat, Nanjing, Peoples R China.; Xiao, Y (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Biomed Res Ctr,Cent Lab, Hangzhou, Peoples R China.; Xia, XY (corresponding author), Southern Med Univ, Nanjing Univ, COVID 19 Res Ctr, Nanjing Clin Coll,Jinling Hosp,Inst Lab Med,Sch M, Nanjing, Peoples R China.; Xia, XY (corresponding author), Wuhan Huoshenshan Hosp, Dept Lab Med & Blood Transfus, Joint Expert Grp COVID 19, Wuhan, Peoples R China.	xiaxynju@163.com; lipengping@njmu.edu.cn; lvsali@njmu.edu.cn; xiaoying.srr@zju.edu.cn	Wang, Chaochen/AAE-6657-2022	Wang, Chaochen/0000-0003-2346-2884; Shen, Hongbing/0000-0002-2581-5906; Wu, Lingxiang/0000-0003-4631-1229	National Natural Science Foundation of China [81972358, 91959113]; Key Foundation of Wuhan Huoshenshan Hospital [2020 [18]]; Key Research & Development Program of Jiangsu Province [BE2017733, BE2018713]; Medical Innovation Project of Logistics Service [18JS005]; Basic Research Program of Jiangsu Province [BK20180036]; Novel coronavirus pneumonia technology project of Kunshan first people's Hospital [XGF202007]; Scientific research funds of Sir Run Run Shaw Hospital [Ytp1902]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Foundation of Wuhan Huoshenshan Hospital; Key Research & Development Program of Jiangsu Province; Medical Innovation Project of Logistics Service; Basic Research Program of Jiangsu Province; Novel coronavirus pneumonia technology project of Kunshan first people's Hospital; Scientific research funds of Sir Run Run Shaw Hospital	This study was supported by the National Natural Science Foundation of China (Grant No. 81972358, 91959113), Key Foundation of Wuhan Huoshenshan Hospital (Grant No. 2020 [18]), Key Research & Development Program of Jiangsu Province (Grant No. BE2017733, BE2018713), Medical Innovation Project of Logistics Service (Grant No. 18JS005), Basic Research Program of Jiangsu Province (Grant No. BK20180036). Novel coronavirus pneumonia technology project of Kunshan first people's Hospital (XGF202007). Scientific research funds of Sir Run Run Shaw Hospital (Ytp1902).	Acter T, 2020, SCI TOTAL ENVIRON, V730, DOI 10.1016/j.scitotenv.2020.138996; [Anonymous], 2002, Bull World Health Organ, V80, P983; Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457; Baek S, 2015, KOREAN J RADIOL, V16, P286, DOI 10.3348/kjr.2015.16.2.286; Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758; Kamat IS, 2020, CLIN INFECT DIS, V70, P538, DOI 10.1093/cid/ciz545; Karakioulaki M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20082004; Kimball A, 2020, MMWR-MORBID MORTAL W, V69, P377, DOI 10.15585/mmwr.mm6913e1; Lee S, 2020, JAMA INTERN MED, V180, P1447, DOI 10.1001/jamainternmed.2020.3862; Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Lin QY, 2020, INT J INFECT DIS, V93, P211, DOI 10.1016/j.ijid.2020.02.058; Lippi G, 2020, CLIN CHIM ACTA, V505, P190, DOI 10.1016/j.cca.2020.03.004; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Macon-Lemaitre L, 2005, IMMUNOLOGY, V115, P170, DOI 10.1111/j.1365-2567.2005.02145.x; Mendez R, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020549; Meng H, 2020, J INFECTION, V81, pE33, DOI 10.1016/j.jinf.2020.04.004; Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180; Moghadas SM, 2020, P NATL ACAD SCI USA, V117, P17513, DOI 10.1073/pnas.2008373117; National Health Commission State Administration of Traditional Chinese Medicine, 2020, CLIN PROT DIAGN TREA; Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Qiu Jane, 2020, Nature, DOI 10.1038/d41586-020-00822-x; Reyfman PA, 2019, AM J RESP CRIT CARE, V199, P1517, DOI 10.1164/rccm.201712-2410OC; Sawano T, 2020, QJM-INT J MED, V113, P309, DOI 10.1093/qjmed/hcaa092; Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4; Wei WE, 2020, MMWR-MORBID MORTAL W, V69, P411, DOI 10.15585/mmwr.mm6914e1; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Zhao DH, 2020, CLIN INFECT DIS, V71, P756, DOI 10.1093/cid/ciaa247; Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2; Zheng XY, 2020, NATL SCI REV, V7, P1527, DOI 10.1093/nsr/nwaa141; Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021; Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490	34	1	1	2	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 9	2021	12								700449	10.3389/fimmu.2021.700449	http://dx.doi.org/10.3389/fimmu.2021.700449			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TP1XY	34305939	Green Published, gold			2022-12-18	WOS:000677392100001
J	Cai, Y; Han, L; Zhu, DS; Peng, J; Li, JP; Ding, J; Luo, JY; Hong, RH; Wang, K; Wan, WB; Xie, C; Zhou, XJ; Zhang, Y; Hao, Y; Guan, YT				Cai, Yu; Han, Lu; Zhu, Desheng; Peng, Jing; Li, Jianping; Ding, Jie; Luo, Jiaying; Hong, Ronghua; Wang, Kan; Wan, Wenbin; Xie, Chong; Zhou, Xiajun; Zhang, Ying; Hao, Yong; Guan, Yangtai			A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis	FRONTIERS IN IMMUNOLOGY			English	Article						myasthenia gravis; neuromuscular junction; clustered acetylcholine receptor; cell-based assay (CBA); stable cell line	MUSCLE ACETYLCHOLINE-RECEPTOR; TYROSINE KINASE MUSK; CLINICAL CHARACTERISTICS; ADULT SUBTYPE; THYMOMA; AUTOANTIBODIES; SEVERITY; FEATURES	Cell-based assays (CBAs) and radioimmunoprecipitation assay (RIPA) are the most sensitive methods for identifying anti-acetylcholine receptor (AChR) antibody in myasthenia gravis (MG). But CBAs are limited in clinical practice by transient transfection. We established a stable cell line (KL525) expressing clustered AChR by infecting HEK 293T cells with dual lentiviral vectors expressing the genes encoding the human AChR alpha 1, beta 1, delta, epsilon and the clustering protein rapsyn. We verified the stable expression of human clustered AChR by immunofluorescence, immunoblotting, and real-time PCR. Fluorescence-activated cell sorting (FACS) was used to detect anti-AChR antibodies in 103 MG patients and 58 healthy individuals. The positive results of MG patients reported by the KL525 was 80.6% (83/103), 29.1% higher than the 51.4% (53/103) of RIPA. 58 healthy individuals tested by both the KL525 CBA and RIPA were all negative. In summary, the stable expression of clustered AChR in our cell line makes it highly sensitive and advantageous for broad clinical application in CBAs.	[Cai, Yu; Han, Lu; Zhu, Desheng; Peng, Jing; Li, Jianping; Ding, Jie; Luo, Jiaying; Hong, Ronghua; Wang, Kan; Wan, Wenbin; Xie, Chong; Zhou, Xiajun; Zhang, Ying; Hao, Yong; Guan, Yangtai] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurol, Shanghai, Peoples R China	Shanghai Jiao Tong University	Guan, YT (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurol, Shanghai, Peoples R China.	yangtaiguan@sina.com	Li, Jing/GYU-5036-2022; zhu, desheng/AGY-8548-2022; li, jian/GSE-0245-2022; LI, JIAN/GRY-2197-2022	zhu, desheng/0000-0003-2454-2173; Wang, Kan/0000-0001-9811-4142; Hao, Yong/0000-0003-3652-0449; Cai, Yu/0000-0001-7787-8610	National Natural Science Foundation of China [81771295, 81230027]; Translational Medicine Collaborative Innovation Cooperation Research Project [TM201706, TM201508]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Translational Medicine Collaborative Innovation Cooperation Research Project	This work was supported by the National Natural Science Foundation of China, Grant/Award Numbers [grant numbers 81771295 and 81230027]; and the Translational Medicine Collaborative Innovation Cooperation Research Project, Grant/Award [grant numbers TM201706 and TM201508].	Beeson D, 1996, NEUROSCI LETT, V207, P57, DOI 10.1016/0304-3940(96)12488-5; Beeson D, 1996, NEUROLOGY, V47, P1552, DOI 10.1212/WNL.47.6.1552; Chan KH, 2007, MUSCLE NERVE, V36, P651, DOI 10.1002/mus.20854; Cortes-Vicente E, 2016, JAMA NEUROL, V73, P1099, DOI 10.1001/jamaneurol.2016.2032; Cruz PMR, 2015, JAMA NEUROL, V72, P642, DOI 10.1001/jamaneurol.2015.0203; Decroos EC, 2014, MUSCLE NERVE, V49, P30, DOI 10.1002/mus.23882; Devic P, 2014, EUR J NEUROL, V21, P130, DOI 10.1111/ene.12270; Gilhus NE, 2016, NAT REV NEUROL, V12, P259, DOI 10.1038/nrneurol.2016.44; Hoch W, 2001, NAT MED, V7, P365, DOI 10.1038/85520; Hong Y, 2017, EUR J NEUROL, V24, P844, DOI 10.1111/ene.13300; Huda S, 2016, MUSCLE NERVE, V54, P1023, DOI 10.1002/mus.25154; Jacob S, 2012, ARCH NEUROL-CHICAGO, V69, P994, DOI 10.1001/archneurol.2012.437; Jaretzki A, 2000, NEUROLOGY, V55, P16, DOI 10.1212/WNL.55.1.16; Kaminski HJ, 2016, JAMA NEUROL, V73, P1055, DOI 10.1001/jamaneurol.2016.2277; Keefe D, 2009, CYTOM PART B-CLIN CY, V76B, P206, DOI 10.1002/cyto.b.20454; Lavrnic D, 2005, J NEUROL NEUROSUR PS, V76, P1099, DOI 10.1136/jnnp.2004.052415; Lazaridis K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00212; Leite MI, 2008, BRAIN, V131, P1940, DOI 10.1093/brain/awn092; Lozier BK, 2015, AM J CLIN PATHOL, V143, P186, DOI 10.1309/AJCPYEOR6SGE8ZLU; Makino T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185976; McConville J, 2004, ANN NEUROL, V55, P580, DOI 10.1002/ana.20061; Mitra M, 2001, J NEUROSCI, V21, P3000, DOI 10.1523/JNEUROSCI.21-09-03000.2001; Nemoto Y, 2005, J NEUROL NEUROSUR PS, V76, P714, DOI 10.1136/jnnp.2004.043125; Park KH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193723; Pevzner A, 2012, J NEUROL, V259, P427, DOI 10.1007/s00415-011-6194-7; Richeh W., 2017, INFLAMMATORY DISORDE, P227; Romi F, 2003, EUR J NEUROL, V10, P701, DOI 10.1046/j.1468-1331.2003.00678.x; Sanders DB, 2003, NEUROLOGY, V60, P1978, DOI 10.1212/01.WNL.0000065882.63904.53; Stathopoulos P, 2019, J IMMUNOL, V202, P2210, DOI 10.4049/jimmunol.1801295; Vernino S, 2004, CLIN CANCER RES, V10, P7270, DOI 10.1158/1078-0432.CCR-04-0735; Vernino S, 2015, JAMA NEUROL, V72, P630, DOI 10.1001/jamaneurol.2015.0205; Vincent A, 2004, SEMIN NEUROL, V24, P125, DOI 10.1055/s-2004-829589; Yamamoto AM, 2001, ARCH NEUROL-CHICAGO, V58, P885, DOI 10.1001/archneur.58.6.885; Yan C, 2019, PEDIATR NEUROL, V98, P74, DOI 10.1016/j.pediatrneurol.2019.01.016; Zhao G, 2015, SCI REP-UK, V5, DOI 10.1038/srep10193; Zhou L, 2004, MUSCLE NERVE, V30, P55, DOI 10.1002/mus.20069; Zisimopoulou P, 2014, J AUTOIMMUN, V52, P139, DOI 10.1016/j.jaut.2013.12.004	37	1	1	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 8	2021	12								666046	10.3389/fimmu.2021.666046	http://dx.doi.org/10.3389/fimmu.2021.666046			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TM4ZA	34305897	gold, Green Published			2022-12-18	WOS:000675557900001
J	Goh, S; Kolakowski, J; Holder, A; Pfuhl, M; Ngugi, D; Ballingall, K; Tombacz, K; Werling, D				Goh, Shan; Kolakowski, Jeannine; Holder, Angela; Pfuhl, Mark; Ngugi, Daniel; Ballingall, Keith; Tombacz, Kata; Werling, Dirk			Development of a Potential Yeast-Based Vaccine Platform for Theileria parva Infection in Cattle	FRONTIERS IN IMMUNOLOGY			English	Article						Theileria parva; East Coast Fever; schizont antigens; oral vaccine; yeast	T-CELL RESPONSES; EAST-COAST FEVER; STRAIN SPECIFICITY; LIVE IMMUNIZATION; DENDRITIC CELLS; ANTIGEN; PROTECTION; PROTEIN; IMMUNE; MICROSATELLITE	East Coast Fever (ECF), caused by the tick-borne apicomplexan parasite Theileria parva, remains one of the most important livestock diseases in sub-Saharan Africa with more than 1 million cattle dying from infection every year. Disease prevention relies on the so-called "Infection and Treatment Method" (ITM), which is costly, complex, laborious, difficult to standardise on a commercial scale and results in a parasite strain-specific, MHC class I-restricted cytotoxic T cell response. We therefore attempted to develop a safe, affordable, stable, orally applicable and potent subunit vaccine for ECF using five different T. parva schizont antigens (Tp1, Tp2, Tp9, Tp10 and N36) and Saccharomyces cerevisiae as an expression platform. Full-length Tp2 and Tp9 as well as fragments of Tp1 were successfully expressed on the surface of S. cerevisiae. In vitro analyses highlighted that recombinant yeast expressing Tp2 can elicit IFN gamma responses using PBMCs from ITM-immunized calves, while Tp2 and Tp9 induced IFN gamma responses from enriched bovine CD8(+) T cells. A subsequent in vivo study showed that oral administration of heat-inactivated, freeze-dried yeast stably expressing Tp2 increased total murine serum IgG over time, but more importantly, induced Tp2-specific serum IgG antibodies in individual mice compared to the control group. While these results will require subsequent experiments to verify induction of protection in neonatal calves, our data indicates that oral application of yeast expressing Theileria antigens could provide an affordable and easy vaccination platform for sub-Saharan Africa. Evaluation of antigen-specific cellular immune responses, especially cytotoxic CD8(+) T cell immunity in cattle will further contribute to the development of a yeast-based vaccine for ECF.	[Goh, Shan; Kolakowski, Jeannine; Holder, Angela; Ngugi, Daniel; Tombacz, Kata; Werling, Dirk] Royal Vet Coll, Dept Pathobiol & Populat Sci, Hatfield, Herts, England; [Pfuhl, Mark] Kings Coll London, Fac Life Sci & Med, London, England; [Ballingall, Keith] Moredun Res Inst, Penicuik, Midlothian, Scotland; [Goh, Shan] Univ Hertfordshire, Sch Life & Med Sci, Hatfield, Herts, England	University of London; University of London Royal Veterinary College; University of London; King's College London; Moredun Research Institute; University of Hertfordshire	Werling, D (corresponding author), Royal Vet Coll, Dept Pathobiol & Populat Sci, Hatfield, Herts, England.	dwerling@rvc.ac.uk	Werling, Dirk/F-5555-2013	Werling, Dirk/0000-0001-5411-4044; Goh, Shan/0000-0002-9028-0303	Bill and Melinda Gates Foundation (BMGF) of the United Kingdom [OPP1078791]; Department for International Development (DFID) of the United Kingdom [OPP1078791]; European Union's Horizon 2020 research and innovation programme [731014KB]; Scottish Government's strategic research programme	Bill and Melinda Gates Foundation (BMGF) of the United Kingdom; Department for International Development (DFID) of the United Kingdom; European Union's Horizon 2020 research and innovation programme; Scottish Government's strategic research programme	This work was funded by the Bill and Melinda Gates Foundation (BMGF) and the Department for International Development (DFID) of the United Kingdom [OPP1078791]. We would like to give our special thanks to Prof. Simon Draper [University of Oxford, Jenner Institute] for his valued comments and suggestions during the planning of this study. KB receives funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 731014KB (VetBioNet) and acknowledges the support received from the Scottish Government's strategic research programme.	Bazan SB, 2018, MED MICROBIOL IMMUN, V207, P75, DOI 10.1007/s00430-017-0528-8; Bishop RP, 2020, TRANSBOUND EMERG DIS, V67, P56, DOI 10.1111/tbed.13325; Blanquet S, 2003, APPL ENVIRON MICROB, V69, P2884, DOI 10.1128/AEM.69.5.2884-2892.2003; Burgess SG, 2015, BIOMOL NMR ASSIGN, V9, P411, DOI 10.1007/s12104-015-9620-4; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; Connelley TK, 2016, IMMUNOLOGY, V149, P172, DOI 10.1111/imm.12637; Cremers CM, 2013, J BIOL CHEM, V288, P26489, DOI 10.1074/jbc.R113.462929; D'Souza WN, 2003, J IMMUNOL, V171, P5727, DOI 10.4049/jimmunol.171.11.5727; Di Giulio G, 2009, TRENDS PARASITOL, V25, P85, DOI 10.1016/j.pt.2008.11.007; Elder MJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00791; Ellis SA, 1999, IMMUNOGENETICS, V50, P319, DOI 10.1007/s002510050608; Fry LM, 2019, VACCINE, V37, P1546, DOI 10.1016/j.vaccine.2019.02.009; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Gao T, 2021, MICROB CELL FACT, V20, DOI 10.1186/s12934-021-01584-5; GODDEERIS BM, 1990, IMMUNOLOGY, V69, P38; Goh S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162571; Graham SP, 2008, INFECT IMMUN, V76, P685, DOI 10.1128/IAI.01244-07; Hammond JA, 2012, IMMUNOGENETICS, V64, P475, DOI 10.1007/s00251-012-0611-7; Han BQ, 2019, FISH SHELLFISH IMMUN, V84, P948, DOI 10.1016/j.fsi.2018.10.065; Hemmink JD, 2018, INT J PARASITOL, V48, P287, DOI 10.1016/j.ijpara.2017.10.006; Hemmink JD, 2016, INT J PARASITOL, V46, P495, DOI 10.1016/j.ijpara.2016.02.007; Howland SW, 2008, J IMMUNOTHER, V31, P607, DOI 10.1097/CJI.0b013e318181c87f; Huang YQ, 2012, PROTEINS, V80, P1610, DOI 10.1002/prot.24055; Hudson LE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112660; Kamiya T, 2018, MUCOSAL IMMUNOL, V11, P763, DOI 10.1038/mi.2017.86; Katzer F, 2011, INT J PARASITOL, V41, P669, DOI 10.1016/j.ijpara.2011.01.001; King TH, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00245-17; King TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101904; Klis FM, 2007, YEAST, V24, P253, DOI 10.1002/yea.1476; Krokoszynska I, 1998, J MOL BIOL, V275, P503, DOI 10.1006/jmbi.1997.1460; Kumar R, 2019, FEMS YEAST RES, V19, DOI 10.1093/femsyr/foz007; Kumar R, 2018, FEMS YEAST RES, V18, DOI 10.1093/femsyr/foy071; Lacasta A, 2018, VACCINE, V36, P1389, DOI 10.1016/j.vaccine.2018.01.087; Lobstein J, 2012, MICROB CELL FACT, V11, DOI 10.1186/1475-2859-11-56; Lu HS, 2001, J BIOL CHEM, V276, P34913, DOI 10.1074/jbc.M102874200; MacHugh ND, 2009, EUR J IMMUNOL, V39, P2459, DOI 10.1002/eji.200939227; Magulu E, 2019, VET PARASITOL REG ST, V17, DOI 10.1016/j.vprsr.2019.100312; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; McKeever DJ, 2007, TRENDS PARASITOL, V23, P565, DOI 10.1016/j.pt.2007.09.002; MCKEEVER DJ, 1994, P NATL ACAD SCI USA, V91, P1959, DOI 10.1073/pnas.91.5.1959; Micsonai A, 2018, NUCLEIC ACIDS RES, V46, pW315, DOI 10.1093/nar/gky497; Morrison WI, 2015, ANNU REV ANIM BIOSCI, V3, P397, DOI 10.1146/annurev-animal-022513-114152; Munson S., 2008, CANC VACCINES TUMOR; Nene V, 2016, PARASITE IMMUNOL, V38, P724, DOI 10.1111/pim.12388; Nene V, 2016, TICKS TICK-BORNE DIS, V7, P549, DOI 10.1016/j.ttbdis.2016.02.001; Norling M, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1910-9; Odongo DO, 2009, J MED ENTOMOL, V46, P888, DOI 10.1603/033.046.0422; Oura CAL, 2007, PARASITOLOGY, V134, P1205, DOI 10.1017/S0031182007002557; Oura CAL, 2003, INT J PARASITOL, V33, P1641, DOI 10.1016/S0020-7519(03)00280-7; Patel EH, 2011, VET PARASITOL, V179, P62, DOI 10.1016/j.vetpar.2011.01.057; Patterson R, 2015, VACCINE, V33, P6199, DOI 10.1016/j.vaccine.2015.10.003; Pelle R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019015; Pellecchia M, 2008, NAT REV DRUG DISCOV, V7, P738, DOI 10.1038/nrd2606; Perry BD, 2016, ONE HEALTH, V2, P103, DOI 10.1016/j.onehlt.2016.07.002; RADLEY D E, 1975, Veterinary Parasitology, V1, P51, DOI 10.1016/0304-4017(75)90007-2; Rochereau N, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001658; Rostkova E, 2018, BIOMOL NMR ASSIGN, V12, P221, DOI 10.1007/s12104-018-9812-9; Rukambile E, 2016, VET PARASITOL, V224, P20, DOI 10.1016/j.vetpar.2016.04.038; Salih DA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171426; SANYAL G, 1995, BBA-PROTEIN STRUCT M, V1249, P100, DOI 10.1016/0167-4838(95)00022-M; Sitt T, 2018, PARASITOLOGY, V145, P1430, DOI [10.1017/S0031182018000264, 10.1017/s0031182018000264]; Skilton RA, 2002, PARASITOLOGY, V124, P265, DOI 10.1017/S0031182001001196; Stubbs AC, 2001, NAT MED, V7, P625, DOI 10.1038/87974; Svitek N, 2015, VET IMMUNOL IMMUNOP, V167, P80, DOI 10.1016/j.vetimm.2015.06.007; Svitek N, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0073-5; Taracha ELN, 1997, J IMMUNOL, V159, P4539; TARACHA ELN, 1995, INFECT IMMUN, V63, P1258, DOI 10.1128/IAI.63.4.1258-1262.1995; Tinega AN, 2009, VET IMMUNOL IMMUNOP, V130, P107, DOI 10.1016/j.vetimm.2009.01.008; Vasoya D, 2016, IMMUNOGENETICS, V68, P765, DOI 10.1007/s00251-016-0945-7; Wang LJ, 2018, VACCINE, V36, P3943, DOI 10.1016/j.vaccine.2018.05.072; Wilkie GM, 2002, VET PARASITOL, V104, P199, DOI 10.1016/S0304-4017(01)00630-6; Zaleska M, 2019, BIOMOL NMR ASSIGN, V13, P255, DOI 10.1007/s12104-019-09887-w	72	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 8	2021	12								674484	10.3389/fimmu.2021.674484	http://dx.doi.org/10.3389/fimmu.2021.674484			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TM4ZE	34305904	Green Published, gold			2022-12-18	WOS:000675558300001
J	Li, ZQ; Peirasmaki, D; Svard, S; Abrink, M				Li, Zhiqiang; Peirasmaki, Dimitra; Svard, Staffan; Abrink, Magnus			Serglycin-Deficiency Causes Reduced Weight Gain and Changed Intestinal Cytokine Responses in Mice Infected With Giardia intestinalis	FRONTIERS IN IMMUNOLOGY			English	Article						serglycin proteoglycan; knockout mouse; infection; Giardia intestinalis; innate intestinal immunity	LAMBLIA INFECTIONS; IMMUNE-RESPONSES; GROWTH; PROTEOGLYCAN; MATURATION; DUODENALIS; PROTEASES; CELLS	The proteoglycan serglycin (SG) is expressed by different innate and adaptive immune cells, e.g. mast cells, macrophages, neutrophils, and cytotoxic T lymphocytes, where SG contributes to correct granule storage and extracellular activity of inflammatory mediators. Here the serglycin-deficient (SG(-/-)) mouse strain was used to investigate the impact of SG on intestinal immune responses during infection with the non-invasive protozoan parasite Giardia intestinalis. Young (asymptotic to 11 weeks old) oral gavage-infected congenic SG(-/-) mice showed reduced weight gain as compared with the infected SG(+/+) littermate mice and the PBS-challenged SG(-/-) and SG(+/+) littermate mice. The infection caused no major morphological changes in the small intestine. However, a SG-independent increased goblet cell and granulocyte cell count was observed, which did not correlate with an increased myeloperoxidase or neutrophil elastase activity. Furthermore, infected mice showed increased serum IL-6 levels, with significantly reduced serum IL-6 levels in infected SG-deficient mice and decreased intestinal expression levels of IL-6 in the infected SG-deficient mice. In infected mice the qPCR analysis of alarmins, chemokines, cytokines, and nitric oxide synthases (NOS), showed that the SG-deficiency caused reduced intestinal expression levels of TNF-alpha and CXCL2, and increased IFN-gamma, CXCL1, and NOS1 levels as compared with SG-competent mice. This study shows that SG plays a regulatory role in intestinal immune responses, reflected by changes in chemokine and cytokine expression levels and a delayed weight gain in young SG(-/-) mice infected with G. intestinalis.	[Li, Zhiqiang] Guizhou Med Univ, Coll Basic Med, Key & Characterist Lab Modern Pathogen Biol, Guiyang, Peoples R China; [Li, Zhiqiang; Abrink, Magnus] Swedish Univ Agr Sci, Dept Biomed Sci, Vet Publ Hlth, Uppsala, Sweden; [Peirasmaki, Dimitra; Svard, Staffan] Uppsala Univ, Dept Cell & Mol Biol, SciLifeLab, Uppsala, Sweden	Guizhou Medical University; Swedish University of Agricultural Sciences; SciLifeLab; Uppsala University	Abrink, M (corresponding author), Swedish Univ Agr Sci, Dept Biomed Sci, Vet Publ Hlth, Uppsala, Sweden.	magnus.abrink@slu.se	Li, Zhiqiang/AFV-6127-2022	Abrink, Magnus/0000-0002-1335-3927	Vetenskapsradet VR-M [201203364, 2011-03533]	Vetenskapsradet VR-M(Swedish Research Council)	This study was in part funded by Vetenskapsradet VR-M, 201203364 (awarded to SS) and 2011-03533 (awarded to MA).	Abrink M, 2004, J BIOL CHEM, V279, P40897, DOI 10.1074/jbc.M405856200; Bartelt LA, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006471; Bartelt LA, 2013, J CLIN INVEST, V123, P2672, DOI 10.1172/JCI67294; Bienz M, 2003, INFECT IMMUN, V71, P1569, DOI 10.1128/IAI.71.3.1569-1573.2003; BURET A, 1990, J PARASITOL, V76, P403, DOI 10.2307/3282675; BURET A, 1990, PARASITOL TODAY, V6, P375, DOI 10.1016/0169-4758(90)90145-T; Burgess SL, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007515; Caccio SM, 2018, INFECT GENET EVOL, V66, P335, DOI 10.1016/j.meegid.2017.12.001; Donowitz JR, 2016, CLIN INFECT DIS, V63, P792, DOI 10.1093/cid/ciw391; Dreesen L, 2014, INFECT IMMUN, V82, P3333, DOI 10.1128/IAI.01536-14; Dreesen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040985; Dubourg A, 2018, GIGASCIENCE, V7, DOI 10.1093/gigascience/giy003; Einarsson E, 2016, CURR OPIN MICROBIOL, V34, P47, DOI 10.1016/j.mib.2016.07.019; Fink MY, 2017, TRENDS PARASITOL, V33, P901, DOI 10.1016/j.pt.2017.08.001; Grit GH, 2014, VET PARASITOL, V202, P145, DOI 10.1016/j.vetpar.2014.03.012; Grujic M, 2005, J BIOL CHEM, V280, P33411, DOI 10.1074/jbc.M501708200; Hafte TT, 2011, GLYCOBIOLOGY, V21, P457, DOI 10.1093/glycob/cwq180; HALLIDAY CEW, 1988, T ROY SOC TROP MED H, V82, P428, DOI 10.1016/0035-9203(88)90153-8; Heyworth MF, 2014, PARASITE, V21, DOI 10.1051/parasite/2014056; Ignatius R, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001677; Jimenez JC, 2014, PARASITOL RES, V113, P2709, DOI 10.1007/s00436-014-3927-4; Karanis P, 2007, J WATER HEALTH, V5, P1, DOI 10.2166/wh.2006.002; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; Lalle M, 2005, J PARASITOL, V91, P203, DOI 10.1645/GE-293R; Li EQ, 2006, J IMMUNOL, V176, P516, DOI 10.4049/jimmunol.176.1.516; Li EQ, 2004, INFECT IMMUN, V72, P6642, DOI 10.1128/IAI.72.11.6642-6649.2004; Li ZQ, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040925; Lin L, 2011, J BIOL CHEM, V286, P37358, DOI 10.1074/jbc.M111.272401; Liu JY, 2018, VIRULENCE, V9, P879, DOI 10.1080/21505594.2018.1451284; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma'ayeh SY, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00244; Ma'ayeh SY, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006120; Maertens B, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-90261-z; Meen AJ, 2015, GLYCOCONJUGATE J, V32, P703, DOI 10.1007/s10719-015-9621-7; Niemann CU, 2007, BLOOD, V109, P4478, DOI 10.1182/blood-2006-02-001719; Peckova R, 2018, PARASITOL RES, V117, P2437, DOI 10.1007/s00436-018-5932-5; Pejler G, 2007, ADV IMMUNOL, V95, P167, DOI 10.1016/S0065-2776(07)95006-3; Pejler G, 2009, BIOFACTORS, V35, P61, DOI 10.1002/biof.11; Pham CTN, 2006, NAT REV IMMUNOL, V6, P541, DOI 10.1038/nri1841; Reine TM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145584; Reine TM, 2014, BBA-GEN SUBJECTS, V1840, P2498, DOI 10.1016/j.bbagen.2014.02.002; Riba B, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay7019; Ringqvist E, 2008, MOL BIOCHEM PARASIT, V159, P85, DOI 10.1016/j.molbiopara.2008.02.005; Rogawski ET, 2018, LANCET GLOB HEALTH, V6, pE1319, DOI [10.1016/S2214-109X(18)30351-6, 10.1016/s2214-109x(18)30351-6]; Roxstrom-Lindquist K, 2006, TRENDS PARASITOL, V22, P26, DOI 10.1016/j.pt.2005.11.005; Roy A, 2016, BMC IMMUNOL, V17, DOI 10.1186/s12865-016-0155-y; Sawant KV, 2021, J LEUKOCYTE BIOL, V109, P777, DOI 10.1002/JLB.3A0820-207R; Serradell MC, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00773-17; Singer SM, 2019, ADV PARASIT, V106, P171, DOI 10.1016/bs.apar.2019.07.004; Solaymani-Mohammadi S, 2010, EXP PARASITOL, V126, P292, DOI 10.1016/j.exppara.2010.06.014; Tako EA, 2013, MBIO, V4, DOI 10.1128/mBio.00660-13; Torgerson PR, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001920; Waern I, 2016, IMMUN INFLAMM DIS, V4, P70, DOI 10.1002/iid3.95; Zhou P, 2007, PARASITE IMMUNOL, V29, P367, DOI 10.1111/j.1365-3024.2007.00953.x; Zhou P, 2003, INFECT IMMUN, V71, P1566, DOI 10.1128/IAI.71.3.1566-1568.2003	55	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 8	2021	12								677722	10.3389/fimmu.2021.677722	http://dx.doi.org/10.3389/fimmu.2021.677722			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TR0ZA	34335577	Green Published, gold			2022-12-18	WOS:000678700500001
J	Zhao, CC; Zhang, Y; Zheng, H				Zhao, Chenchen; Zhang, Yi; Zheng, Hong			The Effects of Interferons on Allogeneic T Cell Response in GVHD: The Multifaced Biology and Epigenetic Regulations	FRONTIERS IN IMMUNOLOGY			English	Review						type I interferon; IFN-gamma; GVHD; epigenetic regulation; alloreactive T cells	VERSUS-HOST-DISEASE; IFN-GAMMA; I INTERFERONS; HISTONE H3; FATE DETERMINATION; FOLLICULAR HELPER; CLONAL EXPANSION; DNA METHYLATION; GENE-EXPRESSION; HYDROXAMIC ACID	Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for hematological malignancies. This beneficial effect is derived mainly from graft-versus-leukemia (GVL) effects mediated by alloreactive T cells. However, these alloreactive T cells can also induce graft-versus-host disease (GVHD), a life-threatening complication after allo-HSCT. Significant progress has been made in the dissociation of GVL effects from GVHD by modulating alloreactive T cell immunity. However, many factors may influence alloreactive T cell responses in the host undergoing allo-HSCT, including the interaction of alloreactive T cells with both donor and recipient hematopoietic cells and host non-hematopoietic tissues, cytokines, chemokines and inflammatory mediators. Interferons (IFNs), including type I IFNs and IFN-gamma, primarily produced by monocytes, dendritic cells and T cells, play essential roles in regulating alloreactive T cell differentiation and function. Many studies have shown pleiotropic effects of IFNs on allogeneic T cell responses during GVH reaction. Epigenetic mechanisms, such as DNA methylation and histone modifications, are important to regulate IFNs' production and function during GVHD. In this review, we discuss recent findings from preclinical models and clinical studies that characterize T cell responses regulated by IFNs and epigenetic mechanisms, and further discuss pharmacological approaches that modulate epigenetic effects in the setting of allo-HSCT.	[Zhao, Chenchen; Zheng, Hong] Penn State Univ, Coll Med, Penn State Canc Inst, Hershey, PA USA; [Zhang, Yi] Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Zheng, H (corresponding author), Penn State Univ, Coll Med, Penn State Canc Inst, Hershey, PA USA.; Zhang, Y (corresponding author), Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA.	yi.zhang@temple.edu; hzheng@pennstatehealth.psu.edu						Adoue V, 2019, IMMUNITY, V50, P629, DOI 10.1016/j.immuni.2019.01.003; Agarwal P, 2009, J IMMUNOL, V183, P1695, DOI 10.4049/jimmunol.0900592; Ali S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00778; Allan RS, 2012, NATURE, V487, P249, DOI 10.1038/nature11173; Araki Y, 2009, IMMUNITY, V30, P912, DOI 10.1016/j.immuni.2009.05.006; Arico E, 2019, CANCERS, V11, DOI 10.3390/cancers11121943; Arvey A, 2014, NAT IMMUNOL, V15, P580, DOI 10.1038/ni.2868; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Badovinac VP, 2000, SCIENCE, V290, P1354, DOI 10.1126/science.290.5495.1354; Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200; Barbet G, 2018, IMMUNITY, V48, P584, DOI 10.1016/j.immuni.2018.02.015; Barrat FJ, 2019, NAT IMMUNOL, V20, P1574, DOI 10.1038/s41590-019-0466-2; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bezerra ED, 2019, LEUKEMIA LYMPHOMA, V60, P2754, DOI 10.1080/10428194.2019.1605508; Bhan A., 2017, GENE REGUL EPIGENET, P29, DOI [10.1002/9783527697274.ch2, DOI 10.1002/9783527697274.CH2]; Bhat P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.67; Bian YJ, 2020, NATURE, V585, P277, DOI 10.1038/s41586-020-2682-1; Blazar BR, 2020, NAT REV CLIN ONCOL, V17, P475, DOI 10.1038/s41571-020-0356-4; Cao KX, 2020, P NATL ACAD SCI USA, V117, P27365, DOI 10.1073/pnas.2001075117; Carniti C, 2015, CLIN CANCER RES, V21, P3740, DOI 10.1158/1078-0432.CCR-14-2758; Chang SJ, 2007, NAT IMMUNOL, V8, P723, DOI 10.1038/ni1473; Choi J, 2018, LEUKEMIA, V32, P2483, DOI 10.1038/s41375-018-0123-z; Choi J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109799; Choi J, 2012, BLOOD, V120, P4093, DOI 10.1182/blood-2012-01-403196; Choi J, 2010, BLOOD, V116, P129, DOI 10.1182/blood-2009-12-257253; Choi SW, 2017, BLOOD, V130, P1760, DOI 10.1182/blood-2017-06-790469; Choi SW, 2014, LANCET ONCOL, V15, P87, DOI 10.1016/S1470-2045(13)70512-6; Cooper ML, 2017, J IMMUNOL, V198, P3746, DOI 10.4049/jimmunol.1502399; Cooper N, 2012, BRIT J HAEMATOL, V156, P550, DOI 10.1111/j.1365-2141.2011.08889.x; Crow MK, 2019, ANNU REV PATHOL-MECH, V14, P369, DOI 10.1146/annurev-pathol-020117-043952; Curtsinger JM, 2005, J IMMUNOL, V174, P4465, DOI 10.4049/jimmunol.174.8.4465; Daenthanasanmak A, 2019, BLOOD, V133, P266, DOI 10.1182/blood-2018-07-863233; Dalton DK, 2000, J EXP MED, V192, P117, DOI 10.1084/jem.192.1.117; Daniel V, 2011, HUM IMMUNOL, V72, P699, DOI 10.1016/j.humimm.2011.05.020; Denton AE, 2011, P NATL ACAD SCI USA, V108, P15306, DOI 10.1073/pnas.1112520108; Ehx G, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1314425; Eriguchi Y, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121886; Fang TC, 2012, J EXP MED, V209, P661, DOI 10.1084/jem.20112343; Field T, 2010, BONE MARROW TRANSPL, V45, P255, DOI 10.1038/bmt.2009.134; Fischer JC, 2019, INT J RADIAT ONCOL, V103, P970, DOI 10.1016/j.ijrobp.2018.11.038; Fischer JC, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag2513; Freeman BE, 2012, P NATL ACAD SCI USA, V109, P9971, DOI 10.1073/pnas.1203543109; Gamper CJ, 2009, J IMMUNOL, V183, P2267, DOI 10.4049/jimmunol.0802960; Gangaplara A, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006985; Ghoneim HE, 2017, CELL, V170, DOI 10.1016/j.cell.2017.06.007; Goschl L, 2018, J AUTOIMMUN, V86, P51, DOI 10.1016/j.jaut.2017.09.008; Gracias DT, 2013, NAT IMMUNOL, V14, P593, DOI 10.1038/ni.2576; Grausenburger R, 2010, J IMMUNOL, V185, P3489, DOI 10.4049/jimmunol.0903610; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Hashimoto H, 2014, CANCER GENE THER, V21, P532, DOI 10.1038/cgt.2014.60; He S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02187-8; He S, 2013, BLOOD, V122, P4119, DOI 10.1182/blood-2013-05-505180; Henden AS, 2019, BLOOD ADV, V3, P3013, DOI 10.1182/bloodadvances.2019000453; Henden AS, 2015, J IMMUNOL, V194, P4604, DOI 10.4049/jimmunol.1500117; Henden AS., 2021, BLOOD, DOI [10.1182/blood.2020006375, DOI 10.1182/BLOOD.2020006375]; Henning AN, 2018, NAT REV IMMUNOL, V18, P340, DOI 10.1038/nri.2017.146; Hida S, 2000, IMMUNITY, V13, P643, DOI 10.1016/S1074-7613(00)00064-9; Hofer MJ, 2012, J VIROL, V86, P6932, DOI 10.1128/JVI.07147-11; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hosokawa H, 2013, P NATL ACAD SCI USA, V110, P4691, DOI 10.1073/pnas.1220865110; Ichiyama K, 2015, IMMUNITY, V42, P613, DOI 10.1016/j.immuni.2015.03.005; Ilander M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087794; IMAMURA M, 1994, BONE MARROW TRANSPL, V13, P745; Ivashkiv LB, 2018, NAT REV IMMUNOL, V18, P545, DOI 10.1038/s41577-018-0029-z; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Iwata S, 2017, IMMUNITY, V46, P983, DOI 10.1016/j.immuni.2017.05.005; Jambhekar A, 2019, NAT REV MOL CELL BIO, V20, P625, DOI 10.1038/s41580-019-0151-1; Jarry A, 2017, CELL MOL GASTROENTER, V3, P72, DOI 10.1016/j.jcmgh.2016.09.007; Jones SC, 2003, J CLIN INVEST, V112, P1880, DOI 10.1172/JCI200319427; Jorgovanovic D, 2020, BIOMARK RES, V8, DOI 10.1186/s40364-020-00228-x; Kagoya Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04262-0; Kakaradov B, 2017, NAT IMMUNOL, V18, P422, DOI 10.1038/ni.3688; Kalia V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02987; Kawashima K, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.145761; Kersh EN, 2006, J IMMUNOL, V176, P4083, DOI 10.4049/jimmunol.176.7.4083; Kolumam GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821; Komori HK, 2015, J IMMUNOL, V194, P1565, DOI 10.4049/jimmunol.1401162; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Koyama M, 2019, IMMUNITY, V51, P885, DOI 10.1016/j.immuni.2019.08.011; Kumar Sandeep, 2017, J Immunol Res Ther, V2, P90; Kwesi-Maliepaard EM, 2020, P NATL ACAD SCI USA, V117, P20706, DOI 10.1073/pnas.1920372117; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lazear HM, 2019, IMMUNITY, V50, P907, DOI 10.1016/j.immuni.2019.03.025; Le Bon A, 2003, NAT IMMUNOL, V4, P1009, DOI 10.1038/ni978; Le Bon A, 2006, J IMMUNOL, V176, P4682, DOI 10.4049/jimmunol.176.8.4682; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lehnertz B, 2010, J EXP MED, V207, P915, DOI 10.1084/jem.20100363; Leng C, 2006, EXP HEMATOL, V34, P776, DOI 10.1016/j.exphem.2006.02.014; Lertmemongkolchai G, 2001, J IMMUNOL, V166, P1097, DOI 10.4049/jimmunol.166.2.1097; Li A, 2020, HAEMATOLOGICA, V105, P2540, DOI 10.3324/haematol.2019.240291; Li QT, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6780; Lin XJ, 2018, ANN HEMATOL, V97, P2195, DOI 10.1007/s00277-018-3429-z; Lu CW, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0635-8; Lubbert M, 2009, BONE MARROW TRANSPL, V44, P585, DOI 10.1038/bmt.2009.64; Maldonado RA, 2009, J EXP MED, V206, P877, DOI 10.1084/jem.20082900; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; Marshall HD, 2011, J VIROL, V85, P5929, DOI 10.1128/JVI.02516-10; Martinet V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8089; McDonald GB, 2020, ANN INTERN MED, V172, P229, DOI 10.7326/M19-2936; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; Miller S, 2019, ANN RHEUM DIS, V78, P519, DOI 10.1136/annrheumdis-2018-214323; Mo XD, 2017, BIOL BLOOD MARROW TR, V23, P1303, DOI 10.1016/j.bbmt.2017.04.023; Myers DR, 2017, CELL REP, V19, P1558, DOI 10.1016/j.celrep.2017.04.076; Nast R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.581241; Nava P, 2010, IMMUNITY, V32, P392, DOI 10.1016/j.immuni.2010.03.001; Newby BN, 2017, DIABETES, V66, P3061, DOI 10.2337/db17-0106; Nikolic B, 2000, J CLIN INVEST, V105, P1289, DOI 10.1172/JCI7894; Oran B, 2020, BLOOD ADV, V4, P5580, DOI 10.1182/bloodadvances.2020002544; Pace L, 2018, SCIENCE, V359, P177, DOI 10.1126/science.aah6499; Perez L, 2018, BONE MARROW TRANSPL, V53, P1434, DOI 10.1038/s41409-018-0163-z; Pestka S, 2007, CURR TOP MICROBIOL, V316, P23; Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105; Pollard KM, 2013, DISCOV MED, V16, P123; Porritt RA, 2015, TRENDS IMMUNOL, V36, P150, DOI 10.1016/j.it.2015.02.002; Pott J, 2011, P NATL ACAD SCI USA, V108, P7944, DOI 10.1073/pnas.1100552108; Prokunina-Olsson L, 2013, NAT GENET, V45, P164, DOI 10.1038/ng.2521; Ramos HJ, 2009, BLOOD, V113, P5516, DOI 10.1182/blood-2008-11-188458; Ray JP, 2014, IMMUNITY, V40, P367, DOI 10.1016/j.immuni.2014.02.005; Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101; Refaeli Y, 2002, J EXP MED, V196, P999, DOI 10.1084/JEM.20020666; Riegel C, 2020, LEUKEMIA, V34, P895, DOI 10.1038/s41375-019-0625-3; Robb RJ, 2012, BLOOD, V119, P5351, DOI 10.1182/blood-2012-02-368076; Robb RJ, 2011, BLOOD, V118, P3399, DOI 10.1182/blood-2010-12-325746; Saha A, 2016, J CLIN INVEST, V126, P2642, DOI 10.1172/JCI85796; Scheer S, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108505; Scheer S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07905-4; Scheer S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00429; Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2; Schoenborn JR, 2007, NAT IMMUNOL, V8, P732, DOI 10.1038/ni1474; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Sommereyns C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000017; Spoerl S, 2014, BLOOD, V123, P3832, DOI 10.1182/blood-2013-12-543736; Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013; Steger DJ, 2008, MOL CELL BIOL, V28, P2825, DOI 10.1128/MCB.02076-07; Stubig T, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/418292; Sun K, 2012, J IMMUNOL, V189, P2033, DOI 10.4049/jimmunol.1102853; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Takashima S, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aay8556; Tanabe Y, 2005, J IMMUNOL, V174, P609, DOI 10.4049/jimmunol.174.2.609; Thomas RM, 2012, J BIOL CHEM, V287, P22900, DOI 10.1074/jbc.M111.312785; Tian YY, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI136774; Tong Q, 2014, J IMMUNOL, V192, P5012, DOI 10.4049/jimmunol.1302943; Toubai T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00066; Tschismarov R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110576; Tumes DJ, 2013, IMMUNITY, V39, P819, DOI 10.1016/j.immuni.2013.09.012; Turner BM, 2007, NAT CELL BIOL, V9, P2, DOI 10.1038/ncb0107-2; Verbaro DJ, 2018, J IMMUNOL, V200, P3891, DOI 10.4049/jimmunol.1701700; Wang H, 2014, IMMUNOL REV, V258, P30, DOI 10.1111/imr.12151; Wang X, 2017, ONCOTARGET, V8, P56802, DOI 10.18632/oncotarget.18063; Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154; Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009; Welniak LA, 2000, BIOL BLOOD MARROW TR, V6, P604, DOI 10.1016/S1083-8791(00)70025-5; Whangbo JS, 2020, EXPERT REV HEMATOL, V13, P141, DOI 10.1080/17474086.2020.1709436; Winders BR, 2004, J IMMUNOL, V173, P7377, DOI 10.4049/jimmunol.173.12.7377; Wojno EDT, 2019, IMMUNITY, V50, P851, DOI 10.1016/j.immuni.2019.03.011; Wood K, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8010011; Woods DM, 2017, BLOOD, V130, P146, DOI 10.1182/blood-2016-08-731505; Xiao HY, 2016, INT J CANCER, V138, P2477, DOI 10.1002/ijc.29979; Yajnanarayana SP, 2015, BRIT J HAEMATOL, V169, P824, DOI 10.1111/bjh.13373; Yang R, 2019, GENOME BIOL, V21, DOI 10.1186/s13059-019-1921-y; Yang XP, 2015, SCI REP-UK, V5, DOI 10.1038/srep10643; Yerinde C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02718; Yi TS, 2009, BLOOD, V114, P3101, DOI 10.1182/blood-2009-05-219402; Zediak VP, 2011, J IMMUNOL, V186, P2705, DOI 10.4049/jimmunol.1003741; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337; Zeng W, 2010, EPIGENETICS-US, V5, P287, DOI 10.4161/epi.5.4.11683; Zhang JN, 2009, J CLIN INVEST, V119, P3048, DOI 10.1172/JCI38902; Zhang Y, 2002, J CLIN INVEST, V109, P1335, DOI 10.1172/JCI200214989; Zhang YX, 2014, BLOOD, V124, P737, DOI 10.1182/blood-2013-12-544106	170	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 8	2021	12								717540	10.3389/fimmu.2021.717540	http://dx.doi.org/10.3389/fimmu.2021.717540			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TM4YO	34305954	Green Published, gold			2022-12-18	WOS:000675556700001
J	Bhagyaraj, E; Wang, HB; Yang, XH; Hoffman, C; Akgul, A; Goodwin, ZI; Pascual, DW				Bhagyaraj, Ella; Wang, Hongbin; Yang, Xinghong; Hoffman, Carol; Akgul, Ali; Goodwin, Zakia, I; Pascual, David W.			Mucosal Vaccination Primes NK Cell-Dependent Development of CD8(+) T Cells Against Pulmonary Brucella Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Brucella; dendritic cells; macrophages; IFN-gamma; chemokines; CD8(+) T cells	NATURAL-KILLER-CELLS; GAMMA-INDUCING FACTOR; DENDRITIC CELLS; INTERFERON-GAMMA; IFN-GAMMA; ACTIVATION; INNATE; DIFFERENTIATION; RECRUITMENT; VACCINES	Past studies with the live, double-mutant B. abortus (znBAZ) strain resulted in nearly complete protection of mice against pulmonary challenge with wild-type (wt) Brucella via a dominant CD8(+) T cell response. To understand the contribution innate immune cells in priming CD8(+) T cell responses, mice were nasally dosed with wt B. abortus, smooth vaccine strain 19 (S19), or znBAZ, and examined for innate immune cell activation. Flow cytometric analysis revealed that znBAZ, but not wt B. abortus nor S19 infection, induces up to a 5-fold increase in the frequency of IFN-gamma-producing NK cells in mouse lungs. These NK cells express increased CXCR3 and Ki67, indicating their recruitment and proliferation subsequent to znBAZ infection. Their activation status was augmented noted by the increased NKp46 and granzyme B, but decreased NKG2A expression. Further analysis demonstrated that both lung caspase-1(+) inflammatory monocytes and monocyte-derived macrophages secrete chemokines and cytokines responsible for NK cell recruitment and activation. Moreover, neutralizing IL-18, an NK cell-activating cytokine, reduced the znBAZ-induced early NK cell response. NK cell depletion also significantly impaired lung dendritic cell (DC) activation and migration to the lower respiratory lymph nodes (LRLNs). Both lung DC activation and migration to LRLNs were significantly impaired in NK cell-depleted or IFN-gamma(-/-) mice, particularly the CD11b(+) and monocytic DC subsets. Furthermore, znBAZ vaccination significantly induced CD8(+) T cells, and upon in vivo NK cell depletion, CD8(+) T cells were reduced 3-fold compared to isotype-treated mice. In summary, these data show that znBAZ induces lung IFN-gamma(+) NK cells, which plays a critical role in influencing lung DC activation, migration, and promoting protective CD8(+) T cell development.	[Bhagyaraj, Ella; Wang, Hongbin; Yang, Xinghong; Hoffman, Carol; Akgul, Ali; Goodwin, Zakia, I; Pascual, David W.] Univ Florida, Dept Infect Dis & Immunol, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Pascual, DW (corresponding author), Univ Florida, Dept Infect Dis & Immunol, Gainesville, FL 32611 USA.	pascuald@ufl.edu	Pascual, David/AAC-2248-2022; Ella, Bhagyaraj/X-2823-2019		National Institute of Allergy and Infectious Diseases [AI123244, AI125516]; NIH [1S10 OD021676]	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by National Institute of Allergy and Infectious Diseases grants AI123244 and AI125516, and NIH 1S10 OD021676 (DP).	Archambaud C, 2010, EUR J IMMUNOL, V40, P3458, DOI 10.1002/eji.201040497; Chaix J, 2008, J IMMUNOL, V181, P1627, DOI 10.4049/jimmunol.181.3.1627; Clavijo-Salomon MA, 2020, BLOOD ADV, V4, P3990, DOI 10.1182/bloodadvances.2020002084; Cong JJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01416; Cook KD, 2014, CRIT REV IMMUNOL, V34, P359, DOI 10.1615/CritRevImmunol.2014010604; de Figueiredo P, 2015, AM J PATHOL, V185, P1505, DOI 10.1016/j.ajpath.2015.03.003; Dean AS, 2012, PLOS NEGLECT TROP D, V6, DOI [10.1371/journal.pntd.0001929, 10.1371/journal.pntd.0001865]; Demars A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01589; Feili-Hariri M, 2005, J LEUKOCYTE BIOL, V78, P656, DOI 10.1189/jlb.1104631; Ferlazzo G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00159; FERNANDES DM, 1995, INFECT IMMUN, V63, P4029, DOI 10.1128/IAI.63.10.4029-4033.1995; Franc KA, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-017-5016-y; Freeman BE, 2015, J VIROL, V89, P7922, DOI 10.1128/JVI.00199-15; Galinska EM, 2013, ANN AGR ENV MED, V20, P233; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Goldszmid RS, 2012, IMMUNITY, V36, P1047, DOI 10.1016/j.immuni.2012.03.026; Gosmann C, 2014, J INVEST DERMATOL, V134, P2562, DOI 10.1038/jid.2014.201; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Hall LJ, 2013, INFECT IMMUN, V81, P460, DOI 10.1128/IAI.00953-12; Higgs R, 2012, MUCOSAL IMMUNOL, V5, P485, DOI 10.1038/mi.2012.54; Hull Noah C., 2018, Infection Ecology & Epidemiology, V8, P1500846, DOI 10.1080/20008686.2018.1500846; Ivanova D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413982; Iwasaki A, 2017, NAT REV IMMUNOL, V17, P7, DOI 10.1038/nri.2016.117; Johansen MV, 2017, ACTA TROP, V165, P1, DOI 10.1016/j.actatropica.2016.11.036; Kaufmann A F, 1980, Ann N Y Acad Sci, V353, P105, DOI 10.1111/j.1749-6632.1980.tb18912.x; Khan MZ, 2018, TROP MED INFECT DIS, V3, DOI 10.3390/tropicalmed3020065; Kim ED, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137608; Kosaka A, 2007, INT IMMUNOL, V19, P249, DOI 10.1093/intimm/dxl140; Legge KL, 2003, IMMUNITY, V18, P265, DOI 10.1016/S1074-7613(03)00023-2; Lodoen MB, 2006, CURR OPIN IMMUNOL, V18, P391, DOI 10.1016/j.coi.2006.05.002; Long EO, 2013, ANNU REV IMMUNOL, V31, P227, DOI 10.1146/annurev-immunol-020711-075005; Ma ZC, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.599205; Moreno E, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00213; Moretta A, 2008, CELL DEATH DIFFER, V15, P226, DOI 10.1038/sj.cdd.4402170; Nakahira M, 2002, J IMMUNOL, V168, P1146, DOI 10.4049/jimmunol.168.3.1146; Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777; Nizard M, 2014, HUM VACC IMMUNOTHER, V10, P2175, DOI 10.4161/hv.29269; O'Connor GM, 2006, IMMUNOLOGY, V117, P1, DOI 10.1111/j.1365-2567.2005.02256.x; Olsen SC, 2014, VET PATHOL, V51, P1076, DOI 10.1177/0300985814540545; Pak-Wittel MA, 2013, P NATL ACAD SCI USA, V110, pE50, DOI 10.1073/pnas.1220456110; Pappas G, 2006, LANCET INFECT DIS, V6, P91, DOI 10.1016/S1473-3099(06)70382-6; Pappas G, 2005, NEW ENGL J MED, V352, P2325, DOI 10.1056/NEJMra050570; Pavot V, 2012, VACCINE, V30, P142, DOI 10.1016/j.vaccine.2011.11.003; Reid-Yu SA, 2013, EUR J IMMUNOL, V43, P2638, DOI 10.1002/eji.201343435; Ruiz AL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6150; SCHARTON TM, 1993, J EXP MED, V178, P567, DOI 10.1084/jem.178.2.567; Steinman RM, 2006, CURR TOP MICROBIOL, V311, P17; Sun JC, 2009, EUR J IMMUNOL, V39, P2059, DOI 10.1002/eji.200939435; van der Touw W, 2012, TRANSPLANTATION, V94, P575, DOI 10.1097/TP.0b013e318264d3c4; Wang HB, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008176; Wong JL, 2013, CANCER RES, V73, P4653, DOI 10.1158/0008-5472.CAN-12-4366; Yang XH, 2016, VACCINE, V34, P5290, DOI 10.1016/j.vaccine.2016.09.004; Yang Xinghong, 2013, Front Biol (Beijing), V8, P60; Yasuda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030649; Zhou D, 2018, ONCOTARGET, V9, P5184, DOI 10.18632/oncotarget.23706; Zhou K, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00521; Zwirner NW, 2010, BIOFACTORS, V36, P274, DOI 10.1002/biof.107	57	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2021	12								697953	10.3389/fimmu.2021.697953	http://dx.doi.org/10.3389/fimmu.2021.697953			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TL6WJ	34305935	Green Published, gold			2022-12-18	WOS:000675000000001
J	Kotraiah, V; Phares, TW; Terry, FE; Hindocha, P; Silk, SE; Nielsen, CM; Moise, L; Tucker, KD; Ashfield, R; Martin, WD; De Groot, AS; Draper, SJ; Gutierrez, GM; Noe, AR				Kotraiah, Vinayaka; Phares, Timothy W.; Terry, Frances E.; Hindocha, Pooja; Silk, Sarah E.; Nielsen, Carolyn M.; Moise, Leonard; Tucker, Kenneth D.; Ashfield, Rebecca; Martin, William D.; De Groot, Anne S.; Draper, Simon J.; Gutierrez, Gabriel M.; Noe, Amy R.			Identification and Immune Assessment of T Cell Epitopes in Five Plasmodium falciparum Blood Stage Antigens to Facilitate Vaccine Candidate Selection and Optimization	FRONTIERS IN IMMUNOLOGY			English	Article						malaria; VAC063; class II T cell epitope; RH5; RIPR; CyRPA; EBA175; AMA1	MALARIA VACCINE; B-CELL; IMMUNOGENICITY; SPECIFICITY; SUPERTYPES; MOLECULES; RESPONSES; SAFETY; ADULTS; MSP1	The hurdles to effective blood stage malaria vaccine design include immune evasion tactics used by the parasite such as redundant invasion pathways and antigen variation among circulating parasite strains. While blood stage malaria vaccine development primarily focuses on eliciting optimal humoral responses capable of blocking erythrocyte invasion, clinically-tested Plasmodium falciparum (Pf) vaccines have not elicited sterile protection, in part due to the dramatically high levels of antibody needed. Recent development efforts with non-redundant, conserved blood stage antigens suggest both high antibody titer and rapid antibody binding kinetics are important efficacy factors. Based on the central role of helper CD4 T cells in development of strong, protective immune responses, we systematically analyzed the class II epitope content in five leading Pf blood stage antigens (RH5, CyRPA, RIPR, AMA1 and EBA175) using in silico, in vitro, and ex vivo methodologies. We employed in silico T cell epitope analysis to enable identification of 67 HLA-restricted class II epitope clusters predicted to bind a panel of nine HLA-DRB1 alleles. We assessed a subset of these for HLA-DRB1 allele binding in vitro, to verify the in silico predictions. All clusters assessed (40 clusters represented by 46 peptides) bound at least two HLA-DR alleles in vitro. The overall epitope prediction to in vitro HLA-DRB1 allele binding accuracy was 71%. Utilizing the set of RH5 class II epitope clusters (10 clusters represented by 12 peptides), we assessed stimulation of T cells collected from HLA-matched RH5 vaccinees using an IFN-gamma T cell recall assay. All clusters demonstrated positive recall responses, with the highest responses - by percentage of responders and response magnitude - associated with clusters located in the N-terminal region of RH5. Finally, a statistically significant correlation between in silico epitope predictions and ex vivo IFN-gamma recall response was found when accounting for HLA-DR matches between the epitope predictions and donor HLA phenotypes. This is the first comprehensive analysis of class II epitope content in RH5, CyRPA, RIPR, AMA1 and EBA175 accompanied by in vitro HLA binding validation for all five proteins and ex vivo T cell response confirmation for RH5.	[Kotraiah, Vinayaka; Phares, Timothy W.; Tucker, Kenneth D.; Gutierrez, Gabriel M.; Noe, Amy R.] Leidos Inc, Leidos Life Sci, Frederick, MD 21702 USA; [Terry, Frances E.; Hindocha, Pooja; Moise, Leonard; Martin, William D.; De Groot, Anne S.] EpiVax Inc, Providence, RI USA; [Silk, Sarah E.; Nielsen, Carolyn M.; Ashfield, Rebecca; Draper, Simon J.] Univ Oxford, Jenner Inst, Oxford, England; [De Groot, Anne S.] Univ Georgia, Ctr Vaccines & Immunol, Athens, GA 30602 USA; [Hindocha, Pooja] IQVIA Inc, London, England	University of Oxford; Jenner Institute; University System of Georgia; University of Georgia	Kotraiah, V (corresponding author), Leidos Inc, Leidos Life Sci, Frederick, MD 21702 USA.	Vinayaka.kotrainh@leidos.com	De Groot, Annie/B-6221-2013; Moise, Lenny/AAE-7448-2019	De Groot, Annie/0000-0001-5911-1459; Moise, Lenny/0000-0002-4410-865X	Office of Infectious Diseases, Bureau for Global Health, U.S. Agency for International Development under Malaria Vaccine Development Program (MVDP) [AID-OAA-C-15-00071]	Office of Infectious Diseases, Bureau for Global Health, U.S. Agency for International Development under Malaria Vaccine Development Program (MVDP)	These studies were made possible through support provided by the Office of Infectious Diseases, Bureau for Global Health, U.S. Agency for International Development (https://www.usaid.gov), under the terms of the Malaria Vaccine Development Program (MVDP) Contract AID-OAA-C-15-00071, for which Leidos, Inc. is the prime contractor. The funders approved study plans but had no direct role in development of study designs, data collection/analysis, or preparation of the manuscript. CN is a Wellcome Trust Sir Henry	Alanine DGW, 2019, CELL, V178, P216, DOI 10.1016/j.cell.2019.05.025; Beeson JG, 2008, TRENDS PARASITOL, V24, P578, DOI 10.1016/j.pt.2008.08.008; Bentebibel SE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005191; Carpio VH, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101310; De Groot AS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00442; Douglas AD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09894-4; Douglas AD, 2014, J IMMUNOL, V192, P245, DOI 10.4049/jimmunol.1302045; Dutta S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008138; El Sahly HM, 2010, CLIN VACCINE IMMUNOL, V17, P1552, DOI 10.1128/CVI.00082-10; Feng YQ, 2015, NATURE, V528, P132, DOI 10.1038/nature16141; Goodman AL, 2010, ANN TROP MED PARASIT, V104, P189, DOI 10.1179/136485910X12647085215534; Gotz A, 2017, P NATL ACAD SCI USA, V114, pE10568, DOI 10.1073/pnas.1708383114; Healer J, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.13030; Horne-Debets JM, 2016, SCI REP-UK, V6, DOI 10.1038/srep26210; Horne-Debets JM, 2013, CELL REP, V5, P1204, DOI 10.1016/j.celrep.2013.11.002; Jin J, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0071-7; Junqueira C, 2018, NAT MED, V24, P1330, DOI 10.1038/s41591-018-0117-4; Khan S, 2020, HUM VACC IMMUNOTHER, V16, P214, DOI 10.1080/21645515.2018.1560772; Koram KA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163066; Koutsakos M, 2019, J IMMUNOL, V202, P360, DOI 10.4049/jimmunol.1800986; Liu R, 2015, HUM VACC IMMUNOTHER, V11, P2241, DOI 10.1080/21645515.2015.1052197; Losikoff PT, 2015, J HEPATOL, V62, P48, DOI 10.1016/j.jhep.2014.08.026; Lund O, 2004, IMMUNOGENETICS, V55, P797, DOI 10.1007/s00251-004-0647-4; Minassian AM, 2021, MED-CAMBRIDGE, V2, P701, DOI 10.1016/j.medj.2021.03.014; Moise L, 2015, HUM VACC IMMUNOTHER, V11, P2312, DOI 10.1080/21645515.2015.1061159; Moise L, 2013, HUM VACC IMMUNOTHER, V9, P1598, DOI 10.4161/hv.25598; Moise L, 2013, HUM VACC IMMUNOTHER, V9, P1577, DOI 10.4161/hv.24615; Nielsen CM, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100207; Payne RO, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.96381; Payne RO, 2017, JCI INSIGHT, V2, DOI [10.1172/jci.insight.93683, 10.1172/jci.insight.96381]; Ragotte RJ, 2020, TRENDS PARASITOL, V36, P545, DOI 10.1016/j.pt.2020.04.003; Reche PA, 2005, NUCLEIC ACIDS RES, V33, pW138, DOI 10.1093/nar/gki357; Schanen BC, 2011, VACCINE, V29, P3299, DOI 10.1016/j.vaccine.2011.02.019; Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594; Sheehy SH, 2012, MOL THER, V20, P2355, DOI 10.1038/mt.2012.223; Sheehy SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031208; Sheehy SH, 2011, MOL THER, V19, P2269, DOI 10.1038/mt.2011.176; Silvie O, 2004, J BIOL CHEM, V279, P9490, DOI 10.1074/jbc.M311331200; Sirima SB, 2017, VACCINE, V35, P6218, DOI 10.1016/j.vaccine.2017.09.027; Southwood S, 1998, J IMMUNOL, V160, P3363; Steere AC, 2006, J EXP MED, V203, P961, DOI 10.1084/jem.20052471; Stephens R, 2005, BLOOD, V106, P1676, DOI 10.1182/blood-2004-10-4047; Texier C, 2001, EUR J IMMUNOL, V31, P1837, DOI 10.1002/1521-4141(200106)31:6&lt;1837::AID-IMMU1837&gt;3.0.CO;2-H; Thera MA, 2011, NEW ENGL J MED, V365, P1004, DOI 10.1056/NEJMoa1008115; Vargas-Inchaustegui DA, 2016, J IMMUNOL, V196, P1700, DOI 10.4049/jimmunol.1502137; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Wada Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01372-5; Wamae KK, 2016, BIOINFORMATION, V12, P82, DOI 10.6026/97320630012082; Wang C, 2016, J IMMUNOL, V197, P1242, DOI 10.4049/jimmunol.1502472; Weber CA, 2009, ADV DRUG DELIVER REV, V61, P965, DOI 10.1016/j.addr.2009.07.001; Wright GJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003943	51	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2021	12								690348	10.3389/fimmu.2021.690348	http://dx.doi.org/10.3389/fimmu.2021.690348			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TL6XZ	34305923	Green Published, gold			2022-12-18	WOS:000675004200001
J	Xia, ZJ; Xu, JH; Lu, EE; He, W; Deng, SL; Gong, AY; Strass-Soukup, J; Martins, GA; Lu, GQ; Chen, XM				Xia, Zijie; Xu, Jihao; Lu, Eugene; He, Wei; Deng, Silu; Gong, Ai-Yu; Strass-Soukup, Juliane; Martins, Gislaine A.; Lu, Guoqing; Chen, Xian-Ming			m(6)A mRNA Methylation Regulates Epithelial Innate Antimicrobial Defense Against Cryptosporidial Infection	FRONTIERS IN IMMUNOLOGY			English	Article						m(6)A; Cryptosporidium; intestinal epithelium; defense; ALKBH5; RNA stability; Irgm2; Igtp	NF-KAPPA-B; INTERFERON-INDUCIBLE GTPASES; NECROSIS-FACTOR-ALPHA; IMMUNE-RESPONSE; HOST-RESISTANCE; MICE DEFICIENT; PARVUM; N-6-METHYLADENOSINE; TRANSLATION; LRG-47	Increasing evidence supports that N6-methyladenosine (m(6)A) mRNA modification may play an important role in regulating immune responses. Intestinal epithelial cells orchestrate gastrointestinal mucosal innate defense to microbial infection, but underlying mechanisms are still not fully understood. In this study, we present data demonstrating significant alterations in the topology of host m(6)A mRNA methylome in intestinal epithelial cells following infection by Cryptosporidium parvum, a coccidian parasite that infects the gastrointestinal epithelium and causes a self-limited disease in immunocompetent individuals but a life-threatening diarrheal disease in AIDS patients. Altered m(6)A methylation in mRNAs in intestinal epithelial cells following C. parvum infection is associated with downregulation of alpha-ketoglutarate-dependent dioxygenase alkB homolog 5 and the fat mass and obesity-associated protein with the involvement of NF-kB signaling. Functionally, m(6)A methylation statuses influence intestinal epithelial innate defense against C. parvum infection. Specifically, expression levels of immune-related genes, such as the immunity-related GTPase family M member 2 and interferon gamma induced GTPase, are increased in infected cells with a decreased m(6)A mRNA methylation. Our data support that intestinal epithelial cells display significant alterations in the topology of their m(6)A mRNA methylome in response to C. parvum infection with the involvement of activation of the NF-kB signaling pathway, a process that modulates expression of specific immune-related genes and contributes to fine regulation of epithelial antimicrobial defense.	[Xia, Zijie; Xu, Jihao; He, Wei; Deng, Silu; Gong, Ai-Yu; Chen, Xian-Ming] Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Omaha, NE 68131 USA; [Lu, Eugene; Lu, Guoqing] Univ Nebraska, Sch Interdisciplinary Informat, Dept Biol, Omaha, NE 68182 USA; [Deng, Silu; Gong, Ai-Yu; Chen, Xian-Ming] Rush Univ, Med Ctr, Dept Microbial Pathogens & Immun, Chicago, IL 60612 USA; [Strass-Soukup, Juliane] Creighton Univ, Coll Arts & Sci, Dept Chem, Omaha, NE 68178 USA; [Martins, Gislaine A.] David Geffen Sch Med, Cedars Sinai Med Ctr, Div Immunol Res, Dept Med & Biomed Sci, Los Angeles, CA USA	Creighton University; University of Nebraska System; Rush University; Creighton University; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chen, XM (corresponding author), Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Omaha, NE 68131 USA.; Chen, XM (corresponding author), Rush Univ, Med Ctr, Dept Microbial Pathogens & Immun, Chicago, IL 60612 USA.	xian_m_chen@rush.edu		Xia, Zijie/0000-0003-2961-835X	National Institutes of Health [AI116323, AI136877, AI141325, AI156370, G20RR024001]; National Center for Research Resources	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by funding from the National Institutes of Health (AI116323, AI136877, AI141325, and AI156370 to X-MC). The project described was also supported by Grant Number G20RR024001 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.	Al-Sadi R, 2016, AM J PATHOL, V186, P1151, DOI 10.1016/j.ajpath.2015.12.016; Alvesalo J, 2008, J INFECT DIS, V197, P156, DOI 10.1086/524142; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Bandyopadhaya A, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01211; Batista PJ, 2017, GENOM PROTEOM BIOINF, V15, P154, DOI 10.1016/j.gpb.2017.03.002; Beaulieu LM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131688; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Cai XM, 2004, MICROBIOL-SGM, V150, P1191, DOI 10.1099/mic.0.26897-0; Checkley W, 2015, LANCET INFECT DIS, V15, P85, DOI 10.1016/S1473-3099(14)70772-8; Chen XM, 2000, GASTROENTEROLOGY, V118, P368, DOI 10.1016/S0016-5085(00)70219-8; Chen XM, 2002, NEW ENGL J MED, V346, P1723, DOI 10.1056/NEJMra013170; Chen XM, 2001, GASTROENTEROLOGY, V120, P1774, DOI 10.1053/gast.2001.24850; Chen XS, 2010, CELL MOL IMMUNOL, V7, P69, DOI 10.1038/cmi.2009.100; Collazo CM, 2001, J EXP MED, V194, P181, DOI 10.1084/jem.194.2.181; Cutrone EC, 1997, FEBS LETT, V404, P197, DOI 10.1016/S0014-5793(97)00129-4; Deng MQ, 2004, INT J PARASITOL, V34, P73, DOI 10.1016/j.ijpara.2003.10.001; Donega V, 2018, CELL REP, V22, P2567, DOI 10.1016/j.celrep.2018.02.030; Farwa A, 2018, PARASITOL RES, V117, P115, DOI 10.1007/s00436-017-5678-5; Feng CG, 2004, J IMMUNOL, V172, P1163, DOI 10.4049/jimmunol.172.2.1163; Gerlach RL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078912; Han DL, 2019, NATURE, V566, P270, DOI 10.1038/s41586-019-0916-x; Henry SC, 2007, J IMMUNOL, V179, P6963, DOI 10.4049/jimmunol.179.10.6963; Heo I, 2018, NAT MICROBIOL, V3, P814, DOI 10.1038/s41564-018-0177-8; Hesser CR, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006995; Hou QM, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aal4045; Huang HL, 2019, NATURE, V567, P414, DOI 10.1038/s41586-019-1016-7; Hunn JP, 2011, MAMM GENOME, V22, P43, DOI 10.1007/s00335-010-9293-3; Imam H, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.584283; Kapel N, 1996, PARASITOL RES, V82, P664, DOI 10.1007/s004360050182; Kast C, 2003, J BIOL CHEM, V278, P6787, DOI 10.1074/jbc.M210935200; Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2; Lacroix S, 2001, INFECT IMMUN, V69, P1635, DOI 10.1128/IAI.69.3.1635-1642.2001; Li M, 2018, J IMMUNOL, V201, P3630, DOI 10.4049/jimmunol.1800566; Li XC, 1997, CELL IMMUNOL, V175, P58, DOI 10.1006/cimm.1996.1050; Lichinchi G, 2016, CELL HOST MICROBE, V20, P666, DOI 10.1016/j.chom.2016.10.002; Lichinchi G, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.11, 10.1038/nmicrobiol.2016.11]; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Liu C, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-021-02918-y; Liu JE, 2021, CELL RES, V31, P404, DOI 10.1038/s41422-020-00465-7; Lu MJ, 2021, J VIROL, V95, DOI 10.1128/JVI.01939-20; Maeda Y, 2016, ARTHRITIS RHEUMATOL, V68, P2646, DOI 10.1002/art.39783; Melzer T, 2008, INFECT IMMUN, V76, P4883, DOI 10.1128/IAI.01288-07; Meunier E, 2016, CELL MICROBIOL, V18, P168, DOI 10.1111/cmi.12546; Ming ZP, 2018, J INFECT DIS, V217, P122, DOI 10.1093/infdis/jix392; Musikacharoen T, 2001, J IMMUNOL, V166, P4516, DOI 10.4049/jimmunol.166.7.4516; Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X; Okumura R, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.20; Pantenburg B, 2008, INFECT IMMUN, V76, P23, DOI 10.1128/IAI.00960-07; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Pilla-Moffett D, 2016, J MOL BIOL, V428, P3495, DOI 10.1016/j.jmb.2016.04.032; Sansonetti PJ, 2004, NAT REV IMMUNOL, V4, P953, DOI 10.1038/nri1499; Santiago HC, 2005, J IMMUNOL, V175, P8165, DOI 10.4049/jimmunol.175.12.8165; Schwerk C, 2011, MICROBES INFECT, V13, P953, DOI 10.1016/j.micinf.2011.05.012; Shi HL, 2019, MOL CELL, V74, P640, DOI 10.1016/j.molcel.2019.04.025; Shi HL, 2017, CELL RES, V27, P315, DOI 10.1038/cr.2017.15; Singh I, 2005, INFECT IMMUN, V73, P5245, DOI 10.1128/IAI.73.8.5245-5248.2005; Striepen B, 2013, NATURE, V503, P189, DOI 10.1038/503189a; Taylor GA, 2000, P NATL ACAD SCI USA, V97, P751, DOI 10.1073/pnas.97.2.751; Trusca Violeta G, 2016, World J Biol Chem, V7, P178, DOI 10.4331/wjbc.v7.i1.178; Wang M, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01249-8; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wang Y, 2019, INFECT IMMUN, V87, DOI [10.1128/IAI.00705-18, 10.1128/iai.00705-18]; Winkler R, 2019, NAT IMMUNOL, V20, P173, DOI 10.1038/s41590-018-0275-z; Xu JH, 2020, ONCOL REP, V44, P973, DOI 10.3892/or.2020.7665; Xu ZB, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2288-z; Yue L, 2008, ENDOCRINOLOGY, V149, P4051, DOI 10.1210/en.2008-0340; Yue YN, 2015, GENE DEV, V29, P1343, DOI 10.1101/gad.262766.115; Zaccara S, 2019, NAT REV MOL CELL BIO, V20, P608, DOI 10.1038/s41580-019-0168-5; Zhang XT, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.13060; Zhou J, 2015, NATURE, V526, P591, DOI 10.1038/nature15377; Zhou R, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002702; Zhou R, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000681	73	1	1	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 6	2021	12								705232	10.3389/fimmu.2021.705232	http://dx.doi.org/10.3389/fimmu.2021.705232			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TL3ER	34295340	Green Published, gold			2022-12-18	WOS:000674739200001
J	Brzoska, J; von Eick, H; Hundgen, M				Brzoska, Josef; von Eick, Harald; Hundgen, Manfred			Commentary: Why Haven't We Found an Effective Treatment for COVID-19? COMMENT	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						COVID-19; coronavirus; interferons - pharmacology; therapeutic use; corticosteroids; clinical trials	INTERFERON					josef.brzoska@t-online.de						Abdolvahab MH, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107171; Brzoska J, 2020, DRUG RES, V70, P291, DOI 10.1055/a-1170-4395; Darazam IA, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86859-y; Davoudi-Monfared E, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01061-20; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2022926, 10.1056/NEJMoa2021436]; Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4; Jagannathan P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22177-1; Jalkanen J, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03048-5; Kow CS, 2021, INT IMMUNOPHARMACOL, V93, P0, DOI 10.1016/j.intimp.2021.107415; MERIGAN TC, 1978, NEW ENGL J MED, V298, P981, DOI 10.1056/NEJM197805042981801; Monk PD, 2021, LANCET RESP MED, V9, P196, DOI 10.1016/S2213-2600(20)30511-7; Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008; Rahmani H, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106903; Ranieri VM, 2020, JAMA-J AM MED ASSOC, V323, P725, DOI 10.1001/jama.2019.22525; Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791; Spicer AJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.644850; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Zhou Q, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01061	18	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 5	2021	12								714175	10.3389/fimmu.2021.714175	http://dx.doi.org/10.3389/fimmu.2021.714175			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TK6HJ	34290716	Green Published, gold			2022-12-18	WOS:000674256900001
J	Llitjos, JF; Bounab, Y; Rousseau, C; Dixneuf, S; Rimbault, B; Chiche, JD; Textoris, J; Pene, F; Vedrine, C				Llitjos, Jean-Francois; Bounab, Yacine; Rousseau, Christophe; Dixneuf, Sophie; Rimbault, Blandine; Chiche, Jean-Daniel; Textoris, Julien; Pene, Frederic; Vedrine, Christophe			Assessing the Functional Heterogeneity of Monocytes in Human Septic Shock: a Proof-of-Concept Microfluidic Assay of TNF alpha Secretion	FRONTIERS IN IMMUNOLOGY			English	Article						septic shock; immune suppression; monocyte; microfluidic; tolerance	EXPRESSION; SEPSIS; SUBSETS; SCORE	Objective The development of advanced single-cell technologies to decipher inter-cellular heterogeneity has enabled the dynamic assessment of individual cells behavior over time, overcoming the limitation of traditional assays. Here, we evaluated the feasibility of an advanced microfluidic assay combined to fluorescence microscopy to address the behavior of circulating monocytes from septic shock patients. Methods Seven septic shock patients and ten healthy volunteers were enrolled in the study. Using the proposed microfluidic assay we investigated the production over time of LPS-elicited TNF alpha by single monocytes encapsulated within droplets. Cellular endocytic activity was assessed by internalization of magnetic nanoparticles. Besides, we assessed HLA-DR membrane expression and LPS-induced TNF alpha production in monocytes through classical flow cytometry assays. Results Consistent with the flow cytometry results, the total number of TNF alpha molecules secreted by encapsulated single monocytes was significantly decreased in septic shock patients compared to healthy donors. TNF alpha production was dampened as soon as 30 and 60 minutes after LPS stimulation in monocytes from septic patients. Furthermore, the microfluidic assay revealed heterogeneous individual behavior of monocytes from septic shock patients. Of note, monocytes from both healthy donors and patients exhibited similar phagocytic activities over time. Conclusion The microfluidic assay highlights the functional heterogeneity of monocytes, and provides in-depth resolution in assessing the hallmark monocyte deactivation encountered in post-septic immunosuppression.	[Llitjos, Jean-Francois; Rousseau, Christophe; Chiche, Jean-Daniel; Pene, Frederic] Inst Cochin, CNRS UMR8104, U1016, Paris, France; [Llitjos, Jean-Francois; Rousseau, Christophe; Chiche, Jean-Daniel; Pene, Frederic] Univ Paris, UMR S8104, Paris, France; [Llitjos, Jean-Francois; Chiche, Jean-Daniel; Pene, Frederic] Hop Cochin, Assistance Publ Hopitaux Paris, APHP CUP, Med Intens & Reanimat, Paris, France; [Bounab, Yacine; Dixneuf, Sophie; Rimbault, Blandine; Vedrine, Christophe] BIOASTER, Bioassays Microsyst & Opt Engn, Lyon, France; [Textoris, Julien] Univ Claude Bernard Lyon 1 HCL BioMerieux, Pathophysiol Injuryinduced Immunosuppress EA7426, Lyon, France; [Textoris, Julien] BioMerieux SA, Med Diagnost Discovery Dept MD3, Lyon, France; [Textoris, Julien] HCL, Anesthesiol & Crit Care Med, Lyon, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; bioMerieux; CHU Lyon	Vedrine, C (corresponding author), BIOASTER, Bioassays Microsyst & Opt Engn, Lyon, France.	christophe.vedrine@bioaster.org	JF, Llitjos/GRS-3317-2022		bioMerieux; SANOFI; GlaxoSmithKline; Ecole Supeerieure de Physique Chimie Industrielles de la Villette Paris-PSL Research University; University Hospital Hospices Civils de Lyon; microbiology technological institute BIOASTER; French Government through the "Investissement d'Avenir" program [ANR-10-AIRT-03]	bioMerieux; SANOFI; GlaxoSmithKline(GlaxoSmithKline); Ecole Supeerieure de Physique Chimie Industrielles de la Villette Paris-PSL Research University; University Hospital Hospices Civils de Lyon; microbiology technological institute BIOASTER; French Government through the "Investissement d'Avenir" program(French National Research Agency (ANR))	The project was funded by a consortium: bioMerieux, SANOFI, GlaxoSmithKline, Ecole Supeerieure de Physique Chimie Industrielles de la Villette Paris-PSL Research University, the University Hospital Hospices Civils de Lyon and the microbiology technological institute BIOASTER. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. This research project has received funding from the French Government through the "Investissement d'Avenir" program (grant no ANR-10-AIRT-03).	Avraham R, 2015, CELL, V162, P1309, DOI 10.1016/j.cell.2015.08.027; Bounab Y, 2020, NAT PROTOC, V15, P2920, DOI 10.1038/s41596-020-0354-0; Cajander S, 2013, CRIT CARE, V17, DOI 10.1186/cc13046; Gossez M., 2018, PROOF CONCEPT STUDY; Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712; Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552; Landelle C, 2010, INTENS CARE MED, V36, P1859, DOI 10.1007/s00134-010-1962-x; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Mazutis L, 2013, NAT PROTOC, V8, P870, DOI 10.1038/nprot.2013.046; Meisel C, 2009, AM J RESP CRIT CARE, V180, P640, DOI 10.1164/rccm.200903-0363OC; Monneret G, 2006, INTENS CARE MED, V32, P1175, DOI 10.1007/s00134-006-0204-8; Patel AA, 2017, J EXP MED, V214, P1913, DOI 10.1084/jem.20170355; Payen D, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4526-x; Shalek AK, 2014, NATURE, V510, P363, DOI 10.1038/nature13437; Shalek AK, 2013, NATURE, V498, P236, DOI 10.1038/nature12172; Shalova IN, 2015, IMMUNITY, V42, P484, DOI 10.1016/j.immuni.2015.02.001; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Tak T, 2017, J INNATE IMMUN, V9, P464, DOI 10.1159/000475665; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Zhang D, 2019, NATURE, V574, P575, DOI 10.1038/s41586-019-1678-1	20	1	1	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 5	2021	12								686111	10.3389/fimmu.2021.686111	http://dx.doi.org/10.3389/fimmu.2021.686111			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TK8ED	34290706	Green Published, gold			2022-12-18	WOS:000674385600001
J	Porzionato, A; Stocco, E; Emmi, A; Contran, M; Macchi, V; Riccetti, S; Sinigaglia, A; Barzon, L; De Caro, R				Porzionato, Andrea; Stocco, Elena; Emmi, Aron; Contran, Martina; Macchi, Veronica; Riccetti, Silvia; Sinigaglia, Alessandro; Barzon, Luisa; De Caro, Raffaele			Hypopharyngeal Ulcers in COVID-19: Histopathological and Virological Analyses - A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; gastrointestinal tract; inflammation; mucosal injury; HSV; histopathology; molecular analysis	DISEASE	In coronavirus disease 2019 (COVID-19), ulcerative lesions have been episodically reported in various segments of the gastrointestinal (GI) tract, including the oral cavity, oropharynx, esophagus, stomach and bowel. In this report, we describe an autopsy case of a COVID-19 patient who showed two undiagnosed ulcers at the level of the anterior and posterior walls of the hypopharynx. Molecular testing of viruses involved in pharyngeal ulcers demonstrated the presence of severe acute respiratory syndrome - coronavirus type 2 (SARS-CoV-2) RNA, together with herpes simplex virus 1 DNA. Histopathologic analysis demonstrated full-thickness lympho-monocytic infiltration (mainly composed of CD68-positive cells), with hemorrhagic foci and necrosis of both the mucosal layer and deep skeletal muscle fibers. Fibrin and platelet microthrombi were also found. Cytological signs of HSV-1 induced damage were not found. Cells expressing SARS-CoV-2 spike subunit 1 were immunohistochemically identified in the inflammatory infiltrations. Immunohistochemistry for HSV1 showed general negativity for inflammatory infiltration, although in the presence of some positive cells. Thus, histopathological, immunohistochemical and molecular findings supported a direct role by SARS-CoV-2 in producing local ulcerative damage, although a possible contributory role by HSV-1 reactivation cannot be excluded. From a clinical perspective, this autopsy report of two undiagnosed lesions put the question if ulcers along the GI tract could be more common (but frequently neglected) in COVID-19 patients.	[Porzionato, Andrea; Stocco, Elena; Emmi, Aron; Contran, Martina; Macchi, Veronica; De Caro, Raffaele] Univ Padua, Sect Human Anat, Dept Neurosci, Padua, Italy; [Riccetti, Silvia; Sinigaglia, Alessandro; Barzon, Luisa] Univ Padua, Dept Mol Med, Padua, Italy	University of Padua; University of Padua	Stocco, E (corresponding author), Univ Padua, Sect Human Anat, Dept Neurosci, Padua, Italy.	elena.stocco@unipd.it	Stocco, Elena/ABD-6226-2020		European Union [874735]	European Union(European Commission)	This research was funded in part by the European Union's Horizon 2020 research and innovation programme, under grant agreement no. 874735 (VEO).	Ansari R, 2021, ORAL DIS, V27, P771, DOI 10.1111/odi.13465; Barberis A, 2020, BRIT J SURG, V107, pE376, DOI 10.1002/bjs.11816; Barzon L, 2009, J INFECT DIS, V199, P372, DOI 10.1086/596053; Brandao TB, 2021, OR SURG OR MED OR PA, V131, pE45, DOI 10.1016/j.oooo.2020.07.014; Chaux-Bodard AG, 2020, J ORAL MED ORAL SURG, V26, P18; Ciccarese G, 2021, J MED VIROL, V93, P129, DOI 10.1002/jmv.26221; Dierssen U, 2008, J CLIN VIROL, V42, P58, DOI 10.1016/j.jcv.2007.11.016; Dominguez-Santas M, 2020, INT J DERMATOL, V59, P1022, DOI 10.1111/ijd.15004; Hedou M, 2020, J EUR ACAD DERMATOL, V34, pE299, DOI 10.1111/jdv.16519; Kato S, 2005, DIS ESOPHAGUS, V18, P340, DOI 10.1111/j.1442-2050.2005.00510.x; Lavezzo E, 2020, NATURE, V584, P425, DOI 10.1038/s41586-020-2488-1; Li XF, 2020, AM J GASTROENTEROL, V115, P1541, DOI 10.14309/ajg.0000000000000757; Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013; Carreras-Presas CM, 2021, ORAL DIS, V27, P710, DOI 10.1111/odi.13382; Martin TA, 2020, AM J GASTROENTEROL, V115, P1609, DOI 10.14309/ajg.0000000000000805; Melazzini F, 2020, AM J GASTROENTEROL, V115, P1139, DOI 10.14309/ajg.0000000000000710; Namvar L, 2005, J CLIN MICROBIOL, V43, P2058, DOI 10.1128/JCM.43.5.2058-2064.2005; Saravanan T, 2012, SINGAP MED J, V53, pE69; Soares CD, 2020, MED ORAL PATOL ORAL, V25, pE563, DOI 10.4317/medoral.24044	19	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 5	2021	12								676828	10.3389/fimmu.2021.676828	http://dx.doi.org/10.3389/fimmu.2021.676828			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TK7WR	34290701	Green Published, gold			2022-12-18	WOS:000674366100001
J	Robbins, A; Bahuaud, M; Hentzien, M; Maestraggi, Q; Barbe, C; Giusti, D; Le Naour, R; Batteux, F; Servettaz, A				Robbins, Ailsa; Bahuaud, Mathilde; Hentzien, Maxime; Maestraggi, Quentin; Barbe, Coralie; Giusti, Delphine; Le Naour, Richard; Batteux, Frederic; Servettaz, Amelie			The 13-Valent Pneumococcal Conjugate Vaccine Elicits Serological Response and Lasting Protection in Selected Patients With Primary Humoral Immunodeficiency	FRONTIERS IN IMMUNOLOGY			English	Article						primary humoral immunodeficiency; common variable immunodeficiency; IgG subclass deficiency; pneumococcal vaccine; conjugate vaccination	ANTIBODIES; TRIAL; HYPORESPONSIVENESS; POLYSACCHARIDE; SEROTYPES; ADULTS; IGG	Background Patients with primary humoral immunodeficiency are more prone to invasive as well as recurrent pneumococcal infections. Therefore, anti-pneumococcal vaccination including the 13-valent conjugate vaccine is recommended. Nevertheless, to date, no data is available on immunogenicity of this vaccine in this population. Objective To assess the immunogenicity and the persistence of protection up to one year after a 13-valent pneumococcal conjugate vaccine in patients with primary humoral immunodeficiency. Methods Twenty-nine patients with common variable immunodeficiency or IgG subclass deficiency were vaccinated. Immune response and immune protection at baseline as well as at one, six and twelve months after vaccination were evaluated by measuring specific IgG serum concentrations (ELISA), and opsonophagocytic activities directed against selected pneumococcal (MOPA). Results By ELISA, half of the patients had protective IgG concentrations before vaccination, 35.7% showed an immune response one month after vaccination, 71.4%, 66.7% and 56.0% of the patients were protected at one, six and twelve months respectively. Conversely, by MOPA, 3.4% of the patients were protected at baseline, 10.7% showed an immune response and 28.6%, 48.2% and 33.3% were protected at one, six and twelve months respectively. IgG subclass deficiency, Ig replacement therapy and higher IgG2 concentrations at diagnosis were associated with long-term protection. Conclusion Pneumococcal conjugate vaccine improves immune protection and antibodies' functionality in a subset of patients with primary immunodeficiency. Prime-boost vaccine strategy needs to be better and individually adapted.	[Robbins, Ailsa; Hentzien, Maxime; Maestraggi, Quentin; Servettaz, Amelie] Univ Hosp Ctr, Internal Med Clin Immunol & Infect Dis Dept, Reims, France; [Robbins, Ailsa; Giusti, Delphine; Le Naour, Richard; Servettaz, Amelie] Univ Reims Champagne Ardenne URCA, IRMAIC, Lab Immunol, EA7509, Reims, France; [Bahuaud, Mathilde] Cochin Hosp, Lab Immunol, Plateforme Immunomonitoring Vaccinal, Paris, France; [Bahuaud, Mathilde] Univ Paris 05, AP HP, Paris, France; [Barbe, Coralie] Univ Reims, Clin Res Dept, EA3797, Reims, France; [Giusti, Delphine] Univ Reims, Reims Univ Hosp, Lab Immunol, Reims, France; [Batteux, Frederic] Univ Paris escartes, Cochin Hosp, Lab Immunol, Plateforme Immunomonitoring Vaccinal, Paris, France	CHU de Reims; Universite de Reims Champagne-Ardenne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Universite de Reims Champagne-Ardenne; CHU de Reims; Universite de Reims Champagne-Ardenne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Robbins, A (corresponding author), Univ Hosp Ctr, Internal Med Clin Immunol & Infect Dis Dept, Reims, France.; Robbins, A (corresponding author), Univ Reims Champagne Ardenne URCA, IRMAIC, Lab Immunol, EA7509, Reims, France.	arobbins@chu-reims.fr	Hentzien, Maxime/H-8730-2019	Hentzien, Maxime/0000-0003-2729-9420; LE NAOUR, Richard/0000-0003-1925-6041	''Societe de Pathologie Infectieuse de Langue Francaise" (SPILF)	''Societe de Pathologie Infectieuse de Langue Francaise" (SPILF)	This work was supported by a grant from the "Societe de Pathologie Infectieuse de Langue Francaise" (SPILF) in 2015.	ACIP, 2019, ALT IMM GUID IMM REC; Bahuaud M, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00441; Baranek T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00123; BARRETT DJ, 1986, CLIN EXP IMMUNOL, V63, P127; Beaute J, 2010, CLIN IMMUNOL, V135, P264, DOI 10.1016/j.clim.2010.02.021; Bittaye M, 2015, EXPERT REV PROTEOMIC, V12, P607, DOI 10.1586/14789450.2015.1108844; Burton RL, 2012, CLIN VACCINE IMMUNOL, V19, P835, DOI 10.1128/CVI.00086-12; Butler AL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01851; de Roux A, 2004, RESP MED, V98, P1187, DOI 10.1016/j.rmed.2004.04.012; Fischinger S, 2019, J IMMUNOL METHODS, V473, DOI 10.1016/j.jim.2019.07.002; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; Gerard AL, 2020, VACCINE, V38, P6859, DOI 10.1016/j.vaccine.2020.08.065; Goldacker S, 2007, CLIN IMMUNOL, V124, P294, DOI 10.1016/j.clim.2007.04.011; HCSP, 2014, VACC PERS IMM OU AS; Home, UAB BACTERIAL1 RESP; Jha V, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010018; Juergens C, 2014, CLIN VACCINE IMMUNOL, V21, P1277, DOI 10.1128/CVI.00172-14; Lee S, 2017, TRANSFUSION, V57, P157, DOI 10.1111/trf.13869; Lejtenyi D, 2008, J ALLERGY CLIN IMMUN, V121, P254, DOI 10.1016/j.jaci.2007.11.001; Lombardi F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156523; Lopez B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01862; Odnoletkova I, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0941-0; Ojal J, 2017, VACCINE, V35, P4652, DOI 10.1016/j.vaccine.2017.05.088; Ouldali N, 2021, LANCET INFECT DIS, V21, P137, DOI 10.1016/S1473-3099(20)30165-1; Parker Antony R, 2016, Pract Lab Med, V5, P1, DOI 10.1016/j.plabm.2016.02.004; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Poolman J, 2011, EXPERT REV VACCINES, V10, P307, DOI [10.1586/ERV.11.8, 10.1586/erv.11.8]; Saba G, 2018, EUR J HEALTH ECON, V19, P533, DOI 10.1007/s10198-017-0900-z; Sacre K, 2018, ANN RHEUM DIS, V77, P1540, DOI 10.1136/annrheumdis-2017-212789; Sadlier C, 2016, SCI REP-UK, V6, DOI 10.1038/srep32076; Sobh A, 2016, J ALLER CL IMM-PRACT, V4, P1066, DOI 10.1016/j.jaip.2016.09.012; Takahashi Y, 2014, J INFECT CHEMOTHER, V20, P794, DOI 10.1016/j.jiac.2014.08.027; Usinger WR, 1999, INFECT IMMUN, V67, P2366, DOI 10.1128/IAI.67.5.2366-2370.1999; van Deursen AMM, 2017, CLIN INFECT DIS, V65, P787, DOI 10.1093/cid/cix419; Wagstaffe HR, 2018, CLIN TRANSL IMMUNOL, V7, DOI 10.1002/cti2.1010; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Zangenah S, 2017, VACCINE, V35, P2654, DOI 10.1016/j.vaccine.2017.03.097	37	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 5	2021	12								697128	10.3389/fimmu.2021.697128	http://dx.doi.org/10.3389/fimmu.2021.697128			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TK7OX	34290713	gold, Green Published			2022-12-18	WOS:000674345900001
J	Spenle, C; Loustau, T; Burckel, H; Riegel, G; Abou Faycal, C; Li, CB; Yilmaz, A; Petti, L; Steinbach, F; Ahowesso, C; Jost, C; Paul, N; Carapito, R; Noel, G; Anjuere, F; Salome, N; Orend, G				Spenle, Caroline; Loustau, Thomas; Burckel, Helene; Riegel, Gilles; Abou Faycal, Cherine; Li, Chengbei; Yilmaz, Alev; Petti, Luciana; Steinbach, Fanny; Ahowesso, Constance; Jost, Camille; Paul, Nicodeme; Carapito, Raphael; Noel, Georges; Anjuere, Fabienne; Salome, Nathalie; Orend, Gertraud			Impact of Tenascin-C on Radiotherapy in a Novel Syngeneic Oral Squamous Cell Carcinoma Model With Spontaneous Dissemination to the Lymph Nodes	FRONTIERS IN IMMUNOLOGY			English	Article						radiotherapy; oral squamous carcinoma; tumor microenvironment; tenascin-C; syngeneic animal model; immune suppression	HEAD; NECK; CANCER; EXPRESSION; DAMAGE; INHIBITION; PREVENTION; SIGNATURES; STRESS; GROWTH	Radiotherapy, the most frequent treatment of oral squamous cell carcinomas (OSCC) besides surgery is employed to kill tumor cells but, radiotherapy may also promote tumor relapse where the immune-suppressive tumor microenvironment (TME) could be instrumental. We established a novel syngeneic grafting model from a carcinogen-induced tongue tumor, OSCC13, to address the impact of radiotherapy on OSCC. This model revealed similarities with human OSCC, recapitulating carcinogen-induced mutations found in smoking associated human tongue tumors, abundant tumor infiltrating leukocytes (TIL) and, spontaneous tumor cell dissemination to the local lymph nodes. Cultured OSCC13 cells and OSCC13-derived tongue tumors were sensitive to irradiation. At the chosen dose of 2 Gy mimicking treatment of human OSCC patients not all tumor cells were killed allowing to investigate effects on the TME. By investigating expression of the extracellular matrix molecule tenascin-C (TNC), an indicator of an immune suppressive TME, we observed high local TNC expression and TIL infiltration in the irradiated tumors. In a TNC knockout host the TME appeared less immune suppressive with a tendency towards more tumor regression than in WT conditions. Altogether, our novel syngeneic tongue OSCC grafting model, sharing important features with the human OSCC disease could be relevant for future anti-cancer targeting of OSCC by radiotherapy and other therapeutic approaches.	[Spenle, Caroline; Ahowesso, Constance; Jost, Camille; Orend, Gertraud] INSERM, U1109 MN3T, Microenvironm Niche Tumorigenesis & Targeted Ther, Strasbourg, France; [Spenle, Caroline; Loustau, Thomas; Riegel, Gilles; Abou Faycal, Cherine; Li, Chengbei; Yilmaz, Alev; Steinbach, Fanny; Ahowesso, Constance; Jost, Camille; Paul, Nicodeme; Carapito, Raphael; Salome, Nathalie; Orend, Gertraud] Univ Strasbourg, Strasbourg, France; [Spenle, Caroline; Loustau, Thomas; Riegel, Gilles; Abou Faycal, Cherine; Li, Chengbei; Yilmaz, Alev; Steinbach, Fanny; Ahowesso, Constance; Jost, Camille; Paul, Nicodeme; Carapito, Raphael; Salome, Nathalie; Orend, Gertraud] Federat Med Translat Strasbourg FMTS, Strasbourg, France; [Loustau, Thomas; Riegel, Gilles; Abou Faycal, Cherine; Li, Chengbei; Yilmaz, Alev; Steinbach, Fanny; Salome, Nathalie; Orend, Gertraud] INSERM, U1109, Tumor Microenvironm Grp, Strasbourg, France; [Burckel, Helene; Noel, Georges] Univ Strasbourg, Inst Cancerol Strasbourg Europe ICANS, UNICANCER, Paul Strauss Comprehens Canc Ctr,Radiobiol Lab, Strasbourg, France; [Petti, Luciana; Anjuere, Fabienne] Univ Cote Azur, CNRS, IPMC, Valbonne, France; [Paul, Nicodeme] Federat Hosp Univ OMICARE, INSERM, Fac Med, UMR S 1109,LabEx,Platform GENOMAX,TRANSPLANTEX, Strasbourg, France; [Noel, Georges] UNICANCER, Inst Cancerol Strasbourg Europe ICANS, Dept Radiat Oncol, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UNICANCER; Centre Paul Strauss; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UNICANCER	Spenle, C; Orend, G (corresponding author), INSERM, U1109 MN3T, Microenvironm Niche Tumorigenesis & Targeted Ther, Strasbourg, France.; Spenle, C; Orend, G (corresponding author), Univ Strasbourg, Strasbourg, France.; Spenle, C; Orend, G (corresponding author), Federat Med Translat Strasbourg FMTS, Strasbourg, France.; Orend, G (corresponding author), INSERM, U1109, Tumor Microenvironm Grp, Strasbourg, France.	cspenle@unistra.fr; gertraud.orend@inserm.fr	Anjuere-Casile, Fabienne/O-5779-2016; Carapito, Raphael/O-5317-2016; Orend, Gertraud/E-8446-2015; Spenle, Caroline/P-6284-2016	Anjuere-Casile, Fabienne/0000-0003-3144-8652; Carapito, Raphael/0000-0002-7036-442X; SALOME, NATHALIE/0000-0002-0349-0258; Abou Faycal, Cherine/0000-0003-4339-9210; Paul, Nicodeme/0000-0003-4680-3012; Loustau, Thomas/0000-0003-4662-5228; Orend, Gertraud/0000-0003-2522-1195; Spenle, Caroline/0000-0002-6353-3109	INCa (FITMANET) [PAIR-VADS11-023]; INCa/LNCC ECMpact [AAP2017.LNCC]; ANR (AngioFib); Ligue contre le cancer (CCIRGE); University Strasbourg; INSERM; Aviesan ITMO cancer (Radio-3R); MRT fellowship; Chinese Scholarship Council	INCa (FITMANET); INCa/LNCC ECMpact; ANR (AngioFib)(French National Research Agency (ANR)); Ligue contre le cancer (CCIRGE); University Strasbourg; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Aviesan ITMO cancer (Radio-3R); MRT fellowship; Chinese Scholarship Council(China Scholarship Council)	This work was supported by INCa (FITMANET, PAIR-VADS11-023) and INCa/LNCC ECMpact (AAP2017.LNCC), ANR (AngioFib), Ligue contre le cancer (CCIRGE), University Strasbourg and INSERM to GO, Aviesan ITMO cancer (Radio-3R) to GO and GN, AAP2017.LNCC (FA), MRT fellowship to AY and fellowship from the Chinese Scholarship Council to CL.	Alexandrov LB, 2016, SCIENCE, V354, P618, DOI 10.1126/science.aag0299; [Anonymous], EXTRACELLULAR MATRIX; Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X; Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012; Badarni M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125341; Bjorkdahl O, 2003, IMMUNOLOGY, V110, P170, DOI 10.1046/j.1365-2567.2003.01727.x; Castelli J, 2018, ACTA ONCOL, V57, P1284, DOI 10.1080/0284186X.2018.1505053; Caudell JJ, 2017, LANCET ONCOL, V18, pE266, DOI 10.1016/S1470-2045(17)30252-8; Chen YF, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5486-7; Chi AC, 2015, CA-CANCER J CLIN, V65, P401, DOI 10.3322/caac.21293; Chow LQM, 2020, NEW ENGL J MED, V382, P60, DOI 10.1056/NEJMra1715715; Czeminski R, 2009, CANCER PREV RES, V2, P27, DOI 10.1158/1940-6207.CAPR-08-0147; Deligne C, 2020, CANCER IMMUNOL RES, V8, P368, DOI 10.1158/2326-6066.CIR-19-0276; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Elkabets M, 2015, CANCER CELL, V27, P533, DOI 10.1016/j.ccell.2015.03.010; Hancox RA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2251; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Jay JJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160519; Kinouchi M, 2018, INT J CANCER, V143, P2551, DOI 10.1002/ijc.31811; Lai ZW, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw227; Lamberti MJ, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030256; Langlois B, 2014, ONCOTARGET, V5, P10529, DOI 10.18632/oncotarget.2470; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401; Ma HL, 2019, BRIT J CANCER, V120, P317, DOI 10.1038/s41416-018-0352-y; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Michikawa C, 2012, ORAL ONCOL, V48, P320, DOI 10.1016/j.oraloncology.2011.11.014; Midwood KS, 2011, CELL MOL LIFE SCI, V68, P3175, DOI 10.1007/s00018-011-0783-6; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Murdamoothoo D, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202013270; Noguti J, 2012, CANCER GENOM PROTEOM, V9, P329; Paluszczak J, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030723; Qian JM, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.608772; Ray S, 2018, INT J PART THER, V5, P15, DOI 10.14338/IJPT-18-00018.1; Russell JS, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00157; Saupe F, 2013, CELL REP, V5, P482, DOI 10.1016/j.celrep.2013.09.014; Shintani S, 2003, INT J CANCER, V107, P1030, DOI 10.1002/ijc.11437; Spenle C, 2020, CANCER IMMUNOL RES, V8, P1122, DOI 10.1158/2326-6066.CIR-20-0074; Spenle C, 2015, CELL ADHES MIGR, V9, P4, DOI 10.1080/19336918.2015.1005452; Spenle C, 2015, CELL ADHES MIGR, V9, P141, DOI 10.1080/19336918.2014.1000074; Sugyo A, 2020, CANCERS, V12, DOI 10.3390/cancers12123652; Sun Z, 2019, MATRIX BIOL, V83, P26, DOI 10.1016/j.matbio.2019.07.001; Sundquist E, 2017, BRIT J CANCER, V116, P640, DOI 10.1038/bjc.2016.455; Tang XH, 2015, ONCOTARGET, V6, P24424, DOI 10.18632/oncotarget.4420; Vitale-Cross L, 2009, CANCER PREV RES, V2, P419, DOI 10.1158/1940-6207.CAPR-09-0058; Wang ZY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13471-0; White RA, 2010, ONCOGENE, V29, P5437, DOI 10.1038/onc.2010.306; Yoshida T, 2015, CELL ADHES MIGR, V9, P96, DOI 10.1080/19336918.2015.1008332	48	1	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 5	2021	12								636108	10.3389/fimmu.2021.636108	http://dx.doi.org/10.3389/fimmu.2021.636108			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TK7WG	34290694	Green Published, gold			2022-12-18	WOS:000674365000001
J	Zhaoyun, L; Rong, F				Zhaoyun, Liu; Rong, Fu			Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients	FRONTIERS IN IMMUNOLOGY			English	Review						immunology; survival predication; immune profiling; multiple myeloma; prognosis	ABSOLUTE LYMPHOCYTE COUNT; NEUTROPHIL-TO-LYMPHOCYTE; MARROW STROMAL CELLS; SUPPRESSOR-CELLS; BONE-MARROW; CLINICAL-PARAMETERS; PROGRESSION-FREE; POOR-PROGNOSIS; HIGH-LEVEL; B-CELLS	Despite new efficacy drugs and cell therapy have been used for multiple myeloma (MM) patients, some patients will relapse over time. We wonder the immune system play a vital role as well as MM cell during the development of disease. It is clear that the characteristic of myeloma cell is associated with the survival of MM patients. However, the link between the immune profiling and the prognosis of the disease is still not entirely clear. As more study focus on the role of immunity on multiple myeloma pathogenesis. There are plenty of study about the predictive role of immunity on the survival of multiple myeloma patients. Up to mow, the majority reviews published have focused on the immunotherapy and immune pathogenesis. It is indispensable to overlook the predictive role of immunity on multiple myeloma patients. Here, we give a review of vital previous works and recent progress related to the predictive role of immune profiling on multiple myeloma, such as absolute lymphocyte count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocytes and cytokines.	[Zhaoyun, Liu; Rong, Fu] Tianjin Med Univ Gen Hosp, Dept Hematol, Tianjin, Peoples R China	Tianjin Medical University	Rong, F (corresponding author), Tianjin Med Univ Gen Hosp, Dept Hematol, Tianjin, Peoples R China.	florai@sina.com			National Natural Science Foundation of China Youth Project [81900131]; Tianjin Municipal Natural Science Foundation [18JCQNJC80400]; Tianjin Education Commission Research Project [2018KJ045]; Tianjin Science and Technology Planning Project [20YFZCSY00060]	National Natural Science Foundation of China Youth Project; Tianjin Municipal Natural Science Foundation(Natural Science Foundation of Tianjin); Tianjin Education Commission Research Project; Tianjin Science and Technology Planning Project	This work was supported by the National Natural Science Foundation of China Youth Project (grant no. 81900131), the Tianjin Municipal Natural Science Foundation (grant no. 18JCQNJC80400), the Tianjin Education Commission Research Project (grant no. 2018KJ043), the Tianjin Education Commission Research Project (grant no. 2018KJ045), and the Tianjin Science and Technology Planning Project (no. 20YFZCSY00060).	Alexandrakis MG, 2006, EUR J INTERN MED, V17, P412, DOI 10.1016/j.ejim.2006.02.012; Alexandrakis MG, 2015, PATHOL ONCOL RES, V21, P929, DOI 10.1007/s12253-015-9921-z; BATAILLE R, 1989, J CLIN ONCOL, V7, P1909, DOI 10.1200/JCO.1989.7.12.1909; Beider K, 2014, ONCOTARGET, V5, P11283, DOI 10.18632/oncotarget.2207; Binsfeld M, 2016, ONCOTARGET, V7, P37931, DOI 10.18632/oncotarget.9270; Brown RD, 2009, LEUKEMIA LYMPHOMA, V50, P1860, DOI 10.3109/10428190903216804; Bryant C, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.34; Carbone E, 2005, BLOOD, V105, P251, DOI 10.1182/blood-2004-04-1422; Corre J, 2020, HAEMATOLOGICA, V105, pE480, DOI 10.3324/haematol.2019.236588; D'Arena G, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/9271469; de la Rosa M, 2004, EUR J IMMUNOL, V34, P2480, DOI 10.1002/eji.200425274; Dosani T, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.32; Ege H, 2008, BRIT J HAEMATOL, V141, P792, DOI 10.1111/j.1365-2141.2008.07123.x; Favaloro J, 2014, LEUKEMIA LYMPHOMA, V55, P2893, DOI 10.3109/10428194.2014.904511; Feyler S, 2013, BLOOD REV, V27, P155, DOI 10.1016/j.blre.2013.04.004; Franssen LE, 2015, BONE MARROW TRANSPL, V50, P822, DOI 10.1038/bmt.2015.48; Garderet L, 2007, LEUKEMIA LYMPHOMA, V48, P2032, DOI 10.1080/10428190701593644; Ghermezi M, 2017, HAEMATOLOGICA, V102, P785, DOI 10.3324/haematol.2016.150896; Giallongo C, 2016, ONCOTARGET, V7, P85764, DOI 10.18632/oncotarget.7969; Giannopoulos K, 2012, BRIT J CANCER, V106, P546, DOI 10.1038/bjc.2011.575; Girlanda S, 2005, CANCER RES, V65, P7502, DOI 10.1158/0008-5472.CAN-05-0731; Gorgun GT, 2013, BLOOD, V121, P2975, DOI 10.1182/blood-2012-08-448548; Hengeveld PJ, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.3; Ho CM, 2017, BLOOD ADV, V1, P1056, DOI 10.1182/bloodadvances.2017005447; Hofmann JN, 2017, OBESITY, V25, P1317, DOI 10.1002/oby.21894; Holstein SA, 2020, BIOL BLOOD MARROW TR, V26, pE7, DOI 10.1016/j.bbmt.2019.09.015; Holstein Sarah A, 2019, Biol Blood Marrow Transplant, V25, pe89, DOI 10.1016/j.bbmt.2018.11.001; Holstein SA, 2018, BIOL BLOOD MARROW TR, V24, P641, DOI 10.1016/j.bbmt.2017.12.774; Jimenez-Zepeda VH, 2015, LEUKEMIA LYMPHOMA, V56, P2668, DOI 10.3109/10428194.2014.1003057; Jurisic V, 2007, MED ONCOL, V24, P312, DOI 10.1007/s12032-007-0007-y; Kawano Y, 2017, CURR CANCER DRUG TAR, V17, P806, DOI 10.2174/1568009617666170214102301; Kay NE, 1997, BLOOD, V90, P340; Kelkitli E, 2014, ANN HEMATOL, V93, P841, DOI 10.1007/s00277-013-1978-8; Kim DS, 2017, KOREAN J INTERN MED, V32, P711, DOI 10.3904/kjim.2016.054; Kim H, 2006, BONE MARROW TRANSPL, V37, P1037, DOI 10.1038/sj.bmt.1705373; Kiraly O, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004901; Koike M, 2002, LEUKEMIA RES, V26, P705, DOI 10.1016/S0145-2126(01)00192-8; Kovacs E, 2010, LEUKEMIA RES, V34, P912, DOI 10.1016/j.leukres.2009.08.012; Lee GW, 2018, ACTA HAEMATOL-BASEL, V140, P146, DOI 10.1159/000490488; Lee SE, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-018-0491-y; Lee SE, 2016, CANCER IMMUNOL IMMUN, V65, P983, DOI 10.1007/s00262-016-1861-2; Lemancewicz D, 2013, LEUKEMIA RES, V37, P1089, DOI 10.1016/j.leukres.2013.05.014; Lemancewicz D, 2012, MED SCI MONITOR, V18, pBR54, DOI 10.12659/MSM.882204; Li YJ, 2017, J CLIN LAB ANAL, V31, DOI 10.1002/jcla.22107; Liu Z, 2021, CLIN EXP IMMUNOL, V205, P53, DOI 10.1111/cei.13594; LUDWIG H, 1991, BLOOD, V77, P2794; Lust JA, 2016, AM J HEMATOL, V91, P571, DOI 10.1002/ajh.24352; Lust JA, 2009, MAYO CLIN PROC, V84, P114, DOI 10.4065/84.2.114; Medeni SS, 2018, CLIN TRANSPLANT, V32, DOI 10.1111/ctr.13359; Meraviglia S, 2015, IMMUNOTHERAPY-UK, V7, P949, DOI 10.2217/imt.15.68; Meyers DE, 2017, BLOOD CANCER J, V7, DOI 10.1038/s41408-017-0020-0; Mileshkin L, 2007, HAEMATOLOGICA, V92, P1075, DOI 10.3324/haematol.11208; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Moreaux J, 2005, BLOOD, V106, P1021, DOI 10.1182/blood-2004-11-4512; Moreaux J, 2011, BLOOD, V117, P1280, DOI 10.1182/blood-2010-04-279760; Musolino C, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/1852517; Napolitano M, 2015, LEUKEMIA LYMPHOMA, V56, P1507, DOI 10.3109/10428194.2014.955021; Narwani V, 2015, CL LYMPH MYELOM LEUK, V15, P222, DOI 10.1016/j.clml.2014.10.002; Nishijima TF, 2015, CANCER TREAT REV, V41, P971, DOI 10.1016/j.ctrv.2015.10.003; Ogawara H, 2005, LEUKEMIA RES, V29, P135, DOI 10.1016/j.leukres.2004.06.003; Onec B, 2017, J CLIN LAB ANAL, V31, DOI 10.1002/jcla.22032; OSTERBORG A, 1990, EUR J HAEMATOL, V45, P153; Paiva B, 2016, BLOOD, V127, P3165, DOI 10.1182/blood-2016-03-705319; Pappa C, 2007, CYTOKINE, V37, P171, DOI 10.1016/j.cyto.2007.02.022; Paramanathan A, 2014, SURG ONCOL, V23, P31, DOI 10.1016/j.suronc.2013.12.001; de Magalhaes RJP, 2013, HAEMATOLOGICA, V98, P79, DOI 10.3324/haematol.2012.067272; Porrata LF, 2010, AM J HEMATOL, V85, P896, DOI 10.1002/ajh.21849; Qiang YW, 2008, BONE, V42, P669, DOI 10.1016/j.bone.2007.12.006; Raja KRM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047077; Ramachandran IR, 2013, J IMMUNOL, V190, P3815, DOI 10.4049/jimmunol.1203373; Romano A, 2015, ANN HEMATOL, V94, P1875, DOI 10.1007/s00277-015-2462-4; Romano A, 2018, EXPERT REV MOL DIAGN, V18, P675, DOI 10.1080/14737159.2018.1470929; Roodman GD, 2004, BLOOD CELL MOL DIS, V32, P290, DOI 10.1016/j.bcmd.2004.01.001; Rosinski SL, 2005, BONE MARROW TRANSPL, V36, P425, DOI 10.1038/sj.bmt.1705073; Rueff Jessica, 2014, Biol Blood Marrow Transplant, V20, P896, DOI 10.1016/j.bbmt.2014.03.007; Saltarella I, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-018-0691-4; Schmidmaier R., 2008, Experimental Oncology, V30, P240; Shi LH, 2017, ONCOTARGET, V8, P18792, DOI 10.18632/oncotarget.13320; Storek J, 2008, EXPERT OPIN BIOL TH, V8, P583, DOI 10.1517/14712598.8.5.583 ; Tanaka Y, 2007, CLIN CANCER RES, V13, P816, DOI 10.1158/1078-0432.CCR-06-2258; Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124; Nguyen-Pham TN, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/397648; Tian Y, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9434637; Braga WMT, 2014, CANCER IMMUNOL IMMUN, V63, P1189, DOI 10.1007/s00262-014-1589-9; UCHIYAMA H, 1993, BLOOD, V82, P3712; Uz B, 2018, ACTA HAEMATOL-BASEL, V140, P157, DOI 10.1159/000491988; Wang H, 2016, BRIT J CANCER, V114, P463, DOI 10.1038/bjc.2016.11; Wang L, 2017, ANN HEMATOL, V96, P2079, DOI 10.1007/s00277-017-3125-4; Wang ZT, 2015, CANCER IMMUNOL IMMUN, V64, P389, DOI 10.1007/s00262-014-1646-4; Wongrakpanich S, 2016, J CLIN LAB ANAL, V30, P1208, DOI 10.1002/jcla.22004; Xiong J, 2021, CANCER GENE THER, V28, P265, DOI 10.1038/s41417-020-00217-0; Xiong YN, 2006, J INTERF CYTOK RES, V26, P83, DOI 10.1089/jir.2006.26.83; Yousef S, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.7; Zdzisinska B, 2008, ARCH IMMUNOL THER EX, V56, P207, DOI 10.1007/s00005-008-0022-5; Zhao ED, 2016, NAT IMMUNOL, V17, P95, DOI 10.1038/ni.3313; Zhou JH, 2019, J CANCER RES CLIN, V145, P329, DOI 10.1007/s00432-018-2790-6; Zhou X, 2018, CANCER BIOMARK, V22, P43, DOI 10.3233/CBM-170795; Zou ZQ, 2021, J CANCER, V12, P2633, DOI 10.7150/jca.53209	98	1	1	2	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 5	2021	12								663748	10.3389/fimmu.2021.663748	http://dx.doi.org/10.3389/fimmu.2021.663748			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TK7OR	34290698	gold, Green Published			2022-12-18	WOS:000674345300001
J	Lai, CC; Liu, XL; Yan, QH; Lv, HL; Zhou, L; Hu, LB; Cai, Y; Wang, GQ; Chen, YF; Chai, RJ; Liu, ZW; Xu, YH; Huang, WD; Xiao, F; Hu, LH; Li, YC; Huang, JH; Zhou, Q; Li, LQ; Peng, T; Zhang, HY; Zhang, ZH; Chen, L; Chen, CB; Ji, TX				Lai, Changchun; Liu, Xinglong; Yan, Qihong; Lv, Hualiang; Zhou, Lei; Hu, Longbo; Cai, Yong; Wang, Guoqiang; Chen, Yufeng; Chai, Renjie; Liu, Zhenwei; Xu, Yuhua; Huang, Wendong; Xiao, Fei; Hu, Linhui; Li, Yaocai; Huang, Jianhong; Zhou, Qiang; Li, Luqian; Peng, Tao; Zhang, Haiye; Zhang, Zhenhui; Chen, Ling; Chen, Chunbo; Ji, Tianxing			Low Innate Immunity and Lagged Adaptive Immune Response in the Re-Tested Viral RNA Positivity of a COVID-19 Patient	FRONTIERS IN IMMUNOLOGY			English	Article						delayed neutralizing antibody response; delayed antigen presentation; delayed anti-RBD; anti-spike IgA conversion; SARS-COV-2; COVID-19; re-tested positivity	INFECTION; GENE; CELL	Recent studies have highlighted observations regarding re-tested positivity (RP) of SARS-CoV-2 RNA in discharged COVID-19 patients, however, the immune mechanisms underlying SARS-CoV-2 RNA RP in immunocompetent patients remain elusive. Herein, we describe the case of an immunocompetent COVID-19 patient with moderate symptoms who was twice re-tested as positive for SARS-CoV-2 RNA, and the period between first and third viral RNA positivity was 95 days, longer than previously reported (18-25 days). The chest computed tomography findings, plasma anti-SARS-CoV-2 antibody, neutralizing antibodies (NAbs) titer, and whole blood transcriptic characteristics in the viral RNA RP patient and other COVID-19 patients were analyzed. During the SARS-CoV-2 RNA RP period, new lung lesions were observed. The COVID-19 patient with viral RNA RP had delayed seroconversion of anti-spike/receptor-binding domain (RBD) IgA antibody and NAbs and were accompanied with disappearance of the lung lesions. Further experimental data validated that NAbs titer was significantly associated with anti-RBD IgA and IgG, and anti-spike IgG. The RP patient had lower interferon-, T cells- and B cell-related genes expression than non-RP patients with mild-to-moderate symptoms, and displayed lower cytokines and chemokines gene expression than severe patients. Interestingly, the RP patient had low expression of antigen presentation-related genes and low B cell counts which might have contributed to the delayed anti-RBD specific antibody and low CD8+ cell response. Collectively, delayed antigen presentation-related gene expression was found related to delayed adaptive immune response and contributed to the SARS-CoV-2 RNA RP in this described immunocompetent patient.	[Lai, Changchun; Chen, Yufeng; Xiao, Fei; Li, Luqian] Maoming Peoples Hosp, Clin Lab Med Dept, Maoming, Peoples R China; [Lai, Changchun; Chen, Chunbo] Maoming Peoples Hosp, Dept Emergency, Maoming, Peoples R China; [Lai, Changchun; Zhang, Haiye] Xinyi Peoples Hosp, Clin Lab Med Dept, Xinyi, Peoples R China; [Liu, Xinglong; Yan, Qihong] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangzhou Regenerat Med & Hlth Guangdong Lab GRMH, Guangzhou, Peoples R China; [Lv, Hualiang] Maoming Peoples Hosp, Pulm & Crit Care Med Dept, Maoming, Peoples R China; [Zhou, Lei] Maoming Peoples Hosp, Pathol Lab Dept, Maoming, Peoples R China; [Hu, Longbo; Peng, Tao] Guangzhou Med Univ, Sch Basic Med Sci, Sino French Hoffmann Inst, State Key Lab Resp Dis, Guangzhou, Peoples R China; [Cai, Yong] Maoming Peoples Hosp, CT Dept, Maoming, Peoples R China; [Wang, Guoqiang] Guangzhou Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp 2, Guangzhou, Peoples R China; [Chai, Renjie] Guangzhou Med Univ, Cardiovasc Dept, Affiliated Hosp 2, Guangzhou, Peoples R China; [Liu, Zhenwei] Guangzhou Med Univ, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Affiliated Hosp 1, Guangzhou, Peoples R China; [Xu, Yuhua] Guangdong South China Vaccine Co Ltd, Vaccine Res & Dev Dept, Guangzhou, Peoples R China; [Huang, Wendong; Chen, Chunbo] Maoming Peoples Hosp, Sci Res Ctr, Maoming, Peoples R China; [Hu, Linhui] Maoming Peoples Hosp, Clin Res Ctr, Maoming, Peoples R China; [Li, Yaocai] Maoming Peoples Hosp, Infect Dept, Maoming, Peoples R China; [Huang, Jianhong] Maoming Peoples Hosp, Med Dept, Maoming, Maoming, Peoples R China; [Zhou, Qiang; Ji, Tianxing] Guangzhou Med Univ, Clin Lab Med Dept, Affiliated Hosp 2, Guangzhou, Peoples R China; [Zhang, Zhenhui] Guangzhou Med Univ, Crit Care Med Dept, Affiliated Hosp 2, Guangzhou, Peoples R China; [Chen, Ling] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Bioland Lab GRMH GDL, Guangzhou, Peoples R China; [Chen, Ling] Guangzhou Med Univ, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis, Affiliated Hosp 1, Guangzhou, Peoples R China	Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS; Guangzhou Regenerative Medicine & Health Guangdong Laboratory (Bioisland Laboratory); Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Guangzhou Medical University; Guangzhou Medical University; Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Guangzhou Medical University; Guangzhou Medical University; Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS; Guangzhou Medical University; State Key Laboratory of Respiratory Disease	Chen, CB (corresponding author), Maoming Peoples Hosp, Dept Emergency, Maoming, Peoples R China.; Chen, CB (corresponding author), Maoming Peoples Hosp, Sci Res Ctr, Maoming, Peoples R China.; Ji, TX (corresponding author), Guangzhou Med Univ, Clin Lab Med Dept, Affiliated Hosp 2, Guangzhou, Peoples R China.; Zhang, ZH (corresponding author), Guangzhou Med Univ, Crit Care Med Dept, Affiliated Hosp 2, Guangzhou, Peoples R China.; Chen, L (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Bioland Lab GRMH GDL, Guangzhou, Peoples R China.; Chen, L (corresponding author), Guangzhou Med Univ, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis, Affiliated Hosp 1, Guangzhou, Peoples R China.	zhzhhicu@126.com; chen_ling@gibh.ac.cn; gghccm@163.com; jitianxing7021@163.com	Chen, Chunbo/ABI-2835-2020; Chen, Chunbo/GRJ-9058-2022; Chen, Chunbo/AAU-6567-2021; Hu, Longbo/S-7060-2018	Chen, Chunbo/0000-0001-5662-497X; Chen, Chunbo/0000-0001-5662-497X; Hu, Longbo/0000-0002-3495-6268	Guangdong Science and Technology Project [2014A020212331]; Guangdong Provincial Department of Education Youth innovative talents Project [2017KQNCX168]; Guangzhou Health Science and technology project [20201A011078]; Guangzhou Science and Technology Project [201904010214, 202102010094]; Emergent Science and Technology Project for Prevention and Treatment of COVID-19 disease [mmkj003]; Maoming Science and Technology Project [2020007]; Guangdong Basic and Applied Basic Research Foundation [2021A1515012550]; Natural Science Foundation of Guangdong Province [2019A1515011681]; Guangzhou Institute of Respiratory Health Open Project [2020GIRHHMS01]; High-level Hospital Construction Research Project of Maoming People's Hospital [zx2020012]	Guangdong Science and Technology Project; Guangdong Provincial Department of Education Youth innovative talents Project; Guangzhou Health Science and technology project; Guangzhou Science and Technology Project; Emergent Science and Technology Project for Prevention and Treatment of COVID-19 disease; Maoming Science and Technology Project; Guangdong Basic and Applied Basic Research Foundation; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangzhou Institute of Respiratory Health Open Project; High-level Hospital Construction Research Project of Maoming People's Hospital	This study received the following funding: Guangdong Science and Technology Project (2014A020212331), Guangdong Provincial Department of Education Youth innovative talents Project (2017KQNCX168), Guangzhou Health Science and technology project (20201A011078), Guangzhou Science and Technology Project (201904010214, 202102010094), Emergent Science and Technology Project for Prevention and Treatment of COVID-19 disease (#mmkj003) and the High-level Hospital Construction Research Project of Maoming People's Hospital (zx2020012), Maoming Science and Technology Project (2020007), Guangdong Basic and Applied Basic Research Foundation (2021A1515012550), Natural Science Foundation of Guangdong Province (2019A1515011681), and Guangzhou Institute of Respiratory Health Open Project (2020GIRHHMS01).	Arunachalam PS, 2020, SCIENCE, V369, P1210, DOI 10.1126/science.abc6261; Avanzato VA, 2020, CELL, V183, P1901, DOI 10.1016/j.cell.2020.10.049; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Choi B, 2020, NEW ENGL J MED, V383, P2291, DOI 10.1056/NEJMc2031364; Chowdhury UF, 2021, GENOMICS, V113, P331, DOI 10.1016/j.ygeno.2020.12.021; Dong Z, 2021, CANCER COMMUN, V41, P349, DOI 10.1002/cac2.12151; Feng LQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18077-5; Fontana LM, 2021, INFECT CONT HOSP EP, V42, P659, DOI 10.1017/ice.2020.1273; Fourati S, 2020, INTENS CARE MED, V46, P1781, DOI 10.1007/s00134-020-06157-5; Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Hassan AO, 2020, CELL, V183, P169, DOI 10.1016/j.cell.2020.08.026; Hu FY, 2020, CELL MOL IMMUNOL, V17, P1119, DOI 10.1038/s41423-020-00550-2; Karatas A, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102871; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Lin AF, 2020, CLIN INFECT DIS, V71, P2061, DOI 10.1093/cid/ciaa490; Liu WD, 2020, J INFECTION, V81, P329, DOI 10.1016/j.jinf.2020.03.063; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Lu J, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102960; Zhang M, 2020, AM J TRANSPLANT, V20, P2626, DOI 10.1111/ajt.15996; Marot S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21111-9; McKie AM, 2020, BMJ CASE REP, V13, DOI 10.1136/bcr-2020-237357; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Niess H, 2021, AM J TRANSPLANT, V21, P1629, DOI 10.1111/ajt.16349; Shah V, 2020, BRIT J HAEMATOL, V190, pE279, DOI 10.1111/bjh.16935; Swain SL, 2012, NAT REV IMMUNOL, V12, P136, DOI 10.1038/nri3152; Varchetta S, 2021, CELL MOL IMMUNOL, V18, P604, DOI 10.1038/s41423-020-00557-9; Wu JR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.9759; Wu QJ, 2020, CANCER COMMUN, V40, P374, DOI 10.1002/cac2.12077; Xing YY, 2020, EUROSURVEILLANCE, V25, P12, DOI 10.2807/1560-7917.ES.2020.25.10.2000191; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yuan M, 2020, SCIENCE, V369, P1119, DOI 10.1126/science.abd2321; Zhou RH, 2020, IMMUNITY, V53, P864, DOI 10.1016/j.immuni.2020.07.026; Zhu L, 2020, EUR UROL, V77, P748, DOI 10.1016/j.eururo.2020.03.039	36	1	1	3	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 1	2021	12								664619	10.3389/fimmu.2021.664619	http://dx.doi.org/10.3389/fimmu.2021.664619			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TL6XV	34305895	Green Published, gold			2022-12-18	WOS:000675003800001
J	Matsuda, Y; Watanabe, T; Li, XK				Matsuda, Yoshiko; Watanabe, Takeshi; Li, Xiao-Kang			Approaches for Controlling Antibody-Mediated Allograft Rejection Through Targeting B Cells	FRONTIERS IN IMMUNOLOGY			English	Review						antibody-mediated allograft rejection; naive-B cell; memory-B cell; germinal center B cell; long-lived plasma cell; B cell biology	KIDNEY-TRANSPLANT RECIPIENTS; PROLIFERATION-INDUCING LIGAND; APOPTOSIS INHIBITORY FACTOR; C1 ESTERASE INHIBITOR; TUMOR-NECROSIS-FACTOR; T-FOLLICULAR HELPER; LIVED PLASMA-CELLS; IGM FC-RECEPTOR; RENAL-TRANSPLANT; GERMINAL CENTER	Both acute and chronic antibody-mediated allograft rejection (AMR), which are directly mediated by B cells, remain difficult to treat. Long-lived plasma cells (LLPCs) in bone marrow (BM) play a crucial role in the production of the antibodies that induce AMR. However, LLPCs survive through a T cell-independent mechanism and resist conventional immunosuppressive therapy. Desensitization therapy is therefore performed, although it is accompanied by severe side effects and the pathological condition may be at an irreversible stage when these antibodies, which induce AMR development, are detected in the serum. In other words, AMR control requires the development of a diagnostic method that predicts its onset before LLPC differentiation and enables therapeutic intervention and the establishment of humoral immune monitoring methods providing more detailed information, including individual differences in the susceptibility to immunosuppressive agents and the pathological conditions. In this study, we reviewed recent studies related to the direct or indirect involvement of immunocompetent cells in the differentiation of naive-B cells into LLPCs, the limitations of conventional methods, and the possible development of novel control methods in the context of AMR. This information will significantly contribute to the development of clinical applications for AMR and improve the prognosis of patients who undergo organ transplantation.	[Matsuda, Yoshiko; Li, Xiao-Kang] Natl Res Inst Child Hlth & Dev, Div Transplantat Immunol, Tokyo, Japan; [Watanabe, Takeshi] Kyoto Univ, Inst Frontier Life & Med Sci, Lab Immunol, Kyoto, Japan	National Center for Child Health & Development - Japan; Kyoto University	Matsuda, Y (corresponding author), Natl Res Inst Child Hlth & Dev, Div Transplantat Immunol, Tokyo, Japan.	Yoshikomatsuday@gmail.com						Adachi T, 2012, EUR J IMMUNOL, V42, P241, DOI 10.1002/eji.201141899; Afzali S, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/6654992; Salazar EKA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00219; Angata T, 2014, GLYCOBIOLOGY, V24, P785, DOI 10.1093/glycob/cwu043; Anglicheau D, 2003, J AM SOC NEPHROL, V14, P1889, DOI 10.1097/01.ASN.0000073901.94759.36; [Anonymous], 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858; Arai S, 2018, SEMIN IMMUNOPATHOL, V40, P567, DOI 10.1007/s00281-018-0717-6; Arai S, 2016, NAT MED, V22, P183, DOI 10.1038/nm.4012; Aschauer C, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1541-5; Badell IR, 2019, AM J TRANSPLANT, V19, P2342, DOI 10.1111/ajt.15319; Bamoulid J, 2017, NEPHROL DIAL TRANSPL, V32, P1601, DOI 10.1093/ndt/gfw368; Barnett ANR, 2013, CLIN TRANSPLANT, V27, pE216, DOI 10.1111/ctr.12102; Barratt-Due A, 2013, IMMUNOBIOLOGY, V218, P683, DOI 10.1016/j.imbio.2012.08.268; Barten MJ, 2018, TRANSPLANTATION, V102, pS828, DOI 10.1097/01.tp.0000543877.96384.6e; Benazzo A, 2019, J HEART LUNG TRANSPL, V38, pS166, DOI 10.1016/j.healun.2019.01.399; Berger M, 2019, TRANSPLANTATION, V103, P1763, DOI 10.1097/TP.0000000000002717; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bhat ZY, 2014, DNA CELL BIOL, V33, P448, DOI 10.1089/dna.2014.2371; Bohmig GA, 2018, TRANSPLANTATION, V102, P1837, DOI 10.1097/TP.0000000000002267; Brenner D, 2014, P NATL ACAD SCI USA, V111, P1060, DOI 10.1073/pnas.1323166111; Brimnes MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113388; Broutier L, 2017, NAT MED, V23, P1424, DOI 10.1038/nm.4438; Brynjolfsson SF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02673; Bujnowska A, 2018, TRANSPL P, V50, P1720, DOI 10.1016/j.transproceed.2018.02.110; BUNJES D, 1981, EUR J IMMUNOL, V11, P657, DOI 10.1002/eji.1830110812; Burghuber CK, 2019, AM J TRANSPLANT, V19, P724, DOI 10.1111/ajt.15067; Burton SA, 2015, CLIN TRANSPLANT, V29, P118, DOI 10.1111/ctr.12491; Butte AJ, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.000497; Cagnotto G, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-2100-y; Cannons JL, 2006, J EXP MED, V203, P1551, DOI 10.1084/jem.20052097; Cannons JL, 2010, IMMUNITY, V32, P253, DOI 10.1016/j.immuni.2010.01.010; Cariappa A, 2009, J EXP MED, V206, P125, DOI 10.1084/jem.20081399; Carpio VN, 2014, EXP CLIN TRANSPLANT, V12, P405, DOI 10.6002/ect.2014.0049; Carroll M C, 2000, Adv Immunol, V74, P61; Casneuf T, 2017, BLOOD ADV, V1, P2105, DOI 10.1182/bloodadvances.2017006866; Chapman NM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04392-5; Chapman TM, 2003, DRUGS, V63, P2803, DOI 10.2165/00003495-200363240-00009; Chappell CP, 2013, J CLIN INVEST, V123, P2778, DOI 10.1172/JCI69670; Charreau Beatrice, 2021, Transplantation, V105, pe156, DOI 10.1097/TP.0000000000003741; Chellappa V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053453; Chen R, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000940; Chen W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01625-3; Chesneau M, 2014, AM J TRANSPLANT, V14, P144, DOI 10.1111/ajt.12508; Chien CH, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0391-3; Choi J, 2017, AM J TRANSPLANT, V17, P2381, DOI 10.1111/ajt.14228; Choi JK, 2021, J MOL BIOL, V433, DOI 10.1016/j.jmb.2020.07.019; Choi SC, 2013, J IMMUNOL, V190, P987, DOI 10.4049/jimmunol.1202227; Chun N, 2017, AM J TRANSPLANT, V17, P2810, DOI 10.1111/ajt.14328; Cippa PE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09092-2; Clark EA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02235; Collins BE, 2004, P NATL ACAD SCI USA, V101, P6104, DOI 10.1073/pnas.0400851101; Conti F, 2003, TRANSPLANTATION, V76, P210, DOI 10.1097/01.TP.0000067530.95852.67; Cooper James E, 2011, Clin Transpl, P359; Corfe SA, 2012, SEMIN IMMUNOL, V24, P198, DOI 10.1016/j.smim.2012.02.001; Cornell LD, 2015, AM J TRANSPLANT, V15, P1293, DOI 10.1111/ajt.13168; Cree BAC, 2019, LANCET, V394, P1352, DOI 10.1016/S0140-6736(19)31817-3; Crotty S, 2003, NATURE, V421, P282, DOI 10.1038/nature01318; Crotty S, 2015, NAT REV IMMUNOL, V15, P185, DOI 10.1038/nri3803; Czar MJ, 2001, P NATL ACAD SCI USA, V98, P7449, DOI 10.1073/pnas.131193098; Daoussis D, 2004, CLIN DIAGN LAB IMMUN, V11, P635, DOI 10.1128/CDLI.11.4.635-641.2004; Dawidowicz K, 2011, CLIN EXP RHEUMATOL, V29, P839; de Herve MGD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019366; de Sousa MV, 2020, ANN TRANSPL, V25, DOI 10.12659/AOT.925488; De Vos J, 2006, IMMUNOL REV, V210, P86, DOI 10.1111/j.0105-2896.2006.00362.x; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Ding YL, 2018, CLIN NEPHROL, V89, P252, DOI 10.5414/CN109278; Doberer K, 2021, J AM SOC NEPHROL, V32, P708, DOI 10.1681/ASN.2020071106; Dong C, 2001, J IMMUNOL, V166, P3659, DOI 10.4049/jimmunol.166.6.3659; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; Duerr C, 2019, INNATE IMMUN-LONDON, V25, P374, DOI 10.1177/1753425919853333; Eckardt KU, 2009, AM J TRANSPLANT, V9, pS1, DOI 10.1111/j.1600-6143.2009.02834.x; Edwards SR, 2007, J BIOL CHEM, V282, P13395, DOI 10.1074/jbc.M700498200; Eskandary F, 2018, AM J TRANSPLANT, V18, P916, DOI 10.1111/ajt.14528; Fehr T, 2012, TRANSPL INT, V25, P623, DOI 10.1111/j.1432-2277.2012.01453.x; Feng XY, 2017, CLIN CANCER RES, V23, P4290, DOI 10.1158/1078-0432.CCR-16-3192; Frampton JE, 2020, DRUGS, V80, P1259, DOI 10.1007/s40265-020-01370-4; Freire PC, 2019, J INVEST DERMATOL, V139, P2417, DOI 10.1016/j.jid.2019.04.025; Furie R, 2020, NEW ENGL J MED, V383, P1117, DOI 10.1056/NEJMoa2001180; Goldstein LD, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0551-y; Gonzales MAM, 2017, TRANSPLANTATION, V101, P1222, DOI 10.1097/TP.0000000000001330; Grimbert P, 2017, TRANSPL INT, V30, P647, DOI 10.1111/tri.12975; Guan QN, 2013, AM J PHYSIOL-RENAL, V305, pF199, DOI 10.1152/ajprenal.00665.2012; Guerriero JL, 2019, INT REV CEL MOL BIO, V342, P73, DOI 10.1016/bs.ircmb.2018.07.001; Guo H, 2013, TRANSPL IMMUNOL, V29, P99, DOI 10.1016/j.trim.2013.10.001; Haas KM, 2018, J IMMUNOL, V200, P1671, DOI 10.4049/jimmunol.1701578; Han M, 2009, HUM IMMUNOL, V70, P29, DOI 10.1016/j.humimm.2008.10.013; Haneda M, 2014, TRANSPLANTATION, V97, P405, DOI 10.1097/01.TP.0000441826.70687.f6; Haruta I, 2001, J BIOL CHEM, V276, P22910, DOI 10.1074/jbc.M100324200; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Heesters BA, 2013, IMMUNITY, V38, P1164, DOI 10.1016/j.immuni.2013.02.023; Heidt S, 2012, AM J TRANSPLANT, V12, P1469, DOI 10.1111/j.1600-6143.2011.03982.x; Hipp N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01475-7; Honjo K, 2012, P NATL ACAD SCI USA, V109, P15882, DOI 10.1073/pnas.1206567109; Huang E, 2020, CLIN J AM SOC NEPHRO, V15, P109, DOI 10.2215/CJN.04840419; Huang HW, 2013, P NATL ACAD SCI USA, V110, P10928, DOI 10.1073/pnas.1309417110; Ichimura T, 2008, J CLIN INVEST, V118, P1657, DOI 10.1172/JCI34487; Imamura R, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9090733; Ius F, 2016, TRANSPLANTATION, V100, P2682, DOI 10.1097/TP.0000000000001027; Iyer SS, 2012, CRIT REV IMMUNOL, V32, P23, DOI 10.1615/CritRevImmunol.v32.i1.30; Jahnmatz M, 2013, J IMMUNOL METHODS, V391, P50, DOI 10.1016/j.jim.2013.02.009; Jain D, 2020, AM J TRANSPLANT, V20, P2675, DOI 10.1111/ajt.15881; Jordan SC, 2017, NEW ENGL J MED, V377, P442, DOI 10.1056/NEJMoa1612567; Jordan SC, 2020, AM J TRANSPLANT, V20, P42, DOI 10.1111/ajt.15913; Jordan SC, 2018, AM J TRANSPLANT, V18, P2955, DOI 10.1111/ajt.14767; Jozsi M, 2002, J IMMUNOL, V168, P2782, DOI 10.4049/jimmunol.168.6.2782; Karnell JL, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aar6584; Khattar M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225624; Khodadadi L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00721; Kim D, 2019, BMB REP, V52, P540, DOI 10.5483/BMBRep.2019.52.9.192; Kim J, 2020, NAT REV MOL CELL BIO, V21, P571, DOI 10.1038/s41580-020-0259-3; Kim TH, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-020-03332-w; Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391; Knight AK, 2007, CLIN IMMUNOL, V124, P182, DOI 10.1016/j.clim.2007.04.012; Knight R, 2018, TRANSPLANTATION, V102, pS39, DOI 10.1097/01.tp.0000542596.39174.b7; Korn T, 2008, P NATL ACAD SCI USA, V105, P18460, DOI 10.1073/pnas.0809850105; Krautz C, 2018, J CRIT CARE, V45, P71, DOI 10.1016/j.jcrc.2018.01.013; Krejcik J, 2016, BLOOD, V128, P384, DOI 10.1182/blood-2015-12-687749; Kreuzaler M, 2012, J IMMUNOL, V188, P497, DOI 10.4049/jimmunol.1102321; Kubagawa H, 2009, J EXP MED, V206, P2779, DOI 10.1084/jem.20091107; Kwun J, 2019, J AM SOC NEPHROL, V30, P1206, DOI 10.1681/ASN.2018121254; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; Latorre I, 2016, TRANSPL IMMUNOL, V35, P1, DOI 10.1016/j.trim.2016.01.004; Le Gallou S, 2012, J IMMUNOL, V189, P161, DOI 10.4049/jimmunol.1200301; Lederer SR, 2005, CLIN TRANSPLANT, V19, P168, DOI 10.1111/j.1399-0012.2005.00261.x; Lee DR, 2018, TRANSPL P, V50, P3452, DOI 10.1016/j.transproceed.2018.06.037; Lefaucheur C, 2018, J AM SOC NEPHROL, V29, P620, DOI 10.1681/ASN.2017050589; Lefaucheur C, 2016, J AM SOC NEPHROL, V27, P293, DOI 10.1681/ASN.2014111120; Lefaucheur C, 2013, LANCET, V381, P313, DOI 10.1016/S0140-6736(12)61265-3; Lenert P, 2005, J CLIN IMMUNOL, V25, P29, DOI 10.1007/s10875-005-0355-6; Levitsky J, 2013, TRANSPLANTATION, V96, P689, DOI 10.1097/TP.0b013e31829f1607; Liefeldt L, 2012, AM J TRANSPLANT, V12, P1192, DOI 10.1111/j.1600-6143.2011.03961.x; Lightman SM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00965; Lin X, 2019, CELL MOL IMMUNOL, V16, P921, DOI 10.1038/s41423-019-0227-z; Liu C, 2021, HUM IMMUNOL, V82, P488, DOI 10.1016/j.humimm.2020.04.009; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00160; Locke JE, 2009, AM J TRANSPLANT, V9, P231, DOI 10.1111/j.1600-6143.2008.02451.x; Lonze BE, 2018, ANN SURG, V268, P488, DOI 10.1097/SLA.0000000000002924; Lu D, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/1919082; Lucia M, 2015, KIDNEY INT, V88, P874, DOI 10.1038/ki.2015.205; Luo YS, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.627496; Luque S, 2017, TRANSPL INT, V30, P955, DOI 10.1111/tri.13014; Lynch RJ, 2013, AM J TRANSPLANT, V13, P1713, DOI 10.1111/ajt.12308; Macauley MS, 2013, J CLIN INVEST, V123, P3074, DOI 10.1172/JCI69187; Maeda K, 2010, BLOOD, V115, P4699, DOI 10.1182/blood-2009-07-230631; Mai HL, 2014, J CLIN INVEST, V124, P1723, DOI 10.1172/JCI66287; Marrari M, 2010, TRANSPL IMMUNOL, V22, P105, DOI 10.1016/j.trim.2009.12.005; Marshall K, 2018, HEPATOLOGY, V67, P721, DOI 10.1002/hep.29512; Masouleh BK, 2009, J IMMUNOL, V182, P4985, DOI 10.4049/jimmunol.0800574; Matsuda Y, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10010004; Matsuda Y, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00432; Matsuda Y, 2015, CELL IMMUNOL, V295, P127, DOI 10.1016/j.cellimm.2015.02.011; Mauer J, 2014, NAT IMMUNOL, V15, P423, DOI 10.1038/ni.2865; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; McCarron MJ, 2017, BLOOD, V129, P2749, DOI 10.1182/blood-2017-01-761643; McHugh Jessica, 2017, Nat Rev Rheumatol, V13, P633, DOI 10.1038/nrrheum.2017.163; Mei HE, 2015, BLOOD, V125, P1739, DOI 10.1182/blood-2014-02-555169; Mele TS, 2000, IMMUNOPHARMACOLOGY, V47, P215, DOI 10.1016/S0162-3109(00)00190-9; Milne CD, 2006, SEMIN IMMUNOL, V18, P20, DOI 10.1016/j.smim.2005.10.003; Moniodis A, 2018, J HEART LUNG TRANSPL, V37, P340, DOI 10.1016/j.healun.2017.03.017; Morath C, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/845040; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Moreso F, 2018, AM J TRANSPLANT, V18, P927, DOI 10.1111/ajt.14520; Moriyama S, 2014, J EXP MED, V211, P1297, DOI 10.1084/jem.20131666; Nakayamada S, 2016, INFLAMM REGEN, V36, DOI 10.1186/s41232-016-0015-4; Nanki Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69488-9; Nankivell BJ, 2018, AM J TRANSPLANT, V18, P364, DOI 10.1111/ajt.14609; Nguyen DC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05853-7; Nguyen TTT, 2017, NAT IMMUNOL, V18, P321, DOI 10.1038/ni.3677; Nguyen TTT, 2016, CRIT REV IMMUNOL, V36, P163, DOI 10.1615/CritRevImmunol.2016018175; Notley CA, 2011, J IMMUNOL, V186, P4967, DOI 10.4049/jimmunol.1003021; Nuckel H, 2005, EUR J PHARMACOL, V514, P217, DOI 10.1016/j.ejphar.2005.03.024; O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330; Ono Y, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-017-0591-z; Ou XJ, 2012, P NATL ACAD SCI USA, V109, P15401, DOI 10.1073/pnas.1200386109; Ouchida R, 2012, P NATL ACAD SCI USA, V109, pE2699, DOI 10.1073/pnas.1210706109; Pandiyan P, 2012, J IMMUNOL, V189, P4237, DOI 10.4049/jimmunol.1201476; Patel JK, 2021, AM J TRANSPLANT, V21, P2479, DOI 10.1111/ajt.16420; Peelen DM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.607953; Perera J, 2015, CELL MOL LIFE SCI, V72, P2657, DOI 10.1007/s00018-015-1895-1; Perrya DK, 2008, AM J TRANSPLANT, V8, P133, DOI 10.1111/j.1600-6143.2007.02039.x; Pillai S, 2009, TRENDS IMMUNOL, V30, P488, DOI 10.1016/j.it.2009.07.006; Pinna D, 2009, EUR J IMMUNOL, V39, P1260, DOI 10.1002/eji.200839129; Pongpirul W, 2018, NEPHROLOGY, V23, P169, DOI 10.1111/nep.12972; Popescu M, 2019, J IMMUNOL, V203, P2415, DOI 10.4049/jimmunol.1900484; Qi H, 2008, NATURE, V455, P764, DOI 10.1038/nature07345; Qu X, 2001, TRANSPLANTATION, V72, P915, DOI 10.1097/00007890-200109150-00029; RANSOM JT, 1995, THER DRUG MONIT, V17, P681, DOI 10.1097/00007691-199512000-00023; Ravichandran AK, 2013, CLIN TRANSPLANT, V27, P961, DOI 10.1111/ctr.12277; Roberts DM, 2012, TRANSPLANTATION, V94, P775, DOI 10.1097/TP.0b013e31825d1587; Roco JA, 2019, IMMUNITY, V51, P337, DOI 10.1016/j.immuni.2019.07.001; Rodriguez-Zhurbenko N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00483; Rookhuizen DC, 2014, P NATL ACAD SCI USA, V111, pE3224, DOI 10.1073/pnas.1323985111; Roos A, 2003, XENOTRANSPLANTATION, V10, P596, DOI 10.1034/j.1399-3089.2003.00063.x; Rosser EC, 2015, IMMUNITY, V42, P607, DOI 10.1016/j.immuni.2015.04.005; Rosser EC, 2014, NAT MED, V20, P1334, DOI 10.1038/nm.3680; Sakurai H, 1997, BBA-MOL BASIS DIS, V1362, P252, DOI 10.1016/S0925-4439(97)00068-9; Salazar-Camarena DC, 2016, LUPUS, V25, P582, DOI 10.1177/0961203315608254; Schinstock CA, 2019, AM J TRANSPLANT, V19, P1671, DOI 10.1111/ajt.15175; Schneider A, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004970; Schwarz C, 2018, EXPERT REV CLIN IMMU, V14, P583, DOI 10.1080/1744666X.2018.1485489; Shankar-Hari M, 2012, CRIT CARE, V16, DOI 10.1186/cc10597; Shen P, 2014, NATURE, V507, P366, DOI 10.1038/nature12979; Shiina Y, 2020, J HEART LUNG TRANSPL, V39, pS196; Shima H, 2010, INT IMMUNOL, V22, P149, DOI 10.1093/intimm/dxp121; Sivozhelezov V, 2008, J CELL BIOCHEM, V103, P1693, DOI 10.1002/jcb.21557; Smith NA, 2020, J VIROL, V94, DOI 10.1128/JVI.00428-20; Snanoudj R, 2015, KIDNEY INT, V87, P1230, DOI 10.1038/ki.2014.390; Sommerer C, 2012, CLIN CHIM ACTA, V413, P1379, DOI 10.1016/j.cca.2011.09.041; Sonkar GK, 2009, SAUDI J KIDNEY DIS T, V20, P1000; Stegall MD, 2011, AM J TRANSPLANT, V11, P2405, DOI 10.1111/j.1600-6143.2011.03757.x; Stegall MD, 2012, NAT REV NEPHROL, V8, P670, DOI 10.1038/nrneph.2012.212; Su H, 2019, KIDNEY DIS-BASEL, V5, P211, DOI 10.1159/000501460; Su L, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016113; Sugisawa R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31580-6; Sugisawa R, 2016, SCI REP-UK, V6, DOI 10.1038/srep35251; Surolia I, 2010, NATURE, V466, P243, DOI 10.1038/nature09115; Suzuki K, 2009, J EXP MED, V206, P1485, DOI 10.1084/jem.20090209; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; Tajima T, 2019, TRANSPLANT DIRECT, V5, DOI 10.1097/TXD.0000000000000932; Tarazon E, 2020, J HEART LUNG TRANSPL, V39, P257, DOI 10.1016/j.healun.2019.11.004; Tay C, 2016, CARDIOVASC RES, V111, P385, DOI 10.1093/cvr/cvw186; Tebbe B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153170; Toyoda M, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/5672523; Tsay GJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01064; Tsuchida Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169646; Tsuji S, 2014, J CLIN INVEST, V124, P4857, DOI 10.1172/JCI74428; van Besouw NM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00748; van de Donk NWCJ, 2018, IMMUNOL LETT, V199, P16, DOI 10.1016/j.imlet.2018.04.005; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; Vaschetto R, 2017, IMMUNOBIOLOGY, V222, P1074, DOI 10.1016/j.imbio.2017.09.002; Vazquez MI, 2015, CYTOKINE, V74, P318, DOI 10.1016/j.cyto.2015.02.007; Velidedeoglu E, 2018, TRANSPLANTATION, V102, pE257, DOI 10.1097/TP.0000000000002141; Viau M, 2005, CLIN IMMUNOL, V114, P17, DOI 10.1016/j.clim.2004.08.019; Viglietti D, 2016, AM J TRANSPLANT, V16, P1596, DOI 10.1111/ajt.13663; Viglietti D, 2018, KIDNEY INT, V94, P773, DOI 10.1016/j.kint.2018.03.015; Vincenti F, 2016, NEW ENGL J MED, V374, P333, DOI 10.1056/NEJMoa1506027; Vo AA, 2014, TRANSPLANTATION, V98, P312, DOI 10.1097/TP.0000000000000064; Wang CJ, 2015, P NATL ACAD SCI USA, V112, P524, DOI 10.1073/pnas.1414576112; Wang L, 2015, MUCOSAL IMMUNOL, V8, P1297, DOI 10.1038/mi.2015.20; Wang S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03750-7; Wang XZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01046; Whitehouse G, 2017, P NATL ACAD SCI USA, V114, P7083, DOI 10.1073/pnas.1620835114; Wiebe C, 2017, J AM SOC NEPHROL, V28, P3353, DOI 10.1681/ASN.2017030287; Wittig M, 2015, NUCLEIC ACIDS RES, V43, pE70, DOI 10.1093/nar/gkv184; Woodle ES, 2020, AM J TRANSPLANT, V20, P33, DOI 10.1111/ajt.15889; Xu H, 2020, AM J TRANSPLANT, V20, P653, DOI 10.1111/ajt.15639; Xu HP, 2013, NATURE, V496, P523, DOI 10.1038/nature12058; Xu YK, 2014, AUTOIMMUNITY, V47, P430, DOI 10.3109/08916934.2014.921810; Yang JYC, 2016, CURR OPIN ORGAN TRAN, V21, P362, DOI 10.1097/MOT.0000000000000328; Yang L, 2015, J CLIN INVEST, V125, P1620, DOI 10.1172/JCI75417; Yang M, 2005, J IMMUNOL, V175, P2814, DOI 10.4049/jimmunol.175.5.2814; Yazdani S, 2019, KIDNEY INT, V95, P188, DOI 10.1016/j.kint.2018.08.027; Young JS, 2016, AM J TRANSPLANT, V16, P2312, DOI 10.1111/ajt.13761; Yusa S, 1999, EUR J IMMUNOL, V29, P1086, DOI 10.1002/(SICI)1521-4141(199904)29:04<1086::AID-IMMU1086>3.3.CO;2-O; Yusuf I, 2010, J IMMUNOL, V185, P190, DOI 10.4049/jimmunol.0903505; Zhang XM, 2013, CELL MOL IMMUNOL, V10, P113, DOI 10.1038/cmi.2012.63; Zheng XX, 2006, TRANSPLANTATION, V81, P109, DOI 10.1097/01.tp.0000188139.11931.98; Zhou R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01884	259	1	1	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 1	2021	12								682334	10.3389/fimmu.2021.682334	http://dx.doi.org/10.3389/fimmu.2021.682334			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TJ8AN	34276669	gold, Green Published			2022-12-18	WOS:000673697600001
J	Wen, SM; Wei, HJ; Liao, QJ; Li, M; Zhong, SY; Cheng, YH; Huang, WJ; Wang, DY; Shu, YL				Wen, Simin; Wei, Hejiang; Liao, Qijun; Li, Mao; Zhong, Shuyi; Cheng, Yanhui; Huang, Weijuan; Wang, Dayan; Shu, Yuelong			Identification of Two Novel Candidate Genetic Variants Associated With the Responsiveness to Influenza Vaccination	FRONTIERS IN IMMUNOLOGY			English	Article						influenza; vaccine; immune response; genetic variant; genome-wide association study; ZBTB46; IQGAP2	CLASSICAL DENDRITIC CELLS; EXPRESSION; PROTEINS; FAMILY; CANCER; IQGAP2	Background Annual vaccination is the most effective prevention of influenza infection. Up to now, a series of studies have demonstrated the role of genetic variants in regulating the antibody response to influenza vaccine. However, among the Chinese population, the relationship between genetic factors and the responsiveness to influenza vaccination has not been clarified through genome-wide association study (GWAS). Method A total of 1,968 healthy volunteers of Chinese descent were recruited and 1,582 of them were available for the subsequent two-stage analysis. In the discovery stage, according to our inclusion criteria, 123 of 1,582 subjects were selected as group 1 and received whole-genome sequencing to identify potential variants and genes. In the verification stage, 29 candidate variants identified by GWAS were selected for further validation in 481 subjects in group 2. Besides, we also analyzed nine variants from previously published reports in our study. Results Multivariate logistic regression analysis showed that compared with the TT genotype of ZBTB46 rs2281929, the TC + CC genotype was associated with a lower risk of low responsiveness to influenza vaccination adjusted for gender and age (Group 2: P = 7.75E-05, OR = 0.466, 95%CI = 0.319-0.680; Combined group: P = 1.18E-06, OR = 0.423, 95%CI = 0.299-0.599). In the combined group, IQGAP2 rs2455230 GC + CC genotype was correlated with a lower risk of low responsiveness to influenza vaccination compared with the GG genotype (P = 8.90E-04, OR = 0.535, 95%CI = 0.370-0.774), but the difference was not statistically significant in group 2 (P = 0.008). The antibody fold rises of subjects with ZBTB46 rs2281929 TT genotype against H1N1, H3N2,and B were all significantly lower than that of subjects with TC + CC genotype (P < 0.001). Compared with IQGAP2 rs2455230 GC + CC carriers, GG carriers had lower antibody fold rises to H1N1 (P = 0.001) and B (P = 0.032). The GG genotype of rs2455230 tended to be correlated with lower antibody fold rises (P = 0.096) against H3N2, but the difference was not statistically significant. No correlation was found between nine SNPs from previously published reports and the serological response to influenza vaccine in our study. Conclusion Our study identified two novel candidate missense variants, ZBTB46 rs2281929 and IQGAP2 rs2455230, were associated with the immune response to influenza vaccination among the Chinese population. Identifying these variants will provide more evidence for future research and improve the individualized influenza vaccination program.	[Wen, Simin; Liao, Qijun; Li, Mao; Zhong, Shuyi; Shu, Yuelong] Sun Yat Sen Univ, Sch Publ Hlth Shenzhen, Guangzhou, Peoples R China; [Wei, Hejiang; Cheng, Yanhui; Huang, Weijuan; Wang, Dayan] Chinese Ctr Dis Prevent & Control, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China	Sun Yat Sen University; Chinese Center for Disease Control & Prevention; National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control & Prevention	Shu, YL (corresponding author), Sun Yat Sen Univ, Sch Publ Hlth Shenzhen, Guangzhou, Peoples R China.; Wang, DY (corresponding author), Chinese Ctr Dis Prevent & Control, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China.	dayanwang@cnic.org.cn; shuylong@mail.sysu.edu.cn	Wen, Simin/GOP-2911-2022		Shenzhen science and technology program [kqtd20180411143323605]; National Natural Science Foundation of China [82041043]	Shenzhen science and technology program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the Shenzhen science and technology program (Grant number: kqtd20180411143323605) and The National Natural Science Foundation of China (Grant number: 82041043).	Amon L, 2019, INT REV CEL MOL BIO, V349, P55, DOI 10.1016/bs.ircmb.2019.10.001; Beaulieu AM, 2011, J IMMUNOL, V187, P2841, DOI 10.4049/jimmunol.1004006; Berglund K, 2016, AGING-US, V8, P1398, DOI 10.18632/aging.100995; Brisac C, 2016, J HEPATOL, V65, P972, DOI 10.1016/j.jhep.2016.06.028; CDC, 2019, SEASONAL INFLUENZA V; CNIC, 2017, TECHNICAL GUIDELINES; Cummins NW, 2012, FASEB J, V26, P2911, DOI 10.1096/fj.11-190017; Egli A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004556; Gelder CM, 2002, J INFECT DIS, V185, P114, DOI 10.1086/338014; Ghaleb AM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129314; Handunnetthi L, 2010, GENES IMMUN, V11, P99, DOI 10.1038/gene.2009.83; Hedman AC, 2015, EMBO REP, V16, P427, DOI 10.15252/embr.201439834; Hswen Y, 2017, AM J PUBLIC HEALTH, V107, P1130, DOI 10.2105/AJPH.2017.303767; Krawczyk M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000058; Kumar D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186977; Lee S, 2012, AM J HUM GENET, V91, P224, DOI 10.1016/j.ajhg.2012.06.007; Lei N, 2020, EMERG MICROBES INFEC, V9, P976, DOI 10.1080/22221751.2020.1756696; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Mackenzie J S, 1977, Dev Biol Stand, V39, P355; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Meredith MM, 2012, J EXP MED, V209, P1583, DOI 10.1084/jem.20121003; Moss AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071376; Narwaney KJ, 2013, VACCINE, V31, P1123, DOI 10.1016/j.vaccine.2012.12.026; Poland GA, 2008, VACCINE, V26, pD35, DOI 10.1016/j.vaccine.2008.07.065; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Satpathy AT, 2018, MODERN PATHOL, V31, P1479, DOI 10.1038/s41379-018-0052-4; Satpathy AT, 2012, J EXP MED, V209, P1135, DOI 10.1084/jem.20120030; Steinman RM, 2012, ANNU REV IMMUNOL, V30, P1, DOI 10.1146/annurev-immunol-100311-102839; Suraweera N, 2016, ONCOTARGET, V7, P36474, DOI 10.18632/oncotarget.9015; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; White CD, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-125; White CD, 2009, FEBS LETT, V583, P1817, DOI 10.1016/j.febslet.2009.05.007; Xia FD, 2014, ASIAN PAC J CANCER P, V15, P4951, DOI 10.7314/APJCP.2014.15.12.4951; Xu L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061968; Zhao YJ, 2017, AM J CANCER RES, V7, P1937	36	1	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 1	2021	12								664024	10.3389/fimmu.2021.664024	http://dx.doi.org/10.3389/fimmu.2021.664024			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TK4HM	34276655	Green Published, gold			2022-12-18	WOS:000674121400001
J	Wennerberg, E; Lundqvist, A; Mao, YM; Mougiakakos, D				Wennerberg, Erik; Lundqvist, Andreas; Mao, Yumeng; Mougiakakos, Dimitrios			Editorial: NK-Myeloid Cell Interactions in the Tumor Microenvironment: Implications for Cancer Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						NK cells; myeloid cells; dendritic cells; MDSCs (myeloid-derived suppressor cells); cancer immunotherapy; platelets; cytokines			[Wennerberg, Erik] Inst Canc Res, Div Radiotherapy & Imaging, London, England; [Lundqvist, Andreas] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Mao, Yumeng] Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Uppsala, Sweden; [Mougiakakos, Dimitrios] Friedrich Alexander Univ FAU, Dept Med Hematol & Clin Oncol, Erlangen, Germany	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Karolinska Institutet; Uppsala University; University of Erlangen Nuremberg	Wennerberg, E (corresponding author), Inst Canc Res, Div Radiotherapy & Imaging, London, England.	erik.ag.wennerberg@gmail.com		Wennerberg, Erik/0000-0001-7689-5988					0	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 1	2021	12								718844	10.3389/fimmu.2021.718844	http://dx.doi.org/10.3389/fimmu.2021.718844			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TJ8FF	34276709	gold, Green Published			2022-12-18	WOS:000673709800001
J	Yang, B; Sylvius, N; Luo, JL; Yang, C; Da, Z; Crotty, C; Nicholson, ML				Yang, Bin; Sylvius, Nicolas; Luo, Jinli; Yang, Cheng; Da, Zhanyun; Crotty, Charlottelrm; Nicholson, Michael L.			Identifying Biomarkers from Transcriptomic Signatures in Renal Allograft Biopsies Using Deceased and Living Donors	FRONTIERS IN IMMUNOLOGY			English	Article						biomarkers; differentially expressed genes; fibrosis; immunity; inflammation; transplant kidney injury	LEUKOCYTE PROTEASE INHIBITOR; ACUTE KIDNEY INJURY; GENE-EXPRESSION; EPITHELIAL-CELLS; CASPASE-3 SIRNA; TRANSPLANTATION; INTERVENTION; CYCLOSPORINE; REJECTION; APOPTOSIS	The survival of transplant kidneys using deceased donors (DD) is inferior to living donors (LD). In this study, we conducted a whole-transcriptome expression analysis of 24 human kidney biopsies paired at 30 minutes and 3 months post-transplantation using DD and LD. The transcriptome profile was found significantly different between two time points regardless of donor types. There were 446 differentially expressed genes (DEGs) between DD and LD at 30 minutes and 146 DEGs at 3 months, with 25 genes common to both time points. These DEGs reflected donor injury and acute immune responses associated with inflammation and cell death as early as at 30 minutes, which could be a precious window of potential intervention. DEGs at 3 months mainly represented the changes of adaptive immunity, immunosuppressive treatment, remodeling or fibrosis via different networks and signaling pathways. The expression levels of 20 highly DEGs involved in kidney diseases and 10 genes dysregulated at 30 minutes were found correlated with renal function and histology at 12 months, suggesting they could be potential biomarkers. These genes were further validated by quantitative polymerase chain reaction (qPCR) in 24 samples analysed by microarray, as well as in a validation cohort of 33 time point unpaired allograft biopsies. This analysis revealed that SERPINA3, SLPI and CBF were up-regulated at 30 minutes in DD compared to LD, while FTCD and TASPN7 were up-regulated at both time points. At 3 months, SERPINA3 was up-regulated in LD, but down-regulated in DD, with increased VCAN and TIMP1, and decreased FOS, in both donors. Taken together, divergent transcriptomic signatures between DD and LD, and changed by the time post-transplantation, might contribute to different allograft survival of two type kidney donors. Some DEGs including FTCD and TASPN7 could be novel biomarkers not only for timely diagnosis, but also for early precise genetic intervention at donor preservation, implantation and post-transplantation, in particular to effectively improve the quality and survival of DD.	[Yang, Bin; Crotty, Charlottelrm; Nicholson, Michael L.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England; [Yang, Bin; Crotty, Charlottelrm; Nicholson, Michael L.] Univ Hosp Leicester, Res & Innovat, Leicester, Leics, England; [Yang, Bin] Affiliated Hosp Nantong Univ, Nantong Leicester Jiont Inst Kidney Sci, Dept Nephrol, Nantong, Peoples R China; [Sylvius, Nicolas] Univ Leicester, Genom Core Facil, Leicester, Leics, England; [Luo, Jinli] Univ Leicester, Bioinformat & Biostat Support Hub Leicester, Leicester, Leics, England; [Yang, Cheng] Fudan Univ, Zhongshan Hosp, Dept Urol, Shanghai, Peoples R China; [Yang, Cheng] Shanghai Key Lab Organ Transplantat, Shanghai, Peoples R China; [Da, Zhanyun] Affiliated Hosp Nantong Univ, Dept Rheumatol & Immunol, Nantong, Peoples R China; [Nicholson, Michael L.] Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge, England	University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; Nantong University; University of Leicester; University of Leicester; Fudan University; Nantong University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Yang, B (corresponding author), Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England.; Yang, B (corresponding author), Univ Hosp Leicester, Res & Innovat, Leicester, Leics, England.; Yang, B (corresponding author), Affiliated Hosp Nantong Univ, Nantong Leicester Jiont Inst Kidney Sci, Dept Nephrol, Nantong, Peoples R China.	by5@le.ac.uk			UK-China Fellowship for Excellence, Department for Business Innovation and Skills (2010/2011); National Nature Science Foundation of China [81170689, 81570677, 81873622]	UK-China Fellowship for Excellence, Department for Business Innovation and Skills (2010/2011); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported the UK-China Fellowship for Excellence, Department for Business Innovation and Skills (2010/2011) and the National Nature Science Foundation of China (81170689, 81570677 and 81873622).	Ajay AK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045628; Akalin E, 2001, TRANSPLANTATION, V72, P948, DOI 10.1097/00007890-200109150-00034; Akalin E, 2010, KIDNEY INT, V78, pS33, DOI 10.1038/ki.2010.420; Arcaroli JJ, 2010, CLIN CANCER RES, V16, P4165, DOI 10.1158/1078-0432.CCR-10-0066; Asakura M, 2009, CIRC J, V73, P1568, DOI 10.1253/circj.CJ-09-0465; Averdunk L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60482-9; Averdunk L, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111931; BERGENFELDT M, 1990, SCAND J CLIN LAB INV, V50, P729, DOI 10.3109/00365519009091066; Berglund SR, 2007, J INVEST DERMATOL, V127, P349, DOI 10.1038/sj.jid.5700557; Catar R, 2013, KIDNEY INT, V84, P1119, DOI 10.1038/ki.2013.217; Cecka J M, 1998, Clin Transpl, P1; Chang HR, 2013, WORLD J SURG, V37, P466, DOI 10.1007/s00268-012-1815-6; Chang J, 2013, AM J PHYSIOL-RENAL, V304, pF348, DOI 10.1152/ajprenal.00568.2012; Charrin S, 2014, J CELL SCI, V127, P3641, DOI 10.1242/jcs.154906; Cheong CM, 2015, EXP CELL RES, V332, P24, DOI 10.1016/j.yexcr.2015.01.006; Cohen DM, 1996, P NATL ACAD SCI USA, V93, P11242, DOI 10.1073/pnas.93.20.11242; Damman J, 2015, TRANSPLANTATION, V99, P1293, DOI 10.1097/TP.0000000000000500; Duncan WC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023595; Famulski KS, 2013, AM J TRANSPLANT, V13, P634, DOI 10.1111/ajt.12080; Fang H, 2017, METHODS MOL BIOL, V1613, P333, DOI 10.1007/978-1-4939-7027-8_13; Fleige Simone, 2006, Molecular Aspects of Medicine, V27, P126, DOI 10.1016/j.mam.2005.12.003; Gao YS, 2002, EUR J CELL BIOL, V81, P391, DOI 10.1078/0171-9335-00260; Grigoryev DN, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-231; Grimm PC, 2003, J AM SOC NEPHROL, V14, P1662, DOI 10.1097/01.ASN.0000066143.02832.5E; Guerrieri D, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/167361; Halloran PF, 2017, AM J TRANSPLANT, V17, P2851, DOI 10.1111/ajt.14329; Hennig D, 1998, J BIOL CHEM, V273, P19602, DOI 10.1074/jbc.273.31.19602; Hernandez-Saavedra D, 2005, BIOMED PHARMACOTHER, V59, P204, DOI 10.1016/j.biopha.2005.03.001; Hirt-Minkowski P, 2014, TRANSPL IMMUNOL, V30, P1, DOI 10.1016/j.trim.2013.11.004; Ibrahim M, 2020, AM J TRANSPLANT, V20, P1309, DOI 10.1111/ajt.15719; Ishida M, 2015, J INTENSIVE CARE, V3, DOI 10.1186/s40560-015-0115-2; Kezic A, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/6305439; Kitamura M, 2002, NEPHROL DIAL TRANSPL, V17, P84, DOI 10.1093/ndt/17.suppl_9.84; Lannan EA, 2012, ENDOCRINOLOGY, V153, P3701, DOI 10.1210/en.2012-1020; Le Quintrec M, 2008, AM J TRANSPLANT, V8, P1694, DOI 10.1111/j.1600-6143.2008.02297.x; Le Quintrec M, 2013, AM J TRANSPLANT, V13, P663, DOI 10.1111/ajt.12077; Lim JH, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/171383; Lin H, 2018, TZU CHI MED J, V30, P61, DOI 10.4103/tcmj.tcmj_37_18; Mao YX, 2004, EMBO J, V23, P2963, DOI 10.1038/sj.emboj.7600327; MARUYAMA M, 1994, J CLIN INVEST, V94, P368, DOI 10.1172/JCI117331; Muhlberger I, 2009, TRANSPLANTATION, V88, pS14, DOI 10.1097/TP.0b013e3181af65b5; Mutch DM, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-17; Mutoh J, 2013, NEUROPHARMACOLOGY, V71, P10, DOI 10.1016/j.neuropharm.2013.03.001; O'Connell PJ, 2016, LANCET, V388, P983, DOI 10.1016/S0140-6736(16)30826-1; Oberbauer R, 1999, J AM SOC NEPHROL, V10, P2006; Ohlsson S, 2001, MEDIAT INFLAMM, V10, P347, DOI 10.1080/09629350120102389; Sanchez-Navarro A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46601-1; Sano C, 2000, CLIN EXP IMMUNOL, V121, P77, DOI 10.1046/j.1365-2249.2000.01269.x; Sarwal M, 2003, NEW ENGL J MED, V349, P125, DOI 10.1056/NEJMoa035588; Saunders RN, 2003, TRANSPLANTATION, V75, P772, DOI 10.1097/00007890-200303270-00008; Scherer A, 2003, TRANSPLANTATION, V75, P1323, DOI 10.1097/01.TP.0000068481.98801.10; Singh R, 2009, CLIN TRANSPLANT, V23, P490, DOI 10.1111/j.1399-0012.2009.00985.x; Summers DM, 2010, LANCET, V376, P1303, DOI 10.1016/S0140-6736(10)60827-6; Summers KM, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000859; Takahashi E, 2013, J PROTEOMICS, V84, P40, DOI 10.1016/j.jprot.2013.03.014; Turnier JL, 2019, RHEUMATOLOGY, V58, P321, DOI 10.1093/rheumatology/key301; Vitalone MJ, 2014, AM J TRANSPLANT, V14, P1912, DOI 10.1111/ajt.12746; Vitalone MJ, 2010, TRANSPLANTATION, V89, P537, DOI 10.1097/TP.0b013e3181ca7389; Waller JR, 2002, BRIT J SURG, V89, P1390, DOI 10.1046/j.1365-2168.2002.02271.x; Waters AM, 2011, PEDIATR NEPHROL, V26, P41, DOI 10.1007/s00467-010-1556-4; Wilflingseder J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104164; Wu YY, 2020, J PHARMACOL EXP THER, V375, P92, DOI 10.1124/jpet.120.000092; Wuttig D, 2012, INT J CANCER, V131, pE693, DOI 10.1002/ijc.27419; Yan Q, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-141; Yang B, 2011, J CELL BIOCHEM, V112, P1337, DOI 10.1002/jcb.23050; Yang B, 2011, TRANSPLANTATION, V91, P501, DOI 10.1097/TP.0b013e318207949f; Yang C, 2014, MOL THER, V22, P1817, DOI 10.1038/mt.2014.111; Yilmaz S, 2007, TRANSPL INT, V20, P608, DOI 10.1111/j.1432-2277.2007.00494.x; Yuen PST, 2006, PHYSIOL GENOMICS, V25, P375, DOI 10.1152/physiolgenomics.00223.2005; Zawada AM, 2014, EPIGENETICS-US, V9, P161, DOI 10.4161/epi.26931; Zhao ZT, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-53; Zhao ZT, 2014, EXP BIOL MED, V239, P193, DOI 10.1177/1535370213514921; Zwaini Z, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56060317	73	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 1	2021	12								657860	10.3389/fimmu.2021.657860	http://dx.doi.org/10.3389/fimmu.2021.657860			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TJ7RA	34276651	Green Published, gold			2022-12-18	WOS:000673672900001
J	Chen, PL; Huang, CY; Sun, Q; Zhong, HX; Xiong, F; Liu, S; Yao, ZH; Liu, ZQ; Wan, CY; Zeng, Y; Diao, LH				Chen, Peilin; Huang, Chunyu; Sun, Qing; Zhong, Huixian; Xiong, Feng; Liu, Su; Yao, Zhihong; Liu, Zhiqiang; Wan, Caiyun; Zeng, Yong; Diao, Lianghui			Granulocyte-Macrophage Colony Stimulating Factor in Single Blastocyst Conditioned Medium as a Biomarker for Predicting Implantation Outcome of Embryo	FRONTIERS IN IMMUNOLOGY			English	Article						embryo quality; granulocyte-macrophage colony-stimulating factor; pregnancy outcome; single-blastocyst conditioned medium; trace protein detection	FACTOR GM-CSF; PREGNANCY; MARKER	Background It is highly desirable to develop new strategies based on secretomics to more accurately selection of embryos with the highest developmental potential for transfer. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been reported to promote embryo development and pregnancy establishment. However, the predictive value of GM-CSF in single blastocyst selection remains unclear. This study is to determine the concentration of GM-CSF in human single-blastocyst conditioned medium (SBCM) and to evaluate its association with embryo quality and pregnancy outcome. Methods The patients with <= 38 years of age receiving the first cycle of assisted reproductive therapy were included in this study. The patients who had <4 top-quality embryos formed by the fertilized two pronuclear zygotes on day 3 were excluded. A total of 126 SBCM samples (SBCMs) were included, of which blastocysts from 77 SBCMs were later transferred in subsequent frozen-thawed embryo transfer. The concentrations of GM-CSF were detected by single-molecule array (SIMOA) and analyzed for their possible association with embryo quality and pregnancy outcomes. The top-quality embryo (TQ), positive HCG (HP), clinical pregnancy (CP), and ongoing pregnancy (OP) rates were determined and compared between groups divided based on GM-CSF concentrations. Results The detection rate of GM-CSF was found to be 50% in all SBCMs. There were significant differences in TQ rate, HP rate, CP rate and OP rate among high concentration group, medium concentration group and low concentration group. Both GM-CSF alone or GM-CSF combined with the morphological score (MS) had a greater AUC of ROC curve than that of MS alone to predict the pregnancy outcome, and GM-CSF combined with MS had the highest AUC. Conclusions The concentration of GM-CSF in SBCM was detected at fg/ml levels, which was associated with embryo quality and pregnancy outcome. Collectively, GM-CSF may be used as a biomarker for prediction of pregnancy outcome and selection of embryos with high developmental potential for transfer in assisted reproductive technology (ART).	[Chen, Peilin; Huang, Chunyu; Sun, Qing; Zhong, Huixian; Xiong, Feng; Liu, Su; Yao, Zhihong; Liu, Zhiqiang; Wan, Caiyun; Zeng, Yong; Diao, Lianghui] Shenzhen Zhongshan Urol Hosp, Fertil Ctr, Shenzhen Zhongshan Inst Reprod & Genet, Shenzhen Key Lab Reprod Immunol Periimplantat, Shenzhen, Peoples R China; [Huang, Chunyu] Univ Hong Kong, Li Ka Shing Fac Med, Dept Paediat & Adolescent Med, Hong Kong, Peoples R China	University of Hong Kong	Zeng, Y; Diao, LH (corresponding author), Shenzhen Zhongshan Urol Hosp, Fertil Ctr, Shenzhen Zhongshan Inst Reprod & Genet, Shenzhen Key Lab Reprod Immunol Periimplantat, Shenzhen, Peoples R China.	zengyong1966@gmail.com; Diaolianghui@gmail.com	Diao, Lianghui/HGD-2938-2022; Diao, Lianghui/AFO-0439-2022	Diao, Lianghui/0000-0002-1159-9261; Diao, Lianghui/0000-0002-1159-9261	National Key Research & Developmental Program of China [2018YFC1003900, 2018YFC1003904]; clinical research special fund of Chinese Medical Association [18010120741]; Shenzhen Natural Science Foundation [JCYJ20190813161801676]; Basic Research Program of Shenzhen [JCYJ20160427113153295]; National Natural Science Foundation of China [21807072]; Sanming Project of Medicine in Shenzhen [SZSM201502035]	National Key Research & Developmental Program of China; clinical research special fund of Chinese Medical Association; Shenzhen Natural Science Foundation; Basic Research Program of Shenzhen; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sanming Project of Medicine in Shenzhen	This study was funded by the National Key Research& Developmental Program of China (2018YFC1003900/2018YFC1003904), clinical research special fund of Chinese Medical Association (18010120741), Shenzhen Natural Science Foundation (JCYJ20190813161801676), Basic Research Program of Shenzhen (JCYJ20160427113153295), National Natural Science Foundation of China (21807072) and Sanming Project of Medicine in Shenzhen (SZSM201502035).	Arce JC, 2006, HUM REPROD, V21, P2141, DOI 10.1093/humrep/del106; Barberet J, 2019, HUM REPROD, V34, P1439, DOI 10.1093/humrep/dez085; Behr B, 2005, J ASSIST REPROD GEN, V22, P25, DOI 10.1007/s10815-005-0817-9; Botros L, 2008, MOL HUM REPROD, V14, P679, DOI 10.1093/molehr/gan066; Bowen JM, 2002, PLACENTA, V23, P239, DOI 10.1053/plac.2001.0781; Chen CY, 2019, CLIN CHIM ACTA, V491, P46, DOI 10.1016/j.cca.2019.01.012; Chen PL, 2020, BIOMICROFLUIDICS, V14, DOI 10.1063/1.5141490; Chen XY, 2013, J ASSIST REPROD GEN, V30, P377, DOI 10.1007/s10815-012-9923-7; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Desai N, 2007, J ASSIST REPROD GEN, V24, P215, DOI 10.1007/s10815-007-9119-8; Descours B, 2017, NATURE, V543, P564, DOI 10.1038/nature21710; Dominguez F, 2008, HUM REPROD, V23, P1993, DOI 10.1093/humrep/den205; Dominguez F, 2015, FERTIL STERIL, V104, P908, DOI 10.1016/j.fertnstert.2015.06.032; Fuzzi B, 2002, EUR J IMMUNOL, V32, P311, DOI 10.1002/1521-4141(200202)32:2<311::AID-IMMU311>3.3.CO;2-#; Gardner DK, 2000, FERTIL STERIL, V73, P1155, DOI 10.1016/S0015-0282(00)00518-5; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; Huang GY, 2017, FERTIL STERIL, V107, P649, DOI 10.1016/j.fertnstert.2016.11.031; Kawamura K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049328; Kotze D, 2013, FERTIL STERIL, V100, P1303, DOI 10.1016/j.fertnstert.2013.07.1977; Montag M, 2013, REPROD BIOMED ONLINE, V27, P539, DOI 10.1016/j.rbmo.2013.05.013; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; Robertson SA, 2000, J REPROD IMMUNOL, V46, P131, DOI 10.1016/S0165-0378(99)00060-1; Robertson SA, 1999, BIOL REPROD, V60, P251, DOI 10.1095/biolreprod60.2.251; ROBERTSON SA, 1992, BIOL REPROD, V46, P1069, DOI 10.1095/biolreprod46.6.1069; Robertson SA, 2001, BIOL REPROD, V64, P1206, DOI 10.1095/biolreprod64.4.1206; Robertson SA, 2007, CYTOKINE GROWTH F R, V18, P287, DOI 10.1016/j.cytogfr.2007.04.008; Sjoblom C, 1999, HUM REPROD, V14, P3069, DOI 10.1093/humrep/14.12.3069; Thouas GA, 2015, ENDOCR REV, V36, P92, DOI 10.1210/er.2014-1046; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; ZHAO Y, 1994, J CLIN ENDOCR METAB, V79, P662, DOI 10.1210/jc.79.2.662; Zhong HX, 2020, J ASSIST REPROD GEN, V37, P1695, DOI 10.1007/s10815-020-01805-7	31	1	2	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 30	2021	12								679839	10.3389/fimmu.2021.679839	http://dx.doi.org/10.3389/fimmu.2021.679839			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TJ2DU	34276668	Green Published, gold			2022-12-18	WOS:000673299800001
J	Curto, D; Tomatis, F; Gastoldi, S; Galbusera, M; Noris, M; Raimondi, F; Lorini, FL; Falanga, A; Marchetti, M; Remuzzi, G; Ruggenenti, P				Curto, Diego; Tomatis, Federica; Gastoldi, Sara; Galbusera, Miriam; Noris, Marina; Raimondi, Federico; Lorini, Ferdinando Luca; Falanga, Anna; Marchetti, Marina; Remuzzi, Giuseppe; Ruggenenti, Piero			Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis	FRONTIERS IN IMMUNOLOGY			English	Article						convalescent antibodies; COVID-19; double filtration plasmapheresis; rituximab; immunosuppression; coagulation biomarkers; hypercoagulability; case report	PLASMA	Passive antibody therapy has been used to treat outbreaks of viral disease, including the ongoing pandemic of severe respiratory acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) or COVID-19. However, the real benefits of the procedure are unclear. We infused a concentrated solution of neutralizing anti-SARS-CoV-2 antibodies obtained from a convalescent donor with a single session of double filtration plasmapheresis (DFPP) into a 56-year-old woman with long history of unremitting, severe COVID-19. She was unable to establish an adequate antiviral immune response because of previous chemotherapy, including the infusion of the anti-CD20 monoclonal antibody rituximab, administered to treat a diffuse large B-cell lymphoma. The disease promptly recovered despite evidence of no endogenous anti-SARS-CoV-2 antibody production. The observation that passive antibody therapy might prove particularly effective in immunodepressed COVID-19 patients requires evaluation in prospective randomized controlled trial.	[Curto, Diego; Gastoldi, Sara; Galbusera, Miriam; Noris, Marina; Remuzzi, Giuseppe; Ruggenenti, Piero] Ist Ric Farmacol Mario Negri IRCCS, Dept Renal Med, Bergamo, Italy; [Curto, Diego; Gastoldi, Sara; Galbusera, Miriam; Noris, Marina; Remuzzi, Giuseppe; Ruggenenti, Piero] Ist Ric Farmacol Mario Negri IRCCS, Dept Rare Dis & Mol Med, Bergamo, Italy; [Curto, Diego; Tomatis, Federica; Ruggenenti, Piero] Azienda Sociosanitaria Terr ASST Papa Giovanni XX, Unit Nephrol & Dialysis, Bergamo, Italy; [Raimondi, Federico] ASST Papa Giovanni XXIII, Unit Pulm Med, Bergamo, Italy; [Raimondi, Federico] Univ Milan, Dept Hlth Sci, Milan, Italy; [Lorini, Ferdinando Luca] ASST Papa Giovanni XXIII, Intens Care Unit, Bergamo, Italy; [Falanga, Anna; Marchetti, Marina] ASST Papa Giovanni XXIII, Immunohematol & Transfus Med, Bergamo, Italy; [Falanga, Anna] Univ Milano Bicocca, Sch Med, Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; ASST Papa Giovanni XXIII; University of Milan; ASST Papa Giovanni XXIII; ASST Papa Giovanni XXIII; University of Milano-Bicocca	Remuzzi, G (corresponding author), Ist Ric Farmacol Mario Negri IRCCS, Dept Renal Med, Bergamo, Italy.; Remuzzi, G (corresponding author), Ist Ric Farmacol Mario Negri IRCCS, Dept Rare Dis & Mol Med, Bergamo, Italy.	giuseppe.remuzzi@marionegri.it		Raimondi, Federico/0000-0001-9599-6864	Brembo SpA (Curno, Bergamo, Italy) under the initiative "Progetto TrexUno"	Brembo SpA (Curno, Bergamo, Italy) under the initiative "Progetto TrexUno"	Brembo SpA (Curno, Bergamo, Italy) partially covered study costs by a liberal grant under the initiative "Progetto TrexUno."	Agarwal A, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3939; Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9; Freedman M, 2010, TRANSFUS APHER SCI, V43, P179, DOI 10.1016/j.transci.2010.07.004; Galbusera M, 2019, AM J KIDNEY DIS, V74, P56, DOI 10.1053/j.ajkd.2018.11.012; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hung IEN, 2013, CHEST, V144, P464, DOI 10.1378/chest.12-2907; Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139; Mineshima M, 2002, THER APHER, V6, P180, DOI 10.1046/j.1526-0968.2002.00428.x; Pau AK, 2021, ANN INTERN MED, V174, P93, DOI 10.7326/M20-6448; Podesta MA, 2020, NEPHRON, V144, P30, DOI 10.1159/000501858; Rock G, 1996, BRIT J HAEMATOL, V94, P383, DOI 10.1046/j.1365-2141.1996.d01-1800.x; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Simonovich VA, 2021, NEW ENGL J MED, V384, P619, DOI 10.1056/NEJMoa2031304; Van Damme KFA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.596761; van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812; von Heymann C, 2009, TRANSFUSION, V49, P913, DOI 10.1111/j.1537-2995.2008.02063.x; Youssef I., 2019, ASIAN HEMATOL RES J, V2, P1; Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359	20	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 30	2021	12								711915	10.3389/fimmu.2021.711915	http://dx.doi.org/10.3389/fimmu.2021.711915			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TJ0PX	34276706	gold, Green Published			2022-12-18	WOS:000673196100001
J	Matar, AJ; Crepeau, RL; Mundinger, GS; Cetrulo, CL; Torabi, R				Matar, Abraham J.; Crepeau, Rebecca L.; Mundinger, Gerhard S.; Cetrulo, Curtis L., Jr.; Torabi, Radbeh			Large Animal Models of Vascularized Composite Allotransplantation: A Review of Immune Strategies to Improve Allograft Outcomes	FRONTIERS IN IMMUNOLOGY			English	Review						vascularized composite allograft; large animal model; transplantation tolerance induction; cellular therapies; ex vivo perfusion	MESENCHYMAL STEM-CELLS; NONHUMAN PRIMATE MODEL; LONG-TERM OUTCOMES; CHRONIC REJECTION; TISSUE ALLOTRANSPLANTATION; HEMATOPOIETIC CHIMERISM; COSTIMULATION BLOCKADE; MHC BARRIERS; T-CELLS; TOLERANCE	Over the past twenty years, significant technical strides have been made in the area of vascularized composite tissue allotransplantation (VCA). As in solid organ transplantation, the allogeneic immune response remains a significant barrier to long-term VCA survival and function. Strategies to overcome acute and chronic rejection, minimize immunosuppression and prolong VCA survival have important clinical implications. Historically, large animals have provided a valuable model for testing the clinical translatability of immune modulating approaches in transplantation, including tolerance induction, co-stimulation blockade, cellular therapies, and ex vivo perfusion. Recently, significant advancements have been made in these arenas utilizing large animal VCA models. In this comprehensive review, we highlight recent immune strategies undertaken to improve VCA outcomes with a focus on relevant preclinical large animal models.	[Matar, Abraham J.; Crepeau, Rebecca L.] Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA; [Mundinger, Gerhard S.; Torabi, Radbeh] Louisiana State Univ, Hlth Sci Ctr, Sch Med, Dept Surg,Div Plast & Reconstruct Surg, New Orleans, LA 70112 USA; [Cetrulo, Curtis L., Jr.] Massachusetts Gen Hosp, Dept Surg, Div Plast Surg, Boston, MA 02114 USA; [Cetrulo, Curtis L., Jr.] Massachusetts Gen Hosp, Ctr Transplantat Sci, Boston, MA 02114 USA; [Cetrulo, Curtis L., Jr.] Shriners Hosp Children, Dept Plast & Reconstruct Surg, Boston, MA USA	Emory University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Torabi, R (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Sch Med, Dept Surg,Div Plast & Reconstruct Surg, New Orleans, LA 70112 USA.	rtorabi516@yahoo.com						Atia A, 2020, TRANSPL INT, V33, P1294, DOI 10.1111/tri.13612; Barth RN, 2011, AM J TRANSPLANT, V11, P1407, DOI 10.1111/j.1600-6143.2011.03551.x; Barth RN, 2009, TRANSPLANTATION, V88, P1242, DOI 10.1097/TP.0b013e3181c1b6d0; Barth RN, 2009, PLAST RECONSTR SURG, V123, P493, DOI 10.1097/PRS.0b013e3181954edd; Bell GM, 2017, ANN RHEUM DIS, V76, P227, DOI 10.1136/annrheumdis-2015-208456; Berman DM, 2010, DIABETES, V59, P2558, DOI 10.2337/db10-0136; Brazio PS, 2015, AM J TRANSPLANT, V15, P2011, DOI 10.1111/ajt.13268; Cendales LC, 2005, TRANSPLANTATION, V80, P1447, DOI 10.1097/01.tp.0000183292.57349.27; Cetrulo CL, 2018, ANN SURG, V267, P983, DOI 10.1097/SLA.0000000000002241; Chang J, 2016, TRANSPLANTATION, V100, pE120, DOI 10.1097/TP.0000000000001496; Detelich D, 2018, CURR OPIN ORGAN TRAN, V23, P151, DOI 10.1097/MOT.0000000000000500; Duran-Struuck R, 2017, TRANSPLANTATION, V101, P274, DOI 10.1097/TP.0000000000001559; Dzhonova DV, 2018, TRANSPLANTATION, V102, P1684, DOI 10.1097/TP.0000000000002283; Eggenhofer E, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00297; Eggenhofer E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00148; Elgendy TKD., 2017, AM J TRANSPL, V17; Ezzelarab MB, 2017, AM J TRANSPLANT, V17, P1476, DOI 10.1111/ajt.14182; Ezzelarab MB, 2013, AM J TRANSPLANT, V13, P1989, DOI 10.1111/ajt.12310; Fahradyan V, 2020, ARTIF ORGANS, V44, P846, DOI 10.1111/aor.13678; Franquesa M, 2013, TRANSPLANTATION, V96, P234, DOI 10.1097/TP.0b013e318298f9fa; Freitas AM, 2015, AM J TRANSPLANT, V15, P2240, DOI 10.1111/ajt.13379; Fries CA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210914; Fries CA, 2019, ANN PLAS SURG, V82, P452, DOI 10.1097/SAP.0000000000001693; Gajanayake T, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008778; Ge W, 2010, TRANSPLANTATION, V90, P1312, DOI 10.1097/TP.0b013e3181fed001; Giannoukakis N, 2011, DIABETES CARE, V34, P2026, DOI 10.2337/dc11-0472; Giwa S, 2017, NAT BIOTECHNOL, V35, P530, DOI 10.1038/nbt.3889; Hettiaratchy S, 2004, TRANSPLANTATION, V77, P514, DOI 10.1097/01.TP.0000113806.52063.42; Kanitakis J, 2016, TRANSPLANTATION, V100, P2053, DOI 10.1097/TP.0000000000001248; Kaufman CL, 2013, CURR OPIN ORGAN TRAN, V18, P652, DOI 10.1097/MOT.0000000000000025; Kawai T, 2004, AM J TRANSPLANT, V4, P1391, DOI 10.1111/j.1600-6143.2004.00523.x; Kawai T, 2002, TRANSPLANTATION, V73, P1757, DOI 10.1097/00007890-200206150-00011; KAWAI T, 1995, TRANSPLANTATION, V59, P256, DOI 10.1097/00007890-199501270-00018; Kawai T, 2008, NEW ENGL J MED, V358, P353, DOI 10.1056/NEJMoa071074; Krezdorn N, 2018, J SURG RES, V232, P137, DOI 10.1016/j.jss.2018.05.067; Krishnan G, 2017, LARYNGOSCOPE, V127, P1861, DOI 10.1002/lary.26503; Kueckelhaus M, 2016, TRANSPL INT, V29, P655, DOI 10.1111/tri.12652; Kuo YR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035459; Kuo YR, 2011, PLAST RECONSTR SURG, V127, P569, DOI 10.1097/PRS.0b013e318200a92c; Kuo YR, 2009, TRANSPLANTATION, V87, P1769, DOI 10.1097/TP.0b013e3181a664f1; Larsen CP, 2005, AM J TRANSPLANT, V5, P443, DOI 10.1111/j.1600-6143.2005.00749.x; Lellouch AG, 2020, PLAST RECONSTR SURG, V145, p757E, DOI 10.1097/PRS.0000000000006676; Leonard DA, 2014, AM J TRANSPLANT, V14, P343, DOI 10.1111/ajt.12560; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Lin CH, 2016, AM J TRANSPLANT, V16, P2030, DOI 10.1111/ajt.13694; Lin CH, 2021, CELL MOL IMMUNOL, V18, P363, DOI 10.1038/s41423-019-0325-y; Mastroianni M, 2018, J BURN CARE RES, V39, P363, DOI 10.1097/BCR.0000000000000597; Matar AJ, 2020, BIOL BLOOD MARROW TR, V26, pS259; Mathes DW, 2014, TRANSPLANTATION, V98, P131, DOI 10.1097/TP.0000000000000204; Mathes DW, 2011, TRANSPLANTATION, V92, P1301, DOI 10.1097/TP.0b013e318237d6d4; Morelli AE, 2014, CURR OPIN ORGAN TRAN, V19, P348, DOI 10.1097/MOT.0000000000000097; Morelon E, 2018, CURR OPIN ORGAN TRAN, V23, P582, DOI 10.1097/MOT.0000000000000571; Mundinger GS, 2014, CURR OPIN ORGAN TRAN, V19, P309, DOI 10.1097/MOT.0000000000000073; Mundinger GS, 2013, TRANSPLANTATION, V95, P1204, DOI 10.1097/TP.0b013e31828d1528; Mundinger GS, 2011, PLAST RECONSTR SURG, V128, P1193, DOI 10.1097/PRS.0b013e318230c5d0; Oh BC, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.128560; Ozer K, 2016, J HAND SURG-AM, V41, P3, DOI 10.1016/j.jhsa.2015.11.003; Ozer K, 2015, TRANSPLANTATION, V99, P2095, DOI 10.1097/TP.0000000000000756; Podesta MA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01287; Pomahac B, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a015651; Pomahac B, 2012, NEW ENGL J MED, V366, P715, DOI 10.1056/NEJMoa1111432; Pullen LC, 2020, AM J TRANSPLANT, V20, P2967, DOI 10.1111/ajt.16339; Ravindra KV, 2008, SURGERY, V144, P638, DOI 10.1016/j.surg.2008.06.025; Schneeberger S, 2013, ANN SURG, V257, P345, DOI 10.1097/SLA.0b013e31826d90bb; Schnider JT, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/495212; Shanmugarajah K, 2017, AM J TRANSPLANT, V17, P1729, DOI 10.1111/ajt.14189; Silverman RP, 2008, ANN PLAS SURG, V60, P209, DOI 10.1097/SAP.0b013e318061b792; Smith RN, 2012, SEMIN IMMUNOL, V24, P115, DOI 10.1016/j.smim.2011.09.002; Tasigiorgos S, 2019, NEW ENGL J MED, V380, P2579, DOI 10.1056/NEJMc1810468; Tonsho M, 2015, AM J TRANSPLANT, V15, P2231, DOI 10.1111/ajt.13274; Villamaria CY, 2014, ANN PLAS SURG, V72, P594, DOI 10.1097/SAP.0000000000000021; Vincenti F, 2016, NEW ENGL J MED, V374, P333, DOI 10.1056/NEJMoa1506027; Wachtman GS, 2011, TRANSPL P, V43, P3541, DOI 10.1016/j.transproceed.2011.10.010; Weiss ARR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01191; Woodall JD., 2014, CURR TRANSPLANT REP, V1, P190, DOI [10.1007/s40472-014-0026-5, DOI 10.1007/S40472-014-0026-5]; Yamada Y, 2012, AM J TRANSPLANT, V12, P330, DOI 10.1111/j.1600-6143.2011.03795.x; Zitsman JS, 2016, COMPARATIVE MED, V66, P308	77	1	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 30	2021	12								664577	10.3389/fimmu.2021.664577	http://dx.doi.org/10.3389/fimmu.2021.664577			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TI9MX	34276656	Green Published, gold			2022-12-18	WOS:000673120300001
J	Xu, YY; Weideman, AM; Abad-Fernandez, M; Mollan, KR; Kallon, S; Samir, S; Warren, JA; Clutton, G; Roan, N; Adimora, AA; Archin, N; Kuruc, J; Gay, C; Hudgens, MG; Goonetilleke, N				Xu, Yinyan; Weideman, Ann Marie; Abad-Fernandez, Maria; Mollan, Katie R.; Kallon, Sallay; Samir, Shahryar; Warren, Joanna A.; Clutton, Genevieve; Roan, Nadia; Adimora, Adaora A.; Archin, Nancie; Kuruc, JoAnn; Gay, Cindy; Hudgens, Michael G.; Goonetilleke, Nilu			Reliable Estimation of CD8 T Cell Inhibition of In Vitro HIV-1 Replication	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; VIA; p24; JRCSF; ROC; CD8; CD4; T-cell	IMMUNODEFICIENCY-VIRUS TYPE-1; CAPACITY; ASSAY; QUANTIFICATION; LYMPHOCYTES; SUPPRESSION	The HIV-1 viral inhibition assay (VIA) measures CD8 T cell-mediated inhibition of HIV replication in CD4 T cells and is increasingly used for clinical testing of HIV vaccines and immunotherapies. The VIA has multiple sources of variability arising from in vitro HIV infection and co-culture of two T cell populations. Here, we describe multiple modifications to a 7-day VIA protocol, the most impactful being the introduction of independent replicate cultures for both HIV infected-CD4 (HIV-CD4) and HIV-CD4:CD8 T cell cultures. Virus inhibition was quantified using a ratio of weighted averages of p24+ cells in replicate cultures and the corresponding 95% confidence interval. An Excel template is provided to facilitate calculations. Virus inhibition was higher in people living with HIV suppressed on antiretroviral therapy (n=14, mean: 40.0%, median: 43.8%, range: 8.2 to 73.3%; p < 0.0001, two-tailed, exact Mann-Whitney test) compared to HIV-seronegative donors (n = 21, mean: -13.7%, median: -14.4%, range: -49.9 to 20.9%) and was stable over time (n = 6, mean %COV 9.4%, range 0.9 to 17.3%). Cross-sectional data were used to define 8% inhibition as the threshold to confidently detect specific CD8 T cell activity and determine the minimum number of culture replicates and p24+ cells needed to have 90% statistical power to detect this threshold. Last, we note that, in HIV seronegative donors, the addition of CD8 T cells to HIV infected CD4 T cells consistently increased HIV replication, though the level of increase varied markedly between donors. This co-culture effect may contribute to the weak correlations observed between CD8 T cell VIA and other measures of HIV-specific CD8 T cell function.	[Xu, Yinyan; Abad-Fernandez, Maria; Kallon, Sallay; Samir, Shahryar; Warren, Joanna A.; Clutton, Genevieve; Goonetilleke, Nilu] Univ N Carolina, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27599 USA; [Weideman, Ann Marie; Hudgens, Michael G.] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA; [Weideman, Ann Marie; Mollan, Katie R.; Adimora, Adaora A.; Hudgens, Michael G.] Univ N Carolina, Ctr AIDS Res, Sch Med, Chapel Hill, NC USA; [Mollan, Katie R.; Adimora, Adaora A.] Univ N Carolina, Gangs Sch Gbbal Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA; [Adimora, Adaora A.; Archin, Nancie; Kuruc, JoAnn; Gay, Cindy; Goonetilleke, Nilu] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA; [Adimora, Adaora A.; Archin, Nancie; Kuruc, JoAnn; Gay, Cindy; Goonetilleke, Nilu] Univ N Carolina, UNC HIV Cure Ctr, Sch Med, Chapel Hill, NC 27599 USA; [Roan, Nadia] Univ Calif San Francisco, Dept Urol, San Francisco, CA USA; [Roan, Nadia] Gladstone Inst Virol & Immunol, San Francisco, CA USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes	Goonetilleke, N (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27599 USA.; Goonetilleke, N (corresponding author), Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA.; Goonetilleke, N (corresponding author), Univ N Carolina, UNC HIV Cure Ctr, Sch Med, Chapel Hill, NC 27599 USA.	nilu_goonetilleke@med.unc.edu	Laboratory Core, HIV STD/AGD-7085-2022	Clutton, Genevieve/0000-0001-5853-9509	National Institute of Allergy and Infectious Disease [U01 AI131310-01]; University of North Carolina at Chapel Hill Center for AIDS Research [P30 AI050410]	National Institute of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); University of North Carolina at Chapel Hill Center for AIDS Research	This work was supported by the National Institute of Allergy and Infectious Disease, U01 AI131310-01 (N.G) and University of North Carolina at Chapel Hill Center for AIDS Research (P30 AI050410).	Archin NM, 2017, J CLIN INVEST, V127, P3126, DOI [10.1172/JCI92684, 10.1172/jci92684]; Baalwa J, 2013, VIROLOGY, V436, P33, DOI 10.1016/j.virol.2012.10.009; Clutton G, 2016, SCI REP-UK, V6, DOI 10.1038/srep30749; Freel SA, 2012, J VIROL, V86, P6835, DOI 10.1128/JVI.00437-12; Freel SA, 2011, IMMUNOL RES, V49, P135, DOI 10.1007/s12026-010-8177-7; Goonetilleke N, 2006, J VIROL, V80, P4717, DOI 10.1128/JVI.80.10.4717-4728.2006; Greene W, 2012, ECONOMETRIC ANAL; Hancock G, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004658; He X, 2016, J IMMUNOL METHODS, V434, P53, DOI 10.1016/j.jim.2016.04.007; Julg B, 2010, J VIROL, V84, P5540, DOI 10.1128/JVI.02031-09; Koup R A, 2001, Curr Protoc Immunol, VChapter 12, DOI 10.1002/0471142735.im1202s05; Liu MKP, 2013, J CLIN INVEST, V123, P380, DOI 10.1172/JCI65330; Moses AV, 1996, J VIROL, V70, P3401, DOI 10.1128/JVI.70.6.3401-3406.1996; Mothe B, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-208; Naarding MA, 2014, J IMMUNOL METHODS, V409, P161, DOI 10.1016/j.jim.2013.11.021; Ochsenbauer C, 2012, J VIROL, V86, P2715, DOI 10.1128/JVI.06157-11; Rothman K., 2008, MODERN EPIDEMIOLOGY, V14, P249; Saez-Cirion A, 2010, NAT PROTOC, V5, P1033, DOI 10.1038/nprot.2010.73; Saez-Cirion A, 2009, J IMMUNOL, V182, P7828, DOI 10.4049/jimmunol.0803928; Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022; Slichter CK, 2014, J IMMUNOL METHODS, V404, P71, DOI 10.1016/j.jim.2013.12.006; Spentzou A, 2010, J INFECT DIS, V201, P720, DOI 10.1086/650492; Sung JA, 2015, J INFECT DIS, V212, P258, DOI 10.1093/infdis/jiv022; Warren JA, 2020, ELIFE, V9, DOI 10.7554/eLife.57246; Xu YY, 2019, MOL THER-METH CLIN D, V15, P9, DOI 10.1016/j.omtm.2019.07.008; Yang HB, 2013, J IMMUNOL METHODS, V391, P174, DOI 10.1016/j.jim.2013.03.001; Yang HB, 2012, J INFECT DIS, V206, P552, DOI 10.1093/infdis/jis379; Yang OO, 1997, P NATL ACAD SCI USA, V94, P11478, DOI 10.1073/pnas.94.21.11478	28	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 30	2021	12								666991	10.3389/fimmu.2021.666991	http://dx.doi.org/10.3389/fimmu.2021.666991			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TJ1CS	34276657	Green Published, gold			2022-12-18	WOS:000673229400001
J	Yang, B; Ji, RL; Li, XS; Fang, W; Chen, QC; Chen, Q; Xu, W; Mai, KS; Ai, QH				Yang, Bo; Ji, Renlei; Li, Xueshan; Fang, Wei; Chen, Qiuchi; Chen, Qiang; Xu, Wei; Mai, Kangsen; Ai, Qinghui			Activation of Autophagy Relieves Linoleic Acid-Induced Inflammation in Large Yellow Croaker (Larimichthys crocea)	FRONTIERS IN IMMUNOLOGY			English	Article						autophagy; inflammation; linoleic acid; large yellow croaker; in vivo; in vitro	GROWTH; REPLICATION; RESISTANCE; PROTECTS	High levels of soybean oil (SO) in fish diets enriched with linoleic acid (LA, 18:2n-6) could induce strong inflammation. However, the molecular mechanism underlying LA-induced inflammation in the liver of large yellow croaker (Larimichthys crocea) has not been elucidated. Based on previous research, autophagy has been considered a new pathway to relieve inflammation. Therefore, the present study was performed to investigate the role of autophagy in regulating LA-induced inflammation in the liver of large yellow croaker in vivo and in vitro. The results of the present study showed that activation of autophagy in liver or hepatocytes could significantly reduce the gene expression of proinflammatory factors, such as tumor necrosis factor alpha (TNF alpha) and interleukin 1 beta (IL1 beta). The results of the present study also showed that inhibition of autophagy could upregulate the gene expression of proinflammatory factors and downregulate the gene expression of anti-inflammatory factors in vivo and in vitro. Furthermore, autophagy could alleviate LA-induced inflammatory cytokine gene expression in vivo and in vitro, while inhibition of autophagy obtained the opposite results. In conclusion, our study shows that autophagy could regulate inflammation and alleviate LA-induced inflammation in the liver of large yellow croaker in vivo and in vitro for the first time, which may offer considerable benefits to the aquaculture industry and human health.	[Yang, Bo; Ji, Renlei; Li, Xueshan; Fang, Wei; Chen, Qiuchi; Chen, Qiang; Xu, Wei; Mai, Kangsen; Ai, Qinghui] Ocean Univ China, Key Lab Aquaculture Nutr & Feed, Minist Agr & Rural Affairs, Qingdao, Peoples R China; [Yang, Bo; Ji, Renlei; Li, Xueshan; Fang, Wei; Chen, Qiuchi; Chen, Qiang; Xu, Wei; Mai, Kangsen; Ai, Qinghui] Qingdao Natl Lab Marine Sci & Technol, Lab Marine Fisheries Sci & Food Prod Proc, Qingdao, Peoples R China	Ministry of Agriculture & Rural Affairs; Ocean University of China; Qingdao National Laboratory for Marine Science & Technology	Ai, QH (corresponding author), Ocean Univ China, Key Lab Aquaculture Nutr & Feed, Minist Agr & Rural Affairs, Qingdao, Peoples R China.; Ai, QH (corresponding author), Qingdao Natl Lab Marine Sci & Technol, Lab Marine Fisheries Sci & Food Prod Proc, Qingdao, Peoples R China.	qhai@ouc.edu.cn	Ji, renlei/GRJ-5811-2022		National Science Fund for Distinguished Young Scholars of China [31525024]; Key Program of National Natural Science Foundation of China [31830103]; Agriculture Research System of China [CARS-47-11]; Scientific and Technological Innovation of Blue Granary [2018YFD0900402]; Ten-thousand Talents Program [2018-29]	National Science Fund for Distinguished Young Scholars of China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); Key Program of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Agriculture Research System of China; Scientific and Technological Innovation of Blue Granary; Ten-thousand Talents Program	This work was supported by the National Science Fund for Distinguished Young Scholars of China (grant number: 31525024), the Key Program of National Natural Science Foundation of China (grant number: 31830103), the Agriculture Research System of China (grant number: CARS-47-11), the Scientific and Technological Innovation of Blue Granary (grant no. 2018YFD0900402) and the Ten-thousand Talents Program (grant no. 2018-29).	Cassano S, 2014, METABOLISM, V63, P1272, DOI 10.1016/j.metabol.2014.06.010; Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012; Cheluvappa R, 2014, INFLAMM BOWEL DIS, V20, P847, DOI 10.1097/MIB.0000000000000034; Chen SS, 2015, CANCER BIOL THER, V16, P770, DOI 10.1080/15384047.2015.1026477; Cotillard A, 2014, J CLIN ENDOCR METAB, V99, pE1466, DOI 10.1210/jc.2014-1074; Ding XW, 2016, ONCOTARGET, V7, P20080, DOI 10.18632/oncotarget.7914; Du JL, 2020, J NUTR, V150, P2469, DOI 10.1093/jn/nxaa185; Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006; Inoue T, 2017, BBA-MOL CELL BIOL L, V1862, P552, DOI 10.1016/j.bbalip.2017.02.010; Kuballa P, 2012, ANNU REV IMMUNOL, V30, P611, DOI 10.1146/annurev-immunol-020711-074948; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Leaver MJ, 2008, REV FISH SCI, V16, P73, DOI 10.1080/10641260802325278; Levine TP, 2011, J CELL BIOL, V195, P927, DOI 10.1083/jcb.201111074; Li C, 2017, FISH SHELLFISH IMMUN, V60, P25, DOI 10.1016/j.fsi.2016.11.037; Li Jing-Qi, 2018, Acta Hydrobiologica Sinica, V42, P232, DOI 10.7541/2018.029; Meng FY, 2015, J FUNCT FOODS, V17, P172, DOI 10.1016/j.jff.2015.05.029; Wang XX, 2015, AQUAC RES, V46, P272, DOI 10.1111/are.12176; Wang Y, 2016, FISH SHELLFISH IMMUN, V55, P415, DOI 10.1016/j.fsi.2016.06.019; White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008; Xu AH, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0836-7; Yang B, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02750-0; Yang BW, 2020, ADV MATER, V32, DOI 10.1002/adma.201907152; Zheng XC, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0206-3; Zuo RT, 2015, LIPIDS, V50, P149, DOI 10.1007/s11745-014-3970-z; Zuo RT, 2012, AQUACULTURE, V334, P101, DOI 10.1016/j.aquaculture.2011.12.045	25	1	1	13	34	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 30	2021	12								649385	10.3389/fimmu.2021.649385	http://dx.doi.org/10.3389/fimmu.2021.649385			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TJ3CF	34276647	Green Published, gold			2022-12-18	WOS:000673363300001
J	Mentis, AFA; Chrousos, GP				Mentis, Alexios-Fotios A.; Chrousos, George P.			Tubarial Salivary Glands in Sjogren Syndrome: Are They Just a Potential Missing Link With No Broader Implications?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						Sjogren's syndrome; autoimmunity; salivary glands; discovery; tubarial glands	CLASSIFICATION CRITERIA; RISK		[Mentis, Alexios-Fotios A.; Chrousos, George P.] Natl & Kapodistrian Univ Athens, Univ Res Inst Maternal & Child Hlth & Precis Med, Med Sch, Athens, Greece; [Mentis, Alexios-Fotios A.; Chrousos, George P.] Natl & Kapodistrian Univ Athens, UNESCO Chair Adolescent Hlth Care, Athens, Greece; [Chrousos, George P.] US Natl Acad Med, Washington, DC 20001 USA	National & Kapodistrian University of Athens; National & Kapodistrian University of Athens; National Academies of Sciences, Engineering & Medicine	Chrousos, GP (corresponding author), Natl & Kapodistrian Univ Athens, Univ Res Inst Maternal & Child Hlth & Precis Med, Med Sch, Athens, Greece.; Chrousos, GP (corresponding author), Natl & Kapodistrian Univ Athens, UNESCO Chair Adolescent Hlth Care, Athens, Greece.; Chrousos, GP (corresponding author), US Natl Acad Med, Washington, DC 20001 USA.	chrousos@gmail.com	Mentis, Alexios-Fotios/AAT-5274-2021	Mentis, Alexios-Fotios/0000-0002-1480-390X				Benias PC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23062-6; Berthaume MA, 2019, J ANAT, V235, P67, DOI 10.1111/joa.12994; Bikker FJ, 2021, RADIOTHER ONCOL, V154, P318, DOI 10.1016/j.radonc.2020.12.005; Coffey JC, 2016, LANCET GASTROENTEROL, V1, P238, DOI 10.1016/S2468-1253(16)30026-7; Danchev V, 2019, ELIFE, V8, DOI 10.7554/eLife.43094; Diogo R, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.180349; Ellsworth SG, 2021, RADIOTHER ONCOL, V154, P312, DOI 10.1016/j.radonc.2020.12.002; Felten R, 2021, ANN RHEUM DIS, DOI [10.1136/annrheumdis-2021-219882, 10.1136/annrheumdis-2020-218467]; Fisher BA, 2020, LANCET RHEUMATOL, V2, pE142, DOI 10.1016/S2665-9913(19)30135-3; Fragkioudaki S, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003766; Franceschini F, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0837-1; Goules AV, 2014, J AUTOIMMUN, V48-49, P42, DOI 10.1016/j.jaut.2014.01.013; Gruneboom A, 2019, NAT METAB, V1, P236, DOI 10.1038/s42255-018-0016-5; Ioannidis JPA, 2002, ARTHRITIS RHEUM, V46, P741, DOI 10.1002/art.10221; Kassan SS, 2004, ARCH INTERN MED, V164, P1275, DOI 10.1001/archinte.164.12.1275; Kwon D., 2020, SCI; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Mariette X, 2018, NEW ENGL J MED, V378, P931, DOI 10.1056/NEJMcp1702514; Mavragani CP, 2014, CAN MED ASSOC J, V186, pE579, DOI 10.1503/cmaj.122037; Mavragani CP, 2013, CURR OPIN RHEUMATOL, V25, P623, DOI 10.1097/BOR.0b013e328363eaa5; Mentis AFA, 2021, MOL PSYCHIATR, V26, P1075, DOI 10.1038/s41380-020-0731-7; Moutsopoulos HM, 2014, J AUTOIMMUN, V51, P1, DOI 10.1016/j.jaut.2014.01.001; Mudry A, 2021, RADIOTHER ONCOL, V154, P314, DOI 10.1016/j.radonc.2020.12.003; Nulent TJWK, 2018, OR SURG OR MED OR PA, V125, P478, DOI 10.1016/j.oooo.2018.01.011; Sandberg R, 2014, NAT METHODS, V11, P22, DOI 10.1038/nmeth.2764; Valstar MH, 2021, RADIOTHER ONCOL, V154, P292, DOI 10.1016/j.radonc.2020.09.034; VITALI C, 1993, ARTHRITIS RHEUM, V36, P340, DOI 10.1002/art.1780360309; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; Zintzaras E, 2005, ARCH INTERN MED, V165, P2337, DOI 10.1001/archinte.165.20.2337	29	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 29	2021	12								684490	10.3389/fimmu.2021.684490	http://dx.doi.org/10.3389/fimmu.2021.684490			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TI0WQ	34267754	gold, Green Published			2022-12-18	WOS:000672504400001
J	Zhang, WR; Tang, ZY; Shi, YJ; Ji, L; Chen, XY; Chen, YR; Wang, XH; Wang, M; Wang, W; Li, D				Zhang, Wenran; Tang, Zhaoyang; Shi, Yanjun; Ji, Long; Chen, Xueyu; Chen, Yanru; Wang, Xiaohui; Wang, Meng; Wang, Wei; Li, Dong			Association Between Gamma-Glutamyl Transferase, Total Bilirubin and Systemic Lupus Erythematosus in Chinese Women	FRONTIERS IN IMMUNOLOGY			English	Article						systemic lupus erythematosus; total bilirubin; gamma-glutamyl transferase; female population; diagnostic marker; case-control study	CARDIOVASCULAR-DISEASE; COMPLEMENT; GLUTAMYLTRANSFERASE; POPULATION; INCREASE; ENZYMES; RISK	Background Systemic lupus erythematosus (SLE) affects many organs and systems of the human organism, at present, its specific pathogenesis is not completely clear, but inflammation is considered to be an important factor involved in the pathogenesis and progression of SLE. Gamma-glutamyl transpeptidase (GGT) and total bilirubin (TBIL) have different effects on inflammation: GGT has pro-inflammatory effects, on the contrary, TBIL has anti-inflammatory effects. Study has found that GGT and TBIL play opposite roles in metabolic diseases. However, the roles of them in SLE are unknown. Meanwhile, the relationship between GGT and SLE also remains unexplored. Method We recruited 341 SLE patients and 332 healthy individuals in Liaocheng People's Hospital from August 2018 to May 2019. We diagnosed SLE using 2019 revised American College of Rheumatology (ACR) SLE criteria, and modeled the study outcomes using logistic regression to explore the respective relationship between GGT, TBIL and SLE. We also analyzed the interaction of GGT and TBIL in the progression of SLE. Results We found that the levels of CRP, IL-6 and TNF-alpha in the aggravated group were significantly higher than those in the unaggravated group, the levels of C3 and C4 in the aggravated group were significantly lower than those in the unaggravated group. According to Spearman correlation analysis, GGT is proportional to CRP (r(s)=0.417) and IL-6 (r(s)=0.412), inversely proportional to C3 (r(s)=-0.177) and C4 (r(s)=0.-132). TBIL was inversely proportional to CRP (r(s)=-0.328) and TNF(r(s)=-0.360), and positively proportional to C3 (r(s)=0.174) and C4 (r(s)=0.172). In the fully adjusted model, compared to the lowest quartile, the highest quartile of GGT exhibited a positive association with the risk of SLE aggravation (OR=2.99, 95% CI: 1.42-6.31, P<0.001). At the same time, compared to the highest quartile, the quartile lowest of TBIL exhibited a positive association with the risk of SLE aggravation (OR=2.66, 95% CI: 1.27-5.59, P<0.001) in the fully adjusted model. Through interaction analysis, we found that women with high GGT levels had an increased risk of SLE aggravation when they had a low level of TBIL (OR=3.68, 95% CI: 1.51-9.01, for women with Q1 TBIL and Q4 GGT compared to women with Q2-Q4 TBIL and Q1-Q3 GGT, P for interaction <0.001), the combined AUC value (AUC(COMBINED)=0.711) of high GGT level and TBIL were higher than their respective values (AUC(GGT)=0.612, AUC(TBIL)=0.614). Conclusion We found that the effects of GGT and TBIL in the progression of SLE are opposite. High GGT level might be a risk factor for SLE aggravation, as GGT levels increased, so did the risk of SLE aggravation. At the same time, we found that low TBIL level might be a risk factor for SLE aggravation. Moreover, high GGT level and low TBIL level had a subadditive effect on the increased risk of SLE aggravation.	[Zhang, Wenran; Tang, Zhaoyang; Ji, Long; Chen, Xueyu; Chen, Yanru; Wang, Xiaohui; Wang, Meng; Wang, Wei; Li, Dong] Shandong First Med Univ & Shandong Acad Med Sci, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Tai An, Shandong, Peoples R China; [Shi, Yanjun] Liaocheng Peoples Hosp, Dept Rheumatol & Immunol, Liaocheng, Shandong, Peoples R China; [Li, Dong] Shandong First Med Univ, Affiliated Hosp 2, Clin Res Ctr, Tai An, Shandong, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences	Wang, W; Li, D (corresponding author), Shandong First Med Univ & Shandong Acad Med Sci, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Tai An, Shandong, Peoples R China.; Li, D (corresponding author), Shandong First Med Univ, Affiliated Hosp 2, Clin Res Ctr, Tai An, Shandong, Peoples R China.	weiwang@ecu.edu.un; tsmcdongli@163.com			National Natural Science Foundation of China [81773527]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (81773527).	Andre P, 2006, DIABETOLOGIA, V49, P2599, DOI 10.1007/s00125-006-0418-x; Aringer M, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2019.102374; Aringer M, 2019, ARTHRITIS RHEUMATOL, V71, P1400, DOI [10.1136/annrheumdis-2018-214819, 10.1002/art.40930]; Basiglio CL, 2010, CLIN SCI, V118, P99, DOI 10.1042/CS20080540; Biljak VR, 2013, COLLEGIUM ANTROPOL, V37, P221; Bjork M, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0621-3; Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200; Chung HY, 2009, AGEING RES REV, V8, P18, DOI 10.1016/j.arr.2008.07.002; Danchenko N, 2006, LUPUS, V15, P308, DOI 10.1191/0961203306lu2305xx; De la Cruz-Mosso U, 2018, CELL IMMUNOL, V324, P42, DOI 10.1016/j.cellimm.2017.12.010; Ding GY, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.010804; Emdin M, 2005, CIRCULATION, V112, P2078, DOI 10.1161/CIRCULATIONAHA.105.571919; Gazzin S, 2016, TRENDS MOL MED, V22, P758, DOI 10.1016/j.molmed.2016.07.004; Giral P, 2010, ATHEROSCLEROSIS, V210, P607, DOI 10.1016/j.atherosclerosis.2009.12.026; Gonzalez LA, 2014, RHEUM DIS CLIN N AM, V40, P433, DOI 10.1016/j.rdc.2014.04.001; Heijke R, 2020, LUPUS, V29, P625, DOI 10.1177/0961203320912338; Horak P, 2006, CLIN RHEUMATOL, V25, P532, DOI 10.1007/s10067-005-0110-4; Ilzecka J, 2003, CLIN NEUROL NEUROSUR, V105, P237, DOI 10.1016/S0303-8467(03)00031-3; Jeon J, 2020, ATHEROSCLEROSIS, V292, P152, DOI 10.1016/j.atherosclerosis.2019.11.004; Kamitaki N, 2020, NATURE, V582, P577, DOI 10.1038/s41586-020-2277-x; KRISTENSON H, 1985, ALCOHOL, V2, P545, DOI 10.1016/0741-8329(85)90132-6; Kunutsor SK, 2016, LIVER INT, V36, P1723, DOI 10.1111/liv.13221; Kunutsor SK, 2015, ATHEROSCLEROSIS, V238, P356, DOI 10.1016/j.atherosclerosis.2014.12.045; Kunutsor SK, 2014, ATHEROSCLEROSIS, V236, P7, DOI 10.1016/j.atherosclerosis.2014.06.006; Macejova Z, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17041315; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257; Mortaz E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02171; Petelin A, 2020, ACTA CLIN CROAT, V59, P19, DOI 10.20471/acc.2020.59.01.03; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Shaikh MF, 2017, CLIN MED, V17, P78, DOI 10.7861/clinmedicine.17-1-78; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Stojakovic T, 2010, ATHEROSCLEROSIS, V208, P564, DOI 10.1016/j.atherosclerosis.2009.07.026; West EE, 2020, IMMUNOL REV, V295, P68, DOI 10.1111/imr.12852; Xiao Hui-jie, 2013, Beijing Da Xue Xue Bao Yi Xue Ban, V45, P323; Yang ZX, 2012, RHEUMATOL INT, V32, P2423, DOI 10.1007/s00296-011-1977-9; ZARIDA H, 1994, EXP TOXICOL PATHOL, V46, P31, DOI 10.1016/S0940-2993(11)80010-2; Zucker SD, 2004, HEPATOLOGY, V40, P827, DOI 10.1002/hep.20407	37	1	1	3	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 29	2021	12								682400	10.3389/fimmu.2021.682400	http://dx.doi.org/10.3389/fimmu.2021.682400			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TI6TS	34276670	Green Published, gold			2022-12-18	WOS:000672935200001
J	Vincent, KL; Frost, PA; Motamedi, M; Dick, EJ; Wei, JN; Yang, JP; White, R; Gauduin, MC				Vincent, Kathleen L.; Frost, Patrice A.; Motamedi, Massoud; Dick, Edward J.; Wei, Jingna; Yang, Jinping; White, Robert; Gauduin, Marie-Claire			High-Resolution Quantitative Mapping of Macaque Cervicovaginal Epithelial Thickness: Implications for Mucosal Vaccine Delivery	FRONTIERS IN IMMUNOLOGY			English	Article						high-resolution optical coherence tomography imaging; depo medroxyprogesterone; intravaginal; mucosal; rhesus macaque; vaccine delivery; cervical epithelial thickness; nonoxynol-9	SIMIAN IMMUNODEFICIENCY VIRUS; OPTICAL COHERENCE TOMOGRAPHY; CELLULAR IMMUNE-RESPONSES; VAGINAL EPITHELIUM; RHESUS MACAQUES; HERPES-SIMPLEX; INFECTION; TRANSMISSION; TRACT; AIDS	Vaginal mucosal surfaces naturally offer some protection against sexually transmitted infections (STIs) including Human Immunodeficiency Virus-1, however topical preventative medications or vaccine designed to boost local immune responses can further enhance this protection. We previously developed a novel mucosal vaccine strategy using viral vectors integrated into mouse dermal epithelium to induce virus-specific humoral and cellular immune responses at the site of exposure. Since vaccine integration occurs at the site of cell replication (basal layer 100-400 micrometers below the surface), temporal epithelial thinning during vaccine application, confirmed with high resolution imaging, is desirable. In this study, strategies for vaginal mucosal thinning were evaluated noninvasively using optical coherence tomography (OCT) to map reproductive tract epithelial thickness (ET) in macaques to optimize basal layer access in preparation for future effective intravaginal mucosal vaccination studies. Twelve adolescent female rhesus macaques (5-7kg) were randomly assigned to interventions to induce vaginal mucosal thinning, including cytobrush mechanical abrasion, the chemical surfactant spermicide nonoxynol-9 (N9), the hormonal contraceptive depomedroxyprogesterone acetate (DMPA), or no intervention. Macaques were evaluated at baseline and after interventions using colposcopy, vaginal biopsies, and OCT imaging, which allowed for real-time in vivo visualization and measurement of ET of the mid-vagina, fornices, and cervix. P value <= 0.05 was considered significant. Colposcopy findings included pink, rugated tissue with variable degrees of white-tipped, thickened epithelium. Baseline ET of the fornices was thinner than the cervix and vagina (p<0.05), and mensing macaques had thinner ET at all sites (p<0.001). ET was decreased 1 month after DMPA (p<0.05) in all sites, immediately after mechanical abrasion (p<0.05) in the fornix and cervix, and after two doses of 4% N9 (1.25ml) applied over 14 hrs in the fornix only (p<0.001). Histological assessment of biopsied samples confirmed OCT findings. In summary, OCT imaging allowed for real time assessment of macaque vaginal ET. While varying degrees of thinning were observed after the interventions, limitations with each were noted. ET decreased naturally during menses, which may provide an ideal opportunity for accessing the targeted vaginal mucosal basal layers to achieve the optimum epithelial thickness for intravaginal mucosal vaccination.	[Vincent, Kathleen L.; Wei, Jingna; Yang, Jinping] Univ Texas Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA; [Frost, Patrice A.] Texas Biomed Res Inst, Populat Hlth Program, San Antonio, TX USA; [Frost, Patrice A.; Dick, Edward J.; Gauduin, Marie-Claire] Southwest Natl Primate Res Ctr, San Antonio, TX 78227 USA; [Motamedi, Massoud] Univ Texas Med Branch, Dept Ophthalmol & Visual Sci, Galveston, TX 77555 USA; [Dick, Edward J.; White, Robert; Gauduin, Marie-Claire] Texas Biomed Res Inst, Dis Intervent & Prevent Program, San Antonio, TX 78227 USA	University of Texas System; University of Texas Medical Branch Galveston; Texas Biomedical Research Institute; Texas Biomedical Research Institute; University of Texas System; University of Texas Medical Branch Galveston; Texas Biomedical Research Institute	Gauduin, MC (corresponding author), Southwest Natl Primate Res Ctr, San Antonio, TX 78227 USA.; Gauduin, MC (corresponding author), Texas Biomed Res Inst, Dis Intervent & Prevent Program, San Antonio, TX 78227 USA.	mcgauduin@txbiomed.org			NIH NIAID [R56AI084171, R01AI090705]; Texas Biomedical Research Center; Southwest National Primate Research Center	NIH NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Texas Biomedical Research Center; Southwest National Primate Research Center	This research was funded by the NIH NIAID R56AI084171 (M-CG) and the NIH NIAID R01AI090705 (M-CG) with the support of the Texas Biomedical Research Center and the Southwest National Primate Research Center.	Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Catchpole H., 1975, INT J PRIMATOL, V2, P117; Cline JM, 2008, TOXICOL PATHOL, V36, p142S, DOI 10.1177/0192623308327117; Dezzutti CS, 2013, JAIDS-J ACQ IMM DEF, V63, P548, DOI 10.1097/QAI.0b013e318291f331; DODOU K, 2012, PHARM J, V289, P238; Gaska JM, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201900495; Genesca M, 2007, J MED PRIMATOL, V36, P266, DOI 10.1111/j.1600-0684.2007.00244.x; Gordon SN, 2012, J IMMUNOL, V188, P714, DOI 10.4049/jimmunol.1101404; Harouse JM, 2001, J VIROL, V75, P1990, DOI 10.1128/JVI.75.4.1990-1995.2001; Hatziioannou T, 2012, NAT REV MICROBIOL, V10, P852, DOI 10.1038/nrmicro2911; Heffron R, 2012, LANCET INFECT DIS, V12, P19, DOI 10.1016/S1473-3099(11)70247-X; Hild-Petito S, 1998, AIDS RES HUM RETROV, V14, pS125; HILL TJ, 1978, J GEN VIROL, V39, P21, DOI 10.1099/0022-1317-39-1-21; Kersh EN, 2015, SEX TRANSM DIS, V42, P694, DOI 10.1097/OLQ.0000000000000367; Kozlowski PA, 1997, INFECT IMMUN, V65, P1387, DOI 10.1128/IAI.65.4.1387-1394.1997; Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288; Mansfield K, 2008, J VIROL, V82, P4135, DOI 10.1128/JVI.00015-08; Mauck CK, 1999, CONTRACEPTION, V60, P15, DOI 10.1016/S0010-7824(99)00058-X; Milligan GN, 1997, VIROLOGY, V229, P259, DOI 10.1006/viro.1997.8441; Mwatelah R, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25346; Nichols WA, 2015, AM J REPROD IMMUNOL, V74, P508, DOI 10.1111/aji.12422; Patton DL, 2004, J MED PRIMATOL, V33, P105, DOI 10.1111/j.1600-0684.2004.00059.x; Pennock JW, 2009, VACCINE, V27, P5830, DOI 10.1016/j.vaccine.2009.07.052; Rodger AJ, 2019, LANCET, V393, P2428, DOI 10.1016/S0140-6736(19)30418-0; Salle B, 2010, J INFECT DIS, V202, P337, DOI 10.1086/653619; Shang L, 2018, J INFECT DIS, V218, P1272, DOI 10.1093/infdis/jiy062; Tasker C, 2020, AIDS, V34, P729, DOI 10.1097/QAD.0000000000002475; Trunova N, 2006, VIROLOGY, V352, P169, DOI 10.1016/j.virol.2006.04.004; Vallender EJ, 2013, ILAR J, V54, P154, DOI 10.1093/ilar/ilt044; Vargas G, 2009, J INFECT DIS, V199, P1546, DOI 10.1086/598221; Vincent KL, 2008, SEX TRANSM DIS, V35, P269, DOI 10.1097/OLQ.0b013e31815abad8; Vincent KL, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2013.01.025; Vincent KL, 2011, OBSTET GYNECOL, V118, P1354, DOI 10.1097/AOG.0b013e318238f563; Vincent KL, 2009, SEX TRANSM DIS, V36, P312, DOI 10.1097/OLQ.0b013e31819496e4; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; White R, 2021, NATURE BIOTECH UNPUB; White R, 2015, VACCINE, V33, P6914, DOI 10.1016/j.vaccine.2013.09.006; WHO/CONRAD, 2004, MAN STAND COLP EV VA	38	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 28	2021	12								660524	10.3389/fimmu.2021.660524	http://dx.doi.org/10.3389/fimmu.2021.660524			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TH2CD	34262561	Green Published, gold			2022-12-18	WOS:000671902000001
J	Escamilla-Rivera, V; Santhanakrishnan, M; Liu, JC; Gibb, DR; Forsmo, JE; Foxman, EF; Eisenbarth, SC; Luckey, CJ; Zimring, JC; Hudson, KE; Stowell, SR; Hendrickson, JE				Escamilla-Rivera, Vicente; Santhanakrishnan, Manjula; Liu, Jingchun; Gibb, David R.; Forsmo, James E.; Foxman, Ellen F.; Eisenbarth, Stephanie C.; Luckey, C. John; Zimring, James C.; Hudson, Krystalyn E.; Stowell, Sean R.; Hendrickson, Jeanne E.			Complement Plays a Critical Role in Inflammation-Induced Immunoprophylaxis Failure in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						red blood cell; complement; antibody; transfusion; alloimmune	MEDIATED IMMUNE SUPPRESSION; ANTIGEN-MODULATION; HUMORAL IMMUNITY; CELL CLEARANCE; ALLOIMMUNIZATION; ACTIVATION; DISEASE; IGG	Complement impacts innate and adaptive immunity. Using a model in which the human KEL glycoprotein is expressed on murine red blood cells (RBCs), we have shown that polyclonal immunoprophylaxis (KELIg) prevents alloimmunization to transfused RBCs when a recipient is in their baseline state of heath but with immunoprophylaxis failure occurring in the presence of a viral-like stimulus. As complement can be detected on antibody coated KEL RBCs following transfusion, we hypothesized that recipient complement synergizes with viral-like inflammation to reduce immunoprophylaxis efficacy. Indeed, we found recipient C3 and C1q were critical to immunoprophylaxis failure in the setting of a viral-like stimulus, with no anti-KEL IgG alloantibodies generated in C3(-/-) or C1q(-/-) mice following KELIg treatment and KEL RBC transfusion. Differences in RBC uptake were noted in mice lacking C3, with lower consumption by splenic and peripheral blood inflammatory monocytes. Finally, no alloantibodies were detected in the setting of a viral-like stimulus following KELIg treatment and KEL RBC transfusion in mice lacking complement receptors (CR1/2(-/-)), narrowing key cells for immunoprophylaxis failure to those expressing these complement receptors. In-vitro studies showed complement fixed opsonized RBCs were significantly less likely to bind to B-cells from CR1/2(-/-) than wild type mice, potentially implicating lowered B-cell activation threshold in the presence of complement as being responsible for these findings. We thus propose a two-hit model for inflammation-induced immunoprophylaxis failure, where the first "hit" is recipient inflammation and the second "hit" is complement production/sensing. These results may have translational relevance to antigen-antibody interactions in humans.	[Escamilla-Rivera, Vicente; Santhanakrishnan, Manjula; Liu, Jingchun; Forsmo, James E.; Foxman, Ellen F.; Eisenbarth, Stephanie C.; Hendrickson, Jeanne E.] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA; [Gibb, David R.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA; [Forsmo, James E.] Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA; [Foxman, Ellen F.; Eisenbarth, Stephanie C.] Yale Univ, Dept Immunobiol, Sch Med, New Haven, CT USA; [Luckey, C. John; Zimring, James C.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; [Hudson, Krystalyn E.] Columbia Univ, Irving Med Ctr, Dept Pathol & Cell Biol, New York, NY USA; [Stowell, Sean R.] Harvard Med Sch, Joint Program Transfus Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Stowell, Sean R.] Harvard Med Sch, Harvard Glyc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Hendrickson, Jeanne E.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA	Yale University; Cedars Sinai Medical Center; University System of Georgia; Georgia Institute of Technology; Yale University; University of Virginia; Columbia University; NewYork-Presbyterian Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Yale University	Hendrickson, JE (corresponding author), Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA.; Hendrickson, JE (corresponding author), Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA.	jeanne.hendrickson@yale.edu		Escamilla-Rivera, Vicente/0000-0003-0973-9728	NIH/NHLBI [R01 HL126076, R01 HL132951, 5 K08 HL141446, P01 HL132819]; NCI [P30CA016359]; NIH/NIDDK [U54 DK106857]	NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was funded by NIH/NHLBI (R01 HL126076 and R01 HL132951) to JH, 5 K08 HL141446 to DG, and P01 HL132819 to JZ. It was also funded in part by NCI P30CA016359 and NIH/NIDDK U54 DK106857 to Yale University.	Bowman J M, 1987, Transfus Med Rev, V1, P101, DOI 10.1016/S0887-7963(87)70010-8; Calabro S, 2016, J EXP MED, V213, P887, DOI 10.1084/jem.20151720; Carroll MC, 2012, IMMUNITY, V37, P199, DOI 10.1016/j.immuni.2012.08.002; CARTER RH, 1988, J IMMUNOL, V141, P457; Cruz-Leal Y, 2021, TRANSFUSION, V61, P1004, DOI 10.1111/trf.16309; Cruz-Leal Y, 2018, J IMMUNOL, V200, P1295, DOI 10.4049/jimmunol.1700874; Das A, 2017, IMMUNITY, V46, P106, DOI 10.1016/j.immuni.2016.12.014; Escamilla-Rivera V, 2020, BLOOD, V135, P1983, DOI 10.1182/blood.2020005018; Floch A, 2020, HAEMATOLOGICA, V105, P2694, DOI 10.3324/haematol.2020.253856; Girard-Pierce KR, 2013, BLOOD, V122, P1793, DOI 10.1182/blood-2013-06-508952; Gruber DR, 2020, BLOOD ADV, V4, P1526, DOI 10.1182/bloodadvances.2019001299; JACQUIERSARLIN MR, 1995, IMMUNOLOGY, V84, P164; Kaczorowski DJ, 2010, J LEUKOCYTE BIOL, V88, P609, DOI 10.1189/jlb.0809588; Kim D, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003233; Kovacs KG, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.620427; Kumpel BM, 2008, CLIN EXP IMMUNOL, V154, P1, DOI 10.1111/j.1365-2249.2008.03735.x; Liu JC, 2016, BLOOD, V128, P3159, DOI [10.1182/blood-201606-724732, 10.1182/blood-2016-06-724732]; Maier CL, 2018, BLOOD ADV, V2, P2986, DOI 10.1182/bloodadvances.2018018408; Mener A, 2019, TRANSFUSION, V59, P371, DOI 10.1111/trf.14939; Mener A, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121631; Merle NS, 2019, TRANSFUS CLIN BIOL, V26, P116, DOI 10.1016/j.tracli.2019.02.008; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257; Patel SR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02516; Smith NH, 2012, TRANSFUSION, V52, P2620, DOI 10.1111/j.1537-2995.2012.03641.x; Stegmann TC, 2017, BLOOD, V129, P1045, DOI 10.1182/blood-2016-05-716365; Stowell SR, 2015, HAEMATOLOGICA, V100, pE394, DOI 10.3324/haematol.2015.128603; Tampaki A, 2021, BLOOD REV, V48, DOI 10.1016/j.blre.2021.100805; Thomas AM, 2019, J IMMUNOL, V203, P1571, DOI 10.4049/jimmunol.1900047; Tormey CA, 2019, BLOOD, V133, P1821, DOI 10.1182/blood-2018-08-833962; Vossoughi S, 2019, TRANSFUSION, V59, P2195, DOI 10.1111/trf.15307; Yu HH, 2014, J IMMUNOL, V193, P2902, DOI 10.4049/jimmunol.1302287; Zelek WM, 2019, MOL IMMUNOL, V114, P341, DOI 10.1016/j.molimm.2019.07.030; Zerra PE, 2021, BLOOD, V138, P706, DOI 10.1182/blood.2020009376; Zhang L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05704-3; Zhang XH, 2007, BLOOD, V110, P228, DOI 10.1182/blood-2006-12-063636; Zou L, 2016, J IMMUNOL, V196, P2788, DOI 10.4049/jimmunol.1502106; Zwiers C, 2018, TRANSFUSION, V58, P1611, DOI 10.1111/trf.14606	38	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 25	2021	12								704072	10.3389/fimmu.2021.704072	http://dx.doi.org/10.3389/fimmu.2021.704072			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TH3JX	34249009	gold, Green Published			2022-12-18	WOS:000671990200001
J	Gregory, EJ; Liu, J; Miller-Handley, H; Kinder, JM; Way, SS				Gregory, Emily J.; Liu, James; Miller-Handley, Hilary; Kinder, Jeremy M.; Way, Sing Sing			Epidemiology of Pregnancy Complications Through the Lens of Immunological Memory	FRONTIERS IN IMMUNOLOGY			English	Article						parity; preeclampsia; prematurity; immunological memory; stillbirth	REGULATORY T-CELLS; GLOBAL BURDEN; RISK-FACTOR; PREECLAMPSIA; SUBSEQUENT; INFECTION; STILLBIRTH; PATERNITY; BIRTH; REACTIVATION	In the fifteen minutes it takes to read this short commentary, more than 400 babies will have been born too early, another 300 expecting mothers will develop preeclampsia, and 75 unborn third trimester fetuses will have died in utero (stillbirth). Given the lack of meaningful progress in understanding the physiological changes that occur to allow a healthy, full term pregnancy, it is perhaps not surprising that effective therapies against these great obstetrical syndromes that include prematurity, preeclampsia, and stillbirth remain elusive. Meanwhile, pregnancy complications remain the leading cause of infant and childhood mortality under age five. Does it have to be this way? What more can we collectively, as a biomedical community, or individually, as clinicians who care for women and newborn babies at high risk for pregnancy complications, do to protect individuals in these extremely vulnerable developmental windows? The problem of pregnancy complications and neonatal mortality is extraordinarily complex, with multiple unique, but complementary perspectives from scientific, epidemiological and public health viewpoints. Herein, we discuss the epidemiology of pregnancy complications, focusing on how the outcome of prior pregnancy impacts the risk of complication in the next pregnancy - and how the fundamental immunological principle of memory may promote this adaptive response.	[Gregory, Emily J.; Liu, James] Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Cincinnati, OH 45267 USA; [Miller-Handley, Hilary; Kinder, Jeremy M.; Way, Sing Sing] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Infect Dis,Ctr Inflammat & Tolerance, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Way, SS (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Infect Dis,Ctr Inflammat & Tolerance, Cincinnati, OH 45229 USA.	singsing.way@cchmc.org			National Institutes of Health, National Institute of Allergy and Infectious Diseases [DP1-AI131080]; Howard Hughes Medical Institute Faculty Scholars Program; Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Disease Award; March of Dimes Ohio Collaborative on Prematurity Research	National Institutes of Health, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Howard Hughes Medical Institute Faculty Scholars Program(Howard Hughes Medical Institute); Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Disease Award(Burroughs Wellcome Fund); March of Dimes Ohio Collaborative on Prematurity Research	This work was supported by the National Institutes of Health, National Institute of Allergy and Infectious Diseases, through grant DP1-AI131080. SSW is supported by the Howard Hughes Medical Institute Faculty Scholars Program, a Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Disease Award, and the March of Dimes Ohio Collaborative on Prematurity Research.	Aluvihare VR, 2006, IMMUNOL REV, V212, P330, DOI 10.1111/j.0105-2896.2006.00408.x; Aneman I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01864; [Anonymous], 2019, Obstet Gynecol, V133, P1, DOI 10.1097/AOG.0000000000003018; Benner M, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108204; Black M, 2008, BJOG-INT J OBSTET GY, V115, P269, DOI 10.1111/j.1471-0528.2007.01562.x; Bonney EA, 2019, PLACENTA, V79, P53, DOI 10.1016/j.placenta.2019.03.003; Bonney EA, 2017, J REPROD IMMUNOL, V123, P65, DOI 10.1016/j.jri.2017.09.005; Burwick RM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.646596; Cappelletti M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138812; Chaturvedi V, 2015, J CLIN INVEST, V125, P1713, DOI 10.1172/JCI78578; Conde-Agudelo A, 2008, AM J OBSTET GYNECOL, V198, P7, DOI 10.1016/j.ajog.2007.07.040; Cornelius DC, 2019, EBIOMEDICINE, V39, P31, DOI 10.1016/j.ebiom.2018.12.053; Crespo AC, 2020, CELL, V182, P1125, DOI 10.1016/j.cell.2020.07.019; Deshmukh H, 2019, ANNU REV PATHOL-MECH, V14, P185, DOI 10.1146/annurev-pathmechdis-012418-012743; Erlebacher A, 2007, J CLIN INVEST, V117, P1399, DOI 10.1172/JCI28214; Erlebacher A, 2013, ANNU REV IMMUNOL, V31, P387, DOI 10.1146/annurev-immunol-032712-100003; Fettke F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00495; Filipovic I, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06918-3; Gamliel M, 2018, IMMUNITY, V48, P951, DOI 10.1016/j.immuni.2018.03.030; Geneugelijk K, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00571; Gordon A, 2012, OBSTET GYNECOL, V119, P509, DOI 10.1097/AOG.0b013e31824781f8; Green ES, 2020, SEMIN IMMUNOPATHOL, V42, P413, DOI 10.1007/s00281-020-00807-y; Guerrero B, 2020, J REPROD IMMUNOL, V142, DOI 10.1016/j.jri.2020.103209; Harrison MS, 2016, SEMIN FETAL NEONAT M, V21, P74, DOI 10.1016/j.siny.2015.12.007; Hernandez-Diaz S, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2255; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; Jiang TT, 2014, J IMMUNOL, V192, P4949, DOI 10.4049/jimmunol.1400498; Kho EM, 2009, J REPROD IMMUNOL, V82, P66, DOI 10.1016/j.jri.2009.04.011; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; Kinder JM, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107784; Kinder JM, 2017, NAT REV IMMUNOL, V17, P483, DOI 10.1038/nri.2017.38; Kinder JM, 2015, CELL, V162, P505, DOI 10.1016/j.cell.2015.07.006; Koike T, 2002, GYNECOL OBSTET INVES, V53, P22, DOI 10.1159/000049406; Krop J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01182; Kussel L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13275-6; Kvalvik LG, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1007; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; Lawn JE, 2016, LANCET, V387, P587, DOI 10.1016/S0140-6736(15)00837-5; Lee J, 2013, AM J REPROD IMMUNOL, V70, P162, DOI 10.1111/aji.12141; Li DK, 2000, AM J EPIDEMIOL, V151, P57, DOI 10.1093/oxfordjournals.aje.a010122; Lissauer D, 2012, J IMMUNOL, V189, P1072, DOI 10.4049/jimmunol.1200544; Malacova E, 2018, BJOG-INT J OBSTET GY, V125, P183, DOI 10.1111/1471-0528.14906; Mbah AK, 2010, EUR J OBSTET GYN R B, V149, P165, DOI 10.1016/j.ejogrb.2009.12.035; McClure EM, 2009, SEMIN FETAL NEONAT M, V14, P182, DOI 10.1016/j.siny.2009.02.003; Mendez S, 2004, J EXP MED, V200, P201, DOI 10.1084/jem.20040298; Muzzio D, 2013, AM J REPROD IMMUNOL, V69, P408, DOI 10.1111/aji.12079; Nadeau HCG, 2016, SEMIN FETAL NEONAT M, V21, P100, DOI 10.1016/j.siny.2015.12.008; Nelson JL, 2012, TRENDS IMMUNOL, V33, P421, DOI 10.1016/j.it.2012.03.002; Nelson RW, 2013, J IMMUNOL, V190, P2828, DOI 10.4049/jimmunol.1202183; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Peterson LS, 2020, SEMIN IMMUNOPATHOL, V42, P397, DOI 10.1007/s00281-019-00772-1; Rasmussen S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181016; Robillard PY, 1996, LANCET, V347, P619, DOI 10.1016/S0140-6736(96)91315-X; Robson S, 2001, AUST NZ J OBSTET GYN, V41, P29, DOI 10.1111/j.1479-828X.2001.tb01290.x; Rowe JH, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002873; Rowe JH, 2012, NATURE, V490, P102, DOI 10.1038/nature11462; Rowe JH, 2011, CELL HOST MICROBE, V10, P54, DOI 10.1016/j.chom.2011.06.005; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Schjenken JE, 2020, PHYSIOL REV, V100, P1077, DOI 10.1152/physrev.00013.2018; Shima T, 2020, J REPROD IMMUNOL, V141, DOI 10.1016/j.jri.2020.103165; Spence T, 2021, J PREGNANCY, V2021, DOI 10.1155/2021/6649608; Steegers EAP, 2010, LANCET, V376, P631, DOI 10.1016/S0140-6736(10)60279-6; Suah AN, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI140715; Trupin LS, 1996, EPIDEMIOLOGY, V7, P240, DOI 10.1097/00001648-199605000-00004; Tubbergen P, 1999, J REPROD IMMUNOL, V45, P81, DOI 10.1016/S0165-0378(99)00040-6; Umesawa M, 2017, HYPERTENS RES, V40, P213, DOI 10.1038/hr.2016.126; Uzonna JE, 2001, J IMMUNOL, V167, P6967, DOI 10.4049/jimmunol.167.12.6967; Valencia-Ortega J, 2020, J OBSTET GYNAECOL RE, V46, P1067, DOI 10.1111/jog.14309; van der Zwan A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02880; Vossoughi S, 2019, TRANSFUSION, V59, P2195, DOI 10.1111/trf.15307; Walani SR, 2020, INT J GYNECOL OBSTET, V150, P31, DOI 10.1002/ijgo.13195; Waldorf KMA, 2011, BJOG-INT J OBSTET GY, V118, P136, DOI 10.1111/j.1471-0528.2010.02728.x	72	1	2	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 25	2021	12								693189	10.3389/fimmu.2021.693189	http://dx.doi.org/10.3389/fimmu.2021.693189			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TF7JK	34248991	gold, Green Published			2022-12-18	WOS:000670893600001
J	Belaid, B; Mahammed, LL; Oussaid, AM; Migaud, M; Khadri, Y; Casanova, JL; Puel, A; Ben Halla, N; Djidjik, R				Belaid, Brahim; Lamara Mahammed, Lydia; Mohand Oussaid, Aida; Migaud, Melanie; Khadri, Yasmine; Casanova, Jean Laurent; Puel, Anne; Ben Halla, Nafissa; Djidjik, Reda			Case Report: Interleukin-2 Receptor Common Gamma Chain Defect Presented as a Hyper-IgE Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						Interleukin-2 receptor gamma; combined immunodeficiency; hypomorphic mutations; hyper-IgE; inborn error of immunity	SEVERE COMBINED IMMUNODEFICIENCY; THYMIC STROMAL LYMPHOPOIETIN; BONE-MARROW-TRANSPLANTATION; NAIVE B-CELLS; MUTATION ANALYSIS; IL2RG MUTATION; T-CELLS; RECEPTOR; IL-2; PHENOTYPE	X-linked severe combined immunodeficiency (X-SCID) is caused by mutations of IL2RG, the gene encoding the interleukin common gamma chain (IL-2R gamma or gamma c) of cytokine receptors for interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Hypomorphic mutations of IL2RG may cause combined immunodeficiencies with atypical clinical and immunological presentations. Here, we report a clinical, immunological, and functional characterization of a missense mutation in exon 1 (c.115G>A; p. Asp39Asn) of IL2RG in a 7-year-old boy. The patient suffered from recurrent sinopulmonary infections and refractory eczema. His total lymphocyte counts have remained normal despite skewed T cell subsets, with a pronounced serum IgE elevation. Surface expression of IL-2R gamma was reduced on his lymphocytes. Signal transducer and activator of transcription (STAT) phosphorylation in response to IL-2, IL-4, and IL-7 showed a partially preserved receptor function. T-cell proliferation in response to mitogens and anti-CD3/anti-CD28 monoclonal antibodies was significantly reduced. Further analysis revealed a decreased percentage of CD4(+) T cells capable of secreting IFN-gamma, but not IL-4 or IL-17. Studies on the functional consequences of IL-2R gamma variants are important to get more insight into the pathogenesis of atypical phenotypes which may lay the ground for novel therapeutic strategies.	[Belaid, Brahim; Lamara Mahammed, Lydia; Djidjik, Reda] Beni Messous Univ, Hosp Ctr, Dept Med Immunol, Algiers, Algeria; [Belaid, Brahim; Lamara Mahammed, Lydia; Mohand Oussaid, Aida; Ben Halla, Nafissa; Djidjik, Reda] Benyoucef Benkhedda Univ Algiers 1, Fac Med, Algiers, Algeria; [Mohand Oussaid, Aida; Khadri, Yasmine; Ben Halla, Nafissa] Beni Messous Univ, Hosp Ctr, Dept Pediat A, Algiers, Algeria; [Migaud, Melanie; Casanova, Jean Laurent; Puel, Anne] Necker Hosp Sick Children, INSERM, Lab Human Genet Infect Dis, UMR 1163, Paris, France; [Migaud, Melanie; Casanova, Jean Laurent; Puel, Anne] Univ Paris, Imagine Inst, Paris, France; [Casanova, Jean Laurent; Puel, Anne] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, 1230 York Ave, New York, NY 10021 USA; [Casanova, Jean Laurent] Howard Hughes Med Inst, New York, NY USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Rockefeller University; Howard Hughes Medical Institute	Djidjik, R (corresponding author), Beni Messous Univ, Hosp Ctr, Dept Med Immunol, Algiers, Algeria.; Djidjik, R (corresponding author), Benyoucef Benkhedda Univ Algiers 1, Fac Med, Algiers, Algeria.	ourtilane@yahoo.fr	Puel, Anne/H-7305-2017	Puel, Anne/0000-0003-2603-0323; Djidjik, Reda/0000-0003-0820-692X; LAMARA MAHAMMED, Lydia/0000-0002-5360-8066; BELAID, Brahim/0000-0001-7618-4051	French National Research Agency (ANR) [ANR-10-IAHU-01]; ANR-FNS LTh-MSMD-CMCD [ANR-18-CE93-0008-01]; Rockefeller University; National Institutes of Health [R01AI127564]	French National Research Agency (ANR)(French National Research Agency (ANR)); ANR-FNS LTh-MSMD-CMCD(French National Research Agency (ANR)); Rockefeller University; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The French National Research Agency (ANR) under the "Investments for the Future" program (ANR-10-IAHU-01), ANR-FNS LTh-MSMD-CMCD (ANR-18-CE93-0008-01), The Rockefeller University and the National Institutes of Health (#R01AI127564).	Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; AL Dossari D., 2015, J GASTROEN HEPATOL, V30, P13, DOI [10.1111/jgh.13088, DOI 10.1111/JGH.13088]; Al-Shami A, 2004, J EXP MED, V200, P159, DOI 10.1084/jem.20031975; Allenspach E., 1993, X-Linked Severe Combined Immunodeficiency; Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Berglund LJ, 2013, BLOOD, V122, P3940, DOI 10.1182/blood-2013-06-506865; Bertrand Y, 1999, J PEDIATR-US, V134, P740, DOI 10.1016/S0022-3476(99)70291-X; Beziat V, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat4956; Blanco E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.608653; BROOKS EG, 1990, J CLIN INVEST, V86, P1623, DOI 10.1172/JCI114884; DESAINTBASILE G, 1992, J CLIN INVEST, V89, P861, DOI 10.1172/JCI115665; DISANTO JP, 1994, P NATL ACAD SCI USA, V91, P9466, DOI 10.1073/pnas.91.20.9466; Dworkin I, 2009, GENETICS, V181, P1065, DOI 10.1534/genetics.108.096453; Erman B, 2015, HAEMATOLOGICA, V100, pE216, DOI 10.3324/haematol.2014.120980; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Fischer A, 2000, CLIN EXP IMMUNOL, V122, P143, DOI 10.1046/j.1365-2249.2000.01359.x; Fuchs S, 2014, EUR J IMMUNOL, V44, P3129, DOI 10.1002/eji.201444689; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Haddad E, 1998, BLOOD, V91, P3646; Hawkins MM, 2008, PEDIATR BLOOD CANCER, V50, P1018, DOI 10.1002/pbc.21335; Illig D, 2019, J CLIN IMMUNOL, V39, P207, DOI 10.1007/s10875-019-00606-7; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Klenerman P, 2016, NAT REV IMMUNOL, V16, P367, DOI 10.1038/nri.2016.38; Kotlarz D, 2013, J EXP MED, V210, P433, DOI 10.1084/jem.20111229; Kuijpers TW, 2013, HAEMATOLOGICA, V98, P1030, DOI 10.3324/haematol.2012.077511; Lachance J, 2013, G3-GENES GENOM GENET, V3, P1893, DOI 10.1534/g3.113.007831; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Linterman MA, 2010, J EXP MED, V207, P353, DOI 10.1084/jem.20091738; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Matthews DJ, 1997, EUR J IMMUNOL, V27, P116, DOI 10.1002/eji.1830270118; MATTHEWS DJ, 1995, BLOOD, V85, P38, DOI 10.1182/blood.V85.1.38.bloodjournal85138; McGuire HM, 2015, J IMMUNOL, V195, P5123, DOI 10.4049/jimmunol.1501463; Milner JD, 2010, J IMMUNOL, V184, P6569, DOI 10.4049/jimmunol.1000674; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Mouillot G, 2010, J CLIN IMMUNOL, V30, P746, DOI 10.1007/s10875-010-9424-3; Nelson BH, 2004, J IMMUNOL, V172, P3983, DOI 10.4049/jimmunol.172.7.3983; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Okuno Y, 2015, J CLIN IMMUNOL, V35, P610, DOI 10.1007/s10875-015-0202-0; Pandey A, 2000, NAT IMMUNOL, V1, P59, DOI 10.1038/76923; Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659; Puck JM, 1997, BLOOD, V89, P1968; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; Puck JM, 1996, IMMUNOL TODAY, V17, P507, DOI 10.1016/0167-5699(96)30062-5; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Rochman Y, 2009, NAT REV IMMUNOL, V9, P480, DOI 10.1038/nri2580; Rochman Y, 2008, J IMMUNOL, V181, P7699, DOI 10.4049/jimmunol.181.11.7699; Roifman CM, 2012, J ALLERGY CLIN IMMUN, V130, P177, DOI 10.1016/j.jaci.2012.04.029; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SCHANDENE L, 1993, EUR J IMMUNOL, V23, P56, DOI 10.1002/eji.1830230110; SCHMALSTIEG FC, 1995, J CLIN INVEST, V95, P1169, DOI 10.1172/JCI117765; Sharfe N, 1997, J CLIN INVEST, V100, P3036, DOI 10.1172/JCI119858; Smyth CM, 2007, BLOOD, V110, P91, DOI 10.1182/blood-2006-11-055442; Somech R, 2005, J PEDIATR-US, V147, P555, DOI 10.1016/j.jpeds.2005.05.010; Stepensky P, 2018, J CLIN IMMUNOL, V38, P527, DOI 10.1007/s10875-018-0514-y; Stepensky P, 2015, HAEMATOLOGICA, V100, pE72, DOI 10.3324/haematol.2014.112508; STEPHAN JL, 1993, J PEDIATR-US, V123, P564, DOI 10.1016/S0022-3476(05)80951-5; Tuovinen EA, 2020, J CLIN IMMUNOL, V40, P503, DOI 10.1007/s10875-020-00745-2; Upton J., 2015, LYMPHOSIGN J, V2, P57, DOI DOI 10.14785/lpsn-2014-0019; Ursini MV, 2002, CLIN EXP IMMUNOL, V129, P502, DOI 10.1046/j.1365-2249.2002.01823.x; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Villa A., 2014, STIEHMS IMMUNE DEFIC, P87, DOI [10.1016/B978-0-12-405546-9.00004-2, DOI 10.1016/B978-0-12-405546-9.00004-2]; Wada T, 2008, BLOOD, V112, P1872, DOI 10.1182/blood-2008-04-149708; Waickman AT, 2016, CELL MOL LIFE SCI, V73, P253, DOI 10.1007/s00018-015-2062-4; Weatherall DJ, 2001, NAT REV GENET, V2, P245, DOI 10.1038/35066048; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Weinstein JS, 2016, NAT IMMUNOL, V17, P1197, DOI 10.1038/ni.3554; Yong PFK, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4069; Zotos D, 2010, J EXP MED, V207, P365, DOI 10.1084/jem.20091777	70	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 24	2021	12								696350	10.3389/fimmu.2021.696350	http://dx.doi.org/10.3389/fimmu.2021.696350			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TF3UY	34248995	gold, Green Published			2022-12-18	WOS:000670643400001
J	Chen, XJ; Ren, AQ; Zheng, L; Zheng, ED; Jiang, T				Chen, Xiao-Juan; Ren, Aiqun; Zheng, Liang; Zheng, En-Dian; Jiang, Tao			Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome	FRONTIERS IN IMMUNOLOGY			English	Article						pan-cancer; liver metastases; immune checkpoint inhibitor; prognosis; treatment outcome	OPEN-LABEL; ATEZOLIZUMAB; DOCETAXEL; NSCLC; MICROENVIRONMENT; MULTICENTER; COMBINATION; NIVOLUMAB; THERAPY; PHASE-3	This study aimed to investigate the predictive value of liver metastases (LM) in patients with various advanced cancers received immune-checkpoint inhibitors (ICIs). First, clinical and survival data from a published cohort of 1,661 patients who received ICIs therapy were downloaded and analyzed. Second, a retrospective review of 182 patients with advanced non-small-cell lung cancer (NSCLC) who received PD-1/PD-L1 monotherapy was identified. Third, a meta-analysis of published trials was performed to explore the impact of LM on the efficacy of anti-PD-1/PD-L1 based therapy in advanced lung cancers. Pan-cancer analysis revealed that patients with LM had significantly shorter overall survival (OS) than those without LM (10 vs. 20 months; P < 0.0001). Subgroup analysis showed that the presence of LM was associated with markedly shorter OS than those without LM in ICI monotherapy group (P < 0.0001), but it did not reach the statistical significance in ICI-based combination therapy (P = 0.0815). In NSCLC, the presence of LM was associated with significantly inferior treatment outcomes in both pan-cancer and real-world cohort. Interestingly, ICI-based monotherapy and combination therapy could simultaneously prolong progression-free survival (PFS) and OS than chemotherapy in patients without LM. However, ICI-based monotherapy could not prolong PFS than chemotherapy in patients with LM while ICI-based combination therapy could dramatically prolong both PFS and OS. Together, these findings suggested that the presence of LM was the negative predictive factor in cancer patients received ICIs monotherapy, especially in NSCLC. ICI-based combination therapy might overcome the intrinsic resistance of LM to ICIs while the optimal combinatorial strategies remain under further investigation.	[Chen, Xiao-Juan; Ren, Aiqun; Zheng, Liang; Zheng, En-Dian] Wenzhou Med Univ, Dept Gastroenterol, Wenzhou Peoples Hosp, Wenzhou Third Clin Inst, Wenzhou, Peoples R China; [Jiang, Tao] Fudan Univ, Shanghai Resp Res Inst, Zhongshan Hosp, Dept Pulm Med, Shanghai, Peoples R China; [Jiang, Tao] Tongji Univ, Sch Med, Dept Med Oncol, Shanghai Pulm Hosp, Shanghai, Peoples R China; [Jiang, Tao] Tongji Univ, Sch Med, Thorac Canc Inst, Shanghai, Peoples R China	Wenzhou Medical University; Fudan University; Tongji University; Tongji University	Chen, XJ (corresponding author), Wenzhou Med Univ, Dept Gastroenterol, Wenzhou Peoples Hosp, Wenzhou Third Clin Inst, Wenzhou, Peoples R China.; Jiang, T (corresponding author), Fudan Univ, Shanghai Resp Res Inst, Zhongshan Hosp, Dept Pulm Med, Shanghai, Peoples R China.; Jiang, T (corresponding author), Tongji Univ, Sch Med, Dept Med Oncol, Shanghai Pulm Hosp, Shanghai, Peoples R China.; Jiang, T (corresponding author), Tongji Univ, Sch Med, Thorac Canc Inst, Shanghai, Peoples R China.	366535255@qq.com; tonyjiangdr@163.com			Shanghai Sailing Program [20YF1407500]	Shanghai Sailing Program	This study was supported in part by the Shanghai Sailing Program (No. 20YF1407500).	Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Brodt P, 2016, CLIN CANCER RES, V22, P5971, DOI 10.1158/1078-0432.CCR-16-0460; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Crispe IN, 2003, NAT REV IMMUNOL, V3, P51, DOI 10.1038/nri981; Doherty DG, 2016, J AUTOIMMUN, V66, P60, DOI 10.1016/j.jaut.2015.08.020; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Gadgeel S, 2020, J CLIN ONCOL, V38, P1505, DOI 10.1200/JCO.19.03136; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hegde PS, 2020, IMMUNITY, V52, P17, DOI 10.1016/j.immuni.2019.12.011; Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778; Hoekstra LT, 2013, ANN SURG, V257, P27, DOI 10.1097/SLA.0b013e31825d5d47; Horn L, 2018, NEW ENGL J MED, V379, P2220, DOI 10.1056/NEJMoa1809064; Jiang T, 2017, CLIN LUNG CANCER, V18, P631, DOI 10.1016/j.cllc.2017.04.015; Jotte R, 2020, J THORAC ONCOL, V15, P1351, DOI 10.1016/j.jtho.2020.03.028; Lee JC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba0759; Li FL, 2013, CELL MOL IMMUNOL, V10, P292, DOI 10.1038/cmi.2013.7; Lin ZB, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-3928; Milette S, 2017, CLIN CANCER RES, V23, P6390, DOI 10.1158/1078-0432.CCR-15-1636; Nishio M, 2021, J THORAC ONCOL, V16, P653, DOI 10.1016/j.jtho.2020.11.025; Osorio JC, 2019, J CLIN ONCOL, V37, P3546, DOI 10.1200/JCO.19.00709; Patel SA, 2018, IMMUNITY, V48, P417, DOI 10.1016/j.immuni.2018.03.007; Qin BD, 2020, CRIT REV ONCOL HEMAT, V147, DOI 10.1016/j.critrevonc.2020.102893; Reck M, 2019, LANCET RESP MED, V7, P387, DOI 10.1016/S2213-2600(19)30084-0; Ren YJ, 2016, ONCOTARGET, V7, P53245, DOI 10.18632/oncotarget.10644; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Riihimaki M, 2014, LUNG CANCER, V86, P78, DOI 10.1016/j.lungcan.2014.07.020; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rudin CM, 2020, J CLIN ONCOL, V38, P2369, DOI 10.1200/JCO.20.00793; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Trefts E, 2017, CURR BIOL, V27, pR1147, DOI 10.1016/j.cub.2017.09.019; Tumeh PC, 2017, CANCER IMMUNOL RES, V5, P417, DOI 10.1158/2326-6066.CIR-16-0325; Vokes EE, 2018, ANN ONCOL, V29, P959, DOI 10.1093/annonc/mdy041; Wang X, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.546604; West H, 2019, LANCET ONCOL, V20, P924, DOI 10.1016/S1470-2045(19)30167-6; Yu JL, 2021, NAT MED, V27, P152, DOI 10.1038/s41591-020-1131-x; Zhou GY, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1448332	39	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 24	2021	12								651086	10.3389/fimmu.2021.651086	http://dx.doi.org/10.3389/fimmu.2021.651086			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TF3UH	34248939	gold, Green Published			2022-12-18	WOS:000670641700001
J	Haring, E; Zeiser, R; Apostolova, P				Haring, Eileen; Zeiser, Robert; Apostolova, Petya			Interfering With Inflammation: Heterogeneous Effects of Interferons in Graft-Versus-Host Disease of the Gastrointestinal Tract and Inflammatory Bowel Disease	FRONTIERS IN IMMUNOLOGY			English	Review						graft-versus-host disease; inflammatory bowel disease; interferon; intestine; ulcerative colitis; Crohn's disease	GUANYLATE-BINDING PROTEIN-1; MESENCHYMAL STEM-CELLS; FECAL MICROBIOTA TRANSPLANTATION; CHRONIC MYELOGENOUS LEUKEMIA; JANUS KINASE INHIBITOR; SEVERE CROHNS-DISEASE; IFN-GAMMA; ULCERATIVE-COLITIS; DENDRITIC CELLS; I INTERFERONS	The intestine can be the target of several immunologically mediated diseases, including graft-versus-host disease (GVHD) and inflammatory bowel disease (IBD). GVHD is a life-threatening complication that occurs after allogeneic hematopoietic stem cell transplantation. Involvement of the gastrointestinal tract is associated with a particularly high mortality. GVHD development starts with the recognition of allo-antigens in the recipient by the donor immune system, which elicits immune-mediated damage of otherwise healthy tissues. IBD describes a group of immunologically mediated chronic inflammatory diseases of the intestine. Several aspects, including genetic predisposition and immune dysregulation, are responsible for the development of IBD, with Crohn's disease and ulcerative colitis being the two most common variants. GVHD and IBD share multiple key features of their onset and development, including intestinal tissue damage and loss of intestinal barrier function. A further common feature in the pathophysiology of both diseases is the involvement of cytokines such as type I and II interferons (IFNs), amongst others. IFNs are a family of protein mediators produced as a part of the inflammatory response, typically to pathogens or malignant cells. Diverse, and partially paradoxical, effects have been described for IFNs in GVHD and IBD. This review summarizes current knowledge on the role of type I, II and III IFNs, including basic concepts and controversies about their functions in the context of GVHD and IBD. In addition, therapeutic options, research developments and remaining open questions are addressed.	[Haring, Eileen; Zeiser, Robert; Apostolova, Petya] Univ Freiburg, Fac Med, Med Ctr, Dept Med 1, Freiburg, Germany; [Haring, Eileen; Zeiser, Robert; Apostolova, Petya] German Canc Consortium DKTK, Partner Site Freiburg, Heidelberg, Germany; [Haring, Eileen; Zeiser, Robert; Apostolova, Petya] German Canc Res Ctr, Heidelberg, Germany	University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Apostolova, P (corresponding author), Univ Freiburg, Fac Med, Med Ctr, Dept Med 1, Freiburg, Germany.; Apostolova, P (corresponding author), German Canc Consortium DKTK, Partner Site Freiburg, Heidelberg, Germany.; Apostolova, P (corresponding author), German Canc Res Ctr, Heidelberg, Germany.	petya.apostolova@uniklinik-freiburg.de	Apostolova, Petya/AAY-6644-2021	Apostolova, Petya/0000-0002-3856-5109; Zeiser, Robert/0000-0001-6565-3393	German Cancer Consortium (DKTK) [FR-01-375]; Baden-Wuerttemberg Ministry of Science, Research and Art; OncoEscape [SFB 1479]; University of Freiburg	German Cancer Consortium (DKTK); Baden-Wuerttemberg Ministry of Science, Research and Art; OncoEscape; University of Freiburg	PA is supported by the German Cancer Consortium (DKTK) (FR-01-375). The article processing charge was funded by the Baden-Wuerttemberg Ministry of Science, Research and Art and the University of Freiburg in the funding programme Open Access Publishing. RZ was supported by the SFB 1479 (P01) OncoEscape.	Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Abe K, 2007, P NATL ACAD SCI USA, V104, P17022, DOI 10.1073/pnas.0708469104; Alspach E, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a028480; Andersson RE, 2001, NEW ENGL J MED, V344, P808, DOI 10.1056/NEJM200103153441104; Andreou NP, 2020, ANN GASTROENTEROL, V33, P125, DOI 10.20524/aog.2020.0457; Ank N, 2008, J IMMUNOL, V180, P2474, DOI 10.4049/jimmunol.180.4.2474; Antunes KH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11152-6; Asavaroengchai W, 2007, BIOL BLOOD MARROW TR, V13, P46, DOI 10.1016/j.bbmt.2006.09.014; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Baldridge MT, 2017, J VIROL, V91, DOI 10.1128/JVI.02079-16; Ball LM, 2008, BONE MARROW TRANSPL, V41, pS58, DOI 10.1038/bmt.2008.56; Baumgart DC, 2007, LANCET, V369, P1627, DOI 10.1016/S0140-6736(07)60750-8; Baumgart DC, 2012, LANCET, V380, P1590, DOI 10.1016/S0140-6736(12)60026-9; Bird L, 2020, NAT REV IMMUNOL, V20, P520, DOI 10.1038/s41577-020-00412-y; Blasius AL, 2010, IMMUNITY, V32, P305, DOI 10.1016/j.immuni.2010.03.012; Bleich A, 2005, PATHOBIOLOGY, V72, P293, DOI 10.1159/000091327; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bradley KC, 2019, CELL REP, V28, P245, DOI 10.1016/j.celrep.2019.05.105; Broggi A, 2020, J EXP MED, V217, DOI 10.1084/jem.20190295; Burman AC, 2007, BLOOD, V110, P1064, DOI 10.1182/blood-2006-12-063982; Butzner JD, 1996, GUT, V38, P568, DOI 10.1136/gut.38.4.568; Capaldo CT, 2012, MUCOSAL IMMUNOL, V5, P681, DOI 10.1038/mi.2012.41; Carniti C, 2015, CLIN CANCER RES, V21, P3740, DOI 10.1158/1078-0432.CCR-14-2758; Cheluvappa R, 2019, INFLAMM BOWEL DIS, V25, P436, DOI 10.1093/ibd/izy332; Chen L, 2019, INFLAMM BOWEL DIS, V25, P1450, DOI 10.1093/ibd/izz046; Chirdo FG, 2005, EUR J IMMUNOL, V35, P1831, DOI 10.1002/eji.200425882; Choi J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109799; Choi J, 2012, BLOOD, V120, P4093, DOI 10.1182/blood-2012-01-403196; Copelan EA, 2006, NEW ENGL J MED, V354, P1813, DOI 10.1056/NEJMra052638; Correa RO, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.17; Crouse J, 2015, NAT REV IMMUNOL, V15, P231, DOI 10.1038/nri3806; Danese S, 2008, MED RES REV, V28, P201, DOI 10.1002/med.20103; Danese S, 2011, NEW ENGL J MED, V365, P1713, DOI 10.1056/NEJMra1102942; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; DeFilipp Z, 2018, BLOOD ADV, V2, P745, DOI 10.1182/bloodadvances.2018017731; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Derby LE, 1998, EPIDEMIOLOGY, V9, P205, DOI 10.1097/00001648-199803000-00018; Dey BR, 1998, BLOOD, V91, P3315, DOI 10.1182/blood.V91.9.3315.3315_3315_3322; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; Duggan AE, 1998, GUT, V43, P494, DOI 10.1136/gut.43.4.494; Ellison CA, 1998, J IMMUNOL, V161, P631; Ellison CA, 2003, IMMUNOLOGY, V109, P440, DOI 10.1046/j.1365-2567.2003.01663.x; Eriguchi Y, 2015, TRANSPL INFECT DIS, V17, P702, DOI 10.1111/tid.12423; Eriguchi Y, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121886; Eriguchi Y, 2012, BLOOD, V120, P223, DOI 10.1182/blood-2011-12-401166; Farin HF, 2014, J EXP MED, V211, P1388, DOI 10.1084/jem.20130753; Fensterl V, 2011, J INTERF CYTOK RES, V31, P71, DOI 10.1089/jir.2010.0101; Ferrara JLM, 2007, BEST PRACT RES CL HA, V20, P91, DOI 10.1016/j.beha.2006.11.004; Ferrara JLM, 2003, INT J HEMATOL, V78, P181, DOI 10.1007/BF02983793; Fischer JC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51431-2; Fischer JC, 2019, INT J RADIAT ONCOL, V103, P970, DOI 10.1016/j.ijrobp.2018.11.038; Fischer JC, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag2513; Gadalla SM, 2020, LANCET HAEMATOL, V7, pE715, DOI 10.1016/S2352-3026(20)30294-5; Galani IE, 2017, IMMUNITY, V46, P875, DOI 10.1016/j.immuni.2017.04.025; Ganetsky A, 2019, BONE MARROW TRANSPL, V54, P212, DOI 10.1038/s41409-018-0236-z; Gilliet M, 2008, NAT REV IMMUNOL, V8, P594, DOI 10.1038/nri2358; Goubau D, 2013, IMMUNITY, V38, P855, DOI 10.1016/j.immuni.2013.05.007; Gunther C, 2019, GASTROENTEROLOGY, V157, P1310, DOI 10.1053/j.gastro.2019.07.031; Guenzi E, 2003, EMBO J, V22, P3772, DOI 10.1093/emboj/cdg382; Guenzi E, 2001, EMBO J, V20, P5568, DOI 10.1093/emboj/20.20.5568; Guo JJ, 2000, VIROLOGY, V267, P209, DOI 10.1006/viro.1999.0135; Gutierrez-Merino J, 2020, GUT MICROBES, V11, DOI 10.1080/19490976.2019.1707015; Haep L, 2015, INFLAMM BOWEL DIS, V21, P2360, DOI 10.1097/MIB.0000000000000490; Hamer HM, 2008, ALIMENT PHARM THER, V27, P104, DOI 10.1111/j.1365-2036.2007.03562.x; Haring E, 2021, HAEMATOLOGICA, V106, P2131, DOI 10.3324/haematol.2019.242990; Hehlmann R, 1999, BLOOD, V94, P3668, DOI 10.1182/blood.V94.11.3668.423a31_3668_3677; Hernandez PP, 2015, NAT IMMUNOL, V16, P698, DOI 10.1038/ni.3180; Hill GR, 1997, BLOOD, V90, P3204, DOI 10.1182/blood.V90.8.3204; Holler E, 2014, BIOL BLOOD MARROW TR, V20, P640, DOI 10.1016/j.bbmt.2014.01.030; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Huang Y, 2016, AM J TRANSL RES, V8, P2490; Ito R, 2006, CLIN EXP IMMUNOL, V146, P330, DOI 10.1111/j.1365-2249.2006.03214.x; Izaguirre A, 2003, J LEUKOCYTE BIOL, V74, P1125, DOI 10.1189/jlb.0603255; Jagasia M, 2020, BLOOD, V135, P1739, DOI 10.1182/blood.2020004823; Jagasia MH, 2015, BIOL BLOOD MARROW TR, V21, P389, DOI 10.1016/j.bbmt.2014.12.001; Jenq RR, 2015, BIOL BLOOD MARROW TR, V21, P1373, DOI 10.1016/j.bbmt.2015.04.016; Jenq RR, 2012, J EXP MED, V209, P902, DOI 10.1084/jem.20112408; Johansson JE, 2007, DIGEST DIS SCI, V52, P2340, DOI 10.1007/s10620-006-9404-x; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Kakihana K, 2016, BLOOD, V128, P2083, DOI 10.1182/blood-2016-05-717652; Kaplan GG, 2014, NAT REV GASTRO HEPAT, V11, P708, DOI 10.1038/nrgastro.2014.182; Kaser A, 2014, BEST PRACT RES CL GA, V28, P437, DOI 10.1016/j.bpg.2014.04.005; Katakura K, 2005, J CLIN INVEST, V115, P695, DOI 10.1172/JCI200522996; Kattner AS, 2020, ANN HEMATOL, V99, P847, DOI 10.1007/s00277-020-03968-w; Kim DS, 2018, EBIOMEDICINE, V28, P261, DOI 10.1016/j.ebiom.2018.01.002; Kim KU, 2021, ARCH PHARM RES, V44, P293, DOI 10.1007/s12272-021-01318-6; Klampfer L, 2003, MOL CANCER RES, V1, P855; Kobayashi T, 2008, GUT, V57, P1682, DOI 10.1136/gut.2007.135053; Kolb HJ, 2004, BLOOD, V103, P767, DOI 10.1182/blood-2003-02-0342; Kole A, 2013, J IMMUNOL, V191, P2771, DOI 10.4049/jimmunol.1301093; Kotenko SV, 2011, CURR OPIN IMMUNOL, V23, P583, DOI 10.1016/j.coi.2011.07.007; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Koutroubakis IE, 2002, INFLAMM BOWEL DIS, V8, P277, DOI 10.1097/00054725-200207000-00007; Krenger W, 1996, IMMUNOL RES, V15, P50, DOI 10.1007/BF02918284; Lee SE, 2012, GASTROENTEROLOGY, V143, P145, DOI 10.1053/j.gastro.2012.03.042; Levine JE, 2013, BLOOD, V122, P1505, DOI 10.1182/blood-2013-02-485813; Lindemans CA, 2015, NATURE, V528, P560, DOI 10.1038/nature16460; Liu TC, 2016, ANNU REV PATHOL-MECH, V11, P127, DOI 10.1146/annurev-pathol-012615-044152; MacMillan ML, 2012, BRIT J HAEMATOL, V157, P732, DOI 10.1111/j.1365-2141.2012.09114.x; Mahlakoiv T, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004782; McFarland AP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016967; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; Mennechet FJD, 2006, BLOOD, V107, P4417, DOI 10.1182/blood-2005-10-4129; Mirpuri J, 2010, J IMMUNOL, V184, P7186, DOI 10.4049/jimmunol.0903116; Montoya M, 2002, BLOOD, V99, P3263, DOI 10.1182/blood.V99.9.3263; Mordstein M, 2010, J VIROL, V84, P5670, DOI 10.1128/JVI.00272-10; Morton AJ, 1998, BLOOD, V92, P394, DOI 10.1182/blood.V92.2.394.414k42_394_401; MOWAT AM, 1989, IMMUNOLOGY, V68, P18; Nalle SC, 2015, MUCOSAL IMMUNOL, V8, P720, DOI 10.1038/mi.2015.40; Naschberger E, 2008, INT J CANCER, V123, P2120, DOI 10.1002/ijc.23764; Nava P, 2014, MOL BIOL CELL, V25, P2894, DOI 10.1091/mbc.E13-09-0512; Nava P, 2010, IMMUNITY, V32, P392, DOI 10.1016/j.immuni.2010.03.001; Neuman MG, 2007, TRANSL RES, V149, P173, DOI 10.1016/j.trsl.2006.11.009; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Ng SC, 2009, INFLAMM BOWEL DIS, V15, P935, DOI 10.1002/ibd.20797; Nice TJ, 2015, SCIENCE, V347, P269, DOI 10.1126/science.1258100; Norona J, 2020, BLOOD, V136, P1442, DOI 10.1182/blood.2020005957; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Odenwald MA, 2013, CLIN GASTROENTEROL H, V11, P1075, DOI 10.1016/j.cgh.2013.07.001; Padovan E, 2002, J LEUKOCYTE BIOL, V71, P669; Paludan SR, 2013, IMMUNITY, V38, P870, DOI 10.1016/j.immuni.2013.05.004; Parlato S, 2001, BLOOD, V98, P3022, DOI 10.1182/blood.V98.10.3022; Pervolaraki K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00459; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; Pestka Sidney, 1997, Cytokine and Growth Factor Reviews, V8, P189, DOI 10.1016/S1359-6101(97)00009-9; Phinney DG, 2007, CELL CYCLE, V6, P2884, DOI 10.4161/cc.6.23.5095; Phinney DG, 2012, J CELL BIOCHEM, V113, P2806, DOI 10.1002/jcb.24166; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Polchert D, 2008, EUR J IMMUNOL, V38, P1745, DOI 10.1002/eji.200738129; Pott J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00258; Pott J, 2011, P NATL ACAD SCI USA, V108, P7944, DOI 10.1073/pnas.1100552108; Radford-Smith GL, 2002, GUT, V51, P808, DOI 10.1136/gut.51.6.808; Radvanyi LG, 1999, SCAND J IMMUNOL, V50, P499; Raetz M, 2013, NAT IMMUNOL, V14, P136, DOI 10.1038/ni.2508; Rauch I, 2014, EUR J IMMUNOL, V44, P2749, DOI 10.1002/eji.201344401; Reich NC, 2013, J INTERF CYTOK RES, V33, P199, DOI 10.1089/jir.2012.0159; Reinisch W, 2010, INFLAMM BOWEL DIS, V16, P233, DOI 10.1002/ibd.21038; REYES VE, 1987, TRANSPLANTATION, V43, P412, DOI 10.1097/00007890-198703000-00018; Ringden O, 2006, TRANSPLANTATION, V81, P1390, DOI 10.1097/01.tp.0000214462.63943.14; Robb RJ, 2011, BLOOD, V118, P3399, DOI 10.1182/blood-2010-12-325746; Rouzaut A, 2010, EUR J IMMUNOL, V40, P3054, DOI 10.1002/eji.201040523; Russel MG, 1997, GASTROENTEROLOGY, V113, P377, DOI 10.1053/gast.1997.v113.pm9247453; Ryan JM, 2007, CLIN EXP IMMUNOL, V149, P353, DOI 10.1111/j.1365-2249.2007.03422.x; Sainathan SK, 2012, INFLAMM BOWEL DIS, V18, P955, DOI 10.1002/ibd.21867; Sandborn WJ, 2016, J CROHNS COLITIS, V10, P418, DOI 10.1093/ecco-jcc/jjv224; Sandborn WJ, 2014, CLIN GASTROENTEROL H, V12, P1485, DOI 10.1016/j.cgh.2014.01.029; Sandborn WJ, 2012, NEW ENGL J MED, V367, P616, DOI 10.1056/NEJMoa1112168; Saxena K, 2017, P NATL ACAD SCI USA, V114, pE570, DOI 10.1073/pnas.1615422114; SCHEPPACH W, 1992, GASTROENTEROLOGY, V103, P51, DOI 10.1016/0016-5085(92)91094-K; Schnoor M, 2009, MUCOSAL IMMUNOL, V2, P33, DOI 10.1038/mi.2008.62; Schoggins JW, 2019, ANNU REV VIROL, V6, P567, DOI 10.1146/annurev-virology-092818-015756; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Seiderer J, 2008, INFLAMM BOWEL DIS, V14, P437, DOI 10.1002/ibd.20339; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Simmons DP, 2012, J IMMUNOL, V188, P3116, DOI 10.4049/jimmunol.1101313; Singh UP, 2016, CYTOKINE, V77, P44, DOI 10.1016/j.cyto.2015.10.008; Sivaprakasam S, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080856; Sommereyns C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000017; Sotiropoulou PA, 2006, STEM CELLS, V24, P462, DOI 10.1634/stemcells.2004-0331; Spindelboeck W, 2017, HAEMATOLOGICA, V102, pE210, DOI 10.3324/haematol.2016.154351; Spoerl S, 2014, BLOOD, V123, P3832, DOI 10.1182/blood-2013-12-543736; Stanifer ML, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.608645; Stanifer ML, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107863; Stanifer ML, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061445; Steinhart AH, 1996, ALIMENT PHARM THER, V10, P729, DOI 10.1046/j.1365-2036.1996.d01-509.x; Swimm A, 2018, BLOOD, V132, P2506, DOI 10.1182/blood-2018-03-838193; Syedbasha M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00119; Sykes M, 1999, Biol Blood Marrow Transplant, V5, P277, DOI 10.1016/S1083-8791(99)70002-9; SYKES M, 1995, BLOOD, V86, P2429, DOI 10.1182/blood.V86.6.2429.bloodjournal8662429; Takaoka A, 2006, CELL MICROBIOL, V8, P907, DOI 10.1111/j.1462-5822.2006.00716.x; Takashima S, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aay8556; Takashima S, 2011, J EXP MED, V208, P285, DOI 10.1084/jem.20101559; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Thomas A, 2014, J AM BOARD FAM MED, V27, P411, DOI 10.3122/jabfm.2014.03.130224; van Lier YF, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz8926; VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5; Verma R, 2013, EUR CYTOKINE NETW, V24, P130, DOI 10.1684/ecn.2013.0343; Vermeire S, 2017, LANCET, V389, P266, DOI 10.1016/S0140-6736(16)32537-5; VERNIA P, 1995, ALIMENT PHARM THERAP, V9, P309; VIDALI G, 1978, P NATL ACAD SCI USA, V75, P2239, DOI 10.1073/pnas.75.5.2239; Wang H, 2014, IMMUNOL REV, V258, P30, DOI 10.1111/imr.12151; Wang YJ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006790.pub3; Weinlander K, 2008, FASEB J, V22, P4168, DOI 10.1096/fj.08-107524; Welniak LA, 2000, BIOL BLOOD MARROW TR, V6, P604, DOI 10.1016/S1083-8791(00)70025-5; Welniak LA, 2007, ANNU REV IMMUNOL, V25, P139, DOI 10.1146/annurev.immunol.25.022106.141606; Winkler ES, 2020, CELL, V182, P901, DOI 10.1016/j.cell.2020.06.029; Yan JB, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/8813558; Yang KT, 2021, J EXP MED, V218, DOI 10.1084/jem.20201915; Yang YG, 2002, BLOOD, V99, P4207, DOI 10.1182/blood.V99.11.4207; Yang YG, 1999, LEUKEMIA LYMPHOMA, V33, P409, DOI 10.3109/10428199909058446; Yitbarek A, 2018, BENEF MICROBES, V9, P417, DOI 10.3920/BM2017.0088; Zeiser R, 2020, NEW ENGL J MED, V382, P1800, DOI 10.1056/NEJMoa1917635; Zeiser R, 2019, BRIT J HAEMATOL, V187, P563, DOI 10.1111/bjh.16190; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337; Zeiser R, 2016, BRIT J HAEMATOL, V175, P191, DOI 10.1111/bjh.14295; Zeng MY, 2017, MUCOSAL IMMUNOL, V10, P18, DOI 10.1038/mi.2016.75; Zhai R, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00239; Zundler S, 2015, CYTOKINE GROWTH F R, V26, P559, DOI 10.1016/j.cytogfr.2015.07.003	203	1	1	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 24	2021	12								705342	10.3389/fimmu.2021.705342	http://dx.doi.org/10.3389/fimmu.2021.705342			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TF3BJ	34249014	gold, Green Published			2022-12-18	WOS:000670585500001
J	Klein, K; Witalisz-Siepracka, A; Gotthardt, D; Agerer, B; Locker, F; Grausenburger, R; Knab, VM; Bergthaler, A; Sexl, V				Klein, Klara; Witalisz-Siepracka, Agnieszka; Gotthardt, Dagmar; Agerer, Benedikt; Locker, Felix; Grausenburger, Reinhard; Knab, Vanessa Maria; Bergthaler, Andreas; Sexl, Veronika			T Cell-Intrinsic CDK6 Is Dispensable for Anti-Viral and Anti-Tumor Responses In Vivo	FRONTIERS IN IMMUNOLOGY			English	Article						CDK6; CD8+T cells; metabolism; interferon signaling; suppressor of cytokine signaling (SOCS); anti-viral response; anti-tumor response	CLONAL EXPANSION; IMMUNE-RESPONSE; KINASE-ACTIVITY; SOCS PROTEINS; CUTTING EDGE; CDK4/6; INHIBITION; SUPPRESSOR; RECEPTOR; PALBOCICLIB	The cyclin-dependent kinase 6 (CDK6) regulates the transition through the G1-phase of the cell cycle, but also acts as a transcriptional regulator. As such CDK6 regulates cell survival or cytokine secretion together with STATs, AP-1 or NF-kappa B. In the hematopoietic system, CDK6 regulates T cell development and promotes leukemia and lymphoma. CDK4/6 kinase inhibitors are FDA approved for treatment of breast cancer patients and have been reported to enhance T cell-mediated anti-tumor immunity. The involvement of CDK6 in T cell functions remains enigmatic. We here investigated the role of CDK6 in CD8+ T cells, using previously generated CDK6 knockout (Cdk6 (-/-)) and kinase-dead mutant CDK6 (Cdk6 (K43M)) knock-in mice. RNA-seq analysis indicated a role of CDK6 in T cell metabolism and interferon (IFN) signaling. To investigate whether these CDK6 functions are T cell-intrinsic, we generated a T cell-specific CDK6 knockout mouse model (Cdk6 (fl/fl) CD4-Cre). T cell-intrinsic loss of CDK6 enhanced mitochondrial respiration in CD8+ T cells, but did not impact on cytotoxicity and production of the effector cytokines IFN-gamma and TNF-alpha by CD8+ T cells in vitro. Loss of CDK6 in peripheral T cells did not affect tumor surveillance of MC38 tumors in vivo. Similarly, while we observed an impaired induction of early responses to type I IFN in CDK6-deficient CD8+ T cells, we failed to observe any differences in the response to LCMV infection upon T cell-intrinsic loss of CDK6 in vivo. This apparent contradiction might at least partially be explained by the reduced expression of Socs1, a negative regulator of IFN signaling, in CDK6-deficient CD8+ T cells. Therefore, our data are in line with a dual role of CDK6 in IFN signaling; while CDK6 promotes early IFN responses, it is also involved in the induction of a negative feedback loop. These data assign CDK6 a role in the fine-tuning of cytokine responses.	[Klein, Klara; Witalisz-Siepracka, Agnieszka; Gotthardt, Dagmar; Grausenburger, Reinhard; Knab, Vanessa Maria; Sexl, Veronika] Univ Vet Med Vienna, Inst Pharmacol & Toxicol, Vienna, Austria; [Witalisz-Siepracka, Agnieszka] Karl Landsteiner Univ Hlth Sci, Div Pharmacol, Dept Pharmacol Physiol & Microbiol, Krems, Austria; [Agerer, Benedikt; Bergthaler, Andreas] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria; [Locker, Felix] Univ Vet Med, Inst Physiol Pathophysiol & Biophys, Vienna, Austria	University of Veterinary Medicine Vienna; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; University of Veterinary Medicine Vienna	Sexl, V (corresponding author), Univ Vet Med Vienna, Inst Pharmacol & Toxicol, Vienna, Austria.	veronika.sexl@vetmeduni.ac.at	Sternberg, Felix/ABE-7814-2021; Bergthaler, Andreas/ABG-5047-2020	Sternberg, Felix/0000-0003-3487-362X; Bergthaler, Andreas/0000-0003-0597-1976; Gotthardt, Dagmar/0000-0002-8416-1236; Knab, Vanessa Maria/0000-0001-9493-7627	Austrian Science Fund FWF [FWF W1212]; FWF [SFB-F06107]; European Research Council (ERC) under the European Union [694354]	Austrian Science Fund FWF(Austrian Science Fund (FWF)); FWF(Austrian Science Fund (FWF)); European Research Council (ERC) under the European Union(European Research Council (ERC))	The work was supported by the Austrian Science Fund FWF funded Ph.D. program, "Inflammation and Immunity" FWF W1212, FWF grant SFB-F06107 and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program grant agreement 694354.	Aichele P, 2006, J IMMUNOL, V176, P4525, DOI 10.4049/jimmunol.176.8.4525; Akhtar LN, 2010, J IMMUNOL, V185, P2393, DOI 10.4049/jimmunol.0903563; Baazim H, 2019, NAT IMMUNOL, V20, P701, DOI 10.1038/s41590-019-0397-y; Bellutti F, 2018, CANCER DISCOV, V8, P884, DOI 10.1158/2159-8290.CD-17-0912; Bhattacharya A, 2015, IMMUNITY, V43, P974, DOI 10.1016/j.immuni.2015.10.013; Chaikovsky AC, 2018, MOL CANCER RES, V16, P1454, DOI 10.1158/1541-7786.MCR-18-0201; Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Chen ZY, 2019, IMMUNITY, V51, P840, DOI 10.1016/j.immuni.2019.09.013; Choi YJ, 2012, CANCER CELL, V22, P438, DOI 10.1016/j.ccr.2012.09.015; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; CORBETT TH, 1975, CANCER RES, V35, P2434; Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0; Croker BA, 2008, SEMIN CELL DEV BIOL, V19, P414, DOI 10.1016/j.semcdb.2008.07.010; Crouse J, 2014, IMMUNITY, V40, P961, DOI 10.1016/j.immuni.2014.05.003; Curtsinger JM, 2005, J IMMUNOL, V174, P4465, DOI 10.4049/jimmunol.174.8.4465; De Simone M, 2016, IMMUNITY, V45, P1135, DOI 10.1016/j.immuni.2016.10.021; Deng JH, 2018, CANCER DISCOV, V8, P216, DOI 10.1158/2159-8290.CD-17-0915; Doma E, 2021, BLOOD ADV, V5, P39, DOI 10.1182/bloodadvances.2020003022; Eckelhart E, 2011, BLOOD, V117, P1565, DOI 10.1182/blood-2010-06-291633; Fenner JE, 2006, NAT IMMUNOL, V7, P33, DOI 10.1038/ni1287; Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303; Franco J, 2016, CELL REP, V14, P979, DOI 10.1016/j.celrep.2015.12.094; Gajewski T F, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2004s43; Geltink RIK, 2018, ANNU REV IMMUNOL, V36, P461, DOI 10.1146/annurev-immunol-042617-053019; Goel S, 2018, TRENDS CELL BIOL, V28, P911, DOI 10.1016/j.tcb.2018.07.002; Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465; Goetz MP, 2017, J CLIN ONCOL, V35, P3638, DOI 10.1200/JCO.2017.75.6155; Handschick K, 2014, MOL CELL, V53, P682, DOI 10.1016/j.molcel.2014.02.008; Haynes NM, 2001, J IMMUNOL, V166, P182, DOI 10.4049/jimmunol.166.1.182; Heller G, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101602; Hortobagyi GN, 2016, NEW ENGL J MED, V375, P1738, DOI 10.1056/NEJMoa1609709; Hu MG, 2011, BLOOD, V117, P6120, DOI 10.1182/blood-2010-08-300517; Hu MG, 2009, CANCER RES, V69, P810, DOI 10.1158/0008-5472.CAN-08-2473; Jiang MM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00070; Klein ME, 2018, CANCER CELL, V34, P9, DOI 10.1016/j.ccell.2018.03.023; Kollmann K, 2013, CANCER CELL, V24, P167, DOI 10.1016/j.ccr.2013.07.012; Kolumam GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; Li P, 2017, P NATL ACAD SCI USA, V114, P12111, DOI 10.1073/pnas.1714019114; Lu CW, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0635-8; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Marchetti P, 2020, FASEB J, V34, P13106, DOI 10.1096/fj.202000767R; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Maurer B, 2021, HAEMATOLOGICA, V106, P2624, DOI 10.3324/haematol.2020.256313; Musella M, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1314424; Nebenfuehr S, 2020, INT J CANCER, V147, P2988, DOI 10.1002/ijc.33054; Palmer DC, 2009, TRENDS IMMUNOL, V30, P592, DOI 10.1016/j.it.2009.09.009; Pernas S, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758835918786451; Pfeffer LM, 2011, J INTERF CYTOK RES, V31, P553, DOI 10.1089/jir.2011.0028; Piganis RAR, 2011, J BIOL CHEM, V286, P33811, DOI 10.1074/jbc.M111.270207; Pothlichet J, 2008, J IMMUNOL, V180, P2034, DOI 10.4049/jimmunol.180.4.2034; Quinn KM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17441-9; Ryan MH, 2001, CANCER IMMUNOL IMMUN, V49, P603, DOI 10.1007/s002620000156; Sawai CM, 2012, CANCER CELL, V22, P452, DOI 10.1016/j.ccr.2012.09.016; Schaer DA, 2018, CELL REP, V22, P2978, DOI 10.1016/j.celrep.2018.02.053; Scheicher R, 2015, BLOOD, V125, P90, DOI 10.1182/blood-2014-06-584417; Schmoellerl J, 2020, BLOOD, V136, P387, DOI 10.1182/blood.2019003267; Sharma Suveena, 2014, Curr Protoc Immunol, V105, DOI 10.1002/0471142735.im1034s105; Skowron MA, 2020, BRIT J CANCER, V123, P378, DOI 10.1038/s41416-020-0891-x; Teo ZL, 2017, CANCER RES, V77, P6340, DOI 10.1158/0008-5472.CAN-17-2210; Tigan AS, 2016, ONCOGENE, V35, P3083, DOI 10.1038/onc.2015.407; Uras IZ, 2019, BLOOD, V133, P1677, DOI 10.1182/blood-2018-08-872648; Uras IZ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123987; Uras IZ, 2016, BLOOD, V127, P2890, DOI 10.1182/blood-2015-11-683581; van der Windt GJW, 2012, IMMUNITY, V36, P68, DOI 10.1016/j.immuni.2011.12.007; Vielnascher RM, 2014, TRANSGENIC RES, V23, P519, DOI 10.1007/s11248-014-9795-y; Wang HZ, 2017, NATURE, V546, P426, DOI 10.1038/nature22797; Welsh RM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002352; Wiesel M, 2011, J IMMUNOL, V186, P754, DOI 10.4049/jimmunol.1003166; Wu TQ, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aai8593; Wu YM, 2020, CANCER MANAG RES, V12, P3477, DOI 10.2147/CMAR.S250632; Xu HC, 2014, IMMUNITY, V40, P949, DOI 10.1016/j.immuni.2014.05.004; YANAGISAWA M, 1984, BIOMED RES-TOKYO, V5, P19, DOI 10.2220/biomedres.5.19; Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093	75	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 24	2021	12								650977	10.3389/fimmu.2021.650977	http://dx.doi.org/10.3389/fimmu.2021.650977			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TF3VR	34248938	Green Published, gold			2022-12-18	WOS:000670645300001
J	Richardson, S; Medhavi, F; Tanner, T; Lundy, S; Omosun, Y; Igietseme, JU; Carroll, D; Eko, FO				Richardson, Shakyra; Medhavi, Fnu; Tanner, Tayhlor; Lundy, Stephanie; Omosun, Yusuf; Igietseme, Joseph U.; Carroll, Darin; Eko, Francis O.			Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine	FRONTIERS IN IMMUNOLOGY			English	Article						Chlamydia abortus; Pmp18D; vaccine delivery; Flt3L; adjuvant	OUTER-MEMBRANE PROTEIN; GENITAL-TRACT INFECTION; INDUCE PROTECTIVE IMMUNITY; OVINE ENZOOTIC ABORTION; VIBRIO-CHOLERAE GHOSTS; CD4(+) T-CELLS; DENDRITIC CELLS; TRACHOMATIS INFECTION; GAMMA-INTERFERON; MURINE MODEL	Efficacious vaccines are needed to control genital chlamydial diseases in humans and the veterinary industry. We previously reported a C. abortus (Cab) vaccine comprising recombinant Vibrio cholerae ghosts (rVCG) expressing the conserved and immunogenic N-terminal region of the Cab polymorphic membrane protein D (rVCG-Pmp18.1) protein that protected mice against intravaginal challenge. In this study, we investigated the immunomodulatory effect of the hematopoietic progenitor activator cytokine, Fms-like tyrosine kinase 3-ligand (FL) when co-administered with the rVCG-Pmp18.1 vaccine as a strategy to enhance the protective efficacy and the potential mechanism of immunomodulation. Groups of female C57BL/6J mice were immunized and boosted twice intranasally (IN) with rVCG-PmpD18.1 with and without FL or purified rPmp18.1 or rVCG-gD2 (antigen control) or PBS (medium) per mouse. The results revealed that co-administration of the vaccine with FL enhanced antigen-specific cellular and humoral immune responses and protected against live Cab genital infection. Comparative analysis of immune cell phenotypes infiltrating mucosal and systemic immune inductive tissue sites following immunization revealed that co-administration of rVCG-Pmp18.1 with FL significantly enhanced the number of macrophages, dendritic and NK cells, gamma delta and NK T cells in the spleen (systemic) and iliac lymph nodes (ILN) draining the genital tract (mucosal) tissues compared to rVCG-Pmp18.1 alone. Furthermore, FL enhanced monocyte infiltration in the ILN, while CD19+ B cells and CD4+ T cells were enhanced in the spleen. These results indicate that the immunomodulatory effect of FL is associated with its ability to mobilize innate immune cells and subsequent activation of robust antigen-specific immune effectors in mucosal and systemic lymphoid tissues.	[Richardson, Shakyra; Medhavi, Fnu; Tanner, Tayhlor; Lundy, Stephanie; Omosun, Yusuf; Eko, Francis O.] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA USA; [Igietseme, Joseph U.; Carroll, Darin] Centers Dis Control & Prevent CDC, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA USA	Morehouse School of Medicine; Centers for Disease Control & Prevention - USA	Eko, FO (corresponding author), Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA USA.	feko@msm.edu			National Institutes of Health [R01AI126897]; National Center for Research Resources, National Institutes of Health [1 C06 RR18386]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This research was funded by the National Institutes of Health (R01AI126897) to FE. The investigation was conducted in a facility constructed with support from Research Facilities Improvement Grant #1 C06 RR18386 from the National Center for Research Resources, National Institutes of Health.	Agrawal T, 2009, J REPROD IMMUNOL, V83, P173, DOI 10.1016/j.jri.2009.07.013; Allam JP, 2009, CURR OPIN ALLERGY CL, V9, P554, DOI 10.1097/ACI.0b013e32833239a9; ARNO JN, 1994, SEX TRANSM DIS, V21, P47, DOI 10.1097/00007435-199401000-00010; Asanuma H, 2012, VACCINE, V30, P803, DOI 10.1016/j.vaccine.2011.10.093; Bagdonas J., 2005, Polish Journal of Veterinary Sciences, V8, P49; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Baud D, 2008, CURR OPIN INFECT DIS, V21, P70, DOI 10.1097/QCO.0b013e3282f3e6a5; Buendia AJ, 2004, J COMP PATHOL, V130, P48, DOI 10.1016/S0021-9975(03)00069-0; Caspe SG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242526; Chaganty BKR, 2010, VACCINE, V28, P2323, DOI 10.1016/j.vaccine.2009.12.064; Champion CI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005409; CLEMENTS C, 1979, AM J OPHTHALMOL, V87, P350, DOI 10.1016/0002-9394(79)90076-X; Cohen CR, 2005, J INFECT DIS, V192, P591, DOI 10.1086/432070; COTTER TW, 1995, INFECT IMMUN, V63, P4704, DOI 10.1128/IAI.63.12.4704-4714.1995; Crane DD, 2006, P NATL ACAD SCI USA, V103, P1894, DOI 10.1073/pnas.0508983103; DAWSON M, 1986, RES VET SCI, V40, P59, DOI 10.1016/S0034-5288(18)30487-9; Eko FO, 2011, VACCINE, V29, P3802, DOI 10.1016/j.vaccine.2011.03.027; Eko FO, 2011, VACCINE, V29, P1472, DOI 10.1016/j.vaccine.2010.12.024; Eko FO, 2000, J BIOTECHNOL, V83, P115, DOI 10.1016/S0168-1656(00)00315-1; Eko FO, 2004, J IMMUNOL, V173, P3375, DOI 10.4049/jimmunol.173.5.3375; Eko FO, 2003, VACCINE, V21, P1694, DOI 10.1016/S0264-410X(02)00677-1; Eko Francis O, 2014, BMC Immunol, V15, P584, DOI 10.1186/s12865-014-0056-x; Ekong EE, 2009, FEMS IMMUNOL MED MIC, V55, P280, DOI 10.1111/j.1574-695X.2008.00493.x; Farris CM, 2010, INFECT IMMUN, V78, P4374, DOI 10.1128/IAI.00622-10; Fong CL, 2002, GENE THER, V9, P1127, DOI 10.1038/sj.gt.3301783; Fukuiwa T, 2008, VACCINE, V26, P4849, DOI 10.1016/j.vaccine.2008.06.091; Fukuyama Y, 2011, J IMMUNOL, V186, P2454, DOI 10.4049/jimmunol.1002837; Gerber Andrea, 2007, BMC Vet Res, V3, P24, DOI 10.1186/1746-6148-3-24; Gomes JP, 2006, J BACTERIOL, V188, P275, DOI 10.1128/JB.188.1.275-286.2006; Gondek DC, 2012, J IMMUNOL, V189, P2441, DOI 10.4049/jimmunol.1103032; Gondek DC, 2009, J IMMUNOL, V183, P1313, DOI 10.4049/jimmunol.0900295; GRAYSTON JT, 1978, SEX TRANSM DIS, V5, P73, DOI 10.1097/00007435-197804000-00011; Gutierrez J, 2011, VET MICROBIOL, V147, P119, DOI 10.1016/j.vetmic.2010.06.015; Hickey DK, 2009, VACCINE, V27, P6217, DOI 10.1016/j.vaccine.2009.08.001; HOUDART R, 1987, GASTROEN CLIN BIOL, V11, P338; Howard C. J., 2004, Animal Health Research Reviews, V5, P1, DOI [10.1079/AHRR200464, 10.1079/AHR200468]; Igietseme Joseph U, 2003, Expert Rev Vaccines, V2, P129, DOI 10.1586/14760584.2.1.129; Igietseme Joseph U, 2004, Expert Rev Vaccines, V3, P23; Igietseme JU, 2009, J INFECT DIS, V200, P926, DOI 10.1086/605411; IGIETSEME JU, 1994, INFECT IMMUN, V62, P5195, DOI 10.1128/IAI.62.11.5195-5197.1994; Igietseme JU, 1998, INFECT IMMUN, V66, P4030; Ito JI, 1999, INFECT IMMUN, V67, P5518, DOI 10.1128/IAI.67.10.5518-5521.1999; Jiao L, 2011, J IMMUNOL, V187, P401, DOI 10.4049/jimmunol.1002519; Johansson M, 1997, INFECT IMMUN, V65, P1032, DOI 10.1128/IAI.65.3.1032-1044.1997; Johnson RM, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00614-17; Johnson RM, 2012, INFECT IMMUN, V80, P2204, DOI 10.1128/IAI.06339-11; Kataoka K, 2011, INFECT IMMUN, V79, P2819, DOI 10.1128/IAI.01360-10; Kiselev AO, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005191; Kodama S, 2010, VACCINE, V28, P2510, DOI 10.1016/j.vaccine.2010.01.043; Lai JY, 2020, NAT IMMUNOL, V21, P914, DOI 10.1038/s41590-020-0676-7; Li LX, 2015, IMMUNOL LETT, V164, P88, DOI 10.1016/j.imlet.2015.02.004; Longbottom D, 2006, VET J, V171, P263, DOI 10.1016/j.tvjl.2004.09.006; Longbottom D, 2002, J CLIN MICROBIOL, V40, P4235, DOI 10.1128/JCM.40.11.4235-4243.2002; Longbottom D, 2018, VACCINE, V36, P3593, DOI 10.1016/j.vaccine.2018.05.042; Longbottom D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057950; Macmillan L, 2007, FEMS IMMUNOL MED MIC, V49, P46, DOI 10.1111/j.1574-695X.2006.00165.x; Manam S, 2013, PATHOG DIS, V67, P221, DOI 10.1111/2049-632X.12032; Moore T, 2003, J INFECT DIS, V188, P617, DOI 10.1086/377134; Moore T, 2002, IMMUNOLOGY, V105, P213, DOI 10.1046/j.0019-2805.2001.01354.x; Morrison RP, 2002, INFECT IMMUN, V70, P2741, DOI 10.1128/IAI.70.6.2741-2751.2002; Morrison SG, 2005, J IMMUNOL, V175, P7536, DOI 10.4049/jimmunol.175.11.7536; Murphey C, 2006, CELL IMMUNOL, V242, P110, DOI 10.1016/j.cellimm.2006.10.002; Murthy AK, 2007, INFECT IMMUN, V75, P666, DOI 10.1128/IAI.01280-06; Murthy AK, 2009, FEMS IMMUNOL MED MIC, V55, P271, DOI 10.1111/j.1574-695X.2008.00517.x; Mwangi W, 2002, J IMMUNOL, V169, P3837, DOI 10.4049/jimmunol.169.7.3837; Navegantes KC, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1141-8; Olivares-Zavaleta N, 2010, VACCINE, V28, P1454, DOI 10.1016/j.vaccine.2009.11.073; Olsen AW, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01652; Pais R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01577; Pal S, 1997, VACCINE, V15, P575, DOI 10.1016/S0264-410X(97)00206-5; Pan Q, 2015, VACCINE, V33, P1865, DOI 10.1016/j.vaccine.2015.02.007; Parrett CJ, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00084; Picard MD, 2015, CLIN VACCINE IMMUNOL, V22, P1206, DOI 10.1128/CVI.00247-15; Qian C, 2018, SEMIN IMMUNOL, V35, P3, DOI 10.1016/j.smim.2017.12.002; RAMSEY KH, 1988, INFECT IMMUN, V56, P1320, DOI 10.1128/IAI.56.5.1320-1325.1988; Stagg AJ, 1998, MOL MED TODAY, V4, P166, DOI 10.1016/S1357-4310(98)01232-5; STARNBACH MN, 1995, INFECT IMMUN, V63, P3527, DOI 10.1128/IAI.63.9.3527-3530.1995; Stary G, 2015, SCIENCE, V348, DOI 10.1126/science.aaa8205; SU H, 1995, VACCINE, V13, P1023, DOI 10.1016/0264-410X(95)00017-U; Tan C, 2009, INFECT IMMUN, V77, P3218, DOI 10.1128/IAI.01566-08; Thomas R, 2021, J IMMUNOL, V206, P1251, DOI 10.4049/jimmunol.2001013; Tifrea DF, 2020, J INFECT DIS, V221, P191, DOI 10.1093/infdis/jiz438; Tifrea DF, 2014, J IMMUNOL, V192, P5201, DOI 10.4049/jimmunol.1303392; Tsapogas P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061115; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Walder G, 2005, OBSTET GYNECOL, V106, P1215, DOI 10.1097/01.AOG.0000161060.69470.9c; Walsh KP, 2013, TRENDS IMMUNOL, V34, P521, DOI 10.1016/j.it.2013.07.006; Wehrl W, 2004, MOL MICROBIOL, V51, P319, DOI 10.1046/j.1365-2958.2003.03838.x; Wheelhouse N, 2010, VACCINE, V28, P5657, DOI 10.1016/j.vaccine.2010.04.114; Wheelhouse N, 2009, VET RES, V40, DOI 10.1051/vetres/2009030; Wheelhouse NM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049190; WILSMORE AJ, 1984, BRIT VET J, V140, P380, DOI 10.1016/0007-1935(84)90130-1; Yang X, 1998, Can J Infect Dis, V9, P99; Yo YT, 2007, CANCER GENE THER, V14, P904, DOI 10.1038/sj.cgt.7701081; Yu H, 2012, INFECT IMMUN, V80, P1510, DOI 10.1128/IAI.06338-11; Zhang F, 2009, ZOONOSES PUBLIC HLTH, V56, P71, DOI 10.1111/j.1863-2378.2008.01160.x; Zhang YC, 2019, VIROL SIN, V34, P662, DOI 10.1007/s12250-019-00144-x; Zhou JZ, 2007, VACCINE, V25, P6367, DOI 10.1016/j.vaccine.2007.06.031	100	1	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 24	2021	12								698737	10.3389/fimmu.2021.698737	http://dx.doi.org/10.3389/fimmu.2021.698737			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TF2VE	34249004	gold, Green Published			2022-12-18	WOS:000670569000001
J	Subiza, JL; Palomares, O; Quinti, I; Sanchez-Ramon, S				Subiza, Jose Luis; Palomares, Oscar; Quinti, Isabella; Sanchez-Ramon, Silvia			Editorial: Trained Immunity-Based Vaccines	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						trained immunity; vaccine; immunostimulant; adjuvant; infection; TIbV			[Subiza, Jose Luis] Inmunotek SL, Alcala De Henares, Spain; [Palomares, Oscar] Univ Complutense Madrid, Fac Chem, Dept Biochem & Mol Biol, Madrid, Spain; [Quinti, Isabella] Sapienza Univ, Fac Med & Psychol, Dept Clin & Mol Med, Rome, Italy; [Sanchez-Ramon, Silvia] San Carlos Univ Clin Hosp, Dept Clin Immunol, Madrid, Spain	Complutense University of Madrid; Sapienza University Rome	Subiza, JL (corresponding author), Inmunotek SL, Alcala De Henares, Spain.	jlsubiza@inmunotek.com	Sanchez-Ramon, Silvia/AAZ-7670-2020; Sanchez-Ramon, Silvia/I-8242-2019	Sanchez-Ramon, Silvia/0000-0001-9585-6167; Sanchez-Ramon, Silvia/0000-0001-9585-6167				Benn CS, 2020, LANCET INFECT DIS, V20, pE274, DOI 10.1016/S1473-3099(19)30742-X; Conejero L., 2021, VIRAL OUTBREAKS; Ifrim DC, 2014, CLIN VACCINE IMMUNOL, V21, P534, DOI 10.1128/CVI.00688-13; Imran S, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101171; Kalafati L, 2020, CELL, V183, P771, DOI 10.1016/j.cell.2020.09.058; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Nieto A, 2021, AM J RESP CRIT CARE, V204, P462, DOI 10.1164/rccm.202003-0520OC; Ochoa-Grullon J, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.611566; Sanchez-Ramon S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02936	9	1	1	6	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 24	2021	12								716296	10.3389/fimmu.2021.716296	http://dx.doi.org/10.3389/fimmu.2021.716296			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TF2SE	34249020	gold, Green Published			2022-12-18	WOS:000670561100001
J	Draberova, L; Tumova, M; Draber, P				Draberova, Lubica; Tumova, Magda; Draber, Petr			Molecular Mechanisms of Mast Cell Activation by Cholesterol-Dependent Cytolysins	FRONTIERS IN IMMUNOLOGY			English	Review						mast cell; cholesterol-dependent cytolysins; pore-forming toxins; Ca2+ signaling; cytokine production; streptolysin O; pneumolysin; listeriolysin O	TUMOR-NECROSIS-FACTOR; CRITICAL PROTECTIVE ROLE; PORE-FORMING TOXINS; PROTEIN-KINASE-C; NF-KAPPA-B; STREPTOLYSIN-O; LISTERIOLYSIN-O; STREPTOCOCCUS-PYOGENES; LIPID RAFTS; CLOSTRIDIUM-PERFRINGENS	Mast cells are potent immune sensors of the tissue microenvironment. Within seconds of activation, they release various preformed biologically active products and initiate the process of de novo synthesis of cytokines, chemokines, and other inflammatory mediators. This process is regulated at multiple levels. Besides the extensively studied IgE and IgG receptors, toll-like receptors, MRGPR, and other protein receptor signaling pathways, there is a critical activation pathway based on cholesterol-dependent, pore-forming cytolytic exotoxins produced by Gram-positive bacterial pathogens. This pathway is initiated by binding the exotoxins to the cholesterol-rich membrane, followed by their dimerization, multimerization, pre-pore formation, and pore formation. At low sublytic concentrations, the exotoxins induce mast cell activation, including degranulation, intracellular calcium concentration changes, and transcriptional activation, resulting in production of cytokines and other inflammatory mediators. Higher toxin concentrations lead to cell death. Similar activation events are observed when mast cells are exposed to sublytic concentrations of saponins or some other compounds interfering with the membrane integrity. We review the molecular mechanisms of mast cell activation by pore-forming bacterial exotoxins, and other compounds inducing cholesterol-dependent plasma membrane perturbations. We discuss the importance of these signaling pathways in innate and acquired immunity.	[Draberova, Lubica; Tumova, Magda; Draber, Petr] Czech Acad Sci, Dept Signal Transduct, Inst Mol Genet, Prague, Czech Republic	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Draberova, L; Draber, P (corresponding author), Czech Acad Sci, Dept Signal Transduct, Inst Mol Genet, Prague, Czech Republic.	draberlu@img.cas.cz; draberpe@img.cas.cz			Czech Science Foundation [18-18521S, 20-16481S];  [RVO 68378050]	Czech Science Foundation(Grant Agency of the Czech Republic); 	This work was supported by projects 18-18521S and 20-16481S from the Czech Science Foundation and by institutional project RVO 68378050.	Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; Agier J, 2018, INFLAMM RES, V67, P737, DOI 10.1007/s00011-018-1164-5; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Arifuzzaman M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav0216; Barbuti G, 2006, INT J MED MICROBIOL, V296, P325, DOI 10.1016/j.ijmm.2005.11.009; BERNHEIM.AW, 1965, SCIENCE, V148, P1229, DOI 10.1126/science.148.3674.1229; Bolz DD, 2015, SHOCK, V43, P178, DOI 10.1097/SHK.0000000000000266; Boyce JA, 2007, IMMUNOL REV, V217, P168, DOI 10.1111/j.1600-065X.2007.00512.x; Brown AM, 1998, MOL BIOL CELL, V9, P1053, DOI 10.1091/mbc.9.5.1053; Bugajev V, 2010, FEBS LETT, V584, P4949, DOI 10.1016/j.febslet.2010.08.045; Bulfone-Paus S, 2017, TRENDS IMMUNOL, V38, P657, DOI 10.1016/j.it.2017.01.008; Carafoli E, 2016, J BIOL CHEM, V291, P20849, DOI 10.1074/jbc.R116.735894; Carrero JA, 2004, J EXP MED, V200, P535, DOI 10.1084/jem.20040769; Carrero JA, 2004, J IMMUNOL, V172, P4866, DOI 10.4049/jimmunol.172.8.4866; Cavalcante MCM, 2002, J STRUCT BIOL, V137, P313, DOI 10.1016/S1047-8477(02)00007-2; Cavalcante MCM, 2000, J BIOL CHEM, V275, P36189, DOI 10.1074/jbc.M005830200; Cheerla R, 2020, J MEMBRANE BIOL, V253, P535, DOI 10.1007/s00232-020-00148-9; Chiarot E, 2013, MBIO, V4, DOI 10.1128/mBio.00387-12; Ayudhya CCN, 2020, J DENT RES, V99, P882, DOI 10.1177/0022034520919107; Christie Michelle P, 2018, Biophys Rev, V10, P1337, DOI 10.1007/s12551-018-0448-x; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; COWELL JL, 1978, ARCH BIOCHEM BIOPHYS, V190, P603, DOI 10.1016/0003-9861(78)90316-8; Cruse G, 2010, J IMMUNOL, V184, P7108, DOI 10.4049/jimmunol.0900802; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Dal Peraro M, 2016, NAT REV MICROBIOL, V14, P77, DOI 10.1038/nrmicro.2015.3; Dietrich N, 2010, P NATL ACAD SCI USA, V107, P8748, DOI 10.1073/pnas.0912551107; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dowd KJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002787; Draber P, 2005, TRENDS IMMUNOL, V26, P621, DOI 10.1016/j.it.2005.09.006; Draber P, 2001, TRENDS GLYCOSCI GLYC, V13, P261, DOI 10.4052/tigg.13.261; Draber P, 2002, MOL IMMUNOL, V38, P1247, DOI 10.1016/S0161-5890(02)00071-8; Draber P, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00095; Draberova L, 2007, J IMMUNOL, V179, P5169, DOI 10.4049/jimmunol.179.8.5169; Dramsi S, 2003, INFECT IMMUN, V71, P3614, DOI 10.1128/IAI.71.6.3614-3618.2003; DUNCAN JL, 1975, J CELL BIOL, V67, P160, DOI 10.1083/jcb.67.1.160; Dwyer DF, 2016, NAT IMMUNOL, V17, P878, DOI 10.1038/ni.3445; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Edelson BT, 2004, BLOOD, V103, P2214, DOI 10.1182/blood-2003-08-2978; Farrand AJ, 2015, J BIOL CHEM, V290, P17733, DOI 10.1074/jbc.M115.656769; Farrand AJ, 2010, P NATL ACAD SCI USA, V107, P4341, DOI 10.1073/pnas.0911581107; Feil SC, 2014, J MOL BIOL, V426, P785, DOI 10.1016/j.jmb.2013.11.020; Flanagan J, 1998, MICROB PATHOGENESIS, V24, P211, DOI 10.1006/mpat.1997.0190; Fleck JD, 2019, MOLECULES, V24, DOI 10.3390/molecules24010171; Fritscher J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00550; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Gekara NO, 2008, CELL MICROBIOL, V10, P225, DOI 10.1111/j.1462-5822.2007.01033.x; Gekara NO, 2007, CELL MICROBIOL, V9, P2008, DOI 10.1111/j.1462-5822.2007.00932.x; Gekara NO, 2010, J INFECT DIS, V202, P1698, DOI 10.1086/657145; Gekara NO, 2005, CELL MICROBIOL, V7, P1345, DOI 10.1111/j.1462-5822.2005.00561.x; Gelber SE, 2008, J BACTERIOL, V190, P3896, DOI 10.1128/JB.01965-07; Giddings KS, 2003, P NATL ACAD SCI USA, V100, P11315, DOI 10.1073/pnas.2033520100; Gilfillan AM, 2006, NAT REV IMMUNOL, V6, P218, DOI 10.1038/nri1782; Gupta N, 2003, MOL BIOL CELL, V14, P432, DOI 10.1091/mbc.02-05-0078; Hancz D, 2019, J INNATE IMMUN, V11, P457, DOI 10.1159/000496403; Harvima IT, 2014, J ALLERGY CLIN IMMUN, V134, P530, DOI 10.1016/j.jaci.2014.03.007; Heiman AS, 1997, PHARMACOLOGY, V54, P153, DOI 10.1159/000139482; Henderson B, 1997, TRENDS MICROBIOL, V5, P454, DOI 10.1016/S0966-842X(97)01125-6; Heuck AP, 2010, SUBCELL BIOCHEM, V51, P551, DOI 10.1007/978-90-481-8622-8_20; Hirasawa N, 1997, CELL SIGNAL, V9, P305, DOI 10.1016/S0898-6568(96)00189-1; Ho NI, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02874; Hotze EM, 2012, BBA-BIOMEMBRANES, V1818, P1028, DOI 10.1016/j.bbamem.2011.07.036; HOWELL TW, 1987, BIOCHIM BIOPHYS ACTA, V927, P177, DOI 10.1016/0167-4889(87)90132-7; Huber M, 2000, J IMMUNOL, V165, P124, DOI 10.4049/jimmunol.165.1.124; Issa E, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00826; Iwaki S, 2005, J BIOL CHEM, V280, P40261, DOI 10.1074/jbc.M506063200; Jacobs T, 1998, MOL MICROBIOL, V28, P1081, DOI 10.1046/j.1365-2958.1998.00858.x; Jobbings CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057102; Kayal S, 1999, MOL MICROBIOL, V31, P1709, DOI 10.1046/j.1365-2958.1999.01305.x; Keyel PA, 2013, TOXINS, V5, P1105, DOI 10.3390/toxins5061105; Koster S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4690; KOFFER A, 1990, J CELL BIOL, V111, P919, DOI 10.1083/jcb.111.3.919; Kozorog M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24692-6; Kramer S, 2008, J IMMUNOL, V181, P1438, DOI 10.4049/jimmunol.181.2.1438; Lam GY, 2011, CELL HOST MICROBE, V10, P627, DOI 10.1016/j.chom.2011.11.005; Logsdon LK, 2011, MBIO, V2, DOI 10.1128/mBio.00332-10; Lorent JH, 2014, ORG BIOMOL CHEM, V12, P8803, DOI 10.1039/c4ob01652a; Ma HT, 2011, ADV EXP MED BIOL, V716, P62, DOI 10.1007/978-1-4419-9533-9_5; Magassa N, 2010, EMBO REP, V11, P400, DOI 10.1038/embor.2010.37; Malaviya R, 2001, IMMUNOL REV, V179, P16, DOI 10.1034/j.1600-065X.2001.790102.x; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MALAVIYA R, 1994, J IMMUNOL, V152, P1907; Malaviya R, 1999, P NATL ACAD SCI USA, V96, P8110, DOI 10.1073/pnas.96.14.8110; Mannel DN, 1996, RES IMMUNOL, V147, P491, DOI 10.1016/S0923-2494(97)85212-1; Marriott HM, 2008, CURR MOL MED, V8, P497, DOI 10.2174/156652408785747924; Marshall JS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174241; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Matsui H, 2011, J MED MICROBIOL, V60, P128, DOI 10.1099/jmm.0.020495-0; MCNEIL PL, 1987, J CELL SCI, V88, P669; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; Menestrina G, 2001, TOXICON, V39, P1661, DOI 10.1016/S0041-0101(01)00153-2; Metz M, 2009, EXP DERMATOL, V18, P160, DOI 10.1111/j.1600-0625.2008.00778.x; Mitchell J, 2011, MOL ORAL MICROBIOL, V26, P89, DOI 10.1111/j.2041-1014.2010.00601.x; Molloy EM, 2011, NAT REV MICROBIOL, V9, P670, DOI 10.1038/nrmicro2624; Morton CJ, 2019, CHEM REV, V119, P7721, DOI 10.1021/acs.chemrev.9b00090; Mukai K, 2018, IMMUNOL REV, V282, P121, DOI 10.1111/imr.12634; Nhieu GT, 2004, BIOL CELL, V96, P93, DOI 10.1016/j.biocel.2003.10.006; Nizet V, 2000, INFECT IMMUN, V68, P4245, DOI 10.1128/IAI.68.7.4245-4254.2000; O'Brien DK, 2004, INFECT IMMUN, V72, P5204, DOI 10.1128/IAI.72.9.5204-5215.2004; Pahle J, 2016, EXPERT OPIN BIOL TH, V16, P443, DOI 10.1517/14712598.2016.1134480; Park SA, 2016, J STRUCT BIOL, V193, P132, DOI 10.1016/j.jsb.2015.12.002; Pillich H, 2012, CELL MICROBIOL, V14, P949, DOI 10.1111/j.1462-5822.2012.01769.x; Pinxteren JA, 2001, BIOCHEM J, V356, P287, DOI 10.1042/0264-6021:3560287; Putney JW, 2009, IMMUNOL REV, V231, P10, DOI 10.1111/j.1600-065X.2009.00810.x; Rai P, 2016, SCI REP-UK, V6, DOI 10.1038/srep22972; Ramachandran R, 2004, NAT STRUCT MOL BIOL, V11, P697, DOI 10.1038/nsmb793; Ramachandran R, 2005, P NATL ACAD SCI USA, V102, P7139, DOI 10.1073/pnas.0500556102; Repp H, 2002, CELL MICROBIOL, V4, P483, DOI 10.1046/j.1462-5822.2002.00207.x; Rivera J, 2006, J ALLERGY CLIN IMMUN, V117, P1214, DOI 10.1016/j.jaci.2006.04.015; Romero M, 2017, CELL DEATH DIFFER, V24, P798, DOI 10.1038/cdd.2017.11; Ronnberg E, 2010, INFECT IMMUN, V78, P854, DOI 10.1128/IAI.01004-09; Savinov SN, 2017, TOXINS, V9, DOI 10.3390/toxins9120381; Schlech WF, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3-0014-2018; Schoenauer R, 2014, BBA-MOL CELL RES, V1843, P915, DOI 10.1016/j.bbamcr.2014.01.024; SEEMAN P, 1967, J CELL BIOL, V32, P55, DOI 10.1083/jcb.32.1.55; Shaik GM, 2009, CELL SIGNAL, V21, P1337, DOI 10.1016/j.cellsig.2009.04.001; Shewell LK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz4926; Shewell LK, 2014, P NATL ACAD SCI USA, V111, pE5312, DOI 10.1073/pnas.1412703111; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stassen M, 2003, INFECT IMMUN, V71, P6171, DOI 10.1128/IAI.71.11.6171-6177.2003; Subramanian H, 2011, J BIOL CHEM, V286, P44739, DOI 10.1074/jbc.M111.277152; Sweeney CR, 2005, J VET INTERN MED, V19, P123, DOI 10.1892/0891-6640(2005)19&lt;123:SEIIHG&gt;2.0.CO;2; Tenenbaum T, 2016, FUTURE MICROBIOL, V11, P941, DOI 10.2217/fmb-2016-0028; Thapa R, 2020, TOXINS, V12, DOI 10.3390/toxins12090531; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038; Tweten RK, 2005, INFECT IMMUN, V73, P6199, DOI 10.1128/IAI.73.10.6199-6209.2005; Tweten RK, 2015, ANNU REV MICROBIOL, V69, P323, DOI 10.1146/annurev-micro-091014-104233; Uchiyama S, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00581; Usmani SM, 2012, CELL MICROBIOL, V14, P299, DOI 10.1111/j.1462-5822.2011.01724.x; van den Boogaard FE, 2014, J INFECT DIS, V210, P1376, DOI 10.1093/infdis/jiu285; van Pee K, 2017, ELIFE, V6, DOI 10.7554/eLife.23644; Vazquez-Boland JA, 2001, CLIN MICROBIOL REV, V14, P584, DOI 10.1128/CMR.14.3.584-640.2001; Verherstraeten S, 2015, TOXINS, V7, P1702, DOI 10.3390/toxins7051702; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; von Beek C, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.13064; Walev I, 2001, FASEB J, V15, P237, DOI 10.1096/fj.01-0572fje; WALEV I, 1994, MICROB PATHOGENESIS, V17, P187, DOI 10.1006/mpat.1994.1065; Wilson BS, 2004, MOL BIOL CELL, V15, P2580, DOI 10.1091/mbc.E03-08-0574; Wong GW, 2014, BIOCHEM BIOPH RES CO, V451, P314, DOI 10.1016/j.bbrc.2014.07.124; Yang J, 2019, WORLD ALLERGY ORGAN, V12, DOI 10.1016/j.waojou.2019.100028; Yang WS, 2006, MOL CANCER THER, V5, P1610, DOI 10.1158/1535-7163.MCT-05-0515; Yoshino M, 2010, J CLIN MICROBIOL, V48, P635, DOI 10.1128/JCM.01362-09	142	1	1	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 23	2021	12								670205	10.3389/fimmu.2021.670205	http://dx.doi.org/10.3389/fimmu.2021.670205			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TE5RQ	34248949	gold, Green Published			2022-12-18	WOS:000670070600001
J	Gupta, A; Chun, HJ				Gupta, Akash; Chun, Hyung J.			Interleukin-1-Receptor Kinase 4 Inhibition: Achieving Immunomodulatory Synergy to Mitigate the Impact of COVID-19	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						COVID-19; irak4; immunomodulator; cytokine; Cytokine release syndrome (CRS)	INNATE		[Gupta, Akash] Yale Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Chun, Hyung J.] Yale Sch Med, Yale Cardiovasc Res Ctr, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT USA	Yale University; Yale University	Gupta, A (corresponding author), Yale Sch Med, Dept Internal Med, New Haven, CT 06510 USA.	akash.gupta.ag2583@yale.edu						Aboudounya MM, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/8874339; Alunno A, 2021, ANN RHEUM DIS, V80, P803, DOI 10.1136/annrheumdis-2020-219725; Ma Lina, 2021, bioRxiv, DOI [10.1126/sciimmunol.abh2259, 10.1101/2021.02.22.432177]; Cameron MJ, 2007, J VIROL, V81, P8692, DOI 10.1128/JVI.00527-07; Cushing L, 2017, J BIOL CHEM, V292, P18689, DOI 10.1074/jbc.M117.796912; Danto SI., 2019 ACRARP ANN M AT; Guthmiller JJ, 2021, MBIO, V12, DOI 10.1128/mBio.02940-20; Holt GE, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74328-x; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Karaba AH, 2022, CLIN INFECT DIS, V74, P254, DOI 10.1093/cid/ciab376; Kelly PN, 2015, J EXP MED, V212, P2189, DOI 10.1084/jem.20151074; Khanmohammadi S, 2021, J MED VIROL, V93, P2735, DOI 10.1002/jmv.26826; Li Y, 2013, MICROBES INFECT, V15, P88, DOI 10.1016/j.micinf.2012.10.008; Lucas C, 2021, NAT MED, V27, P1178, DOI 10.1038/s41591-021-01355-0; Luo P, 2020, J MED VIROL, V92, P814, DOI 10.1002/jmv.25801; Meizlish ML, 2021, BLOOD ADV, V5, P1164, DOI 10.1182/bloodadvances.2020003568; Patra R, 2021, J MED VIROL, V93, P615, DOI 10.1002/jmv.26387; Rodriguez-Guerra Miguel, 2021, Drugs Context, V10, DOI 10.7573/dic.2020-10-3; Tang YJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01708; Veiga VC, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n84; Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	22	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 23	2021	12								693085	10.3389/fimmu.2021.693085	http://dx.doi.org/10.3389/fimmu.2021.693085			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TE8TM	34248990	gold, Green Published			2022-12-18	WOS:000670279800001
J	He, L; Xiao, J; Song, L; Zhou, R; Rong, ZG; He, WF; Dai, F				He, Lei; Xiao, Jun; Song, Lei; Zhou, Rui; Rong, Zhigang; He, Weifeng; Dai, Fei			HVEM Promotes the Osteogenesis of allo-MSCs by Inhibiting the Secretion of IL-17 and IFN-gamma in V gamma 4T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						HVEM-BTLA; V gamma 4T cells; MSc; Tissue engineered bone; IL-17; immunomodulatory	MESENCHYMAL STEM-CELLS; DELTA T-CELLS; BONE-MARROW; OSTEOPROGENITOR CELLS; STROMAL CELLS; BTLA; DIFFERENTIATION; REGENERATION; LYMPHOCYTES	Bone defects are a common orthopaedic concern, and an increasing number of tissue-engineered bones (TEBs) are used to repair bone defects. Allogeneic mesenchymal stem cells (allo-MSCs) are used as seed cells in many approaches to develop TEB constructs, but the immune response caused by allogeneic transplantation may lead to transplant failure. V gamma 4 T (V gamma 4T) cells play an important role in mediating the immune response in the early stage after transplantation; therefore, we wanted to verify whether suppressing V gamma 4T cells by herpesvirus entry mediator (HVEM)/B and T lymphocyte attenuator (BTLA) signalling can promote MSCs osteogenesis in the transplanted area. In vitro experiments showed that the osteogenic differentiation of MSCs and V gamma 4T cells was weakened after co-culture, and an increase in interleukin-17 (IL-17) and interferon-gamma (IFN-gamma) levels was detected in the culture supernatant. HVEM-transfected MSCs (MSCs-HVEM) still exhibited osteogenic differentiation activity after co-culture with V gamma 4T cells, and the levels of IL-17 and IFN-gamma in the co-culture supernatant were significantly reduced. In vivo experiments revealed that inflammation in the transplanted area was reduced and osteogenic repair was enhanced after V gamma 4T cells were removed. MSCs-HVEM can also consistently contribute to reduced inflammation in the transplanted area and enhanced bone repair in wild-type (WT) mice. Therefore, our experiments verified that HVEM can promote the osteogenesis of allo-MSCs by inhibiting IL-17 and IFN-gamma secretion from V gamma 4T cells.	[He, Lei; Song, Lei; Zhou, Rui; Rong, Zhigang; Dai, Fei] Army Med Univ, Affiliated Hosp 1, Dept Orthopaed, Chongqing, Peoples R China; [Xiao, Jun] Special Serv Recuperat Ctr Rocket Army, Guangzhou, Peoples R China; [He, Weifeng] Army Med Univ, Southwest Hosp, Inst Bum Res, State Key Lab Trauma, Chongqing, Peoples R China	Army Medical University; Army Medical University	Dai, F (corresponding author), Army Med Univ, Affiliated Hosp 1, Dept Orthopaed, Chongqing, Peoples R China.; He, WF (corresponding author), Army Med Univ, Southwest Hosp, Inst Bum Res, State Key Lab Trauma, Chongqing, Peoples R China.	whe761211@hotmail.com; david-feifei@163.com			National Natural Science Foundation of China [81874005]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The study was supported by grants from the National Natural Science Foundation of China (no. 81874005).	Albring JC, 2010, J EXP MED, V207, P2551, DOI 10.1084/jem.20102017; Ben-Ari A, 2009, TISSUE ENG PT A, V15, P2537, DOI 10.1089/ten.tea.2008.0567; Breloer M, 2015, J IMMUNOL, V194, P1413, DOI 10.4049/jimmunol.1402510; Caetano-Lopes J, 2009, AUTOIMMUN REV, V8, P250, DOI 10.1016/j.autrev.2008.07.038; Cai YH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4986; Chan JL, 2006, BLOOD, V107, P4817, DOI 10.1182/blood-2006-01-0057; Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110; Chatterjea A, 2014, J CELL MOL MED, V18, P134, DOI 10.1111/jcmm.12172; Coathup MJ, 2013, J BIOMED MATER RES A, V101, P2210, DOI 10.1002/jbm.a.34536; Compaan DM, 2005, J BIOL CHEM, V280, P39553, DOI 10.1074/jbc.M507629200; Dai F, 2006, TISSUE ENG, V12, P2583, DOI 10.1089/ten.2006.12.2583; El-Zayadi AA, 2017, RHEUMATOLOGY, V56, P488, DOI 10.1093/rheumatology/kew384; Hu P, 2019, BURNS TRAUMA, V7, DOI 10.1186/s41038-019-0178-8; Huang YF, 2016, J IMMUNOL, V196, P217, DOI 10.4049/jimmunol.1501064; Kim YG, 2014, ARCH ORAL BIOL, V59, P897, DOI 10.1016/j.archoralbio.2014.05.009; Kimura N, 2012, ANN THORAC SURG, V94, P542, DOI 10.1016/j.athoracsur.2012.03.049; Kwok SK, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3780; Li YS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00240; Li YS, 2017, J INVEST DERMATOL, V137, P2513, DOI 10.1016/j.jid.2017.03.043; Li Z, 2018, BURNS TRAUMA, V6, DOI 10.1186/s41038-018-0117-0; Liu H, 2006, J IMMUNOL, V176, P2864, DOI 10.4049/jimmunol.176.5.2864; Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542; Luu YK, 2009, J BONE MINER RES, V24, P50, DOI 10.1359/JBMR.080817; Meyers CA, 2018, TISSUE ENG PT A, V24, P448, DOI [10.1089/ten.TEA.2017.0023, 10.1089/ten.tea.2017.0023]; Niemeyer P, 2010, BIOMATERIALS, V31, P3572, DOI 10.1016/j.biomaterials.2010.01.085; Okada Kiyotaka, 2018, Bone Rep, V8, P195, DOI 10.1016/j.bonr.2018.04.005; Rong ZG, 2018, TISSUE ENG PT A, V24, P1167, DOI [10.1089/ten.tea.2017.0354, 10.1089/ten.TEA.2017.0354]; Sakoda Y, 2011, BLOOD, V117, P2506, DOI 10.1182/blood-2010-08-301325; Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775; Shui JW, 2012, NATURE, V488, P222, DOI 10.1038/nature11242; Song YJ, 2019, BURNS TRAUMA, V7, DOI 10.1186/s41038-019-0177-9; Spaggiari GM, 2006, BLOOD, V107, P1484, DOI 10.1182/blood-2005-07-2775; Steinberg MW, 2011, IMMUNOL REV, V244, P169, DOI 10.1111/j.1600-065X.2011.01064.x; Tang D, 2016, BIOMATERIALS, V83, P363, DOI 10.1016/j.biomaterials.2016.01.024; Tasso R, 2009, TISSUE ENG PT A, V15, P2203, DOI 10.1089/ten.tea.2008.0269; Vermijlen D, 2007, J IMMUNOL, V178, P4304, DOI 10.4049/jimmunol.178.7.4304; Wang L, 2012, J DENT RES, V91, P1003, DOI 10.1177/0022034512460404; Watanabe N, 2003, NAT IMMUNOL, V4, P670, DOI 10.1038/ni944; Xi JF, 2013, BURNS TRAUMA, V1, DOI 10.4103/2321-3868.113330; Yamaza T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002615; Zhang F, 2017, CELL TISSUE RES, V370, P143, DOI 10.1007/s00441-017-2655-3	41	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 23	2021	12								689269	10.3389/fimmu.2021.689269	http://dx.doi.org/10.3389/fimmu.2021.689269			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TE8SA	34248977	Green Published, gold			2022-12-18	WOS:000670275900001
J	Korshoj, LE; Shi, W; Duan, B; Kielian, T				Korshoj, Lee E.; Shi, Wen; Duan, Bin; Kielian, Tammy			The Prospect of Nanoparticle Systems for Modulating Immune Cell Polarization During Central Nervous System Infection	FRONTIERS IN IMMUNOLOGY			English	Article						central nervous system; infection; biofilm; immunometabolism; nanoparticles; blood-brain barrier; leukocytes; microglia	BLOOD-BRAIN-BARRIER; PEG-PLGA NANOPARTICLES; TOLL-LIKE RECEPTORS; DRUG-DELIVERY; CNS INFECTIONS; CHITOSAN NANOPARTICLES; METABOLIC CHECKPOINT; FOCUSED ULTRASOUND; ENDOTHELIAL-CELLS; TARGETED THERAPY	The blood-brain barrier (BBB) selectively restricts the entry of molecules from peripheral circulation into the central nervous system (CNS) parenchyma. Despite this protective barrier, bacteria and other pathogens can still invade the CNS, often as a consequence of immune deficiencies or complications following neurosurgical procedures. These infections are difficult to treat since many bacteria, such as Staphylococcus aureus, encode a repertoire of virulence factors, can acquire antibiotic resistance, and form biofilm. Additionally, pathogens can leverage virulence factor production to polarize host immune cells towards an anti-inflammatory phenotype, leading to chronic infection. The difficulty of pathogen clearance is magnified by the fact that antibiotics and other treatments cannot easily penetrate the BBB, which requires extended regimens to achieve therapeutic concentrations. Nanoparticle systems are rapidly emerging as a promising platform to treat a range of CNS disorders. Nanoparticles have several advantages, as they can be engineered to cross the BBB with specific functionality to increase cellular and molecular targeting, have controlled release of therapeutic agents, and superior bioavailability and circulation compared to traditional therapies. Within the CNS environment, therapeutic actions are not limited to directly targeting the pathogen, but can also be tailored to modulate immune cell activation to promote infection resolution. This perspective highlights the factors leading to infection persistence in the CNS and discusses how novel nanoparticle therapies can be engineered to provide enhanced treatment, specifically through modulation of immune cell polarization.	[Korshoj, Lee E.; Kielian, Tammy] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Shi, Wen; Duan, Bin] Univ Nebraska Med Ctr, Dept Internal Med, Mary & Dick Holland Regenerat Med Program, Div Cardiol, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Kielian, T (corresponding author), Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA.	tkielian@unmc.edu		Kielian, Tammy/0000-0001-7624-670X	NIH [R01 NS107369, 3P01AI083211]; Nebraska Research Institute Collaborative Grant	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nebraska Research Institute Collaborative Grant	The Kielian laboratory is supported by NIH grants R01 NS107369 and 3P01AI083211 (Project 4 to TK) and a Nebraska Research Institute Collaborative Grant (to TK and BD).	Aldrich A, 2019, ACS APPL MATER INTER, V11, P12298, DOI 10.1021/acsami.9b00264; Aldrich AL, 2021, J IMMUNOL, V206, P751, DOI 10.4049/jimmunol.2001042; Aldrich AL, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01793-6; Amani H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42633-9; Angiari S, 2020, CELL METAB, V31, P391, DOI 10.1016/j.cmet.2019.10.015; [Anonymous], 2014, EUR J PHARM BIOPHARM, V87, P19, DOI 10.1016/j.ejpb.2014.02.013; Aryani A, 2016, MOL NEUROBIOL, V53, P818, DOI 10.1007/s12035-014-9054-5; Aslund AKO, 2015, J CONTROL RELEASE, V220, P287, DOI 10.1016/j.jconrel.2015.10.047; Avgoustakis K, 2002, J CONTROL RELEASE, V79, P123, DOI 10.1016/S0168-3659(01)00530-2; Bai FW, 2010, J INFECT DIS, V202, P1804, DOI 10.1086/657416; Banks WA, 2016, NAT REV DRUG DISCOV, V15, P275, DOI 10.1038/nrd.2015.21; Bantug GR, 2018, NAT REV IMMUNOL, V18, P19, DOI 10.1038/nri.2017.99; Barar J, 2016, BIOIMPACTS, V6, P225, DOI 10.15171/bi.2016.30; Battaglia L, 2014, J PHARM SCI-US, V103, P2157, DOI 10.1002/jps.24002; Beckham JD, 2012, NEUROTHERAPEUTICS, V9, P124, DOI 10.1007/s13311-011-0086-5; Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Bernier LP, 2020, TRENDS NEUROSCI, V43, P854, DOI 10.1016/j.tins.2020.08.008; Betzer O, 2017, NANOMEDICINE-UK, V12, P1533, DOI 10.2217/nnm-2017-0022; Bloomgren G, 2012, NEW ENGL J MED, V366, P1870, DOI 10.1056/NEJMoa1107829; Bowen LN, 2016, NAT REV NEUROL, V12, P662, DOI 10.1038/nrneurol.2016.149; Burmeister AR, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00458; Cain MD, 2019, NEURON, V103, P771, DOI 10.1016/j.neuron.2019.07.015; Cena V, 2018, NANOMEDICINE-UK, V13, P1513, DOI 10.2217/nnm-2018-0139; Cheatle J, 2013, AM J PATHOL, V183, P450, DOI 10.1016/j.ajpath.2013.04.031; Choi B, 2019, NANOSCALE, V11, P19437, DOI 10.1039/c9nr02648g; Courret N, 2006, BLOOD, V107, P309, DOI 10.1182/blood-2005-02-0666; Cragnolini AB, 2020, NEURAL REGEN RES, V15, P838, DOI 10.4103/1673-5374.268897; Dando SJ, 2014, CLIN MICROBIOL REV, V27, P691, DOI 10.1128/CMR.00118-13; de Morais SDB, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.625467; DeBerardinis RJ, 2020, NAT METAB, V2, P127, DOI 10.1038/s42255-020-0172-2; DeMarino C, 2017, J NEUROIMMUNE PHARM, V12, P31, DOI 10.1007/s11481-016-9692-7; Devanney NA, 2020, EXP NEUROL, V329, DOI 10.1016/j.expneurol.2020.113310; Doran KS, 2016, ACTA NEUROPATHOL, V131, P185, DOI 10.1007/s00401-015-1531-z; Elnaggar YSR, 2015, J PHARM SCI-US, V104, P3544, DOI 10.1002/jps.24557; Engelhardt B, 2017, NAT IMMUNOL, V18, P123, DOI 10.1038/ni.3666; Everts B, 2014, NAT IMMUNOL, V15, P323, DOI 10.1038/ni.2833; Barros LF, 2013, TRENDS NEUROSCI, V36, P396, DOI 10.1016/j.tins.2013.04.002; Fillatreau S, 2011, IMMUNOL REV, V240, P52, DOI 10.1111/j.1600-065X.2010.00991.x; Forrester JV, 2018, NAT REV NEUROSCI, V19, P655, DOI 10.1038/s41583-018-0070-8; Fumagalli M, 2018, GLIA, V66, P2531, DOI 10.1002/glia.23484; Gerriets VA, 2015, J CLIN INVEST, V125, P194, DOI 10.1172/JCI76012; Ghosh P, 2018, MBIO, V9, DOI 10.1128/mBio.00160-18; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Greenhalgh AD, 2020, NAT REV NEUROSCI, V21, P139, DOI 10.1038/s41583-020-0263-9; Gutierrez-Murgas Y, 2014, J NEUROIMMUNOL, V276, P1, DOI 10.1016/j.jneuroim.2014.08.006; Haghikia A, 2015, MULT SCLER J, V21, P1262, DOI 10.1177/1352458514561909; Ham AS, 2009, PHARM RES-DORDR, V26, P502, DOI 10.1007/s11095-008-9765-2; Hanke ML, 2011, CLIN SCI, V121, P367, DOI 10.1042/CS20110164; Harker KS, 2014, MBIO, V5, DOI 10.1128/mBio.01111-13; Hasebe R, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-165; Heim CE, 2020, NAT MICROBIOL, V5, P1271, DOI 10.1038/s41564-020-0756-3; Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705; Hernando S, 2018, MOL NEUROBIOL, V55, P145, DOI 10.1007/s12035-017-0728-7; Herold R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215393; Hu KL, 2011, INT J PHARMACEUT, V415, P273, DOI 10.1016/j.ijpharm.2011.05.062; Hu YL, 2020, GLIA, V68, P1031, DOI 10.1002/glia.23760; Injarabian L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010287; Iovino F, 2017, J EXP MED, V214, P1619, DOI 10.1084/jem.20161668; Jellusova J, 2020, IMMUNOL REV, V295, P39, DOI 10.1111/imr.12855; Jha AK, 2015, IMMUNITY, V42, P419, DOI 10.1016/j.immuni.2015.02.005; Jong A, 2012, J BIOL CHEM, V287, P15298, DOI 10.1074/jbc.M112.353375; Jorgensen Julianne, 2016, Critical Reviews in Biomedical Engineering, V44, P91, DOI 10.1615/CritRevBiomedEng.2016017149; Kaushik DK, 2021, J NEUROCHEM, V158, P14, DOI 10.1111/jnc.15206; Kaushik DK, 2019, J CLIN INVEST, V129, P3277, DOI 10.1172/JCI124012; Keppel MP, 2015, J IMMUNOL, V194, P1954, DOI 10.4049/jimmunol.1402099; Khan AR, 2017, J CONTROL RELEASE, V268, P364, DOI 10.1016/j.jconrel.2017.09.001; Kim SS, 2018, MOL THER, V26, P84, DOI 10.1016/j.ymthe.2017.10.003; Klein RS, 2017, IMMUNITY, V46, P891, DOI 10.1016/j.immuni.2017.06.012; Klotz L, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aao5563; Krawczyk CM, 2010, BLOOD, V115, P4742, DOI 10.1182/blood-2009-10-249540; Kreuter J, 2014, ADV DRUG DELIVER REV, V71, P2, DOI 10.1016/j.addr.2013.08.008; Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001; Kuo PC, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01768-7; Kuo YC, 2012, COLLOID SURFACE B, V90, P75, DOI 10.1016/j.colsurfb.2011.09.048; Lai YP, 2016, INT IMMUNOL, V28, P181, DOI 10.1093/intimm/dxv063; Lauro C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00493; Lehman MK, 2019, MBIO, V10, DOI 10.1128/mBio.02553-18; Li HM, 2018, INT J BIOL MACROMOL, V107, P204, DOI 10.1016/j.ijbiomac.2017.08.155; Li L, 2021, BRAIN BEHAV IMMUN, V91, P740, DOI 10.1016/j.bbi.2020.10.007; Li QY, 2018, NAT REV IMMUNOL, V18, P225, DOI 10.1038/nri.2017.125; Lin TT, 2016, ACS NANO, V10, P9999, DOI 10.1021/acsnano.6b04268; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Liu DZ, 2018, NANOMED-NANOTECHNOL, V14, P991, DOI 10.1016/j.nano.2018.01.004; Loh LN, 2017, MBIO, V8, DOI 10.1128/mBio.02030-16; Luan HH, 2016, CELL METAB, V24, P379, DOI 10.1016/j.cmet.2016.08.013; Lynch MA, 2020, PROG NEUROBIOL, V184, DOI 10.1016/j.pneurobio.2019.101719; Macri C, 2018, SEMIN CELL DEV BIOL, V84, P11, DOI 10.1016/j.semcdb.2017.12.009; Mariani MM, 2009, J NEUROIMMUNE PHARM, V4, P448, DOI 10.1007/s11481-009-9170-6; Martinez-Veracoechea FJ, 2011, P NATL ACAD SCI USA, V108, P10963, DOI 10.1073/pnas.1105351108; Matias I, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00059; McDannold N, 2008, ULTRASOUND MED BIOL, V34, P834, DOI 10.1016/j.ultrasmedbio.2007.10.016; Meairs S, 2015, PHARMACEUTICS, V7, P275, DOI 10.3390/pharmaceutics7030275; Mergenthaler P, 2013, TRENDS NEUROSCI, V36, P587, DOI 10.1016/j.tins.2013.07.001; Mills EL, 2016, CELL, V167, P457, DOI 10.1016/j.cell.2016.08.064; Monsalve Y, 2015, NANOMEDICINE-UK, V10, P1735, DOI 10.2217/nnm.15.29; Nau R, 2010, CLIN MICROBIOL REV, V23, P858, DOI 10.1128/CMR.00007-10; O'Neill LAJ, 2016, NAT REV IMMUNOL, V16, P553, DOI 10.1038/nri.2016.70; Orlando A, 2013, INT J NANOMED, V8, P1335, DOI 10.2147/IJN.S40297; Ou HL, 2018, ACTA BIOMATER, V65, P339, DOI 10.1016/j.actbio.2017.10.034; Pardridge William M, 2005, NeuroRx, V2, P3; Pardridge WM, 2002, DRUG DISCOV TODAY, V7, P5, DOI 10.1016/S1359-6446(01)02082-7; Patel MM, 2017, CNS DRUGS, V31, P109, DOI 10.1007/s40263-016-0405-9; Pearce EJ, 2018, NAT REV IMMUNOL, V18, P81, DOI 10.1038/nri.2017.139; Pearce EL, 2013, IMMUNITY, V38, P633, DOI 10.1016/j.immuni.2013.04.005; Phuphanich S, 2007, J NEURO-ONCOL, V81, P201, DOI 10.1007/s11060-006-9218-x; Potter AD, 2020, P NATL ACAD SCI USA, V117, P12394, DOI 10.1073/pnas.1922211117; Poupot R, 2018, INT J NANOMED, V13, P5511, DOI 10.2147/IJN.S146192; Poupot R, 2018, MATERIALS, V11, DOI 10.3390/ma11020270; Prinz M, 2019, CELL, V179, P292, DOI 10.1016/j.cell.2019.08.053; Prinz M, 2017, NAT NEUROSCI, V20, P136, DOI 10.1038/nn.4475; Provenzano F, 2021, TRENDS MOL MED, V27, P47, DOI 10.1016/j.molmed.2020.09.001; Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004; Reynolds JL, 2017, J NEUROIMMUNE PHARM, V12, P1, DOI 10.1007/s11481-017-9725-x; Richard AS, 2017, P NATL ACAD SCI USA, V114, P2024, DOI 10.1073/pnas.1620558114; Rizvi SMD, 2018, BIOMED PHARMACOTHER, V107, P7, DOI 10.1016/j.biopha.2018.07.130; Runtsch MC, 2021, J NEUROCHEM, V158, P36, DOI 10.1111/jnc.15169; Saab AS, 2016, NEURON, V91, P119, DOI 10.1016/j.neuron.2016.05.016; Saeedi M, 2019, BIOMED PHARMACOTHER, V111, P666, DOI 10.1016/j.biopha.2018.12.133; Santiago-Tirado FH, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006680; Santiago-Tirado FH, 2017, MBIO, V8, DOI 10.1128/mBio.02183-16; Schilcher K, 2020, MICROBIOL MOL BIOL R, V84, DOI 10.1128/MMBR.00026-19; Schwab N, 2015, INT IMMUNOL, V27, P47, DOI 10.1093/intimm/dxu096; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Shin BY, 2020, CELL REP, V30, P1898, DOI 10.1016/j.celrep.2020.01.022; Snarr BD, 2020, CURR OPIN MICROBIOL, V58, P41, DOI 10.1016/j.mib.2020.07.011; Sochocka M, 2017, MOL NEUROBIOL, V54, P8071, DOI 10.1007/s12035-016-0297-1; Sofroniew MV, 2020, TRENDS IMMUNOL, V41, P758, DOI 10.1016/j.it.2020.07.004; Sonvico F, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10010034; Srikanth M, 2012, NAT REV NEUROL, V8, P307, DOI 10.1038/nrneurol.2012.76; Tiwari SK, 2014, ACS NANO, V8, P76, DOI 10.1021/nn405077y; Tunkel AR, 2017, CLIN INFECT DIS, V64, pE34, DOI 10.1093/cid/ciw861; Vainchtein ID, 2020, TRENDS NEUROSCI, V43, P144, DOI 10.1016/j.tins.2020.01.003; Velkov T, 2018, PHARMACOL THERAPEUT, V181, P85, DOI 10.1016/j.pharmthera.2017.07.012; Vinogradov SV, 2004, BIOCONJUGATE CHEM, V15, P50, DOI 10.1021/bc034164r; Weidauer S, 2020, CLIN NEURORADIOL, V30, P9, DOI 10.1007/s00062-019-00837-6; Weisel FJ, 2020, NAT IMMUNOL, V21, P331, DOI 10.1038/s41590-020-0598-4; Wen ZY, 2011, J CONTROL RELEASE, V151, P131, DOI 10.1016/j.jconrel.2011.02.022; Wiley DT, 2013, P NATL ACAD SCI USA, V110, P8662, DOI 10.1073/pnas.1307152110; Wiley NJ, 2012, ADV NANO RES, V1, P44, DOI [DOI 10.4236/ANP.2012.13007, 10.4236/anp.2012.13007]; Yamada KJ, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008354; Yamada KJ, 2019, J INNATE IMMUN, V11, P280, DOI 10.1159/000492680; Yang LL, 2016, NEUROTOXICOLOGY, V52, P144, DOI 10.1016/j.neuro.2015.12.008; Zhao NX, 2020, APL BIOENG, V4, DOI 10.1063/5.0013178; Ziai WC, 2009, CURR OPIN NEUROL, V22, P277, DOI 10.1097/WCO.0b013e32832c1396	144	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 23	2021	12								670931	10.3389/fimmu.2021.670931	http://dx.doi.org/10.3389/fimmu.2021.670931			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TE5MZ	34248952	gold, Green Published			2022-12-18	WOS:000670058500001
J	Jeucken, KCM; Koning, JJ; van Hamburg, JP; Mebius, RE; Tas, SW				Jeucken, Kim C. M.; Koning, Jasper J.; van Hamburg, Jan Piet; Mebius, Reina E.; Tas, Sander W.			A Straightforward Method for 3D Visualization of B Cell Clusters and High Endothelial Venules in Lymph Nodes Highlights Differential Roles of TNFRI and -II	FRONTIERS IN IMMUNOLOGY			English	Article						whole mount histology; tissue clearing and labeling technique; tumor necrosis factor receptor superfamily; high endothelial venules; peripheral lymph nodes; B cell clusters	TUMOR-NECROSIS-FACTOR; GERMINAL CENTER; ENTIRE ORGANS; LYMPHOTOXIN; ORGANOGENESIS; MATURATION; MULTIPLEX; BETA; EXPRESSION; TISSUES	Whole mount tissue immunolabeling and imaging of complete organs has tremendous benefits in characterizing organ morphology. Here, we present a straightforward method for immunostaining, clearing and imaging of whole murine peripheral lymph nodes (PLNs) for detailed analysis of their architecture and discuss all procedures in detail in a step-by-step approach. Given the importance of tumor necrosis factor receptor (TNFR) signaling in development of PLNs we used TNFRI-/- and TNFRII-/- mice models as proof-of-concept for this technique by visualizing and analyzing structural changes in PLN B cell clusters and high endothelial venules (HEVs). Samples were subjected to de- and rehydration with methanol, labeled with antibodies for B cells, T cells and high endothelial venules (HEVs) and optically cleared using benzyl alcohol-benzyl benzoate. Imaging was done using LaVision light sheet microscope and analysis with Imaris software. Using these techniques, we confirmed previous findings that TNFRI signaling is essential for formation of individual B cell clusters. In addition, Our data suggest that TNFRII signaling is also to some extent involved in this process as TNFRII-/- PLNs had a B cell cluster morphology reminiscent of TNFRI-/- PLNs. Moreover, visualization and objective quantification of the complete PLN high endothelial vasculature unveiled reduced volume, length and branching points of HEVs in TNFRI-/- PLNs, revealing an earlier unrecognized contribution of TNFRI signaling in HEV morphology. Together, these results underline the potential of whole mount tissue staining and advanced imaging techniques to unravel even subtle changes in lymphoid tissue architecture.	[Jeucken, Kim C. M.; van Hamburg, Jan Piet; Tas, Sander W.] Univ Amsterdam, Amsterdam Univ Med Ctr UMC, Amsterdam Inst Infect & Immun, Dept Expt Immunol, Amsterdam, Netherlands; [Jeucken, Kim C. M.; van Hamburg, Jan Piet; Tas, Sander W.] Univ Amsterdam, Amsterdam Univ Med Ctr UMC, Amsterdam Rheumatol & Immunol Ctr, Dept Clin Immunol & Rheumatol, Amsterdam, Netherlands; [Koning, Jasper J.; Mebius, Reina E.] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam Infect & Immun Inst, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands	University of Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Tas, SW (corresponding author), Univ Amsterdam, Amsterdam Univ Med Ctr UMC, Amsterdam Inst Infect & Immun, Dept Expt Immunol, Amsterdam, Netherlands.; Tas, SW (corresponding author), Univ Amsterdam, Amsterdam Univ Med Ctr UMC, Amsterdam Rheumatol & Immunol Ctr, Dept Clin Immunol & Rheumatol, Amsterdam, Netherlands.	s.w.tas@amsterdamumc.nl		Mebius, Reina/0000-0003-0451-7464	Dutch Arthritis Foundation [RF16-1-302]; Netherlands Organization for Scientific Research grant [ALWOP.271]	Dutch Arthritis Foundation; Netherlands Organization for Scientific Research grant(Netherlands Organization for Scientific Research (NWO))	This work was supported by the Dutch Arthritis Foundation grant to ST (RF16-1-302) and the Netherlands Organization for Scientific Research grant to JK (ALWOP.271).	Ager A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00045; Alcamo E, 2002, J EXP MED, V195, P233, DOI 10.1084/jem.20011885; Azaripour A, 2016, PROG HISTOCHEM CYTO, V51, P9, DOI 10.1016/j.proghi.2016.04.001; Belle M, 2017, CELL, V169, DOI 10.1016/j.cell.2017.03.008; Browning JL, 2005, IMMUNITY, V23, P539, DOI 10.1016/j.immuni.2005.10.002; Chai Q, 2013, IMMUNITY, V38, P1013, DOI 10.1016/j.immuni.2013.03.012; Cuff CA, 1999, J IMMUNOL, V162, P5965; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Erturk A, 2013, EXP NEUROL, V242, P57, DOI 10.1016/j.expneurol.2012.10.018; Erturk A, 2012, NAT PROTOC, V7, P1983, DOI 10.1038/nprot.2012.119; Fu YX, 1997, P NATL ACAD SCI USA, V94, P5739, DOI 10.1073/pnas.94.11.5739; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Gerner MY, 2012, IMMUNITY, V37, P364, DOI 10.1016/j.immuni.2012.07.011; Jeucken KCM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02700; Kelch ID, 2015, SCI REP-UK, V5, DOI 10.1038/srep16534; Kumar V, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00282; Kumar V, 2010, BLOOD, V115, P4725, DOI 10.1182/blood-2009-10-250118; Li WZ, 2019, NAT PROTOC, V14, P1708, DOI 10.1038/s41596-019-0156-4; Li WZ, 2017, P NATL ACAD SCI USA, V114, pE7321, DOI 10.1073/pnas.1708981114; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Liu A, 2019, J MICROSC-OXFORD, V275, P3, DOI 10.1111/jmi.12796; MacEwan DJ, 2002, BRIT J PHARMACOL, V135, P855, DOI 10.1038/sj.bjp.0704549; Maney NJ, 2014, J IMMUNOL, V193, P4914, DOI 10.4049/jimmunol.1302929; Mebius RE, 2003, NAT REV IMMUNOL, V3, P292, DOI 10.1038/nri1054; Mehta AK, 2018, CYTOKINE, V101, P14, DOI 10.1016/j.cyto.2016.08.003; Molbay M, 2021, MOL SYST BIOL, V17, DOI 10.15252/msb.20209807; Pan CC, 2016, NAT METHODS, V13, P859, DOI 10.1038/nmeth.3964; Pan J, 2016, MODERN PATHOL, V29, P557, DOI 10.1038/modpathol.2016.52; Pasparakis M, 1997, P NATL ACAD SCI USA, V94, P6319, DOI 10.1073/pnas.94.12.6319; Renier N, 2014, CELL, V159, P896, DOI 10.1016/j.cell.2014.10.010; Richardson DS, 2015, CELL, V162, P246, DOI 10.1016/j.cell.2015.06.067; Seo J, 2016, MOL CELLS, V39, P439, DOI 10.14348/molcells.2016.0088; Tanaka N, 2017, NAT BIOMED ENG, V1, P796, DOI 10.1038/s41551-017-0139-0; Tkachuk M, 1998, J EXP MED, V187, P469, DOI 10.1084/jem.187.4.469; Wang Y, 2001, J IMMUNOL, V166, P330, DOI 10.4049/jimmunol.166.1.330; Willard-Mack CL, 2006, TOXICOL PATHOL, V34, P409, DOI 10.1080/01926230600867727; Wollenberg I, 2011, J IMMUNOL, V187, P4553, DOI 10.4049/jimmunol.1101328	37	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 21	2021	12								699336	10.3389/fimmu.2021.699336	http://dx.doi.org/10.3389/fimmu.2021.699336			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TD7CL	34234786	gold, Green Published			2022-12-18	WOS:000669480100001
J	Leung, LYT; Khan, S; Budylowski, P; Li, ZJ; Goroshko, S; Liu, YL; Dong, SL; Carlyle, JR; Rini, JM; Ostrowski, M; Ehrhardt, GRA				Leung, Leslie Y. T.; Khan, Srijit; Budylowski, Patrick; Li, Zhijie; Goroshko, Sofiya; Liu, Yanling; Dong, Shilan; Carlyle, James R.; Rini, James M.; Ostrowski, Mario; Ehrhardt, Gotz R. A.			Detection and Neutralization of SARS-CoV-2 Using Non-conventional Variable Lymphocyte Receptor Antibodies of the Evolutionarily Distant Sea Lamprey	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; monoclonal antibody; sea lamprey (Petromyzon marinus); variable lymphocyte receptor; neutralization	PROTEIN; DIVERSIFICATION; SYSTEM	SARS-CoV-2 is a newly emerged betacoronavirus and the causative agent for the COVID-19 pandemic. Antibodies recognizing the viral spike protein are instrumental in natural and vaccine-induced immune responses to the pathogen and in clinical diagnostic and therapeutic applications. Unlike conventional immunoglobulins, the variable lymphocyte receptor antibodies of jawless vertebrates are structurally distinct, indicating that they may recognize different epitopes. Here we report the isolation of monoclonal variable lymphocyte receptor antibodies from immunized sea lamprey larvae that recognize the spike protein of SARS-CoV-2 but not of other coronaviruses. We further demonstrate that these monoclonal variable lymphocyte receptor antibodies can efficiently neutralize the virus and form the basis of a rapid, single step SARS-CoV-2 detection system. This study provides evidence for monoclonal variable lymphocyte receptor antibodies as unique biomedical research and potential clinical diagnostic reagents targeting SARS-CoV-2.	[Leung, Leslie Y. T.; Khan, Srijit; Goroshko, Sofiya; Liu, Yanling; Dong, Shilan; Carlyle, James R.; Ostrowski, Mario; Ehrhardt, Gotz R. A.] Univ Toronto, Dept Immunol, Toronto, ON, Canada; [Budylowski, Patrick; Ostrowski, Mario] Univ Toronto, Dept Med, Toronto, ON, Canada; [Li, Zhijie; Rini, James M.] Univ Toronto, Dept Biochem, Toronto, ON, Canada; [Li, Zhijie; Rini, James M.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto	Ehrhardt, GRA (corresponding author), Univ Toronto, Dept Immunol, Toronto, ON, Canada.	goetz.ehrhardt@utoronto.ca		dong, shilan/0000-0003-0392-4316	CIHR [MM1-17488, MOP106491, PJT159450, OV3-170649]	CIHR(Canadian Institutes of Health Research (CIHR))	This study was supported by CIHR grant MM1-17488 to GE. JC was supported by CIHR grants MOP106491 and PJT159450. JR was supported by CIHR grant OV3-170649.	Abe KT, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.142362; Alder MN, 2008, NAT IMMUNOL, V9, P319, DOI 10.1038/ni1562; Alder MN, 2005, SCIENCE, V310, P1970, DOI 10.1126/science.1119420; [Anonymous], COV 19 WEEKL EP UPD; Banerjee A, 2020, EMERG INFECT DIS, V26, P2054, DOI 10.3201/eid2609.201495; Barnes CO, 2020, CELL, V182, P828, DOI [10.1016/j.cell.2020.06.025, 10.1101/2020.05.28.121533]; Boehm T, 2018, ANNU REV IMMUNOL, V36, P19, DOI 10.1146/annurev-immunol-042617-053028; Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025; Chan JTH, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar7653; Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952; Cossarizza A, 2019, EUR J IMMUNOL, V49, P1457, DOI 10.1002/eji.201970107; Esparza TJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-79036-0; Guo P, 2009, NATURE, V459, P796, DOI 10.1038/nature08068; Han BW, 2008, SCIENCE, V321, P1834, DOI 10.1126/science.1162484; Herrin BR, 2008, P NATL ACAD SCI USA, V105, P2040, DOI 10.1073/pnas.0711619105; Hirano M, 2013, NATURE, V501, P435, DOI 10.1038/nature12467; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053; Khan S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040950; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Lee JJ, 2014, MOL THER, V22, P1254, DOI 10.1038/mt.2014.59; Li ZJ, 2013, P NATL ACAD SCI USA, V110, P5004, DOI 10.1073/pnas.1218620110; Liu YL, 2018, J IMMUNOL, V200, P3962, DOI 10.4049/jimmunol.1701549; Martin Darren P, 2021, medRxiv, DOI 10.1101/2021.02.23.21252268; McKitrick TR, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0819-2; McKitrick TR, 2020, BIOCHEMISTRY-US, V59, P3111, DOI 10.1021/acs.biochem.9b01015; Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4; Pancer Z, 2004, NATURE, V430, P174, DOI 10.1038/nature02740; Papageorgiou AC, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112343; Reed SE, 2006, J VIROL METHODS, V138, P85, DOI 10.1016/j.jviromet.2006.07.024; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520; Rogozin IB, 2007, NAT IMMUNOL, V8, P647, DOI 10.1038/ni1463; Schoof M, 2020, SCIENCE, V370, P1473, DOI 10.1126/science.abe3255; Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069; Velikovsky CA, 2009, NAT STRUCT MOL BIOL, V16, P725, DOI 10.1038/nsmb.1619; Volz E, 2021, NATURE, V593, P266, DOI 10.1038/s41586-021-03470-x; Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028; Wang CY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16256-y; Watanabe Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16567-0; Wolfel R, 2020, NATURE, V581, P465, DOI 10.1038/s41586-020-2196-x; Wong AHM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01706-x; Xu G, 2011, METHODS MOL BIOL, V748, P21, DOI 10.1007/978-1-61779-139-0_2; Yang TJ, 2020, P NATL ACAD SCI USA, V117, P1438, DOI 10.1073/pnas.1908898117; Yu CL, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.84738; Yu CL, 2012, J IMMUNOL METHODS, V386, P43, DOI 10.1016/j.jim.2012.08.016; Zost SJ, 2020, NAT MED, V26, DOI [10.1038/s41591-020-0998-x, 10.1101/2020.05.12.091462]	48	1	1	1	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 21	2021	12								659071	10.3389/fimmu.2021.659071	http://dx.doi.org/10.3389/fimmu.2021.659071			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TD6ZZ	34234774	gold, Green Published			2022-12-18	WOS:000669473700001
J	Li, N; Steiger, S; Fei, LY; Li, CY; Shi, CX; Salei, N; Schraml, BU; Zheng, ZH; Anders, HJ; Lichtnekert, J				Li, Na; Steiger, Stefanie; Fei, Lingyan; Li, Chenyu; Shi, Chongxu; Salei, Natallia; Schraml, Barbara U.; Zheng, Zhihua; Anders, Hans-Joachim; Lichtnekert, Julia			IRF8-Dependent Type I Conventional Dendritic Cells (cDC1s) Control Post-Ischemic Inflammation and Mildly Protect Against Post-Ischemic Acute Kidney Injury and Disease	FRONTIERS IN IMMUNOLOGY			English	Article						interferon regulatory factor 8; type I conventional dendritic cells; dendritic cells; ischemia reperfusion; acute kidney injury	CISPLATIN NEPHROTOXICITY; T-CELLS; RECEPTOR; CD4(+); MACROPHAGES; PHENOTYPES; RESPONSES; ANTIGENS; SURVIVAL; TARGET	Post-ischemic acute kidney injury and disease (AKI/AKD) involve acute tubular necrosis and irreversible nephron loss. Mononuclear phagocytes including conventional dendritic cells (cDCs) are present during different phases of injury and repair, but the functional contribution of this subset remains controversial. Transcription factor interferon regulatory factor 8 (IRF8) is required for the development of type I conventional dendritic cells (cDC1s) lineage and helps to define distinct cDC1 subsets. We identified one distinct subset among mononuclear phagocyte subsets according to the expression patterns of CD11b and CD11c in healthy kidney and lymphoid organs, of which IRF8 was significantly expressed in the CD11b(low)CD11c(high) subset that mainly comprised cDC1s. Next, we applied a Irf8-deficient mouse line (Irf8 (fl/fl) Clec9a (cre) mice) to specifically target Clec9a-expressing cDC1s in vivo. During post-ischemic AKI/AKD, these mice lacked cDC1s in the kidney without affecting cDC2s. The absence of cDC1s mildly aggravated the loss of living primary tubule and decline of kidney function, which was associated with decreased anti-inflammatory Tregs-related immune responses, but increased T helper type 1 (T-H1)-related and pro-inflammatory cytokines, infiltrating neutrophils and acute tubular cell death, while we also observed a reduced number of cytotoxic CD8(+) T cells in the kidney when cDC1s were absent. Together, our data show that IRF8 is indispensable for kidney cDC1s. Kidney cDC1s mildly protect against post-ischemic AKI/AKD, probably via suppressing tissue inflammation and damage, which implies an immunoregulatory role for cDC1s.	[Li, Na; Fei, Lingyan; Zheng, Zhihua] Sun Yat sen Univ, Affiliated Hosp 7, Dept Nephrol, Ctr Kidney & Urol, Shenzhen, Peoples R China; [Li, Na; Steiger, Stefanie; Li, Chenyu; Shi, Chongxu; Anders, Hans-Joachim; Lichtnekert, Julia] Ludwig Maximilian Univ Munich, Univ Hosp, Div Nephrol, Dept Med 4, Munich, Germany; [Salei, Natallia; Schraml, Barbara U.] Ludwig Maximilians Univ Munchen, Univ Hosp, Walter Brendel Ctr Expt Med, Munich, Germany; [Salei, Natallia; Schraml, Barbara U.] Ludwig Maximilians Univ Munchen, Inst Cardiovasc Physiol & Pathophysiol, Biomed Ctr, Fac Med, Munich, Germany	Sun Yat Sen University; University of Munich; University of Munich; University of Munich	Zheng, ZH (corresponding author), Sun Yat sen Univ, Affiliated Hosp 7, Dept Nephrol, Ctr Kidney & Urol, Shenzhen, Peoples R China.; Anders, HJ; Lichtnekert, J (corresponding author), Ludwig Maximilian Univ Munich, Univ Hosp, Div Nephrol, Dept Med 4, Munich, Germany.	zhzhihua@mail.sysu.edu.cn; hjanders@med.uni-muenchen.de; julia.lichtnekert@med.uni-muenchen.de	Anders, Hans-Joachim/ABD-6247-2021	Schraml, Barbara/0000-0002-5801-0151; Zheng, Zhihua/0000-0003-1025-5384	Deutsche Forschungsgemeinschaft (DFG) [AN372/14-3, AN372/24-1, STE2437/2-1, STE2437/2-2]; China Scholarship Council (CSC) [201906380147, CSC 201603250047, CSC 202008080076]; DFG [Schr 1444/1-1, 360372040 -SFB 1335]; European Research Council [ERC-2016-STG-715182]; International Program Fund for doctoral students, Sun Yat-sen University	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); China Scholarship Council (CSC)(China Scholarship Council); DFG(German Research Foundation (DFG)); European Research Council(European Research Council (ERC)European Commission); International Program Fund for doctoral students, Sun Yat-sen University	This study is supported by the Deutsche Forschungsgemeinschaft (DFG) (AN372/14-3 and AN372/24-1 to H-JA, STE2437/2-1 and STE2437/2-2 to SS, the International Program Fund for doctoral students, Sun Yat-sen University, and China Scholarship Council (CSC) 201906380147 to NL, CSC 201603250047 to CS and CSC 202008080076 to CL. Work in the Schraml lab is funded by the DFG [Emmy Noether grant: Schr 1444/1-1 and Project-ID 360372040 -SFB 1335 (project 8)] and the European Research Council (ERC-2016-STG-715182).	Ahrens S, 2012, IMMUNITY, V36, P635, DOI 10.1016/j.immuni.2012.03.008; Anders HJ, 2021, NEPHROL DIAL TRANSPL, V36, P29, DOI 10.1093/ndt/gfaa056; Anders HJ, 2011, KIDNEY INT, V80, P915, DOI 10.1038/ki.2011.217; Bamboat ZM, 2010, J CLIN INVEST, V120, P559, DOI 10.1172/JCI40008; Bedoui S, 2009, NAT IMMUNOL, V10, P488, DOI 10.1038/ni.1724; Bosteels C, 2020, IMMUNITY, V52, P1039, DOI 10.1016/j.immuni.2020.04.005; Breda PC, 2019, AM J PHYSIOL-RENAL, V317, pF77, DOI 10.1152/ajprenal.00427.2018; Brown CC, 2019, CELL, V179, P846, DOI 10.1016/j.cell.2019.09.035; Cao Q, 2016, J AM SOC NEPHROL, V27, P1344, DOI 10.1681/ASN.2015030229; Cao Q, 2015, J AM SOC NEPHROL, V26, P349, DOI 10.1681/ASN.2013121336; Clement M, 2018, CIRC RES, V122, P813, DOI 10.1161/CIRCRESAHA.118.312713; del Fresno C, 2018, SCIENCE, V362, P351, DOI 10.1126/science.aan8423; del Rio ML, 2007, J IMMUNOL, V178, P6861, DOI 10.4049/jimmunol.178.11.6861; Dellepiane S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01546; Dong X, 2007, KIDNEY INT, V71, P619, DOI 10.1038/sj.ki.5002132; Dong XY, 2005, KIDNEY INT, V68, P1096, DOI 10.1111/j.1523-1755.2005.00502.x; Edgtton KL, 2008, J AM SOC NEPHROL, V19, P515, DOI 10.1681/ASN.2007030386; Elhofy A, 2009, J NEUROIMMUNOL, V213, P91, DOI 10.1016/j.jneuroim.2009.05.011; Evers BDG, 2016, J AM SOC NEPHROL, V27, P3368, DOI 10.1681/ASN.2015080873; Ferris ST, 2020, NATURE, V584, P624, DOI 10.1038/s41586-020-2611-3; Gandolfo MT, 2009, KIDNEY INT, V76, P717, DOI 10.1038/ki.2009.259; George JF, 2017, AM J PHYSIOL-RENAL, V312, pF640, DOI 10.1152/ajprenal.00369.2016; Ginhoux F, 2009, J EXP MED, V206, P3115, DOI 10.1084/jem.20091756; Gunthner R, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/731023; Heath WR, 2009, NAT IMMUNOL, V10, P1237, DOI 10.1038/ni.1822; Kawakami T, 2013, J IMMUNOL, V191, P3358, DOI 10.4049/jimmunol.1300342; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kim MG, 2010, NEPHROL DIAL TRANSPL, V25, P2908, DOI 10.1093/ndt/gfq183; Kruger T, 2004, J AM SOC NEPHROL, V15, P613, DOI 10.1097/01.ASN.0000114553.36258.91; Kulkarni OP, 2014, J AM SOC NEPHROL, V25, P978, DOI 10.1681/ASN.2013050528; Kurts C, 2020, NAT REV NEPHROL, V16, P391, DOI 10.1038/s41581-020-0272-y; Kurts C, 2013, NAT REV IMMUNOL, V13, P738, DOI 10.1038/nri3523; Lassen S, 2010, J IMMUNOL, V185, P1976, DOI 10.4049/jimmunol.0904207; Lech M, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/951390; Lech M, 2009, J IMMUNOL, V183, P4109, DOI 10.4049/jimmunol.0900118; Lever JM, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125503; Li L, 2012, J CLIN INVEST, V122, P3931, DOI 10.1172/JCI63170; Li L, 2008, KIDNEY INT, V74, P1526, DOI 10.1038/ki.2008.500; Li N, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1050-x; Marschner JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149489; Mulay SR, 2016, J AM SOC NEPHROL, V27, P27, DOI 10.1681/ASN.2015040405; Nakazawa D, 2017, J AM SOC NEPHROL, V28, P1753, DOI 10.1681/ASN.2016080925; Okusa Mark D, 2012, Trans Am Clin Climatol Assoc, V123, P54; Paust HJ, 2011, KIDNEY INT, V80, P155, DOI 10.1038/ki.2011.108; Riedel JH, 2012, J AM SOC NEPHROL, V23, P1987, DOI 10.1681/ASN.2012040394; Rogers NM, 2009, NEPHROLOGY, V14, P625, DOI 10.1111/j.1440-1797.2009.01200.x; Salei N, 2020, J AM SOC NEPHROL, V31, P257, DOI 10.1681/ASN.2019040419; Salvermoser J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00699; Schraml BU, 2015, CURR OPIN IMMUNOL, V32, P13, DOI 10.1016/j.coi.2014.11.001; Sedin J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02744; Shi CX, 2020, CIRC RES, V126, pE37, DOI 10.1161/CIRCRESAHA.119.315625; Shin JY, 2020, CELL MOL IMMUNOL, V17, P1215, DOI 10.1038/s41423-020-0511-y; Sichien D, 2016, IMMUNITY, V45, P626, DOI 10.1016/j.immuni.2016.08.013; Tadagavadi RK, 2015, TOXINS, V7, P3245, DOI 10.3390/toxins7083245; Tadagavadi RK, 2010, J IMMUNOL, V185, P4904, DOI 10.4049/jimmunol.1000383; Villares R, 2009, EUR J IMMUNOL, V39, P1671, DOI 10.1002/eji.200839123; Weidenbusch M, 2018, PHYSIOL REP, V6, DOI 10.14814/phy2.13817; Weidenbusch M, 2015, AM J PHYSIOL-RENAL, V308, pF1041, DOI 10.1152/ajprenal.00005.2015; Weisheit CK, 2015, CLIN J AM SOC NEPHRO, V10, P1841, DOI 10.2215/CJN.07100714; Yamazaki S, 2008, J IMMUNOL, V181, P6923, DOI 10.4049/jimmunol.181.10.6923; Zhang JG, 2012, IMMUNITY, V36, P646, DOI 10.1016/j.immuni.2012.03.009; Zhao HL, 2018, EBIOMEDICINE, V28, P31, DOI 10.1016/j.ebiom.2018.01.025; Zhou CZ, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109031	63	1	1	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 21	2021	12								685559	10.3389/fimmu.2021.685559	http://dx.doi.org/10.3389/fimmu.2021.685559			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TD7DK	34234783	gold, Green Published			2022-12-18	WOS:000669482600001
J	Acklin, JA; Cattle, JD; Moss, AS; Brown, JA; Foster, GA; Krysztof, D; Stramer, SL; Lim, JK				Acklin, Joshua A.; Cattle, Javier D.; Moss, Arianna S.; Brown, Julia A.; Foster, Gregory A.; Krysztof, David; Stramer, Susan L.; Lim, Jean K.			Evaluating the Safety of West Nile Virus Immunity During Congenital Zika Virus Infection in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						flavivirus; congenital Zika syndrome; antibody dependent enhancement; vaccines; placenta	ANTIBODY-DEPENDENT ENHANCEMENT; BIRTH-DEFECTS; DENGUE; EMERGENCE; INFANTS; PATHOGENESIS; OUTCOMES; FETUSES	Antibody-dependent enhancement (ADE) is a phenomenon that occurs when cross-reactive antibodies generated from a previous flaviviral infection increase the pathogenesis of a related virus. Zika virus (ZIKV) is the most recent flavivirus introduced to the Western Hemisphere and has become a significant public health threat due to the unanticipated impact on the developing fetus. West Nile virus (WNV) is the primary flavivirus that circulates in North America, and we and others have shown that antibodies against WNV are cross-reactive to ZIKV. Thus, there is concern that WNV immunity could increase the risk of severe ZIKV infection, particularly during pregnancy. In this study, we examined the extent to which WNV antibodies could impact ZIKV pathogenesis in a murine pregnancy model. To test this, we passively transferred WNV antibodies into pregnant Stat2(-/-) mice on E6.5 prior to infection with ZIKV. Evaluation of pregnant dams showed weight loss following ZIKV infection; however, no differences in maternal weights or viral loads in the maternal brain, spleen, or spinal cord were observed in the presence of WNV antibodies. Resorption rates, and other fetal parameters, including fetal and placental size, were similarly unaffected. Further, the presence of WNV antibodies did not significantly alter the viral load or the inflammatory response in the placenta or the fetus in response to ZIKV. Our data suggest that pre-existing WNV immunity may not significantly impact the pathogenesis of ZIKV infection during pregnancy. Our findings are promising for the safety of implementing WNV vaccines in the continental US.	[Acklin, Joshua A.; Cattle, Javier D.; Moss, Arianna S.; Brown, Julia A.; Lim, Jean K.] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA; [Acklin, Joshua A.; Brown, Julia A.] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA; [Cattle, Javier D.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA; [Foster, Gregory A.; Krysztof, David; Stramer, Susan L.] Amer Red Cross, Sci Affairs, Gaithersburg, MD USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Columbia University; American Red Cross	Lim, JK (corresponding author), Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.	jean.lim@mssm.edu		Moss, Arianna/0000-0002-5472-7307	NIAID [R01AI150837]; NHLBI [F31HL149295]	NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was funded by NIAID grant R01AI150837 and NHLBI F31HL149295.	Adanns LE, 2019, AM J TROP MED HYG, V101, P884, DOI 10.4269/ajtmh.19-0309; Aguado LC, 2015, CELL HOST MICROBE, V18, P714, DOI 10.1016/j.chom.2015.11.003; Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938; Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365; Terzian ACB, 2017, CLIN INFECT DIS, V65, P1260, DOI 10.1093/cid/cix558; Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412; Brown JA, 2019, IMMUNITY, V50, P751, DOI 10.1016/j.immuni.2019.01.005; Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638; Coyne CB, 2016, NAT REV MICROBIOL, V14, P707, DOI 10.1038/nrmicro.2016.125; Daffis S, 2011, J VIROL, V85, P5664, DOI 10.1128/JVI.00232-11; Pereira HVFS, 2020, LANCET CHILD ADOLESC, V4, P378, DOI 10.1016/S2352-4642(20)30041-9; Fischer C, 2020, LANCET INFECT DIS, V20, P15, DOI 10.1016/S1473-3099(19)30697-8; Gordon A, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002726; Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009; Gupta SK, 2014, GENES GENOM, V36, P31, DOI 10.1007/s13258-013-0137-x; Guzman MG, 2010, VIRUSES-BASEL, V2, P2649, DOI 10.3390/v2122649; Gyawali N, 2016, J VECTOR DIS, V53, P293; Halstead SB, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0022-2014; Hamel R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221179; Heinz FX, 2017, MICROBIOL MOL BIOL R, V81, DOI [10.1128/MMBR.00055-16, 10.1128/mmbr.00055-16]; Honein MA, 2017, JAMA-J AM MED ASSOC, V317, P59, DOI 10.1001/jama.2016.19006; Katzelnick LC, 2020, SCIENCE, V369, P1123, DOI 10.1126/science.abb6143; Katzelnick LC, 2018, CURR OPIN VIROL, V29, P51, DOI 10.1016/j.coviro.2018.03.004; Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836; Keasey SL, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00036-17; Khan E, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00287; Kostyuchenko VA, 2016, NATURE, V533, P425, DOI 10.1038/nature17994; Lazear HM, 2016, J VIROL, V90, P4864, DOI 10.1128/JVI.00252-16; Li M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200478; Messina JP, 2019, NAT MICROBIOL, V4, P1508, DOI 10.1038/s41564-019-0476-8; Moi Meng Ling, 2016, Trop Med Health, V44, P1, DOI 10.1186/s41182-016-0004-y; Moi ML, 2014, ARCH VIROL, V159, P103, DOI 10.1007/s00705-013-1787-3; Mulkey SB, 2020, JAMA PEDIATR, V174, P269, DOI 10.1001/jamapediatrics.2019.5204; Murray KO, 2010, VET RES, V41, DOI 10.1051/vetres/2010039; Narayan R, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.580096; Petersen LR, 2013, JAMA-J AM MED ASSOC, V310, P308, DOI 10.1001/jama.2013.8042; Racherla RG, 2018, INDIAN J MED MICROBI, V36, P236, DOI 10.4103/ijmm.IJMM_18_109; Rathore APS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav3208; Reynolds MR, 2017, MMWR-MORBID MORTAL W, V66, P366, DOI 10.15585/mmwr.mm6613e1; Ripoll DR, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00200; Rodriguez-Barraquer I, 2019, SCIENCE, V363, P607, DOI 10.1126/science.aav6618; Ronca SE, 2019, EMERG INFECT DIS, V25, P325, DOI 10.3201/eid2502.180765; Schaub B, 2017, LANCET INFECT DIS, V17, P520, DOI [10.1016/S1473-3099(17)30102-0, 10.1016/s1473-3099(17)30102-0]; Schwarz MC, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00246-16; Shapiro-Mendoza CK, 2017, MMWR-MORBID MORTAL W, V66, P615, DOI 10.15585/mmwr.mm6623e1; Sirohi D, 2016, SCIENCE, V352, P467, DOI 10.1126/science.aaf5316; Soo KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154760; Takada A, 2003, REV MED VIROL, V13, P387, DOI 10.1002/rmv.405; Taylor A, 2015, IMMUNOL REV, V268, P340, DOI 10.1111/imr.12367; Toh YX, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00388; Wen JS, 2019, CURR OPIN IMMUNOL, V59, P1, DOI 10.1016/j.coi.2019.02.001; Wheeler AC, 2018, PEDIATRICS, V141, pS154, DOI [10.1542/peds.2017-2038D, 10.1542/peds.2017-2038d]; Willis E, 2017, VIROLOGY, V508, P1, DOI 10.1016/j.virol.2017.04.031; Woods L, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00570; Xu X., 2016, PLOS CURR, DOI [10.1371/currents.outbreaks.9aa2e1fb61b0f632f58a098773008c4b, DOI 10.1371/CURRENTS.OUTBREAKS.9AA2E1FB61B0F632F58A098773008C4B]; Zidane N, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-302; Zimmerman MG, 2018, CELL HOST MICROBE, V24, P731, DOI 10.1016/j.chom.2018.10.008	57	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 18	2021	12								686411	10.3389/fimmu.2021.686411	http://dx.doi.org/10.3389/fimmu.2021.686411			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TC8PX	34220838	gold, Green Published			2022-12-18	WOS:000668901800001
J	Emam, M; Tabatabaei, S; Sargolzaei, M; Mallard, B				Emam, Mehdi; Tabatabaei, Saeid; Sargolzaei, Mehdi; Mallard, Bonnie			Response to Oxidative Burst-Induced Hypoxia Is Associated With Macrophage Inflammatory Profiles as Revealed by Cellular Genome-Wide Association	FRONTIERS IN IMMUNOLOGY			English	Article						inflammation; genetic regulation; hypoixa-inducible factor; macrophage; E; coli	EFFECTIVE POPULATION-SIZE; GENETIC-VARIATION; MITOCHONDRIA; ACTIVATION; REGULATOR; MONOCYTES; SELECTION; PROTEIN; JERSEY; KINASE	Background In mammalian species, hypoxia is a prominent feature of inflammation. The role of hypoxia in regulating macrophage responses via alteration in metabolic pathways is well established. Recently, oxidative burst-induced hypoxia has been shown in murine macrophages after phagocytosis. Despite the available detailed information on the regulation of macrophage function at transcriptomic and epigenomic levels, the association of genetic polymorphism and macrophage function has been less explored. Previously, we have shown that host genetics controls approximately 80% of the variation in an oxidative burst as measured by nitric oxide (NO-). Further studies revealed two clusters of transcription factors (hypoxia-related and inflammatory-related) are under the genetic control that shapes macrophages' pro-inflammatory characteristics. Material and Methods In the current study, the association between 43,066 autosomal Single Nucleic Polymorphism (SNPs) and the ability of MDMs in production of NO- in response to E. coli was evaluated in 58 Holstein cows. The positional candidate genes near significant SNPs were selected to perform functional analysis. In addition, the interaction between the positional candidate genes and differentially expressed genes from our previous study was investigated. Results Sixty SNPs on 22 chromosomes of the bovine genome were found to be significantly associated with NO- production of macrophages. The functional genomic analysis showed a significant interaction between positional candidate genes and mitochondria-related differentially expressed genes from the previous study. Further examination showed 7 SNPs located in the vicinity of genes with roles in response to hypoxia, shaping approximately 73% of the observed individual variation in NO- production by MDM. Regarding the normoxic condition of macrophage culture in this study, it was hypothesized that oxidative burst is responsible for causing hypoxia at the cellular level. Conclusion The results suggest that the genetic polymorphism via regulation of response to hypoxia is a candidate step that perhaps shapes macrophage functional characteristics in the pathway of phagocytosis leading to oxidative burst, hypoxia, cellular response to hypoxia and finally the pro-inflammatory responses. Since all cells in one individual carry the same alleles, the effect of genetic predisposition of sensitivity to hypoxia will likely be notable on the clinical outcome to a broad range of host-pathogen interactions.	[Emam, Mehdi; Tabatabaei, Saeid; Sargolzaei, Mehdi; Mallard, Bonnie] Univ Guelph, Dept Pathobiol, Ontario Vet Coll, Guelph, ON, Canada; [Emam, Mehdi] McGill Univ, Dept Human Genet, Fac Med, Montreal, PQ, Canada; [Sargolzaei, Mehdi] Select Sires Inc, Plain City, OH USA; [Mallard, Bonnie] Univ Guelph, Dept Anim Biosci, Ctr Genet Improvement Livestock, Guelph, ON, Canada	University of Guelph; McGill University; University of Guelph	Emam, M (corresponding author), Univ Guelph, Dept Pathobiol, Ontario Vet Coll, Guelph, ON, Canada.; Emam, M (corresponding author), McGill Univ, Dept Human Genet, Fac Med, Montreal, PQ, Canada.	seyedmehdi.emam@mcgill.ca			Natural Sciences and Engineering Research Council (NSERC); Canada First Research Excellence Fund; Natural Sciences and Engineering Research Council	Natural Sciences and Engineering Research Council (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canada First Research Excellence Fund; Natural Sciences and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC))	This research was funded by grants to BM from the Natural Sciences and Engineering Research Council (NSERC). This paper is also a contribution to the Food from Thought research program supported by the Canada First Research Excellence Fund. The funders did not have any role in the design, collection, analysis, and interpretation of data and in writing the manuscript. ME was supported by the Natural Sciences and Engineering Research Council via scholarship.	Alvarez MI, 2018, P NATL ACAD SCI USA, V115, pE3604, DOI 10.1073/pnas.1803533115; Ariel O, 2021, BMC GENOMICS, V22, DOI 10.1186/s12864-021-07487-4; Bain CC, 2014, NAT IMMUNOL, V15, P929, DOI 10.1038/ni.2967; Ball Roderick D, 2013, Methods Mol Biol, V1019, P37, DOI 10.1007/978-1-62703-447-0_3; Chen Y, 2012, METHODS MOL BIOL, V844, P115, DOI 10.1007/978-1-61779-527-5_8; Clarke GM, 2011, NAT PROTOC, V6, P121, DOI 10.1038/nprot.2010.182; de Klerk B, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-5062-6; Dolle C, 2013, FEBS J, V280, P3530, DOI 10.1111/febs.12304; Durinck S, 2009, NAT PROTOC, V4, P1184, DOI 10.1038/nprot.2009.97; Emam M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57089-0; Emam M, 2019, J DAIRY SCI, V102, P9107, DOI 10.3168/jds.2018-15960; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Fuentes-Duculan J, 2010, J INVEST DERMATOL, V130, P2412, DOI 10.1038/jid.2010.165; Fuhrmann DC, 2017, REDOX BIOL, V12, P208, DOI 10.1016/j.redox.2017.02.012; Gerrick KY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208602; Ginhoux F, 2016, NAT IMMUNOL, V17, P34, DOI 10.1038/ni.3324; Glass CK, 2016, NAT IMMUNOL, V17, P26, DOI 10.1038/ni.3306; Glass CK, 2015, ARTERIOSCL THROM VAS, V35, P755, DOI 10.1161/ATVBAHA.114.304051; Gosselin D, 2014, IMMUNOL REV, V262, P96, DOI 10.1111/imr.12213; Habier D, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-186; Hao HX, 2007, P NATL ACAD SCI USA, V104, P15466, DOI 10.1073/pnas.0705407104; Higgins MG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32374-6; Hunt SE, 2018, DATABASE-OXFORD, DOI [10.1093/database/bay119, 10.1186/1471-2164-11-293]; Ibeagha-Awemu EM, 2016, SCI REP-UK, V6, DOI 10.1038/srep31109; Italiani P, 2017, RESULTS PROBL CELL D, V62, P23, DOI 10.1007/978-3-319-54090-0_2; Kemper KE, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3175-3; Kim H, 2017, GENETICS, V207, P1135, DOI 10.1534/genetics.117.300271; Ko DC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003424; Krishnamoorthy K, 2008, TECHNOMETRICS, V50, P69, DOI 10.1198/004017007000000353; Kristiansson K, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-8-109; Langlais D, 2016, J EXP MED, V213, P585, DOI 10.1084/jem.20151764; Lavin Y, 2015, NAT REV IMMUNOL, V15, P731, DOI 10.1038/nri3920; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Li W, 2015, METHODS MOL BIOL, V1241, P39, DOI 10.1007/978-1-4939-1875-1_4; Li Y, 2016, CELL, V167, P1099, DOI 10.1016/j.cell.2016.10.017; Li Y, 2016, NAT MED, V22, P952, DOI 10.1038/nm.4139; LIEW FY, 1972, CELL IMMUNOL, V5, P520, DOI 10.1016/0008-8749(72)90102-5; Liu PS, 2018, MITOCHONDRION, V41, P45, DOI 10.1016/j.mito.2017.11.002; Loker S, 2009, J DAIRY SCI, V92, P1300, DOI 10.3168/jds.2008-1425; Luo BW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12177; Makanjuola BO, 2020, J DAIRY SCI, V103, P5183, DOI 10.3168/jds.2019-18013; McKay SD, 2007, BMC GENET, V8, DOI 10.1186/1471-2156-8-74; Menk AV, 2018, CELL REP, V22, P1509, DOI 10.1016/j.celrep.2018.01.040; Meyer A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00536; Miller SI, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5020039; Mills EL, 2017, NAT IMMUNOL, V18, P488, DOI 10.1038/ni.3704; Mitchell AJ, 2010, J LEUKOCYTE BIOL, V88, P597, DOI 10.1189/jlb.0310184; Moon EJ, 2010, P NATL ACAD SCI USA, V107, P20477, DOI 10.1073/pnas.1006646107; Netea MG, 2016, CELL RES, V26, P145, DOI 10.1038/cr.2016.5; Nishi K, 2008, ANTIOXID REDOX SIGN, V10, P983, DOI 10.1089/ars.2007.1825; Njoroge JM, 2001, CYTOMETRY, V44, P38, DOI 10.1002/1097-0320(20010501)44:1<38::AID-CYTO1080>3.0.CO;2-T; Park L, 2011, GENET RES, V93, P105, DOI 10.1017/S0016672310000558; Piao L, 2011, GENE CHROMOSOME CANC, V50, P13, DOI 10.1002/gcc.20828; Romanoski CE, 2015, TRENDS IMMUNOL, V36, P507, DOI 10.1016/j.it.2015.07.006; Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086; Sargolzaei M, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-478; Seres T, 2000, J IMMUNOL, V165, P3333, DOI 10.4049/jimmunol.165.6.3333; Soehnlein O, 2010, NAT REV IMMUNOL, V10, P427, DOI 10.1038/nri2779; Somers M, 2017, GENES-BASEL, V8, DOI 10.3390/genes8050133; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; ter Horst R, 2016, CELL, V167, P1111, DOI 10.1016/j.cell.2016.10.018; Tur J, 2017, ADV IMMUNOL, V133, P1, DOI 10.1016/bs.ai.2016.12.001; Turcotte ML, 2002, BRIT J CANCER, V86, P619, DOI 10.1038/sj.bjc.6600087; VanLinden MR, 2015, J BIOL CHEM, V290, P27644, DOI 10.1074/jbc.M115.654129; Vashi N, 2017, J BIOL CHEM, V292, P5144, DOI 10.1074/jbc.M116.743047; Wang LY, 2018, CELL HOST MICROBE, V24, P308, DOI 10.1016/j.chom.2018.07.007; Wang N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00614; Wang T, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/9029327; Wiese M, 2012, INFECT IMMUN, V80, P1455, DOI 10.1128/IAI.05972-11; Wiggans GR, 2009, J DAIRY SCI, V92, P3431, DOI 10.3168/jds.2008-1758; Zhang DD, 2015, NUTRIENTS, V7, P7437, DOI 10.3390/nu7095347; Zhu MJ, 2007, INT J BIOL SCI, V3, P420; Zidek Z, 2000, PHARMACOGENETICS, V10, P493, DOI 10.1097/00008571-200008000-00002	73	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 18	2021	12								688503	10.3389/fimmu.2021.688503	http://dx.doi.org/10.3389/fimmu.2021.688503			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TD0LW	34220845	Green Published, gold			2022-12-18	WOS:000669028700001
J	Jabkowski, J; Loidl, A; Auinger, B; Kehrer, H; Sepp, N; Pichler, R				Jabkowski, Joerg; Loidl, Almute; Auinger, Barbara; Kehrer, Helmut; Sepp, Norbert; Pichler, Robert			Pembrolizumab-Induced Thyroiditis Shows PD-L1Expressing Histiocytes and Infiltrating T Cells in Thyroid Tissue - A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						pembrolizumab; thyroiditis; melanoma; FDG; PET	IMMUNE CHECKPOINT INHIBITORS; DYSFUNCTIONS	Context: Immune-related adverse events frequently take place after initiation of immune checkpoint inhibitors (ICI) therapy. The thyroid gland is the endocrine organ most commonly affected by ICI therapy, the pathological mechanism is still poorly understood. Case Description: A 60-year old Upper Austrian male melanoma patient under pembrolizumab therapy received thyroidectomy because of a suspicious FDG avid thyroid nodule. Histopathology showed a pattern comparable with thyroiditis de Quervain. The inflammatory process consisted predominantly of T lymphocytes with a dominance of CD4+ T helper cells. In addition CD68+ histiocytes co-expressing PD-L1 were observed. Conclusion: Clusters of perifollicular histiocytes expressing PD-L1 were observed in this case of pembrolizumab induced thyroiditis - probably induced by the former ICI therapy. This finding might indicate the initial target for the breakdown of self tolerance. In context with other data the immunological process seems to be driven by CD3+ lymphocytes infiltrating the thyroid.	[Jabkowski, Joerg; Kehrer, Helmut; Sepp, Norbert] Ordensklinikum Linz Elisabethinen, Dept Dermatol, Linz, Austria; [Loidl, Almute] Steyr Hosp, Inst Pathol, Steyr, Austria; [Auinger, Barbara] Steyr Hosp, Dept Surg, Steyr, Austria; [Pichler, Robert] Kepler Univ Hosp, Inst Nucl Med, Linz, Austria	Ordensklinikum Linz Elisabethinen; Kepler University Hospital	Pichler, R (corresponding author), Kepler Univ Hosp, Inst Nucl Med, Linz, Austria.	robert.pichler@kepleruniklinikum.at						Ahn S, 2017, ENDOCR-RELAT CANCER, V24, P97, DOI 10.1530/ERC-16-0421; Akturk HK, 2018, J CLIN ENDOCR METAB, V103, P3589, DOI 10.1210/jc.2018-01430; Alvarez-Sierra D, 2019, J AUTOIMMUN, V103, DOI 10.1016/j.jaut.2019.05.013; Azmat U, 2016, CASE REP ENDOCRINOL, V2016, DOI 10.1155/2016/2087525; Brancatella A, 2019, EUR THYROID J, V8, P192, DOI 10.1159/000501824; Chandanwale SS, 2018, J THROID RES, V2018, DOI 10.1155/2018/5246516; Damuzzo V, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1249559; de Filette J, 2019, HORM METAB RES, V51, P145, DOI 10.1055/a-0843-3366; Delivanis DA, 2017, J CLIN ENDOCR METAB, V102, P2770, DOI 10.1210/jc.2017-00448; Edo N, 2018, THYROID RES, V11, DOI 10.1186/s13044-018-0058-5; El Sabbagh R, 2020, INT J GEN MED, V13, P1003, DOI 10.2147/IJGM.S261433; Hommes JW, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.585311; Imblum BA, 2019, ENDOCR PATHOL, V30, P163, DOI 10.1007/s12022-019-9579-2; Karachaliou N, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758834017749748; Khan M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00167; Kotwal A, 2020, THYROID, V30, P1440, DOI 10.1089/thy.2020.0075; Kurimoto C, 2020, CANCER SCI, V111, P1468, DOI 10.1111/cas.14363; Neppl C, 2018, THYROID, V28, P1727, DOI 10.1089/thy.2018.0418; Nogueira E, 2019, THER ADV ENDOCRINOL, V10, DOI 10.1177/2042018819896182; Sakakida T, 2019, ONCOL LETT, V18, P2140, DOI 10.3892/ol.2019.10466; Synoracki S, 2016, PATHOLOGE, V37, P215, DOI 10.1007/s00292-016-0157-9; Varricchi G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163934; Yamauchi I, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216954	23	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 18	2021	12								606056	10.3389/fimmu.2021.606056	http://dx.doi.org/10.3389/fimmu.2021.606056			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TC9BL	34220792	gold, Green Published			2022-12-18	WOS:000668932000001
J	Mormile, I; Rossi, FW; Prevete, N; Granata, F; Pucino, V; de Paulis, A				Mormile, Ilaria; Rossi, Francesca Wanda; Prevete, Nella; Granata, Francescopaolo; Pucino, Valentina; de Paulis, Amato			The N-Formyl Peptide Receptors and Rheumatoid Arthritis: A Dangerous Liaison or Confusing Relationship?	FRONTIERS IN IMMUNOLOGY			English	Review						rheumatoid arthritis; formylpeptide receptors; rheumatoid arthritis histopathotypes; pattern recognition receptors; innate immunity	PATTERN-RECOGNITION RECEPTORS; FUNCTIONAL EXPRESSION; IMMUNE-RESPONSE; DENDRITIC CELLS; ANNEXIN A1; INFLAMMATION; ACTIVATION; CANCER; DIFFERENTIATION; FIBROBLASTS	Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by a progressive symmetric inflammation of the joints resulting in bone erosion and cartilage destruction with a progressive loss of function and joint deformity. An increased number of findings support the role of innate immunity in RA: many innate immune mechanisms are responsible for producing several cytokines and chemokines involved in RA pathogenesis, such as Tumor Necrosis Factor (TNF)-alpha, interleukin (IL)-6, and IL-1. Pattern recognition receptors (PRRs) play a crucial role in modulating the activity of the innate arm of the immune response. We focused our attention over the years on the expression and functions of a specific class of PRR, namely formyl peptide receptors (FPRs), which exert a key function in both sustaining and resolving the inflammatory response, depending on the context and/or the agonist. We performed a broad review of the data available in the literature on the role of FPRs and their ligands in RA. Furthermore, we queried a publicly available database collecting data from 90 RA patients with different clinic features to evaluate the possible association between FPRs and clinic-pathologic parameters of RA patients.	[Mormile, Ilaria; Rossi, Francesca Wanda; Prevete, Nella; Granata, Francescopaolo; de Paulis, Amato] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy; [Rossi, Francesca Wanda; de Paulis, Amato] Univ Naples Federico II, Ctr Basic & Clin Immunol Res CISI, World Allergy Org WAO, Ctr Excellence, Naples, Italy; [Prevete, Nella] CNR, Natl Res Council, Inst Expt Endocrinol & Oncol IEOS, Naples, Italy; [Pucino, Valentina] Univ Birmingham, Inst Inflammat & Ageing, Coll Med & Dent Sci, Birmingham, W Midlands, England	University of Naples Federico II; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Birmingham	Rossi, FW (corresponding author), Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy.; Rossi, FW (corresponding author), Univ Naples Federico II, Ctr Basic & Clin Immunol Res CISI, World Allergy Org WAO, Ctr Excellence, Naples, Italy.	francescawanda.rossi@unina.it	Mormile, Ilaria/AHE-5048-2022; de Paulis, Amato/AHE-5275-2022	Mormile, Ilaria/0000-0001-7599-5426; de Paulis, Amato/0000-0003-0347-2540; Pucino, Valentina/0000-0002-7683-4568	Orpha Biotech	Orpha Biotech	The authors declare that this study received funding from Orpha Biotech. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Babbin BA, 2007, J IMMUNOL, V179, P8112, DOI 10.4049/jimmunol.179.12.8112; Blaschke S, 2000, J RHEUMATOL, V27, P866; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; Chen KD, 2013, J CLIN INVEST, V123, P1694, DOI 10.1172/JCI65569; Cooray SN, 2013, P NATL ACAD SCI USA, V110, P18232, DOI 10.1073/pnas.1308253110; Crocetti L, 2020, BIOORG CHEM, V100, DOI 10.1016/j.bioorg.2020.103880; D'Acquisto F, 2007, BLOOD, V109, P1095, DOI 10.1182/blood-2006-05-022798; de Paulis A, 2004, J IMMUNOL, V172, P7734, DOI 10.4049/jimmunol.172.12.7734; de Paulis A, 2009, J IMMUNOL, V183, P3761, DOI 10.4049/jimmunol.0900863; Dufton N, 2010, J IMMUNOL, V184, P2611, DOI 10.4049/jimmunol.0903526; Fukata M, 2013, MUCOSAL IMMUNOL, V6, P451, DOI 10.1038/mi.2013.13; GOULDING NJ, 1995, ANN RHEUM DIS, V54, P841, DOI 10.1136/ard.54.10.841; Gravina AG, 2018, UNITED EUR GASTROENT, V6, P1428, DOI 10.1177/2050640618793564; Gripentrog JM, 2008, IMMUNOGENETICS, V60, P83, DOI 10.1007/s00251-008-0277-3; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; He HQ, 2017, MOLECULES, V22, DOI 10.3390/molecules22030455; Humby F, 2019, ANN RHEUM DIS, V78, P761, DOI 10.1136/annrheumdis-2018-214539; Humby F, 2009, PLOS MED, V6, P59, DOI 10.1371/journal.pmed.0060001; JACOBS MJM, 1994, IMMUNOLOGY, V83, P390; Kao W, 2014, BRIT J PHARMACOL, V171, P4087, DOI 10.1111/bph.12768; Kim MK, 2007, FEBS LETT, V581, P1917, DOI 10.1016/j.febslet.2007.03.078; Kim SD, 2009, J IMMUNOL, V183, P5511, DOI 10.4049/jimmunol.0802986; Krepel SA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143426; Le YY, 2001, CYTOKINE GROWTH F R, V12, P91, DOI 10.1016/S1359-6101(01)00003-X; Lee MS, 2006, J IMMUNOL, V177, P5585, DOI 10.4049/jimmunol.177.8.5585; Lewis MJ, 2019, CELL REP, V28, P2455, DOI 10.1016/j.celrep.2019.07.091; Lin YJ, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040880; Liotti F, 2021, CANCERS, V13, DOI 10.3390/cancers13040740; Littlejohn EA, 2018, PRIMARY CARE, V45, P237, DOI 10.1016/j.pop.2018.02.010; Lliso-Ribera G, 2019, ANN RHEUM DIS, V78, P1642, DOI 10.1136/annrheumdis-2019-215751; McCormack WJ, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2729; Morand EF, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/73835; Mullen LM, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0645-y; Nagaya T, 2017, IMMUNOL LETT, V181, P51, DOI 10.1016/j.imlet.2016.11.006; Napolitano F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00574; Nerviani A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00845; O'Hara R, 2004, ARTHRITIS RHEUM-US, V50, P1788, DOI 10.1002/art.20301; Odobasic D, 2018, INT IMMUNOPHARMACOL, V61, P140, DOI 10.1016/j.intimp.2018.05.028; Park YJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32963-5; Perretti M, 2009, NAT REV IMMUNOL, V9, P62, DOI 10.1038/nri2470; Pierer M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023539; Prevete N, 2018, CURR PHARM DESIGN, V24, P1966, DOI 10.2174/1381612824666180516102234; Prevete N, 2015, ONCOGENE, V34, P3826, DOI 10.1038/onc.2014.309; Prevete N, 2011, J BIOL REG HOMEOS AG, V25, P553; Prevete N, 2018, PHARMACOL RES, V128, P80, DOI 10.1016/j.phrs.2017.09.024; Prevete N, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1293213; Prevete N, 2015, PHARMACOL RES, V102, P184, DOI 10.1016/j.phrs.2015.09.017; Rabiet MJ, 2011, J BIOL CHEM, V286, P26718, DOI 10.1074/jbc.M111.244590; Rossi FW, 2015, J IMMUNOL, V194, P5161, DOI 10.4049/jimmunol.1402819; Sacks JJ, 2010, ARTHRIT CARE RES, V62, P460, DOI 10.1002/acr.20041; Sampey AV, 2000, MEDIAT INFLAMM, V9, P125, DOI 10.1080/09629350020018357; Satomura K, 2013, MOD RHEUMATOL, V23, P28, DOI 10.1007/s10165-012-0630-0; Sedlmayer F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04223-7; Serhan CN, 1999, ADV EXP MED BIOL, V447, P133; Shin MK, 2011, J BIOL CHEM, V286, P17133, DOI 10.1074/jbc.M110.197772; Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8; Snapkov I, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2545-1; Stama ML, 2017, EUR J MED CHEM, V141, P703, DOI 10.1016/j.ejmech.2017.09.023; Tagoe CE, 2008, J IMMUNOL, V181, P2813, DOI 10.4049/jimmunol.181.4.2813; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Thompson MR, 2011, VIRUSES-BASEL, V3, P920, DOI 10.3390/v3060920; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; van der Heijden IM, 2000, ARTHRITIS RHEUM-US, V43, P593, DOI 10.1002/1529-0131(200003)43:3<593::AID-ANR16>3.0.CO;2-1; Viswanathan A, 2007, STEM CELLS, V25, P1263, DOI 10.1634/stemcells.2006-0522; Wijbrandts CA, 2007, ARTHRITIS RHEUM, V56, P3869, DOI 10.1002/art.22964; Xiang Y, 2016, AM J CANCER RES, V6, P2599; Yang D, 2002, J LEUKOCYTE BIOL, V72, P598; Yang D, 2001, J IMMUNOL, V166, P4092, DOI 10.4049/jimmunol.166.6.4092; Yang YH, 2013, NAT REV RHEUMATOL, V9, P595, DOI 10.1038/nrrheum.2013.126; Ye RD, 2009, PHARMACOL REV, V61, P119, DOI 10.1124/pr.109.001578; Yu N, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12320; Zhang L, 2008, INFLAMM RES, V57, P157, DOI 10.1007/s00011-007-7141-z	72	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 18	2021	12								685214	10.3389/fimmu.2021.685214	http://dx.doi.org/10.3389/fimmu.2021.685214			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TD0LT	34220836	gold, Green Published			2022-12-18	WOS:000669028400001
J	Zhang, L; Jiao, C; Liu, LJ; Wang, AP; Tang, L; Ren, Y; Huang, P; Xu, J; Mao, DA; Liu, LQ				Zhang, Lu; Jiao, Cui; Liu, Lingjuan; Wang, Aiping; Tang, Li; Ren, Yi; Huang, Peng; Xu, Jie; Mao, Dingan; Liu, Liqun			NLRC5: A Potential Target for Central Nervous System Disorders	FRONTIERS IN IMMUNOLOGY			English	Review						pattern recognition receptor; NLRC5; central nervous system; disease; development	NF-KAPPA-B; NUCLEOTIDE-BINDING DOMAIN; FAMILY-MEMBER NLRC5; NOD-LIKE RECEPTORS; CELL-PROLIFERATION; WIDE ASSOCIATION; I/R INJURY; ACTIVATION; MHC; INFLAMMASOME	Nucleotide oligomerization domain-like receptors (NLRs), a class of pattern recognition receptors, participate in the host's first line of defense against invading pathogenic microorganisms. NLR family caspase recruitment domain containing 5 (NLRC5) is the largest member of the NLR family and has been shown to play an important role in inflammatory processes, angiogenesis, immunity, and apoptosis by regulating the nuclear factor-kappa B, type I interferon, and inflammasome signaling pathways, as well as the expression of major histocompatibility complex I genes. Recent studies have found that NLRC5 is also associated with neuronal development and central nervous system (CNS) diseases, such as CNS infection, cerebral ischemia/reperfusion injury, glioma, multiple sclerosis, and epilepsy. This review summarizes the research progress in the structure, expression, and biological characteristics of NLRC5 and its relationship with the CNS.	[Zhang, Lu; Jiao, Cui; Liu, Lingjuan; Wang, Aiping; Tang, Li; Ren, Yi; Huang, Peng; Xu, Jie; Mao, Dingan; Liu, Liqun] Cent South Univ, Xiangya Hosp 2, Dept Pediat, Changsha, Peoples R China; [Zhang, Lu; Jiao, Cui; Liu, Lingjuan; Wang, Aiping; Tang, Li; Ren, Yi; Huang, Peng; Xu, Jie; Mao, Dingan; Liu, Liqun] Cent South Univ, Xiangya Hosp 2, Childrens Brain Dev & Brain Injury Res Off, Changsha, Peoples R China	Central South University; Central South University	Liu, LQ (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Pediat, Changsha, Peoples R China.; Liu, LQ (corresponding author), Cent South Univ, Xiangya Hosp 2, Childrens Brain Dev & Brain Injury Res Off, Changsha, Peoples R China.	liuliqun@csu.edu.cn			National Natural Science Foundation of China [81873762, 81501039]; Program of Hunan Provincial Department of Science and Technology, China [2018SK2069]; Natural Science Foundation of Hunan Province, China [2019JJ50876]; Health Commission of Hunan Province, China [B2018-0311]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program of Hunan Provincial Department of Science and Technology, China; Natural Science Foundation of Hunan Province, China(Natural Science Foundation of Hunan Province); Health Commission of Hunan Province, China	This work was supported by National Natural Science Foundation of China (No. 81873762 to LQL and No. 81501039 to LJL), and the Program of Hunan Provincial Department of Science and Technology, China (No. 2018SK2069 to LQL), and the Natural Science Foundation of Hunan Province, China (No. 2019JJ50876 to JX), and the Program from Health Commission of Hunan Province, China (No. B2018-0311 to LQL).	Al-Obaidi MMJ, 2018, CELL MOL NEUROBIOL, V38, P1349, DOI 10.1007/s10571-018-0609-2; Azouz F, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020162; Benko S, 2010, J IMMUNOL, V185, P1681, DOI 10.4049/jimmunol.0903900; Bergen SE, 2012, MOL PSYCHIATR, V17, P880, DOI 10.1038/mp.2012.73; Bijalwan M., 2017, PATHOGENESIS THEILER; Cao L, 2018, DEV COMP IMMUNOL, V84, P153, DOI 10.1016/j.dci.2018.02.013; Chen Z, 2017, BIOCHEM BIOPH RES CO, V493, P1143, DOI 10.1016/j.bbrc.2017.08.017; Comba A., 2019, PHOTOONCOGENE FYN IN, DOI [10.1101/608505, DOI 10.1101/608505]; Cui J, 2010, CELL, V141, P483, DOI 10.1016/j.cell.2010.03.040; Davis BK, 2011, J IMMUNOL, V186, P1333, DOI 10.4049/jimmunol.1003111; Deng YM, 2019, J CELL BIOCHEM, V120, P17151, DOI 10.1002/jcb.28975; Falcao AM, 2018, NAT MED, V24, P1837, DOI 10.1038/s41591-018-0236-y; Fan YJ, 2020, J INT MED RES, V48, DOI 10.1177/0300060520925352; Fekete T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02314; Fink SL, 2008, P NATL ACAD SCI USA, V105, P4312, DOI 10.1073/pnas.0707370105; Fourgeaud L, 2010, P NATL ACAD SCI USA, V107, P22278, DOI 10.1073/pnas.0914064107; Gharagozloo M, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.02012; Gordon R, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aah4066; Gutte PGM, 2014, BIOCHEMISTRY-US, V53, P3106, DOI 10.1021/bi500177x; Han F, 2018, BIOMED PHARMACOTHER, V103, P222, DOI 10.1016/j.biopha.2018.04.040; He YH, 2016, TOXICOLOGY, V359, P47, DOI 10.1016/j.tox.2016.06.012; Hu ZH, 2016, CURR TOP MICROBIOL, V397, P23, DOI 10.1007/978-3-319-41171-2_2; Huang QX, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117793; Jauhari A, 2018, MOL NEUROBIOL, V55, P936, DOI 10.1007/s12035-016-0359-4; Jongsma MLM, 2019, MOL IMMUNOL, V113, P16, DOI 10.1016/j.molimm.2017.12.005; Kong XX, 2017, J NEUROSCI RES, V95, P1565, DOI 10.1002/jnr.24004; Kuenzel S, 2010, J IMMUNOL, V184, P1990, DOI 10.4049/jimmunol.0900557; Kumar H, 2011, J IMMUNOL, V186, P994, DOI 10.4049/jimmunol.1002094; Kumar M, 2016, SCI REP-UK, V6, DOI 10.1038/srep26350; Labbe K, 2008, CELL DEATH DIFFER, V15, P1339, DOI 10.1038/cdd.2008.91; Langen UH, 2019, ANNU REV CELL DEV BI, V35, P591, DOI 10.1146/annurev-cellbio-100617-062608; Leda AR, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02158; Lee HM, 2014, NATURE, V509, P195, DOI 10.1038/nature13154; Lenart N, 2016, J CEREBR BLOOD F MET, V36, P1668, DOI 10.1177/0271678X16662043; Li L, 2014, INFLAMMATION, V37, P835, DOI 10.1007/s10753-013-9804-y; Li LL, 2021, J RECEPT SIG TRANSD, V41, P53, DOI 10.1080/10799893.2020.1786840; Li P, 2020, J NEUROCHEM, V152, P182, DOI 10.1111/jnc.14876; Ludlow M, 2016, ACTA NEUROPATHOL, V131, P159, DOI 10.1007/s00401-015-1511-3; Meeks KAC, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0403-x; Meffert MK, 2003, NAT NEUROSCI, V6, P1072, DOI 10.1038/nn1110; Meissner TB, 2010, P NATL ACAD SCI USA, V107, P13794, DOI 10.1073/pnas.1008684107; Meng CC, 2019, J MOL NEUROSCI, V69, P411, DOI 10.1007/s12031-019-01370-4; Motyan JA, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-275; Nagyoszi P, 2015, J NEUROCHEM, V135, P551, DOI 10.1111/jnc.13197; Neerincx A, 2010, J BIOL CHEM, V285, P26223, DOI 10.1074/jbc.M110.109736; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Nyul-Toth A, 2017, BRAIN BEHAV IMMUN, V64, P220, DOI 10.1016/j.bbi.2017.04.010; Pacifico R, 2017, MOL PSYCHIATR, V22, P441, DOI 10.1038/mp.2016.94; Peng YY, 2016, CANCER LETT, V376, P10, DOI 10.1016/j.canlet.2016.03.006; Periyasamy P, 2019, BRAIN BEHAV IMMUN, V80, P227, DOI 10.1016/j.bbi.2019.03.011; Qiu LL, 2017, GENE, V597, P23, DOI 10.1016/j.gene.2016.10.026; Ramos HJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003039; Robbins GR, 2012, J BIOL CHEM, V287, P24294, DOI 10.1074/jbc.M112.364604; Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111; Saylor D, 2016, NAT REV NEUROL, V12, P234, DOI [10.1038/nrneurol.2016.27, 10.1038/nrneurol.2016.53]; Shen YQ, 2019, NEUROCHEM RES, V44, P312, DOI 10.1007/s11064-018-2676-7; Shi YS, 2019, FOOD FUNCT, V10, P5323, DOI 10.1039/c9fo01481k; Song MQ, 2019, CANCER RES, V79, P1019, DOI 10.1158/0008-5472.CAN-18-2738; Tan CC, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0233-0; Tang F, 2020, MOL BIOL REP, V47, P2265, DOI 10.1007/s11033-020-05253-5; Tong YZ, 2012, CELL RES, V22, P822, DOI 10.1038/cr.2012.53; Wang HN, 2019, LIFE SCI, V227, P101, DOI 10.1016/j.lfs.2019.04.031; Wang JQ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01352; Wang JS, 2019, J CELL BIOCHEM, V120, P1807, DOI 10.1002/jcb.27480; Wang Q, 2019, CANCER LETT, V444, P9, DOI 10.1016/j.canlet.2018.11.024; Wang Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00302; Wang QD, 2018, CANCER RES, V78, P3163, DOI 10.1158/0008-5472.CAN-17-3107; Wang SY, 2018, EUR J PHARMACOL, V829, P38, DOI 10.1016/j.ejphar.2018.03.045; Wang ZD, 2020, J INFECT DIS, V221, P830, DOI 10.1093/infdis/jiz512; Wang ZY, 2016, P NATL ACAD SCI USA, V113, P13150, DOI 10.1073/pnas.1616336113; Wu YT, 2019, CANCER LETT, V451, P92, DOI 10.1016/j.canlet.2019.03.005; Xu T, 2016, INT J BIOCHEM CELL B, V70, P92, DOI 10.1016/j.biocel.2015.11.010; Yang K, 2019, CLIN SCI, V133, P1845, DOI 10.1042/CS20190203; Yao YK, 2013, PROTEIN CELL, V4, P168, DOI 10.1007/s13238-012-2109-3; Yao Y, 2012, CELL RES, V22, P836, DOI 10.1038/cr.2012.56; Yeung KS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169553; Yoshihama S, 2016, P NATL ACAD SCI USA, V113, P5999, DOI 10.1073/pnas.1602069113; Yu JW, 2016, ARCH PHARM RES, V39, P1503, DOI 10.1007/s12272-016-0827-4; Zaghlool SB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13831-w; Zhang XY, 2016, EPIGENETICS-US, V11, P750, DOI 10.1080/15592294.2016.1221569; Zhang Z, 2020, J INT MED RES, V48, DOI 10.1177/0300060520940455; Zhu C, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1621677; Zong ZQ, 2019, J CELL MOL MED, V23, P5048, DOI 10.1111/jcmm.14362; Zou J, 2014, NAT METHODS, V11, P309, DOI [10.1038/NMETH.2815, 10.1038/nmeth.2815]	84	1	1	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 18	2021	12								704989	10.3389/fimmu.2021.704989	http://dx.doi.org/10.3389/fimmu.2021.704989			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TC8PY	34220868	gold, Green Published			2022-12-18	WOS:000668901900001
J	de Winther, MPJ; Palaga, T				de Winther, Menno P. J.; Palaga, Tanapat			Editorial: Epigenetic Regulation of Innate Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						epigenetics; innate immunity; histone modifications; long noncoding RNA (lncRNA); diseases			[de Winther, Menno P. J.] Univ Amsterdam, Amsterdam Cardiovasc Sci, Amsterdam Infect & Immun, Med Ctr,Dept Med Biochem,Expt Vasc Biol, Amsterdam, Netherlands; [Palaga, Tanapat] Chulalongkorn Univ, Fac Sci, Dept Microbiol, Bangkok, Thailand; [Palaga, Tanapat] Chulalongkorn Univ, Ctr Excellence Immunol & Immune Mediated Dis, Bangkok, Thailand	University of Amsterdam; Chulalongkorn University; Chulalongkorn University	de Winther, MPJ (corresponding author), Univ Amsterdam, Amsterdam Cardiovasc Sci, Amsterdam Infect & Immun, Med Ctr,Dept Med Biochem,Expt Vasc Biol, Amsterdam, Netherlands.; Palaga, T (corresponding author), Chulalongkorn Univ, Fac Sci, Dept Microbiol, Bangkok, Thailand.; Palaga, T (corresponding author), Chulalongkorn Univ, Ctr Excellence Immunol & Immune Mediated Dis, Bangkok, Thailand.	m.dewinther@amsterdamumc.nl; Tanapat.P@chula.ac.th						Kuznetsova T, 2020, NAT REV CARDIOL, V17, P216, DOI 10.1038/s41569-019-0265-3; Mazzone R, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0632-2; Zhang Q, 2019, NAT REV IMMUNOL, V19, P417, DOI 10.1038/s41577-019-0151-6	3	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 17	2021	12								713758	10.3389/fimmu.2021.713758	http://dx.doi.org/10.3389/fimmu.2021.713758			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TC4RQ	34220871	Green Published, gold			2022-12-18	WOS:000668628100001
J	Yu, H; Zhao, Y; Pan, XF; Liu, CY; Fu, R				Yu, Hong; Zhao, Yang; Pan, Xiaofeng; Liu, Chunyan; Fu, Rong			Upregulated Expression of Profilin1 on Dendritic Cells in Patients With Severe Aplastic Anemia	FRONTIERS IN IMMUNOLOGY			English	Article						severe aplastic anemia; myeloid dendritic cells; profilin1; antigen presenting cells; bone marrow failure	DIAGNOSIS	Severe aplastic anemia (SAA) is a life-threatening form of bone marrow failure that is associated with very high mortality. Dendritic cells (DCs) are antigen presenting cells (APCs) with powerful movement ability, which is an important factor affecting immune function. The expression of profilin1 (Pfn1) plays an important role in the regulation of cell movement ability. We detected the expression of Pfn1 mRNA in the bone marrow (BM) myeloid dendritic cells (mDCs) from patients with SAA using RT-PCR. Next, we examined Pfn1 expression on mDCs using flow cytometry (FCM). We also assessed the relationship between Pfn1 expression and cytokine levels. Our data showed increased Pfn1 mRNA expression in patients with SAA. The expression of Pfn1 in BM mDCs increased in SAA patients. The expression of Pfn1 on mDCs and cytokines (TNF-alpha and IFN-gamma) were positively correlated in the serum of untreated patients with SAA. Taken together, we found that the expression of Pfn1 on mDCs of SAA patients increased, which may affect the function of mDCs. Profilin 1 may be involved in the immunopathogenesis of SAA.	[Yu, Hong; Zhao, Yang; Pan, Xiaofeng; Liu, Chunyan; Fu, Rong] Tianjin Med Univ Gen Hosp, Dept Hematol, Tianjin, Peoples R China	Tianjin Medical University	Fu, R (corresponding author), Tianjin Med Univ Gen Hosp, Dept Hematol, Tianjin, Peoples R China.	florai@sina.com			National Natural Science Foundation of China [81970116, 81970115, 81870101, 81500101]; Tianjin Municipal Natural Science Foundation [18JCYBJC91700, 18ZXDBSY00140]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Municipal Natural Science Foundation(Natural Science Foundation of Tianjin)	This work was supported by the National Natural Science Foundation of China (grant nos. 81970116, 81970115, 81870101 and 81500101) and the Tianjin Municipal Natural Science Foundation (grant nos. 18JCYBJC91700 and 18ZXDBSY00140).	Akil C, 2018, NATURE, V562, P439, DOI 10.1038/s41586-018-0548-6; Blanchoin L, 2014, PHYSIOL REV, V94, P235, DOI 10.1152/physrev.00018.2013; Borovac J, 2018, MOL CELL NEUROSCI, V91, P122, DOI 10.1016/j.mcn.2018.07.001; Brettle M, 2015, NEUROSCI LETT, V609, P223, DOI 10.1016/j.neulet.2015.09.034; CAMITTA BM, 1982, NEW ENGL J MED, V306, P645, DOI 10.1056/NEJM198203183061105; CAMITTA BM, 1982, NEW ENGL J MED, V306, P712, DOI 10.1056/NEJM198203253061204; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; Chen JM, 2019, EUR REV MED PHARMACO, V23, P8101, DOI 10.26355/eurrev_201909_19028; Di Nardo A, 2000, J CELL SCI, V113, P3795; Henty-Ridilla JL, 2017, CURR BIOL, V27, P3535, DOI 10.1016/j.cub.2017.10.002; Lin WT, 2018, J CELL PHYSIOL, V233, P259, DOI 10.1002/jcp.25872; Liu BN, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/8789275; Liu CY, 2019, CURR PHARM DESIGN, V25, P236, DOI 10.2174/1381612825666190313113601; Liu CY, 2018, J TRANSL INTERN MED, V6, P134, DOI 10.2478/jtim-2018-0028; Liu CY, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1364165; Liu CY, 2013, CELL IMMUNOL, V285, P141, DOI 10.1016/j.cellimm.2013.09.007; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marsh JCW, 2003, BRIT J HAEMATOL, V123, P782, DOI 10.1046/j.1365-2141.2003.04721.x; Posey AE, 2018, J BIOL CHEM, V293, P3734, DOI 10.1074/jbc.RA117.000357; Qi WW, 2016, CELL IMMUNOL, V304, P9, DOI 10.1016/j.cellimm.2016.04.002; Shao ZH, 2011, INT J HEMATOL, V93, P156, DOI 10.1007/s12185-010-0761-z; Teijeira A, 2014, SEMIN IMMUNOPATHOL, V36, P261, DOI 10.1007/s00281-013-0410-8; Xing LM, 2014, MOL MED REP, V10, P1252, DOI 10.3892/mmr.2014.2344; Young NS, 2018, NEW ENGL J MED, V379, P1643, DOI 10.1056/NEJMra1413485; Young NS., 2000, REV CLIN EXP HEMATOL, V4, P236, DOI [10.1046/j.1468-0734.2000.00017.x, DOI 10.1046/J.1468-0734.2000.00017.X]	25	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 16	2021	12								631954	10.3389/fimmu.2021.631954	http://dx.doi.org/10.3389/fimmu.2021.631954			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TB7GI	34220798	gold, Green Published			2022-12-18	WOS:000668112700001
J	Yuan, Y; Zhao, JP; Chen, M; Liang, HF; Long, X; Zhang, BX; Chen, XP; Chen, Q				Yuan, Yue; Zhao, Jianping; Chen, Min; Liang, Huifang; Long, Xin; Zhang, Bixiang; Chen, Xiaoping; Chen, Qian			Understanding the Pathophysiology of Exosomes in Schistosomiasis: A New Direction for Disease Control and Prevention	FRONTIERS IN IMMUNOLOGY			English	Review						schistosomiasis; exosome; liver fibrosis; diagnosis; macrophage polarization; treatment; Th immune response	EXTRACELLULAR VESICLES; PROTEOMIC ANALYSIS; ENDEMIC AREA; MANSONI; JAPONICUM; DIAGNOSIS; PROTEINS; ANTIGEN; IDENTIFICATION; PREVALENCE	Schistosomiasis is a parasitic disease endemic to freshwater areas of Southeast Asia, Africa, and South America that is capable of causing serious damage to the internal organs. Recent studies have linked exosomes to the progression of schistosomiasis. These structures are important mediators for intercellular communication, assist cells to exchange proteins, lipids, and genetic material and have been shown to play critical roles during host-parasite interactions. This review aims to discuss the pathophysiology of exosomes in schistosomiasis and their roles in regulating the host immune response. Understanding how exosomes are involved in the pathogenesis of schistosomiasis may provide new perspectives in diagnosing and treating this neglected disease.	[Yuan, Yue; Chen, Min; Chen, Qian] Huazhong Univ Sci & Technol HUST, Tongji Hosp, Tongji Med Coll, Div Gastroenterol,Dept Internal Med, Wuhan, Peoples R China; [Zhao, Jianping; Liang, Huifang; Long, Xin; Zhang, Bixiang; Chen, Xiaoping] Huazhong Univ Sci & Technol HUST, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Chen, Q (corresponding author), Huazhong Univ Sci & Technol HUST, Tongji Hosp, Tongji Med Coll, Div Gastroenterol,Dept Internal Med, Wuhan, Peoples R China.; Chen, XP (corresponding author), Huazhong Univ Sci & Technol HUST, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Peoples R China.	chenxpchenxp@163.com; chenqian201579@yahoo.com		Zhao, Jianping/0000-0003-3057-5617	National Natural Science Foundations of China [81974077]	National Natural Science Foundations of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundations of China (No. 81974077 to QC).	Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Amoah AS, 2020, LANCET INFECT DIS, V20, P165, DOI 10.1016/S1473-3099(20)30254-1; Anderson P, 2014, FEBS LETT, V588, P4297, DOI 10.1016/j.febslet.2014.09.001; Anthony B, 2010, EXP PARASITOL, V124, P409, DOI 10.1016/j.exppara.2009.12.009; Barbi J, 2013, IMMUNOL REV, V252, P52, DOI 10.1111/imr.12029; Bexkens ML, 2020, MOL BIOCHEM PARASIT, V238, DOI 10.1016/j.molbiopara.2020.111296; Buck AH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6488; Cai PF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103560; Cai PF, 2017, EBIOMEDICINE, V24, P237, DOI 10.1016/j.ebiom.2017.09.011; Cai Pengfei, 2013, PLoS ONE, V8, pe64003, DOI 10.1371/journal.pone.0064003; Cass CL, 2007, MOL BIOCHEM PARASIT, V155, P84, DOI 10.1016/j.molbiopara.2007.06.002; Catalano M, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2019.1703244; Chen R, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-018-0315-1; Chen YJ, 2020, ACTA TROP, V201, DOI 10.1016/j.actatropica.2019.105184; Cheng GF, 2013, PARASITOLOGY, V140, P1751, DOI 10.1017/S0031182013000917; Coakley G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01010; Coakley G, 2015, TRENDS PARASITOL, V31, P477, DOI 10.1016/j.pt.2015.06.009; Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2; Crellen T, 2016, CLIN INFECT DIS, V63, P1151, DOI 10.1093/cid/ciw506; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Don TA, 2008, INT J INFECT DIS, V12, pE39, DOI 10.1016/j.ijid.2007.10.007; Dong LY, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-019-1539-8; Du PF, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008618; Duarte DB, 2020, TROP MED INT HEALTH, V25, P1140, DOI 10.1111/tmi.13461; Eichenberger RM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00850; EL Andaloussi S, 2013, NAT REV DRUG DISCOV, V12, P348, DOI 10.1038/nrd3978; Essandoh K, 2016, SHOCK, V46, P122, DOI 10.1097/SHK.0000000000000604; Fairfax K, 2012, SEMIN IMMUNOPATHOL, V34, P863, DOI 10.1007/s00281-012-0354-4; Feng JT, 2017, VET PARASITOL, V243, P242, DOI 10.1016/j.vetpar.2017.06.015; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Gao JH, 2020, J HEPATOL, V73, P1144, DOI 10.1016/j.jhep.2020.04.044; Garcia BA, 2005, J PROTEOME RES, V4, P1516, DOI 10.1021/pr0500760; Gardiner C, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.32945; Gebetsberger J, 2013, RNA BIOL, V10, P1798, DOI 10.4161/rna.27177; Ghosh S, 2020, INT J CANCER, V147, P2934, DOI 10.1002/ijc.33111; Gieseck RL, 2018, NAT REV IMMUNOL, V18, P62, DOI 10.1038/nri.2017.90; Giri BR, 2019, INT J PARASITOL, V49, P993, DOI 10.1016/j.ijpara.2019.08.002; Goetzl EJ, 2016, FASEB J, V30, P2058, DOI 10.1096/fj.201500150R; Gong WC, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0007000; He X, 2020, J HEPATOL, V72, P519, DOI 10.1016/j.jhep.2019.10.029; Hirsova P, 2016, HEPATOLOGY, V64, P2219, DOI 10.1002/hep.28814; Hoshino A, 2020, CELL, V182, P1044, DOI 10.1016/j.cell.2020.07.009; Hou X, 2021, HEPATOLOGY, V74, P116, DOI 10.1002/hep.31658; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Keir ME, 2006, J EXP MED, V203, P883, DOI 10.1084/jem.20051776; Kifle DW, 2020, INT J PARASITOL, V50, P685, DOI 10.1016/j.ijpara.2020.05.005; Kogure T, 2011, HEPATOLOGY, V54, P1237, DOI 10.1002/hep.24504; Kuang YY, 2020, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12024; Kuipers ME, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1753420; Lambertz U, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1260-7; Li X, 2019, APL BIOENG, V3, DOI 10.1063/1.5087122; Li X, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1085-0; Lin DD, 2008, ACTA TROP, V107, P128, DOI 10.1016/j.actatropica.2008.05.005; Lin DD, 2008, PARASITOL INT, V57, P281, DOI 10.1016/j.parint.2008.04.005; Lin SJ, 2020, SMALL, V16, DOI 10.1002/smll.201903916; Lin YL, 2006, MOL BIOCHEM PARASIT, V147, P95, DOI 10.1016/j.molbiopara.2006.01.012; Lin Y, 2019, MOL THER-NUCL ACIDS, V18, P400, DOI 10.1016/j.omtn.2019.09.006; Liu JT, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007817; Loukas A, 2007, INT J PARASITOL, V37, P257, DOI 10.1016/j.ijpara.2006.12.001; Marcilla A, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.25040; McManus DP, 2008, CLIN MICROBIOL REV, V21, P225, DOI 10.1128/CMR.00046-07; Mekonnen GG, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030416; Meningher T, 2020, EMBO REP, V21, DOI 10.15252/embr.201947882; Meningher T, 2017, J INFECT DIS, V215, P378, DOI 10.1093/infdis/jiw539; Mori MA, 2019, CELL METAB, V30, P656, DOI 10.1016/j.cmet.2019.07.011; Mouser EEIM, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007924; Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Noonin C, 2021, THERANOSTICS, V11, P4436, DOI 10.7150/thno.54004; Nowacki FC, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.28665; Orr C, 2020, LIVER INT, V40, P1693, DOI 10.1111/liv.14474; Ovchinnikov VY, 2020, INFECT GENET EVOL, V85, DOI 10.1016/j.meegid.2020.104528; Pain A, 2001, P NATL ACAD SCI USA, V98, P1805, DOI 10.1073/pnas.98.4.1805; PAN BT, 1983, CELL, V33, P967, DOI 10.1016/0092-8674(83)90040-5; Paveley RA, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000528; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; Qadeer A, 2021, ACTA TROP, V217, DOI 10.1016/j.actatropica.2021.105851; Regev-Rudzki N, 2013, CELL, V153, P1120, DOI 10.1016/j.cell.2013.04.029; Richards KE, 2017, ONCOGENE, V36, P1770, DOI 10.1038/onc.2016.353; Roderfeld M, 2020, HEPATOLOGY, V72, P626, DOI 10.1002/hep.30192; Russell JO, 2018, ANNU REV PATHOL-MECH, V13, P351, DOI 10.1146/annurev-pathol-020117-044010; Samoil V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21587-4; Shao HL, 2018, CHEM REV, V118, P1917, DOI 10.1021/acs.chemrev.7b00534; Silva TC, 2021, FUTURE MED CHEM, V13, DOI 10.4155/fmc-2020-0311; Sotillo J, 2016, INT J PARASITOL, V46, P1, DOI 10.1016/j.ijpara.2015.09.002; Sotillo J, 2015, INT J PARASITOL, V45, P505, DOI 10.1016/j.ijpara.2015.03.004; Srivastava Kalyan, 2008, Cell Host Microbe, V4, P179, DOI 10.1016/j.chom.2008.07.003; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Thietart S, 2020, J HEPATOL, V73, P1507, DOI 10.1016/j.jhep.2020.07.014; Veerman RE, 2019, TRENDS MOL MED, V25, P382, DOI 10.1016/j.molmed.2019.02.003; Wang LF, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1785738; Wang LF, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00651; Wang LF, 2015, PARASITOL RES, V114, P1865, DOI 10.1007/s00436-015-4373-7; Wang YG, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00101; Wang YF, 2018, ACS SENSORS, V3, P1616, DOI 10.1021/acssensors.8b00360; Wassmer SC, 2004, J INFECT DIS, V189, P180, DOI 10.1086/380761; Winkel BMF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02510; Wu Z., 2020, INVENTORS U SUN YAT, V40; Wu Z., 2020, CN, V147, Patent No. 110760589; Wu Zhenyu, 2018, Front Immunol, V9, P3066, DOI 10.3389/fimmu.2018.03066; Wynn TA, 2004, IMMUNOL REV, V201, P156, DOI 10.1111/j.0105-2896.2004.00176.x; Yu W, 2021, ANN ONCOL, V32, P466, DOI 10.1016/j.annonc.2021.01.074; Zakeri A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02349; Zamanian M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004069; Zhang HY, 2018, NAT CELL BIOL, V20, P332, DOI 10.1038/s41556-018-0040-4; Zhang WC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00090; Zhou XN, 2005, ACTA TROP, V96, P97, DOI 10.1016/j.actatropica.2005.07.005; Zhu LH, 2016, SCI REP-UK, V6, DOI 10.1038/srep25885; Zhu SL, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1845-2	110	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 16	2021	12								634138	10.3389/fimmu.2021.634138	http://dx.doi.org/10.3389/fimmu.2021.634138			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TB7FY	34220800	Green Published, gold			2022-12-18	WOS:000668111700001
J	Chen, CY; Hung, YF; Tsai, CY; Shih, YC; Chou, TF; Lai, MZ; Wang, TF; Hsueh, YP				Chen, Chiung-Ya; Hung, Yun-Fen; Tsai, Ching-Yen; Shih, Yi-Chun; Chou, Ting-Fang; Lai, Ming-Zong; Wang, Ting-Fang; Hsueh, Yi-Ping			Transcriptomic Analysis and C-Terminal Epitope Tagging Reveal Differential Processing and Signaling of Endogenous TLR3 and TLR7	FRONTIERS IN IMMUNOLOGY			English	Article						toll-like receptor; transcriptomic analysis; RNA-seq; epitope tagging; MYD88; signalosome	TOLL-LIKE RECEPTOR; SINGLE-STRANDED RNA; PATTERN-RECOGNITION; INNATE IMMUNITY; EXPRESSION; RESPONSES; MORPHOGENESIS; MECHANISMS; CATHEPSINS; CLEAVAGE	Toll-like receptor (TLR) signaling is critical for defense against pathogenic infection, as well as for modulating tissue development. Activation of different TLRs triggers common inflammatory responses such as cytokine induction. Here, we reveal differential impacts of TLR3 and TLR7 signaling on transcriptomic profiles in bone marrow-derived macrophages (BMDMs). Apart from self-regulation, TLR3, but not TLR7, induced expression of other TLRs, suggesting that TLR3 activation globally enhances innate immunity. Moreover, we observed diverse influences of TLR3 and TLR7 signaling on genes involved in methylation, caspase and autophagy pathways. We compared endogenous TLR3 and TLR7 by using CRISPR/Cas9 technology to knock in a dual Myc-HA tag at the 3' ends of mouse Tlr3 and Tlr7. Using anti-HA antibodies to detect endogenous tagged TLR3 and TLR7, we found that both TLRs display differential tissue expression and posttranslational modifications. C-terminal tagging did not impair TLR3 activity. However, it disrupted the interaction between TLR7 and myeloid differentiation primary response 88 (MYD88), the Tir domain-containing adaptor of TLR7, which blocked its downstream signaling necessary to trigger cytokine and chemokine expression. Our study demonstrates different properties for TLR3 and TLR7, and also provides useful mouse models for further investigation of these two RNA-sensing TLRs.	[Chen, Chiung-Ya; Hung, Yun-Fen; Tsai, Ching-Yen; Shih, Yi-Chun; Chou, Ting-Fang; Lai, Ming-Zong; Wang, Ting-Fang; Hsueh, Yi-Ping] Acad Sinica, Inst Mol Biol, Taipei, Taiwan	Academia Sinica - Taiwan	Hsueh, YP (corresponding author), Acad Sinica, Inst Mol Biol, Taipei, Taiwan.	yph@gate.sinica.edu.tw	Hsueh, Yi-Ping/ABH-5052-2020	Hsueh, Yi-Ping/0000-0002-0866-6275; Tsai, Ching-Yen/0000-0001-7964-6661; Chou, Ting-Fang/0000-0001-7095-3518	Academia Sinica [AS-CFII-108-104]	Academia Sinica(Academia Sinica - Taiwan)	We thank Prof. Kensuke Miyake and Dr. Ryutaro Fukui in the Division of Innate Immunity, Institute of Medical Science, University of Tokyo, for TLR3 (PaT3) and TLR7 (A94B10) antibodies, Dr. Chung Wang for HSP90 antibody, as well as the Transgenic Core Facility (supported by Academia Sinica, AS-CFII-108-104), the Genomics Core, the Bioinformatics Core, Dr. Wan-Chen Li and the Animal Facility of the Institute of Molecular Biology, Academia Sinica, for excellent technical assistance. Dr. John O'Brien conducted English editing and members of Y-PH's laboratory relabeled samples for blind experiments.	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Applequist SE, 2002, INT IMMUNOL, V14, P1065, DOI 10.1093/intimm/dxf069; Brubaker SW, 2015, ANNU REV IMMUNOL, V33, P257, DOI 10.1146/annurev-immunol-032414-112240; Carty M, 2010, CLIN EXP IMMUNOL, V161, P397, DOI 10.1111/j.1365-2249.2010.04196.x; Cavassani KA, 2008, J EXP MED, V205, P2609, DOI 10.1084/jem.20081370; Chen CY, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0584-z; Chen CY, 2017, EMBO REP, V18, P169, DOI 10.15252/embr.201642586; Chen CY, 2011, J CELL BIOL, V193, P769, DOI 10.1083/jcb.201008050; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Ewald SE, 2011, J EXP MED, V208, P643, DOI 10.1084/jem.20100682; Garcia-Cattaneo A, 2012, P NATL ACAD SCI USA, V109, P9053, DOI 10.1073/pnas.1115091109; Gay NJ, 2007, ANNU REV BIOCHEM, V76, P141, DOI 10.1146/annurev.biochem.76.060305.151318; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Huang YH, 2011, BMC EVOL BIOL, V11, DOI 10.1186/1471-2148-11-149; Hung YF, 2018, BRAIN BEHAV IMMUN, V72, P101, DOI 10.1016/j.bbi.2018.06.006; Hung YF, 2018, J CELL BIOL, V217, P2727, DOI 10.1083/jcb.201712113; Kanno A, 2013, INT IMMUNOL, V25, P413, DOI 10.1093/intimm/dxt007; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kim YM, 2008, NATURE, V452, P234, DOI 10.1038/nature06726; Kominsky DJ, 2010, J IMMUNOL, V184, P4062, DOI 10.4049/jimmunol.0903002; Leifer CA, 2016, J LEUKOCYTE BIOL, V100, P927, DOI 10.1189/jlb.2MR0316-117RR; Lester SN, 2014, J MOL BIOL, V426, P1246, DOI 10.1016/j.jmb.2013.11.024; Li JL, 2012, J NEUROSCI RES, V90, P399, DOI 10.1002/jnr.22758; Liu HY, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00428; Liu HY, 2015, EXP NEUROL, V269, P202, DOI 10.1016/j.expneurol.2015.04.011; Liu HY, 2014, NEUROSCI BULL, V30, P645, DOI 10.1007/s12264-014-1445-5; Liu HY, 2013, J NEUROSCI, V33, P11479, DOI 10.1523/JNEUROSCI.5566-12.2013; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Majer O, 2017, CURR OPIN IMMUNOL, V44, P26, DOI 10.1016/j.coi.2016.10.003; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Miyake K, 2019, J LEUKOCYTE BIOL, V106, P853, DOI 10.1002/JLB.MR0119-020R; Miyake K, 2018, INT IMMUNOL, V30, P43, DOI 10.1093/intimm/dxy016; Murakami Y, 2014, J IMMUNOL, V193, P5208, DOI 10.4049/jimmunol.1400386; Price AE, 2018, IMMUNITY, V49, P560, DOI 10.1016/j.immuni.2018.07.016; Qi RS, 2012, J BIOL CHEM, V287, P32617, DOI 10.1074/jbc.M112.387803; Roberts AW, 2017, IMMUNITY, V47, P913, DOI 10.1016/j.immuni.2017.10.006; Sato R, 2017, INT IMMUNOL, V29, P347, DOI 10.1093/intimm/dxx044; Shih PY, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107700; Shmueli A, 2018, NEUROMOL MED, V20, P419, DOI 10.1007/s12017-018-8515-9; Singh MV, 2019, AM J PHYSIOL-HEART C, V316, pH1027, DOI 10.1152/ajpheart.00697.2018; Sun JC, 2006, J BIOL CHEM, V281, P11144, DOI 10.1074/jbc.M510442200; Toscano F, 2013, J IMMUNOL, V190, P764, DOI 10.4049/jimmunol.1202173	45	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 15	2021	12								686060	10.3389/fimmu.2021.686060	http://dx.doi.org/10.3389/fimmu.2021.686060			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TB2PJ	34211474	gold, Green Published			2022-12-18	WOS:000667789700001
J	Natali, EN; Babrak, LM; Miho, E				Natali, Eriberto N.; Babrak, Lmar M.; Miho, Enkelejda			Prospective Artificial Intelligence to Dissect the Dengue Immune Response and Discover Therapeutics	FRONTIERS IN IMMUNOLOGY			English	Review						artificial intelligence; dengue; antibody discovery; B-cell receptor; immune repertoire; virus; immunotherapy; machine learning	VIRUS-INFECTION; NEUTRALIZING ANTIBODY; MONOCLONAL-ANTIBODIES; DOUBLE-BLIND; SEQUENCE; REPERTOIRE; SIGNATURES; DIVERSITY; SELECTION; EPITOPES	Dengue virus (DENV) poses a serious threat to global health as the causative agent of dengue fever. The virus is endemic in more than 128 countries resulting in approximately 390 million infection cases each year. Currently, there is no approved therapeutic for treatment nor a fully efficacious vaccine. The development of therapeutics is confounded and hampered by the complexity of the immune response to DENV, in particular to sequential infection with different DENV serotypes (DENV1-5). Researchers have shown that the DENV envelope (E) antigen is primarily responsible for the interaction and subsequent invasion of host cells for all serotypes and can elicit neutralizing antibodies in humans. The advent of high-throughput sequencing and the rapid advancements in computational analysis of complex data, has provided tools for the deconvolution of the DENV immune response. Several types of complex statistical analyses, machine learning models and complex visualizations can be applied to begin answering questions about the B- and T-cell immune responses to multiple infections, antibody-dependent enhancement, identification of novel therapeutics and advance vaccine research.	[Natali, Eriberto N.; Babrak, Lmar M.; Miho, Enkelejda] Univ Appl Sci & Arts Northwestern Switzerland FHN, Sch Life Sci, Inst Med Engn & Med Informat, Muttenz, Switzerland; [Miho, Enkelejda] SIB Swiss Inst Bioinformat, Lausanne, Switzerland; [Miho, Enkelejda] AiNET GmbH, Basel, Switzerland	FHNW University of Applied Sciences & Arts Northwestern Switzerland; Swiss Institute of Bioinformatics	Miho, E (corresponding author), Univ Appl Sci & Arts Northwestern Switzerland FHN, Sch Life Sci, Inst Med Engn & Med Informat, Muttenz, Switzerland.; Miho, E (corresponding author), SIB Swiss Inst Bioinformat, Lausanne, Switzerland.; Miho, E (corresponding author), AiNET GmbH, Basel, Switzerland.	enkelejda.miho@fhnw.ch			Wellcome Trust [215840/Z/19/Z]	Wellcome Trust(Wellcome TrustEuropean Commission)	This work has been funded by the Wellcome Trust Innovator Award to EM number 215840/Z/19/Z.	Andersen PH, 2006, PROTEIN SCI, V15, P2558, DOI 10.1110/ps.062405906; Andrade DV, 2017, MBIO, V8, DOI [10.1128/mBio.01205-17, 10.1128/mbio.01205-17]; Andrade PE, 2017, J IMMUNOL, V198; Appanna R, 2016, EBIOMEDICINE, V12, P178, DOI 10.1016/j.ebiom.2016.09.003; Basu Sreemanti, 2010, J Vis Exp, DOI 10.3791/1546; Behjati S, 2013, ARCH DIS CHILDHOOD-E, V98, P236, DOI 10.1136/archdischild-2013-304340; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Bjerregaard AM, 2017, CANCER IMMUNOL IMMUN, V66, P1123, DOI 10.1007/s00262-017-2001-3; Blank CU, 2016, SCIENCE, V352, P658, DOI 10.1126/science.aaf2834; Bricault CA, 2019, CELL HOST MICROBE, V25, P59, DOI 10.1016/j.chom.2018.12.001; Burckert JP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01834; Bzdok D, 2018, NAT METHODS, V15, P5, DOI 10.1038/nmeth.4551; Calis JJA, 2014, TRENDS IMMUNOL, V35, P581, DOI 10.1016/j.it.2014.09.004; CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; CHURDBOONCHART V, 1991, AM J TROP MED HYG, V44, P481, DOI 10.4269/ajtmh.1991.44.481; Cinelli M, 2017, BIOINFORMATICS, V33, P951, DOI 10.1093/bioinformatics/btw771; Cologna R, 2005, J VIROL, V79, P853, DOI 10.1128/JVI.79.2.853-859.2005; Deac A, 2019, J COMPUT BIOL, V26, P536, DOI 10.1089/cmb.2018.0175; Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181; DeKosky BJ, 2013, NAT BIOTECHNOL, V31, P166, DOI 10.1038/nbt.2492; Deng YQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016059; Dey L, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005879; Durham ND, 2019, ELIFE, V8, DOI 10.7554/eLife.52384; Dutra NR, 2009, J GLOB INFECT DIS, V1, P38, DOI 10.4103/0974-777X.52980; El Sahili A, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9040091; Eliyahu S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03004; Falconar AKI, 1999, ARCH VIROL, V144, P2313, DOI 10.1007/s007050050646; Garcia-Canadilla P, 2020, FETAL DIAGN THER, V47, P363, DOI 10.1159/000505021; Gil L, 2014, VIROLOGY, V456, P70, DOI 10.1016/j.virol.2014.03.011; Go YY, 2015, GENOME ANNOUNCEMENTS, V3, DOI 10.1128/genomeA.01389-15; Godoi IP, 2017, J COMP EFFECT RES, V6, P165, DOI 10.2217/cer-2016-0045; Godoy-Lozano EE, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0276-1; Gomes T, 2019, TRENDS IMMUNOL, V40, P1011, DOI 10.1016/j.it.2019.09.004; Greiff V, 2017, J IMMUNOL, V199, P2985, DOI 10.4049/jimmunol.1700594; Greiff V, 2015, TRENDS IMMUNOL, V36, P738, DOI 10.1016/j.it.2015.09.006; Greiff V, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0169-8; Gromowski GD, 2018, VACCINE, V36, P2403, DOI 10.1016/j.vaccine.2018.03.055; Guo CC, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00317; Hamet P, 2017, METABOLISM, V69, pS36, DOI 10.1016/j.metabol.2017.01.011; Hoehn KB, 2017, GENETICS, V206, P417, DOI 10.1534/genetics.116.196303; Holmes EC, 2003, INFECT GENET EVOL, V3, P19, DOI [10.1016/S1567-1348(03)00004-2, 10.1016/S1567-1348(02)00153-3]; Hu D, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007836; Huang CH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01726; Hughes HR, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-115; Ichinohe T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00668; Injampa S, 2017, PEERJ, V5, DOI 10.7717/peerj.4021; Jackson KJL, 2014, CELL HOST MICROBE, V16, P105, DOI 10.1016/j.chom.2014.05.013; Joob Beuy, 2016, Med J Armed Forces India, V72, P194, DOI 10.1016/j.mjafi.2015.11.015; Jurtz VI, 2018, BIORXIV, DOI [10.1101/433706., DOI 10.1101/433706, 10.1101/433706]; Khetarpal N, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6803098; Koelzer VH, 2019, VIRCHOWS ARCH, V474, P511, DOI 10.1007/s00428-018-2485-z; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Konishi H, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2853-y; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; KUNO G, 1987, AM J TROP MED HYG, V36, P153, DOI 10.4269/ajtmh.1987.36.153; Kyle JL, 2008, ANNU REV MICROBIOL, V62, P71, DOI 10.1146/annurev.micro.62.081307.163005; Lake F, 2019, FUTURE DRUG DISCOV, V1, DOI DOI 10.4155/FDD-2019-0025; LANDSTEINER K, 1947, SPECIFICITY SEROLOGI; Leitmeyer KC, 1999, J VIROL, V73, P4738, DOI 10.1128/JVI.73.6.4738-4747.1999; Lemmer A, 2004, J CLIN VIROL, V30, P291, DOI 10.1016/j.jcv.2003.11.002; Li J, 2018, STRUCTURE, V26, P51, DOI 10.1016/j.str.2017.11.017; Li LK, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007716; Liberis E, 2018, BIOINFORMATICS, V34, P2944, DOI 10.1093/bioinformatics/bty305; Lin SR, 2004, J VIROL, V78, P12717, DOI 10.1128/JVI.78.22.12717-12721.2004; Lok SM, 2008, NAT STRUCT MOL BIOL, V15, P312, DOI 10.1038/nsmb.1382; Low JG, 2014, LANCET INFECT DIS, V14, P706, DOI 10.1016/S1473-3099(14)70730-3; Lu DR, 2014, CLIN IMMUNOL, V152, P77, DOI 10.1016/j.clim.2014.02.010; Lukman N, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/5253842; Malavige GN, 2004, POSTGRAD MED J, V80, P588, DOI 10.1136/pgmj.2004.019638; Mason DM, 2021, NAT BIOMED ENG, V5, P600, DOI 10.1038/s41551-021-00699-9; Midgey CM, 2012, J IMMUNOL, V188, P4971, DOI 10.4049/jimmunol.1200227; Miho E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09278-8; Miho E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00224; Miller JL, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040017; Muller DA, 2017, J INFECT DIS, V215, pS89, DOI 10.1093/infdis/jiw649; Mustafa M S, 2015, Med J Armed Forces India, V71, P67, DOI 10.1016/j.mjafi.2014.09.011; Nguyen NM, 2013, J INFECT DIS, V207, P1442, DOI 10.1093/infdis/jis470; Osorio JE, 2016, EXPERT REV VACCINES, V15, P497, DOI 10.1586/14760584.2016.1128328; Ostmeyer J, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1814-6; Pal S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113411; Palanichamy A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008930; Parameswaran P, 2013, CELL HOST MICROBE, V13, P691, DOI 10.1016/j.chom.2013.05.008; Parameswaran P, 2012, J VIROL, V86, P8546, DOI 10.1128/JVI.00736-12; Pavlovic M, 2021, IMMUNEML ECOSTYSTEN, DOI [10.1101/2021.03.08.433891, DOI 10.1101/2021.03.08.433891]; Perera R, 2008, CURR OPIN MICROBIOL, V11, P369, DOI 10.1016/j.mib.2008.06.004; Pokidysheva E, 2006, CELL, V124, P485, DOI 10.1016/j.cell.2005.11.042; Pyke AT, 2016, SCI REP-UK, V6, DOI 10.1038/srep22356; Rajamanonmani R, 2009, J GEN VIROL, V90, P799, DOI 10.1099/vir.0.006874-0; Rastogi M, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0590-7; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Robinson LN, 2015, CELL, V162, P493, DOI 10.1016/j.cell.2015.06.057; Robinson WH, 2015, NAT REV RHEUMATOL, V11, P171, DOI 10.1038/nrrheum.2014.220; Rouvinski A, 2015, NATURE, V520, P109, DOI 10.1038/nature14130; Saggy I, 2012, PROTEIN ENG DES SEL, V25, P539, DOI 10.1093/protein/gzs060; Saltz J, 2018, CELL REP, V23, P181, DOI 10.1016/j.celrep.2018.03.086; Schaffitzel C, 1999, J IMMUNOL METHODS, V231, P119, DOI 10.1016/S0022-1759(99)00149-0; Sevakula RK, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.013924; Sheng ZZ, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004940; Shepard DS, 2016, LANCET INFECT DIS, V16, P935, DOI 10.1016/S1473-3099(16)00146-8; Smith SA, 2013, MBIO, V4, DOI 10.1128/mBio.00873-13; Smith SA, 2013, J INFECT DIS, V207, P1898, DOI 10.1093/infdis/jit119; Stern JNH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008879; Sun GP, 2018, ONCOL LETT, V16, P1584, DOI 10.3892/ol.2018.8800; Swarbrick CMD, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx1127; Tan YY, 2011, J GLOB INFECT DIS, V3, P233, DOI 10.4103/0974-777X.83528; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; Thai KTD, 2012, J VIROL, V86, P835, DOI 10.1128/JVI.05985-11; Thakkar N, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2864-8; Tharakaraman K, 2013, P NATL ACAD SCI USA, V110, pE1555, DOI 10.1073/pnas.1303645110; Thepparit C, 2004, J VIROL, V78, P12647, DOI 10.1128/JVI.78.22.12647-12656.2004; Thommen DS, 2018, NAT MED, V24, P994, DOI 10.1038/s41591-018-0057-z; Thullier P, 1999, J BIOTECHNOL, V69, P183, DOI 10.1016/S0168-1656(99)00037-1; Torresi J, 2017, HUM VACC IMMUNOTHER, V13, P1059, DOI 10.1080/21645515.2016.1261770; Twiddy SS, 2003, MOL BIOL EVOL, V20, P122, DOI 10.1093/molbev/msg010; Vasilakis N, 2007, J VIROL, V81, P9591, DOI 10.1128/JVI.02776-06; Vieira MC, 2018, MOL BIOL EVOL, V35, P1135, DOI 10.1093/molbev/msy024; Vu TTH, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000757; Wahala WMPB, 2011, VIRUSES-BASEL, V3, P2374, DOI 10.3390/v3122374; Waickman AT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11634-7; Wan SW, 2017, J IMMUNOL, V199, P2834, DOI 10.4049/jimmunol.1601523; Wang EY, 2000, J VIROL, V74, P3227, DOI 10.1128/JVI.74.7.3227-3234.2000; Wang WK, 2002, VIROLOGY, V303, P181, DOI 10.1006/viro.2002.1635; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Weaver SC, 2009, INFECT GENET EVOL, V9, P523, DOI 10.1016/j.meegid.2009.02.003; Whitehead SS, 2016, EXPERT REV VACCINES, V15, P509, DOI 10.1586/14760584.2016.1115727; WHO, 2019, DENG SEV DENG; Widrich M., 2020, DEEPRC IMMUNE REPETO, V2020, DOI [10.1101/ 2020.04.12.038158, DOI 10.1101/2020.04.12.038158]; Xie Q, 2017, CURR TOP MED CHEM, V17, P371, DOI 10.2174/1568026616666160829155327; Xu MH, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-016-0003-3; Zhu J, 2013, P NATL ACAD SCI USA, V110, pE4088, DOI 10.1073/pnas.1306262110; Zhu J, 2013, P NATL ACAD SCI USA, V110, P6470, DOI 10.1073/pnas.1219320110	137	1	1	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 15	2021	12								574411	10.3389/fimmu.2021.574411	http://dx.doi.org/10.3389/fimmu.2021.574411			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TB1GH	34211454	gold, Green Published			2022-12-18	WOS:000667690600001
J	Sarabia, I; Novis, CL; Macedo, AB; Takata, H; Nell, R; Kakazu, JC; Furler, RL; Shakya, B; Schubert, HL; Hill, CP; DePaula-Silva, AB; Spivak, AM; Trautmann, L; Planelles, V; Bosque, A				Sarabia, Indra; Novis, Camille L.; Macedo, Amanda B.; Takata, Hiroshi; Nell, Racheal; Kakazu, Juyeon C.; Furler, Robert L.; Shakya, Binita; Schubert, Heidi L.; Hill, Christopher P.; DePaula-Silva, Ana Beatriz; Spivak, Adam M.; Trautmann, Lydie; Planelles, Vicente; Bosque, Alberto			Activation of the Anti-Oxidative Stress Response Reactivates Latent HIV-1 Through the Mitochondrial Antiviral Signaling Protein Isoform MiniMAVS	FRONTIERS IN IMMUNOLOGY			English	Article						Dynasore; HIV-1; shock and kill; latency; latency-reversal agents; MAVS; reactive oxygen species; anti-oxidative stress response	HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; NF-KAPPA-B; BET BROMODOMAIN INHIBITION; CD4(+) T-CELLS; KINASE-C; ADAPTER PROTEIN; TRANSCRIPTION; RESERVOIR; DYNASORE	The mitochondrial antiviral signaling protein (MAVS) is part of the cell's innate immune mechanism of defense. MAVS mRNA is bicistronic and can give rise to a full length-MAVS and a shorter isoform termed miniMAVS. In response to viral infections, viral RNA can be sensed by the cytosolic RNA sensors retinoic acid-inducible gene I (RIG-I) and/or melanoma differentiation-associated protein 5 (MDA5) and activate NF-kappa B through interaction with MAVS. MAVS can also sense cellular stress and activate an anti-oxidative stress (AOS) response through the activation of NF-kappa B. Because NF-kappa B is a main cellular transcription factor for HIV-1, we wanted to address what role MAVS plays in HIV-1 reactivation from latency in CD4 T cells. Our results indicate that RIG-I agonists required full length-MAVS whereas the AOS response induced by Dynasore through its catechol group can reactivate latent HIV-1 in a MAVS dependent manner through miniMAVS isoform. Furthermore, we uncover that PKC agonists, a class of latency-reversing agents, induce an AOS response in CD4 T cells and require miniMAVS to fully reactivate latent HIV-1. Our results indicate that the AOS response, through miniMAVS, can induce HIV-1 transcription in response to cellular stress and targeting this pathway adds to the repertoire of approaches to reactivate latent HIV-1 in 'shock-and-kill' strategies.	[Sarabia, Indra; Macedo, Amanda B.; Bosque, Alberto] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA; [Novis, Camille L.; Planelles, Vicente] Univ Utah, Sch Med, Dept Pathol, Div Microbiol & Immunol, Salt Lake City, UT USA; [Takata, Hiroshi; Kakazu, Juyeon C.; Trautmann, Lydie] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97201 USA; [Nell, Racheal; Spivak, Adam M.] Univ Utah, Dept Med, Div Infect Dis, Salt Lake City, UT 84112 USA; [Furler, Robert L.] Weill Cornell Med, Dept Med, Div Infect Dis, New York, NY USA; [Shakya, Binita; Schubert, Heidi L.; Hill, Christopher P.] Univ Utah, Dept Biochem, Salt Lake City, UT USA; [DePaula-Silva, Ana Beatriz] Univ Utah, Coll Pharm, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA	George Washington University; Utah System of Higher Education; University of Utah; Oregon Health & Science University; Utah System of Higher Education; University of Utah; Cornell University; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Bosque, A (corresponding author), George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA.	abosque@gwu.edu		Nell, Racheal/0000-0002-0324-7522; Furler O'Brien, Robert/0000-0001-5706-4871; DePaula-Silva, Ana Beatriz/0000-0002-2452-3215	National Institute of Health [R21-AI106438, R01-AI124722, R01-AI143567, R33AI122377, R21-AI123035]; Henry M. Jackson Foundation [W81XWH-07-2-0067, P50AI150464]; U.S. Department of Defense [W81XWH-07-2-0067, P50AI150464]; National Institutes of Health under the Ruth L. Kirschstein National Research Service Award NIH [F31 AI147814]; University of Utah [5P30CA042014-24]; NIH [AI117970]; NIH Co-Funding and Participating Institutes and Centers: NIAID; NCI; NICHD; NHLBI; NIDA; NIMH; NIA; FIC; NIGMS; NIDDK; OAR	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Henry M. Jackson Foundation; U.S. Department of Defense(United States Department of Defense); National Institutes of Health under the Ruth L. Kirschstein National Research Service Award NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Utah; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Co-Funding and Participating Institutes and Centers: NIAID; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); FIC; NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OAR	This work was partially supported by the National Institute of Health grants R21-AI106438 and R01-AI124722 to AB, R01AI143567, R33AI122377 and R21-AI123035 to VP, cooperative agreement W81XWH-07-2-0067 between the Henry M. Jackson Foundation and the U.S. Department of Defense to LT, and P50AI150464 to CH and HS. IS was supported with a fellowship by the National Institutes of Health under the Ruth L. Kirschstein National Research Service Award NIH F31 AI147814. We thank Dr. Ryan O'Connell (University of Utah) for the lentiCRISPRv2 plasmid, Dr. Jonathan Karn (Case Western Reserve University) for the 2D10 cells, Dr. Eric Verdin (University of California San Francisco) for the J-Lat 10.6 and 6.3 cell clones, Dr. Warner Greene (Gladstone Institute) for the 5A8 cells. This work was supported by the University of Utah Flow Cytometry Facility in addition to the National Cancer Institute through Award Number 5P30CA042014-24. This research has been facilitated by the services and resources provided by the District of Columbia Center for AIDS Research, an NIH funded program (AI117970), which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, NIGMS, NIDDK, and OAR.	Abreu CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097257; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Ailenberg M, 2015, BRIT J PHARMACOL, V172, P3748, DOI 10.1111/bph.13162; Archin NM, 2009, AIDS, V23, P1799, DOI 10.1097/QAD.0b013e32832ec1dc; Banerjee C, 2012, J LEUKOCYTE BIOL, V92, P1147, DOI 10.1189/jlb.0312165; Bartholomeeusen K, 2012, J BIOL CHEM, V287, P36609, DOI 10.1074/jbc.M112.410746; Boehm D, 2013, CELL CYCLE, V12, P452, DOI 10.4161/cc.23309; Bosque A, 2009, BLOOD, V113, P58, DOI 10.1182/blood-2008-07-168393; Brenchley JM, 2004, J VIROL, V78, P1160, DOI 10.1128/JVI.78.3.1160-1168.2004; Brubaker SW, 2014, CELL, V156, P800, DOI 10.1016/j.cell.2014.01.021; Chan JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077749; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; Christian F, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5010012; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; DOERRE S, 1993, P NATL ACAD SCI USA, V90, P1023, DOI 10.1073/pnas.90.3.1023; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Ganor Y, 2019, NAT MICROBIOL, V4, P633, DOI 10.1038/s41564-018-0335-z; Garcia-Vidal E, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01368-17; Giffin MJ, 2003, NAT STRUCT BIOL, V10, P800, DOI 10.1038/nsb981; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Jiang GC, 2014, AIDS, V28, P1555, DOI 10.1097/QAD.0000000000000289; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Jose DP, 2014, VIROLOGY, V462, P328, DOI 10.1016/j.virol.2014.05.033; Kato H, 2008, J EXP MED, V205, P1601, DOI 10.1084/jem.20080091; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kim Y, 2018, CELL HOST MICROBE, V23, P14, DOI 10.1016/j.chom.2017.12.004; KINTER AL, 1990, J VIROL, V64, P4306, DOI 10.1128/JVI.64.9.4306-4312.1990; LAHM HW, 1985, J CHROMATOGR, V326, P357, DOI 10.1016/S0021-9673(01)87461-6; Laird GM, 2015, J CLIN INVEST, V125, P1901, DOI 10.1172/JCI80142; Lei Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005466; Li PL, 2016, NAT MED, V22, P807, DOI 10.1038/nm.4124; Lin J, 2001, J CELL SCI, V114, P243; Macedo AB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02450; Macedo AB, 2018, AIDS RES HUM RETROV, V34, P769, DOI [10.1089/aid.2018.0098, 10.1089/AID.2018.0098]; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Margolis DM, 2017, J INFECT DIS, V215, pS111, DOI 10.1093/infdis/jiw618; Marsden MD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006575; Martins LJ, 2016, AIDS RES HUM RETROV, V32, P187, DOI 10.1089/aid.2015.0106; McNamara LA, 2012, J VIROL, V86, P9337, DOI 10.1128/JVI.00895-12; Mehla R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011160; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Minassian A, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005060; Mochly-Rosen D, 2012, NAT REV DRUG DISCOV, V11, P937, DOI 10.1038/nrd3871; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Novis CL, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-119; NOZAWA R, 1988, J BIOCHEM-TOKYO, V103, P43, DOI 10.1093/oxfordjournals.jbchem.a122236; Park RJ, 2013, J CELL SCI, V126, P5305, DOI 10.1242/jcs.138578; Pearson R, 2008, J VIROL, V82, P12291, DOI 10.1128/JVI.01383-08; Preta G, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0102-1; Pyo CW, 2008, BIOCHEM BIOPH RES CO, V376, P180, DOI 10.1016/j.bbrc.2008.08.114; Rasmussen TA, 2013, HUM VACC IMMUNOTHER, V9, P993, DOI 10.4161/hv.23800; Riddler SA, 2021, CLIN INFECT DIS, V72, pE815, DOI 10.1093/cid/ciaa1534; Rullo EV, 2019, CLIN INFECT DIS, V69, P2236, DOI 10.1093/cid/ciz378; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Saxena M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00725; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shehat MG, 2019, JOVE-J VIS EXP, DOI 10.3791/59167; Spina CA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003834; Spivak AM, 2018, ANNU REV MED, V69, P421, DOI 10.1146/annurev-med-052716-031710; Spivak AM, 2015, ANTIMICROB AGENTS CH, V59, P5984, DOI 10.1128/AAC.01077-15; Sun QM, 2006, IMMUNITY, V24, P633, DOI 10.1016/j.immuni.2006.04.004; Verrier JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020553; Vibholm L, 2017, CLIN INFECT DIS, V64, P1686, DOI 10.1093/cid/cix201; Vibholm LK, 2019, AIDS, V33, P1315, DOI 10.1097/QAD.0000000000002213; Viglianti GA., 2021, J VIRUS ERAD, V95, P02141, DOI [10.1016/S2055-6640(20)30090-X, DOI 10.1016/S2055-6640(20)30090-X]; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wei DG, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004071; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yang HC, 2009, J CLIN INVEST, V119, P3473, DOI 10.1172/JCI39199; Zhong BL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1917-2	75	1	1	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 14	2021	12								682182	10.3389/fimmu.2021.682182	http://dx.doi.org/10.3389/fimmu.2021.682182			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	TA4AM	34194436	gold, Green Published			2022-12-18	WOS:000667191600001
J	Berardicurti, O; Ruscitti, P; Di Benedetto, P; D'Andrea, S; Navarini, L; Marino, A; Cipriani, P; Giacomelli, R				Berardicurti, Onorina; Ruscitti, Piero; Di Benedetto, Paola; D'Andrea, Settimio; Navarini, Luca; Marino, Annalisa; Cipriani, Paola; Giacomelli, Roberto			Association Between Minor Salivary Gland Biopsy During Sjogren's Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis	FRONTIERS IN IMMUNOLOGY			English	Review						Sjogren's syndrome; minor salivary gland biopsy; focus score; germinal center; clinical features; serological biomarkers; autoantibodies	CLASSIFICATION CRITERIA; AMERICAN-COLLEGE; PROGNOSTIC VALUE; DATA-DRIVEN; CONSENSUS; FEATURES; CELLS; PATHOGENESIS; MORTALITY	Objective Patients with primary Sjogren's syndrome (pSS) may develop a potentially severe disease with extra-glandular involvement and lymphoma insurgence. Minor salivary gland biopsy is routinely used in the disease diagnosis, but its potential role as a biomarker for clinical disease presentation and prognosis is still poorly understood. Methods We performed a systematic review and meta-analysis on clinical presentation and prognosis in pSS patients who underwent minor salivary gland biopsy at diagnosis according to the PRISMA guidelines. Results We included five retrospective studies and 589 pSS patients. Ectopic GCs presence was not associated with a significant increase in the odds ratio for the clinical variables explored such as salivary gland swelling, arthritis, and Raynaud's phenomenon. As far as serological features are concerned, ectopic GCs presence accounted for an increased ratio of antibodies anti-SSA (OR = 3.13, 95% CI: 1.25-7.85, p = 0.02, I-2 = 79%), anti-SSB (OR = 3.94, 95% CI: 1.50-10.37, p = 0.0005, I-2 = 80%), and RFs presence (OR = 3.12, 95% CI: 1.94-5.00, p < 0.00001, I-2 = 0%). Conclusions This study showed that the association between ectopic GC in salivary glands identifies a clinical subset characterized by autoantibodies presence, and probably pSS patients affected from a more severe disease.	[Berardicurti, Onorina; Ruscitti, Piero; Di Benedetto, Paola; Cipriani, Paola] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Rheumatol Unit, Laquila, Italy; [D'Andrea, Settimio] Univ Aquila, Androl Unit, Dept Life Hlth & Environm Sci, Laquila, Italy; [Navarini, Luca; Marino, Annalisa; Giacomelli, Roberto] Univ Rome Campus Biomed, Dept Med, Rheumatol & Immunol Unit, Rome, Italy	University of L'Aquila; University of L'Aquila; University Campus Bio-Medico - Rome Italy	Giacomelli, R (corresponding author), Univ Rome Campus Biomed, Dept Med, Rheumatol & Immunol Unit, Rome, Italy.	r.giacomelli@unicampus.it	Ruscitti, Piero/K-4184-2018; Giacomelli, Roberto/AAB-9962-2022; Cipriani, Paola/AAC-7382-2022; Navarini, Luca/AAC-6635-2022	Ruscitti, Piero/0000-0003-3487-8551; Navarini, Luca/0000-0001-8537-1510				Abu-Helu RF, 2001, J AUTOIMMUN, V17, P141, DOI 10.1006/jaut.2001.0524; Bombardieri M, 2017, NAT REV RHEUMATOL, V13, P141, DOI 10.1038/nrrheum.2016.217; Brito-Zeron P, 2016, ANN RHEUM DIS, V75, P348, DOI 10.1136/annrheumdis-2014-206418; Brito-Zeron P, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.47; Carubbi F, 2015, LUPUS, V24, P315, DOI 10.1177/0961203314554251; Carubbi F, 2014, SEMIN ARTHRITIS RHEU, V44, P314, DOI 10.1016/j.semarthrit.2014.05.015; CHISHOLM DM, 1968, J CLIN PATHOL, V21, P656, DOI 10.1136/jcp.21.5.656; Daniels TE, 2011, ARTHRITIS RHEUM-US, V63, P2021, DOI 10.1002/art.30381; Deeks J J, 2003, Health Technol Assess, V7, piii; Fox RI, 2005, LANCET, V366, P321, DOI 10.1016/S0140-6736(05)66990-5; Giacomelli R, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2020.102738; Giacomelli R, 2019, AUTOIMMUN REV, V18, P93, DOI 10.1016/j.autrev.2018.08.003; GREENSPAN JS, 1974, ORAL SURG ORAL MED O, V37, P217, DOI 10.1016/0030-4220(74)90417-4; Guellec D, 2013, AUTOIMMUN REV, V12, P416, DOI 10.1016/j.autrev.2012.08.001; He J, 2017, INT J RHEUM DIS, V20, P245, DOI 10.1111/1756-185X.12856; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Jonsson MV, 2007, J RHEUMATOL, V34, P2044; Kakugawa T, 2018, RESP MED, V137, P95, DOI 10.1016/j.rmed.2018.02.023; Lee KE, 2016, J KOREAN MED SCI, V31, P190, DOI 10.3346/jkms.2016.31.2.190; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]; Nocturne G, 2018, NAT REV RHEUMATOL, V14, P133, DOI 10.1038/nrrheum.2018.1; Ohlsson M, 2002, SCAND J IMMUNOL, V56, P456, DOI 10.1046/j.1365-3083.2002.01072_79.x; Qin BD, 2015, ANN RHEUM DIS, V74, P1983, DOI 10.1136/annrheumdis-2014-205375; Reksten TR, 2009, RHEUMATOLOGY, V48, P1102, DOI 10.1093/rheumatology/kep149; Risselada AP, 2014, ANN RHEUM DIS, V73, P1537, DOI 10.1136/annrheumdis-2013-204634; Salomonsson S, 2003, ARTHRITIS RHEUM-US, V48, P3187, DOI 10.1002/art.11311; Shiboski CH, 2017, ANN RHEUM DIS, V76, P9, DOI [10.1136/annrheumdis-2016-210571, 10.1002/art.39859]; Shiboski SC, 2012, ARTHRIT CARE RES, V64, P475, DOI 10.1002/acr.21591; Singh AG, 2016, RHEUMATOLOGY, V55, P450, DOI 10.1093/rheumatology/kev354; Sjogren H., 1933, ACTA OPHTHALMOL    S, V11, P1, DOI DOI 10.1111/J.1755-3768.1935.TB04186.X; TARPLEY TM, 1974, ORAL SURG ORAL MED O, V37, P64, DOI 10.1016/0030-4220(74)90160-1; Tengner P, 1998, ARTHRITIS RHEUM-US, V41, P2238, DOI 10.1002/1529-0131(199812)41:12<2238::AID-ART20>3.0.CO;2-V; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; WISE CM, 1993, J RHEUMATOL, V20, P1515	34	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 11	2021	12								686457	10.3389/fimmu.2021.686457	http://dx.doi.org/10.3389/fimmu.2021.686457			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SY3JG	34177936	gold, Green Published			2022-12-18	WOS:000665786600001
J	Mazzarino, RC				Mazzarino, Randall C.			Targeting Future Pandemics, a Case for De Novo Purine Synthesis and Basic Research	FRONTIERS IN IMMUNOLOGY			English	Article						nucleotide synthesis; viral response; therapeutic development; immunology & infectious diseases; metabolism	ACTIVATED PROTEIN-KINASE; BIOSYNTHESIS; SARS-COV-2; COVID-19; ACCUMULATION; METHOTREXATE; GEMCITABINE; INTERFERES; INHIBITION; CELLS	We are currently experiencing a deadly novel viral pandemic with no efficacious, readily available anti-viral therapies to SARS-CoV-2. Viruses will hijack host cellular machinery, including metabolic processes. Here, I provide theory and evidence for targeting the host de novo purine synthetic pathway for broad spectrum anti-viral drug development as well as the pursuit of basic science to mitigate the risks of future novel viral outbreaks.	[Mazzarino, Randall C.] Harvard Med Sch, Schepens Eye Res Inst, Mass Eye & Ear Infirm, Boston, MA 02115 USA; [Mazzarino, Randall C.] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Schepens Eye Research Institute; Harvard University; Harvard Medical School	Mazzarino, RC (corresponding author), Harvard Med Sch, Schepens Eye Res Inst, Mass Eye & Ear Infirm, Boston, MA 02115 USA.; Mazzarino, RC (corresponding author), Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.	randall_mazzarino@meei.harvard.edu						Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020; Baresova V, 2016, MOL GENET METAB, V119, P270, DOI 10.1016/j.ymgme.2016.08.004; Batool S, 2017, SAUDI J BIOL SCI, V24, P1155, DOI 10.1016/j.sjbs.2014.11.008; Beigel JH, 2020, NEW ENGL J MED, V383, P994, DOI 10.1056/NEJMc2022236; Bradley BT, 2020, LANCET, V396, P320, DOI 10.1016/S0140-6736(20)31305-2; Bronder JL, 2002, CANCER RES, V62, P5236; Callaway E, 2021, NATURE, V590, P15, DOI 10.1038/d41586-021-00241-6; Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3; Chan CY, 2015, P NATL ACAD SCI USA, V112, P1368, DOI 10.1073/pnas.1423009112; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.tb20498.x; CRONSTEIN BN, 1993, J CLIN INVEST, V92, P2675, DOI 10.1172/JCI116884; DeVito SR, 2014, P NATL ACAD SCI USA, V111, P18019, DOI 10.1073/pnas.1415864111; Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Friedman B, 2019, JOINT BONE SPINE, V86, P301, DOI 10.1016/j.jbspin.2018.07.004; Frohman EM, 2020, J NEUROL SCI, V415, DOI 10.1016/j.jns.2020.116936; Frohman EM, 2020, J NEUROL SCI, V415, DOI 10.1016/j.jns.2020.116935; Garvin MR, 2020, ELIFE, V9, DOI 10.7554/eLife.59177; Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Hoffmann HH, 2011, P NATL ACAD SCI USA, V108, P5777, DOI 10.1073/pnas.1101143108; Klok FA, 2020, THROMB RES, V191, P145, DOI [10.1016/j.thromres.2020.04.013, 10.1016/j.thromres.2020.04.041]; Kondo M, 2000, J BIOCHEM, V128, P57, DOI 10.1093/oxfordjournals.jbchem.a022730; Li JW, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00228-1; Liu Q, 2020, CELL CHEM BIOL, V27, P668, DOI 10.1016/j.chembiol.2020.05.002; Lucas-Hourani M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003678; Mayer KA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01533; Mazzarino RC, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247227; Mazzarino RC, 2020, MOL GENET METAB REP, V25, DOI 10.1016/j.ymgmr.2020.100642; Mazzarino RC, 2019, MOL GENET METAB REP, V21, DOI 10.1016/j.ymgmr.2019.100512; Meares GP, 2013, J IMMUNOL, V190, P372, DOI 10.4049/jimmunol.1202390; O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Quemeneur L, 2004, J IMMUNOL, V173, P4945, DOI 10.4049/jimmunol.173.8.4945; Salminen A, 2011, J MOL MED, V89, P667, DOI 10.1007/s00109-011-0748-0; Shin HJ, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040211; Song JH, 2017, ANTIVIR RES, V145, P6, DOI 10.1016/j.antiviral.2017.07.003; Spurr IB, 2012, CHEMBIOCHEM, V13, P1628, DOI 10.1002/cbic.201200279; Thomas K, 2020, NY TIMES; Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11; V'kovski P, 2021, NAT REV MICROBIOL, V19, P155, DOI 10.1038/s41579-020-00468-6; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; Wang YJ, 2016, ANTIMICROB AGENTS CH, V60, P2834, DOI 10.1128/AAC.02700-15; Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x; World Health Organization, DIS OUTBR YEAR; Xiang HC, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1411-x; Zhang HP, 2020, J INFECTION, V81, pE82, DOI 10.1016/j.jinf.2020.06.036; Zhao H, 2015, J BIOL CHEM, V290, P6705, DOI 10.1074/jbc.M114.628701	48	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 11	2021	12								694300	10.3389/fimmu.2021.694300	http://dx.doi.org/10.3389/fimmu.2021.694300			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SY4AP	34177959	Green Published, gold			2022-12-18	WOS:000665832400001
J	Bier, J; Steiger, SM; Reichardt, HM; Luhder, F				Bier, Jasmina; Steiger, Sebastian M.; Reichardt, Holger M.; Luehder, Fred			Protection of Antigen-Primed Effector T Cells From Glucocorticoid-Induced Apoptosis in Cell Culture and in a Mouse Model of Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Article						glucocorticoids; apoptosis; T cells; antigen-priming; adoptive transfer EAE	ACTIVATION; BCL-2; THYMOCYTES; RECEPTOR; MICE; METHYLPREDNISOLONE; LYMPHOCYTES; SENSITIVITY; INHIBITION; EXPRESSION	Induction of T cell apoptosis constitutes a major mechanism by which therapeutically administered glucocorticoids (GCs) suppress inflammation and associated clinical symptoms, for instance in multiple sclerosis (MS) patients suffering from an acute relapse. The sensitivity of T cells to GC action depends on their maturation and activation status, but the precise effect of antigen-priming in a pathological setting has not been explored. Here we used transgenic and congenic mouse models to compare GC-induced apoptosis between naive and antigen-specific effector T cells from mice immunized with a myelin peptide. Antigen-primed effector T cells were protected from the pro-apoptotic activity of the synthetic GC dexamethasone in a dose-dependent manner, which resulted in their accumulation relative to naive T cells in vitro and in vivo. Notably, the differential sensitivity of T cells to GC-induced apoptosis correlated with their expression level of the anti-apoptotic proteins Bcl-2 and Bcl-X-L and a loss of the mitochondrial membrane potential. Moreover, accumulation of antigen-primed effector T cells following GC treatment in vitro resulted in an aggravated disease course in an adoptive transfer mouse model of MS in vivo, highlighting the clinical relevance of the observed phenomenon. Collectively, our data indicate that antigen-priming influences the T cells' sensitivity to therapeutically applied GCs in the context of inflammatory diseases.	[Bier, Jasmina; Steiger, Sebastian M.; Luehder, Fred] Univ Med Ctr Goettingen, Inst Neuroimmunol & Multiple Sclerosis Res, Gottingen, Germany; [Reichardt, Holger M.] Univ Med Ctr Goettingen, Inst Cellular & Mol Immunol, Gottingen, Germany; [Bier, Jasmina] Univ Med Ctr Hamburg, Inst Neuroimmunol & Multiple Sclerosis, Hamburg, Germany	University of Gottingen; University of Gottingen; University of Hamburg; University Medical Center Hamburg-Eppendorf	Luhder, F (corresponding author), Univ Med Ctr Goettingen, Inst Neuroimmunol & Multiple Sclerosis Res, Gottingen, Germany.; Reichardt, HM (corresponding author), Univ Med Ctr Goettingen, Inst Cellular & Mol Immunol, Gottingen, Germany.	hreichardt@med.uni-goettingen.de; fred.luehder@med.uni-goettingen.de			Deutsche Forschungsgemeinschaft [RE 1631/17-1, FL 377/4-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by grants from the Deutsche Forschungsgemeinschaft (RE 1631/17-1 and FL 377/4-1).	Akbar AN, 1996, EUR J IMMUNOL, V26, P294, DOI 10.1002/eji.1830260204; Banuelos J, 2016, ALLERGY, V71, P640, DOI 10.1111/all.12840; Banuelos J, 2016, CYTOKINE GROWTH F R, V31, P27, DOI 10.1016/j.cytogfr.2016.05.002; Berki T, 2002, INT IMMUNOL, V14, P463, DOI 10.1093/intimm/14.5.463; Bettelli E, 2003, J EXP MED, V197, P1073, DOI 10.1084/jem.20021603; BROOME HE, 1995, J IMMUNOL, V155, P2311; BRUNETTI M, 1995, BLOOD, V86, P4199, DOI 10.1182/blood.V86.11.4199.bloodjournal86114199; Chen X, 2004, EUR J IMMUNOL, V34, P859, DOI 10.1002/eji.200324506; D'Elia M, 2010, AM J PHYSIOL-ENDOC M, V299, pE299, DOI 10.1152/ajpendo.00084.2010; Erlacher M, 2005, BLOOD, V106, P4131, DOI 10.1182/blood-2005-04-1595; Flach AC, 2016, P NATL ACAD SCI USA, V113, P3323, DOI 10.1073/pnas.1519608113; Gold R, 2006, BRAIN, V129, P1953, DOI 10.1093/brain/awl075; HENCH P, 1950, LANCET, V259, P483; Kawabe K, 2012, IMMUNOBIOLOGY, V217, P118, DOI 10.1016/j.imbio.2011.07.018; Kim D, 2020, IMMUNITY, V53, P581, DOI 10.1016/j.immuni.2020.07.002; Luche H, 2007, EUR J IMMUNOL, V37, P43, DOI 10.1002/eji.200636745; MILLIGAN NM, 1987, J NEUROL NEUROSUR PS, V50, P511, DOI 10.1136/jnnp.50.5.511; Mittelstadt PR, 2012, J CLIN INVEST, V122, P2384, DOI 10.1172/JCI63067; Montes-Cobos E, 2017, J CONTROL RELEASE, V245, P157, DOI 10.1016/j.jconrel.2016.12.003; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Prenek L, 2020, APOPTOSIS, V25, P715, DOI 10.1007/s10495-020-01629-x; Rasmussen ML, 2020, INT REV CEL MOL BIO, V353, P255, DOI 10.1016/bs.ircmb.2019.12.005; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Sbiera S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024345; Schmidt J, 2000, BRAIN, V123, P1431, DOI 10.1093/brain/123.7.1431; Schweingruber N, 2014, ACTA NEUROPATHOL, V127, P713, DOI 10.1007/s00401-014-1248-4; Schweingruber N, 2011, J IMMUNOL, V187, P4310, DOI 10.4049/jimmunol.1101604; Strauss G, 2002, CLIN EXP IMMUNOL, V128, P255, DOI 10.1046/j.1365-2249.2002.01777.x; Tuosto L, 1994, EUR J IMMUNOL, V24, P1061, DOI 10.1002/eji.1830240508; van den Brandt J, 2004, EUR J IMMUNOL, V34, P1405, DOI 10.1002/eji.200324735; van den Brandt J, 2004, MOL ENDOCRINOL, V18, P687, DOI 10.1210/me.2003-0390; WALKER PR, 1993, EXP CELL RES, V207, P142, DOI 10.1006/excr.1993.1173; Wang DP, 2006, J IMMUNOL, V176, P1695, DOI 10.4049/jimmunol.176.3.1695; Wiegers GJ, 2001, EUR J IMMUNOL, V31, P2293, DOI 10.1002/1521-4141(200108)31:8<2293::AID-IMMU2293>3.0.CO;2-I; Wust S, 2012, INT J ENDOCRINOL, V2012, DOI 10.1155/2012/417017; Wust S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008202; Wust S, 2008, J IMMUNOL, V180, P8434, DOI 10.4049/jimmunol.180.12.8434; Xie HJ, 1997, MOL IMMUNOL, V34, P987, DOI 10.1016/S0161-5890(97)00128-4; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; ZUBIAGA AM, 1992, J IMMUNOL, V149, P107	40	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 10	2021	12								671258	10.3389/fimmu.2021.671258	http://dx.doi.org/10.3389/fimmu.2021.671258			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SW8DI	34177911	Green Published, gold			2022-12-18	WOS:000664744700001
J	Amundsen, MM; Tartor, H; Andersen, K; Sveinsson, K; Thoen, E; Gjessing, MC; Dahle, MK				Amundsen, Marit M.; Tartor, Haitham; Andersen, Kathrine; Sveinsson, Karoline; Thoen, Even; Gjessing, Mona C.; Dahle, Maria K.			Mucosal and Systemic Immune Responses to Salmon Gill Poxvirus Infection in Atlantic Salmon Are Modulated Upon Hydrocortisone Injection	FRONTIERS IN IMMUNOLOGY			English	Article						salmon gill poxvirus; Atlantic salmon; antiviral immunity; cytotoxic cell; mucosal immunity; gill disease; virulence gene	PANCREATIC NECROSIS VIRUS; VACCINIA VIRUS; SALAR; EXPRESSION; CORTISOL; DISEASE; FISH; INTERFERON; EVOLUTION; STRESS	Salmon Gill Poxvirus Disease (SGPVD) has emerged as a cause of acute mortality in Atlantic salmon (Salmo salar L.) presmolts in Norwegian aquaculture. The clinical phase of the disease is associated with apoptotic cell death in the gill epithelium causing acute respiratory distress, followed by proliferative changes in the regenerating gill in the period after the disease outbreak. In an experimental SGPV challenge trial published in 2020, acute disease was only seen in fish injected with hydrocortisone 24 h prior to infection. SGPV-mediated mortality in the hydrocortisone-injected group was associated with more extensive gill pathology and higher SGPV levels compared to the group infected with SGPV only. In this study based on the same trial, SGPV gene expression and the innate and adaptive antiviral immune response was monitored in gills and spleen in the presence and absence of hydrocortisone. Whereas most SGPV genes were induced from day 3 along with the interferon-regulated innate immune response in gills, the putative SGPV virulence genes of the B22R family were expressed already one day after SGPV exposure, indicating a potential role as early markers of SGPV infection. In gills of the hydrocortisone-injected fish infected with SGPV, MX expression was delayed until day 10, and then expression skyrocketed along with the viral peak, gill pathology and mortality occurring from day 14. A similar expression pattern was observed for Interferon gamma (IFN gamma) and granzyme A (GzmA) in the gills, indicating a role of acute cytotoxic cell activity in SGPVD. Duplex in situ hybridization demonstrated effects of hydrocortisone on the number and localization of GzmA-containing cells, and colocalization with SGPV infected cells in the gill. SGPV was generally not detected in spleen, and gill infection did not induce any corresponding systemic immune activity in the absence of stress hormone injection. However, in fish injected with hydrocortisone, IFN gamma and GzmA gene expression was induced in spleen in the days prior to acute mortality. These data indicate that suppressed mucosal immune response in the gills and the late triggered systemic immune response in the spleen following hormonal stress induction may be the key to the onset of clinical SGPVD.	[Amundsen, Marit M.; Tartor, Haitham; Andersen, Kathrine; Sveinsson, Karoline; Thoen, Even; Gjessing, Mona C.; Dahle, Maria K.] Norwegian Vet Inst, Dept Fish Hlth, As, Norway; [Thoen, Even] Patogen, Alesund, Norway; [Dahle, Maria K.] UiT Arctic Univ Norway, Norwegian Coll Fishery Sci, Tromso, Norway	Norwegian Veterinary Institute; UiT The Arctic University of Tromso	Dahle, MK (corresponding author), Norwegian Vet Inst, Dept Fish Hlth, As, Norway.; Dahle, MK (corresponding author), UiT Arctic Univ Norway, Norwegian Coll Fishery Sci, Tromso, Norway.	maria.dahle@vetinst.no	Dahle, Maria K/AAK-5130-2021	Dahle, Maria K/0000-0003-0380-084X; tartor, Haitham muhammed/0000-0003-3913-7410	Norwegian Research Council [267491, 303415]; Norwegian Veterinary Institute	Norwegian Research Council(Research Council of NorwayEuropean Commission); Norwegian Veterinary Institute	This work was funded by the Norwegian Research Council, grant numbers 267491 (SALPOX) and 303415 (IMMUNOPOX). Open access publishing was funded by the Norwegian Veterinary Institute.	Alzhanova D, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004123; Babkin IV, 2015, VIRUSES-BASEL, V7, P1100, DOI 10.3390/v7031100; Baldanta S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006651; Espelid S, 1996, FISH SHELLFISH IMMUN, V6, P95, DOI 10.1006/fsim.1996.0011; Fast MD, 2008, FISH SHELLFISH IMMUN, V24, P194, DOI 10.1016/j.fsi.2007.10.009; Gadan K, 2012, FISH SHELLFISH IMMUN, V32, P637, DOI 10.1016/j.fsi.2012.01.004; Gjessing MC, 2018, J FISH DIS, V41, P1103, DOI 10.1111/jfd.12802; Gjessing MC, 2016, AQUACULTURE VIROLOGY, P119, DOI 10.1016/B978-0-12-801573-5.00007-3; Gjessing MC, 2017, J FISH DIS, V40, P1253, DOI 10.1111/jfd.12608; Gjessing MC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02154; Gjessing MC, 2015, J VIROL, V89, P9348, DOI 10.1128/JVI.01174-15; Gomez D, 2013, FISH SHELLFISH IMMUN, V35, P1729, DOI 10.1016/j.fsi.2013.09.032; Gubser C, 2004, J GEN VIROL, V85, P105, DOI 10.1099/vir.0.19565-0; Gulla S, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01071; Haller SL, 2014, INFECT GENET EVOL, V21, P15, DOI 10.1016/j.meegid.2013.10.014; LeBlanc F, 2019, J FISH DIS, V42, P315, DOI 10.1111/jfd.12922; Marcos-Lopez M, 2017, FISH SHELLFISH IMMUN, V66, P207, DOI 10.1016/j.fsi.2017.05.029; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; Myoumoto A, 2007, J HUM GENET, V52, P328, DOI 10.1007/s10038-007-0119-4; Niklasson L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094288; Nylund A, 2008, ARCH VIROL, V153, P1299, DOI 10.1007/s00705-008-0117-7; Randelli E, 2008, FISH SHELLFISH IMMUN, V25, P326, DOI 10.1016/j.fsi.2008.03.019; Robertsen B, 2018, DEV COMP IMMUNOL, V80, P41, DOI 10.1016/j.dci.2017.02.005; Robertsen B, 2008, FISH SHELLFISH IMMUN, V25, P351, DOI 10.1016/j.fsi.2008.02.004; Schreck CB, 2016, FISH PHYSIOL, V35, P1, DOI 10.1016/B978-0-12-802728-8.00001-1; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Segner H, 2012, FISH PHYSIOL BIOCHEM, V38, P85, DOI 10.1007/s10695-011-9517-9; Smith GL, 2013, J GEN VIROL, V94, P2367, DOI 10.1099/vir.0.055921-0; Sun BJ, 2011, J VIROL, V85, P9188, DOI 10.1128/JVI.00319-11; Thoen E, 2020, VET RES, V51, DOI 10.1186/s13567-020-00787-9; Tseng RJ, 2005, BRAIN BEHAV IMMUN, V19, P153, DOI 10.1016/j.bbi.2004.07.001; Veenstra KA, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040725; Yang ZL, 2013, VIROLOGY, V447, P213, DOI 10.1016/j.virol.2013.09.007; Yang ZL, 2011, J VIROL, V85, P9899, DOI 10.1128/JVI.05446-11	34	1	1	5	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 9	2021	12								689302	10.3389/fimmu.2021.689302	http://dx.doi.org/10.3389/fimmu.2021.689302			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SW6SJ	34177946	gold, Green Published			2022-12-18	WOS:000664643600001
J	Li, YH; Chen, JJ; Lin, YK; Xu, L; Sang, YF; Li, DJ; Du, MR				Li, Yanhong; Chen, Jiajia; Lin, Yikong; Xu, Ling; Sang, Yifei; Li, Dajin; Du, Meirong			Obesity Challenge Drives Distinct Maternal Immune Response Changes in Normal Pregnant and Abortion-Prone Mouse Models	FRONTIERS IN IMMUNOLOGY			English	Article						maternal obesity; normal pregnancy; spontaneous miscarriage; maternal immunity; overcompensation	NATURAL-KILLER-CELLS; NK CELLS; PERIPHERAL-BLOOD; RECURRENT MISCARRIAGE; MACROPHAGE ACCUMULATION; CYTOTOXICITY RECEPTORS; CYTOKINE PRODUCTION; ADIPOSE-TISSUE; STROMAL CELLS; WEIGHT-GAIN	Obesity is prevalent among women of reproductive age and is associated with increased risk of developing multiple pregnancy disorders. Pregnancy must induce immune tolerance to avoid fetal rejection, while obesity can cause chronic inflammation through activating the immune system. Impaired maternal immuno-tolerance leads to pregnancy failure, such as recurrent spontaneous abortion (RSA), one of the most common complications during early pregnancy. How does maternal immune response change under obesity stress in normal pregnancy and RSA? In turn, is obesity affected by different gestational statuses? Limited information is presently available now. Our study investigated pregnancy outcomes and maternal immune responses in two murine models (normal pregnancy and spontaneous abortion models) after obesity challenge with a high-fat diet (HFD). Abortion-prone mice fed HFD had significantly higher weight gains during pregnancy than normal pregnant mice with HFD feeding. Nonetheless, the embryo implantation and resorption rates were comparable between HFD and normal chow diet (NCD)-fed mice in each model. Evaluation of immune cell subsets showed HFD-induced obesity drove the upregulation of activated NK cell-activating receptor (NKp46)(+) NK cells and pro-inflammatory macrophages (MHCIIhigh M phi) as well as CD4(+) and CD8(+) T cells in the normal pregnancy group. However, in the abortion-prone group, relative more immature NK cells with decreased activity phenotypes were found in obese mice. Moreover, there were increased DCreg (CD11b(high) DC) cells and decreased CD4(+) and CD8(+) T cells detected in the HFD abortion-prone mice relative to those fed the NCD diet. Our findings reveal how pregnancy obesity and maternal immune regulation are mutually influenced. It is worth noting that the abortion-prone model where active maternal immune status was intensified by obesity, in turn stimulated an overcompensation response, leading to an over-tolerized immune status, and predisposing to potential risks of perinatal complications.	[Li, Yanhong; Chen, Jiajia; Lin, Yikong; Xu, Ling; Sang, Yifei; Li, Dajin; Du, Meirong] Fudan Univ, Shanghai Inst Planned Parenthood Res,Shanghai Med, NHC Key Lab Reprod Regulat,Hosp Obstet & Gynecol, Lab Reprod Immunol,Shanghai Key Lab Female Reprod, Shanghai, Peoples R China; [Du, Meirong] South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Obstet & Gynecol, Guangzhou, Peoples R China	Fudan University; South China University of Technology	Li, DJ; Du, MR (corresponding author), Fudan Univ, Shanghai Inst Planned Parenthood Res,Shanghai Med, NHC Key Lab Reprod Regulat,Hosp Obstet & Gynecol, Lab Reprod Immunol,Shanghai Key Lab Female Reprod, Shanghai, Peoples R China.; Du, MR (corresponding author), South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Obstet & Gynecol, Guangzhou, Peoples R China.	mrdu@fudan.edu.cn			National Key R&D Program of China [2017YFC1001403]; National Nature Science Foundation of China [81630036, 31970859, 31900663]; Macao and Shanghai Municipal Commission of science and technology [20410760300]; Strategic Collaborative Research Program of the Ferring Institute of Reproductive Medicine by Ferring Pharmaceuticals; Chinese Academy of Sciences [FIRMX200504]	National Key R&D Program of China; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Macao and Shanghai Municipal Commission of science and technology; Strategic Collaborative Research Program of the Ferring Institute of Reproductive Medicine by Ferring Pharmaceuticals; Chinese Academy of Sciences(Chinese Academy of Sciences)	The work is supported by the National Key R&D Program of China (2017YFC1001403), the National Nature Science Foundation of China (81630036, 31970859, 31900663), International cooperation project between Macao and Shanghai Municipal Commission of science and technology (20410760300), and The Strategic Collaborative Research Program of the Ferring Institute of Reproductive Medicine Supported by Ferring Pharmaceuticals and Chinese Academy of Sciences (FIRMX200504).	Aguilar EG, 2018, CURR OPIN IMMUNOL, V51, P181, DOI 10.1016/j.coi.2018.03.012; Ander SE, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aat6114; Bahr I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00245; Baltayeva J, 2020, BIOL REPROD, V102, P63, DOI 10.1093/biolre/ioz163; Bonney EA, 2014, REPRODUCTION, V147, pR153, DOI 10.1530/REP-13-0583; Bonney EA, 2013, AM J REPROD IMMUNOL, V69, P567, DOI 10.1111/aji.12102; Boots C, 2011, SEMIN REPROD MED, V29, P507, DOI 10.1055/s-0031-1293204; BULMER JN, 1991, HUM REPROD, V6, P791, DOI 10.1093/oxfordjournals.humrep.a137430; BULMER JN, 1984, CLIN EXP IMMUNOL, V57, P393; Challier JC, 2008, PLACENTA, V29, P274, DOI 10.1016/j.placenta.2007.12.010; Chiossone L, 2009, BLOOD, V113, P5488, DOI 10.1182/blood-2008-10-187179; Christiansen OB, 1996, HUM REPROD UPDATE, V2, P271, DOI 10.1093/humupd/2.4.271; CLARK DA, 1986, J IMMUNOL, V136, P1668; CLIFFORD K, 1994, HUM REPROD, V9, P1328, DOI 10.1093/oxfordjournals.humrep.a138703; Croy BA, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.102830; Denison FC, 2010, REPRODUCTION, V140, P373, DOI 10.1530/REP-10-0074; Erlebacher A, 2013, ANNU REV IMMUNOL, V31, P387, DOI 10.1146/annurev-immunol-032712-100003; Farah N, 2009, OBESITY FACTS, V2, P352, DOI 10.1159/000261951; Felker AM, 2017, MUCOSAL IMMUNOL, V10, P1122, DOI 10.1038/mi.2016.126; Felker AM, 2013, PLACENTA, V34, pA50, DOI 10.1016/j.placenta.2013.06.004; Fu BQ, 2014, IMMUNOLOGY, V141, P483, DOI 10.1111/imm.12224; Fu BQ, 2011, IMMUNOLOGY, V133, P350, DOI 10.1111/j.1365-2567.2011.03446.x; Fukui A, 2006, AM J REPROD IMMUNOL, V56, P312, DOI 10.1111/j.1600-0897.2006.00431.x; Fukui A, 2017, J OBSTET GYNAECOL RE, V43, P1678, DOI 10.1111/jog.13448; Gaillard R, 2013, OBESITY, V21, P1046, DOI 10.1002/oby.20088; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322; Hanna J, 2006, NAT MED, V12, P1065, DOI 10.1038/nm1452; Heslehurst N, 2008, OBES REV, V9, P635, DOI 10.1111/j.1467-789X.2008.00511.x; Ingvorsen C, 2014, INT J OBESITY, V38, P1282, DOI 10.1038/ijo.2014.69; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kiran TSU, 2005, BJOG-INT J OBSTET GY, V112, P768, DOI 10.1111/j.1471-0528.2004.00546.x; Larsen EC, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-154; Le Gars M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02469; Li Q, 2008, EUR J IMMUNOL, V38, P2751, DOI 10.1002/eji.200838542; Li YH, 2019, CELL MOL IMMUNOL, V16, P908, DOI 10.1038/s41423-019-0204-6; Mellman I, 2013, CANCER IMMUNOL RES, V1, P145, DOI 10.1158/2326-6066.CIR-13-0102; Metwally M, 2010, FERTIL STERIL, V94, P290, DOI 10.1016/j.fertnstert.2009.03.021; Munoz-Fernandez R, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1284-z; Naujoks W, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.573200; Norman JE, 2011, P NUTR SOC, V70, P450, DOI 10.1017/S0029665111003077; O'Rourke RW, 2005, OBES SURG, V15, P1463, DOI 10.1381/096089205774859308; Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732; Parker VJ, 2014, INT J OBESITY, V38, P766, DOI 10.1038/ijo.2013.164; Perdu S, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85560; Rai R, 2006, LANCET, V368, P601, DOI 10.1016/S0140-6736(06)69204-0; Russell P, 2013, PATHOLOGY, V45, P393, DOI 10.1097/PAT.0b013e328361429b; Schlitzer A, 2015, NAT IMMUNOL, V16, P718, DOI 10.1038/ni.3200; Schmatz M, 2010, J PERINATOL, V30, P441, DOI 10.1038/jp.2009.182; Sebire NJ, 2001, INT J OBESITY, V25, P1175, DOI 10.1038/sj.ijo.0801670; Seijkens T, 2014, DIABETES, V63, P3982, DOI 10.2337/db14-0272; Sen S, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.11.004; Seshadri S, 2014, HUM REPROD UPDATE, V20, P429, DOI 10.1093/humupd/dmt056; Spielmann J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76906-5; St-Germain LE, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113776; Stolarczyk E, 2017, CURR OPIN PHARMACOL, V37, P35, DOI 10.1016/j.coph.2017.08.006; Sureshchandra S, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01089; Theurich S, 2017, CELL METAB, V26, P171, DOI 10.1016/j.cmet.2017.05.018; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wensveen FM, 2015, NAT IMMUNOL, V16, P376, DOI 10.1038/ni.3120; Womack J, 2007, METABOLISM, V56, P998, DOI 10.1016/j.metabol.2007.03.008; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Xu L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.642392; Yang FL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02317; Yokota M, 2013, AM J REPROD IMMUNOL, V69, P202, DOI 10.1111/aji.12062	66	1	1	0	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 9	2021	12								694077	10.3389/fimmu.2021.694077	http://dx.doi.org/10.3389/fimmu.2021.694077			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SW4TT	34177956	Green Published, gold			2022-12-18	WOS:000664510200001
J	Ronchi, DCM; Malaquias, MAS; Rebutini, PZ; do Carmo, LAP; Neto, PC; Marini, ES; Prokopenko, A; Nagashima, S; Zanluca, C; dos Santos, CND; de Noronha, L				Martins Ronchi, Daiane Cristine; Scaranello Malaquias, Mineia Alessandra; Rebutini, Patricia Zadorosnei; Panini do Carmo, Leticia Arianne; Neto, Plinio Cezar; Marini, Emily Scaranello; Prokopenko, Amanda; Nagashima, Seigo; Zanluca, Camila; Duarte dos Santos, Claudia Nunes; de Noronha, Lucia			Placental Morphologic Similarities Between ZIKV-Positive and HIV-Positive Pregnant Women	FRONTIERS IN IMMUNOLOGY			English	Article						Zika virus; HIV; vertical transmission; placenta; morphometric analysis	VIRUS; CELLS; PERSISTENCE; INFECTION	Zika virus (ZIKV) caused global concern due to Brazil's unexpected epidemic, and it was associated with congenital microcephaly and other gestational intercurrences. The study aimed to analyze the placenta morphometric changes of ZIKV-infected pregnant women (ZIKV group; n = 23) compared to placentas of HIV-infected (HIV group; n = 24) and healthy pregnant women (N-control group; n = 22). It also analyzed the relationship between the morphometric results and pathological alterations on conventional microscopy, gestational trimester of infection, and presence of the congenital Zika syndrome (CZS). There was a significant increase in area (p = 0.0172), as well as a higher number of knots (p = 0.0027), sprouts (p < 0.0001), and CD163 +Hofbauer cells (HCs) (p < 0.0001) in the ZIKV group compared to the N-control group, suggesting that villous dysmaturity and HCs hyperplasia could be associated with ZIKV infections. The HIV group had a higher area (p < 0.0001), perimeter (p = 0.0001), sprouts (p < 0.0001), and CD163 + HCs (p < 0.0001) compared to the N-control group, demonstrating that the morphometric abnormalities found in the ZIKV and HIV group are probably similar. However, when ZIKV and HIV groups are compared, it was observed a higher number of sprouts (p = 0.0066) and CD163+ HCs (p < 0.0001) in the first one, suggesting that placental ZIKV congenital changes could be more pronounced.	[Martins Ronchi, Daiane Cristine; Scaranello Malaquias, Mineia Alessandra; Rebutini, Patricia Zadorosnei; Panini do Carmo, Leticia Arianne; Neto, Plinio Cezar; Marini, Emily Scaranello; Prokopenko, Amanda; Nagashima, Seigo; de Noronha, Lucia] Pontificia Univ Catolica Parana, Postgrad Program Hlth Sci, Lab Expt Pathol, Curitiba, Parana, Brazil; [Zanluca, Camila; Duarte dos Santos, Claudia Nunes] Fundacao Oswaldo Cruz, Inst Carlos Chagas, Mol Virol Lab, Curitiba, Parana, Brazil	Pontificia Universidade Catolica do Parana; Fundacao Oswaldo Cruz	de Noronha, L (corresponding author), Pontificia Univ Catolica Parana, Postgrad Program Hlth Sci, Lab Expt Pathol, Curitiba, Parana, Brazil.	lnno.noronha@gmail.com	Rebutini, Patricia Z/I-5283-2017; Zanluca, Camila/O-6943-2017	Rebutini, Patricia Z/0000-0002-7364-6844; Zanluca, Camila/0000-0001-7350-9105	Fiocruz; CNPq [439968/2016-0]; CAPES Zika Fast Track [481-2016, 88887.116626/2016-01]; Fundacao Araucaria [CP04/2016]; CNPq fellowship	Fiocruz; CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CAPES Zika Fast Track(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao Araucaria(Fundacao Araucaria de Apoio ao Desenvolvimento Cientifico e Tecnologico do Estado do Parana FAFundacao de Amparo a Pesquisa e Inovacoo Estado de Santa Catarina (FAPESC)); CNPq fellowship(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This research was funded by Fiocruz, CNPq (439968/2016-0), CAPES Zika Fast Track 481-2016 (88887.116626/2016-01), and Fundacao Arauca ' ria (CP04/2016). CNDS and LN have a CNPq fellowship.	Aagaard KM, 2017, SCI REP-UK, V7, DOI 10.1038/srep41389; Anderson VM, 1997, OBSTET GYN CLIN N AM, V24, P797, DOI 10.1016/S0889-8545(05)70345-4; Aragao MFVV, 2017, AM J NEURORADIOL, V38, P1427, DOI 10.3174/ajnr.A5216; Ayres CFJ, 2016, LANCET INFECT DIS, V16, P278, DOI 10.1016/S1473-3099(16)00073-6; Baurakiades E, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-101; Bhatnagar J, 2017, EMERG INFECT DIS, V23, P405, DOI 10.3201/eid2303.161499; Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412; de Noronha L, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02266; de Noronha L, 2016, MEM I OSWALDO CRUZ, V111, P287, DOI 10.1590/0074-02760160085; Melo ASD, 2016, JAMA NEUROL, V73, P1407, DOI 10.1001/jamaneurol.2016.3720; Hughes BW, 2016, EBIOMEDICINE, V10, P65, DOI 10.1016/j.ebiom.2016.06.026; López Consuelo Lozoya, 2013, J. Bras. Patol. Med. Lab., V49, P437, DOI 10.1590/S1676-24442013000600010; Loukeris K, 2010, PEDIATR DEVEL PATHOL, V13, P305, DOI 10.2350/09-08-0692-OA.1; Luo HL, 2018, ANTIVIR RES, V151, P55, DOI 10.1016/j.antiviral.2018.01.003; Maartens G, 2014, LANCET, V384, P258, DOI 10.1016/S0140-6736(14)60164-1; Mehrjardi Mohammad Zare, 2017, VirusDisease, V28, P247, DOI 10.1007/s13337-017-0399-z; Neu N, 2015, CLIN PERINATOL, V42, P77, DOI 10.1016/j.clp.2014.11.001; Obimbo MM, 2019, JAIDS-J ACQ IMM DEF, V80, P94, DOI 10.1097/QAI.0000000000001871; Oehler E, 2014, EUROSURVEILLANCE, V19, P4; Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113; Rabelo K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01704; Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2; Sheridan MA, 2017, P NATL ACAD SCI USA, V114, pE1587, DOI 10.1073/pnas.1616097114; Solomon Isaac H, 2016, J Neuroinfect Dis, V7; SOUZA A, 2016, CLIN INFECT DIS, V63, P1622, DOI DOI 10.1093/CID/CIW613; Tabata T, 2016, CELL HOST MICROBE, V20, P155, DOI 10.1016/j.chom.2016.07.002; Ventura LO, 2017, J AAPOS, V21, P295, DOI 10.1016/j.jaapos.2017.04.003; Yang SW, 2017, J REPROD IMMUNOL, V124, P30, DOI 10.1016/j.jri.2017.09.012; Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192	29	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 9	2021	12								684194	10.3389/fimmu.2021.684194	http://dx.doi.org/10.3389/fimmu.2021.684194			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SW4PH	34177930	Green Published, gold			2022-12-18	WOS:000664498300001
J	Post, A; Kabore, B; Berendsen, M; Diallo, S; Traore, O; Arts, RJW; Netea, MG; Joosten, LAB; Tinto, H; Jacobs, J; de Mast, Q; van der Ven, A				Post, Annelies; Kabore, Berenger; Berendsen, Mike; Diallo, Salou; Traore, Ousmane; Arts, Rob J. W.; Netea, Mihai G.; Joosten, Leo A. B.; Tinto, Halidou; Jacobs, Jan; de Mast, Quirijn; van der Ven, Andre			Altered Ex-Vivo Cytokine Responses in Children With Asymptomatic Plasmodium falciparum Infection in Burkina Faso: An Additional Argument to Treat Asymptomatic Malaria?	FRONTIERS IN IMMUNOLOGY			English	Article						asymptomatic malaria; bacteraemia; Salmonella; iNTS; bloodstream infection	NONTYPHOIDAL SALMONELLA DISEASE; ENTERICA SEROVAR TYPHIMURIUM; MONOCYTE ACTIVATION; AFRICAN CHILDREN; BACTEREMIA; PARASITE; IMMUNITY; NEUTROPHIL; MANAGEMENT; NANORO	Introduction Patients with clinical malaria have an increased risk for bacterial bloodstream infections. We hypothesized that asymptomatic malaria parasitemia increases susceptibility for bacterial infections through an effect on the innate immune system. We measured circulating cytokine levels and ex-vivo cytokine production capacity in asymptomatic malaria and compared with controls. Methods Data were collected from asymptomatic participants <5 years old with and without positive malaria microscopy, as well as from hospitalized patients <5 years old with clinical malaria, bacteremia, or malaria/bacteremia co-infections in a malaria endemic region of Burkina Faso. Circulating cytokines (TNF-alpha, IFN-gamma, IL-6, IL-10) were measured using multiplex assays. Whole blood from asymptomatic participants with and without positive malaria microscopy were ex-vivo stimulated with S. aureus, E. coli LPS and Salmonella Typhimurium; cytokine concentrations (TNF-alpha, IFN-gamma, IL-1 beta, IL-6, IL-10) were measured on supernatants using ELISA. Results Included were children with clinical malaria (n=118), bacteremia (n=22), malaria and bacteremia co-infection (n=9), asymptomatic malaria (n=125), and asymptomatic controls (n=237). Children with either clinical or asymptomatic malaria had higher plasma cytokine concentrations than controls. Cytokine concentrations correlated positively with malaria parasite density with the strongest correlation for IL-10 in both asymptomatic (r=0.63) and clinical malaria (r=0.53). Patients with bacteremia had lower circulating IL-10, TNF-alpha and IFN-gamma and higher IL-6 concentrations, compared to clinical malaria. Ex-vivo whole blood cytokine production to LPS and S. aureus was significantly lower in asymptomatic malaria compared to controls. Whole blood IFN-gamma and IL-10 production in response to Salmonella was also lower in asymptomatic malaria. Interpretation In children with asymptomatic malaria, cytokine responses upon ex-vivo bacterial stimulation are downregulated. Further studies are needed to explore if the suggested impaired innate immune response to bacterial pathogens also translates into impaired control of pathogens such as Salmonella spp.	[Post, Annelies; Kabore, Berenger; Berendsen, Mike; Arts, Rob J. W.; Netea, Mihai G.; Joosten, Leo A. B.; de Mast, Quirijn; van der Ven, Andre] Radboud Univ Nijmegen, Dept Internal Med, Radboud Ctr Infect Dis, Med Ctr, Nijmegen, Netherlands; [Kabore, Berenger; Diallo, Salou; Traore, Ousmane; Tinto, Halidou] IRSS Clin Res Unit Nanoro CRUN, Nanoro, Burkina Faso; [Berendsen, Mike] Univ Southern Denmark, Inst Clin Res, Bandim Hlth Project, Odense, Denmark; [Berendsen, Mike] Odense Univ Hosp, Odense, Denmark; [Netea, Mihai G.] Univ Bonn, Life & Med Sci Inst LIMES, Dept Genom & Immunoregulat, Bonn, Germany; [Tinto, Halidou] Univ Nazi Boni Bobo Dioulasso, Inst Super Sci Sante, Bobo Dioulasso, Burkina Faso; [Jacobs, Jan] Inst Trop Med, Dept Clin Sci, Antwerp, Belgium; [Jacobs, Jan] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Leuven, Belgium	Radboud University Nijmegen; University of Southern Denmark; University of Southern Denmark; Odense University Hospital; University of Bonn; Institute of Tropical Medicine (ITM); KU Leuven	Post, A; van der Ven, A (corresponding author), Radboud Univ Nijmegen, Dept Internal Med, Radboud Ctr Infect Dis, Med Ctr, Nijmegen, Netherlands.	annelies.post@gmail.com; andre.vanderven@radboudumc.nl	Traore, Ousmane/J-3573-2019; Kaboré, Bérenger/J-2773-2017; Jacobs, Jan/GRX-7316-2022; Post, Annelies/Q-6745-2016	Traore, Ousmane/0000-0003-1873-6473; Kaboré, Bérenger/0000-0002-3719-7033; Berendsen, Mike/0000-0001-9516-6190; Post, Annelies/0000-0002-0471-8250; de Mast, Quirijn/0000-0001-6056-157X	SYSMEX; SYSMEX company	SYSMEX; SYSMEX company	AV and QM have a non-restricted research grant from SYSMEX, which funded the current study. Both the diagnostic accuracy study and the cross-sectional study were funded by a nonrestricted research grant from SYSMEX company.	Ademolue TW, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1796-x; Ao TT, 2015, EMERG INFECT DIS, V21, P941, DOI 10.3201/eid2106.140999; Artavanis-Tsakonas K, 2003, CLIN EXP IMMUNOL, V133, P145, DOI 10.1046/j.1365-2249.2003.02174.x; Biggs HM, 2014, CLIN INFECT DIS, V58, P638, DOI 10.1093/cid/cit798; Bobade D, 2019, MICROBIOLOGYOPEN, V8, DOI 10.1002/mbo3.651; Chen I, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001942; Church J, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-31; Crump JA, 2015, CLIN MICROBIOL REV, V28, P901, DOI 10.1128/CMR.00002-15; Cunnington AJ, 2012, J IMMUNOL, V189, P5336, DOI 10.4049/jimmunol.1201028; de Mast Q, 2015, J INFECTION, V71, P587, DOI 10.1016/j.jinf.2015.08.005; de Mendonca VR, 2015, MEM I OSWALDO CRUZ, V110, P945, DOI 10.1590/0074-02760150241; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Derra K, 2012, INT J EPIDEMIOL, V41, P1293, DOI 10.1093/ije/dys159; Diallo A, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1715-1; Dobano C, 2019, CLIN INFECT DIS, V69, P820, DOI 10.1093/cid/ciy934; Dougan G, 2011, IMMUNOL REV, V240, P196, DOI 10.1111/j.1600-065X.2010.00999.x; Feasey NA, 2012, LANCET, V379, P2489, DOI 10.1016/S0140-6736(11)61752-2; Gilchrist JJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02398-z; Gilchrist JJ, 2016, CLIN VACCINE IMMUNOL, V23, P601, DOI 10.1128/CVI.00128-16; Gordon MA, 2005, INFECT IMMUN, V73, P3445, DOI 10.1128/IAI.73.6.3445-3452.2005; Guiraud I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178577; Jagannathan P, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003864; Jaslow SL, 2018, CELL REP, V23, P3525, DOI 10.1016/j.celrep.2018.05.072; Kalonji LM, 2015, CLIN INFECT DIS, V61, pS346, DOI 10.1093/cid/civ713; Linssen J, 2008, CYTOM PART B-CLIN CY, V74B, P295, DOI 10.1002/cyto.b.20422; Lokken KL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004049; MacLennan CA, 2008, J CLIN INVEST, V118, P1553, DOI 10.1172/JCI33998; Maltha J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089103; Mandala WL, 2016, PARASITE IMMUNOL, V38, P317, DOI 10.1111/pim.12319; Mandala WL, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00533-16, 10.1128/cvi.00533-16]; Metenou S, 2011, J IMMUNOL, V186, P4725, DOI 10.4049/jimmunol.1003778; Mtove G, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-320; Okell LC, 2009, J INFECT DIS, V200, P1509, DOI 10.1086/644781; Ortega-Pajares A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02888; Oyegue-Liabagui SL, 2017, AM J CLIN EXP IMMUNO, V6, P9; Portugal S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004079; Post A, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1334-5; Post AS, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007782; Rhee MSM, 2001, CLIN EXP IMMUNOL, V126, P503, DOI 10.1046/j.1365-2249.2001.01681.x; Roux CM, 2010, INFECT IMMUN, V78, P1520, DOI 10.1128/IAI.00887-09; Ruizendaal E, 2017, BIOMARK RES, V5, DOI 10.1186/s40364-017-0114-7; Takem EN, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-400; Taramelli D, 2000, LAB INVEST, V80, P1781, DOI 10.1038/labinvest.3780189; van Laarhoven A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36696-3; van Santen S, 2013, TRENDS PARASITOL, V29, P220, DOI 10.1016/j.pt.2013.03.006; Were T, 2011, J CLIN MICROBIOL, V49, P671, DOI 10.1128/JCM.01864-10; WHO, 2018, WORLD MAL REP 2018; World Health Organisation, 2013, UN ACC MAL DIAGN TES	48	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 9	2021	12								614817	10.3389/fimmu.2021.614817	http://dx.doi.org/10.3389/fimmu.2021.614817			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SW4VC	34177883	Green Published, gold			2022-12-18	WOS:000664513700001
J	Pellin, D; Claudio, N; Guo, ZH; Ziglari, T; Pucci, F				Pellin, Danilo; Claudio, Natalie; Guo, Zihan; Ziglari, Tahereh; Pucci, Ferdinando			Gene Expression Profiling of Lymph Node Sub-Capsular Sinus Macrophages in Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						cancer; lymph nodes; macrophages; gene expression; immune system; Fc receptors	CHEMOKINES; INFECTION; ANTIGENS; IMMUNITY; INNATE; ACCESS; CELLS	Lymph nodes are key lymphoid organs collecting lymph fluid and migratory cells from the tissue area they survey. When cancerous cells arise within a tissue, the sentinel lymph node is the first immunological organ to mount an immune response. Sub-capsular sinus macrophages (SSMs) are specialized macrophages residing in the lymph nodes that play important roles as gatekeepers against particulate antigenic material. In the context of cancer, SSMs capture tumor-derived extracellular vesicles (tEVs), a form of particulate antigen released in high amounts by tumor cells. We and others have recently demonstrated that SSMs possess anti-tumor activity because in their absence tumors progress faster. A comprehensive profiling of SSMs represents an important first step to identify the cellular and molecular mechanisms responsible for SSM anti-tumor activity. Unfortunately, the isolation of SSMs for molecular analyses is very challenging. Here, we combined an optimized dissociation protocol, careful marker selection and stringent gating strategies to highly purify SSMs. We provide evidence of decreased T and B cell contamination, which allowed us to reveal the gene expression profile of this elusive macrophage subset. Squamous cell carcinomas induced an increase in the expression of Fc receptors, lysosomal and proteasomal enzymes in SSMs. Imaging of mouse and patient lymph nodes confirmed the presence of the top differentially expressed genes. These results suggest that SSMs respond to tumor formation by upregulating the machinery necessary for presentation of tumor particulate antigens to B cells.	[Pellin, Danilo] Harvard Med Sch, Gene Therapy Program, Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA 02115 USA; [Claudio, Natalie; Guo, Zihan; Ziglari, Tahereh; Pucci, Ferdinando] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA; [Claudio, Natalie; Pucci, Ferdinando] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA; [Guo, Zihan] Oregon Hlth & Sci Univ, Program Canc Biol, Portland, OR 97201 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Pucci, F (corresponding author), Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA.; Pucci, F (corresponding author), Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA.	pucci@ohsu.edu		Ziglari, Tahereh/0000-0003-4909-1874	Cancer Early Detection Advanced Research Center at Oregon Health & Science University's Knight Cancer Institute [CRUK6851219]; V Foundation [V2019-012]; OHSU School of Medicine Research Core Initiative	Cancer Early Detection Advanced Research Center at Oregon Health & Science University's Knight Cancer Institute; V Foundation; OHSU School of Medicine Research Core Initiative	We would like to thank the following OHSU core facilities: Flow cytometry, Advanced Light Microscopy, BioLibrary and Massively Parallel Sequencing. This project was supported in part by funding (CRUK6851219) from the Cancer Early Detection Advanced Research Center at Oregon Health & Science University's Knight Cancer Institute (TZ, NC, FP), and in part by funding (V2019-012) from The V Foundation (NC, ZG, FP). We would like to thank OHSU School of Medicine Research Core Initiative for seed grant.	Alvarez-Fernandez SM, 2016, METHODS MOL BIOL, V1393, P11, DOI 10.1007/978-1-4939-3338-9_2; Atif SM, 2018, AM J RESP CELL MOL, V59, P580, DOI 10.1165/rcmb.2018-0159OC; Bhattacharya S, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.15; Diaz-Zaagoza M, 2015, ONCOL REP, V34, P1106, DOI 10.3892/or.2015.4095; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Gaya M, 2018, CELL, V172, P517, DOI 10.1016/j.cell.2017.11.036; Gaya M, 2015, SCIENCE, V347, P667, DOI 10.1126/science.aaa1300; Gerner MY, 2012, IMMUNITY, V37, P364, DOI 10.1016/j.immuni.2012.07.011; Gordon S, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016378; Gray EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038258; Gretz JE, 2000, J EXP MED, V192, P1425, DOI 10.1084/jem.192.10.1425; HOLM S, 1979, SCAND J STAT, V6, P65; Iannacone M, 2010, NATURE, V465, P1079, DOI 10.1038/nature09118; Junt T, 2007, NATURE, V450, P110, DOI 10.1038/nature06287; Komohara Y, 2017, CANCER SCI, V108, P290, DOI 10.1111/cas.13137; Louie DAP, 2019, THESIS U CALGARY CAL; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Moseman EA, 2012, IMMUNITY, V36, P415, DOI 10.1016/j.immuni.2012.01.013; Ozga AJ, 2021, IMMUNITY, V54, P859, DOI 10.1016/j.immuni.2021.01.012; Phan TG, 2009, NAT IMMUNOL, V10, P786, DOI 10.1038/ni.1745; Pucci F, 2016, SCIENCE, V352, P242, DOI 10.1126/science.aaf1328; Qi H, 2014, ANNU REV CELL DEV BI, V30, P141, DOI 10.1146/annurev-cellbio-100913-013254; R Core Team, 2013, R LANG ENV STAT COMP; Sixt M, 2005, IMMUNITY, V22, P19, DOI 10.1016/j.immuni.2004.11.013; Susaki EA, 2014, CELL, V157, P726, DOI 10.1016/j.cell.2014.03.042; Tacconi C, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108993; Tsujikawa T, 2017, CELL REP, V19, P203, DOI 10.1016/j.celrep.2017.03.037	28	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 8	2021	12								672123	10.3389/fimmu.2021.672123	http://dx.doi.org/10.3389/fimmu.2021.672123			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SW0VY	34168645	Green Published, Green Submitted, gold			2022-12-18	WOS:000664236700001
J	Pucca, MB; Bernarde, PS; Rocha, AM; Viana, PF; Farias, RES; Cerni, FA; Oliveira, IS; Ferreira, IG; Sandri, EA; Sachett, J; Wen, FH; Sampaio, V; Laustsen, AH; Sartim, MA; Monteiro, WM				Pucca, Manuela B.; Bernarde, Paulo Sergio; Rocha, Anderson Maciel; Viana, Patrik F.; Farias, Raimundo Erasmo Souza; Cerni, Felipe A.; Oliveira, Isadora S.; Ferreira, Isabela G.; Sandri, Eliseu A.; Sachett, Jacqueline; Wen, Fan Hui; Sampaio, Vanderson; Laustsen, Andreas H.; Sartim, Marco A.; Monteiro, Wuelton M.			Crotalus Durissus Ruruima: Current Knowledge on Natural History, Medical Importance, and Clinical Toxinology	FRONTIERS IN IMMUNOLOGY			English	Review						Crotalus durissus; Crotalus durissus ruruima; rattlesnake; snakebite; envenoming; venom; antivenom	AMINO-ACID OXIDASE; C-TYPE LECTIN; SNAKE-VENOM METALLOPROTEINASES; PHOSPHOLIPASE A(2); STRUCTURAL-CHARACTERIZATION; CASCAVELLA VENOM; TERRIFICUS VENOM; COLLILINEATUS VENOM; SERINE-PROTEASE; CROTOXIN	Crotalus durissus ruruima is a rattlesnake subspecies mainly found in Roraima, the northernmost state of Brazil. Envenomings caused by this subspecies lead to severe clinical manifestations (e.g. respiratory muscle paralysis, rhabdomyolysis, and acute renal failure) that can lead to the victim's death. In this review, we comprehensively describe C. d. ruruima biology and the challenges this subspecies poses for human health, including morphology, distribution, epidemiology, venom cocktail, clinical envenoming, and the current and future specific treatment of envenomings by this snake. Moreover, this review presents maps of the distribution of the snake subspecies and evidence that this species is responsible for some of the most severe envenomings in the country and causes the highest lethality rates. Finally, we also discuss the efficacy of the Brazilian horse-derived antivenoms to treat C. d. ruruima envenomings in Roraima state.	[Pucca, Manuela B.; Cerni, Felipe A.] Univ Fed Roraima, Med Sch, Boa Vista, Parana, Brazil; [Bernarde, Paulo Sergio] Univ Fed Acre, Ctr Multidisciplinar, Lab Herpetol, Cruzeiro Do Sul, Brazil; [Rocha, Anderson Maciel] Cathedral Fac Higher Educ, Biol Dept, Boa Vista, Parana, Brazil; [Viana, Patrik F.; Farias, Raimundo Erasmo Souza] Natl Inst Amazonian Res, Biodivers Coordinat, Lab Anim Genet, Manaus, Amazonas, Brazil; [Cerni, Felipe A.; Oliveira, Isadora S.; Ferreira, Isabela G.] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Biomol Sci, Ribeirao Preto, Brazil; [Sandri, Eliseu A.] Univ Fed Roraima, Insikiram Inst Indigenous Higher Studies, Boa Vista, Parana, Brazil; [Sachett, Jacqueline; Monteiro, Wuelton M.] Amazonas State Univ, Sch Hlth Sci, Dept Med & Nursing, Manaus, Amazonas, Brazil; [Sachett, Jacqueline] Alfredo Matta Fdn, Dept Teaching & Res, Manaus, Amazonas, Brazil; [Wen, Fan Hui] Butantan Inst, Antivenom Prod Sect, Sao Paulo, Brazil; [Sampaio, Vanderson; Sartim, Marco A.; Monteiro, Wuelton M.] Dr Heitor Vieira Dourado Trop Med Fdn, Dept Teaching & Res, Manaus, Amazonas, Brazil; [Laustsen, Andreas H.] Tech Univ Denmark, Dept Biotechnol & Biomed, Lyngby, Denmark; [Sartim, Marco A.] Amazonas Fed Univ, Inst Biol Sci, Manaus, Amazonas, Brazil	Universidade Federal de Roraima; Institute Nacional de Pesquisas da Amazonia; Universidade de Sao Paulo; Universidade Federal de Roraima; Universidade do Estado do Amazonas; Instituto Butantan; Technical University of Denmark	Pucca, MB (corresponding author), Univ Fed Roraima, Med Sch, Boa Vista, Parana, Brazil.; Monteiro, WM (corresponding author), Amazonas State Univ, Sch Hlth Sci, Dept Med & Nursing, Manaus, Amazonas, Brazil.; Monteiro, WM (corresponding author), Dr Heitor Vieira Dourado Trop Med Fdn, Dept Teaching & Res, Manaus, Amazonas, Brazil.	manu.pucca@ufrr.br; wueltonmm@gmail.com	Ferreira, Isabela Gobbo/J-7412-2015; Sérgio Bernarde, Paulo/ABG-3565-2021; Oliveira, Isadora/U-7727-2019; Sartim, Marco/X-4086-2019; Sampaio, Vanderson/M-4337-2015; Fan, Hui Wen/F-8649-2015; Sachett, Jacqueline/I-5642-2017	Ferreira, Isabela Gobbo/0000-0002-7424-7132; Sérgio Bernarde, Paulo/0000-0002-2191-7817; Oliveira, Isadora/0000-0002-2036-1191; Sartim, Marco/0000-0003-4572-3109; Sampaio, Vanderson/0000-0001-7307-8851; Fan, Hui Wen/0000-0002-8191-559X; Sachett, Jacqueline/0000-0001-5723-9977; Laustsen, Andreas Hougaard/0000-0001-6918-5574	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation) [2017/03580-9, 2017/14035-1]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, The National Council for Scientific and Technological Development, scholarship) [307184/2020-0, 309207/2020-7]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES) [001]; Fundacao de Amparo a Pesquisa do Estado do Amazonas [PAPAC 005/2019]; Hamish Ogston Foundation-Global Snakebite Initiative	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, The National Council for Scientific and Technological Development, scholarship)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao de Amparo a Pesquisa do Estado do Amazonas; Hamish Ogston Foundation-Global Snakebite Initiative	We thank Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation; scholarships to IO no. 2017/03580-9 and FC no. 2017/14035-1), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, The National Council for Scientific and Technological Development, scholarship to MP no. 307184/2020-0 and WM n. 309207/2020-7) and the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES, Finance Code 001, scholarship to IF). WM acknowledges funding support from Fundacao de Amparo a Pesquisa do Estado do Amazonas (PAPAC 005/2019, PRO-ESTADO and Posgrad calls). MP (Snakebite Roraima project coordinator) acknowledges funding support from Hamish Ogston Foundation-Global Snakebite Initiative.	Abbas A.K., 2018, CELLULAR MOL IMMUNOL; Abdelkafi-Koubaa Z, 2014, TOXICON, V89, P32, DOI 10.1016/j.toxicon.2014.06.020; Abuys A, 1987, SNAKES SURINAM 19, V31, P282; Ahmadi S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67654-7; Alencar LRV, 2016, MOL PHYLOGENET EVOL, V105, P50, DOI 10.1016/j.ympev.2016.07.029; Almeida-Santos S. M., 2002, Revista Brasileira de Reproducao Animal, V26, P109; Almeida-Santos Selma Maria, 1997, Japanese Journal of Herpetology, V17, P46; Carbajal-Marquez RA, 2020, ZOOTAXA, V4729, P451, DOI 10.11646/zootaxa.4729.4.1; AMARAL CFS, 1991, REV INST MED TROP SP, V33, P251, DOI 10.1590/S0036-46651991000400002; Amaral CFS, 1998, TOXICON, V36, P805, DOI 10.1016/S0041-0101(97)00132-3; Amora DN, 2006, TOXICON, V47, P260, DOI 10.1016/j.toxicon.2005.10.007; [Anonymous], 2007, REV PARAENSE MED, DOI DOI 10.5123/S0101-59072007000300012; Araujo W. F., 2001, Revista Brasileira de Engenharia Agricola e Ambiental, V5, P563, DOI 10.1590/S1415-43662001000300032; Asato Mauro Shosuka, 2020, Toxicon X, V8, P100061, DOI 10.1016/j.toxcx.2020.100061; Azevedo-Marques M., 2003, ANIMAIS PECONHENTOS, P108; Azevedo-Marques M.M., 2003, MEDICINA RIBEIRAO PR, V36, P480; Barros LC, 2011, J VENOM ANIM TOXINS, V17, P23, DOI 10.1590/S1678-91992011000100004; Barros LC, 2009, J TOXICOL ENV HEAL B, V12, P553, DOI 10.1080/10937400903442514; Barros VA, 2012, HERPETOL J, V22, P97; Bastos EGD, 2005, REV BRAS ZOOL, V22, P812, DOI 10.1590/S0101-81752005000300047; Baum RA, 2019, TOXICON, V163, P32, DOI 10.1016/j.toxicon.2019.03.009; Bermudez-Mendez E, 2018, TOXINS, V10, DOI 10.3390/toxins10110452; Blair C, 2016, MOL PHYLOGENET EVOL, V97, P145, DOI 10.1016/j.ympev.2015.12.020; Boldrini-Franca J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61258-x; Boldrini-Franca J, 2015, APPL MICROBIOL BIOT, V99, P9971, DOI 10.1007/s00253-015-6836-2; Boldrini-Franca J, 2010, J PROTEOMICS, V73, P1758, DOI 10.1016/j.jprot.2010.06.001; BON C, 1989, ACTA PHYSIOL PHARM L, V39, P439; Bordon KCF, 2012, BIOCHIMIE, V94, P2740, DOI 10.1016/j.biochi.2012.08.014; Braud S, 2000, BIOCHIMIE, V82, P851, DOI 10.1016/S0300-9084(00)01178-0; Bucaretchi F, 2014, CLIN TOXICOL, V52, P639, DOI 10.3109/15563650.2014.913177; Bucaretchi F, 2013, CLIN TOXICOL, V51, P505, DOI 10.3109/15563650.2013.802796; BUCARETCHI Fábio, 2002, Rev. Inst. Med. trop. S. Paulo, V44, P133, DOI 10.1590/S0036-46652002000300004; Bux Z., 2019, KAIETEUR NEWS; Calvete JJ, 2009, J PROTEOME RES, V8, P3055, DOI 10.1021/pr900249q; Campbell JA, 2004, VENOMOUS REPTILES LA, DOI [10.1086/417006, DOI 10.1086/417006]; Campos LB, 2020, TOXICON, V184, P116, DOI 10.1016/j.toxicon.2020.05.027; Choumet V, 1996, ADV EXP MED BIOL, V391, P197; Clemetson KJ, 2010, TOXICON, V56, P1236, DOI 10.1016/j.toxicon.2010.03.011; Costa CRC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082405; Costa Henrique Caldeira, 2018, Herpetologia Brasileira, V7, P11; Coutinho IJB., 2020, REV PAN-AMAZ SAUDE, V11, P1, DOI [10.5123/S2176-6223202000177, DOI 10.5123/S2176-6223202000177]; Cunha OR., 1980, B MUSEU PARAENSE EMI, P1; Cupo P, 1991, Rev Soc Bras Med Trop, V24, P87; da Cunha DB, 2018, TOXICON, V146, P1, DOI 10.1016/j.toxicon.2018.03.007; da Silva JAA, 2012, CURR MED CHEM, V19, P281; da Silva LN, 2020, J VENOM ANIM TOXINS, V26, DOI [10.1590/1678-9199-JVATITD-2020-0016, 10.1590/1678-9199-jvatitd-2020-0016]; de Carvalho LH, 2019, REV SOC BRAS MED TRO, V52, DOI 10.1590/0037-8682-0526-2018; de Langlada F.G., 1975, Journal Herpet, V9, P349, DOI 10.2307/1562936; de Oliveira DGL, 2009, ACTA BIOCH BIOPH SIN, V41, P21, DOI 10.1093/abbs/gmn003; de Oliveira IS, 2018, J VENOM ANIM TOXINS, V24, DOI 10.1186/s40409-018-0167-6; de Oliveira IS, 2019, J PROTEOMICS, V191, P153, DOI 10.1016/j.jprot.2018.02.020; Diz EBS, 2009, TOXICON, V53, P104, DOI 10.1016/j.toxicon.2008.10.021; Dos-Santos MC, 2005, TOXICON, V46, P958, DOI 10.1016/j.toxicon.2005.06.008; DOSSANTOS MC, 1993, TOXICON, V31, P1459, DOI 10.1016/0041-0101(93)90211-Z; Du XY, 2002, TOXICON, V40, P659, DOI 10.1016/S0041-0101(02)00102-2; Durban J, 2017, J PROTEOME RES, V16, P3370, DOI 10.1021/acs.jproteome.7b00414; Eble JA, 2019, TOXINS, V11, DOI 10.3390/toxins11030136; Fan HW, 2018, TOXICON, V151, P15, DOI 10.1016/j.toxicon.2018.06.070; Fan HW, 2019, REV PANAM SALUD PUBL, V43, pe92, DOI DOI 10.26633/RPSP.2019.92; Farias RES, 2016, TAXOCENOSE SERPENTES; Farrar HC, 2012, CLIN PEDIATR, V51, P945, DOI 10.1177/0009922812441660; Feitosa EL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132237; Figueroa A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161070; Fons S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.587825; Fox JW, 2008, FEBS J, V275, P3016, DOI 10.1111/j.1742-4658.2008.06466.x; Fox JW, 2013, TOXICON, V62, P75, DOI 10.1016/j.toxicon.2012.09.009; Fox JW, 2009, J PROTEOMICS, V72, P200, DOI 10.1016/j.jprot.2009.01.015; Franca SC, 2007, BIOCHEM BIOPH RES CO, V355, P302, DOI 10.1016/j.bbrc.2006.12.217; Frare BT, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/1345923; Garnelo L, 2001, Cad Saude Publica, V17, P273, DOI 10.1590/S0102-311X2001000200003; Cavalcante WLG, 2015, TOXICON, V96, P46, DOI 10.1016/j.toxicon.2015.01.006; Georgieva D, 2010, J PROTEOME RES, V9, P2302, DOI 10.1021/pr901042p; Gimenez BT, 2020, J VENOM ANIM TOXINS, V26, DOI [10.1590/1678-9199-JVATITD-2020-0076, 10.1590/1678-9199-jvatitd-2020-0076]; Graham RLJ, 2005, BIOCHEM BIOPH RES CO, V338, P1587, DOI 10.1016/j.bbrc.2005.10.130; Guo CM, 2012, TOXICON, V60, P302, DOI 10.1016/j.toxicon.2012.05.001; Gutierrez JM, 2000, BIOCHIMIE, V82, P841, DOI 10.1016/S0300-9084(00)01163-9; Gutierrez JM, 2020, TOXINS, V12, DOI 10.3390/toxins12020131; Gutierrez JM, 2016, TOXINS, V8, DOI 10.3390/toxins8040093; Harris HS., 1978, MEMORIAS I BUTANTAN, V40, P305; HAWGOOD BJ, 1992, TOXICON, V30, P573, DOI 10.1016/0041-0101(92)90851-U; HENDON RA, 1971, P NATL ACAD SCI USA, V68, P1560, DOI 10.1073/pnas.68.7.1560; Hernandez M, 2007, EXP TOXICOL PATHOL, V59, P129, DOI 10.1016/j.etp.2007.04.002; Herrera C, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003731; HOGE A R, 1972, Memorias do Instituto Butantan (Sao Paulo), V36, P109; Hoge A.R., 1966, MEM I BUTANTAN, V32, P109; Horton Stephen, 2013, Methods Mol Biol, V992, P155, DOI 10.1007/978-1-62703-339-8_12; Hoyos MA, 2016, BIOTA NEOTROP, V16, DOI 10.1590/1676-0611-BN-2014-0027; HUTTON RA, 1993, BLOOD REV, V7, P176, DOI 10.1016/0268-960X(93)90004-N; Izidoro LFM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/196754; Vargas LJ, 2013, TOXICON, V64, P1, DOI 10.1016/j.toxicon.2012.11.027; JOHNSON EK, 1987, TOXICON, V25, P1169, DOI 10.1016/0041-0101(87)90135-8; JORGE MT, 1992, REV INST MED TROP SP, V34, P347, DOI 10.1590/S0036-46651992000400013; Kini RM, 2011, J THROMB HAEMOST, V9, P195, DOI 10.1111/j.1538-7836.2011.04279.x; Kini RM, 2005, PATHOPHYSIOL HAEMO T, V34, P200, DOI 10.1159/000092424; Kini RM, 2018, TOXINS, V10, DOI 10.3390/toxins10120534; Kini RM, 2003, TOXICON, V42, P827, DOI 10.1016/j.toxicon.2003.11.002; Knudsen C, 2019, TOXICON, V167, P67, DOI 10.1016/j.toxicon.2019.06.005; Krifi M. N., 1999, Journal of Venomous Animals and Toxins, V5, P128; Lafaye P, 1997, IMMUNOTECHNOLOGY, V3, P117, DOI 10.1016/S1380-2933(97)00068-7; LANDUCCI ECT, 1994, TOXICON, V32, P217, DOI 10.1016/0041-0101(94)90111-2; Laustsen A. H., 2016, RECOMBINANT ANTIVENO; Laustsen AH, 2018, NEW BIOTECHNOL, V45, P19, DOI 10.1016/j.nbt.2017.05.005; Laustsen AH, 2018, TOXICON, V146, P151, DOI 10.1016/j.toxicon.2018.03.004; Laustsen AH, 2017, PEERJ, V5, DOI 10.7717/peerj.2924; Laustsen AH, 2015, TOXICON, V104, P43, DOI 10.1016/j.toxicon.2015.07.334; Lima SD, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006700; Lomonte B, 2017, J VENOM ANIM TOXINS, V23, DOI 10.1186/s40409-017-0117-8; Lomonte B, 2011, ACTA CHIM SLOV, V58, P647; Lourenco A, 2013, TOXICON, V69, P75, DOI 10.1016/j.toxicon.2013.01.006; MADSEN T, 1993, OECOLOGIA, V94, P488, DOI 10.1007/BF00566963; Malaque CMS, 2019, CLIN TOXICOL, V57, P213, DOI 10.1080/15563650.2018.1510129; Martins AMC, 2004, BRAZ J MED BIOL RES, V37, P1525, DOI 10.1590/S0100-879X2004001000012; Martins AMC, 2003, PHARMACOL TOXICOL, V92, P14, DOI 10.1034/j.1600-0773.2003.920103.x; Martins AMC, 2002, TOXICON, V40, P1165, DOI 10.1016/S0041-0101(02)00119-8; Martins AMC, 1998, TOXICON, V36, P1441, DOI 10.1016/S0041-0101(98)00082-8; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; Medeiros JM, 2020, REPORTS-BASEL, V3, DOI 10.3390/reports3020009; Melani RD., 2015, EUPA OPEN PROTEOMICS, V8, P144, DOI [10.1016/j.euprot.2015.05.006, DOI 10.1016/J.EUPROT.2015.05.006]; Melendez-Martinez D, 2020, MOLECULES, V25, DOI 10.3390/molecules25153401; Mendonca-da-Silva I, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006068; Meng JX, 1995, BIOCHEM PHARMACOL, V50, P1969; Ministerio da Saude, 2020, DISTR SAN ESP IND LE; Ministerio da Saude, 2001, MAN DIAGN E TRAT AC; Ministerio da Saude, 2019, GUIA VIG SAUD REC EL, V3rd; Monteiro HSA, 2001, BRAZ J MED BIOL RES, V34, P1347, DOI 10.1590/S0100-879X2001001000017; Monteiro WM, 2020, TOXINS, V12, DOI 10.3390/toxins12120772; Morita T, 2005, TOXICON, V45, P1099, DOI 10.1016/j.toxicon.2005.02.021; Nascimento S P, 2000, Cad Saude Publica, V16, P271, DOI 10.1590/S0102-311X2000000100031; Nishioka S de A, 2000, Rev Soc Bras Med Trop, V33, P401; O'Shea M., 1998, REPTILIAN HERPETOFAU, P231; Oguiura N, 2005, TOXICON, V46, P363, DOI 10.1016/j.toxicon.2005.06.009; Olaoba Olamide Tosin, 2020, Toxicon X, V7, P100052, DOI 10.1016/j.toxcx.2020.100052; Oliveira JG, 2009, BASIC CLIN PHARMACOL, V105, P84, DOI 10.1111/j.1742-7843.2008.00322.x; Pardal PPO., 2003, REV PARA MED, V17, P27; Pessenda G, 2016, TOXICON, V112, P59, DOI 10.1016/j.toxicon.2016.01.062; Petejova N, 2014, CRIT CARE, V18, DOI 10.1186/cc13897; Peters J. A, 1970, Bull. U.S. natn. Mus., VNo. 297, P1; Pinho FMO, 2005, KIDNEY INT, V67, P659, DOI 10.1111/j.1523-1755.2005.67122.x; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Ponce-Soto LA, 2007, PROTEIN J, V26, P39, DOI 10.1007/s10930-006-9042-3; Pucca MB, 2020, J VENOM ANIM TOXINS, V26, DOI [10.1590/1678-9199-JVATITD-2020-0083, 10.1590/1678-9199-jvatitd-2020-0083]; Pucca MB, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00611; Pucca MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01598; Pucca MB, 2014, J IMMUNOTOXICOL, V11, P133, DOI 10.3109/1547691X.2013.809175; Pyron RA, 2013, BMC EVOL BIOL, V13, DOI 10.1186/1471-2148-13-93; Radis-Baptista G, 2006, CELL BIOCHEM BIOPHYS, V44, P412, DOI 10.1385/CBB:44:3:412; Santos HLR, 2019, ACTA TROP, V191, P69, DOI 10.1016/j.actatropica.2018.12.030; Resiere D, 2020, CURR TROP MED REP, V7, P48, DOI 10.1007/s40475-020-00203-4; Ribeiro L A, 1998, Rev Assoc Med Bras (1992), V44, P312, DOI 10.1590/S0104-42301998000400010; Rocha A., 2019, HERPETOZOA, V31, P219; Rocha AM., 2017, DIETA COMPORTAMENTO; Rodrigues RS, 2009, BIOCHIMIE, V91, P490, DOI 10.1016/j.biochi.2008.12.004; Rubio M, 1988, RATTLESNAKE PORTRAIT; SALOMAO MD, 1995, STUD NEOTROP FAUNA E, V30, P101, DOI 10.1080/01650529509360946; Sampaio SC, 2010, TOXICON, V55, P1045, DOI 10.1016/j.toxicon.2010.01.011; Samy RP, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-100; Sano-Martins IS, 2001, QJM-INT J MED, V94, P551, DOI 10.1093/qjmed/94.10.551; Sant'Anna SS, 2007, STUD NEOTROP FAUNA E, V42, P169, DOI 10.1080/01650520601148313; Santos S.M.A., 1990, AN ACAD BRAS CIENC, V62, P418; Saravia P, 2002, REV BIOL TROP, V50, P337; Sartim MA, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10050794; Sartim MA, 2018, J VENOM ANIM TOXINS, V24, DOI 10.1186/s40409-018-0178-3; Sawaya Ricardo Jannini, 2008, Biota Neotrop., V8, P0, DOI 10.1590/S1676-06032008000200015; SAZIMA I, 1988, Memorias do Instituto Butantan (Sao Paulo), V50, P83; SCHENBERG S, 1959, SCIENCE, V129, P1361, DOI 10.1126/science.129.3359.1361; Segura A, 2017, J PROTEOMICS, V158, P62, DOI 10.1016/j.jprot.2017.02.015; Siltari A, 2016, PEPTIDES, V85, P46, DOI 10.1016/j.peptides.2016.09.001; Silva LC, 2018, ACTA TROP, V177, P66, DOI 10.1016/j.actatropica.2017.09.001; SILVEIRA PVP, 1992, T ROY SOC TROP MED H, V86, P562, DOI 10.1016/0035-9203(92)90114-R; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Sousa IDL, 2019, INT J BIOL MACROMOL, V131, P127, DOI 10.1016/j.ijbiomac.2019.03.059; Souza AD, 2018, TOXICON, V145, P15, DOI 10.1016/j.toxicon.2018.02.041; Squaiella-Baptistao CC, 2018, TOXICON, V150, P86, DOI 10.1016/j.toxicon.2018.05.008; Tasima LJ, 2020, TOXICON, V185, P26, DOI 10.1016/j.toxicon.2020.07.001; Teixeira TL, 2016, TOXICON, V119, P203, DOI 10.1016/j.toxicon.2016.06.009; Teixeira-Araujo R, 2017, J VENOM ANIM TOXINS, V23, DOI 10.1186/s40409-017-0118-7; Titus James K, 2017, J Venom Res, V8, P19; Tokarnia CH, 2014, PESQUI VET BRASIL, V34, P301, DOI 10.1590/S0100-736X2014000400001; Toyama MH, 2006, TOXICON, V47, P47, DOI 10.1016/j.toxicon.2005.09.008; Tozetti AM, 2008, J NAT HIST, V42, P1435, DOI 10.1080/00222930802007823; Tozetti AM, 2009, HERPETOL J, V19, P201; Vaiyapuri S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009687; Magalhaes SFV, 2020, T ROY SOC TROP MED H, V114, P642, DOI 10.1093/trstmh/traa005; VANEYK HG, 1967, CLIN CHIM ACTA, V16, P429, DOI 10.1016/0009-8981(67)90309-9; Vanzolini PE, 2002, AN ACAD BRAS CIENC, V74, P37, DOI 10.1590/S0001-37652002000100005; Vanzolini PE, 1980, REPTEIS CAATINGAS; Viana PF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69349-5; Wang JH, 2014, MOL MED REP, V10, P3009, DOI 10.3892/mmr.2014.2620; Wiezel GA, 2019, BIOCHIMIE, V163, P33, DOI 10.1016/j.biochi.2019.05.009; Wiezel GA, 2018, J PROTEOME RES, V17, P3941, DOI 10.1021/acs.jproteome.8b00610; Williams HF, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007041; Wuster W, 2005, MOL ECOL, V14, P1095, DOI 10.1111/j.1365-294X.2005.02471.x; de Carvalho AEZ, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/2745286	193	1	1	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 8	2021	12								659515	10.3389/fimmu.2021.659515	http://dx.doi.org/10.3389/fimmu.2021.659515			22	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SW1GO	34168642	Green Published, gold			2022-12-18	WOS:000664266100001
J	Quintarelli, C; Camera, A; Ciccone, R; Alessi, I; Del Bufalo, F; Carai, A; Del Baldo, G; Mastronuzzi, A; De Angelis, B				Quintarelli, Concetta; Camera, Antonio; Ciccone, Roselia; Alessi, Iside; Del Bufalo, Francesca; Carai, Andrea; Del Baldo, Giada; Mastronuzzi, Angela; De Angelis, Biagio			Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?	FRONTIERS IN IMMUNOLOGY			English	Review						CNS; brain tumor; immunotherapy; chimeric antigen receptor; T cell receptor; oncolytic virotherapy; vaccination; immunocheck point inhibitors	CAR-T-CELLS; HUMAN GLIOBLASTOMA-MULTIFORME; ANTIBODY-BASED IMMUNOTHERAPY; PHASE-II TRIAL; RECURRENT GLIOBLASTOMA; HUMAN CYTOMEGALOVIRUS; MACROPHAGE POLARIZATION; ADOPTIVE IMMUNOTHERAPY; ANTITUMOR EFFICACY; PERIPHERAL-BLOOD	Although there are several immunotherapy approaches for the treatment of Central Nervous System (CNS) tumors under evaluation, currently none of these approaches have received approval from the regulatory agencies. CNS tumors, especially glioblastomas, are tumors characterized by highly immunosuppressive tumor microenvironment, limiting the possibility of effectively eliciting an immune response. Moreover, the peculiar anatomic location of these tumors poses relevant challenges in terms of safety, since uncontrolled hyper inflammation could lead to cerebral edema and cranial hypertension. The most promising strategies of immunotherapy in neuro-oncology consist of the use of autologous T cells redirected against tumor cells through chimeric antigen receptor (CAR) constructs or genetically modified T-cell receptors. Trials based on native or genetically engineered oncolytic viruses and on vaccination with tumor-associated antigen peptides are also under evaluation. Despite some sporadic complete remissions achieved in clinical trials, the outcome of patients with CNS tumors treated with different immunotherapeutic approaches remains poor. Based on the lessons learned from these unsatisfactory experiences, novel immune-therapy approaches aimed at overcoming the profound immunosuppressive microenvironment of these diseases are bringing new hope to reach the cure for CNS tumors.	[Quintarelli, Concetta; Camera, Antonio; Ciccone, Roselia; Alessi, Iside; Del Bufalo, Francesca; Del Baldo, Giada; Mastronuzzi, Angela; De Angelis, Biagio] Bambino Gesu Pediat Hosp, IRCCS, Dept Oncohematol Cell & Gene Therapy, Rome, Italy; [Quintarelli, Concetta] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy; [Carai, Andrea] IRCCS Bambino Gesu Childrens Hosp, Dept Neurol & Psychiat Sci, Neurosurg Unit, Rome, Italy	IRCCS Bambino Gesu; University of Naples Federico II; IRCCS Bambino Gesu	Quintarelli, C (corresponding author), Bambino Gesu Pediat Hosp, IRCCS, Dept Oncohematol Cell & Gene Therapy, Rome, Italy.; Quintarelli, C (corresponding author), Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy.	concetta.quintarelli@opbg.net	Camera, Antonio/AAX-4579-2021; DE ANGELIS, BIAGIO/K-4441-2016; Ciccone, Roselia/AAA-6045-2020	Camera, Antonio/0000-0003-3002-3054; DE ANGELIS, BIAGIO/0000-0002-7938-737X; Ciccone, Roselia/0000-0003-1495-1264	Italian Health Ministry [GR-2013-02359212, GR-2016-02364546, CAR T RCR-2019-23669115]; AIRC; Ricerca Corrente (CQ, BDA); "Raffaele Passarelli" Onlus; "Il laboratorio di Chiara," "Fondazione Heal," "IRENE" Onlus; Oscar's Angels Italia; Martina e la sua luna	Italian Health Ministry(Ministry of Health, Italy); AIRC(Fondazione AIRC per la ricerca sul cancro); Ricerca Corrente (CQ, BDA); "Raffaele Passarelli" Onlus; "Il laboratorio di Chiara," "Fondazione Heal," "IRENE" Onlus; Oscar's Angels Italia; Martina e la sua luna	We would like to thank all agencies supporting our work on immunotherapy, in particular the Italian Health Ministry [for GR-2013-02359212, (CQ), GR-2016-02364546-(BDA), CAR T RCR-2019-23669115]; AIRC; Ricerca Corrente (CQ, BDA); All the charities that support our research and clinical translation, including "Raffaele Passarelli" Onlus, "Il laboratorio di Chiara," "Fondazione Heal," "IRENE" Onlus, "Oscar's Angels Italia," and "Martina e la sua luna."	Abbasi A, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-019-0838-y; Abramson JS, 2017, NEW ENGL J MED, V377, P783, DOI 10.1056/NEJMc1704610; Ahmed N, 2017, JAMA ONCOL, V3, P1094, DOI 10.1001/jamaoncol.2017.0184; Ahmed N, 2010, CLIN CANCER RES, V16, P474, DOI 10.1158/1078-0432.CCR-09-1322; AlHarbi M, 2018, ONCOLOGIST, V23, P1401, DOI 10.1634/theoncologist.2018-0163; Alizadeh D, 2010, CLIN CANCER RES, V16, P3399, DOI 10.1158/1078-0432.CCR-09-3087; Antonios JP, 2017, NEURO-ONCOLOGY, V19, P796, DOI 10.1093/neuonc/now287; Bernstock JD, 2020, HUM GENE THER, V31, P1132, DOI 10.1089/hum.2020.101; Beug ST, 2018, NAT COMMUN, V9, DOI 10.1038/ncomms16231; Bielamowicz K, 2018, NEURO-ONCOLOGY, V20, P506, DOI 10.1093/neuonc/nox182; Bloch O, 2014, NEURO-ONCOLOGY, V16, P274, DOI 10.1093/neuonc/not203; Boon K, 2003, ONCOGENE, V22, P7687, DOI 10.1038/sj.onc.1207043; Bouffet E, 2016, J CLIN ONCOL, V34, P2206, DOI 10.1200/JCO.2016.66.6552; Brown CE, 2018, MOL THER, V26, P31, DOI 10.1016/j.ymthe.2017.10.002; Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497; Brown CE, 2015, CLIN CANCER RES, V21, P4062, DOI 10.1158/1078-0432.CCR-15-0428; Brown CE, 2012, CLIN CANCER RES, V18, P2199, DOI 10.1158/1078-0432.CCR-11-1669; Brown NF, 2018, BRIT J CANCER, V119, P1171, DOI 10.1038/s41416-018-0258-8; Callahan MK, 2019, CANCER CELL, V36, P215, DOI 10.1016/j.ccell.2019.08.009; Campillo-Davo D, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071720; Caruso H, 2018, NEURO-ONCOLOGY, V20, P1003, DOI 10.1093/neuonc/noy045; Castriconi R, 2004, P NATL ACAD SCI USA, V101, P12640, DOI 10.1073/pnas.0405025101; Castriconi R, 2007, EUR J IMMUNOL, V37, P3190, DOI 10.1002/eji.200737546; Chandramohan V, 2013, FUTURE ONCOL, V9, P977, DOI [10.2217/FON.13.47, 10.2217/fon.13.47]; Chapuis AG, 2019, NAT MED, V25, P1064, DOI 10.1038/s41591-019-0472-9; Chheda ZS, 2018, J EXP MED, V215, P141, DOI 10.1084/jem.20171046; Choi BD, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0806-7; Choi BD, 2019, NAT BIOTECHNOL, V37, P1049, DOI 10.1038/s41587-019-0192-1; Choi BD, 2019, CLIN CANCER RES, V25, P2042, DOI 10.1158/1078-0432.CCR-18-1625; Cobbs CS, 2002, CANCER RES, V62, P3347; Cripe TP, 2015, MOL THER-ONCOLYTICS, V2, DOI 10.1038/mto.2015.15; Cuccarini V, 2019, J CLIN MED, V8, DOI 10.3390/jcm8112007; De Smet C, 2010, EPIGENETICS-US, V5; Debinski W, 1995, CLIN CANCER RES, V1, P1253; Dersh D, 2021, IMMUNITY, V54, P116, DOI 10.1016/j.immuni.2020.11.002; Dersh D, 2020, NAT REV IMMUNOL, V20, P644, DOI 10.1038/s41577-020-00445-3; Desjardins A, 2018, NEW ENGL J MED, V379, P150, DOI 10.1056/NEJMoa1716435; Dobrenkov K, 2016, PEDIATR BLOOD CANCER, V63, P1780, DOI 10.1002/pbc.26097; Khuong-Quang DA, 2012, ACTA NEUROPATHOL, V124, P439, DOI 10.1007/s00401-012-0998-0; Donovan LK, 2020, NAT MED, V26, P720, DOI 10.1038/s41591-020-0827-2; Dranoff G, 2002, IMMUNOL REV, V188, P147, DOI 10.1034/j.1600-065X.2002.18813.x; Engelhardt B, 2016, ACTA NEUROPATHOL, V132, P317, DOI 10.1007/s00401-016-1606-5; Eoli M, 2019, NEURO-ONCOL ADV, V1, DOI 10.1093/noajnl/vdz022; Erel-Akbaba G, 2019, ACS NANO, V13, P4028, DOI 10.1021/acsnano.8b08177; Everson RG, 2016, NEURO-ONCOLOGY, V18, P368, DOI 10.1093/neuonc/nov153; Feldkamp MM, 1999, NEUROSURGERY, V45, P1442, DOI 10.1097/00006123-199912000-00034; Fernandez L, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00094; Filley AC, 2017, ONCOTARGET, V8, P91779, DOI 10.18632/oncotarget.21586; Flores CT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06182-5; Foster H, 2019, NEURO-ONCOL ADV, V1, DOI 10.1093/noajnl/vdz020; Fournier C, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1363139; Friese MA, 2004, CANCER RES, V64, P7596, DOI 10.1158/0008-5472.CAN-04-1627; Friese MA, 2003, CANCER RES, V63, P8996; Galstyan A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11719-3; Gao J, 2017, CANCER SCI, V108, P1934, DOI 10.1111/cas.13324; Ge HT, 2017, INT J CANCER, V141, P1434, DOI 10.1002/ijc.30830; Geletneky K, 2017, MOL THER, V25, P2620, DOI 10.1016/j.ymthe.2017.08.016; Geletneky K, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-99; Ghazi A, 2012, J IMMUNOTHER, V35, P159, DOI 10.1097/CJI.0b013e318247642f; Goff SL, 2019, J IMMUNOTHER, V42, P126, DOI 10.1097/CJI.0000000000000260; Golubovskaya V, 2016, CANCERS, V8, DOI 10.3390/cancers8030036; Guery T, 2015, CANCER MED-US, V4, P1879, DOI 10.1002/cam4.522; Gularyan SK, 2020, MOL CELL PROTEOMICS, V19, P960, DOI 10.1074/mcp.RA120.001986; Hegde M, 2016, J CLIN INVEST, V126, P3036, DOI 10.1172/JCI83416; Heimberger AB, 2011, NEURO-ONCOLOGY, V13, P3, DOI 10.1093/neuonc/noq169; Held-Feindt J, 2002, INT J CANCER, V98, P352, DOI 10.1002/ijc.10207; Hennequin C, 2013, INT J RADIAT ONCOL, V86, P860, DOI 10.1016/j.ijrobp.2013.03.021; Hinrichs CS, 2014, IMMUNOL REV, V257, P56, DOI 10.1111/imr.12132; Hussain SF, 2006, NEURO-ONCOLOGY, V8, P261, DOI 10.1215/15228517-2006-008; Ishihara M, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07098-4; Ishikawa E, 2004, ANTICANCER RES, V24, P1861; Ishikawa E, 2014, J NEUROSURG, V121, P543, DOI 10.3171/2014.5.JNS132392; Jacobs J, 2015, PHARMACOL THERAPEUT, V155, P1, DOI 10.1016/j.pharmthera.2015.07.007; Jin LC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11869-4; Jin LC, 2018, NEURO-ONCOLOGY, V20, P55, DOI 10.1093/neuonc/nox116; Jones C, 2014, NAT REV CANCER, V14, P651, DOI 10.1038/nrc3811; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kaverina NV, 2018, ONCOGENE, V37, P6069, DOI 10.1038/s41388-018-0395-9; Keskin DB, 2019, NATURE, V565, P234, DOI 10.1038/s41586-018-0792-9; Kipnis J, 2016, SCIENCE, V353, P766, DOI 10.1126/science.aag2638; Kirkin AF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03217-9; Kmiecik J, 2014, J NEURO-ONCOL, V116, P1, DOI 10.1007/s11060-013-1265-5; Kolter Thomas, 2012, ISRN Biochem, V2012, P506160, DOI 10.5402/2012/506160; Kushner BH, 2018, JAMA ONCOL, V4, P1729, DOI 10.1001/jamaoncol.2018.4005; Ladenstein R, 2018, LANCET ONCOL, V19, P1617, DOI 10.1016/S1470-2045(18)30578-3; Lang FF, 2018, J CLIN ONCOL, V36, P1419, DOI 10.1200/JCO.2017.75.8219; Lau SK, 2005, MODERN PATHOL, V18, P838, DOI 10.1038/modpathol.3800352; Leber MF, 2011, MOL THER, V19, P1097, DOI 10.1038/mt.2011.55; Li Z, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-17; Liddelow SA, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00032; Litak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215347; Liu ZJ, 2018, CANCER IMMUNOL IMMUN, V67, P237, DOI 10.1007/s00262-017-2066-z; Louis CU, 2011, BLOOD, V118, P6050, DOI 10.1182/blood-2011-05-354449; Lucas KG, 2011, J NEURO-ONCOL, V103, P231, DOI 10.1007/s11060-010-0383-6; Lyon JG, 2017, ADV DRUG DELIVER REV, V114, P19, DOI 10.1016/j.addr.2017.06.006; Maachani UB, 2020, TRANSL ONCOL, V13, P365, DOI 10.1016/j.tranon.2019.11.006; Majzner RG, 2019, CLIN CANCER RES, V25, P2560, DOI 10.1158/1078-0432.CCR-18-0432; Mansour AM, 2018, BMC UROL, V18, DOI 10.1186/s12894-018-0413-9; Markert JM, 2014, MOL THER, V22, P1048, DOI 10.1038/mt.2014.22; Markert JM, 2009, MOL THER, V17, P199, DOI 10.1038/mt.2008.228; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; McGranahan T, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0619-4; Menard S, 2001, ANN ONCOL, V12, P15, DOI 10.1023/A:1011151505425; Meric-Bernstam F, 2006, CLIN CANCER RES, V12, P6326, DOI 10.1158/1078-0432.CCR-06-1732; Miller MA, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal0225; Mitchell DA, 2008, NEURO-ONCOLOGY, V10, P10, DOI 10.1215/15228517-2007-035; Mitsuya K, 2020, ANTICANCER RES, V40, P6473, DOI 10.21873/anticanres.14669; Mohme M, 2018, CLIN CANCER RES, V24, P4187, DOI 10.1158/1078-0432.CCR-17-2617; Morganti S, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1148; Mount CW, 2018, NAT MED, V24, P572, DOI 10.1038/s41591-018-0006-x; Murakami T, 2018, ANTICANCER RES, V38, P5049, DOI 10.21873/anticanres.12824; Nakazawa T, 2020, ANTICANCER RES, V40, P3231, DOI 10.21873/anticanres.14304; Nakazawa T, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040998; Natsume A, 2008, INT J CANCER, V122, P2542, DOI 10.1002/ijc.23407; Naucler Cecilia Soderberg, 2019, Oncotarget, V10, P4333, DOI 10.18632/oncotarget.27016; Nazha B, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01000; Niklasson M, 2019, J PATHOL, V249, P295, DOI 10.1002/path.5317; O'Rourke DM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaa0984; Oba T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19192-z; Omuro A, 2018, NEURO-ONCOLOGY, V20, P674, DOI 10.1093/neuonc/nox208; Orlando D, 2018, CANCER RES, V78, P3337, DOI 10.1158/0008-5472.CAN-17-3140; Pardridge WM, 2012, J CEREBR BLOOD F MET, V32, P1959, DOI 10.1038/jcbfm.2012.126; Pearson JRD, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.40; Pellegatta S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1412901; Pellegatta S, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao2731; Pfirschke C, 2017, CANCER CELL, V31, P614, DOI 10.1016/j.ccell.2017.04.007; Pohl-Guimaraes F, 2019, MOL THER, V27, P837, DOI 10.1016/j.ymthe.2018.10.007; Pollack IF, 2019, J NEUROSURG-PEDIATR, V23, P261, DOI 10.3171/2018.10.PEDS18377; Post DE, 2007, CANCER RES, V67, P6872, DOI 10.1158/0008-5472.CAN-06-3244; Powell AB, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2055-4; Price RL, 2013, CANCER RES, V73, P3441, DOI 10.1158/0008-5472.CAN-12-3846; Prins RM, 2008, NEW ENGL J MED, V359, P539, DOI 10.1056/NEJMc0804818; Pule MA, 2008, NAT MED, V14, P1264, DOI 10.1038/nm.1882; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Quattrocchi KB, 1999, J NEURO-ONCOL, V45, P141, DOI 10.1023/A:1006293606710; Quintarelli C, 2008, BLOOD, V112, P1876, DOI 10.1182/blood-2008-04-150045; Quintarelli C, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1433518; Rapoport AP, 2015, NAT MED, V21, P914, DOI 10.1038/nm.3910; Rapp M, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2659-7; Rath JA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061485; Ravanpay Ali C, 2019, Oncotarget, V10, P7080, DOI 10.18632/oncotarget.27389; Razavi SM, 2016, FRONT SURG, V3, DOI 10.3389/fsurg.2016.00011; Rius-Rocabert S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207604; Rivera Z, 2012, CLIN CANCER RES, V18, P5352, DOI 10.1158/1078-0432.CCR-12-0628; Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537; Roth TJ, 2007, CANCER RES, V67, P7893, DOI 10.1158/0008-5472.CAN-07-1068; Rubinstein JD, 2020, BIOL BLOOD MARROW TR, V26, pE280, DOI 10.1016/j.bbmt.2020.07.036; Rutkowska A, 2019, J ONCOL, V2019, DOI 10.1155/2019/1092587; Sabatier J, 2005, BRIT J CANCER, V92, P747, DOI 10.1038/sj.bjc.6602339; Saha D, 2017, CANCER CELL, V32, P253, DOI 10.1016/j.ccell.2017.07.006; Saikali S, 2007, J NEURO-ONCOL, V81, P139, DOI 10.1007/s11060-006-9220-3; Sattiraju A, 2017, ONCOTARGET, V8, P42997, DOI 10.18632/oncotarget.17792; Schlager C, 2016, NATURE, V530, P349, DOI 10.1038/nature16939; Schuessler A, 2014, CANCER RES, V74, P3466, DOI 10.1158/0008-5472.CAN-14-0296; SCHULZ G, 1984, CANCER RES, V44, P5914; Sevenich L, 2014, NAT CELL BIOL, V16, P876, DOI 10.1038/ncb3011; Sharma P, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113326; Shum T, 2017, CANCER DISCOV, V7, P1238, DOI 10.1158/2159-8290.CD-17-0538; Sibilia M, 2007, DIFFERENTIATION, V75, P770, DOI 10.1111/j.1432-0436.2007.00238.x; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Sivori S, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101702; Song YJ, 2020, CELL IMMUNOL, V352, DOI 10.1016/j.cellimm.2020.104112; Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003; Spranger S, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-3; Stanimirovic DB, 2018, BIODRUGS, V32, P547, DOI 10.1007/s40259-018-0309-y; Tahtinen S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131242; Tang BT, 2020, CLIN CANCER RES, V26, P2216, DOI 10.1158/1078-0432.CCR-18-3626; Tawbi HA, 2018, NEW ENGL J MED, V379, P722, DOI 10.1056/NEJMoa1805453; Tejada S, 2018, NEUROSURGERY, V83, P1050, DOI 10.1093/neuros/nyx507; Tekle C, 2012, INT J CANCER, V130, P2282, DOI 10.1002/ijc.26238; Theruvath J, 2020, NAT MED, V26, P712, DOI 10.1038/s41591-020-0821-8; Touat M, 2020, NATURE, V580, P517, DOI 10.1038/s41586-020-2209-9; Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279; Tsidulko AY., 2017, TUMOR BIOL, V39, DOI [DOI 10.1177/1010428317724282, 10.1177/1010428317724282]; TSUCHIDA T, 1987, J NATL CANCER I, V78, P45, DOI 10.1093/jnci/78.1.45; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vora P, 2020, CELL STEM CELL, V26, P832, DOI 10.1016/j.stem.2020.04.008; Vranic S, 2021, BOSNIAN J BASIC MED, V21, P1, DOI 10.17305/bjbms.2020.4908; Vulcani-Freitas TM, 2011, ARQ NEURO-PSIQUIAT, V69, P9, DOI 10.1590/S0004-282X2011000100003; Wadelin F, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-226; Wainwright DA, 2014, CLIN CANCER RES, V20, P5290, DOI 10.1158/1078-0432.CCR-14-0514; Wang DR, 2021, CANCER DISCOV, V11, P1192, DOI 10.1158/2159-8290.CD-20-1243; Wang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070689; Wang X, 2010, CURR MOL MED, V10, P419, DOI 10.2174/156652410791316977; Wang XH, 2010, JNCI-J NATL CANCER I, V102, P1496, DOI 10.1093/jnci/djq343; Wang XL, 2011, BLOOD, V117, P1888, DOI 10.1182/blood-2010-10-310599; Wang ZL, 2018, CANCER SCI, V109, P2697, DOI 10.1111/cas.13744; Waters AM, 2017, HUM GENE THER CL DEV, V28, P7, DOI 10.1089/humc.2017.002; Weathers SP, 2020, CLIN CANCER RES, V26, P3565, DOI 10.1158/1078-0432.CCR-20-0176; Weller M, 2017, LANCET ONCOL, V18, P1373, DOI 10.1016/S1470-2045(17)30517-X; Wen PY, 2019, CLIN CANCER RES, V25, P5799, DOI 10.1158/1078-0432.CCR-19-0261; Wildes TJ, 2018, CLIN CANCER RES, V24, P3955, DOI 10.1158/1078-0432.CCR-17-3061; Winograd EK, 2016, IMMUNOTHERAPY-UK, V8, P1293, DOI 10.2217/imt-2016-0059; Wollmann G, 2012, CANCER J, V18, P69, DOI 10.1097/PPO.0b013e31824671c9; Woroniecka K, 2018, CLIN CANCER RES, V24, P4175, DOI 10.1158/1078-0432.CCR-17-1846; Wu L, 2020, CELL MOL IMMUNOL, V17, P600, DOI 10.1038/s41423-020-0470-3; Xu YH, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12770; Yang MJ, 2020, THERANOSTICS, V10, P7622, DOI 10.7150/thno.43991; Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3; Zeng J, 2013, INT J RADIAT ONCOL, V86, P343, DOI 10.1016/j.ijrobp.2012.12.025; Zhang CC, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv375; Zhang JG, 2007, CLIN CANCER RES, V13, P566, DOI 10.1158/1078-0432.CCR-06-1576; Zhu HF, 2020, PATHOL ONCOL RES, V26, P2135, DOI 10.1007/s12253-019-00759-1; Zhu ZY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.588552	205	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 7	2021	12								634031	10.3389/fimmu.2021.634031	http://dx.doi.org/10.3389/fimmu.2021.634031			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SV5AL	34163465	gold, Green Published			2022-12-18	WOS:000663833100001
J	Benhadou, F; Dirix, V; Domont, F; Willaert, F; Van Praet, A; Locht, C; Mascart, F; Corbiere, V				Benhadou, Farida; Dirix, Violette; Domont, Fanny; Willaert, Fabienne; Van Praet, Anne; Locht, Camille; Mascart, Francoise; Corbiere, Veronique			Tuberculosis Risk Stratification of Psoriatic Patients Before Anti-TNF-alpha Treatment	FRONTIERS IN IMMUNOLOGY			English	Article						psoriasis; Tumor necrosis factor-alpha inhibitors; latent tuberculosis infection; tuberculin skin tests; interferon-gamma-release assays; QuantiFERON; heparin-binding haemagglutinin	HEPARIN-BINDING HEMAGGLUTININ; QUANTIFERON-TB GOLD; CELL RESPONSES; RELEASE ASSAY; INFECTION; EFFICACY; MODERATE; THERAPY; GAMMA; INDIVIDUALS	Psoriasis is a skin inflammatory condition for which significant progress has been made in its management by the use of targeted biological drugs. Detection of latent M. tuberculosis infection (LTBI) is mandatory before starting biotherapy that is associated with reactivation risk. Together with evaluation of TB risk factors and chest radiographs, tuberculin skin tests (TST) and/or blood interferon-gamma-release assays (IGRA), like the QuantiFERON (QFT), are usually performed to diagnose M. tuberculosis infection. Using this approach, 14/49 psoriatic patients prospectively included in this study were identified as LTBI (14 TST+, induration size >= 10mm, 8 QFT(+)), and 7/14 received prophylactic anti-TB treatment, the other 7 reporting past-treatment. As the specificity and sensitivity of these tests were challenged, we evaluated the added value of an IGRA in response to a mycobacterial antigen associated with latency, the heparin-binding haemagglutinin (HBHA). All but one TST+ patient had a positive HBHA-IGRA, indicating higher sensitivity than the QFT. The HBHA-IGRA was also positive for 12/35 TST(-)QFT(-) patients. Measurement for 15 psoriatic patients (12 with HBHA-IGRA(+)) of 8 chemokines in addition to IFN-gamma revealed a broad array of HBHA-induced chemokines for TST(+)QFT(-) and TST(-)QFT(-) patients, compared to a more restricted pattern for TST(+)QFT(+) patients. This allowed us to define subgroups within psoriatic patients characterized by different immune responses to M. tuberculosis antigens that may be associated to different risk levels of reactivation of the infection. This approach may help in prioritizing patients who should receive prophylactic anti-TB treatment before starting biotherapies in order to reduce their number.	[Benhadou, Farida; Willaert, Fabienne] Univ Libre Bruxelles ULB, Hop Erasme, Dermatol Dept, Brussels, Belgium; [Dirix, Violette; Domont, Fanny; Van Praet, Anne; Mascart, Francoise; Corbiere, Veronique] Univ Libre Bruxelles ULB, Lab Vaccinol & Mucosal Immun, Brussels, Belgium; [Locht, Camille] Univ Lille, CNRS, INSERM,U1019,UMR 8204, CHU Lille,Inst Pasteur Lille,CIIL Ctr Infect & Im, Lille, France	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CHU Lille; Universite de Lille	Mascart, F (corresponding author), Univ Libre Bruxelles ULB, Lab Vaccinol & Mucosal Immun, Brussels, Belgium.	francoise.mascart@erasme.ulb.ac.be						Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010; Bassukas ID, 2011, EUR RESPIR J, V38, P231, DOI 10.1183/09031936.00016611; Bassukas ID, 2011, ACTA DERM-VENEREOL, V91, P444, DOI 10.2340/00015555-1106; Blauvelt A, 2017, J AM ACAD DERMATOL, V77, P855, DOI 10.1016/j.jaad.2017.06.153; Blauvelt A, 2017, J AM ACAD DERMATOL, V76, P405, DOI 10.1016/j.jaad.2016.11.041; Cadena AM, 2017, NAT REV IMMUNOL, V17, P691, DOI 10.1038/nri.2017.69; Campa M, 2015, EXPERT OPIN INV DRUG, V24, P1343, DOI 10.1517/13543784.2015.1076793; Corbiere V, 2020, J IMMUNOL, V204, P1715, DOI 10.4049/jimmunol.1901214; Corbiere V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043285; Doan TN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188631; Farhat M, 2006, INT J TUBERC LUNG D, V10, P1192; Getahun H, 2015, EUR RESPIR J, V46, P1563, DOI 10.1183/13993003.01245-2015; Hoffmann H, 2016, CLIN MICROBIOL INFEC, V22, P701, DOI 10.1016/j.cmi.2016.05.006; Hougardy JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000926; Hougardy JM, 2007, AM J RESP CRIT CARE, V176, P409, DOI 10.1164/rccm.200701-084OC; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Kim HC, 2014, SCAND J INFECT DIS, V46, P763, DOI 10.3109/00365548.2014.938691; Laffitte E, 2009, BRIT J DERMATOL, V161, P797, DOI 10.1111/j.1365-2133.2009.09331.x; Lefrancois Louise H, 2013, BMC Res Notes, V6, P55, DOI 10.1186/1756-0500-6-55; Lin J, 2008, CLIN IMMUNOL, V126, P13, DOI 10.1016/j.clim.2007.08.012; Masungi C, 2002, J INFECT DIS, V185, P513, DOI 10.1086/338833; Menozzi FD, 1996, J EXP MED, V184, P993, DOI 10.1084/jem.184.3.993; Moorlag SJCFM, 2018, IMMUNOL REV, V281, P28, DOI 10.1111/imr.12617; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X; Parisi R, 2013, J INVEST DERMATOL, V133, P377, DOI 10.1038/jid.2012.339; Parra M, 2004, INFECT IMMUN, V72, P6799, DOI 10.1128/IAI.72.12.6799-6805.2004; Pescitelli L, 2014, J RHEUMATOL, V41, P65, DOI 10.3899/jrheum.140104; Ramagopalan SV, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-97; Sanchez-Moya AI, 2013, J EUR ACAD DERMATOL, V27, P1366, DOI 10.1111/jdv.12011; de Oliveira MDSP, 2015, AN BRAS DERMATOL, V90, P9, DOI 10.1590/abd1806-4841.20153038; Sauzullo I, 2019, MED MICROBIOL IMMUN, V208, P171, DOI 10.1007/s00430-018-00576-4; Serrano CJ, 2015, CLIN IMMUNOL, V157, P145, DOI 10.1016/j.clim.2015.02.008; Sichletidis L, 2006, INT J TUBERC LUNG D, V10, P1127; Temmerman S, 2004, NAT MED, V10, P935, DOI 10.1038/nm1090; Wyndham-Thomas C, 2014, CLIN VACCINE IMMUNOL, V21, P321, DOI 10.1128/CVI.00651-13; Zhang Z, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012567	37	1	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 3	2021	12								672894	10.3389/fimmu.2021.672894	http://dx.doi.org/10.3389/fimmu.2021.672894			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ST1AY	34149708	gold, Green Published			2022-12-18	WOS:000662183600001
J	Yakkala, C; Dagher, J; Sempoux, C; Chiang, CLL; Denys, A; Kandalaft, LE; Koppolu, B; Duran, R				Yakkala, Chakradhar; Dagher, Julien; Sempoux, Christine; Chiang, Cheryl Lai-Lai; Denys, Alban; Kandalaft, Lana E.; Koppolu, Bhanu; Duran, Rafael			Rate of Freeze Impacts the Survival and Immune Responses Post Cryoablation of Melanoma	FRONTIERS IN IMMUNOLOGY			English	Article						cryoablation; melanoma; immunotherapy; immune response; tumors	PROSTATIC-CANCER; CELL; IMMUNOTHERAPY; CRYOTHERAPY; CRYOSURGERY; CARCINOMA; ABLATION; SYNERGY; CRYO	The emergence of ablative therapies has revolutionized the treatment of inoperable solid tumors. Cryoablation stands out for its uniqueness of operation based on hypothermia, and for its ability to unleash the native tumor antigens, resulting in the generation of anti-tumor immune responses. It is not clearly understood how alterations in the rate of freeze impact the immune response outcomes. In this study, we tested fast freeze and slow freeze rates for their locoregional effectiveness and their ability to elicit immune responses in a B16F10 mouse model of melanoma. Tumor bearing mice treated with fast freeze protocol survived better than the ones treated with slow freeze protocol. Fast freeze resulted in a higher magnitude of CD4(+) and CD8(+) T-cell responses, and a significantly extended survival post re-challenge. Thus, fast freeze rate should be applied in any future studies employing cryoablation as an in vivo vaccination tool in conjunction with targeted immunotherapies.	[Yakkala, Chakradhar; Denys, Alban; Duran, Rafael] Lausanne Univ Hosp, Dept Radiol & Intervent Radiol, Lausanne, Switzerland; [Yakkala, Chakradhar; Dagher, Julien; Sempoux, Christine; Denys, Alban; Duran, Rafael] Univ Lausanne, Lausanne, Switzerland; [Dagher, Julien; Sempoux, Christine] Lausanne Univ Hosp, Inst Pathol, Lausanne, Switzerland; [Chiang, Cheryl Lai-Lai; Kandalaft, Lana E.] Univ Lausanne, Ludwig Inst Canc Res, Lausanne Univ Hosp, Dept Oncol, Lausanne, Switzerland; [Kandalaft, Lana E.] Lausanne Univ Hosp, Dept Oncol, Ctr Expt Therapeut, Lausanne, Switzerland; [Koppolu, Bhanu] BTG Boston Sci, Intervent Oncol & Immunooncol, Natick, MA USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Ludwig Institute for Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Duran, R (corresponding author), Lausanne Univ Hosp, Dept Radiol & Intervent Radiol, Lausanne, Switzerland.; Duran, R (corresponding author), Univ Lausanne, Lausanne, Switzerland.	rafael.duran@chuv.ch	CHIANG, Cheryl Lai Lai/AAA-2997-2022; Denys, Alban/GXV-2422-2022	CHIANG, Cheryl Lai Lai/0000-0002-0444-3357; 	BTG/Boston Scientific	BTG/Boston Scientific	This study received funding from BTG/Boston Scientific. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	ABLIN RJ, 1971, CRYOBIOLOGY, V8, P271, DOI 10.1016/0011-2240(71)90050-2; Carretero R, 2015, NAT IMMUNOL, V16, P609, DOI 10.1038/ni.3159; Chu KF, 2014, NAT REV CANCER, V14, P199, DOI 10.1038/nrc3672; de Oliveira S, 2016, NAT REV IMMUNOL, V16, P378, DOI 10.1038/nri.2016.49; den Brok MHMGM, 2006, BRIT J CANCER, V95, P896, DOI 10.1038/sj.bjc.6603341; den Brok MHMGM, 2006, CANCER RES, V66, P7285, DOI 10.1158/0008-5472.CAN-06-0206; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; Gaitanis G, 2009, J EUR ACAD DERMATOL, V23, P1427, DOI 10.1111/j.1468-3083.2009.03224.x; Gamrekelashvili J, 2007, J IMMUNOL, V178, P1573, DOI 10.4049/jimmunol.178.3.1573; GURSEL E, 1972, J UROLOGY, V108, P928, DOI 10.1016/S0022-5347(17)60909-1; Hoffmann NE, 2002, UROLOGY, V60, P40, DOI 10.1016/S0090-4295(02)01683-7; Lin M, 2017, IMMUNOL RES, V65, P880, DOI 10.1007/s12026-017-8927-x; Machlenkin A, 2005, CLIN CANCER RES, V11, P4955, DOI 10.1158/1078-0432.CCR-04-2422; Orchard GE, 1998, AM J DERMATOPATH, V20, P357, DOI 10.1097/00000372-199808000-00006; Przybyla A, 2019, CANCER IMMUNOL IMMUN, V68, P709, DOI 10.1007/s00262-018-02292-7; Raaijmakers TK, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000649; Sabel MS, 2010, ANN SURG ONCOL, V17, P1187, DOI 10.1245/s10434-009-0846-1; Scheffer SR, 2003, INT J CANCER, V103, P205, DOI 10.1002/ijc.10777; Shao Q, 2019, INT J HYPERTHER, V36, P130, DOI 10.1080/02656736.2018.1539253; SOANES WA, 1970, J UROLOGY, V104, P154, DOI 10.1016/S0022-5347(17)61690-2; Vargas FA, 2018, CANCER CELL, V33, P649, DOI 10.1016/j.ccell.2018.02.010; Varricchi G, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1393134; Waitz R, 2012, CANCER RES, V72, P430, DOI 10.1158/0008-5472.CAN-11-1782; Yakkala C, 2020, CURR OPIN BIOTECH, V65, P60, DOI 10.1016/j.copbio.2020.01.006; Yakkala C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02283; Yuan XL, 2015, INT IMMUNOPHARMACOL, V27, P171, DOI 10.1016/j.intimp.2015.04.056	26	1	1	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 3	2021	12								695150	10.3389/fimmu.2021.695150	http://dx.doi.org/10.3389/fimmu.2021.695150			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ST2PG	34149738	gold, Green Published			2022-12-18	WOS:000662291400001
J	Cozzani, E; Muracchioli, A; Murdaca, G; Beccalli, M; Caprioli, S; Zentilin, P; Ameri, P; Grosso, M; Russo, R; Carmisciano, L; Parodi, A				Cozzani, Emanuele; Muracchioli, Andrea; Murdaca, Giuseppe; Beccalli, Mirko; Caprioli, Simone; Zentilin, Patrizia; Ameri, Pietro; Grosso, Marco; Russo, Rodolfo; Carmisciano, Luca; Parodi, Aurora			Correlation Between Skin and Affected Organs in 52 Sclerodermic Patients Followed in a Diseases Management Team: Development of a Risk Prediction Model of Organ-Specific Complications	FRONTIERS IN IMMUNOLOGY			English	Article						systemic sclerosis; scleroderma; mRSS (Rodnan Score); predictive model; organ complications	SYSTEMIC-SCLEROSIS; GASTROESOPHAGEAL-REFLUX; PULMONARY-FIBROSIS; RIGHT HEART; STANDARDIZATION; CLASSIFICATION; INVOLVEMENT; GUIDELINES	Objective To identify the existence of a correlation among the various organs affected, focusing primarily on immuno-dermatological aspects, and to create a risk prediction model of organ-specific complications. Material and Methods Fifty-two patients with stable scleroderma, followed between 2015 and 2019, were investigated through an extensive multidisciplinary evaluation in the last year. Results Patients with lung involvement presented a worse degree of skin fibrosis than patients without it (p <0.001). No relationship was observed for the heart, kidney, and esophagus. Patients with pulmonary involvement had a lower pressure of the low esophagus sphincter and a higher Warrick score than patients without it (p <0.05). Age was significantly higher in patients with kidney involvement. Diffuse scleroderma patients had a worse pulmonary impairment than limited scleroderma patients (p <0.05). The manometric "sclerodermic" pattern was observed to be the most frequent (55.6%, p <0.05) in dcSSc patients while the sclerodermic and normal pattern were equally represented (41.2 and 32.4% respectively, p <0.05) in lcSSc patients. When compared to the negative serological groups, anti-Scl-70 positive patients presented a worse lung involvement while anti-centromere patients presented a better lung outcome (p <0.05). PM-Scl 100/75 positive patients presented mostly a pulmonary fibrotic pattern (p <0.05) and, also, heart complications were more likely associated with anti PM-Scl 100/75 positivity (p <0.05). The risk prediction model for organ-specific complications had an accuracy of 84.4% (95%CI 78, 89) in complication-site prediction, AUC of 0.871, 86% of sensitivity, and 83% of specificity, Cohen's Kappa (k) of 0.68. Conclusions Out of all the organs studied, the skin is the one that correlates with the lung. Patients with a diffuse form of disease presented more frequently the anti Scl-70 antibody and had a worse lung and esophageal involvement (scleroderma pattern) than the negative group. Conversely, patients with limited disease presented all positive for the anti-centromere antibody with a better lung involvement than the negative group, without any difference among the esophageal manometric pattern. Anti PM-Scl 100/75 antibody patients were associated with pulmonary fibrosis and presented cardiac involvement. The model created has demonstrated excellent values of sensitivity, specificity, and accuracy, but further studies are needed for validation.	[Cozzani, Emanuele; Muracchioli, Andrea; Parodi, Aurora] Univ Genoa, DiSSal, IRCCS, Osped Policlin San Martino,Dermatol Unit, Genoa, Italy; [Murdaca, Giuseppe; Beccalli, Mirko] Univ Genoa, Dept Internal Med, Scleroderma Unit, Clin Immunol Unit,Osped Policlin San Martino,IRCC, Genoa, Italy; [Caprioli, Simone; Carmisciano, Luca] Univ Genoa, Dept Healt Sci DiSSal, Osped Policlin San Martino, IRCCS, Genoa, Italy; [Zentilin, Patrizia] Univ Genoa, Dept Internal Med, Div Gastroenterol, Osped Policlin San Martino,IRCCS, Genoa, Italy; [Grosso, Marco] Osped Policlin San Martino, IRCCS, Cardiovasc Dis Unit, Genoa, Italy; [Ameri, Pietro] Univ Genoa, Dept Internal Med, Genoa, Italy; [Grosso, Marco] Osped Policlin San Martino, IRCCS, Intervent Pneumol Unit, Genoa, Italy; [Russo, Rodolfo] Osped Policlin San Martino, IRCCS, Nephrol Dialysis & Transplantat, Genoa, Italy	University of Genoa; University of Genoa; University of Genoa; University of Genoa; University of Genoa	Cozzani, E; Muracchioli, A (corresponding author), Univ Genoa, DiSSal, IRCCS, Osped Policlin San Martino,Dermatol Unit, Genoa, Italy.	emanuele.cozaani@unige.it; andreamuracchioli@gmail.com	Ameri, Pietro/K-8556-2016	Ameri, Pietro/0000-0001-7167-7287; Muracchioli, Andrea/0000-0002-0303-9387; Caprioli, Simone/0000-0002-6017-9968				Allanore Y, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.2; Arif T, 2018, ACTA DERMATOVEN ALP, V27, P169, DOI 10.15570/actaapa.2018.36; Basu D, 2005, AUTOIMMUNITY, V38, P65, DOI 10.1080/08916930400022947; Chifflot H, 2008, SEMIN ARTHRITIS RHEU, V37, P223, DOI 10.1016/j.semarthrit.2007.05.003; Collins GS, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g7594; COTES JE, 1993, EUR RESPIR J, V6, P41, DOI 10.1183/09041950.041s1693; D'Alto M, 2018, HEART FAIL CLIN, V14, P467, DOI 10.1016/j.hfc.2018.03.011; D'Aoust J, 2014, ARTHRITIS RHEUMATOL, V66, P1608, DOI 10.1002/art.38428; Guazzi M, 2013, AM J PHYSIOL-HEART C, V305, pH1373, DOI 10.1152/ajpheart.00157.2013; Kane GC, 1996, RESP MED, V90, P223, DOI 10.1016/S0954-6111(96)90291-7; Khanna D, 2017, J SCLERODERMA RELAT, V2, P11, DOI 10.5301/jsrd.5000231; Koschik RW, 2012, CLIN EXP RHEUMATOL, V30, pS12; LEROY EC, 1988, J RHEUMATOL, V15, P202; Liaskos C, 2017, AUTOIMMUNITY, V50, P414, DOI 10.1080/08916934.2017.1357699; Matsuda KM, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1919-6; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Morelli S, 1997, J RHEUMATOL, V24, P81; Ostojic P, 2006, CLIN RHEUMATOL, V25, P453, DOI 10.1007/s10067-005-0041-0; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, P685, DOI 10.1016/j.echo.2010.05.010; Savarino E, 2008, AM J GASTROENTEROL, V103, P2685, DOI 10.1111/j.1572-0241.2008.02119.x; Savarino E, 2016, DIGEST LIVER DIS, V48, P1124, DOI 10.1016/j.dld.2016.06.021; Savarino Edoardo, 2009, Recenti Progressi in Medicina, V100, P512; Savarino E, 2009, AM J RESP CRIT CARE, V179, P408, DOI 10.1164/rccm.200808-1359OC; Steen VD, 2007, ANN RHEUM DIS, V66, P940, DOI 10.1136/ard.2006.066068; Tublin ME, 2003, AM J ROENTGENOL, V180, P885, DOI 10.2214/ajr.180.4.1800885; WARRICK JH, 1991, J RHEUMATOL, V18, P1520; Weinstein JR, 2010, ADV CHRONIC KIDNEY D, V17, P302, DOI 10.1053/j.ackd.2010.05.002	28	1	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2021	12								588753	10.3389/fimmu.2021.588753	http://dx.doi.org/10.3389/fimmu.2021.588753			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SS7HG	34149680	Green Published, gold			2022-12-18	WOS:000661924900001
J	De Poi, RP; Kowolik, M; Oshida, Y; El Kholy, K				De Poi, Robert P.; Kowolik, Michael; Oshida, Yoshiki; El Kholy, Karim			The Oxidative Response of Human Monocytes to Surface Modified Commercially Pure Titanium	FRONTIERS IN IMMUNOLOGY			English	Article						titanium; monocytes; surface roughness; wettability; surface energy; chemiluminescence; oxidative response; dental implants	LUMINOL-ENHANCED CHEMILUMINESCENCE; EARLY TISSUE-RESPONSE; RABBIT CORTICAL BONE; POLYMORPHONUCLEAR LEUKOCYTES; HUMAN-BLOOD; IMPLANTS; PURIFICATION; MONONUCLEAR; ROUGHNESS; MACROPHAGES	Cellular responses to implanted biomaterials are key to understanding osseointegration. The aim of this investigation was to determine the in vitro priming and activation of the respiratory burst activity of monocytes in response to surface-modified titanium. Human peripheral blood monocytes of healthy blood donors were separated, then incubated with surface-modified grade 2 commercially pure titanium (CPT) disks with a range of known surface energies and surface roughness for 30- or 60-min. Secondary stimulation by phorbol 12-myrisate 13-acetate (PMA) following the priming phase, and luminol-enhanced-chemiluminescence (LCL) was used to monitor oxygen-dependent activity. Comparison among groups was made by incubation time using one-way ANOVA. One sample from each group for each phase of the experiment was viewed under scanning electron microscopy (SEM) and qualitative comparisons made. The results indicate that titanium is capable of priming peripheral blood monocytes following 60-min incubation. In contrast, 30 min incubation time lead to reduced LCL on secondary stimulation as compared to cells alone. At both time intervals, the disk with the lowest surface energy produced significantly less LCL compared to other samples. SEM examination revealed differences in surface morphology at different time points but not between differently surface-modified disks. These results are consistent with the hypothesis that the titanium surface characteristics influenced the monocyte activity, which may be important in regulating the healing response to these materials.	[De Poi, Robert P.] Univ Melbourne, Div Dent Med & Hlth Sci, Melbourne, Vic, Australia; [Kowolik, Michael] Indiana Univ, Sch Dent, Dept Periodontol, Indianapolis, IN USA; [Oshida, Yoshiki] Indiana Univ, Sch Dent, Dept Restorat Dent, Dent Mat, Indianapolis, IN USA; [El Kholy, Karim] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, 188 Longwood Ave, Boston, MA 02115 USA	University of Melbourne; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Harvard University; Harvard School of Dental Medicine	El Kholy, K (corresponding author), Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, 188 Longwood Ave, Boston, MA 02115 USA.	karim_elkholy@hsdm.harvard.edu						ALBRECHT D, 1993, J LEUKOCYTE BIOL, V54, P300, DOI 10.1002/jlb.54.4.300; ALBREKTSSON T, 1988, J PERIODONTOL, V59, P287, DOI 10.1902/jop.1988.59.5.287; Baltadjiev G, 1990, Folia Med (Plovdiv), V32, P17; Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P77; Branemark P I, 1977, Scand J Plast Reconstr Surg Suppl, V16, P1; Brunette DM, 1999, J BIOMECH ENG-T ASME, V121, P49, DOI 10.1115/1.2798042; BUSER D, 1991, J BIOMED MATER RES, V25, P889, DOI 10.1002/jbm.820250708; Cochran DL, 1999, J PERIODONTOL, V70, P1523, DOI 10.1902/jop.1999.70.12.1523; Ducommun J, 2019, CLIN ORAL IMPLAN RES, V30, P1097, DOI 10.1111/clr.13523; El Kholy K, 2020, MATERIALS, V13, DOI 10.3390/ma13153421; Eriksson C, 2001, J LAB CLIN MED, V137, P56, DOI 10.1067/mlc.2001.111470; FERRANTE A, 1978, J IMMUNOL METHODS, V24, P389, DOI 10.1016/0022-1759(78)90143-6; FERRANTE A, 1980, J IMMUNOL METHODS, V36, P109, DOI 10.1016/0022-1759(80)90036-8; GODDEERIS BM, 1986, J IMMUNOL METHODS, V89, P165, DOI 10.1016/0022-1759(86)90354-6; GOTFREDSEN K, 1995, J BIOMED MATER RES, V29, P1223, DOI 10.1002/jbm.820291009; Grinnell F, 1978, Int Rev Cytol, V53, P65; Hayakawa T, 2002, BIOMATERIALS, V23, P1025, DOI 10.1016/S0142-9612(01)00214-9; JOHANSSON A, 1989, J LEUKOCYTE BIOL, V45, P444, DOI 10.1002/jlb.45.5.444; Kasemo B, 1988, Int J Oral Maxillofac Implants, V3, P247; KASEMO B, 1983, J PROSTHET DENT, V49, P832, DOI 10.1016/0022-3913(83)90359-1; LABADIA M, 1990, J LEUKOCYTE BIOL, V48, P420, DOI 10.1002/jlb.48.5.420; LEAKE ES, 1981, J RETICULOENDOTH SOC, V30, P403; Lim YJ, 2001, INT J ORAL MAX IMPL, V16, P333; Lincks J, 1998, BIOMATERIALS, V19, P2219, DOI 10.1016/S0142-9612(98)00144-6; McNally JA, 1996, J BIOLUM CHEMILUM, V11, P99, DOI 10.1002/(SICI)1099-1271(199603)11:2<99::AID-BIO404>3.0.CO;2-3; MURRAY DW, 1989, J BONE JOINT SURG BR, V71, P632, DOI 10.1302/0301-620X.71B4.2670951; Olefjord I, 1993, Int J Oral Maxillofac Implants, V8, P32; Park JY, 2000, CLIN ORAL IMPLAN RES, V11, P530, DOI 10.1034/j.1600-0501.2000.011006530.x; RAE T, 1986, CRIT REV BIOCOMPAT, V2, P97; RICH A, 1981, J CELL SCI, V50, P1; SENNERBY L, 1993, J MATER SCI-MATER M, V4, P240, DOI 10.1007/BF00122275; SENNERBY L, 1993, J MATER SCI-MATER M, V4, P494, DOI 10.1007/BF00120129; Soskolne WA, 2002, CLIN ORAL IMPLAN RES, V13, P86, DOI 10.1034/j.1600-0501.2002.130111.x; Van Nerom A, 1997, J BIOLUM CHEMILUM, V12, P207, DOI 10.1002/(SICI)1099-1271(199707/08)12:4<207::AID-BIO446>3.0.CO;2-2; Weiland M., 1999, BONE ENG, V1, P163; Wennerberg A, 1993, Int J Oral Maxillofac Implants, V8, P622	36	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2021	12								618002	10.3389/fimmu.2021.618002	http://dx.doi.org/10.3389/fimmu.2021.618002			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SS6FU	34149683	Green Published, gold			2022-12-18	WOS:000661850900001
J	Li, DN; Lu, WQ; Yang, BW; Zhang, LY; Jin, B; Wang, S; Che, XF; Li, C; Liu, YP; Qu, XJ				Li, Dan-Ni; Lu, Wen-Qing; Yang, Bo-Wen; Zhang, Ling-Yun; Jin, Bo; Wang, Shuo; Che, Xiao-Fang; Li, Ce; Liu, Yun-Peng; Qu, Xiu-Juan			Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						non-small cell lung cancer (NSCLC); programmed cell death-ligand 1 (PD-L1); atezolizumab; chemotherapy; first-line	PEMBROLIZUMAB	Background Atezolizumab plus chemotherapy has been recommended as a first-line treatment option for patients with advanced non-small cell lung carcinoma (NSCLC) irrespective of programmed cell death-ligand 1 (PD-L1) expression. Currently, little is known about the efficacy and treatment-related adverse effects (TRAEs) of subtracting chemotherapy from the combination for patients with high PD-L1 expression. Thus, we performed an indirect comparison between atezolizumab plus chemotherapy and atezolizumab alone. Methods A total of five eligible randomized controlled trials (RCTs) were identified from PubMed, EMBASE, and Cochrane Central controlled trial registries, using keywords including atezolizumab, PD-1, PD-L1, NSCLC, and RCT. The clinical outcomes of objective response rate (ORR), progression-free survival (PFS), OS, and TRAEs were extracted and evaluated. Using indirect analysis, the efficacy and TRAEs were compared between arm A (atezolizumab plus chemotherapy) and arm C (atezolizumab), linked by arm B (chemotherapy). Results Direct comparison revealed that both atezolizumab plus chemotherapy (HR 0.65, P = 0.003) and atezolizumab alone (HR 0.59, P = 0.010) significantly improved OS compared with chemotherapy. More importantly, the indirect comparison showed that atezolizumab plus chemotherapy was not superior to atezolizumab regarding OS (RR 1.10, P =0.695) and ORR (RR 1.11, P = 0.645). However, patients who received atezolizumab combined with chemotherapy experienced more >= grade 3 TRAEs (RR 4.23, P<0.001) and TRAEs leading to drug discontinuation (RR 3.60, P<0.001) than those treated with atezolizumab monotherapy. Conclusions Atezolizumab monotherapy might be a better treatment option for patients with advanced NSCLC and high PD-L1 expression than atezolizumab plus chemotherapy.	[Li, Dan-Ni; Lu, Wen-Qing; Yang, Bo-Wen; Zhang, Ling-Yun; Jin, Bo; Wang, Shuo; Che, Xiao-Fang; Li, Ce; Liu, Yun-Peng; Qu, Xiu-Juan] China Med Univ, Dept Med Oncol, Hosp 1, Shenyang, Peoples R China; [Li, Dan-Ni; Lu, Wen-Qing; Yang, Bo-Wen; Zhang, Ling-Yun; Jin, Bo; Wang, Shuo; Che, Xiao-Fang; Li, Ce; Liu, Yun-Peng; Qu, Xiu-Juan] China Med Univ, Key Lab Anticanc Drugs & Biotherapy Liaoning Prov, Hosp 1, Shenyang, Peoples R China; [Li, Dan-Ni; Lu, Wen-Qing; Yang, Bo-Wen; Zhang, Ling-Yun; Jin, Bo; Wang, Shuo; Che, Xiao-Fang; Li, Ce; Liu, Yun-Peng; Qu, Xiu-Juan] Liaoning Prov Clin Res Ctr Canc, Shenyang, Peoples R China	China Medical University; China Medical University	Liu, YP; Qu, XJ (corresponding author), China Med Univ, Dept Med Oncol, Hosp 1, Shenyang, Peoples R China.; Liu, YP; Qu, XJ (corresponding author), China Med Univ, Key Lab Anticanc Drugs & Biotherapy Liaoning Prov, Hosp 1, Shenyang, Peoples R China.; Liu, YP; Qu, XJ (corresponding author), Liaoning Prov Clin Res Ctr Canc, Shenyang, Peoples R China.	ypliu@cmu.edu.cn; xiujuanqu@yahoo.com			National Natural Science Foundation of China [82003296]; Key Research and Development Program of Liaoning Province [2018225060]; Technological Special Project of Liaoning Province of China [2019020176-JH1/103]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research and Development Program of Liaoning Province; Technological Special Project of Liaoning Province of China	This work was supported by grants from the National Natural Science Foundation of China under Grant (No.82003296), The Key Research and Development Program of Liaoning Province under Grant (2018225060), and the Technological Special Project of Liaoning Province of China under Grant (2019020176-JH1/103).	Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Emens LA, 2015, CANCER IMMUNOL RES, V3, P436, DOI 10.1158/2326-6066.CIR-15-0064; Herbst R, 2020, J IMMUNOTHER CANCER, V8, pA1, DOI 10.1136/LBA2019.1; Herbst RS, 2020, NEW ENGL J MED, V383, P1328, DOI 10.1056/NEJMoa1917346; Jotte R, 2020, J THORAC ONCOL, V15, P1351, DOI 10.1016/j.jtho.2020.03.028; Kennedy LB, 2020, CA-CANCER J CLIN, V70, P86, DOI 10.3322/caac.21596; Leonetti A, 2019, DRUG RESIST UPDATE, V46, DOI 10.1016/j.drup.2019.100644; Peters S, 2017, J CLIN ONCOL, V35, P2781, DOI 10.1200/JCO.2016.71.9476; Reck M, 2019, LANCET RESP MED, V7, P387, DOI 10.1016/S2213-2600(19)30084-0; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; West H, 2019, LANCET ONCOL, V20, P924, DOI 10.1016/S1470-2045(19)30167-6; Zhou YX, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0600-6; Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216	16	1	1	1	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2021	12								666909	10.3389/fimmu.2021.666909	http://dx.doi.org/10.3389/fimmu.2021.666909			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SU3NH	34149702	gold, Green Published			2022-12-18	WOS:000663047300001
J	Santiago, JL; Sanchez-Perez, L; Perez-Flores, I; de la Higuera, MAM; Romero, NC; Querol-Garcia, J; Urcelay, E; Sanchez-Fructuoso, AI				Luis Santiago, Jose; Sanchez-Perez, Luis; Perez-Flores, Isabel; Moreno de la Higuera, Maria Angeles; Calvo Romero, Natividad; Querol-Garcia, Javier; Urcelay, Elena; Isabel Sanchez-Fructuoso, Ana			Association of Polymorphisms in T-Cell Activation Costimulatory/Inhibitory Signal Genes With Allograft Kidney Rejection Risk	FRONTIERS IN IMMUNOLOGY			English	Article						allograft rejection; Banff classification; cytotoxic T-lymphocyte associated protein 4; kidney transplantation; polymorphism	RABBIT ANTITHYMOCYTE GLOBULIN; ANTIBODY-MEDIATED REJECTION; CTLA-4; TRANSPLANTATION; SUSCEPTIBILITY; IMMUNE; CD86; SURVIVAL; PROGRESS	The genes CD28, CD86 and CTLA-4 conform the costimulatory (CD28-CD86) or inhibitory (CTLA-4-CD86) signal in T-cell activation. T-cell immune response has a critical role in allograft rejection, and single nucleotide polymorphisms (SNPs) located in these genes have been widely analyzed with controversial results. We analyzed a group of SNPs located in the three genes: CD28: rs3116496; CD86: rs1129055; and CTLA-4: rs231775 and rs3087243 in a cohort of 632 consecutively recruited kidney transplanted subjects. All polymorphisms were genotyped by TaqMan chemistry and the diagnosis of rejection was confirmed by biopsy and categorized according to the Banff classification. The analyses showed a statistically significant protective effect to T cell-mediated rejection (TCMR) in carriers of the CTLA-4 rs3087243*G allele, especially in patients with TCMR Banff >= 2 in the overall cohort and in patients without thymoglobulin induction therapy. Both associations were corroborated as independent factors in the multivariate analysis. Interestingly, associations with rejection were not found for any SNP in patients with thymoglobulin induction therapy. As expected, considering the major role of these genes in T-cell activation, no effect was observed for antibody-mediated rejection (ABMR). In conclusion, the SNP rs3087243 located in the CTLA-4 gene may be considered a useful independent biomarker for TCMR risk especially for severe TCMR in patients who did no received thymoglobulin induction therapy.	[Luis Santiago, Jose; Sanchez-Perez, Luis; Querol-Garcia, Javier; Urcelay, Elena] Hosp Clin San Carlos, Lab Genet & Mol Basis Complex Dis, Inst Invest Sanit, IdISSC, Madrid, Spain; [Luis Santiago, Jose] Hosp Fdn Jimenez Diaz, Immunol Dept, Madrid, Spain; [Perez-Flores, Isabel; Moreno de la Higuera, Maria Angeles; Calvo Romero, Natividad; Isabel Sanchez-Fructuoso, Ana] Univ Complutense Madrid, Nephrol Dept, Hosp Clin San Carlos, Fac Med,IdISSC, Madrid, Spain	Hospital Clinico San Carlos; Fundacion Jimenez Diaz; Complutense University of Madrid; Hospital Clinico San Carlos	Santiago, JL (corresponding author), Hosp Clin San Carlos, Lab Genet & Mol Basis Complex Dis, Inst Invest Sanit, IdISSC, Madrid, Spain.; Santiago, JL (corresponding author), Hosp Fdn Jimenez Diaz, Immunol Dept, Madrid, Spain.	jlsantial@gmail.com			project ASF.FERP.15; FIS - ISCIII and [PI16/01135]; European Regional Development Fund (ERDF) "A way to make Europe"; Juan Rodes contract	project ASF.FERP.15; FIS - ISCIII and; European Regional Development Fund (ERDF) "A way to make Europe"; Juan Rodes contract	The authors wish to thank Antonia Rodriguez de la Pena and M. Angel Garci ' a Martinez for expert technical assistance. This publication has been funded by the project ASF.FERP.15. Jose Luis Santiago holds a Juan Rodes contract and a FIS PI16/01135 grant, funded by the ISCIII and co-funded by the European Regional Development Fund (ERDF) "A way to make Europe".	Anjos S, 2002, J BIOL CHEM, V277, P46478, DOI 10.1074/jbc.M206894200; Brennan DC, 2006, NEW ENGL J MED, V355, P1967, DOI 10.1056/NEJMoa060068; Choi J, 2019, CLIN LAB MED, V39, P73, DOI 10.1016/j.cll.2018.11.003; de Reuver P, 2003, AM J TRANSPLANT, V3, P1587, DOI 10.1046/j.1600-6135.2003.00261.x; Delneste Y, 2000, IMMUNOGENETICS, V51, P762, DOI 10.1007/s002510000203; Djamali A, 2014, AM J TRANSPLANT, V14, P255, DOI 10.1111/ajt.12589; Dmitrienko S, 2005, TRANSPLANTATION, V80, P1773, DOI 10.1097/01.tp.0000184624.54005.9f; El-Zoghby ZM, 2009, AM J TRANSPLANT, V9, P527, DOI 10.1111/j.1600-6143.2008.02519.x; Gendzekhadze K, 2006, TRANSPL IMMUNOL, V16, P194, DOI 10.1016/j.trim.2006.09.001; Haas M, 2018, AM J TRANSPLANT, V18, P293, DOI 10.1111/ajt.14625; Haimila K, 2009, TRANSPLANTATION, V87, P393, DOI 10.1097/TP.0b013e318192897a; Han FF, 2014, TRANSPL IMMUNOL, V31, P81, DOI 10.1016/j.trim.2014.06.003; Hart A, 2020, AM J TRANSPLANT, V20, DOI 10.1111/ajt.15672; Kouki T, 2000, J IMMUNOL, V165, P6606, DOI 10.4049/jimmunol.165.11.6606; Krichen H, 2011, IRAN J KIDNEY DIS, V5, P187; Kusztal M, 2010, TRANSPL IMMUNOL, V23, P121, DOI 10.1016/j.trim.2010.05.002; Lamb KE, 2011, AM J TRANSPLANT, V11, P450, DOI 10.1111/j.1600-6143.2010.03283.x; Ligers A, 2001, GENES IMMUN, V2, P145, DOI 10.1038/sj.gene.6363752; Liu K, 2017, META GENE, V12, P118, DOI 10.1016/j.mgene.2017.03.002; Manzotti CN, 2002, EUR J IMMUNOL, V32, P2888, DOI 10.1002/1521-4141(2002010)32:10<2888::AID-IMMU2888>3.0.CO;2-F; Marin LA, 2005, TRANSPL IMMUNOL, V15, P69, DOI 10.1016/j.trim.2005.04.003; Matsushita M, 2000, GENES IMMUN, V1, P428, DOI 10.1038/sj.gene.6363704; Maurer M, 2002, IMMUNOGENETICS, V54, P1, DOI 10.1007/s00251-002-0429-9; Meier-Kriesche HU, 2004, AM J TRANSPLANT, V4, P378, DOI 10.1111/j.1600-6143.2004.00332.x; Misra MK, 2014, J INTERF CYTOK RES, V34, P148, DOI 10.1089/jir.2013.0069; Nankivell BJ, 2010, NEW ENGL J MED, V363, P1451, DOI 10.1056/NEJMra0902927; Noel C, 2009, J AM SOC NEPHROL, V20, P1385, DOI 10.1681/ASN.2008101037; Pascual J, 2016, TRANSPLANT REV-ORLAN, V30, P85, DOI 10.1016/j.trre.2015.12.002; Pawlik A, 2014, TRANSPL IMMUNOL, V30, P84, DOI 10.1016/j.trim.2013.12.002; Perez-Garcia A, 2007, BLOOD, V110, P461, DOI 10.1182/blood-2007-01-069781; Petranyi GG, 2002, TRANSPL IMMUNOL, V10, P91, DOI 10.1016/S0966-3274(02)00054-0; Sayegh MH, 2004, NEW ENGL J MED, V351, P2761, DOI 10.1056/NEJMon043418; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Schwab C, 2018, J ALLERGY CLIN IMMUN, V142, P1932, DOI 10.1016/j.jaci.2018.02.055; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Slavcheva E, 2001, TRANSPLANTATION, V72, P935, DOI 10.1097/00007890-200109150-00032; Slavik JM, 1999, J BIOL CHEM, V274, P3116, DOI 10.1074/jbc.274.5.3116; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Walker LSK, 2015, TRENDS IMMUNOL, V36, P63, DOI 10.1016/j.it.2014.12.001; Wisniewski A, 2006, TRANSPL P, V38, P56, DOI 10.1016/j.transproceed.2005.11.094; Wu P, 2014, AUTOIMMUNITY, V47, P482, DOI 10.3109/08916934.2014.921813; Zhu CL, 2012, MOL BIOL REP, V39, P8701, DOI 10.1007/s11033-012-1727-4	42	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2021	12								650979	10.3389/fimmu.2021.650979	http://dx.doi.org/10.3389/fimmu.2021.650979			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SS6GH	34149691	gold, Green Published			2022-12-18	WOS:000661852200001
J	Shetty, S; Lujambio, A; Tacke, F				Shetty, Shishir; Lujambio, Amaija; Tacke, Frank			Editorial: Overcoming the Immune Microenvironment of Hepatocellular Cancer	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						hepatocellular carcinoma; immunotherapy; tumour microenvironment; chronic liver disease; fibrosis			[Shetty, Shishir] Univ Birmingham, Inst Immunol & Immunotherapy, Sch Med, Ctr Liver & Gastrointestinal Res, Birmingham, W Midlands, England; [Lujambio, Amaija] Icahn Sch Med Mt Sinai, Dept Oncol Sci, Tisch Canc Inst, New York, NY 10029 USA; [Tacke, Frank] Charite Univ Med Berlin, Dept Gastroenterol & Hepatol, Berlin, Germany	University of Birmingham; Icahn School of Medicine at Mount Sinai; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Shetty, S (corresponding author), Univ Birmingham, Inst Immunol & Immunotherapy, Sch Med, Ctr Liver & Gastrointestinal Res, Birmingham, W Midlands, England.	s.shetty@bham.ac.uk	Shetty, Shishir/AAU-4047-2021	Shetty, Shishir/0000-0002-4729-2173	Cancer Research UK Advanced Clinician Scientist fellowship [C53575/A29959]; Cancer Research United Kingdom; Fondazione AIRC; Fundacion Cientifica de la Asociacion Espanola Contra el Cancer; NIH/NCI [R37CA230636]; Damon Runyon-Rachleff Innovator Award	Cancer Research UK Advanced Clinician Scientist fellowship; Cancer Research United Kingdom(Cancer Research UK); Fondazione AIRC(Fondazione AIRC per la ricerca sul cancro); Fundacion Cientifica de la Asociacion Espanola Contra el Cancer; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Damon Runyon-Rachleff Innovator Award	SS is funded by a Cancer Research UK Advanced Clinician Scientist fellowship C53575/A29959 and supported by HUNTER funded through a partnership between Cancer Research United Kingdom, Fondazione AIRC and Fundacion Cientifica de la Asociacion Espanola Contra el Cancer. AL is funded by NIH/NCI R37CA230636 and Damon Runyon-Rachleff Innovator Award.		0	1	1	5	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2021	12								707329	10.3389/fimmu.2021.707329	http://dx.doi.org/10.3389/fimmu.2021.707329			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SS7PG	34149741	Green Published, gold			2022-12-18	WOS:000661945800001
J	Wacrenier, S; Boud'hors, C; Piccoli, G; Augusto, JF; Brilland, B				Wacrenier, Samuel; Boud'hors, Charlotte; Piccoli, Giorgina; Augusto, Jean-Francois; Brilland, Benoit			Commentary: Outcome Predictors of Biopsy-Proven Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						ANCA-associated vasculitis; glomerulonephritis; predictor; death; end stage kidney disease	HISTOPATHOLOGICAL CLASSIFICATION; ANCA-GLOMERULONEPHRITIS; RENAL VASCULITIS; RISK-FACTORS; COHORT; CELLS		[Wacrenier, Samuel; Boud'hors, Charlotte; Augusto, Jean-Francois; Brilland, Benoit] Univ Angers, CHU Angers, Serv Nephrol Dialyse Transplantat, Angers, France; [Wacrenier, Samuel; Piccoli, Giorgina] Ctr Hosp Mans, Serv Nephrol, Le Mans, France; [Wacrenier, Samuel; Augusto, Jean-Francois; Brilland, Benoit] Univ Angers, INSERM, CRCINA, Angers, France	Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Centre Hospitalier Le Mans; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers	Augusto, JF (corresponding author), Univ Angers, CHU Angers, Serv Nephrol Dialyse Transplantat, Angers, France.; Augusto, JF (corresponding author), Univ Angers, INSERM, CRCINA, Angers, France.	jfaugusto@chu-angers.fr	Brilland, Benoît/AAP-3193-2021; Jean-François, Augusto/L-2887-2015	Brilland, Benoît/0000-0001-9622-4014; Jean-François, Augusto/0000-0003-1498-2132				Aasarod K, 2000, NEPHROL DIAL TRANSPL, V15, P611, DOI 10.1093/ndt/15.5.611; Abdulahad WH, 2007, ANN NY ACAD SCI, V1107, P22, DOI 10.1196/annals.1381.003; Ahn JK, 2012, RHEUMATOL INT, V32, P2979, DOI 10.1007/s00296-011-2079-4; Andreiana I, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0091-8; Bakoush O, 2006, NEPHROL DIAL TRANSPL, V21, P1263, DOI 10.1093/ndt/gfk074; Berden AE, 2010, J AM SOC NEPHROL, V21, P1628, DOI 10.1681/ASN.2010050477; Berti A, 2019, NEPHROL DIAL TRANSPL, V34, P1508, DOI 10.1093/ndt/gfy250; Brix SR, 2018, KIDNEY INT, V94, P1177, DOI 10.1016/j.kint.2018.07.020; Chen YX, 2017, J RHEUMATOL, V44, P304, DOI 10.3899/jrheum.160866; Crnogorac M, 2017, INT UROL NEPHROL, V49, P1419, DOI 10.1007/s11255-017-1610-2; Flossmann O, 2011, ANN RHEUM DIS, V70, P488, DOI 10.1136/ard.2010.137778; Ge YF, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.607261; Guibert F, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081218; Henry N, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103177; Hu WH, 2008, NEPHROL DIAL TRANSPL, V23, P1307, DOI 10.1093/ndt/gfm780; Itabashi M, 2010, NEPHRON CLIN PRACT, V115, pE21, DOI 10.1159/000286346; Iwakiri T, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-125; Jourdain P, 2021, KIDNEY INT REP, V6, P1161, DOI 10.1016/j.ekir.2020.12.037; Valenzuela LM, 2019, CLIN KIDNEY J, V12, P503, DOI 10.1093/ckj/sfz029; Moroni G, 2015, CLIN EXP RHEUMATOL, V33, pS56; Solans-Laque R, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006083; Tedesco M, 2019, J NEPHROL, V32, P871, DOI 10.1007/s40620-019-00628-9; Titeca-Beauport D, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882-018-1102-3; van Daalen EE, 2020, CLIN J AM SOC NEPHRO, V15, P1103, DOI 10.2215/CJN.14561119; von Borstel A, 2018, AUTOIMMUN REV, V17, P413, DOI 10.1016/j.autrev.2017.12.002; Wacrenier S, 2022, NEPHROL DIAL TRANSPL, V37, P1078, DOI 10.1093/ndt/gfab158; Wilde B, 2013, ANN RHEUM DIS, V72, P1416, DOI 10.1136/annrheumdis-2012-202986	27	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2021	12								691179	10.3389/fimmu.2021.691179	http://dx.doi.org/10.3389/fimmu.2021.691179			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SS7QC	34149733	Green Published, gold			2022-12-18	WOS:000661948000001
J	Luu, K; Schwarz, H; Lundqvist, A				Luu, Khang; Schwarz, Herbert; Lundqvist, Andreas			B7-H7 Is Inducible on T Cells to Regulate Their Immune Response and Serves as a Marker for Exhaustion	FRONTIERS IN IMMUNOLOGY			English	Article						immunology; immune checkpoint; T lymphocyte; exhaustion; immunotherapy	B7 FAMILY; CHEMOKINE RECEPTORS; IL-2 PRODUCTION; HUMAN CD4(+); EXPRESSION; HHLA2; ACTIVATION; MEMBER; PROLIFERATION; LEUKEMIA	The discovery of immune checkpoints highlights the complexity of T cell signalling during an immune response. Upon activation, T cells express several molecules to regulate their function and to prevent overactivation. B7 homolog 7 (B7-H7) is expressed in tumours and associated with a worse prognosis. However, conflicting data regarding its function suggest that it can be both stimulatory and inhibitory. In this study we report that B7-H7 is also expressed on T cells upon cross-linking of CD3 and CD28 and that additional stimulation via CD137 further enhances the expression of B7-H7. B7-H7 is preferentially expressed on exhausted Th1 and Tc1 cells with an impaired secretion of TNF-alpha and IFN-gamma. Blockade of B7-H7 with its natural receptor, recombinant CD28H, enhances T cell proliferation and activation. Thus, B7-H7 represents another target for immunotherapy and a biomarker to select for active effector T cells with relevance for adoptive cell transfer therapy.	[Luu, Khang; Schwarz, Herbert] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore; [Luu, Khang; Schwarz, Herbert] Natl Univ Singapore, Life Sci Inst, NUS Immunol Programme, Singapore, Singapore; [Luu, Khang; Schwarz, Herbert] Natl Univ Singapore, NUSMED Immunol Translat Res Programme, Singapore, Singapore; [Luu, Khang; Schwarz, Herbert] Natl Univ Singapore, Integrat Sci & Engn Programme, Singapore, Singapore; [Luu, Khang; Lundqvist, Andreas] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden	National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; Karolinska Institutet	Lundqvist, A (corresponding author), Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.	andreas.lundqvist@ki.se	Luu, Khang/AAQ-9046-2021	Luu, Khang/0000-0003-2591-6552	Swedish Cancer Society [CAN 2018/451]; Cancer Research Foundations of Radiumhemmet [181183]	Swedish Cancer Society(Swedish Cancer Society); Cancer Research Foundations of Radiumhemmet	The study was funded by The Swedish Cancer Society (#CAN 2018/451) and The Cancer Research Foundations of Radiumhemmet (#181183).	Alonso R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04524-x; Aznar MA, 2018, CANCER IMMUNOL RES, V6, P69, DOI 10.1158/2326-6066.CIR-17-0159; Santana MA, 2006, INT REV CYTOL, V250, P217, DOI 10.1016/S0074-7696(06)50006-3; Azuma M, 2019, ADV EXP MED BIOL, V1189, P3, DOI 10.1007/978-981-32-9717-3_1; Bhatt RS, 2021, CANCER IMMUNOL RES, V9, P156, DOI 10.1158/2326-6066.CIR-20-0315; Bhojwani D, 2008, J CLIN ONCOL, V26, P4376, DOI 10.1200/JCO.2007.14.4519; Blank CU, 2019, NAT REV IMMUNOL, V19, P665, DOI 10.1038/s41577-019-0221-9; Bonyhadi M, 2005, J IMMUNOL, V174, P2366, DOI 10.4049/jimmunol.174.4.2366; Boulougouris G, 1999, J IMMUNOL, V163, P1809; Chan DV, 2014, GENES IMMUN, V15, P25, DOI 10.1038/gene.2013.57; Chikuma S, 2009, J IMMUNOL, V182, P6682, DOI 10.4049/jimmunol.0900080; Diskin B, 2020, NAT IMMUNOL, V21, P442, DOI 10.1038/s41590-020-0620-x; Drexler H G, 1989, Recent Results Cancer Res, V117, P75; Du HM, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.106113; Dubois S, 2017, CLIN CANCER RES, V23, P2232, DOI 10.1158/1078-0432.CCR-16-1922; Iqbal J, 2014, BLOOD, V123, P2915, DOI 10.1182/blood-2013-11-536359; Janakiram M, 2015, CLIN CANCER RES, V21, P2359, DOI 10.1158/1078-0432.CCR-14-1495; Jing CY, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0554-8; Jones D, 2000, BLOOD, V96, P685; Koirala P, 2016, SCI REP-UK, V6, DOI 10.1038/srep31154; Langenkamp A, 2003, EUR J IMMUNOL, V33, P474, DOI 10.1002/immu.200310023; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Mager DL, 1999, GENOMICS, V59, P255, DOI 10.1006/geno.1999.5877; Mannick JB, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009892; Mazur MA, 2008, BIOL BLOOD MARROW TR, V14, P1190, DOI 10.1016/j.bbmt.2008.07.016; Messal N, 2011, MOL IMMUNOL, V48, P2214, DOI 10.1016/j.molimm.2011.06.436; Mousset CM, 2019, CYTOM PART A, V95A, P647, DOI 10.1002/cyto.a.23724; Noordermeer SM, 2011, BLOOD, V118, P5613, DOI 10.1182/blood-2011-06-359182; Okagawa T, 2016, INFECT IMMUN, V84, P2779, DOI 10.1128/IAI.00278-16; Pauken KE, 2015, CELL, V163, P1038, DOI 10.1016/j.cell.2015.10.054; Rieder SA, 2021, CELL MOL IMMUNOL, V18, P1503, DOI 10.1038/s41423-020-0361-7; Sauce D, 2007, AIDS, V21, P2005, DOI 10.1097/QAD.0b013e3282eee548; Sun SY, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100847; Uhlen M, 2019, SCIENCE, V366, P1471, DOI 10.1126/science.aax9198; Van Vlierberghe P, 2008, BLOOD, V111, P4668, DOI 10.1182/blood-2007-09-111872; Wang JH, 2014, J IMMUNOL, V192; WELTE K, 1983, J IMMUNOL, V131, P2356; Zhao RH, 2013, P NATL ACAD SCI USA, V110, P9879, DOI 10.1073/pnas.1303524110; Zhu YW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3043; Zhu ZW, 2018, ONCOTARGETS THER, V11, P1563, DOI 10.2147/OTT.S160493; Zhuang XX, 2019, CANCER IMMUNOL RES, V7, P939, DOI 10.1158/2326-6066.CIR-18-0733	41	1	1	2	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 1	2021	12								682627	10.3389/fimmu.2021.682627	http://dx.doi.org/10.3389/fimmu.2021.682627			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SS0RT	34140952	gold, Green Published			2022-12-18	WOS:000661450500001
J	Prangtaworn, P; Mahasongkram, K; Saeung, A; Chaisri, U; Seesuay, W; Reamtong, O; Tungtrongchitr, A; Chaicumpa, W; Sookrung, N				Prangtaworn, Pannathee; Mahasongkram, Kodchakorn; Saeung, Atiporn; Chaisri, Urai; Seesuay, Watee; Reamtong, Onrapak; Tungtrongchitr, Anchalee; Chaicumpa, Wanpen; Sookrung, Nitat			A Component-Resolved Therapeutic Vaccine for Cockroach Allergy Made of Per a 9 and Transforming Growth Factor-beta Homologue, an Immunosuppressive Protein of Brugia malayi	FRONTIERS IN IMMUNOLOGY			English	Article						Brugia malayi; transforming growth factor-beta homologue; cockroach allergy; immunotherapy; Periplaneta americana; Per a 9; therapeutic vaccine	REGULATORY T-CELLS; AIRWAY INFLAMMATION; INTERFERON-GAMMA; IMMUNOTHERAPY; ASTHMA; IMMUNE; MECHANISMS; RESPONSES; EXPOSURE; INTRANASAL	Allergen-specific-immunotherapy (ASIT) can cause long-term resolution of allergic diseases, reduces drug use and chances of new allergen sensitization. Nevertheless, therapeutic vaccine and data on ASIT efficacy for cockroach (CR) allergy are relatively scarce. In this study, efficacy and mechanism of a novel intranasal vaccine consisting of liposome (L)-entrapped mixture of American CR (Periplaneta americana) major allergen (Per a 9) and immunosuppressive protein of Brugia malayi nematode named transforming growth factor-beta homologue (TGH) in treatment of CR allergy were investigated along with two other vaccines (L-Per a 9 alone and L-TGH alone). All three vaccines could reduce pathogenic type 2 response and lung immunopathology in the vaccines-treated CR-allergic mice, but by different mechanisms. L-Per a 9 caused a deviation of the pathogenic type 2 to type 1 response (IFN-gamma-upregulation), whereas the L-(TGH + Per a 9) and L-TGH generated regulatory immune responses including up-expression of immunosuppressive cytokine genes and increment of serum adenosine and lung indoleamine-2,3-dioxygenase-1 which are signatures of regulatory T cells (Tregs) and tolerogenic dendritic cells, respectively. The L-(TGH + Per a 9) should be further evaluated towards clinical application, as this vaccine has a propensity to induce broadly effective therapeutic effects for inhalant allergies.	[Prangtaworn, Pannathee] Mahidol Univ, Siriraj Hosp, Dept Immunol, Grad Program Immunol,Fac Med, Bangkok, Thailand; [Prangtaworn, Pannathee; Mahasongkram, Kodchakorn; Seesuay, Watee; Tungtrongchitr, Anchalee; Chaicumpa, Wanpen; Sookrung, Nitat] Mahidol Univ, Siriraj Hosp, Ctr Res Excellence Therapeut Prot & Antibody Engn, Dept Parasitol,Fac Med, Bangkok, Thailand; [Saeung, Atiporn] Chiang Mai Univ, Fac Med, Dept Parasitol, Chiang Mai, Thailand; [Chaisri, Urai] Mahidol Univ, Fac Trop Med, Dept Trop Pathol, Bangkok, Thailand; [Reamtong, Onrapak] Mahidol Univ, Fac Trop Med, Dept Trop Mol Biol & Genet, Bangkok, Thailand; [Sookrung, Nitat] Mahidol Univ, Siriraj Hosp, Dept Res, Biomed Res Incubat Unit,Fac Med, Bangkok, Thailand	Mahidol University; Mahidol University; Chiang Mai University; Mahidol University; Mahidol University; Mahidol University	Sookrung, N (corresponding author), Mahidol Univ, Siriraj Hosp, Ctr Res Excellence Therapeut Prot & Antibody Engn, Dept Parasitol,Fac Med, Bangkok, Thailand.; Sookrung, N (corresponding author), Mahidol Univ, Siriraj Hosp, Dept Res, Biomed Res Incubat Unit,Fac Med, Bangkok, Thailand.	nitat.soo@mahidol.ac.th			Thailand Research Fund [RSA6280100]; NSTDA Chair Professor grant of the National Science and Technology Development Agency (NSTDA) - Crown Property Bureau of Thailand [P-1450624]	Thailand Research Fund(Thailand Research Fund (TRF)); NSTDA Chair Professor grant of the National Science and Technology Development Agency (NSTDA) - Crown Property Bureau of Thailand	This study was co-funded by the Thailand Research Fund (RSA6280100) to NS and the NSTDA Chair Professor grant (P-1450624) of the National Science and Technology Development Agency (NSTDA) funded by the Crown Property Bureau of Thailand to WC. PP received the Royal Golden Jubilee PhD scholarship from the Thailand Research Fund.	Amu S, 2010, J ALLERGY CLIN IMMUN, V125, P1114, DOI 10.1016/j.jaci.2010.01.018; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Boulet LP, 2018, CURR OPIN PULM MED, V24, P56, DOI 10.1097/MCP.0000000000000441; De Groot AS, 2008, BLOOD, V112, P3303, DOI 10.1182/blood-2008-02-138073; Do DC, 2016, ALLERGY, V71, P463, DOI 10.1111/all.12827; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Gravano DM, 2012, CELL MOL LIFE SCI, V69, P1997, DOI 10.1007/s00018-011-0907-z; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Henness S, 2006, AM J PHYSIOL-LUNG C, V290, pL1283, DOI 10.1152/ajplung.00367.2005; Hussaarts L, 2011, J ALLERGY CLIN IMMUN, V128, P733, DOI 10.1016/j.jaci.2011.05.012; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jang E, 2017, J IMMUNOL, V199, P3943, DOI 10.4049/jimmunol.1700211; Karim M, 2005, BLOOD, V105, P4871, DOI 10.1182/blood-2004-10-3888; Laan M, 1999, J IMMUNOL, V162, P2347; Lee HM, 2011, ADV IMMUNOL, V112, P25, DOI 10.1016/B978-0-12-387827-4.00002-4; Liu WM, 2017, J ALLERGY CLIN IMMUN, V139, P1548, DOI 10.1016/j.jaci.2016.08.032; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; McSorley HJ, 2008, J IMMUNOL, V181, P6456, DOI 10.4049/jimmunol.181.9.6456; Meechan P, 2013, INT ARCH ALLERGY IMM, V161, P351, DOI 10.1159/000348314; Mestecky J., 2003, INDUCTIVE EFFECTOR S, V5th; Metenou S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00305; Moingeon P, 2011, IMMUNOL ALLERGY CLIN, V31, P407, DOI 10.1016/j.iac.2011.03.001; Moote W, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0282-5; Nauta AJ, 2008, EUR J PHARMACOL, V585, P354, DOI 10.1016/j.ejphar.2008.02.094; Nials AT, 2008, DIS MODEL MECH, V1, P213, DOI 10.1242/dmm.000323; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Olmedo O, 2011, J ALLERGY CLIN IMMUN, V128, P284, DOI 10.1016/j.jaci.2011.02.044; Passalacqua G, 2014, CURR OPIN ALLERGY CL, V14, P20, DOI 10.1097/ACI.0000000000000018; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Pilette C, 2007, J IMMUNOL, V178, P4658, DOI 10.4049/jimmunol.178.7.4658; Prangtaworn P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33680-9; RAO M, 1995, INFECT IMMUN, V63, P2396, DOI 10.1128/IAI.63.7.2396-2402.1995; Renzi PM, 1999, AM J RESP CRIT CARE, V159, P1417, DOI 10.1164/ajrccm.159.5.9805080; Robinson D, 2017, CLIN EXP ALLERGY, V47, P161, DOI 10.1111/cea.12880; Ronet C, 2010, J IMMUNOL, V184, P886, DOI 10.4049/jimmunol.0901114; Saeung A, 2013, PARASITOL RES, V112, P3259, DOI 10.1007/s00436-013-3504-2; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Schmidt A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00051; Senna G, 2011, CURR OPIN ALLERGY CL, V11, P375, DOI 10.1097/ACI.0b013e328348a7cd; Shamji MH, 2017, ALLERGY, V72, P1156, DOI 10.1111/all.13138; Shaw AR., 2013, PRINCIPLE PRACTICE, VFourth; Singh B, 2013, INDIAN J MED RES, V138, P591; Smits HH, 2007, J ALLERGY CLIN IMMUN, V120, P932, DOI 10.1016/j.jaci.2007.06.009; Sookrung N, 2006, ENVIRON HEALTH PERSP, V114, P875, DOI 10.1289/ehp.8650; Svenningsen S, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00158; Teixeira LK, 2005, MEM I OSWALDO CRUZ, V100, P137, DOI 10.1590/S0074-02762005000900024; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Wirthgen E, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01957; Zhao J, 2013, MUCOSAL IMMUNOL, V6, P335, DOI 10.1038/mi.2012.76	50	1	1	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2021	12								676558	10.3389/fimmu.2021.676558	http://dx.doi.org/10.3389/fimmu.2021.676558			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SR6MF	34135902	Green Published, gold			2022-12-18	WOS:000661156400001
J	Yan, SLS; Hwang, IY; Kamenyeva, O; Kabat, J; Kim, JS; Park, C; Kehrl, JH				Yan, Serena Li-Sue; Hwang, Il-Young; Kamenyeva, Olena; Kabat, Juraj; Kim, Ji Sung; Park, Chung; Kehrl, John H.			Unrestrained G alpha(i2) Signaling Disrupts Neutrophil Trafficking, Aging, and Clearance	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophil; chemotaxis; trafficking; chemoattractants; G-protein; intravital; RGS protein	G-PROTEINS; PROGENITOR CELLS; RGS PROTEINS; REGULATOR; SUBUNIT; INFLAMMATION; ACTIVATION; MIGRATION; MUTATION; CASCADE	Neutrophil trafficking, homeostatic and pathogen elicited, depends upon chemoattractant receptors triggering heterotrimeric G-protein G alpha(i)beta gamma signaling, whose magnitude and kinetics are governed by RGS protein/G alpha(i) interactions. RGS proteins typically limit G alpha(i) signaling by reducing the duration that G alpha(i) subunits remain GTP bound and able to activate downstream effectors. Yet how in totality RGS proteins shape neutrophil chemoattractant receptor activated responses remains unclear. Here, we show that C57Bl/6 mouse neutrophils containing a genomic knock-in of a mutation that disables all RGS protein-G alpha(i2) interactions (G184S) cannot properly balance chemoattractant receptor signaling, nor appropriately respond to inflammatory insults. Mutant neutrophils accumulate in mouse bone marrow, spleen, lung, and liver; despite neutropenia and an intrinsic inability to properly mobilize from the bone marrow. In vitro they rapidly adhere to ICAM-1 coated plates, but in vivo they poorly adhere to blood vessel endothelium. Those few neutrophils that cross blood vessels and enter tissues migrate haphazardly. Following Concanavalin-A administration fragmented G184S neutrophils accumulate in liver sinusoids leading to thrombo-inflammation and perivasculitis. Thus, neutrophil G alpha(i2)/RGS protein interactions both limit and facilitate G alpha(i2) signaling thereby promoting normal neutrophil trafficking, aging, and clearance.	[Yan, Serena Li-Sue; Hwang, Il-Young; Kim, Ji Sung; Park, Chung; Kehrl, John H.] NIAID, Lab Immunoregulat, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Kamenyeva, Olena; Kabat, Juraj] NIAID, Biol Imaging, Res Technol Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kehrl, JH (corresponding author), NIAID, Lab Immunoregulat, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	jkehrl@niaid.nih.gov			Intramural Research Program of National Institute of Allergy and Infectious Diseases	Intramural Research Program of National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by Intramural Research Program of National Institute of Allergy and Infectious Diseases.	Adrover JM, 2020, NAT IMMUNOL, V21, P135, DOI 10.1038/s41590-019-0571-2; Adrover JM, 2019, IMMUNITY, V51, P966, DOI 10.1016/j.immuni.2019.11.001; Adrover JM, 2016, TRENDS IMMUNOL, V37, P334, DOI 10.1016/j.it.2016.03.005; Amulic B, 2017, DEV CELL, V43, P449, DOI 10.1016/j.devcel.2017.10.013; Balenga NA, 2014, J ALLERGY CLIN IMMUN, V134, P451, DOI 10.1016/j.jaci.2014.01.019; Bronte V, 2013, IMMUNITY, V39, P806, DOI 10.1016/j.immuni.2013.10.010; Casanova-Acebes M, 2018, J EXP MED, V215, P2778, DOI 10.1084/jem.20181468; Casanova-Acebes M, 2013, CELL, V153, P1025, DOI 10.1016/j.cell.2013.04.040; Chan EC, 2018, J BIOL CHEM, V293, P12690, DOI 10.1074/jbc.RA118.002404; Cho H, 2012, MOL CELL BIOL, V32, P4561, DOI 10.1128/MCB.00651-12; Cho H, 2009, PROG MOL BIOL TRANSL, V86, P249, DOI 10.1016/S1877-1173(09)86009-2; Eash KJ, 2010, J CLIN INVEST, V120, P2423, DOI 10.1172/JCI41649; Furze RC, 2008, IMMUNOLOGY, V125, P281, DOI 10.1111/j.1365-2567.2008.02950.x; George T, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0266-5; George T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170269; Girbl T, 2018, IMMUNITY, V49, P1062, DOI 10.1016/j.immuni.2018.09.018; Grosse J, 2007, J CLIN INVEST, V117, P3540, DOI 10.1172/JCI32312; Hidalgo A, 2019, TRENDS IMMUNOL, V40, P584, DOI 10.1016/j.it.2019.04.013; Huang XY, 2006, MOL CELL BIOL, V26, P6870, DOI 10.1128/MCB.00314-06; Hwang IY, 2017, J IMMUNOL, V198, P2721, DOI 10.4049/jimmunol.1601433; Hwang IY, 2015, J IMMUNOL, V194, P2128, DOI 10.4049/jimmunol.1401952; INOUE S, 1995, J BIOCHEM-TOKYO, V118, P650, DOI 10.1093/oxfordjournals.jbchem.a124959; Kamenyeva O, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004827; Kamp ME, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010090; Kehrl JH, 2006, IMMUNOL RES, V34, P211, DOI 10.1385/IR:34:3:211; Kehrl JH, 2016, BIOCHEM PHARMACOL, V114, P40, DOI 10.1016/j.bcp.2016.04.005; Lammermann T, 2013, NATURE, V498, P371, DOI 10.1038/nature12175; Lamborn IT., 2016, PUBLICLY ACCESSIBLE, V2016, P160; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Liu Q, 2015, EUR J IMMUNOL, V45, P1855, DOI 10.1002/eji.201445245; Lo Celso C, 2011, NAT PROTOC, V6, P1, DOI 10.1038/nprot.2010.168; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; MURRAYWHELAN R, 1995, EUR J BIOCHEM, V230, P164, DOI 10.1111/j.1432-1033.1995.tb20547.x; Neubig RR, 2015, PROG MOL BIOL TRANSL, V133, P13, DOI 10.1016/bs.pmbts.2015.04.010; Ng LG, 2011, J INVEST DERMATOL, V131, P2058, DOI 10.1038/jid.2011.179; NISHINA H, 1995, J BIOCHEM-TOKYO, V118, P1083, DOI 10.1093/jb/118.5.1083; Park C, 2019, ELIFE, V8, DOI 10.7554/eLife.47776; Pillay J, 2020, J LEUKOCYTE BIOL, V107, P1175, DOI 10.1002/JLB.1MA0420-571RR; Redpath AN, 2017, BLOOD ADV, V1, P1934, DOI 10.1182/bloodadvances.2017006064; Siegmund K, 2013, IMMUNOL LETT, V153, P62, DOI 10.1016/j.imlet.2013.06.005; Signarvic RS, 2010, BLOOD, V116, P6092, DOI 10.1182/blood-2010-05-283846; Tomay F, 2018, IMMUNOL CELL BIOL, V96, P831, DOI 10.1111/imcb.12046; Uhl B, 2016, BLOOD, V128, P2327, DOI 10.1182/blood-2016-05-718999; Woodard GE, 2015, INT REV CEL MOL BIO, V317, P97, DOI 10.1016/bs.ircmb.2015.02.001; Woodfin A, 2011, NAT IMMUNOL, V12, P761, DOI 10.1038/ni.2062; Xie ZH, 2016, AAPS J, V18, P294, DOI 10.1208/s12248-015-9847-0; Yan SLS, 2019, ISCIENCE, V16, P283, DOI 10.1016/j.isci.2019.05.040; Yu YRA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150606	49	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2021	12								679856	10.3389/fimmu.2021.679856	http://dx.doi.org/10.3389/fimmu.2021.679856			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SR6VK	34135907	gold, Green Published			2022-12-18	WOS:000661180300001
J	Liu, H; Lin, XX; Huang, XB; Huang, DH; Song, S; Chen, YJ; Tang, J; Tao, D; Yin, ZN; Mor, G; Liao, AH				Liu, Hong; Lin, Xin-Xiu; Huang, Xiao-Bo; Huang, Dong-Hui; Song, Su; Chen, Yang-Jiao; Tang, Jing; Tao, Ding; Yin, Zhi-Nan; Mor, Gil; Liao, Ai-Hua			Systemic Characterization of Novel Immune Cell Phenotypes in Recurrent Pregnancy Loss	FRONTIERS IN IMMUNOLOGY			English	Article						recurrent pregnancy loss; flow cytometry; peripheral T helper cell; immune cell; NK cell; gamma delta T cell	NATURAL-KILLER-CELLS; DELTA-T-CELLS; SPONTANEOUS-ABORTION; CENTRAL MEMORY; NK CELLS; B-CELLS; WOMEN; CYTOTOXICITY; SUBSETS; IMMUNOGLOBULIN	Recurrent pregnancy loss (RPL) is a disturbing disease in women, and 50% of RPL is reported to be associated with immune dysfunction. Most previous studies of RPL focused mainly on the relationship between RPL and either T cells or natural killer (NK) cells in peripheral blood and the decidua; few studies presented the systemic profiles of the peripheral immune cell subsets in RPL women. Herein, we simultaneously detected 63 immune cell phenotypes in the peripheral blood from nonpregnant women (NPW), women with a history of normal pregnancy (NP) and women with a history of RPL (RPL) by multi-parameter flow cytometry. The results demonstrated that the percentages of naive CD4(+) T cells, central memory CD4(+) T cells, naive CD8(+) T cells, mature NK cells, V delta 1(+) T cells and the ratio of V delta 1(+) T cells/V delta 2(+) T cells were significantly higher in the RPL group than those in the NPW and NP groups, whereas the percentages of terminal differentiated CD4(+) T cells, effective memory CD4(+) T cells, immature NK cells and V delta 2(+) T cells were significantly lower in the RPL group than those in the NPW and NP groups. Interestingly, we found that peripheral T helper (T-PH) cells were more abundant in the NPW group than in the NP and RPL groups. Moreover, the percentage of V delta 2(+)PD-1(+) gamma-delta (gamma delta) T cells was extremely high, above the 95(th) percentile limit, in the NP group compared with the NPW and RPL groups, which has never been reported before. In addition, we also determined the 5(th) percentile lower limit and 95(th) percentile upper limit of the significantly changed immunological parameters based on the files of the NPW group. Taken together, this is the first study to simultaneously characterize the multiple immune cell subsets in the peripheral blood at a relatively large scale in RPL, which might provide a global readout of the immune status for clinicians to identify clinically-relevant immune disorders and guide them to make clear and individualized advice and treatment plans.	[Liu, Hong; Lin, Xin-Xiu; Huang, Xiao-Bo; Huang, Dong-Hui; Mor, Gil; Liao, Ai-Hua] Huazhong Univ Sci & Technol, Tongji Med Coll, Inst Reprod Hlth, Ctr Reprod Med, Wuhan, Peoples R China; [Song, Su; Chen, Yang-Jiao] Huazhong Univ Sci & Technol, Ctr Reprod Med, Tongji Med Coll, Wuhan, Peoples R China; [Tang, Jing] Maternal & Child Hlth Hosp Hubei Prov, Dept Gynecol, Wuhan, Peoples R China; [Tao, Ding] Chinese Univ Hong Kong, Sch Data Sci, Shenzhen, Peoples R China; [Yin, Zhi-Nan] Jinan Univ, Zhuhai Peoples Hosp, Zhuhai Precis Med Ctr, Zhuhai, Peoples R China; [Yin, Zhi-Nan] Jinan Univ, Fac Med Sci, Biomed Translat Res Inst, Guangzhou, Peoples R China; [Mor, Gil] Wayne State Univ, CS Mott Ctr Human Growth & Dev, Sch Med, Detroit, MI 48202 USA	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Chinese University of Hong Kong, Shenzhen; Jinan University; Jinan University; Wayne State University	Liao, AH (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Inst Reprod Hlth, Ctr Reprod Med, Wuhan, Peoples R China.	aihua_liao@sina.com	Liao, Aihua/K-4853-2019	Liao, Aihua/0000-0001-8533-8315; Huang, Xiaobo/0000-0001-7516-8842	National Key Research & Developmental Program of China [2018YFC100 3900, 2018YFC1003904]	National Key Research & Developmental Program of China	This work was supported by National Key Research & Developmental Program of China (2018YFC100 3900; 2018YFC1003904).	Ahmadi M, 2017, BIOMED PHARMACOTHER, V92, P1095, DOI 10.1016/j.biopha.2017.06.001; Ahn E, 2018, P NATL ACAD SCI USA, V115, P4749, DOI 10.1073/pnas.1718217115; Allie SR, 2011, J IMMUNOL, V186, P6280, DOI 10.4049/jimmunol.1003870; Amand M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00699; Azargoon A, 2019, INT J FERTIL STERIL, V13, P12, DOI 10.22074/ijfs.2019.5503; Azizi R, 2019, J CELL PHYSIOL, V234, P19039, DOI 10.1002/jcp.28543; Barrow AD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00909; Bjorkstrom NK, 2016, NAT REV IMMUNOL, V16, P310, DOI 10.1038/nri.2016.34; Brummelman J, 2018, INT REV CEL MOL BIO, V341, P63, DOI 10.1016/bs.ircmb.2018.05.007; Cai DL, 2019, J REPROD IMMUNOL, V131, P57, DOI 10.1016/j.jri.2019.01.003; Cantoni C, 1999, J EXP MED, V189, P787, DOI 10.1084/jem.189.5.787; Carbone J, 2016, J REPROD IMMUNOL, V113, P50, DOI 10.1016/j.jri.2015.11.003; Chen XY, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.09.010; Chen Y, 2018, PATHOL ONCOL RES, V24, P717, DOI 10.1007/s12253-017-0357-5; Chiokadze M, 2019, Georgian Med News, P26; Christophersen A, 2019, NAT MED, V25, P734, DOI 10.1038/s41591-019-0403-9; Cichocki F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02078; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Esensten JH, 2016, IMMUNITY, V44, P973, DOI 10.1016/j.immuni.2016.04.020; Fauriat C, 2010, BLOOD, V115, P2167, DOI 10.1182/blood-2009-08-238469; Feyaerts D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03191-0; Figueiredo AS, 2016, IMMUNOLOGY, V148, P13, DOI 10.1111/imm.12595; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Ghafourian M, 2014, IRAN J IMMUNOL, V11, P84, DOI IJIv11i2A3; Goncalves DR, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.13022; Gordon CL, 2017, J EXP MED, V214, P651, DOI 10.1084/jem.20160758; Guerrero B, 2020, J REPROD IMMUNOL, V142, DOI 10.1016/j.jri.2020.103209; Han XY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01305; Hinz T, 1997, INT IMMUNOL, V9, P1065, DOI 10.1093/intimm/9.8.1065; Janosevic DR, 2020, FOLIA MORPHOL, V79, P296, DOI 10.5603/FM.a2019.0095; Karami N, 2012, J REPROD IMMUNOL, V95, P87, DOI 10.1016/j.jri.2012.06.005; Kieffer TEC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00625; Kirshenbaum M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8112001; Knight A, 2012, CYTOTHERAPY, V14, P1110, DOI 10.3109/14653249.2012.700766; Koushaeian L, 2019, IMMUNOL LETT, V214, P16, DOI 10.1016/j.imlet.2019.08.002; Kumar BV, 2018, IMMUNITY, V48, P202, DOI 10.1016/j.immuni.2018.01.007; Lachapelle MH, 1996, J IMMUNOL, V156, P4027; Lee SK, 2011, HUM REPROD, V26, P2964, DOI 10.1093/humrep/der301; Lee SK, 2013, AM J REPROD IMMUNOL, V70, P398, DOI 10.1111/aji.12137; Li YH, 2018, AUST J GEN PRACT, V47, P432, DOI 10.31128/AJGP-01-18-4459; Liu S, 2017, J REPROD IMMUNOL, V124, P44, DOI 10.1016/j.jri.2017.10.045; Montaldo E, 2013, CYTOM PART A, V83A, P702, DOI 10.1002/cyto.a.22302; Mor G, 2017, NAT REV IMMUNOL, V17, P469, DOI 10.1038/nri.2017.64; Nair S, 2018, SEMIN IMMUNOPATHOL, V40, P425, DOI 10.1007/s00281-018-0680-2; Olson GS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34576-4; Paul S, 2015, J LEUKOCYTE BIOL, V97, P259, DOI 10.1189/jlb.3RU0914-443R; Peters C, 2018, CELL MOL LIFE SCI, V75, P2125, DOI 10.1007/s00018-018-2788-x; Platonova S, 2011, CANCER RES, V71, P5412, DOI 10.1158/0008-5472.CAN-10-4179; Qian JF, 2018, BIOSCI TRENDS, V12, P157, DOI 10.5582/bst.2018.01012; Rao DA, 2019, NAT REV RHEUMATOL, V15, P453, DOI 10.1038/s41584-019-0241-7; Rao DA, 2017, NATURE, V542, P110, DOI 10.1038/nature20810; Ribeiro S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00015; ROBERTSON MJ, 1990, BLOOD, V76, P2421; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 2009, EUR J IMMUNOL, V39, P2076, DOI 10.1002/eji.200939722; Seshadri S, 2014, HUM REPROD UPDATE, V20, P429, DOI 10.1093/humupd/dmt056; Sharma S, 2014, INT J DEV BIOL, V58, P219, DOI 10.1387/ijdb.140109ss; Simoes AE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00929; Simon S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1364828; Sivori S, 2019, CELL MOL IMMUNOL, V16, P430, DOI 10.1038/s41423-019-0206-4; Sprent J, 2011, NAT IMMUNOL, V12, P478, DOI 10.1038/ni.2018; Talukdar A, 2018, CYTOKINE, V102, P117, DOI 10.1016/j.cyto.2017.07.018; Thome JJC, 2016, NAT MED, V22, P72, DOI 10.1038/nm.4008; Ticconi C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215332; Uchida Y, 2020, J DERMATOL SCI, V100, P129, DOI 10.1016/j.jdermsci.2020.09.001; Vahid SA, 2019, J CELL PHYSIOL, V234, P4924, DOI 10.1002/jcp.27290; Wang WJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02025; Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112; Wu L, 2016, AM J REPROD IMMUNOL, V76, P454, DOI 10.1111/aji.12588; Xu B, 2011, P NATL ACAD SCI USA, V108, P2414, DOI 10.1073/pnas.1015433108; Yoo JH, 2012, AM J REPROD IMMUNOL, V68, P38, DOI 10.1111/j.1600-0897.2012.01133.x; Yu X, 2013, TRANSPL IMMUNOL, V29, P118, DOI 10.1016/j.trim.2013.09.001; Zhu L, 2018, CLIN EXP IMMUNOL, V193, P241, DOI 10.1111/cei.13142; Zou C, 2017, ONCOTARGET, V8, P8900, DOI 10.18632/oncotarget.13051; Zuniga-Pflucker JC, 2004, NAT REV IMMUNOL, V4, P67, DOI 10.1038/nri1257	76	1	1	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 28	2021	12								657552	10.3389/fimmu.2021.657552	http://dx.doi.org/10.3389/fimmu.2021.657552			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SQ1DX	34122414	Green Published, gold			2022-12-18	WOS:000660101300001
J	Bouzeyen, R; Chugh, S; Gosain, TP; Barbouche, MR; Haoues, M; Rao, KVS; Essafi, M; Singh, R				Bouzeyen, Rania; Chugh, Saurabh; Gosain, Tannu Priya; Barbouche, Mohamed-Ridha; Haoues, Meriam; Rao, Kanury V. S.; Essafi, Makram; Singh, Ramandeep			Co-Administration of Anticancer Candidate MK-2206 Enhances the Efficacy of BCG Vaccine Against Mycobacterium tuberculosis in Mice and Guinea Pigs	FRONTIERS IN IMMUNOLOGY			English	Article						BCG vaccine; Akt inhibitor; innate immunity; apoptosis; tuberculosis	CD8 T-CELLS; DENDRITIC CELLS; PROTECTIVE IMMUNITY; APOPTOTIC VESICLES; IL-10 PRODUCTION; M. TUBERCULOSIS; NEXT-GENERATION; IN-VITRO; ACTIVATION; RESPONSES	The failure of M. bovis BCG to induce long-term protection has been endowed to its inability to escape the phagolysosome, leading to mild activation of CD8(+) mediated T cell response. Induction of apoptosis in host cells plays an important role in potentiating dendritic cells-mediated priming of CD8(+) T cells, a process defined as "cross-priming." Moreover, IL-10 secretion by infected cells has been reported to hamper BCG-induced immunity against Tuberculosis (TB). Previously, we have reported that apoptosis of BCG-infected macrophages and inhibition of IL-10 secretion is FOXO3 dependent, a transcription factor negatively regulated by the pro-survival activated threonine kinase, Akt. We speculate that FOXO3-mediated induction of apoptosis and abrogation of IL-10 secretion along with M. bovis BCG immunization might enhance the protection imparted by BCG. Here, we have assessed whether co-administration of a known anti-cancer Akt inhibitor, MK-2206, enhances the protective efficacy of M. bovis BCG in mice model of infection. We observed that in vitro MK-2206 treatment resulted in FOXO3 activation, enhanced BCG-induced apoptosis of macrophages and inhibition of IL-10 secretion. Co-administration of M. bovis BCG along with MK-2206 also increased apoptosis of antigen-presenting cells in draining lymph nodes of immunized mice. Further, MK-2206 administration improved BCG-induced CD4(+) and CD8(+) effector T cells responses and its ability to induce both effector and central memory T cells. Finally, we show that co-administration of MK-2206 enhanced the protection imparted by M. bovis BCG against Mtb in aerosol infected mice and guinea pigs. Taken together, we provide evidence that MK-2206-mediated activation of FOXO3 potentiates BCG-induced immunity and imparts protection against Mtb through enhanced innate immune response.	[Bouzeyen, Rania; Barbouche, Mohamed-Ridha; Haoues, Meriam; Essafi, Makram] Inst Pasteur Tunis, LTCII, LR11 IPT02, Tunis, Tunisia; [Chugh, Saurabh; Gosain, Tannu Priya; Rao, Kanury V. S.; Singh, Ramandeep] Translat Hlth Sci & Technol Inst, Faridabad, India	Le Reseau International des Instituts Pasteur (RIIP); Universite de Tunis-El-Manar; Institut Pasteur Tunis; Department of Biotechnology (DBT) India; Translational Health Science & Technology Institute (THSTI)	Essafi, M (corresponding author), Inst Pasteur Tunis, LTCII, LR11 IPT02, Tunis, Tunisia.; Singh, R (corresponding author), Translat Hlth Sci & Technol Inst, Faridabad, India.	makram.essafi@pasteur.tn; ramandeep@thsti.res.in		Singh, Ramandeep/0000-0003-2705-3826	Department of Biotechnology, Govt. of India [BT/IN/Indo-Tunisia/01/2014]; Tunisian Ministry for Higher Education, Scientific Research and Technology; Department of Science and Technology India; FICCI; Council of Scientific and Industrial Research; Department of Biotechnology	Department of Biotechnology, Govt. of India(Department of Biotechnology (DBT) India); Tunisian Ministry for Higher Education, Scientific Research and Technology; Department of Science and Technology India(Department of Science & Technology (India)); FICCI; Council of Scientific and Industrial Research(Council of Scientific & Industrial Research (CSIR) - India); Department of Biotechnology	The authors acknowledge the funding received from Department of Biotechnology, Govt. of India (BT/IN/Indo-Tunisia/01/2014). This work was supported by the Tunisian Ministry for Higher Education, Scientific Research and Technology (Project Tuniso-Indien session 2013-2016). RB acknowledges Department of Science and Technology India and FICCI for providing C.V. Raman International fellowship. SC acknowledges research fellowship received from Council of Scientific and Industrial Research. TG is also thankful to Department of Biotechnology for her fellowship. RS is a recipient of Ramalingaswami Fellowship and National Bioscience Award from Department of Biotechnology. RS is a senior fellow of Wellcome Trust-DBT India Alliance.	Abadie V, 2005, BLOOD, V106, P1843, DOI 10.1182/blood-2005-03-1281; Agarwal E, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-145; Ahlers JD, 2010, BLOOD, V115, P1678, DOI 10.1182/blood-2009-06-227546; Andersen P, 2019, NAT REV IMMUNOL, V19, P550, DOI 10.1038/s41577-019-0174-z; Arlehamn CSL, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a018465; Bai WJ, 2014, CELL SIGNAL, V26, P942, DOI 10.1016/j.cellsig.2014.01.015; Bakhru P, 2014, CELL IMMUNOL, V287, P53, DOI 10.1016/j.cellimm.2013.11.007; Behar SM, 2007, EXPERT REV VACCINES, V6, P441, DOI 10.1586/14760584.6.3.441; Behar SM, 2013, ADV EXP MED BIOL, V783, P141, DOI 10.1007/978-1-4614-6111-1_8; Benmerzoug S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26984-3; Boom WH, 2007, J CLIN INVEST, V117, P2092, DOI 10.1172/JCI32933; Bouzeyen R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02922; Brazier B, 2020, SEMIN IMMUNOPATHOL, V42, P315, DOI 10.1007/s00281-020-00794-0; Chen CY, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000392; Chin'ombe N, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-87; Choi HG, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020300; Clark S, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a018572; Cooney LA, 2011, J IMMUNOL, V187, P4440, DOI 10.4049/jimmunol.1002860; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Das TP, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.403; Dockrell HM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01134; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Essone PN, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44294-0; Farinacci M, 2012, VACCINE, V30, P7608, DOI 10.1016/j.vaccine.2012.10.031; Feng CG, 2002, INFECT IMMUN, V70, P6672, DOI 10.1128/IAI.70.12.6672-6679.2002; Gartner T, 2008, VACCINE, V26, P1458, DOI 10.1016/j.vaccine.2007.12.056; Gengenbacher M, 2016, MBIO, V7, DOI 10.1128/mBio.00679-16; Graves DT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02530; Haoues M, 2014, CELL MICROBIOL, V16, P1378, DOI 10.1111/cmi.12298; Hatherill M, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.03154; Henao-Tamayo MI, 2010, CLIN VACCINE IMMUNOL, V17, P618, DOI 10.1128/CVI.00368-09; Hinchey J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015857; Hu ZD, 2017, MOL THER, V25, P1222, DOI 10.1016/j.ymthe.2017.02.018; Hussain T, 2016, CELL COMMUN SIGNAL, V14, DOI 10.1186/s12964-016-0152-z; Kashino SS, 2008, MICROBES INFECT, V10, P1469, DOI 10.1016/j.micinf.2008.08.010; Kaufmann SHE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00316; Khader SA, 2019, J CLIN INVEST, V129, P3482, DOI 10.1172/JCI128877; Khan A, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0122-8; Kim JH, 2010, IMMUNOL LETT, V134, P47, DOI 10.1016/j.imlet.2010.08.008; Lai R, 2018, J IMMUNOL, V200, P1746, DOI 10.4049/jimmunol.1701109; Lam A, 2017, AM J PHYSIOL-LUNG C, V313, pL218, DOI 10.1152/ajplung.00162.2017; Lewinsohn DA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01262; Li G, 2015, MOL IMMUNOL, V66, P346, DOI 10.1016/j.molimm.2015.04.003; Lindenstrom T, 2009, J IMMUNOL, V182, P8047, DOI 10.4049/jimmunol.0801592; Lovewell RR, 2014, AM J PHYSIOL-LUNG C, V306, pL698, DOI 10.1152/ajplung.00319.2013; Lv YX, 2019, BIOCHEM BIOPH RES CO, V510, P284, DOI 10.1016/j.bbrc.2019.01.091; Mangtani P, 2017, HEALTH TECHNOL ASSES, V21, P1, DOI 10.3310/hta21390; Martins PS, 2006, INT J PHARM, V325, P39, DOI 10.1016/j.ijpharm.2006.06.014; Mehta PK, 1996, INFECT IMMUN, V64, P2673, DOI 10.1128/IAI.64.7.2673-2679.1996; Mendez-Samperio P, 2008, CELL IMMUNOL, V251, P37, DOI 10.1016/j.cellimm.2008.03.002; Mendez-Samperio P, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12772; Mihret A, 2012, VIRULENCE, V3, P654, DOI 10.4161/viru.22586; Moliva Juan I, 2017, Front Immunol, V8, P407, DOI 10.3389/fimmu.2017.00407; Nandakumar S, 2016, SCI REP-UK, V6, DOI 10.1038/srep25837; Neves BM, 2010, AM J PATHOL, V177, P2898, DOI 10.2353/ajpath.2010.100367; Nieuwenhuizen NE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00121; Cavalcanti YVN, 2012, PULM MED, V2012, DOI 10.1155/2012/745483; Pal A, 2020, ACS OMEGA, V5, P19968, DOI 10.1021/acsomega.0c01228; Penteado LD, 2017, IMMUNOLOGY, V151, P304, DOI 10.1111/imm.12731; Pitt JM, 2012, J IMMUNOL, V189, P4079, DOI 10.4049/jimmunol.1201061; Rai PK, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1301-x; Redford PS, 2011, MUCOSAL IMMUNOL, V4, P261, DOI 10.1038/mi.2011.7; Rodrigues MF, 2009, IMMUNOLOGY, V128, pe691, DOI 10.1111/j.1365-2567.2009.03062.x; Ryan AA, 2009, J IMMUNOL, V182, P7172, DOI 10.4049/jimmunol.0801694; Schaible UE, 2003, NAT MED, V9, P1039, DOI 10.1038/nm906; Schaible UE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01755; Scriba TJ, 2020, CELL, V180, P829, DOI 10.1016/j.cell.2020.02.024; Sendide K, 2005, J IMMUNOL, V175, P5324, DOI 10.4049/jimmunol.175.8.5324; Silva-Filho J L, 2014, Biophys Rev, V6, P111, DOI 10.1007/s12551-013-0133-z; Singh R, 2013, J BACTERIOL, V195, P2839, DOI 10.1128/JB.00038-13; Tanner R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01317; Wang J, 2004, J IMMUNOL, V173, P4590, DOI 10.4049/jimmunol.173.7.4590; Wang J, 2002, VACCINE, V20, P2887, DOI 10.1016/S0264-410X(02)00241-4; WHO, 2021, TUBERCULOSIS; Winau F, 2006, IMMUNITY, V24, P105, DOI 10.1016/j.immuni.2005.12.001; Winau F, 2004, CELL MICROBIOL, V6, P599, DOI 10.1111/j.1462-5822.2004.00408.x; Wolf AJ, 2007, J IMMUNOL, V179, P2509, DOI 10.4049/jimmunol.179.4.2509; Wu Y, 2008, INFECT IMMUN, V76, P2249, DOI 10.1128/IAI.00024-08; Xu H, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/8616154; Yao YX, 2005, J EXP MED, V201, P1899, DOI 10.1084/jem.20050324; Zeng GC, 2018, CELL MOL IMMUNOL, V15, P206, DOI 10.1038/cmi.2017.113; Zhao YY, 2014, DRUG DES DEV THER, V8, P1827, DOI 10.2147/DDDT.S67961	82	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2021	12								645962	10.3389/fimmu.2021.645962	http://dx.doi.org/10.3389/fimmu.2021.645962			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SO9LB	34122406	Green Published, gold			2022-12-18	WOS:000659293700001
J	Chen, ZF; Gou, Q; Xiong, QS; Duan, LL; Yuan, Y; Zhu, J; Zou, JT; Chen, LL; Jing, HM; Zhang, XL; Luo, P; Zeng, H; Zou, QM; Zhao, Z; Zhang, JY				Chen, Zhifu; Gou, Qiang; Xiong, Qingshan; Duan, Lianli; Yuan, Yue; Zhu, Jiang; Zou, Jintao; Chen, Longlong; Jing, Haiming; Zhang, Xiaoli; Luo, Ping; Zeng, Hao; Zou, Quanming; Zhao, Zhuo; Zhang, Jinyong			Immunodominance of Epitopes and Protective Efficacy of HI Antigen Are Differentially Altered Using Different Adjuvants in a Mouse Model of Staphylococcus aureus Bacteremia	FRONTIERS IN IMMUNOLOGY			English	Article						Staphylococcus aureus; immunodominant epitope; antibody; adjuvants; bacteremia	VACCINE ADJUVANT; CURRENT STATE; IMMUNOGENICITY; ANTIBODIES; EPIDEMIOLOGY; HEMODIALYSIS; SPECIFICITY; INFECTIONS; MECHANISM; RESISTANT	HI, a fusion protein that consists of the alpha-toxin (Hla) and the N2 domain of iron surface determinant B (IsdB), is one of the antigens in the previously reported S. aureus vaccine rFSAV and has already entered phase II clinical trials. Previous studies revealed that HI is highly immunogenic in both mice and healthy volunteers, and the humoral immune response plays key roles in HI-mediated protection. In this study, we further investigated the protective efficacy of immunization with HI plus four different adjuvants in a mouse bacteremia model. Results showed that HI-mediated protection was altered in response to different adjuvants. Using antisera from immunized mice, we identified seven B-cell immunodominant epitopes on Hla and IsdB, including 6 novel epitopes (Hla(1-18), Hla(84-101), Hla(186-203), IsdB(342-359), IsdB(366-383), and IsdB(384-401)). The immunodominance of B-cell epitopes, total IgG titers and the levels of IFN-gamma and IL-17A from mice immunized with HI plus different adjuvants were different from each other, which may explain the difference in protective immunity observed in each immunized group. Thus, our results indicate that adjuvants largely affected the immunodominance of epitopes and the protective efficacy of HI, which may guide further adjuvant screening for vaccine development and optimization.	[Chen, Zhifu; Gou, Qiang; Xiong, Qingshan; Duan, Lianli; Yuan, Yue; Zou, Jintao; Chen, Longlong; Jing, Haiming; Luo, Ping; Zeng, Hao; Zou, Quanming; Zhao, Zhuo; Zhang, Jinyong] Third Mil Med Univ, Natl Engn Res Ctr Immunol Prod, Dept Microbiol & Biochem Pharm, Coll Pharm, Chongqing, Peoples R China; [Zhu, Jiang] Third Mil Med Univ, Southwest Hosp, Dept Pathol, Chongqing, Peoples R China; [Zhang, Xiaoli] Third Mil Med Univ, Coll Pharm, Dept Clin Hematol, Chongqing, Peoples R China	Army Medical University; Army Medical University; Army Medical University	Zhao, Z; Zhang, JY (corresponding author), Third Mil Med Univ, Natl Engn Res Ctr Immunol Prod, Dept Microbiol & Biochem Pharm, Coll Pharm, Chongqing, Peoples R China.	zhaozhuo198309@163.com; zhangjy198217@126.com	Duan, Lianli/GQP-3771-2022	Zhang, Jinyong/0000-0001-9622-5834	National Natural Science Foundation of China [31970138, 31970869]; Natural Science Foundation Project of Chongqing [cstc2019jcyj-msxmX0320, cstc2019jcyj-msxmX0377]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation Project of Chongqing(Natural Science Foundation of Chongqing)	This work was supported by grants from the National Natural Science Foundation of China (Nos. 31970138 and 31970869) and the Natural Science Foundation Project of Chongqing (cstc2019jcyj-msxmX0320 and cstc2019jcyj-msxmX0377).	Aw-Yong KL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165659; Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114; Batista MT, 2017, VACCINE, V35, P7273, DOI 10.1016/j.vaccine.2017.11.007; Cho JS, 2010, J CLIN INVEST, V120, P1762, DOI 10.1172/JCI40891; Choubini E, 2018, MOL IMMUNOL, V96, P88, DOI 10.1016/j.molimm.2018.03.001; DeForge LE, 2000, J IMMUNOL METHODS, V245, P79, DOI 10.1016/S0022-1759(00)00279-9; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Fattom AI, 2004, VACCINE, V22, P880, DOI 10.1016/j.vaccine.2003.11.034; Fattom A, 2015, HUM VACC IMMUNOTHER, V11, P632, DOI 10.4161/hv.34414; Francois B, 2018, INTENS CARE MED, V44, P1787, DOI 10.1007/s00134-018-5229-2; Frenck RW, 2017, VACCINE, V35, P375, DOI 10.1016/j.vaccine.2016.11.010; Gaudin CFM, 2011, BIOCHEMISTRY-US, V50, P5443, DOI 10.1021/bi200369p; Harro CD, 2012, VACCINE, V30, P1729, DOI 10.1016/j.vaccine.2011.12.045; Kebaier C, 2012, J INFECT DIS, V205, P807, DOI 10.1093/infdis/jir846; Kourtis AP, 2019, MMWR-MORBID MORTAL W, V68, P214, DOI 10.15585/mmwr.mm6809e1; Mei C, 2019, COMPUT STRUCT BIOTEC, V17, P1184, DOI 10.1016/j.csbj.2019.08.003; Mortazavi SS, 2020, MICROB PATHOGENESIS, V140, DOI 10.1016/j.micpath.2019.103945; Maeda DLNF, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01175; O'Hagan DT, 2007, CLIN PHARMACOL THER, V82, P740, DOI 10.1038/sj.clpt.6100402; Ortwine Jessica K, 2018, Hosp Pract (1995), V46, P64, DOI 10.1080/21548331.2018.1435128; Portuondo DLF, 2015, MED MYCOL, V53, P69, DOI 10.1093/mmy/myu045; Rauch S, 2012, INFECT IMMUN, V80, P3721, DOI 10.1128/IAI.00442-12; Redi D, 2018, NEW MICROBIOL, V41, P208; Sharma-Kuinkel BK, 2015, J CLIN MICROBIOL, V53, P227, DOI 10.1128/JCM.02023-14; Shi ST, 2019, VACCINE, V37, P3167, DOI 10.1016/j.vaccine.2019.04.055; Tanaka Y, 2011, PROTEIN SCI, V20, P448, DOI 10.1002/pro.579; Tong SYC, 2015, CLIN MICROBIOL REV, V28, P603, DOI 10.1128/CMR.00134-14; Vaithinathan AG, 2018, PERSPECT PUBLIC HEAL, V138, P87, DOI 10.1177/1757913917743881; Volckmar J, 2019, VACCINE, V37, P4963, DOI 10.1016/j.vaccine.2019.07.019; Wang XY, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040161; Yu W, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22044-y; Zapotoczna M, 2013, CELL MICROBIOL, V15, P1026, DOI 10.1111/cmi.12097; Zeng H, 2021, J INFECT DIS, V223, P1743, DOI 10.1093/infdis/jiaa602; Zeng H, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010134; Zhang JY, 2015, SCI REP-UK, V5, DOI 10.1038/srep15553; Zuo QF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081212	37	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2021	12								684823	10.3389/fimmu.2021.684823	http://dx.doi.org/10.3389/fimmu.2021.684823			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SO9KB	34122448	Green Published, gold			2022-12-18	WOS:000659291100001
J	Zhang, ZX; Aweya, JJ; Yao, DF; Zheng, ZH; Tran, NT; Li, SK; Zhang, YL				Zhang, Zhaoxue; Aweya, Jude Juventus; Yao, Defu; Zheng, Zhihong; Tran, Ngoc Tuan; Li, Shengkang; Zhang, Yueling			Ubiquitination as an Important Host-Immune Response Strategy in Penaeid Shrimp: Inferences From Other Species	FRONTIERS IN IMMUNOLOGY			English	Review						ubiquitination; penaeid shrimp; pathogens; immune response; posttranslational modification	SPOT-SYNDROME-VIRUS; PACIFIC WHITE SHRIMP; BETA-CATENIN HOMOLOG; YELLOW HEAD VIRUS; LITOPENAEUS-VANNAMEI; INNATE IMMUNITY; PROTEIN-DEGRADATION; FUNCTIONAL-ANALYSIS; CONJUGATING ENZYME; PELLINO PROTEINS	Shrimp aquaculture is an essential economic venture globally, but the industry faces numerous challenges, especially pathogenic infections. As invertebrates, shrimp rely mainly on their innate immune system for protection. An increasing number of studies have shown that ubiquitination plays a vital role in the innate immune response to microbial pathogens. As an important form of posttranslational modification (PTM), both hosts and pathogens have exploited ubiquitination and the ubiquitin system as an immune response strategy to outwit the other. This short review brings together recent findings on ubiquitination and how this PTM plays a critical role in immune modulation in penaeid shrimps. Key findings inferred from other species would help guide further studies on ubiquitination as an immune response strategy in shrimp-pathogen interactions.	[Zhang, Zhaoxue; Aweya, Jude Juventus; Yao, Defu; Zheng, Zhihong; Tran, Ngoc Tuan; Li, Shengkang; Zhang, Yueling] Shantou Univ, Inst Marine Sci, Shantou, Peoples R China; [Zhang, Zhaoxue; Aweya, Jude Juventus; Yao, Defu; Zheng, Zhihong; Tran, Ngoc Tuan; Li, Shengkang; Zhang, Yueling] Shantou Univ, Guangdong Prov Key Lab Marine Biotechnol, Shantou, Peoples R China; [Zhang, Zhaoxue; Aweya, Jude Juventus; Yao, Defu; Zheng, Zhihong; Tran, Ngoc Tuan; Li, Shengkang; Zhang, Yueling] Shantou Univ, STU UMT Joint Shellfish Res Lab, Shantou, Peoples R China; [Zhang, Yueling] Southern Marine Sci & Engn Guangdong Lab, Guangzhou, Peoples R China	Shantou University; Shantou University; Shantou University; Southern Marine Science & Engineering Guangdong Laboratory	Aweya, JJ; Zhang, YL (corresponding author), Shantou Univ, Inst Marine Sci, Shantou, Peoples R China.; Aweya, JJ; Zhang, YL (corresponding author), Shantou Univ, Guangdong Prov Key Lab Marine Biotechnol, Shantou, Peoples R China.; Aweya, JJ; Zhang, YL (corresponding author), Shantou Univ, STU UMT Joint Shellfish Res Lab, Shantou, Peoples R China.; Zhang, YL (corresponding author), Southern Marine Sci & Engn Guangdong Lab, Guangzhou, Peoples R China.	jjaweya@stu.edu.cn; zhangyl@stu.edu.cn	Tran, Ngoc Tuan/GXF-6033-2022; Aweya, Jude Juventus/GUD-4163-2022; Aweya, Jude Juventus/D-7034-2013	Tran, Ngoc Tuan/0000-0003-1847-7301; Aweya, Jude Juventus/0000-0003-2554-9369	2020 Li Ka Shing Foundation Cross-Disciplinary Research Grant [2020LKSFG01E]; National Natural Science Foundation of China [31872596, 32073008]; Key Special Project for Introduced Talents Team of Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou) [GML2019ZD0606]; Shantou University Scientific Research Foundation for Talents [NTF19005]	2020 Li Ka Shing Foundation Cross-Disciplinary Research Grant; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Special Project for Introduced Talents Team of Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou); Shantou University Scientific Research Foundation for Talents	This work was sponsored by the 2020 Li Ka Shing Foundation Cross-Disciplinary Research Grant (No. 2020LKSFG01E), National Natural Science Foundation of China (Nos. 31872596 & 32073008), Key Special Project for Introduced Talents Team of Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou) (No. GML2019ZD0606) and Shantou University Scientific Research Foundation for Talents (No. NTF19005).	Aalto AL, 2019, CELL DEATH DIFFER, V26, P860, DOI 10.1038/s41418-018-0164-x; Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Adorisio S, 2017, J AUTOIMMUN, V84, P21, DOI 10.1016/j.jaut.2017.09.001; Angot A, 2007, PLOS PATHOG, V3, P1, DOI 10.1371/journal.ppat.0030003; Baker-Austin C, 2010, ENV MICROBIOL REP, V2, P7, DOI 10.1111/j.1758-2229.2009.00096.x; Bakowski MA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004200; Cameron AM, 2016, SEMIN IMMUNOL, V28, P408, DOI 10.1016/j.smim.2016.10.003; Cao ZF, 2015, IMMUNITY, V43, P715, DOI 10.1016/j.immuni.2015.10.005; Chen AJ, 2013, J VIROL, V87, P636, DOI 10.1128/JVI.01671-12; Chen AJ, 2011, J VIROL, V85, P8069, DOI 10.1128/JVI.00487-11; Chen K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131503; Chen L, 2017, J BIOL CHEM, V292, P8738, DOI 10.1074/jbc.M117.788158; Chen XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073218; Ciechanover A, 2015, NAT REV MOL CELL BIO, V16, P322, DOI 10.1038/nrm3982; Cui JX, 2010, SCIENCE, V329, P1215, DOI 10.1126/science.1193844; Deng HW, 2020, DEV COMP IMMUNOL, V106, DOI 10.1016/j.dci.2019.103581; Duda DM, 2008, CELL, V134, P995, DOI 10.1016/j.cell.2008.07.022; Feng NN, 2014, MOL BIOL REP, V41, P1437, DOI 10.1007/s11033-013-2988-2; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Gack MU, 2007, NATURE, V446, P916, DOI 10.1038/nature05732; Gong T, 2018, TRENDS BIOCHEM SCI, V43, P685, DOI 10.1016/j.tibs.2018.06.008; He F, 2006, J VIROL, V80, P3884, DOI 10.1128/JVI.80.8.3884-3892.2006; He F, 2009, J GEN VIROL, V90, P1483, DOI 10.1099/vir.0.008912-0; Hillesheim A, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-29; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Huai WW, 2019, J EXP MED, V216, P772, DOI 10.1084/jem.20181773; Huang YH, 2016, FISH SHELLFISH IMMUN, V54, P435, DOI 10.1016/j.fsi.2016.04.138; Iwanaga S, 2005, J BIOCHEM MOL BIOL, V38, P128; Ji SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4458; Jia X, 2017, J IMMUNOL, V198, P4652, DOI 10.4049/jimmunol.1601322; Jiang XM, 2012, NAT REV IMMUNOL, V12, P35, DOI 10.1038/nri3111; Joseph SJ, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-228; Keezhedath J, 2013, INDIAN J VIROL, V24, P48, DOI 10.1007/s13337-013-0131-6; Klasse PJ, 1998, ADV DRUG DELIVER REV, V34, P65, DOI 10.1016/S0169-409X(98)00002-7; Koltun B, 2017, INT J DEV BIOL, V61, P319, DOI 10.1387/ijdb.160250ao; Kong TT, 2020, DEV COMP IMMUNOL, V105, DOI 10.1016/j.dci.2019.103580; Kuniyoshi K, 2014, P NATL ACAD SCI USA, V111, P5646, DOI 10.1073/pnas.1401674111; Kurata S, 2006, IMMUNOBIOLOGY, V211, P237, DOI 10.1016/j.imbio.2005.10.016; Kwon YT, 2017, TRENDS BIOCHEM SCI, V42, P873, DOI 10.1016/j.tibs.2017.09.002; Lavie J, 2018, CELL REP, V23, P2852, DOI 10.1016/j.celrep.2018.05.013; Li CZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01785; Li CZ, 2014, DEV COMP IMMUNOL, V44, P341, DOI 10.1016/j.dci.2014.01.012; Li FH, 2013, DEV COMP IMMUNOL, V39, P11, DOI 10.1016/j.dci.2012.03.016; Li HY, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007109; Li XJ, 2015, J VIROL, V89, P6792, DOI 10.1128/JVI.00351-15; Lightner DV, 2011, J INVERTEBR PATHOL, V106, P110, DOI 10.1016/j.jip.2010.09.012; Lin SJ, 2015, J VIROL, V89, P1083, DOI 10.1128/JVI.02318-14; Liu J, 2015, BBA-REV CANCER, V1855, P50, DOI 10.1016/j.bbcan.2014.11.005; Liu J, 2016, IMMUNITY, V45, P15, DOI 10.1016/j.immuni.2016.06.020; Liu XJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006542; Lu HS, 2011, VIROLOGY, V419, P84, DOI 10.1016/j.virol.2011.07.021; Luo ZZ, 2020, AQUACULT REP, V17, DOI 10.1016/j.aqrep.2020.100365; Maculins T, 2016, CELL RES, V26, P499, DOI 10.1038/cr.2016.30; Marques MRF, 2000, AQUACULTURE, V191, P23, DOI 10.1016/S0044-8486(00)00417-8; Munoz-Fontela C, 2011, CELL CYCLE, V10, P3701, DOI 10.4161/cc.10.21.17899; Murphy M, 2015, J BIOL CHEM, V290, P19218, DOI 10.1074/jbc.M115.640128; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Napolitano LM, 2011, BIOCHEM J, V434, P309, DOI 10.1042/BJ20101487; Naujokat C, 2007, STEM CELLS, V25, P2408, DOI 10.1634/stemcells.2007-0255; Niu GJ, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007558; Ou CY, 2002, GENE DEV, V16, P2403, DOI 10.1101/gad.1011402; Park Y, 2014, ADV IMMUNOL, V124, P17, DOI 10.1016/B978-0-12-800147-9.00002-9; Pei G, 2017, AUTOPHAGY, V13, P2041, DOI 10.1080/15548627.2017.1376160; Peruzza L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49836-0; Prasad R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073530; Reily C, 2019, NAT REV NEPHROL, V15, P346, DOI 10.1038/s41581-019-0129-4; Reinstein E, 2006, ANN INTERN MED, V145, P676, DOI 10.7326/0003-4819-145-9-200611070-00010; Rytkonen A, 2007, CELL HOST MICROBE, V1, P13, DOI 10.1016/j.chom.2007.02.003; Schauvliege R, 2007, J CELL MOL MED, V11, P453, DOI 10.1111/j.1582-4934.2007.00040.x; Schauvliege R, 2006, FEBS LETT, V580, P4697, DOI 10.1016/j.febslet.2006.07.046; Seo JK, 2013, MOL IMMUNOL, V53, P88, DOI 10.1016/j.molimm.2012.07.003; Shekhar MS, 2015, J FISH DIS, V38, P599, DOI 10.1111/jfd.12279; Shekhar MS, 2013, FISH SHELLFISH IMMUN, V35, P1957, DOI 10.1016/j.fsi.2013.09.038; Soowannayan C, 2013, J GEN VIROL, V94, P2458, DOI 10.1099/vir.0.054379-0; Soowannayan C, 2010, J GEN VIROL, V91, P2463, DOI 10.1099/vir.0.022111-0; SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939; Stuart LM, 2008, NAT REV IMMUNOL, V8, P131, DOI 10.1038/nri2240; Sun JZ, 2017, DEV COMP IMMUNOL, V76, P412, DOI 10.1016/j.dci.2017.07.003; Sun JJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006626; Sun MZ, 2019, DEV COMP IMMUNOL, V97, P57, DOI 10.1016/j.dci.2019.03.014; Tassanakajon A, 2013, FISH SHELLFISH IMMUN, V34, P954, DOI 10.1016/j.fsi.2012.09.021; Tassanakajon A, 2011, MAR BIOTECHNOL, V13, P639, DOI [10.1007/s10126-011-9381-8, 10.1007/s10126-010-9288-9]; Turner JW, 2009, ISME J, V3, P1082, DOI 10.1038/ismej.2009.50; van der Aa LM, 2012, DEV COMP IMMUNOL, V36, P433, DOI 10.1016/j.dci.2011.08.010; Wang LU, 2005, FISH SHELLFISH IMMUN, V18, P269, DOI 10.1016/j.fsi.2004.07.008; Wang PH, 2014, ANTIVIR RES, V108, P129, DOI 10.1016/j.antiviral.2014.05.013; Wang W, 2008, FISH SHELLFISH IMMUN, V25, P522, DOI 10.1016/j.fsi.2008.07.016; Wang XW, 2009, FISH SHELLFISH IMMUN, V27, P556, DOI 10.1016/j.fsi.2009.07.011; Wang YT, 2012, J IMMUNOL, V189, P5304, DOI 10.4049/jimmunol.1201445; Wang ZL, 2005, J VIROL, V79, P8764, DOI 10.1128/JVI.79.14.8764-8772.2005; Wen R, 2014, FISH SHELLFISH IMMUN, V38, P354, DOI 10.1016/j.fsi.2014.04.002; Xie CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114500; Xu C, 2017, J PROTEOMICS, V162, P1, DOI 10.1016/j.jprot.2017.04.013; Xue SX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076718; Yang F, 2001, J VIROL, V75, P11811, DOI 10.1128/JVI.75.23.11811-11820.2001; Yang L, 2019, FISH SHELLFISH IMMUN, V84, P1041, DOI 10.1016/j.fsi.2018.10.077; Yu YP, 2017, FISH SHELLFISH IMMUN, V60, P33, DOI 10.1016/j.fsi.2016.11.036; Zhang S, 2016, FISH SHELLFISH IMMUN, V54, P411, DOI 10.1016/j.fsi.2016.03.162; Zhang YL, 2018, FISH SHELLFISH IMMUN, V76, P187, DOI 10.1016/j.fsi.2018.03.002; Zhang ZH, 2017, IMMUNOL LETT, V192, P42, DOI 10.1016/j.imlet.2017.10.008; Zheng ZH, 2018, FISH SHELLFISH IMMUN, V74, P10, DOI 10.1016/j.fsi.2017.12.032; Zheng ZR, 2016, J IMMUNOL, V196, P1199, DOI 10.4049/jimmunol.1501045; Zhou R, 2005, J BIOL CHEM, V280, P34048, DOI 10.1074/jbc.M506655200; Zhou Y, 2016, NAT IMMUNOL, V17, P397, DOI 10.1038/ni.3395; Zhu GH, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00212; Zohaib A, 2016, CURR ISSUES MOL BIOL, V18, P1	106	1	1	7	20	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2021	12								697397	10.3389/fimmu.2021.697397	http://dx.doi.org/10.3389/fimmu.2021.697397			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SO9LM	34122458	gold, Green Published			2022-12-18	WOS:000659294800001
J	Delliere, S; Duchateau, M; Wong, SSW; Gianetto, QG; Guegan, H; Matondo, M; Gangneux, JP; Aimanianda, V				Delliere, Sarah; Duchateau, Magalie; Wong, Sarah Sze Wah; Gianetto, Quentin Giai; Guegan, Helene; Matondo, Mariette; Gangneux, Jean-Pierre; Aimanianda, Vishukumar			Proteomic Analysis of Humoral Immune Components in Bronchoalveolar Lavage of Patients Infected or Colonized by Aspergillus fumigatus	FRONTIERS IN IMMUNOLOGY			English	Article						Aspergillus fumigatus; aspergillosis; bronchoalveolar lavage; proteomics; humoral immunity; complement system; pentraxin-3	INVASIVE PULMONARY ASPERGILLOSIS; LONG PENTRAXIN PTX3; HOST; FLUID; LUNG	Humoral immune components have been individually studied in the context of interaction of host with Aspergillus fumigatus, a major airborne fungal pathogen. However, a global view of the multitude and complex nature of humoral immune components is needed to bring new insight into host-Aspergillus interaction. Therefore, we undertook comparative proteomic analysis of the bronchoalveolar lavage fluid collected from individuals infected or colonized with A. fumigatus versus controls, to identify those alveolar humoral components affected upon A. fumigatus infection. Complement proteins C1q, C8 beta-chain, factor-H, ficolin-1, ficolin-2, mannan binding lectin serine peptidase 2, pentraxin-3 and the surfactant protein-D were identified as the major humoral immune components affected by A. fumigatus infection and colonization. Based on this observation, we hypothesize that crosstalk between these humoral components is essential during host-Aspergillus interaction giving new specific leads to study for better understanding the pathogenesis. Furthermore, the affected humoral components could be potential diagnostic markers of A. fumigatus infection or colonization.	[Delliere, Sarah; Wong, Sarah Sze Wah; Aimanianda, Vishukumar] Inst Pasteur, Mol Mycol Unit, CNRS, Paris, France; [Delliere, Sarah] Univ Paris, Paris, France; [Delliere, Sarah] Hop St Louis, Dept Mycol & Parasitol, Paris, France; [Duchateau, Magalie; Gianetto, Quentin Giai; Matondo, Mariette] Inst Pasteur, Mass Spectrometry Biol Unit, CNRS, Prote Platform, Paris, France; [Gianetto, Quentin Giai] Inst Pasteur, Computat Biol Dept, CNRS, Bioinformat & Biostat Hub, Paris, France; [Guegan, Helene; Gangneux, Jean-Pierre] Univ Rennes, CHU Rennes, INSERM, EHESP,Irset Inst Rech Sante Environm & Travail UM, Rennes, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; CHU Rennes; Ecole des Hautes Etudes en Sante Publique (EHESP); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes	Aimanianda, V (corresponding author), Inst Pasteur, Mol Mycol Unit, CNRS, Paris, France.	vkumar@pasteur.fr	Aimanianda, Vishukumar/E-9204-2011; Gangneux, Jean-Pierre/J-2960-2015; Dellière, Sarah/AAB-8282-2019; Wong, Sarah/DOH-8455-2022; Guegan, Hélène/AAO-9627-2020	Aimanianda, Vishukumar/0000-0001-5813-7497; Dellière, Sarah/0000-0003-3821-1762; 	ANR-FUNHYDRO [ANR-16SCE110020-01]	ANR-FUNHYDRO	This work was supported by ANR-FUNHYDRO (ANR-16SCE110020-01) grant.	Behnsen J, 2008, INFECT IMMUN, V76, P820, DOI 10.1128/IAI.01037-07; Chang YY, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008822; Cunha C, 2014, NEW ENGL J MED, V370, P421, DOI 10.1056/NEJMoa1211161; Delliere S, 2020, CURR OPIN MICROBIOL, V58, P24, DOI 10.1016/j.mib.2020.05.005; Denning DW, 2016, EUR RESPIR J, V47, P45, DOI 10.1183/13993003.00583-2015; Donnelly JP, 2020, CLIN INFECT DIS, V71, P1367, DOI 10.1093/cid/ciz1008; Garlanda C, 2002, NATURE, V420, P182, DOI 10.1038/nature01195; Gazi U, 2011, J BIOL CHEM, V286, P7822, DOI 10.1074/jbc.M110.185025; Goncalves SM, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02362; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Inforzato A, 2006, BIOCHEMISTRY-US, V45, P11540, DOI 10.1021/bi0607453; Jensen K, 2017, VIRULENCE, V8, P1870, DOI 10.1080/21505594.2016.1278337; Kabbani D, 2017, J HEART LUNG TRANSPL, V36, P973, DOI 10.1016/j.healun.2017.04.007; Latge JP, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00140-18; Ma YJ, 2009, J BIOL CHEM, V284, P28263, DOI 10.1074/jbc.M109.009225; Machata S, 2020, VIRULENCE, V11, P1337, DOI 10.1080/21505594.2020.1824960; Madan T, 2010, MOL IMMUNOL, V47, P1923, DOI 10.1016/j.molimm.2010.02.027; Parente R, 2020, FEBS LETT, V594, P2480, DOI 10.1002/1873-3468.13744; Shende R, 2018, J BIOL CHEM, V293, P15538, DOI [10.1074/jbc.RA117.001476, 10.1074/jbc.ra117.001476]; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Wong SSW, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00212-20; Wong SSW, 2018, J BIOL CHEM, V293, P4901, DOI [10.1074/jbc.M117.815852, 10.1074/jbc.m117.815852]	22	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2021	12								677798	10.3389/fimmu.2021.677798	http://dx.doi.org/10.3389/fimmu.2021.677798			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SO6HN	34122441	Green Published, gold			2022-12-18	WOS:000659071000001
J	Ren, HY; Zhang, TY; Wang, YR; Yao, Q; Wang, ZY; Zhang, LY; Wang, LX				Ren, Hongyan; Zhang, Tianyu; Wang, Yongren; Yao, Qi; Wang, Ziyu; Zhang, Luyao; Wang, Lixin			Tumor-Derived Autophagosomes (DRibbles) Activate Human B Cells to Induce Efficient Antigen-Specific Human Memory T-Cell Responses	FRONTIERS IN IMMUNOLOGY			English	Article						DRibbles; human B cells; activation; cross-presentation; antigen-specific memory T cells	CROSS-PRESENTATION; GM-CSF; VACCINE; INFLAMMATION; CHEMOKINES; CYTOKINES; PRODUCE; IP-10; NAIVE	We have reported that tumor-derived autophagosomes (DRibbles) were efficient carriers of tumor antigens and DRibbles antigens could be present by DRibbles-activated B cells to stimulate effect and naive T cells in mice. However, the effect of DRibbles on human B cells remains unclear. Herein, we found that DRibbles can also efficiently induce proliferation and activation of human B cells and lead to the production of chemokines, cytokines and hematopoietic growth factors. We further demonstrated human B cells can effectively phagocytose DRibbles directly and cross-present DRibbles antigens to stimulate antigen-specific memory T cells. Furthermore, we found that membrane-bound high-mobility group B1 (HMGB1) on DRibbles was crucial for inducing human B cells activation. Therefore, these findings provide further evidence to promote the clinical application of B-DRibbles vaccines.	[Ren, Hongyan; Yao, Qi; Wang, Ziyu; Zhang, Luyao] Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, Dept Pathol & Pathophysiol, Nanjing, Peoples R China; [Zhang, Tianyu; Wang, Lixin] Southeast Univ, Med Sch, Dept Microbiol & Immunol, Nanjing, Peoples R China; [Wang, Yongren] Nanjing Med Univ, Childrens Hosp, Dept Hematol & Oncol, Nanjing, Peoples R China	Nanjing University of Chinese Medicine; Southeast University - China; Nanjing Medical University	Wang, LX (corresponding author), Southeast Univ, Med Sch, Dept Microbiol & Immunol, Nanjing, Peoples R China.	lxwang@seu.edu.cn			National Natural Sciences Foundation of China [81502681, 31970849]	National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC))	This work was funded by grants from the National Natural Sciences Foundation of China (81502681, 31970849).	Agrawal S, 2011, J CLIN IMMUNOL, V31, P472, DOI [10.1007/s10875-010-9507-1, 10.1007/s10875-010-9456-8]; Auger C, 2021, CANCERS, V13, DOI 10.3390/cancers13051039; Bohacova P, 2020, CELL IMMUNOL, V347, DOI 10.1016/j.cellimm.2019.103987; Cornish AL, 2009, NAT REV RHEUMATOL, V5, P554, DOI 10.1038/nrrheum.2009.178; Dajotoy T, 2004, J LEUKOCYTE BIOL, V76, P685, DOI 10.1189/jlb.0803379; de Wit J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013016; Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195; Greening DW, 2015, SEMIN CELL DEV BIOL, V40, P72, DOI 10.1016/j.semcdb.2015.02.009; Hamasaki M, 2013, NATURE, V495, P389, DOI 10.1038/nature11910; Kondo E, 2009, CLIN EXP IMMUNOL, V155, P249, DOI 10.1111/j.1365-2249.2008.03820.x; Lee EY, 2009, AUTOIMMUN REV, V8, P379, DOI 10.1016/j.autrev.2008.12.002; Lee KMC, 2020, IMMUNOTARGETS THER, V9, P225, DOI 10.2147/ITT.S262566; Leidal AM, 2020, NAT CELL BIOL, V22, P187, DOI 10.1038/s41556-019-0450-y; Li WX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053564; Li YH, 2008, CANCER RES, V68, P6889, DOI 10.1158/0008-5472.CAN-08-0161; Li YH, 2011, CLIN CANCER RES, V17, P7047, DOI 10.1158/1078-0432.CCR-11-0951; Li YH, 2009, AUTOPHAGY, V5, P576, DOI 10.4161/auto.5.4.8366; Lindenbergh MFS, 2018, ANNU REV IMMUNOL, V36, P435, DOI 10.1146/annurev-immunol-041015-055700; Marken J, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075-020-02372-z; Noh HJ, 2014, J MED FOOD, V17, P550, DOI 10.1089/jmf.2013.2912; Ntanasis-Stathopoulos I, 2020, ADV EXP MED BIOL, V1231, P13, DOI 10.1007/978-3-030-36667-4_2; Phadnis-Moghe AS, 2015, TOXICOL SCI, V144, P39, DOI 10.1093/toxsci/kfu257; Ren HY, 2014, J IMMUNOTHER, V37, P383, DOI 10.1097/CJI.0000000000000051; Sato N, 2000, J EXP MED, V192, P205, DOI 10.1084/jem.192.2.205; Su KY, 2016, J IMMUNOL, V197, P4163, DOI 10.4049/jimmunol.1502193; Twitty CG, 2011, CLIN CANCER RES, V17, P6467, DOI 10.1158/1078-0432.CCR-11-0812; Wu XM, 2019, J CELL BIOCHEM, V120, P2994, DOI 10.1002/jcb.27049; Xue M, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0361-4; Yang M, 2010, J IMMUNOL, V184, P3321, DOI 10.4049/jimmunol.0902551; Ye W, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-100; Zhang TY, 2021, CANCER IMMUNOL IMMUN, V70, P463, DOI 10.1007/s00262-020-02695-5; Zhang Y, 2016, INFLAMMOPHARMACOLOGY, V24, P33, DOI 10.1007/s10787-015-0256-x	32	1	1	2	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2021	12								675822	10.3389/fimmu.2021.675822	http://dx.doi.org/10.3389/fimmu.2021.675822			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SO6HV	34122437	Green Published, gold			2022-12-18	WOS:000659071800001
J	Bittencourt, TL; Prata, RBD; Silva, BJD; Barbosa, MGD; Dalcolmo, MP; Pinheiro, RO				Bittencourt, Tamiris Lameira; da Silva Prata, Rhana Berto; de Andrade Silva, Bruno Jorge; de Mattos Barbosa, Mayara Garcia; Dalcolmo, Margareth Pretti; Pinheiro, Roberta Olmo			Autophagy as a Target for Drug Development Of Skin Infection Caused by Mycobacteria	FRONTIERS IN IMMUNOLOGY			English	Review						autophagy; skin; mycobacteria; drug development; skin cells	HOST-CELL AUTOPHAGY; TOLL-LIKE RECEPTORS; VITAMIN-D-RECEPTOR; DENDRITIC CELLS; MAMMALIAN TARGET; TUBERCULOSIS; ZINC; MACROPHAGES; AVIUM; ACTIVATION	Pathogenic mycobacteria species may subvert the innate immune mechanisms and can modulate the activation of cells that cause disease in the skin. Cutaneous mycobacterial infection may present different clinical presentations and it is associated with stigma, deformity, and disability. The understanding of the immunopathogenic mechanisms related to mycobacterial infection in human skin is of pivotal importance to identify targets for new therapeutic strategies. The occurrence of reactional episodes and relapse in leprosy patients, the emergence of resistant mycobacteria strains, and the absence of effective drugs to treat mycobacterial cutaneous infection increased the interest in the development of therapies based on repurposed drugs against mycobacteria. The mechanism of action of many of these therapies evaluated is linked to the activation of autophagy. Autophagy is an evolutionary conserved lysosomal degradation pathway that has been associated with the control of the mycobacterial bacillary load. Here, we review the role of autophagy in the pathogenesis of cutaneous mycobacterial infection and discuss the perspectives of autophagy as a target for drug development and repurposing against cutaneous mycobacterial infection.	[Bittencourt, Tamiris Lameira; da Silva Prata, Rhana Berto; Pinheiro, Roberta Olmo] Oswaldo Cruz Fdn Fiocruz, Oswaldo Cruz Inst, Leprosy Lab, Rio De Janeiro, Brazil; [de Andrade Silva, Bruno Jorge] David Geffen Sch Med, Div Dermatol, Los Angeles, CA USA; [de Mattos Barbosa, Mayara Garcia] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Dalcolmo, Margareth Pretti] Fiocruz MS, Sergio Arouca Natl Sch Publ Hlth, Helio Fraga Reference Ctr, Rio De Janeiro, Brazil	Fundacao Oswaldo Cruz; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Michigan System; University of Michigan; Fundacao Oswaldo Cruz	Pinheiro, RO (corresponding author), Oswaldo Cruz Fdn Fiocruz, Oswaldo Cruz Inst, Leprosy Lab, Rio De Janeiro, Brazil.	robertaolmo@gmail.com	; Pinheiro, Roberta/A-2525-2013	Prata, Rhana/0000-0002-1294-790X; Pinheiro, Roberta/0000-0001-8471-4227	CAPES; FAPERJ; CNPq; Coordination for the Improvement of Higher Education Personnel (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -CAPES) [001]; National Council for Scientific and Technological Development (CNPq) [303834/2017-0]; Rio de Janeiro Carlos Chagas Filho Research Foundation (FAPERJ) [E-26/010.002231/2019]	CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); FAPERJ(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordination for the Improvement of Higher Education Personnel (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Rio de Janeiro Carlos Chagas Filho Research Foundation (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ))	We thank CAPES, FAPERJ, and CNPq funding institutions for all their financial support. This study was partially supported by the Coordination for the Improvement of Higher Education Personnel (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -CAPES) -Finance Code 001. National Council for Scientific and Technological Development (CNPq) -Finance Code 303834/2017-0. Rio de Janeiro Carlos Chagas Filho Research Foundation (FAPERJ) -Finance Code E-26/010.002231/2019.	Abate G, 2016, ANTIMICROB AGENTS CH, V60, P1216, DOI 10.1128/AAC.01567-15; Afsal K, 2018, INT IMMUNOPHARMACOL, V62, P251, DOI 10.1016/j.intimp.2018.07.018; de la Lastral CA, 2007, BIOCHEM SOC T, V35, P1156, DOI 10.1042/BST0351156; Ankley L, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00916-19; Asehnoune K, 2004, J IMMUNOL, V172, P2522, DOI 10.4049/jimmunol.172.4.2522; Aziz DB, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00155-17; Bah A, 2016, FRONT CELL INFECT MI, V6, DOI [10.3389/fcimb.2076.00053, 10.3389/fcimb.2016.00053]; Bailey MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184107; Barbagallo Joseph, 2002, Am J Clin Dermatol, V3, P319, DOI 10.2165/00128071-200203050-00004; Battah B, 2019, MOLECULES, V24, DOI 10.3390/molecules24234373; Bermudez LE, 1999, ANTIMICROB AGENTS CH, V43, P1870, DOI 10.1128/AAC.43.8.1870; Bernard EM, 2021, J CELL SCI, V134, DOI 10.1242/jcs.252973; Bhat SA, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00145; Bravo FG, 2007, CLIN DERMATOL, V25, P173, DOI 10.1016/j.clindermatol.2006.05.005; Brickman M, 2005, AESTHET PLAST SURG, V29, P116, DOI 10.1007/s00266-004-0023-7; Bruning A, 2014, EXP CELL RES, V320, P281, DOI 10.1016/j.yexcr.2013.11.012; Campoy E, 2009, CURR TOP MICROBIOL, V335, P227, DOI 10.1007/978-3-642-00302-8_11; Cardenas-Rodriguez N, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/598493; Carranza C, 2019, AM J MED SCI, V357, P184, DOI 10.1016/j.amjms.2018.12.003; Castillo EF, 2012, P NATL ACAD SCI USA, V109, pE3168, DOI 10.1073/pnas.1210500109; Lerena MC, 2011, CELL MICROBIOL, V13, P814, DOI 10.1111/j.1462-5822.2011.01581.x; Celdran A, 2007, J HOSP INFECT, V66, P374, DOI 10.1016/j.jhin.2007.05.006; Cemma M, 2012, CURR BIOL, V22, pR540, DOI 10.1016/j.cub.2012.06.001; Chai QY, 2020, CELL MOL IMMUNOL, V17, P901, DOI 10.1038/s41423-020-0502-z; Chen Z, 2018, J MOL NEUROSCI, V64, P321, DOI 10.1007/s12031-018-1026-1; Cho YH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58237-7; Choi SW, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.01019-18, 10.1128/aac.01019-18]; Chopra S, 2011, J ANTIMICROB CHEMOTH, V66, P1533, DOI 10.1093/jac/dkr154; Chu CW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030473; Cogen AL, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001869; Costa LL, 2021, AN BRAS DERMATOL, V96, P82, DOI 10.1016/j.abd.2020.01.009; Cuevas LE, 2002, ANN TROP PAEDIATR, V22, P313, DOI 10.1179/027249302125001967; Da Silva Prata RB., 2019, MACROPHAGE ACTIVATIO, P1, DOI [10.5772/INTECHOPEN.88754, DOI 10.5772/INTECHOPEN.88754]; Dang AT, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126955; Silva BJD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006103; de Macedo Cristiana Santos, 2020, F1000Res, V9, DOI 10.12688/f1000research.21383.1; Barbosa MGD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01223; Guerra-De-Blas PD, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02097; Delgado MA, 2008, EMBO J, V27, P1110, DOI 10.1038/emboj.2008.31; Deretic V, 2018, AUTOPHAGY, V14, P243, DOI 10.1080/15548627.2017.1402992; Deshpande D, 2016, ANTIMICROB AGENTS CH, V60, P4652, DOI 10.1128/AAC.02985-15; DETER RL, 1967, J CELL BIOL, V35, pC11, DOI 10.1083/jcb.35.2.C11; Ding BB, 2017, J BIOL CHEM, V292, P8531, DOI 10.1074/jbc.H116.762948; Dong N, 2012, CELL, V150, P1029, DOI 10.1016/j.cell.2012.06.050; Dousa KM, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy168; Drage MG, 2009, CELL IMMUNOL, V258, P29, DOI 10.1016/j.cellimm.2009.03.008; Duarte RS, 2009, J CLIN MICROBIOL, V47, P2149, DOI 10.1128/JCM.00027-09; Dutta NK, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00652-17; Fabri M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003045; Falkinham JO, 2011, EMERG INFECT DIS, V17, P419, DOI 10.3201/eid1703.101510; Ferrari E, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.476; Ferwerda G, 2005, PLOS PATHOG, V1, P279, DOI 10.1371/journal.ppat.0010034; Fiorcari S, 2016, ONCOTARGET, V7, P65968, DOI 10.18632/oncotarget.11782; Fitzgerald KA, 2020, CELL, V180, P1044, DOI 10.1016/j.cell.2020.02.041; Forbes BA, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00038-17; Franco-Paredes C, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00069-18; Fretham SJB, 2013, J NUTR, V143, P260, DOI 10.3945/jn.112.168617; Fujita KI, 2011, AUTOPHAGY, V7, P552, DOI 10.4161/auto.7.5.15101; Fujita KI, 2011, P NATL ACAD SCI USA, V108, P1427, DOI 10.1073/pnas.1014156108; Genestet C, 2018, TUBERCULOSIS, V111, P67, DOI 10.1016/j.tube.2018.05.014; Gervais P, 2014, Rev Med Suisse, V10, P931; Ghulam H, 2009, J INFECT DEV COUNTR, V3, P365; Goldman J, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c5483; Gottlieb RA, 2010, AM J PHYSIOL-CELL PH, V299, pC203, DOI 10.1152/ajpcell.00097.2010; Gravante G, 2008, AESTHET PLAST SURG, V32, P243, DOI 10.1007/s00266-007-9068-8; Greenstein RJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002496; Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST; Griffith DE, 2018, SEMIN RESP CRIT CARE, V39, P351, DOI 10.1055/s-0038-1660472; Guan JL, 2013, AUTOPHAGY, V9, P830, DOI 10.4161/auto.24132; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Harris J, 2017, MOL IMMUNOL, V86, P10, DOI 10.1016/j.molimm.2017.02.013; Hasan A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174112; Hawn TR, 2013, MICROBIOL MOL BIOL R, V77, P608, DOI 10.1128/MMBR.00032-13; Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019; Hu YL, 2020, J INFECTION, V80, pE19, DOI 10.1016/j.jinf.2020.03.003; Hung HH, 2013, CELL BIOL TOXICOL, V29, P415, DOI 10.1007/s10565-013-9261-2; Hwang JJ, 2010, BIOMETALS, V23, P997, DOI 10.1007/s10534-010-9346-9; Ito K, 2016, J DERMATOL, V43, P402, DOI 10.1111/1346-8138.13158; Jo EK, 2010, CELL MICROBIOL, V12, P1026, DOI 10.1111/j.1462-5822.2010.01491.x; Johansen MD, 2020, NAT REV MICROBIOL, V18, P392, DOI 10.1038/s41579-020-0331-1; Juarez E, 2016, AM J RESP CELL MOL, V55, P837, DOI 10.1165/rcmb.2015-0383OC; Karyadi E, 2000, J NUTR, V130, P2953, DOI 10.1093/jn/130.12.2953; Kaushik A, 2019, ANTIMICROB AGENTS CH, V63, DOI [10.1128/aac.00470-19, 10.1128/AAC.00470-19]; Kawamata T, 2017, J BIOL CHEM, V292, P8520, DOI 10.1074/jbc.M116.762948; Kennedy BS, 2012, NEW ENGL J MED, V367, P1020, DOI 10.1056/NEJMoa1205114; Khan FA, 2011, CUTIS, V88, P194; Khan M, 2017, ONCOTARGETS THER, V10, P1909, DOI 10.2147/OTT.S98689; Khan N, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00386; Khan N, 2016, J INNATE IMMUN, V8, P228, DOI 10.1159/000439591; Khan N, 2016, SCI REP-UK, V6, DOI 10.1038/srep19084; Kim JK, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e37; Kim JK, 2017, AUTOPHAGY, V13, P423, DOI 10.1080/15548627.2016.1241922; Kim JJ, 2012, CELL HOST MICROBE, V11, P457, DOI 10.1016/j.chom.2012.03.008; Kim KW, 2011, J THORAC ONCOL, V6, P1542, DOI 10.1097/JTO.0b013e3182208fac; Kim Yi Sak, 2019, Exp Mol Med, V51, P1, DOI 10.1038/s12276-019-0290-7; Kimura T, 2015, J CELL BIOL, V210, P973, DOI 10.1083/jcb.201503023; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Koyanagi A, 2004, ANN TROP MED PARASIT, V98, P391, DOI 10.1179/000349804225003424; Krishna M, 2008, CELL MOL LIFE SCI, V65, P3525, DOI 10.1007/s00018-008-8170-7; Krutzik SR, 2008, J IMMUNOL, V181, P7115, DOI 10.4049/jimmunol.181.10.7115; Kuoa SY, 2015, P NATL ACAD SCI USA, V112, pE4281, DOI 10.1073/pnas.1512289112; Kurgvietiene L, 2016, MEDICINA-LITHUANIA, V52, P148, DOI 10.1016/j.medici.2016.03.003; Lapaquette P, 2012, CELL MICROBIOL, V14, P791, DOI 10.1111/j.1462-5822.2012.01768.x; Lee SJ, 2010, MOL BRAIN, V3, DOI 10.1186/1756-6606-3-30; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Li JH, 2011, J VIROL, V85, P6319, DOI 10.1128/JVI.02627-10; Li L, 2016, ONCOTARGET, V7, P50682, DOI 10.18632/oncotarget.9330; Liu ML, 2010, J BIOL CHEM, V285, P36387, DOI 10.1074/jbc.M110.169284; Liu PT, 2012, NAT MED, V18, P267, DOI 10.1038/nm.2584; Liuzzi JP, 2013, BIOL TRACE ELEM RES, V156, P350, DOI 10.1007/s12011-013-9816-3; Liuzzi JP, 2014, BIOMETALS, V27, P1087, DOI 10.1007/s10534-014-9773-0; Luthra S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02179; Machelart A, 2017, DRUG DISCOV TODAY, V22, P1250, DOI 10.1016/j.drudis.2017.05.005; Marini E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219038; Martineau AR, 2007, J STEROID BIOCHEM, V103, P793, DOI 10.1016/j.jsbmb.2006.12.052; Mauriello JA, 2003, OPHTHALMIC PLAST REC, V19, P182, DOI 10.1097/01.IOP.0000064994.09803.CB; Miao YX, 2015, CELL, V161, P1306, DOI 10.1016/j.cell.2015.05.009; Montoya D, 2009, CELL HOST MICROBE, V6, P343, DOI 10.1016/j.chom.2009.09.002; Munoz-Sanchez S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112372; Murillo J, 2000, ARCH DERMATOL, V136, P1347, DOI 10.1001/archderm.136.11.1347; Naeem MA, 2021, CURR ISSUES MOL BIOL, V41, P597, DOI 10.21775/cimb.041.597; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980; Nakajima S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170138; Nessar R, 2012, J ANTIMICROB CHEMOTH, V67, P810, DOI 10.1093/jac/dkr578; Nowotarska SW, 2017, FOODS, V6, DOI 10.3390/foods6090072; O'Keeffe KM, 2015, INFECT IMMUN, V83, P3445, DOI 10.1128/IAI.00358-15; O'Riordan W, 2019, NEW ENGL J MED, V380, P528, DOI 10.1056/NEJMoa1800170; Oh JE, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00044; Paik S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.603951; Palucci I, 2018, CHEMOTHERAPY, V63, P172, DOI 10.1159/000490478; Pan R, 2015, BIOL TRACE ELEM RES, V166, P89, DOI 10.1007/s12011-015-0287-6; Pang H, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/419392; Parihar SP, 2014, J INFECT DIS, V209, P754, DOI 10.1093/infdis/jit550; Park D, 2016, SCI REP-UK, V6, DOI 10.1038/srep21772; Pellegrini JM, 2021, AUTOPHAGY, V17, P2629, DOI 10.1080/15548627.2020.1825273; Periyasamy KM, 2020, MOL IMMUNOL, V127, P238, DOI 10.1016/j.molimm.2020.08.007; Piccaro G, 2014, ANTIMICROB AGENTS CH, V58, P7527, DOI 10.1128/AAC.03169-14; Pinheiro RO, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00518; Pompei L, 2007, J IMMUNOL, V178, P5192, DOI 10.4049/jimmunol.178.8.5192; Popp L, 2019, ACS OMEGA, V4, P573, DOI 10.1021/acsomega.8b01497; Potocnjak I, 2018, PHYTOTHER RES, V32, P1090, DOI 10.1002/ptr.6048; Prajsnar TK, 2021, AUTOPHAGY, V17, P888, DOI 10.1080/15548627.2020.1739443; Puleston DJ, 2014, IMMUNOLOGY, V141, P1, DOI 10.1111/imm.12165; Rahman SA, 2014, MBIO, V5, DOI 10.1128/mBio.02020-14; Randow F, 2014, CELL HOST MICROBE, V15, P404, DOI 10.1016/j.chom.2014.03.012; Ravenhill BJ, 2019, MOL CELL, V74, P320, DOI 10.1016/j.molcel.2019.01.041; Ray M, 1998, INT J TUBERC LUNG D, V2, P719; Renna M, 2011, J CLIN INVEST, V121, P3554, DOI 10.1172/JCI46095; Ribeiro CMS, 2016, NATURE, V540, P448, DOI 10.1038/nature20567; Rodrigues L, 2008, J ANTIMICROB CHEMOTH, V61, P1076, DOI 10.1093/jac/dkn070; Roscioli E, 2017, AM J PHYSIOL-LUNG C, V313, pL453, DOI 10.1152/ajplung.00083.2017; Sampaio EP, 1996, INT J LEPROSY, V64, P268; Sanguinetti M, 2001, J CLIN MICROBIOL, V39, P816, DOI 10.1128/JCM.39.2.816-819.2001; Schiebler M, 2015, EMBO MOL MED, V7, P127, DOI 10.15252/emmm.201404137; Scollard DM, 2006, CLIN MICROBIOL REV, V19, P338, DOI 10.1128/CMR.19.2.338-381.2006; Seervi M, 2018, BIOMED PHARMACOTHER, V106, P200, DOI 10.1016/j.biopha.2018.06.123; Selvaraj P, 2011, VITAM HORM, V86, P307, DOI 10.1016/B978-0-12-386960-9.00013-7; Shahnazari S, 2011, AUTOPHAGY, V7, P957, DOI 10.4161/auto.7.9.16435; Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215; Shin DM, 2010, CELL MICROBIOL, V12, P1648, DOI 10.1111/j.1462-5822.2010.01497.x; Shin JH, 2012, NEUROSCI LETT, V515, P162, DOI 10.1016/j.neulet.2012.03.040; Shinya E, 2009, BIOCHEM BIOPH RES CO, V386, P40, DOI 10.1016/j.bbrc.2009.05.125; Shoen C, 2019, ANTIMICROB AGENTS CH, V63, DOI [10.1128/AAC.02522-18, 10.1128/aac.02522-18]; Silva T, 2017, MSPHERE, V2, DOI [10.1128/mSphere.00301-17, 10.1128/msphere.00301-17]; Singhal A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009885; Spalletta S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206894; Stanley RE, 2014, TRENDS CELL BIOL, V24, P73, DOI 10.1016/j.tcb.2013.07.008; Starr T, 2012, CELL HOST MICROBE, V11, P33, DOI 10.1016/j.chom.2011.12.002; Sun DQ, 2012, CHEMMEDCHEM, V7, P1541, DOI 10.1002/cmdc.201200253; Sundaramurthy V, 2013, CELL HOST MICROBE, V13, P129, DOI 10.1016/j.chom.2013.01.008; Taneja D P, 1990, J Indian Med Assoc, V88, P280; Tattoli I, 2012, AUTOPHAGY, V8, P1848, DOI 10.4161/auto.21863; Tran PN, 2017, EXPERT OPIN DRUG SAF, V16, P1079, DOI 10.1080/14740338.2017.1344213; Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823; Tsukamoto S, 2008, AUTOPHAGY, V4, P1076, DOI 10.4161/auto.7065; van Zyl L, 2015, TUBERCULOSIS, V95, P629, DOI 10.1016/j.tube.2014.12.006; Vickers NJ, 2017, CURR BIOL, V27, pR713, DOI 10.1016/j.cub.2017.05.064; Virgin HW, 2009, NAT IMMUNOL, V10, P461, DOI 10.1038/ni.1726; Wang RC, 2011, J INVEST DERMATOL, V131, P990, DOI 10.1038/jid.2010.423; Wang SH, 2014, CURR INFECT DIS REP, V16, DOI 10.1007/s11908-014-0438-5; Watson A, 2016, CELL SIGNAL, V28, P412, DOI 10.1016/j.cellsig.2016.01.014; Watson RO, 2015, CELL HOST MICROBE, V17, P811, DOI 10.1016/j.chom.2015.05.004; Wen X, 2020, AUTOPHAGY, V16, P193, DOI 10.1080/15548627.2019.1666580; Wild P, 2011, SCIENCE, V333, P228, DOI 10.1126/science.1205405; Wileman T, 2013, ESSAYS BIOCHEM, V55, P153, DOI [10.1042/BSE0550153, 10.1042/bse0550153]; Williams A, 2008, NAT CHEM BIOL, V4, P295, DOI 10.1038/nchembio.79; Wu ML, 2018, DRUG DISCOV TODAY, V23, P1502, DOI 10.1016/j.drudis.2018.04.001; Wu YC, 2010, NEUROCHEM INT, V57, P198, DOI 10.1016/j.neuint.2010.05.008; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022; Yang CS, 2017, MICROB CELL, V4, P105, DOI 10.15698/mic2017.03.565; Yoshikawa Y, 2009, AUTOPHAGY, V5, P1220, DOI 10.4161/auto.5.8.10177; Yuk JM, 2009, CELL HOST MICROBE, V6, P231, DOI 10.1016/j.chom.2009.08.004; Zhang QW, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02142; Zhang R, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007329; Zhou MX, 2018, EBIOMEDICINE, V35, P345, DOI 10.1016/j.ebiom.2018.08.035; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663; Zhou YY, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20140141; Zullo AJ, 2014, BMC BIOCHEM, V15, DOI 10.1186/1471-2091-15-4; Zumla A, 2015, J INTERN MED, V277, P373, DOI 10.1111/joim.12256; Zumla A, 2016, LANCET INFECT DIS, V16, pE47, DOI 10.1016/S1473-3099(16)00078-5	201	1	1	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2021	12								674241	10.3389/fimmu.2021.674241	http://dx.doi.org/10.3389/fimmu.2021.674241			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SO0UL	34113346	Green Published, gold			2022-12-18	WOS:000658696600001
J	LeibundGut-Landmann, S				LeibundGut-Landmann, Salome			Tissue-Resident Memory T Cells in Antifungal Immunity	FRONTIERS IN IMMUNOLOGY			English	Review						tissue-resident memory T cells (TRM); antifungal immunity; fungal commensals; pathogenic fungi; immunopathology; vaccine immunity (Min; 5-Max; 8)	TRANSCRIPTOME ANALYSIS; ATOPIC-DERMATITIS; COMMENSAL FUNGI; TGF-BETA; RM CELLS; INFECTION; PSORIASIS; HEALTH; MAINTENANCE; ACTIVATION	Fungi are an integral part of the mammalian microbiota colonizing most if not all mucosal surfaces and the skin. Maintaining stable colonization on these surfaces is critical for preventing fungal dysbiosis and infection, which in some cases can lead to life threatening consequences. The epithelial barriers are protected by T cells and additional controlling immune mechanisms. Noncirculating memory T cells that reside stably in barrier tissues play an important role for host protection from commensals and recurrent pathogens due to their fast response and local activity, which provides them a strategic advantage. So far, only a few specific examples of tissue resident memory T cells (TRMs) that act against fungi have been reported. This review provides an overview of the characteristics and functional attributes of TRMs that have been established based on human and mouse studies with various microbes. It highlights what is currently known about fungi specific TRMs mediating immunosurveillance, how they have been targeted in preclinical vaccination approaches and how they can promote immunopathology, if not controlled. A better appreciation of the host protective and damaging roles of TRMs might accelerate the development of novel tissue specific preventive strategies against fungal infections and fungi-driven immunopathologies.	[LeibundGut-Landmann, Salome] Univ Zurich, Vetsuisse Fac, Immunol Sect, Zurich, Switzerland; [LeibundGut-Landmann, Salome] Univ Zurich, Inst Expt Immunol, Zurich, Switzerland	University of Zurich; University of Zurich	LeibundGut-Landmann, S (corresponding author), Univ Zurich, Vetsuisse Fac, Immunol Sect, Zurich, Switzerland.; LeibundGut-Landmann, S (corresponding author), Univ Zurich, Inst Expt Immunol, Zurich, Switzerland.	salome.leibundgut-landmann@uzh.ch		LeibundGut-Landmann, Salome/0000-0002-5724-4837	Swiss National Science Foundation [310030_ 166206, 310030_ 189255, CRSII5_173863]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	Work in the SL-L-lab is supported by the Swiss National Science Foundation (grant 310030_ 166206, 310030_ 189255 and CRSII5_173863).	Allen AC, 2018, MUCOSAL IMMUNOL, V11, P1763, DOI 10.1038/s41385-018-0080-x; Ariotti S, 2014, SCIENCE, V346, P101, DOI 10.1126/science.1254803; Ariotti S, 2012, P NATL ACAD SCI USA, V109, P19739, DOI 10.1073/pnas.1208927109; Aschenbrenner D, 2018, NAT IMMUNOL, V19, P1126, DOI 10.1038/s41590-018-0200-5; Bacher P, 2019, CELL, V176, P1340, DOI 10.1016/j.cell.2019.01.041; Bandura DR, 2009, ANAL CHEM, V81, P6813, DOI 10.1021/ac901049w; Becattini S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18248-4; Bedford JG, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040572; Behr FM, 2020, NAT IMMUNOL, V21, P1070, DOI 10.1038/s41590-020-0723-4; Benoun JM, 2018, P NATL ACAD SCI USA, V115, P10416, DOI 10.1073/pnas.1808339115; Bernstein DI, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0129-1; Bishu S, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00295-19; Bodenmiller B, 2016, CELL SYST, V2, P225, DOI 10.1016/j.cels.2016.03.008; Boehncke WH, 2015, LANCET, V386, P983, DOI 10.1016/S0140-6736(14)61909-7; Budnik B, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1547-5; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Campion SL, 2014, J EXP MED, V211, P1273, DOI 10.1084/jem.20130555; Casey KA, 2012, J IMMUNOL, V188, P4866, DOI 10.4049/jimmunol.1200402; Cheuk S, 2017, IMMUNITY, V46, P287, DOI 10.1016/j.immuni.2017.01.009; Cheuk S, 2014, J IMMUNOL, V192, P3111, DOI 10.4049/jimmunol.1302313; Dainichi T, 2018, NAT IMMUNOL, V19, P1286, DOI 10.1038/s41590-018-0256-2; Davies B, 2017, J IMMUNOL, V198, P2233, DOI 10.4049/jimmunol.1601367; Dobson HE, 2020, MUCOSAL IMMUNOL, V13, P518, DOI 10.1038/s41385-019-0244-3; Dutzan N, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat0797; Eyerich S, 2011, NEW ENGL J MED, V365, P231, DOI 10.1056/NEJMoa1104200; Ezzedine K, 2015, LANCET, V386, P74, DOI 10.1016/S0140-6736(14)60763-7; Galvez-Cancino F, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1442163; Gamradt P, 2019, J ALLERGY CLIN IMMUN, V143, P2147, DOI 10.1016/j.jaci.2018.11.048; Gasper DJ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006064; Ge CH, 2019, CELL REP, V29, P4236, DOI 10.1016/j.celrep.2019.11.103; Gebhardt T, 2018, IMMUNOL REV, V283, P54, DOI 10.1111/imr.12650; Glennie ND, 2015, J EXP MED, V212, P1405, DOI 10.1084/jem.20142101; Guttman-Yassky E, 2017, CURR OPIN IMMUNOL, V48, P68, DOI 10.1016/j.coi.2017.08.008; Haddadi S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02075; Harrison OJ, 2019, SCIENCE, V363, P43, DOI 10.1126/science.aat6280; He HL, 2020, J ALLERGY CLIN IMMUN, V145, P1615, DOI 10.1016/j.jaci.2020.01.042; Hegazy AN, 2017, GASTROENTEROLOGY, V153, P1320, DOI 10.1053/j.gastro.2017.07.047; Hirai T, 2021, IMMUNITY, V54, P84, DOI 10.1016/j.immuni.2020.10.022; Hondowicz BD, 2016, IMMUNITY, V44, P155, DOI 10.1016/j.immuni.2015.11.004; Ichikawa T, 2019, NAT IMMUNOL, V20, P1469, DOI 10.1038/s41590-019-0494-y; Ickrath P, 2018, INT J MOL MED, V42, P1116, DOI 10.3892/ijmm.2018.3653; Iijima N, 2014, SCIENCE, V346, P93, DOI 10.1126/science.1257530; Iliev ID, 2012, SCIENCE, V336, P1314, DOI 10.1126/science.1221789; Jiang TT, 2017, CELL HOST MICROBE, V22, P809, DOI 10.1016/j.chom.2017.10.013; Jiang XD, 2012, NATURE, V483, P227, DOI 10.1038/nature10851; Jozwik A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10224; Kinnear E, 2018, MUCOSAL IMMUNOL, V11, P249, DOI [10.1038/mi.2017.46, 10.1038/mi.2017.79]; Kirchner FR, 2021, MUCOSAL IMMUNOL, V14, P455, DOI 10.1038/s41385-020-0327-1; Klicznik MM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67430-7; Lee HG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08482-w; Leonardi I, 2018, SCIENCE, V359, P232, DOI 10.1126/science.aao1503; Li J, 2017, CURR OPIN MICROBIOL, V40, P46, DOI 10.1016/j.mib.2017.10.016; Li X, 2018, CELL HOST MICROBE, V24, P847, DOI 10.1016/j.chom.2018.11.003; Limon JJ, 2019, CELL HOST MICROBE, V25, P377, DOI 10.1016/j.chom.2019.01.007; Louis L, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00227-19; Low JS, 2020, J EXP MED, V217, DOI 10.1084/jem.20192291; Mackay LK, 2016, SCIENCE, V352, P459, DOI 10.1126/science.aad2035; Mackay LK, 2015, IMMUNITY, V43, P1101, DOI 10.1016/j.immuni.2015.11.008; Mackay LK, 2013, NAT IMMUNOL, V14, P1294, DOI 10.1038/ni.2744; Mackay LK, 2012, P NATL ACAD SCI USA, V109, P7037, DOI 10.1073/pnas.1202288109; Mani V, 2019, SCIENCE, V366, P202, DOI 10.1126/science.aav5728; Martin DA, 2013, J INVEST DERMATOL, V133, P17, DOI 10.1038/jid.2012.194; Matos TR, 2017, J CLIN INVEST, V127, P4031, DOI 10.1172/JCI93396; McGeachy MJ, 2019, IMMUNITY, V50, P892, DOI 10.1016/j.immuni.2019.03.021; Milner JJ, 2017, NATURE, V552, P253, DOI 10.1038/nature24993; Naik S, 2015, NATURE, V520, P104, DOI 10.1038/nature14052; Nolan John P, 2013, Curr Protoc Cytom, VChapter 1, DOI 10.1002/0471142956.cy0127s63; Pallett LJ, 2017, J EXP MED, V214, P1567, DOI 10.1084/jem.20162115; Park CO, 2018, J ALLERGY CLIN IMMUN, V142, P647, DOI 10.1016/j.jaci.2017.09.042; Park SL, 2018, NAT IMMUNOL, V19, P183, DOI 10.1038/s41590-017-0027-5; Ramirez JEV, 2017, ADV DRUG DELIVER REV, V114, P116, DOI 10.1016/j.addr.2017.04.008; Roy S, 2019, J VIROL, V93, DOI 10.1128/JVI.00827-19; Santosuosso M, 2007, J IMMUNOL, V178, P2387, DOI 10.4049/jimmunol.178.4.2387; Scheffold A, 2020, CURR OPIN MICROBIOL, V58, P116, DOI 10.1016/j.mib.2020.09.008; Schenkel JM, 2014, SCIENCE, V346, P98, DOI 10.1126/science.1254536; Sckisel GD, 2014, CLIN EXP IMMUNOL, V175, P79, DOI 10.1111/cei.12186; Shao TY, 2019, CELL HOST MICROBE, V25, P404, DOI 10.1016/j.chom.2019.02.004; Shenoy AT, 2020, MUCOSAL IMMUNOL, V13, P334, DOI 10.1038/s41385-019-0229-2; Sheridan BS, 2014, IMMUNITY, V40, P747, DOI 10.1016/j.immuni.2014.03.007; Shin HN, 2012, NATURE, V491, P463, DOI 10.1038/nature11522; Skalski JH, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007260; Skon CN, 2013, NAT IMMUNOL, V14, P1285, DOI 10.1038/ni.2745; Snyder ME, 2019, CURR OPIN IMMUNOL, V59, P101, DOI 10.1016/j.coi.2019.05.011; Sparber F, 2019, CELL HOST MICROBE, V25, P389, DOI 10.1016/j.chom.2019.02.002; Sparber F, 2017, METHODS MOL BIOL, V1508, P167, DOI 10.1007/978-1-4939-6515-1_8; Steinfelder S, 2017, EUR J IMMUNOL, V47, P353, DOI 10.1002/eji.201646575; Su LF, 2013, IMMUNITY, V38, P373, DOI 10.1016/j.immuni.2012.10.021; Szabo PA, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aas9673; Tang FC, 2009, NAT METHODS, V6, P377, DOI [10.1038/NMETH.1315, 10.1038/nmeth.1315]; Teijaro JR, 2011, J IMMUNOL, V187, P5510, DOI 10.4049/jimmunol.1102243; Thome JJC, 2016, NAT MED, V22, P72, DOI 10.1038/nm.4008; Tse SW, 2013, GENES IMMUN, V14, P302, DOI 10.1038/gene.2013.20; Turner DL, 2018, J IMMUNOL, V200, P1561, DOI 10.4049/jimmunol.1700257; Ueno K, 2019, MUCOSAL IMMUNOL, V12, P265, DOI 10.1038/s41385-018-0094-4; Vesely MCA, 2019, CELL, V178, P1176, DOI 10.1016/j.cell.2019.07.032; Vo S, 2019, BRIT J DERMATOL, V181, P410, DOI 10.1111/bjd.17748; Wakim LM, 2015, MUCOSAL IMMUNOL, V8, P1060, DOI 10.1038/mi.2014.133; Wakim LM, 2012, J IMMUNOL, V189, P3462, DOI 10.4049/jimmunol.1201305; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Wheeler ML, 2016, CELL HOST MICROBE, V19, P865, DOI 10.1016/j.chom.2016.05.003; Wilk MM, 2017, J IMMUNOL, V199, P233, DOI 10.4049/jimmunol.1602051; Zaid A, 2014, P NATL ACAD SCI USA, V111, P5307, DOI 10.1073/pnas.1322292111; Zhang N, 2013, IMMUNITY, V39, P687, DOI 10.1016/j.immuni.2013.08.019; Zhu J, 2013, NATURE, V497, P494, DOI 10.1038/nature12110; Zundler S, 2019, NAT IMMUNOL, V20, P288, DOI 10.1038/s41590-018-0298-5	105	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2021	12								693055	10.3389/fimmu.2021.693055	http://dx.doi.org/10.3389/fimmu.2021.693055			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SO0JO	34113356	Green Accepted, Green Published, gold			2022-12-18	WOS:000658668300001
J	Niu, C; Chen, YC; Li, M; Zhu, S; Zhou, L; Xu, DS; Li, ZZ; Xu, JT; Li, W; Wang, YF; Cui, JW				Niu, Chao; Chen, Yongchong; Li, Min; Zhu, Shan; Zhou, Lei; Xu, Dongsheng; Li, Zhaozhi; Xu, Jianting; Li, Wei; Wang, Yufeng; Cui, Jiuwei			Non-Coated Rituximab Induces Highly Cytotoxic Natural Killer Cells From Peripheral Blood Mononuclear Cells via Autologous B Cells	FRONTIERS IN IMMUNOLOGY			English	Article						rituximab; NK cell; B cell; cytotoxicity; tumor therapy; antibody-dependent cell-mediated cytotoxicity	HUMAN NK CELLS; FEEDER CELLS; EXPANSION; ACTIVATION; TUMOR; EXPRESSION; ANTIBODIES; SYNERGY; IL-21	Natural killer (NK) cells are becoming valuable tools for cancer therapy because of their cytotoxicity against tumor cells without prior sensitization and their involvement in graft-versus-host disease; however, it is difficult to obtain highly cytotoxic NK cells without adding extra feeder cells. In this study, we developed a new method for obtaining highly cytotoxic NK cells from peripheral blood mononuclear cells (PBMCs) independently of extra feeder cell addition using rituximab not coated on a flask (non-coated rituximab). We found that rituximab could promote both the activation and expansion of NK cells from PBMCs, irrespective of being coated on a flask or not. However, NK cells activated by non-coated rituximab had much greater antitumor activity against cancer cells, and these effects were dependent on autologous living B cells. The antibody-dependent cellular cytotoxicity effect of NK cells activated by non-coated rituximab was also more substantial. Furthermore, these cells expressed higher levels of CD107a, perforin, granzyme B, and IFN-gamma. However, there was no difference in the percentage, apoptosis, and cell-cycle progression of NK cells induced by coated and non-coated rituximab. Non-coated rituximab activated NK cells by increasing AKT phosphorylation, further enhancing the abundance of XBP1s. In conclusion, we developed a new method for amplifying NK cells with higher antitumor functions with non-coated rituximab via autologous B cells from PBMCs, and this method more efficiently stimulated NK cell activation than by using coated rituximab.	[Niu, Chao; Chen, Yongchong; Li, Min; Zhou, Lei; Xu, Dongsheng; Li, Zhaozhi; Xu, Jianting; Li, Wei; Cui, Jiuwei] First Hosp Jilin Univ, Dept Canc Ctr, Changchun, Peoples R China; [Zhu, Shan] First Hosp Jilin Univ, Dept Translat Med, Changchun, Peoples R China; [Wang, Yufeng] First Hosp Jilin Univ, Inst Canc, Changchun, Peoples R China	Jilin University; Jilin University; Jilin University	Cui, JW (corresponding author), First Hosp Jilin Univ, Dept Canc Ctr, Changchun, Peoples R China.; Wang, YF (corresponding author), First Hosp Jilin Univ, Inst Canc, Changchun, Peoples R China.	Yufeng_Wang@jlu.edu.cn; cuijw@jlu.edu.cn			National Key Research and Development Program of China [2020YFA0707704]; National Natural Science Foundation of China [31700764, 81972684, 81702589]; Jilin Provincial Science and Technology Department [20200201180JC, 20200602032ZP, 20180101009JC, 20190303146SF]; Scientific and Technological Research of Jilin Provincial Education Department [JJKH20190023KJ]; Jilin Province Finance Department [2018SCZWSZX010]; Science and Technology Achievement Transformation Fund Project of the First Hospital of Jilin University [JDYYZH-1902037, JDYYZH-1902038]; China Guanghua Foundation [JDYYGH2019004, JDYYGH2019012]; First Hospital of Jilin University [JDYYGH2019004, JDYYGH2019012]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jilin Provincial Science and Technology Department; Scientific and Technological Research of Jilin Provincial Education Department; Jilin Province Finance Department; Science and Technology Achievement Transformation Fund Project of the First Hospital of Jilin University; China Guanghua Foundation; First Hospital of Jilin University	This work was supported by grants from the National Key Research and Development Program of China (grant number 2020YFA0707704), the National Natural Science Foundation of China (grant numbers 31700764, 81972684, and 81702589), the Jilin Provincial Science and Technology Department (grant numbers 20200201180JC, 20200602032ZP, 20180101009JC, and 20190303146SF), the Scientific and Technological Research of Jilin Provincial Education Department (grant number JJKH20190023KJ), the Jilin Province Finance Department (grant number 2018SCZWSZX010), the Science and Technology Achievement Transformation Fund Project of the First Hospital of Jilin University (grant numbers JDYYZH-1902037 and JDYYZH-1902038), and the China Guanghua Foundation & First Hospital of Jilin University (grant numbers JDYYGH2019004 and JDYYGH2019012).	Abel AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01869; Omar SY, 2011, IMMUNOLOGY, V133, P94, DOI 10.1111/j.1365-2567.2011.03415.x; Bae DS, 2014, BLOOD RES, V49, P154, DOI 10.5045/br.2014.49.3.154; Bald T, 2020, NAT IMMUNOL, V21, P835, DOI 10.1038/s41590-020-0728-z; Baniyash M, 2004, NAT REV IMMUNOL, V4, P675, DOI 10.1038/nri1434; Bjorkstrom NK, 2010, BLOOD, V116, P3853, DOI 10.1182/blood-2010-04-281675; Boyer-Suavet S, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03069; Bryceson YT, 2006, BLOOD, V107, P159, DOI 10.1182/blood-2005-04-1351; Delahaye NF, 2011, NAT MED, V17, P700, DOI 10.1038/nm.2366; Dumont N, 2009, IMMUNOLOGY, V126, P588, DOI 10.1111/j.1365-2567.2008.02915.x; Enqvist M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02085; Cruz-Munoz ME, 2019, J LEUKOCYTE BIOL, V105, P955, DOI 10.1002/JLB.MR0618-224RR; Franks SE, 2020, CANCERS, V12, DOI 10.3390/cancers12082131; Germain C, 2011, J BIOL CHEM, V286, P37964, DOI 10.1074/jbc.M111.285312; Gonzalez-Rodriguez AP, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101557; Guillerey C, 2016, NAT IMMUNOL, V17, P1025, DOI 10.1038/ni.3518; Hodgins JJ, 2019, J CLIN INVEST, V129, P3499, DOI 10.1172/JCI129338; Hu WL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01205; Karampatzakis A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.641521; Kloss S, 2017, HUM GENE THER, V28, P897, DOI 10.1089/hum.2017.157; Kobyzeva PA, 2020, J LEUKOCYTE BIOL, V108, P1379, DOI 10.1002/JLB.1MA0720-654RR; Locatelli F, 2018, TRENDS IMMUNOL, V39, P577, DOI 10.1016/j.it.2018.04.009; Lusty E, 2017, MOL IMMUNOL, V88, P138, DOI 10.1016/j.molimm.2017.06.025; Mavers M, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/1586905; Phan MTT, 2016, METHODS MOL BIOL, V1441, P167, DOI 10.1007/978-1-4939-3684-7_14; Niu C, 2020, INT J MED SCI, V17, P1964, DOI 10.7150/ijms.47701; Niu C, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0124-x; Ojo EO, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51287-6; Poggi A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062932; Remark R, 2013, CLIN CANCER RES, V19, P4079, DOI 10.1158/1078-0432.CCR-12-3847; Rudnicka D, 2013, BLOOD, V121, P4694, DOI 10.1182/blood-2013-02-482570; Shimasaki N, 2020, NAT REV DRUG DISCOV, V19, P200, DOI 10.1038/s41573-019-0052-1; Srpan K, 2018, J CELL BIOL, V217, P3267, DOI 10.1083/jcb.201712085; Streltsova MA, 2017, J IMMUNOL METHODS, V450, P90, DOI 10.1016/j.jim.2017.08.003; Sun JC, 2010, J EXP MED, V207, P2049, DOI 10.1084/jem.20101748; Tanaka J, 2020, BLOOD REV, V44, DOI 10.1016/j.blre.2020.100678; Vacca P, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03013; Valipour B, 2019, J CELL PHYSIOL, V234, P19352, DOI 10.1002/jcp.28657; Verma C, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0535-8; Wang YF, 2019, NAT IMMUNOL, V20, P10, DOI 10.1038/s41590-018-0265-1; Wilk AJ, 2018, J LEUKOCYTE BIOL, V103, P629, DOI 10.1002/JLB.6RI0917-390R	41	1	1	3	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2021	12								658562	10.3389/fimmu.2021.658562	http://dx.doi.org/10.3389/fimmu.2021.658562			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SO0QG	34113342	gold, Green Published			2022-12-18	WOS:000658685700001
J	Osoegawa, K; Creary, LE; Montero-Martin, G; Mallempati, KC; Gangavarapu, S; Caillier, SJ; Santaniello, A; Isobe, N; Hollenbach, JA; Hauser, SL; Oksenberg, JR; Fernandez-Vina, MA				Osoegawa, Kazutoyo; Creary, Lisa E.; Montero-Martin, Gonzalo; Mallempati, Kalyan C.; Gangavarapu, Sridevi; Caillier, Stacy J.; Santaniello, Adam; Isobe, Noriko; Hollenbach, Jill A.; Hauser, Stephen L.; Oksenberg, Jorge R.; Fernandez-Vina, Marcelo A.			High Resolution Haplotype Analyses of Classical HLA Genes in Families With Multiple Sclerosis Highlights the Role of HLA-DP Alleles in Disease Susceptibility	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis (MS); family; HLA; haplotype; transmission disequilibrium test (TDT); case-control analysis	CASE-PARENT TRIO; RISK; IMMUNOGENETICS; DISEQUILIBRIUM; ASSOCIATIONS; VARIANTS; HLA-DRB1; MARKERS; REGION; LOCUS	Multiple sclerosis (MS) susceptibility shows strong genetic associations with HLA alleles and haplotypes. We genotyped 11 HLA genes in 477 non-Hispanic European MS patients and their 954 unaffected parents using a validated next-generation sequencing (NGS) methodology. HLA haplotypes were assigned unequivocally by tracing HLA allele transmissions. We explored HLA haplotype/allele associations with MS using the genotypic transmission disequilibrium test (gTDT) and multiallelic TDT (mTDT). We also conducted a case-control (CC) study with all patients and 2029 healthy unrelated ethnically matched controls. We performed separate analyses of 54 extended multicase families by reviewing transmission of haplotype blocks. The haplotype fragment including DRB5*01:01:01 similar to DRB1*1 5:01:01:01 was significantly associated with predisposition (gTDT: p < 2.20e-16; mTDT: p =1.61e-07; CC: p < 2.22e-16) as reported previously. A second risk allele, DPB1*104:01 (gTDT: p = 3.69e-03; mTDT: p = 2.99e-03; CC: p = 1.00e-02), independent from the haplotype bearing DRB1*15:01 was newly identified. The allele DRB1*01:01:01 showed significant protection (gTDT: p = 8.68e-06; mTDT: p = 4.50e-03; CC: p = 1.96e-06). Two DQB1 alleles, DQB1*03:01 (gTDT: p = 2.86e-03; mTDT: p = 5.56e-02; CC: p = 4.08e-05) and DQB1*03:03 (gTDT: p = 1.17e-02; mTDT: p = 1.16e-02; CC: p = 1.21e-02), defined at two-field level also showed protective effects. The HLA class I block, A*02:01:01 :01 similar to C*03:04:01:01 similar to B*40:01:02 (gTDT: p = 5.86e-03; mTDT: p = 3.65e-02; CC: p = 9.69e-03) and the alleles 8*27:05 (gTDT: p = 6.28e-04; mTDT: p = 2.15e-03; CC: p = 1.47e-02) and B*38:01 (gTDT: p = 3.20e-03; mTDT: p = 6.14e-03; CC: p = 1.70e-02) showed moderately protective effects independently from each other and from the class II associated factors. By comparing statistical significance of 11 HLA loci and 19 haplotype segments with both untruncated and two-field allele names, we precisely mapped MS candidate alleles/haplotypes while eliminating false signals resulting from 'hitchhiking' alleles. We assessed g enetic burden for the HLA allele/haplotype identified in this study. This family-based study including the highest-resolution of HLA alleles proved to be powerful and efficient for precise identification of HLA genotypes associated with both, susceptibility and protection to development of MS.	[Osoegawa, Kazutoyo; Creary, Lisa E.; Montero-Martin, Gonzalo; Mallempati, Kalyan C.; Gangavarapu, Sridevi; Fernandez-Vina, Marcelo A.] Stanford Blood Ctr, Histocompatibil & Immunogenet Lab, Palo Alto, CA 94304 USA; [Creary, Lisa E.; Montero-Martin, Gonzalo; Fernandez-Vina, Marcelo A.] Stanford Univ, Sch Med, Dept Pathol, Palo Alto, CA 94304 USA; [Caillier, Stacy J.; Santaniello, Adam; Hollenbach, Jill A.; Hauser, Stephen L.; Oksenberg, Jorge R.] Univ Calif San Francisco, Dept Neurol, Weill Inst Neurosci, San Francisco, CA USA; [Isobe, Noriko] Kyushu Univ, Grad Sch Med Sci, Dept Neurol, Fukuoka, Japan	Stanford University; Stanford University; University of California System; University of California San Francisco; Kyushu University	Osoegawa, K (corresponding author), Stanford Blood Ctr, Histocompatibil & Immunogenet Lab, Palo Alto, CA 94304 USA.	kazutoyo@stanford.edu		Fernandez-Vina, Marcelo A./0000-0002-5707-2588	National Institutes of Health [U19NS095774]; National Multiple Sclerosis Society [RG-1611-26299]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Multiple Sclerosis Society(National Multiple Sclerosis Society)	This study was supported by a grant from the National Institutes of Health U19NS095774 (JO and MV). The UCSF DNA biorepository is supported by RG-1611-26299 from the National Multiple Sclerosis Society. The content is solely the responsibility of the authors and does not necessarily reflect the official views of the NIAID, NINDS, NIH or United States Government.	Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277; Ascherio A, 2007, ANN NEUROL, V61, P288, DOI 10.1002/ana.21117; Barcellos LF, 2006, HUM MOL GENET, V15, P2813, DOI 10.1093/hmg/ddl223; Barsakis K, 2019, HUM IMMUNOL, V80, P437, DOI 10.1016/j.humimm.2019.04.001; Bergamaschi L, 2010, GENES IMMUN, V11, P173, DOI 10.1038/gene.2009.101; Caillier SJ, 2008, J IMMUNOL, V181, P5473, DOI 10.4049/jimmunol.181.8.5473; Chang CJ, 2018, HUM IMMUNOL, V79, P77, DOI 10.1016/j.humimm.2017.12.004; Chen JJ, 1999, BIOMETRICS, V55, P1269, DOI 10.1111/j.0006-341X.1999.01269.x; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Creary LE, 2019, HUM IMMUNOL, V80, P807, DOI 10.1016/j.humimm.2019.07.275; Creary LE, 2019, MULT SCLER J, V25, P772, DOI 10.1177/1352458518770019; Crivello P, 2013, HUM IMMUNOL, V74, P970, DOI 10.1016/j.humimm.2013.04.014; Dixon AM, 2014, J BIOL CHEM, V289, P11695, DOI 10.1074/jbc.M113.516997; Field J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013454; Firth D, 2005, J STAT SOFTW, V12, P1; Fujisao S, 1996, HUM IMMUNOL, V45, P131, DOI 10.1016/0198-8859(95)00169-7; Gourraud PA, 2011, ANN NEUROL, V69, P65, DOI 10.1002/ana.22323; Gragert L, 2013, HUM IMMUNOL, V74, P1313, DOI 10.1016/j.humimm.2013.06.025; GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296; Harbo HF, 2014, MULT SCLER J, V20, P660, DOI 10.1177/1352458513506503; Harton Jonathan, 2016, F1000Res, V5, DOI 10.12688/f1000research.7610.1; Hollenbach JA, 2016, GENES IMMUN, V17, P199, DOI 10.1038/gene.2016.5; Hollenbach JA, 2015, J AUTOIMMUN, V64, P13, DOI 10.1016/j.jaut.2015.06.010; Isobe N, 2016, JAMA NEUROL, V73, P795, DOI 10.1001/jamaneurol.2016.0980; Isobe N, 2013, NEUROLOGY, V81, P219, DOI 10.1212/WNL.0b013e31829bfe2f; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Klasberg S, 2019, HUM IMMUNOL, V80, P44, DOI 10.1016/j.humimm.2018.05.006; Koch-Henriksen N, 2010, LANCET NEUROL, V9, P520, DOI 10.1016/S1474-4422(10)70064-8; Lancaster AK, 2007, TISSUE ANTIGENS, V69, P192, DOI 10.1111/j.1399-0039.2006.00769.x; Mack SJ, 2019, GENES IMMUN, V20, P308, DOI 10.1038/s41435-017-0006-8; Mayes MD, 2014, AM J HUM GENET, V94, P47, DOI 10.1016/j.ajhg.2013.12.002; Milius RP, 2013, TISSUE ANTIGENS, V82, P106, DOI 10.1111/tan.12150; Milius RP, 2015, HUM IMMUNOL, V76, P963, DOI 10.1016/j.humimm.2015.08.001; Moutsianas L, 2015, NAT GENET, V47, P1107, DOI 10.1038/ng.3395; Orton SM, 2006, LANCET NEUROL, V5, P932, DOI 10.1016/S1474-4422(06)70581-6; Osoegawa K, 2019, HUM IMMUNOL, V80, P644, DOI 10.1016/j.humimm.2019.05.018; Osoegawa K, 2019, HUM IMMUNOL, V80, P633, DOI 10.1016/j.humimm.2019.01.010; Pappas DJ, 2016, HUM IMMUNOL, V77, P283, DOI 10.1016/j.humimm.2015.12.006; Patsopoulos NA, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003926; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Qiu W, 2011, MULT SCLER J, V17, P382, DOI 10.1177/1352458510391345; Quandt JA, 2012, J IMMUNOL, V189, P2897, DOI 10.4049/jimmunol.1103087; Ramagopalan SV, 2007, PLOS GENET, V3, P1607, DOI 10.1371/journal.pgen.0030150; Ramagopalan SV, 2009, NEUROLOGY, V72, P566, DOI 10.1212/01.wnl.0000341941.24967.e6; REIJONEN H, 1991, DIABETES, V40, P1640, DOI 10.2337/diabetes.40.12.1640; Rioux JD, 2009, P NATL ACAD SCI USA, V106, P18680, DOI 10.1073/pnas.0909307106; Robinson J, 2015, NUCLEIC ACIDS RES, V43, pD423, DOI 10.1093/nar/gku1161; Schaid DJ, 1996, GENET EPIDEMIOL, V13, P423, DOI 10.1002/(SICI)1098-2272(1996)13:5<423::AID-GEPI1>3.0.CO;2-3; Schmidt H, 2007, AM J EPIDEMIOL, V165, P1097, DOI 10.1093/aje/kwk118; Schwender H, 2014, GENET EPIDEMIOL, V38, P516, DOI 10.1002/gepi.21836; Schwender H, 2012, BIOMETRICS, V68, P766, DOI 10.1111/j.1541-0420.2011.01713.x; SHAM PC, 1995, ANN HUM GENET, V59, P323, DOI 10.1111/j.1469-1809.1995.tb00751.x; Simpson S, 2011, J NEUROL NEUROSUR PS, V82, P1132, DOI 10.1136/jnnp.2011.240432; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Stewart CA, 2004, GENOME RES, V14, P1176, DOI 10.1101/gr.2188104; SVEJGAARD A, 1994, TISSUE ANTIGENS, V43, P18, DOI 10.1111/j.1399-0039.1994.tb02291.x; Szumilas M, 2010, J CAN ACAD CHILD ADO, V19, P227; Waldman ID, 1999, ANN HUM GENET, V63, P329, DOI 10.1046/j.1469-1809.1999.6340329.x; Wallin MT, 2004, ANN NEUROL, V55, P65, DOI 10.1002/ana.10788; Wang CL, 2012, P NATL ACAD SCI USA, V109, P8676, DOI 10.1073/pnas.1206614109; Wang J, 2020, CELL, V183, P1264, DOI 10.1016/j.cell.2020.09.054; Yeo TW, 2007, ANN NEUROL, V61, P228, DOI 10.1002/ana.21063; Yoshimura S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048592; Zhao JH, 1999, AM J HUM GENET, V64, P1484, DOI 10.1086/302378	64	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2021	12								644838	10.3389/fimmu.2021.644838	http://dx.doi.org/10.3389/fimmu.2021.644838			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SO0ML	34211458	Green Published, gold			2022-12-18	WOS:000658675800001
J	Yeo, JG; Leong, JY; Tay, SH; Nadua, KD; Anderson, DE; Lim, AJM; Ng, XW; Poh, SL; Guo, DY; Yaung, KN; Kumar, P; Wasser, M; Hazirah, SN; Sutamam, N; Chua, CJH; Qui, M; Foo, R; Gamage, AM; Yeo, KT; Ramakrishna, L; Arkachaisri, T; Young, BE; Lye, DC; Wang, LF; Chong, CY; Tan, NWH; Li, JH; Kam, KQ; Ginhoux, F; Thoon, KC; Chan, JKY; Yung, CF; Albani, S				Yeo, Joo Guan; Leong, Jing Yao; Tay, Shi Huan; Nadua, Karen Donceras; Anderson, Danielle E.; Lim, Amanda Jin Mei; Ng, Xiang Wen; Poh, Su Li; Guo, Dianyan; Yaung, Katherine Nay; Kumar, Pavanish; Wasser, Martin; Hazirah, Sharifah Nur; Sutamam, Nursyuhadah; Chua, Camillus Jian Hui; Qui, Martin; Foo, Randy; Gamage, Akshamal Mihiranga; Yeo, Kee Thai; Ramakrishna, Lakshmi; Arkachaisri, Thaschawee; Young, Barnaby E.; Lye, David Chien; Wang, Lin-Fa; Chong, Chia Yin; Tan, Natalie Woon Hui; Li, Jiahui; Kam, Kai-Qian; Ginhoux, Florent; Thoon, Koh Cheng; Chan, Jerry Kok Yen; Yung, Chee Fu; Albani, Salvatore			A Virus-Specific Immune Rheostat in the Immunome of Patients Recovering From Mild COVID-19	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; SARS-CoV-2; regulatory T cells; follicular helper T cells; mass cytometry	T-CELLS; GENERATION; RESPONSES	An accurate depiction of the convalescent COVID-19 immunome will help delineate the immunological milieu crucial for disease resolution and protection. Using mass cytometry, we characterized the immune architecture in patients recovering from mild COVID-19. We identified a virus-specific immune rheostat composed of an effector T (T-eff) cell recall response that is balanced by the enrichment of a highly specialized regulatory T (T-reg) cell subset. Both components were reactive against a peptide pool covering the receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein. We also observed expansion of IFN gamma(+) memory CD4(+) T cells and virus-specific follicular helper T (T-FH) cells. Overall, these findings pinpoint critical immune effector and regulatory mechanisms essential for a potent, yet harmless resolution of COVID-19 infection.	[Yeo, Joo Guan; Leong, Jing Yao; Tay, Shi Huan; Lim, Amanda Jin Mei; Poh, Su Li; Guo, Dianyan; Yaung, Katherine Nay; Kumar, Pavanish; Wasser, Martin; Hazirah, Sharifah Nur; Sutamam, Nursyuhadah; Chua, Camillus Jian Hui; Yeo, Kee Thai; Ramakrishna, Lakshmi; Ginhoux, Florent; Albani, Salvatore] SingHlth Duke NUS Acad Med Ctr, Translat Immunol Inst, Singapore, Singapore; [Yeo, Joo Guan; Arkachaisri, Thaschawee; Albani, Salvatore] KK Womens & Childrens Hosp, Dept Pediat Subspecial, Rheumatol & Immunol Serv, Singapore, Singapore; [Yeo, Joo Guan; Tay, Shi Huan; Nadua, Karen Donceras; Anderson, Danielle E.; Yaung, Katherine Nay; Qui, Martin; Foo, Randy; Gamage, Akshamal Mihiranga; Yeo, Kee Thai; Arkachaisri, Thaschawee; Wang, Lin-Fa; Chong, Chia Yin; Tan, Natalie Woon Hui; Li, Jiahui; Kam, Kai-Qian; Ginhoux, Florent; Thoon, Koh Cheng; Chan, Jerry Kok Yen; Yung, Chee Fu; Albani, Salvatore] Duke NUS Med Sch, Singapore, Singapore; [Nadua, Karen Donceras; Arkachaisri, Thaschawee; Young, Barnaby E.; Lye, David Chien; Chong, Chia Yin; Tan, Natalie Woon Hui; Li, Jiahui; Kam, Kai-Qian; Thoon, Koh Cheng] Natl Univ Singapore NUS, Yong Loo Lin Sch Med, Singapore, Singapore; [Nadua, Karen Donceras; Chong, Chia Yin; Tan, Natalie Woon Hui; Li, Jiahui; Kam, Kai-Qian; Thoon, Koh Cheng; Yung, Chee Fu] KK Womens & Childrens Hosp, Dept Pediat, Infect Dis Serv, Singapore, Singapore; [Ng, Xiang Wen; Chan, Jerry Kok Yen] KK Womens & Childrens Hosp, Dept Reprod Med, Singapore, Singapore; [Yeo, Kee Thai] KK Womens & Childrens Hosp, Dept Neonatol, Singapore, Singapore; [Young, Barnaby E.; Lye, David Chien] Natl Ctr Infect Dis, Singapore, Singapore; [Young, Barnaby E.; Lye, David Chien] Tan Tock Seng Hosp, Dept Infect Dis, Singapore, Singapore; [Lye, David Chien; Chong, Chia Yin; Tan, Natalie Woon Hui; Thoon, Koh Cheng; Yung, Chee Fu] Lee Kong Chian Sch Med, Singapore, Singapore; [Ginhoux, Florent] ASTAR, Singapore Immunol Network SIgN, Singapore, Singapore	KK Women's & Children's Hospital; National University of Singapore; National University of Singapore; KK Women's & Children's Hospital; KK Women's & Children's Hospital; KK Women's & Children's Hospital; National Centre for Infectious Diseases Singapore; Tan Tock Seng Hospital; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN)	Yeo, JG (corresponding author), SingHlth Duke NUS Acad Med Ctr, Translat Immunol Inst, Singapore, Singapore.; Yeo, JG (corresponding author), KK Womens & Childrens Hosp, Dept Pediat Subspecial, Rheumatol & Immunol Serv, Singapore, Singapore.; Yeo, JG (corresponding author), Duke NUS Med Sch, Singapore, Singapore.	yeo.joo.guan@singhealth.com.sg	Lye, David/ABF-4402-2021; wang, lin/GSE-3040-2022; Tan, Natalie Woon Hui/AGY-5689-2022; Yeo, Joo Guan/GRR-5310-2022; Anderson, Danielle/HCH-2004-2022; Young, Barnaby/GVR-9935-2022; wang, lili/HDL-7210-2022; Qui, Martin/AHE-2661-2022	Yeo, Joo Guan/0000-0001-8981-5000; Ng, Xiang Wen/0000-0002-9544-5656; Qui, Martin/0000-0001-5230-3263; Lye, David/0000-0003-0324-0205; Young, Barnaby/0000-0003-1010-2230; Yeo, Kee Thai/0000-0003-4357-3610; Tay, Shi Huan/0000-0002-3341-5427; Leong, Jing Yao/0000-0002-8651-9801	SingHealth Duke-NUS Academic Medicine COVID-19 Rapid Response Research [AM/COV004/2020, AM/COV001/2020]; National Research Foundation Singapore under its National Medical Research Council (NMRC) Centre Grant Programme [NMRC/CG/M003/2017]; NMRC [NMRC/TA/0059/2017, NMRC/MOHIAFCAT2/005/2015, NMRC/TCR/0015-NCC/2016, NMRC/OFLCG/002/2018, CIRG19may0052, NMRC/CSASI/0008/2016, NMRC/STPRG-FY19-001, NMRC/COVID19RF-001, NMRC/COVID19RF-003]	SingHealth Duke-NUS Academic Medicine COVID-19 Rapid Response Research; National Research Foundation Singapore under its National Medical Research Council (NMRC) Centre Grant Programme; NMRC(National Medical Research Council, Singapore)	This study was conducted with the provision of grant funding from the SingHealth Duke-NUS Academic Medicine COVID-19 Rapid Response Research AM/COV004/2020 (SA) and AM/COV001/2020 (CY). This research was also supported by the National Research Foundation Singapore under its National Medical Research Council (NMRC) Centre Grant Programme (NMRC/CG/M003/2017) (SA) and is administered by the Ministry of Health, Singapore's NMRC. Other NMRC grant support, NMRC/TA/0059/2017 (JY), NMRC/MOHIAFCAT2/005/2015 (SA), NMRC/TCR/0015-NCC/2016 (SA), NMRC/OFLCG/002/2018 (SA), CIRG19may0052 (SA), NMRC/CSASI/0008/2016 (JC), NMRC/STPRG-FY19-001 (L-FW), NMRC/COVID19RF-001 (BY) and NMRC/COVID19RF-003 (L-FW), is gratefully acknowledged.	Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007; Arunachalam PS, 2020, SCIENCE, V369, P1210, DOI 10.1126/science.abc6261; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bentebibel SE, 2016, SCI REP-UK, V6, DOI 10.1038/srep26494; Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545; Brezar V, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030030; Chakraborty I, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138882; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Co MDT, 2008, VACCINE, V26, P1990, DOI 10.1016/j.vaccine.2008.02.024; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Finck R, 2013, CYTOM PART A, V83A, P483, DOI 10.1002/cyto.a.22271; Godefroy E, 2015, HAEMATOLOGICA, V100, P1415, DOI 10.3324/haematol.2015.132738; Gong F, 2020, J CLIN INVEST, V130, P6588, DOI 10.1172/JCI141054; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; He X, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0869-5; Jewett A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01692; Kondrack RM, 2003, J EXP MED, V198, P1797, DOI 10.1084/jem.20030735; Lai LY, 2015, CYTOM PART A, V87A, P369, DOI 10.1002/cyto.a.22640; Laing AG, 2020, NAT MED, V26, P1623, DOI 10.1038/s41591-020-1038-6; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Levine AG, 2017, NATURE, V546, P421, DOI 10.1038/nature22360; Lin PH, 2018, MUCOSAL IMMUNOL, V11, P1239, DOI 10.1038/s41385-018-0004-9; Lucca LE, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124427; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; Maucourant C, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd6832; Maurice NJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12980-2; Mazzoni A, 2020, J CLIN INVEST, V130, P4694, DOI [10.1172/JCI138554, 10.1172/JCI138554.]; Meckiff BJ, 2020, CELL, V183, P1340, DOI 10.1016/j.cell.2020.10.001; Metzemaekers M, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01970; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Neidleman Jason, 2020, bioRxiv, DOI 10.1101/2020.06.08.138826; Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI [10.1038/s41590-020-0782-6, 10.1101/2020.06.05.134551]; Peruzzi B, 2020, IMMUNOLOGY, V161, P345, DOI 10.1111/imm.13254; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Reynolds CJ, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abf3698; Sattler A, 2020, J CLIN INVEST, V130, DOI 10.1172/JCI140965; Schulte-Schrepping J, 2020, CELL, V182, P1419, DOI 10.1016/j.cell.2020.08.001; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y; Song JW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17240-2; Thevarajan I, 2020, NAT MED, V26, P453, DOI 10.1038/s41591-020-0819-2; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Weber LM, 2016, CYTOM PART A, V89A, P1084, DOI 10.1002/cyto.a.23030; Wei WE, 2020, MMWR-MORBID MORTAL W, V69, P411, DOI 10.15585/mmwr.mm6914e1; Wolfel R, 2020, NATURE, V581, P465, DOI 10.1038/s41586-020-2196-x; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yang RR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.10182; Yeo JG, 2020, NAT BIOTECHNOL, V38, P679, DOI 10.1038/s41587-020-0532-1; Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035; Zhou F, 2009, INT REV IMMUNOL, V28, P239, DOI 10.1080/08830180902978120	54	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2021	12								674279	10.3389/fimmu.2021.674279	http://dx.doi.org/10.3389/fimmu.2021.674279			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SO0OL	34113347	Green Published, gold			2022-12-18	WOS:000658681000001
J	Bevington, SL; Fiancette, R; Gajdasik, DW; Keane, P; Soley, JK; Willis, CM; Coleman, DJL; Withers, DR; Cockerill, PN				Bevington, Sarah L.; Fiancette, Remi; Gajdasik, Dominika W.; Keane, Peter; Soley, Jake K.; Willis, Claire M.; Coleman, Daniel J. L.; Withers, David R.; Cockerill, Peter N.			Stable Epigenetic Programming of Effector and Central Memory CD4 T Cells Occurs Within 7 Days of Antigen Exposure In Vivo	FRONTIERS IN IMMUNOLOGY			English	Article						memory T CD4+cells; gene regulatory networks; epigenetics (chromatin remodelling); immunological memory responses; T cell activation	ETS-1 TRANSCRIPTION FACTOR; IMMUNOLOGICAL MEMORY; DIFFERENTIATION; NAIVE; CHROMATIN; RECEPTOR; FAMILY; BETA; ACTIVATION; GENERATION	T cell immunological memory is established within days of an infection, but little is known about the in vivo changes in gene regulatory networks accounting for their ability to respond more efficiently to secondary infections. To decipher the timing and nature of immunological memory we performed genome-wide analyses of epigenetic and transcriptional changes in a mouse model generating antigen-specific T cells. Epigenetic reprogramming for Th differentiation and memory T cell formation was already established by the peak of the T cell response after 7 days. The Th memory T cell program was associated with a gain of open chromatin regions, enriched for RUNX, ETS and T-bet motifs, which remained stable for 56 days. The epigenetic programs for both effector memory, associated with T-bet, and central memory, associated with TCF-1, were established in parallel. Memory T cell-specific regulatory elements were associated with greatly enhanced inducible Th1-biased responses during secondary exposures to antigen. Furthermore, memory T cells responded in vivo to re-exposure to antigen by rapidly reprograming the entire ETS factor gene regulatory network, by suppressing Ets1 and activating Etv6 expression. These data show that gene regulatory networks are epigenetically reprogrammed towards memory during infection, and undergo substantial changes upon re-stimulation.	[Bevington, Sarah L.; Keane, Peter; Soley, Jake K.; Coleman, Daniel J. L.; Cockerill, Peter N.] Univ Birmingham, Inst Canc & Genom Sci, Coll Med & Dent Sci, Birmingham, W Midlands, England; [Fiancette, Remi; Gajdasik, Dominika W.; Willis, Claire M.; Withers, David R.] Univ Birmingham, Inst Immunol & Immunotherapy, Coll Med & Dent Sci, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham	Cockerill, PN (corresponding author), Univ Birmingham, Inst Canc & Genom Sci, Coll Med & Dent Sci, Birmingham, W Midlands, England.; Withers, DR (corresponding author), Univ Birmingham, Inst Immunol & Immunotherapy, Coll Med & Dent Sci, Birmingham, W Midlands, England.	d.withers@bham.ac.uk; p.n.cockerill@bham.ac.uk	; Withers, David/C-7055-2015	Keane, Peter/0000-0001-8738-9693; Coleman, Daniel/0000-0001-9416-7028; Withers, David/0000-0003-3757-7594; Soley, Jake/0000-0001-7131-2560	Medical Research Council [MR/P001319/1]	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was supported by funding from the Medical Research Council (MR/P001319/1).	Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Ai RN, 2016, CANCER BIOL THER, V17, P943, DOI 10.1080/15384047.2016.1210734; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anderson MK, 1999, DEVELOPMENT, V126, P3131; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Barnett DW, 2011, BIOINFORMATICS, V27, P1691, DOI 10.1093/bioinformatics/btr174; Barski A, 2017, SCI REP-UK, V7, DOI 10.1038/srep39785; Bartel FO, 2000, ONCOGENE, V19, P6443, DOI 10.1038/sj.onc.1204038; Bevington SL, 2020, EMBO J, V39, DOI 10.15252/embj.2020105220; Bevington SL, 2017, BIOESSAYS, V39, DOI 10.1002/bies.201600184; Bevington SL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00204; Bevington SL, 2016, EMBO J, V35, P515, DOI 10.15252/embj.201592534; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Brignall R, 2017, J IMMUNOL, V199, P2652, DOI 10.4049/jimmunol.1602033; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Ciuba K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35948-6; Corces MR, 2017, NAT METHODS, V14, P959, DOI [10.1038/NMETH.4396, 10.1038/nmeth.4396]; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Curtsinger JM, 1998, J IMMUNOL, V160, P3236; David-Fung ES, 2009, DEV BIOL, V325, P444, DOI 10.1016/j.ydbio.2008.10.021; Dose M, 2014, P NATL ACAD SCI USA, V111, P391, DOI 10.1073/pnas.1315752111; Eyquem S, 2004, P NATL ACAD SCI USA, V101, P15712, DOI 10.1073/pnas.0405546101; Fouani L, 2019, ANTIOXID REDOX SIGN, V30, P1096, DOI 10.1089/ars.2017.7387; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Gokmen MR, 2013, J IMMUNOL, V191, P5925, DOI 10.4049/jimmunol.1202254; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Grenningloh K, 2005, J EXP MED, V201, P615, DOI 10.1084/jem.20041330; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Jenkins MK, 2001, ANNU REV IMMUNOL, V19, P23, DOI 10.1146/annurev.immunol.19.1.23; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Kakaradov B, 2017, NAT IMMUNOL, V18, P422, DOI 10.1038/ni.3688; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kuwahara M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4555; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mackay LK, 2015, IMMUNITY, V43, P1101, DOI 10.1016/j.immuni.2015.11.008; McKinstry KK, 2007, J EXP MED, V204, P2199, DOI 10.1084/jem.20070041; Meixner A, 2004, EMBO J, V23, P1325, DOI 10.1038/sj.emboj.7600133; Melotte V, 2010, FASEB J, V24, P4153, DOI 10.1096/fj.09-151464; Moon JJ, 2007, IMMUNITY, V27, P203, DOI 10.1016/j.immuni.2007.07.007; Moon JJ, 2009, NAT PROTOC, V4, P565, DOI 10.1038/nprot.2009.9; Mouly E, 2010, J EXP MED, V207, P2113, DOI 10.1084/jem.20092153; Oh YM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9698; Pepper M, 2011, IMMUNITY, V35, P583, DOI 10.1016/j.immuni.2011.09.009; Pepper M, 2011, NAT IMMUNOL, V12, P467, DOI 10.1038/ni.2038; Pepper M, 2010, NAT IMMUNOL, V11, P83, DOI 10.1038/ni.1826; Pihlgren M, 1996, J EXP MED, V184, P2141, DOI 10.1084/jem.184.6.2141; Piper J, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt850; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Read KA, 2016, EXP HEMATOL, V44, P799, DOI 10.1016/j.exphem.2016.06.003; Rogers PR, 2000, J IMMUNOL, V164, P2338, DOI 10.4049/jimmunol.164.5.2338; Roychoudhuri R, 2016, NAT IMMUNOL, V17, P851, DOI 10.1038/ni.3441; Roychoudhuri R, 2013, NATURE, V498, P506, DOI 10.1038/nature12199; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shibukawa Y, 2010, MOL BIOL CELL, V21, P3973, DOI 10.1091/mbc.E10-03-0261; Soon MSF, 2020, NAT IMMUNOL, V21, P1597, DOI 10.1038/s41590-020-0800-8; Sprent J, 2002, ANNU REV IMMUNOL, V20, P551, DOI 10.1146/annurev.immunol.20.100101.151926; Surh CD, 2008, IMMUNITY, V29, P848, DOI 10.1016/j.immuni.2008.11.002; Tsukumo S, 2013, P NATL ACAD SCI USA, V110, P10735, DOI 10.1073/pnas.1306691110; Vahedi G, 2012, CELL, V151, P981, DOI 10.1016/j.cell.2012.09.044; WOTTON D, 1993, LEUKEMIA, V7, pS55; Yukawa M., 2019, J Exp Med, V217, P1, DOI 10.1101/647388; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	72	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2021	12								642807	10.3389/fimmu.2021.642807	http://dx.doi.org/10.3389/fimmu.2021.642807			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SN5MQ	34108962	Green Published, gold			2022-12-18	WOS:000658334000001
J	Rutschman, AS; Wiemken, TL				Rutschman, Ana Santos; Wiemken, Timothy L.			Re-examining Vaccine Staggering Within Hesitancy Frameworks	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						vaccine; immunization; hesitancy; anti-vaccination; infrastructure	UNITED-STATES		[Rutschman, Ana Santos] St Louis Univ, Ctr Hlth Law Studies, Sch Law, St Louis, MO 63103 USA; [Rutschman, Ana Santos; Wiemken, Timothy L.] St Louis Univ, Inst Vaccine Sci & Policy, St Louis, MO 63103 USA; [Wiemken, Timothy L.] St Louis Univ, Sch Med, Dept Internal Med, Div Infect Dis Allergy & Immunol, St Louis, MO 63104 USA; [Wiemken, Timothy L.] St Louis Univ, Syst Infect Prevent Ctr, St Louis, MO 63103 USA	Saint Louis University; Saint Louis University; Saint Louis University; Saint Louis University	Wiemken, TL (corresponding author), St Louis Univ, Inst Vaccine Sci & Policy, St Louis, MO 63103 USA.; Wiemken, TL (corresponding author), St Louis Univ, Sch Med, Dept Internal Med, Div Infect Dis Allergy & Immunol, St Louis, MO 63104 USA.; Wiemken, TL (corresponding author), St Louis Univ, Syst Infect Prevent Ctr, St Louis, MO 63103 USA.	timothy.wiemken@health.slu.edu		Santos Rutschman, Ana/0000-0002-4287-6954				Bonanni P, 2020, HUM VACC IMMUNOTHER, V16, P1313, DOI 10.1080/21645515.2019.1688032; Broniatowski DA, 2018, AM J PUBLIC HEALTH, V108, P1378, DOI 10.2105/AJPH.2018.304567; Larson HJ, 2018, LANCET, V392, P2244, DOI 10.1016/S0140-6736(18)32608-4; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Masters NB, 2019, HUM VACC IMMUNOTHER, V15, P2790, DOI 10.1080/21645515.2019.1616503; Orenstein WA, 2015, PUBLIC HEALTH REP, V130, P573; Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353; Salmon DA, 2015, VACCINE, V33, pD66, DOI 10.1016/j.vaccine.2015.09.035; Wiemken Timothy L, 2015, BMC Res Notes, V8, P813, DOI 10.1186/s13104-015-1816-2; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	10	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2021	12								662814	10.3389/fimmu.2021.662814	http://dx.doi.org/10.3389/fimmu.2021.662814			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SN5CM	34108965	Green Published, gold			2022-12-18	WOS:000658307600001
J	Seifert-Held, T; Eberhard, K; Lechner, C; Macher, S; Hegen, H; Moser, T; Jacob, GB; Puttinger, G; Topakian, R; Guger, M; Kacar, E; Zoche, L; De Simoni, D; Seiser, A; Oberndorfer, S; Baumgartner, C; Struhal, W; Zimprich, F; Sellner, J; Deisenhammer, F; Enzinger, C; Reindl, M; Rauschka, H; Berger, T; Hoftberger, R				Seifert-Held, Thomas; Eberhard, Katharina; Lechner, Christian; Macher, Stefan; Hegen, Harald; Moser, Tobias; Jacob, Gregor Brecl; Puttinger, Gertraud; Topakian, Raffi; Guger, Michael; Kacar, Emrah; Zoche, Lea; De Simoni, Desiree; Seiser, Andreas; Oberndorfer, Stefan; Baumgartner, Christoph; Struhal, Walter; Zimprich, Friedrich; Sellner, Johann; Deisenhammer, Florian; Enzinger, Christian; Reindl, Markus; Rauschka, Helmut; Berger, Thomas; Hoeftberger, Romana			Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmune encephalitis; anti-NMDAR-encephalitis; anti-LGI1-encephalitis; anti-CASPR2-encephalitis; modified Rankin Scale		Background Prospective observations of functional recovery are lacking in patients with autoimmune encephalitis defined by antibodies against synaptic proteins and neuronal cell surface receptors. Methods Adult patients with a diagnosis of autoimmune encephalitis were included into a prospective registry. At 3, 6 and 12 months of follow-up, the patients' modified Rankin Scale (mRS) was obtained. Results Patients were stratified into three groups according to their antibody (Ab) status: anti-NMDAR-Ab (n=12; group I), anti-LGI1/CASPR2-Ab (n=35; group II), and other antibodies (n=24; group III). A comparably higher proportion of patients in group I received plasma exchange/immunoadsorption and second line immunosuppressive treatments at baseline. A higher proportion of patients in group II presented with seizures. Group III mainly included patients with anti-GABA(B)R-, anti-GAD65- and anti-GlyR-Ab. At baseline, one third of them had cancer. Patients in groups I and III had much higher median mRS scores at 3 months compared to patients in group II. A median mRS of 1 was found at all follow-up time points in group II. Conclusions The different dynamics in the recovery of patients with certain autoimmune encephalitides have important implications for clinical trials. The high proportion of patients with significant disability at 3 months after diagnosis in groups I and III points to the need for improving treatment options. More distinct scores rather than the mRS are necessary to differentiate potential neurological improvements in patients with anti-LGI1-/CASPR2-encephalitis.	[Seifert-Held, Thomas; Enzinger, Christian] Med Univ Graz, Dept Neurol, Graz, Austria; [Eberhard, Katharina] Med Univ Graz, Ctr Med Res, Core Facil Computat Bioanalyt, Graz, Austria; [Lechner, Christian] Med Univ Innsbruck, Dept Pediat, Div Pediat Neurol, Innsbruck, Austria; [Lechner, Christian; Hoeftberger, Romana] Med Univ Vienna, Dept Neurol, Div Neuropathol & Neurochem, Vienna, Austria; [Macher, Stefan; Zimprich, Friedrich; Berger, Thomas] Med Univ Vienna, Dept Neurol, Vienna, Austria; [Hegen, Harald; Deisenhammer, Florian; Reindl, Markus] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria; [Moser, Tobias] Paracelsus Med Univ, Christian Doppler Med Ctr, Dept Neurol, Salzburg, Austria; [Jacob, Gregor Brecl] Univ Med Ctr Ljubljana, Dept Neurol, Ljubljana, Slovenia; [Puttinger, Gertraud] Kepler Univ Hosp, Johannes Kepler Univ, Dept Neurol 1, Linz, Austria; [Topakian, Raffi] Acad Teaching Hosp Wels, Dept Neurol, Wels, Austria; [Guger, Michael] Kepler Univ Hosp, Johannes Kepler Univ, Dept Neurol 2, Linz, Austria; [Kacar, Emrah; Seiser, Andreas; Struhal, Walter] Univ Clin Tulln, Karl Landsteiner Univ Hlth Sci, Dept Neurol, Tulln, Austria; [Zoche, Lea; Baumgartner, Christoph] Hosp Hietzing, Dept Neurol, Vienna, Austria; [De Simoni, Desiree; Oberndorfer, Stefan] Univ Clin St, Karl Landsteiner Univ Hlth Sci, Dept Neurol, St Polten, Austria; [Baumgartner, Christoph] Karl Landsteiner Inst Clin Epilepsy Res & Cognit, Vienna, Austria; [Baumgartner, Christoph] Sigmund Freud Univ, Med Fac, Vienna, Austria; [Sellner, Johann] Landesklinikum Mistelbach, Dept Neurol, Mistelbach, Austria; [Rauschka, Helmut] Hosp Donaustadt, Dept Neurol, Vienna, Austria; [Rauschka, Helmut] Karl Landsteiner Inst Neuroimmunol & Neurodegener, Vienna, Austria	Medical University of Graz; Medical University of Graz; Medical University of Innsbruck; Medical University of Vienna; Medical University of Vienna; Medical University of Innsbruck; Paracelsus Private Medical University; University Medical Centre Ljubljana; Johannes Kepler University Linz; Kepler University Hospital; Johannes Kepler University Linz; Kepler University Hospital; Hietzing Hospital	Seifert-Held, T (corresponding author), Med Univ Graz, Dept Neurol, Graz, Austria.	thomas.seifert-held@klinikum-graz.at	Reindl, Markus/ABE-5880-2020; Berger, Thomas U/HGA-3594-2022	Hoftberger, Romana/0000-0002-5769-1100; Lechner, Christian/0000-0002-2720-1019; Reindl, Markus/0000-0003-2817-1402	Austrian Society of Neurology (Osterreichische Gesellschaft fur Neurologie)	Austrian Society of Neurology (Osterreichische Gesellschaft fur Neurologie)	This study was supported by a grant from the Austrian Society of Neurology (Osterreichische Gesellschaft fur Neurologie).	Broadley J, 2019, J AUTOIMMUN, V96, P24, DOI 10.1016/j.jaut.2018.10.014; Cabezudo-Garcia P, 2020, ACTA NEUROL SCAND, V141, P263, DOI 10.1111/ane.13207; Dalmau J, 2018, NEW ENGL J MED, V378, P840, DOI 10.1056/NEJMra1708712; Dalmau J, 2017, PHYSIOL REV, V97, P839, DOI 10.1152/physrev.00010.2016; Dalmau J, 2011, LANCET NEUROL, V10, P63, DOI 10.1016/S1474-4422(10)70253-2; Dubey D, 2020, ANN NEUROL, V87, P313, DOI 10.1002/ana.25655; Gadoth A, 2017, ANN NEUROL, V82, P79, DOI 10.1002/ana.24979; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Hang HL, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00852; Hoftberger R, 2013, NEUROLOGY, V81, P1500, DOI 10.1212/WNL.0b013e3182a9585f; Iro MA, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012356; Lachenicht L., 2004, COURSE STAT SOCIAL S; Lennox B, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3336-1; Lim JA, 2019, ANN NEUROL, V85, P352, DOI 10.1002/ana.25421; Quinn TJ, 2009, STROKE, V40, P762, DOI [10.1161/STROKEAHA.108.522516, 10.1161/STROKEAHA.109.557256]; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wickel J, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04516-7; Xu XL, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000633	19	1	2	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 21	2021	12								641106	10.3389/fimmu.2021.641106	http://dx.doi.org/10.3389/fimmu.2021.641106			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SM5JC	34093529	Green Published, gold			2022-12-18	WOS:000657640600001
J	Zhang, JS; Lohani, SC; Cheng, YL; Wang, T; Guo, LL; Kim, WK; Gorantla, S; Li, QS				Zhang, Jianshui; Lohani, Saroj Chandra; Cheng, Yilun; Wang, Tao; Guo, Lili; Kim, Woong-Ki; Gorantla, Santhi; Li, Qingsheng			Human Microglia Extensively Reconstitute in Humanized-BLT Mice With Human Interleukin-34 Transgene and Support HIV-1 Brain Infection	FRONTIERS IN IMMUNOLOGY			English	Article						microglia; interleukin-34; NOG mice; Hu-BLT mice; HIV-1	ORIGIN	Humanized bone marrow-liver-thymic (hu-BLT) mice develop a functional immune system in periphery, nevertheless, have a limited reconstitution of human myeloid cells, especially microglia, in CNS. Further, whether bone marrow derived hematopoietic stem and progenitor cells (HSPCs) can enter the brain and differentiate into microglia in adults remains controversial. To close these gaps, in this study we unambiguously demonstrated that human microglia in CNS were extensively reconstituted in adult NOG mice with human interleukin-34 transgene (hIL34 Tg) from circulating CD34+ HSPCs, nonetheless not in hu-BLT NOG mice, providing strong evidence that human CD34+ HSPCs can enter adult brain and differentiate into microglia in CNS in the presence of hIL34. Further, the human microglia in the CNS of hu-BLT-hIL34 NOG mice robustly supported HIV-1 infection reenforcing the notion that microglia are the most important target cells of HIV-1 in CNS and demonstrating its great potential as an in vivo model for studying HIV-1 pathogenesis and evaluating curative therapeutics in both periphery and CNS compartments.	[Zhang, Jianshui; Lohani, Saroj Chandra; Cheng, Yilun; Wang, Tao; Li, Qingsheng] Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA; [Zhang, Jianshui; Lohani, Saroj Chandra; Cheng, Yilun; Wang, Tao; Li, Qingsheng] Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68583 USA; [Guo, Lili; Gorantla, Santhi] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA; [Kim, Woong-Ki] Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Medical Center; Eastern Virginia Medical School	Li, QS (corresponding author), Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA.; Li, QS (corresponding author), Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68583 USA.; Gorantla, S (corresponding author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.	sgorantla@unmc.edu; qli@unl.edu	Gorantla, Santhi/ABA-9379-2021	Li, Qingsheng/0000-0003-4101-4073	National Institutes of Health (NIH) [P30 MH062261-16A1, R21 AI143405, R01 AI136756]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study is supported in part by the National Institutes of Health (NIH) Grants P30 MH062261-16A1 Chronic HIV Infection and Aging in NeuroAIDS (CHAIN) Center (to Buch & Fox), R21 AI143405 (to QL). R01 AI136756 (YL, QL). The funders had no role in study design, data collection and analysis, preparation of the manuscript, or decision for publication.	Allen TM, 2019, NAT IMMUNOL, V20, P770, DOI 10.1038/s41590-019-0416-z; Alliot F, 1999, DEV BRAIN RES, V117, P145, DOI 10.1016/S0165-3806(99)00113-3; Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Cosenza MA, 2002, BRAIN PATHOL, V12, P442, DOI 10.1111/j.1750-3639.2002.tb00461.x; Ginhoux F, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00045; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Goldmann T, 2016, NAT IMMUNOL, V17, P797, DOI 10.1038/ni.3423; Gorantla S, 2012, TRENDS NEUROSCI, V35, P197, DOI 10.1016/j.tins.2011.12.006; Gorantla S, 2010, AM J PATHOL, V177, P2938, DOI 10.2353/ajpath.2010.100536; Hess DC, 2004, EXP NEUROL, V186, P134, DOI 10.1016/j.expneurol.2003.11.005; Honeycutt JB, 2018, J CLIN INVEST, V128, P2862, DOI 10.1172/JCI98968; Ito R, 2012, CELL MOL IMMUNOL, V9, P208, DOI 10.1038/cmi.2012.2; Janova H, 2016, GLIA, V64, P635, DOI 10.1002/glia.22955; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kierdorf K, 2013, NAT NEUROSCI, V16, P273, DOI 10.1038/nn.3318; Ko A, 2019, J NEUROIMMUNE PHARM, V14, P110, DOI 10.1007/s11481-018-9809-2; Lan P, 2006, BLOOD, V108, P487, DOI 10.1182/blood-2005-11-4388; Lelios I, 2020, J EXP MED, V217, DOI 10.1084/jem.20190290; Li QS, 2015, JAIDS-J ACQ IMM DEF, V69, P519, DOI 10.1097/QAI.0000000000000687; Li QY, 2018, NAT REV IMMUNOL, V18, P225, DOI 10.1038/nri.2017.125; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; Maleki AF, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00355; Marsden MD, 2015, VIROLOGY, V479, P297, DOI 10.1016/j.virol.2015.01.017; Mathews S, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0311-y; Melkus MW, 2006, NAT MED, V12, P1316, DOI 10.1038/nm1431; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Satoh J, 2016, NEUROPATHOLOGY, V36, P39, DOI 10.1111/neup.12235; Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Sun M, 2016, ARCH VIROL, V161, P2449, DOI 10.1007/s00705-016-2942-4; Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9; Wallet C, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00362; Yuan Z, 2016, J VIROL, V90, P7728, DOI 10.1128/JVI.00860-16	34	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 21	2021	12								672415	10.3389/fimmu.2021.672415	http://dx.doi.org/10.3389/fimmu.2021.672415			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SM8SO	34093573	Green Published, Green Submitted, gold			2022-12-18	WOS:000657868900001
J	Okunuki, Y; Tabor, SJ; Lee, MY; Connor, KM				Okunuki, Yoko; Tabor, Steven J.; Lee, May Y.; Connor, Kip M.			CD47 Deficiency Ameliorates Ocular Autoimmune Inflammation	FRONTIERS IN IMMUNOLOGY			English	Article						uveitis; retina; autoimmune diseases; CD47 antigen; antigen-presenting cells	UVEORETINITIS; EXPRESSION; BLOCKADE; CELLS; MICE	Autoimmune uveitis is a sight-threatening ocular inflammatory condition in which the retina and uveal tissues become a target of autoreactive immune cells. The CD47 is a ubiquitously expressed transmembrane protein which plays multiple roles in fundamental cellular functions including phagocytosis, proliferation, and adhesion. Signal regulatory protein alpha (SIRP alpha), one of the CD47 ligands, is predominantly expressed in myeloid lineage cells such as dendritic cells (DCs) or macrophages, and CD47-SIRP alpha signaling pathway is implicated in the development of autoimmune diseases. Our current study demonstrates how CD47 depletion is effective in the prevention of experimental autoimmune uveitis (EAU), an animal model of human autoimmune uveitis, in animals deficient of CD47 (CD47(-/-) ). Systemic suppression of SIRP alpha(+) DCs in animals deficient in CD47 resulted in the inability of autoreactive CD4(+) T cells to develop, which is crucial to induction of EAU. Of interest, retinal microglia, the resident immune cell of the retina, express SIRP alpha, however these cells were not operative in EAU suppression in response to CD47 depletion. These results identify CD47 as a significant regulator in the development of SIRP alpha(+) DCs that is vital to disease induction in EAU.	[Okunuki, Yoko; Tabor, Steven J.; Lee, May Y.; Connor, Kip M.] Harvard Med Sch, Angiogenesis Lab, Dept Ophthalmol, Massachusetts Eye & Ear, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Connor, KM (corresponding author), Harvard Med Sch, Angiogenesis Lab, Dept Ophthalmol, Massachusetts Eye & Ear, Boston, MA 02115 USA.	kip_connor@meei.harvard.edu			National Institute of Health/National Eye Institute [R01EY031291, R01EY027303]; Massachusetts Lions Eye Research Fund; American Macular Degeneration Foundation Prevention Award	National Institute of Health/National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Massachusetts Lions Eye Research Fund; American Macular Degeneration Foundation Prevention Award	This study was supported by the National Institute of Health/National Eye Institute: Grants: R01EY031291, R01EY027303 (KC), the Massachusetts Lions Eye Research Fund (KC), and the American Macular Degeneration Foundation Prevention Award (KC).	Abcouwer SF, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-149; Agarwal RK, 2004, METH MOLEC MED, V102, P395; Azcutia V, 2017, J LEUKOCYTE BIOL, V101, P493, DOI 10.1189/jlb.3A1215-546RR; Azcutia V, 2012, J IMMUNOL, V189, P2553, DOI 10.4049/jimmunol.1103606; Barbour M, 2014, EUR J IMMUNOL, V44, P3320, DOI 10.1002/eji.201444671; Barclay AN, 2006, NAT REV IMMUNOL, V6, P457, DOI 10.1038/nri1859; Blazar BR, 2001, J EXP MED, V194, P541, DOI 10.1084/jem.194.4.541; Bose T, 2016, AUTOIMMUN REV, V15, P1181, DOI 10.1016/j.autrev.2016.09.001; Caspi RR, 2008, OPHTHAL RES, V40, P169, DOI 10.1159/000119871; CASPI RR, 1988, J IMMUNOL, V140, P1490; Cham LB, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.03.058; CHAN CC, 1990, J AUTOIMMUN, V3, P247, DOI 10.1016/0896-8411(90)90144-H; Chan CC., 1988, INVEST OPHTHALMOL VI, V29; Chen P, 2015, SURV OPHTHALMOL, V60, P242, DOI 10.1016/j.survophthal.2015.01.003; Crane IJ, 2006, J LEUKOCYTE BIOL, V79, P435, DOI 10.1189/jlb.0305130; de Vries HE, 2002, J IMMUNOL, V168, P5832, DOI 10.4049/jimmunol.168.11.5832; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Durrani OM, 2004, BRIT J OPHTHALMOL, V88, P1159, DOI 10.1136/bjo.2003.037226; Fortin G, 2009, J EXP MED, V206, P1995, DOI 10.1084/jem.20082805; Gao QG, 2016, J AUTOIMMUN, V69, P74, DOI 10.1016/j.jaut.2016.03.002; Goto H, 2007, JPN J OPHTHALMOL, V51, P41, DOI 10.1007/s10384-006-0383-4; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Hagnerud S, 2006, J IMMUNOL, V176, P5772, DOI 10.4049/jimmunol.176.10.5772; Han MH, 2012, J EXP MED, V209, P1325, DOI 10.1084/jem.20101974; Hayat SMG, 2020, CELL ONCOL, V43, P19, DOI 10.1007/s13402-019-00469-5; Huang JF, 2013, EXP EYE RES, V111, P36, DOI 10.1016/j.exer.2013.03.012; Huang X, 2018, METHODS MOL BIOL, V1784, P119, DOI 10.1007/978-1-4939-7837-3_12; Ishikawa-Sekigami T, 2006, BLOOD, V107, P341, DOI 10.1182/blood-2005-05-1896; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Ivetic A, 2004, BIOCHEM SOC T, V32, P1118, DOI 10.1042/BST0321118; Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046; Kezuka T, 2004, J IMMUNOL, V173, P1454, DOI 10.4049/jimmunol.173.2.1454; Kunimi K, 2021, OCUL IMMUNOL INFLAMM, V29, P976, DOI 10.1080/09273948.2019.1709649; Latour S, 2001, J IMMUNOL, V167, P2547, DOI 10.4049/jimmunol.167.5.2547; Lee RW, 2014, SEMIN IMMUNOPATHOL, V36, P581, DOI 10.1007/s00281-014-0433-9; Liang DC, 2016, J IMMUNOL, V196, P2646, DOI 10.4049/jimmunol.1502294; Lin W, 2019, IMMUNOL LETT, V209, P4, DOI 10.1016/j.imlet.2019.03.016; Lindberg FP., 1994, J BIOL CHEM, V269, DOI [10.1016/S0021-9258(17)42058-8, DOI 10.1016/S0021-9258(17)42058-8]; Lipski DA, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0915-5; Liu J, 2020, J NEUROSCI RES, V98, P1498, DOI 10.1002/jnr.24618; Liu Y, 2002, J BIOL CHEM, V277, P10028, DOI 10.1074/jbc.M109720200; Liu ZH, 2017, IMMUNOLOGY, V152, P638, DOI 10.1111/imm.12805; Matozaki T, 2009, TRENDS CELL BIOL, V19, P72, DOI 10.1016/j.tcb.2008.12.001; Moen LV, 2017, EUR J IMMUNOL, V47, P1880, DOI 10.1002/eji.201646809; Motegi S, 2003, EMBO J, V22, P2634, DOI 10.1093/emboj/cdg278; Myers LM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08637-9; Nakamura YK, 2016, INVEST OPHTH VIS SCI, V57, P3747, DOI 10.1167/iovs.16-19733; Nishimura T, 2020, EUR J IMMUNOL, V50, P1560, DOI 10.1002/eji.201948410; Okajo J, 2007, J IMMUNOL, V178, P6164, DOI 10.4049/jimmunol.178.10.6164; Okunuki Y, 2019, P NATL ACAD SCI USA, V116, P9989, DOI 10.1073/pnas.1820387116; Okunuki Y, 2013, EXP EYE RES, V116, P291, DOI 10.1016/j.exer.2013.09.017; Pakalniskyte D, 2017, ADV IMMUNOL, V134, P89, DOI 10.1016/bs.ai.2017.01.003; Quast I, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0506-x; REINHOLD MI, 1995, J CELL SCI, V108, P3419; Rizzo LV, 1996, J IMMUNOL, V156, P1654; Rosenbaum JT, 2019, SEMIN ARTHRITIS RHEU, V49, P438, DOI 10.1016/j.semarthrit.2019.06.004; Saito Y, 2010, BLOOD, V116, P3517, DOI 10.1182/blood-2010-03-277244; SANUI H, 1989, J EXP MED, V169, P1947, DOI 10.1084/jem.169.6.1947; Seiffert M, 2001, BLOOD, V97, P2741, DOI 10.1182/blood.V97.9.2741; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Takeda A, 2018, JPN J OPHTHALMOL, V62, P398, DOI 10.1007/s10384-018-0587-4; Tempany JC, 2018, IMMUNOL CELL BIOL, V96, P149, DOI 10.1111/imcb.1020; Thurau SR, 1997, CLIN EXP IMMUNOL, V109, P370, DOI 10.1046/j.1365-2249.1997.4571356.x; Tomizawa T, 2007, J IMMUNOL, V179, P869, DOI 10.4049/jimmunol.179.2.869; Tseng D, 2013, P NATL ACAD SCI USA, V110, P11103, DOI 10.1073/pnas.1305569110; Usui Y, 2006, EUR J IMMUNOL, V36, P3071, DOI 10.1002/eji.200636138; Usui Y, 2009, ARCH OPHTHALMOL-CHIC, V127, P514, DOI 10.1001/archophthalmol.2009.34; Van VQ, 2006, EMBO J, V25, P5560, DOI 10.1038/sj.emboj.7601415; Xu HP, 2002, J LEUKOCYTE BIOL, V72, P1133; Zhang LJ, 2016, J LEUKOCYTE BIOL, V99, P447, DOI 10.1189/jlb.3A0415-157R	70	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2021	12								680568	10.3389/fimmu.2021.680568	http://dx.doi.org/10.3389/fimmu.2021.680568			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SM2KY	34093583	gold, Green Published			2022-12-18	WOS:000657440000001
J	Ramadhin, J; Silva-Moraes, V; Nagy, T; Norberg, T; Harn, D				Ramadhin, Jessica; Silva-Moraes, Vanessa; Nagy, Tamas; Norberg, Thomas; Harn, Donald			A Comparison of Two Structurally Related Human Milk Oligosaccharide Conjugates in a Model of Diet-Induced Obesity	FRONTIERS IN IMMUNOLOGY			English	Article						glycoconjugates; human milk oligosaccharides (HMOs); lacto-N-fucopentaose III (LNFPIII); lacto-N-neotetraose (LNnT); Lewis(x) antigen; metabolic syndrome; obesity	ADIPOSE-TISSUE; DIFFERENTIATION; ACTIVATION; EXPRESSION; HEALTH; COUNT	Obesity is the largest risk factor for the development of chronic diseases in industrialized countries. Excessive fat accumulation triggers a state of chronic low-grade inflammation to the detriment of numerous organs. To address this problem, our lab has been examining the anti-inflammatory mechanisms of two human milk oligosaccharides (HMOs), lacto-N-fucopentaose III (LNFPIII) and lacto-N-neotetraose (LNnT). LNFPIII and LNnT are HMOs that differ in structure via presence/absence of an alpha 1,3-linked fucose. We utilize LNFPIII and LNnT in conjugate form, where 10-12 molecules of LNFPIII or LNnT are conjugated to a 40 kDa dextran carrier (P3DEX/NTDEX). Previous studies from our lab have shown that LNFPIII conjugates are anti-inflammatory, act on multiple cell types, and are therapeutic in a wide range of murine inflammatory disease models. The alpha 1,3-linked fucose residue on LNFPIII makes it difficult and more expensive to synthesize. Therefore, we asked if LNnT conjugates induced similar therapeutic effects to LNFPIII. Herein, we compare the therapeutic effects of P3DEX and NTDEX in a model of diet-induced obesity (DIO). Male C57BL/6 mice were placed on a high-fat diet for six weeks and then injected twice per week for eight weeks with 25 mu g of 40 kDa dextran (DEX; vehicle control), P3DEX, or NTDEX. We found that treatment with P3DEX, but not NTDEX, led to reductions in body weight, adipose tissue (AT) weights, and fasting blood glucose levels. Mice treated with P3DEX also demonstrated improvements in glucose homeostasis and insulin tolerance. Treatment with P3DEX or NTDEX also induced different profiles of serum chemokines, cytokines, adipokines, and incretin hormones, with P3DEX notably reducing circulating levels of leptin and resistin. P3DEX also reduced WAT inflammation and hepatic lipid accumulation, whereas NTDEX seemed to worsen these parameters. These results suggest that the small structural difference between P3DEX and NTDEX has significant effects on the conjugates' therapeutic abilities. Future work will focus on identifying the receptors for these conjugates and delineating the mechanisms by which P3DEX and NTDEX exert their effects.	[Ramadhin, Jessica; Silva-Moraes, Vanessa; Harn, Donald] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA; [Nagy, Tamas] Univ Georgia, Dept Pathol, Athens, GA USA; [Norberg, Thomas] Uppsala Univ, Dept Chem BMC, Uppsala, Sweden	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Uppsala University	Harn, D (corresponding author), Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA.	dharn@uga.edu	Moraes, Vanessa/Q-3291-2018	Moraes, Vanessa/0000-0003-2991-7210	American Heart Association (AHA) Predoctoral Fellowship [17PRE33410423]; UGA's Obesity Initiative	American Heart Association (AHA) Predoctoral Fellowship(American Heart Association); UGA's Obesity Initiative	This project was funded by an American Heart Association (AHA) Predoctoral Fellowship (17PRE33410423) and UGA's Obesity Initiative.	Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Ahmed M, 2010, CYTOKINE GROWTH F R, V21, P449, DOI 10.1016/j.cytogfr.2010.10.005; Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8; Andrikopoulos S, 2008, AM J PHYSIOL-ENDOC M, V295, pE1323, DOI 10.1152/ajpendo.90617.2008; Atochina O, 2005, CLIN DIAGN LAB IMMUN, V12, P1041, DOI 10.1128/CDLI.12.9.1041-1049.2005; Atochina O, 2001, J IMMUNOL, V167, P4293, DOI 10.4049/jimmunol.167.8.4293; Atochina O, 2008, IMMUNOLOGY, V125, P111, DOI 10.1111/j.1365-2567.2008.02826.x; Ayala JE, 2010, DIS MODEL MECH, V3, P525, DOI 10.1242/dmm.006239; Bandara MD, 2019, CARBOHYD RES, V483, DOI 10.1016/j.carres.2019.107743; Beguinot Francesco, 2012, Methods Mol Biol, V933, P219, DOI 10.1007/978-1-62703-068-7_14; Bhargava P, 2012, NAT MED, V18, P1665, DOI 10.1038/nm.2962; Bode L, 2012, GLYCOBIOLOGY, V22, P1147, DOI 10.1093/glycob/cws074; Bohnsack BL, 2004, ANNU REV NUTR, V24, P433, DOI 10.1146/annurev.nutr.23.011702.073203; Bowe JE, 2014, J ENDOCRINOL, V222, pG13, DOI 10.1530/JOE-14-0182; Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071; Chen CC, 2015, CHEM COMMUN, V51, P7689, DOI 10.1039/c5cc01330e; Choi KD, 2011, NAT PROTOC, V6, DOI 10.1038/nprot.2010.184; Christiansen T, 2005, INT J OBESITY, V29, P146, DOI 10.1038/sj.ijo.0802839; Coulet M, 2013, FOOD CHEM TOXICOL, V62, P528, DOI 10.1016/j.fct.2013.09.018; Cummings DE, 2002, NEW ENGL J MED, V346, P1623, DOI 10.1056/NEJMoa012908; Dandona P, 1998, J CLIN ENDOCR METAB, V83, P2907, DOI 10.1210/jc.83.8.2907; Darkhal P, 2015, INT J OBESITY, V39, P1292, DOI 10.1038/ijo.2015.52; De Filippo K, 2013, BLOOD, V121, P4930, DOI 10.1182/blood-2013-02-486217; Di Renzo L, 2007, PHARMACOL RES, V55, P131, DOI 10.1016/j.phrs.2006.11.002; Dixit VD, 2004, J CLIN INVEST, V114, P57, DOI 10.1172/JCI200421134; Dixon JB, 2006, OBES SURG, V16, P251, DOI 10.1381/096089206776116453; El-Kadre LJ, 2013, CURR OPIN CLIN NUTR, V16, P564, DOI 10.1097/MCO.0b013e32836410e6; Elison E, 2016, BRIT J NUTR, V116, P1356, DOI 10.1017/S0007114516003354; Ellingsgaard H, 2011, NAT MED, V17, P1481, DOI 10.1038/nm.2513; Farhangi MA, 2013, J HEALTH POPUL NUTR, V31, P58; FAUST IM, 1978, AM J PHYSIOL, V235, pE279, DOI 10.1152/ajpendo.1978.235.3.E279; Filkova M, 2009, CLIN IMMUNOL, V133, P157, DOI 10.1016/j.clim.2009.07.013; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gee Katrina, 2009, Inflammation & Allergy Drug Targets, V8, P40; Godoy-Matos AF, 2020, DIABETOL METAB SYNDR, V12, DOI 10.1186/s13098-020-00570-y; Goswami R, 2011, J IMMUNOL, V186, P3283, DOI 10.4049/jimmunol.1003049; Halberg N, 2009, MOL CELL BIOL, V29, P4467, DOI 10.1128/MCB.00192-09; Hales Craig M, 2020, NCHS Data Brief, P1; Hegar B, 2019, PEDIATR GASTROENTERO, V22, P330, DOI 10.5223/pghn.2019.22.4.330; Herishanu Y, 2006, EUR J HAEMATOL, V76, P516, DOI 10.1111/j.1600-0609.2006.00658.x; HIRSCH J, 1969, J LIPID RES, V10, P77; Hosogai N, 2007, DIABETES, V56, P901, DOI 10.2337/db06-0911; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Huang X, 2016, J ENDOCRINOL INVEST, V39, P607, DOI 10.1007/s40618-015-0408-2; Huber J, 2008, J CLIN ENDOCR METAB, V93, P3215, DOI 10.1210/jc.2007-2630; Huttunen R, 2013, INT J OBESITY, V37, P333, DOI 10.1038/ijo.2012.62; Huttunen R, 2010, LANCET INFECT DIS, V10, P442, DOI 10.1016/S1473-3099(10)70103-1; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; Jiao P, 2009, DIABETES, V58, P104, DOI 10.2337/db07-1344; Jing YY, 2018, MOL CELL ENDOCRINOL, V461, P256, DOI 10.1016/j.mce.2017.09.025; Kalra S, 2016, DIABETES THER, V7, P1, DOI 10.1007/s13300-016-0160-4; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; Keim NL, 1998, AM J CLIN NUTR, V68, P794, DOI 10.1093/ajcn/68.4.794; Kim JH, 2009, VITAM HORM, V80, P613, DOI 10.1016/S0083-6729(08)00621-3; Kim W, 2008, PHARMACOL REV, V60, P470, DOI 10.1124/pr.108.000604; Koppaka S, 2013, DIABETES, V62, P1843, DOI 10.2337/db12-0868; Lee EH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28371-4; Lehrke M, 2004, PLOS MED, V1, P161, DOI 10.1371/journal.pmed.0010045; Maury E, 2010, MOL CELL ENDOCRINOL, V314, P1, DOI 10.1016/j.mce.2009.07.031; Meier CA, 2002, J CLIN ENDOCR METAB, V87, P1184, DOI 10.1210/jc.87.3.1184; Moreno M, 2010, HEPATOLOGY, V51, P974, DOI 10.1002/hep.23421; Morton GJ, 2006, NATURE, V443, P289, DOI 10.1038/nature05026; Moukarzel S, 2017, CLIN PERINATOL, V44, P193, DOI 10.1016/j.clp.2016.11.014; Myers MG, 2010, TRENDS ENDOCRIN MET, V21, P643, DOI 10.1016/j.tem.2010.08.002; NANJI AA, 1985, AM J CLIN PATHOL, V84, P346, DOI 10.1093/ajcp/84.3.346; Nauck MA, 2018, DIABETES OBES METAB, V20, P5, DOI 10.1111/dom.13129; Ni YH, 2020, OBESITY, V28, P225, DOI 10.1002/oby.22674; Nunemaker CS, 2014, J ENDOCRINOL, V222, P267, DOI 10.1530/JOE-14-0126; OGAWA M, 1993, BLOOD, V81, P2844; Okano M, 1999, J IMMUNOL, V163, P6712; Otto B, 2001, EUR J ENDOCRINOL, V145, pR5; Otto B, 2005, PSYCHONEUROENDOCRINO, V30, P577, DOI 10.1016/j.psyneuen.2005.01.009; Pratley R E, 1995, Obes Res, V3, P563; Ryder E, 2014, DIABETES METAB SYND, V8, P197, DOI 10.1016/j.dsx.2014.09.002; Sajadi SMA, 2013, CLIN LAB, V59, P133, DOI 10.7754/Clin.Lab.2012.120225; SALANS LB, 1968, J CLIN INVEST, V47, P153, DOI 10.1172/JCI105705; Shiiya T, 2002, J CLIN ENDOCR METAB, V87, P240, DOI 10.1210/jc.87.1.240; Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902; Srivastava L, 2014, INFECT IMMUN, V82, P1891, DOI 10.1128/IAI.01293-13; Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232; Terrazas LI, 2001, J IMMUNOL, V167, P5294, DOI 10.4049/jimmunol.167.9.5294; Thomas PG, 2005, J IMMUNOL, V175, P2082, DOI 10.4049/jimmunol.175.4.2082; Thomas PG, 2003, J IMMUNOL, V171, P5837, DOI 10.4049/jimmunol.171.11.5837; Thurl S, 2017, NUTR REV, V75, P920, DOI 10.1093/nutrit/nux044; Toshinai K, 2001, BIOCHEM BIOPH RES CO, V281, P1220, DOI 10.1006/bbrc.2001.4518; Tschop M, 2001, DIABETES, V50, P707, DOI 10.2337/diabetes.50.4.707; Tundup S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137495; Um JY, 2004, CLIN CHEM, V50, P647, DOI 10.1373/clinchem.2003.025858; Vasudevan AR, 2006, J CLIN ENDOCR METAB, V91, P256, DOI 10.1210/jc.2005-1280; Velupillai P, 1997, J IMMUNOL, V158, P338; Vishvanath L, 2016, CELL METAB, V23, P350, DOI 10.1016/j.cmet.2015.10.018; Wang QA, 2013, NAT MED, V19, P1338, DOI 10.1038/nm.3324; Wang Y, 2010, IMMUNOLOGY, V129, P406, DOI 10.1111/j.1365-2567.2009.03193.x; Weigle DS, 1997, J CLIN ENDOCR METAB, V82, P561, DOI 10.1210/jc.82.2.561; Weir CB, 2020, STATPEARLS; Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wensveen FM, 2015, EUR J IMMUNOL, V45, P2446, DOI 10.1002/eji.201545502; Whary MT, 2015, LAB ANIMAL MED, P43, DOI [10.1016/B978-0-12-409527-4.00003-1, DOI 10.1016/B978-0-12-409527-4.00003-1]; Xiao ZY, 2016, J ORG CHEM, V81, P5851, DOI 10.1021/acs.joc.6b00478; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Xue WH, 2019, J CELL PHYSIOL, V234, P3336, DOI 10.1002/jcp.27293; Yanagi S, 2018, CELL METAB, V27, P786, DOI 10.1016/j.cmet.2018.02.008; Zimmet P, 2005, J ATHEROSCLER THROMB, V12, P295, DOI 10.5551/jat.12.295	106	1	1	2	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2021	12								668217	10.3389/fimmu.2021.668217	http://dx.doi.org/10.3389/fimmu.2021.668217			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SM1QN	34093565	Green Published, gold			2022-12-18	WOS:000657386500001
J	Svanberg, C; Ellegard, R; Crisci, E; Khalid, M; Wodlin, NB; Svenvik, M; Nystrom, S; Birse, K; Burgener, A; Shankar, EM; Larsson, M				Svanberg, Cecilia; Ellegard, Rada; Crisci, Elisa; Khalid, Mohammad; Borendal Wodlin, Ninnie; Svenvik, Maria; Nystrom, Sofia; Birse, Kenzie; Burgener, Adam; Shankar, Esaki M.; Larsson, Marie			Complement-Opsonized HIV Modulates Pathways Involved in Infection of Cervical Mucosal Tissues: A Transcriptomic and Proteomic Study	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; human immunodeficiency virus; innate immunity; complement opsonized HIV-1; transcriptomics; proteomics; cervical tissue; primary infection	DENDRITIC CELLS; CAPTURE	Genital mucosal transmission is the most common route of HIV spread. The initial responses triggered at the site of viral entry are reportedly affected by host factors, especially complement components present at the site, and this will have profound consequences on the outcome and pathogenesis of HIV infection. We studied the initial events associated with host-pathogen interactions by exposing cervical biopsies to free or complement-opsonized HIV. Opsonization resulted in higher rates of HIV acquisition/infection in mucosal tissues and emigrating dendritic cells. Transcriptomic and proteomic data showed a significantly more pathways and higher expression of genes and proteins associated with viral replication and pathways involved in different aspects of viral infection including interferon signaling, cytokine profile and dendritic cell maturation for the opsonized HIV. Moreover, the proteomics data indicate a general suppression by the HIV exposure. This clearly suggests that HIV opsonization alters the initial signaling pathways in the cervical mucosa in a manner that promotes viral establishment and infection. Our findings provide a foundation for further studies of the role these early HIV induced events play in HIV pathogenesis.	[Svanberg, Cecilia; Ellegard, Rada; Crisci, Elisa; Khalid, Mohammad; Nystrom, Sofia; Larsson, Marie] Linkoping Univ, Div Mol Med & Virol, Dept Biomed & Clin Sci, Raleigh, NC, Sweden; [Borendal Wodlin, Ninnie] Univ Hosp, Dept Obstet & Gynecol, Linkoping, Sweden; [Svenvik, Maria] Lanssjukhuset, Womens Clin, Kalmar, Sweden; [Nystrom, Sofia] Linkoping Univ, Dept Clin Immunol & Transfus Med, Linkoping, Sweden; [Nystrom, Sofia] Linkoping Univ, Dept Biomed & Clin Sci, Linkoping, Sweden; [Birse, Kenzie] Publ Hlth Agcy Canada, Natl HIV & Retrovirol Labs, JC Wilt Infect Dis Res Ctr, Winnipeg, MB, Canada; [Burgener, Adam] Case Western Reserve Univ, Sch Med, Ctr Global Hlth & Dis, Cleveland, OH USA; [Shankar, Esaki M.] Cent Univ Tamil Nadu, Dept Life Sci, Infect Biol, Thiruvarur, India	Linkoping University; Linkoping University; Linkoping University; Public Health Agency of Canada; Case Western Reserve University; Central University of Tamil Nadu	Larsson, M (corresponding author), Linkoping Univ, Div Mol Med & Virol, Dept Biomed & Clin Sci, Raleigh, NC, Sweden.	marie.larsson@liu.se	Crisci, Elisa/AAF-9263-2020; Muthu, Shankar Esaki/B-3132-2019; NystrÃm, Sofia/GYQ-5893-2022	Crisci, Elisa/0000-0002-4235-8508; Muthu, Shankar Esaki/0000-0002-7866-9818; Larsson, Marie/0000-0002-4524-0177; Khalid, Mohammad/0000-0003-1479-6487; Nystrom, Sofia/0000-0002-0145-4966	Swedish Research Council; Swedish Physicians against AIDS Research Foundation; Linkoping University Hospital Research Fund; Forsknings ALF; Swedish Society of Medicine; SNIC through Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) [b2015293]	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Physicians against AIDS Research Foundation; Linkoping University Hospital Research Fund; Forsknings ALF; Swedish Society of Medicine; SNIC through Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX)	We like to thank Julian W. Bess, Jr and the Biological Products Core of the AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD, USA for providing the HIV-BaL SUPT1-CCR5 CL.30 virus used in these studies. This work has been supported by: The Swedish Research Council,The Swedish Physicians against AIDS Research Foundation, Linkoping University Hospital Research Fund, Forsknings ALF, and The Swedish Society of Medicine for ML. The computations for the RNAseq were performed on resources provided by SNIC through Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) under project b2015293.	Arthos J, 2018, CURR HIV-AIDS REP, V15, P127, DOI 10.1007/s11904-018-0382-3; Ashokkumar M, 2018, J VIROL, V92, DOI 10.1128/JVI.00063-18; Assarsson E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095192; Banki Z, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000891; Bermejo-Jambrina M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02010; Bouhlal H, 2007, J IMMUNOL, V178, P1086, DOI 10.4049/jimmunol.178.2.1086; Burgener A, 2012, AIDS, V26, P1857, DOI 10.1097/QAD.0b013e328357f79c; Cantero-Perez J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12732-2; Carias Ann M., 2019, Current Immunology Reviews, V15, P4, DOI 10.2174/1573395514666180604084404; Crisci E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02889; de Jong MAWP, 2008, J CLIN INVEST, V118, P3440, DOI 10.1172/JCI34721; Dezzutti CS, 2001, J INFECT DIS, V183, P1204, DOI 10.1086/319676; Eastment MC, 2018, AIDS, V32, P687, DOI 10.1097/QAD.0000000000001768; Ellegard R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00899; Ellegard R, 2015, J IMMUNOL, V195, P1698, DOI 10.4049/jimmunol.1500618; Ellegard R, 2014, J IMMUNOL, V193, P4590, DOI 10.4049/jimmunol.1401781; Fahey JV, 2005, HUM REPROD, V20, P1439, DOI 10.1093/humrep/deh806; Gaber T, 2017, NAT REV RHEUMATOL, V13, P267, DOI 10.1038/nrrheum.2017.37; Goode D, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004567; Guay LA, 2002, AIDS, V16, P1391, DOI 10.1097/00002030-200207050-00011; Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302; Hladik F, 2007, IMMUNITY, V26, P257, DOI 10.1016/j.immuni.2007.01.007; HOFMANN B, 1993, AIDS, V7, P659, DOI 10.1097/00002030-199305000-00008; Hornung F, 2000, J IMMUNOL, V164, P6180, DOI 10.4049/jimmunol.164.12.6180; Hu JJ, 2000, J VIROL, V74, P6087, DOI 10.1128/JVI.74.13.6087-6095.2000; Introini Andrea, 2017, PLoS Pathog, V13, pe1006492, DOI 10.1371/journal.ppat.1006492; Joag VR, 2016, MUCOSAL IMMUNOL, V9, P1, DOI 10.1038/mi.2015.28; Joosten LAB, 2003, ARTHRITIS RHEUM, V48, P339, DOI 10.1002/art.10814; Joseph SB, 2015, NAT REV MICROBIOL, V13, P414, DOI 10.1038/nrmicro3471; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Kaldensjo T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021344; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Li QS, 2009, NATURE, V458, P1034, DOI 10.1038/nature07831; Looker KJ, 2020, LANCET INFECT DIS, V20, P240, DOI 10.1016/S1473-3099(19)30470-0; Lundberg M, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr424; Machado JR, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/350195; Marsden V, 2015, J IMMUNOL, V194, P4438, DOI 10.4049/jimmunol.1401706; Masci AM, 2003, J LEUKOCYTE BIOL, V74, P1117, DOI 10.1189/jlb.0503239; Masson L, 2015, CLIN INFECT DIS, V61, P260, DOI 10.1093/cid/civ298; Merbah M, 2011, AM J REPROD IMMUNOL, V65, P268, DOI 10.1111/j.1600-0897.2010.00967.x; Moreno-Fernandez ME, 2012, AIDS RES HUM RETROV, V28, P49, DOI [10.1089/aid.2011.0265, 10.1089/AID.2011.0265]; Mukherji S, 2011, NAT GENET, V43, P854, DOI 10.1038/ng.905; Nasi M, 2014, IMMUNOL LETT, V161, P184, DOI 10.1016/j.imlet.2014.01.008; Nazli A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000852; Nijmeijer BM, 2021, MUCOSAL IMMUNOL, V14, P743, DOI 10.1038/s41385-021-00376-9; Nunn KL, 2015, MBIO, V6, DOI 10.1128/mBio.01084-15; Panico M, 2016, SCI REP-UK, V6, DOI 10.1038/srep32956; Parrish NF, 2013, P NATL ACAD SCI USA, V110, P6626, DOI 10.1073/pnas.1304288110; Pena-Cruz V, 2018, J CLIN INVEST, V128, P3439, DOI 10.1172/JCI98943; Perez-Zsolt D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00825; Prohaszka Z, 1999, CLIN IMMUNOL, V90, P247, DOI 10.1006/clim.1998.4620; Pruenster M, 2005, EUR J IMMUNOL, V35, P2691, DOI 10.1002/eji.200425940; Ramezani A, 2015, J PHARMACOL EXP THER, V354, P376, DOI 10.1124/jpet.115.224485; Rhodes JW, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22375-x; Rieu I, 2009, PLANT CELL, V21, P1031, DOI 10.1105/tpc.109.066001; Rodriguez-Garcia M, 2017, MUCOSAL IMMUNOL, V10, P531, DOI 10.1038/mi.2016.72; Rodriguez-Garcia M, 2014, MUCOSAL IMMUNOL, V7, P1375, DOI 10.1038/mi.2014.26; Rodriguez-Garcia M, 2021, CURR HIV-AIDS REP, V18, P139, DOI 10.1007/s11904-021-00546-1; Rodriguez-Garcia M, 2018, JOVE-J VIS EXP, DOI 10.3791/57100; Sallusto F, 2012, EUR J IMMUNOL, V42, P2215, DOI 10.1002/eji.201242741; Seissler T, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9110322; Serezani CH, 2008, AM J RESP CELL MOL, V39, P127, DOI 10.1165/rcmb.2008-0091TR; Shang L, 2018, MUCOSAL IMMUNOL, V11, P512, DOI 10.1038/mi.2017.69; Shang L, 2017, MUCOSAL IMMUNOL, V10, P508, DOI 10.1038/mi.2016.62; Shen RZ, 2014, J VIROL, V88, P7683, DOI 10.1128/JVI.00766-14; Stoiber H, 2005, MOL IMMUNOL, V42, P153, DOI 10.1016/j.molimm.2004.06.024; Stoiber H, 2008, VACCINE, V26, P3046, DOI 10.1016/j.vaccine.2007.12.003; Su B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02968; Tahamtan A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01377; Tjomsland V, 2013, EUR J IMMUNOL, V43, P2361, DOI 10.1002/eji.201243257; Tjomsland V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023542; Trifonova RT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02719; Trifonova RT, 2014, AM J REPROD IMMUNOL, V71, P252, DOI 10.1111/aji.12198; Utay Netanya S, 2016, Pathog Immun, V1, P107; van Montfort T, 2007, J IMMUNOL, V178, P3177, DOI 10.4049/jimmunol.178.5.3177; Wira CR, 2015, NAT REV IMMUNOL, V15, P217, DOI 10.1038/nri3819; Wira CR, 2011, AM J REPROD IMMUNOL, V65, P196, DOI 10.1111/j.1600-0897.2011.00970.x; Wiredja DD, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0423-4; Xu XQ, 2019, J INNATE IMMUN, V11, P29, DOI 10.1159/000490586; Xu Y, 2017, MOL MED REP, V16, P8854, DOI 10.3892/mmr.2017.7722; Zelcer N, 2006, J CLIN INVEST, V116, P607, DOI 10.1172/JCI27883	81	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2021	12								625649	10.3389/fimmu.2021.625649	http://dx.doi.org/10.3389/fimmu.2021.625649			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SM0DR	34093520	gold, Green Published			2022-12-18	WOS:000657284000001
J	Omar, RA; Verma, N; Arora, PK				Omar, Rishabh Anand; Verma, Nishith; Arora, Pankaj Kumar			Development of ESAT-6 Based Immunosensor for the Detection of Mycobacterium tuberculosis	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacterium tuberculosis; cyclic voltammetry; ESAT-6; immunosensor; reduced graphene oxide; polyaniline	ELECTROCHEMICAL DETECTION; NANOPARTICLES	Early secreted antigenic target of 6 kDa (ESAT-6) has recently been identified as a biomarker for the rapid diagnosis of tuberculosis. We propose a stable and reusable immunosensor for the early diagnosis of tuberculosis based on the detection and quantification of ESAT-6 via cyclic voltammetry (CV). The immunosensor was synthesized by polymerizing aniline dispersed with the reduced graphene oxide (rGO) and Ni nanoparticles, followed by surface modification of the electroconductive polyaniline (PANI) film with anti-ESAT-6 antibody. Physicochemical characterization of the prepared materials was performed by several analytical techniques, including FE-SEM, EDX, XRD, FT-IR, Raman, TGA, TPR, and BET surface area analysis. The antibody-modified Ni-rGO-PANI electrode exhibited an approximately linear response (R-2 = 0.988) towards ESAT-6 during CV measurements over the potential range of -1 to +1 V. The lower detection limit for ESAT-6 was approximately 1.0 ng mL(-1). The novelty of this study includes the development of the reusable Ni-rGO-PANI-based electrochemical immunosensor for the early diagnosis of tuberculosis. Furthermore, this study successfully demonstrates that electro-conductive PANI may be used as a polymeric substrate for Ni nanoparticles and rGO.	[Omar, Rishabh Anand; Arora, Pankaj Kumar] Babasaheb Bhimrao Ambedkar Univ, Dept Environm Microbiol, Lucknow, Uttar Pradesh, India; [Verma, Nishith] Indian Inst Technol Kanpur, Ctr Environm Sci & Engn, Kanpur, Uttar Pradesh, India; [Verma, Nishith] Indian Inst Technol Kanpur, Dept Chem Engn, Kanpur, Uttar Pradesh, India	Babasaheb Bhimrao Ambedkar University; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kanpur; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kanpur	Arora, PK (corresponding author), Babasaheb Bhimrao Ambedkar Univ, Dept Environm Microbiol, Lucknow, Uttar Pradesh, India.; Verma, N (corresponding author), Indian Inst Technol Kanpur, Ctr Environm Sci & Engn, Kanpur, Uttar Pradesh, India.; Verma, N (corresponding author), Indian Inst Technol Kanpur, Dept Chem Engn, Kanpur, Uttar Pradesh, India.	vermanishith@gmail.com; arora484@gmail.com	Omar, Rishabh Anand/GZG-8760-2022		Department of Science and Technology (DST); Ministry of Science and Education, Delhi [DST/CNS/2017239]	Department of Science and Technology (DST)(Department of Science & Technology (India)); Ministry of Science and Education, Delhi	The authors acknowledge the Department of Science and Technology (DST) and Ministry of Science and Education, Delhi for providing financial support (DST/CNS/2017239) for this study.	Absalan G, 2016, J ELECTROANAL CHEM, V761, P1, DOI 10.1016/j.jelechem.2015.11.041; Alwarappan S, 2009, J PHYS CHEM C, V113, P8853, DOI 10.1021/jp9010313; AMANO K, 1994, SYNTHETIC MET, V62, P229, DOI 10.1016/0379-6779(94)90210-0; Ayoub H, 2010, ELECTROANAL, V22, P2483, DOI 10.1002/elan.201000307; Bairagi PK, 2019, SENSOR ACTUAT B-CHEM, V297, DOI 10.1016/j.snb.2019.126754; Bairagi PK, 2019, SENSOR ACTUAT B-CHEM, V289, P216, DOI 10.1016/j.snb.2019.03.057; Bairagi PK, 2018, J ELECTROANAL CHEM, V814, P134, DOI 10.1016/j.jelechem.2018.02.011; Cabrita JF, 2005, ELECTROCHIM ACTA, V50, P2117, DOI 10.1016/j.electacta.2004.09.019; Chen NL, 2017, APPL SURF SCI, V392, P71, DOI 10.1016/j.apsusc.2016.07.168; Chen WC, 2002, SYNTHETIC MET, V128, P179, DOI 10.1016/S0379-6779(01)00667-1; Choi W, 2020, J ELECTROCHEM SCI TE, V11, DOI 10.33961/jecst.2019.00528; Darvishi S, 2017, ELECTROCHIM ACTA, V240, P388, DOI 10.1016/j.electacta.2017.04.086; Diaz-Gonzalez M, 2005, BIOSENS BIOELECTRON, V20, P2035, DOI 10.1016/j.bios.2004.09.035; Diouani MF, 2017, MAT SCI ENG C-MATER, V74, P465, DOI 10.1016/j.msec.2016.12.051; Jayeoye TJ, 2020, NEW J CHEM, V44, P5711, DOI 10.1039/d0nj00897d; Kellum JA, 2000, CRIT CARE, V4, P6, DOI 10.1186/cc644; Kononenko NA, 2015, J SOLID STATE ELECTR, V19, P2623, DOI 10.1007/s10008-015-2829-4; Krishnan SK, 2019, RSC ADV, V9, P8778, DOI 10.1039/c8ra09577a; Kulandaivalu S, 2016, INT J POLYM SCI, V2016, DOI 10.1155/2016/8518293; Kumar A, 2020, CHEMOSPHERE, V248, DOI 10.1016/j.chemosphere.2020.126030; Lashkenari MS, 2021, J MATER SCI-MATER EL, V32, P4833, DOI 10.1007/s10854-020-05222-5; Lavania S, 2018, ACS INFECT DIS, V4, P1718, DOI 10.1021/acsinfecdis.8b00201; Lin SY, 2018, BIOSENS BIOELECTRON, V110, P89, DOI 10.1016/j.bios.2018.03.019; Liu Y, 2010, ANAL CHEM, V82, P8131, DOI 10.1021/ac101409t; Lv W, 2011, J MATER CHEM, V21, P9014, DOI 10.1039/c1jm10400d; Marais BJ, 2007, PAEDIATR RESPIR REV, V8, P124, DOI 10.1016/j.prrv.2007.04.002; Marcano DC, 2010, ACS NANO, V4, P4806, DOI 10.1021/nn1006368; Masuda M, 2015, PEERJ, V3, DOI 10.7717/peerj.1448; Mathebula NS, 2009, CHEM COMMUN, P3345, DOI 10.1039/b905192a; Mi XW, 2012, ANAL CHEM, V84, P939, DOI 10.1021/ac2020728; Miodek A, 2015, ANAL CHEM, V87, P9257, DOI 10.1021/acs.analchem.5b01761; Mogha NK, 2018, J MATER CHEM B, V6, P5181, DOI 10.1039/c8tb01604f; Moharana M, 2013, ELECTROCHIM ACTA, V98, P1, DOI 10.1016/j.electacta.2013.03.031; Nellaiappan S, 2017, J ELECTROANAL CHEM, V801, P171, DOI 10.1016/j.jelechem.2017.07.049; Ng JC, 2019, MATER RES BULL, V112, P213, DOI 10.1016/j.materresbull.2018.12.029; Nie HG, 2011, BIOSENS BIOELECTRON, V30, P28, DOI 10.1016/j.bios.2011.08.022; Omar RA, 2020, FUEL, V277, DOI 10.1016/j.fuel.2020.118208; Pandey I, 2018, SENSOR ACTUAT B-CHEM, V277, P562, DOI 10.1016/j.snb.2018.09.036; Pei YJ, 2018, BIOSENS BIOELECTRON, V117, P758, DOI 10.1016/j.bios.2018.07.021; SCHUH R, 1992, J IMMUNOL METHODS, V152, P59, DOI 10.1016/0022-1759(92)90089-C; Singh A, 2015, BIOELECTROCHEMISTRY, V105, P7, DOI 10.1016/j.bioelechem.2015.03.005; Singh S, 2018, ELECTROCHIM ACTA, V264, P119, DOI 10.1016/j.electacta.2018.01.110; Sun AL, 2012, ELECTROCHIM ACTA, V65, P64, DOI 10.1016/j.electacta.2012.01.007; Thiruppathiraja C, 2011, ANAL BIOCHEM, V417, P73, DOI 10.1016/j.ab.2011.05.034; Torati R, 2016, BIOSENS BIOELECTRON, V78, P483, DOI 10.1016/j.bios.2015.11.098; Torres-Chavolla E, 2011, BIOSENS BIOELECTRON, V26, P4614, DOI 10.1016/j.bios.2011.04.055; Trzaskowski M, 2018, SENSOR ACTUAT B-CHEM, V260, P786, DOI 10.1016/j.snb.2017.12.183; VANOSS CJ, 1986, J CHROMATOGR, V376, P111, DOI 10.1016/S0378-4347(00)80828-2; Wang H, 2015, ADV COLLOID INTERFAC, V221, P41, DOI 10.1016/j.cis.2015.04.005; Yemini M, 2007, BIOELECTROCHEMISTRY, V70, P180, DOI 10.1016/j.bioelechem.2006.03.014; Yu H, 2013, J ELECTROANAL CHEM, V700, P47, DOI 10.1016/j.jelechem.2013.03.015; Zaid MHM, 2017, SENSOR ACTUAT B-CHEM, V241, P1024, DOI 10.1016/j.snb.2016.10.045; Zhang P, 2019, BIOELECTROCHEMISTRY, V127, P163, DOI 10.1016/j.bioelechem.2019.02.003; Zhang XQ, 2019, ACS SENSORS, V4, P849, DOI 10.1021/acssensors.8b01230; Zhao B, 2011, J MATER CHEM, V21, P18792, DOI 10.1039/c1jm13016a; Zhong HA, 2011, TALANTA, V85, P104, DOI 10.1016/j.talanta.2011.03.040; Zhou LX, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/193963; Zhu XF, 2015, J ELECTROANAL CHEM, V757, P183, DOI 10.1016/j.jelechem.2015.09.038; Ziolkowski R, 2012, BIOELECTROCHEMISTRY, V87, P78, DOI 10.1016/j.bioelechem.2011.10.005	59	1	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2021	12								653853	10.3389/fimmu.2021.653853	http://dx.doi.org/10.3389/fimmu.2021.653853			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SL3ZJ	34093542	Green Published, gold			2022-12-18	WOS:000656857500001
J	Zayats, R; Uzonna, JE; Murooka, TT				Zayats, Romaniya; Uzonna, Jude E.; Murooka, Thomas T.			Visualizing the In Vivo Dynamics of Anti-Leishmania Immunity: Discoveries and Challenges	FRONTIERS IN IMMUNOLOGY			English	Review						two-photon intravital microscopy; Leishmania infection; T cells; ear skin imaging; liver imaging; fluorescent reporters; macrophages	CUTANEOUS LEISHMANIASIS; DENDRITIC CELLS; HOST IMMUNITY; IFN-GAMMA; INFECTION; MACROPHAGES; INFLAMMATION; VACCINATION; MICROSCOPY; INDUCTION	Intravital microscopy, such as 2-photon microscopy, is now a mainstay in immunological research to visually characterize immune cell dynamics during homeostasis and pathogen infections. This approach has been especially beneficial in describing the complex process of host immune responses to parasitic infections in vivo, such as Leishmania. Human-parasite co-evolution has endowed parasites with multiple strategies to subvert host immunity in order to establish chronic infections and ensure human-to-human transmission. While much focus has been placed on viral and bacterial infections, intravital microscopy studies during parasitic infections have been comparatively sparse. In this review, we will discuss how in vivo microscopy has provided important insights into the generation of innate and adaptive immunity in various organs during parasitic infections, with a primary focus on Leishmania. We highlight how microscopy-based approaches may be key to providing mechanistic insights into Leishmania persistence in vivo and to devise strategies for better parasite control.	[Zayats, Romaniya; Uzonna, Jude E.; Murooka, Thomas T.] Univ Manitoba, Rady Fac Hlth Sci, Dept Immunol, Winnipeg, MB, Canada; [Uzonna, Jude E.; Murooka, Thomas T.] Univ Manitoba, Rady Fac Hlth Sci, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba	Murooka, TT (corresponding author), Univ Manitoba, Rady Fac Hlth Sci, Dept Immunol, Winnipeg, MB, Canada.; Murooka, TT (corresponding author), Univ Manitoba, Rady Fac Hlth Sci, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada.	thomas.murooka@umanitoba.ca		Zayats, Romaniya/0000-0002-1934-1337	CIHR-GSK Partnered Program; Research Manitoba; University of Manitoba Student Fellowship; CIHR [MOP 114932]	CIHR-GSK Partnered Program; Research Manitoba; University of Manitoba Student Fellowship; CIHR(Canadian Institutes of Health Research (CIHR))	This work was supported by the CIHR-GSK Partnered Program (TM) and a studentship from Research Manitoba and University of Manitoba Student Fellowship (RZ). JU is supported by a CIHR Project grant MOP 114932.	Abdel-Gadir Azza, 2018, F1000Res, V7, P38, DOI 10.12688/f1000research.12650.1; Abdeladhim M, 2014, INFECT GENET EVOL, V28, P691, DOI 10.1016/j.meegid.2014.07.028; Abu-Dayyeh I, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000305; Alex H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15834-4; Allen CDC, 2007, IMMUNITY, V27, P190, DOI 10.1016/j.immuni.2007.07.009; Anderson CF, 2005, J IMMUNOL, V174, P2934, DOI 10.4049/jimmunol.174.5.2934; Aseffa A, 2002, J IMMUNOL, V169, P3232, DOI 10.4049/jimmunol.169.6.3232; Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002; Beattie L, 2013, CELL HOST MICROBE, V14, P357, DOI 10.1016/j.chom.2013.08.004; Beattie L, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000805; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497; Belkaid Y, 2006, CURR OPIN IMMUNOL, V18, P406, DOI 10.1016/j.coi.2006.05.014; Bousso P, 2002, SCIENCE, V296, P1876, DOI 10.1126/science.1070945; Bousso P, 2012, NAT REV IMMUNOL, V12, P858, DOI 10.1038/nri3342; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; Cameron P, 2004, J IMMUNOL, V173, P3297, DOI 10.4049/jimmunol.173.5.3297; Canario A, 2019, CLIN MICROBIOL INFEC, V25, DOI 10.1016/j.cmi.2018.12.027; Carlsen ED, 2015, J INNATE IMMUN, V7, P354, DOI 10.1159/000373923; Carneiro MB, 2020, CELL HOST MICROBE, V27, P752, DOI 10.1016/j.chom.2020.03.011; Carneiro MB, 2017, METHODS, V127, P45, DOI 10.1016/j.ymeth.2017.04.012; Ceccarelli Manuela, 2018, Open Access Maced J Med Sci, V6, P843, DOI 10.3889/oamjms.2018.186; Chakraborty D, 2005, J IMMUNOL, V175, P3214, DOI 10.4049/jimmunol.175.5.3214; Charmoy M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000755; Chatzigeorgiou A, 2009, BIOFACTORS, V35, P474, DOI 10.1002/biof.62; Chaves MM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008674; Chtanova T, 2008, IMMUNITY, V29, P487, DOI 10.1016/j.immuni.2008.07.012; Colpitts SL, 2009, J IMMUNOL, V182, P5702, DOI 10.4049/jimmunol.0803450; Conceicao-Silva F, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01308; Contreras I, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003202; Dasari S, 2015, JOVE-J VIS EXP, DOI 10.3791/52303; DAWSON JB, 1980, PHYS MED BIOL, V25, P695, DOI 10.1088/0031-9155/25/4/008; De Trez C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000494; Deak E, 2010, EUR J IMMUNOL, V40, P1355, DOI 10.1002/eji.200939455; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Dey R, 2018, CELL HOST MICROBE, V23, P134, DOI 10.1016/j.chom.2017.12.002; Dostalova A, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-276; Duque GA, 2014, J IMMUNOL, V193, P2363, DOI 10.4049/jimmunol.1303043; Filardy AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085715; Filipe-Santos O, 2009, CELL HOST MICROBE, V6, P23, DOI 10.1016/j.chom.2009.04.014; Forget G, 2006, INFECT IMMUN, V74, P6272, DOI 10.1128/IAI.00853-05; FRUTH U, 1993, J IMMUNOL, V150, P1857; Ganguly S, 2010, INT J DERMATOL, V49, P921, DOI 10.1111/j.1365-4632.2010.04558.x; Gantt KR, 2001, J IMMUNOL, V167, P893, DOI 10.4049/jimmunol.167.2.893; Gaylo-Moynihan A, 2019, IMMUNITY, V51, P298, DOI 10.1016/j.immuni.2019.06.026; Gimblet C, 2017, CELL HOST MICROBE, V22, P13, DOI 10.1016/j.chom.2017.06.006; Giraud E, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0323-8; Glennie ND, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006349; Glennie ND, 2015, J EXP MED, V212, P1405, DOI 10.1084/jem.20142101; GREEN SJ, 1990, J IMMUNOL, V145, P4290; Habuchi S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003944; HEALTH OW, 2010, WHO TECH REP SER, V949, pR12; Heyde S, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007374; HOWARD JG, 1981, J EXP MED, V153, P557, DOI 10.1084/jem.153.3.557; Hsu AC, 2007, J IMMUNOL, V179, P8200, DOI 10.4049/jimmunol.179.12.8200; Hurrell BP, 2016, TRENDS PARASITOL, V32, P392, DOI 10.1016/j.pt.2016.02.003; Hurrell BP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004929; Ikeogu NM, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8081201; Jain Rohit, 2016, F1000Res, V5, DOI 10.12688/f1000research.8127.1; Kelly BL, 2003, J EXP MED, V198, P1689, DOI 10.1084/jem.20031162; Kelly PH, 2017, MBIO, V8, DOI [10.1128/mBio.01121-16, 10.1128/mbio.01121-16]; Kima PE, 1996, EUR J IMMUNOL, V26, P3163, DOI 10.1002/eji.1830261249; Kloehn J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004683; Konig K, 2000, J MICROSC-OXFORD, V200, P83, DOI 10.1046/j.1365-2818.2000.00738.x; Lammermann T, 2013, NATURE, V498, P371, DOI 10.1038/nature12175; Lee SH, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz4415; Lee SH, 2018, J EXP MED, V215, P357, DOI 10.1084/jem.20171389; Leon B, 2007, IMMUNITY, V26, P519, DOI 10.1016/j.immuni.2007.01.017; Lievin-Le Moal V, 2016, FEBS J, V283, P598, DOI 10.1111/febs.13601; LIEW FY, 1990, J IMMUNOL, V145, P4306; LIEW FY, 1990, J IMMUNOL, V144, P4794; Liu D, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00083; Lonardoni MVC, 2011, ACTA SCI-HEALTH SCI, V33, DOI [10.4025/actascihealthsci.v33i1.6976, DOI 10.4025/ACTASCIHEALTHSCI.V33I1.6976]; Louradour I, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12755; Mandell MA, 2017, P NATL ACAD SCI USA, V114, pE801, DOI 10.1073/pnas.1619265114; Mandl JN, 2014, CURR OPIN IMMUNOL, V29, P8, DOI 10.1016/j.coi.2014.03.002; Marangoni F, 2013, IMMUNITY, V38, P237, DOI 10.1016/j.immuni.2012.09.012; Martinez-Barricarte R, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aau6759; Matheoud D, 2013, CELL HOST MICROBE, V14, P15, DOI 10.1016/j.chom.2013.06.003; Matte C, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005962; Meier CL, 2003, J IMMUNOL, V171, P6706, DOI 10.4049/jimmunol.171.12.6706; Melichar HJ, 2011, IMMUNOL CELL BIOL, V89, P549, DOI 10.1038/icb.2010.122; Melo GD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09085-5; Mempel TR, 2004, CURR OPIN IMMUNOL, V16, P406, DOI 10.1016/j.coi.2004.05.018; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Mendez S, 2004, J EXP MED, V200, P201, DOI 10.1084/jem.20040298; Miller MJ, 2002, SCIENCE, V296, P1869, DOI 10.1126/science.1070051; MITCHELL GF, 1983, AUST J EXP BIOL MED, V61, P11, DOI 10.1038/icb.1983.2; Moore JWJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034143; Morgado FN, 2010, PARASITE IMMUNOL, V32, P285, DOI 10.1111/j.1365-3024.2009.01188.x; Muller AJ, 2013, CELL HOST MICROBE, V14, P460, DOI 10.1016/j.chom.2013.09.008; Muller AJ, 2012, IMMUNITY, V37, P147, DOI 10.1016/j.immuni.2012.05.015; Murooka TT, 2013, J INFECT DIS, V208, pS137, DOI 10.1093/infdis/jit447; Neupane AS, 2020, CELL, V183, P110, DOI 10.1016/j.cell.2020.08.020; Ng LG, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000222; Novais FO, 2009, J IMMUNOL, V183, P8088, DOI 10.4049/jimmunol.0803720; Okwor I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00128; Okwor I, 2009, P NATL ACAD SCI USA, V106, P13951, DOI 10.1073/pnas.0905184106; Pace D, 2014, J INFECTION, V69, pS10, DOI 10.1016/j.jinf.2014.07.016; Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194; Peters NC, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004538; Petritus PM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001858; Prina E, 1996, J IMMUNOL, V156, P4318; Ratto-Kim S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01397; Renia L, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00463; Ribeiro-Gomes FL, 2014, INFECT IMMUN, V82, P2713, DOI 10.1128/IAI.01600-13; Ribeiro-Gomes FL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002536; Ritsma L, 2013, NAT PROTOC, V8, P583, DOI 10.1038/nprot.2013.026; Rodriguez-Sosa M, 2001, IMMUNOL CELL BIOL, V79, P320, DOI 10.1046/j.1440-1711.2001.01014.x; Rogers ME, 2004, NATURE, V430, P463, DOI 10.1038/nature02675; Romano A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006479; Romano A, 2015, J IMMUNOL, V195, P3816, DOI 10.4049/jimmunol.1500752; Romero I, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000819; Ronet C, 2019, J INVEST DERMATOL, V139, P1318, DOI 10.1016/j.jid.2018.12.012; Salei N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171850; Schwickert TA, 2007, NATURE, V446, P83, DOI 10.1038/nature05573; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; Scott P, 2016, NAT REV IMMUNOL, V16, P581, DOI 10.1038/nri.2016.72; Seguin O, 2016, CELL IMMUNOL, V309, P1, DOI 10.1016/j.cellimm.2016.08.004; Sewald X, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10060337; Shweash M, 2011, MOL IMMUNOL, V48, P1800, DOI 10.1016/j.molimm.2011.05.013; Silva JM, 2014, AM J TROP MED HYG, V90, P621, DOI 10.4269/ajtmh.13-0376; Silva-Barrios S, 2016, CELL REP, V15, P2427, DOI 10.1016/j.celrep.2016.05.028; Singh RP, 2012, TROP MED INT HEALTH, V17, P1345, DOI [10.1111/tmi.12044, 10.1111/j.1365-3156.2012.03067.x]; Sousa LMA, 2014, PARASITE IMMUNOL, V36, P13, DOI 10.1111/pim.12078; Stoll S, 2002, SCIENCE, V296, P1873, DOI 10.1126/science.1071065; Surewaard BGJ, 2016, J EXP MED, V213, P1141, DOI 10.1084/jem.20160334; Tabbara KS, 2005, INFECT IMMUN, V73, P4714, DOI 10.1128/IAI.73.8.4714-4722.2005; Uderhardt S, 2019, CELL, V177, P541, DOI 10.1016/j.cell.2019.02.028; Uzonna JE, 2001, J IMMUNOL, V167, P6967, DOI 10.4049/jimmunol.167.12.6967; Weinheber N, 1998, EUR J IMMUNOL, V28, P2467, DOI 10.1002/(SICI)1521-4141(199808)28:08&lt;2467::AID-IMMU2467&gt;3.0.CO;2-1; Weiss G, 2015, IMMUNOL REV, V264, P182, DOI 10.1111/imr.12266; Woelbing F, 2006, J EXP MED, V203, P177, DOI 10.1084/jem.20052288; Wyse BA, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-40; Xin LJ, 2010, J IMMUNOL, V184, P7047, DOI 10.4049/jimmunol.0903273; Zaph C, 2004, NAT MED, V10, P1104, DOI 10.1038/nm1108	136	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2021	12								671582	10.3389/fimmu.2021.671582	http://dx.doi.org/10.3389/fimmu.2021.671582			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SL3XS	34093571	Green Published, gold			2022-12-18	WOS:000656853100001
J	Arts, JJG; Mahlandt, EK; Schimmel, L; Gronloh, MLB; Van der Niet, S; Klein, BJAM; Fernandez-Borja, M; Van Geemen, D; Huveneers, S; Van Rijssel, J; Goedhart, J; Van Buul, JD				Arts, Janine J. G.; Mahlandt, Eike K.; Schimmel, Lilian; Gronloh, Max L. B.; van der Niet, Sanne; Klein, Bart J. A. M.; Fernandez-Borja, Mar; van Geemen, Daphne; Huveneers, Stephan; van Rijssel, Jos; Goedhart, Joachim; van Buul, Jaap D.			Endothelial Focal Adhesions Are Functional Obstacles for Leukocytes During Basolateral Crawling	FRONTIERS IN IMMUNOLOGY			English	Article						transmigration; focal adhesions; small GTPase; RhoJ; Tiam1; endothelium; inflammation	TRANSENDOTHELIAL MIGRATION; NEUTROPHIL TRANSMIGRATION; KINASE; EXTRAVASATION	An inflammatory response requires leukocytes to migrate from the circulation across the vascular lining into the tissue to clear the invading pathogen. Whereas a lot of attention is focused on how leukocytes make their way through the endothelial monolayer, it is less clear how leukocytes migrate underneath the endothelium before they enter the tissue. Upon finalization of the diapedesis step, leukocytes reside in the subendothelial space and encounter endothelial focal adhesions. Using TIRF microscopy, we show that neutrophils navigate around these focal adhesions. Neutrophils recognize focal adhesions as physical obstacles and deform to get around them. Increasing the number of focal adhesions by silencing the small GTPase RhoJ slows down basolateral crawling of neutrophils. However, apical crawling and diapedesis itself are not affected by RhoJ depletion. Increasing the number of focal adhesions drastically by expressing the Rac1 GEF Tiam1 make neutrophils to avoid migrating underneath these Tiam1-expressing endothelial cells. Together, our results show that focal adhesions mark the basolateral migration path of neutrophils.	[Arts, Janine J. G.; Schimmel, Lilian; Gronloh, Max L. B.; van der Niet, Sanne; Klein, Bart J. A. M.; Fernandez-Borja, Mar; van Geemen, Daphne; van Rijssel, Jos; van Buul, Jaap D.] Sanquin Res, Mol Cell Biol Lab, Dept Mol Hematol, Amsterdam, Netherlands; [Arts, Janine J. G.; Schimmel, Lilian; Gronloh, Max L. B.; van der Niet, Sanne; Klein, Bart J. A. M.; Fernandez-Borja, Mar; van Geemen, Daphne; van Rijssel, Jos; van Buul, Jaap D.] Landsteiner Lab, Amsterdam, Netherlands; [Arts, Janine J. G.; Mahlandt, Eike K.; Goedhart, Joachim; van Buul, Jaap D.] Univ Amsterdam, Leeuwenhoek Ctr Adv Microscopy LCAM, Swammerdam Inst Life Sci SILS, Sect Mol Cytol, Amsterdam, Netherlands; [Huveneers, Stephan] Univ Amsterdam, Amsterdam Univ Med Ctr UMC, Dept Med Biochem, Amsterdam Cardiovasc Sci, Amsterdam, Netherlands	University of Amsterdam; University of Amsterdam; University of Amsterdam	Van Buul, JD (corresponding author), Sanquin Res, Mol Cell Biol Lab, Dept Mol Hematol, Amsterdam, Netherlands.; Van Buul, JD (corresponding author), Landsteiner Lab, Amsterdam, Netherlands.; Van Buul, JD (corresponding author), Univ Amsterdam, Leeuwenhoek Ctr Adv Microscopy LCAM, Swammerdam Inst Life Sci SILS, Sect Mol Cytol, Amsterdam, Netherlands.	j.vanbuul@sanquin.nl		Mahlandt, Eike/0000-0001-9458-8543; Schimmel, Lilian/0000-0002-0569-0464	ZonMW NWO Vici grant [91819632]; NWO ALW-OPEN grant [ALWOP.306]	ZonMW NWO Vici grant; NWO ALW-OPEN grant	This work was supported by ZonMW NWO Vici grant #91819632 (JB/MG) and NWO ALW-OPEN grant ALWOP.306 (EM).	Arts JJG., 2021, ENDOTHELIAL JUNCTION; Barzilai S, 2017, CELL REP, V18, P685, DOI 10.1016/j.celrep.2016.12.076; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Chertkova A.O., 2020, ROBUST BRIGHT GENETI; Goedhart J, 2021, MOL BIOL CELL, V32, P470, DOI 10.1091/mbc.E20-09-0583; Hallmann R, 2015, CURR OPIN CELL BIOL, V36, P54, DOI 10.1016/j.ceb.2015.06.006; Heemskerk N, 2014, CELL ADHES MIGR, V8, P67, DOI 10.4161/cam.28244; Hoffman BD, 2014, PROG MOL BIOL TRANSL, V126, P3, DOI 10.1016/B978-0-12-394624-9.00001-4; Hyun YM, 2012, J EXP MED, V209, P1349, DOI 10.1084/jem.20111426; Klems A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19008-0; Kroon J, 2018, J IMMUNOL, V200, P1790, DOI 10.4049/jimmunol.1700702; Kuo JC, 2013, J CELL MOL MED, V17, P704, DOI 10.1111/jcmm.12054; Lee J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00048; Leszczynska K, 2011, BIOCHEM SOC T, V39, P1606, DOI 10.1042/BST20110702; Martin-Ramirez J, 2012, NAT PROTOC, V7, P1709, DOI 10.1038/nprot.2012.093; Millan J, 2006, NAT CELL BIOL, V8, P113, DOI 10.1038/ncb1356; Parsons SA, 2012, EUR J IMMUNOL, V42, P436, DOI 10.1002/eji.201041303; Proebstl D, 2012, J EXP MED, V209, P1219, DOI 10.1084/jem.20111622; Renkawitz J, 2019, NATURE, V568, P546, DOI 10.1038/s41586-019-1087-5; Schimmel L, 2018, CELL REP, V24, P3115, DOI 10.1016/j.celrep.2018.08.045; Schnoor M, 2011, J EXP MED, V208, P1721, DOI 10.1084/jem.20101920; Song J, 2017, CELL REP, V18, P1256, DOI 10.1016/j.celrep.2016.12.092; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stroka KM, 2011, BLOOD, V118, P1632, DOI 10.1182/blood-2010-11-321125; Thompson PW, 2002, J IMMUNOL, V169, P1007, DOI 10.4049/jimmunol.169.2.1007; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; van Buul JD, 2007, J CELL BIOL, V178, P1279, DOI 10.1083/jcb.200612053; van Geemen D, 2014, ARTERIOSCL THROM VAS, V34, P2059, DOI 10.1161/ATVBAHA.114.304180; van Rijssel J, 2012, MOL BIOL CELL, V23, P2831, DOI 10.1091/mbc.E11-11-0907; Vignal E, 2000, J BIOL CHEM, V275, P36457, DOI 10.1074/jbc.M003487200; Voisin MB, 2019, J PATHOL, V247, P662, DOI 10.1002/path.5227; Wang SJ, 2006, J EXP MED, V203, P1519, DOI 10.1084/jem.20051210; Wilson E, 2014, J CELL SCI, V127, P3039, DOI 10.1242/jcs.140434; Yuan L, 2011, BLOOD, V118, P1145, DOI 10.1182/blood-2010-10-315275; Yuan SY, 2012, MICROVASC RES, V83, P82, DOI 10.1016/j.mvr.2011.06.015; Yun S, 2016, NAT CELL BIOL, V18, P1043, DOI 10.1038/ncb3405; Zaidel-Bar R, 2004, BIOCHEM SOC T, V32, P416, DOI 10.1042/BST0320416; Zhang XL, 2020, J EXP MED, V217, DOI 10.1084/jem.20191339	38	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2021	12								667213	10.3389/fimmu.2021.667213	http://dx.doi.org/10.3389/fimmu.2021.667213			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SK6EI	34084168	Green Published, gold			2022-12-18	WOS:000656306700001
J	Bassani, B; Tripodo, C; Portararo, P; Gulino, A; Botti, L; Chiodoni, C; Jachetti, E; Bolli, N; Ciciarello, M; Joehrens, K; Anagnostopoulos, I; Na, IK; Curti, A; Colombo, MP; Sangaletti, S				Bassani, Barbara; Tripodo, Claudio; Portararo, Paola; Gulino, Alessandro; Botti, Laura; Chiodoni, Claudia; Jachetti, Elena; Bolli, Niccolo; Ciciarello, Marilena; Joehrens, Korinna; Anagnostopoulos, Ioannis; Na, Il-Kang; Curti, Antonio; Colombo, Mario P.; Sangaletti, Sabina			CD40 Activity on Mesenchymal Cells Negatively Regulates OX40L to Maintain Bone Marrow Immune Homeostasis Under Stress Conditions	FRONTIERS IN IMMUNOLOGY			English	Article						B-cell development; CD40; OX40L; mesenchymal cell; bone marrow transplantation	T-CELLS	Background Within the bone marrow (BM), mature T cells are maintained under homeostatic conditions to facilitate proper hematopoietic development. This homeostasis depends upon a peculiar elevated frequency of regulatory T cells (Tregs) and immune regulatory activities from BM-mesenchymal stem cells (BM-MSCs). In response to BM transplantation (BMT), the conditioning regimen exposes the BM to a dramatic induction of inflammatory cytokines and causes an unbalanced T-effector (Teff) and Treg ratio. This imbalance negatively impacts hematopoiesis, particularly in regard to B-cell lymphopoiesis that requires an intact cross-talk between BM-MSCs and Tregs. The mechanisms underlying the ability of BM-MSCs to restore Treg homeostasis and proper B-cell development are currently unknown. Methods We studied the role of host radio-resistant cell-derived CD40 in restoring Teff/Treg homeostasis and proper B-cell development in a murine model of BMT. We characterized the host cellular source of CD40 and performed radiation chimera analyses by transplanting WT or Cd40-KO with WT BM in the presence of T-reg and co-infusing WT or - Cd40-KO BM-MSCs. Residual host and donor T cell expansion and activation (cytokine production) and also the expression of Treg fitness markers and conversion to Th17 were analyzed. The presence of Cd40+ BM-MSCs was analyzed in a human setting in correlation with the frequency of B-cell precursors in patients who underwent HSCT and variably developed acute graft-versus-host (aGVDH) disease. Results CD40 expression is nearly undetectable in the BM, yet a Cd40-KO recipient of WT donor chimera exhibited impaired B-cell lymphopoiesis and Treg development. Lethal irradiation promotes CD40 and OX40L expression in radio-resistant BM-MSCs through the induction of pro-inflammatory cytokines. OX40L favors Teff expansion and activation at the expense of Tregs; however, the expression of CD40 dampens OX40L expression and restores Treg homeostasis, thus facilitating proper B-cell development. Indeed, in contrast to dendritic cells in secondary lymphoid organs that require CD40 triggers to express OX40L, BM-MSCs require CD40 to inhibit OX40L expression. Conclusions CD40+ BM-MSCs are immune regulatory elements within BM. Loss of CD40 results in uncontrolled T cell activation due to a reduced number of Tregs, and B-cell development is consequently impaired. GVHD provides an example of how a loss of CD40+ BM-MSCs and a reduction in B-cell precursors may occur in a human setting.	[Bassani, Barbara; Portararo, Paola; Botti, Laura; Chiodoni, Claudia; Jachetti, Elena; Colombo, Mario P.; Sangaletti, Sabina] Fdn IRCCS Ist Nazl Tumori, Dept Res, Milan, Italy; [Tripodo, Claudio; Gulino, Alessandro] Univ Palermo, Sch Med, Palermo, Italy; [Bolli, Niccolo] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy; [Bolli, Niccolo] Fdn Ca Granda IRCCS Policlin, Hematol, Milan, Italy; [Ciciarello, Marilena; Curti, Antonio] Inst Hematol Seragnoli, Dept Expt Diagnost & Specialty Med DIMES, Bologna, Italy; [Joehrens, Korinna] Charite Univ Med Berlin, Inst Pathol, Berlin, Germany; [Anagnostopoulos, Ioannis] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Na, Il-Kang] Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany; [Na, Il-Kang] Berlin Inst Hlth BIH, Berlin, Germany; [Na, Il-Kang] Expt & Clin Res Ctr ECRC, Berlin, Germany	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Palermo; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health	Sangaletti, S (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Res, Milan, Italy.	sabina.sangaletti@istitutotumori.mi.it	Ciciarello, Marilena/AAA-7950-2022; Jachetti, Elena/C-2145-2017; Tripodo, Claudio/AAB-6004-2022	Ciciarello, Marilena/0000-0002-4744-507X; Jachetti, Elena/0000-0001-6483-7350; Tripodo, Claudio/0000-0002-0821-6231; Na, Il-Kang/0000-0001-9902-5424; Curti, Antonio/0000-0002-7752-6049	Italian Ministry of Health [GR-2013-02355637]; Associazione Italiana per la Ricerca sul Cancro [22204]	Italian Ministry of Health(Ministry of Health, Italy); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Italian Ministry of Health (GR-2013-02355637 to SS) and Associazione Italiana per la Ricerca sul Cancro (Investigator Grant number 22204 to SS).	Baratono SR, 2015, EUR J IMMUNOL, V45, P1313, DOI 10.1002/eji.201445319; Beres AJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00163; Chen AI, 1999, IMMUNITY, V11, P689, DOI 10.1016/S1074-7613(00)80143-0; Chow A, 2013, NAT MED, V19, P429, DOI 10.1038/nm.3057; Ehninger A, 2011, J EXP MED, V208, P421, DOI 10.1084/jem.20110132; Guiducci C, 2005, EUR J IMMUNOL, V35, P557, DOI 10.1002/eji.200425810; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; Houlihan DD, 2012, NAT PROTOC, V7, P2103, DOI 10.1038/nprot.2012.125; Ito T, 2006, P NATL ACAD SCI USA, V103, P13138, DOI 10.1073/pnas.0603107103; Kim S, 2015, EUR J IMMUNOL, V45, P167, DOI 10.1002/eji.201444532; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Kumanogoh A, 2001, J IMMUNOL, V166, P353, DOI 10.4049/jimmunol.166.1.353; Lecoeur H, 2001, J IMMUNOL METHODS, V253, P177, DOI 10.1016/S0022-1759(01)00359-3; Lee HJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep44486; Levine JE, 2011, INT J HEMATOL, V93, P571, DOI 10.1007/s12185-011-0803-1; Lindemans CA, 2014, BLOOD, V124, P837, DOI 10.1182/blood-2014-06-576991; Malard F, 2016, MUCOSAL IMMUNOL, V9, P299, DOI 10.1038/mi.2015.143; Maloy KJ, 2005, NAT IMMUNOL, V6, P1071, DOI 10.1038/ni1105-1071; Melenhorst JJ, 2012, HAEMATOL-HEMATOL J, V97, P867, DOI 10.3324/haematol.2011.053363; Mensen A, 2014, BLOOD, V124, P963, DOI 10.1182/blood-2013-11-539031; Naserian S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00010; Nicolay NH, 2015, ONCOTARGET, V6, P19366, DOI 10.18632/oncotarget.4358; Piconese S, 2008, J EXP MED, V205, P825, DOI 10.1084/jem.20071341; Piconese S, 2010, EUR J IMMUNOL, V40, P2902, DOI 10.1002/eji.201040505; Pierini A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15068; Pietras EM, 2017, BLOOD, V130, P1693, DOI 10.1182/blood-2017-06-780882; Sangaletti S, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28989; Schirrmacher V, 2003, TRENDS MOL MED, V9, P526, DOI 10.1016/j.molmed.2003.10.001; Schroeder MA, 2011, DIS MODEL MECH, V4, P318, DOI 10.1242/dmm.006668; Severe N, 2019, CELL STEM CELL, V25, P570, DOI 10.1016/j.stem.2019.06.003; Su XH, 2020, CELL MOL IMMUNOL, V17, P483, DOI 10.1038/s41423-019-0312-3; Tkachev V, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan3085; Tripodo C, 2017, CANCER RES, V77, P3685, DOI 10.1158/0008-5472.CAN-17-1098; Tripodo C, 2012, BLOOD, V120, P3541, DOI 10.1182/blood-2011-12-398537; Uccelli A, 2007, TRENDS IMMUNOL, V28, P219, DOI 10.1016/j.it.2007.03.001; Vu MD, 2007, BLOOD, V110, P2501, DOI 10.1182/blood-2007-01-070748	36	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2021	12								662048	10.3389/fimmu.2021.662048	http://dx.doi.org/10.3389/fimmu.2021.662048			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SL0FE	34084166	Green Published, Green Accepted, gold			2022-12-18	WOS:000656591400001
J	Cheng, L; Li, GM; Pellegry, CM; Yasui, F; Li, F; Zurawski, SM; Zurawski, G; Levy, Y; Ting, JPY; Su, LS				Cheng, Liang; Li, Guangming; Pellegry, Caroline Marnata; Yasui, Fumihiko; Li, Feng; Zurawski, Sandra M.; Zurawski, Gerard; Levy, Yves; Ting, Jenny P. -Y.; Su, Lishan			TLR9-and CD40-Targeting Vaccination Promotes Human B Cell Maturation and IgG Induction via pDC-Dependent Mechanisms in Humanized Mice	FRONTIERS IN IMMUNOLOGY			English	Article						plasmacytoid dendritic cell; IFN-alpha; immunoglobin class-switch; IgG induction; CD40-targeting vaccination; B cell maturation; CpG-B	CD40	Mice reconstituted with a human immune system (humanized mice) provide a robust model to study human immunology, vaccinology, and human infectious diseases. However, the development and function of B cells in humanized mice is impaired. B cells from humanized mice are immature and are impaired in IgM to IgG isotype switch in response to infection or vaccination. In the present study we report that Toll-like receptor 9 (TLR9) agonist CpG-B combined with CD40-targeting vaccination triggered human B cell immunoglobin class-switch from IgM(+) to IgG(+) B cells in humanized mice. Human B cells from mice vaccinated with CpG-B as adjuvant were more mature in phenotype and produced significant levels of both total IgG and antigen-specific IgG. We found that CpG-B treatment activated human pDCs (plasmacytoid dendritic cells) in vivo to induce interferon-alpha (IFN-alpha)expression in humanized mice. Pre-depletion of human pDC in vivo abrogated the adjuvant effect of CpG-B. Our results indicate that TLR9 and CD40-targeting vaccination triggers human B cell maturation and immunoglobulin class-switch in a pDC-dependent manner in humanized mice. The findings also shed light on induction of human IgG antibodies in humanized mouse models.	[Cheng, Liang; Li, Guangming; Pellegry, Caroline Marnata; Yasui, Fumihiko; Li, Feng; Ting, Jenny P. -Y.; Su, Lishan] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Cheng, Liang] Wuhan Univ, Med Res Inst, Frontier Sci Ctr Immunol & Metab, Wuhan, Peoples R China; [Li, Guangming; Su, Lishan] Univ Maryland, Sch Med, Dept Pharmacol, Div Virol Pathogenesis & Canc,Inst Human Virol, Baltimore, MD 21201 USA; [Yasui, Fumihiko] Tokyo Metropolitan Inst Med Sci, Dept Microbiol & Cell Biol, Tokyo, Japan; [Li, Feng] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou, Peoples R China; [Zurawski, Sandra M.; Zurawski, Gerard] Baylor Inst Immunol Res, Vaccine Res Inst, INSERM U955, Dallas, TX USA; [Levy, Yves] Grp Henri Mondor Albert Chenevier, Assistance Publ Hop Paris, Serv Immunol Clin, Creteil, France; [Levy, Yves] Univ Paris Est Creteil, Vaccine Res Inst, Fac Med, INSERM U955, Creteil, France; [Ting, Jenny P. -Y.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27515 USA; [Ting, Jenny P. -Y.] Univ N Carolina, Dept Microbiol Immunol, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill; Wuhan University; University System of Maryland; University of Maryland Baltimore; Tokyo Metropolitan Institute of Medical Science; Guangzhou Medical University; Baylor Scott & White Health; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Cheng, L; Su, LS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA.; Cheng, L (corresponding author), Wuhan Univ, Med Res Inst, Frontier Sci Ctr Immunol & Metab, Wuhan, Peoples R China.; Su, LS (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol, Div Virol Pathogenesis & Canc,Inst Human Virol, Baltimore, MD 21201 USA.	liangcheng@whu.edu.cn; lsu@ihv.umaryland.edu	, UNC Flow Cytometry Core/AGU-9839-2022; , PEP-MX Core/AGV-4051-2022		NIH [R01AI136990, AI141333, AI109784]; Vaccine Research Institute [ANR-10-LABX-77]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vaccine Research Institute	This study was supported in part by NIH grants R01AI136990 (to LS), AI141333 (to JT), AI109784 (to JT and LS), and the Vaccine Research Institute via the ANR-10-LABX-77 grant funded part of this work.	Barr TA, 2003, IMMUNOLOGY, V109, P87, DOI 10.1046/j.1365-2567.2003.01634.x; Beutler BA, 2009, BLOOD, V113, P1399, DOI 10.1182/blood-2008-07-019307; Biswas S, 2011, IMMUNOLOGY, V134, P419, DOI 10.1111/j.1365-2567.2011.03501.x; Chen QF, 2012, J IMMUNOL, V189, P5223, DOI 10.4049/jimmunol.1201789; Chen QF, 2009, P NATL ACAD SCI USA, V106, P21783, DOI 10.1073/pnas.0912274106; Cheng L, 2018, J CLIN INVEST, V128, P4387, DOI 10.1172/JCI99005; Cheng L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00817; Cheng L, 2017, VACCINE, V35, P6143, DOI 10.1016/j.vaccine.2017.09.052; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Flamar AL, 2013, AIDS, V27, P2041, DOI 10.1097/QAD.0b013e3283624305; Godot V, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009025; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Hangalapura BN, 2010, J IMMUNOTHER, V33, P706, DOI 10.1097/CJI.0b013e3181eccbd4; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Ippolito GC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035497; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021; Jangalwe S, 2016, IMMUN INFLAMM DIS, V4, P427, DOI 10.1002/iid3.124; Jego G, 2003, IMMUNITY, V19, P225, DOI 10.1016/S1074-7613(03)00208-5; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Lai F, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110643; Li GM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004291; Li Y, 2018, NAT METHODS, V15, P623, DOI 10.1038/s41592-018-0071-6; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Marsden MD, 2017, ANNU REV VIROL, V4, P393, DOI 10.1146/annurev-virology-101416-041703; Matsumura B, 2003, EXP HEMATOL, V31, P789, DOI 10.1016/S0301-472X(03)00193-0; Mbow ML, 2010, CURR OPIN IMMUNOL, V22, P411, DOI 10.1016/j.coi.2010.04.004; Meixlsperger S, 2013, BLOOD, V121, P5034, DOI 10.1182/blood-2012-12-473413; Melkus MW, 2006, NAT MED, V12, P1316, DOI 10.1038/nm1431; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; O'Neill LAJ, 2010, CURR BIOL, V20, pR328, DOI 10.1016/j.cub.2010.01.044; Seung E, 2013, J INFECT DIS, V208, pS155, DOI 10.1093/infdis/jit448; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; Vuyyuru R, 2011, IMMUNOL RES, V51, P257, DOI 10.1007/s12026-011-8243-9; Watanabe Y, 2009, INT IMMUNOL, V21, P843, DOI 10.1093/intimm/dxp050; Yin WJ, 2016, EBIOMEDICINE, V5, P46, DOI 10.1016/j.ebiom.2016.01.029; Yu H, 2017, BLOOD, V129, P959, DOI 10.1182/blood-2016-04-709584; Zhang LG, 2007, BLOOD, V109, P2978, DOI 10.1182/blood-2006-07-033159; Zhang LG, 2011, BLOOD, V117, P6184, DOI 10.1182/blood-2011-01-331173	41	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2021	12								672143	10.3389/fimmu.2021.672143	http://dx.doi.org/10.3389/fimmu.2021.672143			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SL3WX	34093572	Green Published, gold			2022-12-18	WOS:000656850900001
J	Janicova, A; Haag, F; Xu, BL; Garza, AP; Dunay, IR; Neunaber, C; Nowak, AJ; Cavalli, P; Marzi, I; Sturm, R; Relja, B				Janicova, Andrea; Haag, Florian; Xu, Baolin; Garza, Alejandra P.; Dunay, Ildiko Rita; Neunaber, Claudia; Nowak, Aleksander J.; Cavalli, Paola; Marzi, Ingo; Sturm, Ramona; Relja, Borna			Acute Alcohol Intoxication Modulates Monocyte Subsets and Their Functions in a Time-Dependent Manner in Healthy Volunteers	FRONTIERS IN IMMUNOLOGY			English	Article						ethanol; drinking; innate immunity; inflammasome; LPS; IL-1 beta; CD14; TLR4	DRINKING; ETHANOL	Background: Excessive alcohol intake is associated with adverse immune response-related effects, however, acute and chronic abuse differently modulate monocyte activation. In this study, we have evaluated the phenotypic and functional changes of monocytes in acutely intoxicated healthy volunteers (HV). Methods: Twenty-two HV consumed individually adjusted amounts of alcoholic beverages until reaching a blood alcohol level of 1 parts per thousand after 4h (T4). Peripheral blood was withdrawn before and 2h (T2), 4h (T4), 6h (T6), 24h (T24), and 48h (T48) after starting the experiment and stained for CD14, CD16 and TLR4. CD14(bright)CD16(-), CD14(bright)CD16(+) and CD14(dim)CD16(+) monocyte subsets and their TLR4 expression were analyzed by flow cytometry. Inflammasome activation via caspase-1 in CD14(+) monocytes was measured upon an ex vivo in vitro LPS stimulation. Systemic IL-1 beta and adhesion capacity of isolated CD14(+) monocytes upon LPS stimulation were evaluated. Results: The percentage of CD14(+) monocyte did not change following alcohol intoxication, whereas CD14(bright)CD16(-) monocyte subset significantly increased at T2 and T24, CD14(bright)CD16(+) at T2, T4 and T6 and CD14(dim)CD16(+) at T4 and T6. The relative fraction of TLR4 expressing CD14(+) monocytes as well as the density of TLR4 surface presentation increased at T2 and decreased at T48 significantly. TLR4(+)CD14(+) monocytes were significantly enhanced in all subsets at T2. TLR4 expression significantly decreased in CD14(bright)CD16(-) at T48, in CD14(bright)CD16(+) at T24 and T48, increased in CD14(dim)CD16(+) at T2. IL-1 beta release upon LPS stimulation decreased at T48, correlating with TLR4 receptor expression. Alcohol downregulated inflammasome activation following ex vivo in vitro stimulation with LPS between T2 and T48 vs. T0. The adhesion capacity of CD14(+) monocytes decreased from T2 with significance at T4, T6 and T48. Following LPS administration, a significant reduction of adhesion was observed at T4 and T6. Conclusions: Alcohol intoxication immediately redistributes monocyte subsets toward the pro-inflammatory phenotype with their subsequent differentiation into the anti-inflammatory phenotype. This is paralleled by a significant functional depression, suggesting an alcohol-induced time-dependent hyporesponsiveness of monocytes to pathogenic triggers.	[Janicova, Andrea; Haag, Florian; Xu, Baolin; Nowak, Aleksander J.; Cavalli, Paola; Relja, Borna] Otto von Guericke Univ, Dept Radiol & Nucl Med, Expt Radiol, Magdeburg, Germany; [Garza, Alejandra P.; Dunay, Ildiko Rita] Otto von Guericke Univ, Inst Inflammat & Neurodegenerat, Magdeburg, Germany; [Neunaber, Claudia] Hannover Med Sch, Trauma Dept, Hannover, Germany; [Marzi, Ingo; Sturm, Ramona; Relja, Borna] Goethe Univ, Dept Trauma Hand & Reconstruct Surg, Frankfurt, Germany	Otto von Guericke University; Otto von Guericke University; Hannover Medical School; Goethe University Frankfurt	Relja, B (corresponding author), Otto von Guericke Univ, Dept Radiol & Nucl Med, Expt Radiol, Magdeburg, Germany.; Relja, B (corresponding author), Goethe Univ, Dept Trauma Hand & Reconstruct Surg, Frankfurt, Germany.	borna.relja@med.ovgu.de	Relja, Borna/B-6642-2016	Relja, Borna/0000-0002-5625-8823; Garza, Alejandra Patricia/0000-0002-2993-7679	Deutsche Forschungsgemeinschaft [DFG RE 3304/5-1, DFG RE 3304/9-1, DFG NE 1932/1-3]; Nachwuchsforderung AO Trauma Deutschland	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Nachwuchsforderung AO Trauma Deutschland	The study was supported by grants from the Deutsche Forschungsgemeinschaft (grant nos. DFG RE 3304/5-1, DFG RE 3304/9-1, DFG NE 1932/1-3 and Nachwuchsforderung AO Trauma Deutschland (R.S.).	Afshar M, 2015, ALCOHOL, V49, P57, DOI 10.1016/j.alcohol.2014.10.002; Anton M, 2018, BRIT J PHARMACOL, V175, P4464, DOI 10.1111/bph.14501; Awad F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175336; Bakele M, 2014, J BIOL CHEM, V289, P5320, DOI 10.1074/jbc.M113.505636; Bala S, 2012, J LEUKOCYTE BIOL, V92, P611, DOI 10.1189/jlb.0112050; Burnham EL., 2003, INTENS CARE MED, DOI [10.1007/978-1-4757-5548-0_9, DOI 10.1007/978-1-4757-5548-0_9]; Carmody RJ, 2007, SCIENCE, V317, P675, DOI 10.1126/science.1142953; Dasu MR, 2007, AM J PHYSIOL-ENDOC M, V293, pE337, DOI 10.1152/ajpendo.00718.2006; Dayer JM, 2003, EUR RESPIR J, V22, p10S, DOI 10.1183/09031936.03.00000403b; Donnadieu-Rigole H, 2016, J LEUKOCYTE BIOL, V100, P1191, DOI 10.1189/jlb.5A0216-060RR; Duthie GG, 1998, EUR J CLIN NUTR, V52, P733, DOI 10.1038/sj.ejcn.1600635; Eder C, 2009, IMMUNOBIOLOGY, V214, P543, DOI 10.1016/j.imbio.2008.11.007; Ferrero ME, 1998, AM J CLIN NUTR, V68, P1208, DOI 10.1093/ajcn/68.6.1208; Franz N, 2019, INFLAMMATION, V42, P690, DOI 10.1007/s10753-018-0927-z; Gacouin A, 2014, SHOCK, V42, P192, DOI 10.1097/SHK.0000000000000195; Gomes de Matos E, 2016, SUCHT, V62, P271, DOI DOI 10.1024/0939-5911/A000445; Goral J, 2008, ALCOHOL, V42, P237, DOI 10.1016/j.alcohol.2008.02.003; Greco Marilena, 2019, EJIFCC, V30, P371; Haag F, 2022, EUR J TRAUMA EMERG S, V48, P2689, DOI 10.1007/s00068-021-01643-x; Hadfield RJH, 2001, RESUSCITATION, V48, P25, DOI 10.1016/S0300-9572(00)00315-4; Hildebrand F, 2005, SHOCK, V24, P518, DOI 10.1097/01.shk.0000184212.97488.4e; Horauf JA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093196; Imhof A, 2008, DIABETES VASC DIS RE, V5, P48, DOI 10.3132/dvdr.2008.009; Janicova A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02276; John U, 2002, ALCOHOL ALCOHOLISM, V37, P581, DOI 10.1093/alcalc/37.6.581; Kany S, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/1752836; Kapellos TS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02035; Kral JB, 2016, TRANSFUS MED HEMOTH, V43, P78, DOI 10.1159/000444807; Kratofil RM, 2017, ARTERIOSCL THROM VAS, V37, P35, DOI 10.1161/ATVBAHA.116.308198; Lage SL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01284; Li X, 2013, ALCOHOL, V47, P459, DOI 10.1016/j.alcohol.2013.05.004; Liangpunsakul S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04669-7; Lin SJ, 2002, CLIN LAB HAEMATOL, V24, P353, DOI 10.1046/j.1365-2257.2002.00462.x; Mandrekar P, 2006, ALCOHOL CLIN EXP RES, V30, P135, DOI 10.1111/j.1530-0277.2006.00012.x; Mors K, 2017, CELL PHYSIOL BIOCHEM, V43, P17, DOI 10.1159/000480313; Muralidharan S, 2018, J IMMUNOL, V200, P2291, DOI 10.4049/jimmunol.1600924; Nandy D, 2011, J INVEST MED, V59, P661, DOI 10.2310/JIM.0b013e31820ee432; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Netea MG, 2015, ANNU REV IMMUNOL, V33, P49, DOI 10.1146/annurev-immunol-032414-112306; Neupane SP, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/3758590; Otte JM, 2004, GASTROENTEROLOGY, V126, P1054, DOI 10.1053/j.gastro.2004.01.007; Piano MR, 2017, ALCOHOL RES-CURR REV, V38, P219; Provoost S, 2011, J IMMUNOL, V187, P3331, DOI 10.4049/jimmunol.1004062; Pruett BS, 2006, ALCOHOL, V39, P105, DOI 10.1016/j.alcohol.2006.08.003; Relja B, 2016, INJURY, V47, P640, DOI 10.1016/j.injury.2016.01.016; Relja B, 2015, MOL MED REP, V12, P2991, DOI 10.3892/mmr.2015.3764; Ren ZH, 2016, ONCOTARGET, V7, P54303, DOI 10.18632/oncotarget.11103; Sturm R, 2022, EUR J TRAUMA EMERG S, V48, P1569, DOI 10.1007/s00068-021-01666-4; Sureshchandra S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44302-3; Szabo G, 2015, ALCOHOL RES-CURR REV, V37, P159; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]; Wagner N, 2019, INT J MOL MED, V44, P1127, DOI 10.3892/ijmm.2019.4259; West SD, 2012, J SURG RES, V172, P5, DOI 10.1016/j.jss.2011.04.016; Zhang K, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1241-2	54	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2021	12								652488	10.3389/fimmu.2021.652488	http://dx.doi.org/10.3389/fimmu.2021.652488			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SK6DO	34084163	gold, Green Published			2022-12-18	WOS:000656304700001
J	Lin, YK; Zhang, D; Li, YY; Li, YY; Li, B; Du, MR				Lin, Yikong; Zhang, Di; Li, Yangyang; Li, Yunyun; Li, Bin; Du, Meirong			Decidual NR2F2-Expressing CD4(+) T Cells Promote TH2 Transcriptional Program During Early Pregnancy	FRONTIERS IN IMMUNOLOGY			English	Article						CD4(+)T cell; GATA-3; pregnancy; maternal-fetal immune tolerance	TH2-TYPE CYTOKINES; FETAL LOSS	A unique immunotolerant microenvironment with Th2 bias in the decidua provides an essential security for successful pregnancy. The disorganized maternal-fetal immune tolerance contributes to more than 50% of unexplained recurrent spontaneous abortion (RSA). How the Th2 bias is developed at the maternal-fetal interface remains undefined. NR2F2, a member of steroid/thyroid nuclear receptor superfamily, is endowed with diverse importance in cell-fate specification, organogenesis, angiogenesis, and metabolism. Here, we showed that NR2F2 was absolutely highly expressed in decidual CD4(+)T(dCD4(+)T) cells, but not in peripheral circulating CD4(+)T cells during early pregnancy. Decidual NR2F2-expressing CD4(+)T cells dominantly produced Th2 cytokines. In unexplained RSA patients, NR2F2 expression in dCD4(+)T cells was significantly decreased, accompanied with disordered phenotype of dCD4(+)T cells. Furthermore, overexpression of NR2F2 promoted the Th2 differentiation of naive CD4(+)T cells. Immunoprecipitation experiment confirmed the binding relationship between GATA-3 and NR2F2, which implied GATA-3 may be an important interactive element involved in the immunoregulatory process of NR2F2. This study is the first to reveal a previously unappreciated role for NR2F2-mediated dCD4(+)T cells in maternal-fetal immune tolerance and maintenance of normal pregnancy, in the hope of providing a potential biomarker for prediction and prevention of clinical unexplained RSA.	[Lin, Yikong; Zhang, Di; Li, Yunyun; Du, Meirong] Fudan Univ, Shanghai Med Coll,Hosp Obstet & Gynecol, Lab Reprod Immunol,Shanghai Key Lab Female Reprod, NHC Key Lab Reprod Regulat,Shanghai Inst Planned, Shanghai, Peoples R China; [Zhang, Di] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Obstet & Gynecol, Shanghai, Peoples R China; [Li, Yangyang; Li, Bin] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Dept Immunol & Microbiol, Shanghai, Peoples R China; [Du, Meirong] South China Univ Technol, Guangzhou Peoples Hosp 1, Dept Obstet & Gynecol, Sch Med, Guangzhou, Peoples R China	Fudan University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Jiao Tong University; South China University of Technology	Du, MR (corresponding author), Fudan Univ, Shanghai Med Coll,Hosp Obstet & Gynecol, Lab Reprod Immunol,Shanghai Key Lab Female Reprod, NHC Key Lab Reprod Regulat,Shanghai Inst Planned, Shanghai, Peoples R China.; Li, B (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Dept Immunol & Microbiol, Shanghai, Peoples R China.; Du, MR (corresponding author), South China Univ Technol, Guangzhou Peoples Hosp 1, Dept Obstet & Gynecol, Sch Med, Guangzhou, Peoples R China.	binli@shsmu.edu.cn; mrdu@fudan.edu.cn	lI, Bin/AAR-4966-2021	lI, Bin/0000-0002-7640-8884	National Key R&D Program of China [2017YFC1001403]; National Nature Science Foundation of China [31970859, 81630036]; Macao and Shanghai Municipal Commission of science and technology [20410760300]; Ferring Institute of Reproductive Medicine by Ferring Pharmaceuticals; Chinese Academy of Sciences [FIRMX200504]	National Key R&D Program of China; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Macao and Shanghai Municipal Commission of science and technology; Ferring Institute of Reproductive Medicine by Ferring Pharmaceuticals; Chinese Academy of Sciences(Chinese Academy of Sciences)	The work is supported by the National Key R&D Program of China (2017YFC1001403), the National Nature Science Foundation of China (31970859 and 81630036), International cooperation project between Macao and Shanghai Municipal Commission of science and technology (20410760300), The Strategic Collaborative Research Program of the Ferring Institute of Reproductive Medicine Supported by, Ferring Pharmaceuticals and Chinese Academy of Sciences (FIRMX200504).	Arck PC, 2013, NAT MED, V19, P548, DOI 10.1038/nm.3160; Clark DA, 2003, AM J REPROD IMMUNOL, V49, P297, DOI 10.1034/j.1600-0897.2003.00045.x; Du MR, 2007, BIOL REPROD, V76, P906, DOI 10.1095/biolreprod.106.056648; Du MR, 2014, CELL MOL IMMUNOL, V11, P438, DOI 10.1038/cmi.2014.68; Du MR, 2014, J IMMUNOL, V192, P1502, DOI 10.4049/jimmunol.1203425; Erlebacher A, 2013, ANNU REV IMMUNOL, V31, P387, DOI 10.1146/annurev-immunol-032712-100003; Fu BQ, 2014, CELL MOL IMMUNOL, V11, P564, DOI 10.1038/cmi.2014.54; Guo PF, 2010, BLOOD, V116, P2061, DOI 10.1182/blood-2009-11-252940; HILL JA, 1995, JAMA-J AM MED ASSOC, V273, P1933, DOI 10.1001/jama.273.24.1933; Hu MJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10703-1; Hu XH, 2016, J REPROD IMMUNOL, V118, P92, DOI 10.1016/j.jri.2016.10.113; Hubert MA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009417; Hviid TVF, 2006, HUM REPROD UPDATE, V12, P209, DOI 10.1093/humupd/dmi048; Kahn DA, 2010, P NATL ACAD SCI USA, V107, P9299, DOI 10.1073/pnas.1003909107; Lin FJ, 2011, ENDOCR REV, V32, P404, DOI 10.1210/er.2010-0021; Nahum R, 2004, HUM REPROD, V19, P715, DOI 10.1093/humrep/deh099; Petit FG, 2007, P NATL ACAD SCI USA, V104, P6293, DOI 10.1073/pnas.0702039104; PICCINNI MP, 1995, J IMMUNOL, V155, P128; Piccinni MP, 2001, J REPROD IMMUNOL, V52, P35, DOI 10.1016/S0165-0378(01)00111-5; Piccinni MP, 1998, NAT MED, V4, P1020, DOI 10.1038/2006; Polvani S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010101; Qin J, 2010, P NATL ACAD SCI USA, V107, P3687, DOI 10.1073/pnas.0914619107; Robertson SA, 2018, J CLIN INVEST, V128, P4224, DOI 10.1172/JCI122182; Salvany-Celades M, 2019, CELL REP, V27, P2537, DOI 10.1016/j.celrep.2019.04.109; Schmitt N, 2015, CURR OPIN IMMUNOL, V34, P130, DOI 10.1016/j.coi.2015.03.007; Swain A, 2017, SCIENCE, V357, P648, DOI 10.1126/science.aao2630; Wang SC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1251-0; Wang SC, 2016, HUM REPROD, V31, P700, DOI 10.1093/humrep/dew019; Weetman AP, 1999, THYROID, V9, P643, DOI 10.1089/thy.1999.9.643; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Xin LJ, 2014, J IMMUNOL, V192, P2970, DOI 10.4049/jimmunol.1302678; Xu XX, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.592010; Yu CT, 2012, DEVELOPMENT, V139, P2330, DOI 10.1242/dev.076299; Zhao F, 2017, SCIENCE, V357, P717, DOI 10.1126/science.aai9136; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001; Zhou X, 2015, DEVELOPMENT, V142, P1593, DOI 10.1242/dev.115279; Zhu XY, 2005, BIOL REPROD, V72, P338, DOI 10.1095/biolreprod.104.034108	37	1	1	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2021	12								670777	10.3389/fimmu.2021.670777	http://dx.doi.org/10.3389/fimmu.2021.670777			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SK9VF	34084171	gold, Green Published			2022-12-18	WOS:000656565500001
J	Rayens, E; Rabacal, W; Kang, SE; Celia, BN; Momany, M; Norris, KA				Rayens, Emily; Rabacal, Whitney; Kang, S. Earl; Celia, Brandi N.; Momany, Michelle; Norris, Karen A.			Vaccine-Induced Protection in Two Murine Models of Invasive Pulmonary Aspergillosis	FRONTIERS IN IMMUNOLOGY			English	Article						aspergillus; invasive pulmonary aspergillosis; fungal vaccines; FK506 (tacrolimus); immunocompromised patients		Life-threatening, invasive fungal infections (IFIs) cause over 1.5 million deaths worldwide and are a major public health concern with high mortality rates even with medical treatment. Infections with the opportunistic fungal pathogen, Aspergillus fumigatus are among the most common. Despite the growing clinical need, there are no licensed vaccines for IFIs. Here we evaluated the immunogenicity and protective efficacy of an A. fumigatus recombinant protein vaccine candidate, AF.KEX1, in experimental murine models of drug-induced immunosuppression. Immunization of healthy mice with AF.KEX1 and adjuvant induced a robust immune response. Following AF.KEX1 or sham immunization, mice were immunosuppressed by treatment with either cortisone acetate or hydrocortisone and the calcineurin inhibitor, tacrolimus. To test vaccine efficacy, immunosuppressed mice were intranasally challenged with A. fumigatus conidia (Af293) and weight and body temperature were monitored for 10 days. At study termination, organism burden in the lungs was evaluated by quantitative PCR and Gomori's methanamine silver staining. In both models of immunosuppression, AF.KEX1 vaccinated mice experienced decreased rates of mortality and significantly lower lung organism burden compared to non-vaccinated controls. The lung fungal burden was inversely correlated with the peak anti-AF.KEX1 IgG titer achieved following vaccination. These studies provide the basis for further evaluation of a novel vaccine strategy to protect individuals at risk of invasive aspergillosis due to immunosuppressive treatments.	[Rayens, Emily; Rabacal, Whitney; Norris, Karen A.] Univ Georgia, Ctr Vaccines & Immunol, Athens, GA 30602 USA; [Rayens, Emily; Norris, Karen A.] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA; [Kang, S. Earl; Celia, Brandi N.; Momany, Michelle] Univ Georgia, Dept Plant Pathol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Norris, KA (corresponding author), Univ Georgia, Ctr Vaccines & Immunol, Athens, GA 30602 USA.; Norris, KA (corresponding author), Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA.	kanorris@uga.edu			Georgia Research Alliance; University of Georgia Research Foundation; USDA NIFA [2019-67017-29113]; National Science Foundation [DGE-1545433]	Georgia Research Alliance; University of Georgia Research Foundation; USDA NIFA(United States Department of Agriculture (USDA)); National Science Foundation(National Science Foundation (NSF))	Work in the Norris laboratory was supported by the Georgia Research Alliance and the University of Georgia Research Foundation. Work in the Momany laboratory was supported by the USDA NIFA (MM; 2019-67017-29113) and the National Science Foundation (BC; DGE-1545433).	Bongomin F, 2017, J FUNGI, V3, DOI 10.3390/jof3040057; Denning DW, 2016, EUR RESPIR J, V47, P45, DOI 10.1183/13993003.00583-2015; Denning DW, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-14; Diaz-Arevalo D, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00299; Diaz-Arevalo D, 2011, INFECT IMMUN, V79, P2257, DOI 10.1128/IAI.01311-10; Herbst S, 2013, DIS MODEL MECH, V6, P643, DOI 10.1242/dmm.010330; Ito JI, 2006, INFECT IMMUN, V74, P5075, DOI 10.1128/IAI.00815-06; Johnson GL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040022; Kling HM, 2016, J INFECT DIS, V213, P1586, DOI 10.1093/infdis/jiw032; Kling HM, 2009, J INFECT DIS, V199, P89, DOI 10.1086/595297; Kontoyiannis DP, 2010, CLIN INFECT DIS, V50, P1091, DOI 10.1086/651263; Nanjappa SG, 2014, CURR OPIN IMMUNOL, V28, P27, DOI 10.1016/j.coi.2014.01.014; Pappas PG, 2010, CLIN INFECT DIS, V50, P1101, DOI 10.1086/651262; Stolz DJ, 2018, JOVE-J VIS EXP, DOI 10.3791/57155; Verweij PE, 2016, CLIN INFECT DIS, V62, P362, DOI 10.1093/cid/civ885; Webb BJ, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy187	17	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2021	12								670578	10.3389/fimmu.2021.670578	http://dx.doi.org/10.3389/fimmu.2021.670578			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SK6AQ	34084170	gold, Green Published			2022-12-18	WOS:000656297000001
J	Maiers, M; Mehr, R; Raghavan, M; Kaufman, J; Louzoun, Y				Maiers, Martin; Mehr, Ramit; Raghavan, Malini; Kaufman, Jim; Louzoun, Yoram			Editorial: HLA and KIR Diversity and Polymorphisms: Emerging Concepts	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						HLA; KIR; diversity; immunogenetics; polymorphism SIP; Society for Immune Polymorphism			[Maiers, Martin] Natl Marrow Donor Program, Minneapolis, MN 55401 USA; [Mehr, Ramit; Louzoun, Yoram] Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel; [Raghavan, Malini] Univ Michigan, Michigan Med, Ann Arbor, MI 48109 USA; [Kaufman, Jim] Univ Cambridge, Dept Pathol, Cambridge, England; [Kaufman, Jim] Univ Edinburgh, Inst Immunol & Infect Res, Edinburgh, Midlothian, Scotland	National Marrow Donor Program; Bar Ilan University; University of Michigan System; University of Michigan; University of Cambridge; University of Edinburgh	Maiers, M (corresponding author), Natl Marrow Donor Program, Minneapolis, MN 55401 USA.; Louzoun, Y (corresponding author), Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel.	mmaiers@nmdp.org; louzouy@math.biu.ac.il			NIAID NIH HHS [R01 AI044115] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))			0	1	1	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 17	2021	12								701398	10.3389/fimmu.2021.701398	http://dx.doi.org/10.3389/fimmu.2021.701398			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SK3MW	34079561	Green Published, gold			2022-12-18	WOS:000656123800001
J	Poonpanichakul, T; Chan-In, W; Opasawatchai, A; Loison, F; Matangkasombut, O; Charoensawan, V; Matangkasombut, P				Poonpanichakul, Tiraput; Chan-In, Wilawan; Opasawatchai, Anunya; Loison, Fabien; Matangkasombut, Oranart; Charoensawan, Varodom; Matangkasombut, Ponpan		DENFREE Thailand	Innate Lymphoid Cells Activation and Transcriptomic Changes in Response to Human Dengue Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Dengue; viral infection; innate lymphoid cells; ILCs; immune response to dengue; innate immunity; RNA-seq; transcriptome	VIRUS-INFECTION; T-CELLS; REPLICATION; INDUCTION; IMMUNITY	Background Dengue virus (DENV) infection has a global impact on public health. The clinical outcomes (of DENV) can vary from a flu-like illness called dengue fever (DF), to a more severe form, known as dengue hemorrhagic fever (DHF). The underlying innate immune mechanisms leading to protective or detrimental outcomes have not been fully elucidated. Helper innate lymphoid cells (hILCs), an innate lymphocyte recently discovered, functionally resemble T-helper cells and are important in inflammation and homeostasis. However, the role of hILCs in DENV infection had been unexplored. Methods We performed flow cytometry to investigate the frequency and phenotype of hILCs in peripheral blood mononuclear cells from DENV-infected patients of different disease severities (DF and DHF), and at different phases (febrile and convalescence) of infection. Intracellular cytokine staining of hILCs from DF and DHF were also evaluated by flow cytometry after ex vivo stimulation. Further, the hILCs were sorted and subjected to transcriptome analysis using RNA sequencing. Differential gene expression analysis was performed to compare the febrile and convalescent phase samples in DF and DHF. Selected differentially expressed genes were then validated by quantitative PCR. Results Phenotypic analysis showed marked activation of all three hILC subsets during the febrile phase as shown by higher CD69 expression when compared to paired convalescent samples, although the frequency of hILCs remained unchanged. Upon ex vivo stimulation, hILCs from febrile phase DHF produced significantly higher IFN-gamma and IL-4 when compared to those of DF. Transcriptomic analysis showed unique hILCs gene expression in DF and DHF, suggesting that divergent functions of hILCs may be associated with different disease severities. Differential gene expression analysis indicated that hILCs function both in cytokine secretion and cytotoxicity during the febrile phase of DENV infection. Conclusions Helper ILCs are activated in the febrile phase of DENV infection and display unique transcriptomic changes as well as cytokine production that correlate with severity. Targeting hILCs during early innate response to DENV might help shape subsequent immune responses and potentially lessen the disease severity in the future.	[Poonpanichakul, Tiraput; Chan-In, Wilawan; Opasawatchai, Anunya; Loison, Fabien; Matangkasombut, Ponpan] Mahidol Univ, Dept Microbiol, Fac Sci, Bangkok, Thailand; [Poonpanichakul, Tiraput; Loison, Fabien; Charoensawan, Varodom; Matangkasombut, Ponpan] Mahidol Univ, Syst Biol Dis Res Unit, Fac Sci, Bangkok, Thailand; [Poonpanichakul, Tiraput] Mahidol Univ, Ramathibodi Hosp, Fac Med, Chakri Naruebodindra Med Inst, Samut Prakan, Thailand; [Chan-In, Wilawan] Navamindradhiraj Univ, Vajira Hosp, Fac Med, Dept Clin Pathol, Bangkok, Thailand; [Opasawatchai, Anunya] Mahidol Univ, Fac Dent, Bangkok, Thailand; [Matangkasombut, Oranart] Chulalongkorn Univ, Fac Dent, Dept Microbiol, Bangkok, Thailand; [Matangkasombut, Oranart] Chulalongkorn Univ, Res Unit Oral Microbiol & Immunol, Fac Dent, Bangkok, Thailand; [Matangkasombut, Oranart] Chulabhorn Res Inst, Lab Biotechnol, Bangkok, Thailand; [Charoensawan, Varodom] Mahidol Univ, Dept Biochem, Fac Sci, Bangkok, Thailand; [Charoensawan, Varodom] Mahidol Univ, Integrat Computat BioSci Ctr ICBS, Nakhon Pathom, Thailand	Mahidol University; Mahidol University; Mahidol University; Mahidol University; Chulalongkorn University; Chulalongkorn University; Chulabhorn Research Institute; Mahidol University; Mahidol University	Matangkasombut, P (corresponding author), Mahidol Univ, Dept Microbiol, Fac Sci, Bangkok, Thailand.; Matangkasombut, P (corresponding author), Mahidol Univ, Syst Biol Dis Res Unit, Fac Sci, Bangkok, Thailand.	ponpan.mat@mahidol.edu		Chan-in, Wilawan/0000-0002-1008-3052	European Union Seventh Framework Program [282378]; DENFREE Thailand; Anandamahidol foundation; Thailand Research Fund [TRG5880121, MRG6080235]; Royal Society-Newton Mobility Grant through the Office of Higher Education (Thailand) [NI170094]; Royal Society (UK); Newton Advanced Fellowship through Thailand Research Fund [DBG60800003]; Royal Society [NA160153]; Faculty of Science, Mahidol University; Thailand Science Research and Innovation (TSRI) [PHD/0115/2558]; Mahidol University	European Union Seventh Framework Program(European Commission); DENFREE Thailand; Anandamahidol foundation; Thailand Research Fund(Thailand Research Fund (TRF)); Royal Society-Newton Mobility Grant through the Office of Higher Education (Thailand); Royal Society (UK)(Royal Society of London); Newton Advanced Fellowship through Thailand Research Fund; Royal Society(Royal Society of London); Faculty of Science, Mahidol University; Thailand Science Research and Innovation (TSRI); Mahidol University	This work was supported by European Union Seventh Framework Program (EU/FP7 under Grant Agreement #282378 (DENFREE) to PM and DENFREE Thailand. The PM lab was supported by Anandamahidol foundation, Thailand Research Fund Grant for New Scholar (TRG5880121) and Royal Society-Newton Mobility Grant (NI170094) through the Office of Higher Education (Thailand) and the Royal Society (UK). The VC lab was supported by the Newton Advanced Fellowship through Thailand Research Fund (DBG60800003) and Royal Society (NA160153), and the Thailand Research Fund Grant for New Scholar (MRG6080235). TP was supported by the Scholarship for Young Scientists (2017), Faculty of Science, Mahidol University. This research project was supported by Mahidol University (Basic Research Fund: fiscal year 2021). WC was supported by The Royal Golden Jubilee (RGJ) Ph.D. Program Scholarship (Grant No. PHD/0115/2558) from Thailand Science Research and Innovation (TSRI).	Afonina IS, 2010, IMMUNOL REV, V235, P105, DOI 10.1111/j.0105-2896.2010.00908.x; An ZW, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03111; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Avirutnan P, 2013, ELIFE, V2, DOI 10.7554/eLife.00767; Bal SM, 2020, NAT REV IMMUNOL, V20, P552, DOI 10.1038/s41577-020-0282-9; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86; Bruchard M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00656; Cai T, 2019, J ALLERGY CLIN IMMUN, V143, P229, DOI 10.1016/j.jaci.2018.03.007; Carvelli J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02179; Chan KR, 2014, P NATL ACAD SCI USA, V111, P2722, DOI 10.1073/pnas.1317454111; Cubero FJ, 2012, AM J PHYSIOL-GASTR L, V303, pG228, DOI 10.1152/ajpgi.00465.2011; DeDiego ML, 2019, J VIROL, V93, DOI 10.1128/JVI.01159-19; Dengue research Framework for Resisting Epidemics in Europe, DENFR PROJ FP7 CORDI; Duangchinda T, 2010, P NATL ACAD SCI USA, V107, P16922, DOI 10.1073/pnas.1010867107; Duerr CU, 2016, NAT IMMUNOL, V17, P65, DOI 10.1038/ni.3308; Duong V, 2015, P NATL ACAD SCI USA, V112, P14688, DOI 10.1073/pnas.1508114112; Eberl G, 2015, SCIENCE, V348, DOI 10.1126/science.aaa6566; Ebihara T, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051193; Fensterl V, 2015, J VIROL, V89, P2462, DOI 10.1128/JVI.02744-14; Gladiator A, 2013, J IMMUNOL, V190, P521, DOI 10.4049/jimmunol.1202924; Gorski SA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003615; Green AM, 2014, J MOL BIOL, V426, P1148, DOI 10.1016/j.jmb.2013.11.023; Grifoni A, 2020, IMMUNOLOGY, V160, P3, DOI 10.1111/imm.13161; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Guia S, 2020, TRENDS IMMUNOL, V41, P436, DOI 10.1016/j.it.2020.03.002; Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3; HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154; Halstead SB, 2018, HUM VACC IMMUNOTHER, V14, P2158, DOI 10.1080/21645515.2018.1445448; Han MY, 2017, AM J RESP CELL MOL, V56, P242, DOI 10.1165/rcmb.2016-0056OC; Hazenberg MD, 2014, BLOOD, V124, P700, DOI 10.1182/blood-2013-11-427781; Helfrich S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00930; Hernandez PP, 2015, NAT IMMUNOL, V16, P698, DOI 10.1038/ni.3180; Hirose S, 2019, J VIROL, V93, DOI 10.1128/JVI.00523-19; Hong JY, 2014, J ALLERGY CLIN IMMUN, V134, P429, DOI 10.1016/j.jaci.2014.04.020; Ising R, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010010; Jurak LM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01895; Kamaladasa A, 2016, CLIN EXP IMMUNOL, V185, P228, DOI 10.1111/cei.12778; Kao YT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02860; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; King CA, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.574417; Klose CSN, 2014, CELL, V157, P340, DOI 10.1016/j.cell.2014.03.030; Kloverpris HN, 2016, IMMUNITY, V44, P391, DOI 10.1016/j.immuni.2016.01.006; LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992; Li BWS, 2019, EUR J IMMUNOL, V49, P144, DOI 10.1002/eji.201747421; Li S, 2019, J ALLERGY CLIN IMMUN, V143, P2321, DOI 10.1016/j.jaci.2019.01.047; Liu H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02479; Long TH, 2010, J VIROL, V84, P12982, DOI 10.1128/JVI.01224-10; Loser S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00620; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mangada MM, 2005, J IMMUNOL, V175, P2676, DOI 10.4049/jimmunol.175.4.2676; Matangkasombut P, 2020, INT J INFECT DIS, V101, P90, DOI 10.1016/j.ijid.2020.09.1446; Matangkasombut P, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002955; McMahon SB, 1996, J LEUKOCYTE BIOL, V60, P159, DOI 10.1002/jlb.60.2.159; Merlotti FR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00910; Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Morita H, 2016, J ALLERGY CLIN IMMUN, V138, P1253, DOI 10.1016/j.jaci.2016.09.011; Murphy BR, 2011, ANNU REV IMMUNOL, V29, P587, DOI 10.1146/annurev-immunol-031210-101315; Panda SK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00861; Paquin-Proulx D, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006154; Parodi M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00719; Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122; Picarda G, 2019, J VIROL, V93, DOI 10.1128/JVI.00617-19; Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006; Rahman MA, 2019, J IMMUNOL, V203, P2459, DOI 10.4049/jimmunol.1900572; Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226; Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014; Roy S, 2019, VACCINE, V37, P1266, DOI 10.1016/j.vaccine.2019.01.045; SANGKAWIBHA N, 1984, AM J EPIDEMIOL, V120, P653, DOI 10.1093/oxfordjournals.aje.a113932; Saravia J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005217; Satoh-Takayama N, 2020, IMMUNITY, V52, P635, DOI 10.1016/j.immuni.2020.03.002; Schmid MA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00647; Screaton G, 2015, NAT REV IMMUNOL, V15, P745, DOI 10.1038/nri3916; Shikhagaie MM, 2017, NAT REV RHEUMATOL, V13, P164, DOI 10.1038/nrrheum.2016.218; Shin HJ, 2009, CLIN IMMUNOL, V131, P385, DOI 10.1016/j.clim.2009.02.009; Silver JS, 2016, NAT IMMUNOL, V17, P626, DOI 10.1038/ni.3443; Sonnenberg GE, 2019, NAT REV IMMUNOL, V19, P599, DOI 10.1038/s41577-019-0194-8; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Spits H, 2011, NAT IMMUNOL, V12, P21, DOI 10.1038/ni.1962; Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820; St John AL, 2019, NAT REV IMMUNOL, V19, P218, DOI 10.1038/s41577-019-0123-x; St John AL, 2011, P NATL ACAD SCI USA, V108, P9190, DOI 10.1073/pnas.1105079108; Stier MT, 2017, ANN ALLERG ASTHMA IM, V119, P480, DOI 10.1016/j.anai.2017.08.290; Stier MT, 2017, J IMMUNOL, V199, P510, DOI 10.4049/jimmunol.1601984; Stier MT, 2016, J ALLERGY CLIN IMMUN, V138, P814, DOI 10.1016/j.jaci.2016.01.050; Sun PF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002298; Tian Y, 2019, CELL REP, V29, P4482, DOI 10.1016/j.celrep.2019.11.098; Tian Y, 2019, J CLIN INVEST, V129, P1727, DOI 10.1172/JCI123726; Ubol S, 2008, J INFECT DIS, V197, P1459, DOI 10.1086/587699; Uno N, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0168-0; Vacca P, 2019, MUCOSAL IMMUNOL, V12, P624, DOI 10.1038/s41385-019-0141-9; Vallentin B, 2015, CANCER IMMUNOL RES, V3, P1109, DOI 10.1158/2326-6066.CIR-15-0222; van Wilgenburg B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11653; Vashist N, 2018, FRONT IMMUNOL, V9, DOI [10.3389/fimmu.2018.00505, 10.3389/fiimmu.2018.00505]; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Wagner M, 2019, TRENDS IMMUNOL, V40, P415, DOI 10.1016/j.it.2019.03.004; Watkinson RE, 2013, J VIROL, V87, P7309, DOI 10.1128/JVI.00647-13; Weizman OE, 2019, NAT IMMUNOL, V20, P1004, DOI 10.1038/s41590-019-0430-1; Weizman OE, 2017, CELL, V171, P795, DOI 10.1016/j.cell.2017.09.052; WHO, 2011, EUR CTR ENV HLTH BUR; World Health Organization, 2010, PROGR SAN DRINK WAT, P6; Xiong TT, 2018, SEMIN IMMUNOPATHOL, V40, P393, DOI 10.1007/s00281-018-0670-4; Xu H, 2012, MUCOSAL IMMUNOL, V5, P658, DOI 10.1038/mi.2012.39; Yang K, 2009, J IMMUNOL, V182, P3782, DOI 10.4049/jimmunol.0803126; Zhou SQ, 2020, CELL MOL IMMUNOL, V17, P335, DOI 10.1038/s41423-020-0399-6; Zhu AQ, 2019, BIOINFORMATICS, V35, P2084, DOI 10.1093/bioinformatics/bty895; Zimmer CL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11878-3	111	1	1	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 17	2021	12								599805	10.3389/fimmu.2021.599805	http://dx.doi.org/10.3389/fimmu.2021.599805			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SK3QW	34079535	gold, Green Published			2022-12-18	WOS:000656134400001
J	Sohn, M; Na, HY; Shin, HS; Ryu, SH; Park, S; In, H; Choi, W; Park, JS; Hwang, S; Chu, MK; Park, CG				Sohn, Moah; Na, Hye Young; Shin, Hyun Soo; Ryu, Seul Hye; Park, Sejung; In, Hyunju; Choi, Wanho; Park, Ji Soo; Hwang, Soomin; Chu, Min Kyung; Park, Chae Gyu			Global Gene Expression of T Cells Is Differentially Regulated by Peritoneal Dendritic Cell Subsets in an IL-2 Dependent Manner	FRONTIERS IN IMMUNOLOGY			English	Article						antigen presentation; dendritic cell; interleukin-2; peritoneal cavity; T cell - DC interactions	ACTIVATION; EFFECTOR; CULTURE	Dendritic cells (DCs) in peripheral tissues may have a unique role to regulate innate and adaptive immune responses to antigens that enter the tissues. Peritoneal cavity is the body compartment surrounding various tissues and organs and housing diverse immune cells. Here, we investigated the specialized features of classical DC (cDC) subsets following the intraperitoneal injection of a model antigen ovalbumin (OVA). Peritoneal cDC1s were superior to cDC2s in activating OVA-specific CD8 T cells, while both cDCs were similar in stimulating OVA-specific CD4 T cells. Each peritoneal cDC subset differentially regulated the homing properties of CD8 T cells. CD8 T cells stimulated by cDC1s displayed a higher level of lung-homing receptor CCR4, whereas those stimulated by cDC2s prominently expressed various homing receptors including gut-homing molecules CCR9 and alpha 4 beta 7. Also, we found that cDC1s played a dominating role over cDC2s in controlling the overall gene expression of CD8 T cells. Soluble factor(s) emanating from CD8 T cells stimulated by peritoneal cDC1s were responsible for mediating this dominance of cDC1s, and we identified IL-2 as a soluble factor regulating the global gene expression of T cells. Collectively, our study indicates that different peritoneal cDC subsets effectively diversify T cell responses by altering the level of cytokines, such as IL-2, in the milieu.	[Sohn, Moah; Na, Hye Young; Shin, Hyun Soo; Ryu, Seul Hye; Park, Sejung; In, Hyunju; Choi, Wanho; Park, Ji Soo; Hwang, Soomin; Park, Chae Gyu] Yonsei Univ, Coll Med, Severance Biomed Sci Inst, Lab Immunol, Seoul, South Korea; [Sohn, Moah; Shin, Hyun Soo; Ryu, Seul Hye; Park, Sejung; In, Hyunju; Choi, Wanho; Park, Ji Soo; Hwang, Soomin; Park, Chae Gyu] Yonsei Univ, Coll Med, Brain Korea 21 FOUR Project Med Sci, Seoul, South Korea; [Na, Hye Young; Chu, Min Kyung] Yonsei Univ, Coll Med, Severance Hosp, Dept Neurol, Seoul, South Korea; [Park, Chae Gyu] GENUV Inc, Therapeut Antibody Res Ctr, Seoul, South Korea; [Park, Chae Gyu] Yonsei Univ, Coll Med, Inst Immunol & Immunol Dis, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Park, CG (corresponding author), Yonsei Univ, Coll Med, Severance Biomed Sci Inst, Lab Immunol, Seoul, South Korea.; Park, CG (corresponding author), Yonsei Univ, Coll Med, Brain Korea 21 FOUR Project Med Sci, Seoul, South Korea.; Park, CG (corresponding author), GENUV Inc, Therapeut Antibody Res Ctr, Seoul, South Korea.; Park, CG (corresponding author), Yonsei Univ, Coll Med, Inst Immunol & Immunol Dis, Seoul, South Korea.	ChaeGyu@yuhs.ac		Shin, Hyun Soo/0000-0001-7967-5577; Chu, Min Kyung/0000-0001-6221-1346; Park, Chae Gyu/0000-0003-1906-1308	National Research Foundation of Korea [2017M3A9C8064887, 2019R1F1A1041700, 2017R1A6A3A11028388, 2019R1F1A1053841]; "Dongwha" Faculty Research Assistance Program of the Yonsei University College of Medicine [6-2020-0111]; Brain Korea 21 PLUS/FOUR Project for Medical Science, Yonsei University	National Research Foundation of Korea(National Research Foundation of Korea); "Dongwha" Faculty Research Assistance Program of the Yonsei University College of Medicine; Brain Korea 21 PLUS/FOUR Project for Medical Science, Yonsei University	We were supported by grants from theNational Research Foundation of Korea to CP (2017M3A9C8064887, 2019R1F1A1041700), HYN (2017R1A6A3A11028388), and MC (2019R1F1A1053841), the "Dongwha" Faculty Research Assistance Program of the Yonsei University College of Medicine to CP (6-2020-0111), and the Brain Korea 21 PLUS/FOUR Project for Medical Science, Yonsei University.	Bain CC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11852; Beaten BJG, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00311; Bosteels C, 2020, IMMUNITY, V52, P1039, DOI 10.1016/j.immuni.2020.04.005; Ghosn EEB, 2010, P NATL ACAD SCI USA, V107, P2568, DOI 10.1073/pnas.0915000107; Boyman O, 2006, SCIENCE, V311, P1924, DOI 10.1126/science.1122927; Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Brinkman CC, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00241; Cho JH, 2013, J IMMUNOL, V191, P5559, DOI 10.4049/jimmunol.1302293; Clausen BE, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00534; Feau S, 2011, NAT IMMUNOL, V12, P908, DOI 10.1038/ni.2079; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Helft J, 2015, IMMUNITY, V42, P1197, DOI 10.1016/j.immuni.2015.05.018; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Johansson-Lindbom B, 2005, J EXP MED, V202, P1063, DOI 10.1084/jem.20051100; Kallies A, 2009, IMMUNITY, V31, P283, DOI 10.1016/j.immuni.2009.06.021; Kawabe T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17136-1; Kim KW, 2016, J EXP MED, V213, P1951, DOI 10.1084/jem.20160486; Kim TG, 2018, J INVEST DERMATOL, V138, P844, DOI 10.1016/j.jid.2017.11.003; Konkel JE, 2011, TRENDS MOL MED, V17, P668, DOI 10.1016/j.molmed.2011.07.002; Lamb CA, 2018, J CROHNS COLITIS, V12, pS653, DOI 10.1093/ecco-jcc/jjy060; Liao W, 2013, IMMUNITY, V38, P13, DOI 10.1016/j.immuni.2013.01.004; Mac Sharry J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098648; Mansouri S, 2020, MUCOSAL IMMUNOL, V13, P595, DOI 10.1038/s41385-020-0254-1; Mauffray M, 2015, J IMMUNOL, V194, P1423, DOI 10.4049/jimmunol.1402496; Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950; Mikhak Z, 2013, J EXP MED, V210, P1855, DOI 10.1084/jem.20130091; Mildner A, 2014, IMMUNITY, V40, P642, DOI 10.1016/j.immuni.2014.04.016; Miller JC, 2012, NAT IMMUNOL, V13, P888, DOI 10.1038/ni.2370; Mora JR, 2003, NATURE, V424, P88, DOI 10.1038/nature01726; Raeber ME, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aba5464; Ruane D, 2016, J EXP MED, V213, P53, DOI 10.1084/jem.20150567; Ryu SH, 2017, IMMUNOL LETT, V188, P96, DOI 10.1016/j.imlet.2017.06.010; Ryu SH, 2016, IMMUNOL LETT, V173, P7, DOI 10.1016/j.imlet.2016.03.003; Sela U, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146412; Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982; Shin HS, 2022, ASIAN PAC J ALLERGY, V40, P111, DOI [10.12932/ap-301219-0729, 10.12932/AP-301219-0729]; Sichien D, 2017, MUCOSAL IMMUNOL, V10, P831, DOI 10.1038/mi.2017.8; Singer M, 2016, CELL, V166, P1500, DOI 10.1016/j.cell.2016.08.052; Soares H, 2007, J EXP MED, V204, P1095, DOI 10.1084/jem.20070176; Sohn M, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e15; Steinman RM, 2012, ANNU REV IMMUNOL, V30, P1, DOI 10.1146/annurev-immunol-100311-102839; STEINMAN RM, 1978, P NATL ACAD SCI USA, V75, P5132, DOI 10.1073/pnas.75.10.5132; Travis MA, 2014, ANNU REV IMMUNOL, V32, P51, DOI 10.1146/annurev-immunol-032713-120257; Varol C, 2009, IMMUNITY, V31, P502, DOI 10.1016/j.immuni.2009.06.025; Villablanca EJ, 2011, GASTROENTEROLOGY, V140, P1776, DOI 10.1053/j.gastro.2011.02.015; Williams MA, 2006, NATURE, V441, P890, DOI 10.1038/nature04790; Wuest SC, 2011, NAT MED, V17, P604, DOI 10.1038/nm.2365; Xin A, 2016, NAT IMMUNOL, V17, P422, DOI 10.1038/ni.3410; Zhang N, 2013, IMMUNITY, V39, P687, DOI 10.1016/j.immuni.2013.08.019	51	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 17	2021	12								648348	10.3389/fimmu.2021.648348	http://dx.doi.org/10.3389/fimmu.2021.648348			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SK3RC	34079542	Green Published, gold			2022-12-18	WOS:000656135000001
J	Won, HY; Kim, HK; Crossman, A; Awasthi, P; Gress, RE; Park, JH				Won, Hee Yeun; Kim, Hye Kyung; Crossman, Assiatu; Awasthi, Parirokh; Gress, Ronald E.; Park, Jung-Hyun			The Timing and Abundance of IL-2R beta (CD122) Expression Control Thymic iNKT Cell Generation and NKT1 Subset Differentiation	FRONTIERS IN IMMUNOLOGY			English	Article						cytokines; IL-2 (interleukin-2); IL-15; Tbet; thymocytes	NATURAL-KILLER; SIGNAL STRENGTH; T-CELLS; PLZF	Invariant NKT (iNKT) cells are thymus-generated innate-like T cells, comprised of three distinct subsets with divergent effector functions. The molecular mechanism that drives the lineage trifurcation of immature iNKT cells into the NKT1, NKT2, and NKT17 subsets remains a controversial issue that remains to be resolved. Because cytokine receptor signaling is necessary for iNKT cell generation, cytokines are proposed to contribute to iNKT subset differentiation also. However, the precise roles and requirements of cytokines in these processes are not fully understood. Here, we show that IL-2R beta, a nonredundant component of the IL-15 receptor complex, plays a critical role in both the development and differentiation of thymic iNKT cells. While the induction of IL-2R beta expression on postselection thymocytes is necessary to drive the generation of iNKT cells, surprisingly, premature IL-2R beta expression on immature iNKT cells was detrimental to their development. Moreover, while IL-2R beta is necessary for NKT1 generation, paradoxically, we found that the increased abundance of IL-2R beta suppressed NKT1 generation without affecting NKT2 and NKT17 cell differentiation. Thus, the timing and abundance of IL-2R beta expression control iNKT lineage fate and development, thereby establishing cytokine receptor expression as a critical regulator of thymic iNKT cell differentiation.	[Won, Hee Yeun; Crossman, Assiatu; Park, Jung-Hyun] NCI, Expt Immunol Branch, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA; [Kim, Hye Kyung; Gress, Ronald E.] NCI, Expt Transplantat & Immunotherapy Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Awasthi, Parirokh] Leidos Biomed Res Inc, Lab Anim Sci Program, Frederick Natl Lab Canc Res, Frederick, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Park, JH (corresponding author), NCI, Expt Immunol Branch, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA.	parkhy@mail.nih.gov			Intramural Research Program of the US National Institutes of Health, National Cancer Institute, Center for Cancer Research	Intramural Research Program of the US National Institutes of Health, National Cancer Institute, Center for Cancer Research	We thank Drs. Joo-Young Park (Seoul National University) and Damian Kovalovsky (National Cancer Institute, NIH) for critical review and discussion of this manuscript. This study has been supported by the Intramural Research Program of the US National Institutes of Health, National Cancer Institute, Center for Cancer Research.	Benlagha K, 2002, SCIENCE, V296, P553, DOI 10.1126/science.1069017; Burchill MA, 2003, J IMMUNOL, V171, P5853, DOI 10.4049/jimmunol.171.11.5853; Catlett IM, 2005, NAT IMMUNOL, V6, P715, DOI 10.1038/ni1211; Cheng GY, 2013, J IMMUNOL, V190, P1567, DOI 10.4049/jimmunol.1201218; Chinen T, 2016, NAT IMMUNOL, V17, P1322, DOI 10.1038/ni.3540; Dashtsoodol N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00841; Dickgreber N, 2012, J LEUKOCYTE BIOL, V92, P999, DOI 10.1189/jlb.0512242; Etzensperger R, 2017, NAT IMMUNOL, V18, P1218, DOI 10.1038/ni.3847; Fehniger TA, 2001, J EXP MED, V193, P219, DOI 10.1084/jem.193.2.219; Gapin L, 2016, CURR OPIN IMMUNOL, V39, P68, DOI 10.1016/j.coi.2016.01.001; Gioulbasani M, 2020, NAT IMMUNOL, V21, P1058, DOI 10.1038/s41590-020-0737-y; Gordy LE, 2011, J IMMUNOL, V187, P6335, DOI 10.4049/jimmunol.1003965; Hemmers S, 2019, J EXP MED, V216, P2466, DOI 10.1084/jem.20190993; Hogquist Kristin, 2020, F1000Res, V9, DOI 10.12688/f1000research.21378.1; Hong CW, 2012, SEMIN IMMUNOL, V24, P151, DOI 10.1016/j.smim.2012.02.002; Johnston RJ, 2012, J EXP MED, V209, P243, DOI 10.1084/jem.20111174; Kadakia T, 2019, J EXP MED, V216, P1749, DOI 10.1084/jem.20182285; Keller HR, 2020, J IMMUNOL, V204, P3227, DOI 10.4049/jimmunol.1901276; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Kovalovsky D, 2010, J IMMUNOL, V184, P6746, DOI 10.4049/jimmunol.1000776; Krovi SH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01393; Kwon DI, 2017, IMMUNE NETW, V17, P365, DOI 10.4110/in.2017.17.6.365; Lazarevic V, 2009, NAT IMMUNOL, V10, P306, DOI 10.1038/ni.1696; Lee YJ, 2013, NAT IMMUNOL, V14, P1146, DOI 10.1038/ni.2731; Lin JX, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028449; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Lucas B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16041-x; Minagawa M, 2002, J IMMUNOL, V169, P4153, DOI 10.4049/jimmunol.169.8.4153; Monteiro M, 2013, J IMMUNOL, V190, P805, DOI 10.4049/jimmunol.1201010; Nurieva RI, 2012, J BIOL CHEM, V287, P11234, DOI 10.1074/jbc.M111.324046; Ohteki T, 1997, J IMMUNOL, V159, P5931; Park JY, 2019, CELL REP, V27, P2548, DOI 10.1016/j.celrep.2019.05.012; Park JY, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e14; Park JY, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e13; Park JY, 2016, SCI REP-UK, V6, DOI 10.1038/srep36962; Park JH, 2010, NAT IMMUNOL, V11, P257, DOI 10.1038/ni.1840; Raberger J, 2008, P NATL ACAD SCI USA, V105, P17919, DOI 10.1073/pnas.0805733105; Ranson T, 2003, BLOOD, V101, P4887, DOI 10.1182/blood-2002-11-3392; Sarafova SD, 2009, IMMUNITY, V31, P480, DOI 10.1016/j.immuni.2009.07.006; Seiler MP, 2012, NAT IMMUNOL, V13, P264, DOI 10.1038/ni.2230; Soper DM, 2007, EUR J IMMUNOL, V37, P1817, DOI 10.1002/eji.200737101; Spolski R, 2018, NAT REV IMMUNOL, V18, P648, DOI 10.1038/s41577-018-0046-y; SUWA H, 1995, INT IMMUNOL, V7, P1441, DOI 10.1093/intimm/7.9.1441; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Tuttle KD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05026-6; Vidalain PO, 2002, J VIROL, V76, P6415, DOI 10.1128/JVI.76.13.6415-6424.2002; Waickman AT, 2017, CYTOKINE, V99, P266, DOI 10.1016/j.cyto.2017.08.004; Walker SR, 2007, ONCOGENE, V26, P224, DOI 10.1038/sj.onc.1209775; Wang HG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01450; Weinreich MA, 2010, NAT IMMUNOL, V11, P709, DOI 10.1038/ni.1898; White AJ, 2014, J IMMUNOL, V192, P2659, DOI 10.4049/jimmunol.1303057; Yao ZJ, 2006, P NATL ACAD SCI USA, V103, P1000, DOI 10.1073/pnas.0507350103; Zhang S, 2015, SCI REP-UK, V5, DOI 10.1038/srep12113; Zhu JF, 2012, IMMUNITY, V37, P660, DOI 10.1016/j.immuni.2012.09.007	54	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 14	2021	12								642856	10.3389/fimmu.2021.642856	http://dx.doi.org/10.3389/fimmu.2021.642856			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SJ6HO	34054809	Green Published, gold			2022-12-18	WOS:000655634000001
J	Gogoleva, VS; Atretkhany, KSN; Dygay, AP; Yurakova, TR; Drutskaya, MS; Nedospasov, SA				Gogoleva, Violetta S.; Atretkhany, Kamar-Sulu N.; Dygay, Arina P.; Yurakova, Taisiya R.; Drutskaya, Marina S.; Nedospasov, Sergei A.			Current Perspectives on the Role of TNF in Hematopoiesis Using Mice With Humanization of TNF/LT System	FRONTIERS IN IMMUNOLOGY			English	Article						cytokines; cytokine blockade; steady-state hematopoiesis; emergency hematopoiesis; humanized mouse models	NECROSIS-FACTOR TNF; CROHNS-DISEASE; ALPHA; INFLIXIMAB; INHIBITION; PROTECTS	TNF is a multifunctional cytokine with its key functions attributed to inflammation, secondary lymphoid tissue organogenesis and immune regulation. However, it is also a physiological regulator of hematopoiesis and is involved in development and homeostatic maintenance of various organs and tissues. Somewhat unexpectedly, the most important practical application of TNF biology in medicine is anti-TNF therapy in several autoimmune diseases. With increased number of patients undergoing treatment with TNF inhibitors and concerns regarding possible adverse effects of systemic cytokine blockade, the interest in using humanized mouse models to study the efficacy and safety of TNF-targeting biologics in vivo is justified. This Perspective discusses the main functions of TNF and its two receptors, TNFR1 and TNFR2, in steady state, as well as in emergency hematopoiesis. It also provides a comparative overview of existing mouse lines with humanization of TNF/TNFR system. These genetically engineered mice allow us to study TNF signaling cascades in the hematopoietic compartment in the context of various experimental disease models and for evaluating the effects of various human TNF inhibitors on hematopoiesis and other physiological processes.	[Gogoleva, Violetta S.; Atretkhany, Kamar-Sulu N.; Drutskaya, Marina S.; Nedospasov, Sergei A.] Russian Acad Sci, Ctr Precis Genome Editing & Genet Technol Biomed, Engelhardt Inst Mol Biol, Moscow, Russia; [Gogoleva, Violetta S.; Dygay, Arina P.; Yurakova, Taisiya R.; Drutskaya, Marina S.; Nedospasov, Sergei A.] Sirius Univ Sci & Technol, Dept Immunobiol & Biomed, Sirius, Russia; [Dygay, Arina P.; Yurakova, Taisiya R.] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow, Russia; [Dygay, Arina P.; Yurakova, Taisiya R.; Nedospasov, Sergei A.] Lomonosov Moscow State Univ, Fac Biol, Dept Immunol, Moscow, Russia	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Lomonosov Moscow State University	Gogoleva, VS (corresponding author), Russian Acad Sci, Ctr Precis Genome Editing & Genet Technol Biomed, Engelhardt Inst Mol Biol, Moscow, Russia.; Gogoleva, VS (corresponding author), Sirius Univ Sci & Technol, Dept Immunobiol & Biomed, Sirius, Russia.	violette.gogoleva@gmail.com			Ministry of Science and Higher Education of the Russian Federation [075-152019-1660];  [19-34-51030]	Ministry of Science and Higher Education of the Russian Federation; 	Reverse genetics studies were supported by the grant 075-152019-1660 from the Ministry of Science and Higher Education of the Russian Federation, myelopoiesis studies were supported by RFBR grant 19-34-51030.	Abegunde SO, 2018, EXP HEMATOL, V59, P60, DOI 10.1016/j.exphem.2017.11.002; Adams AE, 2004, J AM ACAD DERMATOL, V51, P660, DOI 10.1016/j.jaad.2004.03.047; Akassoglou K, 1997, J IMMUNOL, V158, P438; AlAskar D, 2020, SAUDI J GASTROENTERO, V26, P210, DOI 10.4103/sjg.SJG_41_20; Ameloot P, 2001, J BIOL CHEM, V276, P37426, DOI 10.1074/jbc.M102020200; Atretkhany KSN, 2020, J LEUKOCYTE BIOL, V107, P893, DOI 10.1002/JLB.2MR0120-510R; Atretkhany KSN, 2018, P NATL ACAD SCI USA, V115, P13051, DOI 10.1073/pnas.1807499115; Atretkhany KSN, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00147; Bessissow T, 2012, ALIMENT PHARM THER, V36, P312, DOI 10.1111/j.1365-2036.2012.05189.x; Bossen C, 2006, J BIOL CHEM, V281, P13964, DOI 10.1074/jbc.M601553200; Bowers E, 2018, NAT MED, V24, P95, DOI 10.1038/nm.4448; Broussais F, 2005, ANN RHEUM DIS, V64, P509, DOI 10.1136/ard.2004.021378; Brown SL, 2002, ARTHRITIS RHEUM-US, V46, P3151, DOI 10.1002/art.10679; Brunasso AMG, 2009, J AM ACAD DERMATOL, V60, P781, DOI 10.1016/j.jaad.2008.12.001; Bryder D, 2001, J EXP MED, V194, P941, DOI 10.1084/jem.194.7.941; Capocasale RJ, 2008, CYTOM PART A, V73A, P148, DOI 10.1002/cyto.a.20512; CAUX C, 1991, BLOOD, V78, P635; D'Haens G, 2017, J CROHNS COLITIS, V11, P680, DOI 10.1093/ecco-jcc/jjw221; Dar S, 1999, EUR J HAEMATOL, V62, P90; Dong Y, 2016, P NATL ACAD SCI USA, V113, P12304, DOI 10.1073/pnas.1605195113; Drize NI, 2000, B EXP BIOL MED+, V130, P676, DOI 10.1007/BF02682103; Drutskaya MS, 2020, J LEUKOCYTE BIOL, V107, P933, DOI 10.1002/JLB.3AB0120-532R; Drutskaya MS, 2005, EXP HEMATOL, V33, P1348, DOI 10.1016/j.exphem.2005.08.001; Dufour C, 2003, BLOOD, V102, P2053, DOI 10.1182/blood-2003-01-0114; Dzierzak E, 2018, CELL STEM CELL, V22, P639, DOI 10.1016/j.stem.2018.04.015; Efimov GA, 2016, P NATL ACAD SCI USA, V113, P3006, DOI 10.1073/pnas.1520175113; Espin-Palazon R, 2014, CELL, V159, P1070, DOI 10.1016/j.cell.2014.10.031; Etzrodt M, 2019, BLOOD, V133, P816, DOI 10.1182/blood-2018-02-832998; Favalli EG, 2005, CLIN EXP RHEUMATOL, V23, P247; Feletar M, 2004, ANN RHEUM DIS, V63, P156, DOI 10.1136/ard.2003.006775; Feltelius N, 2005, ANN RHEUM DIS, V64, P246, DOI 10.1136/ard.2004.023473; Gerloni V, 2008, ANN RHEUM DIS, V67, P1145, DOI 10.1136/ard.2007.069484; Gersuk GR, 1998, BRIT J HAEMATOL, V103, P176, DOI 10.1046/j.1365-2141.1998.00933.x; Gorshkova E A, 2019, Mol Biol (Mosk), V53, P755, DOI 10.1134/S0026898419050070; Gorth DJ, 2018, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1246-x; Hamaguchi M, 2007, CLIN RHEUMATOL, V26, P988, DOI 10.1007/s10067-006-0229-y; Haroon M, 2012, CLIN RHEUMATOL, V31, P151, DOI 10.1007/s10067-011-1822-2; Hastings R, 2010, ARTHRIT CARE RES, V62, P764, DOI 10.1002/acr.20037; Hayward Michael D., 2007, BMC Physiology, V7, P13, DOI 10.1186/1472-6793-7-13; He QP, 2015, BLOOD, V125, P1098, DOI 10.1182/blood-2014-09-601542; Ishida T, 2017, STEM CELLS, V35, P989, DOI 10.1002/stem.2524; Itkin T, 2016, NATURE, V532, P323, DOI 10.1038/nature17624; JACOBSEN FW, 1994, P NATL ACAD SCI USA, V91, P10695, DOI 10.1073/pnas.91.22.10695; Kalliolias GD, 2016, NAT REV RHEUMATOL, V12, P49, DOI 10.1038/nrrheum.2015.169; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KONDO K, 1994, P NATL ACAD SCI USA, V91, P11879, DOI 10.1073/pnas.91.25.11879; Kozak N, 2014, DRUGS R&D, V14, P155, DOI 10.1007/s40268-014-0050-z; Kruglov AA, 2011, ADV EXP MED BIOL, V691, P421, DOI 10.1007/978-1-4419-6612-4_44; Kucka K, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03633-8; Kunisaki Y, 2013, NATURE, V502, P637, DOI 10.1038/nature12612; Kuruvilla J, 2003, EUR J HAEMATOL, V71, P396, DOI 10.1034/j.1600-0609.2003.00115.x; Levalampi T, 2008, RHEUMATOL INT, V28, P261, DOI 10.1007/s00296-007-0436-0; Li Y, 2014, GENE DEV, V28, P2597, DOI 10.1101/gad.253302.114; Liepinsh DJ, 2009, EUR J IMMUNOL, V39, P2906, DOI 10.1002/eji.200839191; Marchesoni A, 2003, RHEUMATOLOGY, V42, P193, DOI 10.1093/rheumatology/key051; Mead AJ, 2017, J EXP MED, V214, P2005, DOI 10.1084/jem.20161418; Menon Y, 2003, RHEUMATOLOGY, V42, P1273, DOI 10.1093/rheumatology/keg341; Mocciaro F, 2013, INFLAMM BOWEL DIS, V19, pE52, DOI 10.1002/ibd.22989; Montane E, 2007, CLIN RHEUMATOL, V26, P1527, DOI 10.1007/s10067-006-0415-y; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; Nagai Y, 2006, IMMUNITY, V24, P801, DOI 10.1016/j.immuni.2006.04.008; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; Olleros ML, 2015, INFECT IMMUN, V83, P3612, DOI 10.1128/IAI.00743-15; Ottaviani S, 2009, JOINT BONE SPINE, V76, P312, DOI 10.1016/j.jbspin.2008.09.017; Pathare SK, 2006, RHEUMATOLOGY, V45, P1313, DOI 10.1093/rheumatology/kel204; Pearl-Yafe M, 2010, STEM CELLS, V28, P1270, DOI 10.1002/stem.448; Pietras EM, 2017, BLOOD, V130, P1693, DOI 10.1182/blood-2017-06-780882; Pietras EM, 2016, NAT CELL BIOL, V18, P607, DOI 10.1038/ncb3346; PROBERT L, 1993, J IMMUNOL, V151, P1894; Pronk CJH, 2011, J EXP MED, V208, P1563, DOI 10.1084/jem.20110752; Quartier P, 2003, ARTHRITIS RHEUM, V48, P1093, DOI 10.1002/art.10885; Rajakulendran S, 2006, ANN RHEUM DIS, V65, P1678, DOI 10.1136/ard.2006.056176; Rebel VI, 1999, J EXP MED, V190, P1493, DOI 10.1084/jem.190.10.1493; Retser E, 2013, ARTHRITIS RHEUM-US, V65, P2290, DOI 10.1002/art.38026; Rezzoug F, 2008, J IMMUNOL, V180, P49, DOI 10.4049/jimmunol.180.1.49; Rieger MA, 2009, SCIENCE, V325, P217, DOI 10.1126/science.1171461; ROUBENOFF R, 1994, J CLIN INVEST, V93, P2379, DOI 10.1172/JCI117244; Salar A, 2007, GUT, V56, P1169, DOI 10.1136/gut.2007.123547; Salles G, 1996, BRIT J HAEMATOL, V93, P352, DOI 10.1046/j.1365-2141.1996.5181059.x; Sanchez-Correa B, 2013, CYTOKINE, V61, P885, DOI 10.1016/j.cyto.2012.12.023; Sawamiphak S, 2014, DEV CELL, V31, P640, DOI 10.1016/j.devcel.2014.11.007; Seiderer J, 2004, DIGESTION, V70, P3, DOI 10.1159/000080075; Selby LA, 2004, INFLAMM BOWEL DIS, V10, P698, DOI 10.1097/00054725-200409000-00033; Steeland S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13984-y; Stinco G, 2008, ACTA DERM-VENEREOL, V88, P281, DOI 10.2340/00015555-0400; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Szalay B, 2011, JCR-J CLIN RHEUMATOL, V17, P377, DOI 10.1097/RHU.0b013e318231fd99; Takizawa H, 2012, BLOOD, V119, P2991, DOI 10.1182/blood-2011-12-380113; Theodoridou A, 2006, RHEUMATOL INT, V27, P201, DOI 10.1007/s00296-006-0187-3; Ueda Y, 2004, J EXP MED, V199, P47, DOI 10.1084/jem.20031104; Jimenez BV, 2020, GASTROENT HEPAT-BARC, V43, P28, DOI 10.1016/j.gastrohep.2019.07.003; Vidal F., 2003, ANN INTERN MED, V139, pW, DOI [10.7326/0003-4819-139-3-200308050-00021-w4, DOI 10.7326/0003-4819-139-3-200308050-00021-W4]; Vieites B, 2011, J CUTAN PATHOL, V38, P443, DOI 10.1111/j.1600-0560.2010.01663.x; Warzocha K, 1998, BRIT J CANCER, V77, P2357, DOI 10.1038/bjc.1998.391; Wenham C, 2008, RHEUMATOLOGY, V47, P376, DOI 10.1093/rheumatology/kem332; Williams SK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31957-7; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; Winsauer C, 2014, CYTOKINE GROWTH F R, V25, P115, DOI 10.1016/j.cytogfr.2013.12.005; Wolf Y, 2017, J EXP MED, V214, P905, DOI 10.1084/jem.20160499; Wolfe F, 2004, ARTHRITIS RHEUM-US, V50, P1740, DOI 10.1002/art.20311; Yamane T, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00080; Yamashita M, 2019, CELL STEM CELL, V25, P357, DOI 10.1016/j.stem.2019.05.019; ZHANG Y, 1995, BLOOD, V86, P2930; Zhao JL, 2014, CELL STEM CELL, V14, P445, DOI 10.1016/j.stem.2014.01.007	104	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2021	12								661900	10.3389/fimmu.2021.661900	http://dx.doi.org/10.3389/fimmu.2021.661900			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SI7AP	34054827	Green Published, gold			2022-12-18	WOS:000654979200001
J	Jiang, ZX; Zhang, YZ; Lin, HY; Cheng, QQ; Lu, XM; Liu, WK; Zhou, R; Zhong, BM; Tian, XG				Jiang, Zaixue; Zhang, Yaozhong; Lin, Huayuan; Cheng, Qingqiu; Lu, Xiaomei; Liu, Wenkuan; Zhou, Rong; Zhong, Baimao; Tian, Xingui			A 10-Day-Old Murine Model of Coxsackievirus A6 Infection for the Evaluation of Vaccines and Antiviral Drugs	FRONTIERS IN IMMUNOLOGY			English	Article						HFMD; coxsackievirus A6; murine model; antiviral therapy; vaccine	MOUTH-DISEASE; MOUSE MODEL; FOOT; HAND; CHINA	Coxsackievirus A6 (CVA6) is recognized as a major enterovirus type that can cause severe hand, foot, and mouth disease and spread widely among children. Vaccines and antiviral drugs may be developed more effectively based on a stable and easy-to-operate CVA6 mouse infection model. In this study, a wild CVA6-W strain was sub-cultured in newborn mice of different ages (in days), for adaptation. Therefore, a CVA6-A mouse-adapted strain capable of stably infecting the mice was generated, and a fatal model was built. As the result indicated, CVA6-A could infect the 10-day-old mice to generate higher levels of IFN-gamma, IL-6, and IL-10. The mice infected with CVA6-A were treated with IFN-alpha 1b at a higher dose, with complete protection. Based on this strain, an animal model with active immunization was built to evaluate antiviral protection by active immunization. The three-day-old mice were pre-immunized with inactivated CVA6 thereby generating IgM and IgG antibodies within 7 days that enabled complete protection of the pre-immunized mice following the CVA6 virus challenge. There were eight mutations in the genome of CVA6-A than in that of CVA6-W, possibly attributed to the virulence of CVA6 in mice. Briefly, the CVA6 infection model of the 10-day-old mice built herein, may serve as an applicable preclinical evaluation model for CVA6 antiviral drugs and vaccine study.	[Jiang, Zaixue; Lin, Huayuan; Liu, Wenkuan; Zhou, Rong; Tian, Xingui] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, Natl Clin Res Ctr Resp Dis,State Key Lab Resp Dis, Guangzhou, Peoples R China; [Jiang, Zaixue; Zhang, Yaozhong; Cheng, Qingqiu; Lu, Xiaomei; Zhong, Baimao] Guangdong Med Univ, Peoples Hosp Dongguan City 8, Dongguan Childrens Hosp, Dongguan Inst Paediat, Dongguan, Peoples R China	Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Guangdong Medical University	Tian, XG (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, Natl Clin Res Ctr Resp Dis,State Key Lab Resp Dis, Guangzhou, Peoples R China.; Zhong, BM (corresponding author), Guangdong Med Univ, Peoples Hosp Dongguan City 8, Dongguan Childrens Hosp, Dongguan Inst Paediat, Dongguan, Peoples R China.	zbm@dgp-institute.com; tianxingui7902@163.com		Tian, Xingui/0000-0001-9761-6677	National Key Research and Development Program of China [2018YFC1200100]; National Natural Science Foundation of China [82072264]; Natural Science Foundation of Guangdong Province [2019A1515011514]; Guangdong Medical Science Research Foundation [B2020187]; Independent Project of the State Key Laboratory of Respiratory Disease [SKLRD-Z-202113]; Post-doctoral Foundation of First Affiliated Hospital of Guangzhou Medical University	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangdong Medical Science Research Foundation; Independent Project of the State Key Laboratory of Respiratory Disease; Post-doctoral Foundation of First Affiliated Hospital of Guangzhou Medical University	Funding support was provided by the National Key Research and Development Program of China (2018YFC1200100) to XT, the National Natural Science Foundation of China (82072264) to XT, the Natural Science Foundation of Guangdong Province (2019A1515011514) to BZ, Guangdong Medical Science Research Foundation (B2020187) to BZ, the Independent Project of the State Key Laboratory of Respiratory Disease (SKLRD-Z-202113) to ZJ, and the Post-doctoral Foundation of First Affiliated Hospital of Guangzhou Medical University to ZJ.	Broccolo F, 2019, J CLIN VIROL, V110, P1, DOI 10.1016/j.jcv.2018.11.003; Caine EA, 2015, VIRUSES-BASEL, V7, P5919, DOI 10.3390/v7112916; Cao L, 2015, MOL MED REP, V12, P2473, DOI 10.3892/mmr.2015.3680; Chen JH, 2018, J VIROL, V92, DOI 10.1128/JVI.01257-17; Chen MM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188640; Chen XP, 2019, ARCH VIROL, V164, P2975, DOI 10.1007/s00705-019-04418-3; Chen XQ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/504563; Fu XM, 2020, VIROL SIN, V35, P21, DOI 10.1007/s12250-019-00169-2; Horsten HH, 2018, ACTA DERM-VENEREOL, V98, P350, DOI 10.2340/00015555-2853; Huo CL, 2017, VACCINE, V35, P7322, DOI 10.1016/j.vaccine.2017.10.101; Kimmis BD, 2018, CUTIS, V102, P353; Lee SY, 2016, VACCINE, V34, P3731, DOI 10.1016/j.vaccine.2016.06.008; Li J, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1253-1; Li JL, 2015, VIRUSES-BASEL, V7, P3891, DOI 10.3390/v7072803; Li SX, 2017, ANTIVIR RES, V144, P247, DOI 10.1016/j.antiviral.2017.06.008; Lim XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029751; Lin YW, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0052490, 10.1371/journal.pone.0030507]; Liu JN, 2020, VIROL J, V17, DOI 10.1186/s12985-020-01328-8; Liu JF, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-018-3624-5; Liu YJ, 2014, VIRUS GENES, V48, P260, DOI 10.1007/s11262-014-1035-2; Mao QY, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0186-y; Mao QY, 2012, J VIROL, V86, P11967, DOI 10.1128/JVI.00902-12; McBride JL, 2018, NEUROBIOL DIS, V119, P65, DOI 10.1016/j.nbd.2018.07.013; Anh NT, 2018, EMERG INFECT DIS, V24, P654, DOI 10.3201/eid2404.171298; Puenpa J, 2016, J GEN VIROL, V97, P3225, DOI 10.1099/jgv.0.000619; REED L. J., 1938, AMER JOUR HYG, V27, P493; Saguil A, 2019, AM FAM PHYSICIAN, V100, P408; Smee DF, 2016, ANTIVIR RES, V131, P61, DOI 10.1016/j.antiviral.2016.04.003; Song Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05618-0; Staring J, 2018, CELL HOST MICROBE, V23, P636, DOI 10.1016/j.chom.2018.03.019; THAKUR AK, 1981, DRUG CHEM TOXICOL, V4, P297, DOI 10.3109/01480548109018136; Tian H, 2012, MED PRIN PRACT, V21, P355, DOI 10.1159/000334619; Ventarola D, 2015, CLIN DERMATOL, V33, P340, DOI 10.1016/j.clindermatol.2014.12.011; Wang SY, 2020, HUM VACC IMMUNOTHER, V16, P1595, DOI 10.1080/21645515.2020.1711678; Wang YF, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-31; Wu YT, 2017, VACCINE, V35, P2728, DOI 10.1016/j.vaccine.2017.03.065; Xu J, 2018, J MED VIROL, V90, P1310, DOI 10.1002/jmv.25081; Xu LF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00477-9; Xu Y, 2017, ANTIVIR RES, V137, P67, DOI 10.1016/j.antiviral.2016.11.008; Yang CH, 2019, J VIROL, V93, DOI 10.1128/JVI.00183-19; Yang XH, 2020, INFECT GENET EVOL, V77, DOI 10.1016/j.meegid.2019.104054; Yeung ML, 2018, J CLIN INVEST, V128, P5163, DOI 10.1172/JCI99411; Yoshitomi H, 2018, J MED VIROL, V90, P1712, DOI 10.1002/jmv.25250; Zhai RW, 2018, CURR ALZHEIMER RES, V15, P1304, DOI 10.2174/1567205015666180904150118; Zhang C, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020058; Zhang W, 2018, EMERG MICROBES INFEC, V7, DOI [10.1038/S41426-018-0094-1, 10.1038/s41426-018-0094-1]; Zhang ZJ, 2019, EMERG MICROBES INFEC, V8, P1445, DOI 10.1080/22221751.2019.1673135; Zhang ZJ, 2017, J VIROL, V91, DOI 10.1128/JVI.02450-16; Zhao YG, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13936-2; Zhu FC, 2014, NEW ENGL J MED, V370, P818, DOI 10.1056/NEJMoa1304923	50	1	1	4	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2021	12								665197	10.3389/fimmu.2021.665197	http://dx.doi.org/10.3389/fimmu.2021.665197			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SI7AY	34054834	Green Published, gold			2022-12-18	WOS:000654980100001
J	Mai, HN; Caro, LFA; Cruz-Flores, R; White, BN; Dhar, AK				Mai, Hung N.; Caro, Luis Fernando Aranguren; Cruz-Flores, Roberto; White, Brenda Noble; Dhar, Arun K.			Differentially Expressed Genes in Hepatopancreas of Acute Hepatopancreatic Necrosis Disease Tolerant and Susceptible Shrimp (Penaeus vannamei)	FRONTIERS IN IMMUNOLOGY			English	Article						AHPND; Penaeus vannamei; AHPND tolerant P vannamei; shrimp immunity; immune genes	VIBRIO-PARAHAEMOLYTICUS; MELANIZATION; SYSTEM; AGENT; AHPND	Acute hepatopancreatic necrosis disease (AHPND) is a lethal disease in marine shrimp that has caused large-scale mortalities in shrimp aquaculture in Asia and the Americas. The etiologic agent is a pathogenic Vibrio sp. carrying binary toxin genes, pirA and pirB in plasmid DNA. Developing AHPND tolerant shrimp lines is one of the prophylactic approaches to combat this disease. A selected genetic line of Penaeus vannamei was found to be tolerant to AHPND during screening for disease resistance. The mRNA expression of twelve immune and metabolic genes known to be involved in bacterial pathogenesis were measured by quantitative RT-PCR in two populations of shrimp, namely P1 that showed susceptibility to AHPND, and P2 that showed tolerance to AHPND. Among these genes, the mRNA expression of chymotrypsin A (ChyA) and serine protease (SP), genes that are involved in metabolism, and crustin-P (CRSTP) and prophenol oxidase activation system 2 (PPAE2), genes involved in bacterial pathogenesis in shrimp, showed differential expression between the two populations. The differential expression of these genes shed light on the mechanism of tolerance against AHPND and these genes can potentially serve as candidate markers for tolerance/susceptibility to AHPND in P. vannamei. This is the first report of a comparison of the mRNA expression profiles of AHPND tolerant and susceptible lines of P. vannamei.	[Mai, Hung N.; Caro, Luis Fernando Aranguren; Cruz-Flores, Roberto; White, Brenda Noble; Dhar, Arun K.] Univ Arizona, Sch Anim & Comparat Biomed Sci, Aquaculture Pathol Lab, Tucson, AZ 85721 USA	University of Arizona	Dhar, AK (corresponding author), Univ Arizona, Sch Anim & Comparat Biomed Sci, Aquaculture Pathol Lab, Tucson, AZ 85721 USA.	adhar@email.arizona.edu			Aquaculture Pathology Laboratory Diagnostic Fund; USDA National Institute of Food and Agriculture, Hatch/Multistate project [1018120]	Aquaculture Pathology Laboratory Diagnostic Fund; USDA National Institute of Food and Agriculture, Hatch/Multistate project	Funding for this research was provided by Aquaculture Pathology Laboratory Diagnostic Fund. Part of this work is also supported by the USDA National Institute of Food and Agriculture, Hatch/Multistate project 1018120.	Amparyup P, 2013, FISH SHELLFISH IMMUN, V34, P990, DOI 10.1016/j.fsi.2012.08.019; Amparyup P, 2012, J BIOL CHEM, V287, P10060, DOI 10.1074/jbc.M111.294744; Apitanyasai K, 2020, DEV COMP IMMUNOL, V106, DOI 10.1016/j.dci.2019.103600; Caro LFA, 2020, J INVERTEBR PATHOL, V174, DOI 10.1016/j.jip.2020.107424; Beschin A, 1998, J BIOL CHEM, V273, P24948, DOI 10.1074/jbc.273.38.24948; Cerenius L, 2008, TRENDS IMMUNOL, V29, P263, DOI 10.1016/j.it.2008.02.009; Cerenius L, 2010, TRENDS BIOCHEM SCI, V35, P575, DOI 10.1016/j.tibs.2010.04.006; Chakravarthy N, 2012, DEV COMP IMMUNOL, V36, P751, DOI 10.1016/j.dci.2011.11.002; Charoensapsri W, 2011, DEV COMP IMMUNOL, V35, P115, DOI 10.1016/j.dci.2010.09.002; Charoensapsri W, 2009, DEV COMP IMMUNOL, V33, P811, DOI 10.1016/j.dci.2009.01.006; Cheng WT, 2005, FISH SHELLFISH IMMUN, V18, P297, DOI 10.1016/j.fsi.2004.08.002; Duran-Avelar MD, 2018, J FISH DIS, V41, P1667, DOI 10.1111/jfd.12874; de la Pena LD, 2015, DIS AQUAT ORGAN, V116, P251, DOI 10.3354/dao02919; Destoumieux D, 1999, EUR J BIOCHEM, V266, P335, DOI 10.1046/j.1432-1327.1999.00855.x; Dhar AK, 2019, DIS AQUAT ORGAN, V132, P241, DOI 10.3354/dao03330; DUVIC B, 1993, J CRUSTACEAN BIOL, V13, P403, DOI 10.2307/1548783; Ericsson JD, 2009, J INVERTEBR PATHOL, V100, P61, DOI 10.1016/j.jip.2008.10.007; Eshik M. M. E., 2017, Journal of Bangladesh Academy of Sciences, V41, P127, DOI 10.3329/jbas.v41i2.35492; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Han JE, 2017, AQUACULTURE, V470, P84, DOI 10.1016/j.aquaculture.2016.12.022; Han JE, 2020, AQUACULTURE, V524, DOI 10.1016/j.aquaculture.2020.735284; Han JE, 2015, DIS AQUAT ORGAN, V113, P33, DOI 10.3354/dao02830; Hart PJ, 1999, BIOCHEMISTRY-US, V38, P2167, DOI 10.1021/bi982284u; Hauton C, 2012, J INVERTEBR PATHOL, V110, P251, DOI 10.1016/j.jip.2012.03.005; HERGENHAHN HG, 1987, BIOCHEM J, V248, P223, DOI 10.1042/bj2480223; Jimenez-Vega F, 2005, FISH SHELLFISH IMMUN, V18, P101, DOI 10.1016/j.fsi.2004.02.001; Jiravanichpaisal P, 2006, IMMUNOBIOLOGY, V211, P213, DOI 10.1016/j.imbio.2005.10.015; Joshi J, 2014, AQUACULTURE, V428, P297, DOI 10.1016/j.aquaculture.2014.03.030; Kan H, 2008, J BIOL CHEM, V283, P25316, DOI 10.1074/jbc.M804364200; Kanost MR, 1999, DEV COMP IMMUNOL, V23, P291, DOI 10.1016/S0145-305X(99)00012-9; Kim YS, 2000, J BIOL CHEM, V275, P32721, DOI 10.1074/jbc.M003934200; Kondo H, 2015, GENOME ANNOUNCEMENTS, V3, DOI 10.1128/genomeA.00978-15; Lai HC, 2015, FISH SHELLFISH IMMUN, V47, P1006, DOI 10.1016/j.fsi.2015.11.008; Lee SY, 2000, J BIOL CHEM, V275, P1337, DOI 10.1074/jbc.275.2.1337; Lin SJ, 2019, TOXINS, V11, DOI 10.3390/toxins11040233; Lin SJ, 2017, MAR DRUGS, V15, DOI 10.3390/md15120373; Liu L, 2016, AQUACULT REP, V3, P220, DOI 10.1016/j.aqrep.2016.04.004; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Tran L, 2013, DIS AQUAT ORGAN, V105, P45, DOI 10.3354/dao02621; Loseva O, 2002, INSECT BIOCHEM MOLEC, V32, P567, DOI 10.1016/S0965-1748(01)00137-0; Munoz M, 2002, EUR J BIOCHEM, V269, P2678, DOI 10.1046/j.1432-1033.2002.02934.x; Nunan L, 2014, DIS AQUAT ORGAN, V111, P81, DOI 10.3354/dao02776; Rausell C, 2004, BBA-BIOMEMBRANES, V1660, P99, DOI 10.1016/j.bbamem.2003.11.004; Roux MM, 2002, J VIROL, V76, P7140, DOI 10.1128/JVI.76.14.7140-7149.2002; Saibu M, 2014, ANTICANCER RES, V34, P4077; Shockey JE, 2009, DEV COMP IMMUNOL, V33, P668, DOI 10.1016/j.dci.2008.11.010; Soo TCC, 2019, GUT PATHOG, V11, DOI 10.1186/s13099-019-0319-4; Soonthornchai W, 2016, DEV COMP IMMUNOL, V65, P53, DOI 10.1016/j.dci.2016.06.013; Soto-Rodriguez SA, 2015, APPL ENVIRON MICROB, V81, P1689, DOI 10.1128/AEM.03610-14; Sritunyalucksana K, 2000, AQUACULTURE, V191, P53, DOI 10.1016/S0044-8486(00)00411-7; Thitamadee S, 2016, AQUACULTURE, V452, P69, DOI 10.1016/j.aquaculture.2015.10.028; Tinwongger S, 2019, FISH SHELLFISH IMMUN, V84, P178, DOI 10.1016/j.fsi.2018.10.005; Valadez-Lira JA, 2012, J INSECT SCI, V12, DOI 10.1673/031.012.8001; Velazquez-Lizarraga AE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220993; Wang RG, 2001, EUR J BIOCHEM, V268, P895, DOI 10.1046/j.1432-1327.2001.01945.x; Wang XW, 2013, FISH SHELLFISH IMMUN, V34, P981, DOI 10.1016/j.fsi.2012.08.008; Wedde M, 1998, EUR J BIOCHEM, V255, P535, DOI 10.1046/j.1432-1327.1998.2550535.x; Yu XQ, 2004, DEV COMP IMMUNOL, V28, P891, DOI 10.1016/j.dci.2004.02.005; Zhao ZY, 2009, J VIROL, V83, P347, DOI 10.1128/JVI.00707-08	59	1	1	5	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2021	12								634152	10.3389/fimmu.2021.634152	http://dx.doi.org/10.3389/fimmu.2021.634152			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SI6ZV	34054803	Green Published, gold			2022-12-18	WOS:000654977200001
J	Manterola, M; Palominos, MF; Calixto, A				Manterola, Marcia; Palominos, M. Fernanda; Calixto, Andrea			The Heritability of Behaviors Associated With the Host Gut Microbiota	FRONTIERS IN IMMUNOLOGY			English	Review						transgenerational inheritance; germ cells; small RNAs; host-bacteria interactions; microbiota; behaviors	EPIGENETIC TRANSGENERATIONAL INHERITANCE; TESTICULAR TISSUE; FOLLICULAR-FLUID; NONCODING RNAS; EXPRESSION; GERMLINE; BRAIN; STRESS; TRANSMISSION; METABOLITES	What defines whether the interaction between environment and organism creates a genetic memory able to be transferred to subsequent generations? Bacteria and the products of their metabolism are the most ubiquitous biotic environments to which every living organism is exposed. Both microbiota and host establish a framework where environmental and genetic factors are integrated to produce adaptive life traits, some of which can be inherited. Thus, the interplay between host and microbe is a powerful model to study how phenotypic plasticity is inherited. Communication between host and microbe can occur through diverse molecules such as small RNAs (sRNAs) and the RNA interference machinery, which have emerged as mediators and carriers of heritable environmentally induced responses. Notwithstanding, it is still unclear how the organism integrates sRNA signaling between different tissues to orchestrate a systemic bacterially induced response that can be inherited. Here we discuss current evidence of heritability produced by the intestinal microbiota from several species. Neurons and gut are the sensing systems involved in transmitting changes through transcriptional and post-transcriptional modifications to the gonads. Germ cells express inflammatory receptors, and their development and function are regulated by host and bacterial metabolites and sRNAs thus suggesting that the dynamic interplay between host and microbe underlies the host's capacity to transmit heritable behaviors. We discuss how the host detects changes in the microbiota that can modulate germ cells genomic functions. We also explore the nature of the interactions that leave permanent or long-term memory in the host and propose mechanisms by which the microbiota can regulate the development and epigenetic reprogramming of germ cells, thus influencing the inheritance of the host. We highlight the vast contribution of the bacterivore nematode C. elegans and its commensal and pathogenic bacteria to the understanding on how behavioral adaptations can be inter and transgenerational inherited.	[Manterola, Marcia] Univ Chile, Programa Genet Humana, Fac Med, Santiago, Chile; [Palominos, M. Fernanda; Calixto, Andrea] Univ Valparaiso, Fac Ciencias, Inst Neurociencia, Ctr Interdisciplinario Neurociencia Valparaiso, Valparaiso, Chile; [Palominos, M. Fernanda] Univ Valparaiso, Fac Ciencias, Programa Doctorado Ciencias, Menc Neurociencia, Valparaiso, Chile	Universidad de Chile; Universidad de Valparaiso; Universidad de Valparaiso	Calixto, A (corresponding author), Univ Valparaiso, Fac Ciencias, Inst Neurociencia, Ctr Interdisciplinario Neurociencia Valparaiso, Valparaiso, Chile.	andrea.calixto@cinv.cl		Palominos, M. Fernanda/0000-0001-8486-4516	Millennium Scientific Initiative [ICM-ANID ICN09-022]; Proyecto Apoyo Redes Formacion de Centros [REDES180138]; CYTED [P918PTE3]; Fondecyt [11181329]; National Agency for Research and Development (ANID) [21161437]; ICM-ANID [IC09-022]; CINV	Millennium Scientific Initiative; Proyecto Apoyo Redes Formacion de Centros; CYTED; Fondecyt(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); National Agency for Research and Development (ANID); ICM-ANID; CINV	Millennium Scientific Initiative ICM-ANID ICN09-022, CINV, Proyecto Apoyo Redes Formacion de Centros (REDES180138), and CYTED grant P918PTE3 to AC; Fondecyt 11181329 to MM. MFP is funded by a doctoral fellowship (21161437) from the National Agency for Research and Development (ANID) and from ICM-ANID IC09-022.	Abdel-Haq R, 2019, J EXP MED, V216, P41, DOI 10.1084/jem.20180794; Abu Elhija M, 2008, EUR CYTOKINE NETW, V19, P15, DOI 10.1684/ecn.2008.0116; Agorastos A, 2019, Psychiatriki, V30, P189, DOI 10.22365/jpsych.2019.303.189; Aho VTE, 2019, EBIOMEDICINE, V44, P691, DOI 10.1016/j.ebiom.2019.05.064; Alegado RA, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016162; Aravin AA, 2008, COLD SH Q B, V73, P283, DOI 10.1101/sqb.2008.73.058; Baj A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061482; Barbosa TD, 2016, MOL METAB, V5, P184, DOI 10.1016/j.molmet.2015.12.002; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; Beale E, 2006, APPL ENVIRON MICROB, V72, P5135, DOI 10.1128/AEM.00611-06; Belicard T, 2018, BMC BIOL, V16, DOI 10.1186/s12915-018-0571-y; Ben Maamar M, 2020, DEV BIOL, V465, P31, DOI 10.1016/j.ydbio.2020.06.008; Ben Maamar M, 2018, ENVIRON EPIGENETICS, V4, DOI 10.1093/eep/dvy010; Ben Maamar M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23612-y; Brennecke J, 2008, SCIENCE, V322, P1387, DOI 10.1126/science.1165171; Buckley BA, 2012, NATURE, V489, P447, DOI 10.1038/nature11352; Camp JG, 2009, GASTROENTEROLOGY, V136, P1989, DOI 10.1053/j.gastro.2009.02.075; Cao X, 2017, CELL REP, V21, P1442, DOI 10.1016/j.celrep.2017.10.050; Cappucci U, 2019, P NATL ACAD SCI USA, V116, P17943, DOI 10.1073/pnas.1903936116; Casadevall A, 2003, NAT REV MICROBIOL, V1, P17, DOI 10.1038/nrmicro732; Celluzzi A, 2016, TRENDS MICROBIOL, V24, P777, DOI 10.1016/j.tim.2016.05.005; Chan JC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15305-w; Chaudhari SN, 2016, DEV CELL, V38, P33, DOI 10.1016/j.devcel.2016.06.013; Chen JJ, 2017, BEHAV BRAIN RES, V322, P34, DOI 10.1016/j.bbr.2017.01.021; Choi HI, 2017, BIOCHEM BIOPH RES CO, V490, P991, DOI 10.1016/j.bbrc.2017.06.152; Chu C, 2019, ANDROLOGY-US, V7, P681, DOI 10.1111/andr.12639; Collins J, 2014, NEUROGASTROENT MOTIL, V26, P98, DOI 10.1111/nmo.12236; Dalfo D, 2012, CURR BIOL, V22, P712, DOI 10.1016/j.cub.2012.02.064; Davis FM, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138443; Daxinger L, 2012, NAT REV GENET, V13, P153, DOI 10.1038/nrg3188; De Vadder F, 2014, CELL, V156, P84, DOI 10.1016/j.cell.2013.12.016; Desselberger U, 2018, PATHOGENS, V7, DOI 10.3390/pathogens7030057; Devanapally S, 2015, P NATL ACAD SCI USA, V112, P2133, DOI 10.1073/pnas.1423333112; Dierking K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01251; Dong TT, 2016, ANDROLOGY-US, V4, P1010, DOI 10.1111/andr.12238; Dong WW, 2016, SCI REP-UK, V6, DOI 10.1038/srep39080; Dupont C, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00337; Elhassan MO, 2012, J BIOL CHEM, V287, P5267, DOI 10.1074/jbc.M111.318865; Engel P, 2013, FEMS MICROBIOL REV, V37, P699, DOI 10.1111/1574-6976.12025; Evans EA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000175; Fast I, 2018, RNA BIOL, V15, P308, DOI 10.1080/15476286.2018.1429881; Feinberg EH, 2003, SCIENCE, V301, P1545, DOI 10.1126/science.1087117; Palominos MF, 2017, MBIO, V8, DOI [10.1128/mbio.01234-17, 10.1128/mBio.01234-17]; Foong JPP, 2020, AM J PHYSIOL-GASTR L, V319, pG541, DOI 10.1152/ajpgi.00288.2020; Forsythe P, 2013, CELL MOL LIFE SCI, V70, P55, DOI 10.1007/s00018-012-1028-z; Foster KJ, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.03.042; Fullston T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166076; Furness JB, 2012, NAT REV GASTRO HEPAT, V9, P286, DOI 10.1038/nrgastro.2012.32; Gabaldon C, 2020, MBIO, V11, DOI 10.1128/mBio.01950-20; Gracida Xicotencatl, 2013, Commun Integr Biol, V6, pe26004, DOI 10.4161/cib.26004; Gracida X, 2013, CURR BIOL, V23, P607, DOI 10.1016/j.cub.2013.02.034; Grant B, 1999, MOL BIOL CELL, V10, P4311, DOI 10.1091/mbc.10.12.4311; Greer EL, 2014, CELL REP, V7, P113, DOI 10.1016/j.celrep.2014.02.044; Griggs EM, 2013, J NEUROSCI, V33, P1734, DOI 10.1523/JNEUROSCI.2873-12.2013; Grishok A, 2013, ADV GENET, V83, P1, DOI 10.1016/B978-0-12-407675-4.00001-8; Gu SG, 2012, NAT GENET, V44, P157, DOI 10.1038/ng.1039; Guo BH, 2020, CANCER METAST REV, V39, P567, DOI 10.1007/s10555-020-09863-0; Ha HI, 2010, NEURON, V68, P1173, DOI 10.1016/j.neuron.2010.11.025; Hammoud SS, 2009, NATURE, V460, P473, DOI 10.1038/nature08162; Hedger MP, 2003, J REPROD IMMUNOL, V58, P1, DOI 10.1016/S0165-0378(02)00060-8; Hegde M, 2020, J BIOL CHEM, V295, P12086, DOI 10.1074/jbc.RA120.012590; Hinas A, 2012, CURR BIOL, V22, P1938, DOI 10.1016/j.cub.2012.08.020; Hoban AE, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0321-3; Hong CL, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001169; Houri-Ze'evi L, 2016, RNA BIOL, V13, P1212, DOI 10.1080/15476286.2016.1229732; Houri-Zeevi L, 2020, CELL, V182, P1186, DOI 10.1016/j.cell.2020.07.022; Iyer LM, 2004, TRENDS GENET, V20, P292, DOI 10.1016/j.tig.2004.05.007; Jin X, 2016, CELL, V164, P632, DOI 10.1016/j.cell.2016.01.007; Jose AM, 2012, P NATL ACAD SCI USA, V109, P14520, DOI 10.1073/pnas.1201153109; Kaletsky R, 2020, NATURE, V586, P445, DOI 10.1038/s41586-020-2699-5; Kamada R, 2018, P NATL ACAD SCI USA, V115, pE9162, DOI 10.1073/pnas.1720930115; Kaneshiro KR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09141-w; Kaparakis M, 2010, CELL MICROBIOL, V12, P372, DOI 10.1111/j.1462-5822.2009.01404.x; Kim CH, 2018, IMMUNOLOGY, V154, P220, DOI 10.1111/imm.12930; Knutson AK, 2017, GENETICS, V206, P163, DOI 10.1534/genetics.116.198549; Koeppen K, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005672; Komsky A, 2012, ANDROLOGIA, V44, P1, DOI 10.1111/j.1439-0272.2010.01090.x; Kronfol Z, 2000, AM J PSYCHIAT, V157, P683, DOI 10.1176/appi.ajp.157.5.683; Kudlow BA, 2012, MOL CELL, V46, P530, DOI 10.1016/j.molcel.2012.03.011; La Spina FA, 2014, J ASSIST REPROD GEN, V31, P45, DOI 10.1007/s10815-013-0137-4; Lacal I, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00292; Lee HC, 2012, CELL, V150, P78, DOI 10.1016/j.cell.2012.06.016; Legue ME., 2021, BIORXIV PREPRINT, DOI [10.1101/2021.03.26.437277, DOI 10.1101/2021.03.26.437277]; Lev I, 2019, CURR BIOL, V29, P2880, DOI 10.1016/j.cub.2019.07.054; Levy M, 2017, CURR OPIN MICROBIOL, V35, P8, DOI 10.1016/j.mib.2016.10.003; Li X, 2018, MOL CELL, V71, P428, DOI 10.1016/j.molcel.2018.06.034; Lindmark B, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-220; Liu HJ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2071; Luczynski P, 2016, EUR J NEUROSCI, V44, P2654, DOI 10.1111/ejn.13291; Machtinger R, 2016, HUM REPROD UPDATE, V22, P182, DOI 10.1093/humupd/dmv055; Macia L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7734; Maciel E, 2019, CHIMIA, V73, P356, DOI 10.2533/chimia.2019.356; Mao H, 2015, CURR BIOL, V25, P2398, DOI 10.1016/j.cub.2015.07.051; Marre J, 2016, P NATL ACAD SCI USA, V113, P12496, DOI 10.1073/pnas.1608959113; Martinez RM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35379-3; Masuzzo A, 2020, TRENDS NEUROSCI, V43, P998, DOI 10.1016/j.tins.2020.09.007; Matsumoto M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01897; McEwan DL, 2012, MOL CELL, V47, P746, DOI 10.1016/j.molcel.2012.07.014; Meerson A, 2010, J MOL NEUROSCI, V40, P47, DOI 10.1007/s12031-009-9252-1; Meisel JD, 2014, CELL, V159, P267, DOI 10.1016/j.cell.2014.09.011; MINUK GY, 1986, SCAND J INFECT DIS, V18, P465, DOI 10.3109/00365548609032366; Moloney GM, 2019, CURR OPIN PHARMACOL, V48, P120, DOI 10.1016/j.coph.2019.08.005; Moore RS, 2019, CELL, V177, P1827, DOI 10.1016/j.cell.2019.05.024; Morgado L, 2017, MOL BIOL EVOL, V34, P2035, DOI 10.1093/molbev/msx150; Mossad O, 2020, BRAIN PATHOL, V30, P1159, DOI 10.1111/bpa.12908; Nast R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.581241; Niu QH, 2010, P NATL ACAD SCI USA, V107, P16631, DOI 10.1073/pnas.1007276107; Noferesti SS, 2015, J OVARIAN RES, V8, DOI 10.1186/s13048-015-0208-5; Nono M, 2020, CELL REP, V30, P3207, DOI 10.1016/j.celrep.2020.02.050; O'Brien EA, 2020, BMC BIOL, V18, DOI 10.1186/s12915-020-00780-w; Tosar JP, 2021, RNA, V27, P403, DOI 10.1261/rna.078444.120; Pate JL, 2001, REPRODUCTION, V122, P665, DOI 10.1530/rep.0.1220665; Pereira AG, 2020, J NEUROGENET, V34, P378, DOI 10.1080/01677063.2020.1819265; Perera BPU, 2019, EPIGENETICS-US, V14, P504, DOI 10.1080/15592294.2019.1600389; Perez MF., 2020, BIORXIV PREPRINT, DOI [10.1101/2020.09.03.279158, DOI 10.1101/2020.09.03.279158]; Posner R, 2019, CELL, V177, P1814, DOI 10.1016/j.cell.2019.04.029; Pradel E, 2007, P NATL ACAD SCI USA, V104, P2295, DOI 10.1073/pnas.0610281104; Prihatno SA, 2020, J ADV VET ANIM RES, V7, P514, DOI 10.5455/javar.2020.g448; Qamar AY, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.589117; Qin YF, 2018, J BIOCHEM, V163, P105, DOI 10.1093/jb/mvx080; Rechavi O, 2014, CELL, V158, P277, DOI 10.1016/j.cell.2014.06.020; Rechavi O, 2011, CELL, V147, P1248, DOI 10.1016/j.cell.2011.10.042; Renelli M, 2004, MICROBIOL-SGM, V150, P2161, DOI 10.1099/mic.0.26841-0; Rodgers AB, 2013, J NEUROSCI, V33, P9003, DOI 10.1523/JNEUROSCI.0914-13.2013; Rosenberg E, 2007, NAT REV MICROBIOL, V5, P355, DOI 10.1038/nrmicro1635; Russell SJ, 2018, REPRODUCTION, V156, pR111, DOI 10.1530/REP-18-0218; Schackwitz WS, 1996, NEURON, V17, P719, DOI 10.1016/S0896-6273(00)80203-2; Schoofs A, 2014, J INSECT PHYSIOL, V69, P118, DOI 10.1016/j.jinsphys.2014.05.022; Sharma A, 2013, PROG BIOPHYS MOL BIO, V113, P439, DOI 10.1016/j.pbiomolbio.2012.12.003; Shih JD, 2011, RNA, V17, P1057, DOI 10.1261/rna.2596511; Skinner MK, 2018, EPIGENET CHROMATIN, V11, DOI 10.1186/s13072-018-0178-0; Skinner MK, 2009, EPIGENOMICS-UK, V1, P111, DOI 10.2217/EPI.09.11; Soder O, 2000, ANDROLOGIA, V32, P52; Spencer NJ, 2020, NAT REV GASTRO HEPAT, V17, P338, DOI 10.1038/s41575-020-0271-2; Stilling RM, 2014, GENES BRAIN BEHAV, V13, P69, DOI 10.1111/gbb.12109; Tesfaye D, 2018, REPRODUCTION, V155, pR121, DOI 10.1530/REP-17-0428; Toyofuku M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00492-w; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; Tsatsaronis JA, 2018, TRENDS MICROBIOL, V26, P401, DOI 10.1016/j.tim.2018.02.009; Turnbull L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11220; Tyebji S, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107573; Urrutia A, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000638; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van Otterdijk SD, 2016, FASEB J, V30, P2457, DOI 10.1096/fj.201500083; Vanaja SK, 2016, CELL, V165, P1106, DOI 10.1016/j.cell.2016.04.015; Verdel A, 2009, INT J DEV BIOL, V53, P245, DOI 10.1387/ijdb.082691av; Wall R, 2014, ADV EXP MED BIOL, V817, P221, DOI 10.1007/978-1-4939-0897-4_10; Wang E, 2017, GENETICS, V207, P547, DOI 10.1534/genetics.117.300067; WATKINS LR, 1995, LIFE SCI, V57, P1011, DOI 10.1016/0024-3205(95)02047-M; Watson E, 2014, CELL, V156, P759, DOI 10.1016/j.cell.2014.01.047; Werner KM, 2014, J BIOL CHEM, V289, P26566, DOI 10.1074/jbc.M114.573832; Wu SE, 2020, NATURE, V586, P108, DOI 10.1038/s41586-020-2604-2; Xie YY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00217-4; Yan W, 2014, MOL CELL ENDOCRINOL, V398, P24, DOI 10.1016/j.mce.2014.09.008; Zhang Y, 2005, NATURE, V438, P179, DOI 10.1038/nature04216; Zhang YF, 2018, NAT CELL BIOL, V20, P535, DOI 10.1038/s41556-018-0087-2; Zhang Z., 2021, NAT COMMUN, V13, P2037, DOI [10.1101/2020.12.19.423587, DOI 10.1101/2020.12.19.423587]	158	1	1	4	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2021	12								658551	10.3389/fimmu.2021.658551	http://dx.doi.org/10.3389/fimmu.2021.658551			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SI7QF	34054822	Green Published, gold			2022-12-18	WOS:000655024200001
J	Wang, XF; Yi, PP; Liang, YJ				Wang, Xiaofang; Yi, Panpan; Liang, Yuejin			The Role of IL-36 in Infectious Diseases: Potential Target for COVID-19?	FRONTIERS IN IMMUNOLOGY			English	Review						IL-36; IL-1 family; cytokine; infection; COVID-19	LUNG INFLAMMATION; SKIN INFLAMMATION; HUMAN BLOOD; EXPRESSION; RECEPTOR; KERATINOCYTES; ANTAGONIST; RESPONSES; DEFENSE; GENE	IL-36 is a member of the interleukin 1 cytokine family, which is currently experiencing a renaissance due to the growing understanding of its context-dependent roles and advances in our understanding of the inflammatory response. The immunological role of IL-36 has revealed its profound and indispensable functional roles in psoriasis, as well as in several inflammatory diseases, including inflammatory bowel disease (IBD), systemic lupus erythematosus, rheumatoid arthritis (RA) and cancer. More recently, an increasing body of evidence suggests that IL-36 plays a crucial role in viral, bacterial and fungal infections. There is a growing interest as to whether IL-36 contributes to host protective immune responses against infection as well as the potential implications of IL-36 for the development of new therapeutic strategies. In this review, we summarize the recent progress in understanding cellular expression, regulatory mechanisms and biological roles of IL-36 in infectious diseases, which suggest more specific strategies to maneuver IL-36 as a diagnostic or therapeutic target, especially in COVID-19.	[Wang, Xiaofang; Yi, Panpan] Cent South Univ, Xiangya Hosp, Dept Infect Dis, Key Lab Viral Hepatitis Hunan, Changsha, Peoples R China; [Wang, Xiaofang; Liang, Yuejin] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; [Liang, Yuejin] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA	Central South University; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Yi, PP (corresponding author), Cent South Univ, Xiangya Hosp, Dept Infect Dis, Key Lab Viral Hepatitis Hunan, Changsha, Peoples R China.; Liang, YJ (corresponding author), Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.; Liang, YJ (corresponding author), Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.	sunandleaf@126.com; yu2liang@utmb.edu			National Natural Science Foundation of China [81800506]; Natural Science Foundation of Hunan Province of China [2019JJ40494]; NIH [AI153586]; UTMB IHII Data Acquisition Grant	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province of China(Natural Science Foundation of Hunan Province); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UTMB IHII Data Acquisition Grant	This work was supported by grants from the National Natural Science Foundation of China 81800506 and Natural Science Foundation of Hunan Province of China 2019JJ40494 to PY. The NIH AI153586 and the UTMB IHII Data Acquisition Grant to YL.	Ahsan F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19476-x; Ahsan F, 2016, J INFECT DIS, V214, P464, DOI 10.1093/infdis/jiw152; Ainscough JS, 2017, P NATL ACAD SCI USA, V114, pE2748, DOI 10.1073/pnas.1620954114; Aoyagi T, 2017, MUCOSAL IMMUNOL, V10, P1043, DOI 10.1038/mi.2016.107; Aoyagi T, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006737; Bachelez H, 2019, NEW ENGL J MED, V380, P981, DOI 10.1056/NEJMc1811317; Bensen JT, 2001, J INTERF CYTOK RES, V21, P899, DOI 10.1089/107999001753289505; Berekmeri A, 2018, J ALLERGY CLIN IMMUN, V142, P988, DOI 10.1016/j.jaci.2018.04.031; Berglof E, 2003, J NEUROIMMUNOL, V139, P36, DOI 10.1016/S0165-5728(03)00130-9; Blumberg H, 2010, J IMMUNOL, V185, P4354, DOI 10.4049/jimmunol.1000313; Boutet MA, 2016, CLIN EXP IMMUNOL, V184, P159, DOI 10.1111/cei.12761; Bozoyan L, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0392-7; Braegelmann J, 2018, J EUR ACAD DERMATOL, V32, pE403, DOI 10.1111/jdv.14994; Camiolo M, 2020, J ALLERGY CLIN IMMUN, V146, P315, DOI 10.1016/j.jaci.2020.05.051; Carrascosa JM, 2020, ACTAS DERMO-SIFILOGR, V111, P734, DOI 10.1016/j.ad.2020.08.002; Carrier Y, 2011, J INVEST DERMATOL, V131, P2428, DOI 10.1038/jid.2011.234; Catapano M, 2020, J INVEST DERMATOL, V140, P816, DOI 10.1016/j.jid.2019.08.444; Cauchois R, 2020, P NATL ACAD SCI USA, V117, P18951, DOI 10.1073/pnas.2009017117; Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2; Chen FE, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-6587-z; Chua RL, 2020, NAT BIOTECHNOL, V38, P970, DOI 10.1038/s41587-020-0602-4; Chustz RT, 2011, AM J RESP CELL MOL, V45, P145, DOI 10.1165/rcmb.2010-0075OC; Clancy DM, 2018, CELL REP, V22, P2937, DOI 10.1016/j.celrep.2018.02.062; Colmenero I, 2020, BRIT J DERMATOL, V183, P729, DOI 10.1111/bjd.19327; Conner KP, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2020.1746520; Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E; Costela-Ruiz VJ, 2020, CYTOKINE GROWTH F R, V54, P62, DOI 10.1016/j.cytogfr.2020.06.001; Debets R, 2001, J IMMUNOL, V167, P1440, DOI 10.4049/jimmunol.167.3.1440; Dietrich D, 2016, CYTOKINE, V84, P88, DOI 10.1016/j.cyto.2016.05.012; Foster AM, 2014, J IMMUNOL, V192, P6053, DOI 10.4049/jimmunol.1301481; Freeman EE, 2020, J AM ACAD DERMATOL, V83, P1118, DOI 10.1016/j.jaad.2020.06.1016; Frey S, 2013, ANN RHEUM DIS, V72, P1569, DOI 10.1136/annrheumdis-2012-202264; Ganesan R, 2017, MABS-AUSTIN, V9, P1143, DOI 10.1080/19420862.2017.1353853; Gao N, 2018, J IMMUNOL, V201, P688, DOI 10.4049/jimmunol.1800046; Gao X, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-020-03283-2; Gao YC, 2019, J IMMUNOL, V203, P922, DOI 10.4049/jimmunol.1900169; Gardner JK, 2018, CYTOKINE, V111, P63, DOI 10.1016/j.cyto.2018.07.034; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Goldstein JD, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000688; Gresnigt MS, 2013, SEMIN IMMUNOL, V25, P458, DOI 10.1016/j.smim.2013.11.003; Gresnigt MS, 2013, EUR J IMMUNOL, V43, P416, DOI 10.1002/eji.201242711; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Han YY, 2019, CELL REP, V27, P835, DOI 10.1016/j.celrep.2019.03.082; Harusato A, 2017, MUCOSAL IMMUNOL, V10, P1455, DOI 10.1038/mi.2017.21; Henry CM, 2016, CELL REP, V14, P708, DOI 10.1016/j.celrep.2015.12.072; Hewitt SL, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat9143; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Johnston A, 2011, J IMMUNOL, V186, P2613, DOI 10.4049/jimmunol.1003162; Joo YH, 2020, CYTOKINE, V125, DOI 10.1016/j.cyto.2019.154798; Koss CK, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01703-3; Kovach MA, 2017, MUCOSAL IMMUNOL, V10, P1320, DOI 10.1038/mi.2016.130; Kumar S, 2000, J BIOL CHEM, V275, P10308, DOI 10.1074/jbc.275.14.10308; Laforge M, 2020, NAT REV IMMUNOL, V20, P515, DOI 10.1038/s41577-020-0407-1; Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109; Li M, 2013, J INVEST DERMATOL, V133, P2637, DOI 10.1038/jid.2013.267; Lian LH, 2012, J INVEST DERMATOL, V132, P1346, DOI 10.1038/jid.2011.482; Liu HY, 2017, CELL HOST MICROBE, V22, P653, DOI 10.1016/j.chom.2017.10.006; Livanos AE, 2021, GASTROENTEROLOGY, V160, P2435, DOI 10.1053/j.gastro.2021.02.056; Louis L, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020042; Macleod T, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108515; Macleod T, 2016, SCI REP-UK, V6, DOI 10.1038/srep24880; Magne D, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1946; Mahil SK, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan2514; Medina-Contreras O, 2016, J IMMUNOL, V196, P34, DOI 10.4049/jimmunol.1501312; Mele D, 2017, J HEPATOL, V67, P1148, DOI 10.1016/j.jhep.2017.07.028; Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4; Mercurio L, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0222969; Mercurio L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1143-3; Milora KA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05363-4; Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004; Mora J, 2016, J MOL CELL BIOL, V8, P426, DOI 10.1093/jmcb/mjw006; Muller A, 2018, P NATL ACAD SCI USA, V115, P10088, DOI 10.1073/pnas.1801377115; Mulero JJ, 1999, BIOCHEM BIOPH RES CO, V263, P702, DOI 10.1006/bbrc.1999.1440; Mutamba S, 2012, EUR J IMMUNOL, V42, P607, DOI 10.1002/eji.201142035; Nakagawa S, 2017, CELL HOST MICROBE, V22, P667, DOI 10.1016/j.chom.2017.10.008; Nanjo Y, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00583-18; Ngo VL, 2018, P NATL ACAD SCI USA, V115, pE5076, DOI 10.1073/pnas.1718902115; Nishida A, 2016, INFLAMM BOWEL DIS, V22, P303, DOI 10.1097/MIB.0000000000000654; Pan QZ, 2013, CANCER IMMUNOL IMMUN, V62, P1675, DOI 10.1007/s00262-013-1471-1; Penha R, 2016, CYTOKINE, V85, P18, DOI 10.1016/j.cyto.2016.05.023; Ramadas RA, 2011, AM J RESP CELL MOL, V44, P134, DOI 10.1165/rcmb.2009-0315OC; Rana AA, 2015, IMMUNOL RES, V63, P228, DOI 10.1007/s12026-015-8692-7; Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE346, DOI 10.1111/jdv.16533; Russell SE, 2016, MUCOSAL IMMUNOL, V9, P1193, DOI 10.1038/mi.2015.134; Sanchez-Cerrillo I, 2020, J CLIN INVEST, V130, P6290, DOI 10.1172/JCI140335; Satoh TK, 2020, J CLIN INVEST, V130, P1417, DOI 10.1172/JCI128678; Scheibe K, 2019, GASTROENTEROLOGY, V156, P1082, DOI 10.1053/j.gastro.2018.11.029; Scheibe K, 2017, GUT, V66, P823, DOI 10.1136/gutjnl-2015-310374; Scheiermann P, 2015, SCI REP-UK, V5, DOI 10.1038/srep08521; Schmitt V, 2017, EUR J IMMUNOL, V47, P2101, DOI 10.1002/eji.201646788; Segueni N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126058; Sequeira RP, 2020, NAT MICROBIOL, V5, P304, DOI 10.1038/s41564-019-0640-1; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Stanfield BA, 2018, VACCINE, V36, P2842, DOI 10.1016/j.vaccine.2018.03.075; Sun XY, 2020, CELL MOL IMMUNOL, V17, P631, DOI 10.1038/s41423-019-0300-7; Swindell WR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00080; Nguyen TT, 2012, J DERMATOL SCI, V68, P63, DOI 10.1016/j.jdermsci.2012.07.010; Todorovic V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45626-w; Tortola L, 2012, J CLIN INVEST, V122, P3965, DOI 10.1172/JCI63451; Towne JE, 2004, J BIOL CHEM, V279, P13677, DOI 10.1074/jbc.M400117200; Towne JE, 2011, J BIOL CHEM, V286, P42594, DOI 10.1074/jbc.M111.267922; Tsurutani N, 2016, J IMMUNOL, V196, P124, DOI 10.4049/jimmunol.1501217; van de Veerdonk FL, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03166-0; van de Veerdonk FL, 2012, P NATL ACAD SCI USA, V109, P3001, DOI 10.1073/pnas.1121534109; Veras FP, 2020, J EXP MED, V217, DOI 10.1084/jem.20201129; Verma AH, 2018, J IMMUNOL, V201, P627, DOI 10.4049/jimmunol.1800515; Vigne S, 2012, BLOOD, V120, P3478, DOI 10.1182/blood-2012-06-439026; Vigne S, 2011, BLOOD, V118, P5813, DOI 10.1182/blood-2011-05-356873; Wang H, 2018, J ALLERGY CLIN IMMUN, V141, P1646, DOI 10.1016/j.jaci.2017.12.972; Wang P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12318-y; Wang PL, 2005, CYTOKINE, V29, P245, DOI 10.1016/j.cyto.2004.12.002; Wang XF, 2015, CANCER CELL, V28, P296, DOI 10.1016/j.ccell.2015.07.014; Wein AN, 2018, J IMMUNOL, V201, P573, DOI 10.4049/jimmunol.1701796; Winkle SM, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00955; Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055; Xue XT, 2021, J INVEST DERMATOL, V141, P206, DOI 10.1016/j.jid.2020.05.087; Yi G, 2017, MICROB PATHOGENESIS, V113, P412, DOI 10.1016/j.micpath.2017.11.023; Yuan ZC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02532; Zhang J, 2017, CYTOKINE, V99, P114, DOI 10.1016/j.cyto.2017.08.022; Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041; Zizzo G, 2020, LANCET RHEUMATOL, V2, pE779, DOI 10.1016/S2665-9913(20)30340-4; Zulli A, 2008, EUR J HISTOCHEM, V52, P39; Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999	123	1	1	2	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2021	12								662266	10.3389/fimmu.2021.662266	http://dx.doi.org/10.3389/fimmu.2021.662266			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SI6UI	34054828	gold, Green Published			2022-12-18	WOS:000654962800001
J	Gojkovic, M; Cunha, PP; Darmasaputra, GS; Barbieri, L; Rundqvist, H; Velica, P; Johnson, RS				Gojkovic, Milos; Cunha, Pedro P.; Darmasaputra, Gabriella S.; Barbieri, Laura; Rundqvist, Helene; Velica, Pedro; Johnson, Randall S.			Oxygen-Mediated Suppression of CD8+T Cell Proliferation by Macrophages: Role of Pharmacological Inhibitors of HIF Degradation	FRONTIERS IN IMMUNOLOGY			English	Article						Nitric oxide; hypoxia; immunosuppression; HIF; myeloid cells; von Hippel-Lindau; Prolyl hydroxylase inhibitors	AXIS	Myeloid cell interactions with cells of the adaptive immune system are an essential aspect of immunity. A key aspect of that interrelationship is its modulation by the microenvironment. Oxygen is known to influence myelosuppression of T cell activation in part via the Hypoxia inducible (HIF) transcription factors. A number of drugs that act on the HIF pathway are currently in clinical use and it is important to evaluate how they act on immune cell function as part of a better understanding of how they will influence patient outcomes. We show here that increased activation of the HIF pathway, either through deletion of the negative regulator of HIF, the von Hippel-Lindau (VHL) gene, in myeloid cells, or through pharmacological inhibitors of VHL-mediated degradation of HIF, potently suppresses T cell proliferation in myeloid cell/T cell culture. These data demonstrate that both pharmacological and genetic activation of HIF in myeloid cells can suppress adaptive cell immune response.	[Gojkovic, Milos; Darmasaputra, Gabriella S.; Barbieri, Laura; Velica, Pedro; Johnson, Randall S.] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden; [Cunha, Pedro P.; Rundqvist, Helene] Karolinska Inst, Dept Lab Med, Stockholm, Sweden; [Johnson, Randall S.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge, England	Karolinska Institutet; Karolinska Institutet; University of Cambridge	Johnson, RS (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden.; Johnson, RS (corresponding author), Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge, England.	randall.johnson@ki.se	Cunha, Pedro Pacheco/AAC-2297-2022	Cunha, Pedro Pacheco/0000-0002-3814-6289; Gojkovic, Milos/0000-0001-6451-9192	Swedish Research Council (Vetenskapsradet) [2019-01485]; Swedish Cancer Society (Cancerfonden) [CAN2018/808]; Swedish Children's Cancer Society (Barncancerfonden) [PR2020-0075]; Knut and Alice Wallenberg Foundation Scholars Award; Wellcome Trust, UK [214283/Z/18/Z]; Portuguese Foundation for Science and Technology (FCT) scholarship [SFRH/BD/115612/2016]	Swedish Research Council (Vetenskapsradet)(Swedish Research Council); Swedish Cancer Society (Cancerfonden)(Swedish Cancer Society); Swedish Children's Cancer Society (Barncancerfonden); Knut and Alice Wallenberg Foundation Scholars Award; Wellcome Trust, UK(Wellcome Trust); Portuguese Foundation for Science and Technology (FCT) scholarship	This study was funded by the Swedish Research Council (Vetenskapsradet 2019-01485), the Swedish Cancer Society (Cancerfonden CAN2018/808), the Swedish Children's Cancer Society (Barncancerfonden PR2020-0075) the Knut and Alice Wallenberg Foundation Scholars Award, and the Wellcome Trust, UK (Principal Research Fellowship 214283/Z/18/Z). PPC was supported by a Portuguese Foundation for Science and Technology (FCT) scholarship (SFRH/BD/115612/2016).	Alexander LEC, 2013, J MOL MED, V91, P637, DOI 10.1007/s00109-012-0986-9; Besarab A, 2015, NEPHROL DIAL TRANSPL, V30, P1665, DOI 10.1093/ndt/gfv302; Brown E, 2018, J PHYSIOL-LONDON, V596, P2985, DOI 10.1113/JP274350; Cecilio CA, 2011, BRAZ J MED BIOL RES, V44, P671, DOI [10.1590/S0100-879X2011007500067, 10.1590/S0100-879X2011000700010]; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Cowburn AS, 2016, P NATL ACAD SCI USA, V113, P8801, DOI 10.1073/pnas.1602978113; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Dhillon S, 2019, DRUGS, V79, P563, DOI 10.1007/s40265-019-01077-1; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Halligan DN, 2019, AM J PHYSIOL-GASTR L, V317, pG90, DOI 10.1152/ajpgi.00049.2019; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hindryckx P, 2010, J IMMUNOL, V185, P6306, DOI 10.4049/jimmunol.1002541; Imtiyaz HZ, 2010, J CLIN INVEST, V120, P2699, DOI 10.1172/JCI39506; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Keely S, 2014, MUCOSAL IMMUNOL, V7, P114, DOI 10.1038/mi.2013.29; Kim YI, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.609689; Lee CT, 2010, INT J HYPERTHER, V26, P232, DOI 10.3109/02656731003601745; Liu Xiaoyu, 2015, Bio Protoc, V5; Mantovani A, 2006, CANCER METAST REV, V25, P315, DOI 10.1007/s10555-006-9001-7; Maxwell PH, 2016, NAT REV NEPHROL, V12, P157, DOI 10.1038/nrneph.2015.193; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Palazon A, 2017, CANCER CELL, V32, P669, DOI 10.1016/j.ccell.2017.10.003; Palazon A, 2014, IMMUNITY, V41, P518, DOI 10.1016/j.immuni.2014.09.008; Peyssonnaux C, 2005, J CLIN INVEST, V115, P1806, DOI 10.1172/JCI23865; Provenzano R, 2016, CLIN J AM SOC NEPHRO, V11, P982, DOI 10.2215/CJN.06890615; Susen RM, 2019, MOL CARCINOGEN, V58, P2127, DOI 10.1002/mc.23103; Tafani M, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00013; Takeda N, 2010, GENE DEV, V24, P491, DOI 10.1101/gad.1881410; Tambuwala MM, 2010, GASTROENTEROLOGY, V139, P2093, DOI 10.1053/j.gastro.2010.06.068; Watts ER, 2019, TRENDS MOL MED, V25, P33, DOI 10.1016/j.molmed.2018.10.006	31	1	2	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2021	12								633586	10.3389/fimmu.2021.633586	http://dx.doi.org/10.3389/fimmu.2021.633586			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SH8ZL	34054802	Green Published, gold			2022-12-18	WOS:000654420000001
J	Lee, CY; Tseng, CJ; Chang, CC; Lee, MC; Yang, SF				Lee, Chung-Yuan; Tseng, Chih-Jen; Chang, Chi-Chang; Lee, Meng-Chih; Yang, Shun-Fa			Postpartum HPV Vaccination Rate and Differences in Background Characteristics Between HPV Vaccinated and Unvaccinated Postpartum Women: Strict Monitoring and Follow-Up of Postpartum HPV Vaccination Program	FRONTIERS IN IMMUNOLOGY			English	Article						postpartum period; uterine cervical neoplasms; vaccination; human papillomavirus (HPV); papillomavirus vaccines	HUMAN-PAPILLOMAVIRUS; SCREENING-PROGRAM; NEOPLASIA; EFFICACY	There is a need to increase the vaccine completion rates in women who have already received human papillomavirus (HPV) vaccines. With vaccines requiring multiple doses, designing a vaccination control program and increasing the proportion of women who complete vaccination are critical and remain as huge challenges. Currently, there are no published reports on the differences in the background characteristics between postpartum women who are vaccinated or unvaccinated against HPV. This study aimed to determine the vaccination rates of the second and third doses of HPV vaccination utilizing an achievable HPV vaccination program in postpartum women. In this retrospective study, 243 postpartum women attending Chiayi Chang Gung Memorial Hospital between March and September 2014 were enrolled. These women were classified into two groups: one group received the HPV vaccine under a practical, controlled postpartum HPV vaccination program, and the other group did not. The rates for the second and third rounds of HPV vaccination in postpartum women were calculated. The differences in the background characteristics between the two groups were determined using the Student's t test, chi-square test or Fisher's exact test, and the multiple logistic models, as appropriate. Under the controlled postpartum HPV vaccination program, the completion rate for the three doses of postpartum HPV vaccination was 97.2%. Significant differences were observed according to maternal age, gender of the newborn, and postpartum Pap smear results between the two groups in our study. In conclusion, the controlled postpartum HPV vaccination program is a reasonable method for achieving an excellent completion rate for the three doses of postpartum HPV vaccination and may be a good model for any multiple-dose vaccination protocol.	[Lee, Chung-Yuan; Lee, Meng-Chih; Yang, Shun-Fa] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Lee, Chung-Yuan] Chiayi Chang Gung Mem Hosp, Dept Obstet & Gynecol, Chiayi, Taiwan; [Lee, Chung-Yuan] Chang Gung Univ Sci & Technol, Dept Nursing, Chiayi, Taiwan; [Tseng, Chih-Jen] Chung Shang Med Univ Hosp, Dept Obstet & Gynecol, Taichung, Taiwan; [Chang, Chi-Chang] E Da Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan; [Yang, Shun-Fa] Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan	Chung Shan Medical University; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology; Chung Shan Medical University; Chung Shan Medical University Hospital; E-Da Hospital; Chung Shan Medical University; Chung Shan Medical University Hospital	Yang, SF (corresponding author), Chung Shan Med Univ, Inst Med, Taichung, Taiwan.; Yang, SF (corresponding author), Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan.	ysf@csmu.edu.tw	Yang, Shun-Fa/AAN-1519-2020	Yang, Shun-Fa/0000-0002-0365-7927				[Anonymous], 2015, OBSTET GYNECOL, V126, pE38, DOI 10.1097/01.AOG.0000471170.79174.84; Arbyn M, 2010, ANN ONCOL, V21, P448, DOI 10.1093/annonc/mdp471; Arbyn M, 2020, LANCET GLOB HEALTH, V8, pE191, DOI 10.1016/S2214-109X(19)30482-6; Bayram A, 2011, J MED VIROL, V83, P1997, DOI 10.1002/jmv.22218; Berenson AB, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.02.032; Breen N, 2001, J NATL CANCER I, V93, P1704, DOI 10.1093/jnci/93.22.1704; Castellsague X, 2011, BRIT J CANCER, V105, P28, DOI 10.1038/bjc.2011.185; Chen J, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz486; Crowe E, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1458; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Eckert LO, 2017, OBSTET GYNECOL, V129, pE173, DOI 10.1097/AOG.0000000000002052; Farnsworth A, 2003, MED J AUSTRALIA, V178, P653, DOI 10.5694/j.1326-5377.2003.tb05398.x; Gakidou E, 2008, PLOS MED, V5, P863, DOI 10.1371/journal.pmed.0050132; Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760; Guevara A, 2017, VACCINE, V35, P5050, DOI 10.1016/j.vaccine.2017.07.017; Hinkula M, 2004, BRIT J CANCER, V90, P1025, DOI 10.1038/sj.bjc.6601650; Huh WK, 2017, LANCET, V390, P2143, DOI 10.1016/S0140-6736(17)31821-4; Joura EA, 2015, NEW ENGL J MED, V372, P711, DOI 10.1056/NEJMoa1405044; Lehtinen M, 2012, LANCET ONCOL, V13, P89, DOI 10.1016/S1470-2045(11)70286-8; Markowitz LE, 2014, MMWR RECOMM REP, V63, P1; McKeever AE, 2015, NURS OUTLOOK, V63, P341, DOI 10.1016/j.outlook.2014.08.011; Munoz N, 2002, LANCET, V359, P1093, DOI 10.1016/S0140-6736(02)08151-5; Munoz N, 2010, JNCI-J NATL CANCER I, V102, P325, DOI 10.1093/jnci/djp534; National HPV Vaccination Program Register, 2015, HPV VACC COV 2015; Nygard JF, 2002, J MED SCREEN, V9, P86, DOI 10.1136/jms.9.2.86; Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5; Paovonen J, 2009, LANCET, V374, P301, DOI 10.1016/S0140-6736(09)61248-4; Peterson CE, 2016, TRANSL BEHAV MED, V6, P672, DOI 10.1007/s13142-016-0441-5; Peto J, 2004, LANCET, V364, P249, DOI 10.1016/S0140-6736(04)16674-9; Pollock KGJ, 2014, BRIT J CANCER, V111, P1824, DOI 10.1038/bjc.2014.479; Rocha-Zavaleta L, 2004, INT J GYNECOL OBSTET, V85, P259, DOI 10.1016/j.ijgo.2003.10.002; Smulian EA, 2016, HUM VACC IMMUNOTHER, V12, P1566, DOI 10.1080/21645515.2015.1125055; Sun L, 2017, MED J OBSTET GYNECOL, V5, P1099; Symonds RP, 2001, CLIN ONCOL-UK, V13, P473, DOI 10.1053/clon.2001.9317; Trottier H, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0675-0; US Centers for Disease Control and Prevention, 2006, 2006 2007 NAT BREAST; Verdenius I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071295; Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741; Wheeler CM, 2016, LANCET INFECT DIS, V16, P1154, DOI 10.1016/S1473-3099(16)30120-7; World Hlth Org, 2017, VACCINE, V35, P5753, DOI 10.1016/j.vaccine.2017.05.069; Wright JD, 2012, OBSTET GYNECOL, V120, P771, DOI 10.1097/AOG.0b013e31826afb56	41	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2021	12								626582	10.3389/fimmu.2021.626582	http://dx.doi.org/10.3389/fimmu.2021.626582			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SH5YS	34054800	Green Published, gold			2022-12-18	WOS:000654212500001
J	Zhang, YY; Zhang, J; Shi, Y; Shen, M; Lv, H; Chen, S; Feng, YJ; Chen, H; Xu, XY; Yang, T; Xu, KF				Zhang, Yuyue; Zhang, Jie; Shi, Yun; Shen, Min; Lv, Hui; Chen, Shu; Feng, Yingjie; Chen, Heng; Xu, Xinyu; Yang, Tao; Xu, Kuanfeng			Differences in Maturation Status and Immune Phenotypes of Circulating Helios(+) and Helios(-) Tregs and Their Disrupted Correlations With Monocyte Subsets in Autoantibody-Positive T1D Individuals	FRONTIERS IN IMMUNOLOGY			English	Article						type 1 diabetes; Tregs; Helios; monocytes; regulatory	REGULATORY T-CELLS	CD4 Tregs are involved in the regulation of various autoimmune diseases but believed to be highly heterogeneous. Studies have indicated that Helios controls a distinct subset of functional Tregs. However, the immunological changes in circulating Helios(+) and Helios(-) Tregs are not fully explored in type 1 diabetes (T1D). Here, we elucidated the differences in maturation status and immune regulatory phenotypes of Helios(+) and Helios(-) Tregs and their correlations with monocyte subsets in T1D individuals. As CD25(-/low) FOXP3(+) Tregs also represent a subset of functional Tregs, we defined Tregs as FOXP3(+)CD127(-/low) and examined circulating Helios(+) and Helios(-) Treg subpopulations in 68 autoantibody-positive T1D individuals and 68 age-matched healthy controls. We found that expression of both FOXP3 and CTLA4 diminished in Helios(-) Tregs, while the proportion of CD25(-/low) Tregs increased in Helios(+) Tregs of T1D individuals. Although the frequencies of neither Helios(+) nor Helios(-) Tregs were affected by investigated T1D genetic risk loci, Helios(+) Tregs correlated with age at T1D diagnosis negatively and disease duration positively. Moreover, the negative correlation between central and effector memory proportions of Helios(+) Tregs in healthy controls was disrupted in T1D individuals. Finally, regulatory non-classical and intermediate monocytes also decreased in T1D individuals, and positive correlations between these regulatory monocytes and Helios(+)/Helios(-) Treg subsets in healthy controls disappeared in T1D individuals. In conclusion, we demonstrated the alternations in maturation status and immune phenotypes in Helios(+) and Helios(-) Treg subsets and revealed the missing association between these Treg subsets and monocyte subsets in T1D individuals, which might point out another option for elucidating T1D mechanisms.	[Zhang, Yuyue; Zhang, Jie; Shi, Yun; Shen, Min; Lv, Hui; Chen, Shu; Feng, Yingjie; Chen, Heng; Xu, Xinyu; Yang, Tao; Xu, Kuanfeng] Nanjing Med Univ, Affiliated Hosp 1, Dept Endocrinol & Metab, Nanjing, Peoples R China	Nanjing Medical University	Xu, KF (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Endocrinol & Metab, Nanjing, Peoples R China.	kuanfengxu@njmu.edu.cn		Shi, Yun/0000-0003-4114-1072	National Natural Science Foundation of China [81670715]; Jiangsu Province Youth Medical Talents Project [QNRC2016584]; Natural Science Foundation of Jiangsu Province [BK2012486]; Jiangsu Government Scholarship for Overseas Studies [JS-2013-260]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Province Youth Medical Talents Project; Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Jiangsu Government Scholarship for Overseas Studies; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This study was supported by grants from the National Natural Science Foundation of China (81670715), Jiangsu Province Youth Medical Talents Project (QNRC2016584), the Natural Science Foundation of Jiangsu Province (BK2012486), Jiangsu Government Scholarship for Overseas Studies (JS-2013-260), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Abeles D, 2012, CYTOM PART A, V81A, P823, DOI 10.1002/cyto.a.22104; Alexander T, 2013, ANN RHEUM DIS, V72, P1549, DOI 10.1136/annrheumdis-2012-202216; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Baine I, 2013, J IMMUNOL, V190, P1008, DOI 10.4049/jimmunol.1200792; Bonelli M, 2009, J IMMUNOL, V182, P1689, DOI 10.4049/jimmunol.182.3.1689; Brusko TM, 2005, DIABETES, V54, P1407, DOI 10.2337/diabetes.54.5.1407; Cari L, 2020, DIABETES, V69, P965, DOI 10.2337/db19-0087; Davis AK, 2015, DIABETES CARE, V38, P476, DOI 10.2337/dc14-1952; Dendrou CA, 2008, J CLIN IMMUNOL, V28, P685, DOI 10.1007/s10875-008-9237-9; Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303; Du WT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056209; Ferreira RC, 2017, J AUTOIMMUN, V84, P75, DOI 10.1016/j.jaut.2017.07.009; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fu WX, 2012, NAT IMMUNOL, V13, P972, DOI 10.1038/ni.2420; Garg G, 2012, J IMMUNOL, V188, P4644, DOI 10.4049/jimmunol.1100272; Getnet D, 2010, MOL IMMUNOL, V47, P1595, DOI 10.1016/j.molimm.2010.02.001; Golding A, 2013, ARTHRITIS RHEUM-US, V65, P2898, DOI 10.1002/art.38119; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Grant CR, 2015, AUTOIMMUN REV, V14, P105, DOI 10.1016/j.autrev.2014.10.012; Guo N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00714; Himmel ME, 2013, J IMMUNOL, V190, P2001, DOI 10.4049/jimmunol.1201379; Holt MP, 2017, J IMMUNOL, V198, P1503, DOI 10.4049/jimmunol.1601670; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hull CM, 2017, DIABETOLOGIA, V60, P1839, DOI 10.1007/s00125-017-4377-1; Irvine KM, 2012, DIABETES, V61, P1281, DOI 10.2337/db11-1549; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Kawanaka N, 2002, ARTHRITIS RHEUM, V46, P2578, DOI 10.1002/art.10545; Kim HJ, 2015, SCIENCE, V350, P334, DOI 10.1126/science.aad0616; Kim YC, 2012, BLOOD, V119, P2810, DOI 10.1182/blood-2011-09-377895; Lindley S, 2005, DIABETES, V54, P92, DOI 10.2337/diabetes.54.1.92; Liu LF, 2019, BMC IMMUNOL, V20, DOI 10.1186/s12865-019-0319-7; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Long SA, 2011, GENES IMMUN, V12, P116, DOI 10.1038/gene.2010.54; Long SA, 2011, J IMMUNOL, V187, P2061, DOI 10.4049/jimmunol.1003224; Long SA, 2010, DIABETES, V59, P407, DOI 10.2337/db09-0694; Mailloux AW, 2012, J IMMUNOL, V189, P3198, DOI 10.4049/jimmunol.1200602; Mason GM, 2015, J IMMUNOL, V195, P2030, DOI 10.4049/jimmunol.1500703; McGovern JL, 2012, ARTHRITIS RHEUM-US, V64, P3129, DOI 10.1002/art.34565; Menning A, 2007, EUR J IMMUNOL, V37, P1575, DOI 10.1002/eji.200737201; Minton K, 2017, NAT REV IMMUNOL, V17, P401, DOI 10.1038/nri.2017.68; Mitsuiki N, 2019, IMMUNOL REV, V287, P33, DOI 10.1111/imr.12721; Nocentini G, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0444-x; Opstelten R, 2020, J IMMUNOL, V204, P3139, DOI 10.4049/jimmunol.1901250; Oras A, 2019, CLIN EXP IMMUNOL, V198, P57, DOI 10.1111/cei.13332; Orru V, 2013, CELL, V155, P242, DOI 10.1016/j.cell.2013.08.041; Parackova Z, 2016, AUTOIMMUNITY, V49, P523, DOI 10.1080/08916934.2016.1217998; Picca CC, 2006, IMMUNOL REV, V212, P74, DOI 10.1111/j.0105-2896.2006.00416.x; Qiao YC, 2017, AUTOIMMUN REV, V16, P1058, DOI 10.1016/j.autrev.2017.08.001; Ren XY, 2017, INT J BIOL SCI, V13, P209, DOI 10.7150/ijbs.15659; Rosenblum MD, 2016, NAT REV IMMUNOL, V16, P90, DOI 10.1038/nri.2015.1; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Sebastian M, 2016, J IMMUNOL, V196, P144, DOI 10.4049/jimmunol.1501704; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Shevach EM, 2014, IMMUNOL REV, V259, P88, DOI 10.1111/imr.12160; Smigiel KS, 2014, J EXP MED, V211, P121, DOI 10.1084/jem.20131142; Spence A, 2018, P NATL ACAD SCI USA, V115, P5265, DOI 10.1073/pnas.1715590115; Stumpf M, 2014, EUR J IMMUNOL, V44, P1737, DOI 10.1002/eji.201343891; Takatori H, 2015, ARTHRITIS RHEUMATOL, V67, P1491, DOI 10.1002/art.39091; Thornton AM, 2019, EUR J IMMUNOL, V49, P398, DOI 10.1002/eji.201847935; Wallberg M, 2013, TRENDS IMMUNOL, V34, P583, DOI 10.1016/j.it.2013.08.005; Zhang B, 2008, ANN RHEUM DIS, V67, P1037, DOI 10.1136/ard.2007.083543; Zhang R, 2013, J CLIN INVEST, V123, P580, DOI 10.1172/JCI65013; Zhong H, 2013, BLOOD, V121, P2494, DOI 10.1182/blood-2012-11-469122; Zhu M, 2019, DIABETES CARE, V42, P1414, DOI 10.2337/dc18-2023; Zoka A, 2015, AUTOIMMUNITY, V48, P289, DOI 10.3109/08916934.2014.992518	65	1	1	4	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2021	12								628504	10.3389/fimmu.2021.628504	http://dx.doi.org/10.3389/fimmu.2021.628504			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SH5ZR	34054801	Green Published, gold			2022-12-18	WOS:000654215000001
J	Bok, J; Hofland, RW; Evans, CA				Bok, Jeroen; Hofland, Regina W.; Evans, Carlton A.			Whole Blood Mycobacterial Growth Assays for Assessing Human Tuberculosis Susceptibility: A Systematic Review and Meta-Analysis	FRONTIERS IN IMMUNOLOGY			English	Review						tuberculosis; mycobacterial growth assay; mycobacterial growth inhibition assay; MGIA; susceptibility; risk	INHIBITION; RESPONSES; IMMUNITY	Background Whole blood mycobacterial growth assays (WBMGA) quantify mycobacterial growth in fresh blood samples and may have potential for assessing tuberculosis vaccines and identifying individuals at risk of tuberculosis. We evaluated the evidence for the underlying assumption that in vitro WBMGA results can predict in vivo tuberculosis susceptibility. Methods A systematic search was done for studies assessing associations between WBMGA results and tuberculosis susceptibility. Meta-analyses were performed for eligible studies by calculating population-weighted averages. Results No studies directly assessed whether WBMGA results predicted tuberculosis susceptibility. 15 studies assessed associations between WBMGA results and proven correlates of tuberculosis susceptibility, which we divided in two categories. Firstly, WBMGA associations with factors believed to reduce tuberculosis susceptibility were statistically significant in all eight studies of: BCG vaccination; vitamin D supplementation; altitude; and HIV-negativity/therapy. Secondly, WBMGA associations with probable correlates of tuberculosis susceptibility were statistically significant in three studies of tuberculosis disease, in a parasitism study and in two of the five studies of latent tuberculosis infection. Meta-analyses for associations between WBMGA results and BCG vaccination, tuberculosis infection, tuberculosis disease and HIV infection revealed consistent effects. There was considerable methodological heterogeneity. Conclusions The study results generally showed significant associations between WBMGA results and correlates of tuberculosis susceptibility. However, no study directly assessed whether WBMGA results predicted actual susceptibility to tuberculosis infection or disease. We recommend optimization and standardization of WBMGA methodology and prospective studies to determine whether WBMGA predict susceptibility to tuberculosis disease.	[Bok, Jeroen; Evans, Carlton A.] Imperial Coll London, Dept Infect Dis, London, England; [Bok, Jeroen; Evans, Carlton A.] Univ Peruana Cayetano Heredia, Innovat Hlth & Dev IFHAD, Lab Res & Dev, Lima, Peru; [Bok, Jeroen; Evans, Carlton A.] Asociac Benef PRISMA, Innovac Salud & Desarrollo IPSYD, Lima, Peru; [Bok, Jeroen; Hofland, Regina W.] Univ Med Ctr Utrecht, Dept Pulmonol & TB, Utrecht, Netherlands	Imperial College London; Universidad Peruana Cayetano Heredia; Utrecht University; Utrecht University Medical Center	Evans, CA (corresponding author), Imperial Coll London, Dept Infect Dis, London, England.; Evans, CA (corresponding author), Univ Peruana Cayetano Heredia, Innovat Hlth & Dev IFHAD, Lab Res & Dev, Lima, Peru.; Evans, CA (corresponding author), Asociac Benef PRISMA, Innovac Salud & Desarrollo IPSYD, Lima, Peru.	Carlton.Evans@IFHAD.org	Bok, Jeroen/AAB-5970-2022	Evans, Carlton/0000-0002-6873-5447	Wellcome Trust [057434/Z/99/Z, 070005/Z/02/Z, 078340/Z/05/Z, 105788/Z/14/Z, 201251/Z/16/Z]; UK-AID DFID-CSCF; Joint Global Health Trials Scheme [MR/K007467/1]; UK Medical Research Council; UK Department of Health and Social Care through the National Institute of Health Research (NIHR); Wellcome; STOP TB partnership's TB REACH initiative - Government of Canada; Bill & Melinda Gates Foundation [OPP1118545, W5_PER_CDT1_PRISMA]; CONCYTEC/FONDECYT [E067-2020-02-01, 083-2020]; charity IFHAD: Innovation For Health And Development; UK Foreign, Commonwealth and Development Office	Wellcome Trust(Wellcome Trust); UK-AID DFID-CSCF; Joint Global Health Trials Scheme; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Department of Health and Social Care through the National Institute of Health Research (NIHR); Wellcome; STOP TB partnership's TB REACH initiative - Government of Canada; Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); CONCYTEC/FONDECYT; charity IFHAD: Innovation For Health And Development; UK Foreign, Commonwealth and Development Office	Funding is gratefully acknowledged from: the Wellcome Trust (awards 057434/Z/99/Z, 070005/Z/02/Z, 078340/Z/05/Z, 105788/Z/14/Z, and 201251/Z/16/Z); UK-AID DFID-CSCF; the Joint Global Health Trials Scheme (award MR/K007467/1) with funding from the UK Foreign, Commonwealth and Development Office, the UK Medical Research Council, the UK Department of Health and Social Care through the National Institute of Health Research (NIHR) and Wellcome; the STOP TB partnership's TB REACH initiative funded by the Government of Canada and the Bill & Melinda Gates Foundation (awards W5_PER_CDT1_PRISMA and OPP1118545); CONCYTEC/FONDECYT award code E067-2020-02-01 number 083-2020; and the charity IFHAD: Innovation For Health And Development.	Andrews JR, 2012, CLIN INFECT DIS, V54, P784, DOI 10.1093/cid/cir951; [Anonymous], GLOBAL TUBERCULOSIS; Babu S, 2016, TRENDS IMMUNOL, V37, P597, DOI 10.1016/j.it.2016.07.005; Baguma R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184563; Banfield S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038556; Barry CE, 2009, NAT REV MICROBIOL, V7, P845, DOI 10.1038/nrmicro2236; Borelli V, 2003, INFECT IMMUN, V71, P605, DOI 10.1128/IAI.71.2.605-613.2003; Cadena AM, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007305; Cegielski JP, 2004, INT J TUBERC LUNG D, V8, P286; Cheon SH, 2002, CLIN DIAGN LAB IMMUN, V9, P901, DOI 10.1128/CDLI.9.4.901-907.2002; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Diel R, 2012, CHEST, V142, P63, DOI 10.1378/chest.11-3157; du Plessis N, 2014, ADV EXP MED BIOL, V828, P49, DOI 10.1007/978-1-4939-1489-0_3; Eisen S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074220; Elias D, 2006, TROP MED INT HEALTH, V11, P551, DOI 10.1111/j.1365-3156.2006.01578.x; Elias D, 2001, CLIN EXP IMMUNOL, V123, P219, DOI 10.1046/j.1365-2249.2001.01446.x; Esmail H, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0437; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; Fletcher HA, 2013, CLIN VACCINE IMMUNOL, V20, P1683, DOI 10.1128/CVI.00427-13; Harrell FE, 2014, HMISC PACKAGE MISCEL; Hoft DF, 2002, J INFECT DIS, V186, P1448, DOI 10.1086/344359; Joosten SA, 2018, J CLIN INVEST, V128, P1837, DOI 10.1172/JCI97508; Kampmann B, 2004, INFECT IMMUN, V72, P6401, DOI 10.1128/IAI.72.11.6401-6407.2004; Kampmann B, 2000, J INFECT DIS, V182, P895, DOI 10.1086/315766; Kampmann B, 2006, AIDS, V20, P1011, DOI 10.1097/01.aids.0000222073.45372.ce; Mandalakas AM, 2012, INT J TUBERC LUNG D, V16, P1033, DOI 10.5588/ijtld.12.0027; Martineau AR, 2007, J CLIN INVEST, V117, P1988, DOI 10.1172/JCI31097; Martineau AR, 2007, AM J RESP CRIT CARE, V176, P208, DOI 10.1164/rccm.200701-007OC; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]; Narasimhan P, 2013, PULM MED, V2013, DOI 10.1155/2013/828939; National Heart Lung and Blood Institute, 2014, QUALITY ASSESSMENT T; Nicol MP, 2007, J INVEST DERMATOL, V127, P2152, DOI 10.1038/sj.jid.5700845; Nnoaham KE, 2008, INT J EPIDEMIOL, V37, P113, DOI 10.1093/ije/dym247; O'Shea MK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02893; O'Shea MK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32755-x; Rangaka MX, 2012, LANCET INFECT DIS, V12, P45, DOI 10.1016/S1473-3099(11)70210-9; Rono J, 2012, INFECT IMMUN, V80, P1900, DOI 10.1128/IAI.06190-11; Roy A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4643; Roy RB, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102891; Saito M, 2006, AM J TROP MED HYG, V75, P49, DOI 10.4269/ajtmh.2006.75.49; Saunders MJ, 2019, LANCET INFECT DIS, V19, P519, DOI 10.1016/S1473-3099(18)30753-9; Saunders MJ, 2017, LANCET INFECT DIS, V17, P1190, DOI 10.1016/S1473-3099(17)30447-4; Tanner R, 2019, J IMMUNOL METHODS, V469, P1, DOI 10.1016/j.jim.2019.01.006; Tanner R, 2017, SCI REP-UK, V7, DOI 10.1038/srep43478; Tanner R, 2016, VACCINE, V34, P4656, DOI 10.1016/j.vaccine.2016.07.058; Tena GN, 2003, J INFECT DIS, V187, P1544, DOI 10.1086/374799; Vargas MH, 2004, INT J TUBERC LUNG D, V8, P1321; Wallis RS, 2009, TUBERCULOSIS, V89, P221, DOI 10.1016/j.tube.2009.02.001; Wallis RS, 2001, J INFECT DIS, V183, P1300, DOI 10.1086/319679; Walzl G, 2011, NAT REV IMMUNOL, V11, P343, DOI 10.1038/nri2960; Weiner J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07635-7; Zak DE, 2016, LANCET, V387, P2312, DOI 10.1016/S0140-6736(15)01316-1	52	1	1	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2021	12								641082	10.3389/fimmu.2021.641082	http://dx.doi.org/10.3389/fimmu.2021.641082			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SG9DM	34046032	gold, Green Published			2022-12-18	WOS:000653740400001
J	Cole, J; Angyal, A; Emes, RD; Mitchell, TJ; Dickman, MJ; Dockrell, DH				Cole, Joby; Angyal, Adrienn; Emes, Richard D.; Mitchell, Tim John; Dickman, Mark J.; Dockrell, David H.			Pneumolysin Is Responsible for Differential Gene Expression and Modifications in the Epigenetic Landscape of Primary Monocyte Derived Macrophages	FRONTIERS IN IMMUNOLOGY			English	Article						histone post translational modifications; Streptococcus pneumoniae; pneumolysin; tumour necrosis factor; monocyte derived macrophages	STREPTOCOCCUS-PNEUMONIAE	Epigenetic modifications regulate gene expression in the host response to a diverse range of pathogens. The extent and consequences of epigenetic modification during macrophage responses to Streptococcus pneumoniae, and the role of pneumolysin, a key Streptococcus pneumoniae virulence factor, in influencing these responses, are currently unknown. To investigate this, we infected human monocyte derived macrophages (MDMs) with Streptococcus pneumoniae and addressed whether pneumolysin altered the epigenetic landscape and the associated acute macrophage transcriptional response using a combined transcriptomic and proteomic approach. Transcriptomic analysis identified 503 genes that were differentially expressed in a pneumolysin-dependent manner in these samples. Pathway analysis highlighted the involvement of transcriptional responses to core innate responses to pneumococci including modules associated with metabolic pathways activated in response to infection, oxidative stress responses and NF kappa B, NOD-like receptor and TNF signalling pathways. Quantitative proteomic analysis confirmed pneumolysin-regulated protein expression, early after bacterial challenge, in representative transcriptional modules associated with innate immune responses. In parallel, quantitative mass spectrometry identified global changes in the relative abundance of histone post translational modifications (PTMs) upon pneumococcal challenge. We identified an increase in the relative abundance of H3K4me1, H4K16ac and a decrease in H3K9me2 and H3K79me2 in a PLY-dependent fashion. We confirmed that pneumolysin blunted early transcriptional responses involving TNF-alpha and IL-6 expression. Vorinostat, a histone deacetylase inhibitor, similarly downregulated TNF-alpha production, reprising the pattern observed with pneumolysin. In conclusion, widespread changes in the macrophage transcriptional response are regulated by pneumolysin and are associated with global changes in histone PTMs. Modulating histone PTMs can reverse pneumolysin-associated transcriptional changes influencing innate immune responses, suggesting that epigenetic modification by pneumolysin plays a role in dampening the innate responses to pneumococci.	[Cole, Joby; Angyal, Adrienn] Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England; [Cole, Joby] Sheffield Teaching Hosp NHS FT, Sheffield, S Yorkshire, England; [Cole, Joby] Univ Sheffield, Florey Inst, Sheffield, S Yorkshire, England; [Cole, Joby; Dickman, Mark J.] Univ Sheffield, Dept Chem & Biol Engn, Sheffield, S Yorkshire, England; [Emes, Richard D.] Univ Nottingham, Adv Data Anal Ctr, Nottingham, England; [Emes, Richard D.] Univ Nottingham, Sch Vet Med & Sci, Nottingham, England; [Mitchell, Tim John] Univ Birmingham, Inst Microbiol & Infect, Edinburgh, Midlothian, Scotland; [Dockrell, David H.] Univ Edinburgh, MRC Ctr Inflammat Res, Edinburgh, Midlothian, Scotland	University of Sheffield; University of Sheffield; University of Sheffield; University of Nottingham; University of Nottingham; University of Birmingham; University of Edinburgh	Dockrell, DH (corresponding author), Univ Edinburgh, MRC Ctr Inflammat Res, Edinburgh, Midlothian, Scotland.	David.Dockrell@ed.ac.uk		Cole, Joby/0000-0002-5258-5835	Wellcome Trust [WT104437/Z/14/Z]; MRC cross council AMR funding initiative SHIELD consortium [MR/N02995X/1]; BBSRC UK [BB/M012166/1]	Wellcome Trust(Wellcome Trust); MRC cross council AMR funding initiative SHIELD consortium; BBSRC UK(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	JC was supported by The Wellcome Trust who funded this work (WT104437/Z/14/Z). DD was supported by MRC cross council AMR funding initiative SHIELD consortium MR/N02995X/1. MD acknowledges support from BBSRC UK (award no. BB/M012166/1). The funders had no role in the study design, data collection, decision to publish, or preparation of the manuscript.	A.Angyal, 2020, bioRxiv, DOI 10.1101/2020.06.08.139980; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Belchamber KBR, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.02244-2018; BENTON KA, 1995, INFECT IMMUN, V63, P448, DOI 10.1128/IAI.63.2.448-455.1995; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bewley MA, 2018, AM J RESP CRIT CARE, V198, P739, DOI 10.1164/rccm.201705-0903OC; Bewley MA, 2017, AM J RESP CRIT CARE, V196, P845, DOI 10.1164/rccm.201608-1714OC; Bewley MA, 2014, MBIO, V5, DOI 10.1128/mBio.01710-14; Breuilh L, 2007, INFECT IMMUN, V75, P5148, DOI 10.1128/IAI.02006-06; Chen W, 2004, J BIOL CHEM, V279, P11129, DOI 10.1074/jbc.M313562200; Cole J, 2019, RAPID COMMUN MASS SP, V33, P897, DOI 10.1002/rcm.8401; Cole J, 2016, PHARMACOL THERAPEUT, V167, P85, DOI 10.1016/j.pharmthera.2016.07.013; Collini PJ, 2018, AM J RESP CRIT CARE, V197, P1604, DOI 10.1164/rccm.201708-1755OC; Connor MG, 2021, NAT MICROBIOL, V6, P257, DOI 10.1038/s41564-020-00805-8; Ding SZ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009875; Dong WY, 2020, CELL REP, V30, P4016, DOI 10.1016/j.celrep.2020.02.116; Eskandarian HA, 2013, SCIENCE, V341, P525, DOI 10.1126/science.1238858; Fang H, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0384-y; Fang RD, 2011, J IMMUNOL, V187, P4890, DOI 10.4049/jimmunol.1100381; Garcia BA, 2007, NAT PROTOC, V2, P933, DOI 10.1038/nprot.2007.106; Goeminne LJE, 2016, MOL CELL PROTEOMICS, V15, P657, DOI 10.1074/mcp.M115.055897; Gordon SB, 2000, INFECT IMMUN, V68, P2286, DOI 10.1128/IAI.68.4.2286-2293.2000; GRAY BM, 1980, J INFECT DIS, V142, P923, DOI 10.1093/infdis/142.6.923; Hamon MA, 2007, P NATL ACAD SCI USA, V104, P13467, DOI 10.1073/pnas.0702729104; Harvey CJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002042; Heber S, 2006, OMICS, V10, P358, DOI 10.1089/omi.2006.10.358; HOULDSWORTH S, 1994, INFECT IMMUN, V62, P1501, DOI 10.1128/IAI.62.4.1501-1503.1994; Hu DK, 2015, EUR J MED RES, V20, DOI 10.1186/s40001-015-0142-4; Hu HB, 2016, CELL RES, V26, P457, DOI 10.1038/cr.2016.40; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones MR, 2005, J IMMUNOL, V175, P7530, DOI 10.4049/jimmunol.175.11.7530; Kadioglu A, 2008, NAT REV MICROBIOL, V6, P288, DOI 10.1038/nrmicro1871; Lugrin J, 2013, BBA-MOL CELL RES, V1833, P1498, DOI 10.1016/j.bbamcr.2013.03.004; McNeela EA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001191; Minshull TC, 2016, J CHROMATOGR A, V1453, P43, DOI 10.1016/j.chroma.2016.05.025; PATON JC, 1984, INFECT IMMUN, V43, P1085, DOI 10.1128/IAI.43.3.1085-1087.1984; Quin LR, 2007, INFECT IMMUN, V75, P2067, DOI 10.1128/IAI.01727-06; Rogers PD, 2003, INFECT IMMUN, V71, P2087, DOI 10.1128/IAI.71.4.2087-2094.2003; Rolando M, 2013, CELL HOST MICROBE, V13, P395, DOI 10.1016/j.chom.2013.03.004; Sander LE, 2011, NATURE, V474, P385, DOI 10.1038/nature10072; Shechter D, 2007, NAT PROTOC, V2, P1445, DOI 10.1038/nprot.2007.202; Starokadomskyy P, 2013, J CLIN INVEST, V123, P2244, DOI 10.1172/JCI66466; Subramanian K, 2019, NAT MICROBIOL, V4, P62, DOI 10.1038/s41564-018-0280-x; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; Tweten RK, 2005, INFECT IMMUN, V73, P6199, DOI 10.1128/IAI.73.10.6199-6209.2005; van Pee K, 2017, ELIFE, V6, DOI 10.7554/eLife.23644; WALKER JA, 1987, INFECT IMMUN, V55, P1184, DOI 10.1128/IAI.55.5.1184-1189.1987; Wilson CL, 2005, BIOINFORMATICS, V21, P3683, DOI 10.1093/bioinformatics/bti605; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Zafar MA, 2017, CELL HOST MICROBE, V21, P73, DOI 10.1016/j.chom.2016.12.005; Zahlten J, 2015, J INFECT DIS, V211, P1822, DOI 10.1093/infdis/jiu806; Zhao HL, 2017, AM J PHYSIOL-LUNG C, V312, pL155, DOI 10.1152/ajplung.00449.2016	52	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2021	12								573266	10.3389/fimmu.2021.573266	http://dx.doi.org/10.3389/fimmu.2021.573266			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SG9GY	34046027	Green Published, Green Submitted, gold			2022-12-18	WOS:000653749600001
J	Norman, MU; Chow, Z; Snelgrove, SL; Prakongtham, P; Hickey, MJ				Norman, M. Ursula; Chow, Zachary; Snelgrove, Sarah L.; Prakongtham, Peemapat; Hickey, Michael J.			Dynamic Regulation of the Molecular Mechanisms of Regulatory T Cell Migration in Inflamed Skin	FRONTIERS IN IMMUNOLOGY			English	Article						regulatory T cell; skin; inflammation; migration; alpha(v) integrin; PI3 kinase		The presence of regulatory T cells (Tregs) in skin is important in controlling inflammatory responses in this peripheral tissue. Uninflamed skin contains a population of relatively immotile Tregs often located in clusters around hair follicles. Inflammation induces a significant increase both in the abundance of Tregs within the dermis, and in the proportion of Tregs that are highly migratory. The molecular mechanisms underpinning Treg migration in the dermis are unclear. In this study we used multiphoton intravital microscopy to examine the role of RGD-binding integrins and signalling through phosphoinositide 3-kinase P110 delta (PI3K p110 delta) in intradermal Treg migration in resting and inflamed skin. We found that inflammation induced Treg migration was dependent on RGD-binding integrins in a context-dependent manner. alpha(v) integrin was important for Treg migration 24 hours after induction of inflammation, but contributed to Treg retention at 48 hours, while beta(1) integrin played a role in Treg retention at the later time point but not during the peak of inflammation. In contrast, inhibition of signalling through PI3K p110 delta reduced Treg migration throughout the entire inflammatory response, and also in the absence of inflammation. Together these observations demonstrate that the molecular mechanisms controlling intradermal Treg migration vary markedly according to the phase of the inflammatory response.	[Norman, M. Ursula; Chow, Zachary; Snelgrove, Sarah L.; Prakongtham, Peemapat; Hickey, Michael J.] Monash Univ, Monash Med Ctr, Dept Med, Ctr Inflammatory Dis, Clayton, Vic, Australia; [Chow, Zachary] Skin Res Inst Singapore SRIS, Singapore, Singapore	Monash University	Hickey, MJ (corresponding author), Monash Univ, Monash Med Ctr, Dept Med, Ctr Inflammatory Dis, Clayton, Vic, Australia.	Michael.hickey@monash.edu	Chow, Zachary/GXG-8693-2022; Hickey, Michael/A-5429-2012	Hickey, Michael/0000-0003-2354-357X	National Health and Medical Research Council (NHMRC), Australia [1042775, 1135971]	National Health and Medical Research Council (NHMRC), Australia(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the National Health and Medical Research Council (NHMRC), Australia (Senior Research Fellowship IDs 1042775 & 1135971) to MH.	Abeynaike LD, 2014, J IMMUNOL, V193, P4934, DOI 10.4049/jimmunol.1400641; Ali K, 2014, NATURE, V510, P407, DOI 10.1038/nature13444; Ali N, 2017, IMMUNOLOGY, V152, P372, DOI 10.1111/imm.12791; Ali N, 2017, CELL, V169, P1119, DOI 10.1016/j.cell.2017.05.002; Billroth-MacLurg AC, 2016, J IMMUNOL, V197, P2208, DOI 10.4049/jimmunol.1502575; Chinen T, 2016, NAT IMMUNOL, V17, P1322, DOI 10.1038/ni.3540; Chow Z, 2013, J IMMUNOL, V191, P3049, DOI 10.4049/jimmunol.1203205; Collins N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11514; Deane JA, 2012, J IMMUNOL, V188, P2179, DOI 10.4049/jimmunol.1102752; Dudda JC, 2008, J EXP MED, V205, P1559, DOI 10.1084/jem.20072594; Fan XY, 2018, J EXP MED, V215, P2796, DOI 10.1084/jem.20181442; Fernandes NRJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01501; Fu HM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4436; Gaylo-Moynihan A, 2019, IMMUNITY, V51, P298, DOI 10.1016/j.immuni.2019.06.026; Gratz IK, 2013, J IMMUNOL, V190, P4483, DOI 10.4049/jimmunol.1300212; Halabi-Tawil M, 2009, BRIT J DERMATOL, V160, P645, DOI 10.1111/j.1365-2133.2008.08835.x; Hanakawa S, 2019, J ALLERGY CLIN IMMUN, V144, P1343, DOI 10.1016/j.jaci.2019.05.033; Hirahara K, 2006, J IMMUNOL, V177, P4488, DOI 10.4049/jimmunol.177.7.4488; Huehn J, 2004, J EXP MED, V199, P303, DOI 10.1084/jem.20031562; Ikebuchi R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01098; Jarmin SJ, 2008, J CLIN INVEST, V118, P1154, DOI 10.1172/JCI33267; Kishore M, 2017, IMMUNITY, V47, P875, DOI 10.1016/j.immuni.2017.10.017; Lammermann T, 2008, NATURE, V453, P51, DOI 10.1038/nature06887; Levine AG, 2014, NAT IMMUNOL, V15, P1070, DOI 10.1038/ni.3004; Li DY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02104; Liu D, 2009, J IMMUNOL, V183, P1921, DOI 10.4049/jimmunol.0901099; Liu Z, 2018, J INVEST DERMATOL, V138, P1328, DOI 10.1016/j.jid.2018.01.018; Liu ZD, 2015, NATURE, V528, P225, DOI 10.1038/nature16169; Mair I, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00264; Mempel TR, 2006, IMMUNITY, V25, P129, DOI 10.1016/j.immuni.2006.04.015; Miragaia RJ, 2019, IMMUNITY, V50, P493, DOI 10.1016/j.immuni.2019.01.001; Mittal D, 2010, EMBO J, V29, P2242, DOI 10.1038/emboj.2010.94; Mostaco-Guidolin L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081772; Mrass P, 2008, IMMUNITY, V29, P971, DOI 10.1016/j.immuni.2008.10.015; Natsuaki Y, 2014, NAT IMMUNOL, V15, P1064, DOI 10.1038/ni.2992; Norman MU, 2008, J IMMUNOL, V180, P510, DOI 10.4049/jimmunol.180.1.510; Okkenhaug K, 2006, J IMMUNOL, V177, P5122, DOI 10.4049/jimmunol.177.8.5122; Overstreet MG, 2013, NAT IMMUNOL, V14, P949, DOI 10.1038/ni.2682; Patton DT, 2006, J IMMUNOL, V177, P6598, DOI 10.4049/jimmunol.177.10.6598; Reif K, 2004, J IMMUNOL, V173, P2236, DOI 10.4049/jimmunol.173.4.2236; Rodriguez RS, 2014, J CLIN INVEST, V124, P1027, DOI 10.1172/JCI72932; Sather BD, 2007, J EXP MED, V204, P1335, DOI 10.1084/jem.20070081; Siegmund K, 2005, BLOOD, V106, P3097, DOI 10.1182/blood-2005-05-1864; Snelgrove SL, 2019, J IMMUNOL, V203, P2850, DOI 10.4049/jimmunol.1900447; Suffia I, 2005, J IMMUNOL, V174, P5444, DOI 10.4049/jimmunol.174.9.5444; Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572; Tang QZ, 2006, NAT IMMUNOL, V7, P83, DOI 10.1038/ni1289; Tomura M, 2010, J CLIN INVEST, V120, P883, DOI 10.1172/JCI40926; Vahl JC, 2014, IMMUNITY, V41, P722, DOI 10.1016/j.immuni.2014.10.012; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Vocanson M, 2010, J ALLERGY CLIN IMMUN, V126, P280, DOI 10.1016/j.jaci.2010.05.022; Ward SG, 2006, TRENDS IMMUNOL, V27, P80, DOI 10.1016/j.it.2005.12.004; Zhang L, 2000, J INVEST DERMATOL, V115, P168, DOI 10.1046/j.1523-1747.2000.00999.x	53	1	1	8	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 10	2021	12								655499	10.3389/fimmu.2021.655499	http://dx.doi.org/10.3389/fimmu.2021.655499			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SG0AA	34040606	gold, Green Published			2022-12-18	WOS:000653107500001
J	van der Maas, NG; von Asmuth, EGJ; Berghuis, D; van Schouwenburg, PA; Putter, H; van der Burg, M; Lankester, AC				van der Maas, Nicolaas G.; von Asmuth, Erik G. J.; Berghuis, Dagmar; van Schouwenburg, Pauline A.; Putter, Hein; van der Burg, Mirjam; Lankester, Arjan C.			Modeling Influencing Factors in B-Cell Reconstitution After Hematopoietic Stem Cell Transplantation in Children	FRONTIERS IN IMMUNOLOGY			English	Article						B lymphocyte; allogeneic; hematopoietic stem cell transplantation; immune reconstitution; pediatric; linear mixed effect modelling		Reduced total and memory B-cell numbers in peripheral blood long term after hematopoietic stem cell transplantation (HSCT) are associated with an increased incidence of infections and immune complications. Using novel modelling strategies, baseline factors influencing B-cell reconstitution can be comprehensively studied. This study aims to investigate the numerical total and memory B-cell reconstitution in children and the association with baseline determinants 0.5-2 years after allogeneic HSCT. Eligible for inclusion were children transplanted in our center between 2004-2017 who received a first HSCT for malignant or non-malignant disorders. The continuous absolute counts of total and memory B-cells were evaluated as outcome measure. Exploratory analysis at one year was done to identify possible determinants. Linear mixed effect modelling was used to analyze the association of these determinants with total and memory B-cell reconstitution 0.5-2 years after HSCT. In a cohort of 223 evaluable patients analyzed at 1-year after HSCT donor age, stem cell source, donor type, recipient age and conditioning were identified as significant determinants for total and memory B-cell numbers. Multivariable analysis revealed that both donor and recipient age were inversely correlated with the size of total and memory B-cell reconstitution. In contrast, no correlation was found with stem cell source, donor type and conditioning. Making use of linear mixed modelling both stem cell donor and recipient age were identified as independent determinants of total and memory B-cell reconstitution 0.5-2 years after HSCT.	[van der Maas, Nicolaas G.; von Asmuth, Erik G. J.; Berghuis, Dagmar; van Schouwenburg, Pauline A.; van der Burg, Mirjam; Lankester, Arjan C.] Leiden Univ, Med Ctr, Willem Alexander Childrens Hosp, Dept Pediat, Leiden, Netherlands; [van der Maas, Nicolaas G.; von Asmuth, Erik G. J.; Berghuis, Dagmar; van Schouwenburg, Pauline A.; van der Burg, Mirjam; Lankester, Arjan C.] Leiden Univ, Med Ctr, Willem Alexander Childrens Hosp, Lab Pediat Immunol, Leiden, Netherlands; [Putter, Hein] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Lankester, AC (corresponding author), Leiden Univ, Med Ctr, Willem Alexander Childrens Hosp, Dept Pediat, Leiden, Netherlands.; Lankester, AC (corresponding author), Leiden Univ, Med Ctr, Willem Alexander Childrens Hosp, Lab Pediat Immunol, Leiden, Netherlands.	A.lankester@lumc.nl	; Putter, Hein/C-2244-2018	von Asmuth, Erik/0000-0001-6256-7457; Putter, Hein/0000-0001-5395-1422				Abdel-Azim H, 2017, BIOL BLOOD MARROW TR, V23, P1437, DOI 10.1016/j.bbmt.2017.05.005; Abrahamsen IW, 2005, HAEMATOLOGICA, V90, P86; Arakawa-Hoyt J, 1999, BONE MARROW TRANSPL, V24, P1167, DOI 10.1038/sj.bmt.1702048; Avanzini MA, 2005, EXP HEMATOL, V33, P480, DOI 10.1016/j.exphem.2005.01.005; Bartelink IH, 2013, BIOL BLOOD MARROW TR, V19, P305, DOI 10.1016/j.bbmt.2012.10.010; Blanco E, 2018, J ALLERGY CLIN IMMUN, V141, P2208, DOI 10.1016/j.jaci.2018.02.017; Chiesa R, 2012, EXPERT REV CLIN IMMU, V8, P255, DOI [10.1586/ECI.12.9, 10.1586/eci.12.9]; Corre E, 2010, HAEMATOL-HEMATOL J, V95, P1025, DOI 10.3324/haematol.2009.018853; Ergen AV, 2012, BLOOD, V119, P2500, DOI 10.1182/blood-2011-11-391730; Gonzalez-Vicent M, 2017, LEUKEMIA RES, V57, P60, DOI 10.1016/j.leukres.2017.03.001; Ogonek J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00507; Pinheiro J., 2020, R PACKAGE VERSION, P1; R Core Team, 2021, R LANG ENV STAT COMP; Rao K, 2005, BLOOD, V105, P879, DOI 10.1182/blood-2004-03-0960; Rossi DJ, 2005, P NATL ACAD SCI USA, V102, P9194, DOI 10.1073/pnas.0503280102; Sarantopoulos S, 2015, BIOL BLOOD MARROW TR, V21, P16, DOI 10.1016/j.bbmt.2014.10.029; Storek J, 2001, BLOOD, V98, P489, DOI 10.1182/blood.V98.2.489; Storek J, 2001, BLOOD, V97, P3380, DOI 10.1182/blood.V97.11.3380; van der Maas NG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00782; van Gent R, 2009, CLIN IMMUNOL, V133, P95, DOI 10.1016/j.clim.2009.05.020; von Asmuth EGJ, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.584156	21	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 7	2021	12								684147	10.3389/fimmu.2021.684147	http://dx.doi.org/10.3389/fimmu.2021.684147			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SF0ZU	34025685	gold, Green Published			2022-12-18	WOS:000652493800001
J	Gao, YJ; Zhang, SY; Yang, L; Li, J; Liu, YH; Wang, T				Gao, Yajuan; Zhang, Shiyu; Yang, Lu; Li, Jian; Liu, Yuehua; Wang, Tao			Skin Responses in Newly Diagnosed Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome After Therapy With Low-Dose Lenalidomide Plus Dexamethasone	FRONTIERS IN IMMUNOLOGY			English	Article						POEMS syndrome; skin changes; vascular endothelial growth factor; lenalidomide; dexamethasone; prospective studies	STEM-CELL TRANSPLANTATION; GROWTH-FACTOR LEVELS; BEVACIZUMAB THERAPY; ELEVATED LEVELS; MANIFESTATIONS; ANTIBODY; PROTEIN; SERUM	Background Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome is a rare paraneoplastic disease with a high prevalence of skin symptoms. Few studies have focused on skin responses to systemic treatment of this disease. Objective To evaluate skin responses after treatment with low-dose lenalidomide plus dexamethasone and determine their relationship with vascular endothelial growth factor (VEGF) and hematological responses. Methods A total of 41 consecutive Chinese patients who were at least 18 years of age with newly diagnosed POEMS syndrome were enrolled. 36 of them completed 12 cycles of treatment. Skin, serum VEGF, hematological and neurological responses were documented at 1, 2, 3, 6, 9, and 12 months during treatment. Results Skin manifestations were not associated with serum VEGF levels at baseline. Of the patients with hyperpigmentation, hemangiomas, hypertrichosis, white nails, or acrocyanosis separately, 26/34 (76.5%), 11/30 (36.7%), 14/15 (93.3%), 21/21 (100%), and 4/4 (100%) achieved complete responses at 12 months. Reduction in hyperpigmentation after 12 months reflected a good VEGF response (P = 0.017). Conclusion Low-dose lenalidomide plus dexamethasone therapy is effective in reversing skin changes in patients with POEMS syndrome.	[Gao, Yajuan; Zhang, Shiyu; Yang, Lu; Liu, Yuehua; Wang, Tao] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Dermatol, Beijing, Peoples R China; [Li, Jian] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital	Liu, YH; Wang, T (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Dermatol, Beijing, Peoples R China.	yuehualiu63@163.com; wangtaopumch@126.com			National Natural Science Foundation of China [81570195]; Beijing Natural Science Foundation [7142130]; Specialized Research Fund for the Doctoral Program of Higher Education [2013110611000]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-002]; National Key Research and Development Program of China [2016YFC0901500]; Fundamental Research Funds for the Central Universities [3332018025]; Beijing Dongcheng District Excellent Talent Support Training project [2019JGM-5]; National Key Research and Development Program of China Grant [2016YFC0901500]; Center for Rare Diseases Research, Chinese Academy of Medical Sciences, Beijing, China;  [NCMIABD02-201709]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Specialized Research Fund for the Doctoral Program of Higher Education(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); CAMS Innovation Fund for Medical Sciences (CIFMS); National Key Research and Development Program of China; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Beijing Dongcheng District Excellent Talent Support Training project; National Key Research and Development Program of China Grant; Center for Rare Diseases Research, Chinese Academy of Medical Sciences, Beijing, China; 	This work had been supported by the National Natural Science Foundation of China (no. 81570195, to JL), the Beijing Natural Science Foundation (no. 7142130, to JL), the Specialized Research Fund for the Doctoral Program of Higher Education (no. 2013110611000, to JL), CAMS Innovation Fund for Medical Sciences (CIFMS, no. 2016-I2M-1-002, to JL), the National Key Research and Development Program of China (no. 2016YFC0901503, to JL), the Fundamental Research Funds for the Central Universities (no.3332018025, to TW), NCMIABD02-201709 (to TW), Beijing Dongcheng District Excellent Talent Support Training project (no.2019JGM-5, to TW), the National Key Research and Development Program of China Grant (no.2016YFC0901500), and the Center for Rare Diseases Research, Chinese Academy of Medical Sciences, Beijing, China. There is no involvement of the funder in study design, data collection, data analysis, and manuscript preparation.	Bachmeyer C, 2012, AM J HEMATOL, V87, P131, DOI 10.1002/ajh.22204; Badros A, 2005, BLOOD, V106, P1135, DOI 10.1182/blood-2005-03-0910; Barete S, 2010, ARCH DERMATOL, V146, P615, DOI 10.1001/archdermatol.2010.100; Buxhofer-Ausch V, 2012, LEUKEMIA RES, V36, pE98, DOI 10.1016/j.leukres.2012.01.018; D'Souza A, 2011, BLOOD, V118, P4663, DOI 10.1182/blood-2011-06-362392; Dietrich PY, 2008, ANN ONCOL, V19, P595, DOI 10.1093/annonc/mdm602; Dispenzieri A, 2004, BLOOD, V104, P3400, DOI 10.1182/blood-2004-05-2046; Dispenzieri A, 2003, BLOOD, V101, P2496, DOI 10.1182/blood-2002-07-2299; Dispenzieri A, 2007, BLOOD REV, V21, P285, DOI 10.1016/j.blre.2007.07.004; Dispenzieri A, 2019, AM J HEMATOL, V94, P812, DOI 10.1002/ajh.25495; Doffoet-Hantz V, 2008, ANN DERMATOL VENER, V135, P320, DOI 10.1016/j.annder.2007.07.008; GHERARDI RK, 1994, BLOOD, V83, P2587; Graham RC, 2006, J NEUROL NEUROSUR PS, V77, P973, DOI 10.1136/jnnp.2005.081547; Guibert C, 2020, J NEUROPATH EXP NEUR, V79, P542, DOI 10.1093/jnen/nlaa021; Guitard J, 2009, CLIN KIDNEY J, V2, P357, DOI 10.1093/ndtplus/sfp094; Hitoshi S, 1992, Rinsho Shinkeigaku, V32, P577; JITSUKAWA K, 1988, Journal of Dermatology (Tokyo), V15, P513; Kanai K, 2007, INTERNAL MED, V46, P311, DOI 10.2169/internalmedicine.46.6246; Kanai K, 2012, NEUROLOGY, V79, P575, DOI 10.1212/WNL.0b013e318263c42b; Keddie S, 2020, NEUROLOGY, V95, pE268, DOI 10.1212/WNL.0000000000009940; Kim Do Wook, 2015, Korean J Ophthalmol, V29, P354, DOI 10.3341/kjo.2015.29.5.354; Kourelis TV, 2016, LEUKEMIA, V30, P1079, DOI 10.1038/leu.2015.344; Li J, 2018, AM J HEMATOL, V93, P803, DOI 10.1002/ajh.25100; Li J, 2011, ANN HEMATOL, V90, P819, DOI 10.1007/s00277-010-1149-0; Lipsker D, 2003, MEDICINE, V82, P51, DOI 10.1097/00005792-200301000-00005; Michizono K, 2001, NEUROLOGY, V56, P807, DOI 10.1212/WNL.56.6.807; Miest RYN, 2013, INT J DERMATOL, V52, P1349, DOI 10.1111/j.1365-4632.2012.05648.x; Ohwada C, 2009, BONE MARROW TRANSPL, V43, P739, DOI 10.1038/bmt.2008.381; Prost MG, 2014, CASE REP OPHTHALM, V5, P416, DOI 10.1159/000369856; Rose C, 1997, LEUKEMIA, V11, P1318, DOI 10.1038/sj.leu.2400733; Rovira M, 2001, BRIT J HAEMATOL, V115, P373, DOI 10.1046/j.1365-2141.2001.03040.x; Samaras P, 2007, HAEMATOLOGICA, V92, P1438, DOI 10.3324/haematol.11315; Sekiguchi Y, 2013, J NEUROL NEUROSUR PS, V84, P1346, DOI 10.1136/jnnp-2012-304874; Sharabi Y, 2000, LEUKEMIA LYMPHOMA, V40, P209, DOI 10.3109/10428190009054899; Solomou EE, 2019, ANN HEMATOL, V98, P2625, DOI 10.1007/s00277-019-03818-4; Song Hyun Beom, 2015, Korean J Ophthalmol, V29, P357, DOI 10.3341/kjo.2015.29.5.357; Straume O, 2006, BLOOD, V107, P4972, DOI 10.1182/blood-2005-12-5045; Suichi T, 2019, NEUROLOGY, V93, pE975, DOI 10.1212/WNL.0000000000008062; TERRY R, 1954, LANCET, V1, P757; Yamada Y, 2013, ANN HEMATOL, V92, P245, DOI 10.1007/s00277-012-1583-2; Yang HB, 2019, LEUKEMIA LYMPHOMA, V60, P483, DOI 10.1080/10428194.2018.1485909; Zhao H, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0073-8	42	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2021	12								681360	10.3389/fimmu.2021.681360	http://dx.doi.org/10.3389/fimmu.2021.681360			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SE6HU	34025681	Green Published, gold			2022-12-18	WOS:000652172300001
J	Hai, L; Shi, XY; Wang, Q				Hai, Lei; Shi, Xiaoyu; Wang, Qian			Attenuated T Cell Responses Are Associated With the Blockade of Cerebral Malaria Development by YOP1-Deficient Plasmodium berghei ANKA	FRONTIERS IN IMMUNOLOGY			English	Article						YOP1; Plasmodium berghei; cerebral malaria; T cell; immune response	ENDOPLASMIC-RETICULUM	Reticulon and the REEP family of proteins stabilize the high curvature of endoplasmic reticulum tubules. The REEP5 homolog in Plasmodium, Plasmodium berghei YOP1 (PbYOP1), plays an important role in the erythrocytic cycle of the P. berghei ANKA and the pathogenesis of experimental cerebral malaria (ECM), but the mechanisms are largely unknown. Here, we show that protection from ECM in Pbyop1 Delta-infected mice is associated with reduced intracerebral Th1 accumulation, decreased expression of pro-inflammatory cytokines and chemokines, and attenuated pathologies in the brainstem, though the total number of CD4(+) and CD8(+) T cells sequestered in the brain are not reduced. Expression of adhesive molecules on brain endothelial cells, including ICAM-1, VCAM-1, and CD36, are decreased, particularly in the brainstem, where fatal pathology is always induced during ECM. Subsequently, CD8(+) T cell-mediated cell apoptosis in the brain is compromised. These findings suggest that Pbyop1 Delta parasites can be a useful tool for mechanistic investigation of cerebral malaria pathogenesis.	[Hai, Lei; Shi, Xiaoyu; Wang, Qian] Tianjin Med Univ, Educ Minist China, Dept Immunol, Sch Basic Med Sci, Tianjin, Peoples R China; [Hai, Lei; Shi, Xiaoyu; Wang, Qian] Tianjin Med Univ, Educ Minist China, Key Lab Immune Microenvironm & Dis, Tianjin Key Lab Cellular & Mol Immunol, Tianjin, Peoples R China; [Wang, Qian] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing, Peoples R China	Tianjin Medical University; Tianjin Medical University; Chinese Academy of Sciences; Institute of Biophysics, CAS	Shi, XY; Wang, Q (corresponding author), Tianjin Med Univ, Educ Minist China, Dept Immunol, Sch Basic Med Sci, Tianjin, Peoples R China.; Shi, XY; Wang, Q (corresponding author), Tianjin Med Univ, Educ Minist China, Key Lab Immune Microenvironm & Dis, Tianjin Key Lab Cellular & Mol Immunol, Tianjin, Peoples R China.; Wang, Q (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing, Peoples R China.	shixy@tmu.edu.cn; wangq@tmu.edu.cn			National Natural Science Foundation of China [32070701]; Tianjin Medical University [115004/000012, 11601502/DW0114]; Science & Technology Development Fund of Tianjin Education Commission for Higher Education [2016KJ0138, 2018KJ085]; National Laboratory of Biomacromolecules [2018kf05, 2020kf11]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Medical University; Science & Technology Development Fund of Tianjin Education Commission for Higher Education; National Laboratory of Biomacromolecules	This work was supported by the National Natural Science Foundation of China (grant number 32070701 to QW), the Startup Funds from Tianjin Medical University (grant numbers 115004/000012 and 11601502/DW0114 to QW), the Science & Technology Development Fund of Tianjin Education Commission for Higher Education (grant number 2016KJ0138 toQWand 2018KJ085 to XS), and the National Laboratory of Biomacromolecules (grant number 2018kf05 and 2020kf11 to QW).	Amante FH, 2010, J IMMUNOL, V185, P3632, DOI 10.4049/jimmunol.1000944; [Anonymous], 2002, Bull World Health Organ, V80, P983; Baptista FG, 2010, INFECT IMMUN, V78, P4033, DOI 10.1128/IAI.00079-10; Bauer PR, 2002, MICROCIRCULATION, V9, P463, DOI 10.1038/sj.mn.7800159; Baumann O, 2001, INT REV CYTOL, V205, P149, DOI 10.1016/S0074-7696(01)05004-5; Belnoue E, 2002, J IMMUNOL, V169, P6369, DOI 10.4049/jimmunol.169.11.6369; Belnoue E, 2008, PARASITE IMMUNOL, V30, P544, DOI 10.1111/j.1365-3024.2008.01053.x; Campanella GSV, 2008, P NATL ACAD SCI USA, V105, P4814, DOI 10.1073/pnas.0801544105; Cunningham DA, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1834-8; Eeka P, 2018, NEUROSCI LETT, V664, P58, DOI 10.1016/j.neulet.2017.11.021; Engwerda C, 2005, CURR TOP MICROBIOL, V297, P103; Franke-Fayard B, 2005, P NATL ACAD SCI USA, V102, P11468, DOI 10.1073/pnas.0503386102; Frevert U, 2013, PARASITE IMMUNOL, V35, P267, DOI 10.1111/pim.12039; Gimenez F, 2003, CELL MOL LIFE SCI, V60, P1623, DOI 10.1007/s00018-003-2347-x; Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017; Gun SY, 2018, CELL MICROBIOL, V20, DOI 10.1111/cmi.12819; Haldar K, 2007, CURR OPIN HEMATOL, V14, P203, DOI 10.1097/MOH.0b013e3280f31b2d; Hanum S, 2003, INT IMMUNOL, V15, P633, DOI 10.1093/intimm/dxg065; Haque A, 2011, EUR J IMMUNOL, V41, P2688, DOI 10.1002/eji.201141539; Haque A, 2011, J IMMUNOL, V186, P6148, DOI 10.4049/jimmunol.1003955; Hermsen C, 1997, PARASITOLOGY, V114, P7, DOI 10.1017/S0031182096008293; Herz J, 2015, J EXP MED, V212, P1153, DOI 10.1084/jem.20142047; Hirahara K, 2016, INT IMMUNOL, V28, P163, DOI 10.1093/intimm/dxw006; Howland SW, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004963; Howland SW, 2013, EMBO MOL MED, V5, P984, DOI 10.1002/emmm.201202273; Howland SW, 2015, SEMIN IMMUNOPATHOL, V37, P221, DOI 10.1007/s00281-015-0476-6; Huggins MA, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00985-16; Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1; Imai T, 2010, EUR J IMMUNOL, V40, P1053, DOI 10.1002/eji.200939525; Lackner P, 2007, NEUROPATH APPL NEURO, V33, P560, DOI 10.1111/j.1365-2990.2007.00833.x; Langhorne J, 2008, NAT IMMUNOL, V9, P725, DOI 10.1038/ni.f.205; Linares M, 2013, BRAIN RES, V1490, P210, DOI 10.1016/j.brainres.2012.10.040; Lopez-Ramirez MA, 2014, FASEB J, V28, P2551, DOI 10.1096/fj.13-248880; Lord SJ, 2003, IMMUNOL REV, V193, P31, DOI 10.1034/j.1600-065X.2003.00044.x; Lossi L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123999; McCormick CJ, 1997, J CLIN INVEST, V100, P2521, DOI 10.1172/JCI119794; McQuillan JA, 2011, INT J PARASITOL, V41, P155, DOI 10.1016/j.ijpara.2010.08.003; Nie CQ, 2007, INFECT IMMUN, V75, P2275, DOI 10.1128/IAI.01783-06; Nitcheu J, 2003, J IMMUNOL, V170, P2221, DOI 10.4049/jimmunol.170.4.2221; O'Shea JJ, 2011, NAT REV IMMUNOL, V11, P239, DOI 10.1038/nri2958; Oakley MS, 2013, J IMMUNOL, V191, P4699, DOI 10.4049/jimmunol.1300396; Patel SN, 2004, J INFECT DIS, V189, P204, DOI 10.1086/380764; Perez-Mazliah D, 2015, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00671; Pino PA, 2011, JOVE-J VIS EXP, DOI 10.3791/2348; Poh CM, 2014, INFECT IMMUN, V82, P4854, DOI 10.1128/IAI.02180-14; Potter S, 2006, INT J PARASITOL, V36, P485, DOI 10.1016/j.ijpara.2005.12.005; Promeneur D, 2013, P NATL ACAD SCI USA, V110, P1035, DOI 10.1073/pnas.1220566110; Riggle BA, 2020, J CLIN INVEST, V130, P1128, DOI 10.1172/JCI133474; Schwarz DS, 2016, CELL MOL LIFE SCI, V73, P79, DOI 10.1007/s00018-015-2052-6; Shaw TN, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00248; Shaw TN, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005210; Shi XY, 2020, MOL MICROBIOL, V114, P454, DOI 10.1111/mmi.14526; Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3; Smith JD, 2013, CELL MICROBIOL, V15, P1976, DOI 10.1111/cmi.12183; Strangward P, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006267; Sun S, 2016, PROTEIN CELL, V7, P615, DOI 10.1007/s13238-016-0290-5; Swanson PA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006022; Taylor TE, 2004, NAT MED, V10, P143, DOI 10.1038/nm986; Villegas-Mendez A, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.01035-16; Villegas-Mendez A, 2012, J IMMUNOL, V189, P968, DOI 10.4049/jimmunol.1200688; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; Wang XB, 2017, ELIFE, V6, DOI [10.7554/elife.23816, 10.7554/eLife.23816]; Yanez DM, 1996, J IMMUNOL, V157, P1620; Yui K, 2013, EMBO MOL MED, V5, P967, DOI 10.1002/emmm.201302849; Zheng W, 2009, FOLIA PARASIT, V56, P242, DOI 10.14411/fp.2009.028	65	1	1	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2021	12								642585	10.3389/fimmu.2021.642585	http://dx.doi.org/10.3389/fimmu.2021.642585			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SF1IX	34025654	gold, Green Published			2022-12-18	WOS:000652517600001
J	Castellano, F; Correale, J; Molinier-Frenkel, V				Castellano, Flavia; Correale, Jorge; Molinier-Frenkel, Valerie			Editorial: Immunosuppressive Amino Acid Catabolizing Enzymes in Heallth and Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immunosuppressive enzymes; amino acids (AA); immunoregulation; T cell response; B cell response; phenylalanine; tryptophan; arginin			[Castellano, Flavia; Molinier-Frenkel, Valerie] Univ Paris Est Creteil, INSERM, IMRB, Creteil, France; [Castellano, Flavia; Correale, Jorge; Molinier-Frenkel, Valerie] Hop Henri Mondor, AP HP, Dept Biol Pathol, Creteil, France; Fdn Lucha Enfermedades Neurol Infancia FLENI, Dept Neurol, Buenos Aires, DF, Argentina	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Castellano, F; Molinier-Frenkel, V (corresponding author), Univ Paris Est Creteil, INSERM, IMRB, Creteil, France.; Castellano, F; Correale, J; Molinier-Frenkel, V (corresponding author), Hop Henri Mondor, AP HP, Dept Biol Pathol, Creteil, France.	flavia.castellano@inserm.fr; jcorreale@fleni.org.ar; valerie.frenkel@inserm.fr		Molinier-Frenkel, Valerie/0000-0002-7250-7295; Castellano, Flavia/0000-0001-9389-6704	Fondation BMS pour la Recherche en Immuno-Oncologie; INCA [2018-155]	Fondation BMS pour la Recherche en Immuno-Oncologie; INCA(Institut National du Cancer (INCA) France)	This work was supported by a grant from the Fondation BMS pour la Recherche en Immuno-Oncologie (FC) and INCA No 2018-155 (VMF, FC).	Grohmann U, 2010, IMMUNOL REV, V236, P243, DOI 10.1111/j.1600-065X.2010.00915.x; McGaha TL, 2012, IMMUNOL REV, V249, P135, DOI 10.1111/j.1600-065X.2012.01149.x; Molinier-Frenkel V, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070757	3	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 5	2021	12								689864	10.3389/fimmu.2021.689864	http://dx.doi.org/10.3389/fimmu.2021.689864			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SD7ZW	34025686	Green Submitted, gold, Green Published			2022-12-18	WOS:000651596000001
J	Aral, AM; Zamora, R; Barclay, D; Yin, JL; El-Dehaibi, F; Erbas, VE; Dong, LW; Zhang, ZX; Sahin, H; Gorantla, VS; Vodovotz, Y				Aral, Ali Mubin; Zamora, Ruben; Barclay, Derek; Yin, Jinling; El-Dehaibi, Fayten; Erbas, Vasil E.; Dong, Liwei; Zhang, Zhaoxiang; Sahin, Huseyin; Gorantla, Vijay S.; Vodovotz, Yoram			The Effects of Tacrolimus on Tissue-Specific, Protein-Level Inflammatory Networks in Vascularized Composite Allotransplantation	FRONTIERS IN IMMUNOLOGY			English	Article						vascularized composite allotransplantation; inflammation; systems biology; network analysis; immunosuppression; acute rejection	ANTIBODY-MEDIATED REJECTION; UPPER EXTREMITY TRANSPLANTATION; IMMUNE-RESPONSE; LEPTIN; HAND; CELL; VASCULOPATHY; EXPRESSION; INJURY; TH1	Systems-level insights into inflammatory events after vascularized composite allotransplantation (VCA) are critical to the success of immunomodulatory strategies of these complex procedures. To date, the effects of tacrolimus (TAC) immunosuppression on inflammatory networks in VCA, such as in acute rejection (AR), have not been investigated. We used a systems biology approach to elucidate the effects of tacrolimus on dynamic networks and principal drivers of systemic inflammation in the context of dynamic tissue-specific immune responses following VCA. Lewis (LEW) rat recipients received orthotopic hind limb VCA from fully major histocompatibility complex-mismatched Brown Norway (BN) donors or matched LEW donors. Group 1 (syngeneic controls) received LEW limbs without TAC, and Group 2 (treatment group) received BN limbs with TAC. Time-dependent changes in 27 inflammatory mediators were analyzed in skin, muscle, and peripheral blood using Principal Component Analysis (PCA), Dynamic Bayesian Network (DyBN) inference, and Dynamic Network Analysis (DyNA) to define principal characteristics, central nodes, and putative feedback structures of systemic inflammation. Analyses were repeated on skin + muscle data to construct a "Virtual VCA", and in skin + muscle + peripheral blood data to construct a "Virtual Animal." PCA, DyBN, and DyNA results from individual tissues suggested important roles for leptin, VEGF, various chemokines, the NLRP3 inflammasome (IL-1 beta, IL-18), and IL-6 after TAC treatment. The chemokines MCP-1, MIP-1 alpha; and IP-10 were associated with AR in controls. Statistical analysis suggested that 24/27 inflammatory mediators were altered significantly between control and TAC-treated rats in peripheral blood, skin, and/or muscle over time. "Virtual VCA" and "Virtual Animal" analyses implicated the skin as a key control point of dynamic inflammatory networks, whose connectivity/complexity over time exhibited a U-shaped trajectory and was mirrored in the systemic circulation. Our study defines the effects of TAC on complex spatiotemporal evolution of dynamic inflammation networks in VCA. We also demonstrate the potential utility of computational analyses to elucidate nonlinear, cross-tissue interactions. These approaches may help define precision medicine approaches to better personalize TAC immunosuppression in VCA recipients.	[Aral, Ali Mubin; Zamora, Ruben; Barclay, Derek; Yin, Jinling; El-Dehaibi, Fayten; Vodovotz, Yoram] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA; [Zamora, Ruben; Vodovotz, Yoram] Univ Pittsburgh, McGowan Inst Regenerat Med, Ctr Inflammat & Regenerat Modeling, Pittsburgh, PA 15260 USA; [Erbas, Vasil E.] Medicalpk Gaziantep Hosp, Dept Plast Reconstruct & Aesthet Surg, Gaziantep, Turkey; [Dong, Liwei; Zhang, Zhaoxiang] XiJing Hosp, Plast & Aesthet Surg Dept, Xian, Peoples R China; [Sahin, Huseyin] Private Cagsu Hosp, Duzce, Turkey; [Gorantla, Vijay S.] Wake Forest Baptist Med Ctr, Wake Forest Inst Regenerat Med, Dept Surg, Winston Salem, NC 27157 USA; [Sahin, Huseyin] Karadeniz Tech Univ, Plast Surg, Trabzon, Turkey	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Medical Park Hospitals Group; Air Force Military Medical University; Wake Forest University; Wake Forest Baptist Medical Center; Karadeniz Technical University	Vodovotz, Y (corresponding author), Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA.; Vodovotz, Y (corresponding author), Univ Pittsburgh, McGowan Inst Regenerat Med, Ctr Inflammat & Regenerat Modeling, Pittsburgh, PA 15260 USA.; Gorantla, VS (corresponding author), Wake Forest Baptist Med Ctr, Wake Forest Inst Regenerat Med, Dept Surg, Winston Salem, NC 27157 USA.	vgorantl@wakehealth.edu; vodovotzy@upmc.edu			Dept. of Defense [W81 XWH15-1-0336]	Dept. of Defense(United States Department of Defense)	This work was supported by Dept. of Defense grant W81 XWH15-1-0336 (YV, PI).	[Anonymous], 2016, ANESTHESIA PERIOPERA, DOI DOI 10.1007/978-1-4939-6377-5_44; Antony AK, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00188; Aomatsu T, 2012, INT J MOL MED, V30, P1152, DOI 10.3892/ijmm.2012.1094; Arnalich F, 1999, J INFECT DIS, V180, P908, DOI 10.1086/314963; Azhar N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078202; Borges TJ, 2016, AM J TRANSPLANT, V16, P2158, DOI 10.1111/ajt.13705; Brandacher G, 2012, EXPERT REV CLIN IMMU, V8, P673, DOI [10.1586/ECI.12.54, 10.1586/eci.12.54]; Brown D, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3636; Brunet M, 2019, THER DRUG MONIT, V41, P261, DOI 10.1097/FTD.0000000000000640; Cakir B, 2005, REGUL PEPTIDES, V125, P135, DOI 10.1016/j.regpep.2004.08.032; Cendales LC, 2008, AM J TRANSPLANT, V8, P1396, DOI 10.1111/j.1600-6143.2008.02243.x; Chandraker A, 2014, AM J TRANSPLANT, V14, P1446, DOI 10.1111/ajt.12715; Day JD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00484; Dedinska I, 2018, J DIABETES COMPLICAT, V32, P863, DOI 10.1016/j.jdiacomp.2018.07.002; DElios M, 1997, KIDNEY INT, V51, P1876, DOI 10.1038/ki.1997.256; Elenkov IJ, 2002, INT REV NEUROBIOL, V52, P163; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; Emr B, 2014, SHOCK, V41, P317, DOI 10.1097/SHK.0000000000000121; Faggioni R, 2001, FASEB J, V15, P2565, DOI 10.1096/fj.01-0431rev; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Fontes P, 2015, AM J TRANSPLANT, V15, P381, DOI 10.1111/ajt.12991; Friedman O, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181507; Fujita Y, 2014, J IMMUNOL, V192, P979, DOI 10.4049/jimmunol.1301685; Gorantla VS, 2011, HAND CLIN, V27, P481, DOI 10.1016/j.hcl.2011.08.006; Gorantla VS, 2000, MICROSURG, V20, P420, DOI 10.1002/1098-2752(2000)20:8<420::AID-MICR13>3.0.CO;2-O; Grzegorczyk M, 2011, BIOINFORMATICS, V27, P693, DOI 10.1093/bioinformatics/btq711; Ho AW, 2019, NAT REV IMMUNOL, V19, P490, DOI 10.1038/s41577-019-0162-3; Huang XL, 2008, ENDOCR REV, V29, P603, DOI 10.1210/er.2008-0006; Janes KA, 2006, NAT REV MOL CELL BIO, V7, P820, DOI 10.1038/nrm2041; JUSKO WJ, 1995, CLIN PHARMACOL THER, V57, P281, DOI 10.1016/0009-9236(95)90153-1; Kaufman CL, 2012, AM J TRANSPLANT, V12, P1004, DOI 10.1111/j.1600-6143.2011.03915.x; Kaufman CL, 2011, HAND CLIN, V27, P417, DOI 10.1016/j.hcl.2011.08.004; Koch I, 2002, DRUG METAB DISPOS, V30, P1108, DOI 10.1124/dmd.30.10.1108; Krezdorn N, 2019, AM J TRANSPLANT, V19, P1168, DOI 10.1111/ajt.15143; LEE WPA, 1991, PLAST RECONSTR SURG, V87, P401, DOI 10.1097/00006534-199103000-00001; Leonard DA, 2013, CURR OPIN ORGAN TRAN, V18, P645, DOI 10.1097/MOT.0000000000000022; Li NYK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002789; Li XC, 1998, J IMMUNOL, V161, P2241; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Marik PE, 2012, J TRAUMA ACUTE CARE, V73, P801, DOI 10.1097/TA.0b013e318265cf87; Messner F, 2020, TRANSPLANTATION, V104, P956, DOI 10.1097/TP.0000000000003075; Metukuri MR, 2009, AM J PHYSIOL-GASTR L, V296, pG499, DOI 10.1152/ajpgi.90526.2008; Mi Q, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019424; Moore SI, 2003, INFECT IMMUN, V71, P4182, DOI 10.1128/IAI.71.7.4182-4185.2003; Morelon E, 2017, AM J TRANSPLANT, V17, P1935, DOI 10.1111/ajt.14218; Namas R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008406; Namas RA, 2012, MOL MED, V18, P1366, DOI 10.2119/molmed.2012.00106; Neunaber C, 2011, RECENT PATENTS INFLA, V5, P17, DOI 10.2174/187221311794474892; Nieman G, 2012, CRIT CARE MED, V40, P1052, DOI 10.1097/CCM.0b013e31823e986a; Olariu R, 2017, J SURG RES, V218, P49, DOI 10.1016/j.jss.2017.05.046; Osuka A, 2014, ACUTE MED SURG, V1, P63, DOI 10.1002/ams2.17; Rao DA, 2008, CRIT REV IMMUNOL, V28, P229, DOI 10.1615/CritRevImmunol.v28.i3.40; Rao DA, 2008, J EXP MED, V205, P3145, DOI 10.1084/jem.20081661; Schneeberger S, 2008, AM J TRANSPLANT, V8, P688, DOI 10.1111/j.1600-6143.2007.02105.x; Schneider M, 2016, TRANSPL INT, V29, P663, DOI 10.1111/tri.12750; Schnider JT, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/495212; Sellares J, 2012, AM J TRANSPLANT, V12, P388, DOI 10.1111/j.1600-6143.2011.03840.x; Shen YH, 2009, MOL MED REP, V2, P295, DOI 10.3892/mmr_00000099; Shores JT, 2015, PLAST RECONSTR SURG, V135, p351E, DOI 10.1097/PRS.0000000000000892; Sucher Robert, 2010, J Vis Exp, DOI 10.3791/2022; Tay SS, 2009, CURR OPIN ORGAN TRAN, V14, P16, DOI 10.1097/MOT.0b013e32831ebdf5; Tsaur I, 2011, KIDNEY INT, V79, P1005, DOI 10.1038/ki.2010.533; Unadkat JV, 2010, AM J TRANSPLANT, V10, P251, DOI 10.1111/j.1600-6143.2009.02941.x; van Loosdregt J, 2006, CIRCULATION, V114, P1599, DOI 10.1161/CIRCULATIONAHA.105.597526; Vitalone MJ, 2011, TRANSPLANTATION, V92, P787, DOI 10.1097/TP.0b013e31822d092c; Vodovotz Y., 2014, TRANSLATIONAL SYSTEM; Vodovotz Y, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000014; Weigt SS, 2017, J CLIN INVEST, V127, P2022, DOI 10.1172/JCI93537; Weissenbacher A, 2014, TRANSPL INT, V27, pE13, DOI 10.1111/tri.12233; Wolfram D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099926; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354; Zaaqoq AM, 2014, CRIT CARE MED, V42, P1487, DOI 10.1097/CCM.0000000000000248; Zamora R, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006582; Zamora R, 2017, J TRAUMA ACUTE CARE, V83, pS50, DOI 10.1097/TA.0000000000001489; Zettel KR, 2013, COMPLEX SYSTEMS COMP, DOI [10.1007/978-1-4614-8008-2_6, DOI 10.1007/978-1-4614-8008-2_6]; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	76	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2021	12								591154	10.3389/fimmu.2021.591154	http://dx.doi.org/10.3389/fimmu.2021.591154			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SD5IL	34017323	gold, Green Published			2022-12-18	WOS:000651406100001
J	Ehlers, AM; Jager, CFD; Kardol-Hoefnagel, T; Katsburg, MMD; Knulst, AC; Otten, HG				Ehlers, Anna M.; Jager, Constance F. den Hartog; Kardol-Hoefnagel, Tineke; Katsburg, Miriam M. D.; Knulst, Andre C.; Otten, Henny G.			Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose?	FRONTIERS IN IMMUNOLOGY			English	Article						monoclonal antibodies; single cell sequencing; immortalization; limiting dilution; antigen-specific B cells	REPERTOIRES	Human monoclonal antibodies (mAbs) are valuable tools to link genetic information with functional features and to provide a platform for conformational epitope mapping. Additionally, combined data on genetic and functional features provide a valuable mosaic for systems immunology approaches. Strategies to generate human mAbs from peripheral blood have been described and used in several studies including single cell sequencing of antigen-binding B cells and the establishment of antigen-specific monoclonal Epstein-Barr Virus (EBV) immortalized lymphoblastoid cell lines (LCLs). However, direct comparisons of these two strategies are scarce. Hence, we sought to set up these two strategies in our laboratory using peanut 2S albumins (allergens) and the autoantigen anti-Rho guanosine diphosphate dissociation inhibitor 2 (RhoGDI2, alternatively 'ARHGDIB') as antigen targets to directly compare these strategies regarding costs, time expenditure, recovery, throughput and complexity. Regarding single cell sequencing, up to 50% of corresponding V(D)J gene transcripts were successfully amplified of which 54% were successfully cloned into expression vectors used for heterologous expression. Seventy-five percent of heterologously expressed mAbs showed specific binding to peanut 2S albumins resulting in an overall recovery of 20.3%, which may be increased to around 29% by ordering gene sequences commercially for antibody cloning. In comparison, the establishment of monoclonal EBV-LCLs showed a lower overall recovery of around 17.6%. Heterologous expression of a mAb carrying the same variable region as its native counterpart showed comparable concentration-dependent binding abilities. By directly comparing those two strategies, single cell sequencing allows a broad examination of antigen-binding mAbs in a moderate-throughput manner, while the establishment of monoclonal EBV-LCLs is a powerful tool to select a small number of highly reactive mAbs restricted to certain B cell subpopulations. Overall, both strategies, initially set-up for peanut 2S albumins, are suitable to obtain human mAbs and they are easily transferrable to other target antigens as shown for ARHGDIB.	[Ehlers, Anna M.; Jager, Constance F. den Hartog; Kardol-Hoefnagel, Tineke; Katsburg, Miriam M. D.; Knulst, Andre C.; Otten, Henny G.] Univ Utrecht, Univ Med Ctr Utrecht, Ctr Translat Immunol, Utrecht, Netherlands; [Ehlers, Anna M.; Jager, Constance F. den Hartog; Knulst, Andre C.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Dermatol Allergol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Ehlers, AM (corresponding author), Univ Utrecht, Univ Med Ctr Utrecht, Ctr Translat Immunol, Utrecht, Netherlands.; Ehlers, AM (corresponding author), Univ Utrecht, Univ Med Ctr Utrecht, Dept Dermatol Allergol, Utrecht, Netherlands.	a.m.ehlers@umcutrecht.nl		Knulst, Andre/0000-0002-1056-3179	EUROIMMUN AG, Lubeck, Germany	EUROIMMUN AG, Lubeck, Germany	For financial support, we want to acknowledge EUROIMMUN AG, Lubeck, Germany.	Abbott WM, 2014, IMMUNOLOGY, V142, P526, DOI 10.1111/imm.12284; Cameron EM, 2009, J NEUROIMMUNOL, V213, P123, DOI 10.1016/j.jneuroim.2009.05.014; Ehlers AM., 2020, AUTHOREA PREPRINTS, DOI [10.22541/au.160588804.43147170/v1, DOI 10.22541/AU.160588804.43147170/V1]; Franz B, 2011, BLOOD, V118, P348, DOI 10.1182/blood-2011-03-341917; Fraussen J, 2010, J AUTOIMMUN, V35, P130, DOI 10.1016/j.jaut.2010.05.001; GOUGH NM, 1981, P NATL ACAD SCI-BIOL, V78, P509, DOI 10.1073/pnas.78.1.509; Guselnikov SV, 2019, BIOTECHNIQUES, V67, P184, DOI 10.2144/btn-2019-0079; Hansen A, 2000, INT ARCH ALLERGY IMM, V123, P36, DOI 10.1159/000024422; Hoh RA, 2016, J ALLERGY CLIN IMMUN, V137, P157, DOI 10.1016/j.jaci.2015.05.029; Jefferis R, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/5358272; Kamburova EG, 2019, AM J TRANSPLANT, V19, P3335, DOI 10.1111/ajt.15493; Kamburova EG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03002; Koppelman SJ, 2005, CLIN EXP ALLERGY, V35, P490, DOI 10.1111/j.1365-2222.2005.02204.x; KUMAR A, 1995, IMMUNOL LETT, V47, P193, DOI 10.1016/0165-2478(95)00092-7; Kwakkenbos MJ, 2010, NAT MED, V16, P123, DOI 10.1038/nm.2071; Lei L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00672; Lonberg N., 2008, V181, P69; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; Mishra AK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00117; O'Connell AE, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00340; Patil SU, 2015, J ALLERGY CLIN IMMUN, V136, P125, DOI 10.1016/j.jaci.2015.03.026; Rajan S, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-017-0006-2; Rondot S, 2001, NAT BIOTECHNOL, V19, P75, DOI 10.1038/83567; Steinitz M, 2014, METHODS MOL BIOL, V1060, P111, DOI 10.1007/978-1-62703-586-6_6; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Titcombe PJ, 2018, ARTHRITIS RHEUMATOL, V70, P1933, DOI 10.1002/art.40590; Tokmakov AA, 2012, J BIOL CHEM, V287, P27106, DOI 10.1074/jbc.M112.366351; Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080; VanDyk L, 1992, Int Rev Immunol, V8, P123, DOI 10.3109/08830189209055568; Wilson PC, 2012, NAT REV IMMUNOL, V12, P709, DOI 10.1038/nri3285; Yang JY, 2010, NATURE, V467, P465, DOI 10.1038/nature09357; Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382	33	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2021	12								660037	10.3389/fimmu.2021.660037	http://dx.doi.org/10.3389/fimmu.2021.660037			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SD7GB	34017336	gold, Green Published			2022-12-18	WOS:000651540300001
J	Lamptey, H; Bonney, EY; Adu, B; Kyei, GB				Lamptey, Helena; Bonney, Evelyn Y.; Adu, Bright; Kyei, George B.			Are Fc Gamma Receptor Polymorphisms Important in HIV-1 Infection Outcomes and Latent Reservoir Size?	FRONTIERS IN IMMUNOLOGY			English	Review						Fc&#947; R polymorphisms; HIV-1 latent reservoirs; HIV-1 cure strategies; HIV-1 disease progression; broadly neutralizing antibodies	VARIABILITY; ANTIBODIES; ACTIVATION	Fc gamma receptors (Fc gamma R) are cell surface glycoproteins which trigger specific effector-cell responses when cross-linked with the Fc portions of immunoglobulin (IgG) antibodies. During HIV-1 infection, the course of disease progression, ART response, and viral reservoir size vary in different individuals. Several factors may account for these differences; however, Fc gamma receptor gene polymorphisms, which influence receptor binding to IgG antibodies, are likely to play a key role. Fc gamma RIIa (CD32) was recently reported as a potential marker for latent HIV reservoir, however, this assertion is still inconclusive. Whether Fc gamma R polymorphisms influence the size of the viral reservoir, remains an important question in HIV cure studies. In addition, potential cure or viral suppression methods such as broadly neutralizing antibody (bNAbs) may depend on Fc gamma Rs to control the virus. Here, we discuss the current evidence on the potential role played by Fc gamma R polymorphisms in HIV-1 infection, treatment and vaccine trial outcomes. Importantly, we highlight contrasting findings that may be due to multiple factors and the relatively limited data from African populations. We recommend further studies especially in sub-Saharan Africa to confirm the role of Fc gamma RIIa in the establishment of latent reservoir and to determine their influence in therapies involving bNAbs.	[Lamptey, Helena; Adu, Bright] Univ Ghana, Noguchi Mem Inst Med Res, Dept Immunol, Accra, Ghana; [Bonney, Evelyn Y.; Kyei, George B.] Univ Ghana, Noguchi Mem Inst Med Res, Dept Virol, Accra, Ghana; [Kyei, George B.] Washington Univ, Dept Med, Sch Med St Louis, St Louis, MO 63110 USA; [Kyei, George B.] Univ Ghana, Univ Ghana Med Ctr, Med & Sci Res Ctr, Accra, Ghana	University of Ghana; University of Ghana; Saint Louis University; Washington University (WUSTL); University of Ghana	Adu, B (corresponding author), Univ Ghana, Noguchi Mem Inst Med Res, Dept Immunol, Accra, Ghana.; Kyei, GB (corresponding author), Univ Ghana, Noguchi Mem Inst Med Res, Dept Virol, Accra, Ghana.; Kyei, GB (corresponding author), Washington Univ, Dept Med, Sch Med St Louis, St Louis, MO 63110 USA.; Kyei, GB (corresponding author), Univ Ghana, Univ Ghana Med Ctr, Med & Sci Res Ctr, Accra, Ghana.	Badu@noguchi.ug.edu.gh; gkyei@noguchi.ug.edu.gh	Adu, Bright/ABA-8631-2020	Adu, Bright/0000-0002-3622-2137; Lamptey, Helena/0000-0002-6426-6540	European Union [TMA2017SF-1955, TMA2018PF-2535]	European Union(European Commission)	This project is part of the EDCTP2 program supported by the European Union with grant numbers TMA2017SF-1955 senior fellowship to GK and TMA2018PF-2535 preparatory fellowship to HL. The funder had no role in the design, analysis, or publication of the study.	Abdel-Mohsen M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar6759; Abela IA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002634; Ackerman ME, 2013, J CLIN INVEST, V123, P2183, DOI 10.1172/JCI65708; Ackerman ME, 2013, J VIROL, V87, P5468, DOI 10.1128/JVI.03403-12; Adu B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046197; Albert BJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07814-4; Altfeld M, 2003, AIDS, V17, P2581, DOI 10.1097/00002030-200312050-00005; Alvarez RA, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.88226; Ananworanich J, 2016, EBIOMEDICINE, V11, P68, DOI 10.1016/j.ebiom.2016.07.024; Ananworanich Jintanat, 2015, Top Antivir Med, V23, P80; Ananworanich J, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-56; Archin NM, 2014, CURR OPIN INFECT DIS, V27, P29, DOI 10.1097/QCO.0000000000000026; Badia R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05157-w; Balazs AB, 2012, NATURE, V481, P81, DOI 10.1038/nature10660; Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744; Barton KM, 2013, CLIN PHARMACOL THER, V93, P46, DOI 10.1038/clpt.2012.202; Bashirova AA, 2011, ANNU REV IMMUNOL, V29, P295, DOI 10.1146/annurev-immunol-031210-101332; Battistini A, 2014, VIRUSES-BASEL, V6, P1715, DOI 10.3390/v6041715; Bertagnolli LN, 2018, NATURE, V561, pE17, DOI 10.1038/s41586-018-0494-3; Boesch AW, 2015, IMMUNOL REV, V268, P296, DOI 10.1111/imr.12339; Bonsignori M, 2012, J VIROL, V86, P11521, DOI 10.1128/JVI.01023-12; Boross P., 2008, ENCY LIFE SCI ELS, P1, DOI [10.1002/9780470015902.a0000916.pub2, DOI 10.1002/9780470015902.A0000916.PUB2]; Bournazos S, 2017, IMMUNOL REV, V275, P285, DOI 10.1111/imr.12482; Bournazos S, 2014, CELL, V158, P1243, DOI 10.1016/j.cell.2014.08.023; Bournazos S, 2014, CURR TOP MICROBIOL, V382, P237, DOI 10.1007/978-3-319-07911-0_11; Breunis WB, 2008, BLOOD, V111, P1029, DOI 10.1182/blood-2007-03-079913; Brouwer KC, 2004, J INFECT DIS, V190, P1192, DOI 10.1086/422850; Brouwer KC, 2004, AIDS, V18, P1187, DOI 10.1097/00002030-200405210-00012; Burton DR, 2011, P NATL ACAD SCI USA, V108, P11181, DOI 10.1073/pnas.1103012108; Buzon MJ, 2014, J VIROL, V88, P10056, DOI 10.1128/JVI.01046-14; Carapito R, 2020, GENES IMMUN, V21, P263, DOI 10.1038/s41435-020-0106-8; Casado C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011079; Chen P, 2007, J VIROL, V81, P12582, DOI 10.1128/JVI.00381-07; Chung AW, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0380-3; Chung AW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007736; Chung AW, 2011, JAIDS-J ACQ IMM DEF, V58, P127, DOI 10.1097/QAI.0b013e31822c62b9; Connolly S, 2018, VIROLOGY, V525, P132, DOI 10.1016/j.virol.2018.09.015; Darcis G, 2020, CELL REP, V30, P2284, DOI 10.1016/j.celrep.2020.01.071; Darcis G, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030255; Darcis G, 2017, TRENDS IMMUNOL, V38, P217, DOI 10.1016/j.it.2016.12.003; Darcis G, 2016, CURR OPIN HIV AIDS, V11, P388, DOI 10.1097/COH.0000000000000288; De Souza MS, 2015, AIDS, V29, P793, DOI 10.1097/QAD.0000000000000616; Deeks SG, 2016, NAT MED, V22, P839, DOI 10.1038/nm.4108; Deepe RN, 2012, HUM IMMUNOL, V73, P263, DOI 10.1016/j.humimm.2011.12.008; Descours B, 2017, NATURE, V543, P564, DOI 10.1038/nature21710; Diamantopoulos PT, 2013, LEUKEMIA LYMPHOMA, V54, P2030, DOI 10.3109/10428194.2012.762512; Diop G, 2006, BIOMED PHARMACOTHER, V60, P569, DOI 10.1016/j.biopha.2006.08.002; Doyle T, 2015, NAT REV MICROBIOL, V13, P403, DOI 10.1038/nrmicro3449; Duncan CJA, 2013, AIDS, V27, P2201, DOI 10.1097/QAD.0b013e3283632ec4; Eisele E, 2012, IMMUNITY, V37, P377, DOI 10.1016/j.immuni.2012.08.010; Emery S, 2007, HUM VACCINES, V3, P260, DOI 10.4161/hv.4627; Emery S, 2005, HUM VACCINES, V1, P232, DOI 10.4161/hv.1.6.2342; Endeman H, 2009, CLIN VACCINE IMMUNOL, V16, P1087, DOI 10.1128/CVI.00037-09; Ernst LK, 2002, J MOL MED, V80, P248, DOI 10.1007/s00109-001-0294-2; Fontaine J, 2009, J INFECT DIS, V199, P1007, DOI 10.1086/597278; Forthal DN, 2007, J IMMUNOL, V179, P7916, DOI 10.4049/jimmunol.179.11.7916; Forthal DN, 2012, BLOOD, V120, P2836, DOI 10.1182/blood-2012-05-431361; Forthal DN, 2009, CURR OPIN HIV AIDS, V4, P388, DOI 10.1097/COH.0b013e32832f0a89; Fourati S, 2014, J ANTIMICROB CHEMOTH, V69, P753, DOI 10.1093/jac/dkt428; French MA, 2010, AIDS, V24, P1983, DOI 10.1097/QAD.0b013e32833c1ce0; Ganesh L, 2004, J VIROL, V78, P11980, DOI 10.1128/JVI.78.21.11980-11987.2004; Garcia G, 2011, INT J INFECT DIS, V15, pE38, DOI 10.1016/j.ijid.2010.09.008; Garcia G, 2010, AM J TROP MED HYG, V82, P1153, DOI 10.4269/ajtmh.2010.09-0353; Gaudinski MR, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002493; Geraghty DE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00970; Grabar S, 2009, AIDS, V23, P1163, DOI 10.1097/QAD.0b013e32832b44c8; Graf EH, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001300; Hans Veenu Madaan, 2015, Contemp Clin Dent, V6, pS141, DOI 10.4103/0976-237X.166831; Hatjiharissi E, 2007, BLOOD, V110, P2561, DOI 10.1182/blood-2007-01-070656; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106; Hessell AJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000433; Hocqueloux L, 2010, AIDS, V24, P1598, DOI 10.1097/QAD.0b013e32833b61ba; Hoffmeyer F, 1997, IMMUNOLOGY, V92, P544, DOI 10.1046/j.1365-2567.1997.00381.x; Hogan LE, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006856; HOMSY J, 1989, SCIENCE, V244, P1357, DOI 10.1126/science.2786647; Israelsson E, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-175; Jansen WTM, 1999, J INFECT DIS, V180, P888, DOI 10.1086/314920; Kaset C, 2013, ANN LAB MED, V33, P426, DOI 10.3343/alm.2013.33.6.426; Kong R, 2015, J VIROL, V89, P2659, DOI 10.1128/JVI.03136-14; Lassauniere R, 2016, GENES IMMUN, V17, P93, DOI 10.1038/gene.2015.60; Lassauniere R, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-016-0272-y; Lehrnbecher T, 1999, BLOOD, V94, P4220, DOI 10.1182/blood.V94.12.4220.424k08_4220_4232; Lehrnbecher T, 2000, BLOOD, V95, P2386; Li HR, 2017, J VIROL, V91, DOI 10.1128/JVI.02425-16; Li SS, 2019, J VIROL, V93, DOI 10.1128/JVI.02041-18; Li SYS, 2014, J CLIN INVEST, V124, P3879, DOI 10.1172/JCI75539; Li X, 2009, GENES IMMUN, V10, P380, DOI 10.1038/gene.2009.35; Li XR, 2014, CURR TOP MICROBIOL, V382, P275, DOI 10.1007/978-3-319-07911-0_13; Liao HX, 2013, IMMUNITY, V38, P176, DOI 10.1016/j.immuni.2012.11.011; Liu Y, 2006, J IMMUNOL, V177, P8440, DOI 10.4049/jimmunol.177.12.8440; Lu CL, 2016, SCIENCE, V352, P1001, DOI 10.1126/science.aaf1279; Machado LR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078165; Malbec M, 2013, J EXP MED, V210, P2813, DOI 10.1084/jem.20131244; Maresco DL, 1996, CYTOGENET CELL GENET, V73, P157, DOI 10.1159/000134330; Martin GE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00928; Martin N, 2010, J VIROL, V84, P3516, DOI 10.1128/JVI.02651-09; Mayr L, 2017, CURR OPIN HIV AIDS, V12, P209, DOI 10.1097/COH.0000000000000357; Mayr LM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01590; McLaren PJ, 2015, NAT IMMUNOL, V16, P577, DOI 10.1038/ni.3147; McLaren PJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003515; Milligan C, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv149; Moi ML, 2010, J GEN VIROL, V91, P103, DOI 10.1099/vir.0.014829-0; Moldt B, 2012, P NATL ACAD SCI USA, V109, P18921, DOI 10.1073/pnas.1214785109; Neumann-Haefelin C, 2013, CURR OPIN RHEUMATOL, V25, P426, DOI 10.1097/BOR.0b013e328362018f; Newling M, 2018, EUR J IMMUNOL, V48, P1796, DOI 10.1002/eji.201847615; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Nimmerjahn F, 2011, CURR TOP MICROBIOL, V350, P105, DOI 10.1007/82_2010_86; Noto A, 2018, J VIROL, V92, DOI [10.1128/jvi.00901-18, 10.1128/JVI.00901-18]; Oboshi W, 2016, HUM IMMUNOL, V77, P165, DOI 10.1016/j.humimm.2015.11.001; Okulicz JF, 2011, CURR OPIN HIV AIDS, V6, P163, DOI 10.1097/COH.0b013e328344f35e; Okulicz JF, 2009, J INFECT DIS, V200, P1714, DOI 10.1086/646609; OSBORNE JM, 1994, J IMMUNOL METHODS, V173, P207, DOI 10.1016/0022-1759(94)90299-2; Osuna CE, 2018, NATURE, V561, pE20, DOI 10.1038/s41586-018-0495-2; PARREN PWHI, 1992, J CLIN INVEST, V90, P1537, DOI 10.1172/JCI116022; Parsons MS, 2019, J CLIN INVEST, V129, P182, DOI 10.1172/JCI122466; Parsons MS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1483; Pasternak A., 2016, CELL ASS HIV 1 UNSPL, DOI [10.1016/S2055-6640(20)31009-8, DOI 10.1016/S2055-6640(20)31009-8]; Perez L, 2018, NATURE, V561, pE9, DOI 10.1038/s41586-018-0493-4; Platonov AE, 1998, CLIN INFECT DIS, V27, P746, DOI 10.1086/514935; Poonia B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015562; Prehn JL, 2007, J IMMUNOL, V178, P4033, DOI 10.4049/jimmunol.178.7.4033; Richardson SI, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006987; Rohatgi S, 2013, MBIO, V4, DOI 10.1128/mBio.00573-13; Rosales Carlos, 2013, Current Immunology Reviews, V9, P44; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; Stein MP, 2000, J CLIN INVEST, V105, P369, DOI 10.1172/JCI7817; Su B, 2015, AIDS RES HUM RETROV, V31, P1187, DOI [10.1089/AID.2015.0041, 10.1089/aid.2015.0041]; Su B, 2014, J VIROL, V88, P10975, DOI 10.1128/JVI.01748-14; TAKEDA A, 1988, SCIENCE, V242, P580, DOI 10.1126/science.2972065; Talathi SP, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4674-z; Tarasenko T, 2007, AUTOIMMUNITY, V40, P409, DOI 10.1080/08916930701464665; Thornhill JP, 2019, MUCOSAL IMMUNOL, V12, P1212, DOI 10.1038/s41385-019-0180-2; Tiemessen C.T., 2012, CMEJ, V30, P282; Tomaras GD, 2013, P NATL ACAD SCI USA, V110, P9019, DOI 10.1073/pnas.1301456110; Tong Y, 2003, ANN HEMATOL, V82, P574, DOI 10.1007/s00277-003-0725-y; UNAIDS, 2019, GLOB HIV AIDS STAR 2; van Schie RCAA, 2000, CLIN DIAGN LAB IMMUN, V7, P676, DOI 10.1128/CDLI.7.4.676-681.2000; Weis JF, 2015, AIDS RES HUM RETROV, V31, P288, DOI [10.1089/aid.2014.0209, 10.1089/AID.2014.0209]; Weiser JN, 1998, J EXP MED, V187, P631, DOI 10.1084/jem.187.4.631; Williams JP, 2014, ELIFE, V3, DOI 10.7554/eLife.03821; Williams WB, 2015, SCIENCE, V349, DOI 10.1126/science.aab1253; Yates NL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007730; Yee AMF, 2000, CLIN INFECT DIS, V30, P25, DOI 10.1086/313588; Yuan FF, 2005, TISSUE ANTIGENS, V66, P291, DOI 10.1111/j.1399-0039.2005.00476.x; Zolla-Pazner S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087572; Zolla-Pazner S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053629; Zuniga J, 2012, EUR RESPIR J, V39, P604, DOI 10.1183/09031936.00020611	148	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2021	12								656894	10.3389/fimmu.2021.656894	http://dx.doi.org/10.3389/fimmu.2021.656894			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SD5CZ	34017334	gold, Green Published			2022-12-18	WOS:000651391700001
J	Meng, LL; Tan, JP; Du, T; Lin, XH; Zhang, SN; Nie, XL; Xie, HT; Lin, JZ; Zhang, JP; Hui, C				Meng, Lili; Tan, Jianping; Du, Tao; Lin, Xianghua; Zhang, Shuning; Nie, Xiaolu; Xie, Haitian; Lin, Jizong; Zhang, Jianping; Hui, Chen			The Effects of LIT and MLR-Bf on Immune Biomarkers and Pregnancy Outcomes in Women With Previous Early Recurrent Miscarriage: A Retrospective Study	FRONTIERS IN IMMUNOLOGY			English	Article						unexplained recurrent miscarriage; MLB-Rf; rheumatoid biomarkers; successful pregnancy; maternal immunity	SPONTANEOUS-ABORTIONS; BLOCKING FACTORS; IMMUNOTHERAPY; LYMPHOCYTES; ANTIBODIES; CELLS	Background: Immunological failure during pregnancy is considered one of the etiologies of recurrent miscarriage (RM). The decreased production of mixed lymphocyte reaction-blocking factors (MLR-Bf) may play a major role in this condition. Lymphocyte immunotherapy (LIT), which induces the production of MLR-Bf, has been used in treating RM patients since 1984. However, the effectiveness of LIT is currently being heatedly debated. In addition to that, possible changes to the maternal immune system upon induced MLR-Bf production by LIT remains unclear. Objectives: To explore the possible impacts that MLR-Bf may have on the expression of immune biomarkers and pregnancy outcomes, and deduce whether the prevention of miscarriages is possible with LIT or MLR-Bf in RM patients. Materials and Methods: Women with previous early RM (eRM) were enrolled in this retrospective study after they got pregnant again. LIT was implemented before pregnancy and during the first trimester. MLR-Bf and immune biomarkers were checked as the clinical routine. Patients were followed up until 12 gestational weeks. Levels of immune biomarkers and successful pregnancy rates were compared between MLR-Bf(-) group and MLR-Bf(+) group stratified by LIT. Independent associations between LIT, or MLR-Bf, and miscarriage were estimated. All data management and analysis were conducted using SPSS 20.0. Results: A total of 1,038 patients, 497 MLR-Bf(-) (49 cases accepted LIT), and 541 MLR-Bf(+)(463 cases induced by LIT) were included in the study. Percentage of lymphocytes, the ratio of CD4+ T cells/lymphocytes, and levels of some rheumatoid biomarkers (anti-U1-nRNP, anti-SAA-52kd, and anti-CENOP B) were statistically higher in MLR-Bf(+) group than in MLR-Bf(-) group among women without LIT. With LIT treatment the successful pregnancy rate was statistically higher in MLR-Bf(+) group than in MLR-Bf(-) group (66.7% vs. 51.0%, P = 0.028) among women with LIT. Meanwhile, LIT was estimated to have an independent negative association with miscarriage. Conclusion: Upon LIT treament levels of immune biomarkers were different in women with and without MLR-Bf when stratified by whether they received LIT. Not MLR-Bf, but LIT, has an independent protective effect on miscarriage.	[Meng, Lili; Tan, Jianping; Du, Tao; Zhang, Shuning; Nie, Xiaolu; Xie, Haitian; Zhang, Jianping; Hui, Chen] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Obstet & Gynecol, Guangzhou, Peoples R China; [Lin, Xianghua] Sun Yat Sen Univ, Dept Clin Lab, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China; [Lin, Jizong] Sun Yat Sen Univ, Dept Gen Surg, Affiliated Hosp 3, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Zhang, JP; Hui, C (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Obstet & Gynecol, Guangzhou, Peoples R China.; Lin, JZ (corresponding author), Sun Yat Sen Univ, Dept Gen Surg, Affiliated Hosp 3, Guangzhou, Peoples R China.	linjzong@mail.sysu.edu.cn; zjp2570@126.com; chenhui9@mail.sysu.edu.cn	meng, li/GVT-2063-2022	Xie, Haitian/0000-0003-3393-4275	National Key Research and Development Program of China [2019YFA0801403]; National Nature Science Foundation of China [81771660, 81741017]; Science and Technology Planning Project of Guangdong Province [2017A020214018, 2017A020214003, 2017A030310209, pdjh2020b0010]; Guangdong Natural Science Foundation [2018A030313023, 2018A030313162, 2018A030310162, 18zxxt56]; Science and Technology Planning Project of Guangzhou City Central Universities [201704020034]; Technology Innovation Strategy Fund of Guangdong Province [2018A030313737]; 5010 projects at Sun Yat-Sen University [2012006]	National Key Research and Development Program of China; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Planning Project of Guangdong Province; Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Science and Technology Planning Project of Guangzhou City Central Universities; Technology Innovation Strategy Fund of Guangdong Province; 5010 projects at Sun Yat-Sen University	This study was supported by the National Key Research and Development Program of China (2019YFA0801403), National Nature Science Foundation of China (81771660,81741017), the Science and Technology Planning Project of Guangdong Province (2017A020214018, 2017A020214003, and 2017A030310209), Guangdong Natural Science Foundation (2018A030313023, 2018A030313162, 2018A030310162, and 18zxxt56), the Science and Technology Planning Project of Guangzhou City Central Universities (201704020034), Technology Innovation Strategy Fund of Guangdong Province (2018A030313737), 5010 projects at Sun Yat-Sen University (2012006), and Science and Technology Planning Project of Guangdong Province (pdjh2020b0010).	Adachi H, 2003, CLIN IMMUNOL, V106, P175, DOI 10.1016/S1521-6616(02)00044-X; Ali S, 2020, SAUDI J BIOL SCI, V27, P2809, DOI 10.1016/j.sjbs.2020.06.049; Barut MU, 2018, MED SCI MONITOR, V24, P4288, DOI 10.12659/MSM.908832; BEER AE, 1985, EXP CLIN IMMUNOGENET, V2, P137; Cavalcante MB, 2020, AM J REPROD IMMUNOL, V83, DOI 10.1111/aji.13215; Cavalcante MB, 2015, J MATERN-FETAL NEO M, V28, P1082, DOI 10.3109/14767058.2014.943175; Christiansen OB, 2013, MOL IMMUNOL, V55, P8, DOI 10.1016/j.molimm.2012.08.025; De Carolis S, 2014, AUTOIMMUN REV, V13, P103, DOI 10.1016/j.autrev.2013.09.003; Dong ZR, 2019, AM J HUM GENET, V105, P1102, DOI 10.1016/j.ajhg.2019.10.003; Ford Holly B, 2009, Rev Obstet Gynecol, V2, P76; Hajipour H, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.12853; Iijima S, 2018, J MATERN-FETAL NEO M, V31, P2079, DOI 10.1080/14767058.2017.1334048; Khonina NA, 2013, ARCH GYNECOL OBSTET, V288, P933, DOI 10.1007/s00404-013-2832-x; Kishore R, 1996, J Obstet Gynaecol Res, V22, P177; Leber A, 2010, AM J REPROD IMMUNOL, V63, P445, DOI 10.1111/j.1600-0897.2010.00821.x; Meng LL, 2011, CHINESE MED J-PEKING, V124, P1310, DOI 10.3760/cma.j.issn.0366-6999.2011.09.007; Molazadeh Morteza, 2014, Iran J Reprod Med, V12, P221; Nonaka T, 2007, AM J REPROD IMMUNOL, V58, P530, DOI 10.1111/j.1600-0897.2007.00536.x; Pandey Manoj Kumar, 2003, BMC Pregnancy Childbirth, V3, P2, DOI 10.1186/1471-2393-3-2; Pandey MK, 2004, INT IMMUNOPHARMACOL, V4, P289, DOI 10.1016/j.intimp.2004.01.001; Sarno Manoel, 2019, Eur J Obstet Gynecol Reprod Biol X, V3, P100036, DOI 10.1016/j.eurox.2019.100036; Shankarkumar U, 2011, Niger Med J, V52, P163, DOI 10.4103/0300-1652.86126; TAKAKUWA K, 1986, AM J REPROD IMMUNOL, V10, P1; TAKEUCHI S, 1980, AM J REPROD IMMUNOL, V1, P23, DOI 10.1111/j.1600-0897.1980.tb00006.x; Ticconi C, 2010, AM J REPROD IMMUNOL, V64, P384, DOI 10.1111/j.1600-0897.2010.00863.x; UNANDER A M, 1992, Transfusion Medicine Reviews, V6, P1; van den Heuvel MJ, 2007, AM J REPROD IMMUNOL, V58, P447, DOI 10.1111/j.1600-0897.2007.00529.x; van der Giessen J, 2020, GUT, V69, P473, DOI 10.1136/gutjnl-2019-318263; Xu L, 2015, EUR J CONTRACEP REPR, V20, P428, DOI 10.3109/13625187.2015.1046593; Yin ZJ, 2018, LUPUS, V27, P2057, DOI 10.1177/0961203318804881; Ying Y, 2013, AM J REPROD IMMUNOL, V70, P221, DOI 10.1111/aji.12111; Yuan J, 2015, J REPROD IMMUNOL, V110, P81, DOI 10.1016/j.jri.2015.05.001; Zucchi D, 2020, RHEUMATOLOGY, V59, P1335, DOI 10.1093/rheumatology/kez440	33	1	1	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2021	12								642120	10.3389/fimmu.2021.642120	http://dx.doi.org/10.3389/fimmu.2021.642120			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SD6JU	34017330	gold, Green Published			2022-12-18	WOS:000651482300001
J	Park, HS; Back, YW; Jang, IT; Lee, KI; Son, YJ; Choi, HG; Dang, TB; Kim, HJ				Park, Hye-Soo; Back, Yong Woo; Jang, In-Taek; Lee, Kang-In; Son, Yeo-Jin; Choi, Han-Gyu; Dang, Thi Binh; Kim, Hwa-Jung			Mycobacterium tuberculosis Rv2145c Promotes Intracellular Survival by STAT3 and IL-10 Receptor Signaling	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacterium tuberculosis; Rv2145c; IL-10; STAT3; pathogenic role	CELL-WALL; INTERACTS; EFFECTOR; DIVIVA; WAG31; TH1	Although Mycobacterium tuberculosis (Mtb) is an intracellular pathogen in phagocytic cells, the factors and mechanisms by which they invade and persist in host cells are still not well understood. Characterization of the bacterial proteins modulating macrophage function is essential for understanding tuberculosis pathogenesis and bacterial virulence. Here we investigated the pathogenic role of the Rv2145c protein in stimulating IL-10 production. We first found that recombinant Rv2145c stimulated bone marrow-derived macrophages (BMDMs) to secrete IL-10, IL-6 and TNF-alpha but not IL-12p70 and to increase the expression of surface molecules through the MAPK, NF-kappa B, and TLR4 pathways and enhanced STAT3 activation and the expression of IL-10 receptor in Mtb-infected BMDMs. Rv2145c significantly enhanced intracellular Mtb growth in BMDMs compared with that in untreated cells, which was abrogated by STAT3 inhibition and IL-10 receptor (IL-10R) blockade. Expression of Rv2145c in Mycobacterium smegmatis (M. smegmatis) led to STAT3-dependent IL-10 production and enhancement of intracellular growth in BMDMs. Furthermore, the clearance of Rv2145c-expressing M. smegmatis in the lungs and spleens of mice was delayed, and these effects were abrogated by administration of anti-IL-10R antibodies. Finally, all mice infected with Rv2145c-expressing M. smegmatis died, but those infected with the vector control strain did not. Our data suggest that Rv2145c plays a role in creating a favorable environment for bacterial survival by modulating host signals.	[Park, Hye-Soo; Back, Yong Woo; Jang, In-Taek; Lee, Kang-In; Son, Yeo-Jin; Choi, Han-Gyu; Dang, Thi Binh; Kim, Hwa-Jung] Chungnam Natl Univ, Coll Med, Dept Microbiol & Med Sci, Daejeon, South Korea; Chungnam Natl Univ, Coll Med, Translat Immunol Inst, Daejeon, South Korea	Chungnam National University; Chungnam National University	Kim, HJ (corresponding author), Chungnam Natl Univ, Coll Med, Dept Microbiol & Med Sci, Daejeon, South Korea.	hjukim@cnu.ac.kr		Dang, Binh Thi/0000-0002-3267-3408	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and future Planning [2017R1A5A2015385, 2020R1A2C1008826]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and future Planning(National Research Foundation of KoreaMinistry of Science, ICT & Future Planning, Republic of Korea)	This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and future Planning (2017R1A5A2015385 and 2020R1A2C1008826).	Back YW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213536; Bansal K, 2010, J BIOL CHEM, V285, P36511, DOI 10.1074/jbc.M110.158055; Bertholet S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001094; Bouzeyen R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02922; Chen W, 2016, MED MICROBIOL IMMUN, V205, P119, DOI 10.1007/s00430-015-0434-x; Choi HG, 2017, ONCOTARGET, V8, P19947, DOI 10.18632/oncotarget.15256; Choi HG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164458; Choukate K, 2020, J STRUCT BIOL, V209, DOI 10.1016/j.jsb.2019.107429; de Souza GA, 2011, J PROTEOMICS, V75, P502, DOI 10.1016/j.jprot.2011.08.016; DeJesus MA, 2017, MBIO, V8, DOI 10.1128/mBio.02133-16; Gengenbacher M, 2016, MBIO, V7, DOI 10.1128/mBio.00679-16; Ghazaei C, 2018, J RES MED SCI, V23, DOI 10.4103/jrms.JRMS_904_17; Griffin JE, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002251; Harding CV, 2010, NAT REV MICROBIOL, V8, P296, DOI 10.1038/nrmicro2321; Harding E, 2020, LANCET RESP MED, V8, P19, DOI 10.1016/S2213-2600(19)30418-7; Hinchey J, 2007, J CLIN INVEST, V117, P2279, DOI 10.1172/JCI31947; Huang DD, 2016, J MICROBIOL IMMUNOL, V49, P859, DOI 10.1016/j.jmii.2014.11.008; Jani C, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-327; Jaslow SL, 2018, CELL REP, V23, P3525, DOI 10.1016/j.celrep.2018.05.072; Kang CM, 2008, MICROBIOL-SGM, V154, P725, DOI 10.1099/mic.0.2007/014076-0; Kumar D, 2012, INFECT GENET EVOL, V12, P737, DOI 10.1016/j.meegid.2011.09.008; Maan P, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00421; Mattow J, 2003, ELECTROPHORESIS, V24, P3405, DOI 10.1002/elps.200305601; Meliilo JA, 2010, J IMMUNOL, V184, P2638, DOI 10.4049/jimmunol.0902960; Meniche X, 2014, P NATL ACAD SCI USA, V111, pE3243, DOI 10.1073/pnas.1402158111; Moreira-Teixeira L, 2017, J IMMUNOL, V199, P613, DOI 10.4049/jimmunol.1601340; Nair S, 2009, J IMMUNOL, V183, P6269, DOI 10.4049/jimmunol.0901367; Negi S, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01173; Nguyen L, 2007, J BACTERIOL, V189, P7896, DOI 10.1128/JB.00726-07; O'Leary S, 2011, AM J RESP CELL MOL, V45, P172, DOI 10.1165/rcmb.2010-0319OC; Park HS, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040944; Park HS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38982-0; Pitt JM, 2012, J IMMUNOL, V189, P4079, DOI 10.4049/jimmunol.1201061; Plocinski P, 2012, J BACTERIOL, V194, P6398, DOI 10.1128/JB.01005-12; Puri RV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070514; Queval CJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep29297; Raman K, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752-0509-2-109; Samten B, 2016, TUBERCULOSIS, V101, pS99, DOI 10.1016/j.tube.2016.09.017; Shiloh MU, 2016, FUTURE MICROBIOL, V11, P1503, DOI 10.2217/fmb-2016-0185; Singh P, 2016, SCI REP-UK, V6, DOI 10.1038/srep21624; Stutz MD, 2018, J LEUKOCYTE BIOL, V103, P259, DOI 10.1002/JLB.4MR0717-277R; Su HB, 2018, J BIOL CHEM, V293, P10287, DOI 10.1074/jbc.RA118.001696; Su HB, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00147; Su HB, 2015, ONCOTARGET, V6, P38517, DOI 10.18632/oncotarget.5956; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Tiwari B, 2015, CELL MICROBIOL, V17, P1653, DOI 10.1111/cmi.12462; Turner J, 2002, J IMMUNOL, V169, P6343, DOI 10.4049/jimmunol.169.11.6343; Turner J, 2018, PATHOG DIS, V76, DOI 10.1093/femspd/fty026; Upadhyay R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35023-0; Wang J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00279-z; Xu Y, 2015, J MOL MED, V93, P645, DOI 10.1007/s00109-014-1243-1; Zhai WJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020340	52	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2021	12								666293	10.3389/fimmu.2021.666293	http://dx.doi.org/10.3389/fimmu.2021.666293			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SD5GD	34017340	Green Published, gold			2022-12-18	WOS:000651400100001
J	Chen, JQ; Ye, HJ; Xiao, W; Mao, YX; Ai, SM; Chen, RX; Lian, XF; Shi, L; Wang, X; Bi, SW; Yang, SL; Ji, X; Zhang, T; Yang, HS				Chen, Jingqiao; Ye, Huijing; Xiao, Wei; Mao, Yuxiang; Ai, Siming; Chen, Rongxin; Lian, Xiufen; Shi, Lu; Wang, Xing; Bi, Shaowei; Yang, Shenglan; Ji, Xian; Zhang, Te; Yang, Huasheng			Increased Dysfunctional and Plastic Regulatory T Cells in Idiopathic Orbital Inflammation	FRONTIERS IN IMMUNOLOGY			English	Article						regulatory T cell; dysfunction; plasticity; interleukin-33; idiopathic orbital inflammation; IgG4-related disease		Background Idiopathic orbital inflammation (IOI) is a disfiguring and vision-threatening fibroinflammatory disorder. The pathogenesis of IOI has not been elucidated. We sought to clarify the regulatory T cell (Treg) distribution and function in patients with IOI. Methods The frequency, phenotype and function of Tregs were identified by multicolor flow cytometry and in vitro cell functional assays. Plasma and tissue samples were obtained to investigate cytokines, chemokines and their receptors of interest by relative real-time polymerase chain reaction (PCR) and Luminex assays. Results Compared with healthy subjects, patients with IOI exhibited obvious increases of Tregs in peripheral blood and affected orbital tissues. Circulating Tregs from patients with IOI were significantly more polarized to a Th17-like phenotype with defective regulatory function, whereas orbit-derived Tregs were polarized to a Th2-like phenotype. Furthermore, ST2 expression levels in circulating Tregs and interleukin (IL)-33 mRNA levels in orbital tissues were decreased in IOI. IL-33 restored the suppressive function of Tregs, reduced interferon (IFN)-gamma production by Tregs and decreased the activation of orbital fibroblasts (OFs) cocultured with Tregs in IOI. Conclusion Increased Tregs with proinflammatory and profibrotic polarization were first identified in IOI, suggesting that Treg plasticity and heterogeneity plays an essential role in IOI pathogenesis. Additionally, our study identified a regulatory effect of IL-33 on inflammation and fibrosis in IOI. Reversing the plastic Tregs via IL-33 might be a potential option for IOI patients.	[Chen, Jingqiao; Ye, Huijing; Xiao, Wei; Mao, Yuxiang; Ai, Siming; Chen, Rongxin; Lian, Xiufen; Shi, Lu; Wang, Xing; Bi, Shaowei; Yang, Shenglan; Ji, Xian; Zhang, Te; Yang, Huasheng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China	Sun Yat Sen University	Yang, HS (corresponding author), Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.	yanghuasheng@gzzoc.com			National Natural Science Foundation of China [81700875, 81870689, 81800866, 81670887]; Fundamental Research Funds of the State Key Laboratory of Ophthalmology	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds of the State Key Laboratory of Ophthalmology	The National Natural Science Foundation of China (no. 81700875, no. 81870689, no. 81800866 and no. 81670887) and The Fundamental Research Funds of the State Key Laboratory of Ophthalmology. We thank the Core Facilities at State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center for technical support.	Abell RG, 2015, OCUL IMMUNOL INFLAMM, V23, P176, DOI 10.3109/09273948.2013.863943; Abignano G, 2014, ANN RHEUM DIS, V73, P420, DOI 10.1136/annrheumdis-2012-202843; Campanella GSV, 2008, J IMMUNOL METHODS, V331, P127, DOI 10.1016/j.jim.2007.12.002; Campbell C, 2020, CELL METAB, V31, P18, DOI 10.1016/j.cmet.2019.09.010; Casciano F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00529; Chaudhry A, 2009, SCIENCE, V326, P986, DOI 10.1126/science.1172702; Chen CC, 2017, J ALLERGY CLIN IMMUN, V140, P1351, DOI 10.1016/j.jaci.2017.01.015; Cretney E, 2013, TRENDS IMMUNOL, V34, P74, DOI 10.1016/j.it.2012.11.002; Duhen T, 2012, BLOOD, V119, P4430, DOI 10.1182/blood-2011-11-392324; Esensten JH, 2018, J ALLERGY CLIN IMMUN, V142, P1710, DOI 10.1016/j.jaci.2018.10.015; Ferreira LMR, 2019, NAT REV DRUG DISCOV, V18, P749, DOI 10.1038/s41573-019-0041-4; Fournie JJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02506; Gabryelska A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00692; Griesenauer B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00475; Halim L, 2017, CELL REP, V20, P757, DOI 10.1016/j.celrep.2017.06.079; Heeringa JJ, 2018, J ALLERGY CLIN IMMUN, V141, P1831, DOI 10.1016/j.jaci.2017.07.024; Jacobs Dina, 2002, Curr Opin Ophthalmol, V13, P347, DOI 10.1097/00055735-200212000-00001; Jeannin P, 1998, J IMMUNOL, V160, P3555; Jiang C, 2019, CLIN IMMUNOL, V209, DOI 10.1016/j.clim.2019.108267; Jiang HR, 2012, EUR J IMMUNOL, V42, P1804, DOI 10.1002/eji.201141947; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Li MC, 2012, J NEUROIMMUNOL, V247, P25, DOI 10.1016/j.jneuroim.2012.03.016; Liston A, 2014, NAT REV IMMUNOL, V14, P154, DOI 10.1038/nri3605; MacDonald KG, 2015, J ALLERGY CLIN IMMUN, V135, P946, DOI 10.1016/j.jaci.2014.12.1932; MCCARTHY JM, 1993, MODERN PATHOL, V6, P581; McClymont SA, 2011, J IMMUNOL, V186, P3918, DOI 10.4049/jimmunol.1003099; Miyara M, 2011, AUTOIMMUN REV, V10, P744, DOI 10.1016/j.autrev.2011.05.004; Miyoshi H, 2008, PANCREAS, V36, P133, DOI 10.1097/MPA.0b013e3181577553; Mizoguchi A, 2006, J IMMUNOL, V176, P705, DOI 10.4049/jimmunol.176.2.705; Mombaerts I, 1996, SURV OPHTHALMOL, V41, P66, DOI 10.1016/S0039-6257(97)81996-0; Oldham KA, 2012, EUR UROL, V61, P385, DOI 10.1016/j.eururo.2011.10.035; Panduro M, 2016, ANNU REV IMMUNOL, V34, P609, DOI 10.1146/annurev-immunol-032712-095948; Parkes J, 2010, GUT, V59, P1245, DOI 10.1136/gut.2009.203166; Pastille E, 2019, MUCOSAL IMMUNOL, V12, P990, DOI 10.1038/s41385-019-0176-y; Pesenacker AM, 2013, BLOOD, V121, P2647, DOI 10.1182/blood-2012-08-443473; Qiu RZ, 2020, CLIN REV ALLERG IMMU, V58, P52, DOI 10.1007/s12016-018-8721-0; Rivas MN, 2015, IMMUNITY, V42, P512, DOI 10.1016/j.immuni.2015.02.004; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Siede J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161507; Suhler EB, 2014, JAMA OPHTHALMOL, V132, P572, DOI 10.1001/jamaophthalmol.2013.8179; Umehara H, 2012, MOD RHEUMATOL, V22, P21, DOI 10.1007/s10165-011-0571-z; Vent-Schmidt J, 2014, INT REV IMMUNOL, V33, P110, DOI 10.3109/08830185.2013.811657; Wang T, 2015, ANN RHEUM DIS, V74, P1293, DOI 10.1136/annrheumdis-2013-204228; WERNER SC, 1977, J CLIN ENDOCR METAB, V44, P203, DOI 10.1210/jcem-44-1-203; Yamazaki T, 2008, J IMMUNOL, V181, P8391, DOI 10.4049/jimmunol.181.12.8391; Yuen SJA, 2003, ARCH OPHTHALMOL-CHIC, V121, P491, DOI 10.1001/archopht.121.4.491; Yuen Sonia J Ahn, 2002, Ophthalmol Clin North Am, V15, P121; Zen Y, 2007, HEPATOLOGY, V45, P1538, DOI 10.1002/hep.21697	49	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2021	12								634847	10.3389/fimmu.2021.634847	http://dx.doi.org/10.3389/fimmu.2021.634847			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SD0MK	34012433	gold, Green Published			2022-12-18	WOS:000651056600001
J	Alharshawi, K; Fey, H; Vogle, A; Klenk, T; Kim, M; Aloman, C				Alharshawi, Khaled; Fey, Holger; Vogle, Alyx; Klenk, Tori; Kim, Miran; Aloman, Costica			Alcohol Consumption Accumulation of Monocyte Derived Macrophages in Female Mice Liver Is Interferon Alpha Receptor Dependent	FRONTIERS IN IMMUNOLOGY			English	Article						monocytes; alcohol (EtOH); liver injury; mouse; female; male; Meadows-Cook model (MC)		Monocytes develop in the bone marrow from the hematopoietic stem cells and represent heterogeneous phagocyte cells in the circulation. In homeostatic and inflammatory conditions, after recruitment into tissues, monocytes differentiate into macrophages and dendritic cells. Alcohol use causes about 3.3 million worldwide deaths per year, which is about 5.9% of all deaths. In the United States and Europe, alcohol use disorders represent the fifth leading cause of death. Females are more susceptible to alcoholic liver injury in both humans and mice. Strikingly, we still do not know how much of this difference in tissue injury is due to the differential effect of alcohol and its toxic metabolites on a) parenchymal or resident cells and/or b) immune response to alcohol. Therefore, we used a model of chronic alcohol exposure in mice to investigate the dynamics of monocytes, an innate immune cell type showed to be critical in alcoholic liver injury, by using immunophenotypic characterization. Our data reveal a sex-dimorphism of alcohol response of hepatic monocytes in female mice that is interferon receptor alpha dependent. This dimorphism could shed light on potential cellular mechanism(s) to explain the susceptibility of females to alcoholic immunopathogenesis and suggests an additional targetable pathway for alcoholic liver injury in females.	[Alharshawi, Khaled; Fey, Holger; Vogle, Alyx; Klenk, Tori; Kim, Miran; Aloman, Costica] Rush Univ, Sect Hepatol, Div Digest Dis & Nutr, Chicago, IL 60612 USA	Rush University	Aloman, C (corresponding author), Rush Univ, Sect Hepatol, Div Digest Dis & Nutr, Chicago, IL 60612 USA.	costica_aloman@rush.edu			National Institutes of Health [AA024762]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work is supported by grant from the National Institutes of Health: AA024762 awarded CA.	Alharshawi K, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107166; Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557; Dal-Secco D, 2015, J EXP MED, V212, P447, DOI 10.1084/jem.20141539; Fulham MA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164225; Gao B, 2019, J HEPATOL, V70, P249, DOI 10.1016/j.jhep.2018.10.023; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Guy Jennifer, 2013, Gastroenterol Hepatol (N Y), V9, P633; Hettinger J, 2013, NAT IMMUNOL, V14, P821, DOI 10.1038/ni.2638; Itoh Y, 1999, LIVER, V19, P97, DOI 10.1111/j.1478-3231.1999.tb00017.x; Itoh Y, 1997, J HEPATOL, V26, P244, DOI 10.1016/S0168-8278(97)80037-2; Ju C, 2015, ALCOHOL RES-CURR REV, V37, P251; Kawaratani H, 2017, INT J MOL MED, V40, P263, DOI 10.3892/ijmm.2017.3015; Kitazawa T, 2003, ALCOHOL CLIN EXP RES, V27, p72S, DOI 10.1097/01.ALC.0000078611.55696.F0; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Kottstorfer J, 2013, INJURY, V44, P930, DOI 10.1016/j.injury.2013.02.028; Lasseaux C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16869-2; Lee PY, 2009, AM J PATHOL, V175, P2023, DOI 10.2353/ajpath.2009.090328; LunaCasado L, 1997, J HEPATOL, V27, P477, DOI 10.1016/S0168-8278(97)80351-0; Marcos M, 2009, AM J EPIDEMIOL, V170, P948, DOI 10.1093/aje/kwp236; McClain CJ, 2002, ALCOHOL, V27, P53, DOI 10.1016/S0741-8329(02)00212-4; McClain CJ, 1998, ALCOHOL CLIN EXP RES, V22, p248S, DOI 10.1111/j.1530-0277.1998.tb04011.x; Meyerholz DK, 2008, J IMMUNOL, V181, P641, DOI 10.4049/jimmunol.181.1.641; Neuman MG, 2015, BIOMOLECULES, V5, P2023, DOI 10.3390/biom5032023; Ohashi Koichiro, 2018, Liver Res, V2, P161, DOI 10.1016/j.livres.2018.11.002; Osna NA, 2017, ALCOHOL RES-CURR REV, V38, P147; Osna NA, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6020020; Rao R, 2009, HEPATOLOGY, V50, P638, DOI 10.1002/hep.23009; Rao RK, 2004, AM J PHYSIOL-GASTR L, V286, pG881, DOI 10.1152/ajpgi.00006.2004; Riva A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00167; Rusyn I, 2013, J HEPATOL, V59, P387, DOI 10.1016/j.jhep.2013.01.035; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Shukla PK, 2018, FASEB J, V32, P6274, DOI 10.1096/fj.201800351R; Siggins RW, 2014, ALCOHOL CLIN EXP RES, V38, P1993, DOI 10.1111/acer.12433; Sobecki M, 2016, ELIFE, V5, DOI 10.7554/eLife.13722; Sunderkotter C, 2004, J IMMUNOL, V172, P4410, DOI 10.4049/jimmunol.172.7.4410; Szabo G, 2015, ALCOHOL RES-CURR REV, V37, P159; Terry RL, 2014, CELL IMMUNOL, V291, P16, DOI 10.1016/j.cellimm.2014.02.008; Vogle A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59188-9; Wagnerberger S, 2013, ALCOHOL ALCOHOLISM, V48, P648, DOI 10.1093/alcalc/agt138; Wang M, 2014, J LEUKOCYTE BIOL, V96, P657, DOI 10.1189/jlb.6A0114-004RR; Wintermeyer P, 2009, GASTROENTEROLOGY, V136, P1048, DOI 10.1053/j.gastro.2008.10.027; Xu RN, 2014, CELL MOL IMMUNOL, V11, P224, DOI 10.1038/cmi.2014.2; Ziegler-Heitbrock L, 2007, J LEUKOCYTE BIOL, V81, P584, DOI 10.1189/jlb.0806510; Zigmond E, 2014, J IMMUNOL, V193, P344, DOI 10.4049/jimmunol.1400574	44	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 30	2021	12								663548	10.3389/fimmu.2021.663548	http://dx.doi.org/10.3389/fimmu.2021.663548			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SB9GE	33995391	gold, Green Published			2022-12-18	WOS:000650292800001
J	Baumgaertner, P; Sankar, M; Herrera, F; Benedetti, F; Barras, D; Thierry, AC; Dangaj, D; Kandalaft, LE; Coukos, G; Xenarios, I; Guex, N; Harari, A				Baumgaertner, Petra; Sankar, Martial; Herrera, Fernanda; Benedetti, Fabrizio; Barras, David; Thierry, Anne-Christine; Dangaj, Denarda; Kandalaft, Lana E.; Coukos, George; Xenarios, Ioannis; Guex, Nicolas; Harari, Alexandre			Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery	FRONTIERS IN IMMUNOLOGY			English	Article						flow cytometry; unsupervised clustering; data-driven analysis; immune monitoring; analytical immunology		Data obtained with cytometry are increasingly complex and their interrogation impacts the type and quality of knowledge gained. Conventional supervised analyses are limited to pre-defined cell populations and do not exploit the full potential of data. Here, in the context of a clinical trial of cancer patients treated with radiotherapy, we performed longitudinal flow cytometry analyses to identify multiple distinct cell populations in circulating whole blood. We cross-compared the results from state-of-the-art recommended supervised analyses with results from MegaClust, a high-performance data-driven clustering algorithm allowing fast and robust identification of cell-type populations. Ten distinct cell populations were accurately identified by supervised analyses, including main T, B, dendritic cell (DC), natural killer (NK) and monocytes subsets. While all ten subsets were also identified with MegaClust, additional cell populations were revealed (e.g. CD4(+)HLA-DR+ and NKT-like subsets), and DC profiling was enriched by the assignment of additional subset-specific markers. Comparison between transcriptomic profiles of purified DC populations and publicly available datasets confirmed the accuracy of the unsupervised clustering algorithm and demonstrated its potential to identify rare and scarcely described cell subsets. Our observations show that data-driven analyses of cytometry data significantly enrich the amount and quality of knowledge gained, representing an important step in refining the characterization of immune responses.	[Baumgaertner, Petra; Benedetti, Fabrizio; Barras, David; Thierry, Anne-Christine; Dangaj, Denarda; Kandalaft, Lana E.; Harari, Alexandre] Univ Hosp Lausanne CHUV, Ctr Expt Therapeut, Dept Oncol, Lausanne, Switzerland; [Baumgaertner, Petra; Herrera, Fernanda; Benedetti, Fabrizio; Barras, David; Thierry, Anne-Christine; Dangaj, Denarda; Kandalaft, Lana E.; Coukos, George; Xenarios, Ioannis; Harari, Alexandre] Univ Hosp Lausanne CHUV, Dept Oncol, Lausanne, Switzerland; [Sankar, Martial; Guex, Nicolas] Swiss Inst Bioinformat, Vital IT, Lausanne, Switzerland; [Dangaj, Denarda; Kandalaft, Lana E.; Coukos, George; Harari, Alexandre] Univ Lausanne UNIL, Ludwig Inst Canc Res, Lausanne, Switzerland; [Guex, Nicolas] Univ Lausanne, Bioinformat Competence Ctr BICC, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Institute of Bioinformatics; Ludwig Institute for Cancer Research; University of Lausanne; University of Lausanne	Baumgaertner, P; Harari, A (corresponding author), Univ Hosp Lausanne CHUV, Ctr Expt Therapeut, Dept Oncol, Lausanne, Switzerland.; Baumgaertner, P; Harari, A (corresponding author), Univ Hosp Lausanne CHUV, Dept Oncol, Lausanne, Switzerland.; Guex, N (corresponding author), Swiss Inst Bioinformat, Vital IT, Lausanne, Switzerland.; Harari, A (corresponding author), Univ Lausanne UNIL, Ludwig Inst Canc Res, Lausanne, Switzerland.; Guex, N (corresponding author), Univ Lausanne, Bioinformat Competence Ctr BICC, Lausanne, Switzerland.	Petra.Baumgaertner@hospvd.ch; Nicolas.Guex@unil.ch; Alexandre.Harari@chuv.ch	Xenarios, Ioannis/ABD-5045-2021	Xenarios, Ioannis/0000-0002-3413-6841; Benedetti, Fabrizio/0000-0002-9959-9142; Harari, Alexandre/0000-0002-1055-2090; Herrera, Fernanda/0000-0001-7984-0472; GUEX, Nicolas/0000-0001-6023-0519	Swiss National Science Foundation [310030_182384]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	AH acknowledges support from the Swiss National Science Foundation (310030_182384).	Aghaeepour N, 2013, NAT METHODS, V10, P228, DOI [10.1038/NMETH.2365, 10.1038/nmeth.2365]; Andreopoulos B, 2009, BRIEF BIOINFORM, V10, P297, DOI 10.1093/bib/bbn058; Attig S, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-108; Chandran PA, 2018, CYTOM PART B-CLIN CY, V94, P342, DOI 10.1002/cyto.b.21397; Collin M, 2018, IMMUNOLOGY, V154, P3, DOI 10.1111/imm.12888; Cosma A, 2018, CYTOM PART A, V93A, P649, DOI 10.1002/cyto.a.23346; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Ester M., 1996, P 2 INT C KNOWL DISC, P226; Faget J, 2017, CELL REP, V21, P3190, DOI 10.1016/j.celrep.2017.11.052; Gouttefangeas C, 2015, CANCER IMMUNOL IMMUN, V64, P585, DOI 10.1007/s00262-014-1649-1; Guzun G, 2017, PROCEEDINGS OF THE EXPLOREDB'17, P31, DOI 10.1145/3077331.3077336; Hartmann FJ, 2019, CELL REP, V28, P819, DOI 10.1016/j.celrep.2019.06.049; Hensley-McBain T, 2014, J IMMUNOL METHODS, V411, P23, DOI 10.1016/j.jim.2014.06.002; Herrera FG, 2019, INT J RADIAT ONCOL, V103, P320, DOI 10.1016/j.ijrobp.2018.09.023; Janetzki S, 2009, IMMUNITY, V31, P527, DOI 10.1016/j.immuni.2009.09.007; Jardine L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00495; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; Maecker HT, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0085-x; Maecker HT, 2012, NAT REV IMMUNOL, V12, P191, DOI 10.1038/nri3158; Mair F, 2016, EUR J IMMUNOL, V46, P34, DOI 10.1002/eji.201545774; McNeil LK, 2013, CYTOM PART A, V83A, P728, DOI [10.1002/cyto.22319, 10.1002/cyto.a.22319]; Montante S, 2019, INT J LAB HEMATOL, V41, P56, DOI 10.1111/ijlh.13016; Pagni M, 2013, BIOINFORMATICS, V29, P1268, DOI 10.1093/bioinformatics/btt149; Pitoiset F, 2018, CYTOM PART A, V93A, P793, DOI 10.1002/cyto.a.23570; Saeys Y, 2018, NAT REV IMMUNOL, V18, P78, DOI 10.1038/nri.2017.151; Saeys Y, 2016, NAT REV IMMUNOL, V16, P449, DOI 10.1038/nri.2016.56; Samusik N, 2016, NAT METHODS, V13, P493, DOI [10.1038/NMETH.3863, 10.1038/nmeth.3863]; Streitz M, 2013, TRANSPLANT RES, V2, DOI 10.1186/2047-1440-2-17; Thorsson V, 2019, IMMUNITY, V51, P411, DOI 10.1016/j.immuni.2019.08.004; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Vera EJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217163; Weber LM, 2016, CYTOM PART A, V89A, P1084, DOI 10.1002/cyto.a.23030; Welters MJP, 2012, CANCER IMMUNOL IMMUN, V61, P967, DOI 10.1007/s00262-012-1282-9	33	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 30	2021	12								633910	10.3389/fimmu.2021.633910	http://dx.doi.org/10.3389/fimmu.2021.633910			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SB5FP	33995353	gold, Green Published			2022-12-18	WOS:000650020200001
J	Li, JT; Qin, B; Huang, MY; Ma, Y; Li, DS; Li, WY; Guo, ZP				Li, Jitian; Qin, Bo; Huang, Manyu; Ma, Yan; Li, Dongsheng; Li, Wuyin; Guo, Zhiping			Tumor-Associated Antigens (TAAs) for the Serological Diagnosis of Osteosarcoma	FRONTIERS IN IMMUNOLOGY			English	Review						osteosarcoma; tumor-associated antigen; autoantibodies; biomarker; immunodiagnosis; prognosis	CANCER; EXPRESSION; PROTEIN; CELLS; TIME	Osteosarcoma (OS) is the most common form of malignant bone tumor found in childhood and adolescence. Although its incidence rate is low among cancers, the prognosis of OS is usually poor. Although some biomarkers, such as p53, have been identified in OS, the association between the biomarkers and clinical outcome is not well understood. Thus, it is necessary to establish a method to identify patients diagnosed with OS at an early stage. It is becoming obvious that anti-tumor-associated antigens (TAAs) autoantibodies (TAAbs) in sera could be used as serological biomarkers in the detection of many different types of cancers. This notion indicates that TAAbs are considered as immunological "sentinels" associated with tumorigenesis underlying molecular events. It provides new insights into the molecular and cellular biology of the differential diagnosis of cancers. What's more, it is reported that a customized TAA array could significantly increase the sensitivity/specificity. TAA arrays also have great application prospects in detecting cancer at an early stage, monitoring cancer progression, discovering new therapeutic targets, and designing personalized treatment. In this review, we provide an overview of the TAAs identified in OS as well as the possibility that TAAs and TAAbs system be used as biomarkers in the immunodiagnosis and prognosis of OS.	[Li, Jitian; Huang, Manyu; Ma, Yan; Li, Dongsheng; Li, Wuyin; Guo, Zhiping] Henan Luoyang Orthoped Hosp, Henan Prov Orthoped Hosp, Henan Inst Orthoped & Traumatol, Luoyang, Peoples R China; [Qin, Bo] Zhengzhou Univ, Transit Med Ctr, Affiliated Hosp 1, Zhengzhou, Peoples R China	Zhengzhou University	Guo, ZP (corresponding author), Henan Luoyang Orthoped Hosp, Henan Prov Orthoped Hosp, Henan Inst Orthoped & Traumatol, Luoyang, Peoples R China.	hlohljt@163.com			National Natural Science Foundation of China [82004397]; Major Project of TCM research in Henan Province [2018ZYZD01, 20-21ZYZD12]; Major Project of Science and Technology in Henan Province [212102310152]; Project of Health Guiding Plan in Luoyang [1930005A]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major Project of TCM research in Henan Province; Major Project of Science and Technology in Henan Province; Project of Health Guiding Plan in Luoyang	This work was supported by the National Natural Science Foundation of China (82004397), the Major Project of TCM research in Henan Province (2018ZYZD01 and 20-21ZYZD12), the Major Project of Science and Technology in Henan Province (212102310152), and the Project of Health Guiding Plan in Luoyang (1930005A).	Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Anderson KS, 2015, J PROTEOME RES, V14, P578, DOI 10.1021/pr500908n; Anderson KS, 2005, J PROTEOME RES, V4, P1123, DOI 10.1021/pr0500814; Asemissen AM, 2009, CANCER IMMUNOL IMMUN, V58, P1169, DOI 10.1007/s00262-009-0706-7; BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103; Bao HX, 2017, EXPERT OPIN THER TAR, V21, P455, DOI 10.1080/14728222.2017.1310194; Bezu L, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1511506; Borys D, 2012, HUM PATHOL, V43, P1948, DOI 10.1016/j.humpath.2012.02.003; Canelle L, 2005, J IMMUNOL METHODS, V299, P77, DOI 10.1016/j.jim.2005.01.015; Casiano CA, 2006, MOL CELL PROTEOMICS, V5, P1745, DOI 10.1074/mcp.R600010-MCP200; Chan HSL, 1997, J NATL CANCER I, V89, P1706, DOI 10.1093/jnci/89.22.1706; Chang L, 2012, J IMMUNOL METHODS, V378, P102, DOI 10.1016/j.jim.2012.02.011; Cheever MA, 2009, CLIN CANCER RES, V15, P5323, DOI 10.1158/1078-0432.CCR-09-0737; Cohen L, 2017, ANNU REV ANAL CHEM, V10, P345, DOI 10.1146/annurev-anchem-061516-045340; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; Dai LP, 2014, CLIN IMMUNOL, V152, P127, DOI 10.1016/j.clim.2014.03.007; Daniels T, 2005, PROSTATE, V62, P14, DOI 10.1002/pros.20112; DESANTOS LA, 1985, SKELETAL RADIOL, V13, P44, DOI 10.1007/BF00349093; Disis M., 2005, AM ASS CANC RES ED B, V2005, P166; Disis ML, 1997, J CLIN ONCOL, V15, P3363, DOI 10.1200/JCO.1997.15.11.3363; Doyle GA, 2000, CANCER RES, V60, P2756; Gautam SK, 2020, SEMIN IMMUNOL, V47, DOI 10.1016/j.smim.2020.101391; Gorlick R, 1999, J CLIN ONCOL, V17, P2781, DOI 10.1200/JCO.1999.17.9.2781; Gu JL, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/649075; Hoo LS, 2002, ONCOGENE, V21, P5006, DOI 10.1038/sj.onc.1205625; Huang GX, 2012, CANCER RES, V72, P271, DOI 10.1158/0008-5472.CAN-11-2778; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Huvos A, 1991, BONE TUMORS DIAGNOSI; Ishida H, 2000, INT J ONCOL, V17, P29; Ishikura H, 2007, INT J ONCOL, V30, P461; Jacobs JFM, 2007, INT J CANCER, V120, P67, DOI 10.1002/ijc.22118; Kaste SC, 1999, CANCER-AM CANCER SOC, V86, P1602, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1602::AID-CNCR31>3.0.CO;2-R; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; Kikuta K, 2010, PROTEOM CLIN APPL, V4, P560, DOI 10.1002/prca.200900172; Klade CS, 2002, CURR OPIN MOL THER, V4, P216; Klade CS, 2001, PROTEOMICS, V1, P890, DOI 10.1002/1615-9861(200107)1:7<890::AID-PROT890>3.0.CO;2-Z; Koziol JA, 2003, CLIN CANCER RES, V9, P5120; Laverdiere C, 2005, CLIN CANCER RES, V11, P2561, DOI 10.1158/1078-0432.CCR-04-1089; Li YT, 2006, PROTEOMICS, V6, P3426, DOI 10.1002/pmic.200500472; Li YT, 2011, CANCER-AM CANCER SOC, V117, P207, DOI 10.1002/cncr.25563; Liao B, 2007, CANCER BIOL THER, V6, P1805, DOI 10.4161/cbt.6.11.4868; Liu HL, 2016, FEBS OPEN BIO, V6, P807, DOI 10.1002/2211-5463.12079; Liu WH, 2011, AUTOIMMUN REV, V10, P331, DOI 10.1016/j.autrev.2010.12.002; Looi KS, 2008, J PROTEOME RES, V7, P4004, DOI 10.1021/pr800273h; Lu HL, 2008, J PROTEOME RES, V7, P1388, DOI 10.1021/pr700818f; Lu ML, 2001, AM J PATHOL, V159, P945, DOI 10.1016/S0002-9440(10)61770-1; Maehara H, 2007, BIOCHEM BIOPH RES CO, V358, P757, DOI 10.1016/j.bbrc.2007.04.183; McGary EC, 2003, CLIN CANCER RES, V9, P6560; Mian S, 2005, J CLIN ONCOL, V23, P5088, DOI 10.1200/JCO.2005.03.164; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Modak S, 2001, CANCER RES, V61, P4048; Multhoff G, 1997, J IMMUNOL, V158, P4341; Old LJ, 1998, J EXP MED, V187, P1163, DOI 10.1084/jem.187.8.1163; Onda M, 1996, CANCER-AM CANCER SOC, V77, P71, DOI 10.1002/(SICI)1097-0142(19960101)77:1<71::AID-CNCR13>3.3.CO;2-L; Osaka E, 2007, J ORTHOP RES, V25, P116, DOI 10.1002/jor.20291; Pedersen JW, 2011, LABMEDICINE, V42, P623, DOI 10.1309/LM2T3OU3RZRTHKSN; Peng B, 2013, J PROTEOME RES, V12, P1789, DOI 10.1021/pr3011342; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Pilla L, 2009, EXPERT OPIN BIOL TH, V9, P1043, DOI 10.1517/14712590903085109; Restifo NP, 2012, NAT REV IMMUNOL, V12, P269, DOI 10.1038/nri3191; Righi A, 2016, HUM PATHOL, V58, P15, DOI 10.1016/j.humpath.2016.07.023; Rodero MP, 2017, J EXP MED, V214, P1547, DOI 10.1084/jem.20161451; ROSENBERG ZS, 1995, AM J ROENTGENOL, V165, P1209, DOI 10.2214/ajr.165.5.7572505; Rouleau C, 2008, CLIN CANCER RES, V14, P7223, DOI 10.1158/1078-0432.CCR-08-0499; Sasaki H, 2010, ONCOL REP, V23, P677, DOI 10.3892/or_00000684; Savitskaya Yulia A, 2010, Biomark Cancer, V2, P65, DOI 10.4137/BIC.S6040; Schneble E, 2016, METHODS MOL BIOL, V1403, P797, DOI 10.1007/978-1-4939-3387-7_46; Serra M, 1999, INT J ONCOL, V14, P301; Serra M, 1995, EUR J CANCER, V31A, P1998, DOI 10.1016/0959-8049(95)00335-5; Shin BK, 2002, J MAMMARY GLAND BIOL, V7, P407, DOI 10.1023/A:1024038132381; Soussi T, 2000, CANCER RES, V60, P1777; Stockert E, 1998, J EXP MED, V187, P1349, DOI 10.1084/jem.187.8.1349; Sudo T, 1997, J ORTHOPAED RES, V15, P128, DOI 10.1002/jor.1100150119; Ta H, 2009, CANCER METAST REV, V28, P247, DOI 10.1007/s10555-009-9186-7; Tan EM, 2001, J CLIN INVEST, V108, P1411, DOI 10.1172/JCI200114451; Teng JW, 2019, J CELL BIOCHEM, V120, P12796, DOI 10.1002/jcb.28550; Trieb K, 1998, HUM PATHOL, V29, P1050, DOI 10.1016/S0046-8177(98)90412-9; Trieb K, 2001, INT J BIOCHEM CELL B, V33, P11, DOI 10.1016/S1357-2725(00)00066-2; Trieb K, 2000, BRIT J CANCER, V82, P85, DOI 10.1054/bjoc.1999.0881; Trieb K, 2000, IMMUNOBIOLOGY, V201, P368, DOI 10.1016/S0171-2985(00)80091-1; Trieb K, 2000, PEDIATR HEMAT ONCOL, V17, P355, DOI 10.1080/08880010050034283; Tsuda N, 2001, J ORTHOP RES, V19, P346, DOI 10.1016/S0736-0266(00)90031-7; Tsukahara T, 2004, CANCER RES, V64, P5442, DOI 10.1158/0008-5472.CAN-04-0522; Tsukahara T, 2008, CANCER SCI, V99, P368, DOI 10.1111/j.1349-7006.2008.00695.x; UEDA Y, 1993, J CANCER RES CLIN, V119, P172, DOI 10.1007/BF01229533; Uozaki H, 1997, CANCER-AM CANCER SOC, V79, P2336, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J; Wang QT, 2020, CANCER IMMUNOL IMMUN, V69, P1375, DOI 10.1007/s00262-020-02496-w; Wang ZY, 2018, ONCOTARGETS THER, V11, P3159, DOI 10.2147/OTT.S161807; Ward E, 2014, CA-CANCER J CLIN, V64, P83, DOI 10.3322/caac.21219; Wu DL, 2016, ANAL CHEM, V88, P8385, DOI 10.1021/acs.analchem.6b02451; Yu AL, 1998, J CLIN ONCOL, V16, P2169, DOI 10.1200/JCO.1998.16.6.2169; Yu AL, 2010, NEW ENGL J MED, V363, P1324, DOI 10.1056/NEJMoa0911123; Yu HY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153601; Yuan DT, 2013, J SURG ONCOL, V108, P157, DOI 10.1002/jso.23368; Zayakin P, 2013, INT J CANCER, V132, P137, DOI 10.1002/ijc.27667; Zhang JY, 2007, J HEPATOL, V46, P107, DOI 10.1016/j.jhep.2006.08.010; Zhang JY, 2010, EXPERT REV MOL DIAGN, V10, P321, DOI 10.1586/ERM.10.12; Zhang JT, 2011, J PROTEOME RES, V10, P2863, DOI 10.1021/pr200141c; Zhang JY, 2003, CANCER EPIDEM BIOMAR, V12, P136; Zhang JY, 1999, J EXP MED, V189, P1101, DOI 10.1084/jem.189.7.1101; Zhu Q, 2013, AUTOIMMUN REV, V12, P1123, DOI 10.1016/j.autrev.2013.06.015; Zou CY, 2012, CANCER-AM CANCER SOC, V118, P1845, DOI 10.1002/cncr.26486	103	1	1	4	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 30	2021	12								665106	10.3389/fimmu.2021.665106	http://dx.doi.org/10.3389/fimmu.2021.665106			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SB5CL	33995397	Green Published, gold			2022-12-18	WOS:000650012000001
J	Mannering, SI; Rubin, AF; Wang, RK; Bhattacharjee, P				Mannering, Stuart, I; Rubin, Alan F.; Wang, Ruike; Bhattacharjee, Pushpak			Identifying New Hybrid Insulin Peptides (HIPs) in Type 1 Diabetes	FRONTIERS IN IMMUNOLOGY			English	Review						hybrid insulin peptides (HIPs); CD4(+) T cell; autoimmunity; type 1 diabetes; epitope	T-CELLS	In 2016 Delong et al. discovered a new type of neoepitope formed by the fusion of two unrelated peptide fragments. Remarkably these neoepitopes, called hybrid insulin peptides, or HIPs, are recognized by pathogenic CD4(+) T cells in the NOD mouse and human pancreatic islet-infiltrating T cells in people with type 1 diabetes. Current data implicates CD4(+) T-cell responses to HIPs in the immune pathogenesis of human T1D. Because of their role in the immune pathogenesis of human T1D it is important to identify new HIPs that are recognized by CD4(+) T cells in people at risk of, or with, T1D. A detailed knowledge of T1D-associated HIPs will allow HIPs to be used in assays to monitor changes in T cell mediated beta-cell autoimmunity. They will also provide new targets for antigen-specific therapies for T1D. However, because HIPs are formed by the fusion of two unrelated peptides there are an enormous number of potential HIPs which makes it technically challenging to identify them. Here we review the discovery of HIPs, how they form and discuss approaches to identifying new HIPs relevant to the immune pathogenesis of human type 1 diabetes.	[Mannering, Stuart, I; Wang, Ruike; Bhattacharjee, Pushpak] St Vincents Inst Med Res, Immunol & Diabet Unit, Melbourne, Vic, Australia; [Mannering, Stuart, I] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia; [Rubin, Alan F.] Walter & Eliza Hall Inst Med Res, Bioinformat Div, Melbourne, Vic, Australia; [Rubin, Alan F.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia	St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne; University of Melbourne; Walter & Eliza Hall Institute; University of Melbourne	Mannering, SI (corresponding author), St Vincents Inst Med Res, Immunol & Diabet Unit, Melbourne, Vic, Australia.; Mannering, SI (corresponding author), Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia.	smannering@svi.edu.au	Bhattacharjee, Pushpak/AFV-4590-2022	Rubin, Alan/0000-0003-1474-605X	Juvenile Diabetes Research Foundation [2-SRA-2020-909-S-B]; National Health and Medical Research Council [NHMRC GNT123586, 1138717]; St. Vincent's Institute Rising Star Award; Victorian Government	Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); St. Vincent's Institute Rising Star Award; Victorian Government	This work was supported by the Juvenile Diabetes Research Foundation (2-SRA-2020-909-S-B) and the National Health and Medical Research Council (NHMRC GNT123586, 1138717) (SM). PB is supported by a St. Vincent's Institute Rising Star Award. The authors acknowledge the support of the Operational Infrastructure Support Program of the Victorian Government.	Ahmed S, 2019, DIABETES, V68, P1366, DOI 10.2337/db19-0119; Arribas-Layton D, 2020, DIABETES, V69, P1492, DOI 10.2337/db19-0620; Babon JAB, 2016, NAT MED, V22, P1482, DOI 10.1038/nm.4203; Baker RL, 2019, DIABETES, V68, P1830, DOI 10.2337/db19-0128; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; CARRINGTON DM, 1985, NATURE, V313, P64, DOI 10.1038/313064a0; Concannon P, 2009, NEW ENGL J MED, V360, P1646, DOI 10.1056/NEJMra0808284; Coppieters KT, 2012, J EXP MED, V209, P51, DOI 10.1084/jem.20111187; Dai YD, 2005, J IMMUNOL, V175, P3621, DOI 10.4049/jimmunol.175.6.3621; Delong T, 2016, SCIENCE, V351, P711, DOI 10.1126/science.aad2791; Dodson G, 1998, CURR OPIN STRUC BIOL, V8, P189, DOI 10.1016/S0959-440X(98)80037-7; Faridi P, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar3947; Fodor S, 2006, ANAL BIOCHEM, V356, P282, DOI 10.1016/j.ab.2006.06.023; Hanada K, 2004, NATURE, V427, P252, DOI 10.1038/nature02240; Haskins K, 2005, ADV IMMUNOL, V87, P123, DOI 10.1016/S0065-2776(05)87004-X; HASKINS K, 1989, P NATL ACAD SCI USA, V86, P8000, DOI 10.1073/pnas.86.20.8000; HASKINS K, 1990, SCIENCE, V249, P1433, DOI 10.1126/science.2205920; James EA, 2020, DIABETES, V69, P1311, DOI 10.2337/dbi19-0022; Judkowski V, 2001, J IMMUNOL, V166, P908, DOI 10.4049/jimmunol.166.2.908; KATZ JD, 1993, CELL, V74, P1089, DOI 10.1016/0092-8674(93)90730-E; Kent SC, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0915-y; Kula T, 2019, CELL, V178, P1016, DOI 10.1016/j.cell.2019.07.009; Liepe J, 2016, SCIENCE, V354, P354, DOI 10.1126/science.aaf4384; Mannering SI, 2016, CLIN EXP IMMUNOL, V183, P8, DOI 10.1111/cei.12699; Mannering SI, 2005, J IMMUNOL METHODS, V298, P83, DOI 10.1016/j.jim.2005.01.001; Marraffini LA, 2006, MICROBIOL MOL BIOL R, V70, P192, DOI 10.1128/MMBR.70.1.192-221.2006; Narendran P, 2003, AUTOIMMUN REV, V2, P204, DOI 10.1016/S1568-9972(03)00009-0; NEPOM BS, 1987, DIABETES, V36, P114, DOI 10.2337/diabetes.36.1.114; Nikoopour E, 2011, J IMMUNOL, V186, P3831, DOI 10.4049/jimmunol.1003617; Noble JA, 2015, J AUTOIMMUN, V64, P101, DOI 10.1016/j.jaut.2015.07.014; Pathiraja V, 2015, DIABETES, V64, P172, DOI 10.2337/db14-0858; Ramirez L, 2013, WORLD J DIABETES, V4, P88, DOI 10.4239/wjd.v4.i4.88; Reed B, 2021, J EXP MED, V218, DOI 10.1084/jem.20192135; Somalinga BR, 2002, J BIOL CHEM, V277, P43253, DOI 10.1074/jbc.M207974200; Stadinski BD, 2010, NAT IMMUNOL, V11, P225, DOI 10.1038/ni.1844; Suckalel J, 2010, TRENDS ENDOCRIN MET, V21, P599, DOI 10.1016/j.tem.2010.06.003; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; Verchere CB, 1996, J BIOL CHEM, V271, P27475, DOI 10.1074/jbc.271.44.27475; Vigneron N, 2004, SCIENCE, V304, P587, DOI 10.1126/science.1095522; Vomund AN, 2015, P NATL ACAD SCI USA, V112, pE5496, DOI 10.1073/pnas.1515954112; Wan XX, 2020, NAT IMMUNOL, V21, P455, DOI 10.1038/s41590-020-0623-7; Weir GC, 2013, ANN NY ACAD SCI, V1281, P92, DOI 10.1111/nyas.12031; Wiles TA, 2019, CLIN EXP IMMUNOL, V198, P306, DOI 10.1111/cei.13335; Wiles TA, 2019, J PROTEOME RES, V18, P814, DOI 10.1021/acs.jproteome.8b00875; Wiles TA, 2021, J PROTEOME RES, V20, P236, DOI 10.1021/acs.jproteome.0c00355	45	1	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 30	2021	12								667870	10.3389/fimmu.2021.667870	http://dx.doi.org/10.3389/fimmu.2021.667870			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SB5BT	33995402	gold, Green Published			2022-12-18	WOS:000650010200001
J	Carvalho, JL; Silva-Carvalho, AE; Garcez, EM; Saldanha-Araujo, F				Carvalho, Juliana Lott; Silva-Carvalho, Amandda Evelin; Garcez, Emanuella Melgaco; Saldanha-Araujo, Felipe			Commentary: Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						stem cells; COVID-19; SARS-CoV-2; advanced therapies; exosomes			[Carvalho, Juliana Lott; Garcez, Emanuella Melgaco] Univ Brasilia, Multidisciplinary Lab Biosci, Fac Med, Brasilia, DF, Brazil; [Silva-Carvalho, Amandda Evelin; Saldanha-Araujo, Felipe] Univ Brasilia, Dept Hlth Sci, Hematol & Stem Cells Lab, Brasilia, DF, Brazil	Universidade de Brasilia; Universidade de Brasilia	Saldanha-Araujo, F (corresponding author), Univ Brasilia, Dept Hlth Sci, Hematol & Stem Cells Lab, Brasilia, DF, Brazil.	felipearaujo@unb.br	Carvalho, Juliana/F-4498-2015	Carvalho, Juliana/0000-0002-1423-0523; Melgaco Garcez, Emanuella/0000-0002-8369-8680	CNPq (National Council of Technological and Scientific Development); CAPES (Coordination for the Improvement of Higher Education Personnel); FAPDF (Federal District Research Foundation)	CNPq (National Council of Technological and Scientific Development)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CAPES (Coordination for the Improvement of Higher Education Personnel)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); FAPDF (Federal District Research Foundation)(Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF))	This work was supported by CNPq (National Council of Technological and Scientific Development), CAPES (Coordination for the Improvement of Higher Education Personnel), and FAPDF (Federal District Research Foundation).	Barros I, 2021, CYTOKINE GROWTH F R, V58, P114, DOI 10.1016/j.cytogfr.2020.12.002; Del Valle DM, 2020, NAT MED, V26, P1636, DOI [10.1101/2020.05.28.20115758, 10.1038/s41591-020-1051-9]; Feng Y, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12947; Hashemian SMR, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02165-4; Lanzoni G, 2021, STEM CELL TRANSL MED, V10, P660, DOI 10.1002/sctm.20-0472; Lopes-Pacheco M, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.593223; Majumder J, 2021, AAPS J, V23, DOI 10.1208/s12248-020-00532-2; Meng FP, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00286-5; Saldanha-Araujo F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01563; Sanchez-Guijo F, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100454; Schafer R, 2021, STEM CELL REP, V16, P419, DOI 10.1016/j.stemcr.2020.09.003; Sengupta V, 2020, STEM CELLS DEV, V29, P747, DOI 10.1089/scd.2020.0080; Servick K., 2021, SCIENCE, DOI [10.1126/science.abi5263, DOI 10.1126/SCIENCE.ABI5263]; Shang YF, 2020, ECLINICALMEDICINE, V24, DOI 10.1016/j.eclinm.2020.100426; Shi L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00488-5; Shu L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01875-5; Wang CD, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00527-1	17	1	1	2	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2021	12								682195	10.3389/fimmu.2021.682195	http://dx.doi.org/10.3389/fimmu.2021.682195			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SB1RT	33995424	Green Published, gold			2022-12-18	WOS:000649779900001
J	Qin, YF; Kong, DJ; Qin, H; Zhu, YL; Li, GM; Sun, CL; Zhao, YM; Wang, HD; Hao, JP; Wang, H				Qin, Ya-fei; Kong, De-jun; Qin, Hong; Zhu, Yang-lin; Li, Guang-ming; Sun, Cheng-lu; Zhao, Yi-ming; Wang, Hong-da; Hao, Jing-peng; Wang, Hao			Melatonin Synergizes With Mesenchymal Stromal Cells Attenuates Chronic Allograft Vasculopathy	FRONTIERS IN IMMUNOLOGY			English	Article						chronic allograft vasculopathy; melatonin; mesenchymal stromal cells; aorta transplantation; mice	STEM-CELLS; ADIPOSE-TISSUE; T-CELLS; TOLERANCE; TRANSPLANTATION; THERAPY; BALANCE; HEART	Background Chronic rejection characterized by chronic allograft vasculopathy (CAV) remains a major obstacle to long-term graft survival. Due to multiple complicated mechanisms involved, a novel therapy for CAV remains exploration. Although mesenchymal stromal cells (MSCs) have been ubiquitously applied to various refractory immune-related diseases, rare research makes a thorough inquiry in CAV. Meanwhile, melatonin (MT), a wide spectrum of immunomodulator, plays a non-negligible role in transplantation immunity. Here, we have investigated the synergistic effects of MT in combination with MSCs in attenuation of CAV. Methods C57BL/6 (B6) mouse recipients receiving BALB/c mouse donor aorta transplantation have been treated with MT and/or adipose-derived MSCs. Graft pathological changes, intragraft immunocyte infiltration, splenic immune cell populations, circulating donor-specific antibodies levels, cytokine profiles were detected on post-operative day 40. The proliferation capacity of CD4(+) and CD8(+) T cells, populations of Th1, Th17, and Tregs were also assessed in vitro. Results Grafts in untreated recipients developed a typical pathological feature of CAV characterized by intimal thickening 40 days after transplantation. Compared to untreated and monotherapy groups, MT in combination with MSCs effectively ameliorated pathological changes of aorta grafts indicated by markedly decreased levels of intimal hyperplasia and the infiltration of CD4(+) cells, CD8(+) cells, and macrophages, but elevated infiltration of Foxp3(+) cells. MT either alone or in combination with MSCs effectively inhibited the proliferation of T cells, decreased populations of Th1 and Th17 cells, but increased the proportion of Tregs in vitro. MT synergized with MSCs displayed much fewer splenic populations of CD4(+) and CD8(+) T cells, Th1 cells, Th17 cells, CD4(+) central memory T cells (Tcm), as well as effector memory T cells (Tem) in aorta transplant recipients. In addition, the percentage of splenic Tregs was substantially increased in the combination therapy group. Furthermore, MT combined with MSCs markedly reduced serum levels of circulating allospecific IgG and IgM, as well as decreased the levels of pro-inflammatory IFN-gamma, TNF-alpha, IL-1 beta, IL-6, IL-17A, and MCP-1, but increased the level of IL-10 in the recipients. Conclusions These data suggest that MT has synergy with MSCs to markedly attenuate CAV and provide a novel therapeutic strategy to improve the long-term allograft acceptance in transplant recipients.	[Qin, Ya-fei; Kong, De-jun; Qin, Hong; Zhu, Yang-lin; Li, Guang-ming; Sun, Cheng-lu; Zhao, Yi-ming; Wang, Hong-da; Wang, Hao] Tianjin Med Univ, Dept Gen Surg, Gen Hosp, Tianjin, Peoples R China; [Qin, Ya-fei; Kong, De-jun; Qin, Hong; Zhu, Yang-lin; Li, Guang-ming; Sun, Cheng-lu; Zhao, Yi-ming; Wang, Hong-da; Wang, Hao] Tianjin Med Univ, Tianjin Gen Surg Inst, Gen Hosp, Tianjin, Peoples R China; [Hao, Jing-peng] Tianjin Med Univ, Hosp 2, Dept Anorectal Surg, Tianjin, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University	Wang, H (corresponding author), Tianjin Med Univ, Dept Gen Surg, Gen Hosp, Tianjin, Peoples R China.; Wang, H (corresponding author), Tianjin Med Univ, Tianjin Gen Surg Inst, Gen Hosp, Tianjin, Peoples R China.	hwangca272@hotmail.com			National Natural Science Foundation of China [82071802]; Tianjin Application Basis and Cutting-Edge Technology Research Grant [14JCZDJC35700]; Jieshou Intestinal Barrier Research Special Fund [LJS_201412]; Natural Science Foundation of Tianjin [18JCZDJC35800]; Tianjin Medical University Talent Fund; Tianjin Research Innovation Project for Postgraduate Students [2019YJSS184, 2020YJSS176, 2020YJSS177]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Application Basis and Cutting-Edge Technology Research Grant; Jieshou Intestinal Barrier Research Special Fund; Natural Science Foundation of Tianjin(Natural Science Foundation of Tianjin); Tianjin Medical University Talent Fund; Tianjin Research Innovation Project for Postgraduate Students	This work was supported by grants to HW from the National Natural Science Foundation of China (No. 82071802), Tianjin Application Basis and Cutting-Edge Technology Research Grant (No. 14JCZDJC35700), Li Jieshou Intestinal Barrier Research Special Fund (No. LJS_201412), Natural Science Foundation of Tianjin (No. 18JCZDJC35800), and Tianjin Medical University Talent Fund; by a grant to D-JK from Tianjin Research Innovation Project for Postgraduate Students (No. 2019YJSS184); by a grant to G-ML from Tianjin Research Innovation Project for Postgraduate Students (2020YJSS176); and by a grant to H-DW from Tianjin Research Innovation Project for Postgraduate Students (2020YJSS177).	Abele-Ohl S, 2010, TRANSPL IMMUNOL, V23, P59, DOI 10.1016/j.trim.2010.04.003; Alvarez-Sanchez N, 2015, BRAIN BEHAV IMMUN, V50, P101, DOI 10.1016/j.bbi.2015.06.021; Andersen LPH, 2016, CLIN DRUG INVEST, V36, P169, DOI 10.1007/s40261-015-0368-5; Antunes Andre, 2017, Rev Port Cir Cardiotorac Vasc, V24, P158; Baaten BJG, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00023; Banner NR, 2008, TRANSPLANTATION, V86, P542, DOI 10.1097/TP.0b013e31818149b9; Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; Blattman JN, 2002, J EXP MED, V195, P657, DOI 10.1084/jem.20001021; Buron F, 2009, TRANSPL P, V41, P3347, DOI 10.1016/j.transproceed.2009.08.030; Calvo JR, 2013, J PINEAL RES, V55, P103, DOI 10.1111/jpi.12075; Casiraghi F, 2008, J IMMUNOL, V181, P3933, DOI 10.4049/jimmunol.181.6.3933; Casiraghi F, 2016, NAT REV NEPHROL, V12, P241, DOI 10.1038/nrneph.2016.7; Chen C, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0283-6; Chen QH, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01612-y; Chen Y, 2004, J IMMUNOL, V172, P5456, DOI 10.4049/jimmunol.172.9.5456; Chih S, 2016, J AM COLL CARDIOL, V68, P80, DOI 10.1016/j.jacc.2016.04.033; Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657; Di Lanni M, 2008, EXP HEMATOL, V36, P309, DOI 10.1016/j.exphem.2007.11.007; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Fischbein MP, 2002, J THORAC CARDIOV SUR, V123, P803, DOI 10.1067/mtc.2002.120008; Gitto E, 2005, J PINEAL RES, V39, P287, DOI 10.1111/j.1600-079X.2005.00251.x; Hamano K, 2000, J SURG RES, V93, P28, DOI 10.1006/jsre.2000.5967; Hoogduijn MJ, 2008, TRANSPLANTATION, V86, P1283, DOI 10.1097/TP.0b013e31818aa536; Hu CX, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-018-1114-8; Huang WC, 2011, PLAST RECONSTR SURG, V127, P1141, DOI 10.1097/PRS.0b013e3182043695; Illigens BM, 2009, EUR J IMMUNOL, V39, P3000, DOI 10.1002/eji.200838980; Inci I, 2002, ANN THORAC SURG, V73, P220, DOI 10.1016/S0003-4975(01)03101-0; Jansen MAA, 2015, TRANSPLANTATION, V99, P2467, DOI 10.1097/TP.0000000000000848; Jung FJ, 2004, J PINEAL RES, V37, P36, DOI 10.1111/j.1600-079X.2004.00133.x; Koga T, 2012, J IMMUNOL, V189, P3490, DOI 10.4049/jimmunol.1201785; Labat A, 2002, LAB ANIM-UK, V36, P426, DOI 10.1258/002367702320389099; Lan X, 2017, STEM CELL TRANSL MED, V6, P1997, DOI 10.1002/sctm.17-0091; Lee JH, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12385; Leventhal JR, 2018, HUM IMMUNOL, V79, P272, DOI 10.1016/j.humimm.2018.01.007; Li JP, 2008, ADV THER, V25, P935, DOI 10.1007/s12325-008-0091-1; Li ZQ, 2009, J PINEAL RES, V46, P365, DOI 10.1111/j.1600-079X.2009.00672.x; Lin GJ, 2009, J PINEAL RES, V47, P284, DOI 10.1111/j.1600-079X.2009.00712.x; Lund LH, 2017, J HEART LUNG TRANSPL, V36, P1037, DOI 10.1016/j.healun.2017.07.019; Luo JH, 2020, LIFE SCI, V242, DOI 10.1016/j.lfs.2019.117191; Luo ZH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00612; Luque-Campos N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00798; Luz-Crawford P, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1307-9; Mannon RB, 2012, CURR OPIN ORGAN TRAN, V17, P20, DOI 10.1097/MOT.0b013e32834ee5b6; Mazini L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102523; Medrano-Campillo P, 2015, J PINEAL RES, V58, P219, DOI 10.1111/jpi.12208; Mishima T, 2014, CELL MOL BIOL LETT, V19, P638, DOI 10.2478/s11658-014-0219-z; Mohseni M., 2020, CHRONIC TRANSPLANTAT; Murayama H, 2008, CARDIOVASC RES, V80, P175, DOI 10.1093/cvr/cvn250; Nagano H, 1997, J CLIN INVEST, V100, P550, DOI 10.1172/JCI119564; Ozdemir AT, 2016, CELL IMMUNOL, V310, P108, DOI 10.1016/j.cellimm.2016.08.008; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Pasztorek M, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00338; Pichler M, 2012, J AM COLL CARDIOL, V59, P1008, DOI 10.1016/j.jacc.2011.11.036; Quaranta P, 2016, STEM CELLS DEV, V25, P1321, DOI 10.1089/scd.2016.0145; Rafat A, 2019, CELL J, V20, P450, DOI 10.22074/cellj.2019.5507; Reiter RJ, 2010, PROG BRAIN RES, V181, P127, DOI 10.1016/S0079-6123(08)81008-4; Ren WK, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12394; Ribeiro A, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt336; Roldan C, 2012, TRANSPL P, V44, P2653, DOI 10.1016/j.transproceed.2012.09.048; Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x; Shaji AV, 1998, CLIN EXP IMMUNOL, V111, P181; SHAW KM, 1973, LANCET, V1, P271; Sho M, 2003, TRANSPLANTATION, V75, P1142, DOI 10.1097/01.TP.0000060567.48258.9D; Syrjala SO, 2010, J HEART LUNG TRANSPL, V29, P1047, DOI 10.1016/j.healun.2010.04.012; Taylor DO, 2008, J HEART LUNG TRANSPL, V27, P943, DOI 10.1016/j.healun.2008.06.017; Tsuji W, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00131; Vairetti M, 2005, J PINEAL RES, V38, P223, DOI 10.1111/j.1600-079X.2004.00193.x; van Loosdregt J, 2006, CIRCULATION, V114, P1599, DOI 10.1161/CIRCULATIONAHA.105.597526; Voisin C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020423; Wang CY, 2000, CIRC RES, V86, P982, DOI 10.1161/01.RES.86.9.982; Wang H, 2014, TRANSPL IMMUNOL, V31, P65, DOI 10.1016/j.trim.2014.06.005; Wang H, 2014, CARDIOVASC DRUG THER, V28, P115, DOI 10.1007/s10557-013-6502-9; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016; Ye K, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/2405698; Yu SY, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1474-8; Yuan XL, 2008, J EXP MED, V205, P3133, DOI 10.1084/jem.20081937; Zahran R, 2020, INT J UROL, V27, P1039, DOI 10.1111/iju.14345; Zhang QW, 2008, AM J TRANSPLANT, V8, P497, DOI 10.1111/j.1600-6143.2007.02096.x; Zhang QW, 2006, J IMMUNOL, V176, P770, DOI 10.4049/jimmunol.176.2.770; Zhao CN, 2019, CYTOKINE GROWTH F R, V48, P1, DOI 10.1016/j.cytogfr.2019.07.002; Zhao YM, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01985-0; Zorn E, 2019, CURR OPIN ORGAN TRAN, V24, P31, DOI 10.1097/MOT.0000000000000591	82	1	1	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2021	12								672849	10.3389/fimmu.2021.672849	http://dx.doi.org/10.3389/fimmu.2021.672849			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SB1ON	33995416	gold, Green Published			2022-12-18	WOS:000649771500001
J	Hayford, FEA; Ozturk, M; Dolman, RC; Blaauw, R; Nienaber, A; Loots, D; Brombacher, F; Smuts, CM; Parihar, SP; Malan, L				Hayford, Frank E. A.; Ozturk, Mumin; Dolman, Robin C.; Blaauw, Renee; Nienaber, Arista; Loots, Du Toit; Brombacher, Frank; Smuts, Cornelius M.; Parihar, Suraj P.; Malan, Linda			Longer-Term Omega-3 LCPUFA More Effective Adjunct Therapy for Tuberculosis Than Ibuprofen in a C3HeB/FeJ Tuberculosis Mouse Model	FRONTIERS IN IMMUNOLOGY			English	Article						ibuprofen; C3HeB/FeJ mice; tuberculosis adjunctive treatment; repurposed drugs; pharmaconutrition; host-directed therapies; n-3 LCPUFAs	HOST-DIRECTED THERAPIES; FATTY-ACIDS; INFLAMMATION	Advancement in the understanding of inflammation regulation during tuberculosis (TB) treatment has led to novel therapeutic approaches being proposed. The use of immune mediators like anti-inflammatory and pro-resolving molecules for such, merits attention. Drug repurposing is a widely used strategy that seeks to identify new targets to treat or manage diseases. The widely explored nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and a more recently explored pharmaconutrition therapy using omega-3 long-chain polyunsaturated fatty acids (n-3 LCPUFAs), have the potential to modulate the immune system and are thus considered potential repurposed drugs in this context. These approaches may be beneficial as supportive therapy to the already existing treatment regimen to improve clinical outcomes. Here, we applied adjunct ibuprofen and n-3 LCPUFA therapy, respectively, with standard anti-TB treatment, in a C3HeB/FeJ murine model of TB. Bacterial loads, lung pathology, lung cytokines/chemokines and lung lipid mediators were measured as outcomes. Lung bacterial load on day 14 post-treatment (PT) was lower in the n-3 LCPUFA, compared to the ibuprofen group (p = 0.039), but was higher in the ibuprofen group than the treated control group (p = 0.0315). Treated control and ibuprofen groups had more free alveolar space initially as compared to the n-3 LCPUFA group (4 days PT, p= 0.0114 and p= 0.002, respectively); however, significantly more alveolar space was present in the n-3 LCPUFA group as compared to the ibuprofen group by end of treatment (14 days PT, p = 0.035). Interleukin 6 (IL-6) was lower in the ibuprofen group as compared to the treated control, EPA/DHA and untreated control groups at 4 days PT (p = 0.019, p = 0.019 and p = 0.002, respectively). Importantly, pro-resolving EPA derived 9-HEPE, 11-HEPE, 12-HEPE and 18-HEPE lipid mediators (LMs) were significantly higher in the EPA/DHA group as compared to the ibuprofen and treated control groups. This suggests that n-3 LCPUFAs do improve pro-resolving and anti-inflammatory properties in TB, and it may be safe and effective to co-administer as adjunct therapy with standard TB treatment, particularly longer-term. Also, our results show host benefits upon short-term co-administration of ibuprofen, but not throughout the entire TB treatment course.	[Hayford, Frank E. A.; Dolman, Robin C.; Nienaber, Arista; Smuts, Cornelius M.; Malan, Linda] North West Univ, Ctr Excellence Nutr, Potchefstroom, South Africa; [Hayford, Frank E. A.] Univ Ghana, Sch Biomed & Allied Hlth Sci, Dept Dietet, Coll Hlth Sci, Accra, Ghana; [Ozturk, Mumin; Brombacher, Frank; Parihar, Suraj P.] Univ Cape Town, Int Ctr Genet Engn & Biotechnol ICGEB, Cape Town Component, Cape Town, South Africa; [Ozturk, Mumin; Brombacher, Frank; Parihar, Suraj P.] Univ Cape Town, Inst Infect Dis & Mol Med IDM, Div Immunol, Cape Town, South Africa; [Ozturk, Mumin; Brombacher, Frank; Parihar, Suraj P.] Univ Cape Town, South African Med Res Council SAMRC Immunol Infec, Cape Town, South Africa; [Blaauw, Renee] Stellenbosch Univ, Div Human Nutr, Cape Town, South Africa; [Loots, Du Toit] North West Univ, Lab Infect Dis Metab, Human Metab, Potchefstroom, South Africa; [Brombacher, Frank; Parihar, Suraj P.] Univ Cape Town, Wellcome Ctr Infect Dis Res Africa CIDRI Africa, Cape Town, South Africa; [Brombacher, Frank; Parihar, Suraj P.] Univ Cape Town, Inst Infect Dis & Mol Med IDM, Cape Town, South Africa; [Parihar, Suraj P.] Univ Cape Town, Inst Infect Dis & Mol Med IDM, Div Med Microbiol, Dept Pathol,Fac Hlth Sci, Cape Town, South Africa	North West University - South Africa; University of Ghana; International Center for Genetic Engineering & Biotechnology (ICGEB); ICGEB Cape Town; University of Cape Town; University of Cape Town; University of Cape Town; Stellenbosch University; North West University - South Africa; University of Cape Town; University of Cape Town; University of Cape Town	Hayford, FEA; Malan, L (corresponding author), North West Univ, Ctr Excellence Nutr, Potchefstroom, South Africa.; Hayford, FEA (corresponding author), Univ Ghana, Sch Biomed & Allied Hlth Sci, Dept Dietet, Coll Hlth Sci, Accra, Ghana.; Parihar, SP (corresponding author), Univ Cape Town, Int Ctr Genet Engn & Biotechnol ICGEB, Cape Town Component, Cape Town, South Africa.; Parihar, SP (corresponding author), Univ Cape Town, Inst Infect Dis & Mol Med IDM, Div Immunol, Cape Town, South Africa.; Parihar, SP (corresponding author), Univ Cape Town, South African Med Res Council SAMRC Immunol Infec, Cape Town, South Africa.; Parihar, SP (corresponding author), Univ Cape Town, Wellcome Ctr Infect Dis Res Africa CIDRI Africa, Cape Town, South Africa.; Parihar, SP (corresponding author), Univ Cape Town, Inst Infect Dis & Mol Med IDM, Cape Town, South Africa.; Parihar, SP (corresponding author), Univ Cape Town, Inst Infect Dis & Mol Med IDM, Div Med Microbiol, Dept Pathol,Fac Hlth Sci, Cape Town, South Africa.	feahayford220580@gmail.com; Suraj.Parihar@uct.ac.za; Linda.Malan@nwu.ac.za	Hayford, Frank/AGR-3353-2022; Parihar, Suraj/HCI-2597-2022; Ozturk, Mumin/G-9739-2016	Parihar, Suraj/0000-0002-4932-7990; Ozturk, Mumin/0000-0001-9152-7614; Dolman, Robin/0000-0003-4042-6228	Wellcome Trust [203135/Z/16/Z]; Nutricia Research Foundation	Wellcome Trust(Wellcome TrustEuropean Commission); Nutricia Research Foundation(Danone Nutricia)	This research was conducted at the UCT BSL3 facilities, supported by core funding from the Wellcome Trust (203135/Z/16/Z) and also student PhD study supported by the Nutricia Research Foundation.	Abreu R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01553; Ahmadi A, 2017, MINI-REV MED CHEM, V17, P799, DOI 10.2174/1389557516666161226155951; Barber DL, 2011, J IMMUNOL, V186, P1598, DOI 10.4049/jimmunol.1003304; Baxter K, 2010, STOCKLEYS DRUG INTER, P495; Bonilla DL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010878; Bonilla DL, 2010, J INFECT DIS, V201, P399, DOI 10.1086/650344; Byrne ST, 2007, J ANTIMICROB CHEMOTH, V59, P313, DOI 10.1093/jac/dkl486; Byrne ST, 2007, ANTIMICROB AGENTS CH, V51, P794, DOI 10.1128/AAC.01145-06; Calder PC, 2017, BIOCHEM SOC T, V45, P1105, DOI 10.1042/BST20160474; Calder PC, 2013, BRIT J CLIN PHARMACO, V75, P645, DOI 10.1111/j.1365-2125.2012.04374.x; Cambier CJ, 2017, IMMUNITY, V47, P552, DOI 10.1016/j.immuni.2017.08.003; Chandrasekaran P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01316; Chiang N, 2012, NATURE, V484, P524, DOI 10.1038/nature11042; Chmiel JF, 2015, J CYST FIBROS, V14, P720, DOI 10.1016/j.jcf.2015.03.007; Cooper AM, 2012, CURR OPIN IMMUNOL, V24, P431, DOI 10.1016/j.coi.2012.04.008; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Dheda K, 2005, J INFECT DIS, V192, P1201, DOI 10.1086/444545; Domingo-Gonzalez R, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.TBTB2-0018-2016; Dunlap MD, 2018, MUCOSAL IMMUNOL, V11, P1727, DOI 10.1038/s41385-018-0071-y; Dutta S, 2016, LIFE SCI, V152, P244, DOI 10.1016/j.lfs.2015.10.025; EICHER SD, 1995, J LEUKOCYTE BIOL, V58, P32, DOI 10.1002/jlb.58.1.32; FOLCH J, 1957, J BIOL CHEM, V226, P497; Guler R, 2015, NAT CHEM BIOL, V11, P748, DOI 10.1038/nchembio.1917; Guler R, 2011, VACCINE, V29, P1339, DOI 10.1016/j.vaccine.2010.10.045; Hasan Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008459; Hawn TR, 2013, MICROBIOL MOL BIOL R, V77, P608, DOI 10.1128/MMBR.00032-13; Ilonidis G, 2006, J BIOL REG HOMEOS AG, V20, P41; Ivanyi J, 2013, J INFECT DIS, V208, P185, DOI 10.1093/infdis/jit153; Jordao L, 2008, MICROBES INFECT, V10, P1379, DOI 10.1016/j.micinf.2008.08.004; Kaartinen T, 2017, CYTOTHERAPY, V19, P689, DOI 10.1016/j.jcyt.2017.03.067; Kaufmann SHE, 2018, NAT REV DRUG DISCOV, V17, P35, DOI 10.1038/nrd.2017.162; Keam SJ, 2019, DRUGS, V79, P1797, DOI 10.1007/s40265-019-01207-9; Kiran D, 2016, SEMIN IMMUNOPATHOL, V38, P167, DOI 10.1007/s00281-015-0537-x; Kolloli A, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00171; Kroesen VM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00772; Lanoix JP, 2015, DIS MODEL MECH, V8, P603, DOI 10.1242/dmm.019513; Lenaerts A, 2015, IMMUNOL REV, V264, P288, DOI 10.1111/imr.12252; Levy BD, 2007, J IMMUNOL, V178, P496, DOI 10.4049/jimmunol.178.1.496; Malan L, 2016, PROSTAG LEUKOTR ESS, V105, P15, DOI 10.1016/j.plefa.2015.12.005; Mancuso P, 1997, CRIT CARE MED, V25, P1198, DOI 10.1097/00003246-199707000-00023; Kroesen VM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00798; Marzo E, 2014, TUBERCULOSIS, V94, P55, DOI 10.1016/j.tube.2013.09.004; Mortensen R, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0530-3; Ndlovu H, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00434; Nienaber A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092897; Nowak J, 2007, CARCINOGENESIS, V28, P1991, DOI 10.1093/carcin/bgm166; O'Garra A, 2013, ANNU REV IMMUNOL, V31, P475, DOI 10.1146/annurev-immunol-032712-095939; Osborne R, 2013, NAT BIOTECHNOL, V31, P89, DOI 10.1038/nbt0213-89; Parihar SP, 2018, MUCOSAL IMMUNOL, V11, P496, DOI 10.1038/mi.2017.68; Parihar SP, 2014, J INFECT DIS, V209, P754, DOI 10.1093/infdis/jit550; Paton NI, 2004, AM J CLIN NUTR, V80, P460, DOI 10.1093/ajcn/80.2.460; Pipkin ME, 2010, IMMUNITY, V32, P79, DOI 10.1016/j.immuni.2009.11.012; Reeme AE, 2016, J IMMUNOL, V196, P1293, DOI 10.4049/jimmunol.1500931; Ricci C, 2020, INT J FOOD SCI NUTR, V71, P256, DOI 10.1080/09637486.2019.1646714; Sasindran SJ, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00002; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan CN, 2018, MOL ASPECTS MED, V64, P1, DOI 10.1016/j.mam.2017.08.002; Serhan CN, 2017, FASEB J, V31, P1273, DOI [10.1096/fj.201601222R, 10.1096/fj.201601222r]; Skerry C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039680; Sotgiu G, 2015, EXPERT REV ANTI-INFE, V13, P305, DOI 10.1586/14787210.2015.1011127; Spite M, 2009, NATURE, V461, P1287, DOI 10.1038/nature08541; Tobin DM, 2012, CELL, V148, P434, DOI 10.1016/j.cell.2011.12.023; Varrassi G, 2020, ADV THER, V37, P61, DOI 10.1007/s12325-019-01144-9; Vilaplana C, 2013, J INFECT DIS, V208, P199, DOI 10.1093/infdis/jit152; Wallace FA, 2001, J LEUKOCYTE BIOL, V69, P449; WHO, 2010, WORLD MALARIA REPORT 2010, P1; World Health Organization & Stop TB Initiative, 2010, TREAT TUB GUID WHO H, V4th; Yaqoob P, 2004, P NUTR SOC, V63, P89, DOI 10.1079/PNS2003328; Young C, 2020, MUCOSAL IMMUNOL, V13, P190, DOI 10.1038/s41385-019-0226-5; Zumla A, 2015, J INTERN MED, V277, P373, DOI 10.1111/joim.12256; Zumla A, 2015, NAT REV DRUG DISCOV, V14, P511, DOI 10.1038/nrd4696	71	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2021	12								659943	10.3389/fimmu.2021.659943	http://dx.doi.org/10.3389/fimmu.2021.659943			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SA4OY	33995381	gold, Green Published			2022-12-18	WOS:000649281300001
J	Lu, MP; Gu, WZ; Sheng, YJ; Wang, JJ; Xu, XF				Lu, Meiping; Gu, Weizhong; Sheng, Yuanjian; Wang, Jingjing; Xu, Xuefeng			Case Report: Activating PIK3CD Mutation in Patients Presenting With Granulomatosis With Polyangiitis	FRONTIERS IN IMMUNOLOGY			English	Article						activated phosphoinositide 3-kinase &#948; syndrome; immunodeficiency; granulomatosis with polyangiitis; PIK3CD gene; children	CHILDHOOD; VASCULITIS	Activated phosphoinositide 3-kinase delta syndrome (APDS) is an autosomal dominant primary immunodeficiency caused by gain-of-function (GOF) mutations in PIK3CD or PIK3R1 genes. The phenotypes of APDS are highly variable, ranging from asymptomatic adults to profound immunodeficiency causing early death in childhood. Herein, we reported two pediatric patients with APDS presented with recurrent lung infections, sinusitis, hematuria, and positive anti-neutrophil cytoplasmic antibody (ANCA), previously diagnosed as granulomatosis with polyangiitis (GPA). Bronchoscopy showed mucosal nodule lymphoid hyperplasia in the entire airway. Many inflammatory cells infiltrated around the airway and in the lung parenchyma, and numbers of CD3(+) T cells and CD20(+) B cells were significantly increased, especially CD3+ T cells. Whole exome sequencing showed that they had the E1021K (c.3061 G >A) mutation in the PIK3CD gene. These are the first reported cases of APDS presenting as childhood-onset GPA. Pediatricians should suspect of APDS in the differential diagnosis of children who present with GPA-like symptoms. Additionally, timely and repeated bronchoscopies could contribute to providing an important diagnostic clue for APDS.	[Lu, Meiping; Xu, Xuefeng] Zhejiang Univ, Childrens Hosp, Dept Rheumatol Immunol & Allergy, Natl Clin Res Ctr Child Hlth,Sch Med, Hangzhou, Peoples R China; [Lu, Meiping; Sheng, Yuanjian; Xu, Xuefeng] Zhejiang Univ, Childrens Hosp, Dept Pulm Med, Natl Clin Res Ctr Child Hlth,Sch Med, Hangzhou, Peoples R China; [Gu, Weizhong] Zhejiang Univ, Childrens Hosp, Dept Pathol, Natl Clin Res Ctr Child Hlth,Sch Med, Hangzhou, Peoples R China; [Wang, Jingjing] Zhejiang Univ, Childrens Hosp, Dept Nephrol, Natl Clin Res Ctr Child Hlth,Sch Med, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University	Xu, XF (corresponding author), Zhejiang Univ, Childrens Hosp, Dept Rheumatol Immunol & Allergy, Natl Clin Res Ctr Child Hlth,Sch Med, Hangzhou, Peoples R China.; Xu, XF (corresponding author), Zhejiang Univ, Childrens Hosp, Dept Pulm Med, Natl Clin Res Ctr Child Hlth,Sch Med, Hangzhou, Peoples R China.	xuxuefeng@zju.edu.cn	xu, xuefeng/ABG-3607-2021	xu, xuefeng/0000-0001-7148-846X	National Natural Science Foundation of China [81871220]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by fund from the National Natural Science Foundation of China (81871220). The funder had no role in study design, data collection and interpretation, or the decision to submit the work for publication.	Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Bier J, 2019, J ALLERGY CLIN IMMUN, V144, P236, DOI 10.1016/j.jaci.2019.01.033; Calatroni M, 2017, ITAL J PEDIATR, V43, DOI 10.1186/s13052-017-0364-x; Coulter TI, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02043; Coulter TI, 2017, J ALLERGY CLIN IMMUN, V139, P597, DOI 10.1016/j.jaci.2016.06.021; Crank MC, 2014, J CLIN IMMUNOL, V34, P272, DOI 10.1007/s10875-014-0012-9; de Graeff N, 2019, RHEUMATOLOGY, V58, P656, DOI 10.1093/rheumatology/key322; Edwards ESJ, 2019, J ALLERGY CLIN IMMUN, V143, P276, DOI 10.1016/j.jaci.2018.04.030; Hartman HN, 2015, J CLIN IMMUNOL, V35, P11, DOI 10.1007/s10875-014-0109-1; Jamee M, 2020, CLIN REV ALLERG IMMU, V59, P323, DOI 10.1007/s12016-019-08738-9; Jariwala MP, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00226; Li ZY, 2016, KIDNEY DIS-BASEL, V1, P216, DOI 10.1159/000441912; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Nichols-Vinueza DX, 2019, J ALLERGY CLIN IMMUN, V143, pAB425, DOI 10.1016/j.jaci.2018.12.958; Ozen S, 2010, ANN RHEUM DIS, V69, P798, DOI 10.1136/ard.2009.116657; Preite S, 2019, IMMUNOL REV, V291, P154, DOI 10.1111/imr.12790; Tangye SG, 2019, J CLIN IMMUNOL, V39, P148, DOI 10.1007/s10875-019-00612-9; Tinazzi I, 2007, RHEUMATOL INT, V27, P989, DOI 10.1007/s00296-007-0314-9; Wallace JG, 2020, CLIN IMMUNOL, V210, DOI 10.1016/j.clim.2019.108311; Walsh CM, 2014, J CLIN INVEST, V124, P3688, DOI 10.1172/JCI77198	20	1	1	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2021	12								670312	10.3389/fimmu.2021.670312	http://dx.doi.org/10.3389/fimmu.2021.670312			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SA4XN	33995405	gold, Green Published			2022-12-18	WOS:000649305700001
J	Namdev, P; Patel, S; Sparling, B; Garg, A				Namdev, Priyanka; Patel, Shiv; Sparling, Brandi; Garg, Ankita			Monocytic-Myeloid Derived Suppressor Cells of HIV-Infected Individuals With Viral Suppression Exhibit Suppressed Innate Immunity to Mycobacterium tuberculosis	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1; myeloid derived suppressor cell; IL-27; M tuberculosis; people living with HIV (PLWH); innate immunity	MACROPHAGES; RESPONSES	Tuberculosis can occur during any stage of Human Immunodeficiency virus 1 (HIV) -infection including times when CD4(+) T cell numbers have reconstituted and viral replication suppressed. We have previously shown that CD11b(+)CD33(+)CD14(+)HLA-DR-/lo monocytic myeloid-derived suppressor cells (MDSC) persist in HIV-infected individuals on combined anti-retroviral therapy (cART) and with virologic suppression. The response of MDSC to Mycobacterium tuberculosis (Mtb) is not known. In this study, we compared the anti-mycobacterial activity of MDSC isolated from HIV -infected individuals on cART with virologic suppression (HIV MDSC) and HIV-uninfected healthy controls (HIV (-) MDSC). Compared to HIV (-) MDSC, HIV MDSC produced significantly less quantities of anti-mycobacterial cytokines IL-12p70 and TNF alpha, and reactive oxygen species when cultured with infectious Mtb or Mtb antigens. Furthermore, HIV MDSC showed changes in the Toll-like receptor and IL-27 signaling, including reduced expression of MyD88 and higher levels of IL-27. Neutralizing IL-27 and overexpression of MyD88 synergistically controlled intracellular replication of Mtb in HIV MDSC. These results demonstrate that MDSC in fully suppressed HIV-infected individuals are permissive to Mtb and exhibit downregulated anti-mycobacterial innate immune activity through mechanisms involving IL-27 and TLR signaling. Our findings suggest MDSC as novel mediators of tuberculosis in HIV-Mtb co-infected individuals with virologic suppression.	[Namdev, Priyanka; Sparling, Brandi; Garg, Ankita] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA; [Patel, Shiv] Univ Georgia, Franklin Coll Arts & Sci, Athens, GA 30602 USA; [Sparling, Brandi] Western Univ Hlth Sci, Coll Vet Med, Pomona, CA USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Western University of Health Sciences	Garg, A (corresponding author), Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA.	agarg@uga.edu			National Institute of Allergy and Infectious Diseases (NIAID) [AI127132]; University of Georgia Research Foundation	National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); University of Georgia Research Foundation	This research was supported by AI127132 from the National Institute of Allergy and Infectious Diseases (NIAID) and The University of Georgia Research Foundation.	Agrawal N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02417; Bezuidenhout J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004228; Campbell GR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002689; Cao SJ, 2002, J IMMUNOL, V169, P5715, DOI 10.4049/jimmunol.169.10.5715; Cervia JS, 2010, PEDIATR INFECT DIS J, V29, P1118, DOI 10.1097/INF.0b013e3181ed9f4c; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Cooper AM, 2000, INFECT IMMUN, V68, P1231, DOI 10.1128/IAI.68.3.1231-1234.2000; Costagliola D, 2005, CLIN INFECT DIS, V41, P1772, DOI 10.1086/498315; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; Dai L, 2013, J EXP MED, V210, P517, DOI 10.1084/jem.20120572; Deretic V, 2004, CELL MICROBIOL, V6, P999, DOI 10.1111/j.1462-5822.2004.00449.x; Devalraju KP, 2018, CYTOKINE, V110, P213, DOI 10.1016/j.cyto.2018.05.005; Dorhoi A, 2020, J CLIN INVEST, V130, P2789, DOI 10.1172/JCI136288; Du Plessis N, 2017, EUR J IMMUNOL, V47, P107, DOI 10.1002/eji.201646658; du Plessis N, 2013, AM J RESP CRIT CARE, V188, P724, DOI 10.1164/rccm.201302-0249OC; El Daker S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123772; Ferreiro DU, 2010, BIOCHEMISTRY-US, V49, P1560, DOI 10.1021/bi901948j; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Garg A, 2021, METHODS MOL BIOL, V2236, P115, DOI 10.1007/978-1-0716-1060-2_11; Garg A, 2017, SCI REP-UK, V7, DOI 10.1038/srep44485; Garg A, 2014, J INFECT DIS, V209, P441, DOI 10.1093/infdis/jit469; Geldmacher C, 2008, J INFECT DIS, V198, P1590, DOI 10.1086/593017; Geldmacher C, 2010, J EXP MED, V207, P2869, DOI 10.1084/jem.20100090; Getahun H, 2010, CLIN INFECT DIS, V50, pS201, DOI 10.1086/651492; GLUSHAKOVA S, 1995, NAT MED, V1, P1320, DOI 10.1038/nm1295-1320; Greten TF, 2011, INT IMMUNOPHARMACOL, V11, P802, DOI 10.1016/j.intimp.2011.01.003; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Gupta A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034156; Guzzo C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045706; Guzzo C, 2010, J BIOL CHEM, V285, P24404, DOI 10.1074/jbc.M110.112599; Happel KI, 2005, INFECT IMMUN, V73, P5782, DOI 10.1128/IAI.73.9.5782-5788.2005; Harris J, 2008, J INFECT DIS, V198, P1842, DOI 10.1086/593174; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; HENDERSON AJ, 1995, J VIROL, V69, P5337, DOI 10.1128/JVI.69.9.5337-5344.1995; Hersperger AR, 2011, BLOOD, V117, P3799, DOI 10.1182/blood-2010-12-322727; Hoechst B, 2008, GASTROENTEROLOGY, V135, P234, DOI 10.1053/j.gastro.2008.03.020; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Iyer SS, 2010, J IMMUNOL, V185, P6599, DOI 10.4049/jimmunol.1002041; Jung JY, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-16; Jung JY, 2013, CYTOKINE, V62, P202, DOI 10.1016/j.cyto.2013.03.010; Kalayjian RC, 2010, J INFECT DIS, V201, P1796, DOI 10.1086/652750; Kalokhe AS, 2015, J INFECT DIS, V211, P635, DOI 10.1093/infdis/jiu505; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Khader SA, 2011, J IMMUNOL, V187, P5402, DOI 10.4049/jimmunol.1101377; Kinoshita SM, 2008, P NATL ACAD SCI USA, V105, P15022, DOI 10.1073/pnas.0807269105; Knaul JK, 2014, AM J RESP CRIT CARE, V190, P1053, DOI 10.1164/rccm.201405-0828OC; Kumawat K, 2010, J BIOL CHEM, V285, P12629, DOI 10.1074/jbc.M109.073320; Ladel CH, 1997, INFECT IMMUN, V65, P4843, DOI 10.1128/IAI.65.11.4843-4849.1997; Leal IS, 1999, INFECT IMMUN, V67, P5747, DOI 10.1128/IAI.67.11.5747-5754.1999; Liu JG, 2007, J EXP MED, V204, P141, DOI 10.1084/jem.20061440; Martino A, 2010, J IMMUNOL, V184, P2038, DOI 10.4049/jimmunol.0903348; Mattila JT, 2013, J IMMUNOL, V191, P773, DOI 10.4049/jimmunol.1300113; Molle C, 2007, J IMMUNOL, V178, P7607, DOI 10.4049/jimmunol.178.12.7607; Mwandumba HC, 2004, J IMMUNOL, V172, P4592, DOI 10.4049/jimmunol.172.7.4592; Noursadeghi M, 2009, J IMMUNOL, V182, P319, DOI 10.4049/jimmunol.182.1.319; Ostrand-Rosenberg S, 2010, CANCER IMMUNOL IMMUN, V59, P1593, DOI 10.1007/s00262-010-0855-8; Patel NR, 2007, J IMMUNOL, V179, P6973, DOI 10.4049/jimmunol.179.10.6973; Patel NR, 2009, J LEUKOCYTE BIOL, V86, P53, DOI [10.1189/JLB.0908574, 10.1189/jlb.0908574]; Pathak S, 2009, SCAND J IMMUNOL, V70, P264, DOI 10.1111/j.1365-3083.2009.02299.x; Pathak S, 2010, INFECT IMMUN, V78, P4022, DOI 10.1128/IAI.00106-10; Pawlowski A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002464; Pirhonen J, 2007, J LEUKOCYTE BIOL, V82, P1185, DOI 10.1189/jlb.0307157; Poschke I, 2010, CANCER RES, V70, P4335, DOI 10.1158/0008-5472.CAN-09-3767; Qin AP, 2013, J VIROL, V87, P1477, DOI 10.1128/JVI.01759-12; Ramachandra L, 2009, CURR OPIN IMMUNOL, V21, P98, DOI 10.1016/j.coi.2009.01.001; Rosas-Taraco AG, 2006, AIDS RES HUM RETROV, V22, P45, DOI 10.1089/aid.2006.22.45; Rychert J, 2010, AIDS RES HUM RETROV, V26, P1139, DOI 10.1089/aid.2009.0290; Saunders BM, 2000, INFECT IMMUN, V68, P3322, DOI 10.1128/IAI.68.6.3322-3326.2000; Scanga CA, 2004, INFECT IMMUN, V72, P2400, DOI 10.1128/IAI.72.4.2400-2404.2004; Schluger NW, 2002, CHEST, V122, P597, DOI 10.1378/chest.122.2.597; Sinha P, 2007, J IMMUNOL, V179, P977, DOI 10.4049/jimmunol.179.2.977; SPEAR GT, 1990, CLIN IMMUNOL IMMUNOP, V54, P184, DOI 10.1016/0090-1229(90)90080-A; Stritesky GL, 2008, J IMMUNOL, V181, P5948, DOI 10.4049/jimmunol.181.9.5948; Sutherland R, 2006, AIDS, V20, P821, DOI 10.1097/01.aids.0000218545.31716.a4; Tomlinson GS, 2014, J INFECT DIS, V209, P1055, DOI 10.1093/infdis/jit621; Torrado E, 2015, J EXP MED, V212, P1449, DOI 10.1084/jem.20141520; Tsiganov EN, 2014, J IMMUNOL, V192, P4718, DOI 10.4049/jimmunol.1301365; UNAIDS, 2010, UN REP GLOB AIDS EP; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; Winau F, 2006, IMMUNITY, V24, P105, DOI 10.1016/j.immuni.2005.12.001; Woodworth JS, 2008, J IMMUNOL, V181, P8595, DOI 10.4049/jimmunol.181.12.8595; World Health Organization, 2015, MEAS AG FRIENDL CIT; Yang BF, 2014, IMMUNOL LETT, V158, P66, DOI 10.1016/j.imlet.2013.12.003; Yang CS, 2009, J IMMUNOL, V182, P3696, DOI 10.4049/jimmunol.0802217; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Zhang JD, 2010, J BIOL CHEM, V285, P21269, DOI 10.1074/jbc.M110.100818	88	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2021	12								647019	10.3389/fimmu.2021.647019	http://dx.doi.org/10.3389/fimmu.2021.647019			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SA5AD	33995365	Green Published, gold			2022-12-18	WOS:000649313200001
J	Padeira, GL; Araujo, C; Cordeiro, AI; Freixo, J; Martins, CG; Neves, JF				Padeira, Goncalo Luzes; Araujo, Catarina; Cordeiro, Ana Isabel; Freixo, Joao; Martins, Catarina Gregorio; Neves, Joao Farela			Case Report: Primary Immunodeficiencies, Massive EBV plus T-Cell Lympoproliferation Leading to the Diagnosis of ICF2 Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						case report; ICF-2; Primary immune deficiencies; EBV; lymphoproliferation		In immunocompromised patients, EBV may elicit B-cell transformation and proliferation. A 5-year-old microcephalic boy was admitted with fever and non-malignant polymorphic T-cell lymphoproliferative disease associated with EBV. A presumptive diagnosis of primary immunodeficiency with inability to control EBV was made and next-generation sequencing led to the identification of a novel ZBTB24 mutation (ICF2-syndrome). This case shows that susceptibility to EBV seems to be particular of ICF-2 as it has not been described in the other types of ICF. It is mandatory to raise the hypothesis of an underlying PID in case of severe EBV infection.	[Padeira, Goncalo Luzes; Cordeiro, Ana Isabel; Neves, Joao Farela] Ctr Hosp Univ Lisboa Cent, Hosp Dona Estefania, Lisbon, Portugal; [Araujo, Catarina] Ctr Hosp Univ Lisboa Cent, Dept Anat Patol, Lisbon, Portugal; [Freixo, Joao] Inst Invest & Inovacao Saude, Inst Biol Mol & Celular, Ctr Genet Predit & Prevent, Porto, Portugal; [Martins, Catarina Gregorio; Neves, Joao Farela] NOVA Med Sch, Chron Dis Res Ctr, CEDOC, Lisbon, Portugal; [Martins, Catarina Gregorio; Neves, Joao Farela] Nova Univ Lisbon, NOVA Med Sch, Comprehens Hlth Res Ctr CHRC, Lisbon, Portugal	Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade Nova de Lisboa	Neves, JF (corresponding author), Ctr Hosp Univ Lisboa Cent, Hosp Dona Estefania, Lisbon, Portugal.; Neves, JF (corresponding author), NOVA Med Sch, Chron Dis Res Ctr, CEDOC, Lisbon, Portugal.; Neves, JF (corresponding author), Nova Univ Lisbon, NOVA Med Sch, Comprehens Hlth Res Ctr CHRC, Lisbon, Portugal.	joao.farelaneves@chlc.min-saude.pt		Luzes Padeira, Goncalo/0000-0003-3163-990X; Farela Neves, Joao/0000-0003-4740-6094	Fundacao Ciencia e Tecnologia, IP national support through CHRC [UIDP/04923/2020]	Fundacao Ciencia e Tecnologia, IP national support through CHRC	The present publication was funded by Fundacao Ciencia e Tecnologia, IP national support through CHRC (UIDP/04923/2020).	Abbas Fedaey, 2020, World J Transplant, V10, P29, DOI 10.5500/wjt.v10.i2.29; Burk CM, 2020, J ALLER CL IMM-PRACT, V8, P1103, DOI 10.1016/j.jaip.2019.08.040; Camacho-Ordonez N, 2021, J ALLERGY CLIN IMMUN, V147, P1602, DOI 10.1016/j.jaci.2021.01.035; Fournier B, 2020, J EXP MED, V217, DOI 10.1084/jem.20192262; Harnisch E, 2016, TRANSPLANTATION, V100, pE35, DOI 10.1097/TP.0000000000001210; Kamae C, 2018, J CLIN IMMUNOL, V38, P927, DOI 10.1007/s10875-018-0559-y; Liang J, 2016, GENES IMMUN, V17, P276, DOI 10.1038/gene.2016.18; Licciardi F, 2019, J CLIN IMMUNOL, V39, P234, DOI 10.1007/s10875-019-00596-6; Schaefer BC, 1997, MOL CELL BIOL, V17, P364, DOI 10.1128/MCB.17.1.364; Sogkas G, 2019, DISEASES-BASEL, V7, DOI 10.3390/diseases7020034; Sterlin D, 2016, J CLIN IMMUNOL, V36, P149, DOI 10.1007/s10875-016-0240-2; Tangye SG, 2020, BLOOD, V135, P644, DOI 10.1182/blood.2019000928; Tangye SG, 2017, J EXP MED, V214, P269, DOI 10.1084/jem.20161846; Thijssen PE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8870; Wu HY, 2019, HUM MUTAT, V40, P1077, DOI 10.1002/humu.23786; Yin HL, 2019, MED MICROBIOL IMMUN, V208, P573, DOI 10.1007/s00430-018-0570-1	16	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2021	12								654167	10.3389/fimmu.2021.654167	http://dx.doi.org/10.3389/fimmu.2021.654167			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SA5EW	33995370	Green Published, gold			2022-12-18	WOS:000649326400001
J	Radke, EE; Li, Z; Hernandez, DN; El Bannoudi, H; Pond, SLK; Shopsin, B; Lopez, P; Fenyo, D; Silverman, GJ				Radke, Emily E.; Li, Zhi; Hernandez, David N.; El Bannoudi, Hanane; Kosakovsky Pond, Sergei L.; Shopsin, Bo; Lopez, Peter; Fenyo, David; Silverman, Gregg J.			Diversity of Functionally Distinct Clonal Sets of Human Conventional Memory B Cells That Bind Staphylococcal Protein A	FRONTIERS IN IMMUNOLOGY			English	Article						single-cell sorting; antigen-specific; superantigen; single-cell sequencing; Staphylococcus aureus; Staphylococcal Protein A; SpA; human memory B cells	HUMAN-IGA; AUREUS; COLONIZATION; ANTIBODIES; CARRIAGE	Staphylococcus aureus, a common cause of serious and often fatal infections, is well-armed with secreted factors that disarm host immune defenses. Highly expressed in vivo during infection, Staphylococcal protein A (SpA) is reported to also contribute to nasal colonization that can be a prelude to invasive infection. Co-evolution with the host immune system has provided SpA with an Fc-antibody binding site, and a Fab-binding site responsible for non-immune superantigen interactions via germline-encoded surfaces expressed on many human BCRs. We wondered whether the recurrent exposures to S. aureus commonly experienced by adults, result in the accumulation of memory B-cell responses to other determinants on SpA. We therefore isolated SpA-specific class-switched memory B cells, and characterized their encoding VH : VL antibody genes. In SpA-reactive memory B cells, we confirmed a striking bias in usage for VH genes, which retain the surface that mediates the SpA-superantigen interaction. We postulate these interactions reflect co-evolution of the host immune system and SpA, which during infection results in immune recruitment of an extraordinarily high prevalence of B cells in the repertoire that subverts the augmentation of protective defenses. Herein, we provide the first evidence that human memory responses are supplemented by B-cell clones, and circulating-antibodies, that bind to SpA determinants independent of the non-immune Fc- and Fab-binding sites. In parallel, we demonstrate that healthy individuals, and patients recovering from S. aureus infection, both have circulating antibodies with these conventional binding specificities. These findings rationalize the potential utility of incorporating specially engineered SpA proteins into a protective vaccine.	[Radke, Emily E.; Hernandez, David N.; El Bannoudi, Hanane; Shopsin, Bo; Silverman, Gregg J.] NYU, Dept Med, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA; [Radke, Emily E.; Li, Zhi; Fenyo, David] NYU, Grossman Sch Med, Dept Biochem & Mol Pharmacol, New York, NY USA; [Li, Zhi; Fenyo, David] NYU, Grossman Sch Med, Inst Syst Genet, New York, NY USA; [Kosakovsky Pond, Sergei L.] Temple Univ, Inst Genom & Evolutionary Med, Philadelphia, PA 19122 USA; [Lopez, Peter] NYU, Dept Pathol, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA	New York University; New York University; New York University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; New York University	Silverman, GJ (corresponding author), NYU, Dept Med, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.	Gregg.Silverman@nyulangone.org	Pond, Sergei LK/G-9830-2012	Pond, Sergei LK/0000-0003-4817-4029; Silverman, Gregg/0000-0001-9480-9457; Lopez, Peter/0000-0002-8587-7148	NIH/NIAID [HHS N272201400019C, T32 GM066704]; Colton Foundation	NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Colton Foundation	This work was supported through the NIH/NIAID contract HHS N272201400019C, "B Cell Epitope Discovery and Mechanisms of Antibody Protection," and T32 GM066704 (ER) and the Colton Foundation (GS).	Al-Zubeidi D, 2014, J PEDIATR INFECT DIS, V3, P261, DOI 10.1093/jpids/pit046; Alamyar Eltaf, 2012, Methods Mol Biol, V882, P569, DOI 10.1007/978-1-61779-842-9_32; Brown AE, 2014, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00507; Cary S, 1999, MOL IMMUNOL, V36, P769, DOI 10.1016/S0161-5890(99)00085-1; Chambers HF, 2009, NAT REV MICROBIOL, V7, P629, DOI 10.1038/nrmicro2200; Chan LC, 2018, P NATL ACAD SCI USA, V115, pE11111, DOI 10.1073/pnas.1808353115; Cheng AG, 2011, TRENDS MICROBIOL, V19, P225, DOI 10.1016/j.tim.2011.01.007; Choi Y, 1995, ANN NY ACAD SCI, V764, P261; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; CUISINIER A-M, 1990, New Biologist, V2, P689; DeDent AC, 2007, J BACTERIOL, V189, P4473, DOI 10.1128/JB.00227-07; DEISENHOFER J, 1978, H-S Z PHYSIOL CHEM, V359, P975, DOI 10.1515/bchm2.1978.359.2.975; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; Deleo FR, 2009, J CLIN INVEST, V119, P2464, DOI 10.1172/JCI38226; El Bannoudi H, 2017, METHODS MOL BIOL, V1643, P45, DOI 10.1007/978-1-4939-7180-0_5; ERIKSEN NHR, 1995, EPIDEMIOL INFECT, V115, P51, DOI 10.1017/S0950268800058118; Falugi F, 2013, MBIO, V4, DOI 10.1128/mBio.00575-13; FORSGREN A, 1974, ANN NY ACAD SCI, V236, P252, DOI 10.1111/j.1749-6632.1974.tb41496.x; Franz B, 2011, BLOOD, V118, P348, DOI 10.1182/blood-2011-03-341917; Fritz SA, 2013, CLIN INFECT DIS, V56, P1554, DOI 10.1093/cid/cit123; Giersing BK, 2016, VACCINE, V34, P2962, DOI 10.1016/j.vaccine.2016.03.110; Goodyear CS, 2004, P NATL ACAD SCI USA, V101, P11392, DOI 10.1073/pnas.0404382101; Gorwitz RJ, 2008, PEDIATR INFECT DIS J, V27, P1, DOI 10.1097/INF.0b013e31815819bb; Graille M, 2000, P NATL ACAD SCI USA, V97, P5399, DOI 10.1073/pnas.97.10.5399; Hernandez DN, 2020, MBIO, V11, DOI 10.1128/mBio.00460-20; Hernandez DN, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00785-19; Hong XF, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00951; INGANAS M, 1981, SCAND J IMMUNOL, V13, P343, DOI 10.1111/j.1365-3083.1981.tb00143.x; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; Jenkins A, 2015, MBIO, V6, DOI 10.1128/mBio.02272-14; Karray S, 1998, J IMMUNOL, V161, P6681; Katzmann JA, 2002, CLIN CHEM, V48, P1437; Keener AB, 2017, J IMMUNOL, V198, P1263, DOI 10.4049/jimmunol.1600093; Kim HK, 2016, P NATL ACAD SCI USA, V113, P5718, DOI 10.1073/pnas.1524267113; Kim HK, 2012, INFECT IMMUN, V80, P3460, DOI 10.1128/IAI.00230-12; Kim HK, 2010, J EXP MED, V207, P1863, DOI 10.1084/jem.20092514; Kirik U, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01433; Kluytmans JAJW, 2005, INFECTION, V33, P3, DOI 10.1007/s15010-005-4012-9; LINDMARK R, 1983, J IMMUNOL METHODS, V62, P1, DOI 10.1016/0022-1759(83)90104-7; Margreitter C, 2018, NUCLEIC ACIDS RES, V46, pW264, DOI 10.1093/nar/gky276; Matsuda F, 1998, J EXP MED, V188, P2151, DOI 10.1084/jem.188.11.2151; Mermel LA, 2011, J CLIN MICROBIOL, V49, P1119, DOI 10.1128/JCM.02601-10; Miller LG, 2015, CLIN INFECT DIS, V60, P753, DOI 10.1093/cid/ciu943; Montgomery CP, 2015, CURR OPIN INFECT DIS, V28, P253, DOI 10.1097/QCO.0000000000000156; Montgomery CP, 2014, INFECT IMMUN, V82, P2125, DOI 10.1128/IAI.01491-14; Palmqvist N, 2005, MICROBES INFECT, V7, P1501, DOI 10.1016/j.micinf.2005.05.008; Palmqvist N, 2002, MICROB PATHOGENESIS, V33, P239, DOI 10.1006/mpat.2002.0533; Pantosti A, 2007, FUTURE MICROBIOL, V2, P323, DOI 10.2217/17460913.2.3.323; Pauli NT, 2014, J EXP MED, V211, P2331, DOI 10.1084/jem.20141404; Pelzek AJ, 2018, MBIO, V9, DOI 10.1128/mBio.02125-17; Radke EE, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31424-3; RICHMAN DD, 1982, J IMMUNOL, V128, P2300; ROBEN PW, 1995, J IMMUNOL, V154, P6437; Rodriguez M, 2014, J PEDIATR-US, V164, P105, DOI 10.1016/j.jpeds.2013.08.072; Salgado-Pabon W, 2014, NAT REV MICROBIOL, V12, P585, DOI 10.1038/nrmicro3308; SASANO M, 1993, J IMMUNOL, V151, P5822; SASSO EH, 1989, J IMMUNOL, V142, P2778; SASSO EH, 1991, J IMMUNOL, V147, P1877; SCHALEN C, 1985, ACTA PATH MICRO IM B, V93, P395; SCHROEDER HW, 1990, INT IMMUNOL, V2, P41, DOI 10.1093/intimm/2.1.41; Sheng ZZ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00537; Silverman GJ, 2006, NAT REV IMMUNOL, V6, P465, DOI 10.1038/nri1853; SILVERMAN GJ, 1993, J IMMUNOL, V151, P5840; SJODAHL J, 1977, EUR J BIOCHEM, V73, P343, DOI 10.1111/j.1432-1033.1977.tb11324.x; SOLOMON A, 1986, BLOOD, V68, P603; Sun Y, 2018, J BACTERIOL, V200, DOI 10.1128/JB.00735-17; Takahashi Y, 2017, CURR OPIN IMMUNOL, V45, P119, DOI 10.1016/j.coi.2017.03.002; Taylor JJ, 2012, J EXP MED, V209, P2065, DOI 10.1084/jem.20112272; Tong SYC, 2015, CLIN MICROBIOL REV, V28, P603, DOI 10.1128/CMR.00134-14; Ulloa-Morales AJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02011	70	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2021	12								662782	10.3389/fimmu.2021.662782	http://dx.doi.org/10.3389/fimmu.2021.662782			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SA5EO	33995388	gold, Green Published			2022-12-18	WOS:000649325400001
J	Yeh, HY; Hung, SH; Chen, SC; Guo, FR; Huang, HL; Peng, JK; Lee, CS; Tsai, JS				Yeh, Hsin-Yu; Hung, Shou-Hung; Chen, Su-Chiu; Guo, Fei-Ran; Huang, Hsien-Liang; Peng, Jen-Kuei; Lee, Chung-Sheng; Tsai, Jaw-Shiun			The Expression of Toll-Like Receptor 4 mRNA in PBMCs Is Upregulated in Smokers and Decreases Upon Smoking Cessation	FRONTIERS IN IMMUNOLOGY			English	Article						peripheral blood mononuclear cells; smoking cessation; smokers; toll-like receptor 4; inflammation		Background Studies have shown in vitro that cigarette smoke condensate stimulates monocytes to express toll-like receptor 4 (TLR4), tumor necrosis factor-alpha (TNF-alpha), and intercellular adhesion molecule 1 (ICAM-1), and enhances their adhesion to the endothelium. However, the same effects of cigarette smoking have not been explored in vivo. This study is to investigate the effect of cigarette smoking and smoking cessation on their mRNA expression in human peripheral blood mononuclear cells (PBMCs). Methods A group of 97 smokers and 62 nonsmokers were enrolled. The RNA from PBMCs was assessed with real-time polymerase chain reaction (PCR) to determine the levels of ICAM-1, TNF-alpha, and TLR4. The same markers in PBMCs of 87 quitters were examined before and at one week, one month, and two months after smoking cessation. Results Of the 97 smokers, 85 (87.6%) were males, and 30 (48.4%) of the nonsmokers were males (p < 0.0001). The mean (SD) age of the smokers was 43.24 (10.89) years, which was younger than 43.45 (11.41) years of nonsmokers (p < 0.0001). The incidence of cardiovascular diseases was 13.4% in smokers, which was higher than 1.6% in nonsmokers (p < 0.05). Both ICAM-1 and TNF-alpha mRNA levels in PBMCs were higher among the smokers (p < 0.0001). In addition, TLR4 mRNA levels in PBMCs were statistically elevated in the smokers (p < 0.0001) comparing with those in the nonsmokers. The mRNA levels of TLR4 and TNF-alpha in PBMCs decreased in those who had quit smoking for 2 months (p < 0.0001). Conclusions ICAM-1, TNF-alpha, and TLR4 mRNA expression levels in PBMCs increased in smokers and decreased after being on a smoking cessation program for 2 months. This finding suggested that TLR4 expression may mediate the atherogenic inflammatory process induced by smoking.	[Yeh, Hsin-Yu; Hung, Shou-Hung; Guo, Fei-Ran; Huang, Hsien-Liang; Peng, Jen-Kuei; Tsai, Jaw-Shiun] Natl Taiwan Univ Hosp, Dept Family Med, Taipei, Taiwan; [Yeh, Hsin-Yu; Hung, Shou-Hung; Guo, Fei-Ran; Huang, Hsien-Liang; Peng, Jen-Kuei; Tsai, Jaw-Shiun] Natl Taiwan Univ, Dept Family Med, Coll Med, Taipei, Taiwan; [Yeh, Hsin-Yu; Hung, Shou-Hung] Natl Taiwan Univ Hosp, Dept Community & Family Med, Yun Lin Branch, Yunlin, Taiwan; [Chen, Su-Chiu] Natl Taipei Univ Nursing & Hlth Sci, Dept Hlth Care Management, Taipei, Taiwan; [Lee, Chung-Sheng] Kainan Univ, Dept Nutr & Hlth Sci, Daxi Township, Taoyuan County, Taiwan; [Tsai, Jaw-Shiun] Natl Taiwan Univ Hosp, Ctr Complementary & Integrated Med, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taipei University of Nursing & Health Science (NTUNHS); Nan Kai University Technology; National Taiwan University; National Taiwan University Hospital	Tsai, JS (corresponding author), Natl Taiwan Univ Hosp, Dept Family Med, Taipei, Taiwan.; Tsai, JS (corresponding author), Natl Taiwan Univ, Dept Family Med, Coll Med, Taipei, Taiwan.; Tsai, JS (corresponding author), Natl Taiwan Univ Hosp, Ctr Complementary & Integrated Med, Taipei, Taiwan.	jawshiun@ntu.edu.tw		Huang, Hsien-Liang/0000-0002-2163-5596; Peng, Jen-Kuei/0000-0001-9997-9842; Tsai, Jaw-Shiun/0000-0002-5227-8894; GUO, FEI-RAN/0000-0003-0671-9529	National Science Council, Taiwan [NSC 98-2314-B-002 -118 -MY2, NSC 101-2314-B-002 -042, NSC 102-2314-B-002 -031, MOST 103-2314-B-002 -129]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by the grant (NSC 98-2314-B-002 -118 -MY2, NSC 101-2314-B-002 -042, NSC 102-2314-B-002 -031, and MOST 103-2314-B-002 -129 to J-ST) from the National Science Council, Taiwan. The financial sponsors played no role in any aspect of the study.	Ao LH, 2007, CYTOKINE, V38, P124, DOI 10.1016/j.cyto.2007.05.018; Barua RS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00572; Cho RL, 2016, AM J PHYSIOL-LUNG C, V310, pL639, DOI 10.1152/ajplung.00109.2014; Florin P., 2000, INT J CHRON OBSTRUCT, V5, P217, DOI [10.2147/copd.s8330, DOI 10.2147/COPD.S8330]; Giunzioni I, 2014, ATHEROSCLEROSIS, V234, P383, DOI 10.1016/j.atherosclerosis.2014.03.029; Hackshaw A, 2018, BMJ-BRIT MED J, V360, DOI [10.1136/bmj.j5855, 10.1136/bmj.k1611]; Halvorsen B, 2007, SCAND J CLIN LAB INV, V67, P604, DOI 10.1080/00365510701283878; Howell KW, 2011, J SURG RES, V171, pE27, DOI 10.1016/j.jss.2011.06.033; Jatoi NA, 2007, HYPERTENSION, V49, P981, DOI 10.1161/HYPERTENSIONAHA.107.087338; KALRA VK, 1994, J CELL PHYSIOL, V160, P154, DOI 10.1002/jcp.1041600118; Karimi K, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-66; Kohashi K, 2018, CIRC J, V82, P1418, DOI 10.1253/circj.CJ-17-0644; Kvarnhammar AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068701; Mahmud A, 2003, HYPERTENSION, V41, P183, DOI 10.1161/01.HYP.0000047464.66901.60; Poussin C, 2014, TOXICOL IN VITRO, V28, P896, DOI 10.1016/j.tiv.2014.03.005; Reichert V, 2009, CHEST, V136, P212, DOI 10.1378/chest.08-2288; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sarir H, 2009, J INFLAMM-LOND, V6, DOI 10.1186/1476-9255-6-12; Scott DA, 2000, BLOOD CELL MOL DIS, V26, P255, DOI 10.1006/bcmd.2000.0304; Sgambato JA, 2018, CYTOKINE, V107, P43, DOI 10.1016/j.cyto.2017.11.013; Song Y, 2011, J SURG RES, V166, P52, DOI 10.1016/j.jss.2009.03.101; Wannamethee SG, 2005, EUR HEART J, V26, P1765, DOI 10.1093/eurheartj/ehi183; Wen CP, 2005, TOB CONTROL, V14, pI51, DOI 10.1136/tc.2004.008011; Xu Y, 2014, AM J RESP CELL MOL, V51, P370, DOI 10.1165/rcmb.2013-0409OC	24	1	1	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2021	12								667460	10.3389/fimmu.2021.667460	http://dx.doi.org/10.3389/fimmu.2021.667460			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	SA4NL	33995400	Green Published, gold			2022-12-18	WOS:000649277300001
J	Gao, YY; Wang, YD; Luo, FF; Chu, YW				Gao, Yiyuan; Wang, Yuedi; Luo, Feifei; Chu, Yiwei			Optimization of T Cell Redirecting Strategies: Obtaining Inspirations From Natural Process of T Cell Activation	FRONTIERS IN IMMUNOLOGY			English	Review						chimeric antigen receptor; bispecific antibody; immunological synapse; metabolism; T cell-based immunotherapy		Chimeric antigen receptors (CARs) or bispecific antibodies (bsAbs) redirected T cell against tumors is one of the most promising immunotherapy approaches. However, insufficient clinical outcomes are still observed in treatments of both solid and non-solid tumors. Limited efficacy and poor persistence are two major challenges in redirected T cell therapies. The immunological synapse (IS) is a vital component during the T cell response, which largely determines the clinical outcomes of T cell-based therapies. Here, we review the structural and signaling characteristics of IS formed by natural T cells and redirected T cells. Furthermore, inspired by the elaborate natural T cell receptor-mediated IS, we provide potential strategies for higher efficacy and longer persistence of redirected T cells.	[Gao, Yiyuan; Wang, Yuedi; Chu, Yiwei] Fudan Univ, Sch Basic Med Sci, Inst Biomed Sci, Shanghai, Peoples R China; [Gao, Yiyuan; Wang, Yuedi; Chu, Yiwei] Fudan Univ, Sch Basic Med Sci, Dept Immunol, Shanghai, Peoples R China; [Gao, Yiyuan; Wang, Yuedi; Luo, Feifei; Chu, Yiwei] Fudan Univ, Biotherapy Res Ctr, Shanghai, Peoples R China; [Luo, Feifei] Fudan Univ, Huashan Hosp, Dept Digest Dis, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University	Chu, YW (corresponding author), Fudan Univ, Sch Basic Med Sci, Inst Biomed Sci, Shanghai, Peoples R China.; Chu, YW (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Immunol, Shanghai, Peoples R China.; Luo, FF; Chu, YW (corresponding author), Fudan Univ, Biotherapy Res Ctr, Shanghai, Peoples R China.; Luo, FF (corresponding author), Fudan Univ, Huashan Hosp, Dept Digest Dis, Shanghai, Peoples R China.	feifeiluo@fudan.edu.cn; yiweichu@fudan.edu.cn	Wang, Yuedi/GXF-7664-2022		National Natural Science Foundation of China [81730045, 81870375]; Shanghai Rising-Star Program [18QA1401000]; Open Research Fund of State Key Laboratory of Genetic Engineering, Fudan University [SKLGE1911]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Rising-Star Program; Open Research Fund of State Key Laboratory of Genetic Engineering, Fudan University	This work was supported by the National Natural Science Foundation of China (81730045, 81870375), Shanghai Rising-Star Program (18QA1401000), and Open Research Fund of State Key Laboratory of Genetic Engineering, Fudan University (SKLGE1911).	Adachi K, 2018, NAT BIOTECHNOL, V36, P346, DOI 10.1038/nbt.4086; Alabanza L, 2017, MOL THER, V25, P2452, DOI 10.1016/j.ymthe.2017.07.013; Arcangeli S, 2017, MOL THER, V25, P1933, DOI 10.1016/j.ymthe.2017.04.017; Asano R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61840-3; Au-Yeung BB, 2009, IMMUNOL REV, V228, P41, DOI 10.1111/j.1600-065X.2008.00753.x; Bachmann MF, 1997, IMMUNITY, V7, P549, DOI 10.1016/S1074-7613(00)80376-3; Bertrand F, 2013, P NATL ACAD SCI USA, V110, P6073, DOI 10.1073/pnas.1218640110; Bitra A, 2018, J BIOL CHEM, V293, P1317, DOI 10.1074/jbc.M117.814905; Brinkmann U, 2017, MABS-AUSTIN, V9, P182, DOI 10.1080/19420862.2016.1268307; Chang VT, 2016, NAT IMMUNOL, V17, P574, DOI 10.1038/ni.3392; Chang ZNL, 2018, NAT CHEM BIOL, V14, P317, DOI [10.1038/nchembio.2565, 10.1038/NCHEMBIO.2565]; Choi BD, 2019, NAT BIOTECHNOL, V37, P1049, DOI 10.1038/s41587-019-0192-1; Claus C, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav5989; Comrie WA, 2015, J CELL BIOL, V208, P475, DOI 10.1083/jcb.201406121; Correnti CE, 2018, LEUKEMIA, V32, P1239, DOI 10.1038/s41375-018-0014-3; Daniels MA, 2000, J EXP MED, V191, P335, DOI 10.1084/jem.191.2.335; Davenport AJ, 2018, P NATL ACAD SCI USA, V115, pE2068, DOI 10.1073/pnas.1716266115; DAVIGNON D, 1981, P NATL ACAD SCI-BIOL, V78, P4535, DOI 10.1073/pnas.78.7.4535; Davis DM, 2004, TRENDS IMMUNOL, V25, P323, DOI 10.1016/j.it.2004.03.007; Delon J, 2001, IMMUNITY, V15, P691, DOI 10.1016/S1074-7613(01)00231-X; Deng Q, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1061-7; Dustin ML, 2010, IMMUNOL REV, V235, P24, DOI 10.1111/j.0105-2896.2010.00904.x; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1; Fraser KA, 2013, IMMUNITY, V39, P171, DOI 10.1016/j.immuni.2013.07.003; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; Fritzsche M, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1603032; Fujiwara K, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051182; Ghorashian S, 2019, NAT MED, V25, P1408, DOI 10.1038/s41591-019-0549-5; Goebeler ME, 2020, NAT REV CLIN ONCOL, V17, P418, DOI 10.1038/s41571-020-0347-5; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Guedan S, 2020, J CLIN INVEST, V130, P3087, DOI 10.1172/JCI133215; Guedj C, 2016, J CELL SCI, V129, P2526, DOI 10.1242/jcs.182311; Hashimoto-Tane A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00255; Hashimoto-Tane A, 2016, J EXP MED, V213, P1609, DOI 10.1084/jem.20151088; Hashimoto-Tane A, 2010, MOL CELL BIOL, V30, P3421, DOI 10.1128/MCB.00160-10; He XH, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43003; Hegde M, 2016, J CLIN INVEST, V126, P3036, DOI 10.1172/JCI83416; Hudecek M, 2015, CANCER IMMUNOL RES, V3, P125, DOI 10.1158/2326-6066.CIR-14-0127; Huehls AM, 2015, IMMUNOL CELL BIOL, V93, P290, DOI 10.1038/icb.2014.93; Jenkins MR, 2010, CURR OPIN IMMUNOL, V22, P308, DOI 10.1016/j.coi.2010.02.008; Johnson MO, 2018, CELL, V175, P1780, DOI 10.1016/j.cell.2018.10.001; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Kagoya Y, 2018, NAT MED, V24, P352, DOI 10.1038/nm.4478; Kantarjian H, 2017, NEW ENGL J MED, V376, P836, DOI 10.1056/NEJMoa1609783; Kawalekar OU, 2016, IMMUNITY, V44, P712, DOI 10.1016/j.immuni.2016.02.023; Kishton RJ, 2017, CELL METAB, V26, P94, DOI 10.1016/j.cmet.2017.06.016; Krummel MF, 2000, SCIENCE, V289, P1349, DOI 10.1126/science.289.5483.1349; Kuramitsu S, 2015, CANCER GENE THER, V22, P487, DOI 10.1038/cgt.2015.47; Leddon SA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01519; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; Leone RD, 2019, SCIENCE, V366, P1013, DOI 10.1126/science.aav2588; Li D, 2009, J BIOL CHEM, V284, P21001, DOI 10.1074/jbc.M109.002865; Li J, 2017, CANCER CELL, V31, P383, DOI 10.1016/j.ccell.2017.02.001; Lin QD, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1092-1; Liu HY, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00038; Luo FF, 2016, CELL RES, V26, P850, DOI 10.1038/cr.2016.81; Ma S, 2019, INT J BIOL SCI, V15, P2548, DOI 10.7150/ijbs.34213; Maciolek JA, 2014, CURR OPIN IMMUNOL, V27, P60, DOI 10.1016/j.coi.2014.01.006; Majzner RG, 2019, NAT MED, V25, P1341, DOI 10.1038/s41591-019-0564-6; Martin-Cofreces NB, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00024; Milner JD, 2010, J IMMUNOL, V184, P6569, DOI 10.4049/jimmunol.1000674; Molgaard K, 2018, CANCER IMMUNOL IMMUN, V67, P1251, DOI 10.1007/s00262-018-2181-5; Mukherjee M, 2017, MOL THER, V25, P1757, DOI 10.1016/j.ymthe.2017.06.003; Newick K, 2017, ANNU REV MED, V68, P139, DOI 10.1146/annurev-med-062315-120245; O'Sullivan D, 2015, TRENDS IMMUNOL, V36, P71, DOI 10.1016/j.it.2014.12.004; O'Sullivan D, 2014, IMMUNITY, V41, P75, DOI 10.1016/j.immuni.2014.06.005; Offner S, 2006, MOL IMMUNOL, V43, P763, DOI 10.1016/j.molimm.2005.03.007; Pearce EL, 2010, CURR OPIN IMMUNOL, V22, P314, DOI 10.1016/j.coi.2010.01.018; Petit AE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12242; Pettitt D, 2018, MOL THER, V26, P342, DOI 10.1016/j.ymthe.2017.10.019; Porter JC, 2002, J IMMUNOL, V168, P6330, DOI 10.4049/jimmunol.168.12.6330; Qin L, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0437-8; Raud B, 2018, IMMUNOL REV, V283, P213, DOI 10.1111/imr.12655; Refaeli Y, 2002, J EXP MED, V196, P999, DOI 10.1084/JEM.20020666; Roig-Martinez M, 2019, RESULTS PROBL CELL D, V67, P223, DOI 10.1007/978-3-030-23173-6_9; Salzer B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17970-3; Schneider D, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00539; Sedykh SE, 2018, DRUG DES DEV THER, V12, P195, DOI 10.2147/DDDT.S151282; Shyer JA, 2020, CELL RES, V30, P649, DOI 10.1038/s41422-020-0379-5; Skokos D, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw7888; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Snook JP, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aas9103; Srivastava S, 2015, TRENDS IMMUNOL, V36, P494, DOI 10.1016/j.it.2015.06.004; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; Thakur A, 2018, BLOOD REV, V32, P339, DOI 10.1016/j.blre.2018.02.004; van der Windt GJW, 2012, IMMUNITY, V36, P68, DOI 10.1016/j.immuni.2011.12.007; Velasquez MP, 2017, CANCER IMMUNOL RES, V5, P860, DOI 10.1158/2326-6066.CIR-17-0171; Verma NK, 2016, J IMMUNOL, V197, P108, DOI 10.4049/jimmunol.1501264; Wang RN, 2012, NAT IMMUNOL, V13, P907, DOI 10.1038/ni.2386; Watanabe N, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1253656; Won EY, 2010, J BIOL CHEM, V285, P9202, DOI 10.1074/jbc.M109.084442; Wu CB, 2009, DRUG NEWS PERSPECT, V22, P453, DOI 10.1358/dnp.2009.22.8.1413783; Wu W, 2020, CELL, V182, P855, DOI 10.1016/j.cell.2020.07.018; Xiong W, 2018, MOL THER, V26, P963, DOI 10.1016/j.ymthe.2018.01.020; Yokosuka T, 2010, CURR TOP MICROBIOL, V340, P81, DOI 10.1007/978-3-642-03858-7_5; Yu XJ, 2020, CANCER CELL, V37, P850, DOI 10.1016/j.ccell.2020.04.013; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837	99	1	1	3	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 26	2021	12								664329	10.3389/fimmu.2021.664329	http://dx.doi.org/10.3389/fimmu.2021.664329			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RZ5UP	33981310	gold, Green Published			2022-12-18	WOS:000648662500001
J	Kulkarni-Munje, A; Malshe, N; Palkar, S; Amlekar, A; Lalwani, S; Mishra, AC; Arankalle, V				Kulkarni-Munje, Archana; Malshe, Nandini; Palkar, Sonali; Amlekar, Aniket; Lalwani, Sanjay; Mishra, Akhilesh Chandra; Arankalle, Vidya			Immune Response of Indian Preterm Infants to Pentavalent Vaccine Varies With Component Antigens and Gestational Age	FRONTIERS IN IMMUNOLOGY			English	Article						preterm birth; immune response; pentavalent vaccine; recall immune responses; immunological memory		Childhood vaccination plays critical role in protecting infants from several dreaded diseases. Of the global 15 million preterm (PT) infants with compromised immune system born annually, India contributes to >3.5 million. Generation of adequate vaccine-induced immune response needs to be ensured of their protection. Immune response of Indian PT (n = 113) and full-term (FT, n = 80) infants to pentavalent vaccine administered as per the national recommendation was studied. Antibody titers against component antigens of pentavalent vaccine, immune cells profiling (T and B cells, monocytes and dendritic cells) and plasma cytokines were determined pre- and post-vaccination. Additionally, cell-mediated recall immune responses to pentavalent antigens were evaluated after short time antigenic exposure to infant PBMCs. Irrespective of gestational age (GA), all the infants developed adequate antibody response against tetanus, diphtheria, and protective but lower antibody levels for Haemophilus influenzae type-b and hepatitis B in preterm infants. Lower (similar to 74%) protective antibody response to pertussis was independent of gestational age. PT-infants exhibited lower frequencies of CD4 T cells/dendritic cells/monocytes, increased plasma IL-10 levels and lower proliferation of central and effector memory T cells than in term-infants. Proliferative central memory response of FT-infants without anti-pertussis antibodies suggests protection from subsequent infection. Responder/non-responder PT-infants lacked immunological memory and could be infected with Bordetella. For hepatitis B, the recall response was gestational age-dependent and antibody status-independent. Humoral/cellular immune responses of PT-infants were dependent on the type of the immunogen. Preterm infants born before 32 weeks of gestation may need an extra dose of pentavalent vaccine for long lived robust immune response.	[Kulkarni-Munje, Archana; Amlekar, Aniket; Mishra, Akhilesh Chandra; Arankalle, Vidya] Bharati Vidyapeeth Deemed Univ Univ, Interact Res Sch Hlth Affairs, Dept Communicable Dis, Pune, Maharashtra, India; [Malshe, Nandini; Palkar, Sonali; Lalwani, Sanjay] Bharati Vidyapeeth Deemed Univ Univ, Dept Paediat, Univ Med Coll, Pune, Maharashtra, India	Bharati Vidyapeeth Deemed University; Bharati Vidyapeeth Deemed University	Arankalle, V (corresponding author), Bharati Vidyapeeth Deemed Univ Univ, Interact Res Sch Hlth Affairs, Dept Communicable Dis, Pune, Maharashtra, India.	varankalle@yahoo.com		Arankalle, Vidya/0000-0002-9940-3437; Kulkarni-Munje, Archana/0000-0002-2302-7594	Department of Health Research, Government of India [R.11012/03/2017-HR]	Department of Health Research, Government of India(Department of Health Research, Government of India)	The study was funded by the Department of Health Research, Government of India under Grant in Aids Scheme Inter-Sectoral Convergence and Coordination for Promotion and Guidance on Health Research with the main objective on research studies with emphasis on public health (grant R.11012/03/2017-HR).	Perin MCAA, 2012, VACCINE, V30, P6521, DOI 10.1016/j.vaccine.2012.08.056; [Anonymous], 2004, WKLY EPIDEMIOL REC; [Anonymous], 2006, WKLY EPIDEMIOL REC, V81, P198; [Anonymous], 2005, WKLY EPIDEMIOL REC; Arora NK, 2002, ACTA PAEDIATR, V91, P995, DOI 10.1080/080352502760272722; Balasubramanian S, 2018, INDIAN PEDIATR, V55, P1066, DOI 10.1007/s13312-018-1444-8; Bassat Q, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002301; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bhave Sheila, 2002, Indian Pediatr, V39, P625; Bonhoeffer J, 2006, ARCH DIS CHILD, V91, P929, DOI 10.1136/adc.2005.086306; Brook B, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax4517; Byington CL, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-1870; Chiappini E, 2019, ITAL J PEDIATR, V45, DOI 10.1186/s13052-019-0742-7; Gagneur A, 2015, HUM VACC IMMUNOTHER, V11, P2556, DOI 10.1080/21645515.2015.1074358; Gandhi DJ, 2016, HUM VACC IMMUNOTHER, V12, P946, DOI 10.1080/21645515.2015.1100779; Garcia-Leon ML, 2015, HUM VACC IMMUNOTHER, V11, P1762, DOI 10.1080/21645515.2015.1032488; Ghirelli C, 2010, BLOOD, V115, P5037, DOI 10.1182/blood-2010-01-266932; Grasse M, 2018, VACCINE, V36, P4672, DOI 10.1016/j.vaccine.2018.06.033; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Higgins SC, 2006, J IMMUNOL, V177, P7980, DOI 10.4049/jimmunol.177.11.7980; Hornik CP, 2012, EARLY HUM DEV, V88, pS69, DOI 10.1016/S0378-3782(12)70019-1; Hwang JS, 2018, LUNG, V196, P129, DOI 10.1007/s00408-018-0084-z; KAYHTY H, 1983, J INFECT DIS, V147, P1100; Kent A, 2019, CLIN INFECT DIS, V69, P84, DOI 10.1093/cid/ciy842; Malloy MH, 2015, J PERINATOL, V35, P885, DOI 10.1038/jp.2015.91; Martinon-Torres F, 2015, PEDIATRICS, V135, pE876, DOI 10.1542/peds.2014-2941; Mollah A H, 2012, Mymensingh Med J, V21, P109; National Health Portal I, 2018, UN IMM PROGR; Omenaca F, 2018, VACCINE, V36, P986, DOI 10.1016/j.vaccine.2018.01.005; Ota MOC, 2002, J IMMUNOL, V168, P919, DOI 10.4049/jimmunol.168.2.919; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Peoples JD, 2009, AM J PERINAT, V26, P647, DOI 10.1055/s-0029-1220788; Rao R, 2009, HUM VACCINES, V5, P425, DOI 10.4161/hv.5.6.7816; Scheible KM, 2015, CLIN IMMUNOL, V161, P65, DOI 10.1016/j.clim.2015.07.003; Sharma H, 2011, VACCINE, V29, P2359, DOI 10.1016/j.vaccine.2011.01.054; Sharma HJ, 2011, HUM VACCINES, V7, P451, DOI 10.4161/hv.7.4.14208; Sil A, 2017, VACCINE, V35, P2999, DOI 10.1016/j.vaccine.2017.03.009; Sood Ajit, 2002, Indian J Gastroenterol, V21, P52; Steiner L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224766; Stoll BJ, 2010, PEDIATRICS, V126, P443, DOI 10.1542/peds.2009-2959; Stoll BJ, 2004, JAMA-J AM MED ASSOC, V292, P2357, DOI 10.1001/jama.292.19.2357; Szynczewska E, 2011, VACCINE, V29, P7107, DOI 10.1016/j.vaccine.2011.06.124; Thayyil-Sudhan S, 1999, ARCH DIS CHILD-FETAL, V81, pF64, DOI 10.1136/fn.81.1.F64; Tsuda K, 2012, PEDIATR INT, V54, P64, DOI 10.1111/j.1442-200X.2011.03505.x; Turunen R, 2009, NEONATOLOGY, V96, P248, DOI 10.1159/000220764; UNICEF, 2020, LEV TRENDS CHILD MOR; Verma C, 2018, INDIAN PEDIATR, V55, P395, DOI 10.1007/s13312-018-1280-x; WHO position paper on Diphtheria vaccine, 2006, WKLY EPIDEMIOL REC, P24; Zhang XQ, 2011, J IMMUNOL, V186, P4895, DOI 10.4049/jimmunol.1000594	49	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 23	2021	12								592731	10.3389/fimmu.2021.592731	http://dx.doi.org/10.3389/fimmu.2021.592731			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RY6TY	33968011	Green Published, gold			2022-12-18	WOS:000648042600001
J	Zhang, X; Zhu, HP; Zheng, X; Jiao, YJ; Ning, LL; Zhou, EM; Mu, Y				Zhang, Xin; Zhu, Haipeng; Zheng, Xu; Jiao, Yunjie; Ning, Lulu; Zhou, En-Min; Mu, Yang			A Double-Antibody Sandwich ELISA for Sensitive and Specific Detection of Swine Fibrinogen-Like Protein 1	FRONTIERS IN IMMUNOLOGY			English	Article						swine FGL1; detection; monoclonal antibody; double-antibody sandwich ELISA; PRRSV-negative and -positive pig sera	HEPASSOCIN	Fibrinogen-like protein 1 (FGL1), a member of the fibrinogen family, is a specific hepatocyte mitogen. Recently, it has been reported that FGL1 is the main inhibitory ligand of lymphocyte activating gene 3 (LAG3). Furthermore, the FGL1-LAG3 pathway has a synergistic effect with programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway and is regarded as a promising immunotherapeutic target. However, swine FGL1 (sFGL1) has not been characterized and its detection method is lacking. In the study, the sFGL1 gene was amplified from the liver tissue of swine and then inserted into a prokaryotic expression vector, pQE-30. The recombinant plasmid pQE30-sFGL1 was transformed into JM109 competent cells. The recombinant sFGL1 was induced expression by isopropyl-beta-d-thiogalactoside (IPTG) and the purified sFGL1 was used as an antigen to produce mouse monoclonal antibody (mAb) and rabbit polyclonal antibody (pAb). After identification, a double-antibody sandwich enzyme-linked immunosorbent assay (DAS-ELISA) for sensitive and specific detection of sFGL1 was developed. Swine FGL1 in samples was captured by anti-sFGL1 mAb followed by detection with anti-sFGL1 rabbit pAb and HRP-conjugated goat anti-rabbit IgG. The limit of detection of the developed sFLG1-DAS-ELISA is 35 pg/ml with recombinant sFLG1. Besides, it does not show cross-reactivity with the control protein. Then serum samples of PRRSV-negative and -positive pigs were tested with the established DAS-ELISA and calculated according to the equation of y=0.0735x+0.0737. The results showed that PRRSV infection enhanced the serum FGL1 levels significantly. Our research provides a platform for the research on the functional roles of swine FGL1.	[Zhang, Xin; Zhu, Haipeng; Zheng, Xu; Jiao, Yunjie; Ning, Lulu; Zhou, En-Min; Mu, Yang] Northwest A&F Univ, Coll Vet Med, Dept Vet Prevent Med, Yangling, Shaanxi, Peoples R China; [Zhang, Xin; Zhu, Haipeng; Zheng, Xu; Jiao, Yunjie; Zhou, En-Min; Mu, Yang] Minist Agr, Sci Observing & Expt Stn Vet Pharmacol & Diagnost, Yangling, Shaanxi, Peoples R China	Northwest A&F University - China; Ministry of Agriculture & Rural Affairs	Zhou, EM; Mu, Y (corresponding author), Northwest A&F Univ, Coll Vet Med, Dept Vet Prevent Med, Yangling, Shaanxi, Peoples R China.; Zhou, EM; Mu, Y (corresponding author), Minist Agr, Sci Observing & Expt Stn Vet Pharmacol & Diagnost, Yangling, Shaanxi, Peoples R China.	zhouem@nwafu.edu.cn; muyang@nwafu.edu.cn			National Natural Science Foundation of China [31972675]; National Training Program of Innovation and Entrepreneurship for Undergraduates [S202010712070]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Training Program of Innovation and Entrepreneurship for Undergraduates	This study was supported by grants from the National Natural Science Foundation of China(grant no. 31972675) and the National Training Program of Innovation and Entrepreneurship for Undergraduates (grant no. S202010712070).	An TQ, 2020, VIRUS RES, V286, DOI 10.1016/j.virusres.2020.197980; Attanasio J, 2016, IMMUNITY, V44, P1052, DOI 10.1016/j.immuni.2016.04.022; Baumeister SH, 2016, ANNU REV IMMUNOL, V34, P539, DOI 10.1146/annurev-immunol-032414-112049; Cao MM, 2011, J CELL BIOCHEM, V112, P2882, DOI 10.1002/jcb.23202; Choi SY, 2020, MICROBIOL IMMUNOL, V64, P72, DOI 10.1111/1348-0421.12751; Dixit CK, 2011, NAT PROTOC, V6, P439, DOI 10.1038/nprot.2011.304; Fan BC, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.540248; FRIGUET B, 1983, J IMMUNOL METHODS, V60, P351, DOI 10.1016/0022-1759(83)90292-2; Gao M, 2014, CELL SIGNAL, V26, P2161, DOI 10.1016/j.cellsig.2014.04.013; Gebauer F, 2020, J CANCER RES CLIN, V146, P2319, DOI 10.1007/s00432-020-03295-7; Graydon CG, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007429; Han J, 2017, VET MICROBIOL, V209, P30, DOI 10.1016/j.vetmic.2017.02.020; Hara H, 2001, BBA-GENE STRUCT EXPR, V1520, P45, DOI 10.1016/S0167-4781(01)00249-4; Hara H, 2000, BBA-GENE STRUCT EXPR, V1492, P31, DOI 10.1016/S0167-4781(00)00056-7; Hu SY, 2020, J AUTOIMMUN, V112, DOI 10.1016/j.jaut.2020.102504; Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010; Jia B, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160196; Joller N, 2017, CURR TOP MICROBIOL, V410, P127, DOI 10.1007/82_2017_62; Kahan SM, 2015, VIROLOGY, V479, P180, DOI 10.1016/j.virol.2014.12.033; Ke HZ, 2017, VET MICROBIOL, V209, P75, DOI 10.1016/j.vetmic.2017.03.014; Li CY, 2010, GUT, V59, P817, DOI 10.1136/gut.2008.171124; Lichtenegger FS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00385; Liu ZL, 2008, BIOCHEM BIOPH RES CO, V365, P729, DOI 10.1016/j.bbrc.2007.11.069; Long Long, 2018, Genes Cancer, V9, P176, DOI 10.18632/genesandcancer.180; Lunney JK, 2016, ANNU REV ANIM BIOSCI, V4, P129, DOI 10.1146/annurev-animal-022114-111025; Luo XG, 2020, J IMMUNOL, V204, P394, DOI 10.4049/jimmunol.1900731; Lv R, 2019, J PHARMACEUT BIOMED, V162, P179, DOI 10.1016/j.jpba.2018.07.049; Nayeb-Hashemi H, 2015, BIOCHEM BIOPH RES CO, V465, P167, DOI 10.1016/j.bbrc.2015.07.078; Richmond O, 2015, VET IMMUNOL IMMUNOP, V168, P24, DOI 10.1016/j.vetimm.2015.09.013; Rijken DC, 2006, BIOCHEM BIOPH RES CO, V350, P191, DOI 10.1016/j.bbrc.2006.09.018; Sun CL, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01477-y; Tang XQ, 2018, J VIROL METHODS, V251, P133, DOI 10.1016/j.jviromet.2017.10.020; TRIEBEL F, 1990, J EXP MED, V171, P1393, DOI 10.1084/jem.171.5.1393; Vashist SK, 2014, ANAL BIOCHEM, V446, P96, DOI 10.1016/j.ab.2013.10.022; Wang G, 2020, TRENDS MICROBIOL, V28, P212, DOI 10.1016/j.tim.2019.10.009; Wang J, 2016, CANCER BIOMARK, V17, P369, DOI 10.3233/CBM-160649; Wang J, 2019, CELL, V176, P334, DOI 10.1016/j.cell.2018.11.010; Wang SJ, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02882; Workman CJ, 2005, J IMMUNOL, V174, P688, DOI 10.4049/jimmunol.174.2.688; Workman CJ, 2004, J IMMUNOL, V172, P5450, DOI 10.4049/jimmunol.172.9.5450; Wu HT, 2020, FASEB J, V34, P2958, DOI 10.1096/fj.201901925R; Wu HT, 2016, DIABETOLOGIA, V59, P1732, DOI 10.1007/s00125-016-3991-7; Wykes MN, 2018, NAT REV IMMUNOL, V18, P91, DOI 10.1038/nri.2017.112; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P681, DOI 10.1006/bbrc.1993.1678; Yan J, 2004, ONCOGENE, V23, P1939, DOI 10.1038/sj.onc.1207306; Zhou EM, 2008, J VIROL METHODS, V149, P300, DOI 10.1016/j.jviromet.2008.01.010; Zhu LJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep16092; Zhuge ZY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029320	48	1	1	5	18	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 23	2021	12								670626	10.3389/fimmu.2021.670626	http://dx.doi.org/10.3389/fimmu.2021.670626			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RY7KT	33968077	gold, Green Published			2022-12-18	WOS:000648086300001
J	Zhou, R; Jiang, F; Cai, HB; Zeng, QM; Yang, H				Zhou, Ran; Jiang, Fei; Cai, Haobing; Zeng, Qiuming; Yang, Huan			Case Report: Antibodies to the N-Methyl-D-Aspartate Receptor in a Patient With Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Article						anti-N-methyl-D-aspartate receptor antibody; multiple sclerosis; disease modifying treatment; case report; impaired consciousness	ENCEPHALITIS	The association between multiple sclerosis and anti-N-Methyl-D-Aspartate receptor encephalitis is limited to merely a few case reports, and the exploration of the pathogenic mechanisms underlying the overlap of these two disease entities is very limited. Therefore, case reports and literature review on N-Methyl-D-aspartate receptor antibody in patients with multiple sclerosis are unusual and noteworthy. A young female had the first episode of paresthesia and motor symptoms with positive anti-N-Methyl-D-Aspartate receptor antibody and recovered after immunotherapy, and at the first relapse, the patient developed disorders of consciousness with positive anti-N-Methyl-D-Aspartate receptor antibody, findings of magnetic resonance imaging showed features of autoimmune encephalitis, which was also controlled by immunotherapy. At the second relapse, anti-N-Methyl-D-Aspartate receptor antibody turned negative while oligoclonal bands presented positive, and findings of magnetic resonance imaging showed features of multiple sclerosis. Afterwards, we followed the patient after receiving disease modifying treatment to monitor the efficacy and safety of teriflunomide. Based on literature review, demyelinating diseases patients with anti-neuronal antibody have complex, diverse and atypical symptoms; therefore, high attention and increased alertness are necessary for neurologists. Conclusively, anti-neuronal antibody may present in many neuroinflammatory conditions, and diagnostic criteria should be used with caution if the clinical presentation is atypical, and neurologists should not rely excessively on laboratory tests to diagnose neurological diseases. Timely and comprehensive examination and consideration as well as early standardized treatment are the key factors to reduce patient recurrence and obtain a good prognosis.	[Zhou, Ran; Jiang, Fei; Cai, Haobing; Zeng, Qiuming; Yang, Huan] Cent South Univ, Xiangya Hosp, Dept Neurol, Changsha, Peoples R China	Central South University	Zeng, QM; Yang, H (corresponding author), Cent South Univ, Xiangya Hosp, Dept Neurol, Changsha, Peoples R China.	zengqiuming1983@126.com; 403850@csu.edu.cn		Zhou, Ran/0000-0001-7756-2755	National Natural Science Foundation of China [81801203, 81771364]; Natural Science Foundation of Hunan Province [2019JJ50973]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province)	This study was supported by the grants from the National Natural Science Foundation of China (Grant Number: 81801203, 81771364) and the Natural Science Foundation of Hunan Province (Grant Number: 2019JJ50973).	Bacchi S, 2018, J CLIN NEUROSCI, V52, P54, DOI 10.1016/j.jocn.2018.03.026; Baheerathan A, 2017, MULT SCLER RELAT DIS, V12, P20, DOI 10.1016/j.msard.2016.12.009; Broadley J, 2019, J AUTOIMMUN, V96, P24, DOI 10.1016/j.jaut.2018.10.014; Dalmau J, 2007, ANN NEUROL, V61, P25, DOI 10.1002/ana.21050; Dalmau J, 2019, LANCET NEUROL, V18, P1045, DOI 10.1016/S1474-4422(19)30244-3; Dalmau J, 2011, LANCET NEUROL, V10, P63, DOI 10.1016/S1474-4422(10)70253-2; Disanto G, 2017, ANN NEUROL, V81, P857, DOI 10.1002/ana.24954; Eijlers AJC, 2018, BRAIN, V141, P2605, DOI 10.1093/brain/awy202; Ferraro D, 2020, EUR J NEUROL, V27, P461, DOI 10.1111/ene.14121; Fleischmann R, 2015, JAMA NEUROL, V72, P96, DOI 10.1001/jamaneurol.2014.1817; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Gresa-Arribas N, 2014, LANCET NEUROL, V13, P167, DOI 10.1016/S1474-4422(13)70282-5; Gulec B, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102075; Hacohen Y, 2014, J NEUROL NEUROSUR PS, V85, P456, DOI 10.1136/jnnp-2013-306411; Hacohen Y, 2014, MOVEMENT DISORD, V29, P90, DOI 10.1002/mds.25626; Hemond CC, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a028969; Huang Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.595417; Johnston J, 2010, J NEUROL NEUROSUR PS, V81, pE56, DOI 10.1136/jnnp.2010.226340.155; Leypoldt F, 2013, NEUROLOGY, V81, P1637, DOI 10.1212/WNL.0b013e3182a9f531; Lipton SA, 2006, NEURON, V50, P10, DOI 10.1016/j.neuron.2006.03.026; Malter MP, 2013, SEIZURE-EUR J EPILEP, V22, P136, DOI 10.1016/j.seizure.2012.12.013; Martinez-Hernandez E, 2020, NEUROLOGY, V94, pE2302, DOI 10.1212/WNL.0000000000009239; Nakken O, 2018, J NEUROL, V265, P1295, DOI 10.1007/s00415-018-8832-9; Ramberger M, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000141; Ren YJ, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01271; Suleman Sadia, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2017-222086; Takeda A, 2014, MULT SCLER RELAT DIS, V3, P391, DOI 10.1016/j.msard.2013.09.005; Tao SX, 2019, MULT SCLER RELAT DIS, V35, P185, DOI 10.1016/j.msard.2019.07.008; Thompson AJ, 2018, LANCET, V391, P1622, DOI 10.1016/S0140-6736(18)30481-1; Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2; Titulaer MJ, 2014, ANN NEUROL, V75, P411, DOI 10.1002/ana.24117; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; Uzawa A, 2012, CLIN NEUROL NEUROSUR, V114, P402, DOI 10.1016/j.clineuro.2011.10.047; Waschbisch Anne, 2014, BMC Res Notes, V7, P948, DOI 10.1186/1756-0500-7-948; Zhang T, 2018, AM J NEURORADIOL, V39, P824, DOI 10.3174/ajnr.A5593; Zhao XY, 2020, REPROD BIOL ENDOCRIN, V18, DOI 10.1186/s12958-020-00661-5	36	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 23	2021	12								664364	10.3389/fimmu.2021.664364	http://dx.doi.org/10.3389/fimmu.2021.664364			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RY6TZ	33968065	Green Published, gold			2022-12-18	WOS:000648042700001
J	Frange, P; Montange, T; Le Chenadec, JM; Batalie, D; Fert, I; Dollfus, C; Faye, A; Blanche, S; Chace, A; Fourcade, C; Hau, I; Levine, M; Mahlaoui, N; Marcou, V; Tabone, MD; Veber, F; Hoctin, A; Wack, T; Avettand-Fenoel, V; Warszawski, J; Buseyne, F				Frange, Pierre; Montange, Thomas; Le Chenadec, Jerome; Batalie, Damien; Fert, Ingrid; Dollfus, Catherine; Faye, Albert; Blanche, Stephane; Chace, Anne; Fourcade, Corine; Hau, Isabelle; Levine, Martine; Mahlaoui, Nizar; Marcou, Valerie; Tabone, Marie-Dominique; Veber, Florence; Hoctin, Alexandre; Wack, Thierry; Avettand-Fenoel, Veronique; Warszawski, Josiane; Buseyne, Florence		ANRS-EP59-Study Grp	Impact of Early Versus Late Antiretroviral Treatment Initiation on Naive T Lymphocytes in HIV-1-Infected Children and Adolescents - The-ANRS-EP59-CLEAC Study	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1; children; adolescents; early ART; T lymphocyte; naive T lymphocyte	HIV-INFECTED PATIENTS; THYMIC OUTPUT; THERAPY; DECADES	Background The early initiation of antiretroviral therapy (ART) in HIV-1-infected infants reduces mortality and prevents early CD4 T-cell loss. However, the impact of early ART on the immune system has not been thoroughly investigated in children over five years of age or adolescents. Here, we describe the levels of naive CD4 and CD8 T lymphocytes (CD4/CD8T(N)), reflecting the quality of immune reconstitution, as a function of the timing of ART initiation (early (<6 months) versus late (>= 24 months of age)). Methods The ANRS-EP59-CLEAC study enrolled 27 children (5-12 years of age) and nine adolescents (13-17 years of age) in the early-treatment group, and 19 children (L-Ch) and 21 adolescents (L-Ado) in the late-treatment group. T lymphocytes were analyzed by flow cytometry and plasma markers were analyzed by ELISA. Linear regression analysis was performed with univariate and multivariate models. Results At the time of evaluation, all patients were on ART and had a good immunovirological status: 83% had HIV RNA loads below 50 copies/mL and the median CD4 T-cell count was 856 cells/mu L (interquartile range: 685-1236 cells/mu L). In children, early ART was associated with higher CD8T(N) percentages (medians: 48.7% vs. 31.0%, P = 0.001), and a marginally higher CD4T(N) (61.2% vs. 53.1%, P = 0.33). In adolescents, early ART was associated with low CD4T(N) percentages and less differentiated memory CD8 T cells. CD4T(N) and CD8T(N) levels were inversely related to cellular activation and gut permeability. Conclusion In children and adolescents, the benefits of early ART for CD8T(N) were clear after long-term ART. The impact of early ART on CD4T(N) appears to be modest, because pediatric patients treated late respond to HIV-driven CD4 T-lymphocyte loss by the de novo production of T-N cells in the thymus. Our data also suggest that current immune activation and/or gut permeability has a negative impact on T-N levels.	[Frange, Pierre; Blanche, Stephane; Mahlaoui, Nizar; Veber, Florence] AP HP Ctr Univ Paris, Hop Necker Enfants Malad, Immunol Hematol & Rhumatol Pediat, Paris, France; [Frange, Pierre; Avettand-Fenoel, Veronique] AP HP Ctr Univ Paris, Hop Necker Enfants Malad, Lab Microbiol Clin, Paris, France; [Frange, Pierre] Univ Paris, Inst Imagine, EHU 7328 PACT, Paris, France; [Montange, Thomas; Batalie, Damien; Fert, Ingrid; Buseyne, Florence] Inst Pasteur, Unite Epidemiol & Physiopathol Virus Oncogenes, Paris, France; [Montange, Thomas; Batalie, Damien; Fert, Ingrid; Buseyne, Florence] UMR CNRS 3569 Inst Pasteur, Dept Virol, Paris, France; [Le Chenadec, Jerome; Hoctin, Alexandre; Wack, Thierry; Warszawski, Josiane] INSERM U1018, Dept Epidemiol, Ctr Rech Epidemiol & Sante Populat, Villejuif, France; [Dollfus, Catherine; Tabone, Marie-Dominique] Hop Trousseau, AP HP, Hematooncol Pediat, Paris, France; [Faye, Albert; Chace, Anne] Hop Robert Debre, AP HP, Pediat Gen, Paris, France; [Chace, Anne] Ctr Hosp Intercommunal Villeuneuve St Georges, Pediat & Neonatol, Villeuneuve St Georges, France; [Fourcade, Corine] Hop Bicetre, AP HP, Pediat Gen, Paris, France; [Hau, Isabelle] Ctr Hosp Intercommunal Creteil, Pediat Gen, Creteil, France; [Levine, Martine] Hop Robert Debre, AP HP, Immunohematol Pediat, Paris, France; [Marcou, Valerie] AP HP Ctr Univ Paris, Hop Cochin, Med & Reanimat Neonatale, Paris, France; [Avettand-Fenoel, Veronique] Univ Paris 05, Inst Cochin, CNRS 8104 INSERM U1016, Paris, France; [Warszawski, Josiane] Univ Paris Sud, INED, Orsay, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay	Buseyne, F (corresponding author), Inst Pasteur, Unite Epidemiol & Physiopathol Virus Oncogenes, Paris, France.; Buseyne, F (corresponding author), UMR CNRS 3569 Inst Pasteur, Dept Virol, Paris, France.	florence.buseyne@pasteur.fr	Frange, Pierre/O-6311-2017		ANRS (France Recherche Nord et Sud SIDA-HIV Hepatites)	ANRS (France Recherche Nord et Sud SIDA-HIV Hepatites)	ANRS (France Recherche Nord et Sud SIDA-HIV Hepatites) funded this study.	Aguilera-Sandoval CR, 2016, AIDS, V30, P701, DOI 10.1097/QAD.0000000000001010; Appay V, 2011, AIDS, V25, P1813, DOI 10.1097/QAD.0b013e32834640e6; Aupiais C, 2014, PEDIATR INFECT DIS J, V33, P1237, DOI 10.1097/INF.0000000000000450; Avettand-Fenoel V, 2021, CLIN INFECT DIS, V73, pE4214, DOI 10.1093/cid/ciaa1931; Avettand-Fenoel V, 2012, J INFECT DIS, V205, P1520, DOI 10.1093/infdis/jis233; Avettand-Fenol V, 2009, J MED VIROL, V81, P217, DOI 10.1002/jmv.21390; Azzoni L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145320; Blanche S, 2014, CLIN INFECT DIS, V58, P573, DOI 10.1093/cid/cit729; Bourgeois C, 2008, P NATL ACAD SCI USA, V105, P8691, DOI 10.1073/pnas.0803732105; Buseyne F, 2005, J INFECT DIS, V192, P1781, DOI 10.1086/497152; Chiappini E, 2018, AGING-US, V10, P3610, DOI 10.18632/aging.101622; Cohen S, 2013, AIDS, V27, P2567, DOI 10.1097/01.aids.0000432451.75980.1b; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, 2008, AIDS, V22, P1463, DOI 10.1097/QAD.0b013e3282f88d02; Cotton MF, 2013, LANCET, V382, P1555, DOI 10.1016/S0140-6736(13)61409-9; De Voeght A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185761; Desmonde S, 2014, AIDS, V28, P1645, DOI 10.1097/QAD.0000000000000272; Dirajlal-Fargo S, 2020, CLIN INFECT DIS, V70, P2413, DOI 10.1093/cid/ciz561; Dollfus C, 2010, CLIN INFECT DIS, V51, P214, DOI 10.1086/653674; Fastenackels S, 2019, AIDS, V33, P1705, DOI 10.1097/QAD.0000000000002275; Ferrando-Martinez S, 2017, CLIN INFECT DIS, V64, P1191, DOI 10.1093/cid/cix095; Gaballa A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01341; Garcia-Prat M, 2019, CYTOM PART B-CLIN CY, V96, P223, DOI 10.1002/cyto.b.21728; Goetghebuer T, 2012, CLIN INFECT DIS, V54, P878, DOI 10.1093/cid/cir950; Guillen S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220552; Kakkar F, 2020, AIDS, V34, P687, DOI 10.1097/QAD.0000000000002454; Koay WLA, 2018, J INFECT DIS, V218, P1085, DOI 10.1093/infdis/jiy271; Lewis J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01162; Lewis J, 2012, J INFECT DIS, V205, P548, DOI 10.1093/infdis/jir787; Nobile M, 2004, BLOOD, V104, P470, DOI 10.1182/blood-2003-12-4265; Novelli S, 2018, CLIN INFECT DIS, V66, P1519, DOI 10.1093/cid/cix1068; Paghera S, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0166-7; Palladino C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096307; Picat MQ, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001542; Prendergast AJ, 2017, J INFECT DIS, V216, P651, DOI 10.1093/infdis/jix367; Rinaldi S, 2020, J IMMUNOL, V204, P540, DOI 10.4049/jimmunol.1900856; Sandler NG, 2011, J INFECT DIS, V203, P780, DOI 10.1093/infdis/jiq118; SCOTT Z, 2001, J IMMUNOL, V167; Shiau S, 2018, LANCET HIV, V5, pE250, DOI 10.1016/S2352-3018(18)30012-2; Turner JE, 2014, AGE, V36, P287, DOI 10.1007/s11357-013-9557-4; van den Heuvel D, 2017, J ALLERGY CLIN IMMUN, V139, P1923, DOI 10.1016/j.jaci.2016.10.023; Zakhour R, 2016, CLIN INFECT DIS, V62, P1029, DOI 10.1093/cid/ciw030; Zicari S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030200	42	1	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2021	12								662894	10.3389/fimmu.2021.662894	http://dx.doi.org/10.3389/fimmu.2021.662894			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RX5VW	33968064	Green Published			2022-12-18	WOS:000647292300001
J	Huang, Q; Xu, WD; Su, LC; Liu, XY; Huang, AF				Huang, Qi; Xu, Wang-Dong; Su, Lin-Chong; Liu, Xiao-Yan; Huang, An-Fang			Association of CD40 Gene Polymorphisms With Systemic Lupus Erythematosus and Rheumatoid Arthritis in a Chinese Han Population	FRONTIERS IN IMMUNOLOGY			English	Article						CD40; polymorphism; systemic lupus erythematosus; rheumatoid arthritis; susceptibility; clinical features; disease activity parameters		Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are complex autoimmune diseases. CD40 participates in inflammatory response, and promotes fibroblast proliferation, leading to occurrence and progression of SLE, RA. This study explores CD40 gene polymorphisms in SLE and RA patients from a Chinese Han population. Two hundred SLE patients, 340 RA patients, and 900 healthy controls were enrolled. Genomic DNA was extracted from peripheral blood, and six polymorphisms of CD40 gene (rs3765456, rs1569723, rs73115010, rs13040307, rs1883832, and rs4810485) were detected by KASP method. Frequencies of rs1569723 genotypes AA, AC, AA+AC were significantly higher in RA patients as compared to those in healthy controls (P = 0.049, P = 0.024, P = 0.022). Frequencies of genotypes CT, CC+CT of rs1883832, and GT, GG+GT of rs4810485 were significantly higher in RA patients as compared to those in healthy controls (P = 0.012, P = 0.018, P = 0.009, P = 0.015). RA patients carrying rs13040307 C allele and rs73115010 T allele showed increased number of swollen joints. Moreover, frequency of allele T of rs13040307 was lower in SLE patients with positive anti-dsDNA and hematuria as compared to that in patients without these parameters (P = 0.038, P = 0.045). There were increased frequencies of genotype TT, allele T for rs13040307 and lower frequencies of genotype TT, allele T for rs73115010 in lupus patients with myositis (all P<0.05). Interestingly, frequencies of rs1569723 A allele, rs4810485 T allele were higher in SLE patients with myositis, and frequencies of rs3765456 A allele, rs1883832 T allele were lower in SLE patients with myositis (All P<0.05). In conclusion, CD40 gene polymorphisms may associate with susceptibility to SLE and RA.	[Huang, Qi; Xu, Wang-Dong] Southwest Med Univ, Sch Publ Hlth, Dept Evidence Based Med, Luzhou, Peoples R China; [Su, Lin-Chong] Hubei Minzu Univ, Minda Hosp, Dept Rheumatol & Immunol, Enshi, Peoples R China; [Liu, Xiao-Yan] Southwest Med Univ, Dept Nutr & Food Hyg, Sch Publ Hlth, Luzhou, Peoples R China; [Huang, An-Fang] Southwest Med Univ, Dept Rheumatol & Immunol, Affiliated Hosp, Luzhou, Peoples R China	Southwest Medical University; Hubei Minzu University; Southwest Medical University; Southwest Medical University	Xu, WD (corresponding author), Southwest Med Univ, Sch Publ Hlth, Dept Evidence Based Med, Luzhou, Peoples R China.; Huang, AF (corresponding author), Southwest Med Univ, Dept Rheumatol & Immunol, Affiliated Hosp, Luzhou, Peoples R China.	loutch123@163.com; loutch211@163.com	Liu, XiaoYan/GQA-7216-2022		National Natural Science Foundation of China [81701606]; Sichuan Provincial Science and Technology Program [2019YJ0540]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sichuan Provincial Science and Technology Program	This work was supported by grants from the National Natural Science Foundation of China (81701606) and the Sichuan Provincial Science and Technology Program (2019YJ0540).	Aleman-Avila I, 2017, ONCOTARGET, V8, P91876, DOI 10.18632/oncotarget.19621; Amariuta T, 2020, IMMUNOL REV, V294, P188, DOI 10.1111/imr.12827; Bahlo M, 2009, NAT GENET, V41, P824, DOI 10.1038/ng.396; BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606; Chamberlain C, 2017, ANN RHEUM DIS, V76, P1837, DOI 10.1136/annrheumdis-2017-211388; Chen JM, 2015, BMC GENET, V16, DOI 10.1186/s12863-015-0279-8; Durcan L, 2019, LANCET, V393, P2332, DOI 10.1016/S0140-6736(19)30237-5; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Hoogendijk Jessica E, 2004, Neuromuscul Disord, V14, P337, DOI 10.1016/j.nmd.2004.02.006; Hosseini N, 2021, IMMUNOL INVEST, V50, P304, DOI 10.1080/08820139.2020.1764028; Joo YB, 2013, RHEUMATOLOGY, V52, P623, DOI 10.1093/rheumatology/kes339; Karnell JL, 2019, ADV DRUG DELIVER REV, V141, P92, DOI 10.1016/j.addr.2018.12.005; Lee YH, 2015, LUPUS, V24, P1177, DOI 10.1177/0961203315583543; Liu RP, 2012, MOL BIOL REP, V39, P6915, DOI 10.1007/s11033-012-1518-y; Lu YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep16037; Mousa TG, 2019, CLIN RHEUMATOL, V38, P777, DOI 10.1007/s10067-018-4349-y; Nathan MJ, 2004, J IMMUNOL, V172, P6626, DOI 10.4049/jimmunol.172.11.6626; Neogi T, 2010, ARTHRITIS RHEUM-US, V62, P2582, DOI 10.1002/art.27580; Nie DQ, 2016, RHEUMATOL INT, V36, P1657, DOI 10.1007/s00296-016-3570-8; Oparina N, 2019, CURR OPIN RHEUMATOL, V31, P659, DOI 10.1097/BOR.0000000000000654; Ota Y, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-0957-6; Perper SJ, 2019, J IMMUNOL, V203, P58, DOI 10.4049/jimmunol.1900043; Peters AL, 2009, SEMIN IMMUNOL, V21, P293, DOI 10.1016/j.smim.2009.05.012; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Raychaudhuri S, 2008, NAT GENET, V40, P1216, DOI 10.1038/ng.233; Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8; Soussi M, 2019, BIOMARKERS, V24, P530, DOI 10.1080/1354750X.2019.1602168; Tapia-Llanos R, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.1014; Vazgiourakis VM, 2011, ANN RHEUM DIS, V70, P2184, DOI 10.1136/ard.2010.146530; Wu CJ, 2016, RHEUMATOL INT, V36, P45, DOI 10.1007/s00296-015-3345-7; Zhao YL, 2020, POSTGRAD MED J, V96, P149, DOI 10.1136/postgradmedj-2018-136372	32	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2021	12								642929	10.3389/fimmu.2021.642929	http://dx.doi.org/10.3389/fimmu.2021.642929			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RX7YO	33968033	gold, Green Published			2022-12-18	WOS:000647436200001
J	Li, RJE; de Haas, A; Rodriguez, E; Kalay, H; Zaal, A; Jimenez, CR; Piersma, SR; Pham, TV; Henneman, AA; Goeij-de Haas, RRD; van Vliet, SJ; van Kooyk, Y				Li, Rui-Jun Eveline; de Haas, Aram; Rodriguez, Ernesto; Kalay, Hakan; Zaal, Anouk; Jimenez, Connie R.; Piersma, Sander R.; Pham, Thang V.; Henneman, Alex A.; de Goeij-de Haas, Richard R.; van Vliet, Sandra J.; van Kooyk, Yvette			Quantitative Phosphoproteomic Analysis Reveals Dendritic Cell- Specific STAT Signaling After alpha 2-3-Linked Sialic Acid Ligand Binding	FRONTIERS IN IMMUNOLOGY			English	Article						dendritic cell; sialic acid; &#945; 2-3sia; STAT3; STAT5; Phosphoproteomics; Siglec; tolerance		Dendritic cells (DCs) are key initiators of the adaptive immunity, and upon recognition of pathogens are able to skew T cell differentiation to elicit appropriate responses. DCs possess this extraordinary capacity to discern external signals using receptors that recognize pathogen-associated molecular patterns. These can be glycan-binding receptors that recognize carbohydrate structures on pathogens or pathogen-associated patterns that additionally bind receptors, such as Toll-like receptors (TLRs). This study explores the early signaling events in DCs upon binding of alpha 2-3 sialic acid (alpha 2-3sia) that are recognized by Immune inhibitory Sialic acid binding immunoglobulin type lectins. alpha 2-3sias are commonly found on bacteria, e.g. Group B Streptococcus, but can also be expressed by tumor cells. We investigated whether alpha 2-3sia conjugated to a dendrimeric core alters DC signaling properties. Through phosphoproteomic analysis, we found differential signaling profiles in DCs after alpha 2-3sia binding alone or in combination with LPS/TLR4 co-stimulation. alpha 2-3sia was able to modulate the TLR4 signaling cascade, resulting in 109 altered phosphoproteins. These phosphoproteins were annotated to seven biological processes, including the regulation of the IL-12 cytokine pathway. Secretion of IL-10, the inhibitory regulator of IL-12 production, by DCs was found upregulated after overnight stimulation with the alpha 2-3sia dendrimer. Analysis of kinase activity revealed altered signatures in the JAK-STAT signaling pathway. PhosphoSTAT3 (Ser727) and phosphoSTAT5A (Ser780), involved in the regulation of the IL-12 pathway, were both downregulated. Flow cytometric quantification indeed revealed de- phosphorylation over time upon stimulation with alpha 2-3sia, but no alpha 2-6sia. Inhibition of both STAT3 and -5A in moDCs resulted in a similar cytokine secretion profile as alpha-3sia triggered DCs. Conclusively, this study revealed a specific alteration of the JAK-STAT pathway in DCs upon simultaneous alpha 2-3sia and LPS stimulation, altering the IL10:IL-12 cytokine secretion profile associated with reduction of inflammation. Targeted control of the STAT phosphorylation status is therefore an interesting lead for the abrogation of immune escape that bacteria or tumors impose on the host.	[Li, Rui-Jun Eveline; de Haas, Aram; Rodriguez, Ernesto; Kalay, Hakan; Zaal, Anouk; van Vliet, Sandra J.; van Kooyk, Yvette] Vrije Univ Amsterdam, Dept Mol Cell Biol & Immunol, Canc Ctr Amsterdam, Amsterdam Infect & Immun Inst,Amsterdam UMC, Amsterdam, Netherlands; [Jimenez, Connie R.; Piersma, Sander R.; Pham, Thang V.; Henneman, Alex A.; de Goeij-de Haas, Richard R.] Vrije Univ Amsterdam, Dept Med Oncol, Canc Ctr Amsterdam, Amsterdam UMC, Amsterdam, Netherlands	University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam	van Kooyk, Y (corresponding author), Vrije Univ Amsterdam, Dept Mol Cell Biol & Immunol, Canc Ctr Amsterdam, Amsterdam Infect & Immun Inst,Amsterdam UMC, Amsterdam, Netherlands.	y.vankooyk@amsterdamumc.nl		Jimenez, Connie R/0000-0002-3103-4508; van Vliet, Sandra/0000-0003-1811-2687	NWO gravitation program 2013 [ICI-024.002.009]; LSH-TKI project DC4Balance [LSHM18056-SGF]	NWO gravitation program 2013; LSH-TKI project DC4Balance	This work was funded by the NWO gravitation program 2013 granted to the Institute for Chemical Immunology (ICI-024.002.009) and the LSH-TKI project DC4Balance (LSHM18056-SGF). Cancer Center Amsterdam is acknowledged for support of the proteomics infrastructure.	Al-Hassi HO, 2013, MUCOSAL IMMUNOL, V6, P751, DOI 10.1038/mi.2012.113; Alphey MS, 2003, J BIOL CHEM, V278, P3372, DOI 10.1074/jbc.M210602200; Bandala-Sanchez E, 2013, NAT IMMUNOL, V14, P741, DOI 10.1038/ni.2610; Barton BE, 2006, EXPERT OPIN THER TAR, V10, P459, DOI 10.1517/14728222.10.3.459; Beekhof R, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20198981; Bell BD, 2013, NAT IMMUNOL, V14, P364, DOI 10.1038/ni.2541; Berger A, 2014, LEUKEMIA, V28, P629, DOI 10.1038/leu.2013.351; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Braun MC, 2001, MICROBES INFECT, V3, P99, DOI 10.1016/S1286-4579(00)01357-5; Bull C, 2015, ACS NANO, V9, P733, DOI 10.1021/nn5061964; Chaffin DO, 2005, J BACTERIOL, V187, P4615, DOI 10.1128/JB.187.13.4615-4626.2005; Chang YC, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003846; Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056; Duan W, 2004, J IMMUNOL, V172, P7053, DOI 10.4049/jimmunol.172.11.7053; Ferens-Sieczkowska M, 2013, POSTEP HIG MED DOSW, V67, P828; Garcia-Vallejo JJ, 2013, MOL IMMUNOL, V53, P387, DOI 10.1016/j.molimm.2012.09.012; HARDIE DG, 1990, SYM SOC EXP BIOL, V44, P241; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Johannssen T, 2017, TRENDS BIOTECHNOL, V35, P334, DOI 10.1016/j.tibtech.2016.10.002; Krug K, 2019, MOL CELL PROTEOMICS, V18, P576, DOI 10.1074/mcp.TIR118.000943; Li R, 2017, SCI REP-UK, V7, DOI 10.1038/srep45395; Lock K, 2004, IMMUNOBIOLOGY, V209, P199, DOI 10.1016/j.imbio.2004.04.007; Lu H, 2015, J DIABETES COMPLICAT, V29, P465, DOI 10.1016/j.jdiacomp.2015.03.005; Luo WJ, 2017, NUCLEIC ACIDS RES, V45, pW501, DOI 10.1093/nar/gkx372; Luo WJ, 2013, BIOINFORMATICS, V29, P1830, DOI 10.1093/bioinformatics/btt285; Macauley MS, 2014, NAT REV IMMUNOL, V14, P653, DOI 10.1038/nri3737; Marampon F, 2009, MOL CANCER THER, V8, P543, DOI 10.1158/1535-7163.MCT-08-0570; McCracken S, 2005, J BIOL CHEM, V280, P42227, DOI 10.1074/jbc.M507410200; Meliilo JA, 2010, J IMMUNOL, V184, P2638, DOI 10.4049/jimmunol.0902960; Novak N, 2010, CLIN EXP IMMUNOL, V161, P28, DOI 10.1111/j.1365-2249.2010.04162.x; O'Reilly MK, 2009, TRENDS PHARMACOL SCI, V30, P240, DOI 10.1016/j.tips.2009.02.005; Perdicchio M, 2016, ONCOTARGET, V7, P8771, DOI 10.18632/oncotarget.6822; Perdicchio M, 2016, P NATL ACAD SCI USA, V113, P3329, DOI 10.1073/pnas.1507706113; Pereira MS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02754; Piersma SR, 2015, J PROTEOMICS, V127, P247, DOI 10.1016/j.jprot.2015.03.019; Qi H, 2003, INFECT IMMUN, V71, P3337, DOI 10.1128/IAI.71.6.3337-3342.2003; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rodrigues E, 2018, CANCERS, V10, DOI 10.3390/cancers10060207; Rosengren AT, 2005, PROTEOMICS, V5, P3137, DOI 10.1002/pmic.200401151; Severi E, 2007, MICROBIOL-SGM, V153, P2817, DOI 10.1099/mic.0.2007/009480-0; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shi GX, 2004, J IMMUNOL, V172, P5175, DOI 10.4049/jimmunol.172.9.5175; Shi ZH, 2017, MOL CELL BIOCHEM, V430, P161, DOI 10.1007/s11010-017-2963-7; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Tang DL, 2012, IMMUNOL REV, V249, P158, DOI 10.1111/j.1600-065X.2012.01146.x; Uchiyama S, 2019, P NATL ACAD SCI USA, V116, P7465, DOI 10.1073/pnas.1815572116; van der Mijn JC, 2015, J PROTEOMICS, V127, P259, DOI 10.1016/j.jprot.2015.04.006; Varki A, 2008, TRENDS MOL MED, V14, P351, DOI 10.1016/j.molmed.2008.06.002; Varki A, 2011, GLYCOBIOLOGY, V21, P1121, DOI 10.1093/glycob/cwr087; Villarroya-Beltri C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3980; Wojcechowskyj JA, 2013, CELL HOST MICROBE, V13, P613, DOI 10.1016/j.chom.2013.04.011; Xiao H, 2016, P NATL ACAD SCI USA, V113, P10304, DOI 10.1073/pnas.1608069113	52	1	1	1	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2021	12								673454	10.3389/fimmu.2021.673454	http://dx.doi.org/10.3389/fimmu.2021.673454			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RX8PY	33968084	gold, Green Published			2022-12-18	WOS:000647481900001
J	Sundqvist, KG				Sundqvist, Karl-Gosta			CD28 Superagonist Shock and Blockage of Motogenic T Cell Cascade	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						costimulation; motiity; adhesion; activation; CD28			[Sundqvist, Karl-Gosta] Karolinska Inst, Div Clin Immunol, Dept Lab Med, Stockholm, Sweden; [Sundqvist, Karl-Gosta] Karolinska Univ Hosp, Clin Immunol & Transfus Med, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Sundqvist, KG (corresponding author), Karolinska Inst, Div Clin Immunol, Dept Lab Med, Stockholm, Sweden.; Sundqvist, KG (corresponding author), Karolinska Univ Hosp, Clin Immunol & Transfus Med, Stockholm, Sweden.	Karl.Sundqvist@sll.se			Swedish Research Council; Swedish Cancer Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Foundation	This work was supported by the Swedish Research Council and the Swedish Cancer Foundation.	ARENCIBIA I, 1987, EXP CELL RES, V172, P124, DOI 10.1016/0014-4827(87)90099-1; Bartholomaeus P, 2014, J IMMUNOL, V192, P2091, DOI 10.4049/jimmunol.1302461; BENZEEV A, 1980, CELL, V21, P365, DOI 10.1016/0092-8674(80)90473-0; Bergstrom SE, 2015, IMMUNOLOGY, V144, P687, DOI 10.1111/imm.12424; Bergstrom SE, 2013, IMMUNOLOGY, V140, P441, DOI 10.1111/imm.12154; Boucher P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000448; Boucher P, 2011, BIOCHEM PHARMACOL, V81, P1, DOI 10.1016/j.bcp.2010.09.018; CHATENOUD L, 1990, TRANSPLANTATION, V49, P697, DOI 10.1097/00007890-199004000-00009; Clotworthy M, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-5; Eastwood D, 2010, BRIT J PHARMACOL, V161, P512, DOI 10.1111/j.1476-5381.2010.00922.x; Eaton VL, 2008, AM J TRANSPLANT, V8, P507, DOI 10.1111/j.1600-6143.2007.02097.x; El Asmar Z, 2016, J BIOL CHEM, V291, P5116, DOI 10.1074/jbc.M116.714485; Fischer UB, 2007, P NATL ACAD SCI USA, V104, P7181, DOI 10.1073/pnas.0608299104; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; Henrickson SE, 2008, NAT IMMUNOL, V9, P282, DOI 10.1038/ni1559; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; Hunig T, 2005, IMMUNOL LETT, V100, P21, DOI 10.1016/j.imlet.2005.06.012; Ivanoff A, 1999, CLIN EXP METASTAS, V17, P695, DOI 10.1023/A:1006749304315; Jacobs SR, 2008, J IMMUNOL, V180, P4476, DOI 10.4049/jimmunol.180.7.4476; Kim HO, 2017, IMMUNE NETW, V17, P201, DOI 10.4110/in.2017.17.4.201; Li SS, 2006, BLOOD, V108, P3112, DOI 10.1182/blood-2006-04-016832; Li SS, 2005, J IMMUNOL, V174, P654, DOI 10.4049/jimmunol.174.2.654; Lillis AP, 2008, PHYSIOL REV, V88, P887, DOI 10.1152/physrev.00033.2007; Limozin L, 2019, P NATL ACAD SCI USA, V116, P16943, DOI 10.1073/pnas.1902141116; Liu CC, 2015, J NEUROSCI, V35, P5851, DOI 10.1523/JNEUROSCI.5180-14.2015; Liu ZW, 2009, J IMMUNOL, V183, P3616, DOI 10.4049/jimmunol.0804336; Muller N, 2008, J CLIN INVEST, V118, P1405, DOI 10.1172/JCI32698; Murphy-Ullrich JE, 2018, MATRIX BIOL, V68-69, P28, DOI 10.1016/j.matbio.2017.12.009; Oh SA, 2013, J IMMUNOL, V191, P3973, DOI 10.4049/jimmunol.1301843; Panezai J, 2017, IMMUNOLOGY, V152, P308, DOI 10.1111/imm.12770; Romer PS, 2011, BLOOD, V118, P6772, DOI 10.1182/blood-2010-12-319780; Stefanova I, 2002, NATURE, V420, P429, DOI 10.1038/nature01146; Sundqvist KG, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.588642; SUNDQVIST KG, 1986, IMMUNOLOGY, V58, P365; SUNDQVIST KG, 1986, SCAND J IMMUNOL, V23, P647, DOI 10.1111/j.1365-3083.1986.tb02000.x; SUNDQVIST KG, 1993, EXP CELL RES, V206, P100, DOI 10.1006/excr.1993.1125; SUNDQVIST KG, 1987, J IMMUNOL, V138, P825; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Talme T, 2014, IMMUNOLOGY, V142, P176, DOI 10.1111/imm.12229; Ueda H, 2011, P NATL ACAD SCI USA, V108, P17099, DOI 10.1073/pnas.1113703108; WIEBKE JL, 1994, LAB INVEST, V70, P392; Wiemer AJ, 2011, J IMMUNOL, V187, P3663, DOI 10.4049/jimmunol.1100103; WILKINSON PC, 1986, IMMUNOLOGY, V57, P281	43	1	1	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2021	12								670864	10.3389/fimmu.2021.670864	http://dx.doi.org/10.3389/fimmu.2021.670864			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RX2DF	33968078	Green Published, gold			2022-12-18	WOS:000647029800001
J	Xu, LM; Wang, XF; Chen, Y; Soong, L; Chen, YP; Cai, JY; Liang, YJ; Sun, JR				Xu, Lanman; Wang, Xiaofang; Chen, Yan; Soong, Lynn; Chen, Yongping; Cai, Jiyang; Liang, Yuejin; Sun, Jiaren			Metformin Modulates T Cell Function and Alleviates Liver Injury Through Bioenergetic Regulation in Viral Hepatitis	FRONTIERS IN IMMUNOLOGY			English	Article						mTOR; T cell; mitochondria; metformin; viral hepatitis	METABOLISM; MTORC1; AMPK; DIFFERENTIATION; ACTIVATION; GENERATION	Metformin is not only the first-line medication for the treatment of type 2 diabetes, but it is also effective as an anti-inflammatory, anti-oxidative and anti-tumor agent. However, the effect of metformin during viral hepatitis remains elusive. Using an adenovirus (Ad)-induced viral hepatitis mouse model, we found that metformin treatment significantly attenuated liver injury, with reduced serum aspartate transaminase (AST) and alanine transaminase (ALT) levels and liver histological changes, presumably via decreased effector T cell responses. We then demonstrated that metformin reduced mTORC1 activity in T cells from infected mice, as evidenced by decreased phosphorylation of ribosome protein S6 (p-S6). The inhibitory effects on the mTORC1 signaling by metformin was dependent on the tuberous sclerosis complex 1 (TSC1). Mechanistically, metformin treatment modulated the phosphorylation of dynamin-related protein 1 (Drp-1) and mitochondrial fission 1 protein (FIS1), resulting in increased mass in effector T cells. Moreover, metformin treatment promoted mitochondrial superoxide production, which can inhibit excessive T cell activation in viral hepatitis. Together, our results revealed a protective role and therapeutic potential of metformin against liver injury in acute viral hepatitis via modulating effector T cell activation via regulating the mTORC1 pathway and mitochondrial functions.	[Xu, Lanman] Ningbo Univ, Affiliated Lihuili Hosp, Dept Infect Dis & Liver Dis,Ningbo Med Ctr, Ningbo Inst Innovat Combined Med & Engn,Lihuil, Ningbo, Peoples R China; [Xu, Lanman; Wang, Xiaofang; Soong, Lynn; Liang, Yuejin; Sun, Jiaren] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; [Wang, Xiaofang] Cent South Univ, Xiangya Hosp, Key Lab Viral Hepatitis Hunan, Dept Infect Dis, Changsha, Peoples R China; [Chen, Yan; Cai, Jiyang] Univ Texas Med Branch, Dept Ophthalmol, Galveston, TX 77555 USA; [Soong, Lynn; Sun, Jiaren] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA; [Soong, Lynn; Liang, Yuejin; Sun, Jiaren] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA; [Chen, Yongping] Wenzhou Med Univ, Affiliated Hosp 1, Dept Infect Dis, Zhejiang Prov Key Lab Accurate Diag & Treatment C, Wenzhou, Peoples R China	Ningbo University; University of Texas System; University of Texas Medical Branch Galveston; Central South University; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Wenzhou Medical University	Liang, YJ; Sun, JR (corresponding author), Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.; Sun, JR (corresponding author), Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.; Liang, YJ; Sun, JR (corresponding author), Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.; Chen, YP (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Infect Dis, Zhejiang Prov Key Lab Accurate Diag & Treatment C, Wenzhou, Peoples R China.	did@wzhospital.cn; yu2liang@utmb.edu; jisun@utmb.edu			NIH [EY028773, AI132674, AI153586]; UTMB Institute of Human Infections AMP; Immunity Pilot grant	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UTMB Institute of Human Infections AMP; Immunity Pilot grant	This work was supported in part by grants from the NIH (EY028773 to JC and JS, AI132674 to LS, and AI153586 to YL), as well as the UTMB Institute of Human Infections & Immunity Pilot grant (to LS and YL).	Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933; Babcook MA, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.500; Ben-Sahra I, 2017, CURR OPIN CELL BIOL, V45, P72, DOI 10.1016/j.ceb.2017.02.012; Bhalla K, 2012, CANCER PREV RES, V5, P544, DOI 10.1158/1940-6207.CAPR-11-0228; Bharath LP, 2020, CELL METAB, V32, P44, DOI 10.1016/j.cmet.2020.04.015; Blagih J, 2015, IMMUNITY, V42, P41, DOI 10.1016/j.immuni.2014.12.030; Brandt A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43228-0; Bray GA, 2012, DIABETES CARE, V35, P731, DOI 10.2337/dc11-1299; Buck MD, 2016, CELL, V166, P63, DOI 10.1016/j.cell.2016.05.035; Campbell EL, 2019, NAT REV GASTRO HEPAT, V16, P106, DOI 10.1038/s41575-018-0079-5; Chakraborty A, 2011, DIABETES RES CLIN PR, V93, P56, DOI 10.1016/j.diabres.2010.11.030; Chen CJ, 2018, GUT, V67, P595, DOI 10.1136/gutjnl-2017-315407; Lopez KGDC, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01373; Curatolo P, 2012, CURR NEUROPHARMACOL, V10, P404, DOI 10.2174/157015912804143595; del Campo JA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191805; Devadas S, 2002, J EXP MED, V195, P59, DOI 10.1084/jem.20010659; Dimeloe S, 2017, IMMUNOLOGY, V150, P35, DOI 10.1111/imm.12655; Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310; Friedman JR, 2014, NATURE, V505, P335, DOI 10.1038/nature12985; Frossi B, 2008, MOL IMMUNOL, V45, P58, DOI 10.1016/j.molimm.2007.05.008; Gnanaprakasam JNR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01075; Hardie DG, 2014, J INTERN MED, V276, P543, DOI 10.1111/joim.12268; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hou LF, 2013, J IMMUNOL, V190, P621, DOI 10.4049/jimmunol.1201970; Howell JJ, 2017, CELL METAB, V25, P463, DOI 10.1016/j.cmet.2016.12.009; Huang H, 2013, AUTOPHAGY, V9, P175, DOI 10.4161/auto.22791; Huang HL, 2020, IMMUNOL REV, V295, P15, DOI 10.1111/imr.12845; Jackson SH, 2004, NAT IMMUNOL, V5, P818, DOI 10.1038/ni1096; Jezek J, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7010013; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; Kauffman Megan E, 2016, React Oxyg Species (Apex), V2, P361, DOI 10.20455/ros.2016.865; KNODELL R, 1981, HEPATOLOGY, V1; Koh SJ, 2014, J GASTROEN HEPATOL, V29, P502, DOI 10.1111/jgh.12435; Kuhla A, 2019, J ALZHEIMERS DIS, V68, P1415, DOI 10.3233/JAD-181017; Ladeiras-Lopes R, 2015, EXPERT OPIN THER TAR, V19, P869, DOI 10.1517/14728222.2015.1025051; Lee CF, 2015, CELL REP, V13, P760, DOI 10.1016/j.celrep.2015.09.036; Lei Y, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0184-9; Li Y, 2013, BIOMED REP, V1, P57, DOI 10.3892/br.2012.18; Liang YJ, 2013, J IMMUNOL, V190, P5666, DOI 10.4049/jimmunol.1300117; Lipton JO, 2014, NEURON, V84, P275, DOI 10.1016/j.neuron.2014.09.034; Liu M, 2001, Expert Rev Mol Med, V2001, P1, DOI 10.1017/S1462399401002812; Lv ZQ, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00191; Ma EH, 2017, CURR OPIN IMMUNOL, V46, P45, DOI 10.1016/j.coi.2017.04.004; Ma SJ, 2016, ONCOTARGET, V7, P66202, DOI 10.18632/oncotarget.11033; Ma SJ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006888; Mankouri J, 2010, P NATL ACAD SCI USA, V107, P11549, DOI 10.1073/pnas.0912426107; Mishra P, 2016, J CELL BIOL, V212, P379, DOI 10.1083/jcb.201511036; Moshfegh CM, 2019, REDOX BIOL, V27, DOI 10.1016/j.redox.2019.101141; Nakashima K, 2011, MICROBIOL IMMUNOL, V55, P774, DOI 10.1111/j.1348-0421.2011.00382.x; Pollizzi KN, 2015, TRENDS IMMUNOL, V36, P13, DOI 10.1016/j.it.2014.11.005; Ramanathan A, 2009, P NATL ACAD SCI USA, V106, P22229, DOI 10.1073/pnas.0912074106; Romero-Gomez M, 2009, HEPATOLOGY, V50, P1702, DOI 10.1002/hep.23206; Rotermund C, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00400; Saito T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070010; Salmond RJ, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00122; Sena LA, 2013, IMMUNITY, V38, P225, DOI 10.1016/j.immuni.2012.10.020; Simeoni L, 2015, BIOL CHEM, V396, P555, DOI 10.1515/hsz-2014-0312; STUMVOLL M, 1995, NEW ENGL J MED, V333, P550, DOI 10.1056/NEJM199508313330903; Tondera D, 2005, J CELL SCI, V118, P3049, DOI 10.1242/jcs.02415; Tsai WL, 2017, ONCOTARGET, V8, P91928, DOI 10.18632/oncotarget.20248; Vakifahmetoglu-Norberg H, 2017, BIOCHEM BIOPH RES CO, V482, P426, DOI 10.1016/j.bbrc.2016.11.088; van der Windt GJW, 2012, IMMUNITY, V36, P68, DOI 10.1016/j.immuni.2011.12.007; Wai T, 2016, TRENDS ENDOCRIN MET, V27, P105, DOI 10.1016/j.tem.2015.12.001; Waickman AT, 2012, IMMUNOL REV, V249, P43, DOI 10.1111/j.1600-065X.2012.01152.x; Welz M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07213-x; Xun YH, 2014, J VIRAL HEPATITIS, V21, P597, DOI 10.1111/jvh.12187; Yan JB, 2011, HEPATOLOGY, V53, P1455, DOI 10.1002/hep.24270; Yang K, 2011, NAT IMMUNOL, V12, P888, DOI 10.1038/ni.2068; Yarosz EL, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e14; Yi PP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04260-0; Yin YM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0835; Yuan HM, 2012, INT IMMUNOPHARMACOL, V12, P682, DOI 10.1016/j.intimp.2012.01.015; Zhou J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102863	73	1	1	2	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2021	12								638575	10.3389/fimmu.2021.638575	http://dx.doi.org/10.3389/fimmu.2021.638575			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RX3BR	33968030	Green Published, gold			2022-12-18	WOS:000647101200001
J	Mueller, TM; Becker, E; Wiendl, M; Schulze, LL; Voskens, C; Voelkl, S; Kremer, AE; Neurath, MF; Zundler, S				Mueller, Tanja M.; Becker, Emily; Wiendl, Maximilian; Schulze, Lisa Lou; Voskens, Caroline; Voelkl, Simon; Kremer, Andreas E.; Neurath, Markus F.; Zundler, Sebastian			Circulating Adaptive Immune Cells Expressing the Gut Homing Marker alpha 4 beta 7 Integrin Are Decreased in COVID-19	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; SARS-CoV-2 infection; T cell trafficking; integrins; gut homing	WUHAN; ACE2	Background Infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a wide range of symptoms including gastrointestinal manifestations, and intestinal epithelial cells are a target of the virus. However, it is unknown how the intestinal immune system contributes to systemic immune responses in coronavirus disease 2019 (COVID-19). Methods We characterized peripheral blood lymphocytes from patients with active COVID-19 and convalescent patients as well as healthy controls by flow cytometry. Results The frequency and absolute number of circulating memory T and B cells expressing the gut homing integrin alpha 4 beta 7 integrin was reduced during COVID-19, whether gastrointestinal symptoms were present or not. While total IgA-expressing B cells were increased, gut-imprinted B cells with IgA expression were stable. Conclusion COVID-19 is associated with a decrease in circulating adaptive immune cells expressing the key gut homing marker alpha 4 beta 7 suggesting that these cells are preferentially recruited to extra-intestinal tissues independently of alpha 4 beta 7 or that the systemic immune response against SARS-CoV-2 is at least numerically dominated by extraintestinal, particularly pulmonary, immune cell priming.	[Mueller, Tanja M.; Becker, Emily; Wiendl, Maximilian; Schulze, Lisa Lou; Kremer, Andreas E.; Neurath, Markus F.; Zundler, Sebastian] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Med 1, Erlangen, Germany; [Mueller, Tanja M.; Becker, Emily; Wiendl, Maximilian; Schulze, Lisa Lou; Kremer, Andreas E.; Neurath, Markus F.; Zundler, Sebastian] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany; [Voskens, Caroline] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Dermatol, Erlangen, Germany; [Voelkl, Simon] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Hematol & Clin Oncol, Dept Internal Med 5, Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg	Zundler, S (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Med 1, Erlangen, Germany.; Zundler, S (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany.	sebastian.zundler@uk-erlangen.de		Muller, Tanja Martina/0000-0003-2768-277X; Volkl, Simon/0000-0003-2193-3048; Bosch-Voskens, Caroline/0000-0001-9398-005X	German Research Foundation (DFG) [ZU 377/4-1, TRR241TP C04]; Interdisciplinary Center for Clinical Research (IZKF) of the University Erlangen-Nuremberg [J63, A84]; Wilhelm Sander-Stiftung [2020.045.1]; Bayerische Forschungsforderung; Bavarian State Ministry for Sciences and Art [TP-10, TP-11]; National research network for University Medicine (NUM)	German Research Foundation (DFG)(German Research Foundation (DFG)); Interdisciplinary Center for Clinical Research (IZKF) of the University Erlangen-Nuremberg; Wilhelm Sander-Stiftung; Bayerische Forschungsforderung; Bavarian State Ministry for Sciences and Art; National research network for University Medicine (NUM)	German Research Foundation (DFG, ZU 377/4-1 to SZ, TRR241TP C04 to CV and MFN), Interdisciplinary Center for Clinical Research (IZKF) of the University Erlangen-Nuremberg (J63, A84 to SZ), Wilhelm Sander-Stiftung (2020.045.1 to SV), "Bayerische Forschungsforderung" (SV), Bavarian State Ministry for Sciences and Art (TP-10 and TP-11 to AK), and National research network for University Medicine (NUM to AK).	Bakdash G, 2015, MUCOSAL IMMUNOL, V8, P265, DOI 10.1038/mi.2014.64; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9; Briskin M, 1997, AM J PATHOL, V151, P97; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chen SY, 2018, J THORAC DIS, V10, pS2280, DOI 10.21037/jtd.2018.03.168; Choudhry A, 2016, VACCINE, V34, P4558, DOI 10.1016/j.vaccine.2016.07.033; D'Amico F, 2020, CLIN GASTROENTEROL H, V18, P1663, DOI 10.1016/j.cgh.2020.04.001; Goffin E, 2019, J VIROL, V93, DOI 10.1128/JVI.00237-19; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Han CQ, 2020, AM J GASTROENTEROL, V115, P916, DOI 10.14309/ajg.0000000000000664; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2022926, 10.1056/NEJMoa2021436]; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926; Karlsson AC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe8063; Kim SV, 2013, SCIENCE, V340, P1456, DOI 10.1126/science.1237013; Kumar VCS, 2020, BMJ OPEN GASTROENTER, V7, DOI 10.1136/bmjgast-2020-000417; Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; Liebowitz D, 2020, LANCET INFECT DIS, V20, P435, DOI 10.1016/S1473-3099(19)30584-5; Mehan Aman, 2020, Ther Adv Vaccines Immunother, V8, p2515135520946503, DOI 10.1177/2515135520946503; Molenaar R, 2011, J IMMUNOL, V186, P1934, DOI 10.4049/jimmunol.1001672; Mora JR, 2006, SCIENCE, V314, P1157, DOI 10.1126/science.1132742; Moss P., 2020, ROBUST SARS COV 2 SP, DOI [10.1101/2020.11.01.362319, DOI 10.1101/2020.11.01.362319, 10.1101/ 2020.11.01.362319]; Muhl L, 2021, BMC GASTROENTEROL, V21, DOI 10.1186/s12876-021-01604-z; Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x; Neurath MF, 2020, GUT, V69, P1335, DOI 10.1136/gutjnl-2020-321269; Neurath MF, 2019, NAT IMMUNOL, V20, P970, DOI 10.1038/s41590-019-0415-0; Nguyen LP, 2015, NAT IMMUNOL, V16, P207, DOI 10.1038/ni.3079; Patankar JV, 2021, GASTROENTEROLOGY, V160, P925, DOI 10.1053/j.gastro.2020.10.021; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Seo GY, 2013, J LEUKOCYTE BIOL, V94, P325, DOI 10.1189/jlb.0313128; Stenstad H, 2006, BLOOD, V107, P3447, DOI 10.1182/blood-2005-07-2860; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Wei XS, 2020, CLIN GASTROENTEROL H, V18, P1753, DOI 10.1016/j.cgh.2020.04.030; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055; Yazdanpanah F, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117900; Zhang H, 2020, INT J INFECT DIS, V96, P19, DOI 10.1016/j.ijid.2020.04.027; Zundler S, 2019, GUT, V68, P1688, DOI 10.1136/gutjnl-2018-317977; Zundler S, 2019, NAT IMMUNOL, V20, P288, DOI 10.1038/s41590-018-0298-5; Zundler S, 2017, IMMUNOL REV, V278, P263, DOI 10.1111/imr.12544; Zundler S, 2017, INFLAMM BOWEL DIS, V23, P379, DOI 10.1097/MIB.0000000000001029	48	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 20	2021	12								639329	10.3389/fimmu.2021.639329	http://dx.doi.org/10.3389/fimmu.2021.639329			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RW6MN	33959123	Green Published, gold			2022-12-18	WOS:000646636700001
J	Chen, XJ; Ren, AQ; Zheng, L; Zheng, ED				Chen, Xiao-Juan; Ren, Ai-Qun; Zheng, Liang; Zheng, En-Dian			Predictive Value of KDM5C Alterations for Immune Checkpoint Inhibitors Treatment Outcomes in Patients With Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						immune checkpoint inhibitors; biomarker; KDM5C; outcome; prognosis		Lysine (K)-specific demethylase 5C (KDM5C) plays a significant role in the tumor cell proliferation, invasion, drug resistance and the regulation of tumor-related gene expression. Here, we aimed to investigate its predictive value in patients with cancers received immune checkpoint inhibitors (ICIs). We explored the predictive value of KDM5C alterations and the association between KDM5C alteration and immune landscape by using published cohort with clinical outcome and sequenced data from online database. The frequency of KDM5C alterations was 2.1% across 48045 tumor samples with different cancers from 185 studies. KDM5C alterations were correlated with markedly inferior overall survival (OS, 53 vs. 102 months, P<0.0001) than those without. However, in ICI-treated group, patients with KDM5C alterations had a substantially prolonged OS than the wild-type group (not reached vs. 18 months, P=0.0041). The predictive value of KDM5C alterations for ICI treatment outcome was not observed in patients with microsatellite-stable tumors (P=0.2875). Intriguingly, patients with non-small-cell lung cancer and KDM5C alterations receiving ICI had the better progression-free survival than wild type group (13.2 vs. 3.2 months, P=0.0762). Mechanistically, KDM5C altered tumors had dramatically higher TMB level and was associated with significantly higher level of CD8+ T cell infiltration and T effector signature. In conclusion, KDM5C alterations was correlated with enhanced tumor immunogenicity and inflamed anti-tumor immunity, thus resulting in better treatment outcome in cancer patients receiving ICIs.	[Chen, Xiao-Juan] Zhejiang Chinese Med Univ, Grad Sch, Dept Clin Med, Hangzhou, Peoples R China; [Chen, Xiao-Juan; Ren, Ai-Qun; Zheng, Liang; Zheng, En-Dian] Wenzhou Med Univ, Wenzhou Clin Inst 3, Wenzhou Peoples Hosp, Dept Gastroenterol, Wenzhou, Peoples R China	Zhejiang Chinese Medical University; Wenzhou Medical University	Chen, XJ (corresponding author), Zhejiang Chinese Med Univ, Grad Sch, Dept Clin Med, Hangzhou, Peoples R China.; Chen, XJ (corresponding author), Wenzhou Med Univ, Wenzhou Clin Inst 3, Wenzhou Peoples Hosp, Dept Gastroenterol, Wenzhou, Peoples R China.	366535255@qq.com						Brahmer JR, 2014, SEMIN ONCOL, V41, P126, DOI 10.1053/j.seminoncol.2013.12.014; Braun DA, 2020, NAT MED, V26, P909, DOI 10.1038/s41591-020-0839-y; Carlo MI, 2017, KIDNEY CANCER, V1, P49, DOI 10.3233/KCA-160003; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen XH, 2018, CANCER RES, V78, P1418, DOI 10.1158/0008-5472.CAN-17-2118; Chen YP, 2017, THERANOSTICS, V7, P3585, DOI 10.7150/thno.21471; Davoli T, 2017, SCIENCE, V355, DOI 10.1126/science.aaf8399; de Cubas AA, 2018, NAT REV UROL, V15, P599, DOI 10.1038/s41585-018-0052-7; Dizman N, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000953; Galluzzi L, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat7807; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gossage L, 2014, GENE CHROMOSOME CANC, V53, P38, DOI 10.1002/gcc.22116; Guo XQ, 2017, J KIDNEY CANCER VHL, V4, P1, DOI 10.15586/jkcvhl.2017.56; Hanse RJ, 2016, NAT MED, V22, P1342, DOI 10.1038/nm.4191; Hong Z, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108793; Ji XN, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1798-4; Keenan TE, 2019, NAT MED, V25, P389, DOI 10.1038/s41591-019-0382-x; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Lin HS, 2018, BIOMED PHARMACOTHER, V107, P1205, DOI 10.1016/j.biopha.2018.08.041; Lin PH, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2021.12430; Marcus L, 2019, CLIN CANCER RES, V25, P3753, DOI 10.1158/1078-0432.CCR-18-4070; Monaghan L, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00705; Motzer RJ, 2020, CANCER CELL, V38, P803, DOI 10.1016/j.ccell.2020.10.011; Nassar AH, 2020, MOL CANCER THER, V19, P690, DOI 10.1158/1535-7163.MCT-19-0642; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Rondinelli B, 2015, J CLIN INVEST, V125, P4625, DOI 10.1172/JCI81040; Rondinelli B, 2015, NUCLEIC ACIDS RES, V43, P2560, DOI 10.1093/nar/gkv090; Sacher AG, 2016, JAMA ONCOL, V2, P1217, DOI 10.1001/jamaoncol.2016.0639; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Wynder C, 2010, EPIGENOMICS-UK, V2, P407, DOI 10.2217/EPI.10.12; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333	33	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2021	12								664847	10.3389/fimmu.2021.664847	http://dx.doi.org/10.3389/fimmu.2021.664847			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RV7ZN	33953726	Green Published, gold			2022-12-18	WOS:000646047000001
J	Saccon, E; Mikaeloff, F; Ivern, PF; Vegvari, A; Sonnerborg, A; Neogi, U; van Domselaar, R				Saccon, Elisa; Mikaeloff, Flora; Ivern, Pol Figueras; Vegvari, Akos; Sonnerborg, Anders; Neogi, Ujjwal; van Domselaar, Robert			Cytotoxic Lymphocytes Target HIV-1 Gag Through Granzyme M-Mediated Cleavage	FRONTIERS IN IMMUNOLOGY			English	Article						cytotoxic lymphocyte; granzyme M; Gag (HIV-1); HIV-1; immune control	IMMUNODEFICIENCY-VIRUS TYPE-1; P6(GAG); VPR; SEQUENCE	Untreated HIV-1 infection leads to a slow decrease in CD4(+) T cell lymphocytes over time resulting in increased susceptibility to opportunistic infections (acquired immunodeficiency syndrome, AIDS) and ultimately death of the infected individual. Initially, the host's immune response controls the infection, but cannot eliminate the HIV-1 from the host. Cytotoxic lymphocytes are the key effector cells in this response and can mediate crucial antiviral responses through the release of a set of proteases called granzymes towards HIV-1-infected cells. However, little is known about the immunological molecular mechanisms by which granzymes could control HIV-1. Since we noted that HIV-1 subtype C (HIV-1C) Gag with the tetrapeptide insertion PYKE contains a putative granzyme M (GrM) cleavage site (KEPL) that overlaps with the PYKE insertion, we analyzed the proteolytic activity of GrM towards Gag. Immunoblot analysis showed that GrM could cleave Gag proteins from HIV-1B and variants from HIV-1C of which the Gag-PYKE variant was cleaved with extremely high efficiency. The main cleavage site was directly after the insertion after leucine residue 483. GrM-mediated cleavage of Gag was also observed in co-cultures using cytotoxic lymphocytes as effector cells and this cleavage could be inhibited by a GrM inhibitor peptide. Altogether, our data indicate towards a noncytotoxic immunological mechanism by which GrM-positive cytotoxic lymphocytes target the HIV-1 Gag protein within infected cells to potentially control HIV-1 infection. This mechanism could be exploited in new therapeutic strategies to treat HIV-1-infected patients to improve immunological control of the infection.	[Saccon, Elisa; Mikaeloff, Flora; Sonnerborg, Anders; Neogi, Ujjwal] Karolinska Inst, Dept Lab Med, Div Clin Microbiol, ANA Future Lab, Stockholm, Sweden; [Ivern, Pol Figueras; Sonnerborg, Anders; van Domselaar, Robert] Karolinska Inst, Dept Med Huddinge, Div Infect Dis, ANA Future Lab, Stockholm, Sweden; [Vegvari, Akos] Karolinska Inst, Div Chem 1, Dept Med Biochem & Biophys, Stockholm, Sweden; [Sonnerborg, Anders; Neogi, Ujjwal] Univ Missouri, Mol Microbiol & Immunol, Columbia, MO USA	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Missouri System; University of Missouri Columbia	van Domselaar, R (corresponding author), Karolinska Inst, Dept Med Huddinge, Div Infect Dis, ANA Future Lab, Stockholm, Sweden.	robert.van.domselear.1@ki.se	Neogi, Ujjwal/ABF-1172-2021; Neogi, Ujjwal/E-4274-2012	Neogi, Ujjwal/0000-0002-0844-3338; Vegvari, Akos/0000-0002-1287-0906	Swedish Research Council [2016-01675, 2017-05848]; CARE [825673]; Stockholm County Council [ALF 20190451, CIMED 20200645]; Swedish Research Council Establishment Grant [2017-01330]; Swedish Physicians Against AIDS Research Foundation [Fob2017-0005]; Stiftelsen Tornspiran; KI Research Foundation [2018-01640]	Swedish Research Council(Swedish Research CouncilEuropean Commission); CARE; Stockholm County Council(Stockholm County Council); Swedish Research Council Establishment Grant; Swedish Physicians Against AIDS Research Foundation; Stiftelsen Tornspiran; KI Research Foundation	The study is funded by grants from the Swedish Research Council (2016-01675 and 2017-05848, AS, https://www.vr.se/), CARE under grant agreement no. 825673 (AS, https://cordis.europa.eu/project/id/825673), and the Stockholm County Council (ALF 20190451 and CIMED 20200645, AS, https://forskningsstod.vmi.se/), Swedish Research Council Establishment Grant (2017-01330, UN, https://www.vr.se/), The Swedish Physicians Against AIDS Research Foundation (Fob2017-0005, RvD, http://www.aidsfond.se/), Stiftelsen Tornspiran (Sep. 2018, RvD, http://stiftelsentornspiran.se/), and KI Research Foundation Grant (2018-01640, RvD, https://ki.se/).	Ajasin DO, 2019, ELIFE, V8, DOI 10.7554/eLife.35546; Amogne W, 2016, AIDS RES HUM RETROV, V32, P471, DOI 10.1089/aid.2015.0380; Andrade F, 2010, IMMUNOL REV, V235, P128, DOI 10.1111/j.0105-2896.2010.00909.x; Bachand F, 1999, J BIOL CHEM, V274, P9083, DOI 10.1074/jbc.274.13.9083; Bengsch B, 2018, IMMUNITY, V48, P1029, DOI 10.1016/j.immuni.2018.04.026; Bovenschen N, 2010, IMMUNOL REV, V235, P117, DOI 10.1111/j.0105-2896.2010.00889.x; Chaturbhuj D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27162-1; Chen G, 2001, BLOOD, V98, P156, DOI 10.1182/blood.V98.1.156; Chowdhury D, 2008, ANNU REV IMMUNOL, V26, P389, DOI 10.1146/annurev.immunol.26.021607.090404; Clayton KL, 2018, NAT IMMUNOL, V19, P475, DOI 10.1038/s41590-018-0085-3; de Koning PJA, 2010, MOL IMMUNOL, V47, P903, DOI 10.1016/j.molimm.2009.10.001; de Poot SAH, 2014, CELL DEATH DIFFER, V21, P416, DOI 10.1038/cdd.2013.155; de Poot SAH, 2011, BIOCHEM J, V437, P431, DOI 10.1042/BJ20110210; Fisher RD, 2007, CELL, V128, P841, DOI 10.1016/j.cell.2007.01.035; Harari A, 2009, J VIROL, V83, P2862, DOI 10.1128/JVI.02528-08; Hersperger AR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000917; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Jouvenet N, 2008, NATURE, V454, P236, DOI 10.1038/nature06998; Jouvenet N, 2006, PLOS BIOL, V4, P2296, DOI 10.1371/journal.pbio.0040435; Knickelbein JE, 2008, SCIENCE, V322, P268, DOI 10.1126/science.1164164; Kondo E, 1996, J VIROL, V70, P159, DOI 10.1128/JVI.70.1.159-164.1996; KONDO E, 1995, J VIROL, V69, P2759, DOI 10.1128/JVI.69.5.2759-2764.1995; LU YL, 1995, J VIROL, V69, P6873, DOI 10.1128/JVI.69.11.6873-6879.1995; Mahrus S, 2005, CHEM BIOL, V12, P567, DOI 10.1016/j.chembiol.2005.03.006; Malbec M, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-80; Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010; Munro JB, 2014, J VIROL, V88, P3577, DOI 10.1128/JVI.03353-13; Neogi U, 2016, AIDS RES HUM RETROV, V32, P80, DOI [10.1089/aid.2015.0266, 10.1089/AID.2015.0266]; Neogi U, 2014, AIDS, V28, P2319, DOI 10.1097/QAD.0000000000000419; Neogi U, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099390; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ono A, 2004, J VIROL, V78, P1552, DOI 10.1128/JVI.78.3.1552-1563.2004; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Suck G, 2005, EXP HEMATOL, V33, P1160, DOI 10.1016/j.exphem.2005.06.024; Sundquist WI, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006924; Tully DC, 2010, AIDS, V24, P1577, DOI 10.1097/QAD.0b013e32833999e1; van Domselaar R, 2013, CELL DEATH DIFFER, V20, P419, DOI 10.1038/cdd.2012.132; van Domselaar R, 2019, J VIROL, V93, DOI 10.1128/JVI.00077-19; van Domselaar R, 2011, REV MED VIROL, V21, P301, DOI 10.1002/rmv.697; van Domselaar R, 2010, J IMMUNOL, V185, P7605, DOI 10.4049/jimmunol.1001503; Willforss J, 2019, J PROTEOME RES, V18, P732, DOI 10.1021/acs.jproteome.8b00523; Zhang B, 2008, INT IMMUNOPHARMACOL, V8, P989, DOI 10.1016/j.intimp.2008.03.001; Zhang W, 2018, EBIOMEDICINE, V27, P40, DOI 10.1016/j.ebiom.2017.11.031	44	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2021	12								669347	10.3389/fimmu.2021.669347	http://dx.doi.org/10.3389/fimmu.2021.669347			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RV7ZA	33953729	Green Submitted, Green Published, gold			2022-12-18	WOS:000646045700001
J	Zhang, WB; Zhu, CH; Xiao, FN; Liu, XD; Xie, AH; Chen, FM; Dong, PP; Lin, PD; Zheng, CY; Zhang, H; Gong, H; Wu, YK				Zhang, Weibin; Zhu, Chunhua; Xiao, Fangnan; Liu, Xiaodong; Xie, Anhua; Chen, Fangman; Dong, Panpan; Lin, Pingdong; Zheng, Chenyang; Zhang, Hong; Gong, Hui; Wu, Yunkun			pH-Controlled Release of Antigens Using Mesoporous Silica Nanoparticles Delivery System for Developing a Fish Oral Vaccine	FRONTIERS IN IMMUNOLOGY			English	Article						vaccine; nanoparticle; oral delivery; large yellow croaker (Larimichthys crocea); immune response	IL-4	The development of effective vaccines and delivery systems in aquaculture is a long-term challenge for controlling emerging and reemerging infections. Cost-efficient and advanced nanoparticle vaccines are of tremendous applicability in prevention of infectious diseases of fish. In this study, dihydrolipoamide dehydrogenase (DLDH) antigens of Vibrio alginolyticus were loaded into mesoporous silica nanoparticles (MSN) to compose the vaccine delivery system. Hydroxypropyl methylcellulose phthalate (HP55) was coated to provide protection of immunogen. The morphology, loading capacity, acid-base triggered release were characterized and the toxicity of nanoparticle vaccine was determined in vitro. Further, the vaccine immune effects were evaluated in large yellow croaker via oral administration. In vitro studies confirmed that the antigen could be stable in enzymes-rich artificial gastric fluid and released under artificial intestinal fluid environment. In vitro cytotoxicity assessment demonstrated the vaccines within 120 mu g/ml have good biocompatibility for large yellow croaker kidney cells. Our data confirmed that the nanoparticle vaccine in vivo could elicit innate and adaptive immune response, and provide good protection against Vibrio alginolyticus challenge. The MSN delivery system prepared may be a potential candidate carrier for fish vaccine via oral administration feeding. Further, we provide theoretical basis for developing convenient, high-performance, and cost-efficient vaccine against infectious diseases in aquaculture.	[Zhang, Weibin; Xiao, Fangnan; Dong, Panpan; Lin, Pingdong; Zheng, Chenyang; Zhang, Hong; Wu, Yunkun] Fujian Normal Univ, Coll Life Sci, Prov Univ Key Lab Cellular Stress Response & Meta, Fuzhou, Peoples R China; [Zhang, Weibin; Zhu, Chunhua; Liu, Xiaodong; Xie, Anhua; Gong, Hui] Fujian Acad Agr Sci, Inst Anim Husb & Vet Med, Inst Biotechnol, Fuzhou, Peoples R China; [Zhang, Weibin; Zhu, Chunhua; Chen, Fangman] Chinese Acad Sci, Fujian Inst Res Struct Matter, State Key Lab Struct Chem, Fuzhou, Peoples R China	Fujian Normal University; Fujian Academy of Agricultural Sciences; Chinese Academy of Sciences; Fujian Institute of Research on the Structure of Matter, CAS	Wu, YK (corresponding author), Fujian Normal Univ, Coll Life Sci, Prov Univ Key Lab Cellular Stress Response & Meta, Fuzhou, Peoples R China.; Gong, H (corresponding author), Fujian Acad Agr Sci, Inst Anim Husb & Vet Med, Inst Biotechnol, Fuzhou, Peoples R China.	ghxfjm@163.com; wuyk@gnu.edu.cn		Liu, Xiaodong/0000-0002-9802-4232	National Thousand Talents Program of China; STS Project of Chinese Academy of Sciences and Fujian Province [2016T3041]; Key Project of Fujian Province [2017N0031]; Fujian Province Natural Science Foundation of China [2019J01280]; Special Funds of the Central Government Guiding Local Science and Technology Development [2020L3008]; National Key R&D Program of China [2019YFD0900102]; Fujian Provincial Public Research Institute of Fundamental Research [2019R1026-4]	National Thousand Talents Program of China; STS Project of Chinese Academy of Sciences and Fujian Province; Key Project of Fujian Province; Fujian Province Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Special Funds of the Central Government Guiding Local Science and Technology Development; National Key R&D Program of China; Fujian Provincial Public Research Institute of Fundamental Research	This work was supported by the National Thousand Talents Program of China, the STS Project of Chinese Academy of Sciences and Fujian Province (2016T3041), the Key Project of Fujian Province (2017N0031), the Fujian Province Natural Science Foundation of China (2019J01280), Special Funds of the Central Government Guiding Local Science and Technology Development (2020L3008), National Key R&D Program of China (2019YFD0900102), Fujian Provincial Public Research Institute of Fundamental Research (2019R1026-4).	Carroll EC, 2016, IMMUNITY, V44, P597, DOI 10.1016/j.immuni.2016.02.004; Chen Q, 2008, DIS AQUAT ORGAN, V80, P181, DOI 10.3354/dao01933; Croissant JG, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700831; Dadar M, 2017, REV FISH SCI AQUAC, V25, P184, DOI 10.1080/23308249.2016.1261277; Duan JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074606; Ebrahimian M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01077; FAO, 2018, STAT WORLDS FISH AQ; Fifis T, 2004, J IMMUNOL, V173, P3148, DOI 10.4049/jimmunol.173.5.3148; Fredriksen BN, 2011, VACCINE, V29, P8338, DOI 10.1016/j.vaccine.2011.08.087; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Gour N, 2015, CYTOKINE, V75, P68, DOI 10.1016/j.cyto.2015.05.014; Gregory AE, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00013; Harun NO, 2011, FISH SHELLFISH IMMUN, V31, P107, DOI 10.1016/j.fsi.2011.04.010; Hwang ES, 2005, J EXP MED, V202, P1289, DOI 10.1084/jem.20051044; Janson G, 2017, BIOINFORMATICS, V33, P444, DOI 10.1093/bioinformatics/btw638; Kole S, 2019, FISH SHELLFISH IMMUN, V91, P136, DOI 10.1016/j.fsi.2019.05.017; Laing KJ, 2004, DEV COMP IMMUNOL, V28, P443, DOI 10.1016/j.dci.2003.09.006; Liu L, 2016, AQUACULT REP, V3, P220, DOI 10.1016/j.aqrep.2016.04.004; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lo D, 1999, IMMUNOL REV, V169, P225, DOI 10.1111/j.1600-065X.1999.tb01318.x; Mahony D, 2014, NANOSCALE, V6, P6617, DOI 10.1039/c4nr01202j; Mao KQ, 2018, FISH SHELLFISH IMMUN, V80, P180, DOI 10.1016/j.fsi.2018.06.002; Mao SR, 2007, INT J PHARM, V334, P137, DOI 10.1016/j.ijpharm.2006.10.036; Marasini N, 2014, EXPERT REV VACCINES, V13, P1361, DOI 10.1586/14760584.2014.936852; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; Mody KT, 2013, NANOSCALE, V5, P5167, DOI 10.1039/c3nr00357d; Mohamedi SA, 2001, ANTIVIR RES, V49, P83, DOI 10.1016/S0166-3542(00)00142-X; Mu PF, 2018, FISH SHELLFISH IMMUN, V81, P309, DOI 10.1016/j.fsi.2018.07.040; Nakajima N, 2014, FISH SHELLFISH IMMUN, V38, P135, DOI 10.1016/j.fsi.2014.03.013; Pang HY, 2016, VACCINE, V34, P1225, DOI 10.1016/j.vaccine.2015.11.001; Peng X, 2018, INT J PHARMACEUT, V549, P115, DOI 10.1016/j.ijpharm.2018.07.047; Pereiro P, 2016, FISH SHELLFISH IMMUN, V59, P25, DOI 10.1016/j.fsi.2016.10.021; Plebanski M, 2013, METHODS, V60, P225, DOI 10.1016/j.ymeth.2013.05.018; Popat A, 2011, NANOSCALE, V3, P2801, DOI 10.1039/c1nr10224a; Rigsby RE, 2016, BIOCHEM MOL BIOL EDU, V44, P433, DOI 10.1002/bmb.20966; Sahdev P, 2014, PHARM RES-DORDR, V31, P2563, DOI 10.1007/s11095-014-1419-y; Salgado-Miranda C, 2013, EXPERT REV VACCINES, V12, P567, DOI [10.1586/ERV.13.38, 10.1586/erv.13.38]; Shaalan M, 2016, NANOMED-NANOTECHNOL, V12, P701, DOI 10.1016/j.nano.2015.11.005; Siegrist F, 2011, J INTERF CYTOK RES, V31, P183, DOI 10.1089/jir.2010.0112; Silin DS, 2007, EXPERT OPIN DRUG DEL, V4, P323, DOI 10.1517/17425247.4.4.323; Smith JD, 2015, CURR OPIN BIOTECH, V34, P217, DOI 10.1016/j.copbio.2015.03.014; Vinay TN, 2018, REV FISH SCI AQUAC, V26, P29, DOI 10.1080/23308249.2017.1334625; Wang XW, 2006, J VIROL METHODS, V133, P76, DOI 10.1016/j.jviromet.2005.10.025; Wang Y, 2015, FISH SHELLFISH IMMUN, V47, P732, DOI 10.1016/j.fsi.2015.10.029; Wang ZH, 2016, FISH SHELLFISH IMMUN, V57, P350, DOI 10.1016/j.fsi.2016.08.051; Wangkahart E, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03054; Xu C, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00290; Xu JL., 2018, CHINA FISHERY STAT Y; Xu WJ, 2009, MATER RES BULL, V44, P606, DOI 10.1016/j.materresbull.2008.07.001; Yan DW, 2018, J VIROL, V92, DOI [10.1128/JVI.00427-18, 10.1128/jvi.00427-18]; Yang PP, 2012, CHEM SOC REV, V41, P3679, DOI 10.1039/c2cs15308d; Zaharoff DA, 2007, VACCINE, V25, P2085, DOI 10.1016/j.vaccine.2006.11.034; Zaman M, 2013, METHODS, V60, P226, DOI 10.1016/j.ymeth.2013.04.014; Zhang K, 2011, MICROPOR MESOPOR MAT, V143, P401, DOI 10.1016/j.micromeso.2011.03.026; Zhang L, 2018, INT J NANOMED, V13, P2973, DOI 10.2147/IJN.S154743; Zhang L, 2016, ACS APPL MATER INTER, V8, P34933, DOI 10.1021/acsami.6b10470; Zhang L, 2016, BIOMATERIALS, V77, P307, DOI 10.1016/j.biomaterials.2015.11.009; Zheng FR, 2016, AQUACULTURE, V452, P263, DOI 10.1016/j.aquaculture.2015.11.013; Zheng LB, 2017, FISH SHELLFISH IMMUN, V71, P239, DOI 10.1016/j.fsi.2017.09.056; Zhou YX, 2018, ACTA PHARM SIN B, V8, P165, DOI 10.1016/j.apsb.2018.01.007; Zhu JF, 2015, CYTOKINE, V75, P14, DOI 10.1016/j.cyto.2015.05.010; Zhu WT, 2019, FISH SHELLFISH IMMUN, V87, P379, DOI 10.1016/j.fsi.2019.01.033	62	1	1	6	17	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2021	12								644396	10.3389/fimmu.2021.644396	http://dx.doi.org/10.3389/fimmu.2021.644396			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RV7ZR	33953716	Green Published, gold			2022-12-18	WOS:000646047400001
J	Bhattacharya, S; Hu, ZC; Butte, AJ				Bhattacharya, Sanchita; Hu, Zicheng; Butte, Atul J.			Opportunities and Challenges in Democratizing Immunology Datasets	FRONTIERS IN IMMUNOLOGY			English	Review						immunology; open-access; democratization; data reuse; public repositories		The field of immunology is rapidly progressing toward a systems-level understanding of immunity to tackle complex infectious diseases, autoimmune conditions, cancer, and beyond. In the last couple of decades, advancements in data acquisition techniques have presented opportunities to explore untapped areas of immunological research. Broad initiatives are launched to disseminate the datasets siloed in the global, federated, or private repositories, facilitating interoperability across various research domains. Concurrently, the application of computational methods, such as network analysis, meta-analysis, and machine learning have propelled the field forward by providing insight into salient features that influence the immunological response, which was otherwise left unexplored. Here, we review the opportunities and challenges in democratizing datasets, repositories, and community-wide knowledge sharing tools. We present use cases for repurposing open-access immunology datasets with advanced machine learning applications and more.	[Bhattacharya, Sanchita; Hu, Zicheng; Butte, Atul J.] Univ Calif San Francisco, Bakar Computat Hlth Sci Inst, San Francisco, CA 94143 USA; [Bhattacharya, Sanchita; Hu, Zicheng; Butte, Atul J.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bhattacharya, S (corresponding author), Univ Calif San Francisco, Bakar Computat Hlth Sci Inst, San Francisco, CA 94143 USA.; Bhattacharya, S (corresponding author), Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA.	Sanchita.Bhattacharya@ucsf.edu			National Institute of Allergy and Infectious Diseases ImmPort [HHSN316201200036W]	National Institute of Allergy and Infectious Diseases ImmPort	This work was supported by the National Institute of Allergy and Infectious Diseases ImmPort contract HHSN316201200036W. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Amezquita RA, 2020, NAT METHODS, V17, P137, DOI 10.1038/s41592-019-0654-x; [Anonymous], ImmGen at 15 | Nature Immunology . Available at:; [Anonymous], BUILDING HIGH QUALIT; [Anonymous], OP ACC DAT COMP RES; [Anonymous], COMPUTATIONAL RESOUR; [Anonymous], WELCOME GEN3; [Anonymous], PLASMA PROTEOMICS ID; [Anonymous], STRIDES Initiative | Data Science at NIH. Available at:; [Anonymous], RECOUNT WORKFLOW ACC; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247; Bhattacharya S, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.15; Breden F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01418; Bui AAT, 2017, J BIOMED INFORM, V69, P115, DOI 10.1016/j.jbi.2017.03.017; Burns NS, 2017, NEW ENGL J MED, V376, P2205, DOI 10.1056/NEJMp1705323; Cohen L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01338; Demaria O, 2019, NATURE, V574, P45, DOI 10.1038/s41586-019-1593-5; FAIRsharing Registry WG, 2014, CONN MET STAND REP P; Finak G, 2016, SCI REP-UK, V6, DOI 10.1038/srep20686; Geifman N, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0525-y; Gielis S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02820; Grossman RL, 2016, NEW ENGL J MED, V375, P1109, DOI 10.1056/NEJMp1607591; Haynes WA, 2017, BIOCOMPUTING, P144, DOI 10.1142/9789813207813_0015; Hu ZC, 2020, P NATL ACAD SCI USA, V117, P21373, DOI 10.1073/pnas.2003026117; Hu ZC, 2018, CELL REP, V24, P1377, DOI 10.1016/j.celrep.2018.07.003; Huber W, 2015, NAT METHODS, V12, P115, DOI [10.1038/NMETH.3252, 10.1038/nmeth.3252]; Jiang BT, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016273; Kidd BA, 2016, NAT BIOTECHNOL, V34, P47, DOI 10.1038/nbt.3367; King G, 2007, SOCIOL METHOD RES, V36, P173, DOI 10.1177/0049124107306660; Lau JW, 2017, CANCER RES, V77, pE3, DOI 10.1158/0008-5472.CAN-17-0387; Maecker HT, 2012, NAT REV IMMUNOL, V12, P191, DOI 10.1038/nri3158; Margolis R, 2014, J AM MED INFORM ASSN, V21, P957, DOI 10.1136/amiajnl-2014-002974; McClain MT, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21289-y; Newell EW, 2012, IMMUNITY, V36, P142, DOI 10.1016/j.immuni.2012.01.002; Noy N, 2019, WEB CONFERENCE 2019: PROCEEDINGS OF THE WORLD WIDE WEB CONFERENCE (WWW 2019), P1365, DOI 10.1145/3308558.3313685; Orange DE, 2018, ARTHRITIS RHEUMATOL, V70, P690, DOI 10.1002/art.40428; Rubelt F, 2017, NAT IMMUNOL, V18, P1274, DOI 10.1038/ni.3873; Sauteraud R, 2016, J IMMUNOL, V196; Spidlen J, 2012, CYTOM PART A, V81A, P727, DOI 10.1002/cyto.a.22106; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Sweeney TE, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf7165; Trisovic A, 2020, P RECS 2020 P 3 INTE, P15, DOI [10.1145/3391800.3398173, DOI 10.1145/3391800.3398173]; Van Horn JD, 2018, BIOCOMPUT-PAC SYM, P292; Wilk AJ, 2020, NAT MED, V26, P1070, DOI [10.1038/s41591-020-0944-y, 10.1101/2020.04.17.20069930]; Wilkinson MD, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.18; Witt M., RE3DATA OPEN INFRAST; Zalocusky KA, 2018, CELL REP, V25, P513, DOI 10.1016/j.celrep.2018.09.021	48	1	1	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 16	2021	12								647536	10.3389/fimmu.2021.647536	http://dx.doi.org/10.3389/fimmu.2021.647536			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RV0QQ	33936065	Green Published, gold			2022-12-18	WOS:000645542800001
J	Etna, MP; Severa, M; Licursi, V; Pardini, M; Cruciani, M; Rizzo, F; Giacomini, E; Macchia, G; Palumbo, O; Stallone, R; Carella, M; Livingstone, M; Negri, R; Pellegrini, S; Coccia, EM				Etna, Marilena P.; Severa, Martina; Licursi, Valerio; Pardini, Manuela; Cruciani, Melania; Rizzo, Fabiana; Giacomini, Elena; Macchia, Gianfranco; Palumbo, Orazio; Stallone, Raffaella; Carella, Massimo; Livingstone, Mark; Negri, Rodolfo; Pellegrini, Sandra; Coccia, Eliana M.			Genome-Wide Gene Expression Analysis of Mtb-Infected DC Highlights the Rapamycin-Driven Modulation of Regulatory Cytokines via the mTOR/GSK-3 beta Axis	FRONTIERS IN IMMUNOLOGY			English	Article						host-directed therapy; Mycobacterium tuberculosis; tuberculosis; rapalogs; IFN; autophagy; transcriptome; translatome	TUBERCULOSIS	In human primary dendritic cells (DC) rapamycin-an autophagy inducer and protein synthesis inhibitor-overcomes the autophagy block induced by Mycobacterium tuberculosis (Mtb) and promotes a Th1 response via IL-12 secretion. Here, the immunostimulatory activity of rapamycin in Mtb-infected DC was further investigated by analyzing both transcriptome and translatome gene profiles. Hundreds of differentially expressed genes (DEGs) were identified by transcriptome and translatome analyses of Mtb-infected DC, and some of these genes were found further modulated by rapamycin. The majority of transcriptome-associated DEGs overlapped with those present in the translatome, suggesting that transcriptionally stimulated mRNAs are also actively translated. In silico analysis of DEGs revealed significant changes in intracellular cascades related to cytokine production, cytokine-induced signaling and immune response to pathogens. In particular, rapamycin treatment of Mtb-infected DC caused an enrichment of IFN-beta, IFN-lambda and IFN-stimulated gene transcripts in the polysome-associated RNA fraction. In addition, rapamycin led to an increase of IL-12, IL-23, IL-1 beta, IL-6, and TNF-alpha but to a reduction of IL-10. Interestingly, upon silencing or pharmacological inhibition of GSK-3 beta, the rapamycin-driven modulation of the pro- and anti-inflammatory cytokine balance was lost, indicating that, in Mtb-infected DC, GSK-3 beta acts as molecular switch for the regulation of the cytokine milieu. In conclusion, our study sheds light on the molecular mechanism by which autophagy induction contributes to DC activation during Mtb infection and points to rapamycin and GSK-3 beta modulators as promising compounds for host-directed therapy in the control of Mtb infection.	[Etna, Marilena P.; Severa, Martina; Pardini, Manuela; Cruciani, Melania; Rizzo, Fabiana; Giacomini, Elena; Coccia, Eliana M.] Ist Super Sanita, Dept Infect Dis, Rome, Italy; [Licursi, Valerio; Negri, Rodolfo] Sapienza Univ, Dept Biol & Biotechnol, Rome, Italy; [Macchia, Gianfranco] Ist Super Sanita, Prote Core Facil, Rome, Italy; [Palumbo, Orazio; Stallone, Raffaella; Carella, Massimo] Fdn IRCCS Casa Sollievo Sofferenza, Div Med Genet, San Giovanni Rotondo, Italy; [Livingstone, Mark; Pellegrini, Sandra] Inst Pasteur, INSERM, Cytokine Signaling Unit, Paris, France	Istituto Superiore di Sanita (ISS); Sapienza University Rome; Istituto Superiore di Sanita (ISS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Etna, MP; Coccia, EM (corresponding author), Ist Super Sanita, Dept Infect Dis, Rome, Italy.	marilenapaola.etna@iss.it; eliana.coccia@iss.it	Etna, Marilena Paola/ABA-8433-2021; PALUMBO, ORAZIO/C-1133-2014; Pellegrini, Sandra/G-5546-2015; Severa, Martina/J-8782-2016	Etna, Marilena Paola/0000-0003-2551-393X; PALUMBO, ORAZIO/0000-0001-6583-3482; Pellegrini, Sandra/0000-0001-5837-7589; Severa, Martina/0000-0002-0411-4545	Italian Ministry of Health [RF-2010-235199]; Lazio Region [FILAS-RU-2014-1036]	Italian Ministry of Health(Ministry of Health, Italy); Lazio Region(Regione Lazio)	This work was supported by grant RF-2010-235199 (to EC) from Italian Ministry of Health and grant FILAS-RU-2014-1036 (to EC) from Lazio Region. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abebe F, 2019, INT REV IMMUNOL, V38, P172, DOI 10.1080/08830185.2019.1632842; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Baindara P, 2019, MICROB PATHOGENESIS, V130, P156, DOI 10.1016/j.micpath.2019.03.003; Burkert S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010067; Cerni S, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020232; Chai QY, 2020, CELL MOL IMMUNOL, V17, P901, DOI 10.1038/s41423-020-0502-z; Cheng Y, 2018, J EXP MED, V215, P2919, DOI 10.1084/jem.20180508; Choudhary E, 2020, J PROTEOME RES, V19, P2316, DOI 10.1021/acs.jproteome.9b00895; Collins AC, 2015, CELL HOST MICROBE, V17, P820, DOI 10.1016/j.chom.2015.05.005; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Duan L, 2016, BIOCHEM BIOPH RES CO, V473, P1229, DOI 10.1016/j.bbrc.2016.04.045; Etna MP, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006790; Etna MP, 2015, SCI REP-UK, V5, DOI 10.1038/srep17078; Etna MP, 2014, SEMIN IMMUNOL, V26, P543, DOI 10.1016/j.smim.2014.09.011; Francois-Newton V, 2012, BIOCHEM J, V446, P509, DOI 10.1042/BJ20120541; Francois-Newton V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022200; Gagliardi MC, 2009, INFECT IMMUN, V77, P4947, DOI 10.1128/IAI.00607-09; Gupta A, 2016, PHARM RES-DORDR, V33, P1899, DOI 10.1007/s11095-016-1926-0; Gygli SM, 2017, FEMS MICROBIOL REV, V41, P354, DOI 10.1093/femsre/fux011; Hare NJ, 2015, PROTEOMICS, V15, P3020, DOI 10.1002/pmic.201400610; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jones RG, 2017, IMMUNITY, V46, P730, DOI 10.1016/j.immuni.2017.04.028; Joshi S, 2010, CYTOKINE, V52, P123, DOI 10.1016/j.cyto.2010.03.019; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kaur S, 2014, J BIOL CHEM, V289, P6581, DOI 10.1074/jbc.M113.537852; Kaur S, 2012, P NATL ACAD SCI USA, V109, P7723, DOI 10.1073/pnas.1118122109; Lehman JA, 2003, J BIOL CHEM, V278, P28130, DOI 10.1074/jbc.M300376200; Liu CH, 2017, CELL MOL IMMUNOL, V14, P963, DOI 10.1038/cmi.2017.88; Liu XY, 2011, J IMMUNOL, V187, P2559, DOI 10.4049/jimmunol.1100963; Livingstone M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133482; Lyadova IV, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/854507; Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221; O'Leary S, 2011, AM J RESP CELL MOL, V45, P172, DOI 10.1165/rcmb.2010-0319OC; Paik S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.603951; Park DW, 2012, J MED FOOD, V15, P788, DOI 10.1089/jmf.2012.2194; Piccirillo CA, 2014, NAT IMMUNOL, V15, P503, DOI 10.1038/ni.2891; Ramachandra L, 2001, J EXP MED, V194, P1421, DOI 10.1084/jem.194.10.1421; Ranjbar S, 2019, ISCIENCE, V22, P299, DOI 10.1016/j.isci.2019.11.001; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rodionova E, 2007, BLOOD, V109, P1584, DOI 10.1182/blood-2006-06-028951; Romagnoli A, 2012, AUTOPHAGY, V8, P1357, DOI 10.4161/auto.20881; Saini NK, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.133, 10.1038/NMICROBIOL.2016.133]; Shin S, 2011, P NATL ACAD SCI USA, V108, pE1204, DOI 10.1073/pnas.1110195108; Simeone R, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002507; Snyder JP, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03145; Surewicz K, 2004, CELL IMMUNOL, V228, P34, DOI 10.1016/j.cellimm.2004.03.007; Tiberi S, 2018, LANCET INFECT DIS, V18, pE183, DOI 10.1016/S1473-3099(18)30110-5; Turnquist HR, 2010, BLOOD, V115, P4758, DOI 10.1182/blood-2009-10-251488; Upadhyay R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35023-0; Wang HZ, 2011, J IMMUNOL, V186, P5217, DOI 10.4049/jimmunol.1002513; Watson RO, 2015, CELL HOST MICROBE, V17, P811, DOI 10.1016/j.chom.2015.05.004; Weichhart T, 2008, IMMUNITY, V29, P565, DOI 10.1016/j.immuni.2008.08.012; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WHO, 2010, WORLD MALARIA REPORT 2010, P1; Yang DQ, 2020, MOL IMMUNOL, V118, P153, DOI 10.1016/j.molimm.2019.12.013; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118	57	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 16	2021	12								649475	10.3389/fimmu.2021.649475	http://dx.doi.org/10.3389/fimmu.2021.649475			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RV2LB	33936070	Green Published, gold			2022-12-18	WOS:000645669000001
J	Mi, LG; Wang, Y; Xu, H; Wang, Y; Wu, J; Dai, H; Zhang, Y				Mi, Ligu; Wang, Yan; Xu, Hui; Wang, Yu; Wu, Jia; Dai, Hui; Zhang, Yu			PRAK Promotes the Pathogen Clearance by Macrophage Through Regulating Autophagy and Inflammasome Activation	FRONTIERS IN IMMUNOLOGY			English	Article						autophagy; pathogen; phagocytosis; macrophage; p38-regulated; activated protein kinase		The p38 regulated/activated protein kinase (PRAK) is a protein kinase downstream of p38MAPK. The present study investigated its function in the macrophage. Myeloid-specific deletion of Prak resulted in a significant reduction in F4/80(+)CD11b(+) peritoneal macrophages with decreased expression of MHC-II and CD80. Upon infection with Listeria monocytogenes, Prak-deficient mice demonstrated an increased mortality, which was accompanied by a higher bacterial load in multiple tissues and elevated levels of proinflammatory cytokines in the serum. While the Prak-deficient macrophage showed similar potency in phagocytosis assays, its bactericidal activity was severely impaired. Moreover, Prak deficiency was associated with defects in ROS production, inflammasome activation as well as autophagy induction. Therefore, PRAK critically contributes to the clearance of intracellular pathogens by affecting multiple aspects of the macrophage function.	[Mi, Ligu; Wang, Yan; Wu, Jia; Dai, Hui; Zhang, Yu] Peking Univ, Dept Immunol, Sch Basic Med Sci, Natl Hlth Commiss NHC,Key Lab Med Immunol, Beijing, Peoples R China; [Mi, Ligu] Shihezi Univ, Sch Basic Med Sci, Dept Immunol, Shihezi, Xinjiang, Peoples R China; [Xu, Hui; Wang, Yu; Zhang, Yu] Jinzhou Med Univ, Inst Biol Sci, Jinzhou, Peoples R China	Peking University; Shihezi University; Jinzhou Medical University	Dai, H; Zhang, Y (corresponding author), Peking Univ, Dept Immunol, Sch Basic Med Sci, Natl Hlth Commiss NHC,Key Lab Med Immunol, Beijing, Peoples R China.; Zhang, Y (corresponding author), Jinzhou Med Univ, Inst Biol Sci, Jinzhou, Peoples R China.	daihui@bjmu.edu.cn; zhangyu007@bjmu.edu.cn			National Natural Science Foundation of China [31970840, 81972041]; Beijing Natural Science Foundation [7172112]; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2019PT320006]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences	This work was supported by grants from the National Natural Science Foundation of China (31970840; 81972041), Beijing Natural Science Foundation (7172112) and Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2019PT320006).	BoseDasgupta S, 2018, SEMIN IMMUNOPATHOL, V40, P577, DOI 10.1007/s00281-018-0710-0; Carr KD, 2011, EUR J IMMUNOL, V41, P2666, DOI 10.1002/eji.201041363; Castillo EF, 2012, P NATL ACAD SCI USA, V109, pE3168, DOI 10.1073/pnas.1210500109; Conlan JW, 1997, INFECT IMMUN, V65, P630, DOI 10.1128/IAI.65.2.630-635.1997; CONLAN JW, 1994, J EXP MED, V179, P259, DOI 10.1084/jem.179.1.259; Crisan TO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018666; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Edelson BT, 2011, IMMUNITY, V35, P236, DOI 10.1016/j.immuni.2011.06.012; Flannagan RS, 2009, NAT REV MICROBIOL, V7, P355, DOI 10.1038/nrmicro2128; Franchi L, 2010, EUR J IMMUNOL, V40, P611, DOI 10.1002/eji.200940180; Guo XZJ, 2017, SEMIN IMMUNOPATHOL, V39, P541, DOI 10.1007/s00281-017-0636-y; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Harris J, 2017, MOL IMMUNOL, V86, P10, DOI 10.1016/j.molimm.2017.02.013; Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911; Henault J, 2012, IMMUNITY, V37, P986, DOI 10.1016/j.immuni.2012.09.014; Kaneko M, 2016, YONSEI MED J, V57, P283, DOI 10.3349/ymj.2016.57.2.283; Kim JJ, 2013, J KOREAN MED SCI, V28, P1415, DOI 10.3346/jkms.2013.28.10.1415; Koh GCKW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054961; Kumar AT, 2009, INDIAN J CRIT CARE M, V13, P74, DOI 10.4103/0972-5229.56052; Lee JPW, 2016, AUTOPHAGY, V12, P907, DOI 10.1080/15548627.2016.1164358; Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005; Li P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122753; Li YY, 2011, INT J MOL MED, V27, P337, DOI 10.3892/ijmm.2011.596; Menu P, 2011, CLIN EXP IMMUNOL, V166, P1, DOI 10.1111/j.1365-2249.2011.04440.x; Moens U, 2013, BIOL CHEM, V394, P1115, DOI 10.1515/hsz-2013-0149; Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980; PINTO AJ, 1991, J LEUKOCYTE BIOL, V49, P579, DOI 10.1002/jlb.49.6.579; RAKHMILEVICH AL, 1995, J LEUKOCYTE BIOL, V57, P827, DOI 10.1002/jlb.57.6.827; ROGERS HW, 1993, INFECT IMMUN, V61, P5090, DOI 10.1128/IAI.61.12.5090-5096.1993; Saitoh T, 2016, J ALLERGY CLIN IMMUN, V138, P28, DOI 10.1016/j.jaci.2016.05.009; Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421; Saxami G, 2017, BENEF MICROBES, V8, P615, DOI 10.3920/BM2016.0202; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Shi C, 2011, J IMMUNOL, V187, P5293, DOI 10.4049/jimmunol.1101721; Takahama M, 2018, IMMUNOL REV, V281, P62, DOI 10.1111/imr.12613; Tattoli I, 2012, AUTOPHAGY, V8, P1848, DOI 10.4161/auto.21863; Thakur PB, 2019, MSYSTEMS, V4, DOI 10.1128/mSystems.00453-19; Vasanthakumar A, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a028506; Wang Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01252	39	1	1	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 16	2021	12								618561	10.3389/fimmu.2021.618561	http://dx.doi.org/10.3389/fimmu.2021.618561			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RV0TA	33936034	Green Published, gold			2022-12-18	WOS:000645549000001
J	Saettini, F; Fazio, G; Moratto, D; Galbiati, M; Zucchini, N; Ippolito, D; Dinelli, ME; Imberti, L; Mauri, M; Melzi, ML; Bonanomi, S; Gerussi, A; Pinelli, M; Barisani, C; Bugarin, C; Chiarini, M; Giacomelli, M; Piazza, R; Cazzaniga, G; Invernizzi, P; Giliani, SC; Badolato, R; Biondi, A				Saettini, Francesco; Fazio, Grazia; Moratto, Daniele; Galbiati, Marta; Zucchini, Nicola; Ippolito, Davide; Dinelli, Marco Emilio; Imberti, Luisa; Mauri, Mario; Melzi, Maria Luisa; Bonanomi, Sonia; Gerussi, Alessio; Pinelli, Marinella; Barisani, Chiara; Bugarin, Cristina; Chiarini, Marco; Giacomelli, Mauro; Piazza, Rocco; Cazzaniga, Giovanni; Invernizzi, Pietro; Giliani, Silvia Clara; Badolato, Raffaele; Biondi, Andrea			Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis	FRONTIERS IN IMMUNOLOGY			English	Article						primary immumunodeficiencies; DOCK 8; EBV; Epstein-Barr Virus; sclerosing cholangitis; thrombocytopenia; lymphopenia; somatic reversion		DOCK8 deficiency is a combined immunodeficiency due to biallelic variants in dedicator of cytokinesis 8 (DOCK8) gene. The disease has a wide clinical spectrum encompassing recurrent infections (candidiasis, viral and bacterial infections), virally driven malignancies and immune dysregulatory features, including autoimmune (cytopenia and vasculitis) as well as allergic disorders (eczema, asthma, and food allergy). Hypomorphic function and somatic reversion of DOCK8 has been reported to result in incomplete phenotype without IgE overproduction. Here we describe a case of DOCK8 deficiency in a 8-year-old Caucasian girl. The patient's disease was initially classified as autoimmune thrombocytopenia, which then evolved toward a combined immunodeficiency phenotype with recurrent infections, persistent EBV infection and lymphoproliferation. Two novel variants (one deletion and one premature stop codon) were characterized, resulting in markedly reduced, but not absent, DOCK8 expression. Somatic reversion of the DOCK8 deletion was identified in T cells. Hypomorphic function and somatic reversion were associated with restricted T cell repertoire, decreased STAT5 phosphorylation and impaired immune synapse functioning in T cells. Although the patient presented with incomplete phenotype (absence of markedly increase IgE and eosinophil count), sclerosing cholangitis was incidentally detected, thus indicating that hypomorphic function and somatic reversion of DOCK8 may delay disease progression but do not necessarily prevent from severe complications.	[Saettini, Francesco; Bonanomi, Sonia; Biondi, Andrea] Fdn MBBM, Dept Pediat, Pediat Hematol Outpatient Clin, Monza, Italy; [Fazio, Grazia; Galbiati, Marta; Bugarin, Cristina; Cazzaniga, Giovanni; Biondi, Andrea] Univ Milano Bicocca, Ctr Ric Tettamanti, Monza, Italy; [Moratto, Daniele; Chiarini, Marco] ASST Spedali Civili, Diagnost Dept, Flow Cytometry Lab, Brescia, Italy; [Zucchini, Nicola] ASST Monza, San Gerardo Hosp, Div Pathol, Monza, Italy; [Ippolito, Davide] San Gerardo Hosp, Dept Diagnost Radiol, Monza, Italy; [Dinelli, Marco Emilio] ASST Monza, Endoscopy Unit, San Gerardo Hosp, Monza, Italy; [Imberti, Luisa] ASST Spedali Civili, Ctr Ric Ematooncol AIL CREA, Brescia, Italy; [Mauri, Mario; Piazza, Rocco; Cazzaniga, Giovanni] Univ Milano Bicocca, Dept Med & Surg, Monza, Italy; [Mauri, Mario; Piazza, Rocco; Cazzaniga, Giovanni] San Gerardo Hosp, Monza, Italy; [Melzi, Maria Luisa] Fdn MBBM, Dept Pediat, Monza, Italy; [Gerussi, Alessio; Invernizzi, Pietro] Univ Milano Bicocca, Div Gastroenterol, Ctr Autoimmune Liver Dis, Dept Med & Surg, Monza, Italy; [Gerussi, Alessio; Invernizzi, Pietro] San Gerardo Hosp, European Reference Network Hepatol Dis ERN RARE L, Monza, Italy; [Pinelli, Marinella; Barisani, Chiara; Giacomelli, Mauro; Giliani, Silvia Clara] Univ Brescia, Spedali Civili, Cytogenet & Med Genet Unit, Dept Mol & Translat Med,A Nocivelli Inst Mol Med, Brescia, Italy; [Badolato, Raffaele] Univ Brescia, ASST Spedali Civili, Dept Clin & Expt Sci, Pediat Clin, Brescia, Italy; [Badolato, Raffaele] Univ Brescia, A Nocivelli Inst Mol Med A, Brescia, Italy	University of Milano-Bicocca; Hospital Spedali Civili Brescia; San Gerardo Hospital; San Gerardo Hospital; San Gerardo Hospital; Hospital Spedali Civili Brescia; University of Milano-Bicocca; San Gerardo Hospital; University of Milano-Bicocca; San Gerardo Hospital; Hospital Spedali Civili Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Brescia; University of Brescia	Saettini, F (corresponding author), Fdn MBBM, Dept Pediat, Pediat Hematol Outpatient Clin, Monza, Italy.	f.saettini@gmail.com	Giacomelli, Mauro/AGX-9755-2022; Zucchini, Nicola/A-6916-2017; Badolato, Raffaele/A-8081-2010; Invernizzi, Pietro/AAB-8367-2022	Zucchini, Nicola/0000-0003-4997-2807; Badolato, Raffaele/0000-0001-7375-5410; Invernizzi, Pietro/0000-0003-3262-1998; Gerussi, Alessio/0000-0002-5086-0514; Imberti, Luisa/0000-0002-2075-8391; Biondi, Andrea/0000-0002-6757-6173	Italian Ministry of University and Research (MIUR) - Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic); AMAF Monza ONLUS; AIRCS	Italian Ministry of University and Research (MIUR) - Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic)(Ministry of Education, Universities and Research (MIUR)); AMAF Monza ONLUS; AIRCS	AG and PI are members of the European Reference Network on Hepatological Diseases (ERN RARE LIVER). These authors thank AMAF Monza ONLUS and AIRCS for the unrestricted research funding. We also acknowledge that this research was partially supported by the Italian Ministry of University and Research (MIUR) - Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic).	Alroqi FJ, 2017, J CLIN IMMUNOL, V37, P811, DOI 10.1007/s10875-017-0451-1; Aydin SE, 2015, J CLIN IMMUNOL, V35, P189, DOI 10.1007/s10875-014-0126-0; Barbouche MR, 2018, CELL MOL IMMUNOL, V15, P610, DOI 10.1038/cmi.2017.140; Ben Yakov G, 2020, J ALLER CL IMM-PRACT, V8, P3663, DOI 10.1016/j.jaip.2020.06.021; Costamagna Guido, 2021, VideoGIE, V6, P176, DOI 10.1016/j.vgie.2020.12.004; Davis BR, 2009, IMMUNOL RES, V44, P127, DOI 10.1007/s12026-008-8091-4; Dinwiddie DL, 2013, J ALLERGY CLIN IMMUN, V131, P594, DOI 10.1016/j.jaci.2012.10.062; Engelhardt KR, 2015, J ALLERGY CLIN IMMUN, V136, P402, DOI 10.1016/j.jaci.2014.12.1945; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Janssen E, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94298; Janssen E, 2014, J ALLERGY CLIN IMMUN, V134, P1365, DOI 10.1016/j.jaci.2014.07.042; Jing H, 2014, J ALLERGY CLIN IMMUN, V133, P1667, DOI 10.1016/j.jaci.2014.03.025; Kienzler AK, 2016, CLIN IMMUNOL, V163, P17, DOI 10.1016/j.clim.2015.12.003; Pillay BA, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI142434; Randall KL, 2011, J EXP MED, V208, P2305, DOI 10.1084/jem.20110345; Rodrigues F, 2004, J PEDIATR-US, V145, P333, DOI 10.1016/j.jpeds.2004.05.037; Saettini F, 2020, CLIN IMMUNOL, V218, DOI 10.1016/j.clim.2020.108525; Saettini F, 2021, ACTA PAEDIATR, V110, P643, DOI 10.1111/apa.15593; Saettini F, 2021, BLOOD, V137, P493, DOI 10.1182/blood.2020006441; Saettini F, 2020, BRIT J HAEMATOL, V189, pE169, DOI 10.1111/bjh.16585; Su HC, 2010, CURR OPIN ALLERGY CL, V10, P515, DOI 10.1097/ACI.0b013e32833fd718; Tessarin G, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103335; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	23	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 16	2021	12								673487	10.3389/fimmu.2021.673487	http://dx.doi.org/10.3389/fimmu.2021.673487			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RV0SK	33936120	gold, Green Published			2022-12-18	WOS:000645547400001
J	Mehra, P; Wells, AD				Mehra, Parul; Wells, Andrew D.			Variant to Gene Mapping to Discover New Targets for Immune Tolerance	FRONTIERS IN IMMUNOLOGY			English	Article						genome-wide association studies; single nucleotide polymorphism; autoimmunity; multi-omics; immune tolerance; variant-to-gene mapping	CELLS; ASSOCIATION; EXPRESSION; SUGGESTS; RISK; TREG	The breakdown of immunological tolerance leads to autoimmune disease, and the mechanisms that maintain self-tolerance, especially in humans, are not fully understood. Genome-wide association studies (GWAS) have identified hundreds of human genetic loci statistically linked to autoimmune disease risk, and epigenetic modifications of DNA and chromatin at these loci have been associated with autoimmune disease risk. Because the vast majority of these signals are located far from genes, identifying causal variants, and their functional consequences on the correct effector genes, has been challenging. These limitations have hampered the translation of GWAS findings into novel drug targets and clinical interventions, but recent advances in understanding the spatial organization of the genome in the nucleus have offered mechanistic insights into gene regulation and answers to questions left open by GWAS. Here we discuss the potential for 'variant-to-gene mapping' approaches that integrate GWAS with 3D functional genomic data to identify human genes involved in the maintenance of tolerance.	[Mehra, Parul; Wells, Andrew D.] Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA; [Wells, Andrew D.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine	Mehra, P; Wells, AD (corresponding author), Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA.; Wells, AD (corresponding author), Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA.	parul.mehra@bms.com; wellsa@chop.edu			NIH [DK122586, AI123539, AI130115, AI054643]; Center for Spatial and Functional Genomics at the Children's Hospital of Philadelphia	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Spatial and Functional Genomics at the Children's Hospital of Philadelphia	AW is funded by NIH grants DK122586, AI123539, AI130115, and AI054643, and by the Center for Spatial and Functional Genomics at the Children's Hospital of Philadelphia.	Akkaraju S, 1997, IMMUNITY, V7, P255, DOI 10.1016/S1074-7613(00)80528-2; Allenspach EJ, 2017, J ALLERGY CLIN IMMUN, V140, P616, DOI 10.1016/j.jaci.2017.02.017; Almlof JC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06516-1; Alvarez-Sanchez N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38897-w; Annunziato F, 2009, NAT REV RHEUMATOL, V5, P325, DOI 10.1038/nrrheum.2009.80; Begovich AB, 2004, AM J HUM GENET, V75, P330, DOI 10.1086/422827; Bentham J, 2015, NAT GENET, V47, P1457, DOI 10.1038/ng.3434; Bluestone JA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad4134; Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323; Bruniquel D, 2003, NAT IMMUNOL, V4, P235, DOI 10.1038/ni887; Chen SH, 2017, CLIN EXP IMMUNOL, V187, P185, DOI 10.1111/cei.12877; Chen XF, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136477; Ciechomska M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090953; Dekker J, 2016, CELL, V164, P1110, DOI 10.1016/j.cell.2016.02.007; Dolff S, 2019, EUR J MED RES, V24, DOI 10.1186/s40001-019-0385-6; Dominguez-Villar M, 2018, NAT IMMUNOL, V19, P665, DOI 10.1038/s41590-018-0120-4; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Farh KKH, 2015, NATURE, V518, P337, DOI 10.1038/nature13835; Fu Y, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1721-x; Gaffney PM, 1998, P NATL ACAD SCI USA, V95, P14875, DOI 10.1073/pnas.95.25.14875; Gerasimova A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054359; Goodwin M, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz0571; Hui-Yuen JS, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1169-9; Issuree PD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05834-w; Janeway C., 2011, IMMUNOBIOLOGY 5 IMMU, V5th; Javierre BM, 2016, CELL, V167, P1369, DOI 10.1016/j.cell.2016.09.037; Jenks SA, 2018, IMMUNITY, V49, P725, DOI 10.1016/j.immuni.2018.08.015; Jiang KY, 2015, ARTHRITIS RHEUMATOL, V67, P1966, DOI 10.1002/art.39135; Jung I, 2019, NAT GENET, V51, P1442, DOI 10.1038/s41588-019-0494-8; Kanno Y, 2012, ANNU REV IMMUNOL, V30, P707, DOI 10.1146/annurev-immunol-020711-075058; Kim HJ, 2015, SCIENCE, V350, P334, DOI 10.1126/science.aad0616; Klein L, 2000, J MOL MED, V78, P483, DOI 10.1007/s001090000146; Krishnan S, 2003, J IMMUNOL, V171, P3325, DOI 10.4049/jimmunol.171.7.3325; Kumar V, 2015, HUM MOL GENET, V24, P397, DOI 10.1093/hmg/ddu453; Lappalainen T, 2013, NATURE, V501, P506, DOI 10.1038/nature12531; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; Li MLJ, 2013, NUCLEIC ACIDS RES, V41, pW150, DOI 10.1093/nar/gkt456; Li YQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15836-2; Manthiram K, 2017, NAT IMMUNOL, V18, P832, DOI 10.1038/ni.3777; Marson A, 2015, J CLIN INVEST, V125, P2234, DOI 10.1172/JCI78086; Martin JC, 2019, CELL, V178, P1493, DOI 10.1016/j.cell.2019.08.008; Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794; Mazzone R, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0632-2; Morikawa H, 2014, IMMUNOL REV, V259, P192, DOI 10.1111/imr.12174; Nambiar MP, 2003, ARTHRITIS RHEUM, V48, P1948, DOI 10.1002/art.11072; Nistala K, 2010, P NATL ACAD SCI USA, V107, P14751, DOI 10.1073/pnas.1003852107; Nistico L, 1996, HUM MOL GENET, V5, P1075, DOI 10.1093/hmg/5.7.1075; Odhams CA, 2017, HUM MOL GENET, V26, P1003, DOI 10.1093/hmg/ddw417; OHASHI P S, 1991, Cell, V65, P305, DOI 10.1016/0092-8674(91)90164-T; Ohl K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/432595; Onengut-Gumuscu S, 2015, NAT GENET, V47, P381, DOI 10.1038/ng.3245; Panwar B., 2020, INTEGRATIVE TRANSCRI, DOI [10.1101/2020.04.27.065227, DOI 10.1101/2020.04.27.065227]; Plenge RM, 2005, AM J HUM GENET, V77, P1044, DOI 10.1086/498651; POWELL BR, 1982, J PEDIATR-US, V100, P731, DOI 10.1016/S0022-3476(82)80573-8; Rai R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166312; Ricano-Ponce I, 2016, J AUTOIMMUN, V68, P62, DOI 10.1016/j.jaut.2016.01.002; RICH SS, 1984, AM J HUM GENET, V36, P1015; Richardson B, 2007, NAT CLIN PRACT RHEUM, V3, P521, DOI 10.1038/ncprheum0573; Romano M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00043; Salehi Z, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159565; Sang A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06293-z; Schierding W, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00039; Schmiedel BJ, 2018, CELL, V175, P1701, DOI 10.1016/j.cell.2018.10.022; Soderquest K, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006587; Soskic B, 2019, NAT GENET, V51, P1486, DOI 10.1038/s41588-019-0493-9; Spence A, 2018, P NATL ACAD SCI USA, V115, P5265, DOI 10.1073/pnas.1715590115; Su C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17089-5; Sumida T, 2018, NAT IMMUNOL, V19, P1391, DOI 10.1038/s41590-018-0236-6; Tenbrock K, 2007, RHEUMATOLOGY, V46, P1525, DOI 10.1093/rheumatology/kem154; Tewhey R, 2016, CELL, V165, P1519, DOI 10.1016/j.cell.2016.04.027; Thomas RM, 2012, J BIOL CHEM, V287, P22900, DOI 10.1074/jbc.M111.312785; Trynka G, 2013, NAT GENET, V45, P124, DOI 10.1038/ng.2504; Velaga MR, 2004, J CLIN ENDOCR METAB, V89, P5862, DOI 10.1210/jc.2004-1108; Visscher PM, 2017, AM J HUM GENET, V101, P5, DOI 10.1016/j.ajhg.2017.06.005; von Spee-Mayer C, 2016, ANN RHEUM DIS, V75, P1407, DOI 10.1136/annrheumdis-2015-207776; Wagner CA, 2020, J CLIN INVEST, V130, P203, DOI 10.1172/JCI132531; Xing Y, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006957; Ye J, 2018, GENES-BASEL, V9, DOI 10.3390/genes9080377; Zemmour D, 2020, SINGLE CELL ANAL FOX, DOI [10.1101/2020.07.06.189589, DOI 10.1101/2020.07.06.189589]; Zhernakova DV, 2017, NAT GENET, V49, P139, DOI 10.1038/ng.3737	80	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 15	2021	12								633219	10.3389/fimmu.2021.633219	http://dx.doi.org/10.3389/fimmu.2021.633219			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RU6PP	33936046	Green Published, gold			2022-12-18	WOS:000645268200001
J	Shang, YF; Liu, T; Li, JF; Kaweme, NM; Wang, XH; Zhou, FL				Shang, Yufeng; Liu, Tao; Li, Jingfeng; Kaweme, Natasha Mupeta; Wang, Xinghuan; Zhou, Fuling			Impact of Treatment Regimens on Antibody Response to the SARS-CoV-2 Coronavirus	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; COVID-19; IgG; cancer; chloroquine; hydroxychloroquine		The coronavirus disease 2019 (COVID-19) is widely spread and remains a global pandemic. Limited evidence on the systematic evaluation of the impact of treatment regimens on antibody responses exists. Our study aimed to analyze the role of antibody response on prognosis and determine factors influencing the IgG antibodies' seroconversion. A total of 1,111 patients with mild to moderate COVID-19 symptoms admitted to Leishenshan Hospital in Wuhan were retrospectively analyzed. A serologic SARS-CoV-2 IgM/IgG antibody test was performed on all the patients 21 days after the onset of symptoms. Patient clinical characteristics were compared. In the study, 42 patients progressed to critical illness, with 6 mortalities reported while 1,069 patients reported mild to moderate disease. Advanced age (P = 0.028), gasping (P < 0.001), dyspnea (P = 0.024), and IgG negativity (P = 0.006) were associated with progression to critical illness. The mortality rate in critically ill patients with IgG antibody was 6.45% (95% CI 1.12-22.84%) and 36.36% (95% CI 12.36-68.38%) in patients with no IgG antibody (P = 0.003). Symptomatic patients were more likely to develop IgG antibody responses than asymptomatic patients. Using univariable analysis, fever (P < 0.001), gasping (P = 0.048), cancer (P < 0.001), cephalosporin (P = 0.015), and chloroquine/hydroxychloroquine (P = 0.021) were associated with IgG response. In the multivariable analysis, fever, cancer, cephalosporins, and chloroquine/hydroxychloroquine correlated independently with IgG response. We determined that the absence of SARS-CoV-2 antibody IgG in the convalescent stage had a specific predictive role in critical illness progression. Importantly, risk factors affecting seropositivity were identified, and the effect of antimalarial drugs on antibody response was determined.	[Shang, Yufeng; Kaweme, Natasha Mupeta; Zhou, Fuling] Wuhan Univ, Dept Hematol, Zhongnan Hosp, Wuhan, Peoples R China; [Liu, Tao; Wang, Xinghuan] Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan, Peoples R China; [Liu, Tao; Wang, Xinghuan] Wuhan Univ, Ctr Evidence Based & Translat Med, Zhongnan Hosp, Wuhan, Peoples R China; [Li, Jingfeng] Wuhan Univ, Dept Orthped, Zhongnan Hosp, Wuhan, Peoples R China	Wuhan University; Wuhan University; Wuhan University; Wuhan University	Zhou, FL (corresponding author), Wuhan Univ, Dept Hematol, Zhongnan Hosp, Wuhan, Peoples R China.; Wang, XH (corresponding author), Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan, Peoples R China.; Wang, XH (corresponding author), Wuhan Univ, Ctr Evidence Based & Translat Med, Zhongnan Hosp, Wuhan, Peoples R China.	wangxinghuan@whu.edu.cn; zhoufuling@whu.edu.cn		Liu, Tao/0000-0002-4202-8218	Key Project for Anti-2019 novel Coronavirus Pneumonia from the Ministry of Science and Technology, China [2020YFC0845500]	Key Project for Anti-2019 novel Coronavirus Pneumonia from the Ministry of Science and Technology, China	This work was supported by the Key Project for Anti-2019 novel Coronavirus Pneumonia from the Ministry of Science and Technology, China (grant number 2020YFC0845500).	Accapezzato D, 2005, J EXP MED, V202, P817, DOI 10.1084/jem.20051106; [Anonymous], 2020, LANCET, V395, pE102, DOI 10.1016/S0140-6736(20)31290-3; Chrzastek K, 2011, POULTRY SCI, V90, P2723, DOI 10.3382/ps.2011-01525; Commission NH , 2020, CHINESE MANAGEMENT G; Santos IKFD, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01739; Devaux Christian A, 2020, Int J Antimicrob Agents, V55, P105938, DOI 10.1016/j.ijantimicag.2020.105938; Dorner T, 2007, IMMUNITY, V27, P384, DOI 10.1016/j.immuni.2007.09.002; Du XW, 2020, J INFECTION, V81, pE78, DOI 10.1016/j.jinf.2020.03.053; Funck-Brentano Christian, 2020, Lancet, DOI 10.1016/S0140-6736(20)31174-0; Garulli B, 2013, VACCINE, V31, P1717, DOI 10.1016/j.vaccine.2013.01.037; Goshen-Lago T, 2020, CANCERS, V12, DOI 10.3390/cancers12092421; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Guo C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17834-w; HALSTEAD SB, 1977, NATURE, V265, P739, DOI 10.1038/265739a0; Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1; Jin YJ, 2020, INT J INFECT DIS, V94, P49, DOI 10.1016/j.ijid.2020.03.065; Keyaerts E, 2009, ANTIMICROB AGENTS CH, V53, P3416, DOI 10.1128/AAC.01509-08; Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727; Liu AD, 2021, J MED VIROL, V93, P144, DOI 10.1002/jmv.26241; Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158; Liu T, 2020, INT J CANCER, V147, P3267, DOI 10.1002/ijc.33148; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]; Pomorska-Mol M, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0586-3; PULVERER G, 1992, INFECTION, V20, pS41, DOI 10.1007/BF01709950; Qaseem A, 2020, ANN INTERN MED, V173, pW88, DOI 10.7326/L20-1007; Ren LL, 2021, CLIN INFECT DIS, V72, pE545, DOI 10.1093/cid/ciaa1247; Roeker LE, 2020, LEUKEMIA, V34, P3047, DOI 10.1038/s41375-020-01030-2; Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630; Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5; Solodky ML, 2020, ANN ONCOL, V31, P1087, DOI 10.1016/j.annonc.2020.04.475; Suthar MS, 2020, CELL REP MED, V1, DOI [10.1016/j.xcrm.2020.100040, 10.1101/2020.05.03.20084442]; Tang DL, 2020, AUTOPHAGY, V16, P2273, DOI 10.1080/15548627.2020.1796014; Thomson K, 2020, JAMA-J AM MED ASSOC, V324, P1282, DOI 10.1001/jama.2020.16253; To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1; Uzunova K, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110668; Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69; Wang XL, 2020, CLIN INFECT DIS, V71, P2688, DOI 10.1093/cid/ciaa721; Xiang F, 2020, CLIN INFECT DIS, V71, P1930, DOI 10.1093/cid/ciaa461; Zhang YC, 2020, EMERG MICROBES INFEC, V9, P833, DOI 10.1080/22221751.2020.1756699; ZHAO J, 2020, CLIN INFECT DIS, DOI [DOI 10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	43	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 15	2021	12								580147	10.3389/fimmu.2021.580147	http://dx.doi.org/10.3389/fimmu.2021.580147			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RU6QZ	33936026	gold, Green Published			2022-12-18	WOS:000645271800001
J	Valenzuela, NM				Valenzuela, Nicole M.			IFN gamma, and to a Lesser Extent TNF alpha, Provokes a Sustained Endothelial Costimulatory Phenotype	FRONTIERS IN IMMUNOLOGY			English	Article						endothelial cell (EC); costimulatory; allogeneic; antigen presentation; vascular		Background Vascular endothelial cells (EC) are critical for regulation of local immune responses, through coordination of leukocyte recruitment from the blood and egress into the tissue. Growing evidence supports an additional role for endothelium in activation and costimulation of adaptive immune cells. However, this function remains somewhat controversial, and the full repertoire and durability of an enhanced endothelial costimulatory phenotype has not been wholly defined. Methods Human endothelium was stimulated with continuous TNF alpha or IFN gamma for 1-48hr; or primed with TNF alpha or IFN gamma for only 3hr, before withdrawal of stimulus for up to 45hr. Gene expression of cytokines, costimulatory molecules and antigen presentation molecules was measured by Nanostring, and publicly available datasets of EC stimulation with TNF alpha or IFN gamma were leveraged to further corroborate the results. Cell surface protein expression was detected by flow cytometry, and secretion of cytokines was assessed by Luminex and ELISA. Key findings were confirmed in primary human endothelial cells from 4-6 different vascular beds. Results TNF alpha triggered mostly positive immune checkpoint molecule expression on endothelium, including CD40, 4-1BB, and ICOSLG but in the context of only HLA class I and immunoproteasome subunits. IFN gamma promoted a more tolerogenic phenotype of high PD-L1 and PD-L2 expression with both HLA class I and class II molecules and antigen processing genes. Both cytokines elicited secretion of IL-15 and BAFF/BLyS, with TNF alpha stimulated EC additionally producing IL-6, TL1A and IL-1 beta. Moreover, endothelium primed for a short period (3hr) with TNF alpha mostly failed to alter the costimulatory phenotype 24-48hr later, with only somewhat augmented expression of HLA class I. In contrast, brief exposure to IFN gamma was sufficient to cause late expression of antigen presentation, cytokines and costimulatory molecules. In particular HLA class I, PD-1 ligand and cytokine expression was markedly high on endothelium two days after IFN gamma was last present. Conclusions Endothelia from multiple vascular beds possess a wide range of other immune checkpoint molecules and cytokines that can shape the adaptive immune response. Our results further demonstrate that IFN gamma elicits prolonged signaling that persists days after initiation and is sufficient to trigger substantial gene expression changes and immune phenotype in vascular endothelium.	[Valenzuela, Nicole M.] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles	Valenzuela, NM (corresponding author), Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA.	npyburn@mednet.ucla.edu	Valenzuela, Nicole M/H-8290-2017	Valenzuela, Nicole M/0000-0003-2024-5382	Norman E. Shumway Career Development Award from the International Society of Heart and Lung Transplantation and Enduring Hearts	Norman E. Shumway Career Development Award from the International Society of Heart and Lung Transplantation and Enduring Hearts	Support for this was provided in part by the Norman E. Shumway Career Development Award from the International Society of Heart and Lung Transplantation and Enduring Hearts (to NV).	Berendam SJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00816; Cheng XX, 2013, J BIOL CHEM, V288, P11771, DOI 10.1074/jbc.M112.448126; Ciccia F, 2017, ANN RHEUM DIS, V76, P235, DOI 10.1136/annrheumdis-2016-209217; Cols M, 2012, J IMMUNOL, V188, P6071, DOI 10.4049/jimmunol.1102066; DAAR AS, 1984, TRANSPLANTATION, V38, P287, DOI 10.1097/00007890-198409000-00018; DAAR AS, 1984, TRANSPLANTATION, V38, P293, DOI 10.1097/00007890-198409000-00019; Dalrymple NA, 2012, J VIROL, V86, P6408, DOI 10.1128/JVI.00213-12; Dame TM, 2007, J IMMUNOL, V178, P1172, DOI 10.4049/jimmunol.178.2.1172; Dengler TJ, 2000, J IMMUNOL, V164, P5146, DOI 10.4049/jimmunol.164.10.5146; Denton MD, 1999, J EXP MED, V190, P555, DOI 10.1084/jem.190.4.555; Eleftheriadis T, 2012, MED HYPOTHESES, V78, P138, DOI 10.1016/j.mehy.2011.10.010; EPPERSON DE, 1994, J IMMUNOL, V153, P5402; FUGGLE SV, 1986, TRANSPLANTATION, V42, P144, DOI 10.1097/00007890-198608000-00008; Grabie N, 2007, CIRCULATION, V116, P2062, DOI 10.1161/CIRCULATIONAHA.107.709360; Hancock WW, 1996, P NATL ACAD SCI USA, V93, P13967, DOI 10.1073/pnas.93.24.13967; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; Huard B, 2001, J IMMUNOL, V167, P6225, DOI 10.4049/jimmunol.167.11.6225; HUGHES CCW, 1990, J EXP MED, V171, P1453, DOI 10.1084/jem.171.5.1453; Hurley D, 2012, NUCLEIC ACIDS RES, V40, P2377, DOI 10.1093/nar/gkr902; Kadl A, 2005, ANTIOXID REDOX SIGN, V7, P1744, DOI 10.1089/ars.2005.7.1744; Kang S, 2017, J IMMUNOL, V198, P2602, DOI 10.4049/jimmunol.1600281; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Katz SC, 2004, J IMMUNOL, V173, P230, DOI 10.4049/jimmunol.173.1.230; Khayyamian S, 2002, P NATL ACAD SCI USA, V99, P6198, DOI 10.1073/pnas.092576699; Knolle PA, 1999, GASTROENTEROLOGY, V116, P1428, DOI 10.1016/S0016-5085(99)70508-1; Kobayashi H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009458; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Lehnert C, 2014, J IMMUNOL, V193, P4021, DOI 10.4049/jimmunol.1303242; Leitner J, 2015, J IMMUNOL, V195, P477, DOI 10.4049/jimmunol.1401917; Li ZD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01312; Lim WC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00565; Limmer A, 2000, NAT MED, V6, P1348, DOI 10.1038/82161; Liu R, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97881; Lozanoska-Ochser B, 2008, J IMMUNOL, V181, P6109, DOI 10.4049/jimmunol.181.9.6109; Ma WL, 1998, J IMMUNOL, V161, P2158; Maia S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020787; Marelli-Berg FM, 1999, J IMMUNOL, V162, P696; Marelli-Berg FM, 2004, IMMUNOL LETT, V93, P109, DOI 10.1016/j.imlet.2004.03.014; MarelliBerg FM, 1996, J EXP MED, V183, P1603, DOI 10.1084/jem.183.4.1603; Mazibrada J, 2010, CANCER LETT, V287, P33, DOI 10.1016/j.canlet.2009.05.035; Mestas J, 2001, J IMMUNOL, V167, P4378, DOI 10.4049/jimmunol.167.8.4378; Metcalfe SM, 2011, GENES IMMUN, V12, P157, DOI 10.1038/gene.2011.9; Muczynski KA, 2003, J AM SOC NEPHROL, V14, P1336, DOI 10.1097/01.ASN.0000061778.08085.9F; Murakami K, 1999, J IMMUNOL, V163, P2667; Ng LG, 2004, J IMMUNOL, V173, P807, DOI 10.4049/jimmunol.173.2.807; Nold-Petry CA, 2009, P NATL ACAD SCI USA, V106, P3883, DOI 10.1073/pnas.0813334106; Olofsson PS, 2008, CIRCULATION, V117, P1292, DOI 10.1161/CIRCULATIONAHA.107.699173; Oppenheimer-Marks N, 1998, J CLIN INVEST, V101, P1261, DOI 10.1172/JCI1986; PAGE CS, 1994, TRANSPLANTATION, V57, P1628; Perez VL, 1998, CELL IMMUNOL, V189, P31, DOI 10.1006/cimm.1998.1362; Pluvinet R, 2008, BLOOD, V112, P3624, DOI 10.1182/blood-2008-03-143305; Pober JS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01907; Rhead B, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230884; Rodig N, 2003, EUR J IMMUNOL, V33, P3117, DOI 10.1002/eji.200324270; ROSE ML, 1986, TRANSPLANTATION, V41, P776, DOI 10.1097/00007890-198606000-00021; Rothermel Annette L, 2004, BMC Immunol, V5, P5, DOI 10.1186/1471-2172-5-5; Sancho D, 1999, BLOOD, V93, P886, DOI 10.1182/blood.V93.3.886.403k10_886_896; SAVAGE COS, 1993, TRANSPLANTATION, V56, P128, DOI 10.1097/00007890-199307000-00024; SEINO K, 1995, INT IMMUNOL, V7, P1331, DOI 10.1093/intimm/7.8.1331; Shen AD, 2013, J VIROL, V87, P9768, DOI 10.1128/JVI.01478-13; Shiao SL, 2007, J IMMUNOL, V179, P4397, DOI 10.4049/jimmunol.179.7.4397; Shiao SL, 2007, TRANSPLANTATION, V83, P304, DOI 10.1097/01.tp.0000251426.46312.d5; Smith X, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004018; STEINHOFF G, 1988, TRANSPLANTATION, V45, P394, DOI 10.1097/00007890-198802000-00030; STLOUIS JD, 1993, J EXP MED, V178, P1597, DOI 10.1084/jem.178.5.1597; Suso JP, 2018, LUPUS, V27, P708, DOI 10.1177/0961203317739132; Taflin C, 2011, P NATL ACAD SCI USA, V108, P2891, DOI 10.1073/pnas.1011811108; Tognarelli S, 2014, J IMMUNOL, V192, P3399, DOI 10.4049/jimmunol.1301508; Urban D, 2011, BIOCHEM BIOPH RES CO, V404, P448, DOI 10.1016/j.bbrc.2010.11.142; Wagner AH, 2002, BLOOD, V99, P520, DOI 10.1182/blood.V99.2.520; Westphal J R, 1993, Transpl Immunol, V1, P183, DOI 10.1016/0966-3274(93)90045-A; Wild AB, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126246; Wittlich M, 2017, J HEPATOL, V66, P978, DOI 10.1016/j.jhep.2016.12.015; Xie CB, 2020, J CLIN INVEST, V130, P3437, DOI 10.1172/JCI135060; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181	75	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 15	2021	12								648946	10.3389/fimmu.2021.648946	http://dx.doi.org/10.3389/fimmu.2021.648946			23	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RU4KV	33936069	gold, Green Published			2022-12-18	WOS:000645118600001
J	Zhu, L; Guo, ZL; Sa, R; Guo, H; Li, JH; Chen, G				Zhu, Lan; Guo, Zhiliang; Sa, Rula; Guo, Hui; Li, Junhua; Chen, Gang			Case Report: Splenic Irradiation for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Allograft Recipients With De Novo Donor-Specific Antibodies	FRONTIERS IN IMMUNOLOGY			English	Article						chronic active antibody-mediated rejection (cABMR); de novo donor-specific antibody; splenic irradiation; renal transplantation; case report		Chronic active antibody-mediated rejection (AMR) in renal transplantation is usually refractory to current conventional treatment with rituximab, plasmapheresis (PP), and intravenous immunoglobulins (IVIG). Splenic irradiation has been reported to be effective in the rescue of early severe acute AMR after kidney transplantation; however, its effect in chronic active AMR has not been reported to date. In order to reduce donor-specific antibody (DSA) and prevent the progression of chronic AMR, we used repetitive low-dose splenic irradiation, together with rituximab and PP/IVIG, in two living-related kidney transplant recipients with pathologically diagnosed chronic active AMR and the presence of long-term class II-de novo DSA. DSA monitoring and repeated renal biopsy revealed significantly reduced DSA levels as well as alleviated glomerulitis and peritubular capillaritis in both patients after treatment, and these therapies may have played a role in delaying the progression of chronic AMR. Although DSA levels in both patients eventually rebounded to some extent after treatment, serum creatinine increased slowly in one patient during the 16-month follow-up period and remained stable in the other during the 12-month follow-up period. Given the poor efficacy of conventional treatment at present, splenic irradiation may still be one of the treatment options for chronic active AMR.	[Zhu, Lan; Guo, Zhiliang; Sa, Rula; Guo, Hui; Chen, Gang] Huazhong Univ Sci & Technol, Tongji Hosp, Inst Organ Transplantat, Tongji Med Coll, Wuhan, Peoples R China; [Zhu, Lan; Guo, Hui; Chen, Gang] Chinese Acad Med Sci, Minist Educ, Key Lab Organ Transplantat, Wuhan, Peoples R China; [Zhu, Lan; Guo, Hui; Chen, Gang] Chinese Acad Med Sci, Minist Publ Hlth, Wuhan, Peoples R China; [Li, Junhua] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Nephrol, Wuhan, Peoples R China	Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Huazhong University of Science & Technology	Chen, G (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Inst Organ Transplantat, Tongji Med Coll, Wuhan, Peoples R China.; Chen, G (corresponding author), Chinese Acad Med Sci, Minist Educ, Key Lab Organ Transplantat, Wuhan, Peoples R China.; Chen, G (corresponding author), Chinese Acad Med Sci, Minist Publ Hlth, Wuhan, Peoples R China.	gchen@tjh.tjmu.edu.cn			Non-Profit Central Research Institute Fund of Chinese Academy of Medical Science [2019PT320014]	Non-Profit Central Research Institute Fund of Chinese Academy of Medical Science	This work was supported by the Non-Profit Central Research Institute Fund of Chinese Academy of Medical Science (grant number 2019PT320014).	Bohmig GA, 2019, TRANSPL INT, V32, P775, DOI 10.1111/tri.13436; Burton SA, 2015, CLIN TRANSPLANT, V29, P118, DOI 10.1111/ctr.12491; Chen G, 2005, NAT MED, V11, P1295, DOI 10.1038/nm1330; Chen S, 2011, AM J TRANSPLANT, V11, P2057, DOI 10.1111/j.1600-6143.2011.03646.x; Guidicelli G, 2016, J AM SOC NEPHROL, V27, P615, DOI 10.1681/ASN.2014040326; Kaplan B, 2010, AM J TRANSPLANT, V10, P1316, DOI 10.1111/j.1600-6143.2010.03067.x; Lakkis FG, 2018, NEW ENGL J MED, V379, P2580, DOI 10.1056/NEJMc1813976; Locke JE, 2007, AM J TRANSPLANT, V7, P842, DOI 10.1111/j.1600-6143.2006.01709.x; Massat M, 2021, AM J TRANSPLANT, V21, P1641, DOI 10.1111/ajt.16391; Moreso F, 2018, AM J TRANSPLANT, V18, P927, DOI 10.1111/ajt.14520; Moroni G, 2019, CLIN EXP NEPHROL, V23, P1076, DOI 10.1007/s10157-019-01740-7; Ntokou ISA, 2011, TRANSPL INT, V24, P1084, DOI 10.1111/j.1432-2277.2011.01312.x; Orandi BJ, 2016, AM J TRANSPLANT, V16, P3041, DOI 10.1111/ajt.13882; Orandi BJ, 2014, TRANSPLANTATION, V98, P857, DOI 10.1097/TP.0000000000000298; Sellares J, 2012, AM J TRANSPLANT, V12, P388, DOI 10.1111/j.1600-6143.2011.03840.x; Shimmura H, 2005, TRANSPLANTATION, V80, P985, DOI 10.1097/01.tp.0000173647.43616.78; Sicard A, 2012, AM J TRANSPLANT, V12, P1708, DOI 10.1111/j.1600-6143.2012.04009.x; Weinmann M, 2001, RADIOTHER ONCOL, V58, P235, DOI 10.1016/S0167-8140(00)00316-9; Weinmann M, 2001, STRAHLENTHER ONKOL, V177, P105, DOI 10.1007/PL00002384; Wiebe C, 2012, AM J TRANSPLANT, V12, P1157, DOI 10.1111/j.1600-6143.2012.04013.x; Zhang RB, 2018, CLIN J AM SOC NEPHRO, V13, P182, DOI 10.2215/CJN.00700117	21	1	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 15	2021	12								661614	10.3389/fimmu.2021.661614	http://dx.doi.org/10.3389/fimmu.2021.661614			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RU6UB	33936098	gold, Green Published			2022-12-18	WOS:000645279800001
J	Cox, JR; Cruickshank, SM; Saunders, AE				Cox, Joshua R.; Cruickshank, Sheena M.; Saunders, Amy E.			Maintenance of Barrier Tissue Integrity by Unconventional Lymphocytes	FRONTIERS IN IMMUNOLOGY			English	Review						innate lymphoid cell; mucosal-associated invariant T cell; &#947; &#948; T cell; repair; barrier; review	EPIDERMAL T-CELLS; REPAIR; DIFFERENTIATION; EVOLUTION; IL-17; TCR	Mucosal surfaces, as a first barrier with the environment are especially susceptible to damage from both pathogens and physical trauma. Thus, these sites require tightly regulated repair programs to maintain barrier function in the face of such insults. Barrier sites are also enriched for unconventional lymphocytes, which lack rearranged antigen receptors or express only a limited range of such receptors, such as ILCs (Innate Lymphoid Cells), gamma delta T Cells and MAIT (Mucosal-Associated Invariant T Cells). Recent studies have uncovered critical roles for unconventional lymphocytes in regulating mucosal barrier function, and, in particular, have highlighted their important involvement in barrier repair. The production of growth factors such as amphiregulin by ILC2, and fibroblast growth factors by gamma delta T cells have been shown to promote tissue repair at multiple barrier sites. Additionally, MAIT cells have been shown to exhibit pro-repair phenotypes and demonstrate microbiota-dependent promotion of murine skin healing. In this review we will discuss how immune responses at mucosal sites are controlled by unconventional lymphocytes and the ways in which these cells promote tissue repair to maintain barrier integrity in the skin, gut and lungs.	[Cox, Joshua R.; Saunders, Amy E.] Univ Manchester, Manchester Collaborat Ctr Inflammat Res, Div Infect Immun & Resp Med,Sch Biol Sci, Fac Biol Med & Hlth,Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Cox, Joshua R.; Cruickshank, Sheena M.; Saunders, Amy E.] Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Div Infect Immun & Resp Med,Sch Biol Sci, Fac Biol Med & Hlth,Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England	University of Manchester; University of Manchester	Saunders, AE (corresponding author), Univ Manchester, Manchester Collaborat Ctr Inflammat Res, Div Infect Immun & Resp Med,Sch Biol Sci, Fac Biol Med & Hlth,Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.; Saunders, AE (corresponding author), Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Div Infect Immun & Resp Med,Sch Biol Sci, Fac Biol Med & Hlth,Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.	amy.saunders@manchester.ac.uk		Cox, Joshua/0000-0002-6308-7831	Wellcome Trust Sir Henry Dale Fellowship [109375/Z/15/Z]; Medical Research Council (MRC) DTP studentship	Wellcome Trust Sir Henry Dale Fellowship; Medical Research Council (MRC) DTP studentship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by a Wellcome Trust Sir Henry Dale Fellowship to AS (109375/Z/15/Z) and a Medical Research Council (MRC) DTP studentship to JC.	Allen JE, 2015, CURR OPIN IMMUNOL, V34, P99, DOI 10.1016/j.coi.2015.03.001; Anderson LS, 2019, J INVEST DERMATOL, V139, P2061, DOI 10.1016/j.jid.2019.02.032; Aparicio-Domingo P, 2015, J EXP MED, V212, P1783, DOI 10.1084/jem.20150318; Avitabile S, 2015, J INVEST DERMATOL, V135, P2862, DOI 10.1038/jid.2015.278; Baarsma HA, 2017, J EXP MED, V214, P143, DOI 10.1084/jem.20160675; Bando JK, 2016, NAT IMMUNOL, V17, P783, DOI 10.1038/ni.3484; Barros RD, 2016, CELL, V167, P203, DOI 10.1016/j.cell.2016.08.030; Bernink JH, 2013, NAT IMMUNOL, V14, P221, DOI 10.1038/ni.2534; Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Castro-Dopico T, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107857; Chen X, 2019, J EXP MED, V216, P195, DOI 10.1084/jem.20171849; Chen YP, 2002, P NATL ACAD SCI USA, V99, P14338, DOI 10.1073/pnas.212290499; Cho HS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08699-9; Chun E, 2019, IMMUNITY, V51, P871, DOI 10.1016/j.immuni.2019.09.014; Constantinides MG, 2019, SCIENCE, V366, P445, DOI 10.1126/science.aax6624; Dagher R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18466-w; Dahlgren MW, 2019, IMMUNITY, V50, P707, DOI 10.1016/j.immuni.2019.02.002; Dalessandri T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12080; Dalton JE, 2006, GASTROENTEROLOGY, V131, P818, DOI 10.1053/j.gastro.2006.06.003; Duffin R, 2016, SCIENCE, V351, P1333, DOI 10.1126/science.aad9903; Dusseaux M, 2011, BLOOD, V117, P1250, DOI 10.1182/blood-2010-08-303339; Fang Y, 2007, BRIT J DERMATOL, V157, P458, DOI 10.1111/j.1365-2133.2007.07979.x; Garcin CL, 2017, EXP DERMATOL, V26, P101, DOI 10.1111/exd.13184; Gay D, 2013, NAT MED, V19, P916, DOI 10.1038/nm.3181; Ghaedi M, 2020, J EXP MED, V217, DOI 10.1084/jem.20182293; Gieseck RL, 2018, NAT REV IMMUNOL, V18, P62, DOI 10.1038/nri.2017.90; Gronke K, 2019, NATURE, V566, P249, DOI 10.1038/s41586-019-0899-7; Guo XZJ, 2018, IMMUNITY, V49, P531, DOI 10.1016/j.immuni.2018.07.011; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Harrison OJ, 2019, SCIENCE, V363, P43, DOI 10.1126/science.aat6280; Havran WL, 2010, J IMMUNOL, V184, P5423, DOI 10.4049/jimmunol.0902733; Hayday AC, 2019, J IMMUNOL, V203, P311, DOI 10.4049/jimmunol.1800934; HEILIG JS, 1986, NATURE, V322, P836, DOI 10.1038/322836a0; Hinks TSC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01014; Hinks TSC, 2019, CELL REP, V28, P3249, DOI 10.1016/j.celrep.2019.07.039; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Ismail AS, 2009, J IMMUNOL, V182, P3047, DOI 10.4049/jimmunol.0802705; Jameson J, 2002, SCIENCE, V296, P747, DOI 10.1126/science.1069639; Jameson JM, 2004, J IMMUNOL, V172, P3573, DOI 10.4049/jimmunol.172.6.3573; Johnson AMF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122195; Jowett GM, 2021, NAT MATER, V20, P250, DOI 10.1038/s41563-020-0783-8; Kabashima K, 2019, NAT REV IMMUNOL, V19, P19, DOI 10.1038/s41577-018-0084-5; Keyes BE, 2016, CELL, V167, P1323, DOI 10.1016/j.cell.2016.10.052; Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605; Kobayashi T, 2019, CELL, V176, P982, DOI 10.1016/j.cell.2018.12.031; Kolumam G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170639; Komori HK, 2012, J IMMUNOL, V188, P2972, DOI 10.4049/jimmunol.1100887; Krishnan S, 2018, P NATL ACAD SCI USA, V115, P10738, DOI 10.1073/pnas.1802320115; Lai YP, 2012, IMMUNITY, V37, P74, DOI 10.1016/j.immuni.2012.04.010; Lamichhane R, 2019, CELL REP, V28, P3061, DOI 10.1016/j.celrep.2019.08.054; Leng TQ, 2019, CELL REP, V28, P3077, DOI 10.1016/j.celrep.2019.08.050; Li YS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01099; Li YS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00240; Li Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11394; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Liu Z, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05950-5; Liu ZY, 2016, AM J TRANSL RES, V8, P2667; Malhotra N, 2016, J ALLERGY CLIN IMMUN, V138, P1098, DOI 10.1016/j.jaci.2016.07.001; Mann A, 2001, J INVEST DERMATOL, V117, P1382, DOI 10.1046/j.0022-202x.2001.01600.x; Mathur AN, 2019, IMMUNITY, V50, P655, DOI 10.1016/j.immuni.2019.02.013; Mazzurana L, 2021, CELL RES, V31, P554, DOI 10.1038/s41422-020-00445-x; McGeachy MJ, 2019, IMMUNITY, V50, P892, DOI 10.1016/j.immuni.2019.03.021; McGinty JW, 2020, CURR OPIN IMMUNOL, V62, P15, DOI 10.1016/j.coi.2019.11.005; McLeod K, 2018, J CELL COMMUN SIGNAL, V12, P281, DOI 10.1007/s12079-018-0453-7; Meehan TF, 2014, MUCOSAL IMMUNOL, V7, P134, DOI 10.1038/mi.2013.32; Meininger I, 2020, TRENDS IMMUNOL, V41, P902, DOI 10.1016/j.it.2020.08.009; Melandri D, 2018, NAT IMMUNOL, V19, P1352, DOI 10.1038/s41590-018-0253-5; Melo-Gonzalez F, 2017, IMMUNOLOGY, V150, P265, DOI 10.1111/imm.12697; Monticelli LA, 2015, P NATL ACAD SCI USA, V112, P10762, DOI 10.1073/pnas.1509070112; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Pantelyushin S, 2012, J CLIN INVEST, V122, P2252, DOI 10.1172/JCI61862; Polese B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00242; Provine NM, 2020, ANNU REV IMMUNOL, V38, P203, DOI 10.1146/annurev-immunol-080719-015428; Rahimpour A, 2015, J EXP MED, V212, P1095, DOI 10.1084/jem.20142110; Rak GD, 2016, J INVEST DERMATOL, V136, P487, DOI 10.1038/JID.2015.406; Ribot JC, 2021, NAT REV IMMUNOL, V21, P221, DOI 10.1038/s41577-020-00452-4; Ricardo-Gonzalez RR, 2018, NAT IMMUNOL, V19, P1093, DOI 10.1038/s41590-018-0201-4; Robinette ML, 2015, NAT IMMUNOL, V16, P306, DOI 10.1038/ni.3094; Romera-Hernandez M, 2020, CELL REP, V30, P37, DOI 10.1016/j.celrep.2019.11.115; Rouxel O, 2017, NAT IMMUNOL, V18, P1321, DOI 10.1038/ni.3854; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Sandrock I, 2018, J EXP MED, V215, P3006, DOI 10.1084/jem.20181439; Sawaya AP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18276-0; Sharp LL, 2005, NAT IMMUNOL, V6, P73, DOI 10.1038/ni1152; Sonnenberg GF, 2011, NAT IMMUNOL, V12, P383, DOI 10.1038/ni.2025; Spits H, 2016, NAT IMMUNOL, V17, P758, DOI 10.1038/ni.3482; Stepp MA, 2015, ADV WOUND CARE, V4, P235, DOI 10.1089/wound.2014.0555; Sutherland TE, 2014, NAT IMMUNOL, V15, P1116, DOI 10.1038/ni.3023; Sutoh Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01059; Suwanpradid J, 2017, J INVEST DERMATOL, V137, P288, DOI 10.1016/j.jid.2016.08.013; Taylor KR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011422; Toor IS, 2020, JACC-BASIC TRANSL SC, V5, P665, DOI 10.1016/j.jacbts.2020.05.005; Toulon A, 2009, J EXP MED, V206, P743, DOI 10.1084/jem.20081787; Turner JE, 2013, J EXP MED, V210, P2951, DOI 10.1084/jem.20130071; Vandereyken M, 2020, MUCOSAL IMMUNOL, V13, P721, DOI 10.1038/s41385-020-0294-6; Vermijlen D, 2018, SEMIN CELL DEV BIOL, V84, P75, DOI 10.1016/j.semcdb.2017.10.009; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Walker CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084553; Wei JJ, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba5683; Weizman OE, 2017, CELL, V171, P795, DOI 10.1016/j.cell.2017.09.052; Witherden DA, 2012, IMMUNITY, V37, P314, DOI 10.1016/j.immuni.2012.05.026; Wu D, 2011, SCIENCE, V332, P243, DOI 10.1126/science.1201475; Wu L, 2015, J EXP MED, V212, P1571, DOI 10.1084/jem.20150204; Xu JJ, 2020, IMMUNITY, V53, P371, DOI 10.1016/j.immuni.2020.06.023; Yoshida S, 2012, J IMMUNOL, V188, P3972, DOI 10.4049/jimmunol.1102886; Zaiss DMW, 2015, IMMUNITY, V42, P216, DOI 10.1016/j.immuni.2015.01.020; Zeis P, 2020, IMMUNITY, V53, P775, DOI 10.1016/j.immuni.2020.09.002; Zhang YL, 2017, INT J ONCOL, V50, P1352, DOI 10.3892/ijo.2017.3896; Zhao DC, 2018, J CLIN INVEST, V128, P4970, DOI 10.1172/JCI99261; Zhu PP, 2019, NAT IMMUNOL, V20, P183, DOI 10.1038/s41590-018-0297-6	111	1	1	2	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2021	12								670471	10.3389/fimmu.2021.670471	http://dx.doi.org/10.3389/fimmu.2021.670471			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RT8ID	33936115	gold, Green Published			2022-12-18	WOS:000644698600001
J	Garrido-Amaro, C; Cardona, P; Gasso, D; Arias, L; Velarde, R; Tvarijonativiciute, A; Serrano, E; Cardona, PJ				Garrido-Amaro, Cristina; Cardona, Paula; Gasso, Diana; Arias, Lilibeth; Velarde, Roser; Tvarijonativiciute, Asta; Serrano, Emmanuel; Cardona, Pere-Joan			Protective Effect of Intestinal Helminthiasis Against Tuberculosis Progression Is Abrogated by Intermittent Food Deprivation	FRONTIERS IN IMMUNOLOGY			English	Article						co-infection; tuberculosis; Trichuris muris; Heligmosomoides polygyrus; environmental mycobacteria Mycobacterium manresensis; fasting; C3HeB; FeJ		Background Tuberculosis (TB) is still a major challenge for humankind. Because regions with the highest incidence also have a high prevalence of helminthiasis and nutritional scarcity, we wanted to understand the impact of these on TB progression. Methods We have developed an experimental murine model for active TB in C3HeB/FeJ, coinfected with Trichuris muris and Heligmosomoides polygyrus nematodes, and exposed to an environmental mycobacterium (M. manresensis) and intermittent fasting. Cause-effect relationships among these factors were explored with Partial Least Squares Path modelling (PLSPM). Results Previous parasitization had a major anti-inflammatory effect and reduced systemic levels of ADA, haptoglobin, local pulmonary levels of IL-1 beta, IL-6, TNF-alpha, CXCL-1, CXCL-5 and IL-10. Oral administration of heat-killed M. manresensis resulted in a similar outcome. Both interventions diminished pulmonary pathology and bacillary load, but intermittent food deprivation reduced this protective effect increasing stress and inflammation. The PLSPM revealed nematodes might have protective effects against TB progression. Conclusions Significantly higher cortisol levels in food-deprivation groups showed it is a stressful condition, which might explain its deleterious effect. This highlights the impact of food security on TB eradication policies and the need to prioritize food supply over deworming activities.	[Garrido-Amaro, Cristina; Gasso, Diana; Velarde, Roser; Serrano, Emmanuel] Univ Autonoma Barcelona UAB, Wildlife Ecol & Hlth Grp WE & H, Bellaterra, Spain; [Garrido-Amaro, Cristina; Gasso, Diana; Velarde, Roser; Serrano, Emmanuel] Univ Autonoma Barcelona UAB, Serv Ecopatol Fauna Salvatge SEFaS, Bellaterra, Spain; [Cardona, Paula; Arias, Lilibeth; Cardona, Pere-Joan] UAB, Inst Germans Trias i Pujol, Unitat TB Expt, Badalona, Spain; [Cardona, Paula; Arias, Lilibeth; Cardona, Pere-Joan] Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain; [Gasso, Diana] Univ Lleida, Dept Anim Sci Agrifood Forestry & Vet Campus, Lleida, Spain; [Tvarijonativiciute, Asta] Univ Murcia, Interdisciplinary Lab Clin Anal Interlab UMU, Reg Campus Int Excellence Campus Mare Nostrum, Murcia, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona; Autonomous University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Universitat de Lleida; University of Murcia	Cardona, PJ (corresponding author), UAB, Inst Germans Trias i Pujol, Unitat TB Expt, Badalona, Spain.; Cardona, PJ (corresponding author), Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain.	pj.cardona@gmail.com	Garrido-Amaro, Cristina/GYV-3967-2022; Cardona, Pere-Joan/A-5258-2011; Gassó, Diana/GXV-2083-2022; Cardona, Paula/H-5034-2017	Cardona, Pere-Joan/0000-0001-5623-7873; Garrido-Amaro, Cristina/0000-0002-6506-4545; Cardona, Paula/0000-0002-8613-9390	la Caixa Foundation [100010434, LCF/PR/GN16/10290002]; Plan Nacional I + D + I; ISCIII-Subdireccion General de Evaluacion; Fondo-EU de Desarrollo Regional (FEDER) [IFI14/00015]; European Commission Horizon 2020 research and innovation program [64338]; Catalan Agency for Management of University and Research Grants (AGAUR) [2017 SGR500]; Spanish Ministerio de Ciencia Innovacion y Universidades (MICINN) through a Ramon y Cajal agreements [RYC-2016-21120, RYC-2017-22992]	la Caixa Foundation(La Caixa Foundation); Plan Nacional I + D + I; ISCIII-Subdireccion General de Evaluacion; Fondo-EU de Desarrollo Regional (FEDER); European Commission Horizon 2020 research and innovation program; Catalan Agency for Management of University and Research Grants (AGAUR)(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); Spanish Ministerio de Ciencia Innovacion y Universidades (MICINN) through a Ramon y Cajal agreements	The project leading to these results has received funding from la Caixa Foundation (ID 100010434), under agreement LCF/PR/GN16/10290002. This work was supported by the Plan Nacional I + D + I co-financed by ISCIII-Subdireccion General de Evaluacion and Fondo-EU de Desarrollo Regional (FEDER) through PC contract IFI14/00015. LA was supported by the European Commission Horizon 2020 research and innovation program under grant agreement TBVAC2020 No. 64338.; The Experimental Tuberculosis Unit accredited by the Catalan Agency for Management of University and Research Grants (AGAUR) with code 2017 SGR500 and the IGTP is a member of the CERCA network of institutes.; ES and AT are supported by the Spanish Ministerio de Ciencia Innovacion y Universidades (MICINN) through a Ramon y Cajal agreements (RYC-2016-21120; RYC-2017-22992). The research activities of CG-A are supported by a research fellow linked to the RYC-2016-21120.	Abate E, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003994; Alemu G, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2195-1; Aleuy OA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72376-x; Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211; [Anonymous], 2019, GLOB TUB REP; Arantes-Rodrigues R, 2012, LAB ANIMAL, V41, P129, DOI 10.1038/laban0512-129; Behnke JM, 2009, PARASITOLOGY, V136, P793, DOI 10.1017/S0031182009006039; Blackwell AD, 2016, INT J WOMENS HEALTH, V8, P651, DOI 10.2147/IJWH.S103529; Blakesley RE, 2009, NEUROPSYCHOLOGY, V23, P255, DOI 10.1037/a0012850; Brandt L, 2002, INFECT IMMUN, V70, P672, DOI 10.1128/IAI.70.2.672-678.2002; Budischak SA, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01914; Cardona P, 2016, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01482; Cardona PJ, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00612; Cortes A, 2015, MED RES REV, V35, P85, DOI 10.1002/med.21324; Dockrell HM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01134; Elias D, 2001, CLIN EXP IMMUNOL, V123, P219, DOI 10.1046/j.1365-2249.2001.01446.x; FAO FAD UNICEF WFP WHO , 2018, STAT FOOD SEC NUTR W; Filbey KJ, 2019, MUCOSAL IMMUNOL, V12, P352, DOI 10.1038/s41385-018-0102-8; Fukakusa M, 2005, J ALLERGY CLIN IMMUN, V115, P280, DOI 10.1016/j.jaci.2004.10.036; Gazzinelli-Guimaraes Pedro H, 2018, F1000Res, V7, DOI 10.12688/f1000research.15596.1; Gil O, 2006, MICROBES INFECT, V8, P628, DOI 10.1016/j.micinf.2005.08.014; Hair JF, 2013, LONG RANGE PLANN, V46, P1, DOI 10.1016/j.lrp.2013.01.001; Hoang T, 2015, INFECT IMMUN, V83, P2118, DOI 10.1128/IAI.03030-14; Hubner MP, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001970; Ishikawa Larissa Lumi Watanabe, 2009, Genet Vaccines Ther, V7, P11, DOI 10.1186/1479-0556-7-11; Jensen TL, 2013, LAB ANIM-UK, V47, P225, DOI 10.1177/0023677213501659; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; Johnston CJC, 2015, JOVE-J VIS EXP, DOI 10.3791/52412; Le S, 2008, J STAT SOFTW, V25, P1, DOI 10.18637/jss.v025.i01; Leung CC, 2007, ARCH INTERN MED, V167, P1297, DOI 10.1001/archinte.167.12.1297; Long SR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51991-3; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Marzo E, 2014, TUBERCULOSIS, V94, P55, DOI 10.1016/j.tube.2013.09.004; McFarlane AJ, 2017, J ALLERGY CLIN IMMUN, V140, P1068, DOI 10.1016/j.jaci.2017.01.016; Menin A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053884; Nel HJ, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-9; O'Shea MK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02893; Obieglo K, 2016, J IMMUNOL, V196, P2262, DOI 10.4049/jimmunol.1500970; Olifiers N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143997; PALMER CE, 1966, AM REV RESPIR DIS, V94, P553; R Core Team R, 2022, R LANG ENV STAT COMP; Rech G, 2015, GENOME ANNOUNCEMENTS, V3, DOI 10.1128/genomeA.01485-14; Co TR, 2007, CLIN EXP IMMUNOL, V147, P45, DOI 10.1111/j.1365-2249.2006.03247.x; Ronchetti S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124090; Salgame P, 2013, NAT IMMUNOL, V14, P1118, DOI 10.1038/ni.2736; Sanchez G., 2013, PLS PATH MODELING R; Serrano E, 2014, EPIDEMIOL INFECT, V142, P530, DOI 10.1017/S0950268813001295; Tenenhaus M, 2005, COMPUT STAT DATA AN, V48, P159, DOI 10.1016/j.csda.2004.03.005; Tenenhaus M., 2004, P 42 SIS SCI M CLEUP, p739e; Tompkins DM, 2011, J ANIM ECOL, V80, P19, DOI 10.1111/j.1365-2656.2010.01742.x; Tristão-Sá Ricardo, 2002, Rev. Soc. Bras. Med. Trop., V35, P533, DOI 10.1590/S0037-86822002000500020; Tvarijonaviciute A, 2017, J ORAL PATHOL MED, V46, P387, DOI 10.1111/jop.12522; Tvarijonaviciute A, 2012, AM J VET RES, V73, P34, DOI 10.2460/ajvr.73.1.34; Verhagen LM, 2012, TUBERCULOSIS, V92, P505, DOI 10.1016/j.tube.2012.07.004; Vong L, 2014, J IMMUNOL, V192, P1870, DOI 10.4049/jimmunol.1302286; WAKELIN D, 1967, PARASITOLOGY, V57, P515, DOI 10.1017/S0031182000072395; Wieland CW, 2005, INT IMMUNOL, V17, P1399, DOI 10.1093/intimm/dxh317; WitkoSarsat V, 1996, KIDNEY INT, V49, P1304, DOI 10.1038/ki.1996.186	58	1	1	2	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2021	12								627638	10.3389/fimmu.2021.627638	http://dx.doi.org/10.3389/fimmu.2021.627638			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RT8IO	33936040	gold, Green Published			2022-12-18	WOS:000644699700001
J	Blank, S; Hilger, C				Blank, Simon; Hilger, Christiane			Editorial: Novel Advances in Allergy Diagnosis and Treatment	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						allergen; allergen-specific immunotherapy (AIT); allergy; allergy diagnosis; atopic diseases			[Blank, Simon] Tech Univ Munich, Fac Med, Ctr Allergy & Environm ZAUM, Munich, Germany; [Blank, Simon] German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Munich, Germany; [Blank, Simon] German Ctr Lung Res DZL, Munich, Germany; [Blank, Simon] Helmholtz Assoc, Immunol & Inflammat Initiat, Munich, Germany; [Hilger, Christiane] Luxembourg Inst Hlth LIH, Dept Infect & Immun, Esch Sur Alzette, Luxembourg	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Luxembourg Institute of Health	Blank, S (corresponding author), Tech Univ Munich, Fac Med, Ctr Allergy & Environm ZAUM, Munich, Germany.; Blank, S (corresponding author), German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Munich, Germany.; Blank, S (corresponding author), German Ctr Lung Res DZL, Munich, Germany.; Blank, S (corresponding author), Helmholtz Assoc, Immunol & Inflammat Initiat, Munich, Germany.; Hilger, C (corresponding author), Luxembourg Inst Hlth LIH, Dept Infect & Immun, Esch Sur Alzette, Luxembourg.	simon.blank@tum.de; christiane.hilger@lih.lu	Blank, Simon/M-7708-2013	Hilger, Christiane/0000-0001-9455-5442	Helmholtz Association, Future Topic "Immunology and Inflammation" [ZT-0027]	Helmholtz Association, Future Topic "Immunology and Inflammation"	This work was supported by the Helmholtz Association, Future Topic "Immunology and Inflammation" (ZT-0027) to SB.	Matricardi PM, 2016, PEDIAT ALLERG IMM-UK, V27, P1, DOI 10.1111/pai.12563; Noon L, 1911, LANCET, V1, P1572; Pfaar O, 2019, ALLERGY, V74, P3, DOI 10.1111/all.14077; Valenta R, 2018, J ALLER CL IMM-PRACT, V6, P1845, DOI 10.1016/j.jaip.2018.08.032; von Pirquet C., 1906, MUNCH MED WOCH, V53, P1475; World Allergy Organization, 2013, WORLD ALL ORG WHIT B	6	1	1	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 13	2021	12								662699	10.3389/fimmu.2021.662699	http://dx.doi.org/10.3389/fimmu.2021.662699			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RT3UH	33927726	Green Published, gold			2022-12-18	WOS:000644387100001
J	Auma, AWN; Shive, CL; Lange, A; Damjanovska, S; Kowal, C; Zebrowski, E; Pandiyan, P; Wilson, B; Kalayjian, RC; Canaday, DH; Anthony, DD				Auma, Ann W. N.; Shive, Carey L.; Lange, Alyssa; Damjanovska, Sofi; Kowal, Corinne; Zebrowski, Elizabeth; Pandiyan, Pushpa; Wilson, Brigid; Kalayjian, Robert C.; Canaday, David H.; Anthony, Donald D.			Naive CD4+T Cell Lymphopenia and Apoptosis in Chronic Hepatitis C Virus Infection Is Driven by the CD31+Subset and Is Partially Normalized in Direct-Acting Antiviral Treated Persons	FRONTIERS IN IMMUNOLOGY			English	Article						hepatitis c virus infection; na&#239; ve cd4+T cells; apoptosis; lymphopenia; direct-acting antiviral		Background The mechanisms underlying naive CD4+ lymphopenia during chronic Hepatitis C Virus (HCV) infection are unclear. Whether direct-acting antiviral (DAA) therapy restores peripheral naive CD4+ T cell numbers and function is unknown. Methods We enumerated frequencies and counts of peripheral naive CD4+, CD4+CD31+ and CD4+CD31- T cells by flow cytometry in a cross sectional analysis comparing chronic HCV infected (n=34), DAA-treated(n=29), and age-range matched controls (n=25), as well as in a longitudinal cohort of HCV DAA treated persons (n=16). The cross-sectional cohort was stratified by cirrhosis state. Cell apoptosis/survival (AnnexinV+7AAD+/BCL-2 labeling) and cell cycle entry (Ki67 expression) of CD31+ and CD31- naive CD4+ T cells was analyzed directly ex vivo and following 3 and 5 days of in vitro culture with media, interleukin (IL) -7 or CD3/CD28 activator. Results In the cross-sectional cohort, naive CD4+ proportions were lower in chronic HCV infected persons compared to controls and DAA-treated persons, an effect in part attributed to cirrhosis. Age was associated with naive cell counts and proportions in HCV infected and treated persons as well. Naive CD4+ cell proportions negatively correlated with plasma levels of soluble CD14 following therapy in DAA-treated persons. Naive CD4+ cells from HCV infected persons exhibited greater direct ex vivo apoptosis and cell-cycling compared to cells from DAA-treated persons and controls, and this was localized to the CD4+CD31+ subset. On the other hand, no remarkable differences in expression of BCL-2 or IL-7 Receptor (CD127) at baseline or following in vitro media or IL7 containing culture were observed. In the longitudinal cohort, naive CD4+CD31+/CD31- ratio tended to increase 24 weeks after DAA therapy initiation. Conclusions Activation and apoptosis of peripheral naive CD4+CD31+ T cells appear to contribute to naive CD4+ lymphopenia in chronic HCV infection, and this defect is partially reversible with HCV DAA therapy. Age and cirrhosis -associated naive CD4+ lymphopenia is present both before and after HCV DAA therapy. These findings have implications for restoration of host immune function after DAA therapy.	[Auma, Ann W. N.; Shive, Carey L.; Pandiyan, Pushpa; Anthony, Donald D.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; [Shive, Carey L.; Lange, Alyssa; Damjanovska, Sofi; Kowal, Corinne; Zebrowski, Elizabeth; Wilson, Brigid; Canaday, David H.; Anthony, Donald D.] VA Northeast Ohio Healthcare Syst, GRECC, Cleveland, OH 44106 USA; [Kalayjian, Robert C.; Anthony, Donald D.] Case Western Reserve Univ, MetroHlth Med Ctr, Dept Med, Cleveland, OH 44106 USA	Case Western Reserve University; Geriatric Research Education & Clinical Center; Case Western Reserve University; MetroHealth System	Anthony, DD (corresponding author), Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.; Anthony, DD (corresponding author), VA Northeast Ohio Healthcare Syst, GRECC, Cleveland, OH 44106 USA.; Anthony, DD (corresponding author), Case Western Reserve Univ, MetroHlth Med Ctr, Dept Med, Cleveland, OH 44106 USA.	dda3@case.edu		Damjanovska, Sofi/0000-0001-6036-9190; Lange, Alyssa/0000-0001-9956-4858	 [D43TW010319];  [IK2CX001471];  [BX001894];  [CX001791]	; ; ; 	This study was Supported by D43TW010319 (AA), IK2CX001471 (CS), BX001894 (DA), CX001791 (DA).	Albillos A, 2004, J HEPATOL, V40, P624, DOI 10.1016/j.jhep.2003.12.010; Beq S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034326; Bousso P, 2000, P NATL ACAD SCI USA, V97, P274, DOI 10.1073/pnas.97.1.274; Cicin-Sain L, 2010, J IMMUNOL, V184, P6739, DOI 10.4049/jimmunol.0904193; Cunningham CA, 2018, CURR OPIN IMMUNOL, V51, P1, DOI 10.1016/j.coi.2017.12.006; El-Bendary M., 2014, EGYPT J BASIC APPL S, V1, P136, DOI [10.1016/j.ejbas.2014.10.002, DOI 10.1016/J.EJBAS.2014.10.002]; Fink PJ, 2013, ANNU REV IMMUNOL, V31, P31, DOI 10.1146/annurev-immunol-032712-100010; Gomez I, 2003, MECH AGEING DEV, V124, P395, DOI 10.1016/S0047-6374(03)00014-9; Hartling HJ, 2013, SCAND J IMMUNOL, V78, P378, DOI 10.1111/sji.12096; Inaba M, 1999, J IMMUNOL, V163, P1315; Junge S, 2007, EUR J IMMUNOL, V37, P3270, DOI 10.1002/eji.200636976; Khaled AR, 2002, NAT REV IMMUNOL, V2, P817, DOI 10.1038/nri931; Kilpatrick RD, 2008, J IMMUNOL, V180, P1499, DOI 10.4049/jimmunol.180.3.1499; Kimmig S, 2002, J EXP MED, V195, P789, DOI 10.1084/jem.20011756; Kohler S, 2005, EUR J IMMUNOL, V35, P1987, DOI 10.1002/eji.200526181; Kostadinova Lenche, 2018, Pathog Immun, V3, P149, DOI 10.20411/pai.v3i1.242; Kostadinova L, 2016, J INFECT DIS, V214, P1438, DOI 10.1093/infdis/jiw372; Lario M, 2013, J HEPATOL, V59, P723, DOI 10.1016/j.jhep.2013.05.042; McGovern BH, 2007, CLIN INFECT DIS, V44, P431, DOI 10.1086/509580; MITA E, 1994, BIOCHEM BIOPH RES CO, V204, P468, DOI 10.1006/bbrc.1994.2483; Moniuszko M, 2004, J VIROL, V78, P9740, DOI 10.1128/JVI.78.18.9740-9749.2004; MORIMOTO C, 1993, CLIN EXP RHEUMATOL, V11, P241; NANDA NK, 1991, P NATL ACAD SCI USA, V88, P9503, DOI 10.1073/pnas.88.21.9503; Rathmell JC, 2001, J IMMUNOL, V167, P6869, DOI 10.4049/jimmunol.167.12.6869; Rickabaugh TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016459; Schulz AR., 2015, J IMMUNOL; Shive CL, 2018, VACCINE, V36, P453, DOI 10.1016/j.vaccine.2017.12.018; Shmagel KV, 2014, AIDS, V28, P2381, DOI 10.1097/QAD.0000000000000418; TAKESHITA S, 1989, EMBO J, V8, P3261, DOI 10.1002/j.1460-2075.1989.tb08486.x; Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; Tanaskovic S, 2010, IMMUNOL CELL BIOL, V88, P321, DOI 10.1038/icb.2009.108; Taya N, 2000, BRIT J HAEMATOL, V110, P89, DOI 10.1046/j.1365-2141.2000.01945.x; Tong QY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01399; Toubi E, 2001, J HEPATOL, V35, P774, DOI 10.1016/S0168-8278(01)00207-0; Vranjkovic A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01926; Wack A, 2001, EUR J IMMUNOL, V31, P166, DOI 10.1002/1521-4141(200101)31:1<166::AID-IMMU166>3.0.CO;2-L; WOODLAND DL, 1990, J IMMUNOL, V144, P379; Yonkers NL, 2011, J INFECT DIS, V203, P635, DOI 10.1093/infdis/jiq101; Zhao J, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0015-4; Zhu LX, 2004, WORLD J GASTROENTERO, V10, P2972	41	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2021	12								641230	10.3389/fimmu.2021.641230	http://dx.doi.org/10.3389/fimmu.2021.641230			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RS3QK	33912168	gold, Green Published			2022-12-18	WOS:000643696300001
J	Orend, G; Tucker, RP				Orend, Gertraud; Tucker, Richard P.			Did Tenascin-C Co-Evolve With the General Immune System of Vertebrates?	FRONTIERS IN IMMUNOLOGY			English	Review						tenascin; immunity; evolution; phylogeny; chemokine; development		Tenascin-C plays important roles in immunity. Toll-like receptor 4, integrin alpha 9 beta 1 and chemokines have already been identified as key players in executing the immune regulatory functions of tenascin-C. Tenascin-C is also found in reticular fibers in lymphoid tissues, which are major sites involved in the regulation of adaptive immunity. Did the "tool box" for reading and interpreting the immune-regulating instructions imposed by tenascins and tenascin-C co-evolve? Though the extracellular matrix is ancient, tenascins evolved relatively recently. Tenascin-like genes are first encountered in cephalochordates and urochordates, which are widely accepted as the early branching chordate lineages. Vertebrates lacking jaws like the lamprey have tenascins, but a tenascin gene that clusters in the tenascin-C clade first appears in cartilaginous fish. Adaptive immunity apparently evolved independently in jawless and jawed vertebrates, with the former using variable lymphocyte receptors for antigen recognition, and the latter using immunoglobulins. Thus, while tenascins predate the appearance of adaptive immunity, the first tenascin-C appears to have evolved in the first organisms with immunoglobulin-based adaptive immunity. While a C-X-C chemokine is present in the lamprey, C-C chemokines also appear in the first organisms with immunoglobulin-based adaptive immunity, as does the major histocompatibility complex, T-cell receptors, Toll-like receptor 4 and integrin alpha 9 beta 1. Given the importance of tenascin-C in inflammatory events, the co-evolution of tenascin-C and key elements of adaptive and innate immunity is suggestive of a fundamental role for this extracellular matrix glycoprotein in the immune response of jawed vertebrates.	[Orend, Gertraud] Inst Hematol Immunol, Hop Civil, Fac Med, Tumor Microenvironm Lab INSERM UMR S 1109,Inserm, Strasbourg, France; [Orend, Gertraud] Univ Strasbourg, Strasbourg, France; [Orend, Gertraud] Federat Med Translat Strasbourg FMTS, Strasbourg, France; [Tucker, Richard P.] Univ Calif Davis, Dept Cell Biol & Human Anat, Davis, CA 95616 USA	CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of California System; University of California Davis	Tucker, RP (corresponding author), Univ Calif Davis, Dept Cell Biol & Human Anat, Davis, CA 95616 USA.	rptucker@ucdavis.edu	Orend, Gertraud/E-8446-2015	Orend, Gertraud/0000-0003-2522-1195	INSERM; University Strasbourg; Agence National de la Recherche (ANR-ACKITEC, ANR-MatrixNash); Institut National Contre le Cancer (INCa PLBIO-TENMAX); L'Alliance nationale pour les sciences de la vie et de la sante (AVIESAN-Radio3R)	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); University Strasbourg; Agence National de la Recherche (ANR-ACKITEC, ANR-MatrixNash)(French National Research Agency (ANR)); Institut National Contre le Cancer (INCa PLBIO-TENMAX); L'Alliance nationale pour les sciences de la vie et de la sante (AVIESAN-Radio3R)	GO is supported by INSERM, the University Strasbourg, Agence National de la Recherche (ANR-ACKITEC, ANR-MatrixNash), Institut National Contre le Cancer (INCa PLBIO-TENMAX), and L'Alliance nationale pour les sciences de la vie et de la sante (AVIESAN-Radio3R).	Adams JC, 2015, CELL ADHES MIGR, V9, P22, DOI 10.4161/19336918.2014.970030; Anlar B, 2012, INT J BIOCHEM CELL B, V44, P1385, DOI 10.1016/j.biocel.2012.05.009; Anthony BA, 2014, TRENDS IMMUNOL, V35, P32, DOI 10.1016/j.it.2013.10.002; Antonacci R, 2020, GENES-BASEL, V11, DOI 10.3390/genes11060624; Bajoghli B, 2013, EUR J IMMUNOL, V43, P1686, DOI 10.1002/eji.201343557; Belmadani A, 2005, J NEUROSCI, V25, P3995, DOI 10.1523/JNEUROSCI.4631-04.2005; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Boehm T, 2012, CURR BIOL, V22, pR722, DOI 10.1016/j.cub.2012.07.003; Brennan JJ, 2018, MOL BIOL EVOL, V35, P1576, DOI 10.1093/molbev/msy050; Bronner ME, 2012, DEV BIOL, V366, P2, DOI 10.1016/j.ydbio.2011.12.042; Chiquet M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.611789; Chiquet-Ehrismann R, 2014, MATRIX BIOL, V37, P112, DOI 10.1016/j.matbio.2014.01.007; Chiquet-Ehrismann R, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004960; Degen M, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.623305; Deligne C, 2020, CANCER IMMUNOL RES, V8, P368, DOI 10.1158/2326-6066.CIR-19-0276; Ewan R, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-31; FINSTAD J, 1964, J EXP MED, V120, P1151, DOI 10.1084/jem.120.6.1151; Flajnik MF, 2018, J IMMUNOL, V201, P1331, DOI 10.4049/jimmunol.1800965; Flajnik MF., 2013, FUNDAMENTAL IMMUNOLO; Fouda GG, 2013, P NATL ACAD SCI USA, V110, P18220, DOI 10.1073/pnas.1307336110; Gong QZ, 2014, BIOL BULL-US, V227, P211, DOI 10.1086/BBLv227n3p211; Herrin BR, 2008, P NATL ACAD SCI USA, V105, P2040, DOI 10.1073/pnas.0711619105; Hinck AP, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022103; Hocking AM, 2015, ADV WOUND CARE, V4, P623, DOI 10.1089/wound.2014.0579; Huang SF, 2008, GENOME RES, V18, P1112, DOI 10.1101/gr.069674.107; Ji J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02525; Kanayama M, 2009, J IMMUNOL, V182, P8015, DOI 10.4049/jimmunol.0900725; Kuriyama N, 2011, HEPATOLOGY, V54, P2125, DOI 10.1002/hep.24639; Liu GS, 2020, GENOME BIOL EVOL, V12, P3615, DOI 10.1093/gbe/evz266; Lowy CM, 2015, CELL ADHES MIGR, V9, P112, DOI 10.1080/19336918.2015.1008331; Mackie EJ, 1999, J CELL SCI, V112, P3847; MACKIE EJ, 1988, DEVELOPMENT, V102, P237; Mangan RJ, 2019, MUCOSAL IMMUNOL, V12, P1004, DOI 10.1038/s41385-019-0164-2; Martinez VG, 2019, CELL REP, V29, P2810, DOI 10.1016/j.celrep.2019.10.103; Marzeda AM, 2018, J HISTOCHEM CYTOCHEM, V66, P289, DOI 10.1369/0022155418757443; Meijer AH, 2004, MOL IMMUNOL, V40, P773, DOI 10.1016/j.molimm.2003.10.003; Midwood K, 2009, NAT MED, V15, P774, DOI 10.1038/nm.1987; Midwood KS, 2016, J CELL SCI, V129, P4321, DOI 10.1242/jcs.190546; Najakshin AM, 1999, EUR J IMMUNOL, V29, P375, DOI 10.1002/(SICI)1521-4141(199902)29:02<375::AID-IMMU375>3.3.CO;2-Y; Ozbek S, 2010, MOL BIOL CELL, V21, P4300, DOI 10.1091/mbc.E10-03-0251; Orend G, 2006, CANCER LETT, V244, P143, DOI 10.1016/j.canlet.2006.02.017; Palti Y, 2011, DEV COMP IMMUNOL, V35, P1263, DOI 10.1016/j.dci.2011.03.006; Pancer Z, 2004, NATURE, V430, P174, DOI 10.1038/nature02740; Renart J, 2018, GENE REP, V13, P28, DOI 10.1016/j.genrep.2018.08.005; Rezzoug F, 2011, CYTOKINE, V56, P760, DOI 10.1016/j.cyto.2011.09.014; Ruhmann M, 2012, ARTHRITIS RHEUM-US, V64, P2179, DOI 10.1002/art.34401; Secombes CJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00209; Smith NC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02292; Sobocinski GP, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-42; Spenle C, 2020, CANCER IMMUNOL RES, V8, P1122, DOI 10.1158/2326-6066.CIR-20-0074; Spenle C, 2015, CELL ADHES MIGR, V9, P4, DOI 10.1080/19336918.2015.1005452; Staniszewska M, 2011, FOLIA HISTOCHEM CYTO, V49, P375, DOI 10.5603/FHC.2011.0053; Tucker RP, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-60; Tucker RP, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00053; Tucker RP, 2015, INT J BIOCHEM CELL B, V65, P165, DOI 10.1016/j.biocel.2015.06.003; Tucker RP, 2014, INT REV CEL MOL BIO, V308, P323, DOI 10.1016/B978-0-12-800097-7.00008-7; Tucker RP, 2009, INT J BIOCHEM CELL B, V41, P424, DOI 10.1016/j.biocel.2008.08.003; TUCKER RP, 1991, DEVELOPMENT, V112, P1031; Tucker RP, 2001, DEV DYNAM, V222, P115, DOI 10.1002/dvdy.1171; Valcourt U, 2015, CELL ADHES MIGR, V9, P154, DOI 10.4161/19336918.2014.994893; Yoshida T, 2015, CELL ADHES MIGR, V9, P96, DOI 10.1080/19336918.2015.1008332; Zhu LY, 2013, DEV COMP IMMUNOL, V39, P39, DOI 10.1016/j.dci.2012.04.001; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X; Zuliani-Alvarez L, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01718-7	64	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2021	12								663902	10.3389/fimmu.2021.663902	http://dx.doi.org/10.3389/fimmu.2021.663902			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RS3OR	33912190	gold, Green Published			2022-12-18	WOS:000643691700001
J	Totsune, E; Nakano, T; Moriya, K; Sato, D; Suzuki, D; Miura, A; Katayama, S; Niizuma, H; Kanno, J; van Zelm, MC; Imai, K; Kanegane, H; Sasahara, Y; Kure, S				Totsune, Eriko; Nakano, Tomohiro; Moriya, Kunihiko; Sato, Daichi; Suzuki, Dai; Miura, Akinobu; Katayama, Saori; Niizuma, Hidetaka; Kanno, Junko; van Zelm, Menno C.; Imai, Kohsuke; Kanegane, Hirokazu; Sasahara, Yoji; Kure, Shigeo			Case Report: Infantile-Onset Fulminant Type 1 Diabetes Mellitus Caused by Novel Compound Heterozygous LRBA Variants	FRONTIERS IN IMMUNOLOGY			English	Article						infantile-onset fulminant type 1 diabetes mellitus; LRBA deficiency; refractory autoimmune cytopenia; CTLA-4 deficiency; transposable elements (TE)		Lipopolysaccharide-responsive beige-like anchor (LRBA) deficiency is a subtype of common variable immune deficiency (CVID). Numerous case reports and cohort studies have described a broad spectrum of clinical manifestations and variable disease phenotypes, including immune dysregulation, enteropathy, and recurrent infections. Although LRBA deficiency is an autosomal recessive primary immunodeficiency resulting in a phenotype similar to CVID, it is a monogenic disease and separate from CVID. Recently, in a report of monogenic primary immunodeficiency disorder associated with CVID and autoimmunity, the most common mutated gene was LRBA. We report the case of a girl who presented with fulminant type 1 diabetes at age 7 months. She later experienced recurrent bacterial infections with neutropenia and idiopathic thrombocytopenic purpura. Clinical genome sequencing revealed compound heterozygosity of the LRBA gene, which bore two novel mutations. A genetic basis should be considered in the differential diagnosis for very young patients with fulminant autoimmunity, and the diagnostic work-up should include evaluation of markers of immunodeficiency.	[Totsune, Eriko; Nakano, Tomohiro; Moriya, Kunihiko; Sato, Daichi; Suzuki, Dai; Miura, Akinobu; Katayama, Saori; Niizuma, Hidetaka; Kanno, Junko; Sasahara, Yoji; Kure, Shigeo] Tohoku Univ, Dept Pediat, Grad Sch Med, Sendai, Miyagi, Japan; [van Zelm, Menno C.] Monash Univ, Dept Immunol & Pathol, Melbourne, Vic, Australia; [van Zelm, Menno C.] Alfred Hosp, Melbourne, Vic, Australia; [van Zelm, Menno C.] Monash Univ, Fac Med Nursing & Hlth Sci, Jeffrey Modell Diagnost & Res Ctr Primary Immunod, Melbourne, Vic, Australia; [Imai, Kohsuke] Tokyo Med & Dent Univ, Dept Community Pediat Perinatal & Maternal Med, Tokyo, Japan; [Kanegane, Hirokazu] Tokyo Med & Dent Univ TMDU, Grad Sch Med & Dent Sci, Dept Chid Hlth & Dev, Tokyo, Japan	Tohoku University; Monash University; Florey Institute of Neuroscience & Mental Health; Monash University; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Moriya, K (corresponding author), Tohoku Univ, Dept Pediat, Grad Sch Med, Sendai, Miyagi, Japan.	kunihiko.moriya.a3@tohoku.ac.jp		Nakano, Tomohiro/0000-0001-9534-5121	Japanese Ministry of Health, Labor and Welfare of Japan [19K23819]; Australian National Health and Medical Research Council (NHMRC) [1117687]; Jeffrey Modell Foundation	Japanese Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Jeffrey Modell Foundation	KM was supported by grant from the Japanese Ministry of Health, Labor and Welfare of Japan (Grant Number 19K23819). MZ was supported by the Australian National Health and Medical Research Council (NHMRC; Senior Research Fellowship 1117687) and the Jeffrey Modell Foundation.	Alkhairy OK, 2016, J CLIN IMMUNOL, V36, P33, DOI 10.1007/s10875-015-0224-7; Azizi G, 2017, EUR ANN ALLERGY CLIN, V49, P235, DOI 10.23822/EurAnnACI.1764-1489.22; Bacchetta R, 2018, ANN NY ACAD SCI, V1417, P5, DOI 10.1111/nyas.13011; Banday AZ, 2020, J CLIN IMMUNOL, V40, P1184, DOI 10.1007/s10875-020-00835-1; Burnett DL, 2017, IMMUNOL CELL BIOL, V95, P775, DOI 10.1038/icb.2017.50; Fischer A, 2017, J ALLERGY CLIN IMMUN, V140, P1388, DOI 10.1016/j.jaci.2016.12.978; Gu Y, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/6924637; Habibi S, 2019, J ALLER CL IMM-PRACT, V7, P2379, DOI 10.1016/j.jaip.2019.04.011; Haseda F, 2011, IMMUNOL LETT, V139, P80, DOI 10.1016/j.imlet.2011.05.003; Hou TZ, 2017, BLOOD, V129, P1458, DOI 10.1182/blood-2016-10-745174; Imagawa A, 2005, DIABETOLOGIA, V48, P294, DOI 10.1007/s00125-004-1626-x; Kanegane H, 2018, ALLERGOL INT, V67, P43, DOI 10.1016/j.alit.2017.06.003; Kiykim A, 2019, J ALLER CL IMM-PRACT, V7, P2790, DOI 10.1016/j.jaip.2019.06.011; Kotani R, 2004, DIABETOLOGIA, V47, P1285, DOI 10.1007/s00125-004-1441-4; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Roep BO, 2003, DIABETOLOGIA, V46, P305, DOI 10.1007/s00125-003-1089-5; Schwab C, 2018, J ALLERGY CLIN IMMUN, V142, P1932, DOI 10.1016/j.jaci.2018.02.055; Shiga K, 2018, ENDOCR J, V65, P795, DOI 10.1507/endocrj.EJ18-0029; Takashima T, 2017, J CLIN IMMUNOL, V37, P486, DOI 10.1007/s10875-017-0405-7; Tesch VK, 2020, J ALLERGY CLIN IMMUN, V145, P1452, DOI 10.1016/j.jaci.2019.12.896; van Zelm MC, 2008, AM J HUM GENET, V82, P320, DOI 10.1016/j.ajhg.2007.10.011	22	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2021	12								677572	10.3389/fimmu.2021.677572	http://dx.doi.org/10.3389/fimmu.2021.677572			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RS3QB	33912197	Green Published, gold			2022-12-18	WOS:000643695400001
J	Wang, SS; Chen, D; He, JJ; Zheng, WB; Tian, AL; Zhao, GH; Elsheikha, HM; Zhu, XQ				Wang, Sha-Sha; Chen, Dan; He, Jun-Jun; Zheng, Wen-Bin; Tian, Ai-Ling; Zhao, Guang-Hui; Elsheikha, Hany M.; Zhu, Xing-Quan			Fasciola gigantica-Derived Excretory-Secretory Products Alter the Expression of mRNAs, miRNAs, lncRNAs, and circRNAs Involved in the Immune Response and Metabolism in Goat Peripheral Blood Mononuclear Cells	FRONTIERS IN IMMUNOLOGY			English	Article						Fasciola gigantica; peripheral blood mononuclear cells; RNA-seq; excretory-secretory products; long noncoding RNA	ALTERNATIVE ACTIVATION; APOPTOSIS; HEPATICA; GENES; INFECTION; EFFICIENT	Fasciola gigantica produces excretory-secretory products (ESPs) with immune-modulating effects to promote its own survival. In this study, we performed RNA-seq to gain a comprehensive global understanding of changes in the expression of mRNAs, miRNAs, lncRNAs, and circRNAs in goat peripheral blood mononuclear cells (PBMCs) treated with F. gigantica ESPs. A total of 1,544 differently expressed mRNAs (790 upregulated and 754 downregulated genes), 30 differently expressed miRNAs (24 upregulated and 6 downregulated genes), 136 differently expressed circRNAs (83 upregulated and 53 downregulated genes), and 1,194 differently expressed lncRNAs (215 upregulated and 979 downregulated genes) were identified. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses revealed that F. gigantica ESPs altered the expression of genes associated with the host immune response, receptor signaling, disease and metabolism. Results from RNA-seq were validated by qRT-PCR. These findings provide an important resource for future investigation of the role of mRNAs and non-coding RNAs in mediating the immune-modulating effects of F. gigantica ESPs.	[Wang, Sha-Sha; He, Jun-Jun; Tian, Ai-Ling; Zhu, Xing-Quan] Chinese Acad Agr Sci, State Key Lab Vet Etiol Biol, Key Lab Vet Parasitol Gansu Prov, Lanzhou Vet Res Inst, Lanzhou, Peoples R China; [Wang, Sha-Sha; Zhao, Guang-Hui] Northwest A&F Univ, Coll Vet Med, Yangling, Shaanxi, Peoples R China; [Chen, Dan] Fudan Univ, Sch Sci, Shanghai, Peoples R China; [Zheng, Wen-Bin; Zhu, Xing-Quan] Shanxi Agr Univ, Coll Vet Med, Taigu, Peoples R China; [Elsheikha, Hany M.] Univ Nottingham, Fac Med & Hlth Sci, Sch Vet Med & Sci, Loughborough, Leics, England; [Zhu, Xing-Quan] Yunnan Agr Univ, Coll Vet Med, Key Lab Vet Publ Hlth Higher Educ Yunnan Prov, Kunming, Yunnan, Peoples R China	Chinese Academy of Agricultural Sciences; Lanzhou Veterinary Research Institute, CAAS; Northwest A&F University - China; Fudan University; Shanxi Agricultural University; University of Nottingham; Yunnan Agricultural University	Zhu, XQ (corresponding author), Chinese Acad Agr Sci, State Key Lab Vet Etiol Biol, Key Lab Vet Parasitol Gansu Prov, Lanzhou Vet Res Inst, Lanzhou, Peoples R China.; Zhu, XQ (corresponding author), Shanxi Agr Univ, Coll Vet Med, Taigu, Peoples R China.; Elsheikha, HM (corresponding author), Univ Nottingham, Fac Med & Hlth Sci, Sch Vet Med & Sci, Loughborough, Leics, England.; Zhu, XQ (corresponding author), Yunnan Agr Univ, Coll Vet Med, Key Lab Vet Publ Hlth Higher Educ Yunnan Prov, Kunming, Yunnan, Peoples R China.	hany.elsheikha@nottingham.ac.uk; xingquanzhu1@hotmail.com	Elsheikha, Hany/G-7573-2011		National Key Basic Research Program (973 Program) of China [2015CB150300]; Agricultural Science and Technology Innovation Program (ASTIP) [CAAS-ASTIP-2016-LVRI03]; Yunnan Expert Workstation [202005AF150041]	National Key Basic Research Program (973 Program) of China(National Basic Research Program of China); Agricultural Science and Technology Innovation Program (ASTIP); Yunnan Expert Workstation	Project financial support was provided by the National Key Basic Research Program (973 Program) of China (grant 2015CB150300), the Agricultural Science and Technology Innovation Program (ASTIP) (grant CAAS-ASTIP-2016-LVRI03) and Yunnan Expert Workstation (grant 202005AF150041).	Alvarez Rojas CA, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0715-7; Ashour DS, 2015, EXPERT REV CLIN IMMU, V11, P771, DOI 10.1586/1744666X.2015.1037286; Bogdan C, 2015, TRENDS IMMUNOL, V36, P161, DOI 10.1016/j.it.2015.01.003; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Brubaker SW, 2015, ANNU REV IMMUNOL, V33, P257, DOI 10.1146/annurev-immunol-032414-112240; Carmona C, 2017, J HELMINTHOL, V91, P99, DOI 10.1017/S0022149X16000560; Chen D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01707; Donnelly S, 2010, J BIOL CHEM, V285, P3383, DOI 10.1074/jbc.M109.060368; El Ridi R, 2007, VET PARASITOL, V149, P219, DOI 10.1016/j.vetpar.2007.08.024; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Falcon C, 2010, VET IMMUNOL IMMUNOP, V137, P36, DOI 10.1016/j.vetimm.2010.04.007; Figueroa-Santiago O, 2014, INFECT IMMUN, V82, P5005, DOI 10.1128/IAI.02541-14; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Flynn RJ, 2007, VET IMMUNOL IMMUNOP, V120, P31, DOI 10.1016/j.vetimm.2007.07.003; Flynn RJ, 2008, INFECT IMMUN, V76, P678, DOI 10.1128/IAI.00732-07; Friedlander MR, 2012, NUCLEIC ACIDS RES, V40, P37, DOI 10.1093/nar/gkr688; Fu Y, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00485; Fu Y, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005015; Gao Y, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0571-3; Girones N, 2007, J INFECT DIS, V195, P1504, DOI 10.1086/514822; Huang SY, 2019, PARASITOL RES, V118, P453, DOI 10.1007/s00436-018-6169-z; Joshi AD, 2008, EUR J IMMUNOL, V38, P3436, DOI 10.1002/eji.200838629; Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882; Kelley JM, 2016, TRENDS PARASITOL, V32, P458, DOI 10.1016/j.pt.2016.03.002; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kong L, 2007, NUCLEIC ACIDS RES, V35, pW345, DOI 10.1093/nar/gkm391; Kozat S, 2010, J PARASITOL, V96, P657, DOI 10.1645/GE-2104.1; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lenton LM, 1996, RES VET SCI, V61, P152, DOI 10.1016/S0034-5288(96)90091-0; Li AM, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-311; Li GF, 2018, EXP THER MED, V16, P2665, DOI 10.3892/etm.2018.6516; Liu Q, 2017, PARASITOL RES, V116, P627, DOI 10.1007/s00436-016-5327-4; Mao XZ, 2005, BIOINFORMATICS, V21, P3787, DOI 10.1093/bioinformatics/bti430; Martin I, 2015, J IMMUNOL, V194, P3924, DOI 10.4049/jimmunol.1401182; Mas-Coma S, 2005, J HELMINTHOL, V79, P207, DOI 10.1079/JOH2005296; Mungube EO, 2006, TROP ANIM HEALTH PRO, V38, P475, DOI 10.1007/s11250-006-4394-4; Novobilsky A, 2007, PARASITOL RES, V101, P357, DOI 10.1007/s00436-007-0463-5; Patel V, 2015, FASEB J, V29, P1859, DOI 10.1096/fj.14-257808; Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122; Phiri IK, 2007, VET PARASITOL, V143, P287, DOI 10.1016/j.vetpar.2006.09.001; Schwantes JB, 2020, J HELMINTHOL, V94, DOI 10.1017/S0022149X19000774; Semnani RT, 2008, BLOOD, V112, P1290, DOI 10.1182/blood-2008-04-149856; Sen GC, 2005, CYTOKINE GROWTH F R, V16, P1, DOI 10.1016/j.cytogfr.2005.01.006; Serradell MC, 2009, MOL BIOCHEM PARASIT, V163, P95, DOI 10.1016/j.molbiopara.2008.10.005; Shi W, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008951; Tian AL, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9090758; Tian AL, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3148-2; Tian AL, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2745-4; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Walsh KP, 2009, J IMMUNOL, V183, P1577, DOI 10.4049/jimmunol.0803803; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; Wang LK, 2010, BIOINFORMATICS, V26, P136, DOI 10.1093/bioinformatics/btp612; Wen M, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-140; Xia BR, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0322-4; Yadav SC, 1999, VET PARASITOL, V82, P285, DOI 10.1016/S0304-4017(99)00005-9; Yin Y, 2014, CLIN CANCER RES, V20, P6187, DOI 10.1158/1078-0432.CCR-14-1030; Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-2-r14; Zhang FK, 2018, MOL IMMUNOL, V94, P18, DOI 10.1016/j.molimm.2017.12.007; Zhang FK, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-1990-2	59	1	1	5	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2021	12								653755	10.3389/fimmu.2021.653755	http://dx.doi.org/10.3389/fimmu.2021.653755			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RS3UN	33912180	Green Published, gold			2022-12-18	WOS:000643707300001
J	Galitska, G; Coscia, A; Forni, D; Steinbrueck, L; De Meo, S; Biolatti, M; De Andrea, M; Cagliani, R; Leone, A; Bertino, E; Schulz, T; Santoni, A; Landolfo, S; Sironi, M; Cerboni, C; Dell'Oste, V				Galitska, Ganna; Coscia, Alessandra; Forni, Diego; Steinbrueck, Lars; De Meo, Simone; Biolatti, Matteo; De Andrea, Marco; Cagliani, Rachele; Leone, Agata; Bertino, Enrico; Schulz, Thomas; Santoni, Angela; Landolfo, Santo; Sironi, Manuela; Cerboni, Cristina; Dell'Oste, Valentina			Genetic Variability of Human Cytomegalovirus Clinical Isolates Correlates With Altered Expression of Natural Killer Cell-Activating Ligands and IFN-gamma	FRONTIERS IN IMMUNOLOGY			English	Article						human cytomegalovirus (HCMV); innate immunity; congenital infection; next generation sequencing; genetic variability; multiple-strain infection; NK cells; immunomodulation		Human cytomegalovirus (HCMV) infection often leads to systemic disease in immunodeficient patients and congenitally infected children. Despite its clinical significance, the exact mechanisms contributing to HCMV pathogenesis and clinical outcomes have yet to be determined. One of such mechanisms involves HCMV-mediated NK cell immune response, which favors viral immune evasion by hindering NK cell-mediated cytolysis. This process appears to be dependent on the extent of HCMV genetic variation as high levels of variability in viral genes involved in immune escape have an impact on viral pathogenesis. However, the link between viral genome variations and their functional effects has so far remained elusive. Thus, here we sought to determine whether inter-host genetic variability of HCMV influences its ability to modulate NK cell responses to infection. For this purpose, five HCMV clinical isolates from a previously characterized cohort of pediatric patients with confirmed HCMV congenital infection were evaluated by next-generation sequencing (NGS) for genetic polymorphisms, phylogenetic relationships, and multiple-strain infection. We report variable levels of genetic characteristics among the selected clinical strains, with moderate variations in genome regions associated with modulation of NK cell functions. Remarkably, we show that different HCMV clinical strains differentially modulate the expression of several ligands for the NK cell-activating receptors NKG2D, DNAM-1/CD226, and NKp30. Specifically, the DNAM-1/CD226 ligand PVR/CD155 appears to be predominantly upregulated by fast-replicating ("aggressive") HCMV isolates. On the other hand, the NGK2D ligands ULBP2/5/6 are downregulated regardless of the strain used, while other NK cell ligands (i.e., MICA, MICB, ULBP3, Nectin-2/CD112, and B7-H6) are not significantly modulated. Furthermore, we show that IFN-gamma; production by NK cells co-cultured with HCMV-infected fibroblasts is directly proportional to the aggressiveness of the HCMV clinical isolates employed. Interestingly, loss of NK cell-modulating genes directed against NK cell ligands appears to be a common feature among the "aggressive" HCMV strains, which also share several gene variants across their genomes. Overall, even though further studies based on a higher number of patients would offer a more definitive scenario, our findings provide novel mechanistic insights into the impact of HCMV genetic variability on NK cell-mediated immune responses.	[Galitska, Ganna; Biolatti, Matteo; De Andrea, Marco; Landolfo, Santo; Dell'Oste, Valentina] Univ Turin, Dept Publ Hlth & Pediat Sci, Lab Pathogenesis Viral Infect, Turin, Italy; [Coscia, Alessandra; Leone, Agata; Bertino, Enrico] Univ Turin, Dept Publ Hlth & Pediat Sci, Neonatal Unit, Turin, Italy; [Forni, Diego; Cagliani, Rachele; Sironi, Manuela] Sci Inst IRCCS E Medea, Lab Bioinformat, Bosisio Parini, Italy; [Steinbrueck, Lars; Schulz, Thomas] Hannover Med Sch, Inst Virol, Hannover, Germany; [De Meo, Simone; Santoni, Angela; Cerboni, Cristina] Sapienza Univ Rome, Dept Mol Med, Lab Mol Immunol & Immunopathol, Rome, Italy; [De Andrea, Marco] Univ Piemonte Orientale, Ctr Translat Res Autoimmune & Allerg Dis CAAD, Novara, Italy; [Galitska, Ganna] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	University of Turin; University of Turin; IRCCS Eugenio Medea; Hannover Medical School; Sapienza University Rome; University of Eastern Piedmont Amedeo Avogadro; University System of Maryland; University of Maryland Baltimore	Dell'Oste, V (corresponding author), Univ Turin, Dept Publ Hlth & Pediat Sci, Lab Pathogenesis Viral Infect, Turin, Italy.; Cerboni, C (corresponding author), Sapienza Univ Rome, Dept Mol Med, Lab Mol Immunol & Immunopathol, Rome, Italy.	cristina.cerboni@uniroma1.it; valentina.delloste@unito.it	De Andrea, Marco/J-5253-2012; Forni, Diego/K-5643-2016; Biolatti, Matteo/AAU-6647-2020; Sironi, manuela/K-5633-2016; coscia, alessandra/AFR-8018-2022	De Andrea, Marco/0000-0002-3188-5783; Forni, Diego/0000-0001-9291-5352; Biolatti, Matteo/0000-0001-7675-0762; Sironi, manuela/0000-0002-2267-5266; coscia, alessandra/0000-0001-5094-1077; DELL'OSTE, Valentina/0000-0002-9336-7906; Galitska, Ganna/0000-0001-9365-6751	European Commission under the Horizon2020 program (H2020-MSCA-ITN-2015); Italian Ministry of Education, University and Research-MIUR (PRIN 2015) [2015W729WH, 2015RMNSTA]; Italian Ministry of Education, University and Research-MIUR (PRIN 2017) [2017 20178ALPCM]; Italian Ministry of Health [RC 2019, RC 2018-2019]	European Commission under the Horizon2020 program (H2020-MSCA-ITN-2015); Italian Ministry of Education, University and Research-MIUR (PRIN 2015)(Ministry of Education, Universities and Research (MIUR)); Italian Ministry of Education, University and Research-MIUR (PRIN 2017)(Ministry of Education, Universities and Research (MIUR)); Italian Ministry of Health(Ministry of Health, Italy)	This work was supported by the European Commission under the Horizon2020 program (H2020-MSCA-ITN-2015), Italian Ministry of Education, University and Research-MIUR (PRIN 2015 to MA and CC, 2015W729WH; PRIN 2015 to VD, 2015RMNSTA; PRIN 2017 to VD and CC, 2017 20178ALPCM), and Italian Ministry of Health (grant No. RC 2019 to MS, grant No. RC 2018-2019 to DF). The funding agencies had no role in study design, data collection and interpretation, as well as in the decision to submit this work for publication.	Adland E, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01016; Ali A, 2019, CURR OPIN VIROL, V34, P130, DOI 10.1016/j.coviro.2019.02.005; Ashiru O, 2009, J VIROL, V83, P12345, DOI 10.1128/JVI.01175-09; Balazs Z, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16262-z; Beck S, 1991, DNA Seq, V2, P33, DOI 10.3109/10425179109008436; Bennett NJ, 2010, J IMMUNOL, V185, P1093, DOI 10.4049/jimmunol.1000789; Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; Bradley AJ, 2009, J GEN VIROL, V90, P2375, DOI 10.1099/vir.0.013250-0; Britt WJ, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080405; Brizic I, 2018, MICROBES INFECT, V20, P543, DOI 10.1016/j.micinf.2017.12.010; Brock I, 2013, J VIROL, V87, P6005, DOI 10.1128/JVI.03558-12; Cappadona I, 2015, J VIROL, V89, P7314, DOI 10.1128/JVI.00603-15; Cha TA, 1996, J VIROL, V70, P78, DOI 10.1128/JVI.70.1.78-83.1996; Chen SJ, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010021; Cudini J, 2019, P NATL ACAD SCI USA, V116, P5693, DOI 10.1073/pnas.1818130116; Dargan DJ, 2010, J GEN VIROL, V91, P1535, DOI 10.1099/vir.0.018994-0; De Maria A, 2011, P NATL ACAD SCI USA, V108, P728, DOI 10.1073/pnas.1012356108; Della Chiesa M, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02297; Dolan A, 2004, J GEN VIROL, V85, P1301, DOI 10.1099/vir.0.79888-0; Dunn W, 2003, P NATL ACAD SCI USA, V100, P14223, DOI 10.1073/pnas.2334032100; Fehr AR, 2010, J VIROL, V84, P291, DOI 10.1128/JVI.01116-09; Feng LY, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006867; Fielding CA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004058; Freud AG, 2017, IMMUNITY, V47, P820, DOI 10.1016/j.immuni.2017.10.008; Fuchs A, 2004, J IMMUNOL, V172, P3994, DOI 10.4049/jimmunol.172.7.3994; Galitska G, 2019, FUTURE VIROL, V14, P247, DOI 10.2217/fvl-2018-0189; Galitska G, 2018, J CLIN VIROL, V108, P132, DOI 10.1016/j.jcv.2018.09.019; Geiger TL, 2016, CURR OPIN IMMUNOL, V39, P82, DOI 10.1016/j.coi.2016.01.007; Giannattasio A, 2017, J CLIN VIROL, V96, P32, DOI 10.1016/j.jcv.2017.09.006; Grainger L, 2010, J VIROL, V84, P9472, DOI 10.1128/JVI.00855-10; Griffiths P, 2015, J PATHOL, V235, P288, DOI 10.1002/path.4437; Guo GQ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171959; Hage E, 2017, J INFECT DIS, V215, P1673, DOI 10.1093/infdis/jix157; Hahn G, 2004, J VIROL, V78, P10023, DOI 10.1128/JVI.78.18.10023-10033.2004; Houldcroft CJ, 2020, P NATL ACAD SCI USA, V117, P818, DOI 10.1073/pnas.1918955117; Hsu JL, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004811; Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030; James SH, 2016, CURR OPIN PEDIATR, V28, P81, DOI 10.1097/MOP.0000000000000305; Jensen JD, 2020, P NATL ACAD SCI USA, V117, P816, DOI 10.1073/pnas.1915295117; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Kim ET, 2009, J VIROL, V83, P12046, DOI 10.1128/JVI.00411-09; La Rosa C, 2012, FUTURE VIROL, V7, P279, DOI 10.2217/FVL.12.8; Lam VC, 2017, CURR OPIN IMMUNOL, V44, P43, DOI 10.1016/j.coi.2016.11.003; Lassalle F, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew017; Lisboa LF, 2012, TRANSPL INFECT DIS, V14, P132, DOI 10.1111/j.1399-3062.2011.00685.x; Long EO, 2013, ANNU REV IMMUNOL, V31, P227, DOI 10.1146/annurev-immunol-020711-075005; Lurain NS, 1999, J VIROL, V73, P10040, DOI 10.1128/JVI.73.12.10040-10050.1999; Manandhar T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153626; Manicklal S, 2013, CLIN MICROBIOL REV, V26, P86, DOI 10.1128/CMR.00062-12; Manuel O, 2013, CLIN INFECT DIS, V56, P817, DOI 10.1093/cid/cis993; Marti-Carreras J, 2019, VIRUS GENES, V55, P138, DOI 10.1007/s11262-018-1627-3; Muhire BM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108277; Murphy E, 2008, CURR TOP MICROBIOL, V325, P1; Nelson CS, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0074-4; Nemcovicova I, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003224; Paludan SR, 2011, NAT REV IMMUNOL, V11, P143, DOI 10.1038/nri2937; Patel M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02214; Peck KM, 2018, J VIROL, V92, DOI 10.1128/JVI.01031-17; Pegram HJ, 2011, IMMUNOL CELL BIOL, V89, P216, DOI 10.1038/icb.2010.78; Perotti M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010035; Picarda G, 2018, J IMMUNOL, V200, P3881, DOI 10.4049/jimmunol.1800171; Pignoloni B, 2016, J IMMUNOL, V197, P4066, DOI 10.4049/jimmunol.1502527; Plotkin SA, 2019, VACCINE, V37, P7437, DOI 10.1016/j.vaccine.2018.02.089; Poole E, 2006, EMBO J, V25, P4390, DOI 10.1038/sj.emboj.7601287; Prichard MN, 2001, REV MED VIROL, V11, P191, DOI 10.1002/rmv.315; Prod'homme V, 2010, J GEN VIROL, V91, P2034, DOI 10.1099/vir.0.021931-0; Puchhammer-Stockl E, 2011, FUTURE VIROL, V6, P259, DOI 10.2217/FVL.10.87; Rasmussen L, 2003, J INFECT DIS, V187, P809, DOI 10.1086/367900; Rawlinson WD, 2017, LANCET INFECT DIS, V17, pE177, DOI 10.1016/S1473-3099(17)30143-3; Renzette N, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003735; Renzette N, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001344; Revello MG, 2001, J GEN VIROL, V82, P1429, DOI 10.1099/0022-1317-82-6-1429; Robertson MJ, 2002, J LEUKOCYTE BIOL, V71, P173; Rolle A, 2003, J IMMUNOL, V171, P902, DOI 10.4049/jimmunol.171.2.902; Rossini G, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/607276; Sackman AM, 2018, PATHOGENS, V7, DOI 10.3390/pathogens7010016; Sainz B, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-14; Savoy SKA, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100959; Schmiedel D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00390; Sedy JR, 2013, J IMMUNOL, V191, P828, DOI 10.4049/jimmunol.1300894; Seidel E, 2015, CELL REP, V10, P968, DOI 10.1016/j.celrep.2015.01.029; Sijmons S, 2015, J VIROL, V89, P7673, DOI 10.1128/JVI.00578-15; Sijmons S, 2014, VIRUSES-BASEL, V6, P1049, DOI 10.3390/v6031049; Sinzger C, 1999, J GEN VIROL, V80, P2867, DOI 10.1099/0022-1317-80-11-2867; Smith MS, 2004, J VIROL, V78, P4444, DOI 10.1128/JVI.78.9.4444-4453.2004; Stamminger T, 2002, J VIROL, V76, P4836, DOI 10.1128/JVI.76.10.4836-4847.2002; Stempel M, 2019, MED MICROBIOL IMMUN, V208, P495, DOI 10.1007/s00430-019-00582-0; Stern-Ginossar N, 2012, SCIENCE, V338, P1088, DOI 10.1126/science.1227919; Suarez NM, 2019, J INFECT DIS, V220, P781, DOI 10.1093/infdis/jiz208; Tomasec P, 2005, NAT IMMUNOL, V6, P181, DOI 10.1038/ni1156; Van Damme E, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00218; Wang JL, 2006, J VIROL, V80, P6003, DOI 10.1128/JVI.00401-06; Wilkinson GWG, 2015, MED MICROBIOL IMMUN, V204, P273, DOI 10.1007/s00430-015-0411-4; Wills MR, 2005, J IMMUNOL, V175, P7457, DOI 10.4049/jimmunol.175.11.7457; Yan N, 2012, NAT IMMUNOL, V13, P214, DOI 10.1038/ni.2229; Yoshie O, 2015, INT IMMUNOL, V27, P11, DOI 10.1093/intimm/dxu079; Yu D, 2003, P NATL ACAD SCI USA, V100, P12396, DOI 10.1073/pnas.1635160100; Zingoni A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00476	98	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 9	2021	12								532484	10.3389/fimmu.2021.532484	http://dx.doi.org/10.3389/fimmu.2021.532484			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RQ3DQ	33897679	Green Published, gold			2022-12-18	WOS:000642303100001
J	Wei, XD; Zhang, JH; Zhou, XY				Wei, Xundong; Zhang, Jianhua; Zhou, Xuyu			Ex-TFRs: A Missing Piece of the SLE Puzzle?	FRONTIERS IN IMMUNOLOGY			English	Review						systemic lupus erythematosus; T regulatory cell; ex-TFRs; Foxp3; stability; autoantibodies	FOLLICULAR REGULATORY CELLS; PROTEIN; HELPER	Systemic lupus erythematosus (SLE) is a chronic multi-organ autoimmune disease involving the production of a wide range of autoantibodies and complement activation. The production of these high-affinity autoantibodies requires T cell/B cell collaboration as well as germinal center (GC) formation. T follicular regulatory cells (TFRs) are functional specialized T regulatory cells (Tregs) that safeguard against both self-reactive T and B cells. However, recent evidence suggests that TFRs are not always stable and can lose Foxp3 expression to become pathogenic "ex-TFRs" that gain potent effector functions. In this review, we summarize the literature on intrinsic and extrinsic mechanisms of regulation of TFR stability and discuss the potential role of TFR reprogramming in autoantibody production and SLE pathogenesis.	[Wei, Xundong] Chinese Acad Med Sci, Beijing Hosp, Ctr Biotherapy, Natl Ctr Gerontol,Inst Geriatr Med, Beijing, Peoples R China; [Wei, Xundong; Zhang, Jianhua; Zhou, Xuyu] Univ Chinese Acad Sci, Savaid Med Sch, Beijing, Peoples R China; [Zhang, Jianhua; Zhou, Xuyu] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China	Beijing Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Institute of Microbiology, CAS	Zhou, XY (corresponding author), Univ Chinese Acad Sci, Savaid Med Sch, Beijing, Peoples R China.; Zhou, XY (corresponding author), Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China.	zhouxy@im.ac.cn	Zhou, Xuyu/L-7422-2019	Zhou, Xuyu/0000-0002-6626-0898	National Natural Science Foundation of China [31870911, 81802872]; National Science and Technology Major Project of China [2016ZX10004222-007, 2018ZX10301-208-002-002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project of China	This work was supported by the National Natural Science Foundation of China (31870911, 81802872), the National Science and Technology Major Project of China (2016ZX10004222-007 and 2018ZX10301-208-002-002).	Alvarado-Sanchez B, 2006, J AUTOIMMUN, V27, P110, DOI 10.1016/j.jaut.2006.06.005; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Ayyoub M, 2009, P NATL ACAD SCI USA, V106, P8635, DOI 10.1073/pnas.0900621106; Bailey-Bucktrout SL, 2013, IMMUNITY, V39, P949, DOI 10.1016/j.immuni.2013.10.016; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bennett CL, 2001, CURR OPIN PEDIATR, V13, P533, DOI 10.1097/00008480-200112000-00007; Blanco P, 2016, EUR J IMMUNOL, V46, P281, DOI 10.1002/eji.201545760; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Botta D, 2017, NAT IMMUNOL, V18, P1249, DOI 10.1038/ni.3837; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Burbelo PD, 2015, DISCOV MED, V20, P17; Burchill MA, 2007, J IMMUNOL, V178, P280, DOI 10.4049/jimmunol.178.1.280; Cameron J, 2020, J IMMUNOL, V205, P2953, DOI 10.4049/jimmunol.2000537; Chavele KM, 2011, FEBS LETT, V585, P3603, DOI 10.1016/j.febslet.2011.07.043; Chen LF, 2019, ADV IMMUNOL, V144, P87, DOI 10.1016/bs.ai.2019.07.001; Chung Y, 2011, NAT MED, V17, P983, DOI 10.1038/nm.2426; Clement RL, 2019, NAT IMMUNOL, V20, P1360, DOI 10.1038/s41590-019-0472-4; Cortez JT, 2020, NATURE, V582, P416, DOI 10.1038/s41586-020-2246-4; Depis F, 2016, P NATL ACAD SCI USA, V113, P1345, DOI 10.1073/pnas.1524660113; DuPage M, 2015, IMMUNITY, V42, P227, DOI 10.1016/j.immuni.2015.01.007; ELOUAAI F, 1994, NEPHROL DIAL TRANSPL, V9, P362; Feldman CH, 2013, ARTHRITIS RHEUM-US, V65, P753, DOI 10.1002/art.37795; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Furtado GC, 2002, J EXP MED, V196, P851, DOI 10.1084/jem.20020190; Hamilton JA, 2019, IMMUNOL REV, V292, P120, DOI 10.1111/imr.12815; Harry O, 2018, J PEDIATR-US, V196, P22, DOI 10.1016/j.jpeds.2018.01.045; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hori S, 2014, IMMUNOL REV, V259, P159, DOI 10.1111/imr.12175; Hou S, 2019, J EXP MED, V216, P605, DOI 10.1084/jem.20181134; Huynh A, 2015, NAT IMMUNOL, V16, P188, DOI 10.1038/ni.3077; Itoh M, 1999, J IMMUNOL, V162, P5317; Jacquemin C, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122167; Jenks SA, 2019, IMMUNOL REV, V288, P136, DOI 10.1111/imr.12741; Jin HS, 2013, J CLIN INVEST, V123, P4923, DOI 10.1172/JCI69355; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kim BS, 2017, CELL REP, V21, P195, DOI 10.1016/j.celrep.2017.09.021; Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109; Koch MA, 2012, IMMUNITY, V37, P501, DOI 10.1016/j.immuni.2012.05.031; Leavenworth JW, 2015, NAT IMMUNOL, V16, P96, DOI 10.1038/ni.3050; Lee JH, 2015, IMMUNITY, V42, P1062, DOI 10.1016/j.immuni.2015.05.016; Levine AG, 2014, NAT IMMUNOL, V15, P1070, DOI 10.1038/ni.3004; Li MO, 2016, NAT REV IMMUNOL, V16, P220, DOI 10.1038/nri.2016.26; Li XD, 2014, CELL, V158, P734, DOI 10.1016/j.cell.2014.07.030; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Liu B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08300-3; Liu C, 2018, INT IMMUNOPHARMACOL, V56, P261, DOI 10.1016/j.intimp.2018.01.038; Loo CS, 2020, IMMUNITY, V53, P143, DOI 10.1016/j.immuni.2020.06.011; Lyssuk EY, 2007, ADV EXP MED BIOL, V601, P113; Maceiras AR, 2017, IMMUNOLOGY, V152, P25, DOI 10.1111/imm.12774; Maceiras AR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15067; Mohan C, 2015, NAT REV NEPHROL, V11, P329, DOI 10.1038/nrneph.2015.33; Mullins GN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78975-y; Muto G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074639; Nelson Brad H, 2002, Curr Dir Autoimmun, V5, P92; Oestreich KJ, 2012, NAT IMMUNOL, V13, P405, DOI 10.1038/ni.2242; Ohkura N, 2012, IMMUNITY, V37, P785, DOI 10.1016/j.immuni.2012.09.010; Pelly VS, 2017, J EXP MED, V214, P1809, DOI 10.1084/jem.20161104; Polansky JK, 2010, J MOL MED, V88, P1029, DOI 10.1007/s00109-010-0642-1; Ritvo PG, 2018, P NATL ACAD SCI USA, V115, P9604, DOI 10.1073/pnas.1808594115; Rudra D, 2009, NAT IMMUNOL, V10, P1170, DOI 10.1038/ni.1795; Sage PT, 2020, CURR OPIN IMMUNOL, V67, P68, DOI 10.1016/j.coi.2020.10.009; Sage PT, 2016, NAT IMMUNOL, V17, P1436, DOI 10.1038/ni.3578; Sage PT, 2016, IMMUNOL REV, V271, P246, DOI 10.1111/imr.12411; Sage PT, 2015, TRENDS IMMUNOL, V36, P410, DOI 10.1016/j.it.2015.05.005; Sage PT, 2014, IMMUNITY, V41, P1026, DOI 10.1016/j.immuni.2014.12.005; Sage PT, 2014, J CLIN INVEST, V124, P5191, DOI 10.1172/JCI76861; Sage PT, 2013, NAT IMMUNOL, V14, P152, DOI 10.1038/ni.2496; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Samstein RM, 2012, CELL, V151, P153, DOI 10.1016/j.cell.2012.06.053; Sawant DV, 2014, IMMUNOL REV, V259, P173, DOI 10.1111/imr.12173; Sayin I, 2018, J EXP MED, V215, P1531, DOI 10.1084/jem.20171940; Sebastian M, 2016, J IMMUNOL, V196, P144, DOI 10.4049/jimmunol.1501704; Shi H, 2018, IMMUNITY, V49, P899, DOI 10.1016/j.immuni.2018.10.010; Shrestha S, 2015, NAT IMMUNOL, V16, P178, DOI 10.1038/ni.3076; Takahashi R, 2017, J IMMUNOL, V199, P149, DOI 10.4049/jimmunol.1600441; Tsuji M, 2009, SCIENCE, V323, P1488, DOI 10.1126/science.1169152; Vahl JC, 2014, IMMUNITY, V41, P722, DOI 10.1016/j.immuni.2014.10.012; Valencia X, 2007, J IMMUNOL, V178, P2579, DOI 10.4049/jimmunol.178.4.2579; Vargas-Rojas MI, 2008, LUPUS, V17, P289, DOI 10.1177/0961203307088307; Voo KS, 2009, P NATL ACAD SCI USA, V106, P4793, DOI 10.1073/pnas.0900408106; Wang L, 2019, CELL REP, V29, P1848, DOI 10.1016/j.celrep.2019.10.012; Wei XD, 2017, CELL REP, V21, P1853, DOI 10.1016/j.celrep.2017.10.090; Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437; Wing JB, 2020, IMMUNOL REV, V296, P104, DOI 10.1111/imr.12888; Wing JB, 2017, P NATL ACAD SCI USA, V114, pE6400, DOI 10.1073/pnas.1705551114; Wollenberg I, 2011, J IMMUNOL, V187, P4553, DOI 10.4049/jimmunol.1101328; Wu D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15876; Wu H, 2016, EUR J IMMUNOL, V46, P1152, DOI 10.1002/eji.201546094; Wu X, 2020, SCIENCE, V369, P984, DOI 10.1126/science.aba6652; Xie MM, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128076; Xu BH, 2017, CLIN IMMUNOL, V183, P46, DOI 10.1016/j.clim.2017.07.004; Yu C, 2014, J AUTOIMMUN, V48-49, P10, DOI 10.1016/j.jaut.2014.01.004; Yue XJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09541-y; Yue XJ, 2016, J EXP MED, V213, P377, DOI 10.1084/jem.20151438; Zhang R, 2017, J IMMUNOL, V199, P3972, DOI 10.4049/jimmunol.1700409; Zhang ZM, 2017, J IMMUNOL, V198, P2612, DOI 10.4049/jimmunol.1601409; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750; Zhou XY, 2008, J EXP MED, V205, P1983, DOI 10.1084/jem.20080707; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774	103	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 9	2021	12								662305	10.3389/fimmu.2021.662305	http://dx.doi.org/10.3389/fimmu.2021.662305			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RQ5CE	33897710	gold, Green Published			2022-12-18	WOS:000642434600001
J	Zhan, PP; Li, HZ; Han, MZ; Wang, Z; Zhao, J; Tu, JP; Shi, XF; Fu, YX				Zhan, Panpan; Li, Haizheng; Han, Mingzhe; Wang, Zhen; Zhao, Jie; Tu, Jinpeng; Shi, Xiaofeng; Fu, Yingxin			PSMP Is Discriminative for Chronic Active Antibody-Mediated Rejection and Associate With Intimal Arteritis in Kidney Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						kidney transplantation; chronic active antibody-mediated rejection; PC3-secreted microprotein; macrophages; intimal arteritis		Chronic active antibody-mediated rejection (CAAMR) is an intermediate process that occurs during the development of chronic antibody-mediated rejection (CAMR), which is a key problem associated with the long-term kidney grafts survival. This study investigated the role played by PC3-secreted microprotein (PSMP) in the progression of CAAMR and CAMR. We showed that CAAMR and CAMR patients' allografts dysfunction with declined survival rate, which suggested that earlier diagnosis and treatment of CAAMR might be important to prevent irreversible chronic injury of CAMR progression. We found PSMP was an important factor in the development of chronic antibody-mediated rejection. The PSMP expression increased significantly in CAAMR biopsy samples but not in CAMR and control patients, which distinguished CAAMR patients from CAMR and non-rejection patients. Moreover, our results showed that infiltration of CD68(+) macrophages in CAAMR increased, and the correlation between CD68(+) macrophages and PSMP expression in CAAMR patients was significant. Additionally, our data also revealed that intimal arteritis (v-lesion) accompanied by increased macrophage infiltration might have contributed to more graft loss in CAAMR, and PSMP expression was significantly associated with the v-lesion score. These results indicated that PSMP played an important role in the recruitment of macrophages and promote intimal arteritis inducing allograft lost in CAAMR progression. In future study PSMP could be a potential histopathological diagnostic biomarker and treatment target for CAAMR in kidney transplantation.	[Zhan, Panpan; Wang, Zhen; Zhao, Jie; Tu, Jinpeng; Shi, Xiaofeng; Fu, Yingxin] Nankai Univ, Tianjin First Cent Hosp, Sch Med, Dept Kidney Transplantat, Tianjin, Peoples R China; [Zhan, Panpan; Fu, Yingxin] Tianjin First Cent Hosp, Dept Kidney Transplantat & Kidney Transplantat Re, Tianjin, Peoples R China; [Zhan, Panpan; Fu, Yingxin] Chinese Acad Med Sci, Key Lab Transplantat, Tianjin, Peoples R China; [Li, Haizheng] Tianjin Med Univ, First Cent Clin Coll, Tianjin, Peoples R China; [Han, Mingzhe] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Tianjin, Peoples R China	Nankai University; Tianjin Medical University; Tianjin Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Tianjin Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Peking Union Medical College	Fu, YX (corresponding author), Nankai Univ, Tianjin First Cent Hosp, Sch Med, Dept Kidney Transplantat, Tianjin, Peoples R China.; Fu, YX (corresponding author), Tianjin First Cent Hosp, Dept Kidney Transplantat & Kidney Transplantat Re, Tianjin, Peoples R China.; Fu, YX (corresponding author), Chinese Acad Med Sci, Key Lab Transplantat, Tianjin, Peoples R China.	fuyingxintj@163.com			National Natural Science Foundation of China [81970654]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (81970654).	Aguado-Dominguez E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02605; Azad TD, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.95659; Brasen JH, 2017, KIDNEY INT, V92, DOI 10.1016/j.kint.2017.01.029; Doberer K, 2021, J AM SOC NEPHROL, V32, P708, DOI 10.1681/ASN.2020071106; Guillen-Gomez E, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.13998; Haas M, 2018, AM J TRANSPLANT, V18, P293, DOI 10.1111/ajt.14625; Haas M, 2014, AM J TRANSPLANT, V14, P272, DOI 10.1111/ajt.12590; Haas M, 2018, AM J TRANSPLANT, V18, P2849, DOI 10.1111/ajt.15088; Hara S, 2017, CLIN EXP NEPHROL, V21, P943, DOI 10.1007/s10157-016-1361-x; Higuchi H, 2020, INT IMMUNOL, V32, P335, DOI 10.1093/intimm/dxaa003; JEANNET M, 1970, NEW ENGL J MED, V282, P111, DOI 10.1056/NEJM197001152820301; Li JH, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/5763430; Loupy A, 2020, AM J TRANSPLANT, V20, P2318, DOI 10.1111/ajt.15898; Matheson PJ, 2005, TRANSPLANTATION, V79, P1658, DOI 10.1097/01.TP.0000167099.51275.EC; Moreau A, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a015461; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Pei XL, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00724; Pei XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05255-7; Pei XL, 2014, J IMMUNOL, V192, P1878, DOI 10.4049/jimmunol.1300758; Reese SR, 2021, TRANSPLANTATION, V105, P1516, DOI 10.1097/TP.0000000000003530; Roufosse C, 2018, TRANSPLANTATION, V102, P1795, DOI 10.1097/TP.0000000000002366; Sablik KA, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03106; Sablik KA, 2019, TRANSPL IMMUNOL, V56, DOI 10.1016/j.trim.2019.101213; Salazar IDR, 2015, J AM SOC NEPHROL, V26, P3190, DOI 10.1681/ASN.2014111064; She SP, 2020, J HEPATOL, V72, P506, DOI 10.1016/j.jhep.2019.09.033; Stevenson HL, 2018, AM J TRANSPLANT, V18, P1534, DOI 10.1111/ajt.14708; Tang PMK, 2019, NAT REV NEPHROL, V15, P144, DOI 10.1038/s41581-019-0110-2; Tillmann FP, 2018, CLIN EXP NEPHROL, V22, P474, DOI 10.1007/s10157-017-1470-1; Toki D, 2014, AM J TRANSPLANT, V14, P2126, DOI 10.1111/ajt.12803; van den Bosch TPP, 2017, AM J TRANSPLANT, V17, P2659, DOI 10.1111/ajt.14280; van den Bosch TPP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00153; van der Zwan M, 2021, TRANSPLANTATION, V105, P478, DOI 10.1097/TP.0000000000003279; Zhao Y, 2018, AM J TRANSPLANT, V18, P604, DOI 10.1111/ajt.14543	33	1	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 9	2021	12								661911	10.3389/fimmu.2021.661911	http://dx.doi.org/10.3389/fimmu.2021.661911			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RQ4ZR	33897709	Green Published, gold			2022-12-18	WOS:000642428100001
J	Angelini, DF; De Angelis, F; Vacca, V; Piras, E; Parisi, C; Nutini, M; Spalloni, A; Pagano, F; Longone, P; Battistini, L; Pavone, F; Marinelli, S				Angelini, Daniela Francesca; De Angelis, Federica; Vacca, Valentina; Piras, Eleonora; Parisi, Chiara; Nutini, Michele; Spalloni, Alida; Pagano, Francesca; Longone, Patrizia; Battistini, Luca; Pavone, Flaminia; Marinelli, Sara			Very Early Involvement of Innate Immunity in Peripheral Nerve Degeneration in SOD1-G93A Mice (vol 11, 575792, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						Peripheral nerve degeneration; demyelination; amyotrophic lateral sclerosis; mast cells; monocytes; macrophages; pro-inflammatory cytokine; autoimmunity			[Angelini, Daniela Francesca; De Angelis, Federica; Piras, Eleonora; Nutini, Michele; Spalloni, Alida; Longone, Patrizia; Battistini, Luca] IRCCS Santa Lucia Fdn, Neuroimmunol Unit, Rome, Italy; [De Angelis, Federica; Vacca, Valentina; Parisi, Chiara; Pagano, Francesca; Pavone, Flaminia; Marinelli, Sara] CNR, Natl Res Council, Inst Biochem & Cell Biol, Rome, Italy; [Nutini, Michele] Osped Pediat Bambino Gesu, IRCCS, Orphanet Italy, Rome, Italy	IRCCS Santa Lucia; Consiglio Nazionale delle Ricerche (CNR); IRCCS Bambino Gesu	Marinelli, S (corresponding author), CNR, Natl Res Council, Inst Biochem & Cell Biol, Rome, Italy.	sara.marinelli@cnr.it	Spalloni, Alida/K-4316-2014; Angelini, Daniela F/J-8001-2018; Battistini, luca/ABE-1882-2021; Pagano, Francesca/V-4204-2019; Battistini, Luca/D-6920-2014	Angelini, Daniela F/0000-0003-4552-9226; Pagano, Francesca/0000-0003-1956-5864; Battistini, Luca/0000-0002-6488-4891				Angelini DF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.575792	1	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 6	2021	12								682508	10.3389/fimmu.2021.682508	http://dx.doi.org/10.3389/fimmu.2021.682508			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RO9XA	33889160	Green Published, gold			2022-12-18	WOS:000641390700001
J	Christley, S; Ostmeyer, J; Quirk, L; Zhang, W; Sirak, B; Giuliano, AR; Zhang, S; Monson, N; Tiro, J; Lucas, E; Cowell, LG				Christley, Scott; Ostmeyer, Jared; Quirk, Lisa; Zhang, Wei; Sirak, Bradley; Giuliano, Anna R.; Zhang, Song; Monson, Nancy; Tiro, Jasmin; Lucas, Elena; Cowell, Lindsay G.			T Cell Receptor Repertoires Acquired via Routine Pap Testing May Help Refine Cervical Cancer and Precancer Risk Estimates	FRONTIERS IN IMMUNOLOGY			English	Article						cervical cancer screening; cervical cancer surveillance; immune repertoire; machine learning; regression biomarker	IMMUNE; LYMPHOCYTES; DISEASE; LESIONS; CD4+	Cervical cancer is the fourth most common cancer and fourth leading cause of cancer death among women worldwide. In low Human Development Index settings, it ranks second. Screening and surveillance involve the cytology-based Papanicolaou (Pap) test and testing for high-risk human papillomavirus (hrHPV). The Pap test has low sensitivity to detect precursor lesions, while a single hrHPV test cannot distinguish a persistent infection from one that the immune system will naturally clear. Furthermore, among women who are hrHPV-positive and progress to high-grade cervical lesions, testing cannot identify the similar to 20% who would progress to cancer if not treated. Thus, reliable detection and treatment of cancers and precancers requires routine screening followed by frequent surveillance among those with past abnormal or positive results. The consequence is overtreatment, with its associated risks and complications, in screened populations and an increased risk of cancer in under-screened populations. Methods to improve cervical cancer risk assessment, particularly assays to predict regression of precursor lesions or clearance of hrHPV infection, would benefit both populations. Here we show that women who have lower risk results on follow-up testing relative to index testing have evidence of enhanced T cell clonal expansion in the index cervical cytology sample compared to women who persist with higher risk results from index to follow-up. We further show that a machine learning classifier based on the index sample T cells predicts this transition to lower risk with 95% accuracy (19/20) by leave-one-out cross-validation. Using T cell receptor deep sequencing and machine learning, we identified a biophysicochemical motif in the complementarity-determining region 3 of T cell receptor beta chains whose presence predicts this transition. While these results must still be tested on an independent cohort in a prospective study, they suggest that this approach could improve cervical cancer screening by helping distinguish women likely to spontaneously regress from those at elevated risk of progression to cancer. The advancement of such a strategy could reduce surveillance frequency and overtreatment in screened populations and improve the delivery of screening to under-screened populations.	[Christley, Scott; Ostmeyer, Jared; Quirk, Lisa; Zhang, Song; Tiro, Jasmin; Cowell, Lindsay G.] UT Southwestern Med Ctr, Dept Populat & Data Sci, Dallas, TX 75390 USA; [Zhang, Wei; Monson, Nancy; Cowell, Lindsay G.] UT Southwestern Med Ctr, Dept Neurol & Neurotherapeut, Dept Immunol, Dallas, TX 75390 USA; [Sirak, Bradley; Giuliano, Anna R.] H Lee Moffitt Canc Ctr & Res Inst, Ctr Immunizat & Infect Res, Tampa, FL USA; [Lucas, Elena] UT Southwestern Med Ctr, Dept Pathol, Dallas, TX USA; [Lucas, Elena] Parkland Hlth & Hosp Syst, Dept Pathol, Dallas, TX USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; H Lee Moffitt Cancer Center & Research Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas	Cowell, LG (corresponding author), UT Southwestern Med Ctr, Dept Populat & Data Sci, Dallas, TX 75390 USA.; Cowell, LG (corresponding author), UT Southwestern Med Ctr, Dept Neurol & Neurotherapeut, Dept Immunol, Dallas, TX 75390 USA.	lindsay.cowell@utsouthwestern.edu			Simmons Comprehensive Cancer Center Development Funds	Simmons Comprehensive Cancer Center Development Funds	This research was supported by Simmons Comprehensive Cancer Center Development Funds and by a charitable donation from Young Texans Against Cancer, both to LC and JT.	Arbyn M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008054.pub2; Atchley WR, 2005, P NATL ACAD SCI USA, V102, P6395, DOI 10.1073/pnas.0408677102; Bagaev DV, 2020, NUCLEIC ACIDS RES, V48, pD1057, DOI 10.1093/nar/gkz874; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruni L, 2016, LANCET GLOB HEALTH, V4, pE453, DOI 10.1016/S2214-109X(16)30099-7; Carbonneau MA, 2018, PATTERN RECOGN, V77, P329, DOI 10.1016/j.patcog.2017.10.009; Carlson CS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3680; Castle PE, 2005, JNCI-J NATL CANCER I, V97, P1066, DOI 10.1093/jnci/dji186; Christley S, 2020, FRONT BIG DATA, V3, DOI 10.3389/fdata.2020.00022; Christley S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00976; Cortes-Alaguero C, 2017, J TURK-GER GYNECOL A, V18, P1, DOI 10.4274/jtgga.2016.0138; Cowell LG, 2020, CANCER RES, V80, P643, DOI 10.1158/0008-5472.CAN-19-1457; Cui JH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02729; Curry SJ, 2018, JAMA-J AM MED ASSOC, V320, P674, DOI [10.1001/jama.2018.10897, 10.1097/01.ogx.0000549540.69362.81]; Cuzick J, 2017, JAMA ONCOL, V3, P1327, DOI 10.1001/jamaoncol.2017.1040; Darragh TM, 2012, J LOW GENIT TRACT DI, V16, P205, DOI 10.1097/PGP.0b013e31826916c7; Del Mistro A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/984528; Egemen D, 2020, J LOW GENIT TRACT DI, V24, P132, DOI 10.1097/LGT.0000000000000529; Elfstrom KM, 2015, EUR J CANCER, V51, P950, DOI 10.1016/j.ejca.2015.03.008; Elfstrom KM, 2015, INT J CANCER, V136, P350, DOI 10.1002/ijc.28984; Farnsworth A, 2011, ACTA CYTOL, V55, P307, DOI 10.1159/000326956; Giuliano AR, 2008, CANCER EPIDEM BIOMAR, V17, P2036, DOI 10.1158/1055-9965.EPI-08-0151; Giuliano AR, 2007, J INFECT DIS, V196, P1146, DOI 10.1086/521629; Goldie SJ, 2005, NEW ENGL J MED, V353, P2158, DOI 10.1056/NEJMsa044278; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Gravitt PE, 1998, J CLIN MICROBIOL, V36, P3020, DOI 10.1128/JCM.36.10.3020-3027.1998; Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357; Hajian-Tilaki K, 2014, J BIOMED INFORM, V48, P193, DOI 10.1016/j.jbi.2014.02.013; Harper DM, 2017, GYNECOL ONCOL, V146, P196, DOI 10.1016/j.ygyno.2017.04.004; Hibma Merilyn H, 2012, Open Virol J, V6, P241, DOI 10.2174/1874357901206010241; Jia QZ, 2015, INT J CLIN EXP MED, V8, P1803; Kim KH, 2012, CANCER IMMUNOL IMMUN, V61, P63, DOI 10.1007/s00262-011-1092-5; Koliopoulos G, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008587.pub2; Kuhs KAL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0178167; Kyrgiou M, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012847; Loke AY, 2017, J PRIM CARE COMMUNIT, V8, P349, DOI 10.1177/2150131917742299; Meijer CJLM, 2017, JAMA ONCOL, V3, P1310, DOI 10.1001/jamaoncol.2017.1522; Monnier-Benoit S, 2006, GYNECOL ONCOL, V102, P22, DOI 10.1016/j.ygyno.2005.11.039; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Nayar Ritu, 2004, Cytojournal, V1, P4, DOI 10.1186/1742-6413-1-4; Newman PA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019206; Origoni M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/831907; Ostmeyer J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229569; Ostmeyer J, 2019, CANCER RES, V79, P1671, DOI 10.1158/0008-5472.CAN-18-2292; Ostmeyer J, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1814-6; Pages F, 2010, ONCOGENE, V29, P1093, DOI 10.1038/onc.2009.416; Perkins RB, 2020, J LOW GENIT TRACT DI, V24, P102, DOI 10.1097/LGT.0000000000000525; Robins HS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007247; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Rubelt F, 2017, NAT IMMUNOL, V18, P1274, DOI 10.1038/ni.3873; Sankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516; Sasagawa T, 2012, J INFECT CHEMOTHER, V18, P807, DOI 10.1007/s10156-012-0485-5; Schiffman M, 2005, NEW ENGL J MED, V353, P2101, DOI 10.1056/NEJMp058171; Schiffman M, 2009, NEW ENGL J MED, V360, P1453, DOI 10.1056/NEJMe0901167; Schlecht NF, 2003, JNCI-J NATL CANCER I, V95, P1336, DOI 10.1093/jnci/djg037; Seresini S, 2007, J IMMUNOL, V179, P7176, DOI 10.4049/jimmunol.179.10.7176; Sevy AM, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3281-8; Sroczynski G, 2020, INT J CANCER, V147, P1131, DOI 10.1002/ijc.32849; Stevanovic S, 2017, SCIENCE, V356, P200, DOI 10.1126/science.aak9510; Stevanovic S, 2015, J CLIN ONCOL, V33, P1543, DOI 10.1200/JCO.2014.58.9093; Tickotsky N, 2017, BIOINFORMATICS, V33, P2924, DOI 10.1093/bioinformatics/btx286; Toh ZQ, 2019, INFECT DRUG RESIST, V12, P1951, DOI 10.2147/IDR.S178381; Trimble CL, 2010, J IMMUNOL, V185, P7107, DOI 10.4049/jimmunol.1002756; Trimble CL, 2010, CANCER IMMUNOL IMMUN, V59, P799, DOI 10.1007/s00262-009-0806-4; Trope A, 2012, J CLIN MICROBIOL, V50, P1927, DOI 10.1128/JCM.00265-12; Usyk M, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008376; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wang LW, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-2069-6; Wang XL, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02896; Weinmann S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0165276; Zoete V, 2019, CANCER RES, V79, P1299, DOI 10.1158/0008-5472.CAN-19-0225; 2005, CERVIX CANC SCREENIN	73	1	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 2	2021	12								624230	10.3389/fimmu.2021.624230	http://dx.doi.org/10.3389/fimmu.2021.624230			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RN5EJ	33868241	Green Published, gold			2022-12-18	WOS:000640374100001
J	Alon, U; Mokryn, O; Hershberg, U				Alon, Uri; Mokryn, Osnat; Hershberg, Uri			Using Domain Based Latent Personal Analysis of B Cell Clone Diversity Patterns to Identify Novel Relationships Between the B Cell Clone Populations in Different Tissues	FRONTIERS IN IMMUNOLOGY			English	Article						Immunity; Complexity; B cell; diversity; Long tail distribution; Population comparison		The B cell population is highly diverse and very skewed. It is divided into clones (B cells with a common mother cell). It is thought that each clone represents an initial B cell receptor specificity. A few clones are very abundant, comprised of hundreds or thousands of B cells while the majority have only a few cells per clone. We suggest a novel method - domain-based latent personal analysis (LPA), a method for spectral exploration of entities in a domain, which can be used to find the spectral spread of sub repertoires within a person. LPA defines a domain-based spectral signature for each sub repertoire. LPA signatures consist of the elements, in our case - the clones, that most differentiate the sub repertoire from the person's abundance of clones. They include both positive elements, which describe overabundant clones, and negative elements that describe missing clones. The signatures can also be used to compare the sub repertoires they represent to each other. Applying LPA to compare the repertoires found in different tissues, we reiterated previous findings that showed that gut and blood tissues have separate repertoires. We further identify a third branch of clonal patterns typical of the lymphatic organs (Spleen, MLN, and bone marrow) separated from the other two categories. We developed a python version of LPA analysis that can easily be applied to compare clonal distributions - https://github.com/ScanLab-ossi/LPA. It could also be easily adapted to study other skewed sequence populations used in the analysis of B cell receptor populations, for instance, k-mers and V gene usage. These analysis types should allow for inter and intra-repertoire comparisons of diversity, which could revolutionize the way we understand repertoire changes and diversity.	[Alon, Uri; Hershberg, Uri] Univ Haifa, Fac Sci, Dept Human Biol, Haifa, Israel; [Mokryn, Osnat] Univ Haifa, Fac Social Sci, Dept Informat Syst, Haifa, Israel	University of Haifa; University of Haifa	Hershberg, U (corresponding author), Univ Haifa, Fac Sci, Dept Human Biol, Haifa, Israel.	uri@sci.haifa.ac.il			NIH [P01 AI106697]; European Union's Horizon 2020 research and innovation program [825821]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Union's Horizon 2020 research and innovation program	This research was funded by NIH P01 AI106697 and the European Union's Horizon 2020 research and innovation program, under grant agreement No 825821.	Bigi B, 2003, LECT NOTES COMPUT SC, V2633, P305; Cancro MP, 2009, TRENDS IMMUNOL, V30, P313, DOI 10.1016/j.it.2009.04.005; de Greef PC, 2020, ELIFE, V9, DOI 10.7554/eLife.49900; Dunn-Walters DK, 2003, BIOCHEM SOC T, V31, P447, DOI 10.1042/BST0310447; Gibson KL, 2009, AGING CELL, V8, P18, DOI 10.1111/j.1474-9726.2008.00443.x; Greiff V, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0169-8; Henry C, 2019, CELL HOST MICROBE, V25, P357, DOI 10.1016/j.chom.2019.01.002; Hershberg U., 2004, COGN SYSTEMS ESSCS, V6, P181; Ivanov PC, 1999, NATURE, V399, P461, DOI 10.1038/20924; KULLBACK S, 1951, ANN MATH STAT, V22, P79, DOI 10.1214/aoms/1177729694; Laydon DJ, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0291; Louzoun Y, 2001, PHYSICA A, V297, P242, DOI 10.1016/S0378-4371(01)00201-1; Madi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017445; Meng WZ, 2017, NAT BIOTECHNOL, V35, P879, DOI 10.1038/nbt.3942; Miho E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00224; Mokryn O., 2020, ARXIV; Mora T, 2010, P NATL ACAD SCI USA, V107, P5405, DOI 10.1073/pnas.1001705107; Schwab DJ, 2014, PHYS REV LETT, V113, DOI 10.1103/PhysRevLett.113.068102; Verbavatz V, 2020, NATURE, V587, P397, DOI 10.1038/s41586-020-2900-x; Wu YCB, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00193; Wuchty S, 2001, MOL BIOL EVOL, V18, P1694, DOI 10.1093/oxfordjournals.molbev.a003957; Zipf G, 1935, PSYCHOBIOLOGY LANGUA	22	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 1	2021	12								642673	10.3389/fimmu.2021.642673	http://dx.doi.org/10.3389/fimmu.2021.642673			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RN4SE	33868278	Green Published, gold			2022-12-18	WOS:000640341700001
J	Nataf, S; Hunot, S; Dorothee, G; Liblau, R				Nataf, Serge; Hunot, Stephane; Dorothee, Guillaume; Liblau, Roland			Editorial: Brain-Targeted Autoimmunity: Beyond Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						autoimmunity; central nervous system; autoantibodies; T-cell; neurodegeneration			[Nataf, Serge] Univ Claude Bernard Lyon 1, Univ Lyon, INSERM, Stem Cell & Brain Res Inst U1208, Bron, France; [Hunot, Stephane] Sorbonne Univ, Hop Pitie Salpetriere, APHP, Inst Cerveau,Paris Brain Inst ICM,Inserm,CNRS, Paris, France; [Dorothee, Guillaume] Sorbonne Univ, Hop St Antoine, Ctr Rech St Antoine, Inserm,Immune Syst & Neuroinflammat Lab, Paris, France; [Liblau, Roland] Univ Toulouse, CNRS, INSERM, Infin,UPS, Toulouse, France; [Liblau, Roland] Hop Purpan, Dept Immunol, CHU Toulouse, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Nataf, S (corresponding author), Univ Claude Bernard Lyon 1, Univ Lyon, INSERM, Stem Cell & Brain Res Inst U1208, Bron, France.	serge.nataf@inserm.fr	DOROTHEE, Guillaume/O-9760-2016	DOROTHEE, Guillaume/0000-0001-5763-3632					0	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 1	2021	12								677577	10.3389/fimmu.2021.677577	http://dx.doi.org/10.3389/fimmu.2021.677577			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RN4QU	33868319	Green Published, gold			2022-12-18	WOS:000640338100001
J	Ahn, SS; Han, M; Yoo, J; Park, YB; Jung, I; Lee, SW				Ahn, Sung Soo; Han, Minkyung; Yoo, Juyoung; Park, Yong-Beom; Jung, Inkyung; Lee, Sang-Won			Risk of Stroke in Systemic Necrotizing Vasculitis: A Nationwide Study Using the National Claims Database	FRONTIERS IN IMMUNOLOGY			English	Article						systemic necrotizing vasculitis; anti-neutrophil cytoplasmic antibody-associated vasculitis; polyarteritis nodosa; stroke; incidence; microscopic polyangiitis		Objective Evidences indicate that the risk of stroke is increased in autoimmune rheumatic diseases. This study aimed to investigate the incidence of stroke in patients with systemic necrotizing vasculitis (SNV) using the national health database. Methods Data were obtained from the Korean National Claims database between 2010 and 2018 to identify incident SNV [anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and polyarteritis nodosa (PAN)] cases. The standardized incidence ratio (SIR) and incidence rate ratio (IRR) were calculated to estimate the risk of stroke in patients with SNV compared to the general population and among disease subgroups. Time-dependent Cox's regression analysis was performed to identify risk factors for stroke. Results Among 2644 incident SNV cases, 159 patients (6.0%) were affected by stroke. The overall risk of stroke was significantly higher in patients with SNV compared to the general population (SIR 8.42). Stroke event rates were the highest within the first year of SNV diagnosis (67.3%). Among disease subgroups, patients with microscopic polyangiitis (MPA) exhibited higher IRR compared to PAN (adjusted IRR 1.98). In Cox's hazard analysis, older age and MPA were associated with higher risk of stroke [hazard ratio (HR) 1.05 and 1.88], whereas the administration of cyclophosphamide, azathioprine/mizoribine, methotrexate, and statins were protective in stroke (HR 0.26, 0.34, 0.49, and 0.50, respectively). Conclusion A considerable number of SNV patients experienced stroke, especially in the early phase of disease. Older age and MPA diagnosis were associated with elevated risk of stroke, while the administration of immunosuppressive agents and statins was beneficial in preventing stroke.	[Ahn, Sung Soo] Yonsei Univ, Coll Med, Yongin Severance Hosp, Dept Internal Med, Yongin, South Korea; [Han, Minkyung] Yonsei Univ, Coll Med, Dept Biomed Syst Informat, Biostat Collaborat Unit, Seoul, South Korea; [Yoo, Juyoung; Park, Yong-Beom; Lee, Sang-Won] Yonsei Univ, Coll Med, Dept Internal Med, Div Rheumatol, Seoul, South Korea; [Park, Yong-Beom; Lee, Sang-Won] Yonsei Univ, Coll Med, Inst Immunol & Immunol Dis, Seoul, South Korea; [Jung, Inkyung] Yonsei Univ, Coll Med, Dept Biomed Syst Informat, Div Biostat, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Lee, SW (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Div Rheumatol, Seoul, South Korea.; Lee, SW (corresponding author), Yonsei Univ, Coll Med, Inst Immunol & Immunol Dis, Seoul, South Korea.; Jung, I (corresponding author), Yonsei Univ, Coll Med, Dept Biomed Syst Informat, Div Biostat, Seoul, South Korea.	ijung@yuhs.ac; sangwonlee@yuhs.ac	Ahn, Sung Soo/AAB-4945-2021	Ahn, Sung Soo/0000-0002-9002-9880; Jung, Inkyung/0000-0003-3780-3213; Lee, Sang-Won/0000-0002-8038-3341; HAN, MINKYUNG/0000-0002-5011-5557; Yoo, Juyoung/0000-0001-8882-1695	Korea Centers for Disease Control and Prevention [2019ER6904-00]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health and Welfare, Republic of Korea [HI14C1324]; Yonsei University College of Medicine [6-2019-0184]	Korea Centers for Disease Control and Prevention; Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health and Welfare, Republic of Korea; Yonsei University College of Medicine(General Electric)	This work was supported by the Research Program funded by the Korea Centers for Disease Control and Prevention (2019ER6904-00), a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (HI14C1324), and a faculty research grant of Yonsei University College of Medicine (6-2019-0184). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn SS, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111871; Aksu K, 2012, CURR PHARM DESIGN, V18, P1478; Almeida SO, 2019, TRENDS CARDIOVAS MED, V29, P451, DOI 10.1016/j.tcm.2019.01.001; Avina-Zubieta JA, 2016, ARTHRITIS RHEUMATOL, V68, P2752, DOI 10.1002/art.39762; Beckman JA, 2006, TRENDS CARDIOVAS MED, V16, P156, DOI 10.1016/j.tcm.2006.03.003; Berti A, 2018, MAYO CLIN PROC, V93, P597, DOI [10.1016/i.mayocp.2018.02.010, 10.1016/j.mayocp.2018.02.010]; Blanco-Colio LM, 2003, KIDNEY INT, V63, P12, DOI 10.1046/j.1523-1755.2003.00744.x; Bobryshev YV, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9582430; Boehme AK, 2017, CIRC RES, V120, P472, DOI 10.1161/CIRCRESAHA.116.308398; Burut DFP, 2010, ANGIOLOGY, V61, P679, DOI 10.1177/0003319710366124; Campbell BCV, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0118-8; Chung SA, 2010, RHEUM DIS CLIN N AM, V36, P545, DOI 10.1016/j.rdc.2010.04.003; Dad T, 2015, SEMIN NEPHROL, V35, P311, DOI 10.1016/j.semnephrol.2015.06.003; Feigin VL, 2017, CIRC RES, V120, P439, DOI 10.1161/CIRCRESAHA.116.308413; Forbess L, 2015, RHEUM DIS CLIN N AM, V41, P33, DOI 10.1016/j.rdc.2014.09.005; Gapud EJ, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926-017-0641-0; Gross WL, 2000, RHEUMATOLOGY, V39, P245, DOI 10.1093/rheumatology/39.3.245; Guillevin L, 2011, MEDICINE, V90, P19, DOI 10.1097/MD.0b013e318205a4c6; Gutierrez J, 2014, NEUROLOGY, V82, P1080, DOI 10.1212/WNL.0000000000000237; Hankey GJ, 2017, LANCET, V389, P641, DOI 10.1016/S0140-6736(16)30962-X; Hong KS, 2013, J STROKE, V15, P2, DOI 10.5853/jos.2013.15.1.2; Hwang J, 2012, J CLIN NEUROL, V8, P109, DOI 10.3988/jcn.2012.8.2.109; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; Kang A, 2019, J RHEUMATOL, V46, P285, DOI 10.3899/jrheum.170896; Khan I, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926-013-0383-6; Kim JA, 2017, J KOREAN MED SCI, V32, P718, DOI 10.3346/jkms.2017.32.5.718; Kim JS, 2014, J STROKE, V16, P105, DOI 10.5853/jos.2014.16.3.105; Kim JY, 2019, J STROKE, V21, P42, DOI 10.5853/jos.2018.03125; Kim L, 2014, EPIDEMIOL HEALTH, V36, DOI 10.4178/epih/e2014008; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; Lane SE, 2005, QJM-INT J MED, V98, P97, DOI 10.1093/qjmed/hci015; Lintermans LL, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00504; Liou TH, 2014, SCI REP-UK, V4, DOI 10.1038/srep05110; Mourguet M, 2019, J AUTOIMMUN, V96, P134, DOI 10.1016/j.jaut.2018.09.004; Mukhtyar C, 2009, ANN RHEUM DIS, V68, P1827, DOI 10.1136/ard.2008.101279; Naidu GSRSNK, 2019, INT J RHEUM DIS, V22, P90, DOI 10.1111/1756-185X.13398; Nesher G, 2004, MEDICINE, V83, P114, DOI 10.1097/01.md.0000119761.27564.c9; Palinski W, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000018400.39687.8C; Ramji DP, 2015, CYTOKINE GROWTH F R, V26, P673, DOI 10.1016/j.cytogfr.2015.04.003; Reichhart MD, 2000, NEUROLOGY, V54, P883, DOI 10.1212/WNL.54.4.883; Sada KE, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4550; Sherer Y, 2006, NAT CLIN PRACT RHEUM, V2, P99, DOI 10.1038/ncprheum0092; Syed R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/402826; Terrier B, 2014, J RHEUMATOL, V41, P723, DOI 10.3899/jrheum.130882; Wiseman SJ, 2016, STROKE, V47, P943, DOI 10.1161/STROKEAHA.115.012052; Woodfield R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140533; Yoo J, 2017, CLIN EXP RHEUMATOL, V35, pS111; Zhang S, 2019, J NATL MED ASSOC, V111, P447, DOI 10.1016/j.jnma.2019.02.004; Zhang X, 2008, IMMUNOL RES, V41, P165, DOI 10.1007/s12026-008-8019-z	49	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2021	12								629902	10.3389/fimmu.2021.629902	http://dx.doi.org/10.3389/fimmu.2021.629902			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RM9ML	33868249	gold, Green Published			2022-12-18	WOS:000639981200001
J	Hui, ZZ; Zhang, JL; Zheng, Y; Yang, LL; Yu, WW; An, Y; Wei, F; Ren, XB				Hui, Zhenzhen; Zhang, Jiali; Zheng, Yu; Yang, Lili; Yu, Wenwen; An, Yang; Wei, Feng; Ren, Xiubao			Single-Cell Sequencing Reveals the Transcriptome and TCR Characteristics of pTregs and in vitro Expanded iTregs	FRONTIERS IN IMMUNOLOGY			English	Article						single-cell sequencing; in vitro; regulatory T cells; colorectal cancer; chemokine receptors		Regulatory T cells (Tregs) play a critical role in the maintenance of immune tolerance and tumor evasion. However, the relative low proportion of these cells in peripheral blood and tissues has hindered many studies. We sought to establish a rapamycin-based in vitro Treg expansion procedure in patients diagnosed with colorectal cancer and perform single-cell sequencing to explore the characteristics of Treg cells. CD25+ cells enriched from peripheral blood mononuclear cells (PBMC) of colorectal tumor patients were cultured in X-VIVO15 medium, supplemented with 5% human AB serum, L-glutamine, rapamycin, interleukin-2 (IL-2), and Dynabeads human Treg expander for 21 days to expand Tregs. Treg cells with satisfactory phenotype and function were successfully expanded from CD4+CD25+ cells in patients with colorectal cancer. The median expansion fold was 75 (range, 20-105-fold), and >90.0% of the harvest cells were CD4+CD25+CD127(dim/-) cells. The ratio of CD4+CD25+Foxp3+ cells exceeded 60%. Functional assays showed that iTregs significantly inhibited CD8+T cell proliferation in vitro. Single-cell sequencing showed that the transcriptome of pTreg (CD4+CD25+CD127(dim/-) cells isolated from PBMC of colorectal cancer patients) and iTreg (CD4+CD25+CD127(dim/-) cells expanded in vitro according to the above regimen) cells were interlaced. pTregs exhibited enhanced suppressive function, whereas iTregs exhibited increased proliferative capacity. TCR repertoire analysis indicated minimal overlap between pTregs and iTregs. Pseudo-time trajectory analysis of Tregs revealed that pTregs were a continuum composed of three main branches: activated/effector, resting and proliferative Tregs. In contrast, in vitro expanded iTregs were a mixture of proliferating and activated/effector cells. The expression of trafficking receptors was also different in pTregs and iTregs. Various chemokine receptors were upregulated in pTregs. Activated effector pTregs overexpressed the chemokine receptor CCR10, which was not expressed in iTregs. The chemokine CCL28 was overexpressed in colorectal cancer and associated with poor prognosis. CCR10 interacted with CCL28 to mediate the recruitment of Treg into tumors and accelerated tumor progression. Depletion of CCR10+Treg cells from tumor microenvironment (TME) could be used as an effective treatment strategy for colorectal cancer patients. Our data distinguished the transcriptomic characteristics of different subsets of Treg cells and revealed the context-dependent functions of different populations of Treg cells, which was crucial to the development of alternative therapeutic strategies for Treg cells in autoimmune disease and cancer.	[Hui, Zhenzhen; Zhang, Jiali; Ren, Xiubao] Tianjin Med Univ Canc Inst & Hosp, Dept Biotherapy, Tianjin, Peoples R China; [Hui, Zhenzhen; Zhang, Jiali; Zheng, Yu; Yang, Lili; Yu, Wenwen; An, Yang; Wei, Feng; Ren, Xiubao] Natl Clin Res Ctr Canc, Tianjin, Peoples R China; [Hui, Zhenzhen; Zhang, Jiali; Zheng, Yu; Yang, Lili; Yu, Wenwen; An, Yang; Wei, Feng; Ren, Xiubao] Tianjin Med Univ Canc Inst & Hosp, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Hui, Zhenzhen; Zhang, Jiali; Zheng, Yu; Yang, Lili; Yu, Wenwen; An, Yang; Wei, Feng; Ren, Xiubao] Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China; [Hui, Zhenzhen; Zhang, Jiali; Zheng, Yu; Yang, Lili; Yu, Wenwen; An, Yang; Wei, Feng; Ren, Xiubao] Tianjin Med Univ Canc Inst & Hosp, Key Lab Canc Immunol & Biotherapy, Tianjin, Peoples R China; [Zheng, Yu; Yang, Lili; Yu, Wenwen; An, Yang; Wei, Feng; Ren, Xiubao] Tianjin Med Univ Canc Inst & Hosp, Dept Immunol, Tianjin, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University	Ren, XB (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Dept Biotherapy, Tianjin, Peoples R China.; Wei, F; Ren, XB (corresponding author), Natl Clin Res Ctr Canc, Tianjin, Peoples R China.; Wei, F; Ren, XB (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.; Wei, F; Ren, XB (corresponding author), Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China.; Wei, F; Ren, XB (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Key Lab Canc Immunol & Biotherapy, Tianjin, Peoples R China.; Wei, F; Ren, XB (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Dept Immunol, Tianjin, Peoples R China.	iwhiffle@hotmail.com; renxiubao@tjmuch.com	Wei, Feng/E-2806-2015	Wei, Feng/0000-0002-4797-449X	National Key RD Program [2018YFC1313400]; National Major Scientific and Technological Special Project for Significant New Drugs Development [2018ZX09201-015]; National Natural Science Foundation of China [81702405, 81702702, 81872166, 81974416]; Tianjin Natural Science Funds [19JCQNJC10800]	National Key RD Program; National Major Scientific and Technological Special Project for Significant New Drugs Development; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Natural Science Funds	This work was supported by the National Key R&D Program under Grant No. 2018YFC1313400; National Major Scientific and Technological Special Project for Significant New Drugs Development under Grant No. 2018ZX09201-015; National Natural Science Foundation of China under Grant Nos. 81702405, 81702702, 81872166, and 81974416; and Tianjin Natural Science Funds under Grant No. 19JCQNJC10800.	Alsuliman A, 2016, CYTOTHERAPY, V18, P1312, DOI 10.1016/j.jcyt.2016.06.012; Asai N, 2019, CANCER INVEST, V37, P163, DOI 10.1080/07357907.2019.1582848; Barua S, 2018, LUNG CANCER, V117, P73, DOI 10.1016/j.lungcan.2018.01.022; Bhairavabhotla R, 2016, HUM IMMUNOL, V77, P201, DOI 10.1016/j.humimm.2015.12.004; Blazar BR, 2018, BLOOD, V131, P2651, DOI 10.1182/blood-2017-11-785865; Cao TH, 2010, CLIN IMMUNOL, V136, P329, DOI 10.1016/j.clim.2010.04.014; Chen LB, 2019, GENE, V692, P119, DOI 10.1016/j.gene.2019.01.001; Colbeck EJ, 2017, CANCER IMMUNOL RES, V5, P1005, DOI 10.1158/2326-6066.CIR-17-0131; De Simone M, 2016, IMMUNITY, V45, P1135, DOI 10.1016/j.immuni.2016.10.021; Del Papa B, 2017, BIOL BLOOD MARROW TR, V23, P1847, DOI 10.1016/j.bbmt.2017.07.009; Dominguez-Villar M, 2018, NAT IMMUNOL, V19, P665, DOI 10.1038/s41590-018-0120-4; Edinger M, 2003, NAT MED, V9, P1144, DOI 10.1038/nm915; Enarsson K, 2006, CLIN IMMUNOL, V121, P358, DOI 10.1016/j.clim.2006.07.002; Erfani N, 2014, IRAN J IMMUNOL, V11, P105, DOI IJIv11i2A5; Facciabene A, 2011, NATURE, V475, P226, DOI 10.1038/nature10169; Finotello F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0402-8; Fisher SA, 2017, IMMUN INFLAMM DIS, V5, P16, DOI 10.1002/iid3.136; Fraser H, 2018, MOL THER-METH CLIN D, V8, P198, DOI 10.1016/j.omtm.2018.01.006; Freeman ZT, 2020, J CLIN INVEST, V130, P1405, DOI 10.1172/JCI128672; Gallimore A, 2019, IMMUNOLOGY, V157, P187, DOI 10.1111/imm.13088; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Grinberg-Bleyer Y, 2017, CELL, V170, P1096, DOI 10.1016/j.cell.2017.08.004; Grzanka J, 2013, INT IMMUNOPHARMACOL, V16, P343, DOI 10.1016/j.intimp.2013.02.004; Guo XY, 2018, NAT MED, V24, P978, DOI 10.1038/s41591-018-0045-3; Hashemi V, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.106087; Kamada T, 2019, P NATL ACAD SCI USA, V116, P9999, DOI 10.1073/pnas.1822001116; Kazama K, 2020, IN VIVO, V34, P849, DOI 10.21873/invivo.11848; Kitagawa Y, 2017, NAT IMMUNOL, V18, P173, DOI 10.1038/ni.3646; Kleinewietfeld M, 2005, BLOOD, V105, P2877, DOI 10.1182/blood-2004-07-2505; Kozela E, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0603-x; Leonard JD, 2017, IMMUNITY, V47, P107, DOI 10.1016/j.immuni.2017.06.015; Liu W, 2017, BIOCHEM BIOPH RES CO, V488, P196, DOI 10.1016/j.bbrc.2017.05.034; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Lu YC, 2019, CANCER IMMUNOL RES, V7, P1824, DOI 10.1158/2326-6066.CIR-19-0299; Maj T, 2017, NAT IMMUNOL, V18, P1332, DOI 10.1038/ni.3868; Malchow S, 2013, SCIENCE, V339, P1219, DOI 10.1126/science.1233913; Mempel TR, 2019, IMMUNOL REV, V289, P129, DOI 10.1111/imr.12761; Motwani K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00611; Plitas G, 2016, IMMUNITY, V45, P1122, DOI 10.1016/j.immuni.2016.10.032; Ren L, 2016, ONCOTARGET, V7, P75763, DOI 10.18632/oncotarget.12409; Saison J, 2013, CYTOM PART B-CLIN CY, V84B, P50, DOI 10.1002/cyto.b.21047; Saito T, 2016, NAT MED, V22, P679, DOI 10.1038/nm.4086; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sakaguchi S, 2020, ANNU REV IMMUNOL, V38, P541, DOI 10.1146/annurev-immunol-042718-041717; Shakurnia A, 2019, COMPLEMENT THER MED, V47, DOI 10.1016/j.ctim.2019.102210; Shin HJ, 2011, BLOOD, V118, P2342, DOI 10.1182/blood-2010-10-313684; Simonetta F, 2010, EUR J IMMUNOL, V40, P2528, DOI 10.1002/eji.201040531; Su HB, 2012, METHODS MOL BIOL, V806, P287, DOI 10.1007/978-1-61779-367-7_20; Sugiyama D, 2013, P NATL ACAD SCI USA, V110, P17945, DOI 10.1073/pnas.1316796110; Sun GW, 2019, J CELL PHYSIOL, V234, P15215, DOI 10.1002/jcp.28163; Szczepanik AM, 2011, WORLD J GASTROENTERO, V17, P343, DOI 10.3748/wjg.v17.i3.343; Thornton AM, 2019, EUR J IMMUNOL, V49, P398, DOI 10.1002/eji.201847935; Toby IT, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1214-3; Villarreal DO, 2018, CANCER RES, V78, P5340, DOI 10.1158/0008-5472.CAN-18-1119; Voskens CJ, 2017, INFLAMM BOWEL DIS, V23, P348, DOI 10.1097/MIB.0000000000001192; Wang J, 2020, J CELL MOL MED, V24, P8491, DOI 10.1111/jcmm.15443; Wang L, 2019, NAT IMMUNOL, V20, P1220, DOI 10.1038/s41590-019-0429-7; Wei S, 2006, BLOOD, V108, P426, DOI 10.1182/blood-2006-01-0177; Whangbo JS, 2020, EXPERT REV HEMATOL, V13, P141, DOI 10.1080/17474086.2020.1709436; Wiesinger M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01371; Wing JB, 2019, IMMUNITY, V50, P302, DOI 10.1016/j.immuni.2019.01.020; Xu Y, 2019, J IMMUNOL, V202, P3447, DOI 10.4049/jimmunol.1800018; Yang SY, 2015, SCIENCE, V348, P589, DOI 10.1126/science.aaa7017; Yu N, 2012, INFLAMMATION, V35, P1773, DOI 10.1007/s10753-012-9496-8; Zemmour D, 2018, NAT IMMUNOL, V19, P291, DOI 10.1038/s41590-018-0051-0; Zeng H, 2017, CURR OPIN IMMUNOL, V46, P103, DOI 10.1016/j.coi.2017.04.005; Zhang L, 2018, NATURE, V564, P268, DOI 10.1038/s41586-018-0694-x; Zhang QF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02359; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	69	1	1	4	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2021	12								619932	10.3389/fimmu.2021.619932	http://dx.doi.org/10.3389/fimmu.2021.619932			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RM7FB	33868236	Green Published, gold			2022-12-18	WOS:000639823800001
J	Jing, CD; Liu, CH; Liu, Y; Feng, RL; Cao, R; Guan, ZC; Xuan, B; Gao, YP; Wang, Q; Yang, NN; Ma, YF; Lan, LF; Feng, JN; Shen, BF; Wang, H; Yu, YY; Yang, G				Jing, Chendi; Liu, Chenghua; Liu, Yu; Feng, Ruli; Cao, Run; Guan, Zhangchun; Xuan, Bo; Gao, Yaping; Wang, Qi; Yang, Nana; Ma, Yuanfang; Lan, Lefu; Feng, Jiannan; Shen, Beifen; Wang, Hui; Yu, Yanyan; Yang, Guang			Antibodies Against Pseudomonas aeruginosa Alkaline Protease Directly Enhance Disruption of Neutrophil Extracellular Traps Mediated by This Enzyme	FRONTIERS IN IMMUNOLOGY			English	Article						Pseudomonas aeruginosa; alkaline protease; alkaline protease inhibitor; neutrophil extracellular traps; antibody-dependent enhancement		Extracellular traps released by neutrophils (NETs) are essential for the clearance of Pseudomonas aeruginosa. Alkaline protease (AprA) secreted by P. aeruginosa negatively correlates with clinical improvement. Moreover, anti-AprA in patients with cystic fibrosis (CF) can help identify patients with aggressive forms of chronic infection. However, the mechanism underlying the clinical outcomes remains unclear. We demonstrated that aprA deficiency in P. aeruginosa decreased the bacterial burden and reduced lung infection. AprA degraded NET components in vitro and in vivo but did not affect NET formation. Importantly, antibodies induced by AprA acted as an agonist and directly enhanced the degrading activities of AprA. Moreover, antisera from patients with P. aeruginosa infection exhibited antibody-dependent enhancement (ADE) similar to that of the antibodies we prepared. Our further investigations showed that the interaction between AprA and the specific antibodies might make the enzyme active sites better exposed, and subsequently enhance the recognition of substrates and accelerate the degradation. Our findings revealed that AprA secreted by P. aeruginosa may aggravate infection by destroying formed NETs, an effect that was further enhanced by its antibodies.	[Jing, Chendi; Liu, Chenghua; Liu, Yu; Guan, Zhangchun; Xuan, Bo; Gao, Yaping; Feng, Jiannan; Shen, Beifen; Yang, Guang] Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing, Peoples R China; [Jing, Chendi; Yu, Yanyan] Peking Univ First Hosp, Dept Infect Dis, Beijing, Peoples R China; [Feng, Ruli] Peking Univ First Hosp, Dept Clin Lab, Beijing, Peoples R China; [Cao, Run; Ma, Yuanfang] Henan Univ, Sch Basic Med Sci, Joint Natl Lab Antibody Drug Engn, Kaifeng, Peoples R China; [Wang, Qi; Wang, Hui] Peking Univ, Dept Clin Lab, Peoples Hosp, Beijing, Peoples R China; [Yang, Nana; Lan, Lefu] Chinese Acad Sci, Shanghai Inst Mat Med, Dept Mol Pharmacol, Shanghai, Peoples R China	Academy of Military Medical Sciences - China; Peking University; Henan University; Peking University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS	Yang, G (corresponding author), Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing, Peoples R China.; Yu, YY (corresponding author), Peking Univ First Hosp, Dept Infect Dis, Beijing, Peoples R China.; Wang, H (corresponding author), Peking Univ, Dept Clin Lab, Peoples Hosp, Beijing, Peoples R China.	wanghui@pkuph.edu.cn; yyy@bjmu.edu.cn; yangg62033@outlook.com	wang, qi/HGV-1859-2022; Yu, Yan/GYV-4514-2022		National Natural Science Foundation of China [81871618, 31870127]; Shandong Provincial Major Scientific and Technological Innovation Project (MSTIP) [2019JZZY011012]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Provincial Major Scientific and Technological Innovation Project (MSTIP)	This work was supported by grants from National Natural Science Foundation of China (http://www.nsfc.gov.cn) [81871618] and [31870127], and Shandong Provincial Major Scientific and Technological Innovation Project (MSTIP) [2019JZZY011012]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bardoel BW, 2012, J MOL BIOL, V415, P573, DOI 10.1016/j.jmb.2011.11.039; Bardoel BW, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002206; Berends ETM, 2010, J INNATE IMMUN, V2, P576, DOI 10.1159/000319909; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Dohrmann S, 2014, INFECT IMMUN, V82, P4011, DOI 10.1128/IAI.01921-14; DORING G, 1983, J INFECT DIS, V147, P744, DOI 10.1093/infdis/147.4.744; Dubin PJ, 2007, AM J PHYSIOL-LUNG C, V292, pL519, DOI 10.1152/ajplung.00312.2006; Dwyer M, 2014, J INNATE IMMUN, V6, P765, DOI 10.1159/000363242; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Gawel Jozef, 2014, Pneumonol Alergol Pol, V82, P336, DOI 10.5603/PiAP.2014.0042; Gellatly SL, 2013, PATHOG DIS, V67, P159, DOI 10.1111/2049-632X.12033; Grabcanovic-Musija F, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0221-7; Halstead SB, 2003, ADV VIRUS RES, V60, P421, DOI 10.1016/S0065-3527(03)60011-4; Hoang TT, 1998, GENE, V212, P77, DOI 10.1016/S0378-1119(98)00130-9; Hoiby N, 2001, THORAX, V56, P667, DOI 10.1136/thorax.56.9.667; HONG YQ, 1992, CLIN IMMUNOL IMMUNOP, V62, P133, DOI 10.1016/0090-1229(92)90065-V; Iankov ID, 2006, J VIROL, V80, P8530, DOI 10.1128/JVI.00593-06; JAFFARBANDJEE MC, 1995, J CLIN MICROBIOL, V33, P924, DOI 10.1128/JCM.33.4.924-929.1995; Jensen EC, 2013, ANAT REC, V296, P378, DOI 10.1002/ar.22641; Koh AY, 2009, INFECT IMMUN, V77, P5300, DOI 10.1128/IAI.00501-09; Kontermann R, 2010, ANTIBODY ENG; Leshner M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00307; Li PX, 2010, J EXP MED, V207, P1853, DOI 10.1084/jem.20100239; Livermore DM, 2002, CLIN INFECT DIS, V34, P634, DOI 10.1086/338782; Lovewell RR, 2014, AM J PHYSIOL-LUNG C, V306, pL591, DOI 10.1152/ajplung.00335.2013; Marcos V, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/408935; Matsumoto K, 2004, BIOL CHEM, V385, P1007, DOI 10.1515/BC.2004.131; Mayer-Hamblett N, 2014, AM J RESP CRIT CARE, V190, P289, DOI 10.1164/rccm.201404-0681OC; Parker CM, 2008, J CRIT CARE, V23, P18, DOI 10.1016/j.jcrc.2008.02.001; PARMELY M, 1990, INFECT IMMUN, V58, P3009, DOI 10.1128/IAI.58.9.3009-3014.1990; Saitoh T, 2012, CELL HOST MICROBE, V12, P109, DOI 10.1016/j.chom.2012.05.015; Sasaki T, 2013, ANTIVIR RES, V98, P423, DOI 10.1016/j.antiviral.2013.03.018; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; Sousa AM, 2014, PATHOGENS, V3, P680, DOI 10.3390/pathogens3030680; Takada A, 2003, J VIROL, V77, P7539, DOI 10.1128/JVI.77.13.7539-7544.2003; TOTH FD, 1994, CLIN EXP IMMUNOL, V96, P389, DOI 10.1111/j.1365-2249.1994.tb06040.x; Toussaint M, 2017, NAT MED, V23, P681, DOI 10.1038/nm.4332; Wang YM, 2009, J CELL BIOL, V184, P205, DOI 10.1083/jcb.200806072; Winterbourn CC, 2013, ANTIOXID REDOX SIGN, V18, P642, DOI 10.1089/ars.2012.4827; Yoo DG, 2014, IMMUNOL LETT, V160, P186, DOI 10.1016/j.imlet.2014.03.003; Yoo DG, 2014, J IMMUNOL, V192, P4728, DOI 10.4049/jimmunol.1301589; Zilberberg MD, 2013, J HOSP MED, V8, P559, DOI 10.1002/jhm.2080	42	1	2	1	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2021	12								654649	10.3389/fimmu.2021.654649	http://dx.doi.org/10.3389/fimmu.2021.654649			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RM7HP	33868297	Green Published, gold			2022-12-18	WOS:000639830400001
J	Tian, R; Chen, X; Yang, CD; Teng, JL; Qu, HP; Liu, HL				Tian, Rui; Chen, Xia; Yang, Chengde; Teng, Jialin; Qu, Hongping; Liu, Hong-Lei			Serum Heparin-Binding Protein as a Potential Biomarker to Distinguish Adult-Onset Still's Disease From Sepsis	FRONTIERS IN IMMUNOLOGY			English	Article						adult-onset Still&#8217; s disease (AOSD); sepsis; heparin-binding protein (HBP); biomarker; autoinflammatory diseases	JUVENILE IDIOPATHIC ARTHRITIS; DIAGNOSTIC-VALUE; PROCALCITONIN; ACCURACY; ANAKINRA	Adult-onset Still's disease (AOSD) is a systemic, multifactorial, autoinflammatory disease for which the etiopathogenesis is not well understood. Given the similarities in clinical and laboratory features between this disease and sepsis, and the differences in treatment strategies for these two diseases, specific diagnostic markers are crucial for the correct diagnosis and management of AOSD. Previous studies have shown plasma heparin-binding protein (HBP) is a promising potential biomarker for AOSD; thus, this study aimed to detect serum HBP levels in patients with AOSD or sepsis to assess its potential as a biomarker for differential diagnosis. We found that serum HBP levels were significantly higher in patients with active AOSD than that in those with inactive AOSD. Patients with sepsis had higher serum HBP levels compared with those who had active or inactive AOSD. We calculated the area under the receiver operating characteristic (ROC) curve to assess whether HBP could be used to differentiate active from inactive AOSD; this was 0.811 with sensitivity 0.650, specificity 0.811, and cutoff HBP value of 35.59 ng/ml. The area under the ROC curve for HBP as a biomarker to differentiate AOSD from sepsis was 0.653, with sensitivity 0.759, and specificity 0.552, and cutoff HBP value of 65.1 ng/ml. Taken together, the results of our study suggest that serum HBP could be a useful diagnostic biomarker to evaluate disease activity in patients with AOSD, and to differentiate AOSD from sepsis.	[Tian, Rui; Qu, Hongping] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Crit Care Med, Shanghai, Peoples R China; [Chen, Xia; Yang, Chengde; Teng, Jialin; Liu, Hong-Lei] Shanghai Jiao Tong Univ, Sch Med, Dept Rheumatol & Immunol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Qu, HP (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Crit Care Med, Shanghai, Peoples R China.; Liu, HL (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Rheumatol & Immunol, Shanghai, Peoples R China.	hongpingqu0412@hotmail.com; hong-lei-liu@163.com			National Natural Science Foundation of China [81502016, 81772040]; Shanghai Municipal Health and Family Planning Commission General Hospital Chinese and Western Medicine Clinical Cooperation Pilot Construction Project [ZY (2018-2020)-FWTX-1108]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Health and Family Planning Commission General Hospital Chinese and Western Medicine Clinical Cooperation Pilot Construction Project	This research was funded by National Natural Science Foundation of China (81502016 and 81772040) and Shanghai Municipal Health and Family Planning Commission General Hospital Chinese and Western Medicine Clinical Cooperation Pilot Construction Project (ZY (2018-2020)-FWTX-1108).	Chew MS, 2012, INFLAMM RES, V61, P375, DOI 10.1007/s00011-011-0422-6; Chi HH, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1555-6; Colafrancesco S, 2012, INT J INFLAMM, V2012, DOI 10.1155/2012/156890; Feist E, 2018, NAT REV RHEUMATOL, V14, P603, DOI 10.1038/s41584-018-0081-x; Fisher J, 2017, J INTERN MED, V281, P562, DOI 10.1111/joim.12604; Fisher J, 2017, SHOCK, V48, P313, DOI 10.1097/SHK.0000000000000862; FLODGAARD H, 1991, EUR J BIOCHEM, V197, P535, DOI 10.1111/j.1432-1033.1991.tb15942.x; Gautam N, 2001, NAT MED, V7, P1123, DOI 10.1038/nm1001-1123; Giacomelli R, 2021, CLIN EXP RHEUMATOL, V39, P187, DOI 10.55563/clinexprheumatol/fsq5vq; Girard C, 2016, RHEUMATOLOGY, V55, P2237, DOI 10.1093/rheumatology/kew300; Harbarth S, 2001, AM J RESP CRIT CARE, V164, P396, DOI 10.1164/ajrccm.164.3.2009052; Hu QY, 2019, CLIN EXP RHEUMATOL, V37, P52; Hu QY, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03099; Jung KH, 2014, SCAND J RHEUMATOL, V43, P162, DOI 10.3109/03009742.2013.824023; Kahn F, 2019, SHOCK, V52, pE135, DOI 10.1097/SHK.0000000000001332; Koga T, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02200-4; Kudela H, 2019, BMC RHEUMATOL, V3, DOI 10.1186/s41927-019-0053-z; Li X, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196423; Linder A, 2015, CRIT CARE MED, V43, P2378, DOI 10.1097/CCM.0000000000001265; Linder A, 2012, CRIT CARE, V16, DOI 10.1186/cc11353; Linder A, 2009, CLIN INFECT DIS, V49, P1044, DOI 10.1086/605563; Liu Y, 2018, LIFE SCI, V203, P92, DOI 10.1016/j.lfs.2018.04.029; Meng JF, 2021, RHEUMATOLOGY, V60, P4520, DOI 10.1093/rheumatology/keab023; Mitrovic S, 2018, JOINT BONE SPINE, V85, P285, DOI 10.1016/j.jbspin.2017.05.011; Mueller RB, 2010, J RHEUMATOL, V37, P2203, DOI 10.3899/jrheum.100783; Pierrakos C, 2010, CRIT CARE, V14, DOI 10.1186/cc8872; Priori R, 2014, J RHEUMATOL, V41, P1118, DOI 10.3899/jrheum.130575; Rau M, 2010, J RHEUMATOL, V37, P2369, DOI 10.3899/jrheum.100247; Sagy M, 2013, CURR PROB PEDIATR AD, V43, P260, DOI 10.1016/j.cppeds.2013.10.001; Scire CA, 2006, CLIN EXP RHEUMATOL, V24, P123; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Sota J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00918; Su YT, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00266; Sun Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02112; Tapper H, 2002, BLOOD, V99, P1785, DOI 10.1182/blood.V99.5.1785; Tverring J, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0330-1; Tyden J, 2017, ACTA ANAESTH SCAND, V61, P797, DOI 10.1111/aas.12913; Tyden J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152035; Vieira ML, 2019, J INFECT DIS, V219, P996, DOI 10.1093/infdis/jiy589; Wang MY, 2019, CHINESE MED J-PEKING, V132, P2856, DOI 10.1097/CM9.0000000000000538; Wang ZH, 2020, RHEUMATOLOGY, V59, P3293, DOI 10.1093/rheumatology/keaa135; Wu YL, 2021, CRIT CARE MED, V49, pE80, DOI 10.1097/CCM.0000000000004738; YAMAGUCHI M, 1992, J RHEUMATOL, V19, P424; Yeh CF, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-018-0479-2; Zeng T, 2009, J RHEUMATOL, V36, P1026, DOI 10.3899/jrheum.080365; Zhang MY, 2021, WIEN KLIN WOCHENSCHR, V133, P118, DOI 10.1007/s00508-020-01668-z; Zhou YX, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026527	47	1	2	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2021	12								654811	10.3389/fimmu.2021.654811	http://dx.doi.org/10.3389/fimmu.2021.654811			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RM6YQ	33868298	gold, Green Published			2022-12-18	WOS:000639806900001
J	Guo, ZL; Zhang, YR; Fu, MP; Zhao, L; Wang, Z; Xu, ZS; Zhu, HF; Lan, XL; Shen, GX; He, Y; Lei, P				Guo, Zilong; Zhang, Yirui; Fu, Mingpeng; Zhao, Liang; Wang, Zhen; Xu, Zhuoshuo; Zhu, Huifen; Lan, Xiaoli; Shen, Guanxin; He, Yong; Lei, Ping			The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies	FRONTIERS IN IMMUNOLOGY			English	Article						transferrin receptor; chimeric antigen receptor; alternative target; hematological malignancies; T-cell acute lymphoblastic leukemia		As many patients ultimately relapse after chimeric antigen receptor (CAR) T-cell therapy, identification of alternative targets is currently being evaluated. Substantial research efforts are underway to develop new targets. The transferrin receptor (TfR) is prevalently expressed on rapidly proliferating tumor cells and holds the potential to be the alternative target. In order to investigate the efficacy and challenges of TfR-targeting on the CAR-based therapy strategy, we generated a TfR-specific CAR and established the TfR-CAR-modified T cells. To take the advantage of TfR being widely shared by multiple tumors, TfR-CAR T cells were assessed against several TfR+ hematological malignant cell lines. Data showed that TfR-CAR T cells were powerfully potent in killing all these types of cells in vitro and in killing T-ALL cells in vivo. These findings suggest that TfR could be a universal target to broaden and improve the therapeutic efficacy of CAR T cells and warrant further efforts to use these cells as an alternative CAR T cell product for the therapy of hematological malignancies.	[Guo, Zilong; Zhang, Yirui; Fu, Mingpeng; Zhao, Liang; Wang, Zhen; Xu, Zhuoshuo; Zhu, Huifen; Shen, Guanxin; Lei, Ping] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Immunol, Wuhan, Peoples R China; [Guo, Zilong; He, Yong] Wuhan Univ, Dept Nucl Med, Zhongnan Hosp, Wuhan, Peoples R China; [Guo, Zilong; He, Yong] Wuhan Univ, PET Ctr, Zhongnan Hosp, Wuhan, Peoples R China; [Fu, Mingpeng] South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Lab Med, Guangzhou, Peoples R China; [Lan, Xiaoli] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Nucl Med, Wuhan, Peoples R China	Huazhong University of Science & Technology; Wuhan University; Wuhan University; South China University of Technology; Huazhong University of Science & Technology	Lei, P (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Immunol, Wuhan, Peoples R China.; He, Y (corresponding author), Wuhan Univ, Dept Nucl Med, Zhongnan Hosp, Wuhan, Peoples R China.; He, Y (corresponding author), Wuhan Univ, PET Ctr, Zhongnan Hosp, Wuhan, Peoples R China.	heyong@znhospital.cn; adaleip@hust.edu.cn			key program of the National Natural Science Foundation of China [82030052]; NSFC [31570937, 81871391]; Improvement Project for Theranostic ability on Difficulty miscellaneous disease (Tumor) [ZLYNXM202007]	key program of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NSFC(National Natural Science Foundation of China (NSFC)); Improvement Project for Theranostic ability on Difficulty miscellaneous disease (Tumor)	This research was funded by grants from the key program of the National Natural Science Foundation of China (Grant No. 82030052), the general program of NSFC (Grant No. 31570937, 81871391), and the Improvement Project for Theranostic ability on Difficulty miscellaneous disease (Tumor) (No. ZLYNXM202007).	Alcantara M, 2018, LEUKEMIA, V32, P2307, DOI 10.1038/s41375-018-0285-8; [Anonymous], 2010, GUIDE USE SUGARCANE; Benmebarek MR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061283; Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497; Chen KH, 2017, LEUKEMIA, V31, P2151, DOI 10.1038/leu.2017.8; Chen KH, 2016, ONCOTARGET, V7, P56219, DOI 10.18632/oncotarget.11019; Chmielewski M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00371; Crepin R, 2010, CANCER RES, V70, P5497, DOI 10.1158/0008-5472.CAN-10-0938; D'Aloia MM, 2016, CYTOTHERAPY, V18, P278, DOI 10.1016/j.jcyt.2015.10.014; Daniels TR, 2006, CLIN IMMUNOL, V121, P144, DOI 10.1016/j.clim.2006.06.010; Daniels-Wells TR, 2016, IMMUNOTHERAPY-UK, V8, P991, DOI 10.2217/imt-2016-0050; Dotti G, 2014, IMMUNOL REV, V257, P107, DOI 10.1111/imr.12131; Figueroa JA, 2015, INT REV IMMUNOL, V34, P154, DOI 10.3109/08830185.2015.1018419; Fu MP, 2020, CURR MED SCI, V40, P28, DOI 10.1007/s11596-020-2143-y; Fu MP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01396; Gomes-Silva D, 2017, BLOOD, V130, P285, DOI 10.1182/blood-2017-01-761320; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Gu ZM, 2015, CANCER RES, V75, P2211, DOI 10.1158/0008-5472.CAN-14-3804; He Qi, 2020, Nanotheranostics, V4, P119, DOI 10.7150/ntno.41741; Henry KE, 2019, CLIN CANCER RES, V25, P166, DOI 10.1158/1078-0432.CCR-18-1485; Hentze MW, 2010, CELL, V142, P24, DOI 10.1016/j.cell.2010.06.028; Hong LK, 2018, CANCER IMMUNOL RES, V6, P1274, DOI 10.1158/2326-6066.CIR-18-0065; Kasakovski D, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0629-x; Kloss CC, 2013, NAT BIOTECHNOL, V31, P71, DOI 10.1038/nbt.2459; Li SS, 2018, HUM GENE THER, V29, P626, DOI 10.1089/hum.2017.241; Luck AN, 2012, CURR TOP MEMBR, V69, P3, DOI 10.1016/B978-0-12-394390-3.00001-X; Mamonkin M, 2015, BLOOD, V126, P983, DOI 10.1182/blood-2015-02-629527; Mohty M, 2019, LEUKEMIA, V33, P2767, DOI 10.1038/s41375-019-0615-5; Neiveyans M, 2019, MABS-AUSTIN, V11, P593, DOI 10.1080/19420862.2018.1564510; Ohkuma M, 2012, ANN SURG ONCOL, V19, P1357, DOI 10.1245/s10434-011-1739-7; Pinz KG, 2017, ONCOTARGET, V8, P112783, DOI 10.18632/oncotarget.22626; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Poynter G, 2009, Cold Spring Harbor Protoc, V2009, DOI 10.1101/pdb.prot5117; Qian ZM, 2002, PHARMACOL REV, V54, P561, DOI 10.1124/pr.54.4.561; Rafiq S, 2020, NAT REV CLIN ONCOL, V17, P147, DOI 10.1038/s41571-019-0297-y; Rasaiyaah J, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99442; Samarasinghe S, 2010, BLOOD, V115, P396, DOI 10.1182/blood-2009-08-235895; Shen X, 2008, INT IMMUNOPHARMACOL, V8, P1813, DOI 10.1016/j.intimp.2008.08.022; Shimizu S, 2007, J AM ACAD DERMATOL, V57, pS115, DOI 10.1016/j.jaad.2006.12.031; Shimosaki S, 2017, BIOCHEM BIOPH RES CO, V485, P144, DOI 10.1016/j.bbrc.2017.02.039; Singh M, 2011, APPL IMMUNOHISTO M M, V19, P417, DOI 10.1097/PAI.0b013e318209716e; Srivastava S, 2015, TRENDS IMMUNOL, V36, P494, DOI 10.1016/j.it.2015.06.004; Turtle CJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8621; Velasco-Hernandez T, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000896; Wang XL, 2018, CLIN CANCER RES, V24, P106, DOI 10.1158/1078-0432.CCR-17-0344; Weber EW, 2020, CELL, V181, P46, DOI 10.1016/j.cell.2020.03.001; Wu CY, 2015, SCIENCE, V350, DOI 10.1126/science.aab4077; Xu GZ, 2011, INT IMMUNOPHARMACOL, V11, P1844, DOI 10.1016/j.intimp.2011.07.014; Xu JJ, 2018, ONCOL LETT, V16, P2063, DOI 10.3892/ol.2018.8946; Ye Q, 2006, CANCER IMMUNOL IMMUN, V55, P1111, DOI 10.1007/s00262-005-0105-7; Yoshikawa T, 2005, AM J OPHTHALMOL, V140, P327, DOI 10.1016/j.ajo.2005.01.049; Zhao XY, 2020, MOL THER-ONCOLYTICS, V18, P272, DOI 10.1016/j.omto.2020.06.016	52	1	1	2	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 29	2021	12								652924	10.3389/fimmu.2021.652924	http://dx.doi.org/10.3389/fimmu.2021.652924			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RL7GW	33854512	Green Published, gold			2022-12-18	WOS:000639137800001
J	Ikewaki, N; Dedeepiya, VD; Iwasaki, M; Abraham, SJK				Ikewaki, Nobunao; Dedeepiya, Vidyasagar Devaprasad; Iwasaki, Masaru; Abraham, Samuel J. K.			Commentary: Beyond "TRIM" Benefits of beta-Glucan by Blood Glucose and Lipid Balancing Potentials in Its Defense Against COVID-19	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						COVID-19; trained immunity; beta-glucan; blood glucose; fasting plasma glucose; lipid; coagulopathy; TRIM			[Ikewaki, Nobunao] Kyushu Univ Hlth & Welf, Dept Med Life Sci, Nobeoka, Japan; [Ikewaki, Nobunao] Junsei Educ Inst, Inst Immunol, Nobeoka, Japan; [Dedeepiya, Vidyasagar Devaprasad; Abraham, Samuel J. K.] Nichi In Ctr Regenerat Med NCRM, Mary Yoshio Translat Hexagon MYTH, Chennai, Tamil Nadu, India; [Iwasaki, Masaru; Abraham, Samuel J. K.] Univ Yamanashi, Sch Med, Chuo, Japan; [Abraham, Samuel J. K.] Edogawa Hosp, Edogawa Evolutionary Lab Sci EELS, Tokyo, Japan; [Abraham, Samuel J. K.] GN Corp Co Ltd, Phylogeny & Evolut LIPE Div, Life Syst Immunol, Kofu, Yamanashi, Japan	University of Yamanashi	Abraham, SJK (corresponding author), Nichi In Ctr Regenerat Med NCRM, Mary Yoshio Translat Hexagon MYTH, Chennai, Tamil Nadu, India.; Abraham, SJK (corresponding author), Univ Yamanashi, Sch Med, Chuo, Japan.; Abraham, SJK (corresponding author), Edogawa Hosp, Edogawa Evolutionary Lab Sci EELS, Tokyo, Japan.; Abraham, SJK (corresponding author), GN Corp Co Ltd, Phylogeny & Evolut LIPE Div, Life Syst Immunol, Kofu, Yamanashi, Japan.	drsam@nichimail.jp	Abraham, Samuel JK/GPK-1414-2022	Abraham, Samuel JK/0000-0003-2646-2687				Arts RJW, 2016, SEMIN IMMUNOL, V28, P425, DOI 10.1016/j.smim.2016.09.002; Chen JZ, 2008, VASC HEALTH RISK MAN, V4, P1265, DOI 10.2147/VHRM.S3803; de Lucena TMC, 2020, DIABETES METAB SYND, V14, P597, DOI 10.1016/j.dsx.2020.05.025; Dedeepiya VD, 2012, CASE REP MED, V2012, DOI 10.1155/2012/895370; Ganesh Jegatheesan Saravana, 2014, Journal of Dietary Supplements, V11, P1, DOI 10.3109/19390211.2013.859211; Geller A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01782; Hariyanto TI, 2020, DIABETES METAB SYND, V14, P1463, DOI 10.1016/j.dsx.2020.07.054; Hussain A, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108142; Ieronymaki E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01330; Ikewaki N, 2020, J DIABETES METAB DIS, V19, P2041, DOI 10.1007/s40200-020-00664-4; Ikewaki N, 2020, THROMB J, V18, DOI 10.1186/s12959-020-00239-6; Novakovic B, 2016, CELL, V167, P1354, DOI 10.1016/j.cell.2016.09.034; Rao KS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01548; Singh VP, 2014, KOREAN J PHYSIOL PHA, V18, P1, DOI 10.4196/kjpp.2014.18.1.1; Wang SF, 2020, DIABETOLOGIA, V63, P2102, DOI 10.1007/s00125-020-05209-1; Yano H., 2008, 55 C JAP SOC NUTR DI; Zhang B, 2020, DIABETES OBES METAB, V22, P1955, DOI 10.1111/dom.14132; Zheng J, 2013, FOOD NUTR RES, V57, DOI 10.3402/fnr.v57i0.22754	18	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 29	2021	12								620658	10.3389/fimmu.2021.620658	http://dx.doi.org/10.3389/fimmu.2021.620658			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RL7AP	33854499	gold, Green Published			2022-12-18	WOS:000639121500001
J	Miladinovic, M; Wittekindt, B; Fischer, S; Gradhand, E; Kunzmann, S; Zimmermann, SY; Bakhtiar, S; Klingebiel, T; Schlosser, R; Lehrnbecher, T				Miladinovic, Milica; Wittekindt, Boris; Fischer, Sebastian; Gradhand, Elise; Kunzmann, Steffen; Zimmermann, Stefanie Y.; Bakhtiar, Shahrzad; Klingebiel, Thomas; Schloesser, Rolf; Lehrnbecher, Thomas			Case Report: Symptomatic Chronic Granulomatous Disease in the Newborn	FRONTIERS IN IMMUNOLOGY			English	Article						chronic granulomatous disease; neonate; early onset; symptoms; outcome	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS	Chronic granulomatous disease (CGD) is a primary immunodeficiency, which is diagnosed in most patients between one and three years of age. Here we report on a boy who presented at birth with extensive skin lesions and lymphadenopathy which were caused by CGD. An analysis of the literature revealed 24 patients with CGD who became symptomatic during the first six weeks of life. Although pulmonary complications and skin lesions due to infection were the leading symptoms, clinical features were extremely heterogenous. As follow-up was not well specified in most patients, the long-term prognosis of children with very early onset of CGD remains unknown.	[Miladinovic, Milica; Wittekindt, Boris; Zimmermann, Stefanie Y.; Bakhtiar, Shahrzad; Klingebiel, Thomas; Schloesser, Rolf; Lehrnbecher, Thomas] Univ Hosp Frankfurt, Hosp Children & Adolescents, Frankfurt, Germany; [Fischer, Sebastian] Univ Hosp Frankfurt, Inst Pathol, Frankfurt, Germany; [Gradhand, Elise] Univ Hosp Frankfurt, Dept Diagnost & Intervent Radiol, Frankfurt, Germany; [Kunzmann, Steffen] Burgerhospital, Clin Neonatol & Pediat Intens Care, Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Lehrnbecher, T (corresponding author), Univ Hosp Frankfurt, Hosp Children & Adolescents, Frankfurt, Germany.	Thomas.Lehrnbecher@kgu.de	Ba, Sha/HGB-9711-2022					Afrough R, 2016, CASE REP INFECT DIS, V2016, DOI 10.1155/2016/5943783; Agarwal S, 2015, J CLIN DIAGN RES, V9, pSD1, DOI 10.7860/JCDR/2015/12139.5945; Alberdi T, 2016, J ALLERGY CLIN IMMUN, V137, pAB221, DOI 10.1016/j.jaci.2015.12.854; Arnold DE, 2017, ADV THER, V34, P2543, DOI 10.1007/s12325-017-0636-2; Baba LA, 2014, J CLIN IMMUNOL, V34, P452, DOI 10.1007/s10875-014-9997-3; Battersby AC, 2017, J ALLERGY CLIN IMMUN, V140, P628, DOI 10.1016/j.jaci.2017.02.029; Beaute J, 2011, PEDIATR INFECT DIS J, V30, P57, DOI 10.1097/INF.0b013e3181f13b23; Chang Jin H, 2007, Paediatr Child Health, V12, P313; Collins CJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00464; Connelly JA, 2018, J PEDIAT INF DIS SOC, V7, pS31, DOI 10.1093/jpids/piy015; Davoodi P, 2015, CLIN PEDIATR, V54, P91, DOI 10.1177/0009922814541809; Dekkers R, 2008, MED MYCOL, V46, P491, DOI 10.1080/13693780801946577; EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509, DOI 10.1056/NEJM199102213240801; FAVARA BE, 1992, SEMIN DIAGN PATHOL, V9, P63; Feagan BG, 2005, NEW ENGL J MED, V352, P2499, DOI 10.1056/NEJMoa042982; Feagan BG, 2008, CLIN GASTROENTEROL H, V6, P1370, DOI 10.1016/j.cgh.2008.06.007; Flanagan E, 2020, ALIMENT PHARM THER, V52, P1551, DOI 10.1111/apt.16102; Gallin JI, 2003, NEW ENGL J MED, V348, P2416, DOI 10.1056/NEJMoa021931; Guo CY, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020599; Harp J, 2015, INT J DERMATOL, V54, P617, DOI 10.1111/ijd.12765; Henriet SSV, 2012, J INFECT DIS, V206, P1128, DOI 10.1093/infdis/jis473; Herman Thomas E, 2002, J Perinatol, V22, P255, DOI 10.1038/sj.jp.7210708; Hou L, 2019, CURR MED SCI, V39, P343, DOI 10.1007/s11596-019-2041-3; Jaggi P, 2005, PEDIATR INFECT DIS J, V24, P1020, DOI 10.1097/01.inf.0000183775.69035.33; JOHNSTON HC, 1989, PEDIATR INFECT DIS J, V8, P526, DOI 10.1097/00006454-198908000-00011; Leclerc-Mercier S, 2019, J EUR ACAD DERMATOL, V33, P1412, DOI 10.1111/jdv.15568; LEE BW, 1994, ARTHRITIS RHEUM, V37, P773, DOI 10.1002/art.1780370524; Lee Eun, 2010, Korean J Pediatr, V53, P722, DOI 10.3345/kjp.2010.53.6.722; Liese J, 2000, J PEDIATR-US, V137, P687, DOI 10.1067/mpd.2000.109112; Martire B, 2008, CLIN IMMUNOL, V126, P155, DOI 10.1016/j.clim.2007.09.008; Matute JD, 2005, BLOOD CELL MOL DIS, V35, P291, DOI 10.1016/j.bcmd.2005.06.010; McElroy JA, 2011, CLIN PEDIATR, V50, P779, DOI 10.1177/0009922810379046; MOUY R, 1995, ARCH PEDIATRIE, V2, P861, DOI 10.1016/0929-693X(96)81264-4; Narchi H, 1999, PEDIATR INFECT DIS J, V18, P471, DOI 10.1097/00006454-199905000-00016; Prindaville B, 2014, J AM ACAD DERMATOL, V71, pE44, DOI 10.1016/j.jaad.2013.12.038; Rajani PS, 2019, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00429; Rider NL, 2018, J PEDIAT INF DIS SOC, V7, pS2, DOI 10.1093/jpids/piy008; Saito S, 2014, J INFECT CHEMOTHER, V20, P220, DOI 10.1016/j.jiac.2013.10.008; Salfa I, 2013, PEDIATR INFECT DIS J, V32, P926, DOI [10.1097/INF.0b013e31829157e9, 10.1097/INF.0b013e31828f682a]; Sandborn WJ, 2013, NEW ENGL J MED, V369, P711, DOI 10.1056/NEJMoa1215739; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Seger RA, 2008, BRIT J HAEMATOL, V140, P255, DOI 10.1111/j.1365-2141.2007.06880.x; Shigemura T, 2014, TRANSFUSION, V54, P516, DOI 10.1111/trf.12325; Valentine G, 2014, PEDIATRICS, V134, pE1727, DOI 10.1542/peds.2014-2175; van den Berg JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005234; Vignesh P, 2021, J ALLER CL IMM-PRACT, V9, P771, DOI 10.1016/j.jaip.2020.11.041; Weening RS, 2000, CLIN EXP IMMUNOL, V122, P410, DOI 10.1046/j.1365-2249.2000.01405.x; Welzen MEB, 2011, PEDIATR INFECT DIS J, V30, P794, DOI 10.1097/INF.0b013e3182195808; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	49	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 29	2021	12								663883	10.3389/fimmu.2021.663883	http://dx.doi.org/10.3389/fimmu.2021.663883			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RL7EK	33854515	gold, Green Published			2022-12-18	WOS:000639131400001
J	Wang, YS; Kong, YF; Wu, MX				Wang, Yensheng; Kong, Yifei; Wu, Mei X.			Innovative Systems to Deliver Allergen Powder for Epicutaneous Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Review						epicutaneous immunotherapy; microneedles; powdered allergens; tolerance; adjuvants	PEANUT ALLERGY; DRUG-DELIVERY; T-CELLS; VACCINATION; IGE; IMMUNIZATION	Allergy is a disorder owing to hyperimmune responses to a particular kind of substance like food and the disease remains a serious healthcare burden worldwide. This unpleasant and sometimes fatal allergic disease has been tackled vigorously by allergen-specific immunotherapy over a century, but the progress made so far is far from satisfactory for some allergies. Herein, we introduce innovative, allergen powder-based epicutaneous immunotherapies (EPIT), which could potentially serve to generate a new stream of technological possibilities that embrace the features of super safety and efficacious immunotherapy by manipulating the plasticity of the skin immune system via sufficient delivery of not only allergens but also tolerogenic adjuvants. We attempt to lay a framework to help understand immune physiology of the skin, epicutaneous delivery of powdered allergy, and potentials for tolerogenic adjuvants. Preclinical and clinical data are reviewed showing that deposition of allergen powder into an array of micropores in the epidermis can confer significant advantages over intradermal or subcutaneous injection of aqueous allergens or other epicutaneous delivery systems to induce immunological responses toward tolerance at little risk of anaphylaxis. Finally, the safety, cost-effectiveness, and acceptability of these novel EPITs are discussed, which offers the perspective of future immunotherapies with all desirable features.	[Wang, Yensheng; Kong, Yifei; Wu, Mei X.] Harvard Med Sch, Wellman Ctr Photomed, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Wu, MX (corresponding author), Harvard Med Sch, Wellman Ctr Photomed, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA.	MWU5@mgh.harvard.edu			National Institute of Health [AI135233, AI149012]; Wellman Center Discretionary Fund	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellman Center Discretionary Fund	This work is supported by National Institute of Health grants AI135233 and AI149012 and the Wellman Center Discretionary Fund (to MW).	Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; Akdis M, 2009, NAT REV DRUG DISCOV, V8, P645, DOI 10.1038/nrd2653; Bacher P, 2018, MUCOSAL IMMUNOL, V11, P1537, DOI 10.1038/s41385-018-0038-z; Bilaver LA, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3678; Cao Y, 2017, J CONTROL RELEASE, V249, P94, DOI 10.1016/j.jconrel.2017.01.030; Chen F, 2017, J CONTROL RELEASE, V255, P36, DOI 10.1016/j.jconrel.2017.03.397; Chen XY, 2012, J CONTROL RELEASE, V159, P43, DOI 10.1016/j.jconrel.2012.01.002; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Cruz MS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01304; Deckers J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00093; Dhami S, 2017, ALLERGY, V72, P1825, DOI 10.1111/all.13208; Di Rosa M, 2011, IMMUNOLOGY, V134, P123, DOI 10.1111/j.1365-2567.2011.03482.x; Dioszeghy V, 2017, CELL MOL IMMUNOL, V14, P770, DOI 10.1038/cmi.2016.14; Dioszeghy V, 2011, J IMMUNOL, V186, P5629, DOI 10.4049/jimmunol.1003134; Ebert CS, 2011, OTOLARYNG CLIN N AM, V44, P537, DOI 10.1016/j.otc.2011.03.001; FRANKLAND A. W., 1955, ACTA ALLERGOL, V9, P183, DOI 10.1111/j.1398-9995.1955.tb03687.x; Freeman J, 1914, LANCET, V1, P1178; Fujimoto T, 2017, LASER SURG MED, V49, P525, DOI 10.1002/lsm.22616; Ghosh P, 2013, MOL PHARMACEUT, V10, P2331, DOI 10.1021/mp3007083; Gupta J, 2011, J CONTROL RELEASE, V154, P148, DOI 10.1016/j.jconrel.2011.05.021; Gupta RS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.5630; Hessenberger M, 2013, VACCINE, V31, P3427, DOI 10.1016/j.vaccine.2012.09.086; Hijnen D, 2005, J INVEST DERMATOL, V125, P1149, DOI 10.1111/j.0022-202X.2005.23932.x; Howell MD, 2018, ANN ALLERG ASTHMA IM, V120, P367, DOI 10.1016/j.anai.2018.02.012; Huehn J, 2005, TRENDS IMMUNOL, V26, P632, DOI 10.1016/j.it.2005.10.001; Jones SM, 2017, J ALLERGY CLIN IMMUN, V139, P1242, DOI 10.1016/j.jaci.2016.08.017; Jones SM, 2016, J ALLERGY CLIN IMMUN, V137, P1258, DOI 10.1016/j.jaci.2016.01.008; Kalluri H, 2011, PHARM RES-DORDR, V28, P82, DOI 10.1007/s11095-010-0122-x; Korotchenko E, 2020, ALLERGY, V75, P1217, DOI 10.1111/all.14164; Kumar MNK, 2016, J CONTROL RELEASE, V235, P82, DOI 10.1016/j.jconrel.2016.05.057; Machado Y, 2017, J CONTROL RELEASE, V266, P87, DOI 10.1016/j.jconrel.2017.09.020; Majewska-Szczepanik M, 2016, J ALLERGY CLIN IMMUN, V138, P262, DOI 10.1016/j.jaci.2015.11.018; Maldonado RA, 2010, ADV IMMUNOL, V108, P111, DOI [10.1016/B978-0-12-380995-7.00004-5, 10.1016/S0065-2776(10)08004_1]; Malissen B, 2014, NAT REV IMMUNOL, V14, P417, DOI 10.1038/nri3683; Manicassamy S, 2011, IMMUNOL REV, V241, P206, DOI 10.1111/j.1600-065X.2011.01015.x; Manicassamy S, 2010, SCIENCE, V329, P849, DOI 10.1126/science.1188510; Manstein D, 2004, LASER SURG MED, V34, P426, DOI 10.1002/lsm.20048; Mazzara JM, 2013, J CONTROL RELEASE, V171, P172, DOI 10.1016/j.jconrel.2013.06.035; Mondoulet L, 2010, CLIN EXP ALLERGY, V40, P659, DOI 10.1111/j.1365-2222.2009.03430.x; Mondoulet L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031967; Moser K, 2001, EUR J PHARM BIOPHARM, V52, P103, DOI 10.1016/S0939-6411(01)00166-7; Ng HI, 2012, J CONTROL RELEASE, V162, P477, DOI 10.1016/j.jconrel.2012.07.024; Norman JJ, 2014, VACCINE, V32, P1856, DOI 10.1016/j.vaccine.2014.01.076; Nurmatov U, 2017, ALLERGY, V72, P1133, DOI 10.1111/all.13124; Obregon C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01514; Pajno GB, 2018, ALLERGY, V73, P799, DOI 10.1111/all.13319; Palomares O, 2017, IMMUNOL REV, V278, P219, DOI 10.1111/imr.12555; Palucka K, 2010, IMMUNITY, V33, P464, DOI 10.1016/j.immuni.2010.10.007; PAUTRIZEL R, 1957, Sem Hop, V33, P1394; Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504; Reddy MB, 2002, PHARM RES-DORDR, V19, P292, DOI 10.1023/A:1014443001802; Renz H, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2017.98; Ring J, 2011, ALLERGY, V66, P713, DOI 10.1111/j.1398-9995.2010.02541.x; Rohani MG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02817; Saedi N, 2011, CLIN PLAST SURG, V38, P449, DOI 10.1016/j.cps.2011.02.008; Sampson HA, 2017, JAMA-J AM MED ASSOC, V318, P1798, DOI 10.1001/jama.2017.16591; Satoh T, 2013, NATURE, V495, P524, DOI 10.1038/nature11930; Senti G, 2015, ALLERGY, V70, P707, DOI 10.1111/all.12600; Shakya AK, 2020, MOL PHARMACEUT, V17, P3033, DOI 10.1021/acs.molpharmaceut.0c00447; Shakya AK, 2019, J CONTROL RELEASE, V314, P38, DOI 10.1016/j.jconrel.2019.09.022; Shakya AK, 2018, J ALLERGY CLIN IMMUN, V142, P2007, DOI 10.1016/j.jaci.2018.08.017; Shakya AK, 2017, J CONTROL RELEASE, V265, P75, DOI 10.1016/j.jconrel.2017.08.012; Spina L, 2015, INT ARCH ALLERGY IMM, V167, P103, DOI 10.1159/000434681; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200425196; Sullivan SP, 2010, NAT MED, V16, P915, DOI 10.1038/nm.2182; Svajger U, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02482; Takenaka MC, 2017, SEMIN IMMUNOPATHOL, V39, P113, DOI 10.1007/s00281-016-0587-8; Thornley TB, 2014, J CLIN INVEST, V124, P3443, DOI 10.1172/JCI73527; Tordesillas L, 2017, J ALLERGY CLIN IMMUN, V139, P189, DOI 10.1016/j.jaci.2016.03.057; Wang J, 2015, P NATL ACAD SCI USA, V112, P5005, DOI 10.1073/pnas.1500408112; Weigmann HJ, 2001, SKIN PHARMACOL APPL, V14, P98, DOI 10.1159/000056397; Weiss R, 2012, J CONTROL RELEASE, V162, P391, DOI 10.1016/j.jconrel.2012.06.031; Yasuda T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167952; Yu W, 2016, NAT REV IMMUNOL, V16, P751, DOI 10.1038/nri.2016.111; Yu Y, 2020, J ALLERGY CLIN IMMUN, V145, P597, DOI 10.1016/j.jaci.2019.11.022; Zhao ZM, 2018, ADV DRUG DELIVER REV, V127, P3, DOI 10.1016/j.addr.2018.03.010	76	1	1	2	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 26	2021	12								647954	10.3389/fimmu.2021.647954	http://dx.doi.org/10.3389/fimmu.2021.647954			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RK3EP	33841430	gold, Green Published			2022-12-18	WOS:000638182900001
J	Almishri, W; Davis, RP; Shaheen, AA; Altonsy, MO; Jenne, CN; Swain, MG				Almishri, Wagdi; Davis, Rachelle P.; Shaheen, Abdel-Aziz; Altonsy, Mohammed O.; Jenne, Craig N.; Swain, Mark G.			The Antidepressant Mirtazapine Rapidly Shifts Hepatic B Cell Populations and Functional Cytokine Signatures in the Mouse	FRONTIERS IN IMMUNOLOGY			English	Article						liver disease; immunity; B cells; inflammation; intravital microscopy		Introduction B cells are important regulators of both adaptive and innate immunity. The normal liver contains significant numbers of B cells, and their numbers increase dramatically in immune-mediated liver diseases. Our previous observations suggest a hepatoprotective effect of the antidepressant mirtazapine in human and experimental immune-mediated liver disease. Therefore, we performed a series of experiments to determine the impact of mirtazapine treatment on hepatic B cell homeostasis, as reflected by B cell number, trafficking and phenotype using flow cytometry (FCM) and intravital microscopy (IVM) analysis. Mirtazapine treatment rapidly induced a significant reduction in total hepatic B cell numbers, paralleled by a compositional shift in the predominant hepatic B cell subtype from B2 to B1. This shift in hepatic B cells induced by mirtazapine treatment was associated with a striking increase in total hepatic levels of the chemokine CXCL10, and increased production of CXCL10 by hepatic macrophages and dendritic cells. Furthermore, mirtazapine treatment led to an upregulation of CXCR3, the cognate chemokine receptor for CXCL10, on hepatic B cells that remained in the liver post-mirtazapine. A significant role for CXCR3 in the hepatic retention of B cells post-mirtazapine was confirmed using CXCR3 receptor blockade. In addition, B cells remaining in the liver post-mirtazapine produced lower amounts of the proinflammatory Th1-like cytokines IFN gamma, TNF alpha, and IL-6, and increased amounts of the Th2-like cytokine IL-4, after stimulation in vitro. Conclusion Mirtazapine treatment rapidly alters hepatic B cell populations, enhancing hepatic retention of CXCR3-expressing innate-like B cells that generate a more anti-inflammatory cytokine profile. Mirtazapine-induced hepatic B cell shifts could potentially represent a novel therapeutic approach to immune-mediated liver diseases characterized by B cell driven pathology.	[Almishri, Wagdi; Davis, Rachelle P.; Altonsy, Mohammed O.; Jenne, Craig N.; Swain, Mark G.] Univ Calgary, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada; [Almishri, Wagdi; Davis, Rachelle P.; Altonsy, Mohammed O.; Jenne, Craig N.; Swain, Mark G.] Univ Calgary, Snyder Inst Chron Dis, Calgary, AB, Canada; [Almishri, Wagdi] Univ Tripoli, Dept Pathol & Clin Pathol, Fac Vet Med, Tripoli, Libya; [Shaheen, Abdel-Aziz; Swain, Mark G.] Univ Calgary, Div Gastroenterol & Hepatol, Dept Med, Calgary, AB, Canada; [Altonsy, Mohammed O.] Sohag Univ, Dept Zool, Fac Sci, Sohag, Egypt	University of Calgary; University of Calgary; University of Calgary; Egyptian Knowledge Bank (EKB); Sohag University	Swain, MG (corresponding author), Univ Calgary, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada.; Swain, MG (corresponding author), Univ Calgary, Snyder Inst Chron Dis, Calgary, AB, Canada.; Swain, MG (corresponding author), Univ Calgary, Div Gastroenterol & Hepatol, Dept Med, Calgary, AB, Canada.	swain@ucalgary.ca	Jenne, Craig/HCH-3413-2022; Shaheen, Abdel Aziz/AAX-3773-2021	Shaheen, Abdel Aziz/0000-0002-2940-897X	Team Grant (Chronic Inflammation Initiative) - Canadian Institutes of Health Research; Cal Wenzel Family Foundation Chair in Hepatology	Team Grant (Chronic Inflammation Initiative) - Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Cal Wenzel Family Foundation Chair in Hepatology	This work was supported by a Team Grant (Chronic Inflammation Initiative) awarded by the Canadian Institutes of Health Research (MS as principal investigator), and by the Cal Wenzel Family Foundation Chair in Hepatology (held by MS).	Akdis CA, 2006, EUR J PHARMACOL, V533, P69, DOI 10.1016/j.ejphar.2005.12.044; Almishri W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00803; Almishri W, 2015, J HEPATOL, V63, P943, DOI 10.1016/j.jhep.2015.06.007; Anttila SAK, 2001, CNS DRUG REV, V7, P249; Branco ACCC, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/9524075; CHOQUET D, 1988, P NATL ACAD SCI USA, V85, P4557, DOI 10.1073/pnas.85.12.4557; Curbishley SM, 2005, AM J PATHOL, V167, P887, DOI 10.1016/S0002-9440(10)62060-3; D'Mello C, 2017, GASTROENTEROLOGY, V153, P1416, DOI 10.1053/j.gastro.2017.08.011; D'Mello C, 2017, CURR TOP BEHAV NEURO, V31, P73, DOI 10.1007/7854_2016_37; Dahl J, 2014, PSYCHONEUROENDOCRINO, V45, P77, DOI 10.1016/j.psyneuen.2014.03.019; Davis RP, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02988; Davis RP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.578654; Dhirapong A, 2011, HEPATOLOGY, V53, P527, DOI 10.1002/hep.24044; Drennan MB, 2009, J IMMUNOL, V183, P2213, DOI 10.4049/jimmunol.0901213; El-Tanbouly DM, 2017, TOXICOL APPL PHARM, V329, P224, DOI 10.1016/j.taap.2017.06.012; Frolkis AD, 2019, GUT, V68, P1606, DOI 10.1136/gutjnl-2018-317182; Graff LA, 2009, INFLAMM BOWEL DIS, V15, P1105, DOI 10.1002/ibd.20873; Haas KM, 2015, ANN NY ACAD SCI, V1362, P98, DOI 10.1111/nyas.12760; Haas KM, 2009, J IMMUNOL, V183, P3661, DOI 10.4049/jimmunol.0901218; Haas KM, 2005, IMMUNITY, V23, P7, DOI 10.1016/j.immuni.2005.04.011; Harris DP, 2000, NAT IMMUNOL, V1, P475, DOI 10.1038/82717; Herr N, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00048; Hirota SA, 2011, INFLAMM BOWEL DIS, V17, P1359, DOI 10.1002/ibd.21478; Huang XQ, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00134; IKEN K, 1995, CELL IMMUNOL, V163, P1, DOI 10.1006/cimm.1995.1092; Katon Wayne J, 2011, Dialogues Clin Neurosci, V13, P7; Klinker MW, 2012, MOL MED, V18, P123, DOI 10.2119/molmed.2011.00333; Lee WY, 2010, NAT IMMUNOL, V11, P295, DOI 10.1038/ni.1855; Leonard Brian E., 2010, Current Immunology Reviews, V6, P205; Li HM, 2008, J IMMUNOL, V181, P2483, DOI 10.4049/jimmunol.181.4.2483; Liu Y, 2016, CLIN SCI, V130, P907, DOI 10.1042/CS20160069; Ma Q, 1999, IMMUNITY, V10, P463, DOI 10.1016/S1074-7613(00)80046-1; Mossner R, 1998, BRAIN BEHAV IMMUN, V12, P249, DOI 10.1006/brbi.1998.0532; Norris S, 1998, J HEPATOL, V28, P84, DOI 10.1016/S0168-8278(98)80206-7; Pena S, 2005, INT IMMUNOPHARMACOL, V5, P1069, DOI 10.1016/j.intimp.2005.02.005; Piali L, 1998, EUR J IMMUNOL, V28, P961, DOI 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4; Rinaldi A, 2010, PATHOBIOLOGY, V77, P129, DOI 10.1159/000292646; Robinson MW, 2016, CELL MOL IMMUNOL, V13, P267, DOI 10.1038/cmi.2016.3; Ruddell RG, 2008, J HEPATOL, V48, P666, DOI 10.1016/j.jhep.2008.01.006; Schmidt-Arras D, 2016, J HEPATOL, V64, P1403, DOI 10.1016/j.jhep.2016.02.004; Shaheen AA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194839; Shimomura Y, 2008, INT IMMUNOL, V20, P729, DOI 10.1093/intimm/dxn031; Stein JV, 2005, IMMUNOLOGY, V116, P1, DOI 10.1111/j.1365-2567.2005.02183.x; Strawbridge R, 2015, EUR NEUROPSYCHOPHARM, V25, P1532, DOI 10.1016/j.euroneuro.2015.06.007; Szalach LP, 2019, ARCH IMMUNOL THER EX, V67, P143, DOI 10.1007/s00005-019-00543-8; Taylor SA, 2019, SEMIN LIVER DIS, V39, P422, DOI 10.1055/s-0039-1688751; Thaunat O, 2010, BLOOD, V116, P515, DOI 10.1182/blood-2010-01-266668; Tilg H, 2006, LIVER INT, V26, P1029, DOI 10.1111/j.1478-3231.2006.01339.x; Luu VP, 2014, AUTOIMMUNITY, V47, P1, DOI 10.3109/08916934.2013.856006; Vigano M, 2014, EXPERT OPIN BIOL TH, V14, P1019, DOI 10.1517/14712598.2014.912273; Wan MJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00186; Wang HS, 2012, BLOOD, V119, P465, DOI 10.1182/blood-2011-03-343608; Wasik M, 2018, MICROBIOL IMMUNOL, V62, P485, DOI 10.1111/1348-0421.12636; Xu W, 2012, J EXP MED, V209, P1813, DOI 10.1084/jem.20112142; Yang YQ, 2016, ONCOTARGET, V7, P26992, DOI 10.18632/oncotarget.8853	55	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2021	12								622537	10.3389/fimmu.2021.622537	http://dx.doi.org/10.3389/fimmu.2021.622537			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RJ6NY	33841403	gold, Green Published			2022-12-18	WOS:000637718300001
J	Jhala, G; Selck, C; Chee, J; Kwong, CTJ; Pappas, EG; Thomas, HE; Kay, TWH; Krishnamurthy, B				Jhala, Gaurang; Selck, Claudia; Chee, Jonathan; Kwong, Chun-Ting J.; Pappas, Evan G.; Thomas, Helen E.; Kay, Thomas W. H.; Krishnamurthy, Balasubramanian			Tolerance to Proinsulin-1 Reduces Autoimmune Diabetes in NOD Mice	FRONTIERS IN IMMUNOLOGY			English	Article						type 1 diabetes; proinsulin-1; CD4+T cells; immune tolerance; NOD mice		T-cell responses to insulin and its precursor proinsulin are central to islet autoimmunity in humans and non-obese diabetic (NOD) mice that spontaneously develop autoimmune diabetes. Mice have two proinsulin genes proinsulin -1 and 2 that are differentially expressed, with predominant proinsulin-2 expression in the thymus and proinsulin-1 in islet beta-cells. In contrast to proinsulin-2, proinsulin-1 knockout NOD mice are protected from autoimmune diabetes. This indicates that proinsulin-1 epitopes in beta-cells maybe preferentially targeted by autoreactive T cells. To study the contribution of proinsulin-1 reactive T cells in autoimmune diabetes, we generated transgenic NOD mice with tetracycline-regulated expression of proinsulin-1 in antigen presenting cells (TIP-1 mice) with an aim to induce immune tolerance. TIP-1 mice displayed a significantly reduced incidence of spontaneous diabetes, which was associated with reduced severity of insulitis and insulin autoantibody development. Antigen experienced proinsulin specific T cells were significantly reduced in in TIP-1 mice indicating immune tolerance. Moreover, T cells from TIP-1 mice expressing proinsulin-1 transferred diabetes at a significantly reduced frequency. However, proinsulin-1 expression in APCs had minimal impact on the immune responses to the downstream antigen islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) and did not prevent diabetes in NOD 8.3 mice with a pre-existing repertoire of IGRP reactive T cells. Thus, boosting immune tolerance to proinsulin-1 partially prevents islet-autoimmunity. This study further extends the previously established role of proinsulin-1 epitopes in autoimmune diabetes in NOD mice.	[Jhala, Gaurang; Selck, Claudia; Kwong, Chun-Ting J.; Pappas, Evan G.; Thomas, Helen E.; Kay, Thomas W. H.; Krishnamurthy, Balasubramanian] St Vincents Inst, Fitzroy, Vic, Australia; [Jhala, Gaurang; Thomas, Helen E.; Kay, Thomas W. H.; Krishnamurthy, Balasubramanian] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic, Australia; [Chee, Jonathan] Univ Western Australia, Inst Resp Hlth, Natl Ctr Asbestos Related Dis, Perth, WA, Australia; [Chee, Jonathan] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia; [Selck, Claudia] Imperial Coll London, London, England	St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne; University of Melbourne; University of Western Australia; University of Western Australia; Imperial College London	Kay, TWH (corresponding author), St Vincents Inst, Fitzroy, Vic, Australia.; Kay, TWH (corresponding author), Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic, Australia.	tkay@svi.edu.au	Chee, Jonathan/D-4634-2017	Chee, Jonathan/0000-0002-7986-2708	National Health and Medical Research Council of Australia [GNT1037321, GNT1150425]; Juvenile Diabetes Research Foundation; Operational Infrastructure Support Scheme of the Government of Victoria	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); Operational Infrastructure Support Scheme of the Government of Victoria	This work was funded by the National Health and Medical Research Council of Australia (GNT1037321 and GNT1150425) and fellowship from Juvenile Diabetes Research Foundation (BK). The St Vincent's Institute receives support from the Operational Infrastructure Support Scheme of the Government of Victoria.	Babaya N, 2009, DIABETES TECHNOL THE, V11, P227, DOI 10.1089/dia.2008.0072; Chee J, 2014, J IMMUNOL, V192, P572, DOI 10.4049/jimmunol.1302100; Chentoufi AA, 2002, DIABETES, V51, P1383, DOI 10.2337/diabetes.51.5.1383; Crawford F, 2011, P NATL ACAD SCI USA, V108, P16729, DOI 10.1073/pnas.1113954108; Daniel C, 2011, J EXP MED, V208, P1501, DOI 10.1084/jem.20110574; Daniel D, 1996, P NATL ACAD SCI USA, V93, P956, DOI 10.1073/pnas.93.2.956; DELTOUR L, 1993, P NATL ACAD SCI USA, V90, P527, DOI 10.1073/pnas.90.2.527; Devendra D, 2004, J AUTOIMMUN, V23, P17, DOI 10.1016/j.jaut.2004.03.008; Elso CM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225021; Faideau B, 2006, J IMMUNOL, V177, P53, DOI 10.4049/jimmunol.177.1.53; Fan Y, 2009, EMBO J, V28, P2812, DOI 10.1038/emboj.2009.212; French MB, 1997, DIABETES, V46, P34, DOI 10.2337/diabetes.46.1.34; Guerau-De-Arellano M, 2009, J EXP MED, V206, P1245, DOI 10.1084/jem.20090300; Halbout P, 2002, J IMMUNOL, V169, P2436, DOI 10.4049/jimmunol.169.5.2436; Heath VL, 1998, J AUTOIMMUN, V11, P309, DOI 10.1006/jaut.1998.0210; Insel RA, 2015, DIABETES CARE, V38, P1964, DOI 10.2337/dc15-1419; Jaeckel E, 2004, NAT IMMUNOL, V5, P1028, DOI 10.1038/ni1120; Jhala G, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86065; Krishnamurthy B, 2008, J IMMUNOL, V180, P4458, DOI 10.4049/jimmunol.180.7.4458; Krishnamurthy B, 2006, J CLIN INVEST, V116, P3258, DOI 10.1172/JCI29602; Levisetti MG, 2008, DIABETES, V57, P1852, DOI 10.2337/db08-0068; LUCASSEN AM, 1993, NAT GENET, V4, P305, DOI 10.1038/ng0793-305; Mannering SI, 2016, CLIN EXP IMMUNOL, V183, P8, DOI 10.1111/cei.12699; Moon JJ, 2009, NAT PROTOC, V4, P565, DOI 10.1038/nprot.2009.9; Moriyama H, 2003, P NATL ACAD SCI USA, V100, P10376, DOI 10.1073/pnas.1834450100; Nakayama M, 2005, NATURE, V435, P220, DOI 10.1038/nature03523; Nakayama M, 2007, J CLIN INVEST, V117, P1835, DOI 10.1172/JCI31368; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; Thebault-Baumont K, 2003, J CLIN INVEST, V111, P851, DOI 10.1172/JCI200316584; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; Verdaguer J, 1997, J EXP MED, V186, P1663, DOI 10.1084/jem.186.10.1663; WEGMANN DR, 1994, EUR J IMMUNOL, V24, P1853, DOI 10.1002/eji.1830240820; WENTWORTH BM, 1986, J MOL EVOL, V23, P305, DOI 10.1007/BF02100639; Wong FS, 2009, DIABETES, V58, P1156, DOI 10.2337/db08-0800; Wong FS, 1999, NAT MED, V5, P1026, DOI 10.1038/12465; Yu LP, 2000, P NATL ACAD SCI USA, V97, P1701, DOI 10.1073/pnas.040556697; Ziegler AG, 2013, JAMA-J AM MED ASSOC, V309, P2473, DOI 10.1001/jama.2013.6285	37	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2021	12								645817	10.3389/fimmu.2021.645817	http://dx.doi.org/10.3389/fimmu.2021.645817			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RJ6RC	33841427	gold, Green Published			2022-12-18	WOS:000637726700001
J	Komaroff, AL; Rizzo, R; Ecker, JL				Komaroff, Anthony L.; Rizzo, Roberta; Ecker, Jeffrey L.			Human Herpesviruses 6A and 6B in Reproductive Diseases	FRONTIERS IN IMMUNOLOGY			English	Review						congenital infection; human herpesvirus-6A; human herpesvirus-6B; inherited chromosomally integrated human herpesvirus 6; preeclampsia; primary unexplained infertility; spontaneous abortion; intrauterine growth retardation (IUGR)	NK CELLS; INFECTION; PREECLAMPSIA; HHV-6A; VIRUS	Human herpesviruses 6A (HHV-6A) and human herpesvirus 6B (HHV-6B)-collectively, HHV-6A/B-are recently-discovered but ancient human viruses. The vast majority of people acquire one or both viruses, typically very early in life, producing an ineradicable lifelong infection. The viruses have been linked to several neurological, pulmonary and hematological diseases. In early human history, the viruses on multiple occasions infected a germ cell, and integrated their DNA into a human chromosome. As a result, about 1% of humans are born with the full viral genome present in every cell, with uncertain consequences for health. HHV-6A may play a role in 43% of cases of primary unexplained infertility. Both the inherited and acquired viruses may occasionally trigger several of the factors that are important in the pathogenesis of preeclampsia. Transplacental infection occurs in 1-2% of pregnancies, with some evidence suggesting adverse health consequences for the child. While emerging knowledge about these viruses in reproductive diseases is not sufficient to suggest any changes in current practice, we write this review to indicate the need for further research that could prove practice-changing.	[Komaroff, Anthony L.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gen Med, Boston, MA 02115 USA; [Rizzo, Roberta] Univ Ferrara, Dept Chem & Pharmaceut Sci, Ferrara, Italy; [Ecker, Jeffrey L.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Ferrara; Harvard University; Harvard Medical School; Massachusetts General Hospital	Komaroff, AL (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gen Med, Boston, MA 02115 USA.	komaroff@hms.harvard.edu			HHV-6 Foundation	HHV-6 Foundation	The HHV-6 Foundation supported the costs of publication.	Adams O, 1998, J INFECT DIS, V178, P544, DOI 10.1086/517470; Agut H, 2015, CLIN MICROBIOL REV, V28, P313, DOI 10.1128/CMR.00122-14; Arbuckle JH, 2010, P NATL ACAD SCI USA, V107, P5563, DOI 10.1073/pnas.0913586107; Arena A, 1996, MICROBIOLOGICA, V19, P183; Aswad A, 2021, MOL BIOL EVOL, V38, P96, DOI 10.1093/molbev/msaa190; AUBIN JT, 1992, LANCET, V340, P482, DOI 10.1016/0140-6736(92)91801-E; Baecher-Lind LE, 2010, OBSTET GYNECOL SURV, V65, P53, DOI 10.1097/OGX.0b013e3181c9e7a1; Baillargeon J, 2000, J CLIN VIROL, V16, P149, DOI 10.1016/S1386-6532(99)00086-4; BARONE SR, 1995, J PEDIATR-US, V127, P95, DOI 10.1016/S0022-3476(95)70263-6; Bortlotti D, 2020, REPROD SCI, V27, P779, DOI 10.1007/s43032-019-00102-8; Bortolotti D, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00226; Braun DK, 1997, CLIN MICROBIOL REV, V10, P521, DOI 10.1128/CMR.10.3.521; Caruso A, 2003, J MED VIROL, V70, P451, DOI 10.1002/jmv.10416; Caruso A, 2002, J MED VIROL, V67, P528, DOI 10.1002/jmv.10133; Caruso A, 2009, P NATL ACAD SCI USA, V106, P20446, DOI 10.1073/pnas.0905535106; Caserta MT, 2007, J INFECT DIS, V196, P1296, DOI 10.1086/522430; Caserta MT, 2014, PEDIATRICS, V134, P1111, DOI 10.1542/peds.2014-0886; Chaiworapongsa T, 2014, NAT REV NEPHROL, V10, P531, DOI 10.1038/nrneph.2014.103; Chaiworapongsa T, 2014, NAT REV NEPHROL, V10, P466, DOI 10.1038/nrneph.2014.102; CHEN M, 1994, AM J PATHOL, V145, P1509; Conde-Agudelo A, 2008, AM J OBSTET GYNECOL, V198, P7, DOI 10.1016/j.ajog.2007.07.040; Csoma E, 2002, J MED VIROL, V67, P67, DOI 10.1002/jmv.2194; De Bolle L, 2005, CLIN MICROBIOL REV, V18, P217, DOI 10.1128/CMR.18.1.217-245.2005; Dekker G, 2011, J REPROD IMMUNOL, V89, P126, DOI 10.1016/j.jri.2010.12.010; Drago F, 2014, J AM ACAD DERMATOL, V71, P198, DOI 10.1016/j.jaad.2014.02.023; Eliassen E, 2020, PEDIATR NEUROL, V105, P10, DOI 10.1016/j.pediatrneurol.2019.10.004; Flamand L, 1996, J CLIN INVEST, V97, P1373, DOI 10.1172/JCI118557; FLAMAND L, 1991, J VIROL, V65, P5105, DOI 10.1128/JVI.65.9.5105-5110.1991; Gaccioli F, 2020, NAT MICROBIOL, V5, P901, DOI 10.1038/s41564-020-0711-3; Gibson CS, 2008, BJOG-INT J OBSTET GY, V115, P492, DOI 10.1111/j.1471-0528.2007.01653.x; Gilbert-Girard S, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008496; Granger JP, 2001, AM J HYPERTENS, V14, p178S, DOI 10.1016/S0895-7061(01)02086-6; Gravel A, 2015, P NATL ACAD SCI USA, V112, P8058, DOI 10.1073/pnas.1502741112; Hall CB, 2008, PEDIATRICS, V122, P513, DOI 10.1542/peds.2007-2838; Hall CB, 2010, J INFECT DIS, V201, P505, DOI 10.1086/650495; Hall CB, 2004, J PEDIATR-US, V145, P472, DOI 10.1016/j.jpeds.2004.06.017; HALL CB, 1994, NEW ENGL J MED, V331, P432, DOI 10.1056/NEJM199408183310703; Harberts E, 2011, P NATL ACAD SCI USA, V108, P13734, DOI 10.1073/pnas.1105143108; Hill JA, 2014, HAND CLINIC, V123, P327, DOI 10.1016/B978-0-444-53488-0.00016-X; Howley PM., 2013, FIELDS VIROLOGY, V2, P2059; Kaufer BB, 2014, CURR OPIN VIROL, V9, P111, DOI 10.1016/j.coviro.2014.09.010; Komaroff AL, 2021, CLIN MICROBIOL REV, V34, DOI 10.1128/CMR.00143-20; KONDO K, 1993, J INFECT DIS, V167, P1197, DOI 10.1093/infdis/167.5.1197; Laina I, 2010, PEDIATR NEUROL, V42, P28, DOI 10.1016/j.pediatrneurol.2009.07.016; LEACH CT, 1994, J INFECT DIS, V169, P1281, DOI 10.1093/infdis/169.6.1281; Lessey BA, 2019, FERTIL STERIL, V111, P611, DOI 10.1016/j.fertnstert.2019.02.009; Lessey BA, 2011, FERTIL STERIL, V96, P522, DOI 10.1016/j.fertnstert.2011.07.1095; LOPEZ C, 1988, J INFECT DIS, V157, P1271, DOI 10.1093/infdis/157.6.1271; Maeda T, 1997, ACTA PAEDIATR JAPON, V39, P653; Marci R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158304; Mayne M, 2001, J VIROL, V75, P11641, DOI 10.1128/JVI.75.23.11641-11650.2001; MCCARTHY AL, 1993, AM J OBSTET GYNECOL, V168, P1323, DOI 10.1016/0002-9378(93)90389-Z; Meeuwsen S, 2005, J NEUROIMMUNOL, V164, P37, DOI 10.1016/j.jneuroim.2005.03.013; Millichap JG, 2006, PEDIATR NEUROL, V35, P165, DOI 10.1016/j.pediatrneurol.2006.06.004; Miura H, 2021, J INFECT DIS, V223, P1717, DOI 10.1093/infdis/jiaa606; Ohashi M, 2002, J MED VIROL, V67, P354, DOI 10.1002/jmv.10083; OKUNO T, 1995, J CLIN MICROBIOL, V33, P1968, DOI 10.1128/JCM.33.7.1968-1970.1995; Pegoraro A, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00096; Pellett PE, 2012, REV MED VIROL, V22, P144, DOI 10.1002/rmv.715; Rana S, 2018, PREGNANCY HYPERTENS, V13, P100, DOI 10.1016/j.preghy.2018.05.008; Reynaud JM, 2014, J VIROL, V88, P5421, DOI 10.1128/JVI.03763-13; Rizzo R, 2018, ACTA MICROBIOL IMM H, V65, P119, DOI 10.1556/030.65.2018.010; Rizzo R, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02143; Rizzo R, 2011, CELL MOL LIFE SCI, V68, P341, DOI 10.1007/s00018-010-0578-1; Roberts JM, 2013, OBSTET GYNECOL, V122, P1122, DOI 10.1097/01.AOG.0000437382.03963.88; Rotola A, 2000, J CLIN MICROBIOL, V38, P3135, DOI 10.1128/JCM.38.8.3135-3136.2000; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; TAKAHASHI K, 1992, PEDIATR INFECT DIS J, V11, P369, DOI 10.1097/00006454-199205000-00006; Talloczy Z, 2006, AUTOPHAGY, V2, P24, DOI 10.4161/auto.2176; TAYLOR RN, 1991, AM J OBSTET GYNECOL, V165, P895, DOI 10.1016/0002-9378(91)90435-T; Ward KN, 2005, ARCH DIS CHILD, V90, P619, DOI 10.1136/adc.2004.062216; Wight DJ, 2020, P NATL ACAD SCI USA, V117, P31410, DOI 10.1073/pnas.2011872117; YAMANISHI K, 1988, LANCET, V1, P1065; You SJ, 2020, J CHILD NEUROL, V35, P132, DOI 10.1177/0883073819879284; Zerr DM, 2001, CLIN INFECT DIS, V33, P763, DOI 10.1086/322642; Zerr DM, 2014, HUMAN HERPESVIRUSES, V3rd, P99	76	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2021	12								648945	10.3389/fimmu.2021.648945	http://dx.doi.org/10.3389/fimmu.2021.648945			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RJ6KR	33841432	gold, Green Published			2022-12-18	WOS:000637709800001
J	Li, J; Zhang, YF; Jilg, AL; Wolk, DM; Khara, HS; Kolinovsky, A; Rolston, DDK; Hontecillas, R; Bassaganya-Riera, J; Williams, MS; Abedi, V; Lee, MTM				Li, Jiang; Zhang, Yanfei; Jilg, Alexandria L.; Wolk, Donna M.; Khara, Harshit S.; Kolinovsky, Amy; Rolston, David D. K.; Hontecillas, Raquel; Bassaganya-Riera, Josep; Williams, Marc S.; Abedi, Vida; Lee, Ming Ta Michael		Regeneron Genetics Ctr	Variants at the MHC Region Associate With Susceptibility to Clostridioides difficile Infection: A Genome-Wide Association Study Using Comprehensive Electronic Health Records	FRONTIERS IN IMMUNOLOGY			English	Article						Clostridioides difficile; MICA; C4a; NOTCH4; GWAS		Background Clostridioides difficile is a major cause of healthcare-associated and community-acquired diarrhea. Host genetic susceptibility to Clostridioides difficile infection has not been studied on a large-scale. Methods A total of 1,160 Clostridioides difficile infection cases and 15,304 controls were identified by applying the eMERGE Clostridioides difficile infection algorithm to electronic health record data. A genome-wide association study was performed using a linear mixed model, adjusted for significant covariates in the full dataset and the antibiotic subgroup. Colocalization and MetaXcan were performed to identify potential target genes in Clostridioides difficile infection - relevant tissue types. Results No significant genome-wide association was found in the meta-analyses of the full Clostridioides difficile infection dataset. One genome-wide significant variant, rs114751021, was identified (OR = 2.42; 95%CI = 1.84-3.11; p=4.50 x 10(-8)) at the major histocompatibility complex region associated with Clostridioides difficile infection in the antibiotic group. Colocalization and MetaXcan identified MICA, C4A/C4B, and NOTCH4 as potential target genes. Down-regulation of MICA, upregulation of C4A and NOTCH4 was associated with a higher risk for Clostridioides difficile infection. Conclusions Leveraging the EHR and genetic data, genome-wide association, and fine-mapping techniques, this study identified variants and genes associated with Clostridioides difficile infection, provided insights into host immune mechanisms, and described the potential for novel treatment strategies for Clostridioides difficile infection. Future replication and functional validation are needed.	[Li, Jiang; Abedi, Vida] Geisinger, Dept Mol & Funct Genom, Danville, PA 17822 USA; [Zhang, Yanfei; Williams, Marc S.; Lee, Ming Ta Michael] Geisinger, Genom Med Inst, Danville, PA 17822 USA; [Jilg, Alexandria L.; Rolston, David D. K.] Geisinger, Dept Internal Med, Danville, PA USA; [Wolk, Donna M.] Geisinger, Dept Lab Med, Diagnost Med Inst, Danville, PA USA; [Khara, Harshit S.] Geisinger, Dept Gastroenterol & Hepatol, Danville, PA USA; [Kolinovsky, Amy] Geisinger, Phenotype Core, Danville, PA USA; [Hontecillas, Raquel; Bassaganya-Riera, Josep] NIMML Inst, Blacksburg, VA USA; Regeneron Genet Ctr, Tarrytown, NY USA	Regeneron	Abedi, V (corresponding author), Geisinger, Dept Mol & Funct Genom, Danville, PA 17822 USA.; Lee, MTM (corresponding author), Geisinger, Genom Med Inst, Danville, PA 17822 USA.	vabedi@geisinger.edu; mlee2@geisinger.edu	Abedi, Vida/AAU-3828-2021	Li, Jiang/0000-0002-7006-1285; Abedi, Vida/0000-0001-7689-933X	Regeneron Genetic Center; Geisinger; Defense Threat Reduction Agency [HDTRA1-18-1-0008]	Regeneron Genetic Center(Regeneron); Geisinger; Defense Threat Reduction Agency(United States Department of DefenseDefense Threat Reduction Agency)	This work was supported by Regeneron Genetic Center which provided funds for MyCode consenting, sample collection, genotyping, and genetic data processing. The internal fund to MTML from Geisinger and the external fund from the Defense Threat Reduction Agency to JB-R, RH, and VA (HDTRA1-18-1-0008) supported the data extraction and analyses. The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.	Abt MC, 2016, NAT REV MICROBIOL, V14, P609, DOI 10.1038/nrmicro.2016.108; Abul-Husn NS, 2016, SCIENCE, V354, DOI 10.1126/science.aaf7000; Ananthakrishnan AN, 2013, ALIMENT PHARM THER, V38, P522, DOI 10.1111/apt.12425; Apewokin S, 2018, SUPPORT CARE CANCER, V26, P3127, DOI 10.1007/s00520-018-4173-6; Barbeira AN, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03621-1; Carey DJ, 2016, GENET MED, V18, P906, DOI 10.1038/gim.2015.187; Connelly TM, 2014, SURGERY, V156, P769, DOI 10.1016/j.surg.2014.06.067; Cookson B, 2007, POSTGRAD MED J, V83, P291, DOI 10.1136/pgmj.2006.056143; Czepiel J, 2018, MICROB PATHOGENESIS, V114, P281, DOI 10.1016/j.micpath.2017.11.066; Deshpande A, 2015, INFECT CONT HOSP EP, V36, P452, DOI 10.1017/ice.2014.88; Dewey FE, 2016, SCIENCE, V354, DOI 10.1126/science.aaf6814; Dial S, 2008, CAN MED ASSOC J, V179, P767, DOI 10.1503/cmaj.071812; Eyre DW, 2013, NEW ENGL J MED, V369, P1195, DOI 10.1056/NEJMoa1216064; Garey KW, 2010, CLIN INFECT DIS, V51, P1406, DOI 10.1086/657398; Guh AY, 2020, NEW ENGL J MED, V382, P1320, DOI 10.1056/NEJMoa1910215; Hasegawa M, 2014, IMMUNITY, V41, P620, DOI 10.1016/j.immuni.2014.09.010; He M, 2013, NAT GENET, V45, P109, DOI 10.1038/ng.2478; Heesterbeek DAC, 2018, J INNATE IMMUN, V10, P455, DOI 10.1159/000491439; Hormozdiari F, 2016, AM J HUM GENET, V99, P1245, DOI 10.1016/j.ajhg.2016.10.003; JENSEN GL, 1994, J INFECT DIS, V170, P227, DOI 10.1093/infdis/170.1.227; Jiang ZD, 2006, AM J GASTROENTEROL, V101, P1112, DOI 10.1111/j.1572-0241.2006.00482.x; Johanesen PA, 2015, GENES-BASEL, V6, P1347, DOI 10.3390/genes6041347; Kumar N, 2019, NAT GENET, V51, P1315, DOI 10.1038/s41588-019-0478-8; Lanier LL, 2015, CANCER IMMUNOL RES, V3, P575, DOI 10.1158/2326-6066.CIR-15-0098; Leffler DA, 2015, NEW ENGL J MED, V372, P1539, DOI 10.1056/NEJMra1403772; Loh PR, 2015, NAT GENET, V47, P284, DOI 10.1038/ng.3190; Miyajima F, 2014, CLIN INFECT DIS, V58, pE148, DOI 10.1093/cid/ciu152; Pepin J, 2005, CLIN INFECT DIS, V41, P1254, DOI 10.1086/496986; Rupnik M, 2008, FEMS MICROBIOL REV, V32, P541, DOI 10.1111/j.1574-6976.2008.00110.x; Sarma JV, 2011, CELL TISSUE RES, V343, P227, DOI 10.1007/s00441-010-1034-0; Schepis D, 2009, SCAND J IMMUNOL, V69, P429, DOI 10.1111/j.1365-3083.2009.02241.x; Solomon K, 2013, J MED MICROBIOL, V62, P1453, DOI 10.1099/jmm.0.058479-0; Spain SL, 2015, HUM MOL GENET, V24, pR111, DOI 10.1093/hmg/ddv260; Tieng V, 2002, P NATL ACAD SCI USA, V99, P2977, DOI 10.1073/pnas.032668099; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Zhang YF, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1405-7; Zheng RJ, 2018, J INFECT DIS, V218, P312, DOI 10.1093/infdis/jix636; Zhou W, 2018, NAT GENET, V50, P1335, DOI 10.1038/s41588-018-0184-y; Zhou X, 2012, NAT GENET, V44, P821, DOI 10.1038/ng.2310	39	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2021	12								638913	10.3389/fimmu.2021.638913	http://dx.doi.org/10.3389/fimmu.2021.638913			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RJ4CZ	33841421	gold, Green Published			2022-12-18	WOS:000637550200001
J	Majumder, K; Morales, AJ				Majumder, Kinjal; Morales, Abigail J.			Utilization of Host Cell Chromosome Conformation by Viral Pathogens: Knowing When to Hold and When to Fold	FRONTIERS IN IMMUNOLOGY			English	Review						epigenetics; topologically associating domains; CTCF; Cohesin; B cells; human gammaherpesviruses; small DNA viruses		Though viruses have their own genomes, many depend on the nuclear environment of their hosts for replication and survival. A substantial body of work has therefore been devoted to understanding how viral and eukaryotic genomes interact. Recent advances in chromosome conformation capture technologies have provided unprecedented opportunities to visualize how mammalian genomes are organized and, by extension, how packaging of nuclear DNA impacts cellular processes. Recent studies have indicated that some viruses, upon entry into host cell nuclei, produce factors that alter host chromatin topology, and thus, impact the 3D organization of the host genome. Additionally, a variety of distinct viruses utilize host genome architectural factors to advance various aspects of their life cycles. Indeed, human gammaherpesviruses, known for establishing long-term reservoirs of latent infection in B lymphocytes, utilize 3D principles of genome folding to package their DNA and establish latency in host cells. This manipulation of host epigenetic machinery by latent viral genomes is etiologically linked to the onset of B cell oncogenesis. Small DNA viruses, by contrast, are tethered to distinct cellular sites that support virus expression and replication. Here, we briefly review the recent findings on how viruses and host genomes spatially communicate, and how this impacts virus-induced pathology.	[Majumder, Kinjal] Univ Wisconsin, Sch Med & Publ Hlth, Carbone Canc Ctr, Inst Mol Virol, Madison, WI 53706 USA; [Majumder, Kinjal] Univ Wisconsin, Sch Med & Publ Hlth, Carbone Canc Ctr, McArdle Lab Canc Res,Human Canc Virol Program, Madison, WI 53706 USA; [Morales, Abigail J.] CUNY Hunter Coll, Dept Med Lab Sci, New York, NY 10021 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; City University of New York (CUNY) System; Hunter College (CUNY)	Majumder, K (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Carbone Canc Ctr, Inst Mol Virol, Madison, WI 53706 USA.; Majumder, K (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Carbone Canc Ctr, McArdle Lab Canc Res,Human Canc Virol Program, Madison, WI 53706 USA.; Morales, AJ (corresponding author), CUNY Hunter Coll, Dept Med Lab Sci, New York, NY 10021 USA.	kmajumder@wisc.edu; ar4835@hunter.cuny.edu			NIH K99/R00 Pathway to Independence Award [AI148511]; University of Wisconsin Office of Vice Chancellor for Research and Graduate Education; University of Wisconsin Carbonne Cancer Center's Human Virology Program; PSC-CUNY Award - Professional Staff Congress [TRADA-51-497]; PSC-CUNY Award - City University of New York [TRADA-51-497]	NIH K99/R00 Pathway to Independence Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Wisconsin Office of Vice Chancellor for Research and Graduate Education; University of Wisconsin Carbonne Cancer Center's Human Virology Program; PSC-CUNY Award - Professional Staff Congress; PSC-CUNY Award - City University of New York	KM is supported by a NIH K99/R00 Pathway to Independence Award (AI148511), University of Wisconsin Office of Vice Chancellor for Research and Graduate Education and the University of Wisconsin Carbonne Cancer Center's Human Virology Program. Additional support for this work was provided by a PSC-CUNY Award, jointly funded by The Professional Staff Congress and the City University of New York (TRADA-51-497; AM).	Adeyemi RO, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001141; Arnould C, 2020, J MOL BIOL, V432, P724, DOI 10.1016/j.jmb.2019.07.036; Arvey A, 2012, CELL HOST MICROBE, V12, P233, DOI 10.1016/j.chom.2012.06.008; Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Barbera AJ, 2006, SCIENCE, V311, P856, DOI 10.1126/science.1120541; Barlow JH, 2013, CELL, V152, P620, DOI 10.1016/j.cell.2013.01.006; Bentley P, 2018, J VIROL, V92, DOI 10.1128/JVI.00356-18; Boftsi M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12121368; Campbell M, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00850; Canaan A, 2009, P NATL ACAD SCI USA, V106, P22421, DOI 10.1073/pnas.0911676106; Canela A, 2019, MOL CELL, V75, P252, DOI 10.1016/j.molcel.2019.04.030; Canela A, 2017, CELL, V170, P507, DOI 10.1016/j.cell.2017.06.034; Carson CT, 2009, EMBO J, V28, P652, DOI 10.1038/emboj.2009.15; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chang HH, 2013, CELL HOST MICROBE, V13, P429, DOI 10.1016/j.chom.2013.03.009; Chau CM, 2006, J VIROL, V80, P5723, DOI 10.1128/JVI.00025-06; Chen HS, 2013, CURR OPIN VIROL, V3, P251, DOI 10.1016/j.coviro.2013.03.004; Chen HS, 2012, J VIROL, V86, P9454, DOI 10.1128/JVI.00787-12; Dahl J, 2005, J VIROL, V79, P13007, DOI 10.1128/JVI.79.20.13007-13017.2005; De Leo A, 2020, TRENDS MICROBIOL, V28, P150, DOI 10.1016/j.tim.2019.09.002; Decorsiere A, 2016, NATURE, V531, P386, DOI 10.1038/nature17170; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Denker A, 2016, GENE DEV, V30, P1357, DOI 10.1101/gad.281964.116; Dileep V, 2015, GENOME RES, V25, P1104, DOI 10.1101/gr.183699.114; Dresang LR, 2009, J VIROL, V83, P2930, DOI 10.1128/JVI.01974-08; Evans JD, 2005, J VIROL, V79, P6207, DOI 10.1128/JVI.79.10.6207-6215.2005; Fay N, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00467; Frohlich J, 2020, SEMIN IMMUNOPATHOL, V42, P143, DOI 10.1007/s00281-020-00787-z; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Grundhoff A, 2003, J VIROL, V77, P2779, DOI 10.1128/JVI.77.4.2779-2783.2003; Guo Y, 2015, CELL, V162, P900, DOI 10.1016/j.cell.2015.07.038; He ML, 2012, CANCER RES, V72, P3582, DOI 10.1158/0008-5472.CAN-11-2876; Heinz S, 2018, CELL, V174, P1522, DOI 10.1016/j.cell.2018.07.047; Holdorf MM, 2011, VIROLOGY, V415, P1, DOI 10.1016/j.virol.2011.04.004; Hu JH, 2002, J VIROL, V76, P11677, DOI 10.1128/JVI.76.22.11677-11687.2002; Jiang SZ, 2017, CELL HOST MICROBE, V22, P561, DOI 10.1016/j.chom.2017.09.001; Kamranvar SA, 2013, ONCOGENE, V32, P5522, DOI 10.1038/onc.2013.189; Kamranvar SA, 2011, LEUKEMIA, V25, P1017, DOI 10.1038/leu.2011.35; Kang H, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002140; Kempfer R, 2020, NAT REV GENET, V21, P207, DOI 10.1038/s41576-019-0195-2; Krithivas A, 2002, J VIROL, V76, P11596, DOI 10.1128/JVI.76.22.11596-11604.2002; Lakdawala SS, 2008, J VIROL, V82, P8362, DOI 10.1128/JVI.00900-08; Li DJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003880; Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369; Lilley CE, 2010, EMBO J, V29, P943, DOI 10.1038/emboj.2009.400; LINDAHL T, 1976, J MOL BIOL, V102, P511, DOI 10.1016/0022-2836(76)90331-4; Lu F, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-262; Lu F, 2010, J VIROL, V84, P2697, DOI 10.1128/JVI.01997-09; Luftig MA, 2014, ANNU REV VIROL, V1, P605, DOI 10.1146/annurev-virology-031413-085548; Lupianez DG, 2015, CELL, V161, P1012, DOI 10.1016/j.cell.2015.04.004; Majumder K, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009002; Majumder K, 2018, ELIFE, V7, DOI 10.7554/eLife.37750; Nagano T, 2017, NATURE, V547, P61, DOI 10.1038/nature23001; Nora EP, 2012, NATURE, V485, P381, DOI 10.1038/nature11049; Paris C, 2015, J VIROL, V89, P4770, DOI 10.1128/JVI.00097-15; Pentland L, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005752; Pereira DJ, 1997, J VIROL, V71, P1079, DOI 10.1128/JVI.71.2.1079-1088.1997; Phillips-Cremins JE, 2013, CELL, V153, P1281, DOI 10.1016/j.cell.2013.04.053; Pope BD, 2014, NATURE, V515, P402, DOI 10.1038/nature13986; QU LR, 1992, J VIROL, V66, P3715, DOI 10.1128/JVI.66.6.3715-3724.1992; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; Rutkowski AJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8126; Saldana-Meyer R, 2019, MOL CELL, V76, P412, DOI 10.1016/j.molcel.2019.08.015; Saldana-Meyer R, 2014, GENE DEV, V28, P723, DOI 10.1101/gad.236869.113; Sanborn AL, 2015, P NATL ACAD SCI USA, V112, pE6456, DOI 10.1073/pnas.1518552112; Scott RS, 2017, CURR OPIN VIROL, V26, P74, DOI 10.1016/j.coviro.2017.07.017; Shah GA, 2015, CELL, V162, P987, DOI 10.1016/j.cell.2015.07.058; Shi YL, 2005, J BIOL CHEM, V280, P40195, DOI 10.1074/jbc.C500400200; Sompallae R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012052; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Stedman W, 2008, EMBO J, V27, P654, DOI 10.1038/emboj.2008.1; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Szabo Q, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw1668; Tempera I, 2014, SEMIN CANCER BIOL, V26, P22, DOI 10.1016/j.semcancer.2014.01.003; Tempera I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002180; Tempera I, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001048; Thorley-Lawson DA, 2004, NEW ENGL J MED, V350, P1328, DOI 10.1056/NEJMra032015; TIERNEY RJ, 1994, J VIROL, V68, P7374, DOI 10.1128/JVI.68.11.7374-7385.1994; Valton AL, 2016, CURR OPIN GENET DEV, V36, P34, DOI 10.1016/j.gde.2016.03.008; Vian L, 2018, CELL, V173, P1165, DOI 10.1016/j.cell.2018.03.072; Wang S, 2009, J VIROL, V83, P11704, DOI 10.1128/JVI.00931-09; Washington SD, 2018, J VIROL, V92, DOI 10.1128/JVI.00156-18; Washington SD, 2018, J VIROL, V92, DOI 10.1128/JVI.00173-18; Weintraub AS, 2017, CELL, V171, P1573, DOI 10.1016/j.cell.2017.11.008; Weitzman MD, 2018, ANNU REV VIROL, V5, P141, DOI 10.1146/annurev-virology-092917-043534; WOISETSCHLAEGER M, 1990, P NATL ACAD SCI USA, V87, P1725, DOI 10.1073/pnas.87.5.1725; Zhan YX, 2017, GENOME RES, V27, P479, DOI 10.1101/gr.212803.116; Zhao X, 2008, J VIROL, V82, P5316, DOI 10.1128/JVI.02677-07	90	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2021	12								633762	10.3389/fimmu.2021.633762	http://dx.doi.org/10.3389/fimmu.2021.633762			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RJ6PW	33841414	gold, Green Published			2022-12-18	WOS:000637723300001
J	Pillay, K; Lewis, L; Rambaran, S; Yende-Zuma, N; Archary, D; Gengiah, S; Govender, D; Hassan-Moosa, R; Samsunder, N; Karim, SAS; McKinnon, LR; Padayatchi, N; Naidoo, K; Sivro, A				Pillay, Kimesha; Lewis, Lara; Rambaran, Santhuri; Yende-Zuma, Nonhlanhla; Archary, Derseree; Gengiah, Santhanalakshmi; Govender, Dhineshree; Hassan-Moosa, Razia; Samsunder, Natasha; Abdool Karim, Salim S.; McKinnon, Lyle R.; Padayatchi, Nesri; Naidoo, Kogieleum; Sivro, Aida			Plasma Biomarkers of Risk of Tuberculosis Recurrence in HIV Co-Infected Patients From South Africa	FRONTIERS IN IMMUNOLOGY			English	Article						inflammation; HIV; microbial translocation; antiretroviral (ARV) therapy; tuberculosis; pulmonary		There is an urgent need to identify immunological markers of tuberculosis (TB) risk in HIV co-infected individuals. Previously we have shown that TB recurrence in HIV co-infected individuals on ART was associated with markers of systemic inflammation (IL-6, IL1 beta and IL-1R alpha). Here we examined the effect of additional acute inflammation and microbial translocation marker expression on risk of TB recurrence. Stored plasma samples were drawn from the TB Recurrence upon Treatment with HAART (TRuTH) study, in which individuals with previously treated pulmonary TB were screened for recurrence quarterly for up to 4 years. Recurrent TB cases (n = 37) were matched to controls (n = 102) by original trial study arm assignment and ART start date. Additional subsets of HIV infected (n = 41) and HIV uninfected (n = 37) individuals from Improving Recurrence Success (IMPRESS) study were sampled at active TB and post successful treatment completion. Plasma concentrations of soluble adhesion molecules (sMAdCAM, sICAM and sVCAM), lipopolysaccharide binding protein (LBP) and transforming growth factor-beta (TGF-beta 1, TGF-beta 2, TGF-beta 3) were measured by multiplex immunoassays and ELISA. Cytokine data was square root transformed in order to reduce variability. Multivariable analysis adjusted for a number of potential confounders measured at sample time-point: age, BMI, CD4 count, viral load (VL) and measured at baseline: presence or absence of lung cavities, previous history of TB, and WHO disease stage (4 vs 3). The following analytes were associated with increased risk of TB recurrence in the multivariable model: sICAM (aOR 1.06, 95% CI: 1.02-1.12, p = 0.009), LBP (aOR 8.78, 95% CI: 1.23-62.66, p = 0.030) and TGF-beta 3 (aOR 1.44, 95% CI 1.01-2.05, p = 0.044). Additionally, we observed a positive correlation between LBP and sICAM (r= 0.347, p<0.0001), and LBP and IL-6, identified to be one of the strongest predictors of TB risk in our previous study (r=0.623, p=0.03). These data show that increased risk of TB recurrence in HIV infected individuals on ART is likely associated with HIV mediated translocation of microbial products and the resulting chronic immune activation.	[Pillay, Kimesha; Lewis, Lara; Rambaran, Santhuri; Yende-Zuma, Nonhlanhla; Archary, Derseree; Gengiah, Santhanalakshmi; Govender, Dhineshree; Hassan-Moosa, Razia; Samsunder, Natasha; Abdool Karim, Salim S.; McKinnon, Lyle R.; Padayatchi, Nesri; Naidoo, Kogieleum; Sivro, Aida] Ctr AIDS Programme Res South Africa CAPRISA, Durban, South Africa; [Yende-Zuma, Nonhlanhla; Hassan-Moosa, Razia; Abdool Karim, Salim S.; Padayatchi, Nesri; Naidoo, Kogieleum] Univ KwaZulu Natal, Doris Duke Med Res Inst, Pathogenesis & Treatment Res Unit, MRC CAPRISA HIV TB, Durban, South Africa; [Archary, Derseree; Sivro, Aida] Univ KwaZulu Natal, Dept Med Microbiol, Durban, South Africa; [Abdool Karim, Salim S.] Columbia Univ, Dept Epidemiol, New York, NY USA; [McKinnon, Lyle R.] Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada; [McKinnon, Lyle R.] Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya	University of Kwazulu Natal; University of Kwazulu Natal; Columbia University; University of Manitoba; University of Nairobi	Sivro, A (corresponding author), Ctr AIDS Programme Res South Africa CAPRISA, Durban, South Africa.; Sivro, A (corresponding author), Univ KwaZulu Natal, Dept Med Microbiol, Durban, South Africa.	aida.sivro@caprisa.org	Abdool Karim, Salim/N-5947-2013	Abdool Karim, Salim/0000-0002-4986-2133; Sivro, Aida/0000-0001-9215-5285	Howard Hughes Medical Institute [55007065]; Centers for Disease Control and Prevention (CDC) [UY2G/PS001350-02]; US National Institutes for Health's Comprehensive International Program of Research on AIDS grant (CIPRA) [AI51794]; European & Developing Countries Clinical Trials partnership (EDCTP) Career Development Fellowship [TMA2016CDF-1582]; National Research Foundation [96354, 108038]; NRF Research Career Advancement Fellowship [RCA13101656388]; European and Developing Countries Clinical Trials Partnership (EDCTP) [TMA2017SF-1960]; KwaZulu-Natal Department of Health; U.S. President's Emergency Plan for AIDS Relief (PEPFAR); Strategic Health Innovation Partnership (SHIP) Unit of the South African Medical Research Council; Bill & Melinda Gates Foundation; South African Medical Research Council	Howard Hughes Medical Institute(Howard Hughes Medical Institute); Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); US National Institutes for Health's Comprehensive International Program of Research on AIDS grant (CIPRA); European & Developing Countries Clinical Trials partnership (EDCTP) Career Development Fellowship; National Research Foundation; NRF Research Career Advancement Fellowship; European and Developing Countries Clinical Trials Partnership (EDCTP); KwaZulu-Natal Department of Health; U.S. President's Emergency Plan for AIDS Relief (PEPFAR)(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Strategic Health Innovation Partnership (SHIP) Unit of the South African Medical Research Council; Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); South African Medical Research Council(South African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The TRUTH study was supported by the Howard Hughes Medical Institute, Grant Number 55007065, as well as the Centers for Disease Control and Prevention (CDC) Cooperative Agreement Number UY2G/PS001350-02. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of either the Howard Hughes Medical Institute or the Centers for Disease Control and Prevention (CDC). The research infrastructure to conduct this trial, including the data management, laboratory and pharmacy cores were established through the US National Institutes for Health's Comprehensive International Program of Research on AIDS grant (CIPRA, grant #AI51794). AS is supported by European & Developing Countries Clinical Trials partnership (EDCTP) Career Development Fellowship (TMA2016CDF-1582). KP and SR was supported by the National Research Foundation (Grant numbers: 96354 and 108038 respectively). DA was supported the NRF Research Career Advancement Fellowship (grant #RCA13101656388) and a senior fellowship through the European and Developing Countries Clinical Trials Partnership (EDCTP) (grant #TMA2017SF-1960) funds. Any opinion, funding, and conclusion or recommendations expressed in this material is that of the author and the NRF does not accept liability in this regard. Patient care was supported by the KwaZulu-Natal Department of Health and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Research reported in this publication was supported by the Strategic Health Innovation Partnership (SHIP) Unit of the South African Medical Research Council, a grantee of the Bill & Melinda Gates Foundation, and the South African Medical Research Council. The funding sources listed here did not have any role in the analysis or preparation of the data in this manuscript, nor was any payment received by these or other funding sources for this manuscript.	Aung H, 2000, TUBERCLE LUNG DIS, V80, P61, DOI 10.1054/tuld.2000.0235; Boulware DR, 2011, J INFECT DIS, V203, P1637, DOI 10.1093/infdis/jir134; Brenchley JM, 2008, MUCOSAL IMMUNOL, V1, P23, DOI 10.1038/mi.2007.1; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Bucsan AN, 2019, J CLIN INVEST, V129, P5254, DOI 10.1172/JCI125810; Budden KF, 2017, NAT REV MICROBIOL, V15, P55, DOI 10.1038/nrmicro.2016.142; Demir T, 2002, INT J TUBERC LUNG D, V6, P155; FROON AHM, 1995, J INFECT DIS, V171, P1250, DOI 10.1093/infdis/171.5.1250; Fukuda K, 2005, INVEST OPHTH VIS SCI, V46, P3095, DOI 10.1167/iovs.04-1365; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; Gutsmann T, 2001, INFECT IMMUN, V69, P6942, DOI 10.1128/IAI.69.11.6942-6950.2001; Hirsch CS, 1997, P NATL ACAD SCI USA, V94, P3926, DOI 10.1073/pnas.94.8.3926; Juffermans NP, 1998, J INFECT DIS, V178, P1839, DOI 10.1086/314492; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Karim SSA, 2011, NEW ENGL J MED, V365, P1492, DOI 10.1056/NEJMoa1014181; Keely S, 2012, MUCOSAL IMMUNOL, V5, P7, DOI 10.1038/mi.2011.55; Lawn SD, 2000, CLIN EXP IMMUNOL, V120, P483, DOI 10.1046/j.1365-2249.2000.01246.x; Lawson C, 2009, PHARMACOL REP, V61, P22, DOI 10.1016/S1734-1140(09)70004-0; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Liu YY, 2018, PATHOGENS, V7, DOI 10.3390/pathogens7010026; Makae H, 2003, RESPIROLOGY, V8, P326, DOI 10.1046/j.1440-1843.2003.00471.x; MARTIN TR, 1992, J CLIN INVEST, V90, P2209, DOI 10.1172/JCI116106; Masson L, 2015, CLIN INFECT DIS, V61, P260, DOI 10.1093/cid/civ298; McKinnon LR, 2018, NAT MED, V24, P491, DOI 10.1038/nm.4506; Morikawa M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021873; Perumal R, 2020, CLIN INFECT DIS, V70, P90, DOI 10.1093/cid/ciz152; RAMIREZ GML, 1994, INFECT IMMUN, V62, P2515; Sandler NG, 2012, NAT REV MICROBIOL, V10, P655, DOI 10.1038/nrmicro2848; Sawa Y, 2008, J HISTOCHEM CYTOCHEM, V56, P97, DOI 10.1369/jhc.7A7299.2007; SCHUMANN RR, 1992, RES IMMUNOL, V143, P11, DOI 10.1016/0923-2494(92)80074-U; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SETH R, 1991, LANCET, V338, P83, DOI 10.1016/0140-6736(91)90077-3; Sigal GB, 2017, EBIOMEDICINE, V25, P112, DOI 10.1016/j.ebiom.2017.10.018; Sivro A, 2017, CLIN INFECT DIS, V65, P819, DOI 10.1093/cid/cix357; Sivro A, 2014, AIDS REV, V16, P43; Sousa J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15832-6; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Sullivan ZA, 2015, EBIOMEDICINE, V2, P334, DOI 10.1016/j.ebiom.2015.03.005; Travis MA, 2014, ANNU REV IMMUNOL, V32, P51, DOI 10.1146/annurev-immunol-032713-120257; vanderPoll T, 1997, BLOOD, V89, P3727; Walzl G, 2011, NAT REV IMMUNOL, V11, P343, DOI 10.1038/nri2960; WHO, 2020, GLOB TUB REP; Yazar A, 2001, AM J GASTROENTEROL, V96, P1511, DOI 10.1111/j.1572-0241.2001.03748.x	43	1	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2021	12								631094	10.3389/fimmu.2021.631094	http://dx.doi.org/10.3389/fimmu.2021.631094			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RJ4CM	33841412	gold, Green Published			2022-12-18	WOS:000637548900001
J	Shen, ZY; Zheng, Y; Pecsok, MK; Wang, K; Li, W; Gong, MJ; Wu, F; Zhang, L				Shen, Zhi-Yuan; Zheng, Yi; Pecsok, Maggie K.; Wang, Ke; Li, Wei; Gong, Min-Jie; Wu, Feng; Zhang, Lin			C-Reactive Protein Suppresses the Th17 Response Indirectly by Attenuating the Antigen Presentation Ability of Monocyte Derived Dendritic Cells in Experimental Autoimmune Encephalomyelitis	FRONTIERS IN IMMUNOLOGY			English	Article						experimental autoimmune encephalomyelitis; C-reactive protein; monocyte derived DC; Fc&#947; R2B; Th17 response		Experimental autoimmune encephalomyelitis (EAE) is a classical murine model for Multiple Sclerosis (MS), a human autoimmune disease characterized by Th1 and Th17 responses. Numerous studies have reported that C-reactive protein (CRP) mitigates EAE severity, but studies on the relevant pathologic mechanisms are insufficient. Our previous study found that CRP suppresses Th1 response directly by receptor binding on naive T cells; however, we did not observe the effect on Th17 response at that time; thus it remains unclear whether CRP could regulate Th17 response. In this study, we verified the downregulation of Th17 response by a single-dose CRP injection in MOG-immunized EAE mice in vivo while the direct and indirect effects of CRP on Th17 response were differentiated by comparing its actions on isolated CD4(+) T cells and splenocytes in vitro, respectively. Moreover, the immune cell composition was examined in the blood and CNS (Central Nervous System), and a blood (monocytes) to CNS (dendritic cells) infiltration pathway is established in the course of EAE development. The infiltrated monocyte derived DCs (moDCs) were proved to be the only candidate antigen presenting cells to execute CRP's function. Conversely, the decrease of Th17 responses caused by CRP disappeared in the above in vivo and in vitro studies with Fc gamma R2B(-/-) mice, indicating that Fc gamma R2B expressed on moDCs mediates CRP function. Furthermore, peripheral blood monocytes were isolated and induced to establish moDCs, which were used to demonstrate that the antigen presenting ability of moDCs was attenuated by CRP through Fc gamma R2B, and then NF-kappa B and ERK signaling pathways were manifested to be involved in this regulation. Ultimately, we perfected and enriched the mechanism studies of CRP in EAE remission, so we are more convinced that CRP plays a key role in protecting against EAE development, which may be a potential therapeutic target for the treatment of MS in human.	[Shen, Zhi-Yuan; Li, Wei; Zhang, Lin] Xi An Jiao Tong Univ, Sch Basic Med, Dept Biochem & Mol Biol, Xian, Peoples R China; [Zheng, Yi] Univ Elect Sci & Technol China, Sch Med, Chengdu, Peoples R China; [Pecsok, Maggie K.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; [Pecsok, Maggie K.] Yale Univ, Sch Med, Dept Immunol, New Haven, CT USA; [Wang, Ke] Lanzhou Univ, Sch Life Sci, MOE Key Lab Cell Act & Stress Adaptat, Lanzhou, Peoples R China; [Gong, Min-Jie] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Otolaryngol Head & Neck Surg, Xian, Peoples R China; [Wu, Feng] Xi An Jiao Tong Univ, Sch Basic Med, Ctr Teaching & Expt Med Post Grad, Xian, Peoples R China	Xi'an Jiaotong University; University of Electronic Science & Technology of China; Yale University; Yale University; Lanzhou University; Xi'an Jiaotong University; Xi'an Jiaotong University	Zhang, L (corresponding author), Xi An Jiao Tong Univ, Sch Basic Med, Dept Biochem & Mol Biol, Xian, Peoples R China.	zhanglinxjtu@foxmail.com		Zheng, Yi/0000-0002-5230-0254	National Natural Science Foundation of China [82070876, 31700685, 31800852]; Scientific Research Fund of Xi'an Jiaotong University [XJJ2018126]; China Postdoctoral Science Foundation [2020M673421]; Project of Shaanxi Key Research and Development Plan [2020SF-082]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Fund of Xi'an Jiaotong University; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Project of Shaanxi Key Research and Development Plan	This work was supported by the following grants: National Natural Science Foundation of China (Nos. 82070876, 31700685, 31800852), Scientific Research Fund of Xi'an Jiaotong University (No. XJJ2018126), China Postdoctoral Science Foundation (No. 2020M673421), and Project of Shaanxi Key Research and Development Plan (No. 2020SF-082).	AMIGORENA S, 1989, EUR J IMMUNOL, V19, P1379, DOI 10.1002/eji.1830190805; Amigorena S, 2002, J EXP MED, V195, pF1, DOI 10.1084/jem.20011925; Axisa PP, 2016, CURR OPIN NEUROL, V29, P345, DOI 10.1097/WCO.0000000000000319; Baleeiro RB, 2017, MOL IMMUNOL, V88, P148, DOI 10.1016/j.molimm.2017.06.028; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; BOOSS J, 1983, J NEUROL SCI, V62, P219, DOI 10.1016/0022-510X(83)90201-0; Bottazzi B, 2010, ANNU REV IMMUNOL, V28, P157, DOI 10.1146/annurev-immunol-030409-101305; Chong WP, 2014, J AUTOIMMUN, V50, P12, DOI 10.1016/j.jaut.2013.08.003; Codarri L, 2011, NAT IMMUNOL, V12, P560, DOI 10.1038/ni.2027; Creusot RJ, 2018, DIABETES, V67, P1481, DOI 10.2337/db17-1564; CROFT SM, 1976, SCIENCE, V193, P685, DOI 10.1126/science.1085034; Damsker JM, 2010, ANN NY ACAD SCI, V1183, P211, DOI 10.1111/j.1749-6632.2009.05133.x; Dardalhon V, 2008, J AUTOIMMUN, V31, P252, DOI 10.1016/j.jaut.2008.04.017; Dhaeze T, 2019, CELL MOL IMMUNOL, V16, P652, DOI 10.1038/s41423-018-0198-5; Du Clos Terry W, 2013, ISRN Inflamm, V2013, P379040, DOI 10.1155/2013/379040; Ferragine CE, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002136; Frohman EM, 2006, NEW ENGL J MED, V354, P942, DOI 10.1056/NEJMra052130; Gaitonde S, 2008, ARTHRIT RHEUM-ARTHR, V59, P1814, DOI 10.1002/art.24316; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Heuertz RM, 1999, J BIOL CHEM, V274, P17968, DOI 10.1074/jbc.274.25.17968; Hilhorst M, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00432; Hu XZ, 2011, AUTOIMMUN DIS, V2011, DOI 10.4061/2011/484936; Jager A, 2009, J IMMUNOL, V183, P7169, DOI 10.4049/jimmunol.0901906; Jimenez RV, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00372; Liu BZ, 2019, J AUTOIMMUN, V102, P77, DOI 10.1016/j.jaut.2019.04.020; Marson A, 2015, J CLIN INVEST, V125, P2234, DOI 10.1172/JCI78086; McQualter JL, 2001, J EXP MED, V194, P873, DOI 10.1084/jem.194.7.873; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Meng S, 2012, DNA CELL BIOL, V31, P30, DOI 10.1089/dna.2010.1178; Mold C, 2013, ARTHRITIS RHEUM-US, V65, P1891, DOI 10.1002/art.37968; MORTENSEN RF, 1975, J EXP MED, V141, P821; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Nowatzky J, 2018, J AUTOIMMUN, V92, P57, DOI 10.1016/j.jaut.2018.05.005; Nylander A, 2012, J CLIN INVEST, V122, P1180, DOI 10.1172/JCI58649; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; Richter A, 1996, LANGENBECK ARCH CHIR, V381, P38; Rostami A, 2013, J NEUROL SCI, V333, P76, DOI 10.1016/j.jns.2013.03.002; Serbina NV, 2008, ANNU REV IMMUNOL, V26, P421, DOI 10.1146/annurev.immunol.26.021607.090326; Sospedra M, 2005, ANNU REV IMMUNOL, V23, P683, DOI 10.1146/annurev.immunol.23.021704.115707; Szalai AJ, 2002, J IMMUNOL, V168, P5792, DOI 10.4049/jimmunol.168.11.5792; Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173; Thomas-Rudolph D, 2007, J IMMUNOL, V178, P7283, DOI 10.4049/jimmunol.178.11.7283; Van Vre EA, 2008, ARTERIOSCL THROM VAS, V28, P511, DOI 10.1161/ATVBAHA.107.157016; van Zanten JJCSV, 2005, ANN RHEUM DIS, V64, P1299, DOI 10.1136/ard.2004.03215; Verma S, 2004, CIRCULATION, V109, P1914, DOI 10.1161/01.CIR.0000127085.32999.64; Wolk K, 2000, BLOOD, V96, P218, DOI 10.1182/blood.V96.1.218.013k04_218_223; Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477; Yang YH, 2009, J EXP MED, V206, P1549, DOI 10.1084/jem.20082584; Yoshimura S, 2001, INT IMMUNOL, V13, P675, DOI 10.1093/intimm/13.5.675; Zhang L, 2019, FASEB J, V33, P6551, DOI 10.1096/fj.201801865RR; Zhang L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00511; Zhang L, 2015, J IMMUNOL, V194, P5243, DOI 10.4049/jimmunol.1402909; Zhang RX, 2006, EUR J IMMUNOL, V36, P2993, DOI 10.1002/eji.200635207	55	1	1	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2021	12								589200	10.3389/fimmu.2021.589200	http://dx.doi.org/10.3389/fimmu.2021.589200			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RJ6QE	33841391	Green Published, gold			2022-12-18	WOS:000637724200001
J	Yeruva, L; Munblit, D; Collado, MC				Yeruva, Laxmi; Munblit, Daniel; Collado, Maria Carmen			Editorial: Impact of Early Life Nutrition on Immune System Development and Related Health Outcomes in Later Life	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						human milk; immunity; infants; metabolites; human milk oligosaccharides; microRNAs; microbiota; allergy	HUMAN-MILK OLIGOSACCHARIDES; NECROTIZING ENTEROCOLITIS; BREAST-MILK; MICROBIOTA; 2-FUCOSYLLACTOSE; LACTOFERRIN; RISK		[Yeruva, Laxmi] Arkansas Childrens Nutr Ctr, Little Rock, AR 72202 USA; [Yeruva, Laxmi] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Yeruva, Laxmi] Arkansas Childrens Res Inst, Little Rock, AR 72202 USA; [Munblit, Daniel] Sechenov First Moscow State Med Univ Sechenov Uni, Inst Childs Hlth, Dept Pediat & Pediat Infect Dis, Moscow, Russia; [Munblit, Daniel] Imperial Coll London, Fac Med, Natl Heart & Lung Inst, Inflammat Repair & Dev Sect, London, England; [Munblit, Daniel] Solovev Res & Clin Ctr Neuropsychiat, Moscow, Russia; [Collado, Maria Carmen] CSIC, Natl Res Council IATA, Inst Agrochem & Food Technol, Dept Biotechnol,Unit Lact Acid Bacteria & Probiot, Valencia, Spain	University of Arkansas System; University of Arkansas Medical Sciences; Imperial College London; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA)	Yeruva, L (corresponding author), Arkansas Childrens Nutr Ctr, Little Rock, AR 72202 USA.; Yeruva, L (corresponding author), Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA.; Yeruva, L (corresponding author), Arkansas Childrens Res Inst, Little Rock, AR 72202 USA.	vlyeruva@uams.edu	COLLADO, MARIA CARMEN/H-4924-2012; Munblit, Daniel/H-7336-2019	COLLADO, MARIA CARMEN/0000-0002-6204-4864; Munblit, Daniel/0000-0001-9652-6856; Yeruva, Laxmi/0000-0003-4289-9109	NIAID NIH HHS [R21 AI146521] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aakko J, 2017, BENEF MICROBES, V8, P563, DOI 10.3920/BM2016.0185; Al-Sheikh Hashem, 2009, Pak J Biol Sci, V12, P91, DOI 10.3923/pjbs.2009.91.94; Alderete TL, 2015, AM J CLIN NUTR, V102, P1381, DOI 10.3945/ajcn.115.115451; Andersson Y, 2000, EARLY HUM DEV, V59, P95, DOI 10.1016/S0378-3782(00)00086-4; Andreas NJ, 2015, EARLY HUM DEV, V91, P629, DOI 10.1016/j.earlhumdev.2015.08.013; Ardeshir A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008791; Arnold D, 2002, ANTIVIR RES, V53, P153, DOI 10.1016/S0166-3542(01)00197-8; Autran CA, 2016, BRIT J NUTR, V116, P294, DOI 10.1017/S0007114516002038; Azad MB, 2013, CAN MED ASSOC J, V185, P385, DOI 10.1503/cmaj.121189; Ballard O, 2013, PEDIATR CLIN N AM, V60, P49, DOI 10.1016/j.pcl.2012.10.002; Bardanzellu F, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00215; Battersby AJ, 2013, PEDIAT ALLERG IMM-UK, V24, P414, DOI 10.1111/pai.12079; Berding K, 2016, J PEDIATR GASTR NUTR, V63, P688, DOI 10.1097/MPG.0000000000001200; Bergstrom A, 2014, APPL ENVIRON MICROB, V80, P2889, DOI 10.1128/AEM.00342-14; Bode L, 2012, AM J CLIN NUTR, V96, P831, DOI 10.3945/ajcn.112.039503; Bode L, 2009, NUTR REV, V67, pS183, DOI 10.1111/j.1753-4887.2009.00239.x; Bridgman SL, 2017, FRONT NUTR, V4, DOI 10.3389/fnut.2017.00011; Brink LR, 2019, J NUTR, V149, P2236, DOI 10.1093/jn/nxz170; Cilieborg MS, 2016, BRIT J NUTR, V116, P834, DOI 10.1017/S0007114516002646; Davis EC, 2017, GUT MICROBES, V8, P143, DOI 10.1080/19490976.2016.1278104; Hanson LA, 2003, ANN ALLERG ASTHMA IM, V90, P59, DOI 10.1016/S1081-1206(10)61662-6; Hanson LA, 2007, P NUTR SOC, V66, P384, DOI 10.1017/S0029665107005654; Hellmuth C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197713; Isganaitis E, 2019, AM J CLIN NUTR, V110, P111, DOI 10.1093/ajcn/nqy334; Kim Su Yeong, 2020, Clin Exp Pediatr, V63, P301, DOI 10.3345/cep.2020.00059; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Larsson MW, 2020, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00521; Lauritzen L, 2006, AM J CLIN NUTR, V84, P190, DOI 10.1093/ajcn/84.1.190; Leghi GE, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040934; Mudd AT, 2016, FRONT PEDIATR, V4, DOI 10.3389/fped.2016.00004; Munblit D, 2015, CLIN EXP ALLERGY, V45, P583, DOI 10.1111/cea.12381; O'Reilly D, 2021, ADV NUTR, V12, P59, DOI 10.1093/advances/nmaa094; Socha P, 2011, AM J CLIN NUTR, V94, p1776S, DOI 10.3945/ajcn.110.000596; Thompson RS, 2017, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00240; van den Elsen LWJ, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00047; Zonneveld MI, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12071	36	1	2	2	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 25	2021	12								668569	10.3389/fimmu.2021.668569	http://dx.doi.org/10.3389/fimmu.2021.668569			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RJ6LW	33841449	gold, Green Published			2022-12-18	WOS:000637712900001
J	Han, Q; Zheng, ZH; Zhang, K; Ding, J; Baraliakos, X; Zhu, P				Han, Qing; Zheng, Zhaohui; Zhang, Kui; Ding, Jin; Baraliakos, Xenofon; Zhu, Ping			A Comprehensive Assessment of Hip Damage in Ankylosing Spondylitis, Especially Early Features	FRONTIERS IN IMMUNOLOGY			English	Article						ankylosing spondylitis; hip; MRI; X-ray; Harris score		Ankylosing spondylitis (AS) is most common in adolescents and the ultimate result is disability, which places a huge burden on patients and society. Therefore, the key to improve the prognosis of AS is the early diagnosis of hip injury. To examine if AS patients whose hip pain is either absent or minimal might already have observable MRI and X-ray hip changes. Clinical and imaging hip data were systematically analyzed in 200 healthy controls (HC) and 300 AS with varying degrees of hip pain. Forty-four patients with early hip osteoarthritis (OA) served as positive imaging controls. In MRI images, BME lesions in the STIR sequence were much more frequent in AS (62%) compared to HC (2%) (p < 0.0001). Most importantly, 42% of AS with no or minimal hip pain had one or more MRI lesions. This was much more frequent compared to the 2% in HC (p < 0.05). These lesions in AS were observed singly or in combination in the trochanters (8%), femoral heads (12%), and acetabula (13%). Parallel finding that X-ray changes were present in patients with minimal or no hip pain was also observed with X-ray. Based on the normal hip width of HC, joint space narrowing was observed in 94.3% of the entire AS cohort, and importantly 56.7% of AS patients with no or mild hip pain. In these latter patients, functional activities of the hips such as walking were normal. At least 40% of AS patients with minimal or no hip pain might already show MRI and X-ray changes.	[Han, Qing; Zheng, Zhaohui; Zhang, Kui; Ding, Jin; Zhu, Ping] Fourth Mil Med Univ, Dept Clin Immunol, PLA Specialized Res Inst Rheumatol & Immunol, Xijing Hosp, Xian, Peoples R China; [Zheng, Zhaohui; Zhang, Kui; Ding, Jin; Zhu, Ping] Natl Translat Sci Ctr Mol Med, Xian, Peoples R China; [Baraliakos, Xenofon] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet Herne, Herne, Germany	Air Force Military Medical University; Rheumazentrum Ruhrgebiet; Ruhr University Bochum	Zhu, P (corresponding author), Fourth Mil Med Univ, Dept Clin Immunol, PLA Specialized Res Inst Rheumatol & Immunol, Xijing Hosp, Xian, Peoples R China.; Zhu, P (corresponding author), Natl Translat Sci Ctr Mol Med, Xian, Peoples R China.	zhuping@fmmu.edu.cn			National Basic Research Program of China [2015CB553704]; National Nature Science Foundation Key Research Project of China [2017YFC0909002]	National Basic Research Program of China(National Basic Research Program of China); National Nature Science Foundation Key Research Project of China	This study was funded by the National Basic Research Program of China (2015CB553704) and the National Nature Science Foundation Key Research Project of China (2017YFC0909002).	Baraliakos X, 2007, RHEUMATOLOGY, V46, P1450, DOI 10.1093/rheumatology/kem166; Baraliakos X, 2010, RHEUMATOLOGY, V49, P3, DOI 10.1093/rheumatology/kep298; Braun J, 2017, ANN RHEUM DIS, V76, P1070, DOI 10.1136/annrheumdis-2016-209730; Brophy S, 2001, J RHEUMATOL, V28, P2283; Burki V, 2012, CLIN EXP RHEUMATOL, V30, P481; Chen HA, 2011, SEMIN ARTHRITIS RHEU, V40, P552, DOI 10.1016/j.semarthrit.2010.07.008; Chen JM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004524.pub4; Chong RWW, 2010, INT J RHEUM DIS, V13, P235, DOI 10.1111/j.1756-185X.2010.01477.x; Gensler LS, 2008, ANN RHEUM DIS, V67, P233, DOI 10.1136/ard.2007.072512; Huang ZG, 2013, EUR J RADIOL, V82, P1487, DOI 10.1016/j.ejrad.2013.03.020; Huang ZX, 2019, CLIN RHEUMATOL, V38, P1595, DOI 10.1007/s10067-019-04466-9; Jeong H, 2017, KOREAN J INTERN MED, V32, P158, DOI 10.3904/kjim.2015.229; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; Sieper J, 2017, LANCET, V390, P73, DOI 10.1016/S0140-6736(16)31591-4; Stolwijk C, 2016, ARTHRIT CARE RES, V68, P1320, DOI 10.1002/acr.22831; Tang WM, 2000, J ARTHROPLASTY, V15, P52, DOI 10.1016/S0883-5403(00)91155-0; van der Heijde D, 2008, ARTHRITIS RHEUM-US, V58, P1324, DOI 10.1002/art.23471; van der Heijde D, 2017, ANN RHEUM DIS, V76, P978, DOI 10.1136/annrheumdis-2016-210770; Vander Cruyssen B, 2013, CURR OPIN RHEUMATOL, V25, P448, DOI 10.1097/BOR.0b013e3283620e04; Vander Cruyssen B, 2010, RHEUMATOLOGY, V49, P73, DOI 10.1093/rheumatology/kep174; Zochling J, 2006, ANN RHEUM DIS, V65, P442, DOI 10.1136/ard.2005.041137	21	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 24	2021	12								668969	10.3389/fimmu.2021.668969	http://dx.doi.org/10.3389/fimmu.2021.668969			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RJ0LR	33841450	gold, Green Published			2022-12-18	WOS:000637295500001
J	Nishibori, M; Stonestreet, BS				Nishibori, Masahiro; Stonestreet, Barbara S.			Understanding of COVID-19 Pathology: Much More Attention to Plasma Proteins	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						COVID-19; histidine-rich glycoprotein; inter-alpha inhibitor proteins; NETs; ARDS; immunothrombosis			[Nishibori, Masahiro] Okayama Univ, Dept Pharmacol, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan; [Stonestreet, Barbara S.] Brown Univ, Dept Pediat, Women & Infants Hosp Rhode Isl, Alpert Med Sch, Providence, RI 02912 USA	Okayama University; Brown University; Women & Infants Hospital Rhode Island	Nishibori, M (corresponding author), Okayama Univ, Dept Pharmacol, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan.	mbori@md.okayama-u.ac.jp			Japan Agency of Medical Research and Development (AMED) [JP19im0210109, 19H03408]; National Institutes of Health (NIH) [1R21NS095130, 1R21NS096525, 2R01HD057100, 2R44 NS084575]	Japan Agency of Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by grants from the Japan Agency of Medical Research and Development (AMED, JP19im0210109) and from a Grant-in-Aid for Scientific Research (no.19H03408) to MN and from National Institutes of Health (NIH) 1R21NS095130, 1R21NS096525, 2R01HD057100, and 2R44 NS084575 to BS. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Avula A, 2020, BRAIN BEHAV IMMUN, V87, P115, DOI 10.1016/j.bbi.2020.04.077; Baek YW, 2003, J PEDIATR-US, V143, P11, DOI 10.1016/S0022-3476(03)00190-2; Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Chaaban H, 2015, BLOOD, V125, P2286, DOI 10.1182/blood-2014-06-582759; Chen LT, 2020, CELL MOL IMMUNOL, V17, P992, DOI 10.1038/s41423-020-0492-x; Cicco S, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/7527953; Gao SZ, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101180; Gao SZ, 2019, BRIT J PHARMACOL, V176, P2808, DOI 10.1111/bph.14711; Goshua G, 2020, LANCET HAEMATOL, V7, pE575, DOI 10.1016/S2352-3026(20)30216-7; Hatayama K, 2019, J MED VIROL, V91, P361, DOI 10.1002/jmv.25330; Htwe SS, 2018, BLOOD ADV, V2, P1923, DOI 10.1182/bloodadvances.2018018986; Kimball AS, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00236; Koraka P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009967; Kuroda K, 2018, CRIT CARE MED, V46, P570, DOI 10.1097/CCM.0000000000002947; Leppkes M, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102925; Liao DY, 2020, LANCET HAEMATOL, V7, pE671, DOI 10.1016/S2352-3026(20)30217-9; Lim YP, 2003, J INFECT DIS, V188, P919, DOI 10.1086/377642; Lord MS, 2020, J HISTOCHEM CYTOCHEM, V68, P907, DOI 10.1369/0022155420940067; MacQuarrie JL, 2011, BLOOD, V117, P4134, DOI 10.1182/blood-2010-07-290551; Mahmud E, 2020, J AM COLL CARDIOL, V76, P1375, DOI 10.1016/j.jacc.2020.04.039; Middleton EA, 2020, BLOOD, V136, P1169, DOI 10.1182/blood.2020007008; Nishibori M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122650; Nishibori M, 2019, J PHARMACOL SCI, V140, P94, DOI 10.1016/j.jphs.2019.04.006; Nishibori M, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2127-5; Nosaka N, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0983-9; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Poon IKH, 2011, BLOOD, V117, P2093, DOI 10.1182/blood-2010-09-303842; Radermecker C, 2020, J EXP MED, V217, DOI 10.1084/jem.20201012; Schurink B, 2020, LANCET MICROBE, V1, pE290, DOI 10.1016/S2666-5247(20)30144-0; Singh K, 2010, PEDIATR RES, V68, P242, DOI 10.1203/00006450-201011001-00474; Stober VP, 2019, LUNG, V197, P361, DOI 10.1007/s00408-019-00228-1; Takahashi Y, 2021, J IMMUNOL, V206, P737, DOI 10.4049/jimmunol.2000817; Wake H, 2016, EBIOMEDICINE, V9, P180, DOI 10.1016/j.ebiom.2016.06.003; Wang YZ, 2019, BRIT J PHARMACOL, V176, P3350, DOI 10.1111/bph.14765; Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Wu RQ, 2004, CRIT CARE MED, V32, P1747, DOI 10.1097/01.CCM.0000132903.14121.0E; Yang H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00484; Yoshii Y, 2020, J PHARMACOL EXP THER, V375, P406, DOI 10.1124/jpet.120.000182; Zhong H, 2018, J PHARMACOL SCI, V136, P97, DOI 10.1016/j.jphs.2017.11.003	43	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 24	2021	12								656099	10.3389/fimmu.2021.656099	http://dx.doi.org/10.3389/fimmu.2021.656099			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RJ0OJ	33841442	gold, Green Published			2022-12-18	WOS:000637302600001
J	Schuhmachers, P; Munz, C				Schuhmachers, Patrick; Munz, Christian			Modification of EBV Associated Lymphomagenesis and Its Immune Control by Co-Infections and Genetics in Humanized Mice	FRONTIERS IN IMMUNOLOGY			English	Review						cytotoxic lymphocytes; human immunodeficiency virus (HIV); Kaposi sarcoma associated herpesvirus (KSHV); HLA-DRB1*1501; mutant Epstein Barr viruses (EBVs)	BARR-VIRUS INFECTION	Epstein Barr virus (EBV) is one of the most successful pathogens in humans with more than 95% of the human adult population persistently infected. EBV infects only humans and threatens these with its potent growth transforming ability that readily allows for immortalization of human B cells in culture. Accordingly, it is also found in around 1-2% of human tumors, primarily lymphomas and epithelial cell carcinomas. Fortunately, however, our immune system has learned to control this most transforming human tumor virus in most EBV carriers, and it requires modification of EBV associated lymphomagenesis and its immune control by either co-infections, such as malaria, Kaposi sarcoma associated herpesvirus (KSHV) and human immunodeficiency virus (HIV), or genetic predispositions for EBV positive tumors to emerge. Some of these can be modelled in humanized mice that, therefore, provide a valuable platform to test curative immunotherapies and prophylactic vaccines against these EBV associated pathologies.	[Schuhmachers, Patrick; Munz, Christian] Univ Zurich, Inst Expt Immunol, Viral Immunobiol, Zurich, Switzerland	University of Zurich	Munz, C (corresponding author), Univ Zurich, Inst Expt Immunol, Viral Immunobiol, Zurich, Switzerland.	christian.muenz@uzh.ch		Schuhmachers, Patrick/0000-0003-2052-738X	Cancer Research Switzerland [KFS4962-02-2020]; CRPP-Precision MS; HMZ ImmunoTargET of the University of Zurich; Cancer Research Center Zurich; Baugarten Foundation; Sobek Foundation; Swiss Vaccine Research Institute; Roche; Novartis; Novartis Foundation [20B099]; Swiss National Science Foundation [310030B_182827, 310030L_197952/1, CRSII5_180323]	Cancer Research Switzerland; CRPP-Precision MS; HMZ ImmunoTargET of the University of Zurich; Cancer Research Center Zurich; Baugarten Foundation; Sobek Foundation; Swiss Vaccine Research Institute; Roche(Roche Holding); Novartis(Novartis); Novartis Foundation(Novartis); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	Our research is supported by Cancer Research Switzerland (KFS4962-02-2020), CRPP-PrecisionMS and HMZ ImmunoTargET of the University of Zurich, the Cancer Research Center Zurich, the Baugarten Foundation, the Sobek Foundation, the Swiss Vaccine Research Institute, Roche, Novartis, Novartis Foundation (20B099), and the Swiss National Science Foundation (310030B_182827, 310030L_197952/1 and CRSII5_180323).	ADLDINGER HK, 1985, VIROLOGY, V141, P221, DOI 10.1016/0042-6822(85)90253-3; Albanese M, 2016, P NATL ACAD SCI USA, V113, pE6467, DOI 10.1073/pnas.1605884113; Antsiferova O, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004333; Azzi T, 2014, BLOOD, V124, P2533, DOI 10.1182/blood-2014-01-553024; Babcock GJ, 2000, IMMUNITY, V13, P497, DOI 10.1016/S1074-7613(00)00049-2; Balfour HH, 2013, J INFECT DIS, V207, P80, DOI 10.1093/infdis/jis646; Bristol JA, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007179; BURKITT D, 1958, BRIT J SURG, V46, P218, DOI 10.1002/bjs.18004619704; Caduff N, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008477; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Cesarman E, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0060-9; Chatterjee B, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007748; Chijioke O, 2015, J INFECT DIS, V212, P803, DOI 10.1093/infdis/jiv114; Chijioke O, 2013, CELL REP, V5, P1489, DOI 10.1016/j.celrep.2013.11.041; Chung BK, 2013, BLOOD, V122, P2600, DOI 10.1182/blood-2013-01-480665; CLEARY ML, 1985, SCIENCE, V228, P722, DOI 10.1126/science.2986287; Coleman CB, 2018, J VIROL, V92, DOI 10.1128/JVI.00813-18; Correia S, 2018, J VIROL, V92, DOI 10.1128/JVI.01132-18; Damania B, 2019, FEMS MICROBIOL REV, V43, P181, DOI 10.1093/femsre/fuy044; DAMBAUGH T, 1984, P NATL ACAD SCI-BIOL, V81, P7632, DOI 10.1073/pnas.81.23.7632; Dunmire SK, 2018, J CLIN VIROL, V102, P84, DOI 10.1016/j.jcv.2018.03.001; Ehlers B, 2010, J GEN VIROL, V91, P630, DOI 10.1099/vir.0.017251-0; EPSTEIN MA, 1985, NATURE, V318, P287, DOI 10.1038/318287a0; EPSTEIN MA, 1965, J EXP MED, V121, P761, DOI 10.1084/jem.121.5.761; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; Faure A, 2019, P NATL ACAD SCI USA, V116, P16519, DOI 10.1073/pnas.1905025116; Fournier B, 2020, J EXP MED, V217, DOI 10.1084/jem.20192262; Gregorovic G, 2015, J VIROL, V89, P11711, DOI 10.1128/JVI.01873-15; Gujer C, 2019, BLOOD ADV, V3, P1129, DOI 10.1182/bloodadvances.2018025536; Gurer C, 2008, BLOOD, V112, P1231, DOI 10.1182/blood-2008-03-148072; He YL, 2009, CANCER RES, V69, P7935, DOI 10.1158/0008-5472.CAN-09-0828; Hendricks DW, 2014, J IMMUNOL, V192, P4492, DOI 10.4049/jimmunol.1303211; Hjalgrim H, 2003, NEW ENGL J MED, V349, P1324, DOI 10.1056/NEJMoa023141; Islas-Ohlmayer M, 2004, J VIROL, V78, P13891, DOI 10.1128/JVI.78.24.13891-13900.2004; Jangalwe S, 2016, IMMUN INFLAMM DIS, V4, P427, DOI 10.1002/iid3.124; Johnson DB, 2019, NAT MED, V25, P1243, DOI 10.1038/s41591-019-0523-2; Kalla M, 2012, EUR J CELL BIOL, V91, P65, DOI 10.1016/j.ejcb.2011.01.014; Kempkes B, 2015, CURR TOP MICROBIOL, V391, P35, DOI 10.1007/978-3-319-22834-1_2; Kieser A, 2015, CURR TOP MICROBIOL, V391, P119, DOI 10.1007/978-3-319-22834-1_4; Klein U, 2003, BLOOD, V101, P4115, DOI 10.1182/blood-2002-10-3090; Labo N, 2019, INT J CANCER, V145, P2468, DOI 10.1002/ijc.32546; Laichalk LL, 2005, J VIROL, V79, P1296, DOI 10.1128/JVI.79.2.1296-1307.2005; Landais E, 2004, BLOOD, V103, P1408, DOI 10.1182/blood-2003-03-0930; Landtwing V, 2016, J CLIN INVEST, V126, P3772, DOI 10.1172/JCI86923; Lang JL, 2013, J IMMUNOL, V190, P2090, DOI 10.4049/jimmunol.1202810; Latour S, 2019, IMMUNOL REV, V291, P174, DOI 10.1111/imr.12791; Li CR, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008590; Li Y, 2018, NAT METHODS, V15, P623, DOI 10.1038/s41592-018-0071-6; Li Z, 2019, NAT MICROBIOL, V4, P2475, DOI 10.1038/s41564-019-0546-y; Lunemann JD, 2008, J EXP MED, V205, P1763, DOI 10.1084/jem.20072397; Lunemann JD, 2006, BRAIN, V129, P1493, DOI 10.1093/brain/awl067; Luzuriaga K, 2010, NEW ENGL J MED, V362, P1993, DOI 10.1056/NEJMcp1001116; Ma SD, 2017, J VIROL, V91, DOI 10.1128/JVI.01928-16; Ma SD, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005642; Ma SD, 2015, J CLIN INVEST, V125, P304, DOI 10.1172/JCI76357; Ma SD, 2012, J VIROL, V86, P7976, DOI 10.1128/JVI.00770-12; Ma SD, 2011, J VIROL, V85, P165, DOI 10.1128/JVI.01512-10; McHugh D, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000640; McHugh D, 2017, CELL HOST MICROBE, V22, P61, DOI 10.1016/j.chom.2017.06.009; Meckiff BJ, 2019, J IMMUNOL, V203, P1276, DOI 10.4049/jimmunol.1900377; Melkus MW, 2006, NAT MED, V12, P1316, DOI 10.1038/nm1431; Munz C, 2019, NAT REV MICROBIOL, V17, P691, DOI 10.1038/s41579-019-0249-7; Murer A, 2019, MBIO, V10, DOI 10.1128/mBio.01941-18; Murer A, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007039; Olsson T, 2017, NAT REV NEUROL, V13, P25, DOI 10.1038/nrneurol.2016.187; Pasquier B, 2005, J EXP MED, V201, P695, DOI 10.1084/jem.20042432; Rochford R, 2005, NAT REV MICROBIOL, V3, P182, DOI 10.1038/nrmicro1089; Romero-Masters JC, 2020, J VIROL, V94, DOI 10.1128/JVI.02168-19; Romero-Masters JC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007221; Rongvaux A, 2014, NAT BIOTECHNOL, V32, P364, DOI 10.1038/nbt.2858; Sallah N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17696-2; SAMPLE J, 1990, J VIROL, V64, P4084, DOI 10.1128/JVI.64.9.4084-4092.1990; Schwab C, 2018, J ALLERGY CLIN IMMUN, V142, P1932, DOI 10.1016/j.jaci.2018.02.055; Shannon-Lowe C, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00713; Shultz LD, 2010, P NATL ACAD SCI USA, V107, P13022, DOI 10.1073/pnas.1000475107; Stripecke R, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201708662; Strowig T, 2009, J EXP MED, V206, P1423, DOI 10.1084/jem.20081720; Tangye SG, 2020, BLOOD, V135, P644, DOI 10.1182/blood.2019000928; Taylor GS, 2015, ANNU REV IMMUNOL, V33, P787, DOI 10.1146/annurev-immunol-032414-112326; Thorley-Lawson DA, 2008, NAT REV MICROBIOL, V6, P913, DOI 10.1038/nrmicro2015; Totonchy J, 2016, CURR OPIN VIROL, V20, P71, DOI 10.1016/j.coviro.2016.09.001; Tsai MH, 2017, ONCOTARGET, V8, P10238, DOI 10.18632/oncotarget.14380; Tsai MH, 2013, CELL REP, V5, P458, DOI 10.1016/j.celrep.2013.09.012; Wang J, 2020, CELL, V183, P1264, DOI 10.1016/j.cell.2020.09.054; Watanabe Y, 2009, INT IMMUNOL, V21, P843, DOI 10.1093/intimm/dxp050; White RE, 2012, J CLIN INVEST, V122, P1487, DOI 10.1172/JCI58092; Williams H, 2005, BRIT J HAEMATOL, V129, P266, DOI 10.1111/j.1365-2141.2005.05452.x; Xiang Z, 2014, CANCER CELL, V26, P565, DOI 10.1016/j.ccr.2014.07.026; Yajima M, 2008, J INFECT DIS, V198, P673, DOI 10.1086/590502; Yajima M, 2009, J INFECT DIS, V200, P1611, DOI 10.1086/644644; Yu H, 2017, BLOOD, V129, P959, DOI 10.1182/blood-2016-04-709584; Zdimerova H, 2021, EUR J IMMUNOL, V51, P64, DOI 10.1002/eji.202048655; Zumwalde NA, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93179	93	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 23	2021	12								640918	10.3389/fimmu.2021.640918	http://dx.doi.org/10.3389/fimmu.2021.640918			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RI3VM	33833760	Green Published, Green Accepted, gold			2022-12-18	WOS:000636838000001
J	Huang, HQ; Li, N; Li, DY; Jing, D; Liu, ZY; Xu, XC; Chen, HP; Dong, LL; Zhang, M; Ying, SM; Li, W; Shen, HH; Li, ZY; Chen, ZH				Huang, Hua-Qiong; Li, Na; Li, Dan-Yang; Jing, Du; Liu, Zheng-Yuan; Xu, Xu-Chen; Chen, Hai-Pin; Dong, Ling-Ling; Zhang, Min; Ying, Song-Min; Li, Wen; Shen, Hua-Hao; Li, Zhou-Yang; Chen, Zhi-Hua			Autophagy Promotes Cigarette Smoke-Initiated and Elastin-Driven Bronchitis-Like Airway Inflammation in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						autophagy; chronic obstructive pulmonary disease-COPD; MMP12; inflammation; elastin	IMPAIRMENT; HEALTH	Cigarette smoke (CS)-induced macrophage activation and airway epithelial injury are both critical for the development of chronic obstructive pulmonary disease (COPD), while the eventual functions of autophagy in these processes remain controversial. We have recently developed a novel COPD mouse model which is based on the autoimmune response sensitized by CS and facilitated by elastin. In the current study, we therefore utilized this model to investigate the roles of autophagy in different stages of the development of bronchitis-like airway inflammation. Autophagic markers were increased in airway epithelium and lung tissues, and Becn(+/-) or Lc3b(-/) (-) mice exhibited reduced neutrophilic airway inflammation and mucus hyperproduction in this COPD mouse model. Moreover, treatment of an autophagic inhibitor 3-methyladenine (3-MA) either during CS-initiated sensitization or during elastin provocation significantly inhibited the bronchitis-like phenotypes in mice. Short CS exposure rapidly induced expression of matrix metallopeptidase 12 (MMP12) in alveolar macrophages, and treatment of doxycycline, a pan metalloproteinase inhibitor, during CS exposure effectively attenuated the ensuing elastin-induced airway inflammation in mice. CS extract triggered MMP12 expression in cultured macrophages, which was attenuated by autophagy impairment (Becn(+/-) or Lc3b(-/) (-)) or inhibition (3-MA or Spautin-1). These data, taken together, demonstrate that autophagy mediates both the CS-initiated MMP12 activation in macrophages and subsequent airway epithelial injury, eventually contributing to development COPD-like airway inflammation. This study reemphasizes that inhibition of autophagy as a novel therapeutic strategy for CS-induced COPD.	[Huang, Hua-Qiong; Li, Na; Li, Dan-Yang; Jing, Du; Liu, Zheng-Yuan; Xu, Xu-Chen; Chen, Hai-Pin; Dong, Ling-Ling; Zhang, Min; Ying, Song-Min; Li, Wen; Shen, Hua-Hao; Li, Zhou-Yang; Chen, Zhi-Hua] Zhejiang Univ, Affiliated Hosp 2, Key Lab Resp Dis Zhejiang Prov, Dept Resp & Crit Care Med,Sch Med, Hangzhou, Peoples R China; [Shen, Hua-Hao] Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou, Peoples R China	Zhejiang University; Guangzhou Medical University; State Key Laboratory of Respiratory Disease	Shen, HH; Li, ZY; Chen, ZH (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Key Lab Resp Dis Zhejiang Prov, Dept Resp & Crit Care Med,Sch Med, Hangzhou, Peoples R China.; Shen, HH (corresponding author), Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou, Peoples R China.	huahaoshen@zju.edu.cn; lizhouyang@zju.edu.cn; zhihuachen@zju.edu.cn	li, danyang/HHS-3319-2022	Li, Zhouyang/0000-0002-7721-0175	National Key R&D Program of China [2016YFA0501602, 2017YFC1310604, 81930003, 81670031, 31970826]; National Natural Science Foundation of China	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work is supported by the National Key R&D Program of China (2016YFA0501602 to Z-HC and 2017YFC1310604 to H-QH), and the Key (81930003 to H-HS) and General (81670031 and 31970826 to Z-HC.) Projects from the National Natural Science Foundation of China.	Agusti A, 2019, NEW ENGL J MED, V381, P1248, DOI 10.1056/NEJMra1900475; Ahmad T, 2015, FASEB J, V29, P2912, DOI 10.1096/fj.14-268276; Akata K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030853; Baghdadi M, 2013, IMMUNITY, V39, P1070, DOI 10.1016/j.immuni.2013.09.014; Barnes PJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.76; Barnes PJ, 2016, AM J RESP CRIT CARE, V193, P813, DOI 10.1164/rccm.201512-2379ED; Bodas M, 2017, ANTIOXID REDOX SIGN, V27, P150, DOI 10.1089/ars.2016.6842; CHEN ZH, 2008, PLOS ONE, V3, DOI DOI 10.1371/JOURNAL.PONE.0003316; Chen ZH, 2016, AUTOPHAGY, V12, P297, DOI 10.1080/15548627.2015.1124224; Chen ZH, 2014, AM J PHYSIOL-LUNG C, V306, pL1016, DOI 10.1152/ajplung.00268.2013; Chen ZH, 2010, P NATL ACAD SCI USA, V107, P18880, DOI 10.1073/pnas.1005574107; Choi AMK, 2013, NEW ENGL J MED, V368, P1845, DOI 10.1056/NEJMc1303158; Heckmann BL, 2019, CELL, V178, P536, DOI 10.1016/j.cell.2019.05.056; Houghton AM, 2015, MATRIX BIOL, V44-46, P167, DOI 10.1016/j.matbio.2015.02.002; Hunninghake GM, 2009, NEW ENGL J MED, V361, P2599, DOI 10.1056/NEJMoa0904006; Kim HP, 2008, AUTOPHAGY, V4, P887, DOI 10.4161/auto.6767; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kulkarni AS, 2020, CELL METAB, V32, P15, DOI 10.1016/j.cmet.2020.04.001; Lam HC, 2013, J CLIN INVEST, V123, P5212, DOI 10.1172/JCI69636; Lee KS, 2006, FASEB J, V20, P455, DOI 10.1096/fj.05-5045com; Leidal AM, 2018, NAT CELL BIOL, V20, P1338, DOI 10.1038/s41556-018-0235-8; Li W, 2020, THORAX, V75, P1047, DOI 10.1136/thoraxjnl-2019-213771; Li XC, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m234; Li ZY, 2018, J IMMUNOL, V200, P2826, DOI 10.4049/jimmunol.1701471; Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037; Martinez J, 2011, P NATL ACAD SCI USA, V108, P17396, DOI 10.1073/pnas.1113421108; McMillan S, 2002, J EXP MED, V195, P51, DOI 10.1084/jem.20011732; Monick MM, 2010, J IMMUNOL, V185, P5425, DOI 10.4049/jimmunol.1001603; Nakahira K, 2016, AM J RESP CRIT CARE, V194, P1196, DOI 10.1164/rccm.201512-2468SO; Neelgundmath M, 2015, BIOORG MED CHEM LETT, V25, P893, DOI 10.1016/j.bmcl.2014.12.065; Ni I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121200; Rabe KF, 2017, LANCET, V389, P1931, DOI 10.1016/S0140-6736(17)31222-9; Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421; Sorheim IC, 2010, THORAX, V65, P480, DOI 10.1136/thx.2009.122002; Soriano JB, 2020, LANCET RESP MED, V8, P585, DOI 10.1016/S2213-2600(20)30105-3; Tai HR, 2017, AUTOPHAGY, V13, P99, DOI 10.1080/15548627.2016.1247143; Townsend EA, 2012, ENDOCR REV, V33, P1, DOI 10.1210/er.2010-0031; Vij N, 2018, AM J PHYSIOL-CELL PH, V314, pC73, DOI 10.1152/ajpcell.00110.2016; Wan JH, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw8523; Wang Y, 2018, J IMMUNOL, V200, P2571, DOI 10.4049/jimmunol.1701681; Wu YF, 2020, AUTOPHAGY, V16, P435, DOI 10.1080/15548627.2019.1628536; Zhou JS, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00404-2020; Zhou JS, 2016, AM J PHYSIOL-LUNG C, V310, pL1042, DOI 10.1152/ajplung.00418.2015; Zhou P, 2016, EXP CELL RES, V348, P165, DOI 10.1016/j.yexcr.2016.09.011; Zhou Y, 2018, MATRIX BIOL, V73, P77, DOI 10.1016/j.matbio.2018.03.005	45	1	1	4	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 22	2021	12								594330	10.3389/fimmu.2021.594330	http://dx.doi.org/10.3389/fimmu.2021.594330			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RI0CL	33828547	gold, Green Published			2022-12-18	WOS:000636578100001
J	Silva-Del Toro, SL; Allen, LAH				Silva-Del Toro, Stephanie L.; Allen, Lee-Ann H.			Microtubules and Dynein Regulate Human Neutrophil Nuclear Volume and Hypersegmentation During H. pylori Infection	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophils; plasticity; hypersegmentation; microtubules; dynein; lamin B receptor		Neutrophils (also called polymorphonuclear leukocytes, PMNs) are heterogeneous and can exhibit considerable phenotypic and functional plasticity. In keeping with this, we discovered previously that Helicobacter pylori infection induces N1-like subtype differentiation of human PMNs that is notable for profound nuclear hypersegmentation. Herein, we utilized biochemical approaches and confocal and super-resolution microscopy to gain insight into the underlying molecular mechanisms. Sensitivity to inhibition by nocodazole and taxol indicated that microtubule dynamics were required to induce and sustain hypersegmentation, and super-resolution Stimulated Emission Depletion (STED) imaging demonstrated that microtubules were significantly more abundant and longer in hypersegmented cells. Dynein activity was also required, and enrichment of this motor protein at the nuclear periphery was enhanced following H. pylori infection. In contrast, centrosome splitting did not occur, and lamin B receptor abundance and ER morphology were unchanged. Finally, analysis of STED image stacks using Imaris software revealed that nuclear volume increased markedly prior to the onset of hypersegmentation and that nuclear size was differentially modulated by nocodazole and taxol in the presence and absence of infection. Taken together, our data define a new mechanism of hypersegmentation that is mediated by microtubules and dynein and as such advance understanding of processes that regulate nuclear morphology.	[Silva-Del Toro, Stephanie L.; Allen, Lee-Ann H.] Univ Iowa, Inflammat Program, Iowa City, IA 52242 USA; [Silva-Del Toro, Stephanie L.; Allen, Lee-Ann H.] Univ Iowa, Immunol Grad Program, Iowa City, IA 52242 USA; [Allen, Lee-Ann H.] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; [Allen, Lee-Ann H.] Univ Iowa, Dept Microbiol & Immunol, Iowa City, IA 52242 USA; [Allen, Lee-Ann H.] Iowa City VA Healthcare Syst, Iowa City, IA 52246 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Allen, LAH (corresponding author), Univ Iowa, Inflammat Program, Iowa City, IA 52242 USA.; Allen, LAH (corresponding author), Univ Iowa, Immunol Grad Program, Iowa City, IA 52242 USA.; Allen, LAH (corresponding author), Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.; Allen, LAH (corresponding author), Univ Iowa, Dept Microbiol & Immunol, Iowa City, IA 52242 USA.; Allen, LAH (corresponding author), Iowa City VA Healthcare Syst, Iowa City, IA 52246 USA.	lee-ann.allen@health.missouri.edu			National Institutes of Health, NIAID [R01 AI119965]; VA Merit Review Grant [1I01BX002108]; National Science Foundation [1546595]	National Institutes of Health, NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); VA Merit Review Grant(US Department of Veterans Affairs); National Science Foundation(National Science Foundation (NSF))	This work was supported by funds from the National Institutes of Health, NIAID R01 AI119965 and VA Merit Review Grant 1I01BX002108 awarded to L-AHA as well as a National Science Foundation predoctoral fellowship #1546595 awarded to SLS-DT.	Allen LAH, 2000, J EXP MED, V191, P115, DOI 10.1084/jem.191.1.115; Allen LAH, 2005, J IMMUNOL, V174, P3658, DOI 10.4049/jimmunol.174.6.3658; Allen LAH, 2014, METHODS MOL BIOL, V1124, P251, DOI 10.1007/978-1-62703-845-4_16; Beyrau M, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120134; BILLS T, 1977, AM J CLIN PATHOL, V68, P263, DOI 10.1093/ajcp/68.2.263; Brown RA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02995; DING M, 1995, EUR J CELL BIOL, V66, P234; Doolin MT, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050427; Edens LJ, 2013, TRENDS CELL BIOL, V23, P151, DOI 10.1016/j.tcb.2012.11.004; Eruslanov EB, 2014, J CLIN INVEST, V124, P5466, DOI 10.1172/JCI77053; Firestone AJ, 2012, NATURE, V484, P125, DOI 10.1038/nature10936; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; FRIEDMAN EW, 1982, BRIT J HAEMATOL, V50, P169, DOI 10.1111/j.1365-2141.1982.tb01901.x; Gerlitz G, 2013, CELL MOL LIFE SCI, V70, P1255, DOI 10.1007/s00018-012-1200-5; Giese MA, 2019, BLOOD, V133, P2159, DOI 10.1182/blood-2018-11-844548; Gravemann S, 2010, NUCLEUS-AUSTIN, V1, P179, DOI 10.4161/nucl.1.2.11113; Hoffmann K, 2007, CHROMOSOMA, V116, P227, DOI 10.1007/s00412-007-0094-8; Huang JB, 2006, METABOLISM, V55, P279, DOI 10.1016/j.metabol.2005.09.002; Im DD, 2015, J PEDIAT HEMATOL ONC, V37, P488, DOI 10.1097/MPH.0000000000000356; Jaillon S, 2020, NAT REV CANCER, V20, P485, DOI 10.1038/s41568-020-0281-y; Jevtic P, 2014, ADV EXP MED BIOL, V773, P537, DOI 10.1007/978-1-4899-8032-8_25; Jodoin JN, 2012, MOL BIOL CELL, V23, P4713, DOI 10.1091/mbc.E12-07-0558; Keeling MC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05467-x; Kruger P, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004651; Lokwani R, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024330; Magiera MM, 2014, CURR BIOL, V24, pR351, DOI 10.1016/j.cub.2014.03.032; Maizels Y, 2015, FEBS J, V282, P3500, DOI 10.1111/febs.13334; Manley HR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02867; McCracken JM, 2016, J INNATE IMMUN, V8, P299, DOI 10.1159/000443882; Mukherjee RN, 2016, NUCLEUS-PHILA, V7, P167, DOI 10.1080/19491034.2016.1162933; Nauseef WM, 2016, IMMUNOL REV, V273, P5, DOI 10.1111/imr.12463; Nauseef WM, 2014, NAT IMMUNOL, V15, P602, DOI 10.1038/ni.2921; Nauseef William M., 2007, V412, P15, DOI 10.1007/978-1-59745-467-4_2; Ohms M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00532; Pillay J, 2012, J CLIN INVEST, V122, P327, DOI 10.1172/JCI57990; Salina D, 2002, CELL, V108, P97, DOI 10.1016/S0092-8674(01)00628-6; Salvermoser M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02680; SCHLIWA M, 1982, CELL, V31, P705, DOI 10.1016/0092-8674(82)90325-7; Schwartz JT, 2012, J IMMUNOL, V188, P3351, DOI 10.4049/jimmunol.1102863; Shekhar N, 2013, CELL MOL BIOENG, V6, P74, DOI 10.1007/s12195-012-0257-4; Silvestre-Roig C, 2019, TRENDS IMMUNOL, V40, P565, DOI 10.1016/j.it.2019.04.012; Singel KL, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122311; Tanenbaum Marvin E, 2011, Commun Integr Biol, V4, P21, DOI 10.4161/cib.4.1.13780; THOMPSON WG, 1989, ACTA HAEMATOL-BASEL, V81, P186, DOI 10.1159/000205559; Whitmore LC, 2017, J IMMUNOL, V198, P1793, DOI 10.4049/jimmunol.1601292; Wiese C, 2006, J CELL SCI, V119, P4143, DOI 10.1242/jcs.03226	46	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 22	2021	12								653100	10.3389/fimmu.2021.653100	http://dx.doi.org/10.3389/fimmu.2021.653100			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RI0DV	33828562	gold, Green Published			2022-12-18	WOS:000636581700001
J	Wang, Y; Gloss, B; Tang, B; Dervish, S; Santner-Nanan, B; Whitehead, C; Masters, K; Skarratt, K; Teoh, S; Schibeci, S; Fewings, N; Brignone, C; Triebel, F; Booth, D; McLean, A; Nalos, M				Wang, Ya; Gloss, Brian; Tang, Benjamin; Dervish, Suat; Santner-Nanan, Brigitte; Whitehead, Christina; Masters, Kristy; Skarratt, Kristen; Teoh, Sally; Schibeci, Stephen; Fewings, Nicole; Brignone, Chrystelle; Triebel, Frederic; Booth, David; McLean, Anthony; Nalos, Marek			Immunophenotyping of Peripheral Blood Mononuclear Cells in Septic Shock Patients With High-Dimensional Flow Cytometry Analysis Reveals Two Subgroups With Differential Responses to Immunostimulant Drugs	FRONTIERS IN IMMUNOLOGY			English	Article						sepsis; high-dimensional flow cytometry; Lipopolysaccharides; interferon-&#947; LAG-3Ig; immunophenotype	C-REACTIVE PROTEIN; HLA-DR EXPRESSION; INTERFERON-GAMMA; SEPSIS; IMMUNOSUPPRESSION; PROCALCITONIN; ACTIVATION; PHENOTYPE; MORTALITY; INFECTION	Sepsis is associated with a dysregulated inflammatory response to infection. Despite the activation of inflammation, an immune suppression is often observed, predisposing patients to secondary infections. Therapies directed at restoration of immunity may be considered but should be guided by the immune status of the patients. In this paper, we described the use of a high-dimensional flow cytometry (HDCyto) panel to assess the immunophenotype of patients with sepsis. We then isolated peripheral blood mononuclear cells (PBMCs) from patients with septic shock and mimicked a secondary infection by stimulating PBMCs for 4 h in vitro with lipopolysaccharide (LPS) with or without prior exposure to either IFN-gamma, or LAG-3Ig. We evaluated the response by means of flow cytometry and high-resolution clustering cum differential analysis and compared the results to PBMCs from healthy donors. We observed a heterogeneous immune response in septic patients and identified two major subgroups: one characterized by hypo-responsiveness (Hypo) and another one by hyper-responsiveness (Hyper). Hypo and Hyper groups showed significant differences in the production of cytokines/chemokine and surface human leukocyte antigen-DR (HLA-DR) expression in response to LPS stimulation, which were observed across all cell types. When pre-treated with either interferon gamma (IFN-gamma) or lymphocyte-activation gene 3 (LAG)-3 recombinant fusion protein (LAG-3Ig) prior to LPS stimulation, cells from the Hypo group were shown to be more responsive to both immunostimulants than cells from the Hyper group. Our results demonstrate the importance of patient stratification based on their immune status prior to any immune therapies. Once sufficiently scaled, this approach may be useful for prescribing the right immune therapy for the right patient at the right time, the key to the success of any therapy.	[Wang, Ya; Tang, Benjamin; Whitehead, Christina; Masters, Kristy; Teoh, Sally; McLean, Anthony; Nalos, Marek] Nepean Hosp, Dept Intens Care Med, Penrith, NSW, Australia; [Wang, Ya; Tang, Benjamin; Schibeci, Stephen; Booth, David] Westmead Inst Med Res, Ctr Immunol & Allergy Res, Sydney, NSW, Australia; [Gloss, Brian] Westmead Inst Med Res, Westmead Res Hub, Sydney, NSW, Australia; [Dervish, Suat] Westmead Inst Med Res, Westmead Cytometry, Sydney, NSW, Australia; [Santner-Nanan, Brigitte] Univ Sydney, Sydney Med Sch Nepean, Charles Perkins Ctr Nepean, Kingswood, NSW, Australia; [Skarratt, Kristen] Univ Sydney, Nepean Clin Sch, Fac Med & Hlth, Dept Med, Kingswood, NSW, Australia; [Fewings, Nicole] Univ Sydney, Westmead Clin Sch, Sydney, NSW, Australia; [Brignone, Chrystelle; Triebel, Frederic] Immutep SAS, Parc Club Orsay, Orsay, France; [Nalos, Marek] Charles Univ Prague, Med Fac Plzen, Dept Med 1, Prague, Czech Republic	Nepean Hospital; University of Sydney; University of Sydney; Westmead Institute for Medical Research; University of Sydney; Westmead Institute for Medical Research; University of Sydney; Westmead Institute for Medical Research; University of Sydney; University of Sydney; University of Sydney; Charles University Prague	Wang, Y (corresponding author), Nepean Hosp, Dept Intens Care Med, Penrith, NSW, Australia.; Wang, Y (corresponding author), Westmead Inst Med Res, Ctr Immunol & Allergy Res, Sydney, NSW, Australia.	ya.wang@sydney.edu.au		Gloss, Brian/0000-0001-7695-4394	Nepean Medical Research Foundation Seeding Funding Grant, University of Sydney	Nepean Medical Research Foundation Seeding Funding Grant, University of Sydney	This study was funded by Nepean Medical Research Foundation Seeding Funding Grant, University of Sydney.	Andreae S, 2003, BLOOD, V102, P2130, DOI 10.1182/blood-2003-01-0273; Andreae S, 2002, J IMMUNOL, V168, P3874, DOI 10.4049/jimmunol.168.8.3874; Atkinson V, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001681; AUGUST DA, 1985, CANCER-AM CANCER SOC, V55, P1490, DOI 10.1002/1097-0142(19850401)55:7<1490::AID-CNCR2820550712>3.0.CO;2-N; Boomer JS, 2014, VIRULENCE, V5, P45, DOI [10.4161/viru.27794, 10.4161/viru.26516]; Brignone C, 2007, J IMMUNOL, V179, P4202, DOI 10.4049/jimmunol.179.6.4202; Brignone C, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-71; Castelli GP, 2004, CRIT CARE, V8, pR234, DOI 10.1186/cc2877; Chaudhry H, 2013, IN VIVO, V27, P669; CHEADLE WG, 1991, AM J SURG, V161, P639, DOI 10.1016/0002-9610(91)91247-G; Delsing CE, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-166; Docke WD, 2005, CLIN CHEM, V51, P2341, DOI 10.1373/clinchem.2005.052639; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Erokhina SA, 2021, J LEUKOCYTE BIOL, V109, P327, DOI 10.1002/JLB.3RU0420-668RR; Erokhina SA, 2018, IMMUNOL CELL BIOL, V96, P212, DOI 10.1111/imcb.1032; Fleischmann C, 2016, AM J RESP CRIT CARE, V193, P259, DOI 10.1164/rccm.201504-0781OC; Garcia-Pineres AJ, 2006, J IMMUNOL METHODS, V313, P209, DOI 10.1016/j.jim.2006.04.004; Hotchkiss RS, 2013, LANCET INFECT DIS, V13, P260, DOI 10.1016/S1473-3099(13)70001-X; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Kalil AC, 2009, CRIT CARE MED, V37, P2350, DOI 10.1097/CCM.0b013e3181a3aa43; Kolde R, 2019, **DATA OBJECT**; Larsson Johan, 2020, CRAN; Lukaszewicz AC, 2009, CRIT CARE MED, V37, P2746, DOI 10.1097/CCM.0b013e3181ab858a; Monaco G, 2016, BIOINFORMATICS, V32, P2473, DOI 10.1093/bioinformatics/btw191; Monneret G, 2003, CRIT CARE MED, V31, P2068, DOI 10.1097/01.CCM.0000069345.78884.0F; Monneret G, 2011, MED MYCOL, V49, pS17, DOI 10.3109/13693786.2010.509744; Muenzer JT, 2010, INFECT IMMUN, V78, P1582, DOI 10.1128/IAI.01213-09; Nalos M, 2012, AM J RESP CRIT CARE, V185, P110, DOI 10.1164/ajrccm.185.1.110; Oberholzer A, 2001, SHOCK, V16, P83, DOI 10.1097/00024382-200116020-00001; Ono S, 2018, ANN GASTROENT SURG, V2, P351, DOI 10.1002/ags3.12194; Payen D, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4526-x; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Peters Van Ton AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01926; Poujol F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144375; R Development Core Team, 2018, R LANG ENV STAT COMP; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Schrijver IT, 2019, FRONT IMMUNOL, V10, DOI [10.3389/fimmu.2019.00327, 10.1155/2014/598654]; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Srenathan U, 2016, IMMUNOL LETT, V178, P20, DOI 10.1016/j.imlet.2016.05.001; Sridharan P, 2013, SURG INFECT, V14, P489, DOI 10.1089/sur.2012.028; Tang BM, 2010, CRIT CARE, V14, DOI 10.1186/cc9392; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Vazquez-Tello A, 2012, INT ARCH ALLERGY IMM, V157, P406, DOI 10.1159/000329527; Weber LM, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0415-5; Zanotelli V., 2020, BODENMILLER GROUP IM	45	1	1	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 22	2021	12								634127	10.3389/fimmu.2021.634127	http://dx.doi.org/10.3389/fimmu.2021.634127			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RI1LD	33828550	Green Published, gold			2022-12-18	WOS:000636670300001
J	Miyashita, H; Oikawa, D; Terawaki, S; Kabata, D; Shintani, A; Tokunaga, F				Miyashita, Hirohisa; Oikawa, Daisuke; Terawaki, Seigo; Kabata, Daijiro; Shintani, Ayumi; Tokunaga, Fuminori			Crosstalk Between NDP52 and LUBAC in Innate Immune Responses, Cell Death, and Xenophagy	FRONTIERS IN IMMUNOLOGY			English	Article						NDP52; ubiquitin; LUBAC; NF-&#954; B; apoptosis; xenophagy	NF-KAPPA-B; LINEAR UBIQUITINATION; PROTEIN; ACTIVATION; EXPRESSION; AUTOPHAGY; MECHANISM; CHAINS; NEMO	Nuclear dot protein 52 kDa (NDP52, also known as CALCOCO2) functions as a selective autophagy receptor. The linear ubiquitin chain assembly complex (LUBAC) specifically generates the N-terminal Met1-linked linear ubiquitin chain, and regulates innate immune responses, such as nuclear factor-kappa B (NF-kappa B), interferon (IFN) antiviral, and apoptotic pathways. Although NDP52 and LUBAC cooperatively regulate bacterial invasion-induced xenophagy, their functional crosstalk remains enigmatic. Here we show that NDP52 suppresses canonical NF-kappa B signaling through the broad specificity of ubiquitin-binding at the C-terminal UBZ domain. Upon TNF-alpha-stimulation, NDP52 associates with LUBAC through the HOIP subunit, but does not disturb its ubiquitin ligase activity, and has a modest suppressive effect on NF-kappa B activation by functioning as a component of TNF-alpha receptor signaling complex I. NDP52 also regulates the TNF-alpha-induced apoptotic pathway, but not doxorubicin-induced intrinsic apoptosis. A chemical inhibitor of LUBAC (HOIPIN-8) cancelled the increased activation of the NF-kappa B and IFN antiviral pathways, and enhanced apoptosis in NDP52-knockout and -knockdown HeLa cells. Upon Salmonella-infection, colocalization of Salmonella, LC3, and linear ubiquitin was detected in parental HeLa cells to induce xenophagy. Treatment with HOIPIN-8 disturbed the colocalization and facilitated Salmonella expansion. In contrast, HOIPIN-8 showed little effect on the colocalization of LC3 and Salmonella in NDP52-knockout cells, suggesting that NDP52 is a weak regulator in LUBAC-mediated xenophagy. These results indicate that the crosstalk between NDP52 and LUBAC regulates innate immune responses, apoptosis, and xenophagy.	[Miyashita, Hirohisa; Oikawa, Daisuke; Terawaki, Seigo; Tokunaga, Fuminori] Osaka City Univ, Grad Sch Med, Dept Pathobiochem, Osaka, Japan; [Kabata, Daijiro; Shintani, Ayumi] Osaka City Univ, Grad Sch Med, Dept Med Stat, Osaka, Japan	Osaka Metropolitan University; Osaka Metropolitan University	Tokunaga, F (corresponding author), Osaka City Univ, Grad Sch Med, Dept Pathobiochem, Osaka, Japan.	ftokunaga@med.osaka-cu.ac.jp		Tokunaga, Fuminori/0000-0003-3626-9119	MEXT/JSPS KAKENHI grants [JP16H06276, JP16H06575, JP18H02619, JP19K22541, JP18K06967, JP19H05296, JP20H05337, JP18K06937]; Takeda Science Foundation; Japan Agency for Medical Research and Development [AMED -19fk0210050h0001]	MEXT/JSPS KAKENHI grants; Takeda Science Foundation(Takeda Science Foundation (TSF)); Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED))	T This work was partly supported by MEXT/JSPS KAKENHI grants (Nos. JP16H06276 (AdAMS), JP16H06575, JP18H02619, and JP19K22541 to FT, JP18K06967, JP19H05296, and JP20H05337 to DO, and JP18K06937 to ST), a grant from the Takeda Science Foundation (to FT and ST), and a Grant for Research Program on Hepatitis from the Japan Agency for Medical Research and Development (AMED -19fk0210050h0001 to FT).	Cabal-Hierro L, 2012, CELL SIGNAL, V24, P1297, DOI 10.1016/j.cellsig.2012.02.006; Cemma M, 2011, AUTOPHAGY, V7, P341, DOI 10.4161/auto.7.3.14046; Chu YY, 2021, AUTOPHAGY, V17, P1684, DOI 10.1080/15548627.2020.1781393; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Dondelinger Y, 2016, CELL MOL LIFE SCI, V73, P2165, DOI 10.1007/s00018-016-2191-4; Dynek JN, 2010, EMBO J, V29, P4198, DOI 10.1038/emboj.2010.300; Ellinghaus D, 2013, GASTROENTEROLOGY, V145, P339, DOI 10.1053/j.gastro.2013.04.040; Emmerich CH, 2011, ADV EXP MED BIOL, V691, P115, DOI 10.1007/978-1-4419-6612-4_12; Falcon B, 2018, J BIOL CHEM, V293, P2438, DOI 10.1074/jbc.M117.809293; Fan SQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062008; Fujita H, 2014, MOL CELL BIOL, V34, P1322, DOI 10.1128/MCB.01538-13; Haas TL, 2009, MOL CELL, V36, P831, DOI 10.1016/j.molcel.2009.10.013; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Huttlin EL, 2017, NATURE, V545, P505, DOI 10.1038/nature22366; Inomata M, 2012, CELL MOL LIFE SCI, V69, P963, DOI 10.1007/s00018-011-0819-y; Iwai K, 2014, NAT REV MOL CELL BIO, V15, P503, DOI 10.1038/nrm3836; Kageyama S, 2011, MOL BIOL CELL, V22, P2290, DOI 10.1091/mbc.E10-11-0893; Kato M, 2009, NATURE, V459, P712, DOI 10.1038/nature07969; Katsuya K, 2019, BIOCHEM BIOPH RES CO, V509, P700, DOI 10.1016/j.bbrc.2018.12.164; Katsuya K, 2018, SLAS DISCOV, V23, P1018, DOI 10.1177/2472555218793066; Kensche T, 2012, J BIOL CHEM, V287, P23626, DOI 10.1074/jbc.M112.347195; Kirisako T, 2006, EMBO J, V25, P4877, DOI 10.1038/sj.emboj.7601360; Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; Kwon DH, 2018, MOL CELLS, V41, P27, DOI 10.14348/molcells.2018.2274; Lee SH, 2019, MOL CELL, V74, P701, DOI 10.1016/j.molcel.2019.03.006; Li ST, 2011, IMMUNITY, V35, P426, DOI 10.1016/j.immuni.2011.06.014; Liu KP, 2018, J MOL CELL BIOL, V10, P205, DOI 10.1093/jmcb/mjy012; Long JS, 2000, AM STAT, V54, P217, DOI 10.2307/2685594; Maruyama H, 2010, NATURE, V465, P223, DOI 10.1038/nature08971; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Morishita H, 2019, ANNU REV CELL DEV BI, V35, P453, DOI 10.1146/annurev-cellbio-100818-125300; Morriswood B, 2007, J CELL SCI, V120, P2574, DOI 10.1242/jcs.007005; Nakamura S, 2020, NAT CELL BIOL, V22, P1252, DOI 10.1038/s41556-020-00583-9; Nakazawa S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12547; Newman AC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00859-z; Noad J, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.63; Oikawa D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093381; Oikawa D, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0882-8; Rozan LM, 2006, CANCER BIOL THER, V5, P1228, DOI 10.4161/cbt.5.9.3295; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Sternsdorf T, 1997, J CELL BIOL, V138, P435, DOI 10.1083/jcb.138.2.435; Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042-7158.2012.01567.x; Thurston TLM, 2009, NAT IMMUNOL, V10, P1215, DOI 10.1038/ni.1800; Till A, 2013, AUTOPHAGY, V9, P1256, DOI 10.4161/auto.25483; Tokunaga F, 2012, EMBO J, V31, P3856, DOI 10.1038/emboj.2012.241; Tokunaga F, 2011, NATURE, V471, P633, DOI 10.1038/nature09815; Tokunaga F, 2009, NAT CELL BIOL, V11, P123, DOI 10.1038/ncb1821; Tumbarello DA, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005174; Van Quickelberghe E, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.289; van Wijk SJL, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.66; Viret C, 2018, TRENDS CELL BIOL, V28, P255, DOI 10.1016/j.tcb.2018.01.003; von Muhlinen N, 2010, AUTOPHAGY, V6, P288, DOI 10.4161/auto.6.2.11118; Vucic D, 2011, NAT REV MOL CELL BIO, V12, P439, DOI 10.1038/nrm3143; Wang J, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.67; Wright A, 2007, DEV CELL, V13, P705, DOI 10.1016/j.devcel.2007.09.007; Xie XQ, 2015, AUTOPHAGY, V11, P1775, DOI 10.1080/15548627.2015.1082025; Zamaraev AV, 2015, CELL MOL LIFE SCI, V72, P505, DOI 10.1007/s00018-014-1757-2	58	1	1	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 19	2021	12								635475	10.3389/fimmu.2021.635475	http://dx.doi.org/10.3389/fimmu.2021.635475			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RH0RN	33815386	gold, Green Published			2022-12-18	WOS:000635935600001
J	Antonangeli, F; Grimsholm, O; Rossi, MN; Velotti, F				Antonangeli, Fabrizio; Grimsholm, Ola; Rossi, Marianna Nicoletta; Velotti, Francesca			Editorial: Cellular Stress and Inflammation: How the Immune System Drives Tissue Homeostasis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						inflammation; immune system; tissue homeostasis; metabolism; stress response; fibrosis; PD-L1; granzymes			[Antonangeli, Fabrizio] Sapienza Univ Rome, Dept Mol Med, Lab Ist Pasteur Italia, Fdn Cenci Bolognetti, Rome, Italy; [Antonangeli, Fabrizio] Natl Res Council CNR, Inst Mol Biol & Pathol, Rome, Italy; [Grimsholm, Ola] Univ Gothenburg, Sahlgrenska Acad, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden; [Rossi, Marianna Nicoletta] Bambino Gesu Pediat Hosp, Lab Immunorheumatol, IRCCS, Rome, Italy; [Velotti, Francesca] Univ Tuscia, Dept Ecol & Biol Sci DEB, Viterbo, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); University of Gothenburg; IRCCS Bambino Gesu; Tuscia University	Antonangeli, F (corresponding author), Sapienza Univ Rome, Dept Mol Med, Lab Ist Pasteur Italia, Fdn Cenci Bolognetti, Rome, Italy.; Antonangeli, F (corresponding author), Natl Res Council CNR, Inst Mol Biol & Pathol, Rome, Italy.	fabrizio.antonangeli@uniroma1.it	Grimsholm, Ola/Q-7995-2019	Grimsholm, Ola/0000-0003-2064-2556; Antonangeli, Fabrizio/0000-0002-6369-2249					0	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 18	2021	12								668876	10.3389/fimmu.2021.668876	http://dx.doi.org/10.3389/fimmu.2021.668876			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RI3DK	33828567	Green Published, gold			2022-12-18	WOS:000636787900001
J	Lisk, C; Yuen, R; Kuniholm, J; Antos, D; Reiser, ML; Wetzler, LM				Lisk, Christina; Yuen, Rachel; Kuniholm, Jeff; Antos, Danielle; Reiser, Michael L.; Wetzler, Lee M.			CD169+Subcapsular Macrophage Role in Antigen Adjuvant Activity	FRONTIERS IN IMMUNOLOGY			English	Article						adjuvants; TLR-ligand based adjuvants; PorB; Neisseria; TLR2; antibody production; follicular dendritic cells; antigen deposition		Vaccines have played a pivotal role in improving public health, however, many infectious diseases lack an effective vaccine. Controlling the spread of infectious diseases requires continuing studies to develop new and improved vaccines. Our laboratory has been investigating the immune enhancing mechanisms of Toll-like receptor (TLR) ligand-based adjuvants, including the TLR2 ligand Neisseria meningitidis outer membrane protein, PorB. Adjuvant use of PorB increases costimulatory factors on antigen presenting cells (APC), increases antigen specific antibody production, and cytokine producing T cells. We have demonstrated that macrophage expression of MyD88 (required for TLR2 signaling) is an absolute requirement for the improved antibody response induced by PorB. Here-in, we specifically investigated the role of subcapsular CD169+ marginal zone macrophages in antibody production induced by the use of TLR-ligand based adjuvants (PorB and CpG) and non-TLR-ligand adjuvants (aluminum salts). CD169 knockout mice and mice treated with low dose clodronate treated animals (which only remove marginal zone macrophages), were used to investigate the role of these macrophages in adjuvant-dependent antibody production. In both sets of mice, total antigen specific immunoglobulins (IgGs) were diminished regardless of adjuvant used. However, the greatest reduction was seen with the use of TLR ligands as adjuvants. In addition, the effect of the absence of CD169+ macrophages on adjuvant induced antigen and antigen presenting cell trafficking to the lymph nodes was examined using immunofluorescence by determining the relative extent of antigen loading on dendritic cells (DCs) and antigen deposition on follicular dendritic cells (FDC). Interestingly, only vaccine preparations containing PorB had significant decreases in antigen deposition in lymphoid follicles and germinal centers in CD169 knockout mice or mice treated with low dose clodronate as compared to wildtype controls. Mice immunized with CpG containing preparations demonstrated decreased FDC networks in the mice treated with low dose clodronate. Conversely, alum containing preparations only demonstrated significant decreases in IgG in CD169 knockout mice. These studies stress that importance of subcapsular macrophages and their unique role in adjuvant-mediated antibody production, potentially due to an effect of these adjuvants on antigen trafficking to the lymph node and deposition on follicular dendritic cells.	[Lisk, Christina; Wetzler, Lee M.] Boston Med Ctr, Dept Med, Infect Dis Sect, Boston, MA 02118 USA; [Yuen, Rachel; Kuniholm, Jeff; Wetzler, Lee M.] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; [Antos, Danielle] Univ Pittsburgh, Sch Med, Dept Microbiol & Immunol, Pittsburgh, PA USA; [Reiser, Michael L.] BaWu Hessen GGmbH, DRK Blutspendedienst, Frankfurt, Germany	Boston Medical Center; Boston University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wetzler, LM (corresponding author), Boston Med Ctr, Dept Med, Infect Dis Sect, Boston, MA 02118 USA.; Wetzler, LM (corresponding author), Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.	lwetzler@bu.edu		Kuniholm, Jeffrey/0000-0003-4588-3284	NIH [AI0404944]; Boston University Training Program in Inflammatory Disorders [T32AI138933]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Boston University Training Program in Inflammatory Disorders	These studies were funded by NIH Grant AI0404944 (LW). CL was funded by the Boston University Training Program in Inflammatory Disorders T32AI138933.	Akira S, 2006, CURR TOP MICROBIOL, V311, P1; Allen CDC, 2008, SEMIN IMMUNOL, V20, P14, DOI 10.1016/j.smim.2007.12.001; Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; Asano K, 2011, IMMUNITY, V34, P85, DOI 10.1016/j.immuni.2010.12.011; Averett DR, 2007, BIOCHEM SOC T, V35, P1468, DOI 10.1042/BST0351468; Beran J, 2000, CLIN INFECT DIS, V31, P1504, DOI 10.1086/317479; Bernhard CA, 2015, P NATL ACAD SCI USA, V112, P5461, DOI 10.1073/pnas.1423356112; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; Delputte PL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016827; Desbien AL, 2016, J IMMUNOL, V197, P4351, DOI 10.4049/jimmunol.1600993; Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320; Durier C, 2006, AIDS, V20, P1039, DOI 10.1097/01.aids.0000222077.68243.22; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Gaya M, 2015, SCIENCE, V347, P667, DOI 10.1126/science.aaa1300; GERMANN T, 1993, EUR J IMMUNOL, V23, P1762, DOI 10.1002/eji.1830230805; Gibson SJ, 2002, CELL IMMUNOL, V218, P74, DOI 10.1016/S0008-8749(02)00517-8; Gould KA, 2017, DIMENS CRIT CARE NUR, V36, P145, DOI 10.1097/DCC.0000000000000250; Gutierrez Andres H, 2012, Hum Vaccin Immunother, V8, P971, DOI 10.4161/hv.20202; Gutjahr A, 2016, TRENDS IMMUNOL, V37, P716, DOI 10.1016/j.it.2016.08.005; Habbeddine M, 2017, CELL REP, V21, P2515, DOI 10.1016/j.celrep.2017.10.111; Hinman AR, 2011, AM J EPIDEMIOL, V174, pS16, DOI 10.1093/aje/kwr306; JOHNSON AG, 1987, REV INFECT DIS, V9, pS512; Junt T, 2007, NATURE, V450, P110, DOI 10.1038/nature06287; Kaufmann SHE, 1999, IMMUNOBIOLOGY, V201, P272, DOI 10.1016/S0171-2985(99)80067-9; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461; Lisk C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01254; Liu Q, 2016, IMMUNOL CELL BIOL, V94, P538, DOI 10.1038/icb.2016.18; Louie DAP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00347; Ludewig B, 2012, NAT IMMUNOL, V13, P13, DOI 10.1038/ni.2189; Mackinnon FG, 1999, J INFECT DIS, V180, P755, DOI 10.1086/314966; Martinez-Pomares L, 2007, CELL, V131, P641, DOI 10.1016/j.cell.2007.10.046; Martinez-Pomares L, 2012, TRENDS IMMUNOL, V33, P66, DOI 10.1016/j.it.2011.11.001; Massari P, 2006, J IMMUNOL, V176, P2373, DOI 10.4049/jimmunol.176.4.2373; Massari P, 2005, PROTEIN EXPRES PURIF, V44, P136, DOI 10.1016/j.pep.2005.04.021; McGaha TL, 2011, BLOOD, V117, P5403, DOI 10.1182/blood-2010-11-320028; Moalli F, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00114; Moran I, 2019, TRENDS IMMUNOL, V40, P35, DOI 10.1016/j.it.2018.11.004; Mosaheb M, 2018, VACCINE, V36, P7689, DOI 10.1016/j.vaccine.2018.10.074; Mosaheb MM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00225; Moyer TJ, 2016, J CLIN INVEST, V126, P799, DOI 10.1172/JCI81083; NOSSAL GJV, 1968, J EXP MED, V127, P263, DOI 10.1084/jem.127.2.263; Orenstein WA, 2017, P NATL ACAD SCI USA, V114, P4031, DOI 10.1073/pnas.1704507114; Phan TG, 2007, NAT IMMUNOL, V8, P992, DOI 10.1038/ni1494; Phan TG, 2009, NAT IMMUNOL, V10, P786, DOI 10.1038/ni.1745; Platt A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082171; Plotkin SA, 2003, J INFECT DIS, V187, P1349, DOI 10.1086/374419; Pulko V, 2009, J IMMUNOL, V183, P3634, DOI 10.4049/jimmunol.0900974; Rappuoli R, 2014, P NATL ACAD SCI USA, V111, P12288, DOI 10.1073/pnas.1402981111; Reed SG, 2016, CURR OPIN IMMUNOL, V41, P85, DOI 10.1016/j.coi.2016.06.007; Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409; Reiser ML, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00555-4; Rueckert C, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003001; Saunderson SC, 2014, BLOOD, V123, P208, DOI 10.1182/blood-2013-03-489732; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; SZAKAL AK, 1983, J IMMUNOL, V131, P1714; Taylor K, 2009, VACCINE, V27, pG3, DOI 10.1016/j.vaccine.2009.10.014; TOMAI MA, 1987, J BIOL RESP MODIF, V6, P99; Usui K, 2012, MOL IMMUNOL, V50, P172, DOI 10.1016/j.molimm.2011.11.010; van Haren SD, 2016, J IMMUNOL, V197, P4413, DOI 10.4049/jimmunol.1600282; Vasou A, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9070186; Veninga H, 2015, EUR J IMMUNOL, V45, P747, DOI 10.1002/eji.201444983; Yuen R, 2019, HUM VACC IMMUNOTHER, V15, P2778, DOI 10.1080/21645515.2019.1609852; Zhang Y, 2016, ELIFE, V5, DOI 10.7554/eLife.18156	68	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 18	2021	12								624197	10.3389/fimmu.2021.624197	http://dx.doi.org/10.3389/fimmu.2021.624197			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RG2OD	33815376	gold, Green Published			2022-12-18	WOS:000635379600001
J	Arildsen, AW; Zachariassen, LF; Krych, L; Hansen, AK; Hansen, CHF				Arildsen, Amalie W.; Zachariassen, Line F.; Krych, Lukasz; Hansen, Axel K.; Hansen, Camilla H. F.			Delayed Gut Colonization Shapes Future Allergic Responses in a Murine Model of Atopic Dermatitis	FRONTIERS IN IMMUNOLOGY			English	Article						allergy; atopic dermatitis; childhood ezcema; early priming; gut microbiota; immune maturation; rikenellaceae; window of opportunity		Epidemiological studies have long reported that perturbations of the childhood microbiome increase the risk of developing allergies, but a causal relationship with atopic dermatitis remains unclear. Here we colonized germ-free mice at birth or at one or eight week-of-age to investigate the role of prenatal and early postnatal microbial exposure on development of oxozolone-induced dermatitis later in life. We demonstrate that only one week delayed microbial colonization increased IgE levels and the total histological score of the inflamed ear compared to mice colonized throughout life. In parallel, several pro-inflammatory cytokines and chemokines were upregulated in the ear tissue demonstrating an enhanced immunological response following delayed postnatal colonization of the gut. In contrast, sensitivity to oxazolone-induced dermatitis was unaffected by the presence of a maternal microbiota during gestation. Mice colonized at eight week-of-age failed to colonize Rikenellaceae, a group of bacteria previously associated with a high-responding phenotype, and did not develop an immunological response to the same extent as the early colonized mice despite pronounced histopathological manifestations. The study provides proof-of-principle that the first intestinal colonizers of mice pups are crucial for the development of oxazolone-induced dermatitis later in life, and that the status of the maternal microbiota during pregnancy has no influence on the offspring's allergic immune response. This highlights an important window of opportunity following birth for microbiota-mediated interventions to prevent atopic responses later in life. How long such a window is open may vary between mice and humans considering species differences in the ontogeny of the immune system.	[Arildsen, Amalie W.; Zachariassen, Line F.; Hansen, Axel K.; Hansen, Camilla H. F.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Vet & Anim Sci, Sect Expt Anim Models, Frederiksberg, Denmark; [Krych, Lukasz] Univ Copenhagen, Fac Sci, Dept Food Sci, Frederiksberg, Denmark	University of Copenhagen; University of Copenhagen	Hansen, CHF (corresponding author), Univ Copenhagen, Fac Hlth & Med Sci, Dept Vet & Anim Sci, Sect Expt Anim Models, Frederiksberg, Denmark.	camfriis@sund.ku.dk		Zachariassen, Line Sidsel Fisker/0000-0001-5425-9841; Hansen, Camilla Hartmann Friis/0000-0002-1860-385X				Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Al Nabhani Z, 2020, MUCOSAL IMMUNOL, V13, P183, DOI 10.1038/s41385-020-0257-y; Azad MB, 2016, BJOG-INT J OBSTET GY, V123, P983, DOI 10.1111/1471-0528.13601; Bian GR, 2016, ENVIRON MICROBIOL, V18, P1566, DOI 10.1111/1462-2920.13272; Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587-019-0209-9; Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; Darling AR, 2014, CLIN IMMUNOL, V150, P153, DOI 10.1016/j.clim.2013.11.010; de Aguero MG, 2016, SCIENCE, V351, P1296, DOI 10.1126/science.aad2571; Drinic M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15663-4; Ege MJ, 2008, J ALLERGY CLIN IMMUN, V122, P407, DOI 10.1016/j.jaci.2008.06.011; Fujiwara R, 2010, BRIT J NUTR, V103, P530, DOI 10.1017/S000711450999198X; Hansen CHF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034043; Holladay SD, 2000, ENVIRON HEALTH PERSP, V108, P463, DOI 10.2307/3454538; Huang FQ, 2020, WORLD J PEDIATR, V16, P143, DOI 10.1007/s12519-019-00301-y; KAPP A, 1991, ACTA DERM-VENEREOL, V71, P403; Kirjavainen PV, 2002, GUT, V51, P51, DOI 10.1136/gut.51.1.51; Lee SY, 2018, ALLERGY ASTHMA IMMUN, V10, P354, DOI 10.4168/aair.2018.10.4.354; Mandal S., 2015, MICROB ECOL HEALTH D, V26, DOI DOI 10.3402/MEHD.V26.27663; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Narla S, 2020, CURR ALLERGY ASTHM R, V20, DOI 10.1007/s11882-020-00971-z; OHMEN JD, 1995, J IMMUNOL, V154, P1956; Petersen EBM, 2019, ACTA DERM-VENEREOL, V99, P5, DOI 10.2340/00015555-3008; Prescott SL, 2013, J ALLERGY CLIN IMMUN, V131, P23, DOI 10.1016/j.jaci.2012.11.019; Schmitt J, 2010, PEDIAT ALLERG IMM-UK, V21, P292, DOI 10.1111/j.1399-3038.2009.00901.x; Spergel JM, 2010, ANN ALLERG ASTHMA IM, V105, P99, DOI 10.1016/j.anai.2009.10.002; Stokholm J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02573-2; Suaini NHA, 2021, PEDIAT ALLERG IMM-UK, V32, P23, DOI 10.1111/pai.13335; TOSHITANI A, 1993, J INVEST DERMATOL, V100, P299, DOI 10.1111/1523-1747.ep12469875; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; Zachariassen LF, 2017, SCI REP-UK, V7, DOI 10.1038/srep44385; Zimmermann P, 2019, J ALLERGY CLIN IMMUN, V143, P467, DOI 10.1016/j.jaci.2018.09.025	31	1	1	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2021	12								650621	10.3389/fimmu.2021.650621	http://dx.doi.org/10.3389/fimmu.2021.650621			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RF8YG	33815411	Green Published, gold			2022-12-18	WOS:000635124000001
J	Filbey, KJ; Finney, CAM; Giacomin, PR; Siracusa, MC				Filbey, Kara J.; Finney, Constance A. M.; Giacomin, Paul R.; Siracusa, Mark C.			Editorial: Recent Advances in the Immunology of Helminth Infection - Protection, Pathogenesis and Panaceas	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						helminth; immuno-modulation; immunity; immunomodulators; pathogen			[Filbey, Kara J.] Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Fac Biol Med & Hlth, Manchester, Lancs, England; [Finney, Constance A. M.] Univ Calgary, Dept Biol Sci, Calgary, AB, Canada; [Giacomin, Paul R.] James Cook Univ, Australian Inst Trop Hlth & Med, Cairns, Qld, Australia; [Siracusa, Mark C.] Rutgers State Univ, Rutgers New Jersey Med Sch, Dept Med, Newark, NJ USA	University of Manchester; University of Calgary; James Cook University; Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Medical Center	Filbey, KJ (corresponding author), Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Fac Biol Med & Hlth, Manchester, Lancs, England.	kara.filbey@manchester.ac.uk		Filbey, Kara/0000-0001-5758-5730; Giacomin, Paul/0000-0002-6326-6792	Kennedy Trust for Rheumatology Research; Canadian Foundation for Innovation [CFI -JELF 33617]; Natural Sciences & Engineering Research Council of Canada [NSERC -RGPIN/04305-2014]; Australian National Health and Medical Research Council [NHMRC -1105300]; National Institutes of Health [NIH -R01 AI131634, R01 AI123224, R01 AI151599-01]	Kennedy Trust for Rheumatology Research; Canadian Foundation for Innovation(Canada Foundation for Innovation); Natural Sciences & Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	KF is funded by The Kennedy Trust for Rheumatology Research (via the Senior Research Fellowship of Dr John Grainger). CF is funded by the Canadian Foundation for Innovation (CFI -JELF 33617) and the Natural Sciences & Engineering Research Council of Canada (NSERC -RGPIN/04305-2014). PG is funded by the Australian National Health and Medical Research Council (NHMRC -1105300). MS is funded by the National Institutes of Health (NIH -R01 AI131634, R01 AI123224 and R01 AI151599-01).	Bouchery T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00623; Enaud R, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00009; Hotez PJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002865; Maizels RM, 2018, IMMUNITY, V49, P801, DOI 10.1016/j.immuni.2018.10.016; Sotillo J, 2020, INT J PARASITOL, V50, P635, DOI 10.1016/j.ijpara.2020.04.010	5	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2021	12								663753	10.3389/fimmu.2021.663753	http://dx.doi.org/10.3389/fimmu.2021.663753			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RF6KQ	33815426	Green Published, gold, Green Accepted			2022-12-18	WOS:000634951600001
J	Damoiseaux, J				Damoiseaux, Jan			ANCA Testing in Clinical Practice: From Implementation to Quality Control and Harmonization	FRONTIERS IN IMMUNOLOGY			English	Review						vasculitis; proteinase 3; myeloperoxidase; standardization; harmonization	ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; INTERNATIONAL CONSENSUS STATEMENT; GATING POLICY; FOLLOW-UP; VASCULITIS; STANDARDIZATION; IMMUNOASSAY; DIAGNOSIS	Analyses for the presence of anti-neutrophil cytoplasmic antibodies (ANCA) are important in the diagnostic work-up of patients with small vessel vasculitis. Since current immuno-assays are predominantly designed for diagnosis of patients with ANCA-associated vasculitis (AAV), implementation in routine clinical practice, internal and external quality control, and harmonization are focused on this particular use. However, ANCA testing may also be relevant for monitoring therapy efficacy and for predicting a clinical relapse in AAV patients, and even for diagnostic purposes in other clinical situations. In the current review, the topics of implementation, quality control, and standardization vs. harmonization are discussed while taking into account the different applications of the ANCA assays in the context of AAV.	[Damoiseaux, Jan] Maastricht Univ, Med Ctr, Cent Diagnost Lab, Maastricht, Netherlands	Maastricht University	Damoiseaux, J (corresponding author), Maastricht Univ, Med Ctr, Cent Diagnost Lab, Maastricht, Netherlands.	jan.damoiseaux@mumc.nl	Damoiseaux, Jan/B-8993-2009	Damoiseaux, Jan/0000-0003-4007-6985				Arnold DF, 2010, J CLIN PATHOL, V63, P678, DOI 10.1136/jcp.2009.072504; Basu N, 2010, ANN RHEUM DIS, V69, P1744, DOI 10.1136/ard.2009.119032; Birck R, 2006, AM J KIDNEY DIS, V47, P15, DOI 10.1053/j.ajkd.2005.09.022; Bizzaro N, 2017, AUTOIMMUN REV, V16, P81, DOI 10.1016/j.autrev.2016.09.021; Bossuyt X, 2021, CLIN CHEM LAB MED, V59, pE35, DOI 10.1515/cclm-2020-1178; Bossuyt X, 2020, ANN RHEUM DIS, V79, P1520, DOI 10.1136/annrheumdis-2020-217416; Bossuyt X, 2017, NAT REV RHEUMATOL, V13, P683, DOI 10.1038/nrrheum.2017.140; Bossuyt X, 2017, RHEUMATOLOGY, V56, P1633, DOI 10.1093/rheumatology/kex266; Bossuyt X, 2009, AUTOIMMUN REV, V8, P543, DOI 10.1016/j.autrev.2009.01.013; Broeders S, 2019, ANN RHEUM DIS, V78, pE113, DOI 10.1136/annrheumdis-2018-214078; Chan EKL, 2007, AUTOIMMUN REV, V6, P577, DOI 10.1016/j.autrev.2007.05.001; Choi HK, 2001, J RHEUMATOL, V28, P1584; Damoiseaux J, 2007, ANN NY ACAD SCI, V1109, P454, DOI 10.1196/annals.1398.051; Damoiseaux J, 2009, ANN RHEUM DIS, V68, P228, DOI 10.1136/ard.2007.086579; Damoiseaux J, 2020, AUTOIMMUN HIGHLIGHTS, V11, DOI 10.1186/s13317-020-0127-3; Damoiseaux J, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-209507; Damoiseaux JGMC, 2005, J CLIN IMMUNOL, V25, P202, DOI 10.1007/s10875-005-3863-2; International Standards Organization, 2012, 151892012 ISO; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; Kemna MJ, 2017, EXPERT OPIN ORPHAN D, V5, P207, DOI 10.1080/21678707.2017.1281123; Mahler M, 2018, CLIN CHEM LAB MED, V56, pE27, DOI 10.1515/cclm-2017-0346; Mahler M, 2013, CLIN CHIM ACTA, V424, P267, DOI 10.1016/j.cca.2013.06.005; ML L, 2002, ARCH INTERN MED, V162, P1509, DOI DOI 10.1001/ARCHINTE.162.13.1509; Moiseev S, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102618; Moiseev S, 2020, AM J RESP CRIT CARE, V202, P1360, DOI 10.1164/rccm.202005-1628SO; Monogioudi E, 2019, CLIN CHEM LAB MED, V57, P1197, DOI 10.1515/cclm-2018-1095; Monogioudi E, 2017, CLIN CHIM ACTA, V467, P48, DOI 10.1016/j.cca.2016.05.031; Mulder L, 2018, AUTOIMMUN REV, V17, P513, DOI 10.1016/j.autrev.2018.03.004; Mummert E, 2018, J IMMUNOL METHODS, V459, P11, DOI 10.1016/j.jim.2018.05.014; Ramponi G, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102759; Rasmussen N, 2018, CLIN CHEM LAB MED, V56, pE39, DOI 10.1515/cclm-2017-0362; Rasmussen N, 2015, NEPHROL DIAL TRANSPL, V30, pi8, DOI 10.1093/ndt/gfv070; Sack U, 2020, AUTOIMMUN HIGHLIGHTS, V11, DOI 10.1186/s13317-020-00134-0; Savige J, 2003, AM J CLIN PATHOL, V120, P312, DOI 10.1309/WAEPADW0K4LPUHFN; Savige J, 1999, AM J CLIN PATHOL, V111, P507; Senant M, 2020, CLIN BIOCHEM, V83, P57, DOI 10.1016/j.clinbiochem.2020.05.019; Sinclair D, 2004, J CLIN PATHOL, V57, P131, DOI 10.1136/jcp.2003.8052; Tervaert JWC, 2012, CLIN REV ALLERG IMMU, V43, P211, DOI 10.1007/s12016-012-8320-4; Tervaert JWC, 2009, APMIS, V117, P55, DOI 10.1111/j.1600-0463.2009.02478.x; Tomasson G, 2012, RHEUMATOLOGY, V51, P100, DOI 10.1093/rheumatology/ker280; Tozzoli R, 2012, AUTOIMMUN REV, V11, P766, DOI 10.1016/j.autrev.2012.02.011; van Beers JJBC, 2019, METHODS MOL BIOL, V1901, P47, DOI 10.1007/978-1-4939-8949-2_4; Vanderlocht J, 2019, METHODS MOL BIOL, V1901, P153, DOI 10.1007/978-1-4939-8949-2_12; Watts R, 2007, ANN RHEUM DIS, V66, P222, DOI 10.1136/ard.2006.054593; Watts RA, 2018, BEST PRACT RES CL RH, V32, P3, DOI 10.1016/j.berh.2018.10.003; Westgard JO, 2013, CLIN LAB MED, V33, P111, DOI 10.1016/j.cll.2012.10.004; Wiik A, 1989, APMIS Suppl, V6, P12	47	1	1	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2021	12								656796	10.3389/fimmu.2021.656796	http://dx.doi.org/10.3389/fimmu.2021.656796			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RF2ZA	33796118	Green Published, gold			2022-12-18	WOS:000634710800001
J	Schmitz, NA; Thakare, RP; Chung, CS; Lee, CM; Elias, JA; Lee, CG; LeBlanc, BW				Schmitz, Nicholas A.; Thakare, Ritesh P.; Chung, Chun-Shiang; Lee, Chang-Min; Elias, Jack A.; Lee, Chun Geun; LeBlanc, Brian W.			Chitotriosidase Activity Is Counterproductive in a Mouse Model of Systemic Candidiasis	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophil (PMN); Candida; candidiasis; chitotriosidase (CHIT1); integrins; clustering		Mammalian cells do not produce chitin, an insoluble polymer of N-acetyl-D-glucosamine (GlcNAc), although chitin is a structural component of the cell wall of pathogenic microorganisms such as Candida albicans. Mammalian cells, including cells of the innate immune system elaborate chitinases, including chitotriosidase (Chit1), which may play a role in the anti-fungal immune response. In the current study, using knockout mice, we determined the role of Chit1 against systemic candidiasis. Chit1-deficient mice showed significant decrease in kidney fungal burden compared to mice expressing the functional enzyme. Using in vitro anti-candidal neutrophil functional assays, the introduction of the Chit1:chitin digestion end-product, chitobiose (N-acetyl-D-glucosamine dimer, GlcNAc2), decreased fungal-induced neutrophil swarming and Candida killing in vitro. Also, a role for the lectin-like binding site on the neutrophil integrin CR3 (Mac-1, CD11b/CD18) was found through physiological competitive interference by chitobiose. Furthermore, chitobiose treatment of wild type mice during systemic candidiasis resulted in the significant increase in fungal burden in the kidney. These data suggest a counterproductive role of Chit1 in mounting an efficient anti-fungal defense against systemic candidiasis.	[Schmitz, Nicholas A.; Thakare, Ritesh P.; Chung, Chun-Shiang; LeBlanc, Brian W.] Rhode Isl Hosp, Div Surg Res, Dept Surg, Providence, RI 02905 USA; [Lee, Chang-Min; Elias, Jack A.; Lee, Chun Geun] Brown Univ, Mol Microbiol & Immunol, Providence, RI 02912 USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University	LeBlanc, BW (corresponding author), Rhode Isl Hosp, Div Surg Res, Dept Surg, Providence, RI 02905 USA.	Brian_Leblanc@Brown.edu	Thakare, Ritesh/AFR-2456-2022	Thakare, Ritesh/0000-0002-7426-2519	NIH/NIGMS [P20GM121344-01A1]	NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH/NIGMS P20GM121344-01A1.	Antachopoulos C, 2007, EUR J PEDIATR, V166, P1099, DOI 10.1007/s00431-007-0527-7; Barone R, 2001, CLIN CHIM ACTA, V306, P91, DOI 10.1016/S0009-8981(01)00398-9; Blumberg HM, 2001, CLIN INFECT DIS, V33, P177, DOI 10.1086/321811; Boot RG, 1999, ARTERIOSCL THROM VAS, V19, P687, DOI 10.1161/01.ATV.19.3.687; Brown GD, 2019, SEMIN CELL DEV BIOL, V89, P1, DOI 10.1016/j.semcdb.2018.06.004; Byrd AS, 2013, J IMMUNOL, V190, P4136, DOI 10.4049/jimmunol.1202671; Chen AS, 2005, BIOL PHARM BULL, V28, P545, DOI 10.1248/bpb.28.545; Chen L, 2009, CLIN EXP DERMATOL, V34, P55, DOI 10.1111/j.1365-2230.2008.03092.x; Cho SJ, 2015, ALLERGY ASTHMA IMMUN, V7, P14, DOI 10.4168/aair.2015.7.1.14; Dantas AD, 2016, CURR OPIN MICROBIOL, V34, P111, DOI 10.1016/j.mib.2016.08.006; Di Rosa M, 2006, EUR J NEUROSCI, V23, P2648, DOI 10.1111/j.1460-9568.2006.04780.x; Di Rosa M, 2013, MOL CELL BIOCHEM, V374, P73, DOI 10.1007/s11010-012-1506-5; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; Elmonem Mohamed A, 2016, Enzyme Res, V2016, P2682680, DOI 10.1155/2016/2682680; Forsyth CB, 2002, INFECT IMMUN, V70, P517, DOI 10.1128/IAI.70.2.517-527.2002; Gazendam RP, 2016, IMMUNOL REV, V273, P299, DOI 10.1111/imr.12454; Giraldo P, 2001, HAEMATOLOGICA, V86, P977; Gordon-Thomson C, 2009, CELL MOL LIFE SCI, V66, P1116, DOI 10.1007/s00018-009-8765-7; Gow NAR, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.FUNK-0035-2016; Johnson CM, 2017, J IMMUNOL, V198, P318, DOI 10.4049/jimmunol.1502381; Kourkoumpetis T, 2010, VIRULENCE, V1, P359, DOI 10.4161/viru.1.5.12795; Kumamoto CA, 2005, CELL MICROBIOL, V7, P1546, DOI 10.1111/j.1462-5822.2005.00616.x; Labadaridis J, 1998, ACTA PAEDIATR, V87, P605, DOI 10.1080/08035259850158407; Lee CG, 2012, J IMMUNOL, V189, P2635, DOI 10.4049/jimmunol.1201115; Lehrnbecher T, 2005, LEUKEMIA, V19, P1745, DOI 10.1038/sj.leu.2403922; Lenardon MD, 2010, CURR OPIN MICROBIOL, V13, P416, DOI 10.1016/j.mib.2010.05.002; Loffler J, 2018, MICROBES INFECT, V20, P521, DOI 10.1016/j.micinf.2017.11.010; Lominadze G, 2005, MOL CELL PROTEOMICS, V4, P1503, DOI 10.1074/mcp.M500143-MCP200; Manolakaki D, 2010, VIRULENCE, V1, P367, DOI 10.4161/viru.1.5.12796; O'Brien XM, 2012, J BIOL CHEM, V287, P3337, DOI 10.1074/jbc.M111.298307; Richardson JP, 2019, SEMIN CELL DEV BIOL, V89, P58, DOI 10.1016/j.semcdb.2018.02.026; ROSS GD, 1983, J EXP MED, V158, P334, DOI 10.1084/jem.158.2.334; ROSS GD, 1985, J IMMUNOL, V134, P3307; Ruiz-Herrera J, 2006, FEMS YEAST RES, V6, P14, DOI 10.1111/j.1567-1364.2005.00017.x; Schuttelkopf AW, 2011, ACS MED CHEM LETT, V2, P428, DOI 10.1021/ml200008b; Thornton BP, 1996, J IMMUNOL, V156, P1235; van Bruggen R, 2009, MOL IMMUNOL, V47, P575, DOI 10.1016/j.molimm.2009.09.018; van Eijk M, 2005, INT IMMUNOL, V17, P1505, DOI 10.1093/intimm/dxh328; van Spriel AB, 2001, BLOOD, V97, P2478, DOI 10.1182/blood.V97.8.2478; Vega Karina, 2012, Int J Microbiol, V2012, P920459, DOI 10.1155/2012/920459; Xia Y, 2002, J IMMUNOL, V169, P6417, DOI 10.4049/jimmunol.169.11.6417	41	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2021	12								626798	10.3389/fimmu.2021.626798	http://dx.doi.org/10.3389/fimmu.2021.626798			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RF0CN	33796101	Green Published, gold			2022-12-18	WOS:000634516200001
J	Wang, HX; Yang, Y; Hu, JY; Zhang, LM; Cai, YF; Guo, H; Xiao, T; Chen, HD; Gao, XH; Qiao, S				Wang, He-Xiao; Yang, Yang; Hu, Jing-Yuan; Zhang, Li-Ming; Cai, Yun-Fei; Guo, Hao; Xiao, Ting; Chen, Hong-Duo; Gao, Xing-Hua; Qiao, Shuai			Serum Detection of Anti-thyroid Peroxidase and Anti-thyroglobulin Antibodies in Chinese Patients With Pemphigus Vulgaris and Pemphigus Foliaceus and Literature Review	FRONTIERS IN IMMUNOLOGY			English	Review						anti-TPO antibody; anti-Tg antibody; pemphigus vulgaris; pemphigus foliaceus; meta-analysis; Chinese population	AUTOANTIBODIES	Background Pemphigus is a rare but life-threatening autoimmune skin disease characterized by blistering on skin and/or mucous membranes. The physiological process of blister formation involves IgG antibodies against the desmogleins (Dsgs) and desmocollins (Dscs). Additional autoAbs have also been suggested to mediate the disease heterogeneity, such as anti-thyroid peroxidase (anti-TPO) and antithyroglobulin (anti-Tg) antibodies, the essential culprits of the immune system in autoimmune thyroid diseases. Purpose To investigate the levels and antibody positivity of anti-TPO and anti-Tg antibodies in pemphigus patients. Methods Antibody positivity and levels of anti-TPO and anti-Tg antibodies in pemphigus patients as compared to healthy controls were examined. A meta-analysis was conducted by reviewing six similar studies. Results 98 Chinese pemphigus patients and 65 healthy controls were enrolled in the study. Our meta-analysis revealed a significant correlation between increased presence of positive anti-TPO and anti-Tg antibodies and pemphigus, particularly for pemphigus vulgaris (PV). Such correlation was also observed in our own hospitalized PV patients, but not in pemphigus foliaceus (PF) patients. In addition, the status of anti-TPO and anti-Tg antibodies were also compared between females and males within PV patients, PF patients or controls, as well as compared for females or males between pemphigus patients and controls. In the analysis of T cell counts, we found abnormal low CD3 + T cell counts (< 690 n/mu l) were only detected in patients whose thyroid antibody levels were less than 20 IU/ml. Conclusion Pemphigus patients showed higher levels and antibody positivity of anti-TPO and anti-Tg antibodies than healthy controls. Further investigations are needed to identify the pathogenic functions of these antibodies in pemphigus, as well as to identify the potential shared susceptibility genes.	[Wang, He-Xiao; Yang, Yang; Hu, Jing-Yuan; Zhang, Li-Ming; Cai, Yun-Fei; Guo, Hao; Xiao, Ting; Chen, Hong-Duo; Gao, Xing-Hua] China Med Univ, Natl Joint Engn Res Ctr Diag & Treatment Immunol, NHC Key Lab Immunodermatol,Minist Educ, Hosp 1,Key Lab Immunodermatol,Dept Dermatol, Shenyang, Peoples R China; [Qiao, Shuai] China Med Univ, Hosp 1, Dept Dermatol, Shenyang, Peoples R China	China Medical University; China Medical University	Gao, XH (corresponding author), China Med Univ, Natl Joint Engn Res Ctr Diag & Treatment Immunol, NHC Key Lab Immunodermatol,Minist Educ, Hosp 1,Key Lab Immunodermatol,Dept Dermatol, Shenyang, Peoples R China.; Qiao, S (corresponding author), China Med Univ, Hosp 1, Dept Dermatol, Shenyang, Peoples R China.	gaobarry@hotmail.com; qs197708@163.com	Guo, Hao/K-1338-2019	Guo, Hao/0000-0003-3183-7607	NSFC [81903198, 81903228]	NSFC(National Natural Science Foundation of China (NSFC))	This work was supported by NSFC (81903228 HG) and NSFC (81903198 QA) for data collection.	Ahmed AR, 2016, EXP DERMATOL, V25, P839, DOI 10.1111/exd.13106; Ameri P, 2013, J AM ACAD DERMATOL, V68, P687, DOI 10.1016/j.jaad.2012.11.022; Ansar A, 2009, J EUR ACAD DERMATOL, V23, P719, DOI 10.1111/j.1468-3083.2009.03172.x; Cianfarani F, 2010, J INVEST DERMATOL, V130, P93, DOI 10.1038/jid.2009.180; Daneshpazhooh M, 2010, J AM ACAD DERMATOL, V62, P349, DOI 10.1016/j.jaad.2009.05.024; Davidson A, 2001, NEW ENGL J MED, V345, P340, DOI 10.1056/NEJM200108023450506; Didona D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01418; Gawkrodger DJ, 2008, BRIT J DERMATOL, V159, P1051, DOI 10.1111/j.1365-2133.2008.08881.x; Gupta VK, 2011, DERMATOL CLIN, V29, P393, DOI 10.1016/j.det.2011.03.016; Hertl M, 2015, J EUR ACAD DERMATOL, V29, P405, DOI 10.1111/jdv.12772; Ishii N, 2015, BRIT J DERMATOL, V173, P59, DOI 10.1111/bjd.13711; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Kasperkiewicz M, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.26; Kavala M, 2012, SCI WORLD J, DOI 10.1100/2012/146897; Kridin K, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00159; Leshem YA, 2011, INT J DERMATOL, V50, P827, DOI 10.1111/j.1365-4632.2010.04818.x; Mindorf S, 2017, EXP DERMATOL, V26, P1267, DOI 10.1111/exd.13409; Nguyen VT, 2000, J CLIN INVEST, V106, P1467, DOI 10.1172/JCI10305; Parameswaran A, 2015, BRIT J DERMATOL, V172, P729, DOI 10.1111/bjd.13433; Pitoia F, 2005, MEDICINA-BUENOS AIRE, V65, P307; Rafei D, 2011, AM J PATHOL, V178, P718, DOI 10.1016/j.ajpath.2010.10.016; Sajda T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00692; Schmidt E, 2019, LANCET, V394, P882, DOI 10.1016/S0140-6736(19)31778-7; Seiffert-Sinha K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00625; Sinha AA, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00218; Somers EC, 2006, EPIDEMIOLOGY, V17, P202, DOI 10.1097/01.ede.0000193605.93416.df; Somers EC, 2009, AM J EPIDEMIOL, V169, P749, DOI 10.1093/aje/kwn408; Spindler V, 2018, J INVEST DERMATOL, V138, P32, DOI 10.1016/j.jid.2017.06.022; Spindler V, 2009, J BIOL CHEM, V284, P30556, DOI 10.1074/jbc.M109.024810; Vrijman C, 2012, BRIT J DERMATOL, V167, P1224, DOI 10.1111/j.1365-2133.2012.11198.x; Zhang LM, 2019, ACTA DERM-VENEREOL, V99, P571, DOI 10.2340/00015555-3149	31	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 16	2021	12								653356	10.3389/fimmu.2021.653356	http://dx.doi.org/10.3389/fimmu.2021.653356			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RF2ZN	33796116	Green Published, gold			2022-12-18	WOS:000634712100001
J	Machado, M; Serra, CR; Oliva-Teles, A; Costas, B				Machado, Marina; Serra, Claudia R.; Oliva-Teles, Aires; Costas, Benjamin			Methionine and Tryptophan Play Different Modulatory Roles in the European Seabass (Dicentrarchus labrax) Innate Immune Response and Apoptosis Signaling-An In Vitro Study	FRONTIERS IN IMMUNOLOGY			English	Article						amino acids; inflammation; fish; AIP56; Photobacterium damselae subsp; piscicida		The range of metabolic pathways that are dependent on a proper supply of specific amino acids (AA) unveils their importance in the support of health. AA play central roles in key pathways vital for immune support and individual AA supplementation has shown to be able to modulate fish immunity. In vitro trials are important tools to evaluate the immunomodulatory role of AA, and the present study was conceived to evaluate methionine and tryptophan roles in immune-related mechanisms aiming to understand their effects in leucocyte functioning and AA pathways. For that purpose, head-kidney leucocytes were isolated and a primary cell culture established. The effect of methionine or tryptophan surplus on cell viability was assessed. Medium L-15 10% FBS without AA addition (0.5mM of L-methionine, 0.1 mM of L-tryptophan) was used as control. To that, L-methionine or L-tryptophan were supplemented at 1 and 2 times (M1x or M2x, and T1x or T2x). Nitric oxide, ATP, total antioxidant capacity, and immune-related genes were evaluated in response to lipopolysaccharides extracted from Photobacterium damselae subsp. piscicida or UV-inactivated bacteria). Moreover, caspase 3 activity and apoptosis-related genes were evaluated in response to the apoptosis-inducing protein, AIP56. Distinct roles in leucocytes' immune response were observed, with contrasting outcomes in the modulation of individual pathways. Methionine surplus improved cell viability, polyamine production, and methionine-related genes expression in response to an inflammatory agent. Also, methionine supplementation lowered signals of apoptosis by AIP56, presenting lower caspase 3 activity and higher il1 beta and nf-kappa b expression. Cells cultured in tryptophan supplemented medium presented signals of an attenuated inflammatory response, with decreased ATP and enhanced expression of anti-inflammatory and catabolism-related genes in macrophages. In response to AIP56, leucocytes cultured in a tryptophan-rich medium presented lower resilience to the toxin, higher caspase 3 activity and expression of caspase 8, and lower expression of several genes, including nf-kappa b and p65. This study showed the ability of methionine surplus to improve leucocytes' response to an inflammatory agent and to lower signals of apoptosis by AIP56 induction, while tryptophan attenuated several cellular signals of the inflammatory response to UV-inactivated bacteria and lowered leucocyte resilience to AIP56.	[Machado, Marina; Serra, Claudia R.; Oliva-Teles, Aires; Costas, Benjamin] Ctr Interdisciplinar Invest Marinha & Ambiental C, Matosinhos, Portugal; [Machado, Marina] Univ Porto, Inst Invest & Inovacao Saude i3S, Porto, Portugal; [Machado, Marina; Costas, Benjamin] Univ Porto, Inst Ciencias Biomed Abel Salazar ICBAS UP, Porto, Portugal; [Machado, Marina] Univ Porto, Inst Biol Mol & Celular, Porto, Portugal; [Oliva-Teles, Aires] Fac Ciencias Univ Porto FCUP, Dept Biol, Porto, Portugal	Universidade do Porto; Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto; Universidade do Porto; Universidade do Porto	Machado, M; Costas, B (corresponding author), Ctr Interdisciplinar Invest Marinha & Ambiental C, Matosinhos, Portugal.; Machado, M (corresponding author), Univ Porto, Inst Invest & Inovacao Saude i3S, Porto, Portugal.; Machado, M; Costas, B (corresponding author), Univ Porto, Inst Ciencias Biomed Abel Salazar ICBAS UP, Porto, Portugal.; Machado, M (corresponding author), Univ Porto, Inst Biol Mol & Celular, Porto, Portugal.	mcasimiro@ciimar.up.pt; bcostas@ciimar.up.pt	Oliva-Teles, Aires/B-3555-2008; Costas, Benjamin/F-9350-2010; Serra, Claudia/D-6771-2011	Oliva-Teles, Aires/0000-0002-5730-836X; Costas, Benjamin/0000-0003-3758-0849; Serra, Claudia/0000-0002-9852-2426	INFLAMMAA [PTDC/CVT-CVT/32349/2017]; European Union through FEDER; European Union through COMPETE 2020; Fundacao para a Ciencia e a Tecnologia (FCT, Portugal); FCT, Portugal [SFRH/BD/108243/2015, IF/00197/2015];  [UIDB/04423/2020];  [UIDP/04423/2020]	INFLAMMAA; European Union through FEDER; European Union through COMPETE 2020; Fundacao para a Ciencia e a Tecnologia (FCT, Portugal)(Portuguese Foundation for Science and Technology); FCT, Portugal(Portuguese Foundation for Science and TechnologyEuropean Commission); ; 	This work was partially supported by UIDB/04423/2020, UIDP/04423/2020 and INFLAMMAA (reference PTDC/CVT-CVT/32349/2017), financed by Portugal and the European Union through FEDER and COMPETE 2020, and national funds through Fundacao para a Ciencia e a Tecnologia (FCT, Portugal). MM and BC were supported by FCT, Portugal (SFRH/BD/108243/2015 and IF/00197/2015, respectively).	Adamidou S, 2009, AQUACULTURE, V289, P106, DOI 10.1016/j.aquaculture.2009.01.015; Azeredo R, 2017, FISH SHELLFISH IMMUN, V70, P76, DOI 10.1016/j.fsi.2017.09.016; Azeredo R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18345-3; Azeredo R, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01226; Azeredo R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139967; Ball HJ, 2009, INT J BIOCHEM CELL B, V41, P467, DOI 10.1016/j.biocel.2008.01.005; Bi DK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01413; Bunchasak C, 2009, J POULT SCI, V46, P169, DOI 10.2141/jpsa.46.169; Cortes J, 2016, DEV COMP IMMUNOL, V65, P73, DOI 10.1016/j.dci.2016.06.020; Costa-Ramos C, 2011, FISH SHELLFISH IMMUN, V30, P173, DOI 10.1016/j.fsi.2010.10.007; Costas B, 2011, FISH SHELLFISH IMMUN, V31, P838, DOI 10.1016/j.fsi.2011.07.024; Cruz CM, 2007, J BIOL CHEM, V282, P2871, DOI 10.1074/jbc.M608083200; Daubener W, 1999, ADV EXP MED BIOL, V467, P517; do Vale A, 2005, MOL MICROBIOL, V58, P1025, DOI 10.1111/j.1365-2958.2005.04893.x; do Vale A, 2003, FISH SHELLFISH IMMUN, V15, P129, DOI 10.1016/S1050-4648(02)00144-4; Dosch M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041222; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Forlenza M, 2011, DEV COMP IMMUNOL, V35, P1246, DOI 10.1016/j.dci.2011.03.008; Grimble RF, 1998, NUTRITION, V14, P605, DOI 10.1016/S0899-9007(98)80041-5; Hoseini SM, 2016, AQUACULTURE, V462, P17, DOI 10.1016/j.aquaculture.2016.04.031; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Jankowski J, 2014, ANN ANIM SCI, V14, P17, DOI 10.2478/aoas-2013-0081; Jiang J, 2015, FISH SHELLFISH IMMUN, V42, P457, DOI 10.1016/j.fsi.2014.11.030; Kuang SY, 2012, FISH SHELLFISH IMMUN, V32, P629, DOI 10.1016/j.fsi.2011.12.012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; Le Floc'h N, 2004, LIVEST PROD SCI, V87, P37, DOI 10.1016/j.livprodsci.2003.09.005; Le Floc'h N, 2007, LIVEST SCI, V112, P23, DOI 10.1016/j.livsci.2007.07.002; Ley K, 2017, J IMMUNOL, V199, P2191, DOI 10.4049/jimmunol.1701135; Li P, 2007, BRIT J NUTR, V98, P237, DOI 10.1017/S000711450769936X; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Machado M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44205-3; Machado M, 2020, BRIT J NUTR, V124, P890, DOI 10.1017/S0007114520001877; Machado M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02672; Machado M, 2015, FISH SHELLFISH IMMUN, V42, P353, DOI 10.1016/j.fsi.2014.11.024; MacKenzie CR, 1998, J INFECT DIS, V178, P875, DOI 10.1086/515347; Martinez Y, 2017, AMINO ACIDS, V49, P2091, DOI 10.1007/s00726-017-2494-2; Mills CD, 2001, CRIT REV IMMUNOL, V21, P399, DOI 10.1615/critrevimmunol.v21.i5.10; Mills CD, 2014, J INNATE IMMUN, V6, P716, DOI 10.1159/000364945; Mills CD, 2012, CRIT REV IMMUNOL, V32, P463, DOI 10.1615/CritRevImmunol.v32.i6.10; Mills CD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00212; Moffett JR, 2003, IMMUNOL CELL BIOL, V81, P247, DOI 10.1046/j.1440-1711.2003.t01-1-01177.x; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Munn DH, 2013, TRENDS IMMUNOL, V34, P137, DOI 10.1016/j.it.2012.10.001; Palti Y, 2011, DEV COMP IMMUNOL, V35, P1263, DOI 10.1016/j.dci.2011.03.006; Parameswaran N, 2010, CRIT REV EUKAR GENE, V20, P87, DOI 10.1615/CritRevEukarGeneExpr.v20.i2.10; Pereira LMG, 2014, INFECT IMMUN, V82, P5270, DOI 10.1128/IAI.02623-14; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rahman MM, 2011, NAT REV MICROBIOL, V9, P291, DOI 10.1038/nrmicro2539; Rezania Simin, 2011, Avicenna Journal of Medical Biotechnology, V3, P3; Sarmento A, 2004, FISH SHELLFISH IMMUN, V17, P489, DOI 10.1016/j.fsi.2004.05.004; Secombes C.J., 1990, TECHNIQUES FISH IMMU, P137; Secombes CJ, 2001, DEV COMP IMMUNOL, V25, P713, DOI 10.1016/S0145-305X(01)00032-5; Sharma J. N., 2007, Inflammopharmacology, V15, P252, DOI 10.1007/s10787-007-0013-x; Silva DS, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003128; Smirnova MG, 2002, EUR CYTOKINE NETW, V13, P161; Song BL, 2021, RES VET SCI, V135, P228, DOI 10.1016/j.rvsc.2019.09.013; Sun XM, 2004, MOL CELL, V14, P81, DOI 10.1016/S1097-2765(04)00156-X; Tafalla C, 2000, DEV COMP IMMUNOL, V24, P623, DOI 10.1016/S0145-305X(99)00087-7; Tan HY, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2795090; Tang L, 2009, AQUACULT NUTR, V15, P477, DOI 10.1111/j.1365-2095.2008.00613.x; Vanaja SK, 2016, CELL, V165, P1106, DOI 10.1016/j.cell.2016.04.015; Wang B, 2014, J ANIM SCI BIOTECHNO, V5, DOI 10.1186/2049-1891-5-44; Waterland RA, 2006, J NUTR, V136, p1706S, DOI 10.1093/jn/136.6.1706S; Wentzel AS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00152; Yang ZH, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00533; Yen CLE, 2002, J NUTR, V132, P1840, DOI 10.1093/jn/132.7.1840; Zhu ZX, 2012, ELECTROPHORESIS, V33, P1220, DOI 10.1002/elps.201100492	70	1	1	4	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 15	2021	12								660448	10.3389/fimmu.2021.660448	http://dx.doi.org/10.3389/fimmu.2021.660448			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RE6MR	33790917	Green Published, gold			2022-12-18	WOS:000634266100001
J	Wang, T; Li, K; Xiao, SX; Xia, YM				Wang, Tian; Li, Ke; Xiao, Shengxiang; Xia, Yumin			A Plausible Role for Collectins in Skin Immune Homeostasis	FRONTIERS IN IMMUNOLOGY			English	Review						collectins; immunity; immune homeostasis; skin; immunotherapy	SURFACTANT-PROTEIN-D; LECTIN; SUSCEPTIBILITY; COMPONENTS; INCREASES; PRODUCE; CELLS; MBL	The skin is a complex organ that faces the external environment and participates in the innate immune system. Skin immune homeostasis is necessary to defend against external microorganisms and to recover from stress to the skin. This homeostasis depends on interactions among a variety of cells, cytokines, and the complement system. Collectins belong to the lectin pathway of the complement system, and have various roles in innate immune responses. Mannose-binding lectin (MBL), collectin kidney 1, and liver (CL-K1, CL-L1) activate the lectin pathway, while all have multiple functions, including recognition of pathogens, opsonization of phagocytosis, and modulation of cytokine-mediated inflammatory responses. Certain collectins are localized in the skin, and their expressions change during skin diseases. In this review, we summarize important advances in our understanding of how MBL, surfactant proteins A and D, CL-L1, and CL-K1 function in skin immune homeostasis. Based on the potential roles of collectins in skin diseases, we suggest therapeutic strategies for skin diseases through the targeting of collectins and relevant regulators.	[Wang, Tian; Xiao, Shengxiang; Xia, Yumin] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Dermatol, Xian, Peoples R China; [Li, Ke] Xi An Jiao Tong Univ, Affiliated Hosp 2, Core Res Lab, Xian, Peoples R China	Xi'an Jiaotong University; Xi'an Jiaotong University	Xia, YM (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Dermatol, Xian, Peoples R China.	xiayumin1202@163.com			Innovation Capability Support Plan of Shaanxi Province [No.2019TD-034]	Innovation Capability Support Plan of Shaanxi Province	This study was supported by the Innovation Capability Support Plan of Shaanxi Province (No.2019TD-034).	Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Aiad HAS, 2012, AM J CLIN DERMATOL, V13, P341, DOI 10.2165/11630720-000000000-00000; Akman A, 2008, ARCH DERMATOL RES, V300, P353, DOI 10.1007/s00403-008-0846-1; Areeshi MY, 2016, SCI REP-UK, V6, DOI 10.1038/srep35728; Ariotti S, 2014, SCIENCE, V346, P101, DOI 10.1126/science.1254803; Atochina-Vasserman EN, 2010, INNATE IMMUN-LONDON, V16, P175, DOI 10.1177/1753425910368871; Axelgaard E, 2013, J BIOL CHEM, V288, P23407, DOI 10.1074/jbc.M113.492603; Bao FF, 2019, AM J TROP MED HYG, V101, P1322, DOI 10.4269/ajtmh.19-0470; Basset C, 2003, VACCINE, V21, pS12, DOI 10.1016/S0264-410X(03)00195-6; Bayarri-Olmos R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114883; Berner T, 2020, J ORAL SCI, V62, P293, DOI 10.2334/josnusd.19-0151; Bordon Y, 2014, NAT REV IMMUNOL, V14, P286, DOI 10.1038/nri3680; Bos JD, 2001, CLIN DERMATOL, V19, P563, DOI 10.1016/S0738-081X(00)00174-7; Brandl C, 2014, NEUROMOL MED, V16, P551, DOI 10.1007/s12017-014-8308-8; Brouwer N, 2009, J IMMUNOL, V183, P3496, DOI 10.4049/jimmunol.0900445; Casals C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01998; Chehoud C, 2013, P NATL ACAD SCI USA, V110, P15061, DOI 10.1073/pnas.1307855110; Chen MS, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0879-y; Chroneos ZC, 2010, CELL PHYSIOL BIOCHEM, V25, P13, DOI 10.1159/000272047; Clark RA, 2006, J IMMUNOL, V176, P4431, DOI 10.4049/jimmunol.176.7.4431; Clayton K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01676; De Blasio D, 2017, J CEREBR BLOOD F MET, V37, P938, DOI 10.1177/0271678X16647397; de Messias-Reason IJ, 2011, ARCH DERMATOL RES, V303, P521, DOI 10.1007/s00403-011-1132-1; Dobo J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01851; Dong X, 2017, J INNATE IMMUN, V9, P529, DOI 10.1159/000478042; Dong XF, 2016, MICROB PATHOGENESIS, V99, P282, DOI 10.1016/j.micpath.2016.08.037; Carreto-Binaghi LE, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0385-9; Fraser DA, 2006, J LEUKOCYTE BIOL, V80, P107, DOI 10.1189/jlb.1105683; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; Gaunsbaek MQ, 2013, LUNG, V191, P295, DOI 10.1007/s00408-013-9452-x; Geherin SA, 2012, J IMMUNOL, V188, P6027, DOI 10.4049/jimmunol.1102639; Giang J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00639; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guzel A, 2012, J MOL HISTOL, V43, P361, DOI 10.1007/s10735-012-9396-0; Hansen S, 2002, IMMUNOBIOLOGY, V205, P498, DOI 10.1078/0171-2985-00150; Hansen S, 2010, J IMMUNOL, V185, P6096, DOI 10.4049/jimmunol.1002185; Hansen SWK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01757; Hayashi M, 2019, J IMMUNOL, V203, P1411, DOI 10.4049/jimmunol.1900605; Henriksen ML, 2013, J IMMUNOL, V191, P6117, DOI 10.4049/jimmunol.1302121; Henriksen ML, 2013, MOL IMMUNOL, V56, P757, DOI 10.1016/j.molimm.2013.07.011; Hoegh SV, 2009, J RHEUMATOL, V36, P2449, DOI 10.3899/jrheum.090069; Hohwy T, 2006, EXP DERMATOL, V15, P168, DOI 10.1111/j.1600-0625.2006.00406.x; Howard M, 2018, SEMIN IMMUNOPATHOL, V40, P75, DOI 10.1007/s00281-017-0642-0; Hwang I, 2017, J INNATE IMMUN, V9, P217, DOI 10.1159/000453316; Ingels C, 2016, PEDIATR RES, V80, P237, DOI 10.1038/pr.2016.76; Janssen WJ, 2008, AM J RESP CRIT CARE, V178, P158, DOI 10.1164/rccm.200711-1661OC; Jorgensen CM, 2019, J CLIN IMMUNOL, V39, P668, DOI 10.1007/s10875-019-00675-8; Kang HJ, 2007, IMMUNOLOGY, V122, P335, DOI 10.1111/j.1365-2567.2007.02644.x; Kawai T, 2002, BIOSCI BIOTECH BIOCH, V66, P2134, DOI 10.1271/bbb.66.2134; Keizer MP, 2014, MOL IMMUNOL, V61, P174, DOI 10.1016/j.molimm.2014.06.005; Keizer MP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01406; Keshi H, 2006, MICROBIOL IMMUNOL, V50, P1001, DOI 10.1111/j.1348-0421.2006.tb03868.x; Kjaer TR, 2016, SCAND J IMMUNOL, V84, P12, DOI 10.1111/sji.12441; Kocsis A, 2010, J IMMUNOL, V185, P4169, DOI 10.4049/jimmunol.1001819; Lai Yuping, 2008, Infectious Disorders - Drug Targets, V8, P144; Ledford JG, 2010, J IMMUNOL, V185, P3884, DOI 10.4049/jimmunol.1000387; Litvack ML, 2010, INNATE IMMUN-LONDON, V16, P191, DOI 10.1177/1753425910369271; Lokitz ML, 2005, J INVEST DERMATOL, V125, P166, DOI 10.1111/j.0022-202X.2005.23794.x; Longhi MP, 2006, TRENDS IMMUNOL, V27, P102, DOI 10.1016/j.it.2005.12.008; Madsen J, 2000, J IMMUNOL, V164, P5866, DOI 10.4049/jimmunol.164.11.5866; MAMICHOUAIB F, 1990, J EXP MED, V172, P1071, DOI 10.1084/jem.172.4.1071; Martel C, 2012, AM HEART J, V164, P43, DOI 10.1016/j.ahj.2012.04.007; McGirt LY, 2006, J ALLERGY CLIN IMMUN, V118, P202, DOI 10.1016/j.jaci.2006.04.033; Miller Christopher, 2010, Clin Mol Allergy, V8, P6, DOI 10.1186/1476-7961-8-6; Minoux M, 2010, DEVELOPMENT, V137, P2605, DOI 10.1242/dev.040048; Mo YK, 2007, J INVEST DERMATOL, V127, P381, DOI 10.1038/sj.jid.5700561; Moller-Kristensen M, 2006, J IMMUNOL, V176, P1769, DOI 10.4049/jimmunol.176.3.1769; Moller-Kristensen M, 2007, J INVEST DERMATOL, V127, P1524, DOI 10.1038/sj.jid.5700748; Moller-Kristensen M, 2007, INT IMMUNOL, V19, P141, DOI 10.1093/intimm/dxl131; Munye MM, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006679; Ndiaye C, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006945; Nguyen AV, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081811; Ni XH, 2020, J LEUKOCYTE BIOL, V108, P485, DOI 10.1002/JLB.5MR0120-439R; Ohtani K, 1999, J BIOL CHEM, V274, P13681, DOI 10.1074/jbc.274.19.13681; Ozaki M, 2016, KIDNEY INT, V90, P774, DOI 10.1016/j.kint.2016.05.011; Panda AK, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4057; Panda AK, 2013, HUM IMMUNOL, V74, P114, DOI 10.1016/j.humimm.2012.09.003; Pavlov VI, 2015, AM J PATHOL, V185, P347, DOI 10.1016/j.ajpath.2014.10.015; Pavlov VI, 2012, CIRCULATION, V126, P2227, DOI 10.1161/CIRCULATIONAHA.112.123968; Peng XD, 2018, INT IMMUNOPHARMACOL, V63, P161, DOI 10.1016/j.intimp.2018.08.003; Polcsello V, 2019, GENET MOL BIOL, V42, P9, DOI [10.1590/1678-4685-GMB-2018-0015, 10.1590/1678-4685-gmb-2018-0015]; Reis ES, 2007, IMMUNOBIOLOGY, V212, P151, DOI 10.1016/j.imbio.2006.11.010; Rooryck C, 2011, NAT GENET, V43, P197, DOI 10.1038/ng.757; Salvesen B, 2009, MOL IMMUNOL, V46, P688, DOI 10.1016/j.molimm.2008.09.001; Sandor N, 2013, IMMUNOBIOLOGY, V218, P652, DOI 10.1016/j.imbio.2012.07.031; Seidel JA, 2018, CLIN EXP IMMUNOL, V194, P79, DOI 10.1111/cei.13189; Selman L, 2012, J IMMUNOL METHODS, V375, P182, DOI 10.1016/j.jim.2011.10.010; Selman L, 2012, IMMUNOBIOLOGY, V217, P851, DOI 10.1016/j.imbio.2011.12.008; Shi CK, 2019, EUR REV MED PHARMACO, V23, P9085, DOI 10.26355/eurrev_201910_19311; Shimizu T, 2009, BBA-GEN SUBJECTS, V1790, P1705, DOI 10.1016/j.bbagen.2009.10.006; Stalman A, 2015, KNEE SURG SPORT TR A, V23, P2682, DOI 10.1007/s00167-014-3010-9; THIEL S, 1992, CLIN EXP IMMUNOL, V90, P31; Thiel S, 2007, MOL IMMUNOL, V44, P3875, DOI 10.1016/j.molimm.2007.06.005; Timar KK, 2007, MOL IMMUNOL, V44, P2943, DOI 10.1016/j.molimm.2007.01.007; Toulon A, 2009, J EXP MED, V206, P743, DOI 10.1084/jem.20081787; Tremante E, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12164; Troldborg A, 2015, CLIN EXP IMMUNOL, V182, P132, DOI 10.1111/cei.12678; Troldborg A, 2018, J RHEUMATOL, V45, P1136, DOI 10.3899/jrheum.171033; Ujma S, 2017, J INNATE IMMUN, V9, P3, DOI 10.1159/000451026; van de Wetering JK, 2004, EUR J BIOCHEM, V271, P1229, DOI 10.1111/j.1432-1033.2004.04040.x; Van den Wijngaard RMJGJ, 2002, BRIT J DERMATOL, V146, P80, DOI 10.1046/j.1365-2133.2002.04604.x; Venkatesha RT, 2005, MOL IMMUNOL, V42, P581, DOI 10.1016/j.molimm.2004.09.009; Wallim LR, 2014, HUM IMMUNOL, V75, P629, DOI 10.1016/j.humimm.2014.04.015; Werth VP, 2002, J INVEST DERMATOL, V119, P1394, DOI 10.1046/j.1523-1747.2002.19608.x; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889; Yanez DA, 2017, PFLUG ARCH EUR J PHY, V469, P455, DOI 10.1007/s00424-017-1953-7; Zeng JQ, 2019, EXP DERMATOL, V28, P1017, DOI 10.1111/exd.13995; Zhang XM, 2013, CELL MOL IMMUNOL, V10, P113, DOI 10.1038/cmi.2012.63	108	1	1	3	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 15	2021	12								594858	10.3389/fimmu.2021.594858	http://dx.doi.org/10.3389/fimmu.2021.594858			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RE9BV	33790889	gold, Green Published			2022-12-18	WOS:000634445500001
J	Jash, A; Usaneerungrueng, C; Howie, HL; Qiu, ANE; Luckey, CJ; Zimring, JC; Hudson, KE				Jash, Arijita; Usaneerungrueng, Chomkan; Howie, Heather L.; Qiu, Annie; Luckey, Chance John; Zimring, James C.; Hudson, Krystalyn E.			Antibodies to Low-Copy Number RBC Alloantigen Convert a Tolerogenic Stimulus to an Immunogenic Stimulus in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						alloantibody; red blood cell; alloimmunization; tolerance; antibody-mediated enhancement		Red blood cells expressing alloantigens are well known to be capable of inducing robust humoral alloantibody responses both in transfusion and pregnancy. However, the majority of transfusion recipients and pregnant women never make alloantibodies, even after repeat exposure to foreign RBCs. More recently, RBCs have been used as a cellular therapeutic-very much like transfusion, engineered RBCs are highly immunogenic in some cases but not others. In animal models of both transfusion and RBC based therapeutics, RBCs that do not induce an immune response also cause tolerance. Despite a robust phenomenology, the mechanisms of what regulates immunity vs. tolerance to RBCs remains unclear. However, it has been reported that copy number of alloantigens on the RBCs is a critical factor, with a very low copy number causing non-responsiveness (in both humans and mice) and also leading to tolerance in mice. Recently, we reported that an IgG2c specific for an RBC antigen can substantially enhance the humoral immune response upon transfusion of RBCs expressing that antigen. Herein, we report that an IgG2c converts RBCs with low antigen copy number from a tolerogenic to an immunogenic stimulus. These findings report the first known stimulus that induces humoral alloimmunization to a low copy number RBC alloantigen and identify a previously undescribed molecular switch that has the ability to affect responder vs. non-responder phenotypes of transfusion recipients.	[Jash, Arijita; Howie, Heather L.; Luckey, Chance John; Zimring, James C.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; [Jash, Arijita; Howie, Heather L.; Luckey, Chance John; Zimring, James C.] Univ Virginia, Carter Immunol Ctr, Charlottesville, VA USA; [Usaneerungrueng, Chomkan] Bloodworks NW Res Inst, Seattle, WA USA; [Qiu, Annie; Hudson, Krystalyn E.] Columbia Univ, Dept Pathol & Cell Biol, Irving Med Ctr, New York, NY 10027 USA	University of Virginia; University of Virginia; Columbia University; NewYork-Presbyterian Hospital	Hudson, KE (corresponding author), Columbia Univ, Dept Pathol & Cell Biol, Irving Med Ctr, New York, NY 10027 USA.	keh2197@cumc.columbia.edu		Luckey, Chance John/0000-0002-0787-9121	National Institutes of Health, National Heart, Lung, and Blood Institute [P01HL132819, R01HL135248]	National Institutes of Health, National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	These studies were supported in part by the National Institutes of Health, National Heart, Lung, and Blood Institute [P01HL132819 (JZ) and R01HL135248 (KH)].	Anderson HL, 2018, J IMMUNOL, V201, P1343, DOI 10.4049/jimmunol.1800565; Arthur CM, 2017, J IMMUNOL, V198, P2671, DOI 10.4049/jimmunol.1601736; Bax BE, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12050435; Brandsma AM, 2016, IMMUNITY, V45, P225, DOI 10.1016/j.immuni.2016.07.006; Cadwell CM, 2008, VOX SANG, V95, P159, DOI 10.1111/j.1423-0410.2008.01066.x; Chiarantini L, 1997, VACCINE, V15, P276, DOI 10.1016/S0264-410X(96)00181-8; Cremel M, 2013, INT J PHARMACEUT, V443, P39, DOI 10.1016/j.ijpharm.2012.12.044; Desmarets M, 2009, BLOOD, V114, P2315, DOI 10.1182/blood-2009-04-214387; Dominici S, 2003, VACCINE, V21, P2073, DOI 10.1016/S0264-410X(02)00746-6; Flegel WA, 2000, TRANSFUSION, V40, P428, DOI 10.1046/j.1537-2995.2000.40040428.x; Gibb DR, 2017, J IMMUNOL, V199, P1041, DOI 10.4049/jimmunol.1700401; Girard-Pierce KR, 2013, BLOOD, V122, P1793, DOI 10.1182/blood-2013-06-508952; Grimm AJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep15907; Gruber DR, 2020, BLOOD ADV, V4, P1526, DOI 10.1182/bloodadvances.2019001299; Howie HL, 2016, TRANSFUSION, V56, P2953, DOI 10.1111/trf.13812; Kim KH, 2009, KOREAN J LAB MED, V29, P361, DOI 10.3343/kjlm.2009.29.4.361; Liu D, 2019, TRANSFUSION, V59, P3243, DOI 10.1111/trf.15482; Maier CL, 2018, BLOOD ADV, V2, P2986, DOI 10.1182/bloodadvances.2018018408; Nazimek Katarzyna, 2019, Folia Med Cracov, V59, P61; Shinde P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01516; Smith NH, 2012, TRANSFUSION, V52, P2620, DOI 10.1111/j.1537-2995.2012.03641.x; Stack G, 2016, BRIT J HAEMATOL, V175, P154, DOI 10.1111/bjh.14175; Stowell SR, 2014, TRANSFUSION, V54, P179, DOI 10.1111/trf.12217; Ukidve A, 2020, P NATL ACAD SCI USA, V117, P17727, DOI 10.1073/pnas.2002880117; WILLIAMSON LM, 1994, BRIT J HAEMATOL, V87, P805, DOI 10.1111/j.1365-2141.1994.tb06741.x; Yang HS, 2015, ANN LAB MED, V35, P554, DOI 10.3343/alm.2015.35.5.554; Zimring JC, 2009, TRANSFUS MED REV, V23, P189, DOI 10.1016/j.tmrv.2009.03.002; Zimring JC, 2005, BLOOD, V106, P1105, DOI 10.1182/blood-2005-03-1040	28	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 12	2021	12								629608	10.3389/fimmu.2021.629608	http://dx.doi.org/10.3389/fimmu.2021.629608			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RC6BB	33777014	gold, Green Published			2022-12-18	WOS:000632883100001
J	Azam, A; Mallart, S; Illiano, S; Duclos, O; Prades, C; Maillere, B				Azam, Aurelien; Mallart, Sergio; Illiano, Stephane; Duclos, Olivier; Prades, Catherine; Maillere, Bernard			Introduction of Non-natural Amino Acids Into T-Cell Epitopes to Mitigate Peptide-Specific T-Cell Responses	FRONTIERS IN IMMUNOLOGY			English	Article						non-natural amino acids; immunogenicity; HLA class II molecules; CD4 T-cell response; T-cell epitope		Non-natural modifications are widely introduced into peptides to improve their therapeutic efficacy, but their impact on immunogenicity remains largely unknown. As the CD4 T-cell response is a key factor in triggering immunogenicity, we investigated the effect of introducing D-amino acids (Daa), amino isobutyric acid (Aib), N-methylation, C-alpha-methylation, reduced amide, and peptoid bonds into an immunoprevalent T-cell epitope on binding to a set of HLA-DR molecules, recognition, and priming of human T cells. Modifications are differentially accepted at multiple positions, but are all tolerated in the flanking regions. Introduction of Aib and Daa in the binding core had the most deleterious effect on binding to HLA-DR molecules and T-cell activation. Their introduction at the positions close to the P1 anchor residue abolished T-cell priming, suggesting they might be sufficient to dampen peptide immunogenicity. Other modifications led to variable effects on binding to HLA-DR molecules and T-cell reactivity, but none exhibited an increased ability to stimulate T cells. Altogether, non-natural modifications appear generally to diminish binding to HLA-DR molecules and hence T-cell stimulation. These data might guide the design of therapeutic peptides to make them less immunogenic.	[Azam, Aurelien; Prades, Catherine] Sanofi, Biol Res, Vitry Sur Seine, France; [Azam, Aurelien; Maillere, Bernard] Univ Paris Saclay, Dept Medicaments & Technol Sante, CEA, INRAE,SIMoS, Gif Sur Yvette, France; [Mallart, Sergio; Duclos, Olivier] Sanofi R&D, Integrated Drug Discovery, Chilly Mazarin, France; [Illiano, Stephane] Sanofi R&D, Cardiovasc Dis Metab, Chilly Mazarin, France	Sanofi-Aventis; Sanofi France; CEA; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France	Maillere, B (corresponding author), Univ Paris Saclay, Dept Medicaments & Technol Sante, CEA, INRAE,SIMoS, Gif Sur Yvette, France.	Bernard.maillere@cea.fr		Mallart, Sergio/0000-0003-1846-8683; Azam, Aurelien/0000-0001-7680-4679; ILLIANO, STEPHANE/0000-0001-9196-0493				Aravinda S, 2008, CHEM BIODIVERS, V5, P1238, DOI 10.1002/cbdv.200890112; Bastian M, 2004, MOL IMMUNOL, V41, P775, DOI 10.1016/j.molimm.2004.04.019; BENKIRANE N, 1993, J BIOL CHEM, V268, P26279; Bossus M, 1997, J PEPT SCI, V3, P47, DOI 10.1002/(SICI)1099-1387(199701)3:1<47::AID-PSC80>3.0.CO;2-V; Castelli FA, 2008, EUR J IMMUNOL, V38, P2821, DOI 10.1002/eji.200738072; Castelli FA, 2007, EUR J IMMUNOL, V37, P1513, DOI 10.1002/eji.200636783; Castelli FA, 2013, J IMMUNOL, V190, P5757, DOI 10.4049/jimmunol.1300145; Chaux P, 1999, J EXP MED, V189, P767, DOI 10.1084/jem.189.5.767; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; Cohen WM, 2006, J IMMUNOL, V176, P5401, DOI 10.4049/jimmunol.176.9.5401; Cotton J, 1998, INT IMMUNOL, V10, P159, DOI 10.1093/intimm/10.2.159; DAVENPORT MP, 1995, P NATL ACAD SCI USA, V92, P6567, DOI 10.1073/pnas.92.14.6567; de Haan EC, 2002, BIOORGAN MED CHEM, V10, P1939, DOI 10.1016/S0968-0896(01)00434-5; Dingman R, 2019, J PHARM SCI-US, V108, P1637, DOI 10.1016/j.xphs.2018.12.014; DINTZIS HM, 1993, PROTEINS, V16, P306, DOI 10.1002/prot.340160309; Ettouati L, 1996, PEPTIDE RES, V9, P248; Gallais Y, 2021, CELL MOL IMMUNOL, V18, P1323, DOI 10.1038/s41423-020-0455-2; GELDER CM, 1995, J VIROL, V69, P7497, DOI 10.1128/JVI.69.12.7497-7506.1995; GELUK A, 1994, J IMMUNOL, V152, P5742; Gentilucci L, 2010, CURR PHARM DESIGN, V16, P3185, DOI 10.2174/138161210793292555; Goodwin D, 2012, CURR MED CHEM, V19, P4451, DOI 10.2174/092986712803251548; GURUNATH R, 1995, FEBS LETT, V361, P176, DOI 10.1016/0014-5793(95)00166-7; Hamze M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00500; Hennecke J, 2002, J EXP MED, V195, P571, DOI 10.1084/jem.20011194; HILL CM, 1994, J IMMUNOL, V152, P2890; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; JATON JC, 1968, J BIOL CHEM, V243, P5616; Jawa V, 2013, CLIN IMMUNOL, V149, P534, DOI 10.1016/j.clim.2013.09.006; Karosiene E, 2013, IMMUNOGENETICS, V65, P711, DOI 10.1007/s00251-013-0720-y; KING TP, 1994, J IMMUNOL, V153, P1124; Koren E, 2007, CLIN IMMUNOL, V124, P26, DOI 10.1016/j.clim.2007.03.544; Kwok WW, 2012, J IMMUNOL, V188, P2537, DOI 10.4049/jimmunol.1102190; Maillere B, 1995, MOL IMMUNOL, V32, P1073, DOI 10.1016/0161-5890(95)00073-9; MARSHALL KW, 1994, J IMMUNOL, V152, P4946; Meunier S, 2020, CELL MOL IMMUNOL, V17, P656, DOI 10.1038/s41423-019-0304-3; Moon JJ, 2007, IMMUNITY, V27, P203, DOI 10.1016/j.immuni.2007.07.007; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555, DOI 10.1038/9858; Texier C, 2000, J IMMUNOL, V164, P3177, DOI 10.4049/jimmunol.164.6.3177; Texier C, 2001, EUR J IMMUNOL, V31, P1837, DOI 10.1002/1521-4141(200106)31:6&lt;1837::AID-IMMU1837&gt;3.0.CO;2-H; Usmani SS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181748; Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938; VOGT AB, 1994, J IMMUNOL, V153, P1665; Wang P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000048; Wang XF, 2008, J IMMUNOL, V181, P431, DOI 10.4049/jimmunol.181.1.431; Zavala-Ruiz Z, 2003, J BIOL CHEM, V278, P44904, DOI 10.1074/jbc.M307652200	47	1	1	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2021	12								637963	10.3389/fimmu.2021.637963	http://dx.doi.org/10.3389/fimmu.2021.637963			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RB9GU	33777029	gold, Green Published			2022-12-18	WOS:000632414000001
J	da Silva, PHL; de Castro, KKG; Mendes, MA; Leal-Calvo, T; Leal, JMP; Nery, JAD; Sarno, EN; Lourenco, RA; Moraes, MO; Lara, FA; Esquenazi, D				da Silva, Pedro Henrique Lopes; de Castro, Katherine Kelda Gomes; Mendes, Mayara Abud; Leal-Calvo, Thyago; Leal, Julia Monteiro Pereira; Nery, Jose Augusto da Costa; Sarno, Euzenir Nunes; Lourenco, Roberto Alves; Moraes, Milton Ozorio; Lara, Flavio Alves; Esquenazi, Danuza			Presence of Senescent and Memory CD8+Leukocytes as Immunocenescence Markers in Skin Lesions of Elderly Leprosy Patients	FRONTIERS IN IMMUNOLOGY			English	Article						leprosy; elderly; immunosenescence; skin lesions; memory T cell; cytomegalovirus	REGULATORY T-CELLS; POLYMERASE-CHAIN-REACTION; COSTIMULATORY MOLECULES; ADAPTIVE IMMUNITY; CD28 EXPRESSION; AGE; MAINTENANCE; POPULATION; MODULATION; DECLINE	Leprosy is an infectious disease that remains endemic in approximately 100 developing countries, where about 200,000 new cases are diagnosed each year. Moreover, multibacillary leprosy, the most contagious form of the disease, has been detected at continuously higher rates among Brazilian elderly people. Due to the so-called immunosenescence, characterized by several alterations in the quality of the immune response during aging, this group is more susceptible to infectious diseases. In view of such data, the purpose of our work was to investigate if age-related alterations in the immune response could influence the pathogenesis of leprosy. As such, we studied 87 individuals, 62 newly diagnosed and untreated leprosy patients distributed according to the age range and to the clinical forms of the disease and 25 healthy volunteers, who were studied as controls. The frequency of senescent and memory CD8(+) leukocytes was assessed by immunofluorescence of biopsies from cutaneous lesions, while the serum levels of IgG anti-CMV antibodies were analyzed by chemiluminescence and the gene expression of T cell receptors' inhibitors by RT-qPCR. We noted an accumulation of memory CD8(+) T lymphocytes, as well as reduced CD8(+)CD28(+) cell expression in skin lesions from elderly patients, when compared to younger people. Alterations in LAG3 and PDCD1 gene expression in cutaneous lesions of young MB patients were also observed, when compared to elderly patients. Such data suggest that the age-related alterations of T lymphocyte subsets can facilitate the onset of leprosy in elderly patients, not to mention other chronic inflammatory diseases.	[da Silva, Pedro Henrique Lopes; de Castro, Katherine Kelda Gomes; Mendes, Mayara Abud; Leal-Calvo, Thyago; Leal, Julia Monteiro Pereira; Nery, Jose Augusto da Costa; Sarno, Euzenir Nunes; Moraes, Milton Ozorio; Esquenazi, Danuza] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Hanseniase, Rio De Janeiro, Brazil; [Lourenco, Roberto Alves] Univ Estado Rio de Janeiro, Lab Envelhecimento Humano, Policlin Piquet Carneiro, GeronLab, Rio De Janeiro, Brazil; [Lara, Flavio Alves] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Microbiol Celular, Rio De Janeiro, Brazil; [Esquenazi, Danuza] Univ Estado Rio de Janeiro, Disciplina Patol Geral, Fac Ciencias Med, Rio De Janeiro, Brazil	Fundacao Oswaldo Cruz; Universidade do Estado do Rio de Janeiro; Fundacao Oswaldo Cruz; Universidade do Estado do Rio de Janeiro	da Silva, PHL; Esquenazi, D (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Hanseniase, Rio De Janeiro, Brazil.; Esquenazi, D (corresponding author), Univ Estado Rio de Janeiro, Disciplina Patol Geral, Fac Ciencias Med, Rio De Janeiro, Brazil.	peddro.henrique10@gmail.com; danuza@ioc.fiocruz.br	Lara, Flavio Alves/L-1861-2013; Moraes, Milton Ozório/G-9753-2011; Moraes, Milton/AFF-1842-2022	Moraes, Milton Ozório/0000-0003-2653-0037; Calvo, Thyago Leal/0000-0001-9520-4791	FIOCRUZ/CAPES (Portuguese: Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) [16.11.38.106]; FIOCRUZ/CNPq (Portuguese: Conselho Nacional de Pesquisa e Desenvolvimento Tecnologico) [18.08.38.140, 18.08.18.013]; FIOCRUZ/CNPq [15.06.38.062, 18.03.37.105]; CNPq [313657/2018-1, 305105/2019-1, 31633/2017-7, 309853/2019-2]; PAEF (Portuguese: Projeto de Acoes Estrategicas para Desenvolvimento e Fortalecimento dos Laboratorios Credenciados e das Areas de Apoio a Pesquisa do IOC) [IOC-023-FIO-18-2-41]; PAPES VI/CNPq/Fiocruz [422.103/2017-9]	FIOCRUZ/CAPES (Portuguese: Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior); FIOCRUZ/CNPq (Portuguese: Conselho Nacional de Pesquisa e Desenvolvimento Tecnologico); FIOCRUZ/CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); PAEF (Portuguese: Projeto de Acoes Estrategicas para Desenvolvimento e Fortalecimento dos Laboratorios Credenciados e das Areas de Apoio a Pesquisa do IOC); PAPES VI/CNPq/Fiocruz(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	PS was a postgraduate student sponsored by FIOCRUZ/CAPES (in Portuguese: Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, number 16.11.38.106). KC and TL-C were postgraduate students sponsored by FIOCRUZ/CNPq (in Portuguese: Conselho Nacional de Pesquisa e Desenvolvimento Tecnologico, numbers 18.08.38.140 and 18.08.18.013 respectively). MMe and JL were postgraduate student sponsored by FIOCRUZ/CNPq, numbers 15.06.38.062 and 18.03.37.105, respectively. MMo (process 313657/2018-1), ES (process 305105/2019-1), FL (process 31633/2017-7), and RL (process 309853/2019-2) are fellows sponsored by CNPq. This investigation received financial support from PAEF (in Portuguese: Projeto de Acoes Estrategicas para Desenvolvimento e Fortalecimento dos Laboratorios Credenciados e das Areas de Apoio a Pesquisa do IOC, process number IOC-023-FIO-18-2-41, MMo) and PAPES VI/CNPq/Fiocruz (process number 422.103/2017-9, DE). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Guerreiro LTA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064748; Silva SRB, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0651-5; Bour-Jordan H, 2011, IMMUNOL REV, V241, P180, DOI 10.1111/j.1600-065X.2011.01011.x; Boyd SD, 2013, CURR OPIN IMMUNOL, V25, P511, DOI 10.1016/j.coi.2013.07.007; Britton WJ, 2004, LANCET, V363, P1209, DOI 10.1016/S0140-6736(04)15952-7; Chaves AT, 2018, IMMUNOBIOLOGY, V223, P397, DOI 10.1016/j.imbio.2017.11.002; Chen XY, 2018, CELL MOL IMMUNOL, V15, P734, DOI 10.1038/cmi.2017.153; Cunha LL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01748; Dagur PK, 2010, MOL IMMUNOL, V47, P943, DOI 10.1016/j.molimm.2009.11.009; de Carvalho JC, 2018, MICROB PATHOGENESIS, V125, P230, DOI 10.1016/j.micpath.2018.09.011; Oliveira JSD, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007709; Derhovanessian E, 2009, CURR OPIN IMMUNOL, V21, P440, DOI 10.1016/j.coi.2009.05.012; Do JS, 2016, MUCOSAL IMMUNOL, V9, P137, DOI 10.1038/mi.2015.45; EFFROS RB, 1994, EXP GERONTOL, V29, P601, DOI 10.1016/0531-5565(94)90073-6; Esensten JH, 2016, IMMUNITY, V44, P973, DOI 10.1016/j.immuni.2016.04.020; Foss NT, 2012, MEM I OSWALDO CRUZ, V107, P28, DOI 10.1590/S0074-02762012000900006; Fulop T, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00271; Goronzy JJ, 2015, J IMMUNOL, V194, P4073, DOI 10.4049/jimmunol.1500046; Graydon CG, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007429; Gupta S, 2004, EXP GERONTOL, V39, P545, DOI 10.1016/j.exger.2003.08.013; Hadrup SR, 2006, J IMMUNOL, V176, P2645, DOI 10.4049/jimmunol.176.4.2645; Hakim FT, 2007, TISSUE ANTIGENS, V70, P179, DOI 10.1111/j.1399-0039.2007.00891.x; Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010; Huff WX, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112810; Bini EI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093831; Lages CS, 2008, J IMMUNOL, V181, P1835, DOI 10.4049/jimmunol.181.3.1835; Liu QL, 2015, CELL MOL IMMUNOL, V12, P708, DOI 10.1038/cmi.2014.118; Liu Z, 1998, INT IMMUNOL, V10, P775, DOI 10.1093/intimm/10.6.775; Lockwood DN, 2012, INT HEALTH, V4, P77, DOI 10.1016/j.inhe.2011.09.006; Matos TS, 2019, AN BRAS DERMATOL, V94, P243, DOI 10.1590/abd1806-4841.20198067; McElhaney JE, 2009, CURR OPIN IMMUNOL, V21, P418, DOI 10.1016/j.coi.2009.05.023; McKinney EF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20594-2; Nguyen LT, 2015, NAT REV IMMUNOL, V15, P45, DOI 10.1038/nri3790; Nikolich-Zugich J, 2008, NAT REV IMMUNOL, V8, P512, DOI 10.1038/nri2318; Nobre ML, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005364; Palermo MD, 2012, MEM I OSWALDO CRUZ, V107, P167, DOI 10.1590/S0074-02762012000900024; Pera A, 2018, THERANOSTICS, V8, P4509, DOI 10.7150/thno.27428; Perkins JR, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-296; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pinzan CF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010757; R Core Team, 2020, **DATA OBJECT**; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Reiser J, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/8941260; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; Ruijter JM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp045; Rutledge RG, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-47; Sadhu S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00604; Schwanninger Angelika, 2008, Immun Ageing, V5, P14, DOI 10.1186/1742-4933-5-14; Scollard DM, 2015, CLIN DERMATOL, V33, P46, DOI 10.1016/j.clindermatol.2014.07.008; Scollard DM, 2006, CLIN MICROBIOL REV, V19, P338, DOI 10.1128/CMR.19.2.338-381.2006; Silva PHL, 2019, AM J TROP MED HYG, V100, P377, DOI 10.4269/ajtmh.18-0517; Snider H, 2009, NEUROIMMUNOMODULAT, V16, P106, DOI 10.1159/000180265; Sridevi K, 2004, INT IMMUNOPHARMACOL, V4, P1, DOI 10.1016/j.intimp.2003.09.001; Teteloshvili N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01400; Tsaknaridis L, 2003, J NEUROSCI RES, V74, P296, DOI 10.1002/jnr.10766; Vallejo AN, 1999, J IMMUNOL, V162, P6572; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vlad G, 2005, J IMMUNOL, V174, P5907, DOI 10.4049/jimmunol.174.10.5907; Wikby A, 2008, BIOGERONTOLOGY, V9, P299, DOI 10.1007/s10522-008-9138-6; World Health Organization (WHO), 1995, GUIDE ELIMINATE LEPR, V1st	60	1	1	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2021	12								647385	10.3389/fimmu.2021.647385	http://dx.doi.org/10.3389/fimmu.2021.647385			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RB9NV	33777045	gold, Green Published			2022-12-18	WOS:000632432500001
J	Metzemaekers, M; Salama, SA; Vandooren, J; Mortier, A; Janssens, R; Vandendriessche, S; Ganseman, E; Martens, E; Gouwy, M; Neerinckx, B; Verschueren, P; De Somer, L; Wouters, C; Struyf, S; Opdenakker, G; Van Damme, J; Proost, P				Metzemaekers, Mieke; Abouelasrar Salama, Sara; Vandooren, Jennifer; Mortier, Anneleen; Janssens, Rik; Vandendriessche, Sofie; Ganseman, Eva; Martens, Erik; Gouwy, Mieke; Neerinckx, Barbara; Verschueren, Patrick; De Somer, Lien; Wouters, Carine; Struyf, Sofie; Opdenakker, Ghislain; Van Damme, Jo; Proost, Paul			From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8	FRONTIERS IN IMMUNOLOGY			English	Article						chemokine; CXCL8; neutrophil; ELISA; proteolysis; posttranslational modification; arthritis; top-down mass spectrometry	NEUTROPHIL CHEMOTACTIC FACTOR; POSTTRANSLATIONAL MODIFICATIONS; CHEMOKINE ACTIVITY; HOST-DEFENSE; INTERLEUKIN-8; IDENTIFICATION; PURIFICATION; QUANTITATION; INTERFERON; RECEPTORS	With ELISAs one detects the ensemble of immunoreactive molecules in biological samples. For biomolecules undergoing proteolysis for activation, potentiation or inhibition, other techniques are necessary to study biology. Here we develop methodology that combines immunosorbent sample preparation and nano-scale liquid chromatography-tandem mass spectrometry (nano-LC-MS/MS) for proteoform analysis (ISTAMPA) and apply this to the aglycosyl chemokine CXCL8. CXCL8, the most powerful human chemokine with neutrophil chemotactic and -activating properties, occurs in different NH2-terminal proteoforms due to its susceptibility to site-specific proteolytic modification. Specific proteoforms display up to 30-fold enhanced activity. The immunosorbent ion trap top-down mass spectrometry-based approach for proteoform analysis allows for simultaneous detection and quantification of full-length CXCL8(1-77), elongated CXCL8(-2-77) and all naturally occurring truncated CXCL8 forms in biological samples. For the first time we demonstrate site-specific proteolytic activation of CXCL8 in synovial fluids from patients with chronic joint inflammation and address the importance of sample collection and processing.	[Metzemaekers, Mieke; Abouelasrar Salama, Sara; Mortier, Anneleen; Janssens, Rik; Vandendriessche, Sofie; Ganseman, Eva; Gouwy, Mieke; Struyf, Sofie; Van Damme, Jo; Proost, Paul] Katholieke Univ Leuven, Rega Inst, Dept Microbiol Immunol & Transplantat, Lab Mol Immunol, Leuven, Belgium; [Vandooren, Jennifer; Martens, Erik; De Somer, Lien; Wouters, Carine; Opdenakker, Ghislain] Katholieke Univ Leuven, Rega Inst, Dept Microbiol Immunol & Transplantat, Lab Immunobiol, Leuven, Belgium; [Neerinckx, Barbara; Verschueren, Patrick] Katholieke Univ Leuven, Skeletal Biol & Engn Res Ctr, Dept Dev & Regenerat, Leuven, Belgium	KU Leuven; KU Leuven; KU Leuven	Proost, P (corresponding author), Katholieke Univ Leuven, Rega Inst, Dept Microbiol Immunol & Transplantat, Lab Mol Immunol, Leuven, Belgium.	paul.proost@kuleuven.be	Metzemaekers, Mieke/U-4989-2017; Vandooren, Jennifer/O-6424-2018; Martens, Erik/F-9214-2015; Opdenakker, Ghislain/Q-3130-2017; Gouwy, Mieke/I-4642-2018; Proost, Paul/V-3052-2017	Metzemaekers, Mieke/0000-0002-8548-0124; Vandooren, Jennifer/0000-0002-7157-3370; Neerinckx, Barbara/0000-0001-9220-9466; De Somer, Lien/0000-0002-8488-5090; Mortier, Anneleen/0000-0002-9662-674X; Ganseman, Eva/0000-0002-2305-7451; Opdenakker, Ghislain/0000-0003-1714-2294; Wouters, Carine/0000-0002-6426-8845; Gouwy, Mieke/0000-0002-4035-4810; Proost, Paul/0000-0002-0133-5545; Abouelasrar Salama, Sara/0000-0002-0484-7765	Research Foundation-Flanders (FWO-Vlaanderen) [G.0808.18N, G0F7519N]; KU Leuven [C16/17/010]; Rega Foundation; European Union's Horizon 2020 research and innovation program (ImmunAID) [779295]; L'Oreal-UNESCO for Women in Science initiative; FWO-Vlaanderen	Research Foundation-Flanders (FWO-Vlaanderen)(FWO); KU Leuven(KU Leuven); Rega Foundation; European Union's Horizon 2020 research and innovation program (ImmunAID); L'Oreal-UNESCO for Women in Science initiative(L'Oreal Group); FWO-Vlaanderen(FWO)	This work was funded by the Research Foundation-Flanders (FWO-Vlaanderen) (G.0808.18N and G0F7519N), a C1 grant (C16/17/010) from KU Leuven, the Rega Foundation and the European Union's Horizon 2020 research and innovation program (ImmunAID; grant agreement No 779295). MM obtained a PhD fellowship supported by the L'Oreal-UNESCO for Women in Science initiative and the FWO-Vlaanderen. FWO-Vlaanderen also provided a PhD-SB fellowship to SV and postdoctoral research mandates to JVa and AM.	Anderson NL, 2004, J PROTEOME RES, V3, P235, DOI 10.1021/pr034086h; Ankney JA, 2018, ANNU REV ANAL CHEM, V11, P49, DOI 10.1146/annurev-anchem-061516-045357; Bachelerie F, 2014, PHARMACOL REV, V66, P1, DOI 10.1124/pr.113.007724; Baggiolini M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00285; BILLIAU A, 1977, ANTIMICROB AGENTS CH, V12, P11, DOI 10.1128/AAC.12.1.11; Broz P, 2010, CELL HOST MICROBE, V8, P471, DOI 10.1016/j.chom.2010.11.007; Casrouge A, 2011, J CLIN INVEST, V121, P308, DOI 10.1172/JCI40594; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; Cupp-Sutton KA, 2020, MOL OMICS, V16, P91, DOI 10.1039/c9mo00154a; Cynis H, 2011, EMBO MOL MED, V3, P545, DOI 10.1002/emmm.201100158; da Silva RB, 2015, NAT IMMUNOL, V16, P850, DOI 10.1038/ni.3201; de Jager W, 2007, ANN RHEUM DIS, V66, P589, DOI 10.1136/ard.2006.061853; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GREGORY H, 1988, BIOCHEM BIOPH RES CO, V151, P883, DOI 10.1016/S0006-291X(88)80364-4; Huttenlocher A, 2015, CURR OPIN RHEUMATOL, V27, P500, DOI 10.1097/BOR.0000000000000204; Jarvis James N, 2007, Pediatr Rheumatol Online J, V5, P13, DOI 10.1186/1546-0096-5-13; Liew PX, 2019, PHYSIOL REV, V99, P1223, DOI 10.1152/physrev.00012.2018; Liu Q, 2016, CYTOKINE GROWTH F R, V31, P61, DOI 10.1016/j.cytogfr.2016.08.002; Loos T, 2009, METHOD ENZYMOL, V461, P3, DOI 10.1016/S0076-6879(09)05401-9; Metzemaekers M, 2021, EUR J IMMUNOL, V51, P157, DOI 10.1002/art.41605; Metzemaekers M, 2020, J LEUKOCYTE BIOL, V107, P1167, DOI 10.1002/JLB.3AB0220-470R; Metzemaekers M, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01970; Metzemaekers M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00483; Mortier A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023913; Mortier A, 2008, PHARMACOL THERAPEUT, V120, P197, DOI 10.1016/j.pharmthera.2008.08.006; Musse AA, 2006, P NATL ACAD SCI USA, V103, P4422, DOI 10.1073/pnas.0509158103; O'Neil LJ, 2019, TRENDS MOL MED, V25, P215, DOI 10.1016/j.molmed.2018.12.008; Opdenakker G, 1998, IMMUNOL TODAY, V19, P182, DOI 10.1016/S0167-5699(97)01243-7; Opdenakker G, 2020, TRENDS IMMUNOL, V41, P367, DOI 10.1016/j.it.2020.03.004; Opdenakker G, 2016, TRENDS MOL MED, V22, P746, DOI 10.1016/j.molmed.2016.07.002; PROOST P, 1993, J IMMUNOL, V150, P1000; Proost P, 2008, J EXP MED, V205, P2085, DOI 10.1084/jem.20080305; Proost P, 2017, J AUTOIMMUN, V85, P45, DOI 10.1016/j.jaut.2017.06.009; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Russo RC, 2014, EXPERT REV CLIN IMMU, V10, P593, DOI 10.1586/1744666X.2014.894886; Schaffer LV, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800361; Schellekens GA, 1998, J CLIN INVEST, V101, P273, DOI 10.1172/JCI1316; SCHRODER JM, 1989, J IMMUNOL, V142, P244; SCHRODER JM, 1990, J IMMUNOL, V144, P2223; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; Vacchini A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123768; Vagesjo E, 2018, P NATL ACAD SCI USA, V115, P1895, DOI 10.1073/pnas.1716580115; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; VANDAMME J, 1989, EUR J IMMUNOL, V19, P1189; VANDAMME J, 1985, NATURE, V314, P266, DOI 10.1038/314266a0; VANDAMME J, 1988, J EXP MED, V167, P1364, DOI 10.1084/jem.167.4.1364; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; Wang WX, 2014, J AM SOC MASS SPECTR, V25, P614, DOI 10.1007/s13361-013-0822-7; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1989, MOL IMMUNOL, V26, P87	52	1	1	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2021	12								644725	10.3389/fimmu.2021.644725	http://dx.doi.org/10.3389/fimmu.2021.644725			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RB9CZ	33777041	Green Published, gold			2022-12-18	WOS:000632403800001
J	Miranda, GS; Resende, SD; Cardoso, DT; Camelo, GMA; Silva, JKAO; de Castro, VN; Geiger, SM; Carneiro, M; Negrao-Correa, D				Miranda, Guilherme Silva; Resende, Samira Diniz; Cardoso, Diogo Tavares; Camelo, Genil Mororo Araujo; Silva, Jeferson Kelvin Alves Oliveira; de Castro, Vanessa Normandio; Geiger, Stefan Michael; Carneiro, Mariangela; Negrao-Correa, Deborah			Previous History of American Tegumentary Leishmaniasis Alters Susceptibility and Immune Response Against Schistosoma mansoni Infection in Humans	FRONTIERS IN IMMUNOLOGY			English	Article						schistosomiasis; tegumentary leishmaniasis; human population; susceptibility; immune response	MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; CUTANEOUS LEISHMANIASIS; GRANULOMA-FORMATION; HELMINTH INFECTIONS; TH2 CYTOKINES; NITRIC-OXIDE; IN-VIVO; IMMUNOPATHOLOGY; BRAZILIENSIS; RESISTANCE	Schistosomiasis and Leishmaniasis are chronic parasitic diseases with high prevalence in some tropical regions and, due to their wide distribution, a risk of co-infections is present in some areas. Nevertheless, the impact of this interaction on human populations is still poorly understood. Thus, the current study evaluated the effect of previous American Tegumentary Leishmaniasis (ATL) on the susceptibility and immune response to Schistosoma mansoni infection in residents from a rural community in Northern of Minas Gerais state, Brazil, an area endemic for both parasitic infections. The participants answered a socioeconomic questionnaire and provided stool and blood samples for parasitological and immunological evaluations. Stool samples were examined by a combination of parasitological techniques to identify helminth infections, especially S. mansoni eggs. Blood samples were used for hemograms and to measure the serum levels of cytokines and chemokines. Reports on previous ATL were obtained through interviews, clinical evaluation forms, and medical records. S. mansoni infection was the most prevalent parasitic infection in the study population (46%), and the majority of the infected individuals had a very low parasite burden. In the same population, 93 individuals (36.2%) reported previous ATL, and the prevalence of S. mansoni infection among these individuals was significantly higher than among individuals with no ATL history. A multiple logistic regression model revealed that S. mansoni infection was positively associated with higher levels of CCL3 and CCL17, and a higher frequency of IL-17 responders. Moreover, this model demonstrated that individuals with an ATL history had a 2-fold higher probability to be infected with S. mansoni (OR = 2.0; 95% CI 1.04-3.68). Among S. mansoni-infected individuals, the logistic regression demonstrated that a previous ATL history was negatively associated with the frequency of IL-17 responders and CXCL10 higher responders, but positively associated with higher IL-27 responders. Altogether, our data suggest that previous ATL may alter the susceptibility and the immune response in S. mansoni-infected individuals, which may likely affect the outcome of schistosomiasis and the severity of the disease in humans.	[Miranda, Guilherme Silva; Resende, Samira Diniz; Camelo, Genil Mororo Araujo; Silva, Jeferson Kelvin Alves Oliveira; Negrao-Correa, Deborah] Univ Fed Minas Gerais, Inst Biol Sci, Dept Parasitol, Lab Immunohelminthol & Schistosomiasis, Belo Horizonte, MG, Brazil; [Miranda, Guilherme Silva] Inst Educ Sci & Technol Maranhao, Dept Biol, Lab Biol, Sao Raimundo Mangabeiras, Brazil; [Cardoso, Diogo Tavares; de Castro, Vanessa Normandio; Geiger, Stefan Michael] Univ Fed Minas Gerais, Inst Biol Sci, Dept Parasitol, Lab Intestinal Helminthiasis, Belo Horizonte, MG, Brazil; [Carneiro, Mariangela] Univ Fed Minas Gerais, Inst Biol Sci, Dept Parasitol, Lab Epidemiol Infect & Parasit Dis, Belo Horizonte, MG, Brazil	Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais	Negrao-Correa, D (corresponding author), Univ Fed Minas Gerais, Inst Biol Sci, Dept Parasitol, Lab Immunohelminthol & Schistosomiasis, Belo Horizonte, MG, Brazil.	denegrao@icb.ufmg.br	Geiger, Stefan M/E-6748-2016; SILVA, JEFERSON KELVIN ALVES DE OLIVEIRA KELVIN ALVES/AAW-7012-2021	SILVA, JEFERSON KELVIN ALVES DE OLIVEIRA KELVIN ALVES/0000-0003-4194-7578; Miranda, Guilherme/0000-0003-3763-2776; Camelo Junior, Genil/0000-0002-0501-2508	National Brazilian Research Council (CNPq) [404405/2012-6]; Fundacao de Amparo a Pesquisa de Minas Gerais (FAPEMIG), within the program PPSUS [APQ 04237-17, APQ 01637-17]; Fundacao de Amparo a Pesquisa e ao Desenvolvimento Cientifico e Tecnologico do Maranhao (FAPEMA)	National Brazilian Research Council (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa de Minas Gerais (FAPEMIG), within the program PPSUS(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); Fundacao de Amparo a Pesquisa e ao Desenvolvimento Cientifico e Tecnologico do Maranhao (FAPEMA)(Fundacao de Amparo a Pesquisa e Desenvolvimento Cientifico do Maranhao (FAPEMA))	The authors received financial support from the National Brazilian Research Council (CNPq) for research in neglected tropical diseases, DECIT program 2012 #404405/2012-6. DNC received financial support from Fundacao de Amparo a Pesquisa de Minas Gerais (FAPEMIG), within the program PPSUS grant#APQ 04237-17 and APQ 01637-17. Our grants can only be used to pay reagents, equipment and field trips, but they cannot be used to pay publication fees. GM received financial from Fundacao de Amparo a Pesquisa e ao Desenvolvimento Cientifico e Tecnologico do Maranhao (FAPEMA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abath FGC, 2006, TRENDS PARASITOL, V22, P85, DOI 10.1016/j.pt.2005.12.004; Allen JE, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002003; Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; AMIRI P, 1992, NATURE, V356, P604, DOI 10.1038/356604a0; Antonelli A, 2014, AUTOIMMUN REV, V13, P272, DOI 10.1016/j.autrev.2013.10.010; Araujo MI, 1996, EUR J IMMUNOL, V26, P1399, DOI 10.1002/eji.1830260633; Azeredo-Coutinho RBG, 2016, ACTA TROP, V154, P42, DOI 10.1016/j.actatropica.2015.10.015; Barron L, 2011, AM J PHYSIOL-GASTR L, V300, pG723, DOI 10.1152/ajpgi.00414.2010; Bittar RC, 2007, MEM I OSWALDO CRUZ, V102, P625, DOI 10.1590/S0074-02762007005000069; BUTTERWORTH AE, 1994, TROP GEOGR MED, V46, P197; Campos TM, 2020, J INFECT DIS, V221, P973, DOI 10.1093/infdis/jiz538; Cardoso DT, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3940-4; Castellano LR, 2009, HUM IMMUNOL, V70, P383, DOI 10.1016/j.humimm.2009.01.007; Castro VN, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02975; Chalin A, 2018, CYTOKINE, V111, P500, DOI 10.1016/j.cyto.2018.05.029; Cheever AW, 2000, IMMUNOL TODAY, V21, P465, DOI 10.1016/S0167-5699(00)01626-1; Coelho PMZ, 2009, MEM I OSWALDO CRUZ, V104, P720, DOI 10.1590/S0074-02762009000500010; COELHO PMZ, 1980, T ROY SOC TROP MED H, V74, P141, DOI 10.1016/0035-9203(80)90038-3; Colley DG, 2014, PARASITE IMMUNOL, V36, P347, DOI 10.1111/pim.12087; Da Silva PLN., 2014, J H SCI I, V32, P38; Davies SJ, 2005, INT J PARASITOL, V35, P851, DOI 10.1016/j.ijpara.2005.02.017; Davies SJ, 2004, INT J PARASITOL, V34, P27, DOI 10.1016/j.ijpara.2003.10.010; de Jesus AR, 2002, J INFECT DIS, V185, P98, DOI 10.1086/324668; deAndres B, 1997, BLOOD, V89, P3826, DOI 10.1182/blood.V89.10.3826.3826_3826_3836; DUNNE DW, 1992, EUR J IMMUNOL, V22, P1483, DOI 10.1002/eji.1830220622; Dunne DW, 1999, MICROBES INFECT, V1, P553, DOI 10.1016/S1286-4579(99)80095-1; Eltayeb NM, 2013, ASIAN PAC J TROP MED, V6, P119, DOI 10.1016/S1995-7645(13)60006-1; Falcao PL, 2002, J INFECT DIS, V186, P1696, DOI 10.1086/345370; Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261; Friedman JF, 2005, TRENDS PARASITOL, V21, P386, DOI 10.1016/j.pt.2005.06.006; Gatlin MR, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000375; Geiger SM, 2013, TROP MED INT HEALTH, V18, P750, DOI 10.1111/tmi.12095; Grant AV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035863; Gregorio AW, 2019, J EUR ACAD DERMATOL, V33, P1781, DOI 10.1111/jdv.15521; GRZYCH JM, 1991, J IMMUNOL, V146, P1322; Guerra Jorge Augusto de Oliveira, 2006, Cad. Saúde Pública, V22, P2319, DOI 10.1590/S0102-311X2006001100006; GUEVARA P, 1993, LANCET, V341, P1341, DOI 10.1016/0140-6736(93)90845-8; Haddad F., 1996, MEM I OSWALDO CRUZ, V91, P185; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; Hams E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00089; He P, 2018, INFECT DIS POVERTY, V7, DOI 10.1186/s40249-018-0390-y; Helmy Ahmed Hazem I., 2005, Journal of the Egyptian Society of Parasitology, V35, P731; Hesse M, 2004, J IMMUNOL, V172, P3157, DOI 10.4049/jimmunol.172.5.3157; HIATT RA, 1980, J INFECT DIS, V142, P665, DOI 10.1093/infdis/142.5.665; Hoffman W. A., 1934, Puerto Rico Journal of Public Health & Tropical Medicine, V9, P283; Hofstede SN, 2014, ACTA TROP, V140, P68, DOI 10.1016/j.actatropica.2014.08.003; Hogg KG, 2003, INFECT IMMUN, V71, P3563, DOI 10.1128/IAI.71.6.3563-3571.2003; Hotez PJ, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000412; Jakubzick C, 2004, AM J PATHOL, V165, P1211, DOI 10.1016/S0002-9440(10)63381-0; Kamdem SD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02827; Kastelein RA, 2007, ANNU REV IMMUNOL, V25, P221, DOI 10.1146/annurev.immunol.22.012703.104758; Kato K., 1954, JAPAN J PARASITOL, V3, P5; Katz N., 2003, CIENC CULT, V55, P38; Khayeka-Wandabwa C, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-244; Krauth SJ, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1165-y; La Flamme AC, 2002, PARASITE IMMUNOL, V24, P339, DOI 10.1046/j.1365-3024.2002.00473.x; Lambertucci JR, 2007, REV SOC BRAS MED TRO, V40, P599, DOI 10.1590/S0037-86822007000500023; Lenzi HL, 1997, MEM I OSWALDO CRUZ, V92, P19, DOI 10.1590/S0074-02761997000800005; Lenzi HL, 1998, MEM I OSWALDO CRUZ, V93, P141, DOI 10.1590/S0074-02761998000700020; Liang YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042490; LIEW FY, 1990, J IMMUNOL, V144, P4794; Lima Filho JHC, 1998, ARQ CATARINENSES MED, V27, P25; Lundy SK, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00039; Magalhaes FD, 2020, PARASITOLOGY, V147, P1140, DOI 10.1017/S003118202000089X; Malaquias LCC, 1997, SCAND J IMMUNOL, V46, P393, DOI 10.1046/j.1365-3083.1997.d01-136.x; Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Maspi N, 2016, PATHOG GLOB HEALTH, V110, P247, DOI 10.1080/20477724.2016.1232042; Mazigo HD, 2013, INFECT DIS POVERTY, V2, DOI 10.1186/2049-9957-2-2; Mbow M, 2013, J INFECT DIS, V207, P186, DOI 10.1093/infdis/jis654; Mukbel RM, 2007, AM J TROP MED HYG, V76, P669, DOI 10.4269/ajtmh.2007.76.669; Negrao-Correa D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088042; Novoa R, 2011, PARASITE IMMUNOL, V33, P132, DOI 10.1111/j.1365-3024.2010.01256.x; Nylen S, 2012, PARASITE IMMUNOL, V34, P551, DOI 10.1111/pim.12007; O'Neal SE, 2007, J INFECT DIS, V195, P142, DOI 10.1086/509808; Oliveira LFA, 2006, INFECT IMMUN, V74, P1215, DOI 10.1128/IAI.74.2.1215-1221.2006; Oliveira WJ, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006232; Pasparakis M, 2014, NAT REV IMMUNOL, V14, P289, DOI 10.1038/nri3646; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; Pellegrino J., 1972, REV I MED TROP SAO P, V14, P399; Resende SD, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03158; Oliveira JLR, 2018, SCAND J IMMUNOL, V87, DOI 10.1111/sji.12642; Rosenfeld Luiz Gastão, 2019, Rev. bras. epidemiol., V22, pE190003.SUPL.2, DOI 10.1590/1980-549720190003.supl.2; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Rutitzky LI, 2011, EUR J IMMUNOL, V41, P2677, DOI 10.1002/eji.201041327; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Scholte RGC, 2014, ACTA TROP, V132, P57, DOI 10.1016/j.actatropica.2013.12.007; Schubach A, 1998, J INFECT DIS, V178, P911, DOI 10.1086/515355; Schwartz C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02492; Sekiya T, 2002, ALLERGY, V57, P173, DOI 10.1034/j.1398-9995.2002.1s3256.x; Shainheit MG, 2007, INFECT IMMUN, V75, P3169, DOI 10.1128/IAI.01053-06; Sombetzki M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00861; Sousa-Pereira SR, 2006, PARASITE IMMUNOL, V28, P473, DOI 10.1111/j.1365-3024.2006.00896.x; Souza ALS, 2005, INFECT IMMUN, V73, P2515, DOI 10.1128/IAI.73.4.2515-2523.2005; Stadecker MJ, 1998, PARASITE IMMUNOL, V20, P217, DOI 10.1046/j.1365-3024.1998.00150.x; Teixeira CF, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000073; Unger A, 2009, AM J TROP MED HYG, V80, P574, DOI 10.4269/ajtmh.2009.80.574; von Stebut E, 2003, J EXP MED, V198, P191, DOI 10.1084/jem.20030159; Wang B, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003434; Weerakoon KGAD, 2015, CLIN MICROBIOL REV, V28, P939, DOI 10.1128/CMR.00137-14; WHO, 2011, HELMINTH CONTROL IN SCHOOL-AGE CHILDREN: A GUIDE FOR MANAGERS OF CONTROL PROGRAMMES, SECOND EDITION, P1; WHO, 2018, GLOB HLTH EST 2019 D	103	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2021	12								630934	10.3389/fimmu.2021.630934	http://dx.doi.org/10.3389/fimmu.2021.630934			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RB9KR	33777015	Green Published, gold			2022-12-18	WOS:000632424200001
J	Kohn, M; Lanfermann, C; Laudeley, R; Glage, S; Rheinheimer, C; Klos, A				Kohn, Martin; Lanfermann, Christian; Laudeley, Robert; Glage, Silke; Rheinheimer, Claudia; Klos, Andreas			Complement and Chlamydia psittaci: Early Complement-Dependent Events Are Important for DC Migration and Protection During Mouse Lung Infection	FRONTIERS IN IMMUNOLOGY			English	Article						complement; Chlamydia; intracellular; adaptive immunity; C3a; dendritic cells; cobra venom factor		The zoonotic intracellular bacterium Chlamydia psittaci causes life-threatening pneumonia in humans. During mouse lung infection, complement factor C3 and the anaphylatoxin C3a augment protection against C. psittaci by a so far unknown mechanism. To clarify how complement contributes to the early, innate and the late, specific immune response and resulting protection, this study addresses the amount of C3, the timing when its presence is required as well as the anaphylatoxin receptor(s) mediating its effects and the complement-dependent migration of dendritic cells. Challenge experiments with C. psittaci on various complement KO mice were combined with transient decomplementation by pharmacological treatment, as well as the analysis of in vivo dendritic cells migration. Our findings reveal that a plasma concentration of C3 close to wildtype levels was required to achieve full protection. The diminished levels of C3 of heterozygote C3(+/-) mice permitted already relative effective protection and improved survival as compared to C3(-/-) mice, but overall recovery of these animals was delayed. Complement was in particular required during the first days of infection. However, additionally, it seems to support protection at later stages. Migration of CD103(+) dendritic cells from the infected lung to the draining lymph node-as prerequisite of antigen presentation-depended on C3 and C3aR and/or C5aR. Our results provide unique mechanistic insight in various aspects of complement-dependent immune responses under almost identical, rather physiological experimental conditions. Our study contributes to an improved understanding of the role of complement, and C3a in particular, in infections by intracellular bacteria.	[Kohn, Martin; Lanfermann, Christian; Laudeley, Robert; Rheinheimer, Claudia; Klos, Andreas] Med Sch Hannover, Inst Med Microbiol & Hosp Epidemiol, Hannover, Germany; [Glage, Silke] Med Sch Hannover, Inst Lab Anim Sci, Hannover, Germany	Hannover Medical School; Hannover Medical School	Klos, A (corresponding author), Med Sch Hannover, Inst Med Microbiol & Hosp Epidemiol, Hannover, Germany.	klos.andreas@mh-hannover.de			Deutsche Forschungsgemeinschaft (DFG) [KL-603/10-1]; Hannover Medical School	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Hannover Medical School	This research project was funded by the Deutsche Forschungsgemeinschaft (DFG): KL-603/10-1. MK was partially funded by the ZIB Ph.D. program from the Hannover Medical School.	Agrawal P, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01117; Alvarez D, 2008, IMMUNITY, V29, P325, DOI 10.1016/j.immuni.2008.08.006; [Anonymous], 2000, MMWR Recomm Rep, V49, P3; Baud D, 2011, CLIN MICROBIOL INFEC, V17, P1312, DOI 10.1111/j.1469-0691.2011.03604.x; Bode J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050327; Cheong HC, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7050146; Cooper P D, 1995, Pharm Biotechnol, V6, P559; de la Maza LM, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00543-16, 10.1128/cvi.00543-16]; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DESPREZ RM, 1975, INFECT IMMUN, V11, P1235, DOI 10.1128/IAI.11.6.1235-1243.1975; Dumke R, 2015, EMERG INFECT DIS, V21, P426, DOI 10.3201/eid2103.140927; Dutow P, 2014, J INFECT DIS, V209, P1269, DOI 10.1093/infdis/jit640; Dutow P, 2013, INFECT IMMUN, V81, P3366, DOI 10.1128/IAI.00334-13; Elwell C, 2016, NAT REV MICROBIOL, V14, P385, DOI 10.1038/nrmicro.2016.30; Engelke C, 2014, J IMMUNOL, V193, P5387, DOI 10.4049/jimmunol.1400080; Fucikova J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02393; Ghannam A, 2014, MOL IMMUNOL, V58, P98, DOI 10.1016/j.molimm.2013.11.010; Goellner S, 2006, INFECT IMMUN, V74, P4801, DOI 10.1128/IAI.01487-05; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; HALL RT, 1993, INFECT IMMUN, V61, P1829, DOI 10.1128/IAI.61.5.1829-1834.1993; Hammerschlag MR, 2000, EUR RESPIR J, V16, P1001, DOI 10.1183/09031936.00.16510010; Harkinezhad T, 2009, VET MICROBIOL, V135, P68, DOI 10.1016/j.vetmic.2008.09.046; Hess C, 2016, IMMUNITY, V45, P240, DOI 10.1016/j.immuni.2016.08.003; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; Ing M, 2018, MOL IMMUNOL, V97, P1, DOI 10.1016/j.molimm.2018.02.018; JOHNSON AP, 1983, BRIT J VENER DIS, V59, P369; Juretzek T, 2007, INT J ANTIMICROB AG, V29, pS638, DOI 10.1016/S0924-8579(07)72043-5; Kandasamy M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003115; Karsten CM, 2017, J IMMUNOL, V199, P3234, DOI 10.4049/jimmunol.1700710; Kemper C, 2007, NAT REV IMMUNOL, V7, P9, DOI 10.1038/nri1994; Kildsgaard J, 2000, J IMMUNOL, V165, P5406, DOI 10.4049/jimmunol.165.10.5406; Killick J, 2018, SEMIN IMMUNOPATHOL, V40, P37, DOI 10.1007/s00281-017-0644-y; Klos A, 2013, PHARMACOL REV, V65, P500, DOI 10.1124/pr.111.005223; Klos A, 2009, MOL IMMUNOL, V46, P2753, DOI 10.1016/j.molimm.2009.04.027; Knittler MR, 2014, INT J MED MICROBIOL, V304, P877, DOI 10.1016/j.ijmm.2014.06.010; Kolev M, 2015, IMMUNITY, V42, P1033, DOI 10.1016/j.immuni.2015.05.024; Kollessery G, 2011, VACCINE, V29, P5904, DOI 10.1016/j.vaccine.2011.06.070; Kopf M, 2002, NAT MED, V8, P373, DOI 10.1038/nm0402-373; Laroucau K, 2009, VET MICROBIOL, V135, P82, DOI 10.1016/j.vetmic.2008.09.048; Laumonnier Y, 2017, MOL IMMUNOL, V89, P44, DOI 10.1016/j.molimm.2017.05.019; Lausen M, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00087-20; Lausen M, 2018, MICROBES INFECT, V20, P328, DOI 10.1016/j.micinf.2018.04.004; Li K, 2011, MOL IMMUNOL, V48, P1121, DOI 10.1016/j.molimm.2011.02.003; LIN JSL, 1992, INFECT IMMUN, V60, P2547, DOI 10.1128/IAI.60.6.2547-2550.1992; Liu YJ, 2001, NAT IMMUNOL, V2, P585, DOI 10.1038/89726; Lubbers R, 2017, CLIN EXP IMMUNOL, V188, P183, DOI 10.1111/cei.12952; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257; Nakayama Y, 2009, J IMMUNOL, V183, P2921, DOI 10.4049/jimmunol.0801191; OSBORN MF, 1985, GENITOURIN MED, V61, P244; Peng Q, 2006, J IMMUNOL, V176, P3330, DOI 10.4049/jimmunol.176.6.3330; Quell KM, 2017, J IMMUNOL, V199, P688, DOI 10.4049/jimmunol.1700318; Sallenbach S, 2011, PEDIAT ALLERG IMM-UK, V22, P424, DOI 10.1111/j.1399-3038.2010.01104.x; Satpathy G, 2017, INDIAN J OPHTHALMOL, V65, P97, DOI 10.4103/ijo.IJO_870_16; Shekhar S, 2018, CELL MOL IMMUNOL, V15, P377, DOI 10.1038/cmi.2016.68; Sommer K, 2009, FEMS IMMUNOL MED MIC, V55, P206, DOI 10.1111/j.1574-695X.2008.00503.x; Stoermer KA, 2011, VIROLOGY, V411, P362, DOI 10.1016/j.virol.2010.12.045; Strainic MG, 2008, IMMUNITY, V28, P425, DOI 10.1016/j.immuni.2008.02.001; Strainic MG, 2013, NAT IMMUNOL, V14, P162, DOI 10.1038/ni.2499; Suresh M, 2003, J IMMUNOL, V170, P788, DOI 10.4049/jimmunol.170.2.788; Vogel CW, 2017, TOXINOLOGY, P345, DOI 10.1007/978-94-007-6410-1_4; Vogel CW, 2010, TOXICON, V56, P1198, DOI 10.1016/j.toxicon.2010.04.007; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; West EE, 2018, ANNU REV IMMUNOL, V36, P309, DOI 10.1146/annurev-immunol-042617-053245	64	1	1	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 9	2021	12								580594	10.3389/fimmu.2021.580594	http://dx.doi.org/10.3389/fimmu.2021.580594			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RA6WG	33767691	Green Published, gold			2022-12-18	WOS:000631556600001
J	Marcus, H; Thompson, E; Zhou, Y; Bailey, M; Donaldson, MM; Stanley, DA; Asiedu, C; Foulds, KE; Roederer, M; Moliva, JI; Sullivan, NJ				Marcus, Hadar; Thompson, Emily; Zhou, Yan; Bailey, Michael; Donaldson, Mitzi M.; Stanley, Daphne A.; Asiedu, Clement; Foulds, Kathryn E.; Roederer, Mario; Moliva, Juan, I; Sullivan, Nancy J.			Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates	FRONTIERS IN IMMUNOLOGY			English	Article						vaccine; Ebola; prime; boost; CD8(+); CD4(+); T-cell; non-human primates		Heterologous prime-boost immunization regimens are a common strategy for many vaccines. DNA prime rAd5-GP boost immunization has been demonstrated to protect non-human primates against a lethal challenge of Ebola virus, a pathogen that causes fatal hemorrhagic disease in humans. This protection correlates with antibody responses and is also associated with IFN gamma(+) TNF alpha(+) double positive CD8(+) T-cells. In this study, we compared single DNA vs. multiple DNA prime immunizations, and short vs. long time intervals between the DNA prime and the rAd5 boost to evaluate the impact of these different prime-boost strategies on vaccine-induced humoral and cellular responses in non-human primates. We demonstrated that DNA/rAd5 prime-boost strategies can be tailored to induce either CD4(+) T-cell or CD8(+) T-cell dominant responses while maintaining a high magnitude antibody response. Additionally, a single DNA prime immunization generated a stable memory response that could be boosted by rAd5 3 years later. These results suggest DNA/rAd5 prime-boost provides a flexible platform that can be fine-tuned to generate desirable T-cell memory responses.	[Marcus, Hadar; Thompson, Emily; Zhou, Yan; Bailey, Michael; Donaldson, Mitzi M.; Stanley, Daphne A.; Asiedu, Clement; Foulds, Kathryn E.; Roederer, Mario; Moliva, Juan, I; Sullivan, Nancy J.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Sullivan, NJ (corresponding author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	nsullivan@nih.gov			Intramural Research Program of the Vaccine Research Center, theNational Institute of Allergy and Infectious Diseases; National Institutes of Health	Intramural Research Program of the Vaccine Research Center, theNational Institute of Allergy and Infectious Diseases; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the Intramural Research Program of the Vaccine Research Center, theNational Institute of Allergy and Infectious Diseases, and the National Institutes of Health.	Amara RR, 2002, J VIROL, V76, P6138, DOI 10.1128/JVI.76.12.6138-6146.2002; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Aoki K, 1999, MOL MED, V5, P224, DOI 10.1007/BF03402119; Bakari M, 2011, VACCINE, V29, P8417, DOI 10.1016/j.vaccine.2011.08.001; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Barouch DH, 2001, J VIROL, V75, P2462, DOI 10.1128/JVI.75.5.2462-2467.2001; Casimiro DR, 2005, J VIROL, V79, P15547, DOI 10.1128/JVI.79.24.15547-15555.2005; Casimiro DR, 2003, J VIROL, V77, P6305, DOI 10.1128/JVI.77.11.6305-6313.2003; Centers for Disease Control and Prevention, 2018, OUTBR CHRON EB VIR D; Chege GK, 2013, J VIROL, V87, P5151, DOI 10.1128/JVI.03178-12; Chege GK, 2009, VACCINE, V27, P4857, DOI 10.1016/j.vaccine.2009.05.064; Churchyard GJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021225; Daniel DP, 2017, SWISS MED WKLY, V147, DOI 10.4414/smw.2017.14465; Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592; De Rosa SC, 2011, J IMMUNOL, V187, P3391, DOI 10.4049/jimmunol.1101421; Delany I, 2014, EMBO MOL MED, V6, P708, DOI 10.1002/emmm.201403876; Doria-Rose NA, 2003, J VIROL, V77, P11563, DOI 10.1128/JVI.77.21.11563-11577.2003; Fiedler M, 2013, J VIROL, V87, P7708, DOI 10.1128/JVI.00645-13; Fournillier A, 2013, J INFECT DIS, V208, P1008, DOI 10.1093/infdis/jit267; Geisbert TW, 2011, J VIROL, V85, P4222, DOI 10.1128/JVI.02407-10; Geisbert TW, 2010, J VIROL, V84, P10386, DOI 10.1128/JVI.00594-10; Goepfert PA, 2011, J INFECT DIS, V203, P610, DOI 10.1093/infdis/jiq105; Gudmundsdotter L, 2009, VACCINE, V27, P4468, DOI 10.1016/j.vaccine.2009.05.018; Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927; Hanke T, 1999, J VIROL, V73, P7524, DOI 10.1128/JVI.73.9.7524-7532.1999; Hayes P, 2013, CLIN VACCINE IMMUNOL, V20, P397, DOI 10.1128/CVI.00637-12; Hensley LE, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000904; Jaoko W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012873; Khurana S, 2013, J INFECT DIS, V208, P413, DOI 10.1093/infdis/jit178; Kibuuka H, 2010, J INFECT DIS, V201, P600, DOI 10.1086/650299; Koblin BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024517; Kong WP, 2003, J VIROL, V77, P12764, DOI 10.1128/JVI.77.23.12764-12772.2003; Koup RA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009015; Lai LL, 2012, VACCINE, V30, P1737, DOI 10.1016/j.vaccine.2011.12.026; Ledgerwood JE, 2013, J INFECT DIS, V208, P418, DOI 10.1093/infdis/jit180; Ledgerwood JE, 2011, LANCET INFECT DIS, V11, P916, DOI 10.1016/S1473-3099(11)70240-7; Lin SC, 2013, BIOTECHNOL J, V8, P1315, DOI 10.1002/biot.201300116; Lin SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039075; Liu MA, 2011, IMMUNOL REV, V239, P62, DOI 10.1111/j.1600-065X.2010.00980.x; Lorin C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122835; Nolz JC, 2011, ADV EXP MED BIOL, V780, P69, DOI 10.1007/978-1-4419-5632-3_7; Perfetto SP, 2006, J IMMUNOL METHODS, V313, P199, DOI 10.1016/j.jim.2006.04.007; Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015; Saade F, 2012, EXPERT REV VACCINES, V11, P189, DOI [10.1586/ERV.11.188, 10.1586/erv.11.188]; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Stanley DA, 2014, NAT MED, V20, P1126, DOI 10.1038/nm.3702; Subbramanian RA, 2003, J VIROL, V77, P10113, DOI 10.1128/JVI.77.18.10113-10118.2003; Sullivan NJ, 2011, NAT MED, V17, P1128, DOI 10.1038/nm.2447; Sullivan NJ, 2009, NAT REV MICROBIOL, V7, P393, DOI 10.1038/nrmicro2129; Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108; Swadling L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009185; Vojnov L, 2011, VACCINE, V29, P7483, DOI 10.1016/j.vaccine.2011.07.048; Vuola JM, 2005, J IMMUNOL, V174, P449, DOI 10.4049/jimmunol.174.1.449; Wilks AB, 2010, J IMMUNOL, V185, P7097, DOI 10.4049/jimmunol.1002751; Yang ZY, 2003, J VIROL, V77, P799, DOI 10.1128/JVI.77.1.799-803.2003; Zhou F, 2012, J VIROL, V86, P6970, DOI 10.1128/JVI.06930-11; Zhou Y, 2015, CURR OPIN IMMUNOL, V35, P131, DOI 10.1016/j.coi.2015.06.006	57	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 9	2021	12								627688	10.3389/fimmu.2021.627688	http://dx.doi.org/10.3389/fimmu.2021.627688			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RA4JK	33790899	Green Published, gold			2022-12-18	WOS:000631383500001
J	Huang, CQ; Xu, R; Liegeois, S; Chen, D; Li, Z; Ferrandon, D				Huang, Chuqin; Xu, Rui; Liegeois, Samuel; Chen, Di; Li, Zi; Ferrandon, Dominique			Differential Requirements for Mediator Complex Subunits in Drosophila melanogaster Host Defense Against Fungal and Bacterial Pathogens	FRONTIERS IN IMMUNOLOGY			English	Article						mediator complex; Drosophila innate immunity; Toll pathway; host defense against fungi and bacteria; RNA interference; survival to infection; humoral immune response		The humoral immune response to bacterial or fungal infections in Drosophila relies largely on a transcriptional response mediated by the Toll and Immune deficiency NF-kappa B pathways. Antimicrobial peptides are potent effectors of these pathways and allow the organism to attack invading pathogens. Dorsal-related Immune Factor (DIF), a transcription factor regulated by the Toll pathway, is required in the host defense against fungal and some Gram-positive bacterial infections. The Mediator complex is involved in the initiation of transcription of most RNA polymerase B (PolB)-dependent genes by forming a functional bridge between transcription factors bound to enhancer regions and the gene promoter region and then recruiting the PolB pre-initiation complex. Mediator is formed by several modules that each comprises several subunits. The Med17 subunit of the head module of Mediator has been shown to be required for the expression of Drosomycin, which encodes a potent antifungal peptide, by binding to DIF. Thus, Mediator is expected to mediate the host defense against pathogens controlled by the Toll pathway-dependent innate immune response. Here, we first focus on the Med31 subunit of the middle module of Mediator and find that it is required in host defense against Aspergillus fumigatus, Enterococcus faecalis, and injected but not topically-applied Metarhizium robertsii. Thus, host defense against M. robertsii requires Dif but not necessarily Med31 in the two distinct infection models. The induction of some Toll-pathway-dependent genes is decreased after a challenge of Med31 RNAi-silenced flies with either A. fumigatus or E. faecalis, while these flies exhibit normal phagocytosis and melanization. We have further tested most Mediator subunits using RNAi by monitoring their survival after challenges to several other microbial infections known to be fought off through DIF. We report that the host defense against specific pathogens involves a distinct set of Mediator subunits with only one subunit for C. glabrata or Erwinia carotovora carotovora, at least one for M. robertsii or a somewhat extended repertoire for A. fumigatus (at least eight subunits) and E. faecalis (eight subunits), with two subunits, Med6 and Med11 being required only against A. fumigatus. Med31 but not Med17 is required in fighting off injected M. robertsii conidia. Thus, the involvement of Mediator in Drosophila innate immunity is more complex than expected.	[Huang, Chuqin; Xu, Rui; Liegeois, Samuel; Chen, Di; Li, Zi; Ferrandon, Dominique] Guangzhou Med Univ, Sino French Hoffman Inst, Guangzhou, Peoples R China; [Xu, Rui; Liegeois, Samuel; Ferrandon, Dominique] Univ Strasbourg, UPR 9022 CNRS, Strasbourg, France	Guangzhou Medical University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Ferrandon, D (corresponding author), Guangzhou Med Univ, Sino French Hoffman Inst, Guangzhou, Peoples R China.; Ferrandon, D (corresponding author), Univ Strasbourg, UPR 9022 CNRS, Strasbourg, France.	D.Ferrandon@ibmc-cnrs.unistra.fr	LIEGEOIS, Samuel/AGG-0452-2022	LIEGEOIS, Samuel/0000-0003-3228-7678; FERRANDON, Dominique/0000-0001-7680-7773	Incubation Project for Innovation Team of the Guangzhou Medical University [B1850004105]; 111 Project [D18010]; China 1,000 Talent program	Incubation Project for Innovation Team of the Guangzhou Medical University; 111 Project(Ministry of Education, China - 111 Project); China 1,000 Talent program	This work was funded through the Incubation Project for Innovation Team of the Guangzhou Medical University (#B1850004105) and the 111 Project (#D18010) as well as support from the China 1,000 Talent program to DF.	Alarco AM, 2004, J IMMUNOL, V172, P5622, DOI 10.4049/jimmunol.172.9.5622; Bosveld F, 2008, DEV BIOL, V313, P802, DOI 10.1016/j.ydbio.2007.11.019; Bourbon HM, 2008, NUCLEIC ACIDS RES, V36, P3993, DOI 10.1093/nar/gkn349; Buchon N, 2014, NAT REV IMMUNOL, V14, P796, DOI 10.1038/nri3763; Busse MS, 2007, EMBO J, V26, P3826, DOI 10.1038/sj.emboj.7601798; Clemmons AW, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004876; Cohen LB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00009; Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954; Duneau D, 2017, ELIFE, V6, DOI 10.7554/eLife.28298; El Khattabi L, 2019, CELL, V178, P1145, DOI 10.1016/j.cell.2019.07.011; Ferrandon D, 2007, NAT REV IMMUNOL, V7, P862, DOI 10.1038/nri2194; Ferrandon D, 2013, CURR OPIN IMMUNOL, V25, P59, DOI 10.1016/j.coi.2012.11.008; Gottar M, 2006, CELL, V127, P1425, DOI 10.1016/j.cell.2006.10.046; Guruharsha KG, 2011, CELL, V147, P690, DOI 10.1016/j.cell.2011.08.047; Immarigeon C, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00477-18; Irving P, 2001, P NATL ACAD SCI USA, V98, P15119, DOI 10.1073/pnas.261573998; Issa N, 2018, MOL CELL, V69, P539, DOI 10.1016/j.molcel.2018.01.029; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kuuluvainen E, 2014, J BIOL CHEM, V289, P16252, DOI 10.1074/jbc.M113.541904; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Li XQ, 2012, DEV COMP IMMUNOL, V36, P648, DOI 10.1016/j.dci.2011.11.005; Limmer S, 2011, P NATL ACAD SCI USA, V108, P17378, DOI 10.1073/pnas.1114907108; Lindsay SA, 2018, J INNATE IMMUN, V10, P306, DOI 10.1159/000489831; Madic J, 2016, Biomol Detect Quantif, V10, P34; Manfruelli P, 1999, EMBO J, V18, P3380, DOI 10.1093/emboj/18.12.3380; McGuire Sean E, 2004, Sci STKE, V2004, ppl6, DOI 10.1126/stke.2202004pl6; Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; Ni JQ, 2011, NAT METHODS, V8, P405, DOI [10.1038/NMETH.1592, 10.1038/nmeth.1592]; Park JM, 2003, MOL CELL BIOL, V23, P1358, DOI 10.1128/MCB.23.4.1358-1367.2003; Philippe B, 2003, INFECT IMMUN, V71, P3034, DOI 10.1128/IAI.71.6.3034-3042.2003; Poss ZC, 2013, CRIT REV BIOCHEM MOL, V48, P575, DOI 10.3109/10409238.2013.840259; Pukkila-Worley R, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004143; Quintin J, 2013, J IMMUNOL, V190, P2818, DOI 10.4049/jimmunol.1201861; Rutschmann S, 2000, IMMUNITY, V12, P569, DOI 10.1016/S1074-7613(00)80208-3; Rutschmann S, 2002, J IMMUNOL, V168, P1542, DOI 10.4049/jimmunol.168.4.1542; Soares MP, 2017, NAT REV IMMUNOL, V17, P83, DOI 10.1038/nri.2016.136; Soutourina J, 2018, NAT REV MOL CELL BIO, V19, P262, DOI 10.1038/nrm.2017.115; Sugui JA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a019786; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; Thurmond J, 2019, NUCLEIC ACIDS RES, V47, pD759, DOI 10.1093/nar/gky1003; Valanne S, 2010, J IMMUNOL, V184, P6188, DOI 10.4049/jimmunol.1000261; Yamamoto S, 2014, CELL, V159, P200, DOI 10.1016/j.cell.2014.09.002; Yin JW, 2014, DEVELOPMENT, V141, P977, DOI 10.1242/dev.098392	45	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 5	2021	11								478958	10.3389/fimmu.2020.478958	http://dx.doi.org/10.3389/fimmu.2020.478958			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QZ1ZQ	33746938	Green Submitted, gold, Green Published			2022-12-18	WOS:000630533300001
J	Wilkinson, KA; Schneider-Luftman, D; Lai, R; Barrington, C; Jhilmeet, N; Lowe, DM; Kelly, G; Wilkinson, RJ				Wilkinson, Katalin A.; Schneider-Luftman, Deborah; Lai, Rachel; Barrington, Christopher; Jhilmeet, Nishtha; Lowe, David M.; Kelly, Gavin; Wilkinson, Robert J.			Antiretroviral Treatment-Induced Decrease in Immune Activation Contributes to Reduced Susceptibility to Tuberculosis in HIV-1/Mtb Co-infected Persons	FRONTIERS IN IMMUNOLOGY			English	Article						antiretroviral treatment; tuberculosis; plasma biomarker; RNAseq; QuantiFERON		Antiretroviral treatment (ART) reduces the risk of developing active tuberculosis (TB) in HIV-1 co-infected persons. In order to understand host immune responses during ART in the context of Mycobacterium tuberculosis (Mtb) sensitization, we performed RNAseq analysis of whole blood-derived RNA from individuals with latent TB infection coinfected with HIV-1, during the first 6 months of ART. A significant fall in RNA sequence abundance of the Hallmark IFN-alpha, IFN-gamma, IL-6/JAK/STAT3 signaling, and inflammatory response pathway genes indicated reduced immune activation and inflammation at 6 months of ART compared to day 0. Further exploratory evaluation of 65 soluble analytes in plasma confirmed the significant decrease of inflammatory markers after 6 months of ART. Next, we evaluated 30 soluble analytes in QuantiFERON Gold in-tube (QFT) samples from the Ag stimulated and Nil tubes, during the first 6 months of ART in 30 patients. There was a significant decrease in IL-1alpha and IL-1beta (Ag-Nil) concentrations as well as MCP-1 (Nil), supporting decreased immune activation and inflammation. At the same time, IP-10 (Ag-nil) concentrations significantly increased, together with chemokine receptor-expressing CD4 T cell numbers. Our data indicate that ART-induced decrease in immune activation combined with improved antigen responsiveness may contribute to reduced susceptibility to tuberculosis in HIV-1/Mtb co-infected persons.	[Wilkinson, Katalin A.; Wilkinson, Robert J.] Francis Crick Inst, TB Lab, London, England; [Wilkinson, Katalin A.; Jhilmeet, Nishtha; Lowe, David M.; Wilkinson, Robert J.] Univ Cape Town, Inst Infect Dis & Mol Med, Wellcome Ctr Infect Dis Res Africa, Cape Town, South Africa; [Schneider-Luftman, Deborah; Barrington, Christopher; Kelly, Gavin] Francis Crick Inst, Bioinformat & Biostat, London, England; [Lai, Rachel; Wilkinson, Robert J.] Imperial Coll London, Dept Infect Dis, London, England; [Lowe, David M.] UCL, Inst Immun & Transplantat, London, England	Francis Crick Institute; University of Cape Town; Francis Crick Institute; Imperial College London; University of London; University College London	Wilkinson, KA (corresponding author), Francis Crick Inst, TB Lab, London, England.; Wilkinson, KA (corresponding author), Univ Cape Town, Inst Infect Dis & Mol Med, Wellcome Ctr Infect Dis Res Africa, Cape Town, South Africa.	katalin.wilkinson@crick.ac.uk	Wilkinson, Katalin/AAQ-7713-2021; Kelly, Gavin/ABG-2715-2021	Wilkinson, Katalin/0000-0002-9796-2040; Kelly, Gavin/0000-0001-7219-560X; Barrington, Christopher/0000-0003-1281-2658; Wilkinson, Robert/0000-0002-2753-1800	Wellcome [104803, 087754, 203135, FC001218]; South African National Research Foundation [443386]; European Union [643381]; Francis Crick Institute from UKRI [FC001218]; Cancer Research UK [FC001218]	Wellcome; South African National Research Foundation(National Research Foundation - South Africa); European Union(European Commission); Francis Crick Institute from UKRI(UK Research & Innovation (UKRI)); Cancer Research UK(Cancer Research UK)	Research supported by Wellcome (104803, 087754, and 203135), The South African National Research Foundation (443386), the European Union Horizon 2020 research and innovation programme under grant agreement no 643381 and The Francis Crick Institute which receives support from UKRI (FC001218), Cancer Research UK (FC001218), andWellcome (FC001218).	Abate E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40121-8; Aken BL, 2017, NUCLEIC ACIDS RES, V45, pD635, DOI 10.1093/nar/gkw1104; Akyuz L., 2017, ADV PREC MED, V2, P1, DOI [10.18063/APM.2017.02.001, DOI 10.18063/APM.2017.02.001]; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Breen EC, 2011, CLIN VACCINE IMMUNOL, V18, P1229, DOI 10.1128/CVI.05032-11; Bucsan AN, 2019, J CLIN INVEST, V129, P5254, DOI 10.1172/JCI125810; Chegou NN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20855-7; Chowdhury F, 2009, J IMMUNOL METHODS, V340, P55, DOI 10.1016/j.jim.2008.10.002; Christiansson L., 2014, EUPA OPEN PROTEOMICS, V3, P37, DOI DOI 10.1016/j.euprot.2014.02.002; DeLuca DS, 2012, BIOINFORMATICS, V28, P1530, DOI 10.1093/bioinformatics/bts196; Di Tommaso P, 2017, NAT BIOTECHNOL, V35, P316, DOI 10.1038/nbt.3820; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dye C, 2019, B WORLD HEALTH ORGAN, V97, P405, DOI 10.2471/BLT.18.228577; Geldmacher C, 2010, J EXP MED, V207, P2869, DOI 10.1084/jem.20100090; Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017; Horvati K, 2016, J INFECTION, V72, P179, DOI 10.1016/j.jinf.2015.10.012; Jhilmeet N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209516; Kamtchum-Tatuene J, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000531; Kim YM, 2011, ANTIOXID REDOX SIGN, V14, P137, DOI 10.1089/ars.2010.3153; Lai RPJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9451; Lawn SD, 2015, LANCET HIV, V2, pE221, DOI 10.1016/S2352-3018(15)00081-8; Lawn SD, 2010, LANCET INFECT DIS, V10, P489, DOI 10.1016/S1473-3099(10)70078-5; Lesosky M, 2019, CLIN INFECT DIS, V69, P295, DOI 10.1093/cid/ciy823; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lowe DM, 2015, ANN AM THORAC SOC, V12, P1627, DOI 10.1513/AnnalsATS.201507-463OC; Maartens G, 2007, LANCET, V370, P2030, DOI 10.1016/S0140-6736(07)61262-8; Mahnke Yolanda D, 2016, Pathog Immun, V1, P260; Manngo PM, 2019, J INFECTION, V79, P228, DOI 10.1016/j.jinf.2019.07.007; Marincowitz C, 2019, FEBS J, V286, P1256, DOI 10.1111/febs.14657; Riou C, 2020, J INFECT DIS, V221, P162, DOI 10.1093/infdis/jiz417; Riou C, 2015, J IMMUNOL, V195, P2273, DOI 10.4049/jimmunol.1500803; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sergushichev AA., 2016, BIORXIV, DOI [10.1101/060012, DOI 10.1101/060012]; Sharan R, 2020, TRENDS MICROBIOL, V28, P619, DOI 10.1016/j.tim.2020.03.015; Singh SK, 2019, J IMMUNOL, V202, P816, DOI 10.4049/jimmunol.1800523; Stacker SA, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8010001; Sudbury EL, 2020, J INFECTION, V81, P873, DOI 10.1016/j.jinf.2020.09.032; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; WHO, 2021, TUBERCULOSIS; Wilkinson KA, 2016, AM J RESP CRIT CARE, V193, P1307, DOI 10.1164/rccm.201601-0116LE; Wilkinson KA, 2009, AM J RESP CRIT CARE, V180, P674, DOI 10.1164/rccm.200904-0568OC	42	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 5	2021	12								645446	10.3389/fimmu.2021.645446	http://dx.doi.org/10.3389/fimmu.2021.645446			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QY9KF	33746987	gold, Green Published			2022-12-18	WOS:000630353900001
J	Yang, QL; Zhang, GH; Su, MW; Leung, G; Lui, H; Zhou, PY; Wu, Y; Zhou, J; Xu, JH; Zhang, XJ; Zhou, YW				Yang, Qianli; Zhang, Guohong; Su, Mingwan; Leung, Gigi; Lui, Harvey; Zhou, Pingyu; Wu, Yan; Zhou, Joshua; Xu, Jinhua; Zhang, Xuejun; Zhou, Youwen			Vitiligo Skin Biomarkers Associated With Favorable Therapeutic Response	FRONTIERS IN IMMUNOLOGY			English	Article						vitiligo; RNA sequencing; biomarkers; response to therapy; phototherapy; tacrolimus; therapeutic markers	ISSUES	Vitiligo is an acquired depigmentation skin disease caused by immune-mediated death of melanocytes. The most common treatment for vitiligo is narrow band ultraviolet B phototherapy, which often is combined with topical therapies such as tacrolimus. However, patients' responses to these treatments show large variations. To date, the mechanism for this heterogeneity is unknown, and there are no molecular indicators that can predict an individual patient's response to therapy. The goal of this study is to identify clinical parameters and gene expression biomarkers associated with vitiligo response to therapy. Six patients with segmental vitiligo and 30 patients with non-segmental vitiligo underwent transcriptome sequencing of lesional and nonlesional skin at baseline before receiving combined UBUVB and tacrolimus therapy for 6 month, and were separated into good response and bad response groups based on target lesion achieving > 10% repigmentation or not. Our study revealed that treatment-responsive vitiligo lesions had significantly shorter disease duration compared with non-responsive vitiligo lesions (2.5 years vs 11.5 years, p=0.046, t-Test), while showing no significant differences in the age, gender, ethnicity, vitiligo subtype, or disease severity. Transcriptomic analyses identified a panel of 68 genes separating the good response from bad response lesions including upregulation of immune active genes, such as CXCL10, FCRL3, and TCR, Further, compared with vitiligo lesions with long disease duration, the lesions with short duration also have much higher level of expression of immune-active genes, including some (such as FCRL3 and TCR genes) that are associated with favorable therapeutic response. In conclusion, our study has identified clinical parameters such as short disease duration and a panel of immune active and other gene expression biomarkers that are associated with favorable response to immune suppressive NBUVB + tacrolimus therapy. These markers may be useful clinically for individualized therapeutic management of vitiligo patients in the future.	[Yang, Qianli; Su, Mingwan; Leung, Gigi; Lui, Harvey; Zhou, Youwen] Univ British Columbia, Dept Dermatol & Skin Sci, Vancouver, BC, Canada; [Yang, Qianli; Xu, Jinhua; Zhang, Xuejun] Fudan Univ, Huashan Hosp, Dept Dermatol, Shanghai, Peoples R China; [Zhang, Guohong] Shantou Univ, Med Coll, Dept Pathol, Shantou, Peoples R China; [Zhou, Pingyu] Tongji Univ, Shanghai Skin Hosp, Shanghai, Peoples R China; [Wu, Yan] China Med Univ, Hosp 1, Dept Dermatol, Shenyang, Peoples R China; [Zhou, Joshua] Univ British Columbia, Fac Dent, Vancouver, BC, Canada; [Zhang, Xuejun] Anhui Med Univ, Inst Dermatol, Hefei, Peoples R China	University of British Columbia; Fudan University; Shantou University; Tongji University; China Medical University; University of British Columbia; Anhui Medical University	Zhou, YW (corresponding author), Univ British Columbia, Dept Dermatol & Skin Sci, Vancouver, BC, Canada.; Xu, JH; Zhang, XJ (corresponding author), Fudan Univ, Huashan Hosp, Dept Dermatol, Shanghai, Peoples R China.; Zhang, XJ (corresponding author), Anhui Med Univ, Inst Dermatol, Hefei, Peoples R China.	xjhhsyy@163.com; ayzxj@vip.sina.com; youwen.zhou@ubc.ca			Canadian Institutes of Health Research; Canadian Dermatology Foundation; National Natural Sciences Foundation of China; Canadian Melanoma Foundation	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Dermatology Foundation; National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); Canadian Melanoma Foundation	This study was funded in part by grants from Canadian Institutes of Health Research, Canadian Dermatology Foundation, National Natural Sciences Foundation of China, and Canadian Melanoma Foundation.	Alikhan A, 2011, J AM ACAD DERMATOL, V65, P473, DOI 10.1016/j.jaad.2010.11.061; AlJasser M, 2016, J EUR ACAD DERMATOL, V30, P1428, DOI 10.1111/jdv.13271; Anbar TS, 2006, PHOTODERMATOL PHOTO, V22, P157, DOI 10.1111/j.1600-0781.2006.00222.x; Arora CJ, 2020, AUSTRALAS J DERMATOL, V61, pE1, DOI 10.1111/ajd.13096; Chang HC, 2021, PHOTODERMATOL PHOTO, V37, P74, DOI 10.1111/phpp.12593; Chen SD, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5416728; Craiglow BG, 2015, JAMA DERMATOL, V151, P1110, DOI 10.1001/jamadermatol.2015.1520; Errichetti E, 2020, DERMATOLOGY THER, V10, P1089, DOI 10.1007/s13555-020-00431-6; Esfandiarpour I, 2009, J DERMATOL TREAT, V20, P14, DOI 10.1080/09546630802155057; Ezzedine K, 2012, PIGM CELL MELANOMA R, V25, pE1, DOI 10.1111/j.1755-148X.2012.00997.x; Ezzedine K, 2020, J INVEST DERMATOL, V140, P1498, DOI 10.1016/j.jid.2020.01.033; Fai D, 2007, J EUR ACAD DERMATOL, V21, P916, DOI 10.1111/j.1468-3083.2006.02101.x; Fried L, 2020, J AM ACAD DERMATOL, V83, P996, DOI 10.1016/j.jaad.2020.03.122; Gan EY, 2017, PIGM CELL MELANOMA R, V30, P28, DOI 10.1111/pcmr.12561; Gauthier Y, 2021, ARCH DERMATOL RES, V313, P383, DOI 10.1007/s00403-020-02068-z; Gill L, 2016, J AM ACAD DERMATOL, V74, P295, DOI 10.1016/j.jaad.2015.08.063; Grimes PE, 2002, J AM ACAD DERMATOL, V47, P789, DOI 10.1067/mjd.2002.126250; Hamzavi I, 2004, ARCH DERMATOL, V140, P677, DOI 10.1001/archderm.140.6.677; Harris JE, 2017, DERMATOL CLIN, V35, P151, DOI 10.1016/j.det.2016.11.006; Henning SW, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227909; Homan MWL, 2008, ARCH DERMATOL, V144, P1062, DOI 10.1001/archderm.144.8.1062; Homan MWL, 2009, J AM ACAD DERMATOL, V61, P411, DOI 10.1016/j.jaad.2009.03.022; Hossani-Madani AR, 2010, GIORN ITAL DERMAT V, V145, P57; Jin Y, 2007, NEW ENGL J MED, V356, P1216, DOI 10.1056/NEJMoa061592; Jin Y, 2010, NEW ENGL J MED, V362, P1686, DOI 10.1056/NEJMoa0908547; Joshipura D, 2018, J AM ACAD DERMATOL, V78, P1205, DOI 10.1016/j.jaad.2018.02.023; Kim BE, 2019, J INVEST DERMATOL, V139, P2387, DOI 10.1016/j.jid.2019.03.1160; Mattoo SK, 2001, J DERMATOL, V28, P424, DOI 10.1111/j.1346-8138.2001.tb00004.x; Mosenson JA, 2013, EXP DERMATOL, V22, P566, DOI 10.1111/exd.12183; Nandi A, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9613090; Nordal EJ, 2011, J EUR ACAD DERMATOL, V25, P1440, DOI 10.1111/j.1468-3083.2011.04002.x; Ongenae K, 2006, J EUR ACAD DERMATOL, V20, P1, DOI 10.1111/j.1468-3083.2005.01369.x; Picardo M, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.11; Quan C, 2010, NAT GENET, V42, P614, DOI 10.1038/ng.603; Rashighi M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007811; Ren YQ, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000523; Rosmarin D, 2020, LANCET, V396, P110, DOI 10.1016/S0140-6736(20)30609-7; Sastry KS, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/2841814; Satyanarayan HS, 2013, INDIAN J DERMATOL VE, V79, P525, DOI 10.4103/0378-6323.113091; Sheth VM, 2013, DERMATOLOGY, V227, P311, DOI 10.1159/000354607; Spritz RA, 2021, J INVEST DERMATOL, V141, P265, DOI 10.1016/j.jid.2020.06.004; Taher ZA, 2009, BRIT J DERMATOL, V161, P654, DOI 10.1111/j.1365-2133.2009.09217.x; Taieb A, 2009, NEW ENGL J MED, V360, P160, DOI 10.1056/NEJMcp0804388; Tang XF, 2013, J INVEST DERMATOL, V133, P403, DOI 10.1038/jid.2012.320; Tarle RG, 2015, EXP DERMATOL, V24, P300, DOI 10.1111/exd.12641; Vine K, 2013, CUTIS, V91, P129; Vrijman C, 2013, BRIT J DERMATOL, V168, P1003, DOI 10.1111/bjd.12162; Westerhof Wiete, 1997, Archives of Dermatology, V133, P1525, DOI 10.1001/archderm.133.12.1525; Wong R, 2006, J DERMATOL SCI, V44, P81, DOI 10.1016/j.jdermsci.2006.08.007; Xu SX, 2010, ACTA DERM-VENEREOL, V90, P131, DOI 10.2340/00015555-0820; Yang C, 2018, GENE, V648, P76, DOI 10.1016/j.gene.2018.01.053; Yu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051040; Zubair R, 2020, DERMATOL CLIN, V38, P55, DOI 10.1016/j.det.2019.08.005	53	1	1	1	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 5	2021	12								613031	10.3389/fimmu.2021.613031	http://dx.doi.org/10.3389/fimmu.2021.613031			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	RG7JP	33815367	gold, Green Published			2022-12-18	WOS:000635710700001
J	Saghafian-Hedengren, S; Sverremark-Ekstrom, E; Nilsson, A				Saghafian-Hedengren, Shanie; Sverremark-Ekstrom, Eva; Nilsson, Anna			T Cell Subsets During Early Life and Their Implication in the Treatment of Childhood Acute Lymphoblastic Leukemia	FRONTIERS IN IMMUNOLOGY			English	Review						T cells; childhood; leukemia; chemotherapy; immunotherapy		The immune system plays a major role in recognizing and eliminating malignant cells, and this has been exploited in the development of immunotherapies aimed at either activating or reactivating the anti-tumor activity of a patient's immune system. A wide range of therapeutic approaches involving T lymphocytes, such as programmed cell death protein ligand-1 (PDL-1) inhibitors, cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) blockers, and CD19-targeted T-cell therapy through chimeric antigen receptor (CAR)-T cells or CD19/CD3 bi-specific T-cell engagers, have been introduced to the field of oncology, leading to significant improvements in overall survival of adult cancer patients. During the past few years, the availability and approval of T-cell based immunotherapies have become a reality also for the treatment of childhood cancers. However, the distribution, ratio of regulatory to effector cells and the quality of T-cell responses early in life are distinct from those during adolescence and adulthood, raising the possibility that these differences impact the efficacy of immunotherapy. Herein we provide a brief overview of the properties of conventional T cell subsets during early life. Focusing on the most common cancer type during childhood, acute lymphoblastic leukemia (ALL), we describe how current conventional therapies used against ALL influence the T-cell compartment of small children. We describe early life T-cell responses in relation to immunotherapies engaging T-cell anticancer reactivity and present our opinion that it is not only immaturity of the adaptive immune system, but also the impact of an immunosuppressive environment that may prove disadvantageous in the setting of immunotherapies targeting pediatric cancer cells.	[Saghafian-Hedengren, Shanie; Nilsson, Anna] Karolinska Inst, Dept Womens & Childrens Hlth, Div Paediat Oncol & Paediat Surg, Stockholm, Sweden; [Sverremark-Ekstrom, Eva] Stockholm Univ, Wenner Gren Inst, Dept Mol Biosci, Stockholm, Sweden	Karolinska Institutet; Stockholm University	Saghafian-Hedengren, S (corresponding author), Karolinska Inst, Dept Womens & Childrens Hlth, Div Paediat Oncol & Paediat Surg, Stockholm, Sweden.	shanie.hedengren@ki.se	Sverremark-Ekström, Eva/A-2305-2016	Sverremark-Ekström, Eva/0000-0001-6271-8681; Nilsson, Anna/0000-0001-5885-7101	Swedish Childhood Cancer Foundation [2018-0084]; Swedish Research Council [2017-02001]; Swedish Cancer Society [2017/460, 20-1117]; Cancer-and Allergy Foundation; Ake Wiberg Foundation [M190342]	Swedish Childhood Cancer Foundation(European Commission); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Cancer-and Allergy Foundation; Ake Wiberg Foundation	This work was supported by the Swedish Childhood Cancer Foundation (grant 2018-0084, AN), the Swedish Research Council (grant 2017-02001, AN), the Swedish Cancer Society (grants 2017/460, 20-1117, ES-E), the Cancer-and Allergy Foundation (ES-E), and Ake Wiberg Foundation (grant M190342, SS-H).	ALANKO S, 1994, PEDIATR HEMAT ONCOL, V11, P281, DOI 10.3109/08880019409141671; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Ateyah ME, 2017, J CLIN PATHOL, V70, P120, DOI 10.1136/jclinpath-2016-203803; Bertho JM, 1997, CELL IMMUNOL, V179, P30, DOI 10.1006/cimm.1997.1148; Bjorkander S, 2016, J ALLERGY CLIN IMMUN, V138, P905, DOI 10.1016/j.jaci.2016.04.027; Boelens JJ, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00454; Brown PA, 2019, BLOOD, V134, DOI 10.1182/blood-2019-132435; BRUGNONI D, 1994, EUR J IMMUNOL, V24, P1919, DOI 10.1002/eji.1830240831; BURNET M, 1957, BRIT MED J, V1, P779, DOI 10.1136/bmj.1.5022.779; Cerrano M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00888; Clave E, 2009, BLOOD, V113, P6477, DOI 10.1182/blood-2008-09-176594; Collier FM, 2015, CLIN TRANSL IMMUNOL, V4, DOI 10.1038/cti.2015.2; Colombo MP, 2007, NAT REV CANCER, V7, P880, DOI 10.1038/nrc2250; Connors TJ, 2018, J IMMUNOL, V201, P432, DOI 10.4049/jimmunol.1800396; Cookson S, 2003, BLOOD, V102, P2195, DOI 10.1182/blood-2003-01-0232; Correa-Rocha R, 2012, PEDIATR RES, V71, P590, DOI 10.1038/pr.2012.6; Das RK, 2019, CANCER DISCOV, V9, P492, DOI 10.1158/2159-8290.CD-18-1314; Dekker L, 2020, CANCERS, V12, DOI 10.3390/cancers12071974; Duell J, 2017, LEUKEMIA, V31, P2181, DOI 10.1038/leu.2017.41; Ek T, 2005, PEDIATR BLOOD CANCER, V44, P461, DOI 10.1002/pbc.20255; Feucht J, 2016, ONCOTARGET, V7, P76902, DOI 10.18632/oncotarget.12357; Flinn AM, 2018, CLIN IMMUNOL, V193, P33, DOI 10.1016/j.clim.2018.01.006; Forsberg MM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53576-6; Fukui T, 1997, IMMUNOL LETT, V59, P21, DOI 10.1016/S0165-2478(97)00093-X; FULEIHAN R, 1994, EUR J IMMUNOL, V24, P1925, DOI 10.1002/eji.1830240832; Gaballa A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01341; Galindo-Albarran AO, 2016, CELL REP, V17, P2151, DOI 10.1016/j.celrep.2016.10.056; Gardner RA, 2017, BLOOD, V129, P3322, DOI 10.1182/blood-2017-02-769208; George AJT, 1996, IMMUNOL TODAY, V17, P267, DOI 10.1016/0167-5699(96)80543-3; Gibbons D, 2014, NAT MED, V20, P1206, DOI 10.1038/nm.3670; Haining WN, 2005, BLOOD, V106, P1749, DOI 10.1182/blood-2005-03-1082; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harbeson D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01077; Hassan J, 1998, EUR J IMMUNOL, V28, P3057, DOI 10.1002/(SICI)1521-4141(199810)28:10<3057::AID-IMMU3057>3.3.CO;2-Q; Hassan J, 2001, J IMMUNOL, V167, P1970, DOI 10.4049/jimmunol.167.4.1970; Hazenberg MD, 2004, BLOOD, V104, P3513, DOI 10.1182/blood-2004-03-0805; Hildeman DA, 2004, FREE RADICAL BIO MED, V36, P1496, DOI 10.1016/j.freeradbiomed.2004.03.023; Huenecke S, 2016, SCAND J IMMUNOL, V84, P291, DOI 10.1111/sji.12474; Ismail AM, 2016, CYTOTECHNOLOGY, V68, P771, DOI 10.1007/s10616-014-9828-7; Jamieson BD, 1999, IMMUNITY, V10, P569, DOI 10.1016/S1074-7613(00)80056-4; Junge S, 2007, EUR J IMMUNOL, V37, P3270, DOI 10.1002/eji.200636976; Koskenvuo M, 2016, PEDIATR BLOOD CANCER, V63, P1653, DOI 10.1002/pbc.26047; Kumar BV, 2018, IMMUNITY, V48, P202, DOI 10.1016/j.immuni.2018.01.007; Lasaviciute G, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1150; Lathrop SK, 2011, NATURE, V478, P250, DOI 10.1038/nature10434; Lesch S, 2020, SEMIN CANCER BIOL, V65, P80, DOI 10.1016/j.semcancer.2019.11.004; Lustfeld I, 2014, ACTA HAEMATOL-BASEL, V131, P28, DOI 10.1159/000351429; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; Mackall CL, 1997, BLOOD, V89, P3700, DOI 10.1182/blood.V89.10.3700.3700_3700_3707; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Mazur B, 2006, LEUKEMIA RES, V30, P33, DOI 10.1016/j.leukres.2005.05.024; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Mold JE, 2008, SCIENCE, V322, P1562, DOI 10.1126/science.1164511; Moorman AV, 2016, HAEMATOLOGICA, V101, P407, DOI 10.3324/haematol.2015.141101; Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266; Nagele V, 2017, EXP HEMATOL ONCOL, V6, DOI 10.1186/s40164-017-0074-5; Nikolich-Zugich J, 2004, NAT REV IMMUNOL, V4, P123, DOI 10.1038/nri1292; O'Donnell JS, 2019, NAT REV CLIN ONCOL, V16, P151, DOI 10.1038/s41571-018-0142-8; O'Neill RM, 2003, TRANSPLANTATION, V76, P1526, DOI 10.1097/01.TP.0000084308.19565.2B; Oshima K, 2016, P NATL ACAD SCI USA, V113, P11306, DOI 10.1073/pnas.1608420113; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Pui CH, 2018, LANCET CHILD ADOLESC, V2, P440, DOI 10.1016/S2352-4642(18)30066-X; Pui CH, 2015, J CLIN ONCOL, V33, P2938, DOI 10.1200/JCO.2014.59.1636; Rafiq S, 2018, NAT BIOTECHNOL, V36, P847, DOI 10.1038/nbt.4195; Ribatti D, 2017, ONCOTARGET, V8, P7175, DOI 10.18632/oncotarget.12739; Rudd BD, 2020, ANNU REV IMMUNOL, V38, P229, DOI 10.1146/annurev-immunol-091319-083608; Saghafian-Hedengren S, 2018, BLOOD REV, V32, P71, DOI 10.1016/j.blre.2017.08.009; Salem ML, 2018, IMMUNOPHARM IMMUNOT, V40, P158, DOI 10.1080/08923973.2018.1424897; Sawant DV, 2019, NAT IMMUNOL, V20, P724, DOI 10.1038/s41590-019-0346-9; Schatorje EJH, 2012, SCAND J IMMUNOL, V75, P436, DOI 10.1111/j.1365-3083.2012.02671.x; Schonland SO, 2003, BLOOD, V102, P1428, DOI 10.1182/blood-2002-11-3591; Sexauer AN, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00248; Silva SL, 2016, ONCOTARGET, V7, P12163, DOI 10.18632/oncotarget.7512; Singh N, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad5222; Soares MVD, 1998, J IMMUNOL, V161, P5909; Splawski JB, 1996, J IMMUNOL, V156, P119; Srivastava S, 2018, J IMMUNOL, V200, P459, DOI 10.4049/jimmunol.1701155; Steinmann G G, 1986, Curr Top Pathol, V75, P43; STEINMANN GG, 1985, SCAND J IMMUNOL, V22, P563, DOI 10.1111/j.1365-3083.1985.tb01916.x; Steliarova-Foucher E, 2017, LANCET ONCOL, V18, P719, DOI 10.1016/S1470-2045(17)30186-9; Sugiyama D, 2013, P NATL ACAD SCI USA, V110, P17945, DOI 10.1073/pnas.1316796110; Sun CC, 2017, ONCOTARGET, V8, P35445, DOI 10.18632/oncotarget.16367; Sun MM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05901-2; Takahata Y, 2004, EXP HEMATOL, V32, P622, DOI 10.1016/j.exphem.2004.03.012; Tanaka A, 2020, J EXP MED, V217, DOI 10.1084/jem.20191009; Telesford KM, 2015, GUT MICROBES, V6, P234, DOI 10.1080/19490976.2015.1056973; Thome JJC, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah6506; Thome JJC, 2016, NAT MED, V22, P72, DOI 10.1038/nm.4008; Togashi Y, 2019, NAT REV CLIN ONCOL, V16, P356, DOI 10.1038/s41571-019-0175-7; Tumis ME, 2016, IMMUNITY, V44, P316, DOI 10.1016/j.immuni.2016.01.013; van Tilburg CM, 2011, LEUKEMIA RES, V35, P484, DOI 10.1016/j.leukres.2010.10.005; van Tilburg CM, 2011, BRIT J HAEMATOL, V152, P201, DOI 10.1111/j.1365-2141.2010.08478.x; von Stackelberg A, 2016, J CLIN ONCOL, V34, P4381, DOI 10.1200/JCO.2016.67.3301; Webster RB, 2007, J BIOL CHEM, V282, P700, DOI 10.1074/jbc.M609501200; White GP, 2002, J IMMUNOL, V168, P2820, DOI 10.4049/jimmunol.168.6.2820; WILSON CB, 1986, J CLIN INVEST, V77, P860, DOI 10.1172/JCI112383; Winters A, 2019, HEMATOL-AM SOC HEMAT, P209, DOI 10.1182/hematology.2019000017; Wu CP, 2012, ONCOL LETT, V3, P421, DOI 10.3892/ol.2011.499; Zens KD, 2017, SEMIN IMMUNOPATHOL, V39, P593, DOI 10.1007/s00281-017-0648-7; Zhao ZW, 2017, ONCOL LETT, V13, P4577, DOI 10.3892/ol.2017.6034	100	1	1	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 4	2021	12								582539	10.3389/fimmu.2021.582539	http://dx.doi.org/10.3389/fimmu.2021.582539			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QY3UG	33763058	gold, Green Published			2022-12-18	WOS:000629968000001
J	Campos, AM; Nuzzo, G; Varone, A; Italiani, P; Boraschi, D; Corda, D; Fontana, A				Campos, Ana Margarida; Nuzzo, Genoveffa; Varone, Alessia; Italiani, Paola; Boraschi, Diana; Corda, Daniela; Fontana, Angelo			Direct LC-MS/MS Analysis of Extra- and Intracellular Glycerophosphoinositol in Model Cancer Cell Lines	FRONTIERS IN IMMUNOLOGY			English	Article						inflammation; cancer; mass spectrometry; autocrine and paracrine mechanism; solid phase extraction; second messenger; lipid metabolism		Glycerophosphoinositols (GPIs) are water-soluble bioactive phospholipid derivatives of increasing interest as intracellular and paracrine mediators of eukaryotic cell functions. The most representative compound of the family is glycerophosphoinositol (GroPIns), an ubiquitous component of mammalian cells that participates in cell proliferation, cell survival and cell response to stimuli. Levels and activity of this compound vary among cell types and deciphering these functions requires accurate measurements in in vitro and in vivo models. The conventional approaches for the analysis of GroPIns pose several issues in terms of sensitivity and product resolution, especially when the product is in the extracellular milieu. Here we present an UPLC-MS study for the quantitative analysis of this lipid derivative in cells and, for the first time, culture supernatants. The method is based on a solid-phase extraction that allows for fast desalting and analyte concentration. The robustness of the procedure was tested on the simultaneous measurements of intra- and extracellular levels of GroPIns in a number of human cell lines where it has been shown that the non-transformed cells are characterized by high extracellular level of GroPIns, whereas the tumor cells tended to have higher intracellular levels.	[Campos, Ana Margarida; Nuzzo, Genoveffa; Fontana, Angelo] CNR, Inst Biomol Chem, Pozzuoli, Italy; [Campos, Ana Margarida; Varone, Alessia; Italiani, Paola; Boraschi, Diana; Corda, Daniela] CNR, Inst Biochem & Cell Biol, Naples, Italy; [Corda, Daniela] CNR, Dept Biomed Sci, Rome, Italy; [Fontana, Angelo] Univ Naples Federico II, Dept Biol, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Fontana, A (corresponding author), CNR, Inst Biomol Chem, Pozzuoli, Italy.; Fontana, A (corresponding author), Univ Naples Federico II, Dept Biol, Naples, Italy.	afontana@icb.cnr.it	Fontana, Angelo/AAO-2741-2021; Italiani, Paola/AAU-5841-2021	Fontana, Angelo/0000-0002-5453-461X; 	INCIPIT COFUND International Ph.D. programme [665403]; HORIZON 2020/Marie Sklodowska Curie Actions; project Antitumor Drugs and Vaccines from the Sea (ADViSE) - POR Campania FESR 2014-2020 Technology Platform for Therapeutic Strategies against Cancer-Action 1.1.2 and 1.2.2 [CUP B43D18000240007 SURF 17061BP000000011]; Italian Ministry of University and Research [20177XJCHX, 20173ZECCM]; project SATIN of the POR program 2014-2020 of Campania Region	INCIPIT COFUND International Ph.D. programme; HORIZON 2020/Marie Sklodowska Curie Actions; project Antitumor Drugs and Vaccines from the Sea (ADViSE) - POR Campania FESR 2014-2020 Technology Platform for Therapeutic Strategies against Cancer-Action 1.1.2 and 1.2.2; Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR)); project SATIN of the POR program 2014-2020 of Campania Region	AMC was supported by INCIPIT COFUND International Ph.D. programme-Grant Agreement No. 665403-co-funded by HORIZON 2020/Marie Sklodowska Curie Actions. AF and GN acknowledged the support of the project Antitumor Drugs and Vaccines from the Sea (ADViSE) (CUP B43D18000240007 SURF 17061BP000000011) funded by POR Campania FESR 2014-2020 Technology Platform for Therapeutic Strategies against Cancer-Action 1.1.2 and 1.2.2. DC and PI acknowledged the support of the Italian Ministry of University and Research through the PRIN 2017 projects no. 20177XJCHX and no. 20173ZECCM, respectively. DC was also grateful for the support to project SATIN of the POR program 2014-2020 of Campania Region.	Balla T, 2013, PHYSIOL REV, V93, P1019, DOI 10.1152/physrev.00028.2012; Berrie CP, 2002, EUR J CANCER, V38, P2463, DOI 10.1016/S0959-8049(02)00485-9; Brousmiche DW, 2008, J CHROMATOGR A, V1191, P108, DOI 10.1016/j.chroma.2008.01.076; Buccione R, 2005, EUR J CANCER, V41, P470, DOI 10.1016/j.ejca.2004.11.011; BUNCE CM, 1992, P ROY SOC B-BIOL SCI, V247, P27, DOI 10.1098/rspb.1992.0005; Chang DY, 2002, ANAL CHEM, V74, P2465, DOI 10.1021/ac010788j; Corda D, 2014, FEBS J, V281, P998, DOI 10.1111/febs.12699; Corda D, 2012, BIOCHEM SOC T, V40, P101, DOI 10.1042/BST20110679; Corda D, 2009, CELL MOL LIFE SCI, V66, P3449, DOI 10.1007/s00018-009-0113-4; Corda D, 2009, J BIOL CHEM, V284, P24848, DOI 10.1074/jbc.M109.035444; De Craene JO, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030634; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Dragani LK, 2004, J CHROMATOGR B, V802, P283, DOI 10.1016/j.jchromb.2003.12.002; Falasca M, 1996, EUR J BIOCHEM, V241, P386, DOI 10.1111/j.1432-1033.1996.00386.x; FRENCH PJ, 1991, P ROY SOC B-BIOL SCI, V245, P193, DOI 10.1098/rspb.1991.0109; Grauso L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123198; IACOVELLI L, 1993, J BIOL CHEM, V268, P20402; Mandal MK, 2010, ANAL METHODS-UK, V2, P1905, DOI 10.1039/c0ay00530d; Mariggio S, 2007, CANCER RES, V67, P11769, DOI 10.1158/0008-5472.CAN-07-1997; Mariggio S, 2006, FEBS LETT, V580, P6789, DOI 10.1016/j.febslet.2006.11.039; Mariggio S, 2006, FASEB J, V20, P2567, DOI 10.1096/fj.05-5397fje; MOUNTFORD JC, 1994, BBA-MOL CELL RES, V1222, P101, DOI 10.1016/0167-4889(94)90030-2; Patrussi L, 2007, CELL SIGNAL, V19, P2351, DOI 10.1016/j.cellsig.2007.07.014; Patrussi L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00213; Thorens B, 2015, DIABETOLOGIA, V58, P221, DOI 10.1007/s00125-014-3451-1; Tsujita K, 2015, BBA-MOL CELL BIOL L, V1851, P824, DOI 10.1016/j.bbalip.2014.10.011; VALITUTTI S, 1991, CELL SIGNAL, V3, P321, DOI 10.1016/0898-6568(91)90061-X; Varone A, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0329-3; Vessichelli M, 2017, J BIOL CHEM, V292, P12828, DOI 10.1074/jbc.M116.773861; Vicinanza M, 2008, CELL MOL LIFE SCI, V65, P2833, DOI 10.1007/s00018-008-8353-2; Yue XF, 2014, J AM SOC MASS SPECTR, V25, P1322, DOI 10.1007/s13361-014-0905-0; Zheng B, 2003, P NATL ACAD SCI USA, V100, P1745, DOI 10.1073/pnas.0337605100; Zizza P, 2012, J BIOL CHEM, V287, P16849, DOI 10.1074/jbc.M111.309419	33	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2021	12								646681	10.3389/fimmu.2021.646681	http://dx.doi.org/10.3389/fimmu.2021.646681			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QX0BQ	33737939	gold, Green Published			2022-12-18	WOS:000629014900001
J	Kato, H; Perl, A				Kato, Hiroshi; Perl, Andras			Double-Edged Sword: Interleukin-2 Promotes T Regulatory Cell Differentiation but Also Expands Interleukin-13-and Interferon-gamma-Producing CD8(+) T Cells via STAT6-GATA-3 Axis in Systemic Lupus Erythematosus	FRONTIERS IN IMMUNOLOGY			English	Article						systemic lupus erythematosus; interleukin-2 (IL-2); interleukin-13 (IL-13); interferon-&#947; (IFN-&#947; ); T&#160; regulatory (Treg) cell; CD8(+) T cells; STAT6; GATA-3	DECREASED PRODUCTION	Interleukin-2 (IL-2) expands the depleted T regulatory (Treg) cell population, and it has emerged as a potential therapy in systemic lupus erythematosus (SLE). However, IL-2 administration may involve the risk of expanding unwanted pro-inflammatory cells. We herein studied the effects of IL-2 on pro-inflammatory cytokine production by CD4(+) and CD8(+) T cells in parallel with Treg development following CD3/CD28 co-stimulation. While Treg cells are depleted in SLE patients, their CD4(+) T cells were poised to receive and activate IL-2 signaling as evidenced by upregulation of CD25 and enhanced IL-2-incued STAT5 phosphorylation during Treg differentiation. In patients with SLE, however, IL-2 also expanded CD8(+) T cells capable of producing interleukin-5, interkeukin-13 (IL-13), and interferon-gamma (IFN-gamma) that occurred with enhanced expression of GATA-3 and phosphorylation of STAT6 but not STAT5. Our data pinpoint a safety signal for systemic administration of IL-2 and challenges a long-held conceptual platform of type 1 and 2 cytokine antagonism by newly documenting the IL-2-dependent development of IL-13 and IFN-gamma double-positive (IL-13(+)IFN gamma(+)) CD8(+) T cells in SLE.	[Kato, Hiroshi; Perl, Andras] SUNY Upstate Med Univ, Coll Med, Div Rheumatol, Dept Med, Syracuse, NY 13210 USA; [Kato, Hiroshi; Perl, Andras] SUNY Upstate Med Univ, Coll Med, Div Rheumatol, Dept Microbiol & Immunol, Syracuse, NY 13210 USA; [Kato, Hiroshi; Perl, Andras] SUNY Upstate Med Univ, Coll Med, Div Rheumatol, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Perl, A (corresponding author), SUNY Upstate Med Univ, Coll Med, Div Rheumatol, Dept Med, Syracuse, NY 13210 USA.	perla@upstate.edu			National Institutes of Health [R01-AI072648, AI122176]; Department of Medicine at the SUNY Upstate Medical University	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Medicine at the SUNY Upstate Medical University	This work was supported by grants R01-AI072648 and AI122176 from the National Institutes of Health and the Department of Medicine at the SUNY Upstate Medical University.	Akahoshi M, 1999, ARTHRITIS RHEUM, V42, P1644, DOI 10.1002/1529-0131(199908)42:8<1644::AID-ANR12>3.0.CO;2-L; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; Bailis W, 2013, IMMUNITY, V39, P148, DOI 10.1016/j.immuni.2013.07.006; Blanco P, 2005, ARTHRITIS RHEUM, V52, P201, DOI 10.1002/art.20745; BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606; Bonelli M, 2008, INT IMMUNOL, V20, P861, DOI 10.1093/intimm/dxn044; Burchill MA, 2007, J IMMUNOL, V178, P280, DOI 10.4049/jimmunol.178.1.280; Crispin JC, 2008, J IMMUNOL, V181, P8761, DOI 10.4049/jimmunol.181.12.8761; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; Fuschiotti P, 2013, ARTHRITIS RHEUM-US, V65, P236, DOI 10.1002/art.37706; He J, 2016, NAT MED, V22, P991, DOI 10.1038/nm.4148; Horwitz DA, 1998, ARTHRITIS RHEUM, V41, P838, DOI 10.1002/1529-0131(199805)41:5<838::AID-ART10>3.0.CO;2-S; Kato H, 2018, ARTHRITIS RHEUMATOL, V70, P427, DOI 10.1002/art.40380; Kato H, 2014, J IMMUNOL, V192, P4134, DOI 10.4049/jimmunol.1301859; Kim EH, 2012, J IMMUNOL, V188, P4305, DOI 10.4049/jimmunol.1103568; Krawczyk CM, 2007, J IMMUNOL, V178, P4080, DOI 10.4049/jimmunol.178.7.4080; Lai ZW, 2018, LANCET, V391, P1186, DOI 10.1016/S0140-6736(18)30485-9; Lai ZW, 2013, J IMMUNOL, V191, P2236, DOI 10.4049/jimmunol.1301005; Liao W, 2011, NAT IMMUNOL, V12, P551, DOI 10.1038/ni.2030; LINKERISRAELI M, 1983, J IMMUNOL, V130, P2651; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; Medsger TA, 2011, ARTHRITIS RHEUM-US, V63, P1738, DOI 10.1002/art.30489; Mellor-Pita S, 2006, ANN RHEUM DIS, V65, P553, DOI 10.1136/ard.2005.044974; Min DJ, 2001, SCAND J RHEUMATOL, V30, P159; Miyahara N, 2004, J IMMUNOL, V172, P2549, DOI 10.4049/jimmunol.172.4.2549; Miyara M, 2005, J IMMUNOL, V175, P8392, DOI 10.4049/jimmunol.175.12.8392; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; Pipkin ME, 2010, IMMUNITY, V32, P79, DOI 10.1016/j.immuni.2009.11.012; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Shi M, 2008, IMMUNITY, V28, P763, DOI 10.1016/j.immuni.2008.04.016; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Tsokos GC, 2011, NEW ENGL J MED, V365, P2110, DOI 10.1056/NEJMra1100359; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Winchester R, 2012, ARTHRITIS RHEUM-US, V64, P1589, DOI 10.1002/art.33488; Yagi R, 2010, IMMUNITY, V32, P507, DOI 10.1016/j.immuni.2010.04.004; Yamane H, 2005, J EXP MED, V202, P793, DOI 10.1084/jem.20051304; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128	38	1	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2021	12								635531	10.3389/fimmu.2021.635531	http://dx.doi.org/10.3389/fimmu.2021.635531			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QX2BW	33763079	gold, Green Published			2022-12-18	WOS:000629153800001
J	Tao, HS; Li, L; Liao, NS; Schluns, KS; Luckhart, S; Sleasman, JW; Zhong, XP				Tao, Huishan; Li, Lei; Liao, Nan-Shih; Schluns, Kimberly S.; Luckhart, Shirley; Sleasman, John W.; Zhong, Xiao-Ping			Thymic Epithelial Cell-Derived IL-15 and IL-15 Receptor alpha Chain Foster Local Environment for Type 1 Innate Like T Cell Development	FRONTIERS IN IMMUNOLOGY			English	Article						IL-15; IL-15R&#945; thymic epithelial cells; iNKT cells; &#947; &#948; T cells; type 1 innate like T cells		Expression of tissue-restricted antigens (TRAs) in thymic epithelial cells (TECs) ensures negative selection of highly self-reactive T cells to establish central tolerance. Whether some of these TRAs could exert their canonical biological functions to shape thymic environment to regulate T cell development is unclear. Analyses of publicly available databases have revealed expression of transcripts at various levels of many cytokines and cytokine receptors such as IL-15, IL-15R alpha, IL-13, and IL-23a in both human and mouse TECs. Ablation of either IL-15 or IL-15R alpha in TECs selectively impairs type 1 innate like T cell, such as iNKT1 and gamma delta T1 cell, development in the thymus, indicating that TECs not only serve as an important source of IL-15 but also trans-present IL-15 to ensure type 1 innate like T cell development. Because type 1 innate like T cells are proinflammatory, our data suggest the possibility that TEC may intrinsically control thymic inflammatory innate like T cells to influence thymic environment.	[Tao, Huishan; Li, Lei; Sleasman, John W.; Zhong, Xiao-Ping] Duke Univ, Med Ctr, Dept Pediat Allergy & Immunol, Durham, NC 27710 USA; [Liao, Nan-Shih] Acad Sinica, Inst Mol Biol, Taipei, Taiwan; [Schluns, Kimberly S.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Luckhart, Shirley] Univ Idaho, Dept Biol Sci, Dept Entomol Plant Pathol & Nematol, Moscow, ID 83843 USA; [Zhong, Xiao-Ping] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; [Zhong, Xiao-Ping] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC 27710 USA	Duke University; Academia Sinica - Taiwan; University of Texas System; UTMD Anderson Cancer Center; Idaho; University of Idaho; Duke University; Duke University	Zhong, XP (corresponding author), Duke Univ, Med Ctr, Dept Pediat Allergy & Immunol, Durham, NC 27710 USA.; Zhong, XP (corresponding author), Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA.; Zhong, XP (corresponding author), Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC 27710 USA.	xiaoping.zhong@duke.edu	Liao, Nan-Shih/ABE-7580-2020	Liao, Nan-Shih/0000-0003-3707-4145	National Institutes of Health [R56AG060984, R56AI079088, R01AI131609]; Translating Duke Health Initiative	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Translating Duke Health Initiative	This study was supported by the National Institutes of Health (R56AG060984 and R56AI079088 for X-PZ and R01AI131609 for SL) and by the Translating Duke Health Initiative.	Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Bacon WA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02523; Bornstein C, 2018, NATURE, V559, P622, DOI 10.1038/s41586-018-0346-1; Brennecke P, 2015, NAT IMMUNOL, V16, P933, DOI 10.1038/ni.3246; Burkett PR, 2004, J EXP MED, V200, P825, DOI 10.1084/jem.20041389; Castillo EF, 2010, BLOOD, V116, P2494, DOI 10.1182/blood-2010-03-277103; Chandra S, 2015, ADV IMMUNOL, V127, P145, DOI 10.1016/bs.ai.2015.03.003; Chang CL, 2011, J IMMUNOL, V187, P1235, DOI 10.4049/jimmunol.1100270; Chen Y, 2012, J IMMUNOL, V189, P61, DOI 10.4049/jimmunol.1103272; Coder BD, 2015, J IMMUNOL, V194, P5825, DOI 10.4049/jimmunol.1500082; Colpitts SL, 2015, P NATL ACAD SCI USA, V112, P9692, DOI 10.1073/pnas.1420741112; Coquet JM, 2008, P NATL ACAD SCI USA, V105, P11287, DOI 10.1073/pnas.0801631105; Coquet JM, 2013, J EXP MED, V210, P715, DOI 10.1084/jem.20112061; Corpuz TM, 2016, J IMMUNOL, V196, P645, DOI 10.4049/jimmunol.1502082; Cosway EJ, 2017, J EXP MED, V214, P3183, DOI 10.1084/jem.20171000; Cowan JE, 2015, EUR J IMMUNOL, V45, P652, DOI 10.1002/eji.201445108; Cowan JE, 2013, J EXP MED, V210, P675, DOI 10.1084/jem.20122070; Cui GW, 2014, P NATL ACAD SCI USA, V111, P1915, DOI 10.1073/pnas.1318281111; De Creus A, 2002, J IMMUNOL, V168, P6486, DOI 10.4049/jimmunol.168.12.6486; Derbinski J, 2001, NAT IMMUNOL, V2, P1032, DOI 10.1038/ni723; Dixit VD, 2012, SEMIN IMMUNOL, V24, P321, DOI 10.1016/j.smim.2012.04.002; Dubois S, 2002, IMMUNITY, V17, P537, DOI 10.1016/S1074-7613(02)00429-6; Gordon J, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-69; Hams E, 2013, J IMMUNOL, V191, P5349, DOI 10.4049/jimmunol.1301176; Hayday AC, 2019, J IMMUNOL, V203, P311, DOI 10.4049/jimmunol.1800934; Hu MD, 2018, J IMMUNOL, V201, P747, DOI 10.4049/jimmunol.1701603; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Kernfeld EM, 2018, IMMUNITY, V48, P1258, DOI 10.1016/j.immuni.2018.04.015; Klein L, 2014, NAT REV IMMUNOL, V14, P377, DOI 10.1038/nri3667; Koay HF, 2016, NAT IMMUNOL, V17, P1300, DOI 10.1038/ni.3565; Legoux F, 2019, NAT IMMUNOL, V20, P1244, DOI 10.1038/s41590-019-0465-3; Liou YH, 2014, J IMMUNOL, V193, P1747, DOI 10.4049/jimmunol.1400868; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Lodolce JP, 2001, J EXP MED, V194, P1187, DOI 10.1084/jem.194.8.1187; Lucas B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16041-x; Lynch L, 2015, NAT IMMUNOL, V16, P85, DOI 10.1038/ni.3047; Lynch L, 2012, IMMUNITY, V37, P574, DOI 10.1016/j.immuni.2012.06.016; Ma LJ, 2009, J IMMUNOL, V183, P1044, DOI 10.4049/jimmunol.0900420; Masters AR, 2017, CLIN EXP IMMUNOL, V187, P6, DOI 10.1111/cei.12851; Matsuda JL, 2006, BLOOD, V107, P2797, DOI 10.1182/blood-2005-08-3103; Matsuda JL, 2002, NAT IMMUNOL, V3, P966, DOI 10.1038/ni837; Michel ML, 2008, P NATL ACAD SCI USA, V105, P19845, DOI 10.1073/pnas.0806472105; Miller CN, 2018, NATURE, V559, P627, DOI 10.1038/s41586-018-0345-2; Miragaia RJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-19100-4; Mortier E, 2008, J EXP MED, V205, P1213, DOI 10.1084/jem.20071913; Mortier E, 2009, IMMUNITY, V31, P811, DOI 10.1016/j.immuni.2009.09.017; Pan Y, 2020, EUR J IMMUNOL, V50, P192, DOI 10.1002/eji.201948289; Pantelyushin S, 2012, J CLIN INVEST, V122, P2252, DOI 10.1172/JCI61862; Papotto PH, 2018, J AUTOIMMUN, V87, P26, DOI 10.1016/j.jaut.2017.11.006; Park JE, 2020, SCIENCE, V367, P868, DOI 10.1126/science.aay3224; Parker ME, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00042; Perry JSA, 2014, IMMUNITY, V41, P414, DOI 10.1016/j.immuni.2014.08.007; Ranson T, 2003, BLOOD, V101, P4887, DOI 10.1182/blood-2002-11-3392; Ranson T, 2003, P NATL ACAD SCI USA, V100, P2663, DOI 10.1073/pnas.0535482100; Ribot JC, 2009, NAT IMMUNOL, V10, P427, DOI 10.1038/ni.1717; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192; Shen SD, 2011, J IMMUNOL, V187, P2122, DOI 10.4049/jimmunol.1100495; Shibata K, 2008, J IMMUNOL, V181, P5940, DOI 10.4049/jimmunol.181.9.5940; Shibata K, 2011, BLOOD, V118, P586, DOI 10.1182/blood-2011-02-334995; Shin J, 2014, P NATL ACAD SCI USA, V111, pE776, DOI 10.1073/pnas.1315435111; Takaba H, 2015, CELL, V163, P975, DOI 10.1016/j.cell.2015.10.013; Vantourout P, 2013, NAT REV IMMUNOL, V13, P88, DOI 10.1038/nri3384; Wang HX, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03099; Wang HX, 2016, J IMMUNOL, V197, P141, DOI 10.4049/jimmunol.1502698; Wang HX, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002370; Wang WK, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00773; Watarai H, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001255; Wendland K, 2018, J IMMUNOL, V201, P524, DOI 10.4049/jimmunol.1800418; White AJ, 2018, J IMMUNOL, V200, P3333, DOI 10.4049/jimmunol.1800120; White AJ, 2014, J IMMUNOL, V192, P2659, DOI 10.4049/jimmunol.1303057; Wu JH, 2014, J CLIN INVEST, V124, P1685, DOI 10.1172/JCI69780; Yang W, 2015, MOL IMMUNOL, V68, P536, DOI 10.1016/j.molimm.2015.07.022; Zeng Y, 2019, IMMUNITY, V51, P930, DOI 10.1016/j.immuni.2019.09.008	75	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 1	2021	12								623280	10.3389/fimmu.2021.623280	http://dx.doi.org/10.3389/fimmu.2021.623280			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QW6TE	33732245	gold, Green Published			2022-12-18	WOS:000628778900001
J	Johnstone, BH; Messner, F; Brandacher, G; Woods, EJ				Johnstone, Brian H.; Messner, Franka; Brandacher, Gerald; Woods, Erik J.			A Large-Scale Bank of Organ Donor Bone Marrow and Matched Mesenchymal Stem Cells for Promoting Immunomodulation and Transplant Tolerance	FRONTIERS IN IMMUNOLOGY			English	Review						immune tolerance; chimerism; bone marrow; vascular composite allograft; regulatory T cells; solid organ transplant; mesenchymal stem cells; hematopoietic stem cell	VERSUS-HOST-DISEASE; STEROID-REFRACTORY ACUTE; BRONCHIOLITIS OBLITERANS SYNDROME; PREVENT ACUTE REJECTION; STROMAL CELLS; MIXED CHIMERISM; KIDNEY-TRANSPLANTATION; ALLOGRAFT SURVIVAL; ACUTE GVHD; RENAL-TRANSPLANTATION	Induction of immune tolerance for solid organ and vascular composite allografts is the Holy Grail for transplantation medicine. This would obviate the need for life-long immunosuppression which is associated with serious adverse outcomes, such as infections, cancers, and renal failure. Currently the most promising means of tolerance induction is through establishing a mixed chimeric state by transplantation of donor hematopoietic stem cells; however, with the exception of living donor renal transplantation, the mixed chimerism approach has not achieved durable immune tolerance on a large scale in preclinical or clinical trials with other solid organs or vascular composite allotransplants (VCA). Ossium Health has established a bank of cryopreserved bone marrow (BM), termed "hematopoietic progenitor cell (HPC), Marrow," recovered from deceased organ donor vertebral bodies. This new source for hematopoietic cell transplant will be a valuable resource for treating hematological malignancies as well as for inducing transplant tolerance. In addition, we have discovered and developed a large source of mesenchymal stem (stromal) cells (MSC) tightly associated with the vertebral body bone fragment byproduct of the HPC, Marrow recovery process. Thus, these vertebral bone adherent MSC (vBA-MSC) are matched to the banked BM obtained from each donor, as opposed to third-party MSC, which enhances safety and potentially efficacy. Isolation and characterization of vBA-MSC from over 30 donors has demonstrated that the cells are no different than traditional BM-MSC; however, their abundance is >1,000-fold higher than obtainable from living donor BM aspirates. Based on our own unpublished data as well as reports published by others, MSC facilitate chimerism, especially at limiting hematopoietic stem and progenitor cell (HSPC) numbers and increase safety by controlling and/or preventing graft-vs.-host-disease (GvHD). Thus, vBA-MSC have the potential to facilitate mixed chimerism, promote complementary peripheral immunomodulatory functions and increase safety of BM infusions. Both HPC, Marrow and vBA-MSC have potential use in current VCA and solid organ transplant (SOT) tolerance clinical protocols that are amenable to "delayed tolerance." Current trials with HPC, Marrow are planned with subsequent phases to include vBA-MSC for tolerance of both VCA and SOT.	[Johnstone, Brian H.; Woods, Erik J.] Ossium Hlth, Indianapolis, IN 46278 USA; [Johnstone, Brian H.; Woods, Erik J.] Marian Univ, Dept Biomed Sci, Coll Osteopath Med, Indianapolis, IN 46222 USA; [Messner, Franka; Brandacher, Gerald] Johns Hopkins Univ, Sch Med, Dept Plast & Reconstruct Surg, Baltimore, MD USA; [Messner, Franka] Med Univ Innsbruck, Dept Visceral Transplant & Thorac Surg, Ctr Operat Med, Innsbruck, Austria; [Woods, Erik J.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	Johns Hopkins University; Medical University of Innsbruck; Indiana University System; Indiana University Bloomington	Woods, EJ (corresponding author), Ossium Hlth, Indianapolis, IN 46278 USA.; Woods, EJ (corresponding author), Marian Univ, Dept Biomed Sci, Coll Osteopath Med, Indianapolis, IN 46222 USA.; Woods, EJ (corresponding author), Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.	erik@ossiumhealth.com		Brandacher, Gerald/0000-0001-7790-441X	NIH/NIAID SBIR grant [AI155196]; Ossium Health	NIH/NIAID SBIR grant; Ossium Health	This work was supported by NIH/NIAID SBIR grant AI155196 (BHJ and EJW) and by Ossium Health, that in part, paid costs of open access publication fees.	Antunes M., 2007, J EUR UNION, V324, P121; Aoyama A, 2015, AM J TRANSPLANT, V15, P1415, DOI 10.1111/ajt.13130; Asch WS, 2016, AM J KIDNEY DIS, V68, P839, DOI 10.1053/j.ajkd.2016.06.009; Bacigalupo A, 2009, BIOL BLOOD MARROW TR, V15, P1628, DOI 10.1016/j.bbmt.2009.07.004; Bader P, 2018, BONE MARROW TRANSPL, V53, P852, DOI 10.1038/s41409-018-0102-z; Ball LM, 2013, BRIT J HAEMATOL, V163, P501, DOI 10.1111/bjh.12545; Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; Bianco P, 2011, BLOOD, V117, P5281, DOI 10.1182/blood-2011-01-315069; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Blakeslee S., 2002, NEW YORK TIMES; Blasszauer B, 1997, J MED ETHICS, V23, P133, DOI 10.1136/jme.23.3.133; Brandacher G, 2018, CURR OPIN ORGAN TRAN, V23, P559, DOI 10.1097/MOT.0000000000000574; Brandacher G, 2012, EXPERT REV CLIN IMMU, V8, P673, DOI [10.1586/ECI.12.54, 10.1586/eci.12.54]; Casiraghi F, 2012, AM J TRANSPLANT, V12, P2373, DOI 10.1111/j.1600-6143.2012.04115.x; Casiraghi F, 2008, J IMMUNOL, V181, P3933, DOI 10.4049/jimmunol.181.6.3933; Chen B, 2012, TRANSPLANTATION, V94, P671, DOI 10.1097/TP.0b013e318264fbc1; Chen JW, 2018, J SURG RES, V224, P132, DOI 10.1016/j.jss.2017.03.050; Chhabra AY, 2017, TRANSPLANTATION, V101, P2682, DOI 10.1097/TP.0000000000001837; Cosio FG, 2005, KIDNEY INT, V67, P2415, DOI 10.1111/j.1523-1755.2005.00349.x; Cuende N, 2018, CYTOTHERAPY, V20, P1401, DOI 10.1016/j.jcyt.2018.09.010; Cutler RL, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-016982; Dabbs AD, 2003, J HEART LUNG TRANSPL, V22, P1268, DOI 10.1016/S1053-2498(02)01227-5; Davis TA, 2014, STEM CELL TRANSL MED, V3, P1444, DOI 10.5966/sctm.2014-0131; Detry O, 2017, J HEPATOL, V67, P47, DOI 10.1016/j.jhep.2017.03.001; Dharnidharka VR, 2006, TRANSPLANTATION, V81, P1662, DOI 10.1097/01.tp.0000226068.66819.37; Dodson BP, 2015, BMC BIOTECHNOL, V15, DOI 10.1186/s12896-015-0190-4; Donnenberg AD, 2011, REGEN MED, V6, P701, DOI [10.2217/rme.11.89, 10.2217/RME.11.89]; Dotoli GM, 2017, BONE MARROW TRANSPL, V52, P859, DOI 10.1038/bmt.2017.35; ECKARDT JR, 1993, BONE MARROW TRANSPL, V11, P125; Elgaz S, 2019, TRANSFUS MED HEMOTH, V46, P27, DOI 10.1159/000496809; Elias N., 2015, AM J TRANSPLANT, P15; English K, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a015560; Erickson K., 2015, AM J TRANSPLANT, P15; Erpicum P, 2019, KIDNEY INT, V95, P693, DOI 10.1016/j.kint.2018.08.046; Ezekian B, 2018, TRANSPLANTATION, V102, P1213, DOI 10.1097/TP.0000000000002242; Fang BJ, 2007, PEDIATR TRANSPLANT, V11, P814, DOI 10.1111/j.1399-3046.2007.00780.x; Farris AB, 2011, AM J TRANSPLANT, V11, P1464, DOI 10.1111/j.1600-6143.2011.03572.x; Farrugia Albert, 2006, Cell and Tissue Banking, V7, P325, DOI 10.1007/s10561-006-9012-1; Fernandez-Garcia M, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0155-5; Francis RS, 2011, EUR J IMMUNOL, V41, P726, DOI 10.1002/eji.201040509; Franquesa M, 2012, STEM CELLS DEV, V21, P3125, DOI 10.1089/scd.2012.0096; Fryer M, 2015, EXPERT REV CLIN IMMU, V11, P1189, DOI 10.1586/1744666X.2015.1078729; Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004; Galipeau J, 2013, CYTOTHERAPY, V15, P2, DOI 10.1016/j.jcyt.2012.10.002; Ge W, 2010, TRANSPLANTATION, V90, P1312, DOI 10.1097/TP.0b013e3181fed001; Giwa S, 2017, NAT BIOTECHNOL, V35, P530, DOI 10.1038/nbt.3889; Gorantla VS, 2012, CYTOTHERAPY, V14, P104, DOI 10.3109/14653249.2011.605350; Green M, 2013, AM J TRANSPLANT, V13, P3, DOI 10.1111/ajt.12093; Guo Y., 2019, PLASTIC RECONSTR SUR, V7, P127, DOI [10.1097/01.GOX.0000558457.79886.05, DOI 10.1097/01.GOX.0000558457.79886.05]; Han JB, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/5432134; Hashmi S, 2016, LANCET HAEMATOL, V3, pE45, DOI 10.1016/S2352-3026(15)00224-0; Herrmann R, 2012, INT J HEMATOL, V95, P182, DOI 10.1007/s12185-011-0989-2; Hotta K, 2018, TRANSPLANTATION, V102, pE128, DOI 10.1097/TP.0000000000002078; Huang WC, 2010, PLAST RECONSTR SURG, V125, P1095, DOI 10.1097/PRS.0b013e3181d0ab80; Huh K., 2016, AM J TRANSPLANT, P16; Ildstad Suzanne T, 2015, Chimerism, V6, P33, DOI 10.1080/19381956.2015.1130780; Introna M, 2014, BIOL BLOOD MARROW TR, V20, P375, DOI 10.1016/j.bbmt.2013.11.033; Jia Z, 2012, EXP EYE RES, V102, P44, DOI 10.1016/j.exer.2012.06.008; Johnstone BH, 2020, CYTOTHERAPY, V22, P617, DOI 10.1016/j.jcyt.2020.07.003; Kawai T, 2019, AM J TRANSPLANT, V19, P324, DOI 10.1111/ajt.15086; Kawai T, 2014, TRANSPLANTATION, V98, P117, DOI 10.1097/TP.0000000000000260; Khalifeh A., 2017, AM J TRANSPLANT, P17; Kovarik J, 2013, PATHOBIOLOGY, V80, P275, DOI 10.1159/000346960; Koyama I, 2007, AM J TRANSPLANT, V7, P1055, DOI 10.1111/j.1600-6143.2006.01703.x; Kueckelhaus M, 2016, TRANSPL INT, V29, P655, DOI 10.1111/tri.12652; Kurtzberg J, 2014, BIOL BLOOD MARROW TR, V20, P229, DOI 10.1016/j.bbmt.2013.11.001; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; Lee KW, 2020, TRANSPLANTATION, V104, P1472, DOI 10.1097/TP.0000000000003006; Lee S, 2013, AM J TRANSPLANT, V13, P3223, DOI 10.1111/ajt.12500; LEE WPA, 1991, PLAST RECONSTR SURG, V87, P401, DOI 10.1097/00006534-199103000-00001; Lellouch AG, 2020, PLAST RECONSTR SURG, V145, p757E, DOI 10.1097/PRS.0000000000006676; Lenk C, 2012, J MED ETHICS, V38, P342, DOI 10.1136/jme.2010.038760; Leventhal J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003509; Leventhal JR, 2018, HUM IMMUNOL, V79, P277, DOI 10.1016/j.humimm.2018.01.010; Leventhal JR, 2018, HUM IMMUNOL, V79, P272, DOI 10.1016/j.humimm.2018.01.007; Leventhal JR, 2015, TRANSPLANTATION, V99, P288, DOI 10.1097/TP.0000000000000605; Leventhal Joseph R, 2013, Clin Transpl, P145; Lioznov M, 2008, BONE MARROW TRANSPL, V42, P121, DOI 10.1038/bmt.2008.93; Locatelli F, 2017, EXPERT REV CLIN IMMU, V13, P43, DOI 10.1080/1744666X.2016.1208086; Lodhi SA, 2011, AM J TRANSPLANT, V11, P1226, DOI 10.1111/j.1600-6143.2011.03539.x; Lohan P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02666; Lucchini G, 2010, BIOL BLOOD MARROW TR, V16, P1293, DOI 10.1016/j.bbmt.2010.03.017; Madariaga MLL, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87019; Mahr B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01762; Manzia TM, 2018, LIVER TRANSPLANT, V24, P1199, DOI 10.1002/lt.25293; Marcen R, 2009, DRUGS, V69, P2227, DOI 10.2165/11319260-000000000-00000; Messner F, 2019, TRANSPLANTATION, V103, P1556, DOI 10.1097/TP.0000000000002711; Morata-Tarifa C, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01592-z; Mudrabettu C, 2015, NEPHROLOGY, V20, P25, DOI 10.1111/nep.12338; Munneke JM, 2016, TRANSPLANTATION, V100, P2309, DOI 10.1097/TP.0000000000001029; Murphy MB, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.94; Nauta AJ, 2006, J IMMUNOL, V177, P2080, DOI 10.4049/jimmunol.177.4.2080; Obermajer N, 2014, J IMMUNOL, V193, P4988, DOI 10.4049/jimmunol.1401776; Ojo AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMoa021744; Omer AK, 2014, AM J HEMATOL, V89, P698, DOI 10.1002/ajh.23716; Oura T, 2019, TRANSPLANTATION, V103, P168, DOI 10.1097/TP.0000000000002417; Ozmen S, 2006, TRANSPL P, V38, P1625, DOI 10.1016/j.transproceed.2006.02.154; Peng YW, 2013, TRANSPLANTATION, V95, P161, DOI 10.1097/TP.0b013e3182754c53; Perez-Simon JA, 2011, HAEMATOL-HEMATOL J, V96, P1072, DOI 10.3324/haematol.2010.038356; Perico N, 2013, TRANSPL INT, V26, P867, DOI 10.1111/tri.12132; Perico N, 2011, CLIN J AM SOC NEPHRO, V6, P412, DOI 10.2215/CJN.04950610; Pilat N, 2012, CURR OPIN ORGAN TRAN, V17, P63, DOI 10.1097/MOT.0b013e32834ee68b; Pinsky BW, 2009, AM J TRANSPLANT, V9, P2597, DOI 10.1111/j.1600-6143.2009.02798.x; Pinson CW, 2000, ANN SURG, V232, P597, DOI 10.1097/00000658-200010000-00015; Pirnay JP, 2012, CELL TISSUE BANK, V13, P487, DOI 10.1007/s10561-012-9323-3; Pittenger MF, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536-019-0083-6; Plock JA, 2017, TRANSPLANTATION, V101, pE1, DOI 10.1097/TP.0000000000001498; Plock JA, 2015, TRANSPLANTATION, V99, P1765, DOI 10.1097/TP.0000000000000731; Podesta MA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01287; Poloni A, 2006, LEUKEMIA, V20, P329, DOI 10.1038/sj.leu.2404018; Rahhal DN, 2009, TRANSPLANTATION, V88, P773, DOI 10.1097/TP.0b013e3181b47cfa; Rama I, 2010, NAT REV NEPHROL, V6, P511, DOI 10.1038/nrneph.2010.102; Rana A, 2015, JAMA SURG, V150, P252, DOI 10.1001/jamasurg.2014.2038; Reinders MEJ, 2013, STEM CELL TRANSL MED, V2, P107, DOI 10.5966/sctm.2012-0114; Resnick IB, 2013, AM J BLOOD RES, V3, P225; Salmenniemi U, 2017, BONE MARROW TRANSPL, V52, P606, DOI 10.1038/bmt.2016.317; Sanchez-Guijo F, 2014, BIOL BLOOD MARROW TR, V20, P1580, DOI 10.1016/j.bbmt.2014.06.015; Sasaki H, 2018, HUM IMMUNOL, V79, P258, DOI 10.1016/j.humimm.2017.11.008; Scandling JD, 2015, AM J TRANSPLANT, V15, P695, DOI 10.1111/ajt.13091; Schneeberger S, 2013, ANN SURG, V257, P345, DOI 10.1097/SLA.0b013e31826d90bb; Sellares J, 2012, AM J TRANSPLANT, V12, P388, DOI 10.1111/j.1600-6143.2011.03840.x; Shah TG, 2019, CLIN TRANSL MED, V8, DOI 10.1186/s40169-019-0242-9; Shores JT, 2015, PLAST RECONSTR SURG, V135, p351E, DOI 10.1097/PRS.0000000000000892; Song Mi-Kyung, 2006, Prog Transplant, V16, P222; Spitzer TR, 2015, BONE MARROW TRANSPL, V50, P469, DOI 10.1038/bmt.2014.296; Spitzer TR, 2019, TRANSPLANTATION, V103, P2366, DOI 10.1097/TP.0000000000002669; Spitzer TR, 2001, BONE MARROW TRANSPL, V27, P893, DOI 10.1038/sj.bmt.1703015; Steinberg EA, 2018, PEDIATR NEPHROL, V33, P361, DOI 10.1007/s00467-017-3637-0; Stockschlader M, 1996, BONE MARROW TRANSPL, V17, P197; STOCKSCHLADER M, 1995, BONE MARROW TRANSPL, V15, P569; Strober S, 2016, BLOOD, V127, P1539, DOI 10.1182/blood-2015-12-685107; Sykes M, 1997, NAT MED, V3, P783, DOI 10.1038/nm0797-783; Sykes M, 2001, IMMUNITY, V14, P417, DOI 10.1016/S1074-7613(01)00122-4; Sykes M, 2019, BONE MARROW TRANSPL, V54, P815, DOI 10.1038/s41409-019-0620-3; Tan JM, 2012, JAMA-J AM MED ASSOC, V307, P1169, DOI 10.1001/jama.2012.316; Tollerud D., 2019, AM J TRANSPLANT, P19; Tonsho M, 2015, AM J TRANSPLANT, V15, P2231, DOI 10.1111/ajt.13274; Tonsho M., 2016, AM J TRANSPLANT, P6; van den Berg JWK, 2000, CHEST, V118, P1648, DOI 10.1378/chest.118.6.1648; Vermeulen KM, 2004, CLIN TRANSPLANT, V18, P377, DOI 10.1111/j.1399-0012.2004.00174.x; von Bahr L, 2012, BIOL BLOOD MARROW TR, V18, P557, DOI 10.1016/j.bbmt.2011.07.023; von Bonin M, 2009, BONE MARROW TRANSPL, V43, P245, DOI 10.1038/bmt.2008.316; Walter J, 2014, LANCET RESP MED, V2, P1016, DOI 10.1016/S2213-2600(14)70217-6; Waltz E, 2006, NAT MED, V12, P487, DOI 10.1038/nm0506-487; Wang Y, 2009, TRANSPL P, V41, P4352, DOI 10.1016/j.transproceed.2009.08.072; Woods EJ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02470-1; Woods EJ, 2016, CYTOTHERAPY, V18, P697, DOI 10.1016/j.jcyt.2016.03.295; Xie Y, 2017, TRANSPLANTATION, V101, P1056, DOI 10.1097/TP.0000000000001684; Yamada Y, 2014, AM J TRANSPLANT, V14, P2704, DOI 10.1111/ajt.12936; Yamada Y, 2012, AM J TRANSPLANT, V12, P330, DOI 10.1111/j.1600-6143.2011.03795.x; Yamada Yohei, 2012, Chimerism, V3, P24; Yolcu ES, 2015, CURR OPIN ORGAN TRAN, V20, P57, DOI 10.1097/MOT.0000000000000156; Zhang W, 2004, STEM CELLS DEV, V13, P263, DOI 10.1089/154732804323099190; Zhao ZG, 2012, IMMUNOL INVEST, V41, P183, DOI 10.3109/08820139.2011.607877; Zhou HP, 2006, TRANSPL P, V38, P3046, DOI 10.1016/j.transproceed.2006.10.002; Zuber J, 2017, TRENDS IMMUNOL, V38, P829, DOI 10.1016/j.it.2017.07.008	156	1	3	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 26	2021	12								622604	10.3389/fimmu.2021.622604	http://dx.doi.org/10.3389/fimmu.2021.622604			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QV2BS	33732244	Green Published, gold			2022-12-18	WOS:000627782400001
J	Patel, VK; Williams, H; Li, SCH; Fletcher, JP; Medbury, HJ				Patel, Vyoma K.; Williams, Helen; Li, Stephen C. H.; Fletcher, John P.; Medbury, Heather J.			Monocyte Subset Recruitment Marker Profile Is Inversely Associated With Blood ApoA1 Levels	FRONTIERS IN IMMUNOLOGY			English	Article						monocytes; atherosclerosis; dyslipidemia; adhesion; migration; cardiovascular disease	CARDIOVASCULAR-DISEASE; CIRCULATING MONOCYTES; INFLAMMATORY PROFILE; ADHESION MOLECULES; DIABETES-MELLITUS; CCR2 EXPRESSION; RECEPTOR CCR2; HYPERCHOLESTEROLEMIA; CHOLESTEROL; MIGRATION	Dyslipidemia promotes development of the atherosclerotic plaques that characterise cardiovascular disease. Plaque progression requires the influx of monocytes into the vessel wall, but whether dyslipidemia is associated with an increased potential of monocytes to extravasate is largely unknown. Here (using flow cytometry) we examined recruitment marker expression on monocytes from generally healthy individuals who differed in lipid profile. Comparisons were made between monocyte subsets, participants and relative to participants' lipid levels. Monocyte subsets differed significantly in their expression of recruitment markers, with highest expression being on either the classical or non-classical subsets. However, these inter-subset differences were largely overshadowed by considerable inter-participant differences with some participants having higher levels of recruitment markers on all three monocyte subsets. Furthermore, when the expression of one recruitment marker was high, so too was that of most of the other markers, with substantial correlations evident between the markers. The inter-participant differences were explained by lipid levels. Most notably, there was a significant inverse correlation for most markers with ApoA1 levels. Our results indicate that dyslipidemia, in particular low levels of ApoA1, is associated with an increased potential of all monocyte subsets to extravasate, and to do so using a wider repertoire of recruitment markers than currently appreciated.	[Patel, Vyoma K.; Williams, Helen; Fletcher, John P.; Medbury, Heather J.] Westmead Hosp, Dept Surg, Vasc Biol Res Ctr, Westmead, NSW, Australia; [Patel, Vyoma K.; Williams, Helen; Fletcher, John P.; Medbury, Heather J.] Univ Sydney, Westmead Clin Sch, Westmead, NSW, Australia; [Li, Stephen C. H.] Western Sydney Univ, Blacktown Mt Druitt Clin Sch, Blacktown Hosp, Blacktown, NSW, Australia; [Li, Stephen C. H.] Westmead Hosp, Inst Clin Pathol & Med Res, Westmead, NSW, Australia	University of Sydney; University of Sydney; Blacktown & Mount Druitt Hospital; Western Sydney University; University of Sydney	Medbury, HJ (corresponding author), Westmead Hosp, Dept Surg, Vasc Biol Res Ctr, Westmead, NSW, Australia.; Medbury, HJ (corresponding author), Univ Sydney, Westmead Clin Sch, Westmead, NSW, Australia.	heather.medbury@sydney.edu.au	Williams, Helen/AAW-9632-2021	Williams, Helen/0000-0001-8221-5766	Westmead Medical Research Foundation (WMRF); Clinical Chemistry Research and Education Fund	Westmead Medical Research Foundation (WMRF); Clinical Chemistry Research and Education Fund	This study was supported by Westmead Medical Research Foundation (WMRF) and Clinical Chemistry Research and Education Fund.	Ancuta P, 2003, J EXP MED, V197, P1701, DOI 10.1084/jem.20022156; Askenase MH, 2015, IMMUNITY, V42, P1130, DOI 10.1016/j.immuni.2015.05.011; Bouma G, 2004, DIABETES, V53, P1979, DOI 10.2337/diabetes.53.8.1979; Boyette LB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176460; Braunersreuther V, 2007, THROMB HAEMOSTASIS, V97, P714, DOI 10.1160/TH07-01-0036; Ceriello A, 1998, HORM METAB RES, V30, P146, DOI 10.1055/s-2007-978854; Combadiere C, 2008, CIRCULATION, V117, P1649, DOI 10.1161/CIRCULATIONAHA.107.745091; Connaughton EP, 2018, IMMUNOL CELL BIOL, V96, P742, DOI 10.1111/imcb.12032; Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012; Diederich W, 2001, ATHEROSCLEROSIS, V159, P313, DOI 10.1016/S0021-9150(01)00518-4; Florvall G, 2006, J GERONTOL A-BIOL, V61, P1262, DOI 10.1093/gerona/61.12.1262; GARFAGNINI A, 1995, EUR HEART J, V16, P465, DOI 10.1093/oxfordjournals.eurheartj.a060937; Guo N, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00272; Hamers AAJ, 2019, ARTERIOSCL THROM VAS, V39, P25, DOI 10.1161/ATVBAHA.118.311022; Han KH, 1999, J LIPID RES, V40, P1053; Han KH, 1998, ARTERIOSCL THROM VAS, V18, P1983, DOI 10.1161/01.ATV.18.12.1983; Hyka N, 2001, BLOOD, V97, P2381, DOI 10.1182/blood.V97.8.2381; Imhof BA, 2004, NAT REV IMMUNOL, V4, P432, DOI 10.1038/nri1375; Iqbal AJ, 2016, ELIFE, V5, DOI 10.7554/eLife.15190; Johnson-Leger C, 2003, CELL TISSUE RES, V314, P93, DOI 10.1007/s00441-003-0775-4; Kapellos TS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02035; Kratofil RM, 2017, ARTERIOSCL THROM VAS, V37, P35, DOI 10.1161/ATVBAHA.116.308198; Leon B, 2008, BLOOD, V111, P3126, DOI 10.1182/blood-2007-07-100610; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Libby P, 2013, SEMIN IMMUNOPATHOL, V35, P553, DOI 10.1007/s00281-013-0387-3; Mandl M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112140; Medbury HJ, 2013, INT ANGIOL, V32, P74; Min JK, 2005, J IMMUNOL, V175, P531, DOI 10.4049/jimmunol.175.1.531; Moens SJB, 2017, EUR HEART J, V38, P1584, DOI 10.1093/eurheartj/ehx002; Murphy AJ, 2008, ARTERIOSCL THROM VAS, V28, P2071, DOI 10.1161/ATVBAHA.108.168690; Nagareddy PR, 2013, CELL METAB, V17, P695, DOI 10.1016/j.cmet.2013.04.001; Nichols M., 2016, AUSTR HEART DIS STAT; Noels H, 2019, ARTERIOSCL THROM VAS, V39, P583, DOI 10.1161/ATVBAHA.118.312037; Patel VK, 2017, ATHEROSCLEROSIS, V263, P15, DOI 10.1016/j.atherosclerosis.2017.05.026; Peschel T, 2003, CYTOM PART B-CLIN CY, V53B, P78, DOI 10.1002/cyto.b.10026; Quintin J, 2012, CELL HOST MICROBE, V12, P223, DOI 10.1016/j.chom.2012.06.006; Rogacev KS, 2015, NEPHROL DIAL TRANSPL, V30, P143, DOI 10.1093/ndt/gfu315; Rogacev KS, 2012, J AM COLL CARDIOL, V60, P1512, DOI 10.1016/j.jacc.2012.07.019; Rogacev KS, 2011, EUR HEART J, V32, P84, DOI 10.1093/eurheartj/ehq371; Shalia KK, 2009, INDIAN J CLIN BIOCHE, V24, P388, DOI 10.1007/s12291-009-0070-6; Shalova IN, 2015, IMMUNITY, V42, P484, DOI 10.1016/j.immuni.2015.02.001; Soehnlein O, 2013, EMBO MOL MED, V5, P471, DOI 10.1002/emmm.201201717; Stansfield BK, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169-014-0040-3; Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950; Swirski FK, 2006, P NATL ACAD SCI USA, V103, P10340, DOI 10.1073/pnas.0604260103; Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549; Thomas GD, 2017, ARTERIOSCL THROM VAS, V37, P1548, DOI 10.1161/ATVBAHA.117.309145; Tolani S, 2013, ATHEROSCLEROSIS, V229, P79, DOI 10.1016/j.atherosclerosis.2013.03.031; Tropea BI, 1996, J VASC SURG, V23, P596, DOI 10.1016/S0741-5214(96)80038-3; Tummala PE, 1999, CIRCULATION, V100, P1223, DOI 10.1161/01.CIR.100.11.1223; Verweij SL, 2018, CARDIOVASC RES, V114, P468, DOI 10.1093/cvr/cvx224; Weber C, 2000, J LEUKOCYTE BIOL, V67, P699, DOI 10.1002/jlb.67.5.699; Weber C, 2016, THROMB HAEMOSTASIS, V116, P626, DOI 10.1160/TH16-02-0091; Williams H, 2017, INT ANGIOL, V36, P145, DOI 10.23736/S0392-9590.16.03661-0; Wong KL, 2012, IMMUNOL RES, V53, P41, DOI 10.1007/s12026-012-8297-3; Wong KL, 2011, BLOOD, V118, pE15, DOI 10.1182/blood-2010-12-326355; Ziegler-Heitbrock L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00023; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558	58	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 26	2021	12								616305	10.3389/fimmu.2021.616305	http://dx.doi.org/10.3389/fimmu.2021.616305			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QV1QH	33717107	gold, Green Published			2022-12-18	WOS:000627752200001
J	Bai, W; Zhang, LX; Zhao, JL; Zhang, SZ; Zhou, JX; Leng, XM; Liu, ZY; Ye, WL; Han, B; Tian, XP; Li, MT; Zhao, Y; Zeng, XF				Bai, Wei; Zhang, Lixia; Zhao, Jiuliang; Zhang, Shangzhu; Zhou, Jiaxin; Leng, Xiaomei; Liu, Zhengyin; Ye, Wenling; Han, Bing; Tian, Xinping; Li, Mengtao; Zhao, Yan; Zeng, Xiaofeng			Renal Involvement and HBV Infection Are Common in Chinese Patients With Cryoglobulinemia	FRONTIERS IN IMMUNOLOGY			English	Article						cryoglobulinemia; vasculitis; HBV infection; autoimmunity diseases; renal involvement		Objectives: This study aimed to describe the main characteristics of Chinese patients with cryoglobulinemia, especially the characteristics of patients with different causes of cryoglobulinemia. Methods: Eighty inpatients diagnosed with cryoglobulinemia from different wards in Peking Union Medical College Hospital were included in this study. Demographic, clinical, biological, and renal pathological data were collected. We analyzed the characteristics of 61 patients with different causes of cryoglobulinemia. Results: Most patients (36/80, 45%) were diagnosed between 40 and 60 years of age. The male: female ratio was 1:1.5. Mixed (II + III) cryoglobulinemia accounted for the majority (43.8%) of cases. Renal involvement (87.5%), cutaneous involvement (57.5%), and fever (27.5%) were the most common clinical manifestations, while other manifestations included serositis and pulmonary and gastrointestinal involvement. The most common renal histopathological pattern was membranoproliferative glomerulonephritis (25/42, 59.5%). The secondary causes of cryoglobulinemia included infectious diseases (26/61, 32.5%), such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, and connective tissue diseases (22/61, 27.5%), such as lupus and hematologic tumors (13/61, 16.3%). Patients with hematologic tumors were diagnosed at an older age (P = 0.044) and mostly had type I cryoglobulinemia (P < 0.001). No significant difference in clinical or biological manifestations was found among patients with different causes of cryoglobulinemia. Conclusions: This is the largest cohort of Chinese patients with cryoglobulinemia. We found that renal involvement and HBV infection might be more common in Chinese patients with cryoglobulinemia.	[Bai, Wei; Zhao, Jiuliang; Zhang, Shangzhu; Zhou, Jiaxin; Leng, Xiaomei; Tian, Xinping; Li, Mengtao; Zhao, Yan; Zeng, Xiaofeng] Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Rheumatol, Beijing, Peoples R China; [Bai, Wei; Zhao, Jiuliang; Zhang, Shangzhu; Zhou, Jiaxin; Leng, Xiaomei; Tian, Xinping; Li, Mengtao; Zhao, Yan; Zeng, Xiaofeng] Minist Sci & Technol, Key Lab Rheumatol & Clin Immunol, Natl Clin Res Ctr Rheumatol, Minist Educ, Beijing, Peoples R China; [Zhang, Lixia] Shunyi Dist Hosp, Dept Rheumatol, Beijing, Peoples R China; [Liu, Zhengyin] Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Infect Dis, Beijing, Peoples R China; [Ye, Wenling] Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Nephrol, Beijing, Peoples R China; [Han, Bing] Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Haematol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital	Leng, XM (corresponding author), Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Rheumatol, Beijing, Peoples R China.; Leng, XM (corresponding author), Minist Sci & Technol, Key Lab Rheumatol & Clin Immunol, Natl Clin Res Ctr Rheumatol, Minist Educ, Beijing, Peoples R China.	lengxm@gmail.com	Jiuliang, Zhao/AAW-5669-2020; Zeng, Xiao/ABG-5938-2021	Jiuliang, Zhao/0000-0001-9308-2858; 	Chinese National Key Technology R&D Program, Ministry of Science and Technology [2017YFC0907600, 2017YFC0907601]	Chinese National Key Technology R&D Program, Ministry of Science and Technology	This study was supported by the Chinese National Key Technology R&D Program, Ministry of Science and Technology (grant numbers 2017YFC0907600 and 2017YFC0907601).	BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3; Cacoub P, 2015, AM J MED, V128, P950, DOI 10.1016/j.amjmed.2015.02.017; Chen YP, 2019, CHINESE MED J-PEKING, V132, P1723, DOI 10.1097/CM9.0000000000000325; Coliche V, 2019, CLIN KIDNEY J, V12, P365, DOI 10.1093/ckj/sfy096; De Vita S, 2011, ANN RHEUM DIS, V70, P1183, DOI 10.1136/ard.2011.150755; Desbois AC, 2019, JOINT BONE SPINE, V86, P707, DOI 10.1016/j.jbspin.2019.01.016; Ferri C, 2004, SEMIN ARTHRITIS RHEU, V33, P355, DOI 10.1016/j.semarthrit.2003.10.001; Galli M, 2017, CLIN EXP RHEUMATOL, V35, pS67; Galli M, 1992, Ann Ital Med Int, V7, P209; Garcia-Carrasco M, 2001, SEMIN ARTHRITIS RHEU, V30, P366, DOI 10.1053/sarh.2001.20265; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; Kolopp-Sarda MN, 2019, ARTHRITIS RHEUMATOL, V71, P1904, DOI 10.1002/art.41003; Li SJ, 2017, NEPHROLOGY, V22, P449, DOI 10.1111/nep.12795; [吕亚男 Lyu Yanan], 2018, [肾脏病与透析肾移植杂志, Chinese Journal of Nephrology, Dialysis & Transplantation], V27, P201; Mazzaro Cesare, 2018, Diseases, V6, DOI 10.3390/diseases6020035; Mazzaro C, 2016, DIGEST LIVER DIS, V48, P780, DOI 10.1016/j.dld.2016.03.018; MCMAHON BJ, 1990, ARCH INTERN MED, V150, P1051, DOI 10.1001/archinte.150.5.1051; MONTI G, 1995, QJM-MON J ASSOC PHYS, V88, P115; Quartuccio L, 2014, RHEUMATOLOGY, V53, P2209, DOI 10.1093/rheumatology/keu271; Ramos-Casals M, 2006, SEMIN ARTHRITIS RHEU, V36, P189, DOI 10.1016/j.semarthrit.2006.08.005; Ramos-Casals M, 2012, LANCET, V379, P348, DOI 10.1016/S0140-6736(11)60242-0; Ren H, 2017, J VIRAL HEPATITIS, V24, P4, DOI 10.1111/jvh.12793; Retamozo S, 2013, MEDICINE, V92, P273, DOI 10.1097/MD.0b013e3182a5cf71; [芮宏亮 Rui Hongliang], 2018, [中国实用内科杂志, Chinese Journal of Practical Internal Medicine], V38, P553; Saadoun D, 2006, ARCH INTERN MED, V166, P2101, DOI 10.1001/archinte.166.19.2101; Shi Xiao-Hu, 2014, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V36, P639, DOI 10.3881/j.issn.1000-503X.2014.06.015; Silva F, 2019, J AUTOIMMUN, V105, DOI 10.1016/j.jaut.2019.102313; Spatola L, 2018, CLIN EXP MED, V18, P465, DOI 10.1007/s10238-018-0514-5; Terrier B, 2015, J AUTOIMMUN, V65, P74, DOI 10.1016/j.jaut.2015.08.008; Terrier B, 2014, AUTOIMMUN REV, V13, P630, DOI 10.1016/j.autrev.2013.11.006; Terrier B, 2013, CLIN RES HEPATOL GAS, V37, P334, DOI 10.1016/j.clinre.2013.02.002; Terrier B, 2012, BLOOD, V119, P5996, DOI 10.1182/blood-2011-12-396028; Terrier B, 2010, GUT, V59, P1709, DOI 10.1136/gut.2010.218123; Trejo O, 2001, MEDICINE, V80, P252, DOI 10.1097/00005792-200107000-00004; Wang C, 2015, INT J CLIN EXP PATHO, V8, P10475	35	1	1	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2021	12								580271	10.3389/fimmu.2021.580271	http://dx.doi.org/10.3389/fimmu.2021.580271			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU2PL	33717064	Green Published, gold			2022-12-18	WOS:000627125600001
J	Husain, I; Luo, XR				Husain, Irma; Luo, Xunrong			Apoptotic Donor Cells in Transplantation	FRONTIERS IN IMMUNOLOGY			English	Review						apoptosis; tolerance; transplantation; EDCI-SP; cell-based therapies		Despite significant advances in prevention and treatment of transplant rejection with immunosuppressive medications, we continue to face challenges of long-term graft survival, detrimental medication side effects to both the recipient and transplanted organ together with risks for opportunistic infections. Transplantation tolerance has so far only been achieved through hematopoietic chimerism, which carries with it a serious and life-threatening risk of graft versus host disease, along with variability in persistence of chimerism and uncertainty of sustained tolerance. More recently, numerous in vitro and in vivo studies have explored the therapeutic potential of silent clearance of apoptotic cells which have been well known to aid in maintaining peripheral tolerance to self. Apoptotic cells from a donor not only have the ability of down regulating the immune response, but also are a way of providing donor antigens to recipient antigen-presenting-cells that can then promote donor-specific peripheral tolerance. Herein, we review both laboratory and clinical evidence that support the utility of apoptotic cell-based therapies in prevention and treatment of graft versus host disease and transplant rejection along with induction of donor-specific tolerance in solid organ transplantation. We have highlighted the potential limitations and challenges of this apoptotic donor cell-based therapy together with ongoing advancements and attempts made to overcome them.	[Husain, Irma; Luo, Xunrong] Duke Univ, Dept Med, Durham, NC 27706 USA	Duke University	Luo, XR (corresponding author), Duke Univ, Dept Med, Durham, NC 27706 USA.	xunrong.luo@duke.edu						Abdolmaleki F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01645; Alfred A, 2017, BRIT J HAEMATOL, V177, P287, DOI 10.1111/bjh.14537; Aoki M, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/8606878; Asano K, 2011, IMMUNITY, V34, P85, DOI 10.1016/j.immuni.2010.12.011; Bak SP, 2008, MOL IMMUNOL, V46, P258, DOI 10.1016/j.molimm.2008.08.266; Benden C, 2008, TRANSPLANTATION, V86, P1625, DOI 10.1097/TP.0b013e31818bc024; Benichou G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00170; Biagi E, 2007, TRANSPLANTATION, V84, P31, DOI 10.1097/01.tp.0000267785.52567.9c; Bittencourt MD, 2001, BLOOD, V98, P224, DOI 10.1182/blood.V98.1.224; Bonnefoy F, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1084-0; Bonnefoy F, 2011, J IMMUNOL, V186, P5696, DOI 10.4049/jimmunol.1001523; Brok HPM, 1998, BONE MARROW TRANSPL, V22, P1005, DOI 10.1038/sj.bmt.1701478; Bryant J, 2014, BIOMATERIALS, V35, P8887, DOI 10.1016/j.biomaterials.2014.06.044; Bryant J, 2014, J IMMUNOL, V192, P6092, DOI 10.4049/jimmunol.1302771; Burns AM, 2011, J IMMUNOL, V186, P214, DOI 10.4049/jimmunol.1001172; Burns AM, 2009, J IMMUNOL, V182, P1314, DOI 10.4049/jimmunol.182.3.1314; Camenisch TD, 1999, J IMMUNOL, V162, P3498; Castellano F, 2000, J CELL SCI, V113, P2955; Chen G, 2012, AM J TRANSPLANT, V12, P2920, DOI 10.1111/j.1600-6143.2012.04203.x; Chen WJ, 2001, IMMUNITY, V14, P715, DOI 10.1016/S1074-7613(01)00147-9; Cheng J, 2009, TRANSPL P, V41, P3893, DOI 10.1016/j.transproceed.2009.05.033; Chong AS, 2012, NAT REV IMMUNOL, V12, P459, DOI 10.1038/nri3215; COSTANZONORDIN MR, 1992, CIRCULATION, V86, P242; Dangi A, 2020, AM J TRANSPLANT, V20, P2728, DOI 10.1111/ajt.15878; Dangi A, 2018, BLOOD ADV, V2, P669, DOI 10.1182/bloodadvances.2017012187; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; DeSmedt T, 1997, EUR J IMMUNOL, V27, P1229, DOI 10.1002/eji.1830270526; Doran AC, 2020, NAT REV IMMUNOL, V20, P254, DOI 10.1038/s41577-019-0240-6; Duran-Struuck R, 2017, TRANSPLANTATION, V101, P274, DOI 10.1097/TP.0000000000001559; EDELSON R, 1987, NEW ENGL J MED, V316, P297, DOI 10.1056/NEJM198702053160603; Ezekian B, 2018, TRANSPLANTATION, V102, P1213, DOI 10.1097/TP.0000000000002242; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Feng JF, 2013, MINERVA CHIR, V68, P183; Flowers MED, 2008, BLOOD, V112, P2667, DOI 10.1182/blood-2008-03-141481; Gordon S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00127; Gorgun G, 2002, BLOOD, V100, P941, DOI 10.1182/blood-2002-01-0068; Gray M, 2007, P NATL ACAD SCI USA, V104, P14080, DOI 10.1073/pnas.0700326104; Greinix HT, 2000, BLOOD, V96, P2426; Hart JW, 2013, THER ADV HEMATOL, V4, P320, DOI 10.1177/2040620713490316; Hayat SMG, 2019, IMMUNOL CELL BIOL, V97, P124, DOI 10.1111/imcb.12206; Henson PM, 2013, J CLIN INVEST, V123, P2773, DOI 10.1172/JCI69344; Hequet O, 2020, EUR J IMMUNOL, V50, P725, DOI 10.1002/eji.201948318; Hlavaty KA, 2016, BIOMATERIALS, V76, P1, DOI 10.1016/j.biomaterials.2015.10.041; Hoechst B, 2008, GASTROENTEROLOGY, V135, P234, DOI 10.1053/j.gastro.2008.03.020; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Jaksch P, 2014, TRANSFUS APHER SCI, V50, P358, DOI 10.1016/j.transci.2014.04.006; JOHNSON HM, 1966, J IMMUNOL, V97, P791; Kang HK, 2017, TRANSPLANTATION, V101, P1801, DOI 10.1097/TP.0000000000001489; Kawai T, 2008, NEW ENGL J MED, V358, P353, DOI 10.1056/NEJMoa071074; Kheradmand T, 2012, J IMMUNOL, V189, P804, DOI 10.4049/jimmunol.1103705; Kleinclauss F, 2006, CELL DEATH DIFFER, V13, P41, DOI 10.1038/sj.cdd.4401699; Knobler R, 2009, J AM ACAD DERMATOL, V61, P652, DOI 10.1016/j.jaad.2009.02.039; Kourtzelis I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00553; Krasagakis K, 1998, DERMATOLOGY, V196, P309, DOI 10.1159/000017927; Kushwah R, 2010, EUR J IMMUNOL, V40, P1022, DOI 10.1002/eji.200939782; Law SH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051149; Lefaucheur C, 2008, AM J TRANSPLANT, V8, P324, DOI 10.1111/j.1600-6143.2007.02072.x; Lei J, 2015, AM J TRANSPLANT, V15, P2739, DOI 10.1111/ajt.13329; Lemke G, 2008, NAT REV IMMUNOL, V8, P327, DOI 10.1038/nri2303; Lemke G, 2010, ANN NY ACAD SCI, V1209, P23, DOI 10.1111/j.1749-6632.2010.05744.x; Leventhal J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003509; Lu QX, 2001, SCIENCE, V293, P306, DOI 10.1126/science.1061663; Luo XR, 2008, P NATL ACAD SCI USA, V105, P14527, DOI 10.1073/pnas.0805204105; Lutterotti A, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006168; Mazzoni A, 2002, J IMMUNOL, V168, P689, DOI 10.4049/jimmunol.168.2.689; McGaha TL, 2011, BLOOD, V117, P5403, DOI 10.1182/blood-2010-11-320028; Meier-Kriesche HU, 2004, AM J TRANSPLANT, V4, P378, DOI 10.1111/j.1600-6143.2004.00332.x; Mevorach D, 2014, BIOL BLOOD MARROW TR, V20, P58, DOI 10.1016/j.bbmt.2013.10.010; Morath C, 2020, J CLIN INVEST, V130, P2364, DOI 10.1172/JCI133595; Moreau A, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a015461; Morelli AE, 2016, STEM CELLS, V34, P1142, DOI 10.1002/stem.2326; Morelli AE, 2010, APOPTOSIS, V15, P1083, DOI 10.1007/s10495-010-0469-9; Mougel F, 2012, DIABETES METAB, V38, P531, DOI 10.1016/j.diabet.2012.08.008; Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood-2007-07-099226; Munoz LE, 2010, NAT REV RHEUMATOL, V6, P280, DOI 10.1038/nrrheum.2010.46; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Newell KA, 2015, AM J TRANSPLANT, V15, P2908, DOI 10.1111/ajt.13480; Notley CA, 2011, J IMMUNOL, V186, P4967, DOI 10.4049/jimmunol.1003021; O'Flynn L, 2013, MOL THER, V21, P2102, DOI 10.1038/mt.2013.167; Ochando JC, 2006, NAT IMMUNOL, V7, P652, DOI 10.1038/ni1333; PANULA P, 1988, J HISTOCHEM CYTOCHEM, V36, P259, DOI 10.1177/36.3.3343510; Peng YF, 2018, INT IMMUNOPHARMACOL, V65, P470, DOI 10.1016/j.intimp.2018.10.019; Perruche S, 2004, AM J TRANSPLANT, V4, P1361, DOI 10.1111/j.1600-6143.2004.00509.x; Pilon C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02908; Pupjalis D, 2011, EMBO MOL MED, V3, P102, DOI 10.1002/emmm.201000113; Raffin C, 2020, NAT REV IMMUNOL, V20, P158, DOI 10.1038/s41577-019-0232-6; Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3; Ravishankar B, 2013, CELL MOL LIFE SCI, V70, P3571, DOI 10.1007/s00018-013-1261-0; Roberts RA, 2015, BIOMATERIALS, V72, P1, DOI 10.1016/j.biomaterials.2015.08.040; Garcia MR, 2010, J CLIN INVEST, V120, P2486, DOI 10.1172/JCI41628; Rollins MR, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/7659462; Rothlin CV, 2007, CELL, V131, P1124, DOI 10.1016/j.cell.2007.10.034; Saas P, 2016, STEM CELLS, V34, P1464, DOI 10.1002/stem.2361; Sagedal S, 2002, AM J TRANSPLANT, V2, P850, DOI 10.1034/j.1600-6143.2002.20907.x; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Scandling JD, 2008, NEW ENGL J MED, V358, P362, DOI 10.1056/NEJMoa074191; Sen P, 2007, BLOOD, V109, P653, DOI 10.1182/blood-2006-04-017368; Simpson J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00590; Singh A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11338-y; Stuart LM, 2002, J IMMUNOL, V168, P1627, DOI 10.4049/jimmunol.168.4.1627; Sun E, 2004, CELL DEATH DIFFER, V11, P1258, DOI 10.1038/sj.cdd.4401500; Sun X, 2012, J CLIN IMMUNOL, V32, P837, DOI 10.1007/s10875-012-9681-4; Takahashi M, 2003, CELL IMMUNOL, V226, P105, DOI 10.1016/j.cellimm.2003.11.008; ten Brinke A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00181; Torchinsky MB, 2009, NATURE, V458, P78, DOI 10.1038/nature07781; Turley DM, 2007, J IMMUNOL, V178, P2212, DOI 10.4049/jimmunol.178.4.2212; Verbovetski I, 2002, J EXP MED, V196, P1553, DOI 10.1084/jem.20020263; Vieyra-Garcia PA, 2020, TRANSFUS MED HEMOTH, V47, P226, DOI 10.1159/000508479; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Wang SS, 2015, CELL TRANSPLANT, V24, P1155, DOI 10.3727/096368914X681027; Wang TM, 2008, J IMMUNOL, V180, P5991, DOI 10.4049/jimmunol.180.9.5991; Wang Z, 2006, AM J TRANSPLANT, V6, P1297, DOI 10.1111/j.1600-6143.2006.01308.x; Wang ZL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004940; Watanabe S, 2008, J IMMUNOL, V181, P3291, DOI 10.4049/jimmunol.181.5.3291; Wu C, 2013, CELL MOL IMMUNOL, V10, P393, DOI 10.1038/cmi.2013.16; YAMAGUCHI J, 1994, TRANSPLANTATION, V57, P412, DOI 10.1097/00007890-199402150-00017; Young JS, 2017, AM J TRANSPLANT, V17, P81, DOI 10.1111/ajt.13910; Yu SJ, 2021, AM J TRANSPLANT, V21, P515, DOI 10.1111/ajt.16197; Zhang L, 2019, AM J TRANSPLANT, V19, P674, DOI 10.1111/ajt.15087; Zhang WT, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1395-9; Zheng HB, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14006	122	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2021	12								626840	10.3389/fimmu.2021.626840	http://dx.doi.org/10.3389/fimmu.2021.626840			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU5NG	33717145	gold, Green Published			2022-12-18	WOS:000627327200001
J	Lee, YJ; Kim, MJ; Jo, S; Jin, SH; Park, PR; Park, K; Song, HC; Kim, J; Kim, JY; Shim, SC; Kim, TH; Hong, SJ; Kang, H; Kim, TJ; Won, EJ				Lee, Yu Jeong; Kim, Moon-Ju; Jo, Sungsin; Jin, So-Hee; Park, Pu-Reum; Park, Kijeong; Song, Ho-Chun; Kim, Jahae; Kim, Ji-Young; Shim, Seung Cheol; Kim, Tae-Hwan; Hong, Sung-Jong; Kang, Hyundeok; Kim, Tae-Jong; Won, Eun Jeong			Clonorchis sinensis-Derived Protein Attenuates Inflammation and New Bone Formation in Ankylosing Spondylitis	FRONTIERS IN IMMUNOLOGY			English	Article						ankylosing spondylitis; Clonorchis sinensis; inflammation; new bone formation; parasite	PREVALENCE	Helminth infections and their components have been shown to have the potential to modulate and attenuate immune responses. The objective of this study was to evaluate the potential protective effects of Clonorchis sinensis-derived protein (CSp) on ankylosing spondylitis (AS). Cytotoxicity of CSp at different doses was assessed by MTS and flow cytometry before performing experiments. Peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) were obtained from AS patients. Inflammatory cytokine-producing cells were analyzed using flow cytometry. The levels of INF- gamma , IL-17A, TNF-alpha, and IL-6 were measured by enzyme-linked immunosorbent assay (ELISA). SKG mice were treated with CSp or vehicles. Inflammation and new bone formation were evaluated using immunohistochemistry, positron emission tomography (PET), and micro-computed tomography (CT). Treatment with CSp resulted in no reduced cell viability of PBMCs or SFMCs until 24 h. In experiments culturing PBMCs and SFMCs, the frequencies of IFN- gamma and IL-17A producing cells were significantly reduced after CSp treatment. In the SKG mouse model, CSp treatment significantly suppressed arthritis, enthesitis, and enteritis. Micro-CT analysis of hind paw revealed reduced new bone formation in CSp-treated mice than in vehicle-treated mice. We provide the first evidence demonstrating that CSp can ameliorate clinical signs and cytokine derangements in AS. In addition, such CSp treatment could reduce the new bone formation of AS.	[Lee, Yu Jeong; Kim, Moon-Ju; Won, Eun Jeong] Chonnam Natl Univ, Dept Parasitol & Trop Med, Med Sch, Gwangju, South Korea; [Jo, Sungsin] Hanyang Univ, Dept Rheumatol, Inst Rheumatol Res, Seoul, South Korea; [Jin, So-Hee; Park, Pu-Reum; Park, Kijeong; Kim, Tae-Jong] Chonnam Natl Univ Med Sch & Hosp, Dept Rheumatol, Gwangju, South Korea; [Song, Ho-Chun; Kim, Jahae] Chonnam Natl Univ Med Sch & Hosp, Dept Nucl Med, Gwangju, South Korea; [Kim, Ji-Young; Shim, Seung Cheol] Chungnam Natl Univ Hosp, Daejeon Rheumatoid & Degenerat Arthrit Ctr, Div Rheumatol, Daejeon, South Korea; [Kim, Tae-Hwan] Hanyang Univ, Dept Rheumatol, Hosp Rheumat Dis, Seoul, South Korea; [Hong, Sung-Jong] Chung Ang Univ, Dept Med Environm Biol, Coll Med, Seoul, South Korea; [Kang, Hyundeok] Yonsei Univ, Dept Biomed Syst Informat, Brain Korea 21 Plus Project Med Sci, Coll Med, Seoul, South Korea	Chonnam National University; Hanyang University; Chonnam National University; Chonnam National University Hospital; Chonnam National University; Chonnam National University Hospital; Chungnam National University; Chungnam National University Hospital; Hanyang University; Chung Ang University; Chung Ang University Hospital; Yonsei University; Yonsei University Health System	Won, EJ (corresponding author), Chonnam Natl Univ, Dept Parasitol & Trop Med, Med Sch, Gwangju, South Korea.; Kim, TJ (corresponding author), Chonnam Natl Univ Med Sch & Hosp, Dept Rheumatol, Gwangju, South Korea.	ktj1562@jnu.ac.kr; Parasite.woni@jnu.ac.kr	Jo, Sungsin/AAL-3659-2021; Won, Eun Jeong/AGX-7670-2022	Jo, Sungsin/0000-0003-3034-5029; 	National Research Foundation of Korea (NRF) - Ministry of Education, Science, and Technology [NRF-2019 R1C1C1004605, NRF-2019R1I1A3A01060016, NRF-2019M3E5D1A02067953, NRF-2017R1A2B4007994, NRF-2019R1A2C2004214]; Chonnam National University Hospital Biomedical Research Institute [BCRI 19047, BCRI 19048]	National Research Foundation of Korea (NRF) - Ministry of Education, Science, and Technology(Ministry of Education, Science & Technology (MEST), Republic of KoreaNational Research Foundation of Korea); Chonnam National University Hospital Biomedical Research Institute	This study was supported by grants from the National Research Foundation of Korea (NRF) Grant funded by the Ministry of Education, Science, and Technology (grant no. NRF-2019 R1C1C1004605; NRF-2019R1I1A3A01060016; NRF-2019M3E5D1A02067953; NRF-2017R1A2B4007994, NRF-2019R1A2C2004214), and by the Chonnam National University Hospital Biomedical Research Institute (grant no. BCRI 19047 and BCRI 19048).	Anandarajah A, 2005, CURR OPIN RHEUMATOL, V17, P247, DOI 10.1097/01.bor.0000159926.42761.dd; Benham H, 2014, ARTHRITIS RHEUMATOL, V66, P1755, DOI 10.1002/art.38638; Braun J, 2020, J RHEUMATOL, V47, P35, DOI 10.3899/jrheum.181040; Dean LE, 2014, RHEUMATOLOGY, V53, P650, DOI 10.1093/rheumatology/ket387; Eissa MM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165916; Exarchou S, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0627-0; Fan DZ, 2015, J RHEUMATOL, V42, P252, DOI 10.3899/jrheum.140416; Fleming JO, 2011, MULT SCLER J, V17, P743, DOI 10.1177/1352458511398054; Gracey E, 2020, J CLIN INVEST, V130, P1863, DOI 10.1172/JCI126567; Gracey E, 2016, ANN RHEUM DIS, V75, P2124, DOI 10.1136/annrheumdis-2015-208902; Harnett MM, 2010, CLIN EXP IMMUNOL, V159, P256, DOI 10.1111/j.1365-2249.2009.04064.x; Heo YJ, 2010, IMMUNOL LETT, V127, P150, DOI 10.1016/j.imlet.2009.10.006; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Jang SW, 2011, KOREAN J PARASITOL, V49, P245, DOI 10.3347/kjp.2011.49.3.245; Jeong YI, 2011, BIOCHEM BIOPH RES CO, V407, P793, DOI 10.1016/j.bbrc.2011.03.102; Jo S, 2021, RHEUMATOLOGY, V60, P3923, DOI 10.1093/rheumatology/keaa846; Jo S, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02217-9; Jo S, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1582-3; Kenna TJ, 2012, ARTHRITIS RHEUM-US, V64, P1420, DOI 10.1002/art.33507; Kiltz U, 2020, J RHEUMAT DIS, V27, P22, DOI 10.4078/jrd.2020.27.1.22; Kim TJ, 2010, JOINT BONE SPINE, V77, P235, DOI 10.1016/j.jbspin.2009.11.015; Lee YJ., 2020, ARTHRITIS RES THER; Li X, 2018, ARTHRITIS RHEUMATOL, V70, P1056, DOI 10.1002/art.40468; Li XY, 2020, BMC IMMUNOL, V21, DOI 10.1186/s12865-020-0336-6; Lubberts E, 2015, NAT REV RHEUMATOL, V11, P415, DOI 10.1038/nrrheum.2015.53; Martinez FD, 2001, RESPIR RES, V2, P129, DOI 10.1186/rr48; Osada Y, 2009, INT J PARASITOL, V39, P457, DOI 10.1016/j.ijpara.2008.08.007; Ranganathan V, 2017, NAT REV RHEUMATOL, V13, P359, DOI 10.1038/nrrheum.2017.56; Raychaudhuri SP, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1249-5; Rudwaleit M, 2004, ANN RHEUM DIS, V63, P665, DOI 10.1136/ard.2003.016386; Shi MQ, 2011, ARTHRITIS RHEUM-US, V63, P434, DOI 10.1002/art.30098; Song XR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023453; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; van der Heijde DM, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2790; van Tok MN, 2019, ARTHRITIS RHEUMATOL, V71, P612, DOI 10.1002/art.40770; VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361; Vieira-Sousa E, 2015, ARTHRITIS RHEUMATOL, V67, P2813, DOI 10.1002/art.39282; Walsh J, 2019, BMC RHEUMATOL, V3, DOI 10.1186/s41927-019-0086-3; Wang XF, 2017, J CELL MOL MED, V21, P475, DOI 10.1111/jcmm.12991; Wu CX, 2013, THERANOSTICS, V3, P448, DOI 10.7150/thno.6592	40	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2021	12								615369	10.3389/fimmu.2021.615369	http://dx.doi.org/10.3389/fimmu.2021.615369			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU5ST	33717104	gold, Green Published, Green Submitted			2022-12-18	WOS:000627342000001
J	Xiao, P; Dienger-Stambaugh, K; Chen, XM; Wei, HL; Phan, S; Beavis, AC; Singh, K; Adhikary, NRD; Tiwari, P; Villinger, F; He, B; Spearman, P				Xiao, Peng; Dienger-Stambaugh, Krista; Chen, Xuemin; Wei, Huiling; Phan, Shannon; Beavis, Ashley C.; Singh, Karnail; Adhikary, Nihar R. Deb; Tiwari, Pooja; Villinger, Francois; He, Biao; Spearman, Paul			Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates	FRONTIERS IN IMMUNOLOGY			English	Article						parainfluenza virus 5 (PIV5); human immunodeficiency virus (HIV) vaccine; virus-like particles (VLP); rhesus macaques; immune responses	BORDETELLA-BRONCHISEPTICA VACCINE; MUCOSAL; PREVENTION; ANTIBODIES; INFECTION	The search for a preventive vaccine against HIV infection remains an ongoing challenge, indicating the need for novel approaches. Parainfluenza virus 5 (PIV5) is a paramyxovirus replicating in the upper airways that is not associated with any animal or human pathology. In animal models, PIV5-vectored vaccines have shown protection against influenza, RSV, and other human pathogens. Here, we generated PIV5 vaccines expressing HIV envelope (Env) and SIV Gag and administered them intranasally to macaques, followed by boosting with virus-like particles (VLPs) containing trimeric HIV Env. Moreover, we compared the immune responses generated by PIV5-SHIV prime/VLPs boost regimen in naive vs a control group in which pre-existing immunity to the PIV5 vector was established. We demonstrate for the first time that intranasal administration of PIV5-based HIV vaccines is safe, well-tolerated and immunogenic, and that boosting with adjuvanted trimeric Env VLPs enhances humoral and cellular immune responses. The PIV5 prime/VLPs boost regimen induced robust and durable systemic and mucosal Env-specific antibody titers with functional activities including ADCC and neutralization. This regimen also induced highly polyfunctional antigen-specific T cell responses. Importantly, we show that diminished responses due to PIV5 pre-existing immunity can be overcome in part with VLP protein boosts. Overall, these results establish that PIV5-based HIV vaccine candidates are promising and warrant further investigation including moving on to primate challenge studies.	[Xiao, Peng; Adhikary, Nihar R. Deb; Villinger, Francois] Univ Louisiana Lafayette, New Iberia Res Ctr, New Iberia, LA 70560 USA; [Dienger-Stambaugh, Krista; Singh, Karnail; Spearman, Paul] Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Dept Pediat, Cincinnati, OH 45229 USA; [Dienger-Stambaugh, Krista; Singh, Karnail; Spearman, Paul] Univ Cincinnati, Cincinnati, OH 45267 USA; [Chen, Xuemin] Emory Univ, Div Infect Dis, Atlanta, GA 30322 USA; [Wei, Huiling; Phan, Shannon; Beavis, Ashley C.; He, Biao] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA; [Tiwari, Pooja] Georgia Inst Technol, Wallace H Coulter Dept Bioengn, Atlanta, GA 30332 USA	University of Louisiana Lafayette; New Iberia Research Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Emory University; University System of Georgia; University of Georgia; University System of Georgia; Georgia Institute of Technology	Villinger, F (corresponding author), Univ Louisiana Lafayette, New Iberia Res Ctr, New Iberia, LA 70560 USA.; Spearman, P (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Dept Pediat, Cincinnati, OH 45229 USA.; Spearman, P (corresponding author), Univ Cincinnati, Cincinnati, OH 45267 USA.; He, B (corresponding author), Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA.	fjv5939@louisiana.edu; bhe@uga.edu; Paul.Spearman@cchmc.org	Xiao, Peng/GLS-6934-2022	Xiao, Peng/0000-0002-5308-8400; Deb Adhikary, Nihar/0000-0002-8016-6785	NIH-NIAID [R01AI111863]	NIH-NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors are indebted to the veterinary, research, and animal care staff of the New Iberia Research center for their outstanding support of the animal studies for this report. The studies were supported by a grant from NIH-NIAID R01AI111863 to PS and BH.	Alpert MD, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002890; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Beyrer C, 2012, LANCET, V380, P367, DOI 10.1016/S0140-6736(12)60821-6; Bomsel M, 2011, IMMUNITY, V34, P269, DOI 10.1016/j.immuni.2011.01.015; Bournazos S, 2014, CELL, V158, P1243, DOI 10.1016/j.cell.2014.08.023; Chen ZH, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1965; Chen ZH, 2015, VACCINE, V33, P7217, DOI 10.1016/j.vaccine.2015.10.124; Chen ZH, 2013, J VIROL, V87, P2986, DOI 10.1128/JVI.02886-12; Chen ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050144; CHLADEK DW, 1981, AM J VET RES, V42, P266; Cohen J, 2020, SCIENCE, V367, P611, DOI 10.1126/science.367.6478.611; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1600693, 10.1056/NEJMoa1105243]; Corey L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7732; CORNWELL HJC, 1976, VET REC, V98, P301, DOI 10.1136/vr.98.15.301; de Taeye SW, 2015, CELL, V163, P1702, DOI 10.1016/j.cell.2015.11.056; Demberg T, 2009, INT REV IMMUNOL, V28, P20, DOI 10.1080/08830180802684331; Esparza J, 2013, VACCINE, V31, P3502, DOI 10.1016/j.vaccine.2013.05.018; Fauci AS, 2014, CLIN INFECT DIS, V59, pS80, DOI 10.1093/cid/ciu420; Ferrari G, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001273; Frieden TR, 2015, NEW ENGL J MED, V373, P2281, DOI 10.1056/NEJMms1513641; Hammonds J, 2003, VIROLOGY, V314, P636, DOI 10.1016/S0042-6822(03)00467-7; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106; Iyer SS, 2016, J VIROL, V90, P8842, DOI 10.1128/JVI.01163-16; Kardani K, 2016, VACCINE, V34, P413, DOI 10.1016/j.vaccine.2015.11.062; Klasse PJ, 2012, AIDS RES HUM RETROV, V28, P1, DOI [10.1089/aid.2011.0053, 10.1089/AID.2011.0053]; KONTOR EJ, 1981, AM J VET RES, V42, P1694; Kozlowski PA, 2000, J ACQ IMMUN DEF SYND, V24, P297; Kozlowski Pamela A., 2019, Current Immunology Reviews, V15, P102, DOI 10.2174/1573395514666180605092054; Leong ML, 2009, INFECT IMMUN, V77, P3958, DOI 10.1128/IAI.01274-08; Li Z, 2013, J VIROL, V87, P9604, DOI 10.1128/JVI.01289-13; Li Z, 2013, J VIROL, V87, P5985, DOI 10.1128/JVI.00120-13; Lycke N, 2012, NAT REV IMMUNOL, V12, P592, DOI 10.1038/nri3251; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; McCoy K, 2007, J VIROL, V81, P6594, DOI 10.1128/JVI.02497-06; McNairy ML, 2013, CURR HIV-AIDS REP, V10, P152, DOI 10.1007/s11904-013-0152-1; Mooney AJ, 2013, J VIROL, V87, P363, DOI 10.1128/JVI.02330-12; Pauthner M, 2017, IMMUNITY, V46, P1073, DOI 10.1016/j.immuni.2017.05.007; Pauthner MG, 2019, IMMUNITY, V50, P241, DOI 10.1016/j.immuni.2018.11.011; Pegu A, 2017, IMMUNOL REV, V275, P296, DOI 10.1111/imr.12511; Peretz Y, 2007, CLIN IMMUNOL, V124, P57, DOI 10.1016/j.clim.2007.04.004; Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786; Phan SI, 2017, J VIROL, V91, DOI 10.1128/JVI.00559-17; Phan SI, 2017, J VIROL, V91, DOI 10.1128/JVI.00560-17; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Riou C, 2014, J VIROL, V88, P1819, DOI 10.1128/JVI.02968-13; Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015; ROONEY JF, 1988, J VIROL, V62, P1530, DOI 10.1128/JVI.62.5.1530-1534.1988; Sanders RW, 2015, SCIENCE, V349, DOI 10.1126/science.aac4223; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Sholukh AM, 2015, VACCINE, V33, P2086, DOI 10.1016/j.vaccine.2015.02.020; Siegrist C.-A., 2018, PLOTKINS VACCINES, DOI DOI 10.1016/B978-0-323-35761-6.00002-X; Singh K, 2020, J VIROL, V94, DOI 10.1128/JVI.01884-19; Spearman P, 2019, J INFECT DIS, V219, P1755, DOI 10.1093/infdis/jiz008; Spearman P, 2011, J INFECT DIS, V203, P1165, DOI 10.1093/infdis/jiq175; Streeck H, 2008, PLOS MED, V5, P790, DOI 10.1371/journal.pmed.0050100; Swayne DE, 2000, AVIAN DIS, V44, P132, DOI 10.2307/1592516; Tompkins SM, 2007, VIROLOGY, V362, P139, DOI 10.1016/j.virol.2006.12.005; UNAIDS, 2020, GLOB HIV AIDS STAT F; Weeratna RD, 2005, VACCINE, V23, P5263, DOI 10.1016/j.vaccine.2005.06.024; Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890; Wright PF, 2004, J INFECT DIS, V189, P1221, DOI 10.1086/382088; Xiao P, 2012, J VIROL, V86, P4644, DOI 10.1128/JVI.06812-11; Xiao P, 2010, J VIROL, V84, P7161, DOI 10.1128/JVI.00410-10	69	1	1	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2021	12								623996	10.3389/fimmu.2021.623996	http://dx.doi.org/10.3389/fimmu.2021.623996			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU5ZY	33717130	gold, Green Published			2022-12-18	WOS:000627361300001
J	Cai, YC; Yang, CL; Hu, W; Song, P; Xu, B; Lu, Y; Ai, L; Chu, YH; Chen, MX; Chen, JX; Chen, SH				Cai, Yu Chun; Yang, Chun Li; Hu, Wei; Song, Peng; Xu, Bin; Lu, Yan; Ai, Lin; Chu, Yan Hong; Chen, Mu Xin; Chen, Jia Xu; Chen, Shao Hong			Molecular Characterization and Immunological Evaluation of Truncated Babesia microti Rhoptry Neck Protein 2 as a Vaccine Candidate	FRONTIERS IN IMMUNOLOGY			English	Article						babesiosis; Babesia microti; invasion; rhoptry neck protein 2; host immune responses		Babesia microti is a protozoan that infects red blood cells. Babesiosis is becoming a new global threat impacting human health. Rhoptry neck proteins (RONs) are proteins located at the neck of the rhoptry and studies indicate that these proteins play an important role in the process of red blood cell invasion. In the present study, we report on the bioinformatic analysis, cloning, and recombinant gene expression of two truncated rhoptry neck proteins 2 (BmRON2), as well as their potential for incorporation in a candidate vaccine for babesiosis. Western blot and immunofluorescence antibody (IFA) assays were performed to detect the presence of specific antibodies against BmRON2 in infected mice and the localization of N-BmRON2 in B. microti parasites. In vitro experiments were carried out to investigate the role of BmRON2 proteins during the B. microti invasion process and in vivo experiments to investigate immunoprotection. Homologous sequence alignment and molecular phylogenetic analysis indicated that BmRON2 showed similarities with RON2 proteins of other Babesia species. We expressed the truncated N-terminal (33-336 aa, designated rN-BmRON2) and C-terminal (915-1171 aa, designated rC-BmRON2) fragments of the BmRON2 protein, with molecular weights of 70 and 29 kDa, respectively. Western blot assays showed that the native BmRON2 protein is approximately 170 kDa, and that rN-BmRON2 was recognized by serum of mice experimentally infected with B. microti. Immunofluorescence analysis indicated that the BmRON2 protein was located at the apical end of merozoites, at the opposite end of the nucleus. In vitro red blood cell invasion inhibition studies with B. microti rBmRON2 proteins showed that relative invasion rate of rN-BmRON2 and rC-BmRON2 group is 45 and 56%, respectively. Analysis of the host immune response after immunization and B. microti infection showed that both rN-BmRON2 and rC-BmRON2 enhanced the immune response, but that rN-BmRON2 conferred better protection than rC-BmRON2. In conclusion, our results indicate that truncated rhoptry neck protein 2, especially its N-terminal fragment (rN-BmRON2), plays an important role in the invasion of host red blood cells, confers immune protection, and shows good potential as a candidate vaccine against babesiosis.	[Cai, Yu Chun; Hu, Wei; Song, Peng; Xu, Bin; Lu, Yan; Ai, Lin; Chu, Yan Hong; Chen, Mu Xin; Chen, Jia Xu; Chen, Shao Hong] Chinese Ctr Dis Control & Prevent, Natl Inst Parasit Dis, Shanghai, Peoples R China; [Cai, Yu Chun; Hu, Wei; Song, Peng; Xu, Bin; Lu, Yan; Ai, Lin; Chu, Yan Hong; Chen, Mu Xin; Chen, Jia Xu; Chen, Shao Hong] Minist Publ Hlth, Lab Parasite & Vector Biol, Shanghai, Peoples R China; [Cai, Yu Chun; Hu, Wei; Song, Peng; Xu, Bin; Lu, Yan; Ai, Lin; Chu, Yan Hong; Chen, Mu Xin; Chen, Jia Xu; Chen, Shao Hong] Minist Sci & Technol, Natl Ctr Int Res Trop Dis, WHO Collaborating Ctr Trop Dis, Shanghai, Peoples R China; [Yang, Chun Li] 903rd Hosp PLA, Dept Clin Res, Hangzhou, Peoples R China; [Hu, Wei] Fudan Univ, Sch Life Sci, Shanghai, Peoples R China	Chinese Center for Disease Control & Prevention; National Institute of Parasitic Diseases, Chinese Center for Disease Control & Prevention; Shanghai Center for Disease Control & Prevention; World Health Organization; Fudan University	Chen, JX; Chen, SH (corresponding author), Chinese Ctr Dis Control & Prevent, Natl Inst Parasit Dis, Shanghai, Peoples R China.; Chen, JX; Chen, SH (corresponding author), Minist Publ Hlth, Lab Parasite & Vector Biol, Shanghai, Peoples R China.; Chen, JX; Chen, SH (corresponding author), Minist Sci & Technol, Natl Ctr Int Res Trop Dis, WHO Collaborating Ctr Trop Dis, Shanghai, Peoples R China.	chenjiaxu7962@163.com; chensh637@163.com			Fund of the Shanghai Municipal Commission of Health and Family Planning [201940236]; National Parasitic Resources Center, the Ministry of Science and Technology [NPRC-2019-194-30]; National Key Research and Development Program of China [2016YFC 1202000, 2016YFC 1202005]	Fund of the Shanghai Municipal Commission of Health and Family Planning; National Parasitic Resources Center, the Ministry of Science and Technology; National Key Research and Development Program of China	This work was supported by the Fund of the Shanghai Municipal Commission of Health and Family Planning (201940236), the National Parasitic Resources Center, the Ministry of Science and Technology (NPRC-2019-194-30), and the National Key Research and Development Program of China (No. 2016YFC 1202000, 2016YFC 1202005).	Aguilar-Delfin I, 2003, INFECT IMMUN, V71, P2002, DOI 10.1128/IAI.71.4.2002-2008.2003; Alexander DL, 2005, PLOS PATHOG, V1, P137, DOI 10.1371/journal.ppat.0010017; Baldi DL, 2002, INFECT IMMUN, V70, P5236, DOI 10.1128/IAI.70.9.5236-5245.2002; Bannister LH, 2000, PARASITOLOGY, V121, P273, DOI 10.1017/S0031182099006320; Besteiro S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000309; Bhoora R, 2010, VET PARASITOL, V169, P279, DOI 10.1016/j.vetpar.2010.01.009; Boonchit S, 2006, VET PARASITOL, V137, P28, DOI 10.1016/j.vetpar.2005.12.025; Bradley PJ, 2005, J BIOL CHEM, V280, P34245, DOI 10.1074/jbc.M504158200; Brown WC, 2006, VET PARASITOL, V138, P75, DOI 10.1016/j.vetpar.2006.01.041; Buddle BM, 2005, VET IMMUNOL IMMUNOP, V108, P45, DOI 10.1016/j.vetimm.2005.08.002; Cai YC, 2018, ACTA TROP, V185, P371, DOI 10.1016/j.actatropica.2018.03.020; Cao J, 2009, PARASITOL INT, V58, P29, DOI 10.1016/j.parint.2008.09.005; Chen DH, 2000, PARASITE IMMUNOL, V22, P81, DOI 10.1046/j.1365-3024.2000.00279.x; Clawson ML, 2002, INFECT IMMUN, V70, P5304, DOI 10.1128/IAI.70.9.5304-5306.2002; DALRYMPLE BP, 1993, MOL BIOCHEM PARASIT, V57, P181, DOI 10.1016/0166-6851(93)90194-3; Dodd RY, 2004, ANNU REV MED, V55, P191, DOI 10.1146/annurev.med.55.091902.103831; Duraisingh MT, 2003, EMBO J, V22, P1047, DOI 10.1093/emboj/cdg096; Filbin MR, 2001, J EMERG MED, V20, P21, DOI 10.1016/S0736-4679(00)00289-4; Froberg MK, 2004, LANCET, V363, P704, DOI 10.1016/S0140-6736(04)15645-6; Ghosh S, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12733; Hayton K, 2008, CELL HOST MICROBE, V4, P40, DOI 10.1016/j.chom.2008.06.001; Hemmer RM, 2000, PARASITOL RES, V86, P121, DOI 10.1007/s004360050021; Homer MJ, 2000, CLIN MICROBIOL REV, V13, P451, DOI 10.1128/CMR.13.3.451-469.2000; HOWARD RF, 1990, EXP PARASITOL, V71, P330, DOI 10.1016/0014-4894(90)90038-E; Igarashi I, 1999, INFECT IMMUN, V67, P4143, DOI 10.1128/IAI.67.8.4143-4148.1999; Jeong YI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046553; Kaneko O, 2002, MOL BIOCHEM PARASIT, V121, P275, DOI 10.1016/S0166-6851(02)00042-7; Krause PJ, 2007, TRENDS PARASITOL, V23, P605, DOI 10.1016/j.pt.2007.09.005; Lamarque M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001276; Lebrun M, 2005, CELL MICROBIOL, V7, P1823, DOI 10.1111/j.1462-5822.2005.00646.x; MACHADO RZ, 1993, EXP PARASITOL, V77, P315, DOI 10.1006/expr.1993.1089; Malobi Ngabu, 2017, Journal of Parasitology Research, P7259630, DOI 10.1155/2017/7259630; Moitra P, 2015, INFECT IMMUN, V83, P3890, DOI 10.1128/IAI.00168-15; NICHOLS BA, 1983, J ULTRA MOL STRUCT R, V83, P85, DOI 10.1016/S0022-5320(83)90067-9; Niu QL, 2016, PARASITOLOGY, V143, P1990, DOI 10.1017/S0031182016001293; Niu QL, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1573-7; Niu QL, 2016, INFECT GENET EVOL, V41, P8, DOI 10.1016/j.meegid.2016.03.007; Niu QL, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1110-0; Niu QL, 2014, INFECT GENET EVOL, V28, P21, DOI 10.1016/j.meegid.2014.08.028; Ord RL, 2016, INFECT IMMUN, V84, P1574, DOI 10.1128/IAI.00107-16; Proellocks NI, 2010, TRENDS PARASITOL, V26, P297, DOI 10.1016/j.pt.2010.02.012; Rayner JC, 2001, J EXP MED, V194, P1571, DOI 10.1084/jem.194.11.1571; Rayner JC, 2000, P NATL ACAD SCI USA, V97, P9648, DOI 10.1073/pnas.160469097; Richard D, 2010, J BIOL CHEM, V285, P14815, DOI 10.1074/jbc.M109.080770; Rick B, 1998, PARASITOL RES, V84, P291, DOI 10.1007/s004360050398; Riglar DT, 2011, CELL HOST MICROBE, V9, P9, DOI 10.1016/j.chom.2010.12.003; SHAW MK, 1992, J CELL SCI, V101, P109; Skuce PJ, 1996, MOL BIOCHEM PARASIT, V77, P99, DOI 10.1016/0166-6851(96)02570-4; Speer CA, 1999, INT J PARASITOL, V29, P1509, DOI 10.1016/S0020-7519(99)00132-0; Straub KW, 2009, CELL MICROBIOL, V11, P590, DOI 10.1111/j.1462-5822.2008.01276.x; Szeto CC, 2000, IMMUNOLOGY, V100, P217, DOI 10.1046/j.1365-2567.2000.00042.x; Terkawi MA, 2009, PARASITOLOGY, V136, P1147, DOI 10.1017/S003118200999045X; Tetley L, 1998, MICROBIOL-SGM, V144, P3249, DOI 10.1099/00221287-144-12-3249; Triglia T, 2001, INFECT IMMUN, V69, P1084, DOI 10.1128/IAI.69.2.1084-1092.2001; Triglia T, 2009, CELL MICROBIOL, V11, P1671, DOI 10.1111/j.1462-5822.2009.01358.x; Vannier E, 2015, LANCET INFECT DIS, V15, P137, DOI 10.1016/S1473-3099(14)71062-X; Wang GB, 2017, EXP PARASITOL, V172, P5, DOI 10.1016/j.exppara.2016.11.001; Weiss GE, 2016, TRENDS PARASITOL, V32, P284, DOI 10.1016/j.pt.2015.12.007; Yokoyama N, 2006, VET PARASITOL, V138, P22, DOI 10.1016/j.vetpar.2006.01.037; Yu Q, 2014, VET PARASITOL, V205, P499, DOI 10.1016/j.vetpar.2014.08.007; Zhang Y, 2013, J PROTEOME RES, V12, P2185, DOI 10.1021/pr400038j; Zhou JL, 2007, VET PARASITOL, V145, P16, DOI 10.1016/j.vetpar.2006.10.022	62	1	1	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2021	12								616343	10.3389/fimmu.2021.616343	http://dx.doi.org/10.3389/fimmu.2021.616343			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT9JP	33717108	gold, Green Published			2022-12-18	WOS:000626903400001
J	Huang, XS; Liu, XH; Ye, Y; Zhang, T; Mei, SY; Zhu, TH; Peng, SM; Cai, JM; Yan, ZH; Zeng, K; Nie, DY; Sun, LN; Hou, XF; Zhao, J				Huang, Xiaosheng; Liu, Xinhua; Ye, Ye; Zhang, Tong; Mei, Shaoyi; Zhu, Tianhui; Peng, Shiming; Cai, Jiamin; Yan, Zonghui; Zeng, Kun; Nie, Danyao; Sun, Liangnan; Hou, Xiaofeng; Zhao, Jun			Polymorphisms and Circulating Plasma Protein Levels of Immune Checkpoints (CTLA-4 and PD-1) Are Associated With Posner-Schlossman Syndrome in Southern Chinese	FRONTIERS IN IMMUNOLOGY			English	Article						Posner-Schlossman syndrome; CTLA-4; PD-1; genetic variants; soluble molecular		Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) are well-known key immune checkpoints that play a crucial dampening effect on regulating T-cell homeostasis and self-tolerance. In this study, we aimed to evaluate the association between immune checkpoints (CTLA-4 and PD-1) and Posner-Schlossman syndrome (PSS) in a southern Chinese population. A total of 137 patients with PSS and 139 healthy controls from a southern Chinese population were recruited. Five single nucleotide polymorphisms (SNPs) of CTLA-4 (rs733618, rs4553808, rs5742909, rs231775, and rs3087243) and five SNPs of PD-1 (rs10204525, rs2227981, rs2227982, rs41386349, and rs36084323) were genotyped by SNaPshot technique. Soluble CTLA-4 (sCTLA-4) and soluble PD-1 (sPD-1) were determined by ELISA and antibody array assay, respectively. The frequencies of T allele at rs733618 and A allele at rs231775 of CTLA-4 were significantly higher in PSS patients than in healthy controls (corrected p (P-c ) = 0.037; P-c = 0.044, respectively). The haplotype frequencies of CACGG haplotype (rs733618-rs4553808-rs5742909-rs231775-rs3087243) of CTLA-4 and TGAGC haplotype (rs10204525-rs2227981-rs2227982-rs41386349-rs36084323) of PD-1 in the PSS group was significantly lower than those in the control group (P-c = 0.015, p = 0.034, respectively). Circulating plasma levels of sCTLA-4 and sPD-1 in PSS patients were significantly higher than those in controls (all p < 0.001). The present study suggests that CTLA-4 and PD-1 genetic polymorphisms are associated with the susceptibility to PSS in a southern Chinese population. The upregulated circulating plasma protein levels of sCTLA-4 and sPD-1 might provide some hints regarding the dysfunction of immune checkpoints in PSS during the active status.	[Huang, Xiaosheng; Liu, Xinhua; Zhang, Tong; Mei, Shaoyi; Zhu, Tianhui; Peng, Shiming; Yan, Zonghui; Zeng, Kun; Nie, Danyao; Sun, Liangnan; Hou, Xiaofeng] Jinan Univ, Shenzhen Eye Hosp, Shenzhen Eye Inst, Shenzhen, Peoples R China; [Huang, Xiaosheng; Liu, Xinhua; Ye, Ye; Mei, Shaoyi; Zhu, Tianhui; Peng, Shiming; Cai, Jiamin; Yan, Zonghui; Zeng, Kun; Nie, Danyao; Sun, Liangnan] Shenzhen Univ, Shenzhen Eye Hosp, Sch Ophthalmol, Optometry, Shenzhen, Peoples R China; [Zhao, Jun] Jinan Univ, Dept Ophthalmol, Shenzhen Peoples Hosp, Clin Med Coll 2, Shenzhen, Peoples R China; [Zhao, Jun] Southern Univ Sci & Technol, Affiliated Hosp 1, Dept Ophthalmol, Shenzhen Peoples Hosp, Shenzhen, Peoples R China	Jinan University; Shenzhen University; Jinan University; Jinan University; Southern University of Science & Technology	Zhao, J (corresponding author), Jinan Univ, Dept Ophthalmol, Shenzhen Peoples Hosp, Clin Med Coll 2, Shenzhen, Peoples R China.; Zhao, J (corresponding author), Southern Univ Sci & Technol, Affiliated Hosp 1, Dept Ophthalmol, Shenzhen Peoples Hosp, Shenzhen, Peoples R China.	doctoahaojun@163.com			Science, Technology, and Innovation Commission of Shenzhen Municipality [JCYJ20180228164400218, GJHZ20180420180937076]; Sanming Project of Medicine in Shenzhen Grant [SZSM201812090]	Science, Technology, and Innovation Commission of Shenzhen Municipality; Sanming Project of Medicine in Shenzhen Grant	This study was supported by the Science, Technology, and Innovation Commission of Shenzhen Municipality under Grant (number JCYJ20180228164400218 and GJHZ20180420180937076) and Sanming Project of Medicine in Shenzhen Grant (number SZSM201812090).	Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Chang BY, 2019, CANCER IMMUNOL IMMUN, V68, P353, DOI 10.1007/s00262-018-2271-4; Chen L, 2009, OCUL IMMUNOL INFLAMM, V17, P47, DOI 10.1080/09273940802491884; Daroszewski J, 2009, EUR J ENDOCRINOL, V161, P787, DOI 10.1530/EJE-09-0600; Du LP, 2008, CLIN IMMUNOL, V127, P43, DOI 10.1016/j.clim.2008.01.004; Gu DQ, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0449-0; HIROSE S, 1985, ARCH OPHTHALMOL-CHIC, V103, P1837; Hofmeyer KA, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/451694; Huang XS, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.11.70; La Rosa C, 2008, J INFECT DIS, V197, P25, DOI 10.1086/523652; Li F, 2019, CLIN EXP IMMUNOL, V197, P230, DOI 10.1111/cei.13298; Li YY, 2019, DNA CELL BIOL, V38, P121, DOI 10.1089/dna.2018.4417; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; Maruyama K, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0438-y; Maurer M, 2002, IMMUNOGENETICS, V54, P1, DOI 10.1007/s00251-002-0429-9; Megaw R, 2017, SURV OPHTHALMOL, V62, P277, DOI 10.1016/j.survophthal.2016.12.005; Meng QL, 2006, INVEST OPHTH VIS SCI, V47, P4444, DOI 10.1167/iovs.06-0201; Meng QL, 2009, MOL VIS, V15, P386; Pohlmann D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199301; POSNER A, 1948, ARCH OPHTHALMOL-CHIC, V39, P517; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Sester U, 2008, AM J TRANSPLANT, V8, P1486, DOI 10.1111/j.1600-6143.2008.02279.x; Sharpe AH, 2018, NAT REV IMMUNOL, V18, P153, DOI 10.1038/nri.2017.108; Shin SP, 2013, MOL THER, V21, P688, DOI 10.1038/mt.2012.252; Song MY, 2011, J IMMUNOTHER, V34, P297, DOI 10.1097/CJI.0b013e318210ed0e; Sun T, 2008, CANCER RES, V68, P7025, DOI 10.1158/0008-5472.CAN-08-0806; Toussirot E, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2747; Wang H, 2015, CURR EYE RES, V40, P1195, DOI 10.3109/02713683.2014.993767; Wang XB, 2008, J INTERN MED, V263, P61, DOI 10.1111/j.1365-2796.2007.01879.x; Wang XB, 2002, J NEUROIMMUNOL, V130, P224, DOI 10.1016/S0165-5728(02)00228-X; Wang X, 2019, CRIT REV CL LAB SCI, V56, P18, DOI 10.1080/10408363.2018.1522292; Ward FJ, 2013, EUR J IMMUNOL, V43, P1274, DOI 10.1002/eji.201242529; Zhao J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175519; Zhao J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132179; Zhu XF, 2007, GRAEF ARCH CLIN EXP, V245, P1549, DOI 10.1007/s00417-007-0591-8	35	1	1	2	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2021	12								607966	10.3389/fimmu.2021.607966	http://dx.doi.org/10.3389/fimmu.2021.607966			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT6YG	33717091	gold, Green Published			2022-12-18	WOS:000626735500001
J	Lore, NI; Chen, K; Bulek, K				Lore, Nicola I.; Chen, Kong; Bulek, Katarzyna			Editorial: The IL-17 Cytokine Family in Tissue Homeostasis and Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						IL-17 cytokine family; host-pathogen; cancer; autoimmunity; inflammatory disease			[Lore, Nicola I.] IRCCS San Raffaele Sci Inst, Emerging Bacterial Pathogens Unit, Div Immunol Transplantat & Infect Dis, Milan, Italy; [Lore, Nicola I.] Univ Vita Salute San Raffaele, Milan, Italy; [Chen, Kong] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA; [Bulek, Katarzyna] Jagiellonian Univ, Dept Immunol, Krakow, Poland; [Bulek, Katarzyna] Cleveland Clin, Dept Inflammat & Immun, Cleveland, OH 44106 USA	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Jagiellonian University; Cleveland Clinic Foundation	Lore, NI (corresponding author), IRCCS San Raffaele Sci Inst, Emerging Bacterial Pathogens Unit, Div Immunol Transplantat & Infect Dis, Milan, Italy.; Lore, NI (corresponding author), Univ Vita Salute San Raffaele, Milan, Italy.	lore.nicolaivan@hsr.it	Lore, Nicola Ivan/K-9285-2016	Lore, Nicola Ivan/0000-0001-9159-1632	Fondazione Cariplo [2016-0572]; National Science Centre in Poland [2015/19/B/NZ6/01578]	Fondazione Cariplo(Fondazione Cariplo); National Science Centre in Poland(National Science Centre, Poland)	This work has been supported by Fondazione Cariplo (grant n. 2016-0572) to NL; by National Science Centre in Poland (grant #2015/19/B/NZ6/01578) to KB.	Lore NI, 2016, CYTOKINE GROWTH F R, V30, P19, DOI 10.1016/j.cytogfr.2016.03.009; McGeachy MJ, 2019, IMMUNITY, V50, P892, DOI 10.1016/j.immuni.2019.03.021	2	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2021	12								641986	10.3389/fimmu.2021.641986	http://dx.doi.org/10.3389/fimmu.2021.641986			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT6XQ	33717197	Green Published, gold			2022-12-18	WOS:000626733800001
J	Shin, JH; Moreno-Nieves, UY; Zhang, LHH; Chen, C; Dixon, AL; Linde, MH; Mace, EM; Sunwoo, JB				Shin, June Ho; Moreno-Nieves, Uriel Y.; Zhang, Luhua H.; Chen, Chen; Dixon, Amera L.; Linde, Miles H.; Mace, Emily M.; Sunwoo, John B.			AHR Regulates NK Cell Migration via ASB2-Mediated Ubiquitination of Filamin A	FRONTIERS IN IMMUNOLOGY			English	Article						tumor; migration; filamin A; ASB2; AHR; NK cells		Natural killer (NK) cells are effector cells of the innate immune system involved in defense against virus-infected and transformed cells. The effector function of NK cells is linked to their ability to migrate to sites of inflammation or damage. Therefore, understanding the factors regulating NK cell migration is of substantial interest. Here, we show that in the absence of aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor, NK cells have reduced capacity to migrate and infiltrate tumors in vivo. Analysis of differentially expressed genes revealed that ankyrin repeat and SOCS Box containing 2 (Asb2) expression was dramatically decreased in Ahr (-/-) NK cells and that AhR ligands modulated its expression. Further, AhR directly regulated the promoter region of the Asb2 gene. Similar to what was observed with murine Ahr (-/-) NK cells, ASB2 knockdown inhibited the migration of human NK cells. Activation of AHR by its agonist FICZ induced ASB2-dependent filamin A degradation in NK cells; conversely, knockdown of endogenous ASB2 inhibited filamin A degradation. Reduction of filamin A increased the migration of primary NK cells and restored the invasion capacity of AHR-deficient NK cells. Our study introduces AHR as a new regulator of NK cell migration, through an AHR-ASB2-filamin A axis and provides insight into a potential therapeutic target for NK cell-based immunotherapies.	[Shin, June Ho; Moreno-Nieves, Uriel Y.; Zhang, Luhua H.; Chen, Chen; Linde, Miles H.; Sunwoo, John B.] Stanford Univ, Sch Med, Stanford Canc Inst, Dept Otolaryngol Head & Neck Surg, Stanford, CA 94305 USA; [Shin, June Ho; Moreno-Nieves, Uriel Y.; Zhang, Luhua H.; Chen, Chen; Linde, Miles H.; Sunwoo, John B.] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA; [Dixon, Amera L.; Mace, Emily M.] Columbia Univ, Dept Pediat, Irving Med Ctr, New York, NY 10027 USA	Stanford Cancer Institute; Stanford University; Stanford University; Columbia University; NewYork-Presbyterian Hospital	Sunwoo, JB (corresponding author), Stanford Univ, Sch Med, Stanford Canc Inst, Dept Otolaryngol Head & Neck Surg, Stanford, CA 94305 USA.; Sunwoo, JB (corresponding author), Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA.	sunwoo@stanford.edu		Linde, Miles/0000-0003-2553-2890; Martinez, Amera/0000-0002-9392-5728; Sunwoo, John/0000-0002-8393-4196	National Institutes of Health [R01CA158516, R35DE030054, R01AI137073]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by funding from the National Institutes of Health (R01CA158516; R35DE030054) to JBS and R01AI137073 to EMM.	Bonaventura P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00168; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Castriconi R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02324; Castriconi R, 2013, J IMMUNOL, V190, P5321, DOI 10.4049/jimmunol.1202693; GONG JH, 1994, LEUKEMIA, V8, P652; Habif G, 2019, CELL MOL IMMUNOL, V16, P415, DOI 10.1038/s41423-019-0224-2; Heuze ML, 2008, BLOOD, V112, P5130, DOI 10.1182/blood-2007-12-128744; Hughes T, 2014, CELL REP, V8, P150, DOI 10.1016/j.celrep.2014.05.042; Jenne CN, 2009, J EXP MED, V206, P2469, DOI 10.1084/jem.20090525; Jin GB, 2010, TOXICOL SCI, V116, P514, DOI 10.1093/toxsci/kfq153; Kim CH, 2016, TRENDS IMMUNOL, V37, P68, DOI 10.1016/j.it.2015.11.003; Kim M, 2017, SCI REP-UK, V7, DOI 10.1038/srep40623; Lamsoul I, 2013, BLOOD, V122, P533, DOI 10.1182/blood-2012-11-466649; Lamsoul I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043798; Lee KM, 2006, BLOOD, V107, P3181, DOI 10.1182/blood-2005-01-0185; Michel T, 2016, J IMMUNOL, V196, P2923, DOI 10.4049/jimmunol.1502570; Miller JS, 2014, BIOL BLOOD MARROW TR, V20, P1252, DOI 10.1016/j.bbmt.2014.05.004; Moreno-Nieves UY, 2018, EUR J IMMUNOL, V48, P771, DOI 10.1002/eji.201747289; Murray IA, 2014, NAT REV CANCER, V14, P801, DOI 10.1038/nrc3846; Nguyen NT, 2013, INT IMMUNOL, V25, P335, DOI 10.1093/intimm/dxt011; Nguyen LP, 2008, CHEM RES TOXICOL, V21, P102, DOI 10.1021/tx7001965; Peng H, 2017, SEMIN IMMUNOL, V31, P3, DOI 10.1016/j.smim.2017.07.006; Razinia Z, 2013, J BIOL CHEM, V288, P32093, DOI 10.1074/jbc.M113.496604; Riggan L, 2019, TRENDS IMMUNOL, V40, P909, DOI 10.1016/j.it.2019.08.005; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Shimasaki N, 2020, NAT REV DRUG DISCOV, V19, P200, DOI 10.1038/s41573-019-0052-1; Shin JH, 2013, P NATL ACAD SCI USA, V110, P12391, DOI 10.1073/pnas.1302856110; Sogawa K, 1997, J BIOCHEM, V122, P1075; Stockinger B, 2014, ANNU REV IMMUNOL, V32, P403, DOI 10.1146/annurev-immunol-032713-120245; Sun YV, 2004, NUCLEIC ACIDS RES, V32, P4512, DOI 10.1093/nar/gkh782; Trikha P, 2020, BBA-REV CANCER, V1873, DOI 10.1016/j.bbcan.2019.188335; van der Woude LL, 2017, TRENDS CANCER, V3, P797, DOI 10.1016/j.trecan.2017.09.006; Wagage S, 2014, J IMMUNOL, V192, P1661, DOI 10.4049/jimmunol.1300497; Ye J, 2017, CELL REP, V21, P2277, DOI 10.1016/j.celrep.2017.10.114; Zhang LH, 2016, J EXP MED, V213, P2249, DOI 10.1084/jem.20151998	35	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2021	12								624284	10.3389/fimmu.2021.624284	http://dx.doi.org/10.3389/fimmu.2021.624284			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT9GS	33717133	gold, Green Published			2022-12-18	WOS:000626895900001
J	Zhang, YY; Huo, W; Sun, LD; Wu, J; Zhang, CB; Wang, HH; Wang, B; Wei, JL; Qu, C; Cao, HS; Jiang, X				Zhang, Yuyu; Huo, Wei; Sun, Lidi; Wu, Jie; Zhang, Chengbin; Wang, Huanhuan; Wang, Bin; Wei, Jinlong; Qu, Chao; Cao, Hongshi; Jiang, Xin			Targeting miR-148b-5p Inhibits Immunity Microenvironment and Gastric Cancer Progression	FRONTIERS IN IMMUNOLOGY			English	Article						gastric cancer; miR-148b-5p; ATPIF1; immune microenvironment; metabolic reprogramming		Background MicroRNAs (miRNAs) have been discovered to dictate the development of various tumors. However, studies on the roles of miRNAs in the progression of gastric cancer (GC) are still lacking. Methods Herein, by analyzing GC cell lines and patients samples, we observed that miR-148b-5p was significantly downregulated in GC. We also confirmed that miR-148b-5p overexpression significantly inhibited GC cell proliferation and invasion in vitro and in vivo. Results Overexpression of miR-148b-5p not only reprogrammed the metabolic properties of GC but also regulated the immune microenvironment by shifting lymphocyte and myeloid populations. Mechanistically, ATPIF1, an important glycolysis-associated gene, was identified as a direct target of miR-148b-5p and mediated the effect of miR-148b-5p. Notably, the low level of miR-148b-5p was significantly related with poor prognosis of GC patients (P < 0.001). Importantly, the levels of miR-148b-5p significantly changed the sensitivity of GC cells to several anti-cancer drugs (Doxorubicin, P < 0.05, Paclitaxel, P < 0.01, Docetaxel, P < 0.05). Conclusions Targeting miR-148b-5p inhibits immunity microenvironment and gastric cancer progression.	[Zhang, Yuyu; Huo, Wei; Sun, Lidi; Wu, Jie; Wang, Huanhuan; Wang, Bin; Wei, Jinlong; Qu, Chao; Jiang, Xin] First Hosp Jilin Univ, Dept Radiat Oncol, Changchun, Peoples R China; [Zhang, Chengbin] First Hosp Jilin Univ, Dept Pathol Oncol, Changchun, Peoples R China; [Cao, Hongshi] First Hosp Jilin Univ, Dept Nursing, Changchun, Peoples R China	Jilin University; Jilin University; Jilin University	Qu, C; Jiang, X (corresponding author), First Hosp Jilin Univ, Dept Radiat Oncol, Changchun, Peoples R China.; Cao, HS (corresponding author), First Hosp Jilin Univ, Dept Nursing, Changchun, Peoples R China.	quchao-007@163.com; 326190150@qq.com; jiangx@jlu.edu.cn	Jiang, Xin/AHA-9454-2022	Jiang, Xin/0000-0002-4613-7438; Wang, Bin/0000-0001-9097-4578	National Natural Science Foundation of China [81702744]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (No. 81702744). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Benson EA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141279; Cho J, 2018, ESMO OPEN, V3, DOI 10.1136/esmoopen-2018-000326; Domblides C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020104; Feichtinger RG, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1320241; Feng X, 2021, AUTOPHAGY, V17, P723, DOI 10.1080/15548627.2020.1731266; He D, 2017, ONCOTARGET, V8, P20165, DOI 10.18632/oncotarget.15529; Hong BS, 2019, CANCER RES, V79, P1520, DOI 10.1158/0008-5472.CAN-18-0891; Hong XH, 2018, ELIFE, V7, DOI 10.7554/eLife.29511; Kohlhapp FJ, 2015, ONCOGENE, V34, P5857, DOI 10.1038/onc.2015.89; Ma F, 2019, HEPATOLOGY, V70, P1785, DOI 10.1002/hep.30703; Matic I, 2016, PHARMACOL RES, V103, P56, DOI 10.1016/j.phrs.2015.10.010; Muluhngwi P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05727-w; Pereira PMR, 2019, J NUCL MED, V60, P1569, DOI 10.2967/jnumed.119.225813; Riffo-Campos AL, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17121987; Shan L, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-76; Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140-6736(20)31288-5; Song RP, 2014, HEPATOLOGY, V60, P1659, DOI 10.1002/hep.27312; Vautrot V, 2019, J ONCOL, V2019, DOI 10.1155/2019/8585276; Wang JK, 2019, CANCER LETT, V454, P134, DOI 10.1016/j.canlet.2019.04.015; Wong NACS, 2018, J CLIN PATHOL, V71, P388, DOI 10.1136/jclinpath-2017-204943; Yu FY, 2018, NEOPLASMA, V65, P406, DOI 10.4149/neo_2018_170608N411; Zhang H, 2017, ONCOTARGET, V8, P2342, DOI 10.18632/oncotarget.13672; Zhang MK, 2019, AM J CANCER RES, V9, P765; Zhou JR, 2018, CANCER IMMUNOL RES, V6, P1578, DOI 10.1158/2326-6066.CIR-17-0479; Zhou QX, 2020, J EXP MED, V217, DOI 10.1084/jem.20191779; Zhu YK, 2018, ONCOTARGETS THER, V11, P5743, DOI 10.2147/OTT.S170246	26	1	2	4	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2021	12								590447	10.3389/fimmu.2021.590447	http://dx.doi.org/10.3389/fimmu.2021.590447			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU1EE	33717068	gold, Green Published			2022-12-18	WOS:000627025600001
J	Zhuang, JM; Hou, JG				Zhuang, Jingming; Hou, Jiangang			The Role of Regulatory Myeloid Cell Therapy in Renal Allograft Rejection	FRONTIERS IN IMMUNOLOGY			English	Review						kidney transplant; regulatory myeloid cell; allograft rejection; immunosuppression; prevention; end-stage renal disease		Kidney transplantation is a primary therapy for end-stage renal disease (ESRD) all the time. But it does not mean that we have fully unraveling the mystery of kidney transplantation and confer every patient favorable prognosis. Immune rejection has always been a stumbling block when we try to increase the success rate of kidney transplantation and improve long-term outcomes. Even if the immune rejection is effectively controlled in acute phase, there is a high possibility that the immune response mediated by chronically activated antibodies will trigger chronic rejection and ultimately lead to graft failure. At present, immunosuppressive agent prepared chemically is mainly used to prevent acute or chronic rejection, but it failed to increase the long-term survival rate of allografts or reduce the incidence of chronic rejection after acute rejection, and is accompanied by many adverse reactions. Therefore, many studies have begun to use immune cells to regulate the immune response in order to control allograft rejection. This article will focus on the latest study and prospects of more popular regulatory myeloid cells in the direction of renal transplantation immunotherapy and introduce their respective progress from experimental research to clinical research.	[Zhuang, Jingming; Hou, Jiangang] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China	Fudan University	Hou, JG (corresponding author), Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China.	hou_jiangang@126.com	Zhuang, Jingming/GZK-6984-2022	Zhuang, Jingming/0000-0003-0529-3220	National Natural Science Foundation of China [81771683]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Publication fees are covered by the National Natural Science Foundation of China (Grant No. 81771683).	Almand B, 2001, J IMMUNOL, V166, P678, DOI 10.4049/jimmunol.166.1.678; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bashuda H, 2005, J CLIN INVEST, V115, P1896, DOI 10.1172/JCI23743; Bernardo ME, 2013, CELL STEM CELL, V13, P392, DOI 10.1016/j.stem.2013.09.006; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Cai SJ, 2017, STEM CELL REP, V8, P1174, DOI 10.1016/j.stemcr.2017.03.020; Casiraghi F, 2018, HUM IMMUNOL, V79, P304, DOI 10.1016/j.humimm.2017.12.008; Chandran S, 2017, AM J TRANSPLANT, V17, P2945, DOI 10.1111/ajt.14415; Chiesa S, 2011, P NATL ACAD SCI USA, V108, P17384, DOI 10.1073/pnas.1103650108; Conde P, 2015, IMMUNITY, V42, P1143, DOI 10.1016/j.immuni.2015.05.009; Cornell LD, 2008, ANNU REV PATHOL-MECH, V3, P189, DOI 10.1146/annurev.pathmechdis.3.121806.151508; Dilek N, 2012, J IMMUNOL, V188, P4209, DOI 10.4049/jimmunol.1101512; Dilek N, 2010, CURR OPIN ORGAN TRAN, V15, P765, DOI 10.1097/MOT.0b013e3283401742; Du LM, 2019, CELL METAB, V29, P1363, DOI 10.1016/j.cmet.2019.01.006; Dugast AS, 2008, J IMMUNOL, V180, P7898, DOI 10.4049/jimmunol.180.12.7898; Eckardt KU, 2009, AM J TRANSPLANT, V9, pS1, DOI 10.1111/j.1600-6143.2009.02834.x; Fisher R, 1998, J CLIN NURS, V7, P553, DOI 10.1046/j.1365-2702.1998.00189.x; Fleming BD, 2011, EUR J IMMUNOL, V41, P2498, DOI 10.1002/eji.201141717; Guo F, 2017, XENOTRANSPLANTATION, V24, DOI 10.1111/xen.12326; Hall BM, 2016, TRANSPLANTATION, V100, P2533, DOI 10.1097/TP.0000000000001436; Halloran PF, 2004, NEW ENGL J MED, V351, P2715, DOI 10.1056/NEJMra033540; Hashmi S, 2016, LANCET HAEMATOL, V3, pE45, DOI 10.1016/S2352-3026(15)00224-0; Hock BD, 2015, TRANSPL IMMUNOL, V32, P164, DOI 10.1016/j.trim.2015.05.001; Hutchinson JA, 2011, J IMMUNOL, V187, P2072, DOI 10.4049/jimmunol.1100762; Jiang XX, 2005, BLOOD, V105, P4120, DOI 10.1182/blood-2004-02-0586; Jose MD, 2003, TRANSPLANTATION, V76, P1015, DOI 10.1097/01.TP.0000083507.67995.13; Karlsson H, 2008, BLOOD, V112, P532, DOI 10.1182/blood-2007-10-119370; Kirchhof J, 2021, ENDOCR METAB IMMUNE, V21, P1083, DOI 10.2174/1871530320999200831161710; Le Blanc K, 2012, NAT REV IMMUNOL, V12, P383, DOI 10.1038/nri3209; Lee YS, 2020, AM J TRANSPLANT, V20, P2343, DOI 10.1111/ajt.15879; Liao JB, 2014, J LEUKOCYTE BIOL, V96, P675, DOI 10.1189/jlb.2HI1113-611RR; Luan Y, 2013, AM J TRANSPLANT, V13, P3123, DOI 10.1111/ajt.12461; Luz-Crawford P, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt216; Ma AL, 2011, INT IMMUNOPHARMACOL, V11, P618, DOI 10.1016/j.intimp.2010.11.001; Manicassamy S, 2011, IMMUNOL REV, V241, P206, DOI 10.1111/j.1600-065X.2011.01015.x; Marin E, 2019, CELL METAB, V30, P1075, DOI 10.1016/j.cmet.2019.11.011; Meier-Kriesche HU, 2004, AM J TRANSPLANT, V4, P378, DOI 10.1111/j.1600-6143.2004.00332.x; Meng FH, 2014, INFLAMMATION, V37, P1799, DOI 10.1007/s10753-014-9910-5; Moreau A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00218; Morelli AE, 2007, NAT REV IMMUNOL, V7, P610, DOI 10.1038/nri2132; MURRAY JE, 1982, WORLD J SURG, V6, P372, DOI 10.1007/BF01653562; Najar M, 2019, CURR STEM CELL RES T, V14, P14, DOI 10.2174/1574888X13666180912125736; Nakamura T, 2016, TRANSPL P, V48, P1275, DOI 10.1016/j.transproceed.2015.10.060; Nakao T, 2018, TRANSPL P, V50, P299, DOI 10.1016/j.transproceed.2017.11.014; Nauta AJ, 2006, J IMMUNOL, V177, P2080, DOI 10.4049/jimmunol.177.4.2080; Oberbarnscheidt MH, 2014, J CLIN INVEST, V124, P3579, DOI 10.1172/JCI74370; Ochando J, 2017, JOVE-J VIS EXP, DOI 10.3791/54242; Okano S, 2018, AM J TRANSPLANT, V18, P2544, DOI 10.1111/ajt.14718; PAK AS, 1995, CLIN CANCER RES, V1, P95; Pang XL, 2019, AGING-US, V11, P8911, DOI 10.18632/aging.102346; Papp G, 2017, AUTOIMMUN REV, V16, P435, DOI 10.1016/j.autrev.2017.03.011; Perico N, 2013, TRANSPL INT, V26, P867, DOI 10.1111/tri.12132; Pistoia V, 2017, INT IMMUNOL, V29, P49, DOI 10.1093/intimm/dxx008; Pool M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184614; Riquelme P, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05167-8; Riquelme P, 2013, MOL THER, V21, P409, DOI 10.1038/mt.2012.168; Rizvi SMH, 2017, JAMA DERMATOL, V153, P1270, DOI 10.1001/jamadermatol.2017.2984; Rosado MM, 2015, STEM CELLS DEV, V24, P93, DOI 10.1089/scd.2014.0155; Rosborough BR, 2014, TRANSPLANTATION, V97, P367, DOI 10.1097/TP.0b013e3182a860de; Sawitzki B, 2020, LANCET, V395, P1627, DOI 10.1016/S0140-6736(20)30167-7; Segovia M, 2014, AM J TRANSPLANT, V14, P1021, DOI 10.1111/ajt.12708; Spaggiari GM, 2013, IMMUNOL CELL BIOL, V91, P27, DOI 10.1038/icb.2012.62; Srinivas TR, 2008, CLIN J AM SOC NEPHRO, V3, pS101, DOI 10.2215/CJN.03510807; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Sun QP, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1422-x; Taylor PA, 2002, BLOOD, V99, P3493, DOI 10.1182/blood.V99.10.3493; Thomson AW, 2018, HUM IMMUNOL, V79, P314, DOI 10.1016/j.humimm.2017.10.017; Thomson AW, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00015; Tsipotis E, 2016, AM J NEPHROL, V44, P206, DOI 10.1159/000449020; Utrero-Rico A, 2020, TRANSPLANTATION, V104, P2599, DOI 10.1097/TP.0000000000003179; van Kooten C, 2011, TRANSPLANTATION, V91, P2, DOI 10.1097/TP.0b013e31820263b3; Wood KJ, 2012, NAT REV IMMUNOL, V12, P417, DOI 10.1038/nri3227; Wood KJ, 2012, TRANSPLANTATION, V93, P1, DOI 10.1097/TP.0b013e31823cab44; Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027; Xu QX, 2018, GENE, V644, P93, DOI 10.1016/j.gene.2017.10.081; Zhao Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00282	76	1	1	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2021	12								625998	10.3389/fimmu.2021.625998	http://dx.doi.org/10.3389/fimmu.2021.625998			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT6YF	33717141	Green Published, gold			2022-12-18	WOS:000626735400001
J	Fernandez-Sendin, M; Di Trani, CA; Bella, A; Vasquez, M; Ardaiz, N; Gomar, C; Arrizabalaga, L; Ciordia, S; Corrales, FJ; Aranda, F; Berraondo, P				Fernandez-Sendin, Myriam; Di Trani, Claudia Augusta; Bella, Angela; Vasquez, Marcos; Ardaiz, Nuria; Gomar, Celia; Arrizabalaga, Leire; Ciordia, Sergio; Corrales, Fernando J.; Aranda, Fernando; Berraondo, Pedro			Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity	FRONTIERS IN IMMUNOLOGY			English	Article						liver; antiviral; apolipoprotein A-I mimetic peptide; type I Interferon; adeno-associated virus		Apolipoprotein A-I mimetic peptides are amphipathic alpha-helix peptides that display similar functions to apolipoprotein A-I. Preclinical and clinical studies have demonstrated the safety and efficacy of apolipoprotein A-I mimetic peptides in multiple indications associated with inflammatory processes. In this study, we evaluated the effect of the long-term expression of L37pA in the liver by an adeno-associated virus (AAV-L37pA) on the expression of an adeno-associated virus encoding interferon-alpha (AAV-IFN alpha). Long-term IFN alpha expression in the liver leads to lethal hematological toxicity one month after AAV administration. Concomitant administration of AAV-L37pA prevented the lethal toxicity since the IFN alpha expression was reduced one month after AAV administration. To identify the mechanism of action of L37pA, a genomic and proteomic analysis was performed 15 days after AAV administration when a similar level of IFN alpha and interferon-stimulated genes were observed in mice treated with AAV-IFN alpha alone and in mice treated with AAV-IFN alpha and AAV-L37pA. The coexpression of the apolipoprotein A-I mimetic peptide L37pA with IFN alpha modulated the gene expression program of IFN alpha, inducing a significant reduction in inflammatory pathways affecting pathogen-associated molecular patterns receptor, dendritic cells, NK cells and Th1 immune response. The proteomic analysis confirmed the impact of the L37pA activity on several inflammatory pathways and indicated an activation of LXR/RXR and PPPAR alpha/gamma nuclear receptors. Thus, long-term expression of L37pA induces an anti-inflammatory effect in the liver that allows silencing of IFN alpha expression mediated by an adeno-associated virus.	[Fernandez-Sendin, Myriam; Di Trani, Claudia Augusta; Bella, Angela; Vasquez, Marcos; Ardaiz, Nuria; Gomar, Celia; Arrizabalaga, Leire; Aranda, Fernando; Berraondo, Pedro] Cima Univ Navarra, Program Immunol & Immunotherapy, Pamplona, Spain; [Fernandez-Sendin, Myriam; Di Trani, Claudia Augusta; Bella, Angela; Vasquez, Marcos; Ardaiz, Nuria; Gomar, Celia; Arrizabalaga, Leire; Aranda, Fernando; Berraondo, Pedro] Navarra Inst Hlth Res IDISNA, Pamplona, Spain; [Ciordia, Sergio; Corrales, Fernando J.] CSIC, Natl Ctr Biotechnol, Funct Prote Lab, Madrid, Spain; [Ciordia, Sergio; Corrales, Fernando J.] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain; [Berraondo, Pedro] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain	University of Navarra; Consejo Superior de Investigaciones Cientificas (CSIC); CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC	Berraondo, P (corresponding author), Cima Univ Navarra, Program Immunol & Immunotherapy, Pamplona, Spain.; Berraondo, P (corresponding author), Navarra Inst Hlth Res IDISNA, Pamplona, Spain.; Berraondo, P (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain.	pberraondol@unav.es	Aranda, Fernando/N-2112-2014; Berraondo, Pedro/J-3154-2012; Aranda, Fernando/N-9649-2019; Fernandez, Myriam/A-5666-2019	Aranda, Fernando/0000-0002-9364-474X; Berraondo, Pedro/0000-0001-7410-1865; Aranda, Fernando/0000-0002-9364-474X; Corrales, Fernando/0000-0002-0231-5159; Fernandez, Myriam/0000-0003-2119-3967	Instituto de Salud Carlos III - Fondos Feder Gobierno de Navarra Proyecto LINTERNA [PI16/00668, PI19/01128, PI20/00002, 00111411-2020-000075]; Joint Translational Call for Proposals 2015 (JTC 2015) TRANSCAN-2 [TRS-2016-00000371]; European Union [765394]; ISCIII (Instituto de Salud Carlos III) by FSE (Fondo Social Europeo) [CP19/00114]; ISCIII [FI20/00058]; University of Navarra; Comunidad de Madrid Grant [B2017/BMD-3817];  [PT17/0019/0001]	Instituto de Salud Carlos III - Fondos Feder Gobierno de Navarra Proyecto LINTERNA; Joint Translational Call for Proposals 2015 (JTC 2015) TRANSCAN-2; European Union(European Commission); ISCIII (Instituto de Salud Carlos III) by FSE (Fondo Social Europeo); ISCIII(Instituto de Salud Carlos III); University of Navarra; Comunidad de Madrid Grant(Comunidad de Madrid); 	This study was supported by the Instituto de Salud Carlos III (PI16/00668, PI19/01128, PI20/00002) cofinanced by Fondos Feder Gobierno de Navarra Proyecto LINTERNA Ref.: 00111411-2020-000075 and Joint Translational Call for Proposals 2015 (JTC 2015) TRANSCAN-2 (code: TRS-2016-00000371). This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 765394. FA receives a Miguel Servet I (CP19/00114) contract from ISCIII (Instituto de Salud Carlos III) co-financed by FSE (Fondo Social Europeo). AB is recipients of PFIS fellowship from ISCIII (FI20/00058), and MF-S is recipients for a fellowship of the Aid Program Assigned to Projects from the University of Navarra. The Proteomics Unit belongs to ProteoRed, PRB3-ISCIII, supported by grant PT17/0019/0001 (FC). Comunidad de Madrid Grant B2017/BMD-3817 (FC).	Abrams ME, 2020, NAT MICROBIOL, V5, P929, DOI 10.1038/s41564-020-0701-5; Ahmed RAM, 2009, ENDOCRINE, V35, P233, DOI 10.1007/s12020-008-9142-2; Anantharamaiah GM, 2016, PROTEIN PEPTIDE LETT, V23, P1024, DOI 10.2174/0929866523666160901154216; Arakawa R, 2004, J BIOL CHEM, V279, P6217, DOI 10.1074/jbc.C300553200; Berraondo P, 2005, MOL THER, V12, P68, DOI 10.1016/j.ymthe.2005.02.017; Bocharov AV, 2004, J BIOL CHEM, V279, P36072, DOI 10.1074/jbc.M314264200; Bosch M, 2020, SCIENCE, V370, P309, DOI 10.1126/science.aay8085; Buchlis G, 2012, BLOOD, V119, P3038, DOI 10.1182/blood-2011-09-382317; Charles-Schoeman C, 2008, CLIN IMMUNOL, V127, P234, DOI 10.1016/j.clim.2008.01.016; Chyu KY, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00187; Cunningham CR, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005356; Fernandez-Sendin M, 2020, METHOD ENZYMOL, V635, P185, DOI 10.1016/bs.mie.2019.05.007; George LA, 2020, MOL THER, V28, P2073, DOI 10.1016/j.ymthe.2020.06.001; Gomaraschi M, 2008, J PHARMACOL EXP THER, V324, P776, DOI 10.1124/jpet.107.129411; Grefhorst A, 2012, ATHEROSCLEROSIS, V222, P382, DOI 10.1016/j.atherosclerosis.2012.02.014; Harris LD, 2010, J VIROL, V84, P7886, DOI 10.1128/JVI.02612-09; Kalaany NY, 2006, ANNU REV PHYSIOL, V68, P159, DOI 10.1146/annurev.physiol.68.033104.152158; Leelahavanichkul A, 2012, J IMMUNOL, V188, P2749, DOI 10.4049/jimmunol.1003445; Lercher A, 2019, IMMUNITY, V51, P1074, DOI 10.1016/j.immuni.2019.10.014; Lopez-Serra P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4608; Maguire AM, 2019, OPHTHALMOLOGY, V126, P1273, DOI 10.1016/j.ophtha.2019.06.017; Malerod L, 2002, BIOCHEM BIOPH RES CO, V299, P916, DOI 10.1016/S0006-291X(02)02760-2; Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198; Meriwether D, 2019, J CLIN INVEST, V129, P3670, DOI 10.1172/JCI123700; Moreira RS, 2020, AM J PHYSIOL-REG I, V318, pR529, DOI 10.1152/ajpregu.00185.2019; Nankar SA, 2020, PROTEIN PEPTIDE LETT, V27, P193, DOI 10.2174/0929866526666191002112655; Omeragic A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45878-6; Paneda A, 2009, HUM GENE THER, V20, P908, DOI 10.1089/hum.2009.031; Pascual-Garcia M, 2013, J IMMUNOL, V190, P6520, DOI 10.4049/jimmunol.1201393; Pastor F, 2018, NAT REV DRUG DISCOV, V17, P751, DOI 10.1038/nrd.2018.132; Peterson SJ, 2008, J LIPID RES, V49, P1658, DOI 10.1194/jlr.M800046-JLR200; Peterson SJ, 2007, J PHARMACOL EXP THER, V322, P514, DOI 10.1124/jpet.107.119479; Ramos-Fernandez A, 2008, MOL CELL PROTEOMICS, V7, P1748, DOI 10.1074/mcp.M800122-MCP200; Ruffenach G, 2020, HYPERTENSION, V76, P985, DOI 10.1161/HYPERTENSIONAHA.120.14697; Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Swaminathan SK, 2020, J PHARMACOL EXP THER, V375, P308, DOI 10.1124/jpet.120.265876; Teijaro JR, 2013, SCIENCE, V340, P207, DOI 10.1126/science.1235214; Van Lenten BJ, 2007, J LIPID RES, V48, P2344, DOI 10.1194/jlr.M700138-JLR200; Vasquez M, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1196309; Verdera HC, 2020, MOL THER, V28, P723, DOI 10.1016/j.ymthe.2019.12.010; Weihrauch D, 2007, AM J PHYSIOL-HEART C, V293, pH1432, DOI 10.1152/ajpheart.00038.2007; Wilson EB, 2013, SCIENCE, V340, P202, DOI 10.1126/science.1235208; Xu LY, 2012, AM J PHYSIOL-ENDOC M, V302, pE788, DOI 10.1152/ajpendo.00337.2011; Yao XL, 2016, CHEST, V150, P283, DOI 10.1016/j.chest.2016.05.035; Zhang XQ, 2015, NATURE, V517, P89, DOI 10.1038/nature13801; Zhou QD, 2020, NAT IMMUNOL, V21, P746, DOI 10.1038/s41590-020-0695-4	47	1	1	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2021	11								620283	10.3389/fimmu.2020.620283	http://dx.doi.org/10.3389/fimmu.2020.620283			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT0LD	33708194	Green Published, gold			2022-12-18	WOS:000626283400001
J	Fischer, S; Stanke, F; Tummler, B				Fischer, Sebastian; Stanke, Frauke; Tuemmler, Burkhard			VJ Segment Usage of TCR-Beta Repertoire in Monozygotic Cystic Fibrosis Twins	FRONTIERS IN IMMUNOLOGY			English	Article						T cell receptor repertoire; immunotyping; VJ usage; cyctic fibrosis; twins; CDR3; TCRB		Sixteen monozygotic cystic fibrosis (CF) twin pairs of whom 14 pairs were homozygous for the most common p.Phe508del CFTR mutation were selected from the European Cystic Fibrosis Twin and Sibling Study Cohort. The monozygotic twins were examined in their T cell receptor (TCR) repertoire in peripheral blood by amplicon sequencing of the CDR3 variable region of the ss-chain. The recruitment of TCR J and V genes for recombination and selection in the thymus showed a strong genetic influence in the CF twin cohort as indicated by the shortest Jensen-Shannon distance to the twin individual. Exceptions were the clinically most discordant and/or most severely affected twin pairs where clonal expansion probably caused by recurrent pulmonary infections overshadowed the impact of the identical genomic blueprint. In general the Simpson clonality was low indicating that the population of TCRss clonotypes of the CF twins was dominated by the naive T-cell repertoire. Intrapair sharing of clonotypes was significantly more frequent among monozygotic CF twins than among pairs of unrelated CF patients. Complete nucleotide sequence identity was observed in about 0.11% of CDR3 sequences which partially should represent persisting fetal clones derived from the same progenitor T cells. Complete amino acid sequence identity was noted in 0.59% of clonotypes. Of the nearly 40,000 frequent amino acid clonotypes shared by at least two twin siblings 99.8% were already known within the immuneACCESS database and only 73 had yet not been detected indicating that the CDR3ss repertoire of CF children and adolescents does not carry a disease-specific signature but rather shares public clones with that of the non-CF community. Clonotypes shared within twin pairs and between unrelated CF siblings were highly abundant among healthy non-CF people, less represented in individuals with infectious disease and uncommon in patients with cancer. This subset of shared CF clonotypes defines CDR3 amino acid sequences that are more common in health than in disease.	[Fischer, Sebastian; Stanke, Frauke; Tuemmler, Burkhard] Hannover Med Sch, Clin Pediat Pneumol Allergol & Neonatol, Hannover, Germany; [Stanke, Frauke; Tuemmler, Burkhard] Hannover Med Sch, German Ctr Lung Res, Biomed Res Endstage & Obstruct Lung Dis Hannover, Hannover, Germany	Hannover Medical School; Hannover Medical School	Fischer, S (corresponding author), Hannover Med Sch, Clin Pediat Pneumol Allergol & Neonatol, Hannover, Germany.	fischer.sebastian@mh-hannover.de		Fischer, Sebastian/0000-0002-3873-6166	Deutsche Forschungsgemeinschaft (DFG) [SFB900/3 -158989968 -Z1]; German Center for Lung Research at BREATH [82DZL002A1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Center for Lung Research at BREATH	This research was funded by the Deutsche Forschungsgemeinschaft (DFG) (Grant Number: SFB900/3 -158989968 -Z1) and the German Center for Lung Research at BREATH (Grant number: 82DZL002A1).	Alawam AS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00858; Bagaev DV, 2020, NUCLEIC ACIDS RES, V48, pD1057, DOI 10.1093/nar/gkz874; Blanchard AC, 2019, SEMIN RESP CRIT CARE, V40, P727, DOI 10.1055/s-0039-1698464; Bobadilla JL, 2002, HUM MUTAT, V19, P575, DOI 10.1002/humu.10041; Boehm T, 2008, CURR OPIN IMMUNOL, V20, P178, DOI 10.1016/j.coi.2008.03.001; Chiba-Falek O, 1998, GENOMICS, V53, P276, DOI 10.1006/geno.1998.5517; Cutting GR, 2015, NAT REV GENET, V16, P45, DOI 10.1038/nrg3849; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Elborn JS, 2016, LANCET, V388, P2519, DOI 10.1016/S0140-6736(16)00576-6; Emerson RO, 2017, NAT GENET, V49, P659, DOI 10.1038/ng.3822; Fu G, 2014, TRENDS IMMUNOL, V35, P311, DOI 10.1016/j.it.2014.05.003; Fuglede B, 2004, 2004 IEEE INTERNATIONAL SYMPOSIUM ON INFORMATION THEORY, PROCEEDINGS, P31; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; Hubeau C, 2001, CLIN EXP IMMUNOL, V124, P69, DOI 10.1046/j.1365-2249.2001.01456.x; Ingersoll SA, 2015, J IMMUNOL, V194, P5520, DOI 10.4049/jimmunol.1500312; Khan MA, 2019, GENES-BASEL, V10, DOI 10.3390/genes10030183; Klein L, 2014, NAT REV IMMUNOL, V14, P377, DOI 10.1038/nri3667; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LIN J, 1990, INT J GEN SYST, V17, P73, DOI 10.1080/03081079008935097; LIN JH, 1991, IEEE T INFORM THEORY, V37, P145, DOI 10.1109/18.61115; Lythe G, 2016, J THEOR BIOL, V389, P214, DOI 10.1016/j.jtbi.2015.10.016; Madi A, 2017, ELIFE, V6, DOI 10.7554/eLife.22057; Madi A, 2014, GENOME RES, V24, P1603, DOI 10.1101/gr.170753.113; McKenzie SG, 2007, PEDIATR PULM, V42, P928, DOI 10.1002/ppul.20685; Mekus F, 2000, Twin Res, V3, P277, DOI 10.1375/136905200320565256; Menezes JS, 2007, J CLIN INVEST, V117, P2176, DOI 10.1172/JCI28277; Monod MY, 2004, BIOINFORMATICS, V20, P379, DOI 10.1093/bioinformatics/bth945; Murugan A, 2012, P NATL ACAD SCI USA, V109, P16161, DOI 10.1073/pnas.1212755109; Park JE, 2020, SCIENCE, V367, P868, DOI 10.1126/science.aay3224; Pogorelyy MV, 2018, P NATL ACAD SCI USA, V115, P12704, DOI 10.1073/pnas.1809642115; Pogorelyy MV, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005572; Prader A, 1989, Helv Paediatr Acta Suppl, V52, P1; Qi Q, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1725; Qi Q, 2014, P NATL ACAD SCI USA, V111, P13139, DOI 10.1073/pnas.1409155111; Ratjen F, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.10; Regamey N, 2012, THORAX, V67, P170, DOI 10.1136/thoraxjnl-2011-200585; Robins HS, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001442; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Rosati E, 2020, J CROHNS COLITIS, V14, P778, DOI 10.1093/ecco-jcc/jjz179; Rubelt F, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11112; Rudolph MG, 2006, ANNU REV IMMUNOL, V24, P419, DOI 10.1146/annurev.immunol.23.021704.115658; Sacchetti L, 1999, CLIN CHEM, V45, P178; Schamschula E, 2021, J CYST FIBROS, V20, P149, DOI 10.1016/j.jcf.2020.06.009; Sethna Z, 2019, BIOINFORMATICS, V35, P2974, DOI 10.1093/bioinformatics/btz035; Stoltz DA, 2015, NEW ENGL J MED, V372, P351, DOI 10.1056/NEJMra1300109; Tanno H, 2020, P NATL ACAD SCI USA, V117, P532, DOI 10.1073/pnas.1915008117; Turner SJ, 2006, NAT REV IMMUNOL, V6, P883, DOI 10.1038/nri1977; Venturi V, 2011, J IMMUNOL, V186, P4285, DOI 10.4049/jimmunol.1003898; Woods CG, 2006, AM J HUM GENET, V78, P889, DOI 10.1086/503875; Zhao YQ, 2016, J IMMUNOL, V196, P4905, DOI 10.4049/jimmunol.1501029; Zvyagin IV, 2014, P NATL ACAD SCI USA, V111, P5980, DOI 10.1073/pnas.1319389111	52	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2021	12								599133	10.3389/fimmu.2021.599133	http://dx.doi.org/10.3389/fimmu.2021.599133			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT0KN	33708199	gold, Green Published			2022-12-18	WOS:000626281800001
J	Morini, R; Bizzotto, M; Perrucci, F; Filipello, F; Matteoli, M				Morini, Raffaella; Bizzotto, Matteo; Perrucci, Fabio; Filipello, Fabia; Matteoli, Michela			Strategies and Tools for Studying Microglial-Mediated Synapse Elimination and Refinement	FRONTIERS IN IMMUNOLOGY			English	Review						microglia; synaptic pruning; phagocytosis; confocal microscopy; flow cytometry	HIGH-DIMENSIONAL ANALYSIS; AMYLOID-BETA; MACROPHAGE PHAGOCYTOSIS; PRENATAL DEVELOPMENT; APOPTOTIC NEURONS; ANALYSIS REVEALS; MASS CYTOMETRY; MOUSE MODEL; CELL-LINES; IN-VITRO	The role of microglia in controlling synapse homeostasis is becoming increasingly recognized by the scientific community. In particular, the microglia-mediated elimination of supernumerary synapses during development lays the basis for the correct formation of neuronal circuits in adulthood, while the possible reactivation of this process in pathological conditions, such as schizophrenia or Alzheimer's Disease, provides a promising target for future therapeutic strategies. The methodological approaches to investigate microglial synaptic engulfment include different in vitro and in vivo settings. Basic in vitro assays, employing isolated microglia and microbeads, apoptotic membranes, liposomes or synaptosomes allow the quantification of the microglia phagocytic abilities, while co-cultures of microglia and neurons, deriving from either WT or genetically modified mice models, provide a relatively manageable setting to investigate the involvement of specific molecular pathways. Further detailed analysis in mice brain is then mandatory to validate the in vitro assays as representative for the in vivo situation. The present review aims to dissect the main technical approaches to investigate microglia-mediated phagocytosis of neuronal and synaptic substrates in critical developmental time windows.	[Morini, Raffaella; Bizzotto, Matteo; Perrucci, Fabio; Filipello, Fabia; Matteoli, Michela] IRCCS, Humanitas Clin & Res Ctr, Neuroctr, Lab Pharmacol & Brain Pathol, Rozzano, Italy; [Bizzotto, Matteo; Perrucci, Fabio; Filipello, Fabia] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy; [Filipello, Fabia] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; [Matteoli, Michela] CNR, Inst Neurosci, URT Humanitas, Rozzano, Italy	IRCCS Humanitas Research Hospital; Humanitas University; Washington University (WUSTL); Consiglio Nazionale delle Ricerche (CNR)	Filipello, F; Matteoli, M (corresponding author), IRCCS, Humanitas Clin & Res Ctr, Neuroctr, Lab Pharmacol & Brain Pathol, Rozzano, Italy.; Filipello, F (corresponding author), Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy.; Filipello, F (corresponding author), Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.; Matteoli, M (corresponding author), CNR, Inst Neurosci, URT Humanitas, Rozzano, Italy.	filipellof@wustl.edu; michela.matteoli@hunimed.eu	Filipello, Fabia/AAO-9663-2021; morini, raffaella/K-9370-2016; Matteoli, Michela/K-4526-2018	Perrucci, Fabio/0000-0001-6810-471X; Bizzotto, Matteo/0000-0003-1622-9371; morini, raffaella/0000-0002-4403-6932; Matteoli, Michela/0000-0002-3569-7843	PRIN (Ministero dell'Istruzione dell'Universita e della Ricerca) [2017A9MK4R]; MinSal FR 2016 (Ministero della Salute) [RF-201602361571]; CARIPLO grant [2018-0364]; Fondazione Umberto Veronesi	PRIN (Ministero dell'Istruzione dell'Universita e della Ricerca); MinSal FR 2016 (Ministero della Salute); CARIPLO grant(Fondazione Cariplo); Fondazione Umberto Veronesi(Fondazione Umberto Veronesi)	The work in our laboratory was supported by PRIN (Ministero dell'Istruzione dell'Universita e della Ricerca, #2017A9MK4R); MinSal FR 2016 (Ministero della Salute #RF-201602361571) and CARIPLO grant 2018 (#2018-0364) to FF. FP was supported by Fondazione Umberto Veronesi 2017 grant. Images created with BioRender.com.	Abud EM, 2017, NEURON, V94, P278, DOI 10.1016/j.neuron.2017.03.042; Ahmad F, 2020, BRAIN RES, V1746, DOI 10.1016/j.brainres.2020.147009; Allen NJ, 2018, SCIENCE, V362, P181, DOI 10.1126/science.aat0473; Allendorf DH, 2020, GLIA, V68, P989, DOI 10.1002/glia.23757; Alliot F, 1996, DEV BRAIN RES, V95, P140, DOI 10.1016/0165-3806(96)00101-0; Amit I, 2016, NAT IMMUNOL, V17, P18, DOI 10.1038/ni.3325; Attardo A, 2015, NATURE, V523, P592, DOI 10.1038/nature14467; Bandura DR, 2009, ANAL CHEM, V81, P6813, DOI 10.1021/ac901049w; BANGHAM AD, 1963, ADV LIPID RES, V1, P65; Barres Ben A, 2014, Cold Spring Harb Protoc, V2014, P1342, DOI 10.1101/pdb.ip073999; Beccari Sol, 2018, Curr Protoc Immunol, V122, pe49, DOI 10.1002/cpim.49; Becher B, 2014, NAT IMMUNOL, V15, P1181, DOI 10.1038/ni.3006; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Berg S, 2019, NAT METHODS, V16, P1226, DOI 10.1038/s41592-019-0582-9; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; Bisht K, 2016, GLIA, V64, P826, DOI 10.1002/glia.22966; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Bohlen CJ, 2019, ANNU REV GENET, V53, P263, DOI 10.1146/annurev-genet-112618-043515; Bohlen CJ, 2017, NEURON, V94, P759, DOI 10.1016/j.neuron.2017.04.043; Boza-Serrano A, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0156-0; Brioschi S, 2020, J IMMUNOL, V204, P294, DOI 10.4049/jimmunol.1900821; BURLESON GR, 1987, P SOC EXP BIOL MED, V184, P468; Butovsky O, 2015, ANN NEUROL, V77, P75, DOI 10.1002/ana.24304; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Cardona AE, 2006, NAT PROTOC, V1, P1947, DOI 10.1038/nprot.2006.327; Chung WS, 2013, NATURE, V504, P394, DOI 10.1038/nature12776; Chung WS., 2018, JOVE-J VIS EXP, V2018, P56647, DOI DOI 10.3791/56647; Cignarella F, 2020, ACTA NEUROPATHOL, V140, P513, DOI 10.1007/s00401-020-02193-z; Constantinescu CS, 2000, NEUROSCI LETT, V287, P171, DOI 10.1016/S0304-3940(00)01184-8; Crespo-Castrillo A, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-1719-6; CUADROS MA, 1993, J COMP NEUROL, V330, P113, DOI 10.1002/cne.903300110; Dailey Michael E, 2013, Cold Spring Harb Protoc, V2013, P1142, DOI 10.1101/pdb.prot079483; Damisah EC, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba3239; Das A, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0644-1; Das A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121117; De Groot CJA, 2000, BRAIN RES PROTOC, V5, P85, DOI 10.1016/S1385-299X(99)00059-8; De Haas AH, 2007, GLIA, V55, P1374, DOI 10.1002/glia.20554; Deczkowska A, 2018, CELL, V173, P1073, DOI 10.1016/j.cell.2018.05.003; Dejanovic B, 2018, NEURON, V100, P1322, DOI 10.1016/j.neuron.2018.10.014; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Desjardins M, 2003, CURR OPIN CELL BIOL, V15, P498, DOI 10.1016/S0955-0674(03)00083-8; Diaz-Aparicio I, 2020, J NEUROSCI, V40, P1453, DOI 10.1523/JNEUROSCI.0993-19.2019; Douvaras P, 2017, STEM CELL REP, V8, P1516, DOI 10.1016/j.stemcr.2017.04.023; DUNN PA, 1983, J IMMUNOL METHODS, V64, P71, DOI 10.1016/0022-1759(83)90385-X; Evans AK, 2020, NEUROBIOL DIS, V146, DOI 10.1016/j.nbd.2020.105089; Evans Gareth J O, 2015, Cold Spring Harb Protoc, V2015, P421, DOI 10.1101/pdb.top074450; FEINBERG I, 1983, J PSYCHIAT RES, V17, P319, DOI 10.1016/0022-3956(82)90038-3; Ferrari D, 1996, J IMMUNOL, V156, P1531; Filipello F, 2018, IMMUNITY, V48, P979, DOI 10.1016/j.immuni.2018.04.016; FORD AL, 1995, J IMMUNOL, V154, P4309; Fricker M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-196; Galatro TF, 2017, NAT NEUROSCI, V20, P1162, DOI 10.1038/nn.4597; Garcia Jenny A, 2014, Curr Protoc Immunol, V104, DOI 10.1002/0471142735.im1435s104; Gingras M, 2007, J NEUROSCI METH, V163, P111, DOI 10.1016/j.jneumeth.2007.02.024; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Goshi N, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01819-z; Gosselin D, 2017, SCIENCE, V356, DOI 10.1126/science.aal3222; Grabert K, 2018, METHODS MOL BIOL, V1784, P77, DOI 10.1007/978-1-4939-7837-3_7; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Gylys KH, 2004, NEUROCHEM INT, V44, P125, DOI 10.1016/S0197-0186(03)00146-3; Haenseler W, 2017, STEM CELL REP, V8, P1727, DOI 10.1016/j.stemcr.2017.05.017; Hambardzumyan D, 2016, NAT NEUROSCI, V19, P20, DOI 10.1038/nn.4185; Hammond TR, 2019, IMMUNITY, V50, P253, DOI 10.1016/j.immuni.2018.11.004; Han MH, 2012, J EXP MED, V209, P1325, DOI 10.1084/jem.20101974; Harms Ashley S, 2013, Methods Mol Biol, V1041, P33, DOI 10.1007/978-1-62703-520-0_5; Harry GJ, 2008, EXPERT OPIN DRUG MET, V4, P1265, DOI [10.1517/17425255.4.10.1265, 10.1517/17425255.4.10.1265 ]; Hashioka S, 2007, FREE RADICAL BIO MED, V42, P945, DOI 10.1016/j.freeradbiomed.2006.12.003; Hasselmann J, 2020, GLIA, V68, P721, DOI 10.1002/glia.23781; HAYES GM, 1988, J NEUROIMMUNOL, V19, P177, DOI 10.1016/0165-5728(88)90001-X; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; He YB, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1195-4; Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818; Henn A, 2009, ALTEX-ALTERN TIEREXP, V26, P83; Hickman SE, 2008, J NEUROSCI, V28, P8354, DOI 10.1523/JNEUROSCI.0616-08.2008; Holtman IR, 2017, J CLIN INVEST, V127, P3220, DOI 10.1172/JCI90604; Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373; Huang YD, 2012, CELL, V148, P1204, DOI 10.1016/j.cell.2012.02.040; Hughes MM, 2010, GLIA, V58, P2017, DOI 10.1002/glia.21070; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Ivannikov MV, 2013, J MOL NEUROSCI, V49, P223, DOI 10.1007/s12031-012-9848-8; Jahn A, 2007, LANGMUIR, V23, P6289, DOI 10.1021/la070051a; Janda E, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00144; Joseph Bertrand, 2013, Methods Mol Biol, V1041, P3, DOI 10.1007/978-1-62703-520-0_1; Kao AW, 2011, P NATL ACAD SCI USA, V108, P4441, DOI 10.1073/pnas.1100650108; Keaney J, 2019, J NEUROIMMUNE PHARM, V14, P448, DOI 10.1007/s11481-019-09839-0; Kierdorf K, 2013, NAT NEUROSCI, V16, P273, DOI 10.1038/nn.3318; Kim HJ, 2017, MOL PSYCHIATR, V22, P1576, DOI 10.1038/mp.2016.103; Kobayashi Y, 2017, ANTICANCER RES, V37, P3917, DOI 10.21873/anticanres.11774; Kopec KK, 1998, J NEUROCHEM, V71, P2123; KORN ED, 1967, J CELL BIOL, V34, P219, DOI 10.1083/jcb.34.1.219; Krasemann S, 2017, IMMUNITY, V47, P566, DOI 10.1016/j.immuni.2017.08.008; Lauro C, 2015, ANN NY ACAD SCI, V1351, P141, DOI 10.1111/nyas.12805; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lecca D, 2018, BRIT J PHARMACOL, V175, P3298, DOI 10.1111/bph.14214; Lee Jae-Kyung, 2013, Methods Mol Biol, V1041, P17, DOI 10.1007/978-1-62703-520-0_3; Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076; Lehrman EK, 2018, NEURON, V100, P120, DOI 10.1016/j.neuron.2018.09.017; Li Y, 2012, DEV CELL, V23, P1189, DOI 10.1016/j.devcel.2012.10.027; Lian Hong, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.1989; Lim JP, 2015, J CELL SCI, V128, P4407, DOI 10.1242/jcs.174359; Lim JP, 2011, IMMUNOL CELL BIOL, V89, P836, DOI 10.1038/icb.2011.20; Lin L, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0877-7; Lorsch JR, 2014, SCIENCE, V346, P1452, DOI 10.1126/science.1259110; Lui HS, 2016, CELL, V165, P921, DOI 10.1016/j.cell.2016.04.001; Madore C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19861-z; Manelli AM, 2007, NEUROBIOL AGING, V28, P1139, DOI 10.1016/j.neurobiolaging.2006.05.024; Martens LH, 2012, J CLIN INVEST, V122, P3955, DOI 10.1172/JCI63113; Masuda T, 2020, NAT IMMUNOL, V21, P1302, DOI 10.1038/s41590-020-0774-6; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; Mazaheri F, 2017, EMBO REP, V18, P1186, DOI 10.15252/embr.201743922; McLaughlin CN, 2019, DEV CELL, V48, P506, DOI 10.1016/j.devcel.2018.12.019; McQuin C, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005970; Miyamoto A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12540; Morsch M, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00321; Moussaud S, 2010, J NEUROSCI METH, V187, P243, DOI 10.1016/j.jneumeth.2010.01.017; Muffat J, 2016, NAT MED, V22, P1358, DOI 10.1038/nm.4189; Nagano T, 2010, BRAIN RES, V1323, P11, DOI 10.1016/j.brainres.2010.01.086; Neher JJ, 2011, J IMMUNOL, V186, P4973, DOI 10.4049/jimmunol.1003600; Neumann H, 2007, J NEUROIMMUNOL, V184, P92, DOI 10.1016/j.jneuroim.2006.11.032; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; Nikodemova M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-147; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nonaka S, 2019, NEUROSCI LETT, V707, DOI 10.1016/j.neulet.2019.134317; Olah M, 2012, GLIA, V60, P96, DOI 10.1002/glia.21251; Ornatsky O, 2010, J IMMUNOL METHODS, V361, P1, DOI 10.1016/j.jim.2010.07.002; Pan J, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01774-9; Pandya H, 2017, NAT NEUROSCI, V20, P753, DOI 10.1038/nn.4534; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Pawelec P, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102277; Pocock JM, 2018, NAT REV NEUROSCI, V19, P445, DOI 10.1038/s41583-018-0030-3; Proudfoot AEI, 2008, J NEUROIMMUNOL, V198, P27, DOI 10.1016/j.jneuroim.2008.04.007; Pul Refik, 2013, Methods Mol Biol, V1041, P121, DOI 10.1007/978-1-62703-520-0_14; Rangaraju S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00405; Reemst K, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00566; Rideau E, 2018, CHEM SOC REV, V47, DOI 10.1039/c8cs00162f; RIGHI M, 1989, EUR J IMMUNOL, V19, P1443, DOI 10.1002/eji.1830190815; ROERDINK F, 1983, BIOCHIM BIOPHYS ACTA, V734, P33, DOI 10.1016/0005-2736(83)90071-8; Roque Pamela J, 2017, Curr Protoc Toxicol, V74, DOI 10.1002/cptx.32; Ryu Keun-Young, 2012, Exp Neurobiol, V21, P151, DOI 10.5607/en.2012.21.4.151; Salter MW, 2017, NAT MED, V23, P1018, DOI 10.1038/nm.4397; Sarn N, 2021, MOL PSYCHIATR, V26, P1458, DOI 10.1038/s41380-020-0681-0; Saura J, 2003, GLIA, V44, P183, DOI 10.1002/glia.10274; SCHAFER D, 2015, COLD SPRING HARB PER, V7, P1; Schafer DP, 2014, JOVE-J VIS EXP, DOI 10.3791/51482; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Schulz C, 2012, SCIENCE, V336, P86, DOI 10.1126/science.1219179; Schulz D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38127-9; Scott-Hewitt N, 2020, EMBO J, V39, DOI 10.15252/embj.2020105380; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Sellgren CM, 2017, MOL PSYCHIATR, V22, P170, DOI 10.1038/mp.2016.220; Sellgren CM, 2019, NAT NEUROSCI, V22, P374, DOI 10.1038/s41593-018-0334-7; SHATZ CJ, 1983, J NEUROSCI, V3, P482; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Sierra A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00006; Sipe GO, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10905; Smith AM, 2014, TRENDS NEUROSCI, V37, P125, DOI 10.1016/j.tins.2013.12.001; Sousa C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00198; SRETAVAN D, 1984, NATURE, V308, P845, DOI 10.1038/308845a0; Stansley B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-115; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611; Takata K, 2017, IMMUNITY, V47, P183, DOI 10.1016/j.immuni.2017.06.017; Takayama F, 2013, J NEUROIMMUNOL, V262, P121, DOI 10.1016/j.jneuroim.2013.06.011; Takenouchi T, 2005, BBA-GEN SUBJECTS, V1726, P177, DOI 10.1016/j.bbagen.2005.08.001; Tanzi RE, 2013, J ALZHEIMERS DIS, V33, pS5, DOI 10.3233/JAD-2012-129044; Tao XR, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00730; Tejera D, 2019, METHODS MOL BIOL, V2034, P287, DOI 10.1007/978-1-4939-9658-2_21; Timmerman R, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00242; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; Tsatas O, 2020, J IMMUNOL METHODS, V477, DOI 10.1016/j.jim.2019.112678; Ueda HR, 2020, NAT REV NEUROSCI, V21, P61, DOI 10.1038/s41583-019-0250-1; Ulland TK, 2018, NAT REV NEUROL, V14, P667, DOI 10.1038/s41582-018-0072-1; Ulrich JD, 2017, NEURON, V94, P237, DOI 10.1016/j.neuron.2017.02.042; URBANEJA MA, 1988, EUR J BIOCHEM, V173, P585, DOI 10.1111/j.1432-1033.1988.tb14039.x; Villani A, 2019, DEV CELL, V49, P77, DOI 10.1016/j.devcel.2019.02.014; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Walker WS, 1995, J NEUROIMMUNOL, V63, P163, DOI 10.1016/0165-5728(95)00146-8; Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049; Weinhard L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03566-5; Witkowska A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27456-4; Witkowska A, 2017, BIOPHYS J, V113, P1251, DOI 10.1016/j.bpj.2017.03.010; Witting A, 2000, J NEUROCHEM, V75, P1060, DOI 10.1046/j.1471-4159.2000.0751060.x; Wu Z, 2011, ARCH IMMUNOL THER EX, V59, P195, DOI 10.1007/s00005-011-0123-4; Yin YT, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0993-4; Yip PK, 2009, J NEUROSCI METH, V183, P223, DOI 10.1016/j.jneumeth.2009.07.002; Zabel MK, 2016, GLIA, V64, P1479, DOI 10.1002/glia.23016; Zhao Xiurong, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.1795; Zhao XR, 2015, J NEUROSCI, V35, P11281, DOI 10.1523/JNEUROSCI.1685-15.2015	192	1	1	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2021	12								640937	10.3389/fimmu.2021.640937	http://dx.doi.org/10.3389/fimmu.2021.640937			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT0KV	33708226	Green Published, gold			2022-12-18	WOS:000626282600001
J	Wang, F				Wang, Fei			Sending Out Alarms: A Perspective on Intercellular Communications in Insect Antiviral Immune Response	FRONTIERS IN IMMUNOLOGY			English	Review						insect; antiviral immunity; cytokine; Dicer-2; intercellular transfer	DROSOPHILA; CELLS; VIRUSES	Viral infection triggers insect immune response, including RNA interference, apoptosis and autophagy, and profoundly changes the gene expression profiles in infected cells. Although intracellular degradation is crucial for restricting viral infection, intercellular communication is required to mount a robust systemic immune response. This review focuses on recent advances in understanding the intercellular communications in insect antiviral immunity, including protein-based and virus-derived RNA based cell-cell communications, with emphasis on the signaling pathway that induces the production of the potential cytokines. The prospects and challenges of future work are also discussed.	[Wang, Fei] Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing, Peoples R China; [Wang, Fei] Southwest Univ, Biol Sci Res Ctr, Chongqing, Peoples R China	Southwest University - China; Southwest University - China	Wang, F (corresponding author), Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing, Peoples R China.; Wang, F (corresponding author), Southwest Univ, Biol Sci Res Ctr, Chongqing, Peoples R China.	massmoca@swu.edu.cn			National Natural Science Foundation of China [31672495]; Natural Science Foundation of Chongqing, China [cstc2020jcyj-msxmX0193]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Chongqing, China(Natural Science Foundation of Chongqing)	This work is supported by grant of "National Natural Science Foundation of China" (No. 31672495) and Natural Science Foundation of Chongqing, China (cstc2020jcyj-msxmX0193).	Abdul-Cader MS, 2016, ARCH VIROL, V161, P2075, DOI 10.1007/s00705-016-2904-x; Ahlers LRH, 2019, CELL REP, V29, P1946, DOI 10.1016/j.celrep.2019.10.029; Asgari S, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00048; Avadhanula V, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000582; Bao YY, 2009, GENOMICS, V94, P138, DOI 10.1016/j.ygeno.2009.04.003; Baroja-Mazo A, 2014, NAT IMMUNOL, V15, P738, DOI 10.1038/ni.2919; Chen HW, 2002, GENE DEV, V16, P388, DOI 10.1101/gad.955202; Coste F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033416; Deddouche S, 2008, NAT IMMUNOL, V9, P1425, DOI 10.1038/ni.1664; Delorme-Axford E, 2019, AUTOPHAGY, V15, P1, DOI 10.1080/15548627.2018.1539585; Dostert C, 2005, NAT IMMUNOL, V6, P946, DOI 10.1038/ni1237; Eleftherianos I, 2014, INFECT IMMUN, V82, P4169, DOI 10.1128/IAI.02318-14; Foley E, 2003, GENE DEV, V17, P115, DOI 10.1101/gad.1018503; Goto A, 2018, IMMUNITY, V49, P225, DOI 10.1016/j.immuni.2018.07.013; Herrera-Ortiz A, 2011, DEV COMP IMMUNOL, V35, P44, DOI 10.1016/j.dci.2010.08.004; Hua XT, 2021, DEV COMP IMMUNOL, V115, DOI 10.1016/j.dci.2020.103862; Hua XT, 2018, J BIOL CHEM, V293, P11878, DOI 10.1074/jbc.RA117.000194; Huang ZJ, 2013, J VIROL, V87, P4272, DOI 10.1128/JVI.03360-12; Hussain M, 2014, J INSECT PHYSIOL, V70, P151, DOI 10.1016/j.jinsphys.2014.08.003; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Ishii K, 2010, J BIOL CHEM, V285, P28635, DOI 10.1074/jbc.M110.138446; Jiang L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.628151; Jiang L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00776; Kalamvoki M, 2014, P NATL ACAD SCI USA, V111, pE4991, DOI 10.1073/pnas.1419338111; Kanthong N, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-290; Karlikow M, 2016, SCI REP-UK, V6, DOI 10.1038/srep27085; Kemp C, 2013, J IMMUNOL, V190, P650, DOI 10.4049/jimmunol.1102486; Kemp C, 2009, CURR OPIN IMMUNOL, V21, P3, DOI 10.1016/j.coi.2009.01.007; Lamiable O, 2016, J VIROL, V90, P5415, DOI 10.1128/JVI.00238-16; Lamiable O, 2016, P NATL ACAD SCI USA, V113, P698, DOI 10.1073/pnas.1516122113; Lamiable O, 2014, CURR OPIN MICROBIOL, V20, P62, DOI 10.1016/j.mib.2014.05.006; Liu B, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003137; Liu SQ, 2015, SCIENCE, V347, P1217, DOI 10.1126/science.aaa2630; Liu Y, 2019, AUTOPHAGY, V15, P174, DOI 10.1080/15548627.2018.1528813; Liu Y, 2018, CELL HOST MICROBE, V24, P57, DOI 10.1016/j.chom.2018.05.022; Luplertlop N, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001252; Majoros A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00029; Makino S, 2018, DEV COMP IMMUNOL, V84, P133, DOI 10.1016/j.dci.2018.02.009; Malagoli D, 2008, CYTOKINE, V44, P269, DOI 10.1016/j.cyto.2008.08.011; Martin M, 2018, CELL REP, V23, P3537, DOI 10.1016/j.celrep.2018.05.029; Merkling SH, 2013, J INSECT PHYSIOL, V59, P159, DOI 10.1016/j.jinsphys.2012.07.004; Mlih M, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005796; Morris R, 2018, PROTEIN SCI, V27, P1984, DOI 10.1002/pro.3519; Moy RH, 2014, IMMUNITY, V40, P51, DOI 10.1016/j.immuni.2013.10.020; Mussabekova A, 2017, CELL MOL LIFE SCI, V74, P2039, DOI 10.1007/s00018-017-2453-9; Nainu F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01220; Nainu F, 2015, J IMMUNOL, V195, P5696, DOI 10.4049/jimmunol.1500613; Nakamoto M, 2012, IMMUNITY, V36, P658, DOI 10.1016/j.immuni.2012.03.003; Nappi AJ, 2000, NITRIC OXIDE-BIOL CH, V4, P423, DOI 10.1006/niox.2000.0294; Niu JZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep34200; Paradkar PN, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002823; Paradkar PN, 2012, P NATL ACAD SCI USA, V109, P18915, DOI 10.1073/pnas.1205231109; Paro S, 2015, CURR OPIN IMMUNOL, V32, P106, DOI 10.1016/j.coi.2015.01.009; Patel SJ, 2009, P NATL ACAD SCI USA, V106, P12867, DOI 10.1073/pnas.0809292106; Petit M, 2016, P NATL ACAD SCI USA, V113, pE4218, DOI 10.1073/pnas.1607952113; Poirier EZ, 2018, CELL HOST MICROBE, V23, P353, DOI 10.1016/j.chom.2018.02.001; Ran Y, 2014, CYTOKINE GROWTH F R, V25, P631, DOI 10.1016/j.cytogfr.2014.05.003; Rosas-Diaz T, 2018, P NATL ACAD SCI USA, V115, P1388, DOI 10.1073/pnas.1715556115; Saleh MC, 2009, NATURE, V458, P346, DOI 10.1038/nature07712; Schneider DS, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030041; Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231; Schoggins JW, 2011, CURR OPIN VIROL, V1, P519, DOI 10.1016/j.coviro.2011.10.008; Settles EW, 2008, J VIROL, V82, P1378, DOI 10.1128/JVI.01941-07; Shelly S, 2009, IMMUNITY, V30, P588, DOI 10.1016/j.immuni.2009.02.009; Srinivasan N, 2016, ELIFE, V5, DOI 10.7554/eLife.19662; Takhampunya R, 2006, J GEN VIROL, V87, P3003, DOI 10.1099/vir.0.81880-0; Tassetto M, 2019, ELIFE, V8, DOI 10.7554/eLife.41244; Tassetto M, 2017, CELL, V169, P314, DOI 10.1016/j.cell.2017.03.033; Trammell CE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02973; Tsuzuki S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5628; Varjak M, 2018, J GEN VIROL, V99, P1551, DOI 10.1099/jgv.0.001157; Wang Fei, 2018, Scientia Agricultura Sinica, V51, P789; Wu JX, 2014, ANNU REV IMMUNOL, V32, P461, DOI 10.1146/annurev-immunol-032713-120156; Wu QF, 2010, P NATL ACAD SCI USA, V107, P1606, DOI 10.1073/pnas.0911353107; Xi ZY, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000098; Xu J, 2014, DEV COMP IMMUNOL, V42, P67, DOI 10.1016/j.dci.2013.05.002; Xu J, 2012, CELL HOST MICROBE, V12, P531, DOI 10.1016/j.chom.2012.08.011; Yan N, 2012, NAT IMMUNOL, V13, P214, DOI 10.1038/ni.2229; Zaghloul HAH, 2017, J VIROL, V91, DOI [10.1128/JVI.00874-17, 10.1128/jvi.00874-17]; Zeidler Martin P, 2013, JAKSTAT, V2, pe25353, DOI 10.4161/jkst.25353	80	1	1	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2021	12								613729	10.3389/fimmu.2021.613729	http://dx.doi.org/10.3389/fimmu.2021.613729			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT2ZS	33708207	gold, Green Published			2022-12-18	WOS:000626460500001
J	Carneiro, VL; da Silva, HBF; Queiroz, GD; Veiga, RV; Oliveira, PRS; Carneiro, NVQ; Pires, AD; da Silva, RR; Sena, F; Belitardo, E; Nascimento, R; Silva, M; Marques, CR; Costa, RD; Alcantra-Neves, NM; Barreto, ML; Cooper, PJ; Figueiredo, CA				Carneiro, Valdirene Leao; da Silva, Hugo Bernardino Ferreira; Queiroz, Gerson de Almeida; Veiga, Rafael Valente; Oliveira, Pablo Rafael Silveira; Carneiro, Norma Vilany Queiroz; Pires, Anaque de Oliveira; da Silva, Raimon Rios; Sena, Flavia; Belitardo, Emilia; Nascimento, Regina; Silva, Milca; Marques, Cintia Rodrigues; Costa, Ryan dos Santos; Alcantra-Neves, Neuza Maria; Barreto, Mauricio L.; Cooper, Philip J.; Figueiredo, Camila Alexandrina			WSB1 and IL21R Genetic Variants Are Involved in Th2 Immune Responses to Ascaris lumbricoides	FRONTIERS IN IMMUNOLOGY			English	Article						Ascaris lumbricoides; immunity; polymorphism; WSB1; IL21R		Genetic and epigenetic factors are considered to be critical for host-parasite interactions. There are limited data on the role of such factors during human infections with Ascaris lumbricoides. Here, we describe the potential role of genetic factors as determinants of the Th2 immune response to A. lumbricoides in Brazilian children. Stool samples were collected from the children to detect A. lumbricoides by microscopy and peripheral blood leukocytes (PBLs) were cultured in whole blood cultures for detection of cytokines (IL-5, IL-10, and IL-13) in vitro. Levels of anti-A. lumbricoides IgE and IgG4 were measured in plasma. DNA was extracted from PBLs and genotyped using Illumina 2.5 Human Omni Beadchip. Candidate genes associated with A. lumbricoides responses were identified and SNVs in these selected genes associated with the Th2 immune response to A. lumbricoides. Haplotype, gene expression, and epigenetic analyses were done to identify potential associations with Th2 immune responses. GWAS on samples from 1,189 children identified WSB1 as a candidate gene, and IL-21R was selected as a biologically relevant linked gene for further analysis. Variants in WSB1 and IL21R were associated with markers of Th2 immune responses: increased A. lumbricoides-specific IgE and IL-5/IL-13 by PBLs from infected compared to uninfected individuals. In infected children, WSB1 but not IL21R gene expression was suppressed and increased methylation was observed in the WSB1 promoter region. This is the first study to show an association between genetic variants in WSB1 and IL21R and Th2 immune responses during A. lumbricoides infections in children. WSB1/IL21R pathways could provide a potential target for the treatment of Th2-mediated diseases.	[Carneiro, Valdirene Leao] Univ Estado Bahia, Dept Life Sci, Salvador, BA, Brazil; [da Silva, Hugo Bernardino Ferreira; Queiroz, Gerson de Almeida; Carneiro, Norma Vilany Queiroz; Pires, Anaque de Oliveira; da Silva, Raimon Rios; Sena, Flavia; Belitardo, Emilia; Nascimento, Regina; Silva, Milca; Costa, Ryan dos Santos; Alcantra-Neves, Neuza Maria; Figueiredo, Camila Alexandrina] Univ Fed Bahia, Inst Hlth Sci, Salvador, BA, Brazil; [Veiga, Rafael Valente; Oliveira, Pablo Rafael Silveira; Barreto, Mauricio L.] Fiocruz MS, Ctr Data & Knowledge Integrat Hlth, Salvador, BA, Brazil; [Oliveira, Pablo Rafael Silveira] Univ Fed Bahia, Inst Biol Sci, Salvador, BA, Brazil; [Marques, Cintia Rodrigues] Univ Fed Bahia, Multidisciplinary Hlth Inst, Salvador, BA, Brazil; [Barreto, Mauricio L.] Univ Fed Bahia, Inst Collect Hlth, Salvador, BA, Brazil; [Cooper, Philip J.] Int Univ Ecuador, Sch Med, Quito, Ecuador; [Cooper, Philip J.] St Georges Univ London, London, England	Universidade do Estado Bahia; Universidade Federal da Bahia; Fundacao Oswaldo Cruz; Universidade Federal da Bahia; Universidade Federal da Bahia; Universidade Federal da Bahia; St Georges University London	Figueiredo, CA (corresponding author), Univ Fed Bahia, Inst Hlth Sci, Salvador, BA, Brazil.	cavfigueiredo@gmail.com	Costa, Ryan S/G-4294-2016; Costa, Ryan/AAV-8643-2021; Figueiredo, Camila Alexandrina/H-3525-2015	Costa, Ryan S/0000-0003-3075-0729; Figueiredo, Camila Alexandrina/0000-0003-1356-6188	SCAALA (Social change, Asthma and Allergy in Latin America) initiative - Wellcome Trust [072405/Z/03/Z]; Brazilian Ministry of Health (Department of Science and Technology from the Secretaria de Ciencia, Tecnologia e Insumos Estrategicos) through Financiadora de Estudos e Projetos; Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)/CNPq [PRONEX-PNX00001/2014, PRONEMPNE0003/2014]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)	SCAALA (Social change, Asthma and Allergy in Latin America) initiative - Wellcome Trust; Brazilian Ministry of Health (Department of Science and Technology from the Secretaria de Ciencia, Tecnologia e Insumos Estrategicos) through Financiadora de Estudos e Projetos; Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)/CNPq; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This study was conducted through the SCAALA (Social change, Asthma and Allergy in Latin America) initiative, funded by the Wellcome Trust, Grant No. 072405/Z/03/Z. It was also supported by the Brazilian Ministry of Health (Department of Science and Technology from the Secretaria de Ciencia, Tecnologia e Insumos Estrategicos) through Financiadora de Estudos e Projetos, Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)/CNPq Grant Nos. PRONEX-PNX00001/2014 and PRONEMPNE0003/2014 and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) for the doctoral fellowship granted.	Acevedo N, 2009, CLIN EXP IMMUNOL, V157, P282, DOI 10.1111/j.1365-2249.2009.03948.x; Acevedo N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167453; Archange C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002475; Avery DT, 2008, BLOOD, V112, P1784, DOI 10.1182/blood-2008-02-142745; Barreto Mauricio L, 2006, BMC Pulm Med, V6, P15, DOI 10.1186/1471-2466-6-15; Barreto ML, 2007, LANCET, V370, P1622, DOI 10.1016/S0140-6736(07)61638-9; Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4; Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112; Buecker C, 2012, TRENDS GENET, V28, P276, DOI 10.1016/j.tig.2012.02.008; Chauhan A, 2015, ASN NEURO, V7, DOI 10.1177/1759091415592126; Coakley G, 2020, PARASITE IMMUNOL, V42, DOI 10.1111/pim.12728; Cooper PJ, 2008, ALLERGY, V63, P409, DOI 10.1111/j.1398-9995.2007.01601.x; Coquet JM, 2015, IMMUNITY, V43, P318, DOI 10.1016/j.immuni.2015.07.015; Costa GNO, 2015, BMC GENET, V16, DOI 10.1186/s12863-015-0296-7; Doerge RW, 1996, GENETICS, V142, P285; Dold C, 2011, MICROBES INFECT, V13, P632, DOI 10.1016/j.micinf.2010.09.012; DOSSANTOSCARVALHO O, 1994, MEM I OSWALDO CRUZ, V89, P509, DOI 10.1590/S0074-02761994000400003; Ekpenyong EA., 2008, ANIM RES INT, V5, P804, DOI [10.4314/ari.v5i1.48715, DOI 10.4314/ARI.V5I1.48715]; Figueiredo CA, 2013, J ALLERGY CLIN IMMUN, V131, P1064, DOI 10.1016/j.jaci.2013.01.016; Figueiredo CA, 2010, INFECT IMMUN, V78, P3160, DOI 10.1128/IAI.01228-09; Figueiredo CA, 2009, ENVIRON HEALTH PERSP, V117, P845, DOI 10.1289/ehp.0800366; Hagel Isabel, 2006, Invest. clín, V47, P241; Haque M, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0270-3; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Hoffman WA., 1934, SEDIMENTATION CONCEN; Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142; King EM, 2005, PARASITE IMMUNOL, V27, P89, DOI 10.1111/j.1365-3024.2005.00753.x; Korpanty GJ, 2017, ONCOTARGET, V8, P28093, DOI 10.18632/oncotarget.15890; Kuchen S, 2007, J IMMUNOL, V179, P5886, DOI 10.4049/jimmunol.179.9.5886; Laurie CC, 2010, GENET EPIDEMIOL, V34, P591, DOI 10.1002/gepi.20516; Mangano VD, 2014, CLIN MICROBIOL INFEC, V20, P1265, DOI 10.1111/1469-0691.12793; Masure D, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002138; Mehta DS, 2004, IMMUNOL REV, V202, P84, DOI 10.1111/j.0105-2896.2004.00201.x; Moller M, 2007, HUM MOL GENET, V16, P1828, DOI 10.1093/hmg/ddm131; Nara H, 2011, CELL IMMUNOL, V269, P54, DOI 10.1016/j.cellimm.2011.03.010; Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665; Orlandi C, 2012, J CELL BIOL, V197, P711, DOI 10.1083/jcb.201202123; Orlando C, 1998, CLIN CHEM LAB MED, V36, P255, DOI 10.1515/CCLM.1998.045; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Pasic I, 2018, MOL CARCINOGEN, V57, P106, DOI 10.1002/mc.22736; Patel N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057843; Peisong G, 2005, GENES IMMUN, V6, P70, DOI 10.1038/sj.gene.6364148; Pene J, 2006, J IMMUNOL, V177, P5006, DOI 10.4049/jimmunol.177.8.5006; Potaczek DP, 2012, CLIN EXP ALLERGY, V42, P852, DOI 10.1111/j.1365-2222.2011.03953.x; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Pullan RL, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-37; Quinnell RJ, 2003, INT J PARASITOL, V33, P1219, DOI 10.1016/S0020-7519(03)00175-9; Rios R, 2017, J ETHNOPHARMACOL, V209, P32, DOI 10.1016/j.jep.2017.07.014; Rodrigues LC, 2008, CLIN EXP ALLERGY, V38, P1769, DOI 10.1111/j.1365-2222.2008.03027.x; Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268; Sutton LP, 2018, ELIFE, V7, DOI 10.7554/eLife.33273; Thornton T, 2012, AM J HUM GENET, V91, P122, DOI 10.1016/j.ajhg.2012.05.024; Turner JD, 2005, MICROBES INFECT, V7, P990, DOI 10.1016/j.micinf.2005.03.036; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang YY, 2016, SCI REP-UK, V6, DOI 10.1038/srep31881; Williams-Blangero S, 2002, P NATL ACAD SCI USA, V99, P5533, DOI 10.1073/pnas.082115999; Zakzuk J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00756; Zamanian M, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006368	58	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2021	12								622051	10.3389/fimmu.2021.622051	http://dx.doi.org/10.3389/fimmu.2021.622051			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QS5WP	33692795	Green Accepted, gold, Green Published			2022-12-18	WOS:000625970600001
J	Pestka, JJ; Pollard, KM; Rosenspire, AJ				Pestka, James J.; Pollard, K. Michael; Rosenspire, Allen J.			The Role of the Environment in Autoimmunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						environment; trigger; toxicant; autoimmunity; inflammation; autoantibody; lupus (SLE); tolerance			[Pestka, James J.] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; [Pestka, James J.] Michigan State Univ, Inst Integrat Toxicol, E Lansing, MI 48824 USA; [Pollard, K. Michael] Scripps Res, Dept Mol Med, La Jolla, CA 92037 USA; [Rosenspire, Allen J.] Wayne State Univ, Dept Biochem Microbiol & Immunol, Detroit, MI 48202 USA	Michigan State University; Michigan State University; Scripps Research Institute; Wayne State University	Pestka, JJ (corresponding author), Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.; Pestka, JJ (corresponding author), Michigan State Univ, Inst Integrat Toxicol, E Lansing, MI 48824 USA.; Pollard, KM (corresponding author), Scripps Res, Dept Mol Med, La Jolla, CA 92037 USA.; Rosenspire, AJ (corresponding author), Wayne State Univ, Dept Biochem Microbiol & Immunol, Detroit, MI 48202 USA.	pestka@msu.edu; mpollard@scripps.edu; arosenspire@wayne.edu			NIH [ES027353, ES029581, ES029484]; USDA NIFA [1020129]; Dr. Robert and Carol Deibel Family Endowment	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); USDA NIFA(United States Department of Agriculture (USDA)); Dr. Robert and Carol Deibel Family Endowment	This research was funded in part by NIH ES027353 (JP), ES029581 (KP), NIH ES029484 (AR), USDA NIFA Hatch Project 1020129 (JP), and the Dr. Robert and Carol Deibel Family Endowment (JP).	Scott DW, 2020, NAT IMMUNOL, V21, P1306, DOI 10.1038/s41590-020-0790-6; Watts G, 2020, LANCET, V396, P880	2	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2021	12								641171	10.3389/fimmu.2021.641171	http://dx.doi.org/10.3389/fimmu.2021.641171			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QS6IU	33692809	Green Published, gold			2022-12-18	WOS:000626002300001
J	Wang, YN; Liu, SY; Jia, TT; Feng, Y; Zhang, WJ; Xu, X; Zhang, DJ				Wang, Ya-nan; Liu, Shiyue; Jia, Tingting; Feng, Yao; Zhang, Wenjing; Xu, Xin; Zhang, Dongjiao			T Cell Protein Tyrosine Phosphatase in Osteoimmunology	FRONTIERS IN IMMUNOLOGY			English	Review						T cell protein tyrosine phosphatase (TCPTP); Protein tyrosine phosphatase non-receptor 2 (PTPN2); osteoimmunology; macrophages; T cell; B cell	INTESTINAL EPITHELIAL-CELLS; PTPN2; PROMOTES; OSTEOCLASTS	Osteoimmunology highlights the two-way communication between bone and immune cells. T cell protein tyrosine phosphatase (TCPTP), also known as protein-tyrosine phosphatase non-receptor 2 (PTPN2), is an intracellular protein tyrosine phosphatase (PTP) essential in regulating immune responses and bone metabolism via dephosphorylating target proteins. Tcptp knockout in systemic or specific immune cells can seriously damage the immune function, resulting in bone metabolism disorders. This review provided fresh insights into the potential role of TCPTP in osteoimmunology. Overall, the regulation of osteoimmunology by TCPTP is extremely complicated. TCPTP negatively regulates macrophages activation and inflammatory factors secretion to inhibit bone resorption. TCPTP regulates T lymphocytes differentiation and T lymphocytes-related cytokines signaling to maintain bone homeostasis. TCPTP is also expected to regulate bone metabolism by targeting B lymphocytes under certain time and conditions. This review offers a comprehensive update on the roles of TCPTP in osteoimmunology, which can be a promising target for the prevention and treatment of inflammatory bone loss.	[Wang, Ya-nan; Jia, Tingting; Feng, Yao; Zhang, Wenjing; Xu, Xin; Zhang, Dongjiao] Shandong Univ, Cheeloo Coll Med, Sch & Hosp Stomatol, Dept Implantol, Jinan, Peoples R China; [Wang, Ya-nan; Liu, Shiyue; Jia, Tingting; Feng, Yao; Zhang, Wenjing; Xu, Xin; Zhang, Dongjiao] Shandong Key Lab Oral Tissue Regenerat, Jinan, Peoples R China; [Wang, Ya-nan; Liu, Shiyue; Jia, Tingting; Feng, Yao; Zhang, Wenjing; Xu, Xin; Zhang, Dongjiao] Shandong Engn Lab Dent Mat & Oral Tissue Regenera, Jinan, Peoples R China; [Liu, Shiyue] Shandong Univ, Dept Periodontol, Sch & Hosp Stomatol, Cheeloo Coll Med, Jinan, Peoples R China	Shandong University; Shandong University	Zhang, DJ (corresponding author), Shandong Univ, Cheeloo Coll Med, Sch & Hosp Stomatol, Dept Implantol, Jinan, Peoples R China.; Zhang, DJ (corresponding author), Shandong Key Lab Oral Tissue Regenerat, Jinan, Peoples R China.; Zhang, DJ (corresponding author), Shandong Engn Lab Dent Mat & Oral Tissue Regenera, Jinan, Peoples R China.	djzhang1109@163.com			National Natural Science Foundation of China [82071148, 82001055]; Construction Engineering Special Fund of Taishan Scholars [TS201511106]; Key Project of Chinese National Programs for Research and Development [2016YFC1102705]; Shandong Provincial Natural Science Foundation [ZR2020QH158]; Fundamental Research Funds of Shandong University [2018GN024]; China Postdoctoral Science Foundation [2019M662371]; Youth scientific research funds of School of Stomatology, Shandong University [2019QNJJ03]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Construction Engineering Special Fund of Taishan Scholars; Key Project of Chinese National Programs for Research and Development; Shandong Provincial Natural Science Foundation(Natural Science Foundation of Shandong Province); Fundamental Research Funds of Shandong University; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Youth scientific research funds of School of Stomatology, Shandong University	This work was supported by the National Natural Science Foundation of China (no. 82071148; no. 82001055), the Construction Engineering Special Fund of Taishan Scholars (TS201511106), the Key Project of Chinese National Programs for Research and Development (2016YFC1102705), the Shandong Provincial Natural Science Foundation (ZR2020QH158), the Fundamental Research Funds of Shandong University (2018GN024), the China Postdoctoral Science Foundation (2019M662371), and the Youth scientific research funds of School of Stomatology, Shandong University (2019QNJJ03).	Aqel SI, 2019, CLIN EXP IMMUNOL, V196, P215, DOI 10.1111/cei.13258; Aradi B, 2015, ARTHRITIS RHEUMATOL, V67, P2624, DOI 10.1002/art.39256; Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196; Asada N, 2013, CELL STEM CELL, V12, P737, DOI 10.1016/j.stem.2013.05.001; Azab E, 2020, FASEB J, V34, P10191, DOI 10.1096/fj.202000366R; Bourdeau A, 2007, BLOOD, V109, P4220, DOI 10.1182/blood-2006-08-044370; Bourdeau A, 2013, STEM CELLS, V31, P293, DOI 10.1002/stem.1276; Bussieres-Marmen S, 2014, METHODS, V65, P239, DOI 10.1016/j.ymeth.2013.08.020; Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100; Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584-018-0109-2; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; Dey I, 2017, MICROB PATHOGENESIS, V113, P248, DOI 10.1016/j.micpath.2017.10.033; Dhodapkar KM, 2008, BLOOD, V112, P2878, DOI 10.1182/blood-2008-03-143222; Dodd GT, 2018, DIABETES, V67, P1246, DOI 10.2337/db17-1485; Doody KM, 2012, ARTHRITIS RHEUM-US, V64, P752, DOI 10.1002/art.33399; Doody KM, 2009, IMMUNOL REV, V228, P325, DOI 10.1111/j.1600-065X.2008.00743.x; Dzierzak E, 2018, CELL STEM CELL, V22, P639, DOI 10.1016/j.stem.2018.04.015; Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003; Flosbach M, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107957; Fujiwara Y, 2016, J BIOL CHEM, V291, P24838, DOI 10.1074/jbc.M116.742452; Fukushima A, 2010, DIABETES, V59, P1906, DOI 10.2337/db09-1365; Galic S, 2003, MOL CELL BIOL, V23, P2096, DOI 10.1128/MCB.23.6.2096-2108.2003; Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074; Gruber R, 2019, J CLIN PERIODONTOL, V46, P52, DOI 10.1111/jcpe.13056; Gurzov EN, 2014, CELL METAB, V20, P85, DOI 10.1016/j.cmet.2014.05.011; He D, 2015, J DENT RES, V94, P129, DOI 10.1177/0022034514553817; Heinonen KM, 2004, BLOOD, V103, P3457, DOI 10.1182/blood-2003-09-3153; Heinonen KM, 2009, P NATL ACAD SCI USA, V106, P9368, DOI 10.1073/pnas.0812109106; Hsieh WC, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.141868; Ibanez L, 2016, J BONE MINER RES, V31, P1899, DOI 10.1002/jbmr.2868; Kiesel JR, 2009, J IMMUNOL, V182, P5477, DOI 10.4049/jimmunol.0803897; Killock David, 2011, Nat Rev Rheumatol, V7, P683, DOI 10.1038/nrrheum.2011.167; Kim JW, 2012, BMB REP, V45, P281, DOI 10.5483/BMBRep.2012.45.5.281; Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Kramer F, 2020, HAEMATOLOGICA, V105, P2083, DOI 10.3324/haematol.2019.226332; Krishnan M, 2017, ANN NY ACAD SCI, V1405, P116, DOI 10.1111/nyas.13439; Kuroyanagi G, 2018, BONE, V116, P221, DOI 10.1016/j.bone.2018.08.011; LaFleur MW, 2019, NAT IMMUNOL, V20, P1335, DOI 10.1038/s41590-019-0480-4; Lazzaro L, 2018, BONE, V112, P120, DOI 10.1016/j.bone.2018.04.015; Lees CW, 2011, GUT, V60, P1739, DOI 10.1136/gut.2009.199679; Li JY, 2019, J BONE MINER RES, V34, P349, DOI 10.1002/jbmr.3600; Li Y, 2018, CELL PHYSIOL BIOCHEM, V46, P118, DOI 10.1159/000488415; Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood-2006-07-037994; Loh K, 2011, CELL METAB, V14, P684, DOI 10.1016/j.cmet.2011.09.011; Luo CY, 2011, CELL MOL IMMUNOL, V8, P50, DOI 10.1038/cmi.2010.54; Madel MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01408; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Marahleh A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02925; Marcil V, 2013, INFLAMM BOWEL DIS, V19, P1149, DOI 10.1097/MIB.0b013e318280b181; Mattila E, 2008, J CELL SCI, V121, P3570, DOI 10.1242/jcs.031898; Mercier FE, 2012, NAT REV IMMUNOL, V12, P49, DOI 10.1038/nri3132; Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449; Miyamoto K, 2011, J EXP MED, V208, P2175, DOI 10.1084/jem.20101890; Nakamura Y, 2010, BLOOD, V116, P1422, DOI 10.1182/blood-2009-08-239194; Niechcial A, 2020, INFLAMM BOWEL DIS, V26, P1038, DOI 10.1093/ibd/izaa013; Onal M, 2012, J BIOL CHEM, V287, P29851, DOI 10.1074/jbc.M112.377945; Orsolini G, 2020, CLIN RHEUMATOL, V39, P727, DOI 10.1007/s10067-020-04930-x; Palmqvist P, 2006, J BIOL CHEM, V281, P2414, DOI 10.1074/jbc.M510160200; Parlato M, 2020, GASTROENTEROLOGY, V159, P1968, DOI 10.1053/j.gastro.2020.07.040; Persson C, 2004, MOL CELL BIOL, V24, P2190, DOI 10.1128/MCB.24.5.2190-2201.2004; Pike KA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02504; Rhee I, 2012, NAT IMMUNOL, V13, P439, DOI 10.1038/ni.2246; Rivollier A, 2004, BLOOD, V104, P4029, DOI 10.1182/blood-2004-01-0041; Samuel RO, 2019, J ENDODONT, V45, P1009, DOI 10.1016/j.joen.2019.05.003; Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775; Sayoc-Becerra A, 2020, INFLAMM BOWEL DIS, V26, P407, DOI 10.1093/ibd/izz266; Scharl M, 2011, GUT, V60, P189, DOI 10.1136/gut.2010.216606; Scharl M, 2010, INFLAMM BOWEL DIS, V16, P2055, DOI 10.1002/ibd.21325; Sharp RC, 2015, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00095; Simoncic PD, 2006, MOL CELL BIOL, V26, P4149, DOI 10.1128/MCB.01932-05; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; Sinder BP, 2015, J BONE MINER RES, V30, P2140, DOI 10.1002/jbmr.2735; Spalinger MR, 2015, MUCOSAL IMMUNOL, V8, P918, DOI 10.1038/mi.2014.122; Spalinger MR, 2020, GASTROENTEROLOGY, V159, P1763, DOI 10.1053/j.gastro.2020.07.004; Spalinger MR, 2018, CELL REP, V22, P1835, DOI 10.1016/j.celrep.2018.01.052; Speziani C, 2007, EUR J IMMUNOL, V37, P747, DOI 10.1002/eji.200636534; Stanoev A, 2018, CELL SYST, V7, P295, DOI 10.1016/j.cels.2018.06.006; Steeve KT, 2004, CYTOKINE GROWTH F R, V15, P49, DOI 10.1016/j.cytogfr.2003.10.005; Stuible M, 2008, CANCER METAST REV, V27, P215, DOI 10.1007/s10555-008-9115-1; Svensson MND, 2019, J CLIN INVEST, V129, P1193, DOI 10.1172/JCI123267; TAICHMAN RS, 1994, J EXP MED, V179, P1677, DOI 10.1084/jem.179.5.1677; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Tang MJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01508; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461; Wang J, 2019, IMMUNOL LETT, V209, P21, DOI 10.1016/j.imlet.2019.03.018; Wang YN, 2019, EXP BIOL MED, V244, P1493, DOI 10.1177/1535370219883419; Weitzmann MN, 2014, CURR OPIN ENDOCRINOL, V21, P461, DOI 10.1097/MED.0000000000000103; Wiede F, 2020, EMBO J, V39, DOI 10.15252/embj.2019103637; Wiede F, 2019, DIABETES, V68, P1251, DOI 10.2337/db18-1362; Wiede F, 2017, J EXP MED, V214, P2733, DOI 10.1084/jem.20161903; Wiede F, 2017, J AUTOIMMUN, V76, P85, DOI 10.1016/j.jaut.2016.09.004; Wiede F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036703; Wiede F, 2011, J CLIN INVEST, V121, P4758, DOI 10.1172/JCI59492; Wing K, 2011, TRENDS IMMUNOL, V32, P428, DOI 10.1016/j.it.2011.06.002; Wu JY, 2008, P NATL ACAD SCI USA, V105, P16976, DOI 10.1073/pnas.0802898105; Wu Q, 2017, CELL PHYSIOL BIOCHEM, V41, P1360, DOI 10.1159/000465455; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Yamashita T, 2011, CARDIOVASC RES, V91, P640, DOI 10.1093/cvr/cvr148; Yan Y, 2015, J DENT RES, V94, P1463, DOI 10.1177/0022034515595003; Yasuda K, 2019, SEMIN IMMUNOPATHOL, V41, P283, DOI 10.1007/s00281-019-00733-8; Yi ZA, 2014, NAT IMMUNOL, V15, P866, DOI 10.1038/ni.2944; YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683; Yu VWC, 2015, J EXP MED, V212, P759, DOI 10.1084/jem.20141843; Zee T, 2012, MOL CELL BIOL, V32, P1080, DOI 10.1128/MCB.06279-11; Zhang DJ, 2019, J CELL MOL MED, V23, P6690, DOI 10.1111/jcmm.14545; Zhang P, 2018, J PERIODONTAL RES, V53, P467, DOI 10.1111/jre.12535; Zhang Q, 2018, BRIT J OPHTHALMOL, V102, P996, DOI 10.1136/bjophthalmol-2017-310820; Zhang Y, 2018, FEBS LETT, V592, P2227, DOI 10.1002/1873-3468.13112; Zheng L, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/3984797; Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood-2006-08-041384	114	1	1	2	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2021	12								620333	10.3389/fimmu.2021.620333	http://dx.doi.org/10.3389/fimmu.2021.620333			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QS8OU	33692794	Green Published, gold			2022-12-18	WOS:000626153600001
J	Zheng, SW; Huang, K; Xia, WJ; Shi, JH; Liu, QL; Zhang, XR; Li, G; Chen, JY; Wang, T; Chen, XY; Xiang, AP				Zheng, Shuwei; Huang, Ke; Xia, Wenjie; Shi, Jiahao; Liu, Qiuli; Zhang, Xiaoran; Li, Gang; Chen, Jieying; Wang, Tao; Chen, Xiaoyong; Xiang, Andy Peng			Mesenchymal Stromal Cells Rapidly Suppress TCR Signaling-Mediated Cytokine Transcription in Activated T Cells Through the ICAM-1/CD43 Interaction	FRONTIERS IN IMMUNOLOGY			English	Article						mesenchymal stromal cells; T cells; TCR signaling; ICAM-1; CD43		Cell-cell contact participates in the process of mesenchymal stromal cell (MSC)-mediated T cell modulation and thus contributes to MSC-based therapies for various inflammatory diseases, especially T cell-mediated diseases. However, the mechanisms underlying the adhesion interactions between MSCs and T cells are still poorly understood. In this study, we explored the interaction between MSCs and T cells and found that activated T cells could rapidly adhere to MSCs, leading to significant reduction of TNF-alpha and IFN-gamma mRNA expression. Furthermore, TCR-proximal signaling in activated T cells was also dramatically suppressed in the MSC co-culture, resulting in weakened Ca2+ signaling. MSCs rapidly suppressed TCR signaling and its downstream signaling in a cell-cell contact-dependent manner, partially through the ICAM-1/CD43 adhesion interaction. Blockade of either ICAM-1 on MSCs or CD43 on T cells significantly reversed this rapid suppression of proinflammatory cytokine expression in T cells. Mechanistically, MSC-derived ICAM-1 likely disrupts CD43-mediated TCR microcluster formation to limit T cell activation. Taken together, our results reveal a fast mechanism of activated T cell inhibition by MSCs, which provides new clues to unravel the MSC-mediated immunoregulatory mechanism for aGVHD and other severe acute T cell-related diseases.	[Zheng, Shuwei; Shi, Jiahao; Zhang, Xiaoran; Li, Gang; Chen, Jieying; Wang, Tao; Chen, Xiaoyong; Xiang, Andy Peng] Sun Yat Sen Univ, Ctr Stem Cell Biol & Tissue Engn, Minist Educ, Key Lab Stem Cells & Tissue Engn, Guangzhou, Peoples R China; [Huang, Ke] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pediat, Guangzhou, Peoples R China; [Xia, Wenjie] Guangzhou Blood Ctr, Inst Blood Transfus, Guangzhou, Peoples R China; [Liu, Qiuli] Sun Yat Sen Univ, Affiliated Hosp 3, Biotherapy Ctr, Guangzhou, Peoples R China; [Chen, Xiaoyong] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou, Peoples R China; [Xiang, Andy Peng] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Peoples R China; [Xiang, Andy Peng] Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Blood Transfusion - CAMS; Guangzhou Blood Center; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Guangzhou Regenerative Medicine & Health Guangdong Laboratory (Bioisland Laboratory)	Chen, XY (corresponding author), Sun Yat Sen Univ, Ctr Stem Cell Biol & Tissue Engn, Minist Educ, Key Lab Stem Cells & Tissue Engn, Guangzhou, Peoples R China.; Chen, XY (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou, Peoples R China.	chenxiaoy@mail.sysu.edu.cn	Chen, Xiaoyong/GZH-3499-2022		National Key Research and Development Program of China, Stem Cell and Translational Research [2017YFA0105501, 2018YFA0107203, 2017YFA0103403]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDA16010103]; National Natural Science Foundation of China [31771616, 81730005, 81971526, 81970109]; Key Scientific and Technological Projects of Guangdong Province [2019B020236004, 2019B020234001, 2019B020235002, 2017B020230004]; Key Scientific and Technological Program of Guangzhou City [201803040011, 201802020023]; Pearl River S&T Nova Program of Guangzhou [201906010095]; Fundamental Research Funds for the Central Universities [20ykpy149]	National Key Research and Development Program of China, Stem Cell and Translational Research; Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Scientific and Technological Projects of Guangdong Province; Key Scientific and Technological Program of Guangzhou City; Pearl River S&T Nova Program of Guangzhou; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by the National Key Research and Development Program of China, Stem Cell and Translational Research (2017YFA0105501, 2018YFA0107203, and 2017YFA0103403); Strategic Priority Research Program of the Chinese Academy of Sciences (XDA16010103), the National Natural Science Foundation of China (31771616, 81730005, 81971526, and 81970109); the Key Scientific and Technological Projects of Guangdong Province (2019B020236004, 2019B020234001, 2019B020235002, and 2017B020230004); Key Scientific and Technological Program of Guangzhou City (201803040011 and 201802020023); and Pearl River S&T Nova Program of Guangzhou (201906010095), Fundamental Research Funds for the Central Universities (20ykpy149).	Alarcon B, 2011, IMMUNOLOGY, V133, P420, DOI 10.1111/j.1365-2567.2011.03458.x; Allenspach EJ, 2001, IMMUNITY, V15, P739, DOI 10.1016/S1074-7613(01)00224-2; Barda-Saad M, 1999, EXP HEMATOL, V27, P834, DOI 10.1016/S0301-472X(99)00010-7; Behnke J, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030682; Bonig H, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121577; Cao W, 2015, IMMUNOL LETT, V168, P147, DOI 10.1016/j.imlet.2015.06.003; Chiossone L, 2016, STEM CELLS, V34, P1909, DOI 10.1002/stem.2369; Christensen JE, 2001, INT IMMUNOL, V13, P593, DOI 10.1093/intimm/13.4.593; Cossarizza A, 2019, EUR J IMMUNOL, V49, P1457, DOI 10.1002/eji.201970107; Courtney AH, 2018, TRENDS BIOCHEM SCI, V43, P108, DOI 10.1016/j.tibs.2017.11.008; Davies LC, 2017, STEM CELLS, V35, P766, DOI 10.1002/stem.2509; Delon J, 2001, IMMUNITY, V15, P691, DOI 10.1016/S1074-7613(01)00231-X; Dhere T, 2016, ALIMENT PHARM THER, V44, P471, DOI 10.1111/apt.13717; Duffy MM, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt75; Duijvestein M, 2010, GUT, V59, P1662, DOI 10.1136/gut.2010.215152; Elgaz S, 2019, TRANSFUS MED HEMOTH, V46, P27, DOI 10.1159/000496809; Ferrara JLM, 2006, SEMIN HEMATOL, V43, P3, DOI 10.1053/j.seminhematol.2005.09.001; Francois M, 2012, MOL THER, V20, P187, DOI 10.1038/mt.2011.189; Gaud G, 2018, NAT REV IMMUNOL, V18, P485, DOI 10.1038/s41577-018-0020-8; Gieseke F, 2010, BLOOD, V116, P3770, DOI 10.1182/blood-2010-02-270777; Han Y, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080886; Holler E, 1997, LEUKEMIA LYMPHOMA, V25, P217, DOI 10.3109/10428199709114161; Huang BS, 2020, TRANSPLANTATION, V104, P428, DOI 10.1097/TP.0000000000002836; Ilani T, 2007, J CELL BIOL, V179, P733, DOI 10.1083/jcb.200707199; Jahromi NH, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03056; Lavigne P, 2005, EXPERT OPIN BIOL TH, V5, P313, DOI 10.1517/14712598.5.3.313; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; Le Blanc K, 2015, IMMUNOL LETT, V168, P140, DOI 10.1016/j.imlet.2015.05.004; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Li X, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1384-9; Liu SY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01076; MANJUNATH N, 1995, NATURE, V377, P535, DOI 10.1038/377535a0; Masterson CH, 2019, INTENS CARE MED EXP, V7, DOI 10.1186/s40635-019-0235-4; Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909; MEYER DM, 1995, J IMMUNOL, V155, P3578; Najar M, 2013, INT IMMUNOPHARMACOL, V15, P693, DOI 10.1016/j.intimp.2013.02.020; Najar M, 2012, STEM CELL REV REP, V8, P1188, DOI 10.1007/s12015-012-9408-1; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Panes J, 2018, GASTROENTEROLOGY, V154, P1334, DOI 10.1053/j.gastro.2017.12.020; Panes J, 2016, LANCET, V388, P1281, DOI 10.1016/S0140-6736(16)31203-X; Peng Y, 2015, LEUKEMIA, V29, P636, DOI 10.1038/leu.2014.225; Pennino D, 2010, J IMMUNOL, V184, P4880, DOI 10.4049/jimmunol.0901767; Purbhoo MA, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000645; Randriamampita C, 2004, BIOL CELL, V96, P69, DOI 10.1016/j.biolcel.2003.10.008; Rasmusson I, 2005, EXP CELL RES, V305, P33, DOI 10.1016/j.yexcr.2004.12.013; Reinisch A, 2015, BLOOD, V125, P249, DOI 10.1182/blood-2014-04-572255; Ren GW, 2011, CELL ADHES MIGR, V5, P20, DOI 10.4161/cam.5.1.13491; Ren GW, 2010, J IMMUNOL, V184, P2321, DOI 10.4049/jimmunol.0902023; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; Sadick JS, 2016, SCI REP-UK, V6, DOI 10.1038/srep33999; Schlosser K, 2019, CRIT CARE MED, V47, P918, DOI 10.1097/CCM.0000000000003657; Shaffer MH, 2009, J IMMUNOL, V182, P1021, DOI 10.4049/jimmunol.182.2.1021; Silva-Carvalho AE, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01659-x; Sima YZ, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00466-4; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Sperling AI, 1998, J IMMUNOL, V161, P6459; Stocker N, 2019, EUR J HAEMATOL, V103, P10, DOI 10.1111/ejh.13233; Sun Y, 2007, TRANSL RES, V150, P197, DOI 10.1016/j.trsl.2007.06.003; Suva D, 2008, J CELL PHYSIOL, V214, P588, DOI 10.1002/jcp.21244; Tang B, 2018, CELL PHYSIOL BIOCHEM, V46, P2624, DOI 10.1159/000489689; Thill PA, 2016, MOL CELL BIOL, V36, P2396, DOI 10.1128/MCB.00165-16; Trebak M, 2019, NAT REV IMMUNOL, V19, P154, DOI 10.1038/s41577-018-0110-7; Walling BL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00952; Wang MY, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3057624; Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002; Wedi B, 1996, ALLERGY, V51, P676; Xhaard A, 2020, BONE MARROW TRANSPL, V55, DOI 10.1038/s41409-019-0633-y; Zhao L, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1287-9; Ziprin P, 2004, BIOL CHEM, V385, P755, DOI 10.1515/BC.2004.092	70	1	1	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2021	12								609544	10.3389/fimmu.2021.609544	http://dx.doi.org/10.3389/fimmu.2021.609544			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QS5TZ	33692786	gold, Green Published			2022-12-18	WOS:000625963800001
J	Szopa, IM; Granica, M; Bujak, JK; Labedz, A; Blaszczyk, M; Paulos, CM; Majchrzak-Kuligowska, K				Szopa, Iwona Monika; Granica, Monika; Bujak, Joanna Katarzyna; Labedz, Agata; Blaszczyk, Maciej; Paulos, Chrystal Mary; Majchrzak-Kuligowska, Kinga			Effective Activation and Expansion of Canine Lymphocytes Using a Novel Nano-Sized Magnetic Beads Approach	FRONTIERS IN IMMUNOLOGY			English	Article						adoptive cell transfer; canine T cells; cellular immunotherapy; domestic dog model; microbeads		Expansion protocols for human T lymphocytes using magnetic beads, which serve as artificial antigen presenting cells (aAPCs), is well-studied. Yet, the efficacy of magnetic beads for propagation and functionality of peripheral blood lymphocytes (PBLs) isolated from companion dogs still remains limited. Domestic dog models are important in immuno-oncology field. Thus, we built the platform for induction of canine PBLs function, proliferation and biological activity using nano-sized magnetic beads (termed as MicroBeads) coated with anti-canine CD3 and CD28 antibodies. Herein we reveal that activation of canine PBLs via MicroBeads induces a range of genes involved in immediate-early response to T cell activation in dogs. Furthermore, canine T lymphocytes are effectively activated by MicroBeads, as measured by cluster formation and induction of activation marker CD25 on canine T cells as quickly as 24 h post stimulation. Similar to human T cells, canine PBLs require lower activation signal strength for efficient proliferation and expansion, as revealed by titration studies using a range of MicroBeads in the culture. Additionally, the impact of temperature was assessed in multiple stimulation settings, showing that both 37 degrees C and 38.5 degrees C are optimal for the expansion of canine T cells. In contrast to stimulation using plant mitogen Concanavalin A (ConA), MicroBead-based activation did not increase activation-induced cell death. In turn, MicroBeads supported the propagation of T cells with an effector memory phenotype that secreted substantial IL-2 and IFN-gamma. Thus, MicroBeads represent an accessible and affordable tool for conducting immunological studies on domestic dog models. Similarities in inducing intracellular signaling pathways further underscore the importance of this model in comparative medicine. Presented herein MicroBead-based expansion platforms for canine PBLs may benefit adoptive immunotherapy in dogs and facilitate the design of next-generation clinical trials in humans.	[Szopa, Iwona Monika; Granica, Monika; Bujak, Joanna Katarzyna; Labedz, Agata; Blaszczyk, Maciej; Majchrzak-Kuligowska, Kinga] Warsaw Univ Life Sci, Inst Vet Med, Dept Physiol Sci, Warsaw, Poland; [Bujak, Joanna Katarzyna] Warsaw Univ Life Sci, Inst Biol, Dept Phys & Biophys, Warsaw, Poland; [Paulos, Chrystal Mary] Emory Univ, Sch Med, Dept Surg, Dept Microbiol & Immunol, Atlanta, GA 30322 USA	Warsaw University of Life Sciences; Warsaw University of Life Sciences; Emory University	Majchrzak-Kuligowska, K (corresponding author), Warsaw Univ Life Sci, Inst Vet Med, Dept Physiol Sci, Warsaw, Poland.	kinga_majchrzak@sggw.edu.pl	Bujak, Joanna/AAH-5403-2021; Szopa, Iwona/AAE-4193-2022	Granica, Monika/0000-0001-8782-7139; Labedz, Agata/0000-0003-2492-2643; Bujak, Joanna/0000-0001-9096-568X	European Union under the European Regional Development Fund, Smart Growth Operational Programme 2014-2020 [POIR.04.04.00-003EE9/17-00]	European Union under the European Regional Development Fund, Smart Growth Operational Programme 2014-2020	This work was financed by the grant No. POIR.04.04.00-003EE9/17-00 entitled "Modification of signaling pathways of canine Th17 lymphocytes subset to improve adoptive cellular immunotherapy for humans" carried out within the First TEAM programme of the Foundation for Polish Science co-financed by the European Union under the European Regional Development Fund, Smart Growth Operational Programme 2014-2020 (to KM-K).	Bachmann MF, 2007, EMBO REP, V8, P1142, DOI 10.1038/sj.embor.7401099; Bae S, 2018, VET DERMATOL, V29, P504, DOI 10.1111/vde.12687; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Bujak JK, 2018, ACTA VET SCAND, V60, DOI 10.1186/s13028-018-0414-4; Butler MO, 2014, IMMUNOL REV, V257, P191, DOI 10.1111/imr.12129; Carr WH, 2017, J IMMUNOL, V198; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Cui WG, 2010, IMMUNOL REV, V236, P151, DOI 10.1111/j.1600-065X.2010.00926.x; Department of Health and Human Services , 2017, CAN IMM TRIALS CORR; Gett AV, 2003, NAT IMMUNOL, V4, P355, DOI 10.1038/ni908; Goral S, 2011, DIALYSIS TRANSPLANT, V40, P14, DOI 10.1002/dat.20527; Gordon I, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000161; Graves SS, 2011, TRANSPLANTATION, V91, P833, DOI 10.1097/TP.0b013e31820f07ff; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Habib-Agahi M, 2007, INT IMMUNOL, V19, P1383, DOI 10.1093/intimm/dxm106; Hartley AN, 2015, VET IMMUNOL IMMUNOP, V164, P127, DOI 10.1016/j.vetimm.2015.02.001; Hoshino Y, 2008, J VET MED SCI, V70, P581, DOI 10.1292/jvms.70.581; Hwang JR, 2020, EXP MOL MED, V52, P750, DOI 10.1038/s12276-020-0435-8; Itoh H, 2003, J VET MED SCI, V65, P329, DOI 10.1292/jvms.65.329; Kalamasz D, 2004, J IMMUNOTHER, V27, P405, DOI 10.1097/00002371-200409000-00010; Kato M, 2007, J VET MED SCI, V69, P481, DOI 10.1292/jvms.69.481; Klingemann H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00133; Kreissl H, 2015, J VET EMERG CRIT CAR, V25, P372, DOI 10.1111/vec.12302; LeBlanc AK, 2016, CLIN CANCER RES, V22, P2133, DOI 10.1158/1078-0432.CCR-15-2347; LeBlanc AK, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf0746; Li YX, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-104; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mace TA, 2011, J LEUKOCYTE BIOL, V90, P951, DOI 10.1189/jlb.0511229; Martkamchan S, 2016, ADV CLIN EXP MED, V25, P821, DOI 10.17219/acem/35771; Mata M, 2014, J IMMUNOTHER, V37, P407, DOI 10.1097/CJI.0000000000000052; Mielcarek M, 2007, BIOL BLOOD MARROW TR, V13, P1286, DOI 10.1016/j.bbmt.2007.07.010; Mizuno S, 1996, J VET MED A, V43, P289, DOI 10.1111/j.1439-0442.1996.tb00455.x; Mortlock SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121169; MUELLER DL, 1995, CURR OPIN IMMUNOL, V7, P375, DOI 10.1016/0952-7915(95)80113-8; Neal Lillian R, 2017, J Immunol Res Ther, V2, P68; O'Connor CM, 2012, SCI REP-UK, V2, DOI 10.1038/srep00249; Oelke M, 2005, TRENDS MOL MED, V11, P412, DOI 10.1016/j.molmed.2005.07.005; Panjwani MK, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2019.1676615; Panjwani MK, 2016, MOL THER, V24, P1602, DOI 10.1038/mt.2016.146; Paoloni M, 2008, NAT REV CANCER, V8, P147, DOI 10.1038/nrc2273; Park SG, 2009, NAT IMMUNOL, V10, P158, DOI 10.1038/ni.1687; Paulos CM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000448; Perica K, 2014, ACS NANO, V8, P2252, DOI 10.1021/nn405520d; Perica K, 2014, NANOMED-NANOTECHNOL, V10, P119, DOI 10.1016/j.nano.2013.06.015; Porter DL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5415; Purvis HA, 2010, BLOOD, V116, P4829, DOI 10.1182/blood-2010-03-272153; Rasmussen AM, 2010, J IMMUNOL METHODS, V355, P52, DOI 10.1016/j.jim.2010.02.004; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Rothe K, 2017, VET IMMUNOL IMMUNOP, V185, P48, DOI 10.1016/j.vetimm.2017.01.005; Sakai O, 2020, VET COMP ONCOL, V18, P739, DOI 10.1111/vco.12602; Sato M, 2013, TRANSPLANTATION, V96, P34, DOI 10.1097/TP.0b013e318295c025; Shatrova AN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167215; SHELTON GD, 1990, VET IMMUNOL IMMUNOP, V24, P1, DOI 10.1016/0165-2427(90)90073-2; Sikora E, 2015, MECH AGEING DEV, V151, P85, DOI 10.1016/j.mad.2015.03.011; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Snook JP, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aas9103; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Tran SEF, 2003, CELL DEATH DIFFER, V10, P1137, DOI 10.1038/sj.cdd.4401278; van Panhuys N, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00006; Wagner JL, 2003, J HERED, V94, P23, DOI 10.1093/jhered/esg002; Wang XY, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.15; Yamamoto T, 2007, IMMUNOLOGY, V121, P383, DOI 10.1111/j.1365-2567.2007.02586.x; Yasuda T, 2008, CELL CYCLE, V7, P3634, DOI 10.4161/cc.7.23.7103; Yin YB, 2018, MOL THER-ONCOLYTICS, V11, P20, DOI 10.1016/j.omto.2018.08.002	66	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 19	2021	12								604066	10.3389/fimmu.2021.604066	http://dx.doi.org/10.3389/fimmu.2021.604066			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QR7UQ	33679741	Green Published, gold			2022-12-18	WOS:000625420300001
J	Zhao, J; Que, WT; Du, XX; Fujino, M; Ichimaru, N; Ueta, H; Tokuda, N; Guo, WZ; Zabrocki, P; de Haard, H; Nonomura, N; Li, XK				Zhao, Jing; Que, Weitao; Du, Xiaoxiao; Fujino, Masayuki; Ichimaru, Naotsugu; Ueta, Hisashi; Tokuda, Nobuko; Guo, Wen-zhi; Zabrocki, Piotr; de Haard, Hans; Nonomura, Norio; Li, Xiao-Kang			Monotherapy With Anti-CD70 Antibody Causes Long-Term Mouse Cardiac Allograft Acceptance With Induction of Tolerogenic Dendritic Cells	FRONTIERS IN IMMUNOLOGY			English	Article						allograft; CD70; dendritic cell; regulatory T cell; rejection; tolerance		Allograft rejection has been an obstacle for the long-term survival of patients. CD70, a tumor necrosis factor (TNF) family member critically expressed on antigen-presenting cells and strongly but transiently up-regulated during lymphocyte activation, represents an important co-stimulatory molecule that induces effective T cell responses. We used a mouse heterotopic cardiac transplantation model to evaluate the effects of monotherapy with the antibody targeting mouse CD70 (FR70) on transplantation tolerance and its immunoregulatory activity. FR70-treated C3H recipient mice permanently accepted B6 fully mismatched cardiac allografts. Consistent with the graft survival, the infiltration of CD8(+) T cells in the graft was reduced, dendritic cells were differentiated into a tolerogenic status, and the number of regulatory T cells was elevated both in the graft and the recipient's spleen. In addition, naive C3H given an adoptive transfer of spleen cells from the primary recipients with FR70 treatment accepted a heart graft from a matching B6 donor but not third-party BALB/c mice.Our findings show that treatment with FR70 induced regulatory cells and inhibited cytotoxic T cell proliferation, which led to long-term acceptance of mouse cardiac allografts. These findings highlight the potential role of anti-CD70 antibodies as a clinically effective treatment for allograft rejection.	[Zhao, Jing; Que, Weitao; Fujino, Masayuki; Li, Xiao-Kang] Natl Res Inst Child Hlth & Dev, Div Transplantat Immunol, Tokyo, Japan; [Zhao, Jing; Ichimaru, Naotsugu; Nonomura, Norio] Osaka Univ, Grad Sch Med, Dept Specif Organ Regulat Urol, Osaka, Japan; [Zhao, Jing] Soochow Univ, Affiliated Hosp 1, Dept Gen Surg, Suzhou, Peoples R China; [Du, Xiaoxiao; Guo, Wen-zhi; Li, Xiao-Kang] Zhengzhou Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Zhengzhou, Peoples R China; [Fujino, Masayuki] Natl Inst Infect Dis, AIDS Res Ctr, Tokyo, Japan; [Ueta, Hisashi; Tokuda, Nobuko] Dokkyo Med Univ, Dept Anat Macro, Mibu, Tochigi, Japan; [Zabrocki, Piotr; de Haard, Hans] Argenx BV, Zwijnaarde, Belgium	National Center for Child Health & Development - Japan; Osaka University; Soochow University - China; Zhengzhou University; National Institute of Infectious Diseases (NIID); Dokkyo Medical University	Li, XK (corresponding author), Natl Res Inst Child Hlth & Dev, Div Transplantat Immunol, Tokyo, Japan.; Li, XK (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Zhengzhou, Peoples R China.; Zabrocki, P (corresponding author), Argenx BV, Zwijnaarde, Belgium.	pzabrocki@argenx.com; ri-k@ncchd.go.jp	UETA, HISASHI/AAJ-1695-2020	UETA, HISASHI/0000-0003-2237-2262	Ministry of Education, Culture, Sports, Science and Technology of Japan [16K11064, 24/17H04277, 18K08558]; National Center for Child Health and Development	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); National Center for Child Health and Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This study was supported by research grants from the Grants of Ministry of Education, Culture, Sports, Science and Technology of Japan (Grants-in-Aid 16K11064, 24/17H04277, 18K08558); and grants from the National Center for Child Health and Development.	Ahmed EB, 2011, AM J TRANSPLANT, V11, P936, DOI 10.1111/j.1600-6143.2011.03476.x; Ahrends T, 2016, CANCER RES, V76, P2921, DOI 10.1158/0008-5472.CAN-15-3130; ASCHER NL, 1984, IMMUNOL REV, V77, P217, DOI 10.1111/j.1600-065X.1984.tb00723.x; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Cai SJ, 2017, STEM CELL REP, V8, P1174, DOI 10.1016/j.stemcr.2017.03.020; Cai SJ, 2016, TRANSPLANTATION, V100, P1032, DOI 10.1097/TP.0000000000001079; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Dai HL, 2011, TRANSPL IMMUNOL, V24, P195, DOI 10.1016/j.trim.2011.02.002; Friberg M, 2002, INT J CANCER, V101, P151, DOI 10.1002/ijc.10645; Garcia P, 2004, J LEUKOCYTE BIOL, V76, P263, DOI 10.1189/jlb.1003508; Goldschneider I, 2003, TRENDS IMMUNOL, V24, P77, DOI 10.1016/S1471-4906(02)00038-8; Hou JG, 2015, J HEART LUNG TRANSPL, V34, P254, DOI 10.1016/j.healun.2014.09.037; Katori M, 2002, TRANSPLANTATION, V74, P905, DOI 10.1097/00007890-200210150-00001; Keller AM, 2007, P NATL ACAD SCI USA, V104, P5989, DOI 10.1073/pnas.0700946104; Keller AM, 2008, IMMUNITY, V29, P934, DOI 10.1016/j.immuni.2008.10.009; Lamb KE, 2011, AM J TRANSPLANT, V11, P450, DOI 10.1111/j.1600-6143.2010.03283.x; Li Q, 2008, EUR J IMMUNOL, V38, P2751, DOI 10.1002/eji.200838542; Liu Z, 2012, TRANSPLANTATION, V93, P1116, DOI 10.1097/TP.0b013e31824fd7cd; Lutz MB, 2009, EUR J IMMUNOL, V39, P2325, DOI 10.1002/eji.200939548; Mellor AL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01360; Miki T, 2001, TRANSPLANT P, V33, P129, DOI 10.1016/S0041-1345(00)02792-5; Minamoto K, 2002, J EXP MED, V196, P1321, DOI 10.1084/jem.20012135; Morelli AE, 2007, NAT REV IMMUNOL, V7, P610, DOI 10.1038/nri2132; Munitic I, 2013, J IMMUNOL, V190, P1169, DOI 10.4049/jimmunol.1202353; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Probst HC, 2005, NAT IMMUNOL, V6, P280, DOI 10.1038/ni1165; Rao DA, 2008, J EXP MED, V205, P3145, DOI 10.1084/jem.20081661; Rosen SJ, 2018, TRANSPLANTATION, V102, P1603, DOI 10.1097/TP.0000000000002239; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Schildknecht A, 2007, EUR J IMMUNOL, V37, P716, DOI 10.1002/eji.200636824; Scroggins SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075158; Shao W, 2011, IMMUNOL LETT, V138, P122, DOI 10.1016/j.imlet.2011.03.009; Singh A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11338-y; Steinman RM, 2003, ANN NY ACAD SCI, V987, P15, DOI 10.1111/j.1749-6632.2003.tb06029.x; Taraban VY, 2004, J IMMUNOL, V173, P6542, DOI 10.4049/jimmunol.173.11.6542; Ueta H, 2008, HEPATOLOGY, V47, P1352, DOI 10.1002/hep.22161; Van Deusen KE, 2010, J LEUKOCYTE BIOL, V87, P477, DOI 10.1189/jlb.0809535; Wang XH, 2013, IMMUNITY, V38, P1, DOI 10.1016/j.immuni.2013.01.005; Yamada A, 2005, J IMMUNOL, V174, P1357, DOI 10.4049/jimmunol.174.3.1357; Zahorchak AF, 2018, CELL IMMUNOL, V323, P9, DOI 10.1016/j.cellimm.2017.08.008; Zhang Q, 2015, GENE THER, V22, P217, DOI 10.1038/gt.2014.119; Zhang Q, 2014, SCI REP-UK, V4, DOI 10.1038/srep03979; Zhao J, 2019, TRANSPL IMMUNOL, V55, DOI 10.1016/j.trim.2019.03.002; Zhao MY, 2016, BIOCHEM BIOPH RES CO, V479, P663, DOI 10.1016/j.bbrc.2016.09.156	44	1	3	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 19	2021	11								555996	10.3389/fimmu.2020.555996	http://dx.doi.org/10.3389/fimmu.2020.555996			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QX2ZV	33737923	gold, Green Published			2022-12-18	WOS:000629217100001
J	Ortutay, Z; Gronholm, A; Laitinen, M; Keresztes-Andrei, M; Hermelo, I; Pesu, M				Ortutay, Zsuzsanna; Gronholm, Anna; Laitinen, Melina; Keresztes-Andrei, Melinda; Hermelo, Ismail; Pesu, Marko			Identification of Novel Genetic Regulatory Region for Proprotein Convertase FURIN and Interferon Gamma in T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						Furin regulation; super-enhancer; interferon gamma; p300; proprotein convertase	SUPER-ENHANCERS; IFN-GAMMA; DIFFERENTIAL EXPRESSION; BINDING-PROTEIN; TRANSCRIPTION; CYTOKINE; RECEPTOR; DATABASE; CLEAVAGE; GTPASE	The proprotein convertase enzyme FURIN promotes the proteolytic maturation of pro-proteins and thereby it serves as an important factor for maintaining cellular homeostasis. In T cells, FURIN is critical for maintaining the T regulatory cell dependent peripheral immune tolerance and intact T helper cell polarization. The enzymatic activity of FURIN is directly associated with its expression levels, but genetic determinants for cell-type specific Furin gene regulation have remained elusive. By exploring the histone acetyltransferase p300 binding patterns in T helper cells, a putative regulatory region at ca. 20kB upstream of Furin gene was identified. When this region was deleted with CRISPR/Cas9 the production of Furin mRNA was significantly reduced in activated mouse T cells. Genome-wide RNA profiling by sequencing revealed that the novel Furin regulator region also impacted the expression of several genes that have previously been associated with the Th1 type hall mark cytokine IFN gamma regulation or function. Finally, Furin genetic regulatory region was found to specifically promote the secretion of IFN gamma by activated T cells. In sum, our data unravels the presence of Furin expression regulatory region in T cells that has characteristics of a super-enhancer for Th1 cell fate.	[Ortutay, Zsuzsanna; Gronholm, Anna; Laitinen, Melina; Pesu, Marko] Tampere Univ, Fac Med & Hlth Technol, Immunoregulat, Tampere, Finland; [Keresztes-Andrei, Melinda] Pazmany Peter Catholic Univ, Fac Informat Technol & Bion, Budapest, Hungary; [Hermelo, Ismail] Tampere Univ, Fac Med & Hlth Technol, Computat Biol, Tampere, Finland; [Pesu, Marko] Fimlab Labs, Tampere, Finland	Tampere University; Tampere University	Ortutay, Z (corresponding author), Tampere Univ, Fac Med & Hlth Technol, Immunoregulat, Tampere, Finland.	zsuzsi.ortutay@gmail.com			Academy of Finland [286477, 295814]; Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital [X50070]; Tampere Tuberculosis Foundation; Cancer Society of Finland; Tays tukisaatio (Tays Support Foundation)	Academy of Finland(Academy of Finland); Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital; Tampere Tuberculosis Foundation; Cancer Society of Finland; Tays tukisaatio (Tays Support Foundation)	This work was supported by the Academy of Finland (Grant No. 286477 and 295814 to MP), the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Grant No. X50070 to MP), the Tampere Tuberculosis Foundation (MP), the Cancer Society of Finland (MP) and Tays tukisaatio (Tays Support Foundation) (to MP).	Ai WC, 2013, INT J ENV RES PUB HE, V10, P3834, DOI 10.3390/ijerph10093834; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Anderson ED, 2002, J BIOL CHEM, V277, P12879, DOI 10.1074/jbc.M108740200; Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; AYOUBI TAY, 1994, J BIOL CHEM, V269, P9298; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; Baralle FE, 2017, NAT REV MOL CELL BIO, V18, P437, DOI 10.1038/nrm.2017.27; Bauer DE, 2015, JOVE-J VIS EXP, DOI 10.3791/52118; Blanchette F, 1997, J CLIN INVEST, V99, P1974, DOI 10.1172/JCI119365; Blanchette F, 2001, J CELL PHYSIOL, V188, P264, DOI 10.1002/jcp.1116; Carullo NVN, 2019, GENES-BASEL, V10, DOI 10.3390/genes10010043; Chen RN, 2008, ENDOCRINOLOGY, V149, P3817, DOI 10.1210/en.2007-0989; Chen Y, 2013, HEPATOL RES, V43, P208, DOI 10.1111/j.1872-034X.2012.01051.x; Cheng YW, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108254; Cordova ZM, 2016, ONCOTARGET, V7, P54392, DOI 10.18632/oncotarget.11106; de Lara JCF, 2019, EPIGENETICS INSIGHTS, V12, DOI 10.1177/2516865719846093; Couture F, 2015, EXPERT OPIN THER PAT, V25, P379, DOI 10.1517/13543776.2014.1000303; Creemers JWM, 2008, FRONT BIOSCI-LANDMRK, V13, P4960, DOI 10.2741/3055; D'Anjou F, 2011, TRANSL ONCOL, V4, P157, DOI 10.1593/tlo.10295; de Cicco RL, 2005, CANCER RES, V65, P4162, DOI 10.1158/0008-5472.CAN-04-2820; DeLong JH, 2018, J IMMUNOL, V200, P1761, DOI 10.4049/jimmunol.1701154; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dollt C, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1011-1; Duckert P, 2004, PROTEIN ENG DES SEL, V17, P107, DOI 10.1093/protein/gzh013; Dupays L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212992; Farh KKH, 2015, NATURE, V518, P337, DOI 10.1038/nature13835; Feitosa MF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198166; Haeussler M, 2019, NUCLEIC ACIDS RES, V47, pD853, DOI 10.1093/nar/gky1095; Han Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15649-3; Heinonen MT, 2015, IMMUNOL CELL BIOL, V93, P158, DOI 10.1038/icb.2014.86; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Hoffmann TJ, 2017, NAT GENET, V49, P54, DOI 10.1038/ng.3715; Huang S, 2019, CURR OPIN IMMUNOL, V60, P71, DOI 10.1016/j.coi.2019.04.017; Huang YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040738; Hurgin V, 2002, P NATL ACAD SCI USA, V99, P16957, DOI 10.1073/pnas.262663399; Hwang EM, 2006, BIOCHEM BIOPH RES CO, V349, P654, DOI 10.1016/j.bbrc.2006.08.077; INOCENCIO NM, 1994, J BIOL CHEM, V269, P31831; Ito I, 2007, J ALLERGY CLIN IMMUN, V119, P89, DOI 10.1016/j.jaci.2006.08.038; Jaaks P, 2017, INT J CANCER, V141, P654, DOI 10.1002/ijc.30714; Jahagirdar R, 2017, MOL PHARMACOL, V92, P694, DOI 10.1124/mol.117.110379; Javed A, 2016, J GEN VIROL, V97, P3400, DOI 10.1099/jgv.0.000632; Kasamatsu J, 2014, J IMMUNOL, V193, P5199, DOI 10.4049/jimmunol.1400924; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Katz Y, 2015, BIOINFORMATICS, V31, P2400, DOI 10.1093/bioinformatics/btv034; Khan A, 2016, NUCLEIC ACIDS RES, V44, pD164, DOI 10.1093/nar/gkv1002; Kim WJ, 2012, MOL CELL BIOL, V32, P3382, DOI 10.1128/MCB.06331-11; Klamp T, 2003, J IMMUNOL, V171, P1255, DOI 10.4049/jimmunol.171.3.1255; Kolde R., 2019, **DATA OBJECT**; Kunugita Naoki, 2007, Journal of Toxicological Sciences, V32, P377, DOI 10.2131/jts.32.377; Labun K, 2019, NUCLEIC ACIDS RES, V47, pW171, DOI 10.1093/nar/gkz365; Laprise MH, 2002, BLOOD, V100, P3578, DOI 10.1182/blood.V100.10.3578; Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401; Lin H, 2012, ARTHRITIS RHEUM-US, V64, P2878, DOI 10.1002/art.34523; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Malik R, 2018, NAT GENET, V50, P524, DOI 10.1038/s41588-018-0058-3; Marshall HD, 2011, IMMUNITY, V35, P633, DOI 10.1016/j.immuni.2011.08.016; McMahon S, 2005, J BIOL CHEM, V280, P6561, DOI 10.1074/jbc.M413248200; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; Oksanen A, 2014, J IMMUNOL, V193, P5470, DOI 10.4049/jimmunol.1401629; Ortutay Z, 2015, J LEUKOCYTE BIOL, V98, P73, DOI 10.1189/jlb.2A0514-257RR; Pesu M, 2008, NATURE, V455, P246, DOI 10.1038/nature07210; Pesu M, 2006, BLOOD, V108, P983, DOI 10.1182/blood-2005-09-3824; Pruitt KD, 2007, NUCLEIC ACIDS RES, V35, pD61, DOI 10.1093/nar/gkl842; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Ranta Noora, 2018, Clin Exp Rheumatol, V36 Suppl 112, P47; Ritz C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0146021; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Santos JC, 2018, J LEUKOCYTE BIOL, V104, P729, DOI 10.1002/JLB.4MR0118-038R; Scamuffa N, 2006, FASEB J, V20, P1954, DOI 10.1096/fj.05-5491rev; Schwerbel K, 2020, J HEPATOL, V73, P771, DOI 10.1016/j.jhep.2020.04.031; Seidah NG, 2013, J BIOL CHEM, V288, P21473, DOI 10.1074/jbc.R113.481549; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Shin HY, 2018, MOL CELLS, V41, P506, DOI 10.14348/molcells.2018.2297; Soares H, 2007, J EXP MED, V204, P1095, DOI 10.1084/jem.20070176; Tamura T, 2015, INT J HEMATOL, V101, P342, DOI 10.1007/s12185-015-1761-9; Tang FQ, 2020, NPJ PRECIS ONCOL, V4, DOI 10.1038/s41698-020-0108-z; Taylor GA, 1996, J BIOL CHEM, V271, P20399, DOI 10.1074/jbc.271.34.20399; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Turpeinen H, 2011, ATHEROSCLEROSIS, V219, P799, DOI 10.1016/j.atherosclerosis.2011.08.011; Umland SP, 2004, AM J RESP CELL MOL, V30, P530, DOI 10.1165/rcmb.2003-0220OC; Vahedi G, 2015, NATURE, V520, P558, DOI 10.1038/nature14154; Visel A, 2007, NUCLEIC ACIDS RES, V35, pD88, DOI 10.1093/nar/gkl822; Visel A, 2009, NATURE, V457, P854, DOI 10.1038/nature07730; WALUNAS TL, 1995, J IMMUNOL, V155, P1873; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Wu HJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02305; Yang XK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0050479; Yucesoy B, 2015, TOXICOL SCI, V146, P192, DOI 10.1093/toxsci/kfv084; Yue F, 2014, NATURE, V515, P355, DOI 10.1038/nature13992; Zha JS, 2017, ONCOTARGET, V8, P60159, DOI 10.18632/oncotarget.18569; Zhu AQ, 2019, BIOINFORMATICS, V35, P2084, DOI 10.1093/bioinformatics/bty895; Zhu JF, 2012, IMMUNITY, V37, P660, DOI 10.1016/j.immuni.2012.09.007	95	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2021	12								630389	10.3389/fimmu.2021.630389	http://dx.doi.org/10.3389/fimmu.2021.630389			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QR3YC	33679774	Green Published, gold			2022-12-18	WOS:000625147100001
J	Rabin, RL; Walter, MR				Rabin, Ronald L.; Walter, Mark R.			Editorial: Structures, Signaling Mechanisms, and Functions of Types I and III Interferons	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						interferon alpha; interferon lambda; interferon subtypes; interferon receptors; interferon structure; interferon signaling; interferon function; interferon therapy			[Rabin, Ronald L.] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA; [Walter, Mark R.] Univ Alabama Birmingham, Birmingham, AL 35294 USA	US Food & Drug Administration (FDA); University of Alabama System; University of Alabama Birmingham	Walter, MR (corresponding author), Univ Alabama Birmingham, Birmingham, AL 35294 USA.	walter@uab.edu			NIH [R01 AI143554]; US Food and Drug Administration internal funds	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Food and Drug Administration internal funds	This work was supported by NIH (R01 AI143554) to MRW and US Food and Drug Administration internal funds to RLR.	ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x	2	1	1	5	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2021	12								638479	10.3389/fimmu.2021.638479	http://dx.doi.org/10.3389/fimmu.2021.638479			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QR3VO	33679797	Green Published, gold			2022-12-18	WOS:000625140500001
J	Sarate, PJ; Srutkova, D; Geissler, N; Schwarzer, M; Schabussova, I; Inic-Kanada, A; Kozakova, H; Wiedermann, U				Sarate, Priya J.; Srutkova, Dagmar; Geissler, Nora; Schwarzer, Martin; Schabussova, Irma; Inic-Kanada, Aleksandra; Kozakova, Hana; Wiedermann, Ursula			Pre- and Neonatal Imprinting on Immunological Homeostasis and Epithelial Barrier Integrity by Escherichia coli Nissle 1917 Prevents Allergic Poly-Sensitization in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						allergic poly-sensitization; germ-free; BALB; c; mucosal tolerance; mouse model; Escherichia coli Nissle 1917; hygiene hypothesis		A steady rise in the number of poly-sensitized patients has increased the demand for effective prophylactic strategies against multi-sensitivities. Probiotic bacteria have been successfully used in clinics and experimental models to prevent allergic mono-sensitization. In the present study, we have investigated whether probiotic bacteria could prevent poly-sensitization by imprinting on the immune system early in life. We used two recombinant variants of probiotic Escherichia coli Nissle 1917 (EcN): i) EcN expressing birch and grass pollen, poly-allergen chimera construct (EcN-Chim), and ii) an "empty" EcN without allergen expression (EcN-Ctrl). Conventional mice (CV) were treated with either EcN-Chim or EcN-Ctrl in the last week of the gestation and lactation period. Gnotobiotic mice received one oral dose of either EcN-Chim or EcN-Ctrl before mating. The offspring from both models underwent systemic allergic poly-sensitization and intranasal challenge with recombinant birch and grass pollen allergens (rBet v 1, rPhl p 1, and rPhl p 5). In the CV setting, the colonization of offspring via treatment of mothers reduced allergic airway inflammation (AAI) in offspring compared to poly-sensitized controls. Similarly, in a gnotobiotic model, AAI was reduced in EcN-Chim and EcN-Ctrl mono-colonized offspring. However, allergy prevention was more pronounced in the EcN-Ctrl mono-colonized offspring as compared to EcN-Chim. Mono-colonization with EcN-Ctrl was associated with a shift toward mixed Th1/Treg immune responses, increased expression of TLR2 and TLR4 in the lung, and maintained levels of zonulin-1 in lung epithelial cells as compared to GF poly-sensitized and EcN-Chim mono-colonized mice. This study is the first one to establish the model of allergic poly-sensitization in gnotobiotic mice. Using two different settings, gnotobiotic and conventional mice, we demonstrated that an early life intervention with the EcN without expressing an allergen is a powerful strategy to prevent poly-sensitization later in life.	[Sarate, Priya J.; Geissler, Nora; Schabussova, Irma; Inic-Kanada, Aleksandra; Wiedermann, Ursula] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Inst Specif Prophylaxis & Trop Med, Vienna, Austria; [Srutkova, Dagmar; Schwarzer, Martin; Kozakova, Hana] Czech Acad Sci, Inst Microbiol, Lab Gnotobiol, Novy Hradek, Czech Republic	Medical University of Vienna; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Inic-Kanada, A; Wiedermann, U (corresponding author), Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Inst Specif Prophylaxis & Trop Med, Vienna, Austria.	aleksandra.inic-kanada@meduniwien.ac.at; ursula.wiedermann@meduniwien.ac.at	Schwarzer, Martin/P-9871-2017; Srutkova, Dagmar/H-8511-2014	Schwarzer, Martin/0000-0002-1401-6578; Wiedermann, Ursula/0000-0002-1302-3223; Srutkova, Dagmar/0000-0003-0054-5396; Inic-Kanada, Aleksandra/0000-0001-7854-3812; Schabussova, Irma/0000-0002-2109-2640	Austrian Science Fund (FWF) [SFB F46]; DK MCCA [W1248-B30]; OeAD WTZ grants [CZ 06/2020, CZ 16/2019]; Czech Science Foundation [19-02261S]; Ministry of Education, Youth and Sports of the Czech Republic [8J20AT011]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); DK MCCA; OeAD WTZ grants; Czech Science Foundation(Grant Agency of the Czech Republic); Ministry of Education, Youth and Sports of the Czech Republic(Ministry of Education, Youth & Sports - Czech Republic)	This work was funded by the Austrian Science Fund (FWF) SFB F46 and DK MCCA W1248-B30; the OeAD WTZ grants CZ 06/2020 and CZ 16/2019; and by the grants: 19-02261S of the Czech Science Foundation and 8J20AT011 of the Ministry of Education, Youth and Sports of the Czech Republic.	Adam E, 2010, EUR J IMMUNOL, V40, P1995, DOI 10.1002/eji.200939913; Amenyogbe N, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00111; Anto JM, 2017, J ALLERGY CLIN IMMUN, V139, P388, DOI 10.1016/j.jaci.2016.12.940; Asarnoj A, 2016, J ALLERGY CLIN IMMUN, V137, P813, DOI 10.1016/j.jaci.2015.09.052; Bermudez-Brito M, 2012, ANN NUTR METAB, V61, P160, DOI 10.1159/000342079; Bickert T, 2009, INT ARCH ALLERGY IMM, V149, P219, DOI 10.1159/000199717; Biedermann T, 2019, ALLERGY, V74, P1237, DOI 10.1111/all.13758; Bohm L, 2015, J IMMUNOL, V194, P887, DOI 10.4049/jimmunol.1401612; Bokanovic D, 2013, ALLERGY, V68, P1403, DOI 10.1111/all.12263; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V87, P737, DOI 10.1016/0091-6749(91)90397-7; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Calderon MA, 2012, J ALLERGY CLIN IMMUN, V129, P929, DOI 10.1016/j.jaci.2011.11.019; Chung KF, 2017, J ALLERGY CLIN IMMUN, V139, P1071, DOI 10.1016/j.jaci.2017.02.004; Ciprandi G, 2010, INT J IMMUNOPATH PH, V23, P1293, DOI 10.1177/039463201002300438; Ciprandi G, 2011, EXPERT OPIN BIOL TH, V11, P715, DOI 10.1517/14712598.2011.576246; Cukrowska B, 2002, SCAND J IMMUNOL, V55, P204, DOI 10.1046/j.1365-3083.2002.01005.x; dos Santos K, 2020, ALLERGOL IMMUNOPATH, V48, P270, DOI 10.1016/j.aller.2019.12.007; Espinosa V, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00272; Flicker S, 2006, J ALLERGY CLIN IMMUN, V117, P1336, DOI 10.1016/j.jaci.2006.02.012; Forkel S, 2020, INT ARCH ALLERGY IMM, V181, P128, DOI 10.1159/000504297; Frey A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00761; Fujimura KE, 2015, CELL HOST MICROBE, V17, P592, DOI 10.1016/j.chom.2015.04.007; Gardlik R, 2012, FOLIA BIOL-PRAGUE, V58, P238; Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Grabig A, 2006, INFECT IMMUN, V74, P4075, DOI 10.1128/IAI.01449-05; Ha EK, 2016, INT ARCH ALLERGY IMM, V171, P251, DOI 10.1159/000453034; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; He L, 2017, ONCOTARGET, V8, P85772, DOI 10.18632/oncotarget.20486; Helps SC, 2012, APPL IMMUNOHISTO M M, V20, P82, DOI 10.1097/PAI.0b013e31821fc8cd; Hill CJ, 2017, MICROBIOME, V5, DOI 10.1186/s40168-016-0213-y; Hufnagl K, 2008, CLIN EXP ALLERGY, V38, P1192, DOI 10.1111/j.1365-2222.2008.02992.x; Hufnagl K, 2005, J ALLERGY CLIN IMMUN, V116, P370, DOI 10.1016/j.jaci.2005.04.002; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kim KW, 2006, J KOREAN MED SCI, V21, P1012, DOI 10.3346/jkms.2006.21.6.1012; Kozakova H, 2016, CELL MOL IMMUNOL, V13, P251, DOI 10.1038/cmi.2015.09; Krogulska A, 2011, J CLIN IMMUNOL, V31, P205, DOI 10.1007/s10875-010-9487-1; Kuitunen M, 2009, J ALLERGY CLIN IMMUN, V123, P335, DOI 10.1016/j.jaci.2008.11.019; Lambrecht BN, 2017, NAT IMMUNOL, V18, P1076, DOI 10.1038/ni.3829; Lara-Villoslada F, 2007, BRIT J NUTR, V98, pS96, DOI 10.1017/S0007114507832910; Larsen JN, 2016, DRUG DISCOV TODAY, V21, P26, DOI 10.1016/j.drudis.2015.07.010; Lynch SV, 2016, CURR OPIN ALLERGY CL, V16, P165, DOI 10.1097/ACI.0000000000000255; Mennini M, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00165; Migueres M, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-16; Moossavi S, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00197; Moverare R, 2002, INT ARCH ALLERGY IMM, V128, P325, DOI 10.1159/000063855; Mustafa HN, 2015, INDIAN J PHARMACOL, V47, P649, DOI 10.4103/0253-7613.169588; Natsume O, 2018, ALLERGOL INT, V67, P24, DOI 10.1016/j.alit.2017.11.003; Nelson HS, 2009, J ALLERGY CLIN IMMUN, V123, P763, DOI 10.1016/j.jaci.2008.12.013; Pablos I, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0603-z; Raciborski F, 2019, CLIN TRANSL ALLERGY, V9, DOI 10.1186/s13601-019-0246-y; Renz H, 2018, J ALLERGY CLIN IMMUN, V141, P1212, DOI 10.1016/j.jaci.2017.11.019; Sarate PJ, 2019, MUCOSAL IMMUNOL, V12, P132, DOI 10.1038/s41385-018-0084-6; Satitsuksanoa P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02939; Schabussova I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040271; Schabussova I, 2011, VACCINE, V29, P1981, DOI 10.1016/j.vaccine.2010.12.101; Schaub B, 2016, ALLERGY IMMUNITY TOL, P1, DOI DOI 10.1016/B978-0-12-420226-9.00001-2; Schwarzer M, 2011, ALLERGY, V66, P368, DOI 10.1111/j.1398-9995.2010.02488.x; Schwarzer M, 2016, SCIENCE, V351, P854, DOI 10.1126/science.aad8588; Schwarzer M, 2013, VACCINE, V31, P5405, DOI 10.1016/j.vaccine.2013.09.014; Silvestri M, 1999, ANN ALLERG ASTHMA IM, V83, P335, DOI 10.1016/S1081-1206(10)62674-9; Silvestri M, 1997, ANN ALLERG ASTHMA IM, V79, P512, DOI 10.1016/S1081-1206(10)63058-X; Skevaki C, 2018, J ALLERGY CLIN IMMUN, V142, P804, DOI 10.1016/j.jaci.2017.07.056; Sonnenborn U, 2016, FEMS MICROBIOL LETT, V363, DOI 10.1093/femsle/fnw212; Sonnenborn Ulrich, 2009, Microbial Ecology in Health and Disease, V21, P122, DOI 10.3109/08910600903444267; Srutkova D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134050; Stokholm J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02573-2; Sturgeon C, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2016.1251384; Sturm A, 2005, INFECT IMMUN, V73, P1452, DOI 10.1128/IAI.73.3.1452-1465.2005; Tang MLK, 2013, PEDIAT ALLERG IMM-UK, V24, P512, DOI 10.1111/pai.12100; Taniuchi S, 2017, HUM VACC IMMUNOTHER, V13, P2443, DOI 10.1080/21645515.2017.1353845; Torow N, 2017, J IMMUNOL, V198, P557, DOI 10.4049/jimmunol.1601253; Tunis MC, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/606383; Verhasselt V, 2010, MUCOSAL IMMUNOL, V3, P326, DOI 10.1038/mi.2010.25; Warm K, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-20; Wehkamp J, 2004, INFECT IMMUN, V72, P5750, DOI 10.1128/IAI.72.10.5750-5758.2004; Westritschnig K, 2008, EUR J CLIN INVEST, V38, P260, DOI 10.1111/j.1365-2362.2008.01938.x; Wickens K, 2008, J ALLERGY CLIN IMMUN, V122, P788, DOI 10.1016/j.jaci.2008.07.011; Winkler B, 2002, CLIN EXP ALLERGY, V32, P30, DOI 10.1046/j.0022-0477.2001.01214.x; Zhang YL, 2012, APPL ENVIRON MICROB, V78, P7603, DOI 10.1128/AEM.01390-12	81	1	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 17	2021	11								612775	10.3389/fimmu.2020.612775	http://dx.doi.org/10.3389/fimmu.2020.612775			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QQ7FW	33679699	gold, Green Published			2022-12-18	WOS:000624688200001
J	Uhl, B; Braun, C; Dominik, J; Luft, J; Canis, M; Reichel, CA				Uhl, Bernd; Braun, Constanze; Dominik, Julian; Luft, Joshua; Canis, Martin; Reichel, Christoph A.			A Novel Experimental Approach for In Vivo Analyses of the Salivary Gland Microvasculature	FRONTIERS IN IMMUNOLOGY			English	Article						salivary gland; in vivo imaging; microcirculation; leukocyte trafficking; microvascular permeability; inflammation; immunology	P-SELECTIN; LEUKOCYTE ACCUMULATION; ADHESION MOLECULES; ENDOTHELIAL-CELLS; SJOGRENS-SYNDROME; TNF-ALPHA; INFLAMMATION; RECRUITMENT; NEUTROPHILS; EXPRESSION	Microvascular dysfunction plays a fundamental role in the pathogenesis of salivary gland disorders. Restoring and preserving microvascular integrity might therefore represent a promising strategy for the treatment of these pathologies. The mechanisms underlying microvascular dysfunction in salivary glands, however, are still obscure, partly due to the unavailability of adequate in vivo models. Here, we present a novel experimental approach that allows comprehensive in vivo analyses of the salivary gland microvasculature in mice. For this purpose, we employed different microscopy techniques including multi-photon in vivo microscopy to quantitatively analyze interactions of distinct immune cell subsets in the submandibular gland microvasculature required for their infiltration into the surrounding parenchyma and their effects on microvascular function. Confocal microscopy and multi-channel flow cytometry in tissue sections/homogenates complemented these real-time analyses by determining the molecular phenotype of the participating cells. To this end, we identified key adhesion and signaling molecules that regulate the subset- and tissue-specific trafficking of leukocytes into inflamed glands and control the associated microvascular leakage. Hence, we established an experimental approach that allows in vivo analyses of microvascular processes in healthy and diseased salivary glands. This enables us to delineate distinct pathogenetic factors as novel therapeutic targets in salivary gland diseases.	[Uhl, Bernd; Canis, Martin; Reichel, Christoph A.] Ludwig Maximilians Univ Munchen, Dept Otorhinolaryngol Head & Neck Surg, Munich, Germany; [Uhl, Bernd; Braun, Constanze; Dominik, Julian; Luft, Joshua; Reichel, Christoph A.] Ludwig Maximilians Univ Munchen, Walter Brendel Ctr Expt Med, Munich, Germany	University of Munich; University of Munich	Uhl, B (corresponding author), Ludwig Maximilians Univ Munchen, Dept Otorhinolaryngol Head & Neck Surg, Munich, Germany.; Uhl, B (corresponding author), Ludwig Maximilians Univ Munchen, Walter Brendel Ctr Expt Med, Munich, Germany.	bernd.uhl@med.uni-muenchen.de			Collaborative Research Centre (CRC) 914 of Deutsche Forschungsgemeinschaft (DFG)	Collaborative Research Centre (CRC) 914 of Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	This study is supported by Collaborative Research Centre (CRC) 914 of Deutsche Forschungsgemeinschaft (DFG).	Ashander LM, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/7945848; Aslan A, 2017, SHOCK, V48, P69, DOI 10.1097/SHK.0000000000000841; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287; Bullard DC, 2002, IMMUNOL RES, V26, P27, DOI 10.1385/IR:26:1-3:027; Cavanaugh VJ, 2003, J VIROL, V77, P1703, DOI 10.1128/JVI.77.3.1703-1717.2003; Choi KY, 2012, THERANOSTICS, V2, P156, DOI 10.7150/thno.4068; Ciccia F, 2013, RHEUMATOLOGY, V52, P1009, DOI 10.1093/rheumatology/kes435; Claesson-Welsh L, 2015, UPSALA J MED SCI, V120, P135, DOI 10.3109/03009734.2015.1064501; Cong X, 2017, J DENT RES, V96, P562, DOI 10.1177/0022034516685048; Cui AF, 2019, TOXICOL LETT, V302, P60, DOI 10.1016/j.toxlet.2018.11.002; Devi S, 2013, NAT MED, V19, P107, DOI 10.1038/nm.3024; DiStasi MR, 2009, TRENDS IMMUNOL, V30, P539, DOI 10.1016/j.it.2009.07.012; Doring A, 2007, J IMMUNOL, V179, P8470, DOI 10.4049/jimmunol.179.12.8470; Drechsler M, 2010, CIRCULATION, V122, P1837, DOI 10.1161/CIRCULATIONAHA.110.961714; Dreymueller D, 2012, EMBO MOL MED, V4, P412, DOI 10.1002/emmm.201200217; Eriksson EE, 2001, J EXP MED, V194, P205, DOI 10.1084/jem.194.2.205; Ficht X, 2018, JOVE-J VIS EXP, DOI 10.3791/57283; FIEBIG E, 1991, INT J MICROCIRC, V10, P127; Fukumura D, 2010, MICROCIRCULATION, V17, P206, DOI 10.1111/j.1549-8719.2010.00029.x; Hannoodee S., 2020, ACUTE INFLAMMATORY R; Iizuka M, 2015, J IMMUNOL, V194, P56, DOI 10.4049/jimmunol.1401118; Jin K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34347-1; Johnston B, 2000, J IMMUNOL, V164, P3337, DOI 10.4049/jimmunol.164.6.3337; Kang EH, 2011, CLIN EXP RHEUMATOL, V29, P970; Kunkel EJ, 1996, J EXP MED, V183, P57, DOI 10.1084/jem.183.1.57; Langley RR, 1999, AM J PHYSIOL-HEART C, V277, pH1156, DOI 10.1152/ajpheart.1999.277.3.H1156; Limaye A, 2019, J DENT RES, V98, P713, DOI 10.1177/0022034519837240; Maas SL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02739; Masedunskas A, 2008, TRAFFIC, V9, P1801, DOI 10.1111/j.1600-0854.2008.00798.x; MAY MJ, 1992, EUR J IMMUNOL, V22, P219, DOI 10.1002/eji.1830220132; Miletich I, 2010, FRONT ORAL BIOL, V14, P1, DOI 10.1159/000313703; Mizrachi A, 2016, RADIAT RES, V186, P189, DOI 10.1667/RR14431.1; Nolan DJ, 2013, DEV CELL, V26, P204, DOI 10.1016/j.devcel.2013.06.017; Nourshargh S, 2014, IMMUNITY, V41, P694, DOI 10.1016/j.immuni.2014.10.008; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schwarz M, 2013, KIDNEY INT, V84, P116, DOI 10.1038/ki.2013.46; Sedger LM, 2014, CYTOKINE GROWTH F R, V25, P453, DOI 10.1016/j.cytogfr.2014.07.016; Sharma R, 2006, J AUTOIMMUN, V27, P289, DOI 10.1016/j.jaut.2006.11.003; Shen J, 1997, J VIROL, V71, P9323, DOI 10.1128/JVI.71.12.9323-9332.1997; Shigeta A, 2008, BLOOD, V112, P4915, DOI 10.1182/blood-2008-04-153866; Soehnlein O, 2010, NAT REV IMMUNOL, V10, P427, DOI 10.1038/nri2779; Soehnlein O, 2009, BLOOD, V114, P4613, DOI 10.1182/blood-2009-06-221630; Soudja SM, 2012, IMMUNITY, V37, P549, DOI 10.1016/j.immuni.2012.05.029; Stellari F, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0976-8; Stolp B, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz4371; Thom JT, 2014, EUR J IMMUNOL, V44, P706, DOI 10.1002/eji.201343992; Uhl B, 2017, ACS NANO, V11, P1498, DOI 10.1021/acsnano.6b06812; Uhl B, 2016, BLOOD, V128, P2327, DOI 10.1182/blood-2016-05-718999; Vajkoczy P, 2001, J CLIN INVEST, V108, P557; Vestweber D, 2012, CURR OPIN HEMATOL, V19, P212, DOI 10.1097/MOH.0b013e3283523e78; Wang J, 2018, CELL TISSUE RES, V371, P531, DOI 10.1007/s00441-017-2785-7; Wilson KF, 2014, AM FAM PHYSICIAN, V89, P882; Zanatta E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225563; Zhao QG, 2020, CANCER RES, V80, P5531, DOI 10.1158/0008-5472.CAN-20-0503; Zhou J, 2017, LAB INVEST, V97, P458, DOI 10.1038/labinvest.2016.141; Zuchtriegel G, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002459; Zuchtriegel G, 2015, ARTERIOSCL THROM VAS, V35, P899, DOI 10.1161/ATVBAHA.114.305143	58	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 17	2021	11								604470	10.3389/fimmu.2020.604470	http://dx.doi.org/10.3389/fimmu.2020.604470			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QQ1TE	33679695	gold, Green Published			2022-12-18	WOS:000624308700001
J	Kovalenko, EI; Zvyagin, IV; Streltsova, MA; Mikelov, AI; Erokhina, SA; Telford, WG; Sapozhnikov, AM; Lebedev, YB				Kovalenko, Elena I.; Zvyagin, Ivan V.; Streltsova, Maria A.; Mikelov, Artem I.; Erokhina, Sofya A.; Telford, William G.; Sapozhnikov, Alexander M.; Lebedev, Yury B.			Surface NKG2C Identifies Differentiated alpha beta T-Cell Clones Expanded in Peripheral Blood	FRONTIERS IN IMMUNOLOGY			English	Article						TCR repertoire; NKT-like cells; NKG2C; T cell differentiation; cytomegalovirus infection		T cells that express CD56 in peripheral blood of healthy humans represent a heterogeneous and poorly studied subset. In this work, we analyzed this subset for NKG2C expression. In both CD56(+) and CD56(-) subsets most of the NKG2C(+) T cells had a phenotype of highly differentiated CD8(+) TEMRA cells. The CD56(+)NKG2C(+) T cells also expressed a number of NK cell receptors, such as NKG2D, CD16, KIR2DL2/DL3, and maturation marker CD57 more often than the CD56(-)NKG2C(+)CD3(+) cells. TCR beta-chain repertoire of the CD3(+)CD56(+)NKG2C(+) cell fraction was limited by the prevalence of one or several clonotypes which can be found within the most abundant clonotypes in total or CD8(+) T cell fraction TCR beta repertoire. Thus, NKG2C expression in highly differentiated CD56(+) T cells was associated with the most expanded alpha beta T cell clones. NKG2C(+) T cells produced almost no IFN-gamma in response to stimulation with HCMV pp65-derived peptides. This may be partially due to the high content of CD45RA(+)CD57(+) cells in the fraction. CD3(+)NKG2C(+) cells showed signs of activation, and the frequency of this T-cell subset in HCMV-positive individuals was positively correlated with the frequency of NKG2C(+) NK cells that may imply a coordinated in a certain extent development of the NKG2C(+) T and NK cell subsets under HCMV infection.	[Kovalenko, Elena I.; Streltsova, Maria A.; Erokhina, Sofya A.; Sapozhnikov, Alexander M.] Shemyakin Ovchinnikov Inst Bioorgan Chem, Dept Immunol, Moscow, Russia; [Zvyagin, Ivan V.; Mikelov, Artem I.; Lebedev, Yury B.] Shemyakin Ovchinnikov Inst Bioorgan Chem, Dept Genom Adapt Immun, Moscow, Russia; [Mikelov, Artem I.] Skolkovo Inst Sci & Technol, Ctr Life Sci, Moscow, Russia; [Telford, William G.] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Skolkovo Institute of Science & Technology; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kovalenko, EI (corresponding author), Shemyakin Ovchinnikov Inst Bioorgan Chem, Dept Immunol, Moscow, Russia.	kovalenelen@gmail.com	Куст, Софья/AAQ-1554-2021; Lebedev, Yury B/G-6738-2012; Sapozhnikov, Alexander M/J-8704-2018; Streltsova, Maria/AAG-9220-2020; Kovalenko, Elena/S-2086-2016; Zvyagin, Ivan/H-9554-2014	Lebedev, Yury B/0000-0003-4554-4733; Streltsova, Maria/0000-0002-5403-0753; Kovalenko, Elena/0000-0001-8119-8247; Zvyagin, Ivan/0000-0002-1769-9116; Sapozhnikov, Alexander/0000-0002-4934-677X	Russian Science Foundation [19-15-00439, 20-15-00351]	Russian Science Foundation(Russian Science Foundation (RSF))	This work was supported by Russian Science Foundation. Research conception and design, flow cytometry, cell sorting, correlation analysis and functional studies were supported by grant #19-15-00439. Sequencing, reconstruction and analysis of TCR repertoires were supported by grant #20-15-00351.	Al Omar SY, 2012, INT IMMUNOL, V24, P409, DOI 10.1093/intimm/dxr122; Almehmadi M, 2014, IMMUNOLOGY, V142, P258, DOI 10.1111/imm.12250; Anfossi N, 2001, IMMUNOL REV, V181, P269, DOI 10.1034/j.1600-065X.2001.1810123.x; Arlettaz L, 2004, EUR J IMMUNOL, V34, P3456, DOI 10.1002/eji.200425210; Bagaev DV, 2020, NUCLEIC ACIDS RES, V48, pD1057, DOI 10.1093/nar/gkz874; Bayard C, 2016, EUR J IMMUNOL, V46, P1168, DOI 10.1002/eji.201546179; Bengner M, 2014, AGE, V36, P571, DOI 10.1007/s11357-013-9587-y; Bergstrom I, 2012, ATHEROSCLEROSIS, V224, P515, DOI 10.1016/j.atherosclerosis.2012.07.033; Bezman NA, 2012, NAT IMMUNOL, V13, P1000, DOI 10.1038/ni.2395; Bigley AB, 2016, CELL IMMUNOL, V300, P26, DOI 10.1016/j.cellimm.2015.11.005; Bjorkstrom NK, 2012, BLOOD, V120, P3455, DOI 10.1182/blood-2012-03-416867; Bolotin DA, 2013, NAT METHODS, V10, P813, DOI [10.1038/nmeth.2555, 10.1038/NMETH.2555]; Bronstein-Sitton N, 2003, NAT IMMUNOL, V4, P957, DOI 10.1038/ni975; Chan WK, 2013, J IMMUNOL, V191, P1625, DOI 10.4049/jimmunol.1300111; Correia MP, 2011, IMMUNOBIOLOGY, V216, P604, DOI 10.1016/j.imbio.2010.09.012; Eugene J, 2020, MODERN PATHOL, V33, P468, DOI 10.1038/s41379-019-0322-9; Fann M, 2005, IMMUNOL REV, V205, P190, DOI 10.1111/j.0105-2896.2005.00262.x; Franceschetti M, 2009, EXP HEMATOL, V37, P616, DOI 10.1016/j.exphem.2009.01.010; Fu GF, 2012, INT IMMUNOL, V24, P197, DOI 10.1093/intimm/dxr124; Godfrey DI, 2019, NAT IMMUNOL, V20, P1110, DOI 10.1038/s41590-019-0444-8; Godfrey DI, 2004, NAT REV IMMUNOL, V4, P231, DOI 10.1038/nri1309; Guma M, 2005, EUR J IMMUNOL, V35, P2071, DOI 10.1002/eji.200425843; Guma M, 2004, BLOOD, V104, P3664, DOI 10.1182/blood-2004-05-2058; Guo C, 2016, SCI REP-UK, V6, DOI 10.1038/srep25567; Hammer Q, 2018, NAT IMMUNOL, V19, P453, DOI 10.1038/s41590-018-0082-6; Heath J, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/7470124; Huard B, 2000, EUR J IMMUNOL, V30, P1665, DOI 10.1002/1521-4141(200006)30:6<1665::AID-IMMU1665>3.0.CO;2-2; Huard B, 2000, NATURE, V403, P325, DOI 10.1038/35002105; Jouand N, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007041; Kanevskiy L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215496; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; Karrer U, 2003, J IMMUNOL, V170, P2022, DOI 10.4049/jimmunol.170.4.2022; Kovalenko Elena I, 2017, Curr Protoc Cytom, V79, DOI 10.1002/cpcy.13; Krakauer T, 2013, TOXINS, V5, P1629, DOI 10.3390/toxins5091629; Lachmann R, 2012, J VIROL, V86, P1001, DOI 10.1128/JVI.00873-11; Lauterbach N, 2015, HUM IMMUNOL, V76, P578, DOI 10.1016/j.humimm.2015.09.003; Le Drean E, 1998, EUR J IMMUNOL, V28, P264, DOI 10.1002/(SICI)1521-4141(199801)28:01<264::AID-IMMU264>3.0.CO;2-O; Lemster BH, 2008, J IMMUNOL, V180, P1979, DOI 10.4049/jimmunol.180.3.1979; Llano M, 1998, EUR J IMMUNOL, V28, P2854, DOI 10.1002/(SICI)1521-4141(199809)28:09<2854::AID-IMMU2854>3.0.CO;2-W; Llewelyn M, 2006, INT IMMUNOL, V18, P1433, DOI 10.1093/intimm/dxl076; Marshall NB, 2017, J IMMUNOL, V198, P1142, DOI 10.4049/jimmunol.1601297; Mazzarino P, 2005, EUR J IMMUNOL, V35, P3240, DOI 10.1002/eji.200535343; Michel JJ, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00530; Mingari MC, 1996, P NATL ACAD SCI USA, V93, P12433, DOI 10.1073/pnas.93.22.12433; Nazarov VI, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0613-1; O'Hara GA, 2012, TRENDS IMMUNOL, V33, P84, DOI 10.1016/j.it.2011.11.005; Omilusik KD, 2019, CURR OPIN IMMUNOL, V58, P89, DOI 10.1016/j.coi.2019.04.009; ORTALDO JR, 1991, CELL IMMUNOL, V136, P486, DOI 10.1016/0008-8749(91)90369-M; Peralbo E, 2007, EXP GERONTOL, V42, P703, DOI 10.1016/j.exger.2007.05.002; Pietra G, 2003, P NATL ACAD SCI USA, V100, P10896, DOI 10.1073/pnas.1834449100; Pietra G, 2001, EUR J IMMUNOL, V31, P3687, DOI 10.1002/1521-4141(200112)31:12<3687::AID-IMMU3687>3.0.CO;2-C; Pittet MJ, 2000, J IMMUNOL, V164, P1148, DOI 10.4049/jimmunol.164.3.1148; Remmerswaal EBM, 2015, J VIROL, V89, P568, DOI 10.1128/JVI.02003-14; Rolle A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02410; Rolle A, 2014, J CLIN INVEST, V124, P5305, DOI 10.1172/JCI77440; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Schlums H, 2015, IMMUNITY, V42, P443, DOI 10.1016/j.immuni.2015.02.008; Shugay M, 2014, NAT METHODS, V11, P653, DOI [10.1038/nmeth.2960, 10.1038/NMETH.2960]; Slezak SL, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-17; Speiser DE, 1999, EUR J IMMUNOL, V29, P1990, DOI 10.1002/(SICI)1521-4141(199906)29:06<1990::AID-IMMU1990>3.3.CO;2-0; Srivastava R, 2008, J VIRAL HEPATITIS, V15, P910, DOI 10.1111/j.1365-2893.2008.01036.x; Streltsova MA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020443; Sullivan LC, 2017, J BIOL CHEM, V292, P21149, DOI 10.1074/jbc.M117.807719; Sullivan LC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135972; Sycheva AL, 2018, VACCINE, V36, P1599, DOI 10.1016/j.vaccine.2018.02.027; Takata H, 2006, J IMMUNOL, V177, P4330, DOI 10.4049/jimmunol.177.7.4330; Tomasec P, 2000, SCIENCE, V287, P1031, DOI 10.1126/science.287.5455.1031; van Montfoort N, 2018, CELL, V175, P1744, DOI 10.1016/j.cell.2018.10.028; Wang ECY, 2002, P NATL ACAD SCI USA, V99, P7570, DOI 10.1073/pnas.112680099; Watanabe H, 2003, PARASITOL INT, V52, P61, DOI 10.1016/S1383-5769(02)00085-5; Welten SPM, 2018, IMMUNOL REV, V283, P161, DOI 10.1111/imr.12649; Wikby A, 2002, EXP GERONTOL, V37, P445, DOI 10.1016/S0531-5565(01)00212-1; Wong EB, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0442-2; Ziegler S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06238-4; Zvyagin IV, 2017, LEUKEMIA, V31, P1145, DOI 10.1038/leu.2016.321	75	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 16	2021	11								613882	10.3389/fimmu.2020.613882	http://dx.doi.org/10.3389/fimmu.2020.613882			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QP8AS	33664730	gold, Green Published			2022-12-18	WOS:000624054100001
J	Barros, M; Teixeira, D; Vilanova, M; Correia, A; Teixeira, N; Borges, M				Barros, Mariana; Teixeira, Daniela; Vilanova, Manuel; Correia, Alexandra; Teixeira, Natercia; Borges, Margarida			Vaccines in Congenital Toxoplasmosis: Advances and Perspectives	FRONTIERS IN IMMUNOLOGY			English	Review						pregnancy; toxoplasmosis; congenital; vaccination; maternal-fetal		Congenital toxoplasmosis has a high impact on human disease worldwide, inducing serious consequences from fetus to adulthood. Despite this, there are currently no human vaccines available to prevent this infection. Most vaccination studies against Toxoplasma gondii infection used animal models in which the infection was established by exogenous inoculation. Here, we review recent research on potential T. gondii vaccines using animal models in which infection was congenitally established. Endeavors in this field have so far revealed that live or subunit vaccines previously found to confer protection against extrinsically established infections can also protect, at least partially, from vertically transmitted infection. Nevertheless, there is no consensus on the more adequate immune response to protect the host and the fetus in congenital infection. Most of the vaccination studies rely on the assessment of maternal systemic immune responses, quantification of parasitic loads in the fetuses, and survival indexes and/or brain parasitic burden in the neonates. More research must be carried out not only to explore new vaccines but also to further study the nature of the elicited immune protection at the maternal-fetal interface. Particularly, the cellular and molecular effector mechanisms at the maternal-fetal interface induced by immunization remain poorly characterized. Deeper knowledge on the immune response at this specific location will certainly help to refine the vaccine-induced immunity and, consequently, to provide the most effective and safest protection against T. gondii vertical infection.	[Barros, Mariana; Teixeira, Daniela] Univ Porto, Fac Farm, Dept Ciencias Biol, Porto, Portugal; [Vilanova, Manuel; Correia, Alexandra] Univ Porto, Immunobiol Grp, Inst Invest Inovacao Saud I3S, Porto, Portugal; [Vilanova, Manuel; Correia, Alexandra] Univ Porto, Inst Biol Mol & Celular IBMC, Porto, Portugal; [Vilanova, Manuel; Correia, Alexandra] Univ Porto, Dept Imuno Fisiol & Farmacol, Inst Ciencias Biomed Abel Salazar ICBAS, Porto, Portugal; [Teixeira, Natercia; Borges, Margarida] Univ Porto, Fac Farm, Appl Mol Biosci Unit Rede Quim & Tecnol UCIBIO RE, Dept Ciencias Biol, Porto, Portugal	Universidade do Porto; Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto; Universidade do Porto; Universidade do Porto	Borges, M (corresponding author), Univ Porto, Fac Farm, Appl Mol Biosci Unit Rede Quim & Tecnol UCIBIO RE, Dept Ciencias Biol, Porto, Portugal.	mborges@ff.up.pt	Correia, Alexandra/AID-6313-2022; teixeira, daniela/GSN-7611-2022; Barros, Mariana/GSJ-4118-2022; Vilanova, Manuel/D-2127-2013; borges, margarida/GWR-0803-2022; Borges, Margarida/E-9021-2013	Correia, Alexandra/0000-0003-0408-6262; Vilanova, Manuel/0000-0001-7007-306X; Borges, Margarida/0000-0001-6035-4095	Applied Molecular Biosciences Unit-UCIBIO - national funds from FCT [UIDP/04378/2020, UIDB/04378/2020]; FCT Individual CEEC 2017 Assistant Researcher Grant [352 CEECIND/01514/2017]	Applied Molecular Biosciences Unit-UCIBIO - national funds from FCT; FCT Individual CEEC 2017 Assistant Researcher Grant	This work was supported by the Applied Molecular Biosciences Unit-UCIBIO, which is financed by national funds from FCT (UIDP/04378/2020 and UIDB/04378/2020). AC was supported by FCT Individual CEEC 2017 Assistant Researcher Grant 352 CEECIND/01514/2017.	Beauvillain C, 2009, VACCINE, V27, P1750, DOI 10.1016/j.vaccine.2009.01.022; Biemans R, 1998, J BIOTECHNOL, V66, P137, DOI 10.1016/S0168-1656(98)00143-6; Borges M, 2019, PARASITE IMMUNOL, V41, DOI 10.1111/pim.12606; Brito C, 2020, PARASITE IMMUNOL, V42, DOI 10.1111/pim.12690; Coakley G, 2015, TRENDS PARASITOL, V31, P477, DOI 10.1016/j.pt.2015.06.009; Couper KN, 2003, VACCINE, V21, P2813, DOI 10.1016/S0264-410X(03)00163-4; Coutinho LB, 2012, INT J PARASITOL, V42, P341, DOI 10.1016/j.ijpara.2012.01.006; Dauby N, 2012, LANCET INFECT DIS, V12, P330, DOI 10.1016/S1473-3099(11)70341-3; Dimier-Poisson I, 2015, BIOMATERIALS, V50, P164, DOI 10.1016/j.biomaterials.2015.01.056; dos Santos TR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165124; Ducournau C, 2017, FUTURE MICROBIOL, V12, P393, DOI 10.2217/fmb-2016-0146; Dunay IR, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00057-17; Elbez-Rubinstein A, 2009, J INFECT DIS, V199, P280, DOI 10.1086/595793; Fisch D, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008097; Flegr J, 2016, PARASITOLOGY, V143, P1974, DOI 10.1017/S0031182016001785; Fonseca BM, 2012, REPROD BIOL, V12, P97, DOI 10.1016/S1642-431X(12)60080-1; Freyre A, 2008, EXP PARASITOL, V120, P142, DOI 10.1016/j.exppara.2008.06.007; Freyre A, 2006, EXP PARASITOL, V112, P8, DOI 10.1016/j.exppara.2005.08.009; Freyre A, 2012, VET PARASITOL, V183, P359, DOI 10.1016/j.vetpar.2011.07.039; Haumont M, 2000, INFECT IMMUN, V68, P4948, DOI 10.1128/IAI.68.9.4948-4953.2000; Innes EA, 2019, FOOD WATERB PARASIT, V15, DOI 10.1016/j.fawpar.2019.e00053; Ismael AB, 2006, J INFECT DIS, V194, P1176, DOI 10.1086/507706; Letscher-Bru V, 2003, INFECT IMMUN, V71, P6615, DOI 10.1128/IAI.71.11.6615-6619.2003; Li YW, 2018, EXPERT OPIN BIOL TH, V18, P273, DOI 10.1080/14712598.2018.1413086; Liang QL, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8030352; Loh FK, 2019, VACCINE, V37, P3989, DOI 10.1016/j.vaccine.2019.05.083; McAuley JB, 2014, J PEDIAT INF DIS SOC, V3, pS30, DOI 10.1093/jpids/piu077; Melchor SJ, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00185; Menzies FM, 2008, IMMUNOL LETT, V115, P83, DOI 10.1016/j.imlet.2007.10.009; Mevelec MN, 2010, VET RES, V41, DOI 10.1051/vetres/2010021; Mevelec MN, 2005, VACCINE, V23, P4489, DOI 10.1016/j.vaccine.2005.04.025; Moroda M, 2017, INFECT IMMUN, V85, DOI [10.1128/IAI.00399-17, 10.1128/iai.00399-17]; Munoz M, 2011, IMMUNOL REV, V240, P269, DOI 10.1111/j.1600-065X.2010.00992.x; Nayeri T, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008103; Pittman KJ, 2015, MICROBIOL MOL BIOL R, V79, P387, DOI 10.1128/MMBR.00027-15; ROBERTS CW, 1994, VACCINE, V12, P1389, DOI 10.1016/0264-410X(94)90147-3; Sasai M, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0353-9; Sasai M, 2018, INT IMMUNOL, V30, P113, DOI 10.1093/intimm/dxy004; Sutterland AL, 2015, ACTA PSYCHIAT SCAND, V132, P161, DOI 10.1111/acps.12423; Suzuki Y, 1995, J PARASITOL, V81, P1032, DOI 10.2307/3284069; Torgerson PR, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001920; Torgerson PR, 2013, B WORLD HEALTH ORGAN, V91, P501, DOI 10.2471/BLT.12.111732; Wang JL, 2020, J IMMUNOL, V204, P1562, DOI 10.4049/jimmunol.1900410; Wang JL, 2019, TRENDS PARASITOL, V35, P239, DOI 10.1016/j.pt.2019.01.005; Wang JL, 2018, J INFECT DIS, V218, P768, DOI 10.1093/infdis/jiy211; Wang JL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00730; Wang WJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02025; Zhang NZ, 2013, EXPERT REV VACCINES, V12, P1287, DOI 10.1586/14760584.2013.844652	48	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 15	2021	11								621997	10.3389/fimmu.2020.621997	http://dx.doi.org/10.3389/fimmu.2020.621997			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QO5TK	33658997	Green Published, gold			2022-12-18	WOS:000623204400001
J	Badolato-Correa, J; Carvalho, FR; Paiva, IA; Familiar-Macedo, D; Dias, HG; Pauvolid-Correa, A; Fernandes-Santos, C; Lima, MDQ; Gandini, M; Silva, AA; Cavalcanti, SMB; de Oliveira, SA; Vianna, RAD; de Azeredo, EL; Cardoso, CAA; Grifoni, A; Sette, A; Weiskopf, D; de-Oliveira-Pinto, LM				Badolato-Correa, Jessica; Carvalho, Fabiana Rabe; Paiva, Iury Amancio; Familiar-Macedo, Debora; Dias, Helver Goncalves; Pauvolid-Correa, Alex; Fernandes-Santos, Caroline; Queiroz Lima, Monique da Rocha; Gandini, Mariana; Silva, Andrea Alice; Baeta Cavalcanti, Silvia Maria; de Oliveira, Solange Artimos; de Oliveira Vianna, Renata Artimos; de Azeredo, Elzinandes Leal; Cardoso, Claudete Aparecida Araujo; Grifoni, Alba; Sette, Alessandro; Weiskopf, Daniela; de-Oliveira-Pinto, Luzia Maria			Differential Longevity of Memory CD4 and CD8 T Cells in a Cohort of the Mothers With a History of ZIKV Infection and Their Children	FRONTIERS IN IMMUNOLOGY			English	Article						Zika; T cells; memory; pregnancy; congenital Zika syndrome (CZS)	VIRUS-INFECTION; SEXUAL TRANSMISSION; CROSS-REACTIVITY; ANTIBODIES; EPITOPES; IMMUNODOMINANT; PREGNANCY; RESPONSES; EXPOSURE; INNATE	Background: Zika virus (ZIKV) infection causes for mild and self-limiting disease in healthy adults. In newborns, it can occasionally lead to a spectrum of malformations, the congenital Zika syndrome (CZS). Thus, little is known if mothers and babies with a history of ZIKV infection were able to develop long-lasting T-cell immunity. To these issues, we measure the prevalence of ZIKV T-cell immunity in a cohort of mothers infected to the ZIKV during pregnancy in the 2016-2017 Zika outbreak, who gave birth to infants affected by neurological complications or asymptomatic ones. Results: Twenty-one mothers and 18 children were tested for IFN-gamma ELISpot and T-cell responses for flow cytometry assays in response to CD4 ZIKV and CD8 ZIKV megapools (CD4 ZIKV MP and CD8 ZIKV MP). IFN-gamma ELISpot responses to ZIKV MPs showed an increased CD4 and CD8 T-cell responses in mothers compared to children. The degranulation activity and IFN-gamma-producing CD4 T cells were detected in most mothers, and children, while in CD8 T-cells, low responses were detected in these study groups. The total Temra T cell subset is enriched for IFN-gamma+ CD4 T cells after stimulation of CD4 ZIKV MP. Conclusion: Donors with a history of ZIKV infection demonstrated long-term CD4 T cell immunity to ZIKV CD4 MP. However, the same was not observed in CD8 T cells with the ZIKV CD8 MP. One possibility is that the cytotoxic and pro-inflammatory activities of CD8 T cells are markedly demonstrated in the early stages of infection, but less detected in the disease resolution phase, when the virus has already been eliminated. The responses of mothers' T cells to ZIKV MPs do not appear to be related to their children's clinical outcome. There was also no marked difference in the T cell responses to ZIKV MP between children affected or not with CZS. These data still need to be investigated, including the evaluation of the response of CD8 T cells to other ZIKV peptides.	[Badolato-Correa, Jessica; Paiva, Iury Amancio; Familiar-Macedo, Debora; Dias, Helver Goncalves; Fernandes-Santos, Caroline; Queiroz Lima, Monique da Rocha; de Azeredo, Elzinandes Leal; de-Oliveira-Pinto, Luzia Maria] Fundacao Oswaldo Cruz, Lab Viral Immunol, Rio De Janeiro, Brazil; [Carvalho, Fabiana Rabe; Silva, Andrea Alice; Cardoso, Claudete Aparecida Araujo] Univ Fed Fluminense, Sch Med, Multiuser Lab Res Nephrol & Med Sci, Niteroi, RJ, Brazil; [Pauvolid-Correa, Alex] Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX USA; [Pauvolid-Correa, Alex] Fiocruz MS, Lab Resp Viruses & Measles, Rio De Janeiro, Brazil; [Gandini, Mariana] Fundacao Oswaldo Cruz, Lab Cellular Microbiol, Rio De Janeiro, Brazil; [Baeta Cavalcanti, Silvia Maria] Univ Fed Fluminense, Biomed Inst, Lab Virol Diag, Niteroi, RJ, Brazil; [de Oliveira, Solange Artimos; de Oliveira Vianna, Renata Artimos; Cardoso, Claudete Aparecida Araujo] Univ Fed Fluminense, Sch Med, Dept Maternal & Child, Niteroi, RJ, Brazil; [Grifoni, Alba; Sette, Alessandro; Weiskopf, Daniela] La Jolla Inst Immunol LJI, Ctr Infect Dis & Vaccine Res, San Diego, CA USA; [Sette, Alessandro] Univ Calif San Diego, Dept Med, Div Infect Dis & Global Publ Hlth, San Diego, CA 92103 USA	Fundacao Oswaldo Cruz; Universidade Federal Fluminense; Texas A&M University System; Texas A&M University College Station; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Universidade Federal Fluminense; Universidade Federal Fluminense; La Jolla Institute for Immunology; University of California System; University of California San Diego	de-Oliveira-Pinto, LM (corresponding author), Fundacao Oswaldo Cruz, Lab Viral Immunol, Rio De Janeiro, Brazil.	lpinto@ioc.fiocruz.br	Carvalho, Fabiana/ABA-2594-2021; Silva, Andrea Alice/J-6729-2012; Pauvolid-Corrêa, Alex/D-3643-2017; Gandini, Mariana/AAZ-6964-2021; Pauvolid-Correa, Alex/AGF-6881-2022; Grifoni, Alba/AAS-7620-2021; Sette, Alessandro/AFO-8916-2022; de-Oliveira-Pinto, Luzia/AAX-6421-2021	Silva, Andrea Alice/0000-0001-5856-6128; Pauvolid-Corrêa, Alex/0000-0002-6924-157X; Pauvolid-Correa, Alex/0000-0002-6924-157X; Grifoni, Alba/0000-0002-2209-5966; Dias, Helver/0000-0001-5181-7078; Familiar-Macedo, Debora/0000-0002-9229-5912; Gandini, Mariana/0000-0003-3603-6921; Fernandes-Santos, Caroline/0000-0002-4984-1287	CNPq; CAPES; IOC/Fiocruz; National Institutes of Health [75N9301900065]; Coordination for the Improvement of Higher Education Personnel (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -CAPES) [001]	CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); IOC/Fiocruz; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Coordination for the Improvement of Higher Education Personnel (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	JB-C, FRC, IAP, DF-M, HGD, and CF-S are recipient of doctoral fellowship from Brazilian research institutions CNPq, CAPES and IOC/Fiocruz. This work was funded by the National Institutes of Health contract Nr. 75N9301900065 (AS and DW). This study was financed in part by the Coordination for the Improvement of Higher Education Personnel (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -CAPES) -Finance Code 001. We thank children and their families that participated in the study, the Multi-function Laboratory to support research in Nephrology and Medical Sciences/LAMAP, the Clinical Research Unit/UPC, Zika Collaborative Group, and Dr. Remberto Mauricio de la Cruz Vargas Vilte for his valuable and stimulating scientific discussions. We also thank the Laboratorio de Flavivirus (LabFLA) of Fiocruz, which provided reference viruses fromtheir arbovirus stocks.	Angelo MA, 2017, J VIROL, V91, DOI 10.1128/JVI.02147-16; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Brady OJ, 2019, LANCET, V394, P1991, DOI 10.1016/S0140-6736(19)32790-4; Brady OJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001760; Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412; Brazil . Ministry of Health of Brazil . Health Surveillance Department, 2017, ZIKA VIRUS BRAZIL SU; Brown JA, 2019, IMMUNITY, V50, P751, DOI 10.1016/j.immuni.2019.01.005; Camargos VN, 2019, EBIOMEDICINE, V44, P516, DOI 10.1016/j.ebiom.2019.05.014; Costa F, 2016, ANN INTERN MED, V164, P689, DOI 10.7326/M16-0332; Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296; D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449; de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8; Vianna RAD, 2019, J TROP PEDIATRICS, V65, P592, DOI 10.1093/tropej/fmz019; de Oliveira WK, 2016, MMWR-MORBID MORTAL W, V65; Dhanda SK, 2018, IMMUNOLOGY, V155, P331, DOI 10.1111/imm.12984; Dhanda SK, 2019, NUCLEIC ACIDS RES, V47, pW502, DOI 10.1093/nar/gkz452; Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297; Franca GVA, 2016, LANCET, V388, P891, DOI 10.1016/S0140-6736(16)30902-3; Freour T, 2016, EUROSURVEILLANCE, V21, P10, DOI 10.2807/1560-7917.ES.2016.21.23.30254; Govero J, 2016, NATURE, V540, P438, DOI 10.1038/nature20556; Grifoni A, 2020, J VIROL, V94, DOI 10.1128/JVI.00089-20; Grifoni A, 2020, IMMUNOLOGY, V160, P3, DOI 10.1111/imm.13161; Grifoni A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01568; Grifoni A, 2018, J IMMUNOL, V201, P3487, DOI 10.4049/jimmunol.1801090; Grifoni A, 2017, J VIROL, V91, DOI [10.1128/JVI.01469-17, 10.1128/jvi.01469-17]; Halai UA, 2017, CLIN INFECT DIS, V65, P877, DOI 10.1093/cid/cix472; Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15; Huang HR, 2017, J VIROL, V91, DOI [10.1128/JVI.00900-17, 10.1128/jvi.00900-17]; Jurado KA, 2018, NAT MICROBIOL, V3, P141, DOI 10.1038/s41564-017-0060-z; Koblischke M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01196; Lai LL, 2018, CLIN INFECT DIS, V66, P1, DOI 10.1093/cid/cix732; Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287; Lima GP, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3908-4; Ma WQ, 2017, CELL, V168, P542, DOI 10.1016/j.cell.2017.01.009; Macedo-da-Silva J, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.577819; Manangeeswaran M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006004; Messina JP, 2016, ELIFE, V5, DOI 10.7554/eLife.15272; Miagostovich MP, 1999, J CLIN VIROL, V14, P183, DOI 10.1016/S1386-6532(99)00059-1; Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008; Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651; Ngono AE, 2018, ANNU REV IMMUNOL, V36, P279, DOI 10.1146/annurev-immunol-042617-053142; Ngono AE, 2017, CELL HOST MICROBE, V21, P35, DOI 10.1016/j.chom.2016.12.010; Pardy RD, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080820; Pardy RD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006184; Patil VS, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aan8664; Paul Sinu, 2016, Curr Protoc Immunol, V114, DOI 10.1002/cpim.12; Paul S, 2015, J IMMUNOL METHODS, V422, P28, DOI 10.1016/j.jim.2015.03.022; Paul S, 2013, J IMMUNOL, V191, P5831, DOI 10.4049/jimmunol.1302101; Pauvolid-Correa A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11121164; Perkins TA, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.126, 10.1038/nmicrobiol.2016.126]; Racicot K, 2017, J CLIN INVEST, V127, P1591, DOI 10.1172/JCI87490; Rathore APS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav3208; Regla-Nava JA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05458-0; Reynolds CJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18781-1; Ribeiro MRC, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12111244; Ricciardi MJ, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006000; Robbiani DF, 2019, J EXP MED, V216, P2302, DOI 10.1084/jem.20191061; Roehrig JT, 2008, VIRAL IMMUNOL, V21, P123, DOI 10.1089/vim.2008.0007; RUSSELL PK, 1967, J IMMUNOL, V99, P285; Secretaria Estadual de Saude do Rio de Janeiro, 2016, B EPIDEMIOLOGICO; Steinhagen K, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.50.30426; Sulleiro E, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015532; Tang WW, 2016, CELL REP, V17, P3091, DOI 10.1016/j.celrep.2016.11.070; Tian Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01728-5; Tonnerre P, 2020, NAT MICROBIOL, V5, P76, DOI 10.1038/s41564-019-0618-z; Venturi G, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.8.30148; Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112; Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110; Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36; Xu Xiaojun, 2016, PLoS Curr, V8, DOI 10.1371/currents.outbreaks.9aa2e1fb61b0f632f58a098773008c4b; Yockey LJ, 2016, CELL, V166, P1247, DOI 10.1016/j.cell.2016.08.004; Zimmerman MG, 2020, CELL HOST MICROBE, V27, P14, DOI 10.1016/j.chom.2019.12.003	72	1	1	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 12	2021	12								610456	10.3389/fimmu.2021.610456	http://dx.doi.org/10.3389/fimmu.2021.610456			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QM2NO	33679748	gold, Green Published			2022-12-18	WOS:000621618100001
J	Breville, G; Zamberg, I; Sadallah, S; Stephan, C; Ponte, B; Seebach, JD				Breville, Gautier; Zamberg, Ido; Sadallah, Salima; Stephan, Caroline; Ponte, Belen; Seebach, Jorg D.			Case Report: Severe Complement-Mediated Thrombotic Microangiopathy in IgG4-Related Disease Secondary to Anti-Factor H IgG4 Autoantibodies	FRONTIERS IN IMMUNOLOGY			English	Article						thrombotic microangiopathy; atypical hemolytic uremic syndrome; IgG4-related disease; antibodies; complement factor H-related protein; complement factor H; anti-factor H auto-antibodies; SARS CoV2		Objective To first describe and estimate the potential pathogenic role of Ig4 autoantibodies in complement-mediated thrombotic microangiopathy (TMA) in a patient with IgG4-related disease (IgG4-RD). Methods This study is a case report presenting a retrospective review of the patient's medical chart. Plasma complement C3 and C4 levels, immunoglobulin isotypes and subclasses were determined by nephelometry, the complement pathways' activity (CH50, AP50, MBL) using WIESLAB(R) Complement System assays. Human complement factor H levels, anti-complement factor H auto-antibodies were analyzed by ELISA, using HRP-labeled secondary antibodies specific for human IgG, IgG4, and IgA, respectively. Genetic analyses were performed by exome sequencing of 14 gens implicated in complement disorders, as well as multiplex ligation-dependent probe amplification looking specifically for CFH, CFHR1-2-3, and 5. Results Our brief report presents the first case of IgG4-RD with complement-mediated TMA originating from both pathogenic CFHR 1 and CFHR 4 genes deletions, and inhibitory anti-complement factor H autoantibodies of the IgG4 subclass. Remission was achieved with plasmaphereses, corticosteroids, and cyclophosphamide. Following remission, the patient was diagnosed with lymphocytic meningitis and SARS-CoV-2 pneumonia with an uneventful recovery. Conclusion IgG4-RD can be associated with pathogenic IgG4 autoantibodies. Genetic predisposition such as CFHR1 and CFHR4 gene deletions enhance the susceptibility to the formation of inhibitory anti-Factor H IgG4 antibodies.	[Breville, Gautier; Seebach, Jorg D.] Geneva Univ Hosp, Div Immunol & Allergy, Dept Med, Geneva, Switzerland; [Breville, Gautier] Geneva Univ Hosp, Div Neurol, Dept Clin Neurosci, Geneva, Switzerland; [Zamberg, Ido] Geneva Univ Hosp, Dept Med, Div Gen Internal Med, Geneva, Switzerland; [Zamberg, Ido] Geneva Univ Hosp, Div Anaesthesiol Clin Pharmacol Intens Care & Eme, Dept Anaesthesiol, Geneva, Switzerland; [Sadallah, Salima] CHU Vaudois, Dept Med Lab & Pathol, Serv Immunol & Allergie, Lausanne, Switzerland; [Stephan, Caroline] Geneva Univ Hosp, Dept Med, Immunohematol Unit, Geneva, Switzerland; [Ponte, Belen] Geneva Univ Hosp, Div Nephrol, Dept Med, Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; University of Geneva	Breville, G (corresponding author), Geneva Univ Hosp, Div Immunol & Allergy, Dept Med, Geneva, Switzerland.; Breville, G (corresponding author), Geneva Univ Hosp, Div Neurol, Dept Clin Neurosci, Geneva, Switzerland.	gautier.breville@hcuge.ch	Breville, Gautier/AAG-5878-2020; Zamberg, Ido/AAF-8939-2019	Breville, Gautier/0000-0003-0890-1981; Zamberg, Ido/0000-0003-4534-4635				Bledsoe JR, 2018, APMIS, V126, P459, DOI 10.1111/apm.12845; Brocklebank V, 2018, CLIN J AM SOC NEPHRO, V13, P300, DOI 10.2215/CJN.00620117; Dragon Durey MA, 2016, NAT REV NEPHROL, V12, P563, DOI 10.1038/nrneph.2016.99; Fakhouri F, 2017, LANCET, V390, P681, DOI 10.1016/S0140-6736(17)30062-4; Ferrari S, 2009, J THROMB HAEMOST, V7, P1703, DOI 10.1111/j.1538-7836.2009.03568.x; Gavriilaki E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00337; George JN, 2014, NEW ENGL J MED, V371, P654, DOI 10.1056/NEJMra1312353; Guo WY, 2019, PEDIATR NEPHROL, V34, P269, DOI 10.1007/s00467-018-4074-4; Hao MJ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003785; Jacobs JFM, 2014, AM J CLIN PATHOL, V142, P76, DOI 10.1309/AJCP41XCVBHEQCEL; Moore I, 2010, BLOOD, V115, P379, DOI 10.1182/blood-2009-05-221549; Noris M, 2012, NAT REV NEPHROL, V8, P622, DOI 10.1038/nrneph.2012.195; Pieringer H, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0110-z; Rigothier C, 2015, AM J KIDNEY DIS, V66, P331, DOI 10.1053/j.ajkd.2015.03.039; Saeki T, 2011, ARTHRIT CARE RES, V63, P1209, DOI 10.1002/acr.20484; Sinkovits G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01646; Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650; TAO MH, 1993, J EXP MED, V178, P661, DOI 10.1084/jem.178.2.661; Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5; Yoshida Y, 2019, J ATHEROSCLER THROMB, V26, P99, DOI 10.5551/jat.RV17026	20	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2021	11								604759	10.3389/fimmu.2020.604759	http://dx.doi.org/10.3389/fimmu.2020.604759			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QL8SO	33643292	Green Published, gold			2022-12-18	WOS:000621351000001
J	Fleury, S; Boukhatem, I; Le Blanc, J; Welman, M; Lordkipanidze, M				Fleury, Samuel; Boukhatem, Imane; Le Blanc, Jessica; Welman, Melanie; Lordkipanidze, Marie			Tissue-Specificity of Antibodies Raised Against TrkB and p75(NTR) Receptors; Implications for Platelets as Models of Neurodegenerative Diseases	FRONTIERS IN IMMUNOLOGY			English	Article						platelet; neurotrophin receptors; tropomyosin receptor kinase B; brain-derived neurotrophic factor; pan-neurotrophic receptor p75(NTR)		Platelets and neurons share many similarities including comparable secretory granule types with homologous calcium-dependent secretory mechanisms as well as internalization, sequestration and secretion of many neurotransmitters. Thus, platelets present a high potential to be used as peripheral biomarkers to reflect neuronal pathologies. The brain-derived neurotrophic factor (BDNF) acts as a neuronal growth factor involved in learning and memory through the binding of two receptors, the tropomyosin receptor kinase B (TrkB) and the 75 kDa pan-neurotrophic receptor (p75(NTR)). In addition to its expression in the central nervous system, BDNF is found in much greater quantities in blood circulation, where it is largely stored within platelets. Levels 100- to 1,000-fold those of neurons make platelets the most important peripheral reservoir of BDNF. This led us to hypothesize that platelets would express canonical BDNF receptors, i.e., TrkB and p75(NTR), and that the receptors on platelets would bear significant resemblance to the ones found in the brain. However, herein we report discrepancies regarding detection of these receptors using antibody-based assays, with antibodies displaying important tissue-specificity. The currently available antibodies raised against TrkB and p75(NTR) should therefore be used with caution to study platelets as models for neurological disorders. Rigorous characterization of antibodies and bioassays appears critical to understand the interplay between platelet and neuronal biology of BDNF.	[Fleury, Samuel; Boukhatem, Imane; Le Blanc, Jessica; Welman, Melanie; Lordkipanidze, Marie] Montreal Heart Inst, Res Ctr, Montreal, PQ, Canada; [Fleury, Samuel; Boukhatem, Imane; Le Blanc, Jessica; Lordkipanidze, Marie] Univ Montreal, Fac Pharm, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal	Lordkipanidze, M (corresponding author), Montreal Heart Inst, Res Ctr, Montreal, PQ, Canada.; Lordkipanidze, M (corresponding author), Univ Montreal, Fac Pharm, Montreal, PQ, Canada.	marie.lordkipanidze@umontreal.ca	Fleury, Samuel/ABC-8205-2020; Lordkipanidzé, Marie/E-6222-2011	Fleury, Samuel/0000-0002-6764-3700; Lordkipanidzé, Marie/0000-0001-7418-6766	Canadian Institute of Health Research [PJT-159569]; Canada Foundation for Innovation Leaders Opportunity Fund [32797]; Faculte de pharmacie de l'Universite de Montreal; Faculte des etudes superieures et postdoctorales of the Universite de Montreal; Canadian Vascular Network; Fonds de recherche du Quebec en Sante (FRQS) [33048]; Canada Research Chair in Platelets as biomarkers and vectors [950-232706]	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Canada Foundation for Innovation Leaders Opportunity Fund(Canada Foundation for Innovation); Faculte de pharmacie de l'Universite de Montreal; Faculte des etudes superieures et postdoctorales of the Universite de Montreal; Canadian Vascular Network; Fonds de recherche du Quebec en Sante (FRQS); Canada Research Chair in Platelets as biomarkers and vectors	This work was supported by the Canadian Institute of Health Research (PJT-159569), the Canada Foundation for Innovation Leaders Opportunity Fund (32797), and by trainee scholarships from the Faculte de pharmacie de l'Universite de Montreal (SF, IB, and JLB), from the Faculte des etudes superieures et postdoctorales of the Universite de Montreal (SF and IB) and from the Canadian Vascular Network (SF). ML was supported by the Fonds de recherche du Quebec en Sante (FRQS) Junior 1 Research Scholarship (33048); and is a Canada Research Chair in Platelets as biomarkers and vectors (950-232706).	Anastasia A, 2015, J NEUROSCI, V35, P11911, DOI 10.1523/JNEUROSCI.0591-15.2015; Arevalo JC, 2006, CELL MOL LIFE SCI, V63, P1523, DOI 10.1007/s00018-006-6010-1; Barbacid M, 1995, ANN NY ACAD SCI, V766, P442, DOI 10.1111/j.1749-6632.1995.tb26693.x; BARKER PA, 1991, J BIOL CHEM, V266, P19113; BARKER PA, 1994, J BIOL CHEM, V269, P30645; Best MG, 2019, NAT PROTOC, V14, P1206, DOI 10.1038/s41596-019-0139-5; Best MG, 2017, CANCER CELL, V32, P238, DOI 10.1016/j.ccell.2017.07.004; Best MG, 2015, CANCER CELL, V28, P666, DOI 10.1016/j.ccell.2015.09.018; BOULLIN DJ, 1970, BRIT J PHARMACOL, V40, P522, DOI 10.1111/j.1476-5381.1970.tb10634.x; BOULLIN DJ, 1970, BRIT J PHARMACOL, V39, P779, DOI 10.1111/j.1476-5381.1970.tb09904.x; Burnouf T, 2012, TRANSFUSION, V52, P1721, DOI 10.1111/j.1537-2995.2011.03494.x; BUXSER SE, 1983, J CELL BIOCHEM, V22, P219, DOI 10.1002/jcb.240220404; Cabelli RJ, 1996, J NEUROSCI, V16, P7965; Canobbio I, 2019, RES PRACT THROMB HAE, V3, P564, DOI 10.1002/rth2.12254; Cattaneo A, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.214; Chacon-Fernandez P, 2016, J BIOL CHEM, V291, P9872, DOI 10.1074/jbc.M116.720029; EAGER KB, 1991, ONCOGENE, V6, P819; Ehrlich D, 2012, WORLD J PSYCHIATR, V2, P91, DOI 10.5498/wjp.v2.i6.91; Fryer RH, 1996, J COMP NEUROL, V374, P21, DOI 10.1002/(SICI)1096-9861(19961007)374:1<21::AID-CNE2>3.0.CO;2-P; Fujimura H, 2002, THROMB HAEMOSTASIS, V87, P728; Giraud S, 2011, INT J ONCOL, V38, P391, DOI 10.3892/ijo.2010.862; Goubau C, 2014, DEV MED CHILD NEUROL, V56, P724, DOI 10.1111/dmcn.12421; Goubau C, 2013, EUR J PAEDIATR NEURO, V17, P117, DOI 10.1016/j.ejpn.2012.08.005; GROB PM, 1985, J BIOL CHEM, V260, P8044; HANIU M, 1995, ARCH BIOCHEM BIOPHYS, V322, P256, DOI 10.1006/abbi.1995.1460; Jeronimo-Santos A, 2015, CEREB CORTEX, V25, P3107, DOI 10.1093/cercor/bhu105; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; Klein AB, 2011, INT J NEUROPSYCHOPH, V14, P347, DOI 10.1017/S1461145710000738; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; Le Blanc J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.575607; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; Manne BK, 2020, BLOOD, V136, P1317, DOI 10.1182/blood.2020007214; Nykjaer A, 2005, CURR OPIN NEUROBIOL, V15, P49, DOI 10.1016/j.conb.2005.01.004; Ohira K, 1999, DEV BRAIN RES, V112, P21, DOI 10.1016/S0165-3806(98)00151-5; Padmakumar M, 2019, RES PRACT THROMB HAE, V3, P566, DOI 10.1002/rth2.12239; Pletscher A, 1980, J Neural Transm Suppl, P7; PliegoRivero FB, 1997, BIOCHEM PHARMACOL, V54, P207, DOI 10.1016/S0006-2952(97)00073-7; PUMA P, 1983, J BIOL CHEM, V258, P3370; Rainesalo S, 2005, MOL BRAIN RES, V141, P161, DOI 10.1016/j.molbrainres.2005.08.013; Reed GL, 2000, BLOOD, V96, P3334; Reed GL, 2004, SEMIN THROMB HEMOST, V30, P441, DOI 10.1055/s-2004-833479; ROSENFELD RD, 1995, PROTEIN EXPRES PURIF, V6, P465, DOI 10.1006/prep.1995.1062; Stoilov P, 2002, BIOCHEM BIOPH RES CO, V290, P1054, DOI 10.1006/bbrc.2001.6301; Takahashi M, 2000, MOL PSYCHIATR, V5, P293, DOI 10.1038/sj.mp.4000718; Tamura S, 2011, THROMB RES, V128, pE55, DOI 10.1016/j.thromres.2011.06.002; Underwood CK, 2008, INT J BIOCHEM CELL B, V40, P1664, DOI 10.1016/j.biocel.2007.06.010; Unsworth AJ, 2019, THROMB HAEMOSTASIS, V119, P104, DOI 10.1055/s-0038-1676344; Vilar M, 2009, NEURON, V62, P72, DOI 10.1016/j.neuron.2009.02.020; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; Yaar M, 2002, J BIOL CHEM, V277, P7720, DOI 10.1074/jbc.M110929200; YAMAMOTO H, 1990, J NEUROSCI, V10, P3469; Zeng F, 2011, BIOCHEM PHARMACOL, V82, P1500, DOI 10.1016/j.bcp.2011.06.040	53	1	1	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2021	12								606861	10.3389/fimmu.2021.606861	http://dx.doi.org/10.3389/fimmu.2021.606861			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QL8YA	33643311	Green Published, gold			2022-12-18	WOS:000621365300001
J	Foray, AP; Dietrich, C; Pecquet, C; Machavoine, F; Chatenoud, L; Leite-de-Moraes, M				Foray, Anne-Perrine; Dietrich, Celine; Pecquet, Coralie; Machavoine, Francois; Chatenoud, Lucienne; Leite-de-Moraes, Maria			IL-4 and IL-17 Are Required for House Dust Mite-Driven Airway Hyperresponsiveness in Autoimmune Diabetes-Prone Non-Obese Diabetic Mice	FRONTIERS IN IMMUNOLOGY			English	Article						asthma; NOD mice; IL-17; iNKT cells; IL-4; house dust mite; iNKT cells; airway hyperreactivity		Allergic asthma is characterized by airway inflammation with a Th2-type cytokine profile, hyper-IgE production, mucus hypersecretion, and airway hyperreactivity (AHR). It is increasingly recognized that asthma is a heterogeneous disease implicating complex immune mechanisms resulting in distinct endotypes observed in patients. In this study, we showed that non-obese diabetic (NOD) mice, which spontaneously develop autoimmune diabetes, undergo more severe allergic asthma airway inflammation and AHR than pro-Th2 BALB/c mice upon house dust mite (HDM) sensitization and challenge. The use of IL-4-deficient NOD mice and the in vivo neutralization of IL-17 demonstrated that both IL-4 and IL-17 are responsible by the exacerbated airway inflammation and AHR observed in NOD mice. Overall, our findings indicate that autoimmune diabetes-prone NOD mice might become useful as a new HDM-induced asthma model to elucidate allergic dysimmune mechanisms involving Th2 and Th17 responses that could better mimic some asthmatic endoytpes.	[Foray, Anne-Perrine; Dietrich, Celine; Pecquet, Coralie; Machavoine, Francois; Chatenoud, Lucienne; Leite-de-Moraes, Maria] Univ Paris, Paris, France; [Foray, Anne-Perrine; Dietrich, Celine; Pecquet, Coralie; Machavoine, Francois; Chatenoud, Lucienne; Leite-de-Moraes, Maria] CNRS, INEM Inst Necker Enfants Malad, Lab Immunoregulat & Immunopathol, UMR8253, Paris, France; [Foray, Anne-Perrine; Dietrich, Celine; Pecquet, Coralie; Machavoine, Francois; Chatenoud, Lucienne; Leite-de-Moraes, Maria] INSERM, UMR1151, Paris, France	UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Leite-de-Moraes, M (corresponding author), Univ Paris, Paris, France.; Leite-de-Moraes, M (corresponding author), CNRS, INEM Inst Necker Enfants Malad, Lab Immunoregulat & Immunopathol, UMR8253, Paris, France.; Leite-de-Moraes, M (corresponding author), INSERM, UMR1151, Paris, France.	maria.leite-demoraes@inserm.fr	de Moraes, Maria Leite/AAV-9159-2020	de Moraes, Maria Leite/0000-0002-2891-2269; Chatenoud, Lucienne/0000-0002-1328-2786; Foray, Anne-Perrine/0000-0002-7718-8473	Fondation Day Solvay; (Institut National de la Sante et de la Recherche Me'dicale); CNRS (Centre National de la Recherche Scientifique)	Fondation Day Solvay(Solvay SA); (Institut National de la Sante et de la Recherche Me'dicale)(Institut National de la Sante et de la Recherche Medicale (Inserm)); CNRS (Centre National de la Recherche Scientifique)(Centre National de la Recherche Scientifique (CNRS))	This work was supported by grants from Fondation Day Solvay, Inserm (Institut National de la Sante et de la Recherche Me ' dicale) and CNRS (Centre National de la Recherche Scientifique). We are grateful to the National Institutes of Health Tetramer Core Facility for providing CD1d tetramer reagents. We would like to thanks the staff of our animal house facilities and of the histology platform (SFR Necker).	Araujo LM, 2004, EUR J IMMUNOL, V34, P327, DOI 10.1002/eji.200324151; Belkadi A, 2019, ALLERGY, V74, P395, DOI 10.1111/all.13618; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Chesne J, 2015, J ALLERGY CLIN IMMUN, V135, P1643, DOI 10.1016/j.jaci.2014.12.1872; Chesne J, 2014, AM J RESP CRIT CARE, V190, P1094, DOI 10.1164/rccm.201405-0859PP; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Cortesi F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02375; DEBRAYSACHS M, 1991, J AUTOIMMUN, V4, P237, DOI 10.1016/0896-8411(91)90021-4; Foster PS, 2017, IMMUNOL REV, V278, P20, DOI 10.1111/imr.12549; Godfrey DI, 2015, NAT IMMUNOL, V16, P1114, DOI 10.1038/ni.3298; Gombert JM, 1996, EUR J IMMUNOL, V26, P2989, DOI 10.1002/eji.1830261226; HEILIG JS, 1986, NATURE, V322, P836, DOI 10.1038/322836a0; Hinks TSC, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.00528-2020; Hirota JA, 2010, CLIN EXP ALLERGY, V40, P820, DOI 10.1111/j.1365-2222.2010.03458.x; Johnson JR, 2007, AM J PHYSIOL-LUNG C, V293, pL730, DOI 10.1152/ajplung.00056.2007; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; Kaur R, 2019, J ALLERGY CLIN IMMUN, V144, P1, DOI 10.1016/j.jaci.2019.05.031; Kero J, 2001, J ALLERGY CLIN IMMUN, V108, P781, DOI 10.1067/mai.2001.119557; Leite-de-Moraes M, 2020, ALLERGY, V75, P3283, DOI 10.1111/all.14474; Lezmi G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01766; Lisbonne M, 2003, J IMMUNOL, V171, P1637, DOI 10.4049/jimmunol.171.4.1637; Michel ML, 2007, J EXP MED, V204, P995, DOI 10.1084/jem.20061551; Michel ML, 2008, P NATL ACAD SCI USA, V105, P19845, DOI 10.1073/pnas.0806472105; Parker ME, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00042; Pavord ID, 2018, LANCET, V391, P350, DOI 10.1016/S0140-6736(17)30879-6; Reddel HK, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01046-2019; Sharif S, 2001, NAT MED, V7, P1057, DOI 10.1038/nm0901-1057; Simoni Y, 2011, EUR J IMMUNOL, V41, P3574, DOI 10.1002/eji.201141751; Smew AI, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0834; Svenningsen S, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00158; Trembleau S, 1997, EUR J IMMUNOL, V27, P2330, DOI 10.1002/eji.1830270930; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Victor JR, 2020, CLIN REV ALLERG IMMU, V59, P371, DOI 10.1007/s12016-020-08784-8; Walker LSK, 2016, CLIN EXP IMMUNOL, V183, P16, DOI 10.1111/cei.12672; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC; You S, 2008, ANN NY ACAD SCI, V1150, P300, DOI 10.1196/annals.1447.046	37	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2021	11								595003	10.3389/fimmu.2020.595003	http://dx.doi.org/10.3389/fimmu.2020.595003			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QL8VO	33643284	Green Published, Green Submitted, gold			2022-12-18	WOS:000621358900001
J	Jang, E; Cho, S; Pyo, S; Nam, JW; Youn, J				Jang, Eunkyeong; Cho, Somi; Pyo, Sungjin; Nam, Jin-Wu; Youn, Jeehee			An Inflammatory Loop Between Spleen-Derived Myeloid Cells and CD4(+) T Cells Leads to Accumulation of Long-Lived Plasma Cells That Exacerbates Lupus Autoimmunity	FRONTIERS IN IMMUNOLOGY			English	Article						long-lived plasma cell; myeloid-derived suppressor cell; autoantibody; lupus; sanroque mice		Splenic long-lived plasma cells are abnormally numerous and deleterious in systemic autoimmune diseases, yet how they accumulate remains poorly understood. We demonstrate here that a pathological role of spleen-derived CD11b(+)Gr-1(+) myeloid cells (SDMCs) underpins the accumulation of splenic long-lived plasma cells in a lupus-prone model named sanroque. We found that SDMCs were progressively accumulated in sanroque mice from the early clinical phase. Transcriptome profiles revealed that SDMCs have a predominant shift toward an inflammatory phenotype relative to the bone marrow-derived counterparts and are distinct from neutrophils and monocytes. SDMCs were expanded in situ via splenic extramedullary myelopoiesis under the proinflammatory cytokine milieu during lupus progression. SDMCs promoted the development of IFN-gamma-secreting Th1 and follicular helper T cells, thereby licensing CD4(+) T cells to be pathologic activators of SDMCs and plasma cells. SDMCs also directly promoted the survival of plasma cells by providing B-cell activating factor of the TNF family. The frequency of SDMCs correlated with that of splenic long-lived plasma cells. Selective depletion of CD11b(+)Gr-1(+) cells reduced autoantibody production in sanroque mice. Thus, our findings suggest that SDMCs expanded in situ establish a positive feedback loop with CD4(+) T cells, leading to accumulation of long-lived plasma cells which exacerbates lupus autoimmunity.	[Jang, Eunkyeong; Youn, Jeehee] Hanyang Univ, Dept Anat & Cell Biol, Coll Med, Lab Autoimmunol, Seoul, South Korea; [Cho, Somi; Youn, Jeehee] Hanyang Univ, Grad Sch Biomed Sci & Engn, Dept Biomed Sci, Seoul, South Korea; [Pyo, Sungjin; Nam, Jin-Wu] Hanyang Univ, Dept Life Sci, Coll Nat Sci, Seoul, South Korea	Hanyang University; Hanyang University; Hanyang University	Jang, E; Youn, J (corresponding author), Hanyang Univ, Dept Anat & Cell Biol, Coll Med, Lab Autoimmunol, Seoul, South Korea.; Youn, J (corresponding author), Hanyang Univ, Grad Sch Biomed Sci & Engn, Dept Biomed Sci, Seoul, South Korea.	eunkyeong.jang@gmail.com; jhyoun@hanyang.ac.kr			National Research Foundation of Korea [NRF-2018R1A2B6004853, NRF-2020R1A4A1018398]	National Research Foundation of Korea(National Research Foundation of Korea)	This work was supported by grants from the National Research Foundation of Korea (NRF-2018R1A2B6004853 and NRF-2020R1A4A1018398).	Barbet G, 2018, IMMUNITY, V48, P584, DOI 10.1016/j.immuni.2018.02.015; Bird AK, 2017, J IMMUNOL, V199, P458, DOI 10.4049/jimmunol.1700354; Cheng QY, 2013, ANN RHEUM DIS, V72, P2011, DOI 10.1136/annrheumdis-2013-203455; Choi SS, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e44; Choi SS, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e7; Condamine T, 2015, J LEUKOCYTE BIOL, V98, P913, DOI 10.1189/jlb.4RI0515-204R; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Craft JE, 2012, NAT REV RHEUMATOL, V8, P337, DOI 10.1038/nrrheum.2012.58; Crook KR, 2015, J LEUKOCYTE BIOL, V97, P573, DOI 10.1189/jlb.4A0314-139R; Denny MR, 2010, J IMMUNOL, V184, P3284, DOI 10.4049/jimmunol.0902199; Der E, 2014, J IMMUNOL, V192, P1570, DOI 10.4049/jimmunol.1302479; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Domeier PP, 2016, J EXP MED, V213, P715, DOI 10.1084/jem.20151722; Dong GJ, 2015, ACTA BIOCH BIOPH SIN, V47, P620, DOI 10.1093/abbs/gmv053; Erickson LD, 2003, P NATL ACAD SCI USA, V100, P12905, DOI 10.1073/pnas.2131686100; Fujii W, 2013, J IMMUNOL, V191, P1073, DOI 10.4049/jimmunol.1203535; Guo CQ, 2016, ANN RHEUM DIS, V75, P278, DOI 10.1136/annrheumdis-2014-205508; Hoyer BF, 2004, J EXP MED, V199, P1577, DOI 10.1084/jem.20040168; Isenberg DA, 2007, RHEUMATOLOGY, V46, P1052, DOI 10.1093/rheumatology/kem112; Ittah M, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1912; Iwata Y, 2010, CLIN EXP NEPHROL, V14, P411, DOI 10.1007/s10157-010-0309-9; Jackson SW, 2016, J EXP MED, V213, P733, DOI 10.1084/jem.20151724; Jang E, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0352-x; Jang E, 2016, J IMMUNOL, V196, P1026, DOI 10.4049/jimmunol.1401059; Jang E, 2011, J IMMUNOL, V186, P1546, DOI 10.4049/jimmunol.1002942; Jeong M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00222; Joshi N., 2011, SICKLE SLIDING WINDO; Knier B, 2018, NAT IMMUNOL, V19, P1341, DOI 10.1038/s41590-018-0237-5; Kohno K, 1997, J IMMUNOL, V158, P1541; Komuczki J, 2019, IMMUNITY, V50, P1289, DOI 10.1016/j.immuni.2019.04.006; Thai LH, 2018, BLOOD, V131, P1545, DOI 10.1182/blood-2017-06-789578; Le S, 2008, J STAT SOFTW, V25, P1, DOI 10.18637/jss.v025.i01; Lee G, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e42; Li Y, 2014, J IMMUNOL, V193, P2127, DOI 10.4049/jimmunol.1400857; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Ma HJ, 2016, J LEUKOCYTE BIOL, V99, P1121, DOI 10.1189/jlb.3A0415-158R; Mahevas M, 2015, J AUTOIMMUN, V62, P22, DOI 10.1016/j.jaut.2015.05.006; Mahevas M, 2013, J CLIN INVEST, V123, P432, DOI 10.1172/JCI65689; Matsuo T, 2019, J IMMUNOL, V202, P3161, DOI 10.4049/jimmunol.1801159; Nurieva RI, 2008, IMMUNITY, V29, P138, DOI 10.1016/j.immuni.2008.05.009; Park MJ, 2016, ARTHRITIS RHEUMATOL, V68, P2717, DOI 10.1002/art.39767; Peperzak V, 2013, NAT IMMUNOL, V14, P290, DOI 10.1038/ni.2527; Puga I, 2012, NAT IMMUNOL, V13, P170, DOI 10.1038/ni.2194; Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886; Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119; Shlomchik MJ, 2012, IMMUNOL REV, V247, P52, DOI 10.1111/j.1600-065X.2012.01124.x; Silverman GJ, 2003, ARTHRITIS RHEUM-US, V48, P1484, DOI 10.1002/art.10947; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suurmond J, 2015, J CLIN INVEST, V125, P2194, DOI 10.1172/JCI78084; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; Tian J, 2019, J IMMUNOL, V202, P1693, DOI 10.4049/jimmunol.1801051; Trigunaite A, 2013, ARTHRITIS RHEUM-US, V65, P2392, DOI 10.1002/art.38048; Tsiganov EN, 2014, J IMMUNOL, V192, P4718, DOI 10.4049/jimmunol.1301365; Tsokos GC, 2020, NAT IMMUNOL, V21, P605, DOI 10.1038/s41590-020-0677-6; Ugolini M, 2018, NAT IMMUNOL, V19, P386, DOI 10.1038/s41590-018-0068-4; Van TC, 2011, NAT IMMUNOL, V12, P151, DOI 10.1038/ni.1981; Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590-017-0022-x; Vinuesa CG, 2009, NAT REV IMMUNOL, V9, P845, DOI 10.1038/nri2637; Vinuesa CG, 2005, NATURE, V435, P452, DOI 10.1038/nature03555; Wang C, 2017, J IMMUNOL, V199, P3094, DOI 10.4049/jimmunol.1700671; Weissman IL, 2008, BLOOD, V112, P3543, DOI 10.1182/blood-2008-08-078220; Wu H, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aae0482; Xu X, 2017, CELL MOL IMMUNOL, V14, P597, DOI 10.1038/cmi.2015.103; Yi HF, 2012, J IMMUNOL, V189, P4295, DOI 10.4049/jimmunol.1200086; Youn JI, 2012, J LEUKOCYTE BIOL, V91, P167, DOI 10.1189/jlb.0311177; Yu D, 2007, NATURE, V450, P299, DOI 10.1038/nature06253	70	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2021	12								631472	10.3389/fimmu.2021.631472	http://dx.doi.org/10.3389/fimmu.2021.631472			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QL6OW	33643317	gold, Green Published			2022-12-18	WOS:000621204900001
J	Luo, XZ; Zhang, J; Zou, SJ; Wang, XQ; Chen, G; Li, Z; Li, KY; Wang, MQ; Chen, ZS; Ming, CS; Zhu, XH; Gong, NQ				Luo, Xianzhang; Zhang, Ji; Zou, Sijuan; Wang, Xinqiang; Chen, Gen; Li, Zhen; Li, Kaiyan; Wang, Mengqing; Chen, Zhishui; Ming, Changshen; Zhu, Xiaohua; Gong, Nianqiao			Bone Fragment Co-transplantation Alongside Bone Marrow Aspirate Infusion Protects Kidney Transplant Recipients	FRONTIERS IN IMMUNOLOGY			English	Article						living kidney transplantation (LKT); bone fragment co-transplantation; bone marrow aspirate infusion; kidney protection; immune regulation		Integration of non-vascularized bone grafting and bone marrow aspirate infusion in transplantation may provide clinical benefit. Here we have incorporated bone fragment co-transplantation and bone marrow aspirate infusion (BF-BM) into living kidney transplantation (LKT). Twenty LKT recipients receiving bone fragments and bone marrow aspirates donated from their corresponding donors were enrolled into a retrospective study. A contemporaneous control group was formed of 38 out of 128 conventional LKT recipients, selected using propensity score matching by a 1:2 Greedy algorithm. Ultrasonography, contrast-enhanced ultrasonography (US/CEUS) and SPECT/CT showed that the co-transplanted bone fragments remained viable for 6 months, subsequently shrank, and finally degenerated 10 months post-transplantation. BF-BM resulted in earlier kidney recovery and more robust long-term kidney function. Throughout 5 years of follow-up, BF-BM had regulatory effects on dendritic cells (DCs), T helper (Th1/Th2) cells and regulatory T cells (Tregs). Both alloantigen-specific lymphocyte proliferation and panel reactive antibody levels were negative in all recipients with or without BF-BM. In addition, the BF-BM group experienced few complications during the 5-year follow-up (as did the donors)-this was not different from the controls. In conclusion, BF-BM is safe and benefits recipients by protecting the kidney and regulating the immune response.	[Luo, Xianzhang; Zhang, Ji; Wang, Xinqiang; Wang, Mengqing; Chen, Zhishui; Ming, Changshen; Gong, Nianqiao] Huazhong Univ Sci & Technol, Tongji Med Coll, Minist Educ, Key Lab Natl Hlth Commiss,Inst Organ Transplantat, Wuhan, Peoples R China; [Luo, Xianzhang; Zhang, Ji; Wang, Xinqiang; Wang, Mengqing; Chen, Zhishui; Ming, Changshen; Gong, Nianqiao] Huazhong Univ Sci & Technol, Chinese Acad Med Sci, Tongji Hosp, Wuhan, Peoples R China; [Luo, Xianzhang] Chongqing Univ, Key Lab Biorheol Sci & Technol, Minist Educ, Canc Hosp, Chongqing, Peoples R China; [Zou, Sijuan; Zhu, Xiaohua] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Nucl Med, Wuhan, Peoples R China; [Chen, Gen; Li, Zhen] Huazhong Univ Sci & Technol, Dept Radiol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China; [Li, Kaiyan] Huazhong Univ Sci & Technol, Dept Med Ultrasound, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China	Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College; Huazhong University of Science & Technology; Chongqing University; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Gong, NQ (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Minist Educ, Key Lab Natl Hlth Commiss,Inst Organ Transplantat, Wuhan, Peoples R China.; Gong, NQ (corresponding author), Huazhong Univ Sci & Technol, Chinese Acad Med Sci, Tongji Hosp, Wuhan, Peoples R China.; Zhu, XH (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Nucl Med, Wuhan, Peoples R China.	evazhu@vip.sina.com; nqgong@tjh.tjmu.edu.cn	Gong, Nianqiao/ABD-9276-2021; Li, Zhen/P-6994-2014; LI, Zhen/AAL-4559-2021	Li, Zhen/0000-0001-8037-4245; LI, Zhen/0000-0001-8037-4245; Zou, Sijuan/0000-0002-6501-3983	National Natural Science Foundation of China [81570678]; Major State Basic Research Development Program of China (973) [2013CB530803]; Ministry of Health [201302009]; Clinical Research Physician Program of Tongji Medical College, HUST	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major State Basic Research Development Program of China (973)(National Basic Research Program of China); Ministry of Health; Clinical Research Physician Program of Tongji Medical College, HUST	This work was supported by grants to NG from the National Natural Science Foundation of China (No. 81570678), to NG from the Major State Basic Research Development Program of China (NO.2013CB530803, 973), to XP Chen from the Special Project of the Ministry of Health (201302009), and to NG from the Clinical Research Physician Program of Tongji Medical College, HUST.	Akbay E, 2014, AURIS NASUS LARYNX, V41, P56, DOI 10.1016/j.anl.2013.07.002; Andreola G, 2011, AM J TRANSPLANT, V11, P1236, DOI 10.1111/j.1600-6143.2011.03566.x; Avecilla ST, 2004, NAT MED, V10, P64, DOI 10.1038/nm973; Aydogan F, 2014, EUR REV MED PHARMACO, V18, P587; BERDING G, 1994, EUR J NUCL MED, V21, P113; Chen FM, 2013, BIOMATERIALS, V34, P6515, DOI 10.1016/j.biomaterials.2013.05.014; Chen Yi-Bin, 2016, Adv Hematol, V2016, P6471901, DOI 10.1155/2016/6471901; Eroglu Muzaffer, 2005, International Urology and Nephrology, V37, P675, DOI 10.1007/s11255-005-0250-0; Geis S, 2013, ULTRASCHALL MED, V34, P272, DOI 10.1055/s-0033-1335133; Gong NQ, 2011, CHINESE MED J-PEKING, V124, P1290, DOI 10.3760/cma.j.issn.0366-6999.2011.09.003; Hara Y, 2011, TRANSPL INT, V24, P1112, DOI 10.1111/j.1432-2277.2011.01328.x; He Y, 2018, STEM CELLS, V36, P1045, DOI 10.1002/stem.2823; Janica J, 2013, ADV MED SCI-POLAND, V58, P408, DOI 10.2478/ams-2013-0027; Kawai T, 2014, AM J TRANSPLANT, V14, P1599, DOI 10.1111/ajt.12731; Klimczak A, 2009, PLAST RECONSTR SURG, V123, p34S, DOI 10.1097/PRS.0b013e318191be13; Kubitskiy A, 2007, TRANSPLANTATION, V83, P1273, DOI 10.1097/01.tp.0000260437.47031.88; Kumar A, 2003, CLIN TRANSPLANT, V17, P498, DOI 10.1046/j.0902-0063.2003.00076.x; Lanzetta M, 2005, TRANSPLANTATION, V79, P1210, DOI 10.1097/01.TP.0000157118.28394.FA; Larrabee WF, 2009, JAMA-J AM MED ASSOC, V302, P2250, DOI 10.1001/jama.2009.1666; Lebranchu Y, 2002, AM J TRANSPLANT, V2, P48, DOI 10.1034/j.1600-6143.2002.020109.x; Lechler RI, 2005, NAT MED, V11, P605, DOI 10.1038/nm1251; Lee H, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-96; Lentine KL, 2016, AM J TRANSPLANT, V16, P1848, DOI 10.1111/ajt.13687; Levato R, 2015, ACTA BIOMATER, V18, P59, DOI 10.1016/j.actbio.2015.02.008; LLULL R, 1995, TRANSPLANT P, V27, P164; Ma YC, 2006, J AM SOC NEPHROL, V17, P2937, DOI 10.1681/ASN.2006040368; MATAS AJ, 1994, TRANSPLANTATION, V57, P857, DOI 10.1097/00007890-199403270-00015; Miura K, 1997, INT ORTHOP, V21, P122, DOI 10.1007/s002640050134; Muller S, 2011, CLIN HEMORHEOL MICRO, V49, P115, DOI 10.3233/CH-2011-1462; Nicholson ML, 2010, BRIT J SURG, V97, P21, DOI 10.1002/bjs.6803; Pascual M, 2002, NEW ENGL J MED, V346, P580, DOI 10.1056/NEJMra011295; Petruzzo P, 2010, TRANSPLANTATION, V90, P1590, DOI 10.1097/TP.0b013e3181ff1472; Prantl L, 2011, CLIN HEMORHEOL MICRO, V49, P251, DOI 10.3233/CH-2011-1475; Rafii S, 1997, LEUKEMIA LYMPHOMA, V27, P375, DOI 10.3109/10428199709058305; RAMSAY SC, 1991, J NUCL MED, V32, P33; RIEHLE RA, 1984, J UROLOGY, V132, P1089, DOI 10.1016/S0022-5347(17)50044-0; Roca I, 2013, PEDIATR RADIOL, V43, P393, DOI 10.1007/s00247-012-2610-0; Sartori S, 2013, WORLD J RADIOL, V5, P372, DOI 10.4329/wjr.v5.i10.372; Sayegh MH, 2004, NEW ENGL J MED, V351, P2761, DOI 10.1056/NEJMon043418; Sipkins DA, 2005, NATURE, V435, P969, DOI 10.1038/nature03703; Spitzer TR, 2011, TRANSPLANTATION, V91, P672, DOI 10.1097/TP.0b013e31820a3068; Telha KA, 2017, TURK J UROL, V40, P549, DOI 10.5152/tud.2017.25738; Uesato Ryoko, 2017, Eur J Orthop Surg Traumatol, V27, P11, DOI 10.1007/s00590-016-1868-6; Wang H, 2009, J IMMUNOL, V182, P5970, DOI 10.4049/jimmunol.0801037; Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779; Yang SL, 2002, UROLOGY, V59, P673, DOI 10.1016/S0090-4295(02)01516-9; Yarlagadda G, 2008, NEPHROL DIAL TRANSPL, V23, P2995, DOI 10.1093/ndt/gfn158; Yin DP, 2003, J IMMUNOL, V170, P853, DOI 10.4049/jimmunol.170.2.853; Yin DP, 2002, TRANSPLANTATION, V74, P345, DOI 10.1097/00007890-200208150-00009; Yin DP, 2002, J IMMUNOL, V168, P5352, DOI 10.4049/jimmunol.168.10.5352; Zhang H, 2018, ACTA BIOMATER, V72, P217, DOI 10.1016/j.actbio.2018.03.032	51	1	1	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2021	12								630710	10.3389/fimmu.2021.630710	http://dx.doi.org/10.3389/fimmu.2021.630710			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QL6NZ	33643315	Green Published, gold			2022-12-18	WOS:000621202600001
J	Ruohtula, T; Kondrashova, A; Lehtonen, J; Oikarinen, S; Hamalainen, AM; Niemela, O; Peet, A; Tillmann, V; Nieminen, JK; Ilonen, J; Knip, M; Vaarala, O; Hyoty, H				Ruohtula, Terhi; Kondrashova, Anita; Lehtonen, Jussi; Oikarinen, Sami; Hamalainen, Anu-Maaria; Niemela, Onni; Peet, Aleksandr; Tillmann, Vallo; Nieminen, Janne K.; Ilonen, Jorma; Knip, Mikael; Vaarala, Outi; Hyoty, Heikki		DIABIMMUNE Study Grp	Immunomodulatory Effects of Rhinovirus and Enterovirus Infections During the First Year of Life	FRONTIERS IN IMMUNOLOGY			English	Article						enterovirus; rhinovirus; regulatory T cell; cytokine; type 1 diabetes	VIRAL-INFECTIONS; CELLS; MYOCARDITIS; ASTHMA; RISK	Early childhood infections have been implicated in the development of immune-mediated diseases, such as allergies, asthma, and type 1 diabetes. We set out to investigate the immunomodulatory effects of early viral infections experienced before the age of one year on the peripheral regulatory T cell population (Treg) and circulating cytokines in a birth-cohort study of Estonian and Finnish infants. We show here a temporal association of virus infection with the expression of FOXP3 in regulatory T cells. Infants with rhinovirus infection during the preceding 30 days had a higher FOXP3 expression in Treg cells and decreased levels of several cytokines related to Th1 and Th2 responses in comparison to the children without infections. In contrast, FOXP3 expression was significantly decreased in highly activated (CD4+CD127-/loCD25+FOXP3high) regulatory T cells (TregFOXP3high) in the infants who had enterovirus infection during the preceding 30 or 60 days. After enterovirus infections, the cytokine profile showed an upregulation of Th1- and Th17-related cytokines and a decreased activation of CCL22, which is a chemokine derived from dendritic cells and associated with Th2 deviation. Our results reveal that immunoregulatory mechanisms are up-regulated after rhinovirus infections, while enterovirus infections are associated with activation of proinflammatory pathways and decreased immune regulation.	[Ruohtula, Terhi; Vaarala, Outi] Univ Helsinki, Clinicum, Helsinki, Finland; [Kondrashova, Anita; Lehtonen, Jussi; Oikarinen, Sami; Hyoty, Heikki] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland; [Hamalainen, Anu-Maaria] Helsinki Univ Hosp, Jorvi Hosp, Dept Pediat, Espoo, Finland; [Niemela, Onni] Seinajoki Cent Hosp, Dept Lab Med, Seinajoki, Finland; [Niemela, Onni] Seinajoki Cent Hosp, Med Res Unit, Seinajoki, Finland; [Niemela, Onni] Univ Tampere, Seinajoki, Finland; [Peet, Aleksandr; Tillmann, Vallo] Univ Tartu, Dept Pediat, Tartu, Estonia; [Peet, Aleksandr; Tillmann, Vallo] Tartu Univ Hosp, Tartu, Estonia; [Nieminen, Janne K.; Knip, Mikael] Univ Helsinki, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland; [Nieminen, Janne K.; Knip, Mikael] Helsinki Univ Hosp, Helsinki, Finland; [Ilonen, Jorma] Univ Turku, Immunogenet Lab, Turku, Finland; [Knip, Mikael] Univ Helsinki, Fac Med, Res Program Clin & Mol Metab, Helsinki, Finland; [Knip, Mikael] Folkhalsan Res Ctr, Helsinki, Finland; [Knip, Mikael] Tampere Univ Hosp, Tampere Ctr Child Hlth Res, Tampere, Finland; [Hyoty, Heikki] Pirkanmaa Hosp Dist, Fimlab Labs, Tampere, Finland	University of Helsinki; Tampere University; University of Helsinki; Helsinki University Central Hospital; Seinajoki Central Hospital; Seinajoki Central Hospital; University of Tartu; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Turku; University of Helsinki; Folkhalsan Research Center; Tampere University; Tampere University Hospital; Pirkanmaa Hospital District	Hyoty, H (corresponding author), Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland.; Knip, M (corresponding author), Univ Helsinki, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland.; Knip, M (corresponding author), Helsinki Univ Hosp, Helsinki, Finland.; Knip, M (corresponding author), Univ Helsinki, Fac Med, Res Program Clin & Mol Metab, Helsinki, Finland.; Knip, M (corresponding author), Folkhalsan Res Ctr, Helsinki, Finland.; Knip, M (corresponding author), Tampere Univ Hosp, Tampere Ctr Child Hlth Res, Tampere, Finland.; Hyoty, H (corresponding author), Pirkanmaa Hosp Dist, Fimlab Labs, Tampere, Finland.	Mikael.knip@helsinki.fi; Heikki.hyoty@tuni.fi	Tillmann, Vallo/G-8118-2012	Tillmann, Vallo/0000-0002-5279-4493; Karapetyan, Tatyana/0000-0001-8129-8133; Virtanen, Suvi/0000-0001-8928-0878; Dorshakova, Natalia/0000-0003-1072-9164; Ilonen, Jorma/0000-0002-9973-2062	Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research [250114]; Novo Nordisk Foundation [34080]; Sigrid Juselius Foundation; Diabetes Research Foundation in Finland; Tampere Tuberculosis Foundation; Academy of Finland [288671]	Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Diabetes Research Foundation in Finland; Tampere Tuberculosis Foundation; Academy of Finland(Academy of Finland)	Our study was supported by the Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research (250114), Novo Nordisk Foundation (grant 34080), Sigrid Juselius Foundation, Diabetes Research Foundation in Finland, Tampere Tuberculosis Foundation, and Academy of Finland (grant 288671).	Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Billerbeck E, 2008, HUM IMMUNOL, V69, P771, DOI 10.1016/j.humimm.2008.07.016; Bremner SA, 2008, ALLERGY, V63, P274, DOI 10.1111/j.1398-9995.2007.01599.x; Cabrera R, 2004, HEPATOLOGY, V40, P1062, DOI 10.1002/hep.20454; Campbell DJ, 2011, NAT REV IMMUNOL, V11, P119, DOI 10.1038/nri2916; Chen C, 2017, EXP THER MED, V13, P1490, DOI 10.3892/etm.2017.4144; Chen JG, 2012, J MED VIROL, V84, P763, DOI 10.1002/jmv.23254; Cohen JI, 2015, CURR TOP MICROBIOL, V390, P241, DOI 10.1007/978-3-319-22822-8_10; Decker ML, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17865-2; Edwards MR, 2017, J ALLERGY CLIN IMMUN, V140, P909, DOI 10.1016/j.jaci.2017.07.025; Quarleri JF, 2016, ANN HEPATOL, V15, P17, DOI 10.5604/16652681.1184193; Feldman AS, 2015, AM J RESP CRIT CARE, V191, P34, DOI 10.1164/rccm.201405-0901PP; Fernandes C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079072; Foxman EF, 2011, NAT REV MICROBIOL, V9, P254, DOI 10.1038/nrmicro2541; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Honkanen H, 2017, DIABETOLOGIA, V60, P424, DOI 10.1007/s00125-016-4177-z; Honkanen H, 2013, J CLIN VIROL, V56, P250, DOI 10.1016/j.jcv.2012.11.020; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Jin HB, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0626-z; Kahrs CR, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l231; Kim B, 2008, VACCINE, V26, P5601, DOI 10.1016/j.vaccine.2008.07.099; Kim CK, 2018, ALLERGY ASTHMA IMMUN, V10, P12, DOI [10.4168/aair.2018.10.1.12, 10.4168/aair.2018.10.6.686]; Korhonen L, 2019, J MED VIROL, V91, P1470, DOI 10.1002/jmv.25455; Krogvold L, 2015, DIABETES, V64, P1682, DOI 10.2337/db14-1370; Lee DCP, 2010, J VIROL, V84, P8790, DOI 10.1128/JVI.00796-10; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lindfors K, 2020, GUT, V69, P1416, DOI 10.1136/gutjnl-2019-319809; Liu W, 2013, AM J PATHOL, V183, P441, DOI 10.1016/j.ajpath.2013.04.015; Lloyd CM, 2017, IMMUNITY, V46, P549, DOI 10.1016/j.immuni.2017.04.005; Lloyd CM, 2009, IMMUNITY, V31, P438, DOI 10.1016/j.immuni.2009.08.007; Lonnrot M, 1999, J MED VIROL, V59, P378, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;378::AID-JMV19&gt;3.0.CO;2-I; Mustonen N, 2018, PEDIATR DIABETES, V19, P293, DOI 10.1111/pedi.12547; O'Garra A, 2013, ANNU REV IMMUNOL, V31, P475, DOI 10.1146/annurev-immunol-032712-095939; Oberste MS, 2003, J CLIN VIROL, V26, P375, DOI 10.1016/S1386-6532(03)00004-0; Pelly VS, 2017, J EXP MED, V214, P1809, DOI 10.1084/jem.20161104; Poojary KV, 2010, AM J PATHOL, V177, P525, DOI 10.2353/ajpath.2010.090936; Principi N, 2017, J CLIN VIROL, V96, P26, DOI 10.1016/j.jcv.2017.09.003; Rewers M, 2016, LANCET, V387, P2340, DOI 10.1016/S0140-6736(16)30507-4; Rouse BT, 2010, NAT REV IMMUNOL, V10, P514, DOI 10.1038/nri2802; Ruohtula T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02494; Sanchez AM, 2012, J IMMUNOL, V189, P2805, DOI 10.4049/jimmunol.1200645; Schulte BM, 2010, VIRAL IMMUNOL, V23, P99, DOI 10.1089/vim.2009.0072; Seiskari T, 2012, J MED VIROL, V84, P268, DOI 10.1002/jmv.23186; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Sillanpaa S, 2015, J CLIN VIROL, V62, P106, DOI 10.1016/j.jcv.2014.11.002; Stokholm J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02573-2; Stoop JN, 2005, HEPATOLOGY, V41, P771, DOI 10.1002/hep.20649; Stross L, 2012, HEPATOLOGY, V56, P873, DOI 10.1002/hep.25765; Su N, 2016, SCI REP-UK, V6, DOI 10.1038/srep22658; Vehik K, 2019, NAT MED, V25, P1865, DOI 10.1038/s41591-019-0667-0; Wang SM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102025; Xie YQ, 2012, FEMS IMMUNOL MED MIC, V64, P343, DOI 10.1111/j.1574-695X.2011.00918.x; Yuan J, 2010, J IMMUNOL, V185, P4004, DOI 10.4049/jimmunol.1001718; Yue FY, 2010, J IMMUNOL, V185, P498, DOI 10.4049/jimmunol.0903915	55	1	1	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2021	11								567046	10.3389/fimmu.2020.567046	http://dx.doi.org/10.3389/fimmu.2020.567046			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QL8RR	33643278	Green Published, gold, Green Submitted			2022-12-18	WOS:000621348600001
J	Yang, MM; Sun, HY; Meng, T; Qiu, SH; Zeng, QQ; Ng, TK; Jiang, L; Deng, TM; Zeng, AN; Wang, J; Luo, XL				Yang, Ming Ming; Sun, Hong Yan; Meng, Ting; Qiu, Shan Hu; Zeng, Qi Qiao; Ng, Tsz Kin; Jiang, Li; Deng, Ting Ming; Zeng, Ai Neng; Wang, Jun; Luo, Xiao Ling			CFH I62V as a Putative Genetic Marker for Posner-Schlossman Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						uveitis; posner-schlossman syndrome (PSS); complement system; genes; single nucleotide polymorphisms; complement factor H		Objective: Posner-Schlossman syndrome (PSS), also known as glaucomatocyclitic crisis, is an ocular condition characterized by recurrent attacks of anterior uveitis and raised intraocular pressure. Previous studies by our team and others have identified the genetic association of complement pathway genes with uveitis and glaucoma. This study aimed to investigate the complement genes in PSS patients with the view of elucidating the genetic background of the disease. Methods: A total of 331 subjects (56 PSS patients and 275 controls) were recruited for this study. We selected 27 variants in six complement pathway genes (SERPING1, C2, CFB, CFH, C3, and C5) and detected them using TaqMan single nucleotide polymorphism (SNP) Genotyping Assays. Univariate SNP association analysis, haplotype-based association analysis, gene-gene interaction analysis among complement genes, and genotype-phenotype correlation analysis were performed. Results: Among the 27 variants of six complement pathway genes, the functional variant I62V (rs800292) at the CFH gene was found to be significantly associated with PSS; there was a significant increase in the frequency of A allele and AA homozygosity in PSS patients than in controls (P = 1.79 x 10(-4); odds ratio (OR) 2.18, 95% CI: 1.44-3.29; P = 4.65 x 10(-4); OR 3.66, 95% CI: 1.70-7.85, respectively). The additive effect of CFH-rs800292 and SERPING1-rs3824988 was identified with an OR of 12.50 (95% CI: 2.16-72.28). Genotype-phenotype analysis indicated that the rs800292 AA genotype was associated with a higher intraocular pressure and higher frequency of recurrence. Unlike a high proportion of human leukocyte antigen (HLA)-B27 positivity in anterior uveitis, only 3 in 56 (5.36%) PSS patients were HLA-B27 positive. In addition, one haplotype block (GC) in the SERPING1 gene showed a nominal association with PSS with an increased risk of 2.04 (P = 0.01; 95% CI: 1.18-3.53), but the P-value could not withstand the Bonferroni correction (P-corr > 0.05). Conclusion: This study revealed a genetic association of a CFH variant with PSS as well as its clinical parameters, implying that the alternative complement pathway might play an important role in the pathogenesis of PSS. Further studies to enrich the understanding of the genetic background of PSS and the role of the complement system in ocular inflammation are warranted.	[Yang, Ming Ming; Sun, Hong Yan; Meng, Ting; Zeng, Qi Qiao; Jiang, Li; Deng, Ting Ming; Zeng, Ai Neng; Luo, Xiao Ling] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Ophthalmol, Shenzhen, Peoples R China; [Yang, Ming Ming; Sun, Hong Yan; Meng, Ting; Qiu, Shan Hu; Zeng, Qi Qiao; Jiang, Li; Deng, Ting Ming; Zeng, Ai Neng; Wang, Jun; Luo, Xiao Ling] Southern Univ Sci & Technol, Filiated Hosp 1, Shenzhen, Peoples R China; [Qiu, Shan Hu; Wang, Jun] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Endocrinol, Shenzhen, Peoples R China; [Ng, Tsz Kin] Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Peoples R China; [Ng, Tsz Kin] Chinese Univ Hong Kong, Shantou, Peoples R China; [Ng, Tsz Kin] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China	Jinan University; Southern University of Science & Technology; Jinan University; Shantou University; Chinese University of Hong Kong	Luo, XL (corresponding author), Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Ophthalmol, Shenzhen, Peoples R China.; Wang, J; Luo, XL (corresponding author), Southern Univ Sci & Technol, Filiated Hosp 1, Shenzhen, Peoples R China.; Wang, J (corresponding author), Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Endocrinol, Shenzhen, Peoples R China.	wangjun4622@163.com; lxl2603@vip.sina.com	Ng, Tsz Kin/I-8061-2014	Ng, Tsz Kin/0000-0001-7863-7229	National Natural Science Foundation of China [82000768]; Shenzhen Science and Technology Project [JCYJ20200109140820699]; Funds for Scientific Research Training Project of Shenzhen People's Hospital	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Science and Technology Project; Funds for Scientific Research Training Project of Shenzhen People's Hospital	This study was supported in part by the National Natural Science Foundation of China (No. 82000768), Shenzhen Science and Technology Project (No. JCYJ20200109140820699), and by the Funds for Scientific Research Training Project of Shenzhen People's Hospital (MY and JW).	Aigner C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040964; Bernabeu-Herrero ME, 2015, MOL IMMUNOL, V67, P276, DOI 10.1016/j.molimm.2015.06.021; Chan NSW, 2018, OCUL IMMUNOL INFLAMM, V26, P107, DOI 10.1080/09273948.2017.1394471; DAVIS AE, 1986, P NATL ACAD SCI USA, V83, P3161, DOI 10.1073/pnas.83.10.3161; Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3; Hedayatfar A, 2014, INT OPHTHALMOL, V34, P1123, DOI 10.1007/s10792-014-9928-6; HIROSE S, 1985, ARCH OPHTHALMOL-CHIC, V103, P1837; Huang XS, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.11.70; Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145; Jiang JH, 2017, BRIT J OPHTHALMOL, V101, P1638, DOI 10.1136/bjophthalmol-2016-309863; Konno Y, 1999, INVEST OPHTH VIS SCI, V40, P1838; Lippert J, 2020, CUREUS, V12, DOI 10.7759/cureus.6584; Lu FT, 2018, GENET TEST MOL BIOMA, V22, P526, DOI 10.1089/gtmb.2018.0110; Megaw R, 2017, SURV OPHTHALMOL, V62, P277, DOI 10.1016/j.survophthal.2016.12.005; Ren LZ, 2010, ADV EXP MED BIOL, V703, P95, DOI 10.1007/978-1-4419-5635-4_7; Rosen AM, 2010, ADV EXP MED BIOL, V703, P75, DOI 10.1007/978-1-4419-5635-4_6; Scotland RS, 2011, BLOOD, V118, P5918, DOI 10.1182/blood-2011-03-340281; Shazly TA, 2011, SEMIN OPHTHALMOL, V26, P282, DOI 10.3109/08820538.2011.605821; Wang J, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/748435; Wang QF, 2016, EYE, V30, P1452, DOI 10.1038/eye.2016.146; Wang YQ, 2014, BRIT J OPHTHALMOL, V98, P1592, DOI 10.1136/bjophthalmol-2014-305296; Yang MM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00833-1; Yang MM, 2014, RETINA-J RET VIT DIS, V34, P1, DOI 10.1097/IAE.0b013e31829f7415; Yang MM, 2013, BRIT J OPHTHALMOL, V97, P1475, DOI 10.1136/bjophthalmol-2013-303679; Yang MM, 2012, MOL VIS, V18, P1865; Yang MM, 2012, INVEST OPHTH VIS SCI, V53, P4969, DOI 10.1167/iovs.12-9478; Yang MM, 2011, MOL VIS, V17, P2655; Yang MM, 2016, IMMUNOL RES, V64, P610, DOI 10.1007/s12026-015-8762-x; Zhao J, 2017, HLA, V90, P136, DOI 10.1111/tan.13058; Zhao J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132179	30	1	3	5	18	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2021	12								608723	10.3389/fimmu.2021.608723	http://dx.doi.org/10.3389/fimmu.2021.608723			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QL6OQ	33643312	Green Published, gold			2022-12-18	WOS:000621204300001
